{"text_format":"3","workbook":"xlsx","n_sheets":2,"sheets":["Supplementary Dataset 1","Supplementary Dataset 2"],"cells_cut":33,"read":"whole","date_system":"1900"}

{"sheet":"Supplementary Dataset 1","index":0,"n_rows":180803,"n_cols":73,"rows_kept":2250,"cut":true,"bounds":{"rows_first":1000,"rows_last":250,"rows_between":1000,"halvings":1}}
["nct_id","outcome_analyses.id","outcome_id","outcome.title","mesh_interv","all_interv","all_interv_types","mesh_cond","all_cond","intervention_model","study_type","primary_purpose","allocation","brief_title","number_of_arms","param_type","param_value","p_value","method","ci_lower_limit","ci_upper_limit","ci_percent","dispersion_type","dispersion_value","gender","enrollment","overall_status","phase","criteria","description"]
["NCT00000378",4517002,8269094,"HAMILTON Rating Scale for DEPRESSION Range","nortriptyline|sertraline","Sertraline|Nortriptyline","Drug|Drug","depression|depressive disorder","Depression|Melancholia","Parallel Assignment","Interventional","Treatment","Randomized","Antidepressant Treatment of Melancholia in Late Life",2,null,"NA",0.05,"Regression, Logistic",{"$nulls":4},"NA","All",110,"Completed","Phase 4","\t"]
["NCT00000392",4516989,8269030,"Change in Global Neurocognitive Performance z Score From Baseline","NA","Peptide T|Placebo","Drug|Drug","cognitive dysfunction|cognition disorders","Cognition Disorders|HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.",2,null,"NA",0.18,"ANOVA",{"$nulls":4},"NA","All",215,"Completed","Phase 2","\t"]
["NCT00001656",4516991,8269042,"Change in Extrapyramidal Movements as Measured by the Simpson Angus Scale Score","clozapine|olanzapine","Olanzapine|Clozapine","Drug|Drug","psychotic disorders|disease|schizophrenia|schizophrenia, childhood|mental disorders","Childhood Schizophrenia|Psychotic Disorder|Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders",2,null,"NA",0.73,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",25,"Completed","Phase 4","\t"]
["NCT00001656",4516992,8269044,"Change in Body Mass Index (BMI)","clozapine|olanzapine","Olanzapine|Clozapine","Drug|Drug","psychotic disorders|disease|schizophrenia|schizophrenia, childhood|mental disorders","Childhood Schizophrenia|Psychotic Disorder|Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders",2,null,"NA",0.76,"t-test, 2 sided",{"$nulls":4},"NA","All",25,"Completed","Phase 4","\t"]
["NCT00001656",4516993,8269045,"Change in Weight","clozapine|olanzapine","Olanzapine|Clozapine","Drug|Drug","psychotic disorders|disease|schizophrenia|schizophrenia, childhood|mental disorders","Childhood Schizophrenia|Psychotic Disorder|Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders",2,null,"NA",0.96,"t-test, 2 sided",{"$nulls":4},"NA","All",25,"Completed","Phase 4","\t"]
["NCT00001656",4516994,8269046,"Change in the Bunney-Hamburg Rating Scale for Anxiety","clozapine|olanzapine","Olanzapine|Clozapine","Drug|Drug","psychotic disorders|disease|schizophrenia|schizophrenia, childhood|mental disorders","Childhood Schizophrenia|Psychotic Disorder|Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders",2,null,"NA",0.11,"ANCOVA",{"$nulls":4},"NA","All",25,"Completed","Phase 4","\t"]
["NCT00001656",4516995,8269047,"Change in Bunney-Hamburg Rating Scale for Mania","clozapine|olanzapine","Olanzapine|Clozapine","Drug|Drug","psychotic disorders|disease|schizophrenia|schizophrenia, childhood|mental disorders","Childhood Schizophrenia|Psychotic Disorder|Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders",2,null,"NA",0.27,"ANCOVA",{"$nulls":4},"NA","All",25,"Completed","Phase 4","\t"]
["NCT00001656",4516996,8269048,"Change in Bunney-Hamburg Rating Scale for Depression","clozapine|olanzapine","Olanzapine|Clozapine","Drug|Drug","psychotic disorders|disease|schizophrenia|schizophrenia, childhood|mental disorders","Childhood Schizophrenia|Psychotic Disorder|Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders",2,null,"NA",0.72,"ANCOVA",{"$nulls":4},"NA","All",25,"Completed","Phase 4","\t"]
["NCT00001656",4516997,8269049,"Change in the Bunney-Hamburg Rating Scale for Psychosis","clozapine|olanzapine","Olanzapine|Clozapine","Drug|Drug","psychotic disorders|disease|schizophrenia|schizophrenia, childhood|mental disorders","Childhood Schizophrenia|Psychotic Disorder|Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders",2,null,"NA",0.59,"ANCOVA",{"$nulls":4},"NA","All",25,"Completed","Phase 4","\t"]
["NCT00001656",4516998,8269050,"Change in the Scale for the Assessment of Positive Symptoms","clozapine|olanzapine","Olanzapine|Clozapine","Drug|Drug","psychotic disorders|disease|schizophrenia|schizophrenia, childhood|mental disorders","Childhood Schizophrenia|Psychotic Disorder|Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders",2,null,"NA",0.19,"ANCOVA",{"$nulls":4},"NA","All",25,"Completed","Phase 4","\t"]
["NCT00001656",4516999,8269051,"Change in the Brief Psychiatric Rating Scale-24","clozapine|olanzapine","Olanzapine|Clozapine","Drug|Drug","psychotic disorders|disease|schizophrenia|schizophrenia, childhood|mental disorders","Childhood Schizophrenia|Psychotic Disorder|Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders",2,null,"NA",0.35,"ANCOVA",{"$nulls":4},"NA","All",25,"Completed","Phase 4","\t"]
["NCT00001656",4517000,8269052,"Change in the Clinical Global Impression Severity of Symptoms Scale","clozapine|olanzapine","Olanzapine|Clozapine","Drug|Drug","psychotic disorders|disease|schizophrenia|schizophrenia, childhood|mental disorders","Childhood Schizophrenia|Psychotic Disorder|Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders",2,null,"NA",0.21,"ANCOVA",{"$nulls":4},"NA","All",25,"Completed","Phase 4","\t"]
["NCT00001656",4517001,8269053,"Change in the Scale for the Assessment of Negative Symptoms","clozapine|olanzapine","Olanzapine|Clozapine","Drug|Drug","psychotic disorders|disease|schizophrenia|schizophrenia, childhood|mental disorders","Childhood Schizophrenia|Psychotic Disorder|Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders",2,null,"NA",0.04,"ANCOVA",{"$nulls":4},"NA","All",25,"Completed","Phase 4","\t"]
["NCT00001723",4516990,8269039,"Change in BMI Standard Deviation Score","orlistat","Orlistat|Placebo","Drug|Drug","sleep apnea syndromes|obesity|metabolic diseases","Diabetes Mellitus|Hypertension|Metabolic Disease|Obesity|Sleep Apnea Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases",2,null,"NA",0.007,"ANCOVA",{"$nulls":4},"NA","All",200,"Completed","Phase 2","\t"]
["NCT00002525",4514753,8265228,"5-year Disease-free Survival Rate in Patients With Dukes' B3/C Disease","calcium|leucovorin|tetrahydrofolates|formyltetrahydrofolates|levoleucovorin|fluorouracil","fluorouracil|leucovorin calcium","Drug|Drug","colonic neoplasms","Colorectal Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed",2,null,"NA",0.847,"Log Rank",{"$nulls":4},"NA","All",859,"Terminated","Phase 3","\t"]
["NCT00002525",4514754,8265229,"5-year Overall Survival Rate in Patients With Dukes' B3/C Disease","calcium|leucovorin|tetrahydrofolates|formyltetrahydrofolates|levoleucovorin|fluorouracil","fluorouracil|leucovorin calcium","Drug|Drug","colonic neoplasms","Colorectal Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed",2,null,"NA",0.178,"Log Rank",{"$nulls":4},"NA","All",859,"Terminated","Phase 3","\t"]
["NCT00002540",4514761,8265248,"Prostate Cancer Death Rates","NA","Laboratory Biomarker Analysis|Medical Examination|Screening Questionnaire Administration","Other|Procedure|Other","prostatic neoplasms","Prostate Carcinoma","Parallel Assignment","Interventional","Screening","Randomized","Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)",2,"Hazard Ratio (HR)",1.09,"NA",null,0.87,1.36,95,null,"NA","Male",76685,"Active, not recruiting","N/A","\t"]
["NCT00002540",4514762,8265258,"Prostate Cancer Incidence Rates","NA","Laboratory Biomarker Analysis|Medical Examination|Screening Questionnaire Administration","Other|Procedure|Other","prostatic neoplasms","Prostate Carcinoma","Parallel Assignment","Interventional","Screening","Randomized","Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)",2,"Hazard Ratio (HR)",1.12,"NA",null,1.07,1.17,95,null,"NA","Male",76685,"Active, not recruiting","N/A","\t"]
["NCT00002540",4514763,8265260,"Death Rates From All Causes","NA","Laboratory Biomarker Analysis|Medical Examination|Screening Questionnaire Administration","Other|Procedure|Other","prostatic neoplasms","Prostate Carcinoma","Parallel Assignment","Interventional","Screening","Randomized","Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)",2,"Hazard Ratio (HR)",0.96,"NA",null,0.93,1,95,null,"NA","Male",76685,"Active, not recruiting","N/A","\t"]
["NCT00002540",4514764,8265262,"Prostate Cancer Deaths","NA","Laboratory Biomarker Analysis|Medical Examination|Screening Questionnaire Administration","Other|Procedure|Other","prostatic neoplasms","Prostate Carcinoma","Parallel Assignment","Interventional","Screening","Randomized","Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)",2,"Hazard Ratio (HR)",1.09,"NA",null,0.87,1.36,95,null,"NA","Male",76685,"Active, not recruiting","N/A","\t"]
["NCT00002597",4514806,8265391,"Positive Re-biopsy Rate at Two Years","goserelin|flutamide|leuprolide","flutamide|Zoladex|Lupron|radiation therapy","Drug|Drug|Drug|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer",2,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","Male",2028,"Completed","Phase 3","\t"]
["NCT00002597",4514807,8265392,"Disease-free Survival Rate (10 Years)","goserelin|flutamide|leuprolide","flutamide|Zoladex|Lupron|radiation therapy","Drug|Drug|Drug|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer",2,"Hazard Ratio (HR)",1.38,1E-3,"Log Rank",1.22,1.56,95,null,"NA","Male",2028,"Completed","Phase 3","\t"]
["NCT00002597",4514808,8265393,"Second Biochemical Relapse Rate (10 Years)","goserelin|flutamide|leuprolide","flutamide|Zoladex|Lupron|radiation therapy","Drug|Drug|Drug|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer",2,"Hazard Ratio (HR)",2.06,1E-3,"Gray's test",1.34,3.16,95,null,"NA","Male",2028,"Completed","Phase 3","\t"]
["NCT00002597",4514809,8265394,"Clinical Relapse Rate (10 Years)","goserelin|flutamide|leuprolide","flutamide|Zoladex|Lupron|radiation therapy","Drug|Drug|Drug|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer",2,"Hazard Ratio (HR)",1.5,1E-3,"Gray's test",1.21,1.85,95,null,"NA","Male",2028,"Completed","Phase 3","\t"]
["NCT00002597",4514810,8265395,"Biochemical Failure Rate (10 Years)","goserelin|flutamide|leuprolide","flutamide|Zoladex|Lupron|radiation therapy","Drug|Drug|Drug|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer",2,"Hazard Ratio (HR)",1.74,1E-3,"Gray's test",1.48,2.04,95,null,"NA","Male",2028,"Completed","Phase 3","\t"]
["NCT00002597",4514811,8265396,"Distant Failure Rate (10 Years)","goserelin|flutamide|leuprolide","flutamide|Zoladex|Lupron|radiation therapy","Drug|Drug|Drug|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer",2,"Hazard Ratio (HR)",1.45,0.035,"Gray's test",1.03,2.06,95,null,"NA","Male",2028,"Completed","Phase 3","\t"]
["NCT00002597",4514812,8265397,"Local Progression Rate (10 Years)","goserelin|flutamide|leuprolide","flutamide|Zoladex|Lupron|radiation therapy","Drug|Drug|Drug|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer",2,"Hazard Ratio (HR)",1.5,0.0013,"Gray's test",1.17,1.93,95,null,"NA","Male",2028,"Completed","Phase 3","\t"]
["NCT00002597",4514813,8265398,"Disease-specific Survival Rate (10 Years)","goserelin|flutamide|leuprolide","flutamide|Zoladex|Lupron|radiation therapy","Drug|Drug|Drug|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer",2,"Hazard Ratio (HR)",1.86,1E-3,"Gray's test",1.27,2.74,95,null,"NA","Male",2028,"Completed","Phase 3","\t"]
["NCT00002597",4514814,8265399,"Overall Survival Rate (10-year)","goserelin|flutamide|leuprolide","flutamide|Zoladex|Lupron|radiation therapy","Drug|Drug|Drug|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer",2,"Hazard Ratio (HR)",1.17,0.0309,"Log Rank",1.01,1.35,95,null,"NA","Male",2028,"Completed","Phase 3","\t"]
["NCT00002651",4515863,8267864,"Vitality","bicalutamide|goserelin","bicalutamide|goserelin acetate|clinical observation","Drug|Drug|Other","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer",2,"Mean Difference (Net)",1.32,0.23,"t-test, 2 sided",-0.83,3.46,95,null,"NA","Male",3040,"Completed","Phase 3","\t"]
["NCT00002651",4515864,8267865,"High Libido","bicalutamide|goserelin","bicalutamide|goserelin acetate|clinical observation","Drug|Drug|Other","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer",2,"Mean Difference (Net)",18,0.04,"t-test, 2 sided",1,36,95,null,"NA","Male",3040,"Completed","Phase 3","\t"]
["NCT00002651",4515865,8267866,"Erectile Dysfunction","bicalutamide|goserelin","bicalutamide|goserelin acetate|clinical observation","Drug|Drug|Other","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer",2,"Mean Difference (Net)",-10,1E-3,"t-test, 2 sided",-14,-5,95,null,"NA","Male",3040,"Completed","Phase 3","\t"]
["NCT00002651",4515866,8267867,"Emotional Functioning as Measured by the SF-36 Mental Health Inventory","bicalutamide|goserelin","bicalutamide|goserelin acetate|clinical observation","Drug|Drug|Other","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer",2,"Mean Difference (Net)",2.88,0.003,"t-test, 2 sided",1,4.76,95,null,"NA","Male",3040,"Completed","Phase 3","\t"]
["NCT00002651",4515867,8267868,"Physical Functioning as Measured by the SF-36","bicalutamide|goserelin","bicalutamide|goserelin acetate|clinical observation","Drug|Drug|Other","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer",2,"Mean Difference (Net)",1.83,0.09,"t-test, 2 sided",-0.31,3.97,95,null,"NA","Male",3040,"Completed","Phase 3","\t"]
["NCT00002651",4515868,8267869,"Overall Survival","bicalutamide|goserelin","bicalutamide|goserelin acetate|clinical observation","Drug|Drug|Other","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer",2,"Hazard Ratio (HR)",1.1,0.15,"Regression, Cox",0.99,1.23,90,null,"NA","Male",3040,"Completed","Phase 3","\t"]
["NCT00002850",4515862,8267857,"Proportion of Patients Experiencing a Serious Bacterial Infection","sulfamethoxazole|ciprofloxacin|ofloxacin|trimethoprim","ciprofloxacin|ofloxacin|160 mg trimethoprim and 800 mg sulfamethoxazole","Drug|Drug|Drug","communicable diseases|multiple myeloma|infection|neoplasms, plasma cell","Infection|Multiple Myeloma","Parallel Assignment","Interventional","Supportive Care","Randomized","Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy",3,null,"NA",0.218,"Fisher Exact",{"$nulls":4},"NA","All",212,"Completed","Phase 3","\t"]
["NCT00002874",4515852,8267848,"Grade 3+ Toxicity","bicalutamide","bicalutamide|radiation therapy|placebo","Drug|Radiation|Drug","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy",2,null,"NA",0.029,"Chi-squared",{"$nulls":4},"NA","Male",840,"Active, not recruiting","Phase 3","\t"]
["NCT00002874",4515853,8267848,"Grade 3+ Toxicity","bicalutamide","bicalutamide|radiation therapy|placebo","Drug|Radiation|Drug","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy",2,null,"NA",0.06,"Chi-squared",{"$nulls":4},"NA","Male",840,"Active, not recruiting","Phase 3","\t"]
["NCT00002874",4515854,8267849,"Progression-free Survival (12-year Rates Reported)","bicalutamide","bicalutamide|radiation therapy|placebo","Drug|Radiation|Drug","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy",2,"Cox Proportional Hazard",0.6,1E-3,"Log Rank",0.5,0.71,95,null,"NA","Male",840,"Active, not recruiting","Phase 3","\t"]
["NCT00002874",4515855,8267850,"Prostate Cancer Death (12-year Rates Reported)","bicalutamide","bicalutamide|radiation therapy|placebo","Drug|Radiation|Drug","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy",2,"Hazard Ratio (HR)",0.49,1E-3,"Gray's test",0.32,0.74,95,null,"NA","Male",840,"Active, not recruiting","Phase 3","\t"]
["NCT00002874",4515856,8267851,"Distant Failure (12-year Rates Reported)","bicalutamide","bicalutamide|radiation therapy|placebo","Drug|Radiation|Drug","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy",2,"Hazard Ratio (HR)",0.63,2E-3,"Gray's test",0.46,0.87,95,null,"NA","Male",840,"Active, not recruiting","Phase 3","\t"]
["NCT00002874",4515857,8267852,"PSA Complete Response at End of Protocol Treatment","bicalutamide","bicalutamide|radiation therapy|placebo","Drug|Radiation|Drug","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy",2,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","Male",840,"Active, not recruiting","Phase 3","\t"]
["NCT00002874",4515858,8267853,"Third PSA Recurrence (12-year Rates Reported)","bicalutamide","bicalutamide|radiation therapy|placebo","Drug|Radiation|Drug","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy",2,"Hazard Ratio (HR)",1.11,0.213,"Gray's test",0.85,1.46,95,null,"NA","Male",840,"Active, not recruiting","Phase 3","\t"]
["NCT00002874",4515859,8267854,"Second PSA Recurrence (12-year Rates Reported)","bicalutamide","bicalutamide|radiation therapy|placebo","Drug|Radiation|Drug","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy",2,"Hazard Ratio (HR)",0.48,1E-3,"Gray's test",0.4,0.58,95,null,"NA","Male",840,"Active, not recruiting","Phase 3","\t"]
["NCT00002874",4515860,8267855,"Non-Prostate Cancer Death (12-year Rates Reported)","bicalutamide","bicalutamide|radiation therapy|placebo","Drug|Radiation|Drug","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy",2,"Cox Proportional Hazard",1.1,0.289,"Gray's test",0.79,1.53,95,null,"NA","Male",840,"Active, not recruiting","Phase 3","\t"]
["NCT00002874",4515861,8267856,"Overall Survival (12-year Rates Reported)","bicalutamide","bicalutamide|radiation therapy|placebo","Drug|Radiation|Drug","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy",2,"Hazard Ratio (HR)",0.77,0.02,"Log Rank",0.59,0.98,95,null,"NA","Male",840,"Active, not recruiting","Phase 3","\t"]
["NCT00003222",4514873,8265539,"Measure of Tumor-antigen-specific Immunity in Sentinel Immunized Node (SIN) by Elispot Assay","sargramostim|freund's adjuvant|aldesleukin|interleukin-2","aldesleukin|gp100 antigen|incomplete Freund's adjuvant|sargramostim|tetanus peptide melanoma vaccine|tyrosinase peptide","Biological|Biological|Biological|Biological|Biological|Biological","melanoma","Melanoma (Skin)","Parallel Assignment","Interventional","Treatment","Randomized","Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma",2,null,"NA",0.004,"Chi-squared",{"$nulls":4},"NA","All",40,"Completed","Phase 2","\t"]
["NCT00003222",4514874,8265540,"Measure of Tumor-antigen-specific Immunity in Peripheral Blood Mononuclear Cells (PBMC) by Elispot Assay","sargramostim|freund's adjuvant|aldesleukin|interleukin-2","aldesleukin|gp100 antigen|incomplete Freund's adjuvant|sargramostim|tetanus peptide melanoma vaccine|tyrosinase peptide","Biological|Biological|Biological|Biological|Biological|Biological","melanoma","Melanoma (Skin)","Parallel Assignment","Interventional","Treatment","Randomized","Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma",2,null,"NA",0.13,"Chi-squared",{"$nulls":4},"NA","All",40,"Completed","Phase 2","\t"]
["NCT00003389",4515850,8267831,"5-year Overall Survival","bleomycin|vinblastine|cyclophosphamide|dacarbazine|mechlorethamine|doxorubicin|vincristine|imidazole|etoposide phosphate|prednisone|liposomal doxorubicin|podophyllotoxin|etoposide","Doxorubicin|Bleomycin|Vinblastine|Dacarbazine|Vincristine|Mechlorethamine|Etoposide|Prednisone|Cyclophosphamide|Radiotherapy","Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Radiation","lymphoma","Lymphoma","Parallel Assignment","Interventional","Treatment","Randomized","Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma",2,null,"NA",0.86,"Log Rank",{"$nulls":4},"NA","All",854,"Completed","Phase 3","\t"]
["NCT00003389",4515851,8267832,"Failure-free Survival at 5 Years","bleomycin|vinblastine|cyclophosphamide|dacarbazine|mechlorethamine|doxorubicin|vincristine|imidazole|etoposide phosphate|prednisone|liposomal doxorubicin|podophyllotoxin|etoposide","Doxorubicin|Bleomycin|Vinblastine|Dacarbazine|Vincristine|Mechlorethamine|Etoposide|Prednisone|Cyclophosphamide|Radiotherapy","Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Radiation","lymphoma","Lymphoma","Parallel Assignment","Interventional","Treatment","Randomized","Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma",2,null,"NA",0.32,"Log Rank",{"$nulls":4},"NA","All",854,"Completed","Phase 3","\t"]
["NCT00003641",4515847,8267773,"5-year Overall Survival Rate","interferon alpha-2|interferons|interferon-alpha","interferon alfa-2b|observation","Biological|Other","melanoma","Melanoma (Skin)","Parallel Assignment","Interventional","Treatment","Randomized","High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma",2,null,"NA",0.558,"Log Rank",{"$nulls":4},"NA","All",1150,"Active, not recruiting","Phase 3","\t"]
["NCT00003641",4515848,8267774,"5-year Relapse-free Survival Rate","interferon alpha-2|interferons|interferon-alpha","interferon alfa-2b|observation","Biological|Other","melanoma","Melanoma (Skin)","Parallel Assignment","Interventional","Treatment","Randomized","High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma",2,null,"NA",0.964,"Log Rank",{"$nulls":4},"NA","All",1150,"Active, not recruiting","Phase 3","\t"]
["NCT00003869",4515842,8267747,"Clinically Significant (10-point) Decrease in Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) Quality of Life (QOL)Assessment From Baseline to Week 8","carboxyamido-triazole","carboxyamidotriazole|placebo|quality-of-life assessment|laboratory biomarker analysis","Drug|Other|Procedure|Other","lung neoplasms|carcinoma, non-small-cell lung","Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer",2,null,"NA",0.18,"Fisher Exact",{"$nulls":4},"NA","All",186,"Completed","Phase 3","\t"]
["NCT00003869",4515843,8267748,"Clinically Significant (10-point) Decrease in UNISCALE Quality of Life (QOL)Assessment From Baseline to Week 8","carboxyamido-triazole","carboxyamidotriazole|placebo|quality-of-life assessment|laboratory biomarker analysis","Drug|Other|Procedure|Other","lung neoplasms|carcinoma, non-small-cell lung","Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer",2,null,"NA",0.04,"Fisher Exact",{"$nulls":4},"NA","All",186,"Completed","Phase 3","\t"]
["NCT00003869",4515844,8267749,"Time to Disease Progression (TTP)","carboxyamido-triazole","carboxyamidotriazole|placebo|quality-of-life assessment|laboratory biomarker analysis","Drug|Other|Procedure|Other","lung neoplasms|carcinoma, non-small-cell lung","Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer",2,null,"NA",0.5,"Log Rank",{"$nulls":4},"NA","All",186,"Completed","Phase 3","\t"]
["NCT00003869",4515845,8267750,"Participants With Severe Non-hematologic Adverse Events","carboxyamido-triazole","carboxyamidotriazole|placebo|quality-of-life assessment|laboratory biomarker analysis","Drug|Other|Procedure|Other","lung neoplasms|carcinoma, non-small-cell lung","Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer",2,null,"NA",0.18,"Fisher Exact",{"$nulls":4},"NA","All",186,"Completed","Phase 3","\t"]
["NCT00003869",4515846,8267751,"Overall Survival (OS)","carboxyamido-triazole","carboxyamidotriazole|placebo|quality-of-life assessment|laboratory biomarker analysis","Drug|Other|Procedure|Other","lung neoplasms|carcinoma, non-small-cell lung","Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer",2,null,"NA",0.54,"Log Rank",{"$nulls":4},"NA","All",186,"Completed","Phase 3","\t"]
["NCT00003895",4515460,8266488,"T Cell Immunity to gp100 Peptide and to E7 12-20 Papilloma Virus Peptide","NA","HPV 16 E7:12-20|gp100:209-217(210M)|laboratory biomarker analysis","Biological|Biological|Other","melanoma","Recurrent Melanoma|Stage IA Melanoma|Stage IB Melanoma|Stage IIA Melanoma|Stage IIB Melanoma|Stage IIC Melanoma|Stage IIIA Melanoma|Stage IIIB Melanoma|Stage IIIC Melanoma","Parallel Assignment","Interventional","Treatment","Randomized","Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma",2,null,"NA",0.59,"t-test, 2 sided",{"$nulls":4},"NA","All",36,"Completed","Phase 2","\t"]
["NCT00003895",4515462,8266488,"T Cell Immunity to gp100 Peptide and to E7 12-20 Papilloma Virus Peptide","NA","HPV 16 E7:12-20|gp100:209-217(210M)|laboratory biomarker analysis","Biological|Biological|Other","melanoma","Recurrent Melanoma|Stage IA Melanoma|Stage IB Melanoma|Stage IIA Melanoma|Stage IIB Melanoma|Stage IIC Melanoma|Stage IIIA Melanoma|Stage IIIB Melanoma|Stage IIIC Melanoma","Parallel Assignment","Interventional","Treatment","Randomized","Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma",2,null,"NA",1E-3,"t-test, 2 sided",{"$nulls":4},"NA","All",36,"Completed","Phase 2","\t"]
["NCT00003895",4515461,8266488,"T Cell Immunity to gp100 Peptide and to E7 12-20 Papilloma Virus Peptide","NA","HPV 16 E7:12-20|gp100:209-217(210M)|laboratory biomarker analysis","Biological|Biological|Other","melanoma","Recurrent Melanoma|Stage IA Melanoma|Stage IB Melanoma|Stage IIA Melanoma|Stage IIB Melanoma|Stage IIC Melanoma|Stage IIIA Melanoma|Stage IIIB Melanoma|Stage IIIC Melanoma","Parallel Assignment","Interventional","Treatment","Randomized","Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma",2,null,"NA",{"v":1E-4,"d":"1.00E-04"},"t-test, 2 sided",{"$nulls":4},"NA","All",36,"Completed","Phase 2","\t"]
["NCT00004054",4515833,8267725,"Disease-free Survival Rate at 5 Years","estramustine|paclitaxel|prolactin release-inhibiting factors|warfarin|hormones|bicalutamide|flutamide|etoposide","bicalutamide|estramustine phosphate sodium|etoposide|flutamide|paclitaxel|Luteinizing hormone releasing hormone [LHRH] agonist|Radiation therapy|warfarin","Drug|Drug|Drug|Drug|Drug|Drug|Radiation|Drug","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer",2,"Hazard Ratio (HR)",0.94,0.61,"Log Rank",0.75,1.19,95,null,"NA","Male",397,"Completed","Phase 3","\t"]
["NCT00004054",4515834,8267726,"Rate of Distant Metastasis at Five Years","estramustine|paclitaxel|prolactin release-inhibiting factors|warfarin|hormones|bicalutamide|flutamide|etoposide","bicalutamide|estramustine phosphate sodium|etoposide|flutamide|paclitaxel|Luteinizing hormone releasing hormone [LHRH] agonist|Radiation therapy|warfarin","Drug|Drug|Drug|Drug|Drug|Drug|Radiation|Drug","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer",2,"Hazard Ratio (HR)",0.81,0.42,"Gray's test",0.48,1.36,95,null,"NA","Male",397,"Completed","Phase 3","\t"]
["NCT00004054",4515835,8267727,"Rate of Local Progression at 5 Years","estramustine|paclitaxel|prolactin release-inhibiting factors|warfarin|hormones|bicalutamide|flutamide|etoposide","bicalutamide|estramustine phosphate sodium|etoposide|flutamide|paclitaxel|Luteinizing hormone releasing hormone [LHRH] agonist|Radiation therapy|warfarin","Drug|Drug|Drug|Drug|Drug|Drug|Radiation|Drug","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer",2,"Hazard Ratio (HR)",0.56,0.09,"Gray's test",0.28,1.1,95,null,"NA","Male",397,"Completed","Phase 3","\t"]
["NCT00004054",4515836,8267728,"Rate of Biochemical Failure at 5 Years","estramustine|paclitaxel|prolactin release-inhibiting factors|warfarin|hormones|bicalutamide|flutamide|etoposide","bicalutamide|estramustine phosphate sodium|etoposide|flutamide|paclitaxel|Luteinizing hormone releasing hormone [LHRH] agonist|Radiation therapy|warfarin","Drug|Drug|Drug|Drug|Drug|Drug|Radiation|Drug","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer",2,"Hazard Ratio (HR)",0.97,0.82,"Gray's test",0.74,1.27,95,null,"NA","Male",397,"Completed","Phase 3","\t"]
["NCT00004054",4515837,8267729,"Overall Survival (5-year Rate Reported)","estramustine|paclitaxel|prolactin release-inhibiting factors|warfarin|hormones|bicalutamide|flutamide|etoposide","bicalutamide|estramustine phosphate sodium|etoposide|flutamide|paclitaxel|Luteinizing hormone releasing hormone [LHRH] agonist|Radiation therapy|warfarin","Drug|Drug|Drug|Drug|Drug|Drug|Radiation|Drug","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer",2,"Hazard Ratio (HR)",1.04,0.81,"Log Rank",0.76,1.43,95,null,"NA","Male",397,"Completed","Phase 3","\t"]
["NCT00004124",4515831,8267715,"Disease Free Survival","prednisone|goserelin|mitoxantrone|bicalutamide","bicalutamide|goserelin|mitoxantrone hydrochloride|prednisone","Drug|Drug|Drug|Drug","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer",2,"Hazard Ratio (HR)",1.01,0.94,"Regression, Cox",0.8,1.27,95,null,"NA","Male",983,"Completed","Phase 3","\t"]
["NCT00004124",4515832,8267716,"Overall Survival","prednisone|goserelin|mitoxantrone|bicalutamide","bicalutamide|goserelin|mitoxantrone hydrochloride|prednisone","Drug|Drug|Drug|Drug","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer",2,"Hazard Ratio (HR)",1.06,0.7,"Regression, Cox",0.79,1.43,95,null,"NA","Male",983,"Completed","Phase 3","\t"]
["NCT00004228",4515829,8267705,"Event-free Survival","cytarabine|daunorubicin|doxorubicin|prednisone|liposomal doxorubicin|vincristine|thioguanine|cyclophosphamide|mercaptopurine|asparaginase|leucovorin|levoleucovorin|dexamethasone|methotrexate","asparaginase|cyclophosphamide|cytarabine|daunorubicin hydrochloride|dexamethasone|doxorubicin hydrochloride|leucovorin calcium|mercaptopurine|methotrexate|prednisone|thioguanine|vincristine sulfate|radiation therapy","Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Radiation","lymphoma, non-hodgkin|lymphoma|precursor cell lymphoblastic leukemia-lymphoma","Lymphoma","Parallel Assignment","Interventional","Treatment","Randomized","Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma",7,null,"NA",0.63,"Regression, Cox",{"$nulls":4},"NA","All",393,"Completed","Phase 3","\t"]
["NCT00004228",4515830,8267705,"Event-free Survival","cytarabine|daunorubicin|doxorubicin|prednisone|liposomal doxorubicin|vincristine|thioguanine|cyclophosphamide|mercaptopurine|asparaginase|leucovorin|levoleucovorin|dexamethasone|methotrexate","asparaginase|cyclophosphamide|cytarabine|daunorubicin hydrochloride|dexamethasone|doxorubicin hydrochloride|leucovorin calcium|mercaptopurine|methotrexate|prednisone|thioguanine|vincristine sulfate|radiation therapy","Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Radiation","lymphoma, non-hodgkin|lymphoma|precursor cell lymphoblastic leukemia-lymphoma","Lymphoma","Parallel Assignment","Interventional","Treatment","Randomized","Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma",7,null,"NA",0.97,"Regression, Cox",{"$nulls":4},"NA","All",393,"Completed","Phase 3","\t"]
["NCT00004259",4515823,8267698,"(Phase III) Progression-free Survival by MGMT Status","carmustine","BCNU 80mg/m2|TMZ 200mg/m2|radiation therapy|CCNU|BCNU 150mg/m2|BCNU 200mg/m2|TMZ 150mg/m2 six 6-week cycles|TMZ 150mg/m2 six 8-week cycles","Drug|Drug|Radiation|Drug|Drug|Drug|Drug|Drug","astrocytoma|nervous system neoplasms|central nervous system neoplasms","Brain and Central Nervous System Tumors","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas",4,"Hazard Ratio (HR)",1.29,0.41,"Log Rank",0.7,2.35,95,null,"NA","All",230,"Completed","Phase 3","\t"]
["NCT00004259",4515824,8267699,"(Phase III) Survival Time by MGMT Status","carmustine","BCNU 80mg/m2|TMZ 200mg/m2|radiation therapy|CCNU|BCNU 150mg/m2|BCNU 200mg/m2|TMZ 150mg/m2 six 6-week cycles|TMZ 150mg/m2 six 8-week cycles","Drug|Drug|Radiation|Drug|Drug|Drug|Drug|Drug","astrocytoma|nervous system neoplasms|central nervous system neoplasms","Brain and Central Nervous System Tumors","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas",4,"Hazard Ratio (HR)",1.78,0.08,"Log Rank",0.93,3.4,95,null,"NA","All",230,"Completed","Phase 3","\t"]
["NCT00004259",4515826,8267700,"(Phase III) Number of Patients With Grade 3 or Higher Toxicity","carmustine","BCNU 80mg/m2|TMZ 200mg/m2|radiation therapy|CCNU|BCNU 150mg/m2|BCNU 200mg/m2|TMZ 150mg/m2 six 6-week cycles|TMZ 150mg/m2 six 8-week cycles","Drug|Drug|Radiation|Drug|Drug|Drug|Drug|Drug","astrocytoma|nervous system neoplasms|central nervous system neoplasms","Brain and Central Nervous System Tumors","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",230,"Completed","Phase 3","\t"]
["NCT00004259",4515825,8267700,"(Phase III) Number of Patients With Grade 3 or Higher Toxicity","carmustine","BCNU 80mg/m2|TMZ 200mg/m2|radiation therapy|CCNU|BCNU 150mg/m2|BCNU 200mg/m2|TMZ 150mg/m2 six 6-week cycles|TMZ 150mg/m2 six 8-week cycles","Drug|Drug|Radiation|Drug|Drug|Drug|Drug|Drug","astrocytoma|nervous system neoplasms|central nervous system neoplasms","Brain and Central Nervous System Tumors","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas",4,null,"NA",0.76,"Chi-squared",{"$nulls":4},"NA","All",230,"Completed","Phase 3","\t"]
["NCT00004259",4515827,8267701,"(Phase III) Time to Tumor Progression (TTP)","carmustine","BCNU 80mg/m2|TMZ 200mg/m2|radiation therapy|CCNU|BCNU 150mg/m2|BCNU 200mg/m2|TMZ 150mg/m2 six 6-week cycles|TMZ 150mg/m2 six 8-week cycles","Drug|Drug|Radiation|Drug|Drug|Drug|Drug|Drug","astrocytoma|nervous system neoplasms|central nervous system neoplasms","Brain and Central Nervous System Tumors","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas",4,"Hazard Ratio (HR)",0.8,0.46,"Gray's test",0.55,1.16,95,null,"NA","All",230,"Completed","Phase 3","\t"]
["NCT00004259",4515828,8267703,"(Phase III) Overall Survival (OS)","carmustine","BCNU 80mg/m2|TMZ 200mg/m2|radiation therapy|CCNU|BCNU 150mg/m2|BCNU 200mg/m2|TMZ 150mg/m2 six 6-week cycles|TMZ 150mg/m2 six 8-week cycles","Drug|Drug|Radiation|Drug|Drug|Drug|Drug|Drug","astrocytoma|nervous system neoplasms|central nervous system neoplasms","Brain and Central Nervous System Tumors","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas",4,"Hazard Ratio (HR)",0.94,0.36,"Log Rank",0.67,1.32,95,null,"NA","All",230,"Completed","Phase 3","\t"]
["NCT00004412",4517009,8269119,"Healing Defined as a Decrease in Ulcer Area by at Least 25% of the Initial Area","arginine butyrate","Arginine Butyrate|Standard local care dressing","Drug|Other","anemia, sickle cell|skin ulcer|ulcer","Sickle Cell Anemia|Skin Ulcers","Parallel Assignment","Interventional","Treatment","Randomized","Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers",3,"Mean Difference (Final Values)",0.5,0.05,"Fisher Exact",{"$nulls":4},"NA","All",23,"Completed","Phase 2","\t"]
["NCT00004732",4516985,8268997,"Differential Efficacy of CAS and CEA in Male and Female Participants in the Primary Endpoint (Any Periprocedural Stroke, Myocardial Infarction, or Death or Postprocedural Ipsilateral Stroke).","NA","Carotid Endarterectomy (CEA)|Carotid Artery Stenting (CAS)","Procedure|Device","myocardial infarction|cerebral infarction|carotid stenosis|infarction|atherosclerosis","Atherosclerosis|Carotid Stenosis|Cerebral Infarction|Myocardial Infarction|Stroke","Parallel Assignment","Interventional","Prevention","Randomized","Carotid Revascularization Endarterectomy Versus Stenting Trial",2,"Hazard Ratio (HR)",1.35,"NA",null,0.82,2.23,95,null,"NA","All",2502,"Completed","N/A","\t"]
["NCT00004732",4516986,8268998,"Any Periprocedural Stroke, Myocardial Infarction, or Death During a 30-day Peri-procedural Period, and Postprocedural Ipsilateral Stroke Thereafter, up to 4-years.","NA","Carotid Endarterectomy (CEA)|Carotid Artery Stenting (CAS)","Procedure|Device","myocardial infarction|cerebral infarction|carotid stenosis|infarction|atherosclerosis","Atherosclerosis|Carotid Stenosis|Cerebral Infarction|Myocardial Infarction|Stroke","Parallel Assignment","Interventional","Prevention","Randomized","Carotid Revascularization Endarterectomy Versus Stenting Trial",2,"Hazard Ratio (HR)",1.11,"NA",null,0.81,1.51,95,null,"NA","All",2502,"Completed","N/A","\t"]
["NCT00004859",4515822,8267695,"Overall Survival Time","carboplatin|paclitaxel|thalidomide","carboplatin|paclitaxel|thalidomide|radiation therapy","Drug|Drug|Drug|Radiation","carcinoma, non-small-cell lung|lung neoplasms","Lung Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer",2,null,"NA",0.99,"Log Rank",{"$nulls":4},"NA","All",589,"Terminated","Phase 3","\t"]
["NCT00004978",4516929,8268880,"Hepatic, Metabolic, and Cardiac Conditions","interleukin-2|aldesleukin","Recombinant interleukin-2 (rIL-2)","Drug","infection","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy",2,"Hazard Ratio (HR)",0.96,0.74,"Regression, Cox",0.76,1.22,95,null,"NA","All",4150,"Completed","Phase 3","\t"]
["NCT00004978",4516930,8268881,"Pattern of Use of Prophylaxis for Opportunistic Infections","interleukin-2|aldesleukin","Recombinant interleukin-2 (rIL-2)","Drug","infection","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy",2,null,"NA",0.97,"Chi-squared",{"$nulls":4},"NA","All",4150,"Completed","Phase 3","\t"]
["NCT00004978",4516931,8268882,"Grade 4 Signs and Symptoms","interleukin-2|aldesleukin","Recombinant interleukin-2 (rIL-2)","Drug","infection","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy",2,"Hazard Ratio (HR)",1.23,0.003,"Regression, Cox",1.07,1.41,95,null,"NA","All",4150,"Completed","Phase 3","\t"]
["NCT00004978",4516932,8268883,"Number of Participants With Changes in Anti-retroviral Treatment (ART)","interleukin-2|aldesleukin","Recombinant interleukin-2 (rIL-2)","Drug","infection","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy",2,"Hazard Ratio (HR)",0.94,0.07,"Regression, Cox",0.88,1,95,null,"NA","All",4150,"Completed","Phase 3","\t"]
["NCT00004978",4516933,8268885,"Absolute CD4 Cell Counts Averaged Throughout Followup","interleukin-2|aldesleukin","Recombinant interleukin-2 (rIL-2)","Drug","infection","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy",2,"Mean Difference (Final Values)",159,"NA",null,145,174,95,null,"NA","All",4150,"Completed","Phase 3","\t"]
["NCT00004978",4516934,8268886,"Participants With a New Disease Progression Event or Death","interleukin-2|aldesleukin","Recombinant interleukin-2 (rIL-2)","Drug","infection","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy",2,"Hazard Ratio (HR)",0.91,0.41,"Regression, Cox",0.73,1.14,95,null,"NA","All",4150,"Completed","Phase 3","\t"]
["NCT00004978",4516935,8268887,"Number of Participants Who Died From Any Cause","interleukin-2|aldesleukin","Recombinant interleukin-2 (rIL-2)","Drug","infection","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy",2,"Hazard Ratio (HR)",0.9,0.42,"Regression, Cox",0.69,1.17,95,null,"NA","All",4150,"Completed","Phase 3","\t"]
["NCT00004978",4516936,8268888,"New or Recurrent Serious HIV Disease Progression Event Including Death","interleukin-2|aldesleukin","Recombinant interleukin-2 (rIL-2)","Drug","infection","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy",2,"Hazard Ratio (HR)",0.94,0.62,"Regression, Cox",0.74,1.2,95,null,"NA","All",4150,"Completed","Phase 3","\t"]
["NCT00004978",4516937,8268889,"New or Recurrent HIV Disease Progression Event Including Death","interleukin-2|aldesleukin","Recombinant interleukin-2 (rIL-2)","Drug","infection","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy",2,"Hazard Ratio (HR)",0.94,0.55,"Regression, Cox",0.75,1.16,95,null,"NA","All",4150,"Completed","Phase 3","\t"]
["NCT00004980",4516981,8268993,"Responder Status","NA","repetitive transcranial magnetic stimulation (rTMS)|sham stimulation","Device|Device","schizophrenia","Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Repetitive Transcranial Magnetic Stimulation for \"Voices\"",2,null,"NA",0.01,"Chi-squared",{"$nulls":4},"NA","All",50,"Completed","Phase 2","\t"]
["NCT00004980",4516982,8268994,"Clinical Global Improvement (CGI) Scale After 9 Active/Shame rTMS Sessions","NA","repetitive transcranial magnetic stimulation (rTMS)|sham stimulation","Device|Device","schizophrenia","Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Repetitive Transcranial Magnetic Stimulation for \"Voices\"",2,"Median Difference (Final Values)",-0.949,1E-3,"t-test, 2 sided",-1.45,-0.44,95,"Standard Error of the Mean",0.524,"All",50,"Completed","Phase 2","\t"]
["NCT00004980",4516983,8268995,"Change From Baseline in Hallucination Frequency After 9 Active/Shame rTMS Sessions","NA","repetitive transcranial magnetic stimulation (rTMS)|sham stimulation","Device|Device","schizophrenia","Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Repetitive Transcranial Magnetic Stimulation for \"Voices\"",2,"Mean Difference (Final Values)",1.27,2E-3,"t-test, 2 sided",0.507,2.03,95,"Standard Error of the Mean",0.327,"All",50,"Completed","Phase 2","\t"]
["NCT00004980",4516984,8268996,"Hallucination Change Score (HCS) After 9 Active/Sham rTMS Sessions","NA","repetitive transcranial magnetic stimulation (rTMS)|sham stimulation","Device|Device","schizophrenia","Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Repetitive Transcranial Magnetic Stimulation for \"Voices\"",2,"Mean Difference (Final Values)",-2.76,0.005,"t-test, 2 sided",-4.65,-0.86,95,"Standard Error of the Mean",0.514,"All",50,"Completed","Phase 2","\t"]
["NCT00005044",4515812,8267683,"Time to Second Biochemical Failure (SBF) (10-year Rates Reported)","bicalutamide|hormones|flutamide|prolactin release-inhibiting factors","Casodex|Eulexin|LHRH agonist|radiation therapy","Drug|Drug|Drug|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer",2,"Hazard Ratio (HR)",0.91,0.62,"Log Rank",0.64,1.3,95,null,"NA","Male",1579,"Active, not recruiting","Phase 3","\t"]
["NCT00005044",4515813,8267684,"Time to First Biochemical Failure (BF) (10-year Rates Reported)","bicalutamide|hormones|flutamide|prolactin release-inhibiting factors","Casodex|Eulexin|LHRH agonist|radiation therapy","Drug|Drug|Drug|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer",2,"Hazard Ratio (HR)",0.97,0.77,"Gray's test",0.79,1.19,95,null,"NA","Male",1579,"Active, not recruiting","Phase 3","\t"]
["NCT00005044",4515814,8267684,"Time to First Biochemical Failure (BF) (10-year Rates Reported)","bicalutamide|hormones|flutamide|prolactin release-inhibiting factors","Casodex|Eulexin|LHRH agonist|radiation therapy","Drug|Drug|Drug|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer",2,"Hazard Ratio (HR)",1.02,0.74,"Gray's test",0.89,1.17,95,null,"NA","Male",1579,"Active, not recruiting","Phase 3","\t"]
["NCT00005044",4515815,8267685,"Clinical Patterns of Tumor Recurrence: Time to Locoregional Progression (LRP) and Time to Distant Metastasis (DM) (10 Year Rates Reported)","bicalutamide|hormones|flutamide|prolactin release-inhibiting factors","Casodex|Eulexin|LHRH agonist|radiation therapy","Drug|Drug|Drug|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer",2,"Hazard Ratio (HR)",1.07,0.8,"Gray's test",0.68,1.66,95,null,"NA","Male",1579,"Active, not recruiting","Phase 3","\t"]
["NCT00005044",4515816,8267685,"Clinical Patterns of Tumor Recurrence: Time to Locoregional Progression (LRP) and Time to Distant Metastasis (DM) (10 Year Rates Reported)","bicalutamide|hormones|flutamide|prolactin release-inhibiting factors","Casodex|Eulexin|LHRH agonist|radiation therapy","Drug|Drug|Drug|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer",2,"Hazard Ratio (HR)",0.65,0.07,"Gray's test",0.4,1.05,95,null,"NA","Male",1579,"Active, not recruiting","Phase 3","\t"]
["NCT00005044",4515817,8267686,"Disease-free Survival (DFS) (10-year Rates Reported)","bicalutamide|hormones|flutamide|prolactin release-inhibiting factors","Casodex|Eulexin|LHRH agonist|radiation therapy","Drug|Drug|Drug|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer",2,"Hazard Ratio (HR)",0.96,0.47,"Log Rank",0.85,1.08,95,null,"NA","Male",1579,"Active, not recruiting","Phase 3","\t"]
["NCT00005044",4515818,8267687,"Overall Survival (OS) (10-year Rates Reported)","bicalutamide|hormones|flutamide|prolactin release-inhibiting factors","Casodex|Eulexin|LHRH agonist|radiation therapy","Drug|Drug|Drug|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer",2,"Hazard Ratio (HR)",0.95,0.62,"Log Rank",0.79,1.15,95,null,"NA","Male",1579,"Active, not recruiting","Phase 3","\t"]
["NCT00005044",4515819,8267688,"Disease-specific Survival (DSS) (10-year Rates Reported)","bicalutamide|hormones|flutamide|prolactin release-inhibiting factors","Casodex|Eulexin|LHRH agonist|radiation therapy","Drug|Drug|Drug|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer",2,"Hazard Ratio (HR)",0.81,0.45,"Log Rank",0.48,1.39,95,null,"NA","Male",1579,"Active, not recruiting","Phase 3","\t"]
["NCT00005957",4515810,8267670,"Disease-free Survival","NA","Standard Breast Irradiation|Breast Radiation plus Regional Radiation","Radiation|Radiation","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer",2,"Hazard Ratio (HR)",0.76,0.01,"Log Rank",0.61,0.94,95,null,"NA","Female",1832,"Completed","N/A","\t"]
["NCT00005957",4515811,8267671,"Overall Survival","NA","Standard Breast Irradiation|Breast Radiation plus Regional Radiation","Radiation|Radiation","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer",2,"Hazard Ratio (HR)",0.91,0.38,"Log Rank",0.72,1.13,95,null,"NA","Female",1832,"Completed","N/A","\t"]
["NCT00006011",4515809,8267669,"Recurrence-Free Survival of Eligible Patients Who Received a Random Treatment Allocation.","lenograstim|paclitaxel|liposomal doxorubicin|doxorubicin","Doxorubicin Hydrochloride|Cisplatin|Filgrastim|Pegfilgrastim|Paclitaxel","Drug|Drug|Biological|Biological|Drug","carcinoma|carcinoma, endometrioid|adenocarcinoma, clear cell|adenocarcinoma|cystadenocarcinoma, serous|carcinoma, adenosquamous","Endometrial Adenocarcinoma|Endometrial Adenosquamous Carcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation|Endometrial Serous Adenocarcinoma|Stage III Uterine Corpus Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer",2,"Hazard Ratio (HR)",0.9,"NA",null,0.69,1.17,95,null,"NA","Female",659,"Completed","Phase 3","\t"]
["NCT00006237",4515807,8267660,"5-year Relapse-Free Survival","interferon-alpha|vinblastine|interferons|aldesleukin|interleukin-2|dacarbazine","interleukin-2|filgrastim|interferon alfa|cisplatin|dacarbazine|vinblastine","Biological|Biological|Biological|Drug|Drug|Drug","melanoma","Melanoma (Skin)","Parallel Assignment","Interventional","Treatment","Randomized","S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma",2,null,"NA",0.02,"Log Rank",{"$nulls":4},"NA","All",432,"Completed","Phase 3","\t"]
["NCT00006237",4515808,8267661,"5-year Overall Survival","interferon-alpha|vinblastine|interferons|aldesleukin|interleukin-2|dacarbazine","interleukin-2|filgrastim|interferon alfa|cisplatin|dacarbazine|vinblastine","Biological|Biological|Biological|Drug|Drug|Drug","melanoma","Melanoma (Skin)","Parallel Assignment","Interventional","Treatment","Randomized","S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma",2,null,"NA",0.49,"Log Rank",{"$nulls":4},"NA","All",432,"Completed","Phase 3","\t"]
["NCT00006289",4516969,8268944,"McGill Pain Questionnaire (MPQ) of Scores After Administration of Test Drugs (Neurotropin or Placebo)","neurotropin","Placebo|Neurotropin","Drug|Drug","neuralgia|complex regional pain syndromes|reflex sympathetic dystrophy|causalgia|syndrome|somatoform disorders","Complex Regional Pain Syndrome Type I|Complex Regional Pain Syndrome Type II","Crossover Assignment","Interventional","Treatment","Randomized","Neurotropin to Treat Chronic Neuropathic Pain",2,null,"NA",0.0058,"t-test, 1 sided",{"$nulls":4},"NA","All",21,"Terminated","Phase 2","\t"]
["NCT00006289",4516970,8268945,"Numeric Rating Scale (NRS) of Pain Scores After Administration of Test Drugs (Neurotropin or Placebo)","neurotropin","Placebo|Neurotropin","Drug|Drug","neuralgia|complex regional pain syndromes|reflex sympathetic dystrophy|causalgia|syndrome|somatoform disorders","Complex Regional Pain Syndrome Type I|Complex Regional Pain Syndrome Type II","Crossover Assignment","Interventional","Treatment","Randomized","Neurotropin to Treat Chronic Neuropathic Pain",2,null,"NA",0.0058,"t-test, 1 sided",{"$nulls":4},"NA","All",21,"Terminated","Phase 2","\t"]
["NCT00006289",4516971,8268946,"Visual Analogue Scale (VAS) of Pain Scores After Administration of Test Drugs (Placebo or Neurotropin )","neurotropin","Placebo|Neurotropin","Drug|Drug","neuralgia|complex regional pain syndromes|reflex sympathetic dystrophy|causalgia|syndrome|somatoform disorders","Complex Regional Pain Syndrome Type I|Complex Regional Pain Syndrome Type II","Crossover Assignment","Interventional","Treatment","Randomized","Neurotropin to Treat Chronic Neuropathic Pain",2,null,"NA",0.0058,"t-test, 1 sided",{"$nulls":4},"NA","All",21,"Terminated","Phase 2","\t"]
["NCT00006400",4516961,8268938,"Change From Baseline in the Renal Function That Was Measured by GFR (Calculated Using New Schwartz Formula)","hydroxyurea","Hydroxyurea|Placebo","Drug|Drug","anemia|anemia, sickle cell|hematologic diseases","Anemia, Sickle Cell|Hematologic Diseases","Parallel Assignment","Interventional","Prevention","Randomized","Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia",2,null,"NA",0.48,"ANOVA",{"$nulls":4},"NA","All",193,"Completed","Phase 3","\t"]
["NCT00006400",4516962,8268939,"Change From Baseline in the Renal Function That Was Measured by Glomerular Filtration Rate (GFR) (Calculated Using Schwartz Formula)","hydroxyurea","Hydroxyurea|Placebo","Drug|Drug","anemia|anemia, sickle cell|hematologic diseases","Anemia, Sickle Cell|Hematologic Diseases","Parallel Assignment","Interventional","Prevention","Randomized","Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia",2,null,"NA",0.43,"ANOVA",{"$nulls":4},"NA","All",193,"Completed","Phase 3","\t"]
["NCT00006400",4516963,8268940,"Change From Baseline in the Renal Function That Was Measured by Diethylenetriaminepentaacetic Acid (DTPA) Glomerular Filtration Rate (GFR)","hydroxyurea","Hydroxyurea|Placebo","Drug|Drug","anemia|anemia, sickle cell|hematologic diseases","Anemia, Sickle Cell|Hematologic Diseases","Parallel Assignment","Interventional","Prevention","Randomized","Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia",2,null,"NA",0.93,"ANOVA",{"$nulls":4},"NA","All",193,"Completed","Phase 3","\t"]
["NCT00006400",4516964,8268941,"Treatment Differences of the Change in Qualitative Splenic Function From Baseline","hydroxyurea","Hydroxyurea|Placebo","Drug|Drug","anemia|anemia, sickle cell|hematologic diseases","Anemia, Sickle Cell|Hematologic Diseases","Parallel Assignment","Interventional","Prevention","Randomized","Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia",2,null,"NA",0.21,"Fisher Exact",{"$nulls":4},"NA","All",193,"Completed","Phase 3","\t"]
["NCT00006721",4515787,8267635,"Overall Survival at 2 Years","cyclophosphamide|prednisone|vincristine|rituximab|doxorubicin","rituximab|cyclophosphamide|doxorubicin|prednisone|vincristine|tositumomab","Biological|Drug|Drug|Drug|Drug|Radiation","lymphoma, non-hodgkin|lymphoma","Lymphoma","Parallel Assignment","Interventional","Treatment","Randomized","S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma",3,"Hazard Ratio (HR)",1.55,0.08,"Regression, Cox",0.95,2.54,95,null,"NA","All",571,"Active, not recruiting","Phase 3","\t"]
["NCT00006721",4515788,8267639,"Progression-free Survival at 2 Years","cyclophosphamide|prednisone|vincristine|rituximab|doxorubicin","rituximab|cyclophosphamide|doxorubicin|prednisone|vincristine|tositumomab","Biological|Drug|Drug|Drug|Drug|Radiation","lymphoma, non-hodgkin|lymphoma","Lymphoma","Parallel Assignment","Interventional","Treatment","Randomized","S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma",3,"Hazard Ratio (HR)",0.79,0.11,"Regression, Cox",0.6,1.05,95,null,"NA","All",571,"Active, not recruiting","Phase 3","\t"]
["NCT00007345",4516960,8268922,"Number of Participants With Adverse Events","romidepsin","Romidepsin","Drug","lymphoma, t-cell, peripheral|lymphoma, t-cell|lymphoma|lymphoma, t-cell, cutaneous","Cutaneous T Cell Lymphoma|Peripheral T Cell Lymphoma","Parallel Assignment","Interventional","Treatment","Randomized","Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma",2,null,"NA",0.01,"Cochran-Armitage trend test",{"$nulls":4},"NA","All",131,"Completed","Phase 2","\t"]
["NCT00008385",4515784,8267625,"5-year Overall Survival Rate","selenium","placebo|selenium","Other|Drug","carcinoma, non-small-cell lung|lung neoplasms","Lung Cancer","Parallel Assignment","Interventional","Prevention","Randomized","Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer",2,null,"NA",0.154,"Log Rank",{"$nulls":4},"NA","All",1772,"Completed","Phase 3","\t"]
["NCT00008385",4515785,8267626,"5-year Progression-free Survival Rate","selenium","placebo|selenium","Other|Drug","carcinoma, non-small-cell lung|lung neoplasms","Lung Cancer","Parallel Assignment","Interventional","Prevention","Randomized","Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer",2,null,"NA",0.069,"Log Rank",{"$nulls":4},"NA","All",1772,"Completed","Phase 3","\t"]
["NCT00008385",4515786,8267627,"Incidence Rate of Second Primary Lung Tumor","selenium","placebo|selenium","Other|Drug","carcinoma, non-small-cell lung|lung neoplasms","Lung Cancer","Parallel Assignment","Interventional","Prevention","Randomized","Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer",2,"Risk Ratio (RR)",1.25,0.294,"Log Rank",0.64,2.37,95,null,"NA","All",1772,"Completed","Phase 3","\t"]
["NCT00009737",4514767,8265281,"Overall Survival","capecitabine|leucovorin|fluorouracil","5-Fluorouracil|Leucovorin|Capecitabine [Xeloda]","Drug|Drug|Drug","colonic neoplasms","Colorectal Cancer","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer",2,"Hazard Ratio (HR)",0.84,0.071,"Wald Chi-Square Test",0.69,1.01,95,null,"NA","All",1987,"Completed","Phase 3","\t"]
["NCT00009737",4514768,8265282,"Relapse-Free Survival","capecitabine|leucovorin|fluorouracil","5-Fluorouracil|Leucovorin|Capecitabine [Xeloda]","Drug|Drug|Drug","colonic neoplasms","Colorectal Cancer","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer",2,"Hazard Ratio (HR)",0.86,0.041,"Wald Chi-Square Test",0.74,0.99,95,null,"NA","All",1987,"Completed","Phase 3","\t"]
["NCT00009737",4514769,8265283,"Disease-free Survival","capecitabine|leucovorin|fluorouracil","5-Fluorouracil|Leucovorin|Capecitabine [Xeloda]","Drug|Drug|Drug","colonic neoplasms","Colorectal Cancer","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer",2,"Hazard Ratio (HR)",0.87,0.053,"Wald Chi-Square Test",0.75,1,95,null,"NA","All",1987,"Completed","Phase 3","\t"]
["NCT00010803",4516946,8268904,"Progression of Cognitive Decline in Standardized Z-score Scale. Higher Z-scores Indicate Worse Performance.","NA","Ginkgo biloba|Placebo","Drug|Drug","alzheimer disease","Alzheimer's Disease|Dementia","Parallel Assignment","Interventional","Prevention","Randomized","Ginkgo Biloba Prevention Trial in Older Individuals",2,"Treatment X Time interaction",-2E-3,0.65,"Mixed Models Analysis",-0.009,0.005,95,null,"NA","All",3069,"Completed","Phase 3","\t"]
["NCT00010803",4516951,8268905,"Number of Participants With the Indicated Cardiovascular Disease or Mortality","NA","Ginkgo biloba|Placebo","Drug|Drug","alzheimer disease","Alzheimer's Disease|Dementia","Parallel Assignment","Interventional","Prevention","Randomized","Ginkgo Biloba Prevention Trial in Older Individuals",2,"Hazard Ratio (HR)",0.91,0.48,"Log Rank",0.71,1.18,95,null,"NA","All",3069,"Completed","Phase 3","\t"]
["NCT00010803",4516954,8268905,"Number of Participants With the Indicated Cardiovascular Disease or Mortality","NA","Ginkgo biloba|Placebo","Drug|Drug","alzheimer disease","Alzheimer's Disease|Dementia","Parallel Assignment","Interventional","Prevention","Randomized","Ginkgo Biloba Prevention Trial in Older Individuals",2,"Hazard Ratio (HR)",1.12,0.54,"Log Rank",0.79,1.58,95,null,"NA","All",3069,"Completed","Phase 3","\t"]
["NCT00010803",4516949,8268905,"Number of Participants With the Indicated Cardiovascular Disease or Mortality","NA","Ginkgo biloba|Placebo","Drug|Drug","alzheimer disease","Alzheimer's Disease|Dementia","Parallel Assignment","Interventional","Prevention","Randomized","Ginkgo Biloba Prevention Trial in Older Individuals",2,"Hazard Ratio (HR)",0.87,0.59,"Log Rank",0.52,1.45,95,null,"NA","All",3069,"Completed","Phase 3","\t"]
["NCT00010803",4516955,8268905,"Number of Participants With the Indicated Cardiovascular Disease or Mortality","NA","Ginkgo biloba|Placebo","Drug|Drug","alzheimer disease","Alzheimer's Disease|Dementia","Parallel Assignment","Interventional","Prevention","Randomized","Ginkgo Biloba Prevention Trial in Older Individuals",2,"Hazard Ratio (HR)",1.06,0.78,"Log Rank",0.7,1.62,95,null,"NA","All",3069,"Completed","Phase 3","\t"]
["NCT00010803",4516950,8268905,"Number of Participants With the Indicated Cardiovascular Disease or Mortality","NA","Ginkgo biloba|Placebo","Drug|Drug","alzheimer disease","Alzheimer's Disease|Dementia","Parallel Assignment","Interventional","Prevention","Randomized","Ginkgo Biloba Prevention Trial in Older Individuals",2,"Hazard Ratio (HR)",0.87,0.25,"Log Rank",0.52,1.45,95,null,"NA","All",3069,"Completed","Phase 3","\t"]
["NCT00010803",4516947,8268905,"Number of Participants With the Indicated Cardiovascular Disease or Mortality","NA","Ginkgo biloba|Placebo","Drug|Drug","alzheimer disease","Alzheimer's Disease|Dementia","Parallel Assignment","Interventional","Prevention","Randomized","Ginkgo Biloba Prevention Trial in Older Individuals",2,"Hazard Ratio (HR)",1,0.98,"Log Rank",0.8,1.25,95,null,"NA","All",3069,"Completed","Phase 3","\t"]
["NCT00010803",4516952,8268905,"Number of Participants With the Indicated Cardiovascular Disease or Mortality","NA","Ginkgo biloba|Placebo","Drug|Drug","alzheimer disease","Alzheimer's Disease|Dementia","Parallel Assignment","Interventional","Prevention","Randomized","Ginkgo Biloba Prevention Trial in Older Individuals",2,"Hazard Ratio (HR)",0.94,0.66,"Log Rank",0.72,1.23,95,null,"NA","All",3069,"Completed","Phase 3","\t"]
["NCT00010803",4516948,8268905,"Number of Participants With the Indicated Cardiovascular Disease or Mortality","NA","Ginkgo biloba|Placebo","Drug|Drug","alzheimer disease","Alzheimer's Disease|Dementia","Parallel Assignment","Interventional","Prevention","Randomized","Ginkgo Biloba Prevention Trial in Older Individuals",2,"Cox Proportional Hazard",1.12,0.42,"Log Rank",0.84,1.5,95,null,"NA","All",3069,"Completed","Phase 3","\t"]
["NCT00010803",4516956,8268905,"Number of Participants With the Indicated Cardiovascular Disease or Mortality","NA","Ginkgo biloba|Placebo","Drug|Drug","alzheimer disease","Alzheimer's Disease|Dementia","Parallel Assignment","Interventional","Prevention","Randomized","Ginkgo Biloba Prevention Trial in Older Individuals",2,"Hazard Ratio (HR)",1.04,0.7,"Log Rank",0.85,1.27,95,null,"NA","All",3069,"Completed","Phase 3","\t"]
["NCT00010803",4516953,8268905,"Number of Participants With the Indicated Cardiovascular Disease or Mortality","NA","Ginkgo biloba|Placebo","Drug|Drug","alzheimer disease","Alzheimer's Disease|Dementia","Parallel Assignment","Interventional","Prevention","Randomized","Ginkgo Biloba Prevention Trial in Older Individuals",2,"Hazard Ratio (HR)",0.84,0.32,"Log Rank",0.61,1.18,95,null,"NA","All",3069,"Completed","Phase 3","\t"]
["NCT00010803",4516957,8268906,"Number of Participants With Incident Dementia","NA","Ginkgo biloba|Placebo","Drug|Drug","alzheimer disease","Alzheimer's Disease|Dementia","Parallel Assignment","Interventional","Prevention","Randomized","Ginkgo Biloba Prevention Trial in Older Individuals",2,"Hazard Ratio (HR)",1.12,0.21,"Log Rank",0.94,1.33,95,null,"NA","All",3069,"Completed","Phase 3","\t"]
["NCT00013611",4516941,8268899,"CD4+ Cell Count","interleukin-2|aldesleukin","Proleukin","Drug","hiv infections","HIV Infection","Parallel Assignment","Interventional","Treatment","Randomized","Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)",2,"Mean Difference (Final Values)",53,1E-3,"Mixed Models Analysis",40.3,65.7,95,"Standard Error of the Mean",6.5,"All",1695,"Completed","Phase 3","\t"]
["NCT00013611",4516942,8268900,"Grade 4 Clinical Events","interleukin-2|aldesleukin","Proleukin","Drug","hiv infections","HIV Infection","Parallel Assignment","Interventional","Treatment","Randomized","Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)",2,"Hazard Ratio (HR)",1.1,0.35,"Regression, Cox",0.9,1.34,95,null,"NA","All",1695,"Completed","Phase 3","\t"]
["NCT00013611",4516943,8268901,"New or Recurrent Disease Progression Events","interleukin-2|aldesleukin","Proleukin","Drug","hiv infections","HIV Infection","Parallel Assignment","Interventional","Treatment","Randomized","Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)",2,"Hazard Ratio (HR)",0.73,0.1,"Regression, Cox",0.51,1.06,95,null,"NA","All",1695,"Completed","Phase 3","\t"]
["NCT00013611",4516944,8268902,"All-cause Mortality","interleukin-2|aldesleukin","Proleukin","Drug","hiv infections","HIV Infection","Parallel Assignment","Interventional","Treatment","Randomized","Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)",2,"Hazard Ratio (HR)",1.06,0.73,"Regression, Cox",0.77,1.44,95,null,"NA","All",1695,"Completed","Phase 3","\t"]
["NCT00013611",4516945,8268903,"New or Recurrent Disease Progression Events, as Defined, or Death.","interleukin-2|aldesleukin","Proleukin","Drug","hiv infections","HIV Infection","Parallel Assignment","Interventional","Treatment","Randomized","Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)",2,"Hazard Ratio (HR)",0.91,0.47,"Regression, Cox",0.7,1.18,95,null,"NA","All",1695,"Completed","Phase 3","\t"]
["NCT00014222",4515782,8267600,"Overall Survival","cyclophosphamide|doxorubicin|epoetin alfa|paclitaxel|liposomal doxorubicin|epirubicin|fluorouracil","epoetin alfa|filgrastim|cyclophosphamide|doxorubicin hydrochloride|epirubicin hydrochloride|fluorouracil|paclitaxel","Biological|Biological|Drug|Drug|Drug|Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer","NA",null,"NA",0.084,"Log Rank",{"$nulls":4},"NA","Female","NA",null,null,"\t"]
["NCT00014222",4515783,8267601,"Disease Free Survival","cyclophosphamide|doxorubicin|epoetin alfa|paclitaxel|liposomal doxorubicin|epirubicin|fluorouracil","epoetin alfa|filgrastim|cyclophosphamide|doxorubicin hydrochloride|epirubicin hydrochloride|fluorouracil|paclitaxel","Biological|Biological|Drug|Drug|Drug|Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer","NA",null,"NA",{"v":0.0007,"d":"7.00E-04"},"Log Rank",{"$nulls":4},"NA","Female","NA",null,null,"\t"]
["NCT00019682",4515775,8267571,"Change in Quality of Life (QOL) Score Assessed by the FACT-G (Functional Assessment of Cancer Therapy- General), FACT-F (Functional Assessment of Cancer Therapy- Fatigue), SF-36 (Short Form 36) and SDS (Symptom Distress Scale)","aldesleukin","Aldesleukin|gp100 Antigen|Montanide ISA 51 VG|Quality-of-Life Assessment|Questionnaire Administration|Laboratory Biomarker Analysis","Biological|Biological|Drug|Other|Other|Other","skin neoplasms|melanoma","Recurrent Melanoma|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma","Parallel Assignment","Interventional","Treatment","Randomized","Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma",2,null,"NA",0.05,"Mixed Models Analysis",{"$nulls":4},"NA","All",185,"Completed","Phase 3","\t"]
["NCT00019682",4515776,8267571,"Change in Quality of Life (QOL) Score Assessed by the FACT-G (Functional Assessment of Cancer Therapy- General), FACT-F (Functional Assessment of Cancer Therapy- Fatigue), SF-36 (Short Form 36) and SDS (Symptom Distress Scale)","aldesleukin","Aldesleukin|gp100 Antigen|Montanide ISA 51 VG|Quality-of-Life Assessment|Questionnaire Administration|Laboratory Biomarker Analysis","Biological|Biological|Drug|Other|Other|Other","skin neoplasms|melanoma","Recurrent Melanoma|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma","Parallel Assignment","Interventional","Treatment","Randomized","Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma",2,null,"NA",0.05,"Mixed Models Analysis",{"$nulls":4},"NA","All",185,"Completed","Phase 3","\t"]
["NCT00019682",4515778,8267571,"Change in Quality of Life (QOL) Score Assessed by the FACT-G (Functional Assessment of Cancer Therapy- General), FACT-F (Functional Assessment of Cancer Therapy- Fatigue), SF-36 (Short Form 36) and SDS (Symptom Distress Scale)","aldesleukin","Aldesleukin|gp100 Antigen|Montanide ISA 51 VG|Quality-of-Life Assessment|Questionnaire Administration|Laboratory Biomarker Analysis","Biological|Biological|Drug|Other|Other|Other","skin neoplasms|melanoma","Recurrent Melanoma|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma","Parallel Assignment","Interventional","Treatment","Randomized","Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma",2,null,"NA",0.05,"Mixed Models Analysis",{"$nulls":4},"NA","All",185,"Completed","Phase 3","\t"]
["NCT00019682",4515777,8267571,"Change in Quality of Life (QOL) Score Assessed by the FACT-G (Functional Assessment of Cancer Therapy- General), FACT-F (Functional Assessment of Cancer Therapy- Fatigue), SF-36 (Short Form 36) and SDS (Symptom Distress Scale)","aldesleukin","Aldesleukin|gp100 Antigen|Montanide ISA 51 VG|Quality-of-Life Assessment|Questionnaire Administration|Laboratory Biomarker Analysis","Biological|Biological|Drug|Other|Other|Other","skin neoplasms|melanoma","Recurrent Melanoma|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma","Parallel Assignment","Interventional","Treatment","Randomized","Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma",2,null,"NA",0.05,"Mixed Models Analysis",{"$nulls":4},"NA","All",185,"Completed","Phase 3","\t"]
["NCT00019682",4515779,8267572,"Change in T-cell Precursors","aldesleukin","Aldesleukin|gp100 Antigen|Montanide ISA 51 VG|Quality-of-Life Assessment|Questionnaire Administration|Laboratory Biomarker Analysis","Biological|Biological|Drug|Other|Other|Other","skin neoplasms|melanoma","Recurrent Melanoma|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma","Parallel Assignment","Interventional","Treatment","Randomized","Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma",2,null,"NA",0.05,"Fisher Exact",{"$nulls":4},"NA","All",185,"Completed","Phase 3","\t"]
["NCT00019682",4515780,8267573,"Progression Free Survival","aldesleukin","Aldesleukin|gp100 Antigen|Montanide ISA 51 VG|Quality-of-Life Assessment|Questionnaire Administration|Laboratory Biomarker Analysis","Biological|Biological|Drug|Other|Other|Other","skin neoplasms|melanoma","Recurrent Melanoma|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma","Parallel Assignment","Interventional","Treatment","Randomized","Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma",2,null,"NA",0.008,"Log Rank",{"$nulls":4},"NA","All",185,"Completed","Phase 3","\t"]
["NCT00019682",4515781,8267574,"Best Response Rate (Partial Response [PR] + Complete Response [CR])","aldesleukin","Aldesleukin|gp100 Antigen|Montanide ISA 51 VG|Quality-of-Life Assessment|Questionnaire Administration|Laboratory Biomarker Analysis","Biological|Biological|Drug|Other|Other|Other","skin neoplasms|melanoma","Recurrent Melanoma|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma","Parallel Assignment","Interventional","Treatment","Randomized","Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma",2,null,"NA",0.035,"Chi-squared",{"$nulls":4},"NA","All",185,"Completed","Phase 3","\t"]
["NCT00021541",4516938,8268892,"Quality of Life (QOL)","tipifarnib","tipifarnib|placebo","Drug|Other","neurofibroma, plexiform|neurofibromatoses|neurofibroma|neurofibromatosis 1","Neurofibroma, Plexiform|Neurofibromatosis Type I","Crossover Assignment","Interventional","Prevention","Randomized","R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas",2,null,"NA",0.66,"Repeated measures ANOVA",{"$nulls":4},"NA","All",62,"Completed","Phase 2","\t"]
["NCT00021541",4516939,8268892,"Quality of Life (QOL)","tipifarnib","tipifarnib|placebo","Drug|Other","neurofibroma, plexiform|neurofibromatoses|neurofibroma|neurofibromatosis 1","Neurofibroma, Plexiform|Neurofibromatosis Type I","Crossover Assignment","Interventional","Prevention","Randomized","R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas",2,null,"NA",0.015,"Repeated measures ANOVA",{"$nulls":4},"NA","All",62,"Completed","Phase 2","\t"]
["NCT00021541",4516940,8268892,"Quality of Life (QOL)","tipifarnib","tipifarnib|placebo","Drug|Other","neurofibroma, plexiform|neurofibromatoses|neurofibroma|neurofibromatosis 1","Neurofibroma, Plexiform|Neurofibromatosis Type I","Crossover Assignment","Interventional","Prevention","Randomized","R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas",2,null,"NA",0.012,"Repeated measures ANOVA",{"$nulls":4},"NA","All",62,"Completed","Phase 2","\t"]
["NCT00022516",4515771,8267546,"Breast Cancer-free Interval","methotrexate|cyclophosphamide","Cyclophosphamide|Methotrexate","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer",2,"Hazard Ratio (HR)",0.78,0.06,"Log Rank",0.6,1.01,95,null,"NA","All",1086,"Completed","Phase 3","\t"]
["NCT00022516",4515772,8267547,"Distant Recurrence-free Interval","methotrexate|cyclophosphamide","Cyclophosphamide|Methotrexate","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer",2,"Hazard Ratio (HR)",0.85,0.3178,"Log Rank",0.62,1.17,95,null,"NA","All",1086,"Completed","Phase 3","\t"]
["NCT00022516",4515773,8267548,"Overall Survival","methotrexate|cyclophosphamide","Cyclophosphamide|Methotrexate","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer",2,"Hazard Ratio (HR)",0.87,0.357,"Log Rank",0.65,1.17,95,null,"NA","All",1086,"Completed","Phase 3","\t"]
["NCT00022516",4515774,8267549,"Disease-free Survival","methotrexate|cyclophosphamide","Cyclophosphamide|Methotrexate","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer",2,"Hazard Ratio (HR)",0.84,0.14,"Log Rank",0.6,1.06,95,null,"NA","All",1086,"Completed","Phase 3","\t"]
["NCT00023309",4516921,8268841,"Histological Response","lamivudine|adefovir|adefovir dipivoxil","Lamivudine and adefovir|Adefovir alone","Drug|Drug","hepatitis, chronic|hepatitis b, chronic|hepatitis b|hepatitis|hepatitis a","HBV (Hepatitis B Virus)|Hepatitis|Hepatitis B","Parallel Assignment","Interventional","Treatment","Randomized","Lamivudine and Adefovir to Treat Chronic Hepatitis B",2,null,"NA",0.0913,"Fisher Exact",{"$nulls":4},"NA","All",41,"Completed","Phase 2","\t"]
["NCT00023309",4516922,8268842,"Biological Response","lamivudine|adefovir|adefovir dipivoxil","Lamivudine and adefovir|Adefovir alone","Drug|Drug","hepatitis, chronic|hepatitis b, chronic|hepatitis b|hepatitis|hepatitis a","HBV (Hepatitis B Virus)|Hepatitis|Hepatitis B","Parallel Assignment","Interventional","Treatment","Randomized","Lamivudine and Adefovir to Treat Chronic Hepatitis B",2,null,"NA",0.0157,"Fisher Exact",{"$nulls":4},"NA","All",41,"Completed","Phase 2","\t"]
["NCT00023309",4516923,8268843,"Virological Response","lamivudine|adefovir|adefovir dipivoxil","Lamivudine and adefovir|Adefovir alone","Drug|Drug","hepatitis, chronic|hepatitis b, chronic|hepatitis b|hepatitis|hepatitis a","HBV (Hepatitis B Virus)|Hepatitis|Hepatitis B","Parallel Assignment","Interventional","Treatment","Randomized","Lamivudine and Adefovir to Treat Chronic Hepatitis B",2,null,"NA",0.0049,"Fisher Exact",{"$nulls":4},"NA","All",41,"Completed","Phase 2","\t"]
["NCT00023309",4516924,8268844,"HBeAg Loss at Week 196","lamivudine|adefovir|adefovir dipivoxil","Lamivudine and adefovir|Adefovir alone","Drug|Drug","hepatitis, chronic|hepatitis b, chronic|hepatitis b|hepatitis|hepatitis a","HBV (Hepatitis B Virus)|Hepatitis|Hepatitis B","Parallel Assignment","Interventional","Treatment","Randomized","Lamivudine and Adefovir to Treat Chronic Hepatitis B",2,null,"NA",0.0325,"Fisher Exact",{"$nulls":4},"NA","All",41,"Completed","Phase 2","\t"]
["NCT00023309",4516925,8268845,"Maintained Combined Response (Virological, Biochemical and Histological Response).","lamivudine|adefovir|adefovir dipivoxil","Lamivudine and adefovir|Adefovir alone","Drug|Drug","hepatitis, chronic|hepatitis b, chronic|hepatitis b|hepatitis|hepatitis a","HBV (Hepatitis B Virus)|Hepatitis|Hepatitis B","Parallel Assignment","Interventional","Treatment","Randomized","Lamivudine and Adefovir to Treat Chronic Hepatitis B",2,null,"NA",0.0294,"Fisher Exact",{"$nulls":4},"NA","All",41,"Completed","Phase 2","\t"]
["NCT00023452",4516911,8268829,"Cumulative Rate of Culture-Confirmed TB Disease in Participants ≥18 Years of Age AND Culture Confirmed or Probable (Clinical) TB Disease Among Participants <18 Years of Age Who Completed Study Phase Therapy Within 33 Months of Enrollment","isoniazid|rifapentine","RPT + INH once weekly for 3 months given by DOT|Isoniazid (INH) daily for 9 months","Drug|Drug","tuberculosis|infection|latent tuberculosis","Tuberculosis","Parallel Assignment","Interventional","Prevention","Randomized","Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection",2,"Difference in Cumulative TB Disease Rate",-0.19,"NA",null,null,0.06,95,null,"NA","All",8053,"Completed","Phase 3","\t"]
["NCT00023452",4516912,8268830,"Percentage of Participants Who Completed the Treatment Regimen","isoniazid|rifapentine","RPT + INH once weekly for 3 months given by DOT|Isoniazid (INH) daily for 9 months","Drug|Drug","tuberculosis|infection|latent tuberculosis","Tuberculosis","Parallel Assignment","Interventional","Prevention","Randomized","Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection",2,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Chi-squared",{"$nulls":4},"NA","All",8053,"Completed","Phase 3","\t"]
["NCT00023452",4516913,8268831,"Percentage of Participants With Drug Discontinuation for Any Reason Associated With 3RPT/INH or 9INH","isoniazid|rifapentine","RPT + INH once weekly for 3 months given by DOT|Isoniazid (INH) daily for 9 months","Drug|Drug","tuberculosis|infection|latent tuberculosis","Tuberculosis","Parallel Assignment","Interventional","Prevention","Randomized","Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection",2,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",8053,"Completed","Phase 3","\t"]
["NCT00023452",4516914,8268833,"Percentage of Participants With Death Due to Any Cause","isoniazid|rifapentine","RPT + INH once weekly for 3 months given by DOT|Isoniazid (INH) daily for 9 months","Drug|Drug","tuberculosis|infection|latent tuberculosis","Tuberculosis","Parallel Assignment","Interventional","Prevention","Randomized","Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection",2,null,"NA",0.22,"Chi-squared",{"$nulls":4},"NA","All",8053,"Completed","Phase 3","\t"]
["NCT00023452",4516915,8268834,"Percentage of Patients With Grade 3 or 4 Drug Toxicities Associated With 3RPT/INH or 9INH","isoniazid|rifapentine","RPT + INH once weekly for 3 months given by DOT|Isoniazid (INH) daily for 9 months","Drug|Drug","tuberculosis|infection|latent tuberculosis","Tuberculosis","Parallel Assignment","Interventional","Prevention","Randomized","Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection",2,null,"NA",0.59,"Chi-squared",{"$nulls":4},"NA","All",8053,"Completed","Phase 3","\t"]
["NCT00023452",4516916,8268834,"Percentage of Patients With Grade 3 or 4 Drug Toxicities Associated With 3RPT/INH or 9INH","isoniazid|rifapentine","RPT + INH once weekly for 3 months given by DOT|Isoniazid (INH) daily for 9 months","Drug|Drug","tuberculosis|infection|latent tuberculosis","Tuberculosis","Parallel Assignment","Interventional","Prevention","Randomized","Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection",2,null,"NA",0.24,"Chi-squared",{"$nulls":4},"NA","All",8053,"Completed","Phase 3","\t"]
["NCT00023452",4516917,8268835,"Percentage of Participants With Drug Discontinuation Due to Adverse Drug Reactions Associated With 3RPT/INH or 9INH","isoniazid|rifapentine","RPT + INH once weekly for 3 months given by DOT|Isoniazid (INH) daily for 9 months","Drug|Drug","tuberculosis|infection|latent tuberculosis","Tuberculosis","Parallel Assignment","Interventional","Prevention","Randomized","Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection",2,null,"NA",0.02,"Chi-squared",{"$nulls":4},"NA","All",8053,"Completed","Phase 3","\t"]
["NCT00023452",4516918,8268836,"Cumulative Rate of Culture-Confirmed or Probable (Clinical) TB Disease (Regardless of Age) At 33 Months After Enrollment","isoniazid|rifapentine","RPT + INH once weekly for 3 months given by DOT|Isoniazid (INH) daily for 9 months","Drug|Drug","tuberculosis|infection|latent tuberculosis","Tuberculosis","Parallel Assignment","Interventional","Prevention","Randomized","Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection",2,"Difference in Cumulative TB Disease Rate",-0.25,"NA",null,null,0.03,95,null,"NA","All",8053,"Completed","Phase 3","\t"]
["NCT00023452",4516919,8268837,"Cumulative Rate of Culture-Confirmed TB Disease in Participants ≥18 Years of Age AND Culture-Confirmed or Probable (Clinical) TB Disease in Participants <18 Years of Age at 24 Months Following Completion of Study Therapy","isoniazid|rifapentine","RPT + INH once weekly for 3 months given by DOT|Isoniazid (INH) daily for 9 months","Drug|Drug","tuberculosis|infection|latent tuberculosis","Tuberculosis","Parallel Assignment","Interventional","Prevention","Randomized","Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection",2,"Difference in Cumulative TB Rate",-0.21,"NA",null,null,0.04,95,null,"NA","All",8053,"Completed","Phase 3","\t"]
["NCT00023452",4516920,8268838,"Cumulative Rate of Culture-Confirmed TB Disease in Participants ≥18 Years of Age AND Culture-Confirmed or Probable (Clinical) TB Disease in Participants Less Than [<]18 Years of Age at 33 Months After Enrollment","isoniazid|rifapentine","RPT + INH once weekly for 3 months given by DOT|Isoniazid (INH) daily for 9 months","Drug|Drug","tuberculosis|infection|latent tuberculosis","Tuberculosis","Parallel Assignment","Interventional","Prevention","Randomized","Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection",2,"Difference in Cumulative TB Disease Rate",-0.24,"NA",null,null,0.01,95,null,"NA","All",8053,"Completed","Phase 3","\t"]
["NCT00023595",4516661,8268723,"H02: Cost of Care","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516662,8268723,"H02: Cost of Care","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.006,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516660,8268723,"H02: Cost of Care","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.004,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516664,8268724,"H01: Cost of Care","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516663,8268724,"H01: Cost of Care","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516665,8268724,"H01: Cost of Care","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516670,8268725,"H02: General Health Rating Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.6,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516669,8268725,"H02: General Health Rating Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.14,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516668,8268725,"H02: General Health Rating Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.57,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516667,8268725,"H02: General Health Rating Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.15,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516666,8268725,"H02: General Health Rating Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.84,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516672,8268726,"H01: General Health Rating Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.009,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516673,8268726,"H01: General Health Rating Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516671,8268726,"H01: General Health Rating Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.32,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516674,8268726,"H01: General Health Rating Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",{"v":0.0002,"d":"2.00E-04"},"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516679,8268727,"H02: Cardiac Self-Efficacy (CSE) Control Symptoms Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.75,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516676,8268727,"H02: Cardiac Self-Efficacy (CSE) Control Symptoms Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.52,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516677,8268727,"H02: Cardiac Self-Efficacy (CSE) Control Symptoms Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.77,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516678,8268727,"H02: Cardiac Self-Efficacy (CSE) Control Symptoms Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.72,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516675,8268727,"H02: Cardiac Self-Efficacy (CSE) Control Symptoms Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.12,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516680,8268728,"H01: Cardiac Self-Efficacy (CSE) Control Symptoms Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.037,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516682,8268728,"H01: Cardiac Self-Efficacy (CSE) Control Symptoms Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.043,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516683,8268728,"H01: Cardiac Self-Efficacy (CSE) Control Symptoms Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.036,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516681,8268728,"H01: Cardiac Self-Efficacy (CSE) Control Symptoms Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.018,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516687,8268729,"H02: Cardiac Self-Efficacy (CSE) Maintain Functioning Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.37,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516685,8268729,"H02: Cardiac Self-Efficacy (CSE) Maintain Functioning Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.15,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516686,8268729,"H02: Cardiac Self-Efficacy (CSE) Maintain Functioning Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.98,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516688,8268729,"H02: Cardiac Self-Efficacy (CSE) Maintain Functioning Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.4,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516684,8268729,"H02: Cardiac Self-Efficacy (CSE) Maintain Functioning Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.04,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516690,8268730,"H01: Cardiac Self-Efficacy (CSE) Maintain Functioning Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.049,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516692,8268730,"H01: Cardiac Self-Efficacy (CSE) Maintain Functioning Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",2E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516689,8268730,"H01: Cardiac Self-Efficacy (CSE) Maintain Functioning Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.038,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516691,8268730,"H01: Cardiac Self-Efficacy (CSE) Maintain Functioning Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.007,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516696,8268731,"H02: Percentage of Patients With a Score of >= 16 on the Center for Epidemiological Studies Depression (CES-D) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.42,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516693,8268731,"H02: Percentage of Patients With a Score of >= 16 on the Center for Epidemiological Studies Depression (CES-D) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.25,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516697,8268731,"H02: Percentage of Patients With a Score of >= 16 on the Center for Epidemiological Studies Depression (CES-D) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.4,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516695,8268731,"H02: Percentage of Patients With a Score of >= 16 on the Center for Epidemiological Studies Depression (CES-D) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.41,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516694,8268731,"H02: Percentage of Patients With a Score of >= 16 on the Center for Epidemiological Studies Depression (CES-D) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.25,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516700,8268732,"H01: Percentage of Patients With a Score of >= 16 on the Center for Epidemiological Studies Depression (CES-D) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.55,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516701,8268732,"H01: Percentage of Patients With a Score of >= 16 on the Center for Epidemiological Studies Depression (CES-D) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.78,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516698,8268732,"H01: Percentage of Patients With a Score of >= 16 on the Center for Epidemiological Studies Depression (CES-D) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.031,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516702,8268732,"H01: Percentage of Patients With a Score of >= 16 on the Center for Epidemiological Studies Depression (CES-D) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.86,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516699,8268732,"H01: Percentage of Patients With a Score of >= 16 on the Center for Epidemiological Studies Depression (CES-D) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.027,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516707,8268733,"H02: EQ-5D Health Status Index Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.31,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516705,8268733,"H02: EQ-5D Health Status Index Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.57,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516703,8268733,"H02: EQ-5D Health Status Index Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.38,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516704,8268733,"H02: EQ-5D Health Status Index Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.95,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516706,8268733,"H02: EQ-5D Health Status Index Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.43,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516708,8268734,"H01: EQ-5D Health Status Index Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.06,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516711,8268734,"H01: EQ-5D Health Status Index Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.007,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516709,8268734,"H01: EQ-5D Health Status Index Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.023,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516710,8268734,"H01: EQ-5D Health Status Index Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.003,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516715,8268735,"H02: EQ-5D Visual Analog Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.53,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516713,8268735,"H02: EQ-5D Visual Analog Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.78,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516714,8268735,"H02: EQ-5D Visual Analog Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.37,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516716,8268735,"H02: EQ-5D Visual Analog Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.96,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516712,8268735,"H02: EQ-5D Visual Analog Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.21,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516720,8268736,"H01: EQ-5D Visual Analog Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516717,8268736,"H01: EQ-5D Visual Analog Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516719,8268736,"H01: EQ-5D Visual Analog Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516718,8268736,"H01: EQ-5D Visual Analog Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516723,8268737,"H02: Seattle Angina Questionnaire (SAQ) Quality-of-Life Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.65,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516724,8268737,"H02: Seattle Angina Questionnaire (SAQ) Quality-of-Life Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.39,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516725,8268737,"H02: Seattle Angina Questionnaire (SAQ) Quality-of-Life Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.86,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516722,8268737,"H02: Seattle Angina Questionnaire (SAQ) Quality-of-Life Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.15,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516721,8268737,"H02: Seattle Angina Questionnaire (SAQ) Quality-of-Life Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.68,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516726,8268738,"H01:Seattle Angina Questionnaire (SAQ) Quality-of-Life Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516729,8268738,"H01:Seattle Angina Questionnaire (SAQ) Quality-of-Life Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516728,8268738,"H01:Seattle Angina Questionnaire (SAQ) Quality-of-Life Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516727,8268738,"H01:Seattle Angina Questionnaire (SAQ) Quality-of-Life Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516731,8268739,"H02: Seattle Angina Questionnaire (SAQ) Anginal Stability Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.95,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516732,8268739,"H02: Seattle Angina Questionnaire (SAQ) Anginal Stability Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.88,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516734,8268739,"H02: Seattle Angina Questionnaire (SAQ) Anginal Stability Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.98,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516733,8268739,"H02: Seattle Angina Questionnaire (SAQ) Anginal Stability Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.16,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516730,8268739,"H02: Seattle Angina Questionnaire (SAQ) Anginal Stability Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.48,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516736,8268740,"H01: Seattle Angina Questionnaire (SAQ) Anginal Stability Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516738,8268740,"H01: Seattle Angina Questionnaire (SAQ) Anginal Stability Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.029,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516737,8268740,"H01: Seattle Angina Questionnaire (SAQ) Anginal Stability Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.042,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516735,8268740,"H01: Seattle Angina Questionnaire (SAQ) Anginal Stability Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.2,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516740,8268741,"H02: Seattle Angina Questionnaire (SAQ) Anginal Frequency Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.46,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516743,8268741,"H02: Seattle Angina Questionnaire (SAQ) Anginal Frequency Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.01,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516741,8268741,"H02: Seattle Angina Questionnaire (SAQ) Anginal Frequency Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.77,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516739,8268741,"H02: Seattle Angina Questionnaire (SAQ) Anginal Frequency Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.27,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516742,8268741,"H02: Seattle Angina Questionnaire (SAQ) Anginal Frequency Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.74,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516746,8268742,"H01: Seattle Angina Questionnaire (SAQ) Anginal Frequency Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516747,8268742,"H01: Seattle Angina Questionnaire (SAQ) Anginal Frequency Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516745,8268742,"H01: Seattle Angina Questionnaire (SAQ) Anginal Frequency Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516744,8268742,"H01: Seattle Angina Questionnaire (SAQ) Anginal Frequency Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.01,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516750,8268743,"H02: KCCQ Overall Summary Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.76,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516749,8268743,"H02: KCCQ Overall Summary Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.89,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516751,8268743,"H02: KCCQ Overall Summary Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.26,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516748,8268743,"H02: KCCQ Overall Summary Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.89,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516752,8268743,"H02: KCCQ Overall Summary Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.53,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516756,8268744,"H01: KCCQ Overall Summary Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516755,8268744,"H01: KCCQ Overall Summary Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516754,8268744,"H01: KCCQ Overall Summary Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.006,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516753,8268744,"H01: KCCQ Overall Summary Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.037,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516758,8268745,"H02: KCCQ Clinical Summary Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.98,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516759,8268745,"H02: KCCQ Clinical Summary Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.66,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516760,8268745,"H02: KCCQ Clinical Summary Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.23,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516761,8268745,"H02: KCCQ Clinical Summary Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.26,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516757,8268745,"H02: KCCQ Clinical Summary Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.86,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516762,8268746,"H01: KCCQ Clinical Summary Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.051,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516763,8268746,"H01: KCCQ Clinical Summary Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.015,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516765,8268746,"H01: KCCQ Clinical Summary Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.033,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516764,8268746,"H01: KCCQ Clinical Summary Score","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",2E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516770,8268747,"H02: KCCQ Social Limitation","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.63,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516766,8268747,"H02: KCCQ Social Limitation","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.68,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516767,8268747,"H02: KCCQ Social Limitation","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.25,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516768,8268747,"H02: KCCQ Social Limitation","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.68,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516769,8268747,"H02: KCCQ Social Limitation","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.29,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516772,8268748,"H01: KCCQ Social Limitation","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.077,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516774,8268748,"H01: KCCQ Social Limitation","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.023,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516771,8268748,"H01: KCCQ Social Limitation","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.17,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516773,8268748,"H01: KCCQ Social Limitation","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516776,8268749,"H02: KCCQ Quality-of-Life Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.84,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516777,8268749,"H02: KCCQ Quality-of-Life Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.87,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516778,8268749,"H02: KCCQ Quality-of-Life Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.47,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516779,8268749,"H02: KCCQ Quality-of-Life Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.7,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516775,8268749,"H02: KCCQ Quality-of-Life Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.82,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516781,8268750,"H01: KCCQ Quality-of-Life Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516783,8268750,"H01: KCCQ Quality-of-Life Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516780,8268750,"H01: KCCQ Quality-of-Life Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.018,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516782,8268750,"H01: KCCQ Quality-of-Life Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516785,8268751,"H02: KCCQ Total Symptoms","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.78,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516788,8268751,"H02: KCCQ Total Symptoms","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.18,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516784,8268751,"H02: KCCQ Total Symptoms","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.48,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516786,8268751,"H02: KCCQ Total Symptoms","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.59,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516787,8268751,"H02: KCCQ Total Symptoms","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.17,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516790,8268752,"H01: KCCQ Total Symptoms","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.026,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516789,8268752,"H01: KCCQ Total Symptoms","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.085,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516792,8268752,"H01: KCCQ Total Symptoms","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.085,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516791,8268752,"H01: KCCQ Total Symptoms","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.007,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516794,8268753,"H02: KCCQ Symptom Burden","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.9,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516793,8268753,"H02: KCCQ Symptom Burden","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.48,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516796,8268753,"H02: KCCQ Symptom Burden","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.43,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516797,8268753,"H02: KCCQ Symptom Burden","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.23,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516795,8268753,"H02: KCCQ Symptom Burden","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.35,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516799,8268754,"H01: KCCQ Symptom Burden","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.039,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516801,8268754,"H01: KCCQ Symptom Burden","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.05,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516798,8268754,"H01: KCCQ Symptom Burden","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.074,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516800,8268754,"H01: KCCQ Symptom Burden","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.006,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516806,8268755,"H02: KCCQ Symptom Frequency","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.19,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516803,8268755,"H02: KCCQ Symptom Frequency","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.67,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516805,8268755,"H02: KCCQ Symptom Frequency","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.07,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516804,8268755,"H02: KCCQ Symptom Frequency","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.94,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516802,8268755,"H02: KCCQ Symptom Frequency","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.44,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516809,8268756,"H01: KCCQ Symptom Frequency","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.017,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516810,8268756,"H01: KCCQ Symptom Frequency","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.205,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516808,8268756,"H01: KCCQ Symptom Frequency","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.028,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516807,8268756,"H01: KCCQ Symptom Frequency","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.123,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516815,8268757,"H02: KCCQ Symptom Stability","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.38,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516814,8268757,"H02: KCCQ Symptom Stability","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.45,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516813,8268757,"H02: KCCQ Symptom Stability","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.62,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516812,8268757,"H02: KCCQ Symptom Stability","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.82,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516811,8268757,"H02: KCCQ Symptom Stability","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.94,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516816,8268758,"H01: KCCQ Symptom Stability","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.26,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516818,8268758,"H01: KCCQ Symptom Stability","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.023,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516817,8268758,"H01: KCCQ Symptom Stability","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.009,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516819,8268758,"H01: KCCQ Symptom Stability","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.005,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516821,8268759,"H02: KCCQ Physical Limitation Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.89,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516823,8268759,"H02: KCCQ Physical Limitation Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.13,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516820,8268759,"H02: KCCQ Physical Limitation Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.87,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516822,8268759,"H02: KCCQ Physical Limitation Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.86,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516824,8268759,"H02: KCCQ Physical Limitation Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.4,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516825,8268760,"H01: KCCQ Physical Limitation Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.097,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516827,8268760,"H01: KCCQ Physical Limitation Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.003,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516826,8268760,"H01: KCCQ Physical Limitation Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.049,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516828,8268760,"H01: KCCQ Physical Limitation Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.05,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516832,8268761,"H02: SF-12 Mental Component Summary (MCS) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.87,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516830,8268761,"H02: SF-12 Mental Component Summary (MCS) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.6,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516831,8268761,"H02: SF-12 Mental Component Summary (MCS) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.03,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516833,8268761,"H02: SF-12 Mental Component Summary (MCS) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.74,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516829,8268761,"H02: SF-12 Mental Component Summary (MCS) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.87,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516835,8268762,"H01: SF-12 Mental Component Summary (MCS) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.007,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516834,8268762,"H01: SF-12 Mental Component Summary (MCS) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.044,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516836,8268762,"H01: SF-12 Mental Component Summary (MCS) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.011,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516837,8268762,"H01: SF-12 Mental Component Summary (MCS) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.004,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516841,8268763,"H02: SF-12 Physical Component Summary (PCS) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.57,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516839,8268763,"H02: SF-12 Physical Component Summary (PCS) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.64,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516840,8268763,"H02: SF-12 Physical Component Summary (PCS) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.15,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516838,8268763,"H02: SF-12 Physical Component Summary (PCS) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.07,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516842,8268763,"H02: SF-12 Physical Component Summary (PCS) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.71,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516844,8268764,"H01:SF-12 Physical Component Summary (PCS) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.065,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516845,8268764,"H01:SF-12 Physical Component Summary (PCS) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.003,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516846,8268764,"H01:SF-12 Physical Component Summary (PCS) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.051,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516843,8268764,"H01:SF-12 Physical Component Summary (PCS) Scale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.83,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516851,8268765,"H02: SF-36 Vitality Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.31,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516847,8268765,"H02: SF-36 Vitality Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.43,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516850,8268765,"H02: SF-36 Vitality Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.42,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516849,8268765,"H02: SF-36 Vitality Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.66,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516848,8268765,"H02: SF-36 Vitality Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.32,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516852,8268766,"H01:SF-36 Vitality Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.024,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516855,8268766,"H01:SF-36 Vitality Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516853,8268766,"H01:SF-36 Vitality Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516854,8268766,"H01:SF-36 Vitality Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516860,8268767,"H02: SF-36 Social Functioning Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.36,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516859,8268767,"H02: SF-36 Social Functioning Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.87,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516857,8268767,"H02: SF-36 Social Functioning Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.12,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516856,8268767,"H02: SF-36 Social Functioning Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.79,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516858,8268767,"H02: SF-36 Social Functioning Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.17,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516863,8268768,"H01:SF-36 Social Functioning Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",2E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516862,8268768,"H01:SF-36 Social Functioning Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.008,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516861,8268768,"H01:SF-36 Social Functioning Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.31,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516864,8268768,"H01:SF-36 Social Functioning Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.039,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516867,8268769,"H02: SF-36 Role Emotional Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.69,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516866,8268769,"H02: SF-36 Role Emotional Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.63,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516869,8268769,"H02: SF-36 Role Emotional Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.82,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516868,8268769,"H02: SF-36 Role Emotional Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.48,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516865,8268769,"H02: SF-36 Role Emotional Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.9,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516871,8268770,"H01:SF-36 Role Emotional Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.168,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516873,8268770,"H01:SF-36 Role Emotional Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.063,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516872,8268770,"H01:SF-36 Role Emotional Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.187,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516870,8268770,"H01:SF-36 Role Emotional Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.05,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516877,8268771,"H02: SF-36 Role Physical Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.61,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516878,8268771,"H02: SF-36 Role Physical Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.74,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516875,8268771,"H02: SF-36 Role Physical Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.94,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516874,8268771,"H02: SF-36 Role Physical Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.29,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516876,8268771,"H02: SF-36 Role Physical Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.78,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516882,8268772,"H01:SF-36 Role Physical Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.31,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516881,8268772,"H01:SF-36 Role Physical Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",2E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516879,8268772,"H01:SF-36 Role Physical Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.079,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516880,8268772,"H01:SF-36 Role Physical Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.028,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516884,8268773,"H02: SF-36 Mental Health Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.96,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516887,8268773,"H02: SF-36 Mental Health Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.91,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516883,8268773,"H02: SF-36 Mental Health Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.78,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516886,8268773,"H02: SF-36 Mental Health Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.62,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516885,8268773,"H02: SF-36 Mental Health Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.04,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516888,8268774,"H01: SF-36 Mental Health Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.44,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516889,8268774,"H01: SF-36 Mental Health Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.011,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516890,8268774,"H01: SF-36 Mental Health Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",2E-3,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516891,8268774,"H01: SF-36 Mental Health Subscale","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,null,"NA",0.015,"Chi-squared",{"$nulls":4},"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516892,8268790,"H01: All-cause Mortality, Heart Transplant or LVAD","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,"Hazard Ratio (HR)",0.84,0.018,"Log Rank",0.73,0.97,95,null,"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516893,8268791,"H02: All-cause Mortality, Heart Transplant or LVAD","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,"Hazard Ratio (HR)",1.05,0.717,"Log Rank",0.83,1.32,95,null,"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516894,8268792,"H01: All-cause Mortality, Heart Transplant or LVAD","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,"Hazard Ratio (HR)",0.86,0.108,"Log Rank",0.72,1.03,95,null,"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516895,8268793,"H01: All-cause Mortality or Revascularization (CABG or PCI)","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,"Hazard Ratio (HR)",0.63,1E-3,"Log Rank",0.55,0.73,95,null,"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516896,8268794,"H02: All-cause Mortality or Revascularization (CABG or PCI)","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,"Hazard Ratio (HR)",0.91,0.414,"Log Rank",0.73,1.13,95,null,"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516897,8268795,"H01: All-cause Mortality or Revascularization (CABG or PCI)","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,"Hazard Ratio (HR)",0.6,1E-3,"Log Rank",0.51,0.71,95,null,"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516898,8268811,"H01: All-cause Mortality or Heart-failure Hospitalization","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,"Hazard Ratio (HR)",0.81,2E-3,"Log Rank",0.71,0.93,95,null,"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516899,8268812,"H02: All-cause Mortality or Heart-failure Hospitalization","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,"Hazard Ratio (HR)",1.08,0.401,"Log Rank",0.89,1.31,95,null,"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516900,8268813,"H01: All-cause Mortality or Heart-failure Hospitalization","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,"Hazard Ratio (HR)",0.84,0.03,"Log Rank",0.71,0.98,95,null,"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516901,8268814,"H02: All-cause Mortality Within 30 Days After Randomization","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,"Odds Ratio (OR)",1.37,0.275,"Regression, Logistic",0.78,2.41,95,null,"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516902,8268815,"H01: All-cause Mortality Within 30 Days After Randomization","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,"Odds Ratio (OR)",3.19,0.008,"Regression, Logistic",1.35,7.52,95,null,"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516903,8268816,"H02: All-cause Mortality","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,"Hazard Ratio (HR)",1,0.98,"Log Rank",0.79,1.26,95,null,"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516904,8268817,"H01: Mortality or Cardiovascular Hospitalization","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,"Hazard Ratio (HR)",0.72,1E-3,"Log Rank",0.64,0.82,95,null,"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516905,8268818,"H01: Mortality or Cardiovascular Hospitalization","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,"Hazard Ratio (HR)",0.74,1E-3,"Log Rank",0.64,0.85,95,null,"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516906,8268819,"H01: Cardiovascular Mortality (Defined as Sudden Death or Death Attributed to Recurrent MI, HF, a Cardiovascular Procedure, Stroke, or Other Cardiovascular Etiology).","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,"Hazard Ratio (HR)",0.81,0.05,"Log Rank",0.66,1,95,null,"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516907,8268820,"H01: Cardiovascular Mortality (Defined as Sudden Death or Death Attributed to Recurrent MI, HF, a Cardiovascular Procedure, Stroke, or Other Cardiovascular Etiology).","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,"Hazard Ratio, log",0.79,0.006,"Log Rank",0.66,0.93,95,null,"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516908,8268821,"H02: All-cause Mortality or Cardiovascular Hospitalization","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,"Hazard Ratio (HR)",0.99,0.9,"Log Rank",0.84,1.17,95,null,"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516909,8268822,"H01: All Cause Mortality","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,"Hazard Ratio (HR)",0.84,0.02,"Log Rank",0.73,0.97,95,null,"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00023595",4516910,8268823,"H01: All Cause Mortality","NA","CABG surgery plus MED|Active Medication Alone|CABG plus MED and SVR","Procedure|Drug|Procedure","coronary disease|heart failure|cardiovascular diseases|heart diseases","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",4,"Hazard Ratio (HR)",0.86,0.12,"Log Rank",0.72,1.04,95,null,"NA","All",2136,"Completed","Phase 3","\t"]
["NCT00024102",4515769,8267502,"Overall Survival Rate at 2.4 Years","doxorubicin|capecitabine","Standard Treatment|capecitabine","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer",2,"Hazard Ratio (HR)",1.85,0.02,"Regression, Cox",1.11,3.08,95,null,"NA","Female",633,"Completed","Phase 3","\t"]
["NCT00024102",4515770,8267503,"Relapse-free Survival Rates at 2.4 Years","doxorubicin|capecitabine","Standard Treatment|capecitabine","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer",2,"Hazard Ratio (HR)",2.09,1E-3,"Regression, Cox",1.38,3.17,95,null,"NA","Female",633,"Completed","Phase 3","\t"]
["NCT00026312",4515764,8267451,"Overall Survival (OS)","vitamin a|aldesleukin|interleukin-2|tretinoin|ch14.18 monoclonal antibody|isotretinoin|sargramostim","Aldesleukin|Dinutuximab|Isotretinoin|Laboratory Biomarker Analysis|Pharmacological Study|Quality-of-Life Assessment|Sargramostim","Biological|Biological|Drug|Other|Other|Other|Biological","neuroblastoma","Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Recurrent Neuroblastoma|Regional Neuroblastoma|Stage 4 Neuroblastoma|Stage 4S Neuroblastoma","Parallel Assignment","Interventional","Treatment","Randomized","Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma",2,"Log-Rank Test Statistic",4.1362,0.042,"Log Rank",null,null,95,null,"NA","All",1449,"Active, not recruiting","Phase 3","\t"]
["NCT00026312",4515765,8267451,"Overall Survival (OS)","vitamin a|aldesleukin|interleukin-2|tretinoin|ch14.18 monoclonal antibody|isotretinoin|sargramostim","Aldesleukin|Dinutuximab|Isotretinoin|Laboratory Biomarker Analysis|Pharmacological Study|Quality-of-Life Assessment|Sargramostim","Biological|Biological|Drug|Other|Other|Other|Biological","neuroblastoma","Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Recurrent Neuroblastoma|Regional Neuroblastoma|Stage 4 Neuroblastoma|Stage 4S Neuroblastoma","Parallel Assignment","Interventional","Treatment","Randomized","Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma",2,"Log Rank Test Statistic",3.4471,0.0634,"Log Rank",null,null,95,null,"NA","All",1449,"Active, not recruiting","Phase 3","\t"]
["NCT00026312",4515766,8267452,"Number of Courses of Therapy Delivered","vitamin a|aldesleukin|interleukin-2|tretinoin|ch14.18 monoclonal antibody|isotretinoin|sargramostim","Aldesleukin|Dinutuximab|Isotretinoin|Laboratory Biomarker Analysis|Pharmacological Study|Quality-of-Life Assessment|Sargramostim","Biological|Biological|Drug|Other|Other|Other|Biological","neuroblastoma","Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Recurrent Neuroblastoma|Regional Neuroblastoma|Stage 4 Neuroblastoma|Stage 4S Neuroblastoma","Parallel Assignment","Interventional","Treatment","Randomized","Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma",2,"Mean Difference (Net)",0,0.0262,"Wilcoxon (Mann-Whitney)",null,null,95,null,"NA","All",1449,"Active, not recruiting","Phase 3","\t"]
["NCT00026312",4515767,8267455,"Event-Free Survival (EFS)","vitamin a|aldesleukin|interleukin-2|tretinoin|ch14.18 monoclonal antibody|isotretinoin|sargramostim","Aldesleukin|Dinutuximab|Isotretinoin|Laboratory Biomarker Analysis|Pharmacological Study|Quality-of-Life Assessment|Sargramostim","Biological|Biological|Drug|Other|Other|Other|Biological","neuroblastoma","Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Recurrent Neuroblastoma|Regional Neuroblastoma|Stage 4 Neuroblastoma|Stage 4S Neuroblastoma","Parallel Assignment","Interventional","Treatment","Randomized","Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma",2,"Log Rank Test Statistic",2.6176,0.1057,"Log Rank",null,null,95,null,"NA","All",1449,"Active, not recruiting","Phase 3","\t"]
["NCT00026312",4515768,8267456,"Event-Free Survival (EFS)","vitamin a|aldesleukin|interleukin-2|tretinoin|ch14.18 monoclonal antibody|isotretinoin|sargramostim","Aldesleukin|Dinutuximab|Isotretinoin|Laboratory Biomarker Analysis|Pharmacological Study|Quality-of-Life Assessment|Sargramostim","Biological|Biological|Drug|Other|Other|Other|Biological","neuroblastoma","Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Recurrent Neuroblastoma|Regional Neuroblastoma|Stage 4 Neuroblastoma|Stage 4S Neuroblastoma","Parallel Assignment","Interventional","Treatment","Randomized","Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma",2,"Log Rank Test Statistic",2.6803,0.1016,"Log Rank",null,null,95,null,"NA","All",1449,"Active, not recruiting","Phase 3","\t"]
["NCT00027378",4516655,8268707,"Alcohol Use Behaviors","fluoxetine","fluoxetine (Prozac)|Placebo plus Treatment As Usual","Drug|Drug","alcoholism|depression","Alcoholism|Depression","Parallel Assignment","Interventional","Treatment","Randomized","Pharmacological Intervention Project (Fluoxetine)",2,"Mean Difference (Final Values)",0.39,0.05,"ANOVA",null,null,95,"Standard Deviation",0.702,"All",50,"Completed","Phase 2","\t"]
["NCT00028093",4516654,8268705,"Change in Hepatitis C Virus RNA Levels During Phase I","peginterferon alfa-2a|ribavirin|interferon-alpha","Peginterferon alfa-2a with Ribavirin|Peginterferon alfa-2a","Drug|Drug","hepatitis, chronic|hepatitis c|hepatitis a|hepatitis|hepatitis c, chronic","Chronic Hepatitis C","Parallel Assignment","Interventional","Treatment","Randomized","Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease",2,null,"NA",0.54,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",50,"Completed","Phase 4","\t"]
["NCT00029146",4516643,8268692,"Ipsilateral Ischemic Stroke in 2 Yrs From Randomization and All Stroke & Death Through 30d Post-surgery; Non-surgical Group:Ipsilateral Ischemic Stroke in 2 Yrs From Randomization and All Stroke & Death Through 30d Post-randomization","NA","extracranial-intracranial bypass surgery|best medical therapy","Procedure|Drug","cerebral infarction|infarction|ischemic attack, transient","Cerebral Infarction|Ischemic Attack, Transient|Stroke","Parallel Assignment","Interventional","Treatment","Randomized","Carotid Occlusion Surgery Study",2,"Difference in estimated 2 yr rates",1.5,0.81,"2-sided z-statistic",-10.7,13.7,95,null,"NA","All",700,"Terminated","Phase 3","\t"]
["NCT00029146",4516644,8268693,"Summary SS-QOL Score","NA","extracranial-intracranial bypass surgery|best medical therapy","Procedure|Drug","cerebral infarction|infarction|ischemic attack, transient","Cerebral Infarction|Ischemic Attack, Transient|Stroke","Parallel Assignment","Interventional","Treatment","Randomized","Carotid Occlusion Surgery Study",2,"Mean Difference (Final Values)",-0.24,0.13,"t-test, 2 sided",-0.54,0.07,95,null,"NA","All",700,"Terminated","Phase 3","\t"]
["NCT00029146",4516645,8268694,"Modified Barthel Index 19-20","NA","extracranial-intracranial bypass surgery|best medical therapy","Procedure|Drug","cerebral infarction|infarction|ischemic attack, transient","Cerebral Infarction|Ischemic Attack, Transient|Stroke","Parallel Assignment","Interventional","Treatment","Randomized","Carotid Occlusion Surgery Study",2,null,"NA",0.85,"Fisher's Exact Test",{"$nulls":4},"NA","All",700,"Terminated","Phase 3","\t"]
["NCT00029146",4516646,8268695,"Modified Rankin 0-2","NA","extracranial-intracranial bypass surgery|best medical therapy","Procedure|Drug","cerebral infarction|infarction|ischemic attack, transient","Cerebral Infarction|Ischemic Attack, Transient|Stroke","Parallel Assignment","Interventional","Treatment","Randomized","Carotid Occlusion Surgery Study",2,"Difference in estimated 2 yr rates",4.4,0.7,"Fisher Exact",-8.2,16.9,95,null,"NA","All",700,"Terminated","Phase 3","\t"]
["NCT00029146",4516647,8268696,"Modified Rankin 0-1","NA","extracranial-intracranial bypass surgery|best medical therapy","Procedure|Drug","cerebral infarction|infarction|ischemic attack, transient","Cerebral Infarction|Ischemic Attack, Transient|Stroke","Parallel Assignment","Interventional","Treatment","Randomized","Carotid Occlusion Surgery Study",2,"Difference in estimated 2 yr rates",-6.6,0.41,"Fisher Exact",-20.6,7.3,95,null,"NA","All",700,"Terminated","Phase 3","\t"]
["NCT00029146",4516648,8268697,"Any Stroke or Death","NA","extracranial-intracranial bypass surgery|best medical therapy","Procedure|Drug","cerebral infarction|infarction|ischemic attack, transient","Cerebral Infarction|Ischemic Attack, Transient|Stroke","Parallel Assignment","Interventional","Treatment","Randomized","Carotid Occlusion Surgery Study",2,"Difference in estimated 2 yr rates",6.5,0.33,"2-sided z-statistic",-6.5,19.6,95,null,"NA","All",700,"Terminated","Phase 3","\t"]
["NCT00029146",4516649,8268698,"Death","NA","extracranial-intracranial bypass surgery|best medical therapy","Procedure|Drug","cerebral infarction|infarction|ischemic attack, transient","Cerebral Infarction|Ischemic Attack, Transient|Stroke","Parallel Assignment","Interventional","Treatment","Randomized","Carotid Occlusion Surgery Study",2,"Difference in estimated 2 yr rates",4,0.13,"2-sided z-statistic",-1.2,9.7,95,null,"NA","All",700,"Terminated","Phase 3","\t"]
["NCT00029146",4516650,8268699,"Fatal Stroke","NA","extracranial-intracranial bypass surgery|best medical therapy","Procedure|Drug","cerebral infarction|infarction|ischemic attack, transient","Cerebral Infarction|Ischemic Attack, Transient|Stroke","Parallel Assignment","Interventional","Treatment","Randomized","Carotid Occlusion Surgery Study",2,"Difference in estimated 2 yr rates",1.3,0.5,"2-sided z-statistic",-2.5,5.2,95,null,"NA","All",700,"Terminated","Phase 3","\t"]
["NCT00029146",4516651,8268700,"Disabling Stroke","NA","extracranial-intracranial bypass surgery|best medical therapy","Procedure|Drug","cerebral infarction|infarction|ischemic attack, transient","Cerebral Infarction|Ischemic Attack, Transient|Stroke","Parallel Assignment","Interventional","Treatment","Randomized","Carotid Occlusion Surgery Study",2,"Difference in estimated 2 yr rates",-3.2,0.27,"2-sided z-statistic",-9,2.6,95,null,"NA","All",700,"Terminated","Phase 3","\t"]
["NCT00029146",4516652,8268701,"All Stroke","NA","extracranial-intracranial bypass surgery|best medical therapy","Procedure|Drug","cerebral infarction|infarction|ischemic attack, transient","Cerebral Infarction|Ischemic Attack, Transient|Stroke","Parallel Assignment","Interventional","Treatment","Randomized","Carotid Occlusion Surgery Study",2,"Difference in estimated 2 yr rates",3.5,0.59,"2-sided z-statistic",-9.2,16.1,95,null,"NA","All",700,"Terminated","Phase 3","\t"]
["NCT00029146",4516653,8268702,"Surgical Group:Ipsilateral Ischemic Stroke in 2 Yrs From Randomization and All Stroke & Death Through 30d Post-surgery; Non-surgical Group:Ipsilateral Ischemic Stroke in 2 Yrs From Randomization and All Stroke & Death Through 30d Post-randomization","NA","extracranial-intracranial bypass surgery|best medical therapy","Procedure|Drug","cerebral infarction|infarction|ischemic attack, transient","Cerebral Infarction|Ischemic Attack, Transient|Stroke","Parallel Assignment","Interventional","Treatment","Randomized","Carotid Occlusion Surgery Study",2,"Difference in estimated 2 yr rates",1.7,0.78,"2-sided z-statistic",-10.4,13.8,95,null,"NA","All",700,"Terminated","Phase 3","\t"]
["NCT00030901",4515763,8267416,"Presence of Carcinoma of the Prostate as Measured by Biopsy","selenium","L-selenomethionine|L-selenomethionine placebo","Drug|Drug","precancerous conditions|prostatic intraepithelial neoplasia|prostatic neoplasms|neoplasms","Precancerous/Nonmalignant Condition|Prostate Cancer","Parallel Assignment","Interventional","Prevention","Randomized","S9917, Selenium in Preventing Cancer in Patients With Neoplasia of the Prostate",2,null,"NA",0.73,"Regression, Logistic",{"$nulls":4},"NA","Male",619,"Completed","Phase 3","\t"]
["NCT00032487",4516642,8268661,"Primary Major Macrovascular Events","rosiglitazone|glimepiride|metformin","Insulin|Glimepiride|Rosiglitazone|Metformin","Drug|Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Type 2 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)",2,"Cox Proportional Hazard",0.79,0.05,"Log Rank",0.79,0.99,95,null,"NA","All",1791,"Completed","Phase 3","\t"]
["NCT00032591",4516641,8268659,"Time to First Event (Death, Stroke, Major Bleed)","thrombin","Weekly patient self-testing of prothrombin time|High quality anticoagulation management (HQACM) with conventional monthly testing","Procedure|Other","atrial fibrillation","Atrial Fibrillation","Parallel Assignment","Interventional","Treatment","Randomized","The Home INR Study",2,"Hazard Ratio (HR)",0.88,0.14,"Log Rank",{"$nulls":4},"NA","All",2922,"Completed","Phase 4","\t"]
["NCT00033293",4515760,8267406,"Functional Outcome as Assessed by Age-appropriate Neuropsychological Testing","corticotropin-releasing hormone|immunoglobulins|gamma-globulins|antibodies|beta-endorphin|adrenocorticotropic hormone|hormones|immunoglobulins, intravenous|prednisone|melanocyte-stimulating hormones|cyclophosphamide|rho(d) immune globulin","therapeutic immune globulin|clinical observation|cyclophosphamide|prednisone|magnetic resonance imaging|laboratory biomarker analysis|Corticotropin-Releasing Hormone","Biological|Other|Drug|Drug|Procedure|Other|Drug","neuroblastoma","Disseminated Neuroblastoma|Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Regional Neuroblastoma|Stage 4S Neuroblastoma","Parallel Assignment","Interventional","Treatment","Randomized","Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma",2,"Mean Difference (Net)",16.75,0.2364,"t-test, 1 sided",{"$nulls":4},"NA","All",53,"Unknown status","Phase 3","\t"]
["NCT00033293",4515761,8267407,"Motor Coordination as Assessed by Neurological Examination and Vineland Adaptive Behavior Scale (VABS)","corticotropin-releasing hormone|immunoglobulins|gamma-globulins|antibodies|beta-endorphin|adrenocorticotropic hormone|hormones|immunoglobulins, intravenous|prednisone|melanocyte-stimulating hormones|cyclophosphamide|rho(d) immune globulin","therapeutic immune globulin|clinical observation|cyclophosphamide|prednisone|magnetic resonance imaging|laboratory biomarker analysis|Corticotropin-Releasing Hormone","Biological|Other|Drug|Drug|Procedure|Other|Drug","neuroblastoma","Disseminated Neuroblastoma|Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Regional Neuroblastoma|Stage 4S Neuroblastoma","Parallel Assignment","Interventional","Treatment","Randomized","Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma",2,"Mean Difference (Net)",60.1979,0.0919,"t-test, 1 sided",{"$nulls":4},"NA","All",53,"Unknown status","Phase 3","\t"]
["NCT00033293",4515762,8267408,"Number of Responders","corticotropin-releasing hormone|immunoglobulins|gamma-globulins|antibodies|beta-endorphin|adrenocorticotropic hormone|hormones|immunoglobulins, intravenous|prednisone|melanocyte-stimulating hormones|cyclophosphamide|rho(d) immune globulin","therapeutic immune globulin|clinical observation|cyclophosphamide|prednisone|magnetic resonance imaging|laboratory biomarker analysis|Corticotropin-Releasing Hormone","Biological|Other|Drug|Drug|Procedure|Other|Drug","neuroblastoma","Disseminated Neuroblastoma|Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Regional Neuroblastoma|Stage 4S Neuroblastoma","Parallel Assignment","Interventional","Treatment","Randomized","Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma",2,"Chi-squared test statistic",8.125,0.0044,"Chi-squared",null,null,95,null,"NA","All",53,"Unknown status","Phase 3","\t"]
["NCT00033631",4515752,8267378,"Number of Participants With Improved, Stable, and Declined Spitzer Quality of Life Index (SQLI) at 12 Months","NA","70.2 Gy 3D-CRT/IMRT|79.2 Gy 3D-CRT/IMRT","Radiation|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy in Treating Patients With Stage II Prostate Cancer",2,null,"NA",0.59,"Chi-squared",{"$nulls":4},"NA","Male",1532,"Active, not recruiting","Phase 3","\t"]
["NCT00033631",4515753,8267379,"Percentage of Participants With Erectile Disfuction at 12 Months","NA","70.2 Gy 3D-CRT/IMRT|79.2 Gy 3D-CRT/IMRT","Radiation|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy in Treating Patients With Stage II Prostate Cancer",2,null,"NA",0.0513,"Chi-squared",{"$nulls":4},"NA","Male",1532,"Active, not recruiting","Phase 3","\t"]
["NCT00033631",4515754,8267380,"Grade 2 or Greater Genitourinary or Gastrointestinal Toxicity","NA","70.2 Gy 3D-CRT/IMRT|79.2 Gy 3D-CRT/IMRT","Radiation|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy in Treating Patients With Stage II Prostate Cancer",2,null,"NA",0.29,"Chi-squared",{"$nulls":4},"NA","Male",1532,"Active, not recruiting","Phase 3","\t"]
["NCT00033631",4515755,8267381,"Distant Metastases","NA","70.2 Gy 3D-CRT/IMRT|79.2 Gy 3D-CRT/IMRT","Radiation|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy in Treating Patients With Stage II Prostate Cancer",2,"Hazard Ratio (HR)",0.65,0.051,"Gray's test",0.42,1.01,95,null,"NA","Male",1532,"Active, not recruiting","Phase 3","\t"]
["NCT00033631",4515756,8267382,"Local Progression","NA","70.2 Gy 3D-CRT/IMRT|79.2 Gy 3D-CRT/IMRT","Radiation|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy in Treating Patients With Stage II Prostate Cancer",2,"Hazard Ratio (HR)",0.41,{"v":1E-4,"d":"1.00E-04"},"Gray's test",0.25,0.66,95,null,"NA","Male",1532,"Active, not recruiting","Phase 3","\t"]
["NCT00033631",4515757,8267383,"Disease Specific Survival","NA","70.2 Gy 3D-CRT/IMRT|79.2 Gy 3D-CRT/IMRT","Radiation|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy in Treating Patients With Stage II Prostate Cancer",2,"Hazard Ratio (HR)",0.66,0.14,"Gray's test",0.38,1.15,95,null,"NA","Male",1532,"Active, not recruiting","Phase 3","\t"]
["NCT00033631",4515758,8267384,"Prostate-specific Antigen (PSA) Failure by American Society for Therapeutic Radiology and Oncology (ASTRO) Definition","NA","70.2 Gy 3D-CRT/IMRT|79.2 Gy 3D-CRT/IMRT","Radiation|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy in Treating Patients With Stage II Prostate Cancer",2,"Hazard Ratio (HR)",0.59,{"v":1E-4,"d":"1.00E-04"},"Gray's test",0.5,0.7,95,null,"NA","Male",1532,"Active, not recruiting","Phase 3","\t"]
["NCT00033631",4515759,8267385,"Overall Survival","NA","70.2 Gy 3D-CRT/IMRT|79.2 Gy 3D-CRT/IMRT","Radiation|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy in Treating Patients With Stage II Prostate Cancer",2,"Hazard Ratio (HR)",1,0.98,"Log Rank",0.83,1.2,95,null,"NA","Male",1532,"Active, not recruiting","Phase 3","\t"]
["NCT00033657",4515751,8267373,"Overall Survival Time","camptothecin|cisplatin|irinotecan|paclitaxel","cisplatin|irinotecan hydrochloride|paclitaxel|conventional surgery|radiation therapy","Drug|Drug|Drug|Procedure|Radiation","esophageal neoplasms|stomach neoplasms","Esophageal Cancer|Gastric Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer",2,null,"NA",0.48,"Log Rank",{"$nulls":4},"NA","All",97,"Completed","Phase 2","\t"]
["NCT00035815",4516638,8268636,"Rate of Change in ALS Functional Rating Scale.","mitogens","Insulin like growth factor, type 1|Placebo","Drug|Drug","motor neuron disease|sclerosis|amyotrophic lateral sclerosis","Amyotrophic Lateral Sclerosis","Parallel Assignment","Interventional","Treatment","Randomized","Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial",2,null,"NA",0.321,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",330,"Completed","Phase 3","\t"]
["NCT00035815",4516639,8268637,"Number of Participants Alive and Tracheostomy-free at 24 Months","mitogens","Insulin like growth factor, type 1|Placebo","Drug|Drug","motor neuron disease|sclerosis|amyotrophic lateral sclerosis","Amyotrophic Lateral Sclerosis","Parallel Assignment","Interventional","Treatment","Randomized","Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial",2,"Cox Proportional Hazard",1.04,0.415,"Regression, Cox",0.77,1.4,95,null,"NA","All",330,"Completed","Phase 3","\t"]
["NCT00035815",4516640,8268638,"Rate of Change in Composite Manual Muscle Testing (MMT) Score","mitogens","Insulin like growth factor, type 1|Placebo","Drug|Drug","motor neuron disease|sclerosis|amyotrophic lateral sclerosis","Amyotrophic Lateral Sclerosis","Parallel Assignment","Interventional","Treatment","Randomized","Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial",2,null,"NA",0.529,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",330,"Completed","Phase 3","\t"]
["NCT00035932",4516582,8268598,"Mean Change From Baseline in HIV RNA at Week 96","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"time-averaged difference",0.11,"NA",null,-0.16,0.38,97.5,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516583,8268598,"Mean Change From Baseline in HIV RNA at Week 96","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"time-averaged difference",0.14,"NA",null,-0.13,0.41,97.5,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516586,8268609,"Lipid Mean Percent Change From Baseline at Week 96, Observed Values","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-7.9,"NA",null,-19,4.8,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516589,8268609,"Lipid Mean Percent Change From Baseline at Week 96, Observed Values","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-11,"NA",null,-19.9,-1.2,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516587,8268609,"Lipid Mean Percent Change From Baseline at Week 96, Observed Values","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-12.7,"NA",null,-22.3,-1.8,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516591,8268609,"Lipid Mean Percent Change From Baseline at Week 96, Observed Values","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-14.4,"NA",null,-20.1,-8.3,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516584,8268609,"Lipid Mean Percent Change From Baseline at Week 96, Observed Values","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-19.8,"NA",null,-36.5,1.3,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516585,8268609,"Lipid Mean Percent Change From Baseline at Week 96, Observed Values","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-24.8,"NA",null,-38.6,-8,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516588,8268609,"Lipid Mean Percent Change From Baseline at Week 96, Observed Values","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-4.1,"NA",null,-14,7,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516590,8268609,"Lipid Mean Percent Change From Baseline at Week 96, Observed Values","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-9,"NA",null,-16.1,-1.3,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516592,8268610,"Lipid Mean Percent Change From Baseline at Week 48","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-38.4,"NA",null,-49.7,-27.1,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516595,8268610,"Lipid Mean Percent Change From Baseline at Week 48","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-8.9,"NA",null,-19,1.2,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516599,8268610,"Lipid Mean Percent Change From Baseline at Week 48","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-12.1,"NA",null,-17,-7.2,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516594,8268610,"Lipid Mean Percent Change From Baseline at Week 48","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-7.4,"NA",null,-17.7,3,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516596,8268610,"Lipid Mean Percent Change From Baseline at Week 48","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"DIfference Estimate",-0.8,"NA",null,-11,9.3,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516597,8268610,"Lipid Mean Percent Change From Baseline at Week 48","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-4.4,"NA",null,-12.4,3.5,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516598,8268610,"Lipid Mean Percent Change From Baseline at Week 48","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-12,"NA",null,-17.4,-6.5,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516593,8268610,"Lipid Mean Percent Change From Baseline at Week 48","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-29.6,"NA",null,-41.6,-17.7,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516603,8268611,"Lipid Mean Percent Change From Baseline at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-6.8,"NA",null,-15.6,3,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516602,8268611,"Lipid Mean Percent Change From Baseline at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-7.3,"NA",null,-15.5,1.8,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516606,8268611,"Lipid Mean Percent Change From Baseline at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-12.4,"NA",null,-16.9,-7.6,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516601,8268611,"Lipid Mean Percent Change From Baseline at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-24.9,"NA",null,-35,-13.2,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516600,8268611,"Lipid Mean Percent Change From Baseline at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-34.2,"NA",null,-43.4,-23.4,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516605,8268611,"Lipid Mean Percent Change From Baseline at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-6.7,"NA",null,-13.6,0.7,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516607,8268611,"Lipid Mean Percent Change From Baseline at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-10.9,"NA",null,-15.5,-6,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516604,8268611,"Lipid Mean Percent Change From Baseline at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-1,"NA",null,-9.3,8.1,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516610,8268613,"Correlation of ATV Minimum Plasma Concentration (Cmin) Inhibitory Quotient (IQ), and Number of PI Mutations at Baseline and CD4 Cell Count Change From Baseline at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,null,"NA",0.05,"t-test, 1 sided",{"$nulls":4},"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516609,8268613,"Correlation of ATV Minimum Plasma Concentration (Cmin) Inhibitory Quotient (IQ), and Number of PI Mutations at Baseline and CD4 Cell Count Change From Baseline at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,null,"NA",0.05,"t-test, 1 sided",{"$nulls":4},"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516608,8268613,"Correlation of ATV Minimum Plasma Concentration (Cmin) Inhibitory Quotient (IQ), and Number of PI Mutations at Baseline and CD4 Cell Count Change From Baseline at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,null,"NA",0.05,"t-test, 1 sided",{"$nulls":4},"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516612,8268615,"Correlation of ATV Minimum Plasma Concentration (Cmin), Inhibitory Quotient (IQ), and Number of Protease Inhibitor (PI) Mutations at Baseline With HIV RNA Change From Baseline at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,null,"NA",0.05,"t-test, 1 sided",{"$nulls":4},"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516611,8268615,"Correlation of ATV Minimum Plasma Concentration (Cmin), Inhibitory Quotient (IQ), and Number of Protease Inhibitor (PI) Mutations at Baseline With HIV RNA Change From Baseline at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,null,"NA",0.05,"t-test, 1 sided",{"$nulls":4},"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516613,8268617,"Change From Baseline in CD4 Cell Count at Week 48","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Time-Averaged Difference",-47.6,"NA",null,-79.2,-16.1,97.5,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516614,8268617,"Change From Baseline in CD4 Cell Count at Week 48","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Time-Averaged Difference",-17.5,"NA",null,-45.6,10.6,97.5,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516615,8268618,"Change From Baseline in CD4 Cell Count at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Time-Averaged Difference",-44.9,"NA",null,-74.5,-15.3,97.5,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516616,8268618,"Change From Baseline in CD4 Cell Count at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Time-Averaged Difference",-18.4,"NA",null,-44.3,7.5,97.5,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516618,8268620,"Participants Achieving Treatment Response (LOQ = 50 c/mL) Without Prior Failure at Week 48","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-6.4,"NA",null,-18.7,5.8,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516617,8268620,"Participants Achieving Treatment Response (LOQ = 50 c/mL) Without Prior Failure at Week 48","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-17.9,"NA",null,-29.9,-5.9,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516620,8268621,"Participants Achieving Treatment Response (LOQ = 50 c/mL) Without Prior Failure at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-2.3,"NA",null,-14.6,10,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516619,8268621,"Participants Achieving Treatment Response (LOQ = 50 c/mL) Without Prior Failure at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-18.9,"NA",null,-30.7,-7.1,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516621,8268622,"Participants Achieving Treatment Response (LOQ = 400 c/mL) Without Prior Failure at Week 96","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-2.4,"NA",null,-15,10.3,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516623,8268623,"Participants Achieving Treatment Response (LOQ = 400 c/mL) Without Prior Failure at Week 48","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-1.1,"NA",null,-13.7,11.4,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516622,8268623,"Participants Achieving Treatment Response (LOQ = 400 c/mL) Without Prior Failure at Week 48","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-17.9,"NA",null,-30.6,-5.3,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516624,8268624,"Participants Achieving Treatment Response (LOQ = 400 c/mL) Without Prior Failure at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-16.7,"NA",null,-29.4,-4,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516625,8268624,"Participants Achieving Treatment Response (LOQ = 400 c/mL) Without Prior Failure at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",3.2,"NA",null,-9.1,15.4,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516626,8268625,"Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 96","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",0.4,"NA",null,-12.5,13.2,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516627,8268627,"Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 48","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-16.1,"NA",null,-28.5,-3.7,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516628,8268627,"Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 48","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-5,"NA",null,-16.9,7,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516630,8268629,"Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",3.6,"NA",null,-7,14.1,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516629,8268629,"Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference Estimate",-11.3,"NA",null,-22.9,0.4,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516631,8268630,"Participants Achieving Virologic Half Log Suppression (LOQ = 400 c/mL) at Week 96","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Difference estimate",-0.5,"NA",null,-13.3,12.3,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516632,8268631,"Mean Change From Baseline in HIV RNA at Week 48","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Time-Averaged Distance",0.33,"NA",null,0.07,0.6,97.5,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516633,8268631,"Mean Change From Baseline in HIV RNA at Week 48","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Time-Averaged Difference",0.13,"NA",null,-0.12,0.39,97.5,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516635,8268634,"Mean Change From Baseline in HIV RNA at Week 2","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Treatment Difference",0.13,"NA",null,-0.04,0.3,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516634,8268634,"Mean Change From Baseline in HIV RNA at Week 2","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Treatment Difference",0.17,"NA",null,-0.01,0.35,95,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516636,8268635,"Mean Change From Baseline in HIV Ribonucleic Acid (RNA) at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Time-Averaged Difference",0.31,"NA",null,0.07,0.55,97.5,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00035932",4516637,8268635,"Mean Change From Baseline in HIV Ribonucleic Acid (RNA) at Week 24","atazanavir sulfate|lopinavir|ritonavir|saquinavir|tenofovir","Atazanavir + ritonavir + tenofovir + nucleoside|Atazanavir + saquinavir + tenofovir + nucleoside|Lopinavir/ritonavir + tenofovir + nucleoside","Drug|Drug|Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",3,"Time-Averaged Difference",0.14,"NA",null,-0.09,0.37,97.5,null,"NA","All",571,"Completed","Phase 3","\t"]
["NCT00036270",4516578,8268586,"Number of Events for Time to Relapse","tamoxifen|exemestane","exemestane (Aromasin)|tamoxifen + exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane",2,"Hazard Ratio (HR)",0.94,0.293,"Log Rank",0.83,1.06,95,null,"NA","Female",9779,"Completed","Phase 3","\t"]
["NCT00036270",4516579,8268588,"Number of Events for Overall Survival (OS)","tamoxifen|exemestane","exemestane (Aromasin)|tamoxifen + exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane",2,"Hazard Ratio (HR)",1,0.951,"Log Rank",0.89,1.14,95,null,"NA","Female",9779,"Completed","Phase 3","\t"]
["NCT00036270",4516580,8268589,"Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 5 Years","tamoxifen|exemestane","exemestane (Aromasin)|tamoxifen + exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane",2,"Hazard Ratio (HR)",0.97,0.604,"Log Rank",0.88,1.08,95,null,"NA","Female",9779,"Completed","Phase 3","\t"]
["NCT00036270",4516581,8268590,"Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years","tamoxifen|exemestane","exemestane (Aromasin)|tamoxifen + exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane",2,"Hazard Ratio (HR)",0.89,0.118,"Log Rank",0.77,1.03,95,null,"NA","Female",9779,"Completed","Phase 3","\t"]
["NCT00037830",4516566,8268570,"Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 96 Assessed Off Medication.","NA","GM1 ganglioside|Placebo","Drug|Drug","parkinson disease","Parkinson Disease","Crossover Assignment","Interventional","Treatment","Randomized","GM1 Ganglioside Effects on Parkinson's Disease",3,null,"NA",0.01,"t-test, 2 sided",{"$nulls":4},"NA","All",94,"Completed","Phase 2","\t"]
["NCT00037830",4516567,8268571,"Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 72 Assessed Off Medication.","NA","GM1 ganglioside|Placebo","Drug|Drug","parkinson disease","Parkinson Disease","Crossover Assignment","Interventional","Treatment","Randomized","GM1 Ganglioside Effects on Parkinson's Disease",3,null,"NA",0.01,"t-test, 2 sided",{"$nulls":4},"NA","All",94,"Completed","Phase 2","\t"]
["NCT00037830",4516568,8268572,"Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 48 Assessed Off Medication.","NA","GM1 ganglioside|Placebo","Drug|Drug","parkinson disease","Parkinson Disease","Crossover Assignment","Interventional","Treatment","Randomized","GM1 Ganglioside Effects on Parkinson's Disease",3,null,"NA",0.01,"t-test, 2 sided",{"$nulls":4},"NA","All",94,"Completed","Phase 2","\t"]
["NCT00037830",4516569,8268573,"Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 24 Assessed Off Medication.","NA","GM1 ganglioside|Placebo","Drug|Drug","parkinson disease","Parkinson Disease","Crossover Assignment","Interventional","Treatment","Randomized","GM1 Ganglioside Effects on Parkinson's Disease",3,null,"NA",0.05,"t-test, 2 sided",{"$nulls":4},"NA","All",94,"Completed","Phase 2","\t"]
["NCT00037830",4516570,8268574,"Change in Total UPDRS Score From Baseline to Week 120 Assessed Off Medication","NA","GM1 ganglioside|Placebo","Drug|Drug","parkinson disease","Parkinson Disease","Crossover Assignment","Interventional","Treatment","Randomized","GM1 Ganglioside Effects on Parkinson's Disease",3,null,"NA",0.131,"t-test, 2 sided",{"$nulls":4},"NA","All",94,"Completed","Phase 2","\t"]
["NCT00037830",4516571,8268575,"Change From Baseline to Week 24 in Total Unified Parkinson's Disease Rating Scale (UPDRS)Score Assessed Off Medication","NA","GM1 ganglioside|Placebo","Drug|Drug","parkinson disease","Parkinson Disease","Crossover Assignment","Interventional","Treatment","Randomized","GM1 Ganglioside Effects on Parkinson's Disease",3,null,"NA",{"v":1E-4,"d":"1.00E-04"},"t-test, 2 sided",{"$nulls":4},"NA","All",94,"Completed","Phase 2","\t"]
["NCT00037830",4516572,8268576,"Estimated Rate of Change in Unified Parkinson's Disease Rating Scale (UPDRS)Motor Scores Assessed Off Medication","NA","GM1 ganglioside|Placebo","Drug|Drug","parkinson disease","Parkinson Disease","Crossover Assignment","Interventional","Treatment","Randomized","GM1 Ganglioside Effects on Parkinson's Disease",3,null,"NA",{"v":0.0003,"d":"3.00E-04"},"estimate slope of change over time",{"$nulls":4},"NA","All",94,"Completed","Phase 2","\t"]
["NCT00037830",4516573,8268576,"Estimated Rate of Change in Unified Parkinson's Disease Rating Scale (UPDRS)Motor Scores Assessed Off Medication","NA","GM1 ganglioside|Placebo","Drug|Drug","parkinson disease","Parkinson Disease","Crossover Assignment","Interventional","Treatment","Randomized","GM1 Ganglioside Effects on Parkinson's Disease",3,null,"NA",0.0502,"estimate of slope of change over time",{"$nulls":4},"NA","All",94,"Completed","Phase 2","\t"]
["NCT00037830",4516575,8268577,"Estimated Change in Points Per Week on Unified Parkinson's Disease Rating Scale (UPDRS) Motor Score Assessed Off Medication","NA","GM1 ganglioside|Placebo","Drug|Drug","parkinson disease","Parkinson Disease","Crossover Assignment","Interventional","Treatment","Randomized","GM1 Ganglioside Effects on Parkinson's Disease",3,null,"NA",0.1903,"estimate of slope of change over time",{"$nulls":4},"NA","All",94,"Completed","Phase 2","\t"]
["NCT00037830",4516574,8268577,"Estimated Change in Points Per Week on Unified Parkinson's Disease Rating Scale (UPDRS) Motor Score Assessed Off Medication","NA","GM1 ganglioside|Placebo","Drug|Drug","parkinson disease","Parkinson Disease","Crossover Assignment","Interventional","Treatment","Randomized","GM1 Ganglioside Effects on Parkinson's Disease",3,null,"NA",6.3E-3,"estimate slope of change over time",{"$nulls":4},"NA","All",94,"Completed","Phase 2","\t"]
["NCT00037830",4516576,8268578,"Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Scores From Baseline to Week 120 Assessed Off Medication.","NA","GM1 ganglioside|Placebo","Drug|Drug","parkinson disease","Parkinson Disease","Crossover Assignment","Interventional","Treatment","Randomized","GM1 Ganglioside Effects on Parkinson's Disease",3,null,"NA",0.0368,"t-test, 2 sided",{"$nulls":4},"NA","All",94,"Completed","Phase 2","\t"]
["NCT00037830",4516577,8268579,"Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 24 Assessed Off Medication.","NA","GM1 ganglioside|Placebo","Drug|Drug","parkinson disease","Parkinson Disease","Crossover Assignment","Interventional","Treatment","Randomized","GM1 Ganglioside Effects on Parkinson's Disease",3,null,"NA",{"v":1E-4,"d":"1.00E-04"},"t-test, 2 sided",{"$nulls":4},"NA","All",94,"Completed","Phase 2","\t"]
["NCT00038103",4516562,8268568,"Number of Subjects With Objective Response","celecoxib|exemestane","Exemestane|Celecoxib + Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen",2,"Objective Response Rate",23.5,"NA",null,12.8,37.5,95,null,"NA","Female",111,"Completed","Phase 2","\t"]
["NCT00038103",4516563,8268568,"Number of Subjects With Objective Response","celecoxib|exemestane","Exemestane|Celecoxib + Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen",2,"Objective Response Rate",22.4,"NA",null,11.8,36.6,95,null,"NA","Female",111,"Completed","Phase 2","\t"]
["NCT00038103",4516564,8268569,"Number of Subjects With Clinical Benefit","celecoxib|exemestane","Exemestane|Celecoxib + Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen",2,"Clinical Benefit Rate",47.1,"NA",null,32.9,61.5,95,null,"NA","Female",111,"Completed","Phase 2","\t"]
["NCT00038103",4516565,8268569,"Number of Subjects With Clinical Benefit","celecoxib|exemestane","Exemestane|Celecoxib + Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen",2,"Clinical Benefit Rate",49,"NA",null,34.4,63.7,95,null,"NA","Female",111,"Completed","Phase 2","\t"]
["NCT00038467",4516499,8268538,"Percentage of Participants With Endometrial Thickness Greater Than or Equal to (>=) 5 Millimeter (mm): Endometrial Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,null,"NA",0.0059,"Chi-squared",{"$nulls":4},"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516500,8268538,"Percentage of Participants With Endometrial Thickness Greater Than or Equal to (>=) 5 Millimeter (mm): Endometrial Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,null,"NA",0.0174,"Chi-squared",{"$nulls":4},"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516496,8268538,"Percentage of Participants With Endometrial Thickness Greater Than or Equal to (>=) 5 Millimeter (mm): Endometrial Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,null,"NA",0.6449,"Chi-squared",{"$nulls":4},"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516497,8268538,"Percentage of Participants With Endometrial Thickness Greater Than or Equal to (>=) 5 Millimeter (mm): Endometrial Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,null,"NA",0.8084,"Chi-squared",{"$nulls":4},"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516498,8268538,"Percentage of Participants With Endometrial Thickness Greater Than or Equal to (>=) 5 Millimeter (mm): Endometrial Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,null,"NA",0.0037,"Chi-squared",{"$nulls":4},"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516503,8268540,"Change From Baseline in Breast Cancer Subscale (BCS) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",0.24,0.53,"t-test, 2 sided",-0.5,0.98,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516502,8268540,"Change From Baseline in Breast Cancer Subscale (BCS) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.61,0.147,"t-test, 2 sided",-1.43,0.21,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516501,8268540,"Change From Baseline in Breast Cancer Subscale (BCS) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.36,0.389,"t-test, 2 sided",-1.18,0.46,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516505,8268540,"Change From Baseline in Breast Cancer Subscale (BCS) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.5,0.195,"t-test, 2 sided",-1.25,0.26,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516506,8268540,"Change From Baseline in Breast Cancer Subscale (BCS) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",0.05,0.876,"t-test, 2 sided",-0.62,0.73,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516504,8268540,"Change From Baseline in Breast Cancer Subscale (BCS) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.18,0.63,"t-test, 2 sided",-0.92,0.55,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516512,8268541,"Change From Baseline in Functional Well-Being (FWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.14,0.648,"t-test, 2 sided",-0.77,0.48,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516511,8268541,"Change From Baseline in Functional Well-Being (FWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.34,0.366,"t-test, 2 sided",-1.08,0.4,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516510,8268541,"Change From Baseline in Functional Well-Being (FWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.65,0.062,"t-test, 2 sided",-1.33,0.03,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516508,8268541,"Change From Baseline in Functional Well-Being (FWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.03,0.932,"t-test, 2 sided",-0.77,0.7,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516507,8268541,"Change From Baseline in Functional Well-Being (FWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.46,0.244,"t-test, 2 sided",-1.24,0.32,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516509,8268541,"Change From Baseline in Functional Well-Being (FWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",0.24,0.545,"t-test, 2 sided",-0.53,1,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516513,8268542,"Change From Baseline in Emotional Well-Being (EWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.24,0.405,"t-test, 2 sided",-0.82,0.33,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516518,8268542,"Change From Baseline in Emotional Well-Being (EWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",0.07,0.792,"t-test, 2 sided",-0.42,0.56,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516517,8268542,"Change From Baseline in Emotional Well-Being (EWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.23,0.405,"t-test, 2 sided",-0.76,0.31,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516515,8268542,"Change From Baseline in Emotional Well-Being (EWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",0.3,0.229,"t-test, 2 sided",-0.19,0.8,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516516,8268542,"Change From Baseline in Emotional Well-Being (EWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.2,0.484,"t-test, 2 sided",-0.75,0.36,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516514,8268542,"Change From Baseline in Emotional Well-Being (EWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.26,0.381,"t-test, 2 sided",-0.84,0.32,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516522,8268543,"Change From Baseline in Relationship With Doctor (RWD) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Substudy","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",0.01,0.883,"t-test, 2 sided",-0.18,0.21,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516519,8268543,"Change From Baseline in Relationship With Doctor (RWD) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Substudy","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",0.12,0.307,"t-test, 2 sided",-0.11,0.34,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516520,8268543,"Change From Baseline in Relationship With Doctor (RWD) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Substudy","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",0.18,0.118,"t-test, 2 sided",-0.05,0.41,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516521,8268543,"Change From Baseline in Relationship With Doctor (RWD) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Substudy","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",0.06,0.604,"t-test, 2 sided",-0.16,0.27,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516523,8268543,"Change From Baseline in Relationship With Doctor (RWD) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Substudy","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",0.02,0.881,"t-test, 2 sided",-0.21,0.24,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516524,8268543,"Change From Baseline in Relationship With Doctor (RWD) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Substudy","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.01,0.892,"t-test, 2 sided",-0.2,0.18,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516529,8268544,"Change From Baseline in Social/Family Well-Being (SWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",0.12,0.712,"t-test, 2 sided",-0.53,0.335,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516528,8268544,"Change From Baseline in Social/Family Well-Being (SWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",0.05,0.899,"t-test, 2 sided",-0.65,0.356,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516527,8268544,"Change From Baseline in Social/Family Well-Being (SWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.05,0.882,"t-test, 2 sided",-0.76,0.359,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516526,8268544,"Change From Baseline in Social/Family Well-Being (SWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",0.19,0.604,"t-test, 2 sided",-0.54,0.37,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516525,8268544,"Change From Baseline in Social/Family Well-Being (SWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.26,0.562,"t-test, 2 sided",-1.16,0.454,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516535,8268545,"Change From Baseline in Physical Well-Being (PWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.3,0.265,"t-test, 2 sided",-0.83,0.23,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516530,8268545,"Change From Baseline in Physical Well-Being (PWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.22,0.454,"t-test, 2 sided",-0.81,0.36,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516534,8268545,"Change From Baseline in Physical Well-Being (PWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-1.21,{"v":0.0002,"d":"2.00E-04"},"t-test, 2 sided",-1.84,-0.57,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516531,8268545,"Change From Baseline in Physical Well-Being (PWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.21,0.449,"t-test, 2 sided",-0.75,0.33,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516533,8268545,"Change From Baseline in Physical Well-Being (PWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.44,0.132,"t-test, 2 sided",-1,0.13,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516532,8268545,"Change From Baseline in Physical Well-Being (PWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.14,0.635,"t-test, 2 sided",-0.7,0.43,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516538,8268546,"Change From Baseline in Total Functional Assessment of Cancer Therapy - General Breast and Endocrine (FACT-GBE) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",0.91,0.563,"t-test, 2 sided",-2.17,3.99,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516541,8268546,"Change From Baseline in Total Functional Assessment of Cancer Therapy - General Breast and Endocrine (FACT-GBE) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.52,0.727,"t-test, 2 sided",-3.46,2.42,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516537,8268546,"Change From Baseline in Total Functional Assessment of Cancer Therapy - General Breast and Endocrine (FACT-GBE) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.73,0.643,"t-test, 2 sided",-3.83,2.36,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516540,8268546,"Change From Baseline in Total Functional Assessment of Cancer Therapy - General Breast and Endocrine (FACT-GBE) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-3.08,0.047,"t-test, 2 sided",-6.12,-0.05,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516536,8268546,"Change From Baseline in Total Functional Assessment of Cancer Therapy - General Breast and Endocrine (FACT-GBE) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-2.91,0.126,"t-test, 2 sided",-6.63,0.82,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516539,8268546,"Change From Baseline in Total Functional Assessment of Cancer Therapy - General Breast and Endocrine (FACT-GBE) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.9,0.553,"t-test, 2 sided",-3.88,2.08,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516542,8268547,"Change From Baseline in Functional Assessment of Cancer Therapy - Endocrine Subscale (FACT-ES) Total Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",0.42,0.537,"t-test, 2 sided",-0.91,1.75,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516544,8268547,"Change From Baseline in Functional Assessment of Cancer Therapy - Endocrine Subscale (FACT-ES) Total Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",0.83,0.192,"t-test, 2 sided",-0.42,2.09,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516547,8268547,"Change From Baseline in Functional Assessment of Cancer Therapy - Endocrine Subscale (FACT-ES) Total Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.65,0.26,"t-test, 2 sided",-1.8,0.49,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516543,8268547,"Change From Baseline in Functional Assessment of Cancer Therapy - Endocrine Subscale (FACT-ES) Total Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.16,0.813,"t-test, 2 sided",-1.46,1.15,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516546,8268547,"Change From Baseline in Functional Assessment of Cancer Therapy - Endocrine Subscale (FACT-ES) Total Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.79,0.209,"t-test, 2 sided",-2.02,0.44,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516545,8268547,"Change From Baseline in Functional Assessment of Cancer Therapy - Endocrine Subscale (FACT-ES) Total Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.23,0.698,"t-test, 2 sided",-1.38,0.92,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516552,8268548,"Change From Baseline in Treatment Outcome Index (TOI) at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-2.1,0.009,"t-test, 2 sided",-3.67,-0.52,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516553,8268548,"Change From Baseline in Treatment Outcome Index (TOI) at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.45,0.5,"t-test, 2 sided",-1.76,0.86,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516549,8268548,"Change From Baseline in Treatment Outcome Index (TOI) at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-0.84,0.302,"t-test, 2 sided",-2.43,0.75,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516550,8268548,"Change From Baseline in Treatment Outcome Index (TOI) at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",0.27,0.729,"t-test, 2 sided",-1.24,1.77,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516548,8268548,"Change From Baseline in Treatment Outcome Index (TOI) at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-1.11,0.187,"t-test, 2 sided",-2.76,0.54,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516551,8268548,"Change From Baseline in Treatment Outcome Index (TOI) at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",-1.35,0.079,"t-test, 2 sided",-2.86,0.16,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516559,8268557,"Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",2.43,{"v":1E-4,"d":"1.00E-04"},"t-test, 2 sided",1.63,3.23,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516556,8268557,"Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",1.79,{"v":1E-4,"d":"1.00E-04"},"t-test, 2 sided",1.12,2.46,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516555,8268557,"Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",3.22,{"v":1E-4,"d":"1.00E-04"},"t-test, 2 sided",2.1,4.35,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516557,8268557,"Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",2.79,{"v":1E-4,"d":"1.00E-04"},"t-test, 2 sided",1.77,3.81,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516558,8268557,"Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",1.18,{"v":0.0002,"d":"2.00E-04"},"t-test, 2 sided",0.57,1.79,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516554,8268557,"Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Mean Difference (Final Values)",1.9,{"v":1E-4,"d":"1.00E-04"},"t-test, 2 sided",1.1,2.69,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516560,8268559,"Overall Survival (OS) at Month 36 Post-Randomization: Main Study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Hazard Ratio (HR)",0.913,0.15737,"Log Rank",0.806,1.036,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038467",4516561,8268560,"Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study","tamoxifen|exemestane","Tamoxifen|Exemestane","Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",2,"Hazard Ratio (HR)",0.69,{"v":3e-05,"d":"3.00E-05"},"Log Rank",0.58,0.82,95,null,"NA","Female",4740,"Completed","Phase 3","\t"]
["NCT00038948",4516493,8268516,"First Occurrence of Biopsy-confirmed Acute Rejection, Graft Loss, or Death.","cyclosporine|sirolimus|cyclosporins|tacrolimus","Sirolimus|tacrolimus|Cyclosporine A","Drug|Drug|Drug","NA","Renal Transplantation","Parallel Assignment","Interventional","Treatment","Randomized","Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients",2,null,"NA",0.135,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",830,"Completed","Phase 3","\t"]
["NCT00038948",4516492,8268516,"First Occurrence of Biopsy-confirmed Acute Rejection, Graft Loss, or Death.","cyclosporine|sirolimus|cyclosporins|tacrolimus","Sirolimus|tacrolimus|Cyclosporine A","Drug|Drug|Drug","NA","Renal Transplantation","Parallel Assignment","Interventional","Treatment","Randomized","Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients",2,null,"NA",0.559,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",830,"Completed","Phase 3","\t"]
["NCT00038948",4516495,8268517,"Nankivell Glomerular Filtration Rate (GFR)","cyclosporine|sirolimus|cyclosporins|tacrolimus","Sirolimus|tacrolimus|Cyclosporine A","Drug|Drug|Drug","NA","Renal Transplantation","Parallel Assignment","Interventional","Treatment","Randomized","Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients",2,"Weighted difference",-2.68,0.575,"ANCOVA",-12.27,6.91,95,null,"NA","All",830,"Completed","Phase 3","\t"]
["NCT00038948",4516494,8268517,"Nankivell Glomerular Filtration Rate (GFR)","cyclosporine|sirolimus|cyclosporins|tacrolimus","Sirolimus|tacrolimus|Cyclosporine A","Drug|Drug|Drug","NA","Renal Transplantation","Parallel Assignment","Interventional","Treatment","Randomized","Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients",2,"Weighted difference",1.31,0.278,"ANCOVA",-1.06,3.69,95,null,"NA","All",830,"Completed","Phase 3","\t"]
["NCT00040443",4516486,8268497,"15-Item Word List Delayed Recall","NA","CX516|Placebo","Drug|Drug","cognitive dysfunction","Mild Cognitive Impairment","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.",2,"Mean Difference (Final Values)",5,0.05,"t-test, 2 sided",null,null,95,"Standard Error of the Mean",1,"All",175,"Completed","Phase 2","\t"]
["NCT00040742",4515744,8267356,"Average Nausea Severity","NA","ginger|placebo","Dietary Supplement|Other","nausea|vomiting","Nausea|Vomiting","Parallel Assignment","Interventional","Prevention","Randomized","Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer",4,"Mean Difference (Final Values)",-0.158,0.738,"Mixed Models Analysis",{"$nulls":3},"Standard Error of the Mean",0.12,"All",745,"Completed","Phase 2/Phase 3","\t"]
["NCT00040742",4515743,8267356,"Average Nausea Severity","NA","ginger|placebo","Dietary Supplement|Other","nausea|vomiting","Nausea|Vomiting","Parallel Assignment","Interventional","Prevention","Randomized","Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer",4,"Mean Difference (Final Values)",-0.35,0.013,"Mixed Models Analysis",{"$nulls":3},"Standard Error of the Mean",0.14,"All",745,"Completed","Phase 2/Phase 3","\t"]
["NCT00040742",4515746,8267356,"Average Nausea Severity","NA","ginger|placebo","Dietary Supplement|Other","nausea|vomiting","Nausea|Vomiting","Parallel Assignment","Interventional","Prevention","Randomized","Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer",4,"Mean Difference (Final Values)",-0.441,0.046,"Mixed Models Analysis",{"$nulls":3},"Standard Error of the Mean",0.127,"All",745,"Completed","Phase 2/Phase 3","\t"]
["NCT00040742",4515745,8267356,"Average Nausea Severity","NA","ginger|placebo","Dietary Supplement|Other","nausea|vomiting","Nausea|Vomiting","Parallel Assignment","Interventional","Prevention","Randomized","Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer",4,"Mean Difference (Final Values)",-0.402,0.076,"Mixed Models Analysis",{"$nulls":3},"Standard Error of the Mean",0.124,"All",745,"Completed","Phase 2/Phase 3","\t"]
["NCT00040742",4515750,8267357,"Change From Baseline of Peak Acute Nausea","NA","ginger|placebo","Dietary Supplement|Other","nausea|vomiting","Nausea|Vomiting","Parallel Assignment","Interventional","Prevention","Randomized","Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer",4,"Mean Difference (Final Values)",-0.566,0.017,"Mixed Models Analysis",{"$nulls":3},"Standard Error of the Mean",0.145,"All",745,"Completed","Phase 2/Phase 3","\t"]
["NCT00040742",4515748,8267357,"Change From Baseline of Peak Acute Nausea","NA","ginger|placebo","Dietary Supplement|Other","nausea|vomiting","Nausea|Vomiting","Parallel Assignment","Interventional","Prevention","Randomized","Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer",4,"Mean Difference (Final Values)",-0.269,0.431,"Mixed Models Analysis",{"$nulls":3},"Standard Error of the Mean",0.137,"All",745,"Completed","Phase 2/Phase 3","\t"]
["NCT00040742",4515749,8267357,"Change From Baseline of Peak Acute Nausea","NA","ginger|placebo","Dietary Supplement|Other","nausea|vomiting","Nausea|Vomiting","Parallel Assignment","Interventional","Prevention","Randomized","Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer",4,"Mean Difference (Final Values)",-0.506,0.036,"Mixed Models Analysis",{"$nulls":3},"Standard Error of the Mean",0.141,"All",745,"Completed","Phase 2/Phase 3","\t"]
["NCT00040742",4515747,8267357,"Change From Baseline of Peak Acute Nausea","NA","ginger|placebo","Dietary Supplement|Other","nausea|vomiting","Nausea|Vomiting","Parallel Assignment","Interventional","Prevention","Randomized","Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer",4,"Mean Difference (Final Values)",-0.47,0.003,"Mixed Models Analysis",{"$nulls":3},"Standard Error of the Mean",0.16,"All",745,"Completed","Phase 2/Phase 3","\t"]
["NCT00041938",4516474,8268462,"Rate Per 100 Patient-years of Minor Hemorrhage.","warfarin|aspirin","aspirin|Warfarin","Drug|Drug","myocardial ischemia|coronary artery disease|heart diseases|infarction|myocardial infarction","Heart Disease|Ischemic Heart Disease|Myocardial Infarction|Stroke","Parallel Assignment","Interventional","Prevention","Randomized","Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial",2,"Rate ratio",1.56,1E-3,"Regression, Poisson",1.34,1.81,95,null,"NA","All",2305,"Completed","Phase 3","\t"]
["NCT00041938",4516475,8268463,"Rate Per 100 Patient Years of Major Hemorrhage","warfarin|aspirin","aspirin|Warfarin","Drug|Drug","myocardial ischemia|coronary artery disease|heart diseases|infarction|myocardial infarction","Heart Disease|Ischemic Heart Disease|Myocardial Infarction|Stroke","Parallel Assignment","Interventional","Prevention","Randomized","Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial",2,"Rate ratio",2.05,1E-3,"Regression, Poisson",1.36,3.12,95,null,"NA","All",2305,"Completed","Phase 3","\t"]
["NCT00041938",4516476,8268464,"Event Rate Per 100 Patient Years of Death Component of Secondary Composite Outcome","warfarin|aspirin","aspirin|Warfarin","Drug|Drug","myocardial ischemia|coronary artery disease|heart diseases|infarction|myocardial infarction","Heart Disease|Ischemic Heart Disease|Myocardial Infarction|Stroke","Parallel Assignment","Interventional","Prevention","Randomized","Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial",2,"Hazard Ratio (HR)",1.03,0.83,"Regression, Cox",0.81,1.3,95,null,"NA","All",2305,"Completed","Phase 3","\t"]
["NCT00041938",4516477,8268465,"Event Rate Per 100 Patient Years of Intracerebral Hemorrhage Component of Secondary Composite Outcome","warfarin|aspirin","aspirin|Warfarin","Drug|Drug","myocardial ischemia|coronary artery disease|heart diseases|infarction|myocardial infarction","Heart Disease|Ischemic Heart Disease|Myocardial Infarction|Stroke","Parallel Assignment","Interventional","Prevention","Randomized","Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial",2,"Hazard Ratio (HR)",1.77,0.51,"Regression, Cox",0.32,9.88,95,null,"NA","All",2305,"Completed","Phase 3","\t"]
["NCT00041938",4516478,8268466,"Event Rate Per 100 Patient Years of Ischemic Stroke Component of Secondary Composite Outcome","warfarin|aspirin","aspirin|Warfarin","Drug|Drug","myocardial ischemia|coronary artery disease|heart diseases|infarction|myocardial infarction","Heart Disease|Ischemic Heart Disease|Myocardial Infarction|Stroke","Parallel Assignment","Interventional","Prevention","Randomized","Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial",2,"Hazard Ratio (HR)",0.55,0.03,"Regression, Cox",0.32,0.96,95,null,"NA","All",2305,"Completed","Phase 3","\t"]
["NCT00041938",4516479,8268467,"Event Rate Per 100 Patient Years of Heart Failure Hospitalization Component of Secondary Composite Outcome.","warfarin|aspirin","aspirin|Warfarin","Drug|Drug","myocardial ischemia|coronary artery disease|heart diseases|infarction|myocardial infarction","Heart Disease|Ischemic Heart Disease|Myocardial Infarction|Stroke","Parallel Assignment","Interventional","Prevention","Randomized","Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial",2,"Hazard Ratio (HR)",1.21,0.053,"Regression, Cox",0.998,1.47,95,null,"NA","All",2305,"Completed","Phase 3","\t"]
["NCT00041938",4516480,8268468,"Event Rate Per 100 Patient Years of Myocardial Infarction Component of Secondary Composite Outcome","warfarin|aspirin","aspirin|Warfarin","Drug|Drug","myocardial ischemia|coronary artery disease|heart diseases|infarction|myocardial infarction","Heart Disease|Ischemic Heart Disease|Myocardial Infarction|Stroke","Parallel Assignment","Interventional","Prevention","Randomized","Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial",2,"Hazard Ratio (HR)",0.98,0.93,"Regression, Cox",0.58,1.64,95,null,"NA","All",2305,"Completed","Phase 3","\t"]
["NCT00041938",4516481,8268469,"Event Rate Per 100 Patient-years for Death","warfarin|aspirin","aspirin|Warfarin","Drug|Drug","myocardial ischemia|coronary artery disease|heart diseases|infarction|myocardial infarction","Heart Disease|Ischemic Heart Disease|Myocardial Infarction|Stroke","Parallel Assignment","Interventional","Prevention","Randomized","Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial",2,"Hazard Ratio (HR)",1.01,0.91,"Regression, Cox",0.85,1.2,95,null,"NA","All",2305,"Completed","Phase 3","\t"]
["NCT00041938",4516482,8268470,"Event Rate Per 100 Patient-years for Intracerebral Hemorrhage","warfarin|aspirin","aspirin|Warfarin","Drug|Drug","myocardial ischemia|coronary artery disease|heart diseases|infarction|myocardial infarction","Heart Disease|Ischemic Heart Disease|Myocardial Infarction|Stroke","Parallel Assignment","Interventional","Prevention","Randomized","Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial",2,"Hazard Ratio (HR)",2.22,0.35,"Regression, Cox",0.43,11.66,95,null,"NA","All",2305,"Completed","Phase 3","\t"]
["NCT00041938",4516483,8268471,"Event Rate Per 100 Patient-years for Ischemic Stroke","warfarin|aspirin","aspirin|Warfarin","Drug|Drug","myocardial ischemia|coronary artery disease|heart diseases|infarction|myocardial infarction","Heart Disease|Ischemic Heart Disease|Myocardial Infarction|Stroke","Parallel Assignment","Interventional","Prevention","Randomized","Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial",2,"Hazard Ratio (HR)",0.52,0.005,"Regression, Cox",0.33,0.82,95,null,"NA","All",2305,"Completed","Phase 3","\t"]
["NCT00041938",4516484,8268472,"Event Rate Per 100 Patient-years for Composite Endpoint of Hospitalization for Heart Failure, Myocardial Infarction, Ischemic Stroke, Intracerebral Hemorrhage, or Death.","warfarin|aspirin","aspirin|Warfarin","Drug|Drug","myocardial ischemia|coronary artery disease|heart diseases|infarction|myocardial infarction","Heart Disease|Ischemic Heart Disease|Myocardial Infarction|Stroke","Parallel Assignment","Interventional","Prevention","Randomized","Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial",2,"Hazard Ratio (HR)",1.07,0.33,"Regression, Cox",0.93,1.23,95,null,"NA","All",2305,"Completed","Phase 3","\t"]
["NCT00041938",4516485,8268473,"Event Rate Per 100 Patient Years for Composite Endpoint of Ischemic Stroke, Intracerebral Hemorrhage, or Death","warfarin|aspirin","aspirin|Warfarin","Drug|Drug","myocardial ischemia|coronary artery disease|heart diseases|infarction|myocardial infarction","Heart Disease|Ischemic Heart Disease|Myocardial Infarction|Stroke","Parallel Assignment","Interventional","Prevention","Randomized","Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial",2,"Hazard Ratio (HR)",0.93,0.4,"Regression, Cox",0.79,1.1,95,null,"NA","All",2305,"Completed","Phase 3","\t"]
["NCT00042432",4516472,8268459,"Percentage Change From Baseline in Mean iPTH During the Efficacy Assessment Phase","cinacalcet","cinacalcet (AMG 073)","Drug","renal insufficiency|renal insufficiency, chronic|hyperparathyroidism|neoplasm metastasis|hyperparathyroidism, secondary","Chronic Renal Insufficiency|Secondary Hyperparathyroidism","Parallel Assignment","Interventional","Treatment","Randomized","Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients",2,null,"NA",1E-3,"ANCOVA",{"$nulls":4},"NA","All",54,"Completed","Phase 2","\t"]
["NCT00042432",4516473,8268460,"Reduction in Mean iPTH of ≥ 30% During the Efficacy Assessment Phase","cinacalcet","cinacalcet (AMG 073)","Drug","renal insufficiency|renal insufficiency, chronic|hyperparathyroidism|neoplasm metastasis|hyperparathyroidism, secondary","Chronic Renal Insufficiency|Secondary Hyperparathyroidism","Parallel Assignment","Interventional","Treatment","Randomized","Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients",2,"Odds Ratio (OR)",5.67,0.006,"Cochran-Mantel-Haenszel",1.6,20.06,95,null,"NA","All",54,"Completed","Phase 2","\t"]
["NCT00043186",4516197,8268416,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.01,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516196,8268416,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516194,8268416,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.02,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516199,8268416,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.218,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516193,8268416,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.02,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516200,8268416,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.142,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516195,8268416,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.01,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516198,8268416,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.003,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516201,8268417,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",2E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516203,8268417,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.003,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516207,8268417,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.058,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516204,8268417,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516205,8268417,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516202,8268417,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.003,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516208,8268417,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.061,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516206,8268417,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516209,8268418,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516216,8268418,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.049,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516215,8268418,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.008,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516210,8268418,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516211,8268418,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.146,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516213,8268418,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516212,8268418,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516214,8268418,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516222,8268419,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516220,8268419,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",2E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516217,8268419,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516224,8268419,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516219,8268419,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516221,8268419,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516218,8268419,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516223,8268419,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516230,8268420,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516228,8268420,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516227,8268420,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516229,8268420,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516232,8268420,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516225,8268420,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516231,8268420,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516226,8268420,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516239,8268421,"Total Body Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2.25,0.092,"ANCOVA",-0.37,4.87,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516236,8268421,"Total Body Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",5.96,1E-3,"ANCOVA",3.44,8.48,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516240,8268421,"Total Body Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",7.02,1E-3,"ANCOVA",4.35,9.69,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516238,8268421,"Total Body Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.22,1E-3,"ANCOVA",3.5,8.94,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516235,8268421,"Total Body Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.29,1E-3,"ANCOVA",3.25,9.34,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516234,8268421,"Total Body Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",5.91,1E-3,"ANCOVA",3.13,8.7,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516233,8268421,"Total Body Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.22,1E-3,"ANCOVA",3.58,8.87,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516237,8268421,"Total Body Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",5.97,1E-3,"ANCOVA",3.51,8.43,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516244,8268422,"Total Body Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2.1,0.949,"ANCOVA",-4.51,8.72,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516246,8268422,"Total Body Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",1.24,0.709,"ANCOVA",-6.81,9.29,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516247,8268422,"Total Body Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.3,0.949,"ANCOVA",-2.7,9.31,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516245,8268422,"Total Body Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",-2.36,0.949,"ANCOVA",-8.55,3.83,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516248,8268422,"Total Body Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2.18,0.949,"ANCOVA",-8.73,13.1,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516243,8268422,"Total Body Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",7.23,0.484,"ANCOVA",-0.83,15.3,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516241,8268422,"Total Body Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",0.29,0.949,"ANCOVA",-10.82,11.4,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516242,8268422,"Total Body Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2.44,0.949,"ANCOVA",-3.77,8.66,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516253,8268423,"Total Body Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.41,2E-3,"ANCOVA",2.07,6.75,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516250,8268423,"Total Body Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.65,0.003,"ANCOVA",2.05,7.24,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516254,8268423,"Total Body Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.2,0.005,"ANCOVA",1.65,6.75,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516256,8268423,"Total Body Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.16,1E-3,"ANCOVA",3.63,8.68,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516251,8268423,"Total Body Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.95,0.009,"ANCOVA",1.22,6.68,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516249,8268423,"Total Body Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.75,1E-3,"ANCOVA",2.28,7.22,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516255,8268423,"Total Body Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",1.32,0.275,"ANCOVA",-1.06,3.7,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516252,8268423,"Total Body Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.65,0.009,"ANCOVA",1.25,6.05,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516264,8268424,"Total Body Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.14,1E-3,"ANCOVA",1.71,4.56,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516262,8268424,"Total Body Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.64,1E-3,"ANCOVA",3.19,6.09,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516258,8268424,"Total Body Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.55,1E-3,"ANCOVA",3.12,5.98,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516263,8268424,"Total Body Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.4,1E-3,"ANCOVA",2.95,5.84,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516260,8268424,"Total Body Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2.53,1E-3,"ANCOVA",1.13,3.94,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516259,8268424,"Total Body Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.09,1E-3,"ANCOVA",4.53,7.64,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516257,8268424,"Total Body Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.23,1E-3,"ANCOVA",2.76,5.69,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516261,8268424,"Total Body Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.22,1E-3,"ANCOVA",2.85,5.58,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516268,8268425,"Total Body Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",0.77,0.202,"ANCOVA",-0.41,1.95,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516266,8268425,"Total Body Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2.02,0.004,"ANCOVA",0.78,3.26,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516271,8268425,"Total Body Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",1.73,0.005,"ANCOVA",0.52,2.93,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516272,8268425,"Total Body Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2.3,1E-3,"ANCOVA",1.09,3.51,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516265,8268425,"Total Body Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2.03,0.004,"ANCOVA",0.8,3.27,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516267,8268425,"Total Body Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2.95,1E-3,"ANCOVA",1.65,4.26,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516270,8268425,"Total Body Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2,0.004,"ANCOVA",0.74,3.25,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516269,8268425,"Total Body Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2.72,1E-3,"ANCOVA",1.54,3.91,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516275,8268426,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.74,1E-3,"ANCOVA",1.71,5.77,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516276,8268426,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2,0.054,"ANCOVA",-0.04,4.04,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516273,8268426,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.39,1E-3,"ANCOVA",4.49,8.28,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516274,8268426,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.05,1E-3,"ANCOVA",4,8.1,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516278,8268426,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.09,1E-3,"ANCOVA",3.91,8.26,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516277,8268426,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",5.72,1E-3,"ANCOVA",3.7,7.73,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516280,8268426,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.41,1E-3,"ANCOVA",4.48,8.34,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516279,8268426,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.44,1E-3,"ANCOVA",4.19,8.7,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516286,8268427,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",5.72,0.503,"ANCOVA",-2.9,14.33,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516281,8268427,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",7.88,0.233,"ANCOVA",0.78,14.97,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516287,8268427,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.6,0.527,"ANCOVA",-6.38,19.59,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516283,8268427,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",7.59,0.503,"ANCOVA",-1.85,17.03,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516285,8268427,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2.68,0.527,"ANCOVA",-6.54,11.89,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516282,8268427,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",7.18,0.503,"ANCOVA",-2.45,16.81,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516284,8268427,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",7.41,0.503,"ANCOVA",-2.19,17.01,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516288,8268427,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.27,0.496,"ANCOVA",-7.16,13.7,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516293,8268428,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.33,1E-3,"ANCOVA",4.75,7.92,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516292,8268428,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",5.73,1E-3,"ANCOVA",4.12,7.33,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516289,8268428,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",5.63,1E-3,"ANCOVA",3.96,7.3,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516294,8268428,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",5.56,1E-3,"ANCOVA",3.87,7.26,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516296,8268428,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2.69,2E-3,"ANCOVA",1.01,4.38,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516290,8268428,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.7,1E-3,"ANCOVA",2.92,6.49,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516291,8268428,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.7,1E-3,"ANCOVA",2.89,6.5,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516295,8268428,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.77,1E-3,"ANCOVA",2.14,5.39,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516298,8268429,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.08,1E-3,"ANCOVA",2.48,5.68,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516303,8268429,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.58,1E-3,"ANCOVA",2.06,5.1,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516301,8268429,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.09,1E-3,"ANCOVA",2.55,5.62,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516304,8268429,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",1.99,0.009,"ANCOVA",0.49,3.49,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516302,8268429,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.26,1E-3,"ANCOVA",2.73,5.78,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516299,8268429,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",5.26,1E-3,"ANCOVA",3.78,6.73,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516300,8268429,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.67,1E-3,"ANCOVA",3.23,6.11,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516297,8268429,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.39,1E-3,"ANCOVA",1.86,4.93,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516311,8268430,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.06,1E-3,"ANCOVA",1.69,4.42,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516308,8268430,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2.91,1E-3,"ANCOVA",1.6,4.21,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516306,8268430,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2.37,1E-3,"ANCOVA",0.99,3.76,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516305,8268430,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2.86,1E-3,"ANCOVA",1.47,4.24,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516310,8268430,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.04,1E-3,"ANCOVA",1.68,4.4,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516312,8268430,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",1.44,0.033,"ANCOVA",0.11,2.76,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516309,8268430,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.26,1E-3,"ANCOVA",1.94,4.57,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516307,8268430,"Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.07,1E-3,"ANCOVA",1.65,4.49,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516318,8268431,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",8.52,1E-3,"ANCOVA",6.74,10.3,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516317,8268431,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",9.58,1E-3,"ANCOVA",7.95,11.21,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516320,8268431,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.69,1E-3,"ANCOVA",2.97,6.41,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516315,8268431,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",7.38,1E-3,"ANCOVA",5.45,9.31,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516316,8268431,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",8.34,1E-3,"ANCOVA",6.7,9.99,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516313,8268431,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",8.97,1E-3,"ANCOVA",7.23,10.72,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516319,8268431,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2.16,0.015,"ANCOVA",0.43,3.89,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516314,8268431,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",7.55,1E-3,"ANCOVA",5.72,9.38,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516326,8268432,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.66,1E-3,"ANCOVA",3.14,10.18,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516327,8268432,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",-0.71,0.677,"ANCOVA",-4.1,2.68,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516324,8268432,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.5,1E-3,"ANCOVA",3.59,9.41,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516321,8268432,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.97,1E-3,"ANCOVA",3.28,10.66,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516322,8268432,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",5.94,0.003,"ANCOVA",2.53,9.36,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516328,8268432,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.94,2E-3,"ANCOVA",1.86,8.02,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516323,8268432,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.33,0.047,"ANCOVA",0.61,8.05,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516325,8268432,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",8.29,1E-3,"ANCOVA",5.26,11.33,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516329,8268433,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",7.63,1E-3,"ANCOVA",6.02,9.24,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516332,8268433,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",7.15,1E-3,"ANCOVA",5.62,8.69,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516330,8268433,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",7.26,1E-3,"ANCOVA",5.56,8.95,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516334,8268433,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",7.17,1E-3,"ANCOVA",5.54,8.8,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516331,8268433,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",1.61,0.07,"ANCOVA",-0.12,3.35,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516336,8268433,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.78,1E-3,"ANCOVA",2.19,5.36,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516333,8268433,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",8.67,1E-3,"ANCOVA",7.13,10.21,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516335,8268433,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",1.41,0.07,"ANCOVA",-0.12,2.94,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516339,8268434,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.95,1E-3,"ANCOVA",5.69,8.21,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516340,8268434,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.54,1E-3,"ANCOVA",3.41,5.67,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516341,8268434,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.89,1E-3,"ANCOVA",5.76,8.01,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516338,8268434,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",5.48,1E-3,"ANCOVA",4.29,6.67,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516337,8268434,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",5.97,1E-3,"ANCOVA",4.76,7.17,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516343,8268434,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.1,1E-3,"ANCOVA",4.93,7.27,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516344,8268434,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",5.19,1E-3,"ANCOVA",4.04,6.34,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516342,8268434,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",5.59,1E-3,"ANCOVA",4.4,6.78,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516346,8268435,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.01,1E-3,"ANCOVA",1.99,4.04,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516351,8268435,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2.9,1E-3,"ANCOVA",1.9,3.89,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516348,8268435,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2.5,1E-3,"ANCOVA",1.55,3.46,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516347,8268435,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.89,1E-3,"ANCOVA",2.83,4.95,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516350,8268435,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.09,1E-3,"ANCOVA",2.07,4.11,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516345,8268435,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.46,1E-3,"ANCOVA",2.43,4.48,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516349,8268435,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.12,1E-3,"ANCOVA",3.13,5.11,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516352,8268435,"Total Hip Bone Mineral Density Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2.67,1E-3,"ANCOVA",1.7,3.64,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516358,8268436,"Urine NTX/Creatinine Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.029,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516357,8268436,"Urine NTX/Creatinine Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.047,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516360,8268436,"Urine NTX/Creatinine Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.01,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516359,8268436,"Urine NTX/Creatinine Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.172,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516353,8268436,"Urine NTX/Creatinine Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.172,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516356,8268436,"Urine NTX/Creatinine Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.015,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516355,8268436,"Urine NTX/Creatinine Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.168,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516354,8268436,"Urine NTX/Creatinine Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.168,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516365,8268437,"Urine NTX/Creatinine Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.032,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516368,8268437,"Urine NTX/Creatinine Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.053,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516362,8268437,"Urine NTX/Creatinine Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.02,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516361,8268437,"Urine NTX/Creatinine Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.053,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516363,8268437,"Urine NTX/Creatinine Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.053,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516367,8268437,"Urine NTX/Creatinine Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.053,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516366,8268437,"Urine NTX/Creatinine Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.022,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516364,8268437,"Urine NTX/Creatinine Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.053,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516369,8268438,"Urine NTX/Creatinine Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.005,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516372,8268438,"Urine NTX/Creatinine Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516376,8268438,"Urine NTX/Creatinine Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.011,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516371,8268438,"Urine NTX/Creatinine Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",2E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516374,8268438,"Urine NTX/Creatinine Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.077,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516370,8268438,"Urine NTX/Creatinine Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",2E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516375,8268438,"Urine NTX/Creatinine Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516373,8268438,"Urine NTX/Creatinine Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",2E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516382,8268439,"Urine NTX/Creatinine Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516381,8268439,"Urine NTX/Creatinine Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516384,8268439,"Urine NTX/Creatinine Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516383,8268439,"Urine NTX/Creatinine Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516377,8268439,"Urine NTX/Creatinine Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.003,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516379,8268439,"Urine NTX/Creatinine Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516378,8268439,"Urine NTX/Creatinine Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516380,8268439,"Urine NTX/Creatinine Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.409,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516390,8268440,"Serum CTX Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.029,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516392,8268440,"Serum CTX Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.015,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516385,8268440,"Serum CTX Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.073,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516389,8268440,"Serum CTX Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516388,8268440,"Serum CTX Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.032,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516386,8268440,"Serum CTX Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.05,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516391,8268440,"Serum CTX Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.05,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516387,8268440,"Serum CTX Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.05,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516399,8268441,"Serum CTX Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.012,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516395,8268441,"Serum CTX Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.012,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516398,8268441,"Serum CTX Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.012,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516393,8268441,"Serum CTX Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516394,8268441,"Serum CTX Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.004,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516397,8268441,"Serum CTX Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",2E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516400,8268441,"Serum CTX Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516396,8268441,"Serum CTX Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.012,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516401,8268442,"Serum CTX Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516403,8268442,"Serum CTX Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516406,8268442,"Serum CTX Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.026,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516407,8268442,"Serum CTX Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516408,8268442,"Serum CTX Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.011,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516404,8268442,"Serum CTX Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516405,8268442,"Serum CTX Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.003,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516402,8268442,"Serum CTX Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516415,8268443,"Serum CTX Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516410,8268443,"Serum CTX Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516411,8268443,"Serum CTX Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516409,8268443,"Serum CTX Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516412,8268443,"Serum CTX Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.622,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516416,8268443,"Serum CTX Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516414,8268443,"Serum CTX Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516413,8268443,"Serum CTX Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516421,8268444,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",12.73,1E-3,"ANCOVA",9.94,15.52,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516424,8268444,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.93,1E-3,"ANCOVA",3.97,9.89,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516419,8268444,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",11.42,1E-3,"ANCOVA",8.12,14.73,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516423,8268444,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",4.89,1E-3,"ANCOVA",1.92,7.85,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516417,8268444,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",11.74,1E-3,"ANCOVA",8.72,14.76,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516420,8268444,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",12.49,1E-3,"ANCOVA",9.66,15.32,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516422,8268444,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",14.15,1E-3,"ANCOVA",11.08,17.21,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516418,8268444,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 48","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",12.32,1E-3,"ANCOVA",9.15,15.49,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516428,8268445,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",8.37,1E-3,"ANCOVA",4.11,12.63,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516427,8268445,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.98,0.292,"ANCOVA",-1.42,9.37,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516432,8268445,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",5.42,0.02,"ANCOVA",0.89,9.95,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516429,8268445,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",8.5,1E-3,"ANCOVA",4.15,12.86,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516426,8268445,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",8.95,0.004,"ANCOVA",3.94,13.96,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516430,8268445,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",8.9,0.004,"ANCOVA",3.72,14.09,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516425,8268445,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.12,0.094,"ANCOVA",0.57,11.67,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516431,8268445,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 42","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",-0.03,0.992,"ANCOVA",-5.07,5.02,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516438,8268446,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",12.43,1E-3,"ANCOVA",10.19,14.68,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516434,8268446,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",10.97,1E-3,"ANCOVA",8.63,13.32,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516435,8268446,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.74,1E-3,"ANCOVA",1.37,6.12,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516433,8268446,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",10.37,1E-3,"ANCOVA",8.16,12.59,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516440,8268446,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.5,1E-3,"ANCOVA",4.32,8.67,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516437,8268446,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",10.84,1E-3,"ANCOVA",8.74,12.94,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516436,8268446,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",9.79,1E-3,"ANCOVA",7.69,11.89,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516439,8268446,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",2.65,0.013,"ANCOVA",0.55,4.75,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516447,8268447,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",9.11,1E-3,"ANCOVA",7.31,10.91,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516445,8268447,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",8.44,1E-3,"ANCOVA",6.69,10.19,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516444,8268447,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",5.19,1E-3,"ANCOVA",3.43,6.94,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516448,8268447,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",7.34,1E-3,"ANCOVA",5.56,9.12,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516442,8268447,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",8.46,1E-3,"ANCOVA",6.62,10.3,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516446,8268447,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",8.56,1E-3,"ANCOVA",6.71,10.41,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516443,8268447,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",10.08,1E-3,"ANCOVA",8.14,12.01,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516441,8268447,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",8.66,1E-3,"ANCOVA",6.8,10.53,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516451,8268449,"Urine NTX/Creatinine Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516455,8268449,"Urine NTX/Creatinine Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516450,8268449,"Urine NTX/Creatinine Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.02,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516449,8268449,"Urine NTX/Creatinine Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516456,8268449,"Urine NTX/Creatinine Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516453,8268449,"Urine NTX/Creatinine Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516452,8268449,"Urine NTX/Creatinine Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516454,8268449,"Urine NTX/Creatinine Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516458,8268450,"Serum CTX Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516457,8268450,"Serum CTX Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516462,8268450,"Serum CTX Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516464,8268450,"Serum CTX Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516461,8268450,"Serum CTX Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516459,8268450,"Serum CTX Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516460,8268450,"Serum CTX Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",0.166,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516463,8268450,"Serum CTX Percent Change From Baseline at Month 12","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516470,8268451,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",6.33,1E-3,"ANCOVA",5.01,7.65,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516468,8268451,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",3.84,1E-3,"ANCOVA",2.6,5.07,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516465,8268451,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",5.21,1E-3,"ANCOVA",3.88,6.55,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516466,8268451,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",5.52,1E-3,"ANCOVA",4.19,6.85,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516469,8268451,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",5.35,1E-3,"ANCOVA",4.07,6.64,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516471,8268451,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",5.87,1E-3,"ANCOVA",4.59,7.16,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043186",4516467,8268451,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms","denosumab|alendronate","Placebo|Denosumab|Alendronate","Drug|Drug|Drug","bone diseases, metabolic","Low Bone Mineral Density","Parallel Assignment","Interventional","Treatment","Randomized","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",9,"Mean Difference (Final Values)",7.5,1E-3,"ANCOVA",6.13,8.87,95,null,"NA","Female",412,"Completed","Phase 2","\t"]
["NCT00043550",4516192,8268415,"Hamilton Rating Scale for Depression-17 Item","venlafaxine hydrochloride|sertraline","Supportive Expressive Therapy|Sertraline|Pill Placebo|Venlafaxine","Behavioral|Drug|Drug|Drug","depression|depressive disorder","Depression","Parallel Assignment","Interventional","Treatment","Randomized","Treatments for Depression: Drug Versus Psychotherapy",3,"Slope",1,0.95,"HLM",{"$nulls":4},"NA","All",156,"Completed","Phase 3","\t"]
["NCT00043550",4516189,8268415,"Hamilton Rating Scale for Depression-17 Item","venlafaxine hydrochloride|sertraline","Supportive Expressive Therapy|Sertraline|Pill Placebo|Venlafaxine","Behavioral|Drug|Drug|Drug","depression|depressive disorder","Depression","Parallel Assignment","Interventional","Treatment","Randomized","Treatments for Depression: Drug Versus Psychotherapy",3,"Slope",0.06,"NA",null,-0.33,0.45,95,null,"NA","All",156,"Completed","Phase 3","\t"]
["NCT00043550",4516191,8268415,"Hamilton Rating Scale for Depression-17 Item","venlafaxine hydrochloride|sertraline","Supportive Expressive Therapy|Sertraline|Pill Placebo|Venlafaxine","Behavioral|Drug|Drug|Drug","depression|depressive disorder","Depression","Parallel Assignment","Interventional","Treatment","Randomized","Treatments for Depression: Drug Versus Psychotherapy",3,null,"NA",{"v":1E-4,"d":"1.00E-04"},"HLM",{"$nulls":4},"NA","All",156,"Completed","Phase 3","\t"]
["NCT00043550",4516190,8268415,"Hamilton Rating Scale for Depression-17 Item","venlafaxine hydrochloride|sertraline","Supportive Expressive Therapy|Sertraline|Pill Placebo|Venlafaxine","Behavioral|Drug|Drug|Drug","depression|depressive disorder","Depression","Parallel Assignment","Interventional","Treatment","Randomized","Treatments for Depression: Drug Versus Psychotherapy",3,"Slope",0.03,"NA",null,-0.35,0.41,95,null,"NA","All",156,"Completed","Phase 3","\t"]
["NCT00044044",4516165,8268388,"Change From Baseline to the End of the Double-blind Treatment in the MADRS (Montgomery Asberg-Depression Scale) Scores","haloperidol decanoate|lurasidone hydrochloride|haloperidol","Lurasidone 20 mg|Lurasidone 40mg|Lurasidone 80 mg|Haloperidol 10mg|Placebo","Drug|Drug|Drug|Drug|Drug","schizophrenia","Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia",5,null,"NA",0.05,"ANCOVA",{"$nulls":4},"NA","All",356,"Completed","Phase 2","\t"]
["NCT00044044",4516166,8268389,"Change From Baseline to the End of the Double-blind Treatment in the CGI-S (Clinical Global Impression of Severity) Scores","haloperidol decanoate|lurasidone hydrochloride|haloperidol","Lurasidone 20 mg|Lurasidone 40mg|Lurasidone 80 mg|Haloperidol 10mg|Placebo","Drug|Drug|Drug|Drug|Drug","schizophrenia","Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia",5,null,"NA",0.05,"ANCOVA",{"$nulls":4},"NA","All",356,"Completed","Phase 2","\t"]
["NCT00044044",4516167,8268390,"Change From Baseline to the End of the Double-blind Treatment in the PANSS (Positive and Negative Syndrome Scale) Scores","haloperidol decanoate|lurasidone hydrochloride|haloperidol","Lurasidone 20 mg|Lurasidone 40mg|Lurasidone 80 mg|Haloperidol 10mg|Placebo","Drug|Drug|Drug|Drug|Drug","schizophrenia","Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia",5,null,"NA",0.05,"ANCOVA",{"$nulls":4},"NA","All",356,"Completed","Phase 2","\t"]
["NCT00044044",4516168,8268391,"Change From Baseline to the End of the Double-blind Treatment in the BPRS (Brief Psychiatric Rating Scale)Total Score","haloperidol decanoate|lurasidone hydrochloride|haloperidol","Lurasidone 20 mg|Lurasidone 40mg|Lurasidone 80 mg|Haloperidol 10mg|Placebo","Drug|Drug|Drug|Drug|Drug","schizophrenia","Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia",5,null,"NA",0.05,"ANCOVA",{"$nulls":4},"NA","All",356,"Completed","Phase 2","\t"]
["NCT00044083",4516170,8268393,"Positive and Negative Syndrome Scale","tolcapone","Placebo|Tolcapone","Other|Drug","schizophrenia","Schizophrenia","Crossover Assignment","Interventional","Other","Randomized","Clinical Trial of Tolcapone for Cognition in Schizophrenia",2,null,"NA",0.4,"t-test, 1 sided",{"$nulls":4},"NA","All",210,"Terminated","Phase 2","\t"]
["NCT00044083",4516171,8268393,"Positive and Negative Syndrome Scale","tolcapone","Placebo|Tolcapone","Other|Drug","schizophrenia","Schizophrenia","Crossover Assignment","Interventional","Other","Randomized","Clinical Trial of Tolcapone for Cognition in Schizophrenia",2,null,"NA",0.7,"t-test, 1 sided",{"$nulls":4},"NA","All",210,"Terminated","Phase 2","\t"]
["NCT00044083",4516169,8268393,"Positive and Negative Syndrome Scale","tolcapone","Placebo|Tolcapone","Other|Drug","schizophrenia","Schizophrenia","Crossover Assignment","Interventional","Other","Randomized","Clinical Trial of Tolcapone for Cognition in Schizophrenia",2,null,"NA",0.12,"t-test, 1 sided",{"$nulls":4},"NA","All",210,"Terminated","Phase 2","\t"]
["NCT00044083",4516173,8268394,"N-Back Task Activation by Genotype in Patients With Schizophrenia","tolcapone","Placebo|Tolcapone","Other|Drug","schizophrenia","Schizophrenia","Crossover Assignment","Interventional","Other","Randomized","Clinical Trial of Tolcapone for Cognition in Schizophrenia",2,null,"NA",0.718,"t-test, 1 sided",{"$nulls":4},"NA","All",210,"Terminated","Phase 2","\t"]
["NCT00044083",4516172,8268394,"N-Back Task Activation by Genotype in Patients With Schizophrenia","tolcapone","Placebo|Tolcapone","Other|Drug","schizophrenia","Schizophrenia","Crossover Assignment","Interventional","Other","Randomized","Clinical Trial of Tolcapone for Cognition in Schizophrenia",2,null,"NA",0.469,"t-test, 1 sided",{"$nulls":4},"NA","All",210,"Terminated","Phase 2","\t"]
["NCT00044083",4516174,8268394,"N-Back Task Activation by Genotype in Patients With Schizophrenia","tolcapone","Placebo|Tolcapone","Other|Drug","schizophrenia","Schizophrenia","Crossover Assignment","Interventional","Other","Randomized","Clinical Trial of Tolcapone for Cognition in Schizophrenia",2,null,"NA",0.041,"t-test, 1 sided",{"$nulls":4},"NA","All",210,"Terminated","Phase 2","\t"]
["NCT00044083",4516175,8268394,"N-Back Task Activation by Genotype in Patients With Schizophrenia","tolcapone","Placebo|Tolcapone","Other|Drug","schizophrenia","Schizophrenia","Crossover Assignment","Interventional","Other","Randomized","Clinical Trial of Tolcapone for Cognition in Schizophrenia",2,null,"NA",0.189,"ANOVA",{"$nulls":4},"NA","All",210,"Terminated","Phase 2","\t"]
["NCT00044083",4516177,8268395,"N-Back Task Activation Genotype Effect in Healthy Volunteers","tolcapone","Placebo|Tolcapone","Other|Drug","schizophrenia","Schizophrenia","Crossover Assignment","Interventional","Other","Randomized","Clinical Trial of Tolcapone for Cognition in Schizophrenia",2,null,"NA",{"v":1E-4,"d":"1.00E-04"},"ANOVA",{"$nulls":4},"NA","All",210,"Terminated","Phase 2","\t"]
["NCT00044083",4516176,8268395,"N-Back Task Activation Genotype Effect in Healthy Volunteers","tolcapone","Placebo|Tolcapone","Other|Drug","schizophrenia","Schizophrenia","Crossover Assignment","Interventional","Other","Randomized","Clinical Trial of Tolcapone for Cognition in Schizophrenia",2,null,"NA",0.167,"ANOVA",{"$nulls":4},"NA","All",210,"Terminated","Phase 2","\t"]
["NCT00044083",4516178,8268396,"N-Back Task Activation in Healthy Volunteers","tolcapone","Placebo|Tolcapone","Other|Drug","schizophrenia","Schizophrenia","Crossover Assignment","Interventional","Other","Randomized","Clinical Trial of Tolcapone for Cognition in Schizophrenia",2,null,"NA",0.73,"t-test, 1 sided",{"$nulls":4},"NA","All",210,"Terminated","Phase 2","\t"]
["NCT00044083",4516179,8268396,"N-Back Task Activation in Healthy Volunteers","tolcapone","Placebo|Tolcapone","Other|Drug","schizophrenia","Schizophrenia","Crossover Assignment","Interventional","Other","Randomized","Clinical Trial of Tolcapone for Cognition in Schizophrenia",2,null,"NA",0.05,"t-test, 1 sided",{"$nulls":4},"NA","All",210,"Terminated","Phase 2","\t"]
["NCT00044083",4516180,8268397,"N-Back Task Activation in DLPFC in Patients With Schizophrenia","tolcapone","Placebo|Tolcapone","Other|Drug","schizophrenia","Schizophrenia","Crossover Assignment","Interventional","Other","Randomized","Clinical Trial of Tolcapone for Cognition in Schizophrenia",2,null,"NA",0.078,"t-test, 1 sided",{"$nulls":4},"NA","All",210,"Terminated","Phase 2","\t"]
["NCT00044083",4516181,8268397,"N-Back Task Activation in DLPFC in Patients With Schizophrenia","tolcapone","Placebo|Tolcapone","Other|Drug","schizophrenia","Schizophrenia","Crossover Assignment","Interventional","Other","Randomized","Clinical Trial of Tolcapone for Cognition in Schizophrenia",2,null,"NA",0.05,"t-test, 1 sided",{"$nulls":4},"NA","All",210,"Terminated","Phase 2","\t"]
["NCT00044083",4516182,8268398,"N-Back Task Activation Drug Effect","tolcapone","Placebo|Tolcapone","Other|Drug","schizophrenia","Schizophrenia","Crossover Assignment","Interventional","Other","Randomized","Clinical Trial of Tolcapone for Cognition in Schizophrenia",2,null,"NA",0.32,"ANOVA",{"$nulls":4},"NA","All",210,"Terminated","Phase 2","\t"]
["NCT00044083",4516183,8268398,"N-Back Task Activation Drug Effect","tolcapone","Placebo|Tolcapone","Other|Drug","schizophrenia","Schizophrenia","Crossover Assignment","Interventional","Other","Randomized","Clinical Trial of Tolcapone for Cognition in Schizophrenia",2,null,"NA",0.05,"ANOVA",{"$nulls":4},"NA","All",210,"Terminated","Phase 2","\t"]
["NCT00044083",4516185,8268399,"N-Back Task Activation Diagnosis Effect","tolcapone","Placebo|Tolcapone","Other|Drug","schizophrenia","Schizophrenia","Crossover Assignment","Interventional","Other","Randomized","Clinical Trial of Tolcapone for Cognition in Schizophrenia",2,null,"NA",{"v":1E-4,"d":"1.00E-04"},"ANOVA",{"$nulls":4},"NA","All",210,"Terminated","Phase 2","\t"]
["NCT00044083",4516184,8268399,"N-Back Task Activation Diagnosis Effect","tolcapone","Placebo|Tolcapone","Other|Drug","schizophrenia","Schizophrenia","Crossover Assignment","Interventional","Other","Randomized","Clinical Trial of Tolcapone for Cognition in Schizophrenia",2,null,"NA",0.014,"ANOVA",{"$nulls":4},"NA","All",210,"Terminated","Phase 2","\t"]
["NCT00044083",4516187,8268400,"N-Back Task Performance","tolcapone","Placebo|Tolcapone","Other|Drug","schizophrenia","Schizophrenia","Crossover Assignment","Interventional","Other","Randomized","Clinical Trial of Tolcapone for Cognition in Schizophrenia",2,null,"NA",{"v":1E-4,"d":"1.00E-04"},"ANOVA",{"$nulls":4},"NA","All",210,"Terminated","Phase 2","\t"]
["NCT00044083",4516186,8268400,"N-Back Task Performance","tolcapone","Placebo|Tolcapone","Other|Drug","schizophrenia","Schizophrenia","Crossover Assignment","Interventional","Other","Randomized","Clinical Trial of Tolcapone for Cognition in Schizophrenia",2,null,"NA",0.0034,"ANOVA",{"$nulls":4},"NA","All",210,"Terminated","Phase 2","\t"]
["NCT00045032",4515691,8267269,"Percentage of Participants With Restricted Disease-Free Survival (RDFS) Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.97,0.7251,"Log Rank",0.84,1.13,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515692,8267271,"Percentage of Participants With DTR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.96,0.6823,"Log Rank",0.8,1.15,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515694,8267273,"Percentage of Participants With Distant Tumor Recurrence (DTR) Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Log Rank",{"$nulls":4},"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515696,8267273,"Percentage of Participants With Distant Tumor Recurrence (DTR) Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Log Rank",{"$nulls":4},"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515695,8267273,"Percentage of Participants With Distant Tumor Recurrence (DTR) Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.72,"NA",null,0.62,0.83,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515693,8267273,"Percentage of Participants With Distant Tumor Recurrence (DTR) Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.69,"NA",null,0.59,0.79,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515697,8267275,"Percentage of Participants With TR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.94,0.45,"Log Rank",0.8,1.1,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515701,8267277,"Percentage of Participants With Tumor Recurrence (TR) Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Log Rank",{"$nulls":4},"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515699,8267277,"Percentage of Participants With Tumor Recurrence (TR) Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Log Rank",{"$nulls":4},"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515698,8267277,"Percentage of Participants With Tumor Recurrence (TR) Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.69,"NA",null,0.61,0.79,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515700,8267277,"Percentage of Participants With Tumor Recurrence (TR) Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.73,"NA",null,0.64,0.83,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515702,8267279,"Percentage of Participants With DDFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",1,0.9626,"Log Rank",0.85,1.17,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515704,8267281,"Percentage of Participants With Distant Disease-Free Survival (DDFS) Events Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Log Rank",{"$nulls":4},"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515703,8267281,"Percentage of Participants With Distant Disease-Free Survival (DDFS) Events Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.75,"NA",null,0.65,0.85,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515706,8267281,"Percentage of Participants With Distant Disease-Free Survival (DDFS) Events Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Log Rank",{"$nulls":4},"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515705,8267281,"Percentage of Participants With Distant Disease-Free Survival (DDFS) Events Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.76,"NA",null,0.67,0.87,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515707,8267283,"Percentage of Participants With RFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.94,0.4755,"Log Rank",0.8,1.11,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515708,8267285,"Percentage of Participants With Recurrence-Free Survival (RFS) Events Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.69,"NA",null,0.61,0.79,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515711,8267285,"Percentage of Participants With Recurrence-Free Survival (RFS) Events Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Log Rank",{"$nulls":4},"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515710,8267285,"Percentage of Participants With Recurrence-Free Survival (RFS) Events Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.73,"NA",null,0.64,0.83,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515709,8267285,"Percentage of Participants With Recurrence-Free Survival (RFS) Events Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Log Rank",{"$nulls":4},"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515712,8267287,"Percentage of Participants With OS Events in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",1.01,0.9156,"Log Rank",0.84,1.21,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515713,8267289,"Percentage of Participants With OS Events Compared to Observation: 11-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.72,"NA",null,0.62,0.83,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515714,8267289,"Percentage of Participants With OS Events Compared to Observation: 11-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.74,"NA",null,0.64,0.86,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515715,8267291,"Percentage of Participants With OS Events Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.74,"NA",null,0.63,0.86,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515718,8267291,"Percentage of Participants With OS Events Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,null,"NA",{"v":0.0005,"d":"5.00E-04"},"Log Rank",{"$nulls":4},"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515716,8267291,"Percentage of Participants With OS Events Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Log Rank",{"$nulls":4},"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515717,8267291,"Percentage of Participants With OS Events Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.76,"NA",null,0.65,0.88,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515720,8267294,"Percentage of Participants With OS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,null,"NA",0.003,"Log Rank",{"$nulls":4},"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515719,8267294,"Percentage of Participants With OS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.47,"NA",null,0.28,0.79,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515721,8267295,"Percentage of Participants With Overall Survival (OS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.75,"NA",null,0.47,1.21,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515722,8267295,"Percentage of Participants With Overall Survival (OS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,null,"NA",0.2379,"Log Rank",{"$nulls":4},"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515723,8267297,"Percentage of Participants With DFS Events in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",1.02,0.7962,"Log Rank",0.89,1.17,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515725,8267304,"Percentage of Participants With DFS Events Compared to Observation: 10-Year Maximum Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.76,"NA",null,0.68,0.86,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515724,8267304,"Percentage of Participants With DFS Events Compared to Observation: 10-Year Maximum Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.77,"NA",null,0.69,0.87,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515729,8267309,"Percentage of Participants With DFS Events Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Log Rank",{"$nulls":4},"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515726,8267309,"Percentage of Participants With DFS Events Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.75,"NA",null,0.67,0.85,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515728,8267309,"Percentage of Participants With DFS Events Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.76,"NA",null,0.67,0.86,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515727,8267309,"Percentage of Participants With DFS Events Compared to Observation: 8-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Log Rank",{"$nulls":4},"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515731,8267312,"Percentage of Participants With DFS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,null,"NA",0,"Log Rank",{"$nulls":4},"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515730,8267312,"Percentage of Participants With DFS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.43,"NA",null,0.34,0.53,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515733,8267313,"Percentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Log Rank",{"$nulls":4},"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00045032",4515732,8267313,"Percentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up","trastuzumab","Herceptin|Herceptin","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",3,"Hazard Ratio (HR)",0.54,"NA",null,0.44,0.67,95,null,"NA","Female",5099,"Completed","Phase 3","\t"]
["NCT00046228",4516137,8268327,"Subjects With Pre-Specified Complications of Index Myocardial Infarction Through Discharge/Day 7","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,"Odds Ratio (OR)",0.9,0.434,"Chi-squared",0.69,1.18,95,null,"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516136,8268327,"Subjects With Pre-Specified Complications of Index Myocardial Infarction Through Discharge/Day 7","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,"Odds Ratio (OR)",0.93,0.589,"Chi-squared",0.71,1.22,95,null,"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516135,8268327,"Subjects With Pre-Specified Complications of Index Myocardial Infarction Through Discharge/Day 7","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,"Odds Ratio (OR)",0.97,0.809,"Chi-squared",0.74,1.27,95,null,"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516139,8268328,"Subjects With Any Investigator Reported Bleeding Events Through Discharge/Day 7","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,null,"NA",0.02,"Fisher Exact",{"$nulls":4},"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516138,8268328,"Subjects With Any Investigator Reported Bleeding Events Through Discharge/Day 7","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,null,"NA",1E-3,"Fisher Exact",{"$nulls":4},"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516140,8268328,"Subjects With Any Investigator Reported Bleeding Events Through Discharge/Day 7","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,null,"NA",1E-3,"Fisher Exact",{"$nulls":4},"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516141,8268329,"Subjects With Severe Thrombocytopenia Through Discharge/Day 7","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,null,"NA",1,"Fisher Exact",{"$nulls":4},"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516143,8268329,"Subjects With Severe Thrombocytopenia Through Discharge/Day 7","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,null,"NA",0.439,"Fisher Exact",{"$nulls":4},"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516142,8268329,"Subjects With Severe Thrombocytopenia Through Discharge/Day 7","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,null,"NA",0.438,"Fisher Exact",{"$nulls":4},"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516146,8268330,"Subjects With Non Intracranial Thrombolysis In Myocardial Infarction (TIMI) Bleeding Events Through Discharge/Day 7","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,"Odds Ratio (OR)",2.28,1E-3,"Fisher Exact",1.63,3.19,95,null,"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516145,8268330,"Subjects With Non Intracranial Thrombolysis In Myocardial Infarction (TIMI) Bleeding Events Through Discharge/Day 7","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,"Odds Ratio (OR)",1.51,0.025,"Fisher Exact",1.05,2.15,95,null,"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516144,8268330,"Subjects With Non Intracranial Thrombolysis In Myocardial Infarction (TIMI) Bleeding Events Through Discharge/Day 7","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,"Odds Ratio (OR)",1.52,0.008,"Fisher Exact",1.12,2.05,95,null,"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516147,8268331,"Subjects With Intracranial Hemorrhage (Including Hemorrhagic Transformation) Through Discharge/Day 7","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,null,"NA",0.062,"Fisher Exact",{"$nulls":4},"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516148,8268331,"Subjects With Intracranial Hemorrhage (Including Hemorrhagic Transformation) Through Discharge/Day 7","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,null,"NA",0.497,"Fisher Exact",{"$nulls":4},"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516149,8268331,"Subjects With Intracranial Hemorrhage (Including Hemorrhagic Transformation) Through Discharge/Day 7","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,null,"NA",0.218,"Fisher Exact",{"$nulls":4},"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516152,8268332,"All-Cause Mortality Through 1 Year","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,"Hazard Ratio (HR)",0.9,0.603,"Log Rank",0.62,1.32,95,null,"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516151,8268332,"All-Cause Mortality Through 1 Year","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,"Hazard Ratio (HR)",1.06,0.765,"Log Rank",0.73,1.52,95,null,"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516150,8268332,"All-Cause Mortality Through 1 Year","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,"Hazard Ratio (HR)",0.86,0.415,"Log Rank",0.59,1.24,95,null,"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516154,8268333,"Subjects With ST-Segment Resolution > 70% From Baseline at 60 to 90 Minutes Following Randomization","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,"Odds Ratio (OR)",1.08,0.67,"Chi-squared",0.76,1.52,95,null,"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516153,8268333,"Subjects With ST-Segment Resolution > 70% From Baseline at 60 to 90 Minutes Following Randomization","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,"Odds Ratio (OR)",1.4,0.042,"Chi-squared",1.01,1.93,95,null,"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516155,8268333,"Subjects With ST-Segment Resolution > 70% From Baseline at 60 to 90 Minutes Following Randomization","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,"Odds Ratio (OR)",1.5,0.016,"Chi-squared",1.08,2.1,95,null,"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516157,8268334,"All-Cause Mortality Through 90 Days","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,"Odds Ratio (OR)",1.25,0.338,"Chi-squared",0.79,1.95,95,null,"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00046228",4516156,8268334,"All-Cause Mortality Through 90 Days","reteplase|tissue plasminogen activator|abciximab","abciximab placebo; reteplase placebo, abciximab, abciximab|Abciximab; reteplase; abciximab placebo; abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|abciximab placebo; reteplase placebo, abciximab, abciximab|abciximab; reteplase placebo; abciximab placebo; abciximab|Abciximab; reteplase; abciximab placebo; abciximab","Drug|Drug|Drug|Drug|Drug|Drug","infarction|myocardial infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",3,"Odds Ratio (OR)",0.94,0.781,"Chi-squared",0.61,1.45,95,null,"NA","All",2461,"Completed","Phase 3","\t"]
["NCT00051363",4515967,8267905,"Executive and Frontal-Lobe (E/F) Function: Sustained Working Memory Test- Mid-day Behavioral Index (SWMT-BehMD)","NA","Active CPAP|Sham CPAP","Device|Device","sleep apnea syndromes|lung diseases|apnea","Lung Diseases|Sleep|Sleep Apnea Syndromes","Parallel Assignment","Interventional","Treatment","Randomized","Apnea Positive Pressure Long-Term Efficacy Study",2,null,"NA",0.89,"Regression, Linear",{"$nulls":4},"NA","All",1105,"Completed","Phase 3","\t"]
["NCT00063635",4515535,8266591,"Number of Participants With Improvement in Lobular Inflammation Score","metformin|vitamin e","Metformin|Vitamin E|Matching placebo","Drug|Dietary Supplement|Drug","liver diseases|fatty liver|non-alcoholic fatty liver disease","Fatty Liver","Parallel Assignment","Interventional","Treatment","Randomized","Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)",3,null,"NA",0.89,"Chi-squared",{"$nulls":4},"NA","All",173,"Completed","Phase 3","\t"]
["NCT00065468",4515452,8266452,"Overall Survival (OS)","sirolimus|interferons|interferon-alpha","Interferon Alfa|CCI-779|Interferon Alfa and CCI-779","Drug|Drug|Drug","carcinoma|carcinoma, renal cell|kidney neoplasms","Carcinoma, Renal Cell|Kidney Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma",3,"Cox Proportional Hazard",0.93,0.4902,"Log Rank",0.75,1.15,95,null,"NA","All",626,"Completed","Phase 3","\t"]
["NCT00070564",4515272,8266087,"Disease-free Survival","paclitaxel|doxorubicin|liposomal doxorubicin|cyclophosphamide","pegfilgrastim|AC regimen|cyclophosphamide|doxorubicin hydrochloride|paclitaxel","Biological|Drug|Drug|Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer",6,null,"NA",0.11,"Log Rank",{"$nulls":4},"NA","All",3294,"Active, not recruiting","Phase 3","\t"]
["NCT00073021",4514974,8265890,"Change From Baseline in Ulcerative Colitis Disease Activity Index (UCDAI) at Week 6, ITT Population","mesalamine","Asacol 800 mg (mesalamine)|Asacol 400 mg (mesalamine)","Drug|Drug","ulcer|colitis|colitis, ulcerative","Ulcerative Colitis","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis",2,null,"NA",{"v":1E-4,"d":"1.00E-04"},"t-test, 2 sided",{"$nulls":4},"NA","All",386,"Completed","Phase 3","\t"]
["NCT00074802",4514928,8265750,"Clinical Global Impression Improvement Scale (CGI-I)","paroxetine","Paroxetine|Cognitive behavioral therapy (CBT)","Drug|Behavioral","anxiety disorders|phobia, social","Social Anxiety Disorder","Parallel Assignment","Interventional","Treatment","Randomized","Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder",2,null,"NA",0.018,"Fisher Exact",{"$nulls":4},"NA","All",150,"Completed","Phase 3","\t"]
["NCT00083889",4514402,8265021,"EuroQoL Five Dimension (EQ-5D) Health State Index","sunitinib|interferon-alpha|interferons","Interferon-alfa|SU011248","Drug|Drug","carcinoma|carcinoma, renal cell","Carcinoma, Renal Cell","Parallel Assignment","Interventional","Treatment","Randomized","SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma",2,"Mean Difference (Final Values)",0.033,0.1561,"Mixed Models Analysis",-0.013,0.079,95,null,"NA","All",750,"Completed","Phase 3","\t"]
["NCT00083889",4514619,8265026,"Functional Assessment of Cancer Therapy-General (FACT-G)","sunitinib|interferon-alpha|interferons","Interferon-alfa|SU011248","Drug|Drug","carcinoma|carcinoma, renal cell","Carcinoma, Renal Cell","Parallel Assignment","Interventional","Treatment","Randomized","SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma",2,"Mean Difference (Final Values)",5.639,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",4.083,7.195,95,null,"NA","All",750,"Completed","Phase 3","\t"]
["NCT00088907",4514160,8264506,"Time to Progression","docetaxel|gefitinib","docetaxel|placebo|gefitinib","Drug|Other|Drug","head and neck neoplasms","Metastatic Head and Neck Cancer|Recurrent Head and Neck Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer",2,null,"NA",0.19,"Log Rank",{"$nulls":4},"NA","All",270,"Terminated","Phase 3","\t"]
["NCT00092443",4513972,8263982,"Number of Subjects With ≥3 Fold Rise in Antibody Titer","NA","RotaTeq™, rotavirus vaccine, live, oral, pentavalent|Comparator: Placebo matching RotaTeq™","Biological|Biological","rotavirus infections","Rotavirus Infections","Parallel Assignment","Interventional","Prevention","Randomized","Dose Confirmation Efficacy Study (V260-007)",2,"Percent of Participants",2.9,"NA",null,0.4,10.1,95,null,"NA","All",1312,"Completed","Phase 3","\t"]
["NCT00094653",4513800,8263719,"Change From Baseline in Health-Related Quality of Life (QOL) as Measured by the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Instrument at Week 12","antibodies, monoclonal|antibodies|vaccines|ipilimumab","MDX-010 (anti-CTLA4) monoclonal antibody|MDX-1379 (gp100) Melanoma Peptide Vaccine","Drug|Biological","melanoma","Melanoma|Metastases","Parallel Assignment","Interventional","Treatment","Randomized","MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma",3,"Mean Difference (Final Values)",-6.3,0.0625,"ANCOVA",-12.8,0.3,95,null,"NA","All",1783,"Completed","Phase 3","\t"]
["NCT00097500",4513629,8263083,"Beta-cell Function 4 Weeks After Cessation of Therapy","exenatide|insulin glargine|metformin","exenatide|Insulin glargine|Metformin","Drug|Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Type 2 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes",2,null,"NA",0.4185,"ANCOVA",{"$nulls":4},"NA","All",69,"Completed","Phase 3","\t"]
["NCT00101933",4513387,8262609,"Seizure Responder Rate","NA","Medtronic DBS Therapy for epilepsy|Medtronic DBS Therapy for epilepsy","Device|Device","epilepsy","Epilepsy","Parallel Assignment","Interventional","Treatment","Randomized","SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy",2,null,"NA",0.83,"Fisher Exact",{"$nulls":4},"NA","All",157,"Completed","Phase 3","\t"]
["NCT00103402",4513316,8262499,"Number of Participants With Decline in Total Score ≥4 for the NIH-CPSI Total Score From Baseline to 12 Weeks","alfuzosin","Alfuzosin|Placebo","Drug|Drug","pelvic pain|prostatitis","Prostatitis","Parallel Assignment","Interventional","Treatment","Randomized","Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome",2,"Risk Difference (RD)",0.1,0.99,"Mantel Haenszel",-11.2,11,95,null,"NA","Male",272,"Completed","Phase 3","\t"]
["NCT00107042",4512921,8261824,"Immunogenicity to Hep B 18 Months After First Immunization","NA","Recombivax|Twinrix","Biological|Biological","hepatitis a|hepatitis b|hepatitis","Hepatitis B","Parallel Assignment","Interventional","Prevention","Randomized","Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths",2,"Responding Rate",88,"NA",null,75.69,95.47,95,null,"NA","All",123,"Completed","Phase 2","\t"]
["NCT00110305",4512814,8261518,"Number of Participants With Virologic Response at Week 96 (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm","reverse transcriptase inhibitors|rilpivirine|efavirenz","TMC278 25 mg|TMC278 75 mg|TMC278 150 mg|Efavirenz|Non-nucleoside reverse transcriptase inhibitor (NRTIs)","Drug|Drug|Drug|Drug|Drug","acquired immunodeficiency syndrome|immunologic deficiency syndromes|hiv infections","Human Immunodeficiency Virus Type 1","Parallel Assignment","Interventional","Treatment","Randomized","A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines",4,"Difference in response rate",0,0.99,"Regression, Logistic",-12.9,12.8,95,null,"NA","All",368,"Completed","Phase 2","\t"]
["NCT00111800",4512667,8261367,"Change From Baseline in Fasting Serum Insulin and Pro-insulin at Week 12","NA","Placebo|DEN 2.5 mg|DEN 7.5 mg|DEN 15 mg|DEN 30 mg|DEN 45 mg","Drug|Drug|Drug|Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","A New Oral Treatment For Type II Diabetes Mellitus",6,"Mean Difference (Net)",-0.35,0.914,"ANCOVA",-6.7,6,95,null,"NA","All",375,"Completed","Phase 2","\t"]
["NCT00114530",4512156,8260769,"Treatment-Related Mortality (Month 54, ITT)","cyclophosphamide","mHSCT|cyclophosphamide","Biological|Drug","autoimmune diseases|scleroderma, diffuse|sclerosis|scleroderma, systemic","Autoimmune Disease|Scleroderma, Systemic|Sclerosis","Parallel Assignment","Interventional","Treatment","Randomized","Scleroderma: Cyclophosphamide or Transplantation",2,null,"NA",0.48,"Fisher Exact",{"$nulls":4},"NA","All",75,"Completed","Phase 2/Phase 3","\t"]
["NCT00114777",4512099,8260723,"Percentage of Participants With a Measured Glomerular Filtration Rate (GFR) <60 mL/Min Per 1.73 m^2 at Month 12 or a Decrease in Measured GFR >=10 mL/Min Per 1.73 m^2 From Month 3 to Month 12","abatacept|cyclosporine|cyclosporins","Cyclosporin A|Belatacept Less Intensive Regimen (LI)|Belatacept More Intensive Regimen (MI)","Drug|Drug|Drug","NA","Renal Transplantation","Parallel Assignment","Interventional","Treatment","Randomized","Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant",3,"Percentage difference",-14.4,1.8E-3,"Chi-squared",-24,-4.7,97.3,null,"NA","All",595,"Completed","Phase 3","\t"]
["NCT00118716",4511700,8260137,"Change From Baseline in Pediatric Asthma Quality of Life Questionnaire (PAQLQ)","salmeterol xinafoate|fluticasone","Fluticasone propionate/salmeterol|Fluticasone Propionate","Drug|Drug","bronchial spasm|asthma, exercise-induced","Activity/Exercise Induced Bronchospasm|Bronchospasm","Parallel Assignment","Interventional","Treatment","Randomized","A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise",2,"Mean Difference (Net)",-0.07,0.551,"ANCOVA",-0.32,0.17,95,"Standard Error of the Mean",0.124,"All",248,"Completed","Phase 4","\t"]
["NCT00127192",4511392,8259308,"Change From Baseline in Fasting Plasma Glucose at Week 12","sitagliptin phosphate","sitagliptin phosphate|Comparator: placebo (unspecified)","Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Type 2 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)",5,"Least-squares Mean Difference",-17.7,1E-3,"Pairwise comparison based on ANCOVA",-24.2,-11.2,95,null,"NA","All",363,"Completed","Phase 2","\t"]
["NCT00131352",4511234,8258725,"Change From Baseline Over the Course of the 26-week Initial Treatment Period in Physical Function Measured by Participants Using the Western Ontario and McMaster Universities Osteoarthritis Index Likert Scale (WOMAC LK Version 3.1) C (Function) Subscale","hylan","hylan G-F 20|Phosphate Buffered Saline","Device|Other","musculoskeletal diseases|osteoarthritis, knee|osteoarthritis","Musculoskeletal Diseases|Osteoarthritis, Knee","Parallel Assignment","Interventional","Treatment","Randomized","A Study of the Safety and Efficacy of Hylan G-F 20 (Synvisc) in Patients With Symptomatic Osteoarthritis of the Knee",2,null,"NA",0.679,"ANCOVA",{"$nulls":4},"NA","All",253,"Completed","Phase 3","\t"]
["NCT00135330",4511091,8258426,"Change in Fasting Insulin","exenatide|rosiglitazone","exenatide|rosiglitazone","Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus",3,null,"NA",0.106,"MMRM",{"$nulls":4},"NA","All",137,"Completed","Phase 3","\t"]
["NCT00137046",4510768,8258251,"Change From Baseline Body Weight","insulin|insulin, globin zinc","Subcutaneous Insulin|Inhaled Insulin","Drug|Drug","diabetes mellitus|diabetes mellitus, type 1","Diabetes Mellitus, Type 1","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes",2,"Mean Difference (Final Values)",-1.872,"NA",null,-3.013,-0.73,90,"Standard Error of the Mean",0.692,"All",582,"Terminated","Phase 3","\t"]
["NCT00139659",4510584,8258086,"Bronchodilator Responsiveness as Determined by the Change in Forced Expiratory Volume in 1 Second (FEV1) Pre-albuterol and 30 Minutes Post-albuterol","insulin, globin zinc|insulin","Inhaled Insulin|Subcutaneous Insulin","Drug|Drug","asthma|diabetes mellitus","Asthma|Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma",2,"Mean Difference (Final Values)",0.044,"NA",null,-1.08,1.169,90,"Standard Error of the Mean",0.683,"All",288,"Completed","Phase 3","\t"]
["NCT00141271",4510247,8257894,"Change in Verbal Memory Trial Performance Total Score at Endpoint","ziprasidone","Geodon (Ziprasidone)|Geodon (Ziprasidone)|Placebo","Drug|Drug|Drug","bipolar disorder","Bipolar Disorder","Parallel Assignment","Interventional","Treatment","Randomized","A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression",3,null,"NA",0.926,"ANCOVA",{"$nulls":4},"NA","All",536,"Completed","Phase 3","\t"]
["NCT00141271",4510355,8257908,"Remission as Measured by Hamilton Depression (HAM-D 17) Total Score Less Than or Equal to 7","ziprasidone","Geodon (Ziprasidone)|Geodon (Ziprasidone)|Placebo","Drug|Drug|Drug","bipolar disorder","Bipolar Disorder","Parallel Assignment","Interventional","Treatment","Randomized","A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression",3,null,"NA",0.3888,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",536,"Completed","Phase 3","\t"]
["NCT00150618",4509672,8256875,"Number of Participants With Improvement in Clinical Global Impression-Improvement (CGI-I)","guanfacine","SPD503 (1 mg)|SPD503 (2 mg)|SPD503 (3 mg)|SPD503 (4 mg)|Placebo","Drug|Drug|Drug|Drug|Drug","hyperkinesis|attention deficit disorder with hyperactivity","Attention Deficit Disorder With Hyperactivity","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17",5,null,"NA",0.0055,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",324,"Completed","Phase 3","\t"]
["NCT00159913",4509408,8256365,"Percent Change From Baseline to Week 16 in Time to Maximum Volume of Oxygen Consumed (VO2)","sodium citrate|sildenafil citrate|citric acid","Sildenafil citrate|Sildenafil citrate|Placebo|Sildenafil citrate","Drug|Drug|Drug|Drug","hypertension|familial primary pulmonary hypertension","Pulmonary Arterial Hypertension, Children","Parallel Assignment","Interventional","Treatment","Randomized","A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.",4,"Mean Difference (Final Values)",5.96,"NA",null,-9.16,21.08,95,"Standard Error of the Mean",7.62,"All",235,"Completed","Phase 3","\t"]
["NCT00165698",4509227,8255979,"Bone Biomarker Osteocalcin (OC) Percentage Change After 12 Months","alfacalcidol|hydroxycholecalciferols","menatetranone|alfacalcidol","Drug|Drug","osteoporosis, postmenopausal|osteoporosis","Postmenopausal Osteoporosis","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women",2,null,"NA",0,"symbols rank sum test",{"$nulls":4},"NA","Female",240,"Completed","Phase 3","\t"]
["NCT00168805",4509159,8255786,"Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period","enoxaparin|dabigatran","enoxaparin|dabigatran etexilate|dabigatran etexilate","Drug|Drug|Drug","thromboembolism","Arthroplasty, Replacement, Knee|Thromboembolism","Parallel Assignment","Interventional","Prevention","Randomized","RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery",3,"Risk Difference (Percentage)",-0.8,0.4715,"Normal approximation",-2.8,1.3,95,null,"NA","All",2101,"Completed","Phase 3","\t"]
["NCT00179309",4508856,8255096,"Progression-free Survival (PFS)","docetaxel|sargramostim","Docetaxel|PANVAC-V|PANVAC-F|Sargramostim","Drug|Biological|Biological|Biological","breast neoplasms","Breast Cancer","Crossover Assignment","Interventional","Treatment","Randomized","Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer",2,null,"NA",0.12,"Log Rank",{"$nulls":4},"NA","All",48,"Completed","Phase 2","\t"]
["NCT00190749",4508525,8254484,"Change From Baseline to 12 Week Endpoint in Eating Behavior Assessment Scale Scores","risperidone|olanzapine","olanzapine|risperidone","Drug|Drug","psychotic disorders|schizophrenia","Schizoaffective Disorder|Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder",2,null,"NA",0.532,"ANCOVA",{"$nulls":4},"NA","All",130,"Completed","Phase 4","\t"]
["NCT00190775",4508474,8254476,"Change From Baseline to 24 Weeks in the Family Assessment Measure Version III (FAM) Dyadic Relationship Scale (DRS) - Participant","atomoxetine hydrochloride","Atomoxetine Hydrochloride|Placebo","Drug|Drug","attention deficit disorder with hyperactivity|hyperkinesis","Attention Deficit Hyperactivity Disorder","Parallel Assignment","Interventional","Treatment","Randomized","A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)",2,null,"NA",0.176,"ANCOVA",{"$nulls":4},"NA","All",502,"Completed","Phase 4","\t"]
["NCT00191282",4508254,8254373,"Number of Participants With Self-Reported Hypoglycemia During Month 1","isophane insulin, beef|isophane insulin, human|insulin, globin zinc|insulin glargine|insulin lispro|insulin, isophane|insulin","Insulin lispro|Human insulin isophane suspension (NPH)|Insulin glargine|Human insulin isophane suspension|Human insulin 30/70","Drug|Drug|Drug|Drug|Drug","myocardial infarction|infarction|diabetes mellitus|diabetes mellitus, type 2|hyperglycemia","Acute Myocardial Infarction|Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes",2,null,"NA",0.7168,"Chi-squared",{"$nulls":4},"NA","All",1116,"Completed","Phase 4","\t"]
["NCT00205803",4507373,8253220,"Percentage of Participants Achieving Predefined Antibody Levels for Haemophilus Influenzae Type b, Diphtheria Toxoid, Polio, Pertussis, Tetanus, and Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series","heptavalent pneumococcal conjugate vaccine|vaccines","13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|7-Valent Pneumococcal Conjugate Vaccine (7vPnC)","Biological|Biological","pneumococcal infections","Healthy Subjects|Pneumococcal Infections","Parallel Assignment","Interventional","Prevention","Randomized","Study Evaluating Pneumococcal Vaccine in Healthy Infants",2,"Difference",0,"NA",null,-9.38,7.73,95,null,"NA","All",249,"Completed","Phase 1/Phase 2","\t"]
["NCT00219544",4507174,8252378,"Intensity of Neuropathic Pain -Visual Analog Scale (NeP - VAS)","pregabalin","Pregabalin (Lyrica)|Pregabalin (Lyrica)|Pregabalin (Lyrica)|Placebo","Drug|Drug|Drug|Drug","neuralgia","Neuropathic Pain","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.",4,"Mean Difference (Net)",-9,0.0069,"ANCOVA",-15.5,-2.5,95,"Standard Error of the Mean",3.3,"All",158,"Completed","Phase 3","\t"]
["NCT00219557",4507058,8252357,"Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score at Day 1 of Every Cycle and End of Study","gemcitabine|axitinib","Gemcitabine|AG-013736|Gemcitabine","Drug|Drug|Drug","pancreatic neoplasms","Pancreatic Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer",2,"Mean Difference (Final Values)",73.33,"NA",null,-16.45,163.12,95,null,"NA","All",111,"Completed","Phase 2","\t"]
["NCT00219557",4507148,8252357,"Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score at Day 1 of Every Cycle and End of Study","gemcitabine|axitinib","Gemcitabine|AG-013736|Gemcitabine","Drug|Drug|Drug","pancreatic neoplasms","Pancreatic Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer",2,"Mean Difference (Final Values)",-1.28,"NA",null,-15.1,12.54,95,null,"NA","All",111,"Completed","Phase 2","\t"]
["NCT00232141",4506629,8251783,"Change From Baseline for MOS (Medical Outcomes Study)-Sleep Subscales and Sleep Problem Indices","pregabalin","pregabalin|Placebo","Drug|Drug","peripheral nervous system diseases","HIV Infections|Peripheral Neuropathy","Parallel Assignment","Interventional","Treatment","Randomized","Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy",2,"Mean Difference (Final Values)",9.34,0.004,"ANCOVA",3.02,15.66,95,"Standard Error of the Mean",3.21,"All",302,"Completed","Phase 3","\t"]
["NCT00241839",4506290,8251148,"Change in Overall Mean BP From Those Obtained by 24 Hour Ambulatory Blood Pressure Measurements (ABPM) 8-10 Weeks Minus Baseline.","allopurinol|chlorthalidone","Allopurinol|Placebo|Chlorthalidone|Potassium chloride","Drug|Drug|Drug|Drug","heart diseases|hypertension|cardiovascular diseases","Cardiovascular Diseases|Heart Diseases|Hypertension","Parallel Assignment","Interventional","Treatment","Randomized","Uric Acid and Hypertension in African Americans",2,"Median Difference (Net)",-6.76,2E-3,"t-test, 2 sided",-11,-2.6,95,"Standard Error of the Mean",2.11,"All",150,"Completed","Phase 3","\t"]
["NCT00247273",4505995,8250634,"Percent Change From Baseline in Serum BAP at Month 24, ITT Population","risedronic acid|etidronic acid","risedronate|risedronate","Drug|Drug","osteoporosis|osteoporosis, postmenopausal","Postmenopausal Osteoporosis","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Monthly Risedronate for Osteoporosis",2,"Mean Difference (Final Values)",-0.77,"NA",null,-3.96,2.43,95,null,"NA","Female",1294,"Completed","Phase 3","\t"]
["NCT00252512",4505833,8250212,"Number of Negative Breath Alcohol and Urine Drug Screens Out of Possible 16","NA","Contingency Management|Placebo","Behavioral|Other","substance-related disorders","Substance Use Disorders","Parallel Assignment","Interventional","Treatment","Randomized","The Effect of a Contingency Management Intervention on Substance Use",2,null,"NA",1E-3,"GEE full factorial modeling",{"$nulls":4},"NA","All",332,"Completed","N/A","\t"]
["NCT00255151",4505766,8250049,"Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Median.","lansoprazole|dexlansoprazole","Dexlansoprazole MR|Dexlansoprazole MR|Placebo","Drug|Drug|Drug","esophagitis, peptic|esophagitis","Esophagitis, Peptic|Esophagitis, Reflux","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis",3,null,"NA",{"v":1e-05,"d":"1.00E-05"},"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",451,"Completed","Phase 3","\t"]
["NCT00257660",4505496,8249811,"Subject VAS for CD Symptom Assessment","botulinum toxins|abobotulinumtoxina|botulinum toxins, type a","Botulinum toxin type A|Placebo","Biological|Drug","dystonia|dystonic disorders|torticollis","Cervical Dystonia","Parallel Assignment","Interventional","Treatment","Randomized","Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia",2,"Mean Difference (Net)",-11.05,0.007,"ANCOVA",-19,-3.1,95,null,"NA","All",116,"Completed","Phase 3","\t"]
["NCT00261443",4505171,8249512,"Median Baseline, Change From Baseline, and Highest Value of Change in Creatine Kinase, Phase 3 Safety Sample","lithium carbonate|aripiprazole|valproic acid","Lithium or Valproate with placebo (PBO)|Lithium or Valproate with Aripiprazole","Drug|Drug","bipolar disorder","Bipolar Disorder","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",2,null,"NA",0.043,"Wilcoxon Rank Sum Test",{"$nulls":4},"NA","All",1270,"Completed","Phase 4","\t"]
["NCT00261443",4505288,8249578,"Adjusted Mean Change in CGI-BP From Preceding Phase (Mania) Through Phase 3","lithium carbonate|aripiprazole|valproic acid","Lithium or Valproate with placebo (PBO)|Lithium or Valproate with Aripiprazole","Drug|Drug","bipolar disorder","Bipolar Disorder","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",2,"Difference",-0.37,0.027,"ANOVA/ANCOVA",-0.7,-0.04,95,null,"NA","All",1270,"Completed","Phase 4","\t"]
["NCT00264147",4504894,8249048,"Patient Global Assessment of Pain (0- to 100-mm Visual Analog Scale) Time Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment I Period (All Patients-Treated Population)","diclofenac|etoricoxib","etoricoxib|etoricoxib|etoricoxib|etoricoxib|Comparator: placebo|etoricoxib|Comparator: diclofenac","Drug|Drug|Drug|Drug|Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Rheumatoid Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)",7,null,"NA",0.08,"ANCOVA",{"$nulls":4},"NA","All",761,"Completed","Phase 2","\t"]
["NCT00265317",4504609,8248879,"OS in Subgroups That Were Defined by Germline PDGFRB Polymorphisms","erlotinib hydrochloride|sunitinib","erlotinib|sunitinib|erlotinib|placebo","Drug|Drug|Drug|Drug","lung neoplasms|carcinoma, non-small-cell lung","Carcinoma, Non-Small-Cell Lung","Parallel Assignment","Interventional","Treatment","Randomized","A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone",2,"Hazard Ratio (HR)",1.112,0.7677,"Log Rank",0.549,2.252,95,null,"NA","All",162,"Completed","Phase 2","\t"]
["NCT00266409",4504428,8248688,"Change From Baseline in HAM-A-insomnia Subscore at Endpoint During the 8 Week Treatment Period","alprazolam","Niravam|SSRI/SNRI","Drug|Drug","disease|anxiety disorders|panic disorder","Generalized Anxiety Disorder|Panic Disorder","Parallel Assignment","Interventional","Treatment","Randomized","Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder",4,null,"NA",0.4639,"ANCOVA",{"$nulls":4},"NA","All",418,"Completed","Phase 4","\t"]
["NCT00267969",4504270,8248453,"Psoriasis Area and Severity Index (PASI) 75 Responders at Week 52","ustekinumab","ustekinumab|placebo","Drug|Drug","psoriasis","Psoriasis","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis",3,null,"NA",1E-3,"Cochran-Mantel-Haenszel (CMH) chi square",{"$nulls":4},"NA","All",766,"Completed","Phase 3","\t"]
["NCT00270855",4504188,8248258,"Change in Total Cholesterol (TC)","NA","Arm Crank Ergometry|FES Cycle Ergometer","Procedure|Procedure","paraplegia|quadriplegia|wounds and injuries|spinal cord injuries|obesity","Diabetes Mellitus|Obesity|Paraplegia|Quadriplegia|Spinal Cord Injury","Parallel Assignment","Interventional","Treatment","Randomized","Exercise to Reduce Obesity in Spinal Cord Injury",2,null,"NA",0.05,"t-test, 2 sided",{"$nulls":4},"NA","All",29,"Completed","N/A","\t"]
["NCT00274716",4503955,8247935,"Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 12 in Participants With Higher Body Mass Indices (BMI)","NA","MK0736|MK0916|Placebo","Drug|Drug|Drug","hypertension","Hypertension","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension (High Blood Pressure)(0736-003)(COMPLETED)",6,"Mean Difference (Final Values)",-4.1,0.099,"ANCOVA",-9,0.8,95,"Standard Error of the Mean",2.5,"All",249,"Completed","Phase 2","\t"]
["NCT00279201",4503597,8247602,"ADDENDUM: 7-point SMPG Profiles","insulin lispro|isophane insulin, insulin lispro drug combination 50:50|insulin, isophane|biphasic insulins|insulin glargine","Insulin glargine|Lispro Low Mix|Lispro Mid Mix|Lispro","Drug|Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)",6,null,"NA",0.348,"ANCOVA",{"$nulls":4},"NA","All",2091,"Completed","Phase 4","\t"]
["NCT00279201",4503787,8247644,"INITIATION: 7-point Self-monitored Plasma Glucose (SMPG) Profiles and Postprandial Excursions","insulin lispro|isophane insulin, insulin lispro drug combination 50:50|insulin, isophane|biphasic insulins|insulin glargine","Insulin glargine|Lispro Low Mix|Lispro Mid Mix|Lispro","Drug|Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)",6,null,"NA",0.165,"ANOVA",{"$nulls":4},"NA","All",2091,"Completed","Phase 4","\t"]
["NCT00280059",4503458,8247537,"Medical Outcomes Study Sleep Scale (MOS-SS): Optimal Sleep Subscale","pregabalin|lamotrigine","Pregabalin|Lamotrigine","Drug|Drug","epilepsies, partial|epilepsy","Epilepsy, Partial","Parallel Assignment","Interventional","Treatment","Randomized","Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy",2,"Odds Ratio (OR)",1.14,0.5096,"Regression, Logistic",0.78,1.66,95,null,"NA","All",660,"Completed","Phase 3","\t"]
["NCT00282464",4503289,8247192,"Remission as Measured by Hamilton Asberg Depression Rating Scale (HAM-D 17) Total Score Less Than or Equal to 7","ziprasidone","Placebo|Geodon (Ziprasidone)","Drug|Drug","bipolar disorder|depression","Bipolar Disorder","Parallel Assignment","Interventional","Treatment","Randomized","A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.",2,null,"NA",0.9863,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",392,"Completed","Phase 3","\t"]
["NCT00286429",4503064,8246892,"Change From Baseline in Fasting Plasma Glucose (Week 16).","insulin|alogliptin|insulin, globin zinc","Alogliptin and insulin|Alogliptin and insulin|Insulin","Drug|Drug|Drug","diabetes mellitus","Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.",3,"Mean Difference (Final Values)",-9.9,0.19,"ANCOVA",-24.7,4.9,95,null,"NA","All",390,"Completed","Phase 3","\t"]
["NCT00286468",4502786,8246751,"Change From Baseline in Fasting Plasma Glucose (Week 16).","glyburide|alogliptin","Alogliptin and glyburide|Alogliptin and glyburide|Glyburide","Drug|Drug|Drug","diabetes mellitus","Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.",3,"Mean Difference (Final Values)",-1.9,0.701,"ANCOVA",-11.6,7.8,95,null,"NA","All",500,"Completed","Phase 3","\t"]
["NCT00286494",4502668,8246692,"Change From Baseline in Fasting Proinsulin (Week 16).","alogliptin|pioglitazone","Alogliptin and pioglitazone|Alogliptin and pioglitazone|Pioglitazone","Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus",3,"Mean Difference (Final Values)",-0.3,0.884,"ANCOVA",-4.9,4.2,95,null,"NA","All",493,"Completed","Phase 3","\t"]
["NCT00289900",4502413,8246210,"Percentage Change From Baseline in Apolipoprotein (Apo) B","simvastatin|atorvastatin","MK-0524A|Atorvastatin|Simvastatin","Drug|Drug|Drug","hyperlipoproteinemia type v|hyperlipidemia, familial combined|lipidoses|hyperlipoproteinemias|hyperlipidemias","Mixed Hyperlipidemia","Parallel Assignment","Interventional","Treatment","Randomized","Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)",6,"Difference in Least Squares Mean",-9.2,1E-3,"ANCOVA",-12.1,-6.3,95,null,"NA","All",2340,"Completed","Phase 3","\t"]
["NCT00293033",4502171,8245761,"Episodes With at Least 33% Decreases in Pain","fentanyl","BEMA™|Placebo","Drug|Drug","breakthrough pain","Cancer|Pain","Crossover Assignment","Interventional","Treatment","Randomized","Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects",2,null,"NA",0.009,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",152,"Completed","Phase 3","\t"]
["NCT00294515",4502124,8245504,"Percentage of Patients Who Developed Cytomegalovirus (CMV) Disease up to Month 12 Post-transplant","valganciclovir","Valganciclovir|Valganciclovir","Drug|Drug","cytomegalovirus infections","Cytomegalovirus Infections","Parallel Assignment","Interventional","Treatment","Randomized","IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients",2,"Odds Ratio (OR)",0.4,0,"Cochran-Mantel-Haenszel",0.25,0.66,95,null,"NA","All",326,"Completed","Phase 3","\t"]
["NCT00303602",4501625,8244364,"Mean Change From Baseline to 16 Week Endpoint in Fasting Lipoproteins (Total Cholesterol, High-Density Lipoprotein Cholesterol [HDL-Cholesterol], Low-Density Lipoprotein Cholesterol [LDL-Cholesterol] [Calculated], and Triglycerides)","olanzapine","Sublingual orally disintegrating olanzapine (SODO)|Oral olanzapine","Drug|Drug","psychotic disorders|schizophrenia|disease|bipolar disorder","Bipolar Disorder|Schizoaffective Disorder|Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)",2,null,"NA",0.581,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",149,"Completed","Phase 4","\t"]
["NCT00307489",4501473,8243823,"HBsAg Loss at Week 168","tenofovir|emtricitabine","emtricitabine /tenofovir DF|tenofovir DF","Drug|Drug","hepatitis b, chronic|hepatitis|hepatitis a|hepatitis b|hepatitis, chronic","Chronic Hepatitis B","Parallel Assignment","Interventional","Treatment","Randomized","Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil",2,null,"NA",0.254,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",106,"Completed","Phase 2","\t"]
["NCT00312494",4501243,8243187,"Change From Baseline in Clinical Global Impression Scale - Severity (CGI-S) Score","ziprasidone","Placebo|Ziprasidone|Ziprasidone","Drug|Drug|Drug","bipolar disorder","Bipolar Disorder","Parallel Assignment","Interventional","Treatment","Randomized","3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects",3,null,"NA",0.242,"Mixed Models Analysis",{"$nulls":4},"NA","All",680,"Completed","Phase 3","\t"]
["NCT00313300",4501190,8243095,"Event Rate for Adjudicated All Bleeding Events During the Treatment Period - Treated Participants With Placebo or Apixaban Low Doses","apixaban","Apixaban|Apixaban|Placebo|Apixaban","Drug|Drug|Drug|Drug","syndrome|acute coronary syndrome","Acute Coronary Syndrome (ACS)","Parallel Assignment","Interventional","Prevention","Randomized","Safety Study of Apixaban in Recent Acute Coronary Syndrome",4,"Adjusted Rate Difference",10,"NA",null,4.8,15.2,95,null,"NA","All",1741,"Completed","Phase 2","\t"]
["NCT00317642",4500964,8242575,"Overall Survival - Overall and by Calculated Strata (CSR 7-April-11)","cytarabine|clofarabine","clofarabine (IV formulation)|placebo|cytarabine","Drug|Drug|Drug","leukemia|leukemia, myeloid|leukemia, myeloid, acute","Acute Myelogenous Leukemia","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)",2,"Hazard Ratio (HR)",1.13,0.4674,"Log Rank",0.81,1.57,95,null,"NA","All",326,"Completed","Phase 3","\t"]
["NCT00323427",4500528,8241722,"Communication Profile for Hearing Impaired: Maladaptive Strategies Subscale","NA","The Living Well with Hearing Loss Workshop|hearing aid services","Behavioral|Device","hearing loss|deafness","Hearing Loss|Stress","Parallel Assignment","Interventional","Treatment","Randomized","Clinical Trial of the \"Living Well With Hearing Loss Workshop\"",2,"Mean Difference (Final Values)",0.039,0.69,"t-test, 2 sided",-0.15,0.23,95,"Standard Error of the Mean",0.0974,"All",135,"Completed","Phase 2","\t"]
["NCT00325130",4500363,8241485,"Geometric Mean Titers (GMTs) for Pertussis Anti-Fimbrial Agglutinogens 2/3 (Anti-FIM) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™","NA","Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine|Comparator: Menactra™ (Concomitant)|Comparator: Adacel™ (Concomitant)|Comparator: Menactra™ (Non-concomitant)|Comparator: Adacel™","Biological|Biological|Biological|Biological|Biological","tetanus|meningitis|neoplasms, glandular and epithelial|diphtheria|whooping cough","Diphtheria|Meningitis|Neoplasms, Glandular and Epithelial|Tetanus|Whooping Cough","Parallel Assignment","Interventional","Prevention","Randomized","Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)",2,null,"NA","NA",{"$nulls":5},"NA","All",1042,"Completed","Phase 3","\t"]
["NCT00327717",4500285,8241174,"Mean Time to First Seizure (Days)","zonisamide","Zonisamide|Placebo","Drug|Drug","seizures","Partial Seizures","Parallel Assignment","Interventional","Treatment","Randomized","Evaluating the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures",2,null,"NA",0.162,"X^2 test",{"$nulls":4},"NA","All",240,"Completed","Phase 3","\t"]
["NCT00331773",4500158,8240420,"Five-year Disease-free Survival (DFS) Rate","NA","Conventional 3D-CRT or IMRT|Hypofractionated 3D-CRT or IMRT","Radiation|Radiation","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Radiation Therapy in Treating Patients With Stage II Prostate Cancer",2,"Hazard Ratio (HR)",0.85,1E-3,"Log Rank",0.64,1.14,95,null,"NA","Male",1115,"Active, not recruiting","Phase 3","\t"]
["NCT00336024",4499823,8240021,"Rates of Nutritional Toxicities","cyclophosphamide|thiotepa|etoposide phosphate|levoleucovorin|etoposide|vincristine|leucovorin|methotrexate|carboplatin","etoposide|cyclophosphamide|cisplatin|filgrastim|carboplatin|thiotepa|methotrexate|leucovorin calcium|vincristine sulfate|autologous hematopoietic stem cell transplantation|laboratory biomarker analysis|quality-of-life assessment","Drug|Drug|Drug|Biological|Drug|Drug|Drug|Drug|Drug|Procedure|Other|Procedure","neuroectodermal tumors, primitive|medulloblastoma|neuroectodermal tumors","Untreated Childhood Medulloblastoma|Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor","Parallel Assignment","Interventional","Treatment","Randomized","Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma",2,null,"NA",0.9,"Chi-squared",{"$nulls":4},"NA","All",91,"Active, not recruiting","Phase 3","\t"]
["NCT00346216",4499370,8239272,"Change From Baseline in Patient's Assessment of Arthritis Pain (VAS)","celecoxib|naproxen|ibuprofen","celecoxib|Ibuprofen|Naproxen","Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Arthritis, Rheumatoid","Parallel Assignment","Interventional","Treatment","Randomized","Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen",3,"Mean Difference (Final Values)",0.43,0.4323,"Mixed Models Analysis",-0.65,1.52,95,"Standard Error of the Mean",0.55,"All",24081,"Completed","Phase 4","\t"]
["NCT00348140",4499285,8239154,"Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score","rosiglitazone","Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 8mg|Placebo","Drug|Drug|Other","alzheimer disease","Alzheimer's Disease","Parallel Assignment","Interventional","Treatment","Randomized","Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease",3,"Mean Difference (Net)",-0.2,0.631,"Mixed model for repeated measures",-1.1,0.6,95,null,"NA","All",1468,"Completed","Phase 3","\t"]
["NCT00351533",4499088,8238722,"Change in Bronchoalveolar Lavage Fluid (BALF) Interleukin (IL)-8","NA","Fish oil (eicosapentaenoic acid and docosahexanoic acid)","Drug","respiratory distress syndrome, adult|lung injury|respiratory distress syndrome, newborn|acute lung injury|wounds and injuries|syndrome","Acute Lung Injury|Acute Respiratory Distress Syndrome|Respiratory Distress Syndrome, Adult","Parallel Assignment","Interventional","Treatment","Randomized","A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)",2,null,"NA",0.55,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",90,"Completed","Phase 2","\t"]
["NCT00356057",4498835,8238195,"Cardiac Remodeling Assessments by Echocardiography - Change in Left Atrial Volume","NA","Protos DR/CLS and Stratos LV CRT pacemakers","Device","heart failure|atrial fibrillation","Atrial Fibrillation|Congestive Heart Failure","Parallel Assignment","Interventional","Treatment","Randomized","Investigational Device Exemption (IDE) Study for the Approval of Closed Loop Stimulation (CLS) and Cardiac Resyncronization Pacing Therapies (CRT) for the Treatment of Atrial Fibrillation (AF) With Ablate and Pace",3,null,"NA",0.005,"t-test, 2 sided",{"$nulls":4},"NA","All",153,"Terminated","N/A","\t"]
["NCT00360490",4498430,8237448,"Absolute Change From Baseline MBL to Mid-study MBL (Cycle 3)","medroxyprogesterone acetate|medroxyprogesterone|levonorgestrel","Levonorgestrel IUS (Mirena, BAY86-5028)|Medroxyprogesterone acetate","Drug|Drug","menorrhagia","Menorrhagia","Parallel Assignment","Interventional","Treatment","Randomized","Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)",2,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",165,"Completed","Phase 3","\t"]
["NCT00362115",4498231,8237267,"Change From Baseline in the 10-12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.","olmesartan|azilsartan medoxomil","Azilsartan Medoxomil|Azilsartan Medoxomil|Azilsartan Medoxomil|Azilsartan Medoxomil|Azilsartan Medoxomil|Olmesartan|Placebo","Drug|Drug|Drug|Drug|Drug|Drug|Drug","hypertension","Hypertension","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension",7,"Mean Difference (Final Values)",-0.2,0.9355,"ANCOVA",-5.74,5.28,95,null,"NA","All",449,"Completed","Phase 2","\t"]
["NCT00362115",4498250,8237269,"Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.","olmesartan|azilsartan medoxomil","Azilsartan Medoxomil|Azilsartan Medoxomil|Azilsartan Medoxomil|Azilsartan Medoxomil|Azilsartan Medoxomil|Olmesartan|Placebo","Drug|Drug|Drug|Drug|Drug|Drug|Drug","hypertension","Hypertension","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension",7,"Mean Difference (Final Values)",-5.6,0.0189,"ANCOVA",-10.26,-0.93,95,null,"NA","All",449,"Completed","Phase 2","\t"]
["NCT00365105",4497930,8236902,"Change in Functional Assessment of Cancer Therapy - General (FACT-G) at One Year","vitamin d|zoledronic acid|calcium","Calcium|Vitamin D|zoledronic acid|Sm-153|Sr-89","Dietary Supplement|Dietary Supplement|Drug|Drug|Radiation","breast neoplasms|lung neoplasms|neoplasm metastasis|prostatic neoplasms","Breast Cancer|Lung Cancer|Metastatic Cancer|Pain|Prostate Cancer","Parallel Assignment","Interventional","Supportive Care","Randomized","Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer",2,null,"NA",0.57,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",261,"Completed","Phase 3","\t"]
["NCT00368459",4497616,8236543,"ADAS-cog","raloxifene hydrochloride","raloxifene|Placebo","Drug|Drug","alzheimer disease","Alzheimer Disease","Parallel Assignment","Interventional","Treatment","Randomized","Raloxifene for Women With Alzheimer's Disease",2,null,"NA",0.1,"ANCOVA",{"$nulls":4},"NA","Female",42,"Completed","Phase 2","\t"]
["NCT00368966",4497519,8236488,"Geometric Mean Antibody Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Group After the Second Dose and After the Third Dose of a 3-Dose Infant Series and After the Toddler Dose","vaccines|heptavalent pneumococcal conjugate vaccine","13-valent Pneumococcal Conjugate Vaccine|7-valent Pneumococcal Conjugate Vaccine","Biological|Biological","NA","Vaccines, Pneumococcal","Parallel Assignment","Interventional","Prevention","Randomized","Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.",2,"Difference",1.15,"NA",null,1.05,1.25,95,null,"NA","All",619,"Completed","Phase 3","\t"]
["NCT00371397",4497372,8236104,"Number of Participants With Detectable C-Reactive Protein (CRP)","NA","Hatha Yoga Classes|Movement Control","Behavioral|Behavioral","NA","Healthy","Crossover Assignment","Interventional","Treatment","Randomized","Yoga, Immune Function, and Health",3,"Odds Ratio (OR)",4.75,0.009,"Regression, Logistic",null,null,95,null,"NA","Female",52,"Completed","N/A","\t"]
["NCT00373256",4497124,8235755,"Percentage of Participants Surviving at 1 and 2 Years","albumin-bound paclitaxel|sunitinib|paclitaxel|bevacizumab","Sunitinib|paclitaxel|bevacizumab|paclitaxel","Drug|Drug|Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer",2,"Percentage",35.5,"NA",null,20.9,50.3,95,null,"NA","All",488,"Completed","Phase 3","\t"]
["NCT00377676",4496897,8235242,"Subjects Experiencing Serious Adverse Events","bromocriptine","Cycloset|Usual Diabetes Therapy plus placebo","Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Type 2 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes",2,"Hazard Ratio (HR)",1.02,0.05,"Regression, Cox",null,1.27,95,null,"NA","All",3095,"Completed","Phase 3","\t"]
["NCT00379769",4496747,8235035,"Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Contemporary Endpoint Definitions","metformin|rosiglitazone","Rosiglitazone|Sulfonylurea|Metformin","Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes",4,"Hazard Ratio (HR)",0.9,"NA",null,0.68,1.21,95,null,"NA","All",4447,"Completed","Phase 3","\t"]
["NCT00380692",4496648,8234846,"ADHD Rating Scale-IV-Parent Version: Investigator Scored - Total Score","atomoxetine hydrochloride","Atomoxetine|Placebo","Drug|Drug","autism spectrum disorder|attention deficit disorder with hyperactivity|hyperkinesis|disease|autistic disorder","Attention Deficit Disorder With Hyperactivity|Autistic Disorder","Parallel Assignment","Interventional","Treatment","Randomized","Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder",2,"Mean Difference (Net)",-6.7,1E-3,"Mixed Models Analysis",-10,-3.4,95,"Standard Error of the Mean",1.7,"All",97,"Completed","Phase 4","\t"]
["NCT00383188",4496256,8234460,"Change From Baseline in Physician Global Assessment of Arthritis at Weeks 1, 2, 4, 8, 12 and 16","NA","placebo|PH-797804|PH-797804|PH-797804|PH-797804","Drug|Drug|Drug|Drug|Drug","arthritis, rheumatoid|arthritis","Arthritis, Rheumatoid","Parallel Assignment","Interventional","Treatment","Randomized","An Oral p38 Inhibitor Investigating Safety, Efficacy, And PK In Subjects With Active Rheumatoid Arthritis",5,"LSM Difference",0.646,0.8693,"ANCOVA",-7.058,8.351,95,"Standard Error of the Mean",3.925,"All",305,"Completed","Phase 2","\t"]
["NCT00383240",4496121,8234445,"Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) for MF/F Versus MF","mometasone furoate|formoterol fumarate","mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|Mometasone furoate MDI (MF MDI) 200 mcg|formoterol fumarate 10 mcg|Placebo","Drug|Drug|Drug|Drug","asthma","Asthma","Parallel Assignment","Interventional","Treatment","Randomized","Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED)",4,null,"NA",0.008,"ANCOVA",{"$nulls":4},"NA","All",781,"Completed","Phase 3","\t"]
["NCT00385671",4495654,8234061,"Number of Participants With Treatment-Emergent Changes in Body Weight","gabapentin|duloxetine hydrochloride|pregabalin","duloxetine hydrochloride|pregabalin|gabapentin","Drug|Drug|Drug","neuralgia|diabetic neuropathies","Diabetic Neuropathy, Painful","Parallel Assignment","Interventional","Treatment","Randomized","An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain",3,null,"NA",0.103,"Fisher Exact",{"$nulls":4},"NA","All",407,"Completed","Phase 4","\t"]
["NCT00385671",4495750,8234068,"Weekly Mean Change in 24 Hour Average Pain Severity by Week by Gabapentin Exposure Subgroup (de Novo Versus Prior Use)","gabapentin|duloxetine hydrochloride|pregabalin","duloxetine hydrochloride|pregabalin|gabapentin","Drug|Drug|Drug","neuralgia|diabetic neuropathies","Diabetic Neuropathy, Painful","Parallel Assignment","Interventional","Treatment","Randomized","An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain",3,"Mean Difference (Final Values)",0.16,0.622,"Mixed Models Analysis",-0.48,0.8,95,null,"NA","All",407,"Completed","Phase 4","\t"]
["NCT00385671",4495878,8234086,"Number of Participants With a ≥ 2-points Reduction on the Weekly Average of the Daily 24-hour Average Pain Scale at 12 Weeks","gabapentin|duloxetine hydrochloride|pregabalin","duloxetine hydrochloride|pregabalin|gabapentin","Drug|Drug|Drug","neuralgia|diabetic neuropathies","Diabetic Neuropathy, Painful","Parallel Assignment","Interventional","Treatment","Randomized","An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain",3,null,"NA",0.2,"Mantel Haenszel",{"$nulls":4},"NA","All",407,"Completed","Phase 4","\t"]
["NCT00387036",4495395,8233780,"Standardized Dyspnea Score at Isotime During Exercise","fluticasone","Fluticasone|Comparator: Placebo","Drug|Drug","pulmonary disease, chronic obstructive|lung diseases, obstructive|lung diseases","Chronic Obstructive Pulmonary Disease (COPD)","Crossover Assignment","Interventional","Treatment","Randomized","Exercise Study in Patient With Chronic Obstructive Pulmonary Disease (0000-036)",2,"Mean Difference (Final Values)",-0.92,"NA",null,-1.59,-0.25,90,"Standard Error of the Mean",0.37,"All",12,"Terminated","Phase 2","\t"]
["NCT00394901",4494996,8232738,"Endpoint Short-Form 36-Item Health Survey Scores: Vitality","pregabalin","Placebo|Pregabalin|Pregabalin|Pregabalin","Drug|Drug|Drug|Drug","neuralgia, postherpetic|neuralgia","Neuralgia, Postherpetic","Parallel Assignment","Interventional","Treatment","Randomized","A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia",4,"Mean Difference (Final Values)",5.64,0.039,"ANCOVA",0.29,11,95,null,"NA","All",372,"Completed","Phase 3","\t"]
["NCT00394901",4495054,8232758,"Endpoint Total Scores of the Short-Form McGill Pain Questionnaire","pregabalin","Placebo|Pregabalin|Pregabalin|Pregabalin","Drug|Drug|Drug|Drug","neuralgia, postherpetic|neuralgia","Neuralgia, Postherpetic","Parallel Assignment","Interventional","Treatment","Randomized","A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia",4,"Mean Difference (Final Values)",-2.61,0.012,"ANCOVA",-4.65,-0.56,95,null,"NA","All",372,"Completed","Phase 3","\t"]
["NCT00397033",4494665,8232216,"The Change From Baseline to Week 6 or the Last Post-randomization Assessment During Double-blind Treatment in the Positive and Negative Symptoms of Schizophrenia (PANSS) Total Score.","paliperidone palmitate","Paliperidone ER|Paliperidone ER|Placebo","Drug|Drug|Drug","mental disorders|disease|psychotic disorders","Psychotic Disorder|Schizoaffective Disorder","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.",3,"LS Means Difference",-8.3,0.003,"ANCOVA",-13.8,-2.9,95,"Standard Error of the Mean",2.8,"All",316,"Completed","Phase 3","\t"]
["NCT00402233",4494372,8231541,"Beck Depression Inventory II","pramipexole","Pramipexole|Placebo","Drug|Drug","parkinson disease","Parkinson Disease","Parallel Assignment","Interventional","Treatment","Randomized","A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients",4,"Mean Difference (Final Values)",-0.47,0.48,"ANCOVA",-1.78,0.84,95,null,"NA","All",312,"Completed","Phase 4","\t"]
["NCT00402987",4493927,8231401,"Total Pain Relief (TOTPAR) at 12 and 24 Hours Post-First Dose","celecoxib","Celecoxib|Celecoxib|celecoxib|placebo","Drug|Drug|Drug|Drug","pharyngitis","Pharyngitis","Parallel Assignment","Interventional","Treatment","Randomized","Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat",4,"Mean Difference (Final Values)",-1.39,0.633,null,-7.1,4.3,95,null,"NA","All",269,"Completed","Phase 3","\t"]
["NCT00402987",4494035,8231409,"Difficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) Within 6 Hours Post-First Dose","celecoxib","Celecoxib|Celecoxib|celecoxib|placebo","Drug|Drug|Drug|Drug","pharyngitis","Pharyngitis","Parallel Assignment","Interventional","Treatment","Randomized","Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat",4,null,"NA",1E-3,{"$nulls":5},"NA","All",269,"Completed","Phase 3","\t"]
["NCT00402987",4494180,8231422,"Sore Throat Relief Rating Scale (STRRS) From 7 to 24 Hours Post-First Dose","celecoxib","Celecoxib|Celecoxib|celecoxib|placebo","Drug|Drug|Drug|Drug","pharyngitis","Pharyngitis","Parallel Assignment","Interventional","Treatment","Randomized","Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat",4,null,"NA",0.046,{"$nulls":5},"NA","All",269,"Completed","Phase 3","\t"]
["NCT00406029",4493364,8231065,"Change From Baseline in UPDRS Part 3 (2 Hours Post-dose)","levodopa","Preladenant|Preladenant|Preladenant|Preladenant|Placebo|L-dopa|Other Parkinson's Disease treatments","Drug|Drug|Drug|Drug|Drug|Drug|Drug","dyskinesias|nervous system diseases|central nervous system diseases|parkinson disease|brain diseases|neurodegenerative diseases|movement disorders","Brain Diseases|Central Nervous System Diseases|Movement Disorders|Neurodegenerative Diseases|Parkinson Disease","Parallel Assignment","Interventional","Treatment","Randomized","Dyskinesia in Parkinson's Disease (Study P04501)",5,"Difference in LS Means",3.9,0.052,"ANCOVA",0,7.8,95,null,"NA","All",253,"Completed","Phase 2","\t"]
["NCT00406029",4493586,8231079,"Change From Baseline in Awake Time Per Day Spent in the \"on\" State (no Dyskinesias)","levodopa","Preladenant|Preladenant|Preladenant|Preladenant|Placebo|L-dopa|Other Parkinson's Disease treatments","Drug|Drug|Drug|Drug|Drug|Drug|Drug","dyskinesias|nervous system diseases|central nervous system diseases|parkinson disease|brain diseases|neurodegenerative diseases|movement disorders","Brain Diseases|Central Nervous System Diseases|Movement Disorders|Neurodegenerative Diseases|Parkinson Disease","Parallel Assignment","Interventional","Treatment","Randomized","Dyskinesia in Parkinson's Disease (Study P04501)",5,"Difference in LS Means",-0.4,0.603,"ANCOVA",-1.9,1.1,95,null,"NA","All",253,"Completed","Phase 2","\t"]
["NCT00406848",4493081,8230872,"Change From Baseline in Electrocardiograms","duloxetine hydrochloride","duloxetine hydrochloride|placebo","Drug|Drug","depressive disorder|depressive disorder, major","Major Depressive Disorder","Parallel Assignment","Interventional","Treatment","Randomized","A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients",2,null,"NA",0.376,"ANCOVA",{"$nulls":4},"NA","All",370,"Completed","Phase 4","\t"]
["NCT00407745",4492982,8230794,"Change From Baseline in Weekly Mean Pain Score by Week","pregabalin","placebo|pregabalin","Drug|Drug","wounds and injuries|neuralgia|spinal cord injuries","Neuralgia|Spinal Cord Injuries","Parallel Assignment","Interventional","Treatment","Randomized","A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury",2,"LS Mean Difference",-0.66,0.0048,"Mixed Models Analysis",-1.11,-0.2,95,"Standard Error of the Mean",0.23,"All",220,"Completed","Phase 3","\t"]
["NCT00409682",4492489,8230477,"Change From Baseline IMPACT III Scores at Week 26 (Observed Case)","adalimumab","Adalimumab|Adalimumab|Adalimumab","Biological|Biological|Biological","crohn disease","Crohn's Disease","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease",3,"Mean Difference (Net)",-4.1,0.161,"ANCOVA",-9.86,1.66,95,"Standard Error of the Mean",2.903,"All",192,"Completed","Phase 3","\t"]
["NCT00411645",4492338,8230142,"Time to Onset of CMV Infection or EC-confirmed CMV Disease Within 6 Months Post- Transplantation","maribavir","maribavir|placebo","Drug|Other","cytomegalovirus infections","Cytomegalovirus Infections","Parallel Assignment","Interventional","Prevention","Randomized","Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients",2,null,"NA",0.129,"Log Rank",{"$nulls":4},"NA","All",681,"Completed","Phase 3","\t"]
["NCT00413283",4492112,8229842,"Gemcitabine Dose Reduction on Day 8 of the First Chemotherapy Cycle","carboplatin|gemcitabine","Romiplostim|Placebo|Gemcitabine|Carboplatin|Cisplatin","Biological|Drug|Drug|Drug|Drug","thrombocytopenia|lung neoplasms|carcinoma, non-small-cell lung","Cancer|Chemotherapy-Induced Thrombocytopenia|Lung Cancer|Lung Neoplasms|Non-Small Cell Lung Cancer|Oncology|Solid Tumors|Thrombocytopenia","Parallel Assignment","Interventional","Supportive Care","Randomized","Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)",4,null,"NA",0.662,"Fisher Exact",{"$nulls":4},"NA","All",63,"Completed","Phase 2","\t"]
["NCT00420095",4491804,8229059,"Change in Total Daily Insulin Dose Values From Baseline to 12 Weeks of Treatment","insulin|insulin, globin zinc|insulin lispro","Human insulin 30/70|Insulin lispro low mix","Drug|Drug","diabetes mellitus, type 1|diabetes mellitus, type 2|diabetes mellitus","Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2","Crossover Assignment","Interventional","Treatment","Randomized","A Study for Patients With Diabetes Mellitus (IOPA)",2,"Mean Difference (Net)",-0.16,0.741,"Mixed Models Analysis",-1.09,0.78,95,null,"NA","All",117,"Completed","Phase 4","\t"]
["NCT00420641",4491635,8228880,"Percentage of Responders and Remitters of MADRS Over Week 10","paroxetine","GSK372475|Paroxetine|Placebo","Drug|Drug|Other","depression|depressive disorder","Depressive Disorder","Parallel Assignment","Interventional","Treatment","Randomized","MDD POC Study GSK372475 Subjects Depressive Disease",3,"Odds Ratio (OR)",0.89,0.8844,"Generalized estimating equation model",0.23,3.48,90,null,"NA","All",492,"Completed","Phase 2","\t"]
["NCT00422461",4491410,8228587,"Change From Baseline in Mean Daytime Diastolic Blood Pressure (DBP) as Measured by ABPM at Day 28","NA","PF-00489791|PF-00489791|PF-00489791|placebo","Drug|Drug|Drug|Drug","hypertension","Hypertension","Parallel Assignment","Interventional","Treatment","Randomized","A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure",4,"LS mean difference",-6.96,{"v":1E-4,"d":"1.00E-04"},"Nonlinear dose response regression model",-10.03,-3.89,95,"Standard Error of the Mean",1.55,"All",140,"Completed","Phase 2","\t"]
["NCT00427895",4490997,8227704,"Percentage of Participants Achieving OPA Titers With at Least Lower Limit of Quantification (LLOQ) 1 Month After Vaccination 1","vaccines|heptavalent pneumococcal conjugate vaccine","13-valent pneumococcal conjugate vaccine (13vPnC)|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|13-valent pneumococcal conjugate vaccine (13vPnC)|13-valent pneumococcal conjugate vaccine (13vPnC)|13-valent pneumococcal conjugate vaccine (13vPnC)|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|13-valent pneumococcal conjugate vaccine (13vPnC)","Biological|Biological|Biological|Biological|Biological|Biological|Biological","pneumococcal infections","Pneumococcal Infections","Parallel Assignment","Interventional","Prevention","Randomized","Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults",7,"Difference in Percentage",3.6,"NA",null,-0.2,7.5,95,null,"NA","All",2141,"Completed","Phase 3","\t"]
["NCT00427895",4491047,8227707,"Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination 1","vaccines|heptavalent pneumococcal conjugate vaccine","13-valent pneumococcal conjugate vaccine (13vPnC)|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|13-valent pneumococcal conjugate vaccine (13vPnC)|13-valent pneumococcal conjugate vaccine (13vPnC)|13-valent pneumococcal conjugate vaccine (13vPnC)|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|13-valent pneumococcal conjugate vaccine (13vPnC)","Biological|Biological|Biological|Biological|Biological|Biological|Biological","pneumococcal infections","Pneumococcal Infections","Parallel Assignment","Interventional","Prevention","Randomized","Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults",7,"GMT Ratio",1,"NA",null,0.84,1.13,95,null,"NA","All",2141,"Completed","Phase 3","\t"]
["NCT00430248",4490688,8227298,"Mean Percent Change From Baseline in Serum Urate Levels at Month 2 Visit.","febuxostat|allopurinol","Febuxostat|Febuxostat|Allopurinol","Drug|Drug|Drug","gout","Gout","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of Oral Febuxostat in Participants With Gout",3,null,"NA",1E-3,"ANOVA",{"$nulls":4},"NA","All",2269,"Completed","Phase 3","\t"]
["NCT00430300",4490553,8227280,"Change From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Symptom Score at Week 1, 2, 3, 4, 5, 6, 7, and 8","NA","UK-432,097|Placebo","Drug|Drug","lung diseases, obstructive|pulmonary disease, chronic obstructive|lung diseases","Pulmonary Disease, Chronic Obstructive","Parallel Assignment","Interventional","Treatment","Randomized","Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease.",2,"Adjusted Mean Difference",0.05,0.3597,"Mixed Models Analysis",-0.17,null,95,"Standard Error of the Mean",0.13,"All",87,"Terminated","Phase 2","\t"]
["NCT00430950",4490390,8227105,"Change in Daytime, Nighttime and 24-hour Blood Pressure Evaluated by Ambulatory Blood Pressure Monitoring 8 Weeks After Baseline.","hydrochlorothiazide|olmesartan medoxomil|olmesartan","olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets|olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg","Drug|Drug","essential hypertension|hypertension","Essential Hypertension","Parallel Assignment","Interventional","Treatment","Randomized","Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension",2,"Mean Difference (Net)",-1.6,0.0016,"ANCOVA",-2.58,-0.6,95,null,"NA","All",1011,"Completed","Phase 3","\t"]
["NCT00432809",4490174,8226811,"Diabetes Medication - Use of Insulin","NA","Gastric bypass|Sleeve Gastrectomy","Procedure|Procedure","diabetes mellitus|diabetes mellitus, type 2","Diabetes Mellitus, Type 2|Obesity","Parallel Assignment","Interventional","Treatment","Randomized","Advanced Medical Therapy Versus Advanced Medical Therapy Plus Bariatric Surgery for the Resolution of Type 2 Diabetes",3,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",150,"Completed","N/A","\t"]
["NCT00438464",4489771,8225880,"Comparison of Biomarkers Between Gleason Grades GG3 & GG4: Percentage of Tumor Cells Within Placebo Treatment Arm for Biomarker Subgroups","finasteride","Finasteride|Placebo|Prostatectomy|Laboratory biomarker analysis","Drug|Other|Procedure|Other","prostatic neoplasms","Adenocarcinoma of the Prostate|Stage II Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery",2,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Male",204,"Completed","Phase 2","\t"]
["NCT00440947",4489649,8225531,"Percentage of Participants (PAR) Who Achieved Plasma HIV-1 RNA <50 Copies (c) /Milliliter (ml) at the Week 84 Visit","lamivudine|ritonavir|dideoxynucleosides|abacavir|atazanavir sulfate","Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)","Drug|Drug","acquired immunodeficiency syndrome|communicable diseases|infection|hiv infections","HIV Infection|Infection, Human Immunodeficiency Virus I","Parallel Assignment","Interventional","Treatment","Randomized","Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection",2,"Risk Difference (RD)",5.4,0.14,"Cochran-Mantel-Haenszel",-1.8,12.5,95,null,"NA","All",515,"Completed","Phase 3","\t"]
["NCT00442546",4489268,8225206,"Range of Motion (ROM) Assessment of the Active Flexion of the Surgical Knee","pregabalin","pregabalin|pregabalin|Placebo","Drug|Drug|Drug","osteoarthritis|pain, postoperative","Osteoarthritis|Postoperative Pain","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",3,"Mean Difference (Final Values)",2.272,0.3966,"ANOVA",-3.006,7.551,95,"Standard Error of the Mean",2.674,"All",307,"Completed","Phase 3","\t"]
["NCT00442546",4489485,8225220,"Pain Interference Index Score as Measured by the m-BPI-sf","pregabalin","pregabalin|pregabalin|Placebo","Drug|Drug|Drug","osteoarthritis|pain, postoperative","Osteoarthritis|Postoperative Pain","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",3,"Mean Difference (Final Values)",-0.222,0.5024,"ANOVA",-0.875,0.43,95,"Standard Error of the Mean",0.331,"All",307,"Completed","Phase 3","\t"]
["NCT00444457",4488952,8224928,"Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Toddler Dose","heptavalent pneumococcal conjugate vaccine","13-valent Pneumococcal Conjugate Vaccine|7vPnC","Biological|Biological","NA","Vaccines, Pneumococcal","Parallel Assignment","Interventional","Prevention","Randomized","Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants",4,"Difference in log-transformed GM",0.11,"NA",null,-0.03,0.25,95,null,"NA","All",1712,"Completed","Phase 3","\t"]
["NCT00444457",4489128,8224936,"Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Infant Series","heptavalent pneumococcal conjugate vaccine","13-valent Pneumococcal Conjugate Vaccine|7vPnC","Biological|Biological","NA","Vaccines, Pneumococcal","Parallel Assignment","Interventional","Prevention","Randomized","Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants",4,"Difference in log-transformed GM",-0.17,"NA",null,-0.33,-0.01,95,null,"NA","All",1712,"Completed","Phase 3","\t"]
["NCT00444925",4488845,8224840,"Change From Baseline in Mean Number of Nocturnal Micturitions Per 24 Hours.","tolterodine tartrate|fesoterodine","fesoterodine fumarate|placebo|tolterodine tartrate","Drug|Drug|Drug","urinary bladder, overactive","Overactive Bladder","Parallel Assignment","Interventional","Treatment","Randomized","Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)",3,"Mean Difference (Final Values)",0,0.5059,"ANCOVA",{"$nulls":3},"Standard Error of the Mean",0.1,"All",1712,"Completed","Phase 3","\t"]
["NCT00445770",4488406,8224670,"Percentage of Participants With an ACR50 Response","etanercept|methotrexate","Etanercept|Etanercept|Methotrexate","Drug|Drug|Drug","arthritis, rheumatoid|arthritis","Arthritis, Rheumatoid","Parallel Assignment","Interventional","Treatment","Randomized","Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis",3,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",550,"Completed","Phase 3","\t"]
["NCT00445770",4488549,8224675,"Change From Baseline in Mean Duration of Morning Stiffness at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52","etanercept|methotrexate","Etanercept|Etanercept|Methotrexate","Drug|Drug|Drug","arthritis, rheumatoid|arthritis","Arthritis, Rheumatoid","Parallel Assignment","Interventional","Treatment","Randomized","Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis",3,null,"NA",0.1649,"ANCOVA",{"$nulls":4},"NA","All",550,"Completed","Phase 3","\t"]
["NCT00446797",4488096,8224542,"Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5F","celecoxib","Non-selective NSAIDS|Celecoxib","Drug|Drug","acute pain|ankle injuries|sprains and strains","Ankle Sprain","Parallel Assignment","Interventional","Treatment","Randomized","Open Label Comparative Study On Celecoxib Efficacy And Safety Vs Non-Selective NSAID In Acute Pain Due To Ankle Sprain",2,"Mean Difference (Final Values)",-0.04,0.828,"ANCOVA",-0.57,0.49,95,"Standard Error of the Mean",0.27,"All",278,"Completed","Phase 4","\t"]
["NCT00449930",4487832,8224113,"Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Nausea","metformin|sitagliptin phosphate","sitagliptin phosphate|Comparator: metformin hydrochloride","Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Type 2 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)",2,"Risk Difference (RD)",-1.9,0.032,"Fisher Exact",-3.9,-0.2,95,null,"NA","All",1050,"Completed","Phase 3","\t"]
["NCT00452530",4487593,8223750,"Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), and Major Bleeding or CRNM","enoxaparin|apixaban","Enoxaparin|Apixaban|Enoxaparin-matching placebo|Apixaban-matching placebo","Drug|Drug|Drug|Drug","embolism|venous thrombosis|pulmonary embolism|thrombosis","Deep Vein Thrombosis|Pulmonary Embolism","Parallel Assignment","Interventional","Treatment","Randomized","Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery",2,"Adjusted difference of event rates",-0.33,0.3014,"Mantel Haenszel",-0.95,0.29,95,null,"NA","All",3221,"Completed","Phase 3","\t"]
["NCT00454584",4487344,8223482,"Number of Participants Achieving a Greater Than or Equal to 90 Percentage Improvement From Baseline in Psoriasis Area and Severity Index (PASI 90) Score at Week 12","ustekinumab|etanercept","CNTO 1275 45 mg|CNTO 1275 90 mg|Etanercept 50 mg","Drug|Drug|Drug","psoriasis","Psoriasis","Parallel Assignment","Interventional","Treatment","Randomized","An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis",3,null,"NA",1E-3,"Cochran-Mantel-Haenszel (CMH) chi square",{"$nulls":4},"NA","All",903,"Completed","Phase 3","\t"]
["NCT00457002",4486994,8223071,"Incidence of Adjudicated Symptomatic Proximal DVT With Onset During the Intended Treatment Period","enoxaparin|apixaban","Apixaban|Enoxaparin","Drug|Drug","pulmonary embolism|venous thrombosis|thrombosis|embolism","Pulmonary Embolism|Venous Thrombosis","Parallel Assignment","Interventional","Prevention","Randomized","Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness",2,"Risk Ratio (RR)",0.41,"NA",null,0.14,1.16,95,null,"NA","All",6758,"Completed","Phase 3","\t"]
["NCT00459706",4486820,8222729,"Percentage of Participants With Only Reading/Writing Capacity Associated With Participant Perception","etanercept","Enbrel 50 mg Prefilled Syringe|Enbrel 50 mg Autoinjector","Device|Device","arthritis, rheumatoid|arthritis","Rheumatoid Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept",2,null,"NA",0.652,"Chi-squared",{"$nulls":4},"NA","All",640,"Completed","Phase 3","\t"]
["NCT00460603",4486771,8222553,"Progression-Free Survival (PFS): Phase 2","bevacizumab|axitinib","bevacizumab|AG-013726|AG-013736 (axitinib)","Drug|Drug|Drug","colorectal neoplasms","Colorectal Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer",3,"Hazard Ratio (HR)",1.49,0.8746,"Log Rank",0.75,2.98,95,null,"NA","All",187,"Completed","Phase 1/Phase 2","\t"]
["NCT00465816",4486499,8221745,"Meningococcal Polysaccharide A Serum Bactericidal Antibodies/Assay, Using Baby Rabbit Complement for Assay (rSBA-MenA), rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers","NA","Nimenrix (Meningococcal vaccine 134612)|Twinrix","Biological|Biological","meningococcal infections","Infections, Meningococcal","Parallel Assignment","Interventional","Prevention","Randomized","Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612",3,"Adjusted GMT ratio",1.01,"NA",null,0.85,1.19,95,null,"NA","All",611,"Completed","Phase 3","\t"]
["NCT00468845",4485999,8221090,"Percent Change From Baseline in Peak Expiratory Flow","pregabalin","pregabalin (Lyrica)|pregabalin (Lyrica)|matched placebo","Drug|Drug|Drug","pain, postoperative","Pain, Postoperative","Parallel Assignment","Interventional","Treatment","Randomized","Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy",3,null,"NA",0.5925,"ANOVA",{"$nulls":4},"NA","Female",501,"Completed","Phase 3","\t"]
["NCT00471146",4485796,8220916,"Percentage of Participants With Objective Response (OR)","gemcitabine|axitinib","AG-013736|Gemcitabine|Gemcitabine|placebo","Drug|Drug|Drug|Drug","pancreatic neoplasms|carcinoma, pancreatic ductal","Carcinoma, Pancreatic Ductal","Parallel Assignment","Interventional","Treatment","Randomized","Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.",2,"Risk Ratio (RR)",3.2,0.038,"Cochran-Mantel-Haenszel",1,10.1,95,null,"NA","All",630,"Completed","Phase 3","\t"]
["NCT00474175",4485544,8220483,"Global Satisfaction Assessment","benzocaine","Placebo gel|benzocaine|benzocaine","Drug|Drug|Drug","toothache","Toothache","Parallel Assignment","Interventional","Treatment","Randomized","Benzocaine Gel Toothache Dose-Response Study",3,"Treatment difference",0.16,0.039,"Cochran-Mantel-Haenszel",0,0.33,95,null,"NA","All",577,"Completed","Phase 4","\t"]
["NCT00474539",4485375,8220380,"Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series","heptavalent pneumococcal conjugate vaccine|vaccines","13-valent pneumococcal conjugate vaccine|7-valent pneumococcal conjugate vaccine","Biological|Biological","NA","Vaccines, Pneumococcal","Parallel Assignment","Interventional","Prevention","Randomized","Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants",2,"Difference",-0.5,"NA",null,-3.3,2,95,null,"NA","All",449,"Completed","Phase 3","\t"]
["NCT00479882",4485104,8219734,"Percentage Change From Baseline in HDL-C at Week 4","simvastatin","Comparator: simvastatin|MK-0524A|Placebo|MK-0524B","Drug|Drug|Drug|Drug","dyslipidemias|hypercholesterolemia","Mixed Dyslipidemia|Primary Hypercholesterolemia","Crossover Assignment","Interventional","Treatment","Randomized","MK-0524B Lipid Study (MK-0524B-063)",4,"Difference in Least Squares Mean",-0.4,0.69,"ANOVA",-2.3,1.5,95,null,"NA","All",2414,"Completed","Phase 3","\t"]
["NCT00482170",4485014,8219503,"Ease of Use of Injection Device Based on Response to Question Concerning Ease in Knowing When Injection is Complete","etanercept","Enbrel (etanercept)|Etanercept","Device|Device","psoriasis","Psoriasis","Parallel Assignment","Interventional","Treatment","Randomized","Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept",2,"Odds Ratio (OR)",1.3,0.21,"Generalized estimating equations",0.86,1.94,95,null,"NA","All",421,"Completed","Phase 3","\t"]
["NCT00482612",4484896,8219452,"Average Total Sleep Time (TST) as Recorded Daily in the Sleep Diary During the 14-day In-treatment Period","mirtazapine","Esmirtazapine|Placebo","Drug|Drug","sleep initiation and maintenance disorders","Insomnia","Parallel Assignment","Interventional","Treatment","Randomized","Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)",4,null,"NA",{"v":1E-4,"d":"1.00E-04"},"ANCOVA",{"$nulls":4},"NA","All",526,"Completed","Phase 3","\t"]
["NCT00487942",4484456,8218705,"Change From Baseline to Week 4 in Epworth Sleepiness Scale (ESS) Total Scores","modafinil","armodafinil|armodafinil|armodafinil|placebo","Drug|Drug|Drug|Drug","schizophrenia|cognitive dysfunction|cognition disorders","Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits",4,"Effect size",0.06,"NA",null,-0.75,0.86,95,null,"NA","All",60,"Completed","Phase 2","\t"]
["NCT00488683",4484231,8218569,"Memory B Cells 1 Month After Primary Vaccination and 1 Week After Third Vaccination by Serogroup A, C, W-135 and Y","vaccines","Hib|MenACWY-CRM|DTaP-Hib-IPV|PCV|MMR","Biological|Biological|Biological|Biological|Biological","meningococcal infections","Meningococcal Disease","Parallel Assignment","Interventional","Prevention","Randomized","B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants",3,"Pearson correlation coefficient",0.98,0.003,"Parametric correlation",null,null,95,null,"NA","All",216,"Completed","Phase 2","\t"]
["NCT00488683",4484345,8218571,"Memory B Cells Per 2x100000 by Serogroup A,C, W-135 and Y at One Month After Primary MenACWY-CRM Vaccination and Third MenACWY-CRM Vaccination","vaccines","Hib|MenACWY-CRM|DTaP-Hib-IPV|PCV|MMR","Biological|Biological|Biological|Biological|Biological","meningococcal infections","Meningococcal Disease","Parallel Assignment","Interventional","Prevention","Randomized","B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants",3,"Pearson correlation coefficient",-0.01,0.94,"Parametric correlation",null,null,95,null,"NA","All",216,"Completed","Phase 2","\t"]
["NCT00489255",4484080,8218515,"Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 (Motor Section) for Visit 3, Pre Apokyn Dose, Period 1","NA","Tigan®|Placebo","Drug|Drug","parkinson disease|nausea|vomiting","Parkinson's Disease","Parallel Assignment","Interventional","Treatment","Randomized","Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment",2,"Mean Difference (Net)",-0.18,0.93,"ANOVA",-4.37,4.02,95,null,"NA","All",117,"Completed","Phase 4","\t"]
["NCT00492557",4483891,8218009,"13vPnC Comparisons: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT)","heptavalent pneumococcal conjugate vaccine","13-valent pneumococcal conjugate vaccine|13vPnC + TIV","Biological|Biological","pneumococcal infections","Pneumococcal Infections","Parallel Assignment","Interventional","Prevention","Randomized","Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults",2,"GMT Ratio",0.7,"NA",null,0.42,1.03,95,null,"NA","All",1185,"Completed","Phase 3","\t"]
["NCT00495469",4483744,8217712,"Number of Participants Who Were Fasting Plasma Glucose (FPG) Responders at Week 12","NA","GSK189075|Placebo","Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive",2,"Odds Ratio (OR)",2.9,0.179,"Regression, Logistic",0.61,13.75,95,null,"NA","All",250,"Completed","Phase 2","\t"]
["NCT00502242",4483408,8216958,"U Alb/c at Baseline and Weeks 3, 4, 8, 12, 24, 30, 36, and 52 Following Conversion to SRL","ramipril","ramipril|ramipril","Drug|Drug","NA","Kidney Transplant","Parallel Assignment","Interventional","Treatment","Randomized","Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus",2,"Adjusted Geometric Mean Fold Change",1.43,"NA",{"$nulls":5},"NA","All",229,"Completed","Phase 4","\t"]
["NCT00507507",4483174,8216342,"Change From Baseline in HBV DNA at Week 144","tenofovir","Tenofovir DF|FTC|Placebo","Drug|Drug|Drug","hepatitis b, chronic|hepatitis, chronic|hepatitis|hepatitis b|hepatitis a","Chronic Hepatitis B","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)",2,null,"NA",0.186,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",126,"Completed","Phase 2","\t"]
["NCT00510146",4483027,8215980,"Percentage of Participants With Major Depressive Episode at Endpoint on Mini International Neuropsychiatric Interview (MINI), Depressive Episode Module (Acute Phase)","olanzapine","Olanzapine|Placebo","Drug|Drug","bipolar disorder","Depression, Bipolar","Parallel Assignment","Interventional","Treatment","Randomized","Olanzapine Treatment of Patients With Bipolar I Disorder",3,null,"NA",0.264,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",514,"Completed","Phase 3","\t"]
["NCT00514683",4482637,8215369,"Change From Baseline in IC","nintedanib","low dose BIBF1120 once daily|low dose BIBF 1120 twice daily|intermediate dose BIBF 1120 twice daily|high dose BIBF 1120 twice daily|placebo","Drug|Drug|Drug|Drug|Drug","pulmonary fibrosis|fibrosis|idiopathic pulmonary fibrosis","Pulmonary Fibrosis","Parallel Assignment","Interventional","Treatment","Randomized","Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis",5,"Mean Difference (Final Values)",-0.021,0.7426,"ANCOVA",-0.149,0.106,95,"Standard Error of the Mean",0.065,"All",432,"Completed","Phase 2","\t"]
["NCT00515502",4482501,8215135,"Mean (0-24 Hours) Heart Rate as Measured From Holter Monitoring at Day 1 of Each Treatment Period","tiotropium bromide","GSK573719|Tiotropium","Drug|Drug","pulmonary disease, chronic obstructive|lung diseases","Pulmonary Disease, Chronic Obstructive","Crossover Assignment","Interventional","Treatment","Randomized","Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease",12,"Mean Difference (Final Values)",-1.8,"NA",null,-3.6,0,95,"Standard Error of the Mean",0.9,"All",24,"Completed","Phase 2","\t"]
["NCT00518882",4482332,8214635,"Change in Mean Postprandial Increment of Plasma Glucose After Lunch at Week 26","liraglutide|exenatide","liraglutide|exenatide","Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Diabetes|Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes",2,"Estimated treatment difference, LS Mean",-0.39,0.143,"ANCOVA",-0.91,0.13,95,null,"NA","All",467,"Completed","Phase 3","\t"]
["NCT00521586",4482085,8214202,"Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose","vaccines|heptavalent pneumococcal conjugate vaccine","13 valent pneumococcal conjugate vaccine|13 valent pneumococcal conjugate vaccine","Biological|Biological","influenza, human","Influenza","Crossover Assignment","Interventional","Prevention","Randomized","Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine",2,"Geometric mean ratio",0.71,"NA",null,0.59,0.86,95,null,"NA","All",1116,"Completed","Phase 3","\t"]
["NCT00524303",4481914,8213782,"Percentage of Participants With Clinical Complete Response (cCR) at 26 Weeks or at End of Treatment (EOT) or Early Withdrawal","paclitaxel|lapatinib|trastuzumab","Trastuzumab|Paclitaxel|FEC75|Lapatinib","Drug|Drug|Drug|Drug","breast neoplasms","Neoplasms, Breast","Parallel Assignment","Interventional","Treatment","Randomized","Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.",3,"Percent Difference",0,1,"Fisher Exact",-25.1,25.1,95,null,"NA","Female",100,"Completed","Phase 2","\t"]
["NCT00525512",4481771,8213581,"Saint George's Respiratory Questionnaire Total Score at 100 Weeks - Open-Label Phase","tiotropium bromide","tiotropium 18 mcg|Placebo","Drug|Drug","pulmonary disease, chronic obstructive","Exercise|Pulmonary Disease, Chronic Obstructive","Parallel Assignment","Interventional","Treatment","Randomized","Tiotropium In Exercise",2,"Mean Difference (Final Values)",-0.61,0.7071,"ANCOVA",-3.81,2.59,95,null,"NA","All",519,"Completed","Phase 4","\t"]
["NCT00529087",4481490,8212882,"Percentage of Patients Having a Rescue-free Bowel Movement (RFBM) Within 4 Hours of the First Dose","bromides|methylnaltrexone","N-methylnaltrexone bromide (MOA-728)|placebo","Drug|Other","constipation","Constipation","Parallel Assignment","Interventional","Treatment","Randomized","Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain",3,"Treatment Difference",24.4,1E-3,"Chi-squared",17.3,31.4,95,null,"NA","All",460,"Completed","Phase 3","\t"]
["NCT00529373",4481431,8212809,"Sarcopenia Substudy PN035: Change From Baseline in Short Physical Performance Battery (SPPB) Score","calcium|vitamin d|cholecalciferol|calcium, dietary|calcium carbonate","Odanacatib|Placebo for Odanacatib|Vitamin D3|Calcium carbonate","Drug|Drug|Dietary Supplement|Dietary Supplement","osteoporosis, postmenopausal|osteoporosis","Postmenopausal Osteoporosis","Parallel Assignment","Interventional","Treatment","Randomized","A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)",2,"Difference in Least Squares Means",0.19,"NA",null,-0.15,0.54,95,null,"NA","Female",16071,"Terminated","Phase 3","\t"]
["NCT00531661",4481176,8212290,"Freedom From Pressure Sensor Failure","NA","HF Pressure Measurement System","Device","heart failure","Heart Failure, Congestive","Parallel Assignment","Interventional","Treatment","Randomized","CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients",2,null,"NA",{"v":1E-4,"d":"1.00E-04"},"exact test of binomial proportions",{"$nulls":4},"NA","All",550,"Completed","N/A","\t"]
["NCT00531752",4481119,8212274,"Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Week 3","NA","PF-03654746|Placebo capsules|PF-03654746","Drug|Drug|Drug","attention deficit disorder with hyperactivity|hyperkinesis","Attention Deficit Hyperactivity Disorder","Crossover Assignment","Interventional","Treatment","Randomized","A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).",3,"LS Mean Difference",-0.2078,0.8216,"Mixed Models Analysis",-1.399,0.98326,80,"Standard Error of the Mean",0.9165,"All",66,"Completed","Phase 2","\t"]
["NCT00535405",4480748,8211690,"Percentage of Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12","simvastatin|atorvastatin|ezetimibe","Atorvastatin 10 mg|Ezetimibe 10 mg/simvastatin 20 mg|Atorvastatin 20 mg|Ezetimibe 10 mg/simvastatin 40 mg|Atorvastatin 40 mg","Drug|Drug|Drug|Drug|Drug","myocardial ischemia|hypercholesterolemia|heart diseases|coronary artery disease|coronary disease","Hypercholesterolemia","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)",5,"Ratio of odds",1.78,0.039,"Logistic Regression using GEE",1.1,2.9,95,"Standard Error of the Mean",0.44,"All",1289,"Completed","Phase 3","\t"]
["NCT00536471",4480376,8211529,"Statistically Significant Changes in Baseline to 9 Month Endpoint Laboratory Values - Hemoglobin","duloxetine hydrochloride","Duloxetine hydrochloride|Placebo","Drug|Drug","depressive disorder|depressive disorder, major|depression","Major Depressive Disorder","Parallel Assignment","Interventional","Treatment","Randomized","A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients",2,null,"NA",0.045,"ANOVA",{"$nulls":4},"NA","All",776,"Completed","Phase 4","\t"]
["NCT00536471",4480571,8211577,"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 6:Insomnia Late","duloxetine hydrochloride","Duloxetine hydrochloride|Placebo","Drug|Drug","depressive disorder|depressive disorder, major|depression","Major Depressive Disorder","Parallel Assignment","Interventional","Treatment","Randomized","A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients",2,null,"NA",0.099,"Mixed Models Analysis",{"$nulls":4},"NA","All",776,"Completed","Phase 4","\t"]
["NCT00540124",4480128,8210972,"Change From Baseline to 12 Week Endpoint in Total, Waking, and Sleeping Voids (Average Number Per Week) Based on Median as Reported in Patient Voiding Dribble Diary","tadalafil|tamsulosin","Tadalafil|Placebo|Tamsulosin","Drug|Drug|Drug","prostatic hyperplasia|hyperplasia","Benign Prostatic Hyperplasia","Parallel Assignment","Interventional","Treatment","Randomized","Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men",3,null,"NA",0.359,"Wilcoxon Rank Sum",{"$nulls":4},"NA","Male",151,"Completed","Phase 2","\t"]
["NCT00542425",4479955,8210688,"Change in Bone Mineral Density, Total Spine.","teriparatide|abaloparatide|parathyroid hormone-related protein","teriparatide|Placebo|BA058 20 µg|BA058 40 µg|BA058 80 µg","Drug|Drug|Drug|Drug|Drug","osteoporosis","Osteoporosis","Parallel Assignment","Interventional","Treatment","Randomized","Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis",5,null,"NA",1E-3,"ANOVA",{"$nulls":4},"NA","Female",222,"Completed","Phase 2","\t"]
["NCT00543725",4479865,8210494,"Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 96","efavirenz|rilpivirine","TMC278|efavirenz","Drug|Drug","hiv infections","HIV-1|HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors",2,"Difference in proportion of response",2.4,{"v":1E-4,"d":"1.00E-04"},"Regression, Logistic",-3.6,8.4,95,null,"NA","All",680,"Completed","Phase 3","\t"]
["NCT00546637",4479463,8209970,"Change From Baseline in Maximum Urinary Flow Rate (QMAX) Per 24 Hours at Week 12","fesoterodine","Fesoterodine|Placebo","Drug|Drug","urinary bladder, overactive","Overactive Bladder Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","Fesoterodine \"add-on\" Male Overactive Bladder Study",2,"Median Difference (Net)",-0.4,0.2251,"Van Elteren's Test",null,null,95,null,"NA","Male",947,"Completed","Phase 3","\t"]
["NCT00549549",4479059,8209509,"Number of Participants With Withdrawal From Treatment Due to Lack of Efficacy","celecoxib|indomethacin","Indomethacin|Celecoxib|Celecoxib|Celecoxib","Drug|Drug|Drug|Drug","arthritis, gouty|arthritis","Arthritis, Gouty","Parallel Assignment","Interventional","Treatment","Randomized","Celebrex In Acute Gouty Arthritis Study",4,null,"NA",0.0317,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",402,"Completed","Phase 3","\t"]
["NCT00549549",4479098,8209514,"Change From Baseline in Patient's Assessment of Pain Intensity on Day 1","celecoxib|indomethacin","Indomethacin|Celecoxib|Celecoxib|Celecoxib","Drug|Drug|Drug|Drug","arthritis, gouty|arthritis","Arthritis, Gouty","Parallel Assignment","Interventional","Treatment","Randomized","Celebrex In Acute Gouty Arthritis Study",4,"Mean Difference (Final Values)",0.47,"NA",null,0.2,0.74,95,"Standard Error of the Mean",0.14,"All",402,"Completed","Phase 3","\t"]
["NCT00551135",4478671,8209195,"Participants With Clinically Meaningful Events (CMEs) for Individual Symptoms Using the Opioid-Related Symptom Distress Scale (OR-SDS)","pregabalin","Pregabalin|placebo|Pregabalin|Pregabalin","Drug|Drug|Drug|Drug","pain, postoperative|hernia|hernia, inguinal","Hernia, Inguinal|Pain, Postoperative","Parallel Assignment","Interventional","Treatment","Randomized","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",4,null,"NA",0.2054,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","Male",425,"Completed","Phase 3","\t"]
["NCT00551135",4478751,8209198,"Total Cumulative Dose of Opioids and Tramadol Used During and After Surgery","pregabalin","Pregabalin|placebo|Pregabalin|Pregabalin","Drug|Drug|Drug|Drug","pain, postoperative|hernia|hernia, inguinal","Hernia, Inguinal|Pain, Postoperative","Parallel Assignment","Interventional","Treatment","Randomized","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",4,null,"NA",0.0694,"ANOVA",{"$nulls":4},"NA","Male",425,"Completed","Phase 3","\t"]
["NCT00551135",4478868,8209206,"Numeric Rating Scale (NRS): Current Pain With Movement - Area Under the Curve (AUC) for Sitting, Walking, and Coughing","pregabalin","Pregabalin|placebo|Pregabalin|Pregabalin","Drug|Drug|Drug|Drug","pain, postoperative|hernia|hernia, inguinal","Hernia, Inguinal|Pain, Postoperative","Parallel Assignment","Interventional","Treatment","Randomized","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",4,null,"NA",0.397,"ANOVA",{"$nulls":4},"NA","Male",425,"Completed","Phase 3","\t"]
["NCT00554099",4478260,8208752,"Withdrawal Due to Surgery for Diverticulitis, Percentage, ITT Population, Week 12","anti-bacterial agents|mesalamine","Mesalamine|Probiotic|Placebo|Dietary Advice|Antibiotic for Diverticulitis","Drug|Drug|Drug|Other|Drug","diverticulitis","Diverticulitis","Parallel Assignment","Interventional","Treatment","Randomized","Asacol Acute Diverticulitis(DIVA)Study",3,"Difference vs. Placebo",-2.4,0.1708,"Cochran-Mantel-Haenszel",null,0.6,90,"Standard Error of the Mean",2.41,"All",117,"Completed","Phase 2","\t"]
["NCT00555321",4478206,8208615,"Percentage of Participants Who Experienced at Least One Episode of Acute Rejection, Graft Loss, or Death by 12 Months","basiliximab|tacrolimus|mycophenolic acid|abatacept","Tacrolimus|Basiliximab|Belatacept More Intensive (MI)|Belatacept Less Intensive (LI)|Mycophenolate Mofetil (MMF)","Drug|Drug|Drug|Drug|Drug","NA","Immunosuppression in Solid Organ Transplant","Parallel Assignment","Interventional","Prevention","Randomized","Belatacept in Liver Transplant Recipients",5,"Mean Difference (Final Values)",33.1,"NA",null,15.8,50.6,95,null,"NA","All",260,"Terminated","Phase 2","\t"]
["NCT00558259",4477965,8208070,"Centrally Confirmed Symptomatic Recurrent Deep Venous Thrombotic (DVT) Events During the Intended Treatment Period","dabigatran","dabigatran etexilate 150 mg twice daily (BID)|matching placebo twice daily (BID)","Drug|Drug","thromboembolism|venous thromboembolism","Venous Thromboembolism","Parallel Assignment","Interventional","Prevention","Randomized","Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE",2,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Fisher Exact",{"$nulls":4},"NA","All",1353,"Completed","Phase 3","\t"]
["NCT00561600",4477740,8207486,"Analysis of Metal Ion Release - Serum Chromium","NA","ASR™-XL Modular Acetabular Cup System|Pinnacle™ acetabular shell","Device|Device","osteoarthritis|joint diseases","Non-inflammatory Degenerative Joint Disease","Parallel Assignment","Interventional","Treatment","Randomized","Multi-Center Comparative Trial of the ASR™-XL Acetabular Cup System vs. the Pinnacle™ Metal- on- Metal Total Hip System",2,null,"NA",0.766,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",265,"Completed","N/A","\t"]
["NCT00565409",4477126,8207065,"Percentage of Participants With an ACR70 Response at Weeks 36, 40, 48, 56, 64, 72, 80 and 88","methotrexate|etanercept","Etanercept|Methotrexate|Etanercept|Methotrexate|Placebo|Methotrexate","Drug|Drug|Drug|Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Arthritis, Rheumatoid","Parallel Assignment","Interventional","Treatment","Randomized","Study Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis",3,"Odds Ratio (OR)",0.85,0.4941,"Cochran-Mantel-Haenszel",0.5,1.3,95,null,"NA","All",834,"Completed","Phase 4","\t"]
["NCT00565409",4477276,8207078,"Change From Week 36 in General Health at Weeks 40, 48, 56, 64, 72, 80, 88","methotrexate|etanercept","Etanercept|Methotrexate|Etanercept|Methotrexate|Placebo|Methotrexate","Drug|Drug|Drug|Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Arthritis, Rheumatoid","Parallel Assignment","Interventional","Treatment","Randomized","Study Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis",3,"Mean Difference (Final Values)",-11.39,{"v":1E-4,"d":"1.00E-04"},"ANCOVA",-14.7,-8.1,95,null,"NA","All",834,"Completed","Phase 4","\t"]
["NCT00565409",4477448,8207101,"Percentage of Participants Achieving DAS28 Low Disease Activity or Remission","methotrexate|etanercept","Etanercept|Methotrexate|Etanercept|Methotrexate|Placebo|Methotrexate","Drug|Drug|Drug|Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Arthritis, Rheumatoid","Parallel Assignment","Interventional","Treatment","Randomized","Study Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis",3,"Odds Ratio (OR)",0.88,0.9399,"Cochran-Mantel-Haenszel",0.5,1.5,95,null,"NA","All",834,"Completed","Phase 4","\t"]
["NCT00565812",4477033,8207001,"Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index Physical Function Subscale Score at Month 3, 6, 12, 18 and 24","NA","SD-6010|SD-6010|Placebo","Drug|Drug|Drug","osteoarthritis|osteoarthritis, knee","Osteoarthritis","Parallel Assignment","Interventional","Treatment","Randomized","A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee",3,"LS mean difference",0.1,0.901,"Mixed Models Analysis",-1.55,1.76,95,"Standard Error of the Mean",0.84,"All",1457,"Completed","Phase 2","\t"]
["NCT00567398",4476709,8206694,"Change From Baseline of Nutritional Status Determined by Albumin and Total Protein (Labs) at Month 3 and 6","icodextrin","Dianeal|Physioneal|Extraneal|Nutrineal","Drug|Drug|Drug|Drug","NA","Diabetes|ESRD","Parallel Assignment","Interventional","Treatment","Randomized","IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients",2,"Mean Difference (Final Values)",0.6,0.338,"ANOVA",-0.6,1.8,95,null,"NA","All",43,"Completed","Phase 3","\t"]
["NCT00568321",4476516,8206561,"Change From Baseline in Modified Brief Pain Inventory-Short Form (mBPI-sf) Scale Score for Worst Pain, Average Pain and Pain Severity at Weeks 1, 2, 4, 6, 8 ,12 and 16","tanezumab","RN624|RN624|Placebo","Drug|Drug|Drug","neuralgia, postherpetic|neuralgia","Neuralgia, Postherpetic","Parallel Assignment","Interventional","Treatment","Randomized","RN624 For Pain Of Post-Herpetic Neuralgia",3,"LS Mean Difference",0.39,0.764,"Repeated Measures Model",-0.51,1.3,90,"Standard Error of the Mean",0.55,"All",99,"Completed","Phase 2","\t"]
["NCT00570739",4476065,8206166,"Area Under the Curve for Plasma Glucose From 0 to 120 Minutes During the Oral Glucose Tolerance Tests in Pre-Diabetic Subjects From Baseline to 16 Weeks","metformin|colesevelam hydrochloride","Metformin HCl and Colesevelam Placebo|Metformin HCl tablets and Colesevelam tablets|Colesevelam placebo|Colesevelam","Drug|Drug|Drug|Drug","prediabetic state|hypercholesterolemia|glucose intolerance|diabetes mellitus|diabetes mellitus, type 2","Hypercholesterolemia|Pre-diabetes|Type 2 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.",4,"Mean Difference (Final Values)",-3,0.7051,"ANCOVA",-18.64,12.64,95,null,"NA","All",502,"Completed","Phase 3","\t"]
["NCT00570739",4476190,8206197,"Change in Waist-to-Hip Ratio When Given to Drug-Naive Diabetic Subjects From Baseline to 16 Weeks","metformin|colesevelam hydrochloride","Metformin HCl and Colesevelam Placebo|Metformin HCl tablets and Colesevelam tablets|Colesevelam placebo|Colesevelam","Drug|Drug|Drug|Drug","prediabetic state|hypercholesterolemia|glucose intolerance|diabetes mellitus|diabetes mellitus, type 2","Hypercholesterolemia|Pre-diabetes|Type 2 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.",4,"Mean Difference (Final Values)",-3.3E-3,0.4584,"ANCOVA",-0.0122,0.0055,95,null,"NA","All",502,"Completed","Phase 3","\t"]
["NCT00570739",4476289,8206220,"1 Hour Post-Meal Glucose Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks","metformin|colesevelam hydrochloride","Metformin HCl and Colesevelam Placebo|Metformin HCl tablets and Colesevelam tablets|Colesevelam placebo|Colesevelam","Drug|Drug|Drug|Drug","prediabetic state|hypercholesterolemia|glucose intolerance|diabetes mellitus|diabetes mellitus, type 2","Hypercholesterolemia|Pre-diabetes|Type 2 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.",4,"Mean Difference (Final Values)",-7,0.195,"ANCOVA",-17.5,3.6,95,null,"NA","All",502,"Completed","Phase 3","\t"]
["NCT00572455",4475929,8205996,"Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I","latanoprost","PF-04217329 - Lowest Dose|PF-04217329 - Low Dose|PF-04217329 - Middle Dose|PF-04217329 - High Middle Dose|PF-04217329 - High Dose|PF-4217329 - Highest Dose|PF-04217329 - Vehicle|Latanoprost Vehicle|PF-04217329 - Low Dose|Latanoprost Vehicle|PF-04217329 - Middle Dose|Latanoprost Vehicle|PF-04217329 - High Dose|Latanoprost 0.005%|PF-04217329 - Low Dose|Latanoprost 0.005%|PF-04217329 - Middle Dose|Latanoprost 0.005%|PF-04217329 - High Dose|Latanoprost 0.005%|PF-04217329 - Vehicle","Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug","glaucoma|glaucoma, open-angle|hypertension|ocular hypertension","Ocular Hypertension|Primary Open-Angle Glaucoma","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.",14,"LS mean difference",1.83,0.269,"ANCOVA",-0.91,4.58,90,null,"NA","All",318,"Completed","Phase 2","\t"]
["NCT00577655",4475524,8205297,"Time To Maximum Forced Expiratory Volume in One Second (FEV1) Over Six Hours Post-Dose On Days 1 and 22","albuterol","Albuterol|Placebo|Proventil® HFA","Drug|Drug|Drug","asthma","Asthma","Parallel Assignment","Interventional","Treatment","Randomized","Albuterol HFA MDI in Pediatric Participants With Asthma",2,"Cox Proportional Hazard",1.477,0.0647,"Regression, Cox",0.98,2.23,95,null,"NA","All",103,"Completed","Phase 3","\t"]
["NCT00581555",4475280,8204696,"Change From Randomization in DLQI to Week 24","etanercept","Etanercept|Placebo","Drug|Other","psoriasis","Psoriasis","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy",2,"Mean Difference (Final Values)",2.4,0.139,"mixed model of ANCOVA",-0.8,5.5,95,"Standard Error of the Mean",1.6,"All",120,"Completed","Phase 4","\t"]
["NCT00587158",4475073,8204022,"Serum Parathyroid Hormone (PTH) Level Over Time","NA","Paricalcitol|Corticosteroid Avoidance Immune Suppression Protocol","Drug|Other","kidney failure, chronic|renal insufficiency|hyperparathyroidism, secondary|hyperparathyroidism","Hyperparathyroidism, Secondary|Renal Disease, End Stage|Transplant; Failure, Kidney","Parallel Assignment","Interventional","Treatment","Randomized","Oral Paricalcitol in Kidney Transplant Recipients",2,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",100,"Completed","N/A","\t"]
["NCT00591578",4474788,8203478,"Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg.","valsartan|azilsartan medoxomil","Azilsartan Medoxomil|Azilsartan Medoxomil|Valsartan","Drug|Drug|Drug","hypertension|essential hypertension","Hypertension","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension",3,"Odds Ratio (OR)",1.63,2E-3,"Regression, Logistic",1.19,2.23,95,null,"NA","All",984,"Completed","Phase 3","\t"]
["NCT00593736",4474606,8203074,"Subjective Getting up in the Morning Measured by a Post-sleep Questionnaire (Nights 6-7)","NA","Ramelteon|Ramelteon|Ramelteon|Placebo","Drug|Drug|Drug|Drug","sleep disorders, circadian rhythm|sleep wake disorders","Sleep Disorders, Circadian Rhythm","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase Syndrome",4,null,"NA",0.498,"ANCOVA",{"$nulls":4},"NA","All",132,"Completed","Phase 2","\t"]
["NCT00594568",4474520,8202933,"Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks","NA","LY450139|Placebo","Drug|Drug","alzheimer disease","Alzheimer's Disease","Parallel Assignment","Interventional","Treatment","Randomized","Effect of LY450139 on the Long Term Progression of Alzheimer's Disease",3,null,"NA",0.134,"Mixed Models Analysis",{"$nulls":4},"NA","All",1537,"Completed","Phase 3","\t"]
["NCT00601172",4474214,8202225,"Percentage of Participants Who Achieved Total Control, Defined as Complete Responders Who Had no Nausea","dexamethasone|ondansetron|casopitant","Casopitant|Dexamethasone|Placebo|Ondansetron","Drug|Drug|Drug|Drug","nausea|vomiting","Nausea and Vomiting, Chemotherapy-Induced","Parallel Assignment","Interventional","Supportive Care","Randomized","A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.",2,"Difference in percentage of participants",-7.3,0.0507,"Chi-squared",-15,0,95,null,"NA","All",710,"Completed","Phase 3","\t"]
["NCT00603382",4474023,8201863,"Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8","NA","GW685698X|Placebo","Drug|Drug","asthma","Asthma","Parallel Assignment","Interventional","Treatment","Randomized","A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.",2,"Mean Difference (Final Values)",0.23,1E-3,"ANCOVA",0.111,0.349,95,null,"NA","All",599,"Completed","Phase 2","\t"]
["NCT00605280",4473960,8201458,"Number of Participants With a ≥ 10 Letter (or 2 Line) Improvement in Vision at 2 Years","NA","Standard of Care|Macugen","Drug|Drug","edema|macular edema","Macular Edema Associated With Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.",2,"Odds Ratio (OR)",1.46,0.1904,"Cochran-Mantel-Haenszel",0.85,2.53,95,null,"NA","All",317,"Completed","Phase 2/Phase 3","\t"]
["NCT00608530",4473759,8200881,"Numeric Pain Rating Scale (Numerical Rating Scale, 0-10) Psychologist-Delivered Treatment Study","NA","Cognitive Behavioral Therapy-Psychologist-Delivered|Supportive Psychotherapy-Psychologist-Delivered|Cognitive Behavioral Therapy Nurse-Delivered|Supportive Psychotherapy-Nurse-Delivered","Behavioral|Behavioral|Behavioral|Behavioral","back pain","Back Pain|Pain","Parallel Assignment","Interventional","Treatment","Randomized","Telehealth Outreach for Chronic Back Pain",4,null,"NA",0.05,"ANOVA",{"$nulls":4},"NA","All",127,"Completed","N/A","\t"]
["NCT00611923",4473427,8200353,"Side Effect Burden Measured by Side Effect Questionnaire","flutamide","Flutamide|Placebo","Drug|Drug","premenstrual syndrome|premenstrual dysphoric disorder","Premenstrual Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","Effectiveness of Flutamide in Treating Women With Premenstrual Dysphoric Disorder",2,null,"NA",0,"t-test, 2 sided",{"$nulls":4},"NA","Female",115,"Completed","Phase 4","\t"]
["NCT00613626",4473343,8200098,"Assess VEGF Polymorphisms and Correlate Subject Response","etoposide","Cisplatin|Etoposide|Placebo|ZD6474","Drug|Drug|Drug|Drug","small cell lung carcinoma|lung neoplasms","Small Cell Lung Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer",3,"Cox Proportional Hazard",0.05,"NA",{"$nulls":3},95,null,"NA","All",74,"Completed","Phase 2","\t"]
["NCT00617305",4473237,8199654,"Change From Baseline in Six Minute Walk Distance (6MWD) Measured at Weeks 4, 12, 24, 36 and 48 (LOCF)","sildenafil citrate|tadalafil|ambrisentan","Ambrisentan|Placebo|Sildenafil|Tadalafil","Drug|Drug|Drug|Drug","familial primary pulmonary hypertension|hypertension","Pulmonary Arterial Hypertension","Parallel Assignment","Interventional","Treatment","Randomized","Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)",2,"Mean Difference (Net)",107,"NA",{"$nulls":4},"Standard Deviation",0,"All",38,"Completed","Phase 4","\t"]
["NCT00619866",4472979,8199253,"Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain at Week 12","NA","Elagolix|placebo","Drug|Drug","endometriosis","Endometriosis, Pain","Parallel Assignment","Interventional","Treatment","Randomized","An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis",3,"LS Mean Difference",-0.36,0.1521,"Repeated Measures Analysis of Covariance",-0.86,0.14,95,"Standard Error of the Mean",0.25,"Female",155,"Completed","Phase 2","\t"]
["NCT00623623",4472640,8198597,"Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke","tenecteplase|clopidogrel|enoxaparin","primary PCI|enoxaparin|catheterisation|tenecteplase|clopidogrel","Procedure|Drug|Procedure|Drug|Drug","myocardial infarction|infarction","Myocardial Infarction","Parallel Assignment","Interventional","Treatment","Randomized","STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction",2,"Relative Risk",0.87,0.22,"modified Poisson regression model",0.69,1.09,95,null,"NA","All",1899,"Completed","Phase 3","\t"]
["NCT00627016",4472541,8198083,"Median Percentage of Nights Without Heartburn Over 4 Weeks as Assessed by Daily Diary.","lansoprazole|dexlansoprazole","Dexlansoprazole|Placebo","Drug|Drug","esophagitis, peptic|heartburn|gastroesophageal reflux","Gastroesophageal Reflux","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn",2,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",305,"Completed","Phase 3","\t"]
["NCT00634933",4472245,8197115,"Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response","prednisone|prednisolone hemisuccinate|methylprednisolone acetate|methylprednisolone|methylprednisolone hemisuccinate|prednisolone|prednisolone acetate|prednisolone phosphate","TRU-015|Methylprednisolone|Prednisone|TRU-015|Methylprednisolone|Prednisone|TRU-015|Methylprednisolone|Prednisone","Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Arthritis, Rheumatoid","Parallel Assignment","Interventional","Treatment","Randomized","Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis",3,null,"NA",0.014,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",222,"Terminated","Phase 2","\t"]
["NCT00637000",4472052,8196734,"CVisual Analog Scale (VAS) Score at Baseline and the Peak (Maximum Increase) VAS up to 23.5 Hours After First Administration for the Question: \"Do You Like the Drug?\"","buprenorphine|naloxone|buprenorphine, naloxone drug combination","Buprenorphine soluble film|Buprenorphine/naloxone film strip|Placebo","Drug|Drug|Drug","opioid-related disorders","Opioid-related Disorders","Parallel Assignment","Interventional","Treatment","Randomized","Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone",2,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Repeated measures model",{"$nulls":4},"NA","All",38,"Completed","Phase 2","\t"]
["NCT00642642",4471857,8195986,"Evaluator Live Acne Scarring Assessment Responders","NA","Autologous Human Fibroblasts (azficel-T)|Placebo","Biological|Biological","cicatrix","Acne Scarring of the Face","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring",2,null,"NA",0.0109,"McNemar",{"$nulls":4},"NA","All",122,"Completed","Phase 2/Phase 3","\t"]
["NCT00651820",4471572,8195194,"Differences in Scar Viscoelasticity Between Wounds Treated With Collagenase Santyl and Its Vehicle","NA","Collagenase Santyl|Collagenase Santyl Vehicle","Drug|Drug","cicatrix","Impaired Wound Healing|Scarring","Parallel Assignment","Interventional","Basic Science","Randomized","Effect of Collagenase on Healing and Scarring",2,"Mean Difference (Final Values)",10.2,0.05,"t-test, 2 sided",null,null,95,null,"NA","All",28,"Completed","Phase 4","\t"]
["NCT00654420",4471409,8194849,"Phase II: Median Progression Free Survival (PFS) in Participants Receiving Dalotuzumab Plus Erlotinib Treatment","erlotinib hydrochloride","Dalotuzumab|Erlotinib","Drug|Drug","carcinoma, non-small-cell lung","Carcinoma, Non-small-cell Lung","Parallel Assignment","Interventional","Treatment","Randomized","A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)",4,"Hazard Ratio (HR)",0.86,0.268,"Finkelstein Proportional Hazards Model",0.47,1.57,95,null,"NA","All",95,"Completed","Phase 2","\t"]
["NCT00656513",4471312,8194568,"Change From Baseline in Symptom Burden at 4, 6, 9 and 15 Months (Phase III)","pilocarpine","Pilocarpine|ALTENS","Drug|Procedure","head and neck neoplasms|xerostomia","Head and Neck Cancer|Xerostomia","Parallel Assignment","Interventional","Supportive Care","Randomized","Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer",3,null,"NA",0.58,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",196,"Completed","Phase 2/Phase 3","\t"]
["NCT00658359",4470833,8194404,"Least Squares Means of Estimated GFR Calculated Using the Cockcroft-Gault Equation by Visit","tofacitinib|cyclosporine|cyclosporins","Cyclosporine|CP-690,550|CP-690,550","Drug|Drug|Drug","NA","Kidney Transplantation","Parallel Assignment","Interventional","Prevention","Randomized","Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients",3,"Mean Difference (Final Values)",17.16,0.0128,"Mixed Models Analysis",11.44,22.88,60,"Standard Error of the Mean",6.77,"All",178,"Completed","Phase 2","\t"]
["NCT00658359",4471078,8194420,"Kaplan-Meier Analysis of Percentage of Participants With Treated Clinical Acute Rejection by Visit","tofacitinib|cyclosporine|cyclosporins","Cyclosporine|CP-690,550|CP-690,550","Drug|Drug|Drug","NA","Kidney Transplantation","Parallel Assignment","Interventional","Prevention","Randomized","Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients",3,"Estimated rate difference",-18.58,0.0111,"Wald Test",-24.74,-12.42,60,"Standard Error of the Mean",7.32,"All",178,"Completed","Phase 2","\t"]
["NCT00658359",4471090,8194420,"Kaplan-Meier Analysis of Percentage of Participants With Treated Clinical Acute Rejection by Visit","tofacitinib|cyclosporine|cyclosporins","Cyclosporine|CP-690,550|CP-690,550","Drug|Drug|Drug","NA","Kidney Transplantation","Parallel Assignment","Interventional","Prevention","Randomized","Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients",3,"Estimated rate difference",-7.64,0.239,"Wald Test",-13.1,-2.18,60,"Standard Error of the Mean",6.49,"All",178,"Completed","Phase 2","\t"]
["NCT00662558",4470521,8193667,"Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale","celecoxib|tramadol","celecoxib|tramadol HCL","Drug|Drug","low back pain|back pain","Low Back Pain","Parallel Assignment","Interventional","Treatment","Randomized","A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain",2,"Mean Difference (Final Values)",-0.22,0.336,"ANCOVA",-0.67,0.23,95,"Standard Error of the Mean",0.23,"All",802,"Completed","Phase 3","\t"]
["NCT00666757",4470070,8192982,"Change From Baseline in HAMD-17 Bech Subscale Score at 12-Week Endpoint (Mood Measure)","citalopram|duloxetine hydrochloride|sertraline|paroxetine|fluoxetine","duloxetine|fluoxetine|citalopram|paroxetine|sertraline","Drug|Drug|Drug|Drug|Drug","depressive disorder|depression","Depression","Parallel Assignment","Interventional","Treatment","Randomized","A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression",5,null,"NA",0.01,"Mixed Models Analysis",{"$nulls":4},"NA","All",750,"Completed","Phase 4","\t"]
["NCT00668707",4469906,8192686,"Lung Cancer Recurrence or Mortality - 5 Years","melatonin","melatonin|placebo","Dietary Supplement|Dietary Supplement","recurrence|lung neoplasms","Non Small Cell Lung Cancer","Parallel Assignment","Interventional","Prevention","Randomized","Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality",2,"Hazard Ratio (HR)",0.75,0.004,"Log Rank",0.61,0.92,95,null,"NA","All",709,"Completed","Phase 3","\t"]
["NCT00669409",4469704,8192517,"Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain During Walking in the Past 24 Hours at Week 9","tanezumab","PF-04383119 (tanezumab)|PF-04383119 (tanezumab)|PF-04383119 (tanezumab)|PF-04383119 (tanezumab)|PF-04383119 (tanezumab)|PF-04383119 (tanezumab)","Drug|Drug|Drug|Drug|Drug|Drug","osteoarthritis, knee|osteoarthritis","Osteoarthritis, Knee","Parallel Assignment","Interventional","Treatment","Randomized","A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee",6,"Least Square Mean Difference",-14.8,"NA",null,-31.4,1.9,95,"Standard Error of the Mean",8.4,"All",83,"Completed","Phase 2","\t"]
["NCT00673452",4469447,8192028,"Change From Baseline in Brief Pain Inventory (BPI) (Modified Short Form) at 12 Week Endpoint","duloxetine hydrochloride","duloxetine hydrochloride|placebo","Drug|Drug","myofascial pain syndromes|fibromyalgia","Fibromyalgia","Parallel Assignment","Interventional","Treatment","Randomized","A Study Comparing Duloxetine and Placebo in the Treatment of Fibromyalgia",2,"Least Squares Mean Difference",-0.75,1E-3,"ANCOVA",-1.19,-0.31,95,null,"NA","All",530,"Completed","Phase 4","\t"]
["NCT00676052",4469215,8191746,"Change From Baseline in Weighted Mean for 0 to 24 Hours Forced Vital Capacity (FVC) on Day 1 to 2 and 28 to 29","NA","GSK233705 12.5mcg|GSK233705 25mcg|GSK233705 50mcg|GSK233705 100mcg|GSK233705 200mcg|Placebo","Drug|Drug|Drug|Drug|Drug|Drug","pulmonary disease, chronic obstructive|lung diseases","Pulmonary Disease, Chronic Obstructive","Parallel Assignment","Interventional","Treatment","Randomized","Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)",6,"Mean Difference (Net)",0.166,1E-3,"Repeated Measures Model",0.094,0.237,95,null,"NA","All",576,"Completed","Phase 2","\t"]
["NCT00676403",4468882,8191671,"Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Adequacy Subscale; Observed Change From Baseline","pregabalin","placebo|Pregabalin|Pregabalin|Pregabalin|Pregabalin|Pregabalin","Drug|Drug|Drug|Drug|Drug|Drug","restless legs syndrome|psychomotor agitation|syndrome","Restless Legs Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients",6,"Mean Difference (Final Values)",2.4,0.7575,"Mixed Models Analysis",-13,17.8,95,"Standard Error of the Mean",7.82,"All",137,"Completed","Phase 2","\t"]
["NCT00676403",4469079,8191678,"Subjective Sleep Questionnaire: Hours of Sleep Subscale; Observed Change From Baseline","pregabalin","placebo|Pregabalin|Pregabalin|Pregabalin|Pregabalin|Pregabalin","Drug|Drug|Drug|Drug|Drug|Drug","restless legs syndrome|psychomotor agitation|syndrome","Restless Legs Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients",6,"Mean Difference (Final Values)",0.07,0.7944,"Mixed Models Analysis",-0.43,0.56,95,"Standard Error of the Mean",0.251,"All",137,"Completed","Phase 2","\t"]
["NCT00676650",4468718,8191608,"Progression-Free Survival (PFS)","sunitinib|prednisone","Prednisone|sunitinib|Placebo|Prednisone","Drug|Drug|Drug|Drug","prostatic neoplasms","Prostatic Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy",2,"Hazard Ratio (HR)",0.725,1E-3,"Log Rank",0.591,0.89,95,null,"NA","Male",873,"Terminated","Phase 3","\t"]
["NCT00679627",4468560,8191226,"Change From Baseline in the Disability Assessment in Dementia (DAD) Subscales (Initiation, Planning and Organization, Effective Performance, Basic, Instrumental, and Leisure)","galantamine","Galantamine|Placebo","Drug|Drug","alzheimer disease","Alzheimer's Disease","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease",2,null,"NA",0.043,"ANCOVA",{"$nulls":4},"NA","All",2051,"Terminated","Phase 3","\t"]
["NCT00688870",4468147,8189878,"Percentage of Participants With Pre-specified Systemic Events: Infant Series Dose 2 (4 Months of Age)","heptavalent pneumococcal conjugate vaccine|vaccines","13-valent pneumococcal conjugate vaccine (13vPnC)|7-valent pneumococcal conjugate vaccine (7vPnC)","Biological|Biological","NA","Pneumococcal Conjugate Vaccine|Vaccines","Parallel Assignment","Interventional","Prevention","Randomized","Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan",2,null,"NA",0.872,"Fisher Exact",{"$nulls":4},"NA","All",168,"Completed","Phase 3","\t"]
["NCT00689351",4468007,8189743,"Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 3 (6 Months of Age)","vaccines|heptavalent pneumococcal conjugate vaccine","13-valent pneumococcal conjugate vaccine|7-valent pneumococcal conjugate vaccine","Biological|Biological","NA","Pneumococcal Vaccine","Parallel Assignment","Interventional","Prevention","Randomized","Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered To Infants In Korea",2,null,"NA",0.692,"Fisher Exact",{"$nulls":4},"NA","All",180,"Completed","Phase 2","\t"]
["NCT00689481",4467967,8189727,"Number of Subjects Who Have Treatment Success at Week 8 Analyzed by Baseline ISGA (Mild or Moderate)","NA","U0267 Foam|Vehicle foam","Drug|Drug","psoriasis","Psoriasis","Parallel Assignment","Interventional","Treatment","Randomized","Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies",2,null,"NA",0.859,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",323,"Completed","Phase 3","\t"]
["NCT00694369",4467763,8189231,"Total Pain Relief Score Over the First 6 Hours Post the Initial Day 1 Dose of the Study Medication (TOPAR6)","codeine|acetaminophen|ibuprofen|etoricoxib","Comparator: etoricoxib|Comparator: ibuprofen|Comparator: acetaminophen + codeine|Comparator: placebo","Drug|Drug|Drug|Drug","toothache","Postoperative Dental Pain","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092)",5,"Difference in LS Means",-0.38,"NA",null,-1.8,1.05,95,null,"NA","All",588,"Completed","Phase 3","\t"]
["NCT00697190",4467430,8188840,"Assessment of Conjunctival Hyperemia in Subjects That Are Oblique Astigmats (Have an Abnormally Curved Cornea)","NA","senofilcon A toric|galyfilcon A toric","Device|Device","astigmatism","Astigmatism","Crossover Assignment","Interventional","Treatment","Randomized","Clinical Performance of Atypical Contact Lens Powers on Subjects With Astigmatism",2,"Mean Difference (Final Values)",-0.07,"NA",null,-0.23,0.1,97.5,"Standard Error of the Mean",0.08,"All",39,"Completed","N/A","\t"]
["NCT00699998",4467284,8188469,"Economic and Quality of Life Outcomes","clopidogrel|prasugrel hydrochloride|aspirin","Clopidogrel|Prasugrel|Commercially-available Aspirin","Drug|Drug|Drug","syndrome|acute coronary syndrome","Acute Coronary Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects",2,null,"NA",0.5,"ANCOVA",{"$nulls":4},"NA","All",9326,"Completed","Phase 3","\t"]
["NCT00705016",4467076,8187686,"Time to Treatment Failure (TTF)","fluorouracil|cetuximab","Cilengitide 2000 mg once weekly|Cilengitide 2000 mg twice weekly|Cetuximab|5-fluorouracil (5-FU)|Cisplatin","Drug|Drug|Drug|Drug|Drug","carcinoma, squamous cell|neoplasms, squamous cell","Squamous Cell Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)",3,"Hazard Ratio (HR)",1.23,0.294,"Cox proportional hazards model",0.84,1.81,95,null,"NA","All",184,"Completed","Phase 1/Phase 2","\t"]
["NCT00706433",4466984,8187428,"Erythema 48 Hours After PDT #1","aminolevulinic acid","aminolevulinic acid HCL (ALA)|Vehicle (VEH)","Drug|Other","acne vulgaris","Acne Vulgaris","Parallel Assignment","Interventional","Treatment","Randomized","Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne",4,null,"NA",0.4143,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",266,"Completed","Phase 2","\t"]
["NCT00708175",4466638,8186995,"Percent Change From Baseline to Month 12 in Bone Mineral Density in the Total Proximal Femur by Dual-Energy-Ray Absorptiometry (DXA)","pioglitazone","Pioglitazone|Placebo","Drug|Drug","NA","Bone Metabolism","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.",2,"Mean Difference (Final Values)",-0.55,0.17,"ANCOVA",-1.33,0.24,95,null,"NA","Female",156,"Completed","Phase 4","\t"]
["NCT00708552",4466531,8186919,"Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline MMSE Scores 16-26) on the CIBIC+ Score at Week 12","donepezil","SB-742457|Donepezil|Placebo","Drug|Drug|Drug","alzheimer disease","Alzheimer's Disease","Parallel Assignment","Interventional","Treatment","Randomized","Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease",4,"Mean Difference (Net)",0.1,0.671,"Mixed model repeated measures",-0.2,0.3,95,null,"NA","All",576,"Completed","Phase 2","\t"]
["NCT00711516",4466207,8186311,"Activation-Performance Relationship Between the Functional Magnetic Resonance Imaging (fMRI) in Anterior Cingulate Cortex (ACC) and 2-Back Working Memory Test - Number of Voxels Activated at Endpoint","modafinil","Armodafinil|Placebo","Drug|Drug","disorders of excessive somnolence|sleepiness","Excessive Sleepiness","Parallel Assignment","Interventional","Treatment","Randomized","Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance",2,null,"NA",0.2727,"Pearson's Correlation Coefficient",{"$nulls":4},"NA","All",40,"Completed","Phase 4","\t"]
["NCT00713609",4466110,8186033,"Absolute Change in Lesion Counts (Total, Inflammatory, and Non-inflammatory) From Baseline to Week 12","clindamycin palmitate|tazarotene|clindamycin phosphate|benzoyl peroxide|clindamycin","Benzoyl peroxide gel|Clindamycin gel|Tazarotene cream|Vehicle gel|Vehicle cream","Drug|Drug|Drug|Drug|Drug","acne vulgaris","Acne Vulgaris","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne",6,null,"NA",0.281,"ANCOVA",{"$nulls":4},"NA","All",591,"Completed","Phase 2","\t"]
["NCT00718549",4465873,8185383,"Progression-Fee Survival (PFS) Assessed According to the NCI Revised Guidelines for the Diagnosis and Treatment of CLL","cyclophosphamide|rituximab|cladribine","Cladribine|Cyclophosphamide|Rituximab","Drug|Drug|Drug","leukemia, lymphoid|leukemia, lymphocytic, chronic, b-cell|leukemia","Lymphocytic Leukemia, Chronic","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)",3,"Hazard Ratio (HR)",0.418,0.033,"Cox's proportional hazards regression",0.187,0.933,95,null,"NA","All",128,"Completed","Phase 3","\t"]
["NCT00725725",4465455,8184158,"Change in Montgomery-Asberg Rating Scale for Depression (MADRS) Score","NA","Cognitive-behavioral therapy|Org 25935|Org 25935|Placebo","Behavioral|Drug|Drug|Drug","panic disorder","Panic Disorder","Parallel Assignment","Interventional","Treatment","Randomized","Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705)",3,"Mean Difference (Final Values)",1.526,0.5488,"Mixed Models Analysis",-3.5495,6.6015,95,null,"NA","All",46,"Terminated","Phase 2","\t"]
["NCT00725725",4465459,8184160,"Change in Structured Interview Guide for the Hamilton Anxiety Scale (SIGH-A) Score","NA","Cognitive-behavioral therapy|Org 25935|Org 25935|Placebo","Behavioral|Drug|Drug|Drug","panic disorder","Panic Disorder","Parallel Assignment","Interventional","Treatment","Randomized","Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705)",3,"Mean Difference (Final Values)",2.0417,0.3765,"Mixed Models Analysis",-2.5526,6.636,95,null,"NA","All",46,"Terminated","Phase 2","\t"]
["NCT00729326",4465223,8183679,"Change in Fasting Blood Glucose After the Morning Meal","sitagliptin phosphate|exenatide","exenatide|sitagliptin|placebo|placebo","Drug|Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Type 2 Diabetes Mellitus","Crossover Assignment","Interventional","Treatment","Randomized","Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione",2,null,"NA",0.766,"ANCOVA",{"$nulls":4},"NA","All",83,"Completed","Phase 4","\t"]
["NCT00733902",4465003,8182740,"Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 2, 4, 8, 12, 24: Baseline Observation Carried Forward (BOCF)","tanezumab","tanezumab|tanezumab|tanezumab|Placebo","Biological|Biological|Biological|Biological","osteoarthritis|osteoarthritis, knee","Arthritis|Osteoarthritis","Parallel Assignment","Interventional","Treatment","Randomized","Tanezumab in Osteoarthritis of the Knee",4,"LS Mean Difference",-0.75,0.006,"ANCOVA",-1.29,-0.21,95,"Standard Error of the Mean",0.27,"All",697,"Completed","Phase 3","\t"]
["NCT00734474",4464860,8182542,"Fasting Insulin Change From Baseline","dulaglutide|metformin|sitagliptin phosphate","LY2189265|Sitagliptin|Placebo solution|Placebo tablet|Metformin","Drug|Drug|Drug|Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin",9,"LS Mean Difference",18.51,0.095,"Mixed Models Analysis",-3.25,40.28,95,null,"NA","All",1202,"Completed","Phase 2/Phase 3","\t"]
["NCT00738699",4464638,8181785,"Overall Survival (OS)","paclitaxel|albumin-bound paclitaxel|farletuzumab","MORAb-003 (farletuzumab)|0.9% Saline|Paclitaxel","Drug|Drug|Drug","ovarian neoplasms|carcinoma, ovarian epithelial","Ovarian Cancer","Parallel Assignment","Interventional","Treatment","Randomized","An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer",2,"Cox Proportional Hazard",1.11,0.7568,"Log Rank",0.83,1.48,95,null,"NA","Female",415,"Terminated","Phase 2","\t"]
["NCT00744471",4464331,8181212,"Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Subscale at Week 2, 4, 8, 12, 16 and 24: Last Observation Carried Forward (LOCF)","tanezumab","tanezumab|tanezumab|tanezumab|Placebo","Biological|Biological|Biological|Biological","osteoarthritis|osteoarthritis, hip","Arthritis|Osteoarthritis|Osteoarthritis, Hip","Parallel Assignment","Interventional","Treatment","Randomized","Tanezumab in Osteoarthritis Of The Hip",4,"LS Mean Difference",-2,1E-3,"ANCOVA",-2.51,-1.49,95,"Standard Error of the Mean",0.26,"All",627,"Completed","Phase 3","\t"]
["NCT00749944",4464042,8180531,"Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Insomnia Domain Subscale","varenicline","varenicline|placebo","Drug|Drug","NA","Smoking Cessation","Parallel Assignment","Interventional","Treatment","Randomized","Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo",2,"Difference (change from baseline)",-0.08,"NA",null,-0.2,0.04,95,null,"NA","All",110,"Completed","Phase 4","\t"]
["NCT00754546",4463868,8179857,"Exercise Endurance Time","formoterol fumarate","Arformoterol tartrate|Placebo: Normal Saline|Treadmill Exercise|Cycle Exercise","Drug|Drug|Other|Other","lung diseases, obstructive|pulmonary disease, chronic obstructive","Chronic Obstructive Pulmonary Disease","Crossover Assignment","Interventional","Treatment","Randomized","Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD",2,null,"NA",0.05,"ANOVA",{"$nulls":4},"NA","All",20,"Completed","Phase 4","\t"]
["NCT00755807",4463756,8179718,"Change From Baseline in Inorganic Phosphorus at Week 6 (Acute Phase)","duloxetine hydrochloride","Duloxetine Hydrochloride (HCI)|Placebo","Drug|Drug","sclerosis|multiple sclerosis","Multiple Sclerosis","Parallel Assignment","Interventional","Treatment","Randomized","Duloxetine for Multiple Sclerosis Pain",2,null,"NA",0.007,"ANOVA",{"$nulls":4},"NA","All",239,"Completed","Phase 3","\t"]
["NCT00759356",4463443,8179175,"Area Under the Curve to Infinity for Plasma Morphine","morphine","morphine sulfate sustained-release capsules|KADIAN","Drug|Drug","disease","Healthy","Crossover Assignment","Interventional","Basic Science","Randomized","Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fed Conditions",2,"mean ratio",101.7,"NA",null,95.9,107.9,90,null,"NA","All",36,"Completed","Phase 1","\t"]
["NCT00762177",4463239,8178716,"Antimicrobial Species in Plaque(Sulfur Bacteria)","triclosan|fluorides|tin fluorides","Fluoride, Triclosan|Fluoride|Stannous Fluoride","Drug|Drug|Drug","NA","Oral Bacteria","Crossover Assignment","Interventional","Treatment","Randomized","Investigate Oral Bacteria in Adult Population",3,null,"NA",0.05,"ANCOVA",{"$nulls":4},"NA","All",24,"Completed","Phase 3","\t"]
["NCT00762359",4463209,8178670,"Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 6)","dexlansoprazole|lansoprazole|gefarnate","Lansoprazole|Gefarnate","Drug|Drug","stomach ulcer|ulcer|duodenal ulcer","Duodenal Ulcer|Stomach Ulcer","Parallel Assignment","Interventional","Treatment","Randomized","A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers",2,null,"NA",0.34,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",461,"Terminated","Phase 3","\t"]
["NCT00763971",4462974,8178289,"Change From Baseline in Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at up to 7 Weeks","lisdexamfetamine dimesylate|methylphenidate","Lisdexamfetamine Dimesylate (LDX)|Methylphenidate Hydrochloride|Placebo","Drug|Drug|Drug","NA","ADHD","Parallel Assignment","Interventional","Treatment","Randomized","Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17",3,"difference in LS means",-0.3,1E-3,"ANCOVA",-0.4,-0.2,95,null,"NA","All",336,"Completed","Phase 3","\t"]
["NCT00767806",4462702,8177739,"Change From Baseline to 12 Weeks in Profile of Mood States - Brief Form","duloxetine hydrochloride","Duloxetine|Placebo","Drug|Drug","back pain|low back pain","Chronic Low Back Pain","Parallel Assignment","Interventional","Treatment","Randomized","A Study for Patient With Chronic Low Back Pain",2,"Mean Difference (Final Values)",-0.88,1E-3,"ANCOVA",-1.38,-0.37,95,null,"NA","All",401,"Completed","Phase 3","\t"]
["NCT00770653",4462509,8177304,"Change From Baseline in Systolic Blood Pressure.","glimepiride|pioglitazone|metformin","Pioglitazone and Metformin|Glimepiride and Metformin","Drug|Drug","diabetes mellitus|dyslipidemias","Diabetes Mellitus|Dyslipidemias","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.",2,"Mean Difference (Final Values)",-2.4903,0.0929,"ANCOVA",-5.3979,0.4172,95,null,"NA","All",305,"Completed","Phase 3","\t"]
["NCT00772005",4462382,8177088,"Mean Change From Baseline to Week 12 on the Positive and Negative Syndrome Scale (PANSS) General Psychopathology Scale Score","modafinil","armodafinil|placebo|armodafinil|armodafinil","Drug|Drug|Drug|Drug","schizophrenia","Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia",4,null,"NA",0.8835,"ANCOVA",{"$nulls":4},"NA","All",287,"Completed","Phase 2","\t"]
["NCT00772005",4462428,8177113,"Mean Change in Total Scores From the Positive and Negative Syndrome Scale (PANSS) From Baseline to Week 16","modafinil","armodafinil|placebo|armodafinil|armodafinil","Drug|Drug|Drug|Drug","schizophrenia","Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia",4,null,"NA",0.1591,"ANCOVA",{"$nulls":4},"NA","All",287,"Completed","Phase 2","\t"]
["NCT00775463",4461943,8176327,"Digital Ulcer Pain VAS","treprostinil","treprostinil diethanolamine|placebo","Drug|Drug","scleroderma, localized|scleroderma, diffuse|scleroderma, systemic","Scleroderma|Systemic Sclerosis","Parallel Assignment","Interventional","Treatment","Randomized","Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine",2,"Hodges-Lehmann Estimate of Treatment Eff",-0.4,0.31,"Wilcoxon (Mann-Whitney)",-1.4,0.4,95,null,"NA","All",148,"Completed","Phase 2","\t"]
["NCT00781937",4461712,8175671,"Percentage of Subjects With Weight Regain (Fasting) More Than or Equal to 5% From Week 0","liraglutide","liraglutide|placebo","Drug|Drug","weight loss|nutrition disorders","Metabolism and Nutrition Disorder|Obesity","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance",2,"Odds Ratio (OR)",0.09,{"v":1E-4,"d":"1.00E-04"},"Regression, Logistic",0.03,0.26,95,null,"NA","All",422,"Completed","Phase 3","\t"]
["NCT00782509",4461510,8175490,"Trough FEV1 Response After 48 Weeks","olodaterol","Olodaterol (BI 1744)|Olodaterol (BI 1744)|Placebo","Drug|Drug|Drug","pulmonary disease, chronic obstructive|lung diseases","Pulmonary Disease, Chronic Obstructive","Parallel Assignment","Interventional","Treatment","Randomized","12 / 48 wk Pivotal PFT vs PBO in COPD II",3,"Mean Difference (Final Values)",0.068,{"v":0.0004,"d":"4.00E-04"},"Mixed Models Analysis",0.031,0.106,95,"Standard Error of the Mean",0.019,"All",644,"Completed","Phase 3","\t"]
["NCT00783198",4461399,8175388,"Average Combined Rhinoconjunctivitis DSS and DMS Over the Entire RS","NA","SCH 39641 6 Amb a 1-U|SCH 39641 12 Amb a 1-U|Placebo","Biological|Biological|Biological","asthma|rhinitis|conjunctivitis|rhinitis, allergic","Conjunctivitis|Rhinitis; Allergic, With Asthma","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)",3,"Mean Difference (Final Values)",-1.8,{"v":0.0003,"d":"3.00E-04"},"ANOVA",-2.78,-0.82,95,null,"NA","All",565,"Completed","Phase 2/Phase 3","\t"]
["NCT00786487",4461095,8174821,"Insulin Sensitivity as Measured by Hyperinsulinemic Euglycemic Clamp at a Single Time Point (6 Hrs) After Intralipid or Glycerol Infusion","soybean oil, phospholipid emulsion|glycerol","20% lipid infusion|glycerol","Drug|Drug","NA","Healthy Volunteers","Parallel Assignment","Interventional","Basic Science","Randomized","Training Effects on Skeletal Muscle Fatty Acid Metabolism",4,null,"NA",0.05,"t-test, 2 sided",{"$nulls":4},"NA","All",33,"Completed","N/A","\t"]
["NCT00789880",4460917,8174323,"Change From Baseline on Day 21 in Relative Abundance of CAMP mRNA in Non-Lesional Skin for Non-Atopic Dermatitis (Non-AD) Participants Who Received Oral Vitamin D3 Versus Vitamin D3-Placebo","vitamins|cholecalciferol|vitamin d|ergocalciferols","Vitamin D3|Placebo","Drug|Drug","dermatitis, atopic|psoriasis|dermatitis|eczema","Atopic Dermatitis|Psoriasis","Parallel Assignment","Interventional","Treatment","Randomized","Analysis of Response of Subjects With Atopic Dermatitis or Psoriasis to Oral Vitamin D3",2,null,"NA",0.3,"ANOVA",{"$nulls":4},"NA","All",82,"Completed","Phase 2","\t"]
["NCT00793624",4460500,8173577,"Patient's Global Rating (PGR) at 12 Weeks","formoterol fumarate|olodaterol","Olodaterol (BI 1744)|Olodaterol (BI 1744)|Formoterol|Placebo|Placebo","Drug|Drug|Drug|Drug|Drug","lung diseases|pulmonary disease, chronic obstructive|lung diseases, obstructive","Pulmonary Disease, Chronic Obstructive","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I",4,"Mean Difference (Final Values)",-0.3,0.0121,"Mixed Models Analysis",-0.5,-0.1,95,"Standard Error of the Mean",0.1,"All",906,"Completed","Phase 3","\t"]
["NCT00793624",4460568,8173596,"Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 12 Weeks","formoterol fumarate|olodaterol","Olodaterol (BI 1744)|Olodaterol (BI 1744)|Formoterol|Placebo|Placebo","Drug|Drug|Drug|Drug|Drug","lung diseases|pulmonary disease, chronic obstructive|lung diseases, obstructive","Pulmonary Disease, Chronic Obstructive","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I",4,"Mean Difference (Final Values)",0.21,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",0.135,0.285,95,"Standard Error of the Mean",0.038,"All",906,"Completed","Phase 3","\t"]
["NCT00795600",4460376,8173277,"Percentage Change in Trunk Lean Mass","insulin, isophane|isophane insulin, beef|insulin, globin zinc|insulin detemir|isophane insulin, human|insulin","insulin detemir|insulin NPH","Drug|Drug","overweight|diabetes mellitus, type 2|diabetes mellitus","Diabetes|Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment",2,"Mean Difference (Final Values)",-0.61,0.716,"ANCOVA",-3.949,2.729,95,"Standard Error of the Mean",1.662,"All",60,"Completed","Phase 4","\t"]
["NCT00796666",4460062,8172928,"Change in 36-Item Short-Form Health Survey (SF-36) From Baseline at Weeks 12, 24 and 48 - Composite Mental Health","sitaxsentan|sildenafil citrate","Sitaxsentan|Sitaxsentan and Sildenafil","Drug|Drug","familial primary pulmonary hypertension|hypertension, pulmonary|hypertension","Pulmonary Arterial Hypertension|Pulmonary Hypertension","Parallel Assignment","Interventional","Treatment","Randomized","Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil",2,"Mean Difference (Final Values)",1.18,"NA",null,-1.21,3.58,95,"Standard Error of the Mean",1.21,"All",131,"Terminated","Phase 3","\t"]
["NCT00797966",4459933,8172755,"Percentage of Participants With MADRS Remission From End of Phase A (Week 8 Visit).","brexpiprazole|sertraline|desvenlafaxine succinate|paroxetine|citalopram|fluoxetine","OPC-34712|Placebo|ADT","Drug|Drug|Drug","depressive disorder|depressive disorder, major|depression|disease","Major Depressive Disorder","Parallel Assignment","Interventional","Treatment","Randomized","Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder",2,"Ratio of Remission Rate",0.83,0.6986,"Cochran-Mantel-Haenszel",0.32,2.18,95,null,"NA","All",850,"Completed","Phase 2","\t"]
["NCT00798434",4459822,8172686,"Change From Baseline in OAB-q Subscale Scores at Weeks 4, 8, 12, and 24","fesoterodine","Placebo|Fesoterodine fumarate","Drug|Drug","urinary bladder, overactive","Urinary Bladder, Overactive","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.",2,"Mean Difference (Final Values)",5.39,{"v":0.0002,"d":"2.00E-04"},"ANCOVA",2.57,8.22,95,"Standard Error of the Mean",1.44,"All",794,"Completed","Phase 4","\t"]
["NCT00800683",4459640,8172383,"HbA1c Change From Baseline at Week 18","linagliptin","BI 1356|placebo","Drug|Drug","renal insufficiency, chronic|diabetes mellitus, type 2","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive",2,"Median Difference (Final Values)",-0.61,{"v":1E-4,"d":"1.00E-04"},"ANCOVA",-0.9,-0.33,95,"Standard Error of the Mean",0.14,"All",133,"Completed","Phase 3","\t"]
["NCT00804986",4459439,8171896,"Change in Visual Analogue Scales (VAS) For Appetite and Satiety From Baseline to Week 12 Endpoint","NA","LY2428757|Placebo","Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","A Study for Patients With Type 2 Diabetes Mellitus",6,"Difference in mean change from baseline",3.3,0.446,"Mixed Models Analysis",null,null,95,null,"NA","All",247,"Completed","Phase 2","\t"]
["NCT00808132",4458981,8171368,"Percentage of Participants With Uterine Bleeding","estrogens|medroxyprogesterone|bazedoxifene|medroxyprogesterone acetate|estrogens, conjugated (usp)","bazedoxifene 20 mg/ conjugated estrogens 0.45 mg|bazedoxifene 20 mg/ conjugated estrogens 0.625 mg|bazedoxifene 20 mg|conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg|Placebo","Drug|Drug|Drug|Drug|Drug","osteoporosis","Menopause|Osteoporosis","Parallel Assignment","Interventional","Treatment","Randomized","Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis",5,null,"NA",0.77,"Fisher Exact",{"$nulls":4},"NA","Female",1886,"Completed","Phase 3","\t"]
["NCT00808132",4459067,8171372,"Percentage of Participants With Breast Tenderness","estrogens|medroxyprogesterone|bazedoxifene|medroxyprogesterone acetate|estrogens, conjugated (usp)","bazedoxifene 20 mg/ conjugated estrogens 0.45 mg|bazedoxifene 20 mg/ conjugated estrogens 0.625 mg|bazedoxifene 20 mg|conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg|Placebo","Drug|Drug|Drug|Drug|Drug","osteoporosis","Menopause|Osteoporosis","Parallel Assignment","Interventional","Treatment","Randomized","Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis",5,null,"NA",0.546,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","Female",1886,"Completed","Phase 3","\t"]
["NCT00809354",4458618,8171151,"Change From Baseline in the Patient Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12 and 24: Baseline Observation Carried Forward (BOCF)","anti-inflammatory agents, non-steroidal|tanezumab","NSAID|tanezumab|tanezumab|tanezumab|NSAID|tanezumab|NSAID","Drug|Biological|Biological|Biological|Drug|Biological|Drug","osteoarthritis, knee|osteoarthritis","Arthritis|Osteoarthritis","Parallel Assignment","Interventional","Treatment","Randomized","Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip",5,"LS mean difference",0.01,0.887,"ANCOVA",-0.11,0.13,95,"Standard Error of the Mean",0.06,"All",2720,"Terminated","Phase 3","\t"]
["NCT00809354",4458803,8171154,"Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)","anti-inflammatory agents, non-steroidal|tanezumab","NSAID|tanezumab|tanezumab|tanezumab|NSAID|tanezumab|NSAID","Drug|Biological|Biological|Biological|Drug|Biological|Drug","osteoarthritis, knee|osteoarthritis","Arthritis|Osteoarthritis","Parallel Assignment","Interventional","Treatment","Randomized","Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip",5,"LS Mean Difference",-0.58,2E-3,"ANCOVA",-0.95,-0.21,95,"Standard Error of the Mean",0.19,"All",2720,"Terminated","Phase 3","\t"]
["NCT00810069",4458450,8171003,"Estimated Probability of Not Reaching Confirmed Response at 12 Weeks Based on the Survival Function for the Time to Confirmed Response","citalopram|duloxetine hydrochloride","Duloxetine Hydrochloride|Escitalopram","Drug|Drug","depressive disorder, major|depression|depressive disorder|disease","Major Depressive Disorder","Parallel Assignment","Interventional","Treatment","Randomized","Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder",2,"survival rate difference",0.02,0.653,"Kaplan Meier analysis",-0.06,0.1,95,null,"NA","All",840,"Completed","Phase 4","\t"]
["NCT00812929",4458153,8170493,"Time to FEV1 Recovery to Within 5 Percent of Baseline Following Exercise Challenge","NA","Placebo|GSK2190915","Drug|Drug","asthma","Asthma","Crossover Assignment","Interventional","Treatment","Randomized","A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise",5,"Hazard Ratio (HR)",1.93,"NA",null,1.01,3.66,95,null,"NA","All",47,"Completed","Phase 2","\t"]
["NCT00814307",4458086,8170235,"Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Month 3","tofacitinib","Placebo|CP-690,550|CP-690,550|Placebo","Drug|Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Arthritis, Rheumatoid","Parallel Assignment","Interventional","Treatment","Randomized","A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis",4,"Least squares mean difference",-0.38,{"v":1E-4,"d":"1.00E-04"},"Linear mixed effect model",-0.5,-0.27,95,null,"NA","All",611,"Completed","Phase 3","\t"]
["NCT00818662",4457955,8169595,"Change From Baseline at 9 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)","rho(d) immune globulin|immunoglobulin g|immunoglobulins, intravenous|gamma-globulins|pharmaceutical solutions|immunoglobulins|antibodies","Placebo solution: Human Albumin 0.25% - 2 mL/kg|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg|Placebo solution: Human Albumin 0.25% - 4 mL/kg","Biological|Biological|Biological|Biological","alzheimer disease","Alzheimer´s Disease","Parallel Assignment","Interventional","Treatment","Randomized","A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease",4,"Difference in least-square means",-0.7,0.368,"ANCOVA",-2.3,0.8,95,null,"NA","All",390,"Completed","Phase 3","\t"]
["NCT00822523",4457745,8169097,"Correlation in Percent Change of the CMAP (With Standard Reference Electrode Location) From EDB After vs. Before Botulinum Toxin Injection Into EDB vs. Percent Change Surface Electromyography (as Measured by Mean Rectified Voltage With 200 ms Window).","botulinum toxins, type a|botulinum toxins|abobotulinumtoxina","Botulinum Toxin, Type A|Botulinum Toxin, Type A|Saline","Drug|Drug|Drug","NA","Botulinum Toxins, Type A|Muscle Strength","Parallel Assignment","Interventional","Diagnostic","Randomized","Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via Strain Gauge and Nerve Conduction Studies",3,"r value",0.7,0.188,"Spearman Correlation Test",{"$nulls":4},"NA","All",13,"Completed","N/A","\t"]
["NCT00829933",4457116,8168119,"Incidence of Bleeding Events (Major Bleeding, Clinically Relevant Non-major Bleeding and Minor Bleeding ) Identified During the Period From the Entry Into the Treatment Period Until Completion or Termination of the Treatment.","edoxaban|warfarin","DU-176b tablets|Warfarin potassium tablets","Drug|Drug","atrial fibrillation","Atrial Fibrillation","Parallel Assignment","Interventional","Prevention","Randomized","Late Phase 2 Study of DU-176b in Patients With Non-Valvular Atrial Fibrillation",4,null,"NA",0.077,"Chi-squared",{"$nulls":4},"NA","All",536,"Completed","Phase 2","\t"]
["NCT00830063",4457057,8168096,"Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 2, 4, 8 and 12: Last Observation Carried Forward (LOCF)","tanezumab|naproxen","tanezumab 10 mg|tanezumab 5 mg|naproxen|placebo","Biological|Biological|Drug|Other","osteoarthritis|osteoarthritis, knee","Arthritis|Osteoarthritis","Parallel Assignment","Interventional","Treatment","Randomized","Tanezumab In Osteoarthritis Of The Knee (2)",4,"LS mean difference",-0.7,0.006,"ANCOVA",-1.19,-0.21,95,"Standard Error of the Mean",0.25,"All",832,"Completed","Phase 3","\t"]
["NCT00833898",4456743,8167488,"Stress as Measured by Caregiver Burden Using the Caregiver Reaction Assessment (CRA)","NA","Paced respiration as part of PEPRR|PEPRR","Device|Behavioral","NA","Hematopoietic/Lymphoid Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)",2,null,"NA",0.4,"Mixed Models Analysis",{"$nulls":4},"NA","All",298,"Completed","Phase 3","\t"]
["NCT00838903",4456313,8166711,"Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 104","sitagliptin phosphate|glimepiride|glucagon-like peptide 1|rglp-1 protein|metformin","albiglutide|sitagliptin|glimepiride|metformin|placebo albiglutide|placebo sitagliptin|placebo glimepiride","Biological|Drug|Drug|Drug|Biological|Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes",4,null,"NA",3.3E-3,"t-test, 2 sided",{"$nulls":4},"NA","All",1049,"Completed","Phase 3","\t"]
["NCT00842712",4456176,8166175,"Randomized Part: Progression Free Survival (PFS) Time - Independent Read","cetuximab|vinorelbine|cisplatin|gemcitabine","Cilengitide|Cilengitide|Cetuximab|Cisplatin|Cisplatin|Gemcitabine|Vinorelbine|Cilengitide|Cilengitide|Cetuximab|Chemotherapy","Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug","carcinoma, non-small-cell lung","Carcinoma, Non-Small-Cell Lung","Parallel Assignment","Interventional","Treatment","Randomized","Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)",7,"Hazard Ratio (HR)",0.718,0.0845,"Log Rank",0.492,1.048,95,null,"NA","All",232,"Completed","Phase 2","\t"]
["NCT00848354",4455852,8165146,"Percentage of Participants Achieving ACR20 Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24","etanercept|methotrexate","Phase 1: Etanercept|Phase 1: Methotrexate|Phase 2: Optional ETN, SSZ, HCQ, MTX|Phase 1: Methotrexate|Phase 1: Conventiaonal DMARD","Biological|Drug|Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Rheumatoid Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy",2,"Odds Ratio (OR)",3.84,{"v":1E-4,"d":"1.00E-04"},"Fisher Exact",2.37,6.21,95,null,"NA","All",429,"Completed","Phase 4","\t"]
["NCT00852995",4455589,8164563,"Percent of Change From Baseline in Target Wound Area at Each of the Twelve Double-blind Treatment Weeks.","NA","HP802-247|Placebo (Vehicle)","Biological|Biological","varicose ulcer|ulcer|leg ulcer","Venous Leg Ulcer|Venous Stasis Ulcers","Parallel Assignment","Interventional","Treatment","Randomized","Dose Finding Study of HP802-247 in Venous Leg Ulcers",5,null,"NA",0.161,"ANCOVA",{"$nulls":4},"NA","All",228,"Completed","Phase 2","\t"]
["NCT00854594",4455189,8164232,"Provider Abilities Scale - Subscale From the Midwest (MW) Clinicians' Network","NA","Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT)","Behavioral","diabetes mellitus","Diabetes Mellitus","Parallel Assignment","Interventional","Prevention","Randomized","Interprofessional Training to Improve Diabetes Care: The ReSPECT Trial",2,null,"NA",0.74,"t-test, 2 sided",{"$nulls":4},"NA","All",117,"Completed","N/A","\t"]
["NCT00855582",4455088,8164060,"Change From Baseline in International Index of Erectile Function - Overall Satisfaction Domain at Week 12 Endpoint","tadalafil","Tadalafil|Placebo","Drug|Drug","erectile dysfunction|hyperplasia|prostatic hyperplasia","Benign Prostatic Hyperplasia|Erectile Dysfunction","Parallel Assignment","Interventional","Treatment","Randomized","A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia",3,"Mean Difference (Final Values)",1.9,1E-3,"ANCOVA",null,null,95,"Standard Error of the Mean",0.2,"Male",606,"Completed","Phase 3","\t"]
["NCT00861146",4454658,8162935,"Smoking Abstinence","NA","behavioral counseling plus contingency management","Behavioral","recurrence|alcohol-related disorders","Alcohol-related Disorders|Tobacco Use Cessation","Parallel Assignment","Interventional","Treatment","Randomized","Concurrent Alcohol and Smoking Treatment: Effects on Alcohol Relapse Risk",2,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",151,"Completed","Phase 2","\t"]
["NCT00863304",4454302,8162588,"Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Weeks 2, 4, 8, 12 and 16: Last Observation Carried Forward (LOCF)","naproxen|tanezumab","tanezumab 10 mg|tanezumab 5 mg|naproxen|placebo","Biological|Biological|Drug|Other","osteoarthritis, hip|osteoarthritis","Osteoarthritis","Parallel Assignment","Interventional","Treatment","Randomized","Tanezumab in Osteoarthritis of the Hip or Knee (2)",4,"LS Mean Difference",-0.59,0.011,"ANCOVA",-1.05,-0.14,95,"Standard Error of the Mean",0.23,"All",849,"Completed","Phase 3","\t"]
["NCT00863798",4454212,8162445,"Number of Participants With a Response on the HAM-D17 at FOT Evaluation (Week 8 or ET)","desvenlafaxine succinate","Desvenlafaxine Succinate Sustained-Release 10mg|Desvenlafaxine Succinate Sustained-Release 50 mg|placebo","Drug|Drug|Drug","depressive disorder|depression|disease|depressive disorder, major","Major Depressive Disorder","Parallel Assignment","Interventional","Treatment","Randomized","Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder",3,"Odds Ratio (OR)",1.254,0.2415,"Regression, Logistic",0.86,1.83,95,null,"NA","All",682,"Completed","Phase 3","\t"]
["NCT00865566",4454116,8162254,"Participant Dropout Prior to Unblinding","vaccines","DNA plasmid vaccine|Recombinant adenoviral serotype 5 (rAD5) vector vaccine|DNA vaccine placebo|HIV-1 recombinant adenovirus vaccine placebo","Biological|Biological|Biological|Biological","hiv infections","HIV Infections","Parallel Assignment","Interventional","Prevention","Randomized","Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men",2,"Hazard Ratio (HR)",0.77,0.05,"Regression, Cox",0.59,1,95,null,"NA","Male",2504,"Terminated","Phase 2","\t"]
["NCT00871000",4453917,8161531,"Number of Seroprotected Subjects Against Polio Types 1, 2 and 3","pentetic acid","Boostrix Polio™ 711866|Priorix Tetra TM 208136|Tetravac TM","Biological|Biological|Biological","diphtheria|poliomyelitis","Acellular Pertussis|Diphtheria|Poliomyelitis|Tetanus","Parallel Assignment","Interventional","Prevention","Randomized","Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.",2,"Difference in seroprotection rate",0,"NA",null,-2.61,2.72,95,null,"NA","All",303,"Completed","Phase 3","\t"]
["NCT00874497",4453573,8161105,"Change From Baseline to Week 104 in 7-day Average Total Symptom Score of Dyspnea, Cough and Sputum","NA","tetomilast|placebo","Drug|Drug","lung diseases, obstructive|pulmonary disease, chronic obstructive|emphysema|lung diseases","Chronic Obstructive Pulmonary Disease","Parallel Assignment","Interventional","Treatment","Randomized","Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema",2,"Mean Difference (Final Values)",-0.07,0.845,"ANCOVA",-0.77,0.64,95,null,"NA","All",84,"Terminated","Phase 2","\t"]
["NCT00879658",4453300,8160315,"Number of Patients Without Any New MRI Disease Activity - Period 1 Only","NA","BAF312|Placebo","Drug|Drug","multiple sclerosis, relapsing-remitting|sclerosis|multiple sclerosis","Relapsing-remitting Multiple Sclerosis","Parallel Assignment","Interventional","Treatment","Randomized","Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",6,null,"NA",0.335,"Regression, Logistic",{"$nulls":4},"NA","All",297,"Completed","Phase 2","\t"]
["NCT00880048",4453256,8160226,"Change From Baseline in the 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR 16) Total Score","NA","orvepitant|Placebo","Drug|Other","depression|depressive disorder|depressive disorder, major","Depressive Disorder","Parallel Assignment","Interventional","Treatment","Randomized","A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder",3,"Mean Difference (Net)",-1.44,0.0239,"Mixed Models Repeated Measures",-2.68,-0.19,95,null,"NA","All",343,"Terminated","Phase 2","\t"]
["NCT00880399",4453129,8160158,"Change From Baseline in the 17-item Hamilton Depression Rating Scale (HAM-D) Total Score","NA","orvepitant|placebo","Drug|Other","depressive disorder|depressive disorder, major|depression","Depressive Disorder, Major","Parallel Assignment","Interventional","Treatment","Randomized","A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder",3,"Mean Difference (Net)",-2.86,0.0082,"Mixed Models Repeated Measures",-4.97,-0.75,95,null,"NA","All",328,"Terminated","Phase 2","\t"]
["NCT00884221",4452828,8159633,"Endocrine Profile (Free Androgen Index), Intention-to-treat (ITT) Analysis Set","menotropins","Highly purified menotrophin|Recombinant FSH","Drug|Drug","infertility","Infertility","Parallel Assignment","Interventional","Treatment","Randomized","MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer",2,null,"NA",1E-3,"Regression, Linear",{"$nulls":4},"NA","Female",749,"Completed","Phase 3","\t"]
["NCT00890825",4452541,8158778,"Progression Free Survival","docetaxel","AZD6244|docetaxel|Placebo","Drug|Drug|Drug","carcinoma, non-small-cell lung","Non Small Cell Lung Cancer","Parallel Assignment","Interventional","Treatment","Randomized","AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients",2,"Hazard Ratio (HR)",0.58,0.0138,"Regression, Cox",0.42,0.79,80,null,"NA","All",88,"Completed","Phase 2","\t"]
["NCT00895895",4452298,8158143,"Change From Baseline in CANTAB SWM - Between Errors (N Boxes) at Week 24","donepezil","Placebo|SAM-531 1.5 mg|SAM-531 3.0 mg|SAM-531 5.0 mg|Donepezil","Drug|Drug|Drug|Drug|Drug","alzheimer disease","Alzheimer Disease","Parallel Assignment","Interventional","Treatment","Randomized","Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease",5,"Mean Difference (Final Values)",-1.4,0.28,"Mixed Models Analysis",-4,1.2,95,null,"NA","All",526,"Terminated","Phase 2","\t"]
["NCT00895895",4452313,8158146,"Change From Baseline in CANTAB Spatial Working Memory (SWM) - Between Errors (4 Boxes) at Week 24","donepezil","Placebo|SAM-531 1.5 mg|SAM-531 3.0 mg|SAM-531 5.0 mg|Donepezil","Drug|Drug|Drug|Drug|Drug","alzheimer disease","Alzheimer Disease","Parallel Assignment","Interventional","Treatment","Randomized","Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease",5,"Mean Difference (Final Values)",0,0.953,"Mixed Models Analysis",-0.7,0.7,95,null,"NA","All",526,"Terminated","Phase 2","\t"]
["NCT00905307",4451922,8157161,"Change From Baseline to Week 6 in Personal and Social Performance Scale (PSP) (Double Blind Phase)","aripiprazole","OPC-34712|Placebo|Aripiprazole","Drug|Drug|Drug","schizophrenia","Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia",6,"Treatment difference",3.25,0.1819,"ANCOVA",-1.53,8.03,95,null,"NA","All",459,"Completed","Phase 2","\t"]
["NCT00910910",4451563,8156318,"Percentage of Participants With a Best Overall Response Based on IWCLL Guidelines With a Later Cut-off Date of 31 March 2014","lenalidomide|chlorambucil","Lenalidomide|Chlorambucil","Drug|Drug","leukemia, lymphoid|leukemia|leukemia, lymphocytic, chronic, b-cell","B-Cell Chronic Lymphocytic Leukemia","Parallel Assignment","Interventional","Treatment","Randomized","Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)",2,"Odds Ratio (OR)",0.66,0.047,"Fisher Exact",0.45,0.98,95,null,"NA","All",450,"Completed","Phase 3","\t"]
["NCT00912964",4451372,8156034,"Change From Baseline to End of Treatment (Final Visit) in Mean Number of Urgency Episodes (Grades 3 or 4) Per 24 Hours","mirabegron","Mirabegron|Placebo","Drug|Drug","urinary bladder, overactive","Urinary Bladder, Overactive","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder",3,"LS Mean Difference",-0.33,0.13,"ANCOVA",-0.76,0.1,95,null,"NA","All",2030,"Completed","Phase 3","\t"]
["NCT00913627",4451002,8155914,"Pain Relief Combined With Pain Intensity Difference (PRID) Score","naproxen|ibuprofen","ibuprofen|ibuprofen|naproxen|Placebo","Drug|Drug|Drug|Drug","toothache","Pain","Parallel Assignment","Interventional","Treatment","Randomized","Study Evaluating Ibuprofen 600 mg Extended Release (ER) For Dental Pain",4,"Mean Difference (Final Values)",2.26,1E-3,"ANOVA",1.14,3.37,95,null,"NA","All",196,"Completed","Phase 2","\t"]
["NCT00913627",4451202,8155919,"Percentage of Participants Achieving Meaningful Pain Relief","naproxen|ibuprofen","ibuprofen|ibuprofen|naproxen|Placebo","Drug|Drug|Drug|Drug","toothache","Pain","Parallel Assignment","Interventional","Treatment","Randomized","Study Evaluating Ibuprofen 600 mg Extended Release (ER) For Dental Pain",4,"CMH adjusted proportions",47.72,1E-3,"Cochran-Mantel-Haenszel",32.25,63.19,95,null,"NA","All",196,"Completed","Phase 2","\t"]
["NCT00918749",4450680,8155246,"Serum BAP Comparing Risedronate 150 mg IRBB Tablet With 75 mg & 100 mg DRFB Tablet, Month 3, ITT Population","NA","150 mg|75 mg|100 mg","Drug|Drug|Drug","osteoporosis, postmenopausal|osteoporosis","Postmenopausal Osteoporosis","Parallel Assignment","Interventional","Treatment","Randomized","Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women",3,"LS Mean Difference",4.926,0.2613,"ANOVA",-2.301,12.153,90,"Standard Error of the Mean",4.371,"Female",205,"Completed","Phase 2","\t"]
["NCT00922207",4450587,8154906,"Percentage of Participants Who Were HBeAg Negative","peginterferon alfa-2a|adefovir|entecavir","Adefovir|Entecavir|Placebo|peginterferon alfa-2a [Pegasys]","Drug|Drug|Drug|Drug","hepatitis|hepatitis a|hepatitis b, chronic|hepatitis b","Hepatitis B, Chronic","Parallel Assignment","Interventional","Treatment","Randomized","A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B",3,"Odds Ratio (OR)",1.57,0.5068,"Cochran-Mantel-Haenszel",0.43,5.77,95,null,"NA","All",280,"Completed","Phase 4","\t"]
["NCT00922974",4450430,8154775,"Change in Brief Pain Inventory (BPI) Worst Pain Score Through Two Years (Phase III)","NA","External beam radiation therapy|Radiosurgery/SBRT","Radiation|Radiation","neoplasm metastasis","Metastatic Cancer|Pain","Parallel Assignment","Interventional","Treatment","Randomized","Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis",2,null,"NA",0.0016,"Mixed Models Analysis",{"$nulls":4},"NA","All",399,"Completed","Phase 2/Phase 3","\t"]
["NCT00927186",4450045,8153974,"Percentage of Eroded Surface/Bone Surface (ES/BS) in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months","zoledronic acid|teriparatide","Teriparatide|Zoledronic Acid","Drug|Drug","osteoporosis|osteoporosis, postmenopausal","Osteoporosis, Post-menopausal","Parallel Assignment","Interventional","Treatment","Randomized","Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women",2,null,"NA",0.092,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",69,"Completed","Phase 4","\t"]
["NCT00929240",4449926,8153588,"Progression Free Survival (Maintenance Phase Data Cutoff October 4, 2013)","bevacizumab|capecitabine","bevacizumab [Avastin]|capecitabine [Xeloda]","Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer",2,"Hazard Ratio (HR)",0.383,{"v":1E-4,"d":"1.00E-04"},"Log Rank",0.266,0.551,95,null,"NA","Female",287,"Completed","Phase 3","\t"]
["NCT00934089",4449703,8152856,"Change From Baseline in Diastolic Ocular Perfusion Pressure (DOPP) at Day 14 (8 AM, 10 AM, 12 PM, 2 PM, 4 PM, 6 PM, 8 PM, 10 PM) and Day 15 (12 AM, 2 AM, 4 AM, 6 AM and 8 AM)","latanoprost","PF-04217329|latanoprost vehicle|PF-04217329|latanoprost","Drug|Drug|Drug|Drug","ocular hypertension|glaucoma, open-angle","Glaucoma, Open-Angle|Ocular Hypertension","Crossover Assignment","Interventional","Treatment","Randomized","A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329",2,"Mean Difference (Final Values)",-2.99,0.2801,"ANCOVA",-7.59,1.6,90,null,"NA","All",31,"Completed","Phase 2","\t"]
["NCT00936065",4449429,8152587,"Change From Baseline in the Percentage of Participants Who Responded \"Yes\" to Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 18, at Weeks 2, 4, 8, 12, 18 and 24","etanercept|acitretin","Etanercept|Etanercept + Acitretin|Acitretin","Drug|Drug|Drug","psoriasis","Moderate to Severe Psoriasis","Parallel Assignment","Interventional","Treatment","Randomized","Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis",3,null,"NA",0.0927,"Fisher Exact",{"$nulls":4},"NA","All",60,"Completed","Phase 4","\t"]
["NCT00936065",4449596,8152618,"Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score","etanercept|acitretin","Etanercept|Etanercept + Acitretin|Acitretin","Drug|Drug|Drug","psoriasis","Moderate to Severe Psoriasis","Parallel Assignment","Interventional","Treatment","Randomized","Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis",3,null,"NA",1,"Fisher Exact",{"$nulls":4},"NA","All",60,"Completed","Phase 4","\t"]
["NCT00937326",4449356,8152448,"Area Under Plasma Concentration Curve From Time 0 to Last Measurable Time Point (AUC 0-t), From Time 0 to Infinity (AUC 0-infinity) and From Time 0 to Trough Concentration (AUC 0-τ) of SRT2104 on Day 1 and Day 28","NA","SRT2104|Placebo","Drug|Drug","diabetes mellitus, type 2","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects",5,"Ratio",110.88,"NA",null,88.18,139.43,90,null,"NA","All",227,"Completed","Phase 2","\t"]
["NCT00943722",4448854,8151303,"Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] Versus 16- to 26-Year-Old Females [Lot 1])","NA","V503","Biological","vaginal neoplasms|papillomavirus infections|vulvar neoplasms","Cervical Cancers|Genital Lesions|HPV Infections|PAP Test Abnormalities|Vaginal Cancer|Vulvar Cancer","Parallel Assignment","Interventional","Prevention","Randomized","A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)",5,"Percentage Point Difference",0.3,1E-3,"Miettinen and Nurminen",-0.4,1.7,95,null,"NA","All",3074,"Completed","Phase 3","\t"]
["NCT00944658",4448805,8151140,"Changes of Apremilast in Patients With AS, Changes in BASDAI Score From Baseline","apremilast","Apremilast|Placebo (sugar pill)","Drug|Drug","spondylitis|spondylitis, ankylosing","Ankylosing Spondylitis","Parallel Assignment","Interventional","Treatment","Randomized","Spondylitis Trial of Apremilast for Better Rheumatic Therapy",2,null,"NA",0.139,"ANCOVA",{"$nulls":4},"NA","All",38,"Completed","Phase 2","\t"]
["NCT00948896",4448610,8150531,"Incidence of Any Adverse Events Defined as Severity Grade 3-4 That Are Possibly, Probably, or Definitely Related to Study Drugs","pyrimethamine|piperaquine|sulfadoxine|dihydroartemisinin|fanasil, pyrimethamine drug combination|sulfamethoxazole|trimethoprim|trimethoprim, sulfamethoxazole drug combination","trimethoprim-sulfamethoxazole (TS; TMP/SMX)|sulfadoxine-pyrimethamine (SP)|dihydroartemisinin-piperaquine (DP)","Drug|Drug|Drug","malaria","Malaria","Parallel Assignment","Interventional","Prevention","Randomized","Chemopreventive Therapy for Malaria in Ugandan Children",4,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Negative Binomial Regression",{"$nulls":4},"NA","All",600,"Completed","Phase 3","\t"]
["NCT00950300",4448464,8150363,"Predicted Ctrough of Trastuzumab Prior to Surgery","cyclophosphamide|docetaxel|fluorouracil|trastuzumab|epirubicin","5-Fluorouracil|Cyclophosphamide|Docetaxel|Epirubicin|Herceptin IV [trastuzumab]|Herceptin SC [trastuzumab]","Drug|Drug|Drug|Drug|Drug|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer",2,"Geometric mean ratio",1.55,"NA",null,1.46,1.64,90,null,"NA","Female",596,"Completed","Phase 3","\t"]
["NCT00960934",4447748,8148509,"LS Mean Percent Change From Baseline to Month 6 in the Ratio of Urinary N-Telopeptides of Type I Collagen to Creatinine (u-NTx/Cr)","cholecalciferol|calcium carbonate|calcium|vitamin d","MK-5442|Placebo|Vitamin D3|Calcium carbonate","Drug|Drug|Dietary Supplement|Dietary Supplement","osteoporosis","Osteoporosis","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-Ranging Study of MK-5442 in Postmenopausal Women With Osteoporosis (MK-5442-001)",6,"LS Mean Difference in Change From BL",-2.83,0.642,"Longitudinal Data Analysis Model",-14.81,9.14,95,null,"NA","Female",383,"Terminated","Phase 2","\t"]
["NCT00962104",4447669,8148333,"Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version: Informant (BRIEF-A: Informant) Score up to 10 Weeks","atomoxetine hydrochloride","Atomoxetine|Placebo","Drug|Drug","attention deficit disorder with hyperactivity|hyperkinesis","Attention Deficit Hyperactivity Disorder","Parallel Assignment","Interventional","Treatment","Randomized","Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder",2,"Least Squares Mean Difference",-3.55,0.153,"ANCOVA",-8.43,1.32,95,null,"NA","All",391,"Completed","Phase 3","\t"]
["NCT00966875",4447428,8147646,"Change From Baseline in Duration of Morning Stiffness (Minutes) - Part A","ixekizumab","LY2439821|Placebo","Biological|Drug","arthritis|arthritis, rheumatoid","Rheumatoid Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","A Study in Patients With Rheumatoid Arthritis",9,null,"NA",0.276,"ANCOVA",{"$nulls":4},"NA","All",448,"Completed","Phase 2","\t"]
["NCT00970632",4447238,8147139,"Change From Baseline in Benign Prostatic Hyperplasia Impact Index (BII) at 12 Weeks","tadalafil|tamsulosin","Tadalafil 5 mg|Placebo tablet|Tamsulosin|Placebo capsule","Drug|Drug|Drug|Drug","hyperplasia|prostatic hyperplasia","Benign Prostatic Hyperplasia (BPH)","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Tadalafil in Men With Benign Prostatic Hyperplasia",3,"Difference in LS Means",-0.6,0.026,"ANCOVA",null,null,95,null,"NA","Male",511,"Completed","Phase 3","\t"]
["NCT00973349",4447015,8146824,"Geometric Mean HI Titer by Vaccine Groups; in Participants 18 to 64 Years of Age and ≥65 Years of Age","NA","MF59-eH1N1_f","Biological","influenza, human","Influenza","Parallel Assignment","Interventional","Prevention","Randomized","Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults",8,"Geometric mean ratio at 43",0.79,"NA",null,0.625,1,95,null,"NA","All",2719,"Completed","Phase 2/Phase 3","\t"]
["NCT00977938",4446535,8145835,"GUSTO Severe or Moderate Bleeding - Randomized BMS ITT","prasugrel hydrochloride|clopidogrel|aspirin","Placebo & Aspirin|Clopidogrel & Aspirin, Prasugrel & Aspirin","Drug|Drug","coronary artery disease","Coronary Artery Disease","Parallel Assignment","Interventional","Treatment","Randomized","The Dual Antiplatelet Therapy Study (DAPT Study)",2,"Risk Difference (RD)",1.03,"NA",null,-0.21,2.28,95,null,"NA","All",25682,"Completed","Phase 4","\t"]
["NCT00982072",4446368,8145356,"Percentage of Participants Achieving Complete Remission From Nephrotic Syndrome at 8 Weeks","tacrolimus|prednisolone","tacrolimus|prednisolone","Drug|Drug","nephrosis, lipoid","Minimal Change Disease","Parallel Assignment","Interventional","Treatment","Randomized","Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease",2,null,"NA",0.12,"Fisher Exact",{"$nulls":4},"NA","All",52,"Completed","Phase 4","\t"]
["NCT00986180",4446177,8144531,"SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Total Score Day 5","oxycodone","NUCYNTA|Oxycodone IR","Drug|Drug","low back pain|back pain","Back Pain|Back Pain With Radiation|Low Back Pain|Pain","Parallel Assignment","Interventional","Treatment","Randomized","NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain",2,null,"NA",0.7246,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",667,"Completed","Phase 3","\t"]
["NCT00988208",4446089,8144284,"Progression-Free Survival (PFS)","lenalidomide|docetaxel|prednisone","Lenalidomide|Docetaxel|Prednisone|Placebo","Drug|Drug|Drug|Drug","prostatic neoplasms","Prostate Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer",2,"Hazard Ratio (HR)",1.32,0.0187,"Log Rank",1.05,1.66,95,null,"NA","Male",1059,"Completed","Phase 3","\t"]
["NCT00991341",4445882,8143769,"Composite of Major Pulmonary Events (Any Mechanical Ventilation From 48 Hours Post-operation to Day 7, Hospital Discharge or Death, Whichever Comes First, or Pulmonary Embolism)","NA","Red blood cell units stored <= 10 days|Red blood cell units stored >= 21 days","Biological|Biological","NA","Cardiac Surgery|Erythrocyte Transfusion","Parallel Assignment","Interventional","Treatment","Randomized","Red Cell Storage Duration Study",2,"Risk Difference (RD)",-0.018,0.41,"Fisher Exact",-0.059,0.023,95,null,"NA","All",1481,"Completed","Phase 3","\t"]
["NCT00996801",4445711,8142912,"Least Squares Mean Percent Change From Baseline To Month 12 in Lumbar Spine Areal Bone Mineral Density (BMD)","vitamin d|calcium carbonate|cholecalciferol|alendronate|calcium","MK-5442|Placebo to MK-5442|Alendronate Sodium|Vitamin D3|Calcium carbonate|Placebo to Alendronate","Drug|Drug|Drug|Drug|Drug|Drug","osteoporosis|osteoporosis, postmenopausal","Osteoporosis|Postmenopausal Osteoporosis","Parallel Assignment","Interventional","Treatment","Randomized","MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)",6,"Difference in Least Squares Means",-1.81,0.019,"Longitudinal Data Analysis Model",-3.37,-0.25,95,null,"NA","Female",526,"Completed","Phase 2","\t"]
["NCT00997984",4445392,8142566,"Change From Baseline in Conner's Parent Rating Scale - Revised Short Version (CPRS-R:S) Score at Week 8 - LOCF","guanfacine","extended-release guanfacine hydrochloride (SPD503)|placebo|extended-release guanfacine hydrochloride","Drug|Drug|Drug","hyperkinesis|attention deficit disorder with hyperactivity","Attention-Deficit/Hyperactivity Disorder","Parallel Assignment","Interventional","Treatment","Randomized","Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)",3,null,"NA",1E-3,"ANCOVA",{"$nulls":4},"NA","All",340,"Completed","Phase 3","\t"]
["NCT01000311",4445216,8142210,"Percentage of Subjects With Seroresponse to Routine Concomitant Vaccinations One Month After Infant Series, When Routine Vaccines Are Administered With MenACWY-CRM Compared With When Routine Vaccines Are Given Alone","heptavalent pneumococcal conjugate vaccine|vaccines","MenACWY-CRM|DTaP-IPV/Hib|HBV|PCV|MMR","Biological|Biological|Biological|Biological|Biological","meningococcal infections","Meningococcal Disease","Parallel Assignment","Interventional","Prevention","Randomized","A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months",2,"Group difference",1,"NA",null,-3.1,5.4,95,null,"NA","All",529,"Completed","Phase 3","\t"]
["NCT01006122",4444898,8141330,"Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score at Day 5, 10, 15, 20 of Titration Phase and Day 7, 14, 21 of Stable Dosing Phase","NA","Placebo|PF-03654746","Drug|Drug","sleepiness|narcolepsy","Excessive Daytime Sleepiness|Narcolepsy","Crossover Assignment","Interventional","Treatment","Randomized","A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy",2,"LS Means Difference",-0.73,0.054,"Mixed Models Analysis",-1.32,-0.15,80,"Standard Error of the Mean",0.457,"All",95,"Completed","Phase 2","\t"]
["NCT01008475",4444797,8141016,"Time to Progression (TTP)","irinotecan|cetuximab","EMD 525797 250 mg|EMD 525797 500 mg|EMD 525797 750 mg|EMD 525797 1000 mg|Cetuximab|Irinotecan","Drug|Drug|Drug|Drug|Drug|Drug","colorectal neoplasms","Metastatic Colorectal Cancer","Parallel Assignment","Interventional","Treatment","Randomized","EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer",7,"Cox Proportional Hazard",1.11,"NA",null,0.75,1.65,95,null,"NA","All",232,"Completed","Phase 1/Phase 2","\t"]
["NCT01011556",4444521,8140528,"Percent Change From Baseline in Procollagen Type 1 N-Terminal Propeptide (P1NP)","hormones|parathyroid hormone|teriparatide","Subcutaneous Teriparatide|Transdermal Teriparatide","Drug|Drug","osteoporosis","Osteoporosis","Parallel Assignment","Interventional","Treatment","Randomized","A Study for the Transdermal Application of Teriparatide",4,null,"NA",0.047,"Wilcoxon Rank Sum Test",{"$nulls":4},"NA","Female",233,"Completed","Phase 2","\t"]
["NCT01013753",4444343,8140214,"FVC Area Under Curve 0-24 Hours (AUC 0-24h) Response","formoterol fumarate|olodaterol","Placebo|Olodaterol (BI 1744) high|Olodaterol (BI 1744) medium|Olodaterol (BI 1744) very low|Formoterol 12 mcg|Olodaterol (BI 1744) low","Drug|Drug|Drug|Drug|Drug|Drug","asthma","Asthma","Crossover Assignment","Interventional","Treatment","Randomized","A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.",6,"Mean Difference (Final Values)",0.097,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",0.051,0.143,95,"Standard Error of the Mean",0.023,"All",198,"Completed","Phase 2","\t"]
["NCT01017029",4444014,8139725,"Hazard Cox's Model Analysis of Pericardial/Pleural Effusions","mycophenolic acid|everolimus","Everolimus|Mycophenolate mofetil + Everolimus","Drug|Drug","NA","Cardiac Transplantation","Parallel Assignment","Interventional","Prevention","Randomized","Everolimus in de Novo Heart Transplant Recipients",2,"Hazard Ratio (HR)",1.847,0.0398,"Regression, Cox",1.029,3.315,95,null,"NA","All",182,"Completed","Phase 4","\t"]
["NCT01018511",4443795,8139475,"Patient Global Impression Scale at End of Treatment: General Health","solifenacin succinate|tamsulosin","Placebo tamsulosin hydrochloride OCAS 0.4 mg|Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg|Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg|tamsulosin hydrochloride OCAS 0.4 mg|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)","Drug|Drug|Drug|Drug|Drug|Drug","prostatic hyperplasia|lower urinary tract symptoms|hyperplasia","Benign Prostatic Hyperplasia|Lower Urinary Tract Symptoms","Parallel Assignment","Interventional","Treatment","Randomized","Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms",4,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","Male",1334,"Completed","Phase 3","\t"]
["NCT01021553",4443536,8139144,"Area Under the Plasma Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time [AUC(0-inf)] and From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration [AUC(0-t)] of GSK557296","diketopiperazines","GSK557296|GSK557296|placebo","Drug|Drug|Drug","premature ejaculation|premature birth","Premature Ejaculation","Parallel Assignment","Interventional","Treatment","Randomized","A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation",3,"Ratio of treatments",2.98,"NA",null,2.51,3.54,90,null,"NA","Male",77,"Completed","Phase 2","\t"]
["NCT01025336",4443089,8138636,"Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 23vPS/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC 1 Year After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)","NA","Blood draw|Blood draw","Other|Other","NA","Healthy","Parallel Assignment","Interventional","Prevention","Randomized","Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated",2,"Ratio of GMT",0.8,"NA",null,0.49,1.22,95,null,"NA","All",962,"Completed","Phase 3","\t"]
["NCT01025336",4443133,8138639,"Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)","NA","Blood draw|Blood draw","Other|Other","NA","Healthy","Parallel Assignment","Interventional","Prevention","Randomized","Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated",2,"Ratio of GMT",1,"NA",null,0.72,1.51,95,null,"NA","All",962,"Completed","Phase 3","\t"]
["NCT01025336",4443323,8138647,"Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)","NA","Blood draw|Blood draw","Other|Other","NA","Healthy","Parallel Assignment","Interventional","Prevention","Randomized","Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated",2,"Geometric mean fold rise",1.4,"NA",null,1.24,1.61,95,null,"NA","All",962,"Completed","Phase 3","\t"]
["NCT01026818",4442626,8138502,"Change From Baseline to Endpoint in the International Index of Erectile Function (IIEF) Domains (Intercourse Satisfaction Domain, Orgasmic Function Domain, Sexual Desire Domain, Overall Satisfaction Domain)","tadalafil","Tadalafil|Placebo","Drug|Drug","erectile dysfunction","Erectile Dysfunction","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Tadalafil After Radical Prostatectomy",3,"LS Mean Differences",0.09,0.863,"Mixed Models Analysis",-0.93,1.11,95,"Standard Error of the Mean",0.52,"Male",583,"Completed","Phase 4","\t"]
["NCT01029262",4442446,8138160,"Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days as Determined by an Independent Review Committee (IRC)","lenalidomide","Lenalidomide|Placebo","Drug|Other","preleukemia|anemia|myelodysplastic syndromes","Anemia","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q",2,"Risk Ratio (RR)",10.616,1E-3,"Fisher Exact",2.639,42.702,95,null,"NA","All",239,"Completed","Phase 3","\t"]
["NCT01032629",4442224,8137605,"Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End-of-Treatment","canagliflozin","Placebo|Canagliflozin (JNJ-28431754) 100 mg|Canagliflozin (JNJ-28431754) 300 mg","Drug|Drug|Drug","diabetes mellitus, type 2|cardiovascular diseases|diabetes mellitus","Cardiovascular Diseases|Diabetes Mellitus, Type 2|Risk Factors","Parallel Assignment","Interventional","Treatment","Randomized","CANVAS - CANagliflozin cardioVascular Assessment Study",3,"Difference of Least Square Mean",-2.96,"NA",null,-3.998,-1.914,95,"Standard Error of the Mean",0.532,"All",4330,"Completed","Phase 3","\t"]
["NCT01035346",4441974,8137087,"Time-weighted Sum of The Temperature Differences From Baseline Through Hour 4 and Hour 8 (STEMPD 0-4 and STEMPD 0-8)","ibuprofen","Ibuprofen|Placebo","Drug|Drug","infection|communicable diseases","Infection","Parallel Assignment","Interventional","Treatment","Randomized","Study Evaluating The Efficacy Of A Novel Ibuprofen Formulation On Fever In Patients With An Uncomplicated Acute Infection",2,"LS mean difference",5.99,0.171,"ANOVA",-3.99,15.97,95,null,"NA","All",16,"Terminated","Phase 3","\t"]
["NCT01037218",4441766,8136935,"Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Derived Score, Subject Version, Week 12/Final Visit, LOCF, mITT","udenafil","Udenafil|Placebo","Drug|Drug","erectile dysfunction","Erectile Dysfunction","Parallel Assignment","Interventional","Treatment","Randomized","Treatment of Erectile Dysfunction II",4,"Difference in LS Means",27.01,{"v":1E-4,"d":"1.00E-04"},"ANOVA",21.44,32.59,95,null,"NA","Male",601,"Completed","Phase 3","\t"]
["NCT01040403",4441267,8136589,"Weekly Mean Number of Puffs of Rescue Medication Used Per Day","olodaterol|tiotropium bromide|bromides","olodaterol (BI 1744) low|low tiotropium bromide|olodaterol (BI 1744) high|medium tiotropium bromide|high tiotropium bromide|Placebo|Respimat","Drug|Drug|Drug|Drug|Drug|Drug|Device","lung diseases|pulmonary disease, chronic obstructive","Pulmonary Disease, Chronic Obstructive","Crossover Assignment","Interventional","Treatment","Randomized","Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)",8,"Mean Difference (Final Values)",0.073,"NA",null,-0.242,0.388,95,"Standard Error of the Mean",0.16,"All",233,"Completed","Phase 2","\t"]
["NCT01040403",4441467,8136605,"Trough Forced Vital Capacity (FVC) Response","olodaterol|tiotropium bromide|bromides","olodaterol (BI 1744) low|low tiotropium bromide|olodaterol (BI 1744) high|medium tiotropium bromide|high tiotropium bromide|Placebo|Respimat","Drug|Drug|Drug|Drug|Drug|Drug|Device","lung diseases|pulmonary disease, chronic obstructive","Pulmonary Disease, Chronic Obstructive","Crossover Assignment","Interventional","Treatment","Randomized","Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)",8,"Mean Difference (Final Values)",0.02,"NA",null,-0.039,0.079,95,"Standard Error of the Mean",0.03,"All",233,"Completed","Phase 2","\t"]
["NCT01040793",4441104,8136533,"Adjusted Mean Total Lung Capacity 30 Minutes Pre-dose After 6 Weeks","olodaterol","Olodaterol (BI 1744)|Olodaterol (BI 1744)|Placebo|Olodaterol (BI1744)|Olodaterol (BI 1744) placebo","Drug|Drug|Drug|Drug|Drug","pulmonary disease, chronic obstructive|lung diseases","Pulmonary Disease, Chronic Obstructive","Crossover Assignment","Interventional","Treatment","Randomized","Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II",3,"Mean Difference (Final Values)",0.029,0.608,"Mixed Models Analysis",-0.081,0.138,95,"Standard Error of the Mean",0.056,"All",157,"Completed","Phase 3","\t"]
["NCT01045993",4440952,8136064,"Individual Time-Point Pain Relief Scores","analgesics","Heat Device|Sham Device|marketed analgesic|Placebo","Device|Device|Drug|Drug","back pain","Pain","Parallel Assignment","Interventional","Treatment","Randomized","A Study To Evaluate Methods To Evaluate Back Pain",4,null,"NA",0.012,"ANOVA",{"$nulls":4},"NA","All",61,"Completed","N/A","\t"]
["NCT01050998",4440542,8135482,"Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20), ACR50 and ACR70 Responses at Day 85 by Region","antibodies, monoclonal|mavrilimumab","Mavrilimumab 10 mg|Mavrilimumab 30 mg|Mavrilimumab 50 mg|Mavrilimumab 100 mg|Placebo","Biological|Biological|Biological|Biological|Other","arthritis|arthritis, rheumatoid","Rheumatoid Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis",5,"Percent difference",17.3,0.026,"Fisher Exact",2.4,34.1,95,null,"NA","All",516,"Completed","Phase 2","\t"]
["NCT01050998",4440585,8135485,"Time to Onset for DAS28 (CRP) and DAS (ESR) Response and Remission by Region","antibodies, monoclonal|mavrilimumab","Mavrilimumab 10 mg|Mavrilimumab 30 mg|Mavrilimumab 50 mg|Mavrilimumab 100 mg|Placebo","Biological|Biological|Biological|Biological|Other","arthritis|arthritis, rheumatoid","Rheumatoid Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis",5,null,"NA",0.005,"Log Rank",{"$nulls":4},"NA","All",516,"Completed","Phase 2","\t"]
["NCT01052714",4440396,8135194,"Mean Body Mass Index (BMI) Change Per Week From Baseline to Termination","NA","Lifestyle Balance","Behavioral","obesity|body weight|weight gain","Diabetes|Obesity|Weight Gain","Crossover Assignment","Interventional","Treatment","Randomized","Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2",3,null,"NA",1E-3,"Mixed Models Analysis",{"$nulls":4},"NA","All",121,"Completed","N/A","\t"]
["NCT01061333",4439899,8134015,"Change in Forced Expiratory Volume in 1 Second (FEV1)","montelukast|mometasone furoate|nedocromil","Nedocromil|Comparator: Montelukast|Comparator: Mometasone|Placebo","Drug|Drug|Drug|Drug","asthma","Asthma","Crossover Assignment","Interventional","Treatment","Randomized","Early Airway Response to Allergen in Asthmatics (MK-0000-176)",4,"Difference in LS mean",16.22,{"v":1E-4,"d":"1.00E-04"},"ANCOVA",10.74,21.69,90,null,"NA","All",16,"Completed","Phase 1","\t"]
["NCT01062256",4439792,8133934,"Number of Cough Bouts Within Each 15-minute Time Interval Postdose","phenylpropanolamine|guaifenesin|chlorpheniramine, phenylpropanolamine drug combination","Placebo|Guaifenesin|Buckwheat Honey","Drug|Drug|Other","communicable diseases|respiratory tract infections|infection","Infection","Parallel Assignment","Interventional","Treatment","Randomized","Study of Count Coughs in Subjects With Acute Upper Respiratory Tract Infections",3,"Odds Ratio (OR)",0.85,0.371,"Poisson regression model",0.6,1.21,95,null,"NA","All",265,"Completed","N/A","\t"]
["NCT01064687",4439678,8133674,"Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)","dulaglutide|metformin|pioglitazone|exenatide","LY2189265|Exenatide|Placebo|Metformin|Pioglitazone","Drug|Drug|Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","A Study in Participants With Type 2 Diabetes Mellitus",4,"LS Mean Difference",-0.56,1E-3,"ANCOVA",-0.73,-0.39,95,null,"NA","All",978,"Completed","Phase 3","\t"]
["NCT01070329",4439219,8132927,"Change From Baseline in the Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) at Week 8","duloxetine hydrochloride","Duloxetine|Placebo","Drug|Drug","depressive disorder|depression|depressive disorder, major","Major Depressive Disorder","Parallel Assignment","Interventional","Treatment","Randomized","A Study in Depression and Associated Painful Physical Symptoms",2,"Mean Difference (Final Values)",-0.4,0.012,"Mixed Models Analysis",-0.72,-0.09,95,null,"NA","All",527,"Completed","Phase 4","\t"]
["NCT01075256",4438805,8132239,"Adjusted Mean Change From Baseline in Cold Water Sensitivity Pain Response on a VAS at Day 3","calcium|calcium, dietary","5% calcium sodium phosphosilicate toothpaste|7.5% calcium sodium phosphosilicate toothpaste|Placebo toothpaste","Device|Device|Device","dentin sensitivity|hypersensitivity","Dental Pain|Dentine Hypersensitivity","Parallel Assignment","Interventional","Treatment","Randomized","Dose Response of a Tubule Occlusion Agent",3,"Adjusted Mean Difference",-1.7,0.7575,"ANCOVA",-12.63,9.25,95,null,"NA","All",195,"Completed","Phase 4","\t"]
["NCT01077973",4438475,8131762,"Cumulative Percentage of Participants With Meaningful Relief","ibuprofen","Novel Ibuprofen|Standard Ibuprofen|Placebo","Drug|Drug|Drug","tension-type headache|headache","Pain","Parallel Assignment","Interventional","Treatment","Randomized","Study Evaluating A Novel Ibuprofen Formulation In Episodic Tension-Type Headache",3,"Difference in proportion",-7.52,0.427,"Cochran-Mantel-Haenszel",-25.96,10.92,95,null,"NA","All",200,"Completed","Phase 3","\t"]
["NCT01080300",4438326,8131358,"Clinical Global Impression of Change (CGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period.","gabapentin","Placebo|Gabapentin Extended Release","Drug|Drug","hot flashes","Hot Flashes","Parallel Assignment","Interventional","Treatment","Randomized","Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women",2,"Risk Difference (RD)",11,0.007,"2-sample Z test",3,19,95,null,"NA","Female",600,"Completed","Phase 3","\t"]
["NCT01082965",4438165,8131049,"Change From Baseline in Arterial Spin Label (ASL) Perfusion at Hour 4 on Day 1 and at Hour 0, 4 on Day 8","donepezil","Donepezil|Placebo","Drug|Drug","alzheimer disease","Alzheimer's Disease","Parallel Assignment","Interventional","Basic Science","Randomized","Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease",2,"LS Mean Difference",-0.32,0.0402,"Mixed Models Analysis",-0.62,-0.02,95,"Standard Error of the Mean",0.125,"All",18,"Terminated","N/A","\t"]
["NCT01094548",4437806,8129481,"Number of Participants With Overall Induced Mucinous Glycoprotein-1 (MUC-1)-Specific Immune Response","cyclophosphamide","Tecemotide (L-BLP25)|Tecemotide (L-BLP25)|Single low dose cyclophosphamide|Multiple low dose cyclophosphamide","Biological|Biological|Drug|Drug","neoplasms, plasma cell|multiple myeloma","Multiple Myeloma","Parallel Assignment","Interventional","Treatment","Randomized","Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy",2,null,"NA",1,"Fisher Exact",{"$nulls":4},"NA","All",34,"Completed","Phase 2","\t"]
["NCT01096680",4437660,8129279,"KSS Scores by Timepoint","modafinil|lisdexamfetamine dimesylate","SPD489 20 mg|SPD489 50 mg|SPD489 70 mg|Armodafinil|Placebo","Drug|Drug|Drug|Drug|Drug","sleep deprivation","Sleep Deprivation","Parallel Assignment","Interventional","Other","Randomized","Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss",5,"Mean Difference (Final Values)",-0.1,0.8358,"Mixed Models Analysis",-0.7,0.6,95,null,"NA","Male",135,"Completed","Phase 2","\t"]
["NCT01098747",4437248,8128879,"Cumulative Percentage of Participants With Treatment Failure","ibuprofen","Novel Ibuprofen|Standard Ibuprofen|Standard Ibuprofen|Placebo","Drug|Drug|Drug|Drug","toothache","Pain","Parallel Assignment","Interventional","Treatment","Randomized","Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain",4,"Difference in proportion",-66.58,1E-3,"Cochran-Mantel-Haenszel",-79.8,-53.35,95,null,"NA","All",335,"Completed","Phase 3","\t"]
["NCT01100307",4437183,8128749,"Change From Baseline in Visual Acuity (VA): Double Masked Phase","NA","pegaptanib sodium|sham injection","Drug|Other","edema|retinal diseases|macular edema","Diabetic Mellitus|Macular Edema|Retinal Disease","Parallel Assignment","Interventional","Treatment","Randomized","A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema",2,"Mean Difference (Final Values)",4.26,{"v":1E-4,"d":"1.00E-04"},"ANCOVA",2.19,6.32,95,null,"NA","All",243,"Completed","Phase 3","\t"]
["NCT01102777",4437070,8128468,"Self-Reported Respiratory-Specific Quality of Life","NA","automated internet-mediated walking program|Usual Care","Behavioral|Other","pulmonary disease, chronic obstructive|lung diseases, obstructive|lung diseases","Chronic Obstructive Pulmonary Disease (COPD)","Parallel Assignment","Interventional","Health Services Research","Randomized","Stepping up to Health - for Veterans With Chronic Obstructive Pulmonary Disease (COPD)",2,null,"NA",0.502,"Mixed Models Analysis",{"$nulls":4},"NA","All",307,"Completed","N/A","\t"]
["NCT01106651",4436904,8127947,"Percent Change in Lumbar Spine Bone Mineral Density (BMD) From Baseline to Week 26","hypoglycemic agents|canagliflozin","Canagliflozin 100 mg|Canagliflozin 300 mg|Antihyperglycemic agent(s)|Placebo","Drug|Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus",3,"Least-Squares Mean Difference",0.2,"NA",null,-0.4,0.8,95,"Standard Error of the Mean",0.3,"All",716,"Completed","Phase 3","\t"]
["NCT01112735",4436476,8127188,"Change From Baseline in Postoperative Skin Sensitivity 1 Inch Below Umbilicus","fibrin tissue adhesive","FS VH S/D 4 s-apr (= two-component fibrin sealant, double virus inactivated, made from pooled human plasma)|Standard of care","Biological|Procedure","seroma|hematoma","Hematoma|Seroma","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of ARTISS for Flap Adherence in Abdominoplasty",2,null,"NA",0.9699,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",40,"Completed","Phase 2","\t"]
["NCT01115452",4436352,8126849,"Between Treatment Comparison of the Adjusted Mean Change From Baseline of Response to Evaporative (Air) Stimuli Immediately Following Treatment on Day 3 Using a VAS","NA","5% Potassium nitrate|2.5% Potassium nitrate|Sterile water","Drug|Drug|Other","dentin sensitivity|hypersensitivity","Dentine Hypersensitivity","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy of Potassium Nitrate Solution in Reducing Dentinal Hypersensitivity",3,"Adjusted mean difference",0.32,0.9428,"ANCOVA",-8.37,9,95,null,"NA","All",32,"Completed","Phase 2","\t"]
["NCT01115855",4436123,8126738,"Change From Baseline in Urine Albumin-to-Creatinine Ratio at Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48 and Final Visit","eplerenone","Eplerenone|Placebo","Drug|Drug","heart failure","Heart Failure","Parallel Assignment","Interventional","Treatment","Randomized","Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure",2,"Least Square Mean Difference",-24.94,"NA",null,-131.27,81.39,95,"Standard Error of the Mean",54.2,"All",221,"Completed","Phase 3","\t"]
["NCT01119846",4435681,8126166,"Part C: Summary of Change From Baseline in Fasted Insulin","sitagliptin phosphate","GSK1292263|GSK1292263 matching placebo|Sitagliptin","Drug|Drug|Drug","diabetes mellitus, type 2","Diabetes Mellitus, Type 2","Crossover Assignment","Interventional","Other","Randomized","A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics",3,"Mean Difference (Net)",-151.722,"NA",null,-295.98,-7.46,95,null,"NA","All",100,"Completed","Phase 2","\t"]
["NCT01119846",4435805,8126174,"Part A: Summary of the AUC 0-12 and iAUC 0-12 of Glucagon, Glucagon-like Peptide (GLP; Active and Total)-1, C-peptide, Total Glucose-dependent Insulinotropic Peptide (GIP) and Total Peptide Tyrosine-tyrosine (PYY) and AUC 0-13 and iAUC 0-13 of Insulin","sitagliptin phosphate","GSK1292263|GSK1292263 matching placebo|Sitagliptin","Drug|Drug|Drug","diabetes mellitus, type 2","Diabetes Mellitus, Type 2","Crossover Assignment","Interventional","Other","Randomized","A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics",3,"Mean Difference (Final Values)",4.999,"NA",null,-1.87,11.87,95,null,"NA","All",100,"Completed","Phase 2","\t"]
["NCT01120405",4435577,8125946,"Number of Participants With Cardiac Troponin I or T Above the 99th Percentile (Local Laboratories)","sevoflurane","Xenon|Sevoflurane","Drug|Drug","coronary artery disease","Coronary Arteries Disease Risk|Elevated Cardiac Risk","Parallel Assignment","Interventional","Screening","Randomized","Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery",2,"Difference of proportion",0.68,0.7715,"Difference of proportion",-3.9,5.25,95,null,"NA","All",600,"Completed","Phase 3","\t"]
["NCT01125358",4435206,8125112,"Clinical Utility Index (CUI)","NA","LY2140023|Placebo","Drug|Drug","schizophrenia","Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","A Study in Schizophrenic Patients",4,"LS Mean Differences",-2.02,"NA",null,-3.37,0,90,null,"NA","All",200,"Terminated","Phase 2","\t"]
["NCT01126580",4435017,8124936,"Change From Baseline to 26 and 52 Weeks in Fasting Blood Glucose","metformin|dulaglutide","Metformin|LY2189265|Placebo (oral)|Placebo (subcutaneous)","Drug|Drug|Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)",3,null,"NA",0.079,"Mixed Models Analysis",{"$nulls":4},"NA","All",807,"Completed","Phase 3","\t"]
["NCT01131260",4433958,8124294,"Number of Infants With Umbilical-artery Blood pH < = 7.05 and Base Deficit in Extracellular Fluid > = 12 mmol/Liter (Primary Outcome Component)","NA","fetal STAN monitor","Device","NA","Obstetric Labor|Parturition|Pregnancy","Parallel Assignment","Interventional","Prevention","Randomized","Fetal ST Segment and T Wave Analysis in Labor",2,"Risk Ratio (RR)",0.37,0.13,"Chi-squared",0.1,1.41,95,null,"NA","Female",11108,"Completed","N/A","\t"]
["NCT01136655",4433784,8123597,"Average 12 Hour Forced Expiratory Volume in 1 Second (FEV1)","formoterol fumarate|budesonide, formoterol fumarate drug combination|budesonide","80/2.25 μg Symbicort pMDI|80/4.5 μg Symbicort pMDI|Foradil Aerolizer 12 μg|40 μg budesonide HFA pMDI|placebo HFA pMDI","Drug|Drug|Drug|Drug|Drug","NA","Asthma","Crossover Assignment","Interventional","Treatment","Randomized","A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy",5,"LS mean difference",-0.114,{"v":1E-4,"d":"1.00E-04"},"ANCOVA",-0.142,-0.086,95,"Standard Error of the Mean",0.0141,"All",54,"Completed","Phase 2","\t"]
["NCT01139775",4433529,8123186,"Phase 2: Clinical Benefit Rate: Percentage of Participant Who Achieved a Response of Stable Disease (SD), Partial Response (PR), or Complete Response (CR)","pemetrexed","Pemetrexed|Cisplatin|LY2603618","Drug|Drug|Drug","lung neoplasms|carcinoma, non-small-cell lung","Non Small Cell Lung Cancer","Parallel Assignment","Interventional","Treatment","Randomized","A Study in Non Small Cell Lung Cancer",3,null,"NA",0.0946,"Chi-squared",{"$nulls":4},"NA","All",76,"Completed","Phase 1/Phase 2","\t"]
["NCT01145391",4433383,8122554,"Blood Pressure","NA","Active Outreach to Patients and Providers","Other","hypertension","Hypertension","Parallel Assignment","Interventional","Health Services Research","Randomized","Reducing Clinical Inertia in Hypertension Treatment: A Pragmatic Trial",2,null,"NA",0.5,"Mixed Models Analysis",{"$nulls":4},"NA","All",591,"Completed","N/A","\t"]
["NCT01147744",4433187,8122255,"Number of Participants Who Withdrew Due to Lack of Efficacy During the 8-Week Treatment Period","montelukast|fluticasone","Fluticasone Propionate 100mcg via ACCUHALER/DISKUS|GSK2190915 100mg|GSK2190915 10mg|GSK2190915 300mg|GSK2190915 30mg|Montelukast 10mg|Placebo GSK2190915 one tablet|Placebo montelukast|Placebo fluticasone propionate via ACCUHALER/DISKUS|Placebo GSK2190915 two tablets","Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug","asthma","Asthma","Parallel Assignment","Interventional","Treatment","Randomized","Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily",7,null,"NA",1,"Fisher Exact",{"$nulls":4},"NA","Female",700,"Completed","Phase 2","\t"]
["NCT01149421",4433046,8121900,"Change From Baseline to 16 and 26 Weeks in Mean 24-hour Diastolic Blood Pressure (DBP)","dulaglutide","LY2189265|Placebo","Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes",3,"Least Squares Mean Difference",0.42,1E-3,"Mixed Models Analysis",-0.67,1.52,97.3,null,"NA","All",755,"Completed","Phase 2","\t"]
["NCT01152450",4432812,8121539,"FEV1 Area Under the Curve 12-24 Hours (AUC12-24h) Response","tiotropium bromide","Tiotropium 2.5 µg b.i.d|Placebo|Tiotropium 5 µg q.d.","Drug|Drug|Drug","asthma","Asthma","Crossover Assignment","Interventional","Treatment","Randomized","A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma",3,"Mean Difference (Final Values)",0.129,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",0.077,0.181,95,"Standard Error of the Mean",0.026,"All",94,"Completed","Phase 2","\t"]
["NCT01154140",4432563,8121127,"Change From Baseline in Lung Cancer Symptom Scores as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 (QLQ- LC13)","NA","treatment|treatment","Drug|Drug","lung neoplasms","Non Squamous Lung Cancer","Parallel Assignment","Interventional","Treatment","Randomized","A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung",2,"Mean Difference (Net)",-4.8149,0.0108,"Mixed Models Analysis",-8.52,-1.11,95,null,"NA","All",343,"Completed","Phase 3","\t"]
["NCT01160198",4432157,8120403,"Percentage of Participants Who Achieved a Target Hb More Than or Equal to 12 gm/dL After 8 Weeks of Treatment","ascorbic acid|chelating agents|glycine","ferrous ascorbate|ferrous bisglycinate chelate 1 OD|ferrous bisglycinate chelate 2 OD","Drug|Dietary Supplement|Dietary Supplement","anemia, iron-deficiency","Haematopoiesis","Parallel Assignment","Interventional","Other","Randomized","A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.",3,null,"NA",0.7,"Chi-squared",{"$nulls":4},"NA","Female",271,"Completed","Phase 3","\t"]
["NCT01162122",4431924,8120129,"Comparison of aTIV Versus TIV in Terms of Percentage of Subjects Achieving Seroconversion Against Heterologous Strains-FAS","vaccines","MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)|Non-adjuvanted trivalent subunit influenza vaccine (TIV)","Biological|Biological","influenza, human","Influenza","Parallel Assignment","Interventional","Prevention","Randomized","Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects","NA","Group difference (B strain-overall)",4.6,"NA",null,0.4,8.8,95,null,"NA","All","NA",null,null,"\t"]
["NCT01162421",4431849,8120089,"Change From Baseline in CRP at Months 3, 6, 9, 12, 18 and 24","adalimumab|methotrexate","adalimumab|Methotrexate","Biological|Drug","arthritis|arthritis, rheumatoid","Rheumatoid Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis",2,"LS Mean Difference",0.2,0.967,"ANCOVA",-7.7,8,95,"Standard Error of the Mean",3.95,"All",77,"Completed","Phase 4","\t"]
["NCT01164579",4431545,8119752,"Disease Activity Score Based on 28-Joint Count and Erythrocyte Sedimentation Rate (DAS28-4 [ESR])","methotrexate|tofacitinib","Tasocitinib plus Methotrexate|Tofacitinib plus placebo methotrexate|Placebo tofacitinib plus Methotrexate","Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Rheumatoid Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)",3,"Mean Difference (Final Values)",-1.28,"NA",null,-1.82,-0.73,90,null,"NA","All",109,"Completed","Phase 2","\t"]
["NCT01166282",4431370,8119482,"Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 70% Response (ACR Pedi70)","adalimumab","adalimumab|placebo for adalimumab","Biological|Biological","arthritis, juvenile|enthesopathy|arthritis","Enthesitis Related Arthritis (ERA)","Parallel Assignment","Interventional","Treatment","Randomized","A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis",3,"Mean Difference (Final Values)",34.8,0,"Fisher Exact",8.1,61.6,95,null,"NA","All",46,"Completed","Phase 3","\t"]
["NCT01172938",4431085,8118605,"Change From Baseline in Patient's Assessment of Pain at Week 24","thalidomide|apremilast","Apremilast 20mg|Apremilast 30mg|Placebo + 20 mg Apremilast|Placebo + 30 mg Apremilast","Drug|Drug|Drug|Drug","arthritis, psoriatic|arthritis","Psoriatic Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis",4,"Adjusted Difference",-10.6,"NA",null,-15.4,-5.7,95,null,"NA","All",504,"Completed","Phase 3","\t"]
["NCT01175382",4430903,8118221,"Change in International Prostate Symptom Score (I-PSS) From Baseline to 6 Weeks. (Last Observation Carried Forward)","tamsulosin|tolterodine tartrate","Behavioral training|Tolterodine + tamsulosin|Combined Behavioral + Drug Therapy","Behavioral|Drug|Other","lower urinary tract symptoms|urinary bladder, overactive","Lower Urinary Tract Symptoms|Overactive Bladder","Parallel Assignment","Interventional","Treatment","Randomized","Combined Behavioral and Drug Treatment of Overactive Bladder in Men",3,null,"NA",{"v":1E-4,"d":"1.00E-04"},"ANCOVA",{"$nulls":4},"NA","Male",204,"Completed","Phase 2/Phase 3","\t"]
["NCT01177137",4430796,8117954,"Change in Tinnitus Questionnaire Sleep Disturbance Sub-scale Scores.","NA","Conventional sound generator (SG)|Placebo sound generator (placebo SG)|Standard of Care (SC)|Directive Counseling (DC)|Directive Counseling (DC)","Device|Device|Behavioral|Behavioral|Behavioral","tinnitus","Subjective Tinnitus","Parallel Assignment","Interventional","Treatment","Randomized","Tinnitus Retraining Therapy Trial",3,"Slope",-0.87,0.015,"repeated measures GEE model",-1.56,-0.17,95,"Standard Error of the Mean",0.35,"All",151,"Completed","Phase 3","\t"]
["NCT01179672",4430598,8117546,"Percentage of Participants Who Experience Equal to or Greater Than 30%, 50% or 75% Reduction From Baseline at 12-Week Endpoint in Weekly Mean of Average Daily Pain","duloxetine hydrochloride","Duloxetine|Placebo","Drug|Drug","diabetic neuropathies|neuralgia","Diabetic Neuropathy, Painful","Parallel Assignment","Interventional","Treatment","Randomized","A Study in Participants With Diabetic Peripheral Neuropathic Pain in China",2,null,"NA",0.014,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",405,"Completed","Phase 3","\t"]
["NCT01186744",4430173,8116711,"Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)","tofacitinib","CP-690,550|CP-690,550|CP-690,550|CP-690,550","Drug|Drug|Drug|Drug","psoriasis","Psoriasis","Parallel Assignment","Interventional","Treatment","Randomized","A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis",4,null,"NA",0.0027,"Log Rank",{"$nulls":4},"NA","All",666,"Completed","Phase 3","\t"]
["NCT01191944",4429934,8115633,"Change From Baseline in Duration of On-time Without or With Non-troublesome Dyskinesia at Week 18","pramipexole","pramipexole immediate release tablet|pramipexole extended release tablet","Drug|Drug","parkinson disease","Parkinson Disease","Parallel Assignment","Interventional","Treatment","Randomized","Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients",2,"Mean Difference (Final Values)",0.031,0.9337,"ANCOVA",-0.704,0.766,95,"Standard Error of the Mean",0.3727,"All",475,"Completed","Phase 3","\t"]
["NCT01193218",4429588,8115329,"Change From Baseline in HbA1c After 12 Weeks of Treatment.","empagliflozin","Placebo (low dose)|Placebo (low dose)|Placebo (mid dose)|Placebo (high dose)|BI 10773|Placebo (mid dose)|Placebo (high dose)|Placebo (high dose)|BI 10773|BI 10773|Placebo (mid dose)|Placebo (high dose)|Placebo (low dose)|Placebo (low dose)|BI 10773|Placebo (mid dose)","Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus",5,"Mean Difference (Final Values)",-0.72,{"v":1E-4,"d":"1.00E-04"},"ANCOVA",-0.87,-0.57,95,"Standard Error of the Mean",0.08,"All",547,"Completed","Phase 2","\t"]
["NCT01193335",4429476,8115258,"Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Persistence 1 Year After Toddler Dose","heptavalent pneumococcal conjugate vaccine|vaccines","13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine","Biological|Biological","premature birth","13-valent Pneumococcal Vaccine|Immunization|Premature Birth|Safety","Parallel Assignment","Interventional","Prevention","Randomized","Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.",2,"GMC Ratio",0.83,"NA",null,0.61,1.12,95,null,"NA","All",200,"Completed","Phase 4","\t"]
["NCT01197521",4429003,8114537,"HAQ-DI Response - Comparison of the Change (>=0.22) From Baseline Between Fostamatinib and Placebo at Week 24","NA","fostamatinib|fostamatinib|placebo, fostamatinib","Drug|Drug|Drug","arthritis, rheumatoid|arthritis","Rheumatoid Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.",3,"Odds Ratio (OR)",1.9,1E-3,"Regression, Logistic",1.38,2.68,95,null,"NA","All",923,"Completed","Phase 3","\t"]
["NCT01200368",4428816,8114143,"Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Toddler Dose","heptavalent pneumococcal conjugate vaccine|vaccines","13-valent pneumococcal conjugate vaccine (13vPnC)|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|7-valent pneumococcal conjugate vaccine (7vPnC)|DTaP|DTaP","Biological|Biological|Biological|Biological|Biological","NA","Healthy Subjects","Parallel Assignment","Interventional","Prevention","Randomized","Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants",3,"GMC ratio",1.85,"NA",null,1.54,2.24,95,null,"NA","All",551,"Completed","Phase 3","\t"]
["NCT01207219",4428635,8113280,"Verbal Acquisition","NA","Yoga therapy|Aerobic exercise","Behavioral|Behavioral","mental disorders|psychotic disorders","Psychotic Disorder","Parallel Assignment","Interventional","Treatment","Randomized","Yoga and Aerobic Exercise in Psychosis",3,null,"NA",0.01,"Mixed Models Analysis",{"$nulls":4},"NA","Female",140,"Completed","N/A","\t"]
["NCT01212445",4428401,8112605,"Percentage of Participants With Successful Bowel Movement (BM) Within 24 Hours of PEG + E Administration","polyethylene glycol 3350|laxatives","PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)","Drug","constipation","Constipation","Parallel Assignment","Interventional","Treatment","Randomized","Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)",3,"Treatment Success Rate",0.196,0.2558,"Fisher Exact",0.098,0.331,95,null,"NA","All",154,"Completed","Phase 2","\t"]
["NCT01214239",4428195,8112283,"Number With HbA1c at Least Lowering 0.5%","linagliptin","Placebo|Linagliptin","Drug|Drug","diabetes mellitus, type 2","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control",2,"Odds Ratio (OR)",2.527,{"v":0.0005,"d":"5.00E-04"},"Regression, Logistic",1.494,4.276,95,null,"NA","All",300,"Completed","Phase 3","\t"]
["NCT01216163",4427860,8111910,"Cumulative Percentage of Participants With Confirmed First Perceptible Relief","ibuprofen|acetaminophen","Novel Ibuprofen|Acetaminophen|Placebo","Drug|Drug|Drug","toothache","Pain","Parallel Assignment","Interventional","Treatment","Randomized","Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain",3,"Difference in proportion",66.44,1E-3,"Cochran-Mantel-Haenszel",53.38,79.51,95,null,"NA","All",218,"Completed","Phase 3","\t"]
["NCT01217073",4427778,8111785,"Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event During the 66-week Extension Period","metformin|pioglitazone","Omarigliptin|Placebo to omarigliptin|Pioglitazone|Metformin|Placebo to metformin","Drug|Drug|Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Type 2 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)",8,"Difference in percent",-1.4,"NA",null,-9.1,2.6,95,null,"NA","All",685,"Completed","Phase 2","\t"]
["NCT01217112",4427712,8111763,"The Change From Baseline in Mean Serum Apolipoprotein B : Apolipoprotein A Ratio After 91 Days (13 Weeks) of Treatment","epidiolex","GWP42003|GWP42003|GWP42004|Placebo","Drug|Drug|Drug|Drug","diabetes mellitus|diabetes mellitus, type 2|dyslipidemias","Diabetes Mellitus, Type 2|Dyslipidemias","Parallel Assignment","Interventional","Treatment","Randomized","GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes",5,"Mean Difference (Final Values)",-0.1,0.075,"ANCOVA",-0.2,-0.01,90,"Standard Error of the Mean",0.056,"All",62,"Completed","Phase 2","\t"]
["NCT01218126",4427473,8111562,"Least Square Mean Ratio to Baseline of Plasma Fibrinogen Over 24 Weeks","NA","losmapimod|placebo","Drug|Drug","lung diseases|lung diseases, obstructive|pulmonary disease, chronic obstructive","Pulmonary Disease, Chronic Obstructive","Parallel Assignment","Interventional","Treatment","Randomized","Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).",4,"Mean Difference (Net)",0.95,0.126,"mixed model repeated measures",0.9,1.01,95,null,"NA","All",604,"Completed","Phase 2","\t"]
["NCT01218204",4427457,8111523,"Percent Change From Baseline for Lipid Metabolism: Apolipoprotein A1 and Apolipoprotein B100 at Day 14","ezetimibe|atorvastatin","10mg atorvastatin|80mg atorvastatin|GSK1292263 Placebo|100mg GSK1292263|300mg GSK1292263|800mg GSK1292263|10mg ezetimibe|Washout","Drug|Drug|Drug|Drug|Drug|Drug|Drug|Other","dyslipidemias","Dyslipidaemias|Dyslipidemias","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin",16,"Mean Difference (Net)",5.473,"NA",null,-15.7096,26.6553,95,null,"NA","All",287,"Completed","Phase 2","\t"]
["NCT01222247",4427206,8110968,"Number of Infants With Neonatal Sepsis","betamethasone","Betamethasone|Placebo","Drug|Drug","respiratory distress syndrome, newborn|respiratory distress syndrome, adult|premature birth","Pregnancy|Pregnancy Outcomes|Preterm Birth|Respiratory Distress Syndrome","Parallel Assignment","Interventional","Prevention","Randomized","Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial",2,"Risk Ratio (RR)",0.8,0.62,"Chi-squared",0.33,1.93,95,null,"NA","Female",2831,"Active, not recruiting","Phase 3","\t"]
["NCT01227564",4426824,8110356,"Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score","saponin qa-21v1","ACC-001 3 μg/ QS-21 50 μg|ACC-001 10 μg/ QS-21 50 μg|Placebo- Phosphate buffered saline (PBS)","Biological|Biological|Other","alzheimer disease","Alzheimer's Disease","Parallel Assignment","Interventional","Treatment","Randomized","Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease",3,"Mean Difference (Final Values)",-4.26,0.0057,"Mixed-Effects Model Repeated Measures",-7.23,-1.29,95,null,"NA","All",63,"Completed","Phase 2","\t"]
["NCT01227564",4426960,8110368,"Change From Baseline in CSF Aβ x-42","saponin qa-21v1","ACC-001 3 μg/ QS-21 50 μg|ACC-001 10 μg/ QS-21 50 μg|Placebo- Phosphate buffered saline (PBS)","Biological|Biological|Other","alzheimer disease","Alzheimer's Disease","Parallel Assignment","Interventional","Treatment","Randomized","Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease",3,"Mean Difference (Final Values)",24.16,0.5818,"ANCOVA",-63.31,111.62,95,null,"NA","All",63,"Completed","Phase 2","\t"]
["NCT01234649",4426519,8109395,"Insulinogenic Index (IGI) /HOMA-IR","liraglutide|metformin","Metformin XR plus placebo|Metformin XR plus liraglutide","Drug|Drug","metabolic syndrome|diabetes mellitus|diabetes mellitus, type 2|diabetes, gestational|glucose intolerance","Disorder of Glucose Regulation|Gestational Diabetes Mellitus|Impaired Glucose Tolerance|Metabolic Syndrome|Type 2 Diabetes Mellitus","Parallel Assignment","Interventional","Prevention","Randomized","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",2,null,"NA",0.05,"ANOVA",{"$nulls":4},"NA","Female",153,"Completed","Phase 3","\t"]
["NCT01235962",4426380,8109154,"Health-related Quality of Life (HRQoL) With Pazopanib 600 mg Daily Initial Dose vs. Placebo Assessed Using NCCN/Functional Assessment of Cancer Therapy-Kidney Symptom Index -19 (FACT FKSI-19) Total Score","NA","pazopanib|placebo|pazopanib|placebo","Drug|Drug|Drug|Drug","carcinoma, renal cell|carcinoma","Cancer|Renal Cell Carcinoma (RCC)","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)","NA","Mean Difference (24M DFS FU)",-0.043,0.93,"analysis of covariance",-1.003,0.917,95,null,"NA","All","NA",null,null,"\t"]
["NCT01241552",4425707,8108464,"Percentage of Participants Who Discontinued Study Medication Due to an AE During 4 Weeks Following Infusion","antibodies, monoclonal","MK-3415|MK-6072|MK-3415A|Placebo|SOC","Biological|Biological|Biological|Biological|Drug","clostridium infections|enterocolitis, pseudomembranous|infection|communicable diseases","Clostridium Difficile Infection","Parallel Assignment","Interventional","Treatment","Randomized","A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",4,"Percentage Difference",0.3,0.311,"Miettinen and Nurminen",-0.7,1.4,95,null,"NA","All",1452,"Completed","Phase 3","\t"]
["NCT01243151",4425591,8108298,"Change From Baseline in Lipid Parameters: Apolipoprotein A1 (ApoA1) at Day 8, 15, 22, 29 and 78","bococizumab","PF-04950615 (RN316)|PF-04950615 (RN316)|PF-04950615 (RN316)|PF-04950615 (RN316)|PF-04950615 (RN316)","Biological|Biological|Biological|Biological|Biological","hypercholesterolemia|dyslipidemias","Dyslipidemia|Hypercholesterolemia","Parallel Assignment","Interventional","Treatment","Randomized","Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia",5,"LS Mean Difference",6.05,0.2563,"ANCOVA",-4.51,16.61,95,"Standard Error of the Mean",5.277,"All",68,"Completed","Phase 1","\t"]
["NCT01244815",4425253,8108022,"Change From Baseline in CDRS-R Total Score at Day 14","asenapine","asenapine|Placebo to match asenapine|Rescue medication","Drug|Drug|Drug","disease|bipolar disorder","Bipolar Disorder, Pediatric","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)",4,"Difference in LS Means",-2.44,0.009,"MMRM",-4.26,-0.63,95,null,"NA","All",404,"Completed","Phase 3","\t"]
["NCT01248780",4425060,8107498,"American College of Rheumatology (ACR) 20 Response, Using CRP (C-reactive Protein), at Week 14","methotrexate","Golimumab|Placebo|Methotrexate (MTX)","Drug|Drug|Drug","arthritis, rheumatoid|arthritis","Rheumatoid Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy",2,null,"NA",1E-3,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",264,"Completed","Phase 3","\t"]
["NCT01255592",4424690,8106323,"Change From Baseline Total and Domain Scores in St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C)","NA","AZD5069|Placebo","Drug|Drug","lung diseases|respiration disorders|bronchiectasis|respiratory tract diseases","Bronchiectasis|Lung Disease|Respiratory Diseases","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis",2,"LS mean difference",-4.88,0.151,"ANCOVA",-10.49,0.74,90,"Standard Error of the Mean",3.342,"All",83,"Completed","Phase 2","\t"]
["NCT01258075",4424520,8105965,"Percent Change in Hemoglobin A1c (HbA1c) From Baseline to Month 6","colesevelam hydrochloride","High-dose colesevelam|Low-dose colesevelam","Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Type 2 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","Colesevelam for Children With Type 2 Diabetes",2,"LS mean difference",-0.13,0.5494,"ANCOVA",-0.54,0.29,95,"Standard Error of the Mean",0.21,"All",236,"Completed","Phase 4","\t"]
["NCT01258738",4424272,8105838,"Change From Baseline in EQ-5D Health State Profile Utility Score at Time Points","anti-inflammatory agents, non-steroidal|etanercept","etanercept|Background NSAID|PLACEBO|Background NSAID","Biological|Drug|Other|Drug","spondylarthritis|spondylitis, ankylosing|spondylitis","Spondylitis, Ankylosing","Parallel Assignment","Interventional","Treatment","Randomized","Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes",2,"Mean Difference (Final Values)",0.05,0.1341,"ANCOVA",-0.02,0.21,95,null,"NA","All",225,"Completed","Phase 3","\t"]
["NCT01258738",4424436,8105875,"Mean Change From Baseline in BASFI Getting Out of an Arm-less Chair at Time Points","anti-inflammatory agents, non-steroidal|etanercept","etanercept|Background NSAID|PLACEBO|Background NSAID","Biological|Drug|Other|Drug","spondylarthritis|spondylitis, ankylosing|spondylitis","Spondylitis, Ankylosing","Parallel Assignment","Interventional","Treatment","Randomized","Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes",2,"Mean Difference (Final Values)",-0.52,0.0659,"ANCOVA",-1.07,0.03,95,null,"NA","All",225,"Completed","Phase 3","\t"]
["NCT01262872",4423938,8105316,"Number of Subjects With Non-vaccine Serotypes of Streptococcus Pneumoniae (S. pn.) in the Nasopharynx - For Cohort 2/Step 2, Subjects Receiving the 3+0 Schedule","vaccines|heptavalent pneumococcal conjugate vaccine","Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Synflorix™|Prevnar13™|Tritanrix™-HepB/Hib|Polio Sabin™|M-Vac™|Stamaril™","Biological|Biological|Biological|Biological|Biological|Biological|Biological|Biological","streptococcal infections","Infections, Streptococcal","Parallel Assignment","Interventional","Prevention","Randomized","Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants",8,"VE",4.5,"NA",null,-21.4,25,95,null,"NA","All",1320,"Completed","Phase 2","\t"]
["NCT01263197",4423872,8105127,"Maximum, Minimum and Average Changes in Heart Rate","propranolol|albuterol|phenylethyl alcohol","LY2216684|albuterol|propranolol|placebo for LY2216684|placebo for albuterol|placebo for propranolol","Drug|Drug|Drug|Drug|Drug|Drug","depressive disorder|depressive disorder, major","Major Depressive Disorder","Crossover Assignment","Interventional","Treatment","Randomized","A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol",6,"LS mean difference",2.2,"NA",null,-2.15,6.56,95,null,"NA","All",48,"Completed","Phase 1","\t"]
["NCT01263470",4423675,8105088,"Change From Baseline in Fasting C-peptide (Week 2).","voglibose|alogliptin","Alogliptin|Alogliptin|Alogliptin|Alogliptin|Voglibose|Placebo","Drug|Drug|Drug|Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan",6,"Mean Difference (Final Values)",2E-3,"NA",null,-0.241,0.245,95,null,"NA","All",480,"Completed","Phase 2","\t"]
["NCT01263496",4423539,8105053,"Change From Baseline in Glycosylated Hemoglobin (Week 44).","voglibose|alogliptin","Alogliptin|Alogliptin|Alogliptin|Alogliptin|Voglibose","Drug|Drug|Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Type 2 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan",5,"Mean Difference (Final Values)",-0.36,"NA",null,-0.608,-0.113,95,null,"NA","All",438,"Completed","Phase 2","\t"]
["NCT01265498",4423267,8104792,"Hepatocellular Ballooning: Change in Score","chenodeoxycholic acid","obeticholic acid|placebo","Drug|Drug","fatty liver|liver diseases|non-alcoholic fatty liver disease","Nonalcoholic Fatty Liver Disease (NAFLD)|Nonalcoholic Steatohepatitis (NASH)","Parallel Assignment","Interventional","Treatment","Randomized","The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)",2,"Mean Difference (Net)",-0.2,0.03,"ANCOVA",-0.5,0,95,null,"NA","All",283,"Completed","Phase 2","\t"]
["NCT01270139",4423021,8104153,"Per Cent of Fibrous Component","NA","Transplantation of nanoparticles|Transplantation of iron-bearing nanoparticles|Stenting","Procedure|Procedure|Device","atherosclerosis|angina, stable|coronary artery disease","Atherosclerosis|Heart Failure|Multivessel Coronary Artery Disease|Stable Angina","Parallel Assignment","Interventional","Treatment","Randomized","Plasmonic Nanophotothermal Therapy of Atherosclerosis",3,null,"NA",0.05,"ANOVA",{"$nulls":4},"NA","All",180,"Completed","N/A","\t"]
["NCT01275131",4422680,8103494,"Early Insulin Exposure (%AUC[0-60]), Stage 1","insulin aspart","Insulin aspart|Recombinant human hyaluronidase PH20 (rHuPH20)","Drug|Drug","diabetes mellitus, type 1|diabetes mellitus","Type 1 Diabetes Mellitus","Crossover Assignment","Interventional","Basic Science","Randomized","Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)",4,"Least Squares Mean Difference",13.95,{"v":0.0009,"d":"9.00E-04"},"Mixed Models Analysis",7.37,20.54,90,null,"NA","All",45,"Completed","Phase 1","\t"]
["NCT01276847",4422510,8103172,"Change From Baseline in Gene Expression Score for Interleukin 17 (IL-17) in Psoriatic Lesions of Participants Treated With Etanercept","ustekinumab|etanercept","Ustekinumab|Etanercept","Drug|Drug","psoriasis","Psoriasis","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)",3,null,"NA",0.098,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",40,"Completed","Phase 1","\t"]
["NCT01280591",4422351,8102850,"Karolinska Sleep Diary - Sufficient Sleep","naproxen","Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|Naproxen sodium 440 mg (BAYH6689)|DPH 50 mg","Drug|Drug|Drug|Drug","pain, postoperative","Pain, Postoperative","Parallel Assignment","Interventional","Treatment","Randomized","Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain",4,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",712,"Completed","Phase 3","\t"]
["NCT01285310",4422098,8102244,"Percentage Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24","thalidomide|apremilast","Apremilast 30 mg|Apremilast 20 mg|Placebo","Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Rheumatoid Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis",3,"Difference in LS Means",1.57,"NA",{"$nulls":5},"NA","All",237,"Terminated","Phase 2","\t"]
["NCT01287897",4421923,8101790,"The CDAI Remission Rate Over Time in Participants Who Received Placebo, PF-04236921 10 mg and PF-04236921 50 mg","NA","PF-04236921 SC injection|PF-04236921 SC injection|PF-04236921 SC injection","Drug|Drug|Drug","crohn disease","Crohn's Disease","Parallel Assignment","Interventional","Treatment","Randomized","A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy",3,"Mean Difference (Final Values)",8,0.0498,"GLMM",0,16,90,"Standard Error of the Mean",4.9,"All",250,"Completed","Phase 2","\t"]
["NCT01288443",4421870,8101744,"Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis","antibodies, monoclonal|atorvastatin","Alirocumab|Placebo (for alirocumab)|Atorvastatin","Drug|Drug|Drug","hypercholesterolemia","Hypercholesterolemia","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy",6,null,"NA",{"v":1E-4,"d":"1.00E-04"},"ANCOVA",{"$nulls":4},"NA","All",183,"Completed","Phase 2","\t"]
["NCT01294163",4421460,8101063,"Log-transformed Blood Level of Troponin I","sevoflurane|propofol","Xenon|Sevoflurane|Propofol","Drug|Drug|Drug","myocardial ischemia|coronary artery disease|coronary disease|drug hypersensitivity","Coronary Artery Bypass Graft Surgery|Coronary Artery Disease|General Anesthetic Drug Allergy","Parallel Assignment","Interventional","Treatment","Randomized","Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery",3,"Mean Difference (Final Values)",-0.09,0.0186,"ANCOVA",-0.3,0.11,95,null,"NA","All",509,"Completed","Phase 3","\t"]
["NCT01301456",4421045,8099955,"Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2","NA","Placebo|PF-04856883|PF-04856883|PF-04856883|Placebo|PF-04856883|PF-04856883|PF-04856883|Placebo|PF-04856883|PF-04856883|PF-04856883|PF-04856883","Biological|Biological|Biological|Biological|Biological|Biological|Biological|Biological|Biological|Biological|Biological|Biological|Biological","metabolic diseases|diabetes mellitus, type 2|glucose metabolism disorders|diabetes mellitus|endocrine system diseases","Diabetes Mellitus|Diabetes Mellitus, Type 2|Endocrine System Diseases|Glucose Metabolism Disorders|Metabolic Diseases","Parallel Assignment","Interventional","Treatment","Randomized","Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females",13,"LS mean Difference",1.11,0.286,"Mixed meal tolerance test",-0.23,2.45,80,"Standard Error of the Mean",1.021,"Female",84,"Completed","Phase 1","\t"]
["NCT01302067",4421001,8099810,"Change From Baseline in Percentage of Micturitions Per 24 Hours at Week 12.","fesoterodine","Fesoterodine 8mg|Fesoterodine 4mg|Placebo","Drug|Drug|Drug","urinary bladder, overactive","Overactive Bladder","Parallel Assignment","Interventional","Treatment","Randomized","A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine",3,null,"NA",{"v":1E-4,"d":"1.00E-04"},"ANCOVA",{"$nulls":4},"NA","All",2012,"Completed","Phase 4","\t"]
["NCT01307423",4420738,8099147,"Percentage of Participants With a ACR 70 Response at Week 16","apremilast|thalidomide","Apremilast 20mg|Apremilast 30mg|Placebo","Drug|Drug|Drug","arthritis|arthritis, psoriatic","Psoriatic Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)",4,"Risk Difference (RD)",2.9,"NA",null,-0.4,6.2,95,null,"NA","All",529,"Completed","Phase 3","\t"]
["NCT01311661",4420497,8098616,"Trough FEV1 Response","olodaterol","Placebo twice daily|Olodaterol low daily dose twice daily|Olodaterol medium daily dose twice daily|Placebo twice daily|Olodaterol high daily dose once daily and placebo|Olodaterol medium daily dose once daily and placebo","Drug|Drug|Drug|Drug|Drug|Drug","asthma","Asthma","Crossover Assignment","Interventional","Treatment","Randomized","A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma",2,"Mean Difference (Final Values)",0.196,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",0.149,0.243,95,"Standard Error of the Mean",0.024,"All",206,"Completed","Phase 2","\t"]
["NCT01313767",4420308,8098239,"MAS(Modified Ashworth Score) of Thumb Flexor","abobotulinumtoxina|botulinum toxins|botulinum toxins, type a","Botulinum toxin type A|Botulinum Toxin type A","Drug|Drug","muscle spasticity","Spasticity","Parallel Assignment","Interventional","Treatment","Randomized","MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity",2,"Mean Difference (Final Values)",0.15,0.3221,"t-test, 2 sided",{"$nulls":4},"NA","All",196,"Completed","Phase 3","\t"]
["NCT01323010",4419908,8097126,"Admission Rates in Patients With the Arg16Gly Polymorphisms","albuterol","Albuterol - Experimental|Albuterol - Control","Drug|Drug","respiratory sounds","Asthma|Children","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of Increasing Doses of Inhaled Albuterol in Children With Acute Wheezing Episodes",2,null,"NA",0.03,"Chi-squared",{"$nulls":4},"NA","All",119,"Completed","N/A","\t"]
["NCT01327547",4419646,8096596,"Mean Change From Baseline in CD38 Expression on CD4 and CD8 Cells at Weeks 48, 96 and 144","maraviroc","Maraviroc|Placebo","Drug|Drug","hepatitis a|hepatitis c|coinfection|hiv infections|hepatitis|hepatitis b","HIV Coinfection","Parallel Assignment","Interventional","Treatment","Randomized","A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B",2,"Difference in LS Mean",-44.93,0.0947,"ANCOVA",-97.72,7.87,95,null,"NA","All",138,"Completed","Phase 4","\t"]
["NCT01328782",4419510,8096312,"Total Dosage in Morphine Equivalents (mg/kg) of All Analgesics Received in Prior to Discharge","acetaminophen|oxycodone|bupivacaine|ropivacaine","Oxycodone with Acetaminophen|Bupivacaine 0.25%|Ropivacaine 0.20%","Drug|Drug|Drug","fractures, bone|pain, postoperative","Elbow Fracture","Parallel Assignment","Interventional","Treatment","Randomized","The Post-Operative Pain Management of Pediatric Supracondylar Elbow Fractures",3,"Mean Difference (Final Values)",0.031,0.078,"ANOVA",-0.004,0.066,95,null,"NA","All",124,"Completed","N/A","\t"]
["NCT01335477",4419098,8095381,"Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation","nintedanib","placebo|BIBF 1120","Drug|Drug","idiopathic pulmonary fibrosis|pulmonary fibrosis|fibrosis","Pulmonary Fibrosis","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II",2,"Hazard Ratio (HR)",0.38,0.005,"Log Rank",0.19,0.77,95,null,"NA","All",551,"Completed","Phase 3","\t"]
["NCT01338870",4418695,8094920,"Change From Baseline in Body Weight at Week 1, 2, 4, 8 and 12","6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1h-imidazol-1-yl)propanamido)nicotinic acid|sitagliptin phosphate|nicotinic acids","Placebo|25 mg PF-04991532|75 mg PF-04991532|150 mg PF-04991532|300 mg PF-04991532|Sitagliptin 100 mg","Drug|Drug|Drug|Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes",6,"LS mean difference",-0.4,0.4253,"Mixed Models Analysis",-1.39,0.59,95,"Standard Error of the Mean",0.504,"All",301,"Completed","Phase 2","\t"]
["NCT01340937",4418162,8094560,"Percentage of Participants Responding to Diphtheria Toxin","heptavalent pneumococcal conjugate vaccine","V419|PENTACEL™|Prevnar 13™|RotaTeq™|Recombivax HB vaccine","Biological|Biological|Biological|Biological|Biological","virus diseases|infection|bacterial infections","Bacterial Infections|Virus Diseases","Parallel Assignment","Interventional","Prevention","Randomized","A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)",4,"Response Rate Difference (Lot A - Lot C)",-1.35,"NA",null,-5.26,2.57,95,null,"NA","All",2808,"Completed","Phase 3","\t"]
["NCT01341639",4418062,8094497,"Percentage of Participants Reporting Solicited Systemic AE From Day 1 to Day 5 After Any Vaccination","heptavalent pneumococcal conjugate vaccine","V419|INFANRIX™ hexa|RotaTeq|Prevenar 13|ProQuad™","Biological|Biological|Biological|Biological|Biological","virus diseases|bacterial infections","Bacterial Infections|Virus Diseases","Parallel Assignment","Interventional","Prevention","Randomized","Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)",2,"Risk Difference (RD)",0.8,"NA",null,-4.4,6,95,null,"NA","All",1250,"Completed","Phase 3","\t"]
["NCT01345188",4417817,8094135,"Dyspnea Assessed by the Rose Dyspnea Questionnaire (RDQ)","ranolazine","Ranexa|Placebo","Drug|Drug","cardiomyopathies|chest pain|dyspnea","Cardiomyopathy|Chest Pain|Dyspnea","Crossover Assignment","Interventional","Treatment","Randomized","Ranolazine in Ischemic Cardiomyopathy",2,null,"NA",0.05,"Wilcoxon Signed rank",{"$nulls":4},"NA","All",28,"Completed","Phase 4","\t"]
["NCT01350141",4417335,8093475,"Percentage of Participants Achieving at Least 30 Percent Decrease in Low-density Lipoprotein Cholesterol (LDL-C)","bococizumab","Placebo|PF-04950615 (RN316)|PF-04950615 (RN316)","Other|Drug|Drug","dyslipidemias|hypercholesterolemia","Dyslipidemia|Hypercholesterolemia","Parallel Assignment","Interventional","Treatment","Randomized","A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins",3,"Odds Ratio (OR)",23.442,0.0025,"Regression, Logistic",3.03,181.11,95,null,"NA","All",46,"Completed","Phase 2","\t"]
["NCT01353898",4417249,8092990,"Change From Baseline to Day 10 in Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Due to Treatment With MK-1972 or Placebo","NA","MK-1972|Placebo to MK-1972","Drug|Drug","NA","HIV-1 Infection","Parallel Assignment","Interventional","Treatment","Randomized","Study of MK-1972 in Human Immunodeficiency Virus (HIV)-1 Infected Participants Who Have Not Previously Received Antiretroviral Therapy (MK-1972-003)",8,"Mean Difference (Final Values)",-0.9,"NA",{"$nulls":5},"NA","Male",12,"Terminated","Phase 1","\t"]
["NCT01357577",4417096,8092643,"CAPS Total Score Analysis Among Participants Completing at Least One Follow-up Assessment.","NA","Cognitive behavioral therapy for PTSD","Behavioral","substance-related disorders","PTSD|Substance Use Disorders","Parallel Assignment","Interventional","Treatment","Randomized","Cognitive Behavioral Therapy (CBT) for PTSD in Veterans With Co-Occurring SUDs",2,null,"NA",0.65,"Mixed Models Analysis",{"$nulls":4},"NA","All",129,"Completed","N/A","\t"]
["NCT01360632",4416834,8092284,"Mean Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in IDS-SR Total Score for the Efficacy Sample Per Final Protocol","NA","OPC-34712 + ADT|Placebo + ADT|Placebo + ADT","Drug|Drug|Drug","depressive disorder|mental disorders|mood disorders|depressive disorder, major|depression|disease","Depression|Depressive Disorder|Depressive Disorder, Major|Mental Disorders|Mood Disorders","Parallel Assignment","Interventional","Treatment","Randomized","Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)",2,"Mean Difference (Final Values)",-1.12,0.0496,"Mixed Models Analysis",-2.24,0,95,null,"NA","All",1539,"Completed","Phase 3","\t"]
["NCT01360645",4416700,8092265,"Mean Clinical Global Impression-Improvement (CGI-I) Scale Score (End of Phase A [Week 8]) to Week 14 by Trial Week for the Efficacy Sample.","NA","OPC-34712 + ADT|Placebo + ADT|Placebo + ADT","Drug|Drug|Drug","depressive disorder, major|depressive disorder|mental disorders|depression|mood disorders|disease","Depression|Depressive Disorder|Depressive Disorder, Major|Mental Disorders|Mood Disorders","Parallel Assignment","Interventional","Treatment","Randomized","Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)",2,"Mean Difference (Final Values)",-0.41,{"v":1E-4,"d":"1.00E-04"},"Cochran-Mantel-Haenszel",-0.62,-0.2,95,null,"NA","All",826,"Completed","Phase 3","\t"]
["NCT01362296",4416488,8092021,"Progression-Free Survival (PFS) as Assessed by the Investigator (INV)","trametinib|docetaxel","GSK1120212|docetaxel","Drug|Drug","lung neoplasms|carcinoma, non-small-cell lung","Lung Cancer, Non-Small Cell","Parallel Assignment","Interventional","Treatment","Randomized","An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer",2,"Hazard Ratio (HR)",1.14,0.5197,"Log Rank",0.75,1.75,95,null,"NA","All",134,"Completed","Phase 2","\t"]
["NCT01370642",4416056,8090962,"Percentage of Participants With One or More Tier 1 Adverse Events (AEs) During the Study","ribavirin","vaniprevir|Placebo to vaniprevir|Peg-IFN|ribavirin","Drug|Drug|Biological|Drug","hepatitis a|hepatitis c, chronic|hepatitis|hepatitis c","Hepatitis C, Chronic","Parallel Assignment","Interventional","Treatment","Randomized","Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)",3,"Difference in percentages",-4.1,0.557,"Miettinen and Nurminen method",-17.5,9.5,95,null,"NA","All",294,"Completed","Phase 3","\t"]
["NCT01371838",4415922,8090826,"Clinical Response at the Test of Cure (TOC) Visit in mMITT Population","ceftriaxone|ceftaroline fosamil","Ceftaroline|Ceftriaxone","Drug|Drug","pneumonia, bacterial|pneumonia","Community-Acquired Bacterial Pneumonia|Lung Infection of Individual Not Recently Hospitalized","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia",2,"Risk Difference (RD)",15.2,"NA",null,2.7,27.1,95,null,"NA","All",848,"Completed","Phase 3","\t"]
["NCT01375075",4415758,8090402,"Change From Baseline to 12 Weeks in Blood Pressure","atorvastatin|evacetrapib","LY2484595|Placebo|Atorvastatin","Drug|Drug|Drug","dyslipidemias","Dyslipidemias","Parallel Assignment","Interventional","Treatment","Randomized","A Study of LY2484595 in Japanese Subjects",6,"LS Mean Difference",2.83,0.257,"Mixed Models Analysis",-1.28,6.94,90,"Standard Error of the Mean",2.48,"All",165,"Completed","Phase 2","\t"]
["NCT01380093",4415220,8089770,"Pupillometry: Area Under Effect Curve (AUE) From 0-4 Hours","morphine|naltrexone","EMBEDA (morphine sulfate / naltrexone hydrochloride)|Placebo|MS Contin (morphine sulfate, controlled release)","Drug|Drug|Drug","opioid-related disorders|crush injuries","Nondependent Opioid Abuse, Episodic","Crossover Assignment","Interventional","Basic Science","Randomized","Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users",3,"LS Mean Difference",-10.1,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",-11.1,-9.2,95,null,"NA","All",80,"Completed","Phase 1","\t"]
["NCT01380093",4415394,8089828,"Good Effects: Area Under Effect Curve (AUE) From 0-8 Hours","morphine|naltrexone","EMBEDA (morphine sulfate / naltrexone hydrochloride)|Placebo|MS Contin (morphine sulfate, controlled release)","Drug|Drug|Drug","opioid-related disorders|crush injuries","Nondependent Opioid Abuse, Episodic","Crossover Assignment","Interventional","Basic Science","Randomized","Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users",3,"LS Mean Difference",325.5,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",282.1,368.9,95,null,"NA","All",80,"Completed","Phase 1","\t"]
["NCT01380327",4415192,8089719,"Change in German Cockroach-Specific Serum IgG Over Time","immunologic factors","Cockroach Sublingual Immunotherapy (SLIT) - Low Dose|Placebo|Cockroach Sublingual Immunotherapy (SLIT) - High Dose","Biological|Other|Biological","rhinitis, allergic, perennial|rhinitis|asthma|rhinitis, allergic","Asthma|Perennial Allergic Rhinitis","Parallel Assignment","Interventional","Treatment","Randomized","Biomarkers of Cockroach Sublingual Immunotherapy 2",3,"Risk Ratio (RR)",1.1,0.11,"Mixed Models Analysis",1,1.2,95,null,"NA","All",99,"Completed","Phase 1/Phase 2","\t"]
["NCT01389856",4414699,8088549,"Change in Arterial Blood Gas (ABG) pH From Baseline to 72 Hours Following Study Drug Administration","bosentan","Bosentan|Matching placebo","Drug|Drug","hypertension, pulmonary|hypertension|persistent fetal circulation syndrome","Persistent Pulmonary Hypertension of the Newborn","Parallel Assignment","Interventional","Treatment","Randomized","Persistent Pulmonary Hypertension of the Newborn",2,null,"NA",0.0824,"Non-parametric ANCOVA",{"$nulls":4},"NA","All",23,"Terminated","Phase 3","\t"]
["NCT01391793",4414557,8088301,"The Distribution of Children With Renal Scarring at the Outcome Dimercaptosuccinic Acid (DMSA) Renal Scan","dexamethasone","Placebo|Dexamethasone","Drug|Drug","communicable diseases|infection|urinary tract infections","Acute Urinary Tract Infection|Urinary Tract Infection","Parallel Assignment","Interventional","Prevention","Randomized","Corticosteroids for Children With Febrile Urinary Tract Infections",2,null,"NA",0.16,"Regression, Logistic",{"$nulls":4},"NA","All",546,"Completed","Phase 3","\t"]
["NCT01392378",4414357,8088187,"Geometric Mean Titer (GMT) for Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) 1 Month After the Infant Series","vaccines|heptavalent pneumococcal conjugate vaccine|ibuprofen|acetaminophen","13-valent pneumococcal conjugate vaccine|INFANRIX hexa|Paracetamol|13-valent pneumococcal conjugate vaccine|INFANRIX hexa|Ibuprofen|13-valent pneumococcal conjugate vaccine|INFANRIX hexa|Paracetamol|13-valent pneumococcal conjugate vaccine|INFANRIX hexa|Ibuprofen|13-valent pneumococcal conjugate vaccine|INFANRIX hexa","Biological|Biological|Drug|Biological|Biological|Drug|Biological|Biological|Drug|Biological|Biological|Drug|Biological|Biological","NA","Pneumococcal Vaccines","Parallel Assignment","Interventional","Prevention","Randomized","Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®",5,"GMT Ratio",0.6,0.0422,"General Linear Model",0.48,0.86,95,null,"NA","All",908,"Completed","Phase 4","\t"]
["NCT01393899",4414123,8087984,"Percentage of Participants in Sustained Clinical Remission (Defined as Being in Clinical Remission at Both Weeks 20 and 26) in the Maintenance Phase","tofacitinib","Placebo|CP-690,550|CP-690,550","Drug|Drug|Drug","crohn disease","Crohn's Disease","Parallel Assignment","Interventional","Treatment","Randomized","The Safety And Efficacy Of Maintenance Therapy With CP-690,550",3,"Difference in Percentage",18.11,"NA",null,5.57,30.64,80,null,"NA","All",180,"Completed","Phase 2","\t"]
["NCT01400932",4413772,8087191,"Number of Participants Who Had an ISGA Score of 0 or 1 at Weeks 1, 2, 4, 8, and 12","benzoyl peroxide","GI148512|vehicle gel","Drug|Drug","acne vulgaris","Acne Vulgaris","Parallel Assignment","Interventional","Treatment","Randomized","Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese Subjects",2,null,"NA",1E-3,"ANCOVA",{"$nulls":4},"NA","All",360,"Completed","Phase 3","\t"]
["NCT01402986",4413562,8086919,"Change From Baseline in Mean ACQ-6 Scores at Week 53 in Subgroups","antibodies, monoclonal","Placebo Q2W|Tralokinumab 300 mg, Q2W|Placebo, Q2/4W|Tralokinumab 300 mg, Q2/4W","Other|Biological|Other|Biological","asthma","Asthma","Parallel Assignment","Interventional","Treatment","Randomized","A Safety and Efficacy Study of Tralokinumab in Adults With Asthma",4,"Difference of LS-mean",-0.07,0.674,"Repeated measure model",-0.42,0.27,95,null,"NA","All",689,"Completed","Phase 2","\t"]
["NCT01402986",4413673,8086950,"Annual Asthma Exacerbation Rate (AER)","antibodies, monoclonal","Placebo Q2W|Tralokinumab 300 mg, Q2W|Placebo, Q2/4W|Tralokinumab 300 mg, Q2/4W","Other|Biological|Other|Biological","asthma","Asthma","Parallel Assignment","Interventional","Treatment","Randomized","A Safety and Efficacy Study of Tralokinumab in Adults With Asthma",4,"Rate Ratio",0.94,0.709,"Poisson regression",0.67,1.31,95,null,"NA","All",689,"Completed","Phase 2","\t"]
["NCT01410240",4413162,8086233,"Change From Baseline at Postoperative Day 3, Week 1, Week 2, and Week 6 in Western Ontario and McMaster Universities (WOMAC) Scores","hemostatics","Standard of Care|FLOSEAL Hemostatic Matrix + Standard of care","Procedure|Drug","osteoarthritis","Knee Replacement Surgery|Osteoarthritis","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty",2,null,"NA",0.077,"two-sided Wilcoxon rank sum test",{"$nulls":4},"NA","All",137,"Completed","Phase 4","\t"]
["NCT01416181",4412913,8085588,"Part 2: Absolute Change From Baseline (Part 1) in EDSS","natalizumab","natalizumab|Placebo","Drug|Drug","sclerosis|multiple sclerosis|multiple sclerosis, chronic progressive|neoplasm metastasis","Secondary Progressive Multiple Sclerosis","Parallel Assignment","Interventional","Treatment","Randomized","A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis",2,null,"NA",0.3861,"ANCOVA",{"$nulls":4},"NA","All",889,"Terminated","Phase 3","\t"]
["NCT01416584",4412871,8085504,"Percentage of Monthly Urine Sample Negative for Opiates","methadone","methadone contingency|Methadone & Abstinence Contingency","Behavioral|Behavioral","opioid-related disorders","Opiate Dependence","Parallel Assignment","Interventional","Treatment","Randomized","A Bridge to Treatment: The Therapeutic Workplace and Methadone Treatment",3,"Odds Ratio (OR)",1.86,0.1,"General Estimating Equation (GEE)",1.53,2.26,95,null,"NA","All",98,"Completed","N/A","\t"]
["NCT01421147",4412641,8085122,"Insulin Dose - Units [Total and by Component [Basal and Bolus (Lispro)])","insulin lispro","LY2963016|Lantus|Insulin Lispro","Drug|Drug|Drug","diabetes mellitus|diabetes mellitus, type 1","Diabetes Mellitus, Type 1","Parallel Assignment","Interventional","Treatment","Randomized","A Study in Adults With Type 1 Diabetes",2,"LS Mean Difference",2.964,0.151,"ANCOVA",-1.081,7.01,95,null,"NA","All",536,"Completed","Phase 3","\t"]
["NCT01422876",4412405,8084927,"Change From Baseline in Fasting Plasma Glucose at Week 24 for Metformin Background Patients","linagliptin|empagliflozin","high dose FDC|BI 10773 high dose|high dose FDC placebo|low dose FDC placebo|high dose FDC placebo|high dose FDC placebo|low dose FDC placebo|low dose FDC placebo|high dose BI 10773 placebo|low dose FDC|high dose FDC placebo|BI 10773 low dose|high dose BI 10773 placebo|high dose BI 10773 placebo|linagliptin|low dose FDC placebo|linagliptin placebo|BI 10773 low dose placebo|linagliptin placebo|low dose BI 10773 placebo|linagliptin placebo|high dose BI 10773 placebo|BI 10773 low dose placebo|low dose BI 10773 placebo|linagliptin placebo","Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients",5,"Mean Difference (Net)",-19.12,{"v":1E-4,"d":"1.00E-04"},"ANCOVA",-26.21,-12.03,95,"Standard Error of the Mean",3.61,"All",1405,"Completed","Phase 3","\t"]
["NCT01430559",4412108,8084054,"Percentage of Participants With at Least 30% and 50% Reduction From Baseline in the WOMAC Pain Subscale at Weeks 2, 4, 8, and 12","meloxicam","Meloxicam|Placebo","Drug|Drug","osteoarthritis|osteoarthritis, knee","Osteoarthritis of the Knee","Parallel Assignment","Interventional","Other","Randomized","Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee",2,"Odds Ratio (OR)",1.56,0.068,"Regression, Logistic",0.97,2.53,95,null,"NA","All",408,"Completed","N/A","\t"]
["NCT01431274",4411875,8083968,"Trough FVC Response on Day 43.","tiotropium bromide|olodaterol","tiotropium + olodaterol|tiotropium|olodaterol|tiotropium|tiotropium + olodaterol|Respimat","Drug|Drug|Drug|Drug|Drug|Device","lung diseases|lung diseases, obstructive|pulmonary disease, chronic obstructive","Pulmonary Disease, Chronic Obstructive","Parallel Assignment","Interventional","Treatment","Randomized","Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)",5,"Adjusted mean difference",0.103,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",0.054,0.152,95,"Standard Error of the Mean",0.025,"All",2624,"Completed","Phase 3","\t"]
["NCT01431274",4411909,8083972,"FVC (Forced Vital Capacity) AUC(0-3h) Response on Day 85","tiotropium bromide|olodaterol","tiotropium + olodaterol|tiotropium|olodaterol|tiotropium|tiotropium + olodaterol|Respimat","Drug|Drug|Drug|Drug|Drug|Device","lung diseases|lung diseases, obstructive|pulmonary disease, chronic obstructive","Pulmonary Disease, Chronic Obstructive","Parallel Assignment","Interventional","Treatment","Randomized","Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)",5,"Adjusted mean difference",0.071,0.0041,"Mixed Models Analysis",0.022,0.119,95,"Standard Error of the Mean",0.025,"All",2624,"Completed","Phase 3","\t"]
["NCT01431287",4411532,8083934,"FEV1 AUC(0-12h) Response in Sub-set of Patients With 12-hour Pulmonary Function Test (PFT) on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)","olodaterol|tiotropium bromide","tiotropium + olodaterol|tiotropium + olodaterol|tiotropium|tiotropium|olodaterol|Respimat","Drug|Drug|Drug|Drug|Drug|Device","pulmonary disease, chronic obstructive|lung diseases|lung diseases, obstructive","Pulmonary Disease, Chronic Obstructive","Parallel Assignment","Interventional","Treatment","Randomized","Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)",5,"Adjusted mean difference",0.047,0.0384,"ANCOVA",0.003,0.092,95,"Standard Error of the Mean",0.023,"All",2539,"Completed","Phase 3","\t"]
["NCT01431287",4411727,8083953,"Saint George's Respiratory Questionnaire (SGRQ) Total Score on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274).","olodaterol|tiotropium bromide","tiotropium + olodaterol|tiotropium + olodaterol|tiotropium|tiotropium|olodaterol|Respimat","Drug|Drug|Drug|Drug|Drug|Device","pulmonary disease, chronic obstructive|lung diseases|lung diseases, obstructive","Pulmonary Disease, Chronic Obstructive","Parallel Assignment","Interventional","Treatment","Randomized","Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)",5,"Adjusted mean difference",-1.693,0.0022,"Mixed Models Analysis",-2.778,-0.608,95,"Standard Error of the Mean",0.553,"All",2539,"Completed","Phase 3","\t"]
["NCT01435759",4411278,8083289,"Change in Average Systolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16","lisdexamfetamine dimesylate|antidepressive agents","Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg|Antidepressant + Placebo","Drug|Drug|Drug|Drug|Drug","depressive disorder|depression|depressive disorder, major","Major Depressive Disorder","Parallel Assignment","Interventional","Treatment","Randomized","SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder",5,"Least Squares Mean",3.16,0.004,"MCP-Mod Analysis",{"$nulls":3},"Standard Error of the Mean",1.01,"All",1197,"Completed","Phase 2","\t"]
["NCT01438957",4411112,8082800,"Dosage of Fentanyl Dosing Required During the Study Drug Administration.","dexmedetomidine","Dexmedetomidine hydrochloride|Placebo","Drug|Drug","NA","Sedation","Parallel Assignment","Interventional","Treatment","Randomized","Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery With Epidural Anesthesia or Spinal Anesthesia Without Intubation",5,null,"NA",0.897,"Mantel Haenszel",{"$nulls":4},"NA","All",119,"Completed","Phase 3","\t"]
["NCT01444417",4410837,8081909,"Number of Weeks With Platelet Response","NA","Romiplostim|Placebo","Drug|Drug","purpura, thrombocytopenic|purpura, thrombocytopenic, idiopathic|purpura|thrombocytopenia","Idiopathic Thrombocytopenic Purpura|Immune Thrombocytopenia|Thrombocytopenia|Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|Thrombocytopenic Purpura","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients",2,null,"NA",{"v":0.0004,"d":"4.00E-04"},"ANOVA",{"$nulls":4},"NA","All",62,"Completed","Phase 3","\t"]
["NCT01449708",4410628,8081365,"PONV Between Different Surgical Procedures (Percentage of Participants)","NA","TIVA NoNarc","Drug","nausea|postoperative nausea and vomiting|vomiting","Postoperative Nausea and Vomiting","Parallel Assignment","Interventional","Prevention","Randomized","Effect of Intraoperative Anesthetic Management on Postoperative Nausea and Vomiting in Bariatric Surgery",2,"Odds Ratio (OR)",3.04,0.009,"Chi-squared",1.28,7.29,95,null,"NA","All",124,"Completed","Phase 4","\t"]
["NCT01455428",4410358,8080581,"Patient Global Impression of Change (PGIC) Score at Endpoint","pregabalin","Lyrica (pregabalin)|Placebo","Drug|Drug","neuralgia, postherpetic|neuralgia","Postherpetic Neuralgia ( PHN )","Parallel Assignment","Interventional","Treatment","Randomized","Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)",2,"Least Squares Mean Difference",-0.49,{"v":1E-4,"d":"1.00E-04"},"ANOVA",-0.72,-0.27,95,"Standard Error of the Mean",0.113,"All",223,"Completed","Phase 4","\t"]
["NCT01457924",4410269,8080300,"Cumulative Number of New and Newly Enlarging GdE T2 Lesions at Week 12","ofatumumab|antibodies, monoclonal","Ofatumumab 3mg|Ofatumumab 30mg|Ofatumumab 60mg|Placebo","Drug|Drug|Drug|Drug","sclerosis|multiple sclerosis|multiple sclerosis, relapsing-remitting","Multiple Sclerosis","Parallel Assignment","Interventional","Treatment","Randomized","Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis",8,"Ratio",0.19,1E-3,"Generalized Linear Model",0.11,0.35,95,null,"NA","All",232,"Completed","Phase 2","\t"]
["NCT01461369",4410044,8079656,"Change From Baseline to Week 6 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.","diclofenac","Diclofenac|Diclofenac|Placebo","Drug|Drug|Drug","osteoarthritis","Osteoarthritis","Parallel Assignment","Interventional","Treatment","Randomized","Study of Diclofenac Capsules to Treat Osteoarthritis Pain",3,"Difference in Least Squares Mean",-12.43,0.0011,"Mixed Models Analysis",-19.87,-4.99,95,"Standard Error of the Mean",3.776,"All",305,"Completed","Phase 3","\t"]
["NCT01469182",4409604,8078367,"Number of Participants Reporting Throat Irritation","NA","SCH 39641|Placebo for SCH 39641","Biological|Drug","hypersensitivity","Allergy","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)",2,"Percent Difference",10.17,1E-3,"Stratified Miettinen and Nurminen",6.6,13.6,95,null,"NA","All",914,"Completed","Phase 3","\t"]
["NCT01474512",4409364,8077694,"Change From Baseline in Nail Psoriasis Severity Index (NAPSI)","ixekizumab","80 mg Ixekizumab Dosing Regimens 1, 2, and 3|Placebo","Drug|Drug","psoriasis","Psoriasis","Parallel Assignment","Interventional","Treatment","Randomized","A Phase 3 Study in Participants With Moderate to Severe Psoriasis",4,null,"NA",1E-3,"Mixed Models Analysis",{"$nulls":4},"NA","All",1296,"Completed","Phase 3","\t"]
["NCT01474772",4409319,8077626,"Norfolk QOL-DN Activities of Daily Living Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)","pregabalin","Pregabalin|placebo","Drug|Other","diabetic neuropathies|peripheral nervous system diseases","Diabetic Peripheral Neuropathy","Crossover Assignment","Interventional","Treatment","Randomized","Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)",2,"Mean Difference (Final Values)",-0.06,0.7542,"Linear mixed effects model",-0.41,0.3,95,"Standard Error of the Mean",0.18,"All",217,"Completed","Phase 3","\t"]
["NCT01479621",4409083,8077081,"Change From Baseline In Weekly Average Of Daily Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period","adrenergic agonists|fluticasone|albuterol","Fp MDPI|Flovent Diskus|albuterol/salbutamol|Placebo MDPI","Drug|Drug|Drug|Drug","asthma","Asthma","Parallel Assignment","Interventional","Treatment","Randomized","A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids",6,"LSM difference",12.78,0.0411,"mixed model for repeated measures",0.52,25.04,95,null,"NA","All",909,"Completed","Phase 2","\t"]
["NCT01485614",4408026,8076424,"Percentage of Participants With A1C at Goal (<7.0%) at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))","metformin|sitagliptin phosphate","Sitagliptin|Metformin|Placebo to sitagliptin|Placebo to metformin|Glycemic Rescue 1|Glycemic Rescue 2","Drug|Drug|Drug|Drug|Drug|Biological","diabetes mellitus, type 2|diabetes mellitus","Diabetes Mellitus|Type 2 Diabetes","Parallel Assignment","Interventional","Treatment","Randomized","Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)",4,"Difference in percentage",6.7,0,"Miettinen and Nurminen",-8.1,21.2,95,null,"NA","All",200,"Completed","Phase 3","\t"]
["NCT01494506",4407738,8075399,"EORTC-QLQ-C30","fluorouracil|leucovorin","MM-398|5 Fluorouracil|Leucovorin","Drug|Drug|Drug","pancreatic neoplasms","Metastatic Pancreatic Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer",3,null,"NA",0.3408,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",417,"Completed","Phase 3","\t"]
["NCT01494532",4407675,8075389,"Percent Change From Baseline in Awake Time Spent \"Off\" at Week 4 of the Maintenance Period","dihydroxyphenylalanine|levodopa|ropinirole","ropinirole/L-dopa|placebo/L-dopa","Drug|Drug","parkinson disease","Parkinson Disease","Parallel Assignment","Interventional","Treatment","Randomized","A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease",2,null,"NA",0.008,"Mixed Models Analysis",{"$nulls":4},"NA","All",352,"Completed","Phase 4","\t"]
["NCT01499368",4407456,8074737,"The Proportion of Days Without 'Cardinal Symptom'","omeprazole|famotidine|lafutidine","Lafutidine|Famotidine|Omeprazole","Drug|Drug|Drug","esophagitis","Erosive Esophagitis","Parallel Assignment","Interventional","Treatment","Randomized","A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients",3,null,"NA",0.05,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",495,"Completed","Phase 3","\t"]
["NCT01506323",4407097,8074097,"PTSD Checklist-Military Version [Diagnostic and Statistical Manual (DSM) IV-TR Version]","NA","Mantram Repetition Program (MRP)|Present Centered Therapy (PCT)","Behavioral|Behavioral","stress disorders, traumatic|stress disorders, post-traumatic","Stress Disorders, Post-Traumatic","Parallel Assignment","Interventional","Treatment","Randomized","Mantram Repetition Meditation for Veterans With PTSD",2,null,"NA",0.04,"Mixed Models Analysis",{"$nulls":4},"NA","All",181,"Completed","Phase 3","\t"]
["NCT01512160",4406905,8073407,"Summed Pain Intensity Difference (SPID) Score at 6 Hours and 24 Hours","ibuprofen","PF-04531083|Placebo|PF-04531083|Placebo|Ibuprofen|Placebo|Placebo|Placebo","Drug|Other|Drug|Other|Drug|Other|Other|Other","toothache","Post-surgical Dental Pain","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy Of Pf-04531083 In Treating Post-Surgical Dental Pain",4,"LS mean difference",-0.4,"NA",null,-2.8,1.9,90,"Standard Error of the Mean",1.4,"Male",90,"Terminated","Phase 2","\t"]
["NCT01516008",4406701,8072933,"Response Rate for 30 Percent or Greater Reduction in Pain Intensity at 12, 24, 48, and 72 Hours","tapentadol","Tapentadol IR 50 mg|Tapentadol IR 75 mg|Placebo","Drug|Drug|Drug","acute pain|hallux valgus","Hallux Valgus","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy",3,null,"NA",1E-3,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",353,"Completed","Phase 3","\t"]
["NCT01517373",4406630,8072831,"Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12","glimepiride","Placebo|PF-04937319 10 mg|PF-04937319 50 mg|PF-04937319 100 mg|Glimepiride","Drug|Drug|Drug|Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin",5,"LS Mean Difference",-0.47,{"v":0.0006,"d":"6.00E-04"},"t-test, 1 sided",-0.65,-0.28,80,"Standard Error of the Mean",0.144,"All",304,"Completed","Phase 2","\t"]
["NCT01520363",4406363,8072423,"Change in Mullen; Visual Reception Sub-scale Scores, Pre- and Post-Intervention","dextromethorphan","dextromethorphan|placebo","Drug|Drug","syndrome|rett syndrome","Rett Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","Placebo Controlled Trial of Dextromethorphan in Rett Syndrome",2,"Mean Difference (Net)",-1.182,0.211,"t-test, 2 sided",-3.086,0.722,95,"Standard Deviation",4.294,"All",57,"Completed","Phase 2","\t"]
["NCT01524887",4406158,8071891,"Change From Baseline to Month 18 in Neuropsychiatric Inventory (NPI)","immunoglobulins|gamma-globulins|rho(d) immune globulin|antibodies|immunoglobulins, intravenous","Immune Globulin Intravenous (Human), 10% Solution|Human albumin 0.25%","Biological|Biological","alzheimer disease","Alzheimer´s Disease","Parallel Assignment","Interventional","Treatment","Randomized","Phase 3 IGIV, 10% in Alzheimer´s Disease",3,"Difference in least square means",1.1,0.571,"Mixed Models Analysis",-2.6,4.7,95,null,"NA","All",508,"Terminated","Phase 3","\t"]
["NCT01527513",4405944,8071447,"Change From Baseline in Standardized Seizure Frequency - Part I","eslicarbazepine acetate","Eslicarbazepine acetate (BIA 2-093)|Placebo","Drug|Drug","epilepsies, partial|seizures|epilepsy","Partial Epilepsy","Parallel Assignment","Interventional","Treatment","Randomized","Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures",2,null,"NA","NA",{"$nulls":5},"NA","All",123,"Completed","Phase 2","\t"]
["NCT01531673",4405746,8071092,"Change in Sweat Chloride From Baseline Through Study Day 28 for Group 1-5b","ivacaftor","VX-661|Ivacaftor|Placebo matched to VX-661|Placebo matched to ivacaftor","Drug|Drug|Drug|Drug","cystic fibrosis|fibrosis","Cystic Fibrosis","Parallel Assignment","Interventional","Treatment","Randomized","Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation",13,"LS Mean Difference",-3.91,0.1686,"MMRM",-9.5,1.68,95,null,"NA","All",194,"Completed","Phase 2","\t"]
["NCT01536405",4405486,8070501,"Percentage of Participants With Measles Virus Antibody Levels >=255 mIU/mL","NA","MMRV (AMP)|MMRV (2006 process)","Biological|Biological","measles|rubella|chickenpox|herpes zoster|mumps","Measles|Mumps|Rubella|Varicella","Parallel Assignment","Interventional","Prevention","Randomized","Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)",2,"Response rate",96.7,1E-3,"One-sample binomial",94.9,97.9,95,null,"NA","All",1412,"Completed","Phase 3","\t"]
["NCT01543685",4405259,8069730,"VASSPID-24. The Time-Weighted Summed Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale (VASSPID) From 0 to 24 Hours After Trial Entry","indomethacin|celecoxib","Indomethacin|Indomethacin|Indomethacin|Celecoxib|Placebo","Drug|Drug|Drug|Drug|Drug","pain, postoperative","Other Acute Postoperative Pain","Parallel Assignment","Interventional","Treatment","Randomized","Study of Indomethacin Capsules to Treat Pain Following Bunionectomy",5,null,"NA",0.015,"t-test, 2 sided",{"$nulls":4},"NA","All",462,"Completed","Phase 3","\t"]
["NCT01545076",4405165,8069493,"Median Change From Baseline in the Mean Grip Strength Scores of the Dominant Hand During the SC Treatment Period","immunoglobulin g","IgPro20 (low dose)|Placebo|IgPro10|IgPro20 (high dose)","Biological|Biological|Biological|Biological","polyradiculoneuropathy|polyradiculoneuropathy, chronic inflammatory demyelinating|polyneuropathies","Chronic Inflammatory Demyelinating Polyneuropathy|Polyradiculoneuropathy","Parallel Assignment","Interventional","Treatment","Randomized","Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)",3,"Median Difference (Net)",7.6,0,"Wilcoxon rank sum",2,14,95,null,"NA","All",208,"Completed","Phase 3","\t"]
["NCT01553747",4404779,8068572,"Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores","eluxadoline","Eluxadoline|Placebo","Drug|Drug","diarrhea|irritable bowel syndrome|syndrome","Irritable Bowel Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)",3,null,"NA",1E-3,"Chi-square test statistic",{"$nulls":4},"NA","All",1146,"Completed","Phase 3","\t"]
["NCT01559116",4404384,8067940,"FVC AUC12-24h Response [L] After 6 Weeks Treatment.","tiotropium bromide|olodaterol","tiotropium + olodaterol|tiotropium|olodaterol|tiotropium|tiotropium + olodaterol|Placebo|Respimat","Drug|Drug|Drug|Drug|Drug|Drug|Device","lung diseases, obstructive|lung diseases|pulmonary disease, chronic obstructive","Pulmonary Disease, Chronic Obstructive","Crossover Assignment","Interventional","Treatment","Randomized","Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease",6,"Mean Difference (Final Values)",0.148,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",0.099,0.197,95,"Standard Error of the Mean",0.025,"All",219,"Completed","Phase 3","\t"]
["NCT01559259",4403613,8067891,"Cumulative Percentage of Participants With Confirmed First Perceptible Relief","ibuprofen|acetaminophen","Ibuprofen/acetaminophen|Ibuprofen/acetaminophen|Ibuprofen/acetaminophen|Ibuprofen|Placebo","Drug|Drug|Drug|Drug|Drug","toothache","Pain","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",5,"Difference in proportion",3.99,0.416,"Cochran-Mantel-Haenszel",-5.52,13.49,95,null,"NA","All",394,"Completed","Phase 2","\t"]
["NCT01559259",4403824,8067893,"Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference on 4-Point Categorical Scale (SPRID4) Over 2, 6 and 12 Hours Post Dose","ibuprofen|acetaminophen","Ibuprofen/acetaminophen|Ibuprofen/acetaminophen|Ibuprofen/acetaminophen|Ibuprofen|Placebo","Drug|Drug|Drug|Drug|Drug","toothache","Pain","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",5,"LS Mean difference",-2.4,0.44,"ANOVA",-8.51,3.71,95,null,"NA","All",394,"Completed","Phase 2","\t"]
["NCT01559259",4403965,8067897,"Sum of Pain Relief Rating and Pain Intensity Difference on 4-Point Categorical Scale (PRID4)","ibuprofen|acetaminophen","Ibuprofen/acetaminophen|Ibuprofen/acetaminophen|Ibuprofen/acetaminophen|Ibuprofen|Placebo","Drug|Drug|Drug|Drug|Drug","toothache","Pain","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",5,"LS Mean difference",-0.05,0.882,"ANOVA",-0.74,0.63,95,null,"NA","All",394,"Completed","Phase 2","\t"]
["NCT01559259",4404220,8067899,"Pain Intensity Difference on 4-Point Categorical Scale (PID4)","ibuprofen|acetaminophen","Ibuprofen/acetaminophen|Ibuprofen/acetaminophen|Ibuprofen/acetaminophen|Ibuprofen|Placebo","Drug|Drug|Drug|Drug|Drug","toothache","Pain","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",5,"LS Mean difference",1.38,1E-3,"ANOVA",1.06,1.7,95,null,"NA","All",394,"Completed","Phase 2","\t"]
["NCT01560234",4403495,8067842,"Statistical Assessment of CXCL10 Ratio-to-baseline - Plasma","NA","AZD8848|Placebo","Drug|Drug","NA","Healthy","Parallel Assignment","Interventional","Basic Science","Randomized","AZD8848 Single Ascending Dose Study",2,"Percentage of Placebo",106.23,"NA",null,66.42,169.93,95,null,"NA","All",47,"Completed","Phase 1","\t"]
["NCT01563172",4403384,8067396,"Percentage Surface Micro Hardness (% SMH) Recovery, of Brushing for 2 Minutes With 0.5g of Experimental Dentifrice vs. Brushing for 2 Minutes With 1.5g of Experimental Dentifrice.","fluorides|listerine|sodium fluoride","Sodium fluoride / silica and carbopol, 0.5g|Sodium fluoride / silica and carbopol, 1.5g|Sodium fluoride / silica and carbopol, 1.5g|Fluoride free dentifrice","Drug|Drug|Drug|Other","dental caries","Dental Caries","Crossover Assignment","Interventional","Treatment","Randomized","Effect of Dentifrice Usage Regime on Delivery and Efficacy of Fluoride",5,"LS mean difference",-10.86,{"v":1E-4,"d":"1.00E-04"},"ANOVA",-14.77,-6.94,95,null,"NA","All",65,"Completed","Phase 4","\t"]
["NCT01568112",4403087,8066745,"Worst Severity Scores of Acute GI Events During Weeks 5 to 8 of Treatment (Combined), as Assessed by MAGISS","aspirin|dimethyl fumarate","BG00012 (dimethyl fumarate)|BG00012 placebo|ASA|ASA placebo","Drug|Drug|Drug|Drug","flushing","Healthy","Parallel Assignment","Interventional","Supportive Care","Randomized","Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate",4,"Mean Difference (Final Values)",-0.7,"NA",null,-1.7,0.4,95,"Standard Error of the Mean",0.52,"All",173,"Completed","Phase 3","\t"]
["NCT01569451",4402924,8066582,"Number of Patients Treated for Relapse With Corticosteroid","(t,g)-a-l|rituximab|glatiramer acetate","Rituximab|Glatiramer Acetate|Placebo","Drug|Drug|Other","sclerosis|multiple sclerosis","Multiple Sclerosis","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate",2,null,"NA",0.094,"Chi-squared",{"$nulls":4},"NA","All",53,"Completed","Phase 2","\t"]
["NCT01573000",4402626,8066111,"Number of Participants With Confirmed Complete Response (CR) as Assessed by the Investigator","iodine-131 anti-b1 antibody|immunoglobulins|antibodies","Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)","Biological","lymphoma|lymphoma, non-hodgkin","Lymphoma, Non-Hodgkin","Crossover Assignment","Interventional","Treatment","Randomized","A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)",2,"percentage of participants",8,"NA",null,0,17,95,null,"NA","All",78,"Completed","Phase 2","\t"]
["NCT01576172",4402421,8065734,"Rates of PSA Decline","prednisone|cortisone|abiraterone acetate|veliparib","Abiraterone Acetate|Laboratory Biomarker Analysis|Prednisone|Veliparib","Drug|Other|Drug|Drug","carcinoma|prostatic neoplasms","Castration-Resistant Prostate Carcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer AJCC v7","Parallel Assignment","Interventional","Treatment","Randomized","Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer",2,null,"NA",0.7,"t-test, 2 sided",{"$nulls":4},"NA","Male",159,"Completed","Phase 2","\t"]
["NCT01578850",4402202,8065409,"Percentage of Participants Achieving ACR20, ACR50, ACR70 and ACR90 (by 66/68 Joint Counts) During Period 2 at Each Visit.","etanercept","Etanercept|placebo","Drug|Drug","arthritis|arthritis, rheumatoid","Rheumatoid Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening",2,"Difference in proportions",17.3,0.004,"Cochran-Mantel-Haenszel",7.12,27.56,95,null,"NA","All",491,"Completed","Phase 4","\t"]
["NCT01584232",4402013,8064920,"Change From Baseline in 8-Point Self-Monitored Blood Glucose (SMBG) at 26 Weeks","insulin glargine|dulaglutide|biguanides","LY2189265|Insulin glargine|Sulfonylureas (SU)|Biguanide (BG)","Drug|Drug|Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Type 2 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus",2,"LS Mean Difference",5.16,0.022,"ANCOVA",0.76,9.56,95,null,"NA","All",361,"Completed","Phase 3","\t"]
["NCT01590810",4401757,8064020,"Change From Baseline in TWA0-12hrs HR in Male Participants With Mild to Moderate Hypertension Administered Single Doses of MK-8150 and Placebo (Panel C)","NA","MK-8150 400 mg|MK-8150 500 mg|MK-8150 2.0 mg|MK-8150 10 mg|MK-8150 40 mg|MK-8150 90 mg|MK-8150 5.0 mg|MK-8150 20 mg|MK-8150 60 mg|MK-8150 120 mg|MK-8150 160 mg|MK-8150 320 mg|MK-8150 600 mg|MK-8150 900 mg|MK-8150 1200 mg|Placebo for MK-8150|MK-8150 50 mg|MK-8150 100 mg|MK-8150 200 mg","Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug","hypertension","Hypertension|Isolated Systolic Hypertension (ISH)","Parallel Assignment","Interventional","Treatment","Randomized","A Single Rising Dose Study of MK-8150 (MK-8150-001)",4,"LS Mean Difference",3.65,0.114,"Mixed Models Analysis",-1.03,8.33,95,"Standard Error of the Mean",2.13,"Male",34,"Completed","Phase 1","\t"]
["NCT01592747",4401510,8063749,"Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Syntax Subscale at Week 12","memantine","Memantine Hydrochloride (HCl)|Memantine Hydrochloride (HCl)|Placebo capsules","Drug|Drug|Drug","autistic disorder|autism spectrum disorder|developmental disabilities|asperger syndrome|child development disorders, pervasive|disease","Asperger's Disorder|Asperger Syndrome|Autism|Autism Spectrum Disorders|Autistic Disorder|Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)","Parallel Assignment","Interventional","Treatment","Randomized","Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine",3,"Least squares mean difference",0.1,0.7611,"ANCOVA",-0.5,0.7,95,null,"NA","All",479,"Completed","Phase 2","\t"]
["NCT01595438",4401384,8063509,"Investigator Determined Clinical Response at LFU (ME at LFU Analysis Set)","sulfamethoxazole|trimethoprim|trimethoprim, sulfamethoxazole drug combination|ciprofloxacin|ceftazidime|doripenem|avibactam","Ceftazidime - Avibactam ( CAZ-AVI)|Doripenem|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)","Drug|Drug|Drug|Drug","urinary tract infections|communicable diseases|pyelonephritis|infection","Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis","Parallel Assignment","Interventional","Treatment","Randomized","Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)",2,"Diff of clinical cure rates",2.2,"NA",null,-2.9,7.24,95,null,"NA","All",598,"Completed","Phase 3","\t"]
["NCT01597635",4401035,8063207,"Biomarker Analysis for Serum Inflammatory Biomarkers, Markers of Neutrophil Activation, Markers of Lung Epithelial Cell Injury, Renin Levels and Aldosterone Levels Upto Day 5 (Part B)","NA","Dose 1 GSK2586881|Dose 2 GSK2586881|Dose 3 GSK2586881|Dose 4 GSK2586881|Placebo (saline)","Drug|Drug|Drug|Drug|Drug","wounds and injuries|lung injury|respiratory distress syndrome, adult|acute lung injury","Lung Injury, Acute","Parallel Assignment","Interventional","Treatment","Randomized","The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury",2,"Ratio of Active/Placebo",0.83,0.8835,"Bayesian repeated measures model",0.609,1.135,95,null,"NA","All",44,"Completed","Phase 2","\t"]
["NCT01599806",4400945,8062934,"Time to First Defervescence While on IV Study Therapy (mMITT Analysis Set)","ceftazidime|sulfamethoxazole|ciprofloxacin|avibactam|doripenem|trimethoprim|trimethoprim, sulfamethoxazole drug combination","Ceftazidime - Avibactam ( CAZ-AVI)|Doripenem|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)","Drug|Drug|Drug|Drug","pyelonephritis|communicable diseases|infection|urinary tract infections","Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis","Parallel Assignment","Interventional","Treatment","Randomized","Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)",2,null,"NA",0.038,"Log Rank",{"$nulls":4},"NA","All",641,"Completed","Phase 3","\t"]
["NCT01603602",4400735,8062348,"Goal Attainment Score (GAS) as Assessed by Physician Using a 6-Point Scale","botulinum toxins|abobotulinumtoxina|botulinum toxins, type a","botulinum toxin Type A|Normal Saline (Placebo)","Biological|Drug","cerebral palsy|muscle spasticity","Cerebral Palsy|Muscle Spasticity|Pediatrics|Stroke","Parallel Assignment","Interventional","Treatment","Randomized","BOTOX® Treatment in Pediatric Upper Limb Spasticity",3,"LS Mean Difference",-0.1,0.636,"ANCOVA",-0.498,0.305,95,null,"NA","All",235,"Completed","Phase 3","\t"]
["NCT01604265",4400682,8062298,"Change From Baseline in the Mean Pain 0-10 Numerical Rating Scale Score at the End of Treatment (4 Weeks)","nabiximols","Placebo|Sativex","Drug|Drug","sclerosis|multiple sclerosis|neuralgia","Multiple Sclerosis|Neuropathic Pain","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis",2,"Estimated mean treatment difference",-1.25,0.005,"ANCOVA",-2.11,-0.39,95,null,"NA","All",66,"Completed","Phase 3","\t"]
["NCT01610063",4400407,8061418,"Percentage Change in Hamilton Depression Rating Scale (HAMD-17) Score From Baseline","NA","Pharmacogenomic algorithm","Other","depression","Depression","Parallel Assignment","Interventional","Diagnostic","Randomized","Evaluation of an Antidepressant Pharmacogenomic Algorithm in an Outpatient Clinical Setting",2,null,"NA",{"v":1E-4,"d":"1.00E-04"},"t-test, 2 sided",{"$nulls":4},"NA","All",227,"Completed","N/A","\t"]
["NCT01617187",4400026,8060680,"Change From Baseline in PANSS Marder Factor Positive Symptom Score at Days 4, 7, 14, 21, 28, 35 and 42","olanzapine|asenapine","Asenapine|Placebo Asenapine|Olanzapine|Placebo Olanzapine","Drug|Drug|Drug|Drug","schizophrenia","Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)",4,"LS means difference",0.3,0.6161,"MMRM",-0.8,1.4,95,"Standard Error of the Mean",0.56,"All",360,"Completed","Phase 3","\t"]
["NCT01617187",4400126,8060685,"Change From Baseline in CGI-S Score at Days 4, 7, 14, 21, 28 and 35","olanzapine|asenapine","Asenapine|Placebo Asenapine|Olanzapine|Placebo Olanzapine","Drug|Drug|Drug|Drug","schizophrenia","Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)",4,"LS means difference",0,0.9789,"MMRM",-0.2,0.2,95,"Standard Error of the Mean",0.12,"All",360,"Completed","Phase 3","\t"]
["NCT01619423",4399834,8060485,"Number of Patients With Neuropathy Grade 2 or Higher (According to the Oxaliplatin Specific Sanofi Scale (OSSS) Criteria Related Paraesthesia/Dysaesthesia)","pyridoxal phosphate|edetic acid","PledOx (2 µmol/kg)|PledOx (5 µmol/kg)|PledOx (10 µmol/kg)|Placebo (0,9% NaCl)","Drug|Drug|Drug|Drug","colorectal neoplasms","Advanced Metastatic (Stage IV) Colorectal Cancer","Parallel Assignment","Interventional","Treatment","Randomized","A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer",4,"Odds Ratio (OR)",0.62,0.16,"Cochran-Mantel-Haenszel",null,1.14,10,null,"NA","All",186,"Completed","Phase 1/Phase 2","\t"]
["NCT01620528",4399613,8060365,"Percent Change From Baseline to Month 3 in Mean Pain Score for NMPP","NA","elagolix|placebo","Drug|Other","endometriosis","Endometriosis","Parallel Assignment","Interventional","Treatment","Randomized","A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain",3,"LS Mean of Difference",-22.49,1E-3,"mixed-effects model",-30.38,-14.6,97.5,"Standard Error of the Mean",3.514,"Female",872,"Completed","Phase 3","\t"]
["NCT01626079",4399315,8059664,"Death or HF Hospitalization Within 24 Months (Finkelstein-Schoenfeld Analysis of All-Cause Death or Recurrent HF Hospitalization Through 24 Months)","NA","MitraClip System","Device","mitral valve insufficiency|heart failure","Heart Failure|Mitral Regurgitation|Mitral Valve Regurgitation|Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure Subjects","Parallel Assignment","Interventional","Treatment","Randomized","Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial)",2,"Win Ratio",1.61,{"v":1E-4,"d":"1.00E-04"},"Finkelstein-Schoenfeld Analysis",1.29,2.04,95,null,"NA","All",614,"Active, not recruiting","N/A","\t"]
["NCT01633112",4399094,8058583,"Change From Baseline in TSQM Scales","(t,g)-a-l|glatiramer acetate|fingolimod hydrochloride","fingolimod|glatiramer acetate","Drug|Drug","multiple sclerosis|sclerosis|multiple sclerosis, relapsing-remitting","Relapsing-remitting Multiple Sclerosis (RRMS)","Parallel Assignment","Interventional","Treatment","Randomized","MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone",3,null,"NA",{"v":0.0005,"d":"5.00E-04"},"Wilcoxon signed-rank test",{"$nulls":4},"NA","All",1064,"Terminated","Phase 3","\t"]
["NCT01634139",4398927,8058500,"Change From Baseline in Asthma Symptom-free Days","tiotropium bromide","Tiotropium low dose QD|Tiotropium high dose QD|Placebo","Drug|Drug|Drug","asthma","Asthma","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma",3,"Median Difference (Net)",0.028,0.5089,"Mixed Models Analysis",-0.056,0.133,95,"Standard Error of the Mean",0.043,"All",403,"Completed","Phase 3","\t"]
["NCT01638000",4398729,8058022,"Percentage of Participants With Normalization of Micturitions at Weeks 4, 8, 12 and Final Visit","mirabegron|solifenacin succinate","Mirabegron|Solifenacin succinate","Drug|Drug","urinary bladder diseases|urologic diseases|urinary bladder, overactive","Urinary Bladder Diseases|Urinary Bladder, Overactive|Urologic Diseases","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.",2,"Odds Ratio (OR)",1.18,0.11,"Regression, Logistic",0.97,1.44,95,null,"NA","All",1887,"Completed","Phase 3","\t"]
["NCT01641653",4398518,8057492,"Maximum Perioperative Blood Glucose Level of 30 Minute Interval Measurements","midazolam","Normal saline|Midazolam","Other|Drug","hernia","Hernia","Parallel Assignment","Interventional","Treatment","Randomized","Does Preop Midazolam Maintain Blood Glucose Norms in the Non Diabetic Perioperative Period",2,null,"NA",0.87,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",60,"Completed","Phase 4","\t"]
["NCT01644500",4398304,8056918,"Percentage of Participants Attaining HbA1c of <7% or ≤6.5% at 26 Weeks","glimepiride|dulaglutide","Dulaglutide|Glimepiride|Placebo as Capsules|Placebo as SC Injection","Drug|Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Type 2 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus",3,"Odds Ratio (OR)",2.7,1E-3,"Fisher Exact",1.8,4.1,5,null,"NA","All",737,"Completed","Phase 3","\t"]
["NCT01646177",4398148,8056717,"Number of Participants Achieving Palmoplantar PASI of ≥75% (PPASI 75) Improvement","ixekizumab|etanercept","Placebo|50 mg etanercept|80 mg ixekizumab","Drug|Drug|Drug","psoriasis","Psoriasis","Parallel Assignment","Interventional","Treatment","Randomized","A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)",4,null,"NA",1E-3,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",1346,"Completed","Phase 3","\t"]
["NCT01649297",4397990,8056392,"HbA1c (Glycosylated Haemoglobin) Change From Baseline at Week 16","empagliflozin","Placebo|Placebo|Placebo|Placebo|Placebo|empagliflozin (low dose qd)|Placebo|Placebo|Placebo|Placebo|Placebo|Placebo|Placebo|Placebo|Placebo|Placebo|Empagliflozin (high dose qd)|empagliflozin (high dose bid)|Placebo|empagliflozin (low dose bid)","Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy",5,null,"NA","NA",{"$nulls":5},"NA","All",983,"Completed","Phase 2","\t"]
["NCT01652729",4397799,8055995,"Change in Body Weight (kg) From Baseline to Week 28","exenatide|sitagliptin phosphate","Exenatide once weekly suspension|Sitagliptin|Placebo","Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Diabetes Type 2","Parallel Assignment","Interventional","Treatment","Randomized","Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus",3,"LS Mean Difference",-1.27,0.0198,"mixed model for repeated measure",-2.34,-0.2,95,"Standard Error of the Mean",0.5419,"All",365,"Completed","Phase 3","\t"]
["NCT01658995",4397380,8055320,"Subject Satisfaction","doxycycline","Doxycycline|Placebo","Drug|Drug","hemorrhage","ESI-related Bleeding","Parallel Assignment","Interventional","Treatment","Randomized","Management of Etonogestrel Subdermal Implant-related Bleeding",2,null,"NA",0.46,"Chi-squared",{"$nulls":4},"NA","Female",82,"Completed","Phase 3","\t"]
["NCT01664247",4397121,8054460,"Change From Baseline in 8-point Profile","liraglutide","insulin degludec|placebo|liraglutide","Drug|Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Diabetes|Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification",2,"Mean Difference (Final Values)",-1.75,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",-2.27,-1.23,95,null,"NA","All",346,"Completed","Phase 3","\t"]
["NCT01668797",4396894,8053929,"Change From Baseline in CGI-S Score at Endpoint - LOCF Analysis","brexpiprazole","Brexpiprazole|Placebo","Drug|Drug","schizophrenia","Acute Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia",2,"Mean Difference (Final Values)",-0.5,{"v":0.0002,"d":"2.00E-04"},"ANCOVA",-0.76,-0.24,95,null,"NA","All",524,"Completed","Phase 3","\t"]
["NCT01673867",4396510,8053271,"Overall Survival (OS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint","docetaxel|nivolumab","Nivolumab|Docetaxel","Biological|Drug","carcinoma, non-small-cell lung|lung neoplasms","Non-Squamous Cell Non-small Cell Lung Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC",2,"Hazard Ratio (HR)",0.9,"NA",null,0.66,1.24,95,null,"NA","All",792,"Active, not recruiting","Phase 3","\t"]
["NCT01681472",4395610,8052266,"Correlation of Gene Expression in Tumor and Adjacent Mucosa","levoleucovorin|leucovorin|tetrahydrofolates","6R-MTHF (arfolitixorin) 200 mg/m2|Levoleucovorin 200 mg/m2|6R-MTHF (arfolitixorin) 60 mg/m2|Levoleucovorin 60 mg/m2","Drug|Drug|Drug|Drug","colonic neoplasms|neoplasms","Colonic Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer",4,"Correlation factor",-0.16724,0.6922,"Pearson Correlation",{"$nulls":4},"NA","All",32,"Completed","Phase 1/Phase 2","\t"]
["NCT01681472",4395776,8052291,"AUC(Last) of [6R]-5,10-methylene-THF","levoleucovorin|leucovorin|tetrahydrofolates","6R-MTHF (arfolitixorin) 200 mg/m2|Levoleucovorin 200 mg/m2|6R-MTHF (arfolitixorin) 60 mg/m2|Levoleucovorin 60 mg/m2","Drug|Drug|Drug|Drug","colonic neoplasms|neoplasms","Colonic Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer",4,null,"NA",0.0022,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",32,"Completed","Phase 1/Phase 2","\t"]
["NCT01682876",4395475,8052065,"Numbers of 6 to 10 Years-Old Subjects Who Reported Solicited Local and Systemic Adverse Events After Any Vaccination","NA","MenACWY-CRM","Biological","meningococcal infections","Infections, Meningococcal|Meningococcal Disease","Parallel Assignment","Interventional","Prevention","Randomized","Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.",4,"Risk Ratio (RR)",1.65,"NA",null,1.06,2.57,95,null,"NA","All",715,"Completed","Phase 3","\t"]
["NCT01687218",4395321,8051523,"Acceptability: Participant Self-report of Ease of Use. I1-Overall How Easy or Difficult Was it to Use the Product?","tenofovir|emtricitabine|emtricitabine, tenofovir disoproxil fumarate drug combination|glycerol","Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)|Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)|Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)","Drug|Drug|Drug","NA","HIV","Crossover Assignment","Interventional","Other","Randomized","Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel",6,"Odds Ratio (OR)",0.56,0.08,"Generalized Estimating Equation (GEE)",0.29,1.08,95,null,"NA","Male",195,"Completed","Phase 2","\t"]
["NCT01691560",4395014,8050980,"Change From Baseline in Evaporative Air Sensitivity Response on VRS at Week 8","fluorophosphate|calcium|sodium fluoride|listerine|fluorides|calcium, dietary","5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice|Sodium monofluorophosphate dentifrice|Sodium fluoride dentifrice","Drug|Drug|Drug|Drug","hypersensitivity|dentin sensitivity","Dentine Hypersensitivity","Parallel Assignment","Interventional","Treatment","Randomized","Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity",4,"Adjusted Mean Difference",0.76,0.0811,"ANCOVA",-0.09,1.61,95,null,"NA","All",140,"Completed","Phase 2","\t"]
["NCT01691560",4395041,8050984,"Change From Baseline in Tactile Sensitivity Pain Response (g) at Week 4","fluorophosphate|calcium|sodium fluoride|listerine|fluorides|calcium, dietary","5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice|Sodium monofluorophosphate dentifrice|Sodium fluoride dentifrice","Drug|Drug|Drug|Drug","hypersensitivity|dentin sensitivity","Dentine Hypersensitivity","Parallel Assignment","Interventional","Treatment","Randomized","Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity",4,"Median Difference (Final Values)",0,0.1133,"Wilcoxon (Mann-Whitney)",0,5,95,null,"NA","All",140,"Completed","Phase 2","\t"]
["NCT01696396",4394839,8050471,"Percentage of Participants With Remission at Week 8","NA","Abrilumab|Placebo","Drug|Drug","crohn disease","Crohn's Disease","Parallel Assignment","Interventional","Treatment","Randomized","Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease",4,"Difference in Adjusted Remission Rates",1.6,"NA",null,-7.9,8.9,90,null,"NA","All",254,"Completed","Phase 2","\t"]
["NCT01702428",4394555,8049805,"Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value","heptavalent pneumococcal conjugate vaccine","Priorix|M-M-R II|Varivax|Havrix|Prevnar 13","Biological|Biological|Biological|Biological|Biological","measles|rubella","Measles|Mumps|Rubella","Parallel Assignment","Interventional","Prevention","Randomized","Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age",4,"Difference in seroresponse rate",0.61,"NA",null,-0.53,1.79,95,null,"NA","All",5016,"Completed","Phase 3","\t"]
["NCT01704287",4394419,8049490,"Interim Overall Survival (OS) - Initial Treatment Period","temozolomide|dacarbazine|paclitaxel|carboplatin|pembrolizumab","Pembrolizumab|Carboplatin|Paclitaxel|Dacarbazine|Temozolomide","Biological|Drug|Drug|Drug|Drug","melanoma","Malignant Melanoma","Parallel Assignment","Interventional","Treatment","Randomized","Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)",5,"Hazard Ratio (HR)",0.74,0.0106,"Log Rank",0.57,0.96,95,null,"NA","All",540,"Completed","Phase 2","\t"]
["NCT01710527",4393991,8048562,"Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) and Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-infinity)","metformin","Metformin 500mg|Glucophage 500mg","Drug|Drug","diabetic foot","Diabetic Foot","Crossover Assignment","Interventional","Basic Science","Randomized","BE Study of Metformin GSK 500mg",2,"Ratio (%)",102.44,0.2702,"ANOVA",98.78,106.23,90,null,"NA","Male",32,"Completed","Phase 2","\t"]
["NCT01714310",4393893,8048083,"Clinical Global Impression - Improvement","lisdexamfetamine dimesylate|fluoxetine","lisdexamfetamine|Placebo|fluoxetine","Drug|Drug|Drug","NA","Severe Mood Dysregulation","Parallel Assignment","Interventional","Treatment","Randomized","Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation",3,null,"NA",0.76,"Chi-squared",{"$nulls":4},"NA","All",34,"Completed","Phase 2","\t"]
["NCT01719003",4393717,8047442,"FPG (Fasting Plasma Glucose) Change From Baseline at Week 24","metformin|empagliflozin","Metformin 500 mg bid|Metformin 1000 mg bid|Empagliflozin low dose qd|Empagliflozin high dose qd|Empagliflozin low dose bid|Metformin 500 mg bid|Empagliflozin high dose bid|Empagliflozin low dose bid|Metformin 1000 mg bid|Metformin 500 mg bid|Metformin 1000 mg bid|Empagliflozin high dose bid|Metformin 1000 mg bid|Empagliflozin high dose bid","Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug","hyperglycemia|diabetes mellitus|diabetes mellitus, type 2","Diabetes Mellitus, Type 2|Hyperglycemia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes",9,"Adjusted mean",-23,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",-29.7,-16.3,95,"Standard Error of the Mean",3.4,"All",1413,"Completed","Phase 3","\t"]
["NCT01725126",4393431,8046770,"Change From Baseline in Weighted Mean Glucose Area Under the Curves From Time 0 to 24 Hours (AUC [0-24 Hours]) During the Double-blind Treatment Period of Part B and C","metformin|liraglutide","GSK2890457|Metformin|Placebo|Liraglutide","Drug|Drug|Drug|Drug","obesity","Obesity","Parallel Assignment","Interventional","Treatment","Randomized","To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes",6,"Mean Difference (Final Values)",-0.853,"NA",null,-2.232,0.526,95,null,"NA","All",53,"Completed","Phase 2","\t"]
["NCT01728584",4393242,8046372,"Score on Surgeon's Assessment of Overall Satisfaction With the Visibility of the Surgical Field: By Depth of NMB (Standard, Deep)","rocuronium|bromides","Rocuronium|Insufflation|Sugammadex","Drug|Other|Drug","gallbladder diseases","Gallbladder Disease","Parallel Assignment","Interventional","Treatment","Randomized","A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982)",4,"Difference in LS Means",0.91,0.063,"ANCOVA",-0.05,1.87,95,null,"NA","All",127,"Completed","Phase 4","\t"]
["NCT01730040",4393112,8046117,"Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis","rosuvastatin calcium|ezetimibe|atorvastatin","Alirocumab|Atorvastatin|Ezetimibe|Rosuvastatin|Placebo","Drug|Drug|Drug|Drug|Drug","hypercholesterolemia","Hypercholesterolemia","Parallel Assignment","Interventional","Treatment","Randomized","Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)",7,"LS Mean Difference",-33.5,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",-45.3,-21.6,99,null,"NA","All",355,"Completed","Phase 3","\t"]
["NCT01741532",4392728,8044564,"Change in Score on Unified Parkinson's Disease Rating Scale","deferiprone","Deferiprone oral solution|Placebo","Drug|Drug","pantothenate kinase-associated neurodegeneration|nerve degeneration","Pantothenate Kinase-Associated Neurodegeneration","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)",2,null,"NA",0.3677,"Mixed Models Analysis",{"$nulls":4},"NA","All",89,"Completed","Phase 3","\t"]
["NCT01746901",4392179,8043982,"Pupillometry: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour, 0-12 Hour, 0-24 Hour and 0-36 Hour","naltrexone|oxycodone","Placebo|intact ALO-02 60 mg/7.2 mg|crushed ALO-02 60 mg/7.2 mg|crushed oxycodone IR 60 mg|crushed ALO-02 40 mg/4.8 mg|crushed oxycodone IR 40 mg","Drug|Drug|Drug|Drug|Drug|Drug","NA","Healthy","Crossover Assignment","Interventional","Other","Randomized","A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers",6,"LS Mean Difference",-12.5,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",-15.86,-9.14,95,null,"NA","All",81,"Completed","Phase 1","\t"]
["NCT01746901",4392244,8043985,"Dizzy: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour, 0-12 Hour, 0-24 Hour and 0-36 Hour","naltrexone|oxycodone","Placebo|intact ALO-02 60 mg/7.2 mg|crushed ALO-02 60 mg/7.2 mg|crushed oxycodone IR 60 mg|crushed ALO-02 40 mg/4.8 mg|crushed oxycodone IR 40 mg","Drug|Drug|Drug|Drug|Drug|Drug","NA","Healthy","Crossover Assignment","Interventional","Other","Randomized","A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers",6,"LS Mean Difference",22.6,{"v":0.0006,"d":"6.00E-04"},"Mixed Models Analysis",9.8,35.5,95,null,"NA","All",81,"Completed","Phase 1","\t"]
["NCT01746901",4392469,8044000,"Good Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour, 0-12 Hour, 0-24 Hour and 0-36 Hour","naltrexone|oxycodone","Placebo|intact ALO-02 60 mg/7.2 mg|crushed ALO-02 60 mg/7.2 mg|crushed oxycodone IR 60 mg|crushed ALO-02 40 mg/4.8 mg|crushed oxycodone IR 40 mg","Drug|Drug|Drug|Drug|Drug|Drug","NA","Healthy","Crossover Assignment","Interventional","Other","Randomized","A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers",6,"LS Mean Difference",200.2,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",108.4,292,95,null,"NA","All",81,"Completed","Phase 1","\t"]
["NCT01751646",4391944,8043494,"Change From Baseline to Week 48 in UCa/Ucr","vitamin d|ergocalciferols|vitamins|cholecalciferol","Vitamin D3 50,000 IU|Vitamin D3 placebo","Dietary Supplement|Dietary Supplement","hiv infections|infection|acquired immunodeficiency syndrome","HIV Infection","Parallel Assignment","Interventional","Diagnostic","Randomized","Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART",2,null,"NA",0.387,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",214,"Completed","N/A","\t"]
["NCT01752842",4391898,8043357,"Change in Cardiac Diastolic Function as Measured by E' (cm/s)","fenofibrate","Fenofibrate|Placebo for fenofibrate","Drug|Drug","diabetes complications|diabetes mellitus, type 2|heart diseases|diabetes mellitus","Diabetes Complications|Type II Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","Lipid Biomarkers for Diabetic Heart Disease",2,"Mean Difference (Final Values)",-0.75,0.07,"ANCOVA",-1.56,0.04,95,null,"NA","All",70,"Completed","N/A","\t"]
["NCT01753856",4391778,8043203,"Change From Baseline to 3 Months in MS/BS in the Endocortical Compartment (EC), Intracortical Compartment (IC), and Periosteal Compartment (PC) of the Iliac Crest Bone Biopsies","teriparatide|demeclocycline|vitamin d|calcium|tetracycline|denosumab","Teriparatide|Denosumab|Demeclocycline|Tetracycline|Calcium Supplement|Vitamin D","Drug|Drug|Drug|Drug|Drug|Drug","osteoporosis","Osteoporosis","Parallel Assignment","Interventional","Treatment","Randomized","Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis",2,null,"NA",1E-3,"ANCOVA",{"$nulls":4},"NA","Female",69,"Completed","Phase 4","\t"]
["NCT01757535",4391548,8042772,"Mean Change in the Functional Assessment of Chronic Illness Therapy (FACIT-Fatigue Scale V 4.0) Score From Baseline","azacitidine","Oral Azacitidine|Placebo","Drug|Drug","leukemia, myeloid, acute|leukemia, myeloid|leukemia","Leukemia, Myeloid, Acute","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission",2,null,"NA",0.603,"t-test, 2 sided",{"$nulls":4},"NA","All",472,"Active, not recruiting","Phase 3","\t"]
["NCT01763827",4391249,8042155,"Percent Change From Baseline in Non-HDL-C at Week 12","evolocumab|ezetimibe|antibodies, monoclonal","Evolocumab|Ezetimibe|Placebo to Evolocumab|Placebo to Ezetimibe","Biological|Drug|Biological|Other","hyperlipidemias","Hyperlipidemia","Parallel Assignment","Interventional","Treatment","Randomized","Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2",6,"LS Mean Treatment Difference",-49.81,1E-3,"Repeated measures linear effects model",-53.34,-46.27,95,"Standard Error of the Mean",1.79,"All",615,"Completed","Phase 3","\t"]
["NCT01763866",4391004,8042127,"Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12","ezetimibe|rosuvastatin calcium|simvastatin|atorvastatin|antibodies, monoclonal|evolocumab","Evolocumab|Ezetimibe|Placebo to Evolocumab|Placebo to Ezetimibe|Atorvastatin|Rosuvastatin|Simvastatin","Biological|Drug|Drug|Drug|Drug|Drug|Drug","hyperlipidemias","Hyperlipidemia","Parallel Assignment","Interventional","Treatment","Randomized","LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2",24,"Treatment Difference",64.9,1E-3,"Cochran-Mantel-Haenszel",49.8,75.2,95,null,"NA","All",2067,"Completed","Phase 3","\t"]
["NCT01764256",4390787,8042037,"Maximum Local or Systemic Reactogenicity After the First Vaccination","NA","P2-VP8 subunit rotavirus vaccine|placebo","Biological|Other","rotavirus infections","Rotavirus Infection","Parallel Assignment","Interventional","Prevention","Randomized","A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine",4,null,"NA",0.6004,"Fisher Exact",{"$nulls":4},"NA","All",48,"Completed","Phase 1","\t"]
["NCT01767116",4390600,8041678,"Percentage of Participants With Hemoglobin Decrease to Below the Lower Limit of Normal (LLN) At End of Treatment","ribavirin","ABT-450/r/ABT-267, ABT-333|Ribavirin|Placebo for ribavirin","Drug|Drug|Drug","hepatitis c|hepatitis c, chronic|hepatitis|communicable diseases|infection|hepatitis a|hepatitis, chronic","Chronic Hepatitis C Infection","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection",2,null,"NA",1E-3,"Fisher Exact",{"$nulls":4},"NA","All",419,"Completed","Phase 3","\t"]
["NCT01774344",4390364,8040828,"Time to Progression (TTP)","NA","Regorafenib (Stivarga, BAY73-4506)|Placebo","Drug|Drug","carcinoma|carcinoma, hepatocellular","Carcinoma, Hepatocellular","Parallel Assignment","Interventional","Treatment","Randomized","Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma",2,"Hazard Ratio (HR)",0.412,{"v":1e-06,"d":"1.00E-06"},"Log Rank",0.334,0.509,95,null,"NA","All",573,"Completed","Phase 3","\t"]
["NCT01782222",4389920,8039768,"Change From Baseline to the End of the Maintenance Period in the Sum Score of the 8-item Parkinson's Disease Questionnaire (PDQ-8)","rotigotine","Rotigotine|Placebo","Drug|Other","parkinson disease","Idiopathic Parkinson's Disease","Parallel Assignment","Interventional","Treatment","Randomized","Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy",3,"Least Square Mean",-5.06,0.111,"ANCOVA",-11.29,1.17,95,"Standard Error of the Mean",3.15,"All",122,"Completed","Phase 4","\t"]
["NCT01782378",4389900,8039724,"Digit Span Total Forward + Backwards","NA","Real LED Treatment|Sham LED Treatment","Device|Device","memory disorders|neurobehavioral manifestations","Gulf War Veterans Illness|Memory Disorders|Neurobehavioral Manifestations","Crossover Assignment","Interventional","Treatment","Randomized","Scalp Application of LED Therapy to Improve Thinking and Memory in Veterans With Gulf War Illness",2,"Mean Difference (Final Values)",-0.14,0.81,"ANOVA",{"$nulls":3},"Standard Error of the Mean",0.59,"All",96,"Completed","N/A","\t"]
["NCT01786668",4389609,8039162,"Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Weeks 2, 4, 8 and 12","tofacitinib","Tofacitinib 2 mg|Tofacitinib 5 mg|Tofacitinib 10 mg|Placebo","Drug|Drug|Drug|Drug","spondylitis|spondylitis, ankylosing","Ankylosing Spondylitis","Parallel Assignment","Interventional","Treatment","Randomized","Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis",4,"Mean Difference (Final Values)",-0.34,0.256,"Mixed Models Analysis",-0.92,0.25,95,"Standard Error of the Mean",0.297,"All",208,"Completed","Phase 2","\t"]
["NCT01792518",4389234,8038481,"HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment","linagliptin","Placebo|Linagliptin 5mg","Drug|Drug","diabetes mellitus|diabetes mellitus, type 2|albuminuria","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin",2,"Mean Difference (Final Values)",-0.6,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",-0.78,-0.43,95,"Standard Error of the Mean",0.09,"All",360,"Completed","Phase 3","\t"]
["NCT01794923",4389087,8038329,"Change From Baseline in Spontaneous Muscle Soreness at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 30, 36, 48, 54, 60 and 72 Hours Post-Dose 1","NA","IBU BID|Placebo BID|IBU TID|Placebo TID","Drug|Drug|Drug|Drug","NA","Pain","Parallel Assignment","Interventional","Treatment","Randomized","Topical Ibuprofen for Delayed Onset Mulscle Soreness",4,null,"NA",0.776,"ANOVA",{"$nulls":4},"NA","All",205,"Completed","Phase 3","\t"]
["NCT01794923",4389151,8038331,"Change From Baseline in Muscle Soreness With Movement at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 30, 36, 48, 54, 60 and 72 Hours Post-Dose 1","NA","IBU BID|Placebo BID|IBU TID|Placebo TID","Drug|Drug|Drug|Drug","NA","Pain","Parallel Assignment","Interventional","Treatment","Randomized","Topical Ibuprofen for Delayed Onset Mulscle Soreness",4,null,"NA",0.151,"ANOVA",{"$nulls":4},"NA","All",205,"Completed","Phase 3","\t"]
["NCT01796236",4388757,8038235,"Health Utilies Index (HUI-III & HUI-II)","NA","Minimally invasive surgery and BA400|Traditional surgery and BA300","Device|Device","hearing loss, mixed conductive-sensorineural|hearing loss, conductive|hearing loss|deafness","Deafness|Hearing Loss|Hearing Loss, Conductive|Hearing Loss, Mixed Conductive-Sensorineural","Parallel Assignment","Interventional","Treatment","Randomized","Clinical and Health Economic Evaluation With a New Baha® Abutment Combined With a Minimally Invasive Surgical Technique",2,null,"NA",0.4,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",106,"Completed","N/A","\t"]
["NCT01798485",4388529,8037939,"Disease Control Rate (DCR) as of 19 October 2015","docetaxel","Docetaxel|Ganetespib","Drug|Drug","adenocarcinoma of lung|adenocarcinoma|lung neoplasms|carcinoma, non-small-cell lung","Non-Small-Cell Lung Adenocarcinoma|Non-small Cell Lung Cancer Metastatic|Non-small Cell Lung Cancer Stage IIIB|Non-small Cell Lung Cancer Stage IV","Parallel Assignment","Interventional","Treatment","Randomized","A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC",2,null,"NA",0.339,"Fisher Exact",{"$nulls":4},"NA","All",696,"Terminated","Phase 3","\t"]
["NCT01807221",4388271,8037092,"Percentage of Participants With a Relative Decrease in NT-proBNP of More Than 30% From Baseline to Day 90","eplerenone","Finerenone (BAY94-8862)|Placebo|Inspra (eplerenone)","Drug|Drug|Drug","kidney diseases|renal insufficiency, chronic|diabetes mellitus, type 2|heart failure|diabetes mellitus","Heart Failure","Parallel Assignment","Interventional","Treatment","Randomized","Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone",6,"Mean Difference (Final Values)",-4.7,0.7945,"Chi-squared",-13.4,4,90,null,"NA","All",1066,"Completed","Phase 2","\t"]
["NCT01809262",4388136,8036717,"FEV1 AUC 0 - 24 Hours","NA","single dose of 5 mcg|single dose of placebo|single dose of 40 mcg|single dose of 20 mcg|single dose of 2 mcg|single dose of 10 mcg","Drug|Drug|Drug|Drug|Drug|Drug","lung diseases|pulmonary disease, chronic obstructive","Pulmonary Disease, Chronic Obstructive","Crossover Assignment","Interventional","Treatment","Randomized","Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease",6,"Mean Difference (Final Values)",0.138,{"v":1E-4,"d":"1.00E-04"},"ANCOVA",0.107,0.168,95,"Standard Error of the Mean",0.015,"All",36,"Completed","Phase 2","\t"]
["NCT01813890",4387996,8036336,"Sum of Pain Intensity Difference (SPID) Over 48 Hours","tapentadol","Tapentadol IR 50 mg|Tapentadol IR 75 mg|Placebo","Drug|Drug|Drug","hallux valgus|acute pain","Hallux Valgus","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo",3,"Median Difference (Net)",126.58,0.004,"ANCOVA",49.5,203.7,95,null,"NA","All",60,"Completed","Phase 3","\t"]
["NCT01817530",4387778,8035916,"Percentage of Participants Who Achieved Suppression of Bleeding During the Last 56 Days of Treatment","norethindrone|estradiol 17 beta-cypionate|norethindrone acetate|estradiol|polyestradiol phosphate|estradiol 3-benzoate","Elagolix placebo|Elagolix|0.5 mg estradiol / 0.1 mg norethindrone acetate|1 mg estradiol / 0.5 mg norethindrone acetate|E2/NETA placebo","Other|Drug|Drug|Drug|Drug","menorrhagia|leiomyoma|myofibroma|hemorrhage|uterine hemorrhage","Heavy Uterine Bleeding|Uterine Fibroids","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)",8,null,"NA",1E-3,"Fisher Exact",{"$nulls":4},"NA","Female",571,"Completed","Phase 2","\t"]
["NCT01825057",4387353,8035176,"Percentage of Motivation Interviewing Sessions Audio Recorded","NA","See One|Do One|Order One","Behavioral|Behavioral|Behavioral","NA","Do One|Order One|See One","Parallel Assignment","Interventional","Health Services Research","Randomized","Three Strategies for Implementing Motivational Interviewing on Medical Inpatient Units",3,"Median Difference (Final Values)",19.7,{"v":1E-4,"d":"1.00E-04"},"Kruskal-Wallis",{"$nulls":4},"NA","All",1211,"Completed","N/A","\t"]
["NCT01832090",4387150,8034393,"Mean Change on the Merz Hand Grading Scale (MHGS), by Hand, Among All Treated Subjects Without Retreatment","NA","Radiesse® Injectable Dermal Filler","Device","NA","Aging Hands","Crossover Assignment","Interventional","Treatment","Randomized","Evaluation of Radiesse® Dermal Filler for Hand Treatment",2,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",118,"Completed","N/A","\t"]
["NCT01843842",4386918,8033125,"Severity of the Disease Within 6 Days Was Assessed Using the \"Area Under the Curve\" for the Total Symptom Score (TSS)","NA","Placebo|Ergoferon","Drug|Drug","communicable diseases|respiratory tract infections|infection","Acute Upper Respiratory Tract Infections","Parallel Assignment","Interventional","Treatment","Randomized","Clinical Trial of Safety and Clinical Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children",2,null,"NA",0.082,"Kruskal-Wallis",{"$nulls":4},"NA","All",306,"Completed","Phase 3","\t"]
["NCT01844531",4386830,8032956,"Cmax for Empagliflozin","empagliflozin|metformin","empagliflozin|metformin (Glucophage®)|metformin (Glucophage®)|empagliflozin|empagliflozin and metformin|empagliflozin and metformin","Drug|Drug|Drug|Drug|Drug|Drug","NA","Healthy","Crossover Assignment","Interventional","Treatment","Randomized","Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets",4,"Adjusted gMean ratio FDC/single tablets",102.96,0,"ANOVA",97.917,108.258,90,"Standard Error of the Mean",9.2,"All",24,"Completed","Phase 1","\t"]
["NCT01854528",4386228,8031757,"Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment","interferons|ribavirin","ABT-450/r/ABT-267, ABT-333|Ribavirin|Pegylated Interferon a-2a (PegINF)|Telaprevir","Drug|Drug|Drug|Drug","hepatitis c, chronic|hepatitis|hepatitis a|infection|hepatitis, chronic|communicable diseases|hepatitis c","Chronic Hepatitis C Infection","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults",2,"Mean Difference (Final Values)",34.26,1E-3,"Stratum adjusted Mantel-Haenszel",21.09,47.42,95,null,"NA","All",148,"Completed","Phase 3","\t"]
["NCT01856686",4385931,8031301,"Mu Wave Frequency at 3 Months","NA","BP22042013|Low carbohydrate diet","Drug|Dietary Supplement","NA","ADD|ADHD","Parallel Assignment","Interventional","Supportive Care","Randomized","Neurocognitive and Neurobiological Improvement in ADHD Children by Modification of Dietary Protein",2,null,"NA",0.94574,"Paired t-test",{"$nulls":4},"NA","All",64,"Completed","Early Phase 1","\t"]
["NCT01857310",4385815,8031193,"Quality of Embryos Transferred Per Cycle, Categorical","folic acid","5 mg folic acid and 30 mg elemental zinc|Placebo Comparator: Placebo","Dietary Supplement|Drug","abortion, spontaneous","Live Birth|Pregnancy|Spontaneous Abortion","Parallel Assignment","Interventional","Treatment","Randomized","Folic Acid and Zinc Supplementation Trial (FAZST)",2,"Risk Ratio (RR)",1.03,"NA",null,0.88,1.21,95,null,"NA","All",2370,"Completed","N/A","\t"]
["NCT01865448",4385449,8030589,"4-HDOHE at 6 Months","NA","Omega-3 DHA|Placebo","Dietary Supplement|Other","weight loss|inflammation","Inflammation|Obesity","Parallel Assignment","Interventional","Treatment","Randomized","Effects of DHA on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment",2,null,"NA",0.0783,"ANCOVA",{"$nulls":4},"NA","All",34,"Completed","N/A","\t"]
["NCT01868646",4385308,8030259,"Change in Average Daily Blood Glucose From a 7-point Patient Self-monitoring of Blood Glucose (SMBG)","NA","Subetta|Placebo","Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Type II Diabetes Mellitus","Parallel Assignment","Interventional","Supportive Care","Randomized","Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus",2,null,"NA",0.599,"Mixed Models Analysis",{"$nulls":4},"NA","All",190,"Completed","Phase 4","\t"]
["NCT01874431",4385075,8029779,"Change From Baseline to Day 90 in EQ-5D Scores (EQ5D - Visual Analog Scale)","NA","Finerenone (BAY94-8862)|Placebo","Drug|Drug","kidney diseases|diabetic nephropathies|diabetes mellitus|diabetes mellitus, type 2","Diabetic Nephropathies","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy",8,"Least square mean difference",-1.682,0.3102,"t-test, 2 sided",-4.935,1.57,95,null,"NA","All",823,"Completed","Phase 2","\t"]
["NCT01881373",4384934,8029125,"Change in Prevalence of Overweight and Obesity Using Body Mass Index","NA","CHL program|Delayed Optimized CHL program","Other|Other","obesity, abdominal|acanthosis nigricans|obesity","Acanthosis Nigricans|Central Obesity|Obesity","Parallel Assignment","Interventional","Prevention","Randomized","Children's Healthy Living Community Randomized Trial",3,"Difference in prevalence",-4.2,0.02,"Regression, Logistic",{"$nulls":4},"NA","All",8371,"Completed","N/A","\t"]
["NCT01888640",4384558,8028426,"Brief Pain Inventory - Interference (0-10 Low to High Scale)","NA","TENS","Device","fibromyalgia|myofascial pain syndromes","Fibromyalgia","Parallel Assignment","Interventional","Treatment","Randomized","Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST)",3,"Mean Difference (Final Values)",-0.7,0.043,"Linear mixed models for repeated measure",-1.3,-0.01,95,null,"NA","Female",301,"Completed","N/A","\t"]
["NCT01893411",4384364,8027953,"Co-primary Variable: Investigator's Global Impression of Change of Plantar Flexor Spasticity Scale (GICS-PF) of the Primary Body Side at Day 29 (Week 4) of the First Injection Cycle","botulinum toxins|botulinum toxins, type a|abobotulinumtoxina|incobotulinumtoxina","IncobotulinumtoxinA (16 Units per kg body weight)|IncobotulinumtoxinA (12 Units per kg body weight)|IncobotulinumtoxinA (4 Units per kg body weight)","Drug|Drug|Drug","muscle spasticity|cerebral palsy","Lower Limb Spasticity Due to Cerebral Palsy","Parallel Assignment","Interventional","Treatment","Randomized","Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy",3,"LS-Mean difference",0.16,0,"Mixed Model Repeated Measure",-0.02,0.34,95,null,"NA","All",311,"Completed","Phase 3","\t"]
["NCT01900314",4384188,8027192,"Depressive Symptoms at 4 Weeks","NA","repetitive Transcranial Magnetic Stimulation (rTMS)","Device","depression|depressive disorder","Depression","Parallel Assignment","Interventional","Basic Science","Randomized","Imaging Biomarkers for TMS Treatment of Depression",2,null,"NA",0.16,"ANCOVA",{"$nulls":4},"NA","All",40,"Completed","N/A","\t"]
["NCT01903460",4384086,8026829,"Change From Baseline to Week 13 (End of Treatment) in Liver Enzymes","NA","LUM001|Placebo","Drug|Drug","liver diseases|alagille syndrome|syndrome","Alagille Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome",2,"LS mean difference from placebo",24,0.2372,"ANCOVA",-17.5,65.5,95,null,"NA","All",20,"Completed","Phase 2","\t"]
["NCT01914757",4383740,8025667,"Proportion of Nights With Awakening Due to Asthma","benralizumab","Benralizumab|Placebo","Biological|Biological","asthma","Asthma","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist",3,"Mean Difference (Final Values)",-0.03,0.146,"Mixed Models Analysis",-0.08,0.01,95,null,"NA","All",2508,"Completed","Phase 3","\t"]
["NCT01920555",4383510,8025082,"Clinical Positive Affect Scale (CPAS)","midazolam|ketamine","Ketamine|Ketamine|Ketamine|Ketamine|Placebo Midazolam","Drug|Drug|Drug|Drug|Drug","depressive disorder|depressive disorder, treatment-resistant|depression","Treatment Resistant Depression","Parallel Assignment","Interventional","Treatment","Randomized","Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)",5,"Mean Difference (Final Values)",8.68,0.82,"Mixed Models Analysis",-2.81,20.16,95,null,"NA","All",99,"Completed","Phase 2","\t"]
["NCT01922011",4383441,8024886,"Percentage of Participants With a Favorable Clinical Outcome","daptomycin|vancomycin|nafcillin","Daptomycin|Vancomycin (or equivalent)|Nafcillin (or equivalent)","Drug|Drug|Drug","osteomyelitis","Acute Hematogenous Osteomyelitis","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)",2,"Common difference",-6.2,0.313,"Wald",-17.5,5,95,null,"NA","All",149,"Completed","Phase 3","\t"]
["NCT01929863",4383032,8023643,"Maximum and Weighted Mean Change From Baseline in Plasma Glucose Concentrations Over a 24 Hour (h) Period on Day 7","metformin","GSK2330672|Placebo|Metformin","Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Diabetes Mellitus, Type 2","Crossover Assignment","Interventional","Treatment","Randomized","Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin",2,"Mean Difference (Net)",-36.58,"NA",null,-62.25,-10.9,95,null,"NA","All",16,"Completed","Phase 2","\t"]
["NCT01930487",4382988,8023568,"Change in Central Retinal Artery Peak Systolic Blood Flow Velocity (cm/s) - No DM","antioxidants","dietary supplement with antioxidants|Placebo","Dietary Supplement|Dietary Supplement","glaucoma, open-angle|glaucoma","Primary Open Angle Glaucoma","Crossover Assignment","Interventional","Basic Science","Randomized","The Effects of an Antioxidant Formulation on Ocular Blood Flow",2,"Mean Difference (Net)",0.92,{"v":0.0009,"d":"9.00E-04"},"paired t-test, 2-sided",{"$nulls":3},"Standard Error of the Mean",0.24,"All",47,"Completed","N/A","\t"]
["NCT01931670",4382866,8023461,"Change From Baseline to Each Month, Except Month 6, in Mean Pain Score for NMPP","NA","placebo|Elagolix","Other|Drug","endometriosis","Endometriosis","Parallel Assignment","Interventional","Treatment","Randomized","A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain",3,"LS Mean of Difference",-0.07,0.11,"mixed-effects model",-0.17,0.03,97.5,"Standard Error of the Mean",0.044,"Female",815,"Completed","Phase 3","\t"]
["NCT01933672",4382587,8023160,"Change From Baseline in Weighted Mean Daily Glucose (WMDG) at Day 14","sitagliptin phosphate","PF-04937319 once-daily|PF-04937319 split-dose|Sitagliptin once-daily","Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Type 2 Diabetes Mellitus","Crossover Assignment","Interventional","Basic Science","Randomized","Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes",3,"Mean Difference (Final Values)",-11.99,"NA",null,-19.81,-4.17,80,null,"NA","All",33,"Completed","Phase 1","\t"]
["NCT01939002",4382321,8022530,"Mean Change From 4-Week Run-In Period at Each Visit for TSQM, Convenience Scale Factor: Overall Population","anti-inflammatory agents, non-steroidal|naproxen|anti-inflammatory agents|interferon-beta|interferon beta-1a|interferons","BIIB017|naproxen","Drug|Drug","sclerosis|multiple sclerosis","Relapsing Multiple Sclerosis","Parallel Assignment","Interventional","Treatment","Randomized","Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)",2,null,"NA",{"v":1E-4,"d":"1.00E-04"},"paired t-test within 1 arm",{"$nulls":4},"NA","All",251,"Completed","Phase 3","\t"]
["NCT01942590",4382105,8021997,"Change in Forced Vital Capacity (FVC) in Pulmonary Function Testing","clenbuterol","Clenbuterol|Placebo","Drug|Drug","glycogen storage disease type ii","Pompe Disease","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy",2,null,"NA",0.2074,"t-test, 1 sided",{"$nulls":4},"NA","All",17,"Completed","Phase 1/Phase 2","\t"]
["NCT01942668",4381424,8021838,"Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Week 12 - (MITT-VMS)","estradiol|estradiol 17 beta-cypionate|estradiol 3-benzoate|progesterone|polyestradiol phosphate","Estradiol|Progesterone|Placebo","Drug|Drug|Drug","NA","Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms",5,"Mean Difference (Final Values)",1.15,0.651,"Mixed Models Analysis",-3.84,6.14,95,"Standard Error of the Mean",2.54,"Female",1845,"Completed","Phase 3","\t"]
["NCT01942668",4381617,8021894,"Number of Subjects Without Bleeding for Consecutive Cycles","estradiol|estradiol 17 beta-cypionate|estradiol 3-benzoate|progesterone|polyestradiol phosphate","Estradiol|Progesterone|Placebo","Drug|Drug|Drug","NA","Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms",5,null,"NA",0.035,"Fisher Exact",{"$nulls":4},"NA","Female",1845,"Completed","Phase 3","\t"]
["NCT01942668",4381752,8021921,"Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 - (MITT-VMS)","estradiol|estradiol 17 beta-cypionate|estradiol 3-benzoate|progesterone|polyestradiol phosphate","Estradiol|Progesterone|Placebo","Drug|Drug|Drug","NA","Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms",5,null,"NA",0.261,"Fisher Exact",{"$nulls":4},"NA","Female",1845,"Completed","Phase 3","\t"]
["NCT01942668",4381997,8021968,"Severity of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS)","estradiol|estradiol 17 beta-cypionate|estradiol 3-benzoate|progesterone|polyestradiol phosphate","Estradiol|Progesterone|Placebo","Drug|Drug|Drug","NA","Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms",5,"Mean Difference (Final Values)",-0.11,0.039,"Mixed Models Analysis",-0.21,-0.01,95,"Standard Error of the Mean",0.052,"Female",1845,"Completed","Phase 3","\t"]
["NCT01944631",4381131,8021445,"Patient Overall Assessment of Efficacy","NA","Placebo|Iota-Carrageenan","Device|Device","common cold","Common Cold","Parallel Assignment","Interventional","Treatment","Randomized","Iota-Carrageenan Nasal Spray in Common Cold",2,"Odds Ratio (OR)",1.1069,0.6954,"Regression, Logistic",0.666,1.84,95,null,"NA","All",200,"Completed","Phase 4","\t"]
["NCT01945034",4381035,8021382,"Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points","NA","Topical IBU twice daily|Placebo twice daily|Topical IBU three times daily|Placebo three times daily","Drug|Drug|Drug|Drug","sprains and strains|ankle injuries","Ankle Injuries","Parallel Assignment","Interventional","Treatment","Randomized","5% Topical Ibuprofen (IBU) for Ankle Sprain",4,"LS Mean Difference",-0.6,0.053,"ANOVA",-1.19,0.01,95,null,"NA","All",304,"Completed","Phase 3","\t"]
["NCT01951638",4380640,8020537,"Change From Baseline to Week 12 in Log-transformed N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)","NA","Vericiguat (BAY1021189) (1.25 mg)|Vericiguat (BAY1021189) (5 mg)|Placebo","Drug|Drug|Drug","heart failure","Heart Failure","Parallel Assignment","Interventional","Treatment","Randomized","Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)",5,"Log-Scale mean difference",0.137,0,"t-test, 1 sided",-0.04,0.31,90,null,"NA","All",477,"Completed","Phase 2","\t"]
["NCT01955083",4380409,8019998,"Percentage of Good Response After MIS","NA","Pillar implant|Radiofrequency","Device|Device","sleep apnea, obstructive|sleep apnea syndromes|snoring","Obstructive Sleep Apnea|Primary Snoring","Parallel Assignment","Interventional","Treatment","Randomized","Analysis of Snore Sound Following Minimal Invasive Surgery in Sleep-disordered Breathing Patients",2,null,"NA",0.05,"Fisher Exact",{"$nulls":4},"NA","All",30,"Completed","N/A","\t"]
["NCT01956110",4380365,8019815,"Proportion of Subjects With Extreme Ovarian Responses, Defined as <4, ≥15 or ≥20 Oocytes Retrieved","follicle stimulating hormone","Follitropin Delta (FE 999049)|Follitropin Alfa (GONAL-F)","Drug|Drug","infertility","Infertility","Parallel Assignment","Interventional","Treatment","Randomized","Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 1",2,null,"NA",0,"Likelihood ratio test",{"$nulls":4},"NA","Female",1329,"Completed","Phase 3","\t"]
["NCT01964352",4380064,8018821,"FVC AUC0-3h Response (Change From Baseline)","olodaterol|tiotropium bromide","tiotropium|placebo|olodaterol|tiotropium|tiotropium|olodaterol","Drug|Drug|Drug|Drug|Drug|Drug","lung diseases|lung diseases, obstructive|pulmonary disease, chronic obstructive","Pulmonary Disease, Chronic Obstructive","Parallel Assignment","Interventional","Treatment","Randomized","Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)",4,"Mean Difference (Final Values)",0.398,{"v":1E-4,"d":"1.00E-04"},"Mixed Effects Model for Repeated Measure",0.331,0.465,95,"Standard Error of the Mean",0.034,"All",813,"Completed","Phase 3","\t"]
["NCT01965652",4379983,8018553,"Change From Baseline in the Number of Bowel Movements Per Week","NA","Naldemedine|Placebo","Drug|Drug","constipation","Opioid-induced Constipation","Parallel Assignment","Interventional","Treatment","Randomized","Long Term Safety of Naldemedine",2,"LS Mean Difference",1,{"v":1E-4,"d":"1.00E-04"},"Mixed-effects model repeated measures",0.53,1.47,95,"Standard Error of the Mean",0.24,"All",1246,"Completed","Phase 3","\t"]
["NCT01968980",4379705,8018092,"Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24 and 52","bococizumab","Bococizumab (PF-04950615;RN316)|Placebo","Drug|Other","hypercholesterolemia|hyperlipoproteinemia type ii","Heterozygous Familial Hypercholesterolemia","Parallel Assignment","Interventional","Treatment","Randomized","A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia",2,"LS Mean Difference",-46.8,"NA",null,-52.1,-41.6,95,"Standard Error of the Mean",2.67,"All",370,"Completed","Phase 3","\t"]
["NCT01972841",4379382,8017518,"Percentage of Participants With ≥ 1 Point Improvement From Baseline in PPBC at Weeks 4, 8, 12 and EoT","solifenacin succinate|mirabegron","Solifenacin succinate|Mirabegron|Placebo to match solifenacin succinate|Placebo to match mirabegron","Drug|Drug|Drug|Drug","urologic diseases|urinary bladder, overactive|urinary bladder diseases","Overactive Bladder|Urgency Incontinence|Urinary Bladder Diseases\\Urologic Diseases|Urinary Bladder Overactive","Parallel Assignment","Interventional","Treatment","Randomized","This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",6,"Odds Ratio (OR)",1.32,0.065,"Logistic regression",0.98,1.78,95,null,"NA","All",3527,"Completed","Phase 3","\t"]
["NCT01975389",4379261,8017165,"Event Rate Per 100 Participant-years for First Occurrence of Any Arterial Revascularizations","bococizumab","bococizumab (PF-04950615)|Placebo","Drug|Drug","cardiovascular diseases","Cardiovascular Disease","Parallel Assignment","Interventional","Prevention","Randomized","The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects",2,"Hazard Ratio (HR)",0.95,0.748975,"Log Rank",0.7,1.3,95,null,"NA","All",10564,"Terminated","Phase 3","\t"]
["NCT01978119",4378921,8016734,"Change From Baseline (BL) in Morning Peak Expiratory Flow Rate (PEFR) Over 12 Weeks (From Paper Diary Card) for Each Treatment Period(TP)","NA","FSC|Placebo","Drug|Drug","asthma","Asthma","Crossover Assignment","Interventional","Treatment","Randomized","A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol (FSC) 250/50 Microgram (mcg) Twice Daily (BID) in Adults and Adolescents With Asthma",2,"Mean Difference (Net)",4.35,"NA",null,-1.34,10.05,95,null,"NA","All",124,"Completed","Phase 3","\t"]
["NCT01983683",4378750,8016214,"Kaplan-Meier Estimates for Resolution of Diarrhea (ROD)","vancomycin|oxazolidinones","Cadazolid|Vancomycin|Cadazolid-matching placebo|Vancomycin-matching placebo","Drug|Drug|Drug|Drug","diarrhea|clostridium infections","Clostridium Difficile Infection","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea",2,"Hazard Ratio (HR)",1.04,0.7794,"Log Rank",0.86,1.24,95,null,"NA","All",631,"Completed","Phase 3","\t"]
["NCT01986881",4378540,8015879,"Time to First Occurrence of the Renal Composite: the Composite of Renal Death, Renal Dialysis/Transplant, or Doubling of Serum Creatinine From Baseline (On-Study Approach) (Overall Cardiovascular Study)","5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol","Ertugliflozin|Placebo|Glycemic Rescue","Drug|Drug|Drug","vascular diseases|diabetes mellitus|diabetes mellitus, type 2","Type 2 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)",3,"Hazard Ratio (HR)",0.76,0.065,"Cox Proportional Hazards Model",0.568,1.028,95.8,null,"NA","All",8246,"Completed","Phase 3","\t"]
["NCT01990742",4378291,8015281,"Number of Nursing Home Residents in Moderate-to-severe Pain","NA","Palliative Care Team (PCTeam)","Behavioral","NA","Palliative Care","Parallel Assignment","Interventional","Health Services Research","Randomized","Improving Palliative Care Through Teamwork",2,null,"NA",0.05,"Monte carlo simulation",{"$nulls":4},"NA","All","NA","Completed","N/A","\t"]
["NCT01993108",4378187,8014970,"Characterize the Effects of Methylphenidate and Naltrexone on Neural Circuits in Prefrontal Cortex Associated With Top-down Control.","naltrexone|methylphenidate","Methylphenidate|Naltrexone|Placebo","Drug|Drug|Drug","attention deficit disorder with hyperactivity","Attention Deficit Hyperactivity Disorder|Healthy","Parallel Assignment","Interventional","Basic Science","Randomized","Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))",2,"Mean Difference (Final Values)",0.01,0.926,"t-test, 2 sided",{"$nulls":4},"NA","All",23,"Completed","Phase 4","\t"]
["NCT01998243",4378005,8014480,"Percentage of Re-operations","NA","Intragastric Balloon (IGB), group A|diet, control group B","Device|Other","obesity|obesity, morbid","Morbid Obesity","Parallel Assignment","Interventional","Treatment","Randomized","Usefulness and Safeness Of Intra-Gastric Balloon Before Bariatric Surgery In Morbid Obesity",2,null,"NA",0.673,"Fisher Exact",{"$nulls":4},"NA","All",81,"Completed","N/A","\t"]
["NCT02007434",4377545,8013398,"Change From Baseline in Pain Visual Analog Scale Scores","epinephrine|deoxycholic acid|loratadine|ibuprofen|lidocaine","Deoxycholic Acid Injection|Placebo|Cold Compress|Lidocaine / Epinephrine|Loratadine|Ibuprofen|Compression Chin Strap","Drug|Drug|Other|Drug|Drug|Drug|Other","NA","Moderate or Severe Submental Fullness","Parallel Assignment","Interventional","Treatment","Randomized","Patient Experience Study of Deoxycholic Acid Injection",8,"LS Mean Placebo-adjusted Difference",0.06,0.914,"ANCOVA",-1.03,1.15,95,"Standard Error of the Mean",0.55,"All",84,"Completed","Phase 3","\t"]
["NCT02010996",4377433,8013066,"Early Complications of Vascular Zone","NA","vacuum assisted closure|Axillary dissection","Procedure|Procedure","seroma","Coronary Bypass Graft Stenosis of Autologous Vein","Parallel Assignment","Interventional","Prevention","Randomized","Preventing Seroma Formation After Stripping Saphenous Vein in Coronary Bypass",2,null,"NA",0.05,"Chi-squared",{"$nulls":4},"NA","All",72,"Completed","N/A","\t"]
["NCT02016482",4377199,8012342,"Change From Baseline in Work Productivity and Activity Impairment Nail Psoriasis (WPAI:NPSO) at Week 26","adalimumab","Adalimumab|Placebo","Biological|Other","psoriasis","Nail Psoriasis|Plaque Psoriasis","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis",2,"LS Mean Difference",-15.2,1E-3,"ANCOVA",-21,-9.3,95,null,"NA","All",217,"Completed","Phase 3","\t"]
["NCT02021318",4376926,8011864,"Change From Baseline to the Average of Weeks 12 to 28 and 36 to 52 in SF-36 Physical Component Score (PCS)","darbepoetin alfa","Roxadustat|Darbepoetin alfa","Drug|Drug","anemia|kidney diseases|renal insufficiency, chronic","Anemia in Chronic Kidney Disease in Non-dialysis Patients","Parallel Assignment","Interventional","Treatment","Randomized","Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa",2,"LSM Difference",-1.068,0.027,"Mixed Models Analysis",-2.012,-0.124,95,null,"NA","All",616,"Completed","Phase 3","\t"]
["NCT02027545",4376659,8011331,"Concordance Between Screening Orders and Screening Benefit","NA","Decision Aid|Provider Education|Performance Measure Modification|Simple Informational Booklet","Behavioral|Behavioral|Behavioral|Behavioral","colorectal neoplasms","Colorectal Cancer","Parallel Assignment","Interventional","Health Services Research","Randomized","Promoting Veteran-Centered Colorectal Cancer Screening",2,null,"NA",0.0458,"Regression, Logistic",{"$nulls":4},"NA","All",436,"Completed","N/A","\t"]
["NCT02033850",4376380,8010627,"Quality of Life (Clinically Significance Approach)","NA","Attention Process Training-II","Behavioral","cognitive dysfunction","Mild Cognitive Impairment","Parallel Assignment","Interventional","Treatment","Randomized","Rehabilitation of Attention in Patients With MCI and Brain Subcortical Vascular Changes Using the APT-II",2,null,"NA",0.576,"Chi-squared",{"$nulls":4},"NA","All",46,"Completed","N/A","\t"]
["NCT02037165",4375970,8010292,"Electronic Visual Analogue Scale (100mm VAS \"Post Laser Pain\" Scales) - Measured in the Capsaicin-irritated Skin Type.","pregabalin|celecoxib","Placebo to BI 1026706|Pregabalin|BI 1026706|Celecoxib","Drug|Drug|Drug|Drug","NA","Healthy","Crossover Assignment","Interventional","Treatment","Randomized","Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB(Ultraviolet)-Irradiated Skin in Healthy Male Volunteers",5,"Adjusted mean difference",-2.46,"NA",null,-7.4,2.5,95,"Standard Error of the Mean",2.4848,"Male",25,"Completed","Phase 1","\t"]
["NCT02037984",4375775,8010203,"Percentage of Infant Participants Achieving the Pneumococcal Immunoglobulin G (IgG) Serotype-specific Antibody Threshold Value of ≥0.35 μg/mL at 1 Month Postdose 4 (PD4): V114 1x:1x:2x vs Prenar 13®","heptavalent pneumococcal conjugate vaccine","Prevnar 13®|V114 1x:1x:1x|V114 2x:2x:2x|V114 2x:1x:2x|V114 1x:1x:2x|V114 0.5x:0.5x:2x","Biological|Biological|Biological|Biological|Biological|Biological","pneumococcal infections|infection|pneumonia|communicable diseases","Pneumococcal Infections|Streptococcus Pneumoniae Infection","Parallel Assignment","Interventional","Prevention","Randomized","Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)",8,"PT3 Percentage Point Difference",14,"NA",null,-5.5,32,95,null,"NA","All",341,"Completed","Phase 1/Phase 2","\t"]
["NCT02037984",4375903,8010215,"Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibodies at 1 Month Postdose 3 (PD3) in Infants: V114 1x:1x:1x vs. Prevnar 13®","heptavalent pneumococcal conjugate vaccine","Prevnar 13®|V114 1x:1x:1x|V114 2x:2x:2x|V114 2x:1x:2x|V114 1x:1x:2x|V114 0.5x:0.5x:2x","Biological|Biological|Biological|Biological|Biological|Biological","pneumococcal infections|infection|pneumonia|communicable diseases","Pneumococcal Infections|Streptococcus Pneumoniae Infection","Parallel Assignment","Interventional","Prevention","Randomized","Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)",8,"PT9V GMC Ratio",0.59,"NA",null,0.39,0.9,95,null,"NA","All",341,"Completed","Phase 1/Phase 2","\t"]
["NCT02043379",4375517,8009558,"Immunoglobulin Concentration in Chest Tube Drainage","immunoglobulins, intravenous","IVIG|Placebo","Drug|Other","heart diseases|agammaglobulinemia","Congenital Heart Disease|Hypogammaglobulinemia","Parallel Assignment","Interventional","Treatment","Randomized","Post-bypass Prophylactic IVIG in Infants and Neonates",2,null,"NA",0.34,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",50,"Completed","N/A","\t"]
["NCT02045862",4375365,8009256,"Change From Baseline to EoT in Mean Volume Voided Per Micturition","mirabegron|solifenacin succinate","Solifenacin succinate|Mirabegron|Placebo to match solifenacin|Placebo to match mirabegron","Drug|Drug|Drug|Drug","urinary bladder diseases|urinary bladder, overactive|urologic diseases","Overactive Bladder|Urgency Incontinence|Urinary Bladder Diseases\\Urologic Diseases|Urinary Bladder Overactive","Parallel Assignment","Interventional","Treatment","Randomized","A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder",3,"Least Squares Mean Difference",12.77,1E-3,"ANCOVA",5.98,19.57,95,"Standard Error of the Mean",3.47,"All",1829,"Completed","Phase 3","\t"]
["NCT02046980",4375239,8009001,"Conversion in Direction of Nystagmus From Apogeotropic to Geotropic or Disappearance of Nystagmus","NA","Gufoni|Vibration|Sham","Procedure|Procedure|Procedure","vertigo|dizziness|benign paroxysmal positional vertigo","Benign Paroxysmal Positional Vertigo","Parallel Assignment","Interventional","Treatment","Randomized","Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo",3,"Odds Ratio (OR)",2.67,0.0366,"Regression, Logistic",1.25,5.67,95,null,"NA","All",209,"Completed","Phase 2","\t"]
["NCT02055547",4375052,8008389,"Maximum Glycemic Excursion (Gmax) During GGI and Tmax After a Single Dose of MK-8521 (Part 3)","NA","MK-8521 35μg|MK-8521 100μg|MK-8521 125μg|MK-8521 150μg|MK-8521 175μg|MK-8521 200μg|MK-8521 300μg|MK-8521 50/72μg|MK-8521 72/125μg|MK-8521 100/150μg|MK-8521 125/150μg|Placebo","Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug","diabetes mellitus, type 2","Type 2 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)",19,"Geometric mean ratio",0.78,0.004,"Linear mixed effect model",0.69,0.89,90,null,"NA","Male",61,"Completed","Phase 1","\t"]
["NCT02055976",4375028,8008353,"Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113","ezetimibe|bococizumab","Bococizumab (PF-04950615;RN316)|Bococizumab (PF-04950615;RN316)|Bococizumab (PF-04950615;RN316)|Placebo|Ezetimibe|Bococizumab (PF-04950615;RN316)|Bococizumab (PF-04950615;RN316)|Bococizumab (PF-04950615;RN316)|Placebo","Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug","hypercholesterolemia","Hypercholesterolemia","Parallel Assignment","Interventional","Treatment","Randomized","Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects",2,"Adjusted Mean Difference",-102.184,1E-3,"Mixed Models Analysis",-113.945,-90.424,95,"Standard Error of the Mean",5.919,"All",218,"Completed","Phase 2","\t"]
["NCT02058147",4374645,8008103,"Change in Plasma Glucose Excursion From Baseline to Week 30","lixisenatide|metformin|insulin|insulin, globin zinc|insulin glargine","Insulin glargine/lixisenatide Fixed Ratio Combination|Insulin glargine (HOE901)|Lixisenatide (AVE0010)|Metformin","Drug|Drug|Drug|Drug","diabetes mellitus, type 2","Type 2 Diabetes","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM",3,"LS Mean Difference",-2.13,{"v":1E-4,"d":"1.00E-04"},"ANCOVA",-2.498,-1.77,95,"Standard Error of the Mean",0.185,"All",1170,"Completed","Phase 3","\t"]
["NCT02059174",4374513,8007884,"PD: Maximum Glucose Infusion Rate (GIRmax)","mk-1293|insulin aspart","MK-1293|EU-Lantus™|Novolog™","Drug|Drug|Drug","diabetes mellitus|diabetes mellitus, type 1","Type 1 Diabetes Mellitus","Crossover Assignment","Interventional","Treatment","Randomized","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)",2,"Ratio of Arithmetic Means",0.96,"NA",null,0.91,1.02,95,null,"NA","All",76,"Completed","Phase 1","\t"]
["NCT02064205",4374251,8007379,"Energy Intake at an ad Libitum Lunch on a Test-day in Normal Weight and Overweight Women.","NA","12.5 g polydextrose|glucose syrup","Dietary Supplement|Dietary Supplement","body weight","Body Weight|Non-restrained Eaters","Crossover Assignment","Interventional","Health Services Research","Randomized","Appetite Suppression Trial With Polydextrose",2,"Mean Difference (Final Values)",18,0.2918,"Mixed Models Analysis",{"$nulls":3},"Standard Deviation",1000,"Female",32,"Completed","Phase 2","\t"]
["NCT02068599",4373996,8006878,"Change From Baseline in the Patient Global Assessment (PGA) Scores at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM)","NA","TV-45070|Placebo","Drug|Drug","osteoarthritis|osteoarthritis, knee","Osteoarthritis of the Knee","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (Ointment) in Participants With Primary Osteoarthritis (OA) Affecting a Single Knee",3,"LSM difference from placebo",2.77,0.2906,"mixed model for repeated measures",-2.377,7.916,95,null,"NA","All",389,"Completed","Phase 2","\t"]
["NCT02074358",4373812,8006286,"PD Parameter: Adjusted Mean Change in Coagulation Parameter International Normalized Ratio (INR) From Day 4 Pre-Infusion (PCC or Placebo) Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo","apixaban","Apixaban|Cofact (4-Factor PCC)|Beriplex P/N (4-Factor PCC)|Placebo (Saline solution)","Drug|Drug|Drug|Drug","NA","Anticoagulation","Crossover Assignment","Interventional","Basic Science","Randomized","A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects",3,"mixed effect model",-0.176,1E-3,"Mixed Models Analysis",-0.242,-0.11,95,null,"NA","All",43,"Completed","Phase 1","\t"]
["NCT02079610",4373555,8005738,"Change From Baseline Hamilton Rating Scale for Depression at 2 Weeks","NA","real-time fMRI neurofeedback: Amygdala|real-time fMRI neurofeedback: HIPS","Behavioral|Behavioral","depression|depressive disorder|depressive disorder, major","Major Depressive Disorder","Parallel Assignment","Interventional","Treatment","Randomized","Effect of Amygdala Neurofeedback on Depressive Symptoms and Processing Biases",2,"Mean Difference (Final Values)",6.8,0.01,"Mixed Models Analysis",{"$nulls":3},"Standard Deviation",3.5,"All",36,"Completed","N/A","\t"]
["NCT02082184",4373318,8005331,"Time Spent >180 mg/dL and >240 mg/dL","NA","Sensor Based Glucose Monitoring System|Standard Blood Glucose Monitoring","Device|Device","diabetes mellitus|diabetes mellitus, type 2","Type 2 Diabetes Mellitus","Parallel Assignment","Interventional","Other","Randomized","An Evaluation of a Novel Glucose Sensing Technology in Type 2 Diabetes",2,"Mean Difference (Final Values)",0.1,0.8729,"ANCOVA",{"$nulls":3},"Standard Error of the Mean",0.46,"All",302,"Completed","N/A","\t"]
["NCT02087904",4373091,8004778,"Change From Baseline in Patient Global Assessment (PGA) of Arthritis of the Index Knee at Week 16","NA","ABT-981|Placebo","Biological|Other","osteoarthritis|osteoarthritis, knee","Knee Osteoarthritis|Medial Compartment Knee Osteoarthritis","Parallel Assignment","Interventional","Treatment","Randomized","A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis",4,"LS Mean Difference",-0.1,0.673,"ANCOVA",-0.79,0.51,95,null,"NA","All",350,"Completed","Phase 2","\t"]
["NCT02091284",4372934,8004545,"Craving","NA","transcranial Direct Current Stimulation","Device","substance-related disorders|alcoholism","Drug Addiction|Executive Dysfunction","Parallel Assignment","Interventional","Treatment","Randomized","Bilateral Prefrontal Modulation in Alcoholism",2,null,"NA",0.01,"ANOVA",{"$nulls":4},"NA","All",49,"Completed","N/A","\t"]
["NCT02096835",4372634,8003858,"Need of Postoperative Metoclopramide","dexamethasone|tropisetron","Transcutaneous electrical acupoint stimulation|Sham transcutaneous electrical acupoint stimulation|Tropisetron|Dexamethasone","Device|Device|Drug|Drug","postoperative nausea and vomiting|nausea|vomiting","Postoperative Nausea and Vomiting","Parallel Assignment","Interventional","Prevention","Randomized","Transcutaneous Electrical Acupoint Stimulation of P6 to Prevent Postoperation Nausea and Vomiting",3,null,"NA",0.571,"Chi-squared",{"$nulls":4},"NA","Female",157,"Completed","N/A","\t"]
["NCT02099838",4372556,8003540,"Change of HbA1c From Baseline at Week 12","pioglitazone|metformin","Pioglitazone and Metformin|Placebo","Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","Effectiveness and Safety of Adding Compound Preparation of Pioglitazone and Metformin for Type 2 Diabetic Patients",2,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",98,"Completed","Phase 4","\t"]
["NCT02101515",4372360,8003267,"Neonatal Intensive Care Unit Admission (Neonates)","NA","Length of Second Stage","Other","obstetric labor complications","Labor Complications","Parallel Assignment","Interventional","Treatment","Randomized","Randomized Control Trial of Second Stage of Labor",2,"Risk Ratio (RR)",0.8,"NA",null,0.46,1.54,95,null,"NA","Female",78,"Completed","N/A","\t"]
["NCT02107898",4371980,8002509,"Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)","antibodies, monoclonal","Placebo (for alirocumab)|Alirocumab|Lipid-Modifying Therapy (LMT)","Drug|Drug|Drug","hyperlipoproteinemia type ii|hypercholesterolemia","Hypercholesterolemia","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)",2,"LS Mean Difference",-64.1,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",-68.5,-59.8,95,null,"NA","All",216,"Completed","Phase 3","\t"]
["NCT02111993",4371811,8001957,"Defibrillation Testings (DFT) vs. Upper Limit of Vulnerability (ULV) (VF Induced)","NA","Standard Defibrillation Testing|Upper Limit of Vulnerability Testing","Device|Device","arrhythmias, cardiac|cardiomyopathies","Cardiac Arrhythmia|Cardiomyopathy|Heart Failure","Parallel Assignment","Interventional","Other","Randomized","Evaluating Myocardial Injury for Defibrillation Threshold Testing Methods for ICD Implantation",2,null,"NA",0.04,"t-test, 2 sided",{"$nulls":4},"NA","All",60,"Completed","N/A","\t"]
["NCT02116621",4371592,8001526,"Change From Baseline in Pain Intensity on the Patient-Reported Outcomes Measurement Information System (PROMIS) Scale at 13 Weeks","NA","Trialist Intervention|smartphone","Behavioral|Device","musculoskeletal pain|chronic pain","Chronic Pain|Musculoskeletal Pain","Parallel Assignment","Interventional","Health Services Research","Randomized","N-of-1 Trials Using mHealth in Chronic Pain",2,"Adjusted difference in differences",0.31,"NA",null,-1.18,1.81,95,null,"NA","All",215,"Completed","N/A","\t"]
["NCT02121535",4371372,8000820,"AUC0-tz for Hydrochlorothiazide","NA","T80/A5 mg FDC tablet|T80/A5 mg FDC tablet|H12.5 mg tablet|T80/A5/H12.5 ng FDC tablet|H12.5 mf tablet|T80/A5/H12.5 mg FDC tablet","Drug|Drug|Drug|Drug|Drug|Drug","NA","Healthy","Crossover Assignment","Interventional","Treatment","Randomized","Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use",2,"Adjusted Mean Ratio",104.3,"NA",null,102.53,106.1,90,null,"NA","Male",72,"Completed","Phase 1","\t"]
["NCT02130024",4371031,8000093,"Percentage of Patients Showing no Intraretinal Fluid (IRF)/Subretinal Fluid (SRF)","ranibizumab","Ranibizumab 0.5 mg|Aflibercept 2.0 mg","Drug|Drug","macular degeneration|geographic atrophy|atrophy","Age-Related Macular Degeneration","Parallel Assignment","Interventional","Treatment","Randomized","A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients",2,"Odds Ratio (OR)",0.72,0.215,"Regression, Logistic",0.44,1.21,95,null,"NA","All",281,"Completed","Phase 4","\t"]
["NCT02132767",4370682,7999688,"Length of Stay (Rehospitalization, Including ED Visits)","calcium channel blockers|digoxin|amiodarone","Amiodarone|DC-cardioversion|Rate Control","Drug|Procedure|Drug","atrial fibrillation","Postoperative Atrial Fibrillation","Parallel Assignment","Interventional","Treatment","Randomized","Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation",2,null,"NA",0.82,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",523,"Completed","Phase 3","\t"]
["NCT02141854",4370191,7998577,"Standardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours PostDose (FEV1 AUEC0-12) at Week 12","fluticasone|albuterol|adrenergic agonists|salmeterol xinafoate","FS MDPI|Fp MDPI|Placebo MDPI|Albuterol/salmeterol HFA MDI","Drug|Drug|Drug|Drug","asthma","Asthma","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma",5,"LSM difference",0.179,{"v":0.0009,"d":"9.00E-04"},"ANCOVA",0.074,0.285,95,null,"NA","All",882,"Completed","Phase 3","\t"]
["NCT02145156",4370010,7998283,"Number of Adolescents, Among All Eligible, Who Completed the HPV Vaccine Series During the Study Period","NA","Tailored educational materials|Untailored educational materials|Survey-only","Behavioral|Behavioral|Behavioral","NA","HPV Vaccination Status","Parallel Assignment","Interventional","Health Services Research","Randomized","Educational Intervention to Minimize Disparities in Humanpapillomavirus Vaccination",3,null,"NA",0.39,"Chi-squared",{"$nulls":4},"NA","All",1294,"Completed","N/A","\t"]
["NCT02146430",4369913,7998099,"Change From Baseline to Week 13 in Multidimensional Fatigue Inventory (MFI-20) General Fatigue Score in Participants Receiving DS-5565, Pregabalin, or Placebo","pregabalin","DS-5565|Pregabalin|Placebo tablet|Placebo capsule","Drug|Drug|Drug|Drug","fibromyalgia|myofascial pain syndromes","Pain Associated With Fibromyalgia","Parallel Assignment","Interventional","Treatment","Randomized","Treatment of Pain Associated With Fibromyalgia",4,"Difference in least squares means",-0.3,0.2474,"ANCOVA",-0.9,0.2,95,"Standard Error of the Mean",0.28,"All",1293,"Completed","Phase 3","\t"]
["NCT02151877",4369559,7997477,"Total Fluid Balance at 48 Hours","nitric oxide","Inhaled Nitric Oxide|placebo","Drug|Drug","ischemia|reperfusion injury|wounds and injuries|inflammation","Inflammatory Reaction After Neonatal Cardiac Surgery|Ischemia/Reperfusion Injury After Neonatal Cardiac Surgery","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy of Nitric Oxide Administration in Attenuating Ischemia/Reperfusion Injury During Neonatal Cardiopulmonary Bypass",2,null,"NA",0.05,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",24,"Completed","N/A","\t"]
["NCT02155881",4369359,7996975,"Change From Baseline Over 2 Weeks in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Total Score","ciclesonide","Ciclesonide|Ciclesonide Placebo","Drug|Drug","rhinitis|rhinitis, allergic, seasonal|rhinitis, allergic","Seasonal Allergic Rhinitis","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia",2,"Mean Difference (Net)",-0.28,0.2968,"ANCOVA",-0.8,0.25,95,null,"NA","All",80,"Completed","Phase 3","\t"]
["NCT02158806",4369227,7996704,"Change in Health-related Quality of Life (Charing Cross Venous Ulcer Questionnaire)","aspirin","Aspirin|Placebo","Drug|Drug","leg ulcer|varicose ulcer|ulcer","Venous Leg Ulcer","Parallel Assignment","Interventional","Treatment","Randomized","Low Dose Aspirin for Venous Leg Ulcers",2,"Mean Difference (Net)",-3,0.257,"Regression, Linear",-8.1,2.2,95,null,"NA","All",251,"Completed","Phase 3","\t"]
["NCT02162719",4369064,7996283,"OS in Participants With PTEN-Low Tumors","paclitaxel","Ipatasertib|Paclitaxel|Placebo","Drug|Drug|Drug","breast neoplasms","Breast Neoplasms","Parallel Assignment","Interventional","Treatment","Randomized","A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors",2,"Hazard Ratio (Stratified Analysis)",0.73,0.4422,"Log Rank",0.32,1.65,95,null,"NA","Female",124,"Completed","Phase 2","\t"]
["NCT02168062",4368706,7995774,"Absolute Change in Bone Density T-score (Randomized Cohort)","goserelin|leuprolide|triptorelin pamoate","Behavioral Dietary Intervention|Counseling|Educational Intervention|Exercise Intervention|Goserelin Acetate|Laboratory Biomarker Analysis|Leuprolide Acetate|Quality-of-Life Assessment|Triptorelin Pamoate","Behavioral|Other|Other|Behavioral|Drug|Other|Drug|Other|Drug","adenocarcinoma","Prostate Adenocarcinoma","Crossover Assignment","Interventional","Supportive Care","Randomized","Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer",2,null,"NA",0.807,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Male",57,"Terminated","Phase 2","\t"]
["NCT02171429",4368599,7995406,"Percentage of Participants in Remission at Week 10 and Week 14, as Determined by the MCS, GA28949 Population","adalimumab|rhumab beta7","Adalimumab|Adalimumab Placebo|Etrolizumab|Etrolizumab Placebo","Drug|Other|Drug|Other","colitis, ulcerative|colitis|ulcer","Ulcerative Colitis","Parallel Assignment","Interventional","Treatment","Randomized","A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors",3,"Difference in Remission Rates",-5.2,0.1801,"Cochran-Mantel-Haenszel",-12.95,2.63,95,null,"NA","All",358,"Completed","Phase 3","\t"]
["NCT02175121",4368444,7994969,"Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C)","NA","Placebo|PF-06291874|PF-06291874|PF-06291874|PF-06291874","Drug|Drug|Drug|Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Diabetes Mellitus, Type II","Parallel Assignment","Interventional","Treatment","Randomized","Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus",5,"Mean Difference (Net)",-0.29,0.9448,"Mixed Models Analysis",-7.25,6.67,90,"Standard Error of the Mean",4.21,"All",172,"Completed","Phase 2","\t"]
["NCT02186847",4368091,7993888,"Percentage of Participants With Local-regional Progression","paclitaxel|metformin|carboplatin","Radiation Therapy|Carboplatin|Metformin|Paclitaxel","Radiation|Drug|Drug|Drug","lung neoplasms|carcinoma, non-small-cell lung|adenocarcinoma, bronchiolo-alveolar|carcinoma|adenocarcinoma of lung","Adenosquamous Lung Carcinoma|Bronchioloalveolar Carcinoma|Large Cell Lung Carcinoma|Lung Adenocarcinoma|Non-Small Cell Lung Carcinoma|Recurrent Non-Small Cell Lung Carcinoma|Squamous Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer","Parallel Assignment","Interventional","Treatment","Randomized","Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer",2,"Hazard Ratio (HR)",1.29,0.4075,"Log Rank",0.71,2.34,95,null,"NA","All",170,"Active, not recruiting","Phase 2","\t"]
["NCT02187029",4368062,7993862,"Change From Baseline in Serum Uric Acid Levels at Day 1, Day 3, Day 7, Day 11, Day 14 and Follow-up","NA","PF-06743649|Placebo|PF-06743649|Placebo","Drug|Other|Drug|Other","gout","Gout","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.",4,"LS Mean Difference",-0.62,"NA",null,-0.92,-0.32,90,"Standard Error of the Mean",0.17,"All",30,"Terminated","Phase 1","\t"]
["NCT02187055",4367903,7993815,"Percentage of Participants Achieving CDAI ≤10 at Month 6","adalimumab|methotrexate|tofacitinib","Adalimumab with methotrexate|Tofacitinib with methotrexate|Tofacitinib without methotrexate","Biological|Drug|Drug","arthritis","Rhematoid Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate",3,"Difference in response rate",-3.93,"NA",null,-10.94,3.09,95,null,"NA","All",1152,"Completed","Phase 4","\t"]
["NCT02187471",4367539,7993723,"Change From Baseline to Week 13 in EuroQol Five Dimensions Questionnaire (EQ-5D) Measure Among Participants Receiving DS-5565, Pregabalin, or Placebo","pregabalin","DS-5565|Pregabalin|Placebo tablet|Placebo capsule","Drug|Drug|Drug|Drug","myofascial pain syndromes|fibromyalgia","Pain Associated With Fibromyalgia","Parallel Assignment","Interventional","Treatment","Randomized","Treatment of Pain Associated With Fibromyalgia",4,"Difference in least squares means",-0.0175,0.2036,"ANCOVA",-0.0446,0.0095,95,"Standard Error of the Mean",0.01378,"All",1301,"Completed","Phase 3","\t"]
["NCT02191397",4367391,7993421,"Change From Baseline in HAMD-17 Retardation Subscale Score (Sum of Scores of Items 1, 7, 8 and 14) at Weeks 1, 2, 4, 6 and 8","bupropion|dexetimide|citalopram","Bupropion|Bupropion Matching Placebo|Escitalopram|Escitalopram Matching Placebo","Drug|Drug|Drug|Drug","depressive disorder, major|disease|depression|depressive disorder","Depressive Disorder, Major","Parallel Assignment","Interventional","Treatment","Randomized","Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder",2,"Mean Difference (Final Values)",0.2,0.427,"Mixed model repeated measures analysis",-0.25,0.58,95,null,"NA","All",534,"Completed","Phase 3","\t"]
["NCT02196324",4367175,7992838,"Numeric Rating Scale (NRS)","serlopitant","serlopitant|Placebo","Drug|Drug","neurodermatitis|prurigo","Prurigo Nodularis","Parallel Assignment","Interventional","Treatment","Randomized","A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)","NA","Mean Difference (Final Values)",-0.9,"NA",null,-1.7,-0.1,95,null,"NA","All","NA",null,null,"\t"]
["NCT02200211",4367020,7992478,"Distribution of Change in Stereoacuity Scores From Baseline","NA","iPad®|Patching 2 hours per day, 7 days per week","Device|Other","amblyopia","Amblyopia","Parallel Assignment","Interventional","Treatment","Randomized","Study of Binocular Computer Activities for Treatment of Amblyopia",2,null,"NA",0.66,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",485,"Completed","N/A","\t"]
["NCT02203591",4366645,7992048,"Skin Flora Recovery 10 Minutes Post-treatment","chlorhexidine|chlorhexidine gluconate|ethanol","3M CHG/IPA Prep C|3M CHG/IPA Prep CH|ChloraPrep|Normal Saline","Drug|Drug|Drug|Drug","NA","Bacterial Reduction Post-product Application","Parallel Assignment","Interventional","Prevention","Randomized","In Vivo Efficacy Study of Patient Preoperative Preps",4,"Mean value",2.88,"NA",{"$nulls":4},"Standard Deviation",0.7,"All",738,"Completed","Phase 3","\t"]
["NCT02207816",4366472,7991628,"Incidence of Clinical Malaria Meeting Case Definition","vaccines","Blood sampling|Malaria Vaccine 257049 (MALARIA-055 PRI)|Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)|Cell-culture rabies vaccine (MALARIA-055 PRI)|TritanrixHepB/Hib (MALARIA-055 PRI)|Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)","Procedure|Biological|Biological|Biological|Biological|Biological","malaria","Malaria","Parallel Assignment","Interventional","Prevention","Randomized","An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa",3,"Vaccine efficacy",13.15,0.0056,"Negative binomial regression",4.05,21.39,95,null,"NA","All",3084,"Completed","Phase 3","\t"]
["NCT02209181",4366357,7991511,"Pain Intensity Difference From Baseline (PID) Scores at 16 Hours Post Dose","acetaminophen","JNJ-10450232 / Not yet marketed|JNJ-10450232 / Not yet marketed|JNJ-10450232 / Not yet marketed|acetaminophen / Tylenol","Drug|Drug|Drug|Drug","toothache","Pain","Parallel Assignment","Interventional","Treatment","Randomized","A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine",4,"Least Squares Mean Difference",2.5,1E-3,"ANOVA",1.52,3.49,95,"Standard Error of the Mean",0.5,"Male",269,"Completed","Phase 2","\t"]
["NCT02209181",4366416,7991523,"Pain Intensity Difference From Baseline (PID) Scores at 1.5 Hours Post Dose","acetaminophen","JNJ-10450232 / Not yet marketed|JNJ-10450232 / Not yet marketed|JNJ-10450232 / Not yet marketed|acetaminophen / Tylenol","Drug|Drug|Drug|Drug","toothache","Pain","Parallel Assignment","Interventional","Treatment","Randomized","A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine",4,"Least Squares Mean Difference",-3.12,1E-3,"ANOVA",-3.9,-2.35,95,"Standard Error of the Mean",0.39,"Male",269,"Completed","Phase 2","\t"]
["NCT02216214",4366086,7990909,"Change From Baseline to EOT in Mean Number of Incontinence Episodes Per 24 Hours","mirabegron","Mirabegron|Placebo","Drug|Drug","urinary bladder, overactive","Overactive Bladder (OAB)","Parallel Assignment","Interventional","Treatment","Randomized","Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)",2,"LSM Difference",-0.55,1E-3,"ANCOVA",-0.82,-0.27,95,"Standard Error of the Mean",0.14,"All",888,"Completed","Phase 4","\t"]
["NCT02223364",4365784,7990125,"POD 2 Opioid Use","bupivacaine|ropivacaine","Peripheral nerve blocks with Bupivacaine|Intra articular injection with Ropivacaine|Intra articular injection with liposomal bupivacaine","Drug|Drug|Drug","NA","Total Knee Arthroplasty","Parallel Assignment","Interventional","Treatment","Randomized","Peripheral Nerve Blocks vs Periarticular Local Anesthetic Injection for Total Knee Arthroplasty (TKA)",3,null,"NA",0.126,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",165,"Completed","Phase 4","\t"]
["NCT02229383",4365524,7989396,"Change in Body Weight From Baseline to Week 28","exenatide","Exenatide|Exenatide matching placebo","Drug|Drug","diabetes mellitus","Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus",2,"Mean Difference (Final Values)",-1.52,1E-3,"Mixed Models Analysis",-2.19,-0.85,95,"Standard Error of the Mean",0.341,"All",464,"Completed","Phase 3","\t"]
["NCT02231580",4365431,7989090,"Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Onset Intervals (IOI) as Assessed by Digitomotography","NA","BN82451B|Placebo","Drug|Drug","huntington disease","Huntington's Disease","Parallel Assignment","Interventional","Treatment","Randomized","Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients",2,"GLS mean ratio",0.953,0,"MMRM",0.662,1.372,90,null,"NA","Male",17,"Terminated","Phase 2","\t"]
["NCT02234284",4365212,7988672,"Proportion (%) of Participants Receiving Guideline-concordant Medications for COPD.","NA","Health Coaching","Behavioral","pulmonary disease, chronic obstructive|lung diseases|lung diseases, obstructive","Chronic Obstructive Pulmonary Disease (COPD)","Parallel Assignment","Interventional","Supportive Care","Randomized","Aides in Respiration Health Coaching for COPD",2,"Mean Difference (Final Values)",14.6,0.01,"Mixed Models Analysis",3.3,25.9,95,null,"NA","All","NA","Completed","N/A","\t"]
["NCT02240693",4365025,7988085,"Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment.","NA","BI 409306|Placebo|BI 409306|Placebo|Placebo|BI 409306|BI 409306|Placebo|Placebo","Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug","alzheimer disease","Alzheimer Disease","Parallel Assignment","Interventional","Treatment","Randomized","Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo","NA","Mean Difference (Final Values)",-0.02,0.8374,"Mixed Model Repeated Measurement (MMRM)",-0.171,0.139,95,"Standard Error of the Mean",0.078,"All","NA",null,null,"\t"]
["NCT02247479",4364780,7987464,"Change From Baseline in Number of Absolute Scotomatous Points as Assessed by Mesopic Micrometry at Week 48","NA","Lampalizumab|Sham","Drug|Other","macular degeneration|atrophy|geographic atrophy","Geographic Atrophy","Parallel Assignment","Interventional","Treatment","Randomized","A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration",3,"Difference in Adjusted Means",-0.2,0.935,"MMRM",-5.2,4.8,95,null,"NA","All",906,"Terminated","Phase 3","\t"]
["NCT02248649",4364694,7987386,"Change From Baseline on Cognitive Section of Alzheimer Disease Assessment Scale (ADAS-Cog) at Month 18","NA","Structured physical activity|Health education","Behavioral|Behavioral","parkinson disease","Parkinson's Disease","Parallel Assignment","Interventional","Other","Randomized","Telemedicine Intervention to Improve Cognitive Function",2,null,"NA",0.02,"Mixed Models Analysis",{"$nulls":4},"NA","All",160,"Completed","N/A","\t"]
["NCT02253173",4364479,7986834,"Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)","estradiol","Estradiol|Placebo","Drug|Drug","atrophy|dyspareunia","Dyspareunia|Menopause|Painful Intercourse|Vulvovaginal Atrophy","Parallel Assignment","Interventional","Treatment","Randomized","Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women",4,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",{"$nulls":4},"NA","Female",764,"Completed","Phase 3","\t"]
["NCT02262260",4364182,7985888,"Proportion of Patients Who Gained ≥10 Letters","NA","Labeled regime arm|Wait and Extend regime arm","Drug|Drug","edema|macular edema","Diabetic Macular Edema","Parallel Assignment","Interventional","Treatment","Randomized","Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME",2,null,"NA",0.072,"Chi-squared",{"$nulls":4},"NA","All",87,"Completed","Phase 3","\t"]
["NCT02269423",4363904,7985262,"Geometric Mean Titers of ZEBOV Envelope Glycoprotein-specific Binding Antibodies","NA","V920|Placebo","Biological|Other","hemorrhagic fever, ebola","Ebola Virus","Parallel Assignment","Interventional","Prevention","Randomized","Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)",4,null,"NA",0.173,"ANOVA",{"$nulls":4},"NA","All",39,"Completed","Phase 1","\t"]
["NCT02273206",4363714,7984931,"Satisfaction With Decision to Participate in Screening and Mental Health Care as Assessed by Decision Scale","NA","Prevention Care Management for Depression and Cancer Screening|Prevention Care Management for Cancer Screening","Behavioral|Behavioral","colorectal neoplasms|uterine cervical neoplasms|depression|depressive disorder","Breast Cancer Screening|Cervical Cancer Screening|Colorectal Cancer Screening|Depression","Parallel Assignment","Interventional","Supportive Care","Randomized","Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women",2,null,"NA",0.2,"Chi-squared",{"$nulls":4},"NA","Female",802,"Completed","N/A","\t"]
["NCT02273973",4363632,7984834,"Percentage of Participants With Total pCR Defined as Having pCR in Both Breast and Axilla, Using AJCC Staging System in PIK3CA WT Participants","letrozole","Letrozole|Placebo|Taselisib","Drug|Other|Drug","breast neoplasms","Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)",2,"Difference in Response Rates",1.05,1,"Fisher Exact",-2.65,4.75,95,null,"NA","Female",334,"Completed","Phase 2","\t"]
["NCT02278341",4363436,7984370,"Change From BL in Low Density Lipoprotein Cholesterol (LDL-C) to the Average LDL-C of Weeks 12 to 28","epoetin alfa|darbepoetin alfa","Roxadustat|Epoetin alfa|Darbepoetin alfa|Iron","Drug|Drug|Drug|Drug","anemia|kidney failure, chronic|kidney diseases","Anemia|End Stage Renal Disease (ESRD)","Parallel Assignment","Interventional","Treatment","Randomized","Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis",2,"LSM Difference",-0.377,1E-3,"Mixed Models Analysis",-0.451,-0.304,95,null,"NA","All",838,"Completed","Phase 3","\t"]
["NCT02285010",4363153,7983691,"Numbers of Participants With Adverse Events as a Measure of Safety and Tolerability","pregabalin","placebo|Pregabalin","Drug|Drug","pain, postoperative","Post Operative Pain","Parallel Assignment","Interventional","Treatment","Randomized","Effect of Pregabalin on Post Operative Pain in Abdominal Hysterectomy Under Spinal Anesthesia With Intrathecal Morphine",2,null,"NA",0.16,"Chi-squared",{"$nulls":4},"NA","All","NA","Completed","Phase 4","\t"]
["NCT02291237",4362876,7982857,"Change in Peak Oxygen Uptake (VO2) Achieved During Cardiopulmonary Exercise Testing (CPET) From Baseline to Week 12","NA","Eleclazine|Placebo","Drug|Drug","hypertrophy|cardiomyopathy, hypertrophic|cardiomyopathies","Hypertrophic Cardiomyopathy","Parallel Assignment","Interventional","Treatment","Randomized","Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy",2,"LS Mean Difference(Eleclazine - Placebo)",-0.42,0.517,"ANCOVA",-1.68,0.85,95,null,"NA","All",172,"Terminated","Phase 2/Phase 3","\t"]
["NCT02293837",4362714,7982545,"Change From Baseline in Average Insulin Use Per Kg, Mixed Model","NA","Tocilizumab (TCZ)|Placebo|Standard of Care","Drug|Drug|Other","diabetes mellitus|diabetes mellitus, type 1","New-onset Type 1 Diabetes Mellitus|T1D|T1DM|Type 1 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","Tocilizumab (TCZ) in New-onset Type 1 Diabetes",2,null,"NA",0.452,"Longitudinal mixed model",{"$nulls":4},"NA","All",136,"Completed","Phase 2","\t"]
["NCT02294734",4362355,7982384,"Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28","NA","GSK2269557|Placebo","Drug|Drug","lung diseases|lung diseases, obstructive|pulmonary disease, chronic obstructive","Pulmonary Disease, Chronic Obstructive","Parallel Assignment","Interventional","Treatment","Randomized","An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease",2,"Posterior Median Ratio",1.19,1.9,"Bayesian repeated measures model",1.01,1.4,95,null,"NA","All",126,"Completed","Phase 2","\t"]
["NCT02295020",4362238,7982335,"KOOS - Symptoms","NA","Standard treatment only|Standard treatment plus Bioskin Ten-7 knee brace","Drug|Device","osteoarthritis, knee","Osteoarthritis of the Knee","Parallel Assignment","Interventional","Treatment","Randomized","Effect of Bioskin Ten-7 vs. Standard Treatment on Patient Reported Outcomes and Cytokine.",2,null,"NA",0.232,"t-test, 2 sided",{"$nulls":4},"NA","All",40,"Completed","N/A","\t"]
["NCT02300077",4362032,7981932,"Intraoperative Opioid Administration","fentanyl|methadone|morphine","methadone|Control (Intra-operative administration of opioids, other than methadone)","Drug|Drug","pain, postoperative","Anesthesia|Post-operative Pain","Parallel Assignment","Interventional","Treatment","Randomized","Methadone in Ambulatory Surgery",3,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Chi-squared",{"$nulls":4},"NA","All",60,"Completed","N/A","\t"]
["NCT02301897",4361976,7981800,"Percentage Change in the Individual UFS-SSS Subscale Score Question 1 From Baseline to the End of Treatment Courses 1 and 2, On-drug Course 2 and the Course 2 Week 24 FU Visit","NA","Telapristone Acetate|Placebo","Drug|Drug","myofibroma|leiomyoma","Uterine Fibroids","Parallel Assignment","Interventional","Treatment","Randomized","A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids",3,null,"NA",0.0059,"Wilcoxon Rank-Sum Test",{"$nulls":4},"NA","Female",43,"Completed","Phase 2","\t"]
["NCT02305849",4361582,7981379,"Change From Baseline in SDAI Score at Week 12","methotrexate|peficitinib","Peficitinib|Placebo|Methotrexate","Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Rheumatoid Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment",3,"LS Mean Difference",-14.67,1E-3,"ANCOVA",-17.35,-11.98,95,"Standard Error of the Mean",1.36,"All",519,"Completed","Phase 3","\t"]
["NCT02307682",4361065,7981266,"Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye","pharmaceutical solutions|ophthalmic solutions","Brolucizumab ophthalmic solution|Aflibercept ophthalmic solution","Drug|Drug","choroidal neovascularization|wet macular degeneration|neovascularization, pathologic|macular degeneration","Choroidal Neovascularization|Neovascular Age-Related Macular Degeneration","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of RTH258 Versus Aflibercept - Study 1",3,"Least Squares Mean Difference",2.4,"NA",null,-8.8,13.6,95,"Standard Error of the Mean",5.7,"All",1775,"Completed","Phase 3","\t"]
["NCT02307682",4361285,7981274,"Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye","pharmaceutical solutions|ophthalmic solutions","Brolucizumab ophthalmic solution|Aflibercept ophthalmic solution","Drug|Drug","choroidal neovascularization|wet macular degeneration|neovascularization, pathologic|macular degeneration","Choroidal Neovascularization|Neovascular Age-Related Macular Degeneration","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of RTH258 Versus Aflibercept - Study 1",3,"Difference in proportions",-0.6,"NA",null,-3.3,2.3,95,null,"NA","All",1775,"Completed","Phase 3","\t"]
["NCT02307682",4361309,7981275,"Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye","pharmaceutical solutions|ophthalmic solutions","Brolucizumab ophthalmic solution|Aflibercept ophthalmic solution","Drug|Drug","choroidal neovascularization|wet macular degeneration|neovascularization, pathologic|macular degeneration","Choroidal Neovascularization|Neovascular Age-Related Macular Degeneration","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of RTH258 Versus Aflibercept - Study 1",3,"Difference in proportions",1.1,"NA",null,-2.4,4.6,95,null,"NA","All",1775,"Completed","Phase 3","\t"]
["NCT02307682",4361515,7981282,"Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye","pharmaceutical solutions|ophthalmic solutions","Brolucizumab ophthalmic solution|Aflibercept ophthalmic solution","Drug|Drug","choroidal neovascularization|wet macular degeneration|neovascularization, pathologic|macular degeneration","Choroidal Neovascularization|Neovascular Age-Related Macular Degeneration","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of RTH258 Versus Aflibercept - Study 1",3,"Least Squares Mean Difference",-0.6,"NA",null,-2.5,1.3,95,"Standard Error of the Mean",0.98,"All",1775,"Completed","Phase 3","\t"]
["NCT02308540",4360747,7981105,"Geometric Mean Concentration of Immunoglobulin G (IgG) for Adults","vaccines|heptavalent pneumococcal conjugate vaccine","SIILPCV10|Pneumovax 23|Prevenar 13","Biological|Biological|Biological","pneumococcal infections","Pneumococcal Disease","Parallel Assignment","Interventional","Prevention","Randomized","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",8,"Pn IgG type 7F GMC Ratio",0.76,0.3365,"t-test, 2 sided",0.47,1.22,90,null,"NA","All",346,"Completed","Phase 1/Phase 2","\t"]
["NCT02312713",4360234,7980639,"Change From Baseline to Month 4 and Change From Baseline to 12 Month in Objective Physical Function- Unilateral Stand Time","NA","Internet Based Exercise Training|Physical Therapy","Behavioral|Behavioral","osteoarthritis|osteoarthritis, knee","Knee Osteoarthritis","Parallel Assignment","Interventional","Treatment","Randomized","Physical Therapy Versus Internet-Based Exercise Training for Patients With Knee Osteoarthritis",3,"Mean Difference (Final Values)",-0.02,0.97,"Mixed Models Analysis",-0.97,0.93,95,null,"NA","All",350,"Completed","N/A","\t"]
["NCT02314923",4360088,7980461,"Geometric Mean Titers (GMTs) of Zaire Ebola Virus- (ZEBOV)-Specific Immunoglobulin-G (IgG) Antibody","NA","V920 Vaccine|Placebo","Biological|Other","hemorrhagic fever, ebola","Ebola Virus","Parallel Assignment","Interventional","Prevention","Randomized","Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)",10,null,"NA",0.951,"ANOVA",{"$nulls":4},"NA","All",513,"Completed","Phase 1","\t"]
["NCT02320396",4359932,7979821,"Change From Baseline in Total Nasal Symptom Score (TNSS) During 2 Weeks of Therapy","desloratadine","Desloratadine 5 mg|Placebo","Drug|Drug","rhinitis, allergic, seasonal|rhinitis, allergic|rhinitis","Seasonal Allergic Rhinitis","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Seasonal Allergic Rhinitis (MK-4117-204)",2,"Difference in Least Squares (LS) Means",-0.83,1E-3,"cLDA model",-1.14,-0.51,95,null,"NA","All",449,"Completed","Phase 3","\t"]
["NCT02325791",4359643,7979237,"Part B: Percentage of Participants With Medically Attended Respiratory Syncytial Virus (RSV) Infection (Hospitalization or Outpatient Visit With Lower Respiratory Tract Infection [LRTI]) Up to Day 150","NA","Suptavumab 30 mg/kg|Placebo Matched to Suptavumab|Suptavumab 30 mg/kg- 1 Dose|Suptavumab 30 mg/kg - 2 Doses","Drug|Drug|Drug|Drug","communicable diseases|respiratory syncytial virus infections|infection","Respiratory Syncytial Virus Infections","Parallel Assignment","Interventional","Treatment","Randomized","Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants",4,"percentage treatment difference",1.15,0.5773,"Cochran-Mantel-Haenszel",-2.898,5.201,95,null,"NA","All",1177,"Completed","Phase 3","\t"]
["NCT02328404",4359550,7978982,"Serum Glucose Concentration in Oral Glucose Tolerance Test 1st hr After Treatment","vitamin d|cholecalciferol","50,000 IU vitamin D3|Placebo","Drug|Drug","overweight|avitaminosis|vitamin d deficiency|polycystic ovary syndrome|syndrome|rickets","Hypovitaminosis D|Polycystic Ovary Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","The Effect of Vitamin D Supplementation Among Overweight Jordanian Women With Polycystic Ovary Syndrome (PCOS)",2,null,"NA",0.51,"t-test, 2 sided",{"$nulls":4},"NA","Female","NA","Completed","Phase 3","\t"]
["NCT02343406",4359123,7977515,"Adult Study: Objective Response Rate (ORR)","temozolomide|lomustine","Depatuxizumab mafodotin|Temozolomide|Lomustine","Drug|Drug|Drug","glioblastoma","Glioblastoma","Parallel Assignment","Interventional","Treatment","Randomized","Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas",5,"Odds Ratio (OR)",1.21,0,"Cochran-Mantel-Haenszel",0.12,12.49,95,null,"NA","All",266,"Completed","Phase 2","\t"]
["NCT02345161",4359094,7977402,"Transitional Dyspnea Index (TDI) Focal Score Expressed as Least Square Mean at Week 52","albuterol|budesonide|formoterol fumarate|budesonide, formoterol fumarate drug combination","Triple FF/UMEC/VI|Placebo to match FF/UMEC/VI|Budesonide/Formoterol|Placebo to match Budesonide/Formoterol combination|Albuterol/salbutamol","Drug|Drug|Drug|Drug|Drug","pulmonary disease, chronic obstructive|lung diseases|lung diseases, obstructive","Pulmonary Disease, Chronic Obstructive","Parallel Assignment","Interventional","Treatment","Randomized","A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",2,"LS Mean difference",0.34,0.279,"Mixed effect repeated measures model",-0.28,0.97,95,"Standard Error of the Mean",0.317,"All",1811,"Completed","Phase 3","\t"]
["NCT02349152",4358829,7976943,"Postoperative Pain","remifentanil|fentanyl","Remifentanil|Fentanyl","Drug|Drug","heart diseases|hyperglycemia","Heart Diseases|Hyperglycemia","Parallel Assignment","Interventional","Prevention","Randomized","Remifentanil and Glycemic Response in Cardiac Surgery",2,null,"NA",0.501,"t-test, 2 sided",{"$nulls":4},"NA","All",116,"Completed","Phase 4","\t"]
["NCT02351934",4358707,7976663,"Number of Participants With Hypokalemia","furosemide|gabapentin|celecoxib","Furosemide|Celecoxib|Gabapentin","Drug|Drug|Drug","NA","Colorectal Disorders","Parallel Assignment","Interventional","Treatment","Randomized","Early Diuresis Following Colorectal Surgery",2,null,"NA",0.985,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",123,"Completed","Phase 4","\t"]
["NCT02357901",4358510,7975884,"Cumulative Distribution Function (CDF) of the Percentage of Urine Samples Negative for Opioids Combined With Self-Reports Negative for Illicit Opioid Use Collected From Week 5 Through Week 24","buprenorphine, naloxone drug combination|buprenorphine","SUBOXONE|RBP-6000|Placebo","Drug|Drug|Drug","opioid-related disorders","Opioid Dependence|Opioid Related Disorders","Parallel Assignment","Interventional","Treatment","Randomized","Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine",4,null,"NA",{"v":1E-4,"d":"1.00E-04"},"Wilcoxon rank-sum test",{"$nulls":4},"NA","All",665,"Completed","Phase 3","\t"]
["NCT02360215",4358337,7975535,"Change From Baseline in the Hopkins Verbal Learning Test -Revised (HVLT-R) Total Recall Score (Neurocognitive Decline)","memantine","Whole brain radiation therapy with hippocampal avoidance|Memantine|Whole brain radiation therapy","Radiation|Drug|Radiation","neoplasms","Cognitive Impairment|Metastatic Malignant Neoplasm in the Brain|Solid Neoplasm","Parallel Assignment","Interventional","Supportive Care","Randomized","Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases",2,null,"NA",0.0048,"Mixed Models Analysis",{"$nulls":4},"NA","All",518,"Completed","Phase 3","\t"]
["NCT02366689",4358032,7974958,"Gingivitis Scores","tin fluorides|cetylpyridinium|fluorides|triclosan","Triclosan/fluoride toothpaste|stannous fluoride toothpaste|fluoride only toothpaste|Cetylpyridinium chloride mouthwash|Fluoride only mouthwash","Drug|Drug|Drug|Drug|Drug","dental plaque|gingivitis","Dental Plaque|Gingivitis","Parallel Assignment","Interventional","Treatment","Randomized","Clinical Study Comparing Dental Plaque and Gingivitis Reduction After Using One of Three Oral Hygiene Multi-component Regimens (Using of a Manual Toothbrush, a Toothpaste and a Mouthwash)",3,null,"NA",1E-3,"ANCOVA",{"$nulls":4},"NA","All",179,"Completed","Phase 4","\t"]
["NCT02367781",4357977,7974734,"Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the ITT-WT Population","paclitaxel|carboplatin|pemetrexed|atezolizumab|antibodies|antibodies, monoclonal","Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Carboplatin|Nab-Paclitaxel|Pemetrexed","Drug|Drug|Drug|Drug","carcinoma, non-small-cell lung","Carcinoma, Non-Squamous Non-Small Cell Lung","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)",2,"Hazard Ratio (HR)",0.639,{"v":1E-4,"d":"1.00E-04"},"Log Rank",0.536,0.763,95,null,"NA","All",723,"Completed","Phase 3","\t"]
["NCT02371980",4357733,7974138,"Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score","vortioxetine","Vortioxetine|Placebo","Drug|Drug","depressive disorder|depression|depressive disorder, major","Major Depressive Disorder","Parallel Assignment","Interventional","Treatment","Randomized","Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)",5,"Least Squares Mean Difference",-2.92,2E-3,"MMRM",-4.76,-1.08,95,"Standard Error of the Mean",0.938,"All",1106,"Completed","Phase 4","\t"]
["NCT02374463",4357419,7973927,"Functional Gait Analysis","NA","MMBI|Tai Chi","Behavioral|Behavioral","mobility limitation","Accidental Falls|Mobility Limitation|Postural Balance","Parallel Assignment","Interventional","Prevention","Randomized","Improving Balance and Mobility",2,null,"NA",0,"ANOVA",{"$nulls":4},"NA","All",41,"Completed","N/A","\t"]
["NCT02384941",4357207,7973100,"Change From Baseline in A1C at Week 24","(2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol","Placebo|Sotagliflozin","Drug|Drug","diabetes mellitus|diabetes mellitus, type 1","Type 1 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy",3,"Least squares mean difference",-0.41,1E-3,"MMRM",null,null,95,"Standard Error of the Mean",0.047,"All",793,"Completed","Phase 3","\t"]
["NCT02391363",4356915,7972444,"Health Service Use at 9 Months","NA","Cognitive behavior treatment|Information and referral","Behavioral|Behavioral","NA","Anxiety","Parallel Assignment","Interventional","Treatment","Randomized","Calmer Life: Treating Worry Among Older Adults In Underserved, Low-income, Minority Communities",2,null,"NA",0.04,"Regression, Logistic",{"$nulls":4},"NA","All",247,"Completed","N/A","\t"]
["NCT02397096",4356671,7971868,"Mean Change From Baseline in Fasting Non-high-density Lipoprotein Cholesterol (Non-HDL-C)","reverse transcriptase inhibitors|protease inhibitors|ritonavir|hiv protease inhibitors|tenofovir|lamivudine|cobicistat","Baseline regimen of a non-nucleoside reverse transcriptase inhibitor|Doravirine, Tenofovir, Lamivudine|Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor|Baseline regimen of cobicistat-boosted elvitegravir|Baseline regimen of two nucleoside reverse transcriptase inhibitors","Drug|Drug|Drug|Drug|Drug","NA","HIV-1 Infection","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)",2,"Treatment Difference",-23.03,{"v":1E-4,"d":"1.00E-04"},"ANCOVA",-28,-18.05,95,null,"NA","All",673,"Active, not recruiting","Phase 3","\t"]
["NCT02401529",4356500,7971534,"Average Frequency of Meals Per Day","dexamethasone|acetaminophen|prednisolone","IV dexamethasone|Oral prednisolone|Paracetamol|IV saline","Drug|Drug|Drug|Drug","nausea|vomiting|postoperative nausea and vomiting","Postoperative Nausea and Vomiting|Postoperative Pain","Parallel Assignment","Interventional","Supportive Care","Randomized","Effect of Steroids on Post-tonsillectomy Morbidities",2,null,"NA",0.019,"Chi-squared",{"$nulls":4},"NA","All",100,"Completed","Phase 2","\t"]
["NCT02409667",4356217,7970651,"Change From Baseline in PASI in Participants With a PASI Response of ≥75 to <90 at Week 24","NA","Secukinumab","Biological","psoriasis","Plaque Psoriasis","Parallel Assignment","Interventional","Treatment","Randomized","Plaque Psoriasis Efficacy and Safety With Secukinumab",4,"LSM estimate",1.47,0.009,"ANCOVA",0.37,2.57,95,null,"NA","All",16487,"Completed","Phase 3","\t"]
["NCT02414854",4355978,7970018,"Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L","albuterol","Levalbuterol/Levosalbutamol|Dupilumab|Placebo|Inhaled corticosteroid (ICS) therapy|Albuterol/Salbutamol","Drug|Drug|Drug|Drug|Drug","asthma","Asthma","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)",4,"LS Mean Difference",0.24,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",0.16,0.32,95,null,"NA","All",1902,"Completed","Phase 3","\t"]
["NCT02417246",4355878,7969658,"Heart Rate (HR) Response Compared Between Brand Name Metoprolol ER and Each Generic (Generic B, Generic A) Formulation of Metoprolol Succinate","metoprolol","brand name metoprolol ER|Generic A|Generic B","Drug|Drug|Drug","NA","Blood Pressure","Crossover Assignment","Interventional","Basic Science","Randomized","Open-Labeled PK-PD Studies of Metoprolol ER",2,"Slope",1.134,0.368,"Mixed Models Analysis",{"$nulls":4},"NA","All","NA","Completed","Phase 4","\t"]
["NCT02421510",4355614,7969213,"Change From Baseline in Diabetes Treatment Satisfaction Questionnaire (DTSQ) Score at Week 24","(2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol","Sotagliflozin|Sotagliflozin|Placebo","Drug|Drug|Drug","diabetes mellitus, type 1|diabetes mellitus","Type 1 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy",3,"Least squares mean difference",2,1E-3,"MMRM",1.3,2.7,95,"Standard Error of the Mean",0.37,"All",782,"Completed","Phase 3","\t"]
["NCT02426918",4355450,7968743,"Early Clinical Response Rate (ECRR): Percentage of Responders to Treatment at 48 to 72 Hours From Randomization as Assessed by the Investigator","vancomycin|linezolid","Vancomycin IV|Debio 1450 IV|Debio 1450 Oral|Linezolid|Debio 1450 Oral Placebo|Linezolid Placebo","Drug|Drug|Drug|Drug|Drug|Drug","infection|communicable diseases|bacterial infections","Bacterial Infections","Parallel Assignment","Interventional","Treatment","Randomized","Study of Debio 1450 for Bacterial Skin Infections",3,"Risk Difference (RD)",-4.2,"NA",null,-11.42,3,95,null,"NA","All",330,"Completed","Phase 2","\t"]
["NCT02434328",4355073,7967836,"Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye","ophthalmic solutions|pharmaceutical solutions","Brolucizumab ophthalmic solution|Aflibercept ophthalmic solution","Drug|Drug","wet macular degeneration|choroidal neovascularization|macular degeneration|neovascularization, pathologic","Choroidal Neovascularization|Neovascular Age-Related Macular Degeneration","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of RTH258 Versus Aflibercept - Study 2",2,"Least Squares Mean Difference",-40.9,"NA",null,-60.4,-21.4,95,"Standard Error of the Mean",9.94,"All",1048,"Completed","Phase 3","\t"]
["NCT02434328",4355153,7967839,"Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye","ophthalmic solutions|pharmaceutical solutions","Brolucizumab ophthalmic solution|Aflibercept ophthalmic solution","Drug|Drug","wet macular degeneration|choroidal neovascularization|macular degeneration|neovascularization, pathologic","Choroidal Neovascularization|Neovascular Age-Related Macular Degeneration","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of RTH258 Versus Aflibercept - Study 2",2,"Difference in proportions",-0.4,"NA",null,-4,3.3,95,null,"NA","All",1048,"Completed","Phase 3","\t"]
["NCT02437487",4354835,7967389,"Number of Subjects With CDI Recurrence","NA","SER-109|Placebo","Drug|Drug","clostridium infections","Clostridium Difficile","Parallel Assignment","Interventional","Prevention","Randomized","SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)",2,"Relative Risk",1.2217,"NA",null,0.7919,1.8849,95,null,"NA","All",89,"Completed","Phase 2","\t"]
["NCT02444715",4354631,7966698,"Change in Systolic Blood Pressure","NA","Standard care|CAPSYS","Behavioral|Behavioral","cerebrovascular disorders|cardiovascular diseases","Cardiovascular Diseases|Cerebrovascular Diseases|CVD Risk Factors|Stroke","Parallel Assignment","Interventional","Prevention","Randomized","Computer-Aided Prevention System",2,null,"NA",0.96,"t-test, 2 sided",{"$nulls":4},"NA","All",94,"Completed","N/A","\t"]
["NCT02450539",4354030,7965989,"Change From Baseline in MD Anderson Symptom Inventory-Lung Cancer (MDASI-LC) Scores","docetaxel","Abemaciclib|Docetaxel","Drug|Drug","lung neoplasms|carcinoma, non-small-cell lung","Non-Small Cell Lung Cancer Stage IV","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer",2,"Mean Difference (Final Values)",0.86,"NA",{"$nulls":4},"Standard Error of the Mean",0.29,"All",159,"Completed","Phase 2","\t"]
["NCT02452463",4353897,7965750,"Portion of Common Terminology Criteria for Adverse Events Grade 2 or Higher Radiation Pneumonitis","antibodies, monoclonal|nintedanib|durvalumab|immunoglobulins|immunoglobulin g","Durvalumab|Nintedanib|Placebo|Quality-of-Life Assessment","Biological|Drug|Other|Procedure","radiation pneumonitis|carcinoma, non-small-cell lung|carcinoma|pneumonia","Lung Non-Squamous Non-Small Cell Carcinoma|Radiation-Induced Pneumonitis|Stage IIA Lung Non-Small Cell Carcinoma AJCC v7|Stage IIB Lung Non-Small Cell Carcinoma AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage II Lung Non-Small Cell Cancer AJCC v7|Stage IV Lung Non-Small Cell Cancer AJCC v7","Parallel Assignment","Interventional","Supportive Care","Randomized","Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy",3,null,"NA",0.107,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",8,"Terminated","Phase 2","\t"]
["NCT02461589",4353604,7964868,"Change in HbA1c (Glycosylated Haemoglobin)","liraglutide","semaglutide|liraglutide|placebo","Drug|Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Diabetes|Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes",13,"Treatment difference",-1.69,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",-1.95,-1.42,95,null,"NA","All",706,"Completed","Phase 2","\t"]
["NCT02466646",4353448,7964489,"Level of Parvimonas Micra","NA","Klorhex® Gel, rinse and spray|Conventional IPT|Full-mouth IPT","Drug|Procedure|Procedure","aggressive periodontitis|periodontitis|aggression","Aggressive Periodontitis","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of Efficacy of Full-mouth Disinfection in Generalized Aggressive Periodontitis Patients",3,null,"NA",0.674,"Kruskal-Wallis",{"$nulls":4},"NA","All",42,"Completed","Phase 4","\t"]
["NCT02475655",4353040,7963595,"Percentage of Participants With Detectable CMV Shedding","NA","Ruxolitinib","Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults",2,null,"NA",0.4,"Fisher Exact",{"$nulls":4},"NA","All",60,"Completed","Phase 2","\t"]
["NCT02475655",4353100,7963627,"Fold Change in the Level of Plasma Transforming Growth Factor Beta 2 (TGF Beta-2)","NA","Ruxolitinib","Drug","hiv infections","HIV Infections","Parallel Assignment","Interventional","Treatment","Randomized","Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults",2,"Mean Difference (Net)",1.39,0.031,"t-test, 2 sided",1.08,1.79,90,null,"NA","All",60,"Completed","Phase 2","\t"]
["NCT02477020",4353002,7963437,"Change From Baseline in PANSS Total Score at Weeks 1, 2, 3, 4 and 5","NA","TAK-063 20 mg|Placebo","Drug|Drug","schizophrenia","Schizophrenia","Parallel Assignment","Interventional","Treatment","Randomized","A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia",2,"Least square mean difference",-2.11,0.504,"MMRM",-8.33,4.11,95,"Standard Error of the Mean",3.147,"All",164,"Completed","Phase 2","\t"]
["NCT02489279",4352439,7962174,"Change From Baseline in Nelson-Denny Reading Test - Comprehension Score","NA","Sustained Attention Control (SAC) Method|Scrabble","Behavioral|Behavioral","hyperkinesis|attention deficit disorder with hyperactivity","Attention Deficit Hyperactivity Disorder","Parallel Assignment","Interventional","Treatment","Randomized","Training Attentional Awareness and Control in ADHD",2,null,"NA",{"v":0.0005,"d":"5.00E-04"},"t-test, 1 sided",{"$nulls":4},"NA","All",107,"Completed","N/A","\t"]
["NCT02493764",4352312,7961809,"Percentage of Participants With All-cause Mortality (ACM) Through Day 28 in the Modified Intention-to-treat (MITT) Population","tazobactam|linezolid|imipenem|cilastatin|mk-7655|piperacillin","Imipenem|Relebactam|Cilastatin|Piperacillin|Tazobactam|Linezolid","Drug|Drug|Drug|Drug|Drug|Drug","pneumonia, bacterial|pneumonia","Bacterial Pneumonia","Parallel Assignment","Interventional","Treatment","Randomized","Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)",2,"Adjusted difference in ACM",-5.3,1E-3,"t-test, 1 sided",-11.9,1.2,95,null,"NA","All",537,"Completed","Phase 3","\t"]
["NCT02495467",4352175,7961580,"Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 2","nitroglycerin","Glyceryl trinitrate|MED Placebo","Drug|Drug","erectile dysfunction","Erectile Dysfunction","Crossover Assignment","Interventional","Treatment","Randomized","Clinical Trial of Topically-applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction (ED)",2,"Means ratio",0.989,0.6746,"Generalized Linear Mixed Model",0.937,1.043,95,null,"NA","All",232,"Completed","Phase 2","\t"]
["NCT02501811",4351994,7960748,"Change From Baseline in Global Strain (HARP MRI)","plasma-lyte 148","Mesenchymal Stem Cells (MSC)|c-kit+ cells|Placebo (Plasmalyte A)","Biological|Biological|Biological","cardiomyopathies","Ischemic Cardiomyopathy","Parallel Assignment","Interventional","Treatment","Randomized","Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure",4,"Mean Difference (Final Values)",0.58,0.282,"ANCOVA",-1.815,2.975,95,"Standard Error of the Mean",1.17,"All",125,"Completed","Phase 2","\t"]
["NCT02504671",4350954,7960357,"Change From Baseline in Physical and Mental Component Scores (PCS, MCS) and in Domain Scores of Short Form 36 (SF-36) at All Assessment Time Points","folic acid","GSK3196165|MTX|Folic acid|Placebo","Drug|Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Arthritis, Rheumatoid","Parallel Assignment","Interventional","Treatment","Randomized","Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis",6,"Mean Difference (Net)",1.53,0.403,"MMRM",-2.07,5.12,95,null,"NA","All",222,"Completed","Phase 2","\t"]
["NCT02504671",4351141,7960361,"Change From Baseline in SDAI at All Assessment Time Points","folic acid","GSK3196165|MTX|Folic acid|Placebo","Drug|Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Arthritis, Rheumatoid","Parallel Assignment","Interventional","Treatment","Randomized","Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis",6,"Mean Difference (Net)",-8.86,0.007,"MMRM",-15.32,-2.41,95,null,"NA","All",222,"Completed","Phase 2","\t"]
["NCT02504671",4351328,7960364,"Percentage of Participants With Index-based ACR/EULAR Remission Rates at All Assessment Time Points","folic acid","GSK3196165|MTX|Folic acid|Placebo","Drug|Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Arthritis, Rheumatoid","Parallel Assignment","Interventional","Treatment","Randomized","Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis",6,"Difference",5.4,"NA",null,-1.9,12.7,95,null,"NA","All",222,"Completed","Phase 2","\t"]
["NCT02504671",4351540,7960365,"Percentage of Participants With American College of Rheumatology's (ACR) 20/50/70 Response Rates at All Assessment Time Points","folic acid","GSK3196165|MTX|Folic acid|Placebo","Drug|Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Arthritis, Rheumatoid","Parallel Assignment","Interventional","Treatment","Randomized","Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis",6,"Difference",24.3,"NA",null,6,42.7,95,null,"NA","All",222,"Completed","Phase 2","\t"]
["NCT02504671",4351626,7960366,"Percentage of Participants Achieving Categorical DAS28(CRP) Response (Moderate/Good [European League Against Rheumatism] EULAR Response) at All Assessment Time Points","folic acid","GSK3196165|MTX|Folic acid|Placebo","Drug|Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Arthritis, Rheumatoid","Parallel Assignment","Interventional","Treatment","Randomized","Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis",6,"Difference",5.4,"NA",null,-4.8,15.6,95,null,"NA","All",222,"Completed","Phase 2","\t"]
["NCT02504775",4350793,7960343,"Maximum Plasma Concentration (Cmax)","acetaminophen","Mejoral® 500 Tablets|Tylenol® Caplets","Drug|Drug","NA","Pain","Crossover Assignment","Interventional","Other","Randomized","Bioequivalence Study for Mejoral 500 Product",2,"Ratio of Averages of Tylenol/Mejoral",106.132,"NA",null,85.151,132.283,90,null,"NA","All",28,"Completed","N/A","\t"]
["NCT02513160",4350497,7959291,"Change From Baseline in Weekly Average of Total Daily (24-Hour) Rescue Medication Use Over the 6-Week Treatment Period","beclomethasone|albuterol","Beclomethasone Dipropionate 640|Placebo|Beclomethasone dipropionate via 320 mcg BAI|albuterol/salbutamol|Beclomethasone dipropionate via 320 mcg MDI","Drug|Drug|Drug|Drug|Drug","asthma","Persistent Asthma","Parallel Assignment","Interventional","Treatment","Randomized","Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma",4,"LSM difference",-1.1,{"v":1E-4,"d":"1.00E-04"},"mixed model for repeated measures",-1.482,-0.717,95,null,"NA","All",713,"Completed","Phase 3","\t"]
["NCT02515942",4350423,7958792,"Change in Best Corrected Visual Acuity (BCVA) From Baseline by Visit up to Day 337 as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS)","NA","CLG561|LFG316|Sham injection","Drug|Drug|Drug","atrophy|geographic atrophy","Geographic Atrophy","Parallel Assignment","Interventional","Treatment","Randomized","CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)",3,"Treatment Effect",-1.94,0.8392,"Mixed Models Analysis",-4.44,0.57,80,null,"NA","All",114,"Completed","Phase 2","\t"]
["NCT02516592",4350215,7958687,"Transitional Dyspnea Index (TDI) Focal Score","salmeterol xinafoate|fluticasone","QVA149 110/50 micrograms|Salmeterol/fluticasone 50/500 microgrammes","Drug|Drug","NA","COPD","Parallel Assignment","Interventional","Treatment","Randomized","Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort",2,"Mean Difference (Final Values)",0.46,0.063,"Mixed Models Analysis",-0.03,0.94,95,null,"NA","All",500,"Completed","Phase 4","\t"]
["NCT02522767",4350072,7958014,"The Change From Baseline in Serum C-reactive Protein (CRP) Levels at Weeks 2, 4, and 8","mesalamine","Mesalamine|Placebo","Drug|Drug","colitis|ulcer|colitis, ulcerative","Ulcerative Colitis","Parallel Assignment","Interventional","Treatment","Randomized","Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)",2,"Treatment difference",-2.39,0.05,"Repeated-measures ANCOVA",-5.46,0.67,95,null,"NA","All",228,"Completed","Phase 3","\t"]
["NCT02528188",4349450,7957622,"Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Walking on a Flat Surface at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56","tanezumab","NSAID|Tanezumab 2.5 mg|Tanezumab 5 mg","Drug|Biological|Biological","osteoarthritis, hip|chronic pain|osteoarthritis, knee|osteoarthritis","Chronic Pain|Osteoarthritis, Hip|Osteoarthritis, Knee","Parallel Assignment","Interventional","Treatment","Randomized","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",3,"LS Mean Difference",0.08,0.5819,"ANCOVA",-0.19,0.35,95,"Standard Error of the Mean",0.14,"All",3021,"Completed","Phase 3","\t"]
["NCT02528188",4349540,7957629,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","tanezumab","NSAID|Tanezumab 2.5 mg|Tanezumab 5 mg","Drug|Biological|Biological","osteoarthritis, hip|chronic pain|osteoarthritis, knee|osteoarthritis","Chronic Pain|Osteoarthritis, Hip|Osteoarthritis, Knee","Parallel Assignment","Interventional","Treatment","Randomized","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",3,"Odds Ratio (OR)",1.04,0.7581,"Regression, Logistic",0.83,1.3,95,null,"NA","All",3021,"Completed","Phase 3","\t"]
["NCT02528188",4349767,7957642,"Number of Participants With Progression of Osteoarthritis in the Index Knee (Kellgren-Lawrence Grade 2 or 3) According to Bland and Altman Method at Weeks 56 and 80","tanezumab","NSAID|Tanezumab 2.5 mg|Tanezumab 5 mg","Drug|Biological|Biological","osteoarthritis, hip|chronic pain|osteoarthritis, knee|osteoarthritis","Chronic Pain|Osteoarthritis, Hip|Osteoarthritis, Knee","Parallel Assignment","Interventional","Treatment","Randomized","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",3,"Odds Ratio (OR)",0.55,0.3002,"Regression, Logistic",0.18,1.7,95,null,"NA","All",3021,"Completed","Phase 3","\t"]
["NCT02528253",4348700,7957527,"Change From Baseline in Work Productivity and Activity Impairment Questionnaire for Low Back Pain (WPAI:LBP) Scores at Weeks 16, 56 and 64","tanezumab|tramadol","Tramadol PR oral|Tanezumab 5 mg SC|Tanezumab 10 mg SC|Placebo to Week 16; tanezumab 5mg SC|Placebo to Week 16, tanezumab 10 mg SC","Biological|Biological|Biological|Biological|Biological","back pain|low back pain","Low Back Pain","Parallel Assignment","Interventional","Treatment","Randomized","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",5,"LS Mean Difference",-0.3,0.8464,"ANCOVA",-3.32,2.72,95,"Standard Error of the Mean",1.53,"All",1832,"Completed","Phase 3","\t"]
["NCT02528253",4348953,7957546,"Change From Baseline in Brief Pain Inventory-short Form (BPI-sf) Score Worst Pain at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56","tanezumab|tramadol","Tramadol PR oral|Tanezumab 5 mg SC|Tanezumab 10 mg SC|Placebo to Week 16; tanezumab 5mg SC|Placebo to Week 16, tanezumab 10 mg SC","Biological|Biological|Biological|Biological|Biological","back pain|low back pain","Low Back Pain","Parallel Assignment","Interventional","Treatment","Randomized","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",5,"LS Mean Difference",-0.49,0.0016,"ANCOVA",-0.79,-0.18,95,"Standard Error of the Mean",0.15,"All",1832,"Completed","Phase 3","\t"]
["NCT02528253",4349089,7957549,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","tanezumab|tramadol","Tramadol PR oral|Tanezumab 5 mg SC|Tanezumab 10 mg SC|Placebo to Week 16; tanezumab 5mg SC|Placebo to Week 16, tanezumab 10 mg SC","Biological|Biological|Biological|Biological|Biological","back pain|low back pain","Low Back Pain","Parallel Assignment","Interventional","Treatment","Randomized","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",5,"Odds Ratio (OR)",1.25,0.125,"Regression, Logistic",0.94,1.67,95,null,"NA","All",1832,"Completed","Phase 3","\t"]
["NCT02528253",4349269,7957554,"Change From Baseline in Roland Morris Disability Questionnaire (RMDQ) Total Score at Weeks 2, 4, 8, 16 (for Tanezumab vs Tramadol) 24, 32, 40, 48 and 56","tanezumab|tramadol","Tramadol PR oral|Tanezumab 5 mg SC|Tanezumab 10 mg SC|Placebo to Week 16; tanezumab 5mg SC|Placebo to Week 16, tanezumab 10 mg SC","Biological|Biological|Biological|Biological|Biological","back pain|low back pain","Low Back Pain","Parallel Assignment","Interventional","Treatment","Randomized","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",5,"LS Mean Difference",-1.32,0.0035,"ANCOVA",-2.21,-0.43,95,"Standard Error of the Mean",0.45,"All",1832,"Completed","Phase 3","\t"]
["NCT02533505",4348392,7956772,"Change in Vt/Ti","formoterol fumarate|budesonide","Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol|Matching Placebo pMDI 160/4.5 μg","Drug|Drug","pulmonary disease, chronic obstructive|lung diseases, obstructive","Chronic Obstructive Pulmonary Disease (COPD)","Crossover Assignment","Interventional","Treatment","Randomized","Phase IV O2 Consumption Study in COPD Patients.",2,"Mean Difference (Final Values)",23.315,0.021,"Mixed Models Analysis",3.723,42.907,95,null,"NA","All",51,"Completed","Phase 4","\t"]
["NCT02545868",4348010,7955591,"Percentage of Participants With Positive Response Against Individual Pneumococcal Serotypes in 13-PCV","vaccines","23-PPV|13-PCV Booster|Influenza Vaccine|KLH|OCR|TT Vaccine","Biological|Biological|Biological|Biological|Drug|Biological","multiple sclerosis|multiple sclerosis, relapsing-remitting|sclerosis","Multiple Sclerosis, Relapsing-Remitting","Parallel Assignment","Interventional","Supportive Care","Randomized","A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis",2,"Normal Distribution Approximation",-64.7,"NA",null,-82.6,-46.8,95,null,"NA","All",102,"Active, not recruiting","Phase 3","\t"]
["NCT02545868",4348015,7955591,"Percentage of Participants With Positive Response Against Individual Pneumococcal Serotypes in 13-PCV","vaccines","23-PPV|13-PCV Booster|Influenza Vaccine|KLH|OCR|TT Vaccine","Biological|Biological|Biological|Biological|Drug|Biological","multiple sclerosis|multiple sclerosis, relapsing-remitting|sclerosis","Multiple Sclerosis, Relapsing-Remitting","Parallel Assignment","Interventional","Supportive Care","Randomized","A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis",2,"Normal Distribution Approximation",-28.1,"NA",null,-50.7,-5.4,95,null,"NA","All",102,"Active, not recruiting","Phase 3","\t"]
["NCT02553915",4347651,7954583,"Percent Change in Plasma Concentration of Inflammatory Biomarkers IL-6 (pg/mL) and PBMC TNF-α (pg/mL)","NA","Placebo|EPA 1 g/day|EPA 2 g/day|EPA 4 g/day","Other|Drug|Drug|Drug","depressive disorder|inflammation|overweight|depressive disorder, major|depression","Inflammation|Major Depressive Disorder|Overweight","Parallel Assignment","Interventional","Treatment","Randomized","Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach",4,null,"NA",0.1,"Kruskal-Wallis",{"$nulls":4},"NA","All",61,"Active, not recruiting","Phase 2/Phase 3","\t"]
["NCT02554786",4347549,7954506,"Post Dose FEV1 (5 Minutes-1 Hour)","fluticasone|mometasone furoate|salmeterol xinafoate","Indacaterol acetate/Mometasone furoate|Mometasone furoate|Salmeterol xinafoate/fluticasone propionate","Drug|Drug|Drug","asthma","Asthma","Parallel Assignment","Interventional","Treatment","Randomized","A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma",5,"LS Mean",0.163,1E-3,"MMRM",0.121,0.206,95,"Standard Error of the Mean",0.0217,"All",2216,"Completed","Phase 3","\t"]
["NCT02554877",4347299,7954457,"Changes From Baseline in Body Weight at Weeks 2, 4, 8, and 12.","NA","PF-06291874|Placebo","Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Type 2 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin",4,"LS Mean difference from placebo",1.39,0.0024,"Mixed Models Analysis",0.65,2.14,90,"Standard Error of the Mean",0.45,"All",206,"Completed","Phase 2","\t"]
["NCT02558231",4347041,7954099,"Change From Baseline to Week 26 in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) Levels","tadalafil|macitentan|selexipag","Macitentan|Tadalafil|Selexipag","Drug|Drug|Drug","familial primary pulmonary hypertension|hypertension","Pulmonary Arterial Hypertension","Parallel Assignment","Interventional","Treatment","Randomized","The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension",2,"Ratio of geometric LS mean",1.03,0.8529,"ANCOVA",0.77,1.371,95,null,"NA","All",247,"Completed","Phase 3","\t"]
["NCT02559570",4346933,7954032,"Change From Baseline (CFB) in 4-week of Severity of Straining","linaclotide","Placebo|LIN Dose A|LIN Dose B|LIN Dose C|LIN 145 µg","Drug|Drug|Drug|Drug|Drug","constipation","Functional Constipation in Children Ages 6-17 Years","Parallel Assignment","Interventional","Treatment","Randomized","A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)",5,"Least Squares Mean Difference",-0.121,0.5602,"ANCOVA",-0.53,0.288,95,"Standard Error of the Mean",0.207,"All",173,"Completed","Phase 2","\t"]
["NCT02564042",4346790,7953443,"Percentage of Participants With >=75 Percent Improvement in Psoriasis Area and Severity Index (PASI) From Baseline to Each Study Visit","NA","GSK2894512 1% Cream|GSK2894512 0.5% Cream|Vehicle cream","Drug|Drug|Drug","psoriasis","Psoriasis","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis",6,"Proportion difference",51,"NA",null,22.2,73.2,95,null,"NA","All",227,"Completed","Phase 2","\t"]
["NCT02571244",4346460,7952609,"Carbon Monoxide Verified Smoking Abstinence","NA","Motivational Interview plus text message","Behavioral","tobacco use disorder","Tobacco Use Cessation|Tobacco Use Disorder","Parallel Assignment","Interventional","Supportive Care","Randomized","Text Messaging for Supporting Quit Attempts",2,"Risk Ratio (RR)",1.44,"NA",null,1.07,1.92,95,null,"NA","All",66,"Completed","N/A","\t"]
["NCT02571777",4346420,7952584,"Trough Forced Expiratory Flow (FEF) Between 25% and 75% of FVC (FEF25-75) at 52 Weeks","fluticasone|salmeterol xinafoate","QVM149 150/50/160|QVM149 150/50/80|QMF149 150/320|QMF149 150/160|salmeterol/fluticasone","Drug|Drug|Drug|Drug|Drug","asthma","Asthma","Parallel Assignment","Interventional","Treatment","Randomized","Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma",5,"LS Mean",0.147,1E-3,"MMRM",0.097,0.198,95,"Standard Error of the Mean",0.0256,"All",3092,"Completed","Phase 3","\t"]
["NCT02575833",4346140,7952247,"Time to Onset of Exercise-induced Angina","erenumab","Erenumab|Placebo","Drug|Drug","angina, stable|angina pectoris","Stable Angina","Parallel Assignment","Interventional","Treatment","Randomized","Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)",2,"Hazard Ratio (HR)",1.11,0.69,"Cox Proportional Hazard",0.73,1.69,90,null,"NA","All",89,"Completed","Phase 2","\t"]
["NCT02584504",4345857,7951326,"Percent Change From Baseline in Calculated LDL-C to Averaged Week 10 to 12: ITT Analysis","atorvastatin","Alirocumab|Placebo|Atorvastatin|Non-statin Lipid-Modifying Therapy|Diet Alone","Drug|Drug|Drug|Drug|Other","hypercholesterolemia","Hypercholesterolemia","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin",3,"LS Mean Difference",-66.2,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",-72.3,-60.1,97.5,null,"NA","All",163,"Completed","Phase 3","\t"]
["NCT02589665",4345621,7950754,"Induction Period: Percentage of Participants With Symptomatic Remission at Week 12","NA","Mirikizumab|Placebo","Drug|Drug","colitis, ulcerative|ulcer|colitis","Ulcerative Colitis","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis",10,"Odds Ratio (OR)",6.54,1E-3,"Regression, Logistic",2.81,15.2,95,null,"NA","All",249,"Completed","Phase 2","\t"]
["NCT02592798",4345431,7950524,"Mean Change From Baseline in Serum Albumine at Day 113","abatacept","Abatacept|Normal Saline|D5W","Drug|Other|Other","glomerulosclerosis, focal segmental|nephrosis|nephrotic syndrome|syndrome|nephrosis, lipoid","Focal Segmental Glomerulosclerosis|Minimal Change Disease|Nephrotic Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)",2,"Mean Difference (Final Values)",0.13,"NA",null,-0.1483,0.4119,95,null,"NA","All",36,"Completed","Phase 2","\t"]
["NCT02595723",4345369,7950366,"Rey Auditory Verbal Learning Test (RAVLT)","megestrol acetate|phenytoin|megestrol","Phenytoin 200 mg capsule|Megestrol 800 mg liquid|Phenytoin-matched Placebo capsule|Megestrol-matched liquid Placebo","Drug|Drug|Drug|Drug","cognitive dysfunction","Cognitive Impairment","Crossover Assignment","Interventional","Other","Randomized","Phenytoin for Memory Impairment Secondary to Megestrol",3,null,"NA",0.003,"Mixed Models Analysis",{"$nulls":4},"NA","All",21,"Completed","Phase 4","\t"]
["NCT02605122",4345055,7949542,"Summary of Early Clinical Response","amoxicillin-potassium clavulanate combination|erythromycin lactobionate|solithromycin|erythromycin estolate|clavulanic acid|clavulanic acids|erythromycin|erythromycin stearate|amoxicillin|erythromycin ethylsuccinate|ceftriaxone|azithromycin|ampicillin","Solithromycin|Standard of Care","Drug|Drug","pneumonia, bacterial|pneumonia","Community-acquired Bacterial Pneumonia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia",2,"Achievement of ECR",62.1,"NA",null,49,74,95,null,"NA","All",97,"Terminated","Phase 2/Phase 3","\t"]
["NCT02607865",4344931,7949254,"Time to Additional Anti-diabetic Medication","sitagliptin phosphate","semaglutide|sitagliptin|placebo","Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Diabetes|Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes",4,"Hazard Ratio (HR)",0.77,0,"Regression, Cox",0.61,0.96,95,null,"NA","All",1864,"Completed","Phase 3","\t"]
["NCT02612610",4344555,7948789,"Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score After 8 Weeks of Treatment (Day 56)","NA","Gefapixant|Placebo (for gefapixant)","Drug|Drug","cough","Refractory Chronic Cough","Parallel Assignment","Interventional","Treatment","Randomized","A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)",4,"LS Mean Difference",1,0.0941,"Mixed Effect Repeated Measures model",-0.2,2.3,95,null,"NA","All",253,"Completed","Phase 2","\t"]
["NCT02614183",4344475,7948570,"Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days","NA","Galcanezumab|Placebo","Drug|Drug","migraine disorders","Migraine","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study",3,"Mean Difference (Final Values)",-1.76,1E-3,"Mixed Models Analysis",-2.31,-1.2,95,"Standard Error of the Mean",0.28,"All",862,"Completed","Phase 3","\t"]
["NCT02621060",4344157,7948047,"Glutamic Oxaloacetic Transaminase (GOT)","magnesium oxide","Placebo|Chlorogenic acid","Drug|Drug","glucose intolerance","Impaired Glucose Tolerance","Parallel Assignment","Interventional","Treatment","Randomized","Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance",2,null,"NA",0.472,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",30,"Completed","Phase 2","\t"]
["NCT02625259",4343997,7947707,"Cmax: Maximum Observed Plasma Concentration for TAK-117","lansoprazole|dexlansoprazole|serabelisib","TAK-117|Lansoprazole|TAK-117","Drug|Drug|Drug","NA","Neoplasm, Advanced or Metastatic","Crossover Assignment","Interventional","Treatment","Randomized","A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants",5,"Geometric mean ratio",0.03,"NA",null,0.02,0.07,90,null,"NA","All",54,"Completed","Phase 1","\t"]
["NCT02631837",4343678,7947073,"Duration of the Surgical Intervention","NA","vNOTES hysterectomy|LSC hysterectomy","Procedure|Procedure","uterine diseases","Uterine Diseases","Parallel Assignment","Interventional","Treatment","Randomized","Hysterectomy by Transabdominal Laparoscopy or NOTES",2,"Median Difference (Final Values)",-34,0.01,"Mann-Whitney U test",-46,-22,95,null,"NA","Female","NA","Completed","N/A","\t"]
["NCT02634151",4343498,7946845,"Change From Baseline in Apolipoprotein C-III","NA","Gemcabene|Placebo","Drug|Drug","hypercholesterolemia","Hypercholesteremia","Parallel Assignment","Interventional","Treatment","Randomized","A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins",2,"LS Mean Difference",-1.3,0.0048,"ANCOVA",-2.3,-0.4,95,null,"NA","All",105,"Completed","Phase 2","\t"]
["NCT02635984",4343369,7946652,"Overall Percentage of Patients Who Had a Complete Response","olanzapine","Olanzapine|Placebo","Drug|Drug","hematologic neoplasms","Complications of Bone Marrow Transplant|Hematologic Neoplasms","Parallel Assignment","Interventional","Supportive Care","Randomized","Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens",2,null,"NA",0.003,"Chi-squared",{"$nulls":4},"NA","All",108,"Completed","Phase 3","\t"]
["NCT02637557",4343170,7946527,"Change From Baseline Over Time in the mRESQ-eD Item 'Hoarseness Severity'","NA","IW-3718|Matching Placebo|PPI","Drug|Drug|Drug","esophagitis, peptic|gastroesophageal reflux","Gastroesophageal Reflux Disease","Parallel Assignment","Interventional","Treatment","Randomized","A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)",4,"LS Mean Difference",0.037,0.7207,"ANCOVA",-0.167,0.241,95,null,"NA","All",282,"Completed","Phase 2","\t"]
["NCT02637557",4343207,7946529,"Change From Baseline Over Time in the mRESQ-eD Item 'Pain Behind Breastbone or Center of Upper Stomach Severity'","NA","IW-3718|Matching Placebo|PPI","Drug|Drug|Drug","esophagitis, peptic|gastroesophageal reflux","Gastroesophageal Reflux Disease","Parallel Assignment","Interventional","Treatment","Randomized","A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)",4,"LS Mean Difference",-0.254,0.1146,"ANCOVA",-0.57,0.062,95,null,"NA","All",282,"Completed","Phase 2","\t"]
["NCT02639338",4342931,7946263,"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","sofosbuvir|velpatasvir","SOF/VEL/VOX|SOF/VEL","Drug|Drug","communicable diseases|hepatitis c|infection","Hepatitis C Virus Infection","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis",2,null,"NA",1E-3,"2-sided exact 1-sample binomial test",{"$nulls":4},"NA","All",220,"Completed","Phase 3","\t"]
["NCT02650284",4342552,7945064,"VAS Pain","NA","Stryker Triathlon Primary Total Knee System|Restoris MCK Multicompartmental Knee System","Device|Device","joint diseases|osteoarthritis","Non-inflammatory Degenerative Joint Disease","Parallel Assignment","Interventional","Treatment","Randomized","A Trial Evaluating TKR Compared to BKR Performed Using Stryker's Mako Robot",2,null,"NA",0.98,"t-test, 2 sided",{"$nulls":4},"NA","All",18,"Terminated","N/A","\t"]
["NCT02655224",4342389,7944586,"Percentage of Participants With Maximum NRS Score of 1 or Less From Day 1 to 28, From Day 29 to 56, and From Day 57 to 84","NA","Relugolix|Relugolix placebo","Drug|Drug","myofibroma|leiomyoma","Uterine Fibroids","Parallel Assignment","Interventional","Treatment","Randomized","A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids",2,"Odds Ratio (OR)",9.865,"NA",null,2.784,34.955,95,null,"NA","Female",65,"Completed","Phase 3","\t"]
["NCT02656173",4342333,7944424,"Change From Baseline to Weeks 4, 8, 12 in Mean Number of Micturitions Per 24 Hours","tamsulosin|mirabegron","Mirabegron|Placebo|Tamsulosin","Drug|Drug|Drug","hypertrophy|prostatic hyperplasia|urinary bladder, overactive","Overactive Bladder","Parallel Assignment","Interventional","Treatment","Randomized","A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)",2,"least square mean difference",-0.48,1E-3,"mixed model repeated measure",-0.78,-0.17,95,null,"NA","Male",568,"Completed","Phase 4","\t"]
["NCT02662582",4342019,7943742,"Change From Period Baseline at Week 2 in Arterial Oxygen Saturation From Pulse Oximetry (SpO2)","NA","Reldesemtiv|Placebo","Drug|Drug","pulmonary disease, chronic obstructive|lung diseases|lung diseases, obstructive","Chronic Obstructive Pulmonary Disease (COPD)","Crossover Assignment","Interventional","Treatment","Randomized","A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease",2,"LSMean difference",0.3,0.399,"Mixed Models Analysis",-0.3,0.9,90,null,"NA","All",46,"Completed","Phase 2","\t"]
["NCT02668692",4341833,7943066,"Number of Subjects With 'Overall Improvement' for the Target Lesion on the Scalp","NA","LEO 80185 gel|Dovobet ® ointment","Drug|Drug","psoriasis","Psoriasis Vulgaris","Parallel Assignment","Interventional","Treatment","Randomized","LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis",2,"Odds Ratio (OR)",1.92,0,"Fisher Exact",0.34,10.72,95,null,"NA","All",213,"Completed","Phase 3","\t"]
["NCT02683746",4341504,7941836,"Change From Baseline in HbA1c Over Time","rglp-1 protein|glucagon-like peptide 1","Lyophilized albiglutide DCC pen injector|Lyophilized albiglutide DCC pen injector matching placebo|Albiglutide liquid auto-injector|Albiglutide liquid auto-injector matching placebo","Drug|Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus",2,"Mean Difference (Net)",0.02,{"v":1E-4,"d":"1.00E-04"},"MMRM model",-0.15,0.19,95,null,"NA","All",308,"Completed","Phase 3","\t"]
["NCT02684370",4341349,7941738,"Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A)","ustekinumab|antibodies, monoclonal","risankizumab|placebo for risankizumab|ustekinumab|placebo for ustekinumab","Drug|Drug|Drug|Drug","psoriasis","Psoriasis","Parallel Assignment","Interventional","Treatment","Randomized","BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis",3,"adjusted difference in percentage",70.3,1E-3,"Cochran-Mantel-Haenszel",64,76.7,95,null,"NA","All",560,"Completed","Phase 3","\t"]
["NCT02691507",4341185,7940983,"Change From Baseline in the Itch Assessment Score 3 Hours After Treatment","decanoic acid","EpiCeram Skin Barrier Emulsion|Experimental Product 1% Colloidal Oatmeal Balm","Device|Drug","dermatitis|pruritus|dermatitis, atopic|eczema","Atopic Dermatitis","Parallel Assignment","Interventional","Treatment","Randomized","Trial to Determine the Therapeutic Benefit of an OTC Cream on Dry, Itchy Skin of Adults and Children With Eczema",2,"Mean Difference (Final Values)",0.28,0.69,"ANCOVA",-1.14,1.709,95,"Standard Error of the Mean",0.708,"All",53,"Completed","Phase 2","\t"]
["NCT02697773",4340709,7940416,"Number of Participants Who Took Rescue Medication During Weeks 2, 4, 8, 12 and 16","tanezumab","Placebo|Tanezumab 2.5 mg|Tanezumab 2.5mg/5mg","Other|Biological|Biological","osteoarthritis, knee|osteoarthritis|osteoarthritis, hip","Osteoarthritis, Hip|Osteoarthritis, Knee","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",3,"Odds Ratio (OR)",0.77,0.1712,"Regression, Logistic",0.53,1.12,95,null,"NA","All",698,"Completed","Phase 3","\t"]
["NCT02697773",4340854,7940445,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >= 30 Percent (%), >=50%, >=70% and >=90% Response","tanezumab","Placebo|Tanezumab 2.5 mg|Tanezumab 2.5mg/5mg","Other|Biological|Biological","osteoarthritis, knee|osteoarthritis|osteoarthritis, hip","Osteoarthritis, Hip|Osteoarthritis, Knee","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",3,"Odds Ratio (OR)",1.48,0.2005,"Regression, Logistic",0.81,2.67,95,null,"NA","All",698,"Completed","Phase 3","\t"]
["NCT02706873",4340343,7939574,"Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 - Japan Sub-study","methotrexate|upadacitinib","Placebo to Upadacitinib|Methotrexate|Placebo to Methotrexate|Upadacitinib","Drug|Drug|Drug|Drug","arthritis, rheumatoid|arthritis","Rheumatoid Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate",4,"LS Mean Difference",-0.54,1E-3,"ANOVA",-0.75,-0.34,95,null,"NA","All",1002,"Active, not recruiting","Phase 3","\t"]
["NCT02709486",4339996,7939281,"Number of Participants Who Took Rescue Medication During Weeks 2, 4, 8, 12, 16 and 24","tanezumab","Tanezumab|Tanezumab|Placebo","Drug|Drug|Drug","osteoarthritis, hip|osteoarthritis|osteoarthritis, knee","Osteoarthritis, Hip|Osteoarthritis, Knee","Parallel Assignment","Interventional","Treatment","Randomized","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",3,"Odds Ratio (OR)",0.5,{"v":1E-4,"d":"1.00E-04"},"Regression, Logistic",0.36,0.7,95,null,"NA","All",849,"Completed","Phase 3","\t"]
["NCT02709486",4340103,7939310,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Osteoarthritis","tanezumab","Tanezumab|Tanezumab|Placebo","Drug|Drug|Drug","osteoarthritis, hip|osteoarthritis|osteoarthritis, knee","Osteoarthritis, Hip|Osteoarthritis, Knee","Parallel Assignment","Interventional","Treatment","Randomized","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",3,"Odds Ratio (OR)",2.41,0.0012,"Regression, Logistic",1.42,4.1,95,null,"NA","All",849,"Completed","Phase 3","\t"]
["NCT02712047",4339842,7939073,"Change From Baseline in Fraction of Exhaled Nitric Oxide (FeNO) Over Time Following the Cessation of Repeat Dose Treatment With FF/VI","fluticasone","Fluticasone furoate (FF) (100 mcg)|Vilanterol (VI) (25 mcg)|Placebo","Drug|Drug|Drug","asthma","Asthma","Crossover Assignment","Interventional","Treatment","Randomized","A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.",2,"Ratio",0.72,"NA",null,0.52,1,95,null,"NA","All",28,"Completed","Phase 2","\t"]
["NCT02712983",4339571,7939006,"Duration of Pulmonary Exacerbation by Exacerbation Category","NA","TIP|TIP and placebo|Placebo","Drug|Drug|Drug","infection|respiratory aspiration|fibrosis|bronchiectasis","Non-cystic Fibrosis Bronchiectasis","Parallel Assignment","Interventional","Treatment","Randomized","Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection",9,"LS Mean Diff (SE) vs pooled placebo",11.9,"NA",null,-17.52,41.29,95,"Standard Error of the Mean",14.44,"All",107,"Completed","Phase 2","\t"]
["NCT02712983",4339617,7939008,"Change From Baseline to Each Post-baseline Visit in Pseudomonas Aeruginosa (P. Aeruginosa) Density in Sputum (log10 CFUs)","NA","TIP|TIP and placebo|Placebo","Drug|Drug|Drug","infection|respiratory aspiration|fibrosis|bronchiectasis","Non-cystic Fibrosis Bronchiectasis","Parallel Assignment","Interventional","Treatment","Randomized","Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection",9,"LS Mean Diff (SE) vs pooled placebo",-1.1,"NA",null,-2.25,-0.04,95,"Standard Error of the Mean",0.56,"All",107,"Completed","Phase 2","\t"]
["NCT02715726",4339337,7938699,"Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 24: ITT Analysis","antibodies, monoclonal|atorvastatin|rosuvastatin calcium|ezetimibe|simvastatin","Alirocumab|Placebo for alirocumab|ezetimibe|placebo for ezetimibe|atorvastatin|rosuvastatin|simvastatin","Drug|Drug|Drug|Drug|Drug|Drug|Drug","hypercholesterolemia","Hypercholesterolemia","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia",2,"Adjusted Mean Difference",-34.273,{"v":1E-4,"d":"1.00E-04"},"Regression, Robust",-39.262,-29.285,95,null,"NA","All",615,"Completed","Phase 3","\t"]
["NCT02718326",4339235,7938482,"Percentage of Participants Who Developed Central Involved-Diabetic Macular Edema (CI-DME) at Week 52","NA","Intravitreal aflibercept injection [IAI]|Sham","Drug|Drug","diabetic retinopathy|retinal diseases","Nonproliferative Diabetic Retinopathy","Parallel Assignment","Interventional","Treatment","Randomized","Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)",3,"percentage difference",-18.9,{"v":1E-4,"d":"1.00E-04"},"Cochran-Mantel-Haenszel",-27.5,-10.4,95,null,"NA","All",402,"Completed","Phase 3","\t"]
["NCT02725411",4338643,7937680,"Percentage of Participants With >=30 Percent (%), >=50%, >=70% and >=90% Reduction From Baseline in Weekly Average Low Back Pain Intensity (LBPI) Score at Weeks 16, 24, 40 and 56","tanezumab|celecoxib","Celecoxib|Tanezumab 5 mg|Tanezumab 10 mg|Placebo for celecoxib|Placebo for tanezumab","Drug|Biological|Biological|Drug|Biological","low back pain|back pain","Low Back Pain","Parallel Assignment","Interventional","Treatment","Randomized","Long Term Safety and Efficacy Study of Tanezumab in Japanese Adult Subjects With Chronic Low Back Pain",3,"Difference in Percentage of Participants",-3.8,"NA",null,-17.9,10.5,95,null,"NA","All",277,"Completed","Phase 3","\t"]
["NCT02731131",4338512,7937138,"Number of Participants With Alanine Aminotransferase (ALT) Normalization Plus Negative Hepatitis D Virus (HDV) Ribonucleic Acid (RNA) at 48 Weeks After End of Treatment","ribavirin|peginterferon alfa-2a","Peginterferon alfa-2a|Ribavirin","Drug|Drug","hepatitis d|hepatitis a|hepatitis d, chronic|hepatitis","Hepatitis D, Chronic","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)",2,null,"NA",0.3,"Fisher Exact",{"$nulls":4},"NA","All",12,"Completed","Phase 2","\t"]
["NCT02741284",4337561,7936182,"Mode of Delivery","NA","Room air|10L Oxygen by nonrebreather mask","Drug|Drug","hypoxia|fetal hypoxia","Electronic Fetal Monitoring|Fetal Hypoxia|Fetal-Placental Circulation","Parallel Assignment","Interventional","Treatment","Randomized","Oxygen for Intrauterine Resuscitation of Category II Fetal Heart Tracings",2,"Risk Ratio (RR)",0.32,0.05,"Chi-squared",0.07,1.48,95,null,"NA","Female",114,"Completed","N/A","\t"]
["NCT02754674",4336930,7935125,"Graft Maturity (SNQ)","NA","type of anterior cruciate ligament reconstruction","Procedure","rupture","Rupture of Anterior Cruciate Ligament","Parallel Assignment","Interventional","Treatment","Randomized","Comparison of Femoral Tunnel and Clinical Outcome Using Two Anterior Cruciate Ligament Reconstruction Techniques",2,null,"NA",0.054,"t-test, 2 sided",{"$nulls":4},"NA","All",67,"Completed","N/A","\t"]
["NCT02757352",4336717,7934866,"Change From Baseline in ASAS Health Index (ASAS HI)","ixekizumab","Ixekizumab|Placebo","Drug|Drug","spondylarthritis","Axial Spondyloarthritis","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis",3,"LS Mean Difference",-0.59,0.33,"Mixed Models Analysis",-1.77,0.6,95,"Standard Error of the Mean",0.601,"All",303,"Completed","Phase 3","\t"]
["NCT02757768",4336682,7934803,"Change From Baseline to Week 4, Week 8, Week 12 and EoT in IPSS Subscale Voiding Score","tamsulosin|mirabegron","Mirabegron|Placebo|Tamsulosin Hydrochloride","Drug|Drug|Drug","urinary bladder, overactive|hyperplasia|lower urinary tract symptoms|prostatic hyperplasia","Benign Prostatic Hyperplasia|Overactive Bladder","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)",2,"LS Mean of Difference",0.1,0.679,"ANCOVA",-0.4,0.7,95,"Standard Error of the Mean",0.3,"Male",715,"Completed","Phase 4","\t"]
["NCT02766023",4336294,7934159,"The Proportion of Participants Reporting Product-related Adverse Events (AEs) and Serious Adverse Events (SAEs) in Each Study Arm.","metronidazole","Lactobacillus crispatus CTV-05|Metronidazole|Placebo","Biological|Drug|Other","vaginosis, bacterial|vaginal diseases","Bacterial Vaginosis","Parallel Assignment","Interventional","Prevention","Randomized","LACTIN-V Study for Recurrent Bacterial Vaginosis",2,"Risk Difference (RD)",0.04,0.467,"Fisher Exact",-0.1,0.18,95,null,"NA","Female",228,"Completed","Phase 2","\t"]
["NCT02780115",4336126,7933284,"Weighted Average Change From Baseline in Uncorrected Near Visual Acuity (UNVA) Letters in the Nondominant Eye","ophthalmic solutions|pharmaceutical solutions","AGN-199201 ophthalmic solution|AGN-190584 ophthalmic solution|AGN-199201 Vehicle|AGN-190584 Vehicle","Drug|Drug|Drug|Drug","presbyopia","Presbyopia","Parallel Assignment","Interventional","Treatment","Randomized","A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia",5,"LS Mean Diff",1.96,0.1663,"ANCOVA",-0.83,4.74,95,null,"NA","All",151,"Completed","Phase 2","\t"]
["NCT02785432",4335831,7932799,"Numeric Pain Rating Scale (NPRS)","NA","Sham low level laser|Active low level laser","Device|Device","chronic pain|musculoskeletal pain","Chronic Pain","Parallel Assignment","Interventional","Treatment","Randomized","Low Level Laser Therapy With Physical Therapy for Chronic Musculoskeletal Pain",2,null,"NA",0.55,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",11,"Terminated","N/A","\t"]
["NCT02790788",4335628,7932454,"Early Postresuscitation Inflammatory Response as Assessed by Serum Cytokine Levels (pg/mL).","hydrocortisone hemisuccinate|hydrocortisone|prednisolone hemisuccinate|prednisolone phosphate|prednisolone|methylprednisolone acetate|methylprednisolone hemisuccinate|prednisolone acetate|methylprednisolone","Methylprednisolone; hydrocortisone|Saline Placebo","Drug|Drug","heart arrest","Inhospital Cardiac Arrest","Parallel Assignment","Interventional","Treatment","Randomized","Physiologic Effects of Steroids in Cardiac Arrest",2,"Median Difference (Net)",0.067,0.61,"t-test, 2 sided",-0.192,0.326,95,"Standard Error of the Mean",0.129,"All","NA","Completed","Phase 1/Phase 2","\t"]
["NCT02791191",4335594,7932448,"Percentage of Participants With Suicidal Ideation and Behaviors Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) Scores","NA","LY3202626|Placebo","Drug|Drug","alzheimer disease|disease progression|dementia","Alzheimer's Disease","Parallel Assignment","Interventional","Treatment","Randomized","A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia",3,null,"NA",0.279,"Fisher Exact",{"$nulls":4},"NA","All",316,"Terminated","Phase 2","\t"]
["NCT02792699",4335480,7932252,"Maximum Observed Drug Concentration (Cmax) After the First Infusion of the First Dose","rituximab","ABP 798|Rituximab (US)|Rituximab (EU)","Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Arthritis, Rheumatoid","Parallel Assignment","Interventional","Treatment","Randomized","Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab",3,"Geometric Mean Ratio",0.9475,"NA",null,0.9021,0.9953,90,null,"NA","All",311,"Completed","Phase 3","\t"]
["NCT02799472",4335054,7931547,"Change From Baseline in Flow Cytometry: 6 Colour TBNK Panel- CD3+CD8+ and T Cell B Cell Natural Killer Lymphocytes (NKL)","NA","GSK3196165|Placebo|MTX|Folic (or folinic) acid","Drug|Drug|Drug|Drug","arthritis, rheumatoid|arthritis","Arthritis, Rheumatoid","Parallel Assignment","Interventional","Treatment","Randomized","Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis",2,"Mean Difference (Net)",-0.157,0.534,"Repeated measures analysis",-0.668,0.354,95,null,"NA","All",39,"Completed","Phase 2","\t"]
["NCT02799472",4335155,7931552,"Change From Baseline in Predictive Biomarkers: Amyloid A, Chemokine (C-C Motif) Ligand 17, Chemokine (C-X-C Motif) Ligand 13, Interleukin 6, Macrophage-Derived Chemokine","NA","GSK3196165|Placebo|MTX|Folic (or folinic) acid","Drug|Drug|Drug|Drug","arthritis, rheumatoid|arthritis","Arthritis, Rheumatoid","Parallel Assignment","Interventional","Treatment","Randomized","Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis",2,"Ratio",1.005,0.976,"Repeated measures analysis",0.726,1.39,95,null,"NA","All",39,"Completed","Phase 2","\t"]
["NCT02809053",4334533,7930832,"Subgroups and Treatment Interactions of Overall Response Rate (ORR) by Region, Age, Gender and Anti-Drug Antibody (ADA) Status at Week 28.","rituximab","SAIT101|MabThera®","Biological|Biological","lymphoma, follicular|lymphoma","Lymphoma, Follicular","Parallel Assignment","Interventional","Treatment","Randomized","A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma",2,null,"NA",0.288,"Gail-Simon",{"$nulls":4},"NA","All",315,"Completed","Phase 3","\t"]
["NCT02819323",4334278,7930199,"Number and Percentage of Subjects With Successful Bowel Cleansing","NA","PEG-ELS|BLI800","Drug|Drug","NA","Colonoscopy","Parallel Assignment","Interventional","Treatment","Randomized","A Safety and Efficacy Study of a Bowel Cleansing Preparation (BLI800) in Pediatric Subjects Undergoing Colonoscopy",3,null,"NA",0.003,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",91,"Completed","Phase 3","\t"]
["NCT02828982",4333983,7929402,"Prosthetic Evaluation Questionnaire (PEQ)","NA","Powered ankle prosthesis|Dynamic Response Foot","Device|Device","amputation, traumatic","Amputation, Traumatic|Unilateral Traumatic Amputation","Crossover Assignment","Interventional","Supportive Care","Randomized","Determining the Potential Benefit of Powered Prostheses",2,null,"NA",0.052,"t-test, 2 sided",{"$nulls":4},"NA","All",12,"Completed","N/A","\t"]
["NCT02831764",4517833,8271048,"Ratio to Baseline in Renal Biomarkers-Urine and Serum Beta-2 Microglobulin (B2M), Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine at Weeks 24, 48","tenofovir|dolutegravir|lamivudine|emtricitabine","Dolutegravir (DTG)|Lamivudine (3TC)|Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)","Drug|Drug|Drug","hiv infections|communicable diseases|acquired immunodeficiency syndrome|infection","HIV Infections|Infection, Human Immunodeficiency Virus","Parallel Assignment","Interventional","Treatment","Randomized","An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2)",2,"Ratio of geometric means",0.888,0.052,"MMRM",0.787,1.001,95,null,"NA","All",722,"Active, not recruiting","Phase 3","\t"]
["NCT02833350",4333540,7929105,"Percentage of Participants Meeting the Boolean-based Remission Criteria","adalimumab|folic acid","GDC-0853|Adalimumab|Folic Acid|MTX|Placebo","Drug|Drug|Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Rheumatoid Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)",7,"Adjusted Difference",0,1,"Cochran-Mantel-Haenszel",-2.92,2.92,95,null,"NA","All",578,"Completed","Phase 2","\t"]
["NCT02833350",4333665,7929110,"Change in Disease Activity Score From Baseline Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP])","adalimumab|folic acid","GDC-0853|Adalimumab|Folic Acid|MTX|Placebo","Drug|Drug|Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Rheumatoid Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)",7,"Adjusted Difference",-0.37,0.0526,"ANCOVA",-0.74,0,95,null,"NA","All",578,"Completed","Phase 2","\t"]
["NCT02842853",4333246,7928458,"Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y And W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine in Adults","vaccines","Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine","Biological|Biological","meningitis|meningococcal infections|meningitis, meningococcal","Meningitis|Meningococcal Infections|Meningococcal Meningitis","Parallel Assignment","Interventional","Prevention","Randomized","Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine",4,"Percentage Difference",26.8,"NA",null,20.7,32.9,95,null,"NA","All",3344,"Completed","Phase 3","\t"]
["NCT02855164",4332995,7927503,"Change in Aspartate Transaminase (AST)","NA","Tropifexor (LJN452)|Placebo","Drug|Drug","non-alcoholic fatty liver disease|fatty liver","Non-alcoholic Steatohepatitis (NASH)","Parallel Assignment","Interventional","Treatment","Randomized","Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)",8,"LS Mean change",0.4,0.413,"ANCOVA",-10.2,11,95,"Standard Error of the Mean",6.43,"All",351,"Terminated","Phase 2","\t"]
["NCT02858401",4332779,7927305,"Change From Baseline in Plasma Log10 HIV-1 RNA at Day 61","vesatolimod","Vesatolimod|Placebo|ARV regimen","Drug|Drug|Drug","NA","HIV-1 Infection","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults",10,null,"NA",0.7526,"Wilcoxon rank sum test",{"$nulls":4},"NA","All",48,"Completed","Phase 1","\t"]
["NCT02858401",4332862,7927323,"Change From Baseline in Plasma Log10 HIV-1 RNA at Day 15","vesatolimod","Vesatolimod|Placebo|ARV regimen","Drug|Drug|Drug","NA","HIV-1 Infection","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults",10,null,"NA",1,"Wilcoxon rank sum test",{"$nulls":4},"NA","All",48,"Completed","Phase 1","\t"]
["NCT02863575",4332444,7926826,"Pain Intensity Difference Scores at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 Hours Post-dose","ibuprofen|caffeine","Ibuprofen/Caffeine|Ibuprofen|Placebo","Drug|Drug|Drug","toothache","Pain","Parallel Assignment","Interventional","Treatment","Randomized","A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine",3,"LS means difference",2.9,1E-3,"ANCOVA",2.06,3.74,95,null,"NA","All",374,"Completed","Phase 3","\t"]
["NCT02868281",4332342,7926452,"Mean Night-time Symptom Score Over the 24-week Treatment Period","NA","ACT guided Routine Treatment|Routine Treatment","Drug|Drug","asthma","Asthma","Parallel Assignment","Interventional","Treatment","Randomized","Asthma Control Test Guided Treatment in Chinese Subjects",2,"Difference in Least Squares Mean",-0.07,0.197,"Mixed Model Repeat Measures",-0.19,0.04,95,null,"NA","All",530,"Completed","Phase 4","\t"]
["NCT02874794",4332072,7926071,"Change From Baseline in Aortic Characteristic Impedance at Week 12","enalaprilat|enalapril|lcz 696|valsartan","LCZ696 (sacubitril/valsartan)|Enalapril|Placebo of Enalapril|Placebo of LCZ696","Drug|Drug|Drug|Drug","heart failure","Heart Failure and Reduced Ejection Fraction","Parallel Assignment","Interventional","Treatment","Randomized","Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction",2,"Median Difference (Final Values)",-2.2,0.7827,"ANCOVA",-17.6,13.2,95,null,"NA","All",465,"Completed","Phase 4","\t"]
["NCT02886728",4331619,7925500,"Percentage of Participants With no Radiographic Progression From Baseline at Weeks 24, and 52","NA","Filgotinib|Placebo to match filgotinib|MTX|Placebo to match MTX","Drug|Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Rheumatoid Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy",4,"Difference in Response Rates",7.9,0.045,"Regression, Logistic",0.7,15.2,95,null,"NA","All",1252,"Completed","Phase 3","\t"]
["NCT02886728",4331828,7925514,"Change From Baseline in Individual ACR Component: Tender Joint Count Based on 68 Joints (TJC68) at Weeks 2, 4, 12, 24, 36, and 52","NA","Filgotinib|Placebo to match filgotinib|MTX|Placebo to match MTX","Drug|Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Rheumatoid Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy",4,"Least Squares Mean Difference",-4,1E-3,"MMRM",-6,-2,95,"Standard Error of the Mean",0.8,"All",1252,"Completed","Phase 3","\t"]
["NCT02888106",4331500,7925425,"Percentage of Patients With Normalized ALT","tenofovir|peginterferon alfa-2a|interferon alpha-2","Myrcludex B|PEG IFN alfa-2a|Tenofovir","Drug|Drug|Drug","hepatitis b, chronic|hepatitis a|hepatitis b|hepatitis","Chronic Viral Hepatitis B With Delta-agent","Parallel Assignment","Interventional","Treatment","Randomized","Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent",6,null,"NA",0.3449,"t-test, 1 sided",{"$nulls":4},"NA","All",90,"Completed","Phase 2","\t"]
["NCT02889796",4331381,7925287,"Change From Baseline in Individual ACR Component: Subject's Global Assessment of Disease Activity (SGA) at Weeks 2, 4, 12, and 24","adalimumab","Filgotinib|Placebo to match filgotinib|Adalimumab|Placebo to match adalimumab|MTX","Drug|Drug|Drug|Drug|Drug","arthritis|arthritis, rheumatoid","Rheumatoid Arthritis","Parallel Assignment","Interventional","Treatment","Randomized","Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate",6,"Least Squares Mean Difference",-9,1E-3,"MMRM",-11,-7,95,"Standard Error of the Mean",1.1,"All",1759,"Completed","Phase 3","\t"]
["NCT02900378",4331011,7924606,"Total Weekly Time Spent in Non-sedentary Daytime Physical Activity","enalaprilat|lcz 696|valsartan|enalapril","LCZ696 (Sacubitril/Valsartan)|Placebo of LCZ696 (Sacubitril/Valsartan)|Enalapril|Placebo of Enalapril","Drug|Drug|Drug|Drug","heart failure","Chronic Heart Failure With Reduced Ejection Fraction","Parallel Assignment","Interventional","Treatment","Randomized","randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure",2,null,"NA",0.1342,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",621,"Completed","Phase 3","\t"]
["NCT02906709",4330848,7924214,"Percentage of Participants Who Discontinued Study Drug Due to an AE Excluding Data After Glycemic Rescue (Phase A)","insulin","Omarigliptin|Placebo|Insulin","Drug|Drug|Biological","diabetes mellitus|diabetes mellitus, type 2","Type 2 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)",2,"Difference in % vs. Placebo",-4.1,"NA",null,-12.8,0.4,95,null,"NA","All",184,"Completed","Phase 4","\t"]
["NCT02912650",4329965,7923469,"Cumulative Percentage of Participants With Meaningful Relief","acetaminophen|ibuprofen","Acetaminophen 650 mg|Placebo|Ibuprofen 250 mg / Acetaminophen 500 mg|Ibuprofen 250 mg","Drug|Drug|Drug|Drug","toothache","Post-surgical Pain Following Extraction of Molar Teeth","Parallel Assignment","Interventional","Treatment","Randomized","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",4,"CMH adjusted proportions",58.46,1E-3,"Cochran-Mantel-Haenszel",46.88,70.03,95,null,"NA","All",568,"Completed","Phase 3","\t"]
["NCT02912650",4329997,7923470,"Cumulative Percentage of Participants With Confirmed First Perceptible Relief","acetaminophen|ibuprofen","Acetaminophen 650 mg|Placebo|Ibuprofen 250 mg / Acetaminophen 500 mg|Ibuprofen 250 mg","Drug|Drug|Drug|Drug","toothache","Post-surgical Pain Following Extraction of Molar Teeth","Parallel Assignment","Interventional","Treatment","Randomized","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",4,"CMH adjusted proportions",50.74,1E-3,"Cochran-Mantel-Haenszel",37.39,64.09,95,null,"NA","All",568,"Completed","Phase 3","\t"]
["NCT02912650",4330332,7923476,"Sum of Pain Relief Rating and Pain Intensity Difference on 4-Point Categorical Scale (PRID4)","acetaminophen|ibuprofen","Acetaminophen 650 mg|Placebo|Ibuprofen 250 mg / Acetaminophen 500 mg|Ibuprofen 250 mg","Drug|Drug|Drug|Drug","toothache","Post-surgical Pain Following Extraction of Molar Teeth","Parallel Assignment","Interventional","Treatment","Randomized","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",4,"LS Mean Difference",0.51,1E-3,"ANOVA",0.21,0.81,95,null,"NA","All",568,"Completed","Phase 3","\t"]
["NCT02912650",4330429,7923478,"Pain Intensity Difference on 11-Point Numerical Scale (PID11)","acetaminophen|ibuprofen","Acetaminophen 650 mg|Placebo|Ibuprofen 250 mg / Acetaminophen 500 mg|Ibuprofen 250 mg","Drug|Drug|Drug|Drug","toothache","Post-surgical Pain Following Extraction of Molar Teeth","Parallel Assignment","Interventional","Treatment","Randomized","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",4,"LS Mean Difference",0.87,0.049,"ANCOVA",0,1.73,95,null,"NA","All",568,"Completed","Phase 3","\t"]
["NCT02912650",4330523,7923479,"Pain Relief Rating (PRR) Score","acetaminophen|ibuprofen","Acetaminophen 650 mg|Placebo|Ibuprofen 250 mg / Acetaminophen 500 mg|Ibuprofen 250 mg","Drug|Drug|Drug|Drug","toothache","Post-surgical Pain Following Extraction of Molar Teeth","Parallel Assignment","Interventional","Treatment","Randomized","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",4,"LS Mean Difference",0.14,0.353,"ANOVA",-0.15,0.43,95,null,"NA","All",568,"Completed","Phase 3","\t"]
["NCT02913105",4329798,7923454,"Change From Baseline in Fasting Lipid Profile: Cholesterol (Chol) and Triglycerides (TG)","NA","LMB763|Placebo","Drug|Drug","non-alcoholic fatty liver disease|fatty liver","Non-alcoholic Steatohepatitis NASH","Parallel Assignment","Interventional","Treatment","Randomized","Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH",2,"Geometric Mean Ratios",1.05,0.159,"ANCOVA",0.99,1.11,90,null,"NA","All",122,"Terminated","Phase 2","\t"]
["NCT02915705",4329650,7923182,"RGI-C Long Leg Score at Week 40","vitamin d","burosumab|Oral Phosphate Supplement|active vitamin D","Biological|Drug|Drug","familial hypophosphatemic rickets|hypophosphatemia","X-Linked Hypophosphatemia","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of Burosumab (KRN23) Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)",2,"LS Mean Difference",0.4,0.0162,"GEE model",0.07,0.72,95,null,"NA","All",61,"Completed","Phase 3","\t"]
["NCT02923245",4329384,7922443,"Median Fill-To-Done (FTD) Time","NA","point-of-care ultrasound","Other","abdominal pain|pelvic pain","Abdominal Pain|Pelvic Pain","Parallel Assignment","Interventional","Other","Randomized","POCUS Assessment of Bladder Fullness for Girls Awaiting Radiology-Performed Transabdominal Pelvic Ultrasound",2,"Mean Difference (Final Values)",49.7,"NA",null,23.4,77.2,95,null,"NA","Female",120,"Completed","N/A","\t"]
["NCT02926573",4329257,7922274,"Mean Pain With Coughing Score as Measured by VAS","gabapentin","Gabapentin|Placebo","Drug|Drug","acute pain","Acute Pain|Head and Neck Cancer|Postoperative Pain","Parallel Assignment","Interventional","Treatment","Randomized","Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients",2,"Mean Difference (Final Values)",11.6,"NA",null,-2.8,26,95,null,"NA","All",123,"Completed","Phase 4","\t"]
["NCT02937701",4328997,7921350,"Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 22","infliximab","ABP 710|Infliximab","Biological|Biological","arthritis, rheumatoid|arthritis","Arthritis, Rheumatoid","Parallel Assignment","Interventional","Treatment","Randomized","Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab",2,"Response Difference",9.37,"NA",null,2.67,15.96,90,null,"NA","All",558,"Completed","Phase 3","\t"]
["NCT02940860",4328778,7920945,"Change in Transferrin Saturation (TSAT) From Baseline to Week 1, 2, 4, and 8","iron isomaltoside 1000|ferric oxide, saccharated|iron","Iron isomaltoside/ferric derisomaltose|Iron sucrose","Drug|Drug","deficiency diseases|renal insufficiency, chronic|anemia|kidney diseases|anemia, iron-deficiency","Chronic Kidney Disease|Iron Deficiency Anaemia|Iron Deficiency Anemia","Parallel Assignment","Interventional","Treatment","Randomized","Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease",2,"Mean Difference (Final Values)",1.3,0.0129,"Mixed model for repeated measures",0.3,2.4,95,null,"NA","All",1538,"Completed","Phase 3","\t"]
["NCT02942004",4328519,7920888,"Change From Baseline in HAM-D Individual Item Scores","pregnanolone","Placebo|SAGE-547 60 μg/kg/h|SAGE-547 90 μg/kg/h","Drug|Drug|Drug","depressive disorder|depression|depression, postpartum","Postpartum Depression","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)",3,"LS mean difference",-0.05,0.7151,"MMRM",-0.32,0.22,95,"Standard Error of the Mean",0.138,"Female",138,"Completed","Phase 3","\t"]
["NCT02942004",4328546,7920888,"Change From Baseline in HAM-D Individual Item Scores","pregnanolone","Placebo|SAGE-547 60 μg/kg/h|SAGE-547 90 μg/kg/h","Drug|Drug|Drug","depressive disorder|depression|depression, postpartum","Postpartum Depression","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)",3,"LS mean difference",0.08,0.469,"MMRM",-0.14,0.29,95,"Standard Error of the Mean",0.108,"Female",138,"Completed","Phase 3","\t"]
["NCT02942017",4327915,7920874,"Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response","NA","Placebo|SAGE-547 90 μg/kg/h","Drug|Drug","depression|depressive disorder|depression, postpartum","Postpartum Depression","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)",2,"Odds Ratio (OR)",5,{"v":0.0005,"d":"5.00E-04"},"GEE method",2,12.5,95,null,"NA","Female",108,"Completed","Phase 3","\t"]
["NCT02942017",4328039,7920876,"Change From Baseline in HAM-D Individual Item Scores","NA","Placebo|SAGE-547 90 μg/kg/h","Drug|Drug","depression|depressive disorder|depression, postpartum","Postpartum Depression","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)",2,"LS Mean Difference",-0.22,0.0311,"MMRM",-0.41,-0.02,95,"Standard Error of the Mean",0.099,"Female",108,"Completed","Phase 3","\t"]
["NCT02944383",4327653,7920696,"Percent Change From Baseline in Lipoprotein Particle Number","NA","Gemcabene|Placebo","Drug|Drug","dyslipidemias|hypertriglyceridemia","Mixed Dyslipidaemia|Severe Hypertriglyceridemia","Parallel Assignment","Interventional","Treatment","Randomized","A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia",3,"Median Difference (Net)",-16.09,0.1548,"Ranked ANCOVA",-36.78,3.76,95,null,"NA","All",91,"Completed","Phase 2","\t"]
["NCT02944383",4327772,7920716,"Percent Change From Baseline in Apolipoprotein A-I","NA","Gemcabene|Placebo","Drug|Drug","dyslipidemias|hypertriglyceridemia","Mixed Dyslipidaemia|Severe Hypertriglyceridemia","Parallel Assignment","Interventional","Treatment","Randomized","A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia",3,"Median Difference (Net)",-0.77,0.7644,"Ranked ANCOVA",-6.31,4.85,95,null,"NA","All",91,"Completed","Phase 2","\t"]
["NCT02946463",4327554,7920549,"Proportion Of Participants With Normalization Of Lactate Dehydrogenase (LDH) Levels","ravulizumab","Ravulizumab|Eculizumab","Biological|Biological","hemoglobinuria, paroxysmal|hemoglobinuria","Paroxysmal Nocturnal Hemoglobinuria (PNH)","Parallel Assignment","Interventional","Treatment","Randomized","ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)",2,null,"NA","NA",{"$nulls":5},"NA","All",246,"Active, not recruiting","Phase 3","\t"]
["NCT02951052",4327324,7920130,"Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12)","rilpivirine","Cabotegravir (CAB) tablet|Rilpivirine (RPV) tablet|Cabotegravir - Injectable Suspension (CAB LA)|Rilpivirine - Injectable Suspension (RPV LA)|2 NRTIs plus an INI, NNRTI, or PI","Drug|Drug|Drug|Drug|Drug","communicable diseases|hiv infections|infection|acquired immunodeficiency syndrome","HIV Infections|Infection, Human Immunodeficiency Virus","Parallel Assignment","Interventional","Treatment","Randomized","Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults",2,"Adjusted difference",0.696,0.092,"ANCOVA",-0.113,1.505,95,null,"NA","All",618,"Active, not recruiting","Phase 3","\t"]
["NCT02954354",4326995,7919716,"Percentage of Participants Reporting Normal Temperature at Each Time Point in Participants Randomized to Baloxavir or Placebo","oseltamivir|baloxavir","Baloxavir Marboxil|Placebo to Baloxavir Marboxil|Oseltamivir|Placebo to Oseltamivir","Drug|Drug|Drug|Drug","influenza, human","Influenza","Parallel Assignment","Interventional","Treatment","Randomized","A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza",5,null,"NA",0.8291,"Mantel Haenszel",{"$nulls":4},"NA","All",1436,"Completed","Phase 3","\t"]
["NCT02954848",4326935,7919608,"Percentage of Days Without Symptoms of Heartburn in Subgroup Stratified by Response (Improved or Not Improved) at Week 2","NA","TAK-438 10 mg|Placebo","Drug|Drug","gastroesophageal reflux|esophagitis, peptic","Non-erosive Gastroesophageal Reflux Disease","Parallel Assignment","Interventional","Treatment","Randomized","Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)",2,"Median Difference (Final Values)",-4.7,0.0871,"Wilcoxon Rank-Sum Test",-17.4,0,95,null,"NA","All",484,"Completed","Phase 3","\t"]
["NCT02959983",4326758,7919131,"Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain And Daily Stool Consistency Scores","eluxadoline","Eluxadoline|Placebo","Drug|Drug","diarrhea|syndrome|irritable bowel syndrome","Irritable Bowel Syndrome With Diarrhea","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use",2,null,"NA",0.0022,"Chi-squared",{"$nulls":4},"NA","All",346,"Completed","Phase 4","\t"]
["NCT02964338",4326458,7918610,"Mean Change From Baseline in the Overall Monthly Average Number of CH Attacks Up to Week 12","NA","Fremanezumab|Placebo","Drug|Drug","headache|cluster headache","Chronic Cluster Headache","Parallel Assignment","Interventional","Treatment","Randomized","A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)",3,"Least square (LS) mean difference",3.5,0.2741,"ANCOVA",-2.8,9.82,95,null,"NA","All",259,"Terminated","Phase 3","\t"]
["NCT02966834",4326437,7918425,"Mean Change From Baseline at Week 16 in the Mean Worst Daily Itch Score","NA","Placebo|GSK2330672","Drug|Drug","cholestasis|pruritus|cholangitis","Cholestasis","Parallel Assignment","Interventional","Treatment","Randomized","Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis",6,"Mean Difference (Net)",-0.88,"NA",null,-2.07,0.31,95,null,"NA","All",147,"Completed","Phase 2","\t"]
["NCT02971293",4325999,7917810,"Change From Baseline in Peak FEV1 Over the Treatment Duration (Days 1-15)","NA","AZD8871 100 µg|AZD8871 600 µg|Placebo","Drug|Drug|Drug","lung diseases, obstructive|pulmonary disease, chronic obstructive","Chronic Obstructive Pulmonary Disease COPD","Crossover Assignment","Interventional","Treatment","Randomized","Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871",3,null,"NA",1E-3,"ANCOVA",{"$nulls":4},"NA","All",42,"Completed","Phase 2","\t"]
["NCT02978183",4325632,7917273,"Nasal Congestion","NA","ST266|Saline (0.9% NaCl)","Biological|Drug","conjunctivitis|conjunctivitis, allergic","Allergic Conjunctivitis","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis",2,null,"NA",0.8978,"ANCOVA",{"$nulls":4},"NA","All",70,"Completed","Phase 2","\t"]
["NCT02978183",4325728,7917280,"Episcleral Redness","NA","ST266|Saline (0.9% NaCl)","Biological|Drug","conjunctivitis|conjunctivitis, allergic","Allergic Conjunctivitis","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis",2,null,"NA",0.0421,"ANCOVA",{"$nulls":4},"NA","All",70,"Completed","Phase 2","\t"]
["NCT02980523",4325475,7916976,"Frequency of Corneal Epithelial Defects","moxifloxacin|ophthalmic solutions|hyaluronic acid|pazufloxacin|gatifloxacin","PRO-157|Vigamox|Zymar®|Lagricel Ofteno®","Drug|Drug|Drug|Drug","conjunctivitis, bacterial|conjunctivitis","Bacterial Conjunctivitis","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)",5,null,"NA",0.829,"Chi-squared, Corrected",{"$nulls":4},"NA","All",150,"Completed","Phase 2","\t"]
["NCT02987972",4324901,7916278,"Geometric Mean Concentration of Serotype-specific Pneumococcal IgG Antibody for the 13 Common Serotypes in V114 and Prevnar 13™ and the 2 Serotypes Unique to V114: 1 Month Post Vaccination 3","heptavalent pneumococcal conjugate vaccine","V114 Lot 1|V114 Lot 2|Prevnar 13™","Biological|Biological|Biological","pneumococcal infections","Pneumococcal Infections","Parallel Assignment","Interventional","Prevention","Randomized","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)",3,"GMC Ratio",0.82,"NA",null,0.73,0.92,95,null,"NA","All",1051,"Completed","Phase 2","\t"]
["NCT02991118",4324746,7916124,"Percent Change From Baseline to Week 12 in HDL-C","8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid","bempedoic acid|placebo","Drug|Drug","hyperlipidemias|hypercholesterolemia|cardiovascular diseases|atherosclerosis|hyperlipoproteinemias","Atherosclerotic Cardiovascular Disease|Hypercholesterolemia","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk",2,"Difference in LS mean",-6.13,1E-3,"ANCOVA",-8.369,-3.896,95,"Standard Error of the Mean",1.139,"All",779,"Completed","Phase 3","\t"]
["NCT03000530",4324504,7915293,"Percentage of Participants With CGI-I Response - Part B","NA","SAGE-217|Placebo","Drug|Drug","depression|depressive disorder, major|depressive disorder","Major Depression","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder",3,"Odds Ratio (OR)",5.5,0.0048,"Generalized Estimating Equation",1.7,17.9,95,null,"NA","All",102,"Completed","Phase 2","\t"]
["NCT03004469",4324343,7914884,"Adjusted Mean International Index of Erectile Function (IIEF-2) Scores at Weeks 4, 8, 12 and 24","finasteride","P-3074|Finasteride|P-3074 Vehicle|Finasteride Placebo","Drug|Drug|Drug|Drug","alopecia|alopecia areata","Alopecia, Androgenetic","Parallel Assignment","Interventional","Treatment","Randomized","Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia",3,"LS Mean Difference",0,0.918,"Mixed linear model",-0.7,0.8,95,"Standard Error of the Mean",0.36,"Male",458,"Completed","Phase 3","\t"]
["NCT03012334",4324130,7914398,"Simulated Driving Performance in Healthy Participants as Measured by Standard Deviation of Lateral Position (SDLP) Using the Cognitive Research Corporation Driving Simulator-MiniSim (CRCDS-MiniSim)","alprazolam","Lasmiditan|Alprazolam|Placebo","Drug|Drug|Other","NA","Migraine","Crossover Assignment","Interventional","Other","Randomized","The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants",5,"LS Mean",-7.36,1E-3,"Mixed Models Analysis",-9.84,-4.88,95,null,"NA","All",90,"Completed","Phase 1","\t"]
["NCT03018028",4323986,7914058,"Time to Additional Anti-diabetic Medication","liraglutide","Semaglutide|Placebo|Liraglutide","Drug|Drug|Drug","diabetes mellitus|diabetes mellitus, type 2","Diabetes|Diabetes Mellitus, Type 2","Parallel Assignment","Interventional","Treatment","Randomized","Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes",5,"Hazard Ratio (HR)",0.25,0.0052,"Regression, Cox",0.1,0.66,95,null,"NA","All",243,"Completed","Phase 3","\t"]
["NCT03027557",4323729,7913243,"Percentage Change in Lumbar Spine Bone Mineral Density","cinacalcet|denosumab","Cinacalcet 30 mg Tablet|Denosumab Inj 60 mg/ml|Placebo tablets|Saline Injection (Placebo)","Drug|Drug|Other|Other","hyperparathyroidism, primary|hyperplasia|hyperparathyroidism|adenoma|parathyroid neoplasms","Parathyroid Adenoma|Parathyroid Hyperplasia|Primary Hyperparathyroidism","Parallel Assignment","Interventional","Treatment","Randomized","Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.",3,null,"NA",0,"ANOVA",{"$nulls":4},"NA","All",46,"Completed","Phase 3","\t"]
["NCT03034915",4323589,7912709,"Mean Change From Baseline in Evaluating Respiratory Symptoms (E-RS) Total Score","salmeterol xinafoate","UMEC/VI 62.5/25 mcg via ELLIPTA|UMEC 62.5 mcg via ELLIPTA|Salmeterol 50 mcg via DISKUS|Placebo via ELLIPTA|Placebo via DISKUS","Drug|Drug|Drug|Drug|Drug","lung diseases|pulmonary disease, chronic obstructive|lung diseases, obstructive","Pulmonary Disease, Chronic Obstructive","Parallel Assignment","Interventional","Treatment","Randomized","A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",3,"Mean Difference (Net)",-0.3,0.159,"Mixed model repeated measures",-0.72,0.12,95,"Standard Error of the Mean",0.214,"All",2696,"Completed","Phase 4","\t"]
["NCT03035916",4323459,7912605,"Physiological Parameters: Plasma Concentration of Cortisol (Cor)","anesthetics","Transversus abdominis plane block|Epidural anesthesia|control","Other|Other|Other","NA","Gastrostomy","Parallel Assignment","Interventional","Treatment","Randomized","Transversus Abdominis Plane Block on Stress Response",3,null,"NA",0.824,"t-test, 2 sided",{"$nulls":4},"NA","All",91,"Completed","N/A","\t"]
["NCT03041792",4323147,7912023,"Change From Baseline in Appetite Score (Mean Rating Area Under Curve From Time 30 to 120 Minutes [AUC30-120min]) for Mean Lunch at Visits 4 and 5","liraglutide","Liraglutide|Placebo","Drug|Other","NA","Obesity","Parallel Assignment","Interventional","Basic Science","Randomized","Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects",2,"Least Square Mean Difference",4.95,0.0263,"Mixed Models Analysis",0.61,9.29,95,"Standard Error of the Mean",2.16,"All",61,"Completed","Phase 1","\t"]
["NCT03051217",4322930,7911407,"Percentage of Subjects Who Achieve a Physician's Global Assessment (PGA) Clear or Almost Clear Response (With at Least 2-category Improvement) at Week 16","certolizumab pegol","Placebo|Certolizumab Pegol","Other|Drug","psoriasis","Generalized Pustular Psoriasis and Erythrodermic Psoriasis|Moderate to Severe Psoriasis","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis",3,"Estimated difference in responder rate",66.7,"NA",null,43.34,90.15,95,null,"NA","All",127,"Completed","Phase 2/Phase 3","\t"]
["NCT03053427",4322796,7911212,"Change From Baseline in IRLS Score at Each Time Point","gabapentin","Placebo|Gabapentin enacarbil","Drug|Drug","restless legs syndrome|psychomotor agitation|syndrome","Restless Legs Syndrome (RLS)","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients",2,"LSM difference",-0.8,0.312,"ANCOVA",-2.4,0.8,95,"Standard Error of the Mean",0.8,"All",375,"Completed","Phase 4","\t"]
["NCT03055156",4322694,7911012,"Periodic Leg Movements (PLM) During Sleep","NA","Low rebound mattress toppers|High rebound mattress toppers","Device|Device","sleep wake disorders|parasomnias","Sleep Disorders","Parallel Assignment","Interventional","Basic Science","Randomized","Effect of High Rebound Mattress Toppers on Sleep and Sleep-Related Symptoms",2,null,"NA",0.55,"t-test, 2 sided",{"$nulls":4},"NA","All",558,"Completed","N/A","\t"]
["NCT03064113",4322306,7910494,"Area Under the Forced Vital Capacity (FVC) vs. Time Curve","ipratropium","Placebo|TD-4208 700 μg|TD-4208 350 μg|Ipratropium 500 μg","Drug|Drug|Drug|Drug","lung diseases|lung diseases, obstructive|pulmonary disease, chronic obstructive","Chronic Obstructive Pulmonary Disease, COPD","Crossover Assignment","Interventional","Treatment","Randomized","Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",4,"Difference of LS Mean",3975.5,1E-3,"t-test, 2 sided",2007.3,5943.7,95,null,"NA","All",32,"Completed","Phase 2","\t"]
["NCT03069482",4322103,7910179,"Recruitment Yield Effort","nicotine","Learn to Quit App|Nicotine patch|Nicotine lozenge|Technical Coaching|NCI QuitGuide App","Device|Drug|Drug|Behavioral|Device","mental disorders","Nicotine Addiction|Serious Mental Illness","Parallel Assignment","Interventional","Treatment","Randomized","Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness",2,"Percent of respondents",58,"NA",{"$nulls":5},"NA","All",63,"Completed","Phase 1","\t"]
["NCT03072732",4322041,7909887,"Difference in Correlation of Thoracic Impedance With Ultra-filtration Volume (UFV) Between uCor and ZOE","NA","u-Cor System|ZOE Fluid Status Monitor","Device|Device","NA","Fluid Retention Tissue","Parallel Assignment","Interventional","Diagnostic","Randomized","Measuring Thoracic Impedance in Hemodialysis Patients With the u-Cor Monitoring System",2,"Mean Difference (Final Values)",0.66,"NA",null,0.57,0.75,95,null,"NA","All",40,"Completed","N/A","\t"]
["NCT03078907",4321759,7909328,"Change From Baseline to Week 24 in Actigraphy Assessed Daily Life Physical Activity (DLPA) for Variables Expressed in Minutes","selexipag","Selexipag|Placebo","Drug|Drug","familial primary pulmonary hypertension|hypertension","Pulmonary Arterial Hypertension","Parallel Assignment","Interventional","Other","Randomized","Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.",2,"Least Square (LS) mean",13.79,"NA",null,13.366,40.944,95,"Standard Error of the Mean",13.695,"All",108,"Completed","Phase 4","\t"]
["NCT03084796",4321499,7909120,"Transition Dyspnea Index (TDI) Focal Score at Week 3 and Week 6","tiotropium bromide|bromides","CHF 5259|Placebo|Tiotropium Bromide 18 µg Inhalation Capsule","Drug|Drug|Drug","lung diseases|pulmonary disease, chronic obstructive|lung diseases, obstructive","Chronic Obstructive Pulmonary Disease|COPD","Parallel Assignment","Interventional","Other","Randomized","A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease",6,"Mean Difference (Final Values)",0.26,0.432,"Mixed Models Analysis",-0.39,0.92,95,null,"NA","All",733,"Completed","Phase 2","\t"]
["NCT03084796",4321622,7909127,"Change From Baseline in FVC AUC(0-4h) Normalized by Time on Day 1 and at Week 6","tiotropium bromide|bromides","CHF 5259|Placebo|Tiotropium Bromide 18 µg Inhalation Capsule","Drug|Drug|Drug","lung diseases|pulmonary disease, chronic obstructive|lung diseases, obstructive","Chronic Obstructive Pulmonary Disease|COPD","Parallel Assignment","Interventional","Other","Randomized","A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease",6,"Mean Difference (Final Values)",0.237,1E-3,"Mixed Models Analysis",0.172,0.302,95,null,"NA","All",733,"Completed","Phase 2","\t"]
["NCT03086460",4321016,7908836,"FVC Peak(0-4h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14","formoterol fumarate","CHF 1531|Formoterol Inhalation Solution|Placebo","Drug|Drug|Drug","asthma","Asthma","Crossover Assignment","Interventional","Other","Randomized","A Dose Ranging Study of CHF 1531 in Asthmatic Subjects",6,"Mean Difference (Final Values)",0.151,1E-3,"ANCOVA",0.078,0.223,95,null,"NA","All",67,"Completed","Phase 2","\t"]
["NCT03091920",4320477,7908569,"Change From Time-Matched Baseline Over Time in ABPM 4-hour Averages of Pulse","NA","IW-1973|Placebo","Drug|Drug","hypertension|diabetes mellitus, type 2|diabetes mellitus","Diabetes Mellitus, Type 2|Hypertension","Parallel Assignment","Interventional","Treatment","Randomized","Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension",3,"Least squares mean difference",6.15,"NA",null,1.22,11.08,95,"Standard Error of the Mean",2.38,"All",26,"Completed","Phase 2","\t"]
["NCT03091920",4320659,7908581,"Change From Time-Matched Baseline Over Time in ABPM 4-hour Averages of Systolic Blood Pressure","NA","IW-1973|Placebo","Drug|Drug","hypertension|diabetes mellitus, type 2|diabetes mellitus","Diabetes Mellitus, Type 2|Hypertension","Parallel Assignment","Interventional","Treatment","Randomized","Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension",3,"Least squares mean difference",-4.43,"NA",null,-15.23,6.37,95,"Standard Error of the Mean",5.21,"All",26,"Completed","Phase 2","\t"]
["NCT03091920",4320689,7908589,"Change From Study Baseline Over Time in Supine Pulse","NA","IW-1973|Placebo","Drug|Drug","hypertension|diabetes mellitus, type 2|diabetes mellitus","Diabetes Mellitus, Type 2|Hypertension","Parallel Assignment","Interventional","Treatment","Randomized","Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension",3,"Least squares mean difference",0.8,"NA",null,-8.5,10.2,95,"Standard Error of the Mean",4.5,"All",26,"Completed","Phase 2","\t"]
["NCT03100058",4320172,7907894,"Change From Baseline in Fasting Lipid Profile (Triglycerides/Cholesterol)","NA","LIK066|Placebo","Drug|Drug","overweight","Obesity|Overweight","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults",13,"Mean Difference (Net)",4.1,0.288,"ANCOVA",-3.52,11.81,95,null,"NA","All",460,"Completed","Phase 2","\t"]
["NCT03100149",4517206,8269869,"Change From Baseline in the MDS-UPDRS Part IA, Part IB, Part I Total, Part II Total, Part III Total and Part III Subscores","NA","RO7046015|RO7046015|Placebo","Drug|Drug|Drug","parkinson disease","Parkinson's Disease","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease",7,"Difference in Adjusted Means",-0.19,0.651,"Mixed Models Analysis",-0.71,0.34,80,"Standard Error of the Mean",0.411,"All",316,"Active, not recruiting","Phase 2","\t"]
["NCT03100344",4320050,7907859,"Number of Participants Achieving Investigator's Global Assessment (IGA) Success (Defined as IGA 0 [Clear] or 1 [Almost Clear]) at Each Timepoint up to Week 24","NA","Nemolizumab|Placebo","Drug|Drug","dermatitis, atopic|dermatitis|eczema","Atopic Dermatitis","Parallel Assignment","Interventional","Treatment","Randomized","Dose-ranging Study of Nemolizumab in Atopic Dermatitis",4,"Mean Difference (Final Values)",20.9,0.008,"Cochran-Mantel-Haenszel",6.1,35.8,95,null,"NA","All",226,"Completed","Phase 2","\t"]
["NCT03100344",4320099,7907864,"Number of Participants With an Improvement of Weekly Average Peak Pruritus Numeric Rating Scale (NRS) ≥4 at Each Timepoint up to Week 24","NA","Nemolizumab|Placebo","Drug|Drug","dermatitis, atopic|dermatitis|eczema","Atopic Dermatitis","Parallel Assignment","Interventional","Treatment","Randomized","Dose-ranging Study of Nemolizumab in Atopic Dermatitis",4,"Mean Difference (Final Values)",27.6,1E-3,"Cochran-Mantel-Haenszel",13.5,41.7,95,null,"NA","All",226,"Completed","Phase 2","\t"]
["NCT03110380",4319610,7907377,"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm","dolutegravir","B/F/TAF|F/TAF|DTG|DTG Placebo|F/TAF Placebo|B/F/TAF Placebo","Drug|Drug|Drug|Drug|Drug|Drug","NA","HIV-1-infection","Parallel Assignment","Interventional","Treatment","Randomized","Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Adults Who Are Virologically Suppressed",3,"Difference in Percentages",2.2,"NA",null,-2.3,6.8,95.001,null,"NA","All",567,"Completed","Phase 3","\t"]
["NCT03119701",4319361,7906934,"Tentative Disease Specific Marker Cluster of Differentiation 73 (CD73, Ecto-5'-Nucleotidase Enzyme) Concentration in Serum Samples","interferon-beta|interferon beta-1a|interferons","Interferon Beta-1A|Placebo","Drug|Drug","multiple organ failure","Multi Organ Failure|Preventive Medicine","Parallel Assignment","Interventional","Prevention","Randomized","Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA",2,null,"NA",0.66,"ANOVA",{"$nulls":4},"NA","All",40,"Terminated","Phase 2","\t"]
["NCT03131687",4319010,7906216,"Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C)","ly3298176|dulaglutide","tirzepatide|Dulaglutide|Placebo","Drug|Drug|Drug","diabetes mellitus, type 2|diabetes mellitus","Type 2 Diabetes Mellitus","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus",6,"Mean Difference (Final Values)",0,0.396,"Mixed Models Analysis",-0.1,0,95,null,"NA","All",318,"Completed","Phase 2","\t"]
["NCT03135431",4318917,7905950,"Estimated Blood Loss","NA","Bilateral Salpingectomy|Bilateral Tubal Ligation","Procedure|Procedure","NA","Contraception","Parallel Assignment","Interventional","Treatment","Randomized","Opportunistic Salpingectomy for Permanent Sterilization at the Time of Cesarean Delivery",2,"Mean Difference (Net)",-9.17,0.77,"t-test, 2 sided",-72.5,54.17,95,null,"NA","Female",40,"Completed","N/A","\t"]
["NCT03143569",4318765,7905456,"Nomogram Feasibility","calcium heparin|heparin","aPTT guided heparin management|Anti-factor Xa guided heparin management","Device|Device","gastrointestinal hemorrhage|thrombosis|heart failure","Anticoagulant Therapy|Anti-factor Xa|aPTT|Gastro Intestinal Bleeding|Heparin|Left Sided Heart Failure|Left Ventricular Assist Device|Thrombosis, LVAD","Parallel Assignment","Interventional","Treatment","Randomized","Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial",2,null,"NA",1,"Fisher Exact",{"$nulls":4},"NA","All",20,"Completed","N/A","\t"]
["NCT03151148",4318626,7905059,"The Change From Baseline Levels of S. Hominis A9 Bacteria Abundance, as Measured by Quantitative Polymerase Chain Reaction (qPCR), on Lesional and Non-Lesional Skin Within Each Treatment Group","NA","TMT Lotion|Placebo Lotion","Biological|Drug","dermatitis|dermatitis, atopic|eczema","Atopic Dermatitis (AD)","Parallel Assignment","Interventional","Treatment","Randomized","Targeted Microbiome Transplant in Atopic Dermatitis",2,"Geometric mean ratio (GMR)",1.86,0.366,"Mixed Models Analysis",0.4833,7.1564,95,null,"NA","All",54,"Completed","Phase 1/Phase 2","\t"]
["NCT03160885",4318301,7904497,"Reduction of Worst Daily Pruritus Numeric Rating Scale (Weekly Average) of at Least 4 From Baseline to Week 16.","NA","Tralokinumab|Placebo","Drug|Drug","dermatitis, atopic|eczema|dermatitis","Atopic Dermatitis","Parallel Assignment","Interventional","Treatment","Randomized","Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)",7,"Risk Difference (RD)",15.6,1E-3,"Cochran-Mantel-Haenszel",10.3,20.9,95,null,"NA","All",794,"Completed","Phase 3","\t"]
["NCT03161938",4318231,7904454,"Number of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4","dexamethasone","Dexamethasone","Drug","postoperative complications|hip dislocation|hip dislocation, congenital","Hip Dysplasia|Postoperative Complications","Parallel Assignment","Interventional","Treatment","Randomized","High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase",2,null,"NA",0.376,"Chi-squared, Corrected",{"$nulls":4},"NA","All",64,"Completed","Phase 4","\t"]
["NCT03182738",4317775,7903150,"Score on Patient-Reported Outcomes Measurement Information System® (PROMIS)-29","NA","VIP app without HIV-related symptom strategies.|VIP app that delivers HIV-related symptom strategies.","Behavioral|Behavioral","acquired immunodeficiency syndrome|hiv infections|immunologic deficiency syndromes","AIDS (Acquired Immunodeficiency Syndrome)|HIV (Human Immunodeficiency Virus)","Parallel Assignment","Interventional","Supportive Care","Randomized","Video Information Provider for HIV-Associated Non-AIDS (VIP-HANA) Symptoms",2,"Difference in Change",0.77,0.96,"Linear mixed model",{"$nulls":4},"NA","All",100,"Completed","N/A","\t"]
["NCT03183908",4317729,7903094,"Number of Participants With System Reactions - Ages 80 +, Population 1","vaccines","FLUAD®|Fluzone® High-Dose","Biological|Biological","drug-related side effects and adverse reactions|injection site reaction","Adverse Drug Event|Injection Site Reaction|Pain|Quality of Life|Side Effect of Drug","Parallel Assignment","Interventional","Prevention","Randomized","FLUAD® vs. Fluzone® High-Dose Study",2,"Difference in proportions",-2.4,"NA",null,-8.1,-0.6,95,null,"NA","All",757,"Completed","Phase 4","\t"]
["NCT03192176",4314818,7902601,"Change From Baseline in Menopause-Specific Quality of Life (MENQoL) at Weeks 4, 8, 12, and 15","NA","fezolinetant|Placebo|Placebo","Drug|Drug|Drug","hot flashes","Hot Flashes|Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",8,"LSMean difference",0.2,0.5575,"MMRM",-0.38,0.71,95,"Standard Error of the Mean",0.28,"Female",356,"Completed","Phase 2","\t"]
["NCT03192176",4314907,7902602,"Change From Baseline in Greene Climacteric Scale (GCS) at Weeks 4, 8, 12, and 15","NA","fezolinetant|Placebo|Placebo","Drug|Drug|Drug","hot flashes","Hot Flashes|Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",8,"LSMean difference",-0.4,0.0304,"MMRM",-0.75,-0.04,95,"Standard Error of the Mean",0.18,"Female",356,"Completed","Phase 2","\t"]
["NCT03192176",4315003,7902603,"Leeds Sleep Evaluation Questionnaire (LSEQ) Domain Scores at Weeks 4, 8, 12 and 15","NA","fezolinetant|Placebo|Placebo","Drug|Drug|Drug","hot flashes","Hot Flashes|Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",8,"LSMean difference",1.1,0.8322,"MMRM",-9.18,11.39,95,"Standard Error of the Mean",5.22,"Female",356,"Completed","Phase 2","\t"]
["NCT03192176",4315244,7902606,"Number of Participants With Absolute Reduction of 4 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","NA","fezolinetant|Placebo|Placebo","Drug|Drug|Drug","hot flashes","Hot Flashes|Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",8,"Odds Ratio (OR)",9.95,0.0058,"Regression, Logistic",1.94,50.97,95,null,"NA","Female",356,"Completed","Phase 2","\t"]
["NCT03192176",4315367,7902607,"Number of Participants With Absolute Reduction of 3 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","NA","fezolinetant|Placebo|Placebo","Drug|Drug|Drug","hot flashes","Hot Flashes|Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",8,"Odds Ratio (OR)",1.33,0.6258,"Regression, Logistic",0.42,4.17,95,null,"NA","Female",356,"Completed","Phase 2","\t"]
["NCT03192176",4315619,7902609,"Number of Participants With Absolute Reduction of 5 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","NA","fezolinetant|Placebo|Placebo","Drug|Drug|Drug","hot flashes","Hot Flashes|Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",8,"Odds Ratio (OR)",4.12,0.0032,"Regression, Logistic",1.6,10.55,95,null,"NA","Female",356,"Completed","Phase 2","\t"]
["NCT03192176",4315725,7902610,"Number of Participants With Absolute Reduction of 4 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","NA","fezolinetant|Placebo|Placebo","Drug|Drug|Drug","hot flashes","Hot Flashes|Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",8,"Odds Ratio (OR)",4.12,0.0034,"Regression, Logistic",1.6,10.62,95,null,"NA","Female",356,"Completed","Phase 2","\t"]
["NCT03192176",4316012,7902613,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week","NA","fezolinetant|Placebo|Placebo","Drug|Drug|Drug","hot flashes","Hot Flashes|Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",8,"Odds Ratio (OR)",4.44,0.1924,"Regression, Logistic",0.47,41.87,95,null,"NA","Female",356,"Completed","Phase 2","\t"]
["NCT03192176",4316156,7902615,"Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week","NA","fezolinetant|Placebo|Placebo","Drug|Drug|Drug","hot flashes","Hot Flashes|Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",8,"Odds Ratio (OR)",4.84,0.0071,"Regression, Logistic",1.54,15.28,95,null,"NA","Female",356,"Completed","Phase 2","\t"]
["NCT03192176",4316377,7902617,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week","NA","fezolinetant|Placebo|Placebo","Drug|Drug|Drug","hot flashes","Hot Flashes|Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",8,"Odds Ratio (OR)",17.02,0.0081,"Regression, Logistic",2.09,138.7,95,null,"NA","Female",356,"Completed","Phase 2","\t"]
["NCT03192176",4316495,7902618,"Number of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week","NA","fezolinetant|Placebo|Placebo","Drug|Drug|Drug","hot flashes","Hot Flashes|Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",8,"Odds Ratio (OR)",3.31,0.1606,"Regression, Logistic",0.62,17.58,95,null,"NA","Female",356,"Completed","Phase 2","\t"]
["NCT03192176",4316682,7902620,"Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week","NA","fezolinetant|Placebo|Placebo","Drug|Drug|Drug","hot flashes","Hot Flashes|Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",8,"Odds Ratio (OR)",2.92,0.0255,"Regression, Logistic",1.14,7.47,95,null,"NA","Female",356,"Completed","Phase 2","\t"]
["NCT03192176",4316833,7902622,"Mean Percent Reduction of Mild, Moderate, And Severe Vasomotor Symptoms From Baseline to Each Study Week","NA","fezolinetant|Placebo|Placebo","Drug|Drug|Drug","hot flashes","Hot Flashes|Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",8,"LSMean difference",5.7,0.455,"MMRM",-9.34,20.8,95,"Standard Error of the Mean",7.66,"Female",356,"Completed","Phase 2","\t"]
["NCT03192176",4317130,7902624,"Change From Baseline in The Hot Flash Score of Mild, Moderate, and Severe VMS to Each Study Week","NA","fezolinetant|Placebo|Placebo","Drug|Drug|Drug","hot flashes","Hot Flashes|Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",8,"LSMean difference",-7.9,{"v":1E-4,"d":"1.00E-04"},"MMRM",-11.73,-4.05,95,"Standard Error of the Mean",1.95,"Female",356,"Completed","Phase 2","\t"]
["NCT03192176",4317207,7902625,"Change From Baseline in The Mean Severity of Moderate and Severe VMS to Each Study Week","NA","fezolinetant|Placebo|Placebo","Drug|Drug|Drug","hot flashes","Hot Flashes|Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",8,"LSMean difference",-0.8,{"v":1E-4,"d":"1.00E-04"},"MMRM",-1.15,-0.39,95,"Standard Error of the Mean",0.19,"Female",356,"Completed","Phase 2","\t"]
["NCT03192176",4317400,7902627,"Change From Baseline in The Mean Frequency of Moderate and Severe VMS to Each Study Week","NA","fezolinetant|Placebo|Placebo","Drug|Drug|Drug","hot flashes","Hot Flashes|Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",8,"LSMean difference",-2.6,0.0021,"MMRM",-4.17,-0.93,95,"Standard Error of the Mean",0.82,"Female",356,"Completed","Phase 2","\t"]
["NCT03192176",4317436,7902628,"Change From Baseline in The Mean Frequency of Mild, Moderate, and Severe VMS to Each Study Week","NA","fezolinetant|Placebo|Placebo","Drug|Drug|Drug","hot flashes","Hot Flashes|Menopause","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",8,"LSMean difference",-1,0.2346,"LSMean difference",-2.74,0.67,95,"Standard Error of the Mean",0.87,"Female",356,"Completed","Phase 2","\t"]
["NCT03197376",4314596,7902341,"Serotype-specific Geometric Mean Concentration of IgG Antibody","NA","Pneumosil|Synflorix","Biological|Biological","pneumonia|pneumonia, pneumococcal","Pneumonia, Pneumococcal","Parallel Assignment","Interventional","Prevention","Randomized","Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants",4,"Pn IgG type 5 GMC Ratio",0.98,"NA",null,0.9,1.07,95,null,"NA","All",2250,"Completed","Phase 3","\t"]
["NCT03201419",4314075,7902061,"Change From Baseline in Nocturnal Diuresis Rate Profiles at Week 12","deamino arginine vasopressin","FE 201836|Desmopressin|Placebo oral solution|Placebo ODT","Drug|Drug|Drug|Drug","polyuria|nocturia","Nocturia","Parallel Assignment","Interventional","Treatment","Randomized","A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults",9,"Mean Difference",-0.091,0.4238,"MMRM",-0.315,0.133,95,null,"NA","All",302,"Completed","Phase 2","\t"]
["NCT03201419",4314259,7902092,"Change From Baseline in Mean NI Diary Total Score at Week 8","deamino arginine vasopressin","FE 201836|Desmopressin|Placebo oral solution|Placebo ODT","Drug|Drug|Drug|Drug","polyuria|nocturia","Nocturia","Parallel Assignment","Interventional","Treatment","Randomized","A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults",9,"Mean Difference",2.79,0.5637,"MMRM",-6.71,12.28,95,null,"NA","All",302,"Completed","Phase 2","\t"]
["NCT03213366",4313873,7901495,"PrEP Barriers","NA","E-PrEP- Peer-Led Intervention about PrEP|BxNow - General Health Campaign","Behavioral|Behavioral","acquired immunodeficiency syndrome","HIV Prevention|PrEP Uptake","Parallel Assignment","Interventional","Prevention","Randomized","Social Media Based Peer-Led Intervention for HIV Prevention",2,"Slope",-0.05747,0.1021,"Mixed Models Analysis",{"$nulls":4},"NA","All",152,"Completed","N/A","\t"]
["NCT03214588",4313610,7901387,"Number of Participants by Patient Global Impression-Improvement (PGI-I) (Global Change) Score Categories","NA","TAK-831|TAK-831 Placebo","Drug|Drug","friedreich ataxia|cerebellar ataxia|ataxia","Friedreich Ataxia","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia",3,null,"NA",0.794,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",67,"Completed","Phase 2","\t"]
["NCT03224299",4313403,7900919,"Antimicrobial Activity of the Investigational Products Compared to Control.","NA","OCT - clear|OCT- tinted|ChloraPrep|Saline","Drug|Drug|Other|Other","NA","Preoperative Skin Preparation","Parallel Assignment","Interventional","Prevention","Randomized","Effectiveness of an Antimicrobial Agent for Preoperative Skin Preparation",4,"Mean Difference (Final Values)",2.33,"NA",null,1.72,2.93,95,null,"NA","All",131,"Completed","Phase 2","\t"]
["NCT03228680",4313232,7900680,"Circulating Levels of Endocrine Parameters (Inhibin B) at End-of-stimulation","follicle stimulating hormone","Follitropin delta|Follitropin beta","Drug|Drug","infertility","Infertility","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Japanese Women",2,"Mean ratio",0.88,0.027,"ANCOVA",0.79,0.99,95,null,"NA","Female",373,"Completed","Phase 3","\t"]
["NCT03237065",4312979,7900108,"Change in Transferrin Saturation (TSAT) From Baseline to Days 1, 7, 8, 14, 21, and 35","iron isomaltoside 1000","Iron isomaltoside/ferric derisomaltose|Ferric carboxymaltose","Drug|Drug","deficiency diseases|anemia|hypophosphatemia|anemia, iron-deficiency","Iron Deficiency Anaemia|Iron Deficiency Anemia","Parallel Assignment","Interventional","Treatment","Randomized","Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia",2,"Mean Difference (Final Values)",2.2,0.5794,"Mixed model for repeated measures",-5.5,9.8,95,null,"NA","All",122,"Completed","Phase 3","\t"]
["NCT03239665",4312831,7899904,"Within-Group Changes in Beliefs About Vaccine-Preventable Diseases and Vaccines","NA","Pharmacist-led Intervention (PHARM)|Peer-led Intervention (PEER)","Behavioral|Behavioral","pneumonia, bacterial|communicable diseases|infection|pneumonia","Infectious Disease|Influenza|Pneumonia, Bacterial|Zoster; Herpes","Parallel Assignment","Interventional","Prevention","Randomized","Vaccination Education Through Pharmacists and Senior Centers (VEPSC)",2,null,"NA",{"v":0.0002,"d":"2.00E-04"},"Sign test",{"$nulls":4},"NA","All",335,"Completed","N/A","\t"]
["NCT03239873",4312755,7899892,"Percentage of Participants With Solicited Injection-site Erythema, Injection-site Swelling, or Injection-site Pain/Tenderness After Vaccination 1","NA","VARIVAX® PE34 Process|VARIVAX® 2016 Commercial Process|M-M-R II®","Biological|Biological|Biological","chickenpox","Varicella","Parallel Assignment","Interventional","Prevention","Randomized","Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)",2,"Difference of Percentage",-1,0.696,"Miettinen & Nurminen",-5.9,4,95,null,"NA","All",600,"Completed","Phase 3","\t"]
["NCT03247543",4312549,7899605,"Effect of SPN-812 Assessed by Conners 3 - Self Report Short Form (C3-SRS)","NA","Placebo|200mg SPN-812|400mg SPN-812","Drug|Drug|Drug","NA","ADHD","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD",3,"Least Square Mean Difference",-2,0.1602,"ANCOVA",-4.9,0.8,95,"Standard Error of the Mean",1.45,"All",313,"Completed","Phase 3","\t"]
["NCT03257410",4312209,7899033,"Change From Baseline in Sodium (mmol/L) at End of Study (up to Week 24)","NA","Theranova 400 dialyzer|Elisio-17H dialyzer","Device|Device","kidney diseases|kidney failure, chronic","End Stage Renal Disease","Parallel Assignment","Interventional","Treatment","Randomized","Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients",2,"Mean Difference (Final Values)",0.2,0.6576,"ANCOVA",{"$nulls":3},"Standard Error of the Mean",0.452,"All",172,"Completed","N/A","\t"]
["NCT03257995",4312018,7898939,"Bronchodilator Effect of Indacaterol Salts Compared to Placebo Measured by FEF25-75%","maleic acid","Indacaterol maleate|Indacaterol acetate|Placebo","Drug|Drug|Drug","asthma","Asthma","Crossover Assignment","Interventional","Treatment","Randomized","Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.",6,"Mean Difference (Final Values)",0.1862,1E-3,"ANOVA",0.0882,0.2842,95,null,"NA","All",54,"Completed","Phase 2","\t"]
["NCT03261167",4311897,7898624,"Percentage of Participants Who Had MAS Score Reduction in Elbow, Wrist, Finger and Thumb Flexors up to Week 12","abobotulinumtoxina|botulinum toxins|botulinum toxins, type a","Botulinum toxin A (GSK1358820)|Placebo","Drug|Drug","muscle spasticity|stroke","Spasticity, Post-Stroke","Parallel Assignment","Interventional","Treatment","Randomized","A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity",3,"Adjusted rate difference",-0.5,"NA",null,-18.8,17.9,95,null,"NA","All",124,"Completed","Phase 3","\t"]
["NCT03277794",4311594,7897731,"World Health Organization Quality of Life Scale - BREF","NA","HOP-C|Transitional Case Management Only","Behavioral|Behavioral","NA","Homelessness|Youth","Parallel Assignment","Interventional","Treatment","Randomized","Generating Evidence for a Support Package to Stabilize Youth Trajectories Out of Homelessness",2,null,"NA",0.811,"Regression, Linear",{"$nulls":4},"NA","All",65,"Completed","N/A","\t"]
["NCT03292016",4311340,7896658,"Area Under the Concentration- Time Curve (AUC Last)","apomorphine","APL-130277|APO-go|Apokyn","Drug|Drug|Drug","parkinson disease","Parkinson Disease","Crossover Assignment","Interventional","Treatment","Randomized","A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by \"OFF\" Episodes",3,"Geometric Mean Ratio (APL-130277/APOKYN)",17.2,"NA",null,13.1,22.5,90,null,"NA","All",8,"Completed","Phase 2","\t"]
["NCT03296527",4311221,7896463,"Proportion of Subjects With Early OHSS (Including OHSS of Moderate/Severe Grade) and/or Preventive Interventions for Early OHSS","follicle stimulating hormone","Follitropin alfa|Follitropin delta","Drug|Drug","NA","Controlled Ovarian Simulation","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Pan-Asian Women",2,"Odds Ratio (OR)",0.33,0.012,"Regression, Logistic",0.13,0.83,95,null,"NA","Female",1011,"Completed","Phase 3","\t"]
["NCT03305809",4310839,7895804,"Change in HBPM for Pulse Rate From Baseline to Week 12","NA","LY3154207|Placebo","Drug|Drug","dementia|alzheimer disease|parkinson disease|lewy body disease","Lewy Body Dementia","Parallel Assignment","Interventional","Treatment","Randomized","A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)",4,"Mean Difference (Net)",-0.6,0.791,"Mixed Models Analysis",-4.96,3.79,95,null,"NA","All",344,"Completed","Phase 2","\t"]
["NCT03307252",4310814,7895714,"Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Rifampin + R1 (T2) vs. R1)","probenecid|metformin|digoxin|cimetidine|rifampin|furosemide|verapamil|rosuvastatin calcium","Rifampin|Cimetidine|Probenecid|Rosuvastatin|Verapamil|Digoxin|Furosemide|Metformin","Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug","NA","Healthy","Crossover Assignment","Interventional","Other","Randomized","This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men",9,"Adjusted gMean ratio",119.78,"NA",null,110.03,130.39,90,"Standard Error of the Mean",12.1,"Male",45,"Completed","Phase 1","\t"]
["NCT03320941",4310200,7894702,"Change From Baseline on Urine Albumin at Week 12","NA","LIK066|Placebo","Drug|Drug","obesity","Obesity","Parallel Assignment","Interventional","Treatment","Randomized","A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity",5,"Mean Difference (Final Values)",1.289,0.493,"ANCOVA",-2.423,5.001,95,"Standard Error of the Mean",1.8741,"All",126,"Completed","Phase 2","\t"]
["NCT03329573",4310081,7894312,"Area Under the Concentration-time Curve From Administration Extrapolated to the Last Time of Quantifiable Concentration (AUC[0-t]) of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fed Condition","paroxetine","Paroxetine IR tablets A|Paroxetine IR tablets B","Drug|Drug","anxiety disorders","Anxiety Disorders","Crossover Assignment","Interventional","Treatment","Randomized","Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured in GlaxoSmithKline Tianjin (GSKT) and Mississauga Sites in Healthy Chinese Subjects",4,"Ratio of Geometrical Mean",1.064,"NA",null,1.01,1.12,90,null,"NA","All",85,"Completed","Phase 1","\t"]
["NCT03334422",4309874,7893935,"Change From Baseline on the Hospital Anxiety and Depression Scale (HADS)","NA","Baricitinib|Placebo","Drug|Drug","dermatitis|eczema|dermatitis, atopic","Atopic Dermatitis","Parallel Assignment","Interventional","Treatment","Randomized","Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis",4,"LSMean Difference",-0.94,0.067,"Mixed Models Analysis",-1.95,0.07,95,"Standard Error of the Mean",0.51,"All",615,"Completed","Phase 3","\t"]
["NCT03334812",4309819,7893854,"Percentage of Donor Site Refilling Based on MRI Measurements.","NA","LNA043|placebo to LNA043","Biological|Biological","NA","Knee Cartilage Lesion","Parallel Assignment","Interventional","Treatment","Randomized","Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation",4,"Mean Difference (Net)",27.82,0.1381,"Mixed Effect Model Repeat Measurement",-26.5,82.1,95,null,"NA","All",14,"Terminated","Phase 2","\t"]
["NCT03339726",4309692,7893541,"Change From Baseline in the Nasal Congestion Severity Score","phenylephrine|oxymetazoline","New Formulation Phenylephrine HCl|Marketed Phenylephrine HCl|Placebo","Drug|Drug|Drug","common cold","Common Cold","Parallel Assignment","Interventional","Treatment","Randomized","Randomized, Double-blind, Placebo-Controlled, Efficacy Study of a New Formulation of Phenylephrine HCL in the Common Cold",3,"Mean Difference (Final Values)",0.28,0.27,"ANOVA",-0.22,0.78,95,"Standard Error of the Mean",0.253,"All",193,"Terminated","Phase 2","\t"]
["NCT03349060",4309104,7893087,"Percentage of Participants With >=11 Points at Baseline and Achieving Score of <11 Points in Hospital Anxiety and Depression Scale: Depression Subscale at Week 2, 4, 8 and 12","NA","PF-04965842 100 mg|PF-04965842 200 mg|Placebo","Drug|Drug|Drug","dermatitis|dermatitis, atopic|eczema","Dermatitis, Atopic","Parallel Assignment","Interventional","Treatment","Randomized","Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis",3,"Difference in Percentage",24.6,0.3173,"Cochran-Mantel-Haenszel",-14.4,63.6,95,null,"NA","All",387,"Completed","Phase 3","\t"]
["NCT03349060",4309156,7893093,"Percentage of Participants With Baseline Children's Dermatology Life Quality Index Score >=2.5 and Achieving >=2.5 Point Improvement From Baseline in CDLQI Score at Week 2, 4, 8 and 12","NA","PF-04965842 100 mg|PF-04965842 200 mg|Placebo","Drug|Drug|Drug","dermatitis|dermatitis, atopic|eczema","Dermatitis, Atopic","Parallel Assignment","Interventional","Treatment","Randomized","Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis",3,"Difference in Percentage",17.1,0.2371,"Cochran-Mantel-Haenszel",-9,43.3,95,null,"NA","All",387,"Completed","Phase 3","\t"]
["NCT03353753",4308964,7892811,"Quality of Life & Disease-Related Symptoms - European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer 30-Item - Role Functioning","NA","DCC-2618|Placebo Oral Tablet","Drug|Drug","gastrointestinal stromal tumors","Gastrointestinal Stromal Tumors","Parallel Assignment","Interventional","Treatment","Randomized","Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies",2,null,"NA",1E-3,"ANCOVA",{"$nulls":4},"NA","All",129,"Active, not recruiting","Phase 3","\t"]
["NCT03364309",4308760,7892185,"Percentage of Participants Achieving an Itch Numeric Rating Scale (NRS) ≥4 Point Reduction From Baseline for Participants Who Had Baseline Itch NRS ≥4","ixekizumab","Ixekizumab|Placebo","Drug|Drug","psoriasis","Plaque Psoriasis","Parallel Assignment","Interventional","Treatment","Randomized","A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis",3,"Odds Ratio (OR)",37.24,1E-3,"Regression, Logistic",13.68,99.99,95,null,"NA","All",438,"Completed","Phase 3","\t"]
["NCT03365934",4308268,7892066,"Skin Barrier Function - Day 2","anti-bacterial agents","ADHESIVE BANDAGE #1|ADHESIVE BANDAGE #2|ADHESIVE BANDAGE #3|Antibacterial Bandage with 0.8% BZK|Intact and No Bandage|Wounded and No Bandage","Device|Device|Device|Device|Other|Other","NA","Healthy Volunteers","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of Changes to Skin Microbiome With Tape-Stripped Wounds",6,"Mean Difference (Net)",8.39,0.006,"ANCOVA",2.3925,14.394,95,"Standard Error of the Mean",3.038,"All",35,"Completed","N/A","\t"]
["NCT03365934",4308397,7892077,"Microbial Community Evenness - Baseline (Day 0)","anti-bacterial agents","ADHESIVE BANDAGE #1|ADHESIVE BANDAGE #2|ADHESIVE BANDAGE #3|Antibacterial Bandage with 0.8% BZK|Intact and No Bandage|Wounded and No Bandage","Device|Device|Device|Device|Other|Other","NA","Healthy Volunteers","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of Changes to Skin Microbiome With Tape-Stripped Wounds",6,null,"NA",0.969093,"t-test, 2 sided",{"$nulls":4},"NA","All",35,"Completed","N/A","\t"]
["NCT03365934",4308675,7892095,"Microbial Community Richness - Baseline (Day 0)","anti-bacterial agents","ADHESIVE BANDAGE #1|ADHESIVE BANDAGE #2|ADHESIVE BANDAGE #3|Antibacterial Bandage with 0.8% BZK|Intact and No Bandage|Wounded and No Bandage","Device|Device|Device|Device|Other|Other","NA","Healthy Volunteers","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of Changes to Skin Microbiome With Tape-Stripped Wounds",6,null,"NA",0.999941,"t-test, 2 sided",{"$nulls":4},"NA","All",35,"Completed","N/A","\t"]
["NCT03371355",4308099,7891840,"Percent Change From Baseline in ANGPTL3, TC, LDL-C, HDL-C, VLDL-C, Non-HDL-C, ApoB (ApoB-48, ApoB-100), ApoCIII, ApoAI, FFA, and Lp(a) at Primary Analysis Time Point","NA","Placebo|ISIS 703802 40 mg|ISIS 703802 80 mg|ISIS 703802 20 mg","Drug|Drug|Drug|Drug","fatty liver|diabetes mellitus, type 2|hypertriglyceridemia|diabetes mellitus|liver diseases|non-alcoholic fatty liver disease","Diabetes Mellitus, Type 2|Fatty Liver, Nonalcoholic|Hypertriglyceridemia|NAFLD","Parallel Assignment","Interventional","Treatment","Randomized","Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease",4,"Mean Difference in % CFB",-47,{"v":1E-4,"d":"1.00E-04"},"ANCOVA",-61,-29,95,null,"NA","All",105,"Completed","Phase 2","\t"]
["NCT03389893",4307711,7891005,"Transepidermal Water Loss (TEWL) Area Under the Curve (AUC) on Non-Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up","antibodies, monoclonal","Dupilumab|Placebo","Drug|Drug","dermatitis|dermatitis, atopic|eczema","Atopic Dermatitis (AD)","Parallel Assignment","Interventional","Treatment","Randomized","Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis",2,"Mean Difference (Final Values)",-22.97,0.546,"Mixed Models Analysis",-99.79,53.86,95,null,"NA","All",72,"Terminated","Phase 4","\t"]
["NCT03392168",4307678,7890958,"Percent Change From Baseline in Target Plaque Area in Cohort 2","NA","ARQ-151 cream 0.5%|ARQ-151 cream 0.15%|ARQ-151 vehicle cream","Drug|Drug|Drug","psoriasis","Psoriasis","Parallel Assignment","Interventional","Treatment","Randomized","Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis",4,"Least squares mean difference",-12.68,0.0276,"Mixed Models Analysis",-23.992,-1.44,95,null,"NA","All",91,"Completed","Phase 1/Phase 2","\t"]
["NCT03400033",4307527,7890683,"Change From Baseline in SBP, DBP and MAP at End of Treatment","epoetin alfa","Daprodustat tablets|Matching placebo tablets|Epoetin alfa vials|Saline vials or bags","Drug|Drug|Drug|Drug","anemia|renal insufficiency, chronic|kidney diseases","Anaemia","Parallel Assignment","Interventional","Treatment","Randomized","Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)",2,"Mean Difference (Net)",-0.5,0.407,"ANCOVA",-4.73,3.72,95,null,"NA","All",407,"Completed","Phase 3","\t"]
["NCT03423173",4307115,7889392,"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 270 in the Immunogenicity Subset","NA","TAK-003|Placebo","Biological|Biological","dengue","Dengue Fever","Parallel Assignment","Interventional","Prevention","Randomized","Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue",4,"GMT Ratio",0.88,"NA",null,0.64,1.21,95,null,"NA","All",923,"Completed","Phase 3","\t"]
["NCT03428100",4306942,7889096,"Change From Baseline in the Patient Global Impression of Severity - Atopic Dermatitis (PGI-S-AD) Score","NA","Baricitinib|Placebo|Topical corticosteroid","Drug|Drug|Drug","dermatitis, atopic|eczema|dermatitis","Atopic Dermatitis","Parallel Assignment","Interventional","Treatment","Randomized","A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable",4,"Mean Difference (Final Values)",-0.58,1E-3,"Mixed Models Analysis",-0.86,-0.29,95,"Standard Error of the Mean",0.145,"All",463,"Active, not recruiting","Phase 3","\t"]
["NCT03433482",4306834,7888930,"Percentages of Subjects With hSBA Titers ≥LLOQ Against Each of the N. Meningitidis Serogroups A, C, W and Y for Each Vaccine Group, and Between-group Differences","NA","MenACWY liquid|MenACWY","Biological|Biological","meningococcal infections|meningitis|meningitis, meningococcal","Meningitis, Meningococcal","Parallel Assignment","Interventional","Prevention","Randomized","A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age",4,"Difference in percentage of subjects",-0.99,"NA",null,-6.66,4.7,95,null,"NA","All",1707,"Completed","Phase 2","\t"]
["NCT03441984",4306360,7888401,"C24 of 3TC in Plasma in Part 2","NA","Treatment A|Treatment B|Treatment C|Treatment D|Treatment E|Treatment F","Drug|Drug|Drug|Drug|Drug|Drug","hiv infections","HIV Infections","Crossover Assignment","Interventional","Treatment","Randomized","To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers",12,"Ratio of geometric LS means",1.0706,"NA",null,0.9961,1.1507,90,null,"NA","All",36,"Completed","Phase 1","\t"]
["NCT03446781",4306185,7887980,"2-level Composite Responders of the Non-target Buttock","NA","EN3835|Placebo","Biological|Biological","edema|cellulite","Edematous Fibrosclerotic Panniculopathy (Cellulite)","Parallel Assignment","Interventional","Treatment","Randomized","Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women",2,null,"NA",0.033,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","Female",422,"Completed","Phase 3","\t"]
["NCT03461965",4305948,7887359,"Change in State-Trait Anxiety Inventory (STAI) Y-1 (State Anxiety) Score","NA","3D printed model|Verbal Counselling","Behavioral|Behavioral","NA","Mohs Micrographic Surgery","Parallel Assignment","Interventional","Supportive Care","Randomized","3D Printed Models in Mohs Micrographic Surgery",2,null,"NA",0.03,"t-test, 2 sided",{"$nulls":4},"NA","All",82,"Completed","N/A","\t"]
["NCT03465436",4305767,7887268,"Change From Baseline in Mean Cardiac Intervals:QRS of Lasmiditan and Moxifloxacin","moxifloxacin","Lasmiditan|Lasmiditan|Placebo|Moxifloxacin","Drug|Drug|Drug|Drug","NA","Healthy","Crossover Assignment","Interventional","Basic Science","Randomized","A Study of Lasmiditan on the Heart in Healthy Participants",4,"LS Mean",0.43,"NA",null,0.01,0.84,90,null,"NA","All",56,"Completed","Phase 1","\t"]
["NCT03467217",4517770,8270924,"Change in Waist-to-hip Ratio at 24 Weeks Compared to Baseline","losartan","Losartan potassium|Placebo losartan capsule","Drug|Drug","fatty liver|non-alcoholic fatty liver disease|liver diseases","NAFLD - Nonalcoholic Fatty Liver Disease","Parallel Assignment","Interventional","Treatment","Randomized","Losartan for the Treatment of Pediatric NAFLD",2,"Mean Difference (Final Values)",0.02,0.08,"ANCOVA",0,0.05,95,null,"NA","All",83,"Completed","Phase 2","\t"]
["NCT03480763",4305458,7886596,"Geometric Mean Concentration of Serotype-specific Immunoglobulin G at 30 Days Following PNEUMOVAX™23","heptavalent pneumococcal conjugate vaccine","V114|Prevnar 13™|PNEUMOVAX™23","Biological|Biological|Biological","pneumococcal infections","Pneumococcal Infections","Parallel Assignment","Interventional","Prevention","Randomized","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",2,"GMC Ratio",0.99,"NA",null,0.85,1.16,95,null,"NA","All",652,"Completed","Phase 3","\t"]
["NCT03493854",4305190,7885987,"Ctrough of Trastuzumab During Cycle 7 (Pre-Dose Cycle 8)","pertuzumab|hormones|paclitaxel|docetaxel|cyclophosphamide|doxorubicin|trastuzumab","Cyclophosphamide|Doxorubicin|Docetaxel|Paclitaxel|Pertuzumab IV|FDC of Pertuzumab and Trastuzumab SC|Trastuzumab IV|Trastuzumab SC|Surgery|Post-operative Radiotherapy|Hormone Therapy","Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Radiation|Drug","breast neoplasms","Early Breast Cancer","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer",2,"Geometric Mean Ratio",1.33,"NA",null,1.24,1.43,90,null,"NA","All",500,"Active, not recruiting","Phase 3","\t"]
["NCT03502616",4305013,7885596,"Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Experience Domain Scores at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48","tofacitinib","Tofacitinib","Drug","spondylitis, ankylosing|spondylitis","Ankylosing Spondylitis","Parallel Assignment","Interventional","Treatment","Randomized","Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)",2,"LS mean difference",2.19,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",1.35,3.02,95,"Standard Error of the Mean",0.423,"All",270,"Completed","Phase 3","\t"]
["NCT03510663",4304795,7885291,"Time-matched Difference Between the OPC-61815/Moxifloxacin and Placebo Data in Change From Baseline for QTcF in 12-lead Holter Electrocardiogram (ECG)","moxifloxacin","OPC-61815 16mg|OPC-61815 32mg|Moxifloxacin|Placebos","Drug|Drug|Drug|Drug","heart failure","Congestive Heart Failure","Crossover Assignment","Interventional","Treatment","Randomized","Phase I Study of OPC-61815",4,"Least Squares Mean Difference",-4.1,"NA",null,-6.3,-1.8,90,null,"NA","Male",48,"Completed","Phase 1","\t"]
["NCT03521635",4304614,7884822,"Epworth Sleepiness Scale (ESS) Score (Change From Baseline)","pramipexole","Pramipexole SR|Pramipexole IR","Drug|Drug","parkinson disease","Parkinson Disease","Parallel Assignment","Interventional","Treatment","Randomized","The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa",2,"Adjusted mean difference",0.2,0.82,"REML-based repeated measures approach",-1.4,1.7,95,"Standard Error of the Mean",0.79,"All",98,"Completed","Phase 4","\t"]
["NCT03549117",4304222,7883782,"Number of Participants Showing Improvement for Each Domain (Sleep, Sleep Time, Symptoms on Waking in the Morning, and Practical Problems) of Nocturnal Rhino Conjunctivitis Quality of Life Questionnaire (NRQLQ) at Day 7","NA","Breathe Right Tan (small/medium) nasal strips|Placebo nasal strip","Device|Other","NA","Congestion, Nasal","Parallel Assignment","Interventional","Treatment","Randomized","A Pivotal Subjective Sleep Study of a Nasal Dilator (Breathe Right Tan)",2,null,"NA",0.2368,"Chi-squared",{"$nulls":4},"NA","All",140,"Completed","Phase 2","\t"]
["NCT03549130",4304177,7883770,"Number of Participants Showing Improvement for Each Domain Problems (Sleep, Sleep Time, Symptoms on Waking in the Morning, and Practical Problems) of Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire at Day 14","NA","Breathe Right Tan (small/medium) nasal strips|Placebo nasal strip","Device|Other","NA","Congestion, Nasal","Parallel Assignment","Interventional","Treatment","Randomized","A Pivotal Study to Assess the Effectiveness of Nasal Dilator (Breathe Right Nasal Strips)",2,null,"NA",0.8285,"Chi-squared",{"$nulls":4},"NA","All",130,"Completed","Phase 2","\t"]
["NCT03567005",4303964,7882997,"Overall Vision","NA","Nelfilcon A digital contact lenses|Nelfilcon A contact lenses","Device|Device","refractive errors","Refractive Errors","Crossover Assignment","Interventional","Treatment","Randomized","Clinical Validation of DACP Digital Design",2,"LSM Difference",0,"NA",null,-0.3,null,95,"Standard Error of the Mean",0.15,"All",60,"Completed","N/A","\t"]
["NCT03575871",4303532,7882510,"Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Visual Analogue Scale (VAS) Sleep Loss at Weeks 2, 4, 8 and 12","NA","PF-04965842 100 mg|PF-04965842 200 mg|Placebo","Drug|Drug|Drug","dermatitis, atopic|dermatitis|eczema","Dermatitis, Atopic","Parallel Assignment","Interventional","Treatment","Randomized","Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis",3,"Difference in LS mean",-1.6,{"v":1E-4,"d":"1.00E-04"},"Mixed Models Analysis",-2.3,-0.9,95,null,"NA","All",391,"Completed","Phase 3","\t"]
["NCT03585712",4303459,7882243,"Effect of Delayed Intake or Missed Pill on Cervical Mucus Score (CMS)","norgestrel","Norgestrel 0.075 mg","Drug","NA","Contraception","Crossover Assignment","Interventional","Treatment","Randomized","Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill",2,null,"NA",0.26,"Mixed Models Analysis",{"$nulls":4},"NA","Female",52,"Completed","Phase 2","\t"]
["NCT03597139",4303182,7881824,"Change From Baseline in Eye Pain Post Dose Instillation on Day 28","cyclosporine|ophthalmic solutions|cyclosporins","Voclosporin Ophthalmic Solution|Restasis®","Drug|Drug","eye diseases|keratoconjunctivitis sicca|dry eye syndromes","Dry Eye","Parallel Assignment","Interventional","Treatment","Randomized","Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease",2,"Mean Difference (Final Values)",5.7,0.1787,"ANCOVA",-2.7,14.1,95,null,"NA","All",100,"Completed","Phase 2","\t"]
["NCT03614975",4303068,7881276,"Determining Geometric Mean Titers (GMTs) at Each Time Point","vaccines","Flucelvax inactivated influenza vaccine|Fluzone inactivated influenza vaccine","Biological|Biological","influenza, human","Immune Response|Influenza, Human","Parallel Assignment","Interventional","Prevention","Randomized","Immunologic Response to Influenza Vaccination in Children and Adolescents",2,null,"NA",0.65,"Kruskal-Wallis",{"$nulls":4},"NA","All",166,"Completed","Phase 4","\t"]
["NCT03622112",4302753,7880967,"Change From Baseline in Average Evening PEF Over the Treatment Period","NA","AZD7594 DPI 55μg/50μg.|AZD7594 DPI 99 µg/90 µg|AZD7594 DPI 198 µg/180 µg|AZD7594 DPI 396 µg/360 µg once daily.|AZD7594 DPI 792 µg/720 µg|Placebo for AZD7594 once daily.|FF 100 µg once daily (open-label)","Drug|Drug|Drug|Drug|Drug|Drug|Drug","asthma","Asthma","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects",7,"Mean Difference (Final Values)",6.129,0.163,"Mixed Models Analysis",-2.479,14.737,95,null,"NA","All",808,"Completed","Phase 2","\t"]
["NCT03627767",4302512,7880698,"Change From Baseline in Dermatology Life Quality Index (DLQI) Score for Adults at Weeks 12, 16, 28, 40 and 52: Double-blind Period","NA","PF-04965842 100 mg|PF-04965842 200 mg|Placebo","Drug|Drug|Drug","eczema|skin diseases, eczematous|skin diseases|dermatitis|hypersensitivity, immediate|genetic diseases, inborn|hypersensitivity|immune system diseases|skin diseases, genetic|dermatitis, atopic","Dermatitis|Dermatitis, Atopic|Eczema|Genetic Diseases, Inborn|Hypersensitivity|Hypersensitivity, Immediate|Immune System Diseases|Skin Diseases|Skin Diseases, Eczematous|Skin Diseases, Genetic","Parallel Assignment","Interventional","Treatment","Randomized","Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects",3,"LSM difference",-0.1,0,"Mixed Models Analysis",-0.7,0.5,95,null,"NA","All",1235,"Completed","Phase 3","\t"]
["NCT03629886",4302367,7880576,"Incidence Rates of Incident Cervical Infection With Any Oncogenic HPV Type or Combination of Oncogenic HPV Types in HPV DNA Negative Subjects at Baseline, Regardless of Initial Serostatus in All Study Groups","NA","HPV (Types 16, 18) Vaccine, Adsorbed","Biological","cervical intraepithelial neoplasia","Cervical Intraepithelial Neoplasia","Parallel Assignment","Interventional","Prevention","Randomized","Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study",2,"Incidence rate per 100-Person years",0.64,"NA",null,0.54,0.77,95,null,"NA","Female",3537,"Completed","Phase 4","\t"]
["NCT03635086",4518118,8271435,"Geometric Mean Titer of Anti-Chikungunya Antibodies Determined by Enzyme Linked Immunosorbent Assay","NA","MV-CHIK lyophilised formulation, low dose|MV-CHIK liquid frozen formulation, low dose|MV-CHIK SPS® formulation, low dose|MV-CHIK liquid frozen formulation, high dose|Placebo","Biological|Biological|Biological|Biological|Other","chikungunya fever","Chikungunya Virus Infection","Parallel Assignment","Interventional","Prevention","Randomized","Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)",5,"Geometric Mean Ratio Estimate",0.6,0.9105,"ANOVA",0.1,3.2,95,null,"NA","All",60,"Completed","Phase 2","\t"]
["NCT03651479",4302108,7879827,"Wolf Motor Function Test","NA","real boxing training|virtual boxing training","Other|Other","stroke|paresis","Hemiparesis|Stroke","Parallel Assignment","Interventional","Treatment","Randomized","The Comparison of Virtual and Real Boxing Training in Hemiparetic Stroke Patients",2,null,"NA",0.004,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",40,"Completed","N/A","\t"]
["NCT03657264",4301980,7879488,"Change-from-baseline Mean Effect of P03277 on QT Interval Expressed as QTc According to Fridericia's Formula (∆QTcF)","moxifloxacin","P03277 0.1 mmol/kg|Moxifloxacin 400mg|NaCl 0.9%|P03277 0.3 mmol/kg","Drug|Drug|Drug|Drug","NA","Healthy Volunteers","Crossover Assignment","Interventional","Diagnostic","Randomized","Cardiac Safety Evaluation of P03277",4,"Least Squares Mean Difference",0.48,"NA",null,-1.32,2.29,90,"Standard Error of the Mean",1.09,"All",48,"Completed","Phase 1","\t"]
["NCT03693742",4301635,7878225,"Salivary Gland Maximal Standardized Uptake Values Corrected for Lean Body Mass (SULmax) for 18F-DCFPyL","NA","18F-DCFPyL PET/CT scan|Placebo drink|MSG drink","Diagnostic Test|Other|Other","prostatic neoplasms","Prostate Cancer|Prostate Cancer Metastatic|Prostatic Neoplasm","Crossover Assignment","Interventional","Diagnostic","Randomized","MSG Use With 18F-DCFPyL PET/CT Imaging",2,null,"NA",1E-3,"Mixed Models Analysis",{"$nulls":4},"NA","Male",10,"Completed","N/A","\t"]
["NCT03698591",4301573,7877984,"Change in Self-reported Effort (Distancing) From Baseline to 30 Minutes Post Stimulation.","NA","Transcranial magnetic stimulation task|Sham transcranial magnetic stimulation task","Device|Device","NA","Emotion Regulation|Real Versus Sham Transcranial Magnetic Stimulation (TMS)","Crossover Assignment","Interventional","Basic Science","Randomized","Testing a Neurocognitive Model of Distancing Using Transcranial Magnetic Stimulation.",2,"F-statistic",4.04,0.054,"ANOVA",{"$nulls":4},"NA","All",40,"Completed","N/A","\t"]
["NCT03723980",4301253,7877145,"Difference of Pain Scores Between Different Age Groups","propolis|calcium","Propolis|Calcium Hydroxide","Drug|Drug","pain, postoperative","Pain, Postoperative","Parallel Assignment","Interventional","Prevention","Randomized","Role of Propolis Paste in Preventing Pain After Root Canal Treatment.",2,null,"NA",0.13,{"$nulls":5},"NA","All",80,"Completed","Phase 3","\t"]
["NCT03733899",4301106,7876919,"Change in Subjective Comfort Scores From Pre-treatment to Post-treatment","anesthetics","Local Anesthesia|Placebo","Diagnostic Test|Diagnostic Test","NA","Visual Acuity","Crossover Assignment","Interventional","Treatment","Randomized","An Investigation of the Impact of Localized Topical Anesthesia of the Ocular Surface on End-of-day Contact Lens Discomfort",6,"Least-sqaure Mean Difference",7.6,"NA",null,-3.7,18.8,95,"Standard Error of the Mean",5.67,"All",22,"Completed","N/A","\t"]
["NCT03783962",4300732,7875664,"Cooking Frequency Change - Dinner","NA","Active Intervention - Cooking|Demonstrations - Cooking","Behavioral|Behavioral","obesity","Obesity","Parallel Assignment","Interventional","Treatment","Randomized","Examining Cooking as a Health Behavior",2,null,"NA",0.05,"Mixed Models Analysis",{"$nulls":4},"NA","All",56,"Completed","N/A","\t"]
["NCT03796676",4300592,7875317,"Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response ≥ 75% Improvement From Baseline at Week 12","NA","Placebo|PF-04965842|PF04965842","Drug|Drug|Drug","dermatitis|dermatitis, atopic|eczema","Atopic Dermatitis","Parallel Assignment","Interventional","Treatment","Randomized","JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis",3,"Estimate of difference",29.4,{"v":1E-4,"d":"1.00E-04"},"Cochran-Mantel-Haenszel",16.3,42.5,95,null,"NA","All",287,"Completed","Phase 3","\t"]
["NCT03808298",4300447,7874909,"Change-From-Baseline Heart Rate Measured on 12-Lead ECGs Extracted From Continuous Recordings","norgestimate, ethinyl estradiol drug combination|moxifloxacin","Moxifloxacin Treatment C|Placebo for Moxifloxacin Treatment C|Placebo for Moxifloxacin Treatment D|Moxifloxacin Treatment D|Balovaptan therapeutic dose Treatment A|Balovaptan supra-therapeutic dose Treatment B|Active control [moxifloxacin] on Day 2 Treatment C|Active control [Moxifloxacin] on Day 15 Treatment D|Placebo for Balovaptan Treatment C|Placebo for Balovaptan Treatment D|Placebo for Moxifloxacin Treatment A|Placebo for Moxifloxacin Treatment B","Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug","NA","Healthy Volunteers","Crossover Assignment","Interventional","Treatment","Randomized","Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects",12,"LS Mean",-1.6,"NA",null,-3.25,0.01,90,"Standard Error of the Mean",0.98,"All",57,"Completed","Phase 1","\t"]
["NCT03831880",4300170,7874255,"Total Score Related to Pen Ease of Use by Treatment in Overall Study, Using DCOA 1 Questionnaire","NA","Genotropin|somatrogon","Drug|Drug","dwarfism, pituitary","Growth Hormone Deficiency","Crossover Assignment","Interventional","Other","Randomized","Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD",2,"Mean Difference (Final Values)",-5.39,0.0017,"Mixed Models Analysis",-8.69,-2.09,95,null,"NA","All",87,"Completed","Phase 3","\t"]
["NCT03855189",4299966,7873482,"Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 8 (Physician-Evaluated)","beclomethasone|mometasone furoate","Mometasone Furoate (MF)|Beclomethasone Dipropionate (BDP)|Placebo","Drug|Drug|Drug","rhinitis|rhinitis, allergic|rhinitis, allergic, seasonal","Seasonal Allergic Rhinitis","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)",3,null,"NA",0.01,"ANOVA",{"$nulls":4},"NA","All",345,"Completed","Phase 3","\t"]
["NCT03879772",4299629,7872897,"Change From Baseline in the Total Nasal Symptom Score (TNSS) on Day 29 as Assessed by Investigator","mometasone furoate|chlorpheniramine|beclomethasone","Placebo nasal spray|Chlorpheniramine maleate syrup|Beclomethasone dipropionate nasal spray|Mometasone furoate nasal spray","Drug|Drug|Drug|Drug","rhinitis|rhinitis, allergic, seasonal|rhinitis, allergic","Rhinitis, Allergic, Seasonal","Parallel Assignment","Interventional","Treatment","Randomized","Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)",5,null,"NA",0.08,"ANOVA",{"$nulls":4},"NA","All",679,"Completed","Phase 3","\t"]
["NCT03880474",4299559,7872880,"Severity of Influenza-like Illness (ILI) Derived From Daily ILI eDiary as Time Weighted AUC","NA","MVA-NP+M1|Saline","Biological|Drug","influenza, human","Influenza","Parallel Assignment","Interventional","Prevention","Randomized","Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults",2,"Geometric Mean Ratio (Active vs Placebo)",1.01,0.8399,"ANOVA",0.86,1.19,95,null,"NA","All",2364,"Terminated","Phase 2","\t"]
["NCT03903822",4299344,7872430,"Percentage of Participants Achieving >=2 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation","NA","PF-06700841|Vehicle (Placebo)","Drug|Drug","dermatitis|dermatitis, atopic|eczema","Atopic Dermatitis","Parallel Assignment","Interventional","Treatment","Randomized","Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis",8,"Risk Difference (RD)",36.7,{"v":0.0007,"d":"7.00E-04"},"Chan and Zhang Exact Method",15.4,54,90,null,"NA","All",292,"Completed","Phase 2","\t"]
["NCT03912259",4299200,7872241,"Number of Participants With Investigator's Global Assessment (IGA) Score of \"0\" or \"1\" and Reduction From Baseline of Greater Than or Equal to (>=) 2 Points at Week 16","emollients","Dupilumab|Placebo|Emollient (moisturizer)","Drug|Drug|Drug","dermatitis, atopic|eczema|dermatitis","Atopic Dermatitis","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis",2,"Difference in Percentage",22,{"v":1E-4,"d":"1.00E-04"},"Cochran-Mantel-Haenszel",11.37,32.65,95,null,"NA","All",165,"Completed","Phase 3","\t"]
["NCT03950856",4298978,7871648,"Geometric Mean Concentration of Serotype-specific Immunoglobulin G (IgG) Following Vaccination With Separate V114 Lots","heptavalent pneumococcal conjugate vaccine","V114|Prevnar 13™","Drug|Drug","pneumonia, pneumococcal|pneumococcal infections|pneumonia","Pneumococcal Infections|Pneumonia, Pneumococcal","Parallel Assignment","Interventional","Prevention","Randomized","Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)",4,"GMC Ratio",0.92,"NA",null,0.78,1.07,95,null,"NA","All",2340,"Completed","Phase 3","\t"]
["NCT03962738",4298658,7871469,"Percentage of Participants With Pain Freedom","NA","Lasmiditan|Placebo","Drug|Drug","migraine disorders","Migraine","Parallel Assignment","Interventional","Treatment","Randomized","A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine",4,"Odds Ratio (OR)",9.05,1E-3,"Regression, Logistic",2.68,30.55,95,null,"NA","All",846,"Completed","Phase 2","\t"]
["NCT03977155",4297821,7871096,"Change in the IBS Global Scale (IBS-GS) at Day 29 Compared to Baseline (Averaged Over the Week Prior to Each Respective Time Point)","NA","BOS-589|Placebo","Drug|Drug","syndrome|irritable bowel syndrome|diarrhea","Diarrhea-predominant Irritable Bowel Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)",3,"Mean Difference (Net)",0.01,"NA",null,-0.27,0.29,95,"Standard Error of the Mean",0.141,"All",133,"Completed","Phase 2","\t"]
["NCT03981822",4297758,7871002,"Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)","NA","VP-102 and applicator","Combination Product","warts|virus diseases|skin diseases, infectious|sexually transmitted diseases|papillomavirus infections|skin diseases, viral|skin diseases|condylomata acuminata|sexually transmitted diseases, viral|infection|communicable diseases","Condylomata Acuminata|Papillomavirus Infections|Sexually Transmitted Diseases|Sexually Transmitted Diseases, Viral|Skin Diseases|Skin Diseases, Infectious|Skin Diseases, Viral|Warts","Parallel Assignment","Interventional","Treatment","Randomized","A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts",6,null,"NA",0.019,"Cochran-Mantel-Haenszel",{"$nulls":4},"NA","All",105,"Completed","Phase 2","\t"]
["NCT04081610",4296973,7868720,"Visual Acuity (VA)","hyaluronic acid","lagricel ofteno multidose|lagricel ofteno single dose","Drug|Drug","keratoconjunctivitis sicca|dry eye syndromes","Dry Eye","Parallel Assignment","Interventional","Treatment","Randomized","Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution",2,null,"NA",1,"Sign test",{"$nulls":4},"NA","All",34,"Completed","Phase 1","\t"]
["NCT04131556",4296814,7868113,"Area Under the Curve Extrapolated to Infinity, Calculated Using the Observed Value of the Last Non-Zero Concentration (AUC0-Inf) of Maribavir in Plasma","maribavir","Maribavir","Drug","NA","Healthy Volunteers","Crossover Assignment","Interventional","Treatment","Randomized","A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants",10,"% Ratio of Geometric least squares means",80.36,"NA",null,73.26,88.16,90,null,"NA","All",20,"Terminated","Phase 1","\t"]
["NCT04275336",4296483,7866783,"Venipuncture Duration","lidocaine","Lidocaine topical|Psychological interventions|Lidocaine combined with psychological interventions","Drug|Behavioral|Other","NA","Child, Hospitalized","Parallel Assignment","Interventional","Supportive Care","Randomized","Pharmacologic and Psychological Interventions for Pediatric Pain During Venipuncture.",3,"Median Difference (Final Values)",1.642,0.44,"Kruskal-Wallis",null,null,95,null,"NA","All",300,"Completed","N/A","\t"]
["NCT04315298",4296408,7866547,"Time to Resolution of Fever for at Least 48 Hours Without Antipyretics by Clinical Severity (Phase 2)","NA","Sarilumab|Placebo","Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19",5,"Hazard Ratio (HR)",2.1,0.0371,"Log Rank",1.01,4.4,95,null,"NA","All",1912,"Completed","Phase 2/Phase 3","\t"]
["NCT04362137",4296071,7865998,"Proportion of Patients Requiring Mechanical Ventilation","NA","Ruxolitinib|Placebo","Drug|Drug","NA","Cytokine Storm (Covid-19)","Parallel Assignment","Interventional","Treatment","Randomized","Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm",2,"Odds Ratio (OR)",0.99,0.987,"Regression, Logistic",0.45,2.21,95,null,"NA","All",432,"Completed","Phase 3","\t"]
["NCT04397445",4295992,7865759,"AUC(0-t) of Plasma DMA","ranitidine|ranitidine bismuth citrate","Ranitidine|Placebo|Low nitrite/NDMA meals|High nitrite/NDMA meals","Drug|Drug|Other|Other","NA","Food-drug Interaction|Pharmacokinetics|Ranitidine Adverse Reaction","Crossover Assignment","Interventional","Basic Science","Randomized","Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration",4,"Geometric Mean Ratio",0.8,0.03,"Mixed Models Analysis",0.65,0.98,95,null,"NA","All",18,"Completed","Phase 1","\t"]
["NCT04397445",4295993,7865759,"AUC(0-t) of Plasma DMA","ranitidine|ranitidine bismuth citrate","Ranitidine|Placebo|Low nitrite/NDMA meals|High nitrite/NDMA meals","Drug|Drug|Other|Other","NA","Food-drug Interaction|Pharmacokinetics|Ranitidine Adverse Reaction","Crossover Assignment","Interventional","Basic Science","Randomized","Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration",4,"Geometric Mean Ratio",0.8,0.02,"Mixed Models Analysis",0.67,0.95,95,null,"NA","All",18,"Completed","Phase 1","\t"]
["NCT04397445",4295996,7865761,"Cumulative Ranitidine Amount Excreted in Urine Over 24 Hours After Drug Administration","ranitidine|ranitidine bismuth citrate","Ranitidine|Placebo|Low nitrite/NDMA meals|High nitrite/NDMA meals","Drug|Drug|Other|Other","NA","Food-drug Interaction|Pharmacokinetics|Ranitidine Adverse Reaction","Crossover Assignment","Interventional","Basic Science","Randomized","Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration",4,"Geometric Mean Ratio",0.81,1E-3,"Mixed Models Analysis",0.72,0.91,95,null,"NA","All",18,"Completed","Phase 1","\t"]
["NCT04397445",4295999,7865762,"Cumulative Dimethylamine (DMA) Amount Excreted in Urine Over 24 Hours After Drug Administration","ranitidine|ranitidine bismuth citrate","Ranitidine|Placebo|Low nitrite/NDMA meals|High nitrite/NDMA meals","Drug|Drug|Other|Other","NA","Food-drug Interaction|Pharmacokinetics|Ranitidine Adverse Reaction","Crossover Assignment","Interventional","Basic Science","Randomized","Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration",4,"Geometric Mean Ratio",0.95,0.74,"Mixed Models Analysis",0.81,1.1,90,null,"NA","All",18,"Completed","Phase 1","\t"]
["NCT04397445",4295998,7865762,"Cumulative Dimethylamine (DMA) Amount Excreted in Urine Over 24 Hours After Drug Administration","ranitidine|ranitidine bismuth citrate","Ranitidine|Placebo|Low nitrite/NDMA meals|High nitrite/NDMA meals","Drug|Drug|Other|Other","NA","Food-drug Interaction|Pharmacokinetics|Ranitidine Adverse Reaction","Crossover Assignment","Interventional","Basic Science","Randomized","Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration",4,"Geometric Mean Ratio",1.05,0.52,"Mixed Models Analysis",0.9,1.23,95,null,"NA","All",18,"Completed","Phase 1","\t"]
["NCT04397445",4295997,7865762,"Cumulative Dimethylamine (DMA) Amount Excreted in Urine Over 24 Hours After Drug Administration","ranitidine|ranitidine bismuth citrate","Ranitidine|Placebo|Low nitrite/NDMA meals|High nitrite/NDMA meals","Drug|Drug|Other|Other","NA","Food-drug Interaction|Pharmacokinetics|Ranitidine Adverse Reaction","Crossover Assignment","Interventional","Basic Science","Randomized","Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration",4,"Geometric Mean Ratio",1.05,0.42,"Mixed Models Analysis",0.93,1.19,95,null,"NA","All",18,"Completed","Phase 1","\t"]
["NCT04397445",4296000,7865762,"Cumulative Dimethylamine (DMA) Amount Excreted in Urine Over 24 Hours After Drug Administration","ranitidine|ranitidine bismuth citrate","Ranitidine|Placebo|Low nitrite/NDMA meals|High nitrite/NDMA meals","Drug|Drug|Other|Other","NA","Food-drug Interaction|Pharmacokinetics|Ranitidine Adverse Reaction","Crossover Assignment","Interventional","Basic Science","Randomized","Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration",4,"Geometric Mean Ratio",0.94,0.92,"Mixed Models Analysis",0.87,1.01,90,null,"NA","All",18,"Completed","Phase 1","\t"]
["NCT04397445",4296001,7865763,"Cumulative NDMA Amount Excreted in Urine Over 24 Hours After Drug Administration (Comparison Between Diets)","ranitidine|ranitidine bismuth citrate","Ranitidine|Placebo|Low nitrite/NDMA meals|High nitrite/NDMA meals","Drug|Drug|Other|Other","NA","Food-drug Interaction|Pharmacokinetics|Ranitidine Adverse Reaction","Crossover Assignment","Interventional","Basic Science","Randomized","Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration",4,null,"NA",0.007,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",18,"Completed","Phase 1","\t"]
["NCT04397445",4296002,7865763,"Cumulative NDMA Amount Excreted in Urine Over 24 Hours After Drug Administration (Comparison Between Diets)","ranitidine|ranitidine bismuth citrate","Ranitidine|Placebo|Low nitrite/NDMA meals|High nitrite/NDMA meals","Drug|Drug|Other|Other","NA","Food-drug Interaction|Pharmacokinetics|Ranitidine Adverse Reaction","Crossover Assignment","Interventional","Basic Science","Randomized","Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration",4,null,"NA",0.005,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",18,"Completed","Phase 1","\t"]
["NCT04397445",4296003,7865764,"Cumulative NDMA Amount Excreted in Urine Over 24 Hours After Drug Administration (Comparison Between Ranitidine and Placebo)","ranitidine|ranitidine bismuth citrate","Ranitidine|Placebo|Low nitrite/NDMA meals|High nitrite/NDMA meals","Drug|Drug|Other|Other","NA","Food-drug Interaction|Pharmacokinetics|Ranitidine Adverse Reaction","Crossover Assignment","Interventional","Basic Science","Randomized","Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration",4,null,"NA",0.71,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",18,"Completed","Phase 1","\t"]
["NCT04397445",4296004,7865764,"Cumulative NDMA Amount Excreted in Urine Over 24 Hours After Drug Administration (Comparison Between Ranitidine and Placebo)","ranitidine|ranitidine bismuth citrate","Ranitidine|Placebo|Low nitrite/NDMA meals|High nitrite/NDMA meals","Drug|Drug|Other|Other","NA","Food-drug Interaction|Pharmacokinetics|Ranitidine Adverse Reaction","Crossover Assignment","Interventional","Basic Science","Randomized","Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration",4,null,"NA",0.54,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",18,"Completed","Phase 1","\t"]
["NCT04399161",4295989,7865755,"Change in Streptococcus Mutans Levels in Dental Plaque","chlorhexidine","Chlorhexidine mouthwash|Xylitol|Probiotic","Drug|Drug|Drug","NA","Cariostatic Agents|Mouthwashes","Parallel Assignment","Interventional","Prevention","Randomized","Anticaries Effect of Xylitol,Probiotic and Chlorhexidine Mouth Rinses Among Individuals at High Risk",2,null,"NA",0.314,"ANOVA",{"$nulls":4},"NA","All",60,"Completed","Phase 2/Phase 3","\t"]
["NCT04399161",4295990,7865755,"Change in Streptococcus Mutans Levels in Dental Plaque","chlorhexidine","Chlorhexidine mouthwash|Xylitol|Probiotic","Drug|Drug|Drug","NA","Cariostatic Agents|Mouthwashes","Parallel Assignment","Interventional","Prevention","Randomized","Anticaries Effect of Xylitol,Probiotic and Chlorhexidine Mouth Rinses Among Individuals at High Risk",2,null,"NA",0.123,"ANOVA",{"$nulls":4},"NA","All",60,"Completed","Phase 2/Phase 3","\t"]
["NCT04400682",4295986,7865749,"AUC0-inf of Favipiravir","NA","FAVIRA 200 MG Film Tablet|AVIGAN 200 MG Film Tablets","Drug|Drug","NA","Bioequivalence","Crossover Assignment","Interventional","Other","Randomized","Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",2,"Mean ratio",1.0108,0,"ANOVA",0.9856,1.0366,90,null,"NA","Male",30,"Completed","Phase 1","\t"]
["NCT04400682",4295987,7865750,"Favipiravir Cmax","NA","FAVIRA 200 MG Film Tablet|AVIGAN 200 MG Film Tablets","Drug|Drug","NA","Bioequivalence","Crossover Assignment","Interventional","Other","Randomized","Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",2,"Mean ratio",1.0361,3.3E-3,"ANOVA",0.9294,1.1551,90,null,"NA","Male",30,"Completed","Phase 1","\t"]
["NCT04400682",4295988,7865751,"AUC0-tlast","NA","FAVIRA 200 MG Film Tablet|AVIGAN 200 MG Film Tablets","Drug|Drug","NA","Bioequivalence","Crossover Assignment","Interventional","Other","Randomized","Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",2,"Mean ratio",1.015,0,"ANOVA",0.9897,1.041,90,null,"NA","Male",30,"Completed","Phase 1","\t"]
["NCT04401202",4295985,7865747,"Percentage of Participants With Clinical Recovery Within 14 Days After Randomization","NA","Nigella sativa oil","Dietary Supplement","NA","COVID-19|SARS-CoV-2","Parallel Assignment","Interventional","Treatment","Randomized","Nigella Sativa in COVID-19",2,null,"NA",1E-3,"Chi-squared",{"$nulls":4},"NA","All",183,"Completed","Phase 2","\t"]
["NCT04401579",4295978,7865703,"Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First","NA","Placebo|Remdesivir|Baricitinib","Other|Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Adaptive COVID-19 Treatment Trial 2 (ACTT-2)",2,"Cox Proportional Hazard",1.24,0.003,"Log Rank",1.07,1.44,95,null,"NA","All",1033,"Completed","Phase 3","\t"]
["NCT04401579",4295979,7865704,"Time to an Improvement of Two Categories Using an Ordinal Scale","NA","Placebo|Remdesivir|Baricitinib","Other|Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Adaptive COVID-19 Treatment Trial 2 (ACTT-2)",2,"Cox Proportional Hazard",1.2,0.005,"Log Rank",1.05,1.38,95,null,"NA","All",1033,"Completed","Phase 3","\t"]
["NCT04401579",4295980,7865705,"Time to an Improvement of One Category Using an Ordinal Scale","NA","Placebo|Remdesivir|Baricitinib","Other|Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Adaptive COVID-19 Treatment Trial 2 (ACTT-2)",2,"Cox Proportional Hazard",1.21,2E-3,"Log Rank",1.06,1.39,95,null,"NA","All",1033,"Completed","Phase 3","\t"]
["NCT04401579",4295981,7865715,"Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15","NA","Placebo|Remdesivir|Baricitinib","Other|Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Adaptive COVID-19 Treatment Trial 2 (ACTT-2)",2,"Odds Ratio (OR)",1.26,0.44,"Regression, Logistic",1.01,1.57,95,null,"NA","All",1033,"Completed","Phase 3","\t"]
["NCT04401579",4295982,7865725,"Percentage of Participants Reporting Serious Adverse Events (SAEs)","NA","Placebo|Remdesivir|Baricitinib","Other|Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Adaptive COVID-19 Treatment Trial 2 (ACTT-2)",2,"Risk Difference (RD)",-5,"NA",null,-10,0,95,null,"NA","All",1033,"Completed","Phase 3","\t"]
["NCT04401579",4295983,7865726,"Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)","NA","Placebo|Remdesivir|Baricitinib","Other|Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Adaptive COVID-19 Treatment Trial 2 (ACTT-2)",2,"Risk Difference (RD)",-6,"NA",null,-12,0,95,null,"NA","All",1033,"Completed","Phase 3","\t"]
["NCT04401579",4295984,7865742,"Time to Recovery","NA","Placebo|Remdesivir|Baricitinib","Other|Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Adaptive COVID-19 Treatment Trial 2 (ACTT-2)",2,"Cox Proportional Hazard",1.15,0.047,"Log Rank",1,1.31,95,null,"NA","All",1033,"Completed","Phase 3","\t"]
["NCT04403399",4295975,7865684,"Attention","varenicline","Varenicline|Placebo","Drug|Drug","parkinson disease","Parkinson's Disease","Crossover Assignment","Interventional","Treatment","Randomized","Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])",2,"Mean Difference (Final Values)",0.08,0.03,"Mixed Models Analysis",{"$nulls":4},"NA","All",34,"Completed","Phase 2","\t"]
["NCT04403399",4295976,7865685,"JERK","varenicline","Varenicline|Placebo","Drug|Drug","parkinson disease","Parkinson's Disease","Crossover Assignment","Interventional","Treatment","Randomized","Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])",2,"Mean Difference (Final Values)",-0.07,0.73,"Mixed Models Analysis",{"$nulls":4},"NA","All",34,"Completed","Phase 2","\t"]
["NCT04403399",4295977,7865686,"Gait Speed","varenicline","Varenicline|Placebo","Drug|Drug","parkinson disease","Parkinson's Disease","Crossover Assignment","Interventional","Treatment","Randomized","Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])",2,"Mean Difference (Final Values)",-3.62,0.003,"Mixed Models Analysis",{"$nulls":4},"NA","All",34,"Completed","Phase 2","\t"]
["NCT04406194",4295965,7865676,"AUC0-inf of Favipiravir","NA","FAVICOVIR 200 mg Film Tablet|AVIGAN 200 mg Film Tablets","Drug|Drug","NA","Bioequivalence","Crossover Assignment","Interventional","Other","Randomized","Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",2,"Mean Ratio",0.9719,0,"ANOVA",0.944,1.0006,90,null,"NA","Male",30,"Completed","Phase 1","\t"]
["NCT04406194",4295966,7865677,"Cmax of Favipiravir","NA","FAVICOVIR 200 mg Film Tablet|AVIGAN 200 mg Film Tablets","Drug|Drug","NA","Bioequivalence","Crossover Assignment","Interventional","Other","Randomized","Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",2,"Mean Ratio",1.0555,0.0155,"ANOVA",0.9292,1.1989,90,null,"NA","Male",30,"Completed","Phase 1","\t"]
["NCT04406194",4295967,7865678,"AUC0-tlast of Favipiravir","NA","FAVICOVIR 200 mg Film Tablet|AVIGAN 200 mg Film Tablets","Drug|Drug","NA","Bioequivalence","Crossover Assignment","Interventional","Other","Randomized","Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",2,"Mean Ratio",0.9684,0,"ANOVA",0.94,0.9977,90,null,"NA","Male",30,"Completed","Phase 1","\t"]
["NCT04415489",4295959,7865648,"Number of Participants With Pathology Found","NA","Office hysteroscopy","Device","infertility","Infertility","Parallel Assignment","Interventional","Diagnostic","Randomized","SIS Versus Office Hysteroscopy for Uterine Cavity Evaluation Prior to IVF",2,null,"NA",0.12,"Fisher Exact",{"$nulls":4},"NA","Female",100,"Completed","N/A","\t"]
["NCT04415489",4295960,7865652,"Number of Patients Requiring Secondary Procedure","NA","Office hysteroscopy","Device","infertility","Infertility","Parallel Assignment","Interventional","Diagnostic","Randomized","SIS Versus Office Hysteroscopy for Uterine Cavity Evaluation Prior to IVF",2,null,"NA",0.01,"Fisher Exact",{"$nulls":4},"NA","Female",100,"Completed","N/A","\t"]
["NCT04415489",4295961,7865653,"Time to Complete","NA","Office hysteroscopy","Device","infertility","Infertility","Parallel Assignment","Interventional","Diagnostic","Randomized","SIS Versus Office Hysteroscopy for Uterine Cavity Evaluation Prior to IVF",2,null,"NA",0.16,"t-test, 2 sided",{"$nulls":4},"NA","Female",100,"Completed","N/A","\t"]
["NCT04415489",4295962,7865654,"Provider Satisfaction","NA","Office hysteroscopy","Device","infertility","Infertility","Parallel Assignment","Interventional","Diagnostic","Randomized","SIS Versus Office Hysteroscopy for Uterine Cavity Evaluation Prior to IVF",2,null,"NA",0.11,"Fisher Exact",{"$nulls":4},"NA","Female",100,"Completed","N/A","\t"]
["NCT04415489",4295963,7865655,"Pain Scores","NA","Office hysteroscopy","Device","infertility","Infertility","Parallel Assignment","Interventional","Diagnostic","Randomized","SIS Versus Office Hysteroscopy for Uterine Cavity Evaluation Prior to IVF",2,null,"NA",0.01,"t-test, 2 sided",{"$nulls":4},"NA","Female",100,"Completed","N/A","\t"]
["NCT04415489",4295964,7865656,"Patient Satisfaction","NA","Office hysteroscopy","Device","infertility","Infertility","Parallel Assignment","Interventional","Diagnostic","Randomized","SIS Versus Office Hysteroscopy for Uterine Cavity Evaluation Prior to IVF",2,null,"NA",0.57,"Fisher Exact",{"$nulls":4},"NA","Female",100,"Completed","N/A","\t"]
["NCT04438785",4295937,7865564,"Pittsburgh Sleep Quality Index","NA","The intervention consists of myofunctional therapy (MT) using the AirwayGym app.","Device","apnea|syndrome|sleep apnea, obstructive","Obstructive Sleep Apnea-hypopnea Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","Effects of Myofunctional Therapy With an Application in Severe Apnea/Hypopnea Sleep Obstructive Syndrome (MTASSAOS)",2,"Mean Difference (Net)",0.98,0.22,"Wilcoxon (Mann-Whitney)",null,null,95,null,"NA","All",40,"Completed","N/A","\t"]
["NCT04438785",4295938,7865565,"Epworth Sleepiness Scale","NA","The intervention consists of myofunctional therapy (MT) using the AirwayGym app.","Device","apnea|syndrome|sleep apnea, obstructive","Obstructive Sleep Apnea-hypopnea Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","Effects of Myofunctional Therapy With an Application in Severe Apnea/Hypopnea Sleep Obstructive Syndrome (MTASSAOS)",2,"Median Difference (Final Values)",-1.23,1E-3,"t-test, 2 sided",null,null,95,null,"NA","All",40,"Completed","N/A","\t"]
["NCT04438785",4295939,7865566,"Body Mass Index BMI","NA","The intervention consists of myofunctional therapy (MT) using the AirwayGym app.","Device","apnea|syndrome|sleep apnea, obstructive","Obstructive Sleep Apnea-hypopnea Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","Effects of Myofunctional Therapy With an Application in Severe Apnea/Hypopnea Sleep Obstructive Syndrome (MTASSAOS)",2,"Mean Difference (Final Values)",0.97,0.98,"t-test, 2 sided",null,null,95,null,"NA","All",40,"Completed","N/A","\t"]
["NCT04438785",4295940,7865567,"Waist Circumference (cm)","NA","The intervention consists of myofunctional therapy (MT) using the AirwayGym app.","Device","apnea|syndrome|sleep apnea, obstructive","Obstructive Sleep Apnea-hypopnea Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","Effects of Myofunctional Therapy With an Application in Severe Apnea/Hypopnea Sleep Obstructive Syndrome (MTASSAOS)",2,"Mean Difference (Final Values)",0.98,0.92,"t-test, 2 sided",{"$nulls":4},"NA","All",40,"Completed","N/A","\t"]
["NCT04438785",4295941,7865568,"Neck Circumference (cm)","NA","The intervention consists of myofunctional therapy (MT) using the AirwayGym app.","Device","apnea|syndrome|sleep apnea, obstructive","Obstructive Sleep Apnea-hypopnea Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","Effects of Myofunctional Therapy With an Application in Severe Apnea/Hypopnea Sleep Obstructive Syndrome (MTASSAOS)",2,"Mean Difference (Final Values)",0.98,0.92,"t-test, 2 sided",null,null,95,null,"NA","All",40,"Completed","N/A","\t"]
["NCT04438785",4295942,7865569,"Iowa Oral Performance Instrument Lip Strength","NA","The intervention consists of myofunctional therapy (MT) using the AirwayGym app.","Device","apnea|syndrome|sleep apnea, obstructive","Obstructive Sleep Apnea-hypopnea Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","Effects of Myofunctional Therapy With an Application in Severe Apnea/Hypopnea Sleep Obstructive Syndrome (MTASSAOS)",2,"Median Difference (Final Values)",-1.131,1E-3,"t-test, 2 sided",null,null,95,null,"NA","All",40,"Completed","N/A","\t"]
["NCT04438785",4295943,7865570,"Evaluation of Iowa Oral Performance Instrument (IOPI) Score","NA","The intervention consists of myofunctional therapy (MT) using the AirwayGym app.","Device","apnea|syndrome|sleep apnea, obstructive","Obstructive Sleep Apnea-hypopnea Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","Effects of Myofunctional Therapy With an Application in Severe Apnea/Hypopnea Sleep Obstructive Syndrome (MTASSAOS)",2,"Mean Difference (Net)",-0.364,1E-3,"t-test, 2 sided",{"$nulls":4},"NA","All",40,"Completed","N/A","\t"]
["NCT04438785",4295944,7865571,"Evaluation of O2 Desaturation Index (ODI)","NA","The intervention consists of myofunctional therapy (MT) using the AirwayGym app.","Device","apnea|syndrome|sleep apnea, obstructive","Obstructive Sleep Apnea-hypopnea Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","Effects of Myofunctional Therapy With an Application in Severe Apnea/Hypopnea Sleep Obstructive Syndrome (MTASSAOS)",2,"Median Difference (Final Values)",-0.971,0.003,"t-test, 2 sided",{"$nulls":4},"NA","All",40,"Completed","N/A","\t"]
["NCT04438785",4295945,7865572,"Apnea Hypopnea Index (AHI)","NA","The intervention consists of myofunctional therapy (MT) using the AirwayGym app.","Device","apnea|syndrome|sleep apnea, obstructive","Obstructive Sleep Apnea-hypopnea Syndrome","Parallel Assignment","Interventional","Treatment","Randomized","Effects of Myofunctional Therapy With an Application in Severe Apnea/Hypopnea Sleep Obstructive Syndrome (MTASSAOS)",2,"Mean Difference (Final Values)",2.58,1E-3,"t-test, 2 sided",{"$nulls":4},"NA","All",40,"Completed","N/A","\t"]
["NCT04448210",4295926,7865522,"Fear Preventing Participation Scores at 1 Week","NA","DigiKnowIt News: Teen","Behavioral","chronic disease|multiple chronic conditions","Chronic Illnesses, Multiple|Healthy","Parallel Assignment","Interventional","Health Services Research","Randomized","Web-based Resource for Children and Adolescents About Clinical Research",2,null,"NA",0.3,"ANOVA",{"$nulls":4},"NA","All",42,"Completed","N/A","\t"]
["NCT04448210",4295927,7865523,"Likelihood of Participation Scores at 1 Week","NA","DigiKnowIt News: Teen","Behavioral","chronic disease|multiple chronic conditions","Chronic Illnesses, Multiple|Healthy","Parallel Assignment","Interventional","Health Services Research","Randomized","Web-based Resource for Children and Adolescents About Clinical Research",2,null,"NA",0.94,"ANOVA",{"$nulls":4},"NA","All",42,"Completed","N/A","\t"]
["NCT04448210",4295928,7865524,"Procedural Fears Scores at 1 Week","NA","DigiKnowIt News: Teen","Behavioral","chronic disease|multiple chronic conditions","Chronic Illnesses, Multiple|Healthy","Parallel Assignment","Interventional","Health Services Research","Randomized","Web-based Resource for Children and Adolescents About Clinical Research",2,null,"NA",0.94,"ANOVA",{"$nulls":4},"NA","All",42,"Completed","N/A","\t"]
["NCT04448210",4295929,7865525,"Confidence Scores at 1 Week","NA","DigiKnowIt News: Teen","Behavioral","chronic disease|multiple chronic conditions","Chronic Illnesses, Multiple|Healthy","Parallel Assignment","Interventional","Health Services Research","Randomized","Web-based Resource for Children and Adolescents About Clinical Research",2,null,"NA",0.38,"ANOVA",{"$nulls":4},"NA","All",42,"Completed","N/A","\t"]
["NCT04448210",4295930,7865526,"Self-Efficacy to Gather Information Scores at 1 Week","NA","DigiKnowIt News: Teen","Behavioral","chronic disease|multiple chronic conditions","Chronic Illnesses, Multiple|Healthy","Parallel Assignment","Interventional","Health Services Research","Randomized","Web-based Resource for Children and Adolescents About Clinical Research",2,null,"NA",0.69,"ANOVA",{"$nulls":4},"NA","All",42,"Completed","N/A","\t"]
["NCT04448210",4295931,7865527,"Self-Efficacy to Communicate Scores at 1 Week","NA","DigiKnowIt News: Teen","Behavioral","chronic disease|multiple chronic conditions","Chronic Illnesses, Multiple|Healthy","Parallel Assignment","Interventional","Health Services Research","Randomized","Web-based Resource for Children and Adolescents About Clinical Research",2,null,"NA",0.43,"ANOVA",{"$nulls":4},"NA","All",42,"Completed","N/A","\t"]
["NCT04448210",4295932,7865528,"Beliefs Scores at 1 Week","NA","DigiKnowIt News: Teen","Behavioral","chronic disease|multiple chronic conditions","Chronic Illnesses, Multiple|Healthy","Parallel Assignment","Interventional","Health Services Research","Randomized","Web-based Resource for Children and Adolescents About Clinical Research",2,null,"NA",0.16,"ANOVA",{"$nulls":4},"NA","All",42,"Completed","N/A","\t"]
["NCT04448210",4295933,7865529,"Attitudes Scores at 1 Week","NA","DigiKnowIt News: Teen","Behavioral","chronic disease|multiple chronic conditions","Chronic Illnesses, Multiple|Healthy","Parallel Assignment","Interventional","Health Services Research","Randomized","Web-based Resource for Children and Adolescents About Clinical Research",2,null,"NA",0.72,"ANOVA",{"$nulls":4},"NA","All",42,"Completed","N/A","\t"]
["NCT04448210",4295934,7865530,"Knowledge Scores at 1 Week","NA","DigiKnowIt News: Teen","Behavioral","chronic disease|multiple chronic conditions","Chronic Illnesses, Multiple|Healthy","Parallel Assignment","Interventional","Health Services Research","Randomized","Web-based Resource for Children and Adolescents About Clinical Research",2,null,"NA",0.25,"ANOVA",{"$nulls":4},"NA","All",42,"Completed","N/A","\t"]
["NCT04448561",4295918,7865498,"Pharmacokinetics (PK) of Morphine-6β-D-glucuronide (M6G) (Morphine Metabolite) in Plasma: Cmax","morphine","ASP8082|morphine|Placebo","Drug|Drug|Drug","substance-related disorders","Opioid Use Disorder","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants",2,"Geometric LS mean ratio",95.1,"NA",null,82.52,109.6,90,null,"NA","All",24,"Completed","Phase 1","\t"]
["NCT04448561",4295919,7865499,"Pharmacokinetics (PK) of Morphine-6β-D-glucuronide (M6G) (Morphine Metabolite) in Plasma: AUClast","morphine","ASP8082|morphine|Placebo","Drug|Drug|Drug","substance-related disorders","Opioid Use Disorder","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants",2,"Geometric LS mean ratio",86.54,"NA",null,76.01,98.52,90,null,"NA","All",24,"Completed","Phase 1","\t"]
["NCT04448561",4295920,7865501,"Pharmacokinetics (PK) of Morphine-3β-D-glucuronide (M3G) (Morphine Metabolite) in Plasma: Cmax","morphine","ASP8082|morphine|Placebo","Drug|Drug|Drug","substance-related disorders","Opioid Use Disorder","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants",2,"Geometric LS mean ratio",96.11,"NA",null,83.03,111.25,90,null,"NA","All",24,"Completed","Phase 1","\t"]
["NCT04448561",4295921,7865502,"Pharmacokinetics (PK) of Morphine-3β-D-glucuronide (M3G) (Morphine Metabolite) in Plasma: AUClast","morphine","ASP8082|morphine|Placebo","Drug|Drug|Drug","substance-related disorders","Opioid Use Disorder","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants",2,"Geometric LS mean ratio",89.08,"NA",null,79.58,99.71,90,null,"NA","All",24,"Completed","Phase 1","\t"]
["NCT04448561",4295922,7865504,"Pharmacokinetics (PK) of Morphine in Plasma: Cmax","morphine","ASP8082|morphine|Placebo","Drug|Drug|Drug","substance-related disorders","Opioid Use Disorder","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants",2,"Geometric LS mean ratio",100.58,"NA",null,81.35,124.36,90,null,"NA","All",24,"Completed","Phase 1","\t"]
["NCT04448561",4295923,7865505,"Pharmacokinetics (PK) of Morphine in Plasma: Area Under the Concentration Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast)","morphine","ASP8082|morphine|Placebo","Drug|Drug|Drug","substance-related disorders","Opioid Use Disorder","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants",2,"Geometric LS mean ratio",100.79,"NA",null,83.35,121.88,90,null,"NA","All",24,"Completed","Phase 1","\t"]
["NCT04448561",4295924,7865507,"Pharmacokinetics (PK) of ASP8062 in Plasma: Maximum Plasma Concentration (Cmax)","morphine","ASP8082|morphine|Placebo","Drug|Drug|Drug","substance-related disorders","Opioid Use Disorder","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants",2,"Geometric LS mean ratio",94.28,"NA",null,89.29,99.54,90,null,"NA","All",24,"Completed","Phase 1","\t"]
["NCT04448561",4295925,7865508,"Pharmacokinetics (PK) of ASP8062 in Plasma: Area Under the Concentration From Time of Dosing to 24 Hours (AUC24)","morphine","ASP8082|morphine|Placebo","Drug|Drug|Drug","substance-related disorders","Opioid Use Disorder","Parallel Assignment","Interventional","Treatment","Randomized","A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants",2,"Geometric Least square (LS) mean ratio",100.64,"NA",null,98.37,102.96,90,null,"NA","All",24,"Completed","Phase 1","\t"]
["NCT04452435",4295905,7865459,"Oxygen Supplementation at Day 14","NA","C21|Placebo","Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of C21 in Subjects With COVID-19",2,null,"NA",0,"Chi-squared",{"$nulls":4},"NA","All",206,"Completed","Phase 2","\t"]
["NCT04452435",4295906,7865461,"Time on Oxygen Supply (for Those Not Needing Mechanical Invasive or Non-invasive Ventilation)","NA","C21|Placebo","Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of C21 in Subjects With COVID-19",2,null,"NA",0,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",206,"Completed","Phase 2","\t"]
["NCT04452435",4295907,7865462,"Time to Need of Mechanical Invasive or Non-invasive Ventilation","NA","C21|Placebo","Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of C21 in Subjects With COVID-19",2,null,"NA",0,"Log Rank",{"$nulls":4},"NA","All",206,"Completed","Phase 2","\t"]
["NCT04452435",4295908,7865463,"Number of Subjects Not in Need of Mechanical Invasive or Non-invasive Ventilation","NA","C21|Placebo","Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of C21 in Subjects With COVID-19",2,null,"NA",0,"Regression, Logistic",{"$nulls":4},"NA","All",206,"Completed","Phase 2","\t"]
["NCT04452435",4295909,7865464,"Number of Subjects Not in Need of Oxygen Supply","NA","C21|Placebo","Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of C21 in Subjects With COVID-19",2,null,"NA",0,"Regression, Logistic",{"$nulls":4},"NA","All",206,"Completed","Phase 2","\t"]
["NCT04452435",4295910,7865465,"Change From Baseline in Ferritin","NA","C21|Placebo","Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of C21 in Subjects With COVID-19",2,null,"NA",0,"ANCOVA",{"$nulls":4},"NA","All",206,"Completed","Phase 2","\t"]
["NCT04452435",4295911,7865466,"Change From Baseline in CA125","NA","C21|Placebo","Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of C21 in Subjects With COVID-19",2,null,"NA",0,"ANCOVA",{"$nulls":4},"NA","All",206,"Completed","Phase 2","\t"]
["NCT04452435",4295912,7865467,"Change From Baseline in TNF","NA","C21|Placebo","Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of C21 in Subjects With COVID-19",2,null,"NA",0,"ANCOVA",{"$nulls":4},"NA","All",206,"Completed","Phase 2","\t"]
["NCT04452435",4295913,7865468,"Change From Baseline in IL-10","NA","C21|Placebo","Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of C21 in Subjects With COVID-19",2,null,"NA",0,"ANCOVA",{"$nulls":4},"NA","All",206,"Completed","Phase 2","\t"]
["NCT04452435",4295914,7865469,"Change From Baseline in IL-6","NA","C21|Placebo","Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of C21 in Subjects With COVID-19",2,null,"NA",0,"ANCOVA",{"$nulls":4},"NA","All",206,"Completed","Phase 2","\t"]
["NCT04452435",4295915,7865470,"Change From Baseline in Body Temperature","NA","C21|Placebo","Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of C21 in Subjects With COVID-19",2,null,"NA",0,"ANCOVA",{"$nulls":4},"NA","All",206,"Completed","Phase 2","\t"]
["NCT04452435",4295916,7865471,"Change From Baseline in C-reactive Protein (CRP) After Treatment With C21 200 mg Daily Dose (100 mg b.i.d.)","NA","C21|Placebo","Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of C21 in Subjects With COVID-19",2,null,"NA",0,"ANCOVA",{"$nulls":4},"NA","All",206,"Completed","Phase 2","\t"]
["NCT04452435",4295917,7865471,"Change From Baseline in C-reactive Protein (CRP) After Treatment With C21 200 mg Daily Dose (100 mg b.i.d.)","NA","C21|Placebo","Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of C21 in Subjects With COVID-19",2,null,"NA",0,"ANCOVA",{"$nulls":4},"NA","All",206,"Completed","Phase 2","\t"]
["NCT04465422",4295892,7865423,"Occupational Therapy Evaluation Scales Measure","NA","Occupational therapy based on the MOHO theory|Occupational therapy","Behavioral|Behavioral","NA","Occupational Therapy|Psychiatric Rehabilitation","Parallel Assignment","Interventional","Treatment","Randomized","Development and Validation of the Client Centered Occupational Therapy Service Model",2,"Mean Difference (Final Values)",-0.2,0.931,"Mixed Models Analysis",-6.25,6.82,95,"Standard Error of the Mean",3.25,"All",33,"Completed","N/A","\t"]
["NCT04465422",4295891,7865423,"Occupational Therapy Evaluation Scales Measure","NA","Occupational therapy based on the MOHO theory|Occupational therapy","Behavioral|Behavioral","NA","Occupational Therapy|Psychiatric Rehabilitation","Parallel Assignment","Interventional","Treatment","Randomized","Development and Validation of the Client Centered Occupational Therapy Service Model",2,"Mean Difference (Final Values)",-1.4,0.981,"Mixed Models Analysis",-1.73,1.69,95,"Standard Error of the Mean",0.85,"All",33,"Completed","N/A","\t"]
["NCT04465422",4295893,7865423,"Occupational Therapy Evaluation Scales Measure","NA","Occupational therapy based on the MOHO theory|Occupational therapy","Behavioral|Behavioral","NA","Occupational Therapy|Psychiatric Rehabilitation","Parallel Assignment","Interventional","Treatment","Randomized","Development and Validation of the Client Centered Occupational Therapy Service Model",2,"Mean Difference (Final Values)",4.1,0.302,"Mixed Models Analysis",-2.29,7.23,95,"Standard Error of the Mean",2.37,"All",33,"Completed","N/A","\t"]
["NCT04465422",4295894,7865423,"Occupational Therapy Evaluation Scales Measure","NA","Occupational therapy based on the MOHO theory|Occupational therapy","Behavioral|Behavioral","NA","Occupational Therapy|Psychiatric Rehabilitation","Parallel Assignment","Interventional","Treatment","Randomized","Development and Validation of the Client Centered Occupational Therapy Service Model",2,"Mean Difference (Final Values)",-0.3,0.592,"Mixed Models Analysis",-3.9,2.25,95,"Standard Error of the Mean",1.53,"All",33,"Completed","N/A","\t"]
["NCT04465422",4295895,7865424,"Occupational Performance History Interview-II (OPHI-II) Total and Subscale Scores","NA","Occupational therapy based on the MOHO theory|Occupational therapy","Behavioral|Behavioral","NA","Occupational Therapy|Psychiatric Rehabilitation","Parallel Assignment","Interventional","Treatment","Randomized","Development and Validation of the Client Centered Occupational Therapy Service Model",2,"Mean Difference (Final Values)",0.9,0.136,"Mixed Models Analysis",-0.19,1.35,95,"Standard Error of the Mean",0.38,"All",33,"Completed","N/A","\t"]
["NCT04465422",4295897,7865424,"Occupational Performance History Interview-II (OPHI-II) Total and Subscale Scores","NA","Occupational therapy based on the MOHO theory|Occupational therapy","Behavioral|Behavioral","NA","Occupational Therapy|Psychiatric Rehabilitation","Parallel Assignment","Interventional","Treatment","Randomized","Development and Validation of the Client Centered Occupational Therapy Service Model",2,"Mean Difference (Final Values)",0.8,0.019,"Mixed Models Analysis",0.23,2.37,95,"Standard Error of the Mean",0.53,"All",33,"Completed","N/A","\t"]
["NCT04465422",4295898,7865424,"Occupational Performance History Interview-II (OPHI-II) Total and Subscale Scores","NA","Occupational therapy based on the MOHO theory|Occupational therapy","Behavioral|Behavioral","NA","Occupational Therapy|Psychiatric Rehabilitation","Parallel Assignment","Interventional","Treatment","Randomized","Development and Validation of the Client Centered Occupational Therapy Service Model",2,"Mean Difference (Final Values)",3.2,1E-3,"Mixed Models Analysis",1.65,5.55,95,"Standard Error of the Mean",0.97,"All",33,"Completed","N/A","\t"]
["NCT04465422",4295896,7865424,"Occupational Performance History Interview-II (OPHI-II) Total and Subscale Scores","NA","Occupational therapy based on the MOHO theory|Occupational therapy","Behavioral|Behavioral","NA","Occupational Therapy|Psychiatric Rehabilitation","Parallel Assignment","Interventional","Treatment","Randomized","Development and Validation of the Client Centered Occupational Therapy Service Model",2,"Mean Difference (Final Values)",1.4,0.006,"Mixed Models Analysis",0.38,2.11,95,"Standard Error of the Mean",0.43,"All",33,"Completed","N/A","\t"]
["NCT04483011",4295864,7865366,"The Change in Checklist Individual Strength (CIS) Questionnaire Outcome After a 7-day Supplementation With Either RiaGev™ or Comparator.","NA","RiaGev","Dietary Supplement","metabolic syndrome|aging, premature","Metabolic Syndrome|Premature Aging","Crossover Assignment","Interventional","Other","Randomized","The Safety and Efficacy Study of RiaGev in Healthy Adults",2,"Mean Difference (Net)",-2.56,0.049,"Wilcoxon (Mann-Whitney)",{"$nulls":3},"Standard Deviation",5.66,"All",18,"Active, not recruiting","N/A","\t"]
["NCT04483011",4295865,7865366,"The Change in Checklist Individual Strength (CIS) Questionnaire Outcome After a 7-day Supplementation With Either RiaGev™ or Comparator.","NA","RiaGev","Dietary Supplement","metabolic syndrome|aging, premature","Metabolic Syndrome|Premature Aging","Crossover Assignment","Interventional","Other","Randomized","The Safety and Efficacy Study of RiaGev in Healthy Adults",2,"Mean Difference (Net)",-8.33,0.014,"Wilcoxon (Mann-Whitney)",{"$nulls":3},"Standard Deviation",12.99,"All",18,"Active, not recruiting","N/A","\t"]
["NCT04483011",4295866,7865367,"The Waking Salivary Cortisol Level After RiaGev Supplementation","NA","RiaGev","Dietary Supplement","metabolic syndrome|aging, premature","Metabolic Syndrome|Premature Aging","Crossover Assignment","Interventional","Other","Randomized","The Safety and Efficacy Study of RiaGev in Healthy Adults",2,"Mean Difference (Net)",-0.16,0.034,"ANCOVA",{"$nulls":3},"Standard Deviation",0.32,"All",18,"Active, not recruiting","N/A","\t"]
["NCT04483011",4295867,7865368,"Serum High Energy Phosphate (ATP + ADP) Concentration After RiaGev Supplementation","NA","RiaGev","Dietary Supplement","metabolic syndrome|aging, premature","Metabolic Syndrome|Premature Aging","Crossover Assignment","Interventional","Other","Randomized","The Safety and Efficacy Study of RiaGev in Healthy Adults",2,"Mean Difference (Net)",24.01,0.029,"ANCOVA",{"$nulls":3},"Standard Deviation",58.2,"All",18,"Active, not recruiting","N/A","\t"]
["NCT04483011",4295868,7865369,"Serum Glutathione (GSH + GSSG) Change Over Baseline After RiaGev Supplementation","NA","RiaGev","Dietary Supplement","metabolic syndrome|aging, premature","Metabolic Syndrome|Premature Aging","Crossover Assignment","Interventional","Other","Randomized","The Safety and Efficacy Study of RiaGev in Healthy Adults",2,"Mean Difference (Net)",15.55,0.766,"Wilcoxon (Mann-Whitney)",{"$nulls":3},"Standard Deviation",88.62,"All",18,"Active, not recruiting","N/A","\t"]
["NCT04483011",4295869,7865369,"Serum Glutathione (GSH + GSSG) Change Over Baseline After RiaGev Supplementation","NA","RiaGev","Dietary Supplement","metabolic syndrome|aging, premature","Metabolic Syndrome|Premature Aging","Crossover Assignment","Interventional","Other","Randomized","The Safety and Efficacy Study of RiaGev in Healthy Adults",2,"Mean Difference (Net)",70.2,0.003,"Wilcoxon (Mann-Whitney)",{"$nulls":3},"Standard Deviation",123.89,"All",18,"Active, not recruiting","N/A","\t"]
["NCT04483011",4295870,7865370,"Serum Insulin Change After RiaGev Supplementation Assessed by OGTT","NA","RiaGev","Dietary Supplement","metabolic syndrome|aging, premature","Metabolic Syndrome|Premature Aging","Crossover Assignment","Interventional","Other","Randomized","The Safety and Efficacy Study of RiaGev in Healthy Adults",2,"Mean Difference (Net)",-134.79,0.758,"Wilcoxon (Mann-Whitney)",{"$nulls":3},"Standard Deviation",1830.16,"All",18,"Active, not recruiting","N/A","\t"]
["NCT04483011",4295871,7865370,"Serum Insulin Change After RiaGev Supplementation Assessed by OGTT","NA","RiaGev","Dietary Supplement","metabolic syndrome|aging, premature","Metabolic Syndrome|Premature Aging","Crossover Assignment","Interventional","Other","Randomized","The Safety and Efficacy Study of RiaGev in Healthy Adults",2,"Mean Difference (Net)",-135.13,0.793,"Wilcoxon (Mann-Whitney)",{"$nulls":3},"Standard Deviation",2153.66,"All",18,"Active, not recruiting","N/A","\t"]
["NCT04483011",4295872,7865371,"Serum Glucose Change After RiaGev Supplementation Assessed by OGTT","NA","RiaGev","Dietary Supplement","metabolic syndrome|aging, premature","Metabolic Syndrome|Premature Aging","Crossover Assignment","Interventional","Other","Randomized","The Safety and Efficacy Study of RiaGev in Healthy Adults",2,"Mean Difference (Net)",-302.08,0.382,"Wilcoxon (Mann-Whitney)",{"$nulls":3},"Standard Deviation",1427.42,"All",18,"Active, not recruiting","N/A","\t"]
["NCT04483011",4295873,7865371,"Serum Glucose Change After RiaGev Supplementation Assessed by OGTT","NA","RiaGev","Dietary Supplement","metabolic syndrome|aging, premature","Metabolic Syndrome|Premature Aging","Crossover Assignment","Interventional","Other","Randomized","The Safety and Efficacy Study of RiaGev in Healthy Adults",2,"Mean Difference (Net)",-1037.92,0.013,"Wilcoxon (Mann-Whitney)",{"$nulls":3},"Standard Deviation",1590.74,"All",18,"Active, not recruiting","N/A","\t"]
["NCT04483011",4295875,7865372,"Whole Blood NAD+ Plus NADP+ Level Change Over Baseline","NA","RiaGev","Dietary Supplement","metabolic syndrome|aging, premature","Metabolic Syndrome|Premature Aging","Crossover Assignment","Interventional","Other","Randomized","The Safety and Efficacy Study of RiaGev in Healthy Adults",2,"Mean Difference (Net)",0.4,0.64,"Wilcoxon (Mann-Whitney)",{"$nulls":3},"Standard Deviation",3.88,"All",18,"Active, not recruiting","N/A","\t"]
["NCT04483011",4295874,7865372,"Whole Blood NAD+ Plus NADP+ Level Change Over Baseline","NA","RiaGev","Dietary Supplement","metabolic syndrome|aging, premature","Metabolic Syndrome|Premature Aging","Crossover Assignment","Interventional","Other","Randomized","The Safety and Efficacy Study of RiaGev in Healthy Adults",2,"Mean Difference (Net)",4.01,0.014,"ANCOVA",{"$nulls":3},"Standard Deviation",6.57,"All",18,"Active, not recruiting","N/A","\t"]
["NCT04483011",4295876,7865372,"Whole Blood NAD+ Plus NADP+ Level Change Over Baseline","NA","RiaGev","Dietary Supplement","metabolic syndrome|aging, premature","Metabolic Syndrome|Premature Aging","Crossover Assignment","Interventional","Other","Randomized","The Safety and Efficacy Study of RiaGev in Healthy Adults",2,"Mean Difference (Net)",4.01,0.004,"Wilcoxon (Mann-Whitney)",{"$nulls":3},"Standard Deviation",6.57,"All",18,"Active, not recruiting","N/A","\t"]
["NCT04483011",4295878,7865373,"Whole Blood NADP+ Level Change Over Baseline After Supplementation","NA","RiaGev","Dietary Supplement","metabolic syndrome|aging, premature","Metabolic Syndrome|Premature Aging","Crossover Assignment","Interventional","Other","Randomized","The Safety and Efficacy Study of RiaGev in Healthy Adults",2,"Mean Difference (Net)",0.34,0.297,"Wilcoxon (Mann-Whitney)",{"$nulls":3},"Standard Deviation",1.34,"All",18,"Active, not recruiting","N/A","\t"]
["NCT04483011",4295879,7865373,"Whole Blood NADP+ Level Change Over Baseline After Supplementation","NA","RiaGev","Dietary Supplement","metabolic syndrome|aging, premature","Metabolic Syndrome|Premature Aging","Crossover Assignment","Interventional","Other","Randomized","The Safety and Efficacy Study of RiaGev in Healthy Adults",2,"Mean Difference (Net)",1.33,0.008,"Wilcoxon (Mann-Whitney)",{"$nulls":3},"Standard Deviation",1.88,"All",18,"Active, not recruiting","N/A","\t"]
["NCT04483011",4295877,7865373,"Whole Blood NADP+ Level Change Over Baseline After Supplementation","NA","RiaGev","Dietary Supplement","metabolic syndrome|aging, premature","Metabolic Syndrome|Premature Aging","Crossover Assignment","Interventional","Other","Randomized","The Safety and Efficacy Study of RiaGev in Healthy Adults",2,"Mean Difference (Net)",1.33,0.04,"ANCOVA",{"$nulls":3},"Standard Deviation",1.88,"All",18,"Active, not recruiting","N/A","\t"]
["NCT04483011",4295880,7865374,"Whole Blood NAD+ Level Change Over Baseline After Supplementation","NA","RiaGev","Dietary Supplement","metabolic syndrome|aging, premature","Metabolic Syndrome|Premature Aging","Crossover Assignment","Interventional","Other","Randomized","The Safety and Efficacy Study of RiaGev in Healthy Adults",2,"Mean Difference (Net)",2.12,0.044,"ANCOVA",{"$nulls":3},"Standard Deviation",4.72,"All",18,"Active, not recruiting","N/A","\t"]
["NCT04483011",4295881,7865374,"Whole Blood NAD+ Level Change Over Baseline After Supplementation","NA","RiaGev","Dietary Supplement","metabolic syndrome|aging, premature","Metabolic Syndrome|Premature Aging","Crossover Assignment","Interventional","Other","Randomized","The Safety and Efficacy Study of RiaGev in Healthy Adults",2,"Mean Difference (Net)",-0.2,0.265,"Wilcoxon (Mann-Whitney)",{"$nulls":3},"Standard Deviation",2.79,"All",18,"Active, not recruiting","N/A","\t"]
["NCT04483011",4295882,7865374,"Whole Blood NAD+ Level Change Over Baseline After Supplementation","NA","RiaGev","Dietary Supplement","metabolic syndrome|aging, premature","Metabolic Syndrome|Premature Aging","Crossover Assignment","Interventional","Other","Randomized","The Safety and Efficacy Study of RiaGev in Healthy Adults",2,"Mean Difference (Net)",2.12,0.034,"Wilcoxon (Mann-Whitney)",{"$nulls":3},"Standard Deviation",4.72,"All",18,"Active, not recruiting","N/A","\t"]
["NCT04491240",4295858,7865341,"Lactic Acid Dehydrogenase (LDH)","NA","EXO 1 inhalation|EXO 2 inhalation|Placebo inhalation","Drug|Drug|Drug","pneumonia","Covid19|COVID-19|SARS-CoV-2 PNEUMONIA","Parallel Assignment","Interventional","Other","Randomized","Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.",3,"Mean Difference (Net)",239.2,0.004873,"t-test, 2 sided",93.20037,385.1996,95,"Standard Deviation",204.0934,"All",30,"Completed","Phase 1/Phase 2","\t"]
["NCT04491240",4295859,7865341,"Lactic Acid Dehydrogenase (LDH)","NA","EXO 1 inhalation|EXO 2 inhalation|Placebo inhalation","Drug|Drug|Drug","pneumonia","Covid19|COVID-19|SARS-CoV-2 PNEUMONIA","Parallel Assignment","Interventional","Other","Randomized","Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.",3,"Mean Difference (Net)",366.63,0.020921,"t-test, 2 sided",69.77651,663.4835,95,"Standard Deviation",414.9726,"All",30,"Completed","Phase 1/Phase 2","\t"]
["NCT04491240",4295860,7865341,"Lactic Acid Dehydrogenase (LDH)","NA","EXO 1 inhalation|EXO 2 inhalation|Placebo inhalation","Drug|Drug|Drug","pneumonia","Covid19|COVID-19|SARS-CoV-2 PNEUMONIA","Parallel Assignment","Interventional","Other","Randomized","Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.",3,"Mean Difference (Net)",331.52,0.008948,"t-test, 2 sided",105.5938,557.4462,95,"Standard Deviation",315.823,"All",30,"Completed","Phase 1/Phase 2","\t"]
["NCT04491240",4295862,7865342,"C-reactive Protein","NA","EXO 1 inhalation|EXO 2 inhalation|Placebo inhalation","Drug|Drug|Drug","pneumonia","Covid19|COVID-19|SARS-CoV-2 PNEUMONIA","Parallel Assignment","Interventional","Other","Randomized","Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.",3,"Mean Difference (Net)",69.56,0.000953,"t-test, 2 sided",36.88502,102.235,95,"Standard Deviation",45.67648,"All",30,"Completed","Phase 1/Phase 2","\t"]
["NCT04491240",4295861,7865342,"C-reactive Protein","NA","EXO 1 inhalation|EXO 2 inhalation|Placebo inhalation","Drug|Drug|Drug","pneumonia","Covid19|COVID-19|SARS-CoV-2 PNEUMONIA","Parallel Assignment","Interventional","Other","Randomized","Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.",3,"Mean Difference (Net)",53.21,0.002233,"t-test, 2 sided",24.69923,81.72077,95,"Standard Deviation",39.85531,"All",30,"Completed","Phase 1/Phase 2","\t"]
["NCT04491240",4295863,7865342,"C-reactive Protein","NA","EXO 1 inhalation|EXO 2 inhalation|Placebo inhalation","Drug|Drug|Drug","pneumonia","Covid19|COVID-19|SARS-CoV-2 PNEUMONIA","Parallel Assignment","Interventional","Other","Randomized","Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.",3,"Mean Difference (Net)",73.29,0.020875,"t-test, 2 sided",13.97687,132.6031,95,"Standard Deviation",82.91404,"All",30,"Completed","Phase 1/Phase 2","\t"]
["NCT04495712",4295855,7865323,"Ventricular Refractoriness","spironolactone","spironolactone|placebo","Drug|Drug","arrhythmias, cardiac","Ventricular Arrhythmias","Parallel Assignment","Interventional","Treatment","Randomized","Antiarrhythmic Effects of Spironolactone in Patients With ICDs",2,null,"NA",0.42,"t-test, 2 sided",{"$nulls":4},"NA","All",90,"Completed","Phase 4","\t"]
["NCT04495712",4295856,7865324,"All Cause Hospitalization","spironolactone","spironolactone|placebo","Drug|Drug","arrhythmias, cardiac","Ventricular Arrhythmias","Parallel Assignment","Interventional","Treatment","Randomized","Antiarrhythmic Effects of Spironolactone in Patients With ICDs",2,null,"NA",0.07,"Log Rank",{"$nulls":4},"NA","All",90,"Completed","Phase 4","\t"]
["NCT04495712",4295857,7865325,"Time to First Appropriate Implantable Cardioverter Defibrillator (ICD) Therapy","spironolactone","spironolactone|placebo","Drug|Drug","arrhythmias, cardiac","Ventricular Arrhythmias","Parallel Assignment","Interventional","Treatment","Randomized","Antiarrhythmic Effects of Spironolactone in Patients With ICDs",2,null,"NA",0.71,"Log Rank",{"$nulls":4},"NA","All",90,"Completed","Phase 4","\t"]
["NCT04502979",4295853,7865305,"Mean Infant Caloric Intake Compared to Estimated Energy Requirements","NA","Responsive Feeding Training","Behavioral","pediatric obesity|obesity","Feeding Behavior|Infant Obesity|Parenting","Parallel Assignment","Interventional","Prevention","Randomized","Learning to Love Mealtime Together",2,"Mean Difference (Net)",-121.16,0.04,"Mixed Models Analysis",-252.73,10.41,95,"Standard Error of the Mean",65.73,"All",71,"Completed","N/A","\t"]
["NCT04502979",4295854,7865306,"Infant Weight-for-Length Z Scores","NA","Responsive Feeding Training","Behavioral","pediatric obesity|obesity","Feeding Behavior|Infant Obesity|Parenting","Parallel Assignment","Interventional","Prevention","Randomized","Learning to Love Mealtime Together",2,"Mean Difference (Net)",0.31,0.07,"Mixed Models Analysis",-0.11,0.73,95,"Standard Error of the Mean",0.21,"All",71,"Completed","N/A","\t"]
["NCT04512482",4295814,7865270,"Composite Plaque Score","NA","Bromelain|Powdered sugar","Drug|Other","dental caries|dental plaque","Dental Caries|Dental Plaque","Crossover Assignment","Interventional","Supportive Care","Randomized","Evaluation of Oral Plaque Removal Utilizing an Adjunct Enzyme Pre-rinse",2,null,"NA",0.044,"ANOVA",{"$nulls":4},"NA","All",46,"Completed","Phase 2","\t"]
["NCT04523831",4295810,7865248,"Number of Patients Remain Persistently Positive for RT-PCR of Covid-19","doxycycline|ivermectin","Ivermectin and Doxycycline|Standard of care","Drug|Drug","NA","Covid19","Parallel Assignment","Interventional","Treatment","Randomized","Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection",2,"Cox Proportional Hazard",0.58,1E-3,"Regression, Logistic",0.44,0.81,95,null,"NA","All",400,"Completed","Phase 3","\t"]
["NCT04523831",4295811,7865249,"Number of Patients Having Clinical Deterioration.","doxycycline|ivermectin","Ivermectin and Doxycycline|Standard of care","Drug|Drug","NA","Covid19","Parallel Assignment","Interventional","Treatment","Randomized","Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection",2,"Cox Proportional Hazard",0.45,0.013,"Regression, Logistic",0.23,0.85,95,null,"NA","All",400,"Completed","Phase 3","\t"]
["NCT04523831",4295812,7865250,"Number of Participants With Late Clinical Recovery","doxycycline|ivermectin","Ivermectin and Doxycycline|Standard of care","Drug|Drug","NA","Covid19","Parallel Assignment","Interventional","Treatment","Randomized","Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection",2,"Cox Proportional Hazard",0.51,0.004,"Regression, Logistic",0.32,0.8,95,null,"NA","All",400,"Completed","Phase 3","\t"]
["NCT04523831",4295813,7865251,"Number of Patients With Early Clinical Improvement","doxycycline|ivermectin","Ivermectin and Doxycycline|Standard of care","Drug|Drug","NA","Covid19","Parallel Assignment","Interventional","Treatment","Randomized","Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection",2,"Cox Proportional Hazard",0.53,0.03,"Regression, Linear",0.3,0.96,95,null,"NA","All",400,"Completed","Phase 3","\t"]
["NCT04533204",4295808,7865228,"Change in Accuracy (vs. Baseline) on Novel Object Location Associations","NA","mnemonic strategy training|spaced retrieval training","Behavioral|Behavioral","cognitive dysfunction","Mild Cognitive Impairment","Parallel Assignment","Interventional","Treatment","Randomized","Mnemonic Strategy Versus Spaced Retrieval Training in Those With Mild Cognitive Impairment",2,"Mean Difference (Final Values)",2.33,0.004,"Mixed Models Analysis",0.75,3.91,95,null,"NA","All",59,"Completed","N/A","\t"]
["NCT04533204",4295809,7865229,"Percent of Correct Object Location Associations Assessed up to 1 Month Post-treatment","NA","mnemonic strategy training|spaced retrieval training","Behavioral|Behavioral","cognitive dysfunction","Mild Cognitive Impairment","Parallel Assignment","Interventional","Treatment","Randomized","Mnemonic Strategy Versus Spaced Retrieval Training in Those With Mild Cognitive Impairment",2,"Mean Difference (Final Values)",18.47,1E-3,"Mixed Models Analysis",12.28,24.67,95,null,"NA","All",59,"Completed","N/A","\t"]
["NCT04540627",4295800,7865186,"Peak Symptom Scores","palivizumab","Palivizumab|Placebo|RSV-A Memphis 37b virus","Drug|Drug|Other","NA","Healthy Adult Participants","Parallel Assignment","Interventional","Other","Randomized","Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV",2,null,"NA",0.0403,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1","\t"]
["NCT04540627",4295801,7865188,"Viral Shedding of RSV-A Memphis 37b in Nasal Samples in Terms of Peak Viral Load, for Double-blind Palivizumab or Placebo (Part 2).","palivizumab","Palivizumab|Placebo|RSV-A Memphis 37b virus","Drug|Drug|Other","NA","Healthy Adult Participants","Parallel Assignment","Interventional","Other","Randomized","Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV",2,null,"NA",0.4868,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1","\t"]
["NCT04540627",4295802,7865193,"Cell Culture Peak Viral Load for Double-blind Palivizumab or Placebo (Part 2).","palivizumab","Palivizumab|Placebo|RSV-A Memphis 37b virus","Drug|Drug|Other","NA","Healthy Adult Participants","Parallel Assignment","Interventional","Other","Randomized","Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV",2,null,"NA",0.2431,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1","\t"]
["NCT04540627",4295803,7865194,"Area Under the Viral Load-time Curve (VL-AUC) as Determined by Cell Culture on Nasal Samples, for Double-blind Palivizumab (Part 2).","palivizumab","Palivizumab|Placebo|RSV-A Memphis 37b virus","Drug|Drug|Other","NA","Healthy Adult Participants","Parallel Assignment","Interventional","Other","Randomized","Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV",2,null,"NA",0.2681,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1","\t"]
["NCT04540627",4295804,7865195,"qRT-PCR Peak Viral Load for Double-blind Palivizumab or Placebo (Part 2).","palivizumab","Palivizumab|Placebo|RSV-A Memphis 37b virus","Drug|Drug|Other","NA","Healthy Adult Participants","Parallel Assignment","Interventional","Other","Randomized","Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV",2,null,"NA",0.4868,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1","\t"]
["NCT04540627",4295805,7865196,"Area Under the Viral Load-time Curve (VL-AUC) as Determined by Polymerase Chain Reaction (qRT-PCR) on Nasal Samples, for Double-blind Palivizumab or Placebo (Part 2).","palivizumab","Palivizumab|Placebo|RSV-A Memphis 37b virus","Drug|Drug|Other","NA","Healthy Adult Participants","Parallel Assignment","Interventional","Other","Randomized","Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV",2,null,"NA",0.5802,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1","\t"]
["NCT04542694",4295793,7865161,"Rate of Transfer to the Intensive Care Unit","NA","Favipiravir|Standard of care","Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19",2,null,"NA",0.4975,"Chi-squared",{"$nulls":4},"NA","All",200,"Completed","Phase 3","\t"]
["NCT04542694",4295794,7865162,"Change in the Level of Lung Damage According to CT","NA","Favipiravir|Standard of care","Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19",2,null,"NA",0.1953,"Chi-squared",{"$nulls":4},"NA","All",200,"Completed","Phase 3","\t"]
["NCT04542694",4295795,7865163,"Time Before the End of Fever","NA","Favipiravir|Standard of care","Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19",2,"Median Difference (Final Values)",1.55,0.052,"Log Rank",{"$nulls":4},"NA","All",200,"Completed","Phase 3","\t"]
["NCT04542694",4295796,7865164,"Rate of Viral Elimination by Day 10","NA","Favipiravir|Standard of care","Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19",2,"The difference in percentages",22.5,0.00016,"Chi-squared",{"$nulls":4},"NA","All",200,"Completed","Phase 3","\t"]
["NCT04542694",4295797,7865165,"Time to Clinical Improvement","NA","Favipiravir|Standard of care","Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19",2,"The difference in days",4,{"v":1E-4,"d":"1.00E-04"},"Log Rank",{"$nulls":4},"NA","All",200,"Completed","Phase 3","\t"]
["NCT04542694",4295798,7865166,"Rate of Clinical Status Improvement","NA","Favipiravir|Standard of care","Drug|Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19",2,"The difference in proportions",0.1313,0.0372,"Chi-squared",-0.0004,0.2367,95,null,"NA","All",200,"Completed","Phase 3","\t"]
["NCT04544787",4295782,7865145,"Seroprotection Rate After a Single Dose of Novel OPV2 in Former OPV Recipients","vaccines","vaccination with novel OPV2 candidate 1 vaccine|vaccination with novel OPV2 candidate 2 vaccine|Placebo (Sirupus simplex, Propylenglycolum,. European Pharmacopoeia (Ph.Eur.))","Biological|Biological|Biological","poliomyelitis","Poliomyelitis","Parallel Assignment","Interventional","Prevention","Randomized","A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates",7,"Difference",2,"NA",null,-1.9,7,95,null,"NA","All",250,"Completed","Phase 2","\t"]
["NCT04544787",4295781,7865145,"Seroprotection Rate After a Single Dose of Novel OPV2 in Former OPV Recipients","vaccines","vaccination with novel OPV2 candidate 1 vaccine|vaccination with novel OPV2 candidate 2 vaccine|Placebo (Sirupus simplex, Propylenglycolum,. European Pharmacopoeia (Ph.Eur.))","Biological|Biological|Biological","poliomyelitis","Poliomyelitis","Parallel Assignment","Interventional","Prevention","Randomized","A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates",7,"Difference",2,"NA",null,-1.8,7,95,null,"NA","All",250,"Completed","Phase 2","\t"]
["NCT04544787",4295783,7865146,"Number of Participants With Serious Adverse Events (SAEs) and Severe Adverse Events","vaccines","vaccination with novel OPV2 candidate 1 vaccine|vaccination with novel OPV2 candidate 2 vaccine|Placebo (Sirupus simplex, Propylenglycolum,. European Pharmacopoeia (Ph.Eur.))","Biological|Biological|Biological","poliomyelitis","Poliomyelitis","Parallel Assignment","Interventional","Prevention","Randomized","A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates",7,null,"NA",0.296,"Fisher Exact",{"$nulls":4},"NA","All",250,"Completed","Phase 2","\t"]
["NCT04544787",4295792,7865146,"Number of Participants With Serious Adverse Events (SAEs) and Severe Adverse Events","vaccines","vaccination with novel OPV2 candidate 1 vaccine|vaccination with novel OPV2 candidate 2 vaccine|Placebo (Sirupus simplex, Propylenglycolum,. European Pharmacopoeia (Ph.Eur.))","Biological|Biological|Biological","poliomyelitis","Poliomyelitis","Parallel Assignment","Interventional","Prevention","Randomized","A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates",7,null,"NA",0.7209,"Fisher Exact",{"$nulls":4},"NA","All",250,"Completed","Phase 2","\t"]
["NCT04544787",4295789,7865146,"Number of Participants With Serious Adverse Events (SAEs) and Severe Adverse Events","vaccines","vaccination with novel OPV2 candidate 1 vaccine|vaccination with novel OPV2 candidate 2 vaccine|Placebo (Sirupus simplex, Propylenglycolum,. European Pharmacopoeia (Ph.Eur.))","Biological|Biological|Biological","poliomyelitis","Poliomyelitis","Parallel Assignment","Interventional","Prevention","Randomized","A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates",7,null,"NA",0.3083,"Fisher Exact",{"$nulls":4},"NA","All",250,"Completed","Phase 2","\t"]
["NCT04544787",4295784,7865146,"Number of Participants With Serious Adverse Events (SAEs) and Severe Adverse Events","vaccines","vaccination with novel OPV2 candidate 1 vaccine|vaccination with novel OPV2 candidate 2 vaccine|Placebo (Sirupus simplex, Propylenglycolum,. European Pharmacopoeia (Ph.Eur.))","Biological|Biological|Biological","poliomyelitis","Poliomyelitis","Parallel Assignment","Interventional","Prevention","Randomized","A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates",7,null,"NA",0.1571,"Fisher Exact",{"$nulls":4},"NA","All",250,"Completed","Phase 2","\t"]
["NCT04544787",4295785,7865146,"Number of Participants With Serious Adverse Events (SAEs) and Severe Adverse Events","vaccines","vaccination with novel OPV2 candidate 1 vaccine|vaccination with novel OPV2 candidate 2 vaccine|Placebo (Sirupus simplex, Propylenglycolum,. European Pharmacopoeia (Ph.Eur.))","Biological|Biological|Biological","poliomyelitis","Poliomyelitis","Parallel Assignment","Interventional","Prevention","Randomized","A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates",7,null,"NA",1,"Fisher Exact",{"$nulls":4},"NA","All",250,"Completed","Phase 2","\t"]
["NCT04544787",4295786,7865146,"Number of Participants With Serious Adverse Events (SAEs) and Severe Adverse Events","vaccines","vaccination with novel OPV2 candidate 1 vaccine|vaccination with novel OPV2 candidate 2 vaccine|Placebo (Sirupus simplex, Propylenglycolum,. European Pharmacopoeia (Ph.Eur.))","Biological|Biological|Biological","poliomyelitis","Poliomyelitis","Parallel Assignment","Interventional","Prevention","Randomized","A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates",7,null,"NA",1,"Fisher Exact",{"$nulls":4},"NA","All",250,"Completed","Phase 2","\t"]
["NCT04544787",4295787,7865146,"Number of Participants With Serious Adverse Events (SAEs) and Severe Adverse Events","vaccines","vaccination with novel OPV2 candidate 1 vaccine|vaccination with novel OPV2 candidate 2 vaccine|Placebo (Sirupus simplex, Propylenglycolum,. European Pharmacopoeia (Ph.Eur.))","Biological|Biological|Biological","poliomyelitis","Poliomyelitis","Parallel Assignment","Interventional","Prevention","Randomized","A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates",7,null,"NA",1,"Fisher Exact",{"$nulls":4},"NA","All",250,"Completed","Phase 2","\t"]
["NCT04544787",4295791,7865146,"Number of Participants With Serious Adverse Events (SAEs) and Severe Adverse Events","vaccines","vaccination with novel OPV2 candidate 1 vaccine|vaccination with novel OPV2 candidate 2 vaccine|Placebo (Sirupus simplex, Propylenglycolum,. European Pharmacopoeia (Ph.Eur.))","Biological|Biological|Biological","poliomyelitis","Poliomyelitis","Parallel Assignment","Interventional","Prevention","Randomized","A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates",7,null,"NA",0.7209,"Fisher Exact",{"$nulls":4},"NA","All",250,"Completed","Phase 2","\t"]
["NCT04544787",4295788,7865146,"Number of Participants With Serious Adverse Events (SAEs) and Severe Adverse Events","vaccines","vaccination with novel OPV2 candidate 1 vaccine|vaccination with novel OPV2 candidate 2 vaccine|Placebo (Sirupus simplex, Propylenglycolum,. European Pharmacopoeia (Ph.Eur.))","Biological|Biological|Biological","poliomyelitis","Poliomyelitis","Parallel Assignment","Interventional","Prevention","Randomized","A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates",7,null,"NA",0.4975,"Fisher Exact",{"$nulls":4},"NA","All",250,"Completed","Phase 2","\t"]
["NCT04544787",4295790,7865146,"Number of Participants With Serious Adverse Events (SAEs) and Severe Adverse Events","vaccines","vaccination with novel OPV2 candidate 1 vaccine|vaccination with novel OPV2 candidate 2 vaccine|Placebo (Sirupus simplex, Propylenglycolum,. European Pharmacopoeia (Ph.Eur.))","Biological|Biological|Biological","poliomyelitis","Poliomyelitis","Parallel Assignment","Interventional","Prevention","Randomized","A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates",7,null,"NA",0.3769,"Fisher Exact",{"$nulls":4},"NA","All",250,"Completed","Phase 2","\t"]
["NCT04560374",4295777,7865114,"Neonate Infant Pain Scale Score","NA","crochet octopus","Device","pain, procedural","Procedural Pain","Parallel Assignment","Interventional","Supportive Care","Randomized","Crochet Octopus in The Process of Heel Lance in Neonates",2,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",100,"Completed","N/A","\t"]
["NCT04574999",4295771,7865091,"Change From Baseline to Week 3 of the Vaginal pH After the 3-week Observation Period","NA","Estriol|Placebo","Drug|Other","atrophy","Vaginal Atrophy","Parallel Assignment","Interventional","Treatment","Randomized","Study to Determine Efficacy & Safety of a Low Concentration Estriol (0.005%) in Postmenopausal Vaginal Atrophy.",2,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",167,"Completed","Phase 3","\t"]
["NCT04574999",4295772,7865092,"Change From Baseline to Week 3 in Maturation Value (MV) After 3 Weeks of Treatment","NA","Estriol|Placebo","Drug|Other","atrophy","Vaginal Atrophy","Parallel Assignment","Interventional","Treatment","Randomized","Study to Determine Efficacy & Safety of a Low Concentration Estriol (0.005%) in Postmenopausal Vaginal Atrophy.",2,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",167,"Completed","Phase 3","\t"]
["NCT04574999",4295773,7865094,"Change From Baseline to Week 12 of the Vaginal pH After the 12-week Observation Period","NA","Estriol|Placebo","Drug|Other","atrophy","Vaginal Atrophy","Parallel Assignment","Interventional","Treatment","Randomized","Study to Determine Efficacy & Safety of a Low Concentration Estriol (0.005%) in Postmenopausal Vaginal Atrophy.",2,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",167,"Completed","Phase 3","\t"]
["NCT04574999",4295774,7865095,"Change From Baseline to Week 12 in Maturation Value (MV) After 12 Weeks of Treatment","NA","Estriol|Placebo","Drug|Other","atrophy","Vaginal Atrophy","Parallel Assignment","Interventional","Treatment","Randomized","Study to Determine Efficacy & Safety of a Low Concentration Estriol (0.005%) in Postmenopausal Vaginal Atrophy.",2,null,"NA",1E-3,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","Female",167,"Completed","Phase 3","\t"]
["NCT04608500",4295760,7865050,"Percentage of Participants Achieving IGA Treatment Success at Week 4 and Week 8","minocycline","FMX103 minocycline foam 1.5%|Vehicle foam","Drug|Drug","facies|rosacea","Facial Papulopustular Rosacea","Parallel Assignment","Interventional","Treatment","Randomized","A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea",2,"Risk Ratio (RR)",1.715,0.0114,"Cochran-Mantel-Haenszel",1.129,2.605,95,null,"NA","All",771,"Completed","Phase 3","\t"]
["NCT04608500",4295759,7865050,"Percentage of Participants Achieving IGA Treatment Success at Week 4 and Week 8","minocycline","FMX103 minocycline foam 1.5%|Vehicle foam","Drug|Drug","facies|rosacea","Facial Papulopustular Rosacea","Parallel Assignment","Interventional","Treatment","Randomized","A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea",2,"Risk Ratio (RR)",1.319,0.0061,"Cochran-Mantel-Haenszel",1.082,1.607,95,null,"NA","All",771,"Completed","Phase 3","\t"]
["NCT04608500",4295761,7865051,"The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Counts at Week 4 and Week 8","minocycline","FMX103 minocycline foam 1.5%|Vehicle foam","Drug|Drug","facies|rosacea","Facial Papulopustular Rosacea","Parallel Assignment","Interventional","Treatment","Randomized","A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea",2,"Mean Difference (Final Values)",5.07,{"v":1E-4,"d":"1.00E-04"},"ANCOVA",3.52,6.63,95,"Standard Error of the Mean",0.793,"All",771,"Completed","Phase 3","\t"]
["NCT04608500",4295762,7865051,"The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Counts at Week 4 and Week 8","minocycline","FMX103 minocycline foam 1.5%|Vehicle foam","Drug|Drug","facies|rosacea","Facial Papulopustular Rosacea","Parallel Assignment","Interventional","Treatment","Randomized","A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea",2,"Mean Difference (Final Values)",4.38,{"v":1E-4,"d":"1.00E-04"},"ANCOVA",2.77,5.99,95,"Standard Error of the Mean",0.821,"All",771,"Completed","Phase 3","\t"]
["NCT04608500",4295763,7865052,"The Percent Change From Day 0/Baseline in Inflammatory Lesion Count at Week 12","minocycline","FMX103 minocycline foam 1.5%|Vehicle foam","Drug|Drug","facies|rosacea","Facial Papulopustular Rosacea","Parallel Assignment","Interventional","Treatment","Randomized","A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea",2,"Mean Difference (Final Values)",11.3,{"v":1E-4,"d":"1.00E-04"},"ANCOVA",6.05,16.54,95,"Standard Error of the Mean",2.672,"All",771,"Completed","Phase 3","\t"]
["NCT04608500",4295764,7865053,"Percentage of Participants Achieving IGA Treatment Success of at Least 2 Grades at Week 12","minocycline","FMX103 minocycline foam 1.5%|Vehicle foam","Drug|Drug","facies|rosacea","Facial Papulopustular Rosacea","Parallel Assignment","Interventional","Treatment","Randomized","A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea",2,"Risk Ratio (RR)",1.193,0.0189,"Cochran-Mantel-Haenszel",1.024,1.39,95,null,"NA","All",771,"Completed","Phase 3","\t"]
["NCT04608500",4295765,7865054,"Percentage of Participants Achieving Investigator Global Assessments (IGA) Treatment Success at Week 12","minocycline","FMX103 minocycline foam 1.5%|Vehicle foam","Drug|Drug","facies|rosacea","Facial Papulopustular Rosacea","Parallel Assignment","Interventional","Treatment","Randomized","A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea",2,"Risk Ratio (RR)",1.263,0.0077,"Cochran-Mantel-Haenszel",1.064,1.499,95,null,"NA","All",771,"Completed","Phase 3","\t"]
["NCT04608500",4295766,7865055,"The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Count at Week 12","minocycline","FMX103 minocycline foam 1.5%|Vehicle foam","Drug|Drug","facies|rosacea","Facial Papulopustular Rosacea","Parallel Assignment","Interventional","Treatment","Randomized","A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea",2,"Mean Difference (Final Values)",3.85,{"v":1E-4,"d":"1.00E-04"},"ANCOVA",2.16,5.54,95,"Standard Error of the Mean",0.861,"All",771,"Completed","Phase 3","\t"]
["NCT04633564",4295752,7865017,"Primary Efficacy Analysis of Overall Response Rate ( ORR) of MYL-1402O as Compared to Avastin","bevacizumab","Bevacizumab as MYL-1402O|Bevacizumab as Avastin","Biological|Biological","NA","NSCLC Stage IV","Parallel Assignment","Interventional","Treatment","Randomized","MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC",2,"Risk Ratio (RR)",0.96,"NA",null,0.83,1.12,90,null,"NA","All",671,"Completed","Phase 3","\t"]
["NCT04646109",4295730,7864962,"Rate of COVID-19 Polymerase Chain Reaction (PCR) Test Negativity","ivermectin|azithromycin|hydroxychloroquine","Ivermectin","Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Ivermectin for Severe COVID-19 Management",2,null,"NA",0.01,"Chi-squared",{"$nulls":4},"NA","All",66,"Completed","Phase 3","\t"]
["NCT04646109",4295731,7864963,"Changes in Serum D-dimer Levels","ivermectin|azithromycin|hydroxychloroquine","Ivermectin","Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Ivermectin for Severe COVID-19 Management",2,null,"NA",0.03,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",66,"Completed","Phase 3","\t"]
["NCT04646109",4295732,7864964,"Changes in Serum Ferritin Levels","ivermectin|azithromycin|hydroxychloroquine","Ivermectin","Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Ivermectin for Severe COVID-19 Management",2,null,"NA",0.005,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",66,"Completed","Phase 3","\t"]
["NCT04646109",4295733,7864965,"Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL/L)","ivermectin|azithromycin|hydroxychloroquine","Ivermectin","Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Ivermectin for Severe COVID-19 Management",2,null,"NA",0.56,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",66,"Completed","Phase 3","\t"]
["NCT04646109",4295734,7864966,"Changes in Serum Lymphocyte Counts","ivermectin|azithromycin|hydroxychloroquine","Ivermectin","Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Ivermectin for Severe COVID-19 Management",2,null,"NA",0.24,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",66,"Completed","Phase 3","\t"]
["NCT04646109",4295735,7864967,"Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2)","ivermectin|azithromycin|hydroxychloroquine","Ivermectin","Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Ivermectin for Severe COVID-19 Management",2,null,"NA",0.39,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",66,"Completed","Phase 3","\t"]
["NCT04646109",4295736,7864968,"Changes in Oxygen Saturation (SpO2) Values","ivermectin|azithromycin|hydroxychloroquine","Ivermectin","Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Ivermectin for Severe COVID-19 Management",2,null,"NA",0.03,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",66,"Completed","Phase 3","\t"]
["NCT04646109",4295737,7864969,"Mortality","ivermectin|azithromycin|hydroxychloroquine","Ivermectin","Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Ivermectin for Severe COVID-19 Management",2,null,"NA",0.37,"Chi-squared",{"$nulls":4},"NA","All",66,"Completed","Phase 3","\t"]
["NCT04646109",4295738,7864970,"Number of Participants With Clinical Response","ivermectin|azithromycin|hydroxychloroquine","Ivermectin","Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Ivermectin for Severe COVID-19 Management",2,null,"NA",0.1,"Chi-squared",{"$nulls":4},"NA","All",66,"Completed","Phase 3","\t"]
["NCT04646109",4295739,7864973,"Changes in Serum D-dimer Levels","ivermectin|azithromycin|hydroxychloroquine","Ivermectin","Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Ivermectin for Severe COVID-19 Management",2,null,"NA",0.22,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",66,"Completed","Phase 3","\t"]
["NCT04646109",4295740,7864974,"Changes in Serum Ferritin Levels","ivermectin|azithromycin|hydroxychloroquine","Ivermectin","Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Ivermectin for Severe COVID-19 Management",2,null,"NA",0.12,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",66,"Completed","Phase 3","\t"]
["NCT04646109",4295741,7864975,"Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL/L)","ivermectin|azithromycin|hydroxychloroquine","Ivermectin","Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Ivermectin for Severe COVID-19 Management",2,null,"NA",0.37,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",66,"Completed","Phase 3","\t"]
["NCT04646109",4295742,7864976,"Changes in Serum Lymphocyte Counts","ivermectin|azithromycin|hydroxychloroquine","Ivermectin","Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Ivermectin for Severe COVID-19 Management",2,null,"NA",0.15,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",66,"Completed","Phase 3","\t"]
["NCT04646109",4295743,7864977,"Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2)","ivermectin|azithromycin|hydroxychloroquine","Ivermectin","Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Ivermectin for Severe COVID-19 Management",2,null,"NA",0.68,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",66,"Completed","Phase 3","\t"]
["NCT04646109",4295744,7864978,"Changes in Oxygen Saturation (SpO2) Values","ivermectin|azithromycin|hydroxychloroquine","Ivermectin","Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Ivermectin for Severe COVID-19 Management",2,null,"NA",0.14,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",66,"Completed","Phase 3","\t"]
["NCT04646109",4295745,7864979,"Number of Participants With Clinical Response","ivermectin|azithromycin|hydroxychloroquine","Ivermectin","Drug","NA","COVID-19","Parallel Assignment","Interventional","Treatment","Randomized","Ivermectin for Severe COVID-19 Management",2,null,"NA",0.43,"Chi-squared",{"$nulls":4},"NA","All",66,"Completed","Phase 3","\t"]
["NCT04673214",4295725,7864935,"Number of Participants Who Were Alive and Had COVID-19 Symptoms by Type of Therapy During a 14-day Follow-up","acetaminophen|azithromycin|ivermectin","Azithromycin / Ivermectin / Ribaroxaban / Paracetamol|Azithromycin / Ribaroxaban / Paracetamol","Drug|Drug","NA","Covid19","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment",2,null,"NA",0.05,"Wilcoxon (Gehan) statistical test",{"$nulls":4},"NA","All",62,"Recruiting","Phase 3","\t"]
["NCT04673214",4295726,7864936,"Average Days of COVID-19 Symptoms Under Treatment of Early Intervention Due to Outcome in UMF 13 and 20 of the IMSS","acetaminophen|azithromycin|ivermectin","Azithromycin / Ivermectin / Ribaroxaban / Paracetamol|Azithromycin / Ribaroxaban / Paracetamol","Drug|Drug","NA","Covid19","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment",2,null,"NA",0.05,"t-test, 2 sided",{"$nulls":4},"NA","All",62,"Recruiting","Phase 3","\t"]
["NCT04673214",4295727,7864937,"Crosstabulated Outcome in Modification of the Evolution Clinical vs Fails Therapeutic by Type of Treatment in Patients With COVID-19 UMF 13 and UMF 20 of the IMSS","acetaminophen|azithromycin|ivermectin","Azithromycin / Ivermectin / Ribaroxaban / Paracetamol|Azithromycin / Ribaroxaban / Paracetamol","Drug|Drug","NA","Covid19","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment",2,null,"NA",0.05,"Chi-squared",{"$nulls":4},"NA","All",62,"Recruiting","Phase 3","\t"]
["NCT04673214",4295728,7864938,"Average Days in COVID-19 Symptoms by Type of Therapy in the UMF 20 and UMF 13 of the IMSS.","acetaminophen|azithromycin|ivermectin","Azithromycin / Ivermectin / Ribaroxaban / Paracetamol|Azithromycin / Ribaroxaban / Paracetamol","Drug|Drug","NA","Covid19","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment",2,null,"NA",0.05,"t-test, 2 sided",{"$nulls":4},"NA","All",62,"Recruiting","Phase 3","\t"]
["NCT04673214",4295729,7864938,"Average Days in COVID-19 Symptoms by Type of Therapy in the UMF 20 and UMF 13 of the IMSS.","acetaminophen|azithromycin|ivermectin","Azithromycin / Ivermectin / Ribaroxaban / Paracetamol|Azithromycin / Ribaroxaban / Paracetamol","Drug|Drug","NA","Covid19","Parallel Assignment","Interventional","Treatment","Randomized","Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment",2,null,"NA",0.05,"Chi-squared",{"$nulls":4},"NA","All",62,"Recruiting","Phase 3","\t"]
["NCT04688346",4295724,7864921,"Hemostasis Efficacy","epinephrine","HemeRX epinephrine pellets","Drug","NA","Epinephrine Causing Adverse Effects in Therapeutic Use","Crossover Assignment","Interventional","Other","Randomized","Cardiovascular Effects of Racemic Epinephrine Pellets",2,"Mean Difference (Final Values)",1,0.05,"t-test, 2 sided",{"$nulls":4},"NA","All",13,"Completed","Phase 2/Phase 3","\t"]
["NCT04728594",4295723,7864876,"Number of Employees Who Scheduled Vaccination Appointments After 3 Days","NA","Social Proof|Reframing|Scarcity Message","Behavioral|Behavioral|Behavioral","NA","Communication|Vaccination Refusal","Parallel Assignment","Interventional","Prevention","Randomized","Emails Promoting COVID-19 Vaccination Among Healthcare Workers",3,"Odds Ratio (OR)",2.11,1E-3,"Regression, Logistic",1.65,2.69,95,null,"NA","All",9566,"Completed","N/A","\t"]
["NCT04728594",4295721,7864876,"Number of Employees Who Scheduled Vaccination Appointments After 3 Days","NA","Social Proof|Reframing|Scarcity Message","Behavioral|Behavioral|Behavioral","NA","Communication|Vaccination Refusal","Parallel Assignment","Interventional","Prevention","Randomized","Emails Promoting COVID-19 Vaccination Among Healthcare Workers",3,"Odds Ratio (OR)",1.07,1E-3,"Regression, Logistic",0.88,1.3,95,null,"NA","All",9566,"Completed","N/A","\t"]
["NCT04728594",4295722,7864876,"Number of Employees Who Scheduled Vaccination Appointments After 3 Days","NA","Social Proof|Reframing|Scarcity Message","Behavioral|Behavioral|Behavioral","NA","Communication|Vaccination Refusal","Parallel Assignment","Interventional","Prevention","Randomized","Emails Promoting COVID-19 Vaccination Among Healthcare Workers",3,"Odds Ratio (OR)",2.26,1E-3,"Regression, Logistic",1.77,2.87,95,null,"NA","All",9566,"Completed","N/A","\t"]
["NCT04737278",4295664,7864824,"Copper","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.03,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295662,7864824,"Copper","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.89,"t-test, 2 sided",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295663,7864824,"Copper","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.1,"t-test, 2 sided",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295666,7864825,"GGT","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.01,"Wilcoxon Signed Rank",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295667,7864825,"GGT","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.11,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295665,7864825,"GGT","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.97,"Wilcoxon Signed-Rank",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295669,7864826,"AST","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.24,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295670,7864826,"AST","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.62,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295668,7864826,"AST","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.11,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295671,7864827,"ALT","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.8,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295673,7864827,"ALT","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.95,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295672,7864827,"ALT","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.4,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295675,7864828,"Bilirubin","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.72,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295674,7864828,"Bilirubin","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.35,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295676,7864828,"Bilirubin","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.36,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295678,7864829,"Chloride","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.003,"t-test, 2 sided",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295679,7864829,"Chloride","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.87,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295677,7864829,"Chloride","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.003,"t-test, 2 sided",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295680,7864830,"Potassium","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",1E-3,"t-test, 2 sided",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295682,7864830,"Potassium","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.58,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295681,7864830,"Potassium","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",1E-3,"t-test, 2 sided",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295683,7864831,"Sodium","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.01,"t-test, 2 sided",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295685,7864831,"Sodium","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.23,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295684,7864831,"Sodium","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.18,"t-test, 2 sided",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295686,7864832,"eGFR","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.01,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295687,7864833,"Creatinine","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.38,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295688,7864834,"Urea","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.51,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295691,7864835,"Glucose","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.06,"t-test, 2 sided",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295690,7864835,"Glucose","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.04,"t-test, 2 sided",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295689,7864835,"Glucose","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.92,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295692,7864836,"NLR","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.025,"ANOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295693,7864837,"Basophil","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.98,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295694,7864838,"Eosinophil","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.11,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295695,7864839,"Monocyte","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.24,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295696,7864839,"Monocyte","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.47,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295697,7864840,"Lymphocyte","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.01,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295698,7864841,"Neutrophils","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.05,"t-test, 2 sided",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295699,7864841,"Neutrophils","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.03,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295700,7864842,"Platelets","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.02,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295701,7864843,"RDW","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.06,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295702,7864844,"MCHC","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.48,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295703,7864845,"MCH","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.01,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295704,7864846,"MCV","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.01,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295705,7864847,"RBC","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.05,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295706,7864848,"WBC","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.63,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295707,7864849,"Hematocrit","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.84,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295708,7864850,"Hemoglobin","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.48,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295709,7864851,"Systolic Blood Pressure","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.31,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295710,7864852,"Diastolic Blood Pressure","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.01,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295711,7864853,"Heart Rate","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.54,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295713,7864854,"Cognition","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.54,"Fisher Exact",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295712,7864854,"Cognition","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.14,"Fisher Exact",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295716,7864855,"Household Chores and Neuro Muscular Sumptoms","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.03,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295717,7864855,"Household Chores and Neuro Muscular Sumptoms","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.01,"ANCOVA",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295714,7864855,"Household Chores and Neuro Muscular Sumptoms","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.07,"t-test, 2 sided",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295715,7864855,"Household Chores and Neuro Muscular Sumptoms","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.01,"Wilcoxon (Mann-Whitney)",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295718,7864856,"Platelet ATP","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.15,"t-test, 2 sided",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295719,7864857,"Neuromuscular Symptoms","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.01,"t-test, 2 sided",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04737278",4295720,7864857,"Neuromuscular Symptoms","nicotinic acids|niacin","Cunermuspir|Placebo","Drug|Other","fatigue|neuralgia|myalgia","Myalgia|Neuralgia","Parallel Assignment","Interventional","Treatment","Randomized","Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain",2,null,"NA",0.01,"t-test, 2 sided",{"$nulls":4},"NA","All",56,"Completed","Phase 1/Phase 2","\t"]
["NCT04780919",4295656,7864792,"Change in VISA-A Questionnaire Score","NA","BTL-6000 FSWT|BTL-6000 FSWT with sham applicator","Device|Device","tendinopathy","Achilles Tendinopathy","Parallel Assignment","Interventional","Treatment","Randomized","Ultrasound-Monitored Changes in Achilles Tendinopathy After Extracorporeal Shock Wave Therapy",2,null,"NA",0.104,"Two-way ANOVA",{"$nulls":4},"NA","All",18,"Completed","N/A","\t"]
["NCT04780919",4295657,7864795,"Change of Ankle Dorsiflexion Range of Motion","NA","BTL-6000 FSWT|BTL-6000 FSWT with sham applicator","Device|Device","tendinopathy","Achilles Tendinopathy","Parallel Assignment","Interventional","Treatment","Randomized","Ultrasound-Monitored Changes in Achilles Tendinopathy After Extracorporeal Shock Wave Therapy",2,null,"NA",0.171,"Two-way ANOVA",{"$nulls":4},"NA","All",18,"Completed","N/A","\t"]
["NCT04780919",4295658,7864796,"Change in Maximum Pain in the Achilles Tendon Area (Follow up)","NA","BTL-6000 FSWT|BTL-6000 FSWT with sham applicator","Device|Device","tendinopathy","Achilles Tendinopathy","Parallel Assignment","Interventional","Treatment","Randomized","Ultrasound-Monitored Changes in Achilles Tendinopathy After Extracorporeal Shock Wave Therapy",2,null,"NA",0.035,"Two-way ANOVA",{"$nulls":4},"NA","All",18,"Completed","N/A","\t"]
["NCT04780919",4295659,7864797,"Change in Maximum Pain in the Achilles Tendon Area","NA","BTL-6000 FSWT|BTL-6000 FSWT with sham applicator","Device|Device","tendinopathy","Achilles Tendinopathy","Parallel Assignment","Interventional","Treatment","Randomized","Ultrasound-Monitored Changes in Achilles Tendinopathy After Extracorporeal Shock Wave Therapy",2,null,"NA",0.096,"Two-way ANOVA",{"$nulls":4},"NA","All",18,"Completed","N/A","\t"]
["NCT04780919",4295660,7864798,"Change in Cross-sectional Area at the Place of Maximum Tendon Width","NA","BTL-6000 FSWT|BTL-6000 FSWT with sham applicator","Device|Device","tendinopathy","Achilles Tendinopathy","Parallel Assignment","Interventional","Treatment","Randomized","Ultrasound-Monitored Changes in Achilles Tendinopathy After Extracorporeal Shock Wave Therapy",2,null,"NA",0.722,"Two-way ANOVA",{"$nulls":4},"NA","All",18,"Completed","N/A","\t"]
["NCT04799782",4295654,7864788,"AHI (Apnea/Hypopnea Index)","mirtazapine","Mirtazapine|Placebo","Drug|Drug","respiratory aspiration|sleep apnea syndromes|spinal cord injuries","Sleep Disordered Breathing|Spinal Cord Injuries","Crossover Assignment","Interventional","Other","Randomized","Role of Mirtazapine in Ameliorating Sleep Disordered Breathing",2,null,"NA",0.82,"t-test, 2 sided",{"$nulls":4},"NA","All","NA","Completed","Phase 2","\t"]
["NCT04799782",4295655,7864789,"CO2 Reserve (Delta-PETCO2-AT)","mirtazapine","Mirtazapine|Placebo","Drug|Drug","respiratory aspiration|sleep apnea syndromes|spinal cord injuries","Sleep Disordered Breathing|Spinal Cord Injuries","Crossover Assignment","Interventional","Other","Randomized","Role of Mirtazapine in Ameliorating Sleep Disordered Breathing",2,null,"NA",0.015,"t-test, 2 sided",{"$nulls":4},"NA","All","NA","Completed","Phase 2","\t"]
["NCT04883541",4295638,7864759,"Comparison of Average Self-sufficiency Scores of Pregnant Women in the Study and Control Groups","NA","yoga and meditation|Birth preparation training","Behavioral|Behavioral","labor pain","Birth, First|Labor Pain|Self Efficacy|State Anxiety","Parallel Assignment","Interventional","Supportive Care","Randomized","Effects of Yoga and Meditation on The Birth Process",2,"Mean Difference (Net)",0.02,0.05,"t-test, 2 sided",null,null,0.05,"Standard Deviation",0.8,"Female",153,"Completed","N/A","\t"]

{"sheet":"Supplementary Dataset 2","index":1,"n_rows":23873,"n_cols":3233,"rows_kept":2250,"cut":true,"bounds":{"rows_first":1000,"rows_last":250,"rows_between":1000,"halvings":1}}
["nct_id","outcome_id","outcome_analyses.id","param_type","param_value","dispersion_type","dispersion_value","ci_lower_limit","ci_upper_limit","ci_percent","p_value","method","all_pmids","all_cit","description","all_cond","all_interv","intervention_model","primary_purpose","allocation","all_interv_types","gender","criteria","brief_title","study_type","overall_status","phase","number_of_arms","enrollment","mesh_cond","mesh_interv","outcome.title"]
["NCT00000113","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12657584|15223788|16009841","Gwiazda J, Hyman L, Hussein M, Everett D, Norton TT, Kurtz D, Leske MC, Manny R, Marsh-Tootle W, Scheiman M. A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children. Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1492-500.|Gwiazda JE, Hyman L, Norton TT, Hussein ME, Marsh-Tootle W, Manny R, Wang Y, Everett D; COMET Grouup. Accommodation and related risk factors associated with myopia progression and their interaction with treatment in COMET children. Invest Ophthalmol Vis Sci. 2004 Jul;45(7):2143-51.|Hyman L, Gwiazda J, Hussein M, Norton TT, Wang Y, Marsh-Tootle W, Everett D. Relationship of age, sex, and ethnicity with myopia progression and axial elongation in the correction of myopia evaluation trial. Arch Ophthalmol. 2005 Jul;123(7):977-87.","\tMyopia\tProgressive Addition Lenses|single vision lenses\tParallel Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Correction of Myopia Evaluation Trial (COMET)","Interventional","Completed","Phase 3",2,469,"myopia","NA","NA"]
["NCT00000116","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15364708|15364709","Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, Hayes KC, Johnson CA, Anderson EJ, Gaudio AR, Willett WC, Schaefer EJ. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol. 2004 Sep;122(9):1297-305.|Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, Hayes KC, Johnson CA, Anderson EJ, Gaudio AR, Willett WC, Schaefer EJ. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol. 2004 Sep;122(9):1306-14.","\tRetinitis Pigmentosa\tVitamin A|Nutritional Supplement\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","retinitis pigmentosa|retinitis","vitamin a","NA"]
["NCT00000135","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","9400786|11919489|12232843|12559647","MSL-109 adjuvant therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the Monoclonal Antibody Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS Research Group. AIDS Clinical Trials Group. Arch Ophthalmol. 1997 Dec;115(12):1528-36. Erratum in: Arch Ophthalmol 1998 Mar;116(3):296.|Jabs DA, Gilpin AM, Min YI, Erice A, Kempen JH, Quinn TC; Studies of Ocular Complications of AIDS Research Group. HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: Monoclonal Antibody Cytomegalovirus Retinitis Trial. AIDS. 2002 Apr 12;16(6):877-87.|Davidson M, Min YI, Holbrook JT, Van Natta M, Quinn TC, Murphy RL, Welch W, Jabs DA, Meinert CL; Studies of Ocular Complications of AIDS Research Group. Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis. J Infect Dis. 2002 Oct 1;186(7):1013-8. Epub 2002 Aug 29.|Gilpin AM, Holbrook JT, Jabs DA, Meinert CL; Studies of Ocular Complications of AIDS Research Group. Data and safety monitoring board deliberations resulting in the early termination of the Monoclonal Antibody Cytomegalovirus Retinitis Trial. Control Clin Trials. 2003 Feb;24(1):92-8.","\tCytomegalovirus Retinitis|HIV Infections\tMSL-109|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Other\tAll\t","Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT)","Interventional","Completed","Phase 2/Phase 3",2,209,"cytomegalovirus retinitis|retinitis","antibodies, monoclonal","NA"]
["NCT00000145","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","11925463|11470690|11097601|10801969|11594943|11594942|15534261|15136320|16606880|15808240|17502507|16877067|17846363|18779490|18201681","Age-Related Eye Disease Study Research Group. The effect of five-year zinc supplementation on serum zinc, serum cholesterol and hematocrit in persons randomly assigned to treatment group in the age-related eye disease study: AREDS Report No. 7. J Nutr. 2002 Apr;132(4):697-702.|Age-Related Eye Disease Study Research Group. Risk factors associated with age-related nuclear and cortical cataract : a case-control study in the Age-Related Eye Disease Study, AREDS Report No. 5. Ophthalmology. 2001 Aug;108(8):1400-8.|Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology. 2000 Dec;107(12):2224-32.|Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study: a clinical trial of zinc and antioxidants--Age-Related Eye Disease Study Report No. 2. J Nutr. 2000 May;130(5S Suppl):1516S-9S. doi: 10.1093/jn/130.5.1516S.|Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthalmol. 2001 Oct;119(10):1439-52. Erratum in: Arch Ophthalmol. 2008 Sep;126(9):1251.|Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001 Oct;119(10):1417-36. Erratum in: Arch Ophthalmol. 2008 Sep;126(9):1251.|Yaffe K, Clemons TE, McBee WL, Lindblad AS; Age-Related Eye Disease Study Research Group. Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial. Neurology. 2004 Nov 9;63(9):1705-7.|Clemons TE, Kurinij N, Sperduto RD; AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No. 13. Arch Ophthalmol. 2004 May;122(5):716-26.|Clemons TE, Rankin MW, McBee WL; Age-Related Eye Disease Study Research Group. Cognitive impairment in the Age-Related Eye Disease Study: AREDS report no. 16. Arch Ophthalmol. 2006 Apr;124(4):537-43.|Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL 3rd; Age-Related Eye Disease Study Research Group. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology. 2005 Apr;112(4):533-9.|SanGiovanni JP, Chew EY, Clemons TE, Davis MD, Ferris FL 3rd, Gensler GR, Kurinij N, Lindblad AS, Milton RC, Seddon JM, Sperduto RD; Age-Related Eye Disease Study Research Group. The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS Report No. 20. Arch Ophthalmol. 2007 May;125(5):671-9.|Milton RC, Sperduto RD, Clemons TE, Ferris FL 3rd; Age-Related Eye Disease Study Research Group. Centrum use and progression of age-related cataract in the Age-Related Eye Disease Study: a propensity score approach. AREDS report No. 21. Ophthalmology. 2006 Aug;113(8):1264-70.|Age-Related Eye Disease Study Research Group, SanGiovanni JP, Chew EY, Clemons TE, Ferris FL 3rd, Gensler G, Lindblad AS, Milton RC, Seddon JM, Sperduto RD. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. Arch Ophthalmol. 2007 Sep;125(9):1225-32.|SanGiovanni JP, Chew EY, Agrón E, Clemons TE, Ferris FL 3rd, Gensler G, Lindblad AS, Milton RC, Seddon JM, Klein R, Sperduto RD; Age-Related Eye Disease Study Research Group. The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23. Arch Ophthalmol. 2008 Sep;126(9):1274-9. doi: 10.1001/archopht.126.9.1274.|Sperduto RD, Clemons TE, Lindblad AS, Ferris FL 3rd; Age-Related Eye Disease Study Research Group. Cataract classification using serial examinations in the age-related eye disease study: age-related eye disease study report no. 24. Am J Ophthalmol. 2008 Mar;145(3):504-8. doi: 10.1016/j.ajo.2007.10.024. Epub 2008 Jan 16.","\tCataract|Lens Opacities|Macular Degeneration\tAntioxidants|Zinc|Antioxidants and zinc\tNA\tNA\tNA\tDietary Supplement|Dietary Supplement|Dietary Supplement\tAll\t","Age-Related Eye Disease Study (AREDS)","Interventional","Completed","Phase 3",4,4757,"eye diseases|cataract|macular degeneration","zinc|antioxidants","NA"]
["NCT00000173","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14732621,"Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR Jr, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ; Alzheimer's Disease Cooperative Study. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004 Jan;61(1):59-66.","\tAlzheimer Disease\tDonepezil|Vitamin E\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","alzheimer disease|cognitive dysfunction","vitamin e|donepezil","NA"]
["NCT00000176","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17195882,"Aloysi A, Van Dyk K, Sano M. Women's cognitive and affective health and neuropsychiatry. Mt Sinai J Med. 2006 Nov;73(7):967-75. Review.","\tAlzheimer Disease|Memory Disorders\tEstrogen|Estrogen and Progesterone\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","memory disorders|alzheimer disease","progesterone|estrogens","NA"]
["NCT00000177","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",10697060,"Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000 Feb 23;283(8):1007-15. Erratum in: JAMA 2000 Nov 22-29;284(20):2597.","\tAlzheimer Disease\tEstrogen\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","alzheimer disease","estrogens","NA"]
["NCT00000178","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",10680787,"Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 2000 Feb 8;54(3):588-93.","\tAlzheimer Disease\tPrednisone\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","alzheimer disease","prednisone","NA"]
["NCT00000179","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11087767,"Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, Foster NL, Schneider LS, Sano M, Whitehouse P, Tariot P, Mellow AM, Auchus AP, Grundman M, Thomas RG, Schafer K, Thal LJ; Alzheimer's Disease Cooperative Study. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000 Nov 14;55(9):1271-8. Erratum in: Neurology 2001 Feb 13;56(3):426.","\tAlzheimer Disease\tTrazodone|Haloperidol\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","alzheimer disease","haloperidol decanoate|trazodone|haloperidol","NA"]
["NCT00000180","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12770610,"Grundman M, Capparelli E, Kim HT, Morris JC, Farlow M, Rubin EH, Heidebrink J, Hake A, Ho G, Schultz AN, Schafer K, Houston W, Thomas R, Thal LJ; Alzheimer's Disease Cooperative Study. A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients. Life Sci. 2003 Jun 20;73(5):539-53.","\tMemory Disorders\tAIT-082\tNA\tNA\tNA\tDrug\tAll\t\tNA\tNA\tNA\tNA\tNA\tNA\tmemory disorders\tNA\tNA\nNCT00000200\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t8819498\tFoltin RW, Fischman MW. Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans. J Pharmacol Exp Ther. 1996 Sep;278(3):1153-64.\t","Cocaine-Related Disorders","Methadone","NA","NA","NA","Drug","All","\tNA\tNA\tNA\tNA\tNA\tNA\tcocaine-related disorders\tmethadone\tNA\nNCT00000271\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t15913920\tMcDowell D, Nunes EV, Seracini AM, Rothenberg J, Vosburg SK, Ma GJ, Petkova E. Desipramine treatment of cocaine-dependent patients with depression: a placebo-controlled trial. Drug Alcohol Depend. 2005 Nov 1;80(2):209-21.\t","Cocaine-Related Disorders|Substance-Related Disorders","Desipramine|Placebo","Parallel Assignment","Treatment","Randomized","Drug|Drug","All","\tNew Approaches to Cocaine Abuse Medications (A) - 6\tInterventional\tCompleted\tPhase 2\t2\t111\tcocaine-related disorders|disease|substance-related disorders\tdesipramine\tNA\nNCT00000273\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t17581533\tComer SD, Sullivan MA, Whittington RA, Vosburg SK, Kowalczyk WJ. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology. 2008 Apr;33(5):1179-91. Epub 2007 Jun 20.\t","Heroin Dependence|Opioid-Related Disorders|Substance-Related Disorders","opiates","NA","NA","NA","Drug","All","\tNA\tNA\tNA\tNA\tNA\tNA\theroin dependence|opioid-related disorders|disease|substance-related disorders\tbuprenorphine|morphine|oxycodone|fentanyl|methadone\tNA\nNCT00000359\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t15103195|15011204|16151355\tCohen HS, Kimball KT, Stewart MG. Benign paroxysmal positional vertigo and comorbid conditions. ORL J Otorhinolaryngol Relat Spec. 2004;66(1):11-5.|Cohen HS, Kimball KT. Treatment variations on the Epley maneuver for benign paroxysmal positional vertigo. Am J Otolaryngol. 2004 Jan-Feb;25(1):33-7.|Cohen HS, Kimball KT. Effectiveness of treatments for benign paroxysmal positional vertigo of the posterior canal. Otol Neurotol. 2005 Sep;26(5):1034-40.\t","Vertigo","Canalith repositioning maneuver (Epley maneuver)|Semont maneuver|Brandt-Daroff exercises|Vestibular habituation exercises|ShamManeuver","NA","NA","NA","Behavioral|Behavioral|Behavioral|Behavioral|Behavioral","All","\tTreatments for Benign Paroxysmal Positional Vertigo (BPPV)\tInterventional\tCompleted\tPhase 2\t5\t150\tvertigo|dizziness|benign paroxysmal positional vertigo\tNA\tNA\nNCT00000369\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t9171907|9262937|9707380|10609422|10831476|12027038|11018230|26975266|10941997|11196004|11256459|11522262|NA|11593071|11874212|11772699|8993082|NA|NA|NA|16143731\tFrank E, Hlastala S, Ritenour A, Houck P, Tu XM, Monk TH, Mallinger AG, Kupfer DJ. Inducing lifestyle regularity in recovering bipolar disorder patients: results from the maintenance therapies in bipolar disorder protocol. Biol Psychiatry. 1997 Jun 15;41(12):1165-73.|Hlastala SA, Frank E, Mallinger AG, Thase ME, Ritenour AM, Kupfer DJ. Bipolar depression: an underestimated treatment challenge. Depress Anxiety. 1997;5(2):73-83.|Malkoff-Schwartz S, Frank E, Anderson B, Sherrill JT, Siegel L, Patterson D, Kupfer DJ. Stressful life events and social rhythm disruption in the onset of manic and depressive bipolar episodes: a preliminary investigation. Arch Gen Psychiatry. 1998 Aug;55(8):702-7.|Frank E, Swartz HA, Mallinger AG, Thase ME, Weaver EV, Kupfer DJ. Adjunctive psychotherapy for bipolar disorder: effects of changing treatment modality. J Abnorm Psychol. 1999 Nov;108(4):579-87.|Feske U, Frank E, Mallinger AG, Houck PR, Fagiolini A, Shear MK, Grochocinski VJ, Kupfer DJ. Anxiety as a correlate of response to the acute treatment of bipolar I disorder. Am J Psychiatry. 2000 Jun;157(6):956-62.|Malkoff-Schwartz S, Frank E, Anderson BP, Hlastala SA, Luther JF, Sherrill JT, Houck PR, Kupfer DJ. Social rhythm disruption and stressful life events in the onset of bipolar and unipolar episodes. Psychol Med. 2000 Sep;30(5):1005-16.|Frank E, Swartz HA, Kupfer DJ. Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. Biol Psychiatry. 2000 Sep 15;48(6):593-604. Review.|Kupfer DJ, Frank E, Grochocinski VJ, Luther JF, Houck PR, Swartz HA, Mailinger AG. Stabilization in the treatment of mania, depression and mixed states. Acta Neuropsychiatr. 2000 Sep;12(3):110-4. doi: 10.1017/S0924270800035547.|Scholle SH, Peele PB, Kelleher KJ, Frank E, Jansen-McWilliams L, Kupfer D. Effect of different recruitment sources on the composition of a bipolar disorder case registry. Soc Psychiatry Psychiatr Epidemiol. 2000 May;35(5):220-7.|Hlastala SA, Frank E, Kowalski J, Sherrill JT, Tu XM, Anderson B, Kupfer DJ. Stressful life events, bipolar disorder, and the \"\"kindling model\"\". J Abnorm Psychol. 2000 Nov;109(4):777-86.\"|Swartz HA, Frank E. Psychotherapy for bipolar depression: a phase-specific treatment strategy? Bipolar Disord. 2001 Feb;3(1):11-22. Review.|Sassi RB, Nicoletti M, Brambilla P, Harenski K, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC. Decreased pituitary volume in patients with bipolar disorder. Biol Psychiatry. 2001 Aug 15;50(4):271-80.|Lenze, E.J., Miller, M.D., Dew, M.A., Martine, L.M., Begley, A.E., Schulz, R., Frank, E. and Reynolds, C.F., III. Health measures as outcomes and predictors of response during acute treatment for late-life depression. International Journal of Geriatric Psychiatry, 16:1-7, 2001.|Fagiolini A, Buysse DJ, Frank E, Houck PR, Luther JF, Kupfer DJ. Tolerability of combined treatment with lithium and paroxetine in patients with bipolar disorder and depression. J Clin Psychopharmacol. 2001 Oct;21(5):474-8.|Kupfer DJ, Frank E, Grochocinski VJ, Cluss PA, Houck PR, Stapf DA. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry. 2002 Feb;63(2):120-5.|Cole DP, Thase ME, Mallinger AG, Soares JC, Luther JF, Kupfer DJ, Frank E. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. Am J Psychiatry. 2002 Jan;159(1):116-21.|Miklowitz DJ, Frank E, George EL. New psychosocial treatments for the outpatient management of bipolar disorder. Psychopharmacol Bull. 1996;32(4):613-21.|Craighead, W.E., Miklowitz, D.J., Vajk, F.C. and Frank, E. Psychosocial treatments for bipolar disorder. In: A Guide to Treatments that Work, edited by P.E. Nathan and J.M. Gorman, Oxford University Press, New York, NY, 240-248, 1997 .|Miklowitz, D.J. and Frank, E. New psychotherapies for bipolar disorder. In: Bipolar Disorder: Clinical Course and Outcome, edited by J. Goldberg and M. Harrow, American Psychiatric Press, Washington, D.C.,57-84, 1999.|Hlastala, S.A. and Frank, E. Biology versus environment: Stessors in the pathophysiology of bipolar disorder. In: Bipolar Disorders: Basic Mechanisms and Therapeutic Implications. J. Soares and S. Gershon (Eds.), Marcel Dekker, Inc., New York, NY, 353-372, 2000.|Frank E, Kupfer DJ, Thase ME, Mallinger AG, Swartz HA, Fagiolini AM, Grochocinski V, Houck P, Scott J, Thompson W, Monk T. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry. 2005 Sep;62(9):996-1004.","\tBipolar Disorder\tIndividual psychotherapy|Lithium carbonate\tNA\tNA\tNA\tBehavioral|Drug\tAll\t","NA","NA","NA","NA","NA","NA","bipolar disorder|disease","lithium carbonate","NA"]
["NCT00000371","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15502972,"Goff DC, Herz L, Posever T, Shih V, Tsai G, Henderson DC, Freudenreich O, Evins AE, Yovel I, Zhang H, Schoenfeld D. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl). 2005 Apr;179(1):144-50. Epub 2004 Oct 21.","\tSchizophrenia\tD-cycloserine|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Trial of D-Cycloserine in Schizophrenia","Interventional","Completed","Phase 3",2,60,"schizophrenia","cycloserine","NA"]
["NCT00000377","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",10450257,"Reynolds CF 3rd, Perel JM, Frank E, Cornes C, Miller MD, Houck PR, Mazumdar S, Stack JA, Pollock BG, Dew MA, Kupfer DJ. Three-year outcomes of maintenance nortriptyline treatment in late-life depression: a study of two fixed plasma levels. Am J Psychiatry. 1999 Aug;156(8):1177-81.","\tDepression\tNortriptyline\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","depression|depressive disorder","nortriptyline","NA"]
["NCT00000380","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16399214|15172206","Vitiello MV, Moe KE, Merriam GR, Mazzoni G, Buchner DH, Schwartz RS. Growth hormone releasing hormone improves the cognition of healthy older adults. Neurobiol Aging. 2006 Feb;27(2):318-23. Epub 2005 Mar 23.|Vitiello MV, Larsen LH, Moe KE. Age-related sleep change: Gender and estrogen effects on the subjective-objective sleep quality relationships of healthy, noncomplaining older men and women. J Psychosom Res. 2004 May;56(5):503-10.","\tSleep Disorders\tGHRH\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","parasomnias|sleep wake disorders","NA","NA"]
["NCT00000381","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12649628,"Birmaher B, Axelson DA, Monk K, Kalas C, Clark DB, Ehmann M, Bridge J, Heo J, Brent DA. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2003 Apr;42(4):415-23.","\tAnxiety Disorders\tFluoxetine\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","anxiety disorders","fluoxetine","NA"]
["NCT00000388","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","10591283|7665456|8885584|NA|9294378|NA|10591284|10637676|10637677|11104317|11104315|11104313|11211364|11211366|11211363|11211365|11211367|11294072|12014781|12108764|12880507|12795577|14998110|15060225|NA|15677282|16135621|16671928|16881772|17710545|17667478|17667481|17053977|17667480|17667479|18573923|18573924|19307987|19318991|20390813|20883582|23834228|23452682","A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999 Dec;56(12):1073-86.|Richters JE, Arnold LE, Jensen PS, Abikoff H, Conners CK, Greenhill LL, Hechtman L, Hinshaw SP, Pelham WE, Swanson JM. NIMH collaborative multisite multimodal treatment study of children with ADHD: I. Background and rationale. J Am Acad Child Adolesc Psychiatry. 1995 Aug;34(8):987-1000. Review.|Greenhill LL, Abikoff HB, Arnold LE, Cantwell DP, Conners CK, Elliott G, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, March JS, Newcorn J, Pelham WE, Severe JB, Swanson JM, Vitiello B, Wells K. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry. 1996 Oct;35(10):1304-13.|Arnold, L. E., Abikoff, H. B., Cantwell, D. P., Conners, C. K., Elliott, G. R., Greenhill, L. L.,Hechtman, L., Hinshaw, S.P., Hoza B., Jensen, P.S., Kraemer, H.C, March, J.S., Newcorn, J.H., Pelham, W.E., Richters, J.E., Schiller, E., Severe, J.B., Swanson, J.M., Vereen, D., Wells, K.C. (1997). NIMH collaborative multimodal treatment study of children with ADHD (MTA): Design, methodology, and protocol evolution. Journal of Attention Disorders, 2(3), 141-158.|Arnold LE, Abikoff HB, Cantwell DP, Conners CK, Elliott G, Greenhill LL, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, March JS, Newcorn JH, Pelham WE, Richters JE, Schiller E, Severe JB, Swanson JM, Vereen D, Wells KC. National Institute of Mental Health Collaborative Multimodal Treatment Study of Children with ADHD (the MTA). Design challenges and choices. Arch Gen Psychiatry. 1997 Sep;54(9):865-70.|Hinshaw, S. P., March, J. S., Abikoff, H., Arnold, L. E., Cantwell, D. P., Conners, C. K., . . . Wigal, T. (1997). Comprehensive assessment of childhood attention-deficit hyperactivity disorder in the context of a multisite, multimodal clinical trial. Journal of Attention Disorders, 1(4), 217-234.|Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999 Dec;56(12):1088-96.|Jensen PS. Fact versus fancy concerning the multimodal treatment study for attention-deficit hyperactivity disorder. Can J Psychiatry. 1999 Dec;44(10):975-80. Review.|Pelham WE Jr. The NIMH multimodal treatment study for attention-deficit hyperactivity disorder: just say yes to drugs alone? Can J Psychiatry. 1999 Dec;44(10):981-90. Review.|Hinshaw SP, Owens EB, Wells KC, Kraemer HC, Abikoff HB, Arnold LE, Conners CK, Elliott G, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Pelham WE, Swanson JM, Vitiello B, Wigal T. Family processes and treatment outcome in the MTA: negative/ineffective parenting practices in relation to multimodal treatment. J Abnorm Child Psychol. 2000 Dec;28(6):555-68.|March JS, Swanson JM, Arnold LE, Hoza B, Conners CK, Hinshaw SP, Hechtman L, Kraemer HC, Greenhill LL, Abikoff HB, Elliott LG, Jensen PS, Newcorn JH, Vitiello B, Severe J, Wells KC, Pelham WE. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). J Abnorm Child Psychol. 2000 Dec;28(6):527-41.|Wells KC, Pelham WE, Kotkin RA, Hoza B, Abikoff HB, Abramowitz A, Arnold LE, Cantwell DP, Conners CK, Del Carmen R, Elliott G, Greenhill LL, Hechtman L, Hibbs E, Hinshaw SP, Jensen PS, March JS, Swanson JM, Schiller E. Psychosocial treatment strategies in the MTA study: rationale, methods, and critical issues in design and implementation. J Abnorm Child Psychol. 2000 Dec;28(6):483-505.|Conners CK, Epstein JN, March JS, Angold A, Wells KC, Klaric J, Swanson JM, Arnold LE, Abikoff HB, Elliott GR, Greenhill LL, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, Newcorn JH, Pelham WE, Severe JB, Vitiello B, Wigal T. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. J Am Acad Child Adolesc Psychiatry. 2001 Feb;40(2):159-67.|Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, Arnold LE, Abikoff HB, Bukstein OG, Conners CK, Elliott GR, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, March JS, Newcorn JH, Severe JB, Wells K, Wigal T. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry. 2001 Feb;40(2):180-7.|Jensen PS, Hinshaw SP, Kraemer HC, Lenora N, Newcorn JH, Abikoff HB, March JS, Arnold LE, Cantwell DP, Conners CK, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Pelham WE, Severe JB, Swanson JM, Wells KC, Wigal T, Vitiello B. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry. 2001 Feb;40(2):147-58.|Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Owens EB, Pelham WE, Schiller E, Severe JB, Simpson S, Vitiello B, Wells K, Wigal T, Wu M. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry. 2001 Feb;40(2):168-79.|Vitiello B, Severe JB, Greenhill LL, Arnold LE, Abikoff HB, Bukstein OG, Elliott GR, Hechtman L, Jensen PS, Hinshaw SP, March JS, Newcorn JH, Swanson JM, Cantwell DP. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry. 2001 Feb;40(2):188-96.|Wells KC. Comprehensive versus matched psychosocial treatment in the MTA study: conceptual and empirical issues. J Clin Child Psychol. 2001 Mar;30(1):131-5.|Abikoff H, Arnold LE, Newcorn JH, Elliott GR, Hechtman L, Severe JB, Wigal T, Shapiro C, Cantwell DP, Conners CK, Greenhill LL, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, March JS, Pelham WE, Swanson JM, Vitiello B, Wells KC. Emergency/Adjunct services and attrition prevention for randomized clinical trials in children: the MTA manual-based solution. J Am Acad Child Adolesc Psychiatry. 2002 May;41(5):498-504.|Swanson JM, Arnold LE, Vitiello B, Abikoff HB, Wells KC, Pelham WE, March JS, Hinshaw SP, Hoza B, Epstein JN, Elliott GR, Greenhill LL, Hechtman L, Jensen PS, Kraemer HC, Kotkin R, Molina B, Newcorn JH, Owens EB, Severe J, Hoagwood K, Simpson S, Wigal T, Hanley T; MTA Group. Multimodal Treatment of Children with Attention Deficit Hyperactivity Disorder. Response to commentary on the multimodal treatment study of ADHD (MTA): mining the meaning of the MTA. J Abnorm Child Psychol. 2002 Aug;30(4):327-32.|Galanter CA, Carlson GA, Jensen PS, Greenhill LL, Davies M, Li W, Chuang SZ, Elliott GR, Arnold LE, March JS, Hechtman L, Pelham WE, Swanson JM. Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. J Child Adolesc Psychopharmacol. 2003 Summer;13(2):123-36.|Owens EB, Hinshaw SP, Kraemer HC, Arnold LE, Abikoff HB, Cantwell DP, Conners CK, Elliott G, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Pelham WE, Severe JB, Swanson JM, Vitiello B, Wells KC, Wigal T. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol. 2003 Jun;71(3):540-52.|Arnold LE, Chuang S, Davies M, Abikoff HB, Conners CK, Elliott GR, Greenhill LL, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, Langworthy-Lam KS, March JS, Newcorn JH, Pelham WE, Severe JB, Swanson JM, Vitiello B, Wells KC, Wigal T. Nine months of multicomponent behavioral treatment for ADHD and effectiveness of MTA fading procedures. J Abnorm Child Psychol. 2004 Feb;32(1):39-51.|MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004 Apr;113(4):762-9.|Arnold, L. E., Elliott, M., Lindsay, R. L., Molina, B., Cornelius, M. D., Vitiello, B., . . . Wells, K. (2005). Gestational and postnatal tobacco smoke exposure as predictor of ADHD, comorbid ODD/CD, and treatment response in the MTA. Clinical Neuroscience Research, 5(5-6), 295-306.|Hoza B, Gerdes AC, Mrug S, Hinshaw SP, Bukowski WM, Gold JA, Arnold LE, Abikoff HB, Conners CK, Elliott GR, Greenhill LL, Hechtman L, Jensen PS, Kraemer HC, March JS, Newcorn JH, Severe JB, Swanson JM, Vitiello B, Wells KC, Wigal T. Peer-assessed outcomes in the multimodal treatment study of children with attention deficit hyperactivity disorder. J Clin Child Adolesc Psychol. 2005 Mar;34(1):74-86.|Jensen PS, Garcia JA, Glied S, Crowe M, Foster M, Schlander M, Hinshaw S, Vitiello B, Arnold LE, Elliott G, Hechtman L, Newcorn JH, Pelham WE, Swanson J, Wells K. Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. Am J Psychiatry. 2005 Sep;162(9):1628-36.|Epstein JN, Conners CK, Hervey AS, Tonev ST, Arnold LE, Abikoff HB, Elliott G, Greenhill LL, Hechtman L, Hoagwood K, Hinshaw SP, Hoza B, Jensen PS, March JS, Newcorn JH, Pelham WE, Severe JB, Swanson JM, Wells K, Vitiello B, Wigal T; MTA Cooperative Study Group. Assessing medication effects in the MTA study using neuropsychological outcomes. J Child Psychol Psychiatry. 2006 May;47(5):446-56.|Wells KC, Chi TC, Hinshaw SP, Epstein JN, Pfiffner L, Nebel-Schwalm M, Owens EB, Arnold LE, Abikoff HB, Conners CK, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March J, Newcorn JH, Pelham WE, Severe JB, Swanson J, Vitiello B, Wigal T. Treatment-related changes in objectively measured parenting behaviors in the multimodal treatment study of children with attention-deficit/hyperactivity disorder. J Consult Clin Psychol. 2006 Aug;74(4):649-57.|Hoza B, Kaiser NM, Hurt E. Multimodal treatments for childhood attention-deficit/hyperactivity disorder: interpreting outcomes in the context of study designs. Clin Child Fam Psychol Rev. 2007 Dec;10(4):318-34. Review.|Jensen PS, Arnold LE, Swanson JM, Vitiello B, Abikoff HB, Greenhill LL, Hechtman L, Hinshaw SP, Pelham WE, Wells KC, Conners CK, Elliott GR, Epstein JN, Hoza B, March JS, Molina BSG, Newcorn JH, Severe JB, Wigal T, Gibbons RD, Hur K. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):989-1002. doi: 10.1097/CHI.0b013e3180686d48.|Molina BSG, Flory K, Hinshaw SP, Greiner AR, Arnold LE, Swanson JM, Hechtman L, Jensen PS, Vitiello B, Hoza B, Pelham WE, Elliott GR, Wells KC, Abikoff HB, Gibbons RD, Marcus S, Conners CK, Epstein JN, Greenhill LL, March JS, Newcorn JH, Severe JB, Wigal T. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):1028-1040. doi: 10.1097/chi.0b013e3180686d96.|Stevens J, Kelleher K, Greenhouse J, Chen G, Xiang H, Kaizar E, Jensen PS, Arnold LE. Empirical evaluation of the generalizability of the sample from the multimodal treatment study for ADHD. Adm Policy Ment Health. 2007 May;34(3):221-32. Epub 2006 Oct 20.|Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, Hechtman L, Epstein JN, Pelham WE, Abikoff HB, Newcorn JH, Molina BSG, Hinshaw SP, Wells KC, Hoza B, Jensen PS, Gibbons RD, Hur K, Stehli A, Davies M, March JS, Conners CK, Caron M, Volkow ND. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):1015-1027. doi: 10.1097/chi.0b013e3180686d7e.|Swanson JM, Hinshaw SP, Arnold LE, Gibbons RD, Marcus S, Hur K, Jensen PS, Vitiello B, Abikoff HB, Greenhill LL, Hechtman L, Pelham WE, Wells KC, Conners CK, March JS, Elliott GR, Epstein JN, Hoagwood K, Hoza B, Molina BSG, Newcorn JH, Severe JB, Wigal T. Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):1003-1014. doi: 10.1097/CHI.0b013e3180686d63.|Swanson J, Arnold LE, Kraemer H, Hechtman L, Molina B, Hinshaw S, Vitiello B, Jensen P, Steinhoff K, Lerner M, Greenhill L, Abikoff H, Wells K, Epstein J, Elliott G, Newcorn J, Hoza B, Wigal T; MTA Cooperative Group. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. J Atten Disord. 2008 Jul;12(1):4-14. doi: 10.1177/1087054708319345.|Swanson J, Arnold LE, Kraemer H, Hechtman L, Molina B, Hinshaw S, Vitiello B, Jensen P, Steinhoff K, Lerner M, Greenhill L, Abikoff H, Wells K, Epstein J, Elliott G, Newcorn J, Hoza B, Wigal T; MTA Cooperative Group. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details. J Atten Disord. 2008 Jul;12(1):15-43. doi: 10.1177/1087054708319525.|Pappadopulos E, Jensen PS, Chait AR, Arnold LE, Swanson JM, Greenhill LL, Hechtman L, Chuang S, Wells KC, Pelham W, Cooper T, Elliott G, Newcorn JH. Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry. 2009 May;48(5):501-510. doi: 10.1097/CHI.0b013e31819c23ed.|Molina BSG, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, Epstein JN, Hoza B, Hechtman L, Abikoff HB, Elliott GR, Greenhill LL, Newcorn JH, Wells KC, Wigal T, Gibbons RD, Hur K, Houck PR; MTA Cooperative Group. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 2009 May;48(5):484-500. doi: 10.1097/CHI.0b013e31819c23d0.|Langberg JM, Arnold LE, Flowers AM, Epstein JN, Altaye M, Hinshaw SP, Swanson JM, Kotkin R, Simpson S, Molina BS, Jensen PS, Abikoff H, Pelham WE Jr, Vitiello B, Wells KC, Hechtman L. Parent-reported homework problems in the MTA study: evidence for sustained improvement with behavioral treatment. J Clin Child Adolesc Psychol. 2010;39(2):220-33. doi: 10.1080/15374410903532700.|Murray-Close D, Hoza B, Hinshaw SP, Arnold LE, Swanson J, Jensen PS, Hechtman L, Wells K. Developmental processes in peer problems of children with attention-deficit/hyperactivity disorder in the Multimodal Treatment Study of Children With ADHD: developmental cascades and vicious cycles. Dev Psychopathol. 2010 Nov;22(4):785-802. doi: 10.1017/S0954579410000465. Erratum in: Dev Psychopathol. 2014 Feb;26(1):287.|Hoza B, McQuade JD, Murray-Close D, Shoulberg E, Molina BS, Arnold LE, Swanson J, Hechtman L. Does childhood positive self-perceptual bias mediate adolescent risky behavior in youth from the MTA study? J Consult Clin Psychol. 2013 Oct;81(5):846-58. doi: 10.1037/a0033536. Epub 2013 Jul 8.|Molina BS, Hinshaw SP, Eugene Arnold L, Swanson JM, Pelham WE, Hechtman L, Hoza B, Epstein JN, Wigal T, Abikoff HB, Greenhill LL, Jensen PS, Wells KC, Vitiello B, Gibbons RD, Howard A, Houck PR, Hur K, Lu B, Marcus S; MTA Cooperative Group. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry. 2013 Mar;52(3):250-63. doi: 10.1016/j.jaac.2012.12.014. Epub 2013 Feb 8.","\tAttention Deficit Disorder With Hyperactivity|Dyssocial Behavior|Substance-related Disorders\tPsychosocial treatment|Anti-ADHD medication|Assessment-and-Referral\tNA\tNA\tNA\tBehavioral|Drug|Behavioral\tAll\t","NA","NA","NA","NA","NA","NA","attention deficit disorder with hyperactivity|disease|hyperkinesis|antisocial personality disorder|substance-related disorders","NA","NA"]
["NCT00000395","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15476202,"Morgan SL, Oster RA, Lee JY, Alarcón GS, Baggott JE. The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis. Arthritis Rheum. 2004 Oct;50(10):3104-11.","\tAdjuvant Arthritis|Rheumatoid Arthritis\tMethotrexate|Folinic acid|Folic acid\tCrossover Assignment\tDiagnostic\tRandomized\tDrug|Dietary Supplement|Dietary Supplement\tAll\t","Antifolate Effectiveness in Arthritis","Interventional","Completed","Phase 2",2,40,"arthritis, experimental|arthritis|arthritis, rheumatoid","leucovorin|levoleucovorin|folic acid|methotrexate","NA"]
["NCT00000397","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16314551,"Edinger JD, Wohlgemuth WK, Krystal AD, Rice JR. Behavioral insomnia therapy for fibromyalgia patients: a randomized clinical trial. Arch Intern Med. 2005 Nov 28;165(21):2527-35.","\tFibromyalgia|Insomnia\tBehavioral insomnia therapy\tParallel Assignment\tTreatment\tRandomized\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","myofascial pain syndromes|fibromyalgia|sleep initiation and maintenance disorders","NA","NA"]
["NCT00000401","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15334493,"Carbone LD, McKown K, Pugazhenthi M, Barrow KD, Warrington K, Somes G, Postlethwaite AE. Dosage effects of orally administered bovine type I collagen on immune function in patients with systemic sclerosis. Arthritis Rheum. 2004 Aug;50(8):2713-5.","\tRheumatoid Arthritis\tOral bovine type II collagen\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Oral Collagen for Rheumatoid Arthritis","Interventional","Completed","Phase 2",2,110,"arthritis, rheumatoid|arthritis","NA","NA"]
["NCT00000402","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14988471,"Matkovic V, Landoll JD, Badenhop-Stevens NE, Ha EY, Crncevic-Orlic Z, Li B, Goel P. Nutrition influences skeletal development from childhood to adulthood: a study of hip, spine, and forearm in adolescent females. J Nutr. 2004 Mar;134(3):701S-705S.","\tOsteoporosis\tCalcium\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","osteoporosis","calcium","NA"]
["NCT00000406","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17013851,"Mikesky AE, Mazzuca SA, Brandt KD, Perkins SM, Damush T, Lane KA. Effects of strength training on the incidence and progression of knee osteoarthritis. Arthritis Rheum. 2006 Oct 15;55(5):690-9.","\tOsteoarthritis, Knee\tProgressive resistance exercise\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","osteoarthritis|osteoarthritis, knee","NA","NA"]
["NCT00000408","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","11926853|16122642","Lorig KR, Laurent DD, Deyo RA, Marnell ME, Minor MA, Ritter PL. Can a Back Pain E-mail Discussion Group improve health status and lower health care costs?: A randomized study. Arch Intern Med. 2002 Apr 8;162(7):792-6.|Bruce B, Lorig K, Laurent D, Ritter P. The impact of a moderated e-mail discussion group on use of complementary and alternative therapies in subjects with recurrent back pain. Patient Educ Couns. 2005 Sep;58(3):305-11.","\tLow Back Pain\tPatient education evaluation\tParallel Assignment\tTreatment\tRandomized\tProcedure\tAll\t","Low Back Pain Patient Education Evaluation","Interventional","Completed","N/A",2,580,"back pain|low back pain","NA","NA"]
["NCT00000409","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17538085|19487505|22048651","Weinstein JN, Lurie JD, Tosteson TD, Hanscom B, Tosteson AN, Blood EA, Birkmeyer NJ, Hilibrand AS, Herkowitz H, Cammisa FP, Albert TJ, Emery SE, Lenke LG, Abdu WA, Longley M, Errico TJ, Hu SS. Surgical versus nonsurgical treatment for lumbar degenerative spondylolisthesis. N Engl J Med. 2007 May 31;356(22):2257-70.|Weinstein JN, Lurie JD, Tosteson TD, Zhao W, Blood EA, Tosteson AN, Birkmeyer N, Herkowitz H, Longley M, Lenke L, Emery S, Hu SS. Surgical compared with nonoperative treatment for lumbar degenerative spondylolisthesis. four-year results in the Spine Patient Outcomes Research Trial (SPORT) randomized and observational cohorts. J Bone Joint Surg Am. 2009 Jun;91(6):1295-304. doi: 10.2106/JBJS.H.00913.|Tosteson AN, Tosteson TD, Lurie JD, Abdu W, Herkowitz H, Andersson G, Albert T, Bridwell K, Zhao W, Grove MR, Weinstein MC, Weinstein JN. Comparative effectiveness evidence from the spine patient outcomes research trial: surgical versus nonoperative care for spinal stenosis, degenerative spondylolisthesis, and intervertebral disc herniation. Spine (Phila Pa 1976). 2011 Nov 15;36(24):2061-8. doi: 10.1097/BRS.0b013e318235457b.","\tLow Back Pain|Spinal Stenosis|Spondylolisthesis\tDecompressive laminectomy|Non-surgical treatments|Fusion--Instrumented|Fusion-Non-instrumented\tParallel Assignment\tTreatment\tRandomized\tProcedure|Other|Procedure|Procedure\tAll\t","Spine Patient Outcomes Research Trial (SPORT): Degenerative Spondylolisthesis With Spinal Stenosis","Interventional","Completed","Phase 4",2,304,"low back pain|spondylolisthesis|spinal stenosis|constriction, pathologic|back pain","NA","NA"]
["NCT00000410","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17119141|17119140|19018250|18777603|22048651","Weinstein JN, Lurie JD, Tosteson TD, Skinner JS, Hanscom B, Tosteson AN, Herkowitz H, Fischgrund J, Cammisa FP, Albert T, Deyo RA. Surgical vs nonoperative treatment for lumbar disk herniation: the Spine Patient Outcomes Research Trial (SPORT) observational cohort. JAMA. 2006 Nov 22;296(20):2451-9.|Weinstein JN, Tosteson TD, Lurie JD, Tosteson AN, Hanscom B, Skinner JS, Abdu WA, Hilibrand AS, Boden SD, Deyo RA. Surgical vs nonoperative treatment for lumbar disk herniation: the Spine Patient Outcomes Research Trial (SPORT): a randomized trial. JAMA. 2006 Nov 22;296(20):2441-50.|Weinstein JN, Lurie JD, Tosteson TD, Tosteson AN, Blood EA, Abdu WA, Herkowitz H, Hilibrand A, Albert T, Fischgrund J. Surgical versus nonoperative treatment for lumbar disc herniation: four-year results for the Spine Patient Outcomes Research Trial (SPORT). Spine (Phila Pa 1976). 2008 Dec 1;33(25):2789-800. doi: 10.1097/BRS.0b013e31818ed8f4.|Tosteson AN, Skinner JS, Tosteson TD, Lurie JD, Andersson GB, Berven S, Grove MR, Hanscom B, Blood EA, Weinstein JN. The cost effectiveness of surgical versus nonoperative treatment for lumbar disc herniation over two years: evidence from the Spine Patient Outcomes Research Trial (SPORT). Spine (Phila Pa 1976). 2008 Sep 1;33(19):2108-15.|Tosteson AN, Tosteson TD, Lurie JD, Abdu W, Herkowitz H, Andersson G, Albert T, Bridwell K, Zhao W, Grove MR, Weinstein MC, Weinstein JN. Comparative effectiveness evidence from the spine patient outcomes research trial: surgical versus nonoperative care for spinal stenosis, degenerative spondylolisthesis, and intervertebral disc herniation. Spine (Phila Pa 1976). 2011 Nov 15;36(24):2061-8. doi: 10.1097/BRS.0b013e318235457b.","\tHerniated Disc|Low Back Pain\tDiskectomy|Non-surgical treatments\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","Spine Patient Outcomes Research Trial (SPORT) - Intervertebral Disc Herniation","Interventional","Completed","Phase 4",2,501,"hernia|intervertebral disc displacement|back pain|low back pain","NA","NA"]
["NCT00000411","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18287602|20453723|19075203|22048651","Weinstein JN, Tosteson TD, Lurie JD, Tosteson AN, Blood E, Hanscom B, Herkowitz H, Cammisa F, Albert T, Boden SD, Hilibrand A, Goldberg H, Berven S, An H; SPORT Investigators. Surgical versus nonsurgical therapy for lumbar spinal stenosis. N Engl J Med. 2008 Feb 21;358(8):794-810. doi: 10.1056/NEJMoa0707136.|Weinstein JN, Tosteson TD, Lurie JD, Tosteson A, Blood E, Herkowitz H, Cammisa F, Albert T, Boden SD, Hilibrand A, Goldberg H, Berven S, An H. Surgical versus nonoperative treatment for lumbar spinal stenosis four-year results of the Spine Patient Outcomes Research Trial. Spine (Phila Pa 1976). 2010 Jun 15;35(14):1329-38. doi: 10.1097/BRS.0b013e3181e0f04d.|Tosteson AN, Lurie JD, Tosteson TD, Skinner JS, Herkowitz H, Albert T, Boden SD, Bridwell K, Longley M, Andersson GB, Blood EA, Grove MR, Weinstein JN; SPORT Investigators. Surgical treatment of spinal stenosis with and without degenerative spondylolisthesis: cost-effectiveness after 2 years. Ann Intern Med. 2008 Dec 16;149(12):845-53.|Tosteson AN, Tosteson TD, Lurie JD, Abdu W, Herkowitz H, Andersson G, Albert T, Bridwell K, Zhao W, Grove MR, Weinstein MC, Weinstein JN. Comparative effectiveness evidence from the spine patient outcomes research trial: surgical versus nonoperative care for spinal stenosis, degenerative spondylolisthesis, and intervertebral disc herniation. Spine (Phila Pa 1976). 2011 Nov 15;36(24):2061-8. doi: 10.1097/BRS.0b013e318235457b.","\tLow Back Pain|Spinal Stenosis\tDecompressive laminectomy|Non-surgical treatments\tParallel Assignment\tTreatment\tRandomized\tProcedure|Other\tAll\t","Spine Patient Outcomes Research Trial (SPORT): Spinal Stenosis","Interventional","Completed","Phase 4",2,289,"spinal stenosis|back pain|constriction, pathologic|low back pain","NA","NA"]
["NCT00000416","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","14613285|NA","Allaire SH, Li W, LaValley MP. Reduction of job loss in persons with rheumatic diseases receiving vocational rehabilitation: a randomized controlled trial. Arthritis Rheum. 2003 Nov;48(11):3212-8.|Allaire SH, Niu J, Lavalley MP. Employment and Satisfaction Outcomes From a Job Retention Intervention Delivered to Persons with Chronic Diseases. Rehabilitation Counseling Bulletin 48(2):100-109, 2005","\tAnkylosing Spondylitis|Osteoarthritis, Knee|Rheumatoid Arthritis|Systemic Lupus Erythematosus\tRehabilitation counseling\tNA\tNA\tNA\tOther\tAll\t","Prevention of Arthritis-Related Work Disability","Interventional","Completed","N/A",2,242,"arthritis|spondylitis|lupus erythematosus, systemic|osteoarthritis, knee|spondylitis, ankylosing","NA","NA"]
["NCT00000419","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15968009,"Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, Merrill JT, Sammaritano L, Lockshin M, Alarcón GS, Manzi S, Belmont HM, Askanase AD, Sigler L, Dooley MA, Von Feldt J, McCune WJ, Friedman A, Wachs J, Cronin M, Hearth-Holmes M, Tan M, Licciardi F. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005 Jun 21;142(12 Pt 1):953-62.","\tSystemic Lupus Erythematosus\tPremarin and Provera\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","lupus erythematosus, systemic","estrogens, conjugated (usp)|medroxyprogesterone acetate","NA"]
["NCT00000420","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16354891,"Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, Lockshin M, Merrill JT, Belmont HM, Askanase AD, McCune WJ, Hearth-Holmes M, Dooley MA, Von Feldt J, Friedman A, Tan M, Davis J, Cronin M, Diamond B, Mackay M, Sigler L, Fillius M, Rupel A, Licciardi F, Buyon JP; OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24):2550-8.","\tSystemic Lupus Erythematosus\tOrtho-Novum 777\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","lupus erythematosus, systemic","norinyl|norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination","NA"]
["NCT00000421","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17075807,"Tseng CE, Buyon JP, Kim M, Belmont HM, Mackay M, Diamond B, Marder G, Rosenthal P, Haines K, Ilie V, Abramson SB. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006 Nov;54(11):3623-32.","\tSystemic Lupus Erythematosus\tPrednisone|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tFemale\t","Serologically Active, Clinically Stable Systemic Lupus Erythematosus","Interventional","Completed","Phase 2",2,154,"lupus erythematosus, systemic","prednisone","NA"]
["NCT00000422","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15943960|NA|NA|15556826|NA|NA","Burwinkle T, Robinson JP, Turk DC. Fear of movement: factor structure of the tampa scale of kinesiophobia in patients with fibromyalgia syndrome. J Pain. 2005 Jun;6(6):384-91.|Robinson JP, Turk DC. Relations between self-reports and physical performance among fibromyalgia syndrome patients. J Pain 4, Number 2 (Suppl 1): 15, 2002.|Turk DC, Robinson JP. Predictors of self-reported activity level and activity limitations in fibromyalgia syndrome. J Pain 4, Number 2 (Suppl 1): 16, 2003.|Turk DC, Robinson JP, Burwinkle T. Prevalence of fear of pain and activity in patients with fibromyalgia syndrome. J Pain. 2004 Nov;5(9):483-90.|Burwinkle T, Robinson JP, Turk DC. The role of physical, demographic, and psychological factors in symptom reporting and treatments of fibromyalgia syndrome patients. J Pain 6 (Suppl 1), S79, 2005.|Robinson JP, Turk DC, Burwinkle T, Showlund M. Prevalence of fear in subgroups of Fibromyalgia Syndrome (FMS) Patients. J Pain 5 (Suppl 1): 1109, 2004.","\tFibromyalgia\tCognitive-behavioral psychotherapy and physical exercise\tNA\tNA\tNA\tBehavioral\tFemale\t","NA","NA","NA","NA","NA","NA","myofascial pain syndromes|fibromyalgia","NA","NA"]
["NCT00000423","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11764222,"Oliver K, Cronan TA, Walen HR, Tomita M. Effects of social support and education on health care costs for patients with fibromyalgia. J Rheumatol. 2001 Dec;28(12):2711-9.","\tFibromyalgia|Quality of Life\tSocial support group|Social support and education group\tNA\tNA\tNA\tBehavioral|Behavioral\tAll\t","NA","NA","NA","NA","NA","NA","fibromyalgia|myofascial pain syndromes","NA","NA"]
["NCT00000424","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11817581,"Bradley JD, Heilman DK, Katz BP, Gsell P, Wallick JE, Brandt KD. Tidal irrigation as treatment for knee osteoarthritis: a sham-controlled, randomized, double-blinded evaluation. Arthritis Rheum. 2002 Jan;46(1):100-8.","\tOsteoarthritis, Knee\tTidal lavage vs. sham lavage of the knee\tParallel Assignment\tTreatment\tRandomized\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","osteoarthritis, knee|osteoarthritis","NA","NA"]
["NCT00000427","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16684825,"Finkelstein JS, Leder BZ, Burnett SM, Wyland JJ, Lee H, de la Paz AV, Gibson K, Neer RM. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab. 2006 Aug;91(8):2882-7. Epub 2006 May 9.","\tOsteoporosis\tParathyroid hormone|Alendronate\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tMale\t","NA","NA","NA","NA","NA","NA","osteoporosis","parathyroid hormone|alendronate|hormones","NA"]
["NCT00000428","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17014022,"Zucker DR, Ruthazer R, Schmid CH, Feuer JM, Fischer PA, Kieval RI, Mogavero N, Rapoport RJ, Selker HP, Stotsky SA, Winston E, Goldenberg DL. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. J Rheumatol. 2006 Oct;33(10):2069-77.","\tFibromyalgia\tAmitriptyline|Amitriptyline plus Fluoxitine\tCrossover Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","myofascial pain syndromes|fibromyalgia","amitriptyline|amitriptyline, perphenazine drug combination","NA"]
["NCT00000439","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15630071,"Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2005 Jan;62(1):37-45.","\tAlcoholism|Bipolar Disorder\tsodium valproate\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Drug Treatment for Alcoholics With Bipolar Disorder","Interventional","Completed","Phase 2",2,72,"bipolar disorder|alcoholism","valproic acid","NA"]
["NCT00000448","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17374042,"O'Malley SS, Sinha R, Grilo CM, Capone C, Farren CK, McKee SA, Rounsaville BJ, Wu R. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial. Alcohol Clin Exp Res. 2007 Apr;31(4):625-34.","\tAlcoholism|Eating Disorder\tnaltrexone|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tFemale\t","Naltrexone Treatment for Alcoholic Women","Interventional","Completed","Phase 4",2,160,"alcoholism|feeding and eating disorders","naltrexone","NA"]
["NCT00000454","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18072840|17874878","Cooney NL, Litt MD, Cooney JL, Pilkey DT, Steinberg HR, Oncken CA. Concurrent brief versus intensive smoking intervention during alcohol dependence treatment. Psychol Addict Behav. 2007 Dec;21(4):570-5.|Cooney NL, Litt MD, Cooney JL, Pilkey DT, Steinberg HR, Oncken CA. Alcohol and tobacco cessation in alcohol-dependent smokers: analysis of real-time reports. Psychol Addict Behav. 2007 Sep;21(3):277-86.","\tAlcoholism|Smoking\tnicotine replacement patch\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","alcoholism","nicotine","NA"]
["NCT00000456","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16012278,"Anton RF, Moak DH, Latham P, Waid LR, Myrick H, Voronin K, Thevos A, Wang W, Woolson R. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol. 2005 Aug;25(4):349-57.","\tAlcohol Dependence|Alcoholism\tnaltrexone (Revia)|cognitive behavior therapy|motivational enhancement therapy\tParallel Assignment\tTreatment\tRandomized\tDrug|Behavioral|Behavioral\tAll\t","NA","NA","NA","NA","NA","NA","alcoholism","naltrexone","NA"]
["NCT00000457","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16240558|19483180","Hurt RD, Patten CA, Offord KP, Croghan IT, Decker PA, Morris RA, Hays JT. Treating nondepressed smokers with alcohol dependence in sustained full remission: nicotine patch therapy tailored to baseline serum cotinine. J Stud Alcohol. 2005 Jul;66(4):506-16.|Hays JT, Hurt RD, Decker PA, Croghan IT, Offord KP, Patten CA. A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics. Nicotine Tob Res. 2009 Jul;11(7):859-67. doi: 10.1093/ntr/ntp077. Epub 2009 May 29.","\tAlcoholism|Smoking\tbupropion (Wellbutrin)|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Pharmacologic Relapse Prevention for Alcoholic Smokers","Interventional","Completed","Phase 2",2,195,"alcoholism","bupropion","NA"]
["NCT00000541","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17698683|18984888|19064521|18460663|19491386|19491213|19116389|19451353|19237716|23066166","Cook NR, Albert CM, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, Buring JE, Manson JE. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med. 2007 Aug 13-27;167(15):1610-8.|Zhang SM, Cook NR, Albert CM, Gaziano JM, Buring JE, Manson JE. Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial. JAMA. 2008 Nov 5;300(17):2012-21. doi: 10.1001/jama.2008.555.|Kang JH, Cook N, Manson J, Buring JE, Albert CM, Grodstein F. A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease. Am J Clin Nutr. 2008 Dec;88(6):1602-10. doi: 10.3945/ajcn.2008.26404.|Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, Buring JE, Manson JE. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008 May 7;299(17):2027-36. doi: 10.1001/jama.299.17.2027.|Song Y, Cook NR, Albert CM, Van Denburgh M, Manson JE. Effects of vitamins C and E and beta-carotene on the risk of type 2 diabetes in women at high risk of cardiovascular disease: a randomized controlled trial. Am J Clin Nutr. 2009 Aug;90(2):429-37. doi: 10.3945/ajcn.2009.27491. Epub 2009 Jun 2.|Song Y, Cook NR, Albert CM, Van Denburgh M, Manson JE. Effect of homocysteine-lowering treatment with folic Acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial. Diabetes. 2009 Aug;58(8):1921-8. doi: 10.2337/db09-0087. Epub 2009 Jun 2.|Lin J, Cook NR, Albert C, Zaharris E, Gaziano JM, Van Denburgh M, Buring JE, Manson JE. Vitamins C and E and beta carotene supplementation and cancer risk: a randomized controlled trial. J Natl Cancer Inst. 2009 Jan 7;101(1):14-23. doi: 10.1093/jnci/djn438. Epub 2008 Dec 30.|Kang JH, Cook NR, Manson JE, Buring JE, Albert CM, Grodstein F. Vitamin E, vitamin C, beta carotene, and cognitive function among women with or at risk of cardiovascular disease: The Women's Antioxidant and Cardiovascular Study. Circulation. 2009 Jun 2;119(21):2772-80. doi: 10.1161/CIRCULATIONAHA.108.816900. Epub 2009 May 18.|Christen WG, Glynn RJ, Chew EY, Albert CM, Manson JE. Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study. Arch Intern Med. 2009 Feb 23;169(4):335-41. doi: 10.1001/archinternmed.2008.574.|Song Y, Manson JE, Lee IM, Cook NR, Paul L, Selhub J, Giovannucci E, Zhang SM. Effect of combined folic acid, vitamin B(6), and vitamin B(12) on colorectal adenoma. J Natl Cancer Inst. 2012 Oct 17;104(20):1562-75. doi: 10.1093/jnci/djs370. Epub 2012 Oct 12.","\tCardiovascular Diseases|Coronary Arteriosclerosis|Coronary Disease|Heart Diseases|Myocardial Infarction|Myocardial Ischemia\tdietary supplements|vitamin C|vitamin E|beta-carotene|folic acid/Vitamin B6/Vitamin B12\tNA\tNA\tNA\tBehavioral|Drug|Drug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","cardiovascular diseases|ischemia|coronary artery disease|myocardial infarction|coronary disease|infarction|myocardial ischemia|arteriosclerosis|heart diseases","beta carotene|carotenoids|folic acid|vitamin e|pyridoxine|pyridoxal|vitamin b 12|hydroxocobalamin|vitamins|vitamin b 6|vitamin b complex","NA"]
["NCT00000572","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","8306022|7812567|7697266|9310029","Morris AH, Wallace CJ, Menlove RL, Clemmer TP, Orme JF Jr, Weaver LK, Dean NC, Thomas F, East TD, Pace NL, Suchyta MR, Beck E, Bombino M, Sittig DF, Böhm S, Hoffmann B, Becks H, Butler S, Pearl J, Rasmusson B. Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO2 removal for adult respiratory distress syndrome. Am J Respir Crit Care Med. 1994 Feb;149(2 Pt 1):295-305. Erratum in: Am J Respir Crit Care Med 1994 Mar;149(3 Pt 1):838.|Habashi NM, Reynolds HN, Borg U, Cowley RA. Randomized clinical trial of pressure-controlled inverse ration ventilation and extra corporeal CO2 removal for ARDS. Am J Respir Crit Care Med. 1995 Jan;151(1):255-6.|Brunet F, Mira JP, Dhainaut JF, Dall'ava-Santucci J. Efficacy of low-frequency positive-pressure ventilation-extracorporeal CO2 removal. Am J Respir Crit Care Med. 1995 Apr;151(4):1269-70.|Falke KJ. Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO2 removal for adult respiratory distress syndrome. Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):1016-7.","\tAcute Respiratory Distress Syndrome|Lung Diseases\tpositive-pressure ventilation|extracorporeal membrane oxygenation (CO2 removal)\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","Extracorporeal Carbon Dioxide Removal for Acute Respiratory Distress Syndrome","Interventional","Completed","Phase 3",2,40,"syndrome|lung diseases|acute lung injury|respiratory distress syndrome, adult|respiratory distress syndrome, newborn","NA","NA"]
["NCT00000611","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16609086|16481635|16467234|16467233|16467232|16880313","Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT; WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006 Apr 12;295(14):1647-57.|Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T, Beresford SA, Black HR, Blanchette P, Bonds DE, Brunner RL, Brzyski RG, Caan B, Cauley JA, Chlebowski RT, Cummings SR, Granek I, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Johnson KC, Judd H, Kotchen JM, Kuller LH, Langer RD, Lasser NL, Limacher MC, Ludlam S, Manson JE, Margolis KL, McGowan J, Ockene JK, O'Sullivan MJ, Phillips L, Prentice RL, Sarto GE, Stefanick ML, Van Horn L, Wactawski-Wende J, Whitlock E, Anderson GL, Assaf AR, Barad D; Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006 Feb 16;354(7):669-83. Erratum in: N Engl J Med. 2006 Mar 9;354(10):1102.|Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML, Wassertheil-Smoller S, Kuller LH, LaCroix AZ, Langer RD, Lasser NL, Lewis CE, Limacher MC, Margolis KL, Mysiw WJ, Ockene JK, Parker LM, Perri MG, Phillips L, Prentice RL, Robbins J, Rossouw JE, Sarto GE, Schatz IJ, Snetselaar LG, Stevens VJ, Tinker LF, Trevisan M, Vitolins MZ, Anderson GL, Assaf AR, Bassford T, Beresford SA, Black HR, Brunner RL, Brzyski RG, Caan B, Chlebowski RT, Gass M, Granek I, Greenland P, Hays J, Heber D, Heiss G, Hendrix SL, Hubbell FA, Johnson KC, Kotchen JM. Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006 Feb 8;295(6):655-66.|Beresford SA, Johnson KC, Ritenbaugh C, Lasser NL, Snetselaar LG, Black HR, Anderson GL, Assaf AR, Bassford T, Bowen D, Brunner RL, Brzyski RG, Caan B, Chlebowski RT, Gass M, Harrigan RC, Hays J, Heber D, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Jackson RD, Kotchen JM, Kuller LH, LaCroix AZ, Lane DS, Langer RD, Lewis CE, Manson JE, Margolis KL, Mossavar-Rahmani Y, Ockene JK, Parker LM, Perri MG, Phillips L, Prentice RL, Robbins J, Rossouw JE, Sarto GE, Stefanick ML, Van Horn L, Vitolins MZ, Wactawski-Wende J, Wallace RB, Whitlock E. Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006 Feb 8;295(6):643-54.|Prentice RL, Caan B, Chlebowski RT, Patterson R, Kuller LH, Ockene JK, Margolis KL, Limacher MC, Manson JE, Parker LM, Paskett E, Phillips L, Robbins J, Rossouw JE, Sarto GE, Shikany JM, Stefanick ML, Thomson CA, Van Horn L, Vitolins MZ, Wactawski-Wende J, Wallace RB, Wassertheil-Smoller S, Whitlock E, Yano K, Adams-Campbell L, Anderson GL, Assaf AR, Beresford SA, Black HR, Brunner RL, Brzyski RG, Ford L, Gass M, Hays J, Heber D, Heiss G, Hendrix SL, Hsia J, Hubbell FA, Jackson RD, Johnson KC, Kotchen JM, LaCroix AZ, Lane DS, Langer RD, Lasser NL, Henderson MM. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006 Feb 8;295(6):629-42.|Yasmeen S, Romano PS, Pettinger M, Johnson SR, Hubbell FA, Lane DS, Hendrix SL. Incidence of cervical cytological abnormalities with aging in the women's health initiative: a randomized controlled trial. Obstet Gynecol. 2006 Aug;108(2):410-9.","\tBone Diseases|Breast Neoplasms|Cardiovascular Diseases|Colonic Neoplasms|Coronary Disease|Heart Diseases|Myocardial Ischemia|Osteoporosis|Postmenopause\thormone replacement therapy|estrogens|progestins|estrogen replacement therapy|diet, fat-restricted|calcium|vitamin D|dietary supplements\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Behavioral|Drug|Drug|Behavioral\tFemale\t","NA","NA","NA","NA","NA","NA","myocardial ischemia|cardiovascular diseases|coronary disease|osteoporosis|bone diseases|colonic neoplasms|breast neoplasms|heart diseases|neoplasms","progestins|estrogens|calcium|vitamin d|hormones","NA"]
["NCT00000615","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21041592,"Robinson TN, Matheson DM, Kraemer HC, Wilson DM, Obarzanek E, Thompson NS, Alhassan S, Spencer TR, Haydel KF, Fujimoto M, Varady A, Killen JD. A randomized controlled trial of culturally tailored dance and reducing screen time to prevent weight gain in low-income African American girls: Stanford GEMS. Arch Pediatr Adolesc Med. 2010 Nov;164(11):995-1004. doi: 10.1001/archpediatrics.2010.197.","\tCardiovascular Diseases|Heart Diseases|Obesity\tdiet, reducing\tNA\tNA\tNA\tBehavioral\tFemale\t","NA","NA","NA","NA","NA","NA","heart diseases|cardiovascular diseases","NA","NA"]
["NCT00000616","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16585662,"Elmer PJ, Obarzanek E, Vollmer WM, Simons-Morton D, Stevens VJ, Young DR, Lin PH, Champagne C, Harsha DW, Svetkey LP, Ard J, Brantley PJ, Proschan MA, Erlinger TP, Appel LJ; PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med. 2006 Apr 4;144(7):485-95.","\tHeart Diseases|Hypertension\tdiet, sodium-restricted|diet, fat-restricted|exercise|diet, reducing|alcohol drinking\tNA\tNA\tNA\tBehavioral|Behavioral|Behavioral|Behavioral|Behavioral\tAll\t","NA","NA","NA","NA","NA","NA","heart diseases","NA","NA"]
["NCT00000620",8269096,4517003,"Hazard Ratio (HR)",0.94,null,"NA",0.85,1.05,95,0.3,"Regression, Cox",18539917,"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.","\tAtherosclerosis|Cardiovascular Diseases|Coronary Disease|Diabetes Mellitus|Diabetes Mellitus, Type 2|Hypercholesterolemia|Hypertension\tAnti-hyperglycemic Agents|Anti-hypertensive Agents|Blinded fenofibrate or placebo plus simvastatin\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","Action to Control Cardiovascular Risk in Diabetes (ACCORD)","Interventional","Completed","Phase 3",6,10251,"atherosclerosis|diabetes mellitus|cardiovascular diseases|hypercholesterolemia|coronary disease|diabetes mellitus, type 2","hypoglycemic agents|antihypertensive agents|metoprolol|insulin|carvedilol|furosemide|amlodipine|hydrochlorothiazide-triamterene|insulin, globin zinc|simvastatin|insulin aspart|hydrochlorothiazide|hydralazine|hydrochlorothiazide, lisinopril drug combination|candesartan cilexetil|diltiazem|candesartan|fenofibrate|chlorthalidone|reserpine|insulin detemir|acarbose|repaglinide|benazepril|pioglitazone|rosiglitazone|valsartan|insulin glargine|glimepiride|metformin|felodipine|terazosin|lisinopril|triamterene","First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial."]
["NCT00000620",8269097,4517004,"Hazard Ratio (HR)",0.92,null,"NA",0.79,1.08,95,0.32,"Regression, Cox",18539917,"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.","\tAtherosclerosis|Cardiovascular Diseases|Coronary Disease|Diabetes Mellitus|Diabetes Mellitus, Type 2|Hypercholesterolemia|Hypertension\tAnti-hyperglycemic Agents|Anti-hypertensive Agents|Blinded fenofibrate or placebo plus simvastatin\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","Action to Control Cardiovascular Risk in Diabetes (ACCORD)","Interventional","Completed","Phase 3",6,10251,"atherosclerosis|diabetes mellitus|cardiovascular diseases|hypercholesterolemia|coronary disease|diabetes mellitus, type 2","hypoglycemic agents|antihypertensive agents|metoprolol|insulin|carvedilol|furosemide|amlodipine|hydrochlorothiazide-triamterene|insulin, globin zinc|simvastatin|insulin aspart|hydrochlorothiazide|hydralazine|hydrochlorothiazide, lisinopril drug combination|candesartan cilexetil|diltiazem|candesartan|fenofibrate|chlorthalidone|reserpine|insulin detemir|acarbose|repaglinide|benazepril|pioglitazone|rosiglitazone|valsartan|insulin glargine|glimepiride|metformin|felodipine|terazosin|lisinopril|triamterene","First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial."]
["NCT00000620",8269098,4517005,"Hazard Ratio (HR)",0.59,null,"NA",0.39,0.89,95,0.01,"Regression, Cox",18539917,"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.","\tAtherosclerosis|Cardiovascular Diseases|Coronary Disease|Diabetes Mellitus|Diabetes Mellitus, Type 2|Hypercholesterolemia|Hypertension\tAnti-hyperglycemic Agents|Anti-hypertensive Agents|Blinded fenofibrate or placebo plus simvastatin\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","Action to Control Cardiovascular Risk in Diabetes (ACCORD)","Interventional","Completed","Phase 3",6,10251,"atherosclerosis|diabetes mellitus|cardiovascular diseases|hypercholesterolemia|coronary disease|diabetes mellitus, type 2","hypoglycemic agents|antihypertensive agents|metoprolol|insulin|carvedilol|furosemide|amlodipine|hydrochlorothiazide-triamterene|insulin, globin zinc|simvastatin|insulin aspart|hydrochlorothiazide|hydralazine|hydrochlorothiazide, lisinopril drug combination|candesartan cilexetil|diltiazem|candesartan|fenofibrate|chlorthalidone|reserpine|insulin detemir|acarbose|repaglinide|benazepril|pioglitazone|rosiglitazone|valsartan|insulin glargine|glimepiride|metformin|felodipine|terazosin|lisinopril|triamterene","Stroke in the Blood Pressure Trial."]
["NCT00000620",8269099,4517006,"Hazard Ratio (HR)",0.88,null,"NA",0.73,1.06,95,0.2,"Regression, Cox",18539917,"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.","\tAtherosclerosis|Cardiovascular Diseases|Coronary Disease|Diabetes Mellitus|Diabetes Mellitus, Type 2|Hypercholesterolemia|Hypertension\tAnti-hyperglycemic Agents|Anti-hypertensive Agents|Blinded fenofibrate or placebo plus simvastatin\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","Action to Control Cardiovascular Risk in Diabetes (ACCORD)","Interventional","Completed","Phase 3",6,10251,"atherosclerosis|diabetes mellitus|cardiovascular diseases|hypercholesterolemia|coronary disease|diabetes mellitus, type 2","hypoglycemic agents|antihypertensive agents|metoprolol|insulin|carvedilol|furosemide|amlodipine|hydrochlorothiazide-triamterene|insulin, globin zinc|simvastatin|insulin aspart|hydrochlorothiazide|hydralazine|hydrochlorothiazide, lisinopril drug combination|candesartan cilexetil|diltiazem|candesartan|fenofibrate|chlorthalidone|reserpine|insulin detemir|acarbose|repaglinide|benazepril|pioglitazone|rosiglitazone|valsartan|insulin glargine|glimepiride|metformin|felodipine|terazosin|lisinopril|triamterene","First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial."]
["NCT00000620",8269100,4517007,"Hazard Ratio (HR)",1.19,null,"NA",1.03,1.38,95,0.02,"Regression, Cox",18539917,"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.","\tAtherosclerosis|Cardiovascular Diseases|Coronary Disease|Diabetes Mellitus|Diabetes Mellitus, Type 2|Hypercholesterolemia|Hypertension\tAnti-hyperglycemic Agents|Anti-hypertensive Agents|Blinded fenofibrate or placebo plus simvastatin\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","Action to Control Cardiovascular Risk in Diabetes (ACCORD)","Interventional","Completed","Phase 3",6,10251,"atherosclerosis|diabetes mellitus|cardiovascular diseases|hypercholesterolemia|coronary disease|diabetes mellitus, type 2","hypoglycemic agents|antihypertensive agents|metoprolol|insulin|carvedilol|furosemide|amlodipine|hydrochlorothiazide-triamterene|insulin, globin zinc|simvastatin|insulin aspart|hydrochlorothiazide|hydralazine|hydrochlorothiazide, lisinopril drug combination|candesartan cilexetil|diltiazem|candesartan|fenofibrate|chlorthalidone|reserpine|insulin detemir|acarbose|repaglinide|benazepril|pioglitazone|rosiglitazone|valsartan|insulin glargine|glimepiride|metformin|felodipine|terazosin|lisinopril|triamterene","Death From Any Cause in the Glycemia Trial."]
["NCT00000620",8269101,4517008,"Hazard Ratio (HR)",0.91,null,"NA",0.81,1.03,95,0.12,"Regression, Cox",18539917,"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.","\tAtherosclerosis|Cardiovascular Diseases|Coronary Disease|Diabetes Mellitus|Diabetes Mellitus, Type 2|Hypercholesterolemia|Hypertension\tAnti-hyperglycemic Agents|Anti-hypertensive Agents|Blinded fenofibrate or placebo plus simvastatin\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","Action to Control Cardiovascular Risk in Diabetes (ACCORD)","Interventional","Completed","Phase 3",6,10251,"atherosclerosis|diabetes mellitus|cardiovascular diseases|hypercholesterolemia|coronary disease|diabetes mellitus, type 2","hypoglycemic agents|antihypertensive agents|metoprolol|insulin|carvedilol|furosemide|amlodipine|hydrochlorothiazide-triamterene|insulin, globin zinc|simvastatin|insulin aspart|hydrochlorothiazide|hydralazine|hydrochlorothiazide, lisinopril drug combination|candesartan cilexetil|diltiazem|candesartan|fenofibrate|chlorthalidone|reserpine|insulin detemir|acarbose|repaglinide|benazepril|pioglitazone|rosiglitazone|valsartan|insulin glargine|glimepiride|metformin|felodipine|terazosin|lisinopril|triamterene","First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial."]
["NCT00000751","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16220994,"Lambert JS. HIV vaccines in infants and children. Paediatr Drugs. 2005;7(5):267-76. Review.","\tHIV Infections|Pregnancy\tAnti-HIV Immune Serum Globulin (Human)|Globulin, Immune|Zidovudine\tNA\tNA\tNA\tDrug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","hiv infections","immune sera|immunoglobulins|antibodies|zidovudine","NA"]
["NCT00000762","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16220994,"Lambert JS. HIV vaccines in infants and children. Paediatr Drugs. 2005;7(5):267-76. Review.","\tHIV Infections\trgp120/HIV-1MN|rgp120/HIV-1 SF-2|gp160 Vaccine (MicroGeneSys)\tNA\tNA\tNA\tBiological|Biological|Biological\tAll\t","NA","NA","NA","NA","NA","NA","infection|hiv infections|communicable diseases|acquired immunodeficiency syndrome","NA","NA"]
["NCT00000797","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","10235512|10509574|10839595|11010840|11176266|11349192|10979903|11064503|11312425|11404529|12626890|11981366|11902857|15061857|12865452|12172526|12240742|11786101|11684935|11588516|10954885|15220706|15090767|15486845|15385731|15356788|14657755|14673762|11797182|15226134|15265968|14970148|14583870|15238776|12853757|14507605|12439806|12792357|15307009|14742653|12854075|15075546|15090836|12789150|12599073|16227797|11716886|16260908|16135508|16603858|16301151|16549012","Massad LS, Riester KA, Anastos KM, Fruchter RG, Palefsky JM, Burk RD, Burns D, Greenblatt RM, Muderspach LI, Miotti P. Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. Women's Interagency HIV Study Group. J Acquir Immune Defic Syndr. 1999 May 1;21(1):33-41.|Anastos K, Kalish LA, Hessol N, Weiser B, Melnick S, Burns D, Delapenha R, DeHovitz J, Cohen M, Meyer W, Bremer J, Kovacs A. The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: results of the women's interagency HIV study. AIDS. 1999 Sep 10;13(13):1717-26. Erratum in: AIDS 2000 May 5;14(7):891.|Feldman JG, Burns DN, Gange SJ, Bacchetti P, Cohen M, Anastos K, Nowicki M, Delapena R, Miotti P. Serum albumin as a predictor of survival in HIV-infected women in the Women's Interagency HIV study. AIDS. 2000 May 5;14(7):863-70.|DeHovitz JA, Kovacs A, Feldman JG, Anastos K, Young M, Cohen M, Gange SJ, Melnick S, Greenblatt RM. The relationship between virus load response to highly active antiretroviral therapy and change in CD4 cell counts: A report from the Women's interagency HIV study. J Infect Dis. 2000 Nov;182(5):1527-30. Epub 2000 Sep 27.|Levine AM, Berhane K, Masri-Lavine L, Sanchez M, Young M, Augenbraun M, Cohen M, Anastos K, Newman M, Gange SJ, Watts H. Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):28-35.|Minkoff H, Ahdieh L, Watts H, Greenblatt RM, Schmidt J, Schneider M, Stek A. The relationship of pregnancy to the use of highly active antiretroviral therapy. Am J Obstet Gynecol. 2001 May;184(6):1221-7.|French AL, Kirstein LM, Massad LS, Semba RD, Minkoff H, Landesman S, Palefsky J, Young M, Anastos K, Cohen MH. Association of vitamin A deficiency with cervical squamous intraepithelial lesions in human immunodeficiency virus-infected women. J Infect Dis. 2000 Oct;182(4):1084-9. Epub 2000 Sep 1.|Greenspan D, Komaroff E, Redford M, Phelan JA, Navazesh M, Alves ME, Kamrath H, Mulligan R, Barr CE, Greenspan JS. Oral mucosal lesions and HIV viral load in the Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):44-50.|Mirmirani P, Hessol NA, Maurer TA, Berger TG, Nguyen P, Khalsa A, Gurtman A, Micci S, Young M, Holman S, Gange SJ, Greenblatt RM. Prevalence and predictors of skin disease in the Women's Interagency HIV Study (WIHS). J Am Acad Dermatol. 2001 May;44(5):785-8.|Stancliff S, Abel S, Agins B. Oral mucosal lesions and HIV viral load in the Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr. 2001 May 1;27(1):96-7.|Justman JE, Benning L, Danoff A, Minkoff H, Levine A, Greenblatt RM, Weber K, Piessens E, Robison E, Anastos K. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):298-302.|Kirstein LM, Greenblatt RM, Anastos K, Levine A, French AL, Minkoff H, Silver S, Gange SJ; Women's Interagency HIV Study Collaborative Research Group. Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):495-503.|Preston-Martin S, Kirstein LM, Pogoda JM, Rimer B, Melnick S, Masri-Lavine L, Silver S, Hessol N, French AL, Feldman J, Sacks HS, Deely M, Levine AM. Use of mammographic screening by HIV-infected women in the Women's Interagency HIV Study (WIHS). Prev Med. 2002 Mar;34(3):386-92.|Mulligan R, Phelan JA, Brunelle J, Redford M, Pogoda JM, Nelson E, Seirawan H, Greenspan JS, Navazesh M, Greenspan D, Alves ME. Baseline characteristics of participants in the oral health component of the Women's Interagency HIV Study. Community Dent Oral Epidemiol. 2004 Apr;32(2):86-98.|Strickler HD, Palefsky JM, Shah KV, Anastos K, Klein RS, Minkoff H, Duerr A, Massad LS, Celentano DD, Hall C, Fazzari M, Cu-Uvin S, Bacon M, Schuman P, Levine AM, Durante AJ, Gange S, Melnick S, Burk RD. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst. 2003 Jul 16;95(14):1062-71.|Silverberg MJ, Ahdieh L, Munoz A, Anastos K, Burk RD, Cu-Uvin S, Duerr A, Greenblatt RM, Klein RS, Massad S, Minkoff H, Muderspach L, Palefsky J, Piessens E, Schuman P, Watts H, Shah KV. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis. 2002 Aug;29(8):427-35.|Richardson JL, Martin EM, Jimenez N, Danley K, Cohen M, Carson VL, Sinclair B, Racenstein JM, Reed RA, Levine AM. Neuropsychological functioning in a cohort of HIV infected women: importance of antiretroviral therapy. J Int Neuropsychol Soc. 2002 Sep;8(6):781-93. Erratum in: J Int Neuropsychol Soc. 2005 Jan;11(1):120.|Szczech LA, Gange SJ, van der Horst C, Bartlett JA, Young M, Cohen MH, Anastos K, Klassen PS, Svetkey LP. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int. 2002 Jan;61(1):195-202.|Minkoff H, Ahdieh L, Massad LS, Anastos K, Watts DH, Melnick S, Muderspach L, Burk R, Palefsky J. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS. 2001 Nov 9;15(16):2157-64.|Augenbraun M, Tarwater P, Greenblatt R, Cohen M, French A, Gore ME, Watts H, Preston-Martin S, Anastos K; Women's Interagency HIV Study (WIHS). Opportunistic infection prophylaxis in the women's interagency HIV study (WIHS). J Acquir Immune Defic Syndr. 2001 Oct 1;28(2):195-6.|Hessol NA, Anastos K, Levine AM, Ameli N, Cohen M, Young M, Augenbraun M, Miotti P, Gange SJ. Factors associated with incident self-reported AIDS among women enrolled in the women's interagency HIV study (WIHS). WIHS Collaboratorive Study Group. AIDS Res Hum Retroviruses. 2000 Aug 10;16(12):1105-11.|Hessol NA, Seaberg EC, Preston-Martin S, Massad LS, Sacks HS, Silver S, Melnick S, Abulafia O, Levine AM; WIHS Collaborative Study Group. Cancer risk among participants in the women's interagency HIV study. J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85.|Palacio H, Li X, Wilson TE, Sacks H, Cohen MH, Richardson J, Young M, Muñoz A; Women's Interagency HIV Study (WIHS). Healthcare use by varied highly active antiretroviral therapy (HAART) strata: HAART use, discontinuation, and naivety. AIDS. 2004 Mar 5;18(4):621-30.|Szczech LA, Hoover DR, Feldman JG, Cohen MH, Gange SJ, Goozé L, Rubin NR, Young MA, Cai X, Shi Q, Gao W, Anastos K. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis. 2004 Oct 15;39(8):1199-206. Epub 2004 Sep 27.|Berhane K, Karim R, Cohen MH, Masri-Lavine L, Young M, Anastos K, Augenbraun M, Watts DH, Levine AM. Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1245-52.|Silverberg MJ, Gore ME, French AL, Gandhi M, Glesby MJ, Kovacs A, Wilson TE, Young MA, Gange SJ. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. Clin Infect Dis. 2004 Sep 1;39(5):717-24. Epub 2004 Aug 16.|Tien PC, Cole SR, Williams CM, Li R, Justman JE, Cohen MH, Young M, Rubin N, Augenbraun M, Grunfeld C. Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):461-6.|Viscidi RP, Ahdieh-Grant L, Schneider MF, Clayman B, Massad LS, Anastos KM, Burk RD, Minkoff H, Palefsky J, Levine A, Strickler H. Serum immunoglobulin A response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis. 2003 Dec 15;188(12):1834-44. Epub 2003 Dec 5.|Wilson TE, Barrón Y, Cohen M, Richardson J, Greenblatt R, Sacks HS, Young M; Women's Interagency HIV Study. Adherence to antiretroviral therapy and its association with sexual behavior in a national sample of women with human immunodeficiency virus. Clin Infect Dis. 2002 Feb 15;34(4):529-34. Epub 2002 Jan 9.|Wilson TE, Gore ME, Greenblatt R, Cohen M, Minkoff H, Silver S, Robison E, Levine A, Gange SJ. Changes in sexual behavior among HIV-infected women after initiation of HAART. Am J Public Health. 2004 Jul;94(7):1141-6.|Ahdieh-Grant L, Li R, Levine AM, Massad LS, Strickler HD, Minkoff H, Moxley M, Palefsky J, Sacks H, Burk RD, Gange SJ. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst. 2004 Jul 21;96(14):1070-6.|Anastos K, Barrón Y, Cohen MH, Greenblatt RM, Minkoff H, Levine A, Young M, Gange SJ. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med. 2004 Feb 17;140(4):256-64.|Augenbraun M, Goedert JJ, Thomas D, Feldman J, Seaberg EC, French AL, Robison E, Nowicki M, Terrault N. Incident hepatitis C virus in women with human immunodeficiency virus infection. Clin Infect Dis. 2003 Nov 15;37(10):1357-64. Epub 2003 Oct 14.|Barrón Y, Cole SR, Greenblatt RM, Cohen MH, Anastos K, DeHovitz JA, Delapenha R, Gange SJ. Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy. AIDS. 2004 Jul 23;18(11):1579-84.|Cejtin HE, Jacobson L, Springer G, Watts DH, Levine A, Greenblatt R, Anastos K, Minkoff HL, Massad LS, Schmidt JB. Effect of hormonal contraceptive use on plasma HIV-1-RNA levels among HIV-infected women. AIDS. 2003 Jul 25;17(11):1702-4.|Cole SR, Hernán MA, Robins JM, Anastos K, Chmiel J, Detels R, Ervin C, Feldman J, Greenblatt R, Kingsley L, Lai S, Young M, Cohen M, Muñoz A. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol. 2003 Oct 1;158(7):687-94.|Falusi O, French AL, Seaberg EC, Tien PC, Watts DH, Minkoff H, Piessens E, Kovacs A, Anastos K, Cohen MH. Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection. Clin Infect Dis. 2002 Dec 1;35(11):1414-7. Epub 2002 Nov 11.|Feldman JG, Gange SJ, Bacchetti P, Cohen M, Young M, Squires KE, Williams C, Goldwasser P, Anastos K. Serum albumin is a powerful predictor of survival among HIV-1-infected women. J Acquir Immune Defic Syndr. 2003 May 1;33(1):66-73.|French AL, Benning L, Anastos K, Augenbraun M, Nowicki M, Sathasivam K, Terrault NA. Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection. Clin Infect Dis. 2004 Aug 1;39(3):402-10. Epub 2004 Jul 12.|Greenspan D, Gange SJ, Phelan JA, Navazesh M, Alves ME, MacPhail LA, Mulligan R, Greenspan JS. Incidence of oral lesions in HIV-1-infected women: reduction with HAART. J Dent Res. 2004 Feb;83(2):145-50.|Landay A, Benning L, Bremer J, Weiser B, Burger H, Nowicki M, Kovacs A. Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugs. J Infect Dis. 2003 Jul 15;188(2):209-18. Epub 2003 Jul 1.|Massad LS, Springer G, Jacobson L, Watts H, Anastos K, Korn A, Cejtin H, Stek A, Young M, Schmidt J, Minkoff H. Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. AIDS. 2004 Jan 23;18(2):281-6.|Massad LS, Seaberg EC, Watts DH, Hessol NA, Melnick S, Bitterman P, Anastos K, Silver S, Levine AM, Minkoff H. Low incidence of invasive cervical cancer among HIV-infected US women in a prevention program. AIDS. 2004 Jan 2;18(1):109-13.|Navazesh M, Mulligan R, Barrón Y, Redford M, Greenspan D, Alves M, Phelan J; Women's Interagency HIV Study participants. A 4-year longitudinal evaluation of xerostomia and salivary gland hypofunction in the Women's Interagency HIV Study participants. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Jun;95(6):693-8.|Philpott S, Weiser B, Tarwater P, Vermund SH, Kleeberger CA, Gange SJ, Anastos K, Cohen M, Greenblatt RM, Kovacs A, Minkoff H, Young MA, Miotti P, Dupuis M, Chen CH, Burger H. CC chemokine receptor 5 genotype and susceptibility to transmission of human immunodeficiency virus type 1 in women. J Infect Dis. 2003 Feb 15;187(4):569-75. Epub 2003 Jan 29.|Gandhi M, Ameli N, Bacchetti P, Sharp GB, French AL, Young M, Gange SJ, Anastos K, Holman S, Levine A, Greenblatt RM. Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS. 2005 Nov 4;19(16):1885-96.|Kovacs A, Wasserman SS, Burns D, Wright DJ, Cohn J, Landay A, Weber K, Cohen M, Levine A, Minkoff H, Miotti P, Palefsky J, Young M, Reichelderfer P; DATRI Study Group; WIHS Study Group. Determinants of HIV-1 shedding in the genital tract of women. Lancet. 2001 Nov 10;358(9293):1593-601. Erratum in: Lancet 2002 Feb 16;359(9306):630.|Schneider MF, Gange SJ, Williams CM, Anastos K, Greenblatt RM, Kingsley L, Detels R, Muñoz A. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS. 2005 Nov 18;19(17):2009-18.|Chu H, Gange SJ, Yamashita TE, Hoover DR, Chmiel JS, Margolick JB, Jacobson LP. Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: an application using a Bayesian random change-point model. Am J Epidemiol. 2005 Oct 15;162(8):787-97. Epub 2005 Aug 31.|Ameli N, Bacchetti P, Morrow RA, Hessol NA, Wilkin T, Young M, Cohen M, Minkoff H, Gange SJ, Greenblatt RM. Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations. AIDS. 2006 Apr 24;20(7):1051-8.|Navazesh M, Mulligan R, Pogoda J, Greenspan D, Alves M, Phelan J, Greenspan J, Slots J. The effect of HAART on salivary microbiota in the Women's Interagency HIV Study (WIHS). Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Dec;100(6):701-8. Epub 2005 Jan 25.|Liu C, Weber K, Robison E, Hu Z, Jacobson LP, Gange SJ. Assessing the effect of HAART on change in quality of life among HIV-infected women. AIDS Res Ther. 2006 Mar 20;3:6.","\tHIV Infections\tNA\tNA\tNA\tNA\tNA\tFemale\t","NA","NA","NA","NA","NA","NA","hiv infections","NA","NA"]
["NCT00000815","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21666159,"Chandwani S, Beeler J, Li H, Audet S, Smith B, Moye J, Nalin D, Krasinski K; PACTG 225 Study Team. Safety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225. J Infect Dis. 2011 Jul;204 Suppl 1:S179-89. doi: 10.1093/infdis/jir089.","\tHIV Infections|Measles\tAttenuvax|M-M-R-II\tParallel Assignment\tTreatment\tRandomized\tBiological|Biological\tAll\t","A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group","Interventional","Completed","Phase 2",2,270,"measles","NA","NA"]
["NCT00000826","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15470330,"Winter HR, Trapnell CB, Slattery JT, Jacobson M, Greenspan DL, Hooton TM, Unadkat JD. The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283). Clin Pharmacol Ther. 2004 Oct;76(4):313-22.","\tBacterial Infections|HIV Infections|Mycoses\tClarithromycin|Rifabutin|Sulfamethoxazole-Trimethoprim|Dapsone|Fluconazole\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","bacterial infections|communicable diseases|infection|mycoses","fluconazole|rifabutin|clarithromycin|trimethoprim, sulfamethoxazole drug combination|trimethoprim|sulfamethoxazole|dapsone","NA"]
["NCT00000841","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15892437|16547789|20547574","Mrus JM, Williams PL, Tsevat J, Cohn SE, Wu AW. Gender differences in health-related quality of life in patients with HIV/AIDS. Qual Life Res. 2005 Mar;14(2):479-91.|Mrus JM, Schackman BR, Wu AW, Freedberg KA, Tsevat J, Yi MS, Zackin R. Variations in self-rated health among patients with HIV infection. Qual Life Res. 2006 Apr;15(3):503-14.|Cole SR, Stuart EA. Generalizing evidence from randomized clinical trials to target populations: The ACTG 320 trial. Am J Epidemiol. 2010 Jul 1;172(1):107-15. doi: 10.1093/aje/kwq084. Epub 2010 Jun 14.","\tHIV Infections\tIndinavir sulfate|Lamivudine|Stavudine|Zidovudine\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections|acquired immunodeficiency syndrome|infection","zidovudine|stavudine|indinavir|lamivudine","NA"]
["NCT00000844","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",10634196,"Alston B, Ellenberg JH, Standiford HC, Muth K, Martinez A, Greaves W, Kumi J. A multicenter, randomized, controlled trial of three preparations of low-dose oral alpha-interferon in HIV-infected patients with CD4+ counts between 50 and 350 cells/mm(3). Division of AIDS Treatment Research Initiative (DATRI) 022 Study Group. J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):348-57.","\tHIV Infections\tInterferon alfa-n3|Interferon alfa-n1\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","interferons|interferon-alpha","NA"]
["NCT00000859","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15002082|16192247","Perez G, MacArthur RD, Walmsley S, Baxter JA, Mullin C, Neaton JD; Terry Beirn Community Programs for Clinical Research on AIDS; Canadian Trials Network. A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102). HIV Clin Trials. 2004 Jan-Feb;5(1):7-18.|MacArthur RD, Perez G, Walmsley S, Baxter JD, Mullin CM, Neaton JD; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) 042/045; Canadian HIV Trials Network (CTN) 102 Protocol Teams. Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy. HIV Clin Trials. 2005 May-Jun;6(3):127-35.","\tHIV Infections\tIndinavir sulfate|Ritonavir|Nelfinavir mesylate\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","indinavir|nelfinavir|ritonavir","NA"]
["NCT00000867","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17721095|20400412","Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, Ernst T, Jarvik JG, Miller EN, Singer EJ, Ellis RJ, Kolson DL, Simpson D, Nath A, Berger J, Shriver SL, Millar LL, Colquhoun D, Lenkinski R, Gonzalez RG, Lipton SA; Adult AIDS Clinical Trial Group (ACTG) 301; 700 Teams; HIV MRS Consortium. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS. 2007 Sep 12;21(14):1877-86.|Zhao Y, Navia BA, Marra CM, Singer EJ, Chang L, Berger J, Ellis RJ, Kolson DL, Simpson D, Miller EN, Lipton SA, Evans SR, Schifitto G; Adult Aids Clinical Trial Group (ACTG) 301 Team. Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin Trials. 2010 Jan-Feb;11(1):59-67. doi: 10.1310/hct1101-59.","\tAIDS Dementia Complex|HIV Infections\tMemantine\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","aids dementia complex|dementia","memantine","NA"]
["NCT00000869","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17584491,"Newell ML, Huang S, Fiore S, Thorne C, Mandelbrot L, Sullivan JL, Maupin R, Delke I, Watts DH, Gelber RD, Cunningham CK; PACTG 316 Study Team. Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USA. BMC Infect Dis. 2007 Jun 20;7:60.","\tHIV Infections|Pregnancy\tNevirapine\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","nevirapine","NA"]
["NCT00000879","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16220994,"Lambert JS. HIV vaccines in infants and children. Paediatr Drugs. 2005;7(5):267-76. Review.","\tHIV Infections|HIV Seronegativity\tALVAC(2)120(B,MN)GNP (vCP1452)|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|ALVAC-HIV MN120TMG (vCP205)\tNA\tNA\tNA\tBiological|Biological|Biological\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","NA","NA"]
["NCT00000883","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21293986,"Cohn SE, Jiang H, McCutchan JA, Koletar SL, Murphy RL, Robertson KR, de St Maurice AM, Currier JS, Williams PL. Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care. 2011 Jun;23(6):775-85. doi: 10.1080/09540121.2010.525617.","\tHIV Infections|Mycobacterium Avium-intracellulare Infection\tAzithromycin\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","mycobacterium avium-intracellulare infection|mycobacterium infections|communicable diseases|infection","azithromycin","NA"]
["NCT00000887","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18474496,"Bryson YJ, Mirochnick M, Stek A, Mofenson LM, Connor J, Capparelli E, Watts DH, Huang S, Hughes MD, Kaiser K, Purdue L, Asfaw Y, Keller M, Smith E; PACTG 353 Team. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clin Trials. 2008 Mar-Apr;9(2):115-25. doi: 10.1310/hct0902-115.","\tHIV Infections|Pregnancy\tNelfinavir mesylate|Lamivudine|Zidovudine\tNA\tNA\tNA\tDrug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","hiv infections","zidovudine|nelfinavir|lamivudine","NA"]
["NCT00000888","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16148846,"Chadwick EG, Rodman JH, Britto P, Powell C, Palumbo P, Luzuriaga K, Hughes M, Abrams EJ, Flynn PM, Borkowsky W, Yogev R; PACTG Protocol 345 Team. Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age. Pediatr Infect Dis J. 2005 Sep;24(9):793-800.","\tHIV Infections|Pregnancy\tRitonavir|Lamivudine|Zidovudine\tNA\tNA\tNA\tDrug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","hiv infections","zidovudine|lamivudine|ritonavir","NA"]
["NCT00000892","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","11023461|12195349|15031785|15295692|16249704|17507321","Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis. 2000 Nov;182(5):1375-84. Epub 2000 Oct 9.|Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D. Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. J Infect Dis. 2002 Sep 1;186(5):626-33. Epub 2002 Aug 9.|Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, Gulick RM. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis. 2004 Apr 1;189(7):1176-84. Epub 2004 Mar 16.|Swanstrom R, Bosch RJ, Katzenstein D, Cheng H, Jiang H, Hellmann N, Haubrich R, Fiscus SA, Fletcher CV, Acosta EP, Gulick RM; AIDS Clinical Trials Group Protocol 359 Team. Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. J Infect Dis. 2004 Sep 1;190(5):886-93. Epub 2004 Jul 23.|Fletcher CV, Testa MA, Brundage RC, Chesney MA, Haubrich R, Acosta EP, Martinez A, Jiang H, Gulick RM. Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359. J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):301-6.|Haubrich RH, Jiang H, Swanstrom R, Bates M, Katzenstein D, Petch L, Fletcher CV, Fiscus SA, Gulick RM; AIDS Clinical Trials Group Protocol 359 Team. Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359. HIV Clin Trials. 2007 Mar-Apr;8(2):63-7.","\tHIV Infections\tRitonavir|Nelfinavir mesylate|Levocarnitine|Adefovir dipivoxil|Saquinavir|Delavirdine mesylate\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","ritonavir|adefovir|adefovir dipivoxil|nelfinavir|delavirdine|saquinavir","NA"]
["NCT00000893","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","10601506|11069252|15750390|17893156","Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, Manion D, Ruiz N, Gersten M, Becker M, McNamara J, Mofenson LM, Purdue L, Siminski S, Graham B, Kornhauser DM, Fiske W, Vincent C, Lischner HW, Dankner WM, Flynn PM. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med. 1999 Dec 16;341(25):1874-81.|Spector SA, Hsia K, Yong FH, Cabral S, Fenton T, Fletcher CV, McNamara J, Mofenson LM, Starr SE. Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children. J Infect Dis. 2000 Dec;182(6):1769-73. Epub 2000 Oct 26.|Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R, Starr S, Spector SA. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS. 2005 Mar 4;19(4):371-80.|Saitoh A, Fenton T, Alvero C, Fletcher CV, Spector SA. Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy. Antimicrob Agents Chemother. 2007 Dec;51(12):4236-42. Epub 2007 Sep 24.","\tHIV Infections\tNelfinavir mesylate|Efavirenz\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","nelfinavir|efavirenz","NA"]
["NCT00000895","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16131307,"MacGregor RR, Hafner R, Wu JW, Murphy RL, Perlman DC, Bermudez LE, Inderlied CB, Picker LJ, Wallis RS, Andersen JW, Mahon LF, Koletar SL, Peterson DM; ACTG Protocol 341 Team. Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study. AIDS Res Hum Retroviruses. 2005 Aug;21(8):689-95.","\tHIV Infections|Mycobacterium Avium-intracellulare Infection\tNelfinavir mesylate|Nevirapine|Azithromycin\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","opportunistic infections|communicable diseases|mycobacterium infections|mycobacterium avium-intracellulare infection|hiv infections|acquired immunodeficiency syndrome|infection","azithromycin|nelfinavir|nevirapine","NA"]
["NCT00000902","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18090046|NA|NA","Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS. 2007 Oct 18;21(16):2191-9.|EV Capparelli, SK Burchett, A Kovacs, M Khoury, R Oyomopito, L Mofenson, B Zimmer, D Holland. Characterization of the Ritonavir-Nelfinavir Pharmacokinetic Interaction in Pediatric Patients with Advanced HIV Disease Using a Mixed Effects Modeling Approach, Pharmacotherapy, (2003), Abstract 67, Vol.23, No.3, pp.401.|S. Burchett, M. Khoury, K. McIntosh, V. Carey, R. Oyomopito, L. Mofenson, E. Smith, A. Kovacs, Viral Load Reduction in Children with Advanced HIV Disease Treated with 4-Drug Antiretroviral Treatment Regimens Including NRTIs, Nevirapine, Nelfinavir and/or Ritonavir, CROI, 2000.","\tHIV Infections\tRitonavir|Nelfinavir mesylate|Nevirapine|Lamivudine|Stavudine|Zidovudine|Zalcitabine|Didanosine\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","ritonavir|zalcitabine|stavudine|lamivudine|didanosine|zidovudine|nevirapine|nelfinavir","NA"]
["NCT00000903","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12934177|15356820|14982784","Fischl MA, Ribaudo HJ, Collier AC, Erice A, Giuliano M, Dehlinger M, Eron JJ Jr, Saag MS, Hammer SM, Vella S, Morse GD, Feinberg JE, Demeter LM, Eshleman SH; Adult AIDS Clinical Trials Group 388 Study Team. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis. 2003 Sep 1;188(5):625-34. Epub 2003 Aug 15. Erratum in: J Infect Dis. 2003 Oct 1;188(7):1083.|Demeter LM, Ribaudo HJ, Erice A, Eshleman SH, Hammer SM, Hellmann NS, Fischl MA; AIDS Clinical Trials Group Protocol 388. HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388. Clin Infect Dis. 2004 Aug 15;39(4):552-8. Epub 2004 Jul 30.|DiCenzo R, Forrest A, Fischl MA, Collier A, Feinberg J, Ribaudo H, DiFrancecso R, Morse GD; AIDS Clinical Trials Group 388/733/5060 Study Team. Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2004 Mar;48(3):918-23.","\tHIV Infections\tIndinavir sulfate|Lamivudine/Zidovudine|Nelfinavir mesylate|Efavirenz\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","lamivudine, zidovudine drug combination|nelfinavir|indinavir|lamivudine|zidovudine|efavirenz","NA"]
["NCT00000905","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16192248,"Wohl DA, Kendall MA, Owens S, Holland G, Nokta M, Spector SA, Schrier R, Fiscus S, Davis M, Jacobson MA, Currier JS, Squires K, Alston-Smith B, Andersen J, Freeman WR, Higgins M, Torriani FJ; ACTG 379 Study Team. The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. HIV Clin Trials. 2005 May-Jun;6(3):136-46.","\tCytomegalovirus Retinitis|HIV Infections\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","retinitis|cytomegalovirus retinitis","NA","NA"]
["NCT00000912","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17726714|21337357","Sun J, Nagaraj HN, Reynolds NR. Discrete stochastic models for compliance analysis based on an AIDS Clinical Trial Group (ACTG) study. Biom J. 2007 Aug;49(5):731-41.|Ghosh P, Ghosh K, Tiwari RC. Joint modeling of longitudinal data and informative dropout time in the presence of multiple changepoints. Stat Med. 2011 Mar 15;30(6):611-26. doi: 10.1002/sim.4119. Epub 2010 Nov 30.","\tHIV Infections\tIndinavir sulfate|Abacavir sulfate|Amprenavir|Nelfinavir mesylate|Efavirenz|Levocarnitine|Adefovir dipivoxil|Saquinavir\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","nelfinavir|amprenavir|efavirenz|adefovir dipivoxil|saquinavir|abacavir|adefovir|indinavir","NA"]
["NCT00000919","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","14668456|14668455|15187476|16103764|16048984|16267764|16810109|17662759","Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC; AIDS Clinical Trials Group 384 Team. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003 Dec 11;349(24):2304-15.|Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dubé MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, Vella S, Merigan TC, Hirsch MS; AIDS Clinical Trials Group 384 Team. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003 Dec 11;349(24):2293-303.|Reynolds NR, Testa MA, Marc LG, Chesney MA, Neidig JL, Smith SR, Vella S, Robbins GK; Protocol Teams of ACTG 384, ACTG 731 and A5031s. Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study. AIDS Behav. 2004 Jun;8(2):141-50.|Hulgan T, Haas DW, Haines JL, Ritchie MD, Robbins GK, Shafer RW, Clifford DB, Kallianpur AR, Summar M, Canter JA. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS. 2005 Sep 2;19(13):1341-9.|Smith PF, Robbins GK, Shafer RW, Wu H, Yu S, Hirsch MS, Merigan TC, Park JG, Forrest A, Fischl MA, Morse GD; ACTG 384-5006 Team. Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2005 Aug;49(8):3558-61.|Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL Jr, Donahue JP, Kim RB. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005 Dec 1;192(11):1931-42. Epub 2005 Nov 1.|Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, Merigan TC, Hirsch MS, Shafer RW, Robbins GK, Pollard RB; ACTG 384 Team. Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):426-34.|Marc LG, Testa MA, Walker AM, Robbins GK, Shafer RW, Anderson NB, Berkman LF; ACTG Data Analysis Concept Sheet Study Team. Educational attainment and response to HAART during initial therapy for HIV-1 infection. J Psychosom Res. 2007 Aug;63(2):207-16.","\tHIV Infections\tIndinavir sulfate|Lamivudine/Zidovudine|Ritonavir|Hydroxyurea|Abacavir sulfate|Amprenavir|Nelfinavir mesylate|Efavirenz|Lamivudine|Stavudine|Zidovudine|Didanosine\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","infection|acquired immunodeficiency syndrome|hiv infections|communicable diseases","lamivudine|hydroxyurea|ritonavir|nelfinavir|lamivudine, zidovudine drug combination|stavudine|didanosine|indinavir|amprenavir|abacavir|efavirenz|zidovudine","NA"]
["NCT00000922","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","11306155|18176329|18977721|17174704","MacArthur RD, Chen L, Mayers DL, Besch CL, Novak R, van den Berg-Wolf M, Yurik T, Peng G, Schmetter B, Brizz B, Abrams D; CPCRA 058 FIRST Trial Study Team. The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial. Control Clin Trials. 2001 Apr;22(2):176-90.|Tedaldi EM, Absalon J, Thomas AJ, Shlay JC, van den Berg-Wolf M. Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):441-8. doi: 10.1097/QAI.0b013e3181609da8.|van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, Chen L, Crane LR, Macarthur RD; CPCRA 058 Study Team, the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA), and The International Network for Strategic Initiative in Global HIV Trials (INSIGHT). Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clin Trials. 2008 Sep-Oct;9(5):324-36. doi: 10.1310/hct0905-324.|MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Hullsiek KH, Kozal MJ, van den Berg-Wolf M, Henely C, Schmetter B, Dehlinger M; CPCRA 058 Study Team; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet. 2006 Dec 16;368(9553):2125-35.","\tHIV Infections\tIndinavir sulfate|Abacavir sulfate|Nelfinavir mesylate|Efavirenz|Nevirapine|Lamivudine|Stavudine|Didanosine\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","abacavir|didanosine|stavudine|lamivudine|nevirapine|efavirenz|nelfinavir|indinavir","NA"]
["NCT00000923","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20687947,"Bosch RJ, Pollard RB, Landay A, Aga E, Fox L, Mitsuyasu R. Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328). AIDS Res Ther. 2010 Aug 5;7:30. doi: 10.1186/1742-6405-7-30.","\tHIV Infections\tIndinavir sulfate|Lamivudine|Stavudine|Zidovudine|Didanosine|Aldesleukin\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","zidovudine|indinavir|lamivudine|stavudine|didanosine|aldesleukin","NA"]
["NCT00000924","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16220085,"King JR, Nachman S, Yogev R, Hodge J, Aldrovandi G, Hughes MD, Chen J, Wiznia A, Damle B, Acosta EP. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403. Pediatr Infect Dis J. 2005 Oct;24(10):880-5.","\tHIV Infections\tRitonavir|Nelfinavir mesylate|Nevirapine|Stavudine|Didanosine\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","nelfinavir|nevirapine|stavudine|didanosine|ritonavir","NA"]
["NCT00000926","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16773032,"Kumwenda N, Hoffman I, Chirenje M, Kelly C, Coletti A, Ristow A, Martinson F, Brown J, Chilongozi D, Richardson B, Rosenberg Z, Padian N, Taha T. HIV incidence among women of reproductive age in Malawi and Zimbabwe. Sex Transm Dis. 2006 Nov;33(11):646-51.","\tHIV Infections\tNonoxynol-9\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","communicable diseases|hiv infections|infection|acquired immunodeficiency syndrome","nonoxynol","NA"]
["NCT00000931","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15234855,"Koblin B, Chesney M, Coates T; EXPLORE Study Team. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet. 2004 Jul 3-9;364(9428):41-50.","\tHIV Infections\tBehavioral intervention|Risk-reduction counseling\tNA\tNA\tNA\tBehavioral|Behavioral\tMale\t","NA","NA","NA","NA","NA","NA","hiv infections","NA","NA"]
["NCT00000932","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19194318,"Goetz MB, Leduc R, Kostman JR, Labriola AM, Lie Y, Weidler J, Coakley E, Bates M, Luskin-Hawk R; Long-Term Monitoring Study (CPCRA 060) and Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection. J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):259-66. doi: 10.1097/QAI.0b013e3181989a8b. Erratum in: J Acquir Immune Defic Syndr. 2009 May 1;51(1):110.","\tHIV Infections\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","NA","NA"]
["NCT00000940","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19696651|21637110","Volberding P, Demeter L, Bosch RJ, Aga E, Pettinelli C, Hirsch M, Vogler M, Martinez A, Little S, Connick E; ACTG 371 Team. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS. 2009 Sep 24;23(15):1987-95. doi: 10.1097/QAD.0b013e32832eb285.|Connick E, Bosch RJ, Aga E, Schlichtemeier R, Demeter LM, Volberding P; ACTG 709 Team. Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection. J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):1-8. doi: 10.1097/QAI.0b013e318224d0c7.","\tHIV Infections\tStavudine|Ritonavir|Abacavir sulfate|Amprenavir|Lamivudine\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","infection|hiv infections|acquired immunodeficiency syndrome","stavudine|abacavir|lamivudine|amprenavir|ritonavir","NA"]
["NCT00000952","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16148846,"Chadwick EG, Rodman JH, Britto P, Powell C, Palumbo P, Luzuriaga K, Hughes M, Abrams EJ, Flynn PM, Borkowsky W, Yogev R; PACTG Protocol 345 Team. Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age. Pediatr Infect Dis J. 2005 Sep;24(9):793-800.","\tHIV Infections\tRitonavir|Lamivudine|Zidovudine\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","ritonavir|lamivudine|zidovudine","NA"]
["NCT00000960","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20103953,"Edathodu J, Halim MM, Dahham MB, Alrajhi AA. Mother-to-child transmission of HIV: experience at a referral hospital in Saudi Arabia. Ann Saudi Med. 2010 Jan-Feb;30(1):15-7. doi: 10.4103/0256-4947.59367.","\tHIV Infections|Pregnancy\tZidovudine\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","zidovudine","NA"]
["NCT00000979","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","8229656|8843205|8843206|15736019","Richardson D, Liou SH, Kahn JO. Uric acid and didanosine compliance in AIDS clinical trials: an analysis of AIDS Clinical Trials Group protocols 116A and 116B/117. J Acquir Immune Defic Syndr (1988). 1993 Nov;6(11):1212-23.|Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, Johnson VA, Kuritzkes DR, D'Aquila RT, Reichelderfer PA, Richman DD, Reichman R, Fischl M, Dolin R, Coombs RW, Kahn JO, McLaren C, Todd J, Kwok S, Crumpacker CS. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. J Infect Dis. 1996 Oct;174(4):696-703.|Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, Johnson VA, Kuritzkes DR, Richman DD, Kwok S, Todd J, Jackson JB, DeGruttola V, Crumpacker CS, Kahn J. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. J Infect Dis. 1996 Oct;174(4):704-12.|Mildvan D, Spritzler J, Grossberg SE, Fahey JL, Johnston DM, Schock BR, Kagan J. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. Clin Infect Dis. 2005 Mar 15;40(6):853-8. Epub 2005 Feb 18.","\tHIV Infections\tZidovudine|Didanosine\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","acquired immunodeficiency syndrome|hiv infections|infection","zidovudine|didanosine","NA"]
["NCT00001060","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",9708408,"Bartlett JA, Wasserman SS, Hicks CB, Dodge RT, Weinhold KJ, Tacket CO, Ketter N, Wittek AE, Palker TJ, Haynes BF. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative. AIDS. 1998 Jul 30;12(11):1291-300.","\tHIV Infections\tHIV-1 C4-V3 Polyvalent Peptide Vaccine\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","NA","NA"]
["NCT00001074","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|15597521","Frank I, Boucher H, Fiscus S, Flexner C, Valentine F, Gulick R, Fox L, Eron J. Phase I/II dosing study of once-daily hydroxyurea (HU) alone vs didanosine (ddI) alone vs ddI + HU. Conf Retroviruses Opportunistic Infect. 1999 Jan 31-Feb 4;6th:143 (abstract no 402)|Frank I, Bosch RJ, Fiscus S, Valentine F, Flexner C, Segal Y, Ruan P, Gulick R, Wood K, Estep S, Fox L, Nevin T, Stevens M, Eron JJ Jr; ACTG 307 Protocol Team. Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307. AIDS Res Hum Retroviruses. 2004 Sep;20(9):916-26.","\tHIV Infections\tHydroxyurea|Didanosine\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections|acquired immunodeficiency syndrome|infection","hydroxyurea|didanosine","NA"]
["NCT00001078","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19617848,"Weinberg A, Huang S, Fenton T, Patterson-Bartlett J, Gona P, Read JS, Dankner WM, Nachman S; IMPAACT P1008 Team. Virologic and immunologic correlates with the magnitude of antibody responses to the hepatitis A vaccine in HIV-infected children on highly active antiretroviral treatment. J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):17-24. doi: 10.1097/QAI.0b013e3181b011f6.","\tHIV Infections\tHepatitis A Vaccine (Inactivated)\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","infection|opportunistic infections|communicable diseases","NA","NA"]
["NCT00001083","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|11840078|10659875|11980557|15687448|17280617","Nachman S. Lack of improvement in growth in HIV-infected children on HAART 39th Intersci Conf Antimicrob Agents Chemother. 1999 Sept 26-29 (abstract no 120)|Yogev R, Lee S, Wiznia A, Nachman S, Stanley K, Pelton S, Mofenson L, Fiscus S, Jimenez E, Rathore MH, Smith ME, Song LY, McIntosh K; Pediatrics AIDS Clinical Trials Group 338 Study Team. Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection. Pediatr Infect Dis J. 2002 Feb;21(2):119-25.|Nachman SA, Stanley K, Yogev R, Pelton S, Wiznia A, Lee S, Mofenson L, Fiscus S, Rathore M, Jimenez E, Borkowsky W, Pitt J, Smith ME, Wells B, McIntosh K. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA. 2000 Jan 26;283(4):492-8.|Nachman SA, Lindsey JC, Pelton S, Mofenson L, McIntosh K, Wiznia A, Stanley K, Yogev R. Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy. Arch Pediatr Adolesc Med. 2002 May;156(5):497-503.|Jeremy RJ, Kim S, Nozyce M, Nachman S, McIntosh K, Pelton SI, Yogev R, Wiznia A, Johnson GM, Krogstad P, Stanley K; Pediatric AIDS Clinical Trials Group (PACTG) 338 & 377 Study Teams. Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children. Pediatrics. 2005 Feb;115(2):380-7.|Fiscus SA, Kovacs A, Petch LA, Hu C, Wiznia AA, Mofenson LM, Yogev R, McIntosh K, Pelton SI, Napravnik S, Stanley K, Nachman SA. Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338). AIDS Res Ther. 2007 Feb 6;4:2.","\tHIV Infections\tIndinavir sulfate|Ritonavir|Nevirapine|Lamivudine|Stavudine|Zidovudine\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","zidovudine|nevirapine|stavudine|lamivudine|ritonavir|indinavir","NA"]
["NCT00001086","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18215978,"Demeter LM, DeGruttola V, Lustgarten S, Bettendorf D, Fischl M, Eshleman S, Spreen W, Nguyen BY, Koval CE, Eron JJ, Hammer S, Squires K. Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials. 2008 Jan-Feb;9(1):11-25. doi: 10.1310/hct0901-11.","\tHIV Infections\tIndinavir sulfate|Abacavir sulfate|Efavirenz\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","abacavir|efavirenz|indinavir","NA"]
["NCT00001091","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|11372025|11880966|11927734|10954886|15687448|16159645|18090046","Eshleman SH, Krogstad P, Jackson JB, Lee S, Wang YG, Wei LJ, Cunningham S, Wantman M, Lindquist C, Nachman S, Palumbo P. Analysis of HIV-1 drug resistance in a randomized, controlled trial of a combination of nucleoside analog reverse transcriptase (RT) inhibitors plus nevirapine (NVP), nelfinavir (NFV), or ritonavir (RTV) in stable antiretroviral therapy-experienced HIV-infected children. 8th Conf Retro and Opportun Infect. 2001 Feb 4-8 (abstract no 468)|Eshleman SH, Krogstad P, Jackson JB, Wang YG, Lee S, Wei LJ, Cunningham S, Wantman M, Wiznia A, Johnson G, Nachman S, Palumbo P. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377). J Infect Dis. 2001 Jun 15;183(12):1732-8. Epub 2001 May 16.|Krogstad P, Lee S, Johnson G, Stanley K, McNamara J, Moye J, Jackson JB, Aguayo R, Dieudonne A, Khoury M, Mendez H, Nachman S, Wiznia A; Pediatric AIDS Clinical Trials Group 377 Study Team. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin Infect Dis. 2002 Apr 1;34(7):991-1001. Epub 2002 Feb 27.|Van Dyke RB, Lee S, Johnson GM, Wiznia A, Mohan K, Stanley K, Morse EV, Krogstad PA, Nachman S; Pediatric AIDS Clinical Trials Group Adherence Subcommittee Pediatric AIDS Clinical Trials Group 377 Study Team. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics. 2002 Apr;109(4):e61.|Wiznia A, Stanley K, Krogstad P, Johnson G, Lee S, McNamara J, Moye J, Jackson JB, Mendez H, Aguayo R, Dieudonne A, Kovacs A, Bamji M, Abrams E, Rana S, Sever J, Nachman S. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team. AIDS Res Hum Retroviruses. 2000 Aug 10;16(12):1113-21.|Jeremy RJ, Kim S, Nozyce M, Nachman S, McIntosh K, Pelton SI, Yogev R, Wiznia A, Johnson GM, Krogstad P, Stanley K; Pediatric AIDS Clinical Trials Group (PACTG) 338 & 377 Study Teams. Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children. Pediatrics. 2005 Feb;115(2):380-7.|Rosenblatt HM, Song LY, Nachman SA, Stanley KE, Krogstad PA, Johnson GM, Wiznia AA; Pediatric Aids Clinical Trials Group 377 Study Team. Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection. J Allergy Clin Immunol. 2005 Sep;116(3):698-703.|Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS. 2007 Oct 18;21(16):2191-9.","\tHIV Infections\tRitonavir|Nelfinavir mesylate|Nevirapine|Lamivudine|Stavudine\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","ritonavir|nelfinavir|stavudine|nevirapine|lamivudine","NA"]
["NCT00001097","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","14767811|15216461|16545007|17961106","Wu H, Lathey J, Ruan P, Douglas SD, Spector SA, Lindsey J, Hughes MD, Rudy BJ, Flynn PM; PACTG 381 Team. Relationship of plasma HIV-1 RNA dynamics to baseline factors and virological responses to highly active antiretroviral therapy in adolescents (aged 12-22 years) infected through high-risk behavior. J Infect Dis. 2004 Feb 15;189(4):593-601. Epub 2004 Jan 29.|Flynn PM, Rudy BJ, Douglas SD, Lathey J, Spector SA, Martinez J, Silio M, Belzer M, Friedman L, D'Angelo L, McNamara J, Hodge J, Hughes MD, Lindsey JC; Pediatric AIDS Clinical Trial Group 381 Study Team. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis. 2004 Jul 15;190(2):271-9. Epub 2004 Jun 18.|Rudy BJ, Lindsey JC, Flynn PM, Bosch RJ, Wilson CM, Hughes ME, Douglas SD; Pediatric Aids Clinical Trials Group 381 Study Team. Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort. AIDS Res Hum Retroviruses. 2006 Mar;22(3):213-21.|Flynn PM, Rudy BJ, Lindsey JC, Douglas SD, Lathey J, Spector SA, Martinez J, Silio M, Belzer M, Friedman L, D'Angelo L, Smith E, Hodge J, Hughes MD; PACTG 381 Study Team. Long-term observation of adolescents initiating HAART therapy: three-year follow-up. AIDS Res Hum Retroviruses. 2007 Oct;23(10):1208-14.","\tHIV Infections\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","NA","NA"]
["NCT00001102","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15845431|17621461","Visnegarwala F, Chen L, Raghavan S, Tedaldi E. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. J Infect. 2005 May;50(4):331-7.|Visnegarwala F, Shlay JC, Barry V, Gibert CL, Xiang Y, Wang J, Kotler D, Raghavan S, El-Sadr WM; for Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Effects of HIV infection on body composition changes among men of different racial/ethnic origins. HIV Clin Trials. 2007 May-Jun;8(3):145-54.","\tHIV Infections\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections|hiv seropositivity","NA","NA"]
["NCT00001109","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14610491,"Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Plaeger S, Stiehm ER, Wara DW, Douglas SD, Luzuriaga K, McFarland EJ, Yogev R, Rathore MH, Levy W, Graham BL, Spector SA; Pediatric AIDS Clinical Trials Group. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol. 2003 Nov;112(5):973-80.","\tHIV Infections|HIV Seronegativity\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","NA","NA"]
["NCT00001118","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12237598|14663459|15295220","Church JA, Cunningham C, Hughes M, Palumbo P, Mofenson LM, Delora P, Smith E, Wiznia A, Purdue L, Hawkins E, Sista P; PACTG P1005 Study Team. Pediatric AIDS Clinical Trials Group. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr Infect Dis J. 2002 Jul;21(7):653-9.|Soy D, Aweeka FT, Church JA, Cunningham CK, Palumbo P, Kosel BW, Sheiner LB; Pediatric AIDS Clinical Trial Group (PACTG) Study P1005 Investigators. Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships. Clin Pharmacol Ther. 2003 Dec;74(6):569-80.|Church JA, Hughes M, Chen J, Palumbo P, Mofenson LM, Delora P, Smith E, Wiznia A, Hawkins E, Sista P, Cunningham CK; Pediatric AIDS Clinical Trials Group P1005 Study Team. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J. 2004 Aug;23(8):713-8.","\tHIV Infections\tEnfuvirtide\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","enfuvirtide","NA"]
["NCT00001119","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16816555,"Stekler J, Maenza J, Stevens C, Holte S, Malhotra U, McElrath MJ, Corey L, Collier AC. Abacavir hypersensitivity reaction in primary HIV infection. AIDS. 2006 Jun 12;20(9):1269-74.","\tHIV Infections\tTetanus Toxoid Vaccine|Indinavir sulfate|Lamivudine/Zidovudine|Ritonavir|Abacavir sulfate|Amprenavir|Efavirenz|Hepatitis B Vaccine (Recombinant)|Lamivudine|Zidovudine\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Biological|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","infection","ritonavir|lamivudine, zidovudine drug combination|vaccines|lamivudine|zidovudine|abacavir|amprenavir|indinavir|efavirenz","NA"]
["NCT00001133","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15483465|15958837|16583266","Acosta EP, Wu H, Hammer SM, Yu S, Kuritzkes DR, Walawander A, Eron JJ, Fichtenbaum CJ, Pettinelli C, Neath D, Ferguson E, Saah AJ, Gerber JG; Adult AIDS Clinical Trials Group 5055 Protocol Team. Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1358-66.|King JR, Gerber JG, Fletcher CV, Bushman L, Acosta EP. Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy. AIDS. 2005 Jul 1;19(10):1059-63.|Wu H, Huang Y, Acosta EP, Park JG, Yu S, Rosenkranz SL, Kuritzkes DR, Eron JJ, Perelson AS, Gerber JG. Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. J Pharmacokinet Pharmacodyn. 2006 Aug;33(4):399-419. Epub 2006 Apr 1.","\tHIV Infections\tIndinavir sulfate|Ritonavir\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","indinavir|ritonavir","NA"]
["NCT00001262","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","8526465|18256395|8295415|8419622|16278898|17482283|22134099|7842019|15923132|8812725|18752978|19194885|20652413|20497190|25281031","Kaler SG, Buist NR, Holmes CS, Goldstein DS, Miller RC, Gahl WA. Early copper therapy in classic Menkes disease patients with a novel splicing mutation. Ann Neurol. 1995 Dec;38(6):921-8.|Kaler SG, Holmes CS, Goldstein DS, Tang J, Godwin SC, Donsante A, Liew CJ, Sato S, Patronas N. Neonatal diagnosis and treatment of Menkes disease. N Engl J Med. 2008 Feb 7;358(6):605-14. doi: 10.1056/NEJMoa070613.|Kaler SG, Gahl WA, Berry SA, Holmes CS, Goldstein DS. Predictive value of plasma catecholamine levels in neonatal detection of Menkes disease. J Inherit Metab Dis. 1993;16(5):907-8.|Kaler SG, Westman JA, Bernes SM, Elsayed AM, Bowe CM, Freeman KL, Wu CD, Wallach MT. Gastrointestinal hemorrhage associated with gastric polyps in Menkes disease. J Pediatr. 1993 Jan;122(1):93-5.|Grange DK, Kaler SG, Albers GM, Petterchak JA, Thorpe CM, DeMello DE. Severe bilateral panlobular emphysema and pulmonary arterial hypoplasia: unusual manifestations of Menkes disease. Am J Med Genet A. 2005 Dec 1;139A(2):151-5.|Price DJ, Ravindranath T, Kaler SG. Internal jugular phlebectasia in Menkes disease. Int J Pediatr Otorhinolaryngol. 2007 Jul;71(7):1145-8. Epub 2007 May 4.|Hicks JD, Donsante A, Pierson TM, Gillespie MJ, Chou DE, Kaler SG. Increased frequency of congenital heart defects in Menkes disease. Clin Dysmorphol. 2012 Apr;21(2):59-63. doi: 10.1097/MCD.0b013e32834ea52b.|Kaler SG, Gallo LK, Proud VK, Percy AK, Mark Y, Segal NA, Goldstein DS, Holmes CS, Gahl WA. Occipital horn syndrome and a mild Menkes phenotype associated with splice site mutations at the MNK locus. Nat Genet. 1994 Oct;8(2):195-202.|Liu PC, Chen YW, Centeno JA, Quezado M, Lem K, Kaler SG. Downregulation of myelination, energy, and translational genes in Menkes disease brain. Mol Genet Metab. 2005 Aug;85(4):291-300.|Kaler SG, Das S, Levinson B, Goldstein DS, Holmes CS, Patronas NJ, Packman S, Gahl WA. Successful early copper therapy in Menkes disease associated with a mutant transcript containing a small In-frame deletion. Biochem Mol Med. 1996 Feb;57(1):37-46.|Tang J, Donsante A, Desai V, Patronas N, Kaler SG. Clinical outcomes in Menkes disease patients with a copper-responsive ATP7A mutation, G727R. Mol Genet Metab. 2008 Nov;95(3):174-81. doi: 10.1016/j.ymgme.2008.06.015. Epub 2008 Aug 26.|Kaler SG, Tang J, Donsante A, Kaneski CR. Translational read-through of a nonsense mutation in ATP7A impacts treatment outcome in Menkes disease. Ann Neurol. 2009 Jan;65(1):108-13. doi: 10.1002/ana.21576.|Kaler SG, Liew CJ, Donsante A, Hicks JD, Sato S, Greenfield JC. Molecular correlates of epilepsy in early diagnosed and treated Menkes disease. J Inherit Metab Dis. 2010 Oct;33(5):583-9. doi: 10.1007/s10545-010-9118-2. Epub 2010 Jul 21.|Desai V, Donsante A, Swoboda KJ, Martensen M, Thompson J, Kaler SG. Favorably skewed X-inactivation accounts for neurological sparing in female carriers of Menkes disease. Clin Genet. 2011 Feb;79(2):176-82. doi: 10.1111/j.1399-0004.2010.01451.x.|Kaler SG. Neurodevelopment and brain growth in classic Menkes disease is influenced by age and symptomatology at initiation of copper treatment. J Trace Elem Med Biol. 2014 Oct;28(4):427-30. doi: 10.1016/j.jtemb.2014.08.008. Epub 2014 Aug 28.","\tKinky Hair Syndrome\tCopper Histidine\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","menkes kinky hair syndrome","copper","NA"]
["NCT00001566","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18676758,"Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, Tesso M, Long LM, Grindler D, Merino M, Kopp W, Tsokos M, Berzofsky JA, Helman LJ. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res. 2008 Aug 1;14(15):4850-8. doi: 10.1158/1078-0432.CCR-07-4065.","\tEwing's Sarcoma|Rhabdomyosarcoma\ttherapeutic autologous dendritic cells|indinavir sulfate|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","sarcoma, ewing|sarcoma|rhabdomyosarcoma","indinavir","NA"]
["NCT00002454","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|4326367","Oleske J, Fishman D, Cooper R, et al.: Autogenous vaccine in the treatment of laryngeal papilloma. In: Proceeding of the 12th International Congress of Chemotherapy, 1981. pp 1099-1101.|Oleske JM, Kushnick T. Juvenile papilloma of the larynx. Am J Dis Child. 1971 May;121(5):417-9.","\tPrecancerous Condition\tautologous tumor cell vaccine\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","precancerous conditions|papilloma","NA","NA"]
["NCT00002459","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18378136|NA","Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, Tateo S, Franchi M, Jobsen JJ, Coens C, Teodorovic I, Vergote I, Vermorken JB; European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008 Apr;44(6):808-18. doi: 10.1016/j.ejca.2008.01.019. Epub 2008 Apr 2. Erratum in: Eur J Cancer. 2008 Jul;44(11):1612.|Reed NS, Mangioni C, Malmstrom H, et al.: First results of a randomised trial comparing radiotherapy versus observation post operatively in patients with uterine sarcomas. An EORTC-GCG study. [Abstract] Int J Gynecol Cancer 13 (Suppl 1): A-PL12, 4, 2003.","\tEndometrial Cancer|Sarcoma\tradiation therapy\tNA\tNA\tNA\tRadiation\tFemale\t","NA","NA","NA","NA","NA","NA","sarcoma|endometrial neoplasms","NA","NA"]
["NCT00002461","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",1403051,"Lazarus HM, Crilley P, Ciobanu N, Creger RJ, Fox RM, Shina DC, Bulova SI, Gucalp R, Cooper BW, Topolsky D, et al. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma. J Clin Oncol. 1992 Nov;10(11):1682-9.","\tLymphoma\tfilgrastim|sargramostim|carmustine|cisplatin|cyclophosphamide|etoposide|autologous bone marrow transplantation|in vitro-treated bone marrow transplantation|peripheral blood stem cell transplantation|radiation therapy\tParallel Assignment\tTreatment\tRandomized\tBiological|Biological|Drug|Drug|Drug|Drug|Procedure|Procedure|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|lymphoma, non-hodgkin|hodgkin disease","etoposide|sargramostim|cyclophosphamide|carmustine","NA"]
["NCT00002462","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17097834|15936157|NA|NA|NA|9187443","Aleman BM, Raemaekers JM, Tomiŝiĉ R, Baaijens MH, Bortolus R, Lybeert ML, van der Maazen RW, Girinsky T, Demeestere G, Lugtenburg P, Lievens Y, de Jong D, Pinna A, Henry-Amar M; European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):19-30. Epub 2006 Nov 9.|Aleman BM, Girinsky T, van der Maazen RW, Strijk S, Meijnders P, Bortolus R, Olofsen-van Acht MJ, Lybeert ML, Lievens Y, Eghbali H, Noordijk EM, Tomsic R, Meerwaldt JH, Poortmans PM, Smit WG, Pinna A, Henry-Amar M, Raemaekers JM; European Organization for Research; Treatment of Cancer (EORTC) Lymphoma Group. Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884). Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1184-90. Epub 2005 Jun 2.|Aleman BMP, Girinsky T, Strijk S, et al.: Quality control of involved-field radiotherapy in patients with advanced stage Hodgkin's lymphoma (HL) enrolled on the EORTC trial 20884. [Abstract] Eur J Haematol 73 (Suppl 65): A-A02, 42, 2004.|Aleman BMP, Raemaekers JMM, Tomsic R, et al.: Radiotherapy in advanced Hodgkin lymphoma (HL) patients in partial remission (PR) after chemotherapy: detailed results from the EORTC lymphoma group trial no.20884. [Abstract] Eur J Haematol 73 (Suppl 65): A-A01, 42, 2004.|Aleman BM, Raemaekers JM, Henry-Amar M, et al.: Involved-field radiotherapy in patients with stage III/IV Hodgkin's lymphoma: first results of the randomised EORTC trial # 20884. [Abstract] Int J Radiat Oncol Biol Phys 51(3 suppl 1): A-3, 2, 2001.|Raemaekers J, Burgers M, Henry-Amar M, Pinna A, Mandard A, Monfardini S, Hagenbeek A, Breed W, Carde P, Vovk M, van Hoof A, Thomas J, Noordijk E. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie. Ann Oncol. 1997;8 Suppl 1:111-4.","\tLymphoma\tbleomycin sulfate|doxorubicin hydrochloride|mechlorethamine hydrochloride|prednisone|procarbazine hydrochloride|vinblastine sulfate|vincristine sulfate|low-LET cobalt-60 gamma ray therapy|low-LET photon therapy|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Radiation|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","hodgkin disease|lymphoma","procarbazine|cobalt|prednisone|bleomycin|doxorubicin|mechlorethamine|liposomal doxorubicin|vinblastine|vincristine","NA"]
["NCT00002463","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Ater J, Worth L, Bruner J, et al.: Young children treated with MOPP or methotrexate-MOP for medulloblastoma: identification of a subset of patients with good prognosis. [Abstract] Proceedings of the American Society of Clinical Oncology 14: A-1397, 1995.|Ater JL, van Eys J, Yung WK, et al.: Response to methotrexate, mechlorethamine, vincristine, procarbazine, and prednizone (MMOPP) for brain tumors. [Abstract] Proceedings of the American Society of Clinical Oncology 10: A-370, 125, 1991.","\tBrain and Central Nervous System Tumors\tMOPP Regimen|Leucovorin Calcium|Mechlorethamine Hydrochloride|Methotrexate|Prednisone|Procarbazine Hydrochloride|Vincristine Sulfate|Conventional Surgery\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","nervous system neoplasms|astrocytoma|neuroectodermal tumors, primitive|neuroectodermal tumors|central nervous system neoplasms","leucovorin|prednisone|methotrexate|procarbazine|calcium|vincristine|mechlorethamine|levoleucovorin","NA"]
["NCT00002466","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","8622067|NA|7595741|NA|NA","Kushner BH, LaQuaglia MP, Wollner N, Meyers PA, Lindsley KL, Ghavimi F, Merchant TE, Boulad F, Cheung NK, Bonilla MA, Crouch G, Kelleher JF Jr, Steinherz PG, Gerald WL. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol. 1996 May;14(5):1526-31.|Kushner BH, LaQuaglia MP, Wollner N, et al.: Desmoplastic small cell tumor (DSCT): prolonged progression-free survival with aggressive multi-modality therapy. [Abstract] Proceedings of the American Society of Clinical Oncology 14: A-1414, 443, 1995.|Kushner BH, Meyers PA, Gerald WL, Healey JH, La Quaglia MP, Boland P, Wollner N, Casper ES, Aledo A, Heller G, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J Clin Oncol. 1995 Nov;13(11):2796-804.|Meyers PA, Gardner S, Lindsley K, et al.: High-risk Ewing's sarcoma (ES)/primitive neuroectodermal tumor (PNET) of bone: consolidation with total body irradiation (TBI), melphalan, and autologous stem cell reconstitution. [Abstract] Proceedings of the American Society of Clinical Oncology 14: A-1447, 451, 1995.|Kushner BH, Meyers PA, Cheung NK, et al.: Very high-dose short-term chemotherapy for poor-risk solid tumors in children and young adults. [Abstract] Proceedings of the American Society of Clinical Oncology 12: A-1416, 413, 1993.","\tKidney Cancer|Sarcoma\tcyclophosphamide|doxorubicin hydrochloride|etoposide|ifosfamide|vincristine sulfate|conventional surgery|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","wilms tumor|neuroectodermal tumors, primitive|sarcoma|sarcoma, ewing|neuroectodermal tumors|neuroectodermal tumors, primitive, peripheral","vincristine|liposomal doxorubicin|etoposide|cyclophosphamide|doxorubicin|ifosfamide","NA"]
["NCT00002470","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Ahlgren JD, Leming PD, Gullo JJ, et al.: Protracted infusional 5-FU (PIF) + alpha2b-interferon (alpha-IFN) in metastatic carcinoid: updated experience with Mid-Atlantic Oncology Program (MAOP) study 5190. [Abstract] Proceedings of the American Society of Clinical Oncology 14: A-552, 219, 1995.|Ahlgren JD, Leming PD, Fryer D, et al.: Protracted infusional 5-FU (PIF) + alpha2b-interferon (alpha-IFN): a well tolerated regimen for palliation of advanced carcinoid: a Mid-Atlantic Oncology Program (MAOP) study. [Abstract] Proceedings of the American Society of Clinical Oncology 12: A-661, 218, 1993.","\tGastrointestinal Carcinoid Tumor|Lung Cancer\trecombinant interferon alfa|fluorouracil\tNA\tNA\tNA\tBiological|Drug\tAll\t","NA","NA","NA","NA","NA","NA","carcinoid tumor|malignant carcinoid syndrome|gastrointestinal neoplasms","interferon-alpha|fluorouracil|interferons","NA"]
["NCT00002473","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21186077|17140723","Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, Colombel M, Klotz L, Skinner E, Keane T, Marreaud S, Collette S, Sylvester R. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011 Apr;59(4):543-52. doi: 10.1016/j.eururo.2010.12.013. Epub 2010 Dec 22.|Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, Marechal JM, Klotz L, Skinner E, Keane T, Claessens I, Sylvester R; European Organization for Research and Treatment of Cancer (EORTC); National Cancer Institute of Canada Clinical Trials Group (NCIC CTG); Southwest Oncology Group (SWOG); Eastern Cooperative Oncology Group (ECOG). A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2007 Jun;51(6):1606-15. Epub 2006 Nov 15.","\tKidney Cancer\tconventional surgery\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","kidney neoplasms|carcinoma, renal cell","NA","NA"]
["NCT00002474","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","7774830|9193322","Stiff P, Bayer R, Camarda M, Tan S, Dolan J, Potkul R, Loutfi S, Kinch L, Sosman J, Peace D, et al. A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome. Gynecol Oncol. 1995 Jun;57(3):278-85.|Stiff PJ, Bayer R, Kerger C, Potkul RK, Malhotra D, Peace DJ, Smith D, Fisher SG. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol. 1997 Apr;15(4):1309-17.","\tOvarian Cancer\tcarboplatin|cyclophosphamide|mitoxantrone hydrochloride|autologous bone marrow transplantation|bone marrow ablation with stem cell support\tNA\tNA\tNA\tDrug|Drug|Drug|Procedure|Procedure\tFemale\t","NA","NA","NA","NA","NA","NA","ovarian neoplasms|carcinoma, ovarian epithelial","mitoxantrone|cyclophosphamide|carboplatin","NA"]
["NCT00002475","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",8368765,"Wiseman C, Presant C, Rao R, Smith J. Clinical responses to intralymphatic whole-cell melanoma vaccine augmented by in vitro incubation with alpha-interferon. Ann N Y Acad Sci. 1993 Aug 12;690:388-91.","\tBreast Cancer|Colorectal Cancer|Kidney Cancer|Lung Cancer|Malignant Mesothelioma|Pancreatic Cancer\tallogeneic tumor cell vaccine|autologous tumor cell vaccine|recombinant interferon alfa|recombinant interferon gamma|sargramostim|cyclophosphamide\tNA\tNA\tNA\tBiological|Biological|Biological|Biological|Biological|Drug\tAll\t","NA","NA","NA","NA","NA","NA","mesothelioma|kidney neoplasms|lung neoplasms|breast neoplasms|pancreatic neoplasms","cyclophosphamide|interferons|vaccines|sargramostim|interferon-alpha|interferon-gamma","NA"]
["NCT00002476","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19875337,"Tobias JS, Monson K, Gupta N, Macdougall H, Glaholm J, Hutchison I, Kadalayil L, Hackshaw A; UK Head and Neck Cancer Trialists' Group. Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. Lancet Oncol. 2010 Jan;11(1):66-74. doi: 10.1016/S1470-2045(09)70306-7. Epub 2009 Oct 29.","\tHead and Neck Cancer\tbleomycin sulfate|fluorouracil|leucovorin calcium|methotrexate|vincristine sulfate|low-LET cobalt-60 gamma ray therapy|low-LET photon therapy|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Radiation|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","calcium|cobalt|fluorouracil|vincristine|leucovorin|methotrexate|bleomycin|levoleucovorin","NA"]
["NCT00002477","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|NA","Swart AC: Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON1). [Abstract] J Clin Oncol 25 (Suppl 18): A-5509, 276s, 2007.|Guthrie D: ICON1: a randomised trial of immediate platinum-based chemotherapy against chemotherapy delayed until indicated in women with ovarian cancer. [Abstract] Br J Cancer 85 (suppl 1): A-9.1, 28, 2001.|Vergote IB, Trimbos BJ, Guthrie D, et al.: Results of a randomized trial in 923 patients with high-risk early ovarian cancer, comparing adjuvant chemotherapy with no further treatment following surgery. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-802, 2001.","\tOvarian Cancer\tcarboplatin|cisplatin|cyclophosphamide|doxorubicin hydrochloride\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","carcinoma, ovarian epithelial|ovarian neoplasms","cyclophosphamide|carboplatin|doxorubicin|liposomal doxorubicin","NA"]
["NCT00002478","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12713990|9469322|NA","Rose PG, Blessing JA, Buller RE, Mannel RS, Webster KD. Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2003 May;89(2):267-70.|Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998 Feb;16(2):405-10.|Kudelka A, ed.: A phase II study of prolonged oral VP-16 in women with refractoy epithelial ovarian carcinoma. [Abstract] Proceedings of the American Society of Clinical Oncology 13: A-888, 276, 1994.","\tCervical Cancer|Ovarian Cancer\tetoposide\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","uterine cervical neoplasms","etoposide","NA"]
["NCT00002479","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Siegel RS, Martone B, Guitart J, et al.: Phase II trial of all-TRA in the treatment of relapsed/refractory mycosis fungoides. 94(1 suppl): A423, 96a, 1999.","\tLymphoma\ttretinoin\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","sezary syndrome|lymphoma|mycosis fungoides|mycoses","tretinoin","NA"]
["NCT00002480","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","7505776|7933238|7939749|8040021|9166467","Leibel SA, Heimann R, Kutcher GJ, Zelefsky MJ, Burman CM, Melian E, Orazem JP, Mohan R, LoSasso TJ, Lo YC, et al. Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate: preliminary results of a phase I dose-escalation study. Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):55-65.|Leibel SA, Zelefsky MJ, Kutcher GJ, Burman CM, Kelson S, Fuks Z. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: interim report of a phase 1 dose-escalation study. J Urol. 1994 Nov;152(5 Pt 2):1792-8.|Leibel SA, Zelefsky MJ, Kutcher GJ, Burman CM, Mohan R, Mageras GS, Ling CC, Fuks Z. The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin Oncol. 1994 Oct;21(5):580-97. Review.|Zelefsky MJ, Leibel SA, Burman CM, Kutcher GJ, Harrison A, Happersett L, Fuks Z. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):755-61.|Zelefsky MJ, Leibel SA, Kutcher GJ, Kelson S, Ling CC, Fuks Z. The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma. Cancer J Sci Am. 1995 Jul-Aug;1(2):142-50.","\tProstate Cancer\tradiation therapy\tNA\tNA\tNA\tRadiation\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","NA","NA"]
["NCT00002484","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","9288852|NA","Armstrong J, Raben A, Zelefsky M, Burt M, Leibel S, Burman C, Kutcher G, Harrison L, Hahn C, Ginsberg R, Rusch V, Kris M, Fuks Z. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol. 1997 Jul;44(1):17-22.|Armstrong J, Zelefsky M, Burt M, et al.: Acute toxicity of high dose 3-dimensional conformal radiation therapy (3-DCRT) for non small-cell lung cancer (NSCLC). [Abstract] Proceedings of the American Society of Clinical Oncology 12: A-1171, 348, 1993.","\tLung Cancer\tradiation therapy\tNA\tNA\tNA\tRadiation\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","NA","NA"]
["NCT00002490","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Harland SJ: A randomised trial of radical radiotherapy in pT1G3 NXM0 bladder cancer (MRC BS06). [Abstract] J Clin Oncol 23 (Suppl 16): A-4505, 379s, 2005.","\tBladder Cancer\tBCG vaccine|mitomycin C|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","urinary bladder neoplasms","mitomycins|bcg vaccine|mitomycin","NA"]
["NCT00002493","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22155678|17033909|16330675|NA|NA","Tewari KS, Filiaci VL, Spirtos NM, Mannel RS, Thigpen JT, Cibull ML, Monk BJ, Randall ME. Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr;125(1):87-93. doi: 10.1016/j.ygyno.2011.12.414. Epub 2011 Dec 8.|Bruner DW, Barsevick A, Tian C, Randall M, Mannel R, Cohn DE, Sorosky J, Spirtos NM. Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: A gynecologic oncology group study. Qual Life Res. 2007 Feb;16(1):89-100. Epub 2006 Oct 11.|Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA; Gynecologic Oncology Group Study. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006 Jan 1;24(1):36-44. Epub 2005 Dec 5.|Randall ME, Brunetto G, Muss H, et al.: Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: a randomized phase III trial of the Gynecologic Oncology Group. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-3, 2, 2003.|Waltkins-Bruner D, Barsevick A, Tian C, et al.: Quality of life trade-off to incremental gain in survival on Gynecologic Oncology Group (GOG) Protocol 122: whole abdominal irradiation (WAI) vs. doxorubicin-platinum (AP) chemotherapy in advanced endometrial cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-1803, 449, 2003.","\tEndometrial Cancer|Psychosocial Effects of Cancer and Its Treatment\tcisplatin|doxorubicin hydrochloride|low-LET photon therapy\tNA\tNA\tNA\tDrug|Drug|Radiation\tFemale\t","NA","NA","NA","NA","NA","NA","endometrial neoplasms","doxorubicin|liposomal doxorubicin","NA"]
["NCT00002494","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15042678|11600602","Rizzieri DA, Johnson JL, Niedzwiecki D, Lee EJ, Vardiman JW, Powell BL, Barcos M, Bloomfield CD, Schiffer CA, Peterson BA, Canellos GP, Larson RA. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004 Apr 1;100(7):1438-48.|Lee EJ, Petroni GR, Schiffer CA, Freter CE, Johnson JL, Barcos M, Frizzera G, Bloomfield CD, Peterson BA. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol. 2001 Oct 15;19(20):4014-22. Review.","\tLeukemia|Lymphoma\tcyclophosphamide|cytarabine|dexamethasone|doxorubicin hydrochloride|etoposide|ifosfamide|leucovorin calcium|mesna|methotrexate|prednisone|therapeutic hydrocortisone|vincristine sulfate|low-LET cobalt-60 gamma ray therapy|low-LET photon therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|leukemia","vincristine|hydrocortisone hemisuccinate|methotrexate|levoleucovorin|hydrocortisone acetate|cyclophosphamide|ifosfamide|liposomal doxorubicin|doxorubicin|cytarabine|dexamethasone|prednisone|hydrocortisone|hydrocortisone 17-butyrate 21-propionate|leucovorin|cobalt|etoposide","NA"]
["NCT00002495","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|12972528|11709567|NA","Ganz PA, Moinpour CM, McCoy S, et al.: Predictors of vitality (energy/fatigue) in early stage Hodgkin's disease (HD): results from Southwest Oncology Group (SWOG) study 9133. [Abstract] J Clin Oncol 22 (Suppl 14): A-6546, 569s, 2004.|Ganz PA, Moinpour CM, Pauler DK, Kornblith AB, Gaynor ER, Balcerzak SP, Gatti GS, Erba HP, McCoy S, Press OW, Fisher RI. Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133. J Clin Oncol. 2003 Sep 15;21(18):3512-9. Erratum in: J Clin Oncol. 2013 Jun 10;31(17):2231-2.|Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol. 2001 Nov 15;19(22):4238-44.|Press OW, LeBlanc M, Lichter A, et al.: A phase III randomized intergroup trial of subtotal lymphoid irradiation (STLI) versus doxorubicin, vinblastine, and STLI for stage IA-IIA Hodgkin's disease (SWOG 9133, CALGB 9391). [Abstract] Blood 96(11 pt 1), A-2471, 575a, 2000.","\tLymphoma\tdoxorubicin hydrochloride|vinblastine|standard subtotal nodal irradiation\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Radiation\tAll\t","SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease","Interventional","Completed","Phase 3",2,348,"hodgkin disease|lymphoma","doxorubicin|liposomal doxorubicin|vinblastine","NA"]
["NCT00002496","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|14645636|12525193|NA|NA","Forastiere AA, Maor M, Weber RS, et al.: Long-term results of intergroup RTOG 91-11: a phase III trial to preserve the larynx--Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. [Abstract] J Clin Oncol 24 (Suppl 18): A-5517, 284s, 2006.|Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003 Nov 27;349(22):2091-8.|Weber RS, Berkey BA, Forastiere A, Cooper J, Maor M, Goepfert H, Morrison W, Glisson B, Trotti A, Ridge JA, Chao KS, Peters G, Lee DJ, Leaf A, Ensley J. Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11. Arch Otolaryngol Head Neck Surg. 2003 Jan;129(1):44-9.|Maor MH, Berkey B, Forastiere A, et al.: Larynx preservation and tumor control in stage III and IV laryngeal cancer: a three-arm randomized intergroup trial: RTOG 91-11. [Abstract] Int J Radiat Oncol Biol Phys 54(2 suppl 1): 2-3, 2002.|Forastiere AA, Berkey B, Maor M, et al.: Phase III trial to preserve the larynx: induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone, Intergroup trial R91-11. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-4, 2a, 2001.","\tHead and Neck Cancer\tchemotherapy|cisplatin|fluorouracil|conventional surgery|low-LET cobalt-60 gamma ray therapy|low-LET electron therapy|low-LET photon therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Procedure|Radiation|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","cobalt|fluorouracil","NA"]
["NCT00002501","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11911406,"Lichtman SM, Petroni G, Schilsky RL, Johnson JL, Perri RT, Niedzwiecki D, Sklar J, Barcos M, Peterson BA. High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150. Leuk Lymphoma. 2001 Nov-Dec;42(6):1255-64.","\tLymphoma\tfilgrastim|cyclophosphamide\tNA\tNA\tNA\tBiological|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|lymphoma, non-hodgkin","cyclophosphamide","NA"]
["NCT00002503","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14572748,"Oosterhof GO, Roberts JT, de Reijke TM, Engelholm SA, Horenblas S, von der Maase H, Neymark N, Debois M, Collette L. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol. 2003 Nov;44(5):519-26.","\tMetastatic Cancer|Prostate Cancer\tstrontium chloride Sr 89\tNA\tNA\tNA\tRadiation\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","NA","NA"]
["NCT00002504","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Dillman RO, Soori G, Tai DF, et al.: Outpatient subcutaneous (SC) interleukin-2 (IL-2) and interferon alpha (IFN) in the management of metastatic cancer: a preliminary report. J Immunother 20(5): 404, 1997.","\tChronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition|Unspecified Adult Solid Tumor, Protocol Specific\taldesleukin|recombinant interferon alfa\tNA\tNA\tNA\tBiological|Biological\tAll\t","NA","NA","NA","NA","NA","NA","myelodysplastic syndromes|myeloproliferative disorders|leukemia|preleukemia|precancerous conditions|multiple myeloma|lymphoma|neoplasms, plasma cell|syndrome","aldesleukin|interferon-alpha|interferons","NA"]
["NCT00002505","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|10850352|NA|NA|NA|8399072|12843799|NA","Dillman RO, Nayak SK, Beutel LD, et al.: Short-term cultures of kidney cancer cells for use as autologous tumor cell vaccines in the treatment of renal cell carcinoma. [Abstract] Proc Am Assoc Cancer Res 40: A1672, 1999.|Dillman RO, Nayak SK, Brown JV, et al.: Short-term cell cultures of ovarian cancer cells for use as autologous tumor cell vaccines as adjuvant therapy of advanced ovarian cancer. [Abstract] Proc Am Assoc Cancer Res 39: A2501, 1998.|Dillman RO, Nayak SK, Barth NM, DeLeon C, Schwartzberg LS, Spitler LE, Church C, O'Connor AA, Beutel LD. Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma. Cancer Biother Radiopharm. 1998 Jun;13(3):165-76.|Dillman RO, Nayak SK, Johnson D, et al.: The potential to use short-term cultures of ovarian cells as autologous tumor cell vaccines. [Abstract] Proc Am Assoc Cancer Res 38: A2676, 1997.|Dillman R, Nayak S, Barth N, et al.: Irradiated, cultured, autologous tumor cells for active specific immunotherapy. [Abstract] Proceedings of the American Society of Clinical Oncology 14: A1810, 546, 1995.|Nayak SK, Meusch T, Dillman RO: Autologous human tumor cell lines established in tissue culture for active specific immunotherapy. [Abstract] J Immunother 17 (2): 123, 1995.|Dillman RO, Nayak SK, Beutel L. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother Emphasis Tumor Immunol. 1993 Jul;14(1):65-9.|Dillman RO, Wiemann M, Nayak SK, DeLeon C, Hood K, DePriest C. Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group. J Immunother. 2003 Jul-Aug;26(4):367-73.|Nayak SK, Dillman RO: Use of autologous tumor cells grown in tissue culture for active specific immunotherapy. [Abstract] Proc Am Assoc Cancer Res 34: A-2937, 1993.","\tUnspecified Adult Solid Tumor, Protocol Specific\tfilgrastim|recombinant interferon gamma|tumor cell lysate vaccine therapy\tNA\tNA\tNA\tBiological|Biological|Biological\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","vaccines|interferons|interferon-gamma","NA"]
["NCT00002506","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Dillman RO, Soori G, Tai DF, et al.: Interferon alpha-2A (FN) and cis-retinoic acid (CRA) for the treatment of squamous cell carcinoma (SCC): a preliminary report. J Immunother 20(5): 404, 1997.","\tCervical Cancer|Esophageal Cancer|Head and Neck Cancer|Lung Cancer|Non-melanomatous Skin Cancer|Penile Cancer\trecombinant interferon alfa|isotretinoin\tNA\tNA\tNA\tBiological|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|penile neoplasms|uterine cervical neoplasms|esophageal neoplasms|skin neoplasms","isotretinoin|interferons|interferon-alpha","NA"]
["NCT00002509","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Klumpp TR, Goldberg SL, Mangan KF, et al.: High dose cyclophosphamide, etoposide, and carboplatin (CEC) with autologous stem cell rescue for chemosensitive metastatic and high risk breast cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 13: A-245, 111, 1994.","\tBreast Cancer\tfilgrastim|carboplatin|cyclophosphamide|etoposide|mesna|autologous bone marrow transplantation|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Procedure|Procedure\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","carboplatin|cyclophosphamide|etoposide","NA"]
["NCT00002511","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|16099293|12208577|17931949|17878474|NA|NA|16941153|16223581","Bolla M, Van Poppel H, Van Cangh P, et al.: Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3N0 prostate cancer (PC)? (EORTC 22911). [Abstract] J Clin Oncol 22 (Suppl 14): A-4504, 383, 2004.|Bolla M, Van Poppel H, Van Cangh P, et al.: Post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improves progression-free survival (PFS) in pT3NO prostate cancer (PC) (EORTC 22911). [Abstract] Int J Radiat Oncol Biol Phys 60 (1 Suppl 1): A-93, S186, 2004. Available online. Last accessed January 27, 2005.|Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Maréchal JM, Scalliet P, Haustermans K, Piérart M; European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005 Aug 13-19;366(9485):572-8.|Davis JB, Reiner B, Dusserre A, Giraud JY, Bolla M; EORTC. Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run. Radiother Oncol. 2002 Jul;64(1):65-73.|Bolla M, Van Poppel H, Collette L; au nom des groupes génito-urinaire et radiothérapie de l'EORTC. [Preliminary results for EORTC trial 22911: radical prostatectomy followed by postoperative radiotherapy in prostate cancers with a high risk of progression]. Cancer Radiother. 2007 Nov;11(6-7):363-9. Epub 2007 Oct 10. French.|Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L, Bosset JF, Kurth KH, Schröder FH, Collette L; EORTC 22911. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol. 2007 Sep 20;25(27):4178-86.|Tombal B, Scaillet P, Opsomer R, et al.: Immediate external beam radiation therapy (EBRT) after radical prostatectomy (PCa): long-term influence on QOL, urinary and rectal symptoms. [Abstract] American Urological Association: Annual Meeting, May 20-25, 2006, Atlanta, GA A-1599, 2006.|van der Kwast TH, Bolla M, van Poppel H, et al.: Gleason Score and margin status are the strongest predictors for benefit of radiotherapy after radical prostatectomy. [Abstract] American Urological Association: Annual Meeting, May 20-25, 2006, Atlanta, GA A-1391, 2006.|van der Kwast TH, Collette L, Van Poppel H, Van Cangh P, Vekemans K, DaPozzo L, Bosset JF, Kurth KH, Schröder FH, Bolla M; European Organisation for Research and Treatment of Cancer Radiotherapy and Genito-Urinary Cancer Groups. Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911). Virchows Arch. 2006 Oct;449(4):428-34. Epub 2006 Aug 29.|Collette L, van Poppel H, Bolla M, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, Piérart M; European Organisation for Research and Treatment of Cancer (EORTC) Radiotherapy and Genito-urinary Groups. Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911). Eur J Cancer. 2005 Nov;41(17):2662-72. Epub 2005 Oct 11.","\tProstate Cancer\tlow-LET photon therapy\tNA\tNA\tNA\tRadiation\tAll\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","NA","NA"]
["NCT00002514","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|22851563|22409379|19863538|19244158|19635999|19828704|18048644|NA|17989709|NA|17032921|NA|17312329|17170120|16556888|16105981|NA|NA|NA|NA|NA|NA|NA|NA|NA|NA|9369422","Goldstone AH, Richards S, Wiernik PH, et al.: Philadelphia chromosome positive patients with adult acute lymphoblastic leukemia (ALL). Early results from the international ALL trial. [Abstract] Blood 94 (suppl 1): 3071a, 1999.|Moorman AV, Schwab C, Ensor HM, Russell LJ, Morrison H, Jones L, Masic D, Patel B, Rowe JM, Tallman M, Goldstone AH, Fielding AK, Harrison CJ. IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. J Clin Oncol. 2012 Sep 1;30(25):3100-8. doi: 10.1200/JCO.2011.40.3907. Epub 2012 Jul 30.|Sive JI, Buck G, Fielding A, Lazarus HM, Litzow MR, Luger S, Marks DI, McMillan A, Moorman AV, Richards SM, Rowe JM, Tallman MS, Goldstone AH. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012 May;157(4):463-71. doi: 10.1111/j.1365-2141.2012.09095.x. Epub 2012 Mar 13.|Patel B, Rai L, Buck G, Richards SM, Mortuza Y, Mitchell W, Gerrard G, Moorman AV, Duke V, Hoffbrand AV, Fielding AK, Goldstone AH, Foroni L. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol. 2010 Jan;148(1):80-9. doi: 10.1111/j.1365-2141.2009.07941.x. Epub 2009 Oct 26.|Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, Marks DI, McMillan AK, Litzow MR, Lazarus HM, Foroni L, Dewald G, Franklin IM, Luger SM, Paietta E, Wiernik PH, Tallman MS, Goldstone AH. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009 May 7;113(19):4489-96. doi: 10.1182/blood-2009-01-199380. Epub 2009 Feb 24.|Mansour MR, Sulis ML, Duke V, Foroni L, Jenkinson S, Koo K, Allen CG, Gale RE, Buck G, Richards S, Paietta E, Rowe JM, Tallman MS, Goldstone AH, Ferrando AA, Linch DC. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol. 2009 Sep 10;27(26):4352-6. doi: 10.1200/JCO.2009.22.0996. Epub 2009 Jul 27.|Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, Ferrando A, Fielding AK, Goldstone AH, Ketterling RP, Litzow MR, Luger SM, McMillan AK, Mansour MR, Rowe JM, Tallman MS, Lazarus HM. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009 Dec 10;114(25):5136-45. doi: 10.1182/blood-2009-08-231217.|Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, Burnett AK, Chopra R, Wiernik PH, Foroni L, Paietta E, Litzow MR, Marks DI, Durrant J, McMillan A, Franklin IM, Luger S, Ciobanu N, Rowe JM. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008 Feb 15;111(4):1827-33. Epub 2007 Nov 29.|Paietta E, Li X, Richards S, et al.: Implications for the use of monoclonal antibodies in future adult ALL trials: analysis of antigen expression in 505 B-lineage (B-Lin) ALL patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup trial. [Abstract] Blood 112 (11): A-1907, 2008.|Patel B, Richards SM, Rowe JM, Goldstone AH, Fielding AK. High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis. Leukemia. 2008 Feb;22(2):308-12. Epub 2007 Nov 8.|Rowe JM, Buck G, Moorman AV, et al.: Standard consolidation/maintenance chemotherapy is consistently superior to a single autologous transplant for adult patients with acute lymphoblastic leukemia: results of the international ALL trial (MRC UKALL XII/ECOG E2993). [Abstract] Blood 112 (11): A-3314, 2008.|Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin IM, McMillan AK, Tallman MS, Rowe JM, Goldstone AH; Medical Research Council of the United Kingdom Adult ALL Working Party; Eastern Cooperative Oncology Group. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007 Feb 1;109(3):944-50. Epub 2006 Oct 10.|Fielding AK, Richards SM, Lazarus HM, et al.: Does imatinib change the outcome in Philapdelphia chromosome positive acute lymphoblastic leukaemia in adults? Data from the UKALLXII/ECOG2993 study. [Abstract] Blood 110 (11): A-8, 2007.|Juric D, Lacayo NJ, Ramsey MC, Racevskis J, Wiernik PH, Rowe JM, Goldstone AH, O'Dwyer PJ, Paietta E, Sikic BI. Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. J Clin Oncol. 2007 Apr 10;25(11):1341-9. Epub 2007 Feb 20.|Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW; Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007 Apr 15;109(8):3189-97. Epub 2006 Dec 14.|Lazarus HM, Richards SM, Chopra R, Litzow MR, Burnett AK, Wiernik PH, Franklin IM, Tallman MS, Cook L, Buck G, Durrant IJ, Rowe JM, Goldstone AH; Medical Research Council (MRC)/National Cancer Research Institute (NCRI) Adult Leukaemia Working Party of the United Kingdom and the Eastern Cooperative Oncology Group. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood. 2006 Jul 15;108(2):465-72. Epub 2006 Mar 23.|Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, Lazarus HM, Franklin IM, Litzow MR, Ciobanu N, Prentice HG, Durrant J, Tallman MS, Goldstone AH; ECOG; MRC/NCRI Adult Leukemia Working Party. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005 Dec 1;106(12):3760-7. Epub 2005 Aug 16.|Goldstone AH, Lazarus HJ, Richards SM, et al.: The outcome of 551 1st CR transplants in adult ALL from the UKALL XII/ECOG 2993 study. [Abstract] Blood 104 (11): A-615, 2004.|Lazarus HM, Richards SM, Chopra R, et al.: Adult patients with acute lymphoblastic leukemia (ALL) and central nervous system (CNS) leukemia at diagnosis may attain durable complete remissions (CR). Results from the International ALL Trial (MRC UKALL-XII/ECOG E2993) . [Abstract] Blood 104 (11): A-4484, 2004.|Goldstone AH, Chopra R, Buck G, et al.: The outcome of 267 Philadelphia positive adults in the international UKALL12/ECOG E 2993 study. Final analysis and the role of allogeneic transplant in those under 50 years. [Abstract] Blood 102 (11 Pt 1): A-268, 2003.|Rowe JM, Buck G, Burnett AK, et al.: Induction therapy for adults with acute lymphoblastic leukemia (ALL): results of nearly 1,400 patients from the international ALL trial (MRC UKALL XII / ECOG E2993). [Abstract] Blood 102 (11 Pt 1): A-785, 2003.|Ferrando AA, Neuberg D, Dodge RK, et al.: Adult T-cell ALL patients whose lymphoblasts express the HOX11 oncogene have an excellent prognosis when treated with chemotherapy and are not candidates for allogeneic bone marrow transplantaton in first remission. [Abstract] Blood 100 (11 pt 1): A-578, 2002.|Paietta E, Kim H, Racevskis J, et al.: Immunophenotypic characteristics, but not age or secondary cytogenetic changes, affect response and survival of BCR/ABL positive adult acute lymphoblastic leukemia (ALL): ECOG/MRC Intergroup trial, E2993. [Abstract] Blood 100 (11 pt 1): A-2990, 2002.|Goldstone AH, Prentice HG, Durrant J, et al.: Allogeneic transplant (related or unrelated donor) Is the preferred treatment for adult Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993). [Abstract] Blood 98 (11 Pt 1): A-3556, 2001.|Paietta E, Kim H, Rowe JM, et al.: Prognostic significance of immunophenotyping and cytogenetics in adult acute lymphoblastic leukemia (ALL): interim analysis of ECOG/MRC phase III intergroup trial, E2993. [Abstract] Blood 98 (11 Pt 1): A-3494, 2001.|Rowe JM, Richards SM, Burnett AK, et al.: Favorable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosome-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR): results from the international ALL trial (MRC UKALL XII/ECOG E2993). [Abstract] Blood 98 (11 Pt 1): A-2009, 2001.|Rowe JM, Richards S, Wiernik PH, et al.: Allogenic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR): early results from the international ALL trial. [Abstract] Blood 94 (suppl 1): 732a, 1999.|Paietta E, Racevskis J, Neuberg D, Rowe JM, Goldstone AH, Wiernik PH. Expression of CD25 (interleukin-2 receptor alpha chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993. Eastern Cooperative Oncology Group/Medical Research Council. Leukemia. 1997 Nov;11(11):1887-90.","\tLeukemia\tsargramostim|asparaginase|cyclophosphamide|cytarabine|daunorubicin hydrochloride|dexamethasone|etoposide|imatinib mesylate|leucovorin calcium|mercaptopurine|methotrexate|prednisone|thioguanine|vincristine sulfate|allogeneic bone marrow transplantation|autologous bone marrow transplantation|peripheral blood stem cell transplantation|radiation therapy\tParallel Assignment\tTreatment\tRandomized\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure|Procedure|Radiation\tAll\t","Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission","Interventional","Completed","Phase 3",2,1929,"leukemia|precursor cell lymphoblastic leukemia-lymphoma|leukemia, lymphoid","vincristine|cyclophosphamide|methotrexate|cytarabine|dexamethasone|sargramostim|mercaptopurine|thioguanine|levoleucovorin|daunorubicin|asparaginase|etoposide|prednisone|imatinib mesylate|leucovorin","NA"]
["NCT00002516","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19760772|18802150|NA|NA","Sari N, Toğral G, Cetindağ MF, Güngör BS, Ilhan IE. Treatment results of the Ewing sarcoma of bone and prognostic factors. Pediatr Blood Cancer. 2010 Jan;54(1):19-24. doi: 10.1002/pbc.22278.|Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, Schuck A, Winkelmann W, Köhler G, Poremba C, Zoubek A, Ladenstein R, van den Berg H, Hunold A, Cassoni A, Spooner D, Grimer R, Whelan J, McTiernan A, Jürgens H; European Intergroup Cooperative Ewing's Sarcoma Study-92. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008 Sep 20;26(27):4385-93. doi: 10.1200/JCO.2008.16.5720.|Whelan J, McTiernan A, Weston C, et al.: Consequences of different approaches to local treatment of Ewing's sarcoma within an international randomised controlled trial: analysis of EICESS-92. [Abstract] J Clin Oncol 24 (Suppl 18): A-9533, 528s, 2006.|Paulussen M, Craft AW, Lewis I, et al.: Ewing tumor of bone - updated report of the European Intergroup Cooperative Ewing's Sarcoma Study EICESS 92. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1568, 2002.","\tSarcoma\tdactinomycin|cyclophosphamide|doxorubicin hydrochloride|etoposide|ifosfamide|mesna|vincristine sulfate|conventional surgery|low-LET cobalt-60 gamma ray therapy|low-LET photon therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","sarcoma, ewing|sarcoma","dactinomycin|etoposide|vincristine|cyclophosphamide|ifosfamide|doxorubicin|cobalt|liposomal doxorubicin","NA"]
["NCT00002517","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16333838|16136166","Brunet AS, Ploton C, Galambrun C, Pondarré C, Pages MP, Bleyzac N, Freydière AM, Barbé G, Bertrand Y. Low incidence of sepsis due to viridans streptococci in a ten-year retrospective study of pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2006 Nov;47(6):765-72.|Entz-Werle N, Suciu S, van der Werff ten Bosch J, Vilmer E, Bertrand Y, Benoit Y, Margueritte G, Plouvier E, Boutard P, Vandecruys E, Ferster A, Lutz P, Uyttebroeck A, Hoyoux C, Thyss A, Rialland X, Norton L, Pages MP, Philippe N, Otten J, Behar C; EORTC Children Leukemia Group. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. Leukemia. 2005 Dec;19(12):2072-81.","\tLeukemia|Myelodysplastic Syndromes\tcytarabine|daunorubicin hydrochloride|dexamethasone|etoposide|idarubicin|mitoxantrone hydrochloride|thioguanine|allogeneic bone marrow transplantation|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","preleukemia|syndrome|leukemia|myelodysplastic syndromes","mitoxantrone|cytarabine|daunorubicin|idarubicin|thioguanine|dexamethasone|etoposide","NA"]
["NCT00002520","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12525530,"Schnoll RA, Zhang B, Rue M, Krook JE, Spears WT, Marcus AC, Engstrom PF. Brief physician-initiated quit-smoking strategies for clinical oncology settings: a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2003 Jan 15;21(2):355-65.","\tBladder Cancer|Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Lymphoma|Prostate Cancer|Testicular Germ Cell Tumor|Tobacco Use Disorder|Unspecified Adult Solid Tumor, Protocol Specific\tnicotine|Usual Care\tNA\tNA\tNA\tDrug|Behavioral\tAll\t","Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer","Interventional","Completed","N/A",2,434,"tobacco use disorder|neoplasms|lymphoma|breast neoplasms|urinary bladder neoplasms|prostatic neoplasms|lung neoplasms|neoplasms, germ cell and embryonal","nicotine","NA"]
["NCT00002523","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20876317|20797891|17906203|16971718|NA|NA|16009958|NA|NA|12204666","Monnien F, Zaki H, Borg C, Mougin C, Bosset JF, Mercier M, Arbez-Gindre F, Kantelip B. Prognostic value of phosphorylated STAT3 in advanced rectal cancer: a study from 104 French patients included in the EORTC 22921 trial. J Clin Pathol. 2010 Oct;63(10):873-8. doi: 10.1136/jcp.2010.076414.|Tiv M, Puyraveau M, Mineur L, Calais G, Maingon P, Bardet E, Mercier M, Bosset JF. Long-term quality of life in patients with rectal cancer treated with preoperative (chemo)-radiotherapy within a randomized trial. Cancer Radiother. 2010 Oct;14(6-7):530-4. doi: 10.1016/j.canrad.2010.06.017. Epub 2010 Aug 24.|Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, Radosevic-Jelic L, Piérart M, Calais G; European Organisation for Research and Treatment of Cancer Radiation Oncology Group. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol. 2007 Oct 1;25(28):4379-86.|Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006 Sep 14;355(11):1114-23. Erratum in: N Engl J Med. 2007 Aug 16;357(7):728.|Bosset J, Calais G, Mineur L, et al.: Preoperative radiotherapy in rectal cancer: role and place of fluorouracil-based chemotherapy. Final results of the EORTC 22921 phase III trial. [Abstract] American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium, 27-29 January 2005, Miami, Florida. A-255, 2005.|Bosset JF, Calais G, Mineur L, et al.: Preoperative radiation (Preop RT) in rectal cancer: effect and timing of additional chemotherapy (CT) 5-year results of the EORTC 22921 trial. [Abstract] J Clin Oncol 23 (Suppl 16): A-3505, 247s, 2005.|Bosset JF, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Briffaux A, Collette L. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921. J Clin Oncol. 2005 Aug 20;23(24):5620-7. Epub 2005 Jul 11.|Bosset JF, Calais G, Mineur L, et al.: Does the addition of chemotherapy (CT) to preoperative radiotherapy (preopRT) increase the pathological response in patients with resected rectal cancer: report of the 22921 EORTC phase III trial. [Abstract] J Clin Oncol 22 (Suppl 14): A-3504, 246, 2004.|Bosset JF, Calais G, Daban A, et al.: Does the addition of chemotherapy to preoperative radiation increase acute toxicity in patients with rectal cancer: report of 22921 EORTC phase III trial . [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-1179, 2003.|Kouloulias VE, Bosset JF, van Tienhoven G, Davis BJ, Pierart M, Poortmans P; EORTC Radiotherapy Group. European Organization for Research and Treatment of Cancer. Quality assurance in the EORTC 22921 trial on preoperative radiotherapy with or without chemotherapy for resectable rectal cancer: evaluation of the individual case review procedure. Eur J Cancer. 2002 Sep;38(14):1849-56.","\tColorectal Cancer\tfluorouracil|leucovorin calcium|conventional surgery|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","rectal neoplasms","fluorouracil|calcium|leucovorin|levoleucovorin","NA"]
["NCT00002526","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16500907,"Leyvraz S, Zweifel M, Jundt G, Lissoni A, Cerny T, Sessa C, Fey M, Dietrich D, Honegger HP; Swiss Group for Clinical Cancer Research. Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Ann Oncol. 2006 Apr;17(4):646-51. Epub 2006 Feb 24.","\tOvarian Cancer|Sarcoma\tfilgrastim|doxorubicin hydrochloride|ifosfamide\tNA\tNA\tNA\tBiological|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","sarcoma","doxorubicin|liposomal doxorubicin|ifosfamide","NA"]
["NCT00002527","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12621132,"Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003 Mar 6;348(10):883-90. Erratum in: N Engl J Med. 2003 May 8;348(19):1939.","\tColorectal Cancer\taspirin|placebo\tParallel Assignment\tPrevention\tRandomized\tDrug|Other\tAll\t","Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically Removed","Interventional","Completed","Phase 3",2,635,"colorectal neoplasms","aspirin","NA"]
["NCT00002528","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16344321,"International Breast Cancer Study Group, Rudenstam CM, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, Rey P, Dent D, Campbell I, Bernhard J, Price KN, Castiglione-Gertsch M, Goldhirsch A, Gelber RD, Coates AS. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol. 2006 Jan 20;24(3):337-44. Epub 2005 Dec 12.","\tBreast Cancer\ttamoxifen citrate|conventional surgery|radiation therapy|Axillary clearance\tParallel Assignment\tTreatment\tRandomized\tDrug|Procedure|Radiation|Procedure\tFemale\t","Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I or Stage IIA Breast Cancer","Interventional","Completed","Phase 3",2,473,"breast neoplasms","tamoxifen","NA"]
["NCT00002536","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17493669,"Eddy GL, Bundy BN, Creasman WT, Spirtos NM, Mannel RS, Hannigan E, O'Connor D. Treatment of (\"bulky\") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol. 2007 Aug;106(2):362-9. Epub 2007 May 9.","\tCervical Cancer\tcisplatin|vincristine sulfate|surgical procedure|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Radiation\tFemale\t","NA","NA","NA","NA","NA","NA","uterine cervical neoplasms","vincristine","NA"]
["NCT00002539","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17227995|NA","Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AH; MRC BO06 and EORTC 80931 collaborators; European Osteosarcoma Intergroup. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007 Jan 17;99(2):112-28.|Lewis IJ, Nooij M: Chemotherapy at standard or increased dose intensity in patients with operable osteosarcoma of the extremity: a randomised controlled trial conducted by the European Osteo Sarcoma Intergroup (ISRCTN 86294690). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-3281, 816, 2003.","\tSarcoma\tfilgrastim|cisplatin|doxorubicin hydrochloride|conventional surgery\tNA\tNA\tNA\tBiological|Drug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","osteosarcoma","doxorubicin|liposomal doxorubicin","NA"]
["NCT00002542","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Bramwell VH, Pritchard KI, Tu D, et al.: Tamoxifen (T) compared to placebo (P), after adjuvant chemotherapy (CT), in premenopausal women with early breast cancer (EBC): interim results of NCIC-CTG MA.12. [Abstract] J Clin Oncol 25 (Suppl 18): A-547, 2007.|Bramwell VHC, Pritchard KI, Tu D, et al.: How compliant are patients with oral hormonal therapies? Data from a randomized, placebo controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (NCIC CTG MA.12). [Abstract] Breast Cancer Res Treat 106 (1): A-3055, 2007.","\tBreast Cancer\tCMF regimen|cyclophosphamide|doxorubicin hydrochloride|epirubicin hydrochloride|fluorouracil|methotrexate|tamoxifen citrate|radiation therapy\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Radiation\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","fluorouracil|cyclophosphamide|doxorubicin|methotrexate|liposomal doxorubicin|tamoxifen|epirubicin","NA"]
["NCT00002544","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12419743,"Heidemann E, Stoeger H, Souchon R, Hirschmann WD, Bodenstein H, Oberhoff C, Fischer JT, Schulze M, Clemens M, Andreesen R, Mahlke M, König M, Scharl A, Fehnle K, Kaufmann M. Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Ann Oncol. 2002 Nov;13(11):1717-29.","\tBreast Cancer\tdocetaxel|mitoxantrone hydrochloride\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","mitoxantrone|docetaxel","NA"]
["NCT00002545","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20383558|15890570|15465203|NA","Anker CJ, Hymas RV, Hazard LJ, Boucher KM, Jensen RL, Shrieve DC. Stereotactic radiosurgery eligibility and selection bias in the treatment of glioblastoma multiforme. J Neurooncol. 2010 Jun;98(2):253-63. doi: 10.1007/s11060-010-0176-y. Epub 2010 Apr 10.|Chakravarti A, Seiferheld W, Tu X, Wang H, Zhang HZ, Ang KK, Hammond E, Curran W Jr, Mehta M. Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):318-27.|Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L, Mehta MP, Curran WJ Jr. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):853-60.|Souhami L, Scott C, Brachman D, et al.: Randomized prospective comparison of stereotactic radiosurgery (SRS) followed by conventional radiotherapy (RT) with BCNU to RT with BCNU alone for selected patients with supratentorial glioblastoma multiforme (GBM): report of RTOG 93-05 protocol. [Abstract] Int J Radiat Oncol Biol Phys 54(2 suppl 1): A-163, 94-95, 2002.","\tBrain and Central Nervous System Tumors\tcarmustine|low-LET photon therapy\tNA\tNA\tNA\tDrug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","glioblastoma|nervous system neoplasms|central nervous system neoplasms","carmustine","NA"]
["NCT00002546","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17822748,"Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, Cohn DE, Ioffe OB. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007 Nov;107(2):177-85. Epub 2007 Sep 5.","\tSarcoma\tcisplatin|ifosfamide|adjuvant therapy|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Radiation\tFemale\t","NA","NA","NA","NA","NA","NA","carcinosarcoma|sarcoma","ifosfamide","NA"]
["NCT00002548","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16432076|NA|NA|NA|NA|NA|NA","Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006 Feb 20;24(6):929-36. Epub 2006 Jan 23. Erratum in: J Clin Oncol. 2006 Jun 10;24(17):2687. Moore, Dennis F Jr [added].|Van Ness BG, Crowley JC, Ramos C, et al.: SNP genotypes show association with common toxicities during both VAD induction and high dose melphalan with autologous transplant support in intergroup trial S9321 for myeloma: from the Bank on a Cure. [Abstract] Blood 106 (11): A-3488, 2005.|Crowley J, Fonseca R, Greipp P, et al.: Comparable survival in newly diagnosed multiple myeloma (MM) after VAD induction with high dose therapy using melphalan 140mg/m2 + TBI 12 Gy (MEL+TBI) versus standard therapy with VBMCP and no benefit from interferon (IFN) maintenance: final clinical results of intergroup trial S9321 in the context of IFM 90 and MRC VII trials. [Abstract] Blood 104 (11): A-539, 2004.|Santana-Davila R, Crowley J, Durie B, et al.: Genetic polymorphisms associated with clinical outcome in the intergroup trial S9321, comparing high dose therapy with standard dose therapy for myelomaon, on behalf of ECOG, SWOG, CALGB, and the Bank on a Cure. [Abstract] Blood 104 (11): A-1495, 2004.|Lee CK, McCoy J, Anderson KC, et al.: Long-term follow-up of previously untreated symptomatic myeloma patients treated with myeloablative therapy and sibling-matched allogeneic transplantation of the SWOG study 9321. [Abstract] Blood 100 (11 pt 1): A-1644, 2002.|Greipp PR, Jacobson JL, Crowley JJ, et al.: BETA 2 microglobulin (beta 2M) and plasma cell labeling index (PCLI) constitute a strong prognostic index in the SWOG intergroup transplant trial S9321: observations on gender and age. [Abstract] Blood 96 (11 pt 1): A-653, 152a, 2000.|Desika R, Salmon S, Anderson K, et al.: Planned melphalan-total body irradiation (MEL-TBI) - based allogeneic transplantation for multiple myeloma (MM) up to age 55: an intergroup experience (CALGB, ECOG and SWOG) under the auspices of the Southwest Oncology Group (SWOG 9321). [Abstract] Blood 94 (10 Pt 1): A-1546, 346a, 1999.","\tMultiple Myeloma\trecombinant interferon alfa|carmustine|cyclophosphamide|dexamethasone|doxorubicin hydrochloride|melphalan|prednisone|vincristine sulfate|allogeneic bone marrow transplantation|autologous bone marrow transplantation|peripheral blood stem cell transplantation|radiation therapy\tParallel Assignment\tTreatment\tRandomized\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure|Procedure|Radiation\tAll\t","SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma","Interventional","Completed","Phase 3",4,899,"neoplasms, plasma cell|multiple myeloma","interferons|melphalan|prednisone|liposomal doxorubicin|vincristine|interferon-alpha|dexamethasone|carmustine|doxorubicin|cyclophosphamide","NA"]
["NCT00002549","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19826132,"Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G, Muus P, Marmont F, Marie JP, Labar B, Thomas X, Di Raimondo F, Willemze R, Liso V, Ferrara F, Baila L, Fazi P, Zittoun R, Amadori S, de Witte T. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol. 2009 Nov 10;27(32):5397-403. doi: 10.1200/JCO.2008.20.6490. Epub 2009 Oct 13. Erratum in: J Clin Oncol. 2010 Mar 10;28(8):1438.","\tLeukemia\tdaunorubicin hydrochloride|etoposide|idarubicin|mesna|mitoxantrone hydrochloride|filgrastim|busulfan|cyclophosphamide|cytarabine|allogeneic bone marrow transplantation|autologous bone marrow transplantation|peripheral blood stem cell transplantation|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Biological|Drug|Drug|Drug|Procedure|Procedure|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","leukemia|leukemia, myeloid|leukemia, myeloid, acute","mitoxantrone|daunorubicin|idarubicin|etoposide|cytarabine|cyclophosphamide|busulfan","NA"]
["NCT00002550","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19632716|NA|NA|NA","Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009 Aug 1;374(9687):379-86. doi: 10.1016/S0140-6736(09)60737-6. Epub 2009 Jul 24.|Albain KS, Swann RS, Rusch VR, et al.: Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). [Abstract] J Clin Oncol 23 (Suppl 16): A-7014, 624s, 2005.|Albain KS, Scott CB, Rusch VR, et al.: Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RTOG 93-09) . [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2497, 2003.|Turrisi AT, Scott CB, Rusch VR, et al.: Randomized trial of chemoradiotherapy to 61 Gy [no S] versus chemoradiotherapy to 45 Gy followed by surgery [S] using cisplatin etoposide in stage IIIa non-small cell lung cancer (NSCLC): intergroup trial 0139, RTOG (9309). [Abstract] Int J Radiat Oncol Biol Phys 57 (2 Suppl): S125-6, 2003.","\tLung Cancer\tcisplatin|etoposide|conventional surgery|radiation therapy\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Procedure|Radiation\tAll\t","Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer","Interventional","Completed","Phase 3",2,429,"carcinoma, non-small-cell lung|lung neoplasms","etoposide","NA"]
["NCT00002551","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|NA|16877719|NA","Ulrich CM, Rankin C, Holmes RS, et al.: Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among stage II or III rectal cancer patients (SWOG 9304). [Abstract] American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium, 25-27 January 2008, Orlando, FL. A-309, 2008.|Zhang W, Rankin CJ, Danenberg KD, et al.: An update of pharmacogenetic analysis of adjuvant rectal cancer patients treated with 5-fluorouracil and pelvic radiation in a phase III intergroup trial (INT-0144, SWOG 9304). [Abstract] J Clin Oncol 26 (Suppl 15): A-4115, 2008.|Zhang W, Rankin C, Nagashima F, et al.: Pharmacogenetic analysis of stage II/III rectal cancer patients treated with 5-fluorouracil and pelvic radiation in a phase III intergroup trial (INT-0144, SWOG 9304). [Abstract] American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium, 25-27 January 2008, Orlando, FL. A-300, 2008.|Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, Fisher B, Rich TA, Martenson JA, Kugler JW, Benson AB 3rd, Haller DG, Mayer RJ, Atkins JN, Cripps C, Pedersen J, Periman PO, Tanaka MS Jr, Leichman CG, Macdonald JS. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol. 2006 Aug 1;24(22):3542-7.|Smalley SR, Benedetti J, Williamson S, et al.: Intergroup 0144 - phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs prolonged venous infusion (PVI) before and after XRT + PVI vs bolus 5-FU + leucovorin (LV) + levamisole (LEV) before and after XRT + bolus 5-FU + LV. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-1006, 2003.","\tColorectal Cancer\tfluorouracil|leucovorin calcium|levamisole hydrochloride|radiation therapy\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Radiation\tAll\t","SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed","Interventional","Completed","Phase 3",3,1917,"rectal neoplasms","levamisole|leucovorin|fluorouracil|levoleucovorin|calcium","NA"]
["NCT00002553","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","7632970|8417795|1994541","Petersdorf EW, Longton GM, Anasetti C, Martin PJ, Mickelson EM, Smith AG, Hansen JA. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood. 1995 Aug 15;86(4):1606-13.|Beatty PG, Anasetti C, Hansen JA, Longton GM, Sanders JE, Martin PJ, Mickelson EM, Choo SY, Petersdorf EW, Pepe MS, et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood. 1993 Jan 1;81(1):249-53.|Beatty PG, Hansen JA, Longton GM, Thomas ED, Sanders JE, Martin PJ, Bearman SI, Anasetti C, Petersdorf EW, Mickelson EM, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation. 1991 Feb;51(2):443-7.","\tLeukemia|Lymphoma\tcyclophosphamide|allogeneic bone marrow transplantation|low-LET cobalt-60 gamma ray therapy\tNA\tNA\tNA\tDrug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","leukemia|lymphoma","cyclophosphamide|cobalt","NA"]
["NCT00002555","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16161069|15128894|NA|9632290","Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lefèbvre JL. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005 Oct;27(10):843-50.|Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M; European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004 May 6;350(19):1945-52.|Bernier J, Domenge C, Eschwege F, et al.: Chemo-radiotherapy, as compared to radiotherapy alone, significantly increases disease-free and overall survival in head and neck cancer patients after surgery: results of EORTC phase III trial 22931. [Abstract] Int J Radiat Oncol Biol Phys 51(3 suppl 1): A-1, 1, 2001.|Valley JF, Bernier J, Tercier PA, Fogliata-Cozzi A, Rosset A, Garavaglia G, Mirimanoff RO. Quality assurance of the EORTC radiotherapy trial 22931 for head and neck carcinomas: the dummy run. Radiother Oncol. 1998 Apr;47(1):37-44.","\tHead and Neck Cancer\tcisplatin|low-LET cobalt-60 gamma ray therapy|low-LET electron therapy|low-LET photon therapy\tNA\tNA\tNA\tDrug|Radiation|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","cobalt","NA"]
["NCT00002558","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20194867|17194908","Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N, Patil S, Bains M, Reich LM, Bosl GJ, Motzer RJ. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010 Apr 1;28(10):1706-13. doi: 10.1200/JCO.2009.25.1561. Epub 2010 Mar 1. Erratum in: J Clin Oncol. 2010 Dec 1;28(34):5126.|Kondagunta GV, Bacik J, Sheinfeld J, Bajorin D, Bains M, Reich L, Deluca J, Budnick A, Ishill N, Mazumdar M, Bosl GJ, Motzer RJ. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol. 2007 Jan 1;25(1):85-90. Erratum in: J Clin Oncol. 2007 May 20;25(15):2149.","\tExtragonadal Germ Cell Tumor|Ovarian Cancer|Testicular Germ Cell Tumor\tfilgrastim|carboplatin|etoposide|ifosfamide|paclitaxel|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms|neoplasms, germ cell and embryonal","paclitaxel|carboplatin|ifosfamide|etoposide","NA"]
["NCT00002561","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17846017|NA|15837968|NA","Macdonald DA, Ding K, Gospodarowicz MK, Wells WA, Pearcey RG, Connors JM, Winter JN, Horning SJ, Djurfeldt MS, Shepherd LE, Meyer RM. Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol. 2007 Oct;18(10):1680-4. Epub 2007 Sep 10.|Macdonald DA, Gospodarowicz MK, Wells WA, et al.: Relapse patterns and subsequent outcomes of patients treated on the NCIC CTG HD.6 (ECOG JHD06) randomized trial evaluating ABVD alone in patients with limited stage Hodgkin's lymphoma (HL). [Abstract] Blood 106 (11): A-817, 2005.|Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA, Burns BF, Winter JN, Horning SJ, Dar AR, Djurfeldt MS, Ding K, Shepherd LE; National Cancer Institute of Canada Clinical Trials Group; Eastern Cooperative Oncology Group. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005 Jul 20;23(21):4634-42. Epub 2005 Apr 18.|Meyer R, Gospodarowicz M, Connors J, et al.: A randomized phase III comparison of single - modality ABVD with a strategy that includes radiation therapy in patients with early-stage Hodgkin's disease: the HD-6 trial of the National Cancer Institute of Canada Clinical Trials Group (Eastern Cooperative Oncology Group Trial JHD06). [Abstract] Blood 102 (11 Pt 1): A-81, 2003.","\tHodgkin Lymphoma\tbleomycin sulfate|dacarbazine|doxorubicin hydrochloride|vinblastine|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Radiation\tAll\t","Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease","Interventional","Completed","Phase 3",2,405,"lymphoma|hodgkin disease","liposomal doxorubicin|bleomycin|vinblastine|doxorubicin|dacarbazine","NA"]
["NCT00002562","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11230468,"Curtin JP, Blessing JA, Webster KD, Rose PG, Mayer AR, Fowler WC Jr, Malfetano JH, Alvarez RD. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2001 Mar 1;19(5):1275-8.","\tCervical Cancer|Vaginal Cancer\tpaclitaxel\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","uterine cervical neoplasms|vaginal neoplasms","paclitaxel","NA"]
["NCT00002564","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19328264|17179478|NA","Hoy MK, Winters BL, Chlebowski RT, Papoutsakis C, Shapiro A, Lubin MP, Thomson CA, Grosvenor MB, Copeland T, Falk E, Day K, Blackburn GL. Implementing a low-fat eating plan in the Women's Intervention Nutrition Study. J Am Diet Assoc. 2009 Apr;109(4):688-96. doi: 10.1016/j.jada.2008.12.016.|Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, Goodman MT, Giuliano AE, Karanja N, McAndrew P, Hudis C, Butler J, Merkel D, Kristal A, Caan B, Michaelson R, Vinciguerra V, Del Prete S, Winkler M, Hall R, Simon M, Winters BL, Elashoff RM. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst. 2006 Dec 20;98(24):1767-76.|Chlebowski RT, Blackburn GL, Elashoff RE, et al.: Dietary fat reduction in postmenopausal women with primary breast cancer: phase III Women's Intervention Nutrition Study (WINS). [Abstract] J Clin Oncol 23 (Suppl 16): A-10, 3s, 2005.","\tBreast Cancer\teducational intervention|therapeutic dietary intervention\tNA\tNA\tNA\tOther|Procedure\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","NA","NA"]
["NCT00002568","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16110020,"Wenzel L, Huang HQ, Monk BJ, Rose PG, Cella D. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2005 Aug 20;23(24):5605-12.","\tOvarian Cancer\tcisplatin|paclitaxel|conventional surgery\tNA\tNA\tNA\tDrug|Drug|Procedure\tFemale\t","NA","NA","NA","NA","NA","NA","NA","cisplatin|paclitaxel","NA"]
["NCT00002569","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|19783377|18371182|16782910|NA|NA|11586105","Cairncross JG, Wang M, Shaw EG, et al.: Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: long-term results of the RTOG 9402 phase III study. [Abstract] J Clin Oncol 30 (Suppl 15): A-2008b, 2012.|Wang M, Cairncross G, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Mehta M, Curran W; Radiation Therapy Oncology Group (RTOG); North Central Cancer Treatment Group (NCCTG); Southwest Oncology Group (SWOG); National Cancer Institute of Canada Clinical Trials Group (NCIC CTG); Eastern Cooperative Oncology Group (ECOG). Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):662-9. doi: 10.1016/j.ijrobp.2009.06.004. Epub 2009 Sep 23.|Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ, Aldape K. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol. 2008 Jul;18(3):360-9. doi: 10.1111/j.1750-3639.2008.00129.x. Epub 2008 Mar 26.|Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006 Jun 20;24(18):2707-14.|Cairncross G, Seiferheld W, Shaw E, et al.: An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: initial report of RTOG 94-02. [Abstract] J Clin Oncol 22 (Suppl 14): A-1500, 107s, 2004.|Shaw EG, Seiferheld W, Cairncross JG, et al.: Radiation therapy (RT) alone vs intensive procarbazine-CCNU-vincristine (I-PCV) chemotherapy followed by radiation therapy for anaplastic oligodendroglioma (AO) and mixed oligo-astrocytoma (MOA): results of Radiation Therapy Oncology Group (RTOG) - intergroup protocol 94-02. [Abstract] Int J Radiat Oncol Biol Phys 60 (1 Suppl 1): A-57, S163, 2004.|Jenkins RB, Curran W, Scott CB, Cairncross G. Pilot evaluation of 1p and 19q deletions in anaplastic oligodendrogliomas collected by a national cooperative cancer treatment group. Am J Clin Oncol. 2001 Oct;24(5):506-8.","\tBrain and Central Nervous System Tumors\tlomustine|procarbazine hydrochloride|vincristine sulfate|radiation therapy\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Radiation\tAll\t","Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma","Interventional","Completed","Phase 3",2,299,"oligodendroglioma|nervous system neoplasms|central nervous system neoplasms","lomustine|vincristine|procarbazine","NA"]
["NCT00002570","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|16265352","Hummer A, Carlo W, Sullivan D, et al.: Extensive hepatic resection does not correlate with toxicity following adjuvant chemotherapy. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-526, 2002.|Ackland SP, Jones M, Tu D, Simes J, Yuen J, Sargeant AM, Dhillon H, Goldberg RM, Abdi E, Shepherd L, Moore MJ. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Br J Cancer. 2005 Nov 28;93(11):1236-43.","\tColorectal Cancer\tfluorouracil|leucovorin calcium\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Immediate Compared With Delayed Chemotherapy in Advanced Colorectal Cancer Without Signs or Symptoms of Disease","Interventional","Completed","Phase 3",2,67,"colorectal neoplasms","leucovorin|fluorouracil|calcium|levoleucovorin","NA"]
["NCT00002575","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21452066|18948801|15141043|11790211","Stucky CC, Pockaj BA, Novotny PJ, Sloan JA, Sargent DJ, O'Connell MJ, Beart RW, Skibber JM, Nelson H, Weeks JC. Long-term follow-up and individual item analysis of quality of life assessments related to laparoscopic-assisted colectomy in the COST trial 93-46-53 (INT 0146). Ann Surg Oncol. 2011 Sep;18(9):2422-31. doi: 10.1245/s10434-011-1650-2. Epub 2011 Mar 31.|Larson DW, Marcello PW, Larach SW, Wexner SD, Park A, Marks J, Senagore AJ, Thorson AG, Young-Fadok TM, Green E, Sargent DJ, Nelson H. Surgeon volume does not predict outcomes in the setting of technical credentialing: results from a randomized trial in colon cancer. Ann Surg. 2008 Nov;248(5):746-50. doi: 10.1097/SLA.0b013e31818a157d.|Clinical Outcomes of Surgical Therapy Study Group, Nelson H, Sargent DJ, Wieand HS, Fleshman J, Anvari M, Stryker SJ, Beart RW Jr, Hellinger M, Flanagan R Jr, Peters W, Ota D. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 2004 May 13;350(20):2050-9.|Weeks JC, Nelson H, Gelber S, Sargent D, Schroeder G; Clinical Outcomes of Surgical Therapy (COST) Study Group. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA. 2002 Jan 16;287(3):321-8.","\tColorectal Cancer\tconventional surgery|laparoscopic surgery\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","Laparoscopic-Assisted Surgery Compared With Open Surgery in Treating Patients With Colon Cancer","Interventional","Completed","Phase 3",2,810,"colonic neoplasms","NA","NA"]
["NCT00002577","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17869017|NA|15667949|NA|NA","Werner-Wasik M, Swann RS, Bradley J, Graham M, Emami B, Purdy J, Sause W. Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):385-90. Epub 2007 Sep 14.|Bradley J, Deasy J, Naqa IE, et al.: Predictors of lung toxicity from the RTOG 9311 radiation dose escalation trial: GTV position is important. [Abstract] Int J Radiat Oncol Biol Phys 63 (2 Suppl 1): A-67, S40, 2005.|Bradley J, Graham MV, Winter K, Purdy JA, Komaki R, Roa WH, Ryu JK, Bosch W, Emami B. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):318-28.|Bradley JD, Graham MV, Winter KW, et al.: Acute and late toxicity results of RTOG 9311: a dose escalation study using 3D conformal radiation therapy in patients with inoperable non-small cell lung cancer. [Abstract] Int J Radiat Oncol Biol Phys 57 (2 Suppl): S137-8, 2003.|Graham MV, Winter K, Purdy JA, et al.: Preliminary results of a Radiation Therapy Oncology Group trial (RTOG 9311): a dose escalation study using 3d conformal radiation therapy in patients with inoperable nonsmall cell lung cancer. [Abstract] Int J Radiat Oncol Biol Phys 51(3 suppl 1): A-34, 19-20, 2001.","\tLung Cancer\tradiation therapy\tNA\tNA\tNA\tRadiation\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","NA","NA"]
["NCT00002580","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",10663329,"Featherstone C, Harnett AN, Brunt AM. Ultrasound localization of the ovaries for radiation-induced ovarian ablation. Clin Oncol (R Coll Radiol). 1999;11(6):393-7.","\tBreast Cancer\tcyclophosphamide|fluorouracil|goserelin acetate|leuprolide acetate|methotrexate|tamoxifen citrate|conventional surgery|laparoscopic surgery|oophorectomy|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure|Procedure|Radiation\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","methotrexate|leuprolide|tamoxifen|goserelin|cyclophosphamide|fluorouracil","NA"]
["NCT00002582","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17405995|17405996","Adjuvant Breast Cancer Trials Collaborative Group. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial. J Natl Cancer Inst. 2007 Apr 4;99(7):506-15.|Adjuvant Breast Cancer Trials Collaborative Group. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. J Natl Cancer Inst. 2007 Apr 4;99(7):516-25.","\tBreast Cancer\tCMF regimen|cyclophosphamide|doxorubicin hydrochloride|fluorouracil|goserelin acetate|leuprolide acetate|methotrexate|tamoxifen citrate|oophorectomy|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Radiation\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","doxorubicin|methotrexate|fluorouracil|leuprolide|liposomal doxorubicin|goserelin|tamoxifen|cyclophosphamide","NA"]
["NCT00002583","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19933915|18809617|NA|NA|NA|17141357|17442999|17289895|NA|NA|NA|15713522|NA|15972865|NA|NA|NA","Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, Johnson DH, Kesler KA, Green M, Vincent M, Cormier Y, Goss G, Findlay B, Johnston M, Tsao MS, Shepherd FA. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2010 Jan 1;28(1):29-34. doi: 10.1200/JCO.2009.24.0333. Epub 2009 Nov 23.|Bezjak A, Lee CW, Ding K, Brundage M, Winton T, Graham B, Whitehead M, Johnson DH, Livingston RB, Seymour L, Shepherd FA. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J Clin Oncol. 2008 Nov 1;26(31):5052-9. doi: 10.1200/JCO.2007.12.6094. Epub 2008 Sep 22.|Jang RW, Le Maître A, Ding K, et al.: A Q-TWiST analysis of adjuvant chemotherapy in non-small cell lung cancer (NSCLC) in the NCIC CTG JBR.10 trial. [Abstract] J Clin Oncol 26 (Suppl 15): A-6535, 2008.|Tsao MS, Zhu C, Ding K, et al.: A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients. [Abstract] J Clin Oncol 26 (Suppl 15): A-7510, 2008.|Bezjak A, Lee CW, Ding K, et al.: Quality of life (QOL) impact of adjuvant chemotherapy for early stage non-small cell lung cancer (NSCLC): final analysis of JBR.10 randomized trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-7585, 405s, 2007.|Gauthier I, Ding K, Winton T, Shepherd FA, Livingston R, Johnson DH, Rigas JR, Whitehead M, Graham B, Seymour L. Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience. Lung Cancer. 2007 Mar;55(3):357-63. Epub 2006 Dec 1.|Pepe C, Hasan B, Winton TL, Seymour L, Graham B, Livingston RB, Johnson DH, Rigas JR, Ding K, Shepherd FA; National Cancer Institute of Canada and Intergroup Study JBR.10. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol. 2007 Apr 20;25(12):1553-61.|Sève P, Lai R, Ding K, Winton T, Butts C, Mackey J, Dumontet C, Dabbagh L, Aviel-Ronen S, Seymour L, Whitehead M, Tsao MS, Shepherd FA, Reiman T. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res. 2007 Feb 1;13(3):994-9.|Tsao MS, Aviel-Ronen S, Ding K, et al.: P53 protein over-expression but not p53 gene mutation is a poor prognostic marker and a predictive marker for survival benefit from adjuvant chemotherapy in non-small cell lung cancer (NSCLC) in the JBR.10 trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-7577, 403s, 2007.|Pepe C, Hasan B, Winton T, et al.: Adjuvant chemotherapy in elderly patients: an analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup BR.10. [Abstract] J Clin Oncol 24 (Suppl 18): A-7009, 2006.|Reiman T, Lai R, Ding K, et al.: Class III beta tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study JBR.10. [Abstract] J Clin Oncol 24 (Suppl 18): A-7051, 376s, 2006.|Alam N, Shepherd FA, Winton T, Graham B, Johnson D, Livingston R, Rigas J, Whitehead M, Ding K, Seymour L. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer. 2005 Mar;47(3):385-94. Review. Erratum in: Lung Cancer. 2005 Nov;50(2):283-4.|Gauthier I, Ding K, Winton T, et al.: Impact of hemoglobin (Hb) on outcomes of adjuvant chemotherapy (ACT) with cisplatin/vinorelbine in patients (pts) with completely resected non small cell lung cancer (NSCLC) in JBR.10. [Abstract] J Clin Oncol 23 (Suppl 16): A-7200, 670s, 2005.|Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T, Shepherd F; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005 Jun 23;352(25):2589-97.|Winton TL, Livingston R, Johnson D, et al.: A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10. [Abstract] J Clin Oncol 22 (Suppl 14): A-7018, 621s, 2004.|Alam N, Shepherd F, Winton T, et al.: Compliance with adjuvant chemotherapy (ACT) in non-small lung cancer (NSCLC): NCIC-CTG BR.10/JBR.10. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2547, 633, 2003.|Beziak A, Winton T, Ding K, et al.: Quality of life in a trial of adjuvant chemotherapy for early stage completely resected non-small cell lung cancer (NCIC CTG BR.10). [Abstract] Lung Cancer 41 (Suppl 2): S20, 2003.","\tLung Cancer\tcisplatin|vinorelbine ditartrate\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Vinorelbine + Cisplatin or No Further Therapy in Non-small Cell Lung Cancer That Has Been Surgically Removed","Interventional","Completed","Phase 3",2,482,"lung neoplasms|carcinoma, non-small-cell lung","vinorelbine","NA"]
["NCT00002586","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19401528,"Kelly K, Kittelson J, Franklin WA, Kennedy TC, Klein CE, Keith RL, Dempsey EC, Lewis M, Jackson MK, Hirsch FR, Bunn PA, Miller YE. A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer. Cancer Prev Res (Phila). 2009 May;2(5):440-9. doi: 10.1158/1940-6207.CAPR-08-0136. Epub 2009 Apr 28.","\tDrug Toxicity|Lung Cancer\t13-cis retinoic acid|Tocopherol\tParallel Assignment\tPrevention\tRandomized\tDrug|Dietary Supplement\tAll\t","13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer","Interventional","Completed","Phase 2",3,96,"lung neoplasms|drug-related side effects and adverse reactions","tocotrienols|vitamin e|isotretinoin|tocopherols|tretinoin|alpha-tocopherol","NA"]
["NCT00002588","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Cooper BW, Lazarus HM, Creger R, et al.: A phase I and pharmacodynamic study of sequential topotecan and etoposide (TE) in adult patients with refractory/relapsed acute leukemia (RAL) (Meeting abstact.). [Abstract] Proceedings of the American Society of Clinical Oncology 15: A1549, 1996.","\tLeukemia\tetoposide|topotecan hydrochloride\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia","topotecan|etoposide","NA"]
["NCT00002590","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18985718|18759768|NA","Lowe EJ, Sposto R, Perkins SL, Gross TG, Finlay J, Zwick D, Abromowitch M; Children's Cancer Group Study 5941. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941. Pediatr Blood Cancer. 2009 Mar;52(3):335-9. doi: 10.1002/pbc.21817.|Abromowitch M, Sposto R, Perkins S, Zwick D, Siegel S, Finlay J, Cairo MS; Children's Oncology Group. Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children's Oncology Group. Br J Haematol. 2008 Oct;143(2):261-7. doi: 10.1111/j.1365-2141.2008.07320.x. Epub 2008 Aug 28.|Abromowitch M, Sposto R, Perkins S, et al.: Outcome of Children's Cancer Group (CCG) 5941: a pilot study for the treatment of newly diagnosed pediatric patients with disseminated lymphoblastic lymphoma. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A2295, 2000.","\tLymphoma\tfilgrastim|cyclophosphamide|cytarabine|daunorubicin hydrochloride|doxorubicin hydrochloride|etoposide|leucovorin calcium|methotrexate|pegaspargase|prednisone|thioguanine|vincristine sulfate|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma","levoleucovorin|methotrexate|leucovorin|cytarabine|liposomal doxorubicin|vincristine|pegaspargase|doxorubicin|daunorubicin|thioguanine|etoposide|prednisone|cyclophosphamide|asparaginase","NA"]
["NCT00002593","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15774775|NA|NA","Poplin EA, Benedetti JK, Estes NC, Haller DG, Mayer RJ, Goldberg RM, Weiss GR, Rivkin SE, Macdonald JS. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol. 2005 Mar 20;23(9):1819-25.|Poplin E, Benedetti J, Estes N, et al.: Phase III randomized trial of bolus 5-FU/leucovorin/levamisole versus 5-FU continuous infusion/levamisole as adjuvant therapy for high risk colon cancer (SWOG 9415/INT-0153). [Abstract] Proceedings of the American Society of Clinical Oncology 19: A931, 2000.|Leichman CG, Poplin E, Zalupski M, et al.: A pilot trial of infusion 5-fluorouracil with levamisole as adjuvant therapy for stage III colon cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 14: A-460, 196, 1995.","\tColorectal Cancer\tfluorouracil|leucovorin calcium|levamisole hydrochloride\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","S9415 Chemotherapy in Patients With Stage II or III Colon Cancer That Has Been Surgically Removed","Interventional","Completed","Phase 3",2,1135,"colonic neoplasms","calcium|levoleucovorin|leucovorin|levamisole|fluorouracil","NA"]
["NCT00002594","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18623206,"Kadota RP, Mahoney DH, Doyle J, Duerst R, Friedman H, Holmes E, Kun L, Zhou T, Pollack IF. Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. Pediatr Blood Cancer. 2008 Nov;51(5):675-8. doi: 10.1002/pbc.21655.","\tBrain Tumor|Central Nervous System Tumor\tSargramostim|cyclophosphamide|melphalan|autologous bone marrow transplantation|bone marrow ablation with stem cell support|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Drug|Drug|Procedure|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms|brain neoplasms|nervous system neoplasms|medulloblastoma|neoplasms, germ cell and embryonal|central nervous system neoplasms","melphalan|molgramostim|cyclophosphamide|sargramostim","NA"]
["NCT00002596","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17235042|NA","Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, Bajorin DF, Lara PN Jr, Einhorn L, Mazumdar M, Bosl GJ. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007 Jan 20;25(3):247-56.|Bajorin DF, Nichols CR, Margolin KA, et al.: Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): a cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB. [Abstract] J Clin Oncol 24 (Suppl 18): A-4510, 2006.","\tChildhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Testicular Germ Cell Tumor\tbleomycin sulfate|filgrastim|carboplatin|cisplatin|cyclophosphamide|etoposide|autologous bone marrow transplantation|bone marrow ablation with stem cell support|conventional surgery|peripheral blood stem cell transplantation|radiation therapy\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug|Drug|Procedure|Procedure|Procedure|Procedure|Radiation\tMale\t","NA","NA","NA","NA","NA","NA","neoplasms, germ cell and embryonal|neoplasms|testicular neoplasms","etoposide|bleomycin|carboplatin|cyclophosphamide","NA"]
["NCT00002602","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22633552|22342302|22673726|21377288|21414514|19577865|20598811|NA|NA|NA|NA|15936549|NA|14967428|15590164|12694838|NA|14529764|10661346|NA|NA","Michalski J, Winter K, Roach M, Markoe A, Sandler HM, Ryu J, Parliament M, Purdy JA, Valicenti RK, Cox JD. Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e363-70. doi: 10.1016/j.ijrobp.2011.12.070.|Tucker SL, Dong L, Michalski JM, Bosch WR, Winter K, Cox JD, Purdy JA, Mohan R. Do intermediate radiation doses contribute to late rectal toxicity? An analysis of data from radiation therapy oncology group protocol 94-06. Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):390-5. doi: 10.1016/j.ijrobp.2011.11.073. Epub 2012 Feb 17.|Tucker SL, Michalski JM, Bosch WR, Mohan R, Dong L, Winter K, Purdy JA, Cox JD. Use of fractional dose-volume histograms to model risk of acute rectal toxicity among patients treated on RTOG 94-06. Radiother Oncol. 2012 Jul;104(1):109-13. doi: 10.1016/j.radonc.2012.04.023. Epub 2012 Jun 5.|Tucker SL, Thames HD, Michalski JM, Bosch WR, Mohan R, Winter K, Cox JD, Purdy JA, Dong L. Estimation of α/β for late rectal toxicity based on RTOG 94-06. Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):600-5. doi: 10.1016/j.ijrobp.2010.11.080. Epub 2011 Mar 4.|Valicenti RK, Bae K, Michalski J, Sandler H, Shipley W, Lin A, Cox J. Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06. Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1323-9. doi: 10.1016/j.ijrobp.2010.01.009.|Michalski JM, Bae K, Roach M, Markoe AM, Sandler HM, Ryu J, Parliament MB, Straube W, Valicenti RK, Cox JD. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):14-22. doi: 10.1016/j.ijrobp.2009.01.062.|Tucker SL, Dong L, Bosch WR, Michalski J, Winter K, Mohan R, Purdy JA, Kuban D, Lee AK, Cheung MR, Thames HD, Cox JD. Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model. Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1253-60. doi: 10.1016/j.ijrobp.2010.01.069. Epub 2010 Jul 2.|Cheung MR, Tucker SL, Dong L, et al.: Dose-volume analyses of grade ≥ 2 late rectal toxicity among patients treated on protocol RTOG 94-06. [Abstract] Int J Radiat Oncol Biol Phys 69 (3 Suppl): A-16, S9, 2007.|Tucker SL, Dong L, Bosch WR, et al.: Fit of a generalized Lyman normal-tissue complication probability (NTCP) model to grade ≥ 2 late rectal toxicity data from patients treated on protocol RTOG 94-06. [Abstract] Int J Radiat Oncol Biol Phys 69 (3 Suppl): A-15, S8-9, 2007.|Valicenti RK, Bae K, Michalski J, et al.: Does adjuvant hormonal therapy improve freedom from biochemical relapse in prostate cancer patients receiving dose- escalated radiation therapy? An analysis of RTOG 94-06. [Abstract] American Society of Clinical Oncology 2007 Prostate Cancer Symposium, 22-24 February 2007, Orlando, FL. A-297, 2007.|Michalski JM, Winter KA, Roach M: Clinical outcome of patients treated with 3D conformal radiation therapy 3D-CRT for prostate cancer on RTOG 9406. [Abstract] American Society of Clinical Oncology 2005 Prostate Cancer Symposium, 17-19 February 2005, Orlando, Florida. A-84, 2005.|Michalski JM, Winter K, Purdy JA, Parliament M, Wong H, Perez CA, Roach M, Bosch W, Cox JD. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):706-13.|Michalski JM, Winter KA, Roach M, et al.: Clinical outcome of patients treated with 3D conformal radiation therapy 3D-CRT for prostate cancer on RTOG 9406. [Abstract] Int J Radiat Oncol Biol Phys 60 (Suppl 1): A-66, S169, 2004.|Michalski JM, Winter K, Purdy JA, Perez CA, Ryu JK, Parliament MB, Valicenti RK, Roach M 3rd, Sandler HM, Markoe AM, Cox JD. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):735-42.|Roach M, Winter K, Michalski JM, Cox JD, Purdy JA, Bosch W, Lin X, Shipley WS. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1351-6.|Michalski JM, Winter K, Purdy JA, Wilder RB, Perez CA, Roach M, Parliament MB, Pollack A, Markoe AM, Harms W, Sandler HM, Cox JD. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):192-8.|Michalski J, Winter K, Purdy JA, et al.: Toxicity following 3D radiation therapy for prostate cancer on RTOG 9406 dose level V. [Abstract] Int J Radiat Oncol Biol Phys 57 (2 Suppl): S151, 2003.|Valicenti RK, Winter K, Cox JD, Sandler HM, Bosch W, Vijayakumar S, Michalski J, Purdy J. RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):614-20.|Michalski JM, Purdy JA, Winter K, Roach M 3rd, Vijayakumar S, Sandler HM, Markoe AM, Ritter MA, Russell KJ, Sailer S, Harms WB, Perez CA, Wilder RB, Hanks GE, Cox JD. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):391-402.|Michalski JM, Winter K, Purdy JA, et al.: Update of toxicity following 3D radiation therapy for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys 48(3 suppl): A-233, 228, 2000.|Roach M, Winter K, Michalski J, et al.: Mean dose of radiation to the bulb of penis correlates with risk of impotence at 24 months: preliminary analysis of Radiation Therapy Oncology Group (RTOG) phase I/II dose escalation trial 94-06. Int J Radiat Oncol Biol Phys 48(3 suppl): A-2104, 316, 2000.","\tProstate Cancer\t3D-CRT\tNA\tNA\tNA\tRadiation\tMale\t","Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer","Interventional","Completed","Phase 1/Phase 2",3,1084,"prostatic neoplasms","NA","NA"]
["NCT00002608","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Gertler SZ, Yau J, Stewart DJ, et al.: Cisplatin, doxorubicin and tamoxifen (CAT) in the treatment of incurable soft tissue and endocrine malignancies-preliminary results. [Abstract] Proceedings of the American Society of Clinical Oncology 15: A1427, 1996.","\tAdrenocortical Carcinoma|Brain and Central Nervous System Tumors|Head and Neck Cancer|Liver Cancer|Malignant Mesothelioma|Pheochromocytoma|Sarcoma\tcisplatin|doxorubicin hydrochloride|tamoxifen citrate|conventional surgery|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|nervous system neoplasms|liver neoplasms|mesothelioma|pheochromocytoma|carcinoma|sarcoma|adrenocortical carcinoma","tamoxifen|doxorubicin|liposomal doxorubicin","NA"]
["NCT00002610","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16547940,"Green DM, Cotton CA, Malogolowkin M, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PR, Grundy PE, D'Angio GJ, Beckwith JB, Shamberger RC, Haase GM, Donaldson M, Weetman R, Coppes MJ, Shearer P, Coccia P, Kletzel M, Macklis R, Tomlinson G, Huff V, Newbury R, Weeks D. Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group. Pediatr Blood Cancer. 2007 May;48(5):493-9.","\tKidney Cancer\tdactinomycin|filgrastim|carboplatin|cyclophosphamide|doxorubicin hydrochloride|etoposide|vincristine sulfate|conventional surgery|radiation therapy\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug|Drug|Drug|Procedure|Radiation\tAll\t","Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors","Interventional","Completed","Phase 3",4,203,"kidney neoplasms|wilms tumor","liposomal doxorubicin|vincristine|lenograstim|etoposide|dactinomycin|sargramostim|carboplatin|doxorubicin|cyclophosphamide","NA"]
["NCT00002611","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22952427|21189373|18989885|19208794|17539021|16710034|16410127|NA|16172460|15868587|16129848|15654272","Gadd S, Huff V, Huang CC, Ruteshouser EC, Dome JS, Grundy PE, Breslow N, Jennings L, Green DM, Beckwith JB, Perlman EJ. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study. Neoplasia. 2012 Aug;14(8):742-56.|Perlman EJ, Grundy PE, Anderson JR, Jennings LJ, Green DM, Dome JS, Shamberger RC, Ruteshouser EC, Huff V. WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a children's oncology group study. J Clin Oncol. 2011 Feb 20;29(6):698-703. doi: 10.1200/JCO.2010.31.5192. Epub 2010 Dec 28.|Fernandez CV, Anderson J, Breslow NE, Dome JS, Grundy PE, Perlman EJ, Green DM; National Wilms Tumor Study Group/Children's Oncology Group. Anthropomorphic measurements and event-free survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009 Feb;52(2):254-8. doi: 10.1002/pbc.21809.|Huang CC, Gadd S, Breslow N, Cutcliffe C, Sredni ST, Helenowski IB, Dome JS, Grundy PE, Green DM, Fritsch MK, Perlman EJ. Predicting relapse in favorable histology Wilms tumor using gene expression analysis: a report from the Renal Tumor Committee of the Children's Oncology Group. Clin Cancer Res. 2009 Mar 1;15(5):1770-8. doi: 10.1158/1078-0432.CCR-08-1030. Epub 2009 Feb 10.|Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PR, Grundy PE, D'Angio GJ, Beckwith JB, Shamberger RC, Haase GM, Donaldson M, Weetman R, Coppes MJ, Shearer P, Coccia P, Kletzel M, Macklis R, Tomlinson G, Huff V, Newbury R, Weeks D; National Wilms Tumor Study Group. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer. 2008 Feb;50(2):236-41.|Dome JS, Cotton CA, Perlman EJ, Breslow NE, Kalapurakal JA, Ritchey ML, Grundy PE, Malogolowkin M, Beckwith JB, Shamberger RC, Haase GM, Coppes MJ, Coccia P, Kletzel M, Weetman RM, Donaldson M, Macklis RM, Green DM. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study. J Clin Oncol. 2006 May 20;24(15):2352-8.|Ehrlich PF, Hamilton TE, Grundy P, Ritchey M, Haase G, Shamberger RC; National Wilms' Tumor Study Group (National Wilms' Tumor Study 5). The value of surgery in directing therapy for patients with Wilms' tumor with pulmonary disease. A report from the National Wilms' Tumor Study Group (National Wilms' Tumor Study 5). J Pediatr Surg. 2006 Jan;41(1):162-7; discussion 162-7.|Seibel NL, Sun J, Anderson JR, et al.: Outcome of clear cell sarcoma of the kidney (CCSK) treated on the National Wilms Tumor Study-5 (NWTS). [Abstract] J Clin Oncol 24 (Suppl 18): A-9000, 502s, 2006.|Dome JS, Bockhold CA, Li SM, Baker SD, Green DM, Perlman EJ, Hill DA, Breslow NE. High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor. J Clin Oncol. 2005 Dec 20;23(36):9138-45. Epub 2005 Sep 19.|Ehrlich PF, Ritchey ML, Hamilton TE, Haase GM, Ou S, Breslow N, Grundy P, Green D, Norkool P, Becker J, Shamberger RC. Quality assessment for Wilms' tumor: a report from the National Wilms' Tumor Study-5. J Pediatr Surg. 2005 Jan;40(1):208-12; discussion 212-3.|Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Donaldson M, Coppes MJ, Malogolowkin M, Shearer P, Thomas PR, Macklis R, Tomlinson G, Huff V, Green DM; National Wilms Tumor Study Group. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005 Oct 10;23(29):7312-21. Epub 2005 Aug 29.|Miller MA, Karacay B, Breslow NE, Li S, O'Dorisio MS, Grundy PE, Sandler AD. Prognostic value of quantifying apoptosis factor expression in favorable histology wilms tumors. J Pediatr Hematol Oncol. 2005 Jan;27(1):11-4.","\tKidney Cancer\tdactinomycin|filgrastim|cyclophosphamide|doxorubicin hydrochloride|etoposide|vincristine sulfate|conventional surgery|radiation therapy\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug|Drug|Procedure|Radiation\tAll\t","Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer","Interventional","Completed","Phase 3",9,3031,"wilms tumor|kidney neoplasms|carcinoma, renal cell","doxorubicin|liposomal doxorubicin|etoposide|vincristine|cyclophosphamide|dactinomycin","NA"]
["NCT00002615","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16822992|NA|NA","Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20.|Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). [Abstract] J Clin Oncol 23 (Suppl 16): A-4001, 308s, 2005.|Allum W, Cunningham D, Weeden S: Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-998, 249, 2003.","\tGastric Cancer\tcisplatin|epirubicin hydrochloride|fluorouracil|conventional surgery\tNA\tNA\tNA\tDrug|Drug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","stomach neoplasms","epirubicin|fluorouracil","NA"]
["NCT00002618","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17439836|15659500","Nasr MR, Laver JH, Chang M, Hutchison RE. Expression of anaplastic lymphoma kinase, tyrosine-phosphorylated STAT3, and associated factors in pediatric anaplastic large cell lymphoma: A report from the children's oncology group. Am J Clin Pathol. 2007 May;127(5):770-8.|Laver JH, Kraveka JM, Hutchison RE, Chang M, Kepner J, Schwenn M, Tarbell N, Desai S, Weitzman S, Weinstein HJ, Murphy SB. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005 Jan 20;23(3):541-7.","\tLymphoma\tfilgrastim|cytarabine|doxorubicin hydrochloride|leucovorin calcium|mercaptopurine|methotrexate|prednisone|vincristine sulfate|low-LET cobalt-60 gamma ray therapy|low-LET electron therapy|low-LET photon therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Radiation|Radiation|Radiation\tAll\t","Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma","Interventional","Completed","Phase 3",2,242,"lymphoma","mercaptopurine|cobalt|leucovorin|cytarabine|doxorubicin|levoleucovorin|methotrexate|prednisone|liposomal doxorubicin|vincristine","NA"]
["NCT00002620","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18248979|8058153","Hildebrand J, Gorlia T, Kros JM, Afra D, Frenay M, Omuro A, Stupp R, Lacombe D, Allgeier A, van den Bent MJ; EORTC Brain Tumour Group investigators. Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). Eur J Cancer. 2008 Jun;44(9):1210-6. doi: 10.1016/j.ejca.2007.12.005. Epub 2008 Jan 14.|Hildebrand J, Sahmoud T, Mignolet F, Brucher JM, Afra D. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group. Neurology. 1994 Aug;44(8):1479-83.","\tBrain and Central Nervous System Tumors\tcarmustine|chemotherapy|mitolactol|low-LET cobalt-60 gamma ray therapy|low-LET photon therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|nervous system neoplasms","mitolactol|carmustine|cobalt","NA"]
["NCT00002622","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15764775|NA|NA","Dresler CM, Olak J, Herndon JE 2nd, Richards WG, Scalzetti E, Fleishman SB, Kernstine KH, Demmy T, Jablons DM, Kohman L, Daniel TM, Haasler GB, Sugarbaker DJ; Cooperative Groups Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; North Central Cooperative Oncology Group; Radiation Therapy Oncology Group. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005 Mar;127(3):909-15.|Fleishman SB, Dresler C, Herndon JE, et al.: Quality of life (QOL) advantage of sclerosis for malignant pleural effusion (MPE) via talc thoracoscopy over chest tube infusion of talc slurry: a cancer and leukemia group B study. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1418, 2002.|Dresler CM, Herndon JE, Daniels T, et al.: Cancer and Leukemia Group B (CALGB) 9334: a phase III, intergroup study of sclerosis of malignant pleural effusion by talc. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A2455, 2000.","\tMetastatic Cancer\ttalc|Talc\tParallel Assignment\tSupportive Care\tRandomized\tDrug|Drug\tAll\t","Talc in Treating Patients With Malignant Pleural Effusion","Interventional","Completed","Phase 3",2,501,"pleural effusion, malignant|pleural effusion","NA","NA"]
["NCT00002623","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|17374834|16785054|NA|NA|16055865|NA|NA","van Schil PE, van Meerbeeck JP, Kramer G, et al.: Surgery after induction chemotherapy: morbidity and mortality in the first 100 patients of the surgery arm of EORTC 08941 trial. [Abstract] Lung Cancer 41 (Suppl 2): A-O-147, S45, 2003.|van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F, Tjan-Heijnen VC, Biesma B, Debruyne C, van Zandwijk N, Splinter TA, Giaccone G; European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007 Mar 21;99(6):442-50.|Kramer GW, Legrand CL, van Schil P, Uitterhoeve L, Smit EF, Schramel F, Biesma B, Tjan-Heijnen V, van Zandwijk N, Splinter T, Giaccone G, van Meerbeeck JP; EORTC-Lung Cancer Group. Quality assurance of thoracic radiotherapy in EORTC 08941: a randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy. Eur J Cancer. 2006 Jul;42(10):1391-8.|Van Meerbeeck JP, Kramer GW, Legrand C, et al.: Does downstaging in patients (pts) with IIIA-N2 non-small cell lung cancer (NSCLC) and a response to induction chemotherapy (ICT) influence outcome with surgery (S) or radiotherapy (RT)? An exploratory analysis of EORTC 08941. [Abstract] J Clin Oncol 24 (Suppl 18): A-7047, 375s, 2006.|Van Meerbeeck JP, Kramer G, Van Schil PE, et al.: A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941). [Abstract] J Clin Oncol 23 (Suppl 16): A-LBA7015, 624s, 2005.|Van Schil P, Van Meerbeeck J, Kramer G, Splinter T, Legrand C, Giaccone G, Manegold C, van Zandwijk N. Morbidity and mortality in the surgery arm of EORTC 08941 trial. Eur Respir J. 2005 Aug;26(2):192-7.|van Meerbeeck JP, Kramer GWPM, van Schil PEY, et al.: Induction chemotherapy (CT) in stage IIIA-N2 non-small cell lung cancer (NSCLC):an analysis of different regimens used in EORTC 08941. [Abstract] Lung Cancer 41 (Suppl 2): A-O-273, S79, 2003.|Splinter TA, Kirkpatrick A, Van Meerbeeck J, et al.: Randomized trial of surgery versus radiotherapy in patients with stage IIIA non-small cell lung cancer after a response to induction chemotherapy. Intergroup study 08941. [Abstract] Proceedings of the American Society of Clinical Oncology 17: A1742, 453a, 1998.","\tLung Cancer\tcarboplatin|cisplatin|conventional surgery|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","carboplatin","NA"]
["NCT00002624","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15821648|NA","Shennib H, Bogart J, Herndon JE, Kohman L, Keenan R, Green M, Sugarbaker D; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group. Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study. J Thorac Cardiovasc Surg. 2005 Apr;129(4):813-8.|Bogart J, Shennib H, Kohman L, et al.: Radiotherapy following thorascopic wedge resection (TWR) of T1 non-small cell lung cancer (NSCLC) in high risk patients: a Cancer and Leukemia Group B and Eastern Cooperative Oncology Group Phase II Trial. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A1907, 2000.","\tLung Cancer\tadjuvant therapy|diagnostic thoracoscopy|therapeutic thoracoscopy|video-assisted surgery|radiation therapy\tNA\tNA\tNA\tProcedure|Procedure|Procedure|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","NA","NA"]
["NCT00002625","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15013589,"Forouzannia A, Schiller J, Berlin J, Hutson P, Boothman D, Storer B, Wilding G, Mehta M. A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies. Lung Cancer. 2004 Apr;44(1):111-9.","\tEsophageal Cancer|Lung Cancer|Lymphoma\ttopotecan hydrochloride|low-LET electron therapy|low-LET photon therapy\tNA\tNA\tNA\tDrug|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|esophageal neoplasms|lung neoplasms","topotecan","NA"]
["NCT00002630","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","10918404|10084252|10482933|10459351|10414914|10414913","Gertz MA, Lacy MQ, Inwards DJ, Gastineau DA, Tefferi A, Chen MG, Witzig TE, Greipp PR, Litzow MR. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant. 2000 Jul;26(1):45-50.|Gertz MA, Lacy MQ, Inwards DJ, Chen MG, Pineda AA, Gastineau DA, Greipp PR, Lust JA, Tefferi A, Witzig TE, Kyle RA, Litzow MR. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Bone Marrow Transplant. 1999 Feb;23(3):221-6.|Rajkumar S, Fonseca R, Lacy M, Witzig T, Lust J, Greipp P, Therneau T, Kyle R, Litzow M, Gertz M. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Bone Marrow Transplant. 1999 Sep;24(5):497-503.|Rajkumar SV, Fonseca R, Dewald GW, Therneau TM, Lacy MQ, Kyle RA, Greipp PR, Gertz MA. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet. 1999 Aug;113(1):73-7.|Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Therneau TM, Kyle RA, Litzow MR, Gertz MA. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant. 1999 Jun;23(12):1267-72.|Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Therneau TM, Kyle RA, Litzow MR, Gertz MA. Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplant. 1999 Jun;23(12):1261-6.","\tMultiple Myeloma and Plasma Cell Neoplasm\tfilgrastim|cyclophosphamide|melphalan|peripheral blood stem cell transplantation|low-LET cobalt-60 gamma ray therapy|low-LET photon therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Procedure|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms, plasma cell|plasmacytoma|multiple myeloma","melphalan|cobalt|cyclophosphamide","NA"]
["NCT00002631","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21673875|11870157|NA|NA","Kachnic LA, Winter K, Wasserman T, Kelsen D, Ginsberg R, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Willett CG, Minsky BD. Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer. Gastrointest Cancer Res. 2011 Mar;4(2):45-52.|Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002 Mar 1;20(5):1167-74.|Kachnic LA, Scott C, Ginsberg R, et al.: One year follow-up reveals no difference in quality of life between high dose and conventional dose radiation: a quality of life assessment of RTOG 94-05. [Abstract] Int J Radiat Oncol Biol Phys 51 (3 suppl 1): A-172, 97, 2001.|Minsky BD, Berkey B, Kelsen DK, et al.: Preliminary results of Intergroup INT 0123 randomized trial of combined modality therapy (CMT) for esophagel cancer: standard vs high dose radiation therapy. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A927, 2000.","\tEsophageal Cancer\tchemotherapy|cisplatin|fluorouracil|low-LET electron therapy|low-LET photon therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","esophageal neoplasms","fluorouracil","NA"]
["NCT00002632","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16470745|NA","Gilbert J, Li Y, Pinto HA, Jennings T, Kies MS, Silverman P, Forastiere AA. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck. 2006 Mar;28(3):197-204.|Jennings T, Li Y, Pinto H, et al.: Phase II trial of paclitaxel in advanced or metastatic salivary gland malignancies: an Eastern Cooperative Oncology Group study. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-942, 2001.","\tHead and Neck Cancer\tpaclitaxel\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","salivary gland neoplasms","paclitaxel","NA"]
["NCT00002633","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22056152,"Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J, Hiltz A, Parmar MK, Sathya J, Anderson J, Hayter C, Hetherington J, Sydes MR, Parulekar W; NCIC CTG PR.3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011 Dec 17;378(9809):2104-11. doi: 10.1016/S0140-6736(11)61095-7. Epub 2011 Nov 2.","\tProstate Cancer\tbicalutamide|buserelin|flutamide|goserelin|leuprolide acetate|nilutamide|orchiectomy|radiation therapy\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug|Drug|Drug|Procedure|Radiation\tMale\t","Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer","Interventional","Completed","Phase 3",2,361,"prostatic neoplasms","leuprolide|nilutamide|bicalutamide|goserelin|flutamide|buserelin","NA"]
["NCT00002642","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17235046|NA|11241082|NA","Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol. 2007 Jan 20;25(3):313-8.|Rusch VW, Giroux D, Kraut MJ, et al.: Induction chemoradiotherapy and surgical resection for non-small cell lung carcinomas of the superior sulcus (pancoast tumors): mature results of Southwest Oncology Group trial 9416 (Intergroup trial 0160). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2548, 2003.|Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Johnson D, Goldberg M, Detterbeck F, Shepherd F, Burkes R, Winton T, Deschamps C, Livingston R, Gandara D. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg. 2001 Mar;121(3):472-83.|Kraut MJ, Rusch VW, Crowley JJ, et al.: Induction chemoradiation plus surgical resection is feasible and highly effective treatment for Pancoast tumors: initial results of SWOG 9416 (Intergroup 0160) trial. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A1906. 487a, 2000.","\tLung Cancer\tcisplatin|etoposide|conventional surgery|low-LET cobalt-60 gamma ray therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","etoposide|cobalt","NA"]
["NCT00002643","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16382125|9771955","Bernstein ML, Devidas M, Lafreniere D, Souid AK, Meyers PA, Gebhardt M, Stine K, Nicholas R, Perlman EJ, Dubowy R, Wainer IW, Dickman PS, Link MP, Goorin A, Grier HE; Pediatric Oncology Group; Children's Cancer Group Phase II Study 9457; Children's Oncology Group. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group. J Clin Oncol. 2006 Jan 1;24(1):152-9.|Souid AK, Newton GL, Dubowy RL, Fahey RC, Bernstein ML. Determination of the cytoprotective agent WR-2721 (Amifostine, Ethyol) and its metabolites in human blood using monobromobimane fluorescent labeling and high-performance liquid chromatography. Cancer Chemother Pharmacol. 1998;42(5):400-6.","\tNeutropenia|Sarcoma\tfilgrastim|amifostine trihydrate|cyclophosphamide|doxorubicin hydrochloride|etoposide|ifosfamide|topotecan hydrochloride|vincristine sulfate|conventional surgery|low-LET cobalt-60 gamma ray therapy|low-LET electron therapy|low-LET photon therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Radiation|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","neuroectodermal tumors|neutropenia|neuroectodermal tumors, primitive|sarcoma","topotecan|cobalt|doxorubicin|vincristine|ifosfamide|etoposide|amifostine|cyclophosphamide|liposomal doxorubicin","NA"]
["NCT00002644","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21483019|19910376|17312304|16921052|15100340|12243915|14659350|22735900|22832202|25497694|27400912|28029312|28661758","Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, Forbes JF, Warren RM. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst. 2011 May 4;103(9):744-52. doi: 10.1093/jnci/djr079. Epub 2011 Apr 11.|Stone J, Warren RM, Pinney E, Warwick J, Cuzick J. Determinants of percentage and area measures of mammographic density. Am J Epidemiol. 2009 Dec 15;170(12):1571-8. doi: 10.1093/aje/kwp313. Epub 2009 Nov 12.|Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A; International Breast Cancer Intervention Study I Investigators. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007 Feb 21;99(4):272-82.|Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol. 2006 Aug 20;24(24):3991-6.|Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst. 2004 Apr 21;96(8):621-8.|Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T; IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002 Sep 14;360(9336):817-24.|Warwick J, Pinney E, Warren RM, Duffy SW, Howell A, Wilson M, Cuzick J. Breast density and breast cancer risk factors in a high-risk population. Breast. 2003 Feb;12(1):10-6.|Sestak I, Kealy R, Nikoloff M, Fontecha M, Forbes JF, Howell A, Cuzick J. Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial. Br J Cancer. 2012 Jul 10;107(2):230-3. doi: 10.1038/bjc.2012.278. Epub 2012 Jun 26.|Palva T, Ranta H, Koivisto AM, Pylkkänen L, Cuzick J, Holli K. A double-blind placebo-controlled study to evaluate endometrial safety and gynaecological symptoms in women treated for up to 5 years with tamoxifen or placebo - a substudy for IBIS I Breast Cancer Prevention Trial. Eur J Cancer. 2013 Jan;49(1):45-51. doi: 10.1016/j.ejca.2012.06.015. Epub 2012 Jul 23.|Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF; IBIS-I Investigators. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015 Jan;16(1):67-75. doi: 10.1016/S1470-2045(14)71171-4. Epub 2014 Dec 11.|Brentnall AR, Cuzick J, Byers H, Segal C, Reuter C, Detre S, Sestak I, Howell A, Powles TJ, Newman WG, Dowsett M. Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials. Breast Cancer Res Treat. 2016 Aug;158(3):591-6. doi: 10.1007/s10549-016-3885-x. Epub 2016 Jul 11.|Cuzick J, Brentnall AR, Segal C, Byers H, Reuter C, Detre S, Lopez-Knowles E, Sestak I, Howell A, Powles TJ, Newman WG, Dowsett M. Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. J Clin Oncol. 2017 Mar;35(7):743-750. doi: 10.1200/JCO.2016.69.8944. Epub 2016 Dec 28.|Smith SG, Sestak I, Howell A, Forbes J, Cuzick J. Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I). J Clin Oncol. 2017 Aug 10;35(23):2666-2673. doi: 10.1200/JCO.2016.71.7439. Epub 2017 Jun 29. Erratum in: J Clin Oncol. 2018 Jan 20;36(3):304.","\tBreast Cancer\tTamoxifen Citrate 20Mg Tab|Placebo\tParallel Assignment\tPrevention\tRandomized\tDrug|Other\tFemale\t","Tamoxifen for the Prevention of Breast Cancer in High-Risk Women","Interventional","Active, not recruiting","Phase 3",2,7154,"breast neoplasms","tamoxifen","NA"]
["NCT00002646","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20878269|NA","Rao RD, Cobleigh MA, Gray R, Graham ML 2nd, Norton L, Martino S, Budd GT, Ingle JN, Wood WC. Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group. Med Oncol. 2011 Dec;28 Suppl 1:S39-47. doi: 10.1007/s12032-010-9682-1. Epub 2010 Sep 28.|Cobleigh MA, Gray R, Graham M, et al.: Fenretinide (FEN) vs placebo in postmenopausal breast cancer patients receiving adjuvant tamoxifen (TAM), an Eastern Cooperative Oncology Group Phase III Intergroup Trial (EB193, INT-0151). [Abstract] Proceedings of the American Society of Clinical Oncology 19: A328, 2000.","\tBreast Cancer\tfenretinide|tamoxifen citrate\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","fenretinide|tamoxifen","NA"]
["NCT00002654","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21300466|15936546|15534360|22726581|27323753|25679310|23916716","Ghadjar P, Simcock M, Studer G, Allal AS, Ozsahin M, Bernier J, Töpfer M, Zimmermann F, Betz M, Glanzmann C, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK). Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94). Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):524-31. doi: 10.1016/j.ijrobp.2010.11.067. Epub 2011 Feb 16.|Taussky D, Rufibach K, Huguenin P, Allal AS. Risk factors for developing a second upper aerodigestive cancer after radiotherapy with or without chemotherapy in patients with head-and-neck cancers: an exploratory outcomes analysis. Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):684-9.|Huguenin P, Beer KT, Allal A, Rufibach K, Friedli C, Davis JB, Pestalozzi B, Schmid S, Thöni A, Ozsahin M, Bernier J, Töpfer M, Kann R, Meier UR, Thum P, Bieri S, Notter M, Lombriser N, Glanzmann C. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol. 2004 Dec 1;22(23):4665-73. Epub 2004 Nov 8. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.|Ghadjar P, Simcock M, Zimmermann F, Betz M, Bodis S, Bernier J, Studer G, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK). Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94). Radiother Oncol. 2012 Aug;104(2):213-8. Epub 2012 Jun 21.|Ghadjar P, Pöttgen C, Joos D, Hayoz S, Baumann M, Bodis S, Budach W, Studer G, Stromberger C, Zimmermann F, Kaul D, Plasswilm L, Olze H, Bernier J, Wust P, Aebersold DM, Budach V. Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers : Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94). Strahlenther Onkol. 2016 Aug;192(8):552-60. doi: 10.1007/s00066-016-0999-3. Epub 2016 Jun 20.|Ghadjar P, Hayoz S, Zimmermann F, Bodis S, Kaul D, Badakhshi H, Bernier J, Studer G, Plasswilm L, Budach V, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK). Impact of weight loss on survival after chemoradiation for locally advanced head and neck cancer: secondary results of a randomized phase III trial (SAKK 10/94). Radiat Oncol. 2015 Jan 17;10:21. doi: 10.1186/s13014-014-0319-y.|Ghadjar P, Sun H, Zimmermann F, Bodis S, Bernier J, Studer G, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK). Physical examination during chemoradiation predicts outcome of locally advanced head and neck cancer. Secondary results of a randomized phase III trial (SAKK 10/94). Oral Oncol. 2013 Oct;49(10):1006-9. doi: 10.1016/j.oraloncology.2013.07.002. Epub 2013 Aug 3.","\tHead and Neck Cancer\tchemotherapy|cisplatin|low-LET cobalt-60 gamma ray therapy|low-LET electron therapy|low-LET photon therapy\tNA\tNA\tNA\tDrug|Drug|Radiation|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","cobalt","NA"]
["NCT00002657","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18645482|14508361|NA|NA","Swinnen LJ, LeBlanc M, Grogan TM, Gordon LI, Stiff PJ, Miller AM, Kasamon Y, Miller TP, Fisher RI. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation. 2008 Jul 27;86(2):215-22. doi: 10.1097/TP.0b013e3181761659.|Gulley ML, Swinnen LJ, Plaisance KT Jr, Schnell C, Grogan TM, Schneider BG; Southwest Oncology Group. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation. 2003 Sep 27;76(6):959-64.|Swinnen LJ, Gulley ML, Hamilton E, et al.: EBV DNA quantitation in serum is highly correlated with the development and regression of post-transplant lymphoproliferative disorder (PTLD) in solid organ transplant recipients. Blood 92(10 suppl 1): A1291, 314-315a, 1998.|Tao Q, Swinnen L, Ambinder RF: Conservation of Epstein-Barr virus (EBV) CTL epitopes in EVB (+) posttransplant lymphomas in solid organ transplant recipients. Blood 90(10 suppl 1): A2281, 512a, 1997.","\tLymphoma|Multiple Myeloma and Plasma Cell Neoplasm\tbleomycin sulfate|recombinant interferon alfa|cyclophosphamide|cytarabine|doxorubicin hydrochloride|etoposide|methotrexate|prednisone|vincristine sulfate|conventional surgery|radiation therapy\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms, plasma cell|lymphoma|multiple myeloma|plasmacytoma","interferons|cytarabine|liposomal doxorubicin|bleomycin|prednisone|etoposide|interferon-alpha|cyclophosphamide|methotrexate|vincristine|doxorubicin","NA"]
["NCT00002658","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20038732,"Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF, Duncombe A, Gibson B, Wheatley K. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010 Feb 1;28(4):586-95. doi: 10.1200/JCO.2009.22.9088. Epub 2009 Dec 28.","\tLeukemia|Neutropenia\tfilgrastim|amsacrine|cyclophosphamide|cytarabine|daunorubicin hydrochloride|etoposide|idarubicin|mitoxantrone hydrochloride|thioguanine|tretinoin|allogeneic bone marrow transplantation|autologous bone marrow transplantation|peripheral blood stem cell transplantation|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, myeloid, acute|leukemia|leukemia, myeloid|neutropenia","amsacrine|mitoxantrone|idarubicin|tretinoin|etoposide|cytarabine|cyclophosphamide|thioguanine|daunorubicin","NA"]
["NCT00002665","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18156492|17170128|NA|NA|NA|NA","Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood. 2008 Mar 1;111(5):2563-72. Epub 2007 Dec 21.|Sala-Torra O, Gundacker HM, Stirewalt DL, Ladne PA, Pogosova-Agadjanyan EL, Slovak ML, Willman CL, Heimfeld S, Boldt DH, Radich JP. Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia. Blood. 2007 Apr 1;109(7):3080-3.|Sala-Torra O, Gundacker HM, Stirewalt DL, et al.: CTGF (CCN2) predicts OS and DFS in adult acute lymphoblastic leukemia. [Abstract] Blood 106 (11): A-336, 2005.|Slovak ML, Kopecky KJ, Gundacker H, et al.: Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia (ALL): a Southwest Oncology Group (SWOG) study (S9400). [Abstract] Blood 102 (11 Pt 1): A-2223, 2003.|Boldt DH, Gundacker HM, Lee DY, et al.: Analysis of multidrug resistance gene-1 (MDR1) expression and function in adult acute lymphoblastic leukemia (ALL). A Southwest Oncology Group (SWOG) study. [Abstract] Blood 100 (11 Pt 1): A-2991, 2002.|Gazitt Y, Lee D, Wang ME, et al.: Functional MDR1 expression in adult acute lymphoblastic leukemia (ALL). Blood 92 (10 Suppl 1): A-2788, 676a, 1998.","\tLeukemia|Neutropenia|Thrombocytopenia\tasparaginase|cyclophosphamide|cytarabine|daunorubicin hydrochloride|dexamethasone|doxorubicin hydrochloride|etoposide|leucovorin calcium|mercaptopurine|methotrexate|prednisone|thioguanine|vincristine sulfate|allogeneic bone marrow transplantation|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","neutropenia|precursor cell lymphoblastic leukemia-lymphoma|thrombocytopenia|leukemia","mercaptopurine|prednisone|asparaginase|liposomal doxorubicin|leucovorin|daunorubicin|cytarabine|thioguanine|methotrexate|doxorubicin|etoposide|dexamethasone|levoleucovorin|cyclophosphamide|vincristine","NA"]
["NCT00002669","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17443000|17023156|16170182|NA","Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM, Keilholz U; American Joint Committee on Cancer Stage IV Melanoma; EORTC 18951. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol. 2007 Apr 20;25(12):1562-9.|Punt CJ, Suciu S, Gore MA, Koller J, Kruit WH, Thomas J, Patel P, Lienard D, Eggermont AM, Keilholz U. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group. Eur J Cancer. 2006 Nov;42(17):2991-5. Epub 2006 Oct 4.|Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suciu S, Eggermont AM. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2005 Sep 20;23(27):6747-55.|Keilholz U, Punt CJ, Gore M, et al.: Dacarbazine, cisplatin and interferon alpha with or without interleukin-2 in advanced melanoma: interim analysis of EORTC trial 18951. [Abstract] Proceedings of the American Society of Clinical Oncology 18: A2043, 530a, 1999.","\tMelanoma (Skin)\taldesleukin|recombinant interferon alfa|cisplatin|dacarbazine\tNA\tNA\tNA\tBiological|Biological|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","melanoma","aldesleukin|dacarbazine|interferons|interferon-alpha","NA"]
["NCT00002670","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22749632|NA|15128893|NA|NA","Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Lustig R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang KK. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1198-205. doi: 10.1016/j.ijrobp.2012.05.008. Epub 2012 Jun 30.|Cooper JS, Pajak TF, Forastiere AA, et al.: Long-term survival results of a phase III intergroup trial (RTOG 95-01) of surgery followed by radiotherapy vs. radiochemotherapy for resectable high risk squamous cell carcinoma of the head and neck. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-25, S14-5, 2006.|Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK; Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004 May 6;350(19):1937-44.|Cooper JS, Pajak TF, Forastiere AA, et al.: Postoperative concurrent radiochemotherapy in high-risk SCCA of the head and neck: initial report of RTOG 9501/intergroup phase III trial. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-903, 2002.|Cooper JS, Pajak TF, Forastiere AA, et al.: Patterns of failure for resected advanced head & neck cancer treated by concurrent chemotherapy and radiation therapy: an analysis of RTOG 9501/intergroup phase III trial. [Abstract] Int J Radiat Oncol Biol Phys 54(2 suppl 1): 2, 2002.","\tHead and Neck Cancer\tchemotherapy|cisplatin|low-LET cobalt-60 gamma ray therapy|low-LET electron therapy|low-LET photon therapy\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Radiation|Radiation|Radiation\tAll\t","Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery","Interventional","Completed","Phase 3",2,459,"head and neck neoplasms","cobalt","NA"]
["NCT00002671","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","14701774|NA","Hochster H, Plimack ER, Runowicz CD, Speyer J, Wallach RC, Sorich J, Mandeli J, Wadler S, Wright J, Muggia FM. Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2004 Jan 1;22(1):120-6.|Speyer JL, Hochster H, Runowicz C, et al.: Phase II study of 72 hr 9-amino-camptothecin (9AC) infusion in second-line therapy of ovarian cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 18: A1401, 363a, 1999.","\tOvarian Cancer\taminocamptothecin\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","ovarian neoplasms|carcinoma, ovarian epithelial","NA","NA"]
["NCT00002676","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20800387|NA","Laack NN, O'Neill BP, Ballman KV, O'Fallon JR, Carrero XW, Kurtin PJ, Scheithauer BW, Brown PD, Habermann TM, Colgan JP, Gilbert MR, Hawkins RB, Morton RF, Windschitl HE, Fitch TR, Pajon ER Jr; North Central Cancer Treatment Group and Mayo Clinic. CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma. Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):476-82. doi: 10.1016/j.ijrobp.2010.06.002. Epub 2010 Aug 26.|O'Neill BP, O'Fallon JR, Cha SS, et al.: Newly diagnosed primary central nervous system lymphoma (PCNSL): initial report of North Central Cancer Treatment Group (NCCTG)/Eastern Cooperative Oncology Group (ECOG) protocol 93 73 51. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-2074, 2002.","\tLymphoma\tcarmustine|cyclophosphamide|cytarabine|dexamethasone|doxorubicin hydrochloride|methotrexate|vincristine sulfate|low-LET cobalt-60 gamma ray therapy|low-LET photon therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|lymphoma, non-hodgkin","cyclophosphamide|methotrexate|carmustine|cytarabine|liposomal doxorubicin|cobalt|doxorubicin|vincristine|dexamethasone","NA"]
["NCT00002678","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17233817|NA|NA","Shustik C, Belch A, Robinson S, Rubin SH, Dolan SP, Kovacs MJ, Grewal KS, Walde D, Barr R, Wilson J, Gill K, Vickars L, Rudinskas L, Sicheri DA, Wilson K, Djurfeldt M, Shepherd LE, Ding K, Meyer RM. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol. 2007 Jan;136(2):203-11.|Shustik C, Belch A, Robinson S, et al.: Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: a National Cancer Institute of Canada Clinical Trials Group study: MY.7. [Abstract] J Clin Oncol 22 (Suppl 14): A-6510, 560s, 2004.|Shustik C, Belch A, Meyer R, et al.: Melphalan-dexamethasone is not superior to melphalan-prednisone as induction therapy in multiple myeloma. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1191, 2001.","\tMultiple Myeloma and Plasma Cell Neoplasm\tdexamethasone|melphalan|prednisone\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","Combination Chemotherapy in Treating Patients With Multiple Myeloma","Interventional","Completed","Phase 3",2,595,"neoplasms, plasma cell|plasmacytoma|multiple myeloma","dexamethasone|prednisone|melphalan","NA"]
["NCT00002692","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|NA","McArdle C: IV versus IHA 5FU/leucovorin for colorectal liver metastases: preliminary results of the MRC CR05 EORTC 40972 randomised trial. [Abstract] Br J Cancer 85 (suppl 1): A-CT2. 1, 2001.|McArdle C, Kerr DJ, Ledermann J, et al.: Intravenous (IV) vs intrahepatic (IHA) 5FU/leucovorin for colorectal (CRC) liver metastases: preliminary results of the MRC CR05/EORTC 40972 randomised trial. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-499, 2001.|McArdle C, Kerr DJ, Ledermann J, et al.: Intravenous (IV) vs intrahepatic arterial (IHA) 5-FU/leucovorin for colorectal (CRC) liver metastasis: preliminary results of the MRC CRO5/EORTC 40972 randomised trial. [Abstract] Eur J Cancer 37 (suppl 6): A-955, s257, 2001.","\tColorectal Cancer|Metastatic Cancer\tfluorouracil|isolated perfusion|leucovorin calcium\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","fluorouracil|leucovorin|calcium|levoleucovorin","NA"]
["NCT00002693","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Kaufmann S, Letendre L, Litzow M, et al.: Phase I study of continuous infusion (CI) topotecan (TPT) and carboplatin (CBDCA) for relapsed or refractory acute leukemia. [Abstract] Proceedings of the American Society of Clinical Oncology 17: A107, 1998.","\tLeukemia|Neutropenia\tfilgrastim|carboplatin|topotecan hydrochloride\tNA\tNA\tNA\tBiological|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, myeloid|neutropenia|leukemia, myelogenous, chronic, bcr-abl positive|leukemia","carboplatin|topotecan","NA"]
["NCT00002695","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19770416|18223210|18094376|NA","Koch WM, Ridge JA, Forastiere A, Manola J. Comparison of clinical and pathological staging in head and neck squamous cell carcinoma: results from Intergroup Study ECOG 4393/RTOG 9614. Arch Otolaryngol Head Neck Surg. 2009 Sep;135(9):851-8. doi: 10.1001/archoto.2009.123. Erratum in: Arch Otolaryngol Head Neck Surg. 2009 Nov;135(11):1136.|Westra WH, Taube JM, Poeta ML, Begum S, Sidransky D, Koch WM. Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2008 Jan 15;14(2):366-9. doi: 10.1158/1078-0432.CCR-07-1402.|Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, Westra W, Sidransky D, Koch WM. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007 Dec 20;357(25):2552-61.|Poeta LM, Goldwasser MA, Forastiere A, et al.: Prognostic implication of p53 mutations in HNSCC: results of intragroup margin study (E4393). [Abstract] J Clin Oncol 24 (Suppl 18): A-5504, 2006.","\tHead and Neck Cancer\tDNA stability analysis|microsatellite instability analysis|mutation analysis|laboratory biomarker analysis\tNA\tNA\tNA\tGenetic|Genetic|Genetic|Other\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","NA","NA"]
["NCT00002700","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20378563|17407135|17611565|17039234|15637138|15353542|NA|12239143","Labar B, Suciu S, Willemze R, Muus P, Marie JP, Fillet G, Berneman Z, Jaksic B, Feremans W, Bron D, Sinnige H, Mistrik M, Vreugdenhil G, De Bock R, Nemet D, Gilotay C, Amadori S, de Witte T; EORTC Leukemia Group. Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group. Haematologica. 2010 Sep;95(9):1489-95. doi: 10.3324/haematol.2009.018580. Epub 2010 Apr 7.|Le QH, Thomas X, Ecochard R, Iwaz J, Lhéritier V, Michallet M, Fiere D. Proportion of long-term event-free survivors and lifetime of adult patients not cured after a standard acute lymphoblastic leukemia therapeutic program: adult acute lymphoblastic leukemia-94 trial. Cancer. 2007 May 15;109(10):2058-67.|Tavernier E, Boiron JM, Huguet F, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lhéritier V, Vernant JP, Dombret H, Thomas X; GET-LALA Group; Swiss Group for Clinical Cancer Research SAKK; Australasian Leukaemia and Lymphoma Group. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007 Sep;21(9):1907-14. Epub 2007 Jul 5.|Vey N, Thomas X, Picard C, Kovascovicz T, Charin C, Cayuela JM, Dombret H, Dastugue N, Huguet F, Bastard C, Stamatoulas A, Giollant M, Tournilhac O, Macintyre E, Buzyn A, Bories D, Kuentz M, Dreyfus F, Delannoy A, Raynaud S, Gratecos N, Bordessoule D, de Botton S, Preudhomme C, Reman O, Troussard X, Pigneux A, Bilhou C, Vernant JP, Boucheix C, Gabert J; GET-LALA Group the Swiss Group for Clinical Cancer Research (SAKK). Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. Leukemia. 2006 Dec;20(12):2155-61. Epub 2006 Oct 12.|Asnafi V, Buzyn A, Thomas X, Huguet F, Vey N, Boiron JM, Reman O, Cayuela JM, Lheritier V, Vernant JP, Fiere D, Macintyre E, Dombret H. Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. Blood. 2005 Apr 15;105(8):3072-8. Epub 2005 Jan 6.|Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Vernant JP, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lhéritier V, Fiere D. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004 Oct 15;22(20):4075-86. Epub 2004 Sep 7.|Asnafi V, Buzyn A, Thomas X, et al.: Impact of immunophenotype and genotype on outcome in LALA94 T-ALLs: toward risk adapted stratification of adult T-ALL. [Abstract] Blood 102 (11): A-67, 2003.|Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Blaise D, Thomas X, Delannoy A, Buzyn A, Bilhou-Nabera C, Cayuela JM, Fenaux P, Bourhis JH, Fegueux N, Charrin C, Boucheix C, Lhéritier V, Espérou H, MacIntyre E, Vernant JP, Fière D; Groupe d'Etude et de Traitement de la Leucémie Aiguë Lymphoblastique de l'Adulte (GET-LALA Group). Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. Blood. 2002 Oct 1;100(7):2357-66.","\tLeukemia|Lymphoma\tasparaginase|cyclophosphamide|cytarabine|daunorubicin hydrochloride|dexamethasone|doxorubicin hydrochloride|leucovorin calcium|mercaptopurine|methotrexate|mitoxantrone hydrochloride|prednisolone|prednisone|therapeutic hydrocortisone|vincristine sulfate|allogeneic bone marrow transplantation|autologous bone marrow transplantation|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|leukemia, lymphoid|precursor cell lymphoblastic leukemia-lymphoma|leukemia","leucovorin|liposomal doxorubicin|asparaginase|mercaptopurine|daunorubicin|prednisolone|hydrocortisone|hydrocortisone 17-butyrate 21-propionate|levoleucovorin|mitoxantrone|doxorubicin|cyclophosphamide|hydrocortisone hemisuccinate|cytarabine|dexamethasone|prednisone|hydrocortisone acetate|methotrexate|vincristine","NA"]
["NCT00002703","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21470787|20207497|20124169|NA|16160131|NA","Coen JJ, Zietman AL, Rossi CJ, Grocela JA, Efstathiou JA, Yan Y, Shipley WU. Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e25-31. doi: 10.1016/j.ijrobp.2011.01.039. Epub 2011 Apr 4.|Nguyen PL, Chen RC, Hoffman KE, Trofimov A, Efstathiou JA, Coen JJ, Shipley WU, Zietman AL, Talcott JA. Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial. Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1081-5. doi: 10.1016/j.ijrobp.2009.09.015. Epub 2010 Mar 6.|Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, Bush DA, Lunt M, Spiegel DY, Skowronski R, Jabola BR, Rossi CJ. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol. 2010 Mar 1;28(7):1106-11. doi: 10.1200/JCO.2009.25.8475. Epub 2010 Feb 1.|Rossi CJ, Zietman AL, DeSilvio M, et al.: A randomized trial comparing conventional dose (70.2GyE) and high-dose (79.2GyE) conformal radiation in early stage adenocarcinoma of the prostate: results of an interim analysis of PROG 95-09. [Abstract] American Society of Clinical Oncology 2005 Prostate Cancer Symposium, 17-19 February 2005, Orlando, Florida. A-58, 2005.|Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, Shipley WU. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005 Sep 14;294(10):1233-9. Erratum in: JAMA. 2008 Feb 27;299(8):899-900.|Zietman AL, DeSilvio M, Slater JD, et al.: A randomized trial comparing conventional dose (70.2GyE) and high-dose (79. 2GyE) conformal radiation in early stage adenocarcinoma of the prostate: results of an interim analysis of PROG 95-09. [Abstract] Int J Radiat Oncol Biol Phys 60 (Suppl 1): A-4, S131, 2004.","\tProstate Cancer\thigh-LET heavy ion therapy|low-LET photon therapy\tNA\tNA\tNA\tRadiation|Radiation\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","NA","NA"]
["NCT00002704","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16809737,"Barredo JC, Devidas M, Lauer SJ, Billett A, Marymont M, Pullen J, Camitta B, Winick N, Carroll W, Ritchey AK. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study. J Clin Oncol. 2006 Jul 1;24(19):3142-9.","\tLeukemia\tfilgrastim|asparaginase|cyclophosphamide|daunorubicin hydrochloride|dexamethasone|etoposide|leucovorin calcium|liposomal cytarabine|mercaptopurine|mesna|methotrexate|therapeutic hydrocortisone|thiotepa|vincristine sulfate|low-LET electron therapy|low-LET photon therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","leukemia|precursor cell lymphoblastic leukemia-lymphoma|leukemia, lymphoid","hydrocortisone hemisuccinate|leucovorin|cytarabine|dexamethasone|mercaptopurine|hydrocortisone|cyclophosphamide|thiotepa|methotrexate|etoposide|daunorubicin|asparaginase|vincristine|levoleucovorin|hydrocortisone 17-butyrate 21-propionate|hydrocortisone acetate","NA"]
["NCT00002705","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11896112,"Furman WL, Stewart CF, Kirstein M, Kepner JL, Bernstein ML, Kung F, Vietti TJ, Steuber CP, Becton DL, Baruchel S, Pratt C. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study. J Clin Oncol. 2002 Mar 15;20(6):1617-24.","\tLeukemia\ttopotecan hydrochloride\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia","topotecan","NA"]
["NCT00002707","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16606972|NA|15837984|NA|14559892|NA","Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006 May 1;24(13):2019-27. Epub 2006 Apr 10.|Julian T, Anderson S, Fourchotte V, et al.: Is invasive lobular breast cancer a prognostic factor for neoadjuvant chemotherapy response and long term outcomes? [Abstract] Breast Cancer Res Treat 100 (Suppl 1): A-3065, S146, 2006.|Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, Bear HD, Caldwell CB, Walker AP, Mikkelson WM, Stauffer JS, Robidoux A, Theoret H, Soran A, Fisher B, Wickerham DL, Wolmark N. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005 Apr 20;23(12):2694-702. Erratum in: J Clin Oncol. 2005 Jul 20;23(21):4808. Sovan, Atilla [corrected to Soran, Atilla].|Bear HD, Anderson S, Smith RE, et al.: A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: results of NSABP B-27. [Abstract] Breast Cancer Res Treat 88 (Suppl 1): A-26, 2004.|Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N; National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003 Nov 15;21(22):4165-74. Epub 2003 Oct 14.|Mamounas EP, Brown A, Smith R, et al.: Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: updated results from NSABP B-27. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-140, 2002.","\tBreast Cancer\tCyclophosphamide|Docetaxel|Doxorubicin|Tamoxifen\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug\tFemale\t","Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed","Interventional","Completed","Phase 3",3,2411,"breast neoplasms","doxorubicin|docetaxel|cyclophosphamide|tamoxifen","NA"]
["NCT00002708","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16062084|15158627|NA|NA","Hazard LJ, Jensen RL, Shrieve DC. Role of stereotactic radiosurgery in the treatment of brain metastases. Am J Clin Oncol. 2005 Aug;28(4):403-10. Review.|Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004 May 22;363(9422):1665-72.|Sperduto PW, Scott C, Andrews D: Stereotactic radiosurgery with whole brain radiation therapy improves survival in patients with brain metastases: report of Radiation Therapy Oncology Group phase III study 95-08. [Abstract] Int J Radiat Oncol Biol Phys 54(2 suppl 1): 3, 2002.|Sperduto P, Scott C, Andrews D, et al.: Preliminary report of RTOG 95-08: a phase III trial comparing whole brain irradiation alone versus whole brain irradiation plus stereotactic radiosurgery for patients with two or three unresected brain metastases. [Abstract] Int J Radiat Oncol Biol Phys 48: A-6, 113, 2000.","\tMetastatic Cancer\tsurgical procedure|radiation therapy|stereotactic radiosurgery\tParallel Assignment\tTreatment\tRandomized\tProcedure|Radiation|Radiation\tAll\t","Radiation Therapy With or Without Radiosurgery in Treating Patients With Brain Metastases","Interventional","Completed","Phase 3",2,333,"neoplasm metastasis","NA","NA"]
["NCT00002715","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","8836420|7537796","Horning SJ, Rosenberg SA, Hoppe RT. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: an update. Ann Oncol. 1996;7 Suppl 4:105-8. Review.|Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol. 1995 May;13(5):1080-8.","\tLymphoma\tBleomycin sulfate|Stanford V regimen|Doxorubicin hydrochloride|Etoposide|Mechlorethamine hydrochloride|Prednisone|Vinblastine|Vincristine sulfate\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma","liposomal doxorubicin|bleomycin|vincristine|mechlorethamine|prednisone|etoposide|doxorubicin|vinblastine","NA"]
["NCT00002716","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16505413|NA|12782596|11913730","Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006 Mar 20;24(9):1395-403. Epub 2006 Feb 27.|Kemeny NE, Niedzwiecki D, Hollis DR, et al.: Final analysis of hepatic arterial infusion (HAI) versus systemic therapy for hepatic metastases from colorectal cancer: a CALGB randomized trial of efficacy, quality of life (QOL), cost effectiveness, and molecular markers. [Abstract] American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium, 27-29 January 2005, Miami, Florida. A-183, 2005.|Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ, Ladner RD. A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 2003 Jun 1;63(11):2898-904.|Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S, Lenz HJ. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 2001;1(1):65-70.","\tColorectal Cancer|Metastatic Cancer\tdexamethasone|floxuridine|fluorouracil|leucovorin calcium|laparotomy|conventional surgery\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug|Procedure|Procedure\tAll\t","Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer","Interventional","Completed","Phase 3",2,135,"neoplasm metastasis|colorectal neoplasms","leucovorin|dexamethasone|fluorouracil|calcium|floxuridine|levoleucovorin","NA"]
["NCT00002717","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17906207|NA","Spriggs DR, Brady MF, Vaccarello L, Clarke-Pearson DL, Burger RA, Mannel R, Boggess JF, Lee RB, Hanly M. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Oct 1;25(28):4466-71.|Spriggs DR, Brady M, Rubin S, et al.: A phase III randomized trial of cisplatin and paclitaxel administered by either 24 hour or 96 hour infusion in patients with selected stage III or stage IV epithelial ovarian cancer (GOG162). [Abstract] J Clin Oncol 22 (Suppl 14): A-5004, 450s, 2004.","\tOvarian Cancer|Primary Peritoneal Cavity Cancer\tcisplatin|paclitaxel\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","carcinoma, ovarian epithelial|ovarian neoplasms","paclitaxel|cisplatin","NA"]
["NCT00002719","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17339189|15761020|NA","Thomas X, Suciu S, Rio B, Leone G, Broccia G, Fillet G, Jehn U, Feremans W, Meloni G, Vignetti M, de Witte T, Amadori S. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study. Haematologica. 2007 Mar;92(3):389-96.|Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, Muus P, Lefrère F, Berneman Z, Fillet G, Denzlinger C, Willemze R, Leoni P, Leone G, Casini M, Ricciuti F, Vignetti M, Beeldens F, Mandelli F, De Witte T; EORTC/GIMEMA Leukemia Group. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood. 2005 Jul 1;106(1):27-34. Epub 2005 Mar 10.|Jehn U, Suciu S, Thomas X, et al.: Oral vs intravenous consolidation chemotherapy in elderly patients with AML. Results of the EORTC-GIMEMA AML-13 phase III trial. [Abstract] Blood 100 (11 Pt 1): A-319, 87a, 2002.","\tLeukemia|Neutropenia\tfilgrastim|amsacrine|carmustine|cytarabine|etoposide|idarubicin|mitoxantrone hydrochloride|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","neutropenia|leukemia","idarubicin|cytarabine|carmustine|amsacrine|etoposide|mitoxantrone","NA"]
["NCT00002723","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15756004|16098367|15484217|NA|12177096|11289126|11448906|NA|NA|NA|NA","George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res. 2005 Mar 1;11(5):1815-20.|Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology. 2005 Aug;66(2):386-91.|Ahles TA, Herndon JE 2nd, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, Stadler W, Palchak D, Marshall ME, Wilding G, Petrylak D, Holland JC; Cancer and Leukemia Group B. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 2004 Nov 15;101(10):2202-8.|Taplin ME, George DJ, Halabi S, et al.: Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 9480. [Abstract] J Clin Oncol 22 (Suppl 14): A-4557, 396s, 2004.|Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol. 2002 Aug 15;20(16):3369-75.|Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA, Small EJ. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res. 2001 Mar 15;61(6):2533-6.|George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, Kantoff PW; Cancer and Leukemia Group B 9480. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res. 2001 Jul;7(7):1932-6.|Bok R, Halabi S, Shaal M, et al.: VEGF and basic FGF urine levels as predictors of response to therapy with suramin in CALGB 9480, a phase III study of hormone refractory prostate cancer (HRPC) patients. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A1367, 2000.|Halabi S, Small EJ, Ansari RH, et al.: Results of CALGB 9480, a phase III trial of 3 different doses of suramin for the treatment of horomone refractory prostate cancer (HRPC). [Abstract] Proceedings of the American Society of Clinical Oncology 19: A1291, 2000.|Kantoff P, Halabi S, Farmer D, et al.: RT-PCR for prostate specific antigen (PSA) in peripheral blood (PB) predicts survival duration in patients with hormone refractory prostate cancer (HRPC): a CALBG study. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A1323, 2000.|Vogelzang N, Small E, Halabi R, et al.: A phase III trial of 3 different doses of suramin (SUR) in metastatic hormone refractory prostate cancer (HRPC): safety profile of CALGB 9480. [Abstract] Proceedings of the American Society of Clinical Oncology 17: A1339, 347a, 1998.","\tProstate Cancer\tsuramin|suramin|Suramin\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tMale\t","Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer","Interventional","Completed","Phase 3",3,390,"prostatic neoplasms","suramin","NA"]
["NCT00002734","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Meredith R, Alvarez R, Khazaeli MB, et al.: Intraperitoneal radioimmunotherapy for refractory epithelial ovarian cancer with Lu-CC49. Minerva Biotechnologica 10: 100-107, 1998.","\tOvarian Cancer|Primary Peritoneal Cavity Cancer\trecombinant interferon alfa|chemotherapy|paclitaxel|topotecan hydrochloride|lutetium Lu 177 monoclonal antibody CC49|yttrium Y 90 monoclonal antibody CC49\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Radiation|Radiation\tFemale\t","NA","NA","NA","NA","NA","NA","carcinoma, ovarian epithelial|ovarian neoplasms","antibodies, monoclonal|immunoglobulins|interferon-alpha|antineoplastic agents, immunological|antibodies|topotecan|interferons|paclitaxel","NA"]
["NCT00002735","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15625363|NA","Urba SG, Moon J, Giri PG, Adelstein DJ, Hanna E, Yoo GH, Leblanc M, Ensley JF, Schuller DE. Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial. J Clin Oncol. 2005 Jan 1;23(1):88-95.|Urba S, Moon J, LeBlanc M, et al.: Induction chemotherapy followed by chemoradiation for organ preservation in patients (pts) with advanced resectable cancer of the base of tongue (BOT) and hypopharynx (HP): a Southwest Oncology Group trial. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-919, 2002.","\tHead and Neck Cancer\tInduction chemotherapy|cisplatin|fluorouracil|low-LET cobalt-60 gamma ray therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","NA","cisplatin|cobalt|fluorouracil","NA"]
["NCT00002737","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15961764,"Aass N, De Mulder PH, Mickisch GH, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol. 2005 Jun 20;23(18):4172-8.","\tKidney Cancer\trecombinant interferon alfa|chemotherapy|isotretinoin\tNA\tNA\tNA\tBiological|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, renal cell|kidney neoplasms","isotretinoin|interferons|interferon-alpha","NA"]
["NCT00002740","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20049927,"Bensimhon P, Villablanca JG, Sender LS, Matthay KK, Park JR, Seeger R, London WB, Yap JS, Kreissman SG. Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group. Pediatr Blood Cancer. 2010 Apr;54(4):596-602. doi: 10.1002/pbc.22344.","\tNeuroblastoma\tfilgrastim|carboplatin|cyclophosphamide|doxorubicin hydrochloride|etoposide|mesna|vincristine sulfate|conventional surgery|peripheral blood stem cell transplantation|low-LET cobalt-60 gamma ray therapy|low-LET photon therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","neuroblastoma","cyclophosphamide|cobalt|lenograstim|liposomal doxorubicin|vincristine|etoposide|carboplatin|doxorubicin|mesna","NA"]
["NCT00002744","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15368546|NA|20124218|19884541|18089878|16609069|NA|NA|NA|NA","Bassal M, La MK, Whitlock JA, Sather HN, Heerema NA, Gaynon PS, Stork LC. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer. 2005 Jan;44(1):21-8.|Malempati S, Gaynon PS, Sather H, et al.: Outcome after relapse among children with standard risk (SR) ALL treated on CCG-1952. [Abstract] Blood 104 (11): A-520, 2004.|Stork LC, Matloub Y, Broxson E, La M, Yanofsky R, Sather H, Hutchinson R, Heerema NA, Sorrell AD, Masterson M, Bleyer A, Gaynon PS. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. Blood. 2010 Apr 8;115(14):2740-8. doi: 10.1182/blood-2009-07-230656. Epub 2010 Feb 1.|Kadan-Lottick NS, Brouwers P, Breiger D, Kaleita T, Dziura J, Northrup V, Chen L, Nicoletti M, Bostrom B, Stork L, Neglia JP. Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia. J Clin Oncol. 2009 Dec 10;27(35):5986-92. doi: 10.1200/JCO.2009.23.5408. Epub 2009 Nov 2.|Malempati S, Gaynon PS, Sather H, La MK, Stork LC; Children's Oncology Group. Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952. J Clin Oncol. 2007 Dec 20;25(36):5800-7.|Matloub Y, Lindemulder S, Gaynon PS, Sather H, La M, Broxson E, Yanofsky R, Hutchinson R, Heerema NA, Nachman J, Blake M, Wells LM, Sorrell AD, Masterson M, Kelleher JF, Stork LC; Children's Oncology Group. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood. 2006 Aug 15;108(4):1165-73. Epub 2006 Apr 11.|\"Stork LC, Sather H, Hutchinson RJ, et al.: Comparison of mercaptopurine (MP) with thioguanine (TG) and IT methotrexate (ITM) with IT \"\"triples\"\" (ITT) in children with SR-ALL: results of CCG-1952. [Abstract] Blood 100 (11 Pt 1): A-585, 156a, 2002.\"|Stork LC, Sather H, Yanofsky R, et al.: Hyperdiploidy with trisomy 10 and TEL-AML1 expression among children with standard risk acute lymphoblastic leukemia (SR-ALL): a CCG-1952 report. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1476, 2001.|Gaynon PS, Stork L, Sather H, et al.: Leukemic progenitor cell content of pre- and post-induction chemotherapy bone marrow specimens from children with newly diagnosed or relapsed acute lymphoblastic leukemia (ALL). [Abstract] Proceedings of the American Society of Clinical Oncology 18: A-2187, 567a, 1999.|Stork LC, Erdmann G, Adamson P, et al.: Oral 6-thioguanine causes relatively mild and reversible hepatic veno-occlusive disease(VOD). J Pediatr Hematol Oncol 20: 400a, 1998.","\tLeukemia\tasparaginase|cyclophosphamide|cytarabine|daunorubicin hydrochloride|dexamethasone|doxorubicin hydrochloride|mercaptopurine|methotrexate|pegaspargase|prednisone|therapeutic hydrocortisone|thioguanine|vincristine sulfate|low-LET cobalt-60 gamma ray therapy|low-LET photon therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Radiation|Radiation\tAll\t","Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia","Interventional","Completed","Phase 3",4,1970,"precursor cell lymphoblastic leukemia-lymphoma|leukemia, lymphoid|leukemia","vincristine|methotrexate|cytarabine|hydrocortisone acetate|cyclophosphamide|daunorubicin|mercaptopurine|prednisone|thioguanine|pegaspargase|asparaginase|cobalt|dexamethasone|hydrocortisone|hydrocortisone 17-butyrate 21-propionate|liposomal doxorubicin|doxorubicin|hydrocortisone hemisuccinate","NA"]
["NCT00002745","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18648813,"Bartlett NL, Johnson JL, Wagner-Johnston N, Ratain MJ, Peterson BA; Cancer and Leukemia Group B. Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. Cancer Chemother Pharmacol. 2009 Apr;63(5):793-8. doi: 10.1007/s00280-008-0803-x. Epub 2008 Jul 23.","\tLymphoma\taminocamptothecin\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|hodgkin disease|lymphoma, non-hodgkin","NA","NA"]
["NCT00002756","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22210879|22488662|NA|17136402","Kang H, Wilson CS, Harvey RC, Chen IM, Murphy MH, Atlas SR, Bedrick EJ, Devidas M, Carroll AJ, Robinson BW, Stam RW, Valsecchi MG, Pieters R, Heerema NA, Hilden JM, Felix CA, Reaman GH, Camitta B, Winick N, Carroll WL, Dreyer ZE, Hunger SP, Willman CL. Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2012 Feb 23;119(8):1872-81. doi: 10.1182/blood-2011-10-382861. Epub 2011 Dec 30.|Salzer WL, Jones TL, Devidas M, Hilden JM, Winick N, Hunger S, Carroll WL, Camitta B, Dreyer ZE. Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407. Pediatr Blood Cancer. 2012 Nov;59(5):834-9. doi: 10.1002/pbc.24132. Epub 2012 Apr 5.|Robinson BW, Devidas M, Carroll AJ, et al.: Specific MLL partner genes in infant acute lymphoblastic leukemia (ALL) associated with outcome are linked to age and white blood cell count (WBC) at diagnosis: A report on the Children's Oncology Group (COG) P9407 trial. [Abstract] Blood 114 (22): A-907, 2009.|Thompson PA, Murry DJ, Rosner GL, Lunagomez S, Blaney SM, Berg SL, Camitta BM, Dreyer ZE, Bomgaars LR. Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2007 May;59(6):847-53. Epub 2006 Nov 29.","\tLeukemia\tfilgrastim|asparaginase|cyclophosphamide|cytarabine|daunorubicin hydrochloride|etoposide|leucovorin calcium|mercaptopurine|methotrexate|prednisone|therapeutic hydrocortisone|vincristine sulfate\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia","mercaptopurine|vincristine|daunorubicin|hydrocortisone hemisuccinate|hydrocortisone|hydrocortisone acetate|hydrocortisone 17-butyrate 21-propionate|cytarabine|levoleucovorin|prednisone|etoposide|asparaginase|methotrexate|leucovorin|cyclophosphamide","NA"]
["NCT00002757","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22215753|21496005|19895612|19020548|18371107|18493992|17138821|17132719|NA|NA|NA|NA|NA|NA|10820362","Cairo MS, Sposto R, Gerrard M, Auperin A, Goldman SC, Harrison L, Pinkerton R, Raphael M, McCarthy K, Perkins SL, Patte C. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012 Feb 1;30(4):387-93. doi: 10.1200/JCO.2010.33.3369. Epub 2012 Jan 3.|Shiramizu B, Goldman S, Kusao I, Agsalda M, Lynch J, Smith L, Harrison L, Morris E, Gross TG, Sanger W, Perkins S, Cairo MS. Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report. Br J Haematol. 2011 Jun;153(6):758-63. doi: 10.1111/j.1365-2141.2011.08681.x. Epub 2011 Apr 18.|Nelson M, Perkins SL, Dave BJ, Coccia PF, Bridge JA, Lyden ER, Heerema NA, Lones MA, Harrison L, Cairo MS, Sanger WG. An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961. Br J Haematol. 2010 Feb;148(4):600-10. doi: 10.1111/j.1365-2141.2009.07967.x. Epub 2009 Nov 4.|Poirel HA, Cairo MS, Heerema NA, Swansbury J, Aupérin A, Launay E, Sanger WG, Talley P, Perkins SL, Raphaël M, McCarthy K, Sposto R, Gerrard M, Bernheim A, Patte C; FAB/LMB 96 International Study Committee. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Leukemia. 2009 Feb;23(2):323-31. doi: 10.1038/leu.2008.312. Epub 2008 Nov 20.|Gerrard M, Cairo MS, Weston C, Auperin A, Pinkerton R, Lambilliote A, Sposto R, McCarthy K, Lacombe MJ, Perkins SL, Patte C; FAB LMB96 International Study Committee. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008 Jun;141(6):840-7. doi: 10.1111/j.1365-2141.2008.07144.x. Epub 2008 Mar 26.|Miles RR, Raphael M, McCarthy K, Wotherspoon A, Lones MA, Terrier-Lacombe MJ, Patte C, Gerrard M, Auperin A, Sposto R, Davenport V, Cairo MS, Perkins SL; SFOP/LMB96/CCG5961/UKCCSG/NHL 9600 Study Group. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group. Pediatr Blood Cancer. 2008 Sep;51(3):369-74. doi: 10.1002/pbc.21619.|Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, Weston C, Perkins SL, Raphael M, McCarthy K, Patte C; FAB LMB96 International Study Committee. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007 Apr 1;109(7):2736-43.|Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS; FAB/LMB96 International Study Committee. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007 Apr 1;109(7):2773-80.|Goldman S, Gerrard M, Sposto R, et al.: Excellent results in children and adolescents with isolated mature B-acute lymphoblastic leukemia (B-ALL) (Burkitt): report from the French-American-British (FAB) international LMB study FAB/LMB96. [Abstract] Blood 106 (11): A-234, 2005.|Poirel HA, Heerema NA, Swansbury J, et al.: In pediatric mature B-cell non Hodgkin's lymphoma (NHL), complex karyotype or del(13q) are linked prognostic factors in Burkitt lymphoma (BL) while 8q24/c-myc rearrangement is associated with a strong adverse effect in diffuse large B-cell lymphoma (DLBCL). [Abstract] Blood 106 (11): A-1905, 2005.|Lones M, Perkins S, Sposto R, et al.: T-cell-rich large B-cell lymphoma (TCRLBCL) in children and adolescents treated on a B-large cell lymphoma trial: a report from the Children's Cancer Group (CCG) study CCG-5961. [Abstract] Ann Oncol 13(suppl 2): A-137, 45, 2002.|Perkins S, Lones M, Sposto R, et al.: B-cell non-Hodgkin lymphoma (NHL) in children and adolescents: central phenotype results from Children's Cancer Group (CCG) study CCG-5961 and implications for future targeted bio-immune therapy (TBIT). [Abstract] Ann Oncol 13(suppl 2): A-136, 45, 2002.|Sanger W, Lones M, Perkins S, et al.: Chromosome abnormalities in B-cell non-Hodgkin lymphoma (NHL) of children and adolescents: a report from Children's Cancer Group (CCG)study CCG-5961. [Abstract] Ann Oncol 13(suppl 2): A-138, 45, 2002.|Perkins SL, Lones MA, Cairo MS, et al.: B-cell lymphoma/leukemia in children and adolescents: central phenotype results from Children's Cancer Group study (CCG)-5961 and implications for future Targeted Bio-Immune Therapy (TBIT). [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1520, 2001.|Lones MA, Cairo MS, Perkins SL. T-cell-rich large B-cell lymphoma in children and adolescents: a clinicopathologic report of six cases from the Children's Cancer Group Study CCG-5961. Cancer. 2000 May 15;88(10):2378-86.","\tLeukemia|Lymphoma\tfilgrastim|cyclophosphamide|cytarabine|doxorubicin hydrochloride|etoposide|methotrexate|prednisolone|prednisone|therapeutic hydrocortisone|vincristine sulfate\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug\tAll\t","TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma","Interventional","Completed","Phase 3",3,1148,"lymphoma|leukemia","cyclophosphamide|hydrocortisone 17-butyrate 21-propionate|doxorubicin|prednisone|hydrocortisone hemisuccinate|etoposide|cytarabine|hydrocortisone|vincristine|methotrexate|liposomal doxorubicin|prednisolone|hydrocortisone acetate","NA"]
["NCT00002760","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17404083|NA|15020604|12560440|NA|NA","Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin Cancer Res. 2007 Apr 1;13(7):2030-7.|Ryan CJ, Halabi S, Kaplan E, et al.: Use of adrenal androgen levels to predict response to ketoconazole in patients with androgen independent prostate cancer: results from CALGB 9583. [Abstract] J Clin Oncol 22 (Suppl 14): A-4558, 396s, 2004.|Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004 Mar 15;22(6):1025-33.|Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff PW. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J Clin Oncol. 2003 Feb 1;21(3):490-5.|Halabi S, Small E, Farmer D, et al.: Reverse transcriptase polymerase chain reaction (RT-PCR) for prostate specific antigen (PSA) as a prognostic factor for survival among androgen independent prostate cancer patients (AICaP): a companion study to CALGB 9583. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-700, 2001.|Vogelzang NV, Halabi S, Picus J, et al.: Prospective assessment of adrenal androgen levels as predictors of survival in androgen independent prostate cancer patients treated with ketoconazole: a correlative study to CALGB protocol 9583. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-749, 2001.","\tProstate Cancer\tketoconazole|therapeutic hydrocortisone|Withdrawal of antiandrogen therapy\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Other\tMale\t","Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer","Interventional","Completed","Phase 3",2,260,"prostatic neoplasms","hydrocortisone hemisuccinate|hydrocortisone 17-butyrate 21-propionate|hydrocortisone acetate|ketoconazole|hydrocortisone|androgen antagonists","NA"]
["NCT00002762","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19487378|NA","Grant CS, Ingle JN, Suman VJ, Dumesic DA, Wickerham DL, Gelber RD, Flynn PJ, Weir LM, Intra M, Jones WO, Perez EA, Hartmann LC. Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study. J Clin Oncol. 2009 Aug 1;27(22):3620-6. doi: 10.1200/JCO.2008.21.3603. Epub 2009 Jun 1.|Grant CS, Hartmann LC, Suman VJ, et al.: Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study. [Abstract] Breast Cancer Res Treat 88 (Suppl 1): A-5088, 2004.","\tBreast Cancer|Perioperative/Postoperative Complications\tpatient interviewing to obtain menstrual history|blood sampling\tNA\tNA\tNA\tBehavioral|Procedure\tFemale\t","NA","NA","NA","NA","NA","NA","postoperative complications|breast neoplasms","NA","NA"]
["NCT00002763","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21546857|21087856|NA|NA|16198768","Bouwhuis MG, Collette S, Suciu S, de Groot ER, Kruit WH, Ten Hagen TL, Aarden LA, Eggermont AM, Swaak AJ; EORTC Melanoma Group. Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-α (EORTC 18952) and prognostic value on treatment outcome. Melanoma Res. 2011 Aug;21(4):344-51. doi: 10.1097/CMR.0b013e328346c17f.|Bouwhuis MG, Suciu S, Kruit W, Salès F, Stoitchkov K, Patel P, Cocquyt V, Thomas J, Liénard D, Eggermont AM, Ghanem G; European Organisation for Research and Treatment of Cancer Melanoma Group. Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952. Eur J Cancer. 2011 Feb;47(3):361-8. doi: 10.1016/j.ejca.2010.10.005. Epub 2010 Nov 17.|Bouwhuis M, Suciu S, Kruit W, et al.: Prognostic value of autoantibodies (auto-AB) in melanoma patients (pts) in the EORTC 18952 trial of adjuvant interferon (IFN) compared to observation (obs). [Abstract] J Clin Oncol 25 (Suppl 18): A-8507, 473s, 2007.|Suciu S, Ghanem G, Kruit W, et al.: Serum S-100B protein is a strong independent prognostic marker for distant-metastasis free survival (DMFS) in stage III melanoma patients: an evaluation of the EORTC randomized trial 18952 comparing IFNα versus observation. [Abstract] J Clin Oncol 25 (Suppl 18): A-8518, 476s, 2007.|Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJ, Delauney M, Sales F, Groenewegen G, Ruiter DJ, Jagiello I, Stoitchkov K, Keilholz U, Lienard D; EORTC Melanoma Group. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005 Oct 1;366(9492):1189-96.","\tMelanoma (Skin)\trecombinant interferon alfa\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","melanoma","interferon-alpha|interferons","NA"]
["NCT00002765","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","10764422|10552943","Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, Waldmann TA, Pastan I. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000 Apr;18(8):1622-36.|Kreitman RJ, Wilson WH, Robbins D, Margulies I, Stetler-Stevenson M, Waldmann TA, Pastan I. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood. 1999 Nov 15;94(10):3340-8.","\tLeukemia|Lymphoma\tLMB-2 immunotoxin\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","leukemia|lymphoma","immunotoxins","NA"]
["NCT00002768","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19289999,"Linker CA, Owzar K, Powell B, Hurd D, Damon LE, Archer LE, Larson RA; Cancer and Leukemia Group B. Auto-SCT for AML in second remission: CALGB study 9620. Bone Marrow Transplant. 2009 Sep;44(6):353-9. doi: 10.1038/bmt.2009.36. Epub 2009 Mar 16.","\tLeukemia\tfilgrastim|busulfan|cytarabine|etoposide|methotrexate|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, myeloid, acute|leukemia|leukemia, myeloid","etoposide|busulfan|cytarabine|methotrexate","NA"]
["NCT00002772","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17404368|NA","Moore HC, Green SJ, Gralow JR, Bearman SI, Lew D, Barlow WE, Hudis C, Wolff AC, Ingle JN, Chew HK, Elias AD, Livingston RB, Martino S; Southwest Oncology Group/Intergroup Study 9623. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. J Clin Oncol. 2007 May 1;25(13):1677-82. Epub 2007 Apr 2.|Bearman SI, Green S, Gralow J, et al.: SWOG/Intergroup 9623: a phase III comparison of intensive sequential chemotherapy to high dose chemotherapy and autologous hematopoietic progenitor cell support (AHPCS) for primary breast cancer in women with =4 involved axillary lymph nodes. [Abstract] J Clin Oncol 23 (Suppl 16): A-572, 21s, 2005.","\tBreast Cancer\tfilgrastim|carboplatin|carmustine|cisplatin|cyclophosphamide|doxorubicin hydrochloride|paclitaxel|tamoxifen citrate|thiotepa|autologous bone marrow transplantation|peripheral blood stem cell transplantation|radiation therapy\tParallel Assignment\tTreatment\tRandomized\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure|Radiation\tFemale\t","S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer","Interventional","Terminated","Phase 3",2,602,"breast neoplasms","paclitaxel|carboplatin|liposomal doxorubicin|carmustine|tamoxifen|doxorubicin|cyclophosphamide|thiotepa","NA"]
["NCT00002774","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16532436,"Le QT, Taira A, Budenz S, Jo Dorie M, Goffinet DR, Fee WE, Goode R, Bloch D, Koong A, Martin Brown J, Pinto HA. Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas. Cancer. 2006 May 1;106(9):1940-9.","\tSquamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)\tTirapazamine|Cisplatin|5-fluorouracil|Radiotherapy (RT)\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Radiation\tAll\t","Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer","Interventional","Completed","Phase 2",2,63,"head and neck neoplasms","tirapazamine|fluorouracil|cisplatin","NA"]
["NCT00002777","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18794551|14760111|NA|NA","Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008 Oct 20;26(30):4883-90. doi: 10.1200/JCO.2007.14.4659. Epub 2008 Sep 15.|Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, Lohrisch C, Cufer T, Lobelle JP, Mattiaci MR, Piccart M, Paridaens R. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Ann Oncol. 2004 Feb;15(2):211-7.|Paridaens R, Therasse P, Dirix L, et al.: First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts): A randomized phase III trial of the EORTC Breast group. [Abstract] J Clin Oncol 22 (Suppl 14): A-515, 6s, 2004.|Paridaens R, Therasse P, Dirix L, et al.: First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) : EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group. [Abstract] Eur J Cancer 2 (Suppl 3): A-241, 126, 2004.","\tBreast Cancer\texemestane|tamoxifen citrate\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","tamoxifen|exemestane","NA"]
["NCT00002784","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19468030|16421418|10076722|10458221|9816037","Colleoni M, Sun Z, Martinelli G, Basser RL, Coates AS, Gelber RD, Green MD, Peccatori F, Cinieri S, Aebi S, Viale G, Price KN, Goldhirsch A; International Breast Cancer Study Group. The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol. 2009 Aug;20(8):1344-51. doi: 10.1093/annonc/mdp024. Epub 2009 May 25.|International Breast Cancer Study Group, Basser RL, O'Neill A, Martinelli G, Green MD, Peccatori F, Cinieri S, Coates AS, Gelber RD, Aebi S, Castiglione-Gertsch M, Viale G, Price KN, Goldhirsch A. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol. 2006 Jan 20;24(3):370-8.|Basser RL, Abraham R, To LB, Fox RM, Green MD. Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer. Ann Oncol. 1999 Jan;10(1):53-8.|Basser RL, To LB, Collins JP, Begley CG, Keefe D, Cebon J, Bashford J, Durrant S, Szer J, Kotasek D, Juttner CA, Russell I, Maher DW, Olver I, Sheridan WP, Fox RM, Green MD. Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-up. J Clin Oncol. 1999 Jan;17(1):82-92.|Basser RL, To LB, Begley CG, Juttner CA, Maher DW, Szer J, Cebon J, Collins JP, Russell I, Olver I, et al. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells. Clin Cancer Res. 1995 Jul;1(7):715-21.","\tBreast Cancer\tfilgrastim|CMF regimen|cyclophosphamide|doxorubicin hydrochloride|epirubicin hydrochloride|fluorouracil|mesna|methotrexate|tamoxifen citrate|peripheral blood stem cell transplantation|low-LET electron therapy|low-LET photon therapy\tParallel Assignment\tTreatment\tRandomized\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Radiation|Radiation\tFemale\t","High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer","Interventional","Completed","Phase 3",2,344,"breast neoplasms","epirubicin|tamoxifen|liposomal doxorubicin|fluorouracil|methotrexate|cyclophosphamide|doxorubicin","NA"]
["NCT00002785","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19648788|NA|16556894|NA","Salzer W, Dinndorf P, Dreyer Z, Hilden J, Reaman GH. Analysis of infectious complications in infants with acute lymphoblastic leukemia treated on the Children's Cancer Group Protocol 1953: a report from the Children's Oncology Group. J Pediatr Hematol Oncol. 2009 Jun;31(6):398-405. doi: 10.1097/MPH.0b013e3181a6dec0.|Robinson BW, Cao K, Hilden JM, et al.: Age is the strongest determinant of leukemia blast cell gene expression in MLL-rearranged infant ALL and MLL-AF4 directs a distinct gene expression profile related to CNS disease. [Abstract] Blood 112 (11): A-1200, 2008.|Hilden JM, Dinndorf PA, Meerbaum SO, Sather H, Villaluna D, Heerema NA, McGlennen R, Smith FO, Woods WG, Salzer WL, Johnstone HS, Dreyer Z, Reaman GH; Children's Oncology Group. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood. 2006 Jul 15;108(2):441-51. Epub 2006 Mar 23.|Hilden JM, Dinndorf PA, Meerbaum SO, et al.: CCG 1953: acute lymphoblastic leukemia in infants: analysis of prognostic factors: a report from the Children's Oncology Group. [Abstract] Blood 106 (11): A-7, 2005.","\tLeukemia\tfilgrastim|asparaginase|cyclophosphamide|cyclosporine|cytarabine|daunorubicin hydrochloride|dexamethasone|etoposide|leucovorin calcium|mercaptopurine|mesna|methotrexate|methylprednisolone|pegaspargase|prednisone|therapeutic hydrocortisone|vincristine sulfate|allogeneic bone marrow transplantation|low-LET cobalt-60 gamma ray therapy|low-LET photon therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","precursor cell lymphoblastic leukemia-lymphoma|leukemia, lymphoid|leukemia","hydrocortisone|leucovorin|cyclophosphamide|asparaginase|hydrocortisone acetate|methotrexate|daunorubicin|dexamethasone|hydrocortisone hemisuccinate|cobalt|etoposide|vincristine|cyclosporins|levoleucovorin|cytarabine|hydrocortisone 17-butyrate 21-propionate|pegaspargase|cyclosporine|mercaptopurine|prednisone|methylprednisolone","NA"]
["NCT00002791","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20572040|16446334|NA","Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, Lucas DR, Harmon DC, Letson GD, Eisenberg B. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. Cancer. 2010 Oct 1;116(19):4613-21. doi: 10.1002/cncr.25350.|Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, Lucas DR, Harmon DC, Letson GD, Eisenberg B; Radiation Therapy Oncology Group Trial 9514. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol. 2006 Feb 1;24(4):619-25.|Kraybill WG, Spiro I, Harris J, et al.: Radiation Therapy Oncology Group (RTOG) 95-14: a phase II study of neoadjuvant chemotherapy (CT) and radiation therapy (RT) in high risk (HR), high grade, soft tissue sarcomas (STS) of the extremities and body wall: a preliminary report. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1387, 2001.","\tSarcoma\tfilgrastim|dacarbazine|doxorubicin hydrochloride|ifosfamide|mesna|conventional surgery|brachytherapy|intraoperative radiation therapy|radioisotope therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Procedure|Radiation|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","sarcoma","doxorubicin|liposomal doxorubicin|ifosfamide|dacarbazine","NA"]
["NCT00002792","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",9326205,"Anderson JE, Sale G, Appelbaum FR, Chauncey TR, Storb R. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol. 1997 Sep;98(4):1010-6.","\tChronic Myeloproliferative Disorders|Leukemia|Myelodysplastic/Myeloproliferative Diseases\tbusulfan|cyclophosphamide|cyclosporine|methotrexate|tacrolimus|allogeneic bone marrow transplantation|peripheral blood stem cell transplantation\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","myeloproliferative disorders|myelodysplastic-myeloproliferative diseases","cyclosporins|methotrexate|busulfan|cyclosporine|cyclophosphamide|tacrolimus","NA"]
["NCT00002802","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12932669|12101494|11464889","Simon T, Hero B, Hunneman DH, Berthold F. Tumour markers are poor predictors for relapse or progression in neuroblastoma. Eur J Cancer. 2003 Sep;39(13):1899-903.|Häberle B, Hero B, Berthold F, von Schweinitz D. Characteristics and outcome of thoracic neuroblastoma. Eur J Pediatr Surg. 2002 Jun;12(3):145-50.|Hero B, Hunneman DH, Gahr M, Berthold F. Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma. Med Pediatr Oncol. 2001 Jan;36(1):220-3.","\tNeuroblastoma\tcarboplatin|cisplatin|cyclophosphamide|dacarbazine|doxorubicin hydrochloride|etoposide|ifosfamide|melphalan|mesna|vincristine sulfate|vindesine|autologous bone marrow transplantation|conventional surgery|low-LET cobalt-60 gamma ray therapy|low-LET electron therapy|low-LET photon therapy|radioisotope therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure|Radiation|Radiation|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","neuroblastoma","ifosfamide|vindesine|dacarbazine|carboplatin|vincristine|cyclophosphamide|melphalan|liposomal doxorubicin|etoposide|doxorubicin|cobalt","NA"]
["NCT00002803","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11857322,"Krams M, Hero B, Berthold F, Parwaresch R, Harms D, Rudolph P. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification. Cancer. 2002 Feb 1;94(3):854-61.","\tNeuroblastoma\tcyclophosphamide|doxorubicin hydrochloride|vincristine sulfate|conventional surgery\tNA\tNA\tNA\tDrug|Drug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","neuroblastoma","vincristine|cyclophosphamide|doxorubicin|liposomal doxorubicin","NA"]
["NCT00002806","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12525516,"Buckner JC, Gesme D Jr, O'Fallon JR, Hammack JE, Stafford S, Brown PD, Hawkins R, Scheithauer BW, Erickson BJ, Levitt R, Shaw EG, Jenkins R. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol. 2003 Jan 15;21(2):251-5.","\tBrain and Central Nervous System Tumors\tlomustine|procarbazine hydrochloride|vincristine sulfate|low-LET photon therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","nervous system neoplasms|central nervous system neoplasms","procarbazine|vincristine|lomustine","NA"]
["NCT00002807","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19070891,"ASTEC/EN.5 Study Group, Blake P, Swart AM, Orton J, Kitchener H, Whelan T, Lukka H, Eisenhauer E, Bacon M, Tu D, Parmar MK, Amos C, Murray C, Qian W. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009 Jan 10;373(9658):137-46. doi: 10.1016/S0140-6736(08)61767-5. Epub 2008 Dec 16. Review.","\tEndometrial Cancer\tradiation therapy\tParallel Assignment\tTreatment\tRandomized\tRadiation\tFemale\t","Radiation or Observation Only in Endometrial Cancer Who Have Undergone Surgery","Interventional","Completed","N/A",2,116,"endometrial neoplasms","NA","NA"]
["NCT00002812","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|NA|18802149|NA|NA|21193696|NA|NA|NA|18648353|22901620|19805689|NA|15154634|NA|15087948|18039957|19688832","Arce FJ, Seibel N, Gaynon PS, et al.: Pharmacokinetics and pharmacodynamics of asparaginases in antibody-negative pediatric patients with higher risk acute lymphoblastic leukemia (ALL): a report from CCG-1961. [Abstract] J Clin Oncol 24 (Suppl 18): A-9027, 508s, 2006.|Avramis VI, Ettinger L, Martin-Aragon S, et al.: Anti-asparaginase (ASNase) antibody (Ab) in pediatric patients in high risk ALL study (CCG-1961): correlation of Ab and clinical allergy. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A2319, 2000.|Avramis VI, Panosyan E, Avramis IA, et al.: Anti-asparaginase (ASNase) antibody (Ab) and ASNase activity in children with higher risk acute lymphoblastic leukemia (HR ALL) (CCG-1961). [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1592, 2002.|Bhojwani D, Kang H, Menezes RX, Yang W, Sather H, Moskowitz NP, Min DJ, Potter JW, Harvey R, Hunger SP, Seibel N, Raetz EA, Pieters R, Horstmann MA, Relling MV, den Boer ML, Willman CL, Carroll WL; Children's Oncology Group Study; Dutch Childhood Oncology Group; German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia. Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. J Clin Oncol. 2008 Sep 20;26(27):4376-84. doi: 10.1200/JCO.2007.14.4519. Erratum in: J Clin Oncol. 2008 Nov 1;26(31):5142..|Dhall G, Jones T, Radvinsky D, et al.: Adverse reactions to PEG and Erwinia asparaginase and correlation with anti-asparaginase antibody data and survival in children with acute lymphoblastic leukemia (ALL): A report from the Children's Oncology Group study CCG 1961. [Abstract] Blood 114 (22): A-3077, 2009.|Dhall G, Robison NJ, Rubin JI, et al.: Incidence of adverse reactions to post-induction asparaginase (ASP) therapy in children and adolescents with high-risk acute lymphoblastic leukemia (ALL): A report from the Children's Oncology Group Study CCG-1961. [Abstract] J Clin Oncol 26 (Suppl 15): A-10021, 2008.|Freyer DR, Devidas M, La M, Carroll WL, Gaynon PS, Hunger SP, Seibel NL. Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. Blood. 2011 Mar 17;117(11):3010-5. doi: 10.1182/blood-2010-07-294678. Epub 2010 Dec 30.|Freyer DR, Seibel NL, La MK, et al.: Survival after relapse in higher risk acute lymphoblastic leukemia (ALL) in children and adolescents is independent of prior treatment intensity: a report from the Children's Oncology Group (COG). [Abstract] Blood 112 (11): A-917, 2008.|Hastings C, Sather HN, Seibel NL, et al.: Outcomes in children and adolescents with a markedly elevated white blood cell count (>200,000) at diagnosis of high risk acute lymphoblastic leukemia (ALL): a report from the Children's Oncology Group. [Abstract] Blood 108 (11): A-1870, 2006.|Hastings C, Whitlock JA, La M, et al.: Improved outcome of children with Down syndrome (DS) and high risk acute lymphocytic leukemia (HR-ALL): a report of CCG-1961. [Abstract] Blood 110 (11): A-586, 2007.|Henze G. Early postinduction intensification therapy is essential in childhood acute lymphoblastic leukemia. Nat Clin Pract Oncol. 2008 Sep;5(9):502-3. doi: 10.1038/ncponc1184. Epub 2008 Jul 22.|Mattano LA Jr, Devidas M, Nachman JB, Sather HN, Hunger SP, Steinherz PG, Gaynon PS, Seibel NL; Children's Oncology Group. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol. 2012 Sep;13(9):906-15. Epub 2012 Aug 15.|Nachman JB, La MK, Hunger SP, Heerema NA, Gaynon PS, Hastings C, Mattano LA Jr, Sather H, Devidas M, Freyer DR, Steinherz PG, Seibel NL. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. J Clin Oncol. 2009 Nov 1;27(31):5189-94. doi: 10.1200/JCO.2008.20.8959. Epub 2009 Oct 5.|Nachman J, Siebel N, Sather H, et al.: Outcome for adolescent and young adults 16-21 years of age (AYA) with acute lymphoblastic leukemia (ALL) treated on the Children' s Cancer Group (CCG) 1961 study. [Abstract] Blood 104 (11): A-683, 2004.|Panosyan EH, Grigoryan RS, Avramis IA, Seibel NL, Gaynon PS, Siegel SE, Fingert HJ, Avramis VI. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res. 2004 Mar-Apr;24(2C):1121-5.|Panosyan EH, Seibel NL, Grigoryan RS, et al.: Pharmacokinetics and pharmacodynamics of three asparaginases in pediatric patients with higher risk acute lymphoblastic leukemia: a report from CCG-1961. [Abstract] Blood 104 (11): A-2745, 2004.|Panosyan EH, Seibel NL, Martin-Aragon S, Gaynon PS, Avramis IA, Sather H, Franklin J, Nachman J, Ettinger LJ, La M, Steinherz P, Cohen LJ, Siegel SE, Avramis VI; Children's Cancer Group Study CCG-1961. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004 Apr;26(4):217-26.|Seibel NL, Steinherz PG, Sather HN, Nachman JB, Delaat C, Ettinger LJ, Freyer DR, Mattano LA Jr, Hastings CA, Rubin CM, Bertolone K, Franklin JL, Heerema NA, Mitchell TL, Pyesmany AF, La MK, Edens C, Gaynon PS. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008 Mar 1;111(5):2548-55. Epub 2007 Nov 26.|Withycombe JS, Post-White JE, Meza JL, Hawks RG, Smith LM, Sacks N, Seibel NL. Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961. Pediatr Blood Cancer. 2009 Dec 15;53(7):1249-54. doi: 10.1002/pbc.22237.","\tLeukemia\tasparaginase|cyclophosphamide|cytarabine|daunorubicin hydrochloride|dexamethasone|doxorubicin hydrochloride|idarubicin|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine sulfate|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Radiation\tAll\t","Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia","Interventional","Completed","Phase 3",4,2078,"leukemia|precursor cell lymphoblastic leukemia-lymphoma","thioguanine|vincristine|daunorubicin|cytarabine|methotrexate|idarubicin|mercaptopurine|asparaginase|pegaspargase|doxorubicin|cyclophosphamide|prednisone|dexamethasone|liposomal doxorubicin","NA"]
["NCT00002813","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15310778,"Morris M, Blessing JA, Monk BJ, McGehee R, Moore DH. Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004 Aug 15;22(16):3340-4.","\tCervical Cancer\tcisplatin|vinorelbine tartrate\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","uterine cervical neoplasms","vinorelbine","NA"]
["NCT00002816","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","11426549|10499612","Uckun FM, Gaynon PS, Stram DO, Sensel MG, Sarquis MB, Willoughby M. Bone marrow leukemic progenitor cell content in pediatric T-lineage acute lymphoblastic leukemia patients with an isolated extramedullary first relapse. Leuk Lymphoma. 2001 Jan;40(3-4):279-85.|Uckun FM, Gaynon PS, Stram DO, Sensel MG, Sarquis MB, Lazarus KH, Willoughby M. Paucity of leukemic progenitor cells in the bone marrow of pediatric B-lineage acute lymphoblastic leukemia patients with an isolated extramedullary first relapse. Clin Cancer Res. 1999 Sep;5(9):2415-20.","\tLeukemia\tcytarabine|dexamethasone|etoposide|idarubicin|ifosfamide|leucovorin calcium|mesna|pegaspargase|therapeutic hydrocortisone|thioguanine|vincristine sulfate|low-LET cobalt-60 gamma ray therapy|low-LET electron therapy|low-LET photon therapy|Methotrexate\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Radiation|Radiation|Radiation|Drug\tAll\t","Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia","Interventional","Completed","Phase 3",2,120,"leukemia, lymphoid|precursor cell lymphoblastic leukemia-lymphoma|leukemia","etoposide|vincristine|ifosfamide|idarubicin|hydrocortisone 17-butyrate 21-propionate|levoleucovorin|pegaspargase|cytarabine|cobalt|methotrexate|hydrocortisone acetate|asparaginase|hydrocortisone|leucovorin|thioguanine|hydrocortisone hemisuccinate|dexamethasone","NA"]
["NCT00002822","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16293867|NA","Thatcher N, Qian W, Clark PI, Hopwood P, Sambrook RJ, Owens R, Stephens RJ, Girling DJ. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial. J Clin Oncol. 2005 Nov 20;23(33):8371-9.|Thatcher N, Qian W, Girling DJ: Ifosfamide, carboplatin and etoposide with mid-cycle vincristine (ICE-V) versus standard chemotherapy (C) in patients with small cell lung cancer (SCLC) and good performance status (PS): results of an MRC randomized trial (LU21). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2489, 619, 2003.","\tLung Cancer\tcarboplatin|cisplatin|cyclophosphamide|doxorubicin hydrochloride|etoposide|ifosfamide|mesna|vincristine sulfate|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","small cell lung carcinoma|lung neoplasms","liposomal doxorubicin|etoposide|cyclophosphamide|carboplatin|ifosfamide|doxorubicin|vincristine","NA"]
["NCT00002823","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21224045|19933916|20978195|17602078|16957145|NA|14736927|NA","Bepler G, Olaussen KA, Vataire AL, Soria JC, Zheng Z, Dunant A, Pignon JP, Schell MJ, Fouret P, Pirker R, Filipits M, Brambilla E. ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol. 2011 Jan;178(1):69-78. doi: 10.1016/j.ajpath.2010.11.029. Epub 2010 Dec 23.|Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, Kozlowski M, Le Péchoux C, Pirker R, Pinel MI, Tarayre M, Le Chevalier T. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010 Jan 1;28(1):35-42. doi: 10.1200/JCO.2009.23.2272. Epub 2009 Nov 23.|Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, Saito M, Dunant A, Pham TC, Petrini I, Lee A, Khan MA, Hainaut P, Pignon JP, Brambilla E, Popper HH, Filipits M, Harris CC, Giaccone G. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res. 2010 Nov 1;70(21):8288-98. doi: 10.1158/0008-5472.CAN-10-1348. Epub 2010 Oct 26.|Filipits M, Pirker R, Dunant A, Lantuejoul S, Schmid K, Huynh A, Haddad V, André F, Stahel R, Pignon JP, Soria JC, Popper HH, Le Chevalier T, Brambilla E. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol. 2007 Jul 1;25(19):2735-40.|Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC; IALT Bio Investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006 Sep 7;355(10):983-91.|Brambilla E, Dunant A, Filipits M, et al.: Prognostic and predictive role of alterations of the P53-bax-bcl2 pathway of apoptosis in the IALT (International Adjuvant Lung Cancer Trial). [Abstract] Lung Cancer 50 (Suppl 2): A-O-021, S10, 2005.|Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004 Jan 22;350(4):351-60.|Le Chevalier T: Results of the Randomized International Adjuvant Lung Cancer Trial (IALT): cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (pts) with resected non-small cell lung cancer (NSCLC). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-6, 2, 2003.","\tLung Cancer\tcisplatin|etoposide|vinblastine sulfate|vindesine|vinorelbine tartrate|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","vinorelbine|vindesine|etoposide|vinblastine","NA"]
["NCT00002825","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16532433,"Zwerdling T, Krailo M, Monteleone P, Byrd R, Sato J, Dunaway R, Seibel N, Chen Z, Strain J, Reaman G; Children's Oncology Group. Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group. Cancer. 2006 Apr 15;106(8):1821-8.","\tBrain and Central Nervous System Tumors|Neuroblastoma|Sarcoma\tfilgrastim|docetaxel\tNA\tNA\tNA\tBiological|Drug\tAll\t","NA","NA","NA","NA","NA","NA","neuroblastoma|central nervous system neoplasms|nervous system neoplasms|sarcoma","docetaxel","NA"]
["NCT00002826","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Carlson RW, O'Neill A, Goldstein L, et al.: A phase II trial of PSC-833 modulation of multidrug resistance to paclitaxel in breast cancer: a pilot trial of the Eastern Cooperative Oncology Group. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-234, 2002.","\tBreast Cancer\tpaclitaxel|valspodar\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","paclitaxel","NA"]
["NCT00002827","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22911615|NA","Tebbi CK, Mendenhall NP, London WB, Williams JL, Hutchison RE, Fitzgerald TJ, de Alarcón PA, Schwartz C, Chauvenet A. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Dec 15;59(7):1259-65. doi: 10.1002/pbc.24279. Epub 2012 Aug 21.|Mendenhall NP, Meyer J, Williams J, et al.: The impact of central quality assurance review prior to radiation therapy on protocol compliance: POG 9426, a trial in pediatric Hodgkin's disease. [Abstract] Blood 106 (11): A-753, 2005.","\tCardiac Toxicity|Lymphoma\tbleomycin sulfate|filgrastim|dexrazoxane hydrochloride|doxorubicin hydrochloride|etoposide|vincristine sulfate|low-LET cobalt-60 gamma ray therapy|low-LET electron therapy|low-LET photon therapy\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug|Drug|Radiation|Radiation|Radiation\tAll\t","Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease","Interventional","Completed","Phase 3",2,294,"lymphoma|hodgkin disease|cardiotoxicity","lenograstim|razoxane|liposomal doxorubicin|doxorubicin|bleomycin|vincristine|dexrazoxane|cobalt|etoposide","NA"]
["NCT00002839","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19176454|NA","Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, Hupperets P, Barzan L, de Raucourt D, Chevalier D, Licitra L, Lunghi F, Stupp R, Lacombe D, Bogaerts J, Horiot JC, Bernier J, Vermorken JB; EORTC Head and Neck Cancer Cooperative Group; EORTC Radiation Oncology Group. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst. 2009 Feb 4;101(3):142-52. doi: 10.1093/jnci/djn460. Epub 2009 Jan 27.|Lefebvre J, Horiot J, Rolland F, et al.: Phase III study on larynx preservation comparing induction chemotherapy and radiotherapy versus alternating chemoradiotherapy in resectable hypopharynx and larynx cancers. EORTC protocol 24954-22950. [Abstract] J Clin Oncol 25 (Suppl 18): A-LBA6016, 303s, 2007.","\tHead and Neck Cancer\tcisplatin|fluorouracil|conventional surgery|neoadjuvant therapy|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","laryngeal diseases","fluorouracil","NA"]
["NCT00002840","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20820870|21246521|21914791|NA|20160062|19224764|19901104|17549014|18089867|18089866|16782911|NA","Idbaih A, Dalmasso C, Kouwenhoven M, Jeuken J, Carpentier C, Gorlia T, Kros JM, French P, Teepen J, Broët P, Delattre O, Mokhtari K, Sanson M, Delattre JY, van den Bent M, Hoang-Xuan K. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. J Neurooncol. 2011 Jun;103(2):221-30. doi: 10.1007/s11060-010-0380-9. Epub 2010 Sep 6.|Mokhtari K, Ducray F, Kros JM, Gorlia T, Idbaih A, Taphoorn M, Wesseling P, Hoang-Xuan K, Van den Bent M, Sanson M. Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951. Cancer. 2011 Jul 1;117(13):3014-26. doi: 10.1002/cncr.25827. Epub 2011 Jan 18.|van den Bent MJ, Gravendeel LA, Gorlia T, Kros JM, Lapre L, Wesseling P, Teepen JL, Idbaih A, Sanson M, Smitt PA, French PJ. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clin Cancer Res. 2011 Nov 15;17(22):7148-55. doi: 10.1158/1078-0432.CCR-11-1274. Epub 2011 Sep 13.|Preusser M, Hoeftberger R, Woehrer A, et al.: Prognostic value and analytical performance (reproducibility) of Ki67 index in anaplastic oligodendroglial tumors: A translational study of the EORTC Brain Tumor Group. [Abstract] J Clin Oncol 28 (Suppl 15): A-2029, 2010.|van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010 Mar 1;16(5):1597-604. doi: 10.1158/1078-0432.CCR-09-2902. Epub 2010 Feb 16.|Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA, Bromberg JE, Mokhtari K, van Duinen SG, Teepen JL, Wesseling P, Vandenbos F, Grisold W, Sipos L, Mirimanoff R, Vecht CJ, Allgeier A, Lacombe D, van den Bent MJ. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro Oncol. 2009 Dec;11(6):737-46. doi: 10.1215/15228517-2009-011.|van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW, Ibdaih A, Brandes AA, Taphoorn MJ, Frenay M, Lacombe D, Gorlia T, Dinjens WN, Kros JM. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2009 Dec 10;27(35):5881-6. doi: 10.1200/JCO.2009.24.1034. Epub 2009 Nov 9.|Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella-Branger D, Giangaspero F, Giannini C, Mokhtari K, Mørk SJ, Paetau A, Reifenberger G, van den Bent MJ. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol. 2007 Jun;66(6):545-51.|Mauer ME, Taphoorn MJ, Bottomley A, Coens C, Efficace F, Sanson M, Brandes AA, van der Rijt CC, Bernsen HJ, Frénay M, Tijssen CC, Lacombe D, van den Bent MJ; EORTC Brain Cancer Group. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. J Clin Oncol. 2007 Dec 20;25(36):5731-7.|Taphoorn MJ, van den Bent MJ, Mauer ME, Coens C, Delattre JY, Brandes AA, Sillevis Smitt PA, Bernsen HJ, Frénay M, Tijssen CC, Lacombe D, Allgeier A, Bottomley A; European Organisation for Research and Treatment of Cancer. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol. 2007 Dec 20;25(36):5723-30.|van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006 Jun 20;24(18):2715-22.|van den Bent MJ, Delattre JY, Brandes AA, et al.: First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma. [Abstract] J Clin Oncol 23 (Suppl 16): A-1503, 114s, 2005.","\tBrain and Central Nervous System Tumors\tlomustine|procarbazine hydrochloride|vincristine sulfate|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","nervous system neoplasms|oligodendroglioma|central nervous system neoplasms","procarbazine|vincristine|lomustine","NA"]
["NCT00002849","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15308571|NA","Dhodapkar MV, Hussein MA, Rasmussen E, Solomon A, Larson RA, Crowley JJ, Barlogie B; United States Intergroup Trial Southwest Oncology Group. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood. 2004 Dec 1;104(12):3520-6. Epub 2004 Aug 12.|Dhodapkar M, Jacobson J, Hussein M, et al.: High dose dexamethasone (Dex) with maintenance Dex / alpha interferon leads to improved survival in patients with primary systemic amyloidosis: results of US Intergroup Trial Southwest Oncology Group (SWOG) S9628. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2278, 2003.","\tMultiple Myeloma\trecombinant interferon alfa|dexamethasone\tNA\tNA\tNA\tBiological|Drug\tAll\t","NA","NA","NA","NA","NA","NA","immunoglobulin light-chain amyloidosis|multiple myeloma|amyloidosis","interferon-alpha|interferons|dexamethasone","NA"]
["NCT00002851","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20100142|17240136|17013570|12957458|11286848|NA|NA","Matzinger O, Heimsoth I, Poortmans P, Collette L, Struikmans H, Van Den Bogaert W, Fourquet A, Bartelink H, Ataman F, Gulyban A, Pierart M, Van Tienhoven G; EORTC Radiation Oncology & Breast Cancer Groups. Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925). Acta Oncol. 2010;49(1):24-34. doi: 10.3109/02841860903352959.|Musat E, Poortmans P, Van den Bogaert W, Struikmans H, Fourquet A, Bartelink H, Kirkove C, Budach V, Pierart M, Collette L. Quality assurance in breast cancer: EORTC experiences in the phase III trial on irradiation of the internal mammary nodes. Eur J Cancer. 2007 Mar;43(4):718-24. Epub 2007 Jan 19.|Poortmans P, Kouloulias V, van Tienhoven G, Collette L, Struikmans H, Venselaar JL, Van den Bogaert W, Davis JB, Lambin P; EORTC Radiation Oncology and Breast Cancer Groups. Quality assurance in the EORTC randomized trial 22922/10925 investigating the role of irradiation of the internal mammary and medial supraclavicular lymph node chain works. Strahlenther Onkol. 2006 Oct;182(10):576-82.|Poortmans P, Kouloulias VE, Venselaar JL, Struikmans H, Davis JB, Huyskens D, van Tienhoven G, Hurkmans C, Mijnheer B, Van den Bogaert W. Quality assurance of EORTC trial 22922/10925 investigating the role of internal mammary--medial supraclavicular irradiation in stage I-III breast cancer: the individual case review. Eur J Cancer. 2003 Sep;39(14):2035-42.|Poortmans PM, Venselaar JL, Struikmans H, Hurkmans CW, Davis JB, Huyskens D, van Tienhoven G, Vlaun V, Lagendijk JJ, Mijnheer BJ, De Winter KA, Van der Hulst MH, Van den Bogaert WF. The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain: a quality-assurance report on the dummy run of EORTC Phase III randomized trial 22922/10925 in Stage I--III breast cancer(1). Int J Radiat Oncol Biol Phys. 2001 Apr 1;49(5):1399-408.|Poortmans P, Van Den Bogaert W, Venselaar J, et al.: Quality assurance in EORTC trial 22922/10925 concerning internal mammary chain (IMC) irradiation: the dummy run. Radiother Oncol 48(suppl 1): A735, s186, 1998.|Poortmans P, Van Den Bogaert W, Venselaar J, et al.: EORTC randomized phase III trials 22922/10925 investigating the role of internal mammary chain (IMC) irradiation in stage I-II breast cancer: a quality assurance report on the dummy run. Eur J Cancer 34(suppl 5): A257, s58, 1998.","\tBreast Cancer\tadjuvant therapy|low-LET electron therapy|low-LET photon therapy\tNA\tNA\tNA\tProcedure|Radiation|Radiation\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","NA","NA"]
["NCT00002855","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19029421,"Millikan RE, Wen S, Pagliaro LC, Brown MA, Moomey B, Do KA, Logothetis CJ. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol. 2008 Dec 20;26(36):5936-42. doi: 10.1200/JCO.2007.15.9830. Epub 2008 Nov 24.","\tProstate Cancer\tBicalutamide|Doxorubicin hydrochloride|Estramustine Phosphate Sodium|Flutamide|Ketoconazole|Nilutamide|Therapeutic Hydrocortisone|Vinblastine|Conventional Surgery\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure\tMale\t","Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer","Interventional","Completed","Phase 3",2,306,"prostatic neoplasms","estramustine|hydrocortisone|bicalutamide|doxorubicin|hydrocortisone 17-butyrate 21-propionate|hydrocortisone acetate|nilutamide|ketoconazole|vinblastine|hydrocortisone hemisuccinate|liposomal doxorubicin|flutamide","NA"]
["NCT00002860","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Sondak VK, Liu PY, Warneke J, et al.: Surgical resection for stage IV melanoma: a Southwest Oncology Group trial (S9430). [Abstract] J Clin Oncol 24 (Suppl 18): A-8019, 457s, 2006.","\tMelanoma (Skin)\tSurgery\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","melanoma","NA","NA"]
["NCT00002864","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|NA|NA|NA","Ali SM, Chapman JW, Demers L, et al.: Effect of adjuvant chemotherapy on bone resorption marker beta C-telopeptide (B-CTX) in postmenopausal women. [Abstract] J Clin Oncol 27 (Suppl 15): A-594, 2009.|Piura E, Chapman JW, Lipton A, et al.: Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial. [Abstract] J Clin Oncol 27 (Suppl 15): A-534, 2009.|Pollak MN, Chapman JW, Pritchard KI, et al.: NCIC-CTG MA14 trial: tamoxifen (tam) vs. tam + octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast cancer. [Abstract] J Clin Oncol 26 (Suppl 15): A-532, 2008.|Pollak MN, Chapman JW, Shepherd L, et al.: Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial. [Abstract] J Clin Oncol 24 (Suppl 18): A-524, 2006.|Pollak M, Pritchard K, Whelan T, et al.: The NCIC CTG MA.14 experience with the gallbladder toxicity of octreotide pamoate (oncolar) in a postmenopausal patient population undergoing adjuvant treatment for stage 1-3 breast cancer. Eur J Cancer 38(suppl 3): s2-s179, 2002.","\tBreast Cancer\toctreotide acetate|tamoxifen citrate\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tFemale\t","Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer","Interventional","Completed","Phase 3",2,667,"breast neoplasms","tamoxifen|octreotide","NA"]
["NCT00002869","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15010373,"Kluin-Nelemans HC, Buck G, le Cessie S, Richards S, Beverloo HB, Falkenburg JH, Littlewood T, Muus P, Bareford D, van der Lelie H, Green AR, Roozendaal KJ, Milne AE, Chapman CS, Shepherd P; MRC and HOVON groups. Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. Blood. 2004 Jun 15;103(12):4408-15. Epub 2004 Mar 9.","\tLeukemia\trecombinant interferon alfa|cytarabine|hydroxyurea\tNA\tNA\tNA\tBiological|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia|leukemia, myeloid|leukemia, myelogenous, chronic, bcr-abl positive","hydroxyurea|cytarabine|interferons|interferon-alpha","NA"]
["NCT00002870","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18037940|NA","Biron P, Durand M, Roché H, Delozier T, Battista C, Fargeot P, Spaeth D, Bachelot T, Poiget E, Monnot F, Tanguy ML, Curé H. Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Bone Marrow Transplant. 2008 Mar;41(6):555-62. Epub 2007 Nov 26.|Biron P, Durand M, Roche H, et al.: High dose thiotepa (TTP), cyclophosphamide (CPM) and stem cell transplantation after 4 FEC 100 compared with 4 FEC alone allowed a better disease free survival but the same overall survival in first line chemotherapy for metastatic breast cancer: results of the PEGASE 03 French protocole. [Abstract] Proceedings of the American Society of Clinical Oncology A-167, 2002.","\tBreast Cancer\tfilgrastim|cyclophosphamide|epirubicin hydrochloride|fluorouracil|thiotepa|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Procedure\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","cyclophosphamide|epirubicin|thiotepa|fluorouracil","NA"]
["NCT00002873","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18294778|18035213|NA|NA|NA|NA","Arthur DW, Winter K, Kuske RR, Bolton J, Rabinovitch R, White J, Hanson WF, Wilenzick RM, McCormick B. A Phase II trial of brachytherapy alone after lumpectomy for select breast cancer: tumor control and survival outcomes of RTOG 95-17. Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):467-73. doi: 10.1016/j.ijrobp.2007.12.056. Epub 2008 Mar 4.|Ibbott GS, Hanson WF, O'Meara E, Kuske RR, Arthur D, Rabinovitch R, White J, Wilenzick RM, Harris I, Tailor RC. Dose specification and quality assurance of radiation therapy oncology group protocol 95-17; a cooperative group study of iridium-192 breast implants as sole therapy. Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1572-8.|Rabinovitch R, Winter K, Taylor M, et al.: Toxicity and cosmesis from RTOG 95-17: a phase I/II trial to evaluate brachytherapy as the sole method of radiation therapy for stage I and II breast carcinoma. [Abstract] Breast Cancer Res Treat 106 (1): A-4078, S192-3, 2007.|Arthur DW, Winter K, Kuske RR, et al.: A phase II trial of brachytherapy alone following lumpectomy for select breast cancer: tumor control and survival outcomes of RTOG 95-17. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-51, S29-30, 2006.|Kuske RR, Winter K, Arthur DW, et al.: A phase II trial of brachytherapy alone following lumpectomy for stage I or II breast cancer: initial outcomes of RTOG 9517. [Abstract] J Clin Oncol 22 (Suppl 14): A-565, 18s, 2004.|Kuske RR, Winter K, Arthur D, et al.: A phase I/II trial of brachytherapy alone following lumpectomy for select breast cancer: toxicity analysis of Radiation Therapy Oncology Group 95-17. [Abstract] Int J Radiat Oncol Biol Phys 54(2 suppl 1): A-151, 87, 2002.","\tBreast Cancer\tbrachytherapy\tNA\tNA\tNA\tRadiation\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","NA","NA"]
["NCT00002875","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16943538|NA","Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, Bayer L, LaFond D, Donahue BR, Marymont MH, Muraszko K, Langston J, Sposto R. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006 Sep 1;24(25):4202-8.|\"Packer RJ, Gajjar A, Vezina G, et al.: 2340 cGy of craniospinal radiotherapy (CSRT) plus chemotherapy for children with \"\"average-risk\"\" medulloblastoma (MB): a prospective randomized Children's Oncology Group study (A9961). [Abstract] Neuro-Oncology 6 (4): TP-06, 387, 2004.\"","\tBrain Tumors|Central Nervous System Tumors\tfilgrastim|cisplatin|cyclophosphamide|lomustine|mesna|vincristine sulfate|low-LET electron therapy|low-LET photon therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Radiation|Radiation\tAll\t","Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma","Interventional","Completed","Phase 3",2,421,"central nervous system neoplasms|medulloblastoma|nervous system neoplasms","cisplatin|vincristine|lomustine|cyclophosphamide","NA"]
["NCT00002878","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16419071,"Friedenberg WR, Rue M, Blood EA, Dalton WS, Shustik C, Larson RA, Sonneveld P, Greipp PR. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer. 2006 Feb 15;106(4):830-8.","\tMultiple Myeloma and Plasma Cell Neoplasm\tdexamethasone|doxorubicin hydrochloride|valspodar|vincristine sulfate\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms, plasma cell|multiple myeloma|plasmacytoma","dexamethasone|doxorubicin|liposomal doxorubicin|vincristine","NA"]
["NCT00002879","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Inwards D, Brown D, Fonseca R, et al.: NCCTG Phase II trial of 2-chlorodeoxyadenosine (2-CDA) as initial therapy for mantle cell lymphoma. A well-tolerated treatment with promising activity. Blood 94(10 suppl 1): A-2930, 660a, 1999.","\tLymphoma\tcladribine\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|lymphoma, mantle-cell","cladribine","NA"]
["NCT00002882","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19430405,"Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Frost AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb;19(1):42-9. doi: 10.1097/CMR.0b013e328314b84a.","\tMelanoma|Skin Cancer\tAldesleukin (IL-2)|Recombinant Interferon Alfa (IFN-A)|Cisplatin|Dacarbazine|Vinblastine|Adjuvant Therapy\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug|Procedure\tAll\t","Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma","Interventional","Completed","Phase 3",3,140,"skin neoplasms|melanoma","interferon-alpha|interferon alpha-2|interleukin-2|interferons|dacarbazine|vinblastine|aldesleukin|cisplatin","NA"]
["NCT00002883","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Boige V, Pignon J, Saint-Aubert B, et al.: Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-4510, 200s, 2007.|Ychou M, Pignon JP, Lasser P, et al.: Phase III preliminary results of preoperative fluorouracil (F) and cisplatin (P) versus surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC 94012-FFCD 9703 trial. [Abstract] J Clin Oncol 24 (Suppl 18): A-4026, 2006.","\tEsophageal Cancer|Gastric Cancer\tcisplatin|fluorouracil|adjuvant therapy|conventional surgery|neoadjuvant therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","stomach neoplasms|esophageal neoplasms","fluorouracil|cisplatin","NA"]
["NCT00002888","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|15908667|NA|15452834|NA","Wells N, Murphy B, Dietrich M, et al.: Quality of life and pain assessment for head and neck cancer patients treated on E1395: a comparison of two different cisplatin-based chemotherapy regimens. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-907, 2002.|Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA; Eastern Cooperative Oncology Group. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005 May 20;23(15):3562-7.|Argiris A, Li Y, Forastiere A, et al.: Prognostic factors and long-term survivorship in patients with recurrent or metastatic head and neck cancer (HNC): an analysis of two Eastern Cooperative Oncology Group (ECOG) randomized trials. [Abstract] J Clin Oncol 22 (Suppl 14): A-5514, 491s, 2004.|Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer. 2004 Nov 15;101(10):2222-9.|Murphy B, Li Y, Cella D, et al.: Phase III study comparing cisplatin (C) & 5-flourouracil (F) versus cisplatin & paclitaxel (T) in metastatic/recurrent head & neck cancer (MHNC). [Abstract] Proceedings of the American Society of Clinical Oncology 20; A-894, 2001.","\tHead and Neck Cancer\tcisplatin|fluorouracil|paclitaxel\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","paclitaxel|fluorouracil","NA"]
["NCT00002889","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18037582|18291508|NA","D'Amico AV, Halabi S, Tempany C, Titelbaum D, Philips GK, Loffredo M, McMahon E, Sanford B, Vogelzang NJ, Small EJ; Cancer and Leukemia Group B. Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):9-15. Epub 2007 Nov 26.|D'Amico AV, Halabi S, Vollmer R, Loffredo M, McMahon E, Sanford B, Archer L, Vogelzang NJ, Small EJ, Kantoff PW; Cancer and Leukemia Group B. p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). Urology. 2008 May;71(5):933-7. doi: 10.1016/j.urology.2007.11.005. Epub 2008 Feb 21.|D'Amico AV, Halabi S, Tempany C, et al.: Changes on endorectal MRI during neoadjuvant hormonal therapy for prostate cancer and biochemical outcome in men managed using radiation therapy: a prospective phase II Cancer and Leukemia Group B study. [Abstract] J Clin Oncol 25 (Suppl 18): A-5072, 252s, 2007.","\tProstate Cancer\tflutamide|goserelin|leuprolide acetate|low-LET photon therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Radiation\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","flutamide|goserelin|leuprolide","NA"]
["NCT00002892","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Hancock BW, Wheatley K, Harrison G, et al.: Aim high-adjuvant interferon In melanoma (high risk), A United Kingdom Co-Ordinating Committee On Cancer Research (UKCCCR) randomised study of observation versus adjuvant low dose extended duration interferon Alpha-2a In high risk resected malignant melanoma. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1393, 2001.","\tMelanoma (Skin)\trecombinant interferon alfa\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","melanoma","interferon-alpha|interferons","NA"]
["NCT00002893","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12047964|NA|NA|NA|NA|NA|NA|NA|NA|NA|NA","Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, Cohen D, Hopwood P, Johnston C, Stephens RJ; British MRC Colorectal Cancer Working Party. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2002 May 4;359(9317):1555-63.|Maughan T: Continous versus intermittent chemotherapy for advanced colorectal cancer: preliminary results of the MRC CR06b randomised trial. [Abstract] Br J Cancer 85 (suppl 1): A-CT1, 1, 2001.|Maughan TS, James RD, Kerr DJ, et al.: Continous vs intermittant chemotherapy for advanced colorectal cancer: preliminary results of the MRC Cr06b randomised trial. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-498, 2001.|Maughan TS, James RJ, Kerr DJ, et al.: Continous versus intermittent chemotherapy for advanced colorectal cancer: preliminary results of the MRC CR06B randomised trial. [Abstract] Eur J Cancer 37 (suppl 6): A-1001, s271, 2001.|Maughan T, James R, Kerr D, et al.: Excess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5FU regimens in the palliative chemotherapy of advanced colorectal cancer (CRC): final analysis of the MRC CR06. [Abstract] Ann Oncol 11 (suppl 4): A-185o, 43, 2000.|Lederman JA, Maughan TS, James RD, et al.: Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (de Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer. [Abstract] Br J Cancer 80 (suppl 2): A-4.10, 20, 1999.|Maughan TS, James RD, Kerr D, et al.: Preliminary results of a multicentre randomised trial comparing three chemotherapy regimens in metastatic colorectal cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 18: A1007, 1999.|Maughan TS, Robbe IJ, Parsons C: Outcomes regarding patient needs in comparing infusional 5FU regimens versus raltitrexed in a MRC multicenter randomised trial of advanced colorectal cancer. [Abstract] Br J Cancer 80 (suppl 2): A-P112, 56, 1999.|Maughan TS, Stephens RJ, Hopwood P, et al.: The value of quality of life outcomes in comparing 3 chemotherapy regimens (de Gramont. Lokich and Raltitrexed) in a multicentre randomised trial of metastatic colorectal cancer. [Abstract] Br J Cancer 80 (suppl 2): A-P113, 57, 1999.|Maughan TS, Stephens RJ, Hopwood T, et al.: The value of quality of life in comparing 3 chemotherapy regimens (de Gramont, Lokich & Raltitrexed) in a multicentre randomised trial of metastatic colorectal cancer. [Abstract] Br J Cancer 80 (suppl 2): A-P113, 57, 1999.|Stephens RJ, Hopwood P, Johnston C, et al.: The value of quality of life (QL) outcomes in comparing 3 chemotherapy regimens (de Gramont, Lokich, and Raltitrexed) in a multicentre randomised trial of metastatic colorectal cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 18: A2220, 1999.","\tColorectal Cancer\tfluorouracil|leucovorin calcium|raltitrexed\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","fluorouracil|calcium|raltitrexed|levoleucovorin|leucovorin","NA"]
["NCT00002894","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|12826431","Ledermann JA: Randomised trial of paclitaxel in combination with platinum chemotherapy versus platinum-based chemotherapy in the treatment of relapsed ovarian cancer (ICON4/OVAR2.2). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-1794, 446, 2003.|Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C; ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003 Jun 21;361(9375):2099-106.","\tOvarian Cancer|Primary Peritoneal Cavity Cancer\tcarboplatin|cisplatin|paclitaxel\tNA\tNA\tNA\tDrug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","ovarian neoplasms|carcinoma, ovarian epithelial","paclitaxel|carboplatin","NA"]
["NCT00002895","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20888993|NA","Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM; MRC OV05; EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010 Oct 2;376(9747):1155-63. doi: 10.1016/S0140-6736(10)61268-8.|Rustin GJ, van der Burg ME: A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). [Abstract] J Clin Oncol 27 (Suppl 18): A-1, 2009.","\tFallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer\tchemotherapy\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","fallopian tube neoplasms|ovarian neoplasms|carcinoma, ovarian epithelial","NA","NA"]
["NCT00002896","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Cionini L, Cartei F, Manfredi B, et al.: Randomized study of preoperative chemoradiation (CTRT) in locally advanced rectal cancer: preliminary results. [Abstract] Int J Radiat Oncol Biol Phys 45 (3 Suppl): A-61, 178, 1999.","\tColorectal Cancer\tchemotherapy|fluorouracil|leucovorin calcium|conventional surgery|low-LET cobalt-60 gamma ray therapy|low-LET photon therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Procedure|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms|rectal neoplasms","levoleucovorin|leucovorin|fluorouracil|cobalt|calcium","NA"]
["NCT00002897","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","11391598|NA","Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, Zaninotto G, Bonavina L, Peracchia A. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer. 2001 Jun 1;91(11):2165-74.|Ancona E, Ruol A, Santi S, et al.: Major response to neoadjuvant chemotherapy leads to improved long-term survival in potentially resectable (T2-3, any N, M0) esophageal squamous cell carcinoma. Final report of a randomized trial of neoadjuvant chemotherapy versus surgery alone. [Abstract] Proceedings of the European Surgical Association 7th annual meeting, Amsterdam, April 14-15, 2000.","\tEsophageal Cancer\tcisplatin|fluorouracil|conventional surgery\tNA\tNA\tNA\tDrug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","esophageal neoplasms","fluorouracil","NA"]
["NCT00002898","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22665534,"Oberlin O, Rey A, Sanchez de Toledo J, Martelli H, Jenney ME, Scopinaro M, Bergeron C, Merks JH, Bouvet N, Ellershaw C, Kelsey A, Spooner D, Stevens MC. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol. 2012 Jul 10;30(20):2457-65. doi: 10.1200/JCO.2011.40.3287. Epub 2012 Jun 4.","\tChildhood Malignant Fibrous Histiocytoma of Bone|Sarcoma\tdactinomycin|carboplatin|cyclophosphamide|epirubicin hydrochloride|etoposide|ifosfamide|vincristine sulfate|adjuvant therapy|conventional surgery|neoadjuvant therapy|brachytherapy|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure|Procedure|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","sarcoma|histiocytoma, benign fibrous|histiocytoma, malignant fibrous|rhabdomyosarcoma|histiocytoma","epirubicin|dactinomycin|cyclophosphamide|ifosfamide|etoposide|vincristine|carboplatin","NA"]
["NCT00002899","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21041710|21584645|NA","Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Collette S, Collette L, Mueller RP. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011 Jan 10;29(2):134-41. doi: 10.1200/JCO.2010.30.1655. Epub 2010 Nov 1.|Mekhail T, Sombeck M, Sollaccio R. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. Curr Oncol Rep. 2011 Aug;13(4):255-8. doi: 10.1007/s11912-011-0180-1.|Mueller RP, Soffietti R, Abacioglu MU, et al.: Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of 1-3 cerebral metastases: results of the EORTC 22952-26001 study. [Abstract] J Clin Oncol 27 (Suppl 15): A-2008, 2009.","\tMetastatic Cancer\tadjuvant therapy|radiation therapy|stereotactic radiosurgery\tNA\tNA\tNA\tProcedure|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","neoplasm metastasis","NA","NA"]
["NCT00002900","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Ganz PA, Green SJ, Hutchins L, et al.: Late cardiac effects of adjuvant CMF vs CAF in women with node negative breast cancer treated on SWOG 8897: initial results from SWOG 9342. [Abstract] Breast Cancer Res Treat 76 (Suppl 1): A-10, 2002.","\tBreast Cancer|Cardiac Toxicity\tmanagement of therapy complications\tNA\tNA\tNA\tProcedure\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms|cardiotoxicity","NA","NA"]
["NCT00002909","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Carducci M, Bowling MK, Eisenberger M, et al.: Phenylbytyrate (PB) for refractory solid tumors: Phase I evaluation of continuous oral PB exposure. [Abstract] Proc Am Assoc Cancer Res 39: A507, 1998.","\tLymphoma|Unspecified Adult Solid Tumor, Protocol Specific\tchemotherapy|oral sodium phenylbutyrate\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma","4-phenylbutyric acid","NA"]
["NCT00002912","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20209646|NA","O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar S, Buck S, Ravindranath Y, Bernstein M, Weinstein H, Chang MN, Arceci RJ, Sikic BI, Dahl GV. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 May;54(5):694-702. doi: 10.1002/pbc.22366.|Lacayo NJ, Lum BL, Chin DL, et al.: Pharmacokinetics of mitoxantrone in a Phase I Trial of PSC-833 (Valspodar) as an MDR1/Pg-P modulator in acute myeloid leukemia (AML) from the children's oncology group (COG). [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1583, 2002.","\tLeukemia\tetoposide|mitoxantrone hydrochloride|valspodar\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia","etoposide|mitoxantrone","NA"]
["NCT00002914","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12448661,"Roth BJ, Manola J, Dreicer R, Graham D, Wilding G; Eastern Cooperative Oncology Group. Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group. Invest New Drugs. 2002 Nov;20(4):425-9.","\tBladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer\tpiritrexim\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","kidney neoplasms|ureteral neoplasms|urethral neoplasms|carcinoma, transitional cell|urinary bladder neoplasms","piritrexim","NA"]
["NCT00002921","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Shroder LE, Glass T, Eisenberger M, et al.: Phase II evaluation of suramin in advanced adrenal carcinoma: Southwest Oncology Group (SWOG) trial 9427. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-2361, 153b, 2001.","\tAdrenocortical Carcinoma\tsuramin|therapeutic hydrocortisone\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma|adrenocortical carcinoma","hydrocortisone hemisuccinate|hydrocortisone 17-butyrate 21-propionate|suramin|hydrocortisone acetate|hydrocortisone","NA"]
["NCT00002922","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15641479,"Langer CJ, Li Y, Jennings T, DeConti RC, Nair S, Cohen RB, Forastiere AA; Eastern Cooperative Oncology Group. Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group. Cancer Invest. 2004;22(6):823-31.","\tHead and Neck Cancer\tpaclitaxel\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","paclitaxel","NA"]
["NCT00002924","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16299243|12860943|NA|NA","Ross RW, Halabi S, Ou SS, Rajeshkumar BR, Woda BA, Vogelzang NJ, Small EJ, Taplin ME, Kantoff PW; Cancer and Leukemia Group B. Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study. Clin Cancer Res. 2005 Nov 15;11(22):8109-13.|Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ; Cancer and Leukemia Group B Study 9663. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol. 2003 Jul 15;21(14):2673-8.|Taplin ME, Halabi S, Rajeshkumar B, et al.: Androgen receptor mutations in androgen independent prostate cancer (APICA) do not correlate with anti-androgen withdrawal response: Cancer and Leukemia Group B (CALGB) 9663. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1738, 2001.|Taplin ME, Rajeskumar B, Woda BA, et al.: Androgen receptor analyses in androgen independent prostate cancer (AIPCA): Cancer and Leukemia Group B (CALGB) 9663. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A1297, 2000.","\tProstate Cancer\tmutation analysis\tNA\tNA\tNA\tOther\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","NA","NA"]
["NCT00002925","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16670265|NA|16275934|NA|15514371|12750167|NA|NA|11331327|11585760|NA|NA","Radmacher MD, Marcucci G, Ruppert AS, Mrózek K, Whitman SP, Vardiman JW, Paschka P, Vukosavljevic T, Baldus CD, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD; Cancer and Leukemia Group B. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood. 2006 Sep 1;108(5):1677-83. Epub 2006 May 2.|Marcucci G, Baldus CD, Ruppert AS, et al.: Overexpression of the ERG gene is an adverse prognostic factor in acute myeloid leukemia (AML) with normal cytogenetics (NC): a Cancer and Leukemia Group B study (CALGB). [Abstract] Blood 106 (11): A-335, 2005.|Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrózek K, Whitman SP, Kolitz JE, Edwards CG, Vardiman JW, Powell BL, Baer MR, Moore JO, Perrotti D, Caligiuri MA, Carroll AJ, Larson RA, de la Chapelle A, Bloomfield CD. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Dec 20;23(36):9234-42. Epub 2005 Nov 7.|Marcucci G, Radmacher MD, Ruppert AS, et al.: Independent validation of prognostic relevance of a previously reported gene-expression signature in acute myeloid leukemia (AML) with normal cytogenetics (NC): a Cancer and Leukemia Group B (CALGB) study. [Abstract] Blood 106 (11): A-755, 2005.|Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, Velez-Garcia E, Moore JO, Shea TC, Hoke E, Caligiuri MA, Vardiman JW, Bloomfield CD, Larson RA; Cancer and Leukemia Group B. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol. 2004 Nov 1;22(21):4290-301.|Baldus CD, Tanner SM, Ruppert AS, Whitman SP, Archer KJ, Marcucci G, Caligiuri MA, Carroll AJ, Vardiman JW, Powell BL, Allen SL, Moore JO, Larson RA, Kolitz JE, de la Chapelle A, Bloomfield CD. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood. 2003 Sep 1;102(5):1613-8. Epub 2003 May 15.|Kolitz JE, George SL, Barrier R, et al.: Treatment of core binding factor (CBF) acute myeloid leukemia (AML) with post-remission high-dose cytarabine (HiDAC): results from CALGB 9621. [Abstract] Blood 102 (11 Pt 1): A-612, 2003.|Kolitz JE, George SL, Barrier R, et al.: A novel post-remission consolidation regimen for patients with acute myeloid leukemia (AML) < 60 years old with normal or unfavorable cytogenetics: results from CALGB 9621. [Abstract] Blood 102 (11 Pt 1): A-609, 2003.|Mrózek K, Prior TW, Edwards C, Marcucci G, Carroll AJ, Snyder PJ, Koduru PR, Theil KS, Pettenati MJ, Archer KJ, Caligiuri MA, Vardiman JW, Kolitz JE, Larson RA, Bloomfield CD. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 2001 May 1;19(9):2482-92.|Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, Carroll AJ, Mrózek K, Vardiman JW, George SL, Kolitz JE, Larson RA, Bloomfield CD, Caligiuri MA. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001 Oct 1;61(19):7233-9.|Kolitz JE, George SL, Hurd D, et al.: Parallel phase I trials of multi-drug resistance (MDR) modulation with PSC-833 in untreated patients (PTS) with acute myeloid leukemia (AML) less than 60 years old: preliminary results of CALGB 9621. Blood 94(suppl 1): A-1705, 384a, 1999.|Kolitz JE, Georg SL, Hurd D, et al.: Cytogenetic risk-adapted intensification followed by immunotherapy with recombinant interleukin-2 (rIL-2) in patients (PTS) less than 60 years old with acute myeloid leukemia (AML) in first complete remission (CR): preliminary results of CALGB 9621. Blood 94(suppl 1): A-2582, 579a, 1999.","\tLeukemia\tara-C|Daunorubicin|Etoposide|PSC-833|Aldesleukin\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Biological\tAll\t","Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia","Interventional","Completed","Phase 1/Phase 2",2,410,"leukemia","etoposide|daunorubicin|aldesleukin","NA"]
["NCT00002926","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20494931,"de Witte T, Hagemeijer A, Suciu S, Belhabri A, Delforge M, Kobbe G, Selleslag D, Schouten HC, Ferrant A, Biersack H, Amadori S, Muus P, Jansen JH, Hellström-Lindberg E, Kovacsovics T, Wijermans P, Ossenkoppele G, Gratwohl A, Marie JP, Willemze R. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. Haematologica. 2010 Oct;95(10):1754-61. doi: 10.3324/haematol.2009.019182. Epub 2010 May 21.","\tLeukemia|Myelodysplastic Syndromes\tcytarabine|etoposide|idarubicin|allogeneic bone marrow transplantation|peripheral blood stem cell transplantation\tNA\tNA\tNA\tDrug|Drug|Drug|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","leukemia|myelodysplastic syndromes|syndrome|leukemia, myeloid|leukemia, myeloid, acute|preleukemia","cytarabine|etoposide|idarubicin","NA"]
["NCT00002932","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|15735120|NA|NA|NA","Kumar P, Robbins KT, Harris J, et al.: Mature results of Radiation Therapy Oncology Group (RTOG) trial 9615 using intra-arterial cisplatin (IA-P) and concurrent radiation therapy (RT) for stage IV-T4 head/neck (H/N) squamous cell carcinoma (SCCa). [Abstract] J Clin Oncol 23 (Suppl 16): A-5579, 519s, 2005.|Robbins KT, Kumar P, Harris J, McCulloch T, Cmelak A, Sofferman R, Levine P, Weisman R, Wilson W, Weymuller E, Fu K. Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615. J Clin Oncol. 2005 Mar 1;23(7):1447-54.|Kumar P, Robbins KT, Harris J, et al.: Intra-arterial (IA) cisplatin (P) and radiation therapy (RT) is feasible in a multi-institutional setting for the treatment of stage IV-T4 head/neck (H/N) squamous cell carcinoma (SCCa): initial results of Radiation Therapy Oncology Group (RTOG) trial 9615. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-918, 230a, 2001.|Targeted chemoradiation (RTOG 96-15) (RADPLAT) for T4 carcinoma of the upper aerodigestive tract: interim analysis of a multi-institutional trial. [Abstract] Proceedings of the International Conference on Head and Neck Cancer A046, 78, 2000.|Kumar P, Harris J, Robbins KT, et al.: The feasibility of using intra-arterial cisplatin & radiation therapy for stage IV-T4 head/neck squamous cell carcinoma in a multi-institutional setting: preliminary results of Radiation Therapy Oncology Group (RTOG) trial 9615. Int J Radiat Oncol Biol Phys 48(3 suppl): A-81, 152, 2000.","\tHead and Neck Cancer\tcisplatin|radiation therapy\tNA\tNA\tNA\tDrug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","cisplatin","NA"]
["NCT00002934","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19826126|NA","Hughes LL, Wang M, Page DL, Gray R, Solin LJ, Davidson NE, Lowen MA, Ingle JN, Recht A, Wood WC. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009 Nov 10;27(32):5319-24. doi: 10.1200/JCO.2009.21.8560. Epub 2009 Oct 13.|Hughes L, Wang M, Page D, et al.: Five year results of intergroup study E5194: local excision alone (without radiation treatment) for selected patients with ductal carcinoma in situ (DCIS). [Abstract] Breast Cancer Res Treat 100 (Suppl 1): A-29, S15, 2006.","\tBreast Cancer\tlong-term screening\tNA\tNA\tNA\tProcedure\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","NA","NA"]
["NCT00002938","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Sokoloff MH, Halabi S, Sanford B, et al.: Management of recurrent prostate cancer after radiotherapy: preliminary results of CALGB 9687, a contemporary salvage prostatectomy series. [Abstract] American Society of Clinical Oncology 2005 Prostate Cancer Symposium, 17-19 February 2005, Orlando, Florida. A-166, 2005.","\tProstate Cancer\tconventional surgery\tNA\tNA\tNA\tProcedure\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","NA","NA"]
["NCT00002941","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20637881,"Harris RE, Termuhlen AM, Smith LM, Lynch J, Henry MM, Perkins SL, Gross TG, Warkentin P, Vlachos A, Harrison L, Cairo MS. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962. Biol Blood Marrow Transplant. 2011 Feb;17(2):249-58. doi: 10.1016/j.bbmt.2010.07.002. Epub 2010 Jul 15.","\tLymphoma\tcarmustine|cyclophosphamide|etoposide|mesna|peripheral blood stem cell transplantation\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|lymphoma, non-hodgkin","etoposide|carmustine|cyclophosphamide","NA"]
["NCT00002942","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Acostamadiedo J, Case D, Perry J, et al.: Randomized trial of G-CSF primed (G') autologous bone marrow (ABM) vs. G' peripheral blood stem cells (PBSC) as hematopoietic support after high-dose cyclophosphamide (C) thiotepa (T), and carboplatin (CB) (CTCB) in poor prognosis breast cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A215, 56a, 2000.","\tBreast Cancer\tautologous bone marrow transplantation|peripheral blood stem cell transplantation\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer","Interventional","Completed","Phase 3",2,136,"breast neoplasms","NA","NA"]
["NCT00002944","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22665535,"Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, Lazarus KH, Packer RJ, Prados M, Sposto R, Vezina G, Wisoff JH, Pollack IF. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jul 20;30(21):2641-7. doi: 10.1200/JCO.2011.36.6054. Epub 2012 Jun 4.","\tBrain Tumors|Central Nervous System Tumors\tcarboplatin|lomustine|procarbazine hydrochloride|thioguanine|vincristine sulfate\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug\tAll\t","Combination Chemotherapy in Treating Children With Progressive Brain Tumors","Interventional","Completed","Phase 3",2,428,"neoplasms|nervous system neoplasms|astrocytoma|central nervous system neoplasms|brain neoplasms","carboplatin|thioguanine|lomustine|procarbazine|vincristine","NA"]
["NCT00002951","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16849759,"Cohen EE, Haraf DJ, List MA, Kocherginsky M, Mittal BB, Rosen F, Brockstein B, Williams R, Witt ME, Stenson KM, Kies MS, Vokes EE. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol. 2006 Jul 20;24(21):3438-44.","\tEsophageal Cancer|Head and Neck Cancer\tfluorouracil|hydroxyurea|surgical procedure|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms|esophageal neoplasms","fluorouracil|hydroxyurea","NA"]
["NCT00002953","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16293863|NA|NA","Langley RE, Carmichael J, Jones AL, Cameron DA, Qian W, Uscinska B, Howell A, Parmar M. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. J Clin Oncol. 2005 Nov 20;23(33):8322-30.|Carmichael J: UKCCCR trial of epirubicin and cyclophosphamide (EC) vs. epirubicin and taxol (ET) in the first line treatment of women with metastatic breast cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-84, 2001.|Carmichael J: UKCCCR trial of epirubucin and cyclophosphamide (EC) versus epirubicin and taxol (ET) in the first line treatment of women with metastatic breast cancer (MBC). [Abstract] Br J Cancer 85 (suppl 1): A-CT6, 2, 2001.","\tBreast Cancer\tcyclophosphamide|epirubicin hydrochloride|paclitaxel\tNA\tNA\tNA\tDrug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","cyclophosphamide|epirubicin|paclitaxel","NA"]
["NCT00002955","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Garcia AA, Leichman L, Baranda J, et al.: Phase II study of trimetrexate (neutrexin), 5-fluorouracil and leucovorin (NFL) in advacne pancreatic. [Abstract] Proceedings of the American Society of Clinical Oncology 18: A971, 253a, 1999.","\tPancreatic Cancer\tfluorouracil|leucovorin calcium|trimetrexate glucuronate\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","pancreatic neoplasms","fluorouracil|levoleucovorin|calcium|leucovorin|trimetrexate","NA"]
["NCT00002960","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12082456|12082455","Buller RE, Shahin MS, Horowitz JA, Runnebaum IB, Mahavni V, Petrauskas S, Kreienberg R, Karlan B, Slamon D, Pegram M. Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Ther. 2002 Jul;9(7):567-72.|Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 2002 Jul;9(7):553-66.","\tFallopian Tube Cancer|Metastatic Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer\trecombinant adenovirus-p53 SCH-58500\tNA\tNA\tNA\tBiological\tFemale\t","NA","NA","NA","NA","NA","NA","fallopian tube neoplasms","NA","NA"]
["NCT00002969","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15860488|NA|NA","West HL, Crowley JJ, Vance RB, Franklin WA, Livingston RB, Dakhil SR, Giguere JK, Rivkin SE, Kraut M, Chansky K, Gandara DR; Southwest Oncology Group. Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study. Ann Oncol. 2005 Jul;16(7):1076-80. Epub 2005 Apr 28.|Franklin WA, Gumerlock PH, Crowley J, et al.: EGFR, HER2 and ERB-B pathway activation in bronchioloalveolar carcinoma (BAC): analysis of SWOG 9417 and lung SPORE tissue samples. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2493, 2003.|Vance RB, Crowly JJ, Livingston RB, et al.: A phase II Southwest Oncology Group trial (S9714) utilizing paclitaxel by 96-hour infusion in stage IIIb and IV bronchioloalveolar carcinoma of the lung (BAC). [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1340, 336a, 2001.","\tLung Cancer\tpaclitaxel\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms","paclitaxel","NA"]
["NCT00002972","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16019107,"Scagliotti GV, Smit E, Bosquee L, O'Brien M, Ardizzoni A, Zatloukal P, Eberhardt W, Smid-Geirnaerdt M, de Bruin HG, Dussenne S, Legrand C, Giaccone G; European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group (LCG). A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung Cancer. 2005 Oct;50(1):91-6.","\tLung Cancer\tpaclitaxel\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms","paclitaxel","NA"]
["NCT00002976","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16446331,"Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS; Gynecologic Oncology Group Study. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2006 Feb 1;24(4):587-92.","\tEndometrial Cancer\tconjugated estrogens\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","endometrial neoplasms","estrogens, conjugated (usp)|estrogens","NA"]
["NCT00002987","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Radford JA, Williams MV, Hancock BW, et al.: Minimal initial chemotherapy plus involved field radiotherapy (RT) vs. mantle field RT for clinical stage IA/IIA supra-diaphragmatic Hodgkin's disease (HD). Results of the UK Lymphoma Group LY07 trial. [Abstract] Eur J Haematol 73 (Suppl 65): A-E08, 39, 2004.","\tLymphoma\tbleomycin sulfate|cyclophosphamide|doxorubicin hydrochloride|etoposide|prednisolone|vincristine sulfate|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","hodgkin disease|lymphoma","vincristine|bleomycin|doxorubicin|prednisolone|etoposide|cyclophosphamide|liposomal doxorubicin","NA"]
["NCT00002993","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12051882,"Edmonson JH, Blessing JA, Cosin JA, Miller DS, Cohn DE, Rotmensch J. Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2002 Jun;85(3):507-10.","\tSarcoma\tcisplatin|doxorubicin hydrochloride|mitomycin C\tNA\tNA\tNA\tDrug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","sarcoma","liposomal doxorubicin|doxorubicin|mitomycin|mitomycins","NA"]
["NCT00002994","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12473581|NA","Fleming GF, Meropol NJ, Rosner GL, Hollis DR, Carson WE 3rd, Caligiuri M, Mortimer J, Tkaczuk K, Parihar R, Schilsky RL, Ratain MJ. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec;8(12):3718-27. Erratum in: Clin Cancer Res. 2003 Apr;9(4):1573.|Fleming GF, Meropol NJ, Hollis DR, et al.: Phase I trial of recombinant human anti-Her2 monoclonal antibody (H) plus low-dose interleukin-2 (IL-2) in patients with solid tumors. [Abstract] Proceedings of the American Society of Clinical Oncology 17: A710, 1999.","\tUnspecified Adult Solid Tumor, Protocol Specific\tinterleukin 2|rhuMAb\tNA\tNA\tNA\tBiological|Biological\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","interleukin-2","NA"]
["NCT00002995","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22104356|21357783","Breneman J, Meza J, Donaldson SS, Raney RB, Wolden S, Michalski J, Laurie F, Rodeberg DA, Meyer W, Walterhouse D, Hawkins DS. Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study. Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):720-6. doi: 10.1016/j.ijrobp.2011.06.2011. Epub 2011 Nov 19.|Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. doi: 10.1200/JCO.2010.30.4469. Epub 2011 Feb 28.","\tSarcoma\tdactinomycin|filgrastim|sargramostim|cyclophosphamide|vincristine sulfate|radiation therapy\tNA\tNA\tNA\tBiological|Biological|Biological|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","rhabdomyosarcoma|sarcoma","sargramostim|cyclophosphamide|vincristine|dactinomycin","NA"]
["NCT00002996","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18073252,"von Gunten CF, Eappen S, Cleary JF, Taylor SG 4th, Moots P, Regevik N, Cleeland C, Cella D. Flecainide for the treatment of chronic neuropathic pain: a Phase II trial. Palliat Med. 2007 Dec;21(8):667-72.","\tPain\tflecainide acetate\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","neuralgia","flecainide","NA"]
["NCT00002998","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15803016,"Burch PA, Mailliard JA, Hillman DW, Perez EA, Krook JE, Rowland KM, Veeder MH, Cannon MW, Ingle JN. Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial. Am J Clin Oncol. 2005 Apr;28(2):195-200.","\tBreast Cancer\tcisplatin|gemcitabine hydrochloride\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","breast neoplasms","gemcitabine","NA"]
["NCT00003006","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|15829324|NA|14654545|11882819","Maddaus MA, Wang X, Vollmer RT, et al.: CALGB 9761: a prospective analysis of IHC and PCR based detection of occult metastatic disease in stage I NSCLC. [Abstract] J Clin Oncol 24 (Suppl 18): A-7030, 371s, 2006.|D'Cunha J, Herndon JE 2nd, Herzan DL, Patterson GA, Kohman LJ, Harpole DH, Kernstine KH, Kern JA, Green MR, Maddaus MA, Kratzke RA; Cancer and Leukemia Group B. Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial. Lung Cancer. 2005 May;48(2):241-6. Epub 2005 Jan 4.|D'Cunha J, Herndon JL, Herzan DL, et al.: Poor correlation between clinical and pathological staging in stage I non-small cell lung cancer: results from CALGB 9761, a prospective trial. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2550, 634, 2003.|Vollmer RT, Herndon JE 2nd, D'Cunha J, Abraham NZ, Solberg J, Fatourechi M, Maruska A, Kern JA, Green MR, Kratzke RA, Maddaus MA; Cancer and Leukemia Group B Trial 9761. Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B Trial 9761. Clin Cancer Res. 2003 Nov 15;9(15):5630-5.|D'Cunha J, Corfits AL, Herndon JE 2nd, Kern JA, Kohman LJ, Patterson GA, Kratzke RA, Maddaus MA. Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761. J Thorac Cardiovasc Surg. 2002 Mar;123(3):484-91; discussion 491.","\tLung Cancer\treverse transcriptase-polymerase chain reaction|immunohistochemistry staining method\tNA\tNA\tNA\tGenetic|Other\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms","NA","NA"]
["NCT00003007","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Jones CM: Myeloablative therapy with interferon maintenance in multiple myeloma: high response rates and correlation with IL-6 and IL-6sR. J Investig Med 46(1): 12A 1998.","\tMultiple Myeloma and Plasma Cell Neoplasm\trecombinant interferon alfa|sargramostim|cyclophosphamide|dexamethasone|melphalan|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","plasmacytoma|multiple myeloma|neoplasms, plasma cell","interferons|sargramostim|dexamethasone|cyclophosphamide|melphalan|interferon-alpha","NA"]
["NCT00003010","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16595036|15570070|NA","Zucker S, Wang M, Sparano JA, Gradishar WJ, Ingle JN, Davidson NE; Eastern Cooperative Oncology Group. Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196. Clin Breast Cancer. 2006 Feb;6(6):525-9.|Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol. 2004 Dec 1;22(23):4683-90. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.|Sparano JA, Bernardo P, Gradishar WJ, et al.: Higher trough marimastat levels are associated with accelerated disease progression and worse survival: results of a randomized phase III trial comparing marimastat with placebo in metastatic breast cancer (MBC) after first-line chemotherapy: an Eastern Cooperative Oncology Group trial (E2196). [Abstract] Breast Cancer Res Treat 76(Suppl 1): A-343, 2002.","\tBreast Cancer\tmarimastat\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","marimastat","NA"]
["NCT00003011","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12431965|NA","Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Sadura A, Zee B. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol. 2002 Nov 15;20(22):4434-9.|Shepherd FA, Giaccone G, Debruyne C, et al.: Randomizd double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy: an NCIC-CTG and EORTC study. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-11, 4a, 2001.","\tLung Cancer\tmarimastat|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer","Interventional","Completed","Phase 3",2,555,"lung neoplasms|small cell lung carcinoma","marimastat","NA"]
["NCT00003012","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18768436,"Bartlett JM, Munro A, Cameron DA, Thomas J, Prescott R, Twelves CJ. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol. 2008 Nov 1;26(31):5027-35. doi: 10.1200/JCO.2007.14.6597. Epub 2008 Sep 2.","\tBreast Cancer\tCMF regimen|cyclophosphamide|epirubicin hydrochloride|fluorouracil|methotrexate\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","fluorouracil|epirubicin|methotrexate|cyclophosphamide","NA"]
["NCT00003013","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19332727,"Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Cussac AL, Bozhok A, Martinez-Agulló A, Greco M, Byakhov M, Lopez JJ, Mansutti M, Valagussa P, Bonadonna G. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol. 2009 May 20;27(15):2474-81. doi: 10.1200/JCO.2008.19.2567. Epub 2009 Mar 30.","\tBreast Cancer\tCMF regimen|cyclophosphamide|doxorubicin hydrochloride|fluorouracil|methotrexate|paclitaxel|tamoxifen citrate|conventional surgery|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Radiation\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","fluorouracil|paclitaxel|cyclophosphamide|tamoxifen|doxorubicin|methotrexate|liposomal doxorubicin","NA"]
["NCT00003014","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16039331|NA|21282539|NA","Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, de Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP; MRC TE19 collaborators and the EORTC 30982 collaborators. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005 Jul 23-29;366(9482):293-300.|Oliver RT, Mason M, Von der Masse H, et al.: A randomised comparison of single agent carboplatin with radiotherapy in the adjuvant treatment of stage I seminoma of the testis, following orchidectomy: MRC TE19/EORTC 30982. [Abstract] J Clin Oncol 22 (Suppl 14): A-4517, 386, 2004.|Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P, Stenning SP. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol. 2011 Mar 10;29(8):957-62. doi: 10.1200/JCO.2009.26.4655. Epub 2011 Jan 31.|Oliver RT, Mead GM, Fogarty PJ, et al.: Radiotherapy versus carboplatin for stage I seminoma: updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214). [Abstract] J Clin Oncol 26 (Suppl 15): A-1, 2008.","\tTesticular Germ Cell Tumor\tcarboplatin|radiation therapy\tNA\tNA\tNA\tDrug|Radiation\tMale\t","NA","NA","NA","NA","NA","NA","seminoma|neoplasms, germ cell and embryonal","carboplatin","NA"]
["NCT00003015","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Gnekow AK, Perilongo G, Zanetti I, et al.: Single dose carboplatin and vincristine (VER) for progressive low-grade glioma (LGG) in childhood. A SIOP/GPOH study. [Abstract] International Symposium on Pediatric Neuro-Oncology, May 18-21, 1994, Houston, Tx. A-89, 1999.","\tBrain and Central Nervous System Tumors\tcarboplatin|vincristine sulfate|conventional surgery|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|nervous system neoplasms|glioma","carboplatin|vincristine","NA"]
["NCT00003017","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14984966,"Wadler S, Levy D, Frederickson HL, Falkson CI, Wang Y, Weller E, Burk R, Ho G, Kadish AS; Eastern Cooperative Oncology Group. A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. Gynecol Oncol. 2004 Mar;92(3):957-64.","\tCervical Cancer\trecombinant interleukin-12\tNA\tNA\tNA\tBiological\tFemale\t","NA","NA","NA","NA","NA","NA","uterine cervical neoplasms","interleukin-12","NA"]
["NCT00003018","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17470859|NA","Isacoff WH, Bendetti JK, Barstis JJ, Jazieh AR, Macdonald JS, Philip PA. Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. J Clin Oncol. 2007 May 1;25(13):1665-9.|Isacoff WH, Benedetti J, MacDonald JS, et al.: Continuous infusion (CI) 5 fluorouracil (5FU), leucovorin (LV), mitomycin C (Mito C) and dipyridamole (D) in patients with locally advanced unresectable pancreatic adenocarcinoma - a phase II trial of the Southwest Oncology Group. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-544, 2002.","\tPancreatic Cancer\tdipyridamole|fluorouracil|leucovorin calcium|mitomycin C\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","pancreatic neoplasms","levoleucovorin|fluorouracil|mitomycins|mitomycin|dipyridamole|leucovorin|calcium","NA"]
["NCT00003019","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17290057,"Skapek SX, Ferguson WS, Granowetter L, Devidas M, Perez-Atayde AR, Dehner LP, Hoffer FA, Speights R, Gebhardt MC, Dahl GV, Grier HE; Pediatric Oncology Group. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol. 2007 Feb 10;25(5):501-6.","\tDesmoid Tumor\tmethotrexate|vinblastine sulfate\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","fibromatosis, aggressive","methotrexate|vinblastine","NA"]
["NCT00003022","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18048828,"Kramer K, Humm JL, Souweidane MM, Zanzonico PB, Dunkel IJ, Gerald WL, Khakoo Y, Yeh SD, Yeung HW, Finn RD, Wolden SL, Larson SM, Cheung NK. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol. 2007 Dec 1;25(34):5465-70.","\tBrain and Central Nervous System Tumors|Intraocular Melanoma|Lung Cancer|Melanoma (Skin)|Neuroblastoma|Retinoblastoma|Sarcoma\tiodine I 131 monoclonal antibody 3F8\tNA\tNA\tNA\tRadiation\tAll\t","NA","NA","NA","NA","NA","NA","neuroblastoma|melanoma|central nervous system neoplasms|sarcoma|nervous system neoplasms|lung neoplasms|retinoblastoma","antibodies, monoclonal|antibodies","NA"]
["NCT00003025","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Maki RG, Lewis JJ, Janetzki S, et al.: Phase I study of HSPPC-96 (oncophage®) vaccine in patients with completely resected pancreatic adenocarcinoma. [Abstract] European Journal of Cancer Supplements 1 (5): A-48, S19, 2003.","\tPancreatic Cancer\tvitespen\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","pancreatic neoplasms","NA","NA"]
["NCT00003026","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19516032|NA|NA","Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Piérart M, Mauer ME, Collette L; EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009 Jun 11;360(24):2516-27. doi: 10.1056/NEJMoa0810095.|Bolla M, van Tienhoven G, de Reijke TM, et al.: Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT--results of the randomized EORTC phase III trial 22961. [Abstract] J Clin Oncol 25 (Suppl 18): A-5014, 238s, 2007.|Giraud JY, Dusserre A, Conil M, et al.: Results of the dummy-run of EORTC trial no.22961: a phase III study of long term hormonal treatment on locally advanced prostatic carcinoma treated by radiation therapy and a 6 months CAB. [Abstract] Int J Radiat Oncol Biol Phys 51(3 suppl 1): A-699, 378, 2001.","\tProstate Cancer\tbicalutamide|flutamide|triptorelin|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","bicalutamide|flutamide|triptorelin pamoate","NA"]
["NCT00003027","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19001327|NA","Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM; Eastern Cooperative Oncology Group. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008 Dec 10;26(35):5748-54. doi: 10.1200/JCO.2008.17.5448. Epub 2008 Nov 10.|Atkins MB, Lee S, Flaherty LE: A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2847, 2003.","\tMelanoma (Skin)\taldesleukin|filgrastim|recombinant interferon alfa|cisplatin|dacarbazine|vinblastine\tNA\tNA\tNA\tBiological|Biological|Biological|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","melanoma","vinblastine|aldesleukin|interferons|dacarbazine|interferon-alpha","NA"]
["NCT00003032","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18025439|NA","Crump M, Gluck S, Tu D, Stewart D, Levine M, Kirkbride P, Dancey J, O'Reilly S, Shore T, Couban S, Girouard C, Marlin S, Shepherd L, Pritchard KI. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol. 2008 Jan 1;26(1):37-43. Epub 2007 Nov 19.|Dancey J, Crump M, Gluck S, et al.: Quality of life (QOL) analysis of a randomized trial of high-dose chemotherapy (HDCT) with peripheral stem cell transplant (PSCT) versus standard chemotherapy (SCT) in women with metastatic breast cancer (MBC): National Cancer Institute of Canada Clinical Trials Group study (NCIC CTG) MA-16 . [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-3010, 749, 2003.","\tBreast Cancer\tfilgrastim|cisplatin|cyclophosphamide|mitoxantrone hydrochloride|tamoxifen citrate\tParallel Assignment\tTreatment\tRandomized\tBiological|Drug|Drug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","cyclophosphamide|mitoxantrone|tamoxifen","NA"]
["NCT00003040","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17938330,"Agrawal A, Moon J, Davis RK, Sakr WA, Giri SP, Valentino J, LeBlanc M, Truelson JM, Yoo GH, Ensley JF, Schuller DE; Southwest Oncology Group. Transoral carbon dioxide laser supraglottic laryngectomy and irradiation in stage I, II, and III squamous cell carcinoma of the supraglottic larynx: report of Southwest Oncology Group Phase 2 Trial S9709. Arch Otolaryngol Head Neck Surg. 2007 Oct;133(10):1044-50.","\tHead and Neck Cancer\tlaser surgery|radiation therapy\tNA\tNA\tNA\tProcedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","NA","NA"]
["NCT00003046","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Lenzi R, Kudelka AP, Veschraegen C, et al.: Intraperitoneal (IP) bioimmunologic responses in patients with ovarian and gastrointestinal cancers at a low toxicity dosing schedule of IP recombinant interleukin-12 (rhIL-12). [Abstract] Proc Am Assoc Cancer Res 40: A3778, 573, 1999.","\tAnal Cancer|Colorectal Cancer|Gallbladder Cancer|Gastric Cancer|Pancreatic Cancer\tRecombinant Interleukin-12\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","pancreatic neoplasms|anus neoplasms|stomach neoplasms|gallbladder neoplasms|colorectal neoplasms","interleukin-12","NA"]
["NCT00003050","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20878462|12610186|10210538","Adams S, Chakravarthy AB, Donach M, Spicer D, Lymberis S, Singh B, Bauer JA, Hochman T, Goldberg JD, Muggia F, Schneider RJ, Pietenpol JA, Formenti SC. Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. Breast Cancer Res Treat. 2010 Dec;124(3):723-32. doi: 10.1007/s10549-010-1181-8. Epub 2010 Sep 29.|Formenti SC, Volm M, Skinner KA, Spicer D, Cohen D, Perez E, Bettini AC, Groshen S, Gee C, Florentine B, Press M, Danenberg P, Muggia F. Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. J Clin Oncol. 2003 Mar 1;21(5):864-70.|Formenti SC, Symmans WF, Volm M, Skinner K, Cohen D, Spicer D, Danenberg PV. Concurrent paclitaxel and radiation therapy for breast cancer. Semin Radiat Oncol. 1999 Apr;9(2 Suppl 1):34-42.","\tBreast Cancer\tcyclophosphamide|doxorubicin hydrochloride|paclitaxel|tamoxifen citrate|surgical procedure|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","breast neoplasms","liposomal doxorubicin|tamoxifen|doxorubicin|paclitaxel|cyclophosphamide","NA"]
["NCT00003052","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20434400|NA|NA","Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, Abdel-Rahman S, Daugaard S, Salat C, Wendtner CM, Vujaskovic Z, Wessalowski R, Jauch KW, Dürr HR, Ploner F, Baur-Melnyk A, Mansmann U, Hiddemann W, Blay JY, Hohenberger P; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG); European Society for Hyperthermic Oncology (ESHO). Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010 Jun;11(6):561-70. doi: 10.1016/S1470-2045(10)70071-1. Epub 2010 Apr 29.|Issels RD, Lindner LH, Wust P, et al.: Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: a phase III randomised pros. [Abstract] J Clin Oncol 25 (Suppl 18): A-10009, 547s, 2007.|Lindner LH, Schlemmer M, Hohenberger P, et al.: Risk assessment of early progression among 213 pts with high-risk soft tissue sarcomas (HR-STS) treated with neoadjuvant chemotherapy regional hyperthermia: EORTC 62961/ESHO-RHT 95 intergroup phase III study. [Abstract] J Clin Oncol 23 (Suppl 16): A-9020, 821s, 2005.","\tSarcoma\tdoxorubicin hydrochloride|etoposide|ifosfamide|conventional surgery|hyperthermia treatment|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Procedure|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","fever|sarcoma","etoposide|ifosfamide|doxorubicin|liposomal doxorubicin","NA"]
["NCT00003054","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12694653,"Gallup DG, Blessing JA, Andersen W, Morgan MA; Gynecologic Oncology Group Study. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2003 Apr;89(1):48-51.","\tSarcoma\tpaclitaxel\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","sarcoma|leiomyosarcoma","paclitaxel","NA"]
["NCT00003058","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","10097144|NA","Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6.|Demetri GD, Spiegelman B, Fletcher CD, et al.: Differentiation of liposarcomas in patients treated with the PPAR g ligand troglitazone: documentation of biologic activity in myxoid/round cell and pleomorphic subtypes. [Abstract] Proceedings of the American Society of Clinical Oncology 18: A2064, 535a, 1999.","\tSarcoma\ttroglitazone\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","sarcoma|liposarcoma","troglitazone","NA"]
["NCT00003061","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","14981168|14597741|NA","Harder H, Holtel H, Bromberg JE, Poortmans P, Haaxma-Reiche H, Kluin-Nelemans HC, Menten J, van den Bent MJ. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology. 2004 Feb 24;62(4):544-7.|Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, Van't Veer M, Hansen M, Soubeyran P, Taphoorn M, Thomas J, Van den Bent M, Fickers M, Van Imhoff G, Rozewicz C, Teodorovic I, van Glabbeke M; European Organization for Research and Treatment of Cancer Lymphoma Group. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol. 2003 Dec 15;21(24):4483-8. Epub 2003 Nov 3.|Kluin-Nelemans JC, Poortmans P, Haaxma-Reicher H, et al.: Final results of the EORTC phase II trial 20962 evaluating high-dose MTX-based chemotherapy followed by consolidating radiotherapy in non-Aids related primary central nervous system lymphoma. [Abstract] Blood 100 (11 pt 1): A-3071, 776a, 2002.","\tLymphoma\tcytarabine|methotrexate|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma","cytarabine|methotrexate","NA"]
["NCT00003062","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12763216,"Dziadziuszko R, Ardizzoni A, Postmus PE, Smit EF, Price A, Debruyne C, Legrand C, Giaccone G; EORTC Lung Cancer Group. Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer. 2003 Jun;39(9):1271-6.","\tLung Cancer\ttemozolomide\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|carcinoma, non-small-cell lung","temozolomide","NA"]
["NCT00003065","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14766258,"Tiersten AD, Selleck MJ, Hershman DL, Smith D, Resnik EE, Troxel AB, Brafman LB, Shriberg L. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol Oncol. 2004 Feb;92(2):635-8.","\tCervical Cancer\tfilgrastim|paclitaxel|topotecan hydrochloride\tNA\tNA\tNA\tBiological|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","uterine cervical neoplasms|neoplasm metastasis","topotecan|paclitaxel","NA"]
["NCT00003067","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",8625188,"Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN, Ransohoff J. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer. 1995 Sep 1;76(5):840-52.","\tBrain and Central Nervous System Tumors\taldesleukin|lymphokine-activated killer cells\tNA\tNA\tNA\tBiological|Biological\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|glioma|nervous system neoplasms","aldesleukin","NA"]
["NCT00003077","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15241836,"Burns CP, Halabi S, Clamon G, Kaplan E, Hohl RJ, Atkins JN, Schwartz MA, Wagner BA, Paskett E. Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. Cancer. 2004 Jul 15;101(2):370-8.","\tLeukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm\tomega-3 fatty acid\tNA\tNA\tNA\tDietary Supplement\tAll\t","NA","NA","NA","NA","NA","NA","plasmacytoma|neoplasms, plasma cell|multiple myeloma","NA","NA"]
["NCT00003078","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20044066|16815535|16230678|9869224","Waggoner SE, Darcy KM, Tian C, Lanciano R. Smoking behavior in women with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Am J Obstet Gynecol. 2010 Mar;202(3):283.e1-7. doi: 10.1016/j.ajog.2009.10.884. Epub 2009 Dec 30.|Waggoner SE, Darcy KM, Fuhrman B, Parham G, Lucci J 3rd, Monk BJ, Moore DH; Gynecologic Oncology Group. Association between cigarette smoking and prognosis in locally advanced cervical carcinoma treated with chemoradiation: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Dec;103(3):853-8. Epub 2006 Jul 3.|Lanciano R, Calkins A, Bundy BN, Parham G, Lucci JA 3rd, Moore DH, Monk BJ, O'Connor DM. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. J Clin Oncol. 2005 Nov 20;23(33):8289-95. Epub 2005 Oct 17.|Varia MA, Bundy BN, Deppe G, Mannel R, Averette HE, Rose PG, Connelly P. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):1015-23.","\tCervical Cancer\tcisplatin|fluorouracil|brachytherapy|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Radiation|Radiation\tFemale\t","NA","NA","NA","NA","NA","NA","uterine cervical neoplasms","fluorouracil","NA"]
["NCT00003081","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",10797354,"Hawkins D, Barnett T, Bensinger W, Gooley T, Sanders J. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors. Med Pediatr Oncol. 2000 May;34(5):328-37.","\tSarcoma\tfilgrastim|busulfan|melphalan|thiotepa|peripheral blood stem cell transplantation|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","sarcoma|neuroectodermal tumors|neuroectodermal tumors, primitive|neuroectodermal tumors, primitive, peripheral|sarcoma, ewing|rhabdomyosarcoma","melphalan|thiotepa|busulfan","NA"]
["NCT00003084","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12610188,"Millikan R, Thall PF, Lee SJ, Jones D, Cannon MW, Kuebler JP, Wade J 3rd, Logothetis CJ. Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol. 2003 Mar 1;21(5):878-83.","\tProstate Cancer\tDoxorubicin Hydrochloride|Estramustine phosphate sodium|Etoposide|Ketoconazole|Paclitaxel|Vinblastine\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug\tMale\t","Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer","Interventional","Completed","Phase 2",2,75,"prostatic neoplasms","ketoconazole|etoposide|vinblastine|estramustine|liposomal doxorubicin|paclitaxel|doxorubicin","NA"]
["NCT00003087","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12167786|NA","Bains MS, Stojadinovic A, Minsky B, Rusch V, Turnbull A, Korst R, Ginsberg R, Kelsen DP, Ilson DH. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J Thorac Cardiovasc Surg. 2002 Aug;124(2):270-7.|Enzinger E, Ilson D, Minsky B, et al.: Phase I/II neoadjuvant concurrent 96 hour taxol, cisplatin, and radiation therapy: promising toxicity profile and response in localized esophageal cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 18: A1038, 1999.","\tEsophageal Cancer\tcisplatin|paclitaxel|surgical procedure|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","esophageal neoplasms","paclitaxel|cisplatin","NA"]
["NCT00003088","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|15743513|NA|15668278|12668651|NA","Citron ML, Berry DA, Cirrincione C, et al.: Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD treatment: update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG. [Abstract] J Clin Oncol 23 (Suppl 16): A-620, 33s, 2005.|Fornier M, Norton L. Dose-dense adjuvant chemotherapy for primary breast cancer. Breast Cancer Res. 2005;7(2):64-9. Epub 2005 Feb 10.|Hudis C, Citron M, Berry D, et al.: Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-41, 2005.|Schwartz J, Domchek SM, Hwang WT, Fox K. Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer. Ann Oncol. 2005 Feb;16(2):247-52.|Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15;21(8):1431-9. Epub 2003 Feb 13. Erratum in: J Clin Oncol. 2003 Jun 1;21(11):2226.|Citron M, Berry D, Cirrincione C, et al.: Superiority of dose-dense (DD) over conventional scheduling (CS) and equivalence of sequential (SC) vs. combination adjuvant chemotherapy (CC) for node-positive breast cancer (CALGB 9741, INT C9741). [Abstract] Breast Cancer Res Treat 76 (Suppl 1): A-15, 2002.","\tBreast Cancer\tcyclophosphamide|doxorubicin hydrochloride|paclitaxel\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tFemale\t","Combination Chemotherapy in Treating Patients With Breast Cancer","Interventional","Completed","Phase 3",4,2005,"breast neoplasms","cyclophosphamide|paclitaxel|doxorubicin|liposomal doxorubicin","NA"]
["NCT00003091","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16706633,"Dillman RO, Wiemann MC, Tai DF, Depriest CB, Soori G, Stark JJ, Mahdavi K, Church CK. Phase II trial of subcutaneous interferon followed by intravenous hybrid bolus/continuous infusion interleukin-2 in the treatment of renal cell carcinoma: final results of Cancer Biotherapy Research Group 95-09. Cancer Biother Radiopharm. 2006 Apr;21(2):130-7.","\tKidney Cancer|Melanoma (Skin)\taldesleukin|recombinant interferon alfa\tNA\tNA\tNA\tBiological|Biological\tAll\t","NA","NA","NA","NA","NA","NA","melanoma|kidney neoplasms|carcinoma, renal cell","aldesleukin|interferons|interferon-alpha","NA"]
["NCT00003092","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16567769|NA","Lichtman SM, Hollis D, Miller AA, Rosner GL, Rhoades CA, Lester EP, Millard F, Byrd J, Cullinan SA, Rosen DM, Parise RA, Ratain MJ, Egorin MJ; Cancer and Leukemia Group B (CALGB 9762). Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol. 2006 Apr 20;24(12):1846-51. Epub 2006 Mar 27.|Lichtman SM, Egorin M, Rosner G, et al.: Clinical pharmacology of paclitaxel in relation to patient age: CALGB 9762. [Abstract] Proceedings of the American Society of Clinical Oncology 18: A732, 1999.","\tUnspecified Adult Solid Tumor, Protocol Specific\tpaclitaxel\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","NA","paclitaxel","NA"]
["NCT00003093","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20879880|NA","Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK; Children's Oncology Group. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010 Sep 30;363(14):1313-23. doi: 10.1056/NEJMoa1001527.|Baker DL, Schmidt M, Cohn S, et al.: A phase III trial of biologically-based therapy reduction for intermediate risk neuroblastoma. [Abstract] J Clin Oncol 25 (Suppl 18): A-9504, 2007.","\tNeuroblastoma\tfilgrastim|sargramostim|carboplatin|cyclophosphamide|doxorubicin hydrochloride|etoposide|conventional surgery|neoadjuvant therapy\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug|Drug|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","neuroblastoma","molgramostim|lenograstim|sargramostim|liposomal doxorubicin|doxorubicin|carboplatin|etoposide|cyclophosphamide","NA"]
["NCT00003097","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|NA|7622291|NA|8145782","Black HS, Wolf JE: Protective influence of a low-fat diet on non-melanoma skin cancer. Dermatologic Therapy: Phototherapy and Photoprotective Therapy 4: 100-105, 1997.|Black HS, Wolf JE: A low-fat diet can reduce skin cancer risk. Primary Care and Cancer 15: 12-13, 1996.|Black HS: Low-fat diet impedes the development of actinic keratosis. Biomedical Pharmacotherapy 49: 46-47, 1995.|Black HS, Thornby JI, Wolf JE Jr, Goldberg LH, Herd JA, Rosen T, Bruce S, Tschen JA, Scott LW, Jaax S, et al. Evidence that a low-fat diet reduces the occurrence of non-melanoma skin cancer. Int J Cancer. 1995 Jul 17;62(2):165-9.|Black HS, Wolk JE Jr: A low-fat diet can reduce skin cancer risk. Skin Cancer Foundation Journal 13: 37/98, 1995.|Black HS, Herd JA, Goldberg LH, Wolf JE Jr, Thornby JI, Rosen T, Bruce S, Tschen JA, Foreyt JP, Scott LW, et al. Effect of a low-fat diet on the incidence of actinic keratosis. N Engl J Med. 1994 May 5;330(18):1272-5.","\tNon-Melanomatous Skin Cancer\tpreventative dietary intervention\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","skin neoplasms","NA","NA"]
["NCT00003105","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19636012,"Milowsky MI, Nanus DM, Maluf FC, Mironov S, Shi W, Iasonos A, Riches J, Regazzi A, Bajorin DF. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol. 2009 Sep 1;27(25):4062-7. doi: 10.1200/JCO.2008.21.2241. Epub 2009 Jul 27.","\tBladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter\tfilgrastim|cisplatin|doxorubicin hydrochloride|gemcitabine hydrochloride|ifosfamide|paclitaxel\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","kidney neoplasms|ureteral neoplasms|urinary bladder neoplasms|carcinoma, transitional cell","liposomal doxorubicin|ifosfamide|paclitaxel|gemcitabine|doxorubicin","NA"]
["NCT00003117","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15625373|NA","Lilenbaum RC, Herndon JE 2nd, List MA, Desch C, Watson DM, Miller AA, Graziano SL, Perry MC, Saville W, Chahinian P, Weeks JC, Holland JC, Green MR. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005 Jan 1;23(1):190-6.|Lilenbaum RC, Herndon J, List M, et al.: Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-2, 2002.","\tLung Cancer\tcarboplatin|paclitaxel\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer","Interventional","Completed","Phase 3",2,584,"lung neoplasms","paclitaxel|carboplatin","NA"]
["NCT00003118","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18309943|NA|NA","Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008 Mar 1;26(7):1086-92. doi: 10.1200/JCO.2007.12.9593.|Krasna M, Tepper JE, Niedzwiecki D, et al.: Trimodality therapy is superior to surgery alone in esophageal cancer: results of CALGB 9781. [Abstract] American Society of Clinical Oncology 2006 Gastrointestinal Cancers Symposium, 26-28 January 2006, San Francisco, California. A-4, 2006.|Tepper JE, Krasna M, Niedzwiecki D, et al.: Superiority of trimodality therapy to surgery alone in esophageal cancer: results of CALGB 9781. [Abstract] J Clin Oncol 24 (Suppl 18): A-4012, 2006.","\tEsophageal Cancer\tcisplatin|fluorouracil|surgical procedure|radiation therapy\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Procedure|Radiation\tAll\t","Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus","Interventional","Completed","Phase 3",2,56,"esophageal neoplasms","fluorouracil","NA"]
["NCT00003119","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22529259,"Strother DR, London WB, Schmidt ML, Brodeur GM, Shimada H, Thorner P, Collins MH, Tagge E, Adkins S, Reynolds CP, Murray K, Lavey RS, Matthay KK, Castleberry R, Maris JM, Cohn SL. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol. 2012 May 20;30(15):1842-8. doi: 10.1200/JCO.2011.37.9990. Epub 2012 Apr 23.","\tNeuroblastoma\tfilgrastim|sargramostim|carboplatin|cyclophosphamide|doxorubicin hydrochloride|etoposide|adjuvant therapy|conventional surgery|radiation therapy\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug|Drug|Procedure|Procedure|Radiation\tAll\t","Surgery in Treating Children With Neuroblastoma","Interventional","Completed","Phase 3",2,968,"neuroblastoma","carboplatin|cyclophosphamide|doxorubicin|etoposide|sargramostim|liposomal doxorubicin","NA"]
["NCT00003120","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|18336399|12829663","Liu P, Moon J, Alberts DS, et al.: A modified CA-125 progression criterion in ovarian cancer (OC) patients (pts) receiving maintenance treatment following complete clinical response (cCR) to primary therapy. [Abstract] J Clin Oncol 24 (Suppl 18): A-5080, 275s, 2006.|Markman M, Liu P, Wilczynski S, et al.: Survival (S) of ovarian cancer (OC) patients (pts) treated on SWOG9701/GOG178: 12 versus (v) 3 cycles (C) of monthly single-agent paclitaxel (PAC) following attainment of a clinically-defined complete response (CR) to platinum (PLAT)/PAC. [Abstract] J Clin Oncol 24 (Suppl 18): A-5005, 257s, 2006.|Markman M. Maintenance chemotherapy in advanced ovarian cancer: the US experience. Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:40-3. doi: 10.1111/j.1525-1438.2007.01104.x. Review.|Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, Alberts D; Southwest Oncology Group; Gynecologic Oncology Group. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003 Jul 1;21(13):2460-5.","\tFallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer\tpaclitaxel\tParallel Assignment\tTreatment\tRandomized\tDrug\tFemale\t","S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission","Interventional","Completed","Phase 3",2,308,"carcinoma, ovarian epithelial|fallopian tube neoplasms|ovarian neoplasms","paclitaxel","NA"]
["NCT00003123","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Terebelo H, Marsico D, Shurafa M, et al.: A phase II trial of amifostine in patients with advanced myelodysplastic syndromes. [Abstract] Proceedings of the American Society of Clinical Oncology 18: A82, 23a, 1999.","\tMyelodysplastic Syndromes\tamifostine trihydrate\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","syndrome|myelodysplastic syndromes|preleukemia","amifostine","NA"]
["NCT00003124","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17194907,"Heymann JJ, Benson MC, O'Toole KM, Malyszko B, Brody R, Vecchio D, Schiff PB, Mansukhani MM, Ennis RD. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer. J Clin Oncol. 2007 Jan 1;25(1):77-84.","\tProstate Cancer\tflutamide|leuprolide acetate|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Radiation\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","leuprolide|flutamide","NA"]
["NCT00003126","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12810695,"Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CP, McDermott D, Smith JW, Gordon MS, Margolin KA. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol. 2003 Aug 15;21(16):3133-40. Epub 2003 Jun 16.","\tKidney Cancer\tInterleukin-2\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer","Interventional","Completed","Phase 3",2,69,"kidney neoplasms|carcinoma, renal cell","interleukin-2|aldesleukin","NA"]
["NCT00003127","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15721401|NA","Scudder SA, Liu PY, Wilczynski SP, Smith HO, Jiang C, Hallum AV 3rd, Smith GB, Hannigan EV, Markman M, Alberts DS; Southwest Oncology Group. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. Gynecol Oncol. 2005 Mar;96(3):610-5.|Scudder SA, Liu PY, Smith HO, et al.: Paclitaxel (PCT) and carboplatin (C) with amifostine (A) in advanced or recurrent endometrial cancer: a Southwest Oncology Group trial (S9720). [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-819, 2001.","\tEndometrial Cancer\tamifostine trihydrate|carboplatin|paclitaxel\tNA\tNA\tNA\tDrug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","endometrial neoplasms","amifostine|paclitaxel|carboplatin","NA"]
["NCT00003128","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17290061,"Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, Monk BJ, Ueland FR; Gynecologic Oncology Group. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Feb 10;25(5):526-31.","\tSarcoma\tfilgrastim|ifosfamide|paclitaxel\tNA\tNA\tNA\tBiological|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","carcinosarcoma|sarcoma","paclitaxel|ifosfamide","NA"]
["NCT00003129","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18639470,"Ignatoff JM, Chen YH, Greenberg RE, Pow-Sang JM, Messing EM, Wilding G. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group. Urol Oncol. 2009 Sep-Oct;27(5):496-501. doi: 10.1016/j.urolonc.2008.05.004. Epub 2008 Jul 17.","\tBladder Cancer\tvalrubicin\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","urinary bladder neoplasms","valrubicin","NA"]
["NCT00003130","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15623609|NA","Miller AA, Rosner GL, Egorin MJ, Hollis D, Lichtman SM, Ratain MJ. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res. 2004 Dec 15;10(24):8325-31.|Miller AA, Rosner GL, Egorin MJ, et al.: Prospective evaluation of body surface area (BSA) as a determinant of paclitaxel pharmacokinetics/pharmacodynamics in women with solid tumors (CALGB 9763). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-500, 125, 2003.","\tUnspecified Adult Solid Tumor, Protocol Specific\tpaclitaxel\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","paclitaxel","NA"]
["NCT00003132","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19221754|NA","Pavlick AC, Wu J, Roberts J, Rosenthal MA, Hamilton A, Wadler S, Farrell K, Carr M, Fry D, Murgo AJ, Oratz R, Hochster H, Liebes L, Muggia F. Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors. Cancer Chemother Pharmacol. 2009 Sep;64(4):803-10. doi: 10.1007/s00280-009-0931-y. Epub 2009 Feb 17.|Pavlick AC, Hamilton A, Liebes L, et al.: Bryostatin 1 and cisplatin: a phase I and pharmacodynamic study. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-328, 2001.","\tUnspecified Adult Solid Tumor, Protocol Specific\tbryostatin 1|cisplatin\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","NA","bryostatin 1","NA"]
["NCT00003134","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19066728|NA","Santisteban M, Buckner JC, Reid JM, Wu W, Scheithauer BW, Ames MM, Felten SJ, Nikcevich DA, Wiesenfeld M, Jaeckle KA, Galanis E; North Central Cancer Treatment Group. Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. J Neurooncol. 2009 Apr;92(2):165-75. doi: 10.1007/s11060-008-9749-4. Epub 2008 Dec 10.|Laack N, Ballman KV, Brown PB, et al.: Whole-brain radiotherapy (WBRT) and high-dose methylprednisolone (HDMP) for elderly patients with primary central nervous system lymphoma (PCNSL): results of North Central Cancer Treatment Group (NCCTG) 96-72-51. [Abstract] Int J Radiat Oncol Biol Phys 60 (1 Suppl 1): A-1007, S260, 2004.","\tBrain and Central Nervous System Tumors\tirinotecan hydrochloride\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Irinotecan in Treating Patients With Recurrent Glioma","Interventional","Completed","Phase 2",2,64,"nervous system neoplasms|glioma|central nervous system neoplasms","irinotecan","NA"]
["NCT00003137","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Erlichman C, Goldberg RM, Mahoney MR, et al.: A phase II trial of CPT-11 in patients (pts) with advanced gastric or gastroesophageal (GE) junction adenocarcinoma (ADCA): a clinical and pharmacodynamic evaluation. A North Central Cancer Treatment Group (NCCTG) study. [Abstract] J Clin Oncol 23 (Suppl 16): A-4026, 314s, 2005.","\tEsophageal Cancer|Gastric Cancer\tirinotecan hydrochloride\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","adenocarcinoma|stomach neoplasms|esophageal neoplasms","irinotecan","NA"]
["NCT00003138","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19564636|NA","Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, Paietta E, van der Jagt R, Houston J, Thomas ML, Cella D, Rowe JM. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009 Sep 17;114(12):2393-400. doi: 10.1182/blood-2009-03-211797. Epub 2009 Jun 29.|Miller KB, Kim HT, Greenberg P, et al.: Phase III prospective randomized trial of EPO with or without G-CSF versus supportive therapy alone in the treatment of myelodysplastic syndromes (MDS): results of the ECOG- CLSG trial (E1996). [Abstract] Blood 104 (11): A-70, 2004.","\tAnemia|Myelodysplastic Syndromes\tErythropoietin|Filgrastim|Transfusion\tParallel Assignment\tTreatment\tRandomized\tBiological|Biological|Procedure\tAll\t","Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes","Interventional","Completed","Phase 3",2,118,"syndrome|myelodysplastic syndromes|anemia|preleukemia","epoetin alfa|lenograstim|sargramostim","NA"]
["NCT00003139","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16724649|12788192|NA|NA|NA","Scarantino C, LeVeque F, Swann RS, White R, Schulsinger A, Hodson DI, Meredith R, Foote R, Brachman D, Lee N. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. J Support Oncol. 2006 May;4(5):252-8.|Fisher J, Scott C, Scarantino CW, Leveque FG, White RL, Rotman M, Hodson DI, Meredith RF, Foote R, Bachman DG, Lee N. Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer--RTOG 97-09. Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):832-6.|Fisher JJ, Scott CB, Scarantino CW, et al.: Phase III quality of life (Qol) study: reduction in hyposalivation does not improve Qol for head and neck (H&N) cancer patients post radiation therapy (P-RT). RTOG 9709. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1423, 2002.|Scarantino CW, Leveque FG, Scott CB, et al.: A phase III study of concomitant oral pilocarpine to reduce hypo-salivation and mucositis associated with curative radiation therapy (RT) in the head and neck (H&N) cancer patients. RTOG 9709. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-897, 225a, 2001.|Scarantino CW, Leveque F, Scott C, et al.: A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients: final results of RTOG 97-09. [Abstract] Int J Radiat Oncol Biol Phys 51(3 suppl 1): A-157, 85-86, 2001.","\tHead and Neck Cancer|Oral Complications\tpilocarpine hydrochloride|Placebo\tCrossover Assignment\tSupportive Care\tRandomized\tDrug|Other\tAll\t","Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer","Interventional","Completed","Phase 3",2,249,"mucositis|head and neck neoplasms","pilocarpine","NA"]
["NCT00003140","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|18332475|18332043|18332474|NA|17452676|NA|16541302|NA|NA|NA|16822845|NA|NA|16145047|NA|NA|NA|NA|NA|16157934|NA|NA|14551341","Goss PE, Ingle JN, Martino S, et al.: Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 trial. [Abstract] 32nd Annual San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, Texas. A-13, 2009.|Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008 Apr 20;26(12):1948-55. doi: 10.1200/JCO.2007.11.6798. Epub 2008 Mar 10. Erratum in: J Clin Oncol. 2008 Jul 20;26(21):3659.|Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol. 2008 May;19(5):877-82. doi: 10.1093/annonc/mdm566. Epub 2008 Mar 10.|Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol. 2008 Apr 20;26(12):1956-64. doi: 10.1200/JCO.2007.12.6334. Epub 2008 Mar 10.|Chapman JW, Meng D, Shepherd L, et al.: Competing causes of death in breast cancer extended adjuvant endocrine therapy: NCIC CTG MA.17. [Abstract] American Society of Clinical Oncology 2007 Breast Cancer Symposium, 7-8 September 2007, San Francisco, California A-56, 2007.|Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL; National Cancer Institute of Canada Clinical Trials Group MA.17. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol. 2007 May 20;25(15):2006-11. Epub 2007 Apr 23.|Goss P: Breaking the 5-year barrier: results from the MA.17 extended adjuvant trial in women who have completed adjuvant tamoxifen treatment. [Abstract] European Journal of Cancer Supplements 4 (9): 10-5, 2006.|Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat. 2006 Oct;99(3):295-300. Epub 2006 Mar 16.|Ingle J, Tu D, Shepherd L, et al.: NCIC CTG MA.17: intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months. [Abstract] J Clin Oncol 24 (Suppl 18): A-549, 2006.|Moy B, Tu D, Shepherd LE, et al.: NCIC CTG MA.17: tolerability of letrozole among ethnic minority women. [Abstract] J Clin Oncol 24 (Suppl 18): A-6018, 305s, 2006.|Pater JL, Tu D, Ingle JN, et al.: An evaluation of the early termination (ET) of MA.17 extended adjuvant therapy trial. [Abstract] Breast Cancer Res Treat 100 (Suppl 1): A-2081, S107-8, 2006.|Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006 Aug 1;24(22):3629-35. Epub 2006 Jul 5.|Robert NJ, Goss PE, Ingle JN, et al.: Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding. [Abstract] J Clin Oncol 24 (Suppl 18): A-550, 2006.|Abetz L, Barghout V, Thomas S, et al.: Letrozole did not worsen quality of life relative to placebo in post-menopausal women with early breast cancer: results from the US subjects of the MA-17 study. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-2047, 2005.|Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005 Sep 7;97(17):1262-71.|Goss PE, Ingle JN, Palmer MJ, et al.: Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-16, 2005.|Goss PE, Ingle JN, Tu D: NCIC CTG MA17: disease free survival according to estrogen receptor and progesterone receptor status of the primary tumor. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-2042, 2005.|Ingle JN, Goss PE, Tu D: Analysis of duration of letrozole extended adjuvant therapy as measured by hazard ratios of disease recurrence over time for patients on NCIC CTG MA.17. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-17, 2005.|Luk C, Goss P, Pritchard K, et al.: Determinants of preferences for starting extended adjuvant letrozole (L) in postmenopausal women following five years of tamoxifen. [Abstract] J Clin Oncol 23 (Suppl 16): A-642, 39s, 2005.|Vachon CM, Ingle JN, Scott CG, et al.: Pilot study of changes in mammographic density in women treated with letrozole or placebo on NCIC CTG MA17. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-6005, 2005.|Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005 Oct 1;23(28):6931-40. Epub 2005 Sep 12.|Goss PE, Ingle JN, Martino S, et al.: Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. [Abstract] J Clin Oncol 22 (Suppl 14): A-847, 88s, 2004.|Whelan T, Goss P, Ingle J, et al.: Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen. [Abstract] J Clin Oncol 22 (Suppl 14): A-517, 7s, 2004.|Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003 Nov 6;349(19):1793-802. Epub 2003 Oct 9.","\tBreast Cancer\tletrozole|placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Other\tFemale\t","Letrozole After Tamoxifen in Treating Women With Breast Cancer","Interventional","Completed","Phase 3",2,5187,"breast neoplasms","letrozole","NA"]
["NCT00003149","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19243818|NA","Lacy MQ, Jacobus S, Blood EA, Kay NE, Rajkumar SV, Greipp PR. Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group. Leuk Res. 2009 Nov;33(11):1485-9. doi: 10.1016/j.leukres.2009.01.020. Epub 2009 Feb 24.|Lacy MQ, Blood E, Kay N, et al.: Interleukin-12 treatment for plateau phase multiple myeloma: an Eastern Cooperative Oncology Group (ECOG) phase II trial (E1A96). [Abstract] Blood 100 (11 pt 1): A-1549, 2002.","\tMultiple Myeloma and Plasma Cell Neoplasm\trecombinant interleukin-12\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms, plasma cell|multiple myeloma|plasmacytoma","interleukin-12","NA"]
["NCT00003150","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20735398|20371683|NA|NA|NA|16754935|16449523|NA|NA|27967294","Advani RH, Chen H, Habermann TM, Morrison VA, Weller EA, Fisher RI, Peterson BA, Gascoyne RD, Horning SJ; Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; Southwest Oncology Group. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol. 2010 Oct;151(2):143-51. doi: 10.1111/j.1365-2141.2010.08331.x.|Winter JN, Li S, Aurora V, Variakojis D, Nelson B, Krajewska M, Zhang L, Habermann TM, Fisher RI, Macon WR, Chhanabhai M, Felgar RE, Hsi ED, Medeiros LJ, Weick JK, Weller EA, Melnick A, Reed JC, Horning SJ, Gascoyne RD. Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. Clin Cancer Res. 2010 Apr 15;16(8):2435-42. doi: 10.1158/1078-0432.CCR-09-1219. Epub 2010 Apr 6.|Aurora V, Li S, Horning SJ, et al.: Prognostic significance of p53/p21 expression in DLBCL treated with CHOP or R-CHOP: a correlative study of E4494. [Abstract] J Clin Oncol 25 (Suppl 18): A-8038, 450s, 2007.|Morrison VA, Weller EA, Habermann TM, et al.: Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): an Intergroup E4494/C9793 update. [Abstract] J Clin Oncol 25 (Suppl 18): A-8011, 443s, 2007.|Advani RH, Chen H, Habermann TM, et al.: Prognostic indices in older DLBCL patients receiving R-CHOP: an analysis of the U.S. Intergroup study (E4494, CALGB 9793). [Abstract] Blood 108 (11): A-813, 2006.|Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006 Jul 1;24(19):3121-7. Epub 2006 Jun 5.|Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM, Fisher RI, Kurtin PJ, Macon WR, Chhanabhai M, Felgar RE, Hsi ED, Medeiros LJ, Weick JK, Reed JC, Gascoyne RD. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. 2006 Jun 1;107(11):4207-13. Epub 2006 Jan 31. Erratum in: Blood. 2007 Mar 15;109(6):2292.|Morrison V, Weller E, Habermann T, et al.: Dose intensity of CHOP alone or with rituximab in diffuse large B-cell lymphoma (DLBCL) in patients >60 years of age: an analysis of the intergroup trial ( CALGB 9793, ECOG-SWOG 4494). [Abstract] Ann Oncol 16 (Suppl 5): A-224, v102, 2005.|Habermann TM, Weller E, Morrison VA, et al.: Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): an update. [Abstract] Blood 104 (11): A-127, 2004.|Morrison VA, Weller EA, Habermann TM, Li S, Fisher RI, Cheson BD, Peterson BA. Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494). Leuk Lymphoma. 2017 Aug;58(8):1814-1822. doi: 10.1080/10428194.2016.1265111. Epub 2016 Dec 14.","\tLymphoma\trituximab|CHOP regimen|cyclophosphamide|doxorubicin hydrochloride|prednisone|vincristine sulfate\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|lymphoma, non-hodgkin","cyclophosphamide|rituximab|doxorubicin|vincristine|liposomal doxorubicin|prednisone","NA"]
["NCT00003156","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15975641,"Miller DS, Blessing JA, Schilder J, Munkarah A, Lee YC. Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 2005 Aug;98(2):217-21.","\tSarcoma\ttopotecan hydrochloride\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","carcinosarcoma|sarcoma","topotecan","NA"]
["NCT00003157","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Martenson JA Jr, Viglitotti AG, Geeraerts LH, et al.: Phase I study of twice weekly gemcitabine (GEM) and cisplatin (CDDP) during radiation therapy (RT) for advanced pancreas and gastric cancer: a progress report. [Abstract] Proceedings of the American Society of Clinical Oncology A-2305, 2001.","\tGastric Cancer|Pancreatic Cancer\tcisplatin|gemcitabine hydrochloride|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","stomach neoplasms|pancreatic neoplasms","gemcitabine","NA"]
["NCT00003158","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17114656|NA","Davies AM, Chansky K, Lau DH, Leigh BR, Gaspar LE, Weiss GR, Wozniak AJ, Crowley JJ, Gandara DR; SWOG S9712. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. J Clin Oncol. 2006 Nov 20;24(33):5242-6.|Davies AM, Lau DH, Crowley J, et al.: Concurrent carboplatin/etoposide and radiation followed by paclitaxel consolidation for poor risk stage III non-small cell lung cancer: a Southwest Oncology Group (SWOG) phase II trial (S9712). [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1191, 2002.","\tLung Cancer\tcarboplatin|etoposide|paclitaxel|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","paclitaxel|etoposide|carboplatin","NA"]
["NCT00003159","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17544497|NA|NA","Gilligan D, Nicolson M, Smith I, Groen H, Dalesio O, Goldstraw P, Hatton M, Hopwood P, Manegold C, Schramel F, Smit H, van Meerbeeck J, Nankivell M, Parmar M, Pugh C, Stephens R. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet. 2007 Jun 9;369(9577):1929-37. Review.|Hopwood P, Nankivell M, Pugh C, et al.: Impact of pre-operative chemotherapy on the quality of life (QL) of patients with resectable non-small cell lung cancer (NSCLC): experience from the MRC LU22/NVALT/EORTC 08012 multicentre randomised trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-9020, 498s, 2007.|Nicolson M, Gilligan D, Smith I, et al.: Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): first results of the MRC LU22/NVALT/EORTC 08012 multi-centre randomised trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-7518, 389s, 2007.","\tLung Cancer\tcarboplatin|cisplatin|docetaxel|gemcitabine hydrochloride|ifosfamide|mitomycin C|paclitaxel|vinblastine sulfate|vinorelbine tartrate|conventional surgery|neoadjuvant therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","mitomycins|ifosfamide|carboplatin|vinblastine|gemcitabine|paclitaxel|vinorelbine|mitomycin|docetaxel","NA"]
["NCT00003162","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19632065|NA|18588404|16814950|15928300|NA|NA|NA|NA","Chow E, James J, Barsevick A, Hartsell W, Ratcliffe S, Scarantino C, Ivker R, Roach M, Suh J, Petersen I, Konski A, Demas W, Bruner D. Functional interference clusters in cancer patients with bone metastases: a secondary analysis of RTOG 9714. Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1507-11. doi: 10.1016/j.ijrobp.2009.04.024. Epub 2009 Jul 23.|Howell DD, James JL, Hartsell WF, et al.: Randomized trial of short-course versus long-course radiotherapy for palliation of painful vertebral bone metastases: A retrospective analysis of RTOG 97-14. [Abstract] J Clin Oncol 27 (Suppl 15): A-9521, 2009.|Hartsell WF, Desilvio M, Bruner DW, Scarantino C, Ivker R, Roach M 3rd, Suh J, Demas WF, Movsas B, Petersen IA, Konski AA. Can physicians accurately predict survival time in patients with metastatic cancer? Analysis of RTOG 97-14. J Palliat Med. 2008 Jun;11(5):723-8. doi: 10.1089/jpm.2007.0259.|Konski A, Desilvio M, Hartsell W, Watkins-Bruner D, Coyne J, Scarantino C, Janjan N. Continuing evidence for poorer treatment outcomes for single male patients: retreatment data from RTOG 97-14. Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):229-33. Epub 2006 Jul 11.|Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M 3rd, Suh JH, Demas WF, Movsas B, Petersen IA, Konski AA, Cleeland CS, Janjan NA, DeSilvio M. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005 Jun 1;97(11):798-804.|Hartsell WF, Winter K, Bruner DW, et al.: Breast cancer patients have better outcomes than prostate cancer patients for palliation of painful bone metastases: results of RTOG 97-14. [Abstract] J Clin Oncol 23 (Suppl 16): A-6073, 546s, 2005.|Bruner DW, Winter K, Hartsell W, et al.: Prospective health-related quality of life valuations (utilities) of 8 Gy in 1 fraction vs 30 Gy in 10 fractions for palliation of painful bone metastases: preliminary results of RTOG 97-14. [Abstract] Int J Radiat Oncol Biol Phys 60 (1 Suppl 1): A-23, S142, 2004.|Hartsell WF, DeSilvio M, Bruner DW, et al.: Can physicians accurately predict survival time in patients with metastatic cancer? Analysis of RTOG 9714. [Abstract] Int J Radiat Oncol Biol Phys 60 (1 Suppl 1): A-25, S143, 2004.|Hartsell WF, Scott C, Bruner DW, et al.: Phase III randomized trial of 8 Gy in 1 fraction vs. 30 Gy in 10 fractions for palliation of painful bone metastases: preliminary results of RTOG 97-14. [Abstract] Int J Radiat Oncol Biol Phys 57 (2 Suppl): S124, 2003.","\tBreast Cancer|Metastatic Cancer|Pain|Prostate Cancer\tpain therapy|radiation therapy\tParallel Assignment\tSupportive Care\tRandomized\tProcedure|Radiation\tAll\t","Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer","Interventional","Completed","Phase 3",2,949,"breast neoplasms|prostatic neoplasms|neoplasm metastasis","NA","NA"]
["NCT00003170","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12721240,"Kozelsky TF, Meyers GE, Sloan JA, Shanahan TG, Dick SJ, Moore RL, Engeler GP, Frank AR, McKone TK, Urias RE, Pilepich MV, Novotny PJ, Martenson JA; North Central Cancer Treatment Group. Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. J Clin Oncol. 2003 May 1;21(9):1669-74.","\tCancer\tglutamine|placebo\tParallel Assignment\tSupportive Care\tRandomized\tDietary Supplement|Other\tAll\t","Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer","Interventional","Completed","Phase 3",2,129,"diarrhea","NA","NA"]
["NCT00003172","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12074329|NA","Wadler S, Brain C, Catalano P, Einzig AI, Cella D, Benson AB 3rd. Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study E6296. Cancer J. 2002 May-Jun;8(3):282-6.|Wadler S, Einzig A, Catalano P, et al.: Randomized phase II trial of either flourouracil (F), parenteral hydroxyurea (H), interferon-alfa-2a (I) and filgrastim (G) or doxorubicin/docetaxel (AD) in patients (PTS) with advanced gastric cancer: Eastern Cooperative Oncology Group (ECOG) study EST 6296. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-659, 2001.","\tGastric Cancer\tfilgrastim|recombinant interferon alfa|docetaxel|doxorubicin hydrochloride|fluorouracil|hydroxyurea\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","stomach neoplasms","doxorubicin|liposomal doxorubicin|hydroxyurea|interferons|interferon-alpha|docetaxel|fluorouracil","NA"]
["NCT00003175","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19269798|NA","Highley MS, Griffiths GO, Uscinska BM, Huddart RA, Barber JB, Parmar MK, Harper PG; NCRI Bladder Cancer Clinical Studies Group. A phase II trial of continuous 5-fluorouracil in recurrent or metastatic transitional cell carcinoma of the urinary tract. Clin Oncol (R Coll Radiol). 2009 Jun;21(5):394-400. doi: 10.1016/j.clon.2009.01.011. Epub 2009 Mar 9.|Highly M, Griffiths G, Uscinska B, et al.: A phase II trial of continous 5-fluorouracil (5-FU) in recurrent locally advanced or metastatic transitional cell of the urinary tract. Br J Cancer 85(suppl 1): A-P77, 52, 2001.","\tBladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer\tfluorouracil\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","urethral neoplasms|urinary bladder neoplasms|carcinoma, transitional cell|kidney neoplasms|ureteral neoplasms","fluorouracil","NA"]
["NCT00003176","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15073861|14769138","Chang SM, Prados MD, Yung WK, Fine H, Junck L, Greenberg H, Robins HI, Mehta M, Fink KL, Jaeckle KA, Kuhn J, Hess K, Schold C. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. Cancer. 2004 Apr 15;100(8):1712-6.|Prados MD, Yung WK, Fine HA, Greenberg HS, Junck L, Chang SM, Nicholas MK, Robins HI, Mehta MP, Fink KL, Jaeckle KA, Kuhn J, Hess KR, Schold SC Jr; North American Brain Tumor Consortium study. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro Oncol. 2004 Jan;6(1):33-7.","\tBrain and Central Nervous System Tumors\tcarmustine|temozolomide\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|nervous system neoplasms|glioma","carmustine|temozolomide","NA"]
["NCT00003178","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22512017,"Chaleff S, Hurwitz CA, Chang M, Dahl G, Alonzo TA, Weinstein H. Phase II study of 2-chlorodeoxyadenosine plus idarubicin for children with acute myeloid leukaemia in first relapse: a paediatric oncology group study. Br J Haematol. 2012 Mar;156(5):649-55.","\tLeukemia\tfilgrastim|cladribine|idarubicin\tNA\tNA\tNA\tBiological|Drug|Drug\tAll\t","Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia","Interventional","Completed","Phase 2",3,120,"leukemia, myeloid, acute|leukemia, myeloid|leukemia","idarubicin|cladribine|lenograstim|sargramostim","NA"]
["NCT00003179","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22155796|16400639","Bartels PH, Garcia FA, Trimble CL, Kauderer J, Curtin J, Lim PC, Hess LM, Silverberg S, Zaino RJ, Yozwiak M, Bartels HG, Alberts DS. Karyometry in atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr;125(1):129-35. doi: 10.1016/j.ygyno.2011.12.422. Epub 2011 Dec 9.|Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, Alberts D, Curtin J. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006 Feb 15;106(4):812-9.","\tEndometrial Cancer\tmedroxyprogesterone\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","endometrial neoplasms","medroxyprogesterone|medroxyprogesterone acetate","NA"]
["NCT00003184","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",10026920,"Schoof DD, Smith JW 2nd, Disis ML, Brant-Zawadski P, Wood W, Doran T, Johnson E, Urba WJ. Immunization of metastatic breast cancer patients with CD80-modified breast cancer cells and GM-CSF. Adv Exp Med Biol. 1998;451:511-8.","\tBreast Cancer\tBCG vaccine|CD80 breast cancer vaccine|sargramostim\tNA\tNA\tNA\tBiological|Biological|Biological\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","sargramostim|vaccines|bcg vaccine","NA"]
["NCT00003185","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",9647171,"Plautz GE, Barnett GH, Miller DW, Cohen BH, Prayson RA, Krauss JC, Luciano M, Kangisser DB, Shu S. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg. 1998 Jul;89(1):42-51.","\tBrain and Central Nervous System Tumors\tautologous tumor cell vaccine|sargramostim|tumor-draining lymph node lymphocyte therapy|cyclophosphamide|conventional surgery\tNA\tNA\tNA\tBiological|Biological|Biological|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","nervous system neoplasms|central nervous system neoplasms|glioblastoma","cyclophosphamide|sargramostim","NA"]
["NCT00003186","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12356141,"Kane JM 3rd, Kahlenberg MS, Rodriguez-Bigas MA, Gibbs JF, Petrelli NJ. Intraoperative hepatic lymphatic mapping in patients with liver metastases from colorectal carcinoma. Am Surg. 2002 Sep;68(9):745-50.","\tColorectal Cancer|Metastatic Cancer\tisosulfan blue|lymphangiography|sentinel lymph node biopsy\tNA\tNA\tNA\tDrug|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","NA","NA"]
["NCT00003191","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16849757|NA","Children's Oncology Group (CCG 09709), Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol. 2006 Jul 20;24(21):3423-30. Erratum in: J Clin Oncol. 2006 Sep 1;24(25):4223. Reynolds, Patrick C [corrected to Reynolds, C Patrick].|Villablanca JG, Ames MW, Reid JM, et al.: Phase I trial of oral [N-(-4-hydroxyphenyl)retinamide] (4-HPR) in children with resistant/recurrent solid tumors: a children's cancer group study (CCG 09709). [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1588, 2002.","\tNeuroblastoma|Unspecified Childhood Solid Tumor, Protocol Specific\tfenretinide\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","neuroblastoma","fenretinide","NA"]
["NCT00003193","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16116597,"Amrein PC, Clark JR, Supko JG, Fabian RL, Wang CC, Colevas AD, Posner MR, Deschler DG, Rocco JW, Finkelstein DM, McIntyre JF. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. Cancer. 2005 Oct 1;104(7):1418-27.","\tHead and Neck Cancer|Oral Complications\tamifostine trihydrate|paclitaxel|conventional surgery|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","paclitaxel|amifostine","NA"]
["NCT00003203","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22665539|NA","Jakacki RI, Burger PC, Zhou T, Holmes EJ, Kocak M, Onar A, Goldwein J, Mehta M, Packer RJ, Tarbell N, Fitz C, Vezina G, Hilden J, Pollack IF. Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study. J Clin Oncol. 2012 Jul 20;30(21):2648-53. doi: 10.1200/JCO.2011.40.2792. Epub 2012 Jun 4.|Jakacki R, Burger P, Zhou T, et al.: Outcome for metastatic (M+) medulloblastoma (MB) treated with carboplatin during craniospinal radiotherapy (CSRT) followed by cyclophosphamide (CPM) and vincristine (VCR): preliminary results of COG 99701. [Abstract] J Clin Oncol 25 (Suppl 18): A-2017, 2007.","\tBrain Tumors|Central Nervous System Tumors|Neuroblastoma\tfilgrastim|carboplatin|cisplatin|cyclophosphamide|vincristine sulfate|adjuvant therapy|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms|neuroblastoma|central nervous system neoplasms|nervous system neoplasms","vincristine|cisplatin|carboplatin|cyclophosphamide","NA"]
["NCT00003211","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18309946|17012043","Laughton SJ, Merchant TE, Sklar CA, Kun LE, Fouladi M, Broniscer A, Morris EB, Sanders RP, Krasin MJ, Shelso J, Xiong Z, Wallace D, Gajjar A. Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. J Clin Oncol. 2008 Mar 1;26(7):1112-8. doi: 10.1200/JCO.2008.13.5293.|Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006 Oct;7(10):813-20. Erratum in: Lancet Oncol. 2006 Oct;7(10):797.","\tBrain and Central Nervous System Tumors\tfilgrastim|amifostine trihydrate|cisplatin|cyclophosphamide|vincristine sulfate|peripheral blood stem cell transplantation|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Procedure|Radiation\tAll\t","Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor","Interventional","Completed","Phase 2",2,94,"neuroectodermal tumors|neuroectodermal tumors, primitive|medulloblastoma|central nervous system neoplasms|nervous system neoplasms","amifostine|vincristine|cyclophosphamide","NA"]
["NCT00003212","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17634494,"Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, Blay JY; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007 Jul 20;25(21):3144-50.","\tSarcoma\tdoxorubicin hydrochloride|ifosfamide\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","sarcoma","liposomal doxorubicin|ifosfamide|doxorubicin","NA"]
["NCT00003213","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12562658|11773155|NA","Aapro MS, Thuerlimann B, Sessa C, De Pree C, Bernhard J, Maibach R; Swiss Group for Clinical Cancer Research. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol. 2003 Feb;14(2):291-7.|Bernhard J, Maibach R, Thürlimann B, Sessa C, Aapro MS; Swiss Group for Clinical Cancer Research. Patients' estimation of overall treatment burden: why not ask the obvious? J Clin Oncol. 2002 Jan 1;20(1):65-72.|Aapro MS, Sessa C, Thurlimann B, et al.: SAKK 90/95: a randomized double-blind trial to compare the clinical efficacy of granisetron to metoclopramide, both combined to dexamethasone in the prophylaxis of chemotherapy induced delayed emesis. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A2360, 2000.","\tNausea and Vomiting|Unspecified Adult Solid Tumor, Protocol Specific\tdexamethasone|granisetron hydrochloride|metoclopramide hydrochloride\tParallel Assignment\tSupportive Care\tRandomized\tDrug|Drug|Drug\tAll\t","Drugs to Reduce the Side Effects of Chemotherapy","Interventional","Completed","Phase 3",2,267,"nausea|vomiting","metoclopramide|bb 1101|dexamethasone acetate|dexamethasone|granisetron","NA"]
["NCT00003214","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",10481771,"Mariotta M, Perewusnyk G, Koechli OR, Little JB, von Knebel Doeberitz M, Mirimanoff RO, Rutz HP. Dexamethasone-induced enhancement of resistance to ionizing radiation and chemotherapeutic agents in human tumor cells. Strahlenther Onkol. 1999 Aug;175(8):392-6.","\tOvarian Cancer\tcarboplatin|cisplatin|cyclophosphamide|doxorubicin hydrochloride|in vitro sensitivity-directed chemotherapy|paclitaxel\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","ovarian neoplasms|carcinoma, ovarian epithelial","doxorubicin|cyclophosphamide|carboplatin|paclitaxel|liposomal doxorubicin","NA"]
["NCT00003215","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16888080,"Betticher DC, Martinelli G, Radford JA, Kaufmann M, Dyer MJ, Kaiser U, Aulitzky WE, Beck J, von Rohr A, Kovascovics T, Cogliatti SB, Cina S, Maibach R, Cerny T, Linch DC. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol. 2006 Oct;17(10):1546-52. Epub 2006 Aug 3.","\tLymphoma\tmelphalan|methotrexate|methylprednisolone|leucovorin calcium|filgrastim|CHOP regimen|cyclophosphamide|cytarabine|doxorubicin hydrochloride|etoposide|mitoxantrone hydrochloride|prednisone|therapeutic hydrocortisone|vincristine sulfate|bone marrow ablation with stem cell support|peripheral blood stem cell transplantation|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Biological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|lymphoma, non-hodgkin","hydrocortisone hemisuccinate|etoposide|leucovorin|mitoxantrone|methylprednisolone|hydrocortisone|hydrocortisone 17-butyrate 21-propionate|doxorubicin|levoleucovorin|prednisone|cytarabine|melphalan|cyclophosphamide|vincristine|methotrexate|liposomal doxorubicin|hydrocortisone acetate","NA"]
["NCT00003216","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21277694|22682806|21625252|21499862|20934270|NA|NA|18992248|NA|19029412|18319412|NA|NA|NA|NA|NA|NA","Abrams RA, Winter KA, Regine WF, Safran H, Hoffman JP, Lustig R, Konski AA, Benson AB, Macdonald JS, Rich TA, Willett CG. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):809-16. doi: 10.1016/j.ijrobp.2010.11.039. Epub 2011 Feb 1.|Berger AC, Winter K, Hoffman JP, Regine WF, Abrams RA, Safran H, Freedman GM, Benson AB 3rd, Macdonald J, Willett CG. Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trial. Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):e291-7. doi: 10.1016/j.ijrobp.2012.04.035. Epub 2012 Jun 9.|Farrell JJ, Bae K, Wong J, Guha C, Dicker AP, Elsaleh H. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704. Pharmacogenomics J. 2012 Oct;12(5):395-403. doi: 10.1038/tpj.2011.22. Epub 2011 May 31.|Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Rich TA, Willett CG. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011 May;18(5):1319-26. doi: 10.1245/s10434-011-1630-6. Epub 2011 Mar 10.|Showalter TN, Winter KA, Berger AC, Regine WF, Abrams RA, Safran H, Hoffman JP, Benson AB, MacDonald JS, Willett CG. The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1328-35. doi: 10.1016/j.ijrobp.2010.07.1993. Epub 2010 Oct 8.|Tempero MA, Winter KA, Kim GE, et al.: S100A2 as a prognostic marker in patients receiving adjuvant therapy for pancreatic cancer (PC): A secondary analysis of RTOG 9704. [Abstract] J Clin Oncol 29 (Suppl 15): A-4118, 2011.|Farrell J, Bae K, Guha C, et al.: Correlation of cytidine deaminase single nucleotide polymorphism and toxicity from gemcitabine in patients with pancreatic cancer from RTOG 9704. [Abstract] American Society of Clinical Oncology 2009 Gastrointestinal Cancers Symposium, 15-17 January 2009, San Francisco, CA. A-115, 2009.|Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009 Jan;136(1):187-95. doi: 10.1053/j.gastro.2008.09.067. Epub 2008 Oct 7.|Piperdi B, Ng S, Piperdi M, et al.: Single institutional experience with oral capecitabine (Cap) in adjuvant therapy for pancreatic cancer: Gemcitabine (G) followed by Cap/RT followed by G. [Abstract] American Society of Clinical Oncology 2009 Gastrointestinal Cancers Symposium, 15-17 January 2009, San Francisco, CA. A-229, 2009.|Berger AC, Garcia M Jr, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB 3rd, MacDonald J, Willett CG. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008 Dec 20;26(36):5918-22. doi: 10.1200/JCO.2008.18.6288. Epub 2008 Nov 24.|Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG, Rich TA. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008 Mar 5;299(9):1019-26. doi: 10.1001/jama.299.9.1019. Erratum in: JAMA. 2008 Apr 23/30;299(16):1902.|Abrams RA, Winter KA, Regine WF, et al.: Correlation of RTOG 9704 (adjuvant therapy (rx) of pancreatic adenocarcinoma (pan ca)) radiation therapy quality assurance scores (RTQASc) with survival (S). [Abstract] J Clin Oncol 25 (Suppl 18): A-4523, 2007.|Berger AC, Winter K, Hoffman J, et al.: Post-resection CA 19-9 predicts overall survival (OS) in patients treated with adjuvant chemoradiation: a secondary endpoint of RTOG 9704. [Abstract] J Clin Oncol 25 (Suppl 18): A-4522, 2007.|Regine WF, Garcia M, Berger AC, et al.: Post-resectional CA 19-9 values >90 are associated with significantly worse survival in patients with pancreatic carcinoma treated with adjuvant therapy on RTOG 9704: implications for current and future trials. [Abstract] Int J Radiat Oncol Biol Phys 69 (3 Suppl): A-137, S78, 2007.|Abrams RA, Winter KA, Regine WF, et al.: RTOG 9704: radiotherapy quality assurance (QA) review and survival. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-39, S22, 2006.|Regine WF, Winter KA, Abrams R, et al.: A phase III intergroup trial (RTOG 97-04) of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-42, S23-4, 2006.|Regine WF, Winter KW, Abrams R, et al.: RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. [Abstract] J Clin Oncol 24 (Suppl 18): A-4007, 180s, 2006.","\tPancreatic Cancer\tfluorouracil|gemcitabine hydrochloride|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","pancreatic neoplasms","fluorouracil|gemcitabine","NA"]
["NCT00003219","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17885756,"Bailey HH, Attia S, Love RR, Fass T, Chappell R, Tutsch K, Harris L, Jumonville A, Hansen R, Shapiro GR, Stewart JA. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother Pharmacol. 2008 Jun;62(1):149-57. Epub 2007 Sep 21.","\tBreast Cancer\tperillyl alcohol\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","breast neoplasms","perillyl alcohol","NA"]
["NCT00003224","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11595689,"Slingluff CL Jr, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP, Ross WG. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001 Oct;7(10):3012-24.","\tMelanoma (Skin)\tQS21|IFA (incomplete Freund's adjuvant)|p946|p946/tet-p|Tet-p\tParallel Assignment\tTreatment\tRandomized\tBiological|Biological|Biological|Biological|Biological\tAll\t","Vaccine Therapy in Treating Patients With Metastatic Melanoma","Interventional","Completed","Phase 1",6,22,"melanoma","freund's adjuvant|vaccines","NA"]
["NCT00003231","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16622435|NA|12721251|30267838","Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris HB; Swiss Group for Clinical Cancer Research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer. 2006 Apr 24;94(8):1099-106.|Betticher D, Hsu Schmitz S, Roth A, et al.: Neoadjuvant therapy with docetaxel and cisplatin in patients with non-small cell lung cancer (NSCLC), stage IIIA, pN2: a large phase II study with 59 months of follow-up. [Abstract] Lung Cancer 50 (Suppl 2): A-O-032, S14, 2005.|Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris HB. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol. 2003 May 1;21(9):1752-9.|Früh M, Betticher DC, Stupp R, Xyrafas A, Peters S, Ris HB, Mirimanoff RO, Ochsenbein AF, Schmid R, Matzinger O, Stahel RA, Weder W, Guckenberger M, Rothschild SI, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Pless M; Swiss Group for Clinical Cancer Research (SAKK). Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). J Thorac Oncol. 2019 Jan;14(1):115-123. doi: 10.1016/j.jtho.2018.09.011. Epub 2018 Sep 26.","\tLung Cancer\tcisplatin|docetaxel|surgical procedure|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|carcinoma, non-small-cell lung","docetaxel","NA"]
["NCT00003232","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|12947070","Taylor SK, Ding K, Ernst SD, et al.: Palliative response measurement in a phase III study of patients with prostate cancer and painful bone metastases: secondary analysis of NCIC-CTG PR6. [Abstract] J Clin Oncol 26 (Suppl 15): A-9636, 2008.|Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol. 2003 Sep 1;21(17):3335-42.","\tPain|Prostate Cancer|Quality of Life\tclodronate disodium|mitoxantrone hydrochloride|prednisone|quality-of-life assessment\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Procedure\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","mitoxantrone|prednisone|clodronic acid","NA"]
["NCT00003234","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19533657,"Kuttesch JF Jr, Krailo MD, Madden T, Johansen M, Bleyer A; Children's Oncology Group. Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study. Pediatr Blood Cancer. 2009 Oct;53(4):590-3. doi: 10.1002/pbc.22133.","\tBrain and Central Nervous System Tumors|Neuroblastoma|Sarcoma\tvinorelbine tartrate\tNA\tNA\tNA\tDrug\tAll\t","Vinorelbine in Treating Children With Recurrent or Refractory Cancers","Interventional","Completed","Phase 2",3,50,"neuroblastoma|sarcoma|central nervous system neoplasms|nervous system neoplasms","vinorelbine","NA"]
["NCT00003235","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15837967|NA","Belani CP, Wang W, Johnson DH, Wagner H, Schiller J, Veeder M, Mehta M; Eastern Cooperative Oncology Group. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol. 2005 Jun 1;23(16):3760-7. Epub 2005 Apr 18. Review.|Mehta MP, Wang W, Johnson D, et al.: Induction chemotherapy followed by standard thoracic radiotherapy vs. hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small cell lung cancer: phase III study of the Eastern Cooperative Oncology Group (ECOG 2597). Int J Radiat Oncol Biol Phys 57 (2 Suppl): S141, 2003.","\tLung Cancer\tcarboplatin|paclitaxel|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|carcinoma, non-small-cell lung","paclitaxel|carboplatin","NA"]
["NCT00003236","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Gradishar WJ, O'Neill A, Cobleigh M, et al.: A phase II trial with antisense oligonucleotide ISIS 3521/Cgp 64128a in patients (Pts) with metastatic breast cancer (MBC): ECOG trial 3197. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-171, 2001.","\tBreast Cancer\tISIS 3521|ISIS 5132\tNA\tNA\tNA\tBiological|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","isis 5132","NA"]
["NCT00003237","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15542799,"Armanios M, Xu R, Forastiere AA, Haller DG, Kugler JW, Benson AB 3rd; Eastern Cooperative Oncology Group. Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group. J Clin Oncol. 2004 Nov 15;22(22):4495-9. Erratum in: J Clin Oncol. 2008 Aug 1;26(22):3819.","\tEsophageal Cancer|Gastric Cancer\tcisplatin|paclitaxel|surgical procedure\tNA\tNA\tNA\tDrug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","esophageal neoplasms|stomach neoplasms","cisplatin|paclitaxel","NA"]
["NCT00003240","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|16157935|NA|NA","Stephens RJ, Gower NH, Spiro SG, et al.: The Big Lung Trial (BLT): a major randomised trial to determine the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer. [Abstract] Lung Cancer 29 (1 Suppl 1): A-61, 20, 2000.|Brown J, Thorpe H, Napp V, Fairlamb DJ, Gower NH, Milroy R, Parmar MK, Rudd RM, Spiro SG, Stephens RJ, Waller D, West P, Peake MD. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol. 2005 Oct 20;23(30):7417-27. Epub 2005 Sep 12.|Fairlamb DJ, Gower N, Milroy R, et al.: The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the radical radiotherapy setting. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2570, 639, 2003.|Waller D, Fairlamb DJ, Gower N, et al.: The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the surgical setting. [Abstract] Proceedings of the American Society of Clinical Oncology 22 : A-2543, 632, 2003.","\tLung Cancer\tcisplatin|ifosfamide|mitomycin C|vinblastine sulfate|vindesine|vinorelbine tartrate|conventional surgery|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","mitomycins|mitomycin|vinblastine|vindesine|ifosfamide|vinorelbine","NA"]
["NCT00003248","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|16344317|12393429|NA|NA|NA","Woyach JA, Ruppert AS, Heerema NA, et al.: Treatment with fludarabine and rituximab produces extended overall survival (OS) and progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) without increased risk of second malignancy: long-term follow up of CALGB study 9712. [Abstract] Blood 114 (22): A-539, 2009.|Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, Lampson B, Larson RA, Caligiuri MA, Heerema NA. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006 Jan 20;24(3):437-43. Epub 2005 Dec 12.|Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, Vardiman JW, Rai K, Schiffer CA, Larson RA. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003 Jan 1;101(1):6-14. Epub 2002 Jul 5.|Morrison VA, Byrd JC, Peterson BL, et al.: Adding Rituximab to Fludarabine therapy for patients with untreated chronic lymphocytic leukemia (CLL) does not Increase the risk of infection: Cancer and Leukemia Group B (CALGB) study 9712. [Abstract] Blood 102 (11 Pt 1): A-1606, 2003.|Byrd JC, Peterson BL, Park K, et al.: Concurrent Rituximab and Fludarabine has a higher complete response rate than sequential treatment in untreated chronic lymphocytic leukemia (CLL) patients: results from CALGB 9712. [Abstract] Blood 98 (11 Pt 1): A-3212, 2001.|Byrd JC, Peterson B, Park K, et al.: Rituximab added to Fludarabine improves response in previously untreated chronic lymphocytic leukemia: preliminary results from CALGB 9712. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1116, 2001.","\tLeukemia\trituximab|fludarabine phosphate\tParallel Assignment\tTreatment\tRandomized\tBiological|Drug\tAll\t","Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia","Interventional","Completed","Phase 2",2,104,"leukemia|leukemia, lymphoid|leukemia, lymphocytic, chronic, b-cell","fludarabine|fludarabine phosphate|rituximab","NA"]
["NCT00003253","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Fruehauf JP, Mehta RS, Parker RJ: Association of invitro resistance to paclitaxel with clinical outcome in metastatic breast cancer patients with taxol: a multi-institutional prospective trial. [Abstract] Proc Am Assoc Cancer Res 41: A-2096, 330, 2000.","\tBreast Cancer\tpaclitaxel|antitumor drug screening assay\tNA\tNA\tNA\tDrug|Other\tAll\t","NA","NA","NA","NA","NA","NA","breast neoplasms","paclitaxel|antineoplastic agents","NA"]
["NCT00003254","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12448660,"Leichman CG, Chansky K, Macdonald JS, Doukas MA, Budd GT, Giguere JK, Abbruzzese JL; Southwest Oncology Group. Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer. Invest New Drugs. 2002 Nov;20(4):419-24.","\tColorectal Cancer\tethynyluracil|fluorouracil\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","fluorouracil|eniluracil","NA"]
["NCT00003256","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14871968,"Liu G, Gandara DR, Lara PN Jr, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim K, Wilding G. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res. 2004 Feb 1;10(3):924-8.","\tProstate Cancer\talvocidib\tNA\tNA\tNA\tDrug\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","alvocidib","NA"]
["NCT00003259","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12142053,"Morant R, Hsu Schmitz SF, Bernhard J, Thürlimann B, Borner M, Wernli M, Egli F, Forrer P, Streit A, Jacky E, Hanselmann S, Bauer J, Hering F, Schmid HP. Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study. Eur J Cancer. 2002 Aug;38(12):1626-32.","\tProstate Cancer\tvinorelbine tartrate\tNA\tNA\tNA\tDrug\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","vinorelbine","NA"]
["NCT00003267","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17466514,"Franchi M, Trimbos JB, Zanaboni F, v d Velden J, Reed N, Coens C, Teodorovic I, Vergote I. Randomised trial of drains versus no drains following radical hysterectomy and pelvic lymph node dissection: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG) study in 234 patients. Eur J Cancer. 2007 May;43(8):1265-8. Epub 2007 Apr 26.","\tCervical Cancer|Endometrial Cancer|Infection|Perioperative/Postoperative Complications|Vaginal Cancer\tinfection prophylaxis and management|management of therapy complications|surgical procedure\tNA\tNA\tNA\tProcedure|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","postoperative complications|vaginal neoplasms|uterine cervical neoplasms|endometrial neoplasms","NA","NA"]
["NCT00003276","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12794246|NA|NA","Alberts SR, Fishkin PA, Burgart LJ, Cera PJ, Mahoney MR, Morton RF, Johnson PA, Nair S, Goldberg RM; North Central Cancer Treatment Group. CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study. Int J Gastrointest Cancer. 2002;32(2-3):107-14.|Fishkin P, Alberts S, Mahoney M, et al.: Irinotecan (CPT-11) in patients (Pts) with advanced gallbladder (GB) Carcinoma (CA): a North Central Cancer Treatment Group (NCCTG) phase II study. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-618, 2001.|Alberts S, Mahoney M, Fishkin P, et al.: Toxicity of irinotecan (CPT-11) in patients (PTS) with advanced gallbladder (GB) or biliary (BILI) tumors: a North Central Cancer Treatment Group (NCCTG) study. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A-1166, 2000.","\tGallbladder Cancer\tirinotecan hydrochloride\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","gallbladder neoplasms","irinotecan","NA"]
["NCT00003278","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16863926|NA","Laack NN, Ballman KV, Brown PB, O'Neill BP; North Central Cancer Treatment Group. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51. Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1429-39.|Laack NN, Ballman KV, Brown PD, et al.: Toxicity of whole-brain radiotherapy (WBRT) and high-dose methylprednisolone (HDMP) for elderly patients (70 years of age and older) with primary central nervous system lymphoma (PCNSL): results of North Central Cancer Treatment Group (NCCTG) 967351. [Abstract] Neuro-Oncology 6 (4): RT-11, 361, 2004.","\tLymphoma\tdexamethasone|radiation therapy\tNA\tNA\tNA\tDrug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma, non-hodgkin|lymphoma","dexamethasone","NA"]
["NCT00003279","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18676140,"Bottomley A, Debruyne C, Felip E, Millward M, Thiberville L, D'Addario G, Rome L, Zatloukal P, Coens C, Giaccone G. Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. Eur J Cancer. 2008 Oct;44(15):2178-84. doi: 10.1016/j.ejca.2008.06.036.","\tLung Cancer\tBCG vaccine|monoclonal antibody BEC2\tNA\tNA\tNA\tBiological|Biological\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|small cell lung carcinoma","bcg vaccine|antibodies, monoclonal|antibodies","NA"]
["NCT00003280","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20697092|NA|16030029|15598978|25142001","Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S, Okkinga E, Stupp R, Stahel R, Heizmann M, Vorobiof D, Lohri A, Dietrich PY, Zucca E, Ghielmini M. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010 Oct 10;28(29):4480-4. doi: 10.1200/JCO.2010.28.4786. Epub 2010 Aug 9.|Ghielmini ME, Hsu Schmitz S, Martinelli G, et al.: Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98. [Abstract] J Clin Oncol 27 (Suppl15): A-8512, 2009.|Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Léger-Falandry C, Cogliatti S, Fey M, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SF. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 2005 Oct;16(10):1675-82. Epub 2005 Jul 19.|Ghielmini M, Schmitz SF, Cogliatti S, Bertoni F, Waltzer U, Fey MF, Betticher DC, Schefer H, Pichert G, Stahel R, Ketterer N, Bargetzi M, Cerny T; Swiss Group for Clinical Cancer Research. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2005 Feb 1;23(4):705-11. Epub 2004 Dec 14.|Lee CS, Ashton-Key M, Cogliatti S, Rondeau S, Schmitz SF, Ghielmini M, Cragg MS, Johnson P. Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98). Br J Haematol. 2015 Jan;168(1):145-8. doi: 10.1111/bjh.13071. Epub 2014 Aug 21.","\tLymphoma\trituximab\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma, mantle-cell|lymphoma","rituximab","NA"]
["NCT00003281","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17409859,"Dy GK, Jett JR, Geoffroy FJ, Krewer KD, Tazelaar H, Maurer M, Rowland K, Mailliard J, Krook J, Dakhil S, Kutteh L, Kugler J, Wender D. Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group. J Thorac Oncol. 2006 Mar;1(3):211-7.","\tLung Cancer\tpaclitaxel|topotecan hydrochloride|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|small cell lung carcinoma","paclitaxel|topotecan","NA"]
["NCT00003283","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|14722038|NA","Aisner SC, Hameed MR, Wang W, et al.: EGFR and C-Kit immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the WHO: an Eastern Cooperative Oncology Group Study. [Abstract] J Clin Oncol 22 (14 Suppl): A-9637, 869s, 2004.|Loehrer PJ Sr, Wang W, Johnson DH, Aisner SC, Ettinger DS; Eastern Cooperative Oncology Group Phase II Trial. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol. 2004 Jan 15;22(2):293-9. Erratum in: J Clin Oncol. 2004 Jun 1;22(11):2261.|Loehrer PJ, Wang W, Ettinger DS, et al.: Phase II study of octreotide treatment in advanced or recurrent thymic malignancies: an Eastern Cooperative Oncology Group study. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1178, 2002.","\tThymoma and Thymic Carcinoma\toctreotide acetate|prednisone\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","thymoma|thymus neoplasms|carcinoma","prednisone|octreotide","NA"]
["NCT00003287","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21859417|16877722|NA|NA|NA|NA","Innominato PF, Giacchetti S, Moreau T, Smaaland R, Focan C, Bjarnason GA, Garufi C, Iacobelli S, Tampellini M, Tumolo S, Carvalho C, Karaboué A, Lévi F; ARTBC International Chronotherapy Group. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). Chronobiol Int. 2011 Aug;28(7):586-600. doi: 10.3109/07420528.2011.597532.|Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Canon JL, Adenis A, Lo Re G, Carvalho C, Schueller J, Anciaux N, Lentz MA, Baron B, Gorlia T, Lévi F; European Organisation for Research and Treatment of Cancer Chronotherapy Group. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol. 2006 Aug 1;24(22):3562-9.|Garufi C, Bjarnason GA, Giacchetti S, et al.: Independent prognostic value of the rest/activity circadian rhythm on overall survival (OS) in patients (pts) with metastatic colorectal cancer (MCC) receiving first line chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin: a companion study to EORTC 05963. [Abstract] J Clin Oncol 23 (Suppl 16): A-3553, 259s, 2005.|Innominato PF, Focan C, Bjarnason GA, et al.: Quality of life (QoL) correlates with the rest/activity circadian rhythm (RAR) in patients (pts) with metastatic colorectal cancer (MCC) on first line chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin : an international multicenter study (EORTC 05963). [Abstract] J Clin Oncol 23 (Suppl 16): A-8029, 736s, 2005.|Lévi F, Gorlia T, Tubiana N, et al.: Gender as a predictor for optimal dynamic scheduling of oxaliplatin, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Results from EORTC randomized phase III trial 05963. [Abstract] J Clin Oncol 23 (Suppl 16): A-3587, 267s, 2005.|Giacchetti S, Bjarnason GA, Garufi C, et al.: First line infusion of 5-fluorouracil, leucovorin, oxaliplatin for metastatic colorectal cancer chronomodulated versus conventional delivery. A multicenter randomized trial of the EORTC chronotherapy group. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-2231, 2002.","\tColorectal Cancer\tFOLFOX regimen|fluorouracil|leucovorin calcium|oxaliplatin\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","calcium|leucovorin|fluorouracil|levoleucovorin|oxaliplatin","NA"]
["NCT00003290","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22119373|21470834|19540054|19836155|18565744|17482880|17391791|16949694|15685244|NA|NA|10869758","Gulliford SL, Partridge M, Sydes MR, Webb S, Evans PM, Dearnaley DP. Parameters for the Lyman Kutcher Burman (LKB) model of Normal Tissue Complication Probability (NTCP) for specific rectal complications observed in clinical practise. Radiother Oncol. 2012 Mar;102(3):347-51. doi: 10.1016/j.radonc.2011.10.022. Epub 2011 Nov 25.|Barnett GC, De Meerleer G, Gulliford SL, Sydes MR, Elliott RM, Dearnaley DP. The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clin Oncol (R Coll Radiol). 2011 Nov;23(9):613-24. doi: 10.1016/j.clon.2011.03.001. Epub 2011 Apr 5.|Gulliford SL, Foo K, Morgan RC, Aird EG, Bidmead AM, Critchley H, Evans PM, Gianolini S, Mayles WP, Moore AR, Sánchez-Nieto B, Partridge M, Sydes MR, Webb S, Dearnaley DP. Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):747-54. doi: 10.1016/j.ijrobp.2009.02.025. Epub 2009 Jun 18.|Syndikus I, Morgan RC, Sydes MR, Graham JD, Dearnaley DP; MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):773-83. doi: 10.1016/j.ijrobp.2009.05.052. Epub 2009 Oct 14.|Stanley S, Griffiths S, Sydes MR, Moore AR, Syndikus I, Dearnaley DP; RT01 Radiographer Trial Implementation Group. Accuracy and reproducibility of conformal radiotherapy using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397). Clin Oncol (R Coll Radiol). 2008 Oct;20(8):582-90. doi: 10.1016/j.clon.2008.04.019. Epub 2008 Jun 18.|Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Millar J, Moore AR, Morgan RC, Russell JM, Scrase CD, Stephens RJ, Syndikus I, Parmar MK; RT01 collaborators. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007 Jun;8(6):475-87.|Dearnaley DP, Sydes MR, Langley RE, Graham JD, Huddart RA, Syndikus I, Matthews JH, Scrase CD, Jose CC, Logue J, Stephens RJ; RT01 Collaborators. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiother Oncol. 2007 Apr;83(1):31-41. Epub 2007 Mar 27.|Mangar SA, Sydes MR, Tucker HL, Coffey J, Sohaib SA, Gianolini S, Webb S, Khoo VS; MRC RT01 Trial Management Group, Dearnaley DP. Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397). Radiother Oncol. 2006 Sep;80(3):355-62. Epub 2006 Sep 1.|Dearnaley DP, Hall E, Lawrence D, Huddart RA, Eeles R, Nutting CM, Gadd J, Warrington A, Bidmead M, Horwich A. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer. 2005 Feb 14;92(3):488-98.|Stephen M, Helen T, Matthew S, et al.: Evaluating the relationship between erectile dysfunction and dose received by the penile bulb in patients undergoing conformal radiotherapy for prostate cancer: analysis of data from the MRC RT01 dose escalation trial (ISRCTN47772397). [Abstract] Int J Radiat Oncol Biol Phys 63 (2 Suppl 1): A-209, S126, 2005.|Stephens RJ, Cowan R, Dearnaley DP, et al.: The effect of hormone therapy on the quality of life of men with locally advanced prostate cancer (based on data from the MRC RT01 randomised trial (ISRCTN 47772397)). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-1665, 414, 2003.|Seddon B, Bidmead M, Wilson J, Khoo V, Dearnaley D. Target volume definition in conformal radiotherapy for prostate cancer: quality assurance in the MRC RT-01 trial. Radiother Oncol. 2000 Jul;56(1):73-83.","\tProstate Cancer\tgonadotrophin releasing hormone|radiation therapy\tNA\tNA\tNA\tBiological|Radiation\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","hormones","NA"]
["NCT00003298","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23293700,"Chakravarthy AB, Catalano PJ, Mondschein JK, Rosenthal DI, Haller DG, Whittington R, Spitz FR, Wagner H, Sigurdson ER, Tschetter LK, Bayer GK, Mulcahy MF, Benson AB. Phase II Trial of Paclitaxel/Cisplatin Followed by Surgery and Adjuvant Radiation Therapy and 5-Fluorouracil/Leucovorin for Gastric Cancer (ECOG E7296). Gastrointest Cancer Res. 2012 Nov;5(6):191-7.","\tGastric Cancer\tcisplatin|fluorouracil|leucovorin calcium|paclitaxel|surgery|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","stomach neoplasms","leucovorin|cisplatin|fluorouracil|levoleucovorin|tetrahydrofolates|formyltetrahydrofolates|paclitaxel|calcium","NA"]
["NCT00003299","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15923572|NA","Niell HB, Herndon JE 2nd, Miller AA, Watson DM, Sandler AB, Kelly K, Marks RS, Perry MC, Ansari RH, Otterson G, Ellerton J, Vokes EE, Green MR; Cancer and Leukemia Group. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol. 2005 Jun 1;23(16):3752-9.|Niell HB, Herndon JE, Miller AA, et al.: Randomized phase III intergroup trial (CALGB 9732) of etoposide (VP-16) and cisplatin (DDP) with or without paclitaxel (TAX) and G-CSF in patients with extensive stage small cell lung cancer (ED-SCLC). [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1169, 2002.","\tLung Cancer\tcisplatin|etoposide|paclitaxel\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer","Interventional","Completed","Phase 3",2,587,"lung neoplasms|small cell lung carcinoma","paclitaxel|etoposide","NA"]
["NCT00003301","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14769136,"Batchelor TT, Gilbert MR, Supko JG, Carson KA, Nabors LB, Grossman SA, Lesser GJ, Mikkelsen T, Phuphanich S; NABTT CNS Consortium. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol. 2004 Jan;6(1):21-7.","\tBrain and Central Nervous System Tumors\tirinotecan hydrochloride\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","nervous system neoplasms|central nervous system neoplasms|glioma","irinotecan","NA"]
["NCT00003302","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16373758|16180227|15585733","Schnall MD, Blume J, Bluemke DA, DeAngelis GA, DeBruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Pisano ED, Causer P, Schnitt SJ, Thickman D, Stelling CB, Weatherall PT, Lehman C, Gatsonis CA. Diagnostic architectural and dynamic features at breast MR imaging: multicenter study. Radiology. 2006 Jan;238(1):42-53.|Schnall MD, Blume J, Bluemke DA, Deangelis GA, Debruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Pisano ED, Causer P, Schnitt SJ, Smazal SF, Stelling CB, Lehman C, Weatherall PT, Gatsonis CA. MRI detection of distinct incidental cancer in women with primary breast cancer studied in IBMC 6883. J Surg Oncol. 2005 Oct 1;92(1):32-8.|Bluemke DA, Gatsonis CA, Chen MH, DeAngelis GA, DeBruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Lehman C, Pisano ED, Causer P, Schnitt SJ, Smazal SF, Stelling CB, Weatherall PT, Schnall MD. Magnetic resonance imaging of the breast prior to biopsy. JAMA. 2004 Dec 8;292(22):2735-42.","\tBreast Cancer\tbiopsy|magnetic resonance imaging|mammography\tNA\tNA\tNA\tProcedure|Diagnostic Test|Diagnostic Test\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","NA","NA"]
["NCT00003304","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12649108,"van den Bent MJ, Chinot O, Boogerd W, Bravo Marques J, Taphoorn MJ, Kros JM, van der Rijt CC, Vecht CJ, De Beule N, Baron B. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol. 2003 Apr;14(4):599-602.","\tBrain and Central Nervous System Tumors\ttemozolomide\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","nervous system neoplasms|central nervous system neoplasms","temozolomide","NA"]
["NCT00003305","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17768625,"Cole PD, Drachtman RA, Masterson M, Smith AK, Glod J, Zebala JA, Lisi S, Drapala DA, Kamen BA. Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2008 Jun;62(1):65-75. Epub 2007 Sep 2.","\tLeukemia\taminopterin|leucovorin calcium\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia","aminopterin|calcium|leucovorin|levoleucovorin","NA"]
["NCT00003308","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16314647,"Manon R, O'Neill A, Knisely J, Werner-Wasik M, Lazarus HM, Wagner H, Gilbert M, Mehta M; Eastern Cooperative Oncology Group. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol. 2005 Dec 1;23(34):8870-6.","\tKidney Cancer|Melanoma (Skin)|Metastatic Cancer|Ovarian Cancer|Sarcoma\tstereotactic radiosurgery\tNA\tNA\tNA\tRadiation\tAll\t","NA","NA","NA","NA","NA","NA","kidney neoplasms|melanoma|carcinoma, renal cell|sarcoma","NA","NA"]
["NCT00003309","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Moots PL, O'Neill A, Barger GR, et al.: Toxicities associated with chemotherapy followed by craniospinal radiation for adults with poor-risk medulloblastoma/PNET and disseminated ependymoma: a preliminary report of ECOG 4397. [Abstract] J Clin Oncol 22 (Suppl 14): A-1573, 125s, 2004.","\tBrain and Central Nervous System Tumors\tfilgrastim|cisplatin|cyclophosphamide|etoposide|vincristine sulfate|adjuvant therapy|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","nervous system neoplasms|ependymoma|central nervous system neoplasms|medulloblastoma","cyclophosphamide|etoposide|vincristine","NA"]
["NCT00003312","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21470793|17084551|15989995|NA|NA","Lawton CA, Hunt D, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky TM, Sandler H. Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):1-7. doi: 10.1016/j.ijrobp.2010.05.056. Epub 2011 Apr 4.|Lawton CA, DeSilvio M, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky T, Sandler H. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):39-47. Epub 2006 Nov 2.|Feigenberg SJ, Lee WR, Desilvio ML, Winter K, Pisansky TM, Bruner DW, Lawton C, Morton G, Baikadi M, Sandler H. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):956-64.|Lawton CA, DeSilvio M, Lee WR, et al.: Correlating prostate seed implant quality with clinical outcomes for patients treated on RTOG protocol 98-05 (a multi-institutional phase II trial of transrectal ultrasound guided prostate seed implant for localized prostate cancer). [Abstract] American Society of Clinical Oncology 2005 Prostate Cancer Symposium, 17-19 February 2005, Orlando, Florida. A-90, 2005.|Lawton CA, DeSilvio M, Lee WR, et al.: Results of a prospective multi-institutional phase II trial (RTOG 98-05) of transrectal ultrasound guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate. [Abstract] Int J Radiat Oncol Biol Phys 60 (Suppl 1): A-90, S184, 2004.","\tProstate Cancer\tiodine I 125\tNA\tNA\tNA\tRadiation\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","NA","NA"]
["NCT00003313","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19858383|18501528|NA|NA|NA|15800308|16015544|NA|11917283","Movsas B, Moughan J, Sarna L, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Wasserman T, Bruner DW. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol. 2009 Dec 1;27(34):5816-22. doi: 10.1200/JCO.2009.23.7420. Epub 2009 Oct 26.|Sarna L, Swann S, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Byhardt R, Wasserman T, Movsas B. Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1378-84. doi: 10.1016/j.ijrobp.2008.03.003. Epub 2008 May 22.|Movsas B, Moughan J, Langer C, et al.: Randomized trial of amifostine in locally advanced non-small cell lung cancer (NSCLC) patients receiving chemotherapy and hyperfractionated radiation (HRT): long-term survival results of Radiation Therapy Oncology Group (RTOG) 9801. [Abstract] J Clin Oncol 25 (Suppl 18): A-7529, 2007.|Nicolaou N, Moughan J, Sarna L, et al.: Quality of life (QOL) supercedes the classic predictors of survival in locally advanced non-small cell lung cancer (NSCLC): an analysis of Radiation Therapy Oncology Group (RTOG) 9801. [Abstract] Int J Radiat Oncol Biol Phys 69 (3 Suppl): A-103, S58-59, 2007.|\"Sarna L, Swann S, Langer C, et al.: Is there a \"\"disconnect\"\" between physician and patient - reported outcomes (PROs): an analysis of RTOG 98-01. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-2595, S541, 2006.\"|Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Smith C, Axelrod R, Sarna L, Wasserman T, Byhardt R. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol. 2005 Apr 1;23(10):2145-54.|Werner-Wasik M, Langer C, Movsas B. Amifostine in chemoradiation therapy for non-small cell lung cancer: review of experience and design of a phase II trial assessing subcutaneous and intravenous bolus administration. Semin Oncol. 2005 Apr;32(2 Suppl 3):S105-8.|Werner-Wasik M, Scott C, Movsas B, et al.: Amifostine as mucosal protectant in patients with locally advanced non-small cell lung cancer (NSCLC) receiving intensive chemotherapy and thoracic radiotherapy (RT): results of the radiation therapy oncology group (RTOG) 98-01 study. [Abstract] Int J Radiat Oncol Biol Phys 57 (2 Suppl): S216, 2003.|Movsas B. Exploring the role of the radioprotector amifostine in locally advanced non-small cell lung cancer: Radiation Therapy Oncology Group trial 98-01. Semin Radiat Oncol. 2002 Jan;12(1 Suppl 1):40-5.","\tDrug/Agent Toxicity by Tissue/Organ|Lung Cancer|Oral Complications|Radiation Toxicity\tfilgrastim|amifostine trihydrate|carboplatin|paclitaxel|radiation therapy\tParallel Assignment\tSupportive Care\tRandomized\tBiological|Drug|Drug|Drug|Radiation\tAll\t","Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer","Interventional","Completed","Phase 3",2,243,"drug-related side effects and adverse reactions|carcinoma, non-small-cell lung|lung neoplasms","amifostine|paclitaxel|carboplatin","NA"]
["NCT00003316","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14766260,"Look KY, Sandler A, Blessing JA, Lucci JA 3rd, Rose PG; Gynecologic Oncology Group (GOG) Study. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol. 2004 Feb;92(2):644-7.","\tSarcoma\tgemcitabine hydrochloride\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","sarcoma|leiomyosarcoma","gemcitabine","NA"]
["NCT00003317","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Perry MC, Kohman L, Bonner J, et al.: Updated analysis of a phase III study of surgical resection and chemotherapy (paclitaxel/carboplatin) (CT) with or without adjuvant radiation therapy (RT) for resected stage III non-small cell lung cancer (NSCLC) CALGB 9734. [Abstract] J Clin Oncol 23 (Suppl 16): A-7145, 656s, 2005.|Perry MC, Kohman LJ, Bonner JA, et al.: A phase III study of surgical resection and chemotherapy (paclitaxel/carboplatin) (CT) with or without adjuvant radiation therapy (RT) for resected stage III non-small cell lung cancer (NSCLC): CALGB 9734. [Abstract] Lung Cancer 41 (Suppl 2): A-O-183, S55, 2003.","\tLung Cancer\tcarboplatin|paclitaxel|radiation therapy|surgery\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Radiation|Procedure\tAll\t","Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Stage IIIA Non-small Cell Lung Cancer","Interventional","Completed","Phase 3",2,480,"lung neoplasms|carcinoma, non-small-cell lung","carboplatin|paclitaxel","NA"]
["NCT00003322","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|16394300|NA|NA|18640939|19596139|NA|NA|16515585|22119995|NA|16368440|NA|17264340|18430468","Armstrong DK, Bundy BN, Baergen R, et al.: Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172). [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-803, 2002.|Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43.|DeLoia JA, Krivak T, Darcy KM, et al.: Relationship between the C8092A polymorphisms in ERCC1 and clinical outcome in optimally-resected, stage III epithelial ovarian cancer treated with intraperitoneal or intravenous cisplatin and paclitaxel: a Gynecologic Oncology Group study. [Abstract] American Association for Cancer Research: 98th Annual Meeting, April 14-18, 2007, Los Angeles, CA. A-1674, 2007.|Krivak TC, Darcy KM, Tian C, et al.: Relationship between polymorphisms in cordon 118 and C8092A in ERCC1 and clinical outcome in optimally-resected, stage III epithelial ovarian cancer treated with intraperitoneal or intravenous cisplatin and paclitaxel: a Gynecologic Oncology Group study. [Abstract] J Clin Oncol 25 (Suppl 18): A-21050, 733s, 2007.|Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB, DeLoia JA; Gynecologic Oncology Group Phase III Trial. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol. 2008 Jul 20;26(21):3598-606. doi: 10.1200/JCO.2008.16.1323.|Krivak TC, Tian C, Rose GS, Armstrong DK, Maxwell GL. A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172. Gynecol Oncol. 2009 Oct;115(1):81-85. doi: 10.1016/j.ygyno.2009.06.021. Epub 2009 Jul 12.|Krivak T, Darcy K, Tian C, et al.: Relationship between polymorphisms in ERCC1 and clinical outcome in optimally resected stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. [Abstract] Society of Gynecologic Oncologists, 2007 Annual Meeting on Women's Cancer, March 3-7, 2007, San Diego, CA. A-146, 2007.|Seamon LG, Carlson MJ, Richardson DL, et al.: Improved intraperitoneal chemotherapeutic toxicity profile for ovarian cancer: A modification of the taxane-platinum protocol in GOG-172. [Abstract] J Clin Oncol 26 (Suppl 15): A-5583, 2008.|Thrall M, Gallion HH, Kryscio R, Kapali M, Armstrong DK, DeLoia JA. BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:166-71.|von Gruenigen VE, Huang HQ, Gil KM, Frasure HE, Armstrong DK, Wenzel LB. The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: a Gynecologic Oncology Group Study. Gynecol Oncol. 2012 Mar;124(3):379-82. doi: 10.1016/j.ygyno.2011.11.032. Epub 2011 Nov 23.|Walker JL, Armstrong D, Huang H, et al.: Intraperitoneal catheter outcomes on GOG 172: a Gynecologic Oncology Group study in women with optimally debulked stage III ovarian cancer. [Abstract] Int J Gynecol Cancer 14 (Suppl 1): A-062, 19, 2004.|Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke-Pearson D. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006 Jan;100(1):27-32.|Wenzel LB, Huang HQ, Armstrong DK, et al.: Baseline quality of life (QOL) as a predictor of tolerance to intraperitoneal (IP) chemotherapy for advanced epithelial ovarian cancer (EOC): a Gynecologic Oncology Group (GOG) study. [Abstract] J Clin Oncol 24 (Suppl 18): A-5007, 257s, 2006.|Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D; Gynecologic Oncology Group. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Feb 1;25(4):437-43.|Wenzel L, Huang HQ, Cella D, Walker JL, Armstrong DK; Gynecologic Oncology Group. Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jul;110(1):60-4. doi: 10.1016/j.ygyno.2008.02.011. Epub 2008 Apr 21.","\tOvarian Cancer|Primary Peritoneal Cavity Cancer\tcisplatin|paclitaxel|quality-of-life assessment\tNA\tNA\tNA\tDrug|Drug|Procedure\tFemale\t","NA","NA","NA","NA","NA","NA","ovarian neoplasms|carcinoma, ovarian epithelial","cisplatin|paclitaxel","NA"]
["NCT00003323","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|NA","Picus J, Halabi S, Small E, et al.: Long term efficacy of peripheral androgen blockade on prostate cancer: CALGB 9782. [Abstract] J Clin Oncol 24 (Suppl 18): A-4573, 2006.|Picus J, Halabi S, Small E, et al.: Efficacy of peripheral androgen blockade on prostate cancer: results of CALGB 9782. [Abstract] J Clin Oncol 22 (Suppl 14): A-4559, 396s, 2004.|Picus J, Halabi S, Hussain A, et al.: Efficacy of peripheral androgen blockade on prostate cancer: initial results of CALGB 9782. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-727, 2002.","\tProstate Cancer|Sexual Dysfunction and Infertility\tfinasteride|flutamide|quality-of-life assessment\tNA\tNA\tNA\tDrug|Drug|Other\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms|infertility","flutamide|finasteride","NA"]
["NCT00003324","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12622453,"Chitapanarux I, Goss B, Vongtama R, Frighetto L, De Salles A, Selch M, Duick M, Solberg T, Wallace R, Cabatan-Awang C, Ford J. Prospective study of stereotactic radiosurgery without whole brain radiotherapy in patients with four or less brain metastases: incidence of intracranial progression and salvage radiotherapy. J Neurooncol. 2003 Jan;61(2):143-9.","\tMetastatic Cancer\tconventional surgery|radiation therapy\tNA\tNA\tNA\tProcedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","neoplasm metastasis","NA","NA"]
["NCT00003325","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22753905|NA","Levenback CF, Ali S, Coleman RL, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM Jr, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ 2nd, Van Le L, Trimble CL. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol. 2012 Nov 1;30(31):3786-91. doi: 10.1200/JCO.2011.41.2528. Epub 2012 Jul 2.|Levenback CF, Tian C, Coleman RL, et al.: Sentinel node (SN) biopsy in patients with vulvar cancer: A Gynecologic Oncology Group (GOG) study. [Abstract] J Clin Oncol 27 (Suppl 15): A-5505, 2009.","\tVulvar Cancer\tSentinel lymph node mapping\tNA\tNA\tNA\tProcedure\tFemale\t","NA","NA","NA","NA","NA","NA","vulvar neoplasms","NA","NA"]
["NCT00003329","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15705877|NA","Larson GP, Ding Y, Cheng LS, Lundberg C, Gagalang V, Rivas G, Geller L, Weitzel J, MacDonald D, Archambeau J, Slater J, Neuberg D, Daly MB, Angel I, Benson AB 3rd, Smith K, Kirkwood JM, O'Dwyer PJ, Raskay B, Sutphen R, Drew R, Stewart JA, Werndli J, Johnson D, Ruckdeschel JC, Elston RC, Krontiris TG. Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHIT. Cancer Res. 2005 Feb 1;65(3):805-14.|Krontiris TG, Larson M, Weitzel JN, et al.: Mapping interactive cancer susceptibility loci: Eastern Cooperative Oncology Group. [Abstract] Proceedings of the American Society of Clinical Oncology 17: A2147, 560a, 1998.","\tBreast Cancer|Colorectal Cancer|Lung Cancer|Prostate Cancer\tgene mapping\tNA\tNA\tNA\tGenetic\tAll\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms|breast neoplasms|lung neoplasms","NA","NA"]
["NCT00003330","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","10815886|11211153","Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res. 2000 May;6(5):1678-92.|Gollob JA, Veenstra KG, Mier JW, Atkins MB. Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12. J Immunother. 2001 Jan-Feb;24(1):91-8.","\tUnspecified Adult Solid Tumor, Protocol Specific\trecombinant interleukin-12\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","NA","interleukin-12","NA"]
["NCT00003334","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Hornreich G, Muggia FM, Wadler S, et al.: Phase II combination doxil-paclitaxel (PacliDox) in uterine carcinomas and sarcomas - an active regimen: a New York Gynecologic Oncology Group study. [Abstract] Society of Gynecologic Oncologists 2003 Annual Meeting on Women's Cancer, January 31 - February 2, 2003, New Orleans, Louisiana. A-606, 2003.","\tEndometrial Cancer|Fallopian Tube Cancer|Ovarian Cancer|Sarcoma\tpaclitaxel|pegylated liposomal doxorubicin hydrochloride\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","endometrial neoplasms|sarcoma|fallopian tube neoplasms","paclitaxel|doxorubicin|liposomal doxorubicin","NA"]
["NCT00003335","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18769450|17910637","Lesniewski ML, Haviernik P, Weitzel RP, Kadereit S, Kozik MM, Fanning LR, Yang YC, Hegerfeldt Y, Finney MR, Ratajczak MZ, Greco N, Paul P, Maciejewski J, Laughlin MJ. Regulation of IL-2 expression by transcription factor BACH2 in umbilical cord blood CD4+ T cells. Leukemia. 2008 Dec;22(12):2201-7. doi: 10.1038/leu.2008.234. Epub 2008 Sep 4.|van Heeckeren WJ, Fanning LR, Meyerson HJ, Fu P, Lazarus HM, Cooper BW, Tse WW, Kindwall-Keller TL, Jaroscak J, Finney MR, Fox RM, Solchaga L, Forster M, Creger RJ, Laughlin MJ. Influence of human leucocyte antigen disparity and graft lymphocytes on allogeneic engraftment and survival after umbilical cord blood transplant in adults. Br J Haematol. 2007 Nov;139(3):464-74.","\tGraft Versus Host Disease|Leukemia|Lymphoma|Myelodysplastic/Myeloproliferative Diseases|Myelodysplastic Syndromes\tanti-thymocyte globulin|busulfan|cyclosporine|melphalan|methylprednisolone|umbilical cord blood transplantation|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","preleukemia|myelodysplastic-myeloproliferative diseases|leukemia|graft vs host disease|lymphoma|syndrome|myelodysplastic syndromes|myeloproliferative disorders","busulfan|melphalan|antilymphocyte serum|cyclosporine|methylprednisolone|cyclosporins","NA"]
["NCT00003351","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Perez EA, Hillman DW, Milliard JA, et al.: Randomized phase II study of 2 schedules of irinotecan (CPT-11) for patients (pts) with refractory metastatic breast cancer (MBC): an NCCTG Cooperative Group study. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-206, 2002.","\tBreast Cancer\tirinotecan hydrochloride\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer","Interventional","Completed","Phase 2",2,104,"breast neoplasms","irinotecan","NA"]
["NCT00003352","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12533263,"Smith RE, Anderson SJ, Brown A, Scholnik AP, Desai AM, Kardinal CG, Lembersky BC, Mamounas EP. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58. Clin Breast Cancer. 2002 Dec;3(5):333-40.","\tBreast Cancer\tcyclophosphamide|Taxotere|Adriamycin\tNA\tNA\tNA\tDrug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","docetaxel|cyclophosphamide|liposomal doxorubicin|doxorubicin","NA"]
["NCT00003353","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15156165,"Gertz MA, Blood E, Vesole DH, Abonour R, Lazarus HM, Greipp PR. A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Marrow Transplant. 2004 Jul;34(2):149-54.","\tMultiple Myeloma and Plasma Cell Neoplasm\tfilgrastim|melphalan|bone marrow ablation with stem cell support|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Drug|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","plasmacytoma|amyloidosis|immunoglobulin light-chain amyloidosis|multiple myeloma|neoplasms, plasma cell","melphalan","NA"]
["NCT00003354","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15894098|15997446|17634484|20629110|20013936","Guillou PJ, Quirke P, Thorpe H, Walker J, Jayne DG, Smith AM, Heath RM, Brown JM; MRC CLASICC trial group. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet. 2005 May 14-20;365(9472):1718-26.|Jayne DG, Brown JM, Thorpe H, Walker J, Quirke P, Guillou PJ. Bladder and sexual function following resection for rectal cancer in a randomized clinical trial of laparoscopic versus open technique. Br J Surg. 2005 Sep;92(9):1124-32.|Jayne DG, Guillou PJ, Thorpe H, Quirke P, Copeland J, Smith AM, Heath RM, Brown JM; UK MRC CLASICC Trial Group. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 2007 Jul 20;25(21):3061-8.|Jayne DG, Thorpe HC, Copeland J, Quirke P, Brown JM, Guillou PJ. Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. Br J Surg. 2010 Nov;97(11):1638-45. doi: 10.1002/bjs.7160.|Taylor GW, Jayne DG, Brown SR, Thorpe H, Brown JM, Dewberry SC, Parker MC, Guillou PJ. Adhesions and incisional hernias following laparoscopic versus open surgery for colorectal cancer in the CLASICC trial. Br J Surg. 2010 Jan;97(1):70-8. doi: 10.1002/bjs.6742.","\tColorectal Cancer\tconventional surgery|laparoscopic surgery\tNA\tNA\tNA\tProcedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","NA","NA"]
["NCT00003358","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15131031,"Sabbatini P, Aghajanian C, Leitao M, Venkatraman E, Anderson S, Dupont J, Dizon D, O'Flaherty C, Bloss J, Chi D, Spriggs D. Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial. Clin Cancer Res. 2004 May 1;10(9):2962-7.","\tFallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer\tchemotherapy|cisplatin|gemcitabine hydrochloride\tNA\tNA\tNA\tDrug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","fallopian tube neoplasms","gemcitabine","NA"]
["NCT00003364","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16921033,"Spiro SG, James LE, Rudd RM, Trask CW, Tobias JS, Snee M, Gilligan D, Murray PA, Ruiz de Elvira MC, O'Donnell KM, Gower NH, Harper PG, Hackshaw AK; London Lung Cancer Group. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol. 2006 Aug 20;24(24):3823-30.","\tLung Cancer\tcisplatin|cyclophosphamide|doxorubicin hydrochloride|etoposide|vincristine sulfate|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","small cell lung carcinoma|lung neoplasms","vincristine|cyclophosphamide|etoposide|doxorubicin|liposomal doxorubicin","NA"]
["NCT00003368","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14630685,"Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol. 2003 Dec;14(12):1783-90.","\tLymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific\tirinotecan hydrochloride\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|intestinal neoplasms","irinotecan","NA"]
["NCT00003369","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16445649|NA","Smith HO, Jiang CS, Weiss GR, Hallum AV 3rd, Liu PY, Robinson WR 3rd, Cheng PC, Scudder SA, Markman M, Alberts DS. Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study. Int J Gynecol Cancer. 2006 Jan-Feb;16(1):298-305.|Smith HO, Jiang C, Weiss GR, et al.: Tirapazamine plus cisplatin in advanced or recurrent squamous or adenosquamous carcinoma of the uterine cervix: a phase II study of the Southwest Oncology Group. [Abstract] Gynecol Oncol 92 (1): A-49, 416, 2004.","\tCervical Cancer\tcisplatin|tirapazamine\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","uterine cervical neoplasms","tirapazamine","NA"]
["NCT00003370","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16317728,"Bomgaars LR, Megason GC, Pullen J, Langevin AM, Dale Weitman S, Hershon L, Kuhn JG, Bernstein M, Blaney SM. Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors. Pediatr Blood Cancer. 2006 Aug;47(2):163-8.","\tUnspecified Childhood Solid Tumor, Protocol Specific\tirofulven\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","irofulven","NA"]
["NCT00003372","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14586216,"Bélanger K, MacDonald D, Cairncross G, Gertler S, Forsyth P, Burdette-Radoux S, Bergeron J, Soulières D, Ludwin S, Wainman N, Eisenhauer E. A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma. Invest New Drugs. 2003 Nov;21(4):473-80.","\tBrain and Central Nervous System Tumors\ttopotecan hydrochloride\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|nervous system neoplasms|oligodendroglioma","topotecan","NA"]
["NCT00003375","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24419119|22851558|18976072|NA|NA","Prabhu RS, Won M, Shaw EG, Hu C, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta MP. Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02. J Clin Oncol. 2014 Feb 20;32(6):535-41. doi: 10.1200/JCO.2013.53.1830. Epub 2014 Jan 13.|Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta MP. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol. 2012 Sep 1;30(25):3065-70. doi: 10.1200/JCO.2011.35.8598. Epub 2012 Jul 30.|Shaw EG, Berkey B, Coons SW, Bullard D, Brachman D, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta M. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg. 2008 Nov;109(5):835-41. doi: 10.3171/JNS/2008/109/11/0835.|Shaw EG, Wang S, Coons S, et al.: Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: radiation therapy (RT) versus RT + procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG). [Abstract] J Clin Oncol 26 (Suppl 15): A-2006, 2008.|Shaw EG, Berkey B, Coons SW, et al.: Initial report of Radiation Therapy Oncology Group (RTOG) 9802: prospective studies in adult low-grade glioma (LGG). [Abstract] J Clin Oncol 24 (Suppl 18): A-1500, 2006.","\tBrain and Central Nervous System Tumors\tlomustine|procarbazine hydrochloride|vincristine sulfate|radiation therapy\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Radiation\tAll\t","Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma","Interventional","Completed","Phase 2/Phase 3",3,370,"nervous system neoplasms|central nervous system neoplasms","vincristine|lomustine|procarbazine","NA"]
["NCT00003376","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15073851|NA","Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer. 2004 Apr 15;100(8):1639-45.|Dreicer R, Manola J, Roth B, et al.: ECOG 4897: phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-1542, 2003.","\tBladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer\tcisplatin|carboplatin|doxorubicin hydrochloride|methotrexate|paclitaxel|vinblastine\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","kidney neoplasms|urinary bladder neoplasms|urethral neoplasms|ureteral neoplasms|carcinoma, transitional cell","paclitaxel|doxorubicin|liposomal doxorubicin|methotrexate|carboplatin|vinblastine","NA"]
["NCT00003377","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19010522,"Walker JL, Morrison A, DiSilvestro P, von Gruenigen VE; Gynecologic Oncology Group. A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study. Gynecol Oncol. 2009 Jan;112(1):78-84. doi: 10.1016/j.ygyno.2008.09.035. Epub 2008 Nov 17.","\tCervical Cancer\tcisplatin|paclitaxel|brachytherapy|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Radiation|Radiation\tFemale\t","NA","NA","NA","NA","NA","NA","uterine cervical neoplasms","cisplatin|paclitaxel","NA"]
["NCT00003378","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22155262|NA|14751144","Gould N, Sill MW, Mannel RS, Thaker PH, Disilvestro P, Waggoner S, Yamada SD, Armstrong DK, Wenzel L, Huang H, Fracasso PM, Walker JL. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr;125(1):54-8. doi: 10.1016/j.ygyno.2011.12.417. Epub 2011 Dec 11.|Look KY, Bookman MA, Brady MF, et al.: An update of the phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer (Eoc/Ppc): a Gynecologic Oncology Group (GOG) study. [Abstract] Society of Gynecologic Oncologists 2004 Annual Meeting on Women's Cancer, 7-11 February 2004, San Diego, California. A-695, 2004.|Look KY, Bookman MA, Schol J, Herzog TJ, Rocereto T, Vinters J; Gynecologic Oncology Group Study. Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Jan;92(1):93-100.","\tOvarian Cancer|Primary Peritoneal Cavity Cancer\tcarboplatin|gemcitabine hydrochloride|paclitaxel\tNA\tNA\tNA\tDrug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","NA","carboplatin|gemcitabine|paclitaxel","NA"]
["NCT00003379","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16889823|NA","DiSilvestro PA, Walker JL, Morrison A, Rose PG, Homesley H, Warshal D; Gynecologic Oncology Group. Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006 Dec;103(3):1038-42. Epub 2006 Aug 4.|Walker J, Morrison A, DiSilvestro P, et al.: GOG protocol 9803: phase I evaluation of the treatment of invasive cervical cancer confined to the pelvis with combination of radiation and weekly cisplatin and paclitaxel. [Abstract] Int J Gynecol Cancer 14 (Suppl 1): A-157, 46, 2004.","\tCervical Cancer\tcisplatin|paclitaxel|brachytherapy|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Radiation|Radiation\tFemale\t","NA","NA","NA","NA","NA","NA","uterine cervical neoplasms","paclitaxel|cisplatin","NA"]
["NCT00003382","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16150481,"Chen MD, Fleming GF, Mitchell S, Horowitz I. A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Jan;100(1):111-5. Epub 2005 Sep 8.","\tFallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer\tfilgrastim|gemcitabine hydrochloride|topotecan hydrochloride\tNA\tNA\tNA\tBiological|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","carcinoma, ovarian epithelial|fallopian tube neoplasms|ovarian neoplasms","topotecan|gemcitabine","NA"]
["NCT00003385","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16959305|10944128","Rose PG, Greer BE, Horowitz IR, Markman M, Fusco N. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group. Gynecol Oncol. 2007 Jan;104(1):114-9. Epub 2006 Sep 7.|Rose PG, Rodriguez M, Waggoner S, Greer BE, Horowitz IR, Fowler JM, McGuire WP. Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study. J Clin Oncol. 2000 Aug;18(16):2957-62.","\tFallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer\tcarboplatin|paclitaxel|pegylated liposomal doxorubicin hydrochloride\tNA\tNA\tNA\tDrug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","fallopian tube neoplasms","liposomal doxorubicin|paclitaxel|doxorubicin|carboplatin","NA"]
["NCT00003387","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19652624|17404369","Stinchcombe TE, Hodgson L, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Niell HB, Atkins JN, Akerley W, Green MR, Vokes EE; Cancer and Leukemia Group B. Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2009 Sep;4(9):1117-25. doi: 10.1097/JTO.0b013e3181b27b33.|Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W, Green MR; Cancer and Leukemia Group B. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007 May 1;25(13):1698-704. Epub 2007 Apr 2.","\tLung Cancer\tcarboplatin|chemotherapy|paclitaxel|radiation therapy\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Radiation\tAll\t","Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery","Interventional","Completed","Phase 3",2,366,"lung neoplasms|carcinoma, non-small-cell lung","carboplatin|paclitaxel","NA"]
["NCT00003404",8267829,4515849,"rate of occurance",0.35,null,"NA",0,8,95,"NA",null,19424757,"Barth RJ Jr, Wells WA, Mitchell SE, Cole BF. A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol. 2009 Aug;16(8):2288-94. doi: 10.1245/s10434-009-0489-2. Epub 2009 May 8.","\tBreast Cancer\tAdjuvant Radiotherapy\tNA\tNA\tNA\tRadiation\tFemale\t","NA","NA","NA","NA","NA","NA","phyllodes tumor","NA","Local Recurrence Rate"]
["NCT00003409","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17560737,"Ford JM, Seiferheld W, Alger JR, Wu G, Endicott TJ, Mehta M, Curran W, Phan SC. Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):831-8. Epub 2007 Jun 8.","\tBrain and Central Nervous System Tumors\tmotexafin gadolinium|radiation therapy\tNA\tNA\tNA\tDrug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","glioblastoma|nervous system neoplasms|central nervous system neoplasms","motexafin gadolinium","NA"]
["NCT00003414","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17889355,"Bolaños-Meade J, Garrett-Mayer E, Luznik L, Anders V, Webb J, Fuchs EJ, Huff CA, Matsui W, Borrello IM, Brodsky R, Kasamon YL, Swinnen LJ, Flinn IW, Ambinder RF, Jones RJ, Hess AD, Vogelsang GB. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant. 2007 Oct;13(10):1185-91. Epub 2007 Aug 3.","\tGraft Versus Host Disease|Lymphoma\taldesleukin|recombinant interferon gamma|busulfan|cyclophosphamide|cyclosporine|peripheral blood stem cell transplantation|radiation therapy\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|graft vs host disease","interferon-gamma|cyclophosphamide|interferons|busulfan|cyclosporins|aldesleukin|cyclosporine","NA"]
["NCT00003415","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","List AF, Talley M, Obregon Y, et al.: Combined treatment with amifostine and topotecan: high remitting potential in advanced myelodysplastic syndrome (MDS). [Abstract] Proceedings of the American Society of Clinical Oncology 19: A103, 28a, 2000.","\tLeukemia|Myelodysplastic Syndromes\tamifostine trihydrate|topotecan hydrochloride\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","preleukemia|syndrome|myelodysplastic syndromes","topotecan|amifostine","NA"]
["NCT00003417","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19533025|18723297|NA|NA","Corn BW, Wang M, Fox S, Michalski J, Purdy J, Simpson J, Kresl J, Curran WJ Jr, Diaz A, Mehta M, Movsas B. Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03. J Neurooncol. 2009 Nov;95(2):247-257. doi: 10.1007/s11060-009-9923-3. Epub 2009 Jun 16.|Tsien C, Moughan J, Michalski JM, Gilbert MR, Purdy J, Simpson J, Kresel JJ, Curran WJ, Diaz A, Mehta MP; Radiation Therapy Oncology Group Trial 98-03. Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03. Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):699-708. doi: 10.1016/j.ijrobp.2008.05.034. Epub 2008 Aug 23.|Fox W, Berkey B, Michalski J, et al.: Health-related quality of life and cognitive status in patiens with glioblastoma multiforme receiving escalating doses of comformal three-dimensional radiation on RTOG 9803. [Abstract] Int J Radiat Oncol Biol Phys 63 (2 Suppll 1): A-128, S78, 2005.|Werner-Wasik M, Seiferheld W, Michalski J, et al.: Phase I/II conformal three-dimensional radiation therapy dose escalation study in patients with supratentorial glioblastoma multiforme: report of the Radiation Therapy Oncology Group 98-03 protocol. [Abstract] Int J Radiat Oncol Biol Phys 60 (1 Suppl 1): A-58, S163-4, 2004. Available online. Last accessed January 27, 2005.","\tBrain and Central Nervous System Tumors\tcarmustine|radiation therapy\tNA\tNA\tNA\tDrug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","glioblastoma|nervous system neoplasms|central nervous system neoplasms","carmustine","NA"]
["NCT00003418","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17267326|17307102|NA|15014181","Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC; Intergroup Exemestane Study group. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007 Feb;8(2):119-27.|Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007 Feb 17;369(9561):559-70. Erratum in: Lancet. 2007 Mar 17;369(9565):906.|Coombes RC, Paridaens R, Jassem J, et al.: First mature analysis of the Intergroup Exemestane Study. [Abstract] J Clin Oncol 24 (Suppl 18): A-LBA527, 2006.|Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004 Mar 11;350(11):1081-92. Erratum in: N Engl J Med. 2004 Dec 2;351(23):2461. N Engl J Med. 2006 Oct 19;355(16):1746. van de Velde, Cornelius [added].","\tBreast Cancer\texemestane|tamoxifen citrate\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","exemestane|tamoxifen","NA"]
["NCT00003420","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17416851|NA","Rustin GJ, Mead GM, Stenning SP, Vasey PA, Aass N, Huddart RA, Sokal MP, Joffe JK, Harland SJ, Kirk SJ; National Cancer Research Institute Testis Cancer Clinical Studies Group. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol. 2007 Apr 10;25(11):1310-5.|Mead GM, Rustin GJ, Stenning SP, et al.: Medical Research Council trial of 2 versus 5 CT scans in the surveillance of patients with stage I non-seminomatous germ cell tumours of the testis. [Abstract] J Clin Oncol 24 (Suppl 18): A-4519, 221s, 2006.","\tTesticular Germ Cell Tumor\tcomputed tomography\tNA\tNA\tNA\tProcedure\tMale\t","NA","NA","NA","NA","NA","NA","neoplasms, germ cell and embryonal","NA","NA"]
["NCT00003421","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16314615,"Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, MacLennan KA, Stenning SP, Clawson S, Smith P, Ryder D, Hancock BW; United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol. 2005 Dec 20;23(36):9208-18. Epub 2005 Nov 28.","\tLymphoma\tbleomycin sulfate|ABVD regimen|chlorambucil|dacarbazine|doxorubicin hydrochloride|etoposide|prednisolone|procarbazine hydrochloride|vinblastine sulfate|vincristine sulfate|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|hodgkin disease","vincristine|chlorambucil|liposomal doxorubicin|bleomycin|dacarbazine|vinblastine|prednisolone|procarbazine|doxorubicin|etoposide","NA"]
["NCT00003422","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|20585099|19269520|19269519|NA","Sebag-Montefiore D, Steele R, Quirke P, et al.: Routine short course pre-op radiotherapy or selective post-op chemoradiotherapy for resectable rectal cancer? Preliminary results of the MRC CR07 randomised trial. [Abstract] J Clin Oncol 24 (Suppl 18): A-3511, 2006.|Sebag-Montefiore D: An update report on the MRC CR07 trial. [Abstract] Br J Cancer 85 (suppl 1): A-9.3, 28, 2001.|Stephens RJ, Thompson LC, Quirke P, Steele R, Grieve R, Couture J, Griffiths GO, Sebag-Montefiore D. Impact of short-course preoperative radiotherapy for rectal cancer on patients' quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. J Clin Oncol. 2010 Sep 20;28(27):4233-9. doi: 10.1200/JCO.2009.26.5264. Epub 2010 Jun 28.|Quirke P, Steele R, Monson J, Grieve R, Khanna S, Couture J, O'Callaghan C, Myint AS, Bessell E, Thompson LC, Parmar M, Stephens RJ, Sebag-Montefiore D; MRC CR07/NCIC-CTG CO16 Trial Investigators; NCRI Colorectal Cancer Study Group. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet. 2009 Mar 7;373(9666):821-8. doi: 10.1016/S0140-6736(09)60485-2.|Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint AS, Bessell E, Griffiths G, Thompson LC, Parmar M. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009 Mar 7;373(9666):811-20. doi: 10.1016/S0140-6736(09)60484-0.|Quirke P, Sebag-Montefiore D, Steele R, et al.: Local recurrence after rectal cancer resection is strongly related to the plane of surgical dissection and is further reduced by pre-operative short course radiotherapy. Preliminary results of the Medical Research Council (MRC) CR07 trial. [Abstract] J Clin Oncol 24 (Suppl 18): A-3512, 2006.","\tColorectal Cancer\tfluorouracil|leucovorin calcium|adjuvant therapy|conventional surgery|neoadjuvant therapy|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Procedure|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","rectal neoplasms","leucovorin|fluorouracil|levoleucovorin|calcium","NA"]
["NCT00003425","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14767498,"Phillips GL, Meisenberg BR, Reece DE, Adams VR, Badros AZ, Brunner JL, Fenton RG, Filicko J, Grosso DL, Hale GA, Howard DS, Johnson VP, Kniska A, Marshall KW, Mookerjee B, Nath R, Rapoport AP, Sarkodee-Adoo C, Takebe N, Vesole DH, Wagner JL, Flomenberg N. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant. 2004 Apr;33(8):781-7.","\tBreast Cancer|Leukemia|Lymphoma|Neuroblastoma|Ovarian Cancer|Sarcoma|Unspecified Adult Solid Tumor, Protocol Specific\tmelphalan|amifostine trihydrate|cyclophosphamide|filgrastim|peripheral blood stem cell transplantation\tNA\tNA\tNA\tDrug|Drug|Drug|Biological|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","sarcoma|lymphoma|neuroblastoma|breast neoplasms|leukemia","cyclophosphamide|amifostine|melphalan","NA"]
["NCT00003427","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12196376,"Kemeny N, Tong W, Gonen M, Stockman J, Di Lauro C, Teitcher J, White P, Price C, Saltz L, Sharma S, Graham MA. Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Ann Oncol. 2002 Sep;13(9):1490-6.","\tAnal Cancer|Colorectal Cancer|Esophageal Cancer|Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Gastric Cancer|Gastrointestinal Carcinoid Tumor|Liver Cancer|Pancreatic Cancer|Small Intestine Cancer\tirinotecan hydrochloride|oxaliplatin\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","intestinal neoplasms|pancreatic neoplasms|malignant carcinoid syndrome|liver neoplasms|gastrointestinal neoplasms|gallbladder neoplasms|esophageal neoplasms|anus neoplasms|stomach neoplasms|bile duct neoplasms|cholangiocarcinoma|carcinoid tumor","oxaliplatin|irinotecan","NA"]
["NCT00003437","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21106984|NA|15952999|15801953|NA|12694250|12780755|12153596|12111109","Ensor HM, Schwab C, Russell LJ, Richards SM, Morrison H, Masic D, Jones L, Kinsey SE, Vora AJ, Mitchell CD, Harrison CJ, Moorman AV. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood. 2011 Feb 17;117(7):2129-36. doi: 10.1182/blood-2010-07-297135. Epub 2010 Nov 24. Erratum in: Blood. 2011 May 5;117(18):5009.|Moorman AV, Ensor HM, Chilton L, et al.: Prognostic relevance of cytogenetics in childhood acute lymphoblastic leukaemia (ALL): final results from MRC ALL97. [Abstract] Blood 114 (22): A-88, 2009.|Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO; Medical Research Council Childhood Leukaemia Working Party. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005 Jun;129(6):734-45.|Roy A, Bradburn M, Moorman AV, Burrett J, Love S, Kinsey SE, Mitchell C, Vora A, Eden T, Lilleyman JS, Hann I, Saha V; Medical Research Council Childhood Leukaemia Working Party. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. Br J Haematol. 2005 Apr;129(1):35-44.|Mitchell CD, Richards SM, Kinsey SE, et al.: Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of UK MRC trial ALL97/99. [Abstract] Pediatr Blood Cancer 43 (4): A-0.082, 2004.|Somervaille TC, Hann IM, Harrison G, Eden TO, Gibson BE, Hill FG, Mitchell C, Kinsey SE, Vora AJ, Lilleyman JS; MRC Childhood Leukaemia Working Party. Intraocular relapse of childhood acute lymphoblastic leukaemia. Br J Haematol. 2003 Apr;121(2):280-8.|Wallace AM, Tucker P, Williams DM, Hughes IA, Ahmed SF. Short-term effects of prednisolone and dexamethasone on circulating concentrations of leptin and sex hormone-binding globulin in children being treated for acute lymphoblastic leukaemia. Clin Endocrinol (Oxf). 2003 Jun;58(6):770-6.|Ahmed SF, Tucker P, Mushtaq T, Wallace AM, Williams DM, Hughes IA. Short-term effects on linear growth and bone turnover in children randomized to receive prednisolone or dexamethasone. Clin Endocrinol (Oxf). 2002 Aug;57(2):185-91.|Lancaster DL, Patel N, Lennard L, Lilleyman JS. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia. Cancer Chemother Pharmacol. 2002 Jul;50(1):33-6. Epub 2002 Apr 27.","\tLeukemia\tasparaginase|cyclophosphamide|cytarabine|daunorubicin hydrochloride|dexamethasone|doxorubicin hydrochloride|mercaptopurine|methotrexate|pegaspargase|prednisolone|thioguanine|vincristine sulfate|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, lymphoid|leukemia|precursor cell lymphoblastic leukemia-lymphoma","thioguanine|cyclophosphamide|doxorubicin|dexamethasone|cytarabine|prednisolone|daunorubicin|asparaginase|methotrexate|liposomal doxorubicin|mercaptopurine|pegaspargase|vincristine","NA"]
["NCT00003447","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12618501|NA","Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferraù F, Piazza E, Rosetti F, Clerici M, Bertetto O, Robbiati SF, Frontini L, Sacco C, Castiglione F, Favaretto A, Novello S, Migliorino MR, Gasparini G, Galetta D, Iaffaioli RV, Gebbia V; MILES Investigators. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003 Mar 5;95(5):362-72.|Gridelli C, Perrone S, Cigolari L, et al.: The MILES (Multicenter Italian Lung Cancer in the Elderly Study) phase 3 trial: gemcitabine + vinorelbine vs vinorelbine and vs gemcitabine in elderly advanced NSCLC patients. [Abstract] Proceedings of the American Society of Clinical Oncology A-1230, 2001.","\tLung Cancer\tgemcitabine hydrochloride|vinorelbine tartrate\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|carcinoma, non-small-cell lung","vinorelbine|gemcitabine","NA"]
["NCT00003518","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17290059|11919245","Einhorn LH, Brames MJ, Juliar B, Williams SD. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol. 2007 Feb 10;25(5):513-6.|Hinton S, Catalano P, Einhorn LH, Loehrer PJ Sr, Kuzel T, Vaughn D, Wilding G. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2002 Apr 1;20(7):1859-63. Erratum in: J Clin Oncol 2002 Sep 1;20(17):3754.","\tOvarian Cancer|Testicular Germ Cell Tumor\tgemcitabine hydrochloride|paclitaxel\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","testicular neoplasms|neoplasms, germ cell and embryonal","paclitaxel|gemcitabine","NA"]
["NCT00003519","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18487567|18678838|NA|NA|NA|NA","Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, Rowley SC, Shak S, Perez EA, Shulman LJ, Martino S, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol. 2008 May 20;26(15):2473-81. doi: 10.1200/JCO.2007.13.6424. Erratum in: J Clin Oncol. 2008 Jul 10;26(20):3472. Perez, Edith D [corrected to Perez, Edith A].|Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, Sledge GW Jr, Perez EA, Shulman LN, Martino S, Sparano JA. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008 Sep 1;26(25):4063-71. doi: 10.1200/JCO.2007.14.4501. Epub 2008 Aug 4. Erratum in: J Clin Oncol. 2009 Jul 20;27(21):3566.|Goldstein LJ, Gray R, Childs BH, et al.: Prognostic utility of 21-gene assay in hormone receptor (HR) positive operable breast cancer and 0-3 positive axillary nodes treated with adjuvant chemohormonal therapy (CHT): an analysis of Intergroup trial E2197. [Abstract] J Clin Oncol 25 (Suppl 18): A-526, 2007.|Goldstein LJ, O'Neill A, Sparano J, et al.: E2197: Phase III AT (doxorubucin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. [Abstract] J Clin Oncol 23 (Suppl 16): A-512, 7s, 2005.|Goldstein LJ, O'Neill A, Sparano JA, et al.: LVEF assessment of adjuvant doxorubicin/cyclophosphamide (AC) vs. doxorubicin/docetaxel (AT) in early stage breast cancer: cardiac safety results of ECOG 2197. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-73, 2003.|Goldstein L, Ravdin P, Gray R, et al.: Prognostic utility of the 21-gene assay compared with adjuvant in hormone receptor (HR) positive operable breast cancer with 0-3 positive axillary nodes treated with adjuvant chemohormonal therapy (CHT): an analysis of intergroup trial E2197. [Abstract] Breast Cancer Res Treat 106 (1): A-63, S17, 2007.","\tBreast Cancer\tcyclophosphamide|docetaxel|doxorubicin hydrochloride\tNA\tNA\tNA\tDrug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","cyclophosphamide|liposomal doxorubicin|docetaxel|doxorubicin","NA"]
["NCT00003523","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15589582,"Miller DS, Blessing JA, Waggoner S, Schilder J, Sorosky J, Bloss J, Schilder R. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2005 Jan;96(1):67-71.","\tOvarian Cancer|Primary Peritoneal Cavity Cancer\taminocamptothecin colloidal dispersion\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","ovarian neoplasms|carcinoma, ovarian epithelial","NA","NA"]
["NCT00003538","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",9849691,"O'Donnell PV, Jones RJ, Vogelsang GB, Seber A, Ambinder RF, Flinn I, Miller C, Marcellus DC, Griffin C, Abrams R, Braine HG, Grever M, Hess AD, Piantadosi S, Noga SJ. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies. Bone Marrow Transplant. 1998 Nov;22(10):947-55.","\tCancer\tgraft versus host disease prophylaxis/therapy|allogeneic bone marrow transplantation\tNA\tNA\tNA\tBiological|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","graft vs host disease","NA","NA"]
["NCT00003539","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","11352950|NA|NA","Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001 May 15;19(10):2587-95.|Seidman AD, Fornier M, Esteva F, et al.: Final report: weekly herceptin and taxol for metastatic breast cancer: analysis of efficacy by HER2 immunophenotype [immunohistochemistry (IHC)] and gene amplification [fluorescent in-situ hybridization (FISH)]. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A319, 2000.|Fornier M, Seidman AD, Esteva FJ, et al.: Weekly herceptin plus one hour taxol: phase II study in HER2 overexpressing (H2+) and non-overexpressing (H2-) metastatic breast cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 18: A482, 1999.","\tBreast Cancer\ttrastuzumab|paclitaxel\tNA\tNA\tNA\tBiological|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","trastuzumab|paclitaxel","NA"]
["NCT00003545","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17344466|NA","DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007 Jun 15;109(12):5136-42. Epub 2007 Mar 7.|De Angelo DJ, Yu D, Dodge RK, et al.: A phase II study of 2-amino-9-b-D-arabinosyl-6-methoxy-9H-purine (506U78) in patients with relapsed or refractory T-Lineage acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): CALGB study 19801. [Abstract] Blood 100 (11 Pt 1): A-743, 2002.","\tLeukemia|Lymphoma\tnelarabine\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","precursor cell lymphoblastic leukemia-lymphoma|leukemia, lymphoid|leukemia|lymphoma","NA","NA"]
["NCT00003546","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15361643,"Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 2003;34(2-3):107-16.","\tPancreatic Cancer\tgemcitabine hydrochloride|radiation therapy\tNA\tNA\tNA\tDrug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","pancreatic neoplasms","gemcitabine","NA"]
["NCT00003553","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",10984562,"Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000 Sep 14;343(11):750-8.","\tKidney Cancer\tHLA Matched Peripheral BLood Stem Cells\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, renal cell|kidney neoplasms","NA","NA"]
["NCT00003554","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18067008,"Baz R, Fanning S, Kunkel L, Gaballa S, Karam MA, Reed J, Kelly M, Hussein M. Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma. Leuk Lymphoma. 2007 Dec;48(12):2338-44.","\tMultiple Myeloma and Plasma Cell Neoplasm\trituximab|melphalan|prednisone\tNA\tNA\tNA\tBiological|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms, plasma cell|multiple myeloma|plasmacytoma","prednisone|rituximab|melphalan","NA"]
["NCT00003563","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18406884|17401015","Li J, Bentzen SM, Li J, Renschler M, Mehta MP. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):64-70. doi: 10.1016/j.ijrobp.2007.09.059.|Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol. 2007 Apr 1;25(10):1260-6.","\tMetastatic Cancer\tWBRT|MGd\tNA\tNA\tNA\tRadiation|Drug\tAll\t","Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases","Interventional","Completed","Phase 3",2,430,"neoplasm metastasis","NA","NA"]
["NCT00003565","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17545536,"Lewis LD, Miller AA, Rosner GL, Dowell JE, Valdivieso M, Relling MV, Egorin MJ, Bies RR, Hollis DR, Levine EG, Otterson GA, Millard F, Ratain MJ; Cancer and Leukemia Group B. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res. 2007 Jun 1;13(11):3302-11.","\tBladder Cancer|Breast Cancer|Head and Neck Cancer|Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific\tdocetaxel\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|head and neck neoplasms|breast neoplasms|urinary bladder neoplasms","docetaxel","NA"]
["NCT00003566","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Jaklitsch MT, Gu L, Harpole DH, et al.: Prospective phase II trial of pre-resection thoracoscopic (VATS) restaging following neoadjuvant therapy for IIIA(N2) non-small cell lung cancer (NSCLC): results of CALGB 39803. [Abstract] J Clin Oncol 23 (Suppl 16): A-7065, 636s, 2005.","\tLung Cancer\tvideothoracoscopy\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|carcinoma, non-small-cell lung","NA","NA"]
["NCT00003571","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","14726676|15386381","Arnold CN, Goel A, Compton C, Marcus V, Niedzwiecki D, Dowell JM, Wasserman L, Inoue T, Mayer RJ, Bertagnolli MM, Boland CR. Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. Cancer Biol Ther. 2004 Jan;3(1):73-8. Epub 2004 Jan 5.|Goel A, Arnold CN, Tassone P, Chang DK, Niedzwiecki D, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer. 2004 Dec 10;112(5):754-9.","\tColorectal Cancer\tmutation analysis|tumor replication error analysis\tNA\tNA\tNA\tGenetic|Genetic\tAll\t","NA","NA","NA","NA","NA","NA","colonic neoplasms","NA","NA"]
["NCT00003576","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16012523,"Soo KC, Tan EH, Wee J, Lim D, Tai BC, Khoo ML, Goh C, Leong SS, Tan T, Fong KW, Lu P, See A, Machin D. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. Br J Cancer. 2005 Aug 8;93(3):279-86.","\tHead and Neck Cancer\tcisplatin|fluorouracil|surgical procedure|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","fluorouracil","NA"]
["NCT00003577","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18797468,"Earl HM, Hiller L, Dunn JA, Bathers S, Harvey P, Stanley A, Grieve RJ, Agrawal RK, Fernando IN, Brunt AM, McAdam K, O'Reilly S, Rea DW, Spooner D, Poole CJ; NEAT Investigators. NEAT: National Epirubicin Adjuvant Trial--toxicity, delivered dose intensity and quality of life. Br J Cancer. 2008 Oct 21;99(8):1226-31. doi: 10.1038/sj.bjc.6604674. Epub 2008 Sep 16.","\tBreast Cancer\tCMF regimen|cyclophosphamide|epirubicin hydrochloride|fluorouracil|methotrexate|adjuvant therapy|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Procedure|Radiation\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","methotrexate|cyclophosphamide|fluorouracil|epirubicin","NA"]
["NCT00003587","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15297403,"Edelman MJ, Clark JI, Chansky K, Albain K, Bhoopalam N, Weiss GR, Giguere JK, Kelly K, Crowley J, Gandara DR. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res. 2004 Aug 1;10(15):5022-6.","\tLung Cancer\tcarboplatin|cisplatin|docetaxel|gemcitabine|paclitaxel|vinorelbine\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug|Drug|Drug\tAll\t","S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer","Interventional","Completed","Phase 2",2,204,"carcinoma, non-small-cell lung|lung neoplasms","paclitaxel|vinorelbine|docetaxel|gemcitabine|carboplatin","NA"]
["NCT00003589","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16968876|14581415","Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, Schramel F, Smit HJ, Gaafar R, Biesma B, Manegold C, Coens C, Giaccone G, Van Meerbeeck J; EORTC Lung Cancer Group and Quality of Life Unit. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol. 2006 Nov;17(11):1698-704. Epub 2006 Sep 12.|Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G; European Organization for Research and Treatment of Cancer Lung Cancer Group. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. J Clin Oncol. 2003 Nov 1;21(21):3909-17.","\tLung Cancer\tcisplatin|gemcitabine hydrochloride|paclitaxel\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","paclitaxel|gemcitabine","NA"]
["NCT00003590","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Swinnen LJ, Rankin C, Rushing EJ, et al.: Phase II study of hydroxyurea for unresectable meningioma (Southwest Oncology Group S9811). [Abstract] J Clin Oncol 27 (Suppl 15): A-2063, 2009.","\tAdult Meningioma\thydroxyurea\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","meningioma","hydroxyurea","NA"]
["NCT00003591","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|14758134|NA","Konski AA, Winter K, Khor L, et al.: Over-expression of RIa subunit (RIas) of protein kinase A may be a marker for favorable pancreatic cancer: an analysis of patients treated on Radiation Therapy Oncology Group (RTOG) 98-12. [Abstract] American Society of Clinical Oncology 2006 Gastrointestinal Cancers Symposium, 26-28 January 2006, San Francisco, California. A-148, 2006.|Rich T, Harris J, Abrams R, Erickson B, Doherty M, Paradelo J, Small W Jr, Safran H, Wanebo HJ. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol. 2004 Feb;27(1):51-6.|Rich T, Harris J, Abrams R, et al.: A phase II study of external irradiation and weekly paclitaxel for non-metastatic, unresectable pancreatic cancer: a preliminary report of RTOG protocol 98-12. [Abstract] Int J Radiat Oncol Biol Phys 51(3 suppl 1): A-51, 29-30, 2001.","\tPancreatic Cancer\tpaclitaxel|radiation therapy\tNA\tNA\tNA\tDrug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","pancreatic neoplasms","paclitaxel","NA"]
["NCT00003593","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22392565|21849481|NA|NA","Sorrell AD, Alonzo TA, Hilden JM, Gerbing RB, Loew TW, Hathaway L, Barnard D, Taub JW, Ravindranath Y, Smith FO, Arceci RJ, Woods WG, Gamis AS. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group. Cancer. 2012 Oct 1;118(19):4806-14. doi: 10.1002/cncr.27484. Epub 2012 Mar 5.|Gamis AS, Alonzo TA, Gerbing RB, Hilden JM, Sorrell AD, Sharma M, Loew TW, Arceci RJ, Barnard D, Doyle J, Massey G, Perentesis J, Ravindranath Y, Taub J, Smith FO. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood. 2011 Dec 22;118(26):6752-9; quiz 6996. doi: 10.1182/blood-2011-04-350017. Epub 2011 Aug 17.|Gamis AS, Alonzo TA, Hilden JM, et al.: Outcome of Down syndrome (DS) children with acute myeloid leukemia (AML) or myelodysplasia (MDS) treated with a uniform prospective clinical trial initial report of the COG trial A2971. [Abstract] Blood 108 (11): A-15, 2006.|Sharma M, Alonzo TA, Sorrell A, et al.: Uniform approach better defines natural history of transient myeloproliferative disorder (TMD) in Down syndrome (DS) neonates: outcomes from Children's Oncology Group (COG) study A2971. [Abstract] Blood 108 (11): A-376, 2006.","\tLeukemia|Myelodysplastic/Myeloproliferative Neoplasms|Myelodysplastic Syndromes\tasparaginase|cytarabine|daunorubicin hydrochloride|methotrexate|therapeutic hydrocortisone|thioguanine\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug\tAll\t","Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome","Interventional","Completed","Phase 3",2,254,"myeloproliferative disorders|myelodysplastic syndromes|syndrome|leukemia|down syndrome|myelodysplastic-myeloproliferative diseases|preleukemia","cytarabine|hydrocortisone|daunorubicin|asparaginase|methotrexate|thioguanine|hydrocortisone 17-butyrate 21-propionate|hydrocortisone hemisuccinate|hydrocortisone acetate","NA"]
["NCT00003594","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21632455|21422438|20697547|20530282|19828593|19636001|19073970|19001325|NA|17687151|NA|NA|16849748|NA|15677624|NA|15470715|NA|14665611|NA|NA|NA","Heun JM, Grothey A, Branda ME, Goldberg RM, Sargent DJ. Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741. Oncologist. 2011;16(6):859-67. doi: 10.1634/theoncologist.2011-0064. Epub 2011 May 31.|Ng K, Sargent DJ, Goldberg RM, Meyerhardt JA, Green EM, Pitot HC, Hollis BW, Pollak MN, Fuchs CS. Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. J Clin Oncol. 2011 Apr 20;29(12):1599-606. doi: 10.1200/JCO.2010.31.7255. Epub 2011 Mar 21.|Goldberg RM, Sargent DJ, McLeod H. Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics. Trans Am Clin Climatol Assoc. 2010;121:21-32; discussion 32-3.|McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Thibodeau SN, Grothey A, Morton RF, Goldberg RM. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol. 2010 Jul 10;28(20):3227-33. doi: 10.1200/JCO.2009.21.7943. Epub 2010 Jun 7.|Goldberg RM, Sargent DJ, Morton RF, Green E, Sanoff HK, McLeod H, Buckner J. NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial. Oncologist. 2009 Oct;14(10):970-8. doi: 10.1634/theoncologist.2009-0175. Epub 2009 Oct 14. Review.|Sanoff HK, Sargent DJ, Green EM, McLeod HL, Goldberg RM. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol. 2009 Sep 1;27(25):4109-15. doi: 10.1200/JCO.2009.21.9527. Epub 2009 Jul 27.|Fuchs CS, Goldberg RM, Sargent DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, Pollak M. Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res. 2008 Dec 15;14(24):8263-9. doi: 10.1158/1078-0432.CCR-08-0480. Epub 2008 Dec 10.|Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008 Dec 10;26(35):5721-7. doi: 10.1200/JCO.2008.17.7147. Epub 2008 Nov 10.|Sargent DJ, Campbell M, Grothey A, et al.: Overall and 12 week tumor response versus actual tumor measurements as predictors of overall survival (OS) in advanced colorectal cancer (ACRC): findings from NCCTG N9741. [Abstract] American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium, 25-27 January 2008, Orlando, FL. A-446, 2008.|Dy GK, Krook JE, Green EM, Sargent DJ, Delaunoit T, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pockaj BA, Sticca RP, Alberts SR, Pitot HC 4th, Goldberg RM; Intergroup N9741. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. J Clin Oncol. 2007 Aug 10;25(23):3469-74. Erratum in: J Clin Oncol. 2007 Nov 20;25(33):5339.|Grothey A, Sargent DJ, Campbell ME, et al.: Waterfall plots provide detailed information on magnitude of response to conventional chemotherapy in colorectal cancer: lessons learned from N9741. [Abstract] American Society of Clinical Oncology 2007 Gastrointestinal Cancers Symposium, 19 -21 January 2007, Orlando, Florida A-337, 2007.|Goldberg RM, McLeod HL, Sargent DJ, et al.: Genetic polymorphisms, toxicity, and response rate in African Americans (AA) with metastatic colorectal cancer (MCRC) compared to Caucasians (C) when treated with IFL, FOLFOX or IROX in Intergroup N9741. [Abstract] J Clin Oncol 24 (Suppl 18): A-3503, 2006.|Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts S. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol. 2006 Jul 20;24(21):3347-53.|McLeod HL, Parodi L, Sargent DJ, et al.: UGT1A1*28, toxicity and outcome in advanced colorectal cancer: results from trial N9741. [Abstract] J Clin Oncol 24 (Suppl 18): A-3520, 2006.|Delaunoit T, Alberts SR, Sargent DJ, Green E, Goldberg RM, Krook J, Fuchs C, Ramanathan RK, Williamson SK, Morton RF, Findlay BP. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol. 2005 Mar;16(3):425-9. Epub 2005 Jan 27.|Dy GK, Krook J, Green E, et al.: Impact of complete response to chemotherapy on overall survival (OS) in advanced colorectal cancer (CRC): results from Intergroup N9741. [Abstract] American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium, 27-29 January 2005, Miami, Florida. A-185, 2005.|Delaunoit T, Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Findlay BP, Thomas SP, Salim M, Schaefer PL, Stella PJ, Green E, Mailliard JA. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer. 2004 Nov 15;101(10):2170-6.|Fuchs C, Pollak M, Sargent DJ, et al.: Insulin-like growth factor-I (IGF-1), IGF binding protein-3 (IGFBP-3), and outcome in metastatic colorectal cancer (CRC): results from intergroup trial N9741. [Abstract] J Clin Oncol 22 (Suppl 14): A-3521, 250s, 2004.|Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004 Jan 1;22(1):23-30. Epub 2003 Dec 9.|Goldberg RM, Morton RF, Sargent DJ, et al.: N9741: oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an intergroup study. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-1009, 252, 2003.|Goldberg RM, Morton RF, Sargent D, et al.: N9741: oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup study. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-511, 2002.|Morton RF, Goldberg RM, Sargent DJ, et al.: Oxaliplatin (OXAL) or CPT-11 Combined with 5FU/Leucovorin (LV) in Advanced Colorectal Cancer (CRC): an NCCTG/CALGB Study. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-495, 2001.","\tColorectal Cancer\tirinotecan|fluorouracil|leucovorin calcium|oxaliplatin\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug\tAll\t","Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer","Interventional","Completed","Phase 3",3,1691,"colorectal neoplasms","levoleucovorin|oxaliplatin|irinotecan|leucovorin|fluorouracil|calcium","NA"]
["NCT00003595","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|15914552","Chen X, Cesarman E, Hyjek E, et al.: FOXP1 expression in AIDS-associated diffuse large B-cell lymphoma (DLBCL): correlation with prognostic parameters in patients from AIDS Malignancies Consortium Trial 010. [Abstract] United States and Canadian Academy of Pathology 95th Annual Meeting, February 11-17, 2006, Atlanta, GA. A-1016, 2006.|Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, Levine AM, Scadden DT. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005 Sep 1;106(5):1538-43. Epub 2005 May 24.","\tLymphoma\tfilgrastim|rituximab|CHOP regimen|cyclophosphamide|doxorubicin hydrochloride|prednisone|vincristine sulfate\tParallel Assignment\tTreatment\tRandomized\tBiological|Biological|Drug|Drug|Drug|Drug|Drug\tAll\t","Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma","Interventional","Completed","Phase 3",2,120,"lymphoma|lymphoma, non-hodgkin","doxorubicin|prednisone|liposomal doxorubicin|vincristine|cyclophosphamide|rituximab","NA"]
["NCT00003596","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|20564111|24035327|19139424|18430910|NA|NA","Gunderson LL, Winter KA, Ajani JA, et al.: Long-term update of U.S. GI intergroup RTOG 98-11 phase III trial for anal carcinoma: disease-free and overall survival with RT+5FU-mitomycin versus RT+5FU-cisplatin. [Abstract] J Clin Oncol 29 (Suppl 15): A-4005, 2011.|Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010 Sep 1;116(17):4007-13. doi: 10.1002/cncr.25188.|Gunderson LL, Moughan J, Ajani JA, Pedersen JE, Winter KA, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):638-45. doi: 10.1016/j.ijrobp.2013.07.035. Epub 2013 Sep 10.|Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol. 2009 Mar 1;27(7):1116-21. doi: 10.1200/JCO.2008.19.6857. Epub 2009 Jan 12.|Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008 Apr 23;299(16):1914-21. doi: 10.1001/jama.299.16.1914.|Ajani JA, Winter KA, Gunderson LL, et al.: Intergroup RTOG 98-11: a phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal. [Abstract] J Clin Oncol 24 (Suppl 18): A-4009, 2006.|Gunderson LL, Winter KA, Ajani JA, et al.: Intergroup RTOG 9811 phase III comparison of chemoradiation with 5-FU and mitomycin vs 5-FU and cisplatin for anal canal carcinoma: impact on disease-free, overall and colostomy-free survival. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-43, S24, 2006.","\tAnal Cancer\tcisplatin|fluorouracil|mitomycin C|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","anus neoplasms","fluorouracil|mitomycins|mitomycin","NA"]
["NCT00003597","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15814645,"Angiolillo AL, Davenport V, Bonilla MA, van de Ven C, Ayello J, Militano O, Miller LL, Krailo M, Reaman G, Cairo MS; Children's Oncology Group. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. Clin Cancer Res. 2005 Apr 1;11(7):2644-50.","\tCancer\trecombinant human thrombopoietin|carboplatin|etoposide|ifosfamide|G-CSF\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Biological\tAll\t","Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors","Interventional","Completed","Phase 1",2,16,"NA","ifosfamide|lenograstim|carboplatin|etoposide|sargramostim","NA"]
["NCT00003606","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","11181777|NA","Pujol JL, Daurès JP, Rivière A, Quoix E, Westeel V, Quantin X, Breton JL, Lemarié E, Poudenx M, Milleron B, Moro D, Debieuvre D, Le Chevalier T. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst. 2001 Feb 21;93(4):300-8.|Pujol JL, Duares JP, Riviere A, et al.: Doublet etoposide - cisplatin (EP) versus quadruplet cisplatin - cyclophosphamide - epirubicin - etoposide (PCDE) in extensive disease small cell lung cancer (Ed-SCLC): a FNCLCC phase III multicenter study. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A-1892, 2000.","\tLung Cancer\tcisplatin|cyclophosphamide|epirubicin hydrochloride|etoposide|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|small cell lung carcinoma","etoposide|epirubicin|cyclophosphamide|cisplatin","NA"]
["NCT00003607","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18048817|NA","Pommier P, Chabaud S, Lagrange JL, Richaud P, Lesaunier F, Le Prise E, Wagner JP, Hay MH, Beckendorf V, Suchaud JP, Pabot du Chatelard PM, Bernier V, Voirin N, Perol D, Carrie C. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol. 2007 Dec 1;25(34):5366-73.|Pommier P, Perol D, Lagrange J, et al.: Does pelvis and prostate radiation therapy compared to prostate radiation therapy alone improve survival in patients with non metastatic prostate carcinoma? Preliminary results of the prospective randomized GETUG 01 trial. [Abstract] Int J Radiat Oncol Biol Phys 63 (Suppl 1): A-33, S19, 2005.","\tProstate Cancer\tradiation therapy\tNA\tNA\tNA\tRadiation\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","NA","NA"]
["NCT00003611","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21882176,"Kadakia KC, Barton DL, Loprinzi CL, Sloan JA, Otley CC, Diekmann BB, Novotny PJ, Alberts SR, Limburg PJ, Pittelkow MR. Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer. 2012 Apr 15;118(8):2128-37. doi: 10.1002/cncr.26374. Epub 2011 Aug 31.","\tNon-melanomatous Skin Cancer\tacitretin|placebo\tParallel Assignment\tPrevention\tRandomized\tDrug|Other\tAll\t","Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation","Interventional","Completed","N/A",2,129,"skin neoplasms","acitretin","NA"]
["NCT00003612","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16381626|NA|NA","Perez EA, Suman VJ, Rowland KM, Ingle JN, Salim M, Loprinzi CL, Flynn PJ, Mailliard JA, Kardinal CG, Krook JE, Thrower AR, Visscher DW, Jenkins RB. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32.|Perez EA, Rowland KM, Suman VJ, et al.: N98-32-52: efficacy and tolerability of two schedules of paclitaxel, carboplatin and trastuzumab in women with HER2 positive metastatic breast cancer: a North Central Cancer Treatment Group randomized phase II trial. [Abstract] Breast Cancer Res Treat 82 (Suppl 1): A-216, S47, 2003.|Rowland KM, Suman VJ, Ingle JN, et al.: NCCTG 98-32-52: randomized phase II trial of weekly versus every 3-week administration of paclitaxel, carboplatin and trastuzumab in women with HER2 positive metastatic breast cancer (MBC). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-31, 2003.","\tBreast Cancer\ttrastuzumab|carboplatin|paclitaxel\tParallel Assignment\tTreatment\tRandomized\tBiological|Drug|Drug\tFemale\t","Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer","Interventional","Completed","Phase 2",2,92,"breast neoplasms","paclitaxel|trastuzumab|carboplatin","NA"]
["NCT00003614","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Hudes GR, Manola J, Conroy J, et al.: Phase II study of weekly paclitaxel (P) by 1-hour infusion plus reduced-dose oral estramustine (EMP) in metastatic hormone-refractory prostate carcinoma (HRPC): a trial of the Eastern Cooperative Oncology Group. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-697, 2001.","\tProstate Cancer\testramustine phosphate sodium|paclitaxel\tNA\tNA\tNA\tDrug|Drug\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","estramustine|paclitaxel","NA"]
["NCT00003615","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17943599,"Kuzel TM, Li S, Eklund J, Foss F, Gascoyne R, Abramson N, Schwerkoske JF, Weller E, Horning SJ. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497. Leuk Lymphoma. 2007 Dec;48(12):2397-402. Epub 2007 Oct 13.","\tLymphoma\tdenileukin diftitox\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma, non-hodgkin|lymphoma","denileukin diftitox","NA"]
["NCT00003616","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16533878|14769140","Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J; North American Brain Tumor Consortium. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006 Apr;8(2):189-93. Epub 2006 Mar 13.|Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY, Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL, Hess KR, Kuhn J; North American Brain Tumor Consortium study. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2004 Jan;6(1):44-54.","\tBrain and Central Nervous System Tumors\tirinotecan hydrochloride\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|glioma|nervous system neoplasms","irinotecan","NA"]
["NCT00003617","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19036078|11895791|NA","Hancock BW, Qian W, Linch D, Delchier JC, Smith P, Jakupovic I, Burton C, Souhami R, Wotherspoon A, Copie-Bergman C, Capella C, Traulle C, Levy M, Cortelazzo S, Ferreri AJ, Ambrosetti A, Pinotti G, Martinelli G, Vitolo U, Cavalli F, Gisselbrecht C, Zucca E. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol. 2009 Feb;144(3):367-75. doi: 10.1111/j.1365-2141.2008.07486.x. Epub 2008 Nov 22.|Bertoni F, Conconi A, Capella C, Motta T, Giardini R, Ponzoni M, Pedrinis E, Novero D, Rinaldi P, Cazzaniga G, Biondi A, Wotherspoon A, Hancock BW, Smith P, Souhami R, Cotter FE, Cavalli F, Zucca E; International Extranodal Lymphoma Study Group; United Kingdom Lymphoma Group. Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood. 2002 Apr 1;99(7):2541-4.|Zucca E, Roggero E, Delchier J, et al.: Interim evaluation of gastric malt lymphoma response to antibiotics in the ongoing LY03 randomized cooperative trial of observation vs chlorambucil after anti-helicobacter therapy. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A12, 2000.","\tGastric Cancer\tchlorambucil|clarithromycin|omeprazole|tinidazole\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","stomach neoplasms","tinidazole|clarithromycin|omeprazole|chlorambucil","NA"]
["NCT00003619","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Besa E, Maiale C, Liman D, et al.: Early data on a new combination chemotherapy using topotecan, fludarabine, ARA-C and G-CSF for aggressive myelodysplastic syndromes in the elderly. [Abstract] Leuk Res 23 (Suppl 1): A-191, S72, 1999.","\tChronic Myeloproliferative Disorders|Leukemia|Myelodysplastic Syndromes|Thrombocytopenia\tfilgrastim|vitamin E|busulfan|cytarabine|etoposide|fludarabine phosphate|isotretinoin|topotecan hydrochloride|bone marrow ablation with stem cell support|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Dietary Supplement|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","myeloproliferative disorders|leukemia|syndrome|preleukemia|myelodysplastic syndromes|thrombocytopenia","cytarabine|vitamin e|topotecan|busulfan|fludarabine|isotretinoin|fludarabine phosphate|etoposide","NA"]
["NCT00003621","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15667956|NA","Rao RD, Krishnan S, Fitch TR, Schomberg PJ, Dinapoli RP, Nordstrom K, Scheithauer B, O'Fallon JR, Maurer MJ, Buckner JC. Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51. Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):380-6.|Jaeckle K, Ballman K, O'Fallon J, et al.: Response to pre-radiation chemotherapy as a predictor of survival in patients with newly diagnosed malignant astrocytoma: a North Central Cancer Treatment Group (NCCTG) study. [Abstract] Neuro-Oncology 6 (4): TA-26, 376, 2004.","\tBrain and Central Nervous System Tumors\tcarmustine|cisplatin|etoposide|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","nervous system neoplasms|central nervous system neoplasms|astrocytoma","carmustine|etoposide","NA"]
["NCT00003624","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14615449,"Moore DH, Donnelly J, McGuire WP, Almadrones L, Cella DF, Herzog TJ, Waggoner SE; Gynecologic Oncology Group. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. J Clin Oncol. 2003 Nov 15;21(22):4207-13.","\tCervical Cancer|Endometrial Cancer|Fallopian Tube Cancer|Neurotoxicity|Ovarian Cancer|Primary Peritoneal Cavity Cancer|Sarcoma\tamifostine trihydrate|cisplatin|paclitaxel\tNA\tNA\tNA\tDrug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","neurotoxicity syndromes|fallopian tube neoplasms|sarcoma|uterine cervical neoplasms|endometrial neoplasms","paclitaxel|amifostine","NA"]
["NCT00003626","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11106233,"Vaishampayan U, Glode M, Du W, Kraft A, Hudes G, Wright J, Hussain M. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res. 2000 Nov;6(11):4205-8. Erratum in: Clin Cancer Res 2000 Dec;6(12):4967.","\tProstate Cancer\tdolastatin 10\tNA\tNA\tNA\tDrug\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","dolastatin 10","NA"]
["NCT00003627","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16376489,"Bensadoun RJ, Bénézery K, Dassonville O, Magné N, Poissonnet G, Ramaïoli A, Lemanski C, Bourdin S, Tortochaux J, Peyrade F, Marcy PY, Chamorey E, Vallicioni J, Seng H, Alzieu C, Géry B, Chauvel P, Schneider M, Santini J, Demard F, Calais G. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):983-94. Epub 2006 Jan 10.","\tHead and Neck Cancer\tcisplatin|fluorouracil|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","oropharyngeal neoplasms","fluorouracil|cisplatin","NA"]
["NCT00003636","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20850296|20818904|NA","Verleye L, Ottevanger PB, Kristensen GB, Ehlen T, Johnson N, van der Burg ME, Reed NS, Verheijen RH, Gaarenstroom KN, Mosgaard B, Seoane JM, van der Velden J, Lotocki R, van der Graaf W, Penninckx B, Coens C, Stuart G, Vergote I. Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. Eur J Cancer. 2011 Jan;47(1):57-64. doi: 10.1016/j.ejca.2010.08.008. Epub 2010 Sep 16.|Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806.|Fruehauf JP, Yu I, Parker R: In vitro drug response and biomarker profiles for ovarian cancer specimens obtained at initial debulking or after neoadjuvant chemotherapy (EORTC 55971). [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-2177, 2002.","\tFallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer\tcarboplatin|cisplatin|conventional surgery|neoadjuvant therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Procedure\tFemale\t","NA","NA","NA","NA","NA","NA","fallopian tube neoplasms","carboplatin","NA"]
["NCT00003642","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18568488,"Poortmans PM, Richaud P, Collette L, Ho Goey S, Pierart M, Van Der Hulst M, Bolla M; EORTC Radiation Oncology Group. Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder. Acta Oncol. 2008;47(5):937-40. doi: 10.1080/02841860801888799.","\tBladder Cancer\tcisplatin|fluorouracil|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","urinary bladder neoplasms","fluorouracil","NA"]
["NCT00003644","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21529904,"Mannel RS, Brady MF, Kohn EC, Hanjani P, Hiura M, Lee R, Degeest K, Cohn DE, Monk BJ, Michael H. A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2011 Jul;122(1):89-94. doi: 10.1016/j.ygyno.2011.03.013. Epub 2011 May 6.","\tOvarian Cancer\tcarboplatin|paclitaxel\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tFemale\t","Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer","Interventional","Completed","Phase 3",2,571,"carcinoma, ovarian epithelial|ovarian neoplasms","paclitaxel|carboplatin","NA"]
["NCT00003649","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18757331|NA|NA","Keedy V, Wang W, Schiller J, Chada S, Slovis B, Coffee K, Worrell J, Thet LA, Johnson DH, Carbone DP. Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597. J Clin Oncol. 2008 Sep 1;26(25):4166-71. doi: 10.1200/JCO.2007.15.6927.|Carbone DP, Adak S, Schiller J, et al.: Adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioalveolar cell lung carcinoma (BAC). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2492, 2003.|Kubba SV, Adak S, Schiller J, et al.: Phase I trial of adenovirus p53 in bronchioalveolar cell lung carcinoma (BAC) administered by bronchioalveolar lavage. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A1904, 2000.","\tLung Cancer\tAd5CMV-p53 gene\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms","NA","NA"]
["NCT00003652","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18191265,"Tournier-Rangeard L, Mercier M, Peiffert D, Gerard JP, Romestaing P, Lemanski C, Mirabel X, Pommier P, Denis B. Radiochemotherapy of locally advanced anal canal carcinoma: prospective assessment of early impact on the quality of life (randomized trial ACCORD 03). Radiother Oncol. 2008 Jun;87(3):391-7. doi: 10.1016/j.radonc.2007.12.004. Epub 2008 Jan 11.","\tAnal Cancer\tcisplatin|fluorouracil|neoadjuvant therapy|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","anus neoplasms","fluorouracil|cisplatin","NA"]
["NCT00003657","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Elias AD, Richardson P, Tretyakov O, et al.: Amifostine with high dose infosfamide, carboplatin, and etoposide (ICE) with hematopoietic STEM cell support. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A197, 2000.","\tBladder Cancer|Brain and Central Nervous System Tumors|Carcinoma of Unknown Primary|Extragonadal Germ Cell Tumor|Head and Neck Cancer|Kidney Cancer|Lung Cancer|Ovarian Cancer|Sarcoma|Testicular Germ Cell Tumor|Unspecified Adult Solid Tumor, Protocol Specific\tfilgrastim|Amifostine|Carboplatin|Etoposide|Ifosfamide|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms, germ cell and embryonal|lung neoplasms|neoplasms, unknown primary|central nervous system neoplasms|neoplasms|head and neck neoplasms|urinary bladder neoplasms|nervous system neoplasms|carcinoma|sarcoma","carboplatin|amifostine|etoposide|ifosfamide","NA"]
["NCT00003658","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16520464|12663715","Lamanna N, Kalaycio M, Maslak P, Jurcic JG, Heaney M, Brentjens R, Zelenetz AD, Horgan D, Gencarelli A, Panageas KS, Scheinberg DA, Weiss MA. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2006 Apr 1;24(10):1575-81. Epub 2006 Mar 6.|Weiss MA, Maslak PG, Jurcic JG, Scheinberg DA, Aliff TB, Lamanna N, Frankel SR, Kossman SE, Horgan D. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol. 2003 Apr 1;21(7):1278-84.","\tLeukemia|Lymphoma\tfilgrastim|rituximab|cyclophosphamide|pentostatin\tNA\tNA\tNA\tBiological|Biological|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, lymphoid|lymphoma|leukemia, lymphocytic, chronic, b-cell|leukemia","cyclophosphamide|pentostatin|rituximab","NA"]
["NCT00003666","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15301880|NA","Sherman CA, Herndon JE 2nd, Watson DM, Green MR; Cancer and Leukemia Group B. A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer. Lung Cancer. 2004 Sep;45(3):387-92.|Sherman CA, Herndon JE, Green MR, et al.: CALGB 39805: phase II trial of 6-hydroxymethylacylfulvene (HMAF; MGI-114) in patients with relapsed or refractory non-small cell lung cancer (NSCLC). [Abstract] Proceedings of the American Society of Clinical Oncology 19: A2163, 2000.","\tLung Cancer\t6-hydroxymethylacylfulvene\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|carcinoma, non-small-cell lung","irofulven","NA"]
["NCT00003675","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16158312|NA|NA","Klein CE, Kastrissios H, Miller AA, Hollis D, Yu D, Rosner GL, Grinblatt DL, Larson RA, Ratain MJ. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol. 2006 Jan;57(2):199-206. Epub 2005 Sep 13.|Grinblatt DL, Yu D, Hars V, et al.: Relationships of response to oral topotecan (Topo) for myelodysplastic syndrome (MDS) with IPSS group and cytogenetics - CALGB study 19803. [Abstract] Blood 100 (11 Pt 1): A-3137, 2002.|Grinblatt DL, Yu D, Klein C, et al.: Two schedules of oral topotecan for myelodysplastic syndrome (MDS)-CALGB study 19803. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1209, 2001.","\tLeukemia|Myelodysplastic Syndromes\ttopotecan hydrochloride\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Topotecan in Treating Patients With Myelodysplastic Syndrome","Interventional","Completed","Phase 2",2,100,"syndrome|preleukemia|myelodysplastic syndromes","topotecan","NA"]
["NCT00003685","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12377323|NA","Bezjak A, Dixon P, Brundage M, Tu D, Palmer MJ, Blood P, Grafton C, Lochrin C, Leong C, Mulroy L, Smith C, Wright J, Pater JL; Clinical Trials Group of the National Cancer Institute of Canada. Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):719-28.|Bezjak A, Dixon P, Brundage M, et al.: Randomized study of single versus fractionated radiotherapy (RT) in the palliation of non-small cell lung cancer: NCIC CTG SC.15. [Abstract] Int J Radiat Oncol Biol Phys 51( 3 suppl 1): A-35, 20, 2001.","\tFatigue|Lung Cancer|Nausea and Vomiting|Pain|Pulmonary Complications|Quality of Life\tfatigue assessment and management|nausea and vomiting therapy|pain therapy|quality-of-life assessment|radiation therapy\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure|Procedure|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","nausea|fatigue|carcinoma, non-small-cell lung|vomiting|lung neoplasms","NA","NA"]
["NCT00003687","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|17397698","MacDonald S, Dudgeon DJ, Bruera E, et al.: A phase III double-blind equivalence study of two different formulations of slow-release morphine followed by a randomization between dextromethorphan or placebo plus Statex SR for chronic cancer pain relief in terminally ill patients. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1521, 2002.|Dudgeon DJ, Bruera E, Gagnon B, Watanabe SM, Allan SJ, Warr DG, MacDonald SM, Savage C, Tu D, Pater JL. A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients. J Pain Symptom Manage. 2007 Apr;33(4):365-71.","\tChronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Pain|Precancerous/Nonmalignant Condition|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific\tdextromethorphan hydrobromide|morphine sulfate\tParallel Assignment\tSupportive Care\tRandomized\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|leukemia|neoplasms, plasma cell|myeloproliferative disorders|syndrome|myelodysplastic syndromes|intestinal neoplasms|precancerous conditions|preleukemia|multiple myeloma","dextromethorphan|morphine","NA"]
["NCT00003688","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16900525,"Covens A, Filiaci VL, Burger RA, Osborne R, Chen MD; Gynecologic Oncology Group. Phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Cancer. 2006 Sep 15;107(6):1280-6.","\tGestational Trophoblastic Tumor\tdactinomycin\tNA\tNA\tNA\tBiological\tFemale\t","NA","NA","NA","NA","NA","NA","gestational trophoblastic disease|trophoblastic neoplasms","dactinomycin","NA"]
["NCT00003691","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15169803|NA|17362317|17945336","Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004 Jun 1;22(11):2159-66.|Fleming GF, Brunetto VL, Mundt AJ, et al.: Randomized trial of doxorubicin (DOX) plus cisplatin (CIS) versus DOX plus CIS plus paclitaxel (TAX) in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-807, 2002.|Huang HQ, Brady MF, Cella D, Fleming G. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer. 2007 Mar-Apr;17(2):387-93.|Grushko TA, Filiaci VL, Mundt AJ, Ridderstråle K, Olopade OI, Fleming GF; Gynecologic Oncology Group. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jan;108(1):3-9. Epub 2007 Oct 18.","\tEndometrial Cancer\tfilgrastim|cisplatin|doxorubicin hydrochloride|paclitaxel\tNA\tNA\tNA\tBiological|Drug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","endometrial neoplasms","liposomal doxorubicin|paclitaxel|doxorubicin","NA"]
["NCT00003692","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17971599|NA","Swanson SJ, Herndon JE 2nd, D'Amico TA, Demmy TL, McKenna RJ Jr, Green MR, Sugarbaker DJ. Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study. J Clin Oncol. 2007 Nov 1;25(31):4993-7.|Swanson SJ, Herndon J, D'Amico A, et al.: Results of CALGB 39802: feasibility of video-assisted thoracic surgery (VATS) lobectomy for early stage lung cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1158, 2002.","\tLung Cancer\ttherapeutic thoracoscopy|video-assisted surgery\tNA\tNA\tNA\tProcedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","NA","NA"]
["NCT00003697","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Rustin GJ, Galbraith S, Taylor N, et al.: Impact on tumour perfusion measured by dynamic magnetic resonance imaging (MRI) in the phase I trial of 5,6-dimethyl xanthenone-4-acetic acid (DMXAA). [Abstract] Ann Oncol 9 (suppl 2): A-483, 126, 1998.|Jameson M, Thompson P, Baguley B, et al.: Comparative pharmacokinetics and plasma protein binding of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in humans and mice. [Abstract] Proceedings of the American Society of Clinical Oncology A-746, 1997.","\tUnspecified Adult Solid Tumor, Protocol Specific\tvadimezan\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","vadimezan","NA"]
["NCT00003698","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12807934,"Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, Price PM. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol. 2003 Aug 1;21(15):2815-22. Epub 2003 Jun 13.","\tUnspecified Adult Solid Tumor, Protocol Specific\tfosbretabulin disodium\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","fosbretabulin","NA"]
["NCT00003700","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Stock W, Yu D, Johnson J, et al.: Intensified Daunorubicin during induction and post-remission therapy of adult acute lymphoblastic leukemia (ALL): results of CALGB 19802. [Abstract] Blood 102 (11 Pt 1): A-1375, 2003.|Stock W, Dodge RK, Vardiman JW, et al.: Treatment of adult acute lymphoblastic leukemia (ALL): phase II trial of dose intensification of Daunorubicin and Cytarabine followed by high-dose Methotrexate and intrathecal Methotrexate in place of cranial irradiation (CALGB 19802). [Abstract] Blood 98 (11 Pt 1): A-2472, 2001.","\tLeukemia\tG-CSF|asparaginase|cyclophosphamide|cytarabine|daunorubicin hydrochloride|leucovorin calcium|mercaptopurine|methotrexate|prednisone|vincristine sulfate|Allopurinol\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","precursor cell lymphoblastic leukemia-lymphoma|leukemia|leukemia, lymphoid","levoleucovorin|cytarabine|prednisone|cyclophosphamide|methotrexate|daunorubicin|asparaginase|allopurinol|vincristine|mercaptopurine|leucovorin","NA"]
["NCT00003703","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12525514,"Panasci L, Stinson SF, Melnychuk D, Sandor V, Miller WH Jr, Batist G, Patenaude F, Bangash N, Panarello L, Alaoui-Jamali M, Sausville E. SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors. J Clin Oncol. 2003 Jan 15;21(2):232-40.","\tUnspecified Adult Solid Tumor, Protocol Specific\tSarCNU\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT00003705","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11331328,"Hidalgo M, Aylesworth C, Hammond LA, Britten CD, Weiss G, Stephenson J Jr, Schwartz G, Patnaik A, Smith L, Molpus K, Felton S, Gupta E, Ferrante KJ, Tortora A, Sonnichsen DS, Skillings J, Rowinsky EK. Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. J Clin Oncol. 2001 May 1;19(9):2493-503.","\tUnspecified Adult Solid Tumor, Protocol Specific\tBMS-184476\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT00003706","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16391300,"Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz JE, Simms L, Chaudhary AK, Johnson RD, Rowinsky EK, Takimoto CH. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. 2006 Feb 1;24(4):552-62. Epub 2006 Jan 3.","\tUnspecified Adult Solid Tumor, Protocol Specific\tpemetrexed disodium\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","NA","pemetrexed","NA"]
["NCT00003723","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18006112,"Kalmadi SR, Rankin C, Kraut MJ, Jacobs AD, Petrylak DP, Adelstein DJ, Keohan ML, Taub RN, Borden EC. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer. 2008 May;60(2):259-63. Epub 2007 Nov 19.","\tMalignant Mesothelioma\tgemcitabine hydrochloride\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","mesothelioma|lung neoplasms","gemcitabine","NA"]
["NCT00003728","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20407035|NA|NA|NA","De Moerloose B, Suciu S, Bertrand Y, Mazingue F, Robert A, Uyttebroeck A, Yakouben K, Ferster A, Margueritte G, Lutz P, Munzer M, Sirvent N, Norton L, Boutard P, Plantaz D, Millot F, Philippet P, Baila L, Benoit Y, Otten J; Children's Leukemia Group of the European Organisation for Research and Treatment of Cancer (EORTC). Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951. Blood. 2010 Jul 8;116(1):36-44. doi: 10.1182/blood-2009-10-247965. Epub 2010 Apr 20.|Bertrand Y, Suciu S, Benoit Y, et al.: Dexamethasone(DEX)(6mg/sm/d) and prednisolone(PRED)(60mg/sm/d) in induction therapy of childhood ALL are equally effective: results of the 2nd interim analysis of EORTC trial 58951. [Abstract] Blood 112 (11): A-8, 2008.|Sirvent N, Suciu S, Benoit Y, et al.: Prognostic significance of central nervous system (CNS) status of children with acute lymphoblastic leukemia (ALL) treated without cranial irradiation: results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group study 58951. [Abstract] Blood 112 (11): A-303, 2008.|Bertrand Y, Goutagny MP, Poulat AL, et al.: Asparagine depletion, safety and antibody production after E coli asparaginase treatment in children with newly diagnosed acute lymphoblastic leukaemia treated with EORTC 58951 protocol: a single center report. [Abstract] Blood 110 (11): A-4337, 2007.","\tLeukemia|Lymphoma\tcyclophosphamide|cytarabine|asparaginase|daunorubicin hydrochloride|dexamethasone|doxorubicin hydrochloride|etoposide|leucovorin calcium|mercaptopurine|methotrexate|methylprednisolone|mitoxantrone hydrochloride|prednisolone|therapeutic hydrocortisone|thioguanine|vincristine sulfate|vindesine|allogeneic bone marrow transplantation|peripheral blood stem cell transplantation\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma, non-hodgkin|leukemia|precursor cell lymphoblastic leukemia-lymphoma|lymphoma|leukemia, lymphoid","cyclophosphamide|levoleucovorin|leucovorin|hydrocortisone hemisuccinate|cytarabine|dexamethasone|mercaptopurine|hydrocortisone 17-butyrate 21-propionate|hydrocortisone acetate|liposomal doxorubicin|mitoxantrone|doxorubicin|hydrocortisone|methotrexate|thioguanine|vincristine|asparaginase|etoposide|prednisolone|methylprednisolone|vindesine|daunorubicin","NA"]
["NCT00003730","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18780198|NA","Coudert B, Focan C, Genet D, Giacchetti S, Cvickovic F, Zambelli A, Fillet G, Chollet P, Amoroso D, Van Der Auwera J, Lentz MA, Marreaud S, Baron B, Gorlia T, Biville F, Lévi F. A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971. Chronobiol Int. 2008 Sep;25(5):680-96. doi: 10.1080/07420520802384036.|Coudert B, Focan C, Genet D, et al.: Optimal circadian time of vinorelbine (V) combined with chronomodulated 5-FU in pretreated metastatic breast cancer patients. EORTC 05971 randomized multicenter study. [Abstract] J Clin Oncol 24 (Suppl 18): A-2066, 2006.","\tBreast Cancer\tfluorouracil|vinorelbine tartrate\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","fluorouracil|vinorelbine","NA"]
["NCT00003731","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12829671,"van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros JM, van der Rijt CC, Vecht ChJ, Allgeier A, Gorlia T; European Organization for Research and Treatment of Cancer Brain Tumor Group. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol. 2003 Jul 1;21(13):2525-8.","\tBrain and Central Nervous System Tumors\ttemozolomide\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","nervous system neoplasms|central nervous system neoplasms","temozolomide","NA"]
["NCT00003733","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|14970858","Guppy AE, Nelstrop A, Agarwal R, et al.: A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-872, 2002.|Guppy AE, Nelstrop AE, Foster T, Agarwal R, Seckl MJ, Rustin GJ. A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer. Br J Cancer. 2004 Feb 23;90(4):810-4.","\tOvarian Cancer\tcarboplatin|paclitaxel|topotecan hydrochloride\tNA\tNA\tNA\tDrug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","ovarian neoplasms|carcinoma, ovarian epithelial","carboplatin|paclitaxel|topotecan","NA"]
["NCT00003734","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20797824,"Armstrong JG, Gillham CM, Dunne MT, Fitzpatrick DA, Finn MA, Cannon ME, Taylor JC, O'Shea CM, Buckney SJ, Thirion PG. A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):35-45. doi: 10.1016/j.ijrobp.2010.04.065. Epub 2010 Aug 25.","\tProstate Cancer\tflutamide|triptorelin|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Radiation\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","triptorelin pamoate|flutamide","NA"]
["NCT00003736","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16180217|15800894","Lehman CD, Blume JD, Thickman D, Bluemke DA, Pisano E, Kuhl C, Julian TB, Hylton N, Weatherall P, O'loughlin M, Schnitt SJ, Gatsonis C, Schnall MD. Added cancer yield of MRI in screening the contralateral breast of women recently diagnosed with breast cancer: results from the International Breast Magnetic Resonance Consortium (IBMC) trial. J Surg Oncol. 2005 Oct 1;92(1):9-15; discussion 15-6.|Lehman CD, Blume JD, Weatherall P, Thickman D, Hylton N, Warner E, Pisano E, Schnitt SJ, Gatsonis C, Schnall M, DeAngelis GA, Stomper P, Rosen EL, O'Loughlin M, Harms S, Bluemke DA; International Breast MRI Consortium Working Group. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer. 2005 May 1;103(9):1898-905.","\tBreast Cancer\tmotexafin gadolinium|biopsy|breast imaging study|comparison of screening methods|magnetic resonance imaging|study of high risk factors\tNA\tNA\tNA\tDrug|Procedure|Procedure|Procedure|Procedure|Procedure\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","motexafin gadolinium","NA"]
["NCT00003739","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15806544|NA","Ozkaynak MF, Krailo M, Chen Z, Feusner J. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2005 Sep;45(3):274-80.|Ozkaynak MF, Krailo M, Chen N, et al.: Randomized comparison of antibiotics alone and with granulocyte colony-stimulating factor (G-CSF) in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group. [Abstract] 2004 Pediatric Academic Societies' Annual Meeting, May 1-4, San Francisco, California. A-1769, 2004. Available online Last accessed August 29, 2005.","\tFever, Sweats, and Hot Flashes|Neutropenia|Unspecified Childhood Solid Tumor, Protocol Specific\tfilgrastim\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","hot flashes|fever|neutropenia","lenograstim","NA"]
["NCT00003745","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16435380|NA","Hawkins DS, Bradfield S, Whitlock JA, Krailo M, Franklin J, Blaney SM, Adamson PC, Reaman G. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2006 Nov;47(6):790-4.|Bradfield S, Hawkins DS, Whitlock J, et al.: Phase II study of 21 day continuous intravenous infusion (CIVI) topotecan for recurrent pediatric solid tumors: a Children's Oncology Group Study (COG A09713). [Abstract] J Clin Oncol 23 (Suppl 16): A-8523, 805s, 2005.","\tSarcoma\ttopotecan hydrochloride\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","sarcoma","topotecan","NA"]
["NCT00003746","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19672771,"Zenhäusern R, Schmitz SF, Solenthaler M, Heim D, Meyer-Monard S, Hess U, Leoncini L, Bargetzi M, Rufener B, Tobler A. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leuk Lymphoma. 2009 Sep;50(9):1501-11. doi: 10.1080/10428190903131755.","\tLeukemia\t2-chlorodeoxyadenosine (CDA) daily|2-chlorodeoxyadenosine weekly\tNA\tNA\tNA\tDrug|Drug\tAll\t","Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia","Interventional","Completed","Phase 3",2,100,"leukemia|leukemia, hairy cell","cladribine","NA"]
["NCT00003749","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19893425|NA|19070889","Barton DP, Naik R, Herod J. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC Trial): a randomized study. Int J Gynecol Cancer. 2009 Nov;19(8):1465. doi: 10.1111/IGC.0b013e3181b89f95.|Kitchener HC: The effect of incision in the surgical treatment of endometrial cancer and long-term follow-up of a randomized trial of lymphadenectomy: results of the MRC ASTEC trial. [Abstract] J Clin Oncol 29 (Suppl 15): A-e15583, 2011.|ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009 Jan 10;373(9658):125-36. doi: 10.1016/S0140-6736(08)61766-3. Epub 2008 Dec 16. Erratum in: Lancet. 2009 May 23;373(9677):1764.","\tEndometrial Cancer\tadjuvant therapy|conventional surgery|brachytherapy|radiation therapy\tNA\tNA\tNA\tProcedure|Procedure|Radiation|Radiation\tFemale\t","NA","NA","NA","NA","NA","NA","endometrial neoplasms","NA","NA"]
["NCT00003750","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16551859,"Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J, Seeger RC, Matthay KK, Reynolds CP, Twist C, Krailo M, Adamson PC, Reisfeld RA, Gillies SD, Sondel PM; Children's Oncology Group. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res. 2006 Mar 15;12(6):1750-9.","\tMelanoma (Skin)|Neuroblastoma|Sarcoma|Unspecified Childhood Solid Tumor, Protocol Specific\thu14.18-IL2 fusion protein\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","sarcoma|neuroblastoma|melanoma","NA","NA"]
["NCT00003751","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16053699|NA","Brem S, Grossman SA, Carson KA, New P, Phuphanich S, Alavi JB, Mikkelsen T, Fisher JD; New Approaches to Brain Tumor Therapy CNS Consortium. Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro Oncol. 2005 Jul;7(3):246-53.|Brem S, Grossman SA, New P, et al.: Phase II study of penicillamine and reduction of copper, for angiosuppressive therapy of glioblastoma: preliminary safety and feasibility study. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A-666, 2000.","\tBrain and Central Nervous System Tumors\tpenicillamine|radiation therapy\tNA\tNA\tNA\tDrug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","glioblastoma|nervous system neoplasms|central nervous system neoplasms","penicillamine","NA"]
["NCT00003752","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12637463,"Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15;21(6):999-1006.","\tBreast Cancer\tbexarotene\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","breast neoplasms","bexarotene","NA"]
["NCT00003757","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18603561,"Zenhäusern R, Simcock M, Gratwohl A, Hess U, Bargetzi M, Tobler A; Swiss Group for Clinical Cancer Research (SAKK). Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98). Haematologica. 2008 Sep;93(9):1426-8. doi: 10.3324/haematol.11564. Epub 2008 Jul 4.","\tLeukemia\trituximab\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","leukemia|leukemia, hairy cell","rituximab","NA"]
["NCT00003764","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17283364|17283363|NA|NA|NA","Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF Jr, Tallman MS. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007 Mar 1;25(7):793-8. Epub 2007 Feb 5.|Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, Flinn IW, Tallman MS, Appelbaum FR, Larson RA, Paietta E, Jelinek DF, Gribben JG, Byrd JC. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol. 2007 Mar 1;25(7):799-804. Epub 2007 Feb 5.|Grever MR, Dewald GW, Neuberg DS, et al.: Select high risk genetic features predict earlier progression following chemotherapy in chronic lymphocytic leukemia: prospective randomized trial (Intergroup E2997) to evaluate justification for risk-adapted therapy. [Abstract] J Clin Oncol 24 (Suppl 18): A-6521, 342s, 2006.|Flinn IW, Kumm E, Grever MR, et al.: Fludarabine and cyclophosphamide produces a higher complete response rate and more durable remissions than fludarabine in patients with previously untreated CLL: Intergroup trial E2997. [Abstract] Blood 104 (11): A-475, 2004.|Grever MR, Lucas DM, Dewald GW, et al.: Outcome of treatment with fludarabine versus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) is adversely impacted by high risk genetic features: results from ECOG 2997. [Abstract] Blood 104 (11 Pt 1): A-3487, 2004.","\tLeukemia\tcyclophosphamide|fludarabine phosphate\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, lymphocytic, chronic, b-cell|leukemia, lymphoid|leukemia","fludarabine|fludarabine phosphate|cyclophosphamide","NA"]
["NCT00003765","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17941066,"Adams DM, Zhou T, Berg SL, Bernstein M, Neville K, Blaney SM; Children's Oncology Group. Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Mar;50(3):549-53.","\tBrain and Central Nervous System Tumors\tO6-benzylguanine|carmustine\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|nervous system neoplasms","o(6)-benzylguanine|carmustine","NA"]
["NCT00003771","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18364505|14962527","Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, Jassem J, Dobaczewska D, Fjosne HE, Peralta O, Arriagada R, Holmqvist M, Maenpaa J; HABITS Study Group. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008 Apr 2;100(7):475-82. doi: 10.1093/jnci/djn058. Epub 2008 Mar 25. Erratum in: J Natl Cancer Inst. 2008 May 7;100(9):685. Maenpa, Johanna [corrected to Maenpaa, Johanna].|Holmberg L, Anderson H; HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. Lancet. 2004 Feb 7;363(9407):453-5.","\tBreast Cancer|Menopausal Symptoms\ttherapeutic estradiol|norethindrone acetate\tNA\tNA\tNA\tBiological|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","norethindrone|estradiol|norethindrone acetate|polyestradiol phosphate|estradiol 3-benzoate|estradiol 17 beta-cypionate","NA"]
["NCT00003772","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20495876|11165129","Chie WC, Tsai CJ, Chiang C, Lee YC. Quality of life of patients with oesophageal cancer in Taiwan: validation and application of the Taiwan Chinese (Mandarin) version of the EORTC QLQ-OES18: a brief communication. Qual Life Res. 2010 Oct;19(8):1127-31. doi: 10.1007/s11136-010-9675-8. Epub 2010 May 22.|Cull A, Howat S, Greimel E, Waldenstrom AC, Arraras J, Kudelka A, Chauvenet L, Gould A; EORTC Quality of Life Group [European Organization for Research and Treatment of Cancer]; Scottish Gynaecological Cancer Trials Group. Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer. 2001 Jan;37(1):47-53.","\tOvarian Cancer\tquality-of-life assessment\tNA\tNA\tNA\tProcedure\tFemale\t","NA","NA","NA","NA","NA","NA","carcinoma, ovarian epithelial|ovarian neoplasms","NA","NA"]
["NCT00003779","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24674149,"Rentsch CA, Birkhäuser FD, Biot C, Gsponer JR, Bisiaux A, Wetterauer C, Lagranderie M, Marchal G, Orgeur M, Bouchier C, Bachmann A, Ingersoll MA, Brosch R, Albert ML, Thalmann GN. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol. 2014 Oct;66(4):677-88. doi: 10.1016/j.eururo.2014.02.061. Epub 2014 Mar 12.","\tBladder Cancer\tConnaught|Tice\tNA\tNA\tNA\tBiological|Biological\tAll\t","Biological Therapy in Treating Patients With Bladder Cancer","Interventional","Completed","Phase 3",2,40,"urinary bladder neoplasms","NA","NA"]
["NCT00003782","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18302020|NA|NA|NA","Swain SM, Land SR, Ritter MW, Costantino JP, Cecchini RS, Mamounas EP, Wolmark N, Ganz PA. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat. 2009 Jan;113(2):315-20. doi: 10.1007/s10549-008-9937-0. Epub 2008 Feb 27.|Ganz PA, Land SR, Geyer CE, et al.: NSABP B-30: definitive analysis of quality of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. [Abstract] 31st Annual San Antonio Breast Cancer Symposium, December 10-14, 2008, San Antonio, Texas. A-76, 2008.|Swain SM, Jeong JH, Geyer CE, et al.: NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. [Abstract] 31st Annual San Antonio Breast Cancer Symposium, December 10-14, 2008, San Antonio, Texas. A-75, 2008.|Swain SM, Land SR, Sundry R, et al.: Amenorrhea in premenopausal women on the doxorubicin (A) and cyclophosphamide (C) followed-by docetaxel (T) arm of NSABP B-30: preliminary results. [Abstract] J Clin Oncol 23 (Suppl 16): A-537, 13s, 2005.","\tBreast Cancer\tcyclophosphamide|docetaxel|doxorubicin\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tFemale\t","Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes","Interventional","Completed","Phase 3",3,5351,"breast neoplasms","cyclophosphamide|doxorubicin|docetaxel","NA"]
["NCT00003784","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16896003|NA|12738671|NA","Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI; Southwest Oncology Group. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006 Sep 1;24(25):4143-9. Epub 2006 Aug 8.|Press OW, Unger J, Maloney D, et al.: An update of a phase II trial of CHOP followed by tositumomab/iodine I-131 tositumomab (Bexxar®) for front-line treatment of advanced stage, follicular lymphoma: Southwest Oncology Group Protocol 9911. [Abstract] Blood 106 (11): A-352, 2005.|Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood. 2003 Sep 1;102(5):1606-12. Epub 2003 May 8.|Press OW, Unger JM, Braziel RM, et al.: A phase II trial of CHOP followed by Bexxar™ (tositumomab and iodine-131-tositumomab) for treatment of newly diagnosed follicular non-Hodgkin's lymphomas (SWOG 9911). [Abstract] Blood 98 (11 Pt 1): A-3504, 2001.","\tLymphoma\tCHOP regimen|cyclophosphamide|doxorubicin hydrochloride|prednisone|vincristine sulfate|tositumomab and iodine I 131 tositumomab\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|lymphoma, non-hodgkin","cyclophosphamide|liposomal doxorubicin|doxorubicin|vincristine|prednisone|iodine-131 anti-b1 antibody","NA"]
["NCT00003787","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21430657|22430275|22648714|21263044|21184262|21415358|20980485|21319157|19075284|19339393|19190138|18656572|17541741|18956493|17028988|NA|17635889|NA|17557947|17123151|16651649|15770526|15746825|15860436|15980988|14747688|14747670|16735939|12505249|14557830","Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, Parker BA, Wu AH, Pierce JP. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011 May;89(5):718-25. doi: 10.1038/clpt.2011.32. Epub 2011 Mar 23.|Caan BJ, Emond JA, Su HI, Patterson RE, Flatt SW, Gold EB, Newman VA, Rock CL, Thomson CA, Pierce JP. Effect of postdiagnosis weight change on hot flash status among early-stage breast cancer survivors. J Clin Oncol. 2012 May 1;30(13):1492-7. doi: 10.1200/JCO.2011.36.8597. Epub 2012 Mar 19.|Nechuta SJ, Caan BJ, Chen WY, Lu W, Chen Z, Kwan ML, Flatt SW, Zheng Y, Zheng W, Pierce JP, Shu XO. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. Am J Clin Nutr. 2012 Jul;96(1):123-32. doi: 10.3945/ajcn.112.035972. Epub 2012 May 30.|Al-Delaimy WK, Flatt SW, Natarajan L, Laughlin GA, Rock CL, Gold EB, Caan BJ, Parker BA, Pierce JP. IGF1 and risk of additional breast cancer in the WHEL study. Endocr Relat Cancer. 2011 Mar 3;18(2):235-44. doi: 10.1530/ERC-10-0121. Print 2011 Apr.|Bertram LA, Stefanick ML, Saquib N, Natarajan L, Patterson RE, Bardwell W, Flatt SW, Newman VA, Rock CL, Thomson CA, Pierce JP. Physical activity, additional breast cancer events, and mortality among early-stage breast cancer survivors: findings from the WHEL Study. Cancer Causes Control. 2011 Mar;22(3):427-35. doi: 10.1007/s10552-010-9714-3. Epub 2010 Dec 24.|Emond JA, Patterson RE, Natarajan L, Laughlin GA, Gold EB, Pierce JP. Sex hormone concentrations and the risk of breast cancer recurrence in postmenopausal women without hot flashes. Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):939-45. doi: 10.1158/1055-9965.EPI-10-1240. Epub 2011 Mar 17.|Jacobs ET, Thomson CA, Flatt SW, Al-Delaimy WK, Hibler EA, Jones LA, Leroy EC, Newman VA, Parker BA, Rock CL, Pierce JP. Vitamin D and breast cancer recurrence in the Women's Healthy Eating and Living (WHEL) Study. Am J Clin Nutr. 2011 Jan;93(1):108-17. doi: 10.3945/ajcn.2010.30009. Epub 2010 Oct 27.|Paxton RJ, Jones LA, Chang S, Hernandez M, Hajek RA, Flatt SW, Natarajan L, Pierce JP. Was race a factor in the outcomes of the Women's Health Eating and Living Study? Cancer. 2011 Aug 15;117(16):3805-13. doi: 10.1002/cncr.25957. Epub 2011 Feb 11.|Gold EB, Pierce JP, Natarajan L, Stefanick ML, Laughlin GA, Caan BJ, Flatt SW, Emond JA, Saquib N, Madlensky L, Kealey S, Wasserman L, Thomson CA, Rock CL, Parker BA, Karanja N, Jones V, Hajek RA, Pu M, Mortimer JE. Dietary pattern influences breast cancer prognosis in women without hot flashes: the women's healthy eating and living trial. J Clin Oncol. 2009 Jan 20;27(3):352-9. doi: 10.1200/JCO.2008.16.1067. Epub 2008 Dec 15.|Pierce JP, Natarajan L, Caan BJ, Flatt SW, Kealey S, Gold EB, Hajek RA, Newman VA, Rock CL, Pu M, Saquib N, Stefanick ML, Thomson CA, Parker B. Dietary change and reduced breast cancer events among women without hot flashes after treatment of early-stage breast cancer: subgroup analysis of the Women's Healthy Eating and Living Study. Am J Clin Nutr. 2009 May;89(5):1565S-1571S. doi: 10.3945/ajcn.2009.26736F. Epub 2009 Apr 1.|Rock CL, Natarajan L, Pu M, Thomson CA, Flatt SW, Caan BJ, Gold EB, Al-Delaimy WK, Newman VA, Hajek RA, Stefanick ML, Pierce JP; Women's Healthy Eating and Living Study Group. Longitudinal biological exposure to carotenoids is associated with breast cancer-free survival in the Women's Healthy Eating and Living Study. Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):486-94. doi: 10.1158/1055-9965.EPI-08-0809. Epub 2009 Feb 3.|Hernández-Valero MA, Thomson CA, Hernández M, Tran T, Detry MA, Theriault RL, Hajek RA, Pierce JP, Flatt SW, Caan BJ, Jones LA. Comparison of baseline dietary intake of Hispanic and matched non-Hispanic white breast cancer survivors enrolled in the Women's Healthy Eating and Living study. J Am Diet Assoc. 2008 Aug;108(8):1323-9. doi: 10.1016/j.jada.2008.05.008.|Mortimer JE, Flatt SW, Parker BA, Gold EB, Wasserman L, Natarajan L, Pierce JP; WHEL Study Group. Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat. 2008 Apr;108(3):421-6. Epub 2007 May 31.|Saxe GA, Madlensky L, Kealey S, Wu DP, Freeman KL, Pierce JP. Disclosure to physicians of CAM use by breast cancer patients: findings from the Women's Healthy Eating and Living Study. Integr Cancer Ther. 2008 Sep;7(3):122-9.|Hong S, Bardwell WA, Natarajan L, Flatt SW, Rock CL, Newman VA, Madlensky L, Mills PJ, Dimsdale JE, Thomson CA, Hajek RA, Chilton JA, Pierce JP. Correlates of physical activity level in breast cancer survivors participating in the Women's Healthy Eating and Living (WHEL) Study. Breast Cancer Res Treat. 2007 Jan;101(2):225-32. Epub 2006 Sep 21.|Parker BA, Flatt SW, Mortimer JA, et al.: Impact of hormone replacement therapy on breast cancer: Women's Healthy Eating and Living (WHEL) study experience. [Abstract] Breast Cancer Res Treat 106 (1): A-1055, S59, 2007.|Pierce JP, Natarajan L, Caan BJ, Parker BA, Greenberg ER, Flatt SW, Rock CL, Kealey S, Al-Delaimy WK, Bardwell WA, Carlson RW, Emond JA, Faerber S, Gold EB, Hajek RA, Hollenbach K, Jones LA, Karanja N, Madlensky L, Marshall J, Newman VA, Ritenbaugh C, Thomson CA, Wasserman L, Stefanick ML. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA. 2007 Jul 18;298(3):289-98.|Pierce JP, Natarajan L, Cann BJ, et al.: The influence of a very high vegetable-fruit-fiber, low-fat diet on prognosis following treatment for breast cancer: results from the Womens Healthy Eating and Living (WHEL) randomized trial. [Abstract] Breast Cancer Res Treat 106 (1): A-61, S16, 2007.|Pierce JP, Stefanick ML, Flatt SW, Natarajan L, Sternfeld B, Madlensky L, Al-Delaimy WK, Thomson CA, Kealey S, Hajek R, Parker BA, Newman VA, Caan B, Rock CL. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol. 2007 Jun 10;25(17):2345-51.|Saquib N, Flatt SW, Natarajan L, Thomson CA, Bardwell WA, Caan B, Rock CL, Pierce JP. Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the women's healthy eating and living (WHEL) study. Breast Cancer Res Treat. 2007 Oct;105(2):177-86. Epub 2006 Nov 23.|Bardwell WA, Natarajan L, Dimsdale JE, Rock CL, Mortimer JE, Hollenbach K, Pierce JP. Objective cancer-related variables are not associated with depressive symptoms in women treated for early-stage breast cancer. J Clin Oncol. 2006 Jun 1;24(16):2420-7. Epub 2006 May 1.|Madlensky L, Flatt SW, Bardwell WA, Rock CL, Pierce JP; WHEL Study group. Is family history related to preventive health behaviors and medical management in breast cancer patients? Breast Cancer Res Treat. 2005 Mar;90(1):47-54.|Newman VA, Thomson CA, Rock CL, Flatt SW, Kealey S, Bardwell WA, Caan BJ, Pierce JP; Women's Healthy Eating and Living (WHEL) Study Group. Achieving substantial changes in eating behavior among women previously treated for breast cancer--an overview of the intervention. J Am Diet Assoc. 2005 Mar;105(3):382-91; quiz 488.|Thomson CA, Giuliano AR, Shaw JW, Rock CL, Ritenbaugh CK, Hakim IA, Hollenbach KA, Alberts DS, Pierce JP. Diet and biomarkers of oxidative damage in women previously treated for breast cancer. Nutr Cancer. 2005;51(2):146-54.|Thornton AA, Madlensky L, Flatt SW, Kaplan RM, Pierce JP. The impact of a second breast cancer diagnosis on health related quality of life. Breast Cancer Res Treat. 2005 Jul;92(1):25-33.|Pierce JP, Newman VA, Flatt SW, Faerber S, Rock CL, Natarajan L, Caan BJ, Gold EB, Hollenbach KA, Wasserman L, Jones L, Ritenbaugh C, Stefanick ML, Thomson CA, Kealey S; Women's Healthy Eating and Living (WHEL) Study Group. Telephone counseling intervention increases intakes of micronutrient- and phytochemical-rich vegetables, fruit and fiber in breast cancer survivors. J Nutr. 2004 Feb;134(2):452-8.|Rock CL, Flatt SW, Thomson CA, Stefanick ML, Newman VA, Jones L, Natarajan L, Pierce JP, Chang RJ, Witztum JL; Women's Healthy Eating and Living (WHEL) Study Group. Plasma triacylglycerol and HDL cholesterol concentrations confirm self-reported changes in carbohydrate and fat intakes in women in a diet intervention trial. J Nutr. 2004 Feb;134(2):342-7.|Gold EB, Flatt SW, Pierce JP, Bardwell WA, Hajek RA, Newman VA, Rock CL, Stefanick ML. Dietary factors and vasomotor symptoms in breast cancer survivors: the WHEL Study. Menopause. 2006 May-Jun;13(3):423-33.|Pierce JP, Faerber S, Wright FA, Rock CL, Newman V, Flatt SW, Kealey S, Jones VE, Caan BJ, Gold EB, Haan M, Hollenbach KA, Jones L, Marshall JR, Ritenbaugh C, Stefanick ML, Thomson C, Wasserman L, Natarajan L, Thomas RG, Gilpin EA; Women's Healthy Eating and Living (WHEL) study group. A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study. Control Clin Trials. 2002 Dec;23(6):728-56.|Wasserman L, Flatt SW, Natarajan L, Laughlin G, Matusalem M, Faerber S, Rock CL, Barrett-Connor E, Pierce JP. Correlates of obesity in postmenopausal women with breast cancer: comparison of genetic, demographic, disease-related, life history and dietary factors. Int J Obes Relat Metab Disord. 2004 Jan;28(1):49-56.","\tBreast Cancer\teducational/counseling intervention|therapeutic dietary intervention\tNA\tNA\tNA\tBehavioral|Behavioral\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","NA","NA"]
["NCT00003794","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19042263|NA","Monahan PO, Champion VL, Zhao Q, Miller AM, Gershenson D, Williams SD, Cella D. Case-control comparison of quality of life in long-term ovarian germ cell tumor survivors: a gynecologic oncology group study. J Psychosoc Oncol. 2008;26(3):19-42.|Williams SD, Miller AM, Cella D, et al.: Relationship issues and sexual functioning in ovarian germ cell cancer survivors. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-845, 2001.","\tOvarian Cancer\tpsychosocial assessment and care|quality-of-life assessment\tNA\tNA\tNA\tProcedure|Procedure\tFemale\t","NA","NA","NA","NA","NA","NA","carcinoma, ovarian epithelial|ovarian neoplasms","NA","NA"]
["NCT00003803","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17084621,"Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, van de Vaart P, Price A, van Walree N, Legrand C, Dussenne S, Bartelink H, Giaccone G, Koning C; EORTC LCG and RT Group. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer. 2007 Jan;43(1):114-21. Epub 2006 Nov 3.","\tLung Cancer\tcisplatin|gemcitabine hydrochloride|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","gemcitabine","NA"]
["NCT00003804","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","10463285|19300220|NA|17084075|15542800|15175957|20582946|18811224","Boccon-Gibod LA. Pathological evaluation of renal tumors in children: international society of pediatric oncology approach. Pediatr Dev Pathol. 1998 May-Jun;1(3):243-8.|Fuchs J, Kienecker K, Furtwängler R, Warmann SW, Bürger D, Thürhoff JW, Hager J, Graf N. Surgical aspects in the treatment of patients with unilateral wilms tumor: a report from the SIOP 93-01/German Society of Pediatric Oncology and Hematology. Ann Surg. 2009 Apr;249(4):666-71. doi: 10.1097/SLA.0b013e31819ed92b.|Furtwangler R, Reinhard H, Beier R, et al.: Clear-cell sarcoma (CCSK) of the kidney - results of the SIOP 93-01/GPOH trial. [Abstract] Pediatr Blood Cancer 45 (4 Suppl 1): A-0.155, 423, 2005.|Ora I, van Tinteren H, Bergeron C, de Kraker J; SIOP Nephroblastoma Study Committee. Progression of localised Wilms' tumour during preoperative chemotherapy is an independent prognostic factor: a report from the SIOP 93-01 nephroblastoma trial and study. Eur J Cancer. 2007 Jan;43(1):131-6. Epub 2006 Nov 2.|Reinhard H, Aliani S, Ruebe C, Stöckle M, Leuschner I, Graf N. Wilms' tumor in adults: results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and Hematology (GPOH) Study. J Clin Oncol. 2004 Nov 15;22(22):4500-6.|Reinhard H, Semler O, Bürger D, Bode U, Flentje M, Göbel U, Gutjahr P, Leuschner I, Maass E, Niggli F, Scheel-Walter HG, Stöckle M, Thüroff JW, Tröger J, Weirich A, von Schweinitz D, Zoubek A, Graf N. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor. Klin Padiatr. 2004 May-Jun;216(3):132-40.|Verschuur AC, Vujanic GM, Van Tinteren H, Jones KP, de Kraker J, Sandstedt B. Stromal and epithelial predominant Wilms tumours have an excellent outcome: the SIOP 93 01 experience. Pediatr Blood Cancer. 2010 Aug;55(2):233-8. doi: 10.1002/pbc.22496.|Vujanić GM, Harms D, Bohoslavsky R, Leuschner I, de Kraker J, Sandstedt B. Nonviable tumor tissue should not upstage Wilms' tumor from stage I to stage II: a report from the SIOP 93-01 nephroblastoma trial and study. Pediatr Dev Pathol. 2009 Mar-Apr;12(2):111-5. doi: 10.2350/08-03-0432.1. Epub 2008 Sep 23.","\tKidney Cancer\tdactinomycin|vincristine sulfate|conventional surgery\tNA\tNA\tNA\tBiological|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","kidney neoplasms|wilms tumor","dactinomycin|vincristine","NA"]
["NCT00003808","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15356646,"Wiernik PH, Paietta E, Goloubeva O, Lee SJ, Makower D, Bennett JM, Wade JL, Ghosh C, Kaminer LS, Pizzolo J, Tallman MS; Eastern Cooperative Oncology Group. Phase II study of theophylline in chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E4998). Leukemia. 2004 Oct;18(10):1605-10.","\tLeukemia\ttheophylline\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, lymphoid|leukemia|leukemia, lymphocytic, chronic, b-cell","theophylline","NA"]
["NCT00003809","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16314626|NA","Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA; Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005 Dec 1;23(34):8646-54. Erratum in: J Clin Oncol. 2006 Feb 1;24(4):724.|Burtness BA, Li Yi, Flood W, et al.: Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC). [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-901, 2002.","\tHead and Neck Cancer\tcetuximab|cisplatin\tNA\tNA\tNA\tBiological|Drug\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","cetuximab","NA"]
["NCT00003810","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15218298|11815964|NA","Shepard RC, Levy DE, Berlin JD, Stuart K, Harris JE, Aviles V, Thomas JP, Benson AB 3rd. Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group. Oncology. 2004;66(4):303-9.|Ryan DP, Kulke MH, Fuchs CS, Grossbard ML, Grossman SR, Morgan JA, Earle CC, Shivdasani R, Kim H, Mayer RJ, Clark JW. A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer. 2002 Jan 1;94(1):97-103.|Shepard RC, Levy D, Stuart K, et al.: Pancreatic cancer: biweekly gemcitabine/docetaxel chemotherapy. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-614, 2001.","\tPancreatic Cancer\tdocetaxel|gemcitabine hydrochloride\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","pancreatic neoplasms","gemcitabine|docetaxel","NA"]
["NCT00003811","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15999362,"Marina N, Chang KW, Malogolowkin M, London WB, Frazier AL, Womer RB, Rescorla F, Billmire DF, Davis MM, Perlman EJ, Giller R, Lauer SJ, Olson TA; Children's Oncology Group. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Cancer. 2005 Aug 15;104(4):841-7.","\tChildhood Germ Cell Tumor|Drug/Agent Toxicity by Tissue/Organ|Extragonadal Germ Cell Tumor|Ovarian Cancer\tbleomycin sulfate|amifostine trihydrate|cisplatin|etoposide|conventional surgery\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms|drug-related side effects and adverse reactions|neoplasms, germ cell and embryonal","etoposide|bleomycin|amifostine","NA"]
["NCT00003812","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15145163|NA|NA","Bogart JA, Herndon JE 2nd, Lyss AP, Watson D, Miller AA, Lee ME, Turrisi AT, Green MR; Cancer and Leukemia Group B study 39808. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):460-8.|Cicchetti MG, Bogart J, Lyss A, et al.: Spinal cord dose in limited stage small cell lung cancer: a preliminary Quality Assurance Review Committee (QARC) report on CALGB 39808, using target thoracic radiotherapy (TRT) doses of 60 - 70 Gy. [Abstract] Int J Radiat Oncol Biol Phys 51(3 suppl 1): A-656, 356, 2001.|Lyss AP, Herndon JE, Bogart JE, et al.: Topotecan (Topo) + paclitaxel (Tax) + G-CSF (G) induction followed by concurrent chemoradiotherapy (CCRT) for patients (pts) with limited stage small cell lung cancer (L-SCLC): preliminary analysis of CALGB 39808. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1270, 2001.","\tLung Cancer\tfilgrastim|carboplatin|etoposide|paclitaxel|topotecan hydrochloride|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","small cell lung carcinoma|lung neoplasms","etoposide|carboplatin|topotecan|paclitaxel","NA"]
["NCT00003817","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12906958,"Roscoe JA, Morrow GR, Hickok JT, Bushunow P, Pierce HI, Flynn PJ, Kirshner JJ, Moore DF, Atkins JN. The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting. A University of Rochester Cancer Center Community Clinical Oncology Program multicenter study. J Pain Symptom Manage. 2003 Aug;26(2):731-42.","\tNausea and Vomiting|Unspecified Adult Solid Tumor, Protocol Specific\tdolasetron mesylate|granisetron hydrochloride|ondansetron|tropisetron|quality-of-life assessment\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","vomiting|nausea","granisetron|tropisetron|dolasetron|ondansetron","NA"]
["NCT00003820","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24516013|NA","Advani RH, Horning SJ, Hoppe RT, Daadi S, Allen J, Natkunam Y, Bartlett NL. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol. 2014 Mar 20;32(9):912-8. doi: 10.1200/JCO.2013.53.2069. Epub 2014 Feb 10.|Horning SJ, Bartlett NL, Breslin S, et al. Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD). Blood [ASH Annual Meeting Abstracts]. 2007;110:abs644.","\tHodgkin Lymphoma (Category)|Lymphoma|Nodular Lymphocyte Predominant Hodgkin Lymphoma\tRituximab\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","hodgkin disease|lymphoma","rituximab","NA"]
["NCT00003824","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17574960,"Wolman SR, Goldman B, Slovak ML, Tangen C, Persons DL, Wood D. Aneusomy for detection of bladder cancer recurrence: a Southwest Oncology Group study. Cancer Genet Cytogenet. 2007 Jul 1;176(1):22-7.","\tBladder Cancer\tcephalexin|surgical procedure|Ciprofloxacin\tParallel Assignment\tTreatment\tRandomized\tDrug|Procedure|Drug\tAll\t","S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer","Interventional","Terminated","Phase 3",2,114,"urinary bladder neoplasms","ciprofloxacin|cephalexin|anti-bacterial agents","NA"]
["NCT00003825","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16601430,"Pilepich MV, Paulus R, St Clair W, Brasacchio RA, Rostock R, Miller RC. Phase III study of pentosanpolysulfate (PPS) in treatment of gastrointestinal tract sequelae of radiotherapy. Am J Clin Oncol. 2006 Apr;29(2):132-7.","\tDiarrhea|Radiation Enteritis\tpentosan polysulfate sodium|quality-of-life assessment\tNA\tNA\tNA\tDrug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","diarrhea|enteritis","pentosan sulfuric polyester","NA"]
["NCT00003828","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15073859|NA","Whitehead RP, Moon J, McCachren SS, Hersh EM, Samlowski WE, Beck JT, Tchekmedyian NS, Sondak VK; Southwest Oncology Group. A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study. Cancer. 2004 Apr 15;100(8):1699-704.|Moon J, Whitehead RP, McCachren S, et al.: Evaluation of vinorelbine tartrate (Navelbine) in patients with dissemminated malignant melanoma and at least one prior systemic therapy, phase II: a Southwest Oncology Group study. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1386, 2002.","\tMelanoma (Skin)\tvinorelbine\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","melanoma","vinorelbine","NA"]
["NCT00003830","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19730364|NA|NA|NA|17851130|NA|17024757|15621990","Weaver DL, Le UP, Dupuis SL, Weaver KA, Harlow SP, Ashikaga T, Krag DN. Metastasis detection in sentinel lymph nodes: comparison of a limited widely spaced (NSABP protocol B-32) and a comprehensive narrowly spaced paraffin block sectioning strategy. Am J Surg Pathol. 2009 Nov;33(11):1583-9. doi: 10.1097/PAS.0b013e3181b274e7.|Land SR, Kopec JA, Lee M, et al.: Quality of life in breast cancer patients receiving sentinel-node (SN) biopsy alone or with axillary dissection (AD): results from NSABP protocol B-32. [Abstract] J Clin Oncol 26 (Suppl 15): A-9533, 2008.|Julian TB, Anderson SJ, Fourchotte V, et al.: Is completion axillary dissection always required after a positive sentinel node biopsy? NSABP B-32. [Abstract] Breast Cancer Res Treat 106 (1): A-51, S15, 2007.|Julian TB, Anderson SJ, Fourchotte V, et al.: Is intraoperative cytology of sentinel nodes useful and predictive for non-sentinel axillary nodes? NSABP B-32. [Abstract] Breast Cancer Res Treat 106 (1): A-3001, 2007.|Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, Weaver DL, Miller BJ, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Mammolito DM, McCready DR, Mamounas EP, Costantino JP, Wolmark N; National Surgical Adjuvant Breast and Bowel Project. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007 Oct;8(10):881-8.|Julian B, Fourchotte V, Anderson S, et al.: Predictive factors that identify patients not requiring a sentinel node biopsy: continued analysis of the NSABP B-32 sentinel node trial. [Abstract] Breast Cancer Res Treat 100 (Suppl 1): A-2003, S80-1, 2006.|Weaver DL, Krag DN, Manna EA, Ashikaga T, Waters BL, Harlow SP, Bauer KD, Julian TB. Detection of occult sentinel lymph node micrometastases by immunohistochemistry in breast cancer. An NSABP protocol B-32 quality assurance study. Cancer. 2006 Aug 15;107(4):661-7.|Harlow SP, Krag DN, Julian TB, Ashikaga T, Weaver DL, Feldman SA, Klimberg VS, Kusminsky R, Moffat FL Jr, Noyes RD, Beitsch PD. Prerandomization Surgical Training for the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 trial: a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer. Ann Surg. 2005 Jan;241(1):48-54.","\tBreast Cancer\tconventional surgery|Sentinel node resection followed by node examination\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tFemale\t","Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer","Interventional","Completed","Phase 3",2,5611,"breast neoplasms","NA","NA"]
["NCT00003831","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23040416|20829340|21335122|NA|16488712","Fibla JJ, Cassivi SD, Brunelli A, Decker PA, Allen MS, Darling GE, Landreneau RJ, Putnam JB. Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set. Lung Cancer. 2012 Dec;78(3):259-62. doi: 10.1016/j.lungcan.2012.09.010. Epub 2012 Oct 3.|Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA, Inculet RI, Jones DR, McKenna RJ, Landreneau RJ, Putnam JB Jr. Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective American College of Surgeons Oncology Group Z0030 trial. Chest. 2011 May;139(5):1124-1129. doi: 10.1378/chest.10-0859. Epub 2010 Sep 9.|Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA, Inculet RI, Jones DR, McKenna RJ, Landreneau RJ, Rusch VW, Putnam JB Jr. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg. 2011 Mar;141(3):662-70. doi: 10.1016/j.jtcvs.2010.11.008.|Allen MS, Darling GE, Decker PA, et al.: Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective ACOSOG Z0030 trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-7555, 398s, 2007.|Allen MS, Darling GE, Pechet TT, Mitchell JD, Herndon JE 2nd, Landreneau RJ, Inculet RI, Jones DR, Meyers BF, Harpole DH, Putnam JB Jr, Rusch VW; ACOSOG Z0030 Study Group. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg. 2006 Mar;81(3):1013-9; discussion 1019-20.","\tLung Cancer\tconventional surgery\tParallel Assignment\tTreatment\tRandomized\tProcedure\tAll\t","Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer","Interventional","Completed","Phase 3",2,1023,"lung neoplasms","NA","NA"]
["NCT00003834","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16230673|NA","Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005 Dec 20;23(36):9243-9. Epub 2005 Oct 17.|Alberts SR, Horvath W, Donohue J, et al.: Oxaliplatin (OXAL), 5-Fluorouracil (5FU), and Leucovorin (CF) for patients (Pts) with liver only metastases (Mets) from colorectal cancer (CRC): a North Central Cancer Treatment Group (NCCTG) phase II study. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-511, 2001.","\tColorectal Cancer|Metastatic Cancer\tfluorouracil|leucovorin calcium|oxaliplatin\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","adenocarcinoma|colorectal neoplasms","levoleucovorin|leucovorin|calcium|fluorouracil|oxaliplatin","NA"]
["NCT00003847","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17285598,"Gandhi L, Harding MW, Neubauer M, Langer CJ, Moore M, Ross HJ, Johnson BE, Lynch TJ. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer. 2007 Mar 1;109(5):924-32.","\tLung Cancer\tbiricodar dicitrate|doxorubicin hydrochloride|vincristine sulfate\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|small cell lung carcinoma","doxorubicin|vincristine|liposomal doxorubicin","NA"]
["NCT00003849","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15657404,"Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, Friedenberg WR, White WL, Chalchal HI, Flynn PJ, Fitch TR, Welker DA. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol. 2005 Feb 20;23(6):1103-8. Epub 2005 Jan 18.","\tLymphoma\trituximab\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|lymphoma, non-hodgkin|hodgkin disease","rituximab","NA"]
["NCT00003851","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19687327,"Chabot JA, Tsai WY, Fine RL, Chen C, Kumah CK, Antman KA, Grann VR. Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer. J Clin Oncol. 2010 Apr 20;28(12):2058-63. doi: 10.1200/JCO.2009.22.8429. Epub 2009 Aug 17.","\tMalnutrition|Pancreatic Cancer\tproteolytic enzymes|gemcitabine hydrochloride|Gonzalez regimen\tNA\tNA\tNA\tBiological|Drug|Procedure\tAll\t","Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pancreatic Cancer","Interventional","Terminated","N/A",2,90,"pancreatic neoplasms|malnutrition","gemcitabine","NA"]
["NCT00003853","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12000194,"Gertz MA, Lacy MQ, Dispenzieri A, Cheson BD, Barlogie B, Kyle RA, Palladini G, Geyer SM, Merlini G. A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid. 2002 Mar;9(1):24-30.","\tMultiple Myeloma and Plasma Cell Neoplasm\t4'-iodo-4'-deoxydoxorubicin\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","immunoglobulin light-chain amyloidosis|multiple myeloma|amyloidosis|neoplasms, plasma cell|plasmacytoma","esorubicin","NA"]
["NCT00003854","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16164916|22868365|21791687|20309640|16514477|16192820","Leitch AM, Beitsch PD, McCall LM, Posther K, Newman LA, Herndon JE 2nd, Hunt KK, Giuliano AE. Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer. Am J Surg. 2005 Oct;190(4):539-42.|Hunt KK, Ballman KV, McCall LM, Boughey JC, Mittendorf EA, Cox CE, Whitworth PW, Beitsch PD, Leitch AM, Buchholz TA, Morrow MA, Giuliano AE. Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial. Ann Surg. 2012 Sep;256(3):428-36.|Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, Morrow M, Leitch AM, Hunt KK, McCall LM, Abati A, Cote R. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 2011 Jul 27;306(4):385-93. doi: 10.1001/jama.2011.1034.|Wilke LG, Ballman KV, McCall LM, Giuliano AE, Whitworth PW, Blumencranz PW, Reintgen DS, Burak WE, Leitch AM, Hunt KK. Adherence to the National Quality Forum (NQF) breast cancer measures within cancer clinical trials: a review from ACOSOG Z0010. Ann Surg Oncol. 2010 Aug;17(8):1989-94. doi: 10.1245/s10434-010-0980-9. Epub 2010 Mar 23.|Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, Gabram SG, Lucci A, Cox CE, Hunt KK, Herndon JE 2nd, Giuliano AE. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006 Apr;13(4):491-500. Epub 2006 Mar 2.|Posther KE, McCall LM, Blumencranz PW, Burak WE Jr, Beitsch PD, Hansen NM, Morrow M, Wilke LG, Herndon JE 2nd, Hunt KK, Giuliano AE. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. Ann Surg. 2005 Oct;242(4):593-9; discussion 599-602.","\tBreast Cancer\timmunohistochemistry staining method|lymphangiography|sentinel lymph node biopsy|therapeutic conventional surgery|whole breast irradiation\tNA\tNA\tNA\tOther|Procedure|Procedure|Procedure|Radiation\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","NA","NA"]
["NCT00003855","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23338762|23037494|21327455|21304082|20739842|17485711","Krishnan MS, Recht A, Bellon JR, Punglia RS. Trade-offs associated with axillary lymph node dissection with breast irradiation versus breast irradiation alone in patients with a positive sentinel node in relation to the risk of non-sentinel node involvement: implications of ACOSOG Z0011. Breast Cancer Res Treat. 2013 Feb;138(1):205-13. doi: 10.1007/s10549-013-2418-0. Epub 2013 Jan 22.|Shah-Khan M, Boughey JC. Evolution of axillary nodal staging in breast cancer: clinical implications of the ACOSOG Z0011 trial. Cancer Control. 2012 Oct;19(4):267-76. Review.|Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EA. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol. 2011 Sep;18(9):2407-12. doi: 10.1245/s10434-011-1593-7.|Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011 Feb 9;305(6):569-75. doi: 10.1001/jama.2011.90.|Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Hunt KK, Morrow M, Ballman K. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010 Sep;252(3):426-32; discussion 432-3. doi: 10.1097/SLA.0b013e3181f08f32.|Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE; American College of Surgeons Oncology Group. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007 Aug 20;25(24):3657-63. Epub 2007 May 7.","\tBreast Cancer\taxillary lymph node dissection|whole breast irradiation\tParallel Assignment\tTreatment\tRandomized\tProcedure|Radiation\tFemale\t","Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer","Interventional","Completed","Phase 3",2,605,"breast neoplasms","NA","NA"]
["NCT00003857","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","McCormick B: RTOG 9804: A prospective randomized trial for \"good risk\" ductal carcinoma in situ (DCIS), comparing radiation (RT) to observation (OBS). [Abstract] J Clin Oncol 30 (Suppl 15): A-1004, 2012.","\tBreast Cancer\ttamoxifen citrate|adjuvant therapy|radiation therapy\tParallel Assignment\tTreatment\tRandomized\tDrug|Procedure|Radiation\tFemale\t","Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ","Interventional","Active, not recruiting","Phase 3",2,636,"carcinoma|carcinoma in situ","tamoxifen","NA"]
["NCT00003858","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11857298,"Levine EG, Halabi S, Roberts JD, Kaplan EB, Rago R, Atkins JN, Vogelzang NJ. Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study. Cancer. 2002 Feb 1;94(3):665-72.","\tProstate Cancer\tmitoxantrone hydrochloride\tNA\tNA\tNA\tDrug\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","mitoxantrone","NA"]
["NCT00003859","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19328574|17878477|16258095|15328187|15001263|12697884","Taylor RE, Donachie PH, Weston CL, Robinson KJ, Lucraft H, Saran F, Ellison DW, Ironside J, Walker DA, Pizer BL; Children's Cancer and Leukaemia Group CNS Tumour Division. Impact of radiotherapy parameters on outcome for patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study. Radiother Oncol. 2009 Jul;92(1):83-8. doi: 10.1016/j.radonc.2009.02.017. Epub 2009 Mar 26.|Bull KS, Spoudeas HA, Yadegarfar G, Kennedy CR; CCLG. Reduction of health status 7 years after addition of chemotherapy to craniospinal irradiation for medulloblastoma: a follow-up study in PNET 3 trial survivors on behalf of the CCLG (formerly UKCCSG). J Clin Oncol. 2007 Sep 20;25(27):4239-45.|Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, Taylor RE, Pearson AD, Clifford SC; United Kingdom Children's Cancer Study Group Brain Tumour Committee. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol. 2005 Nov 1;23(31):7951-7.|Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res. 2004 Aug 15;10(16):5482-93.|Taylor RE, Bailey CC, Robinson KJ, Weston CL, Ellison D, Ironside J, Lucraft H, Gilbertson R, Tait DM, Saran F, Walker DA, Pizer BL, Lashford LS; United Kingdom Children's Cancer Study Group Brain Tumour Committee; International Society of Paediatric Oncology. Impact of radiotherapy parameters on outcome in the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 study of preradiotherapy chemotherapy for M0-M1 medulloblastoma. Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1184-93.|Taylor RE, Bailey CC, Robinson K, Weston CL, Ellison D, Ironside J, Lucraft H, Gilbertson R, Tait DM, Walker DA, Pizer BL, Imeson J, Lashford LS; International Society of Paediatric Oncology; United Kingdom Children's Cancer Study Group. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol. 2003 Apr 15;21(8):1581-91.","\tBrain and Central Nervous System Tumors\tcarboplatin|cyclophosphamide|etoposide|vincristine sulfate|surgical procedure|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","neuroectodermal tumors|neuroectodermal tumors, primitive|nervous system neoplasms|central nervous system neoplasms","vincristine|cyclophosphamide|carboplatin|etoposide","NA"]
["NCT00003862","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16921048|NA","Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006 Aug 20;24(24):3953-8.|Okawara GS, Winter K, Donohue JH, et al.: A phase II trial of preoperative chemotherapy and chemoradiotherapy for potentially resectable adenocarcinoma of the stomach (RTOG 99-04). [Abstract] J Clin Oncol 23 (Suppl 16): A-4019, 312s, 2005.","\tGastric Cancer\tcisplatin|fluorouracil|leucovorin calcium|paclitaxel|conventional surgery|neoadjuvant therapy|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Procedure|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","stomach neoplasms","fluorouracil|levoleucovorin|leucovorin|calcium|paclitaxel","NA"]
["NCT00003864","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21464865,"Rossman JF, Falkson CI, Xu R, Slabber CF, Mason BA, Mulcahy MF, Benson AB 3rd. Phase II Trial of Docetaxel and Carboplatin in Patients With Advanced Squamous Carcinoma of the Esophagus (E2298): A Trial of the Eastern Cooperative Oncology Group. Gastrointest Cancer Res. 2011 Jan;4(1):9-14.","\tEsophageal Cancer\tcarboplatin|docetaxel\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","esophageal neoplasms","docetaxel|carboplatin","NA"]
["NCT00003867","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12393999,"Goel S, Jhawer M, Rajdev L, Hopkins U, Fehn K, Baker C, Chun HG, Makower D, Landau L, Hoffman A, Wadler S, Mani S. Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies. Am J Clin Oncol. 2002 Oct;25(5):528-34.","\tCancer\tcapecitabine|irinotecan hydrochloride\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","NA","capecitabine|irinotecan","NA"]
["NCT00003871","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|15169798|NA","Kaufman HL, Wang W, Manola J, et al.: Phase II prime/boost vaccination using poxviruses expressing PSA in hormone dependent prostate cancer: follow-up clinical results from ECOG 7897. [Abstract] J Clin Oncol 23 (Suppl 16): A-4501, 378s, 2005.|Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, Whiteside TL, Schlom J, Wilding G, Weiner LM. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2004 Jun 1;22(11):2122-32.|Kaufman HL, Wang W, Manola J, et al.: Prime/boost vaccination using poxviruses expressing PSA in D0 prostate cancer: preliminary results of ECOG 7897, a randomized phase II clinical trial. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-12, 2002.","\tProstate Cancer\tfowlpox virus vaccine vector|recombinant vaccinia prostate-specific antigen vaccine\tNA\tNA\tNA\tBiological|Biological\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","vaccines","NA"]
["NCT00003881","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","14981103|NA|NA|NA","Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH; Eastern Cooperative Oncology Group Study 2598. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol. 2004 Apr 1;22(7):1180-7. Epub 2004 Feb 23.|Huang C, Stephenson P, Langer CJ, et al.: Trastuzumab in combination with paclitaxel/carboplatin in advanced non-small cell lung cancer: final report of ECOG 2598. [Abstract] Lung Cancer 41 (Suppl 2): A-P628, S251, 2003.|Schiller J, Langer CJ, Thor A, et al.: Trastuzumab in combination with paclitaxel/carboplatin advanced non-small cell lung cancer: final report of ECOG 2598. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2606, 2003.|Langer CJ, Adak S, Thor A, et al.: Phase II Eastern Cooperative Oncology Group (ECOG) pilot study of paclitaxel (P), carboplatin (C), and trastuzumab (T) in HER-2/neu (+) advanced non-small cell lung cancer (NSCLC): early analysis of E2598. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1257, 2001.","\tLung Cancer\ttrastuzumab|carboplatin|paclitaxel\tNA\tNA\tNA\tBiological|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms","carboplatin|trastuzumab|paclitaxel","NA"]
["NCT00003882","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Schwartz GN, Bong D, Leichman CG, et al.: Phase I evaluation of anhydrovinblastine in patients with advanced malignancies. [Abstract] Proc Am Assoc Cancer Res 41: 3895a, 2000.","\tUnspecified Adult Solid Tumor, Protocol Specific\tanhydrovinblastine\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","NA","NA"]
["NCT00003888","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20842129|17960012|NA|NA|NA","van Herpen CM, Mauer ME, Mesia R, Degardin M, Jelic S, Coens C, Betka J, Bernier J, Remenar E, Stewart JS, Preiss JH, van den Weyngaert D, Bottomley A, Vermorken JB; EORTC Head and Neck Group. Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323). Br J Cancer. 2010 Oct 12;103(8):1173-81. doi: 10.1038/sj.bjc.6605860. Epub 2010 Sep 14.|Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1695-704.|Bernier J, Coens C, Remenar E, et al.: Impact on quality of life (QoL) of the addition of docetaxel (T) to neoadjuvant cisplatin plus 5-fluorouracil treatment in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN): EORTC study 24971. [Abstract] J Clin Oncol 24 (Suppl 18): A-5522, 285s, 2006.|Remenar E, Van Herpen C, Lluch JG, et al.: A randomized phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN). Final analysis of EORTC 24971. [Abstract] J Clin Oncol 24 (Suppl 18): A-5516, 2006.|Vermorken JB, Remenar E, Van Herpen C, et al.: Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). [Abstract] J Clin Oncol 22 (Suppl 14): A-5508, 490s, 2004.","\tHead and Neck Cancer\tcisplatin|docetaxel|fluorouracil|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","docetaxel|fluorouracil","NA"]
["NCT00003890","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12702532,"Stewart DJ, Donehower RC, Eisenhauer EA, Wainman N, Shah AK, Bonfils C, MacLeod AR, Besterman JM, Reid GK. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann Oncol. 2003 May;14(5):766-74.","\tUnspecified Adult Solid Tumor, Protocol Specific\tMG 98\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT00003891","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15122073,"Gelmon K, Hirte H, Fisher B, Walsh W, Ptaszynski M, Hamilton M, Onetto N, Eisenhauer E. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers. Invest New Drugs. 2004 Aug;22(3):263-75.","\tUnspecified Adult Solid Tumor, Protocol Specific\tlurtotecan liposome\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","lurtotecan","NA"]
["NCT00003892","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12694666,"Oza AM, Elit L, Swenerton K, Faught W, Ghatage P, Carey M, McIntosh L, Dorr A, Holmlund JT, Eisenhauer E; NCIC Clinical Trials Group Study (NCIC IND.116). Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116). Gynecol Oncol. 2003 Apr;89(1):129-33.","\tOvarian Cancer\tISIS 5132\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","ovarian neoplasms|carcinoma, ovarian epithelial","isis 5132","NA"]
["NCT00003896","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19464730,"Smith HO, Moon J, Wilczynski SP, Tiersten AD, Hannigan EV, Robinson WR, Rivkin SE, Anderson GL, Liu PY, Markman M. Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer. Gynecol Oncol. 2009 Aug;114(2):206-9. doi: 10.1016/j.ygyno.2009.04.023. Epub 2009 May 23.","\tFallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer\tcisplatin|liposomal doxorubicin|paclitaxel\tNA\tNA\tNA\tDrug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","ovarian neoplasms|carcinoma, ovarian epithelial|fallopian tube neoplasms","liposomal doxorubicin|doxorubicin|paclitaxel","NA"]
["NCT00003898","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|16086046","Aquino VM, Harvey A, Garvin J, et al.: The use of supplemental glutamine to decrease morbidity in children undergoing stem cell transplantation: a Pediatric Blood and Marrow Transplant Consortium study. [Abstract] 2004 Pediatric Academic Societies' Annual Meeting, May 1-4, San Francisco, California. A-1627, 2004. Availabel online Last accessed August 29, 2005.|Aquino VM, Harvey AR, Garvin JH, Godder KT, Nieder ML, Adams RH, Jackson GB, Sandler ES. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant. 2005 Oct;36(7):611-6.","\tOral Complications|Unspecified Childhood Solid Tumor, Protocol Specific\tglutamine\tNA\tNA\tNA\tDietary Supplement\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT00003900","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16777690,"Molina JR, Nikcevich D, Hillman S, Geyer S, Drevyanko T, Jett J, Verdirame J, Tazelaar H, Rowland K, Wos E, Kutteh L, Nair S, Fitch T, Flynn P, Stella P, Adjei AA. A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer. Cancer Invest. 2006 Jun-Jul;24(4):382-9.","\tLung Cancer\tdocetaxel|irinotecan hydrochloride\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","docetaxel|irinotecan","NA"]
["NCT00003901",8267735,4515838,"Cox Proportional Hazard",0.78,null,"NA",0.48,1.28,95,0.332,"Regression, Cox",21990404,"Rusch VW, Hawes D, Decker PA, Martin SE, Abati A, Landreneau RJ, Patterson GA, Inculet RI, Jones DR, Malthaner RA, Cohen RG, Ballman K, Putnam JB Jr, Cote RJ. Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol. 2011 Nov 10;29(32):4313-9. doi: 10.1200/JCO.2011.35.2500. Epub 2011 Oct 11.","\tLung Cancer\timmunohistochemistry staining method|biopsy|surgery\tNA\tNA\tNA\tOther|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms","NA","Disease-Free Survival in Bone Marrow Examined Patients"]
["NCT00003901",8267736,4515839,"Cox Proportional Hazard",1.63,null,"NA",1.13,2.36,95,0.009,"Regression, Cox",21990404,"Rusch VW, Hawes D, Decker PA, Martin SE, Abati A, Landreneau RJ, Patterson GA, Inculet RI, Jones DR, Malthaner RA, Cohen RG, Ballman K, Putnam JB Jr, Cote RJ. Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol. 2011 Nov 10;29(32):4313-9. doi: 10.1200/JCO.2011.35.2500. Epub 2011 Oct 11.","\tLung Cancer\timmunohistochemistry staining method|biopsy|surgery\tNA\tNA\tNA\tOther|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms","NA","Disease-Free Survival in Lymph Nodes Examined Patients"]
["NCT00003901",8267737,4515840,"Cox Proportional Hazard",1.03,null,"NA",0.69,1.54,95,0.886,"Regression, Cox",21990404,"Rusch VW, Hawes D, Decker PA, Martin SE, Abati A, Landreneau RJ, Patterson GA, Inculet RI, Jones DR, Malthaner RA, Cohen RG, Ballman K, Putnam JB Jr, Cote RJ. Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol. 2011 Nov 10;29(32):4313-9. doi: 10.1200/JCO.2011.35.2500. Epub 2011 Oct 11.","\tLung Cancer\timmunohistochemistry staining method|biopsy|surgery\tNA\tNA\tNA\tOther|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms","NA","Overall Survival in Bone Marrow Examined Patients"]
["NCT00003901",8267738,4515841,"Cox Proportional Hazard",1.59,null,"NA",1.13,2.23,95,0.007,"Regression, Cox",21990404,"Rusch VW, Hawes D, Decker PA, Martin SE, Abati A, Landreneau RJ, Patterson GA, Inculet RI, Jones DR, Malthaner RA, Cohen RG, Ballman K, Putnam JB Jr, Cote RJ. Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol. 2011 Nov 10;29(32):4313-9. doi: 10.1200/JCO.2011.35.2500. Epub 2011 Oct 11.","\tLung Cancer\timmunohistochemistry staining method|biopsy|surgery\tNA\tNA\tNA\tOther|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms","NA","Overall Survival in Lymph Nodes Examined Patients"]
["NCT00003902","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18424887|15550580","Hess D, Koberle D, Thurlimann B, Pagani O, Schonenberger A, Mattmann S, Rochlitz C, Rauch D, Schuller JC, Ballabeni P, Ribi K; Swiss Group for Clinical Cancer Research. Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). Oncology. 2007;73(3-4):228-37. doi: 10.1159/000127414. Epub 2008 Apr 17.|Hess D, Thürlimann B, Pagani O, Aebi S, Rauch D, Ballabeni P, Rufener B, Castiglione-Gertsch M, Goldhirsch A; Swiss Group of Clinical Cancer Research (SAKK). Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Ann Oncol. 2004 Dec;15(12):1760-5.","\tBreast Cancer\tcapecitabine|vinorelbine tartrate\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","capecitabine|vinorelbine","NA"]
["NCT00003906","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19105706|19213563|NA|NA|16754728|NA|16754727","Vogel VG. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther. 2009 Jan;9(1):51-60. doi: 10.1586/14737140.9.1.51. Review. Erratum in: Expert Rev Anticancer Ther. 2009 Mar;9(3):388.|Wickerham DL, Costantino JP, Vogel VG, Cronin WM, Cecchini RS, Ford LG, Wolmark N. The use of tamoxifen and raloxifene for the prevention of breast cancer. Recent Results Cancer Res. 2009;181:113-9. Review.|Ganz PA, Land SR, Wickerham DL, et al.: The Study of Tamoxifen and Raloxifene (STAR): Change in patient-reported outcomes (PROs) after the end of treatment. [Abstract] J Clin Oncol 25 (Suppl 18): A-1506, 2007.|Ganz PA, Land SR, Wickerham DL, et al.: The study of tamoxifen and raloxifene (STAR): first report of patient-reported outcomes (PROs) from the NSABP P-2 breast cancer prevention study. [Abstract] J Clin Oncol 24 (Suppl 18): A-LBA561, 2006.|Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, Pajon ER, Wade JL 3rd, Dakhil S, Lockhart JB Jr, Wolmark N, Ganz PA. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006 Jun 21;295(23):2742-51. Epub 2006 Jun 5. Erratum in: JAMA. 2007 Sep 5;298(9):973.|Vogel VG, Costantino JP, Wickerham DL, et al.: The effects of tamoxifen versus raloxifene on the risk of developing noninvasive breast cancer in the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. [Abstract] Breast Cancer Res Treat 100 (Suppl 1): A-33, S16, 2006.|Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006 Jun 21;295(23):2727-41. Epub 2006 Jun 5. Erratum in: JAMA. 2006 Dec 27;296(24):2926. JAMA. 2007 Sep 5;298(9):973.","\tBreast Cancer\tRaloxifene|Tamoxifen\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug\tFemale\t","Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women","Interventional","Completed","Phase 3",2,19747,"breast neoplasms","tamoxifen|raloxifene hydrochloride","NA"]
["NCT00003908","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17530488,"Samlowski WE, Moon J, Kuebler JP, Nichols CR, Gandara DR, Ozer H, Williamson SK, Atkins JN, Schuller DE, Ensley JF. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study. Cancer Invest. 2007 Apr-May;25(3):182-8.","\tHead and Neck Cancer\tcarboplatin|docetaxel\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","docetaxel|carboplatin","NA"]
["NCT00003912","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19846851,"Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. doi: 10.1056/NEJMoa0810613.","\tLiver Cancer\tcarboplatin|cisplatin|doxorubicin hydrochloride|conventional surgery\tNA\tNA\tNA\tDrug|Drug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","hepatoblastoma|liver neoplasms","liposomal doxorubicin|doxorubicin|carboplatin","NA"]
["NCT00003916","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18455252|10549493","Baumert BG, Brada M, Bernier J, Kortmann RD, Dehing-Oberije C, Collette L, Davis JB. EORTC 22972-26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost arm. Radiother Oncol. 2008 Aug;88(2):163-72. doi: 10.1016/j.radonc.2008.03.025. Epub 2008 Apr 30.|Brada M, Baumert B. Focal fractionated conformal stereotactic boost following conventional radiotherapy of high-grade gliomas: a randomized phase III study. A joint study of the EORTC (22972) and the MRC (BR10). Front Radiat Ther Oncol. 1999;33:241-3.","\tBrain and Central Nervous System Tumors\tradiation therapy|stereotactic radiosurgery\tNA\tNA\tNA\tRadiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|nervous system neoplasms","NA","NA"]
["NCT00003917","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17513814,"Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, Poulin R, Preston AJ, Dane G, Ross G. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007 May 20;25(15):2086-92. Erratum in: J Clin Oncol. 2007 Aug 1;25(22):3387..","\tLung Cancer\ttopotecan hydrochloride\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|small cell lung carcinoma","topotecan","NA"]
["NCT00003925","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17414457|10442378","El-Rayes BF, Zalupski M, Shields AF, Manza SG, LoRusso P, Philip PA. A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin. Am J Clin Oncol. 2007 Apr;30(2):101-5.|Philip PA, Ibrahim D, Zalupski M, Arlauskas P, Shields A. Gemcitabine and UFT plus oral calcium folinate: phase I study. Oncology (Williston Park). 1999 Jul;13(7 Suppl 3):116-9.","\tUnspecified Adult Solid Tumor, Protocol Specific\tgemcitabine hydrochloride|leucovorin calcium|tegafur-uracil\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","NA","levoleucovorin|tegafur|leucovorin|gemcitabine|calcium","NA"]
["NCT00003930","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19100600|NA","Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ 3rd, Toonkel LM, Zietman AL, Tanguay S, Sandler HM. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009 Apr;73(4):833-7. doi: 10.1016/j.urology.2008.09.036. Epub 2008 Dec 18.|Kaufman DS, Winter KA, Shipley WU, et al.: Muscle-invading bladder cancer, RTOG Protocol 99-06: initial report of a phase I/II trial of selective bladder-conservation employing TURBT, accelerated irradiation sensitized with cisplatin and paclitaxel followed by adjuvant cisplatin and gemcitabine chemotherapy. [Abstract] J Clin Oncol 23 (Suppl 16): A-4506, 379s, 2005.","\tBladder Cancer\tcisplatin|gemcitabine hydrochloride|paclitaxel|conventional surgery|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","urinary bladder neoplasms","gemcitabine|paclitaxel","NA"]
["NCT00003935","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17278121,"Korones DN, Fisher PG, Kretschmar C, Zhou T, Chen Z, Kepner J, Freeman C. Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study. Pediatr Blood Cancer. 2008 Feb;50(2):227-30.","\tBrain Tumors|Central Nervous System Tumors\tetoposide|vincristine sulfate|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","glioma|central nervous system neoplasms|nervous system neoplasms","vincristine|etoposide","NA"]
["NCT00003939","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15659504|15177491|NA","Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, Di Paola E, Van Glabbeke M, Nielsen OS. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005 Jan 20;23(3):576-84. Erratum in: J Clin Oncol. 2005 Aug 1;23(22):5276.|Blay JY, Le Cesne A, Verweij J, Scurr M, Seynaeve C, Bonvalot S, Hogendoorn P, Jimeno J, Evrard V, van Glabbeke M, Judson I. A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2004 Jun;40(9):1327-31.|Le Cesne A, Judson I, Blay JY, et al.: Phase II study of ET-743 in advanced soft tissue sarcoma (ASTS) in adults: a STBSG-EORTC trial. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A-2182, 2000.","\tBrain and Central Nervous System Tumors|Endometrial Cancer|Gastrointestinal Stromal Tumor|Ovarian Cancer|Sarcoma|Small Intestine Cancer\ttrabectedin\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","nervous system neoplasms|gastrointestinal stromal tumors|sarcoma|intestinal neoplasms|endometrial neoplasms|central nervous system neoplasms","trabectedin","NA"]
["NCT00003941","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21059637,"Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, Marreaud S, Collette L, Lluch JRG, Bokemeyer C, Schmoll HJ. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol. 2011 May;22(5):1054-1061. doi: 10.1093/annonc/mdq575. Epub 2010 Nov 8.","\tMediastinal Cancer|Metastatic Cancer|Testicular Germ Cell Tumor\tbleomycin sulfate|filgrastim|cisplatin|etoposide|ifosfamide|bone marrow ablation with stem cell support|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug|Procedure|Procedure\tMale\t","NA","NA","NA","NA","NA","NA","neoplasms, germ cell and embryonal|mediastinal neoplasms","etoposide|bleomycin|ifosfamide","NA"]
["NCT00003945","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16216315|15911865|15911864|NA|NA","Long HJ 3rd, Monk BJ, Huang HQ, Grendys EC Jr, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV; Gynecologic Oncology Group. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. Gynecol Oncol. 2006 Mar;100(3):537-43. Epub 2005 Oct 10.|Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV; Gynecologic Oncology Group Study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005 Jul 20;23(21):4626-33. Epub 2005 May 23.|Monk BJ, Huang HQ, Cella D, Long HJ 3rd; Gynecologic Oncology Group Study. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005 Jul 20;23(21):4617-25. Epub 2005 May 23. Erratum in: J Clin Oncol. 2005 Nov 20;23(33):8549.|Grendys EC Jr, Long HJ, Bundy BN, et al.: Randomized phase III trial of cisplatin vs cisplatin plus topotecan vs the combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) in stage IVB, recurrent or persistent carcinoma of the uterine cervix: a Gynecologic Oncology Group study. [Abstract] Int J Gynecol Cancer 14 (Suppl 1): A-039, 12, 2004.|Monk BJ, Huang H, Cella D, et al.: Quality of life outcomes from GOG 179: a phase III trial of cisplatin vs cisplatin/topotecan in recurrent or persistent carcinoma of the cervix. [Abstract] Int J Gynecol Cancer 14 (Suppl 1): A-142, 42, 2004.","\tCervical Cancer\tcisplatin|topotecan hydrochloride\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","uterine cervical neoplasms","topotecan","NA"]
["NCT00003946","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12798713,"Covens A, Brunetto VL, Markman M, Orr JW, Lentz SS, Benda J; Gynecologic Oncology Group. Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2003 Jun;89(3):470-4.","\tEndometrial Cancer\tdanazol\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","endometrial neoplasms","danazol","NA"]
["NCT00003950","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15895230,"Desai AA, Kindler HL, Taber D, Agamah E, Mani S, Wade-Oliver K, Ratain MJ, Vokes EE. Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. Cancer Chemother Pharmacol. 2005 Oct;56(4):421-6. Epub 2005 May 13.","\tColorectal Cancer\tcyclosporine|CPT-11\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","irinotecan|cyclosporins|cyclosporine","NA"]
["NCT00003955","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17264331,"Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH; Children's Oncology Group. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J Clin Oncol. 2007 Feb 1;25(4):362-9.","\tSarcoma\tdactinomycin|filgrastim|pegfilgrastim|sargramostim|cyclophosphamide|irinotecan hydrochloride|vincristine sulfate|radiation therapy\tNA\tNA\tNA\tBiological|Biological|Biological|Biological|Drug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","rhabdomyosarcoma|sarcoma","vincristine|cyclophosphamide|irinotecan|dactinomycin|sargramostim","NA"]
["NCT00003966","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|NA","Richardson PG, Soiffer RJ, Antin JH, et al.: Defibrotide (DF) for the treatment of severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post SCT: final results of a phase II, multicenter, randomized study and preliminary analyses of surrogate markers and ultrasound findings. [Abstract] Blood 104 (11): A-350, 2004.|Richardson P, Soiffer RJ, Antin JH, et al.: Defibrotide (DF) is effective in the treatment of severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): results of a phase II, multicenter, randomized study. [Abstract] Blood 102 (11): A-674, 2003.|Richardson PG, Soiffer R, Antin JH, et al.: Defibrotide (DF) appears effective and safe in a phase II, randomized study of patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT). [Abstract] Blood 100 (9): A-414, 2002.","\tVeno-occlusive Disease\tdefibrotide\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation","Interventional","Completed","Phase 2",2,151,"NA","defibrotide","NA"]
["NCT00003967","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16412499,"Rose PG, Markman M, Bell JG, Fusco NL. Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study. Gynecol Oncol. 2006 Aug;102(2):236-9. Epub 2006 Jan 18.","\tFallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer\tetoposide|topotecan hydrochloride\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","fallopian tube neoplasms","etoposide|topotecan","NA"]
["NCT00003969","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15961763,"Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye S, Workman P, Judson I. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol. 2005 Jun 20;23(18):4152-61.","\tUnspecified Adult Solid Tumor, Protocol Specific\ttanespimycin\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT00003979","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15763645,"Ravaud A, Cerny T, Terret C, Wanders J, Bui BN, Hess D, Droz JP, Fumoleau P, Twelves C. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur J Cancer. 2005 Mar;41(5):702-7.","\tUnspecified Adult Solid Tumor, Protocol Specific\tCHS 828\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","NA","NA"]
["NCT00003991","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21546500|21429214","Buyse M, Michiels S, Squifflet P, Lucchesi KJ, Hellstrand K, Brune ML, Castaigne S, Rowe JM. Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission. Haematologica. 2011 Aug;96(8):1106-12. doi: 10.3324/haematol.2010.039131. Epub 2011 May 5.|Buyse M, Squifflet P, Lucchesi KJ, Brune ML, Castaigne S, Rowe JM. Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia. Trials. 2011 Mar 23;12:86. doi: 10.1186/1745-6215-12-86.","\tLeukemia\taldesleukin|histamine dihydrochloride\tNA\tNA\tNA\tBiological|Drug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia|leukemia, myeloid|leukemia, myeloid, acute","histamine phosphate|aldesleukin|histamine","NA"]
["NCT00003992","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Sledge GW, O'Neill A, Thor A, et al.: Adjuvant trastuzumab: long-term results of E2198. [Abstract] Breast Cancer Res Treat 100 (Suppl 1): A-2075, S106, 2006.","\tBreast Cancer\ttrastuzumab|cyclophosphamide|doxorubicin hydrochloride|paclitaxel|tamoxifen citrate\tParallel Assignment\tTreatment\tRandomized\tBiological|Drug|Drug|Drug|Drug\tFemale\t","Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2","Interventional","Completed","Phase 2",2,200,"breast neoplasms","cyclophosphamide|doxorubicin|trastuzumab|tamoxifen|paclitaxel|liposomal doxorubicin","NA"]
["NCT00003995","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15641483,"Ramanathan RK, Hwang JJ, Zamboni WC, Sinicrope FA, Safran H, Wong MK, Earle M, Brufsky A, Evans T, Troetschel M, Walko C, Day R, Chen HX, Finkelstein S. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest. 2004;22(6):858-65.","\tColorectal Cancer\ttrastuzumab|irinotecan hydrochloride\tNA\tNA\tNA\tBiological|Drug\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","trastuzumab|irinotecan","NA"]
["NCT00003996","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Jaeckle K, Ballman K, O'Fallon J, et al.: Response to pre-radiation chemotherapy as a predictor of survival in patients with newly diagnosed malignant astrocytoma: a North Central Cancer Treatment Group (NCCTG) study. [Abstract] Neuro-Oncology 6 (4): TA-26, 376, 2004.|Jaeckle K, Ballman K, Uhm J, et al.: Relationship of administration of enzyme-inducing anticonvulsants (EIAC) to survival in patients with glioblastoma: a North Central Cancer Treatment Group (NCCTG) study. [Abstract] Neuro-Oncology 6 (4): TA-27, 376, 2004.","\tBrain and Central Nervous System Tumors\tcarmustine|chemotherapy|cisplatin|etoposide|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","nervous system neoplasms|central nervous system neoplasms|glioblastoma","etoposide|carmustine","NA"]
["NCT00003998","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17925548|16314640|15547181","Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol. 2007 Oct 10;25(29):4528-35.|Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol. 2005 Dec 1;23(34):8802-11. Erratum in: J Clin Oncol. 2006 Mar 1;24(7):1224.|Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB; Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91.","\tOvarian Cancer|Primary Peritoneal Cavity Cancer\tcarboplatin|docetaxel|paclitaxel|surgical procedure\tNA\tNA\tNA\tDrug|Drug|Drug|Procedure\tFemale\t","NA","NA","NA","NA","NA","NA","carcinoma, ovarian epithelial|ovarian neoplasms","paclitaxel|docetaxel|carboplatin","NA"]
["NCT00004001","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19130298|16622120|16782921|NA|NA|NA|15470214|10604271","Moinpour CM, Donaldson GW, Nakamura Y. Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial. Qual Life Res. 2009 Mar;18(2):147-55. doi: 10.1007/s11136-008-9433-3. Epub 2009 Jan 9.|Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006 Apr 19;98(8):516-21.|Southwest Oncology Group, Berry DL, Moinpour CM, Jiang CS, Ankerst DP, Petrylak DP, Vinson LV, Lara PN, Jones S, Taplin ME, Burch PA, Hussain MH, Crawford ED. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol. 2006 Jun 20;24(18):2828-35.|Berry DL, Moinpour CM, Jiang C, et al.: Quality of life (QOL) and pain in advanced stage prostate cancer: impact of missing data on evaluating palliation in SWOG 9916. [Abstract] J Clin Oncol 22 (Suppl 14): A-4579, 401s, 2004.|Crawford ED, Pauler DK, Tangen CM, et al.: Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): data from Southwest Oncology Group study S9916. [Abstract] J Clin Oncol 22 (Suppl 14): A-4505, 383s, 2004.|Petrylak DP, Tangen C, Hussain M, et al.: SWOG 99-16: randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA). [Abstract] J Clin Oncol 22 (Suppl 14): A-3, 2s, 2004.|Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 7;351(15):1513-20.|Hussain M, Petrylak D, Fisher E, Tangen C, Crawford D. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. Semin Oncol. 1999 Oct;26(5 Suppl 17):55-60.","\tProstate Cancer\tdocetaxel|estramustine|mitoxantrone|prednisone\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug\tMale\t","S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy","Interventional","Completed","Phase 3",2,770,"prostatic neoplasms","docetaxel|estramustine|mitoxantrone|prednisone","NA"]
["NCT00004002","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16135477,"Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol. 2005 Sep 1;23(25):6107-16.","\tLymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific\tbortezomib\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","intestinal neoplasms|lymphoma","bortezomib","NA"]
["NCT00004004","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14670747,"He X, Batchelor TT, Grossman S, Supko JG; New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium. Determination of procarbazine in human plasma by liquid chromatography with electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jan 25;799(2):281-91.","\tBrain and Central Nervous System Tumors\tprocarbazine hydrochloride\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","nervous system neoplasms|central nervous system neoplasms","procarbazine","NA"]
["NCT00004010","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21079154|NA|NA","Kelly KM, Sposto R, Hutchinson R, Massey V, McCarten K, Perkins S, Lones M, Villaluna D, Weiner M. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood. 2011 Mar 3;117(9):2596-603. doi: 10.1182/blood-2010-05-285379. Epub 2010 Nov 15.|Kelly M, Hutchinson R, Sposto R, et al.: BEACOPP chemotherapy is a highly effective regimen in children and adolescents with advanced stage Hodgkin's disease: results from Children's Cancer Group study CCG-59704. [Abstract] Eur J Haematol 75 (Suppl 65): A-WP07, 72, 2004.|Shiramizu B, Morris E, Perkins S, et al.: Identification of patient specific primers (PSPs) of IgH and TCR-y regions by nested PCR in CD20 positive Hodgkin disease: a Children's Cancer Group report (CCG). [Abstract] Ann Oncol 13(suppl 2): A-389, 112, 2002.","\tLymphoma\tbleomycin sulfate|filgrastim|ABVD regimen|cyclophosphamide|dacarbazine|doxorubicin hydrochloride|etoposide|prednisone|procarbazine hydrochloride|vinblastine sulfate|vincristine sulfate|radiation therapy\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|hodgkin disease","bleomycin|dacarbazine|etoposide|vincristine|doxorubicin|liposomal doxorubicin|prednisone|cyclophosphamide|vinblastine|procarbazine","NA"]
["NCT00004011","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20231678|NA|NA","Pisters KM, Vallières E, Crowley JJ, Franklin WA, Bunn PA Jr, Ginsberg RJ, Putnam JB Jr, Chansky K, Gandara D. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol. 2010 Apr 10;28(11):1843-9. doi: 10.1200/JCO.2009.26.1685. Epub 2010 Mar 15.|Pisters K, Vallieres E, Bunn PA, et al.: S9900: surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): follow-up on a phase III trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-7520, 389s, 2007.|Pisters K, Vallieres E, Bunn P, et al.: S9900: a phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): preliminary results. [Abstract] J Clin Oncol 23 (Suppl 16): A-LBA7012, 624s, 2005.","\tLung Cancer\tcarboplatin|paclitaxel|conventional surgery\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Procedure\tAll\t","S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer","Interventional","Completed","Phase 3",2,354,"lung neoplasms|carcinoma, non-small-cell lung","carboplatin|paclitaxel","NA"]
["NCT00004015","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12573762|10394416|NA|12749710|NA|NA|NA|15667958|NA","Verbakel WF, Sauerwein W, Hideghety K, Stecher-Rasmussen F. Boron concentrations in brain during boron neutron capture therapy: in vivo measurements from the phase I trial EORTC 11961 using a gamma-ray telescope. Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):743-56.|Hideghéty K, Sauerwein W, Haselsberger K, Grochulla F, Fankhauser H, Moss R, Huiskamp R, Gabel D, de Vries M. Postoperative treatment of glioblastoma with BNCT at the petten irradiation facility (EORTC protocol 11,961). Strahlenther Onkol. 1999 Jun;175 Suppl 2:111-4.|Gabel D, Touw D, Stecher-Rasmussen F, et al.: Quality control of Na2B12H11SH, a drug boron neutron capture therapy in EORTC trial 11961. [Abstract] Ann Oncol 9(suppl 2): 129, 1998.|Hideghéty K, Sauerwein W, Wittig A, Götz C, Paquis P, Grochulla F, Haselsberger K, Wolbers J, Moss R, Huiskamp R, Fankhauser H, de Vries M, Gabel D. Tissue uptake of BSH in patients with glioblastoma in the EORTC 11961 phase I BNCT trial. J Neurooncol. 2003 Mar-Apr;62(1-2):145-56.|Hideghety W, Sauerwein W, DeVries M, et al.: Post-operative treatment of glioblastoma with boron neutron capture therapy at the European High Flux Reactor Petten (EORTC protocol 11961). [Abstract] Ann Oncol 9(suppl 2): 129, 1998.|Sauerwein W, Hideghety K, De Vries M, et al.: Boron neutron capture therapy (BNCT) for the treatment of glioblastoma (EORTC protocol 11961). [Abstract] Radiother Oncol 48(suppl 1): s157, 1998.|Sauerwein W, Hideghety K, De Vries M, et al.: Conducting phase I clinical trial in binary treatment modality: methodical questions for the evaluation of boron neutron capture therapy. [Abstract] Ann Oncol 9(suppl 2): 129, 1998.|Vos MJ, Turowski B, Zanella FE, Paquis P, Siefert A, Hideghéty K, Haselsberger K, Grochulla F, Postma TJ, Wittig A, Heimans JJ, Slotman BJ, Vandertop WP, Sauerwein W. Radiologic findings in patients treated with boron neutron capture therapy for glioblastoma multiforme within EORTC trial 11961. Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):392-9.|Haselsberger K, Pendl G, Sauerwein W, et al.: BNCT for glioblastoma in Europe: design of the EORTC protocol 11961 and clinical course of the first patient. [Abstract] J Neurooncol 39 (2): A-P155, 147, 1998.","\tBrain and Central Nervous System Tumors\tsodium borocaptate|adjuvant therapy\tNA\tNA\tNA\tDrug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","glioblastoma|nervous system neoplasms|central nervous system neoplasms","NA","NA"]
["NCT00004024","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16817692,"Sloan AE, Dansey R, Zamorano L, Barger G, Hamm C, Diaz F, Baynes R, Wood G. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus. 2000 Dec 15;9(6):e9.","\tBrain and Central Nervous System Tumors\taldesleukin|autologous tumor cell vaccine|muromonab-CD3|sargramostim|therapeutic autologous lymphocytes|surgical procedure|radiation therapy\tNA\tNA\tNA\tBiological|Biological|Biological|Biological|Biological|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","nervous system neoplasms|astrocytoma|oligodendroglioma|central nervous system neoplasms","sargramostim|muromonab-cd3|aldesleukin","NA"]
["NCT00004028","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12721262,"Olivi A, Grossman SA, Tatter S, Barker F, Judy K, Olsen J, Bruce J, Hilt D, Fisher J, Piantadosi S; New Approaches to Brain Tumor Therapy CNS Consortium. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. J Clin Oncol. 2003 May 1;21(9):1845-9.","\tBrain and Central Nervous System Tumors\tcarmustine|conventional surgery\tNA\tNA\tNA\tDrug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|glioma|nervous system neoplasms","carmustine","NA"]
["NCT00004029","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Eder JP Jr, Kantoff PW, Bubley GJ, et al.: A phase I trial of recombinant prostate specific antigen expressing vaccinia virus vaccine, PROSTVAC (rV-PSA) in advanced prostate cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 18: A1692, 439, 1999.|Eder JP Jr, Kantoff PW, Bubley GJ, et al.: A phase I trial of recombinant vaccinia virus, PROSTVAC that expresses prostate specific antigen (rV-PSA) as a vaccine in men with advanced prostate cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 17: A1672, 434, 1998.","\tProstate Cancer\trecombinant viral vaccine therapy|sargramostim\tNA\tNA\tNA\tBiological|Biological\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","vaccines|sargramostim","NA"]
["NCT00004031","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Stiff PJ, Unger JM, Cook J, et al.: Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). [Abstract] J Clin Oncol 29 (Suppl 15): A-8001, 2011.","\tLymphoma\trituximab|CHOP regimen|carmustine|cyclophosphamide|doxorubicin hydrochloride|etoposide|prednisone|vincristine sulfate|bone marrow ablation with stem cell support|peripheral blood stem cell transplantation|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure|Radiation\tAll\t","SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma","Interventional","Completed","Phase 3",2,397,"lymphoma, non-hodgkin|lymphoma","prednisone|vincristine|liposomal doxorubicin|etoposide|cyclophosphamide|rituximab|doxorubicin|carmustine","NA"]
["NCT00004037","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12586591,"Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, Moore DH. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003 Feb;88(2):130-5.","\tOvarian Cancer|Primary Peritoneal Cavity Cancer\tdocetaxel\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","carcinoma, ovarian epithelial|ovarian neoplasms","docetaxel","NA"]
["NCT00004043","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Lowe BA, Henner WD, Lemmon DD, et al.: Long term administration of high dose weekly oral calcitriol in patients with a rising PSA after definitive treatment for prostate cancer (PC): a phase II study. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-2446, 2002.","\tProstate Cancer\tcalcitriol\tNA\tNA\tNA\tDietary Supplement\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","calcitriol","NA"]
["NCT00004047","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12114413,"Giles FJ, Cortes JE, Thomas DA, Garcia-Manero G, Faderl S, Jeha S, De Jager RL, Kantarjian HM. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin Cancer Res. 2002 Jul;8(7):2134-41.","\tLeukemia|Myelodysplastic Syndromes\texatecan mesylate\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia|syndrome|myelodysplastic syndromes|leukemia, myelogenous, chronic, bcr-abl positive|preleukemia","exatecan","NA"]
["NCT00004055","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16755177|NA","Molina JR, Jett JR, Foster N, Lair BS, Carroll TJ, Tazelaar HD, Hillman S, Mailliard JA, Bernath AM Jr, Nikcevich D. Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer. Am J Clin Oncol. 2006 Jun;29(3):246-51.|Jett JR, Bernath AM Jr, Hillman SL, et al.: Oral topotecan and paclitaxel with G-CSF support in patients with untreated extensive stage small cell (ED-SCLC): a phase II trial of the NCCTG. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1301, 2002.","\tLung Cancer\tfilgrastim|paclitaxel|topotecan hydrochloride\tNA\tNA\tNA\tBiological|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|small cell lung carcinoma","topotecan|paclitaxel","NA"]
["NCT00004056","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Hurwitz CA, Chang M, Graham M, et al.: Timed-sequential remission induction and intensification followed by stem cell rescue for childhood AML -a POG pilot study. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1553, 2002.","\tLeukemia\tfilgrastim|asparaginase|cytarabine|daunorubicin hydrochloride|melphalan|thioguanine|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","leukemia","lenograstim|melphalan|daunorubicin|asparaginase|cytarabine|thioguanine|sargramostim","NA"]
["NCT00004066","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12065559,"Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002 Jun 15;20(12):2824-31.","\tOvarian Cancer|Sarcoma|Small Intestine Cancer\tfilgrastim|docetaxel|gemcitabine hydrochloride\tNA\tNA\tNA\tBiological|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","sarcoma|intestinal neoplasms|leiomyosarcoma","docetaxel|gemcitabine","NA"]
["NCT00004067","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|NA|16258083|NA|12048273|16236738|21768458","Rastogi P, Jeong J, Geyer CE, et al.: Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab(H). [Abstract] J Clin Oncol 25 (Suppl 18): A-LBA513, 2007.|Geyer CE, Bryant JL, Romond EH, et al.: Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab (H). [Abstract] J Clin Oncol 24 (Suppl 18): A-581, 2006.|Kim C, Bryant J, Horne Z, et al.: Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-46, 2005.|Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005 Nov 1;23(31):7811-9.|Geyer CE Jr, Bryant J, Romond E: Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of adriamycin® and cyclophosphamide (AC) followed by taxol® to that of AC followed by taxol® plus herceptin® in patients (Pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC). [Abstract] Breast Cancer Res Treat 82 (Suppl 1): A-23, S13, 2003.|Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, Brown A, Yothers G, Anderson S, Smith R, Wickerham DL, Wolmark N. Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002 Jun 5;94(11):852-4.|Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1673-84.|Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011 Sep 1;29(25):3366-73. doi: 10.1200/JCO.2011.35.0868. Epub 2011 Jul 18.","\tBreast Cancer\therceptin|adriamycin|cyclophosphamide|taxol\tParallel Assignment\tTreatment\tRandomized\tBiological|Drug|Drug|Drug\tFemale\t","Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2","Interventional","Completed","Phase 3",2,2130,"breast neoplasms","liposomal doxorubicin|trastuzumab|doxorubicin|cyclophosphamide|paclitaxel","NA"]
["NCT00004068","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16200343|15565574|NA","Broniscer A, Chintagumpala M, Fouladi M, Krasin MJ, Kocak M, Bowers DC, Iacono LC, Merchant TE, Stewart CF, Houghton PJ, Kun LE, Ledet D, Gajjar A. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol. 2006 Feb;76(3):313-9.|Broniscer A, Iacono L, Chintagumpala M, Fouladi M, Wallace D, Bowers DC, Stewart C, Krasin MJ, Gajjar A. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98). Cancer. 2005 Jan 1;103(1):133-9.|Broniscer A, Chintagumpala M, Bowers D, et al.: Upfront protracted irinotecan (CPT-11) followed by radiotherapy (RT) and temozolomide (TMZ) in the treatment of children with newly diagnosed high-grade glioma (HGG) and unfavorable low-grade glioma (LGG): results of a multi-institutional study (SJHG-98). [Abstract] Neuro-Oncology 6 (4): TP-01, 385, 2004.","\tBrain and Central Nervous System Tumors\tirinotecan hydrochloride|temozolomide|conventional surgery|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|nervous system neoplasms","irinotecan|temozolomide","NA"]
["NCT00004073","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14769135,"Laterra JJ, Grossman SA, Carson KA, Lesser GJ, Hochberg FH, Gilbert MR; NABTT CNS Consortium study. Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. Neuro Oncol. 2004 Jan;6(1):15-20.","\tBrain and Central Nervous System Tumors\tsuramin|radiation therapy\tNA\tNA\tNA\tDrug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|glioblastoma|nervous system neoplasms","suramin","NA"]
["NCT00004077","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15999102,"Mead GM, Cullen MH, Huddart R, Harper P, Rustin GJ, Cook PA, Stenning SP, Mason M; MRC Testicular Tumour Working Party. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer. 2005 Jul 25;93(2):178-84.","\tTesticular Germ Cell Tumor\tcisplatin|ifosfamide|paclitaxel\tNA\tNA\tNA\tDrug|Drug|Drug\tMale\t","NA","NA","NA","NA","NA","NA","neoplasms, germ cell and embryonal|testicular neoplasms","paclitaxel|ifosfamide","NA"]
["NCT00004081","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15581974,"Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, Mezzetti L, Atkinson T, Cannistra SA. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol. 2004 Dec;95(3):624-31.","\tOvarian Cancer|Peritoneal Cavity Cancer\tdocetaxel\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","NA","docetaxel","NA"]
["NCT00004093","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15246197,"Argiris A, Liptay M, LaCombe M, Marymont M, Kies MS, Sundaresan S, Masters G. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer. Lung Cancer. 2004 Aug;45(2):243-53.","\tLung Cancer\tcarboplatin|Gemcitabine|paclitaxel|vinorelbine|radiation therapy|Navelbine|Taxol\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Radiation|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|carcinoma, non-small-cell lung","paclitaxel|carboplatin|gemcitabine|vinorelbine","NA"]
["NCT00004095","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Wisinski KB, Mulcahy MF, Newman S, et al.: A phase I study of irinotecan and gemcitabine in solid tumors. [Abstract] American Society of Clinical Oncology 2007 Gastrointestinal Cancers Symposium, 19 -21 January 2007, Orlando, Florida A-140, 2007.","\tBladder Cancer|Breast Cancer|Colorectal Cancer|Kidney Cancer|Lung Cancer|Pancreatic Cancer\tgemcitabine hydrochloride|irinotecan hydrochloride\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","pancreatic neoplasms|breast neoplasms|lung neoplasms|kidney neoplasms|urinary bladder neoplasms","gemcitabine|irinotecan","NA"]
["NCT00004099","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21060024|NA","Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010 Dec 10;28(35):5210-8. doi: 10.1200/JCO.2009.26.6114. Epub 2010 Nov 8.|Schuhmacher C, Schlag P, Lordick F, et al.: Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: randomized EORTC phase III trial #40954. [Abstract] J Clin Oncol 27 (Suppl 15): A-4510, 2009.","\tGastric Cancer\tcisplatin|fluorouracil|leucovorin calcium|neoadjuvant therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","stomach neoplasms","fluorouracil|levoleucovorin|leucovorin|calcium","NA"]
["NCT00004100","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12837810|NA","Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003 Aug 15;21(16):3025-34. Epub 2003 Jul 1.|Gridelli C, Shepherd F, Perrone F, et al.: Gemvin III: a phase III study of gemcitabine plus vinorelbine (GV) compared to cisplatin plus vinorelbine or gemcitabine chemotherapy (PCT) for stage IIIb or IV non-small cell lung cancer (NSCLC): an Italo-Canadian study. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1165, 2002.","\tLung Cancer\tcisplatin|gemcitabine hydrochloride|vinorelbine tartrate\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","gemcitabine|vinorelbine","NA"]
["NCT00004101","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Link BK, Wang H, Byrd JC, et al.: Phase I trial of humanized 1D10 (Hu1D10) monoclonal anitbody class II molecules in patients with relapsed lymphoma. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A86, 2000.","\tLymphoma\tapolizumab\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma, non-hodgkin|lymphoma","NA","NA"]
["NCT00004102","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Hochster HS, Chachoua A, Speyer J, et al.: First-line activity of oxaliplatin with weekly bolus 5FU and low-dose leucovorin (LV) in advanced colorectal cancer (CRC). [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-548, 2001.","\tColorectal Cancer\tFOLFOX regimen|fluorouracil|leucovorin calcium|oxaliplatin\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","oxaliplatin|calcium|leucovorin|fluorouracil|levoleucovorin","NA"]
["NCT00004103","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16399443,"Newman E, Potmesil M, Ryan T, Marcus S, Hiotis S, Yee H, Norwood B, Wendell M, Muggia F, Hochster H. Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study. Semin Oncol. 2005 Dec;32(6 Suppl 9):S97-100.","\tGastric Cancer\tcisplatin|floxuridine|irinotecan hydrochloride|adjuvant therapy|conventional surgery|neoadjuvant therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Procedure|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","stomach neoplasms","irinotecan|floxuridine","NA"]
["NCT00004113","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11772431,"Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro Oncol. 2002 Jan;4(1):39-43. doi: 10.1093/neuonc/4.1.39.","\tBrain and Central Nervous System Tumors\ttemozolomide\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","nervous system neoplasms|central nervous system neoplasms|glioma","temozolomide","NA"]
["NCT00004125","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18420499|NA","Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008 Apr 17;358(16):1663-71. doi: 10.1056/NEJMoa0707056. Erratum in: N Engl J Med. 2008 Jul 3;359(1):106. N Engl J Med. 2009 Apr 16;360(16):1685.|Sparano JA, Wang M, Martino S, et al.: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-48, 2005.","\tBreast Cancer\tcyclophosphamide|docetaxel|doxorubicin hydrochloride|paclitaxel|tamoxifen citrate|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Radiation\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","docetaxel|cyclophosphamide|tamoxifen|doxorubicin|liposomal doxorubicin|paclitaxel","NA"]
["NCT00004126","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15151948,"Winegarden JD, Mauer AM, Otterson GA, Rudin CM, Villalona-Calero MA, Lanzotti VJ, Szeto L, Kasza K, Hoffman PC, Vokes EE; University of Chicago Phase II Network; Ohio State University. A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Ann Oncol. 2004 Jun;15(6):915-20.","\tLung Cancer\toxaliplatin|paclitaxel\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|carcinoma, non-small-cell lung","oxaliplatin|paclitaxel","NA"]
["NCT00004128","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Aslanyan MG, Langemeijer SMC, Cilloni D, et al.: Incidence and clinical impact of TET2 mutations in acute myeloid leukemia patients treated within the EORTC/GIMEMA AML-12/06991 AML trial. [Abstract] Blood 114 (22): A-2609, 2009.|Willemze R, Suciu S, Mandelli F, et al.: Value of low dose IL-2 as maintenance following consolidation treatment or autologous transplantation in acute myelogenous leukemia (AML) patients aged 15-60 years who reached CR after high dose (HD-AraC) vs standard dose (SD-AraC) cytosine arabinoside during induction: results of the AML-12 trial of EORTC and GIMEMA Leukemia Groups. [Abstract] Blood 114 (22): A-791, 2009.","\tLeukemia\taldesleukin|filgrastim|busulfan|cyclophosphamide|cytarabine|daunorubicin hydrochloride|etoposide|autologous bone marrow transplantation|peripheral blood stem cell transplantation|radiation therapy\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","leukemia","aldesleukin|etoposide|daunorubicin|cytarabine|cyclophosphamide|busulfan","NA"]
["NCT00004137","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17409984|NA","Hesketh PJ, McCoy J, Dunphy FR 2nd, Bearden JD 3rd, Weiss GR, Giguere JK, Atkins JN, Dakhil SR, Kelly K, Crowley JJ, Gandara DR. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914. J Thorac Oncol. 2006 Nov;1(9):991-5.|Dunphy F, Hesketh P, Chansky K, et al.: Southwest Oncology Group trial (SWOG) 9914: phase II trial of paclitaxel, carboplatin and topotecan (PCT) in untreated patients (pts) with extensive small cell lung cancer (SCLC). [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1184, 2002.","\tLung Cancer\tfilgrastim|carboplatin|paclitaxel|topotecan hydrochloride\tNA\tNA\tNA\tBiological|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","small cell lung carcinoma|lung neoplasms","topotecan|paclitaxel|carboplatin","NA"]
["NCT00004138","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18355490|14688710","Kozower BD, Meyers BF, Reed CE, Jones DR, Decker PA, Putnam JB Jr. Does positron emission tomography prevent nontherapeutic pulmonary resections for clinical stage IA lung cancer? Ann Thorac Surg. 2008 Apr;85(4):1166-9; discussion 1169-70. doi: 10.1016/j.athoracsur.2008.01.018.|Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF, Heelan RT, MacApinlac HA, Jung SH, Silvestri GA, Siegel BA, Rusch VW; American College of Surgeons Oncology Group Z0050 trial. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003 Dec;126(6):1943-51. Erratum in: J Thorac Cardiovasc Surg. 2007 Apr;133(4):864.","\tLung Cancer\tpositron emission tomography|radionuclide imaging|fludeoxyglucose F 18\tNA\tNA\tNA\tProcedure|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms","fluorodeoxyglucose f18","NA"]
["NCT00004139","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|14998842","Rocha Lima CM, Rizvi NA, Zhang K, et al.: CALGB 39809: Randomized phase II trial of gemcitabine/irinotecan and gemcitabine/docetaxel in stage IIIB (malignant pleural effusion) or stage IV NSCLC. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1344, 2002.|Rocha Lima CM, Rizvi NA, Zhang C, Herndon JE 2nd, Crawford J, Govindan R, King GW, Green MR; Cancer Leukemia Group B. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC. Ann Oncol. 2004 Mar;15(3):410-8. Review.","\tLung Cancer\tdocetaxel|gemcitabine hydrochloride|irinotecan hydrochloride\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer","Interventional","Completed","Phase 2",2,80,"carcinoma, non-small-cell lung|lung neoplasms","docetaxel|irinotecan|gemcitabine","NA"]
["NCT00004144","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17145828,"El-Rayes BF, Gadgeel S, Shields AF, Manza S, Lorusso P, Philip PA. Phase I study of bryostatin 1 and gemcitabine. Clin Cancer Res. 2006 Dec 1;12(23):7059-62.","\tUnspecified Adult Solid Tumor, Protocol Specific\tbryostatin 1|gemcitabine hydrochloride\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","NA","gemcitabine|bryostatin 1","NA"]
["NCT00004147","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21547395,"Rudek MA, New P, Mikkelsen T, Phuphanich S, Alavi JB, Nabors LB, Piantadosi S, Fisher JD, Grossman SA. Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas. J Neurooncol. 2011 Nov;105(2):375-81. doi: 10.1007/s11060-011-0602-9. Epub 2011 May 6.","\tBrain and Central Nervous System Tumors\tincyclinide\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|nervous system neoplasms","NA","NA"]
["NCT00004148","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15937544|10811235","Kaufman HL, Deraffele G, Mitcham J, Moroziewicz D, Cohen SM, Hurst-Wicker KS, Cheung K, Lee DS, Divito J, Voulo M, Donovan J, Dolan K, Manson K, Panicali D, Wang E, Hörig H, Marincola FM. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest. 2005 Jul;115(7):1903-12. Epub 2005 Jun 2.|Kaufman HL, Conkright W, Divito J Jr, Hörig H, Kaleya R, Lee D, Mani S, Panicali D, Rajdev L, Ravikumar TS, Wise-Campbell S, Surhland MJ. A phase I trial of intra lesional RV-B7.1 vaccine in the treatment of malignant melanoma. Hum Gene Ther. 2000 May 1;11(7):1065-82.","\tMelanoma (Skin)\trecombinant vaccinia-B7.1 vaccine\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","melanoma","NA","NA"]
["NCT00004149","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Gallagher RE, Ferrari A, Kaubisch A, et al.: Arsenic trioxide (ATO) in metastatic hormone-refractory prostate cancer (HRPC): results of phase II trial T99-0077. [Abstract] J Clin Oncol 22 (Suppl 14): A-4638, 2004.","\tProstate Cancer\tarsenic trioxide\tNA\tNA\tNA\tDrug\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","arsenic trioxide","NA"]
["NCT00004150","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Carrato A, Köhne C, Bedenne L, et al.: Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer: preliminary analysis of the PETACC-2-study. [Abstract] J Clin Oncol 24 (Suppl 18): A-3563, 2006.","\tColorectal Cancer\tfluorouracil|leucovorin calcium|adjuvant therapy\tNA\tNA\tNA\tDrug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","colonic neoplasms","levoleucovorin|fluorouracil|calcium|leucovorin","NA"]
["NCT00004154","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18172274,"Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP 3rd, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 1;14(1):224-9. doi: 10.1158/1078-0432.CCR-07-0733.","\tBladder Cancer\tFenretinide|Placebo\tNA\tNA\tNA\tDrug|Other\tAll\t","Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer","Interventional","Completed","Phase 3",2,111,"urinary bladder neoplasms","fenretinide","NA"]
["NCT00004156","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11807794,"Musselli C, Ragupathi G, Gilewski T, Panageas KS, Spinat Y, Livingston PO. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int J Cancer. 2002 Feb 10;97(5):660-7.","\tBreast Cancer\tMUC1-KLH vaccine/QS21\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","breast neoplasms","NA","NA"]
["NCT00004160","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16170174,"Divers SG, Spencer SA, Carey D, Busby EM, Hyatt MD, Robert F. Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer. J Clin Oncol. 2005 Sep 20;23(27):6664-73.","\tLung Cancer\tcisplatin|gemcitabine hydrochloride|paclitaxel|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Radiation\tAll\t","Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed","Interventional","Completed","Phase 1/Phase 2",5,72,"carcinoma, non-small-cell lung|lung neoplasms","paclitaxel|gemcitabine","NA"]
["NCT00004179","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20368567|20439641|16873669","van Oers MH, Tönnissen E, Van Glabbeke M, Giurgea L, Jansen JH, Klasa R, Marcus RE, Wolf M, Kimby E, Vranovsky A, Holte H, Hagenbeek A, van der Reijden BA. BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study. J Clin Oncol. 2010 May 1;28(13):2246-52. doi: 10.1200/JCO.2009.25.0852. Epub 2010 Apr 5.|van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010 Jun 10;28(17):2853-8. doi: 10.1200/JCO.2009.26.5827. Epub 2010 May 3.|van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006 Nov 15;108(10):3295-301. Epub 2006 Jul 27.","\tLymphoma\trituximab|CHOP regimen|cyclophosphamide|doxorubicin hydrochloride|prednisone|vincristine sulfate\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|lymphoma, non-hodgkin","cyclophosphamide|prednisone|doxorubicin|vincristine|liposomal doxorubicin|rituximab","NA"]
["NCT00004183","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15084390|NA","Otterson GA, Herndon JE 2nd, Watson D, Green MR, Kindler HL; Cancer and Leukemia Group B. Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). Lung Cancer. 2004 May;44(2):251-9.|Otterson GA, Herndon J, Watson D, et al.: Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 39807). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2778, 691, 2003.","\tMalignant Mesothelioma\tcapecitabine\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|mesothelioma","capecitabine","NA"]
["NCT00004187","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11919232,"Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Müller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol. 2002 Apr 1;20(7):1759-66.","\tColorectal Cancer\tcapecitabine|oxaliplatin\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","oxaliplatin|capecitabine","NA"]
["NCT00004188","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24419114|21328522|NA|NA","Landier W, Knight K, Wong FL, Lee J, Thomas O, Kim H, Kreissman SG, Schmidt ML, Chen L, London WB, Gurney JG, Bhatia S. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group. J Clin Oncol. 2014 Feb 20;32(6):527-34. doi: 10.1200/JCO.2013.51.2038. Epub 2014 Jan 13.|Naranjo A, Parisi MT, Shulkin BL, London WB, Matthay KK, Kreissman SG, Yanik GA. Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Jul 1;56(7):1041-5. doi: 10.1002/pbc.22991. Epub 2011 Feb 15.|Yanik GA, Parisi MT, Naranjo A, et al.: MIBG scoring as a prognostic indicator in patients with stage IV neuroblastoma: A COG study. [Abstract] J Clin Oncol 28 (Suppl 15): A-9516, 2010.|Kreissman SG, Villablanca JG, Diller L, et al.: Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): a Children's Oncology Group (COG A3973) study. [Abstract] J Clin Oncol 25 (Suppl 18): A-9505, 527s, 2007.","\tNeuroblastoma\tvincristine sulfate|filgrastim|carboplatin|cisplatin|cyclophosphamide|doxorubicin hydrochloride|etoposide|isotretinoin|melphalan|topotecan hydrochloride|autologous bone marrow transplantation|bone marrow ablation with stem cell support|conventional surgery|peripheral blood stem cell transplantation|radiation therapy\tParallel Assignment\tTreatment\tRandomized\tDrug|Biological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure|Procedure|Procedure|Radiation\tAll\t","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma","Interventional","Completed","Phase 3",2,495,"neuroblastoma","liposomal doxorubicin|etoposide|isotretinoin|melphalan|carboplatin|mechlorethamine|cisplatin|lenograstim|topotecan|doxorubicin|cyclophosphamide|vincristine","NA"]
["NCT00004190","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12649105|NA","Alberts SR, Townley PM, Goldberg RM, Cha SS, Sargent DJ, Moore DF, Krook JE, Pitot HC, Fitch TR, Wiesenfeld M, Mailliard JA. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study. Ann Oncol. 2003 Apr;14(4):580-5.|Alberts SR, Townley P, Cha SS, et al.: Oxaliplatin and gemcitabine for patients with pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) phase II study. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-501, 2002.","\tPancreatic Cancer\tgemcitabine hydrochloride|oxaliplatin\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","pancreatic neoplasms","oxaliplatin|gemcitabine","NA"]
["NCT00004202","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16135463|NA","Choy H, Nabid A, Stea B, Scott C, Roa W, Kleinberg L, Ayoub J, Smith C, Souhami L, Hamburg S, Spanos W, Kreisman H, Boyd AP, Cagnoni PJ, Curran WJ. Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer. J Clin Oncol. 2005 Sep 1;23(25):5918-28.|Nabid A, Choy H, Stea BD, et al.: Encouraging survival results with RSR13 and concurrent radiation therapy: interim analysis of a phase II study for locally advanced unresectable non-small cell lung cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1236, 2002.","\tLung Cancer\tcarboplatin|chemotherapy|efaproxiral|paclitaxel|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|carcinoma, non-small-cell lung","efaproxiral|paclitaxel|carboplatin","NA"]
["NCT00004205","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|21321298|NA|21986093|NA|21046229|22018631|21635709|21335417|22003243|20144231|20385495|NA|19692688|19528136|19474112|NA|NA|19243946|NA|NA|18332471|18279765|NA|18083065|18981464|19096768|17200148|17998546|NA|17912636|17301074|17492927|NA|17679725|16730270|16382061","Bouzyk M, Gray KP, Regan MM, et al.: ESR1 and ESR2 polymorphisms in BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence for early breast cancer. [Abstract] J Clin Oncol 29 (Suppl 15): A-1002, 2011.|Colleoni M, Giobbie-Hurder A, Regan MM, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Láng I, Smith I, Chirgwin J, Pienkowski T, Wardley A, Price KN, Gelber RD, Coates AS, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol. 2011 Mar 20;29(9):1117-24. doi: 10.1200/JCO.2010.31.6455. Epub 2011 Feb 14.|De Censi A, Sun Z, Thurlimann BJK, et al.: Bone mineral density (BMD) in participants (pts) of trial BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence. [Abstract] J Clin Oncol 29 (Suppl 15): A-516, 2011.|Ejlertsen B, Aldridge J, Nielsen KV, Regan MM, Henriksen KL, Lykkesfeldt AE, Müller S, Gelber RD, Price KN, Rasmussen BB, Viale G, Mouridsen H; Danish Breast Cancer Cooperative Group the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. Ann Oncol. 2012 May;23(5):1138-1144. doi: 10.1093/annonc/mdr438. Epub 2011 Oct 10.|Huober JB, Cole BF, Wu J, et al.: Symptoms of endocrine treatment and outcome: A retrospective analysis of the monotherapy arms of the BIG 1-98 trial. [Abstract] J Clin Oncol 29 (Suppl 15): A-522, 2011.|Phillips KA, Aldridge J, Ribi K, Sun Z, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat. 2011 Feb;126(1):221-6. doi: 10.1007/s10549-010-1235-y. Epub 2010 Nov 3.|Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4. Epub 2011 Oct 20.|Regan MM, Price KN, Giobbie-Hurder A, Thürlimann B, Gelber RD; International Breast Cancer Study Group and BIG 1-98 Collaborative Group. Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Res. 2011 May 26;13(3):209. doi: 10.1186/bcr2837. Review.|Viale G, Regan MM, Dell'Orto P, Mastropasqua MG, Maiorano E, Rasmussen BB, MacGrogan G, Forbes JF, Paridaens RJ, Colleoni M, Láng I, Thürlimann B, Mouridsen H, Mauriac L, Gelber RD, Price KN, Goldhirsch A, Gusterson BA, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol. 2011 Oct;22(10):2201-7. doi: 10.1093/annonc/mdq738. Epub 2011 Feb 18.|Zaman K, Thürlimann B, Huober J, Schönenberger A, Pagani O, Lüthi J, Simcock M, Giobbie-Hurder A, Berthod G, Genton C, Brauchli P, Aebi S; Swiss Group for Clinical Cancer Research (SAKK). Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Ann Oncol. 2012 Jun;23(6):1474-81. doi: 10.1093/annonc/mdr448. Epub 2011 Oct 14.|Antonov J, Popovici V, Delorenzi M, Wirapati P, Baltzer A, Oberli A, Thürlimann B, Giobbie-Hurder A, Viale G, Altermatt HJ, Aebi S, Jaggi R. Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue. BMC Cancer. 2010 Feb 9;10:37. doi: 10.1186/1471-2407-10-37.|Phillips KA, Ribi K, Sun Z, Stephens A, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast. 2010 Oct;19(5):388-95. doi: 10.1016/j.breast.2010.03.025. Epub 2010 Apr 10.|Ribi K, Aldridge J, Phillips K, et al.: Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial. [Abstract] J Clin Oncol 28 (Suppl 15): A-527, 2010.|BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009 Aug 20;361(8):766-76. doi: 10.1056/NEJMoa0810818.|Giobbie-Hurder A, Price KN, Gelber RD; International Breast Cancer Study Group; BIG 1-98 Collaborative Group. Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clin Trials. 2009 Jun;6(3):272-87. doi: 10.1177/1740774509105380.|Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thürlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Láng I, Smith I, Gelber RD, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol. 2009 Sep;20(9):1489-1498. doi: 10.1093/annonc/mdp033. Epub 2009 May 27.|Regan MM, Colleoni M M, Giobbie-Hurder A, et al.: Adjusting for selective crossover in analyses of letrozole (Let) versus tamoxifen (Tam) in the BIG 1-98 trial. [Abstract] 32nd Annual San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, Texas. A-16, 2009.|Ribi KE, Phillips KA, Sun Z, et al.: Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial. [Abstract] J Clin Oncol 27 (Suppl 15): A-510, 2009.|Sun Z, Goldhirsch A, Price KN, Colleoni M, Ravaioli A, Simoncini E, Campbell I, Gelber RD, Towler M. Bone Quality Test (BQT) scores of fingernails in postmenopausal patients treated with adjuvant letrozole or tamoxifen for early breast cancer. Breast. 2009 Apr;18(2):84-8. doi: 10.1016/j.breast.2009.01.003. Epub 2009 Feb 24.|Viale G, Regan MM, Dell'Orto P, et al.: Central review of ER, PgR and HER2 in BIG 1-98 evaluating letrozole vs. letrozole followed by tamoxifen vs. tamoxifen followed by letrozole as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer. [Abstract] 32nd Annual San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, Texas. A-76, 2009.|Zaman K, Thürlimann B, Huober J, et al.: Modelling bone mineral density in Swiss breast cancer patients treated with letrozole, tamoxifen and sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). [Abstract] 32nd Annual San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, Texas. A-5037, 2009.|Crivellari D, Sun Z, Coates AS, Price KN, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens RJ, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Gladieff L, Rabaglio M, Smith IE, Chirgwin JH, Goldhirsch A. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol. 2008 Apr 20;26(12):1972-9. doi: 10.1200/JCO.2007.14.0459. Epub 2008 Mar 10.|Doughty JC. A review of the BIG results: the Breast International Group 1-98 trial analyses. Breast. 2008 Jan;17 Suppl 1:S9-S14. doi: 10.1016/S0960-9776(08)70003-1. Review.|Mouridsen HT, Giobbie-Hurder A, Mauriac L, et al.: BIG 1-98: a randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. [Abstract] 31st Annual San Antonio Breast Cancer Symposium, December 10-14, 2008, San Antonio, Texas. A-13, 2008.|Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 2008 Jan;9(1):23-8. Epub 2007 Dec 20.|Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A; Breast International Group Trial 1-98. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008 Dec 1;26(34):5569-75. doi: 10.1200/JCO.2008.17.0829. Epub 2008 Nov 3.|Wardley AM. Understanding the BIG results: Insights from the BIG 1-98 trial analyses. Adv Ther. 2008 Dec;25(12):1257-75. doi: 10.1007/s12325-008-0128-5. Review.|Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007 Feb 10;25(5):486-92. Epub 2007 Jan 2.|Mouridsen H, Keshaviah A, Coates AS, Rabaglio M, Castiglione-Gertsch M, Sun Z, Thürlimann B, Mauriac L, Forbes JF, Paridaens R, Gelber RD, Colleoni M, Smith I, Price KN, Goldhirsch A. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol. 2007 Dec 20;25(36):5715-22. Epub 2007 Nov 12.|Crivellari D, Sun Z, Coates AS, et al.: Aromatase inhibitors (AI) for elderly patients: efficacy, compliance and safety according to patient age in the BIG 1-98 trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-9033, 501s, 2007.|Koeberle D, Thuerlimann B. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. Breast Cancer Res Treat. 2007;105 Suppl 1:55-66. Epub 2007 Oct 3. Erratum in: Breast Cancer Res Treat. 2008 Nov;112(2):387.|Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes JF, Thürlimann B, Paridaens R, Monnier A, Láng I, Wardley A, Nogaret JM, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A; BIG 1-98 Collaborative Group; International Breast Cancer Study Group. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol. 2007 May;18(5):859-67. Epub 2007 Feb 14.|Monnier AM. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer. Expert Rev Anticancer Ther. 2007 May;7(5):627-34. Review.|Rasmussen BB, Regan MM, Lykkesfeldt AE, et al.: Central assessment of ER, PgR and HER2 in BIG 1-98 evaluating letrozole (L) compared to tamoxifen (T) as initial adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer. [Abstract] J Clin Oncol 25 (18 Suppl 20): A-538, 2007.|Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007 Sep 1;25(25):3846-52. Epub 2007 Aug 6.|Forbes JF. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial. Semin Oncol. 2006 Apr;33(2 Suppl 7):S2-7.|Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005 Dec 29;353(26):2747-57. Erratum in: N Engl J Med. 2006 May 18;354(20):2200. Wardly, Andrew [corrected to Wardley, Andrew ].","\tBreast Cancer\tletrozole|tamoxifen citrate\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tFemale\t","Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer","Interventional","Completed","Phase 3",4,8028,"breast neoplasms","tamoxifen|letrozole","NA"]
["NCT00004208","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21149672,"Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein C, Stadler M, Ossenkoppele G, Hofmann WK, Schilling K, Tichelli A, Ganser A. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. J Clin Oncol. 2011 Jan 20;29(3):303-9. doi: 10.1200/JCO.2010.31.2686. Epub 2010 Dec 13.","\tMyelodysplastic Syndromes\tATG + CSA|Supportive care\tNA\tNA\tNA\tDrug|Behavioral\tAll\t","Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome","Interventional","Completed","Phase 3",2,86,"myelodysplastic syndromes|syndrome|preleukemia","NA","NA"]
["NCT00004210","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21204803|14701766|12622604","Hadley DW, Ashida S, Jenkins JF, Calzone KA, Kirsch IR, Koehly LM. Colonoscopy use following mutation detection in Lynch syndrome: exploring a role for cancer screening in adaptation. Clin Genet. 2011 Apr;79(4):321-8. doi: 10.1111/j.1399-0004.2010.01622.x. Epub 2011 Jan 19.|Hadley DW, Jenkins JF, Dimond E, de Carvalho M, Kirsch I, Palmer CG. Colon cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2004 Jan 1;22(1):39-44.|Hadley DW, Jenkins J, Dimond E, Nakahara K, Grogan L, Liewehr DJ, Steinberg SM, Kirsch I. Genetic counseling and testing in families with hereditary nonpolyposis colorectal cancer. Arch Intern Med. 2003 Mar 10;163(5):573-82.","\tColorectal Cancer\tloss of heterozygosity analysis|microsatellite instability analysis|mutation analysis|counseling intervention\tNA\tNA\tNA\tOther|Other|Other|Other\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","NA","NA"]
["NCT00004211","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11828001,"Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest. 2002 Feb;109(3):409-17.","\tProstate Cancer\tPSA RNA-pulsed dendritic cell vaccine\tNA\tNA\tNA\tBiological\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","NA","NA"]
["NCT00004218","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22168274|21483000|21659360|20511662|19016733|17658394|NA","Else M, Cocks K, Crofts S, Wade R, Richards SM, Catovsky D, Smith AG; UK National Cancer Research Institute (NCRI) Chronic Lymphocytic Leukaemia Trials Group. Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial. Leuk Lymphoma. 2012 Jul;53(7):1289-98. doi: 10.3109/10428194.2011.649479. Epub 2012 Mar 1.|Gonzalez D, Martinez P, Wade R, Hockley S, Oscier D, Matutes E, Dearden CE, Richards SM, Catovsky D, Morgan GJ. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol. 2011 Jun 1;29(16):2223-9. doi: 10.1200/JCO.2010.32.0838. Epub 2011 Apr 11.|Wade R, Di Bernardo MC, Richards S, Rossi D, Crowther-Swanepoel D, Gaidano G, Oscier DG, Catovsky D, Houlston RS. Association between single nucleotide polymorphism-genotype and outcome of patients with chronic lymphocytic leukemia in a randomized chemotherapy trial. Haematologica. 2011 Oct;96(10):1496-503. doi: 10.3324/haematol.2011.043471. Epub 2011 Jun 9.|Oscier D, Wade R, Davis Z, Morilla A, Best G, Richards S, Else M, Matutes E, Catovsky D; Chronic Lymphocytic Leukaemia Working Group, UK National Cancer Research Institute. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica. 2010 Oct;95(10):1705-12. doi: 10.3324/haematol.2010.025338. Epub 2010 May 29.|Else M, Smith AG, Cocks K, Richards SM, Crofts S, Wade R, Catovsky D. Patients' experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial. Br J Haematol. 2008 Dec;143(5):690-7. doi: 10.1111/j.1365-2141.2008.07407.x. Epub 2008 Oct 18.|Catovsky D, Richards S, Matutes E, Oscier D, Dyer M, Bezares RF, Pettitt AR, Hamblin T, Milligan DW, Child JA, Hamilton MS, Dearden CE, Smith AG, Bosanquet AG, Davis Z, Brito-Babapulle V, Else M, Wade R, Hillmen P; UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007 Jul 21;370(9583):230-239. doi: 10.1016/S0140-6736(07)61125-8.|Dearden CE, Wade RL, Else M, et al.: The combination of fludarabine and cyclophosphamide has a beneficial effect on the incidence of hemolytic anemia in chronic lymphocytic leukemia: results from the UK LRF CLL4 trial. [Abstract] Blood 110 (11): A-2044, 2007.","\tLeukemia\tchlorambucil|cyclophosphamide|doxorubicin hydrochloride|fludarabine phosphate|prednisolone|vincristine sulfate\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, lymphocytic, chronic, b-cell|leukemia, lymphoid|leukemia","vincristine|fludarabine phosphate|prednisolone|cyclophosphamide|fludarabine|doxorubicin|liposomal doxorubicin|chlorambucil","NA"]
["NCT00004223","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12767086|NA","Dreicer R, Manola J, Schneider DJ, Schwerkoske JF, George CS, Roth BJ, Wilding G; Eastern Cooperative Oncology Group. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer. 2003 Jun 1;97(11):2743-7.|Manola JB, Dreicer R, Wilding G, et al.: Gemcitabine and docetaxel in advanced carcinoma of the urothelium: report of a phase II Eastern Cooperative Oncology Group trial . [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-796, 2002.","\tBladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer\tdocetaxel|gemcitabine hydrochloride\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","kidney neoplasms|carcinoma, transitional cell|urinary bladder neoplasms|ureteral neoplasms|urethral neoplasms","gemcitabine|docetaxel","NA"]
["NCT00004227","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19897418|16467544|NA|NA","Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010 Jan;11(1):21-8. doi: 10.1016/S1470-2045(09)70311-0. Epub 2009 Nov 10. Erratum in: Lancet Oncol. 2010 Jan;11(1):14.|Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006 Feb 9;354(6):567-78.|Bonner JA, Harari PM, Giralt J, et al.: The relationship of cetuximab-induced rash and survival in patients with head and neck cancer treated with radiotherapy and cetuximab. [Abstract] Int J Radiat Oncol Biol Phys 63 (2 Suppl 1): A-120, S73, 2005.|Bonner JA, Girald J, Harari PM, et al.: Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. [Abstract] Int J Radiat Oncol Biol Phys 60 (1 Suppl 1): A-31, S147-8, 2004. Available online. Last accessed February 3, 2005.","\tHead and Neck Cancer\tcetuximab|conventional surgery|radiation therapy\tParallel Assignment\tTreatment\tRandomized\tBiological|Procedure|Radiation\tAll\t","Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx","Interventional","Terminated","Phase 3",2,32,"head and neck neoplasms","cetuximab","NA"]
["NCT00004231","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18162124,"Evens AM, Winter JN, Hou N, Nelson BP, Rademaker A, Patton D, Singhal S, Frankfurt O, Tallman MS, Rosen ST, Mehta J, Gordon LI. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. Br J Haematol. 2008 Feb;140(4):385-93. Epub 2007 Dec 19.","\tLymphoma\taldesleukin|filgrastim|recombinant interferon alfa|busulfan|cyclophosphamide|cytarabine|doxorubicin hydrochloride|leucovorin calcium|methotrexate|prednisone|teniposide|vincristine sulfate|allogeneic bone marrow transplantation|autologous bone marrow transplantation|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Biological|Biological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma, mantle-cell|lymphoma","cytarabine|levoleucovorin|liposomal doxorubicin|teniposide|interferon-alpha|cyclophosphamide|aldesleukin|busulfan|doxorubicin|interferons|methotrexate|prednisone|leucovorin|vincristine","NA"]
["NCT00004233","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16832602,"Doroshow JH, McCoy S, Macdonald JS, Issell BF, Patel T, Cobb PW, Yost KJ, Abbruzzese JL. Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study. Invest New Drugs. 2006 Nov;24(6):537-42.","\tEsophageal Cancer|Gastric Cancer\tfluorouracil|leucovorin calcium|triacetyluridine\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","esophageal neoplasms|stomach neoplasms","leucovorin|calcium|levoleucovorin|fluorouracil","NA"]
["NCT00004234","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18805649|NA","Bjarnason GA, Mackenzie RG, Nabid A, Hodson ID, El-Sayed S, Grimard L, Brundage M, Wright J, Hay J, Ganguly P, Leong C, Wilson J, Jordan RC, Walker M, Tu D, Parulekar W; National Cancer Institute of Canada Clinical Trials Group (HN3). Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3). Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):166-72. doi: 10.1016/j.ijrobp.2008.07.009. Epub 2008 Sep 19.|Bjarnason GA, MacKenzie R, Hodson I, et al.: A randomized prospective phase-III study comparing the acute oral mucositis of morning vs. afternoon radiotherapy (RT) in patients (pts) with squamous cell carcinoma of the head and neck (SCCHN): NCIC-CTG HN.3. [Abstract] J Clin Oncol 23 (Suppl 16): A-LBA5500, 500s, 2005 .","\tHead and Neck Cancer|Oral Complications\tmanagement of therapy complications|radiation therapy\tNA\tNA\tNA\tProcedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","stomatitis|mucositis","NA","NA"]
["NCT00004235","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12794247|NA","Jatoi A, Tirona MT, Cha SS, Alberts SR, Rowland KM, Morton RF, Nair S, Kardinal CG, Stella PJ, Mailliard JA, Sargen D, Goldberg RM. A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. Int J Gastrointest Cancer. 2002;32(2-3):115-23.|Tria Tirona M, Jatoi A, Cha SS, et al.: A phase II trial of CPT-11 and docetaxel in patients with metastatic esophageal cancer: preliminary toxicity data from the North Central Cancer Treatment Group. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-605, 2002.","\tEsophageal Cancer|Gastric Cancer\tdocetaxel|irinotecan hydrochloride\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","stomach neoplasms|esophageal neoplasms","irinotecan|docetaxel","NA"]
["NCT00004238","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12796370,"Krug LM, Azzoli CG, Kris MG, Miller VA, Khokhar NZ, Tong W, Ginsberg MS, Venkatraman E, Tyson L, Pizzo B, Baez V, Ng KK, Sirotnak FM. 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer. Clin Cancer Res. 2003 Jun;9(6):2072-8.","\tLung Cancer\tpralatrexate\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|carcinoma, non-small-cell lung","NA","NA"]
["NCT00004242","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Basu S, Goel S, Hochster H, et al.: Phase I and pharmacokinetic (PK) study of oxaliplatin (Ox) with gemcitabine (Gem) and continuous intravenous (CIV) infusion 5-fluorouracil (FU) in patients with advanced solid malignancies. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-2132, 2002.","\tUnspecified Adult Solid Tumor, Protocol Specific\tfluorouracil|gemcitabine hydrochloride|oxaliplatin\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","fluorouracil|gemcitabine|oxaliplatin","NA"]
["NCT00004245","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22154022,"Klimek VM, Dolezal EK, Smith L, Soff G, Nimer SD. Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia. Leuk Res. 2012 May;36(5):570-4. doi: 10.1016/j.leukres.2011.10.023. Epub 2011 Dec 9.","\tLeukemia|Myelodysplastic/Myeloproliferative Neoplasms|Myelodysplastic Syndromes\tsodium salicylate\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","syndrome|leukemia|preleukemia|myeloproliferative disorders|myelodysplastic-myeloproliferative diseases|leukemia, myeloid|myelodysplastic syndromes|leukemia, myeloid, acute","salicylsalicylic acid|salicylates|sodium salicylate","NA"]
["NCT00004250","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19282789,"Brady MS, Brown K, Patel A, Fisher C, Marx W. Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial. Melanoma Res. 2009 Apr;19(2):106-11. doi: 10.1097/CMR.0b013e32832985e3.","\tMelanoma (Skin)|Sarcoma\tdactinomycin|isolated limb perfusion|melphalan\tNA\tNA\tNA\tBiological|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","melanoma|sarcoma","melphalan|dactinomycin","NA"]
["NCT00004251","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15304161|NA","Ma BB, Oza A, Eisenhauer E, Stanimir G, Carey M, Chapman W, Latta E, Sidhu K, Powers J, Walsh W, Fyles A. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer. 2004 Jul-Aug;14(4):650-8.|Sidhu K, Fyles A, Eisenhauer E, et al.: Phase II study of the aromatase inhibitor letrozole in endometrial carcinoma - NCIC CTG IND 126. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-2520, 2001.","\tEndometrial Cancer\tletrozole\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","endometrial neoplasms","letrozole","NA"]
["NCT00004254","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12565988,"Baas P, Ardizzoni A, Grossi F, Nackaerts K, Numico G, Van Marck E, van de Vijver M, Monetti F, Smid-Geirnaerdt MJ, van Zandwijk N, Debruyne C, Legrand C, Giaccone G; EORTC Lung Cancer Group. The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur J Cancer. 2003 Feb;39(3):353-7.","\tMalignant Mesothelioma\traltitrexed\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|mesothelioma","raltitrexed","NA"]
["NCT00004256","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16823067,"McAleese JJ, Bishop KM, A'Hern R, Henk JM. Randomized phase II study of GM-CSF to reduce mucositis caused by accelerated radiotherapy of laryngeal cancer. Br J Radiol. 2006 Jul;79(943):608-13.","\tHead and Neck Cancer|Oral Complications|Radiation Toxicity\tsargramostim|quality-of-life assessment|radiation therapy\tNA\tNA\tNA\tBiological|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","laryngeal neoplasms|mucositis","sargramostim","NA"]
["NCT00004257","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Khushalani N, Nava H, Leichman CG, et al.: A phase I study of oxaliplatin in combination with continous infusion 5-fluorouracil and radiation in esophagus cancer. [Abstract] Proc Am Assoc Cancer Res 42: A-3751, 697, 2001.|Pendyala L, Leichman CG, Clark K, et al.: Oxaliplatin, 5-fluorouracil, and radiation in cancer of the esophagus: a pharmacokinetic (PK)/molecular correlates study. [Abstract] Proc Am Assoc Cancer Res 42: A-3347, 623, 2001.","\tEsophageal Cancer\tfluorouracil|oxaliplatin|conventional surgery|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","esophageal neoplasms","oxaliplatin|fluorouracil","NA"]
["NCT00004260","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11756154,"Ansell SM, Witzig TE, Kurtin PJ, Sloan JA, Jelinek DF, Howell KG, Markovic SN, Habermann TM, Klee GG, Atherton PJ, Erlichman C. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood. 2002 Jan 1;99(1):67-74.","\tLymphoma\trecombinant interleukin-12|rituximab\tNA\tNA\tNA\tBiological|Biological\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|lymphoma, non-hodgkin","rituximab|interleukin-12","NA"]
["NCT00004285","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12490682,"Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R; Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002 Dec 19;347(25):2010-9.","\tEnd Stage Renal Disease\tStandard dose, low flux hemodialysis|Standard dose, high flux hemodialysis|High dose, low flux hemodialysis|High dose, high flux hemodialysis\tNA\tNA\tNA\tDevice|Device|Device|Device\tAll\t","Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis","Interventional","Completed","N/A",4,1846,"kidney diseases|kidney failure, chronic","NA","NA"]
["NCT00004449","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16685181|16212446|19933766","Cohen H, Amerine-Dickens M, Smith T. Early intensive behavioral treatment: replication of the UCLA model in a community setting. J Dev Behav Pediatr. 2006 Apr;27(2 Suppl):S145-55.|Sallows GO, Graupner TD. Intensive behavioral treatment for children with autism: four-year outcome and predictors. Am J Ment Retard. 2005 Nov;110(6):417-38.|Hayward D, Eikeseth S, Gale C, Morgan S. Assessing progress during treatment for young children with autism receiving intensive behavioural interventions. Autism. 2009 Nov;13(6):613-33. doi: 10.1177/1362361309340029.","\tAutistic Disorder\tintensive one-on-one behavioral treatment|Individualized in home parent training\tNA\tNA\tNA\tBehavioral|Behavioral\tAll\t","NA","NA","NA","NA","NA","NA","autistic disorder","NA","NA"]
["NCT00004465","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12966125,"Trachtman H, Cnaan A, Christen E, Gibbs K, Zhao S, Acheson DW, Weiss R, Kaskel FJ, Spitzer A, Hirschman GH; Investigators of the HUS-SYNSORB Pk Multicenter Clinical Trial. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA. 2003 Sep 10;290(10):1337-44.","\tHemolytic Uremic Syndrome\tSYNSORB Pk|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome","Interventional","Terminated","Phase 3",2,145,"hemolysis|azotemia|hemolytic-uremic syndrome|syndrome","shiga toxins","NA"]
["NCT00004467","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19524577,"Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, Davern TJ 2nd, Murray NG, McCashland T, Reisch JS, Robuck PR; Acute Liver Failure Study Group. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009 Sep;137(3):856-64, 864.e1. doi: 10.1053/j.gastro.2009.06.006. Epub 2009 Jun 12. Erratum in: Gastroenterology. 2013 Sep;145(3):695. Dosage error in article text.","\tAcute Liver Failure\tN-acetylcysteine (NAC)|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen","Interventional","Completed","Phase 3",2,173,"hepatic insufficiency|liver failure|liver failure, acute","acetylcysteine|n-monoacetylcystine","NA"]
["NCT00004478","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12885750|15666063","Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, Nardin R, Freeman R. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003 Aug 12;108(6):724-8. Epub 2003 Jul 28.|Goldstein DS, Holmes C, Kaufmann H, Freeman R. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res. 2004 Dec;14(6):363-8.","\tOrthostatic Hypotension|Shy-Drager Syndrome\tdroxidopa\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","multiple system atrophy|hypotension, orthostatic|shy-drager syndrome|hypotension","droxidopa","NA"]
["NCT00004486","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15602505,"Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, Iyengar R. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 2005 Mar;30(3):582-9.","\tAutism\tfluoxetine\tCrossover Assignment\tTreatment\tRandomized\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","autistic disorder","fluoxetine","NA"]
["NCT00004533","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12885347,"Flotte TR, Zeitlin PL, Reynolds TC, Heald AE, Pedersen P, Beck S, Conrad CK, Brass-Ernst L, Humphries M, Sullivan K, Wetzel R, Taylor G, Carter BJ, Guggino WB. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther. 2003 Jul 20;14(11):1079-88.","\tCystic Fibrosis\tAdeno-associated virus-CFTR vector\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","cystic fibrosis|fibrosis","NA","NA"]
["NCT00004554","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20231324,"Pettinati HM, Oslin DW, Kampman KM, Dundon WD, Xie H, Gallis TL, Dackis CA, O'Brien CP. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry. 2010 Jun;167(6):668-75. doi: 10.1176/appi.ajp.2009.08060852. Epub 2010 Mar 15.","\tAlcoholism|Depression\tnaltrexone (Revia)|sertraline (Zoloft)|Placebo\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","Sertraline for Alcohol Dependence and Depression","Interventional","Completed","Phase 4",4,171,"depression|alcoholism|depressive disorder","naltrexone|sertraline","NA"]
["NCT00004562","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17105759|22025606","Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, Forman S, Ruzyllo W, Maggioni AP, White H, Sadowski Z, Carvalho AC, Rankin JM, Renkin JP, Steg PG, Mascette AM, Sopko G, Pfisterer ME, Leor J, Fridrich V, Mark DB, Knatterud GL; Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006 Dec 7;355(23):2395-407. Epub 2006 Nov 14.|Hochman JS, Reynolds HR, Dzavík V, Buller CE, Ruzyllo W, Sadowski ZP, Maggioni AP, Carvalho AC, Rankin JM, White HD, Goldberg S, Forman SA, Mark DB, Lamas GA; Occluded Artery Trial Investigators. Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. Circulation. 2011 Nov 22;124(21):2320-8. doi: 10.1161/CIRCULATIONAHA.111.041749. Epub 2011 Oct 24.","\tCardiovascular Diseases|Heart Diseases|Heart Failure|Heart Failure, Congestive|Myocardial Infarction\tBeta adrenergic blockers|Platelet inhibitors|PTCA and stents|ACE Inhibitors\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Procedure|Drug\tAll\t","Occluded Artery Trial (OAT)","Interventional","Completed","Phase 3",2,2201,"myocardial infarction|heart diseases|cardiovascular diseases|infarction|heart failure","platelet aggregation inhibitors|adrenergic beta-antagonists|angiotensin-converting enzyme inhibitors|enzyme inhibitors|adrenergic agents|adrenergic antagonists","NA"]
["NCT00004563","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16790698,"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22;354(25):2655-66.","\tLung Diseases|Pulmonary Fibrosis|Scleroderma, Systemic|Systemic Scleroderma\tCyclophosphamide|Placebo\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug\tAll\t","Scleroderma Lung Disease","Interventional","Completed","Phase 3",2,158,"scleroderma, systemic|scleroderma, localized|scleroderma, diffuse|pulmonary fibrosis|fibrosis|lung diseases","cyclophosphamide","NA"]
["NCT00004635","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19167733,"Figg WD, Hussain MH, Gulley JL, Arlen PM, Aragon-Ching JB, Petrylak DP, Higano CS, Steinberg SM, Chatta GS, Parnes H, Wright JJ, Sartor O, Dahut WL. A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol. 2009 Mar;181(3):1104-13; discussion 1113. doi: 10.1016/j.juro.2008.11.026. Epub 2009 Jan 23.","\tProstate Cancer\tThalidomide|leuprolide acetate|goserelin|Placebo\tCrossover Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Other\tMale\t","Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer","Interventional","Completed","Phase 3",2,159,"prostatic neoplasms","leuprolide|thalidomide|goserelin","NA"]
["NCT00004660","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11535445,"Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL, Earle JD, Forbes GS, Kline RW, Bergstralh EJ, Offord KP, Rademacher DM, Stanley NM, Bartley GB. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology. 2001 Sep;108(9):1523-34. Erratum in: Ophthalmology. 2004 Jul;111(7):1306.","\tGraves' Disease\tRadiotherapy|Sham treatment\tCrossover Assignment\tTreatment\tRandomized\tRadiation|Radiation\tAll\t","Randomized Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy","Interventional","Completed","N/A",2,42,"graves disease|graves ophthalmopathy|eye diseases","NA","NA"]
["NCT00004730","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17166799,"Temkin NR, Anderson GD, Winn HR, Ellenbogen RG, Britz GW, Schuster J, Lucas T, Newell DW, Mansfield PN, Machamer JE, Barber J, Dikmen SS. Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial. Lancet Neurol. 2007 Jan;6(1):29-38.","\tBrain Concussion|Brain Injuries|Head Injury\tmagnesium sulfate\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","brain concussion|wounds and injuries|craniocerebral trauma|brain injuries","magnesium sulfate","NA"]
["NCT00004735","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18752430,"Rigaud M, Borkowsky W, Muresan P, Weinberg A, Larussa P, Fenton T, Read JS, Jean-Philippe P, Fergusson E, Zimmer B, Smith D, Kraimer J; Pediatrics AIDS Clinical Trials Group P1006 Team. Impaired immunity to recall antigens and neoantigens in severely immunocompromised children and adolescents during the first year of effective highly active antiretroviral therapy. J Infect Dis. 2008 Oct 15;198(8):1123-30. doi: 10.1086/592050.","\tHIV Infections\tTetanus toxoid|Hepatitis A Vaccine (Inactivated)\tParallel Assignment\tTreatment\tRandomized\tBiological|Biological\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","NA","NA"]
["NCT00004842","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",10655252,"Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology. 2000 Feb;31(2):318-23.","\tCholangitis, Sclerosing|Liver Cirrhosis, Biliary\tbudesonide\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","liver cirrhosis|cholangitis|fibrosis|liver cirrhosis, biliary|cholangitis, sclerosing","budesonide","NA"]
["NCT00004843","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11114637,"Talpos GB, Bone HG 3rd, Kleerekoper M, Phillips ER, Alam M, Honasoge M, Divine GW, Rao DS. Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: patient description and effects on the SF-36 health survey. Surgery. 2000 Dec;128(6):1013-20;discussion 1020-1.","\tHyperparathyroidism\tparathyroidectomy|Observation\tParallel Assignment\tTreatment\tRandomized\tProcedure|Other\tAll\t","A Randomized Study of Surgery vs No Surgery in Patients With Mild Asymptomatic Primary Hyperparathyroidism","Interventional","Completed","N/A",2,53,"hyperparathyroidism","NA","NA"]
["NCT00004845","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12783912,"Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ; Alzheimer's Disease Cooperative Study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003 Jun 4;289(21):2819-26.","\tAlzheimer Disease\tRofecoxib|Naproxen\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","alzheimer disease","naproxen|rofecoxib","NA"]
["NCT00004857","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19863336|NA|NA","Byrd JC, Peterson BL, Rai KR, Hurd D, Hohl R, Perry MC, Gockerman J, Nattam S, Larson RA. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leuk Lymphoma. 2009 Oct;50(10):1589-96.|Rai KR, Byrd JC, Peterson B: Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB study 19901. [Abstract] Blood 102 (11 Pt 1): A-2506, 2003.|Rai KR, Byrd JC, Peterson BL, et al.: A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer and Leukemia Group B (CALGB) study 19901. [Abstract] Blood 100 (11 Pt 1): A-772, 2002.","\tLeukemia\talemtuzumab|fludarabine phosphate\tNA\tNA\tNA\tBiological|Drug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, lymphoid|leukemia, lymphocytic, chronic, b-cell|leukemia","alemtuzumab|fludarabine|fludarabine phosphate","NA"]
["NCT00004858","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",10632319,"Uckun FM, Messinger Y, Chen CL, O'Neill K, Myers DE, Goldman F, Hurvitz C, Casper JT, Levine A. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clin Cancer Res. 1999 Dec;5(12):3906-13.","\tLeukemia|Lymphoma\tB43-genistein immunoconjugate\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","precursor cell lymphoblastic leukemia-lymphoma|leukemia, lymphoid|lymphoma|leukemia|lymphoma, non-hodgkin","genistein|immunoconjugates","NA"]
["NCT00004860","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18048821|NA","Hochster HS, Luo W, Popa EC, Lyman BT, Mulcahy M, Beatty PA, Benson AB. Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299. J Clin Oncol. 2007 Dec 1;25(34):5397-402.|Popa EC, Luo W, Hochster H, et al.: A phase II study of orzel (UFT+leucovorin) in elderly (=75 years old) patients with colorectal cancer: results of ECOG 1299. [Abstract] J Clin Oncol 23 (Suppl 16): A-3608, 273s, 2005.","\tColorectal Cancer\tleucovorin calcium|tegafur-uracil\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","tegafur|levoleucovorin|leucovorin|calcium","NA"]
["NCT00004867","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18640307,"Veeramachaneni NK, Zoole JB, Decker PA, Putnam JB Jr, Meyers BF; American College of Surgeons Oncology Group Z0060 Trial. Lymph node analysis in esophageal resection: American College of Surgeons Oncology Group Z0060 trial. Ann Thorac Surg. 2008 Aug;86(2):418-21; discussion 421. doi: 10.1016/j.athoracsur.2008.04.043.","\tEsophageal Cancer\tconventional surgery|positron emission tomography|radionuclide imaging|fludeoxyglucose F 18|chemotherapy|Radiotherapy\tNA\tNA\tNA\tProcedure|Procedure|Procedure|Radiation|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","esophageal neoplasms","fluorodeoxyglucose f18","NA"]
["NCT00004873","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17664469,"Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23.","\tGastric Cancer\tcisplatin|docetaxel|epirubicin hydrochloride|fluorouracil\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","stomach neoplasms","docetaxel|fluorouracil|epirubicin","NA"]
["NCT00004876","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21797111|NA","Muthuramalingam SR, Braybrooke JP, Blann AD, Madhusudan S, Wilner S, Jenkins A, Han C, Kaur K, Perren T, Ganesan TS. A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. Eur J Gynaecol Oncol. 2011;32(3):253-8.|Muthuramalingam SR, Braybrooke JP, Madhusudan S, et al.: A randomised phase two study of carboplatin versus carboplatin and thalidomide in patients with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. [Abstract] Int J Gynecol Cancer 14 (Suppl 1): A-303, 86, 2004.","\tOvarian Cancer\tcarboplatin|thalidomide\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","carcinoma, ovarian epithelial|ovarian neoplasms","carboplatin|thalidomide","NA"]
["NCT00004884","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16361622|NA","Lutz MP, Van Cutsem E, Wagener T, Van Laethem JL, Vanhoefer U, Wils JA, Gamelin E, Koehne CH, Arnaud JP, Mitry E, Husseini F, Reichardt P, El-Serafi M, Etienne PL, Lingenfelser T, Praet M, Genicot B, Debois M, Nordlinger B, Ducreux MP; European Organisation for Research and Treatment of Cancer Gastrointestinal Group. Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J Clin Oncol. 2005 Dec 20;23(36):9250-6.|Lutz MP, Ducreux M, Wagener T, et al.: Docetaxel/gemcitabine or docetaxel/cisplatin in advanced pancreatic carcinoma: a randomized phase II study of the EORTC-GI group. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-498, 2002.","\tPancreatic Cancer\tcisplatin|docetaxel|gemcitabine hydrochloride\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","pancreatic neoplasms","docetaxel|gemcitabine","NA"]
["NCT00004885","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15939923|NA|NA","Köhne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, Lorenz M, Reichardt P, Rückle-Lanz H, Frickhofen N, Fuchs R, Mergenthaler HG, Langenbuch T, Vanhoefer U, Rougier P, Voigtmann R, Müller L, Genicot B, Anak O, Nordlinger B; European Organisation for Research and Treatment of Cancer Gastrointestinal Group. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol. 2005 Aug 1;23(22):4856-65. Epub 2005 Jun 6.|Kohne CH, Van Custem E, Wils JA, et al.: Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI Group study 40986. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-1018, 2003.|Kohne C, van Cutsem E, Wils J, et al.: Weekly high dose infusional 5-FU plus folinic acid (FA) with or without irinotecan (IRI) in metastatic colorectal cancer (MCRC): interim safety results of EORTC study 40986. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-532, 2002.","\tColorectal Cancer\tFOLFIRI regimen|fluorouracil|irinotecan hydrochloride|leucovorin calcium\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","leucovorin|irinotecan|calcium|fluorouracil|levoleucovorin","NA"]
["NCT00004891","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17882490|10813118","Nahas CS, Akhurst T, Yeung H, Leibold T, Riedel E, Markowitz AJ, Minsky BD, Paty PB, Weiser MR, Temple LK, Wong WD, Larson SM, Guillem JG. Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation. Ann Surg Oncol. 2008 Mar;15(3):704-11. Epub 2007 Sep 20. Erratum in: Ann Surg Oncol. 2008 Apr;15(4):1265. Leibold, Tobias [added].|Guillem JG, Puig-La Calle J Jr, Akhurst T, Tickoo S, Ruo L, Minsky BD, Gollub MJ, Klimstra DS, Mazumdar M, Paty PB, Macapinlac H, Yeung H, Saltz L, Finn RD, Erdi Y, Humm J, Cohen AM, Larson S. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum. 2000 Jan;43(1):18-24.","\tColorectal Cancer\tchemotherapy|computed tomography|conventional surgery|neoadjuvant therapy|positron emission tomography|radionuclide imaging|fludeoxyglucose F 18|radiation therapy\tNA\tNA\tNA\tDrug|Procedure|Procedure|Procedure|Procedure|Procedure|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","rectal neoplasms","fluorodeoxyglucose f18","NA"]
["NCT00004892","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17264335,"Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, Olivi A, Judy K, Tatter SB, Dolan ME. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol. 2007 Feb 1;25(4):399-404.","\tBrain and Central Nervous System Tumors\tO6-benzylguanine|polifeprosan 20 with carmustine implant|conventional surgery\tNA\tNA\tNA\tDrug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","nervous system neoplasms|glioma|central nervous system neoplasms","carmustine|o(6)-benzylguanine","NA"]
["NCT00004906","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Pecora AL, Lazarus L, Kramer L, et al.: Phase II multi-institution trial of induction docetaxel and doxorubicin followed by sequential high dose chemotherapy for women with metastatic breast cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 17: A-634, 1998.","\tBreast Cancer\tfilgrastim|anastrozole|carboplatin|cisplatin|cyclophosphamide|docetaxel|doxorubicin hydrochloride|etoposide|pamidronate disodium|thiotepa|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","pamidronate|cyclophosphamide|thiotepa|docetaxel|doxorubicin|liposomal doxorubicin|etoposide|anastrozole|carboplatin","NA"]
["NCT00004917","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17716826|NA","Machtay M, Pajak TF, Suntharalingam M, Shenouda G, Hershock D, Stripp DC, Cmelak AJ, Schulsinger A, Fu KK; Radiation Therapy Oncology Group. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1008-17. Epub 2007 Aug 23.|Machtay M, Pajak T, Suntharalingam M, et al.: Definitive radiotherapy +/- erythropoietin for squamous cell carcinoma of the head and neck: preliminary report of RTOG 99-03. [Abstract] Int J Radiat Oncol Biol Phys 60 (Suppl 1): A-5, S132, 2004.","\tAnemia|Head and Neck Cancer\tepoetin alfa|cisplatin|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","epoetin alfa","NA"]
["NCT00004920","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18089874|16446322|16192580|NA","Bottomley A, Coens C, Efficace F, Gaafar R, Manegold C, Burgers S, Vincent M, Legrand C, van Meerbeeck JP; EORTC-NCIC. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol. 2007 Dec 20;25(36):5770-6.|Bottomley A, Gaafar R, Manegold C, Burgers S, Coens C, Legrand C, Vincent M, Giaccone G, Van Meerbeeck J; EORTC Lung-Cancer Group; National Cancer Institute, Canada. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol. 2006 Mar 20;24(9):1435-42. Epub 2006 Jan 30. Erratum in: J Clin Oncol. 2006 Jun 1;24(16):2601. Gaafa, Rabab [corrected to Gaafar, Rahab].|van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G; European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005 Oct 1;23(28):6881-9.|Van Meerbeeck JP, Manegold C, Gaafar R, et al.: A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and NCIC. [Abstract] J Clin Oncol 22 (Suppl 14): A-7021, 622s, 2004.","\tMalignant Mesothelioma\tcisplatin|raltitrexed\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","mesothelioma|lung neoplasms","raltitrexed","NA"]
["NCT00004921","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17698804,"Möbus V, Wandt H, Frickhofen N, Bengala C, Champion K, Kimmig R, Ostermann H, Hinke A, Ledermann JA; AGO-Ovar/AIO; EBMT. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol. 2007 Sep 20;25(27):4187-93. Epub 2007 Aug 13.","\tOvarian Cancer\tfilgrastim|carboplatin|cyclophosphamide|melphalan|paclitaxel|adjuvant therapy|bone marrow ablation with stem cell support|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Procedure|Procedure|Procedure\tFemale\t","NA","NA","NA","NA","NA","NA","ovarian neoplasms|carcinoma, ovarian epithelial","melphalan|carboplatin|cyclophosphamide|paclitaxel","NA"]
["NCT00004925","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19433391,"Theodoulou M, Batist G, Campos S, Winer E, Welles L, Hudis C. Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. Clin Breast Cancer. 2009 May;9(2):101-7. doi: 10.3816/CBC.2009.n.019.","\tBreast Cancer\ttrastuzumab|pegylated liposomal doxorubicin hydrochloride\tNA\tNA\tNA\tBiological|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","liposomal doxorubicin|trastuzumab|doxorubicin","NA"]
["NCT00004927","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17261851,"Aghajanian C, Burris HA 3rd, Jones S, Spriggs DR, Cohen MB, Peck R, Sabbatini P, Hensley ML, Greco FA, Dupont J, O'Connor OA. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol. 2007 Mar 20;25(9):1082-8. Epub 2007 Jan 29.","\tUnspecified Adult Solid Tumor, Protocol Specific\tixabepilone\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT00004932","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15231574|NA","Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, Therrien M, Zoellner U, Blaney SM, Bernstein M; Children's Oncology Group phase 1 study. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood. 2004 Nov 1;104(9):2655-60. Epub 2004 Jul 1.|Champagne MA, Hershon L, Rosamilia M, et al.: STI571 in the Treatment of Pediatric Philadelphia (Ph+) Chromosome-Positive Leukemia: A Children's Oncology Group Phase 1 Study (P-9973). [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1466, 2001.","\tLeukemia\timatinib mesylate\tNA\tNA\tNA\tDrug\tAll\t","STI571 in Treating Patients With Recurrent Leukemia","Interventional","Completed","Phase 1",4,31,"leukemia","imatinib mesylate","NA"]
["NCT00004934","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","14656276|NA|22539562|NA|NA","Kristensen GB, Vergote I, Stuart G, Del Campo JM, Kaern J, Lopez AB, Eisenhauer E, Aavall-Lundquist E, Ridderheim M, Havsteen H, Mirza MR, Scheistroen M, Vrdoljak E. First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:172-7.|Kristensen G, Vergote I, Stuart G, et al.: First line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin (TEC) vs. paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-NCIC CTG Gynecological Cancer Intergroup phase III trial. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-805, 2002.|Lindemann K, Christensen RD, Vergote I, Stuart G, Izquierdo MA, Kærn J, Havsteen H, Eisenhauer E, Ridderheim M, Lopez AB, Hirte H, Aavall-Lundquvist E, Vrdoljak E, Green J, Kristensen GB. First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. Ann Oncol. 2012 Oct;23(10):2613-2619. doi: 10.1093/annonc/mds060. Epub 2012 Apr 26.|Kristensen GB, Vergote I, Stuart G, et al.: First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival. [Abstract] Int J Gynecol Cancer 15 (Suppl 3): 221, 2005.|Kristensen GB, Vergote I, Eisenhauer E, et al.: First line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression free survival. [Abstract] J Clin Oncol 22 (Suppl 14): A-5003, 449s, 2004.","\tFallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer\tcarboplatin|epirubicin hydrochloride|paclitaxel|conventional surgery\tNA\tNA\tNA\tDrug|Drug|Drug|Procedure\tFemale\t","NA","NA","NA","NA","NA","NA","carcinoma, ovarian epithelial|ovarian neoplasms|fallopian tube neoplasms","carboplatin|epirubicin|paclitaxel","NA"]
["NCT00004936","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19019414|17940305|17179104|16234512|16361632","Mitchell DG, Snyder B, Coakley F, Reinhold C, Thomas G, Amendola MA, Schwartz LH, Woodward P, Pannu H, Atri M, Hricak H. Early invasive cervical cancer: MRI and CT predictors of lymphatic metastases in the ACRIN 6651/GOG 183 intergroup study. Gynecol Oncol. 2009 Jan;112(1):95-103. doi: 10.1016/j.ygyno.2008.10.005. Epub 2008 Nov 20.|Hricak H, Gatsonis C, Coakley FV, Snyder B, Reinhold C, Schwartz LH, Woodward PJ, Pannu HK, Amendola M, Mitchell DG. Early invasive cervical cancer: CT and MR imaging in preoperative evaluation - ACRIN/GOG comparative study of diagnostic performance and interobserver variability. Radiology. 2007 Nov;245(2):491-8.|Mitchell DG, Snyder B, Coakley F, Reinhold C, Thomas G, Amendola M, Schwartz LH, Woodward P, Pannu H, Hricak H. Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study. J Clin Oncol. 2006 Dec 20;24(36):5687-94.|Amendola MA, Hricak H, Mitchell DG, Snyder B, Chi DS, Long HJ 3rd, Fiorica JV, Gatsonis C. Utilization of diagnostic studies in the pretreatment evaluation of invasive cervical cancer in the United States: results of intergroup protocol ACRIN 6651/GOG 183. J Clin Oncol. 2005 Oct 20;23(30):7454-9.|Hricak H, Gatsonis C, Chi DS, Amendola MA, Brandt K, Schwartz LH, Koelliker S, Siegelman ES, Brown JJ, McGhee RB Jr, Iyer R, Vitellas KM, Snyder B, Long HJ 3rd, Fiorica JV, Mitchell DG; American College of Radiology Imaging Network 6651; Gynecologic Oncology Group 183. Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J Clin Oncol. 2005 Dec 20;23(36):9329-37.","\tCervical Cancer\tiodinated contrast dye|computed tomography|magnetic resonance imaging|gadopentetate dimeglumine\tNA\tNA\tNA\tDrug|Procedure|Procedure|Radiation\tFemale\t","NA","NA","NA","NA","NA","NA","uterine cervical neoplasms","NA","NA"]
["NCT00004984","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15855569|12037147","Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care. 2005 May;28(5):1068-76.|Diabetes Prevention Trial--Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002 May 30;346(22):1685-91.","\tDiabetes Mellitus, Type 1\tParenteral Insulin|Close Observation|Oral Insulin|Placebo\tParallel Assignment\tPrevention\tRandomized\tDrug|Other|Drug|Drug\tAll\t","The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)","Interventional","Completed","Phase 3",4,711,"diabetes mellitus|diabetes mellitus, type 1","insulin, globin zinc|insulin","NA"]
["NCT00004992","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16855264|11832527","Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, Knowler WC, Nathan DM, Altshuler D; Diabetes Prevention Program Research Group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med. 2006 Jul 20;355(3):241-50.|Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.","\tDiabetes Mellitus, Non-Insulin-Dependent|Glucose Intolerance\tIntensive lifestyle|Metformin|Placebo\tParallel Assignment\tPrevention\tRandomized\tBehavioral|Drug|Drug\tAll\t","Diabetes Prevention Program","Interventional","Completed","Phase 3",3,3234,"diabetes mellitus|glucose intolerance|diabetes mellitus, type 2","metformin","NA"]
["NCT00005005","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","14500804|16093464|16449339|17333451|17164314","Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ; PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003 Sep 25;349(13):1207-15. Epub 2003 Sep 20.|Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ; PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005 Aug 11;353(6):555-65.|Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2006 Apr;91(4):1370-5. Epub 2006 Jan 31.|Sellmeyer DE, Black DM, Palermo L, Greenspan S, Ensrud K, Bilezikian J, Rosen CJ. Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. Osteoporos Int. 2007 Jul;18(7):973-9. Epub 2007 Feb 28.|Antoniucci DM, Sellmeyer DE, Bilezikian JP, Palermo L, Ensrud KE, Greenspan SL, Black DM. Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. J Clin Endocrinol Metab. 2007 Mar;92(3):942-7. Epub 2006 Dec 12.","\tOsteoporosis\tAlendronate|PTH\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tFemale\t","PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis","Interventional","Completed","Phase 2",4,238,"osteoporosis","alendronate","NA"]
["NCT00005007","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12905485|15838068|15751091|15986348|16378799|16646004","Stone JH; Wegener's Granulomatosis Etanercept Trial Research Group. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum. 2003 Aug;48(8):2299-309.|Merkel PA, Lo GH, Holbrook JT, Tibbs AK, Allen NB, Davis JC Jr, Hoffman GS, McCune WJ, St Clair EW, Specks U, Spiera R, Petri M, Stone JH; Wegener's Granulomatosis Etanercept Trial Research Group. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med. 2005 Apr 19;142(8):620-6.|Stone JH, Rajapakse VN, Hoffman GS, Specks U, Merkel PA, Spiera RF, Davis JC, St Clair EW, McCune J, Ross S, Hitt BA, Veenstra TD, Conrads TP, Liotta LA, Petricoin EF 3rd; Wegener's Granulomatosis Etanercept Trial Research Group. A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. Arthritis Rheum. 2005 Mar;52(3):902-10.|Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, Davis JC, Ytterberg SR, St Clair EW, McCune WJ, Specks U, Allen NB, Luqmani RA, Stone JH; WGET Research Group. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum. 2005 Jul;52(7):2168-78.|Wung PK, Holbrook JT, Hoffman GS, Tibbs AK, Specks U, Min YI, Merkel PA, Spiera R, Davis JC, St Clair EW, McCune J, Ytterberg SR, Allen NB, Stone JH; WGET Research Group. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med. 2005 Dec;118(12):1416.|Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI, Specks U, Merkel PA, Spiera R, Davis JC, St Clair EW, McCune WJ, Ytterberg SR, Allen NB, Hoffman GS; Wegener's Granulomatosis Etanercept Trial Research Group. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. 2006 May;54(5):1608-18.","\tWegener's Granulomatosis\tEtanercept\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","granulomatosis with polyangiitis","etanercept","NA"]
["NCT00005013","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","11939866|15876903","Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002 Apr 10;287(14):1807-14.|Vitiello B, Shader RI, Parker CB, Ritz L, Harlan W, Greenblatt DJ, Gadde KM, Krishnan KR, Davidson JR. Hyperforin plasma level as a marker of treatment adherence in the National Institutes of Health Hypericum Depression Trial. J Clin Psychopharmacol. 2005 Jun;25(3):243-9.","\tMajor Depression\tSertraline|Hypericum perforatum (St. John's wort)\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","depressive disorder, major|depressive disorder|depression","sertraline","NA"]
["NCT00005022","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15890573|NA","Komaki R, Swann RS, Ettinger DS, Glisson BS, Sandler AB, Movsas B, Suh J, Byhardt RW. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):342-50.|Komaki R, Swann S, Ettinger D, et al.: Phase I dose-escalation study of thoracic irradiation with concurrent chemotherapy for patients with limited small cell lung cancer (LSCLC). Radiation Therapy Oncology Group (RTOG) protocol 9712. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2539, 2003.","\tLung Cancer\tcisplatin|etoposide|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Radiation\tAll\t","Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer","Interventional","Completed","Phase 1",6,64,"lung neoplasms|small cell lung carcinoma","etoposide","NA"]
["NCT00005026","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16631245,"Bookman MA, McMeekin DS, Fracasso PM. Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. Gynecol Oncol. 2006 Nov;103(2):473-8. Epub 2006 May 2.","\tOvarian Cancer|Primary Peritoneal Cavity Cancer\tcarboplatin|paclitaxel|topotecan hydrochloride\tNA\tNA\tNA\tDrug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","NA","topotecan|carboplatin|paclitaxel","NA"]
["NCT00005027","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Ibrahim D, Hussain M, LoRusso P, et al.: Rebeccamycin analog (BMY-27557-14) in renal cell cancer (RCC): preliminary results of a phase II trial. [Abstract] Proceedings of the American Society of Clinical Oncology A-2373, 2001.","\tKidney Cancer\tbecatecarin\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, renal cell|kidney neoplasms","NA","NA"]
["NCT00005029","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14534883,"Miller DS, Blessing JA, Lentz SS, McMeekin DS. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. Cancer. 2003 Oct 15;98(8):1664-9.","\tOvarian Cancer|Primary Peritoneal Cavity Cancer\ttopotecan hydrochloride\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","NA","topotecan","NA"]
["NCT00005031","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15122083,"Schilder RJ, Blessing JA, Pearl ML, Rose PG. Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. Invest New Drugs. 2004 Aug;22(3):343-9.","\tEndometrial Cancer\tirofulven\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","endometrial neoplasms","irofulven","NA"]
["NCT00005032","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12056703,"Rudin CM, Otterson GA, Mauer AM, Villalona-Calero MA, Tomek R, Prange B, George CM, Szeto L, Vokes EE. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol. 2002 Apr;13(4):539-45.","\tLung Cancer\toblimersen sodium|paclitaxel\tNA\tNA\tNA\tBiological|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|small cell lung carcinoma","paclitaxel|oblimersen","NA"]
["NCT00005045","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16222691|NA","Dutcher JP, Leon L, Manola J, Friedland DM, Roth B, Wilding G; Eastern Cooperative Oncology Group. Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study. Cancer. 2005 Dec 1;104(11):2392-9.|Friedland D, Leon L, Manola J, et al.: Carboxyamidotriazole (CAI) in patients with advanced renal cell cancer (RCC) refractory to immunotherapy: an ECOG phase II trial. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-2424, 2002.","\tKidney Cancer\tcarboxyamidotriazole\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","kidney neoplasms|carcinoma, renal cell","carboxyamido-triazole","NA"]
["NCT00005046","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16626792,"Armstrong DK, Fleming GF, Markman M, Bailey HH. A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Nov;103(2):391-6. Epub 2006 Apr 19.","\tOvarian Cancer|Primary Peritoneal Cavity Cancer\tchemotherapy|paclitaxel\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","ovarian neoplasms|carcinoma, ovarian epithelial","paclitaxel","NA"]
["NCT00005052","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Eggermont AM, Suciu S, Ruka W, et al.: EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results. [Abstract] J Clin Oncol 26 (Suppl 15): A-9004, 2008.","\tMelanoma (Skin)\tGM2-KLH vaccine|QS21|adjuvant therapy\tNA\tNA\tNA\tBiological|Biological|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","melanoma","NA","NA"]
["NCT00005053","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14556925,"Briasoulis E, Pavlidis N, Terret C, Bauer J, Fiedler W, Schöffski P, Raoul JL, Hess D, Selvais R, Lacombe D, Bachmann P, Fumoleau P. Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. Eur J Cancer. 2003 Nov;39(16):2334-40.","\tPancreatic Cancer\tglufosfamide\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","pancreatic neoplasms","NA","NA"]
["NCT00005055","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15010066,"Giaccone G, Smit EF, de Jonge M, Dansin E, Briasoulis E, Ardizzoni A, Douillard JY, Spaeth D, Lacombe D, Baron B, Bachmann P, Fumoleau P; EORTC-New Drug Development Group. Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. Eur J Cancer. 2004 Mar;40(5):667-72.","\tLung Cancer\tglufosfamide\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","NA","NA"]
["NCT00005059","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","14505160|14528068|NA","Jatoi A, Hillman S, Stella PJ, Mailliard JA, Sloan J, Vanone S, Cannon MW, Kutteh L, Kanard A, Jett JR. Daily activities: exploring their spectrum and prognostic impact in older, chemotherapy-treated lung cancer patients. Support Care Cancer. 2003 Jul;11(7):460-4. Epub 2003 Mar 12.|Jatoi A, Stella PJ, Hillman S, Mailliard JA, Vanone S, Perez EA, Cannon MW, Geyer S, Wiesenfeld M, Jett JR. Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (>or=65 years of age): a phase II North Central Cancer Treatment Group study. Am J Clin Oncol. 2003 Oct;26(5):441-7.|Mailliard JA, Jatoi A, Hillman S, et al.: Weekly carboplatin and paclitaxel in elderly non-small cell lung cancer patients (?65 years of age): a phase II North Central Cancer Treatment Group study. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1530, 2002.","\tLung Cancer\tcarboplatin|paclitaxel\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","paclitaxel|carboplatin","NA"]
["NCT00005062","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21139020,"Le Péchoux C, Laplanche A, Faivre-Finn C, Ciuleanu T, Wanders R, Lerouge D, Keus R, Hatton M, Videtic GM, Senan S, Wolfson A, Jones R, Arriagada R, Quoix E, Dunant A; Prophylactic Cranial Irradiation (PCI) Collaborative Group. Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Ann Oncol. 2011 May;22(5):1154-1163. doi: 10.1093/annonc/mdq576. Epub 2010 Dec 7.","\tLung Cancer\tradiation therapy\tNA\tNA\tNA\tRadiation\tAll\t","NA","NA","NA","NA","NA","NA","small cell lung carcinoma|lung neoplasms","NA","NA"]
["NCT00005068","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12963697,"Goetz MP, Erlichman C, Windebank AJ, Reid JM, Sloan JA, Atherton P, Adjei AA, Rubin J, Pitot H, Galanis E, Ames MM, Goldberg RM. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol. 2003 Oct 15;21(20):3761-9. Epub 2003 Sep 8.","\tUnspecified Adult Solid Tumor, Protocol Specific\tfluorouracil|irinotecan hydrochloride|leucovorin calcium|oxaliplatin\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","leucovorin|fluorouracil|oxaliplatin|irinotecan|calcium|levoleucovorin","NA"]
["NCT00005073","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15860850,"Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R, Higano CS. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005 May 1;23(13):2918-25.","\tProstate Cancer\tzoledronic acid\tNA\tNA\tNA\tDrug\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","zoledronic acid","NA"]
["NCT00005074","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12735303,"Kouroukis CT, Belch A, Crump M, Eisenhauer E, Gascoyne RD, Meyer R, Lohmann R, Lopez P, Powers J, Turner R, Connors JM; National Cancer Institute of Canada Clinical Trials Group. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003 May 1;21(9):1740-5.","\tLymphoma\talvocidib\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma, mantle-cell|lymphoma","alvocidib","NA"]
["NCT00005078","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14555506,"Lara PN Jr, Frankel P, Mack PC, Gumerlock PH, Galvin I, Martel CL, Longmate J, Doroshow JH, Lenz HJ, Lau DH, Gandara DR. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study. Clin Cancer Res. 2003 Oct 1;9(12):4356-62.","\tUnspecified Adult Solid Tumor, Protocol Specific\tcarboplatin|paclitaxel|tirapazamine\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","paclitaxel|tirapazamine|carboplatin","NA"]
["NCT00005087","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17947728|NA|NA|NA","Langer CJ, Harris J, Horwitz EM, Nicolaou N, Kies M, Curran W, Wong S, Ang K. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol. 2007 Oct 20;25(30):4800-5.|Horwitz EM, Harris J, Langer CJ, et al.: Concurrent split course hyperfractionated radiotherapy (Hfx RT), cisplatin (DDP) and paclitaxel (P) in patients with recurrent, previously irradiated squamous cell carcinoma of the head and neck (SCCHN): update of RTOG 9911 . [Abstract] J Clin Oncol 23 (Suppl 16): A-5577, 519s, 2005.|Horwitz EM, Harris J, Langer CJ, et al.: Phase II study of paclitaxel and cisplatin in combination with split course concomitant hyperfractioned re-irradiation in patients with recurrent squamous cell cancer of the head and neck : results of RTOG 99-11. [Abstract] Int J Radiat Oncol Biol Phys 63 (2 Suppl 1): A-119, S72, 2005.|Langer CJ, Harris J, Horwitz E, et al.: Phase II trial of concurrent split course hyperfractionated radiotherapy (Hfx RT), cisplatin (DDP) and paclitaxel (P) in patients with recurrent, previously irradiated squamous cell carcinoma of the head and neck (SCCHN): results of RTOG 9911. [Abstract] J Clin Oncol 22 (Suppl 14): A-5509, 490s, 2004.","\tHead and Neck Cancer\tfilgrastim|cisplatin|paclitaxel|conventional surgery|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","cisplatin|paclitaxel","NA"]
["NCT00005088","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18640496|15860857|NA|NA","Garden AS, Harris J, Trotti A, Jones CU, Carrascosa L, Cheng JD, Spencer SS, Forastiere A, Weber RS, Ang KK. Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1351-5. doi: 10.1016/j.ijrobp.2008.04.006.|Ang KK, Harris J, Garden AS, Trotti A, Jones CU, Carrascosa L, Cheng JD, Spencer SS, Forastiere A, Weber RS. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol. 2005 May 1;23(13):3008-15.|Garden AS, Harris J, Jones CU, et al.: Concomitant boost radiation and concurrent cisplatin for advanced head and neck carcinomas: update of a phase II trial of the RTOG (99-14). [Abstract] Int J Radiat Oncol Biol Phys 63 (2 Suppl 1): A-117, S71, 2005.|Ang KK, Harris J, Garden AS, et al.: Concomitant boost radiation and concurrent cisplatin for advanced head and neck carcinomas: preliminary results of a phase II trial of the RTOG (99-14). [Abstract] Int J Radiat Oncol Biol Phys 54(2 suppl 1): A-123, 71, 2002.","\tHead and Neck Cancer\tcisplatin|radiation therapy\tNA\tNA\tNA\tDrug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","cisplatin","NA"]
["NCT00005089","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18413640|NA","Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP; Southwest Oncology Group. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008 May 10;26(14):2258-63. doi: 10.1200/JCO.2007.13.6929. Epub 2008 Apr 14.|Miller TP, Unger JM, Spier C, et al.: Effect of adding rituximab to three cycles of CHOP plus involved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG-0014). [Abstract] Blood 104 (11): A-158, 2004.","\tLymphoma\trituximab|cyclophosphamide|doxorubicin hydrochloride|prednisone|vincristine sulfate|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma, non-hodgkin|lymphoma","prednisone|cyclophosphamide|vincristine|rituximab|liposomal doxorubicin|doxorubicin","NA"]
["NCT00005091","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12871785,"Braybrooke JP, Ranson M, Manegold C, Mattson K, Thatcher N, Cheverton P, Sekiguchi M, Suzuki M, Oyama R, Talbot DC. Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer. Lung Cancer. 2003 Aug;41(2):215-9.","\tLung Cancer\texatecan mesylate\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|carcinoma, non-small-cell lung","exatecan","NA"]
["NCT00005097","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15598753|12903852","Carpenter PM, Linden KG, McLaren CE, Li KT, Arain S, Barr RJ, Hite P, Sun JD, Meyskens FL Jr. Nuclear morphometry and molecular biomarkers of actinic keratosis, sun-damaged, and nonexposed skin. Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):1996-2002.|Linden KG, Carpenter PM, McLaren CE, Barr RJ, Hite P, Sun JD, Li KT, Viner JL, Meyskens FL. Chemoprevention of nonmelanoma skin cancer: experience with a polyphenol from green tea. Recent Results Cancer Res. 2003;163:165-71; discussion 264-6. Review.","\tNon-melanomatous Skin Cancer\tPolyphenon E and Placebo\tParallel Assignment\tPrevention\tRandomized\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","keratosis|skin neoplasms|keratosis, actinic","NA","NA"]
["NCT00005275","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19688045|20339144|20625114","Punjabi NM, Caffo BS, Goodwin JL, Gottlieb DJ, Newman AB, O'Connor GT, Rapoport DM, Redline S, Resnick HE, Robbins JA, Shahar E, Unruh ML, Samet JM. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med. 2009 Aug;6(8):e1000132. doi: 10.1371/journal.pmed.1000132. Epub 2009 Aug 18.|Redline S, Yenokyan G, Gottlieb DJ, Shahar E, O'Connor GT, Resnick HE, Diener-West M, Sanders MH, Wolf PA, Geraghty EM, Ali T, Lebowitz M, Punjabi NM. Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study. Am J Respir Crit Care Med. 2010 Jul 15;182(2):269-77. doi: 10.1164/rccm.200911-1746OC. Epub 2010 Mar 25.|Gottlieb DJ, Yenokyan G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, Shahar E. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010 Jul 27;122(4):352-60. doi: 10.1161/CIRCULATIONAHA.109.901801. Epub 2010 Jul 12.","\tCardiovascular Diseases|Cerebrovascular Accident|Coronary Disease|Heart Diseases|Hypertension|Lung Diseases|Myocardial Infarction|Sleep Apnea Syndromes\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","cardiovascular diseases|stroke|coronary disease|heart diseases|lung diseases|myocardial infarction|hypertension|infarction|sleep apnea syndromes","NA","NA"]
["NCT00005289","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","2235225|1861218|7951809|10632246|9737558|9514131|9470001|8672182|7898966|11549557|16682874|17659600|19180870|18762492|18563166|18459069|19824048|21410692|20921342|22161725|21330462|23886637|23845161|29595875|24499235|29944842","Palta M, Gabbert D, Fryback D, Widjaja I, Peters ME, Farrell P, Johnson J. Development and validation of an index for scoring baseline respiratory disease in the very low birth weight neonate. Severity Index Development and Validation Panels and Newborn Lung Project. Pediatrics. 1990 Nov;86(5):714-21.|Palta M, Gabbert D, Weinstein MR, Peters ME. Multivariate assessment of traditional risk factors for chronic lung disease in very low birth weight neonates. The Newborn Lung Project. J Pediatr. 1991 Aug;119(2):285-92.|Palta M, Weinstein MR, McGuinness G, Gabbert D, Brady W, Peters ME. A population study. Mortality and morbidity after availability of surfactant therapy. Newborn Lung Project. Arch Pediatr Adolesc Med. 1994 Dec;148(12):1295-301.|Palta M, Sadek-Badawi M, Evans M, Weinstein MR, McGuinnes G. Functional assessment of a multicenter very low-birth-weight cohort at age 5 years. Newborn Lung Project. Arch Pediatr Adolesc Med. 2000 Jan;154(1):23-30.|Evans M, Palta M, Sadek M, Weinstein MR, Peters ME. Associations between family history of asthma, bronchopulmonary dysplasia, and childhood asthma in very low birth weight children. Am J Epidemiol. 1998 Sep 1;148(5):460-6.|Palta M, Sadek M, Lim TS, Evans M, McGuinness G. Association of tocolytic therapy with antenatal steroid administration and infant outcomes. Newborn Lung Project. Am J Perinatol. 1998 Feb;15(2):87-92.|Palta M, Sadek M, Barnet JH, Evans M, Weinstein MR, McGuinness G, Peters ME, Gabbert D, Fryback D, Farrell P. Evaluation of criteria for chronic lung disease in surviving very low birth weight infants. Newborn Lung Project. J Pediatr. 1998 Jan;132(1):57-63.|Palta M, Sadek M, Gabbert D, Brady W, Weinstein MR, McGuinness G, Peters ME. The relation of maternal complications to outcomes in very low birthweight infants in an era of changing neonatal care. Am J Perinatol. 1996 Feb;13(2):109-14.|Weinstein MR, Peters ME, Sadek M, Palta M. A new radiographic scoring system for bronchopulmonary dysplasia. Newborn Lung Project. Pediatr Pulmonol. 1994 Nov;18(5):284-9.|Palta M, Sadek-Badawi M, Sheehy M, Albanese A, Weinstein M, McGuinness G, Peters ME. Respiratory symptoms at age 8 years in a cohort of very low birth weight children. Am J Epidemiol. 2001 Sep 15;154(6):521-9.|Hagen EW, Palta M, Albanese A, Sadek-Badawi M. School achievement in a regional cohort of children born very low birthweight. J Dev Behav Pediatr. 2006 Apr;27(2):112-20.|Palta M, Sadek-Badawi M, Madden K, Green C. Pulmonary testing using peak flow meters of very low birth weight children born in the perisurfactant era and school controls at age 10 years. Pediatr Pulmonol. 2007 Sep;42(9):819-28.|Hagen EW, Sadek-Badawi M, Albanese A, Palta M. A comparison of Wisconsin neonatal intensive care units with national data on outcomes and practices. WMJ. 2008 Nov;107(7):320-6.|Hagen EW, Sadek-Badawi M, Carlton DP, Palta M. Permissive hypercapnia and risk for brain injury and developmental impairment. Pediatrics. 2008 Sep;122(3):e583-9. doi: 10.1542/peds.2008-1016.|Palta M, Sadek-Badawi M, Carlton DP. Association of BPD and IVH with early neutrophil and white counts in VLBW neonates with gestational age <32 weeks. J Perinatol. 2008 Sep;28(9):604-10. doi: 10.1038/jp.2008.65. Epub 2008 Jun 19.|Palta M, Sadek-Badawi M. PedsQL relates to function and behavior in very low and normal birth weight 2- and 3-year-olds from a regional cohort. Qual Life Res. 2008 Jun;17(5):691-700. doi: 10.1007/s11136-008-9346-1. Epub 2008 May 6.|Hagen EW, Sadek-Badawi M, Palta M. Daycare attendance and risk for respiratory morbidity among young very low birth weight children. Pediatr Pulmonol. 2009 Nov;44(11):1093-9. doi: 10.1002/ppul.21104.|McManus BM, Robert SA, Albanese A, Sadek-Badawi M, Palta M. Racial disparities in health-related quality of life in a cohort of very low birthweight 2- and 3-year-olds with and without cerebral palsy. Dev Med Child Neurol. 2011 May;53(5):467-9. doi: 10.1111/j.1469-8749.2011.03923.x. Epub 2011 Mar 17.|McManus BM, Robert SA, Albanese A, Sadek-Badawi M, Palta M. Relationship between neighborhood disadvantage and social function of Wisconsin 2- and 3-year-olds born at very low birth weight. Arch Pediatr Adolesc Med. 2011 Feb;165(2):119-25. doi: 10.1001/archpediatrics.2010.185. Epub 2010 Oct 4.|Witt WP, Litzelman K, Spear HA, Wisk LE, Levin N, McManus BM, Palta M. Health-related quality of life of mothers of very low birth weight children at the age of five: results from the Newborn Lung Project Statewide Cohort Study. Qual Life Res. 2012 Nov;21(9):1565-76. doi: 10.1007/s11136-011-0069-3. Epub 2011 Dec 10.|McManus BM, Robert S, Albanese A, Sadek-Badawi M, Palta M. Racial disparities in health-related quality of life in a cohort of very-low-birth-weight 2- and 3-year-olds with and without asthma. J Epidemiol Community Health. 2012 Jul;66(7):579-85. doi: 10.1136/jech.2010.132886. Epub 2011 Feb 17.|Bates ML, Pillers DA, Palta M, Farrell ET, Eldridge MW. Ventilatory control in infants, children, and adults with bronchopulmonary dysplasia. Respir Physiol Neurobiol. 2013 Nov 1;189(2):329-37. doi: 10.1016/j.resp.2013.07.015. Epub 2013 Jul 22. Review.|McManus BM, Robert S, Albanese A, Sadek-Badawi M, Palta M. Predictors of receiving therapy among very low birth weight 2-year olds eligible for Part C early intervention in Wisconsin. BMC Pediatr. 2013 Jul 11;13:106. doi: 10.1186/1471-2431-13-106.|Haraldsdottir K, Watson AM, Goss KN, Beshish AG, Pegelow DF, Palta M, Tetri LH, Barton GP, Brix MD, Centanni RM, Eldridge MW. Impaired autonomic function in adolescents born preterm. Physiol Rep. 2018 Mar;6(6):e13620. doi: 10.14814/phy2.13620.|Bates ML, Farrell ET, Eldridge MW. Abnormal ventilatory responses in adults born prematurely. N Engl J Med. 2014 Feb 6;370(6):584-5. doi: 10.1056/NEJMc1311092.|Goss KN, Beshish AG, Barton GP, Haraldsdottir K, Levin TS, Tetri LH, Battiola TJ, Mulchrone AM, Pegelow DF, Palta M, Lamers LJ, Watson AM, Chesler NC, Eldridge MW. Early Pulmonary Vascular Disease in Young Adults Born Preterm. Am J Respir Crit Care Med. 2018 Dec 15;198(12):1549-1558. doi: 10.1164/rccm.201710-2016OC.","\tBronchopulmonary Dysplasia|Lung Diseases|Respiratory Distress Syndrome\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","respiratory distress syndrome, newborn|bronchopulmonary dysplasia|respiratory distress syndrome, adult|lung diseases","NA","NA"]
["NCT00005305","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|1689390|7831295|2020710","Andes AA, Smiley ML, White II, et al: Hepatitis Delta in Hemophiliacs: Preliminary Observation in Hepatitis B Antigen Positive and Negative Patients. In: Hepadna Viruses, Alan R. Liss, Inc., pp 619-627. 1987|Wang JG, Jansen RW, Brown EA, Lemon SM. Immunogenic domains of hepatitis delta virus antigen: peptide mapping of epitopes recognized by human and woodchuck antibodies. J Virol. 1990 Mar;64(3):1108-16.|Rozzelle JE Jr, Wang JG, Wagner DS, Erickson BW, Lemon SM. Self-association of a synthetic peptide from the N terminus of the hepatitis delta virus protein into an immunoreactive alpha-helical multimer. Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):382-6.|Lemon SM, Becherer PR, Wang JG, White GC, Lesesne H, Janco RL, Hanna WT, Davis C, Johnson CA, Poon MC, et al. Hepatitis delta infection among multiply-transfused hemophiliacs. Prog Clin Biol Res. 1991;364:351-60.","\tBlood Disease|Hemophilia A|Hepatitis, Viral, Human|Liver Diseases\tNo interventions - observational study\tNA\tNA\tNA\tOther\tMale\t","NA","NA","NA","NA","NA","NA","hemophilia a|liver diseases|hepatitis, viral, human|hematologic diseases|hepatitis|hepatitis a","NA","NA"]
["NCT00005520","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22413836,"Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-Dehoff RM, Boerwinkle E, Johnson JA, Bailey KR. Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response. J Transl Med. 2012 Mar 13;10:47. doi: 10.1186/1479-5876-10-47.","\tCardiovascular Diseases|Heart Diseases|Hypertension\tHydrochlorothiazide|Candesartan\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","cardiovascular diseases|hypertension|heart diseases","candesartan|hydrochlorothiazide","NA"]
["NCT00005578","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22689804|19584400|NA|NA","Voss SD, Chen L, Constine LS, Chauvenet A, Fitzgerald TJ, Kaste SC, Slovis T, Schwartz CL. Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jul 20;30(21):2635-40. doi: 10.1200/JCO.2011.40.7841. Epub 2012 Jun 11.|Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, Lipshultz SE, Turner CS, deAlarcon PA, Chauvenet A. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009 Sep 3;114(10):2051-9. doi: 10.1182/blood-2008-10-184143. Epub 2009 Jul 7. Erratum in: Blood. 2016 Jul 28;128(4):605.|Constine LS, Marcus R, Chauvenet A, et al.: Patterns of failure after response-based, dose-dense therapy for intermediate/high risk pediatric Hodgkin's disease (POG 9425). [Abstract] Int J Radiat Oncol Biol Phys 63 (Suppl 1): A-37, S21, 2005.|Schwartz CL, Constine LS, London W, et al.: POG 9425: response-based, intensively timed therapy for intermediate/high stage (IS/HS) pediatric Hodgkin's disease. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1555, 2002.","\tCardiac Toxicity|Lymphoma\tbleomycin sulfate|filgrastim|cyclophosphamide|dexrazoxane hydrochloride|doxorubicin hydrochloride|etoposide|prednisone|vincristine sulfate|radiation therapy\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug|Drug|Drug|Drug|Radiation\tAll\t","Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease","Interventional","Completed","Phase 3",2,219,"lymphoma|hodgkin disease|cardiotoxicity","bleomycin|dexrazoxane|cyclophosphamide|razoxane|liposomal doxorubicin|etoposide|lenograstim|prednisone|vincristine|doxorubicin","NA"]
["NCT00005580","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17020988,"Roberts JD, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ, Honeycutt C, Thune R, Padavic-Shaller K, Carter WH, Ramakrishnan V, Murgo AJ, Grant S. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma. Clin Cancer Res. 2006 Oct 1;12(19):5809-16.","\tLeukemia|Lymphoma\tbryostatin 1|fludarabine phosphate\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma, non-hodgkin|leukemia, lymphoid|leukemia|leukemia, lymphocytic, chronic, b-cell|lymphoma","fludarabine phosphate|fludarabine|bryostatin 1","NA"]
["NCT00005583","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Hogberg T, Rosenberg P, Kristensen G, et al.: A randomized phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). [Abstract] J Clin Oncol 25 (Suppl 18): A-5503, 274s, 2007.","\tEndometrial Cancer\tcisplatin|doxorubicin hydrochloride|epirubicin hydrochloride|adjuvant therapy|conventional surgery|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Procedure|Procedure|Radiation\tFemale\t","NA","NA","NA","NA","NA","NA","endometrial neoplasms","doxorubicin|liposomal doxorubicin|epirubicin","NA"]
["NCT00005584","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|NA|NA|NA|NA","Eghbali H, Brice P, Creemers GY, et al.: Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): preliminary results of the EORTC-GELA H9-F trial. [Abstract] Blood 106 (11): A-814, 2005.|Ferme C, Diviné M, Vranovsky A, et al.: Four ABVD and involved-field radiotherapy in unfavorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): preliminary results of the EORTC-GELA H9-U trial. [Abstract] Blood 106 (11): A-813, 2005.|Girinsky T, Gargi T, Carrie C, et al.: Quality assurance program in the EORTC-GELA H9 randomized study results on 282 patients. [Abstract] Int J Radiat Oncol Biol Phys 63 (2 Suppl 1): A77, S47, 2005.|Noordijk EM, Thomas J, Fermé C, et al.: First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL) . [Abstract] J Clin Oncol 23 (Suppl 16): A-6505, 561s, 2005.|Thomas J, Ferme C, Noordijk EM, et al.: Six cycles of EBVP followed by 36 Gy involved-field irradiation vs. no irradiation in favourable supradiaphragmatic clinical stages I-II Hodgkin's lymphoma: the EORTC-GELA strategy in 771 patients (H9-F trial-20982). [Abstract] Eur J Haematol 75 (Suppl 65): A-E11a, 40, 2004.|Thomas J, Ferme C, Noordijk EM, et al.: Six cycles of ABVD + IF-RT vs. four cycles of ABVD + IF-RT vs. four cycles of BEACOPP + IF-RT in unfavourable supradiaphragmatic clinical stages I-II Hodgkin's lymphoma: the EORTC-GELA H9-U randomized clinical trial (20982) in 808 patients. [Abstract] Eur J Haematol 73 (Supp 65): A-E12, 40, 2004.","\tLymphoma\tbleomycin sulfate|ABVD regimen|BEACOPP regimen|epirubicin hydrochloride|prednisone|vinblastine sulfate|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma","epirubicin|bleomycin|vinblastine|prednisone","NA"]
["NCT00005586","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18083404,"Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007 Dec 15;370(9604):2020-9.","\tColorectal Cancer\tL-leucovorin|fluorouracil|adjuvant therapy\tNA\tNA\tNA\tDrug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","levoleucovorin|leucovorin|fluorouracil","NA"]
["NCT00005587","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20138809|18355913|17236771|15172146","Hopwood P, Haviland JS, Sumo G, Mills J, Bliss JM, Yarnold JR; START Trial Management Group. Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncol. 2010 Mar;11(3):231-40. doi: 10.1016/S1470-2045(09)70382-1. Epub 2010 Feb 6.|START Trialists' Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bentzen SM, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008 Mar 29;371(9618):1098-107. doi: 10.1016/S0140-6736(08)60348-7. Epub 2008 Mar 19.|Hopwood P, Haviland J, Mills J, Sumo G, M Bliss J; START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START Trial (Standardisation of Breast Radiotherapy Trial). Breast. 2007 Jun;16(3):241-51. Epub 2007 Jan 19. Erratum in: Breast. 2008 Feb;17(1):115. START Trial Management Group [added].|Venables K, Miles EA, Aird EG, Hoskin PJ; START Trial Management Group. The use of in vivo thermoluminescent dosimeters in the quality assurance programme for the START breast fractionation trial. Radiother Oncol. 2004 Jun;71(3):303-10.","\tBreast Cancer\tradiation therapy\tNA\tNA\tNA\tRadiation\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","NA","NA"]
["NCT00005588","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20138809|17236771|15172146","Hopwood P, Haviland JS, Sumo G, Mills J, Bliss JM, Yarnold JR; START Trial Management Group. Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncol. 2010 Mar;11(3):231-40. doi: 10.1016/S1470-2045(09)70382-1. Epub 2010 Feb 6.|Hopwood P, Haviland J, Mills J, Sumo G, M Bliss J; START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START Trial (Standardisation of Breast Radiotherapy Trial). Breast. 2007 Jun;16(3):241-51. Epub 2007 Jan 19. Erratum in: Breast. 2008 Feb;17(1):115. START Trial Management Group [added].|Venables K, Miles EA, Aird EG, Hoskin PJ; START Trial Management Group. The use of in vivo thermoluminescent dosimeters in the quality assurance programme for the START breast fractionation trial. Radiother Oncol. 2004 Jun;71(3):303-10.","\tBreast Cancer\tradiation therapy\tNA\tNA\tNA\tRadiation\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","NA","NA"]
["NCT00005590","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16148284,"Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A; Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/- Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005 Sep 8;353(10):988-98.","\tBrain and Central Nervous System Tumors|Breast Cancer|Extragonadal Germ Cell Tumor|Infection|Lung Cancer|Lymphoma|Ovarian Cancer|Small Intestine Cancer|Testicular Germ Cell Tumor|Unspecified Adult Solid Tumor, Protocol Specific\tlevofloxacin\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","nervous system neoplasms|neoplasms|infection|neoplasms, germ cell and embryonal|lung neoplasms|intestinal neoplasms|central nervous system neoplasms|lymphoma","levofloxacin|ofloxacin","NA"]
["NCT00005593","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Cooper BW, Ksenich P, Koc O, et al.: A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan (FCT) for relapsed/refractory acute leukemia (RAL) and advanced myelodysplastic syndromes (MDS). [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1207, 2001.","\tLeukemia|Myelodysplastic Syndromes\tcarboplatin|fludarabine phosphate|topotecan hydrochloride\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","preleukemia|syndrome|leukemia|myelodysplastic syndromes","carboplatin|topotecan|fludarabine phosphate|fludarabine","NA"]
["NCT00005596","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Chen I, Harvey R, Mullighan CG, et al.: Relationship of CRLF2 expression and outcome in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): A report from the Children's Oncology Group. [Abstract] J Clin Oncol 29 (Suppl 15): A-9505, 2011.","\tLeukemia\tcyclophosphamide|cytarabine|daunorubicin hydrochloride|dexamethasone|leucovorin calcium|mercaptopurine|methotrexate|pegaspargase|thioguanine|vincristine sulfate\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug\tAll\t","Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia","Interventional","Completed","Phase 3",4,1076,"leukemia, lymphoid|leukemia|precursor cell lymphoblastic leukemia-lymphoma","leucovorin|thioguanine|mercaptopurine|dexamethasone|cyclophosphamide|methotrexate|vincristine|daunorubicin|pegaspargase|levoleucovorin|cytarabine","NA"]
["NCT00005599","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18270704,"Ku GY, Ilson DH, Schwartz LH, Capanu M, O'Reilly E, Shah MA, Kelsen DP, Schwartz GK. Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother Pharmacol. 2008 Oct;62(5):875-80. doi: 10.1007/s00280-008-0677-y. Epub 2008 Feb 13.","\tEsophageal Cancer|Gastric Cancer\tbryostatin 1|paclitaxel\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","esophageal neoplasms|stomach neoplasms","paclitaxel|bryostatin 1","NA"]
["NCT00005601","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18569634|NA","Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef IN, LaPlant BR, Michalak JC, Salim M, Dalton RJ, Moore DF Jr, Reeder CB; North Central Cancer Treatment Group. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma. 2008 Jun;49(6):1074-80. doi: 10.1080/10428190801993470.|Witzig TE, Geyer SM, Kurtin PJ, et al.: Salvage chemotherapy with rituximab DHAP (RDHAP) for relapsed non-hodgkin lymphoma (NHL): a phase II trial in the North Central Cancer Treatment Group. [Abstract] J Clin Oncol 24 (Suppl 18): A-7574, 440s, 2006.","\tLymphoma\trituximab|cisplatin|cytarabine|dexamethasone|sargramostim\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma, non-hodgkin|lymphoma","cytarabine|dexamethasone|rituximab|sargramostim","NA"]
["NCT00005603","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21360654|21680795|20139093|19880498|NA|NA|NA|NA|NA","Bowman WP, Larsen EL, Devidas M, Linda SB, Blach L, Carroll AJ, Carroll WL, Pullen DJ, Shuster J, Willman CL, Winick N, Camitta BM, Hunger SP, Borowitz MJ. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906. Pediatr Blood Cancer. 2011 Oct;57(4):569-77. doi: 10.1002/pbc.22944. Epub 2011 Feb 25.|Zhang J, Mullighan CG, Harvey RC, Wu G, Chen X, Edmonson M, Buetow KH, Carroll WL, Chen IM, Devidas M, Gerhard DS, Loh ML, Reaman GH, Relling MV, Camitta BM, Bowman WP, Smith MA, Willman CL, Downing JR, Hunger SP. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011 Sep 15;118(11):3080-7. doi: 10.1182/blood-2011-03-341412. Epub 2011 Jun 16.|Harvey RC, Mullighan CG, Chen IM, Wharton W, Mikhail FM, Carroll AJ, Kang H, Liu W, Dobbin KK, Smith MA, Carroll WL, Devidas M, Bowman WP, Camitta BM, Reaman GH, Hunger SP, Downing JR, Willman CL. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010 Jul 1;115(26):5312-21. doi: 10.1182/blood-2009-09-245944. Epub 2010 Feb 4.|Kang H, Chen IM, Wilson CS, Bedrick EJ, Harvey RC, Atlas SR, Devidas M, Mullighan CG, Wang X, Murphy M, Ar K, Wharton W, Borowitz MJ, Bowman WP, Bhojwani D, Carroll WL, Camitta BM, Reaman GH, Smith MA, Downing JR, Hunger SP, Willman CL. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood. 2010 Feb 18;115(7):1394-405. doi: 10.1182/blood-2009-05-218560. Epub 2009 Oct 30.|Mullighan CG, Morin R, Zhang J, et al.: Next generation transcriptomic resequencing identifies novel genetic alterations in high-risk (HR) childhood acute lymphoblastic leukemia (ALL): A report from the Children's Oncology Group (COG) HR ALL TARGET Project. [Abstract] Blood 114 (22): A-704, 2009.|Zhang J, Mullighan CG, Harvey RC, et al.: Mutations in the RAS signaling, B-cell development, TP53/RB1, and JAK signaling pathways are common in high risk B-precursor childhood acute lymphoblastic leukemia (ALL): A report from the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project. [Abstract] Blood 114 (22): A-85, 2009.|Harvey RC, Davidson GS, Wang X, et al.: Expression profiling identifies novel genetic subgroups with distinct clinical features and outcome in high-risk pediatric precursor B acute lymphoblastic leukemia (B-ALL). A Children's Oncology Group study. [Abstract] Blood 110 (11): A-1430, 2007.|Kang H, Bedrick EJ, Chen IM, et al.: Molecular classifiers for prediction of minimal residual disease (MRD) and event free survival (EFS) improve risk assignment at diagnosis in pediatric high-risk B precursor acute lymphoblastic leukemia (ALL): a Childrens Oncology Group study. [Abstract] Blood 110 (11): A-1422, 2007.|Borowitz MJ, Devidas M, Bowman WP, et al.: Prognostic significance of minimal residual disease (MRD) in children with high risk acute lymphoblastic leukemia(ALL): a Children's Oncology Group study. [Abstract] Blood 106 (11): A-85, 2005.","\tLeukemia\tasparaginase|cyclophosphamide|cytarabine|daunorubicin hydrochloride|dexamethasone|doxorubicin hydrochloride|mercaptopurine|methotrexate|prednisone|thioguanine|vincristine sulfate\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia|precursor cell lymphoblastic leukemia-lymphoma|leukemia, lymphoid","liposomal doxorubicin|prednisone|dexamethasone|cytarabine|daunorubicin|mercaptopurine|vincristine|methotrexate|cyclophosphamide|doxorubicin|asparaginase|thioguanine","NA"]
["NCT00005609","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19751237|15370249|15493038","Gertz MA, Abonour R, Heffner LT, Greipp PR, Uno H, Rajkumar SV. Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br J Haematol. 2009 Dec;147(5):677-80. doi: 10.1111/j.1365-2141.2009.07892.x. Epub 2009 Sep 14.|Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma. 2004 Oct;45(10):2047-55.|Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole DH, Gertz MA; Eastern Cooperative Oncology Group. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004 Dec 1;101(11):2593-8.","\tLymphoma\trituximab\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","waldenstrom macroglobulinemia","rituximab","NA"]
["NCT00005627","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15671557,"Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2005 Jan 1;11(1):284-9.","\tProstate Cancer\tcarboplatin|docetaxel|estramustine phosphate sodium\tNA\tNA\tNA\tDrug|Drug|Drug\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","carboplatin|docetaxel|estramustine","NA"]
["NCT00005631","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14739217,"Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, O'Connor O, Filippa DA, Teruya-Feldstein J, Gencarelli A, Qin J, Waxman A, Yahalom J, Moskowitz CH. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004 May 15;103(10):3684-8. Epub 2004 Jan 22.","\tLymphoma\tfilgrastim|rituximab|carboplatin|etoposide|ifosfamide\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma","rituximab|etoposide|ifosfamide|carboplatin","NA"]
["NCT00005638","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12885811,"Ilson DH, Bains M, Kelsen DP, O'Reilly E, Karpeh M, Coit D, Rusch V, Gonen M, Wilson K, Minsky BD. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol. 2003 Aug 1;21(15):2926-32.","\tEsophageal Cancer|Gastric Cancer\tcisplatin|irinotecan hydrochloride|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","esophageal neoplasms|stomach neoplasms","irinotecan","NA"]
["NCT00005639","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19789320,"Lin J, Gilbert J, Rudek MA, Zwiebel JA, Gore S, Jiemjit A, Zhao M, Baker SD, Ambinder RF, Herman JG, Donehower RC, Carducci MA. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res. 2009 Oct 1;15(19):6241-9. doi: 10.1158/1078-0432.CCR-09-0567. Epub 2009 Sep 29.","\tLymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific\tAzacitidine Injection|sodium phenylbutyrate\tNA\tNA\tNA\tDrug|Drug\tAll\t","Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment","Interventional","Completed","Phase 1",3,34,"intestinal neoplasms|lymphoma","4-phenylbutyric acid|azacitidine","NA"]
["NCT00005642","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12231519,"Stopeck A, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res. 2002 Sep;8(9):2798-805.","\tUnspecified Adult Solid Tumor, Protocol Specific\tsemaxanib\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","NA","semaxinib","NA"]
["NCT00005643","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15721421,"Sutton G, Blessing J, Hanjani P, Kramer P; Gynecologic Oncology Group. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 2005 Mar;96(3):749-52.","\tEndometrial Cancer|Sarcoma\tpegylated liposomal doxorubicin hydrochloride\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","sarcoma|endometrial neoplasms|leiomyosarcoma","doxorubicin|liposomal doxorubicin","NA"]
["NCT00005646","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18303437|NA","Graziano SL, Herndon JE 2nd, Socinski MA, Wang X, Watson D, Vokes E, Green MR; Cancer and Leukemia Group B. Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901. J Thorac Oncol. 2008 Feb;3(2):158-62. doi: 10.1097/JTO.0b013e318161225e.|Graziano SL, Socinski MA, Herndon JE, et al.: Dose-dense weekly paclitaxel (P) in extensive stage small cell lung cancer (ES-SCLC): Cancer and Leukemia Group B (CALGB) 39901. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2598, 646, 2003.","\tLung Cancer\tpaclitaxel\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|small cell lung carcinoma","paclitaxel","NA"]
["NCT00005649","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15197193,"Gradishar WJ, Meza LA, Amin B, Samid D, Hill T, Chen YM, Lower EE, Marcom PK. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. J Clin Oncol. 2004 Jun 15;22(12):2321-7.","\tBreast Cancer\tcapecitabine|paclitaxel\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","paclitaxel|capecitabine","NA"]
["NCT00005711","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","9006232|8193683|10980046|NA|NA","Hendricson WD, Wood PR, Hidalgo HA, Ramirez AG, Kromer ME, Selva M, Parcel G. Implementation of individualized patient education for Hispanic children with asthma. Patient Educ Couns. 1996 Nov;29(2):155-65.|Hendricson WD, Wood PR, Hidalgo HA, Kromer ME, Parcel GS, Ramirez AG. Implementation of a physician education intervention. The Childhood Asthma Project. Arch Pediatr Adolesc Med. 1994 Jun;148(6):595-601.|Kromer ME, Prihoda TJ, Hidalgo HA, Wood PR. Assessing quality of life in Mexican-American children with asthma: impact-on-family and functional status. J Pediatr Psychol. 2000 Sep;25(6):415-26.|Hidalgo H, Prihoda T, Arfken C, Evans D, Hanson J, Lapidus J, Malveaux F, Mellins R, Murphy S, Ramos C, Rand C, Strunk R, Sussman L, Thompson L, Wood P. Impact of home smoke exposure on black and hispanic children with asthma: a multi-center study. 1996. p. A420. (Am J Respir Crit Care Med; vol. 153).|Wood PR, Hidalgo HA, Prihoda TJ, Kromer ME, Hendricson WD, Ramirez AG, Marinez YM. Asthma in hispanic children: a controlled study of the impact of patient education on morbidity. 1996. p. A276. (Am J Respir Crit Care Med; vol. 153).","\tAsthma|Lung Diseases\tAsthma self-management education\tParallel Assignment\tTreatment\tRandomized\tBehavioral\tAll\t","Intervention for Hispanic Children With Asthma","Interventional","Completed","N/A",2,145,"lung diseases|asthma","NA","NA"]
["NCT00005762","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16048950,"Morse GD, Rosenkranz S, Para MF, Segal Y, Difrancesco R, Adams E, Brizz B, Yarasheski KE, Reichman RC. Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals. Antimicrob Agents Chemother. 2005 Aug;49(8):3373-81.","\tHIV Infections\tIndinavir sulfate|Ritonavir|Amprenavir|Nelfinavir mesylate|Efavirenz|Saquinavir\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","efavirenz|amprenavir|indinavir|ritonavir|saquinavir|nelfinavir","NA"]
["NCT00005772","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16221780|12165594|17079582|18534246|18720323|18762517|18829776|19020525|19252411|19948631|20921569|3124102","Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan EF, Fanaroff AA, Poole WK, Wright LL, Higgins RD, Finer NN, Carlo WA, Duara S, Oh W, Cotten CM, Stevenson DK, Stoll BJ, Lemons JA, Guillet R, Jobe AH; National Institute of Child Health and Human Development Neonatal Research Network. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med. 2005 Oct 13;353(15):1574-84.|Shankaran S, Laptook A, Wright LL, Ehrenkranz RA, Donovan EF, Fanaroff AA, Stark AR, Tyson JE, Poole K, Carlo WA, Lemons JA, Oh W, Stoll BJ, Papile LA, Bauer CR, Stevenson DK, Korones SB, McDonald S. Whole-body hypothermia for neonatal encephalopathy: animal observations as a basis for a randomized, controlled pilot study in term infants. Pediatrics. 2002 Aug;110(2 Pt 1):377-85.|Ambalavanan N, Carlo WA, Shankaran S, Bann CM, Emrich SL, Higgins RD, Tyson JE, O'Shea TM, Laptook AR, Ehrenkranz RA, Donovan EF, Walsh MC, Goldberg RN, Das A; National Institute of Child Health and Human Development Neonatal Research Network. Predicting outcomes of neonates diagnosed with hypoxemic-ischemic encephalopathy. Pediatrics. 2006 Nov;118(5):2084-93.|Oh W, Perritt R, Shankaran S, Merritts M, Donovan EF, Ehrenkranz RA, O'Shea TM, Tyson JE, Laptook AR, Das A, Higgins RD. Association between urinary lactate to creatinine ratio and neurodevelopmental outcome in term infants with hypoxic-ischemic encephalopathy. J Pediatr. 2008 Sep;153(3):375-8. doi: 10.1016/j.jpeds.2008.03.041. Epub 2008 May 9.|Mietzsch U, Parikh NA, Williams AL, Shankaran S, Lasky RE. Effects of hypoxic-ischemic encephalopathy and whole-body hypothermia on neonatal auditory function: a pilot study. Am J Perinatol. 2008 Aug;25(7):435-41. doi: 10.1055/s-0028-1083842. Epub 2008 Aug 21.|Laptook A, Tyson J, Shankaran S, McDonald S, Ehrenkranz R, Fanaroff A, Donovan E, Goldberg R, O'Shea TM, Higgins RD, Poole WK; National Institute of Child Health and Human Development Neonatal Research Network. Elevated temperature after hypoxic-ischemic encephalopathy: risk factor for adverse outcomes. Pediatrics. 2008 Sep;122(3):491-9. doi: 10.1542/peds.2007-1673.|Shankaran S, Pappas A, Laptook AR, McDonald SA, Ehrenkranz RA, Tyson JE, Walsh M, Goldberg RN, Higgins RD, Das A; NICHD Neonatal Research Network. Outcomes of safety and effectiveness in a multicenter randomized, controlled trial of whole-body hypothermia for neonatal hypoxic-ischemic encephalopathy. Pediatrics. 2008 Oct;122(4):e791-8. doi: 10.1542/peds.2008-0456.|Parikh NA, Lasky RE, Garza CN, Bonfante-Mejia E, Shankaran S, Tyson JE. Volumetric and anatomical MRI for hypoxic-ischemic encephalopathy: relationship to hypothermia therapy and neurosensory impairments. J Perinatol. 2009 Feb;29(2):143-9. doi: 10.1038/jp.2008.184. Epub 2008 Nov 20.|Lasky RE, Parikh NA, Williams AL, Padhye NS, Shankaran S. Changes in the PQRST intervals and heart rate variability associated with rewarming in two newborns undergoing hypothermia therapy. Neonatology. 2009;96(2):93-5. doi: 10.1159/000205385. Epub 2009 Mar 2.|Laptook AR, Shankaran S, Ambalavanan N, Carlo WA, McDonald SA, Higgins RD, Das A; Hypothermia Subcommittee of the NICHD Neonatal Research Network. Outcome of term infants using apgar scores at 10 minutes following hypoxic-ischemic encephalopathy. Pediatrics. 2009 Dec;124(6):1619-26. doi: 10.1542/peds.2009-0934.|Kwon JM, Guillet R, Shankaran S, Laptook AR, McDonald SA, Ehrenkranz RA, Tyson JE, O'Shea TM, Goldberg RN, Donovan EF, Fanaroff AA, Poole WK, Higgins RD, Walsh MC; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Clinical seizures in neonatal hypoxic-ischemic encephalopathy have no independent impact on neurodevelopmental outcome: secondary analyses of data from the neonatal research network hypothermia trial. J Child Neurol. 2011 Mar;26(3):322-8. doi: 10.1177/0883073810380915. Epub 2010 Oct 4.|MacKay VL, Welch SK, Insley MY, Manney TR, Holly J, Saari GC, Parker ML. The Saccharomyces cerevisiae BAR1 gene encodes an exported protein with homology to pepsin. Proc Natl Acad Sci U S A. 1988 Jan;85(1):55-9.","\tHypoxia-Ischemia, Brain|Infant, Newborn\tInduced hypothermia|Control\tParallel Assignment\tTreatment\tRandomized\tDevice|Device\tAll\t","Whole-Body Cooling for Birth Asphyxia in Term Infants","Interventional","Completed","Phase 3",2,208,"ischemia|hypoxia-ischemia, brain|brain ischemia|hypoxia","NA","NA"]
["NCT00005773","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","14993550|17307536","Konduri GG, Solimano A, Sokol GM, Singer J, Ehrenkranz RA, Singhal N, Wright LL, Van Meurs K, Stork E, Kirpalani H, Peliowski A; Neonatal Inhaled Nitric Oxide Study Group. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure. Pediatrics. 2004 Mar;113(3 Pt 1):559-64.|Konduri GG, Vohr B, Robertson C, Sokol GM, Solimano A, Singer J, Ehrenkranz RA, Singhal N, Wright LL, Van Meurs K, Stork E, Kirpalani H, Peliowski A, Johnson Y; Neonatal Inhaled Nitric Oxide Study Group. Early inhaled nitric oxide therapy for term and near-term newborn infants with hypoxic respiratory failure: neurodevelopmental follow-up. J Pediatr. 2007 Mar;150(3):235-40, 240.e1.","\tHypertension, Pulmonary|Infant, Newborn|Persistent Fetal Circulation Syndrome|Pneumonia, Aspiration|Respiratory Distress Syndrome, Newborn|Respiratory Insufficiency\tInhaled Nitric Oxide|Standard iNO therapy\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Early Inhaled Nitric Oxide for Respiratory Failure in Newborns","Interventional","Terminated","Phase 3",2,302,"hypertension|hypertension, pulmonary|respiratory distress syndrome, adult|syndrome|respiratory distress syndrome, newborn|pneumonia|persistent fetal circulation syndrome|pulmonary valve insufficiency|pneumonia, aspiration|respiratory insufficiency","nitric oxide","NA"]
["NCT00005775","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12600870|15121931|16356432|16615955|16818526|17908750|18716628|19403482","Poindexter BB, Ehrenkranz RA, Stoll BJ, Koch MA, Wright LL, Oh W, Papile LA, Bauer CR, Carlo WA, Donovan EF, Fanaroff AA, Korones SB, Laptook AR, Shankaran S, Stevenson DK, Tyson JE, Lemons JA; National Institute of Child Health and Human Development Neonatal Research Network. Effect of parenteral glutamine supplementation on plasma amino acid concentrations in extremely low-birth-weight infants. Am J Clin Nutr. 2003 Mar;77(3):737-43.|Poindexter BB, Ehrenkranz RA, Stoll BJ, Wright LL, Poole WK, Oh W, Bauer CR, Papile LA, Tyson JE, Carlo WA, Laptook AR, Narendran V, Stevenson DK, Fanaroff AA, Korones SB, Shankaran S, Finer NN, Lemons JA; National Institute of Child Health and Human Development Neonatal Research Network. Parenteral glutamine supplementation does not reduce the risk of mortality or late-onset sepsis in extremely low birth weight infants. Pediatrics. 2004 May;113(5):1209-15.|Oh W, Poindexter BB, Perritt R, Lemons JA, Bauer CR, Ehrenkranz RA, Stoll BJ, Poole K, Wright LL; Neonatal Research Network. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr. 2005 Dec;147(6):786-90.|Poindexter BB, Langer JC, Dusick AM, Ehrenkranz RA; National Institute of Child Health and Human Development Neonatal Research Network. Early provision of parenteral amino acids in extremely low birth weight infants: relation to growth and neurodevelopmental outcome. J Pediatr. 2006 Mar;148(3):300-305.|Vohr BR, Poindexter BB, Dusick AM, McKinley LT, Wright LL, Langer JC, Poole WK; NICHD Neonatal Research Network. Beneficial effects of breast milk in the neonatal intensive care unit on the developmental outcome of extremely low birth weight infants at 18 months of age. Pediatrics. 2006 Jul;118(1):e115-23.|Vohr BR, Poindexter BB, Dusick AM, McKinley LT, Higgins RD, Langer JC, Poole WK; National Institute of Child Health and Human Development National Research Network. Persistent beneficial effects of breast milk ingested in the neonatal intensive care unit on outcomes of extremely low birth weight infants at 30 months of age. Pediatrics. 2007 Oct;120(4):e953-9.|Meinzen-Derr J, Poindexter B, Wrage L, Morrow AL, Stoll B, Donovan EF. Role of human milk in extremely low birth weight infants' risk of necrotizing enterocolitis or death. J Perinatol. 2009 Jan;29(1):57-62. doi: 10.1038/jp.2008.117. Epub 2008 Aug 21.|Peralta-Carcelen M, Moses M, Adams-Chapman I, Gantz M, Vohr BR; NICHD Neonatal Research Network; National Institutes of Health. Stability of neuromotor outcomes at 18 and 30 months of age after extremely low birth weight status. Pediatrics. 2009 May;123(5):e887-95. doi: 10.1542/peds.2008-0135.","\tInfant, Low Birth Weight|Infant, Newborn|Infant, Premature|Infant, Small for Gestational Age|Sepsis\tGlutamine|Placebo\tNA\tNA\tNA\tDrug|Drug\tAll\t","Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants","Interventional","Completed","Phase 3",2,1433,"premature birth|birth weight","amino-acid, glucose, and electrolyte solution","NA"]
["NCT00005776","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","9036320|9190553|10802492|11416871|14510322","Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med. 1997 Feb 27;336(9):597-604. Erratum in: N Engl J Med 1997 Aug 7;337(6):434.|Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Pediatrics. 1997 Jun;99(6):838-45.|Inhaled nitric oxide in term and near-term infants: neurodevelopmental follow-up of the neonatal inhaled nitric oxide study group (NINOS). J Pediatr. 2000 May;136(5):611-7.|Sokol GM, Fineberg NS, Wright LL, Ehrenkranz RA. Changes in arterial oxygen tension when weaning neonates from inhaled nitric oxide. Pediatr Pulmonol. 2001 Jul;32(1):14-9.|Sokol GM, Ehrenkranz RA. Inhaled nitric oxide therapy in neonatal hypoxic respiratory failure: insights beyond primary outcomes. Semin Perinatol. 2003 Aug;27(4):311-9. Review.","\tHypertension, Pulmonary|Infant, Newborn|Persistent Fetal Circulation Syndrome|Pneumonia, Aspiration|Respiratory Distress Syndrome, Newborn|Respiratory Insufficiency\tInhaled nitric oxide|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Inhaled Nitric Oxide Study for Respiratory Failure in Newborns","Interventional","Terminated","Phase 3",2,235,"pulmonary valve insufficiency|respiratory distress syndrome, newborn|hypertension, pulmonary|hypertension|pneumonia, aspiration|persistent fetal circulation syndrome|respiratory distress syndrome, adult|respiratory insufficiency|pneumonia|syndrome","nitric oxide","NA"]
["NCT00005777","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12219057|11150359","Carlo WA, Stark AR, Wright LL, Tyson JE, Papile LA, Shankaran S, Donovan EF, Oh W, Bauer CR, Saha S, Poole WK, Stoll B. Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants. J Pediatr. 2002 Sep;141(3):370-4.|Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S, Donovan EF, Oh W, Bauer CR, Saha S, Poole WK, Stoll BJ; National Institute of Child Health and Human Development Neonatal Research Network. Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med. 2001 Jan 11;344(2):95-101.","\tBronchopulmonary Dysplasia|Infant, Low Birth Weight|Infant, Newborn|Infant, Premature|Infant, Small for Gestational Age|Respiratory Distress Syndrome\tMinimal mechanical ventilation management|Routine mechanical ventilation management|Dexamethasone|Placebo\tNA\tNA\tNA\tProcedure|Procedure|Drug|Drug\tAll\t","Minimal Breathing Support and Early Steroids to Prevent Chronic Lung Disease in Extremely Premature Infants (SAVE)","Interventional","Terminated","Phase 3",4,220,"bronchopulmonary dysplasia|lung diseases|birth weight|respiratory distress syndrome, adult|premature birth|respiratory distress syndrome, newborn","dexamethasone","NA"]
["NCT00005791","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19219674,"Ku GY, O'Reilly EM, Saltz LB, Schrag D, Maki RG, Kelsen DP, Ilson DH. Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors. Cancer Invest. 2009 May;27(4):402-6. doi: 10.1080/07357900802406327.","\tUnspecified Adult Solid Tumor, Protocol Specific\tcisplatin|fluorouracil|irinotecan hydrochloride\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","fluorouracil|irinotecan","NA"]
["NCT00005807","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12114401,"McDaid HM, Mani S, Shen HJ, Muggia F, Sonnichsen D, Horwitz SB. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res. 2002 Jul;8(7):2035-43.","\tBreast Cancer|Ovarian Cancer|Unspecified Adult Solid Tumor, Protocol Specific\tBMS-247550\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","breast neoplasms|carcinoma, ovarian epithelial|ovarian neoplasms","epothilones","NA"]
["NCT00005809","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12949715,"Johnson CD, Toledano AY, Herman BA, Dachman AH, McFarland EG, Barish MA, Brink JA, Ernst RD, Fletcher JG, Halvorsen RA Jr, Hara AK, Hopper KD, Koehler RE, Lu DS, Macari M, Maccarty RL, Miller FH, Morrin M, Paulson EK, Yee J, Zalis M; American College of Radiology Imaging Network A6656. Computerized tomographic colonography: performance evaluation in a retrospective multicenter setting. Gastroenterology. 2003 Sep;125(3):688-95.","\tColorectal Cancer\tcomputed tomography|diagnostic colonoscopy\tNA\tNA\tNA\tProcedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","NA","NA"]
["NCT00005810","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","14669278|NA","Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ; Cancer and Leukemia Group B 99813. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer. 2003 Dec 15;98(12):2592-8.|Oh WK, Halabi S, Kelly WK, et al.: A phase II study of estramustine, docetaxel, and carboplatin (EDC) with G-CSF support in men with hormone refractory prostate cancer (HRPC): CALGB 99813. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-779, 2002.","\tProstate Cancer\tfilgrastim|carboplatin|docetaxel|estramustine phosphate sodium\tNA\tNA\tNA\tBiological|Drug|Drug|Drug\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","estramustine|docetaxel|carboplatin","NA"]
["NCT00005812","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Davis TH, Fadul CE, Glantz MJ, et al.: Pilot phase II trial of temozolomide for leptomeningeal metastases: preliminary report. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-460, 2003. ISBN 1932312021","\tBrain Tumors|Central Nervous System Tumors|Leptomeningeal Metastases\ttemozolomide\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasm metastasis|central nervous system neoplasms|meningeal carcinomatosis|neoplasms, second primary|nervous system neoplasms|neoplasms","temozolomide","NA"]
["NCT00005815","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12947072|12039921","Hwu WJ, Krown SE, Menell JH, Panageas KS, Merrell J, Lamb LA, Williams LJ, Quinn CJ, Foster T, Chapman PB, Livingston PO, Wolchok JD, Houghton AN. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol. 2003 Sep 1;21(17):3351-6.|Hwu WJ, Krown SE, Panageas KS, Menell JH, Chapman PB, Livingston PO, Williams LJ, Quinn CJ, Houghton AN. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol. 2002 Jun 1;20(11):2610-5. Erratum in: J Clin Oncol 2002 Aug 1;20(15):3361.","\tIntraocular Melanoma|Melanoma (Skin)\ttemozolomide|thalidomide\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","melanoma","temozolomide|thalidomide","NA"]
["NCT00005816","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12727829,"Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 2003 May 1;63(9):2127-33.","\tKidney Cancer\ttherapeutic autologous dendritic cells|conventional surgery\tNA\tNA\tNA\tBiological|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","kidney neoplasms|carcinoma, renal cell","NA","NA"]
["NCT00005820","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15464920,"Amin A, Halabi S, Gelmann EP, Stadler W, Vogelzang N, Small E. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. Urol Oncol. 2004 Sep-Oct;22(5):398-403.","\tProstate Cancer\tnitrocamptothecin\tNA\tNA\tNA\tDrug\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","NA","NA"]
["NCT00005823","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19291085|17315155|NA|NA|NA","Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M, Sellwood E, Pallis M, Russell N, Hills RK, Wheatley K; United Kingdom National Cancer Research Institute Haematological Oncology Study Group. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol. 2009 May;145(3):318-32. doi: 10.1111/j.1365-2141.2009.07604.x. Epub 2009 Mar 8.|Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley K. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007 Mar 15;109(6):1114-24.|Burnett AK, Milligan DW, Prentice AG, et al.: Modification or dose or treatment duration has no impact on outcome of AML in older patients: preliminary results of the UK NCRI AML14 trial. [Abstract] Blood 106 (11): A-543, 2005.|Burnett AK, Milligan D, Prentice AG, et al.: Low dose Ara-C versus hydroxyurea with or without retinoid in older patients not considered fit for intensive chemotherapy: the UK NCRI AML14 trial. [Abstract] Blood 104 (11): A-872, 2004.|Pallis M, Truran L, Grundy M, et al.: P-Glycoprotein overexpresion and internal tandem duplications of FLT3 are characteristic of discrete populations of elderly AML patients. [Abstract] Blood 104 (11): A-196, 2004.","\tLeukemia|Myelodysplastic/Myeloproliferative Neoplasms|Myelodysplastic Syndromes\tcytarabine|daunorubicin hydrochloride|etoposide|hydroxyurea|idarubicin|mitoxantrone hydrochloride|thioguanine|tretinoin|valspodar\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, myeloid|syndrome|leukemia|leukemia, myeloid, acute|myelodysplastic syndromes|myelodysplastic-myeloproliferative diseases|preleukemia|myeloproliferative disorders","tretinoin|cytarabine|thioguanine|hydroxyurea|idarubicin|etoposide|daunorubicin|mitoxantrone","NA"]
["NCT00005824","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18158962,"Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ, Aboulafia DM, Scadden DT. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant. 2008 Jan;14(1):59-66.","\tLymphoma\tfilgrastim|busulfan|cyclophosphamide|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Drug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|lymphoma, aids-related","cyclophosphamide|busulfan","NA"]
["NCT00005828","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12627508,"Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY, Flynn PJ. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer. 2003 Mar 15;97(6):1442-6.","\tProstate Cancer\tgreen tea extract\tNA\tNA\tNA\tDietary Supplement\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","NA","NA"]
["NCT00005829","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Call TG, Constantinou CL, Kahanic SP, et al.: NCCTG trial of gemcitabine for relapsed B-cell chronic lymphocytic leukemia. [Abstract] J Clin Oncol 22 (Suppl 14): A-6726, 613s, 2004.","\tLeukemia\tgemcitabine hydrochloride\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, lymphoid|leukemia|leukemia, lymphocytic, chronic, b-cell","gemcitabine","NA"]
["NCT00005832","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16133800|NA","Macdonald JS, McCoy S, Whitehead RP, Iqbal S, Wade JL 3rd, Giguere JK, Abbruzzese JL. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs. 2005 Oct;23(5):485-7.|Macdonald JS, Chansky K, Whitehead R, et al.: A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer. A Southwest Oncology Group (SWOG) study. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-548, 2002.","\tPancreatic Cancer\tR115777\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","pancreatic neoplasms","tipifarnib","NA"]
["NCT00005833","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16683076,"Whitehead RP, McCoy S, Macdonald JS, Rivkin SE, Neubauer MA, Dakhil SR, Lenz HJ, Tanaka MS, Abbruzzese JL; Southwest Oncology Group. Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study. Invest New Drugs. 2006 Jul;24(4):335-41.","\tColorectal Cancer\tR115777\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","tipifarnib","NA"]
["NCT00005837","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12821360,"Fracasso PM, Blessing JA, Wolf J, Rocereto TF, Berek JS, Waggoner S. Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 2003 Jul;90(1):177-80.","\tCervical Cancer\toxaliplatin\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","uterine cervical neoplasms","oxaliplatin","NA"]
["NCT00005841","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12684398,"Pullarkat V, Lee PP, Scotland R, Rubio V, Groshen S, Gee C, Lau R, Snively J, Sian S, Woulfe SL, Wolfe RA, Weber JS. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res. 2003 Apr;9(4):1301-12.","\tIntraocular Melanoma|Melanoma (Skin)\tMART-1 antigen|gp100 antigen|incomplete Freund's adjuvant|progenipoietin|tyrosinase peptide\tNA\tNA\tNA\tBiological|Biological|Biological|Biological|Biological\tAll\t","NA","NA","NA","NA","NA","NA","melanoma","freund's adjuvant","NA"]
["NCT00005842","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Schwartz G, Rowinsky EK, Rha SY, et al.: A phase I, pharmacokinetic, and biologic correlative study of R115777 and trastuzumab (herceptin) in patients with advanced cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-322, 2001.","\tCancer\ttrastuzumab|tipifarnib\tNA\tNA\tNA\tBiological|Drug\tAll\t","NA","NA","NA","NA","NA","NA","NA","trastuzumab|tipifarnib","NA"]
["NCT00005843","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12663718,"Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol. 2003 Apr 1;21(7):1301-6.","\tPancreatic Cancer\ttipifarnib\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","pancreatic neoplasms","tipifarnib","NA"]
["NCT00005844","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17538173|NA|NA","Spunt SL, Freeman BB 3rd, Billups CA, McPherson V, Khan RB, Pratt CB, Stewart CF. Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors. J Clin Oncol. 2007 Jun 1;25(16):2274-80.|Iacono LC, Spunt SL, Pratt CB, et al.: Pharmacokinetics of oxaliplatin in children with solid tumors. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-2170, 89b, 2002.|Pratt CB, Spunt SL, Thompson SJ, et al.: Phase I Study of Oxaliplatin in Pediatric Patients with Malignant Solid Tumors. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1498, 2001.","\tUnspecified Childhood Solid Tumor, Protocol Specific\toxaliplatin\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","oxaliplatin","NA"]
["NCT00005847","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20178647,"DiPaola RS, Chen YH, Stein M, Vaughn D, Patrick-Miller L, Carducci M, Roth B, White E, Wilding G. A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899. J Transl Med. 2010 Feb 24;8:20. doi: 10.1186/1479-5876-8-20.","\tProstate Cancer\trecombinant interferon alfa|estramustine phosphate sodium|isotretinoin|mitoxantrone hydrochloride|paclitaxel|vinorelbine ditartrate\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","interferon-alpha|estramustine|paclitaxel|isotretinoin|interferons|mitoxantrone|vinorelbine","NA"]
["NCT00005849","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12581572,"Winegarden JD, Mauer AM, Gajewski TF, Hoffman PC, Krauss S, Rudin CM, Vokes EE. A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer. 2003 Feb;39(2):191-6.","\tLung Cancer\tbryostatin 1|paclitaxel\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|carcinoma, non-small-cell lung","paclitaxel|bryostatin 1","NA"]
["NCT00005857","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15139054,"Lara PN Jr, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Twardowski P, Doroshow JH, Gandara DR. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer. 2004 May 15;100(10):2125-31.","\tProstate Cancer\ttrastuzumab|docetaxel\tNA\tNA\tNA\tBiological|Drug\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","docetaxel|trastuzumab","NA"]
["NCT00005859","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16877733|16170172","Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn KR, Prados MD. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2006 Aug 1;24(22):3651-6.|Cloughesy TF, Kuhn J, Robins HI, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Paquette S, Wright J, Lamborn K, Sebti SM, Prados M. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2005 Sep 20;23(27):6647-56.","\tBrain and Central Nervous System Tumors\ttipifarnib\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","glioma|nervous system neoplasms|central nervous system neoplasms","tipifarnib","NA"]
["NCT00005861","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15975638,"Homesley HD, Blessing JA, Sorosky J, Reid G, Look KY. Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2005 Aug;98(2):294-8.","\tEndometrial Cancer\tpegylated liposomal doxorubicin hydrochloride\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","endometrial neoplasms","doxorubicin|liposomal doxorubicin","NA"]
["NCT00005863","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16484584,"Milligan DW, Wheatley K, Littlewood T, Craig JI, Burnett AK; NCRI Haematological Oncology Clinical Studies Group. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood. 2006 Jun 15;107(12):4614-22. Epub 2006 Feb 16.","\tLeukemia|Myelodysplastic/Myeloproliferative Neoplasms|Myelodysplastic Syndromes\tfilgrastim|cytarabine|daunorubicin hydrochloride|etoposide|fludarabine phosphate|tretinoin\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","preleukemia|myeloproliferative disorders|leukemia|syndrome|myelodysplastic-myeloproliferative diseases|myelodysplastic syndromes","daunorubicin|fludarabine|cytarabine|tretinoin|fludarabine phosphate|etoposide","NA"]
["NCT00005865","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17551300,"Hirsh V, Desjardins P, Needles BM, Rigas JR, Jahanzeb M, Nguyen L, Zembryki D, Leopold LH. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial. Am J Clin Oncol. 2007 Jun;30(3):245-51.","\tLung Cancer\tvinorelbine tartrate\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","vinorelbine","NA"]
["NCT00005868","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16759850|NA|NA","Biesma B, Manegold C, Smit HJ, Willems L, Legrand C, Passioukov A, van Meerbeeck JP, Giaccone G; EORTC Lung Cancer Group. Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984). Eur J Cancer. 2006 Jul;42(10):1399-406. Epub 2006 Jun 8.|Manegold C, Biesma B, Smit H, et al.: Docetaxel and cisplatin as induction chemotherapy in stage IIIA N2 non-small cell lung cancer (NSCLC): an EORTC phase II trial (08984). [Abstract] J Clin Oncol 22 (Suppl 14): A-7166, 657s, 2004.|Manegold C, Biesma B, Debruyne C, et al.: Docetaxel and cisplatin as induction chemotherapy in stage IIIA N2 non-small cell lung cancer (NSCLC): an EORTC phase II trial (08984). [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-2719, 2002.","\tLung Cancer\tcisplatin|docetaxel\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|carcinoma, non-small-cell lung","docetaxel","NA"]
["NCT00005878","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17405999,"Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, Dannenberg AJ, Yang VW, Shar AO, Hawk E, Forastiere AA; Chemoprevention for Barrett's Esophagus Trial Research Group. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst. 2007 Apr 4;99(7):545-57.","\tEsophageal Cancer\tcelecoxib\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","esophageal neoplasms|barrett esophagus","celecoxib","NA"]
["NCT00005887","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16314619|NA|NA|NA|NA|NA","Suh JH, Stea B, Nabid A, Kresl JJ, Fortin A, Mercier JP, Senzer N, Chang EL, Boyd AP, Cagnoni PJ, Shaw E. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol. 2006 Jan 1;24(1):106-14. Epub 2005 Nov 28.|Nabid A, Kresl J, Stea B, et al.: Standard whole brain radiation (WBRT) with supplemental oxygen (O2) with or without RSR13 (efaproxiral) in patients with brain metastases originating from NSCLC: results of a subgroup analysis. [Abstract] J Clin Oncol 22 (Suppl 14): A-7115, 645s, 2004.|Shaw E, Stea B, Pinter T, et al.: Pharmacokinetics (PK) of RSR13 (efaproxiral) predict survival in patients with brain metastases randomized to receive whole brain radiation therapy (WBRT) with or without RSR13 (REACH RT-009). [Abstract] J Clin Oncol 22 (Suppl 14): A-1561, 122s, 2004.|Stea B, Suh J, Shaw E, et al.: Efaproxiral (EFAPROXYN) as an adjunct to whole brain radiation therapy for the treatment of brain metastases originating from breast cancer: updated survival results of the randomized REACH (RT-009) study. [Abstract] Breast Cancer Res Treat 88 (1): A-4064, 2004.|Suh J, Stea BD, Nabid A, et al.: Prognostic factors for survival in patients with brain metastases enrolled on a worldwide phase 3 randomized trial of 538 patients (study RSR13 RT-009). [Abstract] Int J Radiat Oncol Biol Phys 60 (1 Suppl 1): A-60, S165, 2004.|Suh J, Stea B, Nabid A, et al.: Standard whole brain radiation therapy (WBRT) with supplemental oxygen (O2), with or without RSR13 (efaproxiral) in patients with brain metastases: results of the randomized REACH (RT-009) study. [Abstract] J Clin Oncol 22 (Suppl 14): A-1534, 115s, 2004.","\tMetastatic Cancer\tefaproxiral|radiation therapy\tNA\tNA\tNA\tDrug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","neoplasm metastasis","efaproxiral","NA"]
["NCT00005908","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15501952|20012355","Lebowitz PF, Eng-Wong J, Swain SM, Berman A, Merino MJ, Chow CK, Venzon D, Zia F, Danforth D, Liu E, Zujewski J. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res. 2004 Oct 15;10(20):6764-9.|Korde LA, Lusa L, McShane L, Lebowitz PF, Lukes L, Camphausen K, Parker JS, Swain SM, Hunter K, Zujewski JA. Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Breast Cancer Res Treat. 2010 Feb;119(3):685-99. doi: 10.1007/s10549-009-0651-3.","\tBreast Cancer|Breast Neoplasm\tDocetaxel - Dose A|Anastrozole|cyclophosphamide|Docetaxel - Dose B|Doxorubicin hydrochloride|Tamoxifen Citrate|Capecitabine - Dose B|Capecitabine - Dose A\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug\tAll\t","Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer","Interventional","Completed","Phase 2",2,30,"breast neoplasms","cyclophosphamide|liposomal doxorubicin|docetaxel|tamoxifen|doxorubicin|capecitabine|anastrozole","NA"]
["NCT00005915","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17216857|16951642|21297946","Anti-HIV agents. An attempt at treatment interruption--trial CPCRA 064. TreatmentUpdate. 2003 Aug-Sep;15(5):4-5.|Lawrence J, Hullsiek KH, Thackeray LM, Abrams DI, Crane LR, Mayers DL, Jones MC, Saldanha JM, Schmetter BS, Baxter JD. Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study. J Acquir Immune Defic Syndr. 2006 Oct 1;43(2):169-78.|Paquet AC, Baxter J, Weidler J, Lie Y, Lawrence J, Kim R, Bates M, Coakley E, Chappey C. Differences in reversion of resistance mutations to wild-type under structured treatment interruption and related increase in replication capacity. PLoS One. 2011 Jan 31;6(1):e14638. doi: 10.1371/journal.pone.0014638.","\tHIV Infections\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","NA","NA"]
["NCT00005943","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",10890744,"Walsh P, Gonzalez R, Dow S, Elmslie R, Potter T, Glode LM, Baron AE, Balmer C, Easterday K, Allen J, Rosse P. A phase I study using direct combination DNA injections for the immunotherapy of metastatic melanoma. University of Colorado Cancer Center Clinical Trial. Hum Gene Ther. 2000 Jun 10;11(9):1355-68.","\tMelanoma (Skin)\taldesleukin|staphylococcal enterotoxin B\tNA\tNA\tNA\tBiological|Biological\tAll\t","NA","NA","NA","NA","NA","NA","melanoma","aldesleukin","NA"]
["NCT00005945","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|21562038|NA|NA","Matloub Y, Angiolillo A, Bostrom B, et al.: Double delayed intensification (DDI) is equivalent to single DI (SDI) in children with National Cancer Institute (NCI) standard-risk acute lymphoblastic leukemia (SR-ALL) treated on Children's Cancer Group (CCG) clinical trial 1991 (CCG-1991). [Abstract] Blood 108 (11): A-146, 2006.|Matloub Y, Bostrom BC, Hunger SP, Stork LC, Angiolillo A, Sather H, La M, Gastier-Foster JM, Heerema NA, Sailer S, Buckley PJ, Thomson B, Cole C, Nachman JB, Reaman G, Winick N, Carroll WL, Devidas M, Gaynon PS. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011 Jul 14;118(2):243-51. doi: 10.1182/blood-2010-12-322909. Epub 2011 May 11.|Matloub Y, Bostrom BC, Angiolillo AL, et al.: Children with NCI standard risk acute lymphoblastic leukemia (ALL) and TEL-AML1 or favorable chromosome trisomies are almost certain to be cured with graduated intensity therapy: results of the CCG - 1991 study. [Abstract] Blood 114 (22): A-320, 2009.|Matloub Y, Bostrom BC, Hunger SP, et al.: Escalating dose intravenous methotrexate without leucovorin rescue during interim maintenance is superior to oral methotrexate for children with standard risk acute lymphoblastic leukemia (SR-ALL): Children's Oncology Group study 1991. [Abstract] Blood 112 (11): A-9, 2008.","\tLeukemia\tcyclophosphamide|cytarabine|daunorubicin hydrochloride|dexamethasone|doxorubicin hydrochloride|mercaptopurine|methotrexate|pegaspargase|thioguanine|vincristine sulfate|radiation therapy\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Radiation\tAll\t","Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia","Interventional","Completed","Phase 3",7,3054,"leukemia, lymphoid|leukemia|precursor cell lymphoblastic leukemia-lymphoma","cytarabine|mercaptopurine|doxorubicin|daunorubicin|asparaginase|vincristine|liposomal doxorubicin|dexamethasone|cyclophosphamide|thioguanine|methotrexate|pegaspargase","NA"]
["NCT00005947",8265375,4514794,"Hazard Ratio (HR)",1.71,null,"NA",1.13,2.58,95,0.01,"Log Rank",16809734,"Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006 Jul 1;24(19):3089-94.","\tProstate Cancer\tsipuleucel-T|Placebo\tNA\tNA\tNA\tBiological|Biological\tMale\t","Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy","Interventional","Completed","Phase 3",2,127,"prostatic neoplasms","NA","Overall Survival"]
["NCT00005947",8265375,4514793,"Hazard Ratio (HR)",0.586,null,"NA",0.388,0.884,95,0.01,"Log Rank",16809734,"Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006 Jul 1;24(19):3089-94.","\tProstate Cancer\tsipuleucel-T|Placebo\tNA\tNA\tNA\tBiological|Biological\tMale\t","Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy","Interventional","Completed","Phase 3",2,127,"prostatic neoplasms","NA","Overall Survival"]
["NCT00005947",8265376,4514795,"Hazard Ratio (HR)",0.69,null,"NA",0.47,1.01,95,0.052,"Log Rank",16809734,"Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006 Jul 1;24(19):3089-94.","\tProstate Cancer\tsipuleucel-T|Placebo\tNA\tNA\tNA\tBiological|Biological\tMale\t","Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy","Interventional","Completed","Phase 3",2,127,"prostatic neoplasms","NA","Time to Objective Disease Progression"]
["NCT00005947",8265376,4514796,"Hazard Ratio (HR)",1.45,null,"NA",0.99,2.11,95,0.052,"Log Rank",16809734,"Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006 Jul 1;24(19):3089-94.","\tProstate Cancer\tsipuleucel-T|Placebo\tNA\tNA\tNA\tBiological|Biological\tMale\t","Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy","Interventional","Completed","Phase 3",2,127,"prostatic neoplasms","NA","Time to Objective Disease Progression"]
["NCT00005956","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17822557,"Morse MA, Hobeika A, Osada T, Niedzwiecki D, Marcom PK, Blackwell KL, Anders C, Devi GR, Lyerly HK, Clay TM. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J Transl Med. 2007 Sep 6;5:42.","\tBreast Cancer|Gastric Cancer|Ovarian Cancer\tHER-2/neu intracellular domain protein|therapeutic autologous dendritic cells\tNA\tNA\tNA\tBiological|Biological\tAll\t","NA","NA","NA","NA","NA","NA","stomach neoplasms|breast neoplasms","NA","NA"]
["NCT00005962","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19804455|NA","Litzow MR, Othus M, Cripe LD, Gore SD, Lazarus HM, Lee SJ, Bennett JM, Paietta EM, Dewald GW, Rowe JM, Tallman MS; Eastern Cooperative Oncology Group Leukemia Committee. Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol. 2010 Jan;148(2):217-25. doi: 10.1111/j.1365-2141.2009.07917.x. Epub 2009 Oct 5.|Litzow MR, Goloubeva O, Rowe J, et al.: A randomized phase II trial of gemtuzumab ozogamicin vs. liposomal daunorubicin vs. cyclophosphamide plus topotecan, each combined with intermediate dose Ara-C for the treatment of patients with relapsed or refractory acute myelogenous leukemia . [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2359, 2003.","\tLeukemia\tsargramostim|cyclophosphamide|cytarabine|gemtuzumab ozogamicin|liposomal daunorubicin citrate|topotecan hydrochloride\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia|leukemia, myeloid|leukemia, myeloid, acute","cytarabine|gemtuzumab|cyclophosphamide|topotecan|daunorubicin|sargramostim","NA"]
["NCT00005963","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16118507,"Perez EA, Suman VJ, Fitch TR, Mailliard JA, Ingle JN, Cole JT, Veeder MH, Flynn PJ, Walsh DJ, Addo FK. A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932. Oncology. 2005;69(2):117-21. Epub 2005 Aug 23.","\tBreast Cancer\tcarboplatin|docetaxel\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","carboplatin|docetaxel","NA"]
["NCT00005965","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15047228,"Nezhat F, Wadler S, Muggia F, Mandeli J, Goldberg G, Rahaman J, Runowicz C, Murgo AJ, Gardner GJ. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study. Gynecol Oncol. 2004 Apr;93(1):144-8.","\tCervical Cancer\tbryostatin 1|cisplatin\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","uterine cervical neoplasms","bryostatin 1","NA"]
["NCT00005966","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Gordon MS, Manola J, Fairclough D, et al.: Low dose interferon-α2b (IFN) + thalidomide (T) in patients (pts) with previously untreated renal cell cancer (RCC). Improvement in progression-free survival (PFS) but not quality of life (QoL) or overall survival (OS). A phase III study of the Eastern Cooperative Oncology Group (E2898). [Abstract] J Clin Oncol 22 (Suppl 14): A-4516, 386s, 2004.","\tKidney Cancer\trecombinant interferon alfa|thalidomide\tNA\tNA\tNA\tBiological|Drug\tAll\t","NA","NA","NA","NA","NA","NA","kidney neoplasms|carcinoma, renal cell","interferons|interferon-alpha|thalidomide","NA"]
["NCT00005967","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15570084,"Zimmerman TM, Harlin H, Odenike OM, Berk S, Sprague E, Karrison T, Stock W, Larson RA, Ratain MJ, Gajewski TF. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 1;22(23):4816-22. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.","\tChronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes\ttipifarnib\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","myeloproliferative disorders|syndrome|preleukemia|neoplasms, plasma cell|myelodysplastic syndromes|lymphoma|leukemia|multiple myeloma","tipifarnib","NA"]
["NCT00005971","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15122079|NA","Burdette-Radoux S, Tozer RG, Lohmann RC, Quirt I, Ernst DS, Walsh W, Wainman N, Colevas AD, Eisenhauer EA. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs. 2004 Aug;22(3):315-22.|Burdette-Radoux S, Tozer RG, Lohmann R, et al.: NCIC CTG phase II study of flavopiridol in patients with previously untreated metastatic malignant melanoma (IND.137). [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1382, 2002.","\tMelanoma (Skin)\talvocidib\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","melanoma","alvocidib","NA"]
["NCT00005972","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17065590,"Rocha-Lima CM, Herndon JE 2nd, Lee ME, Atkins JN, Mauer A, Vokes E, Green MR; Cancer and Leukemia Group B. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. Ann Oncol. 2007 Feb;18(2):331-7. Epub 2006 Oct 25.","\tLung Cancer\tgemcitabine hydrochloride|irinotecan hydrochloride\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","small cell lung carcinoma|lung neoplasms","gemcitabine|irinotecan","NA"]
["NCT00005974","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17251659,"Morris DG, Bramwell VH, Turcotte R, Figueredo AT, Blackstein ME, Verma S, Matthews S, Eisenhauer EA. A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma. Sarcoma. 2006;2006:64374.","\tSarcoma\talvocidib\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","sarcoma","alvocidib","NA"]
["NCT00005975","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18375894,"Goodwin JW, Green SJ, Moinpour CM, Bearden JD 3rd, Giguere JK, Jiang CS, Lippman SM, Martino S, Albain KS. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. J Clin Oncol. 2008 Apr 1;26(10):1650-6. doi: 10.1200/JCO.2006.10.6179.","\tBreast Cancer|Hot Flashes\tMegestrol Acetate 20mg/day|Megestrol Acetate 40 mg/day|Megestrol Acetate Placebo 20 mg/day|Megestrol Acetate Placebo 40 mg/day\tParallel Assignment\tSupportive Care\tRandomized\tDrug|Drug|Drug|Drug\tFemale\t","S9626: Megestrol in Treating Hot Flashes Following Treatment for Breast Cancer","Interventional","Completed","Phase 3",2,288,"breast neoplasms|hot flashes","megestrol|megestrol acetate","NA"]
["NCT00005976","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16133802,"Galanis E, Buckner JC, Maurer MJ, Reid JM, Kuffel MJ, Ames MM, Scheithauer BW, Hammack JE, Pipoly G, Kuross SA. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial. Invest New Drugs. 2005 Oct;23(5):495-503.","\tBrain and Central Nervous System Tumors\tcarboplatin|pyrazoloacridine\tNA\tNA\tNA\tDrug|Drug\tAll\t","Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma","Interventional","Completed","Phase 2",3,60,"glioma|nervous system neoplasms|central nervous system neoplasms","carboplatin|nsc 366140","NA"]
["NCT00005978","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16421427,"Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol. 2006 Jan 20;24(3):500-6.","\tNeuroblastoma\tfilgrastim|carboplatin|etoposide|melphalan|autologous bone marrow transplantation|peripheral blood stem cell transplantation|iobenguane I 131|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Procedure|Procedure|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","neuroblastoma","carboplatin|melphalan|3-iodobenzylguanidine|etoposide","NA"]
["NCT00005979","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19179549|17510208","Ychou M, Raoul JL, Douillard JY, Gourgou-Bourgade S, Bugat R, Mineur L, Viret F, Becouarn Y, Bouché O, Gamelin E, Ducreux M, Conroy T, Seitz JF, Bedenne L, Kramar A. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol. 2009 Apr;20(4):674-80. doi: 10.1093/annonc/mdn680. Epub 2009 Jan 29.|Côté JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I, Thirouard AS, Selves J, Laurent-Puig P, Ychou M. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res. 2007 Jun 1;13(11):3269-75. Epub 2007 May 17.","\tColorectal Cancer\tFOLFIRI regimen|fluorouracil|irinotecan hydrochloride|leucovorin calcium\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","colonic neoplasms","leucovorin|fluorouracil|irinotecan|levoleucovorin|calcium","NA"]
["NCT00005980","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16520033,"Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, Batter V, Ngalula-Kabanga E, Dittrich C, Piccart M. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer. 2006 May;42(7):882-7. Epub 2006 Mar 7.","\tBreast Cancer\tpegylated liposomal doxorubicin hydrochloride\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","liposomal doxorubicin|doxorubicin","NA"]
["NCT00005991","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12947059,"Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL 3rd, Pusztai L, Hortobagyi GN. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol. 2003 Sep 1;21(17):3249-54.","\tBreast Cancer\tgemcitabine hydrochloride|pegylated liposomal doxorubicin hydrochloride\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","liposomal doxorubicin|gemcitabine|doxorubicin","NA"]
["NCT00005995","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17868728,"Escudier B, Choueiri TK, Oudard S, Szczylik C, Négrier S, Ravaud A, Chevreau C, Venner P, Champagne P, Croteau D, Dupont E, Hariton C, Bukowski RM. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol. 2007 Nov;178(5):1901-5. Epub 2007 Sep 17.","\tKidney Cancer\tshark cartilage extract AE-941\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","kidney neoplasms|carcinoma, renal cell","NA","NA"]
["NCT00005997","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|19399502","Dowlati A, Posey J, Ramanathan RK, et al.: Multicenter phase II and pharmacokinetic study of rebeccamycin analogue (RA) in advanced biliary cancers. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-1070, 2003.|Dowlati A, Posey J, Ramanathan RK, Rath L, Fu P, Chak A, Krishnamurthi S, Brell J, Ingalls S, Hoppel CL, Ivy P, Remick SC. Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers. Cancer Chemother Pharmacol. 2009 Dec;65(1):73-8. doi: 10.1007/s00280-009-1005-x. Epub 2009 Apr 28.","\tExtrahepatic Bile Duct Cancer|Gallbladder Cancer|Liver Cancer\tbecatecarin\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","gallbladder neoplasms|cholangiocarcinoma|bile duct neoplasms|liver neoplasms","NA","NA"]
["NCT00006004","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17264337|NA|NA","Langer C, Li S, Schiller J, Tester W, Rapoport BL, Johnson DH; Eastern Cooperative Oncology Group. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol. 2007 Feb 1;25(4):418-23.|Tester WJ, Stephenson P, Langer CJ, et al.: ECOG 1599: randomized phase II study of paclitaxel/carboplatin or gemcitabine/cisplatin in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC). [Abstract] J Clin Oncol 22 (Suppl 14): A-7055, 630s, 2004.|Langer CJ, Stephenson P, Schiller J, et al.: ECOG 1599: randomized phase II study of paclitaxel/carboplatin vs cisplatin/gemcitabine in performance status (PS) 2 patients with treatment-naive advanced NSCLC. [Abstract] Lung Cancer 41 (Suppl 2): A-O52, S18, 2003.","\tLung Cancer\tcarboplatin|cisplatin|gemcitabine hydrochloride|paclitaxel\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","carboplatin|gemcitabine|paclitaxel","NA"]
["NCT00006006","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16249352,"Schwartz JD, Sung M, Schwartz M, Lehrer D, Mandeli J, Liebes L, Goldenberg A, Volm M. Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist. 2005 Oct;10(9):718-27.","\tLiver Cancer\trecombinant interferon alfa|thalidomide\tNA\tNA\tNA\tBiological|Drug\tAll\t","NA","NA","NA","NA","NA","NA","liver neoplasms","thalidomide|interferons|interferon-alpha","NA"]
["NCT00006007","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16303865|NA","Ma CX, Steen P, Rowland KM, Niedringhaus RD, Fitch TR, Kugler JW, Hillman DW, Perez EA, Ingle JN, Adjei AA. A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study. Ann Oncol. 2006 Feb;17(2):226-31. Epub 2005 Nov 22.|Ma CX, Steen P, Rowland KM, et al.: A phase II study of a combination of pemetrexed (Pem) and gemcitabine (Gem) in patients with metastatic breast cancer (MBC): an NCCTG study. [Abstract] J Clin Oncol 22 (Suppl 14): A-639, 36s, 2004.","\tBreast Cancer\tgemcitabine hydrochloride|pemetrexed disodium\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","pemetrexed|gemcitabine","NA"]
["NCT00006008","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16870552,"Litzow MR, Lee S, Bennett JM, Dewald GW, Gallagher RE, Jain V, Paietta EM, Racevskis J, Rousey SR, Mazza JJ, Tallman MS. A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. Haematologica. 2006 Aug;91(8):1105-8. Epub 2006 Jul 25.","\tLeukemia\tarsenic trioxide\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, lymphoid|leukemia|precursor cell lymphoblastic leukemia-lymphoma","arsenic trioxide","NA"]
["NCT00006010","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21555932|NA","Alberts SR, Reid JM, Morlan BW, Farr GH Jr, Camoriano JK, Johnson DB, Enger JR, Seay TE, Kim GP. Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial. Am J Clin Oncol. 2012 Oct;35(5):418-23.|Kim GP, Alberts SR, Tschetter LK, et al.: Gemcitabine and docetaxel in patients with measurable unresectable or metastatic hepatocellular carcinoma (HCC), a North Central Cancer Treatment Group (NCCTG) phase II trial. [Abstract] J Clin Oncol 22 (Suppl 14): A-4270, 380s, 2004.","\tLiver Cancer\tdocetaxel|gemcitabine hydrochloride\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","liver neoplasms","docetaxel|gemcitabine","NA"]
["NCT00006012","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17336213|NA","Garces YI, Okuno SH, Schild SE, Mandrekar SJ, Bot BM, Martens JM, Wender DB, Soori GS, Moore DF Jr, Kozelsky TF, Jett JR. Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):995-1001.|Garces YI, Okuno SH, Schild SE, et al.: A phase I/II NCCTG trial of escalating doses of twice daily thoracic radiation therapy (TRT) in limited-stage small cell lung cancer (LSCLC). [Abstract] J Clin Oncol 23 (Suppl 16): A-7163, 661s, 2005.","\tDrug/Agent Toxicity by Tissue/Organ|Lung Cancer|Radiation Toxicity\tfilgrastim|amifostine trihydrate|cisplatin|etoposide|paclitaxel|topotecan hydrochloride|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","small cell lung carcinoma|drug-related side effects and adverse reactions|lung neoplasms","amifostine|topotecan|paclitaxel|etoposide","NA"]
["NCT00006015","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Clark JW, Niedzwiecki D, Hollis D, et al.: Phase II trial of 5-fluororuacil (5-FU), leucovorin (LV), oxaliplatin (Ox), and trastuzamab (T) for patients with metastatic colorectal cancer (CRC) refractory to initial therapy. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-3584, 2003.","\tColorectal Cancer\ttrastuzumab|fluorouracil|leucovorin calcium|oxaliplatin\tNA\tNA\tNA\tBiological|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","fluorouracil|levoleucovorin|leucovorin|calcium|trastuzumab|oxaliplatin","NA"]
["NCT00006021","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12473574,"Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez HF, Boise LH, Lee KP. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res. 2002 Dec;8(12):3658-68.","\tMultiple Myeloma and Plasma Cell Neoplasm\tascorbic acid|arsenic trioxide\tNA\tNA\tNA\tDietary Supplement|Drug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms, plasma cell|multiple myeloma|plasmacytoma","arsenic trioxide|ascorbic acid","NA"]
["NCT00006023","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15054447,"Morant R, Bernhard J, Dietrich D, Gillessen S, Bonomo M, Borner M, Bauer J, Cerny T, Rochlitz C, Wernli M, Gschwend A, Hanselmann S, Hering F, Schmid HP. Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. Br J Cancer. 2004 Apr 5;90(7):1312-7.","\tProstate Cancer\tcapecitabine\tNA\tNA\tNA\tDrug\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","capecitabine","NA"]
["NCT00006024","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18497327,"Jakacki RI, Yates A, Blaney SM, Zhou T, Timmerman R, Ingle AM, Flom L, Prados MD, Adamson PC, Pollack IF. A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. Neuro Oncol. 2008 Aug;10(4):569-76. doi: 10.1215/15228517-2008-019. Epub 2008 May 22.","\tBrain Tumor|Central Nervous System Tumor\tlomustine|temozolomide\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|nervous system neoplasms","temozolomide|lomustine","NA"]
["NCT00006025","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18056194,"Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins IH, Aldape KD, Yung WK. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clin Cancer Res. 2007 Dec 1;13(23):7133-8.","\tBrain and Central Nervous System Tumors\tirinotecan hydrochloride|temozolomide\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|nervous system neoplasms|glioma","temozolomide|irinotecan","NA"]
["NCT00006028","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16643994,"Brewer CA, Blessing JA, Nagourney RA, Morgan M, Hanjani P. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006 Nov;103(2):446-50. Epub 2006 Apr 27.","\tOvarian Cancer|Primary Peritoneal Cavity Cancer\tcisplatin|gemcitabine hydrochloride\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","carcinoma, ovarian epithelial|ovarian neoplasms","gemcitabine","NA"]
["NCT00006029","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18452103|17426059|NA","Lai R, Bartlett NL, Mackey JR, Jung SH, Johnson JL, Cook JR, Jones D, Cass CE, Young JD, Said J, Cheson B, Hsi ED. High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study. Leuk Lymphoma. 2008 Jun;49(6):1202-5. doi: 10.1080/10428190802094237.|Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, Zelenetz AD, Cheson BD, Canellos GP; Cancer Leukemia Group B. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol. 2007 Jun;18(6):1071-9. Epub 2007 Apr 10.|Bartlett N, Niedzwiecki D, Johnson J, et al.: A phase I/II study of gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed Hodgkin's disease: preliminary results of CALGB 59804. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2275, 566, 2003.","\tLymphoma\tgemcitabine hydrochloride|pegylated liposomal doxorubicin hydrochloride|vinorelbine tartrate\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma","Interventional","Completed","Phase 1/Phase 2",2,91,"lymphoma","vinorelbine|gemcitabine|doxorubicin|liposomal doxorubicin","NA"]
["NCT00006036","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15033677,"MacKenzie MJ, Hirte HW, Siu LL, Gelmon K, Ptaszynski M, Fisher B, Eisenhauer E. A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers. Ann Oncol. 2004 Apr;15(4):665-70.","\tHead and Neck Cancer|Lung Cancer|Ovarian Cancer|Unspecified Adult Solid Tumor, Protocol Specific\tcisplatin|lurtotecan liposome\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms|lung neoplasms","lurtotecan","NA"]
["NCT00006042","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12171484,"O'Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, Rhubart P, Cowan K, Piantados S, Fuchs EJ. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8(7):377-86.","\tLeukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic/Myeloproliferative Diseases|Myelodysplastic Syndromes\tfilgrastim|cyclophosphamide|fludarabine phosphate|mycophenolate mofetil|tacrolimus|allogeneic bone marrow transplantation|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms, plasma cell|myelodysplastic syndromes|multiple myeloma|preleukemia|myeloproliferative disorders|myelodysplastic-myeloproliferative diseases|syndrome|lymphoma|leukemia","cyclophosphamide|fludarabine|fludarabine phosphate|mycophenolic acid|tacrolimus","NA"]
["NCT00006044","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19375217,"Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz LH, Scher HI. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol. 2009 Aug;56(2):237-44. doi: 10.1016/j.eururo.2009.03.073. Epub 2009 Apr 3.","\tProstate Cancer\ttherapeutic testosterone\tNA\tNA\tNA\tDrug\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","testosterone","NA"]
["NCT00006050","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16009952,"Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob JH, Boige V, Elias D, Delperro JR, Luboinski M; gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005 Aug 1;23(22):4881-7. Epub 2005 Jul 11.","\tColorectal Cancer|Metastatic Cancer\tFOLFOX regimen|fluorouracil|isolated perfusion|leucovorin calcium|oxaliplatin\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","calcium|leucovorin|levoleucovorin|fluorouracil|oxaliplatin","NA"]
["NCT00006053","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Hensley ML, van Hoomissen IC, Krahnke T, et al.: Imatinib in chronic myeloid leukemia (CML): outcomes in >7000 patients treated on expanded access program (EAP). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2328, 2003.|van Hoomissen IC, Hensley ML, Krahnke T, et al.: Imatinib expanded access program (EAP): results of treatment in >7000 patients with chronic myeloid leukemia (CML). [Abstract] Blood 102 (11): A-3370, 2003.","\tLeukemia\timatinib mesylate\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, myelogenous, chronic, bcr-abl positive|leukemia|leukemia, myeloid","imatinib mesylate","NA"]
["NCT00006064","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18614924|18519448|20345880|20631646","Chantry CJ, Hughes MD, Alvero C, Cervia JS, Hodge J, Borum P, Moye J Jr; PACTG 1010 Team. Insulin-like growth factor-1 and lean body mass in HIV-infected children. J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):437-43. doi: 10.1097/QAI.0b013e31817bbe6d.|Chantry CJ, Hughes MD, Alvero C, Cervia JS, Meyer WA 3rd, Hodge J, Borum P, Moye J Jr; PACTG 1010 Team. Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy. Pediatrics. 2008 Jul;122(1):e129-38. doi: 10.1542/peds.2007-2467. Epub 2008 Jun 2.|Chantry CJ, Cervia JS, Hughes MD, Alvero C, Hodge J, Borum P, Moye J Jr; PACTG 1010 Team. Predictors of growth and body composition in HIV-infected children beginning or changing antiretroviral therapy. HIV Med. 2010 Oct 1;11(9):573-83. doi: 10.1111/j.1468-1293.2010.00823.x. Epub 2010 Mar 21.|Cervia JS, Chantry CJ, Hughes MD, Alvero C, Meyer WA 3rd, Hodge J, Borum P, Moye J Jr, Spector SA; PACTG 1010 Team. Associations of proinflammatory cytokine levels with lipid profiles, growth, and body composition in HIV-infected children initiating or changing antiretroviral therapy. Pediatr Infect Dis J. 2010 Dec;29(12):1118-22. doi: 10.1097/INF.0b013e3181ed9f4c.","\tHIV Infections|HIV Wasting Syndrome|Lipodystrophy\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","wasting syndrome|cachexia|hiv wasting syndrome|lipodystrophy","NA","NA"]
["NCT00006080","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15514370,"Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M; North American Brain Tumor Consortium. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol. 2004 Nov 1;22(21):4282-9.","\tBrain and Central Nervous System Tumors\tfenretinide\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|nervous system neoplasms|glioma","fenretinide","NA"]
["NCT00006086","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16428495,"Fishman MN, Garrett CR, Simon GR, Chiappori AA, Lush RM, Dinwoodie WR, Mahany JJ, Dellaportas AM, Cantor A, Gollerki A, Cohen MB, Sullivan DM. Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies. Clin Cancer Res. 2006 Jan 15;12(2):523-8.","\tUnspecified Adult Solid Tumor, Protocol Specific\tcarboplatin|BMS-188797\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","NA","carboplatin","NA"]
["NCT00006093","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17470857|NA","Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD, Grossman SA. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol. 2007 May 1;25(13):1651-7.|Nabors LB, Rosenfeld SS, Mikkelsen T, et al.: NABTT 9911: a phase I trial of EMD 121974 for treatment of patients with recurrent malignant gliomas. [Abstract] Neuro-Oncology 6 (4): TA-39, 379, 2004.","\tBrain and Central Nervous System Tumors\tcilengitide\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","nervous system neoplasms|central nervous system neoplasms","NA","NA"]
["NCT00006100","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15112270,"Lucas KG, Salzman D, Garcia A, Sun Q. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer. 2004 May 1;100(9):1892-901.","\tLymphoma\taldesleukin|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|fludarabine phosphate|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Biological|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma","fludarabine|aldesleukin|fludarabine phosphate","NA"]
["NCT00006101","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18268112,"Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, Ahlering TE, Lieberman R, McLaren CE, Anton-Culver H, Meyskens FL Jr. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):292-9. doi: 10.1158/1055-9965.EPI-07-0658.","\tProstate Cancer\teflornithine|Placebo\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug\tMale\t","Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer","Interventional","Completed","Phase 2",2,76,"prostatic neoplasms","eflornithine","NA"]
["NCT00006102","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17610262,"Langevin AM, Bernstein M, Kuhn JG, Blaney SM, Ivy P, Sun J, Chen Z, Adamson PC; Children's Oncology Group. A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Mar;50(3):577-80.","\tBrain and Central Nervous System Tumors|Lymphoma|Neuroblastoma|Retinoblastoma|Sarcoma|Unspecified Childhood Solid Tumor, Protocol Specific\tbecatecarin\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","retinoblastoma|nervous system neoplasms|neuroblastoma|central nervous system neoplasms|lymphoma|neoplasms","NA","NA"]
["NCT00006117","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19435690|11896099","Afchain P, Chibaudel B, Lledo G, Selle F, Bengrine-Lefevre L, Nguyen S, Paitel JF, Mineur L, Artru P, André T, Louvet C. First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study. Bull Cancer. 2009 May;96(5):E18-22. doi: 10.1684/bdc.2009.0871. Epub 2009 May 12.|Louvet C, André T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E, Flesch M, Cvitkovic E, de Gramont A. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol. 2002 Mar 15;20(6):1512-8.","\tPancreatic Cancer\tgemcitabine hydrochloride|oxaliplatin\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","pancreatic neoplasms","oxaliplatin|gemcitabine","NA"]
["NCT00006122","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|15339678","Amadori S, Suciu S, Willemze R, et al.: Up-front window trial of gemtuzumab ozogamicin (GO) in previously untreated elderly patients with AML: an EORTC leukemia group study. [Abstract] Blood 104 (11): A-877, 2004.|Amadori S, Suciu S, Willemze R, Mandelli F, Selleslag D, Stauder R, Ho A, Denzlinger C, Leone G, Fabris P, Muus P, Vignetti M, Hagemeijer A, Beeldens F, Anak O, De Witte T; EORTC leukemia group; GIMEMA leukemia group. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica. 2004 Aug;89(8):950-6.","\tLeukemia\tcytarabine|etoposide|gemtuzumab ozogamicin|idarubicin|mitoxantrone hydrochloride\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, myeloid, acute|leukemia, myeloid|leukemia","cytarabine|etoposide|idarubicin|mitoxantrone|gemtuzumab","NA"]
["NCT00006125","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16966261|NA","Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos G, Cheson BD, Bartlett NL; Cancer and Leukemia Group B. Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906. Leuk Lymphoma. 2006 Aug;47(8):1511-7.|Smith SM, Johnson JL, Niedzwiecki D, et al.: Sequential topoisomerase I (topo I) and topoisomerase II (topo II) inhibitors in relapsed/refractory aggressive NHL: results of CALGB 59906, a phase II study of doxorubicin and topotecan. [Abstract] Blood 104 (11): A-2500, 2004.","\tLymphoma\tdoxorubicin hydrochloride|topotecan hydrochloride\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma, non-hodgkin|lymphoma","liposomal doxorubicin|doxorubicin|topotecan","NA"]
["NCT00006145","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19632953,"Wohl DA, Kendall MA, Andersen J, Crumpacker C, Spector SA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Lurain N, Jabs D, Benson C, Keiser P, Jacobson MA; A5030 Study Team. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. HIV Clin Trials. 2009 May-Jun;10(3):143-52. doi: 10.1310/hct1003-143.","\tCytomegalovirus Infections|HIV Infections\tValganciclovir\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","infection|communicable diseases|cytomegalovirus infections","valganciclovir","NA"]
["NCT00006164","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19052125,"Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL; HALT-C Trial Investigators. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008 Dec 4;359(23):2429-41. doi: 10.1056/NEJMoa0707615.","\tChronic Hepatitis c|Cirrhosis, Liver|Fibrosis, Liver|Hepatic Cirrhosis\tPeginterferon alfa-2a + Ribavirin|Peginterferon alfa-2a\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug\tAll\t","Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment","Interventional","Completed","Phase 3",2,1050,"hepatitis a|hepatitis c, chronic|hepatitis c|fibrosis|liver cirrhosis|hepatitis","interferon-alpha|ribavirin|peginterferon alfa-2a","NA"]
["NCT00006170",8268953,4516972,null,"NA",null,"NA",{"$nulls":3},0.046,"Regression, Logistic",20308641,"Levine MD, Perkins KA, Kalarchian MA, Cheng Y, Houck PR, Slane JD, Marcus MD. Bupropion and cognitive behavioral therapy for weight-concerned women smokers. Arch Intern Med. 2010 Mar 22;170(6):543-50. doi: 10.1001/archinternmed.2010.33.","\tTobacco Use Disorder\tBupropion|Placebo|weight concerns intervention|smoking cessation intervention\tNA\tNA\tNA\tDrug|Drug|Behavioral|Behavioral\tFemale\t","Bupropion and Weight Control for Smoking Cessation - 1","Interventional","Completed","Phase 4",4,349,"tobacco use disorder","bupropion","Smoking Abstinence"]
["NCT00006170",8268953,4516973,null,"NA",null,"NA",{"$nulls":3},0.45,"Regression, Logistic",20308641,"Levine MD, Perkins KA, Kalarchian MA, Cheng Y, Houck PR, Slane JD, Marcus MD. Bupropion and cognitive behavioral therapy for weight-concerned women smokers. Arch Intern Med. 2010 Mar 22;170(6):543-50. doi: 10.1001/archinternmed.2010.33.","\tTobacco Use Disorder\tBupropion|Placebo|weight concerns intervention|smoking cessation intervention\tNA\tNA\tNA\tDrug|Drug|Behavioral|Behavioral\tFemale\t","Bupropion and Weight Control for Smoking Cessation - 1","Interventional","Completed","Phase 4",4,349,"tobacco use disorder","bupropion","Smoking Abstinence"]
["NCT00006170",8268953,4516974,null,"NA",null,"NA",{"$nulls":3},0.006,"Regression, Logistic",20308641,"Levine MD, Perkins KA, Kalarchian MA, Cheng Y, Houck PR, Slane JD, Marcus MD. Bupropion and cognitive behavioral therapy for weight-concerned women smokers. Arch Intern Med. 2010 Mar 22;170(6):543-50. doi: 10.1001/archinternmed.2010.33.","\tTobacco Use Disorder\tBupropion|Placebo|weight concerns intervention|smoking cessation intervention\tNA\tNA\tNA\tDrug|Drug|Behavioral|Behavioral\tFemale\t","Bupropion and Weight Control for Smoking Cessation - 1","Interventional","Completed","Phase 4",4,349,"tobacco use disorder","bupropion","Smoking Abstinence"]
["NCT00006170",8268954,4516976,null,"NA",null,"NA",{"$nulls":3},0.053,"Regression, Logistic",20308641,"Levine MD, Perkins KA, Kalarchian MA, Cheng Y, Houck PR, Slane JD, Marcus MD. Bupropion and cognitive behavioral therapy for weight-concerned women smokers. Arch Intern Med. 2010 Mar 22;170(6):543-50. doi: 10.1001/archinternmed.2010.33.","\tTobacco Use Disorder\tBupropion|Placebo|weight concerns intervention|smoking cessation intervention\tNA\tNA\tNA\tDrug|Drug|Behavioral|Behavioral\tFemale\t","Bupropion and Weight Control for Smoking Cessation - 1","Interventional","Completed","Phase 4",4,349,"tobacco use disorder","bupropion","Smoking Abstinence"]
["NCT00006170",8268954,4516975,null,"NA",null,"NA",{"$nulls":3},0.08,"Regression, Logistic",20308641,"Levine MD, Perkins KA, Kalarchian MA, Cheng Y, Houck PR, Slane JD, Marcus MD. Bupropion and cognitive behavioral therapy for weight-concerned women smokers. Arch Intern Med. 2010 Mar 22;170(6):543-50. doi: 10.1001/archinternmed.2010.33.","\tTobacco Use Disorder\tBupropion|Placebo|weight concerns intervention|smoking cessation intervention\tNA\tNA\tNA\tDrug|Drug|Behavioral|Behavioral\tFemale\t","Bupropion and Weight Control for Smoking Cessation - 1","Interventional","Completed","Phase 4",4,349,"tobacco use disorder","bupropion","Smoking Abstinence"]
["NCT00006170",8268954,4516977,null,"NA",null,"NA",{"$nulls":3},1E-3,"Regression, Logistic",20308641,"Levine MD, Perkins KA, Kalarchian MA, Cheng Y, Houck PR, Slane JD, Marcus MD. Bupropion and cognitive behavioral therapy for weight-concerned women smokers. Arch Intern Med. 2010 Mar 22;170(6):543-50. doi: 10.1001/archinternmed.2010.33.","\tTobacco Use Disorder\tBupropion|Placebo|weight concerns intervention|smoking cessation intervention\tNA\tNA\tNA\tDrug|Drug|Behavioral|Behavioral\tFemale\t","Bupropion and Weight Control for Smoking Cessation - 1","Interventional","Completed","Phase 4",4,349,"tobacco use disorder","bupropion","Smoking Abstinence"]
["NCT00006170",8268955,4516980,null,"NA",null,"NA",{"$nulls":3},1E-3,"Regression, Logistic",20308641,"Levine MD, Perkins KA, Kalarchian MA, Cheng Y, Houck PR, Slane JD, Marcus MD. Bupropion and cognitive behavioral therapy for weight-concerned women smokers. Arch Intern Med. 2010 Mar 22;170(6):543-50. doi: 10.1001/archinternmed.2010.33.","\tTobacco Use Disorder\tBupropion|Placebo|weight concerns intervention|smoking cessation intervention\tNA\tNA\tNA\tDrug|Drug|Behavioral|Behavioral\tFemale\t","Bupropion and Weight Control for Smoking Cessation - 1","Interventional","Completed","Phase 4",4,349,"tobacco use disorder","bupropion","Smoking Abstinence"]
["NCT00006170",8268955,4516979,null,"NA",null,"NA",{"$nulls":3},0.25,"Regression, Logistic",20308641,"Levine MD, Perkins KA, Kalarchian MA, Cheng Y, Houck PR, Slane JD, Marcus MD. Bupropion and cognitive behavioral therapy for weight-concerned women smokers. Arch Intern Med. 2010 Mar 22;170(6):543-50. doi: 10.1001/archinternmed.2010.33.","\tTobacco Use Disorder\tBupropion|Placebo|weight concerns intervention|smoking cessation intervention\tNA\tNA\tNA\tDrug|Drug|Behavioral|Behavioral\tFemale\t","Bupropion and Weight Control for Smoking Cessation - 1","Interventional","Completed","Phase 4",4,349,"tobacco use disorder","bupropion","Smoking Abstinence"]
["NCT00006170",8268955,4516978,null,"NA",null,"NA",{"$nulls":3},0.07,"Regression, Logistic",20308641,"Levine MD, Perkins KA, Kalarchian MA, Cheng Y, Houck PR, Slane JD, Marcus MD. Bupropion and cognitive behavioral therapy for weight-concerned women smokers. Arch Intern Med. 2010 Mar 22;170(6):543-50. doi: 10.1001/archinternmed.2010.33.","\tTobacco Use Disorder\tBupropion|Placebo|weight concerns intervention|smoking cessation intervention\tNA\tNA\tNA\tDrug|Drug|Behavioral|Behavioral\tFemale\t","Bupropion and Weight Control for Smoking Cessation - 1","Interventional","Completed","Phase 4",4,349,"tobacco use disorder","bupropion","Smoking Abstinence"]
["NCT00006182","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16382063,"Adams RJ, Brambilla D; Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005 Dec 29;353(26):2769-78.","\tAnemia, Sickle Cell|Blood Disease|Cerebrovascular Accident\tBlood Transfusion\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","anemia|hematologic diseases|anemia, sickle cell|stroke","NA","NA"]
["NCT00006184","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22773122,"Foglietta M, Neelapu SS, Kwak LW, Jiang Y, Nattamai D, Lee ST, Fowler DH, Sportes C, Gress RE, Steinberg SM, Vence LM, Radvanyi L, Dwyer KC, Qazilbash MH, Bryant RN, Bishop MR. Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients. Bone Marrow Transplant. 2013 Feb;48(2):269-77. doi: 10.1038/bmt.2012.132. Epub 2012 Jul 9.","\tMultiple Myeloma\tMyeloma Immunoglobulin Idiotype Vaccine|Bortezomib|Cyclophosphamide|Cyclosporine|Doxorubicin hydrochloride|Etoposide|Fludarabine phosphate|Prednisone|Vincristine Sulfate|Methotrexate|GMCSF (granulocyte macrophage colony stimulating factor)|GCSF (granulocyte colony stimulating factor)\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Biological|Biological\tAll\t","Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma","Interventional","Completed","Phase 2",2,20,"multiple myeloma|neoplasms, plasma cell","molgramostim|cyclosporins|cyclophosphamide|etoposide|doxorubicin|immunoglobulins|lenograstim|sargramostim|liposomal doxorubicin|fludarabine phosphate|fludarabine|vincristine|bortezomib|cyclosporine|antibodies|methotrexate|immunoglobulin idiotypes|immunoglobulins, intravenous|prednisone","NA"]
["NCT00006206","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16670409,"Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A; COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006 May 3;295(17):2003-17.","\tAlcoholism\tnaltrexone (Revia)|acamprosate (Campral)\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","alcoholism","naltrexone|acamprosate","NA"]
["NCT00006224","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15589587,"Schilder RJ, Blessing J, Cohn DE. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2005 Jan;96(1):103-7.","\tCervical Cancer\tgemcitabine hydrochloride\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","uterine cervical neoplasms","gemcitabine","NA"]
["NCT00006229","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15837997|NA","Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J, Crawford J, Tu D, Bezjak A, Humphrey JS, Voi M, Galbraith S, Hann K, Seymour L, Shepherd FA. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol. 2005 Apr 20;23(12):2831-9.|Leighl NB, Shepherd F, Paz-Ares L, et al.: Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR.18. [Abstract] J Clin Oncol 22 (Suppl 14): A-7038, 626s, 2004.","\tLung Cancer\tcarboplatin|paclitaxel|rebimastat\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer","Interventional","Completed","Phase 2/Phase 3",2,774,"lung neoplasms|carcinoma, non-small-cell lung","paclitaxel|carboplatin","NA"]
["NCT00006231","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","O'Rourke N, Paul J, Hill J: Radiotherapy to mesothelioma drain sites may not be worthwhile: interim report of a randomized study. Lung Cancer 29(1 Suppl 1): A-568, 168, 2000.","\tMalignant Mesothelioma|Perioperative/Postoperative Complications\tquality-of-life assessment|standard follow-up care|radiation therapy\tNA\tNA\tNA\tProcedure|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","postoperative complications|mesothelioma|lung neoplasms","NA","NA"]
["NCT00006245","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Rathkopf DE, Ilson DH, Yi S, et al.: A phase II trial of sequential paclitaxel and flavopiridol in patients with metastatic paclitaxel-refractory esophageal cancer. [Abstract] American Society of Clinical Oncology 2004 Gastrointestinal Cancers Symposium, 22-24 January 2004, San Francisco, CA. A-67, 2004.","\tEsophageal Cancer\talvocidib|paclitaxel\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","esophageal neoplasms","alvocidib|paclitaxel","NA"]
["NCT00006246","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16533779,"Gururangan S, Petros WP, Poussaint TY, Hancock ML, Phillips PC, Friedman HS, Bomgaars L, Blaney SM, Kun LE, Boyett JM. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res. 2006 Mar 1;12(5):1540-6.","\tBrain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Leukemia|Lymphoma|Metastatic Cancer|Retinoblastoma|Sarcoma\tbusulfan\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms|retinoblastoma|lymphoma|leukemia|neoplasms, germ cell and embryonal|nervous system neoplasms|central nervous system neoplasms","busulfan","NA"]
["NCT00006247","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19065567,"Kieran MW, Supko JG, Wallace D, Fruscio R, Poussaint TY, Phillips P, Pollack I, Packer R, Boyett JM, Blaney S, Banerjee A, Geyer R, Friedman H, Goldman S, Kun LE, Macdonald T; Pediatric Brain Tumor Consortium. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr Blood Cancer. 2009 Feb;52(2):169-76. doi: 10.1002/pbc.21873.","\tBrain and Central Nervous System Tumors\tsemaxanib\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","nervous system neoplasms|central nervous system neoplasms","semaxinib","NA"]
["NCT00006248","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16779801,"Worden FP, Moon J, Samlowski W, Clark JI, Dakhil SR, Williamson S, Urba SG, Ensley J, Hussain MH; Southwest Oncology Group, Head and Neck Working Group. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007. Cancer. 2006 Jul 15;107(2):319-27.","\tHead and Neck Cancer\tcisplatin|fluorouracil|paclitaxel\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","paclitaxel|fluorouracil","NA"]
["NCT00006249","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|20385998|19621225|19433686|19793643|18620949|NA","Eggermont AM, Suciu S, Santinami M, et al.: EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: long-term results at 7.6-years follow-up. [Abstract] J Clin Oncol 29 (Suppl 15): A-8506b, 2011.|Bouwhuis MG, Suciu S, Testori A, Kruit WH, Salès F, Patel P, Punt CJ, Santinami M, Spatz A, Ten Hagen TL, Eggermont AM. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. J Clin Oncol. 2010 May 10;28(14):2460-6. doi: 10.1200/JCO.2009.24.6264. Epub 2010 Apr 12.|Eggermont AM, Bouwhuis MG, Kruit WH, Testori A, ten Hagen T, Yver A, Xu C. Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991). Cancer Chemother Pharmacol. 2010 Mar;65(4):671-7. doi: 10.1007/s00280-009-1072-z. Epub 2009 Jul 21.|Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, Marsden J, Punt C, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Patel P, Schadendorf D, Spatz A, Keilholz U, Eggermont A. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2009 Jun 20;27(18):2916-23. doi: 10.1200/JCO.2008.20.2069. Epub 2009 May 11. Erratum in: J Clin Oncol. 2009 Sep 20;27(27):4630. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.|Fusi A, Collette S, Busse A, Suciu S, Rietz A, Santinami M, Kruit WH, Testori A, Punt CJ, Dalgleish AG, Spatz A, Eggermont AM, Keilholz U. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Eur J Cancer. 2009 Dec;45(18):3189-97. doi: 10.1016/j.ejca.2009.09.004. Epub 2009 Sep 28.|Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U; EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008 Jul 12;372(9633):117-26. doi: 10.1016/S0140-6736(08)61033-8.|Eggermont AM, Suciu S, Santinami M, et al.: EORTC 18991: long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-8504, 473s, 2007.","\tMelanoma (Skin)\tpegylated interferon alfa|adjuvant therapy\tParallel Assignment\tTreatment\tRandomized\tBiological|Procedure\tAll\t","Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma","Interventional","Unknown status","Phase 3",2,1258,"melanoma","interferon-alpha|interferons","NA"]
["NCT00006252","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Shea TC, Johnston J, Walsh W, et al.: Reduced intensity allogeneic transplantation provides high disease-free and overall survival in patients (pts) with advanced indolent NHL and CLL: CALGB 109901. [Abstract] Blood 110 (11): A-486, 2007.","\tLeukemia|Lymphoma\tfludarabine phosphate|Cyclophosphamide|PBSC|G-CSF|Donor lymphocytes\tNA\tNA\tNA\tDrug|Drug|Biological|Drug|Biological\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|leukemia","cyclophosphamide|fludarabine phosphate|fludarabine","NA"]
["NCT00006258","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11835236,"Dhodapkar K, Dunkel IJ, Gardner S, Sapp M, Thoron L, Finlay J. Preliminary results of dose intensive pre-irradiation chemotherapy in patients older than 10 years of age with high risk medulloblastoma and supratentorial primitive neuroectodermal tumors. Med Pediatr Oncol. 2002 Jan;38(1):47-8.","\tBrain and Central Nervous System Tumors\tfilgrastim|cisplatin|cyclophosphamide|etoposide|methotrexate|vincristine sulfate|adjuvant therapy|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Drug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","ependymoma|central nervous system neoplasms|nervous system neoplasms|medulloblastoma|neuroectodermal tumors, primitive|neuroectodermal tumors","cyclophosphamide|etoposide|vincristine|methotrexate","NA"]
["NCT00006264","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16640817,"Aboulafia DM, Ratner L, Miles SA, Harrington WJ Jr; AIDS Associated Malignancies Clinical Trials Consortium. Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma. 2006 Mar;6(5):399-402.","\tLymphoma\taldesleukin|ganciclovir|zidovudine\tNA\tNA\tNA\tBiological|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma","ganciclovir|aldesleukin|zidovudine|ganciclovir triphosphate","NA"]
["NCT00006265","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20688393|NA","Stone RM, Moser B, Sanford B, Schulman P, Kolitz JE, Allen S, Stock W, Galinsky I, Vij R, Marcucci G, Hurd D, Larson RA; Cancer and Leukemia Group B. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res. 2011 Mar;35(3):329-33. doi: 10.1016/j.leukres.2010.07.017. Epub 2010 Aug 4.|Stone RM, Moser B, Schulman P, et al.: A dose escalation and phase II study of gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) for patients (pts) with refractory or relapsed acute myeloid leukemia (AML): CALGB 19902. [Abstract] Blood 104 (11): A-873, 2004.","\tLeukemia\tara-C|gemtuzumab ozogamicin\tNA\tNA\tNA\tDrug|Biological\tAll\t","Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","Interventional","Completed","Phase 2",4,60,"leukemia, myeloid, acute|leukemia, myeloid|leukemia","cytarabine|gemtuzumab","NA"]
["NCT00006279","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16136470|14657758","Lee EJ, Kantor R, Zijenah L, Sheldon W, Emel L, Mateta P, Johnston E, Wells J, Shetty AK, Coovadia H, Maldonado Y, Jones SA, Mofenson LM, Contag CH, Bassett M, Katzenstein DA; HIVNET 023 Study Team. Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. J Infect Dis. 2005 Oct 1;192(7):1260-4. Epub 2005 Aug 23.|Shetty AK, Coovadia HM, Mirochnick MM, Maldonado Y, Mofenson LM, Eshleman SH, Fleming T, Emel L, George K, Katzenstein DA, Wells J, Maponga CC, Mwatha A, Jones SA, Abdool Karim SS, Bassett MT; HIVNET 023 Study Team. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):482-90.","\tHIV Infections\tNevirapine\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","nevirapine","NA"]
["NCT00006286","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15315995|15608541|17135984|17135989|17135988|17135986|17135985|17135987|17909125|17907854","March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J; Treatment for Adolescents With Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004 Aug 18;292(7):807-20.|Treatment for Adolescents with Depression Study (TADS) Team. The Treatment for Adolescents With Depression Study (TADS): demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry. 2005 Jan;44(1):28-40. Review.|March J, Silva S, Vitiello B; TADS Team. The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks. J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1393-403.|Emslie G, Kratochvil C, Vitiello B, Silva S, Mayes T, McNulty S, Weller E, Waslick B, Casat C, Walkup J, Pathak S, Rohde P, Posner K, March J; Columbia Suicidality Classification Group; TADS Team. Treatment for Adolescents with Depression Study (TADS): safety results. J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1440-55.|Curry J, Rohde P, Simons A, Silva S, Vitiello B, Kratochvil C, Reinecke M, Feeny N, Wells K, Pathak S, Weller E, Rosenberg D, Kennard B, Robins M, Ginsburg G, March J; TADS Team. Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1427-39.|Kratochvil C, Emslie G, Silva S, McNulty S, Walkup J, Curry J, Reinecke M, Vitiello B, Rohde P, Feeny N, Casat C, Pathak S, Weller E, May D, Mayes T, Robins M, March J; TADS Team. Acute time to response in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1412-8.|Kennard B, Silva S, Vitiello B, Curry J, Kratochvil C, Simons A, Hughes J, Feeny N, Weller E, Sweeney M, Reinecke M, Pathak S, Ginsburg G, Emslie G, March J; TADS Team. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1404-11.|Vitiello B, Rohde P, Silva S, Wells K, Casat C, Waslick B, Simons A, Reinecke M, Weller E, Kratochvil C, Walkup J, Pathak S, Robins M, March J; TADS Team. Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1419-26.|March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry. 2007 Oct;64(10):1132-43. Erratum in: Arch Gen Psychiatry. 2008 Jan;65(1):101.|Herman KC, Ostrander R, Walkup JT, Silva SG, March JS. Empirically derived subtypes of adolescent depression: latent profile analysis of co-occurring symptoms in the Treatment for Adolescents with Depression Study (TADS). J Consult Clin Psychol. 2007 Oct;75(5):716-28.","\tDepression|Major Depressive Disorder\tFluoxetine|Psychotherapy\tNA\tNA\tNA\tDrug|Behavioral\tAll\t","NA","NA","NA","NA","NA","NA","depressive disorder|depressive disorder, major|depression","fluoxetine","NA"]
["NCT00006298","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15016844|15383595","Masemola A, Mashishi T, Khoury G, Mohube P, Mokgotho P, Vardas E, Colvin M, Zijenah L, Katzenstein D, Musonda R, Allen S, Kumwenda N, Taha T, Gray G, McIntyre J, Karim SA, Sheppard HW, Gray CM; HIVNET 028 Study Team. Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J Virol. 2004 Apr;78(7):3233-43.|Masemola AM, Mashishi TN, Khoury G, Bredell H, Paximadis M, Mathebula T, Barkhan D, Puren A, Vardas E, Colvin M, Zijenah L, Katzenstein D, Musonda R, Allen S, Kumwenda N, Taha T, Gray G, McIntyre J, Karim SA, Sheppard HW, Gray CM; HIVNET 028 Study Team. Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa. J Immunol. 2004 Oct 1;173(7):4607-17.","\tHIV Infections|HIV Seronegativity\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","communicable diseases|infection","NA","NA"]
["NCT00006304","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","9917118|11986480|10225228|12042556|11794218|10969100|11115957|15173535|15764965|15750460|15886376|16849662|17101712|19827220|19131890|20103953|19827949|19188649|18413359|18363489|17296781|17003692|20083530|18647794|20865061|21323533","Culnane M, Fowler M, Lee SS, McSherry G, Brady M, O'Donnell K, Mofenson L, Gortmaker SL, Shapiro DE, Scott G, Jimenez E, Moore EC, Diaz C, Flynn PM, Cunningham B, Oleske J. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA. 1999 Jan 13;281(2):151-7.|Gaughan DM, Mofenson LM, Hughes MD, Seage GR 3rd, Ciupak GL, Oleske JM; Pediatric AIDS Clinical Trials Group Protocol 219 Team. Osteonecrosis of the hip (Legg-Calvé-Perthes disease) in human immunodeficiency virus-infected children. Pediatrics. 2002 May;109(5):E74-4.|Hanson IC, Antonelli TA, Sperling RS, Oleske JM, Cooper E, Culnane M, Fowler MG, Kalish LA, Lee SS, McSherry G, Mofenson L, Shapiro DE. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 15;20(5):463-7.|Gaughan DM, Hughes MD, Seage GR 3rd, Selwyn PA, Carey VJ, Gortmaker SL, Oleske JM. The prevalence of pain in pediatric human immunodeficiency virus/acquired immunodeficiency syndrome as reported by participants in the Pediatric Late Outcomes Study (PACTG 219). Pediatrics. 2002 Jun;109(6):1144-52.|Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR 3rd, Song LY, Dankner WM, Oleske JM; Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001 Nov 22;345(21):1522-8.|Howland LC, Gortmaker SL, Mofenson LM, Spino C, Gardner JD, Gorski H, Fowler MG, Oleske J. Effects of negative life events on immune suppression in children and youth infected with human immunodeficiency virus type 1. Pediatrics. 2000 Sep;106(3):540-6.|Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr. 2000 Nov 1;25(3):261-8.|Gaughan DM, Hughes MD, Oleske JM, Malee K, Gore CA, Nachman S; Pediatric AIDS Clinical Trials Group 219C Team. Psychiatric hospitalizations among children and youths with human immunodeficiency virus infection. Pediatrics. 2004 Jun;113(6):e544-51.|Farley J, Gona P, Crain M, Cervia J, Oleske J, Seage G, Lindsey J; Pediatric AIDS Clinical Trials Group Study 219C Team. Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C. J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):480-7.|Kest H, Brogly S, McSherry G, Dashefsky B, Oleske J, Seage GR 3rd. Malignancy in perinatally human immunodeficiency virus-infected children in the United States. Pediatr Infect Dis J. 2005 Mar;24(3):237-42.|Brogly S, Williams P, Seage GR 3rd, Oleske JM, Van Dyke R, McIntosh K; PACTG 219C Team. Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice. JAMA. 2005 May 11;293(18):2213-20.|Gona P, Van Dyke RB, Williams PL, Dankner WM, Chernoff MC, Nachman SA, Seage GR 3rd. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA. 2006 Jul 19;296(3):292-300.|Williams PL, Storm D, Montepiedra G, Nichols S, Kammerer B, Sirois PA, Farley J, Malee K; PACTG 219C Team. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics. 2006 Dec;118(6):e1745-57. Epub 2006 Nov 13.|Sirois PA, Montepiedra G, Kapetanovic S, Williams PL, Pearson DA, Malee K, Garvie PA, Kammerer BL, Nichols SL, Nozyce ML, Mintz M, Mitchell WG, Oleske JM; IMPAACT/PACTG 219C Team. Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV. J Dev Behav Pediatr. 2009 Oct;30(5):403-12.|Levin MJ, Anderson JP, Seage GR 3rd, Williams PL; PACTG/IMPAACT 219C Team. Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children. J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):182-91. doi: 10.1097/QAI.0b013e31819550a4.|Edathodu J, Halim MM, Dahham MB, Alrajhi AA. Mother-to-child transmission of HIV: experience at a referral hospital in Saudi Arabia. Ann Saudi Med. 2010 Jan-Feb;30(1):15-7. doi: 10.4103/0256-4947.59367.|Kapetanovic S, Aaron L, Montepiedra G, Sirois PA, Oleske JM, Malee K, Pearson DA, Nichols SL, Garvie PA, Farley J, Nozyce ML, Mintz M, Williams PL; Pediatric AIDS Clinical Trials. The use of second-generation antipsychotics and the changes in physical growth in children and adolescents with perinatally acquired HIV. AIDS Patient Care STDS. 2009 Nov;23(11):939-47. doi: 10.1089/apc.2009.0121.|Nachman SA, Chernoff M, Gona P, Van Dyke RB, Dankner WM, Seage GR 3rd, Oleske J, Williams PL; PACTG 219C Team. Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. Arch Pediatr Adolesc Med. 2009 Feb;163(2):164-71. doi: 10.1001/archpedi.163.2.164. Erratum in: Arch Pediatr Adolesc Med. 2009 Apr;163(4):364.|Williams PL, Van Dyke R, Eagle M, Smith D, Vincent C, Ciupak G, Oleske J, Seage GR 3rd; PACTG 219C Team. Association of site-specific and participant-specific factors with retention of children in a long-term pediatric HIV cohort study. Am J Epidemiol. 2008 Jun 1;167(11):1375-86. doi: 10.1093/aje/kwn072. Epub 2008 Apr 15.|Lyon ME, Williams PL, Woods ER, Hutton N, Butler AM, Sibinga E, Brady MT, Oleske JM. Do-not-resuscitate orders and/or hospice care, psychological health, and quality of life among children/adolescents with acquired immune deficiency syndrome. J Palliat Med. 2008 Apr;11(3):459-69. doi: 10.1089/jpm.2007.0148.|Lindsey JC, Malee KM, Brouwers P, Hughes MD; PACTG 219C Study Team. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy. Pediatrics. 2007 Mar;119(3):e681-93. Epub 2007 Feb 12.|Seage GR 3rd, Buchacz K, Weinberg GA, Patel K, McIntosh K, Dankner WM. The Pediatric AIDS Severity Score (PASS): a multidimensional AIDS-severity adjustment for pediatric HIV infection. J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):603-10.|Williams PL, Marino M, Malee K, Brogly S, Hughes MD, Mofenson LM; PACTG 219C Team. Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants. Pediatrics. 2010 Feb;125(2):e250-60. doi: 10.1542/peds.2009-1112. Epub 2010 Jan 18.|Malee K, Williams PL, Montepiedra G, Nichols S, Sirois PA, Storm D, Farley J, Kammerer B; PACTG 219C Team. The role of cognitive functioning in medication adherence of children and adolescents with HIV infection. J Pediatr Psychol. 2009 Mar;34(2):164-75. doi: 10.1093/jpepsy/jsn068. Epub 2008 Jul 22.|Kapetanovic S, Aaron L, Williams PL, Farley J, Sirois PA, Garvie PA, Pearson DA, Oleske JM, Montepiedra G; The IMPAACT PACTG 219C Team. Relationships between the use of second-generation antipsychotics and changes in total cholesterol levels in children and adolescents perinatally infected with HIV. Neurobehav HIV Med. 2010 Aug;2010(2):39-48.|Malee K, Williams P, Montepiedra G, McCabe M, Nichols S, Sirois PA, Storm D, Farley J, Kammerer B; PACTG 219C Team. Medication adherence in children and adolescents with HIV infection: associations with behavioral impairment. AIDS Patient Care STDS. 2011 Mar;25(3):191-200. doi: 10.1089/apc.2010.0181. Epub 2011 Feb 16.","\tHIV Infections|HIV Seronegativity\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","infection","NA","NA"]
["NCT00006340","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17119113|9628848","Perrine SP, Hermine O, Small T, Suarez F, O'Reilly R, Boulad F, Fingeroth J, Askin M, Levy A, Mentzer SJ, Di Nicola M, Gianni AM, Klein C, Horwitz S, Faller DV. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007 Mar 15;109(6):2571-8. Epub 2006 Nov 21.|Mentzer SJ, Fingeroth J, Reilly JJ, Perrine SP, Faller DV. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. Blood Cells Mol Dis. 1998 Jun;24(2):114-23.","\tLeukemia|Lymphoma|Precancerous Condition|Small Intestine Cancer\targinine butyrate|ganciclovir\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|leukemia|precancerous conditions|intestinal neoplasms","arginine butyrate|ganciclovir triphosphate|ganciclovir","NA"]
["NCT00006343","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20679528|19648168|19117345|17151364|12637609","Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP; IRIS investigators. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010 Nov 11;116(19):3758-65. doi: 10.1182/blood-2010-03-273979. Epub 2010 Aug 2.|Guilhot F, Druker B, Larson RA, Gathmann I, So C, Waltzman R, O'Brien SG. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica. 2009 Dec;94(12):1669-75. doi: 10.3324/haematol.2009.010629. Epub 2009 Jul 31.|Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, Krahnke T, Cortes J, Druker BJ; International Randomized Study of Interferon and STI571 (IRIS) Investigators. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 2009 Feb 1;115(3):551-60. doi: 10.1002/cncr.24066. Erratum in: Cancer. 2010 Aug 1;116(15):3750. Santini, Valeria [added].|Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006 Dec 7;355(23):2408-17.|O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003 Mar 13;348(11):994-1004.","\tLeukemia\trecombinant interferon alfa|cytarabine|imatinib mesylate\tNA\tNA\tNA\tBiological|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, myeloid|leukemia, myelogenous, chronic, bcr-abl positive|leukemia","interferon-alpha|interferons|cytarabine|imatinib mesylate","NA"]
["NCT00006346","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19815592,"Nidich SI, Fields JZ, Rainforth MV, Pomerantz R, Cella D, Kristeller J, Salerno JW, Schneider RH. A randomized controlled trial of the effects of transcendental meditation on quality of life in older breast cancer patients. Integr Cancer Ther. 2009 Sep;8(3):228-34. doi: 10.1177/1534735409343000.","\tBreast Cancer|Psychosocial Effects of Cancer and Its Treatment\tpsychosocial assessment and care|quality-of-life assessment\tNA\tNA\tNA\tProcedure|Procedure\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","NA","NA"]
["NCT00006349","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15480814,"Jatoi A, Kahanic SP, Frytak S, Schaefer P, Foote RL, Sloan J, Petersen RC. Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designs. Support Care Cancer. 2005 Jan;13(1):66-9. Epub 2004 Oct 9.","\tCognitive/Functional Effects|Delirium|Depression|Lung Cancer|Radiation Toxicity\tvitamin E|donepezil hydrochloride|placebo\tParallel Assignment\tSupportive Care\tRandomized\tDietary Supplement|Drug|Other\tAll\t","Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer","Interventional","Completed","Phase 3",2,9,"depression|lung neoplasms|small cell lung carcinoma|delirium","vitamin e|donepezil","NA"]
["NCT00006351","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15911238,"Theodore C, Geoffrois L, Vermorken JB, Caponigro F, Fiedler W, Chollet P, Ravaud A, Peters GJ, de Balincourt C, Lacombe D, Fumoleau P. Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur J Cancer. 2005 May;41(8):1150-7.","\tBladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer\tgemcitabine hydrochloride|lonafarnib\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","urinary bladder neoplasms|urethral neoplasms|carcinoma, transitional cell|kidney neoplasms|ureteral neoplasms","gemcitabine|lonafarnib","NA"]
["NCT00006352","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16192577,"Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, Thiberville L, D'addario G, Coens C, Rome LS, Zatloukal P, Masso O, Legrand C. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol. 2005 Oct 1;23(28):6854-64.","\tLung Cancer\tBCG vaccine|monoclonal antibody BEC2\tNA\tNA\tNA\tBiological|Biological\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|small cell lung carcinoma","bcg vaccine|antibodies|antibodies, monoclonal","NA"]
["NCT00006353","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21880994|19269895|18082451|17609661|NA|16735709|NA|16203762|15758010|15758009|16321761|15251162|NA|NA|NA|NA|NA|NA|NA","Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, Stupp R. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011 Sep 20;77(12):1156-64. doi: 10.1212/WNL.0b013e31822f02e1. Epub 2011 Aug 31.|Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 May;10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7. Epub 2009 Mar 9.|Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008 Jan;9(1):29-38. Epub 2007 Dec 21.|Mauer M, Stupp R, Taphoorn MJ, Coens C, Osoba D, Marosi C, Wong R, de Witte O, Cairncross JG, Efficace F, Mirimanoff RO, Forsyth P, van den Bent MJ, Weller M, Bottomley A. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. Br J Cancer. 2007 Aug 6;97(3):302-7. Epub 2007 Jul 3.|Mirimanoff R, Mason W, van den Bent M, et al.: Is long-term survival in glioblastoma possible? Updated results of the EORTC/NCIC phase III randomized trial on radiotherapy (RT) and concomitant and adjuvant temozolomide (TMZ) versus RT alone. [Abstract] Int J Radiat Oncol Biol Phys 69 (3 Suppl): Plenary-3, S2, 2007.|Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006 Jun 1;24(16):2563-9.|Bottomley A, Taphoorn M, Coens C, et al.: Predicting survival using health related quality of life scores in glioblastoma cancers: findings from an international phase III randomised controlled trial. [Abstract] J Clin Oncol 23 (Suppl 16): A-9601, 861s, 2005.|Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6767-71.|Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005 Mar 10;352(10):997-1003.|Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96.|Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, Mason W, Mirimanoff RO, Baumert BG, Eisenhauer E, Forsyth P, Bottomley A; European Organisation for Research and Treatment of Cancer Brain Tumour Group; EORTC Radiotherapy Group; National Cancer Institute of Canada Clinical Trials Group. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. 2005 Dec;6(12):937-44.|Ataman F, Poortmans P, Stupp R, Fisher B, Mirimanoff RO. Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review. Eur J Cancer. 2004 Jul;40(11):1724-30.|Gorlia T, Stupp R, Eisenhauer EA, et al.: Clinical prognostic factors affecting survival in patients with newly diagnosed glioblastoma multiforme (GBM). [Abstract] J Clin Oncol 22 (Suppl 14): A-9599, 859s, 2004.|Hegi M, Diserens A, Hamou M, et al.: Temozolomide (TMZ) targets only glioblastoma with a silenced MGMT-gene. Results of a translational companion study to EORTC 26981/NCIC CE.3 or radiotherapy ± TMZ. [Abstract] Eur J Cancer 2 (8 Suppl 2): A-31, 14, 2004.|Mirimanoff RO, Mason W, Kortmann R, et al.: Radiotherapy (RT) and concomitant and adjuvant temozolomide (TMZ) versus radiotherapy alone for newly diagnosed glioblastoma (GBM): overall results and recursive partitioning analysis (RPA) of a phase III randomized trial of the EORTC Brain Tumor and Radiotherapy Group and the NCIC Clinical Trial Group. [Abstract] Int J Radiat Oncol Biol Phys 60 (1 Suppl 1): A-55, S162, 2004. Available online. Last accessed January 26, 2005.|Murat A, Migliavacca E, Shay T, et al.: Gene expression profiling of human glioblastoma. A translational research study to the randomized trial EORTC 26981/NCIC CE.3 testing radiotherapy ± temozolomide. [Abstract] Eur J Cancer 2 (Suppl 8): A- 654, 197, 2004.|Stupp R, Mason WP, Van Den Bent MJ, et al.: Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. [Abstract] J Clin Oncol 22 (Suppl 14): A-2, 1s, 2004.|Taphoorn MJ, Stupp R, Osoba D, et al.: An international phase III, randomized, controlled trial evaluating health-related quality of life in glioblastoma patients. [Abstract] Neuro-Oncology 6 (4): A-QL-13, 348, 2004.|Taphoorn MJ, Stupp R, Osoba D, et al.: Joint EORTC brain tumour group/radiotherapy group and NCIC CTG phase III randomized controlled trial evaluating health-related quality of life in glioblastoma patients . [Abstract] Ann Oncol 15 (3): A-7810, 2004.","\tBrain and Central Nervous System Tumors\ttemozolomide|radiation therapy\tNA\tNA\tNA\tDrug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","nervous system neoplasms|central nervous system neoplasms|glioblastoma","temozolomide","NA"]
["NCT00006355","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Lesser GJ, Carson K, Supko J, et al.: A phase I/II trial and pharmacokinetic study of pyrazoloacridine in adults with newly diagnosed glioblastoma multiforme. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-485, 121a, 2003.|Lesser GJ, Carson K, Priet R, et al.: A phase I/II trial of pyrazoloacridine (PZA) in adults with newly diagnosed glioblastoma multiforme (GBM). [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-2097, 2002.","\tBrain and Central Nervous System Tumors\tpyrazoloacridine|adjuvant therapy|radiation therapy\tNA\tNA\tNA\tDrug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|glioblastoma|nervous system neoplasms","nsc 366140","NA"]
["NCT00006357","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19088049|15592836|15010069|12957454|12528778|11705489","van Erp N, Gelderblom H, van Glabbeke M, Van Oosterom A, Verweij J, Guchelaar HJ, Debiec-Rychter M, Peng B, Blay JY, Judson I. Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. Clin Cancer Res. 2008 Dec 15;14(24):8308-13. doi: 10.1158/1078-0432.CCR-08-1303.|Judson I, Ma P, Peng B, Verweij J, Racine A, di Paola ED, van Glabbeke M, Dimitrijevic S, Scurr M, Dumez H, van Oosterom A. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol. 2005 Apr;55(4):379-386. doi: 10.1007/s00280-004-0876-0. Epub 2004 Dec 9.|Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, Dimitrijevic S, Sciot R, Stul M, Vranck H, Scurr M, Hagemeijer A, van Glabbeke M, van Oosterom AT; EORTC Soft Tissue and Bone Sarcoma Group. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2004 Mar;40(5):689-95.|Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, Radford J, Le Cesne A, Hogendoorn PC, di Paola ED, Brown M, Nielsen OS. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer. 2003 Sep;39(14):2006-11.|van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato di Paola E, Sciot R, Van Glabbeke M, Dimitrijevic S, Nielsen OS; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002 Sep;38 Suppl 5:S83-7.|van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001 Oct 27;358(9291):1421-3.","\tEndometrial Cancer|Gastrointestinal Stromal Tumor|Ovarian Cancer|Sarcoma|Small Intestine Cancer\timatinib mesylate\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","sarcoma|intestinal neoplasms|gastrointestinal stromal tumors|endometrial neoplasms","imatinib mesylate","NA"]
["NCT00006358","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17031561,"Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol. 2007 Feb;81(3):271-7. Epub 2006 Sep 22.","\tBrain and Central Nervous System Tumors\ttemozolomide|thalidomide\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|nervous system neoplasms|glioblastoma","temozolomide|thalidomide","NA"]
["NCT00006359","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22535500|18407435|NA","Hurwitz MD, Halabi S, Archer L, McGinnis LS, Kuettel MR, DiBiase SJ, Small EJ. Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809. Cancer. 2011 Dec 15;117(24):5579-88. doi: 10.1002/cncr.26203. Epub 2011 Jul 25.|Hurwitz MD, Halabi S, Ou SS, McGinnis LS, Keuttel MR, Dibiase SJ, Small EJ. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):814-9. doi: 10.1016/j.ijrobp.2008.01.010. Epub 2008 Apr 11.|Hurwitz MD, Halabi S, Ou SS, et al.: Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate risk prostate cancer: an initial report of CALGB 99-809. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-2230, S337-8, 2006.","\tProstate Cancer\tLHRH agonist|antiandrogen|radiation therapy|Brachytherapy boost\tNA\tNA\tNA\tDrug|Drug|Radiation|Radiation\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","androgen antagonists","NA"]
["NCT00006360","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19540060|NA","Eisbruch A, Harris J, Garden AS, Chao CK, Straube W, Harari PM, Sanguineti G, Jones CU, Bosch WR, Ang KK. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1333-8. doi: 10.1016/j.ijrobp.2009.04.011. Epub 2009 Jun 18.|Eisbruch A, Harris J, Garden A, et al.: Phase II multi-institutional study of IMRT for oropharyngeal cancer (RTOG 00-22): early results. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-79, S46-7, 2006.","\tHead and Neck Cancer|Radiation Toxicity\tradioprotection|radiation therapy\tNA\tNA\tNA\tDrug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","oropharyngeal neoplasms","NA","NA"]
["NCT00006361","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Zahalsky AJ, Wong RJ, Lis E, et al.: Phase II trial of SU5416 in patients with advanced incurable head and neck cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-902, 2002.","\tCarcinoma of Unknown Primary|Head and Neck Cancer|Non-melanomatous Skin Cancer\tsemaxanib\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","skin neoplasms|head and neck neoplasms|neoplasms, unknown primary|carcinoma","semaxinib","NA"]
["NCT00006365","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|16289906|NA|17118317|22330999|17340591","Lee W, Bae K, Lawton C, et al.: Biochemical recurrence and late toxicity following external beam radiotherapy combined with permanent source prostate brachytherapy: analysis of RTOG 0019. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-100, S57, 2006.|Lee W, Bae K, Lawton CF, et al.: A descriptive analysis of postimplant dosimetric parameters from RTOG P0019. [Abstract] 2006 Prostate Cancer Symposium, February 24-26, 2006, San Francisco, CA. A-83, 2006.|Lee WR, DeSilvio M, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H. A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019. Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):804-9. Epub 2005 Nov 14.|Lee W, DeSilvio M, Lawton C, et al.: Is postimplant dosimetry associated with late morbidity? A secondary analysis of RTOG P-0019. [Abstract] American Society of Clinical Oncology 2005 Prostate Cancer Symposium, 17-19 February 2005, Orlando, Florida. A-96, 2005.|Lee WR, Bae K, Lawton CA, Gillin MT, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H. A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019. Brachytherapy. 2006 Oct-Dec;5(4):239-43.|Lawton CA, Yan Y, Lee WR, Gillin M, Firat S, Baikadi M, Crook J, Kuettel M, Morton G, Sandler H. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):e795-801. doi: 10.1016/j.ijrobp.2011.11.040. Epub 2012 Feb 11.|Lee WR, Bae K, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019. Cancer. 2007 Apr 15;109(8):1506-12.","\tProstate Cancer\tbrachytherapy|iodine I 125|radiation therapy\tNA\tNA\tNA\tRadiation|Radiation|Radiation\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","NA","NA"]
["NCT00006366","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|16446336|NA|NA","Mohiuddin M, Garcia M, Mitchell E, et al.: 3-year results of RTOG-0012 randomized phase II study of neoadjuvant combined modality chemoradiation for distal rectal cancer. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-2092, S260, 2006.|Mohiuddin M, Winter K, Mitchell E, Hanna N, Yuen A, Nichols C, Shane R, Hayostek C, Willett C; Radiation Therapy Oncology Group Trial 0012. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol. 2006 Feb 1;24(4):650-5.|Mitchell EP, Winter K, Mohiuddin M, et al.: Randomized phase II trial of preoperative combined modality chemoradiation for distal rectal cancer. [Abstract] J Clin Oncol 22 (Suppl 14): A-3535, 253s, 2004.|Mohiuddin M, Winter K, Mitchell E, et al.: Results of RTOG-0012 randomized phase II study of neoadjuvant combined modality chemoradiation for distal rectal cancer. [Abstract] Int J Radiat Oncol Biol Phys 60 (Suppl 1): A-16, S138, 2004.","\tColorectal Cancer\tfluorouracil|irinotecan hydrochloride|conventional surgery|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","fluorouracil|irinotecan","NA"]
["NCT00006367","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11468154,"Anderson JE, Tefferi A, Craig F, Holmberg L, Chauncey T, Appelbaum FR, Guardiola P, Callander N, Freytes C, Gazitt Y, Razvillas B, Deeg HJ. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood. 2001 Aug 1;98(3):586-93.","\tChronic Myeloproliferative Disorders\tfilgrastim|busulfan|cytarabine|idarubicin|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","myeloproliferative disorders|primary myelofibrosis","busulfan|cytarabine|idarubicin","NA"]
["NCT00006376","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15812833,"Rosenberg JE, von der Maase H, Seigne JD, Mardiak J, Vaughn DJ, Moore M, Sahasrabudhe D, Palmer PA, Perez-Ruixo JJ, Small EJ. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer. 2005 May 15;103(10):2035-41.","\tBladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter\tchemotherapy|tipifarnib\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","ureteral neoplasms|urinary bladder neoplasms|kidney neoplasms|carcinoma, transitional cell","tipifarnib","NA"]
["NCT00006378","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Bonomi P, Curran W, Choy H, et al.: Randomized 3-arm phase II study of paclitaxel (T), carboplatin (C), and thoracic radiation (TRT) for patients with stage III non-small cell lung cancer (NSCLC). Report of locally advanced multimodality protocol (LAMP) - ACR 427. [Abstract] Lung Cancer 41 (Suppl 2): A-O-263, S77, 2003.","\tLung Cancer\tcarboplatin|paclitaxel|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","carboplatin|paclitaxel","NA"]
["NCT00006382","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20404381|15249451","Croswell JM, Baker SG, Marcus PM, Clapp JD, Kramer BS. Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med. 2010 Apr 20;152(8):505-12, W176-80. doi: 10.7326/0003-4819-152-8-201004200-00007. Erratum in: Ann Intern Med. 2010 Jun 1;152(11):759.|Gohagan J, Marcus P, Fagerstrom R, Pinsky P, Kramer B, Prorok P; Writing Committee, Lung Screening Study Research Group. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute. Chest. 2004 Jul;126(1):114-21.","\tLung Cancer\tradiography|bronchoscopic and lung imaging studies|comparison of screening methods|computed tomography|study of high risk factors\tNA\tNA\tNA\tProcedure|Procedure|Procedure|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms","NA","NA"]
["NCT00006383","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19536896,"Rodriguez MA, Pytlik R, Kozak T, Chhanabhai M, Gascoyne R, Lu B, Deitcher SR, Winter JN; Marqibo Investigators. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study. Cancer. 2009 Aug 1;115(15):3475-82. doi: 10.1002/cncr.24359.","\tLymphoma\tliposomal vincristine sulfate\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|lymphoma, non-hodgkin","vincristine","NA"]
["NCT00006384","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14581348,"Lara PN Jr, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR; California Cancer Consortium. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res. 2003 Oct 15;9(13):4772-81.","\tKidney Cancer\trecombinant interferon alfa|semaxanib\tNA\tNA\tNA\tBiological|Drug\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, renal cell|kidney neoplasms","interferon-alpha|interferons","NA"]
["NCT00006385","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22021080|19228745|NA|NA","Schaefer C, Butterfield LH, Lee S, Kim GG, Visus C, Albers A, Kirkwood JM, Whiteside TL. Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696). Int J Cancer. 2012 Aug 15;131(4):874-84. doi: 10.1002/ijc.26481. Epub 2012 Jan 11.|Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, Whiteside T, Butterfield LH, Weiner L. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res. 2009 Feb 15;15(4):1443-51. doi: 10.1158/1078-0432.CCR-08-1231.|Kirkwood JM, Lee S, Land S, et al.: E1696: final analysis of the clinical and immunological results of a multicenter ECOG phase II trial of multi-epitope peptide vaccination for stage IV melanoma with MART-1 (27-35), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) (MGT) +/- IFNα2b and GM-CSF. [Abstract] J Clin Oncol 22 (Suppl 14): A-7502, 710s, 2004.|Kirkwood JM, Lee S, Land S, et al.: E1696: phase II trial of multi-epitope peptide vaccination for melanoma with MGT (MART-1 (27-35), gp100 (209-217, 210M) and tyrosinase (368-376, 370D))+/- IFN alfa-2b and GM-CSF--immunological and clinical results. [Abstract] 22: A-2850, 709, 2003.","\tMelanoma (Skin)\tMART-1 antigen|gp100 antigen|incomplete Freund's adjuvant|recombinant interferon alfa|sargramostim|tyrosinase peptide\tNA\tNA\tNA\tBiological|Biological|Biological|Biological|Biological|Biological\tAll\t","NA","NA","NA","NA","NA","NA","melanoma","freund's adjuvant|interferons|interferon-alpha|sargramostim","NA"]
["NCT00006386","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Cardinale R, Won M, Choucair A, et al.: A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boosts for supratentorial glioblastoma multiforme. RTOG-0023. [Abstract] J Clin Oncol 23 (Suppl 16): A-1511, 116s, 2005.","\tBrain and Central Nervous System Tumors\tcarmustine|radiation therapy|stereotactic radiosurgery\tNA\tNA\tNA\tDrug|Radiation|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","glioblastoma|nervous system neoplasms|central nervous system neoplasms","carmustine","NA"]
["NCT00006388","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16443947|NA","Robins HI, Won M, Seiferheld WF, Schultz CJ, Choucair AK, Brachman DG, Demas WF, Mehta MP. Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Neuro Oncol. 2006 Jan;8(1):47-52.|Robins HI, Won M, Schultz C, et al.: A phase II trial of conventional radiation therapy (XRT) plus high dose tamoxifen (TAM) for the treatment of supratentorial glioblastoma multiforme (GBM): RTOG protocol BR-0021. [Abstract] J Clin Oncol 22 (Suppl 14): A-1529, 114s, 2004.","\tBrain and Central Nervous System Tumors\ttamoxifen citrate|radiation therapy\tNA\tNA\tNA\tDrug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","glioblastoma|central nervous system neoplasms|nervous system neoplasms","tamoxifen","NA"]
["NCT00006391","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18191187,"Hochster H, Chen TT, Lu JM, Hills D, Sorich J, Escalon J, Ivy P, Liebes L, Muggia F. Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study. Gynecol Oncol. 2008 Mar;108(3):500-4. doi: 10.1016/j.ygyno.2007.11.017. Epub 2008 Jan 11.","\tFallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer\toxaliplatin|topotecan hydrochloride\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","ovarian neoplasms|fallopian tube neoplasms|carcinoma, ovarian epithelial","oxaliplatin|topotecan","NA"]
["NCT00006392",8267644,4515789,"Risk Ratio (RR)",0.99,null,"NA",0.89,1.1,99,0.05,"Chi-squared","19066370|21990298","Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.|Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.","\tProstate Cancer\tVitamin E|Selenium|Vitamin E placebo|selenium placebo\tNA\tNA\tNA\tDrug|Drug|Other|Other\tMale\t","S0000 Selenium and Vitamin E in Preventing Prostate Cancer","Interventional","Completed","Phase 3",4,35533,"prostatic neoplasms","selenium|vitamin e|tocopherols|tocotrienols|alpha-tocopherol|vitamins","Number of Participants With Serious Cardiovascular Events"]
["NCT00006392",8267644,4515791,"Risk Ratio (RR)",0.98,null,"NA",0.88,1.09,99,0.05,"Chi-squared","19066370|21990298","Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.|Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.","\tProstate Cancer\tVitamin E|Selenium|Vitamin E placebo|selenium placebo\tNA\tNA\tNA\tDrug|Drug|Other|Other\tMale\t","S0000 Selenium and Vitamin E in Preventing Prostate Cancer","Interventional","Completed","Phase 3",4,35533,"prostatic neoplasms","selenium|vitamin e|tocopherols|tocotrienols|alpha-tocopherol|vitamins","Number of Participants With Serious Cardiovascular Events"]
["NCT00006392",8267644,4515790,"Risk Ratio (RR)",1.02,null,"NA",0.92,1.13,99,0.05,"Chi-squared","19066370|21990298","Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.|Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.","\tProstate Cancer\tVitamin E|Selenium|Vitamin E placebo|selenium placebo\tNA\tNA\tNA\tDrug|Drug|Other|Other\tMale\t","S0000 Selenium and Vitamin E in Preventing Prostate Cancer","Interventional","Completed","Phase 3",4,35533,"prostatic neoplasms","selenium|vitamin e|tocopherols|tocotrienols|alpha-tocopherol|vitamins","Number of Participants With Serious Cardiovascular Events"]
["NCT00006392",8267645,4515793,"Hazard Ratio (HR)",0.99,null,"NA",0.82,1.19,99,0.05,"Regression, Cox","19066370|21990298","Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.|Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.","\tProstate Cancer\tVitamin E|Selenium|Vitamin E placebo|selenium placebo\tNA\tNA\tNA\tDrug|Drug|Other|Other\tMale\t","S0000 Selenium and Vitamin E in Preventing Prostate Cancer","Interventional","Completed","Phase 3",4,35533,"prostatic neoplasms","selenium|vitamin e|tocopherols|tocotrienols|alpha-tocopherol|vitamins","Prostate Cancer Free Survival; Lung Cancer-free Survival, Colorectal Cancer-free Survival, Cancer-free Survival, Overall Survival"]
["NCT00006392",8267645,4515794,"Hazard Ratio (HR)",0.93,null,"NA",0.77,1.13,99,0.05,"Regression, Cox","19066370|21990298","Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.|Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.","\tProstate Cancer\tVitamin E|Selenium|Vitamin E placebo|selenium placebo\tNA\tNA\tNA\tDrug|Drug|Other|Other\tMale\t","S0000 Selenium and Vitamin E in Preventing Prostate Cancer","Interventional","Completed","Phase 3",4,35533,"prostatic neoplasms","selenium|vitamin e|tocopherols|tocotrienols|alpha-tocopherol|vitamins","Prostate Cancer Free Survival; Lung Cancer-free Survival, Colorectal Cancer-free Survival, Cancer-free Survival, Overall Survival"]
["NCT00006392",8267645,4515792,"Hazard Ratio (HR)",0.94,null,"NA",0.77,1.13,99,0.05,"Regression, Cox","19066370|21990298","Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.|Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.","\tProstate Cancer\tVitamin E|Selenium|Vitamin E placebo|selenium placebo\tNA\tNA\tNA\tDrug|Drug|Other|Other\tMale\t","S0000 Selenium and Vitamin E in Preventing Prostate Cancer","Interventional","Completed","Phase 3",4,35533,"prostatic neoplasms","selenium|vitamin e|tocopherols|tocotrienols|alpha-tocopherol|vitamins","Prostate Cancer Free Survival; Lung Cancer-free Survival, Colorectal Cancer-free Survival, Cancer-free Survival, Overall Survival"]
["NCT00006392",8267646,4515797,"Hazard Ratio (HR)",1.03,null,"NA",0.91,1.17,99,0.05,"Regression, Cox","19066370|21990298","Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.|Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.","\tProstate Cancer\tVitamin E|Selenium|Vitamin E placebo|selenium placebo\tNA\tNA\tNA\tDrug|Drug|Other|Other\tMale\t","S0000 Selenium and Vitamin E in Preventing Prostate Cancer","Interventional","Completed","Phase 3",4,35533,"prostatic neoplasms","selenium|vitamin e|tocopherols|tocotrienols|alpha-tocopherol|vitamins","Number of Participants With Any Diagnosis of Cancer"]
["NCT00006392",8267646,4515796,"Hazard Ratio (HR)",1.01,null,"NA",0.89,1.15,99,0.05,"Regression, Cox","19066370|21990298","Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.|Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.","\tProstate Cancer\tVitamin E|Selenium|Vitamin E placebo|selenium placebo\tNA\tNA\tNA\tDrug|Drug|Other|Other\tMale\t","S0000 Selenium and Vitamin E in Preventing Prostate Cancer","Interventional","Completed","Phase 3",4,35533,"prostatic neoplasms","selenium|vitamin e|tocopherols|tocotrienols|alpha-tocopherol|vitamins","Number of Participants With Any Diagnosis of Cancer"]
["NCT00006392",8267646,4515795,"Hazard Ratio (HR)",1.02,null,"NA",0.9,1.16,99,0.05,"Regression, Cox","19066370|21990298","Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.|Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.","\tProstate Cancer\tVitamin E|Selenium|Vitamin E placebo|selenium placebo\tNA\tNA\tNA\tDrug|Drug|Other|Other\tMale\t","S0000 Selenium and Vitamin E in Preventing Prostate Cancer","Interventional","Completed","Phase 3",4,35533,"prostatic neoplasms","selenium|vitamin e|tocopherols|tocotrienols|alpha-tocopherol|vitamins","Number of Participants With Any Diagnosis of Cancer"]
["NCT00006392",8267647,4515798,"Hazard Ratio (HR)",1.28,null,"NA",0.82,2,99,0.05,"Regression, Cox","19066370|21990298","Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.|Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.","\tProstate Cancer\tVitamin E|Selenium|Vitamin E placebo|selenium placebo\tNA\tNA\tNA\tDrug|Drug|Other|Other\tMale\t","S0000 Selenium and Vitamin E in Preventing Prostate Cancer","Interventional","Completed","Phase 3",4,35533,"prostatic neoplasms","selenium|vitamin e|tocopherols|tocotrienols|alpha-tocopherol|vitamins","Number of Participants With Colorectal Cancer"]
["NCT00006392",8267647,4515799,"Hazard Ratio (HR)",1.05,null,"NA",0.66,1.67,99,0.05,"Regression, Cox","19066370|21990298","Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.|Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.","\tProstate Cancer\tVitamin E|Selenium|Vitamin E placebo|selenium placebo\tNA\tNA\tNA\tDrug|Drug|Other|Other\tMale\t","S0000 Selenium and Vitamin E in Preventing Prostate Cancer","Interventional","Completed","Phase 3",4,35533,"prostatic neoplasms","selenium|vitamin e|tocopherols|tocotrienols|alpha-tocopherol|vitamins","Number of Participants With Colorectal Cancer"]
["NCT00006392",8267647,4515800,"Hazard Ratio (HR)",1.09,null,"NA",0.69,1.73,99,0.05,"Regression, Cox","19066370|21990298","Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.|Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.","\tProstate Cancer\tVitamin E|Selenium|Vitamin E placebo|selenium placebo\tNA\tNA\tNA\tDrug|Drug|Other|Other\tMale\t","S0000 Selenium and Vitamin E in Preventing Prostate Cancer","Interventional","Completed","Phase 3",4,35533,"prostatic neoplasms","selenium|vitamin e|tocopherols|tocotrienols|alpha-tocopherol|vitamins","Number of Participants With Colorectal Cancer"]
["NCT00006392",8267648,4515801,"Hazard Ratio (HR)",1.16,null,"NA",0.9,1.16,99,0.01,"Regression, Cox","19066370|21990298","Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.|Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.","\tProstate Cancer\tVitamin E|Selenium|Vitamin E placebo|selenium placebo\tNA\tNA\tNA\tDrug|Drug|Other|Other\tMale\t","S0000 Selenium and Vitamin E in Preventing Prostate Cancer","Interventional","Completed","Phase 3",4,35533,"prostatic neoplasms","selenium|vitamin e|tocopherols|tocotrienols|alpha-tocopherol|vitamins","Number of Participants With Lung Cancer"]
["NCT00006392",8267648,4515802,"Hazard Ratio (HR)",1.12,null,"NA",0.73,1.72,99,0.01,"Regression, Cox","19066370|21990298","Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.|Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.","\tProstate Cancer\tVitamin E|Selenium|Vitamin E placebo|selenium placebo\tNA\tNA\tNA\tDrug|Drug|Other|Other\tMale\t","S0000 Selenium and Vitamin E in Preventing Prostate Cancer","Interventional","Completed","Phase 3",4,35533,"prostatic neoplasms","selenium|vitamin e|tocopherols|tocotrienols|alpha-tocopherol|vitamins","Number of Participants With Lung Cancer"]
["NCT00006392",8267648,4515803,"Hazard Ratio (HR)",1,null,"NA",0.64,1.55,99,0.05,"Regression, Cox","19066370|21990298","Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.|Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.","\tProstate Cancer\tVitamin E|Selenium|Vitamin E placebo|selenium placebo\tNA\tNA\tNA\tDrug|Drug|Other|Other\tMale\t","S0000 Selenium and Vitamin E in Preventing Prostate Cancer","Interventional","Completed","Phase 3",4,35533,"prostatic neoplasms","selenium|vitamin e|tocopherols|tocotrienols|alpha-tocopherol|vitamins","Number of Participants With Lung Cancer"]
["NCT00006392",8267649,4515806,"Hazard Ratio (HR)",1.13,null,"NA",0.95,1.35,99,0.01,"Regression, Cox","19066370|21990298","Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.|Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.","\tProstate Cancer\tVitamin E|Selenium|Vitamin E placebo|selenium placebo\tNA\tNA\tNA\tDrug|Drug|Other|Other\tMale\t","S0000 Selenium and Vitamin E in Preventing Prostate Cancer","Interventional","Completed","Phase 3",4,35533,"prostatic neoplasms","selenium|vitamin e|tocopherols|tocotrienols|alpha-tocopherol|vitamins","Number of Participants With Prostate Cancer"]
["NCT00006392",8267649,4515804,"Hazard Ratio (HR)",1.05,null,"NA",0.88,1.25,99,0.01,"Regression, Cox","19066370|21990298","Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.|Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.","\tProstate Cancer\tVitamin E|Selenium|Vitamin E placebo|selenium placebo\tNA\tNA\tNA\tDrug|Drug|Other|Other\tMale\t","S0000 Selenium and Vitamin E in Preventing Prostate Cancer","Interventional","Completed","Phase 3",4,35533,"prostatic neoplasms","selenium|vitamin e|tocopherols|tocotrienols|alpha-tocopherol|vitamins","Number of Participants With Prostate Cancer"]
["NCT00006392",8267649,4515805,"Hazard Ratio (HR)",1.04,null,"NA",0.87,1.24,99,0.01,"Regression, Cox","19066370|21990298","Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.|Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.","\tProstate Cancer\tVitamin E|Selenium|Vitamin E placebo|selenium placebo\tNA\tNA\tNA\tDrug|Drug|Other|Other\tMale\t","S0000 Selenium and Vitamin E in Preventing Prostate Cancer","Interventional","Completed","Phase 3",4,35533,"prostatic neoplasms","selenium|vitamin e|tocopherols|tocotrienols|alpha-tocopherol|vitamins","Number of Participants With Prostate Cancer"]
["NCT00006396","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","10485720|13678973|14722443|12439209|11509999|15242535|16123677|16511414|16284468","Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F, Jackson JB. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999 Sep 4;354(9181):795-802.|Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Owor M, Ducar C, Deseyve M, Mwatha A, Emel L, Duefield C, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Gigliotti M, Bray D, Mmiro F. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003 Sep 13;362(9387):859-68.|Eshleman SH, Guay LA, Mwatha A, Brown ER, Cunningham SP, Musoke P, Mmiro F, Jackson JB. Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr. 2004 Feb 1;35(2):126-30.|Eshleman SH, Guay LA, Fleming T, Mwatha A, Mracna M, Becker-Pergola G, Musoke P, Mmiro F, Jackson JB. Survival of Ugandan infants with subtype A and D HIV-1 infection (HIVNET 012). J Acquir Immune Defic Syndr. 2002 Nov 1;31(3):327-30.|Eshleman SH, Becker-Pergola G, Deseyve M, Guay LA, Mracna M, Fleming T, Cunningham S, Musoke P, Mmiro F, Jackson JB. Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study). J Infect Dis. 2001 Oct 1;184(7):914-7. Epub 2001 Aug 13.|Eshleman SH, Guay LA, Mwatha A, Cunningham SP, Brown ER, Musoke P, Mmiro F, Jackson JB. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses. 2004 Jun;20(6):595-9.|Eshleman SH, Guay LA, Wang J, Mwatha A, Brown ER, Musoke P, Mmiro F, Jackson JB. Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):24-9.|Jackson JB, Parsons T, Musoke P, Nakabiito C, Donnell D, Fleming T, Mirochnick M, Mofenson L, Fowler MG, Mmiro F, Guay L. Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission. AIDS. 2006 Jan 9;20(2):217-22.|Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, Fiscus SA, Mmiro F, Musoke P, Jackson JB, Kumwenda N, Taha T. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS. 2005 Dec 2;19(18):2167-9.","\tHIV Infections\tNevirapine|Zidovudine\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","infection","zidovudine|nevirapine","NA"]
["NCT00006398","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16306522,"Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Gao H, Makuch R; Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005 Nov 24;353(21):2254-61.","\tEsophageal and Gastric Varices|Liver Cirrhosis|Portal Hypertension\tTimolol Maleate|Placebo\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug\tAll\t","Prevention of Esophageal Varices by Beta-Adrenergic Blockers","Interventional","Completed","Phase 3",2,213,"fibrosis|esophageal and gastric varices|liver cirrhosis|hypertension, portal|hypertension","timolol","NA"]
["NCT00006401","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16870914,"Kinsella JP, Cutter GR, Walsh WF, Gerstmann DR, Bose CL, Hart C, Sekar KC, Auten RL, Bhutani VK, Gerdes JS, George TN, Southgate WM, Carriedo H, Couser RJ, Mammel MC, Hall DC, Pappagallo M, Sardesai S, Strain JD, Baier M, Abman SH. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med. 2006 Jul 27;355(4):354-64.","\tBronchopulmonary Dysplasia|Lung Diseases\tiNO|Placebo\tParallel Assignment\tPrevention\tRandomized\tDrug|Other\tAll\t","Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants","Interventional","Completed","Phase 3",2,793,"lung diseases|bronchopulmonary dysplasia","nitric oxide","NA"]
["NCT00006409","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15570151|15899688|16294118|15698985|28834509|17079539|16855014|16972999|16397157|16397158|16775560|16826019|16397159|16672847|16397156|16397160|16397161|16397162|16979458|17146024|16879750|17848976|17607326|17212759|17283300|17299117|17292958|18163160|17401691|17636097|17673281","McMurray RG, Ring KB, Treuth MS, Welk GJ, Pate RR, Schmitz KH, Pickrel JL, Gonzalez V, Almedia MJ, Young DR, Sallis JF. Comparison of two approaches to structured physical activity surveys for adolescents. Med Sci Sports Exerc. 2004 Dec;36(12):2135-43.|Birnbaum AS, Evenson KR, Motl RW, Dishman RK, Voorhees CC, Sallis JF, Elder JP, Dowda M. Scale development for perceived school climate for girls' physical activity. Am J Health Behav. 2005 May-Jun;29(3):250-7.|Catellier DJ, Hannan PJ, Murray DM, Addy CL, Conway TL, Yang S, Rice JC. Imputation of missing data when measuring physical activity by accelerometry. Med Sci Sports Exerc. 2005 Nov;37(11 Suppl):S555-62.|Voorhees CC, Murray D, Welk G, Birnbaum A, Ribisl KM, Johnson CC, Pfeiffer KA, Saksvig B, Jobe JB. The role of peer social network factors and physical activity in adolescent girls. Am J Health Behav. 2005 Mar-Apr;29(2):183-90.|Cohen DA, Ashwood S, Scott M, Overton A, Evenson KR, Voorhees CC, Bedimo-Rung A, McKenzie TL. Proximity to School and Physical Activity Among Middle School Girls: The Trial of Activity for Adolescent Girls Study. J Phys Act Health. 2006 Feb;3(s1):S129-S138. doi: 10.1123/jpah.3.s1.s129.|Cohen DA, Ashwood JS, Scott MM, Overton A, Evenson KR, Staten LK, Porter D, McKenzie TL, Catellier D. Public parks and physical activity among adolescent girls. Pediatrics. 2006 Nov;118(5):e1381-9.|Elder JP, Lytle L, Sallis JF, Young DR, Steckler A, Simons-Morton D, Stone E, Jobe JB, Stevens J, Lohman T, Webber L, Pate R, Saksvig BI, Ribisl K. A description of the social-ecological framework used in the trial of activity for adolescent girls (TAAG). Health Educ Res. 2007 Apr;22(2):155-65. Epub 2006 Jul 19.|Evenson KR, Birnbaum AS, Bedimo-Rung AL, Sallis JF, Voorhees CC, Ring K, Elder JP. Girls' perception of physical environmental factors and transportation: reliability and association with physical activity and active transport to school. Int J Behav Nutr Phys Act. 2006 Sep 14;3:28.|\"Gittelsohn J, Steckler A, Johnson CC, Pratt C, Grieser M, Pickrel J, Stone EJ, Conway T, Coombs D, Staten LK. Formative research in school and community-based health programs and studies: \"\"state of the art\"\" and the TAAG approach. Health Educ Behav. 2006 Feb;33(1):25-39.\"|Grieser M, Vu MB, Bedimo-Rung AL, Neumark-Sztainer D, Moody J, Young DR, Moe SG. Physical activity attitudes, preferences, and practices in African American, Hispanic, and Caucasian girls. Health Educ Behav. 2006 Feb;33(1):40-51.|Lohman TG, Ring K, Schmitz KH, Treuth MS, Loftin M, Yang S, Sothern M, Going S. Associations of body size and composition with physical activity in adolescent girls. Med Sci Sports Exerc. 2006 Jun;38(6):1175-81.|McKenzie TL, Catellier DJ, Conway T, Lytle LA, Grieser M, Webber LA, Pratt CA, Elder JP. Girls' activity levels and lesson contexts in middle school PE: TAAG baseline. Med Sci Sports Exerc. 2006 Jul;38(7):1229-35.|Moe SG, Pickrel J, McKenzie TL, Strikmiller PK, Coombs D, Murrie D. Using school-level interviews to develop a Multisite PE intervention program. Health Educ Behav. 2006 Feb;33(1):52-65.|Murray DM, Stevens J, Hannan PJ, Catellier DJ, Schmitz KH, Dowda M, Conway TL, Rice JC, Yang S. School-level intraclass correlation for physical activity in sixth grade girls. Med Sci Sports Exerc. 2006 May;38(5):926-36.|Saunders RP, Moody J. Community agency survey formative research results from the TAAG study. Health Educ Behav. 2006 Feb;33(1):12-24.|Staten LK, Birnbaum AS, Jobe JB, Elder JP. A typology of middle school girls: audience segmentation related to physical activity. Health Educ Behav. 2006 Feb;33(1):66-80.|Vu MB, Murrie D, Gonzalez V, Jobe JB. Listening to girls and boys talk about girls' physical activity behaviors. Health Educ Behav. 2006 Feb;33(1):81-96.|Young DR, Johnson CC, Steckler A, Gittelsohn J, Saunders RP, Saksvig BI, Ribisl KM, Lytle LA, McKenzie TL. Data to action: using formative research to develop intervention programs to increase physical activity in adolescent girls. Health Educ Behav. 2006 Feb;33(1):97-111.|Pfeiffer KA, Schmitz KH, McMurray RG, Treuth MS, Murray DM, Pate RR. Physical activities in adolescent girls: variability in energy expenditure. Am J Prev Med. 2006 Oct;31(4):328-31. Epub 2006 Aug 28.|Pate RR, Stevens J, Pratt C, Sallis JF, Schmitz KH, Webber LS, Welk G, Young DR. Objectively measured physical activity in sixth-grade girls. Arch Pediatr Adolesc Med. 2006 Dec;160(12):1262-8.|Rushovich BR, Voorhees CC, Davis CE, Neumark-Sztainer D, Pfeiffer KA, Elder JP, Going S, Marino VG. The relationship between unsupervised time after school and physical activity in adolescent girls. Int J Behav Nutr Phys Act. 2006 Jul 31;3:20.|Going S, Nichols J, Loftin M, Stewart D, Lohman T, Tuuri G, Ring K, Pickrel J, Blew R, J Stevens. Validation of bioelectrical impedance analysis (BIA) for estimation of body composition in Black, White and Hispanic adolescent girls. Int J Body Compos Res. 2006;4(4):161-167.|Nichols J, Going S, Loftin M, Stewart D, Nowicki E, Pickrel J. Comparison of two bioelectrical impedance analysis instruments for determining body composition in adolescent girls. Int J Body Compos Res. 2006;4(4):153-160.|Young DR, Felton GM, Grieser M, Elder JP, Johnson C, Lee JS, Kubik MY. Policies and opportunities for physical activity in middle school environments. J Sch Health. 2007 Jan;77(1):41-7.|Saksvig BI, Catellier DJ, Pfeiffer K, Schmitz KH, Conway T, Going S, Ward D, Strikmiller P, Treuth MS. Travel by walking before and after school and physical activity among adolescent girls. Arch Pediatr Adolesc Med. 2007 Feb;161(2):153-8.|Evenson KR, Scott MM, Cohen DA, Voorhees CC. Girls' perception of neighborhood factors on physical activity, sedentary behavior, and BMI. Obesity (Silver Spring). 2007 Feb;15(2):430-45.|Scott MM, Cohen DA, Evenson KR, Elder J, Catellier D, Ashwood JS, Overton A. Weekend schoolyard accessibility, physical activity, and obesity: the Trial of Activity in Adolescent Girls (TAAG) study. Prev Med. 2007 May;44(5):398-403. Epub 2006 Dec 29.|Loftin M, Nichols J, Going S, Sothern M, Schmitz KH, Ring K, Tuuri G, Stevens J. Comparison of the validity of anthropometric and bioelectric impedance equations to assess body composition in adolescent girls. Int J Body Compos Res. 2007;5(1):1-8.|Scott MM, Evenson KR, Cohen DA, Cox CE. Comparing perceived and objectively measured access to recreational facilities as predictors of physical activity in adolescent girls. J Urban Health. 2007 May;84(3):346-59.|Treuth MS, Catellier DJ, Schmitz KH, Pate RR, Elder JP, McMurray RG, Blew RM, Yang S, Webber L. Weekend and weekday patterns of physical activity in overweight and normal-weight adolescent girls. Obesity (Silver Spring). 2007 Jul;15(7):1782-8.|Dowda M, McKenzie TL, Cohen DA, Scott MM, Evenson KR, Bedimo-Rung AL, Voorhees CC, Almeida MJ. Commercial venues as supports for physical activity in adolescent girls. Prev Med. 2007 Aug-Sep;45(2-3):163-8. Epub 2007 Jun 7.","\tCardiovascular Diseases|Heart Diseases|Obesity\tTrial of Activity for Adolescent Girls (TAAG)\tParallel Assignment\tPrevention\tRandomized\tBehavioral\tFemale\t","Trial of Activity for Adolescent Girls (TAAG)","Interventional","Completed","Phase 2",2,8727,"heart diseases|cardiovascular diseases","NA","NA"]
["NCT00006411","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15829793|15745770|16371775|16603465|18387407|18387408|19395036|19724216|19056078|20065219|21555600|22488114|22262218|23343949|23493999|24246825|24246826|25119961|25425307|25322173|25439611","Sugar A, Gal RL, Beck rW, Ruedy KJ, Blanton CL, Feder RS, Hardten DR, Holland EJ, Lass JH, Mannis MJ, O'Keefe MB; Cornea Donor Study Group. Baseline donor characteristics in the Cornea Donor Study. Cornea. 2005 May;24(4):389-96.|Lass JH, Gal RL, Ruedy KJ, Benetz BA, Beck RW, Baratz KH, Holland EJ, Kalajian A, Kollman C, Manning FJ, Mannis MJ, McCoy K, Montoya M, Stulting D, Xing D; Cornea Donor Study Group. An evaluation of image quality and accuracy of eye bank measurement of donor cornea endothelial cell density in the Specular Microscopy Ancillary Study. Ophthalmology. 2005 Mar;112(3):431-40. Erratum in: Ophthalmology. 2005 Aug;112(8):1394.|Mannis MJ, Holland EJ, Beck RW, Belin MW, Goldberg MA, Gal RL, Kalajian AD, Kenyon KR, Kollman C, Ruedy KJ, Smith P, Sugar J, Stark WJ; Cornea Donor Study Group. Clinical profile and early surgical complications in the Cornea Donor Study. Cornea. 2006 Feb;25(2):164-70.|Benetz BA, Gal RL, Ruedy KJ, Rice C, Beck RW, Kalajian AD, Lass JH; Cornea Donor Study Group. Specular microscopy ancillary study methods for donor endothelial cell density determination of Cornea Donor Study images. Curr Eye Res. 2006 Apr;31(4):319-27.|Cornea Donor Study Investigator Group, gal RL, Dontchev M, Beck RW, Mannis MJ, Holland EJ, Kollman C, Dunn SP, Heck EL, Lass JH, Montoya MM, Schultze RL, Stulting RD, Sugar A, Sugar J, Tennant B, Verdier DD. The effect of donor age on corneal transplantation outcome results of the cornea donor study. Ophthalmology. 2008 Apr;115(4):620-626.e6. doi: 10.1016/j.ophtha.2008.01.003.|Cornea Donor Study Investigator Group, Lass JH, Gal RL, Dontchev M, Beck RW, Kollman C, Dunn SP, Heck E, Holland EJ, Mannis MJ, Montoya MM, Schultze RL, Stulting RD, Sugar A, Sugar J, Tennant B, Verdier DD. Donor age and corneal endothelial cell loss 5 years after successful corneal transplantation. Specular microscopy ancillary study results. Ophthalmology. 2008 Apr;115(4):627-632.e8. doi: 10.1016/j.ophtha.2008.01.004.|Sugar A, Tanner JP, Dontchev M, Tennant B, Schultze RL, Dunn SP, Lindquist TD, Gal RL, Beck RW, Kollman C, Mannis MJ, Holland EJ; Cornea Donor Study Investigator Group. Recipient risk factors for graft failure in the cornea donor study. Ophthalmology. 2009 Jun;116(6):1023-8. doi: 10.1016/j.ophtha.2008.12.050. Epub 2009 Apr 23.|Sugar J, Montoya M, Dontchev M, Tanner JP, Beck R, Gal R, Gallagher S, Gaster R, Heck E, Holland EJ, Kollman C, Malling J, Mannis MJ, Woody J; Group Cornea Donor Study Investigator Group. Donor risk factors for graft failure in the cornea donor study. Cornea. 2009 Oct;28(9):981-5. doi: 10.1097/ICO.0b013e3181a0a3e6.|Dunn SP, Stark WJ, Stulting RD, Lass JH, Sugar A, Pavilack MA, Smith PW, Tanner JP, Dontchev M, Gal RL, Beck RW, Kollman C, Mannis MJ, Holland EJ; Cornea Donor Study Investigator Group. The effect of ABO blood incompatibility on corneal transplant failure in conditions with low-risk of graft rejection. Am J Ophthalmol. 2009 Mar;147(3):432-438.e3. doi: 10.1016/j.ajo.2008.09.021. Epub 2008 Dec 4.|Lass JH, Sugar A, Benetz BA, Beck RW, Dontchev M, Gal RL, Kollman C, Gross R, Heck E, Holland EJ, Mannis MJ, Raber I, Stark W, Stulting RD; Cornea Donor Study Investigator Group. Endothelial cell density to predict endothelial graft failure after penetrating keratoplasty. Arch Ophthalmol. 2010 Jan;128(1):63-9. doi: 10.1001/archophthalmol.2010.128.63.|Lass JH, Beck RW, Benetz BA, Dontchev M, Gal RL, Holland EJ, Kollman C, Mannis MJ, Price F Jr, Raber I, Stark W, Stulting RD, Sugar A; Cornea Donor Study Investigator Group. Baseline factors related to endothelial cell loss following penetrating keratoplasty. Arch Ophthalmol. 2011 Sep;129(9):1149-54. doi: 10.1001/archophthalmol.2011.102. Epub 2011 May 9. Erratum in: Arch Ophthalmol. 2011 Dec;129(12):1640.|Stulting RD, Sugar A, Beck R, Belin M, Dontchev M, Feder RS, Gal RL, Holland EJ, Kollman C, Mannis MJ, Price F Jr, Stark W, Verdier DD; Cornea Donor Study Investigator Group. Effect of donor and recipient factors on corneal graft rejection. Cornea. 2012 Oct;31(10):1141-7.|Sugar A, Montoya MM, Beck R, Cowden JW, Dontchev M, Gal RL, Kollman C, Malling J, Mannis MJ, Tennant B; Cornea Donor Study Investigator Group. Impact of the cornea donor study on acceptance of corneas from older donors. Cornea. 2012 Dec;31(12):1441-5. doi: 10.1097/ICO.0b013e31823f7550.|Verdier DD, Sugar A, Baratz K, Beck R, Dontchev M, Dunn S, Gal RL, Holland EJ, Kollman C, Lass JH, Mannis MJ, Penta J; Cornea Donor Study Investigator Group. Corneal thickness as a predictor of corneal transplant outcome. Cornea. 2013 Jun;32(6):729-36. doi: 10.1097/ICO.0b013e31827b14c7.|Benetz BA, Lass JH, Gal RL, Sugar A, Menegay H, Dontchev M, Kollman C, Beck RW, Mannis MJ, Holland EJ, Gorovoy M, Hannush SB, Bokosky JE, Caudill JW; Cornea Donor Study Investigator Group. Endothelial morphometric measures to predict endothelial graft failure after penetrating keratoplasty. JAMA Ophthalmol. 2013 May;131(5):601-608. doi: 10.1001/jamaophthalmol.2013.1693.|Writing Committee for the Cornea Donor Study Research Group, Mannis MJ, Holland EJ, Gal RL, Dontchev M, Kollman C, Raghinaru D, Dunn SP, Schultze RL, Verdier DD, Lass JH, Raber IM, Sugar J, Gorovoy MS, Sugar A, Stulting RD, Montoya MM, Penta JG, Benetz BA, Beck RW. The effect of donor age on penetrating keratoplasty for endothelial disease: graft survival after 10 years in the Cornea Donor Study. Ophthalmology. 2013 Dec;120(12):2419-2427. doi: 10.1016/j.ophtha.2013.08.026.|Writing Committee for the Cornea Donor Study Research Group, Lass JH, Benetz BA, Gal RL, Kollman C, Raghinaru D, Dontchev M, Mannis MJ, Holland EJ, Chow C, McCoy K, Price FW Jr, Sugar A, Verdier DD, Beck RW. Donor age and factors related to endothelial cell loss 10 years after penetrating keratoplasty: Specular Microscopy Ancillary Study. Ophthalmology. 2013 Dec;120(12):2428-2435. doi: 10.1016/j.ophtha.2013.08.044.|Dunn SP, Gal RL, Kollman C, Raghinaru D, Dontchev M, Blanton CL, Holland EJ, Lass JH, Kenyon KR, Mannis MJ, Mian SI, Rapuano CJ, Stark WJ, Beck RW; Writing Committee for the Cornea Donor Study Research Group. Corneal graft rejection 10 years after penetrating keratoplasty in the cornea donor study. Cornea. 2014 Oct;33(10):1003-9. doi: 10.1097/ICO.0000000000000212.|Riddlesworth TD, Kollman C, Lass JH, Patel SV, Stulting RD, Benetz BA, Gal RL, Beck RW. A mathematical model to predict endothelial cell density following penetrating keratoplasty with selective dropout from graft failure. Invest Ophthalmol Vis Sci. 2014 Nov 25;55(12):8409-15. doi: 10.1167/iovs.14-15683.|Writing Committee for the Cornea Donor Study Research Group, Sugar A, Gal RL, Kollman C, Raghinaru D, Dontchev M, Croasdale CR, Feder RS, Holland EJ, Lass JH, Macy JI, Mannis MJ, Smith PW, Soukiasian SH, Beck RW. Factors associated with corneal graft survival in the cornea donor study. JAMA Ophthalmol. 2015 Mar;133(3):246-54. doi: 10.1001/jamaophthalmol.2014.3923.|Lass JH, Riddlesworth TD, Gal RL, Kollman C, Benetz BA, Price FW Jr, Sugar A, Terry MA, Soper M, Beck RW; Cornea Donor Study Research Group. The effect of donor diabetes history on graft failure and endothelial cell density 10 years after penetrating keratoplasty. Ophthalmology. 2015 Mar;122(3):448-56. doi: 10.1016/j.ophtha.2014.09.012. Epub 2014 Nov 15.","\tCorneal Disease|Fuch's Dystrophy|Pseudophakic Corneal Edema\tcorneas assigned by donor age group\tNA\tNA\tNA\tOther\tAll\t","Cornea Donor Study","Interventional","Completed","N/A",2,1090,"corneal edema|fuchs' endothelial dystrophy|corneal diseases","NA","NA"]
["NCT00006412","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16218799|17434848|20824151","Aberg JA, Zackin RA, Brobst SW, Evans SR, Alston BL, Henry WK, Glesby MJ, Torriani FJ, Yang Y, Owens SI, Fichtenbaum CJ; ACTG 5087 Study Team. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses. 2005 Sep;21(9):757-67.|Evans SR, Fichtenbaum CJ, Aberg JA; A5087 Study Team. Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087. HIV Clin Trials. 2007 Jan-Feb;8(1):45-52.|Fichtenbaum CJ, Yeh TM, Evans SR, Aberg JA. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J Clin Lipidol. 2010 Jul-Aug;4(4):279-87. doi: 10.1016/j.jacl.2010.04.003.","\tHIV Infections|Lipodystrophy\tPravastatin sodium|Fenofibrate\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lipodystrophy","fenofibrate|pravastatin","NA"]
["NCT00006453","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|15839957|NA|NA|16966687","Pfisterer J, Plante M, Vergote I, et al.: Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. [Abstract] J Clin Oncol 22 (14 Suppl): A-5005, 450s, 2004.|Pfisterer J, Vergote I, Du Bois A, Eisenhauer E; AGO-OVAR,; NCIC CTG; EORTC GCG. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer. 2005 May-Jun;15 Suppl 1:36-41.|Vergote I, Plante M, Richter B, et al.: Improved progression free survival (PFS) and quality of life (QOL) in a randomised study comparing gemcitabine/carboplatinum (GC) vs. carboplatin (C) in platinum sensitive ovarian cancer (OVCA). [Abstract] Int J Gynecol Cancer 14 (Suppl 1): A-155, 45, 2004.|Kurzeder C, Zhao L, Eisenhauer EA, et al.: The impact of dose intensity on the efficacy of gemcitabine plus carboplatin (GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A retrospective analysis of AGO-OVAR 2.5. [Abstract] J Clin Oncol 29 (Suppl 15): A-5088, 2011.|Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E; AGO-OVAR; NCIC CTG; EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006 Oct 10;24(29):4699-707. Epub 2006 Sep 11.","\tOvarian Cancer\tcarboplatin|gemcitabine hydrochloride\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","NA","carboplatin|gemcitabine","NA"]
["NCT00006454","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16882940|NA","Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E; AGO-OVAR; GINECO. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst. 2006 Aug 2;98(15):1036-45.|Pfisterer J, Lortholary A, Kimmig R, et al.: Paclitaxel/carboplatin (TC) vs. paclitaxel/carboplatin followed by topotecan (TC-Top) in first-line treatment of ovarian cancer FIGO stages IIb - IV. Interim results of a gynecologic cancer intergroup phase III trial of the AGO Ovarian Cancer Study Group and GINECO. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-1793, 446, 2003.","\tFallopian Tube Cancer|Ovarian Cancer\tcarboplatin|paclitaxel|topotecan hydrochloride\tNA\tNA\tNA\tDrug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","fallopian tube neoplasms|carcinoma, ovarian epithelial","carboplatin|topotecan|paclitaxel","NA"]
["NCT00006455","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21444917|21280197|20679620","Attarbaschi A, Mann G, Rosolen A, Williams D, Uyttebroeck A, Marky I, Lamant L, Horibe K, Wrobel G, Beishuizen A, Wössmann W, Reiter A, Mauguen A, Le Deley MC, Brugières L; European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) ALCL99 Trial. Limited stage I disease is not necessarily indicative of an excellent prognosis in childhood anaplastic large cell lymphoma. Blood. 2011 May 26;117(21):5616-9. doi: 10.1182/blood-2010-12-324012. Epub 2011 Mar 28.|Wrobel G, Mauguen A, Rosolen A, Reiter A, Williams D, Horibe K, Brugières L, Le Deley MC; European Inter-Group for Childhood, Non-Hodgkin Lymphoma (EICNHL). Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: report of the ALCL99 randomised trial. Pediatr Blood Cancer. 2011 Jul 1;56(7):1071-7. doi: 10.1002/pbc.22940. Epub 2011 Jan 28.|Le Deley MC, Rosolen A, Williams DM, Horibe K, Wrobel G, Attarbaschi A, Zsiros J, Uyttebroeck A, Marky IM, Lamant L, Woessmann W, Pillon M, Hobson R, Mauguen A, Reiter A, Brugières L. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol. 2010 Sep 1;28(25):3987-93. doi: 10.1200/JCO.2010.28.5999. Epub 2010 Aug 2.","\tLymphoma\tcyclophosphamide|cytarabine|dexamethasone|doxorubicin hydrochloride|etoposide|ifosfamide|leucovorin calcium|methotrexate|therapeutic hydrocortisone|vinblastine sulfate\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma, large-cell, anaplastic|lymphoma","hydrocortisone|hydrocortisone hemisuccinate|etoposide|hydrocortisone acetate|levoleucovorin|dexamethasone|hydrocortisone 17-butyrate 21-propionate|cytarabine|doxorubicin|liposomal doxorubicin|cyclophosphamide|leucovorin|methotrexate|vinblastine|ifosfamide","NA"]
["NCT00006462","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15929131,"Angiolillo AL, Whitlock J, Chen Z, Krailo M, Reaman G; Children's Oncology Group. Phase II study of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): a Children's Oncology Group Report. Pediatr Blood Cancer. 2006 Feb;46(2):193-7.","\tLeukemia\tgemcitabine hydrochloride\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, lymphoid|leukemia, myeloid|precursor cell lymphoblastic leukemia-lymphoma|leukemia|leukemia, myeloid, acute","gemcitabine","NA"]
["NCT00006463","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15701855,"Lau L, Supko JG, Blaney S, Hershon L, Seibel N, Krailo M, Qu W, Malkin D, Jimeno J, Bernstein M, Baruchel S. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):672-7.","\tUnspecified Childhood Solid Tumor, Protocol Specific\tECTEINASCIDIN 743\tNA\tNA\tNA\tDrug\tAll\t","Ecteinascidin 743 in Treating Children With Refractory Solid Tumors","Interventional","Completed","Phase 1",2,13,"neoplasms","trabectedin","NA"]
["NCT00006464","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15958629,"Lara PN Jr, Mack PC, Synold T, Frankel P, Longmate J, Gumerlock PH, Doroshow JH, Gandara DR. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res. 2005 Jun 15;11(12):4444-50.","\tUnspecified Adult Solid Tumor, Protocol Specific\t7-hydroxystaurosporine|cisplatin\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","7-hydroxystaurosporine","NA"]
["NCT00006465","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18414865,"Krishnamurthi SS, Brell JM, Hoppel CL, Egorin MJ, Weaver KC, Li X, Ingalls ST, Zuhowski EG, Schluchter MD, Dowlati A, Cooney MM, Gibbons J, Overmoyer BA, Ivy SP, Remick SC. Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. Cancer Chemother Pharmacol. 2009 Feb;63(3):441-50. doi: 10.1007/s00280-008-0754-2. Epub 2008 Apr 15.","\tUnspecified Adult Solid Tumor, Protocol Specific\tcapecitabine|irinotecan hydrochloride|oxaliplatin\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","camptothecin|oxaliplatin|irinotecan|capecitabine","NA"]
["NCT00006467","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15611509,"Alberts SR, Schroeder M, Erlichman C, Steen PD, Foster NR, Moore DF Jr, Rowland KM Jr, Nair S, Tschetter LK, Fitch TR. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial. J Clin Oncol. 2004 Dec 15;22(24):4944-50.","\tPancreatic Cancer\tISIS 2503|gemcitabine hydrochloride\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","pancreatic neoplasms","gemcitabine","NA"]
["NCT00006474","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19289491|16192602","Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE Jr, Walker A, Friedman HS. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro Oncol. 2009 Oct;11(5):556-61. doi: 10.1215/15228517-2009-007. Epub 2009 Mar 16.|Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, Provenzale JM, Gururangan S, Dancey JE, Maxwell J, Tourt-Uhlig S, Herndon JE 2nd, Bigner DD, Friedman HS. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005 Oct 1;23(28):7178-87.","\tBrain and Central Nervous System Tumors\tO6-benzylguanine|temozolomide|conventional surgery\tNA\tNA\tNA\tDrug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|glioma|nervous system neoplasms","o(6)-benzylguanine|temozolomide","NA"]
["NCT00006475","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Hensley ML, van Hoomissen IC, Krahnke T, et al.: Imatinib in chronic myeloid leukemia (CML): outcomes in >7000 patients treated on expanded access program (EAP). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2328, 2003.|van Hoomissen IC, Hensley ML, Krahnke T, et al.: Imatinib expanded access program (EAP): results of treatment in >7000 patients with chronic myeloid leukemia (CML). [Abstract] Blood 102 (11): A-3370, 2003.","\tLeukemia\timatinib mesylate\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, myelogenous, chronic, bcr-abl positive|leukemia|blast crisis|leukemia, myeloid","imatinib mesylate","NA"]
["NCT00006476","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15928663,"Ord JJ, Streeter E, Jones A, Le Monnier K, Cranston D, Crew J, Joel SP, Rogers MA, Banks RE, Roberts IS, Harris AL. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma. Br J Cancer. 2005 Jun 20;92(12):2140-7.","\tBladder Cancer\tsuramin|conventional surgery\tNA\tNA\tNA\tDrug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","urinary bladder neoplasms","suramin","NA"]
["NCT00006477","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18602257,"Bergmann L, Aamdal S, Marreaud S, Lacombe D, Herold M, Yamaguchi T, Wilhelm-Ogunbiyi K, Lentzen H, Zwierzina H; European Organisation for Research and Treatment of Cancer. Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001). Eur J Cancer. 2008 Aug;44(12):1657-62. doi: 10.1016/j.ejca.2008.05.005. Epub 2008 Jul 2.","\tUnspecified Adult Solid Tumor, Protocol Specific\tmistletoe extract\tNA\tNA\tNA\tDietary Supplement\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","NA","NA"]
["NCT00006479","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|19554377|18358928|NA|NA|NA|NA","Sorbye H, Mauer M, Gruenberger T, et al.: Predictive factors for the effect of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC phase III study 40983). [Abstract] J Clin Oncol 28 (Suppl 15): A-3544, 2010.|Sorbye H, Mauer M, Gruenberger T, et al.: Evaluation of carcinoembryonic antigen (CEA) as a predictive baseline factor for the benefit of perioperative FOLFOX in resectable liver metastasis from colorectal cancer (EORTC study 40983). [Abstract] American Society of Clinical Oncology 2010 Gastrointestinal Cancers Symposium, 22-24 January 2010, Orlando, Florida. A-407, 2010.|Benoist S, Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol. 2009 Sep;16(9):2385-90. doi: 10.1245/s10434-009-0492-7. Epub 2009 Jun 25. Review.|Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008 Mar 22;371(9617):1007-16. doi: 10.1016/S0140-6736(08)60455-9.|Julie C, Lutz MP, Aust D, et al.: Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: results of the EORTC Intergroup phase III study 40983. [Abstract] American Society of Clinical Oncology 2007 Gastrointestinal Cancers Symposium, 19 -21 January 2007, Orlando, Florida A-241, 2007.|Nordlinger B, Sorbye H, Collette L, et al.: Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. [Abstract] J Clin Oncol 25 (Suppl 18): A-LBA5, 2007.|Gruenberger T, Sorbye H, Debois M, et al.: Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM). Interim results of EORTC Intergroup randomized phase III study 40983. [Abstract] J Clin Oncol 24 (Suppl 18): A-3500, 2006.|Nordlinger B, Sorbye H, Debois M, et al.: Feasibility and risks of pre-operative chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC Intergroup randomized phase III study 40983. [Abstract] J Clin Oncol 23 (Suppl 16): A-3528, 253s, 2005.","\tColorectal Cancer|Metastatic Cancer\tFOLFOX regimen|fluorouracil|leucovorin calcium|oxaliplatin|adjuvant therapy|conventional surgery|neoadjuvant therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Procedure|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","neoplasm metastasis|colorectal neoplasms","fluorouracil|oxaliplatin|calcium|levoleucovorin|leucovorin","NA"]
["NCT00006481","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16648511,"Elliott EA, Wright JR, Swann RS, Nguyen-Tân F, Takita C, Bucci MK, Garden AS, Kim H, Hug EB, Ryu J, Greenberg M, Saxton JP, Ang K, Berk L; Radiation Therapy Oncology Group Trial 99-13. Phase III Trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99-13. J Clin Oncol. 2006 May 1;24(13):2092-7.","\tHead and Neck Cancer|Skin Reactions Secondary to Radiation Therapy\tBiafine cream|quality-of-life assessment|radiation therapy\tNA\tNA\tNA\tDrug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","NA","NA"]
["NCT00006482","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16271750,"Brewer CA, Blessing JA, Nagourney RA, McMeekin DS, Lele S, Zweizig SL. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006 Feb;100(2):385-8. Epub 2005 Nov 4.","\tCervical Cancer\tcisplatin|gemcitabine hydrochloride\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","uterine cervical neoplasms","gemcitabine","NA"]
["NCT00006484","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18779603|NA|16361616|15251940|NA","Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ, Gandara DR; SWOG. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol. 2008 Oct 10;26(29):4771-6. doi: 10.1200/JCO.2008.17.0662. Epub 2008 Sep 8.|Mack PC, Redman MW, Chansky K, et al.: Elevated osteopontin (OPN) plasma levels are highly prognostic in advanced non-small cell lung cancer (NSCLC): analysis of SWOG S0003. [Abstract] J Clin Oncol 24 (Suppl 18): A-7198, 413s, 2006.|Williamson SK, Crowley JJ, Lara PN Jr, McCoy J, Lau DH, Tucker RW, Mills GM, Gandara DR; Southwest Oncology Group Trial S0003. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol. 2005 Dec 20;23(36):9097-104.|Kimura T, Holland WS, Kawaguchi T, Williamson SK, Chansky K, Crowley JJ, Doroshow JH, Lenz HJ, Gandara DR, Gumerlock PH. Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy. Ann N Y Acad Sci. 2004 Jun;1022:55-60.|Williamson SK, Crowley JJ, Lara PN, et al.: S0003: paclitaxel/carboplatin (PC) versus PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). A phase III Southwest Oncology Group (SWOG) trial. [Abstract] Lung Cancer 41 (Suppl 2): A-O-89, S29, 2003.","\tLung Cancer\tcarboplatin|paclitaxel|tirapazamine\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|carcinoma, non-small-cell lung","paclitaxel|tirapazamine|carboplatin","NA"]
["NCT00006487","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15328179,"Le QT, McCoy J, Williamson S, Ryu J, Gaspar LE, Edelman MJ, Dakhil SR, Sides SD, Crowley JJ, Gandara DR; Southwest oncology group. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study. Clin Cancer Res. 2004 Aug 15;10(16):5418-24.","\tLung Cancer\tcisplatin|etoposide|tirapazamine|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|small cell lung carcinoma","tirapazamine|etoposide","NA"]
["NCT00006565","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15743729|18429012|16887438|17356104","Wilson SE, Kahn RS, Khoury J, Lanphear BP. Racial differences in exposure to environmental tobacco smoke among children. Environ Health Perspect. 2005 Mar;113(3):362-7.|Spanier AJ, Hornung RW, Kahn RS, Lierl MB, Lanphear BP. Seasonal variation and environmental predictors of exhaled nitric oxide in children with asthma. Pediatr Pulmonol. 2008 Jun;43(6):576-83. doi: 10.1002/ppul.20816.|Spanier AJ, Hornung R, Lierl M, Lanphear BP. Environmental exposures and exhaled nitric oxide in children with asthma. J Pediatr. 2006 Aug;149(2):220-6.|Wilson SE, Kahn RS, Khoury J, Lanphear BP. The role of air nicotine in explaining racial differences in cotinine among tobacco-exposed children. Chest. 2007 Mar;131(3):856-862. doi: 10.1378/chest.06-2123.","\tAsthma|Lung Diseases\tHEPA Air Cleaner|Placebo Filtration Unit\tParallel Assignment\tPrevention\tRandomized\tDevice|Device\tAll\t","Randomized Trial to Reduce Environmental Tobacco Smoke in Children With Asthma","Interventional","Completed","Phase 3",2,225,"asthma|lung diseases","NA","NA"]
["NCT00006734","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23091096|21480204|NA","Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, Marcus K, Sailer S, Healey JH, Dormans JP, Weiss AR. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012 Nov 20;30(33):4148-54. doi: 10.1200/JCO.2011.41.5703. Epub 2012 Oct 22. Erratum in: J Clin Oncol. 2015 Mar 1;33(7):814. Dosage error in article text.|Borinstein SC, Barkauskas DA, Krailo M, Scher D, Scher L, Schlottmann S, Kallakury B, Dickman PS, Pawel BR, West DC, Womer RB, Toretsky JA. Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma: a report from the Children's Oncology Group. Cancer. 2011 Nov 1;117(21):4966-76. doi: 10.1002/cncr.26112. Epub 2011 Apr 8.|Womer RB, West DC, Krailo MD, et al.: Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family tumors (ESFT). [Abstract] J Clin Oncol 26 (Suppl 15): A-10504, 2008.","\tSarcoma\tfilgrastim|cyclophosphamide|doxorubicin hydrochloride|etoposide|ifosfamide|vincristine sulfate|adjuvant therapy|conventional surgery|neoadjuvant therapy|brachytherapy|radiation therapy\tParallel Assignment\tTreatment\tRandomized\tBiological|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure|Procedure|Radiation|Radiation\tAll\t","Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor","Interventional","Completed","Phase 3",2,587,"neuroectodermal tumors|sarcoma|sarcoma, ewing","cyclophosphamide|liposomal doxorubicin|ifosfamide|doxorubicin|lenograstim|sargramostim|vincristine|etoposide","NA"]
["NCT00006786","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16873427|NA|NA","Giantonio BJ, Levy DE, O'dwyer PJ, Meropol NJ, Catalano PJ, Benson AB 3rd; Eastern Cooperative Oncology Group. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol. 2006 Sep;17(9):1399-403. Epub 2006 Jul 27.|Giantonio BJ, Levy D, O'Dwyer PJ, et al.: Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (advCRC): results from the Eastern Cooperative Oncology Group (ECOG) Study E2200. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-1024, 2003.|Giantonio BJ, Levy D, Catalano PJ, et al.: Incorporating angiogenesis inhibition with bevacizumab (anti-VEGF) into frontline chemotherapy with irinotecan (CPT-11), fluorouracil and leucovorin (FU/LV) for advanced colorectal cancer (advCRC): a toxicity analysis of ECOG study E2200. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-503, 2002.","\tColorectal Cancer\tbevacizumab|fluorouracil|irinotecan hydrochloride|leucovorin calcium\tNA\tNA\tNA\tBiological|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","levoleucovorin|irinotecan|leucovorin|bevacizumab|calcium|fluorouracil","NA"]
["NCT00006812","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15721430,"Garcia AA, Blessing JA, Lenz HJ, Darcy KM, Mannel RS, Miller DS, Husseinzadeh N; Gynecologic Oncology Group. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study. Gynecol Oncol. 2005 Mar;96(3):810-7.","\tOvarian Cancer|Primary Peritoneal Cavity Cancer\tcapecitabine\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","peritoneal neoplasms","capecitabine","NA"]
["NCT00006890","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Stewart KA, Chen C, Howson-Jan K, et al.: Results of a multi-center randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma following autologous stem cell transplant. [Abstract] Blood 104 (11 Pt 1): A-335, 2004.|Stewart KA, Chen C, Howson-Jan K, et al.: A randomized phase II dose-finding trial of thalidomide and prednisone as maintenance therapy for myeloma following autologous stem cell transplant. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1073, 2002.","\tMultiple Myeloma and Plasma Cell Neoplasm\tprednisone|thalidomide\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","plasmacytoma|multiple myeloma|neoplasms, plasma cell","thalidomide|prednisone","NA"]
["NCT00006981","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19671873|NA|NA","Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res. 2009 Aug 15;15(16):5274-9. doi: 10.1158/1078-0432.CCR-09-0062. Epub 2009 Aug 11.|Hassan R, Kreitman R, Strauss L, et al.: SS1(dsFv)-PE38 anti-mesothelin immunotoxin in advanced malignancies: phase I and pharmacokinetic study of alternate-day infusion. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-113, 2002.|Kreitman R, Squires D, O'Hagan D, et al.: SS1(dsFv)-PE38 anti-mesothelin immunotoxin in advanced malignancies: phase I study of continuous infusion. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1896, 2002.","\tCervical Cancer|Fallopian Tube Cancer|Head and Neck Cancer|Lung Cancer|Malignant Mesothelioma|Ovarian Cancer|Pancreatic Cancer|Primary Peritoneal Cavity Cancer\tSS1(dsFv)-PE38 immunotoxin\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","uterine cervical neoplasms|mesothelioma|pancreatic neoplasms|head and neck neoplasms|fallopian tube neoplasms|lung neoplasms","immunotoxins","NA"]
["NCT00007007","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|15050309","Kwok Y, Won M, Regine WF, et al.: Neurocognitive impact of whole brain radiation on patients with brain metastases: secondary analysis of RTOG BR-0018. [Abstract] Int J Radiat Oncol Biol Phys 69 (3 Suppl): A-184, S103, 2007.|Regine WF, Schmitt FA, Scott CB, Dearth C, Patchell RA, Nichols RC Jr, Gore EM, Franklin RL 3rd, Suh JH, Mehta MP. Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018. Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1346-52.","\tCognitive/Functional Effects|Metastatic Cancer|Radiation Toxicity\tmanagement of therapy complications|quality-of-life assessment\tNA\tNA\tNA\tProcedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","neoplasm metastasis","NA","NA"]
["NCT00007033","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12183720,"Heubi JE, Wiechmann DA, Creutzinger V, Setchell KD, Squires R Jr, Couser R, Rhodes P. Tauroursodeoxycholic acid (TUDCA) in the prevention of total parenteral nutrition-associated liver disease. J Pediatr. 2002 Aug;141(2):237-42.","\tAlagille Syndrome|Biliary Atresia|Cholestasis\tmagnesium gluconate|magnesium sulfate\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","biliary atresia|alagille syndrome|cholestasis","magnesium sulfate","NA"]
["NCT00007189","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17460158|17111043","ADAPT Research Group, Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007 May 22;68(21):1800-8. Epub 2007 Apr 25.|ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006 Nov 17;1(7):e33.","\tAlzheimer Disease\tNaproxen Sodium (Aleve)|Celecoxib (Celebrex)\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","alzheimer disease","celecoxib|naproxen","NA"]
["NCT00007319","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15905673,"Currier JS, Kendall MA, Zackin R, Henry WK, Alston-Smith B, Torriani FJ, Schouten J, Mickelberg K, Li Y, Hodis HN; AACTG 5078 Study Team. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS. 2005 Jun 10;19(9):927-33.","\tAtherosclerosis|HIV Infections|HIV Seronegativity\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","atherosclerosis","NA","NA"]
["NCT00007358","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18195175,"Friedman DM, Kim MY, Copel JA, Davis C, Phoon CK, Glickstein JS, Buyon JP; PRIDE Investigators. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation. 2008 Jan 29;117(4):485-93. doi: 10.1161/CIRCULATIONAHA.107.707661. Epub 2008 Jan 14.","\tAtrioventricular Nodal Dysfunction|Congenital Heart Block|Myocardial Injury|Neonatal Lupus\tDexamethasone or other corticosteroid\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","heart block","dexamethasone","NA"]
["NCT00007501","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15930418|20439572|18419349|19475609|19712037|22828595|20863322|23633406","Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 Jun 2;352(22):2271-84.|Simberkoff MS, Arbeit RD, Johnson GR, Oxman MN, Boardman KD, Williams HM, Levin MJ, Schmader KE, Gelb LD, Keay S, Neuzil K, Greenberg RN, Griffin MR, Davis LE, Morrison VA, Annunziato PW; Shingles Prevention Study Group. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med. 2010 May 4;152(9):545-54. doi: 10.7326/0003-4819-152-9-201005040-00004.|Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J, Chan IS, Williams H, Harbecke R, Marchese R, Straus SE, Gershon A, Weinberg A; Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008 Mar 15;197(6):825-35. doi: 10.1086/528696.|Harbecke R, Oxman MN, Arnold BA, Ip C, Johnson GR, Levin MJ, Gelb LD, Schmader KE, Straus SE, Wang H, Wright PF, Pachucki CT, Gershon AA, Arbeit RD, Davis LE, Simberkoff MS, Weinberg A, Williams HM, Cheney C, Petrukhin L, Abraham KG, Shaw A, Manoff S, Antonello JM, Green T, Wang Y, Tan C, Keller PM; Shingles Prevention Study Group. A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses. J Med Virol. 2009 Jul;81(7):1310-22. doi: 10.1002/jmv.21506.|Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, Marchese RD, Harbecke R, Williams HM, Chan IS, Arbeit RD, Gershon AA, Schödel F, Morrison VA, Kauffman CA, Straus SE, Schmader KE, Davis LE, Levin MJ; US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis. 2009 Oct 1;200(7):1068-77. doi: 10.1086/605611.|Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman C, Marques A, Toney J, Keller PM, Li X, Chan IS, Annunziato P; Shingles Prevention Study Group. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012 Nov 15;55(10):1320-8. doi: 10.1093/cid/cis638. Epub 2012 Jul 24.|Schmader KE, Johnson GR, Saddier P, Ciarleglio M, Wang WW, Zhang JH, Chan IS, Yeh SS, Levin MJ, Harbecke RM, Oxman MN; Shingles Prevention Study Group. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc. 2010 Sep;58(9):1634-41. doi: 10.1111/j.1532-5415.2010.03021.x.|Morrison VA, Oxman MN, Levin MJ, Schmader KE, Guatelli JC, Betts RF, Gelb LD, Pachucki CT, Keay SK, Menzies B, Griffin MR, Kauffman CA, Marques AR, Toney JF, Simberkoff MS, Serrao R, Arbeit RD, Gnann JW, Greenberg RN, Holodniy M, Keitel WA, Yeh SS, Davis LE, Crawford GE, Neuzil KM, Johnson GR, Zhang JH, Harbecke R, Chan IS, Keller PM, Williams HM, Boardman KD, Silber JL, Annunziato PW; Shingles Prevention Study Group. Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis. 2013 Aug 15;208(4):559-63. doi: 10.1093/infdis/jit182. Epub 2013 Apr 30.","\tHerpes Zoster|Postherpetic Neuralgia\tVaricella-zoster vaccine|Placebo\tParallel Assignment\tPrevention\tRandomized\tBiological|Biological\tAll\t","Shingles Prevention Study","Interventional","Completed","Phase 3",2,38456,"herpes zoster|neuralgia, postherpetic|neuralgia","NA","NA"]
["NCT00007605","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12914883,"Singh SN, Singh BN, Reda DJ, Fye CL, Ezekowitz MD, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis HD Jr, Antman EM, Falk RH, Lopez B, Tang XC. Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]). Am J Cardiol. 2003 Aug 15;92(4):468-72.","\tAtrial Fibrillation|Cerebrovascular Accident|Death, Sudden\tAmiodarone|Sotalol\tCrossover Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm","Interventional","Completed","Phase 3",2,706,"stroke|atrial fibrillation|death, sudden","amiodarone|sotalol","NA"]
["NCT00007644","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|7577210|7638470|NA|9268976|NA|9674725|10866876|10717606|NA|11828353|18695131|16406915|22808955|22983306|23271771|23988464|24594482","Wilt T. Expectant management or early intervention for clinically localized prostate cancer? What we need are randomized trials. Clinical Care For Prostatic Diseases. 1994 Jan 6; 1:1-9.|Moon TD, Brawer MK, Wilt TJ. Prostate Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with palliative expectant management for treatment of clinically localized prostate cancer. PIVOT Planning Committee. J Natl Cancer Inst Monogr. 1995;(19):69-71.|Wilt TJ, Brawer MK. Early intervention or expectant management for prostate cancer. The Prostate Cancer Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with expectant management for the treatment of clinically localized prostate cancer. Semin Urol. 1995 May;13(2):130-6.|Wilt T, Brawer M. The Prostate Cancer Intervention versus Observation Trial. Cancer. 1995 May 12; 75:1963-1968.|Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus Observation Trial (PIVOT). Oncology (Williston Park). 1997 Aug;11(8):1133-9; discussion 1139-40, 1143. Review.|Wilt T. The importance of randomized treatment trials in early stage prostate cancer. New Developments in Prostate Cancer and Treatment. 1997 Feb 21; 2:29-35.|Wilt TJ. Prostate cancer screening: practice what the evidence preaches. Am J Med. 1998 Jun;104(6):602-4.|Wilt TJ. Uncertainty in prostate cancer care: the physician's role in clearing the confusion. JAMA. 2000 Jun 28;283(24):3258-60.|Wilt TJ. Prostate carcinoma practice patterns: what do they tell us about the diagnosis, treatment, and outcomes of patients with prostate carcinoma? Cancer. 2000 Mar 15;88(6):1277-81.|Wilt T. Editorial comment. Urology. 2001 Nov 1; 58(6):964-965.|Wilt TJ. Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer. Semin Urol Oncol. 2002 Feb;20(1):10-7. Review.|Wilt TJ. SPCG-4: a needed START to PIVOTal data to promote and protect evidence-based prostate cancer care. J Natl Cancer Inst. 2008 Aug 20;100(16):1123-5. doi: 10.1093/jnci/djn259. Epub 2008 Aug 11.|Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, Kusek JW, Nyberg LM Jr; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol. 2006 Jan;175(1):217-20; discussion 220-1.|Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012 Jul 19;367(3):203-13. doi: 10.1056/NEJMoa1113162. Erratum in: N Engl J Med. 2012 Aug 9;367(6):582.|Wilt TJ. Implications of the prostate intervention versus observation trial (PIVOT). Asian J Androl. 2012 Nov;14(6):815. doi: 10.1038/aja.2012.103. Epub 2012 Sep 17.|Wilt TJ. The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer. J Natl Cancer Inst Monogr. 2012 Dec;2012(45):184-90. doi: 10.1093/jncimonographs/lgs041.|Barry MJ, Andriole GL, Culkin DJ, Fox SH, Jones KM, Carlyle MH, Wilt TJ. Ascertaining cause of death among men in the prostate cancer intervention versus observation trial. Clin Trials. 2013;10(6):907-14. doi: 10.1177/1740774513498008. Epub 2013 Aug 29.|Wilt TJ, Scardino PT, Carlsson SV, Basch E. Prostate-specific antigen screening in prostate cancer: perspectives on the evidence. J Natl Cancer Inst. 2014 Mar;106(3):dju010. doi: 10.1093/jnci/dju010. Epub 2014 Mar 4.","\tProstate Cancer\tRadical prostatectomy\tParallel Assignment\tTreatment\tRandomized\tProcedure\tMale\t","Prostate Cancer Intervention Versus Observation Trial (PIVOT)","Interventional","Completed","Phase 3",2,731,"prostatic neoplasms","NA","NA"]
["NCT00007683","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19289640|19944357","Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O'Connor CM, Schulman KA, Teo K, Warren SR; WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation. 2009 Mar 31;119(12):1616-24. doi: 10.1161/CIRCULATIONAHA.108.801753. Epub 2009 Mar 16.|Patterson ME, Grant WC, Glickman SW, Massie BM, Ammon SE, Armstrong PW, Cleland JG, Collins JF, Teo KK, Schulman KA, Reed SD. Resource use and costs of treatment with anticoagulation and antiplatelet agents: results of the WATCH trial economic evaluation. J Card Fail. 2009 Dec;15(10):819-27. doi: 10.1016/j.cardfail.2009.07.004. Epub 2009 Aug 21.","\tHeart Failure\tWarfarin titrated to an INR of 2.5-3.0|Aspirin|Clopidogrel 75\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","Warfarin and Antiplatelet Therapy in Chronic Heart Failure","Interventional","Completed","Phase 3",3,1587,"heart failure","warfarin|clopidogrel|aspirin","NA"]
["NCT00007722","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18535397|18573277|18792848","Horner RD, Grambow SC, Coffman CJ, Lindquist JH, Oddone EZ, Allen KD, Kasarskis EJ. Amyotrophic lateral sclerosis among 1991 Gulf War veterans: evidence for a time-limited outbreak. Neuroepidemiology. 2008;31(1):28-32. doi: 10.1159/000136648. Epub 2008 Jun 6.|Miranda ML, Alicia Overstreet Galeano M, Tassone E, Allen KD, Horner RD. Spatial analysis of the etiology of amyotrophic lateral sclerosis among 1991 Gulf War veterans. Neurotoxicology. 2008 Nov;29(6):964-70. doi: 10.1016/j.neuro.2008.05.005. Epub 2008 Jun 23.|Kasarskis EJ, Lindquist JH, Coffman CJ, Grambow SC, Feussner JR, Allen KD, Oddone EZ, Kamins KA, Horner RD; Als Gulf War Clinical Review Team. Clinical aspects of ALS in Gulf War veterans. Amyotroph Lateral Scler. 2009 Feb;10(1):35-41. doi: 10.1080/17482960802351029.","\tAmyotrophic Lateral Sclerosis\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","sclerosis|amyotrophic lateral sclerosis|motor neuron disease","NA","NA"]
["NCT00007761","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15654937|15820270|18930558|16213029|15977942|15780700|14702242|14525558|12397882|12023929|11903206|11511403|11349236|11252648|18586992|17978254|16816277|16816276|16399963|15541060|11874218|11869753|18504059","Kilbourne AM, Bauer MS, Pincus H, Williford WO, Kirk GF, Beresford T; Veterans Administration (VA) Cooperative Study #430 Team. Clinical, psychosocial, and treatment differences in minority patients with bipolar disorder. Bipolar Disord. 2005 Feb;7(1):89-97.|Fenn HH, Bauer MS, Altshuler L, Evans DR, Williford WO, Kilbourne AM, Beresford TP, Kirk G, Stedman M, Fiore L; VA Cooperative Study #430 Team. Medical comorbidity and health-related quality of life in bipolar disorder across the adult age span. J Affect Disord. 2005 May;86(1):47-60. Erratum in: J Affect Disord. 2006 Feb;90(2-3):275. Alshuler, Lori [corrected to Altshuler, Lori].|Pirraglia PA, Biswas K, Kilbourne AM, Fenn H, Bauer MS. A prospective study of the impact of comorbid medical disease on bipolar disorder outcomes. J Affect Disord. 2009 Jun;115(3):355-9. doi: 10.1016/j.jad.2008.09.020. Epub 2008 Oct 18.|Brown GR, McBride L, Bauer MS, Williford WO; Cooperative Studies Program 430 Study Team. Impact of childhood abuse on the course of bipolar disorder: a replication study in U.S. veterans. J Affect Disord. 2005 Dec;89(1-3):57-67. Epub 2005 Oct 4.|Bauer MS, Williford WO, McBride L, McBride K, Shea NM. Perceived barriers to health care access in a treated population. Int J Psychiatry Med. 2005;35(1):13-26.|Bauer MS, Altshuler L, Evans DR, Beresford T, Williford WO, Hauger R; VA Cooperative Study #430 Team. Prevalence and distinct correlates of anxiety, substance, and combined comorbidity in a multi-site public sector sample with bipolar disorder. J Affect Disord. 2005 Apr;85(3):301-15.|\"Bauer MS, Mitchner L. What is a \"\"mood stabilizer\"\"? An evidence-based response. Am J Psychiatry. 2004 Jan;161(1):3-18. Review.\"|Glick HA, McBride L, Bauer MS. A manic-depressive symptom self-report in optical scanable format. Bipolar Disord. 2003 Oct;5(5):366-9.|Bauer MS. An evidence-based review of psychosocial treatments for bipolar disorder. Psychopharmacol Bull. 2001 Summer;35(3):109-34. Review.|Bauer MS. A review of quantitative studies of adherence to mental health clinical practice guidelines. Harv Rev Psychiatry. 2002 May-Jun;10(3):138-53. Review.|Bauer MS. The collaborative practice model for bipolar disorder: design and implementation in a multi-site randomized controlled trial. Bipolar Disord. 2001 Oct;3(5):233-44.|Bauer MS, Kirk GF, Gavin C, Williford WO. Determinants of functional outcome and healthcare costs in bipolar disorder: a high-intensity follow-up study. J Affect Disord. 2001 Aug;65(3):231-41.|Vojta C, Kinosian B, Glick H, Altshuler L, Bauer MS. Self-reported quality of life across mood states in bipolar disorder. Compr Psychiatry. 2001 May-Jun;42(3):190-5.|Bauer MS, Vojta C, Kinosian B, Altshuler L, Glick H. The Internal State Scale: replication of its discriminating abilities in a multisite, public sector sample. Bipolar Disord. 2000 Dec;2(4):340-6.|Sajatovic M, Biswas K, Kilbourne AK, Fenn H, Williford W, Bauer MS. Factors associated with prospective long-term treatment adherence among individuals with bipolar disorder. Psychiatr Serv. 2008 Jul;59(7):753-9. doi: 10.1176/appi.ps.59.7.753.|Altshuler L, Tekell J, Biswas K, Kilbourne AM, Evans D, Tang D, Bauer MS. Executive function and employment status among veterans with bipolar disorder. Psychiatr Serv. 2007 Nov;58(11):1441-7.|Bauer MS, McBride L, Williford WO, Glick H, Kinosian B, Altshuler L, Beresford T, Kilbourne AM, Sajatovic M; Cooperative Studies Program 430 Study Team. Collaborative care for bipolar disorder: Part II. Impact on clinical outcome, function, and costs. Psychiatr Serv. 2006 Jul;57(7):937-45.|Bauer MS, McBride L, Williford WO, Glick H, Kinosian B, Altshuler L, Beresford T, Kilbourne AM, Sajatovic M; Cooperative Studies Program 430 Study Team. Collaborative care for bipolar disorder: part I. Intervention and implementation in a randomized effectiveness trial. Psychiatr Serv. 2006 Jul;57(7):927-36.|Sajatovic M, Bauer MS, Kilbourne AM, Vertrees JE, Williford W. Self-reported medication treatment adherence among veterans with bipolar disorder. Psychiatr Serv. 2006 Jan;57(1):56-62.|Glick HA, Kinosian B, McBride L, Williford WO, Bauer MS; CSP #430 Study Team. Clinical nurse specialist care managers' time commitments in a disease-management program for bipolar disorder. Bipolar Disord. 2004 Dec;6(6):452-9.|Polsky D, Onesirosan P, Bauer MS, Glick HA. Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans. J Clin Psychiatry. 2002 Feb;63(2):156-64.|Bauer MS, Williford WO, Dawson EE, Akiskal HS, Altshuler L, Fye C, Gelenberg A, Glick H, Kinosian B, Sajatovic M. Principles of effectiveness trials and their implementation in VA Cooperative Study #430: 'Reducing the efficacy-effectiveness gap in bipolar disorder'. J Affect Disord. 2001 Dec;67(1-3):61-78.|Kilbourne AM, Biswas K, Pirraglia PA, Sajatovic M, Williford WO, Bauer MS. Is the collaborative chronic care model effective for patients with bipolar disorder and co-occurring conditions? J Affect Disord. 2009 Jan;112(1-3):256-61. doi: 10.1016/j.jad.2008.04.010. Epub 2008 May 27.","\tBipolar Disorder\tBipolar Disorder Program|Usual (psychiatric) Care\tNA\tNA\tNA\tBehavioral|Behavioral\tAll\t","Does Bipolar Disease Program (BDP) Intervention Improve Long Term Manic and Depressive Symptoms.","Interventional","Completed","Phase 3",2,382,"bipolar disorder","NA","NA"]
["NCT00007774","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17851042|14645311","Perlick DA, Rosenheck RA, Kaczynski R, Bingham S, Collins J. Association of symptomatology and cognitive deficits to functional capacity in schizophrenia. Schizophr Res. 2008 Feb;99(1-3):192-9. Epub 2007 Sep 12.|Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V; Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA. 2003 Nov 26;290(20):2693-702.","\tSchizoaffective Disorder|Schizophrenia\tHaloperidol|Olanzapine\tNA\tNA\tNA\tDrug|Drug\tAll\t","To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia","Interventional","Completed","Phase 4",2,600,"schizophrenia|psychotic disorders","haloperidol decanoate|olanzapine|haloperidol","NA"]
["NCT00007813","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|9849694","Chen AR, Wiangon S, Noga SJ, et al.: Rapid engraftment of CD34+ selected peripheral blood stem cells (PBSC) after high-dose chemotherapy for patients with recurrent, refractory, or metastatic pediatric solid tumors. [Abstract] Proceedings of the American Society of Clinical Oncology 17: A2038, 530a, 1998.|Leung W, Chen AR, Klann RC, Moss TJ, Davis JM, Noga SJ, Cohen KJ, Friedman AD, Small D, Schwartz CL, Borowitz MJ, Wharam MD, Paidas CN, Long CA, Karandish S, McMannis JD, Kastan MB, Civin CI. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant. 1998 Nov;22(10):971-9.","\tBrain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Liver Cancer|Neuroblastoma|Ovarian Cancer|Sarcoma|Testicular Germ Cell Tumor\tfilgrastim|carboplatin|cyclophosphamide|etoposide|autologous bone marrow transplantation|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","liver neoplasms|nervous system neoplasms|sarcoma|neuroblastoma|central nervous system neoplasms|neoplasms, germ cell and embryonal|neoplasms","cyclophosphamide|carboplatin|etoposide","NA"]
["NCT00008060","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19858398|19884549|17630037|NA|NA|NA","Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, Allan JM, Parmar MK, Quirke P, Seymour MT. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol. 2009 Nov 20;27(33):5519-28. doi: 10.1200/JCO.2008.21.6283. Epub 2009 Oct 26.|Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009 Dec 10;27(35):5931-7. doi: 10.1200/JCO.2009.22.4295. Epub 2009 Nov 2.|Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK, Stephens RJ; FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007 Jul 14;370(9582):143-152. doi: 10.1016/S0140-6736(07)61087-3. Erratum in: Lancet. 2007 Aug 18;370(9587):566.|Maughan T: Fluorouracil (FU), oxaliplatin (OX), CPT-11 (irinotecan, Ir), use and sequencing, in advanced colorectal cancer (ACRC): the UK MRC FOCUS (CR08) trial. [Abstract] American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium, 27-29 January 2005, Miami, Florida. A-165, 2005.|Seymour MT: Fluorouracil, oxaliplatin and CPT-11 (irinotecan), use and sequencing (MRC FOCUS): a 2135-patient randomized trial in advanced colorectal cancer (ACRC). [Abstract] J Clin Oncol 23 (Suppl 16): A-3518, 250s, 2005.|Seymour M: An update on the MRC FOCUS/CR08 trial: the first 300 patients. [Abstract] Br J Cancer 85 (suppl 1): A-P45, 44, 2001.","\tColorectal Cancer\tFOLFIRI regimen|FOLFOX regimen|fluorouracil|irinotecan hydrochloride|leucovorin calcium|oxaliplatin\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","oxaliplatin|irinotecan|leucovorin|levoleucovorin|fluorouracil|calcium","NA"]
["NCT00008138","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19138791,"Tiersten AD, Liu PY, Smith HO, Wilczynski SP, Robinson WR 3rd, Markman M, Alberts DS. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. Gynecol Oncol. 2009 Mar;112(3):444-9. doi: 10.1016/j.ygyno.2008.10.028. Epub 2009 Jan 12.","\tFallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer\tcarboplatin|paclitaxel|debulking surgery\tNA\tNA\tNA\tDrug|Drug|Procedure\tFemale\t","NA","NA","NA","NA","NA","NA","fallopian tube neoplasms|ovarian neoplasms|carcinoma, ovarian epithelial","paclitaxel|carboplatin","NA"]
["NCT00008164","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15107815,"Styczynski J, Cheung YK, Garvin J, Savage DG, Billote GB, Harrison L, Skerrett D, Wolownik K, Wischhover C, Hawks R, Bradley MB, Del Toro G, George D, Yamashiro D, van de Ven C, Cairo MS. Outcomes of unrelated cord blood transplantation in pediatric recipients. Bone Marrow Transplant. 2004 Jul;34(2):129-36.","\tChildhood Langerhans Cell Histiocytosis|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic/Myeloproliferative Neoplasms|Myelodysplastic Syndromes\tumbilical cord blood transplantation\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","myeloproliferative disorders|lymphoma|neoplasms|neoplasms, plasma cell|multiple myeloma|myelodysplastic syndromes|myelodysplastic-myeloproliferative diseases|histiocytosis|syndrome|leukemia|preleukemia|histiocytosis, langerhans-cell","NA","NA"]
["NCT00008203","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17563739,"Vahdat LT, Cohen DJ, Zipin D, Lo KS, Donovan D, Savage D, Tiersten A, Nichols G, Troxel A, Hesdorffer CS. Randomized trial of low-dose interleukin-2 vs cyclosporine A and interferon-gamma after high-dose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer. Bone Marrow Transplant. 2007 Aug;40(3):267-72. Epub 2007 Jun 11.","\tBreast Cancer\taldesleukin|recombinant interferon gamma|carboplatin|cyclophosphamide|cyclosporine|thiotepa|autologous bone marrow transplantation|peripheral blood stem cell transplantation\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug|Drug|Procedure|Procedure\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","aldesleukin|carboplatin|cyclosporins|cyclophosphamide|interferons|cyclosporine|interferon-gamma|thiotepa","NA"]
["NCT00008242","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16398649,"Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T, Zimman R, Drake L, Riedel ER, Hedvat CV, Teruya-Feldstein J, Filippa DA, Fleisher M, Nimer SD, Comenzo RL. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol. 2006 Jan;132(2):155-61.","\tMultiple Myeloma and Plasma Cell Neoplasm\tdexamethasone|doxorubicin hydrochloride|thalidomide\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","plasmacytoma|multiple myeloma|neoplasms, plasma cell","liposomal doxorubicin|thalidomide|dexamethasone|doxorubicin","NA"]
["NCT00008294","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19233901|16009951","Kemeny N, Capanu M, D'Angelica M, Jarnagin W, Haviland D, Dematteo R, Fong Y. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009 Jul;20(7):1236-41. doi: 10.1093/annonc/mdn769. Epub 2009 Feb 20.|Kemeny N, Jarnagin W, Paty P, Gönen M, Schwartz L, Morse M, Leonard G, D'Angelica M, DeMatteo R, Blumgart L, Fong Y. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol. 2005 Aug 1;23(22):4888-96. Epub 2005 Jul 11.","\tColorectal Cancer|Metastatic Cancer\tFOLFOX regimen|dexamethasone|floxuridine|fluorouracil|leucovorin calcium|oxaliplatin\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasm metastasis|colorectal neoplasms","dexamethasone|fluorouracil|oxaliplatin|floxuridine|leucovorin|calcium|levoleucovorin","NA"]
["NCT00008333","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15165094,"Kanard A, Jatoi A, Castillo R, Geyer S, Schulz TK, Fitch TR, Rowland KM, Nair S, Krook JE, Kugler JW. Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity. Lung Cancer. 2004 Mar;43(3):345-53.","\tLung Cancer\tvinorelbine tartrate\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","vinorelbine","NA"]
["NCT00008346","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21502382|18372463|18227537|16878575|16878576|15961755|16169887","Baum JK, Hanna LG, Acharyya S, Mahoney MC, Conant EF, Bassett LW, Pisano ED. Use of BI-RADS 3-probably benign category in the American College of Radiology Imaging Network Digital Mammographic Imaging Screening Trial. Radiology. 2011 Jul;260(1):61-7. doi: 10.1148/radiol.11101285. Epub 2011 Apr 18.|Hendrick RE, Cole EB, Pisano ED, Acharyya S, Marques H, Cohen MA, Jong RA, Mawdsley GE, Kanal KM, D'Orsi CJ, Rebner M, Gatsonis C. Accuracy of soft-copy digital mammography versus that of screen-film mammography according to digital manufacturer: ACRIN DMIST retrospective multireader study. Radiology. 2008 Apr;247(1):38-48. doi: 10.1148/radiol.2471070418.|Pisano ED, Hendrick RE, Yaffe MJ, Baum JK, Acharyya S, Cormack JB, Hanna LA, Conant EF, Fajardo LL, Bassett LW, D'Orsi CJ, Jong RA, Rebner M, Tosteson AN, Gatsonis CA; DMIST Investigators Group. Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST. Radiology. 2008 Feb;246(2):376-83. doi: 10.1148/radiol.2461070200.|Bloomquist AK, Yaffe MJ, Pisano ED, Hendrick RE, Mawdsley GE, Bright S, Shen SZ, Mahesh M, Nickoloff EL, Fleischman RC, Williams MB, Maidment AD, Beideck DJ, Och J, Seibert JA. Quality control for digital mammography in the ACRIN DMIST trial: part I. Med Phys. 2006 Mar;33(3):719-36.|Yaffe MJ, Bloomquist AK, Mawdsley GE, Pisano ED, Hendrick RE, Fajardo LL, Boone JM, Kanal K, Mahesh M, Fleischman RC, Och J, Williams MB, Beideck DJ, Maidment AD. Quality control for digital mammography: part II. Recommendations from the ACRIN DMIST trial. Med Phys. 2006 Mar;33(3):737-52.|Pisano ED, Gatsonis CA, Yaffe MJ, Hendrick RE, Tosteson AN, Fryback DG, Bassett LW, Baum JK, Conant EF, Jong RA, Rebner M, D'Orsi CJ. American College of Radiology Imaging Network digital mammographic imaging screening trial: objectives and methodology. Radiology. 2005 Aug;236(2):404-12. Epub 2005 Jun 16.|Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, Conant EF, Fajardo LL, Bassett L, D'Orsi C, Jong R, Rebner M; Digital Mammographic Imaging Screening Trial (DMIST) Investigators Group. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med. 2005 Oct 27;353(17):1773-83. Epub 2005 Sep 16. Erratum in: N Engl J Med. 2006 Oct 26;355(17):1840.","\tBreast Cancer\tFull Field Digital Mammography|Screen Film Mammography\tParallel Assignment\tScreening\tRandomized\tDiagnostic Test|Diagnostic Test\tFemale\t","Digital Mammography Screening Trial (ACRIN6652)","Interventional","Completed","N/A",2,49528,"breast neoplasms","NA","NA"]
["NCT00008359","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15459300,"Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004 Sep 30;351(14):1391-402.","\tCancer\tcaspofungin acetate|liposomal amphotericin B\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","neutropenia","amphotericin b|liposomal amphotericin b|caspofungin","NA"]
["NCT00008398","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17293228,"Ryu JK, Swann S, LeVeque F, Scarantino CW, Johnson D, Chen A, Fortin A, Pollock J, Kim H, Ang KK. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901. Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):643-50.","\tHead and Neck Cancer|Oral Complications|Radiation Toxicity\tsargramostim|quality-of-life assessment|radiation therapy\tNA\tNA\tNA\tBiological|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms|mucositis","sargramostim","NA"]
["NCT00008411","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18300256,"Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, Broglio KR, Yin G, Esmaeli B, Hortobagyi GN, Valero V. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer. 2008 Apr 1;112(7):1455-61. doi: 10.1002/cncr.23321.","\tBreast Cancer\tDocetaxel|Docetaxel\tNA\tNA\tNA\tDrug|Drug\tFemale\t","Docetaxel in Treating Patients With Metastatic Breast Cancer","Interventional","Completed","Phase 3",2,90,"breast neoplasms","docetaxel","NA"]
["NCT00008463","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15282352|15563253|15685543|15867490|16115185|16439867|20622678","Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C; AIDS Clinical Trials Group A5071 Study Team. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004 Jul 29;351(5):451-9.|Plosker GL, Keating GM. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection. Drugs. 2004;64(24):2823-43. Review.|Sherman KE, Shire NJ, Rouster SD, Peters MG, James Koziel M, Chung RT, Horn PS. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology. 2005 Feb;128(2):313-27.|Graham CS, Wells A, Liu T, Sherman KE, Peters M, Chung RT, Bhan AK, Andersen J, Koziel MJ; ACTG 5071 Study Team. Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. AIDS. 2005 May 20;19(8):767-73.|Jones R, Dunning J, Nelson M. HIV and hepatitis C co-infection. Int J Clin Pract. 2005 Sep;59(9):1082-7. Review.|Graham CS, Wells A, Liu T, Sherman KE, Peters M, Chung RT, Bhan AK, Andersen J, Koziel MJ; ACTG 5071 Study Team. Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection. AIDS. 2006 Feb 14;20(3):345-51.|Bhattacharya D, Umbleja T, Carrat F, Chung RT, Peters MG, Torriani F, Andersen J, Currier JS. Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis. J Acquir Immune Defic Syndr. 2010 Oct;55(2):170-5. doi: 10.1097/QAI.0b013e3181e36420.","\tHepatitis C|HIV Infections\tRibavirin|Interferon alfa-2a|Peginterferon alfa-2a\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","hepatitis c|infection|hepatitis|hepatitis a","interferon alpha-2|interferon-alpha|interferons|ribavirin|peginterferon alfa-2a","NA"]
["NCT00009217","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21845596,"Devanand DP, Pelton GH, Cunqueiro K, Sackeim HA, Marder K. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. Int J Geriatr Psychiatry. 2011 Sep;26(9):937-43. doi: 10.1002/gps.2630. Epub 2010 Dec 28.","\tAgitation|Alzheimer's Disease|Psychosis\tHaloperidol-Haloperidol|Haloperidol-Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Treatment of Behavioral Symptoms in Alzheimer's Disease","Interventional","Completed","Phase 4",2,44,"psychomotor agitation|psychotic disorders|behavioral symptoms|mental disorders|alzheimer disease","haloperidol decanoate|haloperidol","NA"]
["NCT00009620","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","9250849|10625862|12114906","Shankaran S, Papile LA, Wright LL, Ehrenkranz RA, Mele L, Lemons JA, Korones SB, Stevenson DK, Donovan EF, Stoll BJ, Fanaroff AA, Oh W. The effect of antenatal phenobarbital therapy on neonatal intracranial hemorrhage in preterm infants. N Engl J Med. 1997 Aug 14;337(7):466-71.|McCain GC, Donovan EF, Gartside P. Preterm infant behavioral and heart rate responses to antenatal phenobarbital. Res Nurs Health. 1999 Dec;22(6):461-70. Erratum in: Res Nurs Health 2000 Aug;23(4):341.|Shankaran S, Papile LA, Wright LL, Ehrenkranz RA, Mele L, Lemons JA, Korones SB, Stevenson DK, Donovan EF, Stoll BJ, Fanaroff AA, Oh W, Verter J. Neurodevelopmental outcome of premature infants after antenatal phenobarbital exposure. Am J Obstet Gynecol. 2002 Jul;187(1):171-7.","\tInfant, Low Birth Weight|Infant, Newborn|Infant, Premature|Infant, Small for Gestational Age|Intracranial Hemorrhages\tPhenobarbital|Saline\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug\tFemale\t","Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage","Interventional","Completed","Phase 3",2,610,"intracranial hemorrhages|birth weight|hemorrhage","phenobarbital","NA"]
["NCT00009633","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18390958|16647401|17079582|15713907|19117897|16396864|19651577|16549503|17961693|15286223|19067285|18762491|19459909|14510321|16585322|16322158|19564290|17606555|19762176|18678807|15741374|15930228|16982497|17586184|17307536|17403821|15741371|18762517|18245420|15956871|19171637|18166553|18971491|16107873|10802492|18534246|20105142|14523165|15520109|19403482|16615955|11430325|16769377|19281415|15507925|16221780|9250849|12114906|18829776|20032809|19779585|15547163|8922450|18420500|16000352|15995042|14510324|16818526|10835060|16143580|17908750|19111322|15060228|19139085|14520225|17984212|15973322|19204058|22269248|22220735|23460139",{"$cut":{"chars":21918,"head":"Adams-Chapman I, Hansen NI, Stoll BJ, Higgins R; NICHD Research Network. Neurodevelopmental outcome of extremely low birth weight infants with posthemorrhagic hydrocephalus requiring shunt insertion. Pediatrics. 2008 May;121(5):e1167-77. doi: 10.1542/peds.2007-0423. Epub 2008 Apr 7.|Ambalavanan N, Baibergenova A, Carlo WA, Saigal S, Schmidt B, Thorpe KE; Trial of Indomethacin Prophylaxis in Preterms (TIPP) Investigators. Early prediction of poor outcome in extremely low birth weight infants by classification tree analysis. J Pediatr. 2006 Apr;148(4):438-444.|Ambalavanan N, Carlo WA, Shankaran S, Bann CM, Emrich SL, Higgins RD, Tyson JE, O'Shea TM, Laptook AR, Ehrenkranz RA, Donovan EF, Walsh MC, Goldberg RN, Das A; National Institute of Child Health and Human Development Neonatal Research Network. Predicting outcomes of neonates diagnosed with hypoxemic-ischemic encephalopathy. Pediatrics. 2006 Nov;118(5):2084-93.|Ambalavanan N, Tyson JE, Kennedy KA, Hansen NI, Vohr BR, Wright LL, Carlo WA; National Institute of Child Health and Human Development Neonatal Research Network. Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months. Pediatrics. 2005 Mar;115(3):e249-54. Epub 2005 Feb 15.|Bassler D, Stoll BJ, Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS; Trial of Indomethacin Prophylaxis in Preterms Investigators. Using a count of neonatal morbidities to predict poor outcome in extremely low birth weight infants: added role of neonatal infection. Pediatrics. 2009 Jan;123(1):313-8. doi: 10.1542/peds.2008-0377.|Benjamin DK Jr, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, Duara S, Poole K, Laptook A, Goldberg R; National Institute of Child Health and Human Development Neonatal Research Network. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006 Jan;117(1):84-92.|Bhandari V, Finer NN, Ehrenkranz RA, Saha S, Das A, Walsh MC, Engle WA, VanMeurs KP; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Synchronized nasal intermittent positive-pressure ventilation and neonatal outcomes. Pediatrics. 2009 Aug;124(2):517-26. doi: 10.1542/peds.2008-1302. Epub 2009 Jul 27.|Blakely ML, Tyson JE, Lally KP, McDonald S, Stoll BJ, Stevenson DK, Poole WK, Jobe AH, Wright LL, Higgins RD; NICHD Neonatal Research Network. Laparotomy versus peritoneal drainage for necrotizing enterocolitis or isolated intestinal perforation in extremely low birth weight infants: outcomes through 18 months adjusted age. Pediatrics. 2006 Apr;117(4):e680-7. Epub 2006 Mar 20.|Broitman E, Ambalavanan N, Higgins RD, Vohr BR, Das A, Bhaskar B, Murray K, Hintz SR, Carlo WA; National Institute of Child Health and Human Development Neonatal Research Network. Clinical data predict neurodevelopmental outcome better than head ultrasound in extremely low birth weight infants. J Pediatr. 2007 Nov;151(5):500-5, 505.e1-2. Epub 2007 Jul 12.|Castro L, Yolton K, Haberman B, Roberto N, Hansen NI, Ambalavanan N, Vohr BR, Donovan EF. Bias in reported neurodevelopmental outcomes among extremely low birth weight survivors. Pediatrics. 2004 Aug;114(2):404-10.|Chock VY, Van Meurs KP, Hintz SR, Ehrenkranz RA, Lemons JA, Kendrick DE, Stevenson DK; NICHD Neonatal Research Network. Inhaled nitric oxide for preterm premature rupture of membranes, oligohydramnios, and pulmonary hypoplasia. Am J Perinatol. 2009 Apr;26(4):317-22. doi: 10.1055/s-0028-1104743. Epub 2008 Dec 9.|Cole CR, Hansen NI, Higgins RD, Ziegler TR, Stoll BJ; Eunice Kennedy Shriver NICHD Neonatal Research Network. Very low birth weight preterm infants with surgical short bowel syndrome: incidence, morbidity and mortality, and growth outcomes at 18 to 22 months. Pediatrics. 2008 Sep;122(3):e573-82. doi: 10.1542/peds.2007-3449.|Da Costa D, Bann CM, Hansen NI, Shankaran S, Delaney-Black V; National Institute of Child Health and Human Development Neonatal Research Network. Validation of the Functional Status II que"}},"\tInfant, Low Birth Weight|Infant, Newborn|Infant, Premature|Infant, Small for Gestational Age\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","birth weight","NA","NA"]
["NCT00009646","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","11430325|12622582|16647401|16769377|17188612|17307535|18245398|19117897","Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, Solimano A, Vincer M, Wright LL; Trial of Indomethacin Prophylaxis in Preterms Investigators. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med. 2001 Jun 28;344(26):1966-72.|Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS, Whitfield MF; Trial of Indomethacin Prophylaxis in Preterms (TIPP) Investigators. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. JAMA. 2003 Mar 5;289(9):1124-9.|Ambalavanan N, Baibergenova A, Carlo WA, Saigal S, Schmidt B, Thorpe KE; Trial of Indomethacin Prophylaxis in Preterms (TIPP) Investigators. Early prediction of poor outcome in extremely low birth weight infants by classification tree analysis. J Pediatr. 2006 Apr;148(4):438-444.|Schmidt B, Roberts RS, Fanaroff A, Davis P, Kirpalani HM, Nwaesei C, Vincer M; TIPP Investigators. Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). J Pediatr. 2006 Jun;148(6):730-734.|Clyman RI, Saha S, Jobe A, Oh W. Indomethacin prophylaxis for preterm infants: the impact of 2 multicentered randomized controlled trials on clinical practice. J Pediatr. 2007 Jan;150(1):46-50.e2.|Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanaroff A; Trial of Indomethacin Prophylaxis in Preterms Investigators. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr. 2007 Mar;150(3):229-34, 234.e1.|Alfaleh K, Smyth JA, Roberts RS, Solimano A, Asztalos EV, Schmidt B; Trial of Indomethacin Prophylaxis in Preterms Investigators. Prevention and 18-month outcomes of serious pulmonary hemorrhage in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in preterms. Pediatrics. 2008 Feb;121(2):e233-8. doi: 10.1542/peds.2007-0028.|Bassler D, Stoll BJ, Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS; Trial of Indomethacin Prophylaxis in Preterms Investigators. Using a count of neonatal morbidities to predict poor outcome in extremely low birth weight infants: added role of neonatal infection. Pediatrics. 2009 Jan;123(1):313-8. doi: 10.1542/peds.2008-0377.","\tDuctus Arteriosus, Patent|Infant, Premature|Infant, Very Low Birth Weight\tindomethacin|Indomethacin|Placebo\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug|Drug\tAll\t","Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)","Interventional","Completed","Phase 3",2,1202,"ductus arteriosus, patent|birth weight","indomethacin","NA"]
["NCT00009789","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19933904|NA","Bogart JA, Hodgson L, Seagren SL, Blackstock AW, Wang X, Lenox R, Turrisi AT 3rd, Reilly J, Gajra A, Vokes EE, Green MR. Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. J Clin Oncol. 2010 Jan 10;28(2):202-6. doi: 10.1200/JCO.2009.25.0753. Epub 2009 Nov 23.|Bogart J, Watson D, Seagren S, et al.: Accelerated conformal radiotherapy for stage I non-small cell lung cancer (NSCLC) in patients with pulmonary dysfunction: a CALGB phase I study. [Abstract] J Clin Oncol 25 (Suppl 18): A-7556, 398s, 2007.","\tLung Cancer\taccelerated conformational radiotherapy\tNA\tNA\tNA\tRadiation\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","NA","NA"]
["NCT00009880","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18574157|NA|NA","Ajani JA, Winter K, Komaki R, Kelsen DP, Minsky BD, Liao Z, Bradley J, Fromm M, Hornback D, Willett CG. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol. 2008 Oct 1;26(28):4551-6. doi: 10.1200/JCO.2008.16.6918. Epub 2008 Jun 23.|Komaki R, Winter K, Ajani J: Non-operative therapy of local-regional carcinoma of the esophagus: a randomized phase II study of two paclitaxel-based chemoradiotherapy regimens (RTOG 0113). [Abstract] The American Radium Society 89th Annual Meeting, May 5-29, 2007, Amsterdam, Netherlands. A-SS-2, 1, 2007.|Komaki R, Winter K, Ajani A, et al.: A randomized phase II study of two paclitaxel-based chemoradiotherapy regimens for patients with the non-operative esophageal carcinoma (RTOG 0113). [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-142, S79-80, 2006.","\tEsophageal Cancer|Gastric Cancer\tfilgrastim|cisplatin|fluorouracil|paclitaxel|radiation therapy\tNA\tNA\tNA\tBiological|Drug|Drug|Drug|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","esophageal neoplasms|stomach neoplasms","fluorouracil|paclitaxel","NA"]
["NCT00009893","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15558814,"Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR, Levitt R, Windschitl HE, Knost JA, Tschetter LK. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer. 2005 Jan 1;103(1):111-8.","\tExtrahepatic Bile Duct Cancer|Gallbladder Cancer|Liver Cancer\tfluorouracil|gemcitabine hydrochloride|leucovorin calcium\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","liver neoplasms|cholangiocarcinoma|bile duct neoplasms|gallbladder neoplasms","leucovorin|gemcitabine|calcium|levoleucovorin|fluorouracil","NA"]
["NCT00009945","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12814333|NA|12149294","Atula S, Powles T, Paterson A, McCloskey E, Nevalainen J, Kanis J. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drug Saf. 2003;26(9):661-71.|Atula ST, Paterson AHG, Powles TJ, et al.: Safety profile of oral clodronate during long-term use in primary breast cancer patients. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-100, 25, 2003.|Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Männistö E, Suovuori A, Atula S, Nevalainen J, Pylkkänen L. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 2002 Aug 1;20(15):3219-24.","\tBreast Cancer\tclodronate|placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tFemale\t","Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer","Interventional","Completed","Phase 3",2,3323,"breast neoplasms","clodronic acid","NA"]
["NCT00010023","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Chen TT, Ryan T, Potmesil M, et al.: Cisplatin/capecitabine: tolerance and activity in patients with upper gastrointestinal cancers. [Abstract] American Society of Clinical Oncology 2004 Gastrointestinal Cancers Symposium, 22-24 January 2004, San Francisco, CA. A-53, 2004.","\tCancer\tcapecitabine|cisplatin\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","NA","capecitabine","NA"]
["NCT00010049","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16914578|NA","Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006 Aug 15;12(16):4899-907.|Wen PY, Yung WKA, Lamborn K, et al.: Phase I/II study of imatinib mesylate (ST1571) for patients with recurrent malignant gliomas (NABTC 99-08). [Abstract] Neuro-Oncology 6 (4): TA-63, 385, 2004.","\tBrain and Central Nervous System Tumors\timatinib mesylate\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","glioma|nervous system neoplasms|meningioma|central nervous system neoplasms","imatinib mesylate","NA"]
["NCT00010088","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15646530,"André T, Noirclerc M, Hammel P, Meckenstock R, Landi B, Cattan S, Selle F, Codoul JF, Guerrier-Parmentier B, Mokhtar R, Louvet C; GERCOR. Phase II study of leucovorin, 5-fluorouracil and gemcitabine for locally advanced and metastatic pancreatic cancer (FOLFUGEM 2). Gastroenterol Clin Biol. 2004 Aug-Sep;28(8-9):645-50. Review.","\tExtrahepatic Bile Duct Cancer|Pancreatic Cancer\tfluorouracil|gemcitabine hydrochloride|leucovorin calcium|conventional surgery|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","pancreatic neoplasms|cholangiocarcinoma|bile duct neoplasms","fluorouracil|levoleucovorin|leucovorin|gemcitabine|calcium","NA"]
["NCT00010101","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11807556,"Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002 Jan 24;415(6870):436-42.","\tCentral Nervous System Tumor, Pediatric\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|nervous system neoplasms","NA","NA"]
["NCT00010166","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16868545,"Blackstock AW, Mornex F, Partensky C, Descos L, Case LD, Melin SA, Levine EA, Mishra G, Limentani SA, Kachnic LA, Tepper JE. Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer. 2006 Aug 7;95(3):260-5. Epub 2006 Jul 25.","\tPancreatic Cancer\tgemcitabine hydrochloride|adjuvant therapy|radiation therapy\tNA\tNA\tNA\tDrug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","pancreatic neoplasms","gemcitabine","NA"]
["NCT00010179","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15699482|NA|NA","Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, Coleman R, Jayson G, Le T, Ellard S, Trudeau M, Vasey P, Hamilton M, Cameron T, Barrett E, Walsh W, McIntosh L, Eisenhauer EA. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. J Clin Oncol. 2005 Mar 20;23(9):1859-66. Epub 2005 Feb 7.|Calvert AH, Grimshaw R, Poole C, et al.: Randomized phase II trial of two intravenous schedules of the liposomal topoisomerase I inhibitor, NX211, in women with relapsed epithelial ovarian cancer (OVCA): an NCIC CTG study. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-830, 2002.|Wolf J, Hamilton M, Eisenhauer E, et al.: Pharmacokinetics of NX211 (liposomal lurtotecan) using a limited sampling model in a phase II trial of patients with ovarian cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-485, 2002.","\tFallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer\tlurtotecan liposome\tParallel Assignment\tTreatment\tRandomized\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","carcinoma, ovarian epithelial|ovarian neoplasms|fallopian tube neoplasms","lurtotecan","NA"]
["NCT00010218","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15893009|NA","Miller AA, Herndon JE 2nd, Gu L, Green MR; Cancer and Leukemia Group B. Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004). Lung Cancer. 2005 Jun;48(3):399-407. Epub 2005 Jan 23.|Herndon JE, Miller AA, Zhang C, et al.: Phase II trial of karenitecin in patients with refractory non-small cell lung cancer (NSCLC): CALGB 30004 . [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2706, 673, 2003.","\tLung Cancer\tkarenitecin\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|carcinoma, non-small-cell lung","NA","NA"]
["NCT00010244","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21147514,"Beckendorf V, Guerif S, Le Prisé E, Cosset JM, Bougnoux A, Chauvet B, Salem N, Chapet O, Bourdain S, Bachaud JM, Maingon P, Hannoun-Levi JM, Malissard L, Simon JM, Pommier P, Hay M, Dubray B, Lagrange JL, Luporsi E, Bey P. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1056-63. doi: 10.1016/j.ijrobp.2010.03.049. Epub 2010 Dec 14.","\tProstate Cancer\tradiation therapy\tParallel Assignment\tTreatment\tRandomized\tRadiation\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","NA","NA"]
["NCT00010257","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21502559,"Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, Loehrer PJ Sr. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol. 2011 May 20;29(15):2060-5. doi: 10.1200/JCO.2010.32.9607. Epub 2011 Apr 18.","\tThymic Carcinoma|Thymoma\tcarboplatin|paclitaxel\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","thymoma|carcinoma|thymus neoplasms","paclitaxel|carboplatin","NA"]
["NCT00010439","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","1. Key LL Jr., Ries w, Madyastha P, Reed F: Juvenile Osteoporosis: recognizing the risk. J Pediatr Endocrinol Metab. 2003 May; 16 Suppl 3:683-6, PMID: 12795371 2. P Madyastha, W Ries, B Hollis, F Reed, L Key. Alendronate improved bone mineral density in patients with juvenile osteoporosis. JBMR 20:Suppl 1, page S400, 2005.","\tOsteoporosis\tAlendronate\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","osteoporosis","alendronate","NA"]
["NCT00010647","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15611487,"Berman BM, Lao L, Langenberg P, Lee WL, Gilpin AM, Hochberg MC. Effectiveness of acupuncture as adjunctive therapy in osteoarthritis of the knee: a randomized, controlled trial. Ann Intern Med. 2004 Dec 21;141(12):901-10.","\tOsteoarthritis, Knee\tAcupuncture\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","osteoarthritis, knee|osteoarthritis","NA","NA"]
["NCT00011011","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16897661,"Jacobson JM, Pat Bucy R, Spritzler J, Saag MS, Eron JJ Jr, Coombs RW, Wang R, Fox L, Johnson VA, Cu-Uvin S, Cohn SE, Mildvan D, O'Neill D, Janik J, Purdue L, O'Connor DK, Vita CD, Frank I; National Institute of Allergy and Infectious Diseases-AIDS Clinical Trials Group 5068 Protocol Team. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis. 2006 Sep 1;194(5):623-32. Epub 2006 Aug 1.","\tHIV Infections\tALVAC(2)120(B,MN)GNP (vCP1452)\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","NA","NA"]
["NCT00011128","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17041858,"Benson CA, Vaida F, Havlir DV, Downey GF, Lederman MM, Gulick RM, Glesby MJ, Wantman M, Bixby CJ, Rinehart AR, Snyder S, Wang R, Patel S, Mellors JW; ACTG A5086 Study Team. A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086. J Infect Dis. 2006 Nov 1;194(9):1309-18. Epub 2006 Sep 22.","\tHIV Infections\tAntiretroviral Treatment Interruption\tParallel Assignment\tTreatment\tRandomized\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","anti-retroviral agents","NA"]
["NCT00011349","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21773817,"Farwell WR, Lourenco C, Holmberg E, Hall RB, D'Avolio L, Lawler EV, Michael Gaziano J. The association between height and prostate cancer grade in the Early Stage Prostate Cancer Cohort Study. Cancer Causes Control. 2011 Oct;22(10):1453-9. doi: 10.1007/s10552-011-9820-x. Epub 2011 Jul 20.","\tProstate Cancer\tNA\tNA\tNA\tNA\tNA\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","NA","NA"]
["NCT00011362","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","9545359|10400143|10545589|16651303|18245420","Papile LA, Tyson JE, Stoll BJ, Wright LL, Donovan EF, Bauer CR, Krause-Steinrauf H, Verter J, Korones SB, Lemons JA, Fanaroff AA, Stevenson DK. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. N Engl J Med. 1998 Apr 16;338(16):1112-8.|Leitch CA, Ahlrichs J, Karn C, Denne SC. Energy expenditure and energy intake during dexamethasone therapy for chronic lung disease. Pediatr Res. 1999 Jul;46(1):109-13.|Stoll BJ, Temprosa M, Tyson JE, Papile LA, Wright LL, Bauer CR, Donovan EF, Korones SB, Lemons JA, Fanaroff AA, Stevenson DK, Oh W, Ehrenkranz RA, Shankaran S, Verter J. Dexamethasone therapy increases infection in very low birth weight infants. Pediatrics. 1999 Nov;104(5):e63.|Lee BH, Stoll BJ, McDonald SA, Higgins RD; National Institute of Child Health and Human Development Neonatal Research Network. Adverse neonatal outcomes associated with antenatal dexamethasone versus antenatal betamethasone. Pediatrics. 2006 May;117(5):1503-10.|Lee BH, Stoll BJ, McDonald SA, Higgins RD; National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcomes of extremely low birth weight infants exposed prenatally to dexamethasone versus betamethasone. Pediatrics. 2008 Feb;121(2):289-96. doi: 10.1542/peds.2007-1103.","\tBronchopulmonary Dysplasia|Infant, Low Birth Weight|Infant, Newborn|Infant, Premature|Infant, Small for Gestational Age\tDexamethasone Early|Dexamethasone Late\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Dexamethasone Therapy in VLBW Infants at Risk of CLD","Interventional","Completed","Phase 3",2,371,"bronchopulmonary dysplasia|birth weight","dexamethasone|dexamethasone acetate|bb 1101","NA"]
["NCT00011700","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12205270,"Dearborn DG, Smith PG, Dahms BB, Allan TM, Sorenson WG, Montana E, Etzel RA. Clinical profile of 30 infants with acute pulmonary hemorrhage in Cleveland. Pediatrics. 2002 Sep;110(3):627-37.","\tIdiopathic Pulmonary Hemorrhage\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","hemorrhage","NA","NA"]
["NCT00011713","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18359755|18650557|19261274|19594949|20002217|20030380|20656017|21071027|22262702|22416013|22484414|22607889|22564984|22354176|22721761|22884013|23014629|23333816|23912598|24187577|23850856|24149971|23904465|24100206|24636397|24850626|25164027|25198264|29102416|29477955|29084307|29136189|29077936|28830670|28666241|28738300|28278351|28854726|28858831|28583664|27888150|28323984|28187518|27838386|28480049|26705359|27591839|27299194|27474489|27423903|27498136|27465382|27128714|26926253|26545148|26825777|26815879|26787645|26654974|26152565|26573529|26720830|27030583|26456810|26315051|26354529|26206344|26209788|26097060|25767892|25824023|25728410|25577465|25601638|25240079|24896072|24901281|24795899|23461877|23429708|23333513|22892419|21597090|22189045|21567938|20876036|20521814|20194068|19211133|19059903|19429394|18288314|18249523|17637918|17189629|16263507|15507127",{"$cut":{"chars":27782,"head":"Meeker JD, Singh NP, Hauser R. Serum concentrations of estradiol and free T4 are inversely correlated with sperm DNA damage in men from an infertility clinic. J Androl. 2008 Jul-Aug;29(4):379-88. doi: 10.2164/jandrol.107.004416. Epub 2008 Mar 20.|Chavarro JE, Toth TL, Sadio SM, Hauser R. Soy food and isoflavone intake in relation to semen quality parameters among men from an infertility clinic. Hum Reprod. 2008 Nov;23(11):2584-90. doi: 10.1093/humrep/den243. Epub 2008 Jul 23.|Chavarro JE, Toth TL, Wright DL, Meeker JD, Hauser R. Body mass index in relation to semen quality, sperm DNA integrity, and serum reproductive hormone levels among men attending an infertility clinic. Fertil Steril. 2010 May 1;93(7):2222-31. doi: 10.1016/j.fertnstert.2009.01.100. Epub 2009 Mar 3.|Meeker JD, Missmer SA, Altshul L, Vitonis AF, Ryan L, Cramer DW, Hauser R. Serum and follicular fluid organochlorine concentrations among women undergoing assisted reproduction technologies. Environ Health. 2009 Jul 14;8:32. doi: 10.1186/1476-069X-8-32.|Mok-Lin E, Ehrlich S, Williams PL, Petrozza J, Wright DL, Calafat AM, Ye X, Hauser R. Urinary bisphenol A concentrations and ovarian response among women undergoing IVF. Int J Androl. 2010 Apr;33(2):385-93. doi: 10.1111/j.1365-2605.2009.01014.x. Epub 2009 Nov 30.|Meeker JD, Calafat AM, Hauser R. Urinary bisphenol A concentrations in relation to serum thyroid and reproductive hormone levels in men from an infertility clinic. Environ Sci Technol. 2010 Feb 15;44(4):1458-63. doi: 10.1021/es9028292.|Meeker JD, Ehrlich S, Toth TL, Wright DL, Calafat AM, Trisini AT, Ye X, Hauser R. Semen quality and sperm DNA damage in relation to urinary bisphenol A among men from an infertility clinic. Reprod Toxicol. 2010 Dec;30(4):532-9. doi: 10.1016/j.reprotox.2010.07.005. Epub 2010 Jul 23.|Chavarro JE, Furtado J, Toth TL, Ford J, Keller M, Campos H, Hauser R. Trans-fatty acid levels in sperm are associated with sperm concentration among men from an infertility clinic. Fertil Steril. 2011 Apr;95(5):1794-7. doi: 10.1016/j.fertnstert.2010.10.039. Epub 2010 Nov 11.|Braun JM, Smith KW, Williams PL, Calafat AM, Berry K, Ehrlich S, Hauser R. Variability of urinary phthalate metabolite and bisphenol A concentrations before and during pregnancy. Environ Health Perspect. 2012 May;120(5):739-45. doi: 10.1289/ehp.1104139. Epub 2012 Jan 19. Erratum in: Environ Health Perspect. 2013 Apr;121(4):A114-5.|Attaman JA, Toth TL, Furtado J, Campos H, Hauser R, Chavarro JE. Dietary fat and semen quality among men attending a fertility clinic. Hum Reprod. 2012 May;27(5):1466-74. doi: 10.1093/humrep/des065. Epub 2012 Mar 13.|Ehrlich S, Williams PL, Missmer SA, Flaws JA, Berry KF, Calafat AM, Ye X, Petrozza JC, Wright D, Hauser R. Urinary bisphenol A concentrations and implantation failure among women undergoing in vitro fertilization. Environ Health Perspect. 2012 Jul;120(7):978-83. doi: 10.1289/ehp.1104307. Epub 2012 Apr 6.|Chavarro JE, Ehrlich S, Colaci DS, Wright DL, Toth TL, Petrozza JC, Hauser R. Body mass index and short-term weight change in relation to treatment outcomes in women undergoing assisted reproduction. Fertil Steril. 2012 Jul;98(1):109-16. doi: 10.1016/j.fertnstert.2012.04.012. Epub 2012 May 16.|Ferguson KK, Hauser R, Altshul L, Meeker JD. Serum concentrations of p, p'-DDE, HCB, PCBs and reproductive hormones among men of reproductive age. Reprod Toxicol. 2012 Nov;34(3):429-35. doi: 10.1016/j.reprotox.2012.04.006. Epub 2012 May 5.|Meeker JD, Calafat AM, Hauser R. Urinary phthalate metabolites and their biotransformation products: predictors and temporal variability among men and women. J Expo Sci Environ Epidemiol. 2012 Jul;22(4):376-85. doi: 10.1038/jes.2012.7. Epub 2012 Feb 22.|Smith KW, Braun JM, Williams PL, Ehrlich S, Correia KF, Calafat AM, Ye X, Ford J, Keller M, Meeker JD, Hauser R. Predictors and variability of urinary paraben concentrations in men and women, including before and during pregnancy. Environ Health Perspect. 2012 Nov;120(11):1538-43. doi: 10.1289/ehp.1104614. Epub 2012 Jun 21.|Colaci DS, Afeiche M, Gaskins A"}},"\tInfertility\tCompletion questionnaires/providing biological samples\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","infertility","NA","NA"]
["NCT00011960","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19273696|NA|NA","Schwartz GK, Winter K, Minsky BD, Crane C, Thomson PJ, Anne P, Gross H, Willett C, Kelsen D. Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114). J Clin Oncol. 2009 Apr 20;27(12):1956-62. doi: 10.1200/JCO.2008.20.3745. Epub 2009 Mar 9.|Schwartz GK, Winter K, Minsky B, et al.: A randomized phase II trial comparing two paclitaxel (P)-cisplatin (C) containing chemoradiation (CRT) regimens as adjuvant therapy in resected gastric cancer (RTOG 0114). [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-1069, S169, 2006.|Schwartz GK, Winter K, Minsky B, et al.: A randomized phase II trial comparing two paclitaxel (P)-cisplatin (C) containing chemoradiation (CRT) regimens as adjuvant therapy in resected gastric cancer (RTOG Intergroup #0114). [Abstract] J Clin Oncol 23 (Suppl 16): A-4020, 312s, 2005.","\tEsophageal Cancer|Gastric Cancer\tcisplatin|paclitaxel|adjuvant therapy|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","stomach neoplasms|esophageal neoplasms","cisplatin|paclitaxel","NA"]
["NCT00011973","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15744595,"Vaishampayan U, Heilbrun LK, Parchment RE, Jain V, Zwiebel J, Boinpally RR, LoRusso P, Hussain M. Phase II trial of fenretinide in advanced renal carcinoma. Invest New Drugs. 2005 Mar;23(2):179-85.","\tKidney Cancer\tfenretinide\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","kidney neoplasms|carcinoma, renal cell","fenretinide","NA"]
["NCT00011999","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19720915|NA","Rosenthal DI, Harris J, Forastiere AA, Weber RS, Ridge JA, Myers JN, Garden AS, Kuettel MR, Sidhu K, Schultz CJ, Trotti A, Ang KK. Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. J Clin Oncol. 2009 Oct 1;27(28):4727-32. doi: 10.1200/JCO.2008.21.4197. Epub 2009 Aug 31.|Rosenthal DJ, Harris J, Forastiere AA, et al.: Early postoperative paclitaxel followed by paclitaxel and cisplatin concurrent with radiation therapy (RT) (phase II trial RTOG H-0024) is well tolerated for patients with resected, high-risk squamous carcinoma of the head and neck (HNSCC). [Abstract] Int J Radiat Oncol Biol Phys 60 (Suppl 1): A-1111, S322, 2004.","\tHead and Neck Cancer\tcisplatin|paclitaxel|conventional surgery|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","cisplatin|paclitaxel","NA"]
["NCT00012012","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21892091|17398031","Small W Jr, Winter K, Levenback C, Iyer R, Hymes SR, Jhingran A, Gaffney D, Erickson B, Greven K. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin and amifostine for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of arm II of Radiation Therapy Oncology Group (RTOG) 0116. Int J Gynecol Cancer. 2011 Oct;21(7):1266-75. doi: 10.1097/IGC.0b013e31822c2769.|Small W Jr, Winter K, Levenback C, Iyer R, Gaffney D, Asbell S, Erickson B, Jhingran A, Greven K. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1081-7. Epub 2007 Mar 29.","\tCervical Cancer|Radiation Toxicity\tAmifostine trihydrate|Cisplatin|Intracavitary brachytherapy|External beam radiation therapy\tNA\tNA\tNA\tDrug|Drug|Radiation|Radiation\tFemale\t","Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer","Interventional","Completed","Phase 1/Phase 2",2,45,"uterine cervical neoplasms","amifostine","NA"]
["NCT00012025","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16505423|NA","Ingle JN, Suman VJ, Rowland KM, Mirchandani D, Bernath AM, Camoriano JK, Fishkin PA, Nikcevich DA, Perez EA; North Central Cancer Treatment Group Trial N0032. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol. 2006 Mar 1;24(7):1052-6.|Ingle JN, Rowland KM, Suman VJ, et al.: Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the North Central Cancer Treatment Group. [Abstract] Breast Cancer Res Treat 88 (1): A-409, 2004.","\tBreast Cancer\tfulvestrant\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","fulvestrant","NA"]
["NCT00012051","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17971487,"Vellenga E, van Putten WL, van 't Veer MB, Zijlstra JM, Fibbe WE, van Oers MH, Verdonck LF, Wijermans PW, van Imhoff GW, Lugtenburg PJ, Huijgens PC. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood. 2008 Jan 15;111(2):537-43. Epub 2007 Oct 30.","\tLymphoma\tfilgrastim|rituximab|carmustine|cisplatin|cytarabine|dexamethasone|etoposide|ifosfamide|melphalan|methotrexate|bone marrow ablation with stem cell support|peripheral blood stem cell transplantation|radiation therapy\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|lymphoma, non-hodgkin","methotrexate|melphalan|rituximab|cytarabine|dexamethasone|ifosfamide|carmustine|etoposide","NA"]
["NCT00012064","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Dillman RO, Schiltz PM, Selvan R, et al.: Patient-specific cancer vaccine of cultured autologous tumor cells and autologous dendritic cells. [Abstract] J Immunother 24 (5): S5, 2001.","\tMelanoma (Skin)\ttherapeutic autologous dendritic cells\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","melanoma","NA","NA"]
["NCT00012090","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17918264,"Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, Iasonos A, Sabbatini P. A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. Cancer. 2007 Dec 1;110(11):2448-56.","\tFallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer\tbicalutamide|goserelin acetate\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","fallopian tube neoplasms","goserelin|bicalutamide","NA"]
["NCT00012155","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Kemeny N, Jarnagin W, Guilfoyle B, et al.: Results of a phase I, dose-escalating study of the safety, tolerability and anti-tumor activity of a single injection of a genetically engineered herpes simplex virus, nv1020, in subjects with hepatic colorectal metastases. [Abstract] Ann Oncol 16 (Suppl 2): A-480, ii283, 2005.","\tColorectal Cancer|Metastatic Cancer\tNV1020\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","neoplasm metastasis","NA","NA"]
["NCT00012207","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18509084,"Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ, Gopal AK, Pagel JM, Lindgren CG, Greenberg PD, Riddell SR, Press OW. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008 Sep 15;112(6):2261-71. doi: 10.1182/blood-2007-12-128843. Epub 2008 May 28.","\tLeukemia|Lymphoma\taldesleukin|therapeutic autologous lymphocytes|cyclophosphamide|prednisone|vincristine sulfate|adjuvant therapy\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma","vincristine|aldesleukin|prednisone|cyclophosphamide","NA"]
["NCT00012220","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19858396,"Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20;27(33):5506-12. doi: 10.1200/JCO.2009.22.1309. Epub 2009 Oct 26.","\tPancreatic Cancer\tcisplatin|docetaxel|gemcitabine hydrochloride|irinotecan hydrochloride\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug\tAll\t","Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas","Interventional","Completed","Phase 2",4,259,"pancreatic neoplasms","gemcitabine|docetaxel|irinotecan","NA"]
["NCT00012324","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17634485,"Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J, Gallo J, Kennealey GT. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 2007 Jul 20;25(21):3069-75.","\tLiver Cancer\tdoxorubicin hydrochloride|nolatrexed dihydrochloride\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","liver neoplasms","doxorubicin|nolatrexed|liposomal doxorubicin","NA"]
["NCT00012363","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16601427,"Williamson SK, McCoy SA, Gandara DR, Dakhil SR, Yost KJ, Paradelo JC, Atkins JN, Blanke CD, Abbruzzese JL; Southwest Oncology Group (SWOG). Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial. Am J Clin Oncol. 2006 Apr;29(2):116-22.","\tEsophageal Cancer|Gastric Cancer\tgemcitabine hydrochloride|irinotecan hydrochloride\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","stomach neoplasms|esophageal neoplasms","gemcitabine|irinotecan","NA"]
["NCT00012623","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16013585,"Fortney JC, Maciejewski ML, Warren JJ, Burgess JF Jr. Does improving geographic access to VA primary care services impact patients' patterns of utilization and costs? Inquiry. 2005 Spring;42(1):29-42.","\tAngina|Diabetes|Hypertension\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","hypertension","NA","NA"]
["NCT00013091","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15027797,"Dunn NJ, Yanasak E, Schillaci J, Simotas S, Rehm LP, Souchek J, Menke T, Ashton C, Hamilton JD. Personality disorders in veterans with posttraumatic stress disorder and depression. J Trauma Stress. 2004 Feb;17(1):75-82.","\tDepression|PTSD\tSelf-management therapy; Psychoeducational group therapy\tNA\tNA\tNA\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","depressive disorder|depression","NA","NA"]
["NCT00015899","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17634493,"Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, Geyer JR, Gururangan S, Banerjee A, Goldman S, Turner CD, Belasco JB, Broniscer A, Zhu Y, Frank E, Kirschmeier P, Statkevich P, Yver A, Boyett JM, Kun LE. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol. 2007 Jul 20;25(21):3137-43.","\tBrain and Central Nervous System Tumors\tlonafarnib\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|nervous system neoplasms","lonafarnib","NA"]
["NCT00017095","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21570352|NA|20667781|NA|18024211|NA|NA|NA","Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, André S, Litière S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R; EORTC 10994/BIG 1-00 Study Investigators. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol. 2011 Jun;12(6):527-39. doi: 10.1016/S1470-2045(11)70094-8. Epub 2011 May 11. Erratum in: Lancet Oncol. 2013 Feb;14(2):e47.|Bonnefoi HR, Bogaerts J, Piccart M, et al.: Phase III trial (EORTC 10994/BIG 00-01) assessing the value of p53 using a functional assay to predict sensitivity to a taxane versus nontaxane primary chemotherapy in breast cancer: final analysis. [Abstract] J Clin Oncol 28 (Suppl 18): A-LBA503, 2010.|Collingridge D. Expression of concern--validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol. 2010 Sep;11(9):813-4. doi: 10.1016/S1470-2045(10)70185-6. Epub 2010 Jul 26.|Bonnefoi H, Zimmer AS, Piccart M, et al.: P53 functional assay in yeast: evaluation in 1856 patients in a large prospective clinical trial: EORTC 10994/BIG 00-01. [Abstract] 31st Annual San Antonio Breast Cancer Symposium, December 10-14, 2008, San Antonio, Texas. A-1067, 2008.|Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol. 2007 Dec;8(12):1071-1078. doi: 10.1016/S1470-2045(07)70345-5. Epub 2007 Nov 19. Retraction in: Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD. Lancet Oncol. 2011 Feb;12(2):116.|Karina M, Bogaerts J, Piccart M, et al.: Preliminary safety data of the EORTC 10994/BIG 00-01 neoadjuvant trial comparing 3 cycles of docetaxel followed by 3 cycles of epirubicin-docetaxel versus 6 cycles of FEC 100 in patients with locally advanced/inflammatory or large operable breast cancer. [Abstract] Breast Cancer Res Treat 100 (Suppl 1): A-3067, S146-7, 2006.|Bonnefoi H, Farmer P, Delorenzi M, et al.: Is there a regimen-specific gene signature predicting for pathological complete response after neoadjuvant chemotherapy in hormone-negative breast cancer patients? A microarray substudy of 101 patients included in EORTC 10994/BIG 00-01 trial. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-1040, 2005.|Farmer P, Iggo R, Becette V, et al.: High quality gene expression microarray data from a multicentre prospective trial: results of the first microarray analysis in the EORTC 10994/ BIG 00-01 study. [Abstract] Eur J Cancer 2 (Suppl 3): A-155, 99, 2004.","\tBreast Cancer\tfilgrastim|cyclophosphamide|docetaxel|epirubicin hydrochloride|fluorouracil|microarray analysis|immunohistochemistry staining method|laboratory biomarker analysis|biopsy|conventional surgery|neoadjuvant therapy|radiation therapy\tParallel Assignment\tTreatment\tRandomized\tBiological|Drug|Drug|Drug|Drug|Genetic|Other|Other|Procedure|Procedure|Procedure|Radiation\tFemale\t","Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer","Interventional","Completed","Phase 3",2,1856,"breast neoplasms|inflammatory breast neoplasms","docetaxel|cyclophosphamide|epirubicin|fluorouracil","NA"]
["NCT00018655","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18295436|17690799|20853931|21517712|21679267|22406052|20598832|21815915|22578037|23327503|24223036","Drapkin ML, Tate SR, McQuaid JR, Brown SA. Does initial treatment focus influence outcomes for depressed substance abusers? J Subst Abuse Treat. 2008 Oct;35(3):343-50. doi: 10.1016/j.jsat.2007.12.005. Epub 2008 Mar 4.|Glasner-Edwards S, Tate SR, McQuaid JR, Cummins K, Granholm E, Brown SA. Mechanisms of action in integrated cognitive-behavioral treatment versus twelve-step facilitation for substance-dependent adults with comorbid major depression. J Stud Alcohol Drugs. 2007 Sep;68(5):663-72.|Lydecker KP, Tate SR, Cummins KM, McQuaid J, Granholm E, Brown SA. Clinical outcomes of an integrated treatment for depression and substance use disorders. Psychol Addict Behav. 2010 Sep;24(3):453-65. doi: 10.1037/a0019943.|Granholm E, Tate SR, Link PC, Lydecker KP, Cummins KM, McQuaid J, Shriver C, Brown SA. Neuropsychological functioning and outcomes of treatment for co-occurring depression and substance use disorders. Am J Drug Alcohol Abuse. 2011 Jul;37(4):240-9. doi: 10.3109/00952990.2011.570829. Epub 2011 Apr 26.|Tate SR, Mrnak-Meyer J, Shriver CL, Atkinson JH, Robinson SK, Brown SA. Predictors of treatment retention for substance-dependent adults with co-occurring depression. Am J Addict. 2011 Jul-Aug;20(4):357-65. doi: 10.1111/j.1521-0391.2011.00137.x. Epub 2011 May 31.|Worley MJ, Trim RS, Roesch SC, Mrnak-Meyer J, Tate SR, Brown SA. Comorbid depression and substance use disorder: longitudinal associations between symptoms in a controlled trial. J Subst Abuse Treat. 2012 Oct;43(3):291-302. doi: 10.1016/j.jsat.2011.12.010. Epub 2012 Mar 8.|Worley MJ, Trim RS, Tate SR, Hall JE, Brown SA. Service utilization during and after outpatient treatment for comorbid substance use disorder and depression. J Subst Abuse Treat. 2010 Sep;39(2):124-31. doi: 10.1016/j.jsat.2010.05.009. Epub 2010 Jul 3.|Mrnak-Meyer J, Tate SR, Tripp JC, Worley MJ, Jajodia A, McQuaid JR. Predictors of suicide-related hospitalization among U.S. veterans receiving treatment for comorbid depression and substance dependence: who is the riskiest of the risky? Suicide Life Threat Behav. 2011 Oct;41(5):532-42. doi: 10.1111/j.1943-278X.2011.00051.x. Epub 2011 Aug 4.|Worley MJ, Tate SR, Brown SA. Mediational relations between 12-Step attendance, depression and substance use in patients with comorbid substance dependence and major depression. Addiction. 2012 Nov;107(11):1974-83. doi: 10.1111/j.1360-0443.2012.03943.x. Epub 2012 Aug 10.|Worley MJ, Tate SR, McQuaid JR, Granholm EL, Brown SA. 12-step affiliation and attendance following treatment for comorbid substance dependence and depression: a latent growth curve mediation model. Subst Abus. 2013;34(1):43-50. doi: 10.1080/08897077.2012.691451.|Tripp JC, Skidmore JR, Cui R, Tate SR. Impact of Physical Health on Treatment for Co-occurring Depression and Substance Dependence. J Dual Diagn. 2013;9(3). doi: 10.1080/15504263.2013.806111.","\tDepressive Disorder|Substance-Related Disorders\tTwelve Step Facilitation|Integrated Cognitive Behavioral Treatment\tNA\tNA\tNA\tBehavioral|Behavioral\tAll\t","Integrated Intervention for Substance Abusers With Depressive Disorders","Interventional","Completed","Phase 2",2,276,"depression|disease|substance-related disorders|depressive disorder","NA","NA"]
["NCT00019773","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","14981738|NA|11919233|NA","Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve. 2004 Mar;29(3):387-92.|Leonard G, Wright M, Quinn M, et al.: Survey of oxaliplatin-associated neurotoxicity with an interview-based questionnaire. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-3018, 2003.|Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002 Apr 1;20(7):1767-74.|Thomas R, Quinn M, Wilson R, et al.: A phase I trial of capecitabine (CAPE) & oxaliplatin (OHP). [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-530, 2001.","\tCarcinoma of the Appendix|Colorectal Cancer|Small Intestine Cancer\tcapecitabine|oxaliplatin\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","intestinal neoplasms","capecitabine|oxaliplatin","NA"]
["NCT00020657","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16198982,"Hickok JT, Roscoe JA, Morrow GR, Bole CW, Zhao H, Hoelzer KL, Dakhil SR, Moore T, Fitch TR. 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol. 2005 Oct;6(10):765-72. Epub 2005 Sep 13.","\tNausea and Vomiting|Unspecified Adult Solid Tumor, Protocol Specific\tdolasetron mesylate|granisetron hydrochloride|ondansetron|prochlorperazine|quality-of-life assessment\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","nausea|vomiting","dolasetron|prochlorperazine|granisetron|ondansetron","NA"]
["NCT00022087","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Shapiro CL, Halabi S, Gibson G, et al.: Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): first results from CALGB trial 79809. [Abstract] J Clin Oncol 26 (Suppl 15): A-512, 2008.","\tBreast Cancer|Osteoporosis\tcalcium salts|cholecalciferol|zoledronic acid\tParallel Assignment\tSupportive Care\tRandomized\tDietary Supplement|Dietary Supplement|Drug\tFemale\t","Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer","Interventional","Completed","Phase 3",2,439,"osteoporosis|breast neoplasms","calcium|vitamin d|cholecalciferol|zoledronic acid","NA"]
["NCT00023686","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21149658|NA","Crook JM, Gomez-Iturriaga A, Wallace K, Ma C, Fung S, Alibhai S, Jewett M, Fleshner N. Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. J Clin Oncol. 2011 Feb 1;29(4):362-8. doi: 10.1200/JCO.2010.31.7305. Epub 2010 Dec 13.|Crook JM, Gomez-Iturriaga A, Wallace K, et al.: Comparison of health-related quality of life 5 years after SPIRIT (Surgical Prostatectomy [RP] versus Interstitial Radiation [BT] Intervention trial ACOSOG Z0070). [Abstract] 2010 Genitourinary Cancers Symposium, March 5-7, 2010, San Francisco, California. A-11, 2010.","\tProstate Cancer\tsurgery|radiation\tParallel Assignment\tTreatment\tRandomized\tProcedure|Radiation\tMale\t","Surgery Versus Internal Radiation in Treating Patients With Stage II Prostate Cancer","Interventional","Completed","Phase 3",2,190,"prostatic neoplasms","NA","NA"]
["NCT00025441","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20338746,"McDowell HP, Foot AB, Ellershaw C, Machin D, Giraud C, Bergeron C. Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98. Eur J Cancer. 2010 Jun;46(9):1588-95. doi: 10.1016/j.ejca.2010.02.051. Epub 2010 Mar 24.","\tOvarian Cancer|Sarcoma|Small Intestine Cancer\tdactinomycin|filgrastim|carboplatin|cyclophosphamide|doxorubicin hydrochloride|epirubicin hydrochloride|etoposide|ifosfamide|vincristine sulfate|peripheral blood stem cell transplantation|radiation therapy\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","rhabdomyosarcoma|intestinal neoplasms|sarcoma","vincristine|etoposide|cyclophosphamide|liposomal doxorubicin|doxorubicin|carboplatin|epirubicin|dactinomycin|ifosfamide","NA"]
["NCT00027625","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17694310,"Prados MD, Yung WK, Wen PY, Junck L, Cloughesy T, Fink K, Chang S, Robins HI, Dancey J, Kuhn J. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol. 2008 May;61(6):1059-67. Epub 2007 Aug 11.","\tBrain and Central Nervous System Tumors\tgefitinib|temozolomide\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","glioma|central nervous system neoplasms|nervous system neoplasms","temozolomide|gefitinib","NA"]
["NCT00029172","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17303771,"Williams LS, Kroenke K, Bakas T, Plue LD, Brizendine E, Tu W, Hendrie H. Care management of poststroke depression: a randomized, controlled trial. Stroke. 2007 Mar;38(3):998-1003. Epub 2007 Feb 15.","\tDepression|Stroke\tcase management\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","depression|depressive disorder|stroke","NA","NA"]
["NCT00030810","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19604722|NA|30267838|27358380","Stupp R, Mayer M, Kann R, Weder W, Zouhair A, Betticher DC, Roth AD, Stahel RA, Majno SB, Peters S, Jost L, Furrer M, Thierstein S, Schmid RA, Hsu-Schmitz SF, Mirimanoff RO, Ris HB, Pless M. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncol. 2009 Aug;10(8):785-93. doi: 10.1016/S1470-2045(09)70172-X. Epub 2009 Jul 13.|Pless M, Stupp R, Kann R, et al.: Preoperative chemoradiotherapy in non-small cell lung cancer (NSCLC) patients with operable stage IIIB disease: a phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). [Abstract] J Clin Oncol 25 (Suppl 18): A-18021, 685s, 2007.|Früh M, Betticher DC, Stupp R, Xyrafas A, Peters S, Ris HB, Mirimanoff RO, Ochsenbein AF, Schmid R, Matzinger O, Stahel RA, Weder W, Guckenberger M, Rothschild SI, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Pless M; Swiss Group for Clinical Cancer Research (SAKK). Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). J Thorac Oncol. 2019 Jan;14(1):115-123. doi: 10.1016/j.jtho.2018.09.011. Epub 2018 Sep 26.|Früh M, Ris HB, Xyrafas A, Peters S, Mirimanoff RO, Gautschi O, Pless M, Stupp R. Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial. Ann Oncol. 2016 Oct;27(10):1971-3. doi: 10.1093/annonc/mdw251. Epub 2016 Jun 29.","\tLung Cancer\tHyperfractionated|Taxotere/Cisplatin|conventional surgery\tNA\tNA\tNA\tRadiation|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms","docetaxel","NA"]
["NCT00030992","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20179242,"Huang H, Menefee M, Edgerly M, Zhuang S, Kotz H, Poruchynsky M, Huff LM, Bates S, Fojo T. A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2010 Mar 1;16(5):1634-41. doi: 10.1158/1078-0432.CCR-09-0379. Epub 2010 Feb 23.","\tRenal Cell Carcinoma\tBMS-247550|Ranitidine|Diphenhydramine\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, renal cell|carcinoma","diphenhydramine|ranitidine bismuth citrate|ranitidine|promethazine","NA"]
["NCT00032357","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12850465|17026909|17299195|17617342|20304584|22903331|22093213|18612130|15389223|10650308","DePalma RG, Hayes VW, Cafferata HT, Mohammadpour HA, Chow BK, Zacharski LR, Hall MR. Cytokine signatures in atherosclerotic claudicants. J Surg Res. 2003 May 15;111(2):215-21.|DePalma RG, Hayes VW, May PE, Cafferata HT, Mohammadpour HA, Brigg LA, Chow BK, Shamayeva G, Zacharski LR. Statins and biomarkers in claudicants with peripheral arterial disease: cross-sectional study. Vascular. 2006 Jul-Aug;14(4):193-200.|Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK, Lavori PW. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA. 2007 Feb 14;297(6):603-10.|DePalma RG, Hayes VW, Zacharski LR. Bloodletting: past and present. J Am Coll Surg. 2007 Jul;205(1):132-44. Epub 2007 May 17.|Depalma RG, Hayes VW, Chow BK, Shamayeva G, May PE, Zacharski LR. Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial. J Vasc Surg. 2010 Jun;51(6):1498-503. doi: 10.1016/j.jvs.2009.12.068. Epub 2010 Mar 20.|\"Depalma RG, Zacharski LR. Iron reduction benefits: positive results from a \"\"negative\"\" prospective randomized controlled trial. Vasc Endovascular Surg. 2012 Oct;46(7):596-7. doi: 10.1177/1538574412456304. Epub 2012 Aug 17.\"|Zacharski LR, Shamayeva G, Chow BK. Effect of controlled reduction of body iron stores on clinical outcomes in peripheral arterial disease. Am Heart J. 2011 Nov;162(5):949-957.e1. doi: 10.1016/j.ahj.2011.08.013.|Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK, Lavori PW. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst. 2008 Jul 16;100(14):996-1002. doi: 10.1093/jnci/djn209. Epub 2008 Jul 8.|Zacharski LR, Chow BK, Howes PS, Lavori PW, Shamayeva G. Implementation of an iron reduction protocol in patients with peripheral vascular disease: VA cooperative study no. 410: the Iron (Fe) and Atherosclerosis Study (FeAST). Am Heart J. 2004 Sep;148(3):386-92.|Zacharski LR, Chow B, Lavori PW, Howes PS, Bell MR, DiTommaso MA, Carnegie NM, Bech F, Amidi M, Muluk S. The iron (Fe) and atherosclerosis study (FeAST): a pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease. Am Heart J. 2000 Feb;139(2 Pt 1):337-45.","\tAtherosclerosis|Intermittent Claudication|Peripheral Vascular Diseases\tFerritin reduction to 25 ng/ml by phlebotomy\tParallel Assignment\tDiagnostic\tRandomized\tProcedure\tAll\t","Does the Reduction of Total Body Iron Storage (TBIS) Alter Mortality in a Population of Patients With Advanced PVD?","Interventional","Completed","Phase 3",2,1277,"vascular diseases|atherosclerosis|intermittent claudication|peripheral vascular diseases|peripheral arterial disease","NA","NA"]
["NCT00039585","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Hussain M, Kotz H, Minasian L, et al.: Occurrence of ascites secondary to STI571 in ovarian cancer patients . [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-880, 2003.","\tFallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer\timatinib mesylate\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","ovarian neoplasms|carcinoma, ovarian epithelial|fallopian tube neoplasms","imatinib mesylate","NA"]
["NCT00041067","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21826527,"Livingston RB, Barlow WE, Kash JJ, Albain KS, Gralow JR, Lew DL, Flaherty LE, Royce ME, Hortobagyi GN. SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. Breast Cancer Res Treat. 2011 Nov;130(1):123-31. doi: 10.1007/s10549-011-1698-5. Epub 2011 Aug 9.","\tBreast Cancer\tfilgrastim|trastuzumab|docetaxel|vinorelbine\tNA\tNA\tNA\tBiological|Biological|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","docetaxel|trastuzumab|vinorelbine","NA"]
["NCT00042926","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20142602,"Civantos FJ, Zitsch RP, Schuller DE, Agrawal A, Smith RB, Nason R, Petruzelli G, Gourin CG, Wong RJ, Ferris RL, El Naggar A, Ridge JA, Paniello RC, Owzar K, McCall L, Chepeha DB, Yarbrough WG, Myers JN. Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial. J Clin Oncol. 2010 Mar 10;28(8):1395-400. doi: 10.1200/JCO.2008.20.8777. Epub 2010 Feb 8.","\tHead and Neck Cancer\timmunohistochemistry staining method|conventional surgery|lymphangiography|radionuclide imaging|sentinel lymph node biopsy|technetium Tc 99m sulfur colloid\tNA\tNA\tNA\tOther|Procedure|Procedure|Procedure|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","technetium tc 99m sulfur colloid","NA"]
["NCT00044577","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|NA","EFFICACY AND SAFETY OF A ONCE DAILY FIXED-DOSE COMBINATION OF ABACAVIR/LAMIVUDINE (ABC/3TC) [FDC ] VERSUS ABC TWICE DAILY AND 3TC ONCE DAILY AS SEPARATE ENTITIES [SE] IN ART-EXPERIENCED HIV-1 INFECTED SUBJECTS (CAL30001): 48 WEEK DATA. Clumeck, N., LaMarca, A., Fu, K., Gordon, D., Craig, C., Zhao, H. , Paes, D., and Scott, T. (WePe6.3C13), 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro; Brazil, 7/24/2005|C Craig, C Stone, T Bonny, K Fu. Similar virology findings in ABC/3TC fixed dose combination (FDC) OAD compared with standard dosing in experienced subjects (CAL30001, ALTO). 7th ICDTHI, Glasgow, UK, 14-18 November 2004. Abstract 98|Clumeck N, Lamarca A, Fu K, Gordon D, Craig C, Zhao H, Paes D, Scott T. Safety and efficacy of a once daily (OAD) Fixed-Dose Combination (FDC) of ABC/3TC [FDC arm] versus ABC twice daily (BID) and 3TC OAD as separate entities [SE arm] in ART-Experienced HIV-1 Infected Patients. 44th ICAAC, Washington, DC, 30 October-2 November 2004. Abstr. H-558","\tHIV Infection|Infection, Human Immunodeficiency Virus I\tabacavir/lamivudine|abacavir|lamivudine|tenofovir\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","acquired immunodeficiency syndrome|hiv infections|infection|communicable diseases","tenofovir|dideoxynucleosides|abacavir|lamivudine","NA"]
["NCT00046566","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21768541|21952693","He J, Wofford MR, Reynolds K, Chen J, Chen CS, Myers L, Minor DL, Elmer PJ, Jones DW, Whelton PK. Effect of dietary protein supplementation on blood pressure: a randomized, controlled trial. Circulation. 2011 Aug 2;124(5):589-95. doi: 10.1161/CIRCULATIONAHA.110.009159. Epub 2011 Jul 18.|Wofford MR, Rebholz CM, Reynolds K, Chen J, Chen CS, Myers L, Xu J, Jones DW, Whelton PK, He J. Effect of soy and milk protein supplementation on serum lipid levels: a randomized controlled trial. Eur J Clin Nutr. 2012 Apr;66(4):419-25. doi: 10.1038/ejcn.2011.168. Epub 2011 Sep 28.","\tCardiovascular Diseases|Heart Diseases|Hypertension\tSoy protein-milk protein-carbohydrate|Milk protein-carbohydrate-soy protein|Carbohydrate-soy protein-milk protein\tCrossover Assignment\tPrevention\tRandomized\tDietary Supplement|Dietary Supplement|Behavioral\tAll\t","Clinical Trial of Dietary Protein and Blood Pressure","Interventional","Completed","N/A",3,352,"cardiovascular diseases|heart diseases","caseins","NA"]
["NCT00049075","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19812607,"Shustik C, Turner AR, Desjardins P, Fernandez L, Rubin S, Larratt L, Duncan AM, Rizi D, Sadura A, Shepherd L, Li D, Rassenti L, Kipps T. Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia. 2010 Jan;24(1):237-9. doi: 10.1038/leu.2009.205. Epub 2009 Oct 8.","\tLeukemia\tfludarabine phosphate\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, lymphocytic, chronic, b-cell|leukemia, lymphoid|leukemia","fludarabine phosphate|fludarabine","NA"]
["NCT00050908","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19956354,"Stein JH, Komarow L, Cotter BR, Currier JS, Dubé MP, Fichtenbaum CJ, Gerschenson M, Mitchell CK, Murphy RL, Squires K, Parker RA, Torriani FJ; ACTG 5152s Study Team. Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy. J Clin Lipidol. 2008 Dec;2(6):464-471.","\tHIV Infections\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","NA","NA"]
["NCT00053820","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20153039|NA","Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, James N, Oliver RT, Mardiak J, Hussain T, Sylvester R, Parmar MK, Royston P, Mulders PF. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet. 2010 Feb 20;375(9715):641-8. doi: 10.1016/S0140-6736(09)61921-8. Epub 2010 Feb 10.|Gore ME: Interferon-α (IFN), interleukin-2 (IL2) and 5-fluorouracil (5FU) vs IFN alone in patients with metastatic renal cell carcinoma (mRCC): results of the randomised MRC/EORTC RE04 trial. [Abstract] J Clin Oncol 26 (Suppl 15): A-5039, 2008.","\tKidney Cancer\taldesleukin|recombinant interferon alfa|fluorouracil\tNA\tNA\tNA\tBiological|Biological|Drug\tAll\t","NA","NA","NA","NA","NA","NA","kidney neoplasms|carcinoma, renal cell","interferons|interferon-alpha|fluorouracil|aldesleukin","NA"]
["NCT00056225","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18854539,"Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ; Alzheimer Disease Cooperative Study. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008 Oct 15;300(15):1774-83. doi: 10.1001/jama.300.15.1774.","\tAlzheimer's Disease\tFolate|Vitamin B6|Vitamin B12\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","alzheimer disease","vitamins|vitamin b 12|vitamin b complex|hydroxocobalamin|vitamin b 6|pyridoxal|pyridoxine","NA"]
["NCT00058058",8266792,4515588,"Binomial Proportion",0.031,"Standard Error of the Mean",0.00556,0.021,0.044,95,"NA",null,"22915431|20501712|17392300","DeMartini WB, Hanna L, Gatsonis C, Mahoney MC, Lehman CD. Evaluation of tissue sampling methods used for MRI-detected contralateral breast lesions in the American College of Radiology Imaging Network 6667 trial. AJR Am J Roentgenol. 2012 Sep;199(3):W386-91. doi: 10.2214/AJR.11.7000.|Weinstein SP, Hanna LG, Gatsonis C, Schnall MD, Rosen MA, Lehman CD. Frequency of malignancy seen in probably benign lesions at contrast-enhanced breast MR imaging: findings from ACRIN 6667. Radiology. 2010 Jun;255(3):731-7. doi: 10.1148/radiol.10081712.|Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, Peacock S, Smazal SF, Maki DD, Julian TB, DePeri ER, Bluemke DA, Schnall MD; ACRIN Trial 6667 Investigators Group. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 2007 Mar 29;356(13):1295-303. Epub 2007 Mar 28.","\tBreast Cancer|Contralateral Breast Cancer\tMRI\tNA\tNA\tNA\tProcedure\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","NA","MRI Detection of Cancer in the Contralateral Breast for the Estimation of Diagnostic Accuracy"]
["NCT00059202","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19585548,"Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009 Sep;50(3):808-14. doi: 10.1002/hep.23082.","\tPrimary Sclerosing Cholangitis\tUrsodeoxycholic Acid|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Trial of High-dose Urso in Primary Sclerosing Cholangitis","Interventional","Terminated","Phase 2/Phase 3",2,150,"cholangitis|cholangitis, sclerosing","ursodeoxycholic acid","NA"]
["NCT00074490","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23426943,"Fowler DH, Mossoba ME, Steinberg SM, Halverson DC, Stroncek D, Khuu HM, Hakim FT, Castiello L, Sabatino M, Leitman SF, Mariotti J, Gea-Banacloche JC, Sportes C, Hardy NM, Hickstein DD, Pavletic SZ, Rowley S, Goy A, Donato M, Korngold R, Pecora A, Levine BL, June CH, Gress RE, Bishop MR. Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. Blood. 2013 Apr 11;121(15):2864-74. doi: 10.1182/blood-2012-08-446872. Epub 2013 Feb 20.","\tLeukemia|Lymphoma|Multiple Myleoma|Myelodysplastic Syndrome|Myeloproliferative Disorders\tRituximab|Fludarabine|Etoposide|Doxorubicin|Vincristine|Cyclophosphamide|Peripheral blood stem cell (PBSC) transplantation|T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells|Prednisone|Allogeneic hematopoietic stem cell transplant (HSCT)|Filgrastim|T-Rapa cell Donor Lymphocyte Infusion (DLI)\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug|Drug|Drug|Procedure|Genetic|Drug|Procedure|Drug|Genetic\tAll\t","Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers","Interventional","Terminated","Phase 2",6,442,"lymphoma|preleukemia|myeloproliferative disorders|syndrome|leukemia|myelodysplastic syndromes","cyclophosphamide|doxorubicin|vincristine|etoposide|rituximab|fludarabine|prednisone","NA"]
["NCT00076102",8265585,4514890,null,"NA",null,"NA",{"$nulls":3},0.0301,"ANOVA",24753394,"Widemann BC, Babovic-Vuksanovic D, Dombi E, Wolters PL, Goldman S, Martin S, Goodwin A, Goodspeed W, Kieran MW, Cohen B, Blaney SM, King A, Solomon J, Patronas N, Balis FM, Fox E, Steinberg SM, Packer RJ. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer. 2014 Sep;61(9):1598-602. doi: 10.1002/pbc.25041. Epub 2014 Apr 22.","\tNeurofibroma, Plexiform|Neurofibromatosis 1\tPirfenidone\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","neurofibroma, plexiform|neurofibromatosis 1|neurofibromatoses|neurofibroma","pirfenidone","Quality of Life (QOL) Using the Impact of Pediatric Illness (IPI) Scale at Baseline"]
["NCT00077792","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16537665,"Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, López-Sendón JL, Guneri S, Jiang F, White HD, Fox KA, Braunwald E; ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006 Apr 6;354(14):1477-88. Epub 2006 Mar 14.","\tAcute ST-Segment Elevation|Myocardial Infarction\tEnoxaparin sodium (XRP4563)\tParallel Assignment\tPrevention\tRandomized\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","infarction|myocardial infarction","enoxaparin","NA"]
["NCT00081237","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17520255,"Clamp AR, Schöffski P, Valle JW, Wilson RH, Marreaud S, Govaerts AS, Debois M, Lacombe D, Twelves C, Chick J, Jayson GC; EORTC New Drug Development Group. A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2008 Apr;61(4):579-85. Epub 2007 May 23.","\tColorectal Cancer\tOSI-7904L|oxaliplatin\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","oxaliplatin","NA"]
["NCT00083044","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|NA|NA|NA","Bhandare DJ, Nayar R, Masood S, et al.: Reproducibility of ductal lavage findings in high-risk women. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-4015, 2005.|Fackler MJ, Malone K, Schilling E, et al.: Methylated genes in ductal lavage fluid from women with known breast cancer undergoing mastectomy. [Abstract] Breast Cancer Res Treat 94 (Suppl 1): A-2007, S85, 2005.|Bhandare D, Bryk M, Nayar R, et al.: Effect of Tamoxifen (TAM) on estrogen-related biomarkers in ductal lavage (DL) samples a study on follow-up lavages. [Abstract] Breast Cancer Research and Treatment 88 (Suppl 1): A-4031, 2004.|Bhandare D, Golewale N, Geiger A, et al.: Estrogen related biomarkers and cellular atypia in ductal lavage (DL) samples from women at high risk for breast cancer. [Abstract] Breast Cancer Res Treat 82 (Suppl 1): A-1032, S178, 2003.|Didwania A, Golewale NH, Khan SA, et al.: Influence of ductal lavage (DL) findings on tamoxifen decision for high risk women. [Abstract] Breast Cancer Res Treat 82 (Suppl 1): A-1037, S179, 2003.","\tBreast Cancer\tNA\tNA\tNA\tNA\tNA\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","NA","NA"]
["NCT00083824","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19155011|18174456|19489872|20580029","Lamon-Fava S, Herrington DM, Reboussin DM, Sherman M, Horvath K, Schaefer EJ, Asztalos BF. Changes in remnant and high-density lipoproteins associated with hormone therapy and progression of coronary artery disease in postmenopausal women. Atherosclerosis. 2009 Jul;205(1):325-30. doi: 10.1016/j.atherosclerosis.2008.12.020. Epub 2008 Dec 24.|Lamon-Fava S, Herrington DM, Reboussin DM, Sherman M, Horvath KV, Cupples LA, White C, Demissie S, Schaefer EJ, Asztalos BF. Plasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographically-defined coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):575-9. doi: 10.1161/ATVBAHA.107.157123. Epub 2008 Jan 3.|Lamon-Fava S, Asztalos BF, Howard TD, Reboussin DM, Horvath KV, Schaefer EJ, Herrington DM. Association of polymorphisms in genes involved in lipoprotein metabolism with plasma concentrations of remnant lipoproteins and HDL subpopulations before and after hormone therapy in postmenopausal women. Clin Endocrinol (Oxf). 2010 Feb;72(2):169-75. doi: 10.1111/j.1365-2265.2009.03644.x. Epub 2009 May 29.|Lamon-Fava S, Herrington DM, Horvath KV, Schaefer EJ, Asztalos BF. Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status. Metabolism. 2010 Dec;59(12):1794-800. doi: 10.1016/j.metabol.2010.05.012. Epub 2010 Jun 26.","\tCardiovascular Diseases|Coronary Arteriosclerosis|Coronary Disease|Heart Diseases\tEstrogens, Conjugated (USP)|Medroxyprogesterone 17-Acetate|Placebo\tParallel Assignment\tHealth Services Research\tRandomized\tDrug|Drug|Drug\tFemale\t","Estrogen, HDL, and Coronary Heart Disease in Women","Interventional","Completed","Phase 2/Phase 3",3,309,"cardiovascular diseases|heart diseases|coronary disease|arteriosclerosis|coronary artery disease|myocardial ischemia","estrogens, conjugated (usp)|estrogens|medroxyprogesterone acetate|medroxyprogesterone","NA"]
["NCT00084929",8264888,4514305,"Sensitivity: P(T+|D+)",0.65,null,"NA",0.579,0.727,95,"NA",null,"22361006|21364081|21512073|NA|18799557","Johnson CD, Herman BA, Chen MH, Toledano AY, Heiken JP, Dachman AH, Kuo MD, Menias CO, Siewert B, Cheema JI, Obregon R, Fidler JL, Zimmerman P, Horton KM, Coakley KJ, Iyer RB, Hara AK, Halvorsen RA Jr, Casola G, Yee J, Blevins M, Burgart LJ, Limburg PJ, Gatsonis CA. The National CT Colonography Trial: assessment of accuracy in participants 65 years of age and older. Radiology. 2012 May;263(2):401-8. doi: 10.1148/radiol.12102177. Epub 2012 Feb 23.|Hara AK, Blevins M, Chen MH, Dachman AH, Kuo MD, Menias CO, Siewert B, Cheema JI, Obregon RG, Fidler JL, Zimmerman P, Horton KM, Coakley KJ, Iyer RB, Halvorsen RA Jr, Casola G, Yee J, Herman BA, Johnson CD. ACRIN CT colonography trial: does reader's preference for primary two-dimensional versus primary three-dimensional interpretation affect performance? Radiology. 2011 May;259(2):435-41. doi: 10.1148/radiol.11100250. Epub 2011 Mar 1.|Hara AK, Kuo MD, Blevins M, Chen MH, Yee J, Dachman A, Menias CO, Siewert B, Cheema JI, Obregon RG, Fidler JL, Zimmerman P, Horton KM, Coakley K, Iyer RB, Halvorsen RA Jr, Casola G, Johnson CD. National CT colonography trial (ACRIN 6664): comparison of three full-laxative bowel preparations in more than 2500 average-risk patients. AJR Am J Roentgenol. 2011 May;196(5):1076-82. doi: 10.2214/AJR.10.4334.|Siewert B, Gareen I, Vanness D, et al.: ACRIN 6664: patient acceptance and preferance of CT colonography compared to optical colonoscopy for colon cancer screening. [Abstract] J Clin Oncol 27 (Suppl 15): A-4034, 2009.|Johnson CD, Chen MH, Toledano AY, Heiken JP, Dachman A, Kuo MD, Menias CO, Siewert B, Cheema JI, Obregon RG, Fidler JL, Zimmerman P, Horton KM, Coakley K, Iyer RB, Hara AK, Halvorsen RA Jr, Casola G, Yee J, Herman BA, Burgart LJ, Limburg PJ. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med. 2008 Sep 18;359(12):1207-17. doi: 10.1056/NEJMoa0800996. Erratum in: N Engl J Med. 2008 Dec 25;359(26):2853.","\tColorectal Cancer\tCT Colonography\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","NA","Number of Participants With Advanced Adenomas (>=5mm) Detected by CT Colonoscopy (Per Patient)"]
["NCT00084929",8264892,4514326,"Area Under the Curve (AUC)",0.89,null,"NA",0.853,0.93,95,"NA",null,"22361006|21364081|21512073|NA|18799557","Johnson CD, Herman BA, Chen MH, Toledano AY, Heiken JP, Dachman AH, Kuo MD, Menias CO, Siewert B, Cheema JI, Obregon R, Fidler JL, Zimmerman P, Horton KM, Coakley KJ, Iyer RB, Hara AK, Halvorsen RA Jr, Casola G, Yee J, Blevins M, Burgart LJ, Limburg PJ, Gatsonis CA. The National CT Colonography Trial: assessment of accuracy in participants 65 years of age and older. Radiology. 2012 May;263(2):401-8. doi: 10.1148/radiol.12102177. Epub 2012 Feb 23.|Hara AK, Blevins M, Chen MH, Dachman AH, Kuo MD, Menias CO, Siewert B, Cheema JI, Obregon RG, Fidler JL, Zimmerman P, Horton KM, Coakley KJ, Iyer RB, Halvorsen RA Jr, Casola G, Yee J, Herman BA, Johnson CD. ACRIN CT colonography trial: does reader's preference for primary two-dimensional versus primary three-dimensional interpretation affect performance? Radiology. 2011 May;259(2):435-41. doi: 10.1148/radiol.11100250. Epub 2011 Mar 1.|Hara AK, Kuo MD, Blevins M, Chen MH, Yee J, Dachman A, Menias CO, Siewert B, Cheema JI, Obregon RG, Fidler JL, Zimmerman P, Horton KM, Coakley K, Iyer RB, Halvorsen RA Jr, Casola G, Johnson CD. National CT colonography trial (ACRIN 6664): comparison of three full-laxative bowel preparations in more than 2500 average-risk patients. AJR Am J Roentgenol. 2011 May;196(5):1076-82. doi: 10.2214/AJR.10.4334.|Siewert B, Gareen I, Vanness D, et al.: ACRIN 6664: patient acceptance and preferance of CT colonography compared to optical colonoscopy for colon cancer screening. [Abstract] J Clin Oncol 27 (Suppl 15): A-4034, 2009.|Johnson CD, Chen MH, Toledano AY, Heiken JP, Dachman A, Kuo MD, Menias CO, Siewert B, Cheema JI, Obregon RG, Fidler JL, Zimmerman P, Horton KM, Coakley K, Iyer RB, Hara AK, Halvorsen RA Jr, Casola G, Yee J, Herman BA, Burgart LJ, Limburg PJ. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med. 2008 Sep 18;359(12):1207-17. doi: 10.1056/NEJMoa0800996. Erratum in: N Engl J Med. 2008 Dec 25;359(26):2853.","\tColorectal Cancer\tCT Colonography\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","NA","Number of Participants With Advanced Adenomas (>=9mm) Detected by CT Colonoscopy (Per Patient)"]
["NCT00088075","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20035579,"Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009 Dec;19(6):611-21. doi: 10.1089/cap.2008.0144.","\tSchizophrenia\tRisperidone\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","schizophrenia","risperidone","NA"]
["NCT00090233",8264189,4514082,"GMTR for pneumococcal serotype 19F",1.1,null,"NA",0.8,1.4,95,1E-3,"t-test, 1 sided",16394299,"Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM; Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006 Jan 5;354(1):23-33.","\tRotavirus Infections\tRotateq™|Comparator: Placebo\tNA\tNA\tNA\tBiological|Biological\tAll\t","Rotavirus Efficacy and Safety Trial (REST)(V260-006)","Interventional","Completed","Phase 3",2,69274,"rotavirus infections","NA","Geometric Mean Antibody Titer(s) (GMT) to Pneumococcal Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F"]
["NCT00091247","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20820817|18543329|NA","Jatoi A, Dakhil SR, Sloan JA, Kugler JW, Rowland KM Jr, Schaefer PL, Novotny PJ, Wender DB, Gross HM, Loprinzi CL; North Central Cancer Treatment Group. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Support Care Cancer. 2011 Oct;19(10):1601-7. doi: 10.1007/s00520-010-0988-5. Epub 2010 Sep 6.|Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer. 2008 Aug 15;113(4):847-53. doi: 10.1002/cncr.23621.|Jatoi A, Rowland K, Sloan JA, et al.: Does tetracycline prevent/palliate epidermal growth factor receptor (EGFR) inhibitor-induced rash? A phase III trial from the North Central Cancer Treatment Group (N03CB). [Abstract] J Clin Oncol 25 (Suppl 18): A-LBA9006, 494s, 2007.","\tUnspecified Adult Solid Tumor, Protocol Specific\ttetracycline hydrochloride|placebo\tParallel Assignment\tSupportive Care\tRandomized\tDrug|Other\tAll\t","Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer","Interventional","Completed","N/A",2,130,"exanthema","tetracycline","NA"]
["NCT00093249","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17898366,"Levy JH, Mancao MY, Gitter R, Kereiakes DJ, Grigore AM, Aronson S, Newman MF. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1. Anesth Analg. 2007 Oct;105(4):918-25, table of contents.","\tHypertension\tclevidipine|placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)","Interventional","Completed","Phase 3",2,105,"hypertension","clevidipine","NA"]
["NCT00095992","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18196204,"Knox JJ, Gill S, Synold TW, Biagi JJ, Major P, Feld R, Cripps C, Wainman N, Eisenhauer E, Seymour L. A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Invest New Drugs. 2008 Jun;26(3):265-72. doi: 10.1007/s10637-007-9103-2. Epub 2008 Jan 15.","\tLiver Cancer\tispinesib\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","liver neoplasms","NA","NA"]
["NCT00096031","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Gold PJ, Goldman B, Iqbal S, et al.: Cetuximab as second-line therapy in patients with metastatic esophageal cancer: a phase II Southwest Oncology Group study. [Abstract] American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium, 25-27 January 2008, Orlando, FL. A-96, 2008.","\tEsophageal Cancer\tcetuximab\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","esophageal neoplasms","cetuximab","NA"]
["NCT00098254",8263021,4513583,null,"NA",null,"NA",{"$nulls":3},0.0027,"Kaplan-Meier",21224376,"Kelly RJ, Rajan A, Force J, Lopez-Chavez A, Keen C, Cao L, Yu Y, Choyke P, Turkbey B, Raffeld M, Xi L, Steinberg SM, Wright JJ, Kummar S, Gutierrez M, Giaccone G. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. Clin Cancer Res. 2011 Mar 1;17(5):1190-9. doi: 10.1158/1078-0432.CCR-10-2331. Epub 2011 Jan 11.","\tNon-Small-Cell Lung Carcinoma\tBAY 43-9006 (Sorafenib)\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|lung neoplasms","sorafenib","Overall Survival Reported Separately for Participants With a Change in PLGF Below 11 pg/ml and Above 12 pg/ml"]
["NCT00099645","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20130470,"Para MF, Schouten J, Rosenkranz SL, Yu S, Weiner D, Tebas P, White CJ, Reeds D, Lertora J, Patterson KB, Daar ES, Cavert W, Brizz B; ACTG A5200 Team of the ACTG. Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200. J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):491-5. doi: 10.1097/QAI.0b013e3181d142cb.","\tHIV Infections\tMifepristone\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","mifepristone","NA"]
["NCT00102817","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Cohen P, Rogol A, Kappelgaard A-M, Weng W, Germak J, Rosenfeld RG on behalf of the American Norditropin Study Group. Efficacy of IGF-I Based Growth Hormone (GH) Dose Titration in Non-GH Deficient (Non-GHD) Children with Short Stature Associated with IGF-I Deficiency (IGFD). Pediatric Academic Societies (PAS)/Lawson Wilkins Pediatric Endocrine Society (LWPES) 2007; Country: Canada City: Toronto|Cohen P, Rosenfeld R, Rogol A, Kappelgaard A-M, Mak C, Germak J. Validation of the Efficacy and Safety of IGF-based Dose-titration in Children with Growth Failure Associated with Non-GH-deficient, IGF-I Deficiency: Results of Clinical Trial HGH 2147 on Behalf of the American Norditropin® Clinical Studies Group. 3rd International Congress of the Growth Hormone Research Society and the IGF Society 2006; Country: Japan City: Kobe","\tGrowth Hormone Disorder|Pituitary Dwarfism\tsomatropin\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","dwarfism|dwarfism, pituitary","NA","NA"]
["NCT00105508","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18175337,"Goetz CG, Laska E, Hicking C, Damier P, Müller T, Nutt J, Warren Olanow C, Rascol O, Russ H. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord. 2008 Apr 15;23(5):700-7. doi: 10.1002/mds.21897.","\tDyskinesia|Parkinson's Disease\tSarizotan|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia","Interventional","Completed","Phase 3",2,506,"dyskinesias|parkinson disease","NA","NA"]
["NCT00105898","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18689358|17551796","Conlin PR. Genes and environment in blood pressure control--salt intake again shows its importance. Am J Clin Nutr. 2008 Aug;88(2):255-6.|Kerfoot BP, Conlin PR, Travison T, McMahon GT. Patient safety knowledge and its determinants in medical trainees. J Gen Intern Med. 2007 Aug;22(8):1150-4. Epub 2007 Jun 6.","\tDiabetes Mellitus|Hypertension\tWeb-based care management|Telephone and face-to-face care management|Internet access alone\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure|Procedure\tAll\t","Internet-based Diabetes Education and Case Management","Interventional","Completed","N/A",3,152,"hypertension|diabetes mellitus","NA","NA"]
["NCT00106834","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17673380|16704649|16226614","Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, Li S, Dooley LT, Griffiths CE. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol. 2007 Sep-Oct;17(5):381-6. Epub 2007 Aug 2.|Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol. 2006 Jun;154(6):1161-8.|Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE; EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005 Oct 15-21;366(9494):1367-74.","\tPsoriasis\tInfliximab\tCrossover Assignment\tTreatment\tRandomized\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","psoriasis","infliximab","NA"]
["NCT00108251","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21807324,"Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail. 2011 Aug;17(8):634-42. doi: 10.1016/j.cardfail.2011.04.007. Epub 2011 May 31.","\tCongestive Heart Failure|Diastole\tEplerenone|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Aldosterone Antagonism in Diastolic Heart Failure","Interventional","Completed","Phase 4",2,48,"heart failure|heart failure, diastolic","eplerenone","NA"]
["NCT00110929","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19696213,"Sprague SM, Evenepoel P, Curzi MP, González MT, Husserl FE, Kopyt N, Sterling LR, Mix C, Wong G. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol. 2009 Sep;4(9):1465-76. doi: 10.2215/CJN.06141108. Epub 2009 Aug 20.","\tEnd Stage Renal Disease\tAMG 073\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","hyperparathyroidism|kidney failure, chronic|hyperparathyroidism, secondary|kidney diseases","cinacalcet","NA"]
["NCT00112112","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21496468,"Halasa N, Englund JA, Nachman S, Weinberg GA, Huber VC, Allison K, Dubovsky F, Yi T, McCullers JA, Flynn PM. Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. Vaccine. 2011 May 31;29(24):4110-5. doi: 10.1016/j.vaccine.2011.03.097. Epub 2011 Apr 13.","\tCancer\tFluMist|Placebo\tParallel Assignment\tPrevention\tRandomized\tBiological|Biological\tAll\t","Safety Study to Evaluate FluMist in Immunocompromised Children","Interventional","Completed","Phase 1",2,20,"NA","NA","NA"]
["NCT00112892","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17989978,"Fakih MG, Pendyala L, Brady W, Smith PF, Ross ME, Creaven PJ, Badmaev V, Prey JD, Rustum YM. A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors. Cancer Chemother Pharmacol. 2008 Aug;62(3):499-508. Epub 2007 Nov 8.","\tUnspecified Adult Solid Tumor, Protocol Specific\tselenium|irinotecan hydrochloride\tNA\tNA\tNA\tDietary Supplement|Drug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","selenium|irinotecan","NA"]
["NCT00114556","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16490909,"Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, McCaughan GW. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006 Feb 21;144(4):239-48.","\tFractures|Liver Transplantation|Osteoporosis\tzoledronic acid\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","osteoporosis","zoledronic acid","NA"]
["NCT00117052","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18793528,"Schaefer RM, Bover J, Dellanna F, Sanz D, Asensio C, Sánchez González MC, Gross P, Zani V, Carter D, Jehle PM. Efficacy of cinacalcet administered with the first meal after dialysis: the SENSOR Study. Clin Nephrol. 2008 Aug;70(2):126-34.","\tEnd Stage Renal Disease|Secondary Hyperparathyroidism\tcinacalcet\tNA\tNA\tNA\tDrug\tAll\t","SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism","Interventional","Completed","Phase 3",2,673,"kidney diseases|hyperparathyroidism, secondary|kidney failure, chronic|hyperparathyroidism|neoplasm metastasis","cinacalcet","NA"]
["NCT00119522","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15839290|15598002|20684896","Gavin-Dreschnack D, Nelson A, Fitzgerald S, Harrow J, Sanchez-Anguiano A, Ahmed S, Powell-Cope G. Wheelchair-related falls: current evidence and directions for improved quality care. J Nurs Care Qual. 2005 Apr-Jun;20(2):119-27. Review.|Gavin-Dreschnack D. Effects of wheelchair posture on patient safety. Rehabil Nurs. 2004 Nov-Dec;29(6):221-6. Review.|Nelson AL, Groer S, Palacios P, Mitchell D, Sabharwal S, Kirby RL, Gavin-Dreschnack D, Powell-Cope G. Wheelchair-related falls in veterans with spinal cord injury residing in the community: a prospective cohort study. Arch Phys Med Rehabil. 2010 Aug;91(8):1166-73. doi: 10.1016/j.apmr.2010.05.008.","\tSpinal Cord Injury\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","wounds and injuries|spinal cord injuries","NA","NA"]
["NCT00120445","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20937993,"Sinawat S, Ratanapakorn T, Sanguansak T, Prompol S, Laopaiboon M, Yospaiboon Y. Air vs perfluoropropane gas in pneumatic retinopexy: a randomized noninferiority trial. Arch Ophthalmol. 2010 Oct;128(10):1243-7. doi: 10.1001/archophthalmol.2010.230.","\tRetinal Detachment\tair|expansile gas\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","retinal detachment","NA","NA"]
["NCT00121901","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12432183|12555016|12555013|12555018|12806612|8319838|11531863|12518122|11862294|12921486|12806633|2070995","Freeman ML. Post-ERCP pancreatitis: patient and technique-related risk factors. JOP. 2002 Nov;3(6):169-76. Review.|Demols A, Deviere J. New frontiers in the pharmacological prevention of post-ERCP pancreatitis: the cytokines. JOP. 2003 Jan;4(1):49-57. Review.|Testoni PA. Preventing post-ERCP pancreatitis: where are we? JOP. 2003 Jan;4(1):22-32. Review.|Mariani A. Pharmacological prevention of post-ERCP pancreatitis: which therapy is best? JOP. 2003 Jan;4(1):68-74. Review.|Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology. 2003 Jun;124(7):1786-91.|Sand J, Nordback I. Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography. Digestion. 1993;54(2):105-11.|Sudhindran S, Bromwich E, Edwards PR. Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis. Br J Surg. 2001 Sep;88(9):1178-82.|Moretó M, Zaballa M, Casado I, Merino O, Rueda M, Ramírez K, Urcelay R, Baranda A. Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: A randomized double-blind trial. Gastrointest Endosc. 2003 Jan;57(1):1-7.|Harrison LI, Riedel DJ, Machacek JH, Crowley JK, Kanniainen CM, Hoglin JA, Robison TS, Zumhofe JM. Bioequivalence Comparison of Two Drug-in-Adhesive Transdermal Nitroglycerin Patches. Am J Ther. 1996 Aug;3(8):580-585.|Pande H, Thuluvath P. Pharmacological prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Drugs. 2003;63(17):1799-812. Review.|Freeman ML. Prevention of post-ERCP pancreatitis: pharmacologic solution or patient selection and pancreatic stents? Gastroenterology. 2003 Jun;124(7):1977-80.|Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, Liguory C, Nickl N. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991 May-Jun;37(3):383-93. Review.","\tPancreatitis\tglyceryl nitrate\tParallel Assignment\tPrevention\tRandomized\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","pancreatitis","NA","NA"]
["NCT00122902","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","14570299|16434915|NA","Mrus JM, Yi MS, Freedberg KA, Wu AW, Zackin R, Gorski H, Tsevat J. Utilities derived from visual analog scale scores in patients with HIV/AIDS. Med Decis Making. 2003 Sep-Oct;23(5):414-21.|Mrus JM, Sherman KE, Leonard AC, Sherman SN, Mandell KL, Tsevat J. Health values of patients coinfected with HIV/hepatitis C: are two viruses worse than one? Med Care. 2006 Feb;44(2):158-66.|Jacobson CJ Jr., Luckhaupt SE, DeLaney S, Tsevat J. Religio-biography, coping, and meaning-making among persons with HIV/AIDS. Journal for the Scientific Study of Religion. 2006;45:39-56.","\tHIV Infections\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","acquired immunodeficiency syndrome|hiv infections","NA","NA"]
["NCT00125489","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17093247,"Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE, Plowe CV. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med. 2006 Nov 9;355(19):1959-66.","\tMalaria|Plasmodium Falciparum Malaria\tchloroquine sulfate|sulfadoxine/pyrimethamine\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","malaria, falciparum|malaria","chloroquine diphosphate|chloroquine|sulfadoxine|pyrimethamine","NA"]
["NCT00126737",8259329,4511414,"Mean Difference (Final Values)",28.129,null,"NA",10.767,45.492,95,1.8E-3,"ANCOVA","18712641|20665344|20437315","Collins E, O'Connell S, Jelinek C, Miskevics S, Budiman-Mak E. Evaluation of psychometric properties of Walking Impairment Questionnaire in overweight patients with osteoarthritis of knee. J Rehabil Res Dev. 2008;45(4):559-66.|Wolf S, Foley S, Budiman-Mak E, Moritz T, O'Connell S, Jelinek C, Collins EG. Predictors of weight loss in overweight veterans with knee osteoarthritis who participated in a clinical trial. J Rehabil Res Dev. 2010;47(3):171-81.|Possley D, Budiman-Mak E, O'Connell S, Jelinek C, Collins EG. Relationship between depression and functional measures in overweight and obese persons with osteoarthritis of the knee. J Rehabil Res Dev. 2009;46(9):1091-8.","\tChronic Diseases|Obesity|Osteoarthritis|Pain\tWeight Control Nutritional Program|Home-based exercise program\tNA\tNA\tNA\tOther|Other\tAll\t","Home-Based Exercise and Weight Control Program for Pain Control in Overweight Elderly With Osteoarthritis of the Knee","Interventional","Completed","N/A",4,110,"osteoarthritis, knee|chronic disease|osteoarthritis|overweight","NA","Stair Total (Climb, Descend)"]
["NCT00127062",8259318,4511409,null,"NA",null,"NA",{"$nulls":3},0.05,"t-test, 2 sided",19449765,"Zhang JJ, McCreanor JE, Cullinan P, Chung KF, Ohman-Strickland P, Han IK, Järup L, Nieuwenhuijsen MJ. Health effects of real-world exposure to diesel exhaust in persons with asthma. Res Rep Health Eff Inst. 2009 Feb;(138):5-109; discussion 111-23.","\tAsthma\tOxford street|Hyde park\tNA\tNA\tNA\tOther|Other\tAll\t","Health Effects of Diesel Exhaust in Asthmatic Patients: A Real-world Study in a London Street","Interventional","Completed","N/A",2,60,"asthma","NA","Spirometry, Percentage Change in FEV1 From Baseline"]
["NCT00129662","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19879092,"Roberts NJ, Evans G, Blenkhorn P, Partridge MR. Development of an electronic pictorial asthma action plan and its use in primary care. Patient Educ Couns. 2010 Jul;80(1):141-6. doi: 10.1016/j.pec.2009.09.040. Epub 2009 Oct 29.","\tAsthma|COPD\tPictorial action plan\tNA\tNA\tNA\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","asthma","NA","NA"]
["NCT00132418","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17470434,"Weisman MH, Paulus HE, Burch FX, Kivitz AJ, Fierer J, Dunn M, Kerr DR, Tsuji W, Baumgartner SW. A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology (Oxford). 2007 Jul;46(7):1122-5. Epub 2007 Apr 29.","\tRheumatoid Arthritis\tEnbrel|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders","Interventional","Completed","Phase 4",2,564,"arthritis, rheumatoid|arthritis","etanercept","NA"]
["NCT00135902","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20093894,"Harper M, Thom E, Klebanoff MA, Thorp J Jr, Sorokin Y, Varner MW, Wapner RJ, Caritis SN, Iams JD, Carpenter MW, Peaceman AM, Mercer BM, Sciscione A, Rouse DJ, Ramin SM, Anderson GD; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Omega-3 fatty acid supplementation to prevent recurrent preterm birth: a randomized controlled trial. Obstet Gynecol. 2010 Feb;115(2 Pt 1):234-242. doi: 10.1097/AOG.0b013e3181cbd60e.","\tPreterm Birth\t17 alpha-Hydroxyprogesterone Caproate and Omega-3 supplement|17 alpha-hydroxy progesterone caproate and Placebo supplement\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug\tFemale\t","Omega-3 Fatty Acid Supplementation to Prevent Preterm Birth in High Risk Pregnancies","Interventional","Completed","Phase 3",2,800,"premature birth","11-hydroxyprogesterone|progesterone|17 alpha-hydroxyprogesterone caproate","NA"]
["NCT00136214",8258328,4510994,null,"NA",null,"NA",{"$nulls":3},0.4,"Wilcoxon (Mann-Whitney)",22027578,"Byrnes V, Miller A, Lowry D, Hill E, Weinstein C, Alsop D, Lenkinski R, Afdhal NH. Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. J Hepatol. 2012 Mar;56(3):549-56. doi: 10.1016/j.jhep.2011.09.015. Epub 2011 Oct 23.","\tHepatitis C\tMR brain and neuropsychiatric tests\tNA\tNA\tNA\tDiagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","hepatitis c|hepatitis|hepatitis a","NA","Ratios of Cerebral Metabolites Choline (CH), Myoinisitol (MI) and N-acety Aspartate (NAA)to Creatine (Cr) in 3 Brain Regions Including Basal Ganglia, Frontal Cortex and Left Dorsolateral Prefrontal Cortex"]
["NCT00137280",8258225,4510726,"Mean Difference (Final Values)",13.02,"Standard Error of the Mean",5.93,{"$nulls":3},0.03,"ANCOVA","18279505|20077148|20658320|23407006|24138608|28287773","Brown AH, Cohen AN, Chinman MJ, Kessler C, Young AS. EQUIP: implementing chronic care principles and applying formative evaluation methods to improve care for schizophrenia: QUERI Series. Implement Sci. 2008 Feb 15;3:9. doi: 10.1186/1748-5908-3-9.|Hamilton AB, Cohen AN, Young AS. Organizational readiness in specialty mental health care. J Gen Intern Med. 2010 Jan;25 Suppl 1:27-31. doi: 10.1007/s11606-009-1133-3.|Young AS, Niv N, Chinman M, Dixon L, Eisen SV, Fischer EP, Smith J, Valenstein M, Marder SR, Owen RR. Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI. Community Ment Health J. 2011 Apr;47(2):123-35. doi: 10.1007/s10597-010-9328-y. Epub 2010 Jul 25.|Cohen AN, Chinman MJ, Hamilton AB, Whelan F, Young AS. Using patient-facing kiosks to support quality improvement at mental health clinics. Med Care. 2013 Mar;51(3 Suppl 1):S13-20. doi: 10.1097/MLR.0b013e31827da859.|Hamilton AB, Cohen AN, Glover DL, Whelan F, Chemerinski E, McNagny KP, Mullins D, Reist C, Schubert M, Young AS. Implementation of evidence-based employment services in specialty mental health. Health Serv Res. 2013 Dec;48(6 Pt 2):2224-44. doi: 10.1111/1475-6773.12115. Epub 2013 Oct 21.|Pedersen ER, Huang W, Cohen AN, Young AS. Alcohol use and service utilization among veterans in treatment for schizophrenia. Psychol Serv. 2018 Feb;15(1):21-30. doi: 10.1037/ser0000109. Epub 2017 Mar 13.","\tChronic Illness|Psychotic Disorder|Schizophrenia|Weight Gain\tCollaborative Chronic Illness Care Model\tNA\tNA\tNA\tBehavioral\tAll\t","Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)","Interventional","Completed","N/A",2,1067,"psychotic disorders|chronic disease|mental disorders|weight gain|schizophrenia","NA","The Effect of Care Model Implementation on Treatment Appropriateness: Patient Weight Outcomes"]
["NCT00138294",8258154,4510666,"Incidence Rate Ratio",0.69,null,"NA",0.67,0.71,95,"NA",null,"18401289|17698577|17395338|16140685|15694506|14706961|12915495","Gaglani MJ, Piedra PA, Riggs M, Herschler G, Fewlass C, Glezen WP. Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J. 2008 May;27(5):444-52. doi: 10.1097/INF.0b013e3181660c2e.|Piedra PA, Gaglani MJ, Kozinetz CA, Herschler GB, Fewlass C, Harvey D, Zimmerman N, Glezen WP. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics. 2007 Sep;120(3):e553-64. Epub 2007 Aug 13.|Halloran ME, Piedra PA, Longini IM Jr, Gaglani MJ, Schmotzer B, Fewlass C, Herschler GB, Glezen WP. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine. 2007 May 16;25(20):4038-45. Epub 2007 Mar 12.|Piedra PA, Gaglani MJ, Riggs M, Herschler G, Fewlass C, Watts M, Kozinetz C, Hessel C, Glezen WP. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics. 2005 Sep;116(3):e397-407.|Piedra PA, Gaglani MJ, Kozinetz CA, Herschler G, Riggs M, Griffith M, Fewlass C, Watts M, Hessel C, Cordova J, Glezen WP. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine. 2005 Feb 18;23(13):1540-8.|Gaglani MJ, Piedra PA, Herschler GB, Griffith ME, Kozinetz CA, Riggs MW, Fewlass C, Halloran ME, Longini IM Jr, Glezen WP. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med. 2004 Jan;158(1):65-73.|Halloran ME, Longini IM Jr, Gaglani MJ, Piedra PA, Chu H, Herschler GB, Glezen WP. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol. 2003 Aug 15;158(4):305-11.","\tInfluenza\tlive attenuated and inactivated influenza vaccines\tNA\tNA\tNA\tBiological\tAll\t","Control of Epidemic Influenza Through a School-based Influenza Vaccination Program","Interventional","Completed","Phase 4",2,29255,"influenza, human","NA","MAARI Rate During the Epidemic Period (2008-2009)"]
["NCT00142337","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20158398,"Lallemant M, Ngo-Giang-Huong N, Jourdain G, Traisaithit P, Cressey TR, Collins IJ, Jarupanich T, Sukhumanant T, Achalapong J, Sabsanong P, Chotivanich N, Winiyakul N, Ariyadej S, Kanjanasing A, Ratanakosol J, Hemvuttiphan J, Kengsakul K, Wannapira W, Sittipiyasakul V, Pornkitprasarn W, Liampongsabuddhi P, McIntosh K, Van Dyke RB, Frenkel LM, Koetsawang S, Le Coeur S, Kanchana S; PHPT-4 Study Team. Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine. Clin Infect Dis. 2010 Mar 15;50(6):898-908. doi: 10.1086/650745.","\tHIV Infections\tZidovudine (ZDV)|Didanosine (ddI)\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","hiv infections","didanosine|zidovudine","NA"]
["NCT00144690","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21883097,"Krauss GL, Bar M, Biton V, Klapper JA, Rektor I, Vaiciene-Magistris N, Squillacote D, Kumar D. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand. 2012 Jan;125(1):8-15. doi: 10.1111/j.1600-0404.2011.01588.x. Epub 2011 Aug 29.","\tEpilepsy\tE2007 (perampanel)|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","seizures|epilepsy","NA","NA"]
["NCT00146458","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15050330,"Tsai CS, Chang TC, Lai CH, Tsai CC, Ng KK, Hsueh S, Yen TC, Hong JH. Preliminary report of using FDG-PET to detect extrapelvic lesions in cervical cancer patients with enlarged pelvic lymph nodes on MRI/CT. Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1506-12.","\tCervical Cancer\t18F-fluorodeoxyglucose positron emission tomography\tParallel Assignment\tDiagnostic\tRandomized\tProcedure\tFemale\t","NA","NA","NA","NA","NA","NA","uterine cervical neoplasms","fluorodeoxyglucose f18","NA"]
["NCT00147316","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16763187,"Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, Shinohara Y; Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke. 2006 Jul;37(7):1810-5. Epub 2006 Jun 8.","\tBrain Ischemia|Cerebral Infarction\tAlteplase\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","infarction|cerebral infarction|brain ischemia|ischemia","tissue plasminogen activator","NA"]
["NCT00150891","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12270445|15691277|15919463|16771810","Weimer R, Streller S, Staak A, Heilke M, Li D, Dietrich H, Daniel V, Feustel A, Rainer L, Zinn S, Friemann S, Ernst W, Grimm H, Padberg W, Zimmermann T, Opelz G. Effects of three immunosuppressive regimens on CD4 helper function, B cell monocyte and cytokine responses in renal transplant recipients: 4-month follow-up of a prospective randomized study. Transplant Proc. 2002 Sep;34(6):2377-8.|Weimer R, Staak A, Süsal C, Streller S, Yildiz S, Pelzl S, Renner F, Dietrich H, Daniel V, Rainer L, Kamali-Ernst S, Ernst W, Padberg W, Opelz G. ATG induction therapy: long-term effects on Th1 but not on Th2 responses. Transpl Int. 2005 Feb;18(2):226-36.|Weimer R, Süsal C, Yildiz S, Streller S, Pelzl S, Staak A, Renner F, Dietrich H, Daniel V, Feuring E, Kamali-Ernst S, Ernst W, Padberg W, Opelz G. sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil. Transplant Proc. 2005 May;37(4):1776-8.|Weimer R, Süsal C, Yildiz S, Staak A, Pelzl S, Renner F, Dietrich H, Daniel V, Kamali-Ernst S, Ernst W, Padberg W, Opelz G. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transplant. 2006 Aug;6(8):1865-74. Epub 2006 Jun 9.","\tRenal Failure, Chronic\tKidney transplantation|cyclosporine A|tacrolimus|azathioprine|mycophenolate mofetil\tNA\tNA\tNA\tProcedure|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","kidney failure, chronic","cyclosporine|azathioprine|tacrolimus|mycophenolic acid|cyclosporins","NA"]
["NCT00152893","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20163347|18288980","Aghdassi E, Arendt BM, Salit IE, Mohammed SS, Jalali P, Bondar H, Allard JP. In patients with HIV-infection, chromium supplementation improves insulin resistance and other metabolic abnormalities: a randomized, double-blind, placebo controlled trial. Curr HIV Res. 2010 Mar;8(2):113-20.|Arendt BM, Aghdassi E, Mohammed SS, Fung LY, Jalali P, Salit IE, Allard JP. Dietary intake and physical activity in a Canadian population sample of male patients with HIV infection and metabolic abnormalities. Curr HIV Res. 2008 Jan;6(1):82-90.","\tHIV Infections\tchromium nicotinate|Placebo\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug\tAll\t","To Determine if Chromium Nicotinate Supplementation Will Improve Insulin Resistance in HIV Patients With Metabolic Abnormalities","Interventional","Completed","Phase 2",2,52,"acquired immunodeficiency syndrome|infection|hiv infections","chromium|niacin","NA"]
["NCT00154284","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Grinyo JM, Paul J, Novoa P, et al. (2010). Better renal function in renal-transplant recipients treated with everolimus plus cyclosporine elimination compared with cyclosporine minimisation, Am J Transplant; 10(Suppl 4): 503: Abstract 1636.","\tOrgan Transplantation, Renal Transplantation\tEverolimus (Certican)|Cyclosporine (Neoral)|Steroid|Basiliximab (Simulect)\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug\tAll\t","Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients","Interventional","Completed","Phase 3",2,114,"NA","cyclosporins|everolimus|basiliximab|prednisone|cyclosporine","NA"]
["NCT00157118","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Gelmont D., Hays T., Bomgaars L., Palascak J., Shapiro A., Geil J., Montgomery J., Fritsch S., Maritsch F., Pavlova B., Ehrlich H.J. A Phase II/III Clinical Study for the Determination of the Efficacy and Safety of Protein C Concentrate in Subjects with Severe Congenital Protein C Deficiency -Interim Study Analysis. Accepted for poster presentation at the 20th International Society on Thrombosis and Haemostasis Congress. Sydney, Australia, August 6-12 2005. (ISTH 2005)","\tProtein C Deficiency\tProtein C Concentrate (Human) Vapor Heated\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","protein c deficiency","protein c","NA"]
["NCT00158561","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17519409,"Leslie T, Mayan MI, Hasan MA, Safi MH, Klinkenberg E, Whitty CJ, Rowland M. Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial. JAMA. 2007 May 23;297(20):2201-9.","\tMalaria|Vivax Malaria\tsulfadoxine-pyrimethamine and chlorproguanil-dapsone\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","malaria, vivax|malaria","fanasil, pyrimethamine drug combination|chlorproguanil|sulfadoxine|pyrimethamine|dapsone","NA"]
["NCT00161083","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16729326,"Venneman NG, Besselink MG, Keulemans YC, Vanberge-Henegouwen GP, Boermeester MA, Broeders IA, Go PM, van Erpecum KJ. Ursodeoxycholic acid exerts no beneficial effect in patients with symptomatic gallstones awaiting cholecystectomy. Hepatology. 2006 Jun;43(6):1276-83.","\tCholecystolithiasis\tursodeoxycholic acid\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","cholelithiasis|cholecystolithiasis|gallstones","ursodeoxycholic acid","NA"]
["NCT00165542","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19422022,"Manley P, Li X, Turner C, Chi S, Zimmerman MA, Chordas C, Gordon A, Baker A, Ullrich NJ, Goumnerova L, Marcus K, Hoffman K, Kieran MW. A prospective, blinded analysis of A-PROTEIN (recoverin or CAR protein) levels in pediatric patients with central nervous system tumors. Pediatr Blood Cancer. 2009 Sep;53(3):343-7. doi: 10.1002/pbc.22017.","\tMalignant Childhood Central Nervous System Neoplasm\tA PROTEIN level\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","central nervous system neoplasms|brain neoplasms|nervous system neoplasms","NA","NA"]
["NCT00166673","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|17192334|17425442|17889075|NA|18221427","Buckingham B, Ruedy K, Kollman C, Beck R, Tamborlane W, Mauras N, Weinzimer S, Chase P, Tsalikian E; and the Diabetes Research in Children Network (DirecNet) Study Group. Family Assessment of the Utility of the DirecNet Applied Treatment Algorithm (DATA) for Insulin Adjustments in Real-Time and Retrospective Analyses of Continuous Glucose Monitoring (CGM) Diabetes 2006; 55(Suppl.1): A453|Fiallo-Scharer R, Tamborlane W, Buckingham B, Wysocki T, Weinzimer S, Tsalikian E, Beck R, Ruedy K, Kollman C; and the Diabetes Research in Children Network (DirecNet) Study Group. Diabetes Research in Children Network (DirecNet) Pilot Study to Evaluate the FreeStyle Navigator® Continuous Glucose Monitoring System in the Management of T1D in Children. Diabetes 2006; 55(Suppl.1): A452.|Wilson DM, Beck RW, Tamborlane WV, Dontchev MJ, Kollman C, Chase P, Fox LA, Ruedy KJ, Tsalikian E, Weinzimer SA; DirecNet Study Group. The accuracy of the FreeStyle Navigator continuous glucose monitoring system in children with type 1 diabetes. Diabetes Care. 2007 Jan;30(1):59-64.|Diabetes Research in Children Network (DirecNet) Study Group. Relative accuracy of the BD Logic and FreeStyle blood glucose meters. Diabetes Technol Ther. 2007 Apr;9(2):165-8.|Diabetes Research in Children Network (DirecNet) Study Group, Buckingham B, Beck RW, Tamborlane WV, Xing D, Kollman C, Fiallo-Scharer R, Mauras N, Ruedy KJ, Tansey M, Weinzimer SA, Wysocki T. Continuous glucose monitoring in children with type 1 diabetes. J Pediatr. 2007 Oct;151(4):388-93, 393.e1-2. Epub 2007 Aug 24.|Messer L, Ruedy K, Coffey J, Englert K, Caswell K, Steffen A; and the Diabetes Research in Children Network (DirecNet) Study Group. Pediatric Educators' Role in Successful Continuous Glucose Monitoring. Diabetes 2007; 56(Suppl.1): A617.|Diabetes Research In Children Network (DirecNet) Study Group, Buckingham B, Xing D, Weinzimer S, Fiallo-Scharer R, Kollman C, Mauras N, Tsalikian E, Tamborlane W, Wysocki T, Ruedy K, Beck R. Use of the DirecNet Applied Treatment Algorithm (DATA) for diabetes management with a real-time continuous glucose monitor (the FreeStyle Navigator). Pediatr Diabetes. 2008 Apr;9(2):142-7. doi: 10.1111/j.1399-5448.2007.00301.x. Epub 2008 Jan 24.","\tDiabetes Mellitus, Insulin-Dependent\tFreeStyle Navigator Continuous Glucose Monitoring System\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","diabetes mellitus|diabetes mellitus, type 1","NA","NA"]
["NCT00168662","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","10342702|11228365|11672911|12443658|12798618|14506371|15082642|15626943|15659474","Garly ML, Martins CL, Balé C, da Costa F, Dias F, Whittle H, Aaby P. Early two-dose measles vaccination schedule in Guinea-Bissau: good protection and coverage in infancy. Int J Epidemiol. 1999 Apr;28(2):347-52.|Garly ML, Balé C, Martins CL, Monteiro M, George E, Kidd M, Dias F, Aaby P, Whittle HC. Measles antibody responses after early two dose trials in Guinea-Bissau with Edmonston-Zagreb and Schwarz standard-titre measles vaccine: better antibody increase from booster dose of the Edmonston-Zagreb vaccine. Vaccine. 2001 Feb 28;19(15-16):1951-9.|Garly ML, Balé C, Martins CL, Baldé MA, Hedegaard KL, Whittle HC, Aaby P. BCG vaccination among West African infants is associated with less anergy to tuberculin and diphtheria-tetanus antigens. Vaccine. 2001 Nov 12;20(3-4):468-74.|Aaby P, Jensen H, Garly ML, Balé C, Martins C, Lisse I. Routine vaccinations and child survival in a war situation with high mortality: effect of gender. Vaccine. 2002 Nov 22;21(1-2):15-20.|Garly ML, Martins CL, Balé C, Baldé MA, Hedegaard KL, Gustafson P, Lisse IM, Whittle HC, Aaby P. BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG? Vaccine. 2003 Jun 20;21(21-22):2782-90.|Aaby P, Garly ML, Balé C, Martins C, Jensen H, Lisse I, Whittle H. Survival of previously measles-vaccinated and measles-unvaccinated children in an emergency situation: an unplanned study. Pediatr Infect Dis J. 2003 Sep;22(9):798-805.|Aaby P, Jensen H, Rodrigues A, Garly ML, Benn CS, Lisse IM, Simondon F. Divergent female-male mortality ratios associated with different routine vaccinations among female-male twin pairs. Int J Epidemiol. 2004 Apr;33(2):367-73.|Garly ML, Jensen H, Martins CL, Balé C, Baldé MA, Lisse IM, Aaby P. Hepatitis B vaccination associated with higher female than male mortality in Guinea-bissau: an observational study. Pediatr Infect Dis J. 2004 Dec;23(12):1086-92.|Roth A, Gustafson P, Nhaga A, Djana Q, Poulsen A, Garly ML, Jensen H, Sodemann M, Rodriques A, Aaby P. BCG vaccination scar associated with better childhood survival in Guinea-Bissau. Int J Epidemiol. 2005 Jun;34(3):540-7. Epub 2005 Jan 19.","\tMeasles\tMeasles and inactivated polio vaccine\tParallel Assignment\tPrevention\tRandomized\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","measles","NA","NA"]
["NCT00180310","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19755303|19737711|19608482|18926156|NA|NA|NA|NA|20031737|21232715","Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrié D, Thuesen L, Boone E, Miquel-Herbert K, Daemen J. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. EuroIntervention. 2006 Nov;2(3):286-94.|Ruygrok PN, Desaga M, Van Den Branden F, Rasmussen K, Suryapranata H, Dorange C, Veldhof S, Serruys PW. One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study. EuroIntervention. 2007 Nov;3(3):315-20.|Khattab AA, Richardt G, Verin V, Kelbaek H, Macaya C, Berland J, Miquel-Hebert K, Dorange C, Serruys PW. Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial. EuroIntervention. 2008 Mar;3(5):566-73.|Wiemer M, Seth A, Chandra P, Neuzner J, Richardt G, Piek JJ, Desaga M, Macaya C, Bol CJ, Miquel-Hebert K, De Roeck K, Serruys PW. Systemic exposure of everolimus after stent implantation: a pharmacokinetic study. Am Heart J. 2008 Oct;156(4):751.e1-7. doi: 10.1016/j.ahj.2008.07.005.|SPIRIT II study: A clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions. Serruys Patrick W (Reprint). Erasmus MC, Ctr Thorax, Rotterdam, Netherlands. Journal of the American College of Cardiology 51 ( 10, Suppl. A ): p A261 MAR 11 2008|A clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with cle novo native coronary artery lesions. Ruygrok Peter(Reprint). Auckland City Hosp, Auckland, New Zealand Journal: Journal of the American College of Cardiology 49 ( 9, Suppl. B ): p 28B-29B MAR 6 2007 2007 i2 Summit 2007 on Innovation in Intervention New Orleans, LA, USA March 24 -27, 2007; 20070324 ISSN: 0735-1097|A clinical evaluation of the XIENCE V Everolimus Eluting CSS in the treatment of patients with de novo, native coronary artery lesions. Pharmaco kinetic substudy. Seth A (Reprint); Neuzner J; Richardt G; Wiemer M; Piek J J; Desaga M; Macaya C; Serruys P W; Spirit II Investigators (Reprint) Author Address: Max Hosp, Vasc Inst, New Delhi, India. European Heart Journal 27 ( Suppl. 1 ): p 767 AUG 2006 2006 World Congress of Cardiology Barcelona, SPAIN September 02 -06, 2006; 20060902 ISSN: 0195-668X Document Type: Meeting; Meeting Poster|Serruys, P. SPIRIT II Clinical Study: A clinical evaluation of the XIENCE™ V Everolimus Eluting CSS in the treatment of patients with de novo, native coronary artery lesions - IVUS substudy. Transcatheter Cardiovascular Therapeutics - TCT Congress 2006|Claessen BE, Beijk MA, Legrand V, Ruzyllo W, Manari A, Varenne O, Suttorp MJ, Tijssen JG, Miquel-Hebert K, Veldhof S, Henriques JP, Serruys PW, Piek JJ. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial. Circ Cardiovasc Interv. 2009 Aug;2(4):339-47. doi: 10.1161/CIRCINTERVENTIONS.108.831800.108.831800. Epub 2009 Jul 22.|Caixeta A, Lansky AJ, Serruys PW, Hermiller JB, Ruygrok P, Onuma Y, Gordon P, Yaqub M, Miquel-Hebert K, Veldhof S, Sood P, Su X, Jonnavithula L, Sudhir K, Stone GW; SPIRIT II and III Investigators. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials. JACC Cardiovasc Interv. 2010 Dec;3(12):1220-8. doi: 10.1016/j.jcin.2010.07.017.","\tCoronary Artery Disease|Coronary Disease|Coronary Restenosis\tXIENCE V® Everolimus Eluting Coronary Stent|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent\tParallel Assignment\tTreatment\tRandomized\tDevice|Device\tAll\t","SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System","Interventional","Completed","Phase 3",2,300,"coronary disease|coronary restenosis|myocardial ischemia|coronary artery disease","albumin-bound paclitaxel|everolimus|paclitaxel","NA"]
["NCT00184119","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16635934,"Vaaler AE, Morken G, Fløvig JC, Iversen VC, Linaker OM. Effects of a psychiatric intensive care unit in an acute psychiatric department. Nord J Psychiatry. 2006;60(2):144-9.","\tMental Disorders\tPsychiatric Intensive Care Unit|Care in whole acute unit\tNA\tNA\tNA\tProcedure|Procedure\tAll\t","Effects of a Psychiatric Intensive Care Unit","Interventional","Completed","N/A",2,118,"mental disorders","NA","NA"]
["NCT00184392","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17075402,"Bugten V, Nordgård S, Steinsvåg S. The effects of debridement after endoscopic sinus surgery. Laryngoscope. 2006 Nov;116(11):2037-43.","\tAcute Recurrent Rhinosinusitis\tdebridement or saline irrigation\tParallel Assignment\tTreatment\tRandomized\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","sinusitis","NA","NA"]
["NCT00185029","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15249979,"Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Barentsz JO. Cost-analysis of staging methods for lymph nodes in patients with prostate cancer: MRI with a lymph node-specific contrast agent compared to pelvic lymph node dissection or CT. Eur Radiol. 2004 Sep;14(9):1707-12. Epub 2004 Jul 13.","\tLymphatic Metastasis|Prostatic Neoplasms\tFerumoxtran-10 enhanced MRI (MRL)\tNA\tNA\tNA\tProcedure\tMale\t","NA","NA","NA","NA","NA","NA","lymphatic metastasis|prostatic neoplasms","NA","NA"]
["NCT00185380","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22222193|24726226","Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril. 2012 Mar;97(3):616-22.e1-3. doi: 10.1016/j.fertnstert.2011.12.003. Epub 2012 Jan 4.|Apter D, Gemzell-Danielsson K, Hauck B, Rosen K, Zurth C. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. Fertil Steril. 2014 Jun;101(6):1656-62.e1-4. doi: 10.1016/j.fertnstert.2014.03.004. Epub 2014 Apr 14.","\tContraception\tLevonorgestrel IUS (BAY86-5028, G04209B)|Levonorgestrel IUS (BAY86-5028, G04209C)|Levonorgestrel IUS (Mirena, BAY86-5028)\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug|Drug\tFemale\t","Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS)","Interventional","Completed","Phase 2",3,742,"NA","levonorgestrel","NA"]
["NCT00186979","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|NA","A Phase I Study of Gefitinib and irinotecan (IRN) in pediatric patients with refractory solid tumors. WL Furman et al. Vol 22, No 14S (July 15 Supplement), 2004: 8521|Effect of Gefitinib on the bioavailability of oral irinotecan in children with refractory solid tumors. K.R. Crews, W.L. Furman, J.C. Panetta, B.B. Freeman, L.C. Iacono, P.J. Houghton, C.F. Stewart. Proceeding of ASCO. Vol 22, No 14S, 2004:2012.|Effect of gefitinib on the systemic dispositon of intravenous irinotecan (IRN) in pediatric patients with refractory solid tumors. L.C. Iacono, W.L. Furman, K.R. Crews, J.C. Panetta, B.B. Freeman, N.C. Daw, C.F. Stewart. Proceedings of ASCO. Vol 22, No 14S, 2004:2011.","\tSolid Tumors\tIrinotecan, ZD1839, Vincristine, Cefixime, Cefpodoxime.\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","cefixime|cefpodoxime proxetil|irinotecan|vincristine|cefpodoxime|gefitinib","NA"]
["NCT00187421","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20006356,"Singh SK, Desai ND, Chikazawa G, Tsuneyoshi H, Vincent J, Zagorski BM, Pen V, Moussa F, Cohen GN, Christakis GT, Fremes SE. The Graft Imaging to Improve Patency (GRIIP) clinical trial results. J Thorac Cardiovasc Surg. 2010 Feb;139(2):294-301, 301.e1. doi: 10.1016/j.jtcvs.2009.09.048. Epub 2009 Dec 16.","\tCoronary Disease\tIndocyanine green intraoperative angiogram and transit-time flowmetry\tParallel Assignment\tPrevention\tRandomized\tProcedure\tAll\t","Using Intraoperative Coronary Bypass Graft Imaging to Improve Graft Patency","Interventional","Completed","Phase 3",2,156,"coronary disease|coronary artery disease","NA","NA"]
["NCT00191126","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22124104,"Scagliotti GV, Pastorino U, Vansteenkiste JF, Spaggiari L, Facciolo F, Orlowski TM, Maiorino L, Hetzel M, Leschinger M, Visseren-Grul C, Torri V. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol. 2012 Jan 10;30(2):172-8. doi: 10.1200/JCO.2010.33.7089. Epub 2011 Nov 28.","\tNon-Small Cell Lung Cancer\tgemcitabine|Cisplatin|surgery\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Procedure\tAll\t","Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC","Interventional","Completed","Phase 3",2,263,"carcinoma, non-small-cell lung|lung neoplasms","gemcitabine","NA"]
["NCT00193232","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17553208,"Hainsworth JD, Meluch AA, Spigel DR, Barton J Jr, Simons L, Meng C, Gould B, Greco FA. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial. Clin Genitourin Cancer. 2007 Mar;5(4):278-83.","\tProstate Cancer\tDocetaxel|Bortezomib\tNA\tNA\tNA\tDrug|Drug\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","bortezomib|docetaxel","NA"]
["NCT00194038","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18312036,"Sajatovic M, Coconcea N, Ignacio RV, Blow FC, Hays RW, Cassidy KA, Meyer WJ. Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. J Clin Psychiatry. 2008 Jan;69(1):41-6.","\tBipolar Disorder\tAripiprazole\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","disease|bipolar disorder","aripiprazole","NA"]
["NCT00197548","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17409323,"Fawzi WW, Msamanga GI, Urassa W, Hertzmark E, Petraro P, Willett WC, Spiegelman D. Vitamins and perinatal outcomes among HIV-negative women in Tanzania. N Engl J Med. 2007 Apr 5;356(14):1423-31.","\tInfant, Low Birth Weight|Pregnancy|Pregnancy Outcomes|Premature Birth\tMultivitamins-vitamins B-complex, C, and E|Placebo\tParallel Assignment\tPrevention\tRandomized\tDietary Supplement|Dietary Supplement\tFemale\t","A Trial of Micronutrients and Adverse Pregnancy Outcomes","Interventional","Completed","Phase 3",2,8468,"birth weight|premature birth","vitamin b complex|folic acid","NA"]
["NCT00201591","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18365893,"Amundsen BH, Rognmo Ø, Hatlen-Rebhan G, Slørdahl SA. High-intensity aerobic exercise improves diastolic function in coronary artery disease. Scand Cardiovasc J. 2008 Apr;42(2):110-7. doi: 10.1080/14017430701744477.","\tCoronary Artery Disease\tExercise training for 10 weeks\tParallel Assignment\tTreatment\tRandomized\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","coronary disease|coronary artery disease|myocardial ischemia","NA","NA"]
["NCT00201864",8253461,4508062,null,"NA",null,"NA",{"$nulls":3},0.9102,"Wilcoxon (Mann-Whitney)",22444722,"Mrózek E, Layman R, Ramaswamy B, Schaaf L, Li X, Ottman S, Shapiro CL. Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer. Clin Breast Cancer. 2012 Apr;12(2):151-6. doi: 10.1016/j.clbc.2012.01.003.","\tBreast Cancer\tExemestane|Fulvestrant\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","fulvestrant|exemestane","Maximum Plasma Concentration (Cmax) of Exemestane When Administered Alone and With Fulvestrant"]
["NCT00205205","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Veith, E.M., Sherman, J.E., Pellino, T.A. Yasui, T.Y. (2006). Qualitative analysis of the peer-mentoring relationship among individuals with spinal cord injury, Rehabilitation Psychology, 51, 289-298.","\tSpinal Cord Injury\tpeer mentoring\tNA\tNA\tNA\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","spinal cord injuries|wounds and injuries","NA","NA"]
["NCT00210405","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17374671|19161543","Menon P, Ruel MT, Loechl CU, Arimond M, Habicht JP, Pelto G, Michaud L. Micronutrient Sprinkles reduce anemia among 9- to 24-mo-old children when delivered through an integrated health and nutrition program in rural Haiti. J Nutr. 2007 Apr;137(4):1023-30.|Loechl CU, Menon P, Arimond M, Ruel MT, Pelto G, Habicht JP, Michaud L. Using programme theory to assess the feasibility of delivering micronutrient Sprinkles through a food-assisted maternal and child health and nutrition programme in rural Haiti. Matern Child Nutr. 2009 Jan;5(1):33-48. doi: 10.1111/j.1740-8709.2008.00154.x.","\tAnemia\t\"Sprinkles\"\" containing mulitple micronutrients|Education/communication on use of micronutrient sprinkles|Fortified food aid (corn-soy blend)\"","Parallel Assignment","Treatment","Randomized","Dietary Supplement|Behavioral|Dietary Supplement","All","\tFeasibility and Effectiveness of Distributing Micronutrient Sprinkles to Reduce Prevalence of Anemia\tInterventional\tCompleted\tN/A\t2\t450\tanemia\ttrace elements|micronutrients\tNA\nNCT00210418\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t15646314|18280329|16060227|18287379|20392883\tRuel MT, Menon P, Loechl C, Pelto G. Donated fortified cereal blends improve the nutrient density of traditional complementary foods in Haiti, but iron and zinc gaps remain for infants. Food Nutr Bull. 2004 Dec;25(4):361-76.|Ruel MT, Menon P, Habicht JP, Loechl C, Bergeron G, Pelto G, Arimond M, Maluccio J, Michaud L, Hankebo B. Age-based preventive targeting of food assistance and behaviour change and communication for reduction of childhood undernutrition in Haiti: a cluster randomised trial. Lancet. 2008 Feb 16;371(9612):588-95. doi: 10.1016/S0140-6736(08)60271-8.|Menon P, Ruel MT, Loechl C, Pelto G. From research to program design: use of formative research in Haiti to develop a behavior change communication program to prevent malnutrition. Food Nutr Bull. 2005 Jun;26(2):241-2.|Menon P, Mbuya M, Habicht JP, Pelto G, Loechl CU, Ruel MT. Assessing supervisory and motivational factors in the context of a program evaluation in rural Haiti. J Nutr. 2008 Mar;138(3):634-7.|Donegan S, Maluccio JA, Myers CK, Menon P, Ruel MT, Habicht JP. Two food-assisted maternal and child health nutrition programs helped mitigate the impact of economic hardship on child stunting in Haiti. J Nutr. 2010 Jun;140(6):1139-45. doi: 10.3945/jn.109.114272. Epub 2010 Apr 14.\t","Malnutrition","Fortified food rations|Education and communication to improve feeding practices","Parallel Assignment","Prevention","Randomized","Dietary Supplement|Behavioral","All","\tEffectiveness of Targeting Food Aid to Malnourished Children Compared to Targeting All Children Under Two Years\tInterventional\tCompleted\tN/A\t2\t1500\tmalnutrition\tNA\tNA\nNCT00210457\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t18248639\tChanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P, Delemer B; Lanreotide Acromegaly Study Group. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf). 2008 Aug;69(2):299-305. doi: 10.1111/j.1365-2265.2008.03208.x. Epub 2008 Jan 31.\t","Acromegaly","Lanreotide (Autogel formulation)","NA","NA","NA","Drug","All","\tNA\tNA\tNA\tNA\tNA\tNA\tacromegaly\tangiopeptin|lanreotide\tNA\nNCT00210470\t8252800\t4507295\t\tNA\t\tNA\t\t\t\t0.1\tSpearman Rank\t20539208|21284052|22057678|22109700\tFreeman SM, Franco JL, Kenady DE, Baltzer L, Roth Z, Brandwein HJ, Hadden JW. A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2011 Apr;34(2):173-8. doi: 10.1097/COC.0b013e3181dbb9d8.|Wolf GT, Fee WE Jr, Dolan RW, Moyer JS, Kaplan MJ, Spring PM, Suen J, Kenady DE, Newman JG, Carroll WR, Gillespie MB, Freeman SM, Baltzer L, Kirkley TD, Brandwein HJ, Hadden JW. Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head Neck. 2011 Dec;33(12):1666-74. doi: 10.1002/hed.21660. Epub 2011 Jan 31.|Berinstein NL, Wolf GT, Naylor PH, Baltzer L, Egan JE, Brandwein HJ, Whiteside TL, Goldstein LC, El-Naggar A, Badoual C, Fridman WH, White JM, Hadden JW. Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol Immunother. 2012 Jun;61(6):771-82. doi: 10.1007/s00262-011-1134-z. Epub 2011 Nov 6.|Whiteside TL, Butterfield LH, Naylor PH, Egan JE, Hadden JW, Baltzer L, Wolf GT, Berinstein NL. A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma. Cancer Immunol Immunother. 2012 Jun;61(6):783-8. doi: 10.1007/s00262-011-1136-x. Epub 2011 Nov 23.\t","Squamous Cell Carcinoma of the Head and Neck","IRX-2|Cyclophosphamide|Indomethacin|Zinc|Omeprazole","NA","NA","NA","Biological|Drug|Drug|Drug|Drug","All","\tNA\tNA\tNA\tNA\tNA\tNA\tsquamous cell carcinoma of head and neck\tcyclophosphamide|omeprazole|indomethacin|zinc\tClinical and Histological Tumor Responses\nNCT00210509\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t17300358\tMathew NT, Finlayson G, Smith TR, Cady RK, Adelman J, Mao L, Wright P, Greenberg SJ; AEGIS Investigator Study Group. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study). Headache. 2007 Feb;47(2):189-98.\t","Migraine","almotriptan malate","Parallel Assignment","Treatment","Randomized","Drug","All","\tNA\tNA\tNA\tNA\tNA\tNA\tmigraine disorders|headache\talmotriptan\tNA\nNCT00210639\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t17901792\tNoel GJ, Bradley JS, Kauffman RE, Duffy CM, Gerbino PG, Arguedas A, Bagchi P, Balis DA, Blumer JL. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J. 2007 Oct;26(10):879-91.\t","Musculoskeletal Diseases","No intervention","NA","NA","NA","Drug","All","\tNA\tNA\tNA\tNA\tNA\tNA\tmusculoskeletal diseases|bacterial infections\tNA\tNA\nNCT00210743\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t17699416\tBenz R, Schmidt R, Kelly K, Wolfson M. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. Clin J Am Soc Nephrol. 2007 Mar;2(2):215-21. Epub 2007 Jan 10.\t","Anemia|Kidney Diseases","epoetin alfa","NA","NA","NA","Drug","All","\tNA\tNA\tNA\tNA\tNA\tNA\tanemia|kidney diseases\tepoetin alfa\tNA\nNCT00210808\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t17258690\tMcElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR; Topiramate Binge Eating Disorder Research Group. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry. 2007 May 1;61(9):1039-48. Epub 2007 Jan 29.\t","Binge-Eating Disorder|Obesity","topiramate","Parallel Assignment","Treatment","Randomized","Drug","All","\tNA\tNA\tNA\tNA\tNA\tNA\tfeeding and eating disorders|binge-eating disorder|disease|obesity|bulimia\ttopiramate\tNA\nNCT00210834\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t16834839\tHenry DH, Gordan LN, Charu V, Wilhelm FE, Williams D, Xie J, Woodman RC. Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia. Curr Med Res Opin. 2006 Jul;22(7):1403-13.\t","Anemia","epoetin alfa","Parallel Assignment","Treatment","Randomized","Drug","All","\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tepoetin alfa\tNA\nNCT00210847\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t17257476\tFreeman R, Raskin P, Hewitt DJ, Vorsanger GJ, Jordan DM, Xiang J, Rosenthal NR; CAPSS-237 Study Group. Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Curr Med Res Opin. 2007 Jan;23(1):147-61.\t","Diabetic Neuropathies","tramadol, acetaminophen","Parallel Assignment","Treatment","Randomized","Drug","All","\tNA\tNA\tNA\tNA\tNA\tNA\tperipheral nervous system diseases|diabetic neuropathies\tacetaminophen|tramadol\tNA\nNCT00210886\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t18242357|17880755|18042477\tPeterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology. 2008 Jan;71(1):17-22. doi: 10.1016/j.urology.2007.09.002.|Klausner HA, Brown P, Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Curr Med Res Opin. 2007 Nov;23(11):2637-45.|Peterson J, Kaul S, Khashab M, Fisher A, Kahn JB. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006. Clin Ther. 2007 Oct;29(10):2215-21.\t","Pyelonephritis|Urinary Tract Infections","levofloxacin","Parallel Assignment","Treatment","Randomized","Drug","All","\tNA\tNA\tNA\tNA\tNA\tNA\tcommunicable diseases|infection|urinary tract infections|pyelonephritis\tofloxacin|levofloxacin\tNA\nNCT00210899\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t18225981\tNoel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis. 2008 Mar 1;46(5):647-55. doi: 10.1086/526527.\t","Skin Diseases, Bacterial|Skin Diseases, Infectious|Staphylococcal Skin Infections","ceftobiprole medocaril|Vancomycin plus Ceftazidime","Parallel Assignment","Treatment","Randomized","Drug|Drug","All","\tCeftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections\tInterventional\tCompleted\tPhase 3\t2\t828\tskin diseases, bacterial|infection|skin diseases|communicable diseases|skin diseases, infectious|cellulitis|staphylococcal skin infections\tvancomycin|ceftobiprole medocaril|ceftazidime|ceftobiprole\tNA\nNCT00210912\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t17300356\tSilberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, Brandes JL, Bigal M, Saper J, Ascher S, Jordan DM, Greenberg SJ, Hulihan J; Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007 Feb;47(2):170-80.\t","Migraine","topiramate","Parallel Assignment","Prevention","Randomized","Drug","All","\tNA\tNA\tNA\tNA\tNA\tNA\tmigraine disorders\ttopiramate\tNA\nNCT00210925\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t17925516\tJohnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM; Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007 Oct 10;298(14):1641-51.\t","Alcoholism","topiramate","Parallel Assignment","Treatment","Randomized","Drug","All","\tNA\tNA\tNA\tNA\tNA\tNA\talcoholism\ttopiramate\tNA\nNCT00211094\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t16962882\tPryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, Miloslavsky M, Kell S; Dapoxetine Study Group. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet. 2006 Sep 9;368(9539):929-37.\t","Ejaculation","Dapoxetine","Parallel Assignment","Treatment","Randomized","Drug","Male","\tNA\tNA\tNA\tNA\tNA\tNA\tpremature ejaculation\tNA\tNA\nNCT00211107\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t16962882\tPryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, Miloslavsky M, Kell S; Dapoxetine Study Group. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet. 2006 Sep 9;368(9539):929-37.\t","Ejaculation","Dapoxetine","Parallel Assignment","Treatment","Randomized","Drug","Male","\tNA\tNA\tNA\tNA\tNA\tNA\tpremature ejaculation\tNA\tNA\nNCT00211120\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t17108343\tSingh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16;355(20):2085-98.\t","Anemia","Epoetin Alfa","Parallel Assignment","Treatment","Randomized","Drug","All","\tNA\tNA\tNA\tNA\tNA\tNA\trenal insufficiency\tepoetin alfa\tNA\nNCT00211133\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t16087945\tLeyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005 Sep 1;23(25):5960-72. Epub 2005 Aug 8.\t","Anemia|Breast Neoplasms|Quality of Life","epoetin alfa","Parallel Assignment","Treatment","Randomized","Drug","Female","\tNA\tNA\tNA\tNA\tNA\tNA\tbreast neoplasms\tepoetin alfa\tNA\nNCT00211159\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t17030655|25616438|24934544|24410954|22545106\tFreund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol. 2006 Oct;63(10):1402-8.|Wang X, Hjorth E, Vedin I, Eriksdotter M, Freund-Levi Y, Wahlund LO, Cederholm T, Palmblad J, Schultzberg M. Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. J Lipid Res. 2015 Mar;56(3):674-681. doi: 10.1194/jlr.P055418. Epub 2015 Jan 23.|Freund-Levi Y, Vedin I, Hjorth E, Basun H, Faxén Irving G, Schultzberg M, Eriksdotter M, Palmblad J, Vessby B, Wahlund LO, Cederholm T, Basu S. Effects of supplementation with omega-3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. J Alzheimers Dis. 2014;42(3):823-31. doi: 10.3233/JAD-132042.|Freund Levi Y, Vedin I, Cederholm T, Basun H, Faxén Irving G, Eriksdotter M, Hjorth E, Schultzberg M, Vessby B, Wahlund LO, Salem N Jr, Palmblad J. Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. J Intern Med. 2014 Apr;275(4):428-36. doi: 10.1111/joim.12166. Epub 2014 Jan 11.|Vedin I, Cederholm T, Freund-Levi Y, Basun H, Garlind A, Irving GF, Eriksdotter-Jönhagen M, Wahlund LO, Dahlman I, Palmblad J. Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One. 2012;7(4):e35425. doi: 10.1371/journal.pone.0035425. Epub 2012 Apr 24.\t","Alzheimer's Disease","EPAX 1050TG","Crossover Assignment","Treatment","Randomized","Drug","All","\tNA\tNA\tNA\tNA\tNA\tNA\talzheimer disease\tNA\tNA\nNCT00211172\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t18332291\tSmith DH, Kramer JM, Perrin N, Platt R, Roblin DW, Lane K, Goodman M, Nelson WW, Yang X, Soumerai SB. A randomized trial of direct-to-patient communication to enhance adherence to beta-blocker therapy following myocardial infarction. Arch Intern Med. 2008 Mar 10;168(5):477-83; discussion 483; quiz 447. doi: 10.1001/archinternmed.2007.132.\t","Acute Myocardial Infarction (AMI)","Beta-blocker adherence after an AMI","Parallel Assignment","Health Services Research","Randomized","Behavioral","All","\tHMO Research Network CERT: Acute Myocardial Infarction\tInterventional\tCompleted\tN/A\t2\t836\tmyocardial infarction|infarction\tadrenergic beta-antagonists\tNA\nNCT00211185\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tFrancine M. Foss, Nelida Sjak-Shie, Andre Goy, Ranjana Advani, Eric Jacobsen, and Mark Acosta A Phase II Study of Denileukin Diftitox (Ontak®) with CHOP Chemotherapy in Patients with Newly-Diagnosed Aggressive T-Cell Lymphomas, the CONCEPT Trial: Interim Analysis. Blood (ASH Annual Meeting Abstracts), Nov 2006; 108: 2461.\t","Lymphoma, T-Cell, Peripheral","Denileukin diftitox|Cyclophosphamide|Doxorubicin|Vincristine|Prednisone|Pegfilgrastim","NA","NA","NA","Drug|Drug|Drug|Drug|Drug|Other","All","\tNA\tNA\tNA\tNA\tNA\tNA\tlymphoma, t-cell, peripheral|lymphoma|lymphoma, t-cell\tprednisone|cyclophosphamide|vincristine|lenograstim|sargramostim|doxorubicin|denileukin diftitox\tNA\nNCT00211692\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t21221804\tHo SB, Aqel B, Dieperink E, Liu S, Tetrick L, Falck-Ytter Y, DeComarmond C, Smith CI, McKee DP, Boyd W, Kulig CC, Bini EJ, Pedrosa MC. U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for \"\"difficult-to-treat\"\" HCV genotype 1 patients. Dig Dis Sci. 2011 Mar;56(3):880-8. doi: 10.1007/s10620-010-1504-y. Epub 2011 Jan 11.\"","\tChronic Hepatitis C\tconsensus interferon (Interferon Alfacon-1) and ribavirin|Consensus Interferon alfa (CIFN) and ribavirin\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial","Interventional","Completed","Phase 3",2,64,"hepatitis|hepatitis c, chronic|hepatitis c|hepatitis a","interferons|ribavirin|interferon-alpha|interferon alfacon-1","NA"]
["NCT00212862","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18266401,"Larholt K, Pashos CL, Wang Q, Bookhart B, McKenzie RS, Piech CT. Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE) : a registry for characterizing anaemia management and outcomes in oncology patients. Clin Drug Investig. 2008;28(3):159-67.","\tAnemia|Cancer\tPatients with chemotherapy induced anemia\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","anemia","NA","NA"]
["NCT00216099","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19605506,"Hahn NM, Zon RT, Yu M, Ademuyiwa FO, Jones T, Dugan W, Whalen C, Shanmugam R, Skaar T, Sweeney CJ. A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67. Ann Oncol. 2009 Dec;20(12):1971-6. doi: 10.1093/annonc/mdp244. Epub 2009 Jul 15.","\tProstate Cancer\tPemetrexed|Folic Acid|Vitamin B12\tNA\tNA\tNA\tDrug|Dietary Supplement|Dietary Supplement\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","pemetrexed|folic acid|hydroxocobalamin|vitamin b 12","NA"]
["NCT00218062","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22969732,"Schmitz JM, Rathnayaka N, Green CE, Moeller FG, Dougherty AE, Grabowski J. Combination of Modafinil and d-amphetamine for the Treatment of Cocaine Dependence: A Preliminary Investigation. Front Psychiatry. 2012 Aug 30;3:77. doi: 10.3389/fpsyt.2012.00077. eCollection 2012.","\tCocaine-Related Disorders\tD-Amphetamine 30mg|D-Amphetamine 60mg|Modafinil 200mg|Modafinil 400mg|Therapy|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug|Behavioral|Drug\tAll\t","Effectiveness of Modafinil and D-amphetamine in Treating Cocaine Dependent Individuals","Interventional","Completed","Phase 2",4,73,"cocaine-related disorders","modafinil|amphetamine|dextroamphetamine","NA"]
["NCT00221676","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16831228,"Michiels B, Philips H, Coenen S, Yane F, Steinhauser T, Stuyck S, Denekens J, Van Royen P. The effect of giving influenza vaccination to general practitioners: a controlled trial [NCT00221676]. BMC Med. 2006 Jul 10;4:17.","\tInfluenza\tAlfarix\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","influenza, human","NA","NA"]
["NCT00222885","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15613423,"Bertoldo A, Price J, Mathis C, Mason S, Holt D, Kelley C, Cobelli C, Kelley DE. Quantitative assessment of glucose transport in human skeletal muscle: dynamic positron emission tomography imaging of [O-methyl-11C]3-O-methyl-D-glucose. J Clin Endocrinol Metab. 2005 Mar;90(3):1752-9. Epub 2004 Dec 21.","\tDiabetes|Obesity\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT00225264","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17101640|18413496|18469202|17327456|19228869|19744248","Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr, Perez A, Provost JC, Haffner SM. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006 Dec 6;296(21):2572-81. Epub 2006 Nov 13.|Davidson M, Meyer PM, Haffner S, Feinstein S, D'Agostino R Sr, Kondos GT, Perez A, Chen Z, Mazzone T. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation. 2008 Apr 22;117(16):2123-30. doi: 10.1161/CIRCULATIONAHA.107.746610. Epub 2008 Apr 14.|Sam S, Haffner S, Davidson MH, D'Agostino RB Sr, Feinstein S, Kondos G, Perez A, Mazzone T. Relationship of abdominal visceral and subcutaneous adipose tissue with lipoprotein particle number and size in type 2 diabetes. Diabetes. 2008 Aug;57(8):2022-7. doi: 10.2337/db08-0157. Epub 2008 May 9.|Mazzone T, Meyer PM, Kondos GT, Davidson MH, Feinstein SB, D'Agostino RB Sr, Perez A, Haffner SM. Relationship of traditional and nontraditional cardiovascular risk factors to coronary artery calcium in type 2 diabetes. Diabetes. 2007 Mar;56(3):849-55.|Sam S, Haffner S, Davidson MH, D'Agostino RB Sr, Feinstein S, Kondos G, Perez A, Mazzone T. Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care. 2009 May;32(5):932-7. doi: 10.2337/dc08-1856. Epub 2009 Feb 19.|Betteridge DJ. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. Fundam Clin Pharmacol. 2009 Dec;23(6):675-9. doi: 10.1111/j.1472-8206.2009.00741.x. Epub 2009 Sep 10. Review.","\tDiabetes Mellitus\tPioglitazone|Glimepiride\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.","Interventional","Completed","Phase 3",2,458,"diabetes mellitus","pioglitazone|glimepiride","NA"]
["NCT00227292","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","11110112|10534584","Dickens C, Jayson M, Sutton C, Creed F. The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain. Psychosomatics. 2000 Nov-Dec;41(6):490-9.|Atkinson JH, Slater MA, Wahlgren DR, Williams RA, Zisook S, Pruitt SD, Epping-Jordan JE, Patterson TL, Grant I, Abramson I, Garfin SR. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain. 1999 Nov;83(2):137-45.","\tDepression|Low Back Pain\tEscitalopram|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain","Interventional","Withdrawn","Phase 4",2,0,"depression|back pain|low back pain","citalopram","NA"]
["NCT00228267","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19923528,"Simmonds MK, Rashiq S, Sobolev IA, Dick BD, Gray DP, Stewart BJ, Jamieson-Lega KI. The effect of single-dose propofol injection on pain and quality of life in chronic daily headache: a randomized, double-blind, controlled trial. Anesth Analg. 2009 Dec;109(6):1972-80. doi: 10.1213/ANE.0b013e3181be3f86.","\tAnalgesic Rebound Headache|Chronic Daily Headache|Chronic Headache|Headache, Intractable\tPropofol\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","headache disorders|headache disorders, secondary|headache","propofol","NA"]
["NCT00230919","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19502017,"Klemsdal TO, Holme I, Nerland H, Pedersen TR, Tonstad S. Effects of a low glycemic load diet versus a low-fat diet in subjects with and without the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2010 Mar;20(3):195-201. doi: 10.1016/j.numecd.2009.03.010. Epub 2009 Jun 6.","\tMetabolic Syndrome|Obesity\tDiet counseling\tParallel Assignment\tPrevention\tRandomized\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","metabolic syndrome|weight loss","NA","NA"]
["NCT00232869","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17154704,"Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V, Tielbeek A, Anderson J, Wiesinger B, Tepe G, Lansky A, Jaff MR, Mudde C, Tielemans H, Beregi JP. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006 Dec;13(6):701-10.","\tPeripheral Artery Disease\tdrug-eluting stent|bare-metal stent\tParallel Assignment\tTreatment\tRandomized\tDevice|Device\tAll\t","A Study of the SMART Stent in the Treatment SFA Disease.","Interventional","Completed","Phase 2",2,93,"peripheral arterial disease","NA","NA"]
["NCT00233597","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19176796,"Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009 Feb;4(2):386-93. doi: 10.2215/CJN.02840608. Epub 2009 Jan 28.","\tAnemia\tferumoxytol or oral iron\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","anemia","ferrosoferric oxide","NA"]
["NCT00234286",8251595,4506480,"Odds Ratio (OR)",0.71,null,"NA",0.53,0.96,95,0.03,"Generalized Estimating Equations","22765968|22536938","Bailey FA, Williams BR, Goode PS, Woodby LL, Redden DT, Johnson TM 2nd, Taylor JW, Burgio KL. Opioid pain medication orders and administration in the last days of life. J Pain Symptom Manage. 2012 Nov;44(5):681-91. doi: 10.1016/j.jpainsymman.2011.11.006. Epub 2012 Jul 4.|Bailey FA, Allen RS, Williams BR, Goode PS, Granstaff S, Redden DT, Burgio KL. Do-not-resuscitate orders in the last days of life. J Palliat Med. 2012 Jul;15(7):751-9. doi: 10.1089/jpm.2011.0321. Epub 2012 Apr 26.","\tDeath|Dyspnea|Pain\tComfort care education intervention\tNA\tNA\tNA\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","dyspnea","NA","Individuals With a Nasogastric Tube"]
["NCT00235716",8251493,4506396,"Mean Difference (Net)",-0.47,null,"NA",-2.57,1.63,95,0.94,"Mixed Models Analysis",24381967,"Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014 Jan 1;311(1):33-44. doi: 10.1001/jama.2013.282834. Erratum in: JAMA. 2014 Mar 19;311(11):1161.","\tAlzheimer's Disease\tdl-alpha-tocopherol|Memantine|dl-alpha-tocopherol|Memantine|Placebo\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug\tAll\t","A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease","Interventional","Completed","Phase 3",4,613,"alzheimer disease","vitamins|tocotrienols|alpha-tocopherol|memantine|vitamin e|tocopherols","Neuropsychiatric Inventory Change From Baseline"]
["NCT00235716",8251497,4506416,"Mean Difference (Net)",1.98,null,"NA",-0.24,4.2,95,0.4,"Mixed Models Analysis",24381967,"Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014 Jan 1;311(1):33-44. doi: 10.1001/jama.2013.282834. Erratum in: JAMA. 2014 Mar 19;311(11):1161.","\tAlzheimer's Disease\tdl-alpha-tocopherol|Memantine|dl-alpha-tocopherol|Memantine|Placebo\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug\tAll\t","A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease","Interventional","Completed","Phase 3",4,613,"alzheimer disease","vitamins|tocotrienols|alpha-tocopherol|memantine|vitamin e|tocopherols","Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS/ADL) Inventory Change From Baseline"]
["NCT00236782","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","11849631|11849634","Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril. 2002 Feb;77(2 Suppl 2):S13-8.|Zacur HA, Hedon B, Mansour D, Shangold GA, Fisher AC, Creasy GW. Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertil Steril. 2002 Feb;77(2 Suppl 2):S32-5.","\tContraception\tnorelgestromin + ethinyl estradiol; mercilon\tParallel Assignment\tTreatment\tRandomized\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","NA","estradiol|ethinyl estradiol|norelgestromin","NA"]
["NCT00237588","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16988754,"Aksnes TA, Reims HM, Guptha S, Moan A, Os I, Kjeldsen SE. Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors. J Hum Hypertens. 2006 Nov;20(11):860-6. Epub 2006 Sep 21.","\tHypertension\tAmlodipine 10 mg or Losartan 100 mg + Amlodipine 5 mg\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","hypertension","amlodipine|losartan","NA"]
["NCT00238147","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Rao S, Oelschlager BK, Koh WJ, et al.: Phase I trial with weekly docetaxel, capecitabine and carboplatin followed by concomitant capecitabine and radiotherapy in patients with locally advanced esophageal cancer. [Abstract] American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium, 25-27 January 2008, Orlando, FL. A-123, 2008.","\tEsophageal Cancer\tcapecitabine|carboplatin|docetaxel|conventional surgery|neoadjuvant therapy|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Procedure|Procedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","esophageal neoplasms","docetaxel|capecitabine|carboplatin","NA"]
["NCT00239083","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18261583,"Nart A, Sipahi S, Aykas A, Uslu A, Hoşcoşkun C, Toz H. Efficacy and safety of enteric-coated mycophenolate sodium in de novo and maintenance renal transplant patients. Transplant Proc. 2008 Jan-Feb;40(1):189-92. doi: 10.1016/j.transproceed.2007.11.066.","\tKidney Transplantation\tEnteric-Coated Mycophenolate Sodium (EC-MPS)\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","NA","mycophenolic acid","NA"]
["NCT00243893","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18212521,"Frenzel T, Lee CZ, Kim H, Quinnine NJ, Hashimoto T, Lawton MT, Guglielmo BJ, McCulloch CE, Young WL. Feasibility of minocycline and doxycycline use as potential vasculostatic therapy for brain vascular malformations: pilot study of adverse events and tolerance. Cerebrovasc Dis. 2008;25(1-2):157-63. doi: 10.1159/000113733. Epub 2008 Jan 23.","\tAneurysms|Arteriovenous Malformations\tminocycline|doxycycline\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms","Interventional","Completed","Phase 1",2,26,"hemangioma|congenital abnormalities|intracranial arteriovenous malformations|aneurysm|arteriovenous malformations","minocycline|doxycycline","NA"]
["NCT00244374",8250951,4506106,"Odds Ratio (OR)",1.99,null,"NA",1.11,3.59,95,0.01,"Regression, Logistic","17980513|21241735|18233994","Hahn JA, Page-Shafer K, Ford J, Paciorek A, Lum PJ. Traveling young injection drug users at high risk for acquisition and transmission of viral infections. Drug Alcohol Depend. 2008 Jan 11;93(1-2):43-50. Epub 2007 Nov 5.|Etcheverry MF, Lum PJ, Evans JL, Sanchez E, de Lazzari E, Mendez-Arancibia E, Sierra E, Gatell JM, Page K, Joseph J. HIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco. Vaccine. 2011 Feb 24;29(10):1991-6. doi: 10.1016/j.vaccine.2010.12.043. Epub 2011 Jan 15.|Lum PJ, Hahn JA, Shafer KP, Evans JL, Davidson PJ, Stein E, Moss AR. Hepatitis B virus infection and immunization status in a new generation of injection drug users in San Francisco. J Viral Hepat. 2008 Mar;15(3):229-36. doi: 10.1111/j.1365-2893.2007.00933.x.","\tHepatitis A|Hepatitis B|Hepatitis C|Medication Adherence|Risk Behavior|Substance Abuse, Intravenous\tHepatitis A & B vaccine|Outreach|AIC|SEP\tNA\tNA\tNA\tBiological|Behavioral|Behavioral|Behavioral\tAll\t","A Randomized Trial of Vaccine Adherence in Young Injection Drug Users","Interventional","Completed","N/A",4,546,"substance-related disorders|hepatitis c|hepatitis|hepatitis b|hepatitis a|substance abuse, intravenous","vaccines","Viral Transmission Risk Behavior Association With Travel"]
["NCT00246779","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20176212,"Boodhwani M, Hamilton A, de Varennes B, Mesana T, Williams K, Wells GA, Nathan H, Dupuis JY, Babaev A, Wells P, Rubens FD. A multicenter randomized controlled trial to assess the feasibility of testing modified ultrafiltration as a blood conservation technology in cardiac surgery. J Thorac Cardiovasc Surg. 2010 Mar;139(3):701-6. doi: 10.1016/j.jtcvs.2009.11.056.","\tHeart Diseases\tModified ultrafiltration\tParallel Assignment\tTreatment\tRandomized\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","heart diseases","NA","NA"]
["NCT00248261","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20631571,"Kellner M, Muhtz C, Wiedemann K. Primary add-on of ziprasidone in sertraline treatment of posttraumatic stress disorder: lessons from a stopped trial? J Clin Psychopharmacol. 2010 Aug;30(4):471-3. doi: 10.1097/JCP.0b013e3181e79600.","\tPost-traumatic Stress Disorder\tziprasidone, sertraline\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","stress disorders, post-traumatic|stress disorders, traumatic","ziprasidone|sertraline","NA"]
["NCT00249899","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21518985,"Stein EA, Bays H, O'Brien D, Pedicano J, Piper E, Spezzi A. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation. 2011 May 10;123(18):1974-85. doi: 10.1161/CIRCULATIONAHA.110.975284. Epub 2011 Apr 25.","\tHypercholesterolemia\tLapaquistat acetate and stable statin therapy|Stable statin therapy\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia","Interventional","Terminated","Phase 3",2,649,"hypercholesterolemia","rosuvastatin calcium|atorvastatin|simvastatin|hydroxymethylglutaryl-coa reductase inhibitors","NA"]
["NCT00252850","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18387850,"Marks WJ Jr, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, Taylor R, Cahn-Weiner DA, Stoessl AJ, Olanow CW, Bartus RT. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 2008 May;7(5):400-8. doi: 10.1016/S1474-4422(08)70065-6. Epub 2008 Apr 2.","\tParkinson's Disease\tCERE-120: AAV2-NTN\tNA\tNA\tNA\tGenetic\tAll\t","NA","NA","NA","NA","NA","NA","parkinson disease","NA","NA"]
["NCT00253045","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21165692|21663541","Holstad MM, DiIorio C, Kelley ME, Resnicow K, Sharma S. Group motivational interviewing to promote adherence to antiretroviral medications and risk reduction behaviors in HIV infected women. AIDS Behav. 2011 Jul;15(5):885-96. doi: 10.1007/s10461-010-9865-y.|Holstad MM, Diiorio C, McCarty F. Adherence, sexual risk, and viral load in HIV-infected women prescribed antiretroviral therapy. AIDS Patient Care STDS. 2011 Jul;25(7):431-8. doi: 10.1089/apc.2010.0331. Epub 2011 Jun 11.","\tAIDS|HIV\tMotivational groups\tNA\tNA\tNA\tBehavioral\tFemale\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT00255437","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22874106,"Fishbane S, Bolton WK, Winkelmayer WC, Strauss W, Li Z, Pereira BJ. Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clin Nephrol. 2012 Sep;78(3):181-8.","\tAnemia\tferumoxytol or oral iron\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","kidney diseases|renal insufficiency, chronic|anemia","ferrosoferric oxide","NA"]
["NCT00257153","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17045887,"Silva-Orrego P, Colombo P, Bigi R, Gregori D, Delgado A, Salvade P, Oreglia J, Orrico P, de Biase A, Piccalò G, Bossi I, Klugmann S. Thrombus aspiration before primary angioplasty improves myocardial reperfusion in acute myocardial infarction: the DEAR-MI (Dethrombosis to Enhance Acute Reperfusion in Myocardial Infarction) study. J Am Coll Cardiol. 2006 Oct 17;48(8):1552-9. Epub 2006 Sep 26.","\tAcute Myocardial Infarction\tCoronary thrombus aspiration catheter\tParallel Assignment\tTreatment\tRandomized\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","infarction|myocardial infarction","NA","NA"]
["NCT00259194","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19245381|18513345","May O, Schlosser H, Skytte L. A high blood pressure predicts bleeding complications and a longer hospital stay after elective coronary angiography using the femoral approach. J Interv Cardiol. 2009 Apr;22(2):175-8. doi: 10.1111/j.1540-8183.2009.00427.x. Epub 2009 Feb 24.|May O, Schlosser H, Skytte L. A randomized trial assessing the influence of lying still or being allowed to move in the observation period following coronary angiography using the femoral approach. J Interv Cardiol. 2008 Aug;21(4):347-9. doi: 10.1111/j.1540-8183.2008.00359.x. Epub 2008 May 29.","\tCoronary Arteriosclerosis|Myocardial Ischemia\tMoving|No Moving\tParallel Assignment\tPrevention\tRandomized\tBehavioral|Behavioral\tAll\t","Observation and Prediction of Complications After Coronary Angiography","Interventional","Completed","N/A",2,1000,"arteriosclerosis|myocardial ischemia|ischemia|coronary artery disease","NA","NA"]
["NCT00260104","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17884032,"Tang NP, Wang LS, Yang L, Gu HJ, Zhu HJ, Zhou B, Sun QM, Cong RH, Wang B. Preproghrelin Leu72Met polymorphism in Chinese subjects with coronary artery disease and controls. Clin Chim Acta. 2008 Jan;387(1-2):42-7. Epub 2007 Sep 5.","\tCoronary Artery Disease\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","myocardial ischemia|coronary disease|coronary artery disease","NA","NA"]
["NCT00263588","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20179708,"Sutherland S, Ashley S, Miles D, Chan S, Wardley A, Davidson N, Bhatti R, Shehata M, Nouras H, Camburn T, Johnston SR. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. Br J Cancer. 2010 Mar 16;102(6):995-1002. doi: 10.1038/sj.bjc.6605586. Epub 2010 Feb 23.","\tNeoplasms, Breast\tlapatinib\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasm metastasis|breast neoplasms","lapatinib","NA"]
["NCT00265031","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21990399,"Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011 Nov 10;29(32):4234-42. doi: 10.1200/JCO.2010.33.9549. Epub 2011 Oct 11.","\tHodgkin´s Lymphoma\tCyclophosphamide|Adriamycin|Etoposide|Procarbazine|Prednisone|Vincristine|Bleomycin|radiation therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","hodgkin disease","etoposide|procarbazine|cyclophosphamide|prednisone|vincristine|bleomycin|doxorubicin|liposomal doxorubicin","NA"]
["NCT00266331","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15862509,"Miko Enomoto T, Johnson T, Peterson N, Homer L, Walts D, Johnson N. Combination glutathione and anthocyanins as an alternative for skin care during external-beam radiation. Am J Surg. 2005 May;189(5):627-30; discussion 630-1.","\tBreast Cancer\tReduced glutathione\tParallel Assignment\tPrevention\tRandomized\tDrug\tFemale\t","RayGel-An Alternative for Skin Care During External Beam Radiation","Interventional","Completed","Phase 2",2,150,"breast neoplasms","NA","NA"]
["NCT00267696","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18829088,"Richardson DL, Backes FJ, Seamon LG, Zanagnolo V, O'Malley DM, Cohn DE, Fowler JM, Copeland LJ. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol. 2008 Dec;111(3):461-6. doi: 10.1016/j.ygyno.2008.08.011. Epub 2008 Sep 30. Erratum in: Gynecol Oncol. 2010 Dec;119(3):603. Dosage error in article text.","\tFallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer\tBevacizumab|Gemcitabine|Carboplatin\tNA\tNA\tNA\tDrug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","ovarian neoplasms|peritoneal neoplasms|fallopian tube neoplasms","carboplatin|bevacizumab|gemcitabine","NA"]
["NCT00270621","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17227604|18025870","Lingely-Pottie P, McGrath PJ. A therapeutic alliance can exist without face-to-face contact. J Telemed Telecare. 2006;12(8):396-9.|Lingley-Pottie P, McGrath PJ. Distance therapeutic alliance: the participant's experience. ANS Adv Nurs Sci. 2007 Oct-Dec;30(4):353-66.","\tEnuresis\tFHP Night time ENuresis Intervention\tParallel Assignment\tTreatment\tRandomized\tBehavioral\tAll\t","Family Help Program: Nighttime Enuresis Treatment Program","Interventional","Completed","Phase 2",2,56,"urinary incontinence|nocturnal enuresis|enuresis","NA","NA"]
["NCT00271401","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","10636365|9672272","Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, Talley D, Sapp S, Booth J, Cabot CF, Anderson KM, Califf RM. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 1999 Dec 11;354(9195):2019-24. Erratum in: Lancet 2000 Mar 25;355(9209):1104.|EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998 Jul 11;352(9122):87-92.","\tAngioplasty, Transluminal, Percutaneous Coronary\tAngioplasty|Intracoronary Stent|Abxicimab|Heparin|Placebo\tParallel Assignment\tTreatment\tRandomized\tOther|Other|Drug|Drug|Drug\tAll\t","A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With Abciximab","Interventional","Completed","Phase 3",3,2399,"NA","heparin","NA"]
["NCT00274924","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19767508|NA","Horning SJ, Juweid ME, Schöder H, Wiseman G, McMillan A, Swinnen LJ, Advani R, Gascoyne R, Quon A. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010 Jan 28;115(4):775-7; quiz 918. doi: 10.1182/blood-2009-08-234351. Epub 2009 Sep 18. Erratum in: Blood. 2012 May 31;119(22):5340.|Horning SJ, Juweid ME, Schoder H, et al.: Interim positron emission tomography (PET) in diffuse large B-cell lymphoma: independent expert nuclear medicine evaluation of ECOG 3404. [Abstract] Blood 112 (11): A-372, 2008.","\tLymphoma\tfilgrastim|rituximab|carboplatin|cyclophosphamide|doxorubicin hydrochloride|etoposide|ifosfamide|prednisone|vincristine\tNA\tNA\tNA\tBiological|Biological|Drug|Drug|Drug|Drug|Drug|Drug|Drug\tAll\t","Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma","Interventional","Completed","Phase 2",2,100,"lymphoma, non-hodgkin|lymphoma","liposomal doxorubicin|etoposide|vincristine|lenograstim|ifosfamide|rituximab|cyclophosphamide|carboplatin|podophyllotoxin|prednisone|doxorubicin","NA"]
["NCT00276939","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16873779|18926128|19167953|19339401|18834717","Barnard ND, Cohen J, Jenkins DJ, Turner-McGrievy G, Gloede L, Jaster B, Seidl K, Green AA, Talpers S. A low-fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. Diabetes Care. 2006 Aug;29(8):1777-83.|Turner-McGrievy GM, Barnard ND, Cohen J, Jenkins DJ, Gloede L, Green AA. Changes in nutrient intake and dietary quality among participants with type 2 diabetes following a low-fat vegan diet or a conventional diabetes diet for 22 weeks. J Am Diet Assoc. 2008 Oct;108(10):1636-45. doi: 10.1016/j.jada.2008.07.015.|Barnard ND, Gloede L, Cohen J, Jenkins DJ, Turner-McGrievy G, Green AA, Ferdowsian H. A low-fat vegan diet elicits greater macronutrient changes, but is comparable in adherence and acceptability, compared with a more conventional diabetes diet among individuals with type 2 diabetes. J Am Diet Assoc. 2009 Feb;109(2):263-72. doi: 10.1016/j.jada.2008.10.049.|Barnard ND, Cohen J, Jenkins DJ, Turner-McGrievy G, Gloede L, Green A, Ferdowsian H. A low-fat vegan diet and a conventional diabetes diet in the treatment of type 2 diabetes: a randomized, controlled, 74-wk clinical trial. Am J Clin Nutr. 2009 May;89(5):1588S-1596S. doi: 10.3945/ajcn.2009.26736H. Epub 2009 Apr 1.|Barnard ND, Noble EP, Ritchie T, Cohen J, Jenkins DJ, Turner-McGrievy G, Gloede L, Green AA, Ferdowsian H. D2 dopamine receptor Taq1A polymorphism, body weight, and dietary intake in type 2 diabetes. Nutrition. 2009 Jan;25(1):58-65. doi: 10.1016/j.nut.2008.07.012. Epub 2008 Oct 2.","\tDiabetes Mellitus, Type 2\tLow-fat, low-Glycemic Index, vegan diet\tParallel Assignment\tTreatment\tRandomized\tBehavioral\tAll\t","Plant-Based Dietary Intervention in Type 2 Diabetes","Interventional","Completed","N/A",2,99,"diabetes mellitus|diabetes mellitus, type 2","NA","NA"]
["NCT00277888","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18505951|20154599|20558562|22076877|24982071","Parienti JJ, Thirion M, Mégarbane B, Souweine B, Ouchikhe A, Polito A, Forel JM, Marqué S, Misset B, Airapetian N, Daurel C, Mira JP, Ramakers M, du Cheyron D, Le Coutour X, Daubin C, Charbonneau P; Members of the Cathedia Study Group. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. JAMA. 2008 May 28;299(20):2413-22. doi: 10.1001/jama.299.20.2413.|Parienti JJ, Mégarbane B, Fischer MO, Lautrette A, Gazui N, Marin N, Hanouz JL, Ramakers M, Daubin C, Mira JP, Charbonneau P, du Cheyron D; Cathedia Study Group. Catheter dysfunction and dialysis performance according to vascular access among 736 critically ill adults requiring renal replacement therapy: a randomized controlled study. Crit Care Med. 2010 Apr;38(4):1118-25. doi: 10.1097/CCM.0b013e3181d454b3.|Parienti JJ, Dugué AE, Daurel C, Mira JP, Mégarbane B, Mermel LA, Daubin C, du Cheyron D; Members of the Cathedia Study Group. Continuous renal replacement therapy may increase the risk of catheter infection. Clin J Am Soc Nephrol. 2010 Aug;5(8):1489-96. doi: 10.2215/CJN.02130310. Epub 2010 Jun 17.|Dugué AE, Levesque SP, Fischer MO, Souweine B, Mira JP, Megarbane B, Daubin C, du Cheyron D, Parienti JJ; Cathedia Study Group. Vascular access sites for acute renal replacement in intensive care units. Clin J Am Soc Nephrol. 2012 Jan;7(1):70-7. doi: 10.2215/CJN.06570711. Epub 2011 Nov 10.|Parienti JJ, Deryckère S, Mégarbane B, Valette X, Seguin A, Sauneuf B, Mira JP, Souweine B, Cattoir V, Daubin C, du Cheyron D; Cathedia Study Group. Quasi-experimental study of sodium citrate locks and the risk of acute hemodialysis catheter infection among critically ill patients. Antimicrob Agents Chemother. 2014 Oct;58(10):5666-72. doi: 10.1128/AAC.03079-14. Epub 2014 Jun 30.","\tCritical Illness|Kidney Failure, Acute\tFemoral route for hemodialysis|Jugular route for hemodialysis\tParallel Assignment\tPrevention\tRandomized\tProcedure|Procedure\tAll\t","Comparison of Femoral Versus Jugular Routes for Temporary Hemodialysis in Seriously Ill Patients","Interventional","Completed","N/A",2,750,"acute kidney injury|critical illness|renal insufficiency","NA","NA"]
["NCT00281892","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26293380|26377031","Goede V, Busch R, Bahlo J, Chataline V, Kremers S, Müller L, Reschke D, Schlag R, Schmidt B, Vehling-Kaiser U, Wedding U, Stilgenbauer S, Hallek M. Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group. Leuk Lymphoma. 2016;57(3):596-603. doi: 10.3109/10428194.2015.1079314. Epub 2015 Oct 12.|Goede V, Bahlo J, Chataline V, Eichhorst B, Dürig J, Stilgenbauer S, Kolb G, Honecker F, Wedding U, Hallek M. Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group. Leuk Lymphoma. 2016;57(4):789-96. doi: 10.3109/10428194.2015.1091933. Epub 2015 Oct 13.","\tAnemia|Chronic Lymphocytic Leukemia\tFludarabine plus Darbopoetin|Fludarabine mono\tParallel Assignment\tTreatment\tRandomized\tBiological|Drug\tAll\t","Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia","Interventional","Completed","Phase 3",2,97,"leukemia, lymphocytic, chronic, b-cell|leukemia|leukemia, lymphoid","vidarabine|fludarabine|fludarabine phosphate","NA"]
["NCT00283413","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16892434,"Turco MA, Buchbinder M, Popma JJ, Weissman NJ, Mann T, Doucet S, Johnson WL Jr, Greenberg JD, Leadley K, Russell ME. Pivotal, randomized U.S. study of the Symbiottrade mark covered stent system in patients with saphenous vein graft disease: eight-month angiographic and clinical results from the Symbiot III trial. Catheter Cardiovasc Interv. 2006 Sep;68(3):379-88.","\tSymptomatic Ischemic Saphenous Vein Graft Disease\tCovered Stent System|Bare metal stent\tParallel Assignment\tTreatment\tRandomized\tDevice|Device\tAll\t","Symbiot III: A Prospective Randomized Trial Evaluating the Symbiot Covered Stent System in Saphenous Vein Grafts","Interventional","Completed","N/A",2,514,"NA","NA","NA"]
["NCT00286221","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19249923|22156333","Morad AH, Winters BD, Yaster M, Stevens RD, White ED, Thompson RE, Weingart JD, Gottschalk A. Efficacy of intravenous patient-controlled analgesia after supratentorial intracranial surgery: a prospective randomized controlled trial. Clinical article. J Neurosurg. 2009 Aug;111(2):343-50. doi: 10.3171/2008.11.JNS08797.|Morad A, Winters B, Stevens R, White E, Weingart J, Yaster M, Gottschalk A. The efficacy of intravenous patient-controlled analgesia after intracranial surgery of the posterior fossa: a prospective, randomized controlled trial. Anesth Analg. 2012 Feb;114(2):416-23. doi: 10.1213/ANE.0b013e31823f0c5a. Epub 2011 Dec 9.","\tIntracranial Surgery\tPCA fentanyl|PRN fentanyl\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","IVPCA in the Management of Pain Following Major Intracranial Surgery","Interventional","Completed","Phase 2/Phase 3",4,159,"NA","fentanyl","NA"]
["NCT00287573","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16531618,"Stone GW, Ellis SG, O'Shaughnessy CD, Martin SL, Satler L, McGarry T, Turco MA, Kereiakes DJ, Kelley L, Popma JJ, Russell ME; TAXUS V ISR Investigators. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA. 2006 Mar 15;295(11):1253-63. Epub 2006 Mar 12.","\tCoronary Restenosis\tTAXUS Express2|Brachytherapy (beta source)\tParallel Assignment\tTreatment\tRandomized\tDevice|Procedure\tAll\t","Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis","Interventional","Completed","Phase 2/Phase 3",2,488,"coronary restenosis","NA","NA"]
["NCT00313079","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21993685,"Liedtke M, Twist CJ, Medeiros BC, Gotlib JR, Berube C, Bieber MM, Bhat NM, Teng NN, Coutre SE. Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Haematologica. 2012 Jan;97(1):30-7. doi: 10.3324/haematol.2011.045997. Epub 2011 Oct 11.","\tAcute Lymphocytic Leukemia|Leukemia|Leukemia, Lymphocytic\tMAb 216|Vincristine\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, lymphoid|precursor cell lymphoblastic leukemia-lymphoma|leukemia","vincristine","NA"]
["NCT00314795","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19890127,"Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M, Eckardt KU. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med. 2009 Nov 5;361(19):1848-55. doi: 10.1056/NEJMoa074037.","\tAnemia|Chronic Kidney Disease|Chronic Renal Failure|Pure Red Cell Aplasia\tPeginesatide\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","anemia|renal insufficiency|red-cell aplasia, pure|kidney diseases|renal insufficiency, chronic|kidney failure, chronic","NA","NA"]
["NCT00316472","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18385391,"Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol. 2008 Jul;3(4):1131-8. doi: 10.2215/CJN.04211007. Epub 2008 Apr 2.","\tHyperphosphatemia\tNiacinamide\tCrossover Assignment\tTreatment\tRandomized\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","hyperphosphatemia","niacinamide|niacin|nicotinic acids","NA"]
["NCT00317759","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19270751,"Wallen H, Thompson JA, Reilly JZ, Rodmyre RM, Cao J, Yee C. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One. 2009;4(3):e4749. doi: 10.1371/journal.pone.0004749. Epub 2009 Mar 9.","\tMelanoma (Skin)\ttherapeutic autologous lymphocytes|fludarabine phosphate\tNA\tNA\tNA\tBiological|Drug\tAll\t","NA","NA","NA","NA","NA","NA","melanoma","fludarabine phosphate|fludarabine","NA"]
["NCT00320762","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",10937547,"Hsu WC, Spilker MH, Yannas IV, Rubin PA. Inhibition of conjunctival scarring and contraction by a porous collagen-glycosaminoglycan implant. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2404-11.","\tGlaucoma|Pterygium\tOculusGen Biodegradable Collagen Matrix Implant\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","glaucoma|pterygium","NA","NA"]
["NCT00321100","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22294255,"Dotan E, Meropol NJ, Burtness B, Denlinger CS, Lee J, Mintzer D, Zhu F, Ruth K, Tuttle H, Sylvester J, Cohen SJ. A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. J Gastrointest Cancer. 2012 Dec;43(4):562-9.","\tColorectal Neoplasms\tbevacizumab|Cetuximab|Oxaliplatin|Capecitabine\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug\tAll\t","Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab","Interventional","Terminated","Phase 2",2,23,"colorectal neoplasms","cetuximab|bevacizumab|capecitabine|oxaliplatin","NA"]
["NCT00322621",8241825,4500567,null,"NA",null,"NA",{"$nulls":3},0.713,"t-test, 2 sided",19637208,"Skljarevski V, Desaiah D, Zhang Q, Chappell AS, Detke MJ, Gross JL, Ziegler D. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain. Diabetes Metab Res Rev. 2009 Oct;25(7):623-31. doi: 10.1002/dmrr.1000.","\tDiabetic Neuropathies\tDuloxetine\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","diabetic neuropathies|neuralgia","duloxetine hydrochloride","Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Sleep at Week 34 Endpoint"]
["NCT00322621",8241836,4500578,null,"NA",null,"NA",{"$nulls":3},0.011,"t-test, 2 sided",19637208,"Skljarevski V, Desaiah D, Zhang Q, Chappell AS, Detke MJ, Gross JL, Ziegler D. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain. Diabetes Metab Res Rev. 2009 Oct;25(7):623-31. doi: 10.1002/dmrr.1000.","\tDiabetic Neuropathies\tDuloxetine\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","diabetic neuropathies|neuralgia","duloxetine hydrochloride","Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Pain Right Now Score at Week 34 Endpoint"]
["NCT00324714","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Singh S, Cuzick J, Edwards R, et al.: Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II). [Abstract] Breast Cancer Res Treat 106 (1): A-28, S9, 2007.","\tBreast Cancer|Osteoporosis\trisedronate sodium|diagnostic laboratory biomarker analysis\tNA\tNA\tNA\tDrug|Other\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms|carcinoma in situ|osteoporosis","risedronic acid","NA"]
["NCT00327288","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19499186,"Moulder S, Dhillon N, Ng C, Hong D, Wheler J, Naing A, Tse S, La Paglia A, Dorr R, Hersh E, Boytim M, Kurzrock R. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs. 2010 Oct;28(5):634-40. doi: 10.1007/s10637-009-9273-1. Epub 2009 Jun 6.","\tBreast Cancer|Non-small Cell Lung Cancer|Prostate Cancer\timexon|docetaxel\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","breast neoplasms|prostatic neoplasms|carcinoma, non-small-cell lung|lung neoplasms","docetaxel","NA"]
["NCT00328133","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21115374,"Knudson MM, Cohen MJ, Reidy R, Jaeger S, Bacchetti P, Jin C, Wade CE, Holcomb JB. Trauma, transfusions, and use of recombinant factor VIIa: A multicenter case registry report of 380 patients from the Western Trauma Association. J Am Coll Surg. 2011 Jan;212(1):87-95. doi: 10.1016/j.jamcollsurg.2010.08.020. Epub 2010 Nov 5.","\tHemorrhagic Shock|Traumatic Hemorrhage\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","hemorrhage|shock, hemorrhagic","NA","NA"]
["NCT00331448","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16186728|16837863","Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, Saag M, Scherzer R, Shlipak M, Tien P; Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):121-31.|Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr. 2006 Aug 15;42(5):562-71.","\tAtherosclerosis|Diabetes|HIV Infections|Hyperlipidemia|Lipodystrophy\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","infection|lipodystrophy|hyperlipidemias|acquired immunodeficiency syndrome|atherosclerosis|hiv infections","NA","NA"]
["NCT00332098","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24626789,"Miklowitz DJ, Schneck CD, George EL, Taylor DO, Sugar CA, Birmaher B, Kowatch RA, DelBello MP, Axelson DA. Pharmacotherapy and family-focused treatment for adolescents with bipolar I and II disorders: a 2-year randomized trial. Am J Psychiatry. 2014 Jun;171(6):658-67. doi: 10.1176/appi.ajp.2014.13081130.","\tBipolar Disorder\tFamily-Focused Treatment Plus Pharmacotherapy|Enhanced Care Plus Pharmacotherapy\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral\tAll\t","Effectiveness of Family-Focused Treatment Plus Pharmacotherapy for Bipolar Disorder in Adolescents","Interventional","Completed","Phase 3",2,145,"bipolar disorder","NA","NA"]
["NCT00336583","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18839172,"Sym SJ, Lee DH, Kang HJ, Nam SH, Kim HY, Kim SJ, Eom HS, Kim WS, Suh C. A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma. Cancer Chemother Pharmacol. 2009 Jun;64(1):27-33. doi: 10.1007/s00280-008-0847-y. Epub 2008 Oct 7.","\tNon-Hodgkin's Lymphoma\tOxaliplatin\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma, non-hodgkin|lymphoma","oxaliplatin|cytarabine|methylprednisolone|etoposide","NA"]
["NCT00337077","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Stein MN, Chen Y, Hudes GR, Carducci MA, Tan W, DiPaola RS. ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 28:15s, 2010 (suppl; abstr 4556)","\tAdenocarcinoma of the Prostate|Hormone-refractory Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer\teribulin mesylate\tNA\tNA\tNA\tDrug\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","NA","NA"]
["NCT00345059","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|18632181","Gebbia V, Morena R, Frontini L, Aitini E, Daniele B, Gamucci T, Di Maio M, Morabito A, Gallo C, Gridelli C. The DISTAL-2 phase III randomized trial of single agent weekly docetaxel (wD) vs wD plus gemcitabine (G) or vinorelbine (V) vs wD plus capecitabine (X) as second-line treatment of advanced non-small-cell lung cancer (NSCLC) patients (pts). J Clin Oncol 26: 2008 (May 20 suppl; abstr 19057)|Gebbia V, Gridelli C, Verusio C, Frontini L, Aitini E, Daniele B, Gamucci T, Mancuso G, Di Maio M, Gallo C, Perrone F, Morabito A. Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial. Lung Cancer. 2009 Feb;63(2):251-8. doi: 10.1016/j.lungcan.2008.05.027. Epub 2008 Jul 15.","\tAdvanced Non-Small Cell Lung Cancer\tdocetaxel|vinorelbine|gemcitabine|capecitabine\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug\tAll\t","The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer","Interventional","Terminated","Phase 3",3,84,"carcinoma, non-small-cell lung|lung neoplasms","docetaxel|vinorelbine|capecitabine|gemcitabine","NA"]
["NCT00348491","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17933588,"Fricke J, Davis N, Yu V, Krammer G. Lumiracoxib 400 mg compared with celecoxib 400 mg and placebo for treating pain following dental surgery: a randomized, controlled trial. J Pain. 2008 Jan;9(1):20-7. Epub 2007 Oct 15.","\tPain\tLumiracoxib\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","NA","lumiracoxib","NA"]
["NCT00353470","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27464313,"Milrod B, Chambless DL, Gallop R, Busch FN, Schwalberg M, McCarthy KS, Gross C, Sharpless BA, Leon AC, Barber JP. Psychotherapies for Panic Disorder: A Tale of Two Sites. J Clin Psychiatry. 2016 Jul;77(7):927-35. doi: 10.4088/JCP.14m09507.","\tAgoraphobia|Anxiety Disorders|Panic Disorder\tCognitive behavioral therapy|Applied relaxation training (ART)|Panic focused psychodynamic psychotherapy (PFPP)\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral|Behavioral\tAll\t","Comparison of Psychotherapy Programs to Treat Panic Disorder","Interventional","Completed","Phase 3",3,201,"agoraphobia|anxiety disorders|disease|panic disorder","NA","NA"]
["NCT00354081","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12324494|12507972|14699020|15321804|15910853|16613998|16543037|17645592|18510727|18620104|18714059|19125808|19549699|20484456|20494665","Nexo E, Hvas AM, Bleie Ø, Refsum H, Fedosov SN, Vollset SE, Schneede J, Nordrehaug JE, Ueland PM, Nygard OK. Holo-transcobalamin is an early marker of changes in cobalamin homeostasis. A randomized placebo-controlled study. Clin Chem. 2002 Oct;48(10):1768-71.|Bor MV, Refsum H, Bisp MR, Bleie Ø, Schneede J, Nordrehaug JE, Ueland PM, Nygard OK, Nexø E. Plasma vitamin B6 vitamers before and after oral vitamin B6 treatment: a randomized placebo-controlled study. Clin Chem. 2003 Jan;49(1):155-61.|Holm PI, Bleie Ø, Ueland PM, Lien EA, Refsum H, Nordrehaug JE, Nygård O. Betaine as a determinant of postmethionine load total plasma homocysteine before and after B-vitamin supplementation. Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):301-7. Epub 2003 Dec 29.|Bleie Ø, Refsum H, Ueland PM, Vollset SE, Guttormsen AB, Nexo E, Schneede J, Nordrehaug JE, Nygård O. Changes in basal and postmethionine load concentrations of total homocysteine and cystathionine after B vitamin intervention. Am J Clin Nutr. 2004 Sep;80(3):641-8.|Gavasso S, Nygård O, Pedersen ER, Aarseth JH, Bleie O, Myhr KM, Vedeler CA. Fcgamma receptor IIIA polymorphism as a risk-factor for coronary artery disease. Atherosclerosis. 2005 Jun;180(2):277-82. Epub 2005 Jan 25.|Mørkbak AL, Hvas AM, Lloyd-Wright Z, Sanders TA, Bleie O, Refsum H, Nygaard OK, Nexø E. Effect of vitamin B12 treatment on haptocorrin. Clin Chem. 2006 Jun;52(6):1104-11. Epub 2006 Apr 13.|Ulvik B, Wentzel-Larsen T, Hanestad BR, Omenaas E, Nygård OK. Relationship between provider-based measures of physical function and self-reported health-related quality of life in patients admitted for elective coronary angiography. Heart Lung. 2006 Mar-Apr;35(2):90-100.|Bleie Ø, Semb AG, Grundt H, Nordrehaug JE, Vollset SE, Ueland PM, Nilsen DW, Bakken AM, Refsum H, Nygård OK. Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease. J Intern Med. 2007 Aug;262(2):244-53.|Ulvik B, Nygård O, Hanestad BR, Wentzel-Larsen T, Wahl AK. Associations between disease severity, coping and dimensions of health-related quality of life in patients admitted for elective coronary angiography - a cross sectional study. Health Qual Life Outcomes. 2008 May 29;6:38. doi: 10.1186/1477-7525-6-38.|Ulvik B, Bjelland I, Hanestad BR, Omenaas E, Wentzel-Larsen T, Nygård O. Comparison of the Short Form 36 and the Hospital Anxiety and Depression Scale measuring emotional distress in patients admitted for elective coronary angiography. Heart Lung. 2008 Jul-Aug;37(4):286-95. doi: 10.1016/j.hrtlng.2007.08.001.|Ebbing M, Bleie Ø, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, Refsum H, Pedersen EK, Nygård O. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA. 2008 Aug 20;300(7):795-804. doi: 10.1001/jama.300.7.795.|Lønnebakken MT, Bleie O, Strand E, Staal EM, Nygård OK, Gerdts E. Myocardial contrast echocardiography in assessment of stable coronary artery disease at intermediate dobutamine-induced stress level. Echocardiography. 2009 Jan;26(1):52-60. doi: 10.1111/j.1540-8175.2008.00738.x.|Lønnebakken MT, Staal EM, Bleie Ø, Strand E, Nygård OK, Gerdts E. Quantitative contrast stress echocardiography in assessment of restenosis after percutaneous coronary intervention in stable coronary artery disease. Eur J Echocardiogr. 2009 Oct;10(7):858-64. doi: 10.1093/ejechocard/jep090. Epub 2009 Jun 23.|Manger MS, Strand E, Ebbing M, Seifert R, Refsum H, Nordrehaug JE, Nilsen DW, Drevon CA, Tell GS, Bleie O, Vollset SE, Pedersen ER, Nygård O. Dietary intake of n-3 long-chain polyunsaturated fatty acids and coronary events in Norwegian patients with coronary artery disease. Am J Clin Nutr. 2010 Jul;92(1):244-51. doi: 10.3945/ajcn.2010.29175. Epub 2010 May 19.|Løland KH, Bleie O, Blix AJ, Strand E, Ueland PM, Refsum H, Ebbing M, Nordrehaug JE, Nygård O. Effect of homocysteine-lowering B vitamin treatment on angiographic progression of coronary artery disease: a Western Norway B Vitamin Intervention Trial (WENBIT) substudy. Am J Cardiol. 2010 Jun 1;105(11):1577-84. doi: 10.1016/j.amjcard.2010.01.019. Epub 2010 Apr 10.","\tCerebrovascular Stroke|Coronary Artery Disease|Myocardial Infarction\tfolic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine)|folic acid, vitamin B12 (cyanocobalamin)|vitamin B6 (pyridoxine)|placebo\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tAll\t","WENBIT - Western Norway B Vitamin Intervention Trial","Interventional","Completed","Phase 3",4,3096,"stroke|myocardial infarction|myocardial ischemia|coronary disease|infarction|coronary artery disease","hydroxocobalamin|vitamin b 12|pyridoxine|pyridoxal|folic acid|vitamin b complex|vitamins|vitamin b 6","NA"]
["NCT00357214","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18940881|19727904","Dawson-Hughes B, Harris SS, Palermo NJ, Castaneda-Sceppa C, Rasmussen HM, Dallal GE. Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women. J Clin Endocrinol Metab. 2009 Jan;94(1):96-102. doi: 10.1210/jc.2008-1662. Epub 2008 Oct 21.|Dawson-Hughes B, Castaneda-Sceppa C, Harris SS, Palermo NJ, Cloutier G, Ceglia L, Dallal GE. Impact of supplementation with bicarbonate on lower-extremity muscle performance in older men and women. Osteoporos Int. 2010 Jul;21(7):1171-9. doi: 10.1007/s00198-009-1049-0. Epub 2009 Sep 1.","\tOsteoporosis|Sarcopenia\tPotassium Bicarbonate|Sodium Bicarbonate|Potassium Chloride|placebo (microcrystalline cellulose)\tParallel Assignment\tPrevention\tRandomized\tDietary Supplement|Dietary Supplement|Dietary Supplement|Dietary Supplement\tAll\t","Effect of Potassium Bicarbonate Supplementation on Bone and Muscle in Older Adults","Interventional","Completed","N/A",4,171,"osteoporosis|sarcopenia","NA","NA"]
["NCT00359047","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19333675|24519745|21927921|21311871|17641811","Bessette L, Jean S, Davison KS, Roy S, Ste-Marie LG, Brown JP. Factors influencing the treatment of osteoporosis following fragility fracture. Osteoporos Int. 2009 Nov;20(11):1911-9. doi: 10.1007/s00198-009-0898-x. Epub 2009 Mar 31.|Beaudoin C, Bessette L, Jean S, Ste-Marie LG, Brown JP. The impact of educational interventions on modifiable risk factors for osteoporosis after a fragility fracture. Osteoporos Int. 2014 Jul;25(7):1821-30. doi: 10.1007/s00198-014-2618-4. Epub 2014 Feb 12.|Bessette L, Jean S, Lapointe-Garant MP, Belzile EL, Davison KS, Ste-Marie LG, Brown JP. Direct medical costs attributable to peripheral fractures in Canadian post-menopausal women. Osteoporos Int. 2012 Jun;23(6):1757-68. doi: 10.1007/s00198-011-1785-9. Epub 2011 Sep 17.|Bessette L, Davison KS, Jean S, Roy S, Ste-Marie LG, Brown JP. The impact of two educational interventions on osteoporosis diagnosis and treatment after fragility fracture: a population-based randomized controlled trial. Osteoporos Int. 2011 Dec;22(12):2963-72. doi: 10.1007/s00198-011-1533-1. Epub 2011 Feb 11.|Bessette L, Ste-Marie LG, Jean S, Davison KS, Beaulieu M, Baranci M, Bessant J, Brown JP. The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int. 2008 Jan;19(1):79-86. Epub 2007 Jul 20.","\tOsteoporosis\tDocumentation|Video\tParallel Assignment\tOther\tRandomized\tBehavioral|Behavioral\tFemale\t","Recognizing Osteoporosis and Its Consequences in Quebec (ROCQ) Programme","Interventional","Active, not recruiting","N/A",2,2830,"osteoporosis","NA","NA"]
["NCT00362986","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20798191,"Jatoi A, Thrower A, Sloan JA, Flynn PJ, Wentworth-Hartung NL, Dakhil SR, Mattar BI, Nikcevich DA, Novotny P, Sekulic A, Loprinzi CL. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). Oncologist. 2010;15(9):1016-22. doi: 10.1634/theoncologist.2010-0082. Epub 2010 Aug 26.","\tDermatologic Complications|Unspecified Adult Solid Tumor, Protocol Specific\tsunscreen|placebo\tParallel Assignment\tSupportive Care\tRandomized\tDrug|Other\tAll\t","Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer","Interventional","Completed","Phase 3",2,116,"exanthema","sunscreening agents","NA"]
["NCT00364910","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20441725,"Shemesh E, Annunziato RA, Weatherley BD, Cotter G, Feaganes JR, Santra M, Yehuda R, Rubinstein D. A randomized controlled trial of the safety and promise of cognitive-behavioral therapy using imaginal exposure in patients with posttraumatic stress disorder resulting from cardiovascular illness. J Clin Psychiatry. 2011 Feb;72(2):168-74. doi: 10.4088/JCP.09m05116blu. Epub 2010 Apr 6.","\tStress Disorders, Post-Traumatic\tEducational session and treatment as usual|Cognitive behavioral therapy (CBT)\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral\tAll\t","Safety and Efficacy of Cognitive Behavior Therapy for People With Post-traumatic Stress and Cardiovascular Illness","Interventional","Completed","N/A",2,60,"stress disorders, post-traumatic|stress disorders, traumatic","NA","NA"]
["NCT00366990","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22007645|23657296|23654212|22703865|20508622|26333626|22998737|25866258|24879662|23408709","Cooper JN, Tepper P, Barinas-Mitchell E, Woodard GA, Sutton-Tyrrell K. Serum aldosterone is associated with inflammation and aortic stiffness in normotensive overweight and obese young adults. Clin Exp Hypertens. 2012;34(1):63-70. doi: 10.3109/10641963.2011.618200. Epub 2011 Oct 18.|Cooper JN, Fried L, Tepper P, Barinas-Mitchell E, Conroy MB, Evans RW, Mori Brooks M, Woodard GA, Sutton-Tyrrell K. Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults. Hypertens Res. 2013 Oct;36(10):895-901. doi: 10.1038/hr.2013.45. Epub 2013 May 9.|Cooper JN, Evans RW, Mori Brooks M, Fried L, Holmes C, Barinas-Mitchell E, Sutton-Tyrrell K. Associations between arterial stiffness and platelet activation in normotensive overweight and obese young adults. Clin Exp Hypertens. 2014;36(3):115-22. doi: 10.3109/10641963.2013.789045. Epub 2013 May 8.|Cooper JN, Buchanich JM, Youk A, Brooks MM, Barinas-Mitchell E, Conroy MB, Sutton-Tyrrell K. Reductions in arterial stiffness with weight loss in overweight and obese young adults: potential mechanisms. Atherosclerosis. 2012 Aug;223(2):485-90. doi: 10.1016/j.atherosclerosis.2012.05.022. Epub 2012 May 30.|Njoroge JN, El Khoudary SR, Fried LF, Barinas-Mitchell E, Sutton-Tyrrell K. High urinary sodium is associated with increased carotid intima-media thickness in normotensive overweight and obese adults. Am J Hypertens. 2011 Jan;24(1):70-6. doi: 10.1038/ajh.2010.113. Epub 2010 May 27.|Lee JJ, Woodard GA, Gianaros PJ, Barinas-Mitchell E, Tepper PG, Conroy MB. Ectopic adiposity is associated with autonomic risk factors and subclinical cardiovascular disease in young adults. Obesity (Silver Spring). 2015 Oct;23(10):2030-6. doi: 10.1002/oby.21138. Epub 2015 Sep 3.|Hughes TM, Althouse AD, Niemczyk NA, Hawkins MS, Kuipers AL, Sutton-Tyrrell K. Effects of weight loss and insulin reduction on arterial stiffness in the SAVE trial. Cardiovasc Diabetol. 2012 Sep 22;11:114. doi: 10.1186/1475-2840-11-114.|Niemczyk NA, Catov JM, Barinas-Mitchell E, McClure CK, Roberts JM, Tepper PG, Sutton-Tyrrell K. Nulliparity is associated with less healthy markers of subclinical cardiovascular disease in young women with overweight and obesity. Obesity (Silver Spring). 2015 May;23(5):1085-91. doi: 10.1002/oby.21044. Epub 2015 Apr 10.|Hawkins M, Gabriel KP, Cooper J, Storti KL, Sutton-Tyrrell K, Kriska A. The impact of change in physical activity on change in arterial stiffness in overweight or obese sedentary young adults. Vasc Med. 2014 Aug;19(4):257-263. Epub 2014 May 30.|Smith HA, Storti KL, Arena VC, Kriska AM, Gabriel KK, Sutton-Tyrrell K, Hames KC, Conroy MB. Associations between accelerometer-derived physical activity and regional adiposity in young men and women. Obesity (Silver Spring). 2013 Jun;21(6):1299-305. doi: 10.1002/oby.20308.","\tCardiovascular Diseases|Obesity\tLow Sodium Diet|Regular Sodium Intake\tParallel Assignment\tPrevention\tRandomized\tBehavioral|Behavioral\tAll\t","Low Sodium Diet and Behavioral Intervention for Reversing Arterial Stiffening in Overweight Individuals","Interventional","Completed","N/A",2,349,"cardiovascular diseases","NA","NA"]
["NCT00368316","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20056180,"Passwell JH, Ashkenazi S, Banet-Levi Y, Ramon-Saraf R, Farzam N, Lerner-Geva L, Even-Nir H, Yerushalmi B, Chu C, Shiloach J, Robbins JB, Schneerson R; Israeli Shigella Study Group. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine. 2010 Mar 2;28(10):2231-2235. doi: 10.1016/j.vaccine.2009.12.050. Epub 2010 Jan 5. Erratum in: Vaccine. 2019 Aug 23;37(36):5504.","\tShigellosis\tShigella conjugate vaccines\tParallel Assignment\tPrevention\tRandomized\tBiological\tAll\t","Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel","Interventional","Completed","Phase 3",2,2799,"dysentery, bacillary","NA","NA"]
["NCT00371631","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21813209,"Burns AC, Petersen NJ, Garza A, Arya M, Patterson JE, Naik AD, Trautner BW. Accuracy of a urinary catheter surveillance protocol. Am J Infect Control. 2012 Feb;40(1):55-8. doi: 10.1016/j.ajic.2011.04.006. Epub 2011 Aug 3.","\tSpinal Cord Injury|Urinary Tract Infection\tInsertion of urinary catheters coated with E. coli 83972\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","urinary tract infections|spinal cord injuries|urinary bladder, neurogenic","NA","NA"]
["NCT00376558",8235409,4496992,null,"NA",null,"NA",{"$nulls":3},0.003,"ANOVA",21406463,"Martinez D, Carpenter KM, Liu F, Slifstein M, Broft A, Friedman AC, Kumar D, Van Heertum R, Kleber HD, Nunes E. Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. Am J Psychiatry. 2011 Jun;168(6):634-41. doi: 10.1176/appi.ajp.2010.10050748. Epub 2011 Mar 15. Erratum in: Am J Psychiatry. 2011 May;168(5):553.","\tCocaine Dependence\tCommunity Reinforcement Approach\tNA\tNA\tNA\tBehavioral\tAll\t","Imaging the Neurobiology of a Behavioral Treatment for Cocaine Dependence","Interventional","Completed","N/A",2,50,"cocaine-related disorders","NA","Change From Baseline in the Binding Potential of [11C]Raclopride"]
["NCT00377988","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17267834,"Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol. 2007 Feb;109(2 Pt 1):339-46. Erratum in: Obstet Gynecol. 2008 Jun;111(6):1449.","\tContraception|Female Contraception\tTransdermal Contraceptive System|Norgestimate-containing oral contraceptives with EE\tNA\tNA\tNA\tDrug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","myocardial infarction|venous thromboembolism|infarction|thromboembolism","contraceptives, oral|contraceptive agents|norgestimate","NA"]
["NCT00381771","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19572282,"Baek CH, Chung MK, Choi JY, So YK, Son YI, Jeong HS. Role of salivary function in patients with globus pharyngeus. Head Neck. 2010 Feb;32(2):244-52. doi: 10.1002/hed.21176.","\tGlobus Pharyngeus\tConservative management for xerostomia\tNA\tNA\tNA\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","conversion disorder","NA","NA"]
["NCT00383747","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17443126|17976537|18548234","Barr RS, Culhane MA, Jubelt LE, Mufti RS, Dyer MA, Weiss AP, Deckersbach T, Kelly JF, Freudenreich O, Goff DC, Evins AE. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology. 2008 Feb;33(3):480-90. Epub 2007 Apr 18.|Barr RS, Pizzagalli DA, Culhane MA, Goff DC, Evins AE. A single dose of nicotine enhances reward responsiveness in nonsmokers: implications for development of dependence. Biol Psychiatry. 2008 Jun 1;63(11):1061-5. Epub 2007 Nov 5.|Jubelt LE, Barr RS, Goff DC, Logvinenko T, Weiss AP, Evins AE. Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia. Psychopharmacology (Berl). 2008 Jul;199(1):89-98. doi: 10.1007/s00213-008-1133-8. Epub 2008 Jun 12.","\tSchizophrenia\ttransdermal nicotine patch|Transdermal Nicotine Patch\tCrossover Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","The Effects of Nicotine on Cognition in Schizophrenia","Interventional","Completed","Phase 4",2,60,"schizophrenia","nicotine","NA"]
["NCT00386984","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",10761474,"Allgaier HP, Becker G, Blum HE. [A therapeutic study of hepatocellular carcinoma using octreotide (HECTOR). Hepatocellular Carcinoma: Treatment with Octreotide]. Dtsch Med Wochenschr. 2000 Mar 17;125(11):320. German.","\tCarcinoma, Hepatocellular\tSomatostatin (octreotide)\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma|carcinoma, hepatocellular","octreotide|somatostatin","NA"]
["NCT00389311","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23325915,"Fuchs EJ, Grohskopf LA, Lee LA, Bakshi RP, Hendrix CW. Quantitative assessment of altered rectal mucosal permeability due to rectally applied nonoxynol-9, biopsy, and simulated intercourse. J Infect Dis. 2013 May 1;207(9):1389-96. doi: 10.1093/infdis/jit030. Epub 2013 Jan 16.","\tHIV Infections\tNormosol-R|Nonoxynol-9|Gastrointestinal instrumentation\tNA\tNA\tNA\tDrug|Drug|Procedure\tMale\t","A Pilot Study for Toxicity Evaluation of HIV Rectal Microbicides","Interventional","Completed","Early Phase 1",3,12,"hiv infections","nonoxynol","NA"]
["NCT00391456","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Cole K, Gawlinski A, Steers N. Animal assisted therapy decreases hemodynamics, plasma epinephrine and state anxiety in hospitalized heart failure patients. Circulation 112(17 Supplement II):527, 2005.","\tHeart Failure\tAnimal-assisted Therapy\tNA\tNA\tNA\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","heart failure","NA","NA"]
["NCT00392184","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15480513|15533801|15973598","Ott OJ, Pötter R, Hammer J, Hildebrandt G, Lotter M, Resch A, Pöhls U, Beckmann MW, Sauer R, Strnad V. Accelerated partial breast irradiation with iridium-192 multicatheter PDR/HDR brachytherapy. Preliminary results of the German-Austrian multicenter trial. Strahlenther Onkol. 2004 Oct;180(10):642-9.|Strnad V, Ott O, Pötter R, Hildebrandt G, Hammer J, Resch A, Lotter M, Ackermann S, Beckmann MW, Sauer R. Interstitial brachytherapy alone after breast conserving surgery: interim results of a German-Austrian multicenter phase II trial. Brachytherapy. 2004;3(3):115-9.|Ott OJ, Pötter R, Hildebrandt G, Hammer J, Lotter M, Beckmann MW, Sauer R, Strnad V. [Partial breast irradiation for early breast cancer with favorable prognostic factors: 3-year results of the German-Austrian phase II-trial]. Rofo. 2005 Jul;177(7):962-7. German.","\tBreast Cancer\tAccelerated partial breast irradiation\tNA\tNA\tNA\tProcedure\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","NA","NA"]
["NCT00394706",8232805,4495083,"Mean Difference (Final Values)",0,null,"NA",-0.06,0.05,95,"NA",null,21879896,"Stiell IG, Nichol G, Leroux BG, Rea TD, Ornato JP, Powell J, Christenson J, Callaway CW, Kudenchuk PJ, Aufderheide TP, Idris AH, Daya MR, Wang HE, Morrison LJ, Davis D, Andrusiek D, Stephens S, Cheskes S, Schmicker RH, Fowler R, Vaillancourt C, Hostler D, Zive D, Pirrallo RG, Vilke GM, Sopko G, Weisfeldt M; ROC Investigators. Early versus later rhythm analysis in patients with out-of-hospital cardiac arrest. N Engl J Med. 2011 Sep 1;365(9):787-97. doi: 10.1056/NEJMoa1010076.","\tHeart Arrest\tImpedance Threshold Device (ITD)|Sham ITD|Analyze early|Analyze later\tNA\tNA\tNA\tDevice|Device|Other|Other\tAll\t","Resuscitation Outcomes Consortium (ROC) Prehospital Resuscitation Using an Impedance Valve","Interventional","Terminated","Phase 3",4,11738,"heart arrest","NA","Health Utilities Index III Score and Geriatric Depression Scale Score 6 Months"]
["NCT00395993","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|18567277|NA|18752459","Gordon S, Hadley PE, Van Wyck DB, Mangione A. Ferric Carboxymaltose, a New IV Iron Agent for Iron Deficiency Anemia in Heavy Uterine Bleeding. Society for the Advancement of Blood Management 6th Annual Meeting 2007.|Gordon S, Hadley PE, Van Wyck DB, Mangione A. Iron Carboxymaltose, a New Intravenous Iron Agent for Iron Deficiency Anemia in Heavy Uterine Bleeding. American College of Obstetricians & Gynecologists: 108S 2007.|Morrison J, Patel ST, Watson W, Zaidi QR, Mangione A, Goss TF. Assessment of the prevalence and impact of anemia on women hospitalized for gynecologic conditions associated with heavy uterine bleeding. J Reprod Med. 2008 May;53(5):323-30.|James A, Patel S, Dinh Q. Impact of Anemia on Medical Resource Utilization and Hospitalization Cost in Women with Obstretrical Bleeding. The Journal of Reproductive Medicine 2008.|James AH, Patel ST, Watson W, Zaidi QR, Mangione A, Goss TF. An assessment of medical resource utilization and hospitalization cost associated with a diagnosis of anemia in women with obstetrical bleeding in the United States. J Womens Health (Larchmt). 2008 Oct;17(8):1279-84. doi: 10.1089/jwh.2007.0605.","\tAnemia\tFerric Carboxymaltose (FCM)|Ferrous Sulfate tablets\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tFemale\t","Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding","Interventional","Completed","Phase 3",2,456,"hemorrhage|uterine hemorrhage|anemia","NA","NA"]
["NCT00399711","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19531054|19476470","Raskin P, Lewin A, Reinhardt R, Lyness W; Repaglinide/Metformin Fixed-Dose Combination Study Group. Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control. Diabetes Obes Metab. 2009 Oct;11(10):947-52. doi: 10.1111/j.1463-1326.2009.01069.x. Epub 2009 Jun 16.|Raskin P, Lewin A, Reinhardt R, Lyness W; Repaglinide/Metformin Fixed-Dose Combination Study Group. Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet. Diabetes Obes Metab. 2009 Sep;11(9):865-73. doi: 10.1111/j.1463-1326.2009.01062.x. Epub 2009 May 19.","\tDiabetes|Diabetes Mellitus, Type 2\trepaglinide and metformin combination tablet|rosiglitazone and metformin combination tablet\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","diabetes mellitus|diabetes mellitus, type 2","repaglinide|metformin|rosiglitazone","NA"]
["NCT00400478","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25911553|26521299","Jaeger U, Trneny M, Melzer H, Praxmarer M, Nawarawong W, Ben Yehuda D, Goldstein D, Mihaljevic B, Ilhan O, Ballova V, Hedenus M, Hsiao LT, Au WY, Burgstaller S, Weidinger G, Keil F, Dittrich C, Skrabs C, Klingler A, Chott A, Fridrik MA, Greil R; AGMT-NHL13 Investigators. Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. Haematologica. 2015 Jul;100(7):955-63. doi: 10.3324/haematol.2015.125344. Epub 2015 Apr 24.|Jaeger U, Praxmarer M, Greil R; AGMT-NHL13 investigators. Response to comment by P. Vassilakopoulos and colleagues. Haematologica. 2015 Nov;100(11):e482. doi: 10.3324/haematol.2015.134288.","\tDiffuse Large B-Cell Lymphoma (DLBCL)|Follicular NHL Grade 3b\tRituximab\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13","Interventional","Completed","Phase 3",2,683,"lymphoma|lymphoma, b-cell|lymphoma, large b-cell, diffuse","rituximab","NA"]
["NCT00401544",8231672,4494440,"Percentage of participants",68,null,"NA",59,76,95,"NA",null,20661916,"Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Shao J, Bridges K. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol. 2010 Sep;85(9):655-63. doi: 10.1002/ajh.21779.","\tAnemia|Non-Myeloid Malignancies\tdarbepoetin alfa|IV iron dextran\tNA\tNA\tNA\tDrug|Drug\tAll\t","Darbepoetin Alfa With or Without Intravenous (IV) Iron","Interventional","Completed","Phase 2",4,243,"neoplasms|anemia","darbepoetin alfa|iron-dextran complex|dextrans","Number of Participants With a Hematopoietic Response, by Darbepoetin Alfa Dose"]
["NCT00402389","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16390366,"Freeman MP, Hibbeln JR, Wisner KL, Brumbach BH, Watchman M, Gelenberg AJ. Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression. Acta Psychiatr Scand. 2006 Jan;113(1):31-5.","\tDepression|Depression, Postpartum\tOmega-3 Fatty Acids (EPA plus DHA)|Supportive psychotherapy|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Behavioral|Drug\tFemale\t","Use of Omega-3 Fatty Acids for Perinatal Depression","Interventional","Completed","Phase 2",2,50,"depression|depressive disorder|depression, postpartum","NA","NA"]
["NCT00405054","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25127392,"Seymour JF, Kim DW, Rubin E, Haregewoin A, Clark J, Watson P, Hughes T, Dufva I, Jimenez JL, Mahon FX, Rousselot P, Cortes J, Martinelli G, Papayannidis C, Nagler A, Giles FJ. A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer J. 2014 Aug 15;4:e238. doi: 10.1038/bcj.2014.60.","\tLeukemia\tMK0457\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia","NA","NA"]
["NCT00407602","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22244176|2342673|22661464|20881025","Humayun MS, Dorn JD, da Cruz L, Dagnelie G, Sahel JA, Stanga PE, Cideciyan AV, Duncan JL, Eliott D, Filley E, Ho AC, Santos A, Safran AB, Arditi A, Del Priore LV, Greenberg RJ; Argus II Study Group. Interim results from the international trial of Second Sight's visual prosthesis. Ophthalmology. 2012 Apr;119(4):779-88. doi: 10.1016/j.ophtha.2011.09.028. Epub 2012 Jan 11.|Fiddes TM, Monk NA, Hashish AF, Richards BJ, Bardwell LM, Watt AJ, Gardner RJ. Early prenatal diagnosis of genetic abnormality by chorion villus sampling. N Z Med J. 1990 Apr 11;103(887):157-8.|Barry MP, Dagnelie G; Argus II Study Group. Use of the Argus II retinal prosthesis to improve visual guidance of fine hand movements. Invest Ophthalmol Vis Sci. 2012 Aug 1;53(9):5095-101. doi: 10.1167/iovs.12-9536.|Ahuja AK, Dorn JD, Caspi A, McMahon MJ, Dagnelie G, Dacruz L, Stanga P, Humayun MS, Greenberg RJ; Argus II Study Group. Blind subjects implanted with the Argus II retinal prosthesis are able to improve performance in a spatial-motor task. Br J Ophthalmol. 2011 Apr;95(4):539-43. doi: 10.1136/bjo.2010.179622. Epub 2010 Sep 29.","\tRetinitis Pigmentosa\tArgus II Retinal Stimulation System\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","retinitis|retinitis pigmentosa","NA","NA"]
["NCT00409591","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20625263|26372485","Cressey TR, Jourdain G, Rawangban B, Varadisai S, Kongpanichkul R, Sabsanong P, Yuthavisuthi P, Chirayus S, Ngo-Giang-Huong N, Voramongkol N, Pattarakulwanich S, Lallemant M; PHPT-5 Team. Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS. 2010 Sep 10;24(14):2193-200. doi: 10.1097/QAD.0b013e32833ce57d.|Lallemant M, Le Coeur S, Sirirungsi W, Cressey TR, Ngo-Giang-Huong N, Traisathit P, Klinbuayaem V, Sabsanong P, Kanjanavikai P, Jourdain G, Mcintosh K, Koetsawang S; PHPT-5 study investigators. Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand. AIDS. 2015 Nov 28;29(18):2497-507. doi: 10.1097/QAD.0000000000000865.","\tHIV Infections|Pregnancy\tMaternal and infant nevirapine|Maternal placebo and infant nevirapine|Maternal lopinavir+ritonavir|zidovudine\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug|Drug|Drug\tAll\t","Maternal/Infant Peripartum NVP, Versus Infant Only Peripartum NVP, or Maternal LPV/r in Addition to Standard ZDV Prophylaxis for the Prevention of Perinatal (PMTCT) HIV in Thailand","Interventional","Terminated","Phase 3",3,435,"infection|hiv infections","ritonavir|lopinavir|zidovudine|nevirapine","NA"]
["NCT00412360",8230071,4492290,null,"NA",null,"NA",{"$nulls":3},0.11,"Log Rank",25354103,"Wagner JE Jr, Eapen M, Carter S, Wang Y, Schultz KR, Wall DA, Bunin N, Delaney C, Haut P, Margolis D, Peres E, Verneris MR, Walters M, Horowitz MM, Kurtzberg J; Blood and Marrow Transplant Clinical Trials Network. One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med. 2014 Oct 30;371(18):1685-94. doi: 10.1056/NEJMoa1405584.","\tAcute Lymphocytic Leukemia|Acute Myelogenous Leukemia|Chronic Myelogenous Leukemia|Myelodysplastic Syndrome|Natural Killer Cell Lymphoblastic Leukemia/Lymphoma\tSingle Umbilical Cord Blood Unit Transplant|Double Umbilical Cord Blood Unit Transplant|Total Body Irradiation|Cyclophosphamide|Fludarabine|Cyclosporine A|Mycophenolate Mofetil\tNA\tNA\tNA\tBiological|Biological|Radiation|Drug|Drug|Drug|Drug\tAll\t","Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)","Interventional","Completed","Phase 3",2,224,"myelodysplastic syndromes|leukemia, myeloid|leukemia|precursor cell lymphoblastic leukemia-lymphoma|leukemia, myeloid, acute|leukemia, myelogenous, chronic, bcr-abl positive","cyclophosphamide|fludarabine|cyclosporine|mycophenolic acid|cyclosporins","Percentage of Participants With Disease-free Survival"]
["NCT00416611","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17134065,"Karagiannis A, Athyros VG, Papageorgiou A, Tziomalos K, Elisaf M. Should atenolol still be recommended as first-line therapy for primary hypertension? Hellenic J Cardiol. 2006 Sep-Oct;47(5):298-307. Review.","\tHigh Blood Pressure\tImplementation of guidelines\tNA\tNA\tNA\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","hypertension","NA","NA"]
["NCT00419341",8229189,4491824,"Geometric mean ratio (GMR)",1.002,null,"NA",0.951,1.055,90,"NA",null,"20454851|21553933","Hagan JB, Fasano MB, Spector S, Wasserman RL, Melamed I, Rojavin MA, Zenker O, Orange JS. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010 Sep;30(5):734-45. doi: 10.1007/s10875-010-9423-4. Epub 2010 May 8.|Wasserman RL, Melamed I, Nelson RP Jr, Knutsen AP, Fasano MB, Stein MR, Rojavin MA, Church JA. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet. 2011 Jun;50(6):405-14. doi: 10.2165/11587030-000000000-00000.","\tPrimary Immune Deficiency\tHuman Normal Immunoglobulin for Subcutaneous Administration\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","immunologic deficiency syndromes","immunoglobulins, intravenous|immunoglobulins|antibodies","Area Under the Concentration-time Curve (AUC) of Total Serum Immunoglobulin G (IgG)"]
["NCT00420680","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19455040,"Dahl V, Pendeville PE, Hollmann MW, Heier T, Abels EA, Blobner M. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol. 2009 Oct;26(10):874-84. doi: 10.1097/EJA.0b013e32832c605b.","\tAnesthesia\tSugammadex|Sugammadex|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","Safety and Efficacy Evaluation of Sugammadex in Cardiac Patients (19.4.309)(P05934)","Interventional","Completed","Phase 3",3,120,"NA","NA","NA"]
["NCT00423150","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23443801,"Hochhauser D, Glynne-Jones R, Potter V, Grávalos C, Doyle TJ, Pathiraja K, Zhang Q, Zhang L, Sausville EA. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther. 2013 May;12(5):809-18. doi: 10.1158/1535-7163.MCT-12-0710. Epub 2013 Feb 26.","\tCarcinoma, Non-Small-Cell Lung|Colorectal Neoplasm|Esophageal Neoplasm|Head and Neck Neoplasm\tTemozolomide\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","esophageal neoplasms|neoplasms|carcinoma, non-small-cell lung|colorectal neoplasms|head and neck neoplasms","temozolomide","NA"]
["NCT00425724","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21626222,"Jauhola O, Ronkainen J, Autio-Harmainen H, Koskimies O, Ala-Houhala M, Arikoski P, Hölttä T, Jahnukainen T, Rajantie J, Ormälä T, Nuutinen M. Cyclosporine A vs. methylprednisolone for Henoch-Schönlein nephritis: a randomized trial. Pediatr Nephrol. 2011 Dec;26(12):2159-66. doi: 10.1007/s00467-011-1919-5. Epub 2011 May 28. Erratum in: Pediatr Nephrol. 2011 Dec;26(12):2263-4.","\tPurpura, Schoenlein-Henoch\tMethylprednisolone pulses plus prednisone versus Cyclosporine A\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","purpura, schoenlein-henoch|glomerulonephritis|purpura","prednisone|cyclosporine|cyclosporins|methylprednisolone","NA"]
["NCT00430482","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23398222|23061323|25364993","McHugh RK, Murray HW, Hearon BA, Pratt EM, Pollack MH, Safren SA, Otto MW. Predictors of dropout from psychosocial treatment in opioid-dependent outpatients. Am J Addict. 2013 Jan;22(1):18-22. doi: 10.1111/j.1521-0391.2013.00317.x.|McHugh RK, Weitzman M, Safren SA, Murray HW, Pollack MH, Otto MW. Sexual HIV risk behaviors in a treatment-refractory opioid-dependent sample. J Psychoactive Drugs. 2012 Jul-Aug;44(3):237-42.|Otto MW, Hearon BA, McHugh RK, Calkins AW, Pratt E, Murray HW, Safren SA, Pollack MH. A randomized, controlled trial of the efficacy of an interoceptive exposure-based CBT for treatment-refractory outpatients with opioid dependence. J Psychoactive Drugs. 2014 Nov-Dec;46(5):402-11. doi: 10.1080/02791072.2014.960110.","\tSubstance Dependence\tCognitive Behavioral Therapy|Individual Counseling\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral\tAll\t","Stress, Distress Intolerance, and Drug Dependence","Interventional","Completed","N/A",2,133,"substance-related disorders","NA","NA"]
["NCT00430859","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19114895|19048243","Heemskerk S, Masereeuw R, Moesker O, Bouw MP, van der Hoeven JG, Peters WH, Russel FG, Pickkers P; APSEP Study Group. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med. 2009 Feb;37(2):417-23, e1. doi: 10.1097/CCM.0b013e31819598af.|Pickkers P, Snellen F, Rogiers P, Bakker J, Jorens P, Meulenbelt J, Spapen H, Tulleken JE, Lins R, Ramael S, Bulitta M, van der Hoeven JG. Clinical pharmacology of exogenously administered alkaline phosphatase. Eur J Clin Pharmacol. 2009 Apr;65(4):393-402. doi: 10.1007/s00228-008-0591-6. Epub 2008 Dec 2.","\tMultiple Organ Dysfunction Syndrome|Sepsis\tAlkaline Phosphatase|Placebo\tNA\tNA\tNA\tDrug|Drug\tAll\t","Bovine Intestinal Alkaline Phosphatase for the Treatment of Patients With Sepsis","Interventional","Completed","Phase 2",2,37,"toxemia|multiple organ failure|sepsis","NA","NA"]
["NCT00436306","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16394049|17714677|18360319|18313637|18395692|18468575|19245303|21514555|21843690","Matteson KA, Peipert JF, Allsworth J, Phipps MG, Redding CA. Unplanned pregnancy: does past experience influence the use of a contraceptive method? Obstet Gynecol. 2006 Jan;107(1):121-7.|Peipert JF, Lapane KL, Allsworth JE, Redding CA, Blume JL, Lozowski F, Stein MD. Women at risk for sexually transmitted diseases: correlates of intercourse without barrier contraception. Am J Obstet Gynecol. 2007 Nov;197(5):474.e1-8. Epub 2007 Aug 21.|Peipert JF, Lapane KL, Allsworth JE, Redding CA, Blume JD, Stein MD. Bacterial vaginosis, race, and sexually transmitted infections: does race modify the association? Sex Transm Dis. 2008 Apr;35(4):363-7. doi: 10.1097/OLQ.0b013e31815e4179.|Krings KM, Matteson KA, Allsworth JE, Mathias E, Peipert JF. Contraceptive choice: how do oral contraceptive users differ from condom users and women who use no contraception? Am J Obstet Gynecol. 2008 May;198(5):e46-7. doi: 10.1016/j.ajog.2007.12.025. Epub 2008 Mar 7.|Peipert JF, Redding CA, Blume JD, Allsworth JE, Matteson KA, Lozowski F, Mayer KH, Morokoff PJ, Rossi JS. Tailored intervention to increase dual-contraceptive method use: a randomized trial to reduce unintended pregnancies and sexually transmitted infections. Am J Obstet Gynecol. 2008 Jun;198(6):630.e1-8. doi: 10.1016/j.ajog.2008.01.038. Epub 2008 Apr 8.|Kuroki LM, Allsworth JE, Redding CA, Blume JD, Peipert JF. Is a previous unplanned pregnancy a risk factor for a subsequent unplanned pregnancy? Am J Obstet Gynecol. 2008 Nov;199(5):517.e1-7. doi: 10.1016/j.ajog.2008.03.049. Epub 2008 May 12.|Allsworth JE, Anand M, Redding CA, Peipert JF. Physical and sexual violence and incident sexually transmitted infections. J Womens Health (Larchmt). 2009 Apr;18(4):529-34. doi: 10.1089/jwh.2007.0757.|Allsworth JE, Peipert JF. Severity of bacterial vaginosis and the risk of sexually transmitted infection. Am J Obstet Gynecol. 2011 Aug;205(2):113.e1-6. doi: 10.1016/j.ajog.2011.02.060. Epub 2011 Feb 27.|Peipert JF, Zhao Q, Meints L, Peipert BJ, Redding CA, Allsworth JE. Adherence to dual-method contraceptive use. Contraception. 2011 Sep;84(3):252-8. doi: 10.1016/j.contraception.2011.01.023. Epub 2011 Apr 16.","\tContraception|Pregnancy|Sexually Transmitted Diseases\tIndividualized Intervention|Computer-based contraceptive information\tParallel Assignment\tPrevention\tRandomized\tBehavioral|Behavioral\tFemale\t","Stage Matched Intervention to Increase Dual Method Use","Interventional","Completed","Phase 4",2,550,"sexually transmitted diseases","contraceptive agents","NA"]
["NCT00439335","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22891287,"Patel SM, Atmar RL, El Sahly HM, Guo K, Hill H, Keitel WA. Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis. 2012 Oct 1;206(7):1069-77. doi: 10.1093/infdis/jis402. Epub 2012 Aug 13.","\tInfluenza\tInactivated Influenza A Vaccine A/H5N1|Inactivated Influenza A Vaccine A/H5N1|Placebo (IM)|Placebo (ID)\tParallel Assignment\tPrevention\tRandomized\tBiological|Biological|Drug|Drug\tAll\t","Higher Dose Intradermal H5 Vaccine","Interventional","Completed","Phase 1/Phase 2",2,227,"influenza, human","vaccines","NA"]
["NCT00444314","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21174224,"Bruce JY, Eickhoff J, Pili R, Logan T, Carducci M, Arnott J, Treston A, Wilding G, Liu G. A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Invest New Drugs. 2012 Apr;30(2):794-802. doi: 10.1007/s10637-010-9618-9. Epub 2010 Dec 22.","\tMetastatic Renal Cell Carcinoma\tPanzem® NCD|Sunitinib Malate\tNA\tNA\tNA\tDrug|Drug\tAll\t","Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma","Interventional","Completed","Phase 2",2,82,"carcinoma|carcinoma, renal cell","sunitinib","NA"]
["NCT00447772",8224417,4488013,"Mean difference",-0.322,null,"NA",-0.877,0.233,95,0,"ANCOVA","23604344|22021883","Hefter H, Benecke R, Erbguth F, Jost W, Reichel G, Wissel J. An open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport). BMJ Open. 2013 Apr 18;3(4). pii: e001853. doi: 10.1136/bmjopen-2012-001853. Print 2013.|Hefter H, Kupsch A, Müngersdorf M, Paus S, Stenner A, Jost W; Dysport Cervical Dystonia Study Group. A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis. BMJ Open. 2011 Jan 1;1(2):e000196. doi: 10.1136/bmjopen-2011-000196.","\tCervical Dystonia\tBotulinum toxin type A\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","dystonia|torticollis|dystonic disorders","botulinum toxins, type a|abobotulinumtoxina|botulinum toxins","Change From Baseline in the Total Score of the Tsui Rating Scale (Patient in Sitting Position) at the First On-treatment Visit (Week 4 or Week 12)"]
["NCT00450034","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22091692,"Legrain S, Tubach F, Bonnet-Zamponi D, Lemaire A, Aquino JP, Paillaud E, Taillandier-Heriche E, Thomas C, Verny M, Pasquet B, Moutet AL, Lieberherr D, Lacaille S. A new multimodal geriatric discharge-planning intervention to prevent emergency visits and rehospitalizations of older adults: the optimization of medication in AGEd multicenter randomized controlled trial. J Am Geriatr Soc. 2011 Nov;59(11):2017-28. doi: 10.1111/j.1532-5415.2011.03628.x. Epub 2011 Sep 27.","\tGlobal Medical Assessment of Elderly Frail Patients\tdrug - oriented multifaceted intervention\tParallel Assignment\tTreatment\tRandomized\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT00453895","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22837187,"Kroiss M, Quinkler M, Johanssen S, van Erp NP, Lankheet N, Pöllinger A, Laubner K, Strasburger CJ, Hahner S, Müller HH, Allolio B, Fassnacht M. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab. 2012 Oct;97(10):3495-503. doi: 10.1210/jc.2012-1419. Epub 2012 Jul 26.","\tAdrenocortical Carcinoma\tSunitinib\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","adrenocortical carcinoma|carcinoma","sunitinib","NA"]
["NCT00455182","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15777857,"Usichenko TI, Dinse M, Hermsen M, Witstruck T, Pavlovic D, Lehmann C. Auricular acupuncture for pain relief after total hip arthroplasty - a randomized controlled study. Pain. 2005 Apr;114(3):320-327. doi: 10.1016/j.pain.2004.08.021.","\tPain|Postoperative Complications\tAcupuncture|Sham Acupuncture|Standard medical care\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure|Procedure\tAll\t","Acupuncture for Pain Management After Hip or Knee Arthroplasty","Interventional","Withdrawn","N/A",3,0,"postoperative complications","NA","NA"]
["NCT00458848","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21623761,"Messina M, Chiaretti S, Iacobucci I, Tavolaro S, Lonetti A, Santangelo S, Elia L, Papayannidis C, Paoloni F, Vitale A, Guarini A, Martinelli G, Foà R. AICDA expression in BCR/ABL1-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile. Br J Haematol. 2011 Mar;152(6):727-32. doi: 10.1111/j.1365-2141.2010.08449.x. Epub 2011 Jan 31.","\tLeukemia\tperipheral blood stem cell transplantation|radiation therapy|allogeneic hematopoietic stem cell transplantation|autologous hematopoietic stem cell transplantation|asparaginase|daunorubicin hydrochloride|etoposide|idarubicin|imatinib mesylate|mercaptopurine|methotrexate|methylprednisolone|mitoxantrone hydrochloride|prednisone|vincristine sulfate\tNA\tNA\tNA\tProcedure|Radiation|Procedure|Procedure|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","leukemia|leukemia, lymphoid|precursor cell lymphoblastic leukemia-lymphoma","mercaptopurine|mitoxantrone|vincristine|asparaginase|daunorubicin|methotrexate|idarubicin|imatinib mesylate|methylprednisolone|etoposide|prednisone","NA"]
["NCT00460629","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16990776,"Bornhauser M, Thiede C, Babatz J, Schetelig J, Illmer T, Kiani A, Platzbecker U, Herr W, Rieber EP, Ehninger G, Schmitz M. Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34+ selected allogeneic hematopoietic cell transplantation. Leukemia. 2006 Nov;20(11):2055-7. Epub 2006 Aug 31.","\tChronic Myeloid Leukemia\tApplication of activated donor T cells\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, myeloid|leukemia, myelogenous, chronic, bcr-abl positive|leukemia","NA","NA"]
["NCT00462917","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28726810|26810768|25642295|25634646","Christensen KD, Uhlmann WR, Roberts JS, Linnenbringer E, Whitehouse PJ, Royal CDM, Obisesan TO, Cupples LA, Butson MB, Fasaye GA, Hiraki S, Chen CA, Siebert U, Cook-Deegan R, Green RC. A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone. Genet Med. 2018 Jan;20(1):132-141. doi: 10.1038/gim.2017.103. Epub 2017 Jul 20.|Christensen KD, Roberts JS, Whitehouse PJ, Royal CD, Obisesan TO, Cupples LA, Vernarelli JA, Bhatt DL, Linnenbringer E, Butson MB, Fasaye GA, Uhlmann WR, Hiraki S, Wang N, Cook-Deegan R, Green RC; REVEAL Study Group*. Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial. Ann Intern Med. 2016 Feb 2;164(3):155-63. doi: 10.7326/M15-0187. Epub 2016 Jan 26.|Christensen KD, Roberts JS, Zikmund-Fisher BJ, Kardia SL, McBride CM, Linnenbringer E, Green RC; REVEAL Study Group. Associations between self-referral and health behavior responses to genetic risk information. Genome Med. 2015 Jan 31;7(1):10. doi: 10.1186/s13073-014-0124-0. eCollection 2015.|Besser AG, Sanderson SC, Roberts JS, Chen CA, Christensen KD, Lautenbach DM, Cupples LA, Green RC. Factors affecting recall of different types of personal genetic information about Alzheimer's disease risk: the REVEAL study. Public Health Genomics. 2015;18(2):78-86. doi: 10.1159/000368888. Epub 2015 Jan 24.","\tAlzheimer Disease\tPleiotropic info, in-person disclosure|AD-only info, in-person disclosure|Pleiotropic info, phone disclosure|AD-only info, phone disclosure\tNA\tNA\tNA\tBehavioral|Behavioral|Behavioral|Behavioral\tAll\t","REVEAL III: Risk Evaluation and Education for Alzheimer's Disease","Interventional","Completed","N/A",4,290,"alzheimer disease","NA","NA"]
["NCT00466622","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24423336,"Stridsklev S, Carlsen SM, Salvesen Ø, Clemens I, Vanky E. Midpregnancy Doppler ultrasound of the uterine artery in metformin- versus placebo-treated PCOS women: a randomized trial. J Clin Endocrinol Metab. 2014 Mar;99(3):972-7. doi: 10.1210/jc.2013-3227. Epub 2014 Jan 1.","\tPolycystic Ovary Syndrome\tMetformin|Placebo\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug\tFemale\t","Uterine Artery Blood Flow in Pregnant Women With PCOS Treated With Metformin","Interventional","Completed","Phase 3",2,48,"syndrome|polycystic ovary syndrome","metformin","NA"]
["NCT00471471","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22495394,"Tarhini AA, Leng S, Moschos SJ, Yin Y, Sander C, Lin Y, Gooding WE, Kirkwood JM. Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunother. 2012 May;35(4):359-66. doi: 10.1097/CJI.0b013e31825481fe. Erratum in: J Immunother. 2012 Oct;35(8):650.","\tIntraocular Melanoma|Malignant Conjunctival Neoplasm|Melanoma (Skin)\tPeptide vaccine|GM-CSF|PF3512676\tNA\tNA\tNA\tBiological|Biological|Biological\tAll\t","NA","NA","NA","NA","NA","NA","melanoma|conjunctival neoplasms","sargramostim","NA"]
["NCT00475241","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23696427,"Sripada RK, Rauch SA, Tuerk PW, Smith E, Defever AM, Mayer RA, Messina M, Venners M. Mild traumatic brain injury and treatment response in prolonged exposure for PTSD. J Trauma Stress. 2013 Jun;26(3):369-75. doi: 10.1002/jts.21813. Epub 2013 May 20.","\tCombat Disorders|Posttraumatic Stress Disorder\tProlonged Exposure therapy for PTSD|Present centered therapy for PTSD\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral\tAll\t","Exposure Therapy for Chronic PTSD: Efficacy and Mechanisms","Interventional","Completed","Phase 2/Phase 3",2,36,"disease|stress disorders, post-traumatic|combat disorders|stress disorders, traumatic","NA","NA"]
["NCT00475501",8220197,4485300,"Mean Difference (Net)",0.587,"Standard Error of the Mean",0.743,-0.869,2.043,95,0.433,"Mixed Models Analysis","24012740|24326421","Yarrow JF, Beck DT, Conover CF, Beggs LA, Goldberger BA, Borst SE. Invalidation of a commercially available human 5α-dihydrotestosterone immunoassay. Steroids. 2013 Dec 11;78(12-13):1220-5. doi: 10.1016/j.steroids.2013.08.013. Epub 2013 Sep 6.|Borst SE, Yarrow JF, Conover CF, Nseyo U, Meuleman JR, Lipinska JA, Braith RW, Beck DT, Martin JS, Morrow M, Roessner S, Beggs LA, McCoy SC, Cannady DF 2nd, Shuster JJ. Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial. Am J Physiol Endocrinol Metab. 2014 Feb 15;306(4):E433-42. doi: 10.1152/ajpendo.00592.2013. Epub 2013 Dec 10.","\tBenign Prostate Hypertrophy|Male Hypogonadism|Muscle Atrophy|Sarcopenia\tTestosterone Enanthate|Finasteride|Placebo\tNA\tNA\tNA\tDrug|Drug|Other\tMale\t","5-Alpha Reductase and Anabolic Effects of Testosterone","Interventional","Completed","Phase 2",4,60,"prostatic hyperplasia|hypogonadism|hypertrophy|muscular atrophy|sarcopenia|atrophy","testosterone|testosterone undecanoate|testosterone enanthate|finasteride|testosterone 17 beta-cypionate|methyltestosterone","Benton Judgment of Line Orientation Test"]
["NCT00477178","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20947399,"Nilsen HK, Landrø NI, Kaasa S, Jenssen GD, Fayers P, Borchgrevink PC. Driving functions in a video simulator in chronic non-malignant pain patients using and not using codeine. Eur J Pain. 2011 Apr;15(4):409-15. doi: 10.1016/j.ejpain.2010.09.008. Epub 2010 Oct 13.","\tHealthy\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT00480714","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15502839,"McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, Fletcher HA, Hill AV. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med. 2004 Nov;10(11):1240-4. Epub 2004 Oct 24. Erratum in: Nat Med. 2004 Dec;10(12):1397.","\tTB\tBCG (SSI Strain)\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT00483405","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22043322,"Sanoff HK, Bernard S, Goldberg RM, Morse MA, Garcia R, Woods L, Moore DT, O'Neil BH. Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma. Gastrointest Cancer Res. 2011 May;4(3):78-83.","\tLiver Cancer\tcetuximab|capecitabine|oxaliplatin\tNA\tNA\tNA\tBiological|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","liver neoplasms","cetuximab|capecitabine|oxaliplatin","NA"]
["NCT00486603","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24991840,"Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, Wang D, Chang YC, Hu J, McAfee Q, Fisher J, Troxel AB, Piao S, Heitjan DF, Tan KS, Pontiggia L, O'Dwyer PJ, Davis LE, Amaravadi RK. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy. 2014 Aug;10(8):1359-68. doi: 10.4161/auto.28984. Epub 2014 May 20.","\tBrain and Central Nervous System Tumors\thydroxychloroquine|temozolomide|pharmacological study|Radiation\tNA\tNA\tNA\tDrug|Drug|Other|Radiation\tAll\t","Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Interventional","Completed","Phase 1/Phase 2",5,92,"nervous system neoplasms|glioblastoma|central nervous system neoplasms","temozolomide|hydroxychloroquine","NA"]
["NCT00493194","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12438948|10221490|10798738|12761269","Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, Savas K, Cook DJ, Novick AC. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation. 2002 Oct 27;74(8):1070-6.|Groth CG, Bäckman L, Morales JM, Calne R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol JM, Durand D, Wramner L, Brattström C, Charpentier B. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation. 1999 Apr 15;67(7):1036-42.|Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthoux FC, Brattström C, Lebranchu Y, Vialtel P. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation. 2000 Apr 15;69(7):1252-60.|Grimm PC, Nickerson P, Gough J, McKenna R, Stern E, Jeffery J, Rush DN. Computerized image analysis of Sirius Red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol. 2003 Jun;14(6):1662-8.","\tImmunosuppression|Interstitial Fibrosis|Kidney Failure, Chronic|Transplantation\tsirolimus|cyclosporine|daclizumab\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","kidney failure, chronic|renal insufficiency|fibrosis|lung diseases, interstitial","sirolimus|cyclosporins|cyclosporine|daclizumab","NA"]
["NCT00493844","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20152214,"Sanchis J, Bosch X, Bodí V, Núñez J, Doltra A, Heras M, Mainar L, Santas E, Bragulat E, García-Alvarez A, Carratalá A, Llácer A. Randomized comparison between clinical evaluation plus N-terminal pro-B-type natriuretic peptide versus exercise testing for decision making in acute chest pain of uncertain origin. Am Heart J. 2010 Feb;159(2):176-82. doi: 10.1016/j.ahj.2009.11.010.","\tChest Pain\tExercise testing|Clinical evaluation + NTproBNP\tParallel Assignment\tDiagnostic\tRandomized\tOther|Other\tAll\t","N-terminal Pro B-type Natriuretic Peptide (Nt-proBNP) Versus Exercise Test for Evaluation of Acute Chest Pain","Interventional","Completed","N/A",2,320,"chest pain","NA","NA"]
["NCT00499577","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21030558|20864577","Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang HB, Cai L, Janofsky S, Chew A, Storek J, Akpek G, Badros A, Yanovich S, Tan MT, Veloso E, Pasetti MF, Cross A, Philip S, Murphy H, Bhagat R, Zheng Z, Milliron T, Cotte J, Cannon A, Levine BL, Vonderheide RH, June CH. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood. 2011 Jan 20;117(3):788-97. doi: 10.1182/blood-2010-08-299396. Epub 2010 Oct 28.|Stadtmauer EA, Vogl DT, Luning Prak E, Boyer J, Aqui NA, Rapoport AP, McDonald KR, Hou X, Murphy H, Bhagat R, Mangan PA, Chew A, Veloso EA, Levine BL, Vonderheide RH, Jawad AF, June CH, Sullivan KE. Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. Blood. 2011 Jan 6;117(1):63-71. doi: 10.1182/blood-2010-07-296822. Epub 2010 Sep 23.","\tMultiple Myeloma and Plasma Cell Neoplasm\tCMV pp65 peptide|hTERT I540/R572Y/D988Y multipeptide vaccine|pneumococcal polyvalent vaccine|survivin Sur1M2 peptide vaccine\tNA\tNA\tNA\tBiological|Biological|Biological|Biological\tAll\t","Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma","Interventional","Completed","Phase 1/Phase 2",4,56,"neoplasms, plasma cell|multiple myeloma|plasmacytoma","vaccines|heptavalent pneumococcal conjugate vaccine","NA"]
["NCT00501293",8217005,4483453,null,"NA",null,"NA",{"$nulls":3},1E-3,"t-test, 2 sided",20973707,"Findling RL, Katic A, Rubin R, Moon E, Civil R, Li Y. A 6-month, open-label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2010 Oct;20(5):365-75. doi: 10.1089/cap.2009.0122.","\tADHD\tMethylphenidate Transdermal System\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","NA","methylphenidate","Change From Baseline in Conner's Parent Rating Scale-revised Short Version (CPRS-R) at 6 Months"]
["NCT00504348","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",31539061,"Takada K, Katada Y, Ito S, Hayashi T, Kishi J, Itoh K, Yamashita H, Hirakata M, Kawahata K, Kawakami A, Watanabe N, Atsumi T, Takasaki Y, Miyasaka N. Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial. Rheumatology (Oxford). 2020 May 1;59(5):1084-1093. doi: 10.1093/rheumatology/kez394.","\tDermatomyositis|Interstitial Pneumonitis|Polymyositis\tTacrolimus\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","pneumonia|lung diseases, interstitial|polymyositis|dermatomyositis","tacrolimus","NA"]
["NCT00506831",8216424,4483191,null,"NA",null,"NA",{"$nulls":3},0.005,"t-test, 2 sided",19180499,"Chung L, Fiorentino DF, Benbarak MJ, Adler AS, Mariano MM, Paniagua RT, Milano A, Connolly MK, Ratiner BD, Wiskocil RL, Whitfield ML, Chang HY, Robinson WH. Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum. 2009 Feb;60(2):584-91. doi: 10.1002/art.24221.","\tScleroderma, Systemic\tImatinib mesylate\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","scleroderma, diffuse|scleroderma, systemic","imatinib mesylate","Percent Change in Modified Rodnan Skin Score at 6 Months Compared to Baseline"]
["NCT00512629","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23770843,"Nehra D, Fallon EM, Potemkin AK, Voss SD, Mitchell PD, Valim C, Belfort MB, Bellinger DC, Duggan C, Gura KM, Puder M. A comparison of 2 intravenous lipid emulsions: interim analysis of a randomized controlled trial. JPEN J Parenter Enteral Nutr. 2014 Aug;38(6):693-701. doi: 10.1177/0148607113492549. Epub 2013 Jun 14.","\tCholestasis|Parenteral Nutrition\tOmegaven|Intralipid\tNA\tNA\tNA\tDrug|Drug\tAll\t","Cholestasis Prevention: Efficacy of IV Fish Oil","Interventional","Completed","Phase 1",2,19,"cholestasis","soybean oil, phospholipid emulsion","NA"]
["NCT00515541",8215110,4482492,null,"NA",null,"NA",{"$nulls":3},1E-3,"Wilcoxon (Mann-Whitney)",21621252,"Cohen MG, Rossi JS, Garbarino J, Bowling R, Motsinger-Reif AA, Schuler C, Dupont AG, Gabriel D. Insights into the inhibition of platelet activation by omega-3 polyunsaturated fatty acids: beyond aspirin and clopidogrel. Thromb Res. 2011 Oct;128(4):335-40. doi: 10.1016/j.thromres.2011.04.023. Epub 2011 May 28.","\tBleeding|Cardiovascular Disease\tLovaza\tNA\tNA\tNA\tDrug\tAll\t","Lovaza's Effect on the Activation of Platelets","Interventional","Completed","Phase 2",4,43,"cardiovascular diseases|hemorrhage","NA","EQELS (Electrophoretic Quasi Elastic Light Scattering: Change in Mobility After the Addition of Arachidonic Acid"]
["NCT00518518","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19134016,"Stelmach I, Kaczmarek-Woźniak J, Majak P, Olszowiec-Chlebna M, Jerzynska J. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp Allergy. 2009 Mar;39(3):401-8. doi: 10.1111/j.1365-2222.2008.03159.x. Epub 2008 Dec 23.","\tAsthma\tStaloral 300|placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Safety and Efficacy of Ultra-Rush Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen","Interventional","Completed","Phase 4",2,50,"asthma","NA","NA"]
["NCT00519805","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19807917,"Griffiths GO, Burns S, Noble SI, Macbeth FR, Cohen D, Maughan TS. FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer. BMC Cancer. 2009 Oct 6;9:355. doi: 10.1186/1471-2407-9-355.","\tLung Cancer|Thromboembolism\tdalteparin|quality-of-life assessment\tNA\tNA\tNA\tDrug|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","thromboembolism|lung neoplasms","tinzaparin|heparin, low-molecular-weight|dalteparin","NA"]
["NCT00521339",8214258,4482111,null,"NA",null,"NA",{"$nulls":3},0.13,"Wilcoxon (Mann-Whitney)",23986162,"Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C, Schafer PH, Krueger JG. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol. 2013 Aug;12(8):888-97.","\tPlaque-Type Psoriasis|Psoriasis-Type Psoriasis\tApremilast\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","psoriasis","apremilast","Percent Change From Baseline of Langerin in the Epidermis of the Psoriatic Skin Biopsy at Week 12"]
["NCT00523835","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16801584,"Bojesen A, Kristensen K, Birkebaek NH, Fedder J, Mosekilde L, Bennett P, Laurberg P, Frystyk J, Flyvbjerg A, Christiansen JS, Gravholt CH. The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care. 2006 Jul;29(7):1591-8.","\tCardiovascular Disease|Diabetes|Klinefelter Syndrome|Metabolic Syndrome|Osteoporosis\tNA\tNA\tNA\tNA\tNA\tMale\t","NA","NA","NA","NA","NA","NA","osteoporosis|cardiovascular diseases|klinefelter syndrome|syndrome|metabolic syndrome","NA","NA"]
["NCT00525967","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","9779694|11387363|10506634|16051965|14701781|15310785|9817288","Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol. 1998 Oct;16(10):3216-21.|Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P, Gebbia V, Ripamonti C. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol. 2001 Jun 1;19(11):2898-904.|Mercadante S, Casuccio A, Calderone L. Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol. 1999 Oct;17(10):3307-12.|Mercadante S, Ferrera P, Villari P, Casuccio A. Rapid switching between transdermal fentanyl and methadone in cancer patients. J Clin Oncol. 2005 Aug 1;23(22):5229-34.|Bruera E, Palmer JL, Bosnjak S, Rico MA, Moyano J, Sweeney C, Strasser F, Willey J, Bertolino M, Mathias C, Spruyt O, Fisch MJ. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol. 2004 Jan 1;22(1):185-92.|Stockler M, Vardy J, Pillai A, Warr D. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol. 2004 Aug 15;22(16):3389-94.|Mercadante S, Casuccio A, Agnello A, Serretta R, Calderone L, Barresi L. Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. J Clin Oncol. 1998 Nov;16(11):3656-61.","\tCancer|Pain|Palliative Care\tMethadone plus Acetaminophen or Placebo\tParallel Assignment\tSupportive Care\tRandomized\tDrug\tAll\t","Switching From Morphine to Oral Methadone Plus Acetaminophen in the Treatment of Cancer Pain","Interventional","Unknown status","Phase 2/Phase 3",2,50,"cancer pain","acetaminophen|methadone","NA"]
["NCT00530335",8212544,4481223,null,"NA",null,"NA",{"$nulls":3},1E-3,"t-test, 2 sided",21265936,"Takahashi M, Takita Y, Goto T, Ichikawa H, Saito K, Matsumoto H, Tanaka Y. An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder. Psychiatry Clin Neurosci. 2011 Feb;65(1):55-63. doi: 10.1111/j.1440-1819.2010.02159.x.","\tAttention Deficit Hyperactivity Disorder\tAtomoxetine\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","hyperkinesis|attention deficit disorder with hyperactivity","atomoxetine hydrochloride","Change From Endpoint to Baseline in Stroop Color Word Test"]
["NCT00530335",8212549,4481228,null,"NA",null,"NA",{"$nulls":3},1E-3,"t-test, 2 sided",21265936,"Takahashi M, Takita Y, Goto T, Ichikawa H, Saito K, Matsumoto H, Tanaka Y. An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder. Psychiatry Clin Neurosci. 2011 Feb;65(1):55-63. doi: 10.1111/j.1440-1819.2010.02159.x.","\tAttention Deficit Hyperactivity Disorder\tAtomoxetine\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","hyperkinesis|attention deficit disorder with hyperactivity","atomoxetine hydrochloride","Change From Endpoint to Baseline in Connors's Adult ADHD Rating Scale-Self Report: Screening Version - Japanese Version (CAARS-S:SV-J)"]
["NCT00533013","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28457231,"Kalter-Leibovici O, Freimark D, Freedman LS, Kaufman G, Ziv A, Murad H, Benderly M, Silverman BG, Friedman N, Cukierman-Yaffe T, Asher E, Grupper A, Goldman D, Amitai M, Matetzky S, Shani M, Silber H; Israel Heart Failure Disease Management Study (IHF-DMS) investigators. Disease management in the treatment of patients with chronic heart failure who have universal access to health care: a randomized controlled trial. BMC Med. 2017 May 1;15(1):90. doi: 10.1186/s12916-017-0855-z.","\tHeart Failure\tUsual Care|Disease Management and Tele-Monitoring\tParallel Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Comprehensive Heart Failure Disease Management Community Program","Interventional","Completed","N/A",2,1360,"heart failure","NA","NA"]
["NCT00537290","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23124321,"Erkan D, Vega J, Ramón G, Kozora E, Lockshin MD. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013 Feb;65(2):464-71. doi: 10.1002/art.37759.","\tAntiphospholipid Syndrome\tRituximab\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","syndrome|antiphospholipid syndrome","rituximab","NA"]
["NCT00539877","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","9654118|10628373|9704725|12663720","Guichard S, Chatelut E, Lochon I, Bugat R, Mahjoubi M, Canal P. Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice. Cancer Chemother Pharmacol. 1998;42(2):165-70.|Maruyama M, Nagahama T, Yuasa Y. Intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis. Anticancer Res. 1999 Sep-Oct;19(5B):4187-91.|Rosen HR, Jatzko G, Repse S, Potrc S, Neudorfer H, Sandbichler P, Zacherl J, Rabl H, Holzberger P, Lisborg P, Czeijka M. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol. 1998 Aug;16(8):2733-8.|Rothenberg ML, Liu PY, Braly PS, Wilczynski SP, Hannigan EV, Wadler S, Stuart G, Jiang C, Markman M, Alberts DS. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial. J Clin Oncol. 2003 Apr 1;21(7):1313-9.","\tStomach Neoplasms\tirinotecan\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","stomach neoplasms","irinotecan","NA"]
["NCT00542178",8210718,4479966,"Hazard Ratio (HR)",1.015,null,"NA",0.865,1.19,95,0.86,"Regression, Cox",20587587,"ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010 Jul 15;363(3):233-44. doi: 10.1056/NEJMoa1001288. Epub 2010 Jun 29. Erratum in: N Engl J Med. 2011 Jan 13;364(2):190. N Engl J Med. 2012 Dec 20;367(25):2458.","\tDiabetic Retinopathy\tHypoglycemic Agents|Standard glycemia control|Intensive BP treatment|Standard BP control|Fenofibrate|Simvastatin|Placebo\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug\tAll\t","Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)","Interventional","Completed","Phase 3",6,3472,"retinal diseases|diabetic retinopathy","hypoglycemic agents|simvastatin|fenofibrate","Cataract Extraction"]
["NCT00545064",8210363,4479804,"Mean Difference (Net)",3.2,"Standard Deviation",20.2,-0.6,7,95,0.097,"t-test, 2 sided",20668720,"Hutnik C, Neima D, Ibrahim F, Scott R, Vaillancourt J, Haine D, Sampalis JS, Bastien N, Foucart S. Tolerability and effectiveness of preservative-free dorzolamide-timolol (preservative-free COSOPT) in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2010 Jul 21;4:581-90.","\tOcular Hypertension|Open Angle Glaucoma\tdorzolamide hydrochloride (+) timolol maleate\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","hypertension|glaucoma|ocular hypertension|glaucoma, open-angle","dorzolamide|timolol","Change in Glaucoma Symptom Scale (GSS)-SYMP-6 Score"]
["NCT00546390","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22222469,"Lucchinetti E, Bestmann L, Feng J, Freidank H, Clanachan AS, Finegan BA, Zaugg M. Remote ischemic preconditioning applied during isoflurane inhalation provides no benefit to the myocardium of patients undergoing on-pump coronary artery bypass graft surgery: lack of synergy or evidence of antagonism in cardioprotection? Anesthesiology. 2012 Feb;116(2):296-310. doi: 10.1097/ALN.0b013e318242349a.","\tMyocardial Protection|Remote Ischemic Preconditioning\tBlood Pressure Cuff\tParallel Assignment\tPrevention\tRandomized\tDevice\tAll\t","Protection of the Heart With Remote Ischemic Preconditioning During Heart Surgery: A Pilot Study","Interventional","Completed","N/A",2,57,"ischemia","NA","NA"]
["NCT00549393","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23363666,"Milstone AM, Elward A, Song X, Zerr DM, Orscheln R, Speck K, Obeng D, Reich NG, Coffin SE, Perl TM; Pediatric SCRUB Trial Study Group. Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial. Lancet. 2013 Mar 30;381(9872):1099-106. doi: 10.1016/S0140-6736(12)61687-0. Epub 2013 Jan 28.","\tNosocomial Infections\t2% Chlorhexidine gluconate cloth\tCrossover Assignment\tPrevention\tRandomized\tDrug\tAll\t","Study of Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit","Interventional","Completed","Phase 2/Phase 3",2,5659,"cross infection|communicable diseases|infection","chlorhexidine|chlorhexidine gluconate","NA"]
["NCT00552760","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22963894,"Norris ER, Karen Burke, Correll JR, Zemanek KJ, Lerman J, Primelo RA, Kaufmann MW. A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder. J Affect Disord. 2013 Jan 10;144(1-2):141-7. doi: 10.1016/j.jad.2012.06.023. Epub 2012 Sep 7.","\tBipolar Disorder\tRamelteon|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder","Interventional","Completed","Phase 4",2,90,"bipolar disorder","NA","NA"]
["NCT00555776","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17960408,"Bakhshaee M, Ghasemi M, Azarpazhooh M, Khadivi E, Rezaei S, Shakeri M, Tale M. Gabapentin effectiveness on the sensation of subjective idiopathic tinnitus: a pilot study. Eur Arch Otorhinolaryngol. 2008 May;265(5):525-30. Epub 2007 Oct 25.","\tSubjective Tinnitus\tGabapentin|placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Effect of Gabapentin on Idiopathic Subjective Tinnitus","Interventional","Unknown status","Phase 2",2,70,"tinnitus","gabapentin","NA"]
["NCT00557908","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25688461|25381842|22823000|17059476","Holm E, Abshire TC, Bowen J, Álvarez MT, Bolton-Maggs P, Carcao M, Federici AB, Gill JC, Halimeh S, Kempton C, Key NS, Kouides P, Lail A, Landorph A, Leebeek F, Makris M, Mannucci P, Mauser-Bunschoten EP, Nugent D, Valentino LA, Winikoff R, Berntorp E. Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network. Blood Coagul Fibrinolysis. 2015 Jun;26(4):383-8. doi: 10.1097/MBC.0000000000000257.|Makris M, Federici AB, Mannucci PM, Bolton-Maggs PH, Yee TT, Abshire T, Berntorp E. The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease. Haemophilia. 2015 May;21(3):338-42. doi: 10.1111/hae.12571. Epub 2014 Nov 7.|Abshire TC, Federici AB, Alvárez MT, Bowen J, Carcao MD, Cox Gill J, Key NS, Kouides PA, Kurnik K, Lail AE, Leebeek FW, Makris M, Mannucci PM, Winikoff R, Berntorp E; VWD PN. Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia. 2013 Jan;19(1):76-81. doi: 10.1111/j.1365-2516.2012.02916.x. Epub 2012 Jul 23.|Berntorp E, Abshire T; von Willebrand Disease Prophylaxis Network Steering Committee. The von Willebrand disease prophylaxis network: exploring a treatment concept. J Thromb Haemost. 2006 Nov;4(11):2511-2.","\tVon Willebrand Disease\tVWF/FVIII products\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","von willebrand diseases","NA","NA"]
["NCT00564759","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16582916,"Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kühlcke K, Schilz A, Kunkel H, Naundorf S, Brinkmann A, Deichmann A, Fischer M, Ball C, Pilz I, Dunbar C, Du Y, Jenkins NA, Copeland NG, Lüthi U, Hassan M, Thrasher AJ, Hoelzer D, von Kalle C, Seger R, Grez M. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006 Apr;12(4):401-9. Epub 2006 Apr 2.","\tGranulomatous Disease, Chronic\tretroviral SF71-gp91phox transduced CD34+ cells\tNA\tNA\tNA\tDrug\tMale\t","NA","NA","NA","NA","NA","NA","granulomatous disease, chronic|granuloma","NA","NA"]
["NCT00568048","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21527587|NA|NA|NA|22614944","von Moos R, Seifert B, Simcock M, Goldinger SM, Gillessen S, Ochsenbein A, Michielin O, Cathomas R, Schläppi M, Moch H, Schraml PH, Mjhic-Probst D, Mamot C, Schönewolf N, Dummer R; Swiss Group for Clinical Cancer Research (SAKK). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol. 2012 Feb;23(2):531-6. doi: 10.1093/annonc/mdr126. Epub 2011 Apr 28.|Dummer R, Michielin O, Seifert B, et al.: First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07). [Abstract] J Clin Oncol 28 (Suppl 15): A-8521, 2010.|Fuerstenberger G, Boneberg E, Simcock M, et al.: Predictive and prognostic potential of angiogenic serum factors and circulating endothelial cells in metastatic melanoma patients receiving temozolamide plus bevacizumab (SAKK 50/07). [Abstract] J Clin Oncol 28 (Suppl 15): A-8585, 2010.|Ochsenbein AF, Schraml P, Mihic D, et al.: MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab (SAKK 50/07). [Abstract] J Clin Oncol 28 (Suppl 15): A-8558, 2010.|Schraml P, von Teichman A, Mihic-Probst D, Simcock M, Ochsenbein A, Dummer R, Michielin O, Seifert B, Schläppi M, Moch H, von Moos R. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncol Rep. 2012 Aug;28(2):654-8. doi: 10.3892/or.2012.1826. Epub 2012 May 18.","\tMelanoma (Skin)\tbevacizumab|temozolomide\tNA\tNA\tNA\tBiological|Drug\tAll\t","NA","NA","NA","NA","NA","NA","melanoma","temozolomide|bevacizumab","NA"]
["NCT00569244","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22454006,"Strowitzki T, Kirsch B, Elliesen J. Efficacy of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: an open-label, multicentre, randomised, controlled study. J Fam Plann Reprod Health Care. 2012 Apr;38(2):94-101. doi: 10.1136/jfprhc-2011-100225.","\tPrimary Dysmenorrhea\tDrug: YAZ flex (SH T00186D)|YAZ (SH T00186D)\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tFemale\t","SH T00186 in the Treatment of Primary Dysmenorrhea","Interventional","Completed","Phase 3",2,223,"dysmenorrhea","drospirenone and ethinyl estradiol combination","NA"]
["NCT00571727","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17192294,"Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE; GH Insensitivity Syndrome Collaborative Group. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab. 2007 Mar;92(3):902-10. Epub 2006 Dec 27.","\tGrowth Hormone Insensitivity Syndrome\tmecasermin\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","syndrome|laron syndrome","mecasermin","NA"]
["NCT00572936",8205935,4475809,null,"NA",null,"NA",{"$nulls":3},0.05,"Kruskal-Wallis",22332206,"Gulati V, Fan S, Zhao M, Maslonka MA, Gangahar C, Toris CB. Diurnal and nocturnal variations in aqueous humor dynamics of patients with ocular hypertension undergoing medical therapy. Arch Ophthalmol. 2012 Jun;130(6):677-84. doi: 10.1001/archophthalmol.2011.2573.","\tGlaucoma\tLatanoprost|Dorzolamide|Timolol\tCrossover Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","glaucoma","dorzolamide|timolol|latanoprost","Uvescleral Outflow"]
["NCT00575536","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26157986,"Cayce JM, Wells JD, Malphrus JD, Kao C, Thomsen S, Tulipan NB, Konrad PE, Jansen ED, Mahadevan-Jansen A. Infrared neural stimulation of human spinal nerve roots in vivo. Neurophotonics. 2015 Jan;2(1):015007. doi: 10.1117/1.NPh.2.1.015007. Epub 2015 Feb 23.","\tSpasticity\tRhizotomy for children with spasticity\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","muscle spasticity","NA","NA"]
["NCT00578318","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22984337|22354616|21512751|20564682","Breland-Noble AM, Bell CC, Burriss A, Poole HK; The AAKOMA Project Adult Advisory Board. The Significance of Strategic Community Engagement in Recruiting African American Youth & Families for Clinical Research. J Child Fam Stud. 2012 Apr 1;21(2):273-280. Epub 2011 Mar 4.|Breland-Noble AM; AAKOMA Project Adult Advisory Board. Community and treatment engagement for depressed African American youth: the AAKOMA FLOA pilot. J Clin Psychol Med Settings. 2012 Mar;19(1):41-8. doi: 10.1007/s10880-011-9281-0.|\"Breland-Noble AM, Bell CC, Burriss A; AAKOMA Project Adult Advisory Board. \"\"Mama just won't accept this\"\": adult perspectives on engaging depressed African American teens in clinical research and treatment. J Clin Psychol Med Settings. 2011 Sep;18(3):225-34. doi: 10.1007/s10880-011-9235-6.\"|Breland-Noble AM, Burriss A, Poole HK; AAKOMA PROJECT Adult Advisory Board. Engaging depressed African American adolescents in treatment: lessons from the AAKOMA PROJECT. J Clin Psychol. 2010 Aug;66(8):868-79. doi: 10.1002/jclp.20708.","\tDepression\tMotivational Interviewing Active\tParallel Assignment\tTreatment\tRandomized\tBehavioral\tAll\t","African American Knowledge Optimized for Mindfully Healthy Adolescents","Interventional","Completed","N/A",2,16,"depression","NA","NA"]
["NCT00580814","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Volkow, N.d., Wand, G., Kollins., Wigal, T., Newcorn, J., Telang, F., Fowler, J., Solanto, M.V., Logan, J., Ma, Y., Pradham. K., Wong, C., Zhu, W. & Swanson, J.M. Dopamine Reward Pathway Disrupted in Patients with ADHD: Therapeutic Implications, Journal of American Medical Association.","\tAttention Deficit Hyperactivity Disorder\tMethylphenidate\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","attention deficit disorder with hyperactivity","methylphenidate","NA"]
["NCT00585208","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20861739,"McElroy SL, Winstanley EL, Martens B, Patel NC, Mori N, Moeller D, McCoy J, Keck PE Jr. A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance. Int Clin Psychopharmacol. 2011 Jan;26(1):48-53. doi: 10.1097/YIC.0b013e3283400d35.","\tBipolar Disorder|Insomnia\tRamelteon|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Add-On Ramelteon in Bipolar I Disorder With Clinically Significant Sleep Disturbance","Interventional","Terminated","Phase 3",2,21,"bipolar disorder|dyssomnias|disease|sleep initiation and maintenance disorders|parasomnias","NA","NA"]
["NCT00587171","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23563444,"Lyon DW, Hopkins K, Chu RH, Tamkins SM, Cotter SA, Melia BM, Holmes JM, Repka MX, Wheeler DT, Sala NA, Dumas J, Silbert DI; Pediatric Eye Disease Investigator Group. Feasibility of a clinical trial of vision therapy for treatment of amblyopia. Optom Vis Sci. 2013 May;90(5):475-81. doi: 10.1097/OPX.0b013e31828def04.","\tAmblyopia\tPatching|Near activities|Active vision therapy|Control vision therapy\tParallel Assignment\tTreatment\tRandomized\tDevice|Procedure|Procedure|Procedure\tAll\t","Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia","Interventional","Terminated","Phase 3",2,19,"amblyopia","NA","NA"]
["NCT00612079","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21890590,"Holstein DH, Csomor PA, Geyer MA, Huber T, Brugger N, Studerus E, Vollenweider FX. The effects of sertindole on sensory gating, sensorimotor gating, and cognition in healthy volunteers. J Psychopharmacol. 2011 Dec;25(12):1600-13. doi: 10.1177/0269881111415734. Epub 2011 Sep 2.","\tHealthy\tSertindole|Placebo\tCrossover Assignment\tBasic Science\tRandomized\tDrug|Drug\tMale\t","The Effect of Sertindole on Sensory Gating and Cognition in Healthy Volunteers","Interventional","Completed","N/A",2,30,"NA","sertindole","NA"]
["NCT00616421","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20943209,"Halperin SA, Gupta A, Jeanfreau R, Klein NP, Reisinger K, Walter E, Bedell L, Gill C, Dull PM. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. Vaccine. 2010 Nov 23;28(50):7865-72. doi: 10.1016/j.vaccine.2010.09.092. Epub 2010 Oct 29.","\tMeningococcal Infections\tMenACWY-CRM|MenACWY-CRM|Licensed meningococcal ACWY vaccine\tParallel Assignment\tPrevention\tRandomized\tBiological|Biological|Biological\tAll\t","Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children","Interventional","Completed","Phase 3",3,2907,"meningitis|meningococcal infections","NA","NA"]
["NCT00620373",8199113,4472840,null,"NA",null,"NA",{"$nulls":3},0.5,"McNemar",21045179,"Rhodes DJ, Hruska CB, Phillips SW, Whaley DH, O'Connor MK. Dedicated dual-head gamma imaging for breast cancer screening in women with mammographically dense breasts. Radiology. 2011 Jan;258(1):106-18. doi: 10.1148/radiol.10100625. Epub 2010 Nov 2.","\tBreast Cancer\tMolecular Breast Imaging|Conventional Mammography|Technetium (99mTc) sestamibi\tNA\tNA\tNA\tDevice|Device|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","technetium tc 99m sestamibi","Sensitivity"]
["NCT00623883","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17119054|12917207","Glebov OK, Rodriguez LM, Soballe P, DeNobile J, Cliatt J, Nakahara K, Kirsch IR. Gene expression patterns distinguish colonoscopically isolated human aberrant crypt foci from normal colonic mucosa. Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2253-62.|Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, DeNobile J, Soballe P, Simon R, Wright G, Lynch P, Patterson S, Lynch H, Gallinger S, Buchbinder A, Gordon G, Hawk E, Kirsch IR. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):755-62.","\tColorectal Neoplasms\tSurgical removal of ACF|Colonoscopic evaluation only\tParallel Assignment\tPrevention\tRandomized\tProcedure|Procedure\tAll\t","Colonoscopic Removal of Aberrant Crypt Foci: a Prospective, Randomized, Blinded Trial","Interventional","Completed","N/A",2,98,"aberrant crypt foci|colorectal neoplasms","NA","NA"]
["NCT00626626","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22080968,"Karch J, Zhu J, Ehmann WC, Claxton D. Clofarabine and CY do not yield reliable engraftment of hematopoietic stem cells. Bone Marrow Transplant. 2012 Aug;47(8):1134-5. doi: 10.1038/bmt.2011.224. Epub 2011 Nov 14.","\tChronic Myelogenous Leukemia|Hodgkin's Lymphoma|Leukemia|Lymphoma|Multiple Myeloma|Myelodysplastic Syndrome\tClofar, Cyclophos, Alemtuzumab|Clofar, Cyclophos,Alemtuzumab(Ph II)\tNA\tNA\tNA\tDrug|Drug\tAll\t","Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation","Interventional","Terminated","Phase 1/Phase 2",2,8,"leukemia, myelogenous, chronic, bcr-abl positive|multiple myeloma|preleukemia|leukemia|myelodysplastic syndromes|leukemia, myeloid|lymphoma","clofarabine|alemtuzumab|cyclophosphamide","NA"]
["NCT00628927","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22771145,"Winhusen TM, Somoza EC, Lewis DF, Kropp FB, Horigian VE, Adinoff B. Frontal systems deficits in stimulant-dependent patients: evidence of pre-illness dysfunction and relationship to treatment response. Drug Alcohol Depend. 2013 Jan 1;127(1-3):94-100. doi: 10.1016/j.drugalcdep.2012.06.017. Epub 2012 Jul 6.","\tStimulant Dependence\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT00630214","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",8156110,"Moore FD Jr. Oral calcium supplements to enhance early hospital discharge after bilateral surgical treatment of the thyroid gland or exploration of the parathyroid glands. J Am Coll Surg. 1994 Jan;178(1):11-6.","\tHypocalcemia\tOral calcium plus vitamin D|Oral calcium alone\tParallel Assignment\tPrevention\tRandomized\tDietary Supplement|Dietary Supplement\tAll\t","Prevention of Hypocalcemia in Patients Undergoing Total Thyroidectomy Plus Central Neck Dissection","Interventional","Completed","Phase 2",4,200,"hypocalcemia","vitamins|calcium carbonate|calcium, dietary|vitamin d|ergocalciferols|calcium","NA"]
["NCT00634426","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22682804|24594004|25247954","Fitzpatrick D, Grabarz D, Wang L, Bezjak A, Fehlings MG, Fosker C, Rampersaud R, Wong RK. How effective is a virtual consultation process in facilitating multidisciplinary decision-making for malignant epidural spinal cord compression? Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):e167-72. doi: 10.1016/j.ijrobp.2012.03.057. Epub 2012 Jun 8.|Fisher CG, Schouten R, Versteeg AL, Boriani S, Varga PP, Rhines LD, Kawahara N, Fourney D, Weir L, Reynolds JJ, Sahgal A, Fehlings MG, Gokaslan ZL. Reliability of the Spinal Instability Neoplastic Score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases. Radiat Oncol. 2014 Mar 4;9:69. doi: 10.1186/1748-717X-9-69.|Fisher CG, Versteeg AL, Schouten R, Boriani S, Varga PP, Rhines LD, Heran MK, Kawahara N, Fourney D, Reynolds JJ, Fehlings MG, Gokaslan ZL. Reliability of the spinal instability neoplastic scale among radiologists: an assessment of instability secondary to spinal metastases. AJR Am J Roentgenol. 2014 Oct;203(4):869-74. doi: 10.2214/AJR.13.12269.","\tMetastatic Epidural Spinal Cord Compression\tSurgical excision of the metastatic process|Radiotherapy of the metastatic spine process\tNA\tNA\tNA\tProcedure|Radiation\tAll\t","NA","NA","NA","NA","NA","NA","spinal cord compression","NA","NA"]
["NCT00637546","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19921145|19900232|19138520|18579384","Allet L, Armand S, de Bie RA, Golay A, Monnin D, Aminian K, Staal JB, de Bruin ED. The gait and balance of patients with diabetes can be improved: a randomised controlled trial. Diabetologia. 2010 Mar;53(3):458-66. doi: 10.1007/s00125-009-1592-4. Epub 2009 Nov 17.|Allet L, Armand S, de Bie RA, Golay A, Pataky Z, Aminian K, de Bruin ED. Clinical factors associated with gait alterations in diabetic patients. Diabet Med. 2009 Oct;26(10):1003-9. doi: 10.1111/j.1464-5491.2009.02811.x.|Allet L, Armand S, de Bie RA, Pataky Z, Aminian K, Herrmann FR, de Bruin ED. Gait alterations of diabetic patients while walking on different surfaces. Gait Posture. 2009 Apr;29(3):488-93. doi: 10.1016/j.gaitpost.2008.11.012. Epub 2009 Jan 9. Erratum in: Gait Posture. 2009 Oct;30(3):394.|Allet L, Armand S, de Bie RA, Golay A, Monnin D, Aminian K, de Bruin ED. Reliability of diabetic patients' gait parameters in a challenging environment. Gait Posture. 2008 Nov;28(4):680-6. doi: 10.1016/j.gaitpost.2008.05.006. Epub 2008 Jun 25.","\tDiabetes Type 2\tPhysiotherapy\tParallel Assignment\tTreatment\tRandomized\tOther\tAll\t","NA","NA","NA","NA","NA","NA","diabetes mellitus, type 2","NA","NA"]
["NCT00640445","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24913102,"Sayer NA, Orazem RJ, Noorbaloochi S, Gravely A, Frazier P, Carlson KF, Schnurr PP, Oleson H. Iraq and Afghanistan War Veterans with Reintegration Problems: Differences by Veterans Affairs Healthcare User Status. Adm Policy Ment Health. 2015 Jul;42(4):493-503. doi: 10.1007/s10488-014-0564-2.","\tPosttraumatic Stress Disorder\tExpressive Writing|Control Writing\tNA\tNA\tNA\tBehavioral|Behavioral\tAll\t","Military to Civilian: Trial of an Intervention to Promote Postdeployment Reintegration","Interventional","Completed","Phase 2/Phase 3",3,1292,"stress disorders, post-traumatic","NA","NA"]
["NCT00641771","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21448918,"Shapses SA, Kendler DL, Robson R, Hansen KE, Sherrell RM, Field MP, Woolf E, Berd Y, Mantz AM, Santora AC 2nd. Effect of alendronate and vitamin D₃ on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women. J Bone Miner Res. 2011 Aug;26(8):1836-44. doi: 10.1002/jbmr.395.","\tOsteoporosis\talendronate sodium (+) cholecalciferol|Comparator: Placebo (unspecified)\tNA\tNA\tNA\tDrug|Drug\tFemale\t","4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)","Interventional","Completed","Phase 1",2,56,"osteoporosis","cholecalciferol|alendronate","NA"]
["NCT00652145","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24793028,"Osterman MT, Aberra FN, Cross R, Liakos S, McCabe R, Shafran I, Wolf D, Hardi R, Nessel L, Brensinger C, Gilroy E, Lewis JD; DEAR Investigators. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2014 Nov;12(11):1887-93.e3. doi: 10.1016/j.cgh.2014.03.035. Epub 2014 Apr 30.","\tUlcerative Colitis\tmesalamine\tParallel Assignment\tPrevention\tRandomized\tDrug\tAll\t","Dose Escalation and Remission (DEAR)","Interventional","Completed","Phase 4",2,119,"ulcer|colitis|colitis, ulcerative","mesalamine","NA"]
["NCT00653796","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17407633,"Blagden MD, Chipperfield R. Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Curr Med Res Opin. 2007 Apr;23(4):767-75.","\tAtherosclerosis|Hypercholesterolemia\tEzetimibe + Atorvastatin|Atorvastatin\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)","Interventional","Completed","Phase 4",2,148,"atherosclerosis|hypercholesterolemia","ezetimibe|atorvastatin","NA"]
["NCT00656747","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21760724,"Wilson R, Anzueto A, Miravitlles M, Arvis P, Faragó G, Haverstock D, Trajanovic M, Sethi S. A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology. Int J Chron Obstruct Pulmon Dis. 2011;6:373-83. doi: 10.2147/COPD.S21071. Epub 2011 Jun 29.","\tChronic Bronchitis\tAvelox (Moxifloxacin, BAY12-8039)|Amoxicillin clavulanic acid\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis","Interventional","Completed","Phase 4",2,1372,"acute disease|bronchitis|bronchitis, chronic","norgestimate, ethinyl estradiol drug combination|amoxicillin|amoxicillin-potassium clavulanate combination|clavulanic acid|moxifloxacin|clavulanic acids","NA"]
["NCT00659906","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22996743,"Winters-Stone KM, Dobek J, Nail LM, Bennett JA, Leo MC, Torgrimson-Ojerio B, Luoh SW, Schwartz A. Impact + resistance training improves bone health and body composition in prematurely menopausal breast cancer survivors: a randomized controlled trial. Osteoporos Int. 2013 May;24(5):1637-46. doi: 10.1007/s00198-012-2143-2. Epub 2012 Sep 21.","\tBreast Neoplasm|Osteoporosis, Postmenopausal\tResistance Exercise|Flexibility Training\tParallel Assignment\tSupportive Care\tRandomized\tBehavioral|Behavioral\tFemale\t","Optimizing Body Composition & Health After Breast Cancer","Interventional","Completed","N/A",2,71,"osteoporosis|breast neoplasms|osteoporosis, postmenopausal","NA","NA"]
["NCT00661726",8193774,4470592,null,"NA",null,"NA",{"$nulls":3},0.045,"Regression, Linear",21700776,"Olivieri NF, Saunthararajah Y, Thayalasuthan V, Kwiatkowski J, Ware RE, Kuypers FA, Kim HY, Trachtenberg FL, Vichinsky EP; Thalassemia Clinical Research Network. A pilot study of subcutaneous decitabine in β-thalassemia intermedia. Blood. 2011 Sep 8;118(10):2708-11. doi: 10.1182/blood-2011-03-341909. Epub 2011 Jun 23.","\tThalassemia\tDecitabine (USAN, INN)\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","beta-thalassemia|thalassemia","azacitidine|decitabine","Change in Indirect Bilirubin From Baseline to Nadir (the Follow-up Time Point With the Lowest Value)"]
["NCT00666874","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12684358,"Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003 Apr 9;289(14):1799-804.","\tObesity\tlifestyle changes|Control - general information\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral\tFemale\t","Effect of Weight Loss and Lifestyle Changes on Vascular Inflammatory Markers in Obese Women","Interventional","Completed","N/A",2,120,"weight loss","NA","NA"]
["NCT00670488",8192363,4469578,"GMR",0.133,null,"NA",0.051,0.347,95,"NA",null,22025163,"Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol. 2011 Dec 10;29(35):4688-95. doi: 10.1200/JCO.2011.35.5263. Epub 2011 Oct 24.","\tCancer|Locally Advanced Tumors|Metastatic Solid Tumors|Neoplasms\tMK-2206\tNA\tNA\tNA\tDrug\tAll\t","Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)","Interventional","Completed","Phase 1",10,104,"neoplasms","NA","Phosphorylated Protein Kinase B (pAkt) Level on Cycle 1 Day 15 (C1D15) After Treatment With MK-2206 at the Maximum Tolerated Dose (MTD)"]
["NCT00670800",8192337,4469571,null,"NA",null,"NA",{"$nulls":3},0.717,"t-test, 2 sided",21486668,"Berent-Spillson A, Love T, Pop-Busui R, Sowers M, Persad CC, Pennington KP, Eyvazaddeh AD, Padmanabhan V, Zubieta JK, Smith YR. Insulin resistance influences central opioid activity in polycystic ovary syndrome. Fertil Steril. 2011 Jun 30;95(8):2494-8. doi: 10.1016/j.fertnstert.2011.03.031. Epub 2011 Apr 12.","\tPolycystic Ovary Syndrome\tMetformin\tNA\tNA\tNA\tDrug\tFemale\t","Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome","Interventional","Completed","N/A",2,14,"polycystic ovary syndrome|syndrome","metformin","Mu-opioid Binding Potential Measured in Right Nucleus Accumbens"]
["NCT00671229","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18036642,"Levesque MC, Hauswirth DW, Mervin-Blake S, Fernandez CA, Patch KB, Alexander KM, Allgood S, McNair PD, Allen AS, Sundy JS. Determinants of exhaled nitric oxide levels in healthy, nonsmoking African American adults. J Allergy Clin Immunol. 2008 Feb;121(2):396-402.e3. Epub 2007 Nov 26.","\tAsthma|Healthy\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","asthma","NA","NA"]
["NCT00673400",8192032,4469449,null,"NA",null,"NA",{"$nulls":3},0.01,"Wilcoxon (Mann-Whitney)",20485001,"Wolff K, Marti L, Beutner U, Steffen T, Lange J, Hetzer FH. Functional outcome and quality of life after stapled transanal rectal resection for obstructed defecation syndrome. Dis Colon Rectum. 2010 Jun;53(6):881-8. doi: 10.1007/DCR.0b013e3181cdb445.","\tIntussusception|Obstructed Defecation Syndrome|Rectocele|SNS\tStapled transanal rectum resection\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","intussusception|rectocele","NA","SF36 Component Summary Scores"]
["NCT00676325","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18351281,"Riccetto C, Miyaoka R, de Fraga R, Barbosa R, Dambros M, Teixeira A, Palma P. Impact of the structure of polypropylene meshes in local tissue reaction: in vivo stereological study. Int Urogynecol J Pelvic Floor Dysfunct. 2008 Aug;19(8):1117-23. doi: 10.1007/s00192-008-0582-2. Epub 2008 Mar 20.","\tCystocele|Hernia\tSurgical treatment of Anterior Vaginal Prolapse|NAZCA TC™ POP REPAIR SYSTEM ,promedon® , argentina.|surgical treatment for anterior vaginal wall prolapse\tParallel Assignment\tTreatment\tRandomized\tProcedure|Device|Procedure\tFemale\t","Surgical Treatment To Greater Anterior Vaginal Prolapse","Interventional","Unknown status","Phase 4",2,70,"cystocele|prolapse|uterine prolapse","NA","NA"]
["NCT00678834","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22298568,"Patel V, Rink C, Gordillo GM, Khanna S, Gnyawali U, Roy S, Shneker B, Ganesh K, Phillips G, More JL, Sarkar A, Kirkpatrick R, Elkhammas EA, Klatte E, Miller M, Firstenberg MS, Chiocca EA, Nesaretnam K, Sen CK. Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patients. J Nutr. 2012 Mar;142(3):513-9. doi: 10.3945/jn.111.151902. Epub 2012 Feb 1.","\tEnd Stage Cardiac Failure|End Stage Liver Disease|Healthy Subjects|Morbid Obesity|Pulmonary Failure|Recalcitrant Epilepsy Requiring Surgery\tTo surgery patients, Tocopherol capsules.|Tocotrienol to healthy subjects.|To surgery patients, Tocotrienol capsules.\tNA\tNA\tNA\tDietary Supplement|Dietary Supplement|Dietary Supplement\tAll\t","Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol","Interventional","Completed","Early Phase 1",3,80,"heart failure|obesity, morbid|liver diseases|end stage liver disease","tocotrienols|tocopherols|vitamin e|alpha-tocopherol","NA"]
["NCT00684411","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25012943,"Jacobsen E, Pozdnyakova O, Redd R, Fisher DC, Dorfman DM, Dal Cin P, LaCasce A, Armand P, Hochberg E, Cote G, Shahsafaei A, Neuberg D, Brown JR, Freedman AS. Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma. Leuk Lymphoma. 2015 Apr;56(4):993-8. doi: 10.3109/10428194.2014.941835. Epub 2014 Aug 20.","\tT Cell Non-Hodgkin Lymphoma\tImatinib mesylate\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma, t-cell|lymphoma, non-hodgkin|lymphoma","imatinib mesylate","NA"]
["NCT00684515","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20947374,"Shinohara Y, Goto S, Doi M, Jensen P. Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke. J Stroke Cerebrovasc Dis. 2012 May;21(4):318-24. doi: 10.1016/j.jstrokecerebrovasdis.2010.09.005. Epub 2010 Oct 14.","\tCerebral Infarction\tVorapaxar 2.5 mg|Vorapaxar 1 mg|Placebo|Aspirin 75-150 mg\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug\tAll\t","Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)","Interventional","Completed","Phase 2",3,90,"infarction|cerebral infarction","vorapaxar|aspirin","NA"]
["NCT00691756","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19028052,"Lemaire SA, Jones MM, Conklin LD, Carter SA, Criddell MD, Wang XL, Raskin SA, Coselli JS. Randomized comparison of cold blood and cold crystalloid renal perfusion for renal protection during thoracoabdominal aortic aneurysm repair. J Vasc Surg. 2009 Jan;49(1):11-9; discussion 19. doi: 10.1016/j.jvs.2008.08.048. Epub 2008 Nov 22.","\tRenal Failure\tCold blood renal perfusion|Cold crystalloid renal perfusion\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","A Comparison of Renal Perfusion in Thoracoabdominal Aortic Aneurysm (TAAA) Repair","Interventional","Completed","N/A",2,172,"aneurysm|aortic aneurysm|renal insufficiency|aortic aneurysm, thoracic","NA","NA"]
["NCT00694304","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22978748,"Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin. 2012 Oct;28(10):1717-24. doi: 10.1185/03007995.2012.725035. Epub 2012 Sep 17.","\tMajor Depressive Disorder\tVortioxetine (Lu AA21004)\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","depressive disorder, major|disease|depression|depressive disorder","vortioxetine","NA"]
["NCT00697151","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12045168|15232117|13678932","Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP; PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation. 2002 Jun 4;105(22):2625-31.|Homma S, DiTullio MR, Sacco RL, Sciacca RR, Mohr JP; PICSS Investigators. Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. Stroke. 2004 Sep;35(9):2145-9. Epub 2004 Jul 1.|Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Atrial anatomy in non-cardioembolic stroke patients: effect of medical therapy. J Am Coll Cardiol. 2003 Sep 17;42(6):1066-72.","\tIschemic Stroke|Patent Foramen Ovale\tWarfarin|Aspirin\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug\tAll\t","Patent Foramen Ovale in Cryptogenic Stroke Study","Interventional","Completed","Phase 4",2,630,"foramen ovale, patent|stroke","warfarin|aspirin","NA"]
["NCT00700947","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23580745|19329766|17543250","Pu M, Gao Z, Pu DK, Davidson WR Jr. Effects of early, late, and long-term nonselective β-blockade on left ventricular remodeling, function, and survival in chronic organic mitral regurgitation. Circ Heart Fail. 2013 Jul;6(4):756-62. doi: 10.1161/CIRCHEARTFAILURE.112.000196. Epub 2013 Apr 11.|Pu M, Gao Z, Zhang X, Liao D, Pu DK, Brennan T, Davidson WR Jr. Impact of mitral regurgitation on left ventricular anatomic and molecular remodeling and systolic function: implication for outcome. Am J Physiol Heart Circ Physiol. 2009 Jun;296(6):H1727-32. doi: 10.1152/ajpheart.00882.2008. Epub 2009 Mar 27.|Pu M. The frequency, impact, and management of mitral regurgitation in patients with heart failure. Curr Cardiol Rep. 2006 May;8(3):226-31. Review.","\tHeart Disease|Heart Valve Disease|Mitral Regurgitation|Mitral Valve Insufficiency\tBeta-blocker therapy (TOPROL-XL® )\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Using Beta Blockers to Treat Mitral Regurgitation","Interventional","Terminated","Phase 1",3,27,"heart valve diseases|mitral valve insufficiency|heart diseases","metoprolol|adrenergic beta-antagonists","NA"]
["NCT00703508",8187864,4467141,null,"NA",null,"NA",{"$nulls":3},0.118,"Regression, Linear","NA","Cheang KI, Bhavi Modi, Maria Shulleeta, William S. Evans, Lubna Pal, Jerome F. Strauss and John E. Nestler: Genetic Polymorphisms and Ovulatory Responsiveness to Metformin in Women with Polycystic Ovary Syndrome. Endo Reviews 36 (2): Supplement THR-109, Apr. 2015.","\tPolycystic Ovary Syndrome\tMetformin 500 mg tablet\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","polycystic ovary syndrome","metformin","Determine in Which Genotype(s) Frequency of Ovulation Correlates With Improvement in Reduction in Total Testosterone and Insulin Sensitivity as Measured by the Matsuda Index."]
["NCT00706394","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19679425,"Jordan WD Jr, Moore WM Jr, Melton JG, Brown OW, Carpenter JP; Endologix Investigators. Secure fixation following EVAR with the Powerlink XL System in wide aortic necks: results of a prospective, multicenter trial. J Vasc Surg. 2009 Nov;50(5):979-86. doi: 10.1016/j.jvs.2009.05.057. Epub 2009 Aug 12.","\tAbdominal Aortic Aneurysm\tEndologix Powerlink 34 mm stent graft cuff\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","aortic aneurysm, abdominal|aneurysm|aortic aneurysm","NA","NA"]
["NCT00709280","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22610452,"Rosenfeld M, Ratjen F, Brumback L, Daniel S, Rowbotham R, McNamara S, Johnson R, Kronmal R, Davis SD; ISIS Study Group. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA. 2012 Jun 6;307(21):2269-77. doi: 10.1001/jama.2012.5214.","\tCystic Fibrosis\t7% Hypertonic Saline (HS)|0.9% Isotonic Saline (IS)\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Infant Study of Inhaled Saline in Cystic Fibrosis","Interventional","Completed","N/A",2,321,"cystic fibrosis|fibrosis","NA","NA"]
["NCT00710593",8186545,4466304,"Overall aquistion rate",3.6,null,"NA",null,null,95,1,"Fisher Exact","22525109|22820809|23667266","Kahn JA, Xu J, Zimet GD, Liu N, Gonin R, Dillard ME, Squires K; Adolescent Trials Network for HIV/AIDS Interventions. Risk perceptions after human papillomavirus vaccination in HIV-infected adolescents and young adult women. J Adolesc Health. 2012 May;50(5):464-70. doi: 10.1016/j.jadohealth.2011.09.005. Epub 2011 Nov 4.|Kahn JA, Burk RD, Squires KE, Kapogiannis BG, Rudy B, Xu J, Gonin R, Liu N, Worrell C, Wilson CM. Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination. J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):390-9. doi: 10.1097/QAI.0b013e3182676fe3.|Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, Wilson CM, Worrell C, Squires KE. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis. 2013 Sep;57(5):735-44. doi: 10.1093/cid/cit319. Epub 2013 May 10.","\tHIV Infection\tHPV vaccine for strains -6, -11, -16, and -18\tNA\tNA\tNA\tBiological\tFemale\t","Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women","Interventional","Completed","Phase 2",2,99,"hiv infections","NA","Acquisition of HPV-11 DNA by Study Group and Study Visit (Week 48)."]
["NCT00712387","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12368674|15026925|17512301","Seymour NE, Gallagher AG, Roman SA, O'Brien MK, Bansal VK, Andersen DK, Satava RM. Virtual reality training improves operating room performance: results of a randomized, double-blinded study. Ann Surg. 2002 Oct;236(4):458-63; discussion 463-4.|Gallagher AG, Lederman AB, McGlade K, Satava RM, Smith CD. Discriminative validity of the Minimally Invasive Surgical Trainer in Virtual Reality (MIST-VR) using criteria levels based on expert performance. Surg Endosc. 2004 Apr;18(4):660-5. Epub 2004 Mar 19.|Ahlberg G, Enochsson L, Gallagher AG, Hedman L, Hogman C, McClusky DA 3rd, Ramel S, Smith CD, Arvidsson D. Proficiency-based virtual reality training significantly reduces the error rate for residents during their first 10 laparoscopic cholecystectomies. Am J Surg. 2007 Jun;193(6):797-804.","\tComputer Simulation|Education|Training\tLapSim simulator\tNA\tNA\tNA\tBehavioral\tAll\t","Trial of Proficiency- Based Simulation Training for General Surgical Trainees","Interventional","Unknown status","N/A",2,24,"NA","NA","NA"]
["NCT00716482",8185663,4465942,"median elasticity ratio sensitivity",0.983,null,"NA",null,null,95,0.083,null,"22210408|22282182","Cosgrove DO, Berg WA, Doré CJ, Skyba DM, Henry JP, Gay J, Cohen-Bacrie C; BE1 Study Group. Shear wave elastography for breast masses is highly reproducible. Eur Radiol. 2012 May;22(5):1023-32. doi: 10.1007/s00330-011-2340-y. Epub 2011 Dec 31.|Berg WA, Cosgrove DO, Doré CJ, Schäfer FK, Svensson WE, Hooley RJ, Ohlinger R, Mendelson EB, Balu-Maestro C, Locatelli M, Tourasse C, Cavanaugh BC, Juhan V, Stavros AT, Tardivon A, Gay J, Henry JP, Cohen-Bacrie C; BE1 Investigators. Shear-wave elastography improves the specificity of breast US: the BE1 multinational study of 939 masses. Radiology. 2012 Feb;262(2):435-49. doi: 10.1148/radiol.11110640.","\tBreast Neoplasms\tNA\tNA\tNA\tNA\tNA\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","NA","Estimates of Effect of Selectively Upgrading BIRADS Category 3 and Downgrading BIRADS 4a Masses Based on SWE Features. Overall Specificity and Sensitivity of BI-RADS Score Using Conventional B-mode Ultrasound vs. B-mode + Certain SWE Characteristics"]
["NCT00719251","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Kawalec, JS. Pfennigwerth, TC. Hetherington, VJ. Logan, JS. A review of lasers in healing diabetic ulcers. The foot. 14:68-71, 2004.","\tDiabetic Foot Ulcer\tHigh voltage pulsed current|Low level laser|Standard nursing care\tParallel Assignment\tTreatment\tRandomized\tDevice|Device|Other\tAll\t","Effects of High Voltage Pulsed Current (HVPC) and Low Level Laser Therapy (LLLT) on Wound Healing in Diabetic Ulcers","Interventional","Completed","N/A",3,28,"foot ulcer|diabetic foot|ulcer","NA","NA"]
["NCT00721799",8184795,4465572,"Hazard Ratio (HR)",0.81,null,"NA",{"$nulls":3},0.67,"Regression, Cox","19525472|20447554|20439512","Menda Y, Boles Ponto LL, Dornfeld KJ, Tewson TJ, Watkins GL, Schultz MK, Sunderland JJ, Graham MM, Buatti JM. Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. J Nucl Med. 2009 Jul;50(7):1028-35. doi: 10.2967/jnumed.108.058495. Epub 2009 Jun 12.|Menda Y, Ponto LL, Dornfeld KJ, Tewson TJ, Watkins GL, Gupta AK, Anderson C, McGuire S, Schultz MK, Sunderland JJ, Graham MM, Buatti JM. Investigation of the pharmacokinetics of 3'-deoxy-3'-[18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer. Nucl Med Biol. 2010 May;37(4):433-8. doi: 10.1016/j.nucmedbio.2010.02.005.|Juweid ME, Thomas D, Menda Y, Tewson T, Graham MM, Herrmann K, Buck AK, Fayad L. PET/CT with 18F-FLT is unlikely to cause significant hepatorenal or hematologic toxicity. J Nucl Med. 2010 May;51(5):824-5. doi: 10.2967/jnumed.110.075945.","\tHead and Neck Neoplasms|Laryngeal Neoplasms|Mouth Neoplasms|Oropharyngeal Neoplasms\t18F-Fluorothymidine PET scan\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","mouth neoplasms|laryngeal neoplasms|head and neck neoplasms|oropharyngeal neoplasms|neoplasms","NA","Efficacy of FLT Flux (K-FLT) Mid-therapy in Predicting Overall Survival (OS)."]
["NCT00721799",8184797,4465575,"C-statistic",0.61,null,"NA",{"$nulls":3},0.35,"Regression, Cox","19525472|20447554|20439512","Menda Y, Boles Ponto LL, Dornfeld KJ, Tewson TJ, Watkins GL, Schultz MK, Sunderland JJ, Graham MM, Buatti JM. Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. J Nucl Med. 2009 Jul;50(7):1028-35. doi: 10.2967/jnumed.108.058495. Epub 2009 Jun 12.|Menda Y, Ponto LL, Dornfeld KJ, Tewson TJ, Watkins GL, Gupta AK, Anderson C, McGuire S, Schultz MK, Sunderland JJ, Graham MM, Buatti JM. Investigation of the pharmacokinetics of 3'-deoxy-3'-[18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer. Nucl Med Biol. 2010 May;37(4):433-8. doi: 10.1016/j.nucmedbio.2010.02.005.|Juweid ME, Thomas D, Menda Y, Tewson T, Graham MM, Herrmann K, Buck AK, Fayad L. PET/CT with 18F-FLT is unlikely to cause significant hepatorenal or hematologic toxicity. J Nucl Med. 2010 May;51(5):824-5. doi: 10.2967/jnumed.110.075945.","\tHead and Neck Neoplasms|Laryngeal Neoplasms|Mouth Neoplasms|Oropharyngeal Neoplasms\t18F-Fluorothymidine PET scan\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","mouth neoplasms|laryngeal neoplasms|head and neck neoplasms|oropharyngeal neoplasms|neoplasms","NA","Efficacy of Mean Mid-therapy FLT Uptake (SUVmean) in Predicting Overall Survival (OS)"]
["NCT00721799",8184808,4465598,"Hazard Ratio (HR)",1.58,null,"NA",{"$nulls":3},0.18,"Regression, Cox","19525472|20447554|20439512","Menda Y, Boles Ponto LL, Dornfeld KJ, Tewson TJ, Watkins GL, Schultz MK, Sunderland JJ, Graham MM, Buatti JM. Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. J Nucl Med. 2009 Jul;50(7):1028-35. doi: 10.2967/jnumed.108.058495. Epub 2009 Jun 12.|Menda Y, Ponto LL, Dornfeld KJ, Tewson TJ, Watkins GL, Gupta AK, Anderson C, McGuire S, Schultz MK, Sunderland JJ, Graham MM, Buatti JM. Investigation of the pharmacokinetics of 3'-deoxy-3'-[18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer. Nucl Med Biol. 2010 May;37(4):433-8. doi: 10.1016/j.nucmedbio.2010.02.005.|Juweid ME, Thomas D, Menda Y, Tewson T, Graham MM, Herrmann K, Buck AK, Fayad L. PET/CT with 18F-FLT is unlikely to cause significant hepatorenal or hematologic toxicity. J Nucl Med. 2010 May;51(5):824-5. doi: 10.2967/jnumed.110.075945.","\tHead and Neck Neoplasms|Laryngeal Neoplasms|Mouth Neoplasms|Oropharyngeal Neoplasms\t18F-Fluorothymidine PET scan\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","mouth neoplasms|laryngeal neoplasms|head and neck neoplasms|oropharyngeal neoplasms|neoplasms","NA","Efficacy of Percent Change in Mean FLT Uptake (SUVmean) Between Scan 1 & 2 in Predicting Progression Free Survival (PFS)"]
["NCT00723073",8184704,4465537,null,"NA",null,"NA",{"$nulls":3},0.66,"Chi-squared",20435233,"Kubiak DW, Bryar JM, McDonnell AM, Delgado-Flores JO, Mui E, Baden LR, Marty FM. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin Ther. 2010 Apr;32(4):637-48. doi: 10.1016/j.clinthera.2010.04.005.","\tFebrile Neutropenia\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","neutropenia|fever|febrile neutropenia","NA","Duration of Echinocadin Therapy for Persistent Febrile Neutropenia (FN)"]
["NCT00727129","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Hedrick RE. Low-dose estradiol gel 0.1% for the treatment of vasomotor symptoms associated with menopause. Expert Review of Obstetrics & Gynecology, 3(2): Pages 155-162, Mar 2008.","\tPostmenopausal Symptoms\tDivigel\tParallel Assignment\tTreatment\tRandomized\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","NA","polyestradiol phosphate|estradiol 17 beta-cypionate|estradiol|estradiol 3-benzoate","NA"]
["NCT00729612","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26123189,"Bertino EM, Williams TM, Nana-Sinkam SP, Shilo K, Chatterjee M, Mo X, Rahmani M, Phillips GS, Villalona-Calero MA, Otterson GA. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients. Clin Lung Cancer. 2015 Nov;16(6):466-74. doi: 10.1016/j.cllc.2015.05.004. Epub 2015 May 13.","\tLung Cancer\tcarboplatin|paclitaxel albumin-stabilized nanoparticle formulation|protein expression analysis|immunoenzyme technique|immunohistochemistry staining method|laboratory biomarker analysis\tNA\tNA\tNA\tDrug|Drug|Genetic|Other|Other|Other\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms","paclitaxel|carboplatin|albumin-bound paclitaxel","NA"]
["NCT00733941","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24516645,"Hatle H, Støbakk PK, Mølmen HE, Brønstad E, Tjønna AE, Steinshamn S, Skogvoll E, Wisløff U, Ingul CB, Rognmo Ø. Effect of 24 sessions of high-intensity aerobic interval training carried out at either high or moderate frequency, a randomized trial. PLoS One. 2014 Feb 7;9(2):e88375. doi: 10.1371/journal.pone.0088375. eCollection 2014.","\tExercise Test|Healthy Subjects\tHigh frequency training|normal frequence training\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral\tAll\t","Interval Training in Young Healthy Individuals","Interventional","Completed","N/A",2,24,"NA","NA","NA"]
["NCT00736723","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Weiss M, Huber M, Nass M, Huber-Lang M, Koenig W, Schneider M. NT-proBNP and HMGB1 in surgical critically ill patients with hypovolemic or septic shock.Infection Suppl. II September 2011; 39: S116-117 5th International Congress of the German Sepsis Society, Weimar Sepsis Update Bridging The Gap, Weimar, 07. - 10.09.2011.|Weiss M, Huber M, Nass M, Huber-Lang M, Koenig W, Schneider M. NT-proBNP serum concentrations in surgical critically ill patients with non-septic and septic shock. INNOVATIVE JOURNAL OF MEDICAL AND HEALTH SCIENCE 3 (4): 177-184, 2013.","\tCritically Ill|Multiple Organ Dysfunction Syndrome|Sepsis|Shock|SIRS\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","sepsis|critical illness|toxemia|shock|multiple organ failure","NA","NA"]
["NCT00739752",8181715,4464591,"Risk Ratio (RR)",1.16,null,"NA",1.05,1.28,95,0.01,"Regression, Poisson","NA","Cox AD, Cox D, Zimet G. Promoting prevention and early detection: The impact of message framing, product function and perceived product risk. J Marketing 2006;70:79-91.","\tHepatitis B Virus\tNon-Framed-Offered|Non-Framed-Recommended|Gain-Framed-Offered|Gain-Framed-Recommended|Loss-Framed-Offered|Loss-Framed-Recommended\tNA\tNA\tNA\tBehavioral|Behavioral|Behavioral|Behavioral|Behavioral|Behavioral\tAll\t","Interventions to Increase HBV Vaccinations in Sexually Transmitted Disease (STD) Clinics","Interventional","Completed","N/A",6,1747,"hepatitis b","NA","Mean Number of Doses of HBV Vaccine Received"]
["NCT00742300","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","11056673|15119545|11254005|18292651|11319598","Rosen O, Thiel A, Massenkeil G, Hiepe F, Häupl T, Radtke H, Burmester GR, Gromnica-Ihle E, Radbruch A, Arnold R. Autologous stem-cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cells. Arthritis Res. 2000;2(4):327-36. Epub 2000 Jun 8.|Jayne D, Passweg J, Marmont A, Farge D, Zhao X, Arnold R, Hiepe F, Lisukov I, Musso M, Ou-Yang J, Marsh J, Wulffraat N, Besalduch J, Bingham SJ, Emery P, Brune M, Fassas A, Faulkner L, Ferster A, Fiehn C, Fouillard L, Geromin A, Greinix H, Rabusin M, Saccardi R, Schneider P, Zintl F, Gratwohl A, Tyndall A; European Group for Blood and Marrow Transplantation; European League Against Rheumatism Registry. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus. 2004;13(3):168-76.|Rosen O, Hiepe F, Massenkeil G, Thiel A, Arnold R. Relapse of systemic lupus erythematosus. Lancet. 2001 Mar 10;357(9258):807-8.|Thiel A, Alexander T, Schmidt CA, Przybylski GK, Kimmig S, Kohler S, Radtke H, Gromnica-Ihle E, Massenkeil G, Radbruch A, Arnold R, Hiepe F. Direct assessment of thymic reactivation after autologous stem cell transplantation. Acta Haematol. 2008;119(1):22-7. doi: 10.1159/000117824. Epub 2008 Feb 22.|Rosen O, Massenkeil G, Hiepe F, Pest S, Hauptmann S, Radtke H, Burmester G, Thiel A, Radbruch A, Heymer B, Arnold R. Cardiac death after autologous stem cell transplantation (ASCT) for treatment of systemic sclerosis (SSc): no evidence for cyclophosphamide-induced cardiomyopathy. Bone Marrow Transplant. 2001 Mar;27(6):657-8.","\tAutoimmune Diseases\tAutologous hematopoietic stem cell transplantation\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","autoimmune diseases","cyclophosphamide","NA"]
["NCT00745901",8180961,4464220,null,"NA",null,"NA",{"$nulls":3},0.012,"Fisher Exact",19935020,"Kaunitz AM, Burkman RT, Fisher AC, LaGuardia KD. Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial. Obstet Gynecol. 2009 Dec;114(6):1205-1212. doi: 10.1097/AOG.0b013e3181beab47.","\tContraception\tNorgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol\tParallel Assignment\tTreatment\tRandomized\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","NA","norgestimate|drospirenone|estradiol 17 beta-cypionate|ethinyl estradiol|estradiol 3-benzoate|polyestradiol phosphate|estradiol|drospirenone and ethinyl estradiol combination","Number of Participants With Breakthrough Bleeding/Spotting Cycle 2"]
["NCT00746447","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21138455,"Kruis W, Jonaitis L, Pokrotnieks J, Mikhailova TL, Horynski M, Bátovský M, Lozynsky YS, Zakharash Y, Rácz I, Kull K, Vcev A, Faszczyk M, Dilger K, Greinwald R, Mueller R; International Salofalk OD Study Group. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther. 2011 Feb;33(3):313-22. doi: 10.1111/j.1365-2036.2010.04537.x. Epub 2010 Dec 8.","\tColitis, Ulcerative|Recurrence\tmesalamine granules|mesalamine granules|mesalamine granules\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug|Drug\tAll\t","Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)","Interventional","Completed","Phase 3",3,648,"recurrence|ulcer|colitis|colitis, ulcerative","mesalamine","NA"]
["NCT00751270","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21844505,"Chiocca EA, Aguilar LK, Bell SD, Kaur B, Hardcastle J, Cavaliere R, McGregor J, Lo S, Ray-Chaudhuri A, Chakravarti A, Grecula J, Newton H, Harris KS, Grossman RG, Trask TW, Baskin DS, Monterroso C, Manzanera AG, Aguilar-Cordova E, New PZ. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J Clin Oncol. 2011 Sep 20;29(27):3611-9. doi: 10.1200/JCO.2011.35.5222. Epub 2011 Aug 15.","\tAnaplastic Astrocytoma|Glioblastoma Multiforme|Malignant Glioma\tAdV-tk|Valacyclovir\tNA\tNA\tNA\tBiological|Drug\tAll\t","Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas","Interventional","Completed","Phase 1",2,15,"glioblastoma|astrocytoma|glioma","valacyclovir","NA"]
["NCT00753324","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23324656,"Gartland MG, Chintu NT, Li MS, Lembalemba MK, Mulenga SN, Bweupe M, Musonda P, Stringer EM, Stringer JS, Chi BH. Field effectiveness of combination antiretroviral prophylaxis for the prevention of mother-to-child HIV transmission in rural Zambia. AIDS. 2013 May 15;27(8):1253-62. doi: 10.1097/QAD.0b013e32835e3937.","\tHIV Infections\tRoutine three-drug antiretroviral prophylaxis\tParallel Assignment\tPrevention\tRandomized\tDrug\tFemale\t","Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia","Interventional","Completed","Phase 4",2,284,"hiv infections","anti-retroviral agents","NA"]
["NCT00759317","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22384265,"Leuchter AF, Cook IA, Hunter AM, Cai C, Horvath S. Resting-state quantitative electroencephalography reveals increased neurophysiologic connectivity in depression. PLoS One. 2012;7(2):e32508. doi: 10.1371/journal.pone.0032508. Epub 2012 Feb 24.","\tDepression\tvenlafaxine (Effexor)\tParallel Assignment\tBasic Science\tRandomized\tDrug\tAll\t","Physiologic Monitoring of Antidepressant Treatment Response","Interventional","Completed","Phase 4",2,37,"depression","venlafaxine hydrochloride","NA"]
["NCT00760526","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22210571,"Mauras N, Beck R, Xing D, Ruedy K, Buckingham B, Tansey M, White NH, Weinzimer SA, Tamborlane W, Kollman C; Diabetes Research in Children Network (DirecNet) Study Group. A randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to <10 years. Diabetes Care. 2012 Feb;35(2):204-10. doi: 10.2337/dc11-1746. Epub 2011 Dec 30.","\tDiabetes Mellitus, Type 1\tContinuous glucose monitor|Home blood glucose monitor\tParallel Assignment\tSupportive Care\tRandomized\tDevice|Device\tAll\t","Randomized Trial to Assess Efficacy and Safety of Continuous Glucose Monitoring in Children 4-<10 Years With T1DM","Interventional","Completed","Phase 3",2,146,"diabetes mellitus, type 1","NA","NA"]
["NCT00766298","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19401446|18617627|19127201|22262160|16799133","Amati F, Dubé JJ, Coen PM, Stefanovic-Racic M, Toledo FG, Goodpaster BH. Physical inactivity and obesity underlie the insulin resistance of aging. Diabetes Care. 2009 Aug;32(8):1547-9. doi: 10.2337/dc09-0267. Epub 2009 Apr 28.|Amati F, Dubé JJ, Shay C, Goodpaster BH. Separate and combined effects of exercise training and weight loss on exercise efficiency and substrate oxidation. J Appl Physiol (1985). 2008 Sep;105(3):825-31. doi: 10.1152/japplphysiol.90384.2008. Epub 2008 Jul 10.|Amati F, Dubé JJ, Stefanovic-Racic M, Toledo FG, Goodpaster BH. Improvements in insulin sensitivity are blunted by subclinical hypothyroidism. Med Sci Sports Exerc. 2009 Feb;41(2):265-9. doi: 10.1249/MSS.0b013e318187c010.|Amati F, Pennant M, Azuma K, Dubé JJ, Toledo FG, Rossi AP, Kelley DE, Goodpaster BH. Lower thigh subcutaneous and higher visceral abdominal adipose tissue content both contribute to insulin resistance. Obesity (Silver Spring). 2012 May;20(5):1115-7. doi: 10.1038/oby.2011.401. Epub 2012 Jan 19.|Menshikova EV, Ritov VB, Fairfull L, Ferrell RE, Kelley DE, Goodpaster BH. Effects of exercise on mitochondrial content and function in aging human skeletal muscle. J Gerontol A Biol Sci Med Sci. 2006 Jun;61(6):534-40.","\tType 2 Diabetes Mellitus\tExercise|Weight Loss|Exercise and weight loss\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral|Behavioral\tAll\t","Skeletal Muscle Lipid and Insulin Resistance: Effects of Physical Activity and Weight Loss","Interventional","Completed","N/A",3,102,"diabetes mellitus|insulin resistance|diabetes mellitus, type 2|weight loss","NA","NA"]
["NCT00770276","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22555362|23009954","Lammert A, Hasenberg T, Kräupner C, Schnülle P, Hammes HP. Improved arteriole-to-venule ratio of retinal vessels resulting from bariatric surgery. Obesity (Silver Spring). 2012 Nov;20(11):2262-7. doi: 10.1038/oby.2012.122. Epub 2012 May 4.|Lammert A, Hasenberg T, Imhof I, Schnülle P, Benck U, Krämer BK, Hammes HP. High prevalence of retinal endothelial dysfunction in obesity WHO class III. Microvasc Res. 2012 Nov;84(3):362-6. doi: 10.1016/j.mvr.2012.09.004. Epub 2012 Sep 23.","\tObesity\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","obesity","NA","NA"]
["NCT00773812","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22537359,"Arnold LE, Aman MG, Hollway J, Hurt E, Bates B, Li X, Farmer C, Anand R, Thompson S, Ramadan Y, Williams C. Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders. J Child Adolesc Psychopharmacol. 2012 Jun;22(3):198-205. doi: 10.1089/cap.2011.0056. Epub 2012 Apr 26.","\tAutistic Disorder|Pervasive Developmental Disorder\tmecamylamine|placebo\tNA\tNA\tNA\tDrug|Drug\tAll\t","Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders","Interventional","Completed","Phase 1",2,20,"autism spectrum disorder|child development disorders, pervasive|disease|autistic disorder|developmental disabilities","mecamylamine","NA"]
["NCT00778843","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",17311621,"Vilar Gomez E, Gra Oramas B, Soler E, Llanio Navarro R, Ruenes Domech C. Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Liver Int. 2007 Mar;27(2):247-59.","\tChronic Hepatitis C\tViusid|Placebo\tParallel Assignment\tTreatment\tRandomized\tDietary Supplement|Other\tAll\t","Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C","Interventional","Completed","Phase 3",2,60,"hepatitis c, chronic|hepatitis|hepatitis c|hepatitis, chronic|hepatitis a","NA","NA"]
["NCT00782717","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22927737,"Singh R, Alpern L, Jaffe GJ, Lehmann RP, Lim J, Reiser HJ, Sall K, Walters T, Sager D. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol. 2012;6:1259-69. doi: 10.2147/OPTH.S31902. Epub 2012 Aug 3.","\tMacular Edema\tNepafenac ophthalmic suspension, 0.1% (NEVANAC)|Nepafenac ophthalmic suspension vehicle|Prednisolone acetate ophthalmic suspension (OMNIPRED)\tParallel Assignment\tPrevention\tRandomized\tDrug|Other|Drug\tAll\t","A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients","Interventional","Completed","Phase 2",2,263,"macular edema|diabetic retinopathy|cataract|retinal diseases","prednisolone hemisuccinate|methylprednisolone acetate|methylprednisolone|methylprednisolone hemisuccinate|nepafenac|prednisolone phosphate|prednisolone acetate|prednisolone","NA"]
["NCT00784459","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23292882,"Parulekar AD, Boomer JS, Patterson BM, Yin-Declue H, Deppong CM, Wilson BS, Jarjour NN, Castro M, Green JM. A randomized controlled trial to evaluate inhibition of T-cell costimulation in allergen-induced airway inflammation. Am J Respir Crit Care Med. 2013 Mar 1;187(5):494-501. doi: 10.1164/rccm.201207-1205OC. Epub 2013 Jan 4.","\tAtopic Asthma\tabatacept|Placebo\tParallel Assignment\tBasic Science\tRandomized\tDrug|Drug\tAll\t","The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics","Interventional","Completed","Phase 2",2,24,"asthma","abatacept","NA"]
["NCT00788775","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25695690,"Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD, Chapman PB, Sullivan RJ, Teitcher JB, Ramaiya N, Giobbie-Hurder A, Antonescu CR, Heinrich MC, Bastian BC, Corless CL, Fletcher JA, Hodi FS. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res. 2015 May 15;21(10):2289-96. doi: 10.1158/1078-0432.CCR-14-1630. Epub 2015 Feb 18.","\tAcral Melanoma|Melanoma|Mucosal Lentiginous Melanoma\tNilotinib\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","melanoma","NA","NA"]
["NCT00792532","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16206144,"Martin AJ, Larson PS, Ostrem JL, Keith Sootsman W, Talke P, Weber OM, Levesque N, Myers J, Starr PA. Placement of deep brain stimulator electrodes using real-time high-field interventional magnetic resonance imaging. Magn Reson Med. 2005 Nov;54(5):1107-14.","\tDystonia|Parkinson's Disease\tinterventional MRI for implantation of DBS electrodes|DBS electrodes\tNA\tNA\tNA\tProcedure|Device\tAll\t","NA","NA","NA","NA","NA","NA","parkinson disease|dystonia","NA","NA"]
["NCT00795860","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16670153,"Schenk S, Horowitz JF. Coimmunoprecipitation of FAT/CD36 and CPT I in skeletal muscle increases proportionally with fat oxidation after endurance exercise training. Am J Physiol Endocrinol Metab. 2006 Aug;291(2):E254-60. Epub 2006 May 2.","\tInsulin Resistance and Type 2 Diabetes\tWeight loss - diet only|Weight loss plus exercise\tParallel Assignment\tBasic Science\tRandomized\tBehavioral|Behavioral\tFemale\t","Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise","Interventional","Completed","N/A",2,36,"insulin resistance|hypersensitivity","NA","NA"]
["NCT00801099","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19212189,"Saxer F, Widmer A, Fehr J, Soka I, Kibatala P, Urassa H, Frei R, Smith T, Hatz C. Benefit of a single preoperative dose of antibiotics in a sub-saharan district hospital: minimal input, massive impact. Ann Surg. 2009 Feb;249(2):322-6. doi: 10.1097/SLA.0b013e31819782fd.","\tSurgical Site Infection\tAmoxicillin/Clavulanic Acid\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","infection|communicable diseases|surgical wound infection","clavulanic acid|amoxicillin-potassium clavulanate combination|clavulanic acids|amoxicillin","NA"]
["NCT00804895","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21903477,"Leroux E, Valade D, Taifas I, Vicaut E, Chagnon M, Roos C, Ducros A. Suboccipital steroid injections for transitional treatment of patients with more than two cluster headache attacks per day: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011 Oct;10(10):891-7. doi: 10.1016/S1474-4422(11)70186-7. Epub 2011 Sep 6.","\tCluster Headache\tALTIM, cortivazol injections|PROAMP, subcutaneous serum physiological saline|Verapamil\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","Cluster Headache Cortivazol Injection (CHCI)","Interventional","Completed","Phase 2/Phase 3",2,43,"headache|cluster headache","cortivazol|verapamil","NA"]
["NCT00805207",8171853,4459348,null,"NA",null,"NA",{"$nulls":3},0.26,"ANOVA","22619349|22252942|24694337|24203065","Wang X, Magkos F, Patterson BW, Reeds DN, Kampelman J, Mittendorfer B. Low-dose dexamethasone administration for 3 weeks favorably affects plasma HDL concentration and composition but does not affect very low-density lipoprotein kinetics. Eur J Endocrinol. 2012 Aug;167(2):217-23. doi: 10.1530/EJE-12-0180. Epub 2012 May 22.|Wang X, Smith GI, Patterson BW, Reeds DN, Kampelman J, Magkos F, Mittendorfer B. Testosterone increases the muscle protein synthesis rate but does not affect very-low-density lipoprotein metabolism in obese premenopausal women. Am J Physiol Endocrinol Metab. 2012 Mar 15;302(6):E740-6. doi: 10.1152/ajpendo.00533.2011. Epub 2012 Jan 17.|Smith GI, Reeds DN, Okunade AL, Patterson BW, Mittendorfer B. Systemic delivery of estradiol, but not testosterone or progesterone, alters very low density lipoprotein-triglyceride kinetics in postmenopausal women. J Clin Endocrinol Metab. 2014 Jul;99(7):E1306-10. doi: 10.1210/jc.2013-4470. Epub 2014 Apr 2.|Smith GI, Yoshino J, Reeds DN, Bradley D, Burrows RE, Heisey HD, Moseley AC, Mittendorfer B. Testosterone and progesterone, but not estradiol, stimulate muscle protein synthesis in postmenopausal women. J Clin Endocrinol Metab. 2014 Jan;99(1):256-65. doi: 10.1210/jc.2013-2835. Epub 2013 Dec 20.","\tObesity|Obstructive Sleep Apnea|Polycystic Ovary Syndrome (PCOS)\tProgesterone|testosterone|glucocorticoid|continuous positive airway pressure|Estrogen|Control\tNA\tNA\tNA\tDrug|Drug|Drug|Device|Drug|Other\tAll\t","Sex Steroids, Sleep, and Metabolic Dysfunction in Women","Interventional","Completed","N/A",9,61,"polycystic ovary syndrome|sleep apnea syndromes|sleep apnea, obstructive","testosterone|glucocorticoids|estrogens|progesterone|estradiol","Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Secretion Rate"]
["NCT00807001","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23070151,"Lalezari J, Asmuth D, Casiró A, Vargas H, Lawrence S, Dubuc-Patrick G, Chen J, McCarville J, Pietropaolo K, Zhou XJ, Sullivan-Bólyai J, Mayers D. Short-term monotherapy with IDX184, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother. 2012 Dec;56(12):6372-8. doi: 10.1128/AAC.01521-12. Epub 2012 Oct 15.","\tChronic Hepatitis C (HCV)\tIDX184\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects","Interventional","Completed","Phase 1/Phase 2",4,41,"hepatitis, chronic|hepatitis c|hepatitis c, chronic|hepatitis a|hepatitis","NA","NA"]
["NCT00814840","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22651239,"Lenarczyk R, Kowalski O, Sredniawa B, Pruszkowska-Skrzep P, Mazurek M, Jędrzejczyk-Patej E, Woźniak A, Pluta S, Głowacki J, Kalarus Z. Implantation feasibility, procedure-related adverse events and lead performance during 1-year follow-up in patients undergoing triple-site cardiac resynchronization therapy: a substudy of TRUST CRT randomized trial. J Cardiovasc Electrophysiol. 2012 Nov;23(11):1228-36. doi: 10.1111/j.1540-8167.2012.02375.x. Epub 2012 May 31.","\tCongestive Heart Failure|Heart Disease\tCardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with two intracardiac leads|Triple-site cardiac resynchronization\tParallel Assignment\tTreatment\tRandomized\tDevice|Device\tAll\t","Efficiency Study of Triple-Site Cardiac Resynchronization in Patients With Heart Failure","Interventional","Completed","Phase 2/Phase 3",2,100,"heart failure|heart diseases","NA","NA"]
["NCT00816712","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21475673,"Chen F, Lam R, Shaywitz D, Hendrickson RC, Opiteck GJ, Wishengrad D, Liaw A, Song Q, Stewart AJ, Cummings CE, Beals C, Yarasheski KE, Reicin A, Ruddy M, Hu X, Yates NA, Menetski J, Herman GA. Evaluation of early biomarkers of muscle anabolic response to testosterone. J Cachexia Sarcopenia Muscle. 2011 Mar;2(1):45-56. Epub 2011 Feb 26.","\tMuscle Anabolism\tComparator: Testosterone 300 mg, intramuscular injection|Comparator: Testosterone 100 mg, Intramuscular injection|Comparator: Placebo given by Intramuscular Injection\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tMale\t","A Study to Evaluate the Effect of Testosterone on Muscle Fractional Synthetic Rate (MK-0000-064)","Interventional","Completed","Phase 1",3,28,"NA","testosterone undecanoate|testosterone|testosterone enanthate|methyltestosterone|testosterone 17 beta-cypionate","NA"]
["NCT00821821","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24135530,"Kaste M, Murayama S, Ford GA, Dippel DW, Walters MR, Tatlisumak T; MCI-186 study group. Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen. Cerebrovasc Dis. 2013;36(3):196-204. doi: 10.1159/000353680. Epub 2013 Oct 12. Erratum in: Cerebrovasc Dis. 2013;36(5-6):461.","\tAcute Ischemic Stroke (AIS)\tMCI-186|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke","Interventional","Completed","Phase 2",2,36,"cerebral infarction|ischemia|stroke","edaravone","NA"]
["NCT00827528","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18978116|18779916|18715243|18092333|17513926|16141767|17636742|15915320","Sung VW, Rogers RG, Schaffer JI, Balk EM, Uhlig K, Lau J, Abed H, Wheeler TL 2nd, Morrill MY, Clemons JL, Rahn DD, Lukban JC, Lowenstein L, Kenton K, Young SB; Society of Gynecologic Surgeons Systematic Review Group. Graft use in transvaginal pelvic organ prolapse repair: a systematic review. Obstet Gynecol. 2008 Nov;112(5):1131-42. doi: 10.1097/AOG.0b013e3181898ba9. Review.|Bako A, Dhar R. Review of synthetic mesh-related complications in pelvic floor reconstructive surgery. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Jan;20(1):103-11. doi: 10.1007/s00192-008-0717-5. Epub 2008 Sep 9. Review.|Jia X, Glazener C, Mowatt G, MacLennan G, Bain C, Fraser C, Burr J. Efficacy and safety of using mesh or grafts in surgery for anterior and/or posterior vaginal wall prolapse: systematic review and meta-analysis. BJOG. 2008 Oct;115(11):1350-61. doi: 10.1111/j.1471-0528.2008.01845.x. Epub 2008 Aug 19. Review.|Maher C, Baessler K, Glazener CM, Adams EJ, Hagen S. Surgical management of pelvic organ prolapse in women: a short version Cochrane review. Neurourol Urodyn. 2008;27(1):3-12. Review.|Chen CC, Ridgeway B, Paraiso MF. Biologic grafts and synthetic meshes in pelvic reconstructive surgery. Clin Obstet Gynecol. 2007 Jun;50(2):383-411. Review.|Silva WA, Karram MM. Scientific basis for use of grafts during vaginal reconstructive procedures. Curr Opin Obstet Gynecol. 2005 Oct;17(5):519-29. Review.|Maher C, Baessler K, Glazener CM, Adams EJ, Hagen S. Surgical management of pelvic organ prolapse in women. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD004014. Review. Update in: Cochrane Database Syst Rev. 2010;(4):CD004014.|Maher C, Baessler K. Surgical management of anterior vaginal wall prolapse: an evidencebased literature review. Int Urogynecol J Pelvic Floor Dysfunct. 2006 Feb;17(2):195-201. Epub 2005 May 25. Review.","\tPelvic Organ Prolapse\tTraditional correction of anterior vaginal wall prolapse|Biologic Graft (SIS)\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tFemale\t","SIS Graft and Traditional Repair in Vaginal Wall Prolapse","Interventional","Completed","Phase 4",2,56,"pelvic organ prolapse|prolapse","NA","NA"]
["NCT00831662","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15502479,"Tauber J, Davitt WF, Bokosky JE, Nichols KK, Yerxa BR, Schaberg AE, LaVange LM, Mills-Wilson MC, Kellerman DJ. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea. 2004 Nov;23(8):784-92. Erratum in: Cornea. 2007 May;26(4):514.","\tDry Eye Disease\tDiquafosol tetrasodium ophthalmic solution, 2%|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","The Effects of Diquafosol Tetrasodium Ophthalmic Solution, 2% in Subjects With Dry Eye Disease (P08637)","Interventional","Completed","Phase 3",2,490,"keratoconjunctivitis sicca|eye diseases|dry eye syndromes","ophthalmic solutions","NA"]
["NCT00832455",8167710,4456834,null,"NA",null,"NA",{"$nulls":3},1E-3,"McNemar-Bowker",24932181,"Bérubé D, Djandji M, Sampalis JS, Becker A. Effectiveness of montelukast administered as monotherapy or in combination with inhaled corticosteroid in pediatric patients with uncontrolled asthma: a prospective cohort study. Allergy Asthma Clin Immunol. 2014 May 6;10(1):21. doi: 10.1186/1710-1492-10-21. eCollection 2014.","\tAsthma\tmontelukast sodium\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","asthma","montelukast","Patient Global Satisfaction"]
["NCT00833313","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28464817|27923400","Sigurdsson MI, Saddic L, Heydarpour M, Chang TW, Shekar P, Aranki S, Couper GS, Shernan SK, Muehlschlegel JD, Body SC. Post-operative atrial fibrillation examined using whole-genome RNA sequencing in human left atrial tissue. BMC Med Genomics. 2017 May 2;10(1):25. doi: 10.1186/s12920-017-0270-5.|Sigurdsson MI, Saddic L, Heydarpour M, Chang TW, Shekar P, Aranki S, Couper GS, Shernan SK, Seidman JG, Body SC, Muehlschlegel JD. Allele-specific expression in the human heart and its application to postoperative atrial fibrillation and myocardial ischemia. Genome Med. 2016 Dec 6;8(1):127.","\tAtrial Fibrillation\tAtrial biopsy\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","atrial fibrillation","NA","NA"]
["NCT00837356","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21443634,"Martinowitz U, Bjerre J, Brand B, Klamroth R, Misgav M, Morfini M, Santagostino E, Tiede A, Viuff D. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia. 2011 Nov;17(6):854-9. doi: 10.1111/j.1365-2516.2011.02495.x. Epub 2011 Mar 28.","\tCongenital Bleeding Disorder|Haemophilia A\tAdvate®|turoctocog alfa\tNA\tNA\tNA\tDrug|Drug\tMale\t","NA","NA","NA","NA","NA","NA","blood coagulation disorders|hemophilia a|hemostatic disorders","NA","NA"]
["NCT00841386","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17720054|17457184|17457183|16952090|16900027|16765803|16565005|12719068|17531694","Natarajan R, Padmanabhan P, Guruswami S. Hydration behavior of porcine cornea crosslinked with riboflavin and ultraviolet A. J Cataract Refract Surg. 2007 Sep;33(9):1503.|Mazzotta C, Balestrazzi A, Traversi C, Baiocchi S, Caporossi T, Tommasi C, Caporossi A. Treatment of progressive keratoconus by riboflavin-UVA-induced cross-linking of corneal collagen: ultrastructural analysis by Heidelberg Retinal Tomograph II in vivo confocal microscopy in humans. Cornea. 2007 May;26(4):390-7.|Spoerl E, Mrochen M, Sliney D, Trokel S, Seiler T. Safety of UVA-riboflavin cross-linking of the cornea. Cornea. 2007 May;26(4):385-9. Review.|Mazzotta C, Traversi C, Baiocchi S, Sergio P, Caporossi T, Caporossi A. Conservative treatment of keratoconus by riboflavin-uva-induced cross-linking of corneal collagen: qualitative investigation. Eur J Ophthalmol. 2006 Jul-Aug;16(4):530-5.|Wollensak G. Crosslinking treatment of progressive keratoconus: new hope. Curr Opin Ophthalmol. 2006 Aug;17(4):356-60. Review.|Caporossi A, Baiocchi S, Mazzotta C, Traversi C, Caporossi T. Parasurgical therapy for keratoconus by riboflavin-ultraviolet type A rays induced cross-linking of corneal collagen: preliminary refractive results in an Italian study. J Cataract Refract Surg. 2006 May;32(5):837-45.|Kohlhaas M, Spoerl E, Schilde T, Unger G, Wittig C, Pillunat LE. Biomechanical evidence of the distribution of cross-links in corneas treated with riboflavin and ultraviolet A light. J Cataract Refract Surg. 2006 Feb;32(2):279-83.|Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol. 2003 May;135(5):620-7.|Mencucci R, Mazzotta C, Rossi F, Ponchietti C, Pini R, Baiocchi S, Caporossi A, Menchini U. Riboflavin and ultraviolet A collagen crosslinking: in vivo thermographic analysis of the corneal surface. J Cataract Refract Surg. 2007 Jun;33(6):1005-8.","\tKeratoconus\tRiboflavin-5-phosphate|Sham cross-linking\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Treatment of Keratoconus Using Collagen Cross-Linking","Interventional","Unknown status","Phase 2/Phase 3",2,150,"keratoconus","riboflavin|flavin mononucleotide","NA"]
["NCT00848198",8165179,4455875,"Specificity",73.3,null,"NA",68.3,78.3,95,"NA",null,"21310379|20631232","Lemp MA, Bron AJ, Baudouin C, Benítez Del Castillo JM, Geffen D, Tauber J, Foulks GN, Pepose JS, Sullivan BD. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol. 2011 May;151(5):792-798.e1. doi: 10.1016/j.ajo.2010.10.032. Epub 2011 Feb 18.|Sullivan BD, Whitmer D, Nichols KK, Tomlinson A, Foulks GN, Geerling G, Pepose JS, Kosheleff V, Porreco A, Lemp MA. An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6125-30. doi: 10.1167/iovs.10-5390. Epub 2010 Jul 14.","\tKeratoconjunctivitis Sicca\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","keratoconjunctivitis sicca|keratoconjunctivitis|eye diseases|dry eye syndromes","NA","Diagnostic Test Data for Disease Using Ocular Surface Disease Index Threshold > 15/100"]
["NCT00849199","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22275995,"Smith J, Baer L, Blank S, Dilawari A, Carapetyan K, Alvear M, Utate M, Curtin J, Muggia F. A screening and prevention programme serving an ethnically diverse population of women at high risk of developing breast and/or ovarian cancer. Ecancermedicalscience. 2009;3:123. doi: 10.3332/ecancer.2008.123. Epub 2009 Mar 16.","\tBreast Cancer|Ovarian Cancer\tNA\tNA\tNA\tNA\tNA\tFemale\t","NA","NA","NA","NA","NA","NA","ovarian neoplasms","NA","NA"]
["NCT00851799",8164694,4455647,"Difference in annual rate of change",-4.7,null,"NA",-8.9,-0.4,97.5,0.013,"Mixed Models Analysis","26372383|25904376|25948863|23196938|23591634","Stein JH, Ribaudo HJ, Hodis HN, Brown TT, Tran TT, Yan M, Brodell EL, Kelesidis T, McComsey GA, Dube MP, Murphy RL, Currier JS. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS. 2015 Sep 10;29(14):1775-83. doi: 10.1097/QAD.0000000000000762. Erratum in: AIDS. 2016 Jan;30(2):337.|Kelesidis T, Tran TT, Stein JH, Brown TT, Moser C, Ribaudo HJ, Dube MP, Murphy R, Yang OO, Currier JS, McComsey GA. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. Clin Infect Dis. 2015 Aug 15;61(4):651-60. doi: 10.1093/cid/civ327. Epub 2015 Apr 22.|Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, Yang O, Dubé MP, Murphy RL, Stein JH, McComsey GA. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. J Infect Dis. 2015 Oct 15;212(8):1241-9. doi: 10.1093/infdis/jiv194. Epub 2015 May 5. Erratum in: J Infect Dis. 2020 Jun 11;221(12):2083-2084.|Stein JH, Brown TT, Ribaudo HJ, Chen Y, Yan M, Lauer-Brodell E, McComsey GA, Dubé MP, Murphy RL, Hodis HN, Currier JS. Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. AIDS. 2013 Mar 27;27(6):929-937. doi: 10.1097/QAD.0b013e32835ce27e.|Brown TT, Chen Y, Currier JS, Ribaudo HJ, Rothenberg J, Dubé MP, Murphy R, Stein JH, McComsey GA. Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):323-30. doi: 10.1097/QAI.0b013e318295eb1d.","\tHIV Infection\tEmtricitabine/tenofovir disoproxil fumarate|Ritonavir|Atazanavir|Raltegravir|Darunavir\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","hiv infections","darunavir|tenofovir|ritonavir|emtricitabine, tenofovir disoproxil fumarate drug combination|emtricitabine|raltegravir potassium|atazanavir sulfate","Annual Rate of Change in Right Common Carotid Artery Intima-media Thickness (CIMT)"]
["NCT00853671",8164333,4455361,null,"NA",null,"NA",{"$nulls":3},{"v":1E-4,"d":"1.00E-04"},"Pearson Correlation","19744616|20093513|19936863|22222164|22210535|22146505","Blankstein R, Shturman LD, Rogers IS, Rocha-Filho JA, Okada DR, Sarwar A, Soni AV, Bezerra H, Ghoshhajra BB, Petranovic M, Loureiro R, Feuchtner G, Gewirtz H, Hoffmann U, Mamuya WS, Brady TJ, Cury RC. Adenosine-induced stress myocardial perfusion imaging using dual-source cardiac computed tomography. J Am Coll Cardiol. 2009 Sep 15;54(12):1072-84. doi: 10.1016/j.jacc.2009.06.014.|Rocha-Filho JA, Blankstein R, Shturman LD, Bezerra HG, Okada DR, Rogers IS, Ghoshhajra B, Hoffmann U, Feuchtner G, Mamuya WS, Brady TJ, Cury RC. Incremental value of adenosine-induced stress myocardial perfusion imaging with dual-source CT at cardiac CT angiography. Radiology. 2010 Feb;254(2):410-9. doi: 10.1148/radiol.09091014.|Okada DR, Ghoshhajra BB, Blankstein R, Rocha-Filho JA, Shturman LD, Rogers IS, Bezerra HG, Sarwar A, Gewirtz H, Hoffmann U, Mamuya WS, Brady TJ, Cury RC. Direct comparison of rest and adenosine stress myocardial perfusion CT with rest and stress SPECT. J Nucl Cardiol. 2010 Jan-Feb;17(1):27-37. doi: 10.1007/s12350-009-9156-z.|Uthamalingam S, Gurm GS, Sidhu MS, Verdini DJ, Vorasettakarnkij Y, Engel LC, Blankstein R, Mamuya WS, Hoffman U, Brady TJ, Cury RC, Ghoshhajra BB. Comparison of dual-source 64-slice adenosine stress CT perfusion with stress-gated SPECT-MPI for evaluation of left ventricular function and volumes. J Cardiovasc Comput Tomogr. 2012 Jan-Feb;6(1):24-30. doi: 10.1016/j.jcct.2011.10.016. Epub 2011 Nov 18.|Ghoshhajra BB, Maurovich-Horvat P, Techasith T, Medina HM, Verdini D, Sidhu MS, Blankstein R, Brady TJ, Cury RC. Infarct detection with a comprehensive cardiac CT protocol. J Cardiovasc Comput Tomogr. 2012 Jan-Feb;6(1):14-23. doi: 10.1016/j.jcct.2011.10.014. Epub 2011 Nov 18.|Ghoshhajra BB, Rogers IS, Maurovich-Horvat P, Techasith T, Verdini D, Sidhu MS, Drzezga NK, Medina HM, Blankstein R, Brady TJ, Cury RC. A comparison of reconstruction and viewing parameters on image quality and accuracy of stress myocardial CT perfusion. J Cardiovasc Comput Tomogr. 2011 Nov-Dec;5(6):459-66. doi: 10.1016/j.jcct.2011.10.011. Epub 2011 Oct 31.","\tCoronary Artery Disease\tAdenosine Stress Dual-source CTP\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","myocardial ischemia|coronary artery disease|coronary disease","adenosine","Per-Patient Correlation Between CTP and SPECT at Rest."]
["NCT00856726","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22246283,"Gutiérrez OM, Smith KT, Barchi-Chung A, Patel NM, Isakova T, Wolf M. (1-34) Parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers. Clin J Am Soc Nephrol. 2012 Jan;7(1):139-45. doi: 10.2215/CJN.06240611.","\tControl\t1-34 parathyroid infusion\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","NA","parathyroid hormone","NA"]
["NCT00858234",8163271,4454759,"Accumulation ratio",1.08,null,"NA",0.8,1.45,90,"NA",null,26619834,"Ogawa Y, Ogura M, Tobinai K, Ando K, Suzuki T, Watanabe T, Ohmachi K, Uchida T, Hanson ME, Tanaka Y, Koh Y, Shimamoto T, Hotta T. A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Int J Hematol. 2016 Jan;103(1):25-33. doi: 10.1007/s12185-015-1897-7. Epub 2015 Nov 30.","\tMultiple Myeloma\tVorinostat|Bortezomib\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms, plasma cell|multiple myeloma","vorinostat|bortezomib","Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours Postdose (AUC0-24hr) of Vorinostat Administered With Bortezomib on Days 1 and 11"]
["NCT00862823",8162656,4454422,"Geometric Mean Ratio",0.97,null,"NA",null,null,90,0.05,"log transformation",22046602,"King J, McCall M, Cannella A, Markiewicz MA, James A, Hood CB, Acosta EP. A randomized crossover study to determine relative bioequivalence of tenofovir, emtricitabine, and efavirenz (Atripla) fixed-dose combination tablet compared with a compounded oral liquid formulation derived from the tablet. J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):e130-2.","\tHealthy\ttenofovir, emtricitabine and efavirenz fixed dose tablet|tenofovir, emtricitabine and efavirenz tablet added to solution\tNA\tNA\tNA\tDrug|Drug\tAll\t","The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers","Interventional","Completed","Phase 4",2,14,"NA","efavirenz|emtricitabine|tenofovir","Area Under the Concentration Time Curve for Tenofovir, Emtricitabine and Efavirenz"]
["NCT00868582","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18362365|18997054|19016303|21080232|22448033|23481033|24221994|24578240|24819422|25593113","Hillner BE, Siegel BA, Liu D, Shields AF, Gareen IF, Hanna L, Stine SH, Coleman RE. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol. 2008 May 1;26(13):2155-61. doi: 10.1200/JCO.2007.14.5631. Epub 2008 Mar 24. Erratum in: J Clin Oncol. 2008 Sep 1;26(25): 4229.|Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hunt E, Coleman RE. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med. 2008 Dec;49(12):1928-35. doi: 10.2967/jnumed.108.056713. Epub 2008 Nov 7.|Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hanna L, Stine SH, Coleman RE. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. Cancer. 2009 Jan 15;115(2):410-8. doi: 10.1002/cncr.24000. Erratum in: Cancer. 2009 Mar 1;115(5):1133.|Hillner BE, Siegel BA, Shields AF, Duan F, Gareen IF, Hanna L, Coleman RE. Impact of dedicated brain PET on intended patient management in participants of the national oncologic PET Registry. Mol Imaging Biol. 2011 Feb;13(1):161-5. doi: 10.1007/s11307-010-0427-5.|Hillner BE, Siegel BA, Hanna L, Shields AF, Duan F, Gareen IF, Quinn B, Coleman RE. Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohorts. J Nucl Med. 2012 May;53(5):831-7. doi: 10.2967/jnumed.112.103911. Epub 2012 Mar 23.|Hillner BE, Tosteson TD, Tosteson AN, Wang Q, Song Y, Onega T, Hanna LG, Siegel BA. Intended versus inferred management after PET for cancer restaging: analysis of Medicare claims linked to a coverage with evidence development registry. Med Care. 2013 Apr;51(4):361-7. doi: 10.1097/MLR.0b013e318287d860.|Hillner BE, Tosteson AN, Tosteson TD, Wang Q, Song Y, Hanna LG, Siegel BA. Intended versus inferred care after PET performed for initial staging in the National Oncologic PET Registry. J Nucl Med. 2013 Dec;54(12):2024-31. doi: 10.2967/jnumed.113.123430. Epub 2013 Nov 12.|Hillner BE, Siegel BA, Hanna L, Duan F, Shields AF, Coleman RE. Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry. J Nucl Med. 2014 Apr;55(4):574-81. doi: 10.2967/jnumed.113.130005. Epub 2014 Feb 27.|Hillner BE, Siegel BA, Hanna L, Duan F, Shields AF, Quinn B, Coleman RE. Impact of (18)F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry. J Nucl Med. 2014 Jul;55(7):1054-61. doi: 10.2967/jnumed.113.135475. Epub 2014 May 12.|Hillner BE, Siegel BA, Hanna L, Duan F, Quinn B, Shields AF. 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry. J Nucl Med. 2015 Feb;56(2):222-8. doi: 10.2967/jnumed.114.150391. Epub 2015 Jan 15.","\tCancer\tPET scanning in cancer\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT00872170",8161311,4453754,null,"NA",null,"NA",{"$nulls":3},0.33,"Mixed Models Analysis",23585527,"Morris CR, Kim HY, Wood J, Porter JB, Klings ES, Trachtenberg FL, Sweeters N, Olivieri NF, Kwiatkowski JL, Virzi L, Singer ST, Taher A, Neufeld EJ, Thompson AA, Sachdev V, Larkin S, Suh JH, Kuypers FA, Vichinsky EP; Thalassemia Clinical Research Network. Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica. 2013 Sep;98(9):1359-67. doi: 10.3324/haematol.2012.082065. Epub 2013 Apr 12.","\tHypertension, Pulmonary|Thalassemia\tSildenafil\tNA\tNA\tNA\tDrug\tAll\t","Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension","Interventional","Completed","Phase 2/Phase 3",2,27,"hypertension|thalassemia|hypertension, pulmonary","sildenafil citrate","Change in Lactate Dehydrogenase (LDH) From Baseline to Week 12 Among Sildenafil Group"]
["NCT00874237","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24375070,"Spyker DA, Voloshko P, Heyman ER, Cassella JV. Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects. J Clin Pharmacol. 2014 Jun;54(6):665-74. doi: 10.1002/jcph.257. Epub 2014 Jan 22.","\tThorough QT/QTc Study\tInhaled loxapine|Inhaled placebo|Oral moxifloxacin|Oral placebo\tCrossover Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug\tAll\t","Staccato Loxapine Thorough QT/QTc Study","Interventional","Completed","Phase 1",6,48,"NA","loxapine|moxifloxacin","NA"]
["NCT00874731",8161074,4453561,"Mean Difference (Final Values)",2.49,null,"NA",-0.79,5.78,95,"NA",null,22878520,"Lush RM, Patnaik A, Sullivan D, Papadopoulos KP, Trucksis M, McCrea J, Cerchio K, Li X, Stroh M, Selverian D, Orford K, Ebbinghaus S, Agrawal N, Iwamoto M, Wagner JA, Tolcher A. A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer. Cancer Chemother Pharmacol. 2012 Oct;70(4):567-74. Epub 2012 Aug 10.","\tMetastatic or Locally Advanced Cancer\tRidaforolimus 100 mg|Ridaforolimus 40 mg|Placebo\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","sirolimus","Part 1. Mean Change From Baseline in Rate-Corrected (Fridericia's) QT Interval (QTcF) at 6 Hours"]
["NCT00878631","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19930566,"Morrison LJ, Rizoli SB, Schwartz B, Rhind SG, Simitciu M, Perreira T, Macdonald R, Trompeo A, Stuss DT, Black SE, Kiss A, Baker AJ. The Toronto prehospital hypertonic resuscitation-head injury and multi organ dysfunction trial (TOPHR HIT)--methods and data collection tools. Trials. 2009 Nov 20;10:105. doi: 10.1186/1745-6215-10-105.","\tBrain Injuries\thypertonic saline mixed with dextran|Normal Saline\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Feasibility Trial of Traumatic Brain Injured Patients Randomized in the Prehospital Setting to Either Hypertonic Saline and Dextran Versus Normal Saline","Interventional","Completed","Phase 2/Phase 3",2,113,"brain injuries","dextrans","NA"]
["NCT00887185","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18842619|17721407","Fernandez SA, Wiet GJ, Butler NN, Welling B, Jarjoura D. Reliability of surgical skills scores in otolaryngology residents: analysis using generalizability theory. Eval Health Prof. 2008 Dec;31(4):419-36. doi: 10.1177/0163278708324444. Epub 2008 Oct 7.|Butler NN, Wiet GJ. Reliability of the Welling scale (WS1) for rating temporal bone dissection performance. Laryngoscope. 2007 Oct;117(10):1803-8.","\tComputer Simulation|Education\tSimulator training for temporal bone surgery\tParallel Assignment\tHealth Services Research\tRandomized\tOther\tAll\t","Validation/Dissemination Of A Temporal Bone Dissection Simulator","Interventional","Completed","Phase 2",2,100,"NA","NA","NA"]
["NCT00890552","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23716538,"Dinner S, Witteles W, Afghahi A, Witteles R, Arai S, Lafayette R, Schrier SL, Liedtke M. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica. 2013 Oct;98(10):1593-9. doi: 10.3324/haematol.2013.084574. Epub 2013 May 28.","\tAmyloidosis|Leukemia\tLenalidomide|Melphalan|Dexamethasone\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","immunoglobulin light-chain amyloidosis|amyloidosis","lenalidomide|dexamethasone acetate|melphalan|dexamethasone|bb 1101","NA"]
["NCT00895310","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25667107,"Lo EN, Beckett LA, Pan CX, Robles D, Suga JM, Sands JM, Lara PN Jr. Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients. Prostate Cancer Prostatic Dis. 2015 Jun;18(2):144-8. doi: 10.1038/pcan.2015.2. Epub 2015 Feb 10.","\tProstate Cancer\tKetoconazole|Hydrocortisone\tNA\tNA\tNA\tDrug|Drug\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","ketoconazole|hydrocortisone","NA"]
["NCT00898677","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11284463,"Tfelt-Hansen P, Teall J, Rodriguez F, Giacovazzo M, Paz J, Malbecq W, Block GA, Reines SA, Visser WH. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group. Headache. 1998 Nov-Dec;38(10):748-55.","\tMigraine Headache\trizatriptan benzoate|rizatriptan benzoate|Comparator: sumatriptan|Comparator: Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug\tAll\t","Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)","Interventional","Completed","Phase 3",4,1268,"migraine disorders|headache","sumatriptan|rizatriptan","NA"]
["NCT00910819","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25945067,"Marschner N, Arnold D, Engel E, Hutzschenreuter U, Rauh J, Freier W, Hartmann H, Frank M, Jänicke M. Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer - Results from a prospective cohort study. Clin Epidemiol. 2015 Apr 20;7:295-303. doi: 10.2147/CLEP.S73857. eCollection 2015.","\tColorectal Cancer\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","NA","NA"]
["NCT00916357",8155519,4450763,null,"NA",null,"NA",{"$nulls":3},0.18,"Repeated Measures Analysis of Variance",22136324,"Hompesch M, Muchmore DB, Morrow L, Ludington E, Vaughn DE. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. Diabetes Technol Ther. 2012 Mar;14(3):218-24. doi: 10.1089/dia.2011.0117. Epub 2011 Dec 2.","\tDiabetes Mellitus, Type 2\tHumalog|Humulin-R|Recombinant human hyaluronidase PH20 (rHuPH20)\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)","Interventional","Completed","Phase 2",6,23,"diabetes mellitus|diabetes mellitus, type 2","insulin, globin zinc|insulin lispro|insulin","Time to Percentage of Insulin Exposure (as Measured by Area Under the Curve [AUC])"]
["NCT00916357",8155522,4450774,null,"NA",null,"NA",{"$nulls":3},0.012,"Repeated Measures Analysis of Variance",22136324,"Hompesch M, Muchmore DB, Morrow L, Ludington E, Vaughn DE. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. Diabetes Technol Ther. 2012 Mar;14(3):218-24. doi: 10.1089/dia.2011.0117. Epub 2011 Dec 2.","\tDiabetes Mellitus, Type 2\tHumalog|Humulin-R|Recombinant human hyaluronidase PH20 (rHuPH20)\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)","Interventional","Completed","Phase 2",6,23,"diabetes mellitus|diabetes mellitus, type 2","insulin, globin zinc|insulin lispro|insulin","Area Under the Time-Concentration Curve for Blood Glucose (AUC[BG])"]
["NCT00916357",8155529,4450804,null,"NA",null,"NA",{"$nulls":3},{"v":1E-4,"d":"1.00E-04"},"Repeated measures Analysis of Variance",22136324,"Hompesch M, Muchmore DB, Morrow L, Ludington E, Vaughn DE. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. Diabetes Technol Ther. 2012 Mar;14(3):218-24. doi: 10.1089/dia.2011.0117. Epub 2011 Dec 2.","\tDiabetes Mellitus, Type 2\tHumalog|Humulin-R|Recombinant human hyaluronidase PH20 (rHuPH20)\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)","Interventional","Completed","Phase 2",6,23,"diabetes mellitus|diabetes mellitus, type 2","insulin, globin zinc|insulin lispro|insulin","Postprandial Glucose (PPG) Excursion Following a Liquid Meal"]
["NCT00918619","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24880345,"Moench C, Mihaljevic AL, Hermanutz V, Thasler WE, Suna K, Diener MK, Seehofer D, Mischinger HJ, Jansen-Winkeln B, Knaebel HP, Bechstein WO. Randomized controlled multicenter trial on the effectiveness of the collagen hemostat Sangustop® compared with a carrier-bound fibrin sealant during liver resection (ESSCALIVER study, NCT00918619). Langenbecks Arch Surg. 2014 Aug;399(6):725-33. doi: 10.1007/s00423-014-1203-9. Epub 2014 Jun 1.","\tHemostasis|Liver Surgery\tSangustop|Tachosil\tParallel Assignment\tTreatment\tRandomized\tDevice|Drug\tAll\t","Efficacy and Safety of Sangustop® as Haemostatic Agent Versus a Carrier-Bound Fibrin Sealant During Liver Resection","Interventional","Completed","Phase 4",2,128,"NA","NA","NA"]
["NCT00924313",8154517,4450289,null,"NA",null,"NA",{"$nulls":3},0.407,"Spearman rank correlation",22343504,"Mena E, Turkbey B, Mani H, Adler S, Valera VA, Bernardo M, Shah V, Pohida T, McKinney Y, Kwarteng G, Daar D, Lindenberg ML, Eclarinal P, Wade R, Linehan WM, Merino MJ, Pinto PA, Choyke PL, Kurdziel KA. 11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med. 2012 Apr;53(4):538-45. doi: 10.2967/jnumed.111.096032. Epub 2012 Feb 17.","\tProstate Cancer\t(C-11 Acetate)\tNA\tNA\tNA\tDrug\tMale\t","NA","NA","NA","NA","NA","NA","prostatic neoplasms","NA","11C-Acetate Standardized Uptake Value (SUV)Max and Serum Prostate Specific Antigen (PSA) Levels Using Spearman Correlation"]
["NCT00928915","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27302126,"Steiner T, Poli S, Griebe M, Hüsing J, Hajda J, Freiberger A, Bendszus M, Bösel J, Christensen H, Dohmen C, Hennerici M, Kollmer J, Stetefeld H, Wartenberg KE, Weimar C, Hacke W, Veltkamp R. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol. 2016 May;15(6):566-73. doi: 10.1016/S1474-4422(16)00110-1. Epub 2016 Apr 11.","\tIntracranial Hemorrhages\tProthrombin complex concentrate (PCC); fresh frozen plasma (FFP)\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","International Normalized Ratio (INR) Normalization in Coumadin Associated Intracerebral Haemorrhage","Interventional","Completed","Phase 4",2,54,"intracranial hemorrhages|cerebral hemorrhage|hemorrhage","thrombin","NA"]
["NCT00929591","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|NA|NA|NA|NA","Albain K, Barlow W, Shak S, et al.: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100). [Abstract] Breast Cancer Res Treat 106 (1): A-10, 2007.|Albain K, Barlow W, O'Malley F, et al.: Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal , node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). [Abstract] Breast Cancer Res Treat 88 (Suppl 1): A-37, 2004.|Albain KS, Green SJ, Ravdin PM, et al.: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-143, 2002.|Albain K, Green S, Ravdin P, et al.: Overall survival after cyclophosphamide, adriamycin, 5-Fu, and tamoxifen (CAFT) is superior to T alone in postmenopausal, receptor(+), node(+) breast cancer: new findings from phase III Southwest Oncology Group intergroup trial S8814 (INT-0100). [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-94, 24a, 2001.|Ravdin P, Green S, Albain K, et al.: Initial report of the SWOG biological correlative study of c-erB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone. [Abstract] Proceedings of the American Society of Clinical Oncology 17: A374, 97a, 1998.|Albain K, Green S, Osborne K, et al.: Tamoxifen (T) versus cyclophosphamide, adriamycin and 5-FU plus either concurrent or sequential T in postmenopausal, receptor(+), node(+) breast cancer: a Southwest Oncology Group phase III intergroup trial (SWOG-8814, INT-0100). [Abstract] Proceedings of the American Society of Clinical Oncology 16: A-450, 128a, 1997.","\tBreast Cancer\tcyclophosphamide|doxorubicin hydrochloride|endocrine therapy|endocrine-modulating drug therapy|fluorouracil|tamoxifen citrate|brachytherapy|low-LET electron therapy|low-LET photon therapy|radiation therapy\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug|Drug|Drug|Radiation|Radiation|Radiation|Radiation\tFemale\t","SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer","Interventional","Completed","Phase 3",3,1558,"breast neoplasms","fluorouracil|liposomal doxorubicin|tamoxifen|cyclophosphamide|doxorubicin","NA"]
["NCT00933478","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",9616461,"Cairns W. The patulous Eustachian tube syndrome. Palliat Med. 1998 Jan;12(1):59-60.","\tPatulous Eustachian Tube Dysfunction\tClay\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT00940511","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|23557249","Michalopoulos C, Manno MS, Warren A, Somers J. Managing Health Care for Medicaid Recipients with Disabilities: Final Report on the Kaiser Permanente Colorado Coordinated Care Pilot Program. New York: MDRC|Kim SE, Michalopoulos C, Kwong RM, Warren A, Manno MS. Telephone care management's effectiveness in coordinating care for Medicaid beneficiaries in managed care: a randomized controlled study. Health Serv Res. 2013 Oct;48(5):1730-49. doi: 10.1111/1475-6773.12060. Epub 2013 Apr 5.","\tChronic Conditions Faced by Medicaid Recipients With Disabilities\tCoordinated care\tNA\tNA\tNA\tBehavioral\tAll\t","Effects of Coordinated Care for Disabled Medicaid Recipients","Interventional","Completed","N/A",2,2618,"disease","NA","NA"]
["NCT00943631","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22537984,"Chen WH, Winokur PL, Edwards KM, Jackson LA, Wald A, Walter EB, Noah DL, Wolff M, Kotloff KL; Pandemic H1N1 Vaccine Adult Study Group. Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. Vaccine. 2012 Jun 13;30(28):4240-8. doi: 10.1016/j.vaccine.2012.04.044. Epub 2012 Apr 23.","\tInfluenza\tInactivated H1N1 Vaccine\tParallel Assignment\tPrevention\tRandomized\tBiological\tAll\t","Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations","Interventional","Completed","Phase 2",2,406,"influenza, human","NA","NA"]
["NCT00948480","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19538053,"Dillman RO, Selvan SR, Schiltz PM, McClay EF, Barth NM, DePriest C, de Leon C, Mayorga C, Cornforth AN, Allen K. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report. Cancer Biother Radiopharm. 2009 Jun;24(3):311-9. doi: 10.1089/cbr.2008.0599.","\tMetastatic Melanoma\tAutologous tumor cells plus dendritic cells|GM-CSF\tNA\tNA\tNA\tBiological|Drug\tAll\t","NA","NA","NA","NA","NA","NA","melanoma","sargramostim","NA"]
["NCT00951080","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21362084,"Armstrong DG, Marston WA, Reyzelman AM, Kirsner RS. Comparison of negative pressure wound therapy with an ultraportable mechanically powered device vs. traditional electrically powered device for the treatment of chronic lower extremity ulcers: a multicenter randomized-controlled trial. Wound Repair Regen. 2011 Mar-Apr;19(2):173-80. doi: 10.1111/j.1524-475X.2010.00658.x.","\tUlcers|Wounds\tTraditional NPWT System|SNaP Wound Care System\tParallel Assignment\tTreatment\tRandomized\tDevice|Device\tAll\t","SNaP Wound Care System Versus Traditional NPWT Device for Treatment of Chronic Wounds","Interventional","Completed","N/A",2,132,"wounds and injuries|ulcer","NA","NA"]
["NCT00954109",8149611,4448263,null,"NA",null,"NA",{"$nulls":3},0.05,"t-test, 1 sided",21737826,"Mikus CR, Fairfax ST, Libla JL, Boyle LJ, Vianna LC, Oberlin DJ, Uptergrove GM, Deo SH, Kim A, Kanaley JA, Fadel PJ, Thyfault JP. Seven days of aerobic exercise training improves conduit artery blood flow following glucose ingestion in patients with type 2 diabetes. J Appl Physiol (1985). 2011 Sep;111(3):657-64. doi: 10.1152/japplphysiol.00489.2011. Epub 2011 Jul 7.","\tInsulin Resistance\tExercise\tNA\tNA\tNA\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","insulin resistance","NA","Blood Flow in Response to Oral Glucose Tolerance Tests"]
["NCT00962156","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22738085,"Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, Madsen KR, Møller MH, Elkjær JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Søe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjældgaard AL, Fabritius ML, Mondrup F, Pott FC, Møller TP, Winkel P, Wetterslev J; 6S Trial Group; Scandinavian Critical Care Trials Group. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med. 2012 Jul 12;367(2):124-34. doi: 10.1056/NEJMoa1204242. Epub 2012 Jun 27. Erratum in: N Engl J Med. 2012 Aug 2;367(5):481.","\tSeptic Shock|Severe Sepsis\t6% Hydroxyethyl starch 130/0.4|Ringers acetate\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Scandinavian Starch for Severe Sepsis/Septic Shock Trial","Interventional","Completed","Phase 3",2,804,"shock, septic|shock|toxemia|sepsis","hydroxyethyl starch derivatives","NA"]
["NCT00965705","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27852348|24235091","Chen EY, Cacioppo J, Fettich K, Gallop R, McCloskey MS, Olino T, Zeffiro TA. An adaptive randomized trial of dialectical behavior therapy and cognitive behavior therapy for binge-eating. Psychol Med. 2017 Mar;47(4):703-717. doi: 10.1017/S0033291716002543. Epub 2016 Nov 17.|Southward MW, Christensen KA, Fettich KC, Weissman J, Berona J, Chen EY. Loneliness mediates the relationship between emotion dysregulation and bulimia nervosa/binge eating disorder psychopathology in a clinical sample. Eat Weight Disord. 2014 Dec;19(4):509-13. doi: 10.1007/s40519-013-0083-2.","\tBinge Eating Disorder\tTherapy\tParallel Assignment\tTreatment\tRandomized\tBehavioral\tFemale\t","Stepped Care Treatment for Binge-Eating","Interventional","Completed","N/A",3,109,"binge-eating disorder|feeding and eating disorders|bulimia","NA","NA"]
["NCT00968227",8147467,4447359,null,"NA",null,"NA",{"$nulls":3},1E-3,"t-test, 2 sided",19628806,"Dhar R, Zazulia AR, Videen TO, Zipfel GJ, Derdeyn CP, Diringer MN. Red blood cell transfusion increases cerebral oxygen delivery in anemic patients with subarachnoid hemorrhage. Stroke. 2009 Sep;40(9):3039-44. doi: 10.1161/STROKEAHA.109.556159. Epub 2009 Jul 23.","\tSubarachnoid Hemorrhage|Vasospasm\tRed blood cell transfusion\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","subarachnoid hemorrhage|hemorrhage","NA","Change in Oxygen Delivery in Vulnerable Brain Regions"]
["NCT00971009","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25525672,"Børøsund E, Cvancarova M, Moore SM, Ekstedt M, Ruland CM. Comparing effects in regular practice of e-communication and Web-based self-management support among breast cancer patients: preliminary results from a randomized controlled trial. J Med Internet Res. 2014 Dec 18;16(12):e295. doi: 10.2196/jmir.3348.","\tBreast Cancer\tOPPC service|WebChoice IHCA\tParallel Assignment\tSupportive Care\tRandomized\tBehavioral|Behavioral\tFemale\t","Effects of Internet Support for Cancer Patients","Interventional","Completed","N/A",3,200,"NA","NA","NA"]
["NCT00975858","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",14656913,"Eefting F, Nathoe H, van Dijk D, Jansen E, Lahpor J, Stella P, Suyker W, Diephuis J, Suryapranata H, Ernst S, Borst C, Buskens E, Grobbee D, de Jaegere P. Randomized comparison between stenting and off-pump bypass surgery in patients referred for angioplasty. Circulation. 2003 Dec 9;108(23):2870-6. Epub 2003 Dec 1.","\tCoronary Artery Disease\tCoronary Revascularization\tParallel Assignment\tTreatment\tRandomized\tProcedure\tAll\t","Long-term Comparison of Stenting Versus Off-pump Coronary Bypass Surgery","Interventional","Completed","N/A",2,280,"coronary disease|coronary artery disease|myocardial ischemia","NA","NA"]
["NCT00977288","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23958252,"Teramoto T, Shirakawa M, Kikuchi M, Nakagomi M, Tamura S, Surks HK, McCrary Sisk C, Numaguchi H. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia. Atherosclerosis. 2013 Sep;230(1):52-60. doi: 10.1016/j.atherosclerosis.2013.05.012. Epub 2013 Jun 5.","\tDyslipidemia\tanacetrapib|Comparator: atorvastatin|Comparator: Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)","Interventional","Completed","Phase 2",10,408,"dyslipidemias","anacetrapib|atorvastatin","NA"]
["NCT00982423",8145275,4446349,null,"NA",null,"NA",{"$nulls":3},0.075,"t-test, 2 sided",25262369,"McKie PM, Schirger JA, Benike SL, Harstad LK, Chen HH. The effects of dose reduction of furosemide on glomerular filtration rate in stable systolic heart failure. JACC Heart Fail. 2014 Dec;2(6):675-7. doi: 10.1016/j.jchf.2014.05.014. Epub 2014 Sep 24.","\tHeart Failure|Kidney Dysfunction\tFurosemide\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","heart failure","furosemide","Plasma Cyclic Guanosine Monophosphate (cGMP) at Baseline and in Response to Decreasing Furosemide Dose"]
["NCT00986232","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16094218,"Shinefield H, Black S, Williams WR, Marchant C, Reisinger K, Stewart T, Meissner HC, Guerrero J, Klopfer SO, Xu J, Schödel F, Kuter BJ; Dose Selection Study Group for Proquad. Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005 Aug;24(8):670-5. Erratum in: Pediatr Infect Dis J. 2005 Nov;24(11):983.","\tMeasles|Mumps|Rubella|Varicella\tMeasles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|Comparator: M-M-R II|Comparator: PUVV\tParallel Assignment\tPrevention\tRandomized\tBiological|Biological|Biological\tAll\t","ProQuad Dose Selection Study (V221-011)(COMPLETED)","Interventional","Completed","Phase 2",4,1551,"chickenpox|rubella|herpes zoster|measles","NA","NA"]
["NCT00987883","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16697086,"Lochs H, Allison SP, Meier R, Pirlich M, Kondrup J, Schneider S, van den Berghe G, Pichard C. Introductory to the ESPEN Guidelines on Enteral Nutrition: Terminology, definitions and general topics. Clin Nutr. 2006 Apr;25(2):180-6. Epub 2006 May 11.","\tGastroenterological Cancer|Malnutrition|Surgical Procedures, Operative\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","malnutrition","NA","NA"]
["NCT00990548","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23536121|23321779|22901971|21962999|21330929|23468321|23416934","Aggarwal B, Liao M, Mosca L. Medication adherence is associated with having a caregiver among cardiac patients. Ann Behav Med. 2013 Oct;46(2):237-42. doi: 10.1007/s12160-013-9492-8.|Mochari-Greenberger H, Mosca M, Aggarwal B, Umann TM, Mosca L. Caregiver status: a simple marker to identify cardiac surgery patients at risk for longer postoperative length of stay, rehospitalization, or death. J Cardiovasc Nurs. 2014 Jan-Feb;29(1):12-9. doi: 10.1097/JCN.0b013e318274d19b.|Hammond G, Mochari-Greenberger H, Liao M, Mosca L. Effect of gender, caregiver, on cholesterol control and statin use for secondary prevention among hospitalized patients with coronary heart disease. Am J Cardiol. 2012 Dec 1;110(11):1613-8. doi: 10.1016/j.amjcard.2012.07.028. Epub 2012 Aug 15.|Mosca L, Aggarwal B, Mochari-Greenberger H, Liao M, Blair J, Cheng B, Comellas M, Rehm L, Suero-Tejeda N, Umann T. Association between having a caregiver and clinical outcomes 1 year after hospitalization for cardiovascular disease. Am J Cardiol. 2012 Jan 1;109(1):135-9. doi: 10.1016/j.amjcard.2011.07.072. Epub 2011 Sep 29.|Mosca L, Mochari-Greenberger H, Aggarwal B, Liao M, Suero-Tejeda N, Comellas M, Rehm L, Umann TM, Mehran R. Patterns of caregiving among patients hospitalized with cardiovascular disease. J Cardiovasc Nurs. 2011 Jul-Aug;26(4):305-11. doi: 10.1097/JCN.0b013e3181f34bb3.|Villanueva C, Aggarwal B. The association between neighborhood socioeconomic status and clinical outcomes among patients 1 year after hospitalization for cardiovascular disease. J Community Health. 2013 Aug;38(4):690-7. doi: 10.1007/s10900-013-9666-0.|Blair J, Volpe M, Aggarwal B. Challenges, needs, and experiences of recently hospitalized cardiac patients and their informal caregivers. J Cardiovasc Nurs. 2014 Jan-Feb;29(1):29-37. doi: 10.1097/JCN.0b013e3182784123.","\tCardiovascular Diseases|Heart Diseases\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","cardiovascular diseases|heart diseases","NA","NA"]
["NCT00993213","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21475140,"Hernandez TL, Kittelson JM, Law CK, Ketch LL, Stob NR, Lindstrom RC, Scherzinger A, Stamm ER, Eckel RH. Fat redistribution following suction lipectomy: defense of body fat and patterns of restoration. Obesity (Silver Spring). 2011 Jul;19(7):1388-95. doi: 10.1038/oby.2011.64. Epub 2011 Apr 7.","\tDisproportionate Shape|Expanded Fat Pads\tStandard of Care with Liposuction|Standard of Care without Liposuction\tParallel Assignment\tTreatment\tRandomized\tProcedure|Other\tFemale\t","Mechanisms Defending Fat Mass in Humans After Lipectomy","Interventional","Completed","N/A",2,32,"NA","NA","NA"]
["NCT00994747","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21310829|21187303","Mennella JA, Lukasewycz LD, Castor SM, Beauchamp GK. The timing and duration of a sensitive period in human flavor learning: a randomized trial. Am J Clin Nutr. 2011 May;93(5):1019-24. doi: 10.3945/ajcn.110.003541. Epub 2011 Feb 10.|Mennella JA, Ventura AK, Beauchamp GK. Differential growth patterns among healthy infants fed protein hydrolysate or cow-milk formulas. Pediatrics. 2011 Jan;127(1):110-8. doi: 10.1542/peds.2010-1675. Epub 2010 Dec 27.","\tHealthy\tNutramigen (Flavor and Type of Infant Formula)|Enfamil, milk-based formula\tParallel Assignment\tBasic Science\tRandomized\tOther|Other\tAll\t","Sensitive Periods in Early Flavor Learning","Interventional","Completed","N/A",6,79,"hypersensitivity","NA","NA"]
["NCT00997074","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22265034,"Avraham S, Gat I, Duvdevani NR, Haas J, Frenkel Y, Seidman DS. Pre-emptive effect of ibuprofen versus placebo on pain relief and success rates of medical abortion: a double-blind, randomized, controlled study. Fertil Steril. 2012 Mar;97(3):612-5. doi: 10.1016/j.fertnstert.2011.12.041. Epub 2012 Jan 20.","\tPain|Pregnancy\tibuprofen\tParallel Assignment\tTreatment\tRandomized\tDrug\tFemale\t","Efficacy Study of Prophylactic Ibuprofen Versus Placebo on Pain Relief and Success Rates of Medical Abortion","Interventional","Completed","Phase 3",2,61,"NA","ibuprofen|anti-inflammatory agents|anti-inflammatory agents, non-steroidal","NA"]
["NCT01001546","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22038468|21769051|21523829|NA|22338598","Gierisch JM, Bastian LA, Calhoun PS, McDuffie JR, Williams JW Jr. Smoking cessation interventions for patients with depression: a systematic review and meta-analysis. J Gen Intern Med. 2012 Mar;27(3):351-60. doi: 10.1007/s11606-011-1915-2. Epub 2011 Oct 26. Review.|Zaborowski DE, Dedert EA, Straits-Troster K, Lee S, Wilson SM, Calhoun PS, Moore SD, Acheson S, Hamlett-Berry KW, Beckham JC. Public health clinical demonstration project for smoking cessation in american veterans who served since september 11, 2001. J Addict Med. 2011 Mar;5(1):79-83. doi: 10.1097/ADM.0b013e3181df97d5.|Calhoun PS, Levin HF, Dedert EA, Johnson Y; VA Mid-Atlantic Mental Illness Research, Education, Clinical Center Registry Workgroup, Beckham JC. The relationship between posttraumatic stress disorder and smoking outcome expectancies among U.S. military veterans who served since September 11, 2001. J Trauma Stress. 2011 Jun;24(3):303-8. doi: 10.1002/jts.20634. Epub 2011 Apr 26.|Straits-Troster K, Acheson S, Beckham JC, Calhoun PS, Gierisch JM, Hamlett-Berry K. Tobacco use and cessation among returning combat veterans: A mixed methods study. [Abstract]. Behavioral medicine update : a publication of the Society of Behavioral Medicine. 2010 Apr 10; 39(S1).|Gierisch JM, Straits-Tröster K, Calhoun PS, Beckham JC, Acheson S, Hamlett-Berry K. Tobacco use among Iraq- and Afghanistan-era veterans: a qualitative study of barriers, facilitators, and treatment preferences. Prev Chronic Dis. 2012;9:E58. Epub 2012 Feb 16.","\tSmoking Cessation\tInternet-based|Standard Clinic-Based\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral\tAll\t","Internet-Based Smoking Cessation for Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans","Interventional","Completed","N/A",2,413,"NA","NA","NA"]
["NCT01006057","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24163264,"Kiss I, Arold G, Roepstorff C, Bøttcher SG, Klim S, Haahr H. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet. 2014 Feb;53(2):175-83. doi: 10.1007/s40262-013-0113-2.","\tDiabetes|Healthy\tinsulin degludec|insulin degludec|insulin degludec|insulin degludec|insulin degludec\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug\tAll\t","A Trial Investigating the NN1250 Concentration-time Curve in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function","Interventional","Completed","Phase 1",5,32,"renal insufficiency","insulin|insulin, globin zinc|insulin, long-acting","NA"]
["NCT01010204","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25006684,"Chengappa KN, Perkins KA, Brar JS, Schlicht PJ, Turkin SR, Hetrick ML, Levine MD, George TP. Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014 Jul;75(7):765-72. doi: 10.4088/JCP.13m08756.","\tBipolar Disorder|Smoking Cessation\tVarenicline|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder","Interventional","Completed","Phase 4",2,60,"bipolar disorder|disease","varenicline","NA"]
["NCT01011452","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Ramsay, CF., Oral Motelukast in Patients with Acute Severe Asthma. Abstract NO P3609. ERJ Sept 2007","\tAcute Asthma Exacerbation\tMontelukast|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Acute Montelukast in Asthma","Interventional","Completed","Phase 4",2,87,"asthma","montelukast","NA"]
["NCT01014741","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26850076|22034996","Singh SM, d'Avila A, Kim YH, Aryana A, Mangrum JM, Michaud GF, Dukkipati SR, Barrett CD, Heist EK, Parides MK, Thorpe KE, Reddy VY. The modified stepwise ablation guided by low-dose ibutilide in chronic atrial fibrillation trial (The MAGIC-AF Study). Eur Heart J. 2016 May 21;37(20):1614-21. doi: 10.1093/eurheartj/ehw003. Epub 2016 Feb 4.|Singh SM, D'Avila A, Kim YH, Aryana A, Mangrum JM, Michaud GF, Dukkipati SR, Callans DJ, Barrett CD, Beras-Jovine MR, Reddy VY. The Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation (MAGIC-AF) Study: clinical background and study design. J Cardiovasc Electrophysiol. 2012 Apr;23(4):352-8. doi: 10.1111/j.1540-8167.2011.02198.x. Epub 2011 Oct 28.","\tPersistent Atrial Fibrillation\tIbutilide|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation","Interventional","Completed","N/A",2,200,"atrial fibrillation","ibutilide","NA"]
["NCT01016301","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21209140|22223840","Bladh L, Ottosson E, Karlsson J, Klintberg L, Wallerstedt SM. Effects of a clinical pharmacist service on health-related quality of life and prescribing of drugs: a randomised controlled trial. BMJ Qual Saf. 2011 Sep;20(9):738-46. doi: 10.1136/bmjqs.2009.039693. Epub 2011 Jan 5.|Wallerstedt SM, Bladh L, Ramsberg J. A cost-effectiveness analysis of an in-hospital clinical pharmacist service. BMJ Open. 2012 Jan 5;2:e000329. doi: 10.1136/bmjopen-2011-000329. Print 2012.","\tQuality of Life\tPharmacist service\tParallel Assignment\tHealth Services Research\tRandomized\tOther\tAll\t","Effects of a Clinical Pharmacist Service on Health-related Quality of Life","Interventional","Completed","N/A",2,400,"NA","NA","NA"]
["NCT01018732",8139432,4443694,"ratio of titer",40,null,"NA",20,80,95,"NA",null,"21177912|23114372","Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol. 2011 Mar;18(3):483-6. doi: 10.1128/CVI.00304-10. Epub 2010 Dec 22.|Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrljin T, Dull PM. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents. Pediatr Infect Dis J. 2013 Apr;32(4):e170-7. doi: 10.1097/INF.0b013e318279ac38.","\tMeningococcal Disease|Meningococcal Meningitis\tNovartis Meningococcal (MenACWY-CRM) vaccine\tNA\tNA\tNA\tBiological\tAll\t","A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY","Interventional","Completed","Phase 2",3,155,"meningitis, meningococcal|meningitis|meningococcal infections","lactitol","Geometric Mean Titer After Booster Vaccination"]
["NCT01023256",8139000,4443463,null,"NA",null,"NA",{"$nulls":3},0.135,"Fisher Exact",24534756,"Behrens F, Tak PP, Østergaard M, Stoilov R, Wiland P, Huizinga TW, Berenfus VY, Vladeva S, Rech J, Rubbert-Roth A, Korkosz M, Rekalov D, Zupanets IA, Ejbjerg BJ, Geiseler J, Fresenius J, Korolkiewicz RP, Schottelius AJ, Burkhardt H. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis. 2015 Jun;74(6):1058-64. doi: 10.1136/annrheumdis-2013-204816. Epub 2014 Feb 17.","\tRheumatoid Arthritis\tMOR103|MOR103|MOR103\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis","Interventional","Completed","Phase 1/Phase 2",3,96,"arthritis|arthritis, rheumatoid","antibodies, monoclonal","Percentages of Subjects With American College of Rheumatology 20% Improvement (ACR20) at Week 4"]
["NCT01029808","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26346645|24509327","Olsson A, Hellgren M, Berntorp E, Baghaei F. Association between bleeding tendency and health-related quality of life in carriers of moderate and severe haemophilia. Haemophilia. 2015 Nov;21(6):742-6. doi: 10.1111/hae.12796. Epub 2015 Sep 8.|Olsson A, Hellgren M, Berntorp E, Ljung R, Baghaei F. Clotting factor level is not a good predictor of bleeding in carriers of haemophilia A and B. Blood Coagul Fibrinolysis. 2014 Jul;25(5):471-5. doi: 10.1097/MBC.0000000000000083.","\tHemophilia\tNA\tNA\tNA\tNA\tNA\tFemale\t","NA","NA","NA","NA","NA","NA","hemophilia a","NA","NA"]
["NCT01034124","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19114462,"Ngo N, Yan Z, Graf TN, Carrizosa DR, Kashuba AD, Dees EC, Oberlies NH, Paine MF. Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans. Drug Metab Dispos. 2009 Mar;37(3):514-22. doi: 10.1124/dmd.108.024968. Epub 2008 Dec 29.","\tPharmacokinetics\twarfarin, vitamin K, midazolam\tCrossover Assignment\tBasic Science\tRandomized\tDrug\tAll\t","Mechanisms Underlying Drug-Diet Interactions","Interventional","Completed","N/A",2,19,"NA","warfarin|vitamin k|midazolam","NA"]
["NCT01037127",8136955,4441796,"percentage of participants",26,null,"NA",14.3,41.4,95,"NA",null,23248257,"Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis KD. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 1;31(4):482-9. doi: 10.1200/JCO.2012.43.5966. Epub 2012 Dec 17.","\tCancer\tGSK1120212\tNA\tNA\tNA\tDrug\tAll\t","Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor","Interventional","Completed","Phase 2",2,97,"melanoma","trametinib","Number of Participants With Best Confirmed Response in the Indicated Subgroups of Participants Previously Treated With Standard Therapy But Not BRAF Inhibitors"]
["NCT01041209","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24039234,"Torres FA, Pasarelli I, Cutri A, Ossorio MF, Ferrero F. Impact assessment of a decision rule for using antibiotics in pneumonia: a randomized trial. Pediatr Pulmonol. 2014 Jul;49(7):701-6. doi: 10.1002/ppul.22849. Epub 2013 Aug 23.","\tPneumonia\tStrategy based on BPS guided antibiotic use|Enforced Guidelines\tParallel Assignment\tDiagnostic\tRandomized\tBehavioral|Behavioral\tAll\t","Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Community Acquired Pneumonia","Interventional","Completed","N/A",2,120,"pneumonia|pneumonia, bacterial","anti-bacterial agents","NA"]
["NCT01045356","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12151929,"Dowd NP, Karski JM, Cheng DC, Carroll JA, Lin Y, James RL, Butterworth J. Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology. 2002 Aug;97(2):390-9.","\tCongenital Heart Disease\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","heart defects, congenital|heart diseases","NA","NA"]
["NCT01050478","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Audenaert K, Godenir F, Geerts P, Van Gils L, Wouters C, Detraux J. IMPACT (Invega in the Management of Patients in the ACute seTting): results from a Belgian study using paliperidone extended-release in the management of psychotic patients with acute agitation and/or aggression. Acta Psychiatrica Belgica 2013 113 (4) 21-30.","\tAcute Disease|Psychomotor Agitation\tPaliperidone ER|Benzodiazepine\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","acute disease|psychomotor agitation","paliperidone palmitate","NA"]
["NCT01056718",8134657,4440160,null,"NA",null,"NA",{"$nulls":3},0.05,"t-test, 2 sided",10109801,"EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199-208.","\tHypertension\tNebivolol\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","hypertension","nebivolol","Mitral Valve Inflow (E) Velocity"]
["NCT01057550","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","a randomised control trial comparing TVT, Pelvicol and autologous fascial slings for the treatment of stress urinary incontinence in women. BJU Int 2008:101:supp 5;p27","\tStress Urinary Incontinence\tAutologous fascial sling|TVT|Pelvicol\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure|Procedure\tFemale\t","Randomised Controlled Trial Comparing Tension-Free Vaginal Tape (TVT), Pelvicol & Autologous Slings for Stress Urinary Incontinence(SUI)","Interventional","Completed","Phase 3",3,201,"enuresis|urinary incontinence, stress|urinary incontinence","NA","NA"]
["NCT01059799","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23130654|26484727|24170235|26232910|26663320|25081590|24812526|24843715","Ratner RE, Gough SC, Mathieu C, Del Prato S, Bode B, Mersebach H, Endahl L, Zinman B. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013 Feb;15(2):175-84. doi: 10.1111/dom.12032. Epub 2012 Dec 3.|Heller S, Mathieu C, Kapur R, Wolden ML, Zinman B. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia. Diabet Med. 2016 Apr;33(4):478-87. doi: 10.1111/dme.13002. Epub 2015 Dec 13.|Sorli C, Warren M, Oyer D, Mersebach H, Johansen T, Gough SC. Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials. Drugs Aging. 2013 Dec;30(12):1009-18. doi: 10.1007/s40266-013-0128-2.|Russell-Jones D, Gall MA, Niemeyer M, Diamant M, Del Prato S. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials. Nutr Metab Cardiovasc Dis. 2015 Oct;25(10):898-905. doi: 10.1016/j.numecd.2015.06.005. Epub 2015 Jun 18. Review.|Vora J, Seufert J, Solberg H, Kinduryte O, Johansen T, Hollander P. Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials. Diabetes Obes Metab. 2016 Jul;18(7):716-20. doi: 10.1111/dom.12621. Epub 2016 Feb 8.|Vora J, Christensen T, Rana A, Bain SC. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther. 2014 Dec;5(2):435-46. doi: 10.1007/s13300-014-0076-9. Epub 2014 Aug 1.|Aye MM, Atkin SL. Patient safety and minimizing risk with insulin administration - role of insulin degludec. Drug Healthc Patient Saf. 2014 Apr 30;6:55-67. doi: 10.2147/DHPS.S59566. eCollection 2014. Review.|Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC, Park S. Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig. 2013 Nov 27;4(6):605-12. doi: 10.1111/jdi.12102. Epub 2013 Jun 3.","\tDiabetes|Diabetes Mellitus, Type 2\tinsulin degludec|insulin glargine\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes","Interventional",null,null,"NA","NA","diabetes mellitus|diabetes mellitus, type 2","insulin|insulin, globin zinc|insulin glargine","NA"]
["NCT01062685","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23824446|21939529","Skibsted S, Arnold R, Sherwin R, Singh S, Lundy D, Nelson T, Puskarich MA, Trzeciak S, Jones AE, Shapiro NI. The association of near infrared spectroscopy-derived StO2 measurements and biomarkers of endothelial activation in sepsis. Intern Emerg Med. 2013 Sep;8(6):529-36. doi: 10.1007/s11739-013-0973-3. Epub 2013 Jul 4.|Shapiro NI, Arnold R, Sherwin R, O'Connor J, Najarro G, Singh S, Lundy D, Nelson T, Trzeciak SW, Jones AE; Emergency Medicine Shock Research Network (EMShockNet). The association of near-infrared spectroscopy-derived tissue oxygenation measurements with sepsis syndromes, organ dysfunction and mortality in emergency department patients with sepsis. Crit Care. 2011;15(5):R223. doi: 10.1186/cc10463. Epub 2011 Sep 22.","\tSeptic Shock\tNear-infrared spectroscopy assessment\tNA\tNA\tNA\tDiagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","shock, septic","NA","NA"]
["NCT01067144","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29238824,"Hah J, Mackey SC, Schmidt P, McCue R, Humphreys K, Trafton J, Efron B, Clay D, Sharifzadeh Y, Ruchelli G, Goodman S, Huddleston J, Maloney WJ, Dirbas FM, Shrager J, Costouros JG, Curtin C, Carroll I. Effect of Perioperative Gabapentin on Postoperative Pain Resolution and Opioid Cessation in a Mixed Surgical Cohort: A Randomized Clinical Trial. JAMA Surg. 2018 Apr 1;153(4):303-311. doi: 10.1001/jamasurg.2017.4915. Erratum in: JAMA Surg. 2018 Apr 1;153(4):396.","\tBreast Cancer|Lung Cancer|Pain\tGabapentin|Lorazepam (active control)|Placebo (inactive)\tParallel Assignment\tSupportive Care\tRandomized\tDrug|Drug|Drug\tAll\t","Stanford Accelerated Recovery Trial (START)","Interventional","Terminated","Phase 3",2,422,"NA","lorazepam|gabapentin","NA"]
["NCT01073657",8132507,4438957,"Mean Difference (Net)",18,"Standard Deviation",33.9,14,38,95,0.0059,"t-test, 2 sided",22246119,"Ellison ML, Mueller L, Smelson D, Corrigan PW, Torres Stone RA, Bokhour BG, Najavits LM, Vessella JM, Drebing C. Supporting the education goals of post-9/11 veterans with self-reported PTSD symptoms: a needs assessment. Psychiatr Rehabil J. 2012 Winter;35(3):209-17. doi: 10.2975/35.3.2012.209.217.","\tPTSD\tSupported Education|General Peer Support\tNA\tNA\tNA\tOther|Other\tAll\t","Supported Education Pilot","Interventional","Completed","Early Phase 1",2,33,"NA","NA","\"Supported Education Process Measure\""]
["NCT01076712","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19025984|11175678|17398252|12360555","Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N; Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15;23(15):2129-70. doi: 10.1002/mds.22340.|\"Morris S, Morris ME, Iansek R. Reliability of measurements obtained with the Timed \"\"Up & Go\"\" test in people with Parkinson disease. Phys Ther. 2001 Feb;81(2):810-8.\"|Mak MK, Lau AL, Law FS, Cheung CC, Wong IS. Validation of the Chinese translated Activities-Specific Balance Confidence scale. Arch Phys Med Rehabil. 2007 Apr;88(4):496-503.|Tsang KL, Chi I, Ho SL, Lou VW, Lee TM, Chu LW. Translation and validation of the standard Chinese version of PDQ-39: a quality-of-life measure for patients with Parkinson's disease. Mov Disord. 2002 Sep;17(5):1036-40.","\tParkinson Disease\tPhysiotherapy Interventions|Education Classes\tParallel Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Effectiveness of Physiotherapy Interventions for Patients With Parkinson's Disease","Interventional","Unknown status","N/A",2,112,"parkinson disease","NA","NA"]
["NCT01077011","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","http://www.aaopt.org/evaluation-efficacy-and-patient-acceptance-new-lubricant-eye-gel","\tDry Eye\tLubricant eye drop FID 115958D|GenTeal Gel\tCrossover Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Acute Comfort and Blur Profile of a Lubricant Eye Drop Versus a Marketed Lubricant Eye Gel","Interventional","Completed","N/A",2,25,"keratoconjunctivitis sicca|dry eye syndromes","lubricant eye drops|ophthalmic solutions","NA"]
["NCT01083524","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15375007,"McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K, Michelakis ED. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res. 2004 Oct 15;95(8):830-40. Epub 2004 Sep 16.","\tPulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)\tDichloroacetate Sodium|Dichloroacetate Sodium|Dichloroacetate Sodium\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension","Interventional","Completed","Phase 1",3,30,"hypertension|hypertension, pulmonary","NA","NA"]
["NCT01085318",8130678,4438121,"Median Difference (Final Values)",864.1,null,"NA",{"$nulls":3},0.061,"Wilcoxon (Mann-Whitney)","26559139|24625687","Dwyer MG, Zivadinov R, Tao Y, Zhang X, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Weinstock-Guttman B, Hayward B, Dangond F, Markovic-Plese S. Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial. BMC Neurol. 2015 Nov 11;15:232. doi: 10.1186/s12883-015-0488-9.|Zivadinov R, Dwyer MG, Markovic-Plese S, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B. Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study. PLoS One. 2014 Mar 13;9(3):e91098. doi: 10.1371/journal.pone.0091098. eCollection 2014.","\tMultiple Sclerosis\tRebif\tNA\tNA\tNA\tDrug\tAll\t","Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial","Interventional","Completed","Phase 4",2,38,"multiple sclerosis|sclerosis","NA","Change in Volume (in Millimeters Cubed) of Normal Appearing Brain Tissue (NABT) With Increasing (Indicative of Remyelination) Voxel-wise Magnetization Transfer Ratio (VW-MTR) From Baseline to 6 Months"]
["NCT01087905",8130371,4438036,"Odds Ratio (OR)",0.89,null,"NA",0.69,1.14,95,0.343,"Regression, Logistic",22992296,"Smith SS, Keller PA, Kobinsky KH, Baker TB, Fraser DL, Bush T, Magnusson B, Zbikowski SM, McAfee TA, Fiore MC. Enhancing tobacco quitline effectiveness: identifying a superior pharmacotherapy adjuvant. Nicotine Tob Res. 2013 Mar;15(3):718-28. doi: 10.1093/ntr/nts186. Epub 2012 Sep 19.","\tSmoking|Smoking Cessation\tNicotine patch|Nicotine gum|CMAC\tNA\tNA\tNA\tDrug|Drug|Behavioral\tAll\t","Improving the Population-Wide Effectiveness of U.S. Tobacco Cessation Quitlines","Interventional","Completed","Phase 4",8,987,"NA","nicotine","7-Day Point Prevalence Abstinence From Smoking by Intervention"]
["NCT01090193","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",7620083,"Green J, Better OS. Systemic hypotension and renal failure in obstructive jaundice-mechanistic and therapeutic aspects. J Am Soc Nephrol. 1995 May;5(11):1853-71. Review.","\tPatients With Obstructive Jaundice\tWhipple operation,Hepaticojejunostomy\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","jaundice, obstructive|jaundice","NA","NA"]
["NCT01093651",8129654,4437826,null,"NA",null,"NA",{"$nulls":3},0.04,"Mixed Models Analysis","NA|23264399","Goodwin SR, Reeds DN, Royal M, Struthers H, Laciny E, Yarasheski KE. Dipeptidyl Peptidase IV Inhibition Does Not Adversely Affect Immune and Virologic Status of HIV+ Men and Women. Diabetes. 2012;61(Suppl 1) A237 (abstract # 932-P).|Goodwin SR, Reeds DN, Royal M, Struthers H, Laciny E, Yarasheski KE. Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study. J Clin Endocrinol Metab. 2013 Feb;98(2):743-51. doi: 10.1210/jc.2012-3532. Epub 2012 Dec 21.","\tDiabetes|Insulin Resistance\tSitagliptin|Placebo\tNA\tNA\tNA\tDrug|Drug\tAll\t","Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV","Interventional","Completed","Phase 2/Phase 3",2,20,"insulin resistance","sitagliptin phosphate","Oral Glucose Tolerance"]
["NCT01099410","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25847945|23497334","Bourdonnay E, Zasłona Z, Penke LR, Speth JM, Schneider DJ, Przybranowski S, Swanson JA, Mancuso P, Freeman CM, Curtis JL, Peters-Golden M. Transcellular delivery of vesicular SOCS proteins from macrophages to epithelial cells blunts inflammatory signaling. J Exp Med. 2015 May 4;212(5):729-42. doi: 10.1084/jem.20141675. Epub 2015 Apr 6.|Todt JC, Freeman CM, Brown JP, Sonstein J, Ames TM, McCubbrey AL, Martinez FJ, Chensue SW, Beck JM, Curtis JL. Smoking decreases the response of human lung macrophages to double-stranded RNA by reducing TLR3 expression. Respir Res. 2013 Mar 9;14:33. doi: 10.1186/1465-9921-14-33.","\tChronic Obstructive Pulmonary Disease\tFiberoptic bronchoscopy|blood draw|intravenous catheter\tNA\tNA\tNA\tProcedure|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","pulmonary disease, chronic obstructive|lung diseases, obstructive","NA","NA"]
["NCT01102374","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27861708,"Ginde AA, Blatchford P, Breese K, Zarrabi L, Linnebur SA, Wallace JI, Schwartz RS. High-Dose Monthly Vitamin D for Prevention of Acute Respiratory Infection in Older Long-Term Care Residents: A Randomized Clinical Trial. J Am Geriatr Soc. 2017 Mar;65(3):496-503. doi: 10.1111/jgs.14679. Epub 2016 Nov 16.","\tRespiratory Infection\tHigh Dose Vitamin D|Standard Dose Vitamin D|Placebo|Usual Care\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug|Drug|Dietary Supplement\tAll\t","Vitamin D Supplementation and Acute Respiratory Infection in Older Long-Term Care Residents","Interventional","Completed","Phase 2",2,107,"communicable diseases|infection|respiratory tract infections","vitamins|ergocalciferols|vitamin d","NA"]
["NCT01106300","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24108501|24519306","Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, Hopkinson NS, Phadke R, Dew T, Sidhu PS, Velloso C, Seymour J, Agley CC, Selby A, Limb M, Edwards LM, Smith K, Rowlerson A, Rennie MJ, Moxham J, Harridge SD, Hart N, Montgomery HE. Acute skeletal muscle wasting in critical illness. JAMA. 2013 Oct 16;310(15):1591-600. Erratum in: JAMA. 2014 Feb 12;311(6):625. Padhke, Rahul [corrected to Phadke, Rahul].|Puthucheary ZA, McPhail MJ, Hart N. Acute muscle wasting among critically ill patients--reply. JAMA. 2014 Feb 12;311(6):622-3. doi: 10.1001/jama.2013.285426.","\tCritical Illness|Organ Failure|Septic Shock|Trauma\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","critical illness","NA","NA"]
["NCT01108094",8127684,4436714,"Mean Difference (Final Values)",24,null,"NA",18.2,30,95,"NA",null,24493717,"Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, Fu T, Gilliam A, Molgo M, Beachy PA, Tang JY. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014 Mar 10;32(8):745-51. doi: 10.1200/JCO.2013.49.9525. Epub 2014 Feb 3.","\tBasal Cell Carcinoma (BCC)|Skin Cancer\tItraconazole\tNA\tNA\tNA\tDrug\tAll\t","Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas","Interventional","Completed","Phase 2",3,29,"carcinoma, basal cell|skin neoplasms|carcinoma","itraconazole","Tumor Size"]
["NCT01111149",8127386,4436546,null,"NA",null,"NA",{"$nulls":3},0.05,"ANOVA",23507358,"Fatemi SH, Yousefi MK, Kneeland RE, Liesch SB, Folsom TD, Thuras PD. Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: a double-blind placebo and bupropion-controlled study. Schizophr Res. 2013 May;146(1-3):376-8. doi: 10.1016/j.schres.2013.02.015. Epub 2013 Mar 16.","\tSchizophrenia|Smoking Cessation\tSugar Pill|Varenicline|Bupropion HCl\tNA\tNA\tNA\tOther|Drug|Drug\tAll\t","Varenicline and Smoking Cessation in Schizophrenia","Interventional","Completed","Phase 2",3,24,"schizophrenia","bupropion|varenicline","Abnormal Movements - AIMS"]
["NCT01111149",8127401,4436580,null,"NA",null,"NA",{"$nulls":3},0.05,"ANOVA",23507358,"Fatemi SH, Yousefi MK, Kneeland RE, Liesch SB, Folsom TD, Thuras PD. Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: a double-blind placebo and bupropion-controlled study. Schizophr Res. 2013 May;146(1-3):376-8. doi: 10.1016/j.schres.2013.02.015. Epub 2013 Mar 16.","\tSchizophrenia|Smoking Cessation\tSugar Pill|Varenicline|Bupropion HCl\tNA\tNA\tNA\tOther|Drug|Drug\tAll\t","Varenicline and Smoking Cessation in Schizophrenia","Interventional","Completed","Phase 2",3,24,"schizophrenia","bupropion|varenicline","Abnormal Movements - BAS and SAS"]
["NCT01111149",8127404,4436590,null,"NA",null,"NA",{"$nulls":3},0.05,"Fisher Exact",23507358,"Fatemi SH, Yousefi MK, Kneeland RE, Liesch SB, Folsom TD, Thuras PD. Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: a double-blind placebo and bupropion-controlled study. Schizophr Res. 2013 May;146(1-3):376-8. doi: 10.1016/j.schres.2013.02.015. Epub 2013 Mar 16.","\tSchizophrenia|Smoking Cessation\tSugar Pill|Varenicline|Bupropion HCl\tNA\tNA\tNA\tOther|Drug|Drug\tAll\t","Varenicline and Smoking Cessation in Schizophrenia","Interventional","Completed","Phase 2",3,24,"schizophrenia","bupropion|varenicline","Side Effects"]
["NCT01111149",8127408,4436626,null,"NA",null,"NA",{"$nulls":3},0.05,"ANOVA",23507358,"Fatemi SH, Yousefi MK, Kneeland RE, Liesch SB, Folsom TD, Thuras PD. Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: a double-blind placebo and bupropion-controlled study. Schizophr Res. 2013 May;146(1-3):376-8. doi: 10.1016/j.schres.2013.02.015. Epub 2013 Mar 16.","\tSchizophrenia|Smoking Cessation\tSugar Pill|Varenicline|Bupropion HCl\tNA\tNA\tNA\tOther|Drug|Drug\tAll\t","Varenicline and Smoking Cessation in Schizophrenia","Interventional","Completed","Phase 2",3,24,"schizophrenia","bupropion|varenicline","Smoking Abstinence - Serum/Urine Measurements"]
["NCT01112358","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","M.J. Fernández Ramírez, A. Monzó, T. García-Gimeno, J.M. Rubio, V. Montañana, C. Duque, G. Herrero, A. Romeu. Role of LH administration during the follicullar phase in women with risk of low response in ovarian stimulation with FSH and cetrorelix for IVF, REVISTA IBEROAMERICANA DE FERTILIDAD, Vol. 23- nº 5 - Septiembre-Octubre 2006","\tOvarian Stimulation\tr-FSH|r-hLH|Analogous GnRH antagonist|r-hCG|Progesterone\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug|Drug\tFemale\t","Lutropin Alfa in Women at Risk of Poor Response","Interventional","Completed","Phase 2",2,58,"NA","progesterone|cetrorelix","NA"]
["NCT01118949","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28086164,"Wechsler RT, Yates SL, Messenheimer J, Leroy R, Beller C, Doty P. Lacosamide for uncontrolled primary generalized tonic-clonic seizures: An open-label pilot study with 59-week extension. Epilepsy Res. 2017 Feb;130:13-20. doi: 10.1016/j.eplepsyres.2016.12.015. Epub 2016 Dec 29.","\tEpilepsy\tLacosamide\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","epilepsy|seizures","lacosamide","NA"]
["NCT01121185","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23356386,"Chung RT, Gordon FD, Curry MP, Schiano TD, Emre S, Corey K, Markmann JF, Hertl M, Pomposelli JJ, Pomfret EA, Florman S, Schilsky M, Broering TJ, Finberg RW, Szabo G, Zamore PD, Khettry U, Babcock GJ, Ambrosino DM, Leav B, Leney M, Smith HL, Molrine DC. Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant. 2013 Apr;13(4):1047-1054. doi: 10.1111/ajt.12083. Epub 2013 Jan 28.","\tHCV Infection|Liver Transplantation\tMBL-HCV1|0.9% Sodium chloride Placebo\tParallel Assignment\tPrevention\tRandomized\tBiological|Other\tAll\t","Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C","Interventional","Terminated","Phase 2",2,13,"hepatitis c|hepatitis|hepatitis a","NA","NA"]
["NCT01124448","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24880136,"Vázquez-Fresno R, Llorach R, Marinic J, Tulipani S, Garcia-Aloy M, Espinosa-Martos I, Jiménez E, Rodríguez JM, Andres-Lacueva C. Urinary metabolomic fingerprinting after consumption of a probiotic strain in women with mastitis. Pharmacol Res. 2014 Sep;87:160-5. doi: 10.1016/j.phrs.2014.05.010. Epub 2014 May 29.","\tMastitis\tLactobacillus salivarius PS2|Lactobacillus salivarius PS2\tNA\tNA\tNA\tBiological|Biological\tFemale\t","Global Effects of a Probiotic Strain on Lactating Women","Interventional","Completed","N/A",2,40,"mastitis","tff1 protein, human","NA"]
["NCT01129622","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22258545,"Mousa NA, Eiada R, Crystal P, Nayot D, Casper RF. The effect of acute aromatase inhibition on breast parenchymal enhancement in magnetic resonance imaging: a prospective pilot clinical trial. Menopause. 2012 Apr;19(4):420-5. doi: 10.1097/gme.0b013e31823772a8.","\tBreast Cancer\tletrozole\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","NA","letrozole","NA"]
["NCT01133106","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Kirkness, CJ, Buzaitis, A, Habermann, B, Jessup, NM, McClennon, SM, McKenzie, S, Weaver, M, Weisman, P, Mitchell PH, Bakas, T. (2014) Methodological issues in telephone interventions for stroke survivors and family caregivers. Abstract 86. Stroke. 45(Suppl_1) (Supplement 1):A86, February 2014|Kirkness CJ, Becker KJ, Cain KC, Kohen, R, Tirschwell, DL, Teri L, Veith RR, Mitchell PH (2015) Telephone versus in-person psychosocial behavioral treatment in post-stroke depression. Abstract WP:125. Stroke 46 (supplement 1): WP 125, February 2015. http://stroke.ahajournals.org/content/46/Suppl_1/AWP125.abstract?sid=441a6914-e14e-4969-85f9-964367d56ed7","\tCerebrovascular Stroke|Depression\tBrief pleasurable events/behavioral therapy|Standard care\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Other\tAll\t","Living Well With Stroke","Interventional","Completed","N/A",3,100,"stroke|depression","NA","NA"]
["NCT01137084","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19857686|19502970|19459814|17889125|17645714","Foroncewicz B, Mucha K, Ryszkowska E, Ciszek M, Ziółkowski J, Porowski D, Krawczyk M, Paczek L. Safety and efficacy of steroid-free immunosuppression with tacrolimus and daclizumab in liver transplant recipients: 6-year follow-up in a single center. Transplant Proc. 2009 Oct;41(8):3103-6. doi: 10.1016/j.transproceed.2009.07.082.|Sutherland S, Li L, Concepcion W, Salvatierra O, Sarwal MM. Steroid-free immunosuppression in pediatric renal transplantation: rationale for and [corrected] outcomes following conversion to steroid based therapy. Transplantation. 2009 Jun 15;87(11):1744-8. doi: 10.1097/TP.0b013e3181a5df60. Erratum in: Transplantation. 2009 Sep 27;88(6):852.|Li L, Chang A, Naesens M, Kambham N, Waskerwitz J, Martin J, Wong C, Alexander S, Grimm P, Concepcion W, Salvatierra O, Sarwal MM. Steroid-free immunosuppression since 1999: 129 pediatric renal transplants with sustained graft and patient benefits. Am J Transplant. 2009 Jun;9(6):1362-72. doi: 10.1111/j.1600-6143.2009.02640.x. Epub 2009 May 13.|Mastrobuoni S, Ubilla M, Cordero A, Herreros J, Rabago G. Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience. Transplant Proc. 2007 Sep;39(7):2163-6.|Humar A, Crotteau S, Gruessner A, Kandaswamy R, Gruessner R, Payne W, Lake J. Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes. Clin Transplant. 2007 Jul-Aug;21(4):526-31.","\tHepatocellular Carcinoma|Immunosuppression|Liver Transplantation|Post-operative Complications\tsolu medrol|a steroid-free immunosuppression protocol\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Liver Transplantation Results in Hepatocellular Carcinoma Patients With Immunosuppression Without Steroids","Interventional","Completed","N/A",2,300,"carcinoma|postoperative complications|carcinoma, hepatocellular","methylprednisolone|prednisolone acetate|prednisolone phosphate|methylprednisolone hemisuccinate|prednisolone hemisuccinate|methylprednisolone acetate|prednisolone","NA"]
["NCT01140386","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Department of Health and Human Services, Centers for Disease Control and Prevention: http://www.cdc.gov/nchs/data/series/sr_23/sr23_024.pdf 2. L.T. Vu, K.K. Nobuhara, and H. Lee et al., Determination of risk factors for deep venous thrombosis in hospitalized children. Journal of Pediatric Surgery 43 (2008), pp 1095-1099. 3. M.S. Vavilala, A.B. Nathens and G.J. Jurkovich et al., Risk factors for venous thromboembolism in pediatric trauma, J Trauma 52 (2002), pp. 922-927 4. National Health and Nutrition Exam Survey (NHANES); Dept of Health and Human Services, Centers for Disease Control and Prevention: http://www.cdc.gov/nccdphp/dnpa/obesity/childhood/prevalence.htm 5. P.D. Stein, F. Kayali and R.E Olson et al. Incidence of venous thromboembolism in infants and children: Data from the National Hospital Discharge Survey, The Journal of Pediatrics 145 (2004), pp 563-565. 6. R. Pendleton, M. Wheeler, and G. Rodgers. Venous Thromboembolism Prevention in the Acutely Ill Medical Patient: A Review of the Literature and Focus on Special Patient Populations, American Journal of Hematology 79 (2005), pp 229-237.","\tDeep Venous Thrombosis|Pediatrics|Venous Thromboembolism\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","venous thromboembolism|thrombosis|thromboembolism|venous thrombosis","NA","NA"]
["NCT01144468","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22318095,"Cheung AM, Tile L, Cardew S, Pruthi S, Robbins J, Tomlinson G, Kapral MK, Khosla S, Majumdar S, Erlandson M, Scher J, Hu H, Demaras A, Lickley L, Bordeleau L, Elser C, Ingle J, Richardson H, Goss PE. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):275-84. doi: 10.1016/S1470-2045(11)70389-8. Epub 2012 Feb 7.","\tBreast Cancer|Osteoporosis\tNA\tNA\tNA\tNA\tNA\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms|osteoporosis","NA","NA"]
["NCT01148199","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19523620|18294506|19877248","Mahajan A, Ho H, Sauer B, Phillips MS, Shami VM, Ellen K, Rehan M, Schmitt TM, Kahaleh M. Temporary placement of fully covered self-expandable metal stents in benign biliary strictures: midterm evaluation (with video). Gastrointest Endosc. 2009 Aug;70(2):303-9. doi: 10.1016/j.gie.2008.11.029. Epub 2009 Jun 11.|Kahaleh M, Behm B, Clarke BW, Brock A, Shami VM, De La Rue SA, Sundaram V, Tokar J, Adams RB, Yeaton P. Temporary placement of covered self-expandable metal stents in benign biliary strictures: a new paradigm? (with video). Gastrointest Endosc. 2008 Mar;67(3):446-54. doi: 10.1016/j.gie.2007.06.057.|Traina M, Tarantino I, Barresi L, Volpes R, Gruttadauria S, Petridis I, Gridelli B. Efficacy and safety of fully covered self-expandable metallic stents in biliary complications after liver transplantation: a preliminary study. Liver Transpl. 2009 Nov;15(11):1493-8. doi: 10.1002/lt.21886.","\tBiliary Anastomotic Stenosis|Biliary Stricture\tSelf-expandable metalic stent|Multiple plastic stents\tParallel Assignment\tTreatment\tRandomized\tDevice|Device\tAll\t","Self-expandable Metallic Stent Versus Multiple Plastic Stents in Post Orthotopic Liver Transplantation Biliary Stenosis","Interventional","Completed","Phase 2/Phase 3",2,64,"constriction, pathologic","NA","NA"]
["NCT01156701",8120721,4432346,"Risk Difference (RD)",0.93,null,"NA",-2.29,4.14,95,"NA",null,"NA","Kandace Amend, Vani Vannappagari, Maria Wood-Armany, Rob Gately, John Seeger; Effectiveness of Zanamivir Prophylaxis for Influenza.26th ICPE: International Conference on Pharmacoepidemiology & Therapeutic Risk Management August 19-22, 2010, Brighton, UK","\tAsthma|Bronchitis|Bronchospasm|Exacerbation of COPD|Influenza, Human|Otitis Maedia|Pneumonia|Pulmonary Disease, Chronic Obstructive|Respiratory Disease|Sinusitis\tReceiving a prescription of Relenza for prophylaxis|No prophylaxis with Relenza\tNA\tNA\tNA\tDrug|Other\tAll\t","NA","NA","NA","NA","NA","NA","sinusitis|influenza, human|bronchitis|pulmonary disease, chronic obstructive|bronchial spasm|respiration disorders|respiratory tract diseases|pneumonia","zanamivir","Number of Patients With Any Respiratory Diagnosis"]
["NCT01156701",8120723,4432360,"Risk Ratio (RR)",1,null,"NA",1,1,95,"NA",null,"NA","Kandace Amend, Vani Vannappagari, Maria Wood-Armany, Rob Gately, John Seeger; Effectiveness of Zanamivir Prophylaxis for Influenza.26th ICPE: International Conference on Pharmacoepidemiology & Therapeutic Risk Management August 19-22, 2010, Brighton, UK","\tAsthma|Bronchitis|Bronchospasm|Exacerbation of COPD|Influenza, Human|Otitis Maedia|Pneumonia|Pulmonary Disease, Chronic Obstructive|Respiratory Disease|Sinusitis\tReceiving a prescription of Relenza for prophylaxis|No prophylaxis with Relenza\tNA\tNA\tNA\tDrug|Other\tAll\t","NA","NA","NA","NA","NA","NA","sinusitis|influenza, human|bronchitis|pulmonary disease, chronic obstructive|bronchial spasm|respiration disorders|respiratory tract diseases|pneumonia","zanamivir","Number of Patients With Pneumonia"]
["NCT01156701",8120725,4432381,"Risk Ratio (RR)",1,null,"NA",0.99,1.02,95,"NA",null,"NA","Kandace Amend, Vani Vannappagari, Maria Wood-Armany, Rob Gately, John Seeger; Effectiveness of Zanamivir Prophylaxis for Influenza.26th ICPE: International Conference on Pharmacoepidemiology & Therapeutic Risk Management August 19-22, 2010, Brighton, UK","\tAsthma|Bronchitis|Bronchospasm|Exacerbation of COPD|Influenza, Human|Otitis Maedia|Pneumonia|Pulmonary Disease, Chronic Obstructive|Respiratory Disease|Sinusitis\tReceiving a prescription of Relenza for prophylaxis|No prophylaxis with Relenza\tNA\tNA\tNA\tDrug|Other\tAll\t","NA","NA","NA","NA","NA","NA","sinusitis|influenza, human|bronchitis|pulmonary disease, chronic obstructive|bronchial spasm|respiration disorders|respiratory tract diseases|pneumonia","zanamivir","Number of Patients With Influenza"]
["NCT01157247","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19471833|14609894|12708207","Almeida GP, Boos GL, Alencar TG, Oliveira Filho GR. [Onset of 1% lidocaine for skin infiltrative anesthesia]. Rev Bras Anestesiol. 2005 Jun;55(3):284-8. Portuguese.|Kaur G, Gupta P, Kumar A. A randomized trial of eutectic mixture of local anesthetics during lumbar puncture in newborns. Arch Pediatr Adolesc Med. 2003 Nov;157(11):1065-70.|Calderón E, Pernia A, Román MD, Pérez AC, Torres LM. [Analgesia and sedation in the subarachnoid anesthesia technique: comparative study between remifentanil and fentanyl/midazolam]. Rev Esp Anestesiol Reanim. 2003 Mar;50(3):121-5. Spanish.","\tAnesthesia|Spinal Puncture\tComparison of intravenous fentanyl and local anesthetic infiltration in pain reducing during spinal needle puncture\tNA\tNA\tNA\tProcedure\tAll\t","Intravenous Fentanyl or Local Anesthetic Infiltration for Pain Reducing During Spinal Needle Insertion","Interventional","Completed","N/A",4,88,"NA","anesthetics, local|anesthetics|fentanyl","NA"]
["NCT01163045","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19177420,"Barczyński M, Konturek A, Cichoń S. Randomized clinical trial of visualization versus neuromonitoring of recurrent laryngeal nerves during thyroidectomy. Br J Surg. 2009 Mar;96(3):240-6. doi: 10.1002/bjs.6417.","\tThyroidectomy\tthyroidectomy\tParallel Assignment\tTreatment\tRandomized\tProcedure\tAll\t","Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerve Versus Neurostimulation","Interventional","Completed","Phase 2",2,250,"NA","NA","NA"]
["NCT01167452",8119352,4431359,"Slope",-0.56,"Standard Deviation",0.2,{"$nulls":3},{"v":1E-4,"d":"1.00E-04"},"Regression, Linear",27869362,"Hall RG Nd, Pasipanodya JG, Meek C, Leff RD, Swancutt M, Gumbo T. Fractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People. CPT Pharmacometrics Syst Pharmacol. 2016 Dec;5(12):674-681. doi: 10.1002/psp4.12146. Epub 2016 Nov 21.","\tMRSA|Obesity|PCP|Pharmacokinetics|Tuberculosis\tSulfamethoxazole/trimethoprim\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","obesity|tuberculosis","sulfamethoxazole|trimethoprim|trimethoprim, sulfamethoxazole drug combination","Elimination Rate Constants for Sulfamethoxazole and Trimethoprim"]
["NCT01172457","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19151054,"Fai KR, Engleback M, Norman JB, Griffiths R. Interlaminar approach for epiduroscopy in patients with failed back surgery syndrome. Br J Anaesth. 2009 Feb;102(2):280; author reply 280-1. doi: 10.1093/bja/aen371.","\tFailed Back Surgery Syndrome|Low Back Pain\tEpiduroscopy with oxygen therapy|Epiduroscopy with ozone therapy\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","The Effect of Epiduroscopy and Ozone Therapy in Patients With Failed Back Surgery Syndrome","Interventional","Completed","Phase 2",2,40,"low back pain|syndrome|failed back surgery syndrome|back pain","NA","NA"]
["NCT01178320","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29301785|25216871|25084698|25245415","Hippe DS, Phan BAP, Sun J, Isquith DA, O'Brien KD, Crouse JR, Anderson T, Huston J, Marcovina SM, Hatsukami TS, Yuan C, Zhao XQ. Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy: An Analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Carotid Magnetic Resonance Imaging Substudy-Brief Report. Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):673-678. doi: 10.1161/ATVBAHA.117.310368. Epub 2018 Jan 4.|Sun J, Zhao XQ, Balu N, Hippe DS, Hatsukami TS, Isquith DA, Yamada K, Neradilek MB, Cantón G, Xue Y, Fleg JL, Desvigne-Nickens P, Klimas MT, Padley RJ, Vassileva MT, Wyman BT, Yuan C. Carotid magnetic resonance imaging for monitoring atherosclerotic plaque progression: a multicenter reproducibility study. Int J Cardiovasc Imaging. 2015 Jan;31(1):95-103. doi: 10.1007/s10554-014-0532-7. Epub 2014 Sep 13.|Chen H, Sun J, Kerwin WS, Balu N, Neradilek MB, Hippe DS, Isquith D, Xue Y, Yamada K, Peck S, Yuan C, O'Brien KD, Zhao XQ. Scan-rescan reproducibility of quantitative assessment of inflammatory carotid atherosclerotic plaque using dynamic contrast-enhanced 3T CMR in a multi-center study. J Cardiovasc Magn Reson. 2014 Aug 1;16:51. doi: 10.1186/s12968-014-0051-7.|Zhao XQ, Hatsukami TS, Hippe DS, Sun J, Balu N, Isquith DA, Crouse JR 3rd, Anderson T, Huston J 3rd, Polissar N, O'Brien K, Yuan C; AIM-HIGH Carotid MRI Sub-study Investigators. Clinical factors associated with high-risk carotid plaque features as assessed by magnetic resonance imaging in patients with established vascular disease (from the AIM-HIGH Study). Am J Cardiol. 2014 Nov 1;114(9):1412-9. doi: 10.1016/j.amjcard.2014.08.001. Epub 2014 Aug 13.","\tAtherosclerosis|Carotid Artery Diseases|Coronary Artery Disease\tSimvastatin, simvastatin plus extended-release niacin\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","coronary artery disease|atherosclerosis|carotid artery diseases","niacin|niacinamide|simvastatin|nicotinic acids","NA"]
["NCT01182350","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29741745,"Gupta N, Goumnerova LC, Manley P, Chi SN, Neuberg D, Puligandla M, Fangusaro J, Goldman S, Tomita T, Alden T, DiPatri A, Rubin JB, Gauvain K, Limbrick D, Leonard J, Geyer JR, Leary S, Browd S, Wang Z, Sood S, Bendel A, Nagib M, Gardner S, Karajannis MA, Harter D, Ayyanar K, Gump W, Bowers DC, Weprin B, MacDonald TJ, Aguilera D, Brahma B, Robison NJ, Kiehna E, Krieger M, Sandler E, Aldana P, Khatib Z, Ragheb J, Bhatia S, Mueller S, Banerjee A, Bredlau AL, Gururangan S, Fuchs H, Cohen KJ, Jallo G, Dorris K, Handler M, Comito M, Dias M, Nazemi K, Baird L, Murray J, Lindeman N, Hornick JL, Malkin H, Sinai C, Greenspan L, Wright KD, Prados M, Bandopadhayay P, Ligon KL, Kieran MW. Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol. 2018 Oct 9;20(11):1547-1555. doi: 10.1093/neuonc/noy070.","\tDiffuse Intrinsic Pontine Glioma\tBevacizumab|Erlotinib|Temozolomide|Radiation\tNA\tNA\tNA\tDrug|Drug|Drug|Radiation\tAll\t","Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)","Interventional","Terminated","Phase 2",4,53,"glioma","temozolomide|erlotinib hydrochloride|bevacizumab","NA"]
["NCT01186926","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22043118,"Eastwood PR, Barnes M, Walsh JH, Maddison KJ, Hee G, Schwartz AR, Smith PL, Malhotra A, McEvoy RD, Wheatley JR, O'Donoghue FJ, Rochford PD, Churchward T, Campbell MC, Palme CE, Robinson S, Goding GS, Eckert DJ, Jordan AS, Catcheside PG, Tyler L, Antic NA, Worsnop CJ, Kezirian EJ, Hillman DR. Treating obstructive sleep apnea with hypoglossal nerve stimulation. Sleep. 2011 Nov 1;34(11):1479-86. doi: 10.5665/sleep.1380.","\tObstructive Sleep Apnea\tHGNS Treatment\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","sleep apnea syndromes|apnea|sleep apnea, obstructive","NA","NA"]
["NCT01187992","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20367555,"Colivicchi F, Tubaro M, Mocini D, Genovesi Ebert A, Strano S, Melina G, Uguccioni M, Santini M. Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease. Curr Med Res Opin. 2010 Jun;26(6):1277-84. doi: 10.1185/03007991003751496.","\tAcute Coronary Syndrome|Coronary Artery Disease\tAtorvastatin\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Full-dose Atorvastatin After Acute Coronary Syndrome (ACS) in Non-revascularisable Coronary Artery Disease","Interventional","Terminated","Phase 3",2,290,"coronary disease|syndrome|myocardial ischemia|acute coronary syndrome|coronary artery disease","atorvastatin","NA"]
["NCT01193907","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21980445,"van Damme P, Kafeja F, Anemona A, Basile V, Hilbert AK, De Coster I, Rondini S, Micoli F, Qasim Khan RM, Marchetti E, Di Cioccio V, Saul A, Martin LB, Podda A. Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. PLoS One. 2011;6(9):e25398. doi: 10.1371/journal.pone.0025398. Epub 2011 Sep 30.","\tTyphoid Fever\tNVGH Vi-CRM197 12.5 mcg|NVGH Vi-CRM197 5.0 mcg|NVGH Vi-CRM197 1.25 mcg|Vi-polysaccharide vaccine\tParallel Assignment\tPrevention\tRandomized\tBiological|Biological|Biological|Biological\tAll\t","Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)","Interventional","Completed","Phase 2",4,88,"typhoid fever","NA","NA"]
["NCT01195870","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22298944,"D'Arcy C, Thomas D, Stoneman D, Parkes L. Patient assessment of an electronic device for subcutaneous self-injection of interferon β-1a for multiple sclerosis: an observational study in the UK and Ireland. Patient Prefer Adherence. 2012;6:55-61. doi: 10.2147/PPA.S26250. Epub 2012 Jan 18.","\tMultiple Sclerosis\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","sclerosis|multiple sclerosis","NA","NA"]
["NCT01201226","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18192670|20479243|12798878","Hansen KR, Knowlton NS, Thyer AC, Charleston JS, Soules MR, Klein NA. A new model of reproductive aging: the decline in ovarian non-growing follicle number from birth to menopause. Hum Reprod. 2008 Mar;23(3):699-708. doi: 10.1093/humrep/dem408. Epub 2008 Jan 11.|Li J, Kawamura K, Cheng Y, Liu S, Klein C, Liu S, Duan EK, Hsueh AJ. Activation of dormant ovarian follicles to generate mature eggs. Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10280-4. doi: 10.1073/pnas.1001198107. Epub 2010 May 17.|Yoon TK, Kim TJ, Park SE, Hong SW, Ko JJ, Chung HM, Cha KY. Live births after vitrification of oocytes in a stimulated in vitro fertilization-embryo transfer program. Fertil Steril. 2003 Jun;79(6):1323-6.","\tLow Ovarian Reserve|Poor Responders to Gonadotropihins Treatment\tRemoval of half an ovary\tNA\tNA\tNA\tOther\tFemale\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT01206322","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24101698|25249577","Novak V, Milberg W, Hao Y, Munshi M, Novak P, Galica A, Manor B, Roberson P, Craft S, Abduljalil A. Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes. Diabetes Care. 2014;37(3):751-9. doi: 10.2337/dc13-1672. Epub 2013 Oct 7.|Zhang H, Hao Y, Manor B, Novak P, Milberg W, Zhang J, Fang J, Novak V. Intranasal insulin enhanced resting-state functional connectivity of hippocampal regions in type 2 diabetes. Diabetes. 2015 Mar;64(3):1025-34. doi: 10.2337/db14-1000. Epub 2014 Sep 23.","\tType 2 Diabetes Mellitus\tIntranasal insulin|Placebo\tCrossover Assignment\tOther\tRandomized\tDrug|Drug\tAll\t","Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes","Interventional","Completed","Phase 2",2,30,"diabetes mellitus|diabetes mellitus, type 2","insulin","NA"]
["NCT01210066","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25901477,"Compton P, Griffis C, Breen EC, Torrington M, Sadakane R, Tefera E, Irwin MR. Opioid treatment of experimental pain activates nuclear factor-κB. J Opioid Manag. 2015 Mar-Apr;11(2):115-25. doi: 10.5055/jom.2015.0261.","\tImmunologic Activity Alteration|Pro-inflammatory Activity\tFentanyl|Cold pressor test|Fentanyl plus cold pressor test\tNA\tNA\tNA\tDrug|Other|Other\tAll\t","Pain, Opioids and Pro-Inflammatory Immune Responses","Interventional","Terminated","Phase 1",3,21,"NA","analgesics, opioid|vasoconstrictor agents|fentanyl","NA"]
["NCT01213589","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20952217,"Virtue Registry Investigators. The VIRTUE Registry of type B thoracic dissections--study design and early results. Eur J Vasc Endovasc Surg. 2011 Feb;41(2):159-66. doi: 10.1016/j.ejvs.2010.08.016. Epub 2010 Oct 16.","\tAortic Dissection\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","aneurysm, dissecting","NA","NA"]
["NCT01217385",8111716,4427593,"Odds Ratio (OR)",16.5,null,"NA",1.09,250.15,95,0.043,"Regression, Logistic","NA|27527559","Tromberg BJ, Butler JA, Mankoff DA, et al.: ACRIN 6691 monitoring and predicting breast cancer neoadjuvant chemotherapy response using diffuse optical spectroscopic imaging (DOSI). [Abstract] J Clin Oncol 29 (Suppl 15): A-TPS249, 2011.|Tromberg BJ, Zhang Z, Leproux A, O'Sullivan TD, Cerussi AE, Carpenter PM, Mehta RS, Roblyer D, Yang W, Paulsen KD, Pogue BW, Jiang S, Kaufman PA, Yodh AG, Chung SH, Schnall M, Snyder BS, Hylton N, Boas DA, Carp SA, Isakoff SJ, Mankoff D; ACRIN 6691 investigators. Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging. Cancer Res. 2016 Oct 15;76(20):5933-5944. Epub 2016 Aug 15.","\tBreast Cancer\tDOSI\tNA\tNA\tNA\tProcedure\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","NA","Accuracy of %Change in TOI Between Baseline and Mid-therapy to Predict pCR+; Stratified by Oxygen Saturation (St02)"]
["NCT01221181","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22403278,"Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D'Agati VD, Canetta PA, Radhakrishnan J, Appel GB. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol. 2012 May;7(5):748-56. doi: 10.2215/CJN.12901211. Epub 2012 Mar 8.","\tDense Deposit Disease|Membranoproliferative Glomerulonephritis\tEculizumab\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","glomerulonephritis, membranoproliferative|glomerulonephritis|kidney diseases","NA","NA"]
["NCT01224366","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23961326,"Kozlovski P, Foley J, Shao Q, Lukashevich V, Kothny W. Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes. World J Diabetes. 2013 Aug 15;4(4):151-6. doi: 10.4239/wjd.v4.i4.151.","\tType 2 Diabetes Mellitus\tVildagliptin|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus","Interventional","Completed","Phase 3",2,448,"diabetes mellitus|diabetes mellitus, type 2","vildagliptin","NA"]
["NCT01228318","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27193748,"Ofotokun I, Titanji K, Lahiri CD, Vunnava A, Foster A, Sanford SE, Sheth AN, Lennox JL, Knezevic A, Ward L, Easley KA, Powers P, Weitzmann MN. A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial. Clin Infect Dis. 2016 Sep 1;63(5):663-671. doi: 10.1093/cid/ciw331. Epub 2016 May 18.","\tBone Loss|HIV Infection|Osteopenia|Osteoporosis\tZoledronic acid\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)","Interventional","Completed","Phase 2",2,63,"hiv infections|acquired immunodeficiency syndrome|osteoporosis|bone diseases, metabolic","zoledronic acid","NA"]
["NCT01234714","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21997548,"Raptis DA, Fischer MA, Graf R, Nanz D, Weber A, Moritz W, Tian Y, Oberkofler CE, Clavien PA. MRI: the new reference standard in quantifying hepatic steatosis? Gut. 2012 Jan;61(1):117-27. doi: 10.1136/gutjnl-2011-300155. Epub 2011 Oct 13.","\tFatty Liver|Surgery\tNon-invasive Magnetic Resonance Imaging (MRI)|Major liver resection\tNA\tNA\tNA\tOther|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","fatty liver|postoperative complications","liver extracts","NA"]
["NCT01238523","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23079877,"Silva M, Eagan MJ, Wong MA, Dichter DH, Ebramzadeh E, Zionts LE. A comparison of two approaches for the closed treatment of low-energy tibial fractures in children. J Bone Joint Surg Am. 2012 Oct 17;94(20):1853-60. doi: 10.2106/JBJS.J.01728.","\tTibial Shaft Fractures in Children\tLong leg cast in full extension|Long leg cast with 45 degrees of flexion\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","Study of Tibial Shaft Fractures in Children","Interventional","Completed","N/A",2,81,"fractures, bone","calpastatin","NA"]
["NCT01241253","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22494488|22916816|28976933","Thompson SV, Winham DM, Hutchins AM. Bean and rice meals reduce postprandial glycemic response in adults with type 2 diabetes: a cross-over study. Nutr J. 2012 Apr 11;11:23. doi: 10.1186/1475-2891-11-23.|Hutchins AM, Winham DM, Thompson SV. Phaseolus beans: impact on glycaemic response and chronic disease risk in human subjects. Br J Nutr. 2012 Aug;108 Suppl 1:S52-65. doi: 10.1017/S0007114512000761. Review.|Winham DM, Hutchins AM, Thompson SV. Glycemic Response to Black Beans and Chickpeas as Part of a Rice Meal: A Randomized Cross-Over Trial. Nutrients. 2017 Oct 4;9(10). pii: E1095. doi: 10.3390/nu9101095.","\tBlood Glucose|Type 2 Diabetes Mellitus\tWhole cooked beans with rice meals\tCrossover Assignment\tBasic Science\tRandomized\tOther\tAll\t","NA","NA","NA","NA","NA","NA","diabetes mellitus|diabetes mellitus, type 2","NA","NA"]
["NCT01245569","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24621109,"Singh D, Nicolini G, Bindi E, Corradi M, Guastalla D, Kampschulte J, Pierzchała W, Sayiner A, Szilasi M, Terzano C, Vestbo J; FUTURE (Foster Upgrades TherapeUtic care in REspiratory disease) study group. Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD. BMC Pulm Med. 2014 Mar 12;14:43. doi: 10.1186/1471-2466-14-43.","\tChronic Obstructive Pulmonary Disease\tFoster® 100/6 µg/unit dose|Seretide Accuhaler® 500/50 µg/actuation\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","A Study in Patients With Chronic Obstructive Pulmonary Disease","Interventional","Completed","Phase 3",2,373,"lung diseases, obstructive|lung diseases|pulmonary disease, chronic obstructive","fluticasone-salmeterol drug combination","NA"]
["NCT01246934","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Paley D, Sen C, Tetsworth K. Acute Shortening With Subsequent Relengthening Versus Bone Transport In The Treatment Of Tibial Bone Defect, 11th Asami North America Annual Scientific Meeting, February 18-25, Berkeley Ca, 2001","\tTIBIA PSEUDOARTHROSES\tASR METHOD\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","pseudarthrosis","NA","NA"]
["NCT01255215","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","9036320|9480993|10190913|9603111|9428538|9603127|10501745|12663340|15069048","Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med. 1997 Feb 27;336(9):597-604. Erratum in: N Engl J Med 1997 Aug 7;337(6):434.|Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R, Rhines J, Chang CT. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group. Pediatrics. 1998 Mar;101(3 Pt 1):325-34.|Dobyns EL, Cornfield DN, Anas NG, Fortenberry JD, Tasker RC, Lynch A, Liu P, Eells PL, Griebel J, Baier M, Kinsella JP, Abman SH. Multicenter randomized controlled trial of the effects of inhaled nitric oxide therapy on gas exchange in children with acute hypoxemic respiratory failure. J Pediatr. 1999 Apr;134(4):406-12.|Michael JR, Barton RG, Saffle JR, Mone M, Markewitz BA, Hillier K, Elstad MR, Campbell EJ, Troyer BE, Whatley RE, Liou TG, Samuelson WM, Carveth HJ, Hinson DM, Morris SE, Davis BL, Day RW. Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1372-80.|Dellinger RP, Zimmerman JL, Taylor RW, Straube RC, Hauser DL, Criner GJ, Davis K Jr, Hyers TM, Papadakos P. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med. 1998 Jan;26(1):15-23.|Troncy E, Collet JP, Shapiro S, Guimond JG, Blair L, Ducruet T, Francoeur M, Charbonneau M, Blaise G. Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1483-8.|Lundin S, Mang H, Smithies M, Stenqvist O, Frostell C. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European Study Group of Inhaled Nitric Oxide. Intensive Care Med. 1999 Sep;25(9):911-9.|Gerlach H, Keh D, Semmerow A, Busch T, Lewandowski K, Pappert DM, Rossaint R, Falke KJ. Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled study. Am J Respir Crit Care Med. 2003 Apr 1;167(7):1008-15.|Taylor RW, Zimmerman JL, Dellinger RP, Straube RC, Criner GJ, Davis K Jr, Kelly KM, Smith TC, Small RJ; Inhaled Nitric Oxide in ARDS Study Group. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA. 2004 Apr 7;291(13):1603-9.","\tSevere Malaria\tInhaled Nitric Oxide\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial","Interventional","Completed","Phase 1/Phase 2",2,180,"malaria","nitric oxide","NA"]
["NCT01259414","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19721826|11981766|12049862|1320447|16250051|18507107|8939223|3031724|18295692","Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol. 2009 Sep-Oct;10(5):425-34. doi: 10.3348/kjr.2009.10.5.425. Epub 2009 Aug 25. Review.|Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002 May;35(5):1164-71.|Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002 May 18;359(9319):1734-9.|Raoul JL, Heresbach D, Bretagne JF, Ferrer DB, Duvauferrier R, Bourguet P, Messner M, Gosselin M. Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer. 1992 Aug 1;70(3):585-90.|Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005 Nov;42(5):1208-36.|Takaki Y, Kaminou T, Shabana M, Ihaya T, Otsubo K, Ogawa T. Suitable blending method of lipiodol-cisplatin in transcatheter arterial embolization for hepatocellular carcinoma: evaluation of sustained release and accumulation nature. Hepatogastroenterology. 2008 Jan-Feb;55(81):202-6.|de Baere T, Zhang X, Aubert B, Harry G, Lagrange C, Ropers J, Dufaux J, Lumbroso J, Rougier P, Ducreux M, Roche A. Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study. Radiology. 1996 Dec;201(3):731-5.|Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M, Hasegawa H, Hirohashi S. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology. 1987 May;163(2):345-51.|Tzeng WS, Wu RH, Chang SC, Chou CK, Lin CY, Chen JJ, Yang SC, Lin CH. Ionic versus nonionic contrast media solvents used with an epirubicin-based agent for transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2008 Mar;19(3):342-50. doi: 10.1016/j.jvir.2007.10.021.","\tHepatocellular Carcinoma\tSolvent with specific gravity less than lipiodol|Solvent with specific gravity equivalent to lipiodol\tParallel Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma","Interventional","Completed","Phase 3",2,812,"carcinoma, hepatocellular|carcinoma","ethiodized oil","NA"]
["NCT01262846","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23277897,"McKittrick N, Frank I, Jacobson JM, White CJ, Kim D, Kappes R, DiGiorgio C, Kenney T, Boyer J, Tebas P. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med. 2013 Jan 1;158(1):19-26. doi: 10.7326/0003-4819-158-1-201301010-00005.","\tHIV Infection\tFluzone®|Fluzone®\tParallel Assignment\tPrevention\tRandomized\tBiological|Biological\tAll\t","Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals","Interventional","Completed","Phase 4",2,195,"hiv infections","NA","NA"]
["NCT01264562","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25882713|26898732","Hermelink K, Voigt V, Kaste J, Neufeld F, Wuerstlein R, Bühner M, Münzel K, Rjosk-Dendorfer D, Grandl S, Braun M, von Koch FE, Härtl K, Hasmüller S, Bauerfeind I, Debus G, Herschbach P, Harbeck N. Elucidating pretreatment cognitive impairment in breast cancer patients: the impact of cancer-related post-traumatic stress. J Natl Cancer Inst. 2015 Apr 16;107(7). pii: djv099. doi: 10.1093/jnci/djv099. Print 2015 Jul.|Voigt V, Neufeld F, Kaste J, Bühner M, Sckopke P, Wuerstlein R, Hellerhoff K, Sztrókay-Gaul A, Braun M, von Koch FE, Silva-Zürcher E, Hasmüller S, Bauerfeind I, Debus G, Herschbach P, Mahner S, Harbeck N, Hermelink K. Clinically assessed posttraumatic stress in patients with breast cancer during the first year after diagnosis in the prospective, longitudinal, controlled COGNICARES study. Psychooncology. 2017 Jan;26(1):74-80. doi: 10.1002/pon.4102. Epub 2016 Feb 22.","\tBreast Cancer\tNA\tNA\tNA\tNA\tNA\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","NA","NA"]
["NCT01269736","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20832819|28174175","Funk M, Winkler CG, May JL, Stephens K, Fennie KP, Rose LL, Turkman YE, Drew BJ. Unnecessary arrhythmia monitoring and underutilization of ischemia and QT interval monitoring in current clinical practice: baseline results of the Practical Use of the Latest Standards for Electrocardiography trial. J Electrocardiol. 2010 Nov-Dec;43(6):542-7. doi: 10.1016/j.jelectrocard.2010.07.018. Epub 2010 Sep 15.|Funk M, Fennie KP, Stephens KE, May JL, Winkler CG, Drew BJ; PULSE Site Investigators. Association of Implementation of Practice Standards for Electrocardiographic Monitoring With Nurses' Knowledge, Quality of Care, and Patient Outcomes: Findings From the Practical Use of the Latest Standards of Electrocardiography (PULSE) Trial. Circ Cardiovasc Qual Outcomes. 2017 Feb;10(2). pii: e003132. doi: 10.1161/CIRCOUTCOMES.116.003132. Erratum in: Circ Cardiovasc Qual Outcomes. 2017 Oct;10(10):.","\tCardiovascular Disease\tEducation\tCrossover Assignment\tHealth Services Research\tRandomized\tBehavioral\tAll\t","Implementation of Practice Standards for ECG Monitoring","Interventional","Completed","N/A",2,92057,"cardiovascular diseases","NA","NA"]
["NCT01275911","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17959952|11159231|9728851|14633533|15377583|19302635|1683182|11867379","Collard V, Mistraletti G, Taqi A, Asenjo JF, Feldman LS, Fried GM, Carli F. Intraoperative esmolol infusion in the absence of opioids spares postoperative fentanyl in patients undergoing ambulatory laparoscopic cholecystectomy. Anesth Analg. 2007 Nov;105(5):1255-62, table of contents.|Coloma M, Chiu JW, White PF, Armbruster SC. The use of esmolol as an alternative to remifentanil during desflurane anesthesia for fast-track outpatient gynecologic laparoscopic surgery. Anesth Analg. 2001 Feb;92(2):352-7.|Johansen JW, Schneider G, Windsor AM, Sebel PS. Esmolol potentiates reduction of minimum alveolar isoflurane concentration by alfentanil. Anesth Analg. 1998 Sep;87(3):671-6.|White PF, Wang B, Tang J, Wender RH, Naruse R, Sloninsky A. The effect of intraoperative use of esmolol and nicardipine on recovery after ambulatory surgery. Anesth Analg. 2003 Dec;97(6):1633-8.|Chia YY, Chan MH, Ko NH, Liu K. Role of beta-blockade in anaesthesia and postoperative pain management after hysterectomy. Br J Anaesth. 2004 Dec;93(6):799-805. Epub 2004 Sep 17.|Erdil F, Demirbilek S, Begec Z, Ozturk E, But A, Ozcan Ersoy M. The effect of esmolol on the QTc interval during induction of anaesthesia in patients with coronary artery disease. Anaesthesia. 2009 Mar;64(3):246-50. doi: 10.1111/j.1365-2044.2008.05754.x.|Smith I, Van Hemelrijck J, White PF. Efficacy of esmolol versus alfentanil as a supplement to propofol-nitrous oxide anesthesia. Anesth Analg. 1991 Nov;73(5):540-6.|White PF. The role of non-opioid analgesic techniques in the management of pain after ambulatory surgery. Anesth Analg. 2002 Mar;94(3):577-85. Review.","\tPain\tEsmolol|Remifentanil\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Non-opioid Analgesia for Fast-track Surgery","Interventional","Completed","N/A",2,40,"NA","remifentanil|esmolol","NA"]
["NCT01282424",8102551,4422263,null,"NA",null,"NA",{"$nulls":3},{"v":1E-4,"d":"1.00E-04"},"Exact binomial test","NA|24450858","Salles GA, Kahl, BS, Wagner-Johnston ND, et al. Interim results from a phase 2 study of PI3Kδ inhibitor idelalisib in patients with relapsed indolent non-Hodgki lymphoma (iNHL) refractory to both rituximab and an alkylating agent. 12th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, June 19-22, 2013 Abstract No: 064bis.|Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014 Mar 13;370(11):1008-18. doi: 10.1056/NEJMoa1314583. Epub 2014 Jan 22.","\tFollicular Lymphoma|Lymphoplasmacytic Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma\tIdelalisib\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma, follicular|lymphoma, b-cell, marginal zone|lymphoma, b-cell|lymphoma|waldenstrom macroglobulinemia|lymphoma, non-hodgkin|leukemia, lymphocytic, chronic, b-cell","idelalisib","Overall Response Rate"]
["NCT01287104","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25452614,"Shah NN, Baird K, Delbrook CP, Fleisher TA, Kohler ME, Rampertaap S, Lemberg K, Hurley CK, Kleiner DE, Merchant MS, Pittaluga S, Sabatino M, Stroncek DF, Wayne AS, Zhang H, Fry TJ, Mackall CL. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. Blood. 2015 Jan 29;125(5):784-92. doi: 10.1182/blood-2014-07-592881. Epub 2014 Dec 1.","\tLeukemia|Lymphoma\tNatural Killer (NK) Cell Infusion|Stem Cell Infusion\tNA\tNA\tNA\tBiological|Biological\tAll\t","NA","NA","NA","NA","NA","NA","leukemia|lymphoma","NA","NA"]
["NCT01340586",8094691,4418239,"Geometric Mean Ratio",0.855,null,"NA",0.707,1.033,90,"NA",null,26331581,"Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Zhang D, Song Y, Pursley J, Boyd RA, Frost C. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016 May;56(5):628-36. doi: 10.1002/jcph.628. Epub 2015 Dec 22.","\tEnd Stage Renal Disease\tApixaban|Apixaban\tNA\tNA\tNA\tDrug|Drug\tAll\t","Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis","Interventional","Completed","Phase 1",2,18,"kidney failure, chronic","apixaban","Geometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Single 5mg Oral Dose of Apixaban"]
["NCT01345916","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25088067,"Kanniess F, Scuri M, Vezzoli S, Francisco C, Petruzzelli S. Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler(®)) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: A randomised, double-blind trial. Pulm Pharmacol Ther. 2015 Feb;30:121-7. doi: 10.1016/j.pupt.2014.07.006. Epub 2014 Aug 1.","\tAsthma\tCHF 1535 100/6 NEXT DPI® 2 months|CHF 1535 100/6 pMDI 2 months|BDP DPI 2 months\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients","Interventional","Completed","Phase 3",3,932,"asthma","NA","NA"]
["NCT01346488",8093965,4417641,null,"NA",null,"NA",{"$nulls":3},{"v":1E-4,"d":"1.00E-04"},"Paired t-test","NA|NA","A Large-Scale Prospective Single Cohort Observational Study of Work Productivity and Activity Impairment In Japanese Patients With Rheumatoid Arthritis Receiving Adalimumab: The Final Analysis of 48-Week Data From the ANOUVEAU Study. EULAR2016 (9 June 2016), poster no. THU0159.|Economic Impact of Adalimumab Treatment in Japanese Patients with Rheumatoid Arthritis from the ANOUVEAU Study. ACR2016 (13 November 2016), poster no. 609","\tRheumatoid Arthritis\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","arthritis, rheumatoid|arthritis","NA","Change From Baseline in European Quality of Life-5 Dimensions Questionnaire (EQ-5D) Summary Index Score"]
["NCT01346488",8093969,4417664,null,"NA",null,"NA",{"$nulls":3},{"v":1E-4,"d":"1.00E-04"},"Paired t-test","NA|NA","A Large-Scale Prospective Single Cohort Observational Study of Work Productivity and Activity Impairment In Japanese Patients With Rheumatoid Arthritis Receiving Adalimumab: The Final Analysis of 48-Week Data From the ANOUVEAU Study. EULAR2016 (9 June 2016), poster no. THU0159.|Economic Impact of Adalimumab Treatment in Japanese Patients with Rheumatoid Arthritis from the ANOUVEAU Study. ACR2016 (13 November 2016), poster no. 609","\tRheumatoid Arthritis\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","arthritis, rheumatoid|arthritis","NA","Change From Baseline in DAS28-4 Erythrocyte Sedimentation Rate (ESR)"]
["NCT01346488",8093973,4417691,null,"NA",null,"NA",{"$nulls":3},{"v":1E-4,"d":"1.00E-04"},"Paired t-test","NA|NA","A Large-Scale Prospective Single Cohort Observational Study of Work Productivity and Activity Impairment In Japanese Patients With Rheumatoid Arthritis Receiving Adalimumab: The Final Analysis of 48-Week Data From the ANOUVEAU Study. EULAR2016 (9 June 2016), poster no. THU0159.|Economic Impact of Adalimumab Treatment in Japanese Patients with Rheumatoid Arthritis from the ANOUVEAU Study. ACR2016 (13 November 2016), poster no. 609","\tRheumatoid Arthritis\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","arthritis, rheumatoid|arthritis","NA","Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score"]
["NCT01347619","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22264855|24074962|23385262|24374410","Tjia J, Gurwitz JH, Briesacher BA. Challenge of changing nursing home prescribing culture. Am J Geriatr Pharmacother. 2012 Feb;10(1):37-46. doi: 10.1016/j.amjopharm.2011.12.005. Epub 2012 Jan 20. Review.|Lemay CA, Mazor KM, Field TS, Donovan J, Kanaan A, Briesacher BA, Foy S, Harrold LR, Gurwitz JH, Tjia J. Knowledge of and perceived need for evidence-based education about antipsychotic medications among nursing home leadership and staff. J Am Med Dir Assoc. 2013 Dec;14(12):895-900. doi: 10.1016/j.jamda.2013.08.009. Epub 2013 Sep 24.|Briesacher BA, Tjia J, Field T, Peterson D, Gurwitz JH. Antipsychotic use among nursing home residents. JAMA. 2013 Feb 6;309(5):440-2. doi: 10.1001/jama.2012.211266.|Tjia J, Field T, Lemay C, Mazor K, Pandolfi M, Spenard A, Ho SY, Kanaan A, Donovan J, Gurwitz JH, Briesacher B. Antipsychotic use in nursing homes varies by psychiatric consultant. Med Care. 2014 Mar;52(3):267-71. doi: 10.1097/MLR.0000000000000076.","\tOff-label Use of Atypical Antipsychotic Drugs\tToolkit only with Web Access to Online Version|Toolkit, Periodic Audit/Feedback, Educational Messages|Items in Arm 2 plus Academic Detailing Program\tParallel Assignment\tHealth Services Research\tRandomized\tOther|Other|Other\tAll\t","iADAPT: Off Label Use of Antipsychotics in the Nursing Home","Interventional","Completed","N/A",3,42,"NA","NA","NA"]
["NCT01350505","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27448415,"McBean AL, Najjar RP, Schuchard RA, Hall CD, Wang CA, Ku B, Zeitzer JM. Standing Balance and Spatiotemporal Aspects of Gait Are Impaired Upon Nocturnal Awakening in Healthy Late Middle-Aged and Older Adults. J Clin Sleep Med. 2016 Nov 15;12(11):1477-1486.","\tAging|Balance|Falls|Insomnia\tWhite light exposure|Dim white light exposure|Very dim white light exposure|Dim orange light exposure\tNA\tNA\tNA\tBehavioral|Behavioral|Behavioral|Behavioral\tAll\t","NA","NA","NA","NA","NA","NA","sleep initiation and maintenance disorders","NA","NA"]
["NCT01351805",8093280,4417291,"Percent change in means",-0.73,null,"NA",-6.87,5.81,95,0.97,"as above","31699704|32583982","Costenbader KH, MacFarlane LA, Lee IM, Buring JE, Mora S, Bubes V, Kotler G, Camargo CA Jr, Manson JE, Cook NR. Effects of One Year of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Biomarkers of Systemic Inflammation in Older US Adults. Clin Chem. 2019 Dec;65(12):1508-1521. doi: 10.1373/clinchem.2019.306902. Epub 2019 Nov 7.|MacFarlane LA, Cook NR, Kim E, Lee IM, Iversen MD, Gordon D, Buring JE, Katz JN, Manson JE, Costenbader KH. The Effects of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Chronic Knee Pain in Older US Adults: Results From a Randomized Trial. Arthritis Rheumatol. 2020 Nov;72(11):1836-1844. doi: 10.1002/art.41416. Epub 2020 Oct 3.","\tAutoimmune Diseases|Knee Pain Chronic|Osteoarthritis|Rheumatoid Arthritis|Systemic Inflammatory Process\tFish Oil|Vitamin D|placebo pill\tNA\tNA\tNA\tDrug|Dietary Supplement|Other\tAll\t","Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain","Interventional","Active, not recruiting","N/A",4,25871,"inflammation|arthritis|autoimmune diseases|osteoarthritis|arthritis, rheumatoid","vitamin d|vitamins|cholecalciferol|ergocalciferols","Serum Levels of Biomarkers of Systemic Inflammation: Interleukin-6 (IL-6)"]
["NCT01354886","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28591833,"Abd-Elaziz K, Duijkers I, Stöckl L, Dietrich B, Klipping C, Eckert K, Goletz S. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials. Hum Reprod. 2017 Aug 1;32(8):1639-1647. doi: 10.1093/humrep/dex220.","\tFemale Infertility\tFSH-GEX™|Gonal-f|Bravelle|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug\tFemale\t","Single Dose FSH-GEX™ in Healthy Volunteers","Interventional","Completed","Phase 1",7,19,"infertility|infertility, female","follicle stimulating hormone","NA"]
["NCT01362049","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25452017|24662210|24065623","Lomond KV, Jacobs JV, Hitt JR, DeSarno MJ, Bunn JY, Henry SM. Effects of low back pain stabilization or movement system impairment treatments on voluntary postural adjustments: a randomized controlled trial. Spine J. 2015 Apr 1;15(4):596-606. doi: 10.1016/j.spinee.2014.10.020. Epub 2014 Oct 29.|Henry SM, Van Dillen LR, Ouellette-Morton RH, Hitt JR, Lomond KV, DeSarno MJ, Bunn JY. Outcomes are not different for patient-matched versus nonmatched treatment in subjects with chronic recurrent low back pain: a randomized clinical trial. Spine J. 2014 Dec 1;14(12):2799-810. doi: 10.1016/j.spinee.2014.03.024. Epub 2014 Mar 22.|Lomond KV, Henry SM, Jacobs JV, Hitt JR, Horak FB, Cohen RG, Schwartz D, Dumas JA, Naylor MR, Watts R, DeSarno MJ. Protocol to assess the neurophysiology associated with multi-segmental postural coordination. Physiol Meas. 2013 Oct;34(10):N97-105. doi: 10.1088/0967-3334/34/10/N97. Epub 2013 Sep 25.","\tLow Back Pain\tPhysical Therapy rehabilitation: Stabilization exercises.|Physical Therapy rehabilitation. Movement System Impairment (MSI) classification based exercise\tParallel Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Mechanisms of Specific Trunk Exercises in Low Back Pain","Interventional","Completed","N/A",4,102,"back pain|low back pain","NA","NA"]
["NCT01370382","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21952408|23375478|23314553","Bahrmann P, Heppner HJ, Christ M, Bertsch T, Sieber C. Early detection of non-ST-elevation myocardial infarction in geriatric patients by a new high-sensitive cardiac troponin T assay. Aging Clin Exp Res. 2012 Jun;24(3):290-4. doi: 10.3275/7927. Epub 2011 Sep 26.|Bahrmann P, Christ M, Bahrmann A, Rittger H, Heppner HJ, Achenbach S, Bertsch T, Sieber CC. A 3-hour diagnostic algorithm for non-ST-elevation myocardial infarction using high-sensitivity cardiac troponin T in unselected older patients presenting to the emergency department. J Am Med Dir Assoc. 2013 Jun;14(6):409-16. doi: 10.1016/j.jamda.2012.12.005. Epub 2013 Jan 30.|Bahrmann P, Bahrmann A, Breithardt OA, Daniel WG, Christ M, Sieber CC, Bertsch T. Additional diagnostic and prognostic value of copeptin ultra-sensitive for diagnosis of non-ST-elevation myocardial infarction in older patients presenting to the emergency department. Clin Chem Lab Med. 2013 Jun;51(6):1307-19. doi: 10.1515/cclm-2012-0401.","\tAcute Coronary Syndrome\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","acute coronary syndrome|syndrome","NA","NA"]
["NCT01374919","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23828252,"Auerbach M, Strauss W, Auerbach S, Rineer S, Bahrain H. Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min. Am J Hematol. 2013 Nov;88(11):944-7. doi: 10.1002/ajh.23534. Epub 2013 Sep 9.","\tIron Deficiency Anemia\tferumoxytol\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","anemia, iron-deficiency|anemia|deficiency diseases","ferrosoferric oxide","NA"]
["NCT01380184","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23829943,"Liu L, Zhang W, Li W, Lv F, Xia Z, Zhang S, Liu W, Zandvliet AS, Waajen S, Zhang LX, Yan L, Li J. A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors. J Hematol Oncol. 2013 Jul 8;6:48. doi: 10.1186/1756-8722-6-48.","\tCancer, Advanced\tridaforolimus\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","NA","sirolimus","NA"]
["NCT01386905","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","http://www.oecd.org/document/16/0,2340,en_2649_34631_2085200_1_1_1_1,00.html","\tObesity\tBAROnova™ TransPyloric Shuttle™ (TPS™)\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","weight loss","NA","NA"]
["NCT01390428",8088466,4414658,"GMR",1.37,null,"NA",0.83,2.27,90,"NA",null,28947470,"Caro L, Wenning L, Guo Z, Fraser IP, Fandozzi C, Talaty J, Panebianco D, Ho M, Uemura N, Reitmann C, Angus P, Gane E, Marbury T, Smith WB, Iwamoto M, Butterton JR, Yeh WW. Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor. Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e00813-17. doi: 10.1128/AAC.00813-17. Print 2017 Dec.","\tHepatitis C\tGrazoprevir\tNA\tNA\tNA\tDrug\tAll\t","Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013)","Interventional","Completed","Phase 1",6,50,"hepatitis c|liver failure|hepatic insufficiency","mk-5172","Maximum Concentration (Cmax) of Grazoprevir"]
["NCT01390428",8088467,4414663,"GMR",5.03,null,"NA",2.19,11.56,90,"NA",null,28947470,"Caro L, Wenning L, Guo Z, Fraser IP, Fandozzi C, Talaty J, Panebianco D, Ho M, Uemura N, Reitmann C, Angus P, Gane E, Marbury T, Smith WB, Iwamoto M, Butterton JR, Yeh WW. Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor. Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e00813-17. doi: 10.1128/AAC.00813-17. Print 2017 Dec.","\tHepatitis C\tGrazoprevir\tNA\tNA\tNA\tDrug\tAll\t","Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013)","Interventional","Completed","Phase 1",6,50,"hepatitis c|liver failure|hepatic insufficiency","mk-5172","Area Under the Concentration Time-curve From 0 to 24 Hours (AUC0-24) of Grazoprevir"]
["NCT01397747","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24645800,"Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, Berger BM. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014 Apr 3;370(14):1287-97. doi: 10.1056/NEJMoa1311194. Epub 2014 Mar 19.","\tColonic Diseases|Colorectal Cancer|Colorectal Neoplasms|Digestive System Diseases\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms|adenomatous polyps|neoplasms|gastrointestinal diseases|colonic diseases|digestive system diseases","NA","NA"]
["NCT01401582","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28891446|28891445|28780910|28746708|28364258|28160100|27716668|27534949|27239503|27143912|27031481|27031480|26890767|26785854|26639964|26510524|26277428|25765916|27239495|25391382|25247664|25147117|25125471|24898640|24811145|24225205|24152974|22575023","Reiner K, Eichler T, Hertel J, Hoffmann W, Thyrian JR. The Clock Drawing Test: A Reasonable Instrument to Assess Probable Dementia in Primary Care? Curr Alzheimer Res. 2018;15(1):38-43. doi: 10.2174/1567205014666170908101822.|Eichler T, Thyrian JR, Hertel J, Richter S, Michalowsky B, Wucherer D, Dreier A, Kilimann I, Teipel S, Hoffmann W. Patient Variables Associated with the Assignment of a Formal Dementia Diagnosis to Positively Screened Primary Care Patients. Curr Alzheimer Res. 2018;15(1):44-50. doi: 10.2174/1567205014666170908095707.|Wucherer D, Thyrian JR, Eichler T, Hertel J, Kilimann I, Richter S, Michalowsky B, Zwingmann I, Dreier-Wolfgramm A, Ritter CA, Teipel S, Hoffmann W. Drug-related problems in community-dwelling primary care patients screened positive for dementia. Int Psychogeriatr. 2017 Nov;29(11):1857-1868. doi: 10.1017/S1041610217001442. Epub 2017 Aug 7.|Thyrian JR, Hertel J, Wucherer D, Eichler T, Michalowsky B, Dreier-Wolfgramm A, Zwingmann I, Kilimann I, Teipel S, Hoffmann W. Effectiveness and Safety of Dementia Care Management in Primary Care: A Randomized Clinical Trial. JAMA Psychiatry. 2017 Oct 1;74(10):996-1004. doi: 10.1001/jamapsychiatry.2017.2124.|Dreier-Wolfgramm A, Michalowsky B, Austrom MG, van der Marck MA, Iliffe S, Alder C, Vollmar HC, Thyrian JR, Wucherer D, Zwingmann I, Hoffmann W. Dementia care management in primary care : Current collaborative care models and the case for interprofessional education. Z Gerontol Geriatr. 2017 May;50(Suppl 2):68-77. doi: 10.1007/s00391-017-1220-8. Epub 2017 Mar 31. Review.|Michalowsky B, Flessa S, Eichler T, Hertel J, Dreier A, Zwingmann I, Wucherer D, Rau H, Thyrian JR, Hoffmann W. Healthcare utilization and costs in primary care patients with dementia: baseline results of the DelpHi-trial. Eur J Health Econ. 2018 Jan;19(1):87-102. doi: 10.1007/s10198-017-0869-7. Epub 2017 Feb 3.|Wucherer D, Eichler T, Hertel J, Kilimann I, Richter S, Michalowsky B, Thyrian JR, Teipel S, Hoffmann W. Potentially Inappropriate Medication in Community-Dwelling Primary Care Patients who were Screened Positive for Dementia. J Alzheimers Dis. 2017;55(2):691-701.|Thyrian JR, Winter P, Eichler T, Reimann M, Wucherer D, Dreier A, Michalowsky B, Zarm K, Hoffmann W. Relatives' burden of caring for people screened positive for dementia in primary care : Results of the DelpHi study. Z Gerontol Geriatr. 2017 Jan;50(1):4-13. doi: 10.1007/s00391-016-1119-9. Epub 2016 Aug 17.|Eichler T, Thyrian JR, Hertel J, Wucherer D, Michalowsky B, Reiner K, Dreier A, Kilimann I, Teipel S, Hoffmann W. Subjective memory impairment: No suitable criteria for case-finding of dementia in primary care. Alzheimers Dement (Amst). 2015 Apr 30;1(2):179-86. doi: 10.1016/j.dadm.2015.02.004. eCollection 2015 Jun.|Thyrian JR, Eichler T, Pooch A, Albuerne K, Dreier A, Michalowsky B, Wucherer D, Hoffmann W. Systematic, early identification of dementia and dementia care management are highly appreciated by general physicians in primary care - results within a cluster-randomized-controlled trial (DelpHi). J Multidiscip Healthc. 2016 Apr 19;9:183-90. doi: 10.2147/JMDH.S96055. eCollection 2016.|Thyrian JR, Eichler T, Michalowsky B, Wucherer D, Reimann M, Hertel J, Richter S, Dreier A, Hoffmann W. Community-Dwelling People Screened Positive for Dementia in Primary Care: A Comprehensive, Multivariate Descriptive Analysis Using Data from the DelpHi-Study. J Alzheimers Dis. 2016 Mar 30;52(2):609-17. doi: 10.3233/JAD-151076.|Eichler T, Hoffmann W, Hertel J, Richter S, Wucherer D, Michalowsky B, Dreier A, Thyrian JR. Living Alone with Dementia: Prevalence, Correlates and the Utilization of Health and Nursing Care Services. J Alzheimers Dis. 2016;52(2):619-29. doi: 10.3233/JAD-151058.|Eichler T, Thyrian JR, Hertel J, Richter S, Wucherer D, Michalowsky B, Teipel S, Kilimann I, Dreier A, Hoffmann W. Unmet Needs of Community-Dwelling Primary Care Patients with Dementia in Germany: Prevalence and Correlates. J Alzheimers Dis. 2016;51(3):847-55. doi: 10.3233/JAD-150935.|Thyrian JR, Eichler T, Reimann M, Wucherer D, Dreier A, Michalowsky B, Hoffmann W. Depressive symptoms and depression in people screened positive for dementia in primary care - results of the DelpHi-study. Int Psychogeriatr. 2016 Jun;28(6):929-37. doi: 10.1017/S1041610215002458. Epub 2016 Jan 20.|Michalowsky B, Thyrian JR, Eichler T, Hertel J, Wucherer D, Flessa S, Hoffmann W. Economic Analysis of Formal Care, Informal Care, and Productivity Losses in Primary Care Patients who Screened Positive for Dementia in Germany. J Alzheimers Dis. 2016;50(1):47-59. doi: 10.3233/JAD-150600.|Michalowsky B, Eichler T, Thyrian JR, Hertel J, Wucherer D, Hoffmann W, Flessa S. Healthcare resource utilization and cost in dementia: are there differences between patients screened positive for dementia with and those without a formal diagnosis of dementia in primary care in Germany? - ERRATUM. Int Psychogeriatr. 2016 Mar;28(3):371. doi: 10.1017/S1041610215001908. Epub 2015 Oct 29.|Dreier A, Thyrian JR, Eichler T, Hoffmann W. Qualifications for nurses for the care of patients with dementia and support to their caregivers: A pilot evaluation of the dementia care management curriculum. Nurse Educ Today. 2016 Jan;36:310-7. doi: 10.1016/j.nedt.2015.07.024. Epub 2015 Jul 31.|Thyrian JR, Eichler T, Hertel J, Wucherer D, Dreier A, Michalowsky B, Killimann I, Teipel S, Hoffmann W. Burden of Behavioral and Psychiatric Symptoms in People Screened Positive for Dementia in Primary Care: Results of the DelpHi-Study. J Alzheimers Dis. 2015;46(2):451-9. doi: 10.3233/JAD-143114.|Eichler T, Thyrian JR, Hertel J, Michalowsky B, Wucherer D, Dreier A, Kilimann I, Teipel S, Hoffmann W. Rates of formal diagnosis of dementia in primary care: The effect of screening. Alzheimers Dement (Amst). 2015 Mar 29;1(1):87-93. doi: 10.1016/j.dadm.2014.11.007. eCollection 2015 Mar.|Wucherer D, Eichler T, Kilimann I, Hertel J, Michalowsky B, Thyrian JR, Teipel S, Hoffmann W. Antidementia drug treatment in people screened positive for dementia in primary care. J Alzheimers Dis. 2015;44(3):1015-21. doi: 10.3233/JAD-142064.|Teipel SJ, Thyrian JR, Hertel J, Eichler T, Wucherer D, Michalowsky B, Kilimann I, Hoffmann W. Neuropsychiatric symptoms in people screened positive for dementia in primary care. Int Psychogeriatr. 2015 Jan;27(1):39-48. doi: 10.1017/S1041610214001987. Epub 2014 Sep 23.|Eichler T, Wucherer D, Thyrian JR, Kilimann I, Hertel J, Michalowsky B, Teipel S, Hoffmann W. Antipsychotic drug treatment in ambulatory dementia care: prevalence and correlates. J Alzheimers Dis. 2015;43(4):1303-11. doi: 10.3233/JAD-141554.|Michalowsky B, Eichler T, Thyrian JR, Hertel J, Wucherer D, Laufs S, Fleßa S, Hoffmann W. Medication cost of persons with dementia in primary care in Germany. J Alzheimers Dis. 2014;42(3):949-58. doi: 10.3233/JAD-140804.|Eichler T, Thyrian JR, Hertel J, Köhler L, Wucherer D, Dreier A, Michalowsky B, Teipel S, Hoffmann W. Rates of formal diagnosis in people screened positive for dementia in primary care: results of the DelpHi-Trial. J Alzheimers Dis. 2014;42(2):451-8. doi: 10.3233/JAD-140354.|Eichler T, Thyrian JR, Fredrich D, Köhler L, Wucherer D, Michalowsky B, Dreier A, Hoffmann W. The benefits of implementing a computerized intervention-management-system (IMS) on delivering integrated dementia care in the primary care setting. Int Psychogeriatr. 2014 Aug;26(8):1377-85. doi: 10.1017/S1041610214000830. Epub 2014 May 9.|Fiß T, Thyrian JR, Wucherer D, Aßmann G, Kilimann I, Teipel SJ, Hoffmann W. Medication management for people with dementia in primary care: description of implementation in the DelpHi study. BMC Geriatr. 2013 Nov 13;13:121. doi: 10.1186/1471-2318-13-121.|Eichler T, Thyrian JR, Dreier A, Wucherer D, Köhler L, Fiß T, Böwing G, Michalowsky B, Hoffmann W. Dementia care management: going new ways in ambulant dementia care within a GP-based randomized controlled intervention trial. Int Psychogeriatr. 2014 Feb;26(2):247-56. doi: 10.1017/S1041610213001786. Epub 2013 Oct 23.|Thyrian JR, Fiß T, Dreier A, Böwing G, Angelow A, Lueke S, Teipel S, Fleßa S, Grabe HJ, Freyberger HJ, Hoffmann W. Life- and person-centred help in Mecklenburg-Western Pomerania, Germany (DelpHi): study protocol for a randomised controlled trial. Trials. 2012 May 10;13:56. doi: 10.1186/1745-6215-13-56.","\tDementia\tImplementation of Dementia Care Manager\tParallel Assignment\tSupportive Care\tRandomized\tOther\tAll\t","Intervention Study to Improve Life and Care for People With Dementia and Their Caregivers in Primary Care","Interventional","Active, not recruiting","N/A",2,634,"dementia","NA","NA"]
["NCT01408901",8086404,4413216,"Mean Difference (Final Values)",-0.005,null,"NA",-0.01,-1E-3,95,0.03,"t-test, 2 sided",29141087,"McDermott MM, Ferrucci L, Tian L, Guralnik JM, Lloyd-Jones D, Kibbe MR, Polonsky TS, Domanchuk K, Stein JH, Zhao L, Taylor D, Skelly C, Pearce W, Perlman H, McCarthy W, Li L, Gao Y, Sufit R, Bloomfield CL, Criqui MH. Effect of Granulocyte-Macrophage Colony-Stimulating Factor With or Without Supervised Exercise on Walking Performance in Patients With Peripheral Artery Disease: The PROPEL Randomized Clinical Trial. JAMA. 2017 Dec 5;318(21):2089-2098. doi: 10.1001/jama.2017.17437.","\tPeripheral Arterial Disease\tSupervised Treadmill Exercise Therapy|Health education sessions (Control)|granulocyte macrophage colony stimulating factor (GM-CSF)\tNA\tNA\tNA\tBehavioral|Other|Drug\tAll\t","Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD)","Interventional","Completed","N/A",4,210,"peripheral arterial disease|peripheral vascular diseases","molgramostim|sargramostim","Change in CD34_CD45loCD133_ at 12-week Follow-up"]
["NCT01410344","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28380315,"Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2017 Apr 10;35(11):1154-1161. doi: 10.1200/JCO.2016.70.7091. Epub 2017 Feb 13.","\tHIV|Leukemia|Lymphoma\tFludarabine and Busulfan|Fludarabine and Melphalan|Busulfan and Fludarabine|Cyclophosphamide and Total Body Irradiation\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma","melphalan|busulfan|fludarabine|vidarabine|fludarabine phosphate|cyclophosphamide","NA"]
["NCT01414790","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12533152,"Sinha UK, Saadat D, Doherty CM, Rice DH. Use of AlloDerm implant to prevent frey syndrome after parotidectomy. Arch Facial Plast Surg. 2003 Jan-Feb;5(1):109-12.","\tParotid Tumor\tADM\tParallel Assignment\tPrevention\tRandomized\tProcedure\tAll\t","The Use of Human Acellular Dermal Matrix to Improve Infraauricular Depressed Deformities and Frey's Syndrome","Interventional","Completed","Phase 3",2,70,"sweating, gustatory|parotid neoplasms","NA","NA"]
["NCT01417962","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21740313|21349673|20661883|20515965|19910149|19665645|19282335|18768277|18761215|22347922","Sebire NJ, Weber MA, Thayyil S, Mushtaq I, Taylor A, Chitty LS. Minimally invasive perinatal autopsies using magnetic resonance imaging and endoscopic postmortem examination (\"keyhole autopsy\"): feasibility and initial experience. J Matern Fetal Neonatal Med. 2012 May;25(5):513-8. doi: 10.3109/14767058.2011.601368. Epub 2011 Aug 10.|Thayyil S, De Vita E, Sebire NJ, Bainbridge A, Thomas D, Gunny R, Chong K, Lythgoe MF, Golay X, Robertson NJ, Cady EB, Taylor AM. Post-mortem cerebral magnetic resonance imaging T1 and T2 in fetuses, newborns and infants. Eur J Radiol. 2012 Mar;81(3):e232-8. doi: 10.1016/j.ejrad.2011.01.105. Epub 2011 Feb 23.|Thayyil S, Chitty LS, Robertson NJ, Taylor AM, Sebire NJ. Minimally invasive fetal postmortem examination using magnetic resonance imaging and computerised tomography: current evidence and practical issues. Prenat Diagn. 2010 Aug;30(8):713-8. doi: 10.1002/pd.2534. Review.|Thayyil S. Less invasive autopsy: an evidenced based approach. Arch Dis Child. 2011 Jul;96(7):681-7. doi: 10.1136/adc.2009.165704. Epub 2010 Jun 1. Review.|Thayyil S, Chandrasekaran M, Chitty LS, Wade A, Skordis-Worrall J, Bennett-Britton I, Cohen M, Withby E, Sebire NJ, Robertson NJ, Taylor AM. Diagnostic accuracy of post-mortem magnetic resonance imaging in fetuses, children and adults: a systematic review. Eur J Radiol. 2010 Jul;75(1):e142-8. doi: 10.1016/j.ejrad.2009.10.007. Epub 2009 Nov 11. Review.|Thayyil S, Cleary JO, Sebire NJ, Scott RJ, Chong K, Gunny R, Owens CM, Olsen OE, Offiah AC, Parks HG, Chitty LS, Price AN, Yousry TA, Robertson NJ, Lythgoe MF, Taylor AM. Post-mortem examination of human fetuses: a comparison of whole-body high-field MRI at 9.4 T with conventional MRI and invasive autopsy. Lancet. 2009 Aug 8;374(9688):467-75. doi: 10.1016/S0140-6736(09)60913-2.|Thayyil S, Robertson NJ, Scales A, Weber MA, Jacques TS, Sebire NJ, Taylor AM; MaRIAS (Magnetic Resonance Imaging Autopsy Study) Collaborative Group. Prospective parental consent for autopsy research following sudden unexpected childhood deaths: a successful model. Arch Dis Child. 2009 May;94(5):354-8. doi: 10.1136/adc.2008.150904. Epub 2009 Mar 12.|Thayyil S, Schievano S, Robertson NJ, Jones R, Chitty LS, Sebire NJ, Taylor AM; MaRIAS (Magnetic Resonance Imaging Autopsy Study) Collaborative group. A semi-automated method for non-invasive internal organ weight estimation by post-mortem magnetic resonance imaging in fetuses, newborns and children. Eur J Radiol. 2009 Nov;72(2):321-6. doi: 10.1016/j.ejrad.2008.07.013. Epub 2008 Sep 2.|Thayyil S, Robertson NJ, Scales A, Sebire NJ, Taylor AM. Parental consent for research and sudden infant death. Lancet. 2008 Aug 30;372(9640):715. doi: 10.1016/S0140-6736(08)61298-2. Erratum in: Lancet. 2008 Oct 4;372(9645):1222.|Schievano S, Sebire NJ, Robertson NJ, Taylor AM, Thayyil S. Reconstruction of fetal and infant anatomy using rapid prototyping of post-mortem MR images. Insights Imaging. 2010 Sep;1(4):281-286. Epub 2010 Jun 19.","\tStillbirths|Sudden Infant Death\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","stillbirth|infant death|sudden infant death","NA","NA"]
["NCT01422031","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21673357|25593904","Lam CL, Leung GM, Mercer SW, Fong DY, Lee A, Lam TP, Lo YT. Utilisation patterns of primary health care services in Hong Kong: does having a family doctor make any difference? Hong Kong Med J. 2011 Jun;17(3 Suppl 3):28-32.|Lam CL, Yu EY, Lo YY, Wong CK, Mercer SM, Fong DY, Lee A, Lam TP, Leung GM. Having a Family Doctor is Associated with Some Better Patient-Reported Outcomes of Primary Care Consultations. Front Med (Lausanne). 2014 Sep 15;1:29. doi: 10.3389/fmed.2014.00029. eCollection 2014.","\tFamily Practice|Health Services Utilization|Primary Care\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT01429545","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12892684,"Doret M, Mellier G, Gaucherand P, Saade GR, Benchaib M, Frutoso J, Pasquier JC. The in vitro effect of dual combinations of ritodrine, nicardipine and atosiban on contractility of pregnant rat myometrium. BJOG. 2003 Aug;110(8):731-4.","\tPreterm Labour\tAtosiban|Atosiban and nifedipine\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tFemale\t","Single Versus Combination Therapy in Acute Tocolysis","Interventional","Completed","Phase 2",2,110,"obstetric labor, premature|premature birth","nifedipine|vasotocin|atosiban","NA"]
["NCT01430403",8084087,4412152,"Mean Difference (Net)",-0.52,"Standard Error of the Mean",0.3,-1.11,0.07,95,0.09,"Regression, Linear",26518090,"Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ Jr, Calatroni A, Wildfire JJ, Gergen PJ, Cohen RT, Pongracic JA, Kercsmar CM, Khurana Hershey GK, Gruchalla RS, Liu AH, Zoratti EM, Kattan M, Grindle KA, Gern JE, Busse WW, Szefler SJ. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015 Dec;136(6):1476-1485. doi: 10.1016/j.jaci.2015.09.008. Epub 2015 Oct 27.","\tAsthma\tOmalizumab|Inhaled Corticosteroid Boost Therapy (ICS)|Placebo omalizumab|Placebo fluticasone\tNA\tNA\tNA\tBiological|Drug|Biological|Biological\tAll\t","Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations","Interventional","Completed","Phase 4",3,478,"asthma","antibodies, monoclonal|fluticasone|omalizumab","Composite Asthma Severity Index (CASI), Treatment Steps 2-5: Omalizumab vs. Placebo"]
["NCT01431313",8083920,4411439,null,"NA",null,"NA",{"$nulls":3},0.8,"Mixed Models Analysis",27812547,"Simon MA, Vanderpool RR, Nouraie M, Bachman TN, White PM, Sugahara M, Gorcsan J 3rd, Parsley EL, Gladwin MT. Acute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction. JCI Insight. 2016 Nov 3;1(18):e89620. doi: 10.1172/jci.insight.89620.","\tHeart Failure, Diastolic|Pulmonary Hypertension\tInhaled Nitrite\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","heart failure, diastolic|hypertension|hypertension, pulmonary|heart failure","NA","Change in Systemic Vascular Resistance (SVR)"]
["NCT01433666","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29098341|29241652","Heckman PRA, Van Duinen MA, Blokland A, Uz T, Prickaerts J, Sambeth A. Acute administration of roflumilast enhances sensory gating in healthy young humans in a randomized trial. Psychopharmacology (Berl). 2018 Jan;235(1):301-308. doi: 10.1007/s00213-017-4770-y. Epub 2017 Nov 3.|Van Duinen MA, Sambeth A, Heckman PRA, Smit S, Tsai M, Lahu G, Uz T, Blokland A, Prickaerts J. Acute administration of roflumilast enhances immediate recall of verbal word memory in healthy young adults. Neuropharmacology. 2018 Mar 15;131:31-38. doi: 10.1016/j.neuropharm.2017.12.019. Epub 2017 Dec 11.","\tDementia\troflumilast (EU: Daxas, USA: Daliresp)|Placebo|roflumilast\tCrossover Assignment\tBasic Science\tRandomized\tDrug|Drug|Drug\tAll\t","Roflumilast and Cognition","Interventional","Completed","Phase 2",4,22,"dementia","phosphodiesterase 4 inhibitors","NA"]
["NCT01436097","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","3920715|9158910|NA|NA|15313080|10168262|15313079|15313077|11189801|NA|NA|17443205|20724401|10500021|15941896|20720258|15078651|20231566","Blair SN, Jacobs DR Jr, Powell KE. Relationships between exercise or physical activity and other health behaviors. Public Health Rep. 1985 Mar-Apr;100(2):172-80.|Coulson NS, Eiser C, Eiser JR. Diet, smoking and exercise: interrelationships between adolescent health behaviours. Child Care Health Dev. 1997 May;23(3):207-16.|Basiotis, PP, Carlson, A, Gerrior, SA, Juan, WY, & Lino, M. Nutrition Insight 28: Report Card on the Quality of Americans' Diets. Family Economics and Nutrition Review 16(2): 66-68, 2004.|Garasky, S, Morton, LW, & Greder, K. The Food Environment and Food Insecurity: Perceptions of Rural, Suburban, and Urban Food Pantry Clients in Iowa. Family Economics and Nutrition Review 16(2): 41-48, 2004.|Seymour JD, Yaroch AL, Serdula M, Blanck HM, Khan LK. Impact of nutrition environmental interventions on point-of-purchase behavior in adults: a review. Prev Med. 2004 Sep;39 Suppl 2:S108-36. Review.|Kristal AR, Goldenhar L, Muldoon J, Morton RF. Evaluation of a supermarket intervention to increase consumption of fruits and vegetables. Am J Health Promot. 1997 Jul-Aug;11(6):422-5.|French SA, Wechsler H. School-based research and initiatives: fruit and vegetable environment, policy, and pricing workshop. Prev Med. 2004 Sep;39 Suppl 2:S101-7. Review.|Glanz K, Hoelscher D. Increasing fruit and vegetable intake by changing environments, policy and pricing: restaurant-based research, strategies, and recommendations. Prev Med. 2004 Sep;39 Suppl 2:S88-93. Review.|French SA, Jeffery RW, Story M, Breitlow KK, Baxter JS, Hannan P, Snyder MP. Pricing and promotion effects on low-fat vending snack purchases: the CHIPS Study. Am J Public Health. 2001 Jan;91(1):112-7.|Basiotis, PP, Carlson, A, Gerrior, SA, Juan, WY, & Lino, M. The Healthy Eating Index: 1999-2000. U.S. Department of Agriculture, Center for Nutrition Policy and Promotion. CNPP-12, 2002|Lin, BH, Yen, ST, Dong, D, & Smallwood, DM. Economic incentives for dietary improvement among food stamp recipients. Contemporary Economic Policy 28 (4): 524-536, 2010|He FJ, Nowson CA, Lucas M, MacGregor GA. Increased consumption of fruit and vegetables is related to a reduced risk of coronary heart disease: meta-analysis of cohort studies. J Hum Hypertens. 2007 Sep;21(9):717-28. Epub 2007 Apr 19.|Mann J, Aune D. Can specific fruits and vegetables prevent diabetes? BMJ. 2010 Aug 18;341:c4395. doi: 10.1136/bmj.c4395.|Brown L, Rimm EB, Seddon JM, Giovannucci EL, Chasan-Taber L, Spiegelman D, Willett WC, Hankinson SE. A prospective study of carotenoid intake and risk of cataract extraction in US men. Am J Clin Nutr. 1999 Oct;70(4):517-24.|Christen WG, Liu S, Schaumberg DA, Buring JE. Fruit and vegetable intake and the risk of cataract in women. Am J Clin Nutr. 2005 Jun;81(6):1417-22.|Drewnowski A. The cost of US foods as related to their nutritive value. Am J Clin Nutr. 2010 Nov;92(5):1181-8. doi: 10.3945/ajcn.2010.29300. Epub 2010 Aug 18.|Halpern SD, Karlawish JH, Casarett D, Berlin JA, Asch DA. Empirical assessment of whether moderate payments are undue or unjust inducements for participation in clinical trials. Arch Intern Med. 2004 Apr 12;164(7):801-3.|Halpern SD, Raz A, Kohn R, Rey M, Asch DA, Reese P. Regulated payments for living kidney donation: an empirical assessment of the ethical concerns. Ann Intern Med. 2010 Mar 16;152(6):358-65. doi: 10.7326/0003-4819-152-6-201003160-00005.","\tNutrition Therapy\tInformation provision intervention|information provision + flat incentive|Information provision + tiered incentive|Usual Care\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral|Behavioral|Behavioral\tAll\t","Randomized Trial of Healthy Eating Interventions","Interventional","Completed","N/A",4,42,"NA","NA","NA"]
["NCT01446822","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29497859,"Gramann T, Schwab C, Zumstein V, Betschart P, Meier M, Schmid HP, Engeler DS. Transurethral resection of bladder cancer on the lateral bladder wall without obturator nerve block: extent of adductor spasms using the monopolar versus bipolar technique-a prospective randomised study. World J Urol. 2018 Jul;36(7):1085-1091. doi: 10.1007/s00345-018-2248-0. Epub 2018 Mar 1.","\tNeoplasm of Lateral Wall of Urinary Bladder\tBipolar transurethral resection of the urinary bladder (PlasmaKinetic, Gyrus, Fresenius)|Monopolar transurethral resection of the urinary bladder (Storz GmbH &Co., Erbotom, Purisole)\tParallel Assignment\tTreatment\tRandomized\tDevice|Device\tAll\t","Safety Study of Bipolar Versus Monopolar Transurethral Resection of Bladder Tumors","Interventional","Completed","N/A",2,44,"urinary bladder neoplasms","NA","NA"]
["NCT01446965","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",30280654,"Olgin JE, Pletcher MJ, Vittinghoff E, Wranicz J, Malik R, Morin DP, Zweibel S, Buxton AE, Elayi CS, Chung EH, Rashba E, Borggrefe M, Hue TF, Maguire C, Lin F, Simon JA, Hulley S, Lee BK; VEST Investigators. Wearable Cardioverter-Defibrillator after Myocardial Infarction. N Engl J Med. 2018 Sep 27;379(13):1205-1215. doi: 10.1056/NEJMoa1800781.","\tMyocardial Infarction|Sudden Death|Ventricular Dysfunction|Ventricular Fibrillation|Ventricular Tachycardia\twearable defibrillator\tParallel Assignment\tTreatment\tRandomized\tDevice\tAll\t","Vest Prevention of Early Sudden Death Trial and VEST Registry","Interventional","Completed","N/A",2,2348,"tachycardia, ventricular|ventricular dysfunction|ventricular fibrillation|infarction|myocardial infarction|death|tachycardia|death, sudden","NA","NA"]
["NCT01452880","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16037145,"Medina HJ, Galvin EM, Dirckx M, Banwarie P, Ubben JF, Zijlstra FJ, Klein J, Verbrugge SJ. Remifentanil as a single drug for extracorporeal shock wave lithotripsy: a comparison of infusion doses in terms of analgesic potency and side effects. Anesth Analg. 2005 Aug;101(2):365-70, table of contents.","\tKidney Calculi\tRemifentanil|Remifentanil\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","kidney calculi|calculi|nephrolithiasis","remifentanil","NA"]
["NCT01461850","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20818904|18801470|16791447","Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806.|Fagotti A, Ferrandina G, Fanfani F, Garganese G, Vizzielli G, Carone V, Salerno MG, Scambia G. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol. 2008 Dec;199(6):642.e1-6. doi: 10.1016/j.ajog.2008.06.052. Epub 2008 Sep 17.|Fagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M, Scambia G. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol. 2006 Aug;13(8):1156-61. Epub 2006 Jun 21.","\tStage IIIC Ovarian Cancer\tNeoadjuvant chemotherapy + Interval Debulking Surgery|Primary Debulking Surgery + Adjuvant Chemotherapy\tParallel Assignment\tTreatment\tRandomized\tDrug|Procedure\tFemale\t","Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm","Interventional","Completed","Phase 3",2,171,"neoplasms|ovarian neoplasms","NA","NA"]
["NCT01467947","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27788880,"Farkas H, Varga L, Moldovan D, Obtulowicz K, Shirov T, Machnig T, Feuersenger H, Edelman J, Williams-Herman D, Rojavin M. Assessment of inhibitory antibodies in patients with hereditary angioedema treated with plasma-derived C1 inhibitor. Ann Allergy Asthma Immunol. 2016 Nov;117(5):508-513. doi: 10.1016/j.anai.2016.08.025. Epub 2016 Oct 24.","\tHereditary Angioedema Types I and II\tBerinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","angioedema|hereditary angioedema types i and ii|angioedemas, hereditary","complement c1 inactivator proteins|complement c1 inhibitor protein","NA"]
["NCT01471873","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22906447,"Labiris G, Giarmoukakis A, Sideroudi H, Bougatsou P, Lazaridis I, Kozobolis VP. Variability in Scheimpflug image-derived posterior elevation measurements in keratoconus and collagen-crosslinked corneas. J Cataract Refract Surg. 2012 Sep;38(9):1616-25. doi: 10.1016/j.jcrs.2012.04.039.","\tKeratoconus\tCorneal Collagen Cross-linking (CXL)\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","keratoconus","NA","NA"]
["NCT01474616","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25271194,"Slaughter SE, Wagg AS, Jones CA, Schopflocher D, Ickert C, Bampton E, Jantz A, Milke D, Schalm C, Lycar C, Estabrooks CA. Mobility of Vulnerable Elders study: effect of the sit-to-stand activity on mobility, function, and quality of life. J Am Med Dir Assoc. 2015 Feb;16(2):138-43. doi: 10.1016/j.jamda.2014.07.020. Epub 2014 Sep 27.","\tMobility Limitation\tSit-to-Stand Activity\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","mobility limitation","NA","NA"]
["NCT01479153","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26398070|27311311","Parienti JJ, Mongardon N, Mégarbane B, Mira JP, Kalfon P, Gros A, Marqué S, Thuong M, Pottier V, Ramakers M, Savary B, Seguin A, Valette X, Terzi N, Sauneuf B, Cattoir V, Mermel LA, du Cheyron D; 3SITES Study Group. Intravascular Complications of Central Venous Catheterization by Insertion Site. N Engl J Med. 2015 Sep 24;373(13):1220-9. doi: 10.1056/NEJMoa1500964.|Pages J, Hazera P, Mégarbane B, du Cheyron D, Thuong M, Dutheil JJ, Valette X, Fournel F, Mermel LA, Mira JP, Daubin C, Parienti JJ; 3SITES Study Group. Comparison of alcoholic chlorhexidine and povidone-iodine cutaneous antiseptics for the prevention of central venous catheter-related infection: a cohort and quasi-experimental multicenter study. Intensive Care Med. 2016 Sep;42(9):1418-26. doi: 10.1007/s00134-016-4406-4. Epub 2016 Jun 16.","\tCatheterization|Critical Care|ICU\tRandomization of the site for catheterization\tParallel Assignment\tPrevention\tRandomized\tProcedure\tAll\t","Venous Site for Central Catheterization","Interventional","Completed","N/A",3,3471,"NA","NA","NA"]
["NCT01482273","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19017588|21325669|20347543|21256773|15866245|20578224","Kahn SR, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Lamping DL, Johri M, Ginsberg JS. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med. 2008 Nov 18;149(10):698-707.|Popuri RK, Vedantham S. The role of thrombolysis in the clinical management of deep vein thrombosis. Arterioscler Thromb Vasc Biol. 2011 Mar;31(3):479-84. doi: 10.1161/ATVBAHA.110.213413. Review.|Grewal NK, Martinez JT, Andrews L, Comerota AJ. Quantity of clot lysed after catheter-directed thrombolysis for iliofemoral deep venous thrombosis correlates with postthrombotic morbidity. J Vasc Surg. 2010 May;51(5):1209-14. doi: 10.1016/j.jvs.2009.12.021. Epub 2010 Mar 27.|Grommes J, Strijkers R, Greiner A, Mahnken AH, Wittens CH. Safety and feasibility of ultrasound-accelerated catheter-directed thrombolysis in deep vein thrombosis. Eur J Vasc Endovasc Surg. 2011 Apr;41(4):526-32. doi: 10.1016/j.ejvs.2010.11.035. Epub 2011 Jan 21.|Hull RD, Marder VJ, Mah AF, Biel RK, Brant RF. Quantitative assessment of thrombus burden predicts the outcome of treatment for venous thrombosis: a systematic review. Am J Med. 2005 May;118(5):456-64. Review.|Sharifi M, Mehdipour M, Bay C, Smith G, Sharifi J. Endovenous therapy for deep venous thrombosis: the TORPEDO trial. Catheter Cardiovasc Interv. 2010 Sep 1;76(3):316-25. doi: 10.1002/ccd.22638.","\tPostthrombotic Syndrome|Venous Thrombosis\tCDT+US group|CDT-US group\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","Ultrasound-enhanced Thrombolysis Versus Standard Catheter Directed Thrombolysis for Ilio-femoral Deep Vein Thrombosis","Interventional","Completed","N/A",2,48,"postthrombotic syndrome|thrombosis|venous thrombosis|postphlebitic syndrome","NA","NA"]
["NCT01489111","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32293786,"Tosetto A, Neff A, Lentz SR, Santagostino E, Nemes L, Sathar J, Meijer K, Chowdary P, Shen C, Landorph A, Hampton K. Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials. Haemophilia. 2020 May;26(3):450-458. doi: 10.1111/hae.13980. Epub 2020 Apr 15.","\tCongenital Bleeding Disorder|Haemophilia A\tturoctocog alfa pegol\tNA\tNA\tNA\tDrug\tMale\t","NA","NA","NA","NA","NA","NA","hemophilia a|blood coagulation disorders|hemostatic disorders","NA","NA"]
["NCT01490931",8075764,4407944,null,"NA",null,"NA",{"$nulls":3},{"v":1E-4,"d":"1.00E-04"},"t-test, 2 sided",24564610,"Bockow R, Korostoff J, Pinto A, Hutcheson M, Secreto SA, Bodner L, Hersh EV. Characterization and treatment of postsurgical dental implant pain employing intranasal ketorolac. Compend Contin Educ Dent. 2013 Sep;34(8):570-6.","\tAcute Pain\tKetorolac Nasal Spray\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","acute pain","ketorolac","Comparison of Pain Intensity Scores at 20 Minutes With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period."]
["NCT01495468","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28566441,"Luo X, Hou L, Liang L, Dong G, Shen S, Zhao Z, Gong CX, Li Y, Du ML, Su Z, Du H, Yan C. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies. Eur J Endocrinol. 2017 Aug;177(2):195-205. doi: 10.1530/EJE-16-0905. Epub 2017 May 31.","\tGrowth Hormone Deficiency\tPEG-somatropin\tParallel Assignment\tTreatment\tRandomized\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","endocrine system diseases|dwarfism, pituitary","hormones","NA"]
["NCT01498328","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32034072,"Reardon DA, Desjardins A, Vredenburgh JJ, O'Rourke DM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Ashby LS, Duic JP, Mrugala MM, Cruickshank S, Vitale L, He Y, Green JA, Yellin MJ, Turner CD, Keler T, Davis TA, Sampson JH; ReACT trial investigators. Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. Clin Cancer Res. 2020 Apr 1;26(7):1586-1594. doi: 10.1158/1078-0432.CCR-18-1140. Epub 2020 Feb 7.","\tGiant Cell Glioblastoma|Glioblastoma|Glioblastoma With Oligodendroglial Component|Gliosarcoma|Recurrent Glioblastoma|Relapsed Glioblastoma|Small Cell Glioblastoma\tBevacizumab|Rindopepimut (CDX-110) with GM-CSF|KLH\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma","Interventional","Completed","Phase 2",3,127,"glioblastoma|gliosarcoma","bevacizumab|rindopepimut","NA"]
["NCT01502670","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23595643,"Amzat R, Taleghani P, Miller DL, Beitler JJ, Bellamy LM, Nye JA, Yu W, Savir-Baruch B, Osunkoya AO, Chen Z, Auffermann WF, Goodman MM, Schuster DM. Pilot study of the utility of the synthetic PET amino-acid radiotracer anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid for the noninvasive imaging of pulmonary lesions. Mol Imaging Biol. 2013 Oct;15(5):633-43. doi: 10.1007/s11307-012-0606-7.","\tLung Cancer\t18F-FACBC Radiotracer\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT01507298","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25625191,"Kwasnicki RM, Ley Greaves R, Ali R, Gummett PA, Yang GZ, Darzi A, Hoare J. Implementation of objective activity monitoring to supplement the interpretation of ambulatory esophageal PH investigations. Dis Esophagus. 2016 Apr;29(3):255-61. doi: 10.1111/dote.12312. Epub 2015 Jan 27.","\tGastro-oesophageal Reflux Disease\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","gastroesophageal reflux","NA","NA"]
["NCT01515839","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21304145|21615001","Amen DG, Newberg A, Thatcher R, Jin Y, Wu J, Keator D, Willeumier K. Impact of playing American professional football on long-term brain function. J Neuropsychiatry Clin Neurosci. 2011 Winter;23(1):98-106. doi: 10.1176/appi.neuropsych.23.1.98.|Amen DG, Wu JC, Taylor D, Willeumier K. Reversing brain damage in former NFL players: implications for traumatic brain injury and substance abuse rehabilitation. J Psychoactive Drugs. 2011 Jan-Mar;43(1):1-5. doi: 10.1080/02791072.2011.566489.","\tTraumatic Brain Injury\tMultivitamin Supplement intervention\tNA\tNA\tNA\tDietary Supplement\tMale\t","NA","NA","NA","NA","NA","NA","brain injuries, traumatic|brain injuries","huperzine a|vinpocetine|thioctic acid|acetylcarnitine|acetylcysteine","NA"]
["NCT01519453","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",33016987,"Eakin MN, Zaeh S, Eckmann T, Ruvalcaba E, Rand CS, Hilliard ME, Riekert KA. Effectiveness of a Home- and School-Based Asthma Educational Program for Head Start Children With Asthma: A Randomized Clinical Trial. JAMA Pediatr. 2020 Dec 1;174(12):1191-1198. doi: 10.1001/jamapediatrics.2020.3375.","\tAsthma\tHome Based Asthma Education\tParallel Assignment\tTreatment\tRandomized\tBehavioral\tAll\t","Reducing Asthma Morbidity In High Risk Minority Preschool Children","Interventional","Completed","N/A",2,404,"asthma","NA","NA"]
["NCT01519817",8072535,4406425,null,"NA",null,"NA",{"$nulls":3},0.4347,"Wilcoxon test",26130065,"Heery CR, Singh BH, Rauckhorst M, Marté JL, Donahue RN, Grenga I, Rodell TC, Dahut W, Arlen PM, Madan RA, Schlom J, Gulley JL. Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. Cancer Immunol Res. 2015 Nov;3(11):1248-56. doi: 10.1158/2326-6066.CIR-15-0119. Epub 2015 Jun 30.","\tAdenocarcinoma|Colon Neoplasms|Malignant Solid Tumors|Neoplasms\tGI-6301 (Yeast Brachyury Vaccine)\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","colonic neoplasms|neoplasms","vaccines","Changes in Serum Levels of Cytokines"]
["NCT01519817",8072536,4406439,null,"NA",null,"NA",{"$nulls":3},0.74,"Wilcoxon test",26130065,"Heery CR, Singh BH, Rauckhorst M, Marté JL, Donahue RN, Grenga I, Rodell TC, Dahut W, Arlen PM, Madan RA, Schlom J, Gulley JL. Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. Cancer Immunol Res. 2015 Nov;3(11):1248-56. doi: 10.1158/2326-6066.CIR-15-0119. Epub 2015 Jun 30.","\tAdenocarcinoma|Colon Neoplasms|Malignant Solid Tumors|Neoplasms\tGI-6301 (Yeast Brachyury Vaccine)\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","colonic neoplasms|neoplasms","vaccines","Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC)"]
["NCT01519817",8072536,4406461,null,"NA",null,"NA",{"$nulls":3},7.6E-3,"Wilcoxon test",26130065,"Heery CR, Singh BH, Rauckhorst M, Marté JL, Donahue RN, Grenga I, Rodell TC, Dahut W, Arlen PM, Madan RA, Schlom J, Gulley JL. Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. Cancer Immunol Res. 2015 Nov;3(11):1248-56. doi: 10.1158/2326-6066.CIR-15-0119. Epub 2015 Jun 30.","\tAdenocarcinoma|Colon Neoplasms|Malignant Solid Tumors|Neoplasms\tGI-6301 (Yeast Brachyury Vaccine)\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","colonic neoplasms|neoplasms","vaccines","Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC)"]
["NCT01519817",8072536,4406434,null,"NA",null,"NA",{"$nulls":3},0.36,"Wilcoxon test",26130065,"Heery CR, Singh BH, Rauckhorst M, Marté JL, Donahue RN, Grenga I, Rodell TC, Dahut W, Arlen PM, Madan RA, Schlom J, Gulley JL. Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. Cancer Immunol Res. 2015 Nov;3(11):1248-56. doi: 10.1158/2326-6066.CIR-15-0119. Epub 2015 Jun 30.","\tAdenocarcinoma|Colon Neoplasms|Malignant Solid Tumors|Neoplasms\tGI-6301 (Yeast Brachyury Vaccine)\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","colonic neoplasms|neoplasms","vaccines","Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC)"]
["NCT01519817",8072536,4406492,null,"NA",null,"NA",{"$nulls":3},0.88,"Wilcoxon test",26130065,"Heery CR, Singh BH, Rauckhorst M, Marté JL, Donahue RN, Grenga I, Rodell TC, Dahut W, Arlen PM, Madan RA, Schlom J, Gulley JL. Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. Cancer Immunol Res. 2015 Nov;3(11):1248-56. doi: 10.1158/2326-6066.CIR-15-0119. Epub 2015 Jun 30.","\tAdenocarcinoma|Colon Neoplasms|Malignant Solid Tumors|Neoplasms\tGI-6301 (Yeast Brachyury Vaccine)\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","colonic neoplasms|neoplasms","vaccines","Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC)"]
["NCT01526980","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19527481,"Dashora U, Ashwell SG, Home PD. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes. Diabetes Obes Metab. 2009 Jul;11(7):680-7. doi: 10.1111/j.1463-1326.2008.01024.x.","\tDiabetes|Diabetes Mellitus, Type 2\tbiphasic insulin aspart 30|biphasic insulin aspart 70|biphasic human insulin 30\tCrossover Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes","Interventional","Completed","Phase 2",2,31,"diabetes mellitus, type 2|diabetes mellitus","insulin, long-acting|insulin degludec, insulin aspart drug combination|biphasic insulins|insulin aspart, insulin aspart protamine drug combination 30:70|insulin, globin zinc|insulin aspart|insulin","NA"]
["NCT01531387","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26414435,"Hankins JS, McCarville MB, Rankine-Mullings A, Reid ME, Lobo CL, Moura PG, Ali S, Soares DP, Aldred K, Jay DW, Aygun B, Bennett J, Kang G, Goldsmith JC, Smeltzer MP, Boyett JM, Ware RE. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: A Phase III international randomized clinical trial. Am J Hematol. 2015 Dec;90(12):1099-105. doi: 10.1002/ajh.24198. Epub 2015 Nov 17.","\tSickle Cell Anemia\tHydroxyurea\tParallel Assignment\tPrevention\tRandomized\tDrug\tAll\t","Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE)","Interventional","Terminated","Phase 3",2,38,"anemia, sickle cell|anemia","hydroxyurea","NA"]
["NCT01534169","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19850691|22219499","Mao XM, Li HQ, Li Q, Li DM, Xie XJ, Yin GP, Zhang P, Xu XH, Wu JD, Chen SW, Wang SK. Prevention of relapse of Graves' disease by treatment with an intrathyroid injection of dexamethasone. J Clin Endocrinol Metab. 2009 Dec;94(12):4984-91. doi: 10.1210/jc.2009-1252. Epub 2009 Oct 22.|Hu Y, Tian W, Zhang LL, Liu H, Yin GP, He BS, Mao XM. Function of regulatory T-cells improved by dexamethasone in Graves' disease. Eur J Endocrinol. 2012 Apr;166(4):641-6. doi: 10.1530/EJE-11-0879. Epub 2012 Jan 4.","\tGraves' Disease\tDexamethasone\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","graves disease","dexamethasone","NA"]
["NCT01538836","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27732859|26150260|25475435","Smith GI, Yoshino J, Kelly SC, Reeds DN, Okunade A, Patterson BW, Klein S, Mittendorfer B. High-Protein Intake during Weight Loss Therapy Eliminates the Weight-Loss-Induced Improvement in Insulin Action in Obese Postmenopausal Women. Cell Rep. 2016 Oct 11;17(3):849-861. doi: 10.1016/j.celrep.2016.09.047.|Smith GI, Patterson BW, Klein SJ, Mittendorfer B. Effect of hyperinsulinaemia-hyperaminoacidaemia on leg muscle protein synthesis and breakdown: reassessment of the two-pool arterio-venous balance model. J Physiol. 2015 Sep 15;593(18):4245-57. doi: 10.1113/JP270774. Epub 2015 Aug 14.|Smith GI, Yoshino J, Stromsdorfer KL, Klein SJ, Magkos F, Reeds DN, Klein S, Mittendorfer B. Protein Ingestion Induces Muscle Insulin Resistance Independent of Leucine-Mediated mTOR Activation. Diabetes. 2015 May;64(5):1555-63. doi: 10.2337/db14-1279. Epub 2014 Dec 4.","\tMenopause|Obesity|Osteoporosis|Sarcopenia\tWeight loss with normal protein intake|Weight loss with protein supplementation\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral\tFemale\t","Calorie Restriction, Protein Supplementation and Metabolic Health","Interventional","Completed","N/A",3,75,"osteoporosis|sarcopenia","NA","NA"]
["NCT01540045",8070164,4405375,null,"NA",null,"NA",{"$nulls":3},0.889,"Wilcoxon (Mann-Whitney)","20306090|6413712|2305710|17280921|19273394|19289621|20667968|20334666|21351269","Brennan MT, Elting LS, Spijkervet FK. Systematic reviews of oral complications from cancer therapies, Oral Care Study Group, MASCC/ISOO: methodology and quality of the literature. Support Care Cancer. 2010 Aug;18(8):979-84. doi: 10.1007/s00520-010-0856-3. Epub 2010 Mar 20. Review.|Gallagher P, Tweedle DE. Taste threshold and acceptability of commercial diets in cancer patients. JPEN J Parenter Enteral Nutr. 1983 Jul-Aug;7(4):361-3.|Mattes RD, Cowart BJ, Schiavo MA, Arnold C, Garrison B, Kare MR, Lowry LD. Dietary evaluation of patients with smell and/or taste disorders. Am J Clin Nutr. 1990 Feb;51(2):233-40.|Hutton JL, Baracos VE, Wismer WV. Chemosensory dysfunction is a primary factor in the evolution of declining nutritional status and quality of life in patients with advanced cancer. J Pain Symptom Manage. 2007 Feb;33(2):156-65.|Rehwaldt M, Wickham R, Purl S, Tariman J, Blendowski C, Shott S, Lappe M. Self-care strategies to cope with taste changes after chemotherapy. Oncol Nurs Forum. 2009 Mar;36(2):E47-56. doi: 10.1188/09.ONF. E47-E56.|Steinbach S, Hummel T, Böhner C, Berktold S, Hundt W, Kriner M, Heinrich P, Sommer H, Hanusch C, Prechtl A, Schmidt B, Bauerfeind I, Seck K, Jacobs VR, Schmalfeldt B, Harbeck N. Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. J Clin Oncol. 2009 Apr 10;27(11):1899-905. doi: 10.1200/JCO.2008.19.2690. Epub 2009 Mar 16.|Zabernigg A, Gamper EM, Giesinger JM, Rumpold G, Kemmler G, Gattringer K, Sperner-Unterweger B, Holzner B. Taste alterations in cancer patients receiving chemotherapy: a neglected side effect? Oncologist. 2010;15(8):913-20. doi: 10.1634/theoncologist.2009-0333. Epub 2010 Jul 28.|Sánchez-Lara K, Sosa-Sánchez R, Green-Renner D, Rodríguez C, Laviano A, Motola-Kuba D, Arrieta O. Influence of taste disorders on dietary behaviors in cancer patients under chemotherapy. Nutr J. 2010 Mar 24;9:15. doi: 10.1186/1475-2891-9-15.|Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.","\tDysgeusia|Lung Neoplasms|Non-Small Cell Lung Cancer|Small Cell Lung Carcinoma|Taste Disorders\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung|taste disorders|small cell lung carcinoma|lung neoplasms|dysgeusia","NA","Quality o f Life"]
["NCT01547338","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24923524,"Gilmour A, Mackay IR, Young D, Hill ME, Brown L, Malyon AD. The use of real-time digital video in the assessment of post-operative outcomes of breast reconstruction. J Plast Reconstr Aesthet Surg. 2014 Oct;67(10):1357-63. doi: 10.1016/j.bjps.2014.05.036. Epub 2014 Jun 2.","\tBreast Neoplasms|Breast Reconstruction\tNA\tNA\tNA\tNA\tNA\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","NA","NA"]
["NCT01550081","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23988787,"Aamot IL, Forbord SH, Karlsen T, Støylen A. Does rating of perceived exertion result in target exercise intensity during interval training in cardiac rehabilitation? A study of the Borg scale versus a heart rate monitor. J Sci Med Sport. 2014 Sep;17(5):541-5. doi: 10.1016/j.jsams.2013.07.019. Epub 2013 Aug 8.","\tCoronary Artery Disease\tRate of perceived exertion|Heart rate monitor\tNA\tNA\tNA\tOther|Other\tAll\t","Target Heart Rate and Aerobic Interval Training","Interventional","Completed","N/A",2,10,"coronary artery disease","NA","NA"]
["NCT01550965",8068908,4405017,"Mean Difference (Final Values)",0.13,null,"NA",0.11,0.15,95,1E-3,"Paired t-test, 2 sided",28981846,"Travis S, Feagan BG, Peyrin-Biroulet L, Panaccione R, Danese S, Lazar A, Robinson AM, Petersson J, Pappalardo BL, Bereswill M, Chen N, Wang S, Skup M, Thakkar RB, Chao J. Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. J Crohns Colitis. 2017 Oct 27;11(11):1317-1325. doi: 10.1093/ecco-jcc/jjx093.","\tUlcerative Colitis\tAdalimumab\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","colitis|colitis, ulcerative|ulcer","adalimumab","Mean Change From Baseline in European Quality of Life - 5 Dimensions - 5 Level (EQ-5D-5L) Total Score"]
["NCT01550965",8068914,4405038,"Mean Difference (Final Values)",24.37,null,"NA",21.5,27.25,95,1E-3,"Paired t-test, 2 sided",28981846,"Travis S, Feagan BG, Peyrin-Biroulet L, Panaccione R, Danese S, Lazar A, Robinson AM, Petersson J, Pappalardo BL, Bereswill M, Chen N, Wang S, Skup M, Thakkar RB, Chao J. Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. J Crohns Colitis. 2017 Oct 27;11(11):1317-1325. doi: 10.1093/ecco-jcc/jjx093.","\tUlcerative Colitis\tAdalimumab\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","colitis|colitis, ulcerative|ulcer","adalimumab","Mean Change From Baseline in Participant's Satisfaction Using Treatment Satisfaction Questionnaire for Medication (TSQM)"]
["NCT01551420",8068847,4404977,"Mean Difference (Net)",-0.02,"Standard Deviation",0.06,-0.05,0,95,0.0511,"t-test, 2 sided","28375687|29342217|29741966|29779455|30240420|30335781","Resnik L, Cancio J, Klinger S, Latlief G, Sasson N, Smurr-Walters L. Predictors of retention and attrition in a study of an advanced upper limb prosthesis: implications for adoption of the DEKA Arm. Disabil Rehabil Assist Technol. 2018 Feb;13(2):206-210. doi: 10.1080/17483107.2017.1304585. Epub 2017 Apr 4.|Resnik LJ, Borgia ML, Acluche F, Cancio JM, Latlief G, Sasson N. How do the outcomes of the DEKA Arm compare to conventional prostheses? PLoS One. 2018 Jan 17;13(1):e0191326. doi: 10.1371/journal.pone.0191326. eCollection 2018.|Resnik L, Klinger S, Gill A, Ekerholm Biester S. Feminine identity and functional benefits are key factors in women's decision making about upper limb prostheses: a case series. Disabil Rehabil Assist Technol. 2019 Feb;14(2):194-208. doi: 10.1080/17483107.2018.1467973. Epub 2018 May 9.|Resnik L, Acluche F, Borgia M, Cancio J, Latlief G, Sasson N. Function, quality of life, and community integration of DEKA Arm users after discharge from prosthetic training: Impact of home use experience. Prosthet Orthot Int. 2018 Dec;42(6):571-582. doi: 10.1177/0309364618774054. Epub 2018 May 19.|Resnik LJ, Acluche F, Lieberman Klinger S. User experience of controlling the DEKA Arm with EMG pattern recognition. PLoS One. 2018 Sep 21;13(9):e0203987. doi: 10.1371/journal.pone.0203987. eCollection 2018.|Resnik LJ, Acluche F, Borgia M, Cancio J, Latlief G, Phillips S, Sasson N. EMG pattern recognition compared to foot control of the DEKA Arm. PLoS One. 2018 Oct 18;13(10):e0204854. doi: 10.1371/journal.pone.0204854. eCollection 2018.","\tTraumatic Amputation of Arm\tAdvanced upper limb prosthetic device IMU controlled|Advanced upper limb prosthetic EMG-PR controlled\tNA\tNA\tNA\tDevice|Device\tAll\t","Home Study of an Advanced Upper Limb Prosthesis","Interventional","Completed","N/A",2,52,"amputation, traumatic","NA","Jebsen-Taylor Hand Function Test (JTHFT) 7 Subtests"]
["NCT01551420",8068850,4404988,"Mean Difference (Net)",-0.22,"Standard Deviation",0.94,-0.55,0.11,95,0.186,"t-test, 2 sided","28375687|29342217|29741966|29779455|30240420|30335781","Resnik L, Cancio J, Klinger S, Latlief G, Sasson N, Smurr-Walters L. Predictors of retention and attrition in a study of an advanced upper limb prosthesis: implications for adoption of the DEKA Arm. Disabil Rehabil Assist Technol. 2018 Feb;13(2):206-210. doi: 10.1080/17483107.2017.1304585. Epub 2017 Apr 4.|Resnik LJ, Borgia ML, Acluche F, Cancio JM, Latlief G, Sasson N. How do the outcomes of the DEKA Arm compare to conventional prostheses? PLoS One. 2018 Jan 17;13(1):e0191326. doi: 10.1371/journal.pone.0191326. eCollection 2018.|Resnik L, Klinger S, Gill A, Ekerholm Biester S. Feminine identity and functional benefits are key factors in women's decision making about upper limb prostheses: a case series. Disabil Rehabil Assist Technol. 2019 Feb;14(2):194-208. doi: 10.1080/17483107.2018.1467973. Epub 2018 May 9.|Resnik L, Acluche F, Borgia M, Cancio J, Latlief G, Sasson N. Function, quality of life, and community integration of DEKA Arm users after discharge from prosthetic training: Impact of home use experience. Prosthet Orthot Int. 2018 Dec;42(6):571-582. doi: 10.1177/0309364618774054. Epub 2018 May 19.|Resnik LJ, Acluche F, Lieberman Klinger S. User experience of controlling the DEKA Arm with EMG pattern recognition. PLoS One. 2018 Sep 21;13(9):e0203987. doi: 10.1371/journal.pone.0203987. eCollection 2018.|Resnik LJ, Acluche F, Borgia M, Cancio J, Latlief G, Phillips S, Sasson N. EMG pattern recognition compared to foot control of the DEKA Arm. PLoS One. 2018 Oct 18;13(10):e0204854. doi: 10.1371/journal.pone.0204854. eCollection 2018.","\tTraumatic Amputation of Arm\tAdvanced upper limb prosthetic device IMU controlled|Advanced upper limb prosthetic EMG-PR controlled\tNA\tNA\tNA\tDevice|Device\tAll\t","Home Study of an Advanced Upper Limb Prosthesis","Interventional","Completed","N/A",2,52,"amputation, traumatic","NA","Trinity Amputations and Prosthetics Experience Scale (TAPES) Satisfaction Scale"]
["NCT01558596","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27688236,"Garcia S, Rector TS, Zakharova M, Herrmann RR, Adabag S, Bertog S, Sandoval Y, Santilli S, Brilakis ES, McFalls EO. Cardiac Remote Ischemic Preconditioning Prior to Elective Vascular Surgery (CRIPES): A Prospective, Randomized, Sham-Controlled Phase II Clinical Trial. J Am Heart Assoc. 2016 Sep 29;5(10). pii: e003916.","\tPeripheral Arterial Disease|Vascular Surgery\tPreconditioning|Control\tParallel Assignment\tPrevention\tRandomized\tProcedure|Procedure\tAll\t","Remote Ischemic Preconditioning Prior to Vascular Surgery","Interventional","Completed","Phase 1/Phase 2",2,201,"peripheral vascular diseases|peripheral arterial disease","NA","NA"]
["NCT01561040","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20631232|18234997|20393114|20597641","Sullivan BD, Whitmer D, Nichols KK, Tomlinson A, Foulks GN, Geerling G, Pepose JS, Kosheleff V, Porreco A, Lemp MA. An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6125-30. doi: 10.1167/iovs.10-5390. Epub 2010 Jul 14.|Chen Z, Tong L, Li Z, Yoon KC, Qi H, Farley W, Li DQ, Pflugfelder SC. Hyperosmolarity-induced cornification of human corneal epithelial cells is regulated by JNK MAPK. Invest Ophthalmol Vis Sci. 2008 Feb;49(2):539-49. doi: 10.1167/iovs.07-0569.|Suzuki M, Massingale ML, Ye F, Godbold J, Elfassy T, Vallabhajosyula M, Asbell PA. Tear osmolarity as a biomarker for dry eye disease severity. Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4557-61. doi: 10.1167/iovs.09-4596. Epub 2010 Apr 14.|Versura P, Profazio V, Campos EC. Performance of tear osmolarity compared to previous diagnostic tests for dry eye diseases. Curr Eye Res. 2010 Jul;35(7):553-64. doi: 10.3109/02713683.2010.484557.","\tDry Eye Syndrome\tOmega 3, Vitamins A, D3 and E\tNA\tNA\tNA\tDietary Supplement\tAll\t","NA","NA","NA","NA","NA","NA","dry eye syndromes|keratoconjunctivitis sicca","vitamin d|vitamin a","NA"]
["NCT01567553","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24691080,"Crimi A, Commowick O, Maarouf A, Ferré JC, Bannier E, Tourbah A, Berry I, Ranjeva JP, Edan G, Barillot C. Predictive value of imaging markers at multiple sclerosis disease onset based on gadolinium- and USPIO-enhanced MRI and machine learning. PLoS One. 2014 Apr 1;9(4):e93024. doi: 10.1371/journal.pone.0093024. eCollection 2014.","\tInflammatory Disease|Multiple Sclerosis (MS)\tUSPIO MRI - Gadolinium MRI\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","sclerosis|multiple sclerosis","NA","NA"]
["NCT01571921","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20929592,"Nesaretnam K, Selvaduray KR, Abdul Razak G, Veerasenan SD, Gomez PA. Effectiveness of tocotrienol-rich fraction combined with tamoxifen in the management of women with early breast cancer: a pilot clinical trial. Breast Cancer Res. 2010;12(5):R81. doi: 10.1186/bcr2726. Epub 2010 Oct 8.","\tHealthy Subjects\tGamma-Delta Tocotrienol and Tocotrienol Rich Fraction\tCrossover Assignment\tTreatment\tRandomized\tDietary Supplement\tAll\t","Gamma-delta Tocotrienol as Potential Maintenance Treatment in Women With Metastatic Breast Cancer","Interventional","Completed","Phase 1",2,12,"NA","vitamin e|tocotrienols|tocopherols","NA"]
["NCT01577459","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29899212,"Flanagan S, Minassian SL, Prokocimer P. Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers. J Clin Med. 2018 Jun 14;7(6). pii: E150. doi: 10.3390/jcm7060150.","\tHealthy Subjects\tTR-701 FA with PSE|TR-701 FA Placebo with PSE\tCrossover Assignment\tOther\tRandomized\tDrug|Other\tAll\t","A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response","Interventional","Completed","Phase 1",2,18,"NA","tedizolid phosphate|tedizolid","NA"]
["NCT01581476","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22416821,"Cherney DZ, Scholey JW, Daneman D, Dunger DB, Dalton RN, Moineddin R, Mahmud FH, Dekker R, Elia Y, Sochett E, Reich HN. Urinary markers of renal inflammation in adolescents with Type 1 diabetes mellitus and normoalbuminuria. Diabet Med. 2012 Oct;29(10):1297-302. doi: 10.1111/j.1464-5491.2012.03651.x.","\tType 1 Diabetes\tStatin|ACE inhibitor|Placebo|Combination therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tAll\t","Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial","Interventional","Completed","Phase 3",4,443,"diabetes mellitus, type 1|diabetes mellitus","quinapril|angiotensin-converting enzyme inhibitors|atorvastatin","NA"]
["NCT01584596","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24376252|25569324|25687483","Harrington DM, Champagne CM, Broyles ST, Johnson WD, Tudor-Locke C, Katzmarzyk PT. Steps ahead: a randomized trial to reduce unhealthy weight gain in the Lower Mississippi Delta. Obesity (Silver Spring). 2014 May;22(5):E21-8. doi: 10.1002/oby.20684. Epub 2014 Jan 25.|Harrington DM, Champagne CM, Broyles ST, Johnson WD, Tudor-Locke C, Katzmarzyk PT. Cardiometabolic risk factor response to a lifestyle intervention: a randomized trial. Metab Syndr Relat Disord. 2015 Apr;13(3):125-31. doi: 10.1089/met.2014.0112. Epub 2015 Jan 8.|Barreira TV, Harrington DM, Schuna JM Jr, Tudor-Locke C, Katzmarzyk PT. Pattern changes in step count accumulation and peak cadence due to a physical activity intervention. J Sci Med Sport. 2016 Mar;19(3):227-231. doi: 10.1016/j.jsams.2015.01.008. Epub 2015 Feb 3.","\tObesity\tAdapted Dietary Guidelines|Adapted Physical Activity Guidelines\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral\tAll\t","Steps Ahead, Adapting Physical Activity Guidelines for the Lower Mississippi Delta Population","Interventional","Completed","Phase 1/Phase 2",2,129,"NA","NA","NA"]
["NCT01594567","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24710915|24014659","Ha V, Sievenpiper JL, de Souza RJ, Jayalath VH, Mirrahimi A, Agarwal A, Chiavaroli L, Mejia SB, Sacks FM, Di Buono M, Bernstein AM, Leiter LA, Kris-Etherton PM, Vuksan V, Bazinet RP, Josse RG, Beyene J, Kendall CW, Jenkins DJ. Effect of dietary pulse intake on established therapeutic lipid targets for cardiovascular risk reduction: a systematic review and meta-analysis of randomized controlled trials. CMAJ. 2014 May 13;186(8):E252-62. doi: 10.1503/cmaj.131727. Epub 2014 Apr 7. Review.|Jayalath VH, de Souza RJ, Sievenpiper JL, Ha V, Chiavaroli L, Mirrahimi A, Di Buono M, Bernstein AM, Leiter LA, Kris-Etherton PM, Vuksan V, Beyene J, Kendall CW, Jenkins DJ. Effect of dietary pulses on blood pressure: a systematic review and meta-analysis of controlled feeding trials. Am J Hypertens. 2014 Jan;27(1):56-64. doi: 10.1093/ajh/hpt155. Epub 2013 Sep 7. Review.","\tCardiovascular Disease|Diabetes|Dysglycemia|Dyslipidemia|Hypertension|Metabolic Syndrome|Obesity|Overweight|Prediabetes\tDietary pulses\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","overweight|metabolic syndrome|dyslipidemias|cardiovascular diseases","NA","NA"]
["NCT01598454","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26154941,"Cacciavillano W, Sampor C, Venier C, Gabri MR, de Dávila MT, Galluzzo ML, Guthmann MD, Fainboim L, Alonso DF, Chantada GL. A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies. Pediatr Blood Cancer. 2015 Dec;62(12):2120-4. doi: 10.1002/pbc.25631. Epub 2015 Jul 7.","\tEwing's Sarcoma|Glioma|Neuroblastoma|Retinoblastoma|Wilm's Tumor\tracotumomab\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","retinoblastoma|neuroblastoma|sarcoma, ewing|wilms tumor","NA","NA"]
["NCT01601639","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25650636,"Zepeda-Gómez S, Sultanian R, Teshima C, Sandha G, Van Zanten S, Montano-Loza AJ. Gastric antral vascular ectasia: a prospective study of treatment with endoscopic band ligation. Endoscopy. 2015 Jun;47(6):538-40. doi: 10.1055/s-0034-1391395. Epub 2015 Feb 4.","\tGastric Antral Vascular Ectasia\tEndoscopic Band Ligation|Argon plasma Coagulation (APC) for GAVE\tParallel Assignment\tTreatment\tRandomized\tDevice|Device\tAll\t","Endoscopic Band Ligation Versus Argon Plasma Coagulation for the Treatment of Gastric Antral Vascular Ectasia: a Randomized Clinical Trial","Interventional","Completed","Phase 3",2,30,"dilatation, pathologic|gastric antral vascular ectasia","NA","NA"]
["NCT01606670","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27883297,"Timmermann L, Oehlwein C, Ransmayr G, Fröhlich H, Will E, Schroeder H, Lauterbach T, Bauer L, Kassubek J. Patients' perception of Parkinson's disease-associated pain following initiation of rotigotine: a multicenter non-interventional study. Postgrad Med. 2017 Jan;129(1):46-54. doi: 10.1080/00325481.2017.1258953. Epub 2016 Nov 24.","\tIdiopathic Parkinson's Disease\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","parkinson disease","NA","NA"]
["NCT01615185","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12747876|11229973|15521794|16870959","Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003 May 10;361(9369):1581-9. Review.|Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry. 2001 Mar;158(3):360-9. Review.|McKeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs. 2004;18(13):933-56. Review.|Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, Tapp A, Keefe RS, Rosenheck RA. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv. 2006 Aug;57(8):1094-101.","\tSchizophrenia\tfull-dose amisulpride\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","A Randomized, Double-blind, Comparison of the Efficacy and Safety of Amisulpride Versus Low-dose Amisulpride Plus Low-dose Sulpiride in the Treatment of Schizophrenia","Interventional","Terminated","Phase 4",2,96,"schizophrenia","amisulpride","NA"]
["NCT01616069","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22480207|22459932|22440381|22004267","Chung PC, Huang PC, Liu YF, Chen KB. Transesophageal echocardiography, more than a diagnostic tool: use during surgical ligation of coronary artery fistulae - a case report. J Cardiothorac Surg. 2012 Apr 6;7:28. doi: 10.1186/1749-8090-7-28.|De Mey N, Couture P, Laflamme M, Denault AY, Perrault LP, Deschamps A, Rochon AG. Intraoperative changes in regional wall motion: can postoperative coronary artery bypass graft failure be predicted? J Cardiothorac Vasc Anesth. 2012 Jun;26(3):371-5. doi: 10.1053/j.jvca.2012.02.005. Epub 2012 Mar 28.|Salgado Filho MF, Siciliano A, Siciliano A, Oliveira AJ, Salgado J, Palitot I. The importance of transesophageal echocardiography in heart harvesting for cardiac transplantation. Rev Bras Anestesiol. 2012 Mar-Apr;62(2):262-8. doi: 10.1016/S0034-7094(12)70124-1.|Fattouch K, Castrovinci S, Murana G, Novo G, Caccamo G, Bertolino EC, Sampognaro R, Novo S, Ruvolo G, Lancellotti P. Multiplane two-dimensional versus real time three-dimensional transesophageal echocardiography in ischemic mitral regurgitation. Echocardiography. 2011 Nov;28(10):1125-32. doi: 10.1111/j.1540-8175.2011.01528.x. Epub 2011 Oct 17.","\tCardiopulmonary Bypass Graft\tepinephrine and levosimendan\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Assessment of Hemodynamic Response in Cardiopulmonary Bypass Graft After Cardiopulmonary Bypass Using Transesophegeal Echocardiography","Interventional","Completed","Phase 4",2,81,"NA","simendan|epinephrine","NA"]
["NCT01621867","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",10459902,"Alton EW, Stern M, Farley R, Jaffe A, Chadwick SL, Phillips J, Davies J, Smith SN, Browning J, Davies MG, Hodson ME, Durham SR, Li D, Jeffery PK, Scallan M, Balfour R, Eastman SJ, Cheng SH, Smith AE, Meeker D, Geddes DM. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet. 1999 Mar 20;353(9157):947-54.","\tCystic Fibrosis\tpGM169/GL67A|Placebo\tNA\tNA\tNA\tDrug|Drug\tAll\t","Repeated Application of Gene Therapy in CF Patients","Interventional","Completed","Phase 2",2,130,"fibrosis|cystic fibrosis","NA","NA"]
["NCT01625663","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30924938|28196853","Cade WT, Bohnert KL, Peterson LR, Patterson BW, Bittel AJ, Okunade AL, de Las Fuentes L, Steger-May K, Bashir A, Schweitzer GG, Chacko SK, Wanders RJ, Pacak CA, Byrne BJ, Reeds DN. Blunted fat oxidation upon submaximal exercise is partially compensated by enhanced glucose metabolism in children, adolescents, and young adults with Barth syndrome. J Inherit Metab Dis. 2019 May;42(3):480-493. doi: 10.1002/jimd.12094. Epub 2019 Apr 11.|Bashir A, Bohnert KL, Reeds DN, Peterson LR, Bittel AJ, de Las Fuentes L, Pacak CA, Byrne BJ, Cade WT. Impaired cardiac and skeletal muscle bioenergetics in children, adolescents, and young adults with Barth syndrome. Physiol Rep. 2017 Feb;5(3). pii: e13130. doi: 10.14814/phy2.13130.","\tBarth Syndrome\tNA\tNA\tNA\tNA\tNA\tMale\t","NA","NA","NA","NA","NA","NA","syndrome|barth syndrome","NA","NA"]
["NCT01635309","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25902738,"Sheth T, Chan M, Butler C, Chow B, Tandon V, Nagele P, Mitha A, Mrkobrada M, Szczeklik W, Faridah Y, Biccard B, Stewart LK, Heels-Ansdell D, Devereaux PJ; Coronary Computed Tomographic Angiography and Vascular Events in Noncardiac Surgery Patients Cohort Evaluation Study Investigators. Prognostic capabilities of coronary computed tomographic angiography before non-cardiac surgery: prospective cohort study. BMJ. 2015 Apr 22;350:h1907. doi: 10.1136/bmj.h1907.","\tCardiovascular Disease\tCoronary CT Angiogram\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","cardiovascular diseases","NA","NA"]
["NCT01637935",8058046,4398782,"Cox Proportional Hazard",1.06,null,"NA",0.89,1.26,95,"NA",null,"21447663|26197187","Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, Vaughn DJ, Nessel L, Selby J, Strom BL. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011 Apr;34(4):916-22. doi: 10.2337/dc10-1068.|Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, Ehrlich SF, Mamtani R, Bilker W, Vaughn DJ, Nessel L, Van Den Eeden SK, Ferrara A. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. JAMA. 2015 Jul 21;314(3):265-77. doi: 10.1001/jama.2015.7996.","\tBladder Cancer|Diabetes\tPioglitazone\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","urinary bladder neoplasms|diabetes mellitus","pioglitazone","Incident Diagnosis of Bladder Cancer (10-year Analysis)"]
["NCT01644409","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22151641,"van der Pal F, van Balken MR, Heesakkers JP, Debruyne FM, Bemelmans BL. Implant-Driven Tibial Nerve Stimulation in the Treatment of Refractory Overactive Bladder Syndrome: 12-Month Follow-up. Neuromodulation. 2006 Apr;9(2):163-71. doi: 10.1111/j.1525-1403.2006.00056.x.","\tOveractive Bladder|Urinary Frequency or Urgency Adverse Event|Urinary Incontinence, Urge\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","urinary incontinence, urge|urinary bladder, overactive|urinary incontinence","NA","NA"]
["NCT01648946","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20940381,"Hajjar LA, Vincent JL, Galas FR, Nakamura RE, Silva CM, Santos MH, Fukushima J, Kalil Filho R, Sierra DB, Lopes NH, Mauad T, Roquim AC, Sundin MR, Leão WC, Almeida JP, Pomerantzeff PM, Dallan LO, Jatene FB, Stolf NA, Auler JO Jr. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA. 2010 Oct 13;304(14):1559-67. doi: 10.1001/jama.2010.1446.","\tAnemia\tRed blood cell transfusion|Red blood cell transfusion\tParallel Assignment\tTreatment\tRandomized\tBiological|Biological\tAll\t","Transfusion Requirements in Critically Ill Oncologic Patient","Interventional","Unknown status","Phase 3",2,300,"NA","NA","NA"]
["NCT01653587","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24345099|27514319","de Andrade PB, E Mattos LA, Tebet MA, Rinaldi FS, Esteves VC, Nogueira EF, França JÍ, de Andrade MV, Barbosa RA, Labrunie A, Abizaid AA, Sousa AG. Design and rationale of the AngioSeal versus the Radial approach In acute coronary SyndromE (ARISE) trial: a randomized comparison of a vascular closure device versus the radial approach to prevent vascular access site complications in non-ST-segment elevation acute coronary syndrome patients. Trials. 2013 Dec 18;14:435. doi: 10.1186/1745-6215-14-435.|Andrade PB, Mattos LA, Rinaldi FS, Bienert IC, Barbosa RA, Labrunie A, Tebet M, Esteves V, Abizaid A, Sousa AR. Comparison of a vascular closure device versus the radial approach to reduce access site complications in non-ST-segment elevation acute coronary syndrome patients: The angio-seal versus the radial approach in acute coronary syndrome trial. Catheter Cardiovasc Interv. 2017 May;89(6):976-982. doi: 10.1002/ccd.26689. Epub 2016 Aug 12.","\tAcute Coronary Syndrome\tPercutaneous coronary intervention\tParallel Assignment\tSupportive Care\tRandomized\tDevice\tAll\t","AngioSeal Versus Radial Approach in Acute Coronary Syndrome","Interventional","Completed","Phase 4",2,240,"syndrome|acute coronary syndrome","NA","NA"]
["NCT01659879","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23684375,"Botngård A, Skranes LP, Skranes J, Døllner H. Multimedia based health information to parents in a pediatric acute ward: a randomized controlled trial. Patient Educ Couns. 2013 Dec;93(3):389-93. doi: 10.1016/j.pec.2013.04.017. Epub 2013 May 15.","\tHealth Communication\tMultimedia information|verbal information\tParallel Assignment\tHealth Services Research\tRandomized\tBehavioral|Behavioral\tAll\t","Multimedia Based Information to Parents in a Pediatric Acute Ward: A Randomized Controlled Trial","Interventional","Completed","N/A",2,101,"NA","NA","NA"]
["NCT01665911",8054289,4397042,null,"NA",null,"NA",{"$nulls":3},0,"ANOVA",24513113,"Lippert F, Martinez-Mier EA, Zero DT. An in situ caries study on the interplay between fluoride dose and concentration in milk. J Dent. 2014 Jul;42(7):883-90. doi: 10.1016/j.jdent.2014.01.010. Epub 2014 Feb 7.","\tCaries\t1.5 mg Sodium Fluoride in 100 ml milk|1.5 mg sodium fluoride in 200 ml milk|3 mg sodium fluoride in 100 ml milk|3 mg sodium fluoride in 200 ml milk|Non-fluoridated milk, 200 ml\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Other\tAll\t","An in Situ Study on the Impact of Fluoride Dose and Concentration in Milk on Its Anti-caries Efficacy","Interventional","Completed","N/A",5,28,"NA","sodium fluoride|listerine|fluorides","Enamel Fluoride Uptake Per Each of Five Arms"]
["NCT01665911",8054291,4397061,null,"NA",null,"NA",{"$nulls":3},0.0017,"ANOVA",24513113,"Lippert F, Martinez-Mier EA, Zero DT. An in situ caries study on the interplay between fluoride dose and concentration in milk. J Dent. 2014 Jul;42(7):883-90. doi: 10.1016/j.jdent.2014.01.010. Epub 2014 Feb 7.","\tCaries\t1.5 mg Sodium Fluoride in 100 ml milk|1.5 mg sodium fluoride in 200 ml milk|3 mg sodium fluoride in 100 ml milk|3 mg sodium fluoride in 200 ml milk|Non-fluoridated milk, 200 ml\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Other\tAll\t","An in Situ Study on the Impact of Fluoride Dose and Concentration in Milk on Its Anti-caries Efficacy","Interventional","Completed","N/A",5,28,"NA","sodium fluoride|listerine|fluorides","% Surface Microhardness (SMH) Recovery Score Per Each of Five Arms"]
["NCT01668368","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19001507,"Talmor D, Sarge T, Malhotra A, O'Donnell CR, Ritz R, Lisbon A, Novack V, Loring SH. Mechanical ventilation guided by esophageal pressure in acute lung injury. N Engl J Med. 2008 Nov 13;359(20):2095-104. doi: 10.1056/NEJMoa0708638. Epub 2008 Nov 11.","\tAcute Respiratory Failure|ARDS\tesophageal balloon\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","respiratory insufficiency|respiratory distress syndrome, adult","NA","NA"]
["NCT01678196",8052684,4395961,null,"NA",null,"NA",{"$nulls":3},0.67,"ANCOVA","23937084|25373044|24402979|24398700|25158635|25384001|26543913|26842254","Reger GM, Hoffman J, Riggs D, Rothbaum BO, Ruzek J, Holloway KM, Kuhn E. The \"PE coach\" smartphone application: an innovative approach to improving implementation, fidelity, and homework adherence during prolonged exposure. Psychol Serv. 2013 Aug;10(3):342-349. doi: 10.1037/a0032774.|Erbes CR, Stinson R, Kuhn E, Polusny M, Urban J, Hoffman J, Ruzek JI, Stepnowsky C, Thorp SR. Access, utilization, and interest in mHealth applications among veterans receiving outpatient care for PTSD. Mil Med. 2014 Nov;179(11):1218-22. doi: 10.7205/MILMED-D-14-00014.|Kuhn E, Greene C, Hoffman J, Nguyen T, Wald L, Schmidt J, Ramsey KM, Ruzek J. Preliminary evaluation of PTSD Coach, a smartphone app for post-traumatic stress symptoms. Mil Med. 2014 Jan;179(1):12-8. doi: 10.7205/MILMED-D-13-00271.|Kuhn E, Eftekhari A, Hoffman JE, Crowley JJ, Ramsey KM, Reger GM, Ruzek JI. Clinician perceptions of using a smartphone app with prolonged exposure therapy. Adm Policy Ment Health. 2014 Nov;41(6):800-7. doi: 10.1007/s10488-013-0532-2.|Ruzek JI, Eftekhari A, Rosen CS, Crowley JJ, Kuhn E, Foa EB, Hembree EA, Karlin BE. Factors related to clinician attitudes toward prolonged exposure therapy for PTSD. J Trauma Stress. 2014 Aug;27(4):423-9. doi: 10.1002/jts.21945.|Whealin JM, Kuhn E, Pietrzak RH. Applying behavior change theory to technology promoting veteran mental health care seeking. Psychol Serv. 2014 Nov;11(4):486-94. doi: 10.1037/a0037232.|Owen JE, Jaworski BK, Kuhn E, Makin-Byrd KN, Ramsey KM, Hoffman JE. mHealth in the Wild: Using Novel Data to Examine the Reach, Use, and Impact of PTSD Coach. JMIR Ment Health. 2015 Mar 25;2(1):e7. doi: 10.2196/mental.3935. eCollection 2015 Jan-Mar.|Williams EC, Gupta S, Rubinsky AD, Jones-Webb R, Bensley KM, Young JP, Hagedorn H, Gifford E, Harris AH. Racial/Ethnic Differences in the Prevalence of Clinically Recognized Alcohol Use Disorders Among Patients from the U.S. Veterans Health Administration. Alcohol Clin Exp Res. 2016 Feb;40(2):359-66. doi: 10.1111/acer.12950.","\tAlcohol Abuse|PTSD\tVA-CRAFT|Control\tNA\tNA\tNA\tBehavioral|Other\tAll\t","Helping Families Help Veterans With PTSD and Alcohol Abuse: An RCT of VA-CRAFT","Interventional","Completed","N/A",2,66,"alcoholism","NA","Family Member Psychosocial Wellbeing: Brief Symptom Inventory - 18"]
["NCT01680328",8052500,4395888,"Least Square Mean Difference",1.6,null,"NA",0.3,2.8,95,"NA",null,24720741,"Heise T, Nosek L, Dellweg S, Zijlstra E, Præstmark KA, Kildegaard J, Nielsen G, Sparre T. Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial. Diabetes Obes Metab. 2014 Oct;16(10):971-6. doi: 10.1111/dom.12304. Epub 2014 May 11.","\tDelivery Systems|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2\t19 injections|sodium chloride 0.9% solution\tCrossover Assignment\tSupportive Care\tRandomized\tOther|Drug\tAll\t","NA","NA","NA","NA","NA","NA","diabetes mellitus, type 1|diabetes mellitus|diabetes mellitus, type 2","NA","Estimated Mean Differences in the Volume of Backflow (uL) in the Thighs After Different Injection Volumes and Speeds as Compared to Needle Insertion"]
["NCT01680328",8052505,4395919,"Least Squares Mean",3.5,null,"NA",0.4,6.6,95,"NA",null,24720741,"Heise T, Nosek L, Dellweg S, Zijlstra E, Præstmark KA, Kildegaard J, Nielsen G, Sparre T. Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial. Diabetes Obes Metab. 2014 Oct;16(10):971-6. doi: 10.1111/dom.12304. Epub 2014 May 11.","\tDelivery Systems|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2\t19 injections|sodium chloride 0.9% solution\tCrossover Assignment\tSupportive Care\tRandomized\tOther|Drug\tAll\t","NA","NA","NA","NA","NA","NA","diabetes mellitus, type 1|diabetes mellitus|diabetes mellitus, type 2","NA","Injection Pain (VAS mm)"]
["NCT01682707","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19466360|19471727","Nora FS, Klipel R, Ayala G, Oliveira Filho GR. [Remifentanil: does the infusion regimen make a difference in the prevention of hemodynamic responses to tracheal intubation?]. Rev Bras Anestesiol. 2007 Jun;57(3):247-60. Portuguese.|Almeida MC, Martins RS, Martins AL. [Tracheal intubation conditions at 60 seconds in children, adults and elderly patients.]. Rev Bras Anestesiol. 2004 Apr;54(2):204-11. Portuguese.","\tCoronary Disease Undergoing CABG\tlaryngoscopy|track light\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","Assessment of Hemodynamic Response During Intubation Between Rigid Laryngoscopy and Track Light in Coronary Patients","Interventional","Completed","Phase 4",2,40,"coronary artery disease|coronary disease","NA","NA"]
["NCT01688232","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17008531|19858404|21245428","Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006 Sep 29;313(5795):1960-4.|Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009 Dec 10;27(35):5944-51. doi: 10.1200/JCO.2008.19.6147. Epub 2009 Oct 26.|Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, Galon J. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011 Feb 20;29(6):610-8. doi: 10.1200/JCO.2010.30.5425. Epub 2011 Jan 18.","\tColorectal Cancer|Surgical Resection of the Colorectal Tumor\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","NA","NA"]
["NCT01692249","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19734131,"Forestier R, Desfour H, Tessier JM, Françon A, Foote AM, Genty C, Rolland C, Roques CF, Bosson JL. Spa therapy in the treatment of knee osteoarthritis: a large randomised multicentre trial. Ann Rheum Dis. 2010 Apr;69(4):660-5. doi: 10.1136/ard.2009.113209. Epub 2009 Sep 3.","\tSelf Efficacy\timmediate spa therapy\tParallel Assignment\tTreatment\tRandomized\tOther\tAll\t","Efficacy and Safety of Spa Treatment in Chronic Shoulder Pain Due to Rotator Cuff Tendinopathy","Interventional","Completed","N/A",2,186,"shoulder pain|tendinopathy","NA","NA"]
["NCT01699555","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23200102,"Curtin F, Lang AB, Perron H, Laumonier M, Vidal V, Porchet HC, Hartung HP. GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study. Clin Ther. 2012 Dec;34(12):2268-78. doi: 10.1016/j.clinthera.2012.11.006. Epub 2012 Nov 29.","\tMultiple Sclerosis\tGNbAC1|GNbAC1 placebo\tParallel Assignment\tTreatment\tRandomized\tBiological|Biological\tMale\t","First-in-Human Study With GNbAC1 in Healthy Volunteers","Interventional","Completed","Phase 1",2,33,"multiple sclerosis|sclerosis","NA","NA"]
["NCT01701583","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29671921,"Stitt JM, Dzieciatkowska M, Edwards MG, Hansen K, Hedlund G, Dreskin SC. The basophil proteome in chronic spontaneous urticaria distinguishes responders to omalizumab from non-responders. Clin Exp Allergy. 2018 Jul;48(7):898-901. doi: 10.1111/cea.13149. Epub 2018 May 20.","\tChronic Urticaria\tOmalizumab\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","urticaria","omalizumab","NA"]
["NCT01707966","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27457964,"Cathomas R, Crabb SJ, Mark M, Winterhalder R, Rothermundt C, Elliott T, von Burg P, Kenner H, Hayoz S, Vilei SB, Rauch D, Roggero E, Mohaupt MG, Bernhard J, Manetsch G, Gillessen S; Swiss Group for Clinical Cancer Research SAKK. Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11). Prostate. 2016 Dec;76(16):1519-1527. doi: 10.1002/pros.23236. Epub 2016 Jul 25.","\tProstate Cancer\tOrteronel|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tMale\t","Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy","Interventional","Completed","Phase 3",2,47,"prostatic neoplasms","NA","NA"]
["NCT01715090","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21893723|22874288|22874403","Simon AC, Holleman F, Hoekstra JB, De Clercq PA, Lemkes BA, Hermanides J, Peek N. Development of a web-based decision support system for insulin self-titration. Stud Health Technol Inform. 2011;169:103-7.|Simon AC, Holleman F, Gude WT, Hoekstra JB, Peek N. Safety of a web-based insulin titration system for patients with type 2 diabetes mellitus - pilot study. Stud Health Technol Inform. 2012;180:731-5.|Gude WT, Simon AC, Peute LW, Holleman F, Hoekstra JB, Peek N, Jaspers MW. Formative usability evaluation of a web-based insulin self-titration system: preliminary results. Stud Health Technol Inform. 2012;180:1209-11.","\tDiabetes Mellitus, Type 2\tWeb-based insulin titration\tParallel Assignment\tTreatment\tRandomized\tDevice\tAll\t","Web-based Insulin Titration - An Efficacy Study","Interventional","Completed","N/A",2,73,"diabetes mellitus, type 2","insulin","NA"]
["NCT01718522",8047465,4393736,null,"NA",null,"NA",{"$nulls":3},0.3,"Wilcoxon Signed-Rank Test","NA","Tsioli C, Danne T für die RANSuP-Studiengruppe. RANSuP-Registerstudie: Anwendung der Sensorunterstützten Pumpentherapie unter Alltagsbedingungen. Diabetologie und Stoffwechsel 2013; 8: S62","\tDiabetes Mellitus, Type 1\tsensor augmented pump (SAP)\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","diabetes mellitus, type 1","NA","Hemoglobin A1c (HbA1c) Values (%) at Baseline and 3 Months"]
["NCT01723735","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27287699,"Rey J, Poitiers F, Paehler T, Brunet A, DiCioccio AT, Cannon CP, Surks HK, Pinquier JL, Hanotin C, Sasiela WJ. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies. J Am Heart Assoc. 2016 Jun 10;5(6). pii: e003323. doi: 10.1161/JAHA.116.003323.","\tHypercholesterolemia\tAlirocumab|Ezetimibe|Ezetimibe Placebo|Fenofibrate\tParallel Assignment\tBasic Science\tRandomized\tDrug|Drug|Drug|Drug\tAll\t","Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects","Interventional","Completed","Phase 1",3,79,"hypercholesterolemia","fenofibrate|ezetimibe","NA"]
["NCT01725763","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24349224|25372980|26942293","Reiter U, Reiter G, Kovacs G, Stalder AF, Gulsun MA, Greiser A, Olschewski H, Fuchsjäger M. Evaluation of elevated mean pulmonary arterial pressure based on magnetic resonance 4D velocity mapping: comparison of visualization techniques. PLoS One. 2013 Dec 12;8(12):e82212. doi: 10.1371/journal.pone.0082212. eCollection 2013.|Reiter G, Reiter U, Kovacs G, Olschewski H, Fuchsjäger M. Blood flow vortices along the main pulmonary artery measured with MR imaging for diagnosis of pulmonary hypertension. Radiology. 2015 Apr;275(1):71-9. doi: 10.1148/radiol.14140849. Epub 2014 Nov 5.|Reiter U, Reiter G, Fuchsjäger M. MR phase-contrast imaging in pulmonary hypertension. Br J Radiol. 2016 Jul;89(1063):20150995. doi: 10.1259/bjr.20150995. Epub 2016 Apr 6. Review.","\tElevated Mean Pulmonary Arterial Pressure|Normal Mean Pulmonary Arterial Pressure|Pulmonary Hypertension\tCardiac MRI\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","hypertension, pulmonary|hypertension","NA","NA"]
["NCT01734044","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19846889|19005182|12944568|17077333","Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010 Jan 14;115(2):168-86. doi: 10.1182/blood-2009-06-225565. Epub 2009 Oct 21. Review.|Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kühne T, Ruggeri M, George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009 Mar 12;113(11):2386-93. doi: 10.1182/blood-2008-07-162503. Epub 2008 Nov 12.|Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP, Wong WS, Cheng G. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003 Aug 28;349(9):831-6.|Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Gugliotta L, Vianelli N, Avvisati G, Rodeghiero F, Amendola A, Baronci C, Carbone C, Quattrin S, Fioritoni G, D'Alfonso G, Mandelli F; Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Thrombocytopenia Working Party. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007 Feb 15;109(4):1401-7. Epub 2006 Oct 31.","\tIdiopathic Thrombocytopenic Purpura|Purpura\trecombinant human thrombopoietin (rhTPO); dexamethasone|Dexamethasone\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP","Interventional","Completed","Phase 3",2,158,"purpura, thrombocytopenic, idiopathic|purpura|purpura, thrombocytopenic","dexamethasone|dexamethasone acetate|bb 1101","NA"]
["NCT01744197","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20975464|19151049","Wallace MS, Kopecky EA, Ma T, Brophy F, Campbell JC. Evaluation of the depth and duration of anesthesia from heated lidocaine/tetracaine (Synera) patches compared with placebo patches applied to healthy adult volunteers. Reg Anesth Pain Med. 2010 Nov-Dec;35(6):507-13. doi: 10.1097/AAP.0b013e3181fa69b8.|Sawyer J, Febbraro S, Masud S, Ashburn MA, Campbell JC. Heated lidocaine/tetracaine patch (Synera, Rapydan) compared with lidocaine/prilocaine cream (EMLA) for topical anaesthesia before vascular access. Br J Anaesth. 2009 Feb;102(2):210-5. doi: 10.1093/bja/aen364.","\tPain|Palliative Care|Phlebotomy\tSynera (lidocaine 70mg/tetracaine 70mg)\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Synera Venipuncture Pain","Interventional","Completed","Phase 2",2,61,"NA","lidocaine|tetracaine","NA"]
["NCT01746264",8044068,4392621,null,"NA",null,"NA",{"$nulls":3},0.21,"Wilcoxon (Mann-Whitney)",26273791,"Javed A, Kullo IJ, Balagopal PB, Kumar S. Effect of vitamin D3 treatment on endothelial function in obese adolescents. Pediatr Obes. 2016 Aug;11(4):279-84. doi: 10.1111/ijpo.12059. Epub 2015 Aug 14.","\tEndothelial Dysfunction|Obesity|Vitamin D Deficiency\tVitamin D3\tNA\tNA\tNA\tDietary Supplement\tAll\t","NA","NA","NA","NA","NA","NA","vitamin d deficiency","vitamin d|cholecalciferol","International Physical Activity Questionnaire (IPAQ) Short Form Score"]
["NCT01749995","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24729471,"Lycke M, Ketelaars L, Boterberg T, Pottel L, Pottel H, Vergauwe P, Goethals L, Van Eygen K, Werbrouck P, Debruyne D, Derijcke S, Borms M, Ghekiere V, Wildiers H, Debruyne PR. Validation of the Freund Clock Drawing Test as a screening tool to detect cognitive dysfunction in elderly cancer patients undergoing comprehensive geriatric assessment. Psychooncology. 2014 Oct;23(10):1172-7. doi: 10.1002/pon.3540. Epub 2014 Apr 11.","\tCognitive Impairment|Elderly Cancer Patients\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","cognitive dysfunction","NA","NA"]
["NCT01758614","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22068990|21960571|22668888|9757852|17494672","Powers WJ, Clarke WR, Grubb RL Jr, Videen TO, Adams HP Jr, Derdeyn CP; COSS Investigators. Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial. JAMA. 2011 Nov 9;306(18):1983-92. doi: 10.1001/jama.2011.1610. Erratum in: JAMA. 2011 Dec 28;306(24):2672. Obviagele, Bruce [corrected to Ovbiagele, Bruce].|Carlson AP, Yonas H, Chang YF, Nemoto EM. Failure of cerebral hemodynamic selection in general or of specific positron emission tomography methodology?: Carotid Occlusion Surgery Study (COSS). Stroke. 2011 Dec;42(12):3637-9. doi: 10.1161/STROKEAHA.111.627745. Epub 2011 Sep 29.|Amin-Hanjani S, Barker FG 2nd, Charbel FT, Connolly ES Jr, Morcos JJ, Thompson BG; Cerebrovascular Section of the American Association of Neurological Surgeons; Congress of Neurological Surgeons. Extracranial-intracranial bypass for stroke-is this the end of the line or a bump in the road? Neurosurgery. 2012 Sep;71(3):557-61.|Grubb RL Jr, Derdeyn CP, Fritsch SM, Carpenter DA, Yundt KD, Videen TO, Spitznagel EL, Powers WJ. Importance of hemodynamic factors in the prognosis of symptomatic carotid occlusion. JAMA. 1998 Sep 23-30;280(12):1055-60.|Waaijer A, van der Schaaf IC, Velthuis BK, Quist M, van Osch MJ, Vonken EP, van Leeuwen MS, Prokop M. Reproducibility of quantitative CT brain perfusion measurements in patients with symptomatic unilateral carotid artery stenosis. AJNR Am J Neuroradiol. 2007 May;28(5):927-32.","\tCarotid Artery Occlusion|Middle Cerebral Artery Occlusion|Stroke\tbypass surgery|Aspirin|Clopidogrel\tParallel Assignment\tTreatment\tRandomized\tProcedure|Drug|Drug\tAll\t","The Carotid and Middle Cerebral Artery Occlusion Surgery Study","Interventional","Active, not recruiting","Phase 3",2,330,"arterial occlusive diseases|infarction, middle cerebral artery","clopidogrel|aspirin","NA"]
["NCT01760278","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18765009,"Lemmen JG, Agerholm I, Ziebe S. Kinetic markers of human embryo quality using time-lapse recordings of IVF/ICSI-fertilized oocytes. Reprod Biomed Online. 2008 Sep;17(3):385-91.","\tAneuploidy|Blastocyst Disintegration|Chemical Pregnancy|Complication of Implant|Embryo/Fetus Death\trecombinant Follicle Stimulating Hormone (rFSH)\tParallel Assignment\tTreatment\tRandomized\tDrug\tFemale\t","Assessment of Implantation Potential of Embryos by Time-lapse Technology","Interventional","Unknown status","Phase 4",2,200,"aneuploidy|embryo loss","cetrorelix|progesterone|hormones|follicle stimulating hormone","NA"]
["NCT01765673",8041846,4390701,null,"NA",null,"NA",{"$nulls":3},0.229,"paired t test","16633868|19390893","Theurer JA, Bihari F, Barr AM, Martin RE. Oropharyngeal stimulation with air-pulse trains increases swallowing frequency in healthy adults. Dysphagia. 2005 Fall;20(4):254-60.|Theurer JA, Czachorowski KA, Martin LP, Martin RE. Effects of oropharyngeal air-pulse stimulation on swallowing in healthy older adults. Dysphagia. 2009 Sep;24(3):302-13. doi: 10.1007/s00455-009-9207-2. Epub 2009 Apr 24.","\tOropharyngeal Dysphagia\tVibrotactile stimulation\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","deglutition disorders","NA","Change in Discomfort 110 Hz"]
["NCT01765673",8041857,4390712,null,"NA",null,"NA",{"$nulls":3},0.017,"paired t test","16633868|19390893","Theurer JA, Bihari F, Barr AM, Martin RE. Oropharyngeal stimulation with air-pulse trains increases swallowing frequency in healthy adults. Dysphagia. 2005 Fall;20(4):254-60.|Theurer JA, Czachorowski KA, Martin LP, Martin RE. Effects of oropharyngeal air-pulse stimulation on swallowing in healthy older adults. Dysphagia. 2009 Sep;24(3):302-13. doi: 10.1007/s00455-009-9207-2. Epub 2009 Apr 24.","\tOropharyngeal Dysphagia\tVibrotactile stimulation\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","deglutition disorders","NA","Change in Swallow Frequency 70 Hz"]
["NCT01769469",8041233,4390504,null,"NA",null,"NA",{"$nulls":3},0.4933,"Wilcoxon (Mann-Whitney)",28013265,"Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N, Wilson CM, Hazra R, Hosek SG, Anderson PL, Seifert SM, Kapogiannis BG, Mulligan K; Adolescent Medicine Trials Network for HIV/AIDS Interventions 117 study team. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis. Clin Infect Dis. 2017 Feb 1;64(3):317-325. doi: 10.1093/cid/ciw765. Epub 2016 Nov 15.","\tHIV Infection\tFTC/TDF (Truvada®)\tNA\tNA\tNA\tDrug\tMale\t","NA","NA","NA","NA","NA","NA","hiv infections","emtricitabine, tenofovir disoproxil fumarate drug combination","Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 24 in TRP, by Overall Drug Exposure"]
["NCT01769469",8041289,4390524,null,"NA",null,"NA",{"$nulls":3},0.6545,"Wilcoxon Signed Rank Test",28013265,"Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N, Wilson CM, Hazra R, Hosek SG, Anderson PL, Seifert SM, Kapogiannis BG, Mulligan K; Adolescent Medicine Trials Network for HIV/AIDS Interventions 117 study team. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis. Clin Infect Dis. 2017 Feb 1;64(3):317-325. doi: 10.1093/cid/ciw765. Epub 2016 Nov 15.","\tHIV Infection\tFTC/TDF (Truvada®)\tNA\tNA\tNA\tDrug\tMale\t","NA","NA","NA","NA","NA","NA","hiv infections","emtricitabine, tenofovir disoproxil fumarate drug combination","Change From Baseline to Week 48 in Serum Calcium (SCa)"]
["NCT01773902","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27893064,"Maas C, Mathes M, Bleeker C, Vek J, Bernhard W, Wiechers C, Peter A, Poets CF, Franz AR. Effect of Increased Enteral Protein Intake on Growth in Human Milk-Fed Preterm Infants: A Randomized Clinical Trial. JAMA Pediatr. 2017 Jan 1;171(1):16-22. doi: 10.1001/jamapediatrics.2016.2681.","\tExtreme Prematurity\tHigh Dose Protein (Individualized)|High Dose Protein (Standardized)|Standard Protein Supplementation\tParallel Assignment\tSupportive Care\tRandomized\tDietary Supplement|Dietary Supplement|Dietary Supplement\tAll\t","Protein for Premies","Interventional","Completed","N/A",3,60,"premature birth","NA","NA"]
["NCT01779479","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28768217,"Kümmel S, Paepke S, Huober J, Schem C, Untch M, Blohmer JU, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Jackisch C, Schneeweiss A, Denkert C, Engels K, Klare P, Fasching PA, von Minckwitz G, Burchardi N, Loibl S. Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). Eur J Cancer. 2017 Oct;84:1-8. doi: 10.1016/j.ejca.2017.06.037. Epub 2017 Jul 30.","\tPrimary Breast Cancer\tCabacitaxel|Paclitaxel\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tFemale\t","Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)","Interventional","Completed","Phase 2",2,333,"breast neoplasms","paclitaxel","NA"]
["NCT01782014","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19231497|19555938|20619405|21686105|21686106|21776425|1397911|18959640|21611947","Leung FW, Aharonian HS, Leung JW, Guth PH, Jackson G. Impact of a novel water method on scheduled unsedated colonoscopy in U.S. veterans. Gastrointest Endosc. 2009 Mar;69(3 Pt 1):546-50. doi: 10.1016/j.gie.2008.08.014.|Leung JW, Mann SK, Siao-Salera R, Ransibrahmanakul K, Lim B, Cabrera H, Canete W, Barredo P, Gutierrez R, Leung FW. A randomized, controlled comparison of warm water infusion in lieu of air insufflation versus air insufflation for aiding colonoscopy insertion in sedated patients undergoing colorectal cancer screening and surveillance. Gastrointest Endosc. 2009 Sep;70(3):505-10. doi: 10.1016/j.gie.2008.12.253. Epub 2009 Jun 24.|Leung FW, Harker JO, Jackson G, Okamoto KE, Behbahani OM, Jamgotchian NJ, Aharonian HS, Guth PH, Mann SK, Leung JW. A proof-of-principle, prospective, randomized, controlled trial demonstrating improved outcomes in scheduled unsedated colonoscopy by the water method. Gastrointest Endosc. 2010 Oct;72(4):693-700. doi: 10.1016/j.gie.2010.05.020. Epub 2010 Jul 8.|Leung JW, Do LD, Siao-Salera RM, Ngo C, Parikh DA, Mann SK, Leung FW. Retrospective analysis showing the water method increased adenoma detection rate - a hypothesis generating observation. J Interv Gastroenterol. 2011 Jan;1(1):3-7.|Leung FW, Leung JW, Siao-Salera RM, Mann SK. The water method significantly enhances proximal diminutive adenoma detection rate in unsedated patients. J Interv Gastroenterol. 2011 Jan;1(1):8-13.|Leung FW, Leung JW, Siao-Salera RM, Mann SK, Jackson G. The water method significantly enhances detection of diminutive lesions (adenoma and hyperplastic polyp combined) in the proximal colon in screening colonoscopy - data derived from two RCT in US veterans. J Interv Gastroenterol. 2011 Apr;1(2):48-52.|Stevenson GW, Wilson JA, Wilkinson J, Norman G, Goodacre RL. Pain following colonoscopy: elimination with carbon dioxide. Gastrointest Endosc. 1992 Sep-Oct;38(5):564-7.|Wong JC, Yau KK, Cheung HY, Wong DC, Chung CC, Li MK. Towards painless colonoscopy: a randomized controlled trial on carbon dioxide-insufflating colonoscopy. ANZ J Surg. 2008 Oct;78(10):871-4. doi: 10.1111/j.1445-2197.2008.04683.x.|Leung FW, Leung JW, Mann SK, Friedland S, Ramirez FC. The water method significantly enhances patient-centered outcomes in sedated and unsedated colonoscopy. Endoscopy. 2011 Sep;43(9):816-21. doi: 10.1055/s-0030-1256407. Epub 2011 May 24.","\tScreening Colonoscopy\tcolonoscopy\tParallel Assignment\tScreening\tRandomized\tProcedure\tAll\t","Comparison of Adenoma Detection Rate Among Water, Carbon Dioxide and Air Methods of Minimal Sedation Colonoscopy","Interventional","Terminated","Phase 3",3,450,"adenoma","NA","NA"]
["NCT01785680","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26423737,"Maust A, Koroma AS, Abla C, Molokwu N, Ryan KN, Singh L, Manary MJ. Severe and Moderate Acute Malnutrition Can Be Successfully Managed with an Integrated Protocol in Sierra Leone. J Nutr. 2015 Nov;145(11):2604-9. doi: 10.3945/jn.115.214957. Epub 2015 Sep 30.","\tMalnutrition\tIntegrated Protocol|Current protocol\tParallel Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Moderate Acute Malnutrition (MAM) and Severe Acute Malnutrition (SAM) in Sierra Leone","Interventional","Completed","N/A",2,1957,"malnutrition","NA","NA"]
["NCT01789593","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29188338,"Gejl M, Gjedde A, Brock B, Møller A, van Duinkerken E, Haahr HL, Hansen CT, Chu PL, Stender-Petersen KL, Rungby J. Effects of hypoglycaemia on working memory and regional cerebral blood flow in type 1 diabetes: a randomised, crossover trial. Diabetologia. 2018 Mar;61(3):551-561. doi: 10.1007/s00125-017-4502-1. Epub 2017 Nov 29.","\tDiabetes|Diabetes Mellitus, Type 1\tglucose clamp\tCrossover Assignment\tDiagnostic\tRandomized\tOther\tAll\t","A Trial Investigating the Effect of Acute Hypoglycaemia on Cognitive Function and Brain Activation Patterns in Subjects With Type 1 Diabetes","Interventional","Completed","Phase 1",2,29,"diabetes mellitus, type 1|diabetes mellitus|hypoglycemia","NA","NA"]
["NCT01796223","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",30113180,"Brattland H, Koksvik JM, Burkeland O, Gråwe RW, Klöckner C, Linaker OM, Ryum T, Wampold B, Lara-Cabrera ML, Iversen VC. The effects of routine outcome monitoring (ROM) on therapy outcomes in the course of an implementation process: A randomized clinical trial. J Couns Psychol. 2018 Oct;65(5):641-652. doi: 10.1037/cou0000286. Epub 2018 Aug 16.","\tMental Disorders\tFeedback|Control\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral\tAll\t","Effects of Systematic Patient Feedback on Therapy Outcome","Interventional","Completed","N/A",2,170,"mental disorders","NA","NA"]
["NCT01799369","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24992418,"Haddow JB, Adwan H, Clark SE, Tayeh S, Antonowicz SS, Jayia P, Chicken DW, Wiggins T, Davenport R, Kaptanis S, Fakhry M, Knowles CH, Elmetwally AS, Geddoa E, Nair MS, Naeem I, Adegbola S, Muirhead LJ; London Surgical Research Group. Use of the surgical Apgar score to guide postoperative care. Ann R Coll Surg Engl. 2014 Jul;96(5):352-8. doi: 10.1308/003588414X13946184900840.","\tPostoperative Care\tSurgical Apgar Score\tParallel Assignment\tSupportive Care\tRandomized\tBehavioral\tAll\t","Surgical Apgar Score in Clinical Practice: a Pilot Study","Interventional","Completed","N/A",2,143,"NA","NA","NA"]
["NCT01806987","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24015056|27158175","Pears KC, Fisher PA, Kim HK, Bruce J, Healey CV, Yoerger K. Immediate Effects of a School Readiness Intervention for Children in Foster Care. Early Educ Dev. 2013 Aug;24(6):771-791.|Pears KC, Kim HK, Fisher PA. Decreasing Risk Factors for Later Alcohol Use and Antisocial Behaviors in Children in Foster Care by Increasing Early Promotive Factors. Child Youth Serv Rev. 2016 May;65:156-165.","\tSchool Readiness\tKITS Program\tParallel Assignment\tPrevention\tRandomized\tBehavioral\tAll\t","A Test of the Kids in Transition to School (KITS) Program in Disadvantaged Neighborhoods","Interventional","Completed","N/A",2,265,"NA","NA","NA"]
["NCT01810185","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17222320|23188075|21991594","Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol. 2007 Apr;102(4):820-8. Epub 2007 Jan 11.|Smith JP, Field D, Bingaman SI, Evans R, Mauger DT. Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study. J Clin Gastroenterol. 2013 Apr;47(4):339-45. doi: 10.1097/MCG.0b013e3182702f2b.|Low-dose naltrexone: tricking the body to heal itself. Exp Biol Med (Maywood). 2011 Sep;236(9):vii-viii.","\tCrohn's Disease|Inflammatory Bowel Disease|Ulcerative Colitis\tLow dose naltrexone|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease","Interventional","Withdrawn","Phase 2",2,0,"intestinal diseases|ulcer|crohn disease|colitis, ulcerative|inflammatory bowel diseases|colitis","naltrexone","NA"]
["NCT01816516","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24280320,"Horodynski MA, Baker S, Van Egeren L, Olson B, Brophy-Herb H, Auld G. The healthy babies curriculum. J Nutr Educ Behav. 2014 Mar-Apr;46(2):151-2. doi: 10.1016/j.jneb.2013.10.002. Epub 2013 Nov 23.","\tFeeding Behavior|Feeding Patterns|Infant Overnutrition|Obesity|Overweight\tHealthy Babies|Expanded Food and Nutrition Education Program\tParallel Assignment\tPrevention\tRandomized\tBehavioral|Behavioral\tFemale\t","Healthy Babies Through Infant Centered Feeding","Interventional","Completed","N/A",2,546,"overnutrition|overweight|infant nutrition disorders","NA","NA"]
["NCT01818791","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28971273|27245158","Chinman M, Acosta J, Ebener P, Malone PS, Slaughter ME. A Cluster-Randomized Trial of Getting To Outcomes' Impact on Sexual Health Outcomes in Community-Based Settings. Prev Sci. 2018 May;19(4):437-448. doi: 10.1007/s11121-017-0845-6.|Chinman M, Acosta J, Ebener P, Malone PS, Slaughter ME. Can implementation support help community-based settings better deliver evidence-based sexual health promotion programs? A randomized trial of Getting To Outcomes®. Implement Sci. 2016 May 31;11(1):78. doi: 10.1186/s13012-016-0446-y.","\tHIV|Pregnancy in Adolescence\tMaking Proud Choices|Making Proud Choices AND Getting To Outcomes\tCrossover Assignment\tPrevention\tRandomized\tBehavioral|Behavioral\tAll\t","Enhancing Quality Interventions Promoting Healthy Sexuality","Interventional","Active, not recruiting","N/A",2,960,"NA","NA","NA"]
["NCT01822119",8035487,4387438,null,"NA",null,"NA",{"$nulls":3},0.0499,"Fisher's non-parametric permutation test",25634465,"Briggs R, Van Hasselt A, Luntz M, Goycoolea M, Wigren S, Weber P, Smeds H, Flynn M, Cowan R. Clinical performance of a new magnetic bone conduction hearing implant system: results from a prospective, multicenter, clinical investigation. Otol Neurotol. 2015 Jun;36(5):834-41. doi: 10.1097/MAO.0000000000000712.","\tDeafness|Hearing Loss|Hearing Loss, Conductive\tBaha Attract System\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","deafness|hearing loss|hearing loss, conductive","NA","Hearing Performance, Individual Frequencies"]
["NCT01823926","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19484669|22781558|12684289","Brandao DC, Lima VM, Filho VG, Silva TS, Campos TF, Dean E, de Andrade AD. Reversal of bronchial obstruction with bi-level positive airway pressure and nebulization in patients with acute asthma. J Asthma. 2009 May;46(4):356-61. doi: 10.1080/02770900902718829.|Galindo-Filho VC, Brandão DC, Ferreira Rde C, Menezes MJ, Almeida-Filho P, Parreira VF, Silva TN, Rodrigues-Machado Mda G, Dean E, Dornelas de Andrade A. Noninvasive ventilation coupled with nebulization during asthma crises: a randomized controlled trial. Respir Care. 2013 Feb;58(2):241-9. doi: 10.4187/respcare.01371.|Soroksky A, Stav D, Shpirer I. A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack. Chest. 2003 Apr;123(4):1018-25.","\tAsthma\tNoninvasive ventilation|Jet nebulizer|The vibrating mesh nebulizer (VMN)\tCrossover Assignment\tTreatment\tRandomized\tOther|Device|Device\tAll\t","Asthma and Quantifying Delivery Of Radio Labeled Aerosol","Interventional","Completed","N/A",2,13,"asthma","NA","NA"]
["NCT01834846","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27443441|28648540","Pettersen Ø, Wiseth R, Hegbom K, Nordhaug DO. Pedicled Vein Grafts in Coronary Surgery Exhibit Reduced Intimal Hyperplasia at 6 Months. J Am Coll Cardiol. 2016 Jul 26;68(4):427-9. doi: 10.1016/j.jacc.2016.04.058.|Pettersen Ø, Haram PM, Winnerkvist A, Karevold A, Wahba A, Stenvik M, Wiseth R, Hegbom K, Nordhaug DO. Pedicled Vein Grafts in Coronary Surgery: Perioperative Data From a Randomized Trial. Ann Thorac Surg. 2017 Oct;104(4):1313-1317. doi: 10.1016/j.athoracsur.2017.03.076. Epub 2017 Jun 23.","\tMyocardial Ischemia\tno-touch|conventional\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","Impact of Perivascular Tissue on Endothelial Function in Coronary Artery Bypass Grafting","Interventional","Active, not recruiting","N/A",2,100,"ischemia|myocardial ischemia","NA","NA"]
["NCT01836978","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23052535,"Li C, Carli F, Lee L, Charlebois P, Stein B, Liberman AS, Kaneva P, Augustin B, Wongyingsinn M, Gamsa A, Kim DJ, Vassiliou MC, Feldman LS. Impact of a trimodal prehabilitation program on functional recovery after colorectal cancer surgery: a pilot study. Surg Endosc. 2013 Apr;27(4):1072-82. doi: 10.1007/s00464-012-2560-5. Epub 2012 Oct 9.","\tBladder Cancer|Entire Ileal Conduit|Urinary Bladder Cancer\tPrehabilitation\tParallel Assignment\tSupportive Care\tRandomized\tOther\tAll\t","Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy","Interventional","Completed","N/A",2,70,"urinary bladder neoplasms","NA","NA"]
["NCT01839708",8033531,4386981,null,"NA",null,"NA",{"$nulls":3},0.05,"Mixed Models Analysis",28187726,"Chang MW, Brown R, Nitzke S. Results and lessons learned from a prevention of weight gain program for low-income overweight and obese young mothers: Mothers In Motion. BMC Public Health. 2017 Feb 10;17(1):182. doi: 10.1186/s12889-017-4109-y.","\tObesity|Overweight\tLifestyle Counseling\tNA\tNA\tNA\tBehavioral\tFemale\t","Mothers in Motion Program to Prevent Weight Gain in WIC Mothers (MIM)","Interventional","Completed","N/A",2,569,"weight gain|overweight","NA","T2 Physical Activity"]
["NCT01842789","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26471917,"Galen DI. Electromagnetic image guidance in gynecology: prospective study of a new laparoscopic imaging and targeting technique for the treatment of symptomatic uterine fibroids. Biomed Eng Online. 2015 Oct 15;14:90. doi: 10.1186/s12938-015-0086-5.","\tUterine Fibroids\tAcessa Procedure\tParallel Assignment\tOther\tRandomized\tDevice\tFemale\t","Post Market Evaluation of Acessa With TAG","Interventional","Terminated","N/A",2,18,"leiomyoma","NA","NA"]
["NCT01846455",8032721,4386703,"ratio of parameter means, %",87.64,null,"NA",40.3,190.59,90,"NA",null,25603822,"Nasser AF, Heidbreder C, Liu Y, Fudala PJ. Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers. Clin Pharmacokinet. 2015 Aug;54(8):837-49. doi: 10.1007/s40262-015-0238-6.","\tChronic Hepatitis C Infection With Hepatic Coma|Hepatic Failure|Hepatic Impairment\t2.0mg Buprenorphine/0.5mg Naloxone|Promethazine\tNA\tNA\tNA\tDrug|Drug\tAll\t","Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects","Interventional","Completed","Phase 4",5,43,"hepatic insufficiency|hepatitis c, chronic|hepatitis|hepatic encephalopathy|liver failure|hepatitis c","diphenhydramine|buprenorphine|naloxone|promethazine","Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Buprenorphine, Norbuprenorphine, Naloxone and Naloxone-3-β-D-Glucuronide"]
["NCT01846455",8032722,4386729,"ratio of parameter means, %",126.25,null,"NA",64.5,247.11,90,"NA",null,25603822,"Nasser AF, Heidbreder C, Liu Y, Fudala PJ. Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers. Clin Pharmacokinet. 2015 Aug;54(8):837-49. doi: 10.1007/s40262-015-0238-6.","\tChronic Hepatitis C Infection With Hepatic Coma|Hepatic Failure|Hepatic Impairment\t2.0mg Buprenorphine/0.5mg Naloxone|Promethazine\tNA\tNA\tNA\tDrug|Drug\tAll\t","Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects","Interventional","Completed","Phase 4",5,43,"hepatic insufficiency|hepatitis c, chronic|hepatitis|hepatic encephalopathy|liver failure|hepatitis c","diphenhydramine|buprenorphine|naloxone|promethazine","Maximum Observed Plasma Concentration (Cmax) of Buprenorphine, Norbuprenorphine, Naloxone and Naloxone-3-β-D-Glucuronide"]
["NCT01846455",8032723,4386770,"ratio of parameter means, %",126.66,null,"NA",81.87,195.97,90,"NA",null,25603822,"Nasser AF, Heidbreder C, Liu Y, Fudala PJ. Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers. Clin Pharmacokinet. 2015 Aug;54(8):837-49. doi: 10.1007/s40262-015-0238-6.","\tChronic Hepatitis C Infection With Hepatic Coma|Hepatic Failure|Hepatic Impairment\t2.0mg Buprenorphine/0.5mg Naloxone|Promethazine\tNA\tNA\tNA\tDrug|Drug\tAll\t","Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects","Interventional","Completed","Phase 4",5,43,"hepatic insufficiency|hepatitis c, chronic|hepatitis|hepatic encephalopathy|liver failure|hepatitis c","diphenhydramine|buprenorphine|naloxone|promethazine","Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUC0-last) of Buprenorphine, Norbuprenorphine, Naloxone and Naloxone-3-β-D-Glucuronide"]
["NCT01849640","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25877962,"Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, Se Y, Chann S, Ittiverakul M, Sia-ngam P, Kuntawunginn W, Arsanok M, Buathong N, Chaorattanakawee S, Gosi P, Ta-aksorn W, Chanarat N, Sundrakes S, Kong N, Heng TK, Nou S, Teja-isavadharm P, Pichyangkul S, Phann ST, Balasubramanian S, Juliano JJ, Meshnick SR, Chour CM, Prom S, Lanteri CA, Lon C, Saunders DL. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis. 2015 Jun;15(6):683-91. doi: 10.1016/S1473-3099(15)70049-6. Epub 2015 Apr 12.","\tUncomplicated Plasmodium Falciparum Malaria\tDHA-piperaquine and Primaquine\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Antimalarial Drug Resistance With Assessment of Transmission Blocking Activity","Interventional","Suspended","N/A",2,150,"malaria, falciparum|malaria","primaquine|piperaquine","NA"]
["NCT01850966","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Mod Rheumatol. 2017;27:755-65.|Rheumatology. 2018;59: 222-32.","\tRheumatoid Arthritis\tIguratimod\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","arthritis, rheumatoid|arthritis","NA","NA"]
["NCT01859312",8031001,4385754,null,"NA",null,"NA",{"$nulls":3},0.004,"t-test, 2 sided",27680873,"Nella AA, Mallappa A, Perritt AF, Gounden V, Kumar P, Sinaii N, Daley LA, Ling A, Liu CY, Soldin SJ, Merke DP. A Phase 2 Study of Continuous Subcutaneous Hydrocortisone Infusion in Adults With Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2016 Dec;101(12):4690-4698. Epub 2016 Sep 28.","\tAdrenal Insufficiency|Congenital Adrenal Hyperplasia (CAH)|Excess Androgen\tHydrocortisone (Solucortef)|Insulin pump (Medtronic)\tNA\tNA\tNA\tDrug|Device\tAll\t","NA","NA","NA","NA","NA","NA","adrenal insufficiency|adrenocortical hyperfunction|adrenogenital syndrome|hyperplasia|adrenal hyperplasia, congenital","hydrocortisone hemisuccinate|hydrocortisone","Participants Mean Level of ACTH Area Under the Curve (AUC) - Midday (1500 - 2300)"]
["NCT01859312",8031023,4385765,null,"NA",null,"NA",{"$nulls":3},0.008,"t-test, 2 sided",27680873,"Nella AA, Mallappa A, Perritt AF, Gounden V, Kumar P, Sinaii N, Daley LA, Ling A, Liu CY, Soldin SJ, Merke DP. A Phase 2 Study of Continuous Subcutaneous Hydrocortisone Infusion in Adults With Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2016 Dec;101(12):4690-4698. Epub 2016 Sep 28.","\tAdrenal Insufficiency|Congenital Adrenal Hyperplasia (CAH)|Excess Androgen\tHydrocortisone (Solucortef)|Insulin pump (Medtronic)\tNA\tNA\tNA\tDrug|Device\tAll\t","NA","NA","NA","NA","NA","NA","adrenal insufficiency|adrenocortical hyperfunction|adrenogenital syndrome|hyperplasia|adrenal hyperplasia, congenital","hydrocortisone hemisuccinate|hydrocortisone","Participants Mean Level of 17-OHP Area Under the Curve (AUC) - Daytime (0700-1500)"]
["NCT01865500","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19532028,"Gunen H, Mirici A, Meral M, Akgün M. Steroids in acute exacerbations of chronic obstructive pulmonary disease: are nebulized and systemic forms comparable? Curr Opin Pulm Med. 2009 Mar;15(2):133-7. doi: 10.1097/MCP.0b013e32832185da. Review.","\tChronic Obstructive Pulmonary Disease\tBudesonide 4 mg|Budesonide 8 mg|Metil prednisolone\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","Two Different Dosages of Nebulized Steroid Versus Parenteral Steroid in the Management of COPD Exacerbations","Interventional","Completed","Phase 4",3,100,"lung diseases, obstructive|pulmonary disease, chronic obstructive","budesonide|prednisolone","NA"]
["NCT01868334",8030312,4385327,null,"NA",null,"NA",{"$nulls":3},0.05,"Cochran-Armitage trend test","27809793|27755655|27576073","Lin CJ, Nowalk MP, Pavlik VN, Brown AE, Zhang S, Raviotta JM, Moehling KK, Hawk M, Ricci EM, Middleton DB, Patel S, South-Paul JE, Zimmerman RK. Using the 4 pillars™ practice transformation program to increase adult influenza vaccination and reduce missed opportunities in a randomized cluster trial. BMC Infect Dis. 2016 Nov 3;16(1):623.|Zimmerman RK, Brown AE, Pavlik VN, Moehling KK, Raviotta JM, Lin CJ, Zhang S, Hawk M, Kyle S, Patel S, Ahmed F, Nowalk MP. Using the 4 Pillars Practice Transformation Program to Increase Pneumococcal Immunizations for Older Adults: A Cluster-Randomized Trial. J Am Geriatr Soc. 2017 Jan;65(1):114-122. doi: 10.1111/jgs.14451. Epub 2016 Oct 18.|Nowalk MP, Lin CJ, Pavlik VN, Brown AE, Zhang S, Moehling KK, Raviotta JM, South-Paul JE, Hawk M, Ricci EM, Middleton DB, Patel SA, Ahmed F, Zimmerman RK. Using the 4 Pillars™ Practice Transformation Program to increase adult Tdap immunization in a randomized controlled cluster trial. Vaccine. 2016 Sep 22;34(41):5026-5033. doi: 10.1016/j.vaccine.2016.07.053. Epub 2016 Aug 26.","\tAdult Influenza Vaccinations|Adult PPSV Vaccinations|Adult Tdap/Td Vaccinations\tPillar 1: Convenient Vaccination Services|Pillar 2: Patient notification|Pillar 3: Enhanced Office Systems|Pillar 4: Motivation\tNA\tNA\tNA\tBehavioral|Behavioral|Behavioral|Behavioral\tAll\t","SOP Toolkit in Diverse Practices Implemented & Tested With RE-AIM","Interventional","Completed","N/A",2,70549,"influenza, human","vaccines","Year 2 Pre-post Study: Change From Year 1 in the Percentage of Participants Who Were Vaccinated at the End of Year 2"]
["NCT01877733","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28901118|32301372","Husby VS, Foss OA, Husby OS, Winther SB. Randomized controlled trial of maximal strength training vs. standard rehabilitation following total knee arthroplasty. Eur J Phys Rehabil Med. 2018 Jun;54(3):371-379. doi: 10.23736/S1973-9087.17.04712-8. Epub 2017 Sep 13.|Winther SB, Foss OA, Klaksvik J, Husby VS. Pain and load progression following an early maximal strength training program in total hip- and knee arthroplasty patients. J Orthop Surg (Hong Kong). 2020 Jan-Apr;28(2):2309499020916392. doi: 10.1177/2309499020916392.","\tOsteoarthritis\tMaximal strength training\tParallel Assignment\tTreatment\tRandomized\tOther\tAll\t","Effective Rehabilitation of Patients Operated With Total Knee Arthroplasty","Interventional","Completed","N/A",2,41,"osteoarthritis","NA","NA"]
["NCT01880723","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21889619|21893217|21050829|21703359|21923601","Foxx-Lupo WT, Wheatley CM, Baker SE, Cassuto NA, Delamere NA, Snyder EM. Genetic variation of the alpha subunit of the epithelial Na+ channel influences exhaled Na+ in healthy humans. Respir Physiol Neurobiol. 2011 Dec 15;179(2-3):205-11. doi: 10.1016/j.resp.2011.08.008. Epub 2011 Aug 26.|Baker SE, Wheatley CM, Cassuto NA, Foxx-Lupo WT, Sprissler R, Snyder EM. Genetic variation of αENaC influences lung diffusion during exercise in humans. Respir Physiol Neurobiol. 2011 Dec 15;179(2-3):212-8. doi: 10.1016/j.resp.2011.08.007. Epub 2011 Aug 26.|Wheatley CM, Foxx-Lupo WT, Cassuto NA, Wong EC, Daines CL, Morgan WJ, Snyder EM. Impaired lung diffusing capacity for nitric oxide and alveolar-capillary membrane conductance results in oxygen desaturation during exercise in patients with cystic fibrosis. J Cyst Fibros. 2011 Jan;10(1):45-53. doi: 10.1016/j.jcf.2010.09.006. Epub 2010 Nov 2.|Traylor BR, Wheatley CM, Skrentny TT Jr, Foxx-Lupo WT, Phan H, Patanwala AE, Morgan WJ, Daines CL, Sprissler R, Snyder EM. Influence of genetic variation of the β2-adrenergic receptor on lung diffusion in patients with cystic fibrosis. Pulm Pharmacol Ther. 2011 Oct;24(5):610-6. doi: 10.1016/j.pupt.2011.06.001. Epub 2011 Jun 15.|Snyder EM, Wong EC, Foxx-Lupo WT, Wheatley CM, Cassuto NA, Patanwala AE. Effects of an inhaled β2-agonist on cardiovascular function and sympathetic activity in healthy subjects. Pharmacotherapy. 2011 Aug;31(8):748-56. doi: 10.1592/phco.31.8.748.","\tCystic Fibrosis|Healthy\tAlbuterol|Placebo saline\tNA\tNA\tNA\tDrug|Drug\tAll\t","Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis","Interventional","Completed","N/A",2,32,"cystic fibrosis|fibrosis","albuterol","NA"]
["NCT01884545",8028786,4384767,null,"NA",null,"NA",{"$nulls":3},0.4768,"Regression, Linear",24416670,"Vorderstrasse AA, Ginsburg GS, Kraus WE, Maldonado MC, Wolever RQ. Health coaching and genomics-potential avenues to elicit behavior change in those at risk for chronic disease: protocol for personalized medicine effectiveness study in air force primary care. Glob Adv Health Med. 2013 May;2(3):26-38. doi: 10.7453/gahmj.2013.035.","\tCoronary Heart Disease, Susceptibility to, 5|Prediabetic State\tGenetic risk counseling|Health coaching|Standard risk assessment\tNA\tNA\tNA\tGenetic|Behavioral|Behavioral\tAll\t","Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease","Interventional","Completed","N/A",4,220,"coronary disease|heart diseases|coronary artery disease|myocardial ischemia|disease susceptibility|prediabetic state|diabetes mellitus, type 2","NA","Unmanaged Stress as Measured by the Perceived Stress Scale (PSS)"]
["NCT01884545",8028798,4384807,null,"NA",null,"NA",{"$nulls":3},0.1466,"Regression, Linear",24416670,"Vorderstrasse AA, Ginsburg GS, Kraus WE, Maldonado MC, Wolever RQ. Health coaching and genomics-potential avenues to elicit behavior change in those at risk for chronic disease: protocol for personalized medicine effectiveness study in air force primary care. Glob Adv Health Med. 2013 May;2(3):26-38. doi: 10.7453/gahmj.2013.035.","\tCoronary Heart Disease, Susceptibility to, 5|Prediabetic State\tGenetic risk counseling|Health coaching|Standard risk assessment\tNA\tNA\tNA\tGenetic|Behavioral|Behavioral\tAll\t","Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease","Interventional","Completed","N/A",4,220,"coronary disease|heart diseases|coronary artery disease|myocardial ischemia|disease susceptibility|prediabetic state|diabetes mellitus, type 2","NA","Triglycerides"]
["NCT01884545",8028800,4384811,null,"NA",null,"NA",{"$nulls":3},0.4673,"Regression, Linear",24416670,"Vorderstrasse AA, Ginsburg GS, Kraus WE, Maldonado MC, Wolever RQ. Health coaching and genomics-potential avenues to elicit behavior change in those at risk for chronic disease: protocol for personalized medicine effectiveness study in air force primary care. Glob Adv Health Med. 2013 May;2(3):26-38. doi: 10.7453/gahmj.2013.035.","\tCoronary Heart Disease, Susceptibility to, 5|Prediabetic State\tGenetic risk counseling|Health coaching|Standard risk assessment\tNA\tNA\tNA\tGenetic|Behavioral|Behavioral\tAll\t","Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease","Interventional","Completed","N/A",4,220,"coronary disease|heart diseases|coronary artery disease|myocardial ischemia|disease susceptibility|prediabetic state|diabetes mellitus, type 2","NA","High-density Lipoprotein (HDL)"]
["NCT01886677","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28114897,"Demark-Wahnefried W, Nix JW, Hunter GR, Rais-Bahrami S, Desmond RA, Chacko B, Morrow CD, Azrad M, Frugé AD, Tsuruta Y, Ptacek T, Tully SA, Segal R, Grizzle WE. Erratum to: Feasibility outcomes of a presurgical randomized controlled trial exploring the impact of caloric restriction and increased physical activity versus a wait-list control on tumor characteristics and circulating biomarkers in men electing prostatectomy for prostate cancer. BMC Cancer. 2017 Jan 23;17(1):71. doi: 10.1186/s12885-016-3025-3.","\tProstate Cancer\tImmediate diet and exercise intervention|Delayed diet and exercise intervention\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral\tMale\t","Improving Energy Balance in Men With Prostate Cancer","Interventional","Completed","N/A",2,40,"prostatic neoplasms","NA","NA"]
["NCT01892150","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",7822517,"Lavker RM, Gerberick GF, Veres D, Irwin CJ, Kaidbey KH. Cumulative effects from repeated exposures to suberythemal doses of UVB and UVA in human skin. J Am Acad Dermatol. 1995 Jan;32(1):53-62.","\tSolar Elastosis\tSunscreen\tNA\tNA\tNA\tOther\tFemale\t","NA","NA","NA","NA","NA","NA","NA","sunscreening agents","NA"]
["NCT01896830","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29116880,"Matsuoka O, Patel DM, Sasaki S, Oka H, Sasaki T, Pietrobon PJ, Laot T, Bouckenooghe A, Menezes J, de Bruyn G. Safety and immunogenicity of Clostridium difficile toxoid vaccine in Japanese adults. Hum Vaccin Immunother. 2018 Feb 1;14(2):322-328. doi: 10.1080/21645515.2017.1395538. Epub 2017 Dec 6.","\tClostridium Difficile Infection\tClostridium difficile Toxoid Vaccine|0.9% normal saline\tParallel Assignment\tPrevention\tRandomized\tBiological|Biological\tAll\t","Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan","Interventional","Completed","Phase 1/Phase 2",2,102,"clostridium infections","NA","NA"]
["NCT01913613","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27025436|27852653|28949052|30311437|30354556|31653352","Hasenfuß G, Hayward C, Burkhoff D, Silvestry FE, McKenzie S, Gustafsson F, Malek F, Van der Heyden J, Lang I, Petrie MC, Cleland JG, Leon M, Kaye DM; REDUCE LAP-HF study investigators. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet. 2016 Mar 26;387(10025):1298-304. doi: 10.1016/S0140-6736(16)00704-2.|Kaye DM, Hasenfuß G, Neuzil P, Post MC, Doughty R, Trochu JN, Kolodziej A, Westenfeld R, Penicka M, Rosenberg M, Walton A, Muller D, Walters D, Hausleiter J, Raake P, Petrie MC, Bergmann M, Jondeau G, Feldman T, Veldhuisen DJ, Ponikowski P, Silvestry FE, Burkhoff D, Hayward C. One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2016 Dec;9(12). pii: e003662.|Wolsk E, Kaye D, Borlaug BA, Burkhoff D, Kitzman DW, Komtebedde J, Lam CSP, Ponikowski P, Shah SJ, Gustafsson F. Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2018 Apr;20(4):715-722. doi: 10.1002/ejhf.976. Epub 2017 Sep 26.|Kaye DM, Petrie MC, McKenzie S, Hasenfuβ G, Malek F, Post M, Doughty RN, Trochu JN, Gustafsson F, Lang I, Kolodziej A, Westenfeld R, Penicka M, Rosenberg M, Hausleiter J, Raake P, Jondeau G, Bergmann MW, Spelman T, Aytug H, Ponikowski P, Hayward C; REDUCE LAP-HF study investigators. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. ESC Heart Fail. 2019 Feb;6(1):62-69. doi: 10.1002/ehf2.12350. Epub 2018 Oct 11.|Wessler J, Kaye D, Gustafsson F, Petrie MC, Hasenfuβ G, Lam CSP, Borlaug BA, Komtebedde J, Feldman T, Shah SJ, Burkhoff D; REDUCE-LAP-HF Trial Investigators and Advisors. Impact of Baseline Hemodynamics on the Effects of a Transcatheter Interatrial Shunt Device in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2018 Aug;11(8):e004540. doi: 10.1161/CIRCHEARTFAILURE.117.004540.|Hanff TC, Kaye DM, Hayward CS, Post MC, Malek F, Hasenfuβ G, Gustafsson F, Burkhoff D, Shah SJ, Litwin SE, Kahwash R, Hummel SL, Borlaug BA, Solomon SD, Lam CSP, Komtebedde J, Silvestry FE; REDUCE LAP-HF study investigators, and research staff. Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial). Am J Cardiol. 2019 Dec 15;124(12):1912-1917. doi: 10.1016/j.amjcard.2019.09.019. Epub 2019 Sep 26.","\tHeart Failure\tIASD\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","heart failure","NA","NA"]
["NCT01919528","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25697988|26993368","Czarnik T, Gawda R, Nowotarski J. Real-time, ultrasound-guided infraclavicular axillary vein cannulation for renal replacement therapy in the critical care unit-A prospective intervention study. J Crit Care. 2015 Jun;30(3):624-8. doi: 10.1016/j.jcrc.2015.01.002. Epub 2015 Jan 8.|Czarnik T, Gawda R, Nowotarski J. Real-time ultrasound-guided infraclavicular axillary vein cannulation: A prospective study in mechanically ventilated critically ill patients. J Crit Care. 2016 Jun;33:32-7. doi: 10.1016/j.jcrc.2016.02.021. Epub 2016 Mar 2.","\tCritical Illness\tultrasound\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","critical illness","NA","NA"]
["NCT01922245","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23799617,"Elsner B, Kugler J, Pohl M, Mehrholz J. Transcranial direct current stimulation (tDCS) for improving aphasia in patients after stroke. Cochrane Database Syst Rev. 2013 Jun 25;(6):CD009760. doi: 10.1002/14651858.CD009760.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;(5):CD009760.","\tAphasia\tSoterix 1x1 tDCS\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","aphasia","NA","NA"]
["NCT01930617","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28644099,"Sjåvik K, Bartek J Jr, Sagberg LM, Henriksen ML, Gulati S, Ståhl FL, Kristiansson H, Solheim O, Förander P, Jakola AS. Assessment of drainage techniques for evacuation of chronic subdural hematoma: a consecutive population-based comparative cohort study. J Neurosurg. 2017 Jun 23:1-7. doi: 10.3171/2016.12.JNS161713. [Epub ahead of print]","\tHematoma, Subdural, Chronic\tBurr hole surgery with various drainage techniques\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","hematoma, subdural, chronic|hematoma, subdural|hematoma","NA","NA"]
["NCT01933802","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29449193,"Harris VK, Stark J, Vyshkina T, Blackshear L, Joo G, Stefanova V, Sara G, Sadiq SA. Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis. EBioMedicine. 2018 Mar;29:23-30. doi: 10.1016/j.ebiom.2018.02.002. Epub 2018 Feb 3.","\tMultiple Sclerosis\tintrathecal administration of autologous MSC-NP\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","sclerosis|multiple sclerosis","NA","NA"]
["NCT01937975",8022671,4382411,"Geometric Mean Ratio",0.94,null,"NA",0.63,1.42,90,"NA",null,30680407,"Caro L, Wenning L, Feng HP, Guo Z, Du L, Bhagunde P, Fandozzi C, Panebianco D, Marshall WL, Butterton JR, Iwamoto M, Yeh WW. Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment. Eur J Clin Pharmacol. 2019 May;75(5):665-675. doi: 10.1007/s00228-018-2585-3. Epub 2019 Jan 25.","\tChronic Hepatitis C|Renal Impairment\tGrazoprevir|Elbasvir\tNA\tNA\tNA\tDrug|Drug\tAll\t","The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)","Interventional","Completed","Phase 1",3,24,"renal insufficiency|hepatitis c, chronic|hepatitis c","mk-5172","Apparent Volume of Distribution After Extravascular Administration (Vz/F) of Grazoprevir"]
["NCT01937975",8022676,4382421,"Geometric Mean Ratio",0.78,null,"NA",0.53,1.14,90,"NA",null,30680407,"Caro L, Wenning L, Feng HP, Guo Z, Du L, Bhagunde P, Fandozzi C, Panebianco D, Marshall WL, Butterton JR, Iwamoto M, Yeh WW. Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment. Eur J Clin Pharmacol. 2019 May;75(5):665-675. doi: 10.1007/s00228-018-2585-3. Epub 2019 Jan 25.","\tChronic Hepatitis C|Renal Impairment\tGrazoprevir|Elbasvir\tNA\tNA\tNA\tDrug|Drug\tAll\t","The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)","Interventional","Completed","Phase 1",3,24,"renal insufficiency|hepatitis c, chronic|hepatitis c","mk-5172","Plasma Concentration at 24 Hours Postdose (C24hr) of Grazoprevir"]
["NCT01942564","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27464575,"Yuhas PT, Shorter PD, McDaniel CE, Earley MJ, Hartwick AT. Blue and Red Light-Evoked Pupil Responses in Photophobic Subjects with TBI. Optom Vis Sci. 2017 Jan;94(1):108-117. doi: 10.1097/OPX.0000000000000934.","\tHead Injury|Photophobia|Photosensitivity|Traumatic Brain Injury (TBI)\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","photosensitivity disorders|brain injuries, traumatic|brain injuries|craniocerebral trauma|photophobia|wounds and injuries","NA","NA"]
["NCT01948986",8020923,4380731,"Ratio: Mod. Ren. Impa./T2DM Norm. Renal",86.52,null,"NA",54.78,136.65,95,"NA",null,28703316,"Sahasrabudhe V, Terra SG, Hickman A, Saur D, Shi H, O'Gorman M, Zhou Z, Cutler DL. The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus. J Clin Pharmacol. 2017 Nov;57(11):1432-1443. doi: 10.1002/jcph.955. Epub 2017 Jul 13.","\tRenal Impairment|Type 2 Diabetes Mellitus\tErtugliflozin\tNA\tNA\tNA\tDrug\tAll\t","Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)","Interventional","Completed","Phase 1",5,36,"diabetes mellitus|renal insufficiency|diabetes mellitus, type 2","5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol","Change From Baseline in 24 Hour Inhibition of Glucose Reabsorption"]
["NCT01955954","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28194546,"Tolin DF, McGrath PB, Hale LR, Weiner DN, Gueorguieva R. A Multisite Benchmarking Trial of Capnometry Guided Respiratory Intervention for Panic Disorder in Naturalistic Treatment Settings. Appl Psychophysiol Biofeedback. 2017 Mar;42(1):51-58. doi: 10.1007/s10484-017-9354-4.","\tPanic Disorder\tCanary Breathing System\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","respiratory aspiration|panic disorder|disease","NA","NA"]
["NCT01960842",8019201,4380183,"Mean Difference (Net)",-1.5,null,"NA",-7.3,4.2,95,0,"One-sample t-test, 2-sided",28725701,"Murata M, Mihara M, Hasegawa K, Jeon B, Tsai CH, Nishikawa N, Oeda T, Yokoyama M, Robieson WZ, Ryman D, Eaton S, Chatamra K, Benesh J. Efficacy and safety of levodopa-carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson's disease patients. NPJ Parkinsons Dis. 2016 Nov 3;2:16020. doi: 10.1038/npjparkd.2016.20. eCollection 2016.","\tAdvanced Parkinson's Disease\tLevodopa-carbidopa intestinal gel|CADD-Legacy® 1400 ambulatory infusion pump|PEG tube|J-tube\tNA\tNA\tNA\tDrug|Device|Device|Device\tAll\t","NA","NA","NA","NA","NA","NA","parkinson disease","levodopa|carbidopa|carbidopa, levodopa drug combination","Parkinson's Disease Questionnaire (PDQ-39) Mobility, Emotional Well-Being, Stigma, Social Support, Cognition, Communication, and Bodily Discomfort Domain Scores: Change From Baseline To The Final PEG-J Visit"]
["NCT01962350","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22827578|20854181","Bersani FS, Girardi N, Sanna L, Mazzarini L, Santucci C, Kotzalidis GD, Sani G, De Rossi P, Raccah RN, Caltagirone SS, Battipaglia M, Capezzuto S, Bersani G, Girardi P. Deep transcranial magnetic stimulation for treatment-resistant bipolar depression: a case report of acute and maintenance efficacy. Neurocase. 2013;19(5):451-7. doi: 10.1080/13554794.2012.690429. Epub 2012 Jul 24.|Harel EV, Zangen A, Roth Y, Reti I, Braw Y, Levkovitz Y. H-coil repetitive transcranial magnetic stimulation for the treatment of bipolar depression: an add-on, safety and feasibility study. World J Biol Psychiatry. 2011 Mar;12(2):119-26. doi: 10.3109/15622975.2010.510893. Epub 2010 Sep 21.","\tBipolar Depression\tDeep Brain Transcranial Magnetic Stimulation\tParallel Assignment\tTreatment\tRandomized\tDevice\tAll\t","Treatment of Bipolar Depression With H1-Coil Deep Brain rTMS: Clinical-Cognitive and Safety Evaluation","Interventional","Completed","N/A",2,50,"bipolar disorder|depressive disorder|depression","NA","NA"]
["NCT01969669","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27859472,"Agarwal SK, Salem AH, Danilov AV, Hu B, Puvvada S, Gutierrez M, Chien D, Lewis LD, Wong SL. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. Br J Clin Pharmacol. 2017 Apr;83(4):846-854. doi: 10.1111/bcp.13175. Epub 2017 Jan 18.","\tNon-Hodgkin's Lymphoma\tABT-199|Ketoconazole\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma, non-hodgkin","ketoconazole|venetoclax","NA"]
["NCT01972685","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23328889,"Yarmus L, Akulian J, Gilbert C, Illei P, Shah P, Merlo C, Orens J, Feller-Kopman D. Cryoprobe transbronchial lung biopsy in patients after lung transplantation: a pilot safety study. Chest. 2013 Mar;143(3):621-626. doi: 10.1378/chest.12-2290.","\tInterstitial Lung Disease\tCryobiopsy biopsy|Transbronchial Biopsy|VATS biopsy\tNA\tNA\tNA\tProcedure|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","lung diseases, interstitial|lung diseases","NA","NA"]
["NCT01983605","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23062528,"Bartus K, Han FT, Bednarek J, Myc J, Kapelak B, Sadowski J, Lelakowski J, Bartus S, Yakubov SJ, Lee RJ. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am Coll Cardiol. 2013 Jul 9;62(2):108-118. doi: 10.1016/j.jacc.2012.06.046. Epub 2012 Oct 10.","\tAtrial Appendage\tLARIAT Suture Delivery Device\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT01986725","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23290987|20686386|22675922|23107862|23384847|23535473","Senn B, Eicher M, Mueller MD, Hornung R, Fink D, Baessler K, Hampl M, Denhaerynck K, Spirig R, Engberg S. A patient-reported outcome measure to identify occurrence and distress of post-surgery symptoms of WOMen with vulvAr Neoplasia (WOMAN-PRO) - a cross sectional study. Gynecol Oncol. 2013 Apr;129(1):234-40. doi: 10.1016/j.ygyno.2012.12.038. Epub 2013 Jan 3.|Senn B, Mueller MD, Cignacco EL, Eicher M. Period prevalence and risk factors for postoperative short-term wound complications in vulvar cancer: a cross-sectional study. Int J Gynecol Cancer. 2010 May;20(4):646-54. doi: 10.1111/IGC.0b013e3181d92723.|\"Senn B, Eicher M, Mueller MD, Engberg S, Spirig R. [Needs based nursing care in gynecology. \"\"My symptom diary\"\"]. Krankenpfl Soins Infirm. 2012;105(5):32-3. German.\"|Senn B, Mueller MD, Hasenburg A, Blankenstein T, Kammermann B, Hartmann A, Donovan H, Eicher M, Spirig R, Engberg S. Development of a postsurgical patient-reported outcome instrument for women with vulvar neoplasia. Oncol Nurs Forum. 2012 Nov;39(6):E489-98. doi: 10.1188/12.ONF.E489-E498.|Senn B, Eicher M, Mueller MD, Gafner D, Engberg S, Spirig R. [Development and validation of a patient reported outcome instrument for women with vulvar cancers and surgical treatment - a mixed method study]. Pflege. 2013 Feb;26(1):65-8. doi: 10.1024/1012-5302/a000265. German.|Gafner D, Eicher M, Spirig R, Senn B. [Between anxiety and hope: the experiences of women with vulval intraepithelial neoplasia during their illness trajectory - a qualitative approach]. Pflege. 2013 Apr;26(2):85-95. doi: 10.1024/1012-5302/a000273. German.","\tVulvar Cancer|Vulvar Intraepithelial Neoplasia\tstandardized care (Intervention I)|Standardized care + WOMAN-PRO II program (Intervention II)\tParallel Assignment\tSupportive Care\tRandomized\tBehavioral|Behavioral\tFemale\t","The Impact of the \"WOMAN-PRO II Program\" on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence","Interventional","Completed","Phase 2",2,45,"neoplasms|vulvar neoplasms","NA","NA"]
["NCT01993355","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Castellano-Tejedor, C., Costa-Requena, G., Lusilla-Palacios, P., Biedermann-Villagra, T., Barnola-Serra, E. Calidad del sueño en pacientes con lumbalgia crónica inespecífica. Rehabilitación 48(4): 219-225, 2014. DOI: 10.1016/j.rh.2014.05.003|Castellano-Tejedor, C., Costa-Requena, G., Lusilla-Palacios, P., Barnola-Serra, E. Calidad de vida en pacientes con dolor lumbar crónico: efectos de un programa de intervención multidisciplinar a los 6 meses de seguimiento. Comunicació tipus pòster presentada a les II Jornades BiblioPro del Parc de Recerca Biomédica de Barcelona, Barcelona 19 de febrer de 2015.","\tChronic Pain\tPhysiotherapy|Intervention 1|Intervention 2\tNA\tNA\tNA\tOther|Other|Behavioral\tAll\t","Chronic Low Back Pain: A Multidisciplinary Approach","Interventional","Completed","N/A",3,66,"low back pain|chronic pain|back pain","NA","NA"]
["NCT01999595","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","14581113|12583868|12237203","Chesterton LS, Foster NE, Wright CC, Baxter GD, Barlas P. Effects of TENS frequency, intensity and stimulation site parameter manipulation on pressure pain thresholds in healthy human subjects. Pain. 2003 Nov;106(1-2):73-80.|Chesterton LS, Barlas P, Foster NE, Baxter DG, Wright CC. Gender differences in pressure pain threshold in healthy humans. Pain. 2003 Feb;101(3):259-266. doi: 10.1016/S0304-3959(02)00330-5.|Chesterton LS, Barlas P, Foster NE, Lundeberg T, Wright CC, Baxter GD. Sensory stimulation (TENS): effects of parameter manipulation on mechanical pain thresholds in healthy human subjects. Pain. 2002 Sep;99(1-2):253-62.","\tAnalgesia|Blunt Pressure Pain|Pad Size|Pulse Frequency|Transcutaneous Electrical Nerve Stimulation\tControl TENS|Sham TENS|High frequency TENS with large pads|Low frequency TENS with large pads|High frequency TENS with small pads|Low frequency TENS with small pads\tParallel Assignment\tTreatment\tRandomized\tDevice|Device|Device|Device|Device|Device\tAll\t","The Antalgic Effect of Pulse Frequency and Pad Size of TENS on Blunt Pressure Pain","Interventional","Unknown status","N/A",6,180,"NA","NA","NA"]
["NCT02009592","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16521351|22098272|19210289|20804522","Day CP. Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med (Lond). 2006 Jan-Feb;6(1):19-25. Review.|Kalambokis GN, Mouzaki A, Rodi M, Tsianos EV. Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia. Liver Int. 2012 Mar;32(3):467-75. doi: 10.1111/j.1478-3231.2011.02650.x. Epub 2011 Sep 26.|Vlachogiannakos J, Saveriadis AS, Viazis N, Theodoropoulos I, Foudoulis K, Manolakopoulos S, Raptis S, Karamanolis DG. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther. 2009 May 1;29(9):992-9. doi: 10.1111/j.1365-2036.2009.03958.x. Epub 2009 Feb 7.|Diamant M, Blaak EE, de Vos WM. Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? Obes Rev. 2011 Apr;12(4):272-81. doi: 10.1111/j.1467-789X.2010.00797.x. Epub 2010 Aug 26. Review.","\tFatty Liver|Steatohepatitis\tRifaximin\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Efficacy of Rifaximin on Hepatosteatosis and Steatohepatitis Patients","Interventional","Completed","N/A",2,42,"fatty liver","rifaximin","NA"]
["NCT02010619","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26837684,"Enander J, Andersson E, Mataix-Cols D, Lichtenstein L, Alström K, Andersson G, Ljótsson B, Rück C. Therapist guided internet based cognitive behavioural therapy for body dysmorphic disorder: single blind randomised controlled trial. BMJ. 2016 Feb 2;352:i241. doi: 10.1136/bmj.i241.","\tBDD|Body Dysmorphic Disorder\tCognitive behavior therapy|Supportive therapy\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral\tAll\t","Internet Delivered CBT for Body Dysmorphic Disorder","Interventional","Completed","N/A",2,94,"body dysmorphic disorders","NA","NA"]
["NCT02016014","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23432189,"Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013 Apr 4;368(14):1279-90. doi: 10.1056/NEJMoa1200303. Epub 2013 Feb 25. Erratum in: N Engl J Med. 2014 Feb 27;370(9):886. Corrected and republished in: N Engl J Med. 2018 Jun 21;378(25):e34. Retraction in: N Engl J Med. 2018 Jun 21;378(25):2441-2442.","\tHealthy Subjects Without Cardiovascular Disease\tSmartphone with APP|Counseling on lifestyles\tParallel Assignment\tPrevention\tRandomized\tDevice|Behavioral\tAll\t","Effectiveness of the Use of a Mobile Tool in Improving Lifestyles","Interventional","Completed","N/A",2,833,"cardiovascular diseases","NA","NA"]
["NCT02020252",8012006,4377013,null,"NA",null,"NA",{"$nulls":3},0.009,"t-test, 2 sided",30811591,"Polite BN, Cipriano-Steffens TM, Liao C, Miller EL, Arndt NL, Hahn EA. Investigation of a multimedia, computer-based approach to improve knowledge, attitudes, self-efficacy, and receptivity to cancer clinical trials among newly diagnosed patients with diverse health literacy skills. Cancer. 2019 Jun 15;125(12):2066-2075. doi: 10.1002/cncr.31991. Epub 2019 Feb 27.","\tGastric Cancer|Lung Cancer|Pancreatic Cancer\tTesting an interactive technology in a diverse health literary population\tNA\tNA\tNA\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","Clinical Trials Attitudes, Knowledge, and Interest"]
["NCT02027363","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19777259|20676676","Li YH, Luo HY, Wang FH, Wang ZQ, Qiu MZ, Shi YX, Xiang XJ, Chen XQ, He YJ, Xu RH. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. 2010 Apr;136(4):503-10. doi: 10.1007/s00432-009-0682-5. Epub 2009 Sep 24.|Waddell T, Gollins S, Soe W, Valle J, Allen J, Bentley D, Morris J, Lloyd A, Swindell R, Taylor MB, Saunders MP. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study. Cancer Chemother Pharmacol. 2011 May;67(5):1111-7. doi: 10.1007/s00280-010-1322-0. Epub 2010 Jul 30.","\tColorectal Neoplasms|Neoplasms Metastasis\tCapecitabine|Observation\tParallel Assignment\tTreatment\tRandomized\tDrug|Other\tAll\t","Maintenance Treatment With Capecitabine in Colorectal Cancer Patients","Interventional","Unknown status","Phase 2",2,245,"neoplasm metastasis|neoplasms|colorectal neoplasms","capecitabine","NA"]
["NCT02028676",8011180,4376533,null,"NA",null,"NA",{"$nulls":3},0.08,"Generalised estimating equations","23473847|24382064","ARROW Trial team. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet. 2013 Apr 20;381(9875):1391-1403. doi: 10.1016/S0140-6736(12)62198-9. Epub 2013 Mar 7.|Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, Nahirya-Ntege P, Keishanyu R, Nathoo K, Spyer MJ, Kekitiinwa A, Lutaakome J, Mhute T, Kasirye P, Munderi P, Musiime V, Gibb DM, Walker AS, Prendergast AJ. A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa. N Engl J Med. 2014 Jan 2;370(1):41-53. doi: 10.1056/NEJMoa1214901. Erratum in: N Engl J Med. 2014 Jan 30;370(5):488. Dosage error in article text.","\tHuman Immunodeficiency Virus\tClinically Driven Monitoring (CDM)|Laboratory plus Clinical Monitoring (LCM)|Arm A: ABC+3TC+NNRTI|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|Once-daily ABC+3TC|Twice-daily ABC+3TC|Continued cotrimoxazole prophylaxis|Stopped cotrimoxazole prophylaxis\tNA\tNA\tNA\tOther|Other|Drug|Drug|Drug|Drug|Drug|Drug|Other\tAll\t","Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa","Interventional","Completed","Phase 4",9,1206,"acquired immunodeficiency syndrome|hiv infections","trimethoprim, sulfamethoxazole drug combination|zidovudine|sulfamethoxazole|efavirenz|lamivudine|dideoxynucleosides|nevirapine|abacavir|trimethoprim|lamivudine, zidovudine drug combination","Once Versus Twice Daily Abacavir+Lamivudine: Body Mass Index-for-age Z-score"]
["NCT02028676",8011196,4376558,"Hazard Ratio (HR)",0.672,null,"NA",0.42,1.075,95,0.09,"Log Rank","23473847|24382064","ARROW Trial team. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet. 2013 Apr 20;381(9875):1391-1403. doi: 10.1016/S0140-6736(12)62198-9. Epub 2013 Mar 7.|Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, Nahirya-Ntege P, Keishanyu R, Nathoo K, Spyer MJ, Kekitiinwa A, Lutaakome J, Mhute T, Kasirye P, Munderi P, Musiime V, Gibb DM, Walker AS, Prendergast AJ. A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa. N Engl J Med. 2014 Jan 2;370(1):41-53. doi: 10.1056/NEJMoa1214901. Erratum in: N Engl J Med. 2014 Jan 30;370(5):488. Dosage error in article text.","\tHuman Immunodeficiency Virus\tClinically Driven Monitoring (CDM)|Laboratory plus Clinical Monitoring (LCM)|Arm A: ABC+3TC+NNRTI|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|Once-daily ABC+3TC|Twice-daily ABC+3TC|Continued cotrimoxazole prophylaxis|Stopped cotrimoxazole prophylaxis\tNA\tNA\tNA\tOther|Other|Drug|Drug|Drug|Drug|Drug|Drug|Other\tAll\t","Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa","Interventional","Completed","Phase 4",9,1206,"acquired immunodeficiency syndrome|hiv infections","trimethoprim, sulfamethoxazole drug combination|zidovudine|sulfamethoxazole|efavirenz|lamivudine|dideoxynucleosides|nevirapine|abacavir|trimethoprim|lamivudine, zidovudine drug combination","LCM vs CDM, Induction ART: New Grade 3 or 4 Adverse Event Definitely/Probably or Uncertainly Related to ART"]
["NCT02028676",8011201,4376566,null,"NA",null,"NA",{"$nulls":3},0.01,"Regression, Linear","23473847|24382064","ARROW Trial team. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet. 2013 Apr 20;381(9875):1391-1403. doi: 10.1016/S0140-6736(12)62198-9. Epub 2013 Mar 7.|Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, Nahirya-Ntege P, Keishanyu R, Nathoo K, Spyer MJ, Kekitiinwa A, Lutaakome J, Mhute T, Kasirye P, Munderi P, Musiime V, Gibb DM, Walker AS, Prendergast AJ. A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa. N Engl J Med. 2014 Jan 2;370(1):41-53. doi: 10.1056/NEJMoa1214901. Erratum in: N Engl J Med. 2014 Jan 30;370(5):488. Dosage error in article text.","\tHuman Immunodeficiency Virus\tClinically Driven Monitoring (CDM)|Laboratory plus Clinical Monitoring (LCM)|Arm A: ABC+3TC+NNRTI|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|Once-daily ABC+3TC|Twice-daily ABC+3TC|Continued cotrimoxazole prophylaxis|Stopped cotrimoxazole prophylaxis\tNA\tNA\tNA\tOther|Other|Drug|Drug|Drug|Drug|Drug|Drug|Other\tAll\t","Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa","Interventional","Completed","Phase 4",9,1206,"acquired immunodeficiency syndrome|hiv infections","trimethoprim, sulfamethoxazole drug combination|zidovudine|sulfamethoxazole|efavirenz|lamivudine|dideoxynucleosides|nevirapine|abacavir|trimethoprim|lamivudine, zidovudine drug combination","LCM vs CDM, Induction ART: Change From Baseline in Absolute CD4 to Week 72"]
["NCT02028676",8011210,4376587,"Hazard Ratio (HR)",0.97,null,"NA",0.52,1.81,95,0.93,"Regression, Cox","23473847|24382064","ARROW Trial team. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet. 2013 Apr 20;381(9875):1391-1403. doi: 10.1016/S0140-6736(12)62198-9. Epub 2013 Mar 7.|Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, Nahirya-Ntege P, Keishanyu R, Nathoo K, Spyer MJ, Kekitiinwa A, Lutaakome J, Mhute T, Kasirye P, Munderi P, Musiime V, Gibb DM, Walker AS, Prendergast AJ. A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa. N Engl J Med. 2014 Jan 2;370(1):41-53. doi: 10.1056/NEJMoa1214901. Erratum in: N Engl J Med. 2014 Jan 30;370(5):488. Dosage error in article text.","\tHuman Immunodeficiency Virus\tClinically Driven Monitoring (CDM)|Laboratory plus Clinical Monitoring (LCM)|Arm A: ABC+3TC+NNRTI|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|Once-daily ABC+3TC|Twice-daily ABC+3TC|Continued cotrimoxazole prophylaxis|Stopped cotrimoxazole prophylaxis\tNA\tNA\tNA\tOther|Other|Drug|Drug|Drug|Drug|Drug|Drug|Other\tAll\t","Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa","Interventional","Completed","Phase 4",9,1206,"acquired immunodeficiency syndrome|hiv infections","trimethoprim, sulfamethoxazole drug combination|zidovudine|sulfamethoxazole|efavirenz|lamivudine|dideoxynucleosides|nevirapine|abacavir|trimethoprim|lamivudine, zidovudine drug combination","LCM vs CDM, Induction ART: All-cause Mortality"]
["NCT02044094",8009469,4375417,"LSM difference",3.316,"Standard Error of the Mean",2.367,-1.425,8.025,95,"NA",null,26650971,"Nasser AF, Greenwald MK, Vince B, Fudala PJ, Twumasi-Ankrah P, Liu Y, Jones JP 3rd, Heidbreder C. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder. J Clin Psychopharmacol. 2016 Feb;36(1):18-26. doi: 10.1097/JCP.0000000000000434.","\tOpioid Use Disorder\tBuprenorphine|buprenorphine and naloxone|hydromorphone|placebo\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","disease|substance-related disorders","hydromorphone|buprenorphine|naloxone","Opioid Blockade Following Administration of Hydromorphone Challenge As Measured Using the Subjective Opioid Effects Rating for the Question \"Do You Like the Drug?\" Visual Analog Scale (VAS) at Weeks 1-4 Analyzed by Mixed Model for Repeated Measures"]
["NCT02047136","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17490952|NA","Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr. 2007 May;85(5):1185-96. Review.|Janice M. Vickerstaff Joneja, Cabrini Carmona-Silva. Outcome of a Histamine-restricted Diet Based on Chart Audit. Journal of Nutritional and Environmental Medicine 11(4): 249-262, 2001.","\tChronic Urticaria|Diet Modification\tWell-balanced diet|Treatment group (on low histamine diet)\tParallel Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Dietary Treatment for Chronic Urticaria","Interventional","Terminated","N/A",2,8,"urticaria","histamine","NA"]
["NCT02057900","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18841094,"Puymirat E, Geha R, Tomescot A, Bellamy V, Larghero J, Trinquart L, Bruneval P, Desnos M, Hagège A, Pucéat M, Menasché P. Can mesenchymal stem cells induce tolerance to cotransplanted human embryonic stem cells? Mol Ther. 2009 Jan;17(1):176-82. doi: 10.1038/mt.2008.208. Epub 2008 Oct 7.","\tIschemic Heart Disease\tHuman embryonic stem cell-derived CD15+ Isl-1+ progenitors\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","heart diseases|myocardial ischemia|coronary artery disease|heart failure","NA","NA"]
["NCT02064933","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24139498|27262745|25075835|24331379|24290292|23818196|20004776|32268350","Griffith LM, Cowan MJ, Notarangelo LD, Kohn DB, Puck JM, Pai SY, Ballard B, Bauer SC, Bleesing JJ, Boyle M, Brower A, Buckley RH, van der Burg M, Burroughs LM, Candotti F, Cant AJ, Chatila T, Cunningham-Rundles C, Dinauer MC, Dvorak CC, Filipovich AH, Fleisher TA, Bobby Gaspar H, Gungor T, Haddad E, Hovermale E, Huang F, Hurley A, Hurley M, Iyengar S, Kang EM, Logan BR, Long-Boyle JR, Malech HL, McGhee SA, Modell F, Modell V, Ochs HD, O'Reilly RJ, Parkman R, Rawlings DJ, Routes JM, Shearer WT, Small TN, Smith H, Sullivan KE, Szabolcs P, Thrasher A, Torgerson TR, Veys P, Weinberg K, Zuniga-Pflucker JC; workshop participants. Primary Immune Deficiency Treatment Consortium (PIDTC) report. J Allergy Clin Immunol. 2014 Feb;133(2):335-47. doi: 10.1016/j.jaci.2013.07.052. Epub 2013 Oct 15.|Griffith LM, Cowan MJ, Notarangelo LD, Kohn DB, Puck JM, Shearer WT, Burroughs LM, Torgerson TR, Decaluwe H, Haddad E; workshop participants. Primary Immune Deficiency Treatment Consortium (PIDTC) update. J Allergy Clin Immunol. 2016 Aug;138(2):375-85. doi: 10.1016/j.jaci.2016.01.051. Epub 2016 Apr 22. Review.|Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, Kapoor N, Hanson IC, Filipovich AH, Jyonouchi S, Sullivan KE, Small TN, Burroughs L, Skoda-Smith S, Haight AE, Grizzle A, Pulsipher MA, Chan KW, Fuleihan RL, Haddad E, Loechelt B, Aquino VM, Gillio A, Davis J, Knutsen A, Smith AR, Moore TB, Schroeder ML, Goldman FD, Connelly JA, Porteus MH, Xiang Q, Shearer WT, Fleisher TA, Kohn DB, Puck JM, Notarangelo LD, Cowan MJ, O'Reilly RJ. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014 Jul 31;371(5):434-46. doi: 10.1056/NEJMoa1401177.|Haddad E, Allakhverdi Z, Griffith LM, Cowan MJ, Notarangelo LD. Survey on retransplantation criteria for patients with severe combined immunodeficiency. J Allergy Clin Immunol. 2014 Feb;133(2):597-9. doi: 10.1016/j.jaci.2013.10.022. Epub 2013 Dec 10.|Shearer WT, Dunn E, Notarangelo LD, Dvorak CC, Puck JM, Logan BR, Griffith LM, Kohn DB, O'Reilly RJ, Fleisher TA, Pai SY, Martinez CA, Buckley RH, Cowan MJ. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol. 2014 Apr;133(4):1092-8. doi: 10.1016/j.jaci.2013.09.044. Epub 2013 Nov 28.|Dvorak CC, Cowan MJ, Logan BR, Notarangelo LD, Griffith LM, Puck JM, Kohn DB, Shearer WT, O'Reilly RJ, Fleisher TA, Pai SY, Hanson IC, Pulsipher MA, Fuleihan R, Filipovich A, Goldman F, Kapoor N, Small T, Smith A, Chan KW, Cuvelier G, Heimall J, Knutsen A, Loechelt B, Moore T, Buckley RH. The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. J Clin Immunol. 2013 Oct;33(7):1156-64. doi: 10.1007/s10875-013-9917-y. Epub 2013 Jul 2.|Griffith LM, Cowan MJ, Notarangelo LD, Puck JM, Buckley RH, Candotti F, Conley ME, Fleisher TA, Gaspar HB, Kohn DB, Ochs HD, O'Reilly RJ, Rizzo JD, Roifman CM, Small TN, Shearer WT; Workshop Participants. Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. J Allergy Clin Immunol. 2009 Dec;124(6):1152-60.e12. doi: 10.1016/j.jaci.2009.10.022.|Burroughs LM, Petrovic A, Brazauskas R, Liu X, Griffith LM, Ochs HD, Bleesing JJ, Edwards S, Dvorak CC, Chaudhury S, Prockop SE, Quinones R, Goldman FD, Quigg TC, Chandrakasan S, Smith AR, Parikh S, Dávila Saldaña BJ, Thakar MS, Phelan R, Shenoy S, Forbes LR, Martinez C, Chellapandian D, Shereck E, Miller HK, Kapoor N, Barnum JL, Chong H, Shyr DC, Chen K, Abu-Arja R, Shah AJ, Weinacht KG, Moore TB, Joshi A, DeSantes KB, Gillio AP, Cuvelier GDE, Keller MD, Rozmus J, Torgerson T, Pulsipher MA, Haddad E, Sullivan KE, Logan BR, Kohn DB, Puck JM, Notarangelo LD, Pai SY, Rawlings DJ, Cowan MJ. Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. Blood. 2020 Jun 4;135(23):2094-2105. doi: 10.1182/blood.2019002939.","\tWiskott-Aldrich Syndrome\tNA\tNA\tNA\tNA\tNA\tMale\t","NA","NA","NA","NA","NA","NA","wiskott-aldrich syndrome|syndrome","NA","NA"]
["NCT02075203","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29996082,"Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, Mabwe S, Makhethe L, Erasmus M, Toefy A, Mulenga H, Hanekom WA, Self SG, Bekker LG, Ryall R, Gurunathan S, DiazGranados CA, Andersen P, Kromann I, Evans T, Ellis RD, Landry B, Hokey DA, Hopkins R, Ginsberg AM, Scriba TJ, Hatherill M; C-040-404 Study Team. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. N Engl J Med. 2018 Jul 12;379(2):138-149. doi: 10.1056/NEJMoa1714021.","\tTuberculosis\tAERAS-404|Placebo|Bacillus Calmette-Guérin (BCG)\tParallel Assignment\tPrevention\tRandomized\tBiological|Drug|Biological\tAll\t","Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents","Interventional","Completed","Phase 2",3,989,"tuberculosis","bcg vaccine","NA"]
["NCT02081547","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","3690235|18655729|9129139|15540303|19571710","Skipper D, Cooper AJ, Marston JE, Taylor I. Exfoliated cells and in vitro growth in colorectal cancer. Br J Surg. 1987 Nov;74(11):1049-52.|Kristensen AT, Wiig JN, Larsen SG, Giercksky KE, Ekstrøm PO. Molecular detection (k-ras) of exfoliated tumour cells in the pelvis is a prognostic factor after resection of rectal cancer? BMC Cancer. 2008 Jul 27;8:213. doi: 10.1186/1471-2407-8-213.|Uras C, Altinkaya E, Yardimci H, Göksel S, Yavuz N, Kaptanoğlu L, Akçal T. Peritoneal cytology in the determination of free tumour cells within the abdomen in colon cancer. Surg Oncol. 1996 Oct-Dec;5(5-6):259-63.|\"Maeda K, Maruta M, Hanai T, Sato H, Horibe Y. Irrigation volume determines the efficacy of \"\"rectal washout\"\". Dis Colon Rectum. 2004 Oct;47(10):1706-10.\"|Noura S, Ohue M, Seki Y, Yano M, Ishikawa O, Kameyama M. Long-term prognostic value of conventional peritoneal lavage cytology in patients undergoing curative colorectal cancer resection. Dis Colon Rectum. 2009 Jul;52(7):1312-20. doi: 10.1007/DCR.0b013e3181a745a4.","\tRectal Cancer\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","rectal neoplasms","NA","NA"]
["NCT02086890","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29222719|29130647|28910168","Bittner AK, Seger K. Longevity of visual improvements following transcorneal electrical stimulation and efficacy of retreatment in three individuals with retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol. 2018 Feb;256(2):299-306. doi: 10.1007/s00417-017-3858-8. Epub 2017 Dec 8.|Bittner AK, Seger K, Salveson R, Kayser S, Morrison N, Vargas P, Mendelsohn D, Han J, Bi H, Dagnelie G, Benavente A, Ramella-Roman J. Randomized controlled trial of electro-stimulation therapies to modulate retinal blood flow and visual function in retinitis pigmentosa. Acta Ophthalmol. 2018 May;96(3):e366-e376. doi: 10.1111/aos.13581. Epub 2017 Nov 11.|Kayser S, Vargas P, Mendelsohn D, Han J, Bi H, Benavente A, Bittner AK. Reduced Central Retinal Artery Blood Flow Is Related to Impaired Central Visual Function in Retinitis Pigmentosa Patients. Curr Eye Res. 2017 Nov;42(11):1503-1510. doi: 10.1080/02713683.2017.1338350. Epub 2017 Sep 14.","\tRetinitis Pigmentosa\tElectro-acupuncture|Laser Acupuncture|Transcorneal Electrical Stimulation|Sham Electro-acupuncture|Sham laser acupuncture|Sham transcorneal electrical stimulation\tCrossover Assignment\tTreatment\tRandomized\tDevice|Device|Device|Device|Device|Device\tAll\t","Electro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis Pigmentosa","Interventional","Active, not recruiting","N/A",6,21,"retinitis|retinitis pigmentosa","NA","NA"]
["NCT02089659",8004663,4372997,"Geometric Mean Ratio",0.9,null,"NA",0.66,1.24,90,"NA",null,28026013,"Khalilieh S, Yee KL, Liu R, Fan L, Sanchez RI, Auger P, Triantafyllou I, Stypinski D, Lasseter KC, Marbury T, Iwamoto M. Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics. J Clin Pharmacol. 2017 Jun;57(6):777-783. doi: 10.1002/jcph.857. Epub 2016 Dec 27.","\tHIV-1 Infection\tDoravirine\tNA\tNA\tNA\tDrug\tAll\t","A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)","Interventional","Completed","Phase 1",3,16,"hepatic insufficiency|liver failure","NA","Maximum Observed Plasma Concentration (Cmax) of Doravirine"]
["NCT02094898",8004067,4372785,null,"NA",null,"NA",{"$nulls":3},0.08,"t-test, 2 sided",27656788,"Vande Voort JL, Morgan RJ, Kung S, Rasmussen KG, Rico J, Palmer BA, Schak KM, Tye SJ, Ritter MJ, Frye MA, Bobo WV. Continuation phase intravenous ketamine in adults with treatment-resistant depression. J Affect Disord. 2016 Dec;206:300-304. doi: 10.1016/j.jad.2016.09.008. Epub 2016 Sep 12. Erratum in: J Affect Disord. 2018 Aug 15;236:313.","\tDepression|Suicide\tKetamine\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","depressive disorder|suicide|depression","ketamine","MADRS Factor 4 Score at Baseline and Last Acute Phase Observation"]
["NCT02098551","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26518092,"Campana R, Moritz K, Marth K, Neubauer A, Huber H, Henning R, Blatt K, Hoermann G, Brodie TM, Kaider A, Valent P, Sallusto F, Wöhrl S, Valenta R. Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments. J Allergy Clin Immunol. 2016 Feb;137(2):601-609.e8. doi: 10.1016/j.jaci.2015.08.042. Epub 2015 Oct 28.","\tAtopic Dermatitis\tSPT and APT\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","dermatitis, atopic|eczema|dermatitis","NA","NA"]
["NCT02105727","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24440795|24731226","Land MA, Webster J, Christoforou A, Praveen D, Jeffery P, Chalmers J, Smith W, Woodward M, Barzi F, Nowson C, Flood V, Neal B. Salt intake assessed by 24 h urinary sodium excretion in a random and opportunistic sample in Australia. BMJ Open. 2014 Jan 16;4(1):e003720. doi: 10.1136/bmjopen-2013-003720.|Land MA, Jeffery P, Webster J, Crino M, Chalmers J, Woodward M, Nowson C, Smith W, Flood V, Neal B. Protocol for the implementation and evaluation of a community-based intervention seeking to reduce dietary salt intake in Lithgow, Australia. BMC Public Health. 2014 Apr 14;14:357. doi: 10.1186/1471-2458-14-357.","\tBlood Pressure|Cardiovascular Disease|Hypertension\tCommunity-based salt reduction\tNA\tNA\tNA\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","cardiovascular diseases","NA","NA"]
["NCT02108184","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24073312,"Kim JS, Kim BW, Ham JH, Park HW, Kim YK, Lee MY, Ji JS, Lee BI, Choi H. Sequential Therapy for Helicobacter pylori Infection in Korea: Systematic Review and Meta-Analysis. Gut Liver. 2013 Sep;7(5):546-51. doi: 10.5009/gnl.2013.7.5.546. Epub 2013 Aug 14.","\tHelicobacter Pylori Infection\tSequential therapy 10 days|Sequential therapy 14 days|Concomitant therapy 10 days|Concomitant therapy 14 days\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug\tAll\t","Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy","Interventional","Unknown status","Phase 4",4,264,"infection|helicobacter infections","NA","NA"]
["NCT02115204","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24827128|25721604","Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol. 2014 Aug;25(8):1551-7. doi: 10.1093/annonc/mdu186. Epub 2014 May 14. Erratum in: Ann Oncol. 2017 Nov 1;28(11):2899. Ann Oncol. 2017 Nov;28(11):2899.|Erber R, Gluz O, Brünner N, Kreipe HH, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Moustafa Z, Liedtke C, Möbus V, Augustin D, Thomssen C, Jänicke F, Kiechle M, Kuhn W, Nitz U, Harbeck N, Hartmann A. Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial. Breast Cancer Res Treat. 2015 Apr;150(2):279-88. doi: 10.1007/s10549-015-3310-x. Epub 2015 Feb 28.","\tBreast Cancer\tEpirubicin|Cyclophosphamide|Docetaxel|Methotrexate|5-fluorouracil\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug|Drug\tFemale\t","4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF","Interventional","Completed","Phase 3",2,2011,"breast neoplasms","methotrexate|epirubicin|fluorouracil|cyclophosphamide|docetaxel","NA"]
["NCT02127580","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29182764,"Strauch J, Wendt D, Diegeler A, Heimeshoff M, Hofmann S, Holzhey D, Oertel F, Wahlers T, Kurucova J, Thoenes M, Deutsch C, Bramlage P, Schröfel H. Balloon-expandable transapical transcatheter aortic valve implantation with or without predilation of the aortic valve: results of a multicentre registry. Eur J Cardiothorac Surg. 2018 Apr 1;53(4):771-777. doi: 10.1093/ejcts/ezx397.","\tAortic Valve Stenosis\tBAV|without BAV\tNA\tNA\tNA\tProcedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","aortic valve stenosis","NA","NA"]
["NCT02137512",7999125,4370389,null,"NA",null,"NA",{"$nulls":3},0.006,"t-test, 2 sided",27208316,"Anderson SM, Raghinaru D, Pinsker JE, Boscari F, Renard E, Buckingham BA, Nimri R, Doyle FJ 3rd, Brown SA, Keith-Hynes P, Breton MD, Chernavvsky D, Bevier WC, Bradley PK, Bruttomesso D, Del Favero S, Calore R, Cobelli C, Avogaro A, Farret A, Place J, Ly TT, Shanmugham S, Phillip M, Dassau E, Dasanayake IS, Kollman C, Lum JW, Beck RW, Kovatchev B; Control to Range Study Group. Multinational Home Use of Closed-Loop Control Is Safe and Effective. Diabetes Care. 2016 Jul;39(7):1143-50. doi: 10.2337/dc15-2468. Epub 2016 Apr 13.","\tType 1 Diabetes\tClosed-Loop Control System|Sensor-Augmented Pump (SAP)\tNA\tNA\tNA\tDevice|Device\tAll\t","Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use","Interventional","Completed","N/A",2,30,"diabetes mellitus, type 1","NA","Time Spent >13.9 mmol/L (250 mg/dL) - Extension Phase"]
["NCT02137512",7999135,4370405,null,"NA",null,"NA",{"$nulls":3},0.006,"t-test, 2 sided",27208316,"Anderson SM, Raghinaru D, Pinsker JE, Boscari F, Renard E, Buckingham BA, Nimri R, Doyle FJ 3rd, Brown SA, Keith-Hynes P, Breton MD, Chernavvsky D, Bevier WC, Bradley PK, Bruttomesso D, Del Favero S, Calore R, Cobelli C, Avogaro A, Farret A, Place J, Ly TT, Shanmugham S, Phillip M, Dassau E, Dasanayake IS, Kollman C, Lum JW, Beck RW, Kovatchev B; Control to Range Study Group. Multinational Home Use of Closed-Loop Control Is Safe and Effective. Diabetes Care. 2016 Jul;39(7):1143-50. doi: 10.2337/dc15-2468. Epub 2016 Apr 13.","\tType 1 Diabetes\tClosed-Loop Control System|Sensor-Augmented Pump (SAP)\tNA\tNA\tNA\tDevice|Device\tAll\t","Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use","Interventional","Completed","N/A",2,30,"diabetes mellitus, type 1","NA","Time Spent >300 mg/dL - Main Phase, Day and Night"]
["NCT02137512",7999142,4370426,null,"NA",null,"NA",{"$nulls":3},0.003,"t-test, 2 sided",27208316,"Anderson SM, Raghinaru D, Pinsker JE, Boscari F, Renard E, Buckingham BA, Nimri R, Doyle FJ 3rd, Brown SA, Keith-Hynes P, Breton MD, Chernavvsky D, Bevier WC, Bradley PK, Bruttomesso D, Del Favero S, Calore R, Cobelli C, Avogaro A, Farret A, Place J, Ly TT, Shanmugham S, Phillip M, Dassau E, Dasanayake IS, Kollman C, Lum JW, Beck RW, Kovatchev B; Control to Range Study Group. Multinational Home Use of Closed-Loop Control Is Safe and Effective. Diabetes Care. 2016 Jul;39(7):1143-50. doi: 10.2337/dc15-2468. Epub 2016 Apr 13.","\tType 1 Diabetes\tClosed-Loop Control System|Sensor-Augmented Pump (SAP)\tNA\tNA\tNA\tDevice|Device\tAll\t","Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use","Interventional","Completed","N/A",2,30,"diabetes mellitus, type 1","NA","ADRR - Main Phase, Day and Night"]
["NCT02137512",7999154,4370461,null,"NA",null,"NA",{"$nulls":3},1E-3,"t-test, 2 sided",27208316,"Anderson SM, Raghinaru D, Pinsker JE, Boscari F, Renard E, Buckingham BA, Nimri R, Doyle FJ 3rd, Brown SA, Keith-Hynes P, Breton MD, Chernavvsky D, Bevier WC, Bradley PK, Bruttomesso D, Del Favero S, Calore R, Cobelli C, Avogaro A, Farret A, Place J, Ly TT, Shanmugham S, Phillip M, Dassau E, Dasanayake IS, Kollman C, Lum JW, Beck RW, Kovatchev B; Control to Range Study Group. Multinational Home Use of Closed-Loop Control Is Safe and Effective. Diabetes Care. 2016 Jul;39(7):1143-50. doi: 10.2337/dc15-2468. Epub 2016 Apr 13.","\tType 1 Diabetes\tClosed-Loop Control System|Sensor-Augmented Pump (SAP)\tNA\tNA\tNA\tDevice|Device\tAll\t","Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use","Interventional","Completed","N/A",2,30,"diabetes mellitus, type 1","NA","Time Spent <60 mg/dL - Main Phase, Day and Night"]
["NCT02137512",7999161,4370482,null,"NA",null,"NA",{"$nulls":3},1E-3,"t-test, 2 sided",27208316,"Anderson SM, Raghinaru D, Pinsker JE, Boscari F, Renard E, Buckingham BA, Nimri R, Doyle FJ 3rd, Brown SA, Keith-Hynes P, Breton MD, Chernavvsky D, Bevier WC, Bradley PK, Bruttomesso D, Del Favero S, Calore R, Cobelli C, Avogaro A, Farret A, Place J, Ly TT, Shanmugham S, Phillip M, Dassau E, Dasanayake IS, Kollman C, Lum JW, Beck RW, Kovatchev B; Control to Range Study Group. Multinational Home Use of Closed-Loop Control Is Safe and Effective. Diabetes Care. 2016 Jul;39(7):1143-50. doi: 10.2337/dc15-2468. Epub 2016 Apr 13.","\tType 1 Diabetes\tClosed-Loop Control System|Sensor-Augmented Pump (SAP)\tNA\tNA\tNA\tDevice|Device\tAll\t","Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use","Interventional","Completed","N/A",2,30,"diabetes mellitus, type 1","NA","Glucose Standard Deviation - Main Phase, Day Only"]
["NCT02137512",7999168,4370504,null,"NA",null,"NA",{"$nulls":3},2E-3,"t-test, 2 sided",27208316,"Anderson SM, Raghinaru D, Pinsker JE, Boscari F, Renard E, Buckingham BA, Nimri R, Doyle FJ 3rd, Brown SA, Keith-Hynes P, Breton MD, Chernavvsky D, Bevier WC, Bradley PK, Bruttomesso D, Del Favero S, Calore R, Cobelli C, Avogaro A, Farret A, Place J, Ly TT, Shanmugham S, Phillip M, Dassau E, Dasanayake IS, Kollman C, Lum JW, Beck RW, Kovatchev B; Control to Range Study Group. Multinational Home Use of Closed-Loop Control Is Safe and Effective. Diabetes Care. 2016 Jul;39(7):1143-50. doi: 10.2337/dc15-2468. Epub 2016 Apr 13.","\tType 1 Diabetes\tClosed-Loop Control System|Sensor-Augmented Pump (SAP)\tNA\tNA\tNA\tDevice|Device\tAll\t","Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use","Interventional","Completed","N/A",2,30,"diabetes mellitus, type 1","NA","Mean Sensor Glucose - Main Phase, Night Only"]
["NCT02137512",7999172,4370516,null,"NA",null,"NA",{"$nulls":3},1E-3,"t-test, 2 sided",27208316,"Anderson SM, Raghinaru D, Pinsker JE, Boscari F, Renard E, Buckingham BA, Nimri R, Doyle FJ 3rd, Brown SA, Keith-Hynes P, Breton MD, Chernavvsky D, Bevier WC, Bradley PK, Bruttomesso D, Del Favero S, Calore R, Cobelli C, Avogaro A, Farret A, Place J, Ly TT, Shanmugham S, Phillip M, Dassau E, Dasanayake IS, Kollman C, Lum JW, Beck RW, Kovatchev B; Control to Range Study Group. Multinational Home Use of Closed-Loop Control Is Safe and Effective. Diabetes Care. 2016 Jul;39(7):1143-50. doi: 10.2337/dc15-2468. Epub 2016 Apr 13.","\tType 1 Diabetes\tClosed-Loop Control System|Sensor-Augmented Pump (SAP)\tNA\tNA\tNA\tDevice|Device\tAll\t","Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use","Interventional","Completed","N/A",2,30,"diabetes mellitus, type 1","NA","Time in Range 70-180 mg/dL - Main Phase, Day and Night"]
["NCT02142517","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23494109|14639354|17895850|11898041|22773303|24238526","El Nakeeb A, Salah T, Sultan A, El Hemaly M, Askr W, Ezzat H, Hamdy E, Atef E, El Hanafy E, El-Geidie A, Abdel Wahab M, Abdallah T. Pancreatic anastomotic leakage after pancreaticoduodenectomy. Risk factors, clinical predictors, and management (single center experience). World J Surg. 2013 Jun;37(6):1405-18. doi: 10.1007/s00268-013-1998-5.|Bassi C, Falconi M, Molinari E, Mantovani W, Butturini G, Gumbs AA, Salvia R, Pederzoli P. Duct-to-mucosa versus end-to-side pancreaticojejunostomy reconstruction after pancreaticoduodenectomy: results of a prospective randomized trial. Surgery. 2003 Nov;134(5):766-71.|Hayashibe A, Kameyama M. The clinical results of duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy in consecutive 55 cases. Pancreas. 2007 Oct;35(3):273-5.|Hosotani R, Doi R, Imamura M. Duct-to-mucosa pancreaticojejunostomy reduces the risk of pancreatic leakage after pancreatoduodenectomy. World J Surg. 2002 Jan;26(1):99-104. Epub 2001 Nov 26.|Zhang JL, Xiao ZY, Lai DM, Sun J, He CC, Zhang YF, Chen S, Wang J. Comparison of duct-to-mucosa and end-to-side pancreaticojejunostomy reconstruction following pancreaticoduodenectomy. Hepatogastroenterology. 2013 Jan-Feb;60(121):176-9.|Bai XL, Zhang Q, Masood N, Masood W, Gao SL, Zhang Y, Shahed S, Liang TB. Duct-to-mucosa versus invagination pancreaticojejunostomy after pancreaticoduodenectomy: a meta-analysis. Chin Med J (Engl). 2013 Nov;126(22):4340-7.","\tPancreatic Anastomotic Leak\tDuct to mucosa PJ group|Invagination PJ group\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","Comparative Study Between Duct to Mucosa and Invagination Pancreaticojejunostomy After Pancreaticoduodenectomy:","Interventional","Completed","N/A",2,120,"anastomotic leak","NA","NA"]
["NCT02153723",7997218,4369503,"Mean Difference (Final Values)",0.8,null,"NA",{"$nulls":3},0.86,"Wilcoxon (Mann-Whitney)",27363291,"Djukic A, Holtzer R, Shinnar S, Muzumdar H, Rose SA, Mowrey W, Galanopoulou AS, Shinnar R, Jankowski JJ, Feldman JF, Pillai S, Moshé SL. Pharmacologic Treatment of Rett Syndrome With Glatiramer Acetate. Pediatr Neurol. 2016 Aug;61:51-7. doi: 10.1016/j.pediatrneurol.2016.05.010. Epub 2016 May 27.","\tRett Syndrome\tGlatiramer Acetate\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","rett syndrome|syndrome","glatiramer acetate|(t,g)-a-l","Visual Attention (Number of Fixations) Assessed by Eye-tracking TX300 Tobii Computer."]
["NCT02158663","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",30641346,"Kozel FA, Van Trees K, Larson V, Phillips S, Hashimie J, Gadbois B, Johnson S, Gallinati J, Barrett B, Toyinbo P, Weisman M, Centorino M, Gibson CA, Catalano G. One hertz versus ten hertz repetitive TMS treatment of PTSD: A randomized clinical trial. Psychiatry Res. 2019 Mar;273:153-162. doi: 10.1016/j.psychres.2019.01.004. Epub 2019 Jan 3.","\tDepression|Posttraumatic Stress Disorder\tRepetitive Transcranial Magnetic Stimulation\tParallel Assignment\tTreatment\tRandomized\tDevice\tAll\t","Study Testing if Fast or Slow rTMS is Better for the Treatment of Posttraumatic Stress Disorder (PTSD)","Interventional","Completed","N/A",2,44,"stress disorders, post-traumatic|stress disorders, traumatic","NA","NA"]
["NCT02159911","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20542898|23701149","Lee YY, Kim TJ, Kang H, Choi CH, Lee JW, Kim BG, Bae DS. The use of misoprostol before hysteroscopic surgery in non-pregnant premenopausal women: a randomized comparison of sublingual, oral and vaginal administrations. Hum Reprod. 2010 Aug;25(8):1942-8. doi: 10.1093/humrep/deq083. Epub 2010 Jun 11.|Bastu E, Celik C, Nehir A, Dogan M, Yuksel B, Ergun B. Cervical priming before diagnostic operative hysteroscopy in infertile women: a randomized, double-blind, controlled comparison of 2 vaginal misoprostol doses. Int Surg. 2013 Apr-Jun;98(2):140-4. doi: 10.9738/INTSURG-D-12-00024.1.","\tAdverse Effects|Cervical Laceration\tMisoprostol administered orally one hour before surgery\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","lacerations","misoprostol","NA"]
["NCT02166047",7995871,4368735,"LS Mean Difference",0,null,"NA",-0.069,0.069,95,0.996,"MMRM","29378197|29104121","Boni C, Vecchi A, Rossi M, Laccabue D, Giuberti T, Alfieri A, Lampertico P, Grossi G, Facchetti F, Brunetto MR, Coco B, Cavallone D, Mangia A, Santoro R, Piazzolla V, Lau A, Gaggar A, Subramanian GM, Ferrari C. TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues. Gastroenterology. 2018 May;154(6):1764-1777.e7. doi: 10.1053/j.gastro.2018.01.030. Epub 2018 Jan 31.|Janssen HLA, Brunetto MR, Kim YJ, Ferrari C, Massetto B, Nguyen AH, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Yoshida EM, Ahn SH, Tsai NCS, Fung S, Gane EJ. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. J Hepatol. 2018 Mar;68(3):431-440. doi: 10.1016/j.jhep.2017.10.027. Epub 2017 Dec 11.","\tChronic Hepatitis B\tVesatolimod|Placebo\tNA\tNA\tNA\tDrug|Drug\tAll\t","Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants","Interventional","Completed","Phase 2",12,162,"hepatitis b|hepatitis b, chronic|hepatitis, chronic|hepatitis|hepatitis a","vesatolimod","Change From Baseline in Serum Hepatitis B Surface Antigen (HBsAg) Level at Week 24"]
["NCT02175160","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",10795670,"Hau R, Csongvay S, Bartlett J. Driving reaction time after right knee arthroscopy. Knee Surg Sports Traumatol Arthrosc. 2000;8(2):89-92.","\tOsteoarthritis|Total Knee Arthroplasty\tBraking and functionality\tNA\tNA\tNA\tOther\tAll\t","Predictability of the Ability to Perform an Emergency Stop","Interventional","Completed","N/A",2,60,"emergencies|osteoarthritis","NA","NA"]
["NCT02185794","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|29063860","Rodriguez-Torres M, Glass S, Hill J, Freilich B, Hassman D, Di Bisceglie A, Taylor J, Kirby B, Yang J, An D, Stamm L, Brainard D, Kim S, Krefetz D, Smith W, Marbury T, Lawitz E. The Pangenotypic NS3/4A Protease Inhibitor GS-9857 Demonstrates Potent Antiviral Activity in Patients Infected With HCV Genotype 1, 2, 3, or 4 in a 3-Day Monotherapy Study [Poster P0901]. Presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress 2015, April 22-26, 2015, Vienna, Austria.|Lawitz E, Yang JC, Stamm LM, Taylor JG, Cheng G, Brainard DM, Miller MD, Mo H, Dvory-Sobol H. Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor. Antivir Ther. 2018;23(4):325-334. doi: 10.3851/IMP3202.","\tHepatitis C Virus Infection\tVoxilaprevir|Placebo to match voxilaprevir|SOF/VEL\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection","Interventional","Completed","Phase 1",16,101,"hepatitis a|hepatitis c|hepatitis c, chronic|hepatitis|infection|virus diseases|communicable diseases","NA","NA"]
["NCT02190474","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28088398,"Ali A, Weiss TR, Dutton A, McKee D, Jones KD, Kashikar-Zuck S, Silverman WK, Shapiro ED. Mindfulness-Based Stress Reduction for Adolescents with Functional Somatic Syndromes: A Pilot Cohort Study. J Pediatr. 2017 Apr;183:184-190. doi: 10.1016/j.jpeds.2016.12.053. Epub 2017 Jan 12.","\tChronic Widespread Pain|Fibromyalgia\tMindfulness Group\tNA\tNA\tNA\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","fibromyalgia|myofascial pain syndromes|chronic pain","NA","NA"]
["NCT02196155","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","10534247|15811212|23386757","Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22;53(7):1431-8.|Bihari K. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm. Curr Med Res Opin. 2005 Mar;21(3):433-8.|Elizondo-Rodriguez J, Araujo-Lopez Y, Moreno-Gonzalez JA, Cardenas-Estrada E, Mendoza-Lemus O, Acosta-Olivo C. A comparison of botulinum toxin a and intralesional steroids for the treatment of plantar fasciitis: a randomized, double-blinded study. Foot Ankle Int. 2013 Jan;34(1):8-14. doi: 10.1177/1071100712460215.","\tPlantar Fasciitis\tBotulinum toxin A|cortisone|Saline\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","Botulinum Toxin A Versus Steroids for the Treatment of Chronic Plantar Fasciitis","Interventional","Recruiting","N/A",3,54,"fasciitis|fasciitis, plantar","cortisone|botulinum toxins, type a|botulinum toxins|abobotulinumtoxina","NA"]
["NCT02208076","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA","Koledova, E. et al. (2017) Analysis of results from the global, 5-year Easypod™ Connect Observational Study (ECOS) study in children with growth disorders. 10th International Meeting for Pediatric Endocrinology; 2017 Sep 14-17; Washington, DC.|Wit, JM. et al. (2017) Effect of adherence on the 2-year growth response to growth hormone treatment in prepubertal children with idiopathic isolated growth hormone deficiency participating in the EasypodTM Connect Observational Study (ECOS). 10th International Meeting of Paediatric Endocrinology; 2017 Sep 14-17; Washington, DC.","\tGrowth Disorders\teasypod™\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","growth disorders","NA","NA"]
["NCT02213770","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21765276|22659939|23906899|22900793","Nytrøen K, Myers J, Chan KN, Geiran OR, Gullestad L. Chronotropic responses to exercise in heart transplant recipients: 1-yr follow-up. Am J Phys Med Rehabil. 2011 Jul;90(7):579-88. doi: 10.1097/PHM.0b013e31821f711d.|Nytrøen K, Rustad LA, Gude E, Hallén J, Fiane AE, Rolid K, Holm I, Aakhus S, Gullestad L. Muscular exercise capacity and body fat predict VO(2peak) in heart transplant recipients. Eur J Prev Cardiol. 2014 Jan;21(1):21-9. doi: 10.1177/2047487312450540. Epub 2012 Jun 1.|Nytrøen K, Rustad LA, Erikstad I, Aukrust P, Ueland T, Lekva T, Gude E, Wilhelmsen N, Hervold A, Aakhus S, Gullestad L, Arora S. Effect of high-intensity interval training on progression of cardiac allograft vasculopathy. J Heart Lung Transplant. 2013 Nov;32(11):1073-80. doi: 10.1016/j.healun.2013.06.023. Epub 2013 Jul 29.|Nytrøen K, Rustad LA, Aukrust P, Ueland T, Hallén J, Holm I, Rolid K, Lekva T, Fiane AE, Amlie JP, Aakhus S, Gullestad L. High-intensity interval training improves peak oxygen uptake and muscular exercise capacity in heart transplant recipients. Am J Transplant. 2012 Nov;12(11):3134-42. doi: 10.1111/j.1600-6143.2012.04221.x. Epub 2012 Aug 17.","\tHeart Transplant Recipients\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT02217579","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28730743,"Reimer RA, Willis HJ, Tunnicliffe JM, Park H, Madsen KL, Soto-Vaca A. Inulin-type fructans and whey protein both modulate appetite but only fructans alter gut microbiota in adults with overweight/obesity: A randomized controlled trial. Mol Nutr Food Res. 2017 Nov;61(11). doi: 10.1002/mnfr.201700484. Epub 2017 Aug 29.","\tObesity\tProtein|Prebiotic fiber|Protein plus prebiotic fiber|Control\tParallel Assignment\tTreatment\tRandomized\tDietary Supplement|Dietary Supplement|Dietary Supplement|Dietary Supplement\tAll\t","Effect of Protein and Prebiotic Fiber Intake on Adiposity in Overweight and Obese Adults","Interventional","Completed","N/A",4,132,"overweight","NA","NA"]
["NCT02222701","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25100406|24907560","Moncada G, Vildósola P, Fernández E, Estay J, de Oliveira Júnior OB, de Andrade MF, Martin J, Mjör IA, Gordan VV. Longitudinal results of a 10-year clinical trial of repair of amalgam restorations. Oper Dent. 2015 Jan-Feb;40(1):34-43. doi: 10.2341/14-045-C. Epub 2014 Aug 6.|Fernández E, Martín J, Vildósola P, Oliveira Junior OB, Gordan V, Mjor I, Bersezio C, Estay J, de Andrade MF, Moncada G. Can repair increase the longevity of composite resins? Results of a 10-year clinical trial. J Dent. 2015 Feb;43(2):279-86. doi: 10.1016/j.jdent.2014.05.015. Epub 2014 Jun 4.","\tUnsatisfactory Restoration of Tooth\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT02233842","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27019325|26888828","Land SR, Warren GW, Crafts JL, Hatsukami DK, Ostroff JS, Willis GB, Chollette VY, Mitchell SA, Folz JN, Gulley JL, Szabo E, Brandon TH, Duffy SA, Toll BA. Cognitive testing of tobacco use items for administration to patients with cancer and cancer survivors in clinical research. Cancer. 2016 Jun 1;122(11):1728-34. doi: 10.1002/cncr.29964. Epub 2016 Mar 28.|Land SR, Toll BA, Moinpour CM, Mitchell SA, Ostroff JS, Hatsukami DK, Duffy SA, Gritz ER, Rigotti NA, Brandon TH, Prindiville SA, Sarna LP, Schnoll RA, Herbst RS, Cinciripini PM, Leischow SJ, Dresler CM, Fiore MC, Warren GW. Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research. Clin Cancer Res. 2016 Apr 15;22(8):1907-13. doi: 10.1158/1078-0432.CCR-16-0104. Epub 2016 Feb 17.","\tBladder Cancer|Lung Cancer|Prostate Cancer|Thymic Cancer\tParticipant interview\tNA\tNA\tNA\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","thymus neoplasms","NA","NA"]
["NCT02240186",7988114,4365042,null,"NA",null,"NA",{"$nulls":3},0.01,"ANOVA",30077128,"Kaufman KR, Bernhardt KA, Symms K. Functional assessment and satisfaction of transfemoral amputees with low mobility (FASTK2): A clinical trial of microprocessor-controlled vs. non-microprocessor-controlled knees. Clin Biomech (Bristol, Avon). 2018 Oct;58:116-122. doi: 10.1016/j.clinbiomech.2018.07.012. Epub 2018 Jul 19.","\tLower Limb Amputation Above Knee (Injury)\tMicroprocessor Knee (MPK)|Non-Microprocessor Knee (NMPK)\tNA\tNA\tNA\tDevice|Device\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","Daily Activity Measured With Triaxial Accelerometers"]
["NCT02249182",7987247,4364641,"Percentage Geometric Mean Ratio",94.08,null,"NA",82.51,107.27,90,"NA",null,"NA|NA|NA|NA|27997679|28957984|NA|NA|30070726","Kirby B, German P, Kanwar B, Ni L, Lakatos I, Ling J, Mathias A. Pharmacokinetics of Once-Daily Sofosbuvir and Ledipasvir/Sofosbuvir in HCV-Infected Adolescents. Hepatology 2015;62 (S1): 1040A-1041A|Garrison KL, Mathias A, Kersey K, Kanwar B, Ni L, Jain A, et al. Pharmacokinetics of Once-Daily Sofosbuvir and Ledipasvir/Sofosbuvir in HCV-Infected Pediatrics Aged 6 to < 12 Years Old. Hepatology 2016;64 (S1): 436A|Schwarz K, Murray KF, Rosenthal P, Bansal S, Lin CH, Ni L, et al. High Rates of SVR12 in Adolescents Treated with the Combination of Ledipasvir/Sofosbuvir. J Hepatol 2016; 64 (2): S184-S185|K.F. Murray, W. Balistreri, S. Bansal, S. Whitworth, H. Evans, R.P. Gonzalez-Peralta, et al. Ledipasvir/sofosbuvir ± ribavirin for 12 or 24 weeks is safe and effective in children 6-11 years old with chronic hepatitis C infection. J Hepatol 2017;66: S33-S62|Balistreri WF, Murray KF, Rosenthal P, Bansal S, Lin CH, Kersey K, Massetto B, Zhu Y, Kanwar B, German P, Svarovskaia E, Brainard DM, Wen J, Gonzalez-Peralta RP, Jonas MM, Schwarz K. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017 Aug;66(2):371-378. doi: 10.1002/hep.28995. Epub 2017 Jun 19.|Younossi ZM, Stepanova M, Balistreri W, Schwarz K, Murray KF, Rosenthal P, Bansal S, Hunt S. Health-related Quality of Life in Adolescent Patients With Hepatitis C Genotype 1 Treated With Sofosbuvir and Ledipasvir. J Pediatr Gastroenterol Nutr. 2018 Jan;66(1):112-116. doi: 10.1097/MPG.0000000000001754.|Begley R, Meng A, Massetto B, Shao J, Ling J, and Mathias A. Pharmacokinetics of Once Daily Sofosbuvir or Ledipasvir/Sofosbuvir in HCV-Infected Pediatrics Aged 3 to <6 Years Old. Hepatology 2018;68 (S1): 582A.|Schwarz KB, Rosenthal P, Murray KF, Honegger JR, Hardikar W, Hague R, et al. Ledipasvir/Sofosbuvir for 12 Weeks Is Safe and Effective in Children 3 to <6 Years Old with Chronic Hepatitis C Virus Infection. Hepatology 2018;68 (S1): 116A-117A.|Murray KF, Balistreri WF, Bansal S, Whitworth S, Evans HM, Gonzalez-Peralta RP, Wen J, Massetto B, Kersey K, Shao J, Garrison KL, Parhy B, Brainard DM, Arnon R, Gillis LA, Jonas MM, Lin CH, Narkewicz MR, Schwarz K, Rosenthal P. Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11. Hepatology. 2018 Dec;68(6):2158-2166. doi: 10.1002/hep.30123. Epub 2018 Nov 17.","\tHepatitis C Virus Infection\tRBV|LDV/SOF\tNA\tNA\tNA\tDrug|Drug\tAll\t","Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection","Interventional","Completed","Phase 2",3,226,"communicable diseases|hepatitis c|infection","ledipasvir|ribavirin|ledipasvir, sofosbuvir drug combination|sofosbuvir","For Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF), LDV, and SOF"]
["NCT02249182",7987247,4364639,"Percentage Geometric Mean Ratio",82.25,null,"NA",61.34,110.3,90,"NA",null,"NA|NA|NA|NA|27997679|28957984|NA|NA|30070726","Kirby B, German P, Kanwar B, Ni L, Lakatos I, Ling J, Mathias A. Pharmacokinetics of Once-Daily Sofosbuvir and Ledipasvir/Sofosbuvir in HCV-Infected Adolescents. Hepatology 2015;62 (S1): 1040A-1041A|Garrison KL, Mathias A, Kersey K, Kanwar B, Ni L, Jain A, et al. Pharmacokinetics of Once-Daily Sofosbuvir and Ledipasvir/Sofosbuvir in HCV-Infected Pediatrics Aged 6 to < 12 Years Old. Hepatology 2016;64 (S1): 436A|Schwarz K, Murray KF, Rosenthal P, Bansal S, Lin CH, Ni L, et al. High Rates of SVR12 in Adolescents Treated with the Combination of Ledipasvir/Sofosbuvir. J Hepatol 2016; 64 (2): S184-S185|K.F. Murray, W. Balistreri, S. Bansal, S. Whitworth, H. Evans, R.P. Gonzalez-Peralta, et al. Ledipasvir/sofosbuvir ± ribavirin for 12 or 24 weeks is safe and effective in children 6-11 years old with chronic hepatitis C infection. J Hepatol 2017;66: S33-S62|Balistreri WF, Murray KF, Rosenthal P, Bansal S, Lin CH, Kersey K, Massetto B, Zhu Y, Kanwar B, German P, Svarovskaia E, Brainard DM, Wen J, Gonzalez-Peralta RP, Jonas MM, Schwarz K. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017 Aug;66(2):371-378. doi: 10.1002/hep.28995. Epub 2017 Jun 19.|Younossi ZM, Stepanova M, Balistreri W, Schwarz K, Murray KF, Rosenthal P, Bansal S, Hunt S. Health-related Quality of Life in Adolescent Patients With Hepatitis C Genotype 1 Treated With Sofosbuvir and Ledipasvir. J Pediatr Gastroenterol Nutr. 2018 Jan;66(1):112-116. doi: 10.1097/MPG.0000000000001754.|Begley R, Meng A, Massetto B, Shao J, Ling J, and Mathias A. Pharmacokinetics of Once Daily Sofosbuvir or Ledipasvir/Sofosbuvir in HCV-Infected Pediatrics Aged 3 to <6 Years Old. Hepatology 2018;68 (S1): 582A.|Schwarz KB, Rosenthal P, Murray KF, Honegger JR, Hardikar W, Hague R, et al. Ledipasvir/Sofosbuvir for 12 Weeks Is Safe and Effective in Children 3 to <6 Years Old with Chronic Hepatitis C Virus Infection. Hepatology 2018;68 (S1): 116A-117A.|Murray KF, Balistreri WF, Bansal S, Whitworth S, Evans HM, Gonzalez-Peralta RP, Wen J, Massetto B, Kersey K, Shao J, Garrison KL, Parhy B, Brainard DM, Arnon R, Gillis LA, Jonas MM, Lin CH, Narkewicz MR, Schwarz K, Rosenthal P. Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11. Hepatology. 2018 Dec;68(6):2158-2166. doi: 10.1002/hep.30123. Epub 2018 Nov 17.","\tHepatitis C Virus Infection\tRBV|LDV/SOF\tNA\tNA\tNA\tDrug|Drug\tAll\t","Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection","Interventional","Completed","Phase 2",3,226,"communicable diseases|hepatitis c|infection","ledipasvir|ribavirin|ledipasvir, sofosbuvir drug combination|sofosbuvir","For Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF), LDV, and SOF"]
["NCT02256046","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","2783677|3873388|3286356|16374843|18462268|15094222|18346683|10643628|1421595|NA|11328251|8495829","Rigau J, Bosch J, Bordas JM, Navasa M, Mastai R, Kravetz D, Bruix J, Feu F, Rodés J. Endoscopic measurement of variceal pressure in cirrhosis: correlation with portal pressure and variceal hemorrhage. Gastroenterology. 1989 Mar;96(3):873-80.|Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology. 1985 May-Jun;5(3):419-24.|Calès P, Pascal JP. [Natural history of esophageal varices in cirrhosis (from origin to rupture)]. Gastroenterol Clin Biol. 1988 Mar;12(3):245-54. Review. French.|de Franchis R. Endoscopy critics vs. endoscopy enthusiasts for primary prophylaxis of variceal bleeding. Hepatology. 2006 Jan;43(1):24-6.|Garcia-Pagan JC, De Gottardi A, Bosch J. Review article: the modern management of portal hypertension--primary and secondary prophylaxis of variceal bleeding in cirrhotic patients. Aliment Pharmacol Ther. 2008 Jul;28(2):178-86. doi: 10.1111/j.1365-2036.2008.03729.x. Epub 2008 May 2. Review.|Villanueva C, López-Balaguer JM, Aracil C, Kolle L, González B, Miñana J, Soriano G, Guarner C, Balanzó J. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol. 2004 May;40(5):757-65.|Villanueva C, Colomo A, Aracil C, Guarner C. Current endoscopic therapy of variceal bleeding. Best Pract Res Clin Gastroenterol. 2008;22(2):261-78. doi: 10.1016/j.bpg.2007.11.012. Review.|de Franchis R, Primignani M. Endoscopic treatments for portal hypertension. Semin Liver Dis. 1999;19(4):439-55. Review.|Westaby D. Emergency and elective endoscopic therapy for variceal haemorrhage. Baillieres Clin Gastroenterol. 1992 Sep;6(3):465-80. Review.|Villanueva C, Sancho-Poch F, Balanz Jea. Esophagic Histophathologic changes induced by variceal sclerosing therapy. Gastroenterol Hepatol 1990; 13: 15-19|Helmy A, Hayes PC. Review article: current endoscopic therapeutic options in the management of variceal bleeding. Aliment Pharmacol Ther. 2001 May;15(5):575-94. Review.|Young MF, Sanowski RA, Rasche R. Comparison and characterization of ulcerations induced by endoscopic ligation of esophageal varices versus endoscopic sclerotherapy. Gastrointest Endosc. 1993 Mar-Apr;39(2):119-22.","\tCirrhosis|Esophageal and Gastric Varices|Hypertension, Portal|Ulcer\tEsophagogastroduodenoscope\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","hypertension, portal|ulcer|varicose veins|esophageal and gastric varices","NA","NA"]
["NCT02262351","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30072410|30144961","Quinn FR, Gladstone DJ, Ivers NM, Sandhu RK, Dolovich L, Ling A, Nakamya J, Ramasundarahettige C, Frydrych PA, Henein S, Ng K, Congdon V, Birtwhistle RV, Ward R, Healey JS. Diagnostic accuracy and yield of screening tests for atrial fibrillation in the family practice setting: a multicentre cohort study. CMAJ Open. 2018 Aug 2;6(3):E308-E315. doi: 10.9778/cmajo.20180001. Print 2018 Jul-Sep.|Tarride JE, Quinn FR, Blackhouse G, Sandhu RK, Burke N, Gladstone DJ, Ivers NM, Dolovich L, Thornton A, Nakamya J, Ramasundarahettige C, Frydrych PA, Henein S, Ng K, Congdon V, Birtwhistle RV, Ward R, Healey JS. Is Screening for Atrial Fibrillation in Canadian Family Practices Cost-Effective in Patients 65 Years and Older? Can J Cardiol. 2018 Nov;34(11):1522-1525. doi: 10.1016/j.cjca.2018.05.016. Epub 2018 Jun 21.","\tAtrial Fibrillation\t30 Second Pulse Check|Watch BP Home A|HeartCheck Hand-held ECG device\tNA\tNA\tNA\tOther|Device|Device\tAll\t","NA","NA","NA","NA","NA","NA","atrial fibrillation","NA","NA"]
["NCT02270151","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","11343485|16527828|8841326|17577005","Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9;285(18):2370-5.|Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006 Apr;27(8):949-53. Epub 2006 Mar 9.|Jørgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke. 1996 Oct;27(10):1765-9.|Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jun 19;146(12):857-67.","\tAtrial Fibrillation\tMyDiagnostick\tParallel Assignment\tScreening\tRandomized\tDevice\tAll\t","Improving DEtection of Atrial fibriLlation in Primary Care With the MyDiagnostick","Interventional","Completed","Phase 3",2,16000,"atrial fibrillation","NA","NA"]
["NCT02270918","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27170068,"Nagalla S, Thomson L, Oppong Y, Bachman B, Chervoneva I, Kraft WK. Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers. Clin Transl Sci. 2016 Jun;9(3):176-80. doi: 10.1111/cts.12398. Epub 2016 May 12.","\tThrombosis\tKcentra|Apixaban|Placebo\tCrossover Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra","Interventional","Completed","Phase 1",2,12,"thrombosis","apixaban","NA"]
["NCT02273908",7984856,4363646,"Least square mean difference",2.729,null,"NA",0.9047,4.5533,95,0.004,"Mixed Models Analysis",26346468,"Taguchi T, Igarashi A, Watt S, Parsons B, Sadosky A, Nozawa K, Hayakawa K, Yoshiyama T, Ebata N, Fujii K. Effectiveness of pregabalin for the treatment of chronic low back pain with accompanying lower limb pain (neuropathic component): a non-interventional study in Japan. J Pain Res. 2015 Aug 5;8:487-97. doi: 10.2147/JPR.S88642. eCollection 2015.","\tLow-Back Pain\tNo intervention\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","low back pain|back pain","NA","Change From Baseline in Roland Morris Disability Questionnaire (RMDQ)-Japanese Standardized Score-"]
["NCT02276326","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29160817|28828217","Ceccarelli G, Brenchley JM, Cavallari EN, Scheri GC, Fratino M, Pinacchio C, Schietroma I, Fard SN, Scagnolari C, Mezzaroma I, Vullo V, d'Ettorre G. Impact of High-Dose Multi-Strain Probiotic Supplementation on Neurocognitive Performance and Central Nervous System Immune Activation of HIV-1 Infected Individuals. Nutrients. 2017 Nov 21;9(11). pii: E1269. doi: 10.3390/nu9111269.|Ceccarelli G, Fratino M, Selvaggi C, Giustini N, Serafino S, Schietroma I, Corano Scheri G, Pavone P, Passavanti G, Alunni Fegatelli D, Mezzaroma I, Antonelli G, Vullo V, Scagnolari C, d'Ettorre G. A pilot study on the effects of probiotic supplementation on neuropsychological performance and microRNA-29a-c levels in antiretroviral-treated HIV-1-infected patients. Brain Behav. 2017 Jul 16;7(8):e00756. doi: 10.1002/brb3.756. eCollection 2017 Aug.","\tART|HIV Seropositivity\tVSL#3 sachets\tNA\tNA\tNA\tDietary Supplement\tAll\t","NA","NA","NA","NA","NA","NA","hiv seropositivity","NA","NA"]
["NCT02288819","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29056238|28971753|27594125","Martens P, Verbrugge FH, Boonen L, Nijst P, Dupont M, Mullens W. Value of routine investigations to predict loop diuretic down-titration success in stable heart failure. Int J Cardiol. 2018 Jan 1;250:171-175. doi: 10.1016/j.ijcard.2017.10.018. Epub 2017 Oct 6.|Verbrugge FH, Martens P, Boonen L, Nijst P, Verhaert D, Noyens P, De Vusser P, Dupont M, Tang WHW, Mullens W. Loop diuretic down-titration in stable chronic heart failure is often achievable, especially when urinary chloride concentration is low. Acta Cardiol. 2018 Aug;73(4):335-341. doi: 10.1080/00015385.2017.1385152. Epub 2017 Oct 3.|Boonen L, Verbrugge FH, Nijst P, Noyens P, De Vusser P, Verhaert D, Van Lierde J, Vrolix M, Dupont M, Mullens W. Subclinical volume overload in stable outpatients with chronic heart failure. Acta Cardiol. 2016 Jun;71(3):299-307. doi: 10.2143/AC.71.3.3152090.","\tHeart Failure\tWeight monitoring|Loop diuretic downtitration\tNA\tNA\tNA\tDevice|Drug\tAll\t","NA","NA","NA","NA","NA","NA","heart failure","diuretics|sodium potassium chloride symporter inhibitors","NA"]
["NCT02290600","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29032732,"Zavitsanou S, Lee JB, Pinsker JE, Church MM, Doyle FJ 3rd, Dassau E. A Personalized Week-to-Week Updating Algorithm to Improve Continuous Glucose Monitoring Performance. J Diabetes Sci Technol. 2017 Nov;11(6):1070-1079. doi: 10.1177/1932296817734367. Epub 2017 Oct 16.","\tDiabetes\tContinuous Glucose Monitor\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT02295579","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21854593,"Larsson PG, Brandsborg E, Forsum U, Pendharkar S, Andersen KK, Nasic S, Hammarström L, Marcotte H. Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses. BMC Infect Dis. 2011 Aug 19;11:223. doi: 10.1186/1471-2334-11-223.","\tBacterial Vaginosis\tlactobacillus (EcoVag)\tNA\tNA\tNA\tOther\tFemale\t","NA","NA","NA","NA","NA","NA","vaginosis, bacterial|vaginal diseases","NA","NA"]
["NCT02301884","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24439076|24035151|22464647|21725898|19680119|19001265|23374268","Kündig TM, Johansen P, Bachmann MF, Cardell LO, Senti G. Intralymphatic immunotherapy: time interval between injections is essential. J Allergy Clin Immunol. 2014 Mar;133(3):930-1. doi: 10.1016/j.jaci.2013.11.036. Epub 2014 Jan 15.|Witten M, Malling HJ, Blom L, Poulsen BC, Poulsen LK. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol. 2013 Nov;132(5):1248-1252.e5. doi: 10.1016/j.jaci.2013.07.033. Epub 2013 Sep 13.|Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N, Steiner M, Hothorn LA, Grönlund H, Tivig C, Zaleska A, Soyer O, van Hage M, Akdis CA, Akdis M, Rose H, Kündig TM. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012 May;129(5):1290-6. doi: 10.1016/j.jaci.2012.02.026. Epub 2012 Mar 30.|Senti G, Johansen P, Kündig TM. Intralymphatic immunotherapy: from the rationale to human applications. Curr Top Microbiol Immunol. 2011;352:71-84. doi: 10.1007/82_2011_133. Review.|Senti G, Johansen P, Kündig TM. Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol. 2009 Dec;9(6):537-43. doi: 10.1097/ACI.0b013e3283310ff7. Review.|Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ, Simard JJ, Wüthrich B, Crameri R, Graf N, Johansen P, Kündig TM. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17908-12. doi: 10.1073/pnas.0803725105. Epub 2008 Nov 10.|Hylander T, Latif L, Petersson-Westin U, Cardell LO. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol. 2013 Feb;131(2):412-20. doi: 10.1016/j.jaci.2012.10.056.","\tAllergic Rhinitis\tAllergen extract\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","rhinitis, allergic|rhinitis","NA","NA"]
["NCT02306681","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28951336|29433560|30090731","Emral R, Pathan F, Cortés CAY, El-Hefnawy MH, Goh SY, Gómez AM, Murphy A, Abusnana S, Rudijanto A, Jain A, Ma Z, Mirasol R; IO HAT Investigator Group. Self-reported hypoglycemia in insulin-treated patients with diabetes: Results from an international survey on 7289 patients from nine countries. Diabetes Res Clin Pract. 2017 Dec;134:17-28. doi: 10.1016/j.diabres.2017.07.031. Epub 2017 Aug 9.|Emral R, Tetiker T, Sahin I, Sari R, Kaya A, Yetkin İ, Cil SU, Tütüncü NB; IO HAT investigator group. An international survey on hypoglycemia among insulin-treated type I and type II diabetes patients: Turkey cohort of the non-interventional IO HAT study. BMC Endocr Disord. 2018 Feb 13;18(1):9. doi: 10.1186/s12902-018-0238-2.|Pathan MF, Fariduddin M, Nazimuddin K, Mollah AS, Islam Siddiqui MN, Hassan KA, Ferdous HS, Rahman MH, Ashrafuzzaman SM, Sobhan MJ, E-Tanvir Haider MR, Amin MF. The Incidence of Hypoglycemia among Insulin-Treated Patients with Type 1 or Type 2 Diabetes: Bangladeshi Cohort of International Operations-Hypoglycemia Assessment Tool Study. Indian J Endocrinol Metab. 2018 May-Jun;22(3):379-386. doi: 10.4103/ijem.IJEM_545_17.","\tDiabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2\tNo treatment given\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","diabetes mellitus, type 1|diabetes mellitus|diabetes mellitus, type 2","NA","NA"]
["NCT02316236","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24338578|23524149|14693585","Yang S, Lee H. A dose-finding study of preoperative intravenous dexmedetomidine in children's emergence delirium after epiblepharon surgery. Eur J Ophthalmol. 2014 May-Jun;24(3):417-23. doi: 10.5301/ejo.5000396. Epub 2013 Nov 29.|Kim SY, Kim JM, Lee JH, Song BM, Koo BN. Efficacy of intraoperative dexmedetomidine infusion on emergence agitation and quality of recovery after nasal surgery. Br J Anaesth. 2013 Aug;111(2):222-8. doi: 10.1093/bja/aet056. Epub 2013 Mar 22.|Ibacache ME, Muñoz HR, Brandes V, Morales AL. Single-dose dexmedetomidine reduces agitation after sevoflurane anesthesia in children. Anesth Analg. 2004 Jan;98(1):60-3, table of contents.","\tAnesthesia\tdexmedetomidine|loading dose|sustaining dose\tParallel Assignment\tTreatment\tRandomized\tDrug|Other|Other\tAll\t","Dexmedetomidine to Improve Outcomes During Emergence From Retroperitoneal Laparoscopic Surgery","Interventional","Unknown status","N/A",2,60,"NA","dexmedetomidine","NA"]
["NCT02323412","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",31619437,"Bråten LCH, Rolfsen MP, Espeland A, Wigemyr M, Aßmus J, Froholdt A, Haugen AJ, Marchand GH, Kristoffersen PM, Lutro O, Randen S, Wilhelmsen M, Winsvold BS, Kadar TI, Holmgard TE, Vigeland MD, Vetti N, Nygaard ØP, Lie BA, Hellum C, Anke A, Grotle M, Schistad EI, Skouen JS, Grøvle L, Brox JI, Zwart JA, Storheim K; AIM study group. Efficacy of antibiotic treatment in patients with chronic low back pain and Modic changes (the AIM study): double blind, randomised, placebo controlled, multicentre trial. BMJ. 2019 Oct 16;367:l5654. doi: 10.1136/bmj.l5654. Erratum in: BMJ. 2020 Feb 11;368:m546.","\tLow Back Pain|Modic Changes Type I or II Seen on MRI\tAmoxicillin (Amoksicillintrihydrat)|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Antibiotics In Modic Changes","Interventional","Completed","Phase 3",2,180,"low back pain|back pain","amoxicillin","NA"]
["NCT02328534","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25466430,"Malvezzi H, Sharma R, Agarwal A, Abuzenadah AM, Abu-Elmagd M. Sperm quality after density gradient centrifugation with three commercially available media: a controlled trial. Reprod Biol Endocrinol. 2014 Dec 2;12:121. doi: 10.1186/1477-7827-12-121.","\tInfertility\tBlastocyst Formation Rate|Blastocyst Rate|Pregnancy Rate\tNA\tNA\tNA\tBehavioral|Procedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","infertility","NA","NA"]
["NCT02329600","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16225582|22582895|12419687|21827739|22322481","Sander CS, Cooper SM, Ali I, Dean D, Thiele JJ, Wojnarowska F. Decreased antioxidant enzyme expression and increased oxidative damage in erosive lichen planus of the vulva. BJOG. 2005 Nov;112(11):1572-5.|Agha-Hosseini F, Mirzaii-Dizgah I, Farmanbar N, Abdollahi M. Oxidative stress status and DNA damage in saliva of human subjects with oral lichen planus and oral squamous cell carcinoma. J Oral Pathol Med. 2012 Nov;41(10):736-40. doi: 10.1111/j.1600-0714.2012.01172.x. Epub 2012 May 15.|Nakagawa T, Yokozawa T. Direct scavenging of nitric oxide and superoxide by green tea. Food Chem Toxicol. 2002 Dec;40(12):1745-50.|Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol. 2011 Dec 15;82(12):1807-21. doi: 10.1016/j.bcp.2011.07.093. Epub 2011 Jul 30. Review.|Zhang J, Zhou G. Green tea consumption: an alternative approach to managing oral lichen planus. Inflamm Res. 2012 Jun;61(6):535-9. doi: 10.1007/s00011-012-0440-z. Epub 2012 Feb 10. Review.","\tOral Lichen Planus\tgreen tea tablets (Green tea extract 5:1) 200 mg|Triamcinolone Acetonide\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Evaluation of Green Tea as Antioxidant Agent in Management of Oral Lichen Planus","Interventional","Completed","Phase 3",3,40,"lichen planus, oral|lichen planus","triamcinolone diacetate|triamcinolone hexacetonide|triamcinolone|triamcinolone acetonide","NA"]
["NCT02337218","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20663438,"Najafi B, Horn D, Marclay S, Crews RT, Wu S, Wrobel JS. Assessing postural control and postural control strategy in diabetes patients using innovative and wearable technology. J Diabetes Sci Technol. 2010 Jul 1;4(4):780-91.","\tDiabetic Peripheral Neuropathy\tSENSUS Pain Management System\tParallel Assignment\tTreatment\tRandomized\tDevice\tAll\t","Electrical Stimulation for Improving Balance in Diabetes","Interventional","Completed","N/A",2,28,"peripheral nervous system diseases","NA","NA"]
["NCT02342860","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29565302,"Chard AN, Freeman MC. Design, Intervention Fidelity, and Behavioral Outcomes of a School-Based Water, Sanitation, and Hygiene Cluster-Randomized Trial in Laos. Int J Environ Res Public Health. 2018 Mar 22;15(4). pii: E570. doi: 10.3390/ijerph15040570.","\tHygiene\tWASH in Schools (WinS) programme\tParallel Assignment\tPrevention\tRandomized\tOther\tAll\t","The Impact of Improved WASH in Schools on Absence, Diarrhea and Helminth Infection in Lao PDR","Interventional","Completed","N/A",2,8873,"NA","NA","NA"]
["NCT02348346","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","1. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2013. Reporting on 2011 surveillance data and 2012 epidemic intelligence data. Stockholm: ECDC; 2013.","\tEnvironmental Contamination\tMVX (titanium dioxide)\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","communicable diseases|infection","titanium dioxide","NA"]
["NCT02352376","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24286408|8737210|24715877|21085891|24520952|24965685|15201553|16306058|19017864|25278968|21167508","Zhu GF, Wang DJ, Liu S, Jia M, Jia SJ. Efficacy and safety of noninvasive positive pressure ventilation in the treatment of acute respiratory failure after cardiac surgery. Chin Med J (Engl). 2013 Dec;126(23):4463-9.|Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J. 1996 Mar;17(3):354-81.|Carnevali L, Sgoifo A. Vagal modulation of resting heart rate in rats: the role of stress, psychosocial factors, and physical exercise. Front Physiol. 2014 Mar 24;5:118. doi: 10.3389/fphys.2014.00118. eCollection 2014. Review.|Pantoni CB, Di Thommazo L, Mendes RG, Catai AM, Luzzi S, Amaral Neto O, Borghi-Silva A. Effects of different levels of positive airway pressure on breathing pattern and heart rate variability after coronary artery bypass grafting surgery. Braz J Med Biol Res. 2011 Jan;44(1):38-45. Epub 2010 Nov 19.|Ozyilmaz E, Ugurlu AO, Nava S. Timing of noninvasive ventilation failure: causes, risk factors, and potential remedies. BMC Pulm Med. 2014 Feb 13;14:19. doi: 10.1186/1471-2466-14-19. Review.|Sasaki K, Maruyama R. Consciously controlled breathing decreases the high-frequency component of heart rate variability by inhibiting cardiac parasympathetic nerve activity. Tohoku J Exp Med. 2014 Jul;233(3):155-63.|Radaelli A, Raco R, Perfetti P, Viola A, Azzellino A, Signorini MG, Ferrari AU. Effects of slow, controlled breathing on baroreceptor control of heart rate and blood pressure in healthy men. J Hypertens. 2004 Jul;22(7):1361-70.|Pinsky MR. Cardiovascular issues in respiratory care. Chest. 2005 Nov;128(5 Suppl 2):592S-597S. Review.|Zarbock A, Mueller E, Netzer S, Gabriel A, Feindt P, Kindgen-Milles D. Prophylactic nasal continuous positive airway pressure following cardiac surgery protects from postoperative pulmonary complications: a prospective, randomized, controlled trial in 500 patients. Chest. 2009 May;135(5):1252-1259. doi: 10.1378/chest.08-1602. Epub 2008 Nov 18.|Yang LX, Zhou YJ, Wang ZJ, Li YP, Chai M. Impact of invasive treatment strategy on health-related quality of life six months after non-ST-elevation acute coronary syndrome. J Geriatr Cardiol. 2014 Sep;11(3):206-11. doi: 10.11909/j.issn.1671-5411.2014.03.003.|Yan TD, Padang R, Poh C, Cao C, Wilson MK, Bannon PG, Vallely MP. Drug-eluting stents versus coronary artery bypass grafting for the treatment of coronary artery disease: a meta-analysis of randomized and nonrandomized studies. J Thorac Cardiovasc Surg. 2011 May;141(5):1134-44. doi: 10.1016/j.jtcvs.2010.07.001. Epub 2010 Dec 17. Review.","\tCoronary Artery Bypass\tConventional ventilator|Specific ventilator\tCrossover Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Noninvasive Ventilation After Coronary Bypass Grafting","Interventional","Completed","Phase 4",2,10,"NA","NA","NA"]
["NCT02357745","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24355959|18062118|12146530|9495569|16510912","Arjunkumar R, Sudhakar U, Jayakumar P, Arunachalam L, Suresh S, Virupapuram P. Comparative analysis of gingival crevicular fluid neopterin levels in health and periodontal disease: a biochemical study. Indian J Dent Res. 2013 Sep-Oct;24(5):582-6. doi: 10.4103/0970-9290.123376.|Pradeep AR, Kumar MS, Ramachandraprasad MV, Shikha C. Gingival crevicular fluid levels of neopterin in healthy subjects and in patients with different periodontal diseases. J Periodontol. 2007 Oct;78(10):1962-7.|Ozmeriç N, Baydar T, Bodur A, Engin AB, Uraz A, Eren K, Sahin G. Level of neopterin, a marker of immune cell activation in gingival crevicular fluid, saliva, and urine in patients with aggressive periodontitis. J Periodontol. 2002 Jul;73(7):720-5.|Vrecko K, Staedtler P, Mischak I, Maresch L, Reibnegger G. Periodontitis and concentrations of the cellular immune activation marker neopterin in saliva and urine. Clin Chim Acta. 1997 Dec 10;268(1-2):31-40.|Bakhtadze MG, Margvelashvili VV, Kamkamidze GK. [Interferon-gamma and neopterin in blood serum of patients with chronic periodontitis]. Georgian Med News. 2006 Jan;(130):50-3. Russian.","\tPeriodontitis\tNon surgical periodontal therapy\tNA\tNA\tNA\tProcedure\tFemale\t","NA","NA","NA","NA","NA","NA","periodontitis","NA","NA"]
["NCT02367300","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20825903|23359586|20722504|24040943|25054838|25727167","Naunheim RS, Treaster M, English J, Casner T. Automated electroencephalogram identifies abnormalities in the ED. Am J Emerg Med. 2011 Oct;29(8):845-8. doi: 10.1016/j.ajem.2010.03.010. Epub 2010 May 1.|O'Neil B, Prichep LS, Naunheim R, Chabot R. Quantitative brain electrical activity in the initial screening of mild traumatic brain injuries. West J Emerg Med. 2012 Nov;13(5):394-400. doi: 10.5811/westjem.2011.12.6815.|Naunheim RS, Treaster M, English J, Casner T, Chabot R. Use of brain electrical activity to quantify traumatic brain injury in the emergency department. Brain Inj. 2010;24(11):1324-9. doi: 10.3109/02699052.2010.506862.|Hanley DF, Chabot R, Mould WA, Morgan T, Naunheim R, Sheth KN, Chiang W, Prichep LS. Use of brain electrical activity for the identification of hematomas in mild traumatic brain injury. J Neurotrauma. 2013 Dec 15;30(24):2051-6. doi: 10.1089/neu.2013.3062. Epub 2013 Nov 23.|Prichep LS, Naunheim R, Bazarian J, Mould WA, Hanley D. Identification of hematomas in mild traumatic brain injury using an index of quantitative brain electrical activity. J Neurotrauma. 2015 Jan 1;32(1):17-22. doi: 10.1089/neu.2014.3365.|Ayaz SI, Thomas C, Kulek A, Tolomello R, Mika V, Robinson D, Medado P, Pearson C, Prichep LS, O'Neil BJ. Comparison of quantitative EEG to current clinical decision rules for head CT use in acute mild traumatic brain injury in the ED. Am J Emerg Med. 2015 Apr;33(4):493-6. doi: 10.1016/j.ajem.2014.11.015. Epub 2014 Nov 20.","\tBrain Injuries\tBrainScope Ahead 200\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","brain injuries","NA","NA"]
["NCT02370641",7974279,4357774,"Mean Difference (Final Values)",2.6,null,"NA",{"$nulls":3},0.009,"Wilcoxon (Mann-Whitney)",26189645,"Li Z, Henning SM, Lee RP, Lu QY, Summanen PH, Thames G, Corbett K, Downes J, Tseng CH, Finegold SM, Heber D. Pomegranate extract induces ellagitannin metabolite formation and changes stool microbiota in healthy volunteers. Food Funct. 2015 Aug;6(8):2487-95. doi: 10.1039/c5fo00669d. Epub 2015 Jul 20.","\tUrolith\tPomX\tNA\tNA\tNA\tDietary Supplement\tAll\t","Effects of Pomegranate Extract on Intestinal Flora","Interventional","Completed","N/A",2,26,"NA","NA","Change in Percentage of Total Microflora Between Urolithin Excretors and Non-excretors"]
["NCT02374762","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23591442,"Riella MC, Roy-Chaudhury P. Vascular access in haemodialysis: strengthening the Achilles' heel. Nat Rev Nephrol. 2013 Jun;9(6):348-57. doi: 10.1038/nrneph.2013.76. Epub 2013 Apr 16. Review.","\tChronic Kidney Disease|Fistula|Hemodialysis Fistula Thrombosis\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","renal insufficiency, chronic|fistula|thrombosis|arteriovenous fistula|kidney diseases","NA","NA"]
["NCT02378805","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22997344|22237748|22166847|27402170|30691124","Temme J, Kramer A, Jager KJ, Lange K, Peters F, Müller GA, Kramar R, Heaf JG, Finne P, Palsson R, Reisæter AV, Hoitsma AJ, Metcalfe W, Postorino M, Zurriaga O, Santos JP, Ravani P, Jarraya F, Verrina E, Dekker FW, Gross O. Outcomes of male patients with Alport syndrome undergoing renal replacement therapy. Clin J Am Soc Nephrol. 2012 Dec;7(12):1969-76. doi: 10.2215/CJN.02190312. Epub 2012 Sep 20.|Temme J, Peters F, Lange K, Pirson Y, Heidet L, Torra R, Grunfeld JP, Weber M, Licht C, Müller GA, Gross O. Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney Int. 2012 Apr;81(8):779-83. doi: 10.1038/ki.2011.452. Epub 2012 Jan 11.|Gross O, Licht C, Anders HJ, Hoppe B, Beck B, Tönshoff B, Höcker B, Wygoda S, Ehrich JH, Pape L, Konrad M, Rascher W, Dötsch J, Müller-Wiefel DE, Hoyer P; Study Group Members of the Gesellschaft für Pädiatrische Nephrologie, Knebelmann B, Pirson Y, Grunfeld JP, Niaudet P, Cochat P, Heidet L, Lebbah S, Torra R, Friede T, Lange K, Müller GA, Weber M. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int. 2012 Mar;81(5):494-501. doi: 10.1038/ki.2011.407. Epub 2011 Dec 14.|Stock J, Kuenanz J, Glonke N, Sonntag J, Frese J, Tönshoff B, Höcker B, Hoppe B, Feldkötter M, Pape L, Lerch C, Wygoda S, Weber M, Müller GA, Gross O. Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations. Pediatr Nephrol. 2017 Jan;32(1):131-137. Epub 2016 Jul 11.|Frese J, Kettwig M, Zappel H, Hofer J, Gröne HJ, Nagel M, Sunder-Plassmann G, Kain R, Neuweiler J, Gross O. Kidney Injury by Variants in the COL4A5 Gene Aggravated by Polymorphisms in Slit Diaphragm Genes Causes Focal Segmental Glomerulosclerosis. Int J Mol Sci. 2019 Jan 26;20(3). pii: E519. doi: 10.3390/ijms20030519.","\tAlport Syndrome|Familial Benign Hematuria|Hereditary Kidney Disease|Pediatric Kidney Disease|Thin Basement Membrane Disease\tACE-inhibitor|AT1-inhibitor|HMG-Coenzyme inhibitor (statin)|Spironolactone|Paricalcitol\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","kidney diseases|syndrome|renal insufficiency|hematuria|nephritis, hereditary","angiotensin-converting enzyme inhibitors|ramipril|spironolactone","NA"]
["NCT02386761","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",30425469,"Mariotti F, Govoni M, Lucci G, Santoro D, Nandeuil MA. Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers. Int J Chron Obstruct Pulmon Dis. 2018 Oct 18;13:3399-3410. doi: 10.2147/COPD.S174156. eCollection 2018.","\tChronic Obstructive Pulmonary Disease\tSingle Ascending Dose (SAD)|Multiple Ascending Dose (MAD)\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001","Interventional","Completed","Phase 1",2,48,"lung diseases, obstructive|pulmonary disease, chronic obstructive","NA","NA"]
["NCT02393729","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27546352|26729293","Biotteau M, Péran P, Vayssière N, Tallet J, Albaret JM, Chaix Y. Neural changes associated to procedural learning and automatization process in Developmental Coordination Disorder and/or Developmental Dyslexia. Eur J Paediatr Neurol. 2017 Mar;21(2):286-299. doi: 10.1016/j.ejpn.2016.07.025. Epub 2016 Aug 12.|Biotteau M, Albaret JM, Lelong S, Chaix Y. Neuropsychological status of French children with developmental dyslexia and/or developmental coordination disorder: Are both necessarily worse than one? Child Neuropsychol. 2017 May;23(4):422-441. doi: 10.1080/09297049.2015.1127339. Epub 2016 Jan 4.","\tDevelopmental Coordination Disorder|Developmental Dyslexia\tNeuropsychological assessment|MRI Study\tNA\tNA\tNA\tBehavioral|Other\tAll\t","Functional MRI Study in Children With a Developmental Coordination Disorder (DCD) and/or Developmental Dyslexia (DD)","Interventional","Completed","N/A",4,65,"motor skills disorders|dyslexia","NA","NA"]
["NCT02397707",7971761,4356632,"GLSM Ratio (%)",399.24,null,"NA",210.89,755.81,90,"NA",null,"NA","Lawitz E, Marbury T, Kirby BJ, Au NT, Mathias A, Stamm LM, et al. The Effect of Renal or Hepatic Impairment on the Pharmacokinetics of GS-9857, A Pan-Genotypic HCV NS3/4A Protease Inhibitor [Abstract FRI-167]. J Hepatology 2016:S613-S4.","\tHCV Infection\tVoxilaprevir\tNA\tNA\tNA\tDrug\tAll\t","Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment","Interventional","Completed","Phase 1",2,33,"hepatitis c","NA","PK Parameter of Voxilaprevir: AUCinf"]
["NCT02399397","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24370612,"de Moraes NV, Lauretti GR, Filgueira GC, Lopes BC, Lanchote VL. Analysis of rocuronium in human plasma by liquid chromatography-tandem mass spectrometry with application in clinical pharmacokinetics. J Pharm Biomed Anal. 2014 Mar;90:180-5. doi: 10.1016/j.jpba.2013.11.032. Epub 2013 Dec 7.","\tSepsis|Septic Shock|Systemic Inflammatory Response Syndrome\tSerial blood sampling|Train of four monitoring|Blood testing for liver and renal function|General anesthesia|Small to medium sized surgery under general anesthesia\tNA\tNA\tNA\tProcedure|Procedure|Procedure|Drug|Procedure\tAll\t","Influence of Age, Sepsis and SLCO1A2 Polymorphisms on Rocuronium Pharmacokinetics","Interventional","Completed","Phase 4",3,36,"sepsis|systemic inflammatory response syndrome|toxemia","midazolam|fentanyl|propofol|rocuronium|anesthetics","NA"]
["NCT02420197","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",30132009,"Iversen VM, Vasseljen O, Mork PJ, Fimland MS. Resistance training vs general physical exercise in multidisciplinary rehabilitation of chronic neck pain: A randomized controlled trial. J Rehabil Med. 2018 Aug 22;50(8):743-750. doi: 10.2340/16501977-2370.","\tNeck Pain\tHigh-intensity resistance training|General physical activity|Multidisciplinary rehabilitation program\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral|Behavioral\tAll\t","Effects of Resistance Training on Pain, Function and Work Ability in Patients With Moderate to Severe Neck Pain","Interventional","Completed","N/A",2,74,"neck pain","NA","NA"]
["NCT02444598","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","9356079|17414553|23999350|10898201|21316515|20084702|17543685|17099530|18646080|25287701|21712971|18808432|20358706|12046489|9188971","Aboutanos MB, Baker SP. Wartime civilian injuries: epidemiology and intervention strategies. J Trauma. 1997 Oct;43(4):719-26. Review.|Owens BD, Kragh JF Jr, Macaitis J, Svoboda SJ, Wenke JC. Characterization of extremity wounds in Operation Iraqi Freedom and Operation Enduring Freedom. J Orthop Trauma. 2007 Apr;21(4):254-7.|Fares Y, El-Zaatari M, Fares J, Bedrosian N, Yared N. Trauma-related infections due to cluster munitions. J Infect Public Health. 2013 Dec;6(6):482-6. doi: 10.1016/j.jiph.2013.05.006. Epub 2013 Jul 31.|Covey DC, Lurate RB, Hatton CT. Field hospital treatment of blast wounds of the musculoskeletal system during the Yugoslav civil war. J Orthop Trauma. 2000 May;14(4):278-86; discussion 277.|Krug E, Berg L, Lee C, Hudson D, Birke-Sorensen H, Depoorter M, Dunn R, Jeffery S, Duteille F, Bruhin A, Caravaggi C, Chariker M, Dowsett C, Ferreira F, Martínez JM, Grudzien G, Ichioka S, Ingemansson R, Malmsjo M, Rome P, Vig S, Runkel N, Martin R, Smith J; International Expert Panel on Negative Pressure Wound Therapy [NPWT-EP]. Evidence-based recommendations for the use of Negative Pressure Wound Therapy in traumatic wounds and reconstructive surgery: steps towards an international consensus. Injury. 2011 Feb;42 Suppl 1:S1-12. doi: 10.1016/S0020-1383(11)00041-6. Review.|Machen S. Management of traumatic war wounds using vacuum-assisted closure dressings in an austere environment. US Army Med Dep J. 2007 Jan-Mar:17-23.|Peck MA, Clouse WD, Cox MW, Bowser AN, Eliason JL, Jenkins DH, Smith DL, Rasmussen TE. The complete management of extremity vascular injury in a local population: a wartime report from the 332nd Expeditionary Medical Group/Air Force Theater Hospital, Balad Air Base, Iraq. J Vasc Surg. 2007 Jun;45(6):1197-204; discussion 1204-5.|Leininger BE, Rasmussen TE, Smith DL, Jenkins DH, Coppola C. Experience with wound VAC and delayed primary closure of contaminated soft tissue injuries in Iraq. J Trauma. 2006 Nov;61(5):1207-11.|Ubbink DT, Westerbos SJ, Evans D, Land L, Vermeulen H. Topical negative pressure for treating chronic wounds. Cochrane Database Syst Rev. 2008 Jul 16;(3):CD001898. doi: 10.1002/14651858.CD001898.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;6:CD001898.|Webster J, Scuffham P, Stankiewicz M, Chaboyer WP. Negative pressure wound therapy for skin grafts and surgical wounds healing by primary intention. Cochrane Database Syst Rev. 2014 Oct 7;(10):CD009261. doi: 10.1002/14651858.CD009261.pub3. Review. Update in: Cochrane Database Syst Rev. 2019 Mar 26;3:CD009261.|Peinemann F, Sauerland S. Negative-pressure wound therapy: systematic review of randomized controlled trials. Dtsch Arztebl Int. 2011 Jun;108(22):381-9. doi: 10.3238/arztebl.2011.0381. Epub 2011 Jun 3. Review.|Bovill E, Banwell PE, Teot L, Eriksson E, Song C, Mahoney J, Gustafsson R, Horch R, Deva A, Whitworth I; International Advisory Panel on Topical Negative Pressure. Topical negative pressure wound therapy: a review of its role and guidelines for its use in the management of acute wounds. Int Wound J. 2008 Oct;5(4):511-29. doi: 10.1111/j.1742-481X.2008.00437.x. Epub 2008 Sep 19. Review.|Hinck D, Franke A, Gatzka F. Use of vacuum-assisted closure negative pressure wound therapy in combat-related injuries--literature review. Mil Med. 2010 Mar;175(3):173-81. Review.|Krasner DL. Managing wound pain in patients with vacuum-assisted closure devices. Ostomy Wound Manage. 2002 May;48(5):38-43. Review.|Argenta LC, Morykwas MJ. Vacuum-assisted closure: a new method for wound control and treatment: clinical experience. Ann Plast Surg. 1997 Jun;38(6):563-76; discussion 577.","\tArm Injuries|Leg Injuries|Wound Infection|Wounds, Gunshot\tVaccum Assisted Closure device|Conventional wound dressings\tParallel Assignment\tTreatment\tRandomized\tDevice|Procedure\tAll\t","Trial of Negative-pressure Wound Therapy Use in Conflict-related Extremity Wounds","Interventional","Completed","N/A",2,116,"wounds and injuries|wound infection|arm injuries|leg injuries|wounds, gunshot","NA","NA"]
["NCT02449044",7966085,4354104,null,"NA",null,"NA",{"$nulls":3},0.0277,"Student's t-test",20185637,"Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, Czerwiec FS; SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010 Apr;21(4):705-12. doi: 10.1681/ASN.2009080857. Epub 2010 Feb 25. Erratum in: J Am Soc Nephrol. 2010 Aug;21(8):1407.","\tHyponatremia\tTolvaptan\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","hyponatremia","tolvaptan","Mean Change From Baseline in SF-12 (Health Survey) Mental Component Summary (MCS)"]
["NCT02449044",7966085,4354098,null,"NA",null,"NA",{"$nulls":3},0.6923,"Student's t-test",20185637,"Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, Czerwiec FS; SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010 Apr;21(4):705-12. doi: 10.1681/ASN.2009080857. Epub 2010 Feb 25. Erratum in: J Am Soc Nephrol. 2010 Aug;21(8):1407.","\tHyponatremia\tTolvaptan\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","hyponatremia","tolvaptan","Mean Change From Baseline in SF-12 (Health Survey) Mental Component Summary (MCS)"]
["NCT02449044",7966087,4354150,null,"NA",null,"NA",{"$nulls":3},0.1054,"Student's t-test",20185637,"Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, Czerwiec FS; SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010 Apr;21(4):705-12. doi: 10.1681/ASN.2009080857. Epub 2010 Feb 25. Erratum in: J Am Soc Nephrol. 2010 Aug;21(8):1407.","\tHyponatremia\tTolvaptan\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","hyponatremia","tolvaptan","Mean Change From Baseline in Body Weight by Visit for Those Participants Who Had Clinical Evidence of Hypervolemia at Baseline"]
["NCT02449044",7966094,4354170,null,"NA",null,"NA",{"$nulls":3},{"v":1E-4,"d":"1.00E-04"},"Student's t-test",20185637,"Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, Czerwiec FS; SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010 Apr;21(4):705-12. doi: 10.1681/ASN.2009080857. Epub 2010 Feb 25. Erratum in: J Am Soc Nephrol. 2010 Aug;21(8):1407.","\tHyponatremia\tTolvaptan\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","hyponatremia","tolvaptan","Mean Change From Baseline in Serum Sodium Measurements"]
["NCT02453594","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28441111,"Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH; KEYNOTE-087. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 2017 Jul 1;35(19):2125-2132. doi: 10.1200/JCO.2016.72.1316. Epub 2017 Apr 25.","\tHodgkin Lymphoma\tpembrolizumab\tNA\tNA\tNA\tBiological\tAll\t","Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)","Interventional","Active, not recruiting","Phase 2",3,211,"hodgkin disease|lymphoma","pembrolizumab","NA"]
["NCT02458040","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28761069,"Vivot A, Boutron I, Béraud-Chaulet G, Zeitoun JD, Ravaud P, Porcher R. Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing. Sci Rep. 2017 Jul 31;7(1):6882. doi: 10.1038/s41598-017-07358-7.","\tNeoplasms\tDrug selected in the study\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT02461342","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25903694|25594612|25555369|25287103|25201002|24772443|24633734|24360155|23940593|23890865|23770583|24371189","Liao XP, Zhu HW, Zeng F, Tang ZH. The association and interaction analysis of hypertension and uric acid on cardiovascular autonomic neuropathy. J Endocrinol Invest. 2015 Oct;38(10):1075-82. doi: 10.1007/s40618-015-0291-x. Epub 2015 Apr 23.|Tang ZH, Zeng F, Zhang XZ. Human genetics of diabetic nephropathy. Ren Fail. 2015 Apr;37(3):363-71. doi: 10.3109/0886022X.2014.1000801. Epub 2015 Jan 16. Review.|Zhang L, Tang ZH, Zeng F, Li Z, Zhou L, Li Y. Clinical risk model assessment for cardiovascular autonomic dysfunction in the general Chinese population. J Endocrinol Invest. 2015 Jun;38(6):615-22. doi: 10.1007/s40618-014-0229-8. Epub 2015 Jan 3.|Tang ZH, Wang L, Zeng F, Li Z, Yu X, Zhang K, Zhou L. Bayesian estimation of cardiovascular autonomic neuropathy diagnostic test based on short-term heart rate variability without a gold standard. BMJ Open. 2014 Oct 6;4(9):e005096. doi: 10.1136/bmjopen-2014-005096.|Tang ZH, Wang L, Zeng F, Zhang K. Human genetics of diabetic retinopathy. J Endocrinol Invest. 2014 Dec;37(12):1165-74. doi: 10.1007/s40618-014-0172-8. Epub 2014 Sep 9. Review.|Tang ZH, Zeng F, Li Z, Zhou L. Association and predictive value analysis for resting heart rate and diabetes mellitus on cardiovascular autonomic neuropathy in general population. J Diabetes Res. 2014;2014:215473. doi: 10.1155/2014/215473. Epub 2014 Mar 18.|Zeng F, Tang ZH, Li Z, Yu X, Zhou L. Normative reference of short-term heart rate variability and estimation of cardiovascular autonomic neuropathy prevalence in Chinese people. J Endocrinol Invest. 2014 Apr;37(4):385-91. doi: 10.1007/s40618-013-0047-4. Epub 2014 Jan 9.|Tang ZH, Zeng F, Yu X, Zhou L. Bayesian estimation of cardiovascular autonomic neuropathy diagnostic test based on baroreflex sensitivity in the absence of a gold standard. Int J Cardiol. 2014 Feb 15;171(3):e78-80. doi: 10.1016/j.ijcard.2013.11.100. Epub 2013 Dec 6.|Tang ZH, Liu J, Zeng F, Li Z, Yu X, Zhou L. Comparison of prediction model for cardiovascular autonomic dysfunction using artificial neural network and logistic regression analysis. PLoS One. 2013 Aug 5;8(8):e70571. doi: 10.1371/journal.pone.0070571. Print 2013. Erratum in: PLoS One. 2017 Apr 25;12 (4):e0176771.|Tang ZH, Zeng F, Li Z, Zhou L. A risk score of cardiovascular autonomic dysfunction for targeted screening in the Chinese population. Int J Cardiol. 2013 Oct 12;168(5):4861-2. doi: 10.1016/j.ijcard.2013.07.062. Epub 2013 Jul 25.|Li Z, Tang ZH, Zeng F, Zhou L. Associations between the severity of metabolic syndrome and cardiovascular autonomic function in a Chinese population. J Endocrinol Invest. 2013 Dec;36(11):993-9. doi: 10.3275/9005. Epub 2013 Jun 17.|Tang ZH, Fang Z, Zhou L. Human genetics of diabetic vascular complications. J Genet. 2013 Dec;92(3):677-94. Review.","\tCardiovascular Autonomic Neuropathy\tnot intervention\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","peripheral nervous system diseases|nervous system diseases","NA","NA"]
["NCT02464644","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23404156|23445111|24146883|24354965|24458873","Silva BM, Hosman AE, Devlin HL, Shovlin CL. Lifestyle and dietary influences on nosebleed severity in hereditary hemorrhagic telangiectasia. Laryngoscope. 2013 May;123(5):1092-9. doi: 10.1002/lary.23893. Epub 2013 Feb 12.|Devlin HL, Hosman AE, Shovlin CL. Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia. N Engl J Med. 2013 Feb 28;368(9):876-8. doi: 10.1056/NEJMc1213554.|Finnamore H, Le Couteur J, Hickson M, Busbridge M, Whelan K, Shovlin CL. Hemorrhage-adjusted iron requirements, hematinics and hepcidin define hereditary hemorrhagic telangiectasia as a model of hemorrhagic iron deficiency. PLoS One. 2013 Oct 16;8(10):e76516. doi: 10.1371/journal.pone.0076516. eCollection 2013.|Hosman AE, Devlin HL, Silva BM, Shovlin CL. Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls. Orphanet J Rare Dis. 2013 Dec 20;8:195. doi: 10.1186/1750-1172-8-195.|Elphick A, Shovlin CL. Relationships between epistaxis, migraines, and triggers in hereditary hemorrhagic telangiectasia. Laryngoscope. 2014 Jul;124(7):1521-8. doi: 10.1002/lary.24526. Epub 2014 Jan 23.","\tHereditary Hemorrhagic Telangiectasia (HHT)\tQuestionnaire\tNA\tNA\tNA\tOther\tAll\t","Frequency of Common Medical Conditions in People With and Without HHT","Interventional","Completed","N/A",2,2174,"telangiectasia, hereditary hemorrhagic|telangiectasis","NA","NA"]
["NCT02472652",7963883,4353228,"change in prolactin",30,null,"NA",{"$nulls":3},"NA",null,21720224,"de Boer MK, Wiersma D, Bous J, Sytema S, van der Moolen AE, Wilffert B, Hamamura T, Knegtering H. A randomized open-label comparison of the impact of aripiprazole versus risperidone on sexual functioning (RAS study). J Clin Psychopharmacol. 2011 Aug;31(4):523-5. doi: 10.1097/JCP.0b013e318222bb29.","\tSexual Dysfunction\tAbilify Maintena\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","NA","aripiprazole","Prolactin Concentrations ng/ml (Normal Range 4.0 - 15.2ng/ml)"]
["NCT02475226","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19038914|10668696","Sacco S, Marini C, Toni D, Olivieri L, Carolei A. Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke. 2009 Feb;40(2):394-9. doi: 10.1161/STROKEAHA.108.523209. Epub 2008 Nov 26.|Schwarz S, Häfner K, Aschoff A, Schwab S. Incidence and prognostic significance of fever following intracerebral hemorrhage. Neurology. 2000 Jan 25;54(2):354-61.","\tBrain Injuries\ttype of the brain injury|type of the brain injury|type of the brain injury|type of the brain injury|type of the brain injury|type of the brain injury\tNA\tNA\tNA\tOther|Other|Other|Other|Other|Other\tAll\t","NA","NA","NA","NA","NA","NA","brain injuries","NA","NA"]
["NCT02477592","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22386883|22922413|22550126|20206320|20339034|21965530|21539635|15653029|20601148|21955090|19307477|19602027","Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haissaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D; Heart Rhythm Society Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm. 2012 Apr;9(4):632-696.e21. doi: 10.1016/j.hrthm.2011.12.016. Epub 2012 Mar 1.|Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33(21):2719-47. doi: 10.1093/eurheartj/ehs253. Epub 2012 Aug 24. Erratum in: Eur Heart J. 2013 Mar;34(10):790. Eur Heart J. 2013 Sep;34(36):2850-1.|Chao TF, Tsao HM, Lin YJ, Tsai CF, Lin WS, Chang SL, Lo LW, Hu YF, Tuan TC, Suenari K, Li CH, Hartono B, Chang HY, Ambrose K, Wu TJ, Chen SA. Clinical outcome of catheter ablation in patients with nonparoxysmal atrial fibrillation: results of 3-year follow-up. Circ Arrhythm Electrophysiol. 2012 Jun 1;5(3):514-20. doi: 10.1161/CIRCEP.111.968032. Epub 2012 May 1.|Brooks AG, Stiles MK, Laborderie J, Lau DH, Kuklik P, Shipp NJ, Hsu LF, Sanders P. Outcomes of long-standing persistent atrial fibrillation ablation: a systematic review. Heart Rhythm. 2010 Jun;7(6):835-46. doi: 10.1016/j.hrthm.2010.01.017. Epub 2010 Jan 22. Review.|Sawhney N, Anousheh R, Chen W, Feld GK. Circumferential pulmonary vein ablation with additional linear ablation results in an increased incidence of left atrial flutter compared with segmental pulmonary vein isolation as an initial approach to ablation of paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol. 2010 Jun;3(3):243-8. doi: 10.1161/CIRCEP.109.924878. Epub 2010 Mar 25.|Sawhney N, Anand K, Robertson CE, Wurdeman T, Anousheh R, Feld GK. Recovery of mitral isthmus conduction leads to the development of macro-reentrant tachycardia after left atrial linear ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2011 Dec;4(6):832-7. doi: 10.1161/CIRCEP.111.964817. Epub 2011 Sep 30.|Chen M, Yang B, Chen H, Ju W, Zhang F, Tse HF, Cao K. Randomized comparison between pulmonary vein antral isolation versus complex fractionated electrogram ablation for paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2011 Sep;22(9):973-81. doi: 10.1111/j.1540-8167.2011.02051.x. Epub 2011 May 3.|Verma A, Wazni OM, Marrouche NF, Martin DO, Kilicaslan F, Minor S, Schweikert RA, Saliba W, Cummings J, Burkhardt JD, Bhargava M, Belden WA, Abdul-Karim A, Natale A. Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. J Am Coll Cardiol. 2005 Jan 18;45(2):285-92.|Mahnkopf C, Badger TJ, Burgon NS, Daccarett M, Haslam TS, Badger CT, McGann CJ, Akoum N, Kholmovski E, Macleod RS, Marrouche NF. Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: implications for disease progression and response to catheter ablation. Heart Rhythm. 2010 Oct;7(10):1475-81. doi: 10.1016/j.hrthm.2010.06.030. Epub 2010 Jul 1.|Teh AW, Kistler PM, Lee G, Medi C, Heck PM, Spence SJ, Sparks PB, Morton JB, Kalman JM. Electroanatomic remodeling of the left atrium in paroxysmal and persistent atrial fibrillation patients without structural heart disease. J Cardiovasc Electrophysiol. 2012 Mar;23(3):232-8. doi: 10.1111/j.1540-8167.2011.02178.x. Epub 2011 Sep 28.|Oakes RS, Badger TJ, Kholmovski EG, Akoum N, Burgon NS, Fish EN, Blauer JJ, Rao SN, DiBella EV, Segerson NM, Daccarett M, Windfelder J, McGann CJ, Parker D, MacLeod RS, Marrouche NF. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation. 2009 Apr 7;119(13):1758-67. doi: 10.1161/CIRCULATIONAHA.108.811877. Epub 2009 Mar 23.|Park JH, Pak HN, Choi EJ, Jang JK, Kim SK, Choi DH, Choi JI, Hwang C, Kim YH. The relationship between endocardial voltage and regional volume in electroanatomical remodeled left atria in patients with atrial fibrillation: comparison of three-dimensional computed tomographic images and voltage mapping. J Cardiovasc Electrophysiol. 2009 Dec;20(12):1349-56. doi: 10.1111/j.1540-8167.2009.01557.x.","\tAtrial Fibrillation\tindividualized substrate modification|stepwise ablation\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","a Novel Individualized Substrate Modification Approach for the Treatment of Long-standing Persistent Atrial Fibrillation","Interventional","Unknown status","N/A",2,220,"atrial fibrillation","NA","NA"]
["NCT02481921","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29276763|29940335","Cohen LB, Parent M, Taveira TH, Dev S, Wu WC. A Description of Patient and Provider Experience and Clinical Outcomes After Heart Failure Shared Medical Appointment. J Patient Exp. 2017 Dec;4(4):169-176. doi: 10.1177/2374373517714452. Epub 2017 Jun 20.|Wu WC, Parent M, Dev S, Hearns R, Taveira TH, Cohen L, Shell-Boyd J, Jewett-Tennant J, Marshall V, Gee J, Schaub K, LaForest S, Ball S. Group medical visits after heart failure hospitalization: Study protocol for a randomized-controlled trial. Contemp Clin Trials. 2018 Aug;71:140-145. doi: 10.1016/j.cct.2018.06.015. Epub 2018 Jun 22.","\tHeart Failure\tGroup medical visits\tParallel Assignment\tTreatment\tRandomized\tBehavioral\tAll\t","Group Medical Visits in Heart Failure","Interventional","Completed","N/A",2,239,"heart failure","NA","NA"]
["NCT02483611",7962730,4352598,"Mean Difference (Final Values)",73.4,"Standard Deviation",7.94,54,80,95,0.8746,"ANOVA","19919585|22260297|22183158|22778886|9301400|19468625|12229137|21334502|22752440|23635996|17042843|7743572|156513|11506113|21574968|4315659|568429|2275325|19468561|25829048","Czarnetzki C, Lysakowski C, Elia N, Tramèr MR. Time course of rocuronium-induced neuromuscular block after pre-treatment with magnesium sulphate: a randomised study. Acta Anaesthesiol Scand. 2010 Mar;54(3):299-306. doi: 10.1111/j.1399-6576.2009.02160.x. Epub 2009 Nov 16.|Czarnetzki C, Lysakowski C, Elia N, Tramèr MR. Intravenous lidocaine has no impact on rocuronium-induced neuromuscular block. Randomised study. Acta Anaesthesiol Scand. 2012 Apr;56(4):474-81. doi: 10.1111/j.1399-6576.2011.02625.x. Epub 2012 Jan 19.|Hans GA, Bosenge B, Bonhomme VL, Brichant JF, Venneman IM, Hans PC. Intravenous magnesium re-establishes neuromuscular block after spontaneous recovery from an intubating dose of rocuronium: a randomised controlled trial. Eur J Anaesthesiol. 2012 Feb;29(2):95-9. doi: 10.1097/EJA.0b013e32834e13a6.|Kim SH, So KY, Jung KT. Effect of magnesium sulfate pretreatment on onset and recovery characteristics of cisatracurium. Korean J Anesthesiol. 2012 Jun;62(6):518-23. doi: 10.4097/kjae.2012.62.6.518. Epub 2012 Jun 19.|Kussman B, Shorten G, Uppington J, Comunale ME. Administration of magnesium sulphate before rocuronium: effects on speed of onset and duration of neuromuscular block. Br J Anaesth. 1997 Jul;79(1):122-4.|Cardoso LS, Martins CR, Tardelli MA. Effects of intravenous lidocaine on the pharmacodynamics of rocuronium. Rev Bras Anestesiol. 2005 Aug;55(4):371-80. English, Portuguese.|Nonaka A, Sugawara T, Suzuki S, Masamune T, Kumazawa T. [Pretreatment with lidocaine accelerates onset of vecuronium-induced neuromuscular blockade]. Masui. 2002 Aug;51(8):880-3. Japanese.|Vivancos GG, Klamt JG, Garcia LV. Effects of 2 mg.kg-¹ of intravenous lidocaine on the latency of two different doses of rocuronium and on the hemodynamic response to orotracheal intubation. Rev Bras Anestesiol. 2011 Jan-Feb;61(1):1-12. doi: 10.1016/S0034-7094(11)70001-0.|Ghodraty MR, Saif AA, Kholdebarin AR, Rokhtabnak F, Pournajafian AR, Nikzad-Jamnani AR, Shah A, Nader ND. The effects of magnesium sulfate on neuromuscular blockade by cisatracurium during induction of anesthesia. J Anesth. 2012 Dec;26(6):858-63. doi: 10.1007/s00540-012-1439-x. Epub 2012 Jul 3.|Rotava P, Cavalcanti IL, Barrucand L, Vane LA, Verçosa N. Effects of magnesium sulphate on the pharmacodynamics of rocuronium in patients aged 60 years and older: A randomised trial. Eur J Anaesthesiol. 2013 Oct;30(10):599-604. doi: 10.1097/EJA.0b013e328361d342.|Gupta K, Vohra V, Sood J. The role of magnesium as an adjuvant during general anaesthesia. Anaesthesia. 2006 Nov;61(11):1058-63.|McCoy EP, Connolly FM, Mirakhur RK, Loan PB, Paxton LD. Nondepolarizing neuromuscular blocking drugs and train-of-four fade. Can J Anaesth. 1995 Mar;42(3):213-6.|Viby-Mogensen J, Jørgensen BC, Ording H. Residual curarization in the recovery room. Anesthesiology. 1979 Jun;50(6):539-41.|Kopman AF, Kumar S, Klewicka MM, Neuman GG. The staircase phenomenon: implications for monitoring of neuromuscular transmission. Anesthesiology. 2001 Aug;95(2):403-7.|Staals LM, Driessen JJ, Van Egmond J, De Boer HD, Klimek M, Flockton EA, Snoeck MM. Train-of-four ratio recovery often precedes twitch recovery when neuromuscular block is reversed by sugammadex. Acta Anaesthesiol Scand. 2011 Jul;55(6):700-7. doi: 10.1111/j.1399-6576.2011.02448.x. Epub 2011 May 16.|Katz RL, Gissen AJ. Effects of intravenous and intra-arterial procaine and lidocaine on neuromuscular transmission in man. Acta Anaesthesiol Scand Suppl. 1969;36:103-13.|Matsuo S, Rao DB, Chaudry I, Foldes FF. Interaction of muscle relaxants and local anesthetics at the neuromuscular junction. Anesth Analg. 1978 Sep-Oct;57(5):580-7.|Toft P, Kirkegaard Nielsen H, Severinsen I, Helbo-Hansen HS. Effect of epidurally administered bupivacaine on atracurium-induced neuromuscular blockade. Acta Anaesthesiol Scand. 1990 Nov;34(8):649-52.|Loyola YC, Braga Ade F, Potério GM, Sousa SR, Fernandes SC, Braga FS. [Influence of lidocaine on the neuromuscular block produced by rocuronium: study in rat phrenic-diaphragmatic nerve preparation.]. Rev Bras Anestesiol. 2006 Apr;56(2):147-56. Portuguese.|Germano Filho PA, Cavalcanti IL, Barrucand L, Verçosa N. Effect of magnesium sulphate on sugammadex reversal time for neuromuscular blockade: a randomised controlled study. Anaesthesia. 2015 Aug;70(8):956-61. doi: 10.1111/anae.12987. Epub 2015 Apr 1.","\tNeuromuscular Block\tMagnesium Sulfate|Lidocaine|Isotonic Solution|Cisatracurium\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tAll\t","Effects of Intravenous Lidocaine Associated With Magnesium Sulfate on the Cisatracurium-Induced Neuromuscular Block","Interventional","Completed","Phase 4",3,48,"NA","magnesium sulfate|lidocaine|cisatracurium","HR - M7a (Heart Rate in the Moment 7a)"]
["NCT02483611",7962740,4352630,"Mean Difference (Final Values)",72.94,"Standard Deviation",10.96,58,92,95,0.8067,"ANOVA","19919585|22260297|22183158|22778886|9301400|19468625|12229137|21334502|22752440|23635996|17042843|7743572|156513|11506113|21574968|4315659|568429|2275325|19468561|25829048","Czarnetzki C, Lysakowski C, Elia N, Tramèr MR. Time course of rocuronium-induced neuromuscular block after pre-treatment with magnesium sulphate: a randomised study. Acta Anaesthesiol Scand. 2010 Mar;54(3):299-306. doi: 10.1111/j.1399-6576.2009.02160.x. Epub 2009 Nov 16.|Czarnetzki C, Lysakowski C, Elia N, Tramèr MR. Intravenous lidocaine has no impact on rocuronium-induced neuromuscular block. Randomised study. Acta Anaesthesiol Scand. 2012 Apr;56(4):474-81. doi: 10.1111/j.1399-6576.2011.02625.x. Epub 2012 Jan 19.|Hans GA, Bosenge B, Bonhomme VL, Brichant JF, Venneman IM, Hans PC. Intravenous magnesium re-establishes neuromuscular block after spontaneous recovery from an intubating dose of rocuronium: a randomised controlled trial. Eur J Anaesthesiol. 2012 Feb;29(2):95-9. doi: 10.1097/EJA.0b013e32834e13a6.|Kim SH, So KY, Jung KT. Effect of magnesium sulfate pretreatment on onset and recovery characteristics of cisatracurium. Korean J Anesthesiol. 2012 Jun;62(6):518-23. doi: 10.4097/kjae.2012.62.6.518. Epub 2012 Jun 19.|Kussman B, Shorten G, Uppington J, Comunale ME. Administration of magnesium sulphate before rocuronium: effects on speed of onset and duration of neuromuscular block. Br J Anaesth. 1997 Jul;79(1):122-4.|Cardoso LS, Martins CR, Tardelli MA. Effects of intravenous lidocaine on the pharmacodynamics of rocuronium. Rev Bras Anestesiol. 2005 Aug;55(4):371-80. English, Portuguese.|Nonaka A, Sugawara T, Suzuki S, Masamune T, Kumazawa T. [Pretreatment with lidocaine accelerates onset of vecuronium-induced neuromuscular blockade]. Masui. 2002 Aug;51(8):880-3. Japanese.|Vivancos GG, Klamt JG, Garcia LV. Effects of 2 mg.kg-¹ of intravenous lidocaine on the latency of two different doses of rocuronium and on the hemodynamic response to orotracheal intubation. Rev Bras Anestesiol. 2011 Jan-Feb;61(1):1-12. doi: 10.1016/S0034-7094(11)70001-0.|Ghodraty MR, Saif AA, Kholdebarin AR, Rokhtabnak F, Pournajafian AR, Nikzad-Jamnani AR, Shah A, Nader ND. The effects of magnesium sulfate on neuromuscular blockade by cisatracurium during induction of anesthesia. J Anesth. 2012 Dec;26(6):858-63. doi: 10.1007/s00540-012-1439-x. Epub 2012 Jul 3.|Rotava P, Cavalcanti IL, Barrucand L, Vane LA, Verçosa N. Effects of magnesium sulphate on the pharmacodynamics of rocuronium in patients aged 60 years and older: A randomised trial. Eur J Anaesthesiol. 2013 Oct;30(10):599-604. doi: 10.1097/EJA.0b013e328361d342.|Gupta K, Vohra V, Sood J. The role of magnesium as an adjuvant during general anaesthesia. Anaesthesia. 2006 Nov;61(11):1058-63.|McCoy EP, Connolly FM, Mirakhur RK, Loan PB, Paxton LD. Nondepolarizing neuromuscular blocking drugs and train-of-four fade. Can J Anaesth. 1995 Mar;42(3):213-6.|Viby-Mogensen J, Jørgensen BC, Ording H. Residual curarization in the recovery room. Anesthesiology. 1979 Jun;50(6):539-41.|Kopman AF, Kumar S, Klewicka MM, Neuman GG. The staircase phenomenon: implications for monitoring of neuromuscular transmission. Anesthesiology. 2001 Aug;95(2):403-7.|Staals LM, Driessen JJ, Van Egmond J, De Boer HD, Klimek M, Flockton EA, Snoeck MM. Train-of-four ratio recovery often precedes twitch recovery when neuromuscular block is reversed by sugammadex. Acta Anaesthesiol Scand. 2011 Jul;55(6):700-7. doi: 10.1111/j.1399-6576.2011.02448.x. Epub 2011 May 16.|Katz RL, Gissen AJ. Effects of intravenous and intra-arterial procaine and lidocaine on neuromuscular transmission in man. Acta Anaesthesiol Scand Suppl. 1969;36:103-13.|Matsuo S, Rao DB, Chaudry I, Foldes FF. Interaction of muscle relaxants and local anesthetics at the neuromuscular junction. Anesth Analg. 1978 Sep-Oct;57(5):580-7.|Toft P, Kirkegaard Nielsen H, Severinsen I, Helbo-Hansen HS. Effect of epidurally administered bupivacaine on atracurium-induced neuromuscular blockade. Acta Anaesthesiol Scand. 1990 Nov;34(8):649-52.|Loyola YC, Braga Ade F, Potério GM, Sousa SR, Fernandes SC, Braga FS. [Influence of lidocaine on the neuromuscular block produced by rocuronium: study in rat phrenic-diaphragmatic nerve preparation.]. Rev Bras Anestesiol. 2006 Apr;56(2):147-56. Portuguese.|Germano Filho PA, Cavalcanti IL, Barrucand L, Verçosa N. Effect of magnesium sulphate on sugammadex reversal time for neuromuscular blockade: a randomised controlled study. Anaesthesia. 2015 Aug;70(8):956-61. doi: 10.1111/anae.12987. Epub 2015 Apr 1.","\tNeuromuscular Block\tMagnesium Sulfate|Lidocaine|Isotonic Solution|Cisatracurium\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tAll\t","Effects of Intravenous Lidocaine Associated With Magnesium Sulfate on the Cisatracurium-Induced Neuromuscular Block","Interventional","Completed","Phase 4",3,48,"NA","magnesium sulfate|lidocaine|cisatracurium","HR - M3 (Heart Rate in the Moment 3)"]
["NCT02483611",7962744,4352640,"Median Difference (Final Values)",67,null,"NA",56,85,95,0.0731,"Kruskal-Wallis","19919585|22260297|22183158|22778886|9301400|19468625|12229137|21334502|22752440|23635996|17042843|7743572|156513|11506113|21574968|4315659|568429|2275325|19468561|25829048","Czarnetzki C, Lysakowski C, Elia N, Tramèr MR. Time course of rocuronium-induced neuromuscular block after pre-treatment with magnesium sulphate: a randomised study. Acta Anaesthesiol Scand. 2010 Mar;54(3):299-306. doi: 10.1111/j.1399-6576.2009.02160.x. Epub 2009 Nov 16.|Czarnetzki C, Lysakowski C, Elia N, Tramèr MR. Intravenous lidocaine has no impact on rocuronium-induced neuromuscular block. Randomised study. Acta Anaesthesiol Scand. 2012 Apr;56(4):474-81. doi: 10.1111/j.1399-6576.2011.02625.x. Epub 2012 Jan 19.|Hans GA, Bosenge B, Bonhomme VL, Brichant JF, Venneman IM, Hans PC. Intravenous magnesium re-establishes neuromuscular block after spontaneous recovery from an intubating dose of rocuronium: a randomised controlled trial. Eur J Anaesthesiol. 2012 Feb;29(2):95-9. doi: 10.1097/EJA.0b013e32834e13a6.|Kim SH, So KY, Jung KT. Effect of magnesium sulfate pretreatment on onset and recovery characteristics of cisatracurium. Korean J Anesthesiol. 2012 Jun;62(6):518-23. doi: 10.4097/kjae.2012.62.6.518. Epub 2012 Jun 19.|Kussman B, Shorten G, Uppington J, Comunale ME. Administration of magnesium sulphate before rocuronium: effects on speed of onset and duration of neuromuscular block. Br J Anaesth. 1997 Jul;79(1):122-4.|Cardoso LS, Martins CR, Tardelli MA. Effects of intravenous lidocaine on the pharmacodynamics of rocuronium. Rev Bras Anestesiol. 2005 Aug;55(4):371-80. English, Portuguese.|Nonaka A, Sugawara T, Suzuki S, Masamune T, Kumazawa T. [Pretreatment with lidocaine accelerates onset of vecuronium-induced neuromuscular blockade]. Masui. 2002 Aug;51(8):880-3. Japanese.|Vivancos GG, Klamt JG, Garcia LV. Effects of 2 mg.kg-¹ of intravenous lidocaine on the latency of two different doses of rocuronium and on the hemodynamic response to orotracheal intubation. Rev Bras Anestesiol. 2011 Jan-Feb;61(1):1-12. doi: 10.1016/S0034-7094(11)70001-0.|Ghodraty MR, Saif AA, Kholdebarin AR, Rokhtabnak F, Pournajafian AR, Nikzad-Jamnani AR, Shah A, Nader ND. The effects of magnesium sulfate on neuromuscular blockade by cisatracurium during induction of anesthesia. J Anesth. 2012 Dec;26(6):858-63. doi: 10.1007/s00540-012-1439-x. Epub 2012 Jul 3.|Rotava P, Cavalcanti IL, Barrucand L, Vane LA, Verçosa N. Effects of magnesium sulphate on the pharmacodynamics of rocuronium in patients aged 60 years and older: A randomised trial. Eur J Anaesthesiol. 2013 Oct;30(10):599-604. doi: 10.1097/EJA.0b013e328361d342.|Gupta K, Vohra V, Sood J. The role of magnesium as an adjuvant during general anaesthesia. Anaesthesia. 2006 Nov;61(11):1058-63.|McCoy EP, Connolly FM, Mirakhur RK, Loan PB, Paxton LD. Nondepolarizing neuromuscular blocking drugs and train-of-four fade. Can J Anaesth. 1995 Mar;42(3):213-6.|Viby-Mogensen J, Jørgensen BC, Ording H. Residual curarization in the recovery room. Anesthesiology. 1979 Jun;50(6):539-41.|Kopman AF, Kumar S, Klewicka MM, Neuman GG. The staircase phenomenon: implications for monitoring of neuromuscular transmission. Anesthesiology. 2001 Aug;95(2):403-7.|Staals LM, Driessen JJ, Van Egmond J, De Boer HD, Klimek M, Flockton EA, Snoeck MM. Train-of-four ratio recovery often precedes twitch recovery when neuromuscular block is reversed by sugammadex. Acta Anaesthesiol Scand. 2011 Jul;55(6):700-7. doi: 10.1111/j.1399-6576.2011.02448.x. Epub 2011 May 16.|Katz RL, Gissen AJ. Effects of intravenous and intra-arterial procaine and lidocaine on neuromuscular transmission in man. Acta Anaesthesiol Scand Suppl. 1969;36:103-13.|Matsuo S, Rao DB, Chaudry I, Foldes FF. Interaction of muscle relaxants and local anesthetics at the neuromuscular junction. Anesth Analg. 1978 Sep-Oct;57(5):580-7.|Toft P, Kirkegaard Nielsen H, Severinsen I, Helbo-Hansen HS. Effect of epidurally administered bupivacaine on atracurium-induced neuromuscular blockade. Acta Anaesthesiol Scand. 1990 Nov;34(8):649-52.|Loyola YC, Braga Ade F, Potério GM, Sousa SR, Fernandes SC, Braga FS. [Influence of lidocaine on the neuromuscular block produced by rocuronium: study in rat phrenic-diaphragmatic nerve preparation.]. Rev Bras Anestesiol. 2006 Apr;56(2):147-56. Portuguese.|Germano Filho PA, Cavalcanti IL, Barrucand L, Verçosa N. Effect of magnesium sulphate on sugammadex reversal time for neuromuscular blockade: a randomised controlled study. Anaesthesia. 2015 Aug;70(8):956-61. doi: 10.1111/anae.12987. Epub 2015 Apr 1.","\tNeuromuscular Block\tMagnesium Sulfate|Lidocaine|Isotonic Solution|Cisatracurium\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tAll\t","Effects of Intravenous Lidocaine Associated With Magnesium Sulfate on the Cisatracurium-Induced Neuromuscular Block","Interventional","Completed","Phase 4",3,48,"NA","magnesium sulfate|lidocaine|cisatracurium","MAP - M5 (Mean Arterial Pressure in the Moment 5)"]
["NCT02486484","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25677668|27030277","Mansour AM, Al-Ghadban SI, Yunis MH, El-Sabban ME. Ziv-aflibercept in macular disease. Br J Ophthalmol. 2015 Aug;99(8):1055-9. doi: 10.1136/bjophthalmol-2014-306319. Epub 2015 Feb 12.|Mansour AM, Chhablani J, Antonios RS, Yogi R, Younis MH, Dakroub R, Chahine H. Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration. Br J Ophthalmol. 2016 Dec;100(12):1629-1633. doi: 10.1136/bjophthalmol-2015-308319. Epub 2016 Mar 30.","\tChoroidal Neovascularization|Cystoid Macular Edema|Diabetic Retinopathy|Macular Degeneration|Neovascularization|Recurrent Pterygium|Retinal Neovascularization|Retinal Vein Occlusion\tziv-aflibercept\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","pterygium|retinal diseases|neovascularization, pathologic|retinal vein occlusion|diabetic retinopathy|retinal neovascularization|macular degeneration|macular edema|choroidal neovascularization","NA","NA"]
["NCT02487316","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25559471,"Boi M, Zucca E, Inghirami G, Bertoni F. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas. Br J Haematol. 2015 Mar;168(6):771-83. doi: 10.1111/bjh.13265. Epub 2015 Jan 6. Review.","\tSystemic Anaplastic Large-Cell Lymphoma\tcrizotinib\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma, large-cell, anaplastic|lymphoma|lymphoma, non-hodgkin","crizotinib","NA"]
["NCT02494245","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16084807|1178004|21402330|17517569|20682071|15735997|25936730|18655723","Michael KM, Allen JK, Macko RF. Reduced ambulatory activity after stroke: the role of balance, gait, and cardiovascular fitness. Arch Phys Med Rehabil. 2005 Aug;86(8):1552-6.|Gresham GE, Fitzpatrick TE, Wolf PA, McNamara PM, Kannel WB, Dawber TR. Residual disability in survivors of stroke--the Framingham study. N Engl J Med. 1975 Nov 6;293(19):954-6.|Alzahrani MA, Ada L, Dean CM. Duration of physical activity is normal but frequency is reduced after stroke: an observational study. J Physiother. 2011;57(1):47-51. doi: 10.1016/S1836-9553(11)70007-8.|Michael K, Macko RF. Ambulatory activity intensity profiles, fitness, and fatigue in chronic stroke. Top Stroke Rehabil. 2007 Mar-Apr;14(2):5-12.|Rand D, Eng JJ, Tang PF, Hung C, Jeng JS. Daily physical activity and its contribution to the health-related quality of life of ambulatory individuals with chronic stroke. Health Qual Life Outcomes. 2010 Aug 3;8:80. doi: 10.1186/1477-7525-8-80.|Ivey FM, Macko RF, Ryan AS, Hafer-Macko CE. Cardiovascular health and fitness after stroke. Top Stroke Rehabil. 2005 Winter;12(1):1-16. Review.|Paul L, Brewster S, Wyke S, Gill JM, Alexander G, Dybus A, Rafferty D. Physical activity profiles and sedentary behaviour in people following stroke: a cross-sectional study. Disabil Rehabil. 2016;38(4):362-7. doi: 10.3109/09638288.2015.1041615. Epub 2015 May 4.|Fitzsimons CF, Baker G, Wright A, Nimmo MA, Ward Thompson C, Lowry R, Millington C, Shaw R, Fenwick E, Ogilvie D, Inchley J, Foster CE, Mutrie N. The 'Walking for Wellbeing in the West' randomised controlled trial of a pedometer-based walking programme in combination with physical activity consultation with 12 month follow-up: rationale and study design. BMC Public Health. 2008 Jul 26;8:259. doi: 10.1186/1471-2458-8-259.","\tStroke\tSTARFISH\tParallel Assignment\tSupportive Care\tRandomized\tOther\tAll\t","Increasing Physical Activity in Stroke Survivors Using STARFISH, an Interactive Mobile Phone App","Interventional","Unknown status","N/A",2,128,"stroke","NA","NA"]
["NCT02500212","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",30552587,"Kamar N, Cassuto E, Piotti G, Govoni M, Ciurlia G, Geraci S, Poli G, Nicolini G, Mariat C, Essig M, Malvezzi P, Le Meur Y, Garrigue V, Del Bello A, Rostaing L. Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study. Adv Ther. 2019 Feb;36(2):462-477. doi: 10.1007/s12325-018-0855-1. Epub 2018 Dec 14.","\tOrgan or Tissue Transplant; Complications\tENVARSUS®|ADVAGRAF®\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Pharmacokinetic Study of ENVARSUS in Adult De-novo Kidney Transplant Patients","Interventional","Completed","Phase 4",2,75,"NA","tacrolimus","NA"]
["NCT02513576","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18760163|17934967|18047460|19272785|21529357|19303579|16305872|20625667|13129420|17768574|16055882","El-Ansary D, Waddington G, Adams R. Control of separation in sternal instability by supportive devices: a comparison of an adjustable fastening brace, compression garment, and sports tape. Arch Phys Med Rehabil. 2008 Sep;89(9):1775-81. doi: 10.1016/j.apmr.2008.01.025.|El-Ansary D, Waddington G, Adams R. Relationship between pain and upper limb movement in patients with chronic sternal instability following cardiac surgery. Physiother Theory Pract. 2007 Sep-Oct;23(5):273-80.|El-Ansary D, Waddington G, Adams R. Trunk stabilisation exercises reduce sternal separation in chronic sternal instability after cardiac surgery: a randomised cross-over trial. Aust J Physiother. 2007;53(4):255-60.|Gorlitzer M, Folkmann S, Meinhart J, Poslussny P, Thalmann M, Weiss G, Bijak M, Grabenwoeger M. A newly designed thorax support vest prevents sternum instability after median sternotomy. Eur J Cardiothorac Surg. 2009 Aug;36(2):335-9; discussion 339. doi: 10.1016/j.ejcts.2009.01.038. Epub 2009 Mar 9.|Fawzy H, Osei-Tutu K, Errett L, Latter D, Bonneau D, Musgrave M, Mahoney J. Sternal plate fixation for sternal wound reconstruction: initial experience (retrospective study). J Cardiothorac Surg. 2011 Apr 29;6:63. doi: 10.1186/1749-8090-6-63.|Lepelletier D, Poupelin L, Corvec S, Bourigault C, Bizouarn P, Blanloeil Y, Reynaud A, Duveau D, Despins P. Risk factors for mortality in patients with mediastinitis after cardiac surgery. Arch Cardiovasc Dis. 2009 Feb;102(2):119-25. doi: 10.1016/j.acvd.2008.11.003. Epub 2009 Feb 3.|Cowan KN, Teague L, Sue SC, Mahoney JL. Vacuum-assisted wound closure of deep sternal infections in high-risk patients after cardiac surgery. Ann Thorac Surg. 2005 Dec;80(6):2205-12.|Costa D, Gonçalves HA, Lima LP, Ike D, Cancelliero KM, Montebelo MI. New reference values for maximal respiratory pressures in the Brazilian population. J Bras Pneumol. 2010 May-Jun;36(3):306-12. English, Portuguese. Erratum in: J Bras Pneumol. 2010 Oct;36(5):667.|Sakamoto H, Fukuda I, Oosaka M, Nakata H. Risk factors and treatment of deep sternal wound infection after cardiac operation. Ann Thorac Cardiovasc Surg. 2003 Aug;9(4):226-32.|Gelape CL. Surgical wound infection following heart surgery. Arq Bras Cardiol. 2007 Jul;89(1):e3-9. Review. English, Portuguese.|Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38.","\tCardiovascular Infections|Coronary Artery Disease|Mediastinitis\tphysiotherapy exercises\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","coronary artery disease|cardiovascular infections|mediastinitis","NA","NA"]
["NCT02515552","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24251273,"Collinge W, Yarnold P, Soltysik R. Fibromyalgia Symptom Reduction by Online Behavioral Self-monitoring, Longitudinal Single Subject Analysis and Automated Delivery of Individualized Guidance. N Am J Med Sci. 2013 Sep;5(9):546-53. doi: 10.4103/1947-2714.118920.","\tFibromyalgia\tThe Fibromyalgia Wellness Project\tNA\tNA\tNA\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","fibromyalgia|myofascial pain syndromes","NA","NA"]
["NCT02523846","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",8740614,"Macintyre PE, Jarvis DA. Age is the best predictor of postoperative morphine requirements. Pain. 1996 Feb;64(2):357-364. doi: 10.1016/0304-3959(95)00128-X.","\tPost-operative Pain\tmorphine|Patient re-education\tParallel Assignment\tTreatment\tRandomized\tDrug|Behavioral\tAll\t","Patient Re-education vs. Background Morphine to IV-PCA in Patient With Unsatisfactory Analgesia Post Laparotomy","Interventional","Unknown status","Phase 4",2,160,"pain, postoperative","morphine","NA"]
["NCT02527980","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",31058284,"Piper ME, Baker TB, Benowitz NL, Jorenby DE. Changes in Use Patterns Over 1 Year Among Smokers and Dual Users of Combustible and Electronic Cigarettes. Nicotine Tob Res. 2020 Apr 21;22(5):672-680. doi: 10.1093/ntr/ntz065. Erratum in: Nicotine Tob Res. 2020 Oct 8;22(10):1934.","\tNicotine Dependence|Smoking\tNo intervention: observation only\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","tobacco use disorder","NA","NA"]
["NCT02531295","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27977742|28842560|30031972","Cary DC, Fujinaga K, Peterlin BM. Euphorbia Kansui Reactivates Latent HIV. PLoS One. 2016 Dec 15;11(12):e0168027. doi: 10.1371/journal.pone.0168027. eCollection 2016.|Wang P, Lu P, Qu X, Shen Y, Zeng H, Zhu X, Zhu Y, Li X, Wu H, Xu J, Lu H, Ma Z, Zhu H. Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui. Sci Rep. 2017 Aug 25;7(1):9451. doi: 10.1038/s41598-017-07157-0.|Liu Q, Li W, Huang L, Asada Y, Morris-Natschke SL, Chen CH, Lee KH, Koike K. Identification, structural modification, and dichotomous effects on human immunodeficiency virus type 1 (HIV-1) replication of ingenane esters from Euphorbia kansui. Eur J Med Chem. 2018 Aug 5;156:618-627. doi: 10.1016/j.ejmech.2018.07.020. Epub 2018 Jul 19.","\tHIV|Human Immunodeficiency Virus\tEuphorbia kansui extract powder prepared as tea\tNA\tNA\tNA\tDrug\tAll\t","Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study","Interventional","Suspended","Phase 1",3,9,"hiv infections|acquired immunodeficiency syndrome","NA","NA"]
["NCT02536144","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21087902|24501724","Spada C, Hassan C, Ingrosso M, Repici A, Riccioni ME, Pennazio M, Pirozzi GA, Pagano N, Cesaro P, Spera G, Petruzziello L, Costamagna G. A new regimen of bowel preparation for PillCam colon capsule endoscopy: a pilot study. Dig Liver Dis. 2011 Apr;43(4):300-4. doi: 10.1016/j.dld.2010.10.005. Epub 2010 Nov 18.|Hagel AF, Gäbele E, Raithel M, Hagel WH, Albrecht H, de Rossi TM, Singer C, Schneider T, Neurath MF, Farnbacher MJ. Colon capsule endoscopy: detection of colonic polyps compared with conventional colonoscopy and visualization of extracolonic pathologies. Can J Gastroenterol Hepatol. 2014 Feb;28(2):77-82.","\tAbdominal Pain|Diarrhea|Hematochezia\tmagnetic-controlled capsule endoscopy system|Colonoscopy\tNA\tNA\tNA\tProcedure|Procedure\tAll\t","The Clinical Application of MCCES in Examination of Human Colon","Interventional","Unknown status","N/A",2,80,"diarrhea|gastrointestinal hemorrhage|abdominal pain","NA","NA"]
["NCT02549859",7955089,4347770,null,"NA",null,"NA",{"$nulls":3},0.05,"Paired t-test, 2 sided","25540305|29654112","Xie T, Vigil J, MacCracken E, Gasparaitis A, Young J, Kang W, Bernard J, Warnke P, Kang UJ. Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. Neurology. 2015 Jan 27;84(4):415-20. doi: 10.1212/WNL.0000000000001184. Epub 2014 Dec 24.|Xie T, Bloom L, Padmanaban M, Bertacchi B, Kang W, MacCracken E, Dachman A, Vigil J, Satzer D, Zadikoff C, Markopoulou K, Warnke P, Kang UJ. Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD. J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):989-994. doi: 10.1136/jnnp-2018-318060. Epub 2018 Apr 13.","\tParkinson's Disease\tDeep Brain Stimulation (DBS) at 60 Hz|Deep Brain Stimulation (DBS) at 130 Hz|Deep Brain Stimulation (DBS) Off (Sham)\tNA\tNA\tNA\tDevice|Device|Device\tAll\t","NA","NA","NA","NA","NA","NA","parkinson disease","NA","Unified Parkinson's Disease Rating Scale-III Total Score at Visit 2"]
["NCT02554006","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28832589,"Biscaglia S, Tonet E, Pavasini R, Serenelli M, Bugani G, Cimaglia P, Gallo F, Spitaleri G, Del Franco A, Aquila G, Vieceli Dalla Sega F, Tebaldi M, Tumscitz C, Ferrari R, Campo G. A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial. PLoS One. 2017 Aug 23;12(8):e0182124. doi: 10.1371/journal.pone.0182124. eCollection 2017.","\tHemorrhage|Myocardial Ischemia|Platelet Aggregation Inhibitors|Quality of Life\tgood clinical practice|bundle group\tParallel Assignment\tSupportive Care\tRandomized\tBehavioral|Behavioral\tAll\t","Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings","Interventional","Completed","N/A",2,448,"myocardial ischemia|ischemia|hemorrhage","NA","NA"]
["NCT02558868","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24982456,"Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, Görner M, Mölle M, Greten TF, Lakner V, Bischoff S, Sinn M, Dörken B, Pelzer U. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014 Aug 10;32(23):2423-9. doi: 10.1200/JCO.2013.53.6995. Epub 2014 Jun 30.","\tPancreatic Neoplasms\tIrinotecan|Oxaliplatin\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer","Interventional","Completed","Phase 2",2,80,"pancreatic neoplasms","irinotecan|oxaliplatin","NA"]
["NCT02564640","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17572317|16507195","Xue FS, Zhang GH, Li XY, Sun HT, Li P, Li CW, Liu KP. Comparison of hemodynamic responses to orotracheal intubation with the GlideScope videolaryngoscope and the Macintosh direct laryngoscope. J Clin Anesth. 2007 Jun;19(4):245-50.|Xue FS, Zhang GH, Li XY, Sun HT, Li P, Sun HY, Xu YC, Liu Y. Comparison of haemodynamic responses to orotracheal intubation with GlideScope videolaryngoscope and fibreoptic bronchoscope. Eur J Anaesthesiol. 2006 Jun;23(6):522-6. Epub 2006 Mar 1.","\tAnesthesia Intubation Complication\tvideolaryngoscope|Macintosh laryngoscope\tParallel Assignment\tPrevention\tRandomized\tDevice|Device\tAll\t","Comparison of Hemodynamic Changes by Using the Videolaryngoscope and the Macintosh Laryngoscope","Interventional","Completed","N/A",2,100,"NA","NA","NA"]
["NCT02565745","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|23955535|NA","Bergstrom N, Allman RM, Alvarez OM, Bennett MA, Carlson CE, Frantz RA, Garber SL, Jackson BS, Kaminski Jr MV, Kemp MG, Krouskop TA, Lewis Jr VL, Maklebust J, Margolis DJ, Marvel EM, Reger SI, Rodeheaver GT, Salcido R, Xakellis GC, Yarkony GM. Treatment of pressure ulcers. Clinical Practice Guideline, No. 15. 1994. AHCPR Publication No. 95-0652. Rockville, MD: U.S. Bergstrom, N, Braden, B, Champagne, M, Kemp, M, & Ruby, E. Predicting pressure ulcer risk: a multisite study of the predictive validity of the Braden Scale. Nursing Research, 1998;47(5):261-269.|Moore ZE, Webster J. Dressings and topical agents for preventing pressure ulcers. Cochrane Database Syst Rev. 2013 Aug 18;(8):CD009362. doi: 10.1002/14651858.CD009362.pub2. Review. Update in: Cochrane Database Syst Rev. 2018 Dec 06;12:CD009362.|McInnes E., Jammali-Blasi A., Bell-Syer S., Dumville JC., Cullum N. Support surfaces for pressure ulcer prevention (Review). The Cochrane Library. Published Online: 13 Apr 2011.http://www.thecochranelibrary.com.wiley.com/doi/10.1002.","\tPressure Ulcer\tSkin dressing|Moisturizing cream\tParallel Assignment\tPrevention\tRandomized\tCombination Product|Other\tAll\t","Skin Dressings Versus Lubrication to Prevent Pressure Ulcers: A Randomized Trial","Interventional","Terminated","Phase 3",2,689,"pressure ulcer|ulcer","NA","NA"]
["NCT02573415","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19897849|22542990|24582522|11880127|23084266|23830110|23108346|16253976|19617209|21159686|14507815|20879912|19696628|20519245|21354071|20519250|18405252|21475964|22647448|22454459|21896546|17062584|2474865|20587138|25171537|16554530","Brännström M, Wranning CA, Altchek A. Experimental uterus transplantation. Hum Reprod Update. 2010 May-Jun;16(3):329-45. doi: 10.1093/humupd/dmp049. Epub 2009 Nov 7. Review.|Brännström M, Diaz-Garcia C, Hanafy A, Olausson M, Tzakis A. Uterus transplantation: animal research and human possibilities. Fertil Steril. 2012 Jun;97(6):1269-76. doi: 10.1016/j.fertnstert.2012.04.001. Epub 2012 Apr 28. Review.|Brännström M, Johannesson L, Dahm-Kähler P, Enskog A, Mölne J, Kvarnström N, Diaz-Garcia C, Hanafy A, Lundmark C, Marcickiewicz J, Gäbel M, Groth K, Akouri R, Eklind S, Holgersson J, Tzakis A, Olausson M. First clinical uterus transplantation trial: a six-month report. Fertil Steril. 2014 May;101(5):1228-36. doi: 10.1016/j.fertnstert.2014.02.024. Epub 2014 Feb 27.|Fageeh W, Raffa H, Jabbad H, Marzouki A. Transplantation of the human uterus. Int J Gynaecol Obstet. 2002 Mar;76(3):245-51.|Ozkan O, Akar ME, Ozkan O, Erdogan O, Hadimioglu N, Yilmaz M, Gunseren F, Cincik M, Pestereli E, Kocak H, Mutlu D, Dinckan A, Gecici O, Bektas G, Suleymanlar G. Preliminary results of the first human uterus transplantation from a multiorgan donor. Fertil Steril. 2013 Feb;99(2):470-6. doi: 10.1016/j.fertnstert.2012.09.035. Epub 2012 Oct 18.|Erman Akar M, Ozkan O, Aydinuraz B, Dirican K, Cincik M, Mendilcioglu I, Simsek M, Gunseren F, Kocak H, Ciftcioglu A, Gecici O, Ozkan O. Clinical pregnancy after uterus transplantation. Fertil Steril. 2013 Nov;100(5):1358-63. doi: 10.1016/j.fertnstert.2013.06.027. Epub 2013 Jul 3.|Johannesson L, Enskog A, Mölne J, Diaz-Garcia C, Hanafy A, Dahm-Kähler P, Tekin A, Tryphonopoulos P, Morales P, Rivas K, Ruiz P, Tzakis A, Olausson M, Brännström M. Preclinical report on allogeneic uterus transplantation in non-human primates. Hum Reprod. 2013 Jan;28(1):189-98. doi: 10.1093/humrep/des381. Epub 2012 Oct 28.|El-Akouri RR, Mölne J, Groth K, Kurlberg G, Brännström M. Rejection patterns in allogeneic uterus transplantation in the mouse. Hum Reprod. 2006 Feb;21(2):436-42. Epub 2005 Oct 27.|Groth K, Akouri R, Wranning CA, Mölne J, Brännström M. Rejection of allogenic uterus transplant in the mouse: time-dependent and site-specific infiltration of leukocyte subtypes. Hum Reprod. 2009 Nov;24(11):2746-54. doi: 10.1093/humrep/dep248. Epub 2009 Jul 17.|Wranning CA, Akhi SN, Diaz-Garcia C, Brännström M. Pregnancy after syngeneic uterus transplantation and spontaneous mating in the rat. Hum Reprod. 2011 Mar;26(3):553-8. doi: 10.1093/humrep/deq358. Epub 2010 Dec 15.|Racho El-Akouri R, Kurlberg G, Brännström M. Successful uterine transplantation in the mouse: pregnancy and post-natal development of offspring. Hum Reprod. 2003 Oct;18(10):2018-23.|Díaz-García C, Akhi SN, Wallin A, Pellicer A, Brännström M. First report on fertility after allogeneic uterus transplantation. Acta Obstet Gynecol Scand. 2010 Nov;89(11):1491-4. doi: 10.3109/00016349.2010.520688. Epub 2010 Sep 30.|Avison DL, DeFaria W, Tryphonopoulos P, Tekin A, Attia GR, Takahashi H, Jin Y, Palaios E, Pararas N, Carreno MR, Santiago S, Bazer F, Ruiz P, Tzakis A. Heterotopic uterus transplantation in a swine model. Transplantation. 2009 Aug 27;88(4):465-9. doi: 10.1097/TP.0b013e3181b07666.|Wranning CA, Marcickiewicz J, Enskog A, Dahm-Kähler P, Hanafy A, Brännström M. Fertility after autologous ovine uterine-tubal-ovarian transplantation by vascular anastomosis to the external iliac vessels. Hum Reprod. 2010 Aug;25(8):1973-9. doi: 10.1093/humrep/deq130. Epub 2010 Jun 2.|Ramirez ER, Ramirez Nessetti DK, Nessetti MB, Khatamee M, Wolfson MR, Shaffer TH, Ramirez VZ, Ramirez HA. Pregnancy and outcome of uterine allotransplantation and assisted reproduction in sheep. J Minim Invasive Gynecol. 2011 Mar-Apr;18(2):238-45. doi: 10.1016/j.jmig.2010.11.006.|Enskog A, Johannesson L, Chai DC, Dahm-Kähler P, Marcickiewicz J, Nyachieo A, Mwenda JM, Brännström M. Uterus transplantation in the baboon: methodology and long-term function after auto-transplantation. Hum Reprod. 2010 Aug;25(8):1980-7. doi: 10.1093/humrep/deq109. Epub 2010 Jun 2.|Del Priore G, Schlatt S, Malanowska-Stega J. Uterus transplant techniques in primates: 10 years' experience. Exp Clin Transplant. 2008 Mar;6(1):87-94.|Kisu I, Mihara M, Banno K, Hara H, Yamamoto T, Araki J, Iida T, Hayashi Y, Moriguchi H, Aoki D. A new surgical technique of uterine auto-transplantation in cynomolgus monkey: preliminary report about two cases. Arch Gynecol Obstet. 2012 Jan;285(1):129-37. doi: 10.1007/s00404-011-1901-2. Epub 2011 Apr 8.|Mihara M, Kisu I, Hara H, Iida T, Araki J, Shim T, Narushima M, Yamamoto T, Moriguchi H, Kato Y, Tonsho M, Banno K, Aoki D, Suganuma N, Kagawa N, Takehara Y, Kato O, Koshima I. Uterine autotransplantation in cynomolgus macaques: the first case of pregnancy and delivery. Hum Reprod. 2012 Aug;27(8):2332-40. doi: 10.1093/humrep/des169. Epub 2012 May 30.|Johannesson L, Enskog A, Dahm-Kähler P, Hanafy A, Chai DC, Mwenda JM, Díaz-García C, Olausson M, Brännström M. Uterus transplantation in a non-human primate: long-term follow-up after autologous transplantation. Hum Reprod. 2012 Jun;27(6):1640-8. doi: 10.1093/humrep/des093. Epub 2012 Mar 27.|Gauthier T, Bertin F, Fourcade L, Maubon A, Saint Marcoux F, Piver P, Marquet P, Pommepuy I, Plainard X, Couquet C, Cornuejols MJ, Essig M, Aubard Y. Uterine allotransplantation in ewes using an aortocava patch. Hum Reprod. 2011 Nov;26(11):3028-36. doi: 10.1093/humrep/der288. Epub 2011 Sep 6.|Wranning CA, El-Akouri RR, Groth K, Mölne J, Parra AK, Brännström M. Rejection of the transplanted uterus is suppressed by cyclosporine A in a semi-allogeneic mouse model. Hum Reprod. 2007 Feb;22(2):372-9. Epub 2006 Oct 24.|Todo S, Demetris A, Ueda Y, Imventarza O, Cadoff E, Zeevi A, Starzl TE. Renal transplantation in baboons under FK 506. Surgery. 1989 Aug;106(2):444-50; discussion 450-1.|Han D, Berman DM, Willman M, Buchwald P, Rothen D, Kenyon NM, Kenyon NS. Choice of immunosuppression influences cytomegalovirus DNAemia in cynomolgus monkey (Macaca fascicularis) islet allograft recipients. Cell Transplant. 2010;19(12):1547-61. doi: 10.3727/096368910X513973. Epub 2010 Jun 29.|Tryphonopoulos P, Tzakis AG, Tekin A, Johannesson L, Rivas K, Morales PR, Wagner J, Mölne J, Enskog A, Diaz-Garcia C, Dahm-Kähler P, Berho M, Zimberg S, Falcone T, Ruiz P, Olausson M, Brännström M. Allogeneic uterus transplantation in baboons: surgical technique and challenges to long-term graft survival. Transplantation. 2014 Sep 15;98(5):e51-6. doi: 10.1097/TP.0000000000000322.|McKay DB, Josephson MA. Pregnancy in recipients of solid organs--effects on mother and child. N Engl J Med. 2006 Mar 23;354(12):1281-93. Review.","\tPrimary Uterine Infertility\tUterus Transplant\tNA\tNA\tNA\tProcedure\tFemale\t","NA","NA","NA","NA","NA","NA","infertility","NA","NA"]
["NCT02577289","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","6993637|18437791|9509780|8803342|1737600|2098563|2002427","Boyne PJ, James RA. Grafting of the maxillary sinus floor with autogenous marrow and bone. J Oral Surg. 1980 Aug;38(8):613-6.|Aghaloo TL, Moy PK. Which hard tissue augmentation techniques are the most successful in furnishing bony support for implant placement? Int J Oral Maxillofac Implants. 2007;22 Suppl:49-70. Review. Erratum in: Int J Oral Maxillofac Implants. 2008 Jan-Feb;23(1):56.|Fugazzotto PA, Vlassis J. Long-term success of sinus augmentation using various surgical approaches and grafting materials. Int J Oral Maxillofac Implants. 1998 Jan-Feb;13(1):52-8.|Hürzeler MB, Kirsch A, Ackermann KL, Quiñones CR. Reconstruction of the severely resorbed maxilla with dental implants in the augmented maxillary sinus: a 5-year clinical investigation. Int J Oral Maxillofac Implants. 1996 Jul-Aug;11(4):466-75.|Smiler DG, Johnson PW, Lozada JL, Misch C, Rosenlicht JL, Tatum OH Jr, Wagner JR. Sinus lift grafts and endosseous implants. Treatment of the atrophic posterior maxilla. Dent Clin North Am. 1992 Jan;36(1):151-86; discussion 187-8. Review.|Chanavaz M. Maxillary sinus: anatomy, physiology, surgery, and bone grafting related to implantology--eleven years of surgical experience (1979-1990). J Oral Implantol. 1990;16(3):199-209.|Jaffin RA, Berman CL. The excessive loss of Branemark fixtures in type IV bone: a 5-year analysis. J Periodontol. 1991 Jan;62(1):2-4.","\tAtrophied Posterior Maxillary Ridge\tEvaluation of bone quantity in open sinus lift technique with simultaneous implantation ( Nano crystalline hydroxyapatite)|Evaluation of bone quantity in open sinus lift technique with simultaneous implantation (PRF)\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","Open Sinus Lift Technique With Simultaneous Implantation Using Platelet Rich Fibrin (PRF) Versus Nano-crystalline Hydroxyapatite","Interventional","Unknown status","N/A",2,18,"atrophy","NA","NA"]
["NCT02581384","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",33305087,"Liu KX, Chen YH, Kozono D, Mak RH, Boyle PJ, Janeway KA, Mullen EA, Marcus KJ. Phase I/II Study of Stereotactic Body Radiation Therapy for Pulmonary Metastases in Pediatric Patients. Adv Radiat Oncol. 2020 Sep 23;5(6):1267-1273. doi: 10.1016/j.adro.2020.09.004. eCollection 2020 Nov-Dec.","\tClear Cell Renal Cell Carcinoma|Ewing Sarcoma|Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Nos|Osteosarcoma|Renal Tumor|Rhabdoid Tumor|Rhabdomyosarcoma|Sarcoma|Sarcoma, Ewing|Soft Tissue Sarcoma|Wilms Tumor\tStereotactic Body Radiotherapy (SBRT)\tNA\tNA\tNA\tRadiation\tAll\t","Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors","Interventional","Terminated","Phase 1/Phase 2",6,5,"rhabdomyosarcoma|neoplasm metastasis|carcinoma, renal cell|neoplasms|sarcoma, ewing|wilms tumor|neuroectodermal tumors, primitive, peripheral|sarcoma|rhabdoid tumor|osteosarcoma","NA","NA"]
["NCT02598947","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25213604,"Holmgren T, Hallgren HB, Oberg B, Adolfsson L, Johansson K. Effect of specific exercise strategy on need for surgery in patients with subacromial impingement syndrome: randomised controlled study. Br J Sports Med. 2014 Oct;48(19):1456-7. doi: 10.1136/bjsports-2014-e787rep.","\tShoulder Impingement Syndrome\tManual therapy\tParallel Assignment\tTreatment\tRandomized\tOther\tAll\t","The Effectiveness of a Treatment for Posterior Shoulder Tightness: A Feasibility Study","Interventional","Unknown status","N/A",2,60,"syndrome|rotator cuff injuries|shoulder impingement syndrome","NA","NA"]
["NCT02609425","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22910197|23371971","Cerfolio RJ, Bryant AS, Hawn MT. Technical aspects and early results of robotic esophagectomy with chest anastomosis. J Thorac Cardiovasc Surg. 2013 Jan;145(1):90-6. doi: 10.1016/j.jtcvs.2012.04.022. Epub 2012 Aug 19.|Sarkaria IS, Rizk NP, Finley DJ, Bains MS, Adusumilli PS, Huang J, Rusch VW. Combined thoracoscopic and laparoscopic robotic-assisted minimally invasive esophagectomy using a four-arm platform: experience, technique and cautions during early procedure development. Eur J Cardiothorac Surg. 2013 May;43(5):e107-15. doi: 10.1093/ejcts/ezt013. Epub 2013 Jan 30.","\tEsophageal Cancer\tStratafix PGA Suture\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT02612207","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25420178,"Lamola AA, Bhutani VK, Du L, Castillo Cuadrado M, Chen L, Shen Z, Wong RJ, Stevenson DK. Neonatal bilirubin binding capacity discerns risk of neurological dysfunction. Pediatr Res. 2015 Feb;77(2):334-9. doi: 10.1038/pr.2014.191. Epub 2014 Nov 24.","\tBilirubin-Induced Neurological Dysfunction (BIND)|Hyperbilirubinemia|Jaundice, Neonatal\tBilirubin Binding Capacity by hematofluorometry\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","hyperbilirubinemia|jaundice, neonatal|jaundice","bilirubin","NA"]
["NCT02618044","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19190606|12184547|10875990|15122609|12119661","Vela MF. Non-acid reflux: detection by multichannel intraluminal impedance and pH, clinical significance and management. Am J Gastroenterol. 2009 Feb;104(2):277-80. doi: 10.1038/ajg.2008.23. Review.|Sundbom M, Hedenström H, Gustavsson S. Duodenogastric bile reflux after gastric bypass: a cholescintigraphic study. Dig Dis Sci. 2002 Aug;47(8):1891-6.|Collard JM, Romagnoli R. Roux-en-Y jejunal loop and bile reflux. Am J Surg. 2000 Apr;179(4):298-303.|Mabrut JY, Collard JM, Romagnoli R, Gutschow C, Salizzoni M. Oesophageal and gastric bile exposure after gastroduodenal surgery with Henley's interposition or a Roux-en-Y loop. Br J Surg. 2004 May;91(5):580-5.|Barak N, Ehrenpreis ED, Harrison JR, Sitrin MD. Gastro-oesophageal reflux disease in obesity: pathophysiological and therapeutic considerations. Obes Rev. 2002 Feb;3(1):9-15. Review.","\tGastroesophageal Reflux|Obesity\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","gastroesophageal reflux","NA","NA"]
["NCT02622191","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26550975,"Zangalli CS, Ahmed OM, Waisbourd M, H Ali M, Cvintal V, Affel E, Gupta L, Katz LJ, C Sergott R. Segmental Analysis of Macular Layers in Patients With Unilateral Primary Open-Angle Glaucoma. J Glaucoma. 2016 Apr;25(4):e401-7. doi: 10.1097/IJG.0000000000000336.","\tGlaucoma\tSpectral domain Optical Coherence Tomography\tParallel Assignment\tDiagnostic\tRandomized\tDevice\tAll\t","Analysis of the Eye in Patients With Primary Open-Angle Glaucoma and a Visual Field Defect in One Eye","Interventional","Completed","N/A",2,"NA","glaucoma|glaucoma, open-angle","NA","NA"]
["NCT02627638","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29728845,"Steel A, Tricou C, Monsarrat T, Ruer M, Deslandes C, Sisoix C, Filbet M. The perceptions and experiences of osteopathic treatment among cancer patients in palliative care: a qualitative study. Support Care Cancer. 2018 Oct;26(10):3627-3633. doi: 10.1007/s00520-018-4233-y. Epub 2018 May 4.","\tCancer Patients\tOstheopathic treatment\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT02634216","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22701284|12065146","Hiraganahalli BD, Chinampudur VC, Dethe S, Mundkinajeddu D, Pandre MK, Balachandran J, Agarwal A. Hepatoprotective and antioxidant activity of standardized herbal extracts. Pharmacogn Mag. 2012 Apr;8(30):116-23. doi: 10.4103/0973-1296.96553.|Sabu MC, Kuttan R. Anti-diabetic activity of medicinal plants and its relationship with their antioxidant property. J Ethnopharmacol. 2002 Jul;81(2):155-60.","\tType I Diabetes\tCapros\tNA\tNA\tNA\tDietary Supplement\tAll\t","NA","NA","NA","NA","NA","NA","diabetes mellitus|diabetes mellitus, type 1","NA","NA"]
["NCT02639845","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26358235,"Eaton AM, Gordon GM, Konowal A, Allen A, Allen M, Sgarlata A, Gao G, Wafapoor H, Avery RL. A novel eye drop application monitor to assess patient compliance with a prescribed regimen: a pilot study. Eye (Lond). 2015 Oct;29(10):1383-91. doi: 10.1038/eye.2015.155. Epub 2015 Sep 11.","\tAny Condition That Requires Ophthalmic Drops|Cataracts|Glaucoma|Retina Surgery\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","cataract","NA","NA"]
["NCT02644538","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23518903|15014185|19729084|19187608|22436845|23046671|21182232|21701902|24915612","Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, Kapprell HP, Rothe V, Popescu M, Brunetto MR. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int. 2013 Mar;7(1):88-97. doi: 10.1007/s12072-012-9343-x. Epub 2012 Mar 23.|Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004 Mar 11;350(11):1118-29. Review. Erratum in: N Engl J Med. 2004 Sep 16;351(12):351.|Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y. Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009 Nov 5;27(47):6550-7. doi: 10.1016/j.vaccine.2009.08.048. Epub 2009 Sep 1.|Lu FM, Zhuang H. Management of hepatitis B in China. Chin Med J (Engl). 2009 Jan 5;122(1):3-4.|European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012 Jul;57(1):167-85. doi: 10.1016/j.jhep.2012.02.010. Epub 2012 Mar 20. Erratum in: J Hepatol. 2013 Jan;58(1):201. Janssen, Harry [corrected to Janssen, Harry L A].|Micco L, Peppa D, Loggi E, Schurich A, Jefferson L, Cursaro C, Panno AM, Bernardi M, Brander C, Bihl F, Andreone P, Maini MK. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol. 2013 Feb;58(2):225-33. doi: 10.1016/j.jhep.2012.09.029. Epub 2012 Oct 6.|Chen J, Wang Y, Wu XJ, Li J, Hou FQ, Wang GQ. Pegylated interferon α-2b up-regulates specific CD8+ T cells in patients with chronic hepatitis B. World J Gastroenterol. 2010 Dec 28;16(48):6145-50.|Piratvisuth T, Marcellin P, Popescu M, Kapprell HP, Rothe V, Lu ZM. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int. 2013 Jun;7(2):429-36. doi: 10.1007/s12072-011-9280-0. Epub 2011 Jun 24.|Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol. 2014 Oct;61(4):777-84. doi: 10.1016/j.jhep.2014.05.044. Epub 2014 Jun 7.","\tHepatitis B\tPegIFN alfa-2a\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides","Interventional","Unknown status","Phase 4",2,196,"hepatitis b","peginterferon alfa-2a","NA"]
["NCT02645903","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22286518,"Abdallah FW, Chan VW, Brull R. Transversus abdominis plane block: a systematic review. Reg Anesth Pain Med. 2012 Mar-Apr;37(2):193-209. doi: 10.1097/AAP.0b013e3182429531. Review.","\tAcute Pain\tTransversus Abdominis Plane Block|standard general anesthesia\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Transversus Abdominis Plane Block for Postoperative Analgesia in Living Donor Hepatectomy","Interventional","Completed","Phase 4",2,50,"acute pain","morphine","NA"]
["NCT02662972","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",31342515,"Crespi J, Bratbak D, Dodick DW, Matharu M, Jamtøy KA, Tronvik E. Pilot Study of Injection of OnabotulinumtoxinA Toward the Sphenopalatine Ganglion for the Treatment of Classical Trigeminal Neuralgia. Headache. 2019 Sep;59(8):1229-1239. doi: 10.1111/head.13608. Epub 2019 Jul 25.","\tHeadache Disorders|Trigeminal Neuralgia\tBotulinum Toxin Type A\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","neuralgia|headache disorders|trigeminal neuralgia|ganglion cysts|headache","abobotulinumtoxina|botulinum toxins|botulinum toxins, type a","NA"]
["NCT02665390","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22413004,"Yamauchi Y, Izumi Y, Hashimoto K, Yashiro H, Inoue M, Nakatsuka S, Goto T, Anraku M, Ohtsuka T, Kohno M, Kawamura M, Nomori H. Percutaneous cryoablation for the treatment of medically inoperable stage I non-small cell lung cancer. PLoS One. 2012;7(3):e33223. doi: 10.1371/journal.pone.0033223. Epub 2012 Mar 8.","\tLung Cancer\tPercutaneous cryoablation\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms","NA","NA"]
["NCT02672891","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",7717779,"Schmidt J, Hotz HG, Foitzik T, Ryschich E, Buhr HJ, Warshaw AL, Herfarth C, Klar E. Intravenous contrast medium aggravates the impairment of pancreatic microcirculation in necrotizing pancreatitis in the rat. Ann Surg. 1995 Mar;221(3):257-64.","\tPostpartum Hemorrhage\tcondom balloon catheter\tNA\tNA\tNA\tDevice\tFemale\t","NA","NA","NA","NA","NA","NA","hemorrhage|postpartum hemorrhage","NA","NA"]
["NCT02680392","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25468584|26079800|20551021|25041873|24121608","Patterson ME, Bland KS, Thomas LC, Elliott CE, Soberon JR Jr, Nossaman BD, Osteen K. The adductor canal block provides effective analgesia similar to a femoral nerve block in patients undergoing total knee arthroplasty--a retrospective study. J Clin Anesth. 2015 Feb;27(1):39-44. doi: 10.1016/j.jclinane.2014.08.005. Epub 2014 Nov 22.|Machi AT, Sztain JF, Kormylo NJ, Madison SJ, Abramson WB, Monahan AM, Khatibi B, Ball ST, Gonzales FB, Sessler DI, Mascha EJ, You J, Nakanote KA, Ilfeld BM. Discharge Readiness after Tricompartment Knee Arthroplasty: Adductor Canal versus Femoral Continuous Nerve Blocks-A Dual-center, Randomized Trial. Anesthesiology. 2015 Aug;123(2):444-56. doi: 10.1097/ALN.0000000000000741.|Carli F, Clemente A, Asenjo JF, Kim DJ, Mistraletti G, Gomarasca M, Morabito A, Tanzer M. Analgesia and functional outcome after total knee arthroplasty: periarticular infiltration vs continuous femoral nerve block. Br J Anaesth. 2010 Aug;105(2):185-95. doi: 10.1093/bja/aeq112. Epub 2010 Jun 14.|Shah NA, Jain NP. Is continuous adductor canal block better than continuous femoral nerve block after total knee arthroplasty? Effect on ambulation ability, early functional recovery and pain control: a randomized controlled trial. J Arthroplasty. 2014 Nov;29(11):2224-9. doi: 10.1016/j.arth.2014.06.010. Epub 2014 Jun 19.|Jæger P, Zaric D, Fomsgaard JS, Hilsted KL, Bjerregaard J, Gyrn J, Mathiesen O, Larsen TK, Dahl JB. Adductor canal block versus femoral nerve block for analgesia after total knee arthroplasty: a randomized, double-blind study. Reg Anesth Pain Med. 2013 Nov-Dec;38(6):526-32. doi: 10.1097/AAP.0000000000000015.","\tOsteoarthritis, Knee\tPulsed and Continuous Radiofrequency|Continuous Adductor Canal Block\tParallel Assignment\tTreatment\tRandomized\tProcedure|Drug\tAll\t","Functional Outcome and Analgesia in TKA: Radiofrequency vs Continuous Adductor Canal Block","Interventional","Unknown status","N/A",2,40,"osteoarthritis, knee","NA","NA"]
["NCT02684812","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23680226,"Germans MR, Post R, Coert BA, Rinkel GJ, Vandertop WP, Verbaan D. Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials. 2013 May 16;14:143. doi: 10.1186/1745-6215-14-143.","\tSubarachnoid Hemorrhage\tTranexamic Acid\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Ultra-early Tranexamic Acid After Subarachnoid Hemorrhage.","Interventional","Completed","Phase 2/Phase 3",2,955,"hemorrhage|subarachnoid hemorrhage","tranexamic acid","NA"]
["NCT02688010","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","9836852|19171620|18034183|23913547","Noise: a hazard for the fetus and newborn. American Academy of Pediatrics. Committee on Environmental Health. Pediatrics. 1997 Oct;100(4):724-7.|Lasky RE, Williams AL. Noise and light exposures for extremely low birth weight newborns during their stay in the neonatal intensive care unit. Pediatrics. 2009 Feb;123(2):540-6. doi: 10.1542/peds.2007-3418.|Laudert S, Liu WF, Blackington S, Perkins B, Martin S, Macmillan-York E, Graven S, Handyside J; NIC/Q 2005 Physical Environment Exploratory Group. Implementing potentially better practices to support the neurodevelopment of infants in the NICU. J Perinatol. 2007 Dec;27 Suppl 2:S75-93.|Morag I, Ohlsson A. Cycled light in the intensive care unit for preterm and low birth weight infants. Cochrane Database Syst Rev. 2013 Aug 3;(8):CD006982. doi: 10.1002/14651858.CD006982.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;8:CD006982.","\tPreterm Infants\tNoise reduction and cycled light\tParallel Assignment\tSupportive Care\tRandomized\tBehavioral\tAll\t","Effect of Reduced Noise Levels and Cycled Light on Visual and Neural Development in Preterm Infants","Interventional","Completed","N/A",2,109,"premature birth","NA","NA"]
["NCT02692625","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15286119|15286120|14242024|21454978|21309653|23293413|23342560","Kidd EA, Fejerskov O. What constitutes dental caries? Histopathology of carious enamel and dentin related to the action of cariogenic biofilms. J Dent Res. 2004;83 Spec No C:C35-8. Review.|Featherstone JD. The continuum of dental caries--evidence for a dynamic disease process. J Dent Res. 2004;83 Spec No C:C39-42. Review.|LILLY DM, STILLWELL RH. PROBIOTICS: GROWTH-PROMOTING FACTORS PRODUCED BY MICROORGANISMS. Science. 1965 Feb 12;147(3659):747-8.|Aminabadi NA, Erfanparast L, Ebrahimi A, Oskouei SG. Effect of chlorhexidine pretreatment on the stability of salivary lactobacilli probiotic in six- to twelve-year-old children: a randomized controlled trial. Caries Res. 2011;45(2):148-54. doi: 10.1159/000325741. Epub 2011 Mar 31.|Cildir SK, Sandalli N, Nazli S, Alp F, Caglar E. A novel delivery system of probiotic drop and its effect on dental caries risk factors in cleft lip/palate children. Cleft Palate Craniofac J. 2012 May;49(3):369-72. doi: 10.1597/10-035. Epub 2011 Feb 10.|Sudhir R, Praveen P, Anantharaj A, Venkataraghavan K. Assessment of the effect of probiotic curd consumption on salivary pH and streptococcus mutans counts. Niger Med J. 2012 Jul;53(3):135-9. doi: 10.4103/0300-1652.104382.|Juneja A, Kakade A. Evaluating the effect of probiotic containing milk on salivary mutans streptococci levels. J Clin Pediatr Dent. 2012 Fall;37(1):9-14.","\tDental Caries\t(L. reuteri Prodentis®).|Placebo lozenges\tParallel Assignment\tPrevention\tRandomized\tDietary Supplement|Dietary Supplement\tAll\t","Consumption Effect of Probiotic Products on Salivary Cariogenic Bacterial Counts in Preschool Children.","Interventional","Unknown status","Phase 4",2,160,"dental caries","NA","NA"]
["NCT02696733","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21655015,"Thallaj A, Rabah D. Efficacy of ultrasound-guided obturator nerve block in transurethral surgery. Saudi J Anaesth. 2011 Jan;5(1):42-4. doi: 10.4103/1658-354X.76507.","\tNerve Block|Transurethral Resection|Urinary Bladder Neoplasms\tUltrasound|lidocaine 2%|0.9% Natrium Chloratum with a 2nd generation cephalosporin\tNA\tNA\tNA\tDevice|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","urinary bladder neoplasms","cephalosporins|lidocaine","NA"]
["NCT02704585","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21091987,"Baquero H, Alviz R, Castillo A, Neira F, Sola A. Avoiding hyperoxemia during neonatal resuscitation: time to response of different SpO2 monitors. Acta Paediatr. 2011 Apr;100(4):515-8. doi: 10.1111/j.1651-2227.2010.02097.x. Epub 2011 Jan 17.","\tHypoxia\tNellcor|Masimo\tParallel Assignment\tDiagnostic\tRandomized\tDevice|Device\tAll\t","Comparison of Two Pulse Oximeters in Delivery Room","Interventional","Unknown status","N/A",2,100,"hypoxia","NA","NA"]
["NCT02712476","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23237936|17511554|26445777|3117392|6415245|10961491|10961490|23354336|18073543|6802937|11818776|17122580","Bebawy JF, Ramaiah VK, Zeeni C, Hemmer LB, Koht A, Gupta DK. The effect of furosemide on intravascular volume status and electrolytes in patients receiving mannitol: an intraoperative safety analysis. J Neurosurg Anesthesiol. 2013 Jan;25(1):51-4. doi: 10.1097/ANA.0b013e318269c335.|Brain Trauma Foundation; American Association of Neurological Surgeons; Congress of Neurological Surgeons; Joint Section on Neurotrauma and Critical Care, AANS/CNS, Bratton SL, Chestnut RM, Ghajar J, McConnell Hammond FF, Harris OA, Hartl R, Manley GT, Nemecek A, Newell DW, Rosenthal G, Schouten J, Shutter L, Timmons SD, Ullman JS, Videtta W, Wilberger JE, Wright DW. Guidelines for the management of severe traumatic brain injury. XV. Steroids. J Neurotrauma. 2007;24 Suppl 1:S91-5. Erratum in: J Neurotrauma. 2008 Mar;25(3):276-8. multiple author names added.|Li Q, Chen H, Hao JJ, Yin NN, Xu M, Zhou JX. Agreement of measured and calculated serum osmolality during the infusion of mannitol or hypertonic saline in patients after craniotomy: a prospective, double-blinded, randomised controlled trial. BMC Anesthesiol. 2015 Oct 7;15:138. doi: 10.1186/s12871-015-0119-4.|Manninen PH, Lam AM, Gelb AW, Brown SC. The effect of high-dose mannitol on serum and urine electrolytes and osmolality in neurosurgical patients. Can J Anaesth. 1987 Sep;34(5):442-6. Review.|Pollay M, Fullenwider C, Roberts PA, Stevens FA. Effect of mannitol and furosemide on blood-brain osmotic gradient and intracranial pressure. J Neurosurg. 1983 Dec;59(6):945-50.|Procaccio F, Stocchetti N, Citerio G, Berardino M, Beretta L, Della Corte F, D'Avella D, Brambilla GL, Delfini R, Servadei F, Tomei G. Guidelines for the treatment of adults with severe head trauma (part II). Criteria for medical treatment. J Neurosurg Sci. 2000 Mar;44(1):11-8.|Procaccio F, Stocchetti N, Citerio G, Berardino M, Beretta L, Della Corte F, D'Avella D, Brambilla GL, Delfini R, Servadei F, Tomei G. Guidelines for the treatment of adults with severe head trauma (part I). Initial assessment; evaluation and pre-hospital treatment; current criteria for hospital admission; systemic and cerebral monitoring. J Neurosurg Sci. 2000 Mar;44(1):1-10.|Quentin C, Charbonneau S, Moumdjian R, Lallo A, Bouthilier A, Fournier-Gosselin MP, Bojanowski M, Ruel M, Sylvestre MP, Girard F. A comparison of two doses of mannitol on brain relaxation during supratentorial brain tumor craniotomy: a randomized trial. Anesth Analg. 2013 Apr;116(4):862-8. doi: 10.1213/ANE.0b013e318282dc70. Epub 2013 Jan 25.|Rozet I, Tontisirin N, Muangman S, Vavilala MS, Souter MJ, Lee LA, Kincaid MS, Britz GW, Lam AM. Effect of equiosmolar solutions of mannitol versus hypertonic saline on intraoperative brain relaxation and electrolyte balance. Anesthesiology. 2007 Nov;107(5):697-704.|Schettini A, Stahurski B, Young HF. Osmotic and osmotic-loop diuresis in brain surgery. Effects on plasma and CSF electrolytes and ion excretion. J Neurosurg. 1982 May;56(5):679-84.|Thenuwara K, Todd MM, Brian JE Jr. Effect of mannitol and furosemide on plasma osmolality and brain water. Anesthesiology. 2002 Feb;96(2):416-21.|Todd MM, Cutkomp J, Brian JE. Influence of mannitol and furosemide, alone and in combination, on brain water content after fluid percussion injury. Anesthesiology. 2006 Dec;105(6):1176-81.","\tBrain Tumors\tmannitol|Furosemide|placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","Brain Relaxation With Mannitol and Furosemide","Interventional","Completed","N/A",2,47,"brain neoplasms","furosemide|mannitol","NA"]
["NCT02714283",7938817,4339418,"Hazard Ratio (HR)",1.02,null,"NA",0.8,1.32,95,0.87,"Regression, Cox",31000676,"Henkle E, Curtis JR, Chen L, Chan B, Aksamit TR, Daley CL, Griffith DE, Winthrop KL. Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. Eur Respir J. 2019 Jul 18;54(1). pii: 1801896. doi: 10.1183/13993003.01896-2018. Print 2019 Jul.","\tBronchiectasis\tinhaled corticosteroid therapy|macrolide therapy\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","bronchiectasis","azithromycin|erythromycin","Hip Fracture"]
["NCT02716181","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25345257,"Jirabundansuk P, Ophaswongse S, Udompataikul M. Comparative trial of moisturizer containing spent grain wax, Butyrospermum parkii extract, Argania spinosa kernel oil vs. 1% hydrocortisone cream in the treatment of childhood atopic dermatitis. J Med Assoc Thai. 2014 Aug;97(8):820-6.","\tAtopic Dermatitis\t\"Атопик Soothing Cream\"\"|Placebo\"","Parallel Assignment","Treatment","Randomized","Device|Device","All","\tEfficacy of the \"\"Атопик Soothing Cream\"\" in Children With Mild to Moderate Atopic Dermatitis\"","Interventional","Completed","N/A",4,74,"eczema|dermatitis, atopic|dermatitis","NA","NA"]
["NCT02718378","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24932461|18464023","Phillips I, Shah SI, Duong T, Abel P, Langley RE. Androgen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer. Oncol Hematol Rev. 2014 Spring;10(1):42-47.|Coelingh Bennink HJ, Holinka CF, Diczfalusy E. Estetrol review: profile and potential clinical applications. Climacteric. 2008;11 Suppl 1:47-58. doi: 10.1080/13697130802073425. Review.","\tProstatic Neoplasms\testetrol|placebo\tParallel Assignment\tBasic Science\tRandomized\tDrug|Drug\tMale\t","Evaluation of Safety and Efficacy of Estetrol in Healthy Men","Interventional","Completed","Phase 1",4,45,"prostatic neoplasms","NA","NA"]
["NCT02724865","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15187032,"Hoekema A, Stegenga B, De Bont LG. Efficacy and co-morbidity of oral appliances in the treatment of obstructive sleep apnea-hypopnea: a systematic review. Crit Rev Oral Biol Med. 2004 Jun 4;15(3):137-55. Review.","\tObstructive Sleep Apnea\tSomnodent® (Oral appliance therapy)|Herbst® (Oral appliance therapy)\tParallel Assignment\tTreatment\tRandomized\tDevice|Device\tAll\t","Somnodent vs Herbst in Mild and Moderate OSA Patients","Interventional","Unknown status","Phase 4",2,140,"sleep apnea, obstructive","NA","NA"]
["NCT02727855","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22461716|19819004|7148820","Ali M, Lopez AL, You YA, Kim YE, Sah B, Maskery B, Clemens J. The global burden of cholera. Bull World Health Organ. 2012 Mar 1;90(3):209-218A. doi: 10.2471/BLT.11.093427. Epub 2012 Jan 24.|Sur D, Lopez AL, Kanungo S, Paisley A, Manna B, Ali M, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Rao R, Nguyen TV, Donner A, Ganguly NK, Nair GB, Bhattacharya SK, Clemens JD. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet. 2009 Nov 14;374(9702):1694-702. doi: 10.1016/S0140-6736(09)61297-6. Epub 2009 Oct 8. Erratum in: Lancet. 2010 Oct 23;376(9750):1392.|Glass RI, Becker S, Huq MI, Stoll BJ, Khan MU, Merson MH, Lee JV, Black RE. Endemic cholera in rural Bangladesh, 1966-1980. Am J Epidemiol. 1982 Dec;116(6):959-70.","\tCholera\tShanchol\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","cholera","NA","NA"]
["NCT02734654","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26088589,"García-de-la-Asunción J, García-del-Olmo E, Perez-Griera J, Martí F, Galan G, Morcillo A, Wins R, Guijarro R, Arnau A, Sarriá B, García-Raimundo M, Belda J. Oxidative lung injury correlates with one-lung ventilation time during pulmonary lobectomy: a study of exhaled breath condensate and blood. Eur J Cardiothorac Surg. 2015 Sep;48(3):e37-44. doi: 10.1093/ejcts/ezv207. Epub 2015 Jun 18.","\tAcute Lung Injury\tremote ischemic preconditioning (RIPC)\tParallel Assignment\tPrevention\tRandomized\tProcedure\tAll\t","Limb RIPC in Patients Undergoing Lung Lobectomy. Study of Oxidative Lung Damage","Interventional","Completed","N/A",2,53,"lung injury|acute lung injury|respiratory distress syndrome, adult","NA","NA"]
["NCT02736812","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21332727|21112053|18090009|25816119|25647203|26002260|26680132|17109736","de Biasi AR, Stansbury LG, Dutton RP, Stein DM, Scalea TM, Hess JR. Blood product use in trauma resuscitation: plasma deficit versus plasma ratio as predictors of mortality in trauma (CME). Transfusion. 2011 Sep;51(9):1925-32. doi: 10.1111/j.1537-2995.2010.03050.x. Epub 2011 Feb 18.|Floccard B, Rugeri L, Faure A, Saint Denis M, Boyle EM, Peguet O, Levrat A, Guillaume C, Marcotte G, Vulliez A, Hautin E, David JS, Négrier C, Allaouchiche B. Early coagulopathy in trauma patients: an on-scene and hospital admission study. Injury. 2012 Jan;43(1):26-32. doi: 10.1016/j.injury.2010.11.003. Epub 2010 Nov 26.|Borgman MA, Spinella PC, Perkins JG, Grathwohl KW, Repine T, Beekley AC, Sebesta J, Jenkins D, Wade CE, Holcomb JB. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma. 2007 Oct;63(4):805-13.|Peltan ID, Vande Vusse LK, Maier RV, Watkins TR. An International Normalized Ratio-Based Definition of Acute Traumatic Coagulopathy Is Associated With Mortality, Venous Thromboembolism, and Multiple Organ Failure After Injury. Crit Care Med. 2015 Jul;43(7):1429-38. doi: 10.1097/CCM.0000000000000981.|Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, del Junco DJ, Brasel KJ, Bulger EM, Callcut RA, Cohen MJ, Cotton BA, Fabian TC, Inaba K, Kerby JD, Muskat P, O'Keeffe T, Rizoli S, Robinson BR, Scalea TM, Schreiber MA, Stein DM, Weinberg JA, Callum JL, Hess JR, Matijevic N, Miller CN, Pittet JF, Hoyt DB, Pearson GD, Leroux B, van Belle G; PROPPR Study Group. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015 Feb 3;313(5):471-82. doi: 10.1001/jama.2015.12.|Sunde GA, Vikenes B, Strandenes G, Flo KC, Hervig TA, Kristoffersen EK, Heltne JK. Freeze dried plasma and fresh red blood cells for civilian prehospital hemorrhagic shock resuscitation. J Trauma Acute Care Surg. 2015 Jun;78(6 Suppl 1):S26-30. doi: 10.1097/TA.0000000000000633.|Moore HB, Moore EE, Morton AP, Gonzalez E, Fragoso M, Chapman MP, Dzieciatkowska M, Hansen KC, Banerjee A, Sauaia A, Silliman CC. Shock-induced systemic hyperfibrinolysis is attenuated by plasma-first resuscitation. J Trauma Acute Care Surg. 2015 Dec;79(6):897-903; discussion 903-4. doi: 10.1097/TA.0000000000000792.|Rugeri L, Levrat A, David JS, Delecroix E, Floccard B, Gros A, Allaouchiche B, Negrier C. Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. J Thromb Haemost. 2007 Feb;5(2):289-95. Epub 2006 Nov 16.","\tShock Hemorrhagic\tFrench Lyophilized Plasma|Normale Saline Solution\tParallel Assignment\tTreatment\tRandomized\tBiological|Biological\tAll\t","Pre-hospital Administration of Lyophilized Plasma for Post-traumatic Coagulopathy Treatment (PREHO-PLYO)","Interventional","Completed","Phase 3",2,140,"shock|shock, hemorrhagic|hemostatic disorders|blood coagulation disorders","NA","NA"]
["NCT02748447","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19299799|16598294|19595375|26144575","Kurth CD, McCann JC, Wu J, Miles L, Loepke AW. Cerebral oxygen saturation-time threshold for hypoxic-ischemic injury in piglets. Anesth Analg. 2009 Apr;108(4):1268-77. doi: 10.1213/ane.0b013e318196ac8e.|Laptook AR, Salhab W, Allen J, Saha S, Walsh M. Pulse oximetry in very low birth weight infants: can oxygen saturation be maintained in the desired range? J Perinatol. 2006 Jun;26(6):337-41.|Claure N, D'Ugard C, Bancalari E. Automated adjustment of inspired oxygen in preterm infants with frequent fluctuations in oxygenation: a pilot clinical trial. J Pediatr. 2009 Nov;155(5):640-5.e1-2. doi: 10.1016/j.jpeds.2009.04.057.|van Kaam AH, Hummler HD, Wilinska M, Swietlinski J, Lal MK, te Pas AB, Lista G, Gupta S, Fajardo CA, Onland W, Waitz M, Warakomska M, Cavigioli F, Bancalari E, Claure N, Bachman TE. Automated versus Manual Oxygen Control with Different Saturation Targets and Modes of Respiratory Support in Preterm Infants. J Pediatr. 2015 Sep;167(3):545-50.e1-2. doi: 10.1016/j.jpeds.2015.06.012. Epub 2015 Jul 2.","\tCerebrovascular Circulation|Premature Infants\tAutomated FiO2 adjustment\tCrossover Assignment\tSupportive Care\tRandomized\tDevice\tAll\t","Automated Adjustment of Inspired Oxygen to Maintaining Regional Cerebral Oxygenation in Preterm Infants on Respiratory Support","Interventional","Unknown status","N/A",2,60,"respiratory aspiration","NA","NA"]
["NCT02753517","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22293167|20869070|20395336|21163547|21484773","Bennink RJ, Tulchinsky M, de Graaf W, Kadry Z, van Gulik TM. Liver function testing with nuclear medicine techniques is coming of age. Semin Nucl Med. 2012 Mar;42(2):124-37. doi: 10.1053/j.semnuclmed.2011.10.003. Review.|de Graaf W, Heger M, Spruijt O, Maas A, de Bruin K, Hoekstra R, Bennink RJ, van Gulik TM. Quantitative assessment of liver function after ischemia-reperfusion injury and partial hepatectomy in rats. J Surg Res. 2012 Jan;172(1):85-94. doi: 10.1016/j.jss.2010.06.038. Epub 2010 Jul 21.|de Graaf W, Bennink RJ, Veteläinen R, van Gulik TM. Nuclear imaging techniques for the assessment of hepatic function in liver surgery and transplantation. J Nucl Med. 2010 May;51(5):742-52. doi: 10.2967/jnumed.109.069435. Epub 2010 Apr 15. Review.|de Graaf W, Häusler S, Heger M, van Ginhoven TM, van Cappellen G, Bennink RJ, Kullak-Ublick GA, Hesselmann R, van Gulik TM, Stieger B. Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green. J Hepatol. 2011 Apr;54(4):738-45. doi: 10.1016/j.jhep.2010.07.047. Epub 2010 Oct 1.|de Graaf W, van Lienden KP, van den Esschert JW, Bennink RJ, van Gulik TM. Increase in future remnant liver function after preoperative portal vein embolization. Br J Surg. 2011 Jun;98(6):825-34. doi: 10.1002/bjs.7456. Epub 2011 Apr 11.","\tHepatic Insufficiency\tHepatobiliary scintigraphy\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","liver failure|hepatic insufficiency","NA","NA"]
["NCT02755948","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26687547|26873992","Jozwik A, Habibi MS, Paras A, Zhu J, Guvenel A, Dhariwal J, Almond M, Wong EHC, Sykes A, Maybeno M, Del Rosario J, Trujillo-Torralbo MB, Mallia P, Sidney J, Peters B, Kon OM, Sette A, Johnston SL, Openshaw PJ, Chiu C. RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection. Nat Commun. 2015 Dec 21;6:10224. doi: 10.1038/ncomms10224. Erratum in: Nat Commun. 2016;7:11011.|Currie SM, Gwyer Findlay E, McFarlane AJ, Fitch PM, Böttcher B, Colegrave N, Paras A, Jozwik A, Chiu C, Schwarze J, Davidson DJ. Cathelicidins Have Direct Antiviral Activity against Respiratory Syncytial Virus In Vitro and Protective Function In Vivo in Mice and Humans. J Immunol. 2016 Mar 15;196(6):2699-710. doi: 10.4049/jimmunol.1502478. Epub 2016 Feb 12.","\tInfluenza, Human|Respiratory Syncytial Virus Infections\tRSV A Memphis 37|Influenza A/California/04/2009\tNA\tNA\tNA\tBiological|Biological\tAll\t","A Study of Protective Immunity Against RSV and Influenza in Experimental Human Challenge of Volunteers","Interventional","Recruiting","N/A",2,120,"virus diseases|respiratory syncytial virus infections|influenza, human","NA","NA"]
["NCT02760719","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23900970|25389139|26416925","Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2013 Jul 31;(7):CD006458. doi: 10.1002/14651858.CD006458.pub3. Review. Update in: Cochrane Database Syst Rev. 2017 Dec 21;12 :CD006458.|Everard ML, Hind D, Ugonna K, Freeman J, Bradburn M, Cooper CL, Cross E, Maguire C, Cantrill H, Alexander J, McNamara PS; SABRE Study Team. SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis. Thorax. 2014 Dec;69(12):1105-12. doi: 10.1136/thoraxjnl-2014-205953.|Zhang L, Mendoza-Sassi RA, Klassen TP, Wainwright C. Nebulized Hypertonic Saline for Acute Bronchiolitis: A Systematic Review. Pediatrics. 2015 Oct;136(4):687-701. doi: 10.1542/peds.2015-1914. Review. Erratum in: Pediatrics. 2016 Apr;137(4):.","\tBronchiolitis\tnebulized 3% hypertonic solution\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","The Effectiveness of Nebulized Hypertonic Saline Solution for Acute Bronchiolitis","Interventional","Terminated","Phase 2",2,100,"bronchiolitis","NA","NA"]
["NCT02771197","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17213292|19509382|12721664|18756622|19423728|19188168|15297412|17363736|19420358|18294387|17360651|11015443|21105040|19417016|16313258|19724059|20570856|19023118|17255288|17273561|19952961|12242449|15800326","Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, van Marwijk Kooy M, Wijermans P, Schouten H, Huijgens PC, van der Lelie H, Fey M, Ferrant A, Maertens J, Gratwohl A, Lowenberg B. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007 May 1;109(9):3658-66. Epub 2007 Jan 9.|Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Döhner H, Antin JH, Soiffer RJ, Cutler C. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009 Jun 10;301(22):2349-61. doi: 10.1001/jama.2009.813. Review.|Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med (Berl). 2003 May;81(5):281-7. Epub 2003 Apr 30. Review.|Chen X, Liu S, Wang L, Zhang W, Ji Y, Ma X. Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia. Cancer Biol Ther. 2008 May;7(5):622-7.|Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009 Aug 20;114(8):1537-44. doi: 10.1182/blood-2008-12-195792. Epub 2009 May 7.|Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS, Xu Y, Fan J. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009 Feb 1;15(3):971-9. doi: 10.1158/1078-0432.CCR-08-1608.|Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004 Aug 1;10(15):5094-100.|Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, Saudemont A, Quesnel B. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007 Jul 1;110(1):296-304. Epub 2007 Mar 15.|Mumprecht S, Schürch C, Schwaller J, Solenthaler M, Ochsenbein AF. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood. 2009 Aug 20;114(8):1528-36. doi: 10.1182/blood-2008-09-179697. Epub 2009 May 6.|Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer. 2008 Feb 23;8:57. doi: 10.1186/1471-2407-8-57.|Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T, Fujii S. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5. Epub 2007 Feb 21.|Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000 Oct 2;192(7):1027-34.|Shenghui Z, Yixiang H, Jianbo W, Kang Y, Laixi B, Yan Z, Xi X. Elevated frequencies of CD4⁺ CD25⁺ CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer. 2011 Sep 15;129(6):1373-81. doi: 10.1002/ijc.25791. Epub 2011 Feb 26.|Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, Foon KA, Whiteside TL, Boyiadzis M. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res. 2009 May 15;15(10):3325-32. doi: 10.1158/1078-0432.CCR-08-3010. Epub 2009 May 5.|Wang X, Zheng J, Liu J, Yao J, He Y, Li X, Yu J, Yang J, Liu Z, Huang S. Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol. 2005 Dec;75(6):468-76.|Zhou Q, Bucher C, Munger ME, Highfill SL, Tolar J, Munn DH, Levine BL, Riddle M, June CH, Vallera DA, Weigel BJ, Blazar BR. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood. 2009 Oct 29;114(18):3793-802. doi: 10.1182/blood-2009-03-208181. Epub 2009 Sep 1.|Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M, Sharpe AH, Vallera DA, Azuma M, Levine BL, June CH, Murphy WJ, Munn DH, Blazar BR. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood. 2010 Oct 7;116(14):2484-93. doi: 10.1182/blood-2010-03-275446. Epub 2010 Jun 22.|Shvets A, Chakrabarti R, Gonzalez-Quintial R, Baccala R, Theofilopoulos AN, Prud'homme GJ. Impaired negative regulation of homeostatically proliferating T cells. Blood. 2009 Jan 15;113(3):622-5. doi: 10.1182/blood-2008-03-139964. Epub 2008 Nov 20.|Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, Baccarini S, Maccari S, Ramoni C, Belardelli F, Proietti E. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):644-53.|Wrzesinski C, Paulos CM, Gattinoni L, Palmer DC, Kaiser A, Yu Z, Rosenberg SA, Restifo NP. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest. 2007 Feb;117(2):492-501.|Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA, Restifo NP. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother. 2010 Jan;33(1):1-7. doi: 10.1097/CJI.0b013e3181b88ffc.|Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002 Oct 25;298(5594):850-4. Epub 2002 Sep 19.|Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005 Apr 1;23(10):2346-57.","\tAcute Myeloid Leukemia\tFludarabine|Melphalan|Pembrolizumab\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","NA","melphalan|fludarabine|pembrolizumab","NA"]
["NCT02777034","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22948838|15932565|22241289","Spinelli A, Bazzi P, Sacchi M, Danese S, Fiorino G, Malesci A, Gentilini L, Poggioli G, Montorsi M. Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease: a case-matched analysis. J Gastrointest Surg. 2013 Jan;17(1):126-32; discussion p.132. doi: 10.1007/s11605-012-2012-5. Epub 2012 Sep 5.|Andersen J, Kehlet H. Fast track open ileo-colic resections for Crohn's disease. Colorectal Dis. 2005 Jul;7(4):394-7.|Veenhof AA, Vlug MS, van der Pas MH, Sietses C, van der Peet DL, de Lange-de Klerk ES, Bonjer HJ, Bemelman WA, Cuesta MA. Surgical stress response and postoperative immune function after laparoscopy or open surgery with fast track or standard perioperative care: a randomized trial. Ann Surg. 2012 Feb;255(2):216-21. doi: 10.1097/SLA.0b013e31824336e2.","\tCrohn's Disease\tER|UR\tNA\tNA\tNA\tOther|Other\tAll\t","Laparoscopy Combined With Enhanced Recovery Pathway","Interventional","Unknown status","N/A",2,30,"crohn disease","NA","NA"]
["NCT02782312","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21778259|15741443|24913725","Martínez-García MÁ, Soler-Cataluña JJ, Catalán-Serra P, Román-Sánchez P, Tordera MP. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest. 2012 Feb;141(2):461-468. doi: 10.1378/chest.11-0180. Epub 2011 Jul 21.|Tsang KW, Tan KC, Ho PL, Ooi GC, Ho JC, Mak J, Tipoe GL, Ko C, Yan C, Lam WK, Chan-Yeung M. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax. 2005 Mar;60(3):239-43.|Goyal V, Chang AB. Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis. Cochrane Database Syst Rev. 2014 Jun 10;(6):CD010327. doi: 10.1002/14651858.CD010327.pub2. Review.","\tBronchiectasis\tICS+LABA|routine therapy\tParallel Assignment\tTreatment\tRandomized\tDrug|Other\tAll\t","Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis","Interventional","Completed","Phase 4",2,120,"bronchiectasis","fluticasone-salmeterol drug combination","NA"]
["NCT02784613",7932850,4335844,null,"NA",null,"NA",{"$nulls":3},0.05,"t-test, 2 sided",29678557,"Goldstein SW, Winter AG, Goldstein I. Improvements to the Vulva, Vestibule, Urethral Meatus, and Vagina in Women Treated With Ospemifene for Moderate to Severe Dyspareunia: A Prospective Vulvoscopic Pilot Study. Sex Med. 2018 Jun;6(2):154-161. doi: 10.1016/j.esxm.2018.03.002. Epub 2018 Apr 18.","\tDyspareunia|Vulvovaginal Atrophy\tOspemifene\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","atrophy|dyspareunia","NA","Visible Changes to the Vulva, Vestibule and Vaginal Region on Photography"]
["NCT02790372","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",30917815,"Nakrem S, Stensvik GT, Skjong RJ, Ostaszkiewicz J. Staff experiences with implementing a case conferencing care model in nursing homes: a focus group study. BMC Health Serv Res. 2019 Mar 27;19(1):191. doi: 10.1186/s12913-019-4034-0.","\tDementia|Neurobehavioral Manifestations\tCase conferencing\tParallel Assignment\tTreatment\tRandomized\tOther\tAll\t","The Effect of Case Conferencing in Nursing Homes","Interventional","Completed","N/A",2,309,"neurobehavioral manifestations","NA","NA"]
["NCT02800200","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26610183,"Wu YT, Ke MJ, Chou YC, Chang CY, Lin CY, Li TY, Shih FM, Chen LC. Effect of radial shock wave therapy for carpal tunnel syndrome: A prospective randomized, double-blind, placebo-controlled trial. J Orthop Res. 2016 Jun;34(6):977-84. doi: 10.1002/jor.23113. Epub 2015 Dec 10.","\tCarpal Tunnel Syndrome\tPlatelet rich plasma|shock wave\tParallel Assignment\tTreatment\tRandomized\tProcedure|Device\tAll\t","The Effect of Combined PRP and ESWT for Carpal Tunnel Syndrome","Interventional","Completed","N/A",3,40,"carpal tunnel syndrome|syndrome","NA","NA"]
["NCT02801786","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",9415502,"Kashikar-Zuck S, Keefe FJ, Kornguth P, Beaupre P, Holzberg A, Delong D. Pain coping and the pain experience during mammography: a preliminary study. Pain. 1997 Nov;73(2):165-172. doi: 10.1016/S0304-3959(97)00114-0.","\tDiscomfort|Pain\tPlacebo|Lidocaine|Tamoxifen\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug|Drug\tFemale\t","TAmoxifen Versus LIdocaine Cream. A Randomized Clinical Trial for Reducing Pain and Discomfort During Mammography","Interventional","Not yet recruiting","Phase 2/Phase 3",3,450,"NA","lidocaine|tamoxifen","NA"]
["NCT02808988","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16018754|14742657|17355365|22326720|23327689|21261673","Lane N, Armitage GC, Loomer P, Hsieh S, Majumdar S, Wang HY, Jeffcoat M, Munoz T. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. J Periodontol. 2005 Jul;76(7):1113-22.|Mogi M, Otogoto J, Ota N, Togari A. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. J Dent Res. 2004 Feb;83(2):166-9.|Bostanci N, Ilgenli T, Emingil G, Afacan B, Han B, Töz H, Atilla G, Hughes FJ, Belibasakis GN. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: implications of their relative ratio. J Clin Periodontol. 2007 May;34(5):370-6. Epub 2007 Mar 13.|Babür C, Ozcan G, Cebi DU, Pervane B, Ozdemir B, Yücel A, Biri AA, Babür C. Gingival crevicular fluid levels of osteoprotegerin (OPG) in premenopausal and postmenopausal women with or without chronic periodontitis. J Dent. 2012 May;40(5):364-71. doi: 10.1016/j.jdent.2012.01.013. Epub 2012 Feb 2.|Gümüş P, Buduneli E, Bıyıkoğlu B, Aksu K, Saraç F, Nile C, Lappin D, Buduneli N. Gingival crevicular fluid, serum levels of receptor activator of nuclear factor-κB ligand, osteoprotegerin, and interleukin-17 in patients with rheumatoid arthritis and osteoporosis and with periodontal disease. J Periodontol. 2013 Nov;84(11):1627-37. doi: 10.1902/jop.2013.120595. Epub 2013 Jan 17.|Bostanci N, Saygan B, Emingil G, Atilla G, Belibasakis GN. Effect of periodontal treatment on receptor activator of NF-κB ligand and osteoprotegerin levels and relative ratio in gingival crevicular fluid. J Clin Periodontol. 2011 May;38(5):428-33. doi: 10.1111/j.1600-051X.2011.01701.x. Epub 2011 Jan 24.","\tChronic Periodontitis\tperiodontal phase 1 therapy|gingival crevicular fluid collection|zoledronic acid\tNA\tNA\tNA\tProcedure|Procedure|Other\tFemale\t","Changes of GCF Levels of RANKL and Osteoprotegerin in Postmenopausal Osteoporosis","Interventional","Completed","Phase 4",4,47,"osteoporosis|periodontitis|chronic periodontitis|osteoporosis, postmenopausal","zoledronic acid","NA"]
["NCT02811588","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",31695357,"Dreher M, Neuzeret PC, Windisch W, Martens D, Hoheisel G, Gröschel A, Woehrle H, Fetsch T, Graml A, Köhnlein T. Prevalence Of Chronic Hypercapnia In Severe Chronic Obstructive Pulmonary Disease: Data From The HOmeVent Registry. Int J Chron Obstruct Pulmon Dis. 2019 Oct 18;14:2377-2384. doi: 10.2147/COPD.S222803. eCollection 2019.","\tChronic Obstructive Pulmonary Disease\tNon-invasive ventilation\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","lung diseases|lung diseases, obstructive|pulmonary disease, chronic obstructive","NA","NA"]
["NCT02818842","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29804133,"Hurault-Delarue C, Lacroix I, Bénard-Laribière A, Montastruc JL, Pariente A, Damase-Michel C. Antidepressants during pregnancy: a French drug utilisation study in EFEMERIS cohort. Eur Arch Psychiatry Clin Neurosci. 2019 Oct;269(7):841-849. doi: 10.1007/s00406-018-0906-2. Epub 2018 May 26.","\tPregnancy\tPrimary Health Insurance Fund data|Prenatal Diagnostic Center of Toulouse University Hospital data|Mother and child protection data collection|Medicalisation Program of Information Systems data\tNA\tNA\tNA\tOther|Other|Other|Other\tFemale\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT02820246","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19573957|20434820|25039263|26000634|27236599","Hiesmayr M, Schindler K, Pernicka E, Schuh C, Schoeniger-Hekele A, Bauer P, Laviano A, Lovell AD, Mouhieddine M, Schuetz T, Schneider SM, Singer P, Pichard C, Howard P, Jonkers C, Grecu I, Ljungqvist O; NutritionDay Audit Team. Decreased food intake is a risk factor for mortality in hospitalised patients: the NutritionDay survey 2006. Clin Nutr. 2009 Oct;28(5):484-91. doi: 10.1016/j.clnu.2009.05.013. Epub 2009 Jul 1.|Schindler K, Pernicka E, Laviano A, Howard P, Schütz T, Bauer P, Grecu I, Jonkers C, Kondrup J, Ljungqvist O, Mouhieddine M, Pichard C, Singer P, Schneider S, Schuh C, Hiesmayr M; NutritionDay Audit Team. How nutritional risk is assessed and managed in European hospitals: a survey of 21,007 patients findings from the 2007-2008 cross-sectional nutritionDay survey. Clin Nutr. 2010 Oct;29(5):552-9. doi: 10.1016/j.clnu.2010.04.001.|Lainscak M, Farkas J, Frantal S, Singer P, Bauer P, Hiesmayr M, Schindler K. Self-rated health, nutritional intake and mortality in adult hospitalized patients. Eur J Clin Invest. 2014 Sep;44(9):813-24. doi: 10.1111/eci.12300.|Hiesmayr M, Frantal S, Schindler K, Themessl-Huber M, Mouhieddine M, Schuh C, Pernicka E, Schneider S, Singer P, Ljunqvist O, Pichard C, Laviano A, Kosak S, Bauer P. The Patient- And Nutrition-Derived Outcome Risk Assessment Score (PANDORA): Development of a Simple Predictive Risk Score for 30-Day In-Hospital Mortality Based on Demographics, Clinical Observation, and Nutrition. PLoS One. 2015 May 22;10(5):e0127316. doi: 10.1371/journal.pone.0127316. eCollection 2015. Erratum in: PLoS One. 2016;11(6):e0158023.|Cereda E, Klersy C, Hiesmayr M, Schindler K, Singer P, Laviano A, Caccialanza R; NutritionDay Survey Collaborators. Body mass index, age and in-hospital mortality: The NutritionDay multinational survey. Clin Nutr. 2017 Jun;36(3):839-847. doi: 10.1016/j.clnu.2016.05.001. Epub 2016 May 15.","\tMalnutrition\tnutrition\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","malnutrition","NA","NA"]
["NCT02829385","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26884585|24140268|23464465|23510598|24307987|24484722|24472472|25862517|24511038|24500024|26341920|24024839","Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016 May 1;34(13):1448-54. doi: 10.1200/JCO.2015.63.5995. Epub 2016 Feb 16.|Tabernero J, Van Cutsem E, Lakomý R, Prausová J, Ruff P, van Hazel GA, Moiseyenko VM, Ferry DR, McKendrick JJ, Soussan-Lazard K, Chevalier S, Allegra CJ. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer. 2014 Jan;50(2):320-31. doi: 10.1016/j.ejca.2013.09.013. Epub 2013 Oct 16.|Kara O, Duman BB, Kara B, Erdogan S, Parsak CK, Sakman G. Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy. Asian Pac J Cancer Prev. 2012;13(12):6397-401.|Custodio A, Barriuso J, de Castro J, Martínez-Marín V, Moreno V, Rodríguez-Salas N, Feliu J. Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives. Cancer Treat Rev. 2013 Dec;39(8):908-24. doi: 10.1016/j.ctrv.2013.02.004. Epub 2013 Mar 16. Review.|Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E. Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients. Biomed Res Int. 2013;2013:143273. doi: 10.1155/2013/143273. Epub 2013 Nov 6.|Sclafani F, Cunningham D. Bevacizumab in elderly patients with metastatic colorectal cancer. J Geriatr Oncol. 2014 Jan;5(1):78-88. doi: 10.1016/j.jgo.2013.08.006. Epub 2013 Sep 20. Review.|Naeim A, Ward PR, Wang HJ, Dichmann R, Liem AK, Chan D, Patel R, Hu EH, Tchekmedyian NS, Wainberg ZA, Hecht JR. A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer. J Geriatr Oncol. 2013 Oct;4(4):302-9. doi: 10.1016/j.jgo.2013.05.001. Epub 2013 Jun 7.|Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, Tol J, Braun HJ, Nieboer P, van der Hoeven JJ, Haasjes JG, Jansen RL, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJ, Koopman M. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015 May 9;385(9980):1843-52. doi: 10.1016/S0140-6736(14)62004-3. Epub 2015 Apr 7.|Kiss I, Bortlicek Z, Melichar B, Poprach A, Halamkova J, Vyzula R, Dusek L, Buchler T. Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma. Anticancer Res. 2014 Feb;34(2):949-54.|Kishiki T, Ohnishi H, Masaki T, Ohtsuka K, Ohkura Y, Furuse J, Watanabe T, Sugiyama M. Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS. Cancer Chemother Pharmacol. 2014 Apr;73(4):749-57. doi: 10.1007/s00280-014-2401-4. Epub 2014 Feb 6.|Peeters M, Oliner KS, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, He P, Yu H, Koukakis R, Terwey JH, Jung AS, Sidhu R, Patterson SD. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. Clin Cancer Res. 2015 Dec 15;21(24):5469-79. doi: 10.1158/1078-0432.CCR-15-0526. Epub 2015 Sep 4.|Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013 Sep 12;369(11):1023-34. doi: 10.1056/NEJMoa1305275.","\tColorectal Neoplasms\tApatinib and XELOX combined treatment group\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","apatinib","NA"]
["NCT02832765","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24890347|22172095|23101946|23052695","Ryu S, Pugh SL, Gerszten PC, Yin FF, Timmerman RD, Hitchcock YJ, Movsas B, Kanner AA, Berk LB, Followill DS, Kachnic LA. RTOG 0631 phase 2/3 study of image guided stereotactic radiosurgery for localized (1-3) spine metastases: phase 2 results. Pract Radiat Oncol. 2014 Mar-Apr;4(2):76-81. doi: 10.1016/j.prro.2013.05.001. Epub 2013 Jun 4.|Guckenberger M, Sweeney RA, Flickinger JC, Gerszten PC, Kersh R, Sheehan J, Sahgal A. Clinical practice of image-guided spine radiosurgery--results from an international research consortium. Radiat Oncol. 2011 Dec 15;6:172. doi: 10.1186/1748-717X-6-172.|Katsoulakis E, Riaz N, Cox B, Mechalakos J, Zatcky J, Bilsky M, Yamada Y. Delivering a third course of radiation to spine metastases using image-guided, intensity-modulated radiation therapy. J Neurosurg Spine. 2013 Jan;18(1):63-8. doi: 10.3171/2012.9.SPINE12433. Epub 2012 Oct 26.|Chung Y, Yoon HI, Kim JH, Nam KC, Koom WS. Is helical tomotherapy accurate and safe enough for spine stereotactic body radiotherapy? J Cancer Res Clin Oncol. 2013 Feb;139(2):243-8. doi: 10.1007/s00432-012-1321-0. Epub 2012 Oct 2.","\tVertebral Bony Metastases\tA|B|C|D\tNA\tNA\tNA\tRadiation|Radiation|Radiation|Radiation\tAll\t","Intensity-modulated Radiotherapy With Integrated-boost in Patients With Spinal Bone Metastases","Interventional","Unknown status","Phase 2",4,120,"neoplasms, second primary|neoplasm metastasis","NA","NA"]
["NCT02840916","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20821818,"Hu WL, Chang CH, Hung YC. Clinical observations on laser acupuncture in simple obesity therapy. Am J Chin Med. 2010;38(5):861-7.","\tPostpartum Weight Retention\tlaser acupuncture|sham laser acupuncture\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tFemale\t","Laser Acupuncture for Postpartum Weight Retention","Interventional","Completed","Phase 3",2,66,"body weight|gestational weight gain","NA","NA"]
["NCT02847611","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18796752|8124439|16110735|10718222|25531922","Hamilton GF, McDonald C, Chenier TC. Measurement of grip strength: validity and reliability of the sphygmomanometer and jamar grip dynamometer. J Orthop Sports Phys Ther. 1992;16(5):215-9.|Härkönen R, Harju R, Alaranta H. Accuracy of the Jamar dynamometer. J Hand Ther. 1993 Oct-Dec;6(4):259-62.|Bautmans I, Mets T. A fatigue resistance test for elderly persons based on grip strength: reliability and comparison with healthy young subjects. Aging Clin Exp Res. 2005 Jun;17(3):217-22.|Bellace JV, Healy D, Besser MP, Byron T, Hohman L. Validity of the Dexter Evaluation System's Jamar dynamometer attachment for assessment of hand grip strength in a normal population. J Hand Ther. 2000 Jan-Mar;13(1):46-51.|Martín-Ponce E, Hernández-Betancor I, González-Reimers E, Hernández-Luis R, Martínez-Riera A, Santolaria F. Prognostic value of physical function tests: hand grip strength and six-minute walking test in elderly hospitalized patients. Sci Rep. 2014 Dec 22;4:7530. doi: 10.1038/srep07530.","\tHealthy Volunteers\tDynamometer LABIN\tCrossover Assignment\tDiagnostic\tRandomized\tDevice\tAll\t","Validation of the Dynamometer LABIN","Interventional","Completed","N/A",2,30,"NA","NA","NA"]
["NCT02875639","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23741058,"WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013 Oct 15;128(16):e240-327. doi: 10.1161/CIR.0b013e31829e8776. Epub 2013 Jun 5.","\tIschemic Heart Failure\tYiqi prescription|Huoxue prescription|Buyang huanwu decoction|QISHEN YIQI DRIPPING PILLS|Placebo 1|Placebo 2\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug|Drug|Drug\tAll\t","A Clinical Research of Qi Deficiency and Blood Stasis Syndrome (Different Disease With Syndrome)","Interventional","Unknown status","Phase 2",5,180,"heart failure","NA","NA"]
["NCT02878031","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22078721|22285055","Bari A, Sadruddin S, Khan A, Khan Iu, Khan A, Lehri IA, Macleod WB, Fox MP, Thea DM, Qazi SA. Community case management of severe pneumonia with oral amoxicillin in children aged 2-59 months in Haripur district, Pakistan: a cluster randomised trial. Lancet. 2011 Nov 19;378(9805):1796-803. doi: 10.1016/S0140-6736(11)61140-9. Epub 2011 Nov 10.|Soofi S, Ahmed S, Fox MP, MacLeod WB, Thea DM, Qazi SA, Bhutta ZA. Effectiveness of community case management of severe pneumonia with oral amoxicillin in children aged 2-59 months in Matiari district, rural Pakistan: a cluster-randomised controlled trial. Lancet. 2012 Feb 25;379(9817):729-37. doi: 10.1016/S0140-6736(11)61714-5. Epub 2012 Jan 27.","\tPneumonia\tOral amoxicillin for CI pneumonia\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","pneumonia","amoxicillin","NA"]
["NCT02882880","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17165292|26329448|26225899|25633110|24635459|24235894|23953215|23115152|22480810|22467991|21837291|20194385|19548407|17323720|16553016|16052775|12841373|27474257|27426276|27422230|27354030|27025267|26897026|26758348|26527205|26285347|26215023|26022906|25859272|25512839|25416461|25363423|25283030|25191887|25004051|24942041|24923944|24864394|24843394|24596907|24392483|24269982|24247058|24168714|24110501|23756884|23643652|23427844|23385700","Landry ML, Rompré PH, Manzini C, Guitard F, de Grandmont P, Lavigne GJ. Reduction of sleep bruxism using a mandibular advancement device: an experimental controlled study. Int J Prosthodont. 2006 Nov-Dec;19(6):549-56.|Carra MC, Huynh N, Fleury B, Lavigne G. Overview on Sleep Bruxism for Sleep Medicine Clinicians. Sleep Med Clin. 2015 Sep;10(3):375-84, xvi. doi: 10.1016/j.jsmc.2015.05.005. Epub 2015 Jul 8. Review.|Mayer P, Heinzer R, Lavigne G. Sleep Bruxism in Respiratory Medicine Practice. Chest. 2016 Jan;149(1):262-71. doi: 10.1378/chest.15-0822. Epub 2016 Jan 6. Review.|Klasser GD, Rei N, Lavigne GJ. Sleep bruxism etiology: the evolution of a changing paradigm. J Can Dent Assoc. 2015;81:f2. Review.|Saito M, Yamaguchi T, Mikami S, Watanabe K, Gotouda A, Okada K, Hishikawa R, Shibuya E, Lavigne G. Temporal association between sleep apnea-hypopnea and sleep bruxism events. J Sleep Res. 2013 Nov 4. doi: 10.1111/jsr.12099. [Epub ahead of print]|Hasegawa Y, Lavigne G, Rompré P, Kato T, Urade M, Huynh N. Is there a first night effect on sleep bruxism? A sleep laboratory study. J Clin Sleep Med. 2013 Nov 15;9(11):1139-45. doi: 10.5664/jcsm.3152.|Abe S, Gagnon JF, Montplaisir JY, Postuma RB, Rompré PH, Huynh NT, Kato T, Kawano F, Lavigne GJ. Sleep bruxism and oromandibular myoclonus in rapid eye movement sleep behavior disorder: a preliminary report. Sleep Med. 2013 Oct;14(10):1024-30. doi: 10.1016/j.sleep.2013.04.021. Epub 2013 Aug 15.|Raphael KG, Sirois DA, Janal MN, Wigren PE, Dubrovsky B, Nemelivsky LV, Klausner JJ, Krieger AC, Lavigne GJ. Sleep bruxism and myofascial temporomandibular disorders: a laboratory-based polysomnographic investigation. J Am Dent Assoc. 2012 Nov;143(11):1223-31.|Carra MC, Huynh N, Lavigne G. Sleep bruxism: a comprehensive overview for the dental clinician interested in sleep medicine. Dent Clin North Am. 2012 Apr;56(2):387-413. doi: 10.1016/j.cden.2012.01.003. Review.|Nashed A, Lanfranchi P, Rompré P, Carra MC, Mayer P, Colombo R, Huynh N, Lavigne G. Sleep bruxism is associated with a rise in arterial blood pressure. Sleep. 2012 Apr 1;35(4):529-36. doi: 10.5665/sleep.1740.|Franco L, Rompre PH, de Grandmont P, Abe S, Lavigne GJ. A mandibular advancement appliance reduces pain and rhythmic masticatory muscle activity in patients with morning headache. J Orofac Pain. 2011 Summer;25(3):240-9.|Lavigne G, Palla S. Transient morning headache: recognizing the role of sleep bruxism and sleep-disordered breathing. J Am Dent Assoc. 2010 Mar;141(3):297-9.|Landry-Schönbeck A, de Grandmont P, Rompré PH, Lavigne GJ. Effect of an adjustable mandibular advancement appliance on sleep bruxism: a crossover sleep laboratory study. Int J Prosthodont. 2009 May-Jun;22(3):251-9.|Huynh NT, Rompré PH, Montplaisir JY, Manzini C, Okura K, Lavigne GJ. Comparison of various treatments for sleep bruxism using determinants of number needed to treat and effect size. Int J Prosthodont. 2006 Sep-Oct;19(5):435-41. Review.|Huynh N, Lavigne GJ, Lanfranchi PA, Montplaisir JY, de Champlain J. The effect of 2 sympatholytic medications--propranolol and clonidine--on sleep bruxism: experimental randomized controlled studies. Sleep. 2006 Mar;29(3):307-16.|Lavigne G, Kato T. Usual and unusual orofacial motor activities associated with tooth wear. Int J Prosthodont. 2005 Jul-Aug;18(4):291-2.|Miyawaki S, Lavigne GJ, Pierre M, Guitard F, Montplaisir JY, Kato T. Association between sleep bruxism, swallowing-related laryngeal movement, and sleep positions. Sleep. 2003 Jun 15;26(4):461-5.|Ohmure H, Kanematsu-Hashimoto K, Nagayama K, Taguchi H, Ido A, Tominaga K, Arakawa T, Miyawaki S. Evaluation of a Proton Pump Inhibitor for Sleep Bruxism: A Randomized Clinical Trial. J Dent Res. 2016 Dec;95(13):1479-1486. Epub 2016 Jul 29.|Cahlin BJ, Hedner J, Dahlström L. A randomised, open-label, crossover study of the dopamine agonist, pramipexole, in patients with sleep bruxism. J Sleep Res. 2017 Feb;26(1):64-72. doi: 10.1111/jsr.12440. Epub 2016 Jul 17.|Solanki N, Singh BP, Chand P, Siddharth R, Arya D, Kumar L, Tripathi S, Jivanani H, Dubey A. Effect of mandibular advancement device on sleep bruxism score and sleep quality. J Prosthet Dent. 2017 Jan;117(1):67-72. doi: 10.1016/j.prosdent.2016.04.009. Epub 2016 Jul 14.|Okura K, Shigemoto S, Suzuki Y, Noguchi N, Omoto K, Abe S, Matsuka Y. Mandibular movement during sleep bruxism associated with current tooth attrition. J Prosthodont Res. 2017 Jan;61(1):87-95. doi: 10.1016/j.jpor.2016.06.003. Epub 2016 Jun 25.|Zhou WN, Fu HY, Du YF, Sun JH, Zhang JL, Wang C, Svensson P, Wang KL. Short-term effects of repetitive transcranial magnetic stimulation on sleep bruxism - a pilot study. Int J Oral Sci. 2016 Mar 30;8(1):61-5. doi: 10.1038/ijos.2015.35.|Guaita M, Högl B. Current Treatments of Bruxism. Curr Treat Options Neurol. 2016 Feb;18(2):10. doi: 10.1007/s11940-016-0396-3.|Castrillon EE, Ou KL, Wang K, Zhang J, Zhou X, Svensson P. Sleep bruxism: an updated review of an old problem. Acta Odontol Scand. 2016 Jul;74(5):328-34. doi: 10.3109/00016357.2015.1125943. Epub 2016 Jan 12. Review.|Minakuchi H, Sogawa C, Miki H, Hara ES, Maekawa K, Sogawa N, Kitayama S, Matsuka Y, Clark GT, Kuboki T. Sleep bruxism frequency and platelet serotonin transporter activities in young adult subjects. Sleep Breath. 2016 Mar;20(1):271-6. doi: 10.1007/s11325-015-1281-0. Epub 2015 Nov 2.|Malcmacher L. Ensuring Restorative Success With Bruxism Testing. Dent Today. 2015 Jul;34(7):131-3.|Malcmacher L. Bruxism--Are You Helping or Hurting Your Patients? J N J Dent Assoc. 2015 Winter;86(1):14-6.|Kostrzewa-Janicka J, Jurkowski P, Zycinska K, Przybyłowska D, Mierzwińska-Nastalska E. Sleep-Related Breathing Disorders and Bruxism. Adv Exp Med Biol. 2015;873:9-14. doi: 10.1007/5584_2015_151. Review.|Gu W, Yang J, Zhang F, Yin X, Wei X, Wang C. Efficacy of biofeedback therapy via a mini wireless device on sleep bruxism contrasted with occlusal splint: a pilot study. J Biomed Res. 2015 Apr;29(2):160-8. doi: 10.7555/JBR.28.20130145. Epub 2014 Nov 18.|Gomes CA, El Hage Y, Amaral AP, Politti F, Biasotto-Gonzalez DA. Effects of massage therapy and occlusal splint therapy on electromyographic activity and the intensity of signs and symptoms in individuals with temporomandibular disorder and sleep bruxism: a randomized clinical trial. Chiropr Man Therap. 2014 Dec 15;22(1):43. doi: 10.1186/s12998-014-0043-6. eCollection 2014.|Stark CD, Stark RJ. Sleep and chronic daily headache. Curr Pain Headache Rep. 2015 Jan;19(1):468. doi: 10.1007/s11916-014-0468-6. Review.|Matsumoto H, Tsukiyama Y, Kuwatsuru R, Koyano K. The effect of intermittent use of occlusal splint devices on sleep bruxism: a 4-week observation with a portable electromyographic recording device. J Oral Rehabil. 2015 Apr;42(4):251-8. doi: 10.1111/joor.12251. Epub 2014 Nov 1.|Malcmacher L. Are you prescribing bruxism appliances? Dent Today. 2014 Sep;33(9):126-9.|Yamaguchi K, Ishiura Y, Tanaka S, Baba K. Influence of the rigidity of a provisional restoration supported on four immediately loaded implants in the edentulous maxilla on biomechanical bone-implant interactions under simulated bruxism conditions: a three-dimensional finite element analysis. Int J Prosthodont. 2014 Sep-Oct;27(5):442-50. doi: 10.11607/ijp.3857.|Porporatti AL, Costa YM, Conti PC, Bonjardim LR, Calderon Pdos S. Primary headaches interfere with the efficacy of temporomandibular disorders management. J Appl Oral Sci. 2015 Mar-Apr;23(2):129-34. doi: 10.1590/1678-775720130557. Epub 2014 Jul 4.|Sjoholm T, Kauko T, Kemppainen P, Rauhala E. Long-term use of occlusal appliance has impact on sleep structure. J Oral Rehabil. 2014 Nov;41(11):795-800. doi: 10.1111/joor.12201. Epub 2014 Jun 18.|Chate R. Summary of: Over-the-counter (OTC) bruxism splints available on the Internet. Br Dent J. 2014 Jun 13;216(11):642-3. doi: 10.1038/sj.bdj.2014.480.|de-la-Hoz JL. Sleep bruxism: review and update for the restorative dentist. Alpha Omegan. 2013 Spring-Summer;106(1-2):23-8. Review.|Karakis D, Dogan A, Bek B. Evaluation of the effect of two different occlusal splints on maximum occlusal force in patients with sleep bruxism: a pilot study. J Adv Prosthodont. 2014 Apr;6(2):103-8. doi: 10.4047/jap.2014.6.2.103. Epub 2014 Apr 22.|Mainieri VC, Saueressig AC, Fagondes SC, Teixeira ER, Rehm DD, Grossi ML. Analysis of the effects of a mandibular advancement device on sleep bruxism using polysomnography, the BiteStrip, the sleep assessment questionnaire, and occlusal force. Int J Prosthodont. 2014 Mar-Apr;27(2):119-26. doi: 10.11607/ijp.3675.|Sumiya M, Mizumori T, Kobayashi Y, Inano S, Yatani H. Suppression of sleep bruxism: effect of electrical stimulation of the masseter muscle triggered by heart rate elevation. Int J Prosthodont. 2014 Jan-Feb;27(1):80-6. doi: 10.11607/ijp.3330.|Huang H, Song YH, Wang JJ, Guo Q, Liu WC. Excitability of the central masticatory pathways in patients with sleep bruxism. Neurosci Lett. 2014 Jan 13;558:82-6. doi: 10.1016/j.neulet.2013.11.014. Epub 2013 Nov 20.|Saletu B, Anderer P, Saletu-Zyhlarz GM. Recent advances in sleep research. Psychiatr Danub. 2013 Dec;25(4):426-34. Review.|Lin XL, Tang SY. Sodium valproate may be a treatment for sleep bruxism. J Child Adolesc Psychopharmacol. 2013 Nov;23(9):636-7. doi: 10.1089/cap.2013.0015. Epub 2013 Oct 29.|Aqueveque P, Pino E, López R. Electrical stimulation device as possible treatment for nocturnal bruxism: preliminary results. Annu Int Conf IEEE Eng Med Biol Soc. 2013;2013:3571-3. doi: 10.1109/EMBC.2013.6610314.|Wang LF, Long H, Deng M, Xu H, Fang J, Fan Y, Bai D, Han XL. Biofeedback treatment for sleep bruxism: a systematic review. Sleep Breath. 2014 May;18(2):235-42. doi: 10.1007/s11325-013-0871-y. Epub 2013 Jun 12. Review.|Carra MC, Huynh NT, El-Khatib H, Remise C, Lavigne GJ. Sleep bruxism, snoring, and headaches in adolescents: short-term effects of a mandibular advancement appliance. Sleep Med. 2013 Jul;14(7):656-61. doi: 10.1016/j.sleep.2013.03.009. Epub 2013 May 2.|Dowd ET. Nocturnal bruxism and hypnotherapy: a case study. Int J Clin Exp Hypn. 2013;61(2):205-18. doi: 10.1080/00207144.2013.753832.|Silber MH. Sleep-related movement disorders. Continuum (Minneap Minn). 2013 Feb;19(1 Sleep Disorders):170-84. doi: 10.1212/01.CON.0000427207.13553.68. Review.","\tMigraine Headache|Sleep Bruxism|Tension Headache\tThe Luco Hybrid OSA Appliance\tNA\tNA\tNA\tDevice\tAll\t","Treatment Sleep Bruxism With the Luco Hybrid OSA Appliance","Interventional","Completed","N/A",2,51,"tension-type headache|sleep bruxism|headache|bruxism|migraine disorders","NA","NA"]
["NCT02891408",7925144,4331234,"GLSM ratio",2719,null,"NA",1994,3708,90,"NA",null,"NA","Nelson C, Weber E, Yue MS, Millward V, Qin AR, Marbury TC, et al. The Pharmacokinetics of GS-0976, an Acetyl-CoA Carboxylase (ACC) Inhibitor, in Subjects with Mild, Moderate, and Severe Hepatic Impairment [Abstract 1719]. Hepatology AASLD Abstracts 2018;68 (Suppl 1):979A-80A.","\tNonalcoholic Steatohepatitis (NASH)\tFirsocostat|Fenofibrate\tNA\tNA\tNA\tDrug|Drug\tAll\t","Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function","Interventional","Completed","Phase 1",8,74,"fatty liver|non-alcoholic fatty liver disease","fenofibrate|firsocostat","PK Parameter: Cmax of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)"]
["NCT02891408",7925145,4331237,"GLSM ratio",125,null,"NA",89,174,90,"NA",null,"NA","Nelson C, Weber E, Yue MS, Millward V, Qin AR, Marbury TC, et al. The Pharmacokinetics of GS-0976, an Acetyl-CoA Carboxylase (ACC) Inhibitor, in Subjects with Mild, Moderate, and Severe Hepatic Impairment [Abstract 1719]. Hepatology AASLD Abstracts 2018;68 (Suppl 1):979A-80A.","\tNonalcoholic Steatohepatitis (NASH)\tFirsocostat|Fenofibrate\tNA\tNA\tNA\tDrug|Drug\tAll\t","Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function","Interventional","Completed","Phase 1",8,74,"fatty liver|non-alcoholic fatty liver disease","fenofibrate|firsocostat","PK Parameter: AUCinf of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)"]
["NCT02896543","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","8874199|22070887|19449008|11453631|12354382|16951687|21658276","Laszik Z, Jansen PJ, Cummings RD, Tedder TF, McEver RP, Moore KL. P-selectin glycoprotein ligand-1 is broadly expressed in cells of myeloid, lymphoid, and dendritic lineage and in some nonhematopoietic cells. Blood. 1996 Oct 15;88(8):3010-21.|Hussain M, Javeed A, Ashraf M, Riaz A, Mushtaq MH. Aspirin may do wonders by the induction of immunological self-tolerance against autoimmune atherosclerosis. Med Hypotheses. 2012 Jan;78(1):171-3. doi: 10.1016/j.mehy.2011.10.019. Epub 2011 Nov 8.|Packard RR, Lichtman AH, Libby P. Innate and adaptive immunity in atherosclerosis. Semin Immunopathol. 2009 Jun;31(1):5-22. doi: 10.1007/s00281-009-0153-8. Epub 2009 May 16. Review.|Kieffer JD, Fuhlbrigge RC, Armerding D, Robert C, Ferenczi K, Camphausen RT, Kupper TS. Neutrophils, monocytes, and dendritic cells express the same specialized form of PSGL-1 as do skin-homing memory T cells: cutaneous lymphocyte antigen. Biochem Biophys Res Commun. 2001 Jul 20;285(3):577-87.|Schäkel K, Kannagi R, Kniep B, Goto Y, Mitsuoka C, Zwirner J, Soruri A, von Kietzell M, Rieber E. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity. 2002 Sep;17(3):289-301.|Bonasio R, Scimone ML, Schaerli P, Grabie N, Lichtman AH, von Andrian UH. Clonal deletion of thymocytes by circulating dendritic cells homing to the thymus. Nat Immunol. 2006 Oct;7(10):1092-100. Epub 2006 Sep 3. Erratum in: Nat Immunol. 2006 Nov;7(11):1234.|Yao K, Lu H, Huang R, Zhang S, Hong X, Shi H, Sun A, Qian J, Zou Y, Ge J. Changes of dendritic cells and fractalkine in type 2 diabetic patients with unstable angina pectoris: a preliminary report. Cardiovasc Diabetol. 2011 Jun 10;10:50. doi: 10.1186/1475-2840-10-50.","\tAcute Myocardial Infarction\tmeasurement\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","infarction|myocardial infarction","NA","NA"]
["NCT02911844","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",31314997,"Kawut SM, Pinder D, Al-Naamani N, McCormick A, Palevsky HI, Fritz J, Smith KA, Mazurek JA, Doyle MF, MacLean MR, DeMichele A, Mankoff DA. Fulvestrant for the Treatment of Pulmonary Arterial Hypertension. Ann Am Thorac Soc. 2019 Nov;16(11):1456-1459. doi: 10.1513/AnnalsATS.201904-328RL.","\tPulmonary Arterial Hypertension\tFulvestrant\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","familial primary pulmonary hypertension|hypertension","fulvestrant","NA"]
["NCT02919085","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16132895|23153874|23153875","Williams TA, Dobb GJ, Finn JC, Webb SA. Long-term survival from intensive care: a review. Intensive Care Med. 2005 Oct;31(10):1306-15. Epub 2005 Aug 24. Review.|Rossi PJ, Edmiston CE Jr. Patient safety in the critical care environment. Surg Clin North Am. 2012 Dec;92(6):1369-86. doi: 10.1016/j.suc.2012.08.007. Epub 2012 Oct 6. Review.|Neideen T. Monitoring devices in the intensive care unit. Surg Clin North Am. 2012 Dec;92(6):1387-402. doi: 10.1016/j.suc.2012.08.010. Epub 2012 Oct 13. Review.","\tIntensive Care Unit Syndrome|Muscle Weakness\tEarly ambulation\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","muscle weakness","NA","NA"]
["NCT02922803","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24345271,"Kalliokoski P, Bergqvist Y, Löfvander M. Physical performance and 25-hydroxyvitamin D: a cross-sectional study of pregnant Swedish and Somali immigrant women and new mothers. BMC Pregnancy Childbirth. 2013 Dec 17;13:237. doi: 10.1186/1471-2393-13-237.","\tMuscle Weakness|Vitamin D Deficiency\t1 combination tablet of Vitamin D3/calcium per day|2 combination tablets of Vitamin D3/calcium per day\tNA\tNA\tNA\tDrug|Drug\tFemale\t","Vitamin D and Physical Performance Before and After Intervention and Birth Outcome in Pregnant Somali and Swedish Women","Interventional","Completed","N/A",2,123,"muscle weakness|vitamin d deficiency","calcium|cholecalciferol|vitamins|calcium, dietary|vitamin d|ergocalciferols","NA"]
["NCT02933632","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32844909,"Marchisio AE, Ribeiro TA, Umpierres CSA, GalvÃo L, Rosito R, Macedo CAS, Galia CR. Accelerated rehabilitation versus conventional rehabilitation in total hip arthroplasty (ARTHA): a randomized double blinded clinical trial. Rev Col Bras Cir. 2020;47:e20202548. doi: 10.1590/0100-6991e-20202548. Epub 2020 Aug 12. Portuguese, English.","\tOsteoarthritis\tPhysical Therapy-SAP|Physical Therapy-ARP\tParallel Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Accelerated Rehabilitation in Hip Arthroplasty","Interventional","Completed","N/A",2,48,"osteoarthritis","NA","NA"]
["NCT02937012","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24671010|19554543|15128074|22245904|16299032|17399846|15017671|12360466|9934730|16863557|10347106|16848809|16530513|10051462|23141888|18752324|22271046|22911624|24625898|2803071|10343514|15468571|22259000","Flores A, Mayo MJ. Primary biliary cirrhosis in 2014. Curr Opin Gastroenterol. 2014 May;30(3):245-52. doi: 10.1097/MOG.0000000000000058.|Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009 Jul;50(1):291-308. doi: 10.1002/hep.22906.|Selmi C, Invernizzi P, Keeffe EB, Coppel RL, Podda M, Rossaro L, Ansari AA, Gershwin ME. Epidemiology and pathogenesis of primary biliary cirrhosis. J Clin Gastroenterol. 2004 Mar;38(3):264-71. Review. Erratum in: J Clin Gastroenterol. 2004 May-Jun;38(5):following table of contents. Keefe EB [corrected to Keeffe EB].|Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012 May;56(5):1181-1188. doi: 10.1016/j.jhep.2011.10.025. Epub 2012 Jan 13. Review.|Jones DE, Bhala N, Burt J, Goldblatt J, Prince M, Newton JL. Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut. 2006 Apr;55(4):536-41. Epub 2005 Nov 18.|van Os E, van den Broek WW, Mulder PG, ter Borg PC, Bruijn JA, van Buuren HR. Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol. 2007 Jun;46(6):1099-103. Epub 2007 Mar 2.|Talwalkar JA, Souto E, Jorgensen RA, Lindor KD. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2003 Jul;1(4):297-302.|Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology. 2002 Oct;123(4):1044-51.|Springer J, Cauch-Dudek K, O'Rourke K, Wanless IR, Heathcote EJ. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol. 1999 Jan;94(1):47-53.|Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2006 Jul;101(7):1529-38.|Poupon RE, Bonnand AM, Chrétien Y, Poupon R. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology. 1999 Jun;29(6):1668-71.|ter Borg PC, Schalm SW, Hansen BE, van Buuren HR; Dutch PBC Study Group. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol. 2006 Sep;101(9):2044-50. Epub 2006 Jul 18.|Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology. 2006 Mar;130(3):715-20.|Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology. 1999 Mar;29(3):644-7.|Corpechot C. Primary biliary cirrhosis and bile acids. Clin Res Hepatol Gastroenterol. 2012 Sep;36 Suppl 1:S13-20. doi: 10.1016/S2210-7401(12)70016-5. Review.|Corpechot C, Abenavoli L, Rabahi N, Chrétien Y, Andréani T, Johanet C, Chazouillères O, Poupon R. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008 Sep;48(3):871-7. doi: 10.1002/hep.22428.|Corpechot C, Carrat F, Poujol-Robert A, Gaouar F, Wendum D, Chazouillères O, Poupon R. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology. 2012 Jul;56(1):198-208. doi: 10.1002/hep.25599. Epub 2012 Jun 5.|Honda A, Ikegami T, Nakamuta M, Miyazaki T, Iwamoto J, Hirayama T, Saito Y, Takikawa H, Imawari M, Matsuzaki Y. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology. 2013 May;57(5):1931-41. doi: 10.1002/hep.26018. Epub 2013 Apr 5.|Cuperus FJ, Halilbasic E, Trauner M. Fibrate treatment for primary biliary cirrhosis. Curr Opin Gastroenterol. 2014 May;30(3):279-86. doi: 10.1097/MOG.0000000000000056. Review.|Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989 Oct;46(10):1121-3.|Zúniga MA, Carrillo-Jiménez GT, Fos PJ, Gandek B, Medina-Moreno MR. [Evaluation of health status using Survey SF-36: preliminary results in Mexico]. Salud Publica Mex. 1999 Mar-Apr;41(2):110-8. Spanish.|Durán-Arenas L, Gallegos-Carrillo K, Salinas-Escudero G, Martínez-Salgado H. [Towards a Mexican normative standard for measurement of the short format 36 health-related quality of life instrument]. Salud Publica Mex. 2004 Jul-Aug;46(4):306-15. Spanish.|Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Bezafibrate for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012 Jan 18;1:CD009145. doi: 10.1002/14651858.CD009145.pub2. Review.","\tPrimary Biliary Cirrhosis\tBezafibrate|Ursodeoxycholic Acid|Placebo (for Bezafibrate)\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders","Interventional","Unknown status","Phase 3",2,34,"fibrosis|liver cirrhosis, biliary|liver cirrhosis","bezafibrate|ursodeoxycholic acid","NA"]
["NCT02946112","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","13680185|25467608|9365352|21944077|12839208|23791560|9110628|18713477|1589462","Gangnet N, Pomero V, Dumas R, Skalli W, Vital JM. Variability of the spine and pelvis location with respect to the gravity line: a three-dimensional stereoradiographic study using a force platform. Surg Radiol Anat. 2003 Nov-Dec;25(5-6):424-33. Epub 2003 Sep 16.|Ruivo RM, Pezarat-Correia P, Carita AI. Intrarater and interrater reliability of photographic measurement of upper-body standing posture of adolescents. J Manipulative Physiol Ther. 2015 Jan;38(1):74-80. doi: 10.1016/j.jmpt.2014.10.009. Epub 2014 Nov 12.|Raine S, Twomey LT. Head and shoulder posture variations in 160 asymptomatic women and men. Arch Phys Med Rehabil. 1997 Nov;78(11):1215-23.|Ozunlu N, Tekeli H, Baltaci G. Lateral scapular slide test and scapular mobility in volleyball players. J Athl Train. 2011 Jul-Aug;46(4):438-44.|Koslow PA, Prosser LA, Strony GA, Suchecki SL, Mattingly GE. Specificity of the lateral scapular slide test in asymptomatic competitive athletes. J Orthop Sports Phys Ther. 2003 Jun;33(6):331-6.|Ribeiro A, Pascoal AG. Resting scapular posture in healthy overhead throwing athletes. Man Ther. 2013 Dec;18(6):547-50. doi: 10.1016/j.math.2013.05.010. Epub 2013 Jun 20.|Van Maanen CJ, Zonnenberg AJ, Elvers JW, Oostendorp RA. Intra/interrater reliability of measurements on body posture photographs. Cranio. 1996 Oct;14(4):326-31. Erratum in: Cranio 1997 Jan;15(1):8.|van Niekerk SM, Louw Q, Vaughan C, Grimmer-Somers K, Schreve K. Photographic measurement of upper-body sitting posture of high school students: a reliability and validity study. BMC Musculoskelet Disord. 2008 Aug 20;9:113. doi: 10.1186/1471-2474-9-113.|Griegel-Morris P, Larson K, Mueller-Klaus K, Oatis CA. Incidence of common postural abnormalities in the cervical, shoulder, and thoracic regions and their association with pain in two age groups of healthy subjects. Phys Ther. 1992 Jun;72(6):425-31.","\tShoulder Pain\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","shoulder pain","NA","NA"]
["NCT02950168","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",31492505,"Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimitz PE, Smolnik R, Zierhut W, Goette A. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019 Oct 12;394(10206):1335-1343. doi: 10.1016/S0140-6736(19)31872-0. Epub 2019 Sep 3.","\tAtrial Fibrillation|Venous Thromboembolism\tEdoxaban\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","venous thromboembolism|atrial fibrillation|thromboembolism","edoxaban","NA"]
["NCT02965729","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28440662,"Staiano AE, Beyl RA, Hsia DS, Jarrell AR, Katzmarzyk PT, Mantzor S, Newton RL Jr, Tyson P. Step Tracking with Goals Increases Children's Weight Loss in Behavioral Intervention. Child Obes. 2017 Aug;13(4):283-290. doi: 10.1089/chi.2017.0047. Epub 2017 Apr 25.","\tPediatric Obesity|Weight Loss\tFamily-based weight management|Pedometer|Individualized step goals\tNA\tNA\tNA\tBehavioral|Behavioral|Behavioral\tAll\t","Our Lifestyles Our Lives","Interventional","Completed","N/A",3,105,"obesity|weight loss|pediatric obesity","NA","NA"]
["NCT02970071","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17556383|16807954|14528474","Wren C, Reinhardt Z, Khawaja K. Twenty-year trends in diagnosis of life-threatening neonatal cardiovascular malformations. Arch Dis Child Fetal Neonatal Ed. 2008 Jan;93(1):F33-5. Epub 2007 Jun 7.|Kim N, Friedberg MK, Silverman NH. Diagnosis and prognosis of fetuses with double outlet right ventricle. Prenat Diagn. 2006 Aug;26(8):740-5.|DeVore GR, Falkensammer P, Sklansky MS, Platt LD. Spatio-temporal image correlation (STIC): new technology for evaluation of the fetal heart. Ultrasound Obstet Gynecol. 2003 Oct;22(4):380-7.","\tCongenital Heart Disease\tNA\tNA\tNA\tNA\tNA\tFemale\t","NA","NA","NA","NA","NA","NA","heart diseases|heart defects, congenital","NA","NA"]
["NCT02974972","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31538283|32212069|30185898|31333167|31948438|32184035","Murnane PM, Miller JD, Tuthill EL, Collins SM, Neilands TB, Onono M, Cohen CR, Weiser SD, Laudenslager ML, Young SL. Perinatal Food Insecurity and Postpartum Psychosocial Stress are Positively Associated Among Kenyan Women of Mixed HIV Status. AIDS Behav. 2020 Jun;24(6):1632-1642. doi: 10.1007/s10461-019-02676-5.|Wang M, Miller JD, Collins SM, Santoso MV, Wekesa P, Okochi H, Onono M, Weiser S, Gandhi M, Young SL. Social Support Mitigates Negative Impact of Food Insecurity on Antiretroviral Adherence Among Postpartum Women in Western Kenya. AIDS Behav. 2020 Oct;24(10):2885-2894. doi: 10.1007/s10461-020-02839-9.|Widen EM, Tsai I, Collins SM, Wekesa P, China J, Krumdieck N, Miller JD, Weiser SD, Onono M, Young SL. HIV infection and increased food insecurity are associated with adverse body composition changes among pregnant and lactating Kenyan women. Eur J Clin Nutr. 2019 Mar;73(3):474-482. doi: 10.1038/s41430-018-0285-9. Epub 2018 Sep 5.|Miller JD, Fitzgerald KG, Smith AL, Young SL. Geophagy among a Cohort of Kenyan Women with Mixed HIV Status: A Longitudinal Analysis. Am J Trop Med Hyg. 2019 Sep;101(3):654-660. doi: 10.4269/ajtmh.19-0149.|Tuthill EL, Miller JD, Collins SM, Widen EM, Onono M, Young SL. HIV infection, hunger, breastfeeding self-efficacy, and depressive symptoms are associated with exclusive breastfeeding to six months among women in western Kenya: a longitudinal observational study. Int Breastfeed J. 2020 Jan 16;15(1):4. doi: 10.1186/s13006-019-0251-8.|Benzaken CL, Miller JD, Onono M, Young SL. Development of a cumulative metric of vaccination adherence behavior and its application among a cohort of 12-month-olds in western Kenya. Vaccine. 2020 Apr 16;38(18):3429-3435. doi: 10.1016/j.vaccine.2020.03.011. Epub 2020 Mar 14.","\tFood Insecurity|HIV|Maternal and Child Health|Nutrition\tNA\tNA\tNA\tNA\tNA\tFemale\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT02979847","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23512204|23935092|21907170|17573836|23390124|22331500","Eckstein J, Zeemering S, Linz D, Maesen B, Verheule S, van Hunnik A, Crijns H, Allessie MA, Schotten U. Transmural conduction is the predominant mechanism of breakthrough during atrial fibrillation: evidence from simultaneous endo-epicardial high-density activation mapping. Circ Arrhythm Electrophysiol. 2013 Apr;6(2):334-41. doi: 10.1161/CIRCEP.113.000342. Epub 2013 Mar 19.|Lee G, Kumar S, Teh A, Madry A, Spence S, Larobina M, Goldblatt J, Brown R, Atkinson V, Moten S, Morton JB, Sanders P, Kistler PM, Kalman JM. Epicardial wave mapping in human long-lasting persistent atrial fibrillation: transient rotational circuits, complex wavefronts, and disorganized activity. Eur Heart J. 2014 Jan;35(2):86-97. doi: 10.1093/eurheartj/eht267. Epub 2013 Aug 8.|Lee G, Spence S, Teh A, Goldblatt J, Larobina M, Atkinson V, Brown R, Morton JB, Sanders P, Kistler PM, Kalman JM. High-density epicardial mapping of the pulmonary vein-left atrial junction in humans: insights into mechanisms of pulmonary vein arrhythmogenesis. Heart Rhythm. 2012 Feb;9(2):258-64. doi: 10.1016/j.hrthm.2011.09.010. Epub 2011 Sep 9.|Pak HN, Hwang C, Lim HE, Kim JS, Kim YH. Hybrid epicardial and endocardial ablation of persistent or permanent atrial fibrillation: a new approach for difficult cases. J Cardiovasc Electrophysiol. 2007 Sep;18(9):917-23. Epub 2007 Jun 16.|Verheule S, Tuyls E, Gharaviri A, Hulsmans S, van Hunnik A, Kuiper M, Serroyen J, Zeemering S, Kuijpers NH, Schotten U. Loss of continuity in the thin epicardial layer because of endomysial fibrosis increases the complexity of atrial fibrillatory conduction. Circ Arrhythm Electrophysiol. 2013 Feb;6(1):202-11. doi: 10.1161/CIRCEP.112.975144. Epub 2013 Feb 6.|Eckstein J, Schotten U. Rotors and breakthroughs as three-dimensional perpetuators of atrial fibrillation. Cardiovasc Res. 2012 Apr 1;94(1):8-9. doi: 10.1093/cvr/cvs093. Epub 2012 Feb 13.","\tPersistent Atrial Fibrillation\thybrid approach|conventional endocardial approach\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","Epicardial Approach in Recurred Atrial Fibrillation","Interventional","Completed","N/A",2,100,"atrial fibrillation","NA","NA"]
["NCT02984943",7916513,4325211,null,"NA",null,"NA",{"$nulls":3},"NA",null,12577851,"Varga OIu, Ignat'ev VK, Vezikova NN, Kheĭfetz IV. [Radiation-modifying effect of oxygen barotherapy in complex treatment of patients with rheumatoid arthritis and osteoarthrosis]. Ter Arkh. 2002;74(12):83-6. Russian.","\tRheumatoId Arthritis\tHyperbaric Oxygen\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","arthritis, rheumatoid|arthritis","NA","MRI - Bone Erosion, Combined Score (CS), Right, 3 Months"]
["NCT02984943",7916537,4325235,null,"NA",null,"NA",{"$nulls":3},0.004,"Skillings-Mack test",12577851,"Varga OIu, Ignat'ev VK, Vezikova NN, Kheĭfetz IV. [Radiation-modifying effect of oxygen barotherapy in complex treatment of patients with rheumatoid arthritis and osteoarthrosis]. Ter Arkh. 2002;74(12):83-6. Russian.","\tRheumatoId Arthritis\tHyperbaric Oxygen\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","arthritis, rheumatoid|arthritis","NA","Sleep Quality - Night Pain, 6 Weeks"]
["NCT02986126","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17826170|12837712|10634337|18522664|17130383|12785564|22013611|22352077|23649787|25402400|25930037|21190455|NA","Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007 Sep 8;370(9590):851-8.|Miranda J, Chung JY, Green BL, Krupnick J, Siddique J, Revicki DA, Belin T. Treating depression in predominantly low-income young minority women: a randomized controlled trial. JAMA. 2003 Jul 2;290(1):57-65.|Wells KB, Sherbourne C, Schoenbaum M, Duan N, Meredith L, Unützer J, Miranda J, Carney MF, Rubenstein LV. Impact of disseminating quality improvement programs for depression in managed primary care: a randomized controlled trial. JAMA. 2000 Jan 12;283(2):212-20. Erratum in: JAMA 2000 Jun 28;283(24):3204.|Wells KB, Tang L, Miranda J, Benjamin B, Duan N, Sherbourne CD. The effects of quality improvement for depression in primary care at nine years: results from a randomized, controlled group-level trial. Health Serv Res. 2008 Dec;43(6):1952-74. doi: 10.1111/j.1475-6773.2008.00871.x. Epub 2008 Jun 3.|Gilbody S, Bower P, Fletcher J, Richards D, Sutton AJ. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch Intern Med. 2006 Nov 27;166(21):2314-21. Review.|Miranda J, Duan N, Sherbourne C, Schoenbaum M, Lagomasino I, Jackson-Triche M, Wells KB. Improving care for minorities: can quality improvement interventions improve care and outcomes for depressed minorities? Results of a randomized, controlled trial. Health Serv Res. 2003 Apr;38(2):613-30.|Institute of Medicine (US) Committee on Lesbian, Gay, Bisexual, and Transgender Health Issues and Research Gaps and Opportunities. The Health of Lesbian, Gay, Bisexual, and Transgender People: Building a Foundation for Better Understanding. Washington (DC): National Academies Press (US); 2011.|Springgate BF, Wennerstrom A, Meyers D, Allen CE 3rd, Vannoy SD, Bentham W, Wells KB. Building community resilience through mental health infrastructure and training in post-Katrina New Orleans. Ethn Dis. 2011 Summer;21(3 Suppl 1):S1-20-9.|Wells KB, Jones L, Chung B, Dixon EL, Tang L, Gilmore J, Sherbourne C, Ngo VK, Ong MK, Stockdale S, Ramos E, Belin TR, Miranda J. Community-partnered cluster-randomized comparative effectiveness trial of community engagement and planning or resources for services to address depression disparities. J Gen Intern Med. 2013 Oct;28(10):1268-78. doi: 10.1007/s11606-013-2484-3. Epub 2013 May 7. Erratum in: J Gen Intern Med. 2013 Nov;28(11):1534.|Chung B, Ong M, Ettner SL, Jones F, Gilmore J, McCreary M, Sherbourne C, Ngo V, Koegel P, Tang L, Dixon E, Miranda J, Belin TR, Wells KB. 12-month outcomes of community engagement versus technical assistance to implement depression collaborative care: a partnered, cluster, randomized, comparative effectiveness trial. Ann Intern Med. 2014 Nov 18;161(10 Suppl):S23-34. doi: 10.7326/M13-3011.|Chung B, Ngo VK, Ong MK, Pulido E, Jones F, Gilmore J, Stoker-Mtume N, Johnson M, Tang L, Wells KB, Sherbourne C, Miranda J. Participation in Training for Depression Care Quality Improvement: A Randomized Trial of Community Engagement or Technical Support. Psychiatr Serv. 2015 Aug 1;66(8):831-9. doi: 10.1176/appi.ps.201400099. Epub 2015 May 1.|Katon WJ, Lin EH, Von Korff M, Ciechanowski P, Ludman EJ, Young B, Peterson D, Rutter CM, McGregor M, McCulloch D. Collaborative care for patients with depression and chronic illnesses. N Engl J Med. 2010 Dec 30;363(27):2611-20. doi: 10.1056/NEJMoa1003955.|U.S. Department of Health and Human Services. Advancing LGBT Health & Well-Being: 2014 Report. 2014; http://www.hhs.gov/programs/topic-sites/lgbt/index.html.","\tDepressive Symptoms\tResiliency Class|Resource for Services (RS)\tParallel Assignment\tPrevention\tRandomized\tBehavioral|Other\tAll\t","Resilience Against Depression Disparities (Also Known as Resilience Education to Reduce Depression Disparities)","Interventional","Unknown status","N/A",2,265,"depression|depressive disorder","NA","NA"]
["NCT02993705","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25341582|18755503|17936342|16271748|18378136|17822748|11063636|15721404|15350372|17395252|17290061|11479630|11304695|23410977|23397080|10655437","Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, Beale P, Glasspool RM, Creutzberg CL, Harter P, Kim JW, Reed NS, Ray-Coquard I. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S55-60. doi: 10.1097/IGC.0000000000000228. Review.|Makker V, Abu-Rustum NR, Alektiar KM, Aghajanian CA, Zhou Q, Iasonos A, Hensley ML. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. Gynecol Oncol. 2008 Nov;111(2):249-54. doi: 10.1016/j.ygyno.2008.06.035. Epub 2008 Aug 27.|Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, Aydin Y, Topuz E. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Gynecol Oncol. 2008 Jan;108(1):136-40. Epub 2007 Oct 23.|Jonson AL, Bliss RL, Truskinovsky A, Judson P, Argenta P, Carson L, Dusenbery K, Downs LS Jr. Clinical features and outcomes of uterine and ovarian carcinosarcoma. Gynecol Oncol. 2006 Mar;100(3):561-4. Epub 2005 Nov 4.|Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, Tateo S, Franchi M, Jobsen JJ, Coens C, Teodorovic I, Vergote I, Vermorken JB; European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008 Apr;44(6):808-18. doi: 10.1016/j.ejca.2008.01.019. Epub 2008 Apr 2. Erratum in: Eur J Cancer. 2008 Jul;44(11):1612.|Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, Cohn DE, Ioffe OB. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007 Nov;107(2):177-85. Epub 2007 Sep 5.|Sutton G, Brunetto VL, Kilgore L, Soper JT, McGehee R, Olt G, Lentz SS, Sorosky J, Hsiu JG. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecol Oncol. 2000 Nov;79(2):147-53.|Sutton G, Kauderer J, Carson LF, Lentz SS, Whitney CW, Gallion H; Gynecologic Oncology Group. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 2005 Mar;96(3):630-4.|Toyoshima M, Akahira J, Matsunaga G, Niikura H, Ito K, Yaegashi N, Tase T. Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. Gynecol Oncol. 2004 Sep;94(3):774-8.|Leiser AL, Chi DS, Ishill NM, Tew WP. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol. 2007 Jun;105(3):657-61. Epub 2007 Mar 28.|Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, Monk BJ, Ueland FR; Gynecologic Oncology Group. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Feb 10;25(5):526-31.|Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, Kraemer KH, Pommier Y. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med. 2001 Aug;7(8):961-6. Erratum in: Nat Med 2001 Nov;7(11):1255.|Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, Foiani M, D'Incalci M. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer. 2001 May 15;92(4):583-8.|Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D'Incalci M, Allavena P. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013 Feb 11;23(2):249-62. doi: 10.1016/j.ccr.2013.01.008.|del Campo JM, Sessa C, Krasner CN, Vermorken JB, Colombo N, Kaye S, Gore M, Zintl P, Gómez J, Parekh T, Park YC, McMeekin S. Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. Med Oncol. 2013 Mar;30(1):435. doi: 10.1007/s12032-012-0435-1. Epub 2013 Feb 9.|Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16.","\tCarcinosarcoma, Ovarian|Carcinosarcomas Uterine\tTrabectedin\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","mixed tumor, mullerian|carcinosarcoma","trabectedin","NA"]
["NCT02995772","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24002511|29584099|12490681|15894097|27557300|18809056|24882348|10076721|20700118|26019189|22286607|20586616|24409418|17538978|6802332|18258986|23704196|26657653|2260873|8520164|20194852|12804433|3139179|26363985","von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Kümmel S, Paepke S, Schneeweiss A, Untch M, Zahm DM, Mehta K, Loibl S. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2013 Oct 10;31(29):3623-30. doi: 10.1200/JCO.2012.45.0940. Epub 2013 Sep 3.|Beatson GT. On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases. Trans Med Chir Soc Edinb. 1896;15:153-179.|van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002 Dec 19;347(25):1999-2009.|Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 May 14-20;365(9472):1687-717.|Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.|Asad J, Jacobson AF, Estabrook A, Smith SR, Boolbol SK, Feldman SM, Osborne MP, Boachie-Adjei K, Twardzik W, Tartter PI. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surg. 2008 Oct;196(4):527-9. doi: 10.1016/j.amjsurg.2008.06.021.|Teshome M, Hunt KK. Neoadjuvant therapy in the treatment of breast cancer. Surg Oncol Clin N Am. 2014 Jul;23(3):505-23. doi: 10.1016/j.soc.2014.03.006. Epub 2014 Apr 24. Review.|Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, Dilhuydy JM, Bonichon F. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS). Ann Oncol. 1999 Jan;10(1):47-52.|Chia YH, Ellis MJ, Ma CX. Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. Br J Cancer. 2010 Sep 7;103(6):759-64. doi: 10.1038/sj.bjc.6605845. Epub 2010 Aug 10. Review.|Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D; Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol. 2015 Jul;26(7):1280-91. doi: 10.1093/annonc/mdv161. Epub 2015 May 27. Review.|Chuang E, Paul C, Flam A, McCarville K, Forst M, Shin S, Vahdat L, Swistel A, Simmons R, Osborne M. Breast cancer subtypes in Asian-Americans differ according to Asian ethnic group. J Immigr Minor Health. 2012 Oct;14(5):754-8.|Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010 Jul;134(7):e48-72. doi: 10.1043/1543-2165-134.7.e48. Review.|Marcus DM, Switchenko JM, Prabhu R, O'Regan R, Zelnak A, Fasola C, Mister D, Torres MA. Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer. Front Oncol. 2013 Dec 27;3:317. doi: 10.3389/fonc.2013.00317. eCollection 2013.|Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, Melnikova OA, Paltuev RM, Kletzel A, Berstein LM. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007 Jul 15;110(2):244-54.|Preece PE, Wood RA, Mackie CR, Cuschieri A. Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. Br Med J (Clin Res Ed). 1982 Mar 20;284(6319):869-70.|Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008 Feb 10;26(5):778-85. doi: 10.1200/JCO.2007.15.0235. Erratum in: J Clin Oncol. 2008 Jun 1;26(16):2793.|Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013 Sep;24(9):2278-84. doi: 10.1093/annonc/mdt182. Epub 2013 May 22.|Hamy AS, Belin L, Bonsang-Kitzis H, Paquet C, Pierga JY, Lerebours F, Cottu P, Rouzier R, Savignoni A, Lae M, Reyal F. Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort. Br J Cancer. 2016 Jan 12;114(1):44-52. doi: 10.1038/bjc.2015.426. Epub 2015 Dec 10. Erratum in: Br J Cancer. 2018 Feb 20;:.|Tashiro H, Nomura Y, Hisamatsu K. [A randomized trial of endocrine therapy, chemotherapy, and chemo-endocrine therapy in advanced breast cancer]. Gan To Kagaku Ryoho. 1990 Dec;17(12):2369-73. Japanese.|Abe O, Asaishi K, Izuo M, Enomoto K, Koyama H, Tominaga T, Nomura Y, Ohshima A, Aoki N, Tsukada T. Effects of medroxyprogesterone acetate therapy on advanced or recurrent breast cancer and its influences on blood coagulation and the fibrinolytic system. Surg Today. 1995;25(8):701-10.|Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol. 2010 Apr 10;28(11):1958-62. doi: 10.1200/JCO.2009.25.5414. Epub 2010 Mar 1. Review.|Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev. 2003;(2):CD002747. Review.|Robertson JF, Todd JH, Ellis IO, Elston CW, Blamey RW. Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer. BMJ. 1988 Aug 20-27;297(6647):511-4.|Badwe R, Hawaldar R, Nair N, Kaushik R, Parmar V, Siddique S, Budrukkar A, Mittra I, Gupta S. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015 Oct;16(13):1380-8. doi: 10.1016/S1470-2045(15)00135-7. Epub 2015 Sep 9.","\tBreast Cancer\tAromatase Inhibitors (Arimidex)|Tamoxifen|SOB|FAC|Aromatase Inhibitors (Femara)|Aromatase Inhibitors (Aromasin)\tNA\tNA\tNA\tDrug|Drug|Procedure|Drug|Drug|Drug\tFemale\t","Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients","Interventional","Completed","Phase 3",2,122,"breast neoplasms","aromatase inhibitors|exemestane|letrozole|anastrozole|tamoxifen|fluorouracil","NA"]
["NCT03004430","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17764203|19123875|25003880","Ospina MB, Bond K, Karkhaneh M, Tjosvold L, Vandermeer B, Liang Y, Bialy L, Hooton N, Buscemi N, Dryden DM, Klassen TP. Meditation practices for health: state of the research. Evid Rep Technol Assess (Full Rep). 2007 Jun;(155):1-263. Review.|Ospina MB, Bond K, Karkhaneh M, Buscemi N, Dryden DM, Barnes V, Carlson LE, Dusek JA, Shannahoff-Khalsa D. Clinical trials of meditation practices in health care: characteristics and quality. J Altern Complement Med. 2008 Dec;14(10):1199-213. doi: 10.1089/acm.2008.0307. Review.|Goyal M, Bass EB, Haythornthwaite JA. Meditation intervention reviews--reply. JAMA Intern Med. 2014 Jul;174(7):1195. doi: 10.1001/jamainternmed.2014.1393.","\tDepression\tMantra Meditation|Progressive Muscle Relaxation\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral\tAll\t","Mantra Meditation in Major Depression","Interventional","Terminated","N/A",2,123,"depressive disorder|depression","NA","NA"]
["NCT03006562","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32444264,"Patel HD, Faisal FA, Trock BJ, Joice GA, Schwen ZR, Pierorazio PM, Johnson MH, Bivalacqua TJ, Han M, Gorin MA, Carter HB, Partin AW, Pavlovich CP, Allaf ME. Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. Eur Urol. 2020 Sep;78(3):360-368. doi: 10.1016/j.eururo.2020.05.001. Epub 2020 May 19.","\tDeep Venous Thrombosis|Lymphocele After Surgical Procedure|Prostate Cancer|Pulmonary Embolism|Venous Thromboembolism\tSubcutaneous Heparin\tParallel Assignment\tPrevention\tRandomized\tDrug\tMale\t","PREvention of VENous ThromboEmbolism Following Radical Prostatectomy","Interventional","Terminated","Phase 4",2,501,"thromboembolism|pulmonary embolism|thrombosis|venous thrombosis|embolism|venous thromboembolism|lymphocele","heparin","NA"]
["NCT03010839","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21304084|14407094|4056048|19283744|11090541|3769170|7680290|8901671|9362234|15519191|12460865|18456674|25961420|25593060|15965583|17707752|19508973|20495811|23953384|19188504|20189026|26436208|26436207|25022819|22222469|24014392|26768477|25464262","Domanski MJ, Mahaffey K, Hasselblad V, Brener SJ, Smith PK, Hillis G, Engoren M, Alexander JH, Levy JH, Chaitman BR, Broderick S, Mack MJ, Pieper KS, Farkouh ME. Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA. 2011 Feb 9;305(6):585-91. doi: 10.1001/jama.2011.99.|JENNINGS RB, SOMMERS HM, SMYTH GA, FLACK HA, LINN H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol. 1960 Jul;70:68-78.|Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest. 1985 Nov;76(5):1713-9.|Sullivan PJ, Sweeney KJ, Hirpara KM, Malone CB, Curtin W, Kerin MJ. Cyclical ischaemic preconditioning modulates the adaptive immune response in human limb ischaemia-reperfusion injury. Br J Surg. 2009 Apr;96(4):381-90. doi: 10.1002/bjs.6554.|Bolli R. The late phase of preconditioning. Circ Res. 2000 Nov 24;87(11):972-83. Review.|Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986 Nov;74(5):1124-36.|Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation. 1993 Mar;87(3):893-9.|Gho BC, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD. Myocardial protection by brief ischemia in noncardiac tissue. Circulation. 1996 Nov 1;94(9):2193-200.|Oxman T, Arad M, Klein R, Avazov N, Rabinowitz B. Limb ischemia preconditions the heart against reperfusion tachyarrhythmia. Am J Physiol. 1997 Oct;273(4):H1707-12. doi: 10.1152/ajpheart.1997.273.4.H1707.|Li G, Labruto F, Sirsjö A, Chen F, Vaage J, Valen G. Myocardial protection by remote preconditioning: the role of nuclear factor kappa-B p105 and inducible nitric oxide synthase. Eur J Cardiothorac Surg. 2004 Nov;26(5):968-73.|Kharbanda RK, Mortensen UM, White PA, Kristiansen SB, Schmidt MR, Hoschtitzky JA, Vogel M, Sorensen K, Redington AN, MacAllister R. Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation. 2002 Dec 3;106(23):2881-3.|Hausenloy DJ, Yellon DM. Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res. 2008 Aug 1;79(3):377-86. doi: 10.1093/cvr/cvn114. Epub 2008 May 2. Review.|Sivaraman V, Pickard JM, Hausenloy DJ. Remote ischaemic conditioning: cardiac protection from afar. Anaesthesia. 2015 Jun;70(6):732-48. doi: 10.1111/anae.12973. Epub 2015 Feb 26. Review.|Heusch G, Bøtker HE, Przyklenk K, Redington A, Yellon D. Remote ischemic conditioning. J Am Coll Cardiol. 2015 Jan 20;65(2):177-95. doi: 10.1016/j.jacc.2014.10.031. Review.|Kerendi F, Kin H, Halkos ME, Jiang R, Zatta AJ, Zhao ZQ, Guyton RA, Vinten-Johansen J. Remote postconditioning. Brief renal ischemia and reperfusion applied before coronary artery reperfusion reduces myocardial infarct size via endogenous activation of adenosine receptors. Basic Res Cardiol. 2005 Sep;100(5):404-12. Epub 2005 Jun 17.|Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, Ashley E, Vichare S, Di Salvo C, Kolvekar S, Hayward M, Keogh B, MacAllister RJ, Yellon DM. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet. 2007 Aug 18;370(9587):575-9.|Venugopal V, Hausenloy DJ, Ludman A, Di Salvo C, Kolvekar S, Yap J, Lawrence D, Bognolo J, Yellon DM. Remote ischaemic preconditioning reduces myocardial injury in patients undergoing cardiac surgery with cold-blood cardioplegia: a randomised controlled trial. Heart. 2009 Oct;95(19):1567-71. doi: 10.1136/hrt.2008.155770. Epub 2009 Jun 8.|Thielmann M, Kottenberg E, Boengler K, Raffelsieper C, Neuhaeuser M, Peters J, Jakob H, Heusch G. Remote ischemic preconditioning reduces myocardial injury after coronary artery bypass surgery with crystalloid cardioplegic arrest. Basic Res Cardiol. 2010 Sep;105(5):657-64. doi: 10.1007/s00395-010-0104-5. Epub 2010 May 21.|Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, Price V, Tsagakis K, Neuhäuser M, Peters J, Jakob H, Heusch G. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet. 2013 Aug 17;382(9892):597-604. doi: 10.1016/S0140-6736(13)61450-6. Erratum in: Lancet. 2013 Sep 14;382(9896):940.|Hoole SP, Heck PM, Sharples L, Khan SN, Duehmke R, Densem CG, Clarke SC, Shapiro LM, Schofield PM, O'Sullivan M, Dutka DP. Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial. Circulation. 2009 Feb 17;119(6):820-7. doi: 10.1161/CIRCULATIONAHA.108.809723. Epub 2009 Feb 2.|Bøtker HE, Kharbanda R, Schmidt MR, Bøttcher M, Kaltoft AK, Terkelsen CJ, Munk K, Andersen NH, Hansen TM, Trautner S, Lassen JF, Christiansen EH, Krusell LR, Kristensen SD, Thuesen L, Nielsen SS, Rehling M, Sørensen HT, Redington AN, Nielsen TT. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet. 2010 Feb 27;375(9716):727-34. doi: 10.1016/S0140-6736(09)62001-8.|Meybohm P, Bein B, Brosteanu O, Cremer J, Gruenewald M, Stoppe C, Coburn M, Schaelte G, Böning A, Niemann B, Roesner J, Kletzin F, Strouhal U, Reyher C, Laufenberg-Feldmann R, Ferner M, Brandes IF, Bauer M, Stehr SN, Kortgen A, Wittmann M, Baumgarten G, Meyer-Treschan T, Kienbaum P, Heringlake M, Schön J, Sander M, Treskatsch S, Smul T, Wolwender E, Schilling T, Fuernau G, Hasenclever D, Zacharowski K; RIPHeart Study Collaborators. A Multicenter Trial of Remote Ischemic Preconditioning for Heart Surgery. N Engl J Med. 2015 Oct 8;373(15):1397-407. doi: 10.1056/NEJMoa1413579. Epub 2015 Oct 5.|Hausenloy DJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar S, Knight R, Kunst G, Laing C, Nicholas J, Pepper J, Robertson S, Xenou M, Clayton T, Yellon DM; ERICCA Trial Investigators. Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery. N Engl J Med. 2015 Oct 8;373(15):1408-17. doi: 10.1056/NEJMoa1413534. Epub 2015 Oct 5.|Remote Preconditioning Trialists' Group, Healy DA, Khan WA, Wong CS, Moloney MC, Grace PA, Coffey JC, Dunne C, Walsh SR, Sadat U, Gaunt ME, Chen S, Tehrani S, Hausenloy DJ, Yellon DM, Kramer RS, Zimmerman RF, Lomivorotov VV, Shmyrev VA, Ponomarev DN, Rahman IA, Mascaro JG, Bonser RS, Jeon Y, Hong DM, Wagner R, Thielmann M, Heusch G, Zacharowski K, Meybohm P, Bein B, Tang TY. Remote preconditioning and major clinical complications following adult cardiovascular surgery: systematic review and meta-analysis. Int J Cardiol. 2014 Sep;176(1):20-31. doi: 10.1016/j.ijcard.2014.06.018. Epub 2014 Jun 27. Review.|Lucchinetti E, Bestmann L, Feng J, Freidank H, Clanachan AS, Finegan BA, Zaugg M. Remote ischemic preconditioning applied during isoflurane inhalation provides no benefit to the myocardium of patients undergoing on-pump coronary artery bypass graft surgery: lack of synergy or evidence of antagonism in cardioprotection? Anesthesiology. 2012 Feb;116(2):296-310. doi: 10.1097/ALN.0b013e318242349a.|Hong DM, Lee EH, Kim HJ, Min JJ, Chin JH, Choi DK, Bahk JH, Sim JY, Choi IC, Jeon Y. Does remote ischaemic preconditioning with postconditioning improve clinical outcomes of patients undergoing cardiac surgery? Remote Ischaemic Preconditioning with Postconditioning Outcome Trial. Eur Heart J. 2014 Jan;35(3):176-83. doi: 10.1093/eurheartj/eht346. Epub 2013 Sep 7.|Johnsen J, Pryds K, Salman R, Løfgren B, Kristiansen SB, Bøtker HE. The remote ischemic preconditioning algorithm: effect of number of cycles, cycle duration and effector organ mass on efficacy of protection. Basic Res Cardiol. 2016 Mar;111(2):10. doi: 10.1007/s00395-016-0529-6. Epub 2016 Jan 14.|Yamaguchi T, Izumi Y, Nakamura Y, Yamazaki T, Shiota M, Sano S, Tanaka M, Osada-Oka M, Shimada K, Miura K, Yoshiyama M, Iwao H. Repeated remote ischemic conditioning attenuates left ventricular remodeling via exosome-mediated intercellular communication on chronic heart failure after myocardial infarction. Int J Cardiol. 2015 Jan 15;178:239-46. doi: 10.1016/j.ijcard.2014.10.144. Epub 2014 Oct 30.","\tMyocardial Injury|Remote Ischemic Preconditioning\tModified Remote Ischemic Preconditioning|Control\tParallel Assignment\tPrevention\tRandomized\tProcedure|Procedure\tAll\t","Cardiopulmonary Protective Effects of Modified Remote Ischaemic Preconditioning in Mitral Valve Replacement Surgery","Interventional","Completed","N/A",2,86,"ischemia","NA","NA"]
["NCT03021343","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27502857,"Tabbalat RA, Hamad NM, Alhaddad IA, Hammoudeh A, Akasheh BF, Khader Y. Effect of ColchiciNe on the InciDence of Atrial Fibrillation in Open Heart Surgery Patients: END-AF Trial. Am Heart J. 2016 Aug;178:102-7. doi: 10.1016/j.ahj.2016.05.006. Epub 2016 May 17.","\tArrhythmia\tColchicine\tParallel Assignment\tPrevention\tRandomized\tDrug\tAll\t","Effect of Colchicine on the Incidence of Atrial Fibrillation in Open Heart Surgery Patients","Interventional","Completed","Phase 3",2,360,"atrial fibrillation","colchicine","NA"]
["NCT03023488","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26381037,"Sener TE, Cloutier J, Villa L, Marson F, Butticè S, Doizi S, Traxer O. Can We Provide Low Intrarenal Pressures with Good Irrigation Flow by Decreasing the Size of Ureteral Access Sheaths? J Endourol. 2016 Jan;30(1):49-55. doi: 10.1089/end.2015.0387. Epub 2015 Sep 18. Erratum in: J Endourol. 2017 Jan;31(1):110.","\tCirculatory; Change\tflexible ureteroscopy|Doppler Ultrasound examination|laser lithotripsy\tNA\tNA\tNA\tProcedure|Device|Device\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT03027375","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26727047,"van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016 Mar;18(3):242-52. doi: 10.1002/ejhf.483. Epub 2016 Jan 4. Review.","\tCardiovascular Diseases|Heart Failure\tQishen Granules|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Evaluating the Safety and Efficacy of Qishen Granules Among Patients With Chronic Heart Failure","Interventional","Unknown status","Phase 2",2,200,"cardiovascular diseases|heart failure","NA","NA"]
["NCT03034642","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25987742|26718338|25803243|28196961|26177175|29565180|29676596|32518181|32343599","Stolberg VR, McCubbrey AL, Freeman CM, Brown JP, Crudgington SW, Taitano SH, Saxton BL, Mancuso P, Curtis JL. Glucocorticoid-Augmented Efferocytosis Inhibits Pulmonary Pneumococcal Clearance in Mice by Reducing Alveolar Macrophage Bactericidal Function. J Immunol. 2015 Jul 1;195(1):174-84. doi: 10.4049/jimmunol.1402217. Epub 2015 May 18.|McCubbrey AL, Nelson JD, Stolberg VR, Blakely PK, McCloskey L, Janssen WJ, Freeman CM, Curtis JL. MicroRNA-34a Negatively Regulates Efferocytosis by Tissue Macrophages in Part via SIRT1. J Immunol. 2016 Feb 1;196(3):1366-75. doi: 10.4049/jimmunol.1401838. Epub 2015 Dec 30.|Dickson RP, Erb-Downward JR, Freeman CM, McCloskey L, Beck JM, Huffnagle GB, Curtis JL. Spatial Variation in the Healthy Human Lung Microbiome and the Adapted Island Model of Lung Biogeography. Ann Am Thorac Soc. 2015 Jun;12(6):821-30. doi: 10.1513/AnnalsATS.201501-029OC.|Dickson RP, Erb-Downward JR, Freeman CM, McCloskey L, Falkowski NR, Huffnagle GB, Curtis JL. Bacterial Topography of the Healthy Human Lower Respiratory Tract. mBio. 2017 Feb 14;8(1). pii: e02287-16. doi: 10.1128/mBio.02287-16.|Dickson RP, Erb-Downward JR, Prescott HC, Martinez FJ, Curtis JL, Lama VN, Huffnagle GB. Intraalveolar Catecholamines and the Human Lung Microbiome. Am J Respir Crit Care Med. 2015 Jul 15;192(2):257-9. doi: 10.1164/rccm.201502-0326LE.|Mancuso P, Curtis JL, Freeman CM, Peters-Golden M, Weinberg JB, Myers MG Jr. Ablation of the leptin receptor in myeloid cells impairs pulmonary clearance of Streptococcus pneumoniae and alveolar macrophage bactericidal function. Am J Physiol Lung Cell Mol Physiol. 2018 Jul 1;315(1):L78-L86. doi: 10.1152/ajplung.00447.2017. Epub 2018 Mar 22.|Finch DK, Stolberg VR, Ferguson J, Alikaj H, Kady MR, Richmond BW, Polosukhin VV, Blackwell TS, McCloskey L, Curtis JL, Freeman CM. Lung Dendritic Cells Drive Natural Killer Cytotoxicity in Chronic Obstructive Pulmonary Disease via IL-15Rα. Am J Respir Crit Care Med. 2018 Nov 1;198(9):1140-1150. doi: 10.1164/rccm.201712-2513OC.|Erb-Downward JR, Falkowski NR, D'Souza JC, McCloskey LM, McDonald RA, Brown CA, Shedden K, Dickson RP, Freeman CM, Stringer KA, Foxman B, Huffnagle GB, Curtis JL, Adar SD. Critical Relevance of Stochastic Effects on Low-Bacterial-Biomass 16S rRNA Gene Analysis. mBio. 2020 Jun 9;11(3). pii: e00258-20. doi: 10.1128/mBio.00258-20.|Yue M, Kim JH, Evans CR, Kachman M, Erb-Downward JR, D'Souza J, Foxman B, Adar SD, Curtis JL, Stringer KA. Measurement of Short-chain Fatty Acids in Respiratory Samples. Am J Respir Crit Care Med. 2020 Apr 28. doi: 10.1164/rccm.201909-1840LE. [Epub ahead of print]","\tPneumonia, Bacterial|Pulmonary Disease, Chronic Obstructive\tBronchoscopy with bilateral bronchoalveolar lavages\tNA\tNA\tNA\tProcedure\tAll\t","Modulation of Steroid Immunosuppression by Alveolar Efferocytosis","Interventional","Recruiting","N/A",2,60,"pneumonia, bacterial|pulmonary disease, chronic obstructive|pneumonia","NA","NA"]
["NCT03039972","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24578332|19215832","Navaneethan SD, Wehbe E, Heresi GA, Gaur V, Minai OA, Arrigain S, Nally JV Jr, Schold JD, Rahman M, Dweik RA. Presence and outcomes of kidney disease in patients with pulmonary hypertension. Clin J Am Soc Nephrol. 2014 May;9(5):855-63. doi: 10.2215/CJN.10191013. Epub 2014 Feb 27.|Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009 Feb 17;53(7):582-588. doi: 10.1016/j.jacc.2008.08.080.","\tPulmonary Hypertension|Renal Function Abnormal\tNo intervention\tNA\tNA\tNA\tDiagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","hypertension, pulmonary|hypertension","NA","NA"]
["NCT03046745","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23800201|2059685|1891020|11511555|26836587|11391635|14529588|19440811","Lim SH, Kwon JW, Kim N, Kim GH, Kang JM, Park MJ, Yim JY, Kim HU, Baik GH, Seo GS, Shin JE, Joo YE, Kim JS, Jung HC. Prevalence and risk factors of Helicobacter pylori infection in Korea: nationwide multicenter study over 13 years. BMC Gastroenterol. 2013 Jun 24;13:104. doi: 10.1186/1471-230X-13-104.|Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N, Sitas F. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991 Jun 1;302(6788):1302-5.|Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991 Oct 17;325(16):1127-31.|Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001 Sep;49(3):347-53. Review.|Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, Graham DY. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology. 2016 May;150(5):1113-1124.e5. doi: 10.1053/j.gastro.2016.01.028. Epub 2016 Feb 2. Review.|Dhillon PK, Farrow DC, Vaughan TL, Chow WH, Risch HA, Gammon MD, Mayne ST, Stanford JL, Schoenberg JB, Ahsan H, Dubrow R, West AB, Rotterdam H, Blot WJ, Fraumeni JF Jr. Family history of cancer and risk of esophageal and gastric cancers in the United States. Int J Cancer. 2001 Jul 1;93(1):148-52.|Minami Y, Tateno H. Associations between cigarette smoking and the risk of four leading cancers in Miyagi Prefecture, Japan: a multi-site case-control study. Cancer Sci. 2003 Jun;94(6):540-7.|Iijima K, Koike T, Abe Y, Ara N, Uno K, Imatani A, Ohara S, Shimosegawa T. Alteration of correlation between serum pepsinogen concentrations and gastric acid secretion after H. pylori eradication. J Gastroenterol. 2009;44(8):819-25. doi: 10.1007/s00535-009-0066-2. Epub 2009 May 14.","\tGastric Cancer\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","stomach neoplasms","NA","NA"]
["NCT03052894","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","1952146|4037404|20442261|4254032|10754616|9105219|9366453|9366929","Brull SJ, Silverman DG. Visual assessment of train-of-four and double burst-induced fade at submaximal stimulating currents. Anesth Analg. 1991 Nov;73(5):627-32.|Viby-Mogensen J, Jensen NH, Engbaek J, Ording H, Skovgaard LT, Chraemmer-Jørgensen B. Tactile and visual evaluation of the response to train-of-four nerve stimulation. Anesthesiology. 1985 Oct;63(4):440-3.|Brull SJ, Murphy GS. Residual neuromuscular block: lessons unlearned. Part II: methods to reduce the risk of residual weakness. Anesth Analg. 2010 Jul;111(1):129-40. doi: 10.1213/ANE.0b013e3181da8312. Epub 2010 May 4. Review. Erratum in: Anesth Analg. 2012 Feb;114(2):390.|Ali HH, Utting JE, Gray TC. Quantitative assessment of residual antidepolarizing block. II. Br J Anaesth. 1971 May;43(5):478-85.|Sundman E, Witt H, Olsson R, Ekberg O, Kuylenstierna R, Eriksson LI. The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium. Anesthesiology. 2000 Apr;92(4):977-84.|Kopman AF, Yee PS, Neuman GG. Relationship of the train-of-four fade ratio to clinical signs and symptoms of residual paralysis in awake volunteers. Anesthesiology. 1997 Apr;86(4):765-71.|Eriksson LI, Sundman E, Olsson R, Nilsson L, Witt H, Ekberg O, Kuylenstierna R. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans: simultaneous videomanometry and mechanomyography of awake human volunteers. Anesthesiology. 1997 Nov;87(5):1035-43.|Berg H, Roed J, Viby-Mogensen J, Mortensen CR, Engbaek J, Skovgaard LT, Krintel JJ. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand. 1997 Oct;41(9):1095-1103.","\tNeuromuscular Blockade\tHydraulic Monitoring Device|Standard EMG Monitoring Device\tNA\tNA\tNA\tDevice|Device\tAll\t","Validation of a Muscle Relaxation Monitor","Interventional","Terminated","N/A",2,1,"NA","NA","NA"]
["NCT03055247","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22909900|24869932|19410294|1423182|20673987|21045810|24161820|19504359|22458355|23485965|19965657|21878903|22078471|16582916|25143186|22339604|20167518|22009006|18217895|20978475|21116026|23460590|20098431|24001178|21952171|22198747","Aiuti A, Bacchetta R, Seger R, Villa A, Cavazzana-Calvo M. Gene therapy for primary immunodeficiencies: Part 2. Curr Opin Immunol. 2012 Oct;24(5):585-91. doi: 10.1016/j.coi.2012.07.012. Epub 2012 Aug 18. Review.|Chiriaco M, Farinelli G, Capo V, Zonari E, Scaramuzza S, Di Matteo G, Sergi LS, Migliavacca M, Hernandez RJ, Bombelli F, Giorda E, Kajaste-Rudnitski A, Trono D, Grez M, Rossi P, Finocchi A, Naldini L, Gentner B, Aiuti A. Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis. Mol Ther. 2014 Aug;22(8):1472-1483. doi: 10.1038/mt.2014.87. Epub 2014 May 29.|Di Matteo G, Giordani L, Finocchi A, Ventura A, Chiriaco M, Blancato J, Sinibaldi C, Plebani A, Soresina A, Pignata C, Dellepiane RM, Trizzino A, Cossu F, Rondelli R, Rossi P, De Mattia D, Martire B; IPINET (Italian Network for Primary Immunodeficiencies). Molecular characterization of a large cohort of patients with Chronic Granulomatous Disease and identification of novel CYBB mutations: an Italian multicenter study. Mol Immunol. 2009 Jun;46(10):1935-41. doi: 10.1016/j.molimm.2009.03.016. Epub 2009 May 1.|Edmonson JH, Hartmann LC, Long HJ, Colon-Otero G, Fitch TR, Jefferies JA, Braich TA, Maples WJ. Granulocyte-macrophage colony-stimulating factor. Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin. Cancer. 1992 Nov 15;70(10):2529-39.|Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ, Veys P, Amrolia PJ, Gaspar HB, Davies EG, Friedrich W, Hoenig M, Notarangelo LD, Mazzolari E, Porta F, Bredius RG, Lankester AC, Wulffraat NM, Seger R, Güngör T, Fasth A, Sedlacek P, Neven B, Blanche S, Fischer A, Cavazzana-Calvo M, Landais P; Inborn Errors Working Party of the European Group for Blood and Marrow Transplantation; European Society for Immunodeficiency. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010 Sep;126(3):602-10.e1-11. doi: 10.1016/j.jaci.2010.06.015. Epub 2010 Jul 31.|Grez M, Reichenbach J, Schwäble J, Seger R, Dinauer MC, Thrasher AJ. Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther. 2011 Jan;19(1):28-35. doi: 10.1038/mt.2010.232. Epub 2010 Nov 2. Review.|Güngör T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, Vermont C, Ahmad I, Shaw PJ, Telles da Cunha JM, Schlegel PG, Hough R, Fasth A, Kentouche K, Gruhn B, Fernandes JF, Lachance S, Bredius R, Resnick IB, Belohradsky BH, Gennery A, Fischer A, Gaspar HB, Schanz U, Seger R, Rentsch K, Veys P, Haddad E, Albert MH, Hassan M; Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014 Feb 1;383(9915):436-48. doi: 10.1016/S0140-6736(13)62069-3. Epub 2013 Oct 23.|Holland SM. Chronic granulomatous disease. Clin Rev Allergy Immunol. 2010 Feb;38(1):3-10. doi: 10.1007/s12016-009-8136-z. Review.|Hong KT, Kang HJ, Kim NH, Kim MS, Lee JW, Kim H, Park KD, Shin HY, Ahn HS. Successful mobilization using a combination of plerixafor and G-CSF in pediatric patients who failed previous chemomobilization with G-CSF alone and possible complications of the treatment. J Hematol Oncol. 2012 Mar 30;5:14. doi: 10.1186/1756-8722-5-14.|Hoggatt J, Mohammad KS, Singh P, Hoggatt AF, Chitteti BR, Speth JM, Hu P, Poteat BA, Stilger KN, Ferraro F, Silberstein L, Wong FK, Farag SS, Czader M, Milne GL, Breyer RM, Serezani CH, Scadden DT, Guise TA, Srour EF, Pelus LM. Differential stem- and progenitor-cell trafficking by prostaglandin E2. Nature. 2013 Mar 21;495(7441):365-9. doi: 10.1038/nature11929. Epub 2013 Mar 13.|Kang EM, Choi U, Theobald N, Linton G, Long Priel DA, Kuhns D, Malech HL. Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood. 2010 Jan 28;115(4):783-91. doi: 10.1182/blood-2009-05-222760. Epub 2009 Dec 1.|Kang HJ, Bartholomae CC, Paruzynski A, Arens A, Kim S, Yu SS, Hong Y, Joo CW, Yoon NK, Rhim JW, Kim JG, Von Kalle C, Schmidt M, Kim S, Ahn HS. Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I/II trial. Mol Ther. 2011 Nov;19(11):2092-101. doi: 10.1038/mt.2011.166. Epub 2011 Aug 30.|Martinez CA, Shah S, Shearer WT, Rosenblatt HM, Paul ME, Chinen J, Leung KS, Kennedy-Nasser A, Brenner MK, Heslop HE, Liu H, Wu MF, Hanson IC, Krance RA. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol. 2012 Jan;129(1):176-83. doi: 10.1016/j.jaci.2011.10.005. Epub 2011 Nov 12.|Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kühlcke K, Schilz A, Kunkel H, Naundorf S, Brinkmann A, Deichmann A, Fischer M, Ball C, Pilz I, Dunbar C, Du Y, Jenkins NA, Copeland NG, Lüthi U, Hassan M, Thrasher AJ, Hoelzer D, von Kalle C, Seger R, Grez M. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006 Apr;12(4):401-9. Epub 2006 Apr 2.|Panch SR, Yau YY, Kang EM, De Ravin SS, Malech HL, Leitman SF. Mobilization characteristics and strategies to improve hematopoietic progenitor cell mobilization and collection in patients with chronic granulomatous disease and severe combined immunodeficiency. Transfusion. 2015 Feb;55(2):265-74. doi: 10.1111/trf.12830. Epub 2014 Aug 21.|Pham HP, Patel N, Semedei-Pomales M, Bhatia M, Schwartz J. The use of plerixafor in hematopoietic progenitor cell collection in pediatric patients: a single center experience. Cytotherapy. 2012 Apr;14(4):467-72. doi: 10.3109/14653249.2012.658912. Epub 2012 Feb 20.|Roos D, Kuhns DB, Maddalena A, Bustamante J, Kannengiesser C, de Boer M, van Leeuwen K, Köker MY, Wolach B, Roesler J, Malech HL, Holland SM, Gallin JI, Stasia MJ. Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (second update). Blood Cells Mol Dis. 2010 Apr 15;44(4):291-9. doi: 10.1016/j.bcmd.2010.01.009. Epub 2010 Feb 18. Review.|Sevilla J, Schiavello E, Madero L, Pardeo M, Guggiari E, Baragaño M, Luksch R, Massimino M. Priming of hematopoietic progenitor cells by plerixafor and filgrastim in children with previous failure of mobilization with chemotherapy and/or cytokine treatment. J Pediatr Hematol Oncol. 2012 Mar;34(2):146-50. doi: 10.1097/MPH.0b013e31821c2cb8.|Seger RA. Modern management of chronic granulomatous disease. Br J Haematol. 2008 Feb;140(3):255-66. doi: 10.1111/j.1365-2141.2007.06880.x. Review.|Santilli G, Almarza E, Brendel C, Choi U, Beilin C, Blundell MP, Haria S, Parsley KL, Kinnon C, Malech HL, Bueren JA, Grez M, Thrasher AJ. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther. 2011 Jan;19(1):122-32. doi: 10.1038/mt.2010.226. Epub 2010 Oct 26.|Seger RA. Chronic granulomatous disease: recent advances in pathophysiology and treatment. Neth J Med. 2010 Nov;68(11):334-40. Review.|Son MH, Kang ES, Kim DH, Lee SH, Yoo KH, Sung KW, Koo HH, Kim DW, Kim JY, Cho EJ. Efficacy and toxicity of plerixafor for peripheral blood stem cell mobilization in children with high-risk neuroblastoma. Pediatr Blood Cancer. 2013 Aug;60(8):E57-9. doi: 10.1002/pbc.24506. Epub 2013 Mar 4.|Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, Schmidt M, Krämer A, Schwäble J, Glimm H, Koehl U, Preiss C, Ball C, Martin H, Göhring G, Schwarzwaelder K, Hofmann WK, Karakaya K, Tchatchou S, Yang R, Reinecke P, Kühlcke K, Schlegelberger B, Thrasher AJ, Hoelzer D, Seger R, von Kalle C, Grez M. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010 Feb;16(2):198-204. doi: 10.1038/nm.2088. Epub 2010 Jan 24.|Yannaki E, Karponi G, Zervou F, Constantinou V, Bouinta A, Tachynopoulou V, Kotta K, Jonlin E, Papayannopoulou T, Anagnostopoulos A, Stamatoyannopoulos G. Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with β-thalassemia major. Hum Gene Ther. 2013 Oct;24(10):852-60. doi: 10.1089/hum.2013.163.|Yannaki E, Papayannopoulou T, Jonlin E, Zervou F, Karponi G, Xagorari A, Becker P, Psatha N, Batsis I, Kaloyannidis P, Tahynopoulou V, Constantinou V, Bouinta A, Kotta K, Athanassiadou A, Anagnostopoulos A, Fassas A, Stamatoyannopoulos G. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther. 2012 Jan;20(1):230-8. doi: 10.1038/mt.2011.195. Epub 2011 Sep 27. Erratum in: Mol Ther. 2012 Feb;20(2):469.|Wu C, Dunbar CE. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity. Front Med. 2011 Dec;5(4):356-71. doi: 10.1007/s11684-011-0159-1. Epub 2011 Dec 27. Review.","\tChronic Granulomatous Disease X-linked (X-CGD)\tIbuprofen|Myelostim|Mozobil\tNA\tNA\tNA\tDrug|Drug|Drug\tMale\t","NA","NA","NA","NA","NA","NA","granulomatous disease, chronic","plerixafor octahydrochloride|ibuprofen","NA"]
["NCT03061916","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26347778|25591663|NA|NA|NA","Azizi A, Aghayan S, Zaker S, Shakeri M, Entezari N, Lawaf S. In Vitro Effect of Zingiber officinale Extract on Growth of Streptococcus mutans and Streptococcus sanguinis. Int J Dent. 2015;2015:489842. doi: 10.1155/2015/489842. Epub 2015 Aug 12.|Hasan S, Danishuddin M, Khan AU. Inhibitory effect of zingiber officinale towards Streptococcus mutans virulence and caries development: in vitro and in vivo studies. BMC Microbiol. 2015 Jan 16;15:1. doi: 10.1186/s12866-014-0320-5.|Weli, Tuqa Akram, and Ahlam Taha Mohammed. Effect of ginger extract on Mutans streptococci in comparison to chlorhexidine gluconate. Journal of Baghdad College of Dentistry 25.2 (2013): 179-184.|Al-Duboni, Ghada, Muhamed T. Osman, and R. Al-Naggar. Antimicrobial activity of aqueous extracts of cinnamon and ginger on two oral pathogens causing dental caries. Research Journal of Pharmaceutical, Biological and Chemical Sciences 4 (2013): 957-965.|Rashad, J. M. Effect of water cinnamon extract on mutans streptococci, in comparison to chlorhexidine gluconate and zac (in vitro and in vivo study). Mustansiria Dent J 5 (2008): 250-60.","\tDental Caries\tCinnamon|Ginger|Chlorhexidine Gluconate\tParallel Assignment\tPrevention\tRandomized\tDietary Supplement|Dietary Supplement|Drug\tAll\t","Cinnamon and Ginger in Comparison to Chlorhexidine Gluconate 0.2% on Oral Streptococcus Mutans","Interventional","Unknown status","Phase 3",3,21,"dental caries","chlorhexidine gluconate|chlorhexidine","NA"]
["NCT03069391","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30200183|30233154","Wall K, Stark J, Schillaci A, Saulnier ET, McLaren E, Striegnitz K, Cohen BD, Arciero PJ, Kramer AF, Anderson-Hanley C. The Enhanced Interactive Physical and Cognitive Exercise System (iPACES(TM) v2.0): Pilot Clinical Trial of an In-Home iPad-Based Neuro-Exergame for Mild Cognitive Impairment (MCI). J Clin Med. 2018 Aug 30;7(9). pii: E249. doi: 10.3390/jcm7090249.|Anderson-Hanley C, Stark J, Wall KM, VanBrakle M, Michel M, Maloney M, Barcelos N, Striegnitz K, Cohen BD, Kramer AF. The interactive Physical and Cognitive Exercise System (iPACES™): effects of a 3-month in-home pilot clinical trial for mild cognitive impairment and caregivers. Clin Interv Aging. 2018 Sep 4;13:1565-1577. doi: 10.2147/CIA.S160756. eCollection 2018.","\tAging|Alzheimer Disease, Early Onset|Cognitive Change|Cognitive Impairment|MCI|Mild Cognitive Impairment|Neurocognitive Disorder\tphysical exercise alone (PES) first|cognitive exercise alone (iCE) first|interactive Physical and Cognitive Exercise (iPACES™)\tNA\tNA\tNA\tBehavioral|Device|Device\tAll\t","The Interactive Physical and Cognitive Exercise System","Interventional","Active, not recruiting","N/A",2,31,"cognitive dysfunction|neurocognitive disorders|alzheimer disease","NA","NA"]
["NCT03076619","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27843854,"Bakhda RN. Clinical study of fundus findings in pregnancy induced hypertension. J Family Med Prim Care. 2016 Apr-Jun;5(2):424-429.","\tHypertension, Pregnancy-Induced\tclinical ophthalmoscopy\tNA\tNA\tNA\tOther\tFemale\t","NA","NA","NA","NA","NA","NA","hypertension|pre-eclampsia|toxemia|hypertension, pregnancy-induced","NA","NA"]
["NCT03079245","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22500166|26658124|25024755|22128773|27302327|27021036|26336605","Patel SJ, Saiman L, Duchon JM, Evans D, Ferng YH, Larson E. Development of an antimicrobial stewardship intervention using a model of actionable feedback. Interdiscip Perspect Infect Dis. 2012;2012:150367. doi: 10.1155/2012/150367. Epub 2012 Feb 21.|Prasad PA, Wong-McLoughlin J, Patel S, Coffin SE, Zaoutis TE, Perlman J, DeLaMora P, Alba L, Ferng YH, Saiman L. Surgical site infections in a longitudinal cohort of neonatal intensive care unit patients. J Perinatol. 2016 Apr;36(4):300-5. doi: 10.1038/jp.2015.191. Epub 2015 Dec 10.|Hum RS, Cato K, Sheehan B, Patel S, Duchon J, DeLaMora P, Ferng YH, Graham P, Vawdrey DK, Perlman J, Larson E, Saiman L. Developing clinical decision support within a commercial electronic health record system to improve antimicrobial prescribing in the neonatal ICU. Appl Clin Inform. 2014 Apr 9;5(2):368-87. doi: 10.4338/ACI-2013-09-RA-0069. eCollection 2014.|Larson EL, Patel SJ, Evans D, Saiman L. Feedback as a strategy to change behaviour: the devil is in the details. J Eval Clin Pract. 2013 Apr;19(2):230-4. doi: 10.1111/j.1365-2753.2011.01801.x. Epub 2011 Nov 29. Review.|Patel SJ, Green N, Clock SA, Paul DA, Perlman JM, Zaoutis T, Ferng YH, Alba L, Jia H, Larson EL, Saiman L. Gram-Negative Bacilli in Infants Hospitalized in The Neonatal Intensive Care Unit. J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):227-230. doi: 10.1093/jpids/piw032.|Clock SA, Ferng YH, Tabibi S, Alba L, Patel SJ, Jia H, DeLaMora P, Perlman JM, Paul DA, Zaoutis T, Larson EL, Saiman L. Colonization With Antimicrobial-Resistant Gram-Negative Bacilli at Neonatal Intensive Care Unit Discharge. J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):219-226. doi: 10.1093/jpids/piw014.|Ferng YH, Clock SA, Wong-Mcloughlin J, DeLaMora PA, Perlman JM, Gray KS, Paul DA, Prasad PA, Zaoutis TE, Alba LR, Whittier S, Larson EL, Saiman L. Multicenter Study of Hand Carriage of Potential Pathogens by Neonatal ICU Healthcare Personnel. J Pediatric Infect Dis Soc. 2015 Sep;4(3):276-9. doi: 10.1093/jpids/piu022. Epub 2014 Mar 30.","\tInfants in Neonatal Intensive Care Units\tEducation Plus (E+)|Clinical Decision Support|Prescriber Audit and Feedback\tParallel Assignment\tPrevention\tRandomized\tOther|Other|Other\tAll\t","Improving Antimicrobial Prescribing Practices in the Neonatal ICU","Interventional","Completed","N/A",4,6184,"NA","NA","NA"]
["NCT03090425","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26094644,"Pankuweit S, Lüers C, Richter A, Ruppert V, Gelbrich G, Maisch B; German Competence Network Heart Failure. Influence of different aetiologies on clinical course and outcome in patients with dilated cardiomyopathy. Eur J Clin Invest. 2015 Sep;45(9):906-17. doi: 10.1111/eci.12483. Epub 2015 Aug 6.","\tNon Ischemic Cardiomyopathy\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","autoimmune diseases|cardiomyopathy, dilated|cardiomyopathies","NA","NA"]
["NCT03093415","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23884067|23884071|16183464|20425880|23616960|26005037","Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis. 2013 Aug;57 Suppl 2:S56-61. doi: 10.1093/cid/cit271. Review.|Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, Goldberg DJ, Hellard ME. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013 Aug;57 Suppl 2:S80-9. doi: 10.1093/cid/cit306. Review.|Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat. 2005 Oct;29(3):159-65.|Grebely J, Knight E, Genoway KA, Viljoen M, Khara M, Elliott D, Gallagher L, Storms M, Raffa JD, DeVlaming S, Duncan F, Conway B. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol. 2010 Mar;22(3):270-7.|Newman AI, Beckstead S, Beking D, Finch S, Knorr T, Lynch C, MacKenzie M, Mayer D, Melles B, Shore R. Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centre. Can J Gastroenterol. 2013 Apr;27(4):217-23.|Mason K, Dodd Z, Sockalingam S, Altenberg J, Meaney C, Millson P, Powis J. Beyond viral response: A prospective evaluation of a community-based, multi-disciplinary, peer-driven model of HCV treatment and support. Int J Drug Policy. 2015 Oct;26(10):1007-13. doi: 10.1016/j.drugpo.2015.04.012. Epub 2015 Apr 29.","\tHepatitis C|Substance Abuse, Intravenous|Substance Use Disorders\telbasvir-grazoprevir (50 mg/100 mg)\tNA\tNA\tNA\tDrug\tAll\t","Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care","Interventional","Completed","Phase 4",3,100,"hepatitis a|substance abuse, intravenous|substance-related disorders|hepatitis c|hepatitis","mk-5172","NA"]
["NCT03101618","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25104279|17021840","Moghtaderi M, Farjadian S, Abbaszadeh Hasiri M. Animal allergen sensitization in veterinarians and laboratory animal workers. Occup Med (Lond). 2014 Oct;64(7):516-20. doi: 10.1093/occmed/kqu097. Epub 2014 Aug 7.|Krakowiak A, Wiszniewska M, Krawczyk P, Szulc B, Wittczak T, Walusiak J, Pałczynski C. Risk factors associated with airway allergic diseases from exposure to laboratory animal allergens among veterinarians. Int Arch Occup Environ Health. 2007 May;80(6):465-75. Epub 2006 Oct 5.","\tAllergic Conjunctivitis|Allergic Rhinitis|Asthma|Urticaria\tAnimal allergy|Non-animal allergy\tNA\tNA\tNA\tOther|Other\tAll\t","NA","NA","NA","NA","NA","NA","rhinitis|urticaria|rhinitis, allergic|hypersensitivity|conjunctivitis|conjunctivitis, allergic","NA","NA"]
["NCT03105518",7907561,4319717,"1-way Test, ChiSquare Approximation",2.7205,null,"NA",{"$nulls":3},0.0991,"Kruskal-Wallis","12351295|2221417|6650889","Harnett MJ, Bhavani-Shankar K, Datta S, Tsen LC. In vitro fertilization-induced alterations in coagulation and fibrinolysis as measured by thromboelastography. Anesth Analg. 2002 Oct;95(4):1063-6, table of contents.|Bader AM, Datta S, Moller RA, Covino BG. Acute progesterone treatment has no effect on bupivacaine-induced conduction blockade in the isolated rabbit vagus nerve. Anesth Analg. 1990 Nov;71(5):545-8.|Datta S, Lambert DH, Gregus J, Gissen AJ, Covino BG. Differential sensitivities of mammalian nerve fibers during pregnancy. Anesth Analg. 1983 Dec;62(12):1070-2.","\tOocyte Retrieval|Postoperative Pain\tFentanyl|Acetaminophen|Oxycodone\tNA\tNA\tNA\tDrug|Drug|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","pain, postoperative","acetaminophen|oxycodone|fentanyl","Amount of Discomfort Following Discharge Until Embryo Transfer"]
["NCT03110341","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25534356|27244862|27187300|25157725|27130143","O'Gorman RL, Bucher HU, Held U, Koller BM, Hüppi PS, Hagmann CF; Swiss EPO Neuroprotection Trial Group. Tract-based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain. 2015 Feb;138(Pt 2):388-97. doi: 10.1093/brain/awu363. Epub 2014 Dec 22.|Wu YW, Mathur AM, Chang T, McKinstry RC, Mulkey SB, Mayock DE, Van Meurs KP, Rogers EE, Gonzalez FF, Comstock BA, Juul SE, Msall ME, Bonifacio SL, Glass HC, Massaro AN, Dong L, Tan KW, Heagerty PJ, Ballard RA. High-Dose Erythropoietin and Hypothermia for Hypoxic-Ischemic Encephalopathy: A Phase II Trial. Pediatrics. 2016 Jun;137(6). pii: e20160191. doi: 10.1542/peds.2016-0191. Epub 2016 May 2.|Natalucci G, Latal B, Koller B, Rüegger C, Sick B, Held L, Bucher HU, Fauchère JC; Swiss EPO Neuroprotection Trial Group. Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years: A Randomized Clinical Trial. JAMA. 2016 May 17;315(19):2079-85. doi: 10.1001/jama.2016.5504.|Leuchter RH, Gui L, Poncet A, Hagmann C, Lodygensky GA, Martin E, Koller B, Darqué A, Bucher HU, Hüppi PS. Association between early administration of high-dose erythropoietin in preterm infants and brain MRI abnormality at term-equivalent age. JAMA. 2014 Aug 27;312(8):817-24. doi: 10.1001/jama.2014.9645.|Song J, Sun H, Xu F, Kang W, Gao L, Guo J, Zhang Y, Xia L, Wang X, Zhu C. Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Ann Neurol. 2016 Jul;80(1):24-34. doi: 10.1002/ana.24677. Epub 2016 May 11.","\tCerebral Palsy|Intracranial Hemorrhages|Periventricular Leukomalacia|Premature Infants\tErythropoietin|Normal saline\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Effect of Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome","Interventional","Unknown status","Phase 3",2,400,"intracranial hemorrhages|hemorrhage|leukomalacia, periventricular|cerebral palsy|premature birth","epoetin alfa","NA"]
["NCT03112798","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","13608313|15488063|25062740|24690084|25691129|22270505|9754506|10522589","DAVENPORT HT, ROSALES JK. Endotracheal intubation of infants and children. Can Anaesth Soc J. 1959 Jan;6(1):65-74.|Jones RM, Jones PL, Gildersleve CD, Hall JE, Harding LJ, Chawathe MS. The Cardiff paediatric laryngoscope blade: a comparison with the Miller size 1 and Macintosh size 2 laryngoscope blades. Anaesthesia. 2004 Oct;59(10):1016-9.|Passi Y, Sathyamoorthy M, Lerman J, Heard C, Marino M. Comparison of the laryngoscopy views with the size 1 Miller and Macintosh laryngoscope blades lifting the epiglottis or the base of the tongue in infants and children <2 yr of age. Br J Anaesth. 2014 Nov;113(5):869-74. doi: 10.1093/bja/aeu228. Epub 2014 Jul 25.|Varghese E, Kundu R. Does the Miller blade truly provide a better laryngoscopic view and intubating conditions than the Macintosh blade in small children? Paediatr Anaesth. 2014 Aug;24(8):825-9. doi: 10.1111/pan.12394. Epub 2014 Apr 2.|Lingappan K, Arnold JL, Shaw TL, Fernandes CJ, Pammi M. Videolaryngoscopy versus direct laryngoscopy for tracheal intubation in neonates. Cochrane Database Syst Rev. 2015 Feb 18;(2):CD009975. doi: 10.1002/14651858.CD009975.pub2. Review. Update in: Cochrane Database Syst Rev. 2018 Jun 04;6:CD009975.|Fiadjoe JE, Gurnaney H, Dalesio N, Sussman E, Zhao H, Zhang X, Stricker PA. A prospective randomized equivalence trial of the GlideScope Cobalt® video laryngoscope to traditional direct laryngoscopy in neonates and infants. Anesthesiology. 2012 Mar;116(3):622-8. doi: 10.1097/ALN.0b013e318246ea4d.|Levitan RM, Ochroch EA, Kush S, Shofer FS, Hollander JE. Assessment of airway visualization: validation of the percentage of glottic opening (POGO) scale. Acad Emerg Med. 1998 Sep;5(9):919-23.|Ochroch EA, Hollander JE, Kush S, Shofer FS, Levitan RM. Assessment of laryngeal view: percentage of glottic opening score vs Cormack and Lehane grading. Can J Anaesth. 1999 Oct;46(10):987-90.","\tNewborn\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT03125915",7906488,4319177,"Beta",-0.49,null,"NA",-1.07,0.09,95,0.1,"multi-level latent growth curve",30887190,"Starks TJ, Dellucci TV, Gupta S, Robles G, Stephenson R, S Sullivan P, Parsons JT. A Pilot Randomized Trial of Intervention Components Addressing Drug Use in Couples HIV Testing and Counseling (CHTC) with Male Couples. AIDS Behav. 2019 Sep;23(9):2407-2420. doi: 10.1007/s10461-019-02455-2.","\tDrug Use|Sex, Unsafe\tCommunication skills training video|substance use module|Couples HIV Testing and Counseling\tNA\tNA\tNA\tBehavioral|Behavioral|Behavioral\tMale\t","Addressing Substance Use Through CVCT","Interventional","Completed","N/A",4,"NA","NA","NA","Drug Abuse Screening Test-10 Total Scores"]
["NCT03125915",7906490,4319193,"Beta",-2.3,null,"NA",-5.37,0.77,95,0.14,"multi-level latent growth curve",30887190,"Starks TJ, Dellucci TV, Gupta S, Robles G, Stephenson R, S Sullivan P, Parsons JT. A Pilot Randomized Trial of Intervention Components Addressing Drug Use in Couples HIV Testing and Counseling (CHTC) with Male Couples. AIDS Behav. 2019 Sep;23(9):2407-2420. doi: 10.1007/s10461-019-02455-2.","\tDrug Use|Sex, Unsafe\tCommunication skills training video|substance use module|Couples HIV Testing and Counseling\tNA\tNA\tNA\tBehavioral|Behavioral|Behavioral\tMale\t","Addressing Substance Use Through CVCT","Interventional","Completed","N/A",4,"NA","NA","NA","Proportion of Respondents Reporting Any Drug Use"]
["NCT03127384","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",30358630,"Dierickx C, Larsson MK, Blomster S. Effectiveness and Safety of Acne Scar Treatment With Nonanimal Stabilized Hyaluronic Acid Gel. Dermatol Surg. 2018 Nov;44 Suppl 1:S10-S18. doi: 10.1097/DSS.0000000000001689.","\tHealthy Volunteers\tNo-treatment control|Restylane Lidocaine\tParallel Assignment\tTreatment\tRandomized\tOther|Device\tAll\t","Performance and Safety of Restylane Lidocaine for Treatment of Depressed Facial Acne Scars","Interventional","Completed","Phase 4",2,49,"depression","lidocaine","NA"]
["NCT03134079","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29476623,"Peters JC, Marker R, Pan Z, Breen JA, Hill JO. The Influence of Adding Spices to Reduced Sugar Foods on Overall Liking. J Food Sci. 2018 Mar;83(3):814-821. doi: 10.1111/1750-3841.14069. Epub 2018 Feb 24.","\tTaste Testing\tapple crisp|tea|oatmeal\tCrossover Assignment\tOther\tRandomized\tOther|Other|Other\tAll\t","Influence on Food Liking of Adding Spices to Replace Dietary Sugar","Interventional","Completed","N/A",3,160,"NA","NA","NA"]
["NCT03140540","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","11376533|24354071","Guarracino F. [The role of transesophageal echocardiography in intraoperative hemodynamic monitoring]. Minerva Anestesiol. 2001 Apr;67(4):320-4. Italian.|Trinooson CD, Gold ME. Impact of goal-directed perioperative fluid management in high-risk surgical procedures: a literature review. AANA J. 2013 Oct;81(5):357-68. Review.","\tFluid Therapy\tTEE guided fluid therapy will be administered|Stroke volume variation guided intravenous fluid.\tParallel Assignment\tHealth Services Research\tRandomized\tOther|Other\tAll\t","TEE as a Guide for Fluid Optimization in Major Abdominal Oncosurgery","Interventional","Completed","N/A",2,60,"NA","NA","NA"]
["NCT03149263","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18977158|16785117|19854692|25454692","Molenaers G, Schörkhuber V, Fagard K, Van Campenhout A, De Cat J, Pauwels P, Ortibus E, De Cock P, Desloovere K. Long-term use of botulinum toxin type A in children with cerebral palsy: treatment consistency. Eur J Paediatr Neurol. 2009 Sep;13(5):421-9. doi: 10.1016/j.ejpn.2008.07.008. Epub 2008 Nov 1.|Schroeder AS, Berweck S, Lee SH, Heinen F. Botulinum toxin treatment of children with cerebral palsy - a short review of different injection techniques. Neurotox Res. 2006 Apr;9(2-3):189-96. Review.|Brochard S, Blajan V, Lempereur M, Le Moine P, Peudenier S, Lefranc J, Rémy-Néris O. Effectiveness of nitrous oxide and analgesic cream (lidocaine and prilocaine) for prevention of pain during intramuscular botulinum toxin injections in children. Ann Phys Rehabil Med. 2009 Dec;52(10):704-16. doi: 10.1016/j.rehab.2009.09.001. Epub 2009 Oct 6.|Bayon-Mottu M, Gambart G, Deries X, Tessiot C, Richard I, Dinomais M. Pain during injections of botulinum toxin in children: Influence of the localization technique. Ann Phys Rehabil Med. 2014 Dec;57(9-10):578-86. doi: 10.1016/j.rehab.2014.09.010. Epub 2014 Oct 8.","\tCerebral Palsy|Muscle Hypertonia\tdistraction\tNA\tNA\tNA\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","muscle hypertonia|cerebral palsy","NA","NA"]
["NCT03154762","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17050561|21493723|15475599","Lafond C, Sériès F, Lemière C. Impact of CPAP on asthmatic patients with obstructive sleep apnoea. Eur Respir J. 2007 Feb;29(2):307-11. Epub 2006 Oct 18.|Xue Z, Yu Y, Gao H, Gunst SJ, Tepper RS. Chronic continuous positive airway pressure (CPAP) reduces airway reactivity in vivo in an allergen-induced rabbit model of asthma. J Appl Physiol (1985). 2011 Aug;111(2):353-7. doi: 10.1152/japplphysiol.01345.2010. Epub 2011 Apr 14.|Salerno FG, Pellegrino R, Trocchio G, Spanevello A, Brusasco V, Crimi E. Attenuation of induced bronchoconstriction in healthy subjects: effects of breathing depth. J Appl Physiol (1985). 2005 Mar;98(3):817-21. Epub 2004 Oct 8.","\tAsthma Acute\tNIPPV|CPAP\tParallel Assignment\tTreatment\tRandomized\tDevice|Device\tAll\t","Anti-inflammatory Effect of Nocturnal NIPPV on Acute Asthma","Interventional","Completed","N/A",2,20,"asthma","NA","NA"]
["NCT03171480","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20567177,"Collingham JP, Fuh KC, Caughey AB, Pullen KM, Lyell DJ, El-Sayed YY. Oral misoprostol and vaginal isosorbide mononitrate for labor induction: a randomized controlled trial. Obstet Gynecol. 2010 Jul;116(1):121-126. doi: 10.1097/AOG.0b013e3181e408f2.","\tLabor, Premature|Preeclampsia\tMonoket Pill\tParallel Assignment\tPrevention\tRandomized\tDrug\tFemale\t","Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia","Interventional","Completed","Phase 4",2,176,"obstetric labor, premature|pre-eclampsia","isosorbide dinitrate|isosorbide|isosorbide-5-mononitrate","NA"]
["NCT03173261","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21420161,"Lawn SD, Zumla AI. Tuberculosis. Lancet. 2011 Jul 2;378(9785):57-72. doi: 10.1016/S0140-6736(10)62173-3. Epub 2011 Mar 21. Review.","\tExtra Pulmonary Tuberculosis\tGenexpert\tNA\tNA\tNA\tDiagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","tuberculosis, pulmonary|tuberculosis","NA","NA"]
["NCT03181594",7903192,4317844,null,"NA",null,"NA",{"$nulls":3},1E-3,"t-test, 2 sided","31566744|33616224","Chang MT, Song S, Hwang PH. Cryosurgical ablation for treatment of rhinitis: A prospective multicenter study. Laryngoscope. 2020 Aug;130(8):1877-1884. doi: 10.1002/lary.28301. Epub 2019 Sep 30.|Ow RA, O'Malley EM, Han JK, Lam KK, Yen DM. Cryosurgical Ablation for Treatment of Rhinitis: Two-Year Results of a Prospective Multicenter Study. Laryngoscope. 2021 Feb 22. doi: 10.1002/lary.29453. [Epub ahead of print]","\tChronic Rhinitis\tClariFix Device\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","rhinitis","NA","Change From Baseline in the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)"]
["NCT03186092","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24355641|24355639|26318161|24609926|21282809|12091180|10412550|15194173|16982941|25909652","Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D42-50. doi: 10.1016/j.jacc.2013.10.032. Review.|Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D34-41. doi: 10.1016/j.jacc.2013.10.029. Review. Erratum in: J Am Coll Cardiol. 2014 Feb 25;63(7):746. Erratum in: J Am Coll Cardiol. 2014 Feb 25;63(7):746.|Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015 Oct;46(4):903-75. doi: 10.1183/13993003.01032-2015. Epub 2015 Aug 29. Erratum in: Eur Respir J. 2015 Dec;46(6):1855-6.|Ehlken N, Verduyn C, Tiede H, Staehler G, Karger G, Nechwatal R, Opitz CF, Klose H, Wilkens H, Rosenkranz S, Halank M, Grünig E. Economic evaluation of exercise training in patients with pulmonary hypertension. Lung. 2014 Jun;192(3):359-66. doi: 10.1007/s00408-014-9558-9. Epub 2014 Mar 8.|Gosselink R, De Vos J, van den Heuvel SP, Segers J, Decramer M, Kwakkel G. Impact of inspiratory muscle training in patients with COPD: what is the evidence? Eur Respir J. 2011 Feb;37(2):416-25. doi: 10.1183/09031936.00031810. Review.|ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. Erratum in: Am J Respir Crit Care Med. 2016 May 15;193(10):1185.|Neder JA, Andreoni S, Lerario MC, Nery LE. Reference values for lung function tests. II. Maximal respiratory pressures and voluntary ventilation. Braz J Med Biol Res. 1999 Jun;32(6):719-27.|Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):5S-12S. Review.|Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, Meyer FJ, Karger G, Buss J, Juenger J, Holzapfel N, Opitz C, Winkler J, Herth FF, Wilkens H, Katus HA, Olschewski H, Grünig E. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006 Oct 3;114(14):1482-9. Epub 2006 Sep 18.|Saglam M, Arikan H, Vardar-Yagli N, Calik-Kutukcu E, Inal-Ince D, Savci S, Akdogan A, Yokusoglu M, Kaya EB, Tokgozoglu L. Inspiratory muscle training in pulmonary arterial hypertension. J Cardiopulm Rehabil Prev. 2015 May-Jun;35(3):198-206. doi: 10.1097/HCR.0000000000000117.","\tRespiratory Muscle Strength\trespiratory muscle training|sham muscle training\tParallel Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Effects of Training in Pulmonary Hypertension","Interventional","Completed","N/A",2,14,"hypertension|hypertension, pulmonary","NA","NA"]
["NCT03191591","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32282612,"Blake-Lamb T, Boudreau AA, Matathia S, Perkins ME, Roche B, Cheng ER, Kotelchuck M, Shtasel D, Taveras EM. Association of the First 1,000 Days Systems-Change Intervention on Maternal Gestational Weight Gain. Obstet Gynecol. 2020 May;135(5):1047-1057. doi: 10.1097/AOG.0000000000003752.","\tDiet Habit|Feeding Behavior|Overweight and Obesity|Physical Activity|Sleep|Social Determinants of Health\tFirst 1,000 Days Program Site\tNA\tNA\tNA\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","obesity|pediatric obesity|overweight","NA","NA"]
["NCT03199781","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18719762|9502849|11420530|16401454","Milani GB, Natal Filho A, Amado João SM. Correlation between lumbar lordosis angle and degree of gynoid lipodystrophy (cellulite) in asymptomatic women. Clinics (Sao Paulo). 2008 Aug;63(4):503-8.|Chang P, Wiseman J, Jacoby T, Salisbury AV, Ersek RA. Noninvasive mechanical body contouring: (Endermologie) a one-year clinical outcome study update. Aesthetic Plast Surg. 1998 Mar-Apr;22(2):145-53.|Adcock D, Paulsen S, Jabour K, Davis S, Nanney LB, Shack RB. Analysis of the effects of deep mechanical massage in the porcine model. Plast Reconstr Surg. 2001 Jul;108(1):233-40.|Gordon C, Emiliozzi C, Zartarian M. Use of a mechanical massage technique in the treatment of fibromyalgia: a preliminary study. Arch Phys Med Rehabil. 2006 Jan;87(1):145-7.","\tCellulitis of Leg\tMotorized mechanical massage with the Dermothonus Slim® Ibramed with cosmetics\tNA\tNA\tNA\tDevice\tFemale\t","NA","NA","NA","NA","NA","NA","lipodystrophy|cellulitis","NA","NA"]
["NCT03206346","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","A.A.Shul'dyakov, E.P.Lyapina, V.I.Kuznetsov, N.I.Zryachkin, I.G.Sitnikov, O.A.Perminova, V.A.Anokhin4, G.R.Fatkullina. New possibilities in therapy of acute respiratory viral infections in children. Vopr. Prakt. Pediatrii. 2015 vol10 n5 pp21-28. Russian","\tAcute Respiratory Infection|Common Cold|Influenza, Human|Viral Infection\tIngavirin|Placebo oral capsule\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o.","Interventional","Completed","Phase 3",2,161,"common cold|communicable diseases|respiratory tract infections|infection|influenza, human|virus diseases","pentanedioic acid imidazolyl ethanamide","NA"]
["NCT03209726","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29754992|32354451","Thomas JA, Perez-Alday EA, Hamilton C, Kabir MM, Park EA, Tereshchenko LG. The utility of routine clinical 12-lead ECG in assessing eligibility for subcutaneous implantable cardioverter defibrillator. Comput Biol Med. 2018 Nov 1;102:242-250. doi: 10.1016/j.compbiomed.2018.05.002. Epub 2018 May 8.|Wang L, Javadekar N, Rajagopalan A, Rogovoy NM, Haq KT, Broberg CS, Tereshchenko LG. Eligibility for subcutaneous implantable cardioverter-defibrillator in congenital heart disease. Heart Rhythm. 2020 May;17(5 Pt B):860-869. doi: 10.1016/j.hrthm.2020.01.016.","\tImplantable Defibrillator User\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT03214120","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","7505562|11568065|26237992|23804904|10468251|11388523|11825729|9535437|12842527|24522100","Moat NE, Rebuck N, Shore DF, Evans TW, Finn AH. Humoral and cellular activation in a simulated extracorporeal circuit. Ann Thorac Surg. 1993 Dec;56(6):1509-14.|Luciani GB, Menon T, Vecchi B, Auriemma S, Mazzucco A. Modified ultrafiltration reduces morbidity after adult cardiac operations: a prospective, randomized clinical trial. Circulation. 2001 Sep 18;104(12 Suppl 1):I253-9.|Kane LC, Woodward CS, Husain SA, Frei-Jones MJ. Thromboelastography--does it impact blood component transfusion in pediatric heart surgery? J Surg Res. 2016 Jan;200(1):21-7. doi: 10.1016/j.jss.2015.07.011. Epub 2015 Jul 10.|Niebler RA, Gill JC, Brabant CP, Mitchell ME, Nugent M, Simpson P, Tweddell JS, Ghanayem NS. Thromboelastography in the assessment of bleeding following surgery for congenital heart disease. World J Pediatr Congenit Heart Surg. 2012 Oct 1;3(4):433-8. doi: 10.1177/2150135112447540.|Williams GD, Bratton SL, Riley EC, Ramamoorthy C. Coagulation tests during cardiopulmonary bypass correlate with blood loss in children undergoing cardiac surgery. J Cardiothorac Vasc Anesth. 1999 Aug;13(4):398-404.|Chew MS, Brandslund I, Brix-Christensen V, Ravn HB, Hjortdal VE, Pedersen J, Hjortdal K, Hansen OK, Tønnesen E. Tissue injury and the inflammatory response to pediatric cardiac surgery with cardiopulmonary bypass: a descriptive study. Anesthesiology. 2001 May;94(5):745-53; discussion 5A.|Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothorac Surg. 2002 Feb;21(2):232-44. Review.|Bando K, Vijay P, Turrentine MW, Sharp TG, Means LJ, Ensing GJ, Lalone BJ, Sekine Y, Szekely L, Brown JW. Dilutional and modified ultrafiltration reduces pulmonary hypertension after operations for congenital heart disease: a prospective randomized study. J Thorac Cardiovasc Surg. 1998 Mar;115(3):517-25; discussion 525-7.|Huang H, Yao T, Wang W, Zhu D, Zhang W, Chen H, Fu W. Continuous ultrafiltration attenuates the pulmonary injury that follows open heart surgery with cardiopulmonary bypass. Ann Thorac Surg. 2003 Jul;76(1):136-40.|Forman KR, Wong E, Gallagher M, McCarter R, Luban NL, Massaro AN. Effect of temperature on thromboelastography and implications for clinical use in newborns undergoing therapeutic hypothermia. Pediatr Res. 2014 May;75(5):663-9. doi: 10.1038/pr.2014.19. Epub 2014 Feb 12.","\tCongenital Heart Disease\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","heart diseases","NA","NA"]
["NCT03218514","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28938272|29452290","Gaborit B, Aron-Wisnewsky J, Salem JE, Bege T, Frere C. Pharmacologic Venous Thromboprophylaxis After Bariatric Surgery: Burning Questions Regarding Doses, Duration, and Strategy. Ann Surg. 2018 Dec;268(6):e51-e52. doi: 10.1097/SLA.0000000000002536.|Gaborit B, Moulin PA, Bege T, Boullu S, Vincentelli C, Emungania O, Morange PE, Berdah S, Salem JE, Dutour A, Frere C. Lean body weight is the best scale for venous thromboprophylaxis algorithm in severely obese patients undergoing bariatric surgery. Pharmacol Res. 2018 May;131:211-217. doi: 10.1016/j.phrs.2018.02.012. Epub 2018 Feb 13.","\tObesity\tDalteparin\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","obesity","heparin, low-molecular-weight|tinzaparin|dalteparin","NA"]
["NCT03223311","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19028057|17980540","Alvarez-Tostado JA, Moise MA, Bena JF, Pavkov ML, Greenberg RK, Clair DG, Kashyap VS. The brachial artery: a critical access for endovascular procedures. J Vasc Surg. 2009 Feb;49(2):378-85; discussion 385. doi: 10.1016/j.jvs.2008.09.017. Epub 2008 Nov 22.|Chuter TA, Rapp JH, Hiramoto JS, Schneider DB, Howell B, Reilly LM. Endovascular treatment of thoracoabdominal aortic aneurysms. J Vasc Surg. 2008 Jan;47(1):6-16. Epub 2007 Nov 5.","\tThoracoabdominal Aortic Aneurysm\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","aneurysm|aortic aneurysm, thoracic|aortic aneurysm","NA","NA"]
["NCT03229746","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24254965,"Khellaf M, Chabrol A, Mahevas M, Roudot-Thoraval F, Limal N, Languille L, Bierling P, Michel M, Godeau B. Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. Am J Hematol. 2014 Feb;89(2):194-8. doi: 10.1002/ajh.23609. Epub 2013 Nov 20.","\tImmune Thrombocytopenia\tHydroxychloroquine|vincristine|azathioprine\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia","Interventional","Completed","Phase 4",3,40,"thrombocytopenia|purpura, thrombocytopenic, idiopathic","hydroxychloroquine|vincristine|azathioprine","NA"]
["NCT03233464","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27080963|28032070","Yannam SD, Amarlal D, Rekha CV. Prevalence of molar incisor hypomineralization in school children aged 8-12 years in Chennai. J Indian Soc Pedod Prev Dent. 2016 Apr-Jun;34(2):134-8. doi: 10.4103/0970-4388.180438.|Salem K, Aziz D, Asadi M. Prevalence and Predictors of Molar Incisor Hypomineralization (MIH) among Rural Children in Northern Iran. Iran J Public Health. 2016 Nov;45(11):1528-1530.","\tMolar Incisor Hypomineralization\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","dental enamel hypoplasia","NA","NA"]
["NCT03238898","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",9029067,"Bertolasi L, Priori A, Tomelleri G, Bongiovanni LG, Fincati E, Simonati A, De Grandis D, Rizzuto N. Botulinum toxin treatment of muscle cramps: a clinical and neurophysiological study. Ann Neurol. 1997 Feb;41(2):181-6.","\tDiabetes Mellitus|Muscle Cramps Aggravated\tBotulinum toxin type A|Normal saline\tParallel Assignment\tTreatment\tRandomized\tDrug|Other\tAll\t","Botulinum Toxin for Cramps in Diabetic Neuropathy","Interventional","Completed","Phase 2",2,50,"diabetic neuropathies|spasm|muscle cramp","botulinum toxins, type a|abobotulinumtoxina|botulinum toxins","NA"]
["NCT03241524","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23745356,"Damjanović A, Duisin D, Barisić J. The evolution of the female sexual response concept: treatment implications. Srp Arh Celok Lek. 2013 Mar-Apr;141(3-4):268-74. Review.","\tPhysical Activity|Sexual Dysfunction, Physiological|Sexual Dysfunctions, Psychological\tExercise program for pelvic muscle floor\tNA\tNA\tNA\tOther\tFemale\t","NA","NA","NA","NA","NA","NA","sexual dysfunctions, psychological|sexual dysfunction, physiological","NA","NA"]
["NCT03249623","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27930361|26737495|25962614","Rees SE, Karbing DS. Determining the appropriate model complexity for patient-specific advice on mechanical ventilation. Biomed Tech (Berl). 2017 Apr 1;62(2):183-198. doi: 10.1515/bmt-2016-0061.|Rees SE, Karbing DS. Model-based advice for mechanical ventilation: From research (INVENT) to product (Beacon Caresystem). Annu Int Conf IEEE Eng Med Biol Soc. 2015;2015:5331-4. doi: 10.1109/EMBC.2015.7319595.|Weinreich UM, Thomsen LP, Rees SE, Rasmussen BS. The effects of oxygen induced pulmonary vasoconstriction on bedside measurement of pulmonary gas exchange. J Clin Monit Comput. 2016 Apr;30(2):207-14. doi: 10.1007/s10877-015-9703-x. Epub 2015 May 12.","\tVentilatory Failure\tBeacon Caresystem\tNA\tNA\tNA\tDevice\tAll\t","Individualised Weaning From Mechanical Ventilation in General ICU","Interventional","Recruiting","N/A",2,274,"hypoventilation","NA","NA"]
["NCT03256123","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24384995|11271856|16846498","Al-Mekhlafi HM, Al-Zabedi EM, Al-Maktari MT, Atroosh WM, Al-Delaimy AK, Moktar N, Sallam AA, Abdullah WA, Jani R, Surin J. Effects of vitamin A supplementation on iron status indices and iron deficiency anaemia: a randomized controlled trial. Nutrients. 2013 Dec 31;6(1):190-206. doi: 10.3390/nu6010190.|van Stuijvenberg ME, Faber M, Dhansay MA, Lombard CJ, Vorster N, Benadé AJ. Red palm oil as a source of beta-carotene in a school biscuit used to address vitamin A deficiency in primary school children. Int J Food Sci Nutr. 2000;51 Suppl:S43-50.|Zeba AN, Martin Prével Y, Somé IT, Delisle HF. The positive impact of red palm oil in school meals on vitamin A status: study in Burkina Faso. Nutr J. 2006 Jul 17;5:17.","\tVitamin A Deficiency in Children\tred palm shortening group|palm shortening group\tParallel Assignment\tTreatment\tRandomized\tDietary Supplement|Dietary Supplement\tAll\t","The Effects of Biscuits Containing Red Palm Oil on School Children With Vitamin A Deficiency in West and East Malaysia","Interventional","Unknown status","N/A",2,300,"vitamin a deficiency|night blindness","NA","NA"]
["NCT03260140","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32473403,"Hoerster KD, Collins MP, Au DH, Lane A, Epler E, McDowell J, Barón AE, Rise P, Plumley R, Nguyen T, Schooler M, Schuttner L, Ma J. Testing a self-directed lifestyle intervention among veterans: The D-ELITE pragmatic clinical trial. Contemp Clin Trials. 2020 Aug;95:106045. doi: 10.1016/j.cct.2020.106045. Epub 2020 May 28.","Most Veterans who receive VA healthcare have obesity (41%) or are classified as overweight (37%), putting them at higher risk for multiple serious chronic health conditions. Providing evidence-based behavioral weight management programs to Veterans with obesity is a priority for the VA National Center for Health Promotion and Disease Prevention (NCP). While the VA NCP's MOVE! program-primarily delivered with in-person group visits-helps Veterans with obesity lose weight, its reach has been limited because of various barriers to care. Some Veterans may do better with a program they can complete from home at their own pace. In this trial, study investigators are examining the effectiveness among Veterans of a previously proven self-directed lifestyle intervention (called DVD Lifestyle Intervention (D-ELITE)) that targets modest, clinically meaningful weight loss over the course of a year using recorded video lessons (DVD or online streaming), written self-study aids, and optional lifestyle coaching. The study will compare participants randomly assigned to receive D-ELITE to those continuing in usual care on weight and self-reported general physical health status, one year after enrollment. Secondary outcomes include weight and general physical health status two years after enrollment; and obesity-related biometric measures (blood pressure and HbA1c) and self-report psychological and behavioral factors such as physical activity and sleep quality, at one- and two-years following enrollment.\tObesity\tbehavioral lifestyle intervention\tParallel Assignment\tTreatment\tRandomized\tBehavioral\tAll\tInclusion Criteria:","DVD Lifestyle Intervention","Interventional","Completed","Not Applicable",2,511,"NA","NA","NA"]
["NCT03269292","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26696800|19055865|16041665|19105232|25271314|18644324|26696797","Packman CH. The Clinical Pictures of Autoimmune Hemolytic Anemia. Transfus Med Hemother. 2015 Sep;42(5):317-24. doi: 10.1159/000440656. Epub 2015 Sep 11. Review.|Dhingra KK, Jain D, Mandal S, Khurana N, Singh T, Gupta N. Evans syndrome: a study of six cases with review of literature. Hematology. 2008 Dec;13(6):356-60. doi: 10.1179/102453308X343518. Review.|Garratty G. Immune hemolytic anemia associated with negative routine serology. Semin Hematol. 2005 Jul;42(3):156-64. Review.|Kamesaki T, Oyamada T, Omine M, Ozawa K, Kajii E. Cut-off value of red-blood-cell-bound IgG for the diagnosis of Coombs-negative autoimmune hemolytic anemia. Am J Hematol. 2009 Feb;84(2):98-101. doi: 10.1002/ajh.21336.|Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica. 2014 Oct;99(10):1547-54. doi: 10.3324/haematol.2014.114561. Review.|Michel M. [Characteristics of warm autoimmune hemolytic anemia and Evans syndrome in adults]. Presse Med. 2008 Sep;37(9):1309-18. doi: 10.1016/j.lpm.2008.01.026. Epub 2008 Jul 17. Review. French.|Salama A. Treatment Options for Primary Autoimmune Hemolytic Anemia: A Short Comprehensive Review. Transfus Med Hemother. 2015 Sep;42(5):294-301. doi: 10.1159/000438731. Epub 2015 Aug 10. Review.","\tAutoimmune Hemolytic Anemia\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","anemia, hemolytic, autoimmune|hemolysis|anemia, hemolytic|anemia","NA","NA"]
["NCT03276598","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17324745|18475165|25622599","Hiltunen TP, Suonsyrjä T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Strandberg T, Tikkanen I, Tilvis R, Pentikäinen PJ, Virolainen J, Kontula K. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). Am J Hypertens. 2007 Mar;20(3):311-8. Erratum in: Am J Hypertens. 2018 Nov 13;31(12):1333.|Suonsyrjä T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Donner K, Strandberg T, Tikkanen I, Tilvis R, Pentikäinen PJ, Kontula K, Hiltunen TP. Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study. J Hypertens. 2008 Jun;26(6):1250-6. doi: 10.1097/HJH.0b013e3282fcc37f.|Hiltunen TP, Donner KM, Sarin AP, Saarela J, Ripatti S, Chapman AB, Gums JG, Gong Y, Cooper-DeHoff RM, Frau F, Glorioso V, Zaninello R, Salvi E, Glorioso N, Boerwinkle E, Turner ST, Johnson JA, Kontula KK. Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs. J Am Heart Assoc. 2015 Jan 26;4(1):e001521. doi: 10.1161/JAHA.115.001778.","\tHypertension|Pharmacogenetics\tAmlodipine|Bisoprolol|Hydrochlorothiazide|Losartan|Placebo\tCrossover Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug|Drug\tMale\t","A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension","Interventional","Completed","Phase 4",5,233,"essential hypertension|hypertension","hydrochlorothiazide|bisoprolol|amlodipine|losartan","NA"]
["NCT03282669","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25536092|24570244|26655725|18699897","Lee LA, Caplan RA, Stephens LS, Posner KL, Terman GW, Voepel-Lewis T, Domino KB. Postoperative opioid-induced respiratory depression: a closed claims analysis. Anesthesiology. 2015 Mar;122(3):659-65. doi: 10.1097/ALN.0000000000000564.|Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014 Feb 26;311(8):806-14. doi: 10.1001/jama.2014.732.|Practice Guidelines for the Prevention, Detection, and Management of Respiratory Depression Associated with Neuraxial Opioid Administration: An Updated Report by the American Society of Anesthesiologists Task Force on Neuraxial Opioids and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology. 2016 Mar;124(3):535-52. doi: 10.1097/ALN.0000000000000975.|McCormack JG, Kelly KP, Wedgwood J, Lyon R. The effects of different analgesic regimens on transcutaneous CO2 after major surgery. Anaesthesia. 2008 Aug;63(8):814-21. doi: 10.1111/j.1365-2044.2008.05487.x.","\tObesity|Pain, Postoperative|Respiratory Insufficiency\tIntrathecal Morphine|Intravenous hydromorphone\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tFemale\t","TC02 Obese Women Using It Morphine vs PCA IV Hydromorphone for Post-Cesarean Analgesia","Interventional","Withdrawn","Phase 4",2,0,"pain, postoperative|respiratory insufficiency|pulmonary valve insufficiency","hydromorphone|morphine","NA"]
["NCT03287323","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25233330|11815899|17133189|16304319|22080644|26556622","Hua M, Wunsch H. Integrating palliative care in the ICU. Curr Opin Crit Care. 2014 Dec;20(6):673-80. doi: 10.1097/MCC.0000000000000149. Review.|Heyland DK, Tranmer JE; Kingston General Hospital ICU Research Working Group. Measuring family satisfaction with care in the intensive care unit: the development of a questionnaire and preliminary results. J Crit Care. 2001 Dec;16(4):142-9.|Wall RJ, Engelberg RA, Downey L, Heyland DK, Curtis JR. Refinement, scoring, and validation of the Family Satisfaction in the Intensive Care Unit (FS-ICU) survey. Crit Care Med. 2007 Jan;35(1):271-9.|Selecky PA, Eliasson CA, Hall RI, Schneider RF, Varkey B, McCaffree DR; American College of Chest Physicians. Palliative and end-of-life care for patients with cardiopulmonary diseases: American College of Chest Physicians position statement. Chest. 2005 Nov;128(5):3599-610.|Mosenthal AC, Weissman DE, Curtis JR, Hays RM, Lustbader DR, Mulkerin C, Puntillo KA, Ray DE, Bassett R, Boss RD, Brasel KJ, Campbell M, Nelson JE. Integrating palliative care in the surgical and trauma intensive care unit: a report from the Improving Palliative Care in the Intensive Care Unit (IPAL-ICU) Project Advisory Board and the Center to Advance Palliative Care. Crit Care Med. 2012 Apr;40(4):1199-206. doi: 10.1097/CCM.0b013e31823bc8e7.|Braus N, Campbell TC, Kwekkeboom KL, Ferguson S, Harvey C, Krupp AE, Lohmeier T, Repplinger MD, Westergaard RP, Jacobs EA, Roberts KF, Ehlenbach WJ. Prospective study of a proactive palliative care rounding intervention in a medical ICU. Intensive Care Med. 2016 Jan;42(1):54-62. doi: 10.1007/s00134-015-4098-1. Epub 2015 Nov 10.","\tPalliative Care\tProactive Palliative Care\tNA\tNA\tNA\tOther\tAll\t","Proactive Palliative Care Intervention in a Surgical ICU: Influence on Family Satisfaction and Patient Distress","Interventional","Recruiting","N/A",2,200,"NA","NA","NA"]
["NCT03293134","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20690116,"Thomas S, Encha-Razavi F, Devisme L, Etchevers H, Bessieres-Grattagliano B, Goudefroye G, Elkhartoufi N, Pateau E, Ichkou A, Bonnière M, Marcorelle P, Parent P, Manouvrier S, Holder M, Laquerrière A, Loeuillet L, Roume J, Martinovic J, Mougou-Zerelli S, Gonzales M, Meyer V, Wessner M, Feysot CB, Nitschke P, Leticee N, Munnich A, Lyonnet S, Wookey P, Gyapay G, Foliguet B, Vekemans M, Attié-Bitach T. High-throughput sequencing of a 4.1 Mb linkage interval reveals FLVCR2 deletions and mutations in lethal cerebral vasculopathy. Hum Mutat. 2010 Oct;31(10):1134-41. doi: 10.1002/humu.21329.","\tProliferative Vasculopathy\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","vascular diseases","NA","NA"]
["NCT03296319","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12386506|16714767|20975548|19593546|21508838|21729812|21792055|27536694|12065368|3928249|25185073|18467896","Jonas MM, Tanser SJ. Lithium dilution measurement of cardiac output and arterial pulse waveform analysis: an indicator dilution calibrated beat-by-beat system for continuous estimation of cardiac output. Curr Opin Crit Care. 2002 Jun;8(3):257-61. Review.|National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, Connors AF Jr, Hite RD, Harabin AL. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006 Jun 15;354(24):2564-75. Epub 2006 May 21.|Boyd JH, Forbes J, Nakada TA, Walley KR, Russell JA. Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med. 2011 Feb;39(2):259-65. doi: 10.1097/CCM.0b013e3181feeb15.|Squara P, Cecconi M, Rhodes A, Singer M, Chiche JD. Tracking changes in cardiac output: methodological considerations for the validation of monitoring devices. Intensive Care Med. 2009 Oct;35(10):1801-8. doi: 10.1007/s00134-009-1570-9. Epub 2009 Jul 11.|Cecconi M, Parsons AK, Rhodes A. What is a fluid challenge? Curr Opin Crit Care. 2011 Jun;17(3):290-5. doi: 10.1097/MCC.0b013e32834699cd. Review.|Hofer CK, Cannesson M. Monitoring fluid responsiveness. Acta Anaesthesiol Taiwan. 2011 Jun;49(2):59-65. doi: 10.1016/j.aat.2011.05.001. Epub 2011 Jun 24. Review.|\"Vincent JL. \"\"Let's give some fluid and see what happens\"\" versus the \"\"mini-fluid challenge\"\". Anesthesiology. 2011 Sep;115(3):455-6. doi: 10.1097/ALN.0b013e318229a521.\"|Frazee E, Kashani K. Fluid Management for Critically Ill Patients: A Review of the Current State of Fluid Therapy in the Intensive Care Unit. Kidney Dis (Basel). 2016 Jun;2(2):64-71. doi: 10.1159/000446265. Epub 2016 May 18. Review.|Michard F, Teboul JL. Predicting fluid responsiveness in ICU patients: a critical analysis of the evidence. Chest. 2002 Jun;121(6):2000-8. Review.|Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985 Oct;13(10):818-29.|Chen C, Kollef MH. Conservative fluid therapy in septic shock: an example of targeted therapeutic minimization. Crit Care. 2014 Aug 29;18(4):481. doi: 10.1186/s13054-014-0481-5. Review.|Teboul JL, Monnet X. Prediction of volume responsiveness in critically ill patients with spontaneous breathing activity. Curr Opin Crit Care. 2008 Jun;14(3):334-9. doi: 10.1097/MCC.0b013e3282fd6e1e. Review.","\tEchocardiography|Fluid Responsiveness\tEchocardiography\tParallel Assignment\tTreatment\tRandomized\tDevice\tAll\t","Echocardiography Guided Fluid Resuscitation in Critically Ill Patients.","Interventional","Completed","N/A",2,120,"critical illness","NA","NA"]
["NCT03306368","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26820059|20626723","Vo HT, Robbins E, Westwood M, Lezama D, Fishman M. Relapse prevention medications in community treatment for young adults with opioid addiction. Subst Abus. 2016 Jul-Sep;37(3):392-397. Epub 2016 Jan 28.|Fishman MJ, Winstanley EL, Curran E, Garrett S, Subramaniam G. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility. Addiction. 2010 Sep;105(9):1669-76. doi: 10.1111/j.1360-0443.2010.03015.x. Epub 2010 Jul 9.","\tOpioid-Related Disorders\tYouth Opioid Recovery Support\tParallel Assignment\tTreatment\tRandomized\tBehavioral\tAll\t","Youth Opioid Recovery Support: A Developmentally-specific Intervention for Home Delivery of Extended Release Naltrexone","Interventional","Completed","N/A",2,40,"opioid-related disorders","analgesics, opioid","NA"]
["NCT03313453","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27723364,"Park HK, Cheng KC, Tetteh AO, Hildemann LM, Nadeau KC. Effectiveness of air purifier on health outcomes and indoor particles in homes of children with allergic diseases in Fresno, California: A pilot study. J Asthma. 2017 May;54(4):341-346. doi: 10.1080/02770903.2016.1218011. Epub 2016 Oct 10.","\tAllergic Rhinitis\tPuriCare (HEPA Air Cleaner)|Mock device of PuriCare\tParallel Assignment\tTreatment\tRandomized\tDevice|Device\tAll\t","Effect of Air Cleaner on the Indoor Allergen Sensitized Allergic Rhinitis Patients","Interventional","Completed","N/A",2,44,"rhinitis, allergic|rhinitis","NA","NA"]
["NCT03318224","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32893501|32860177","Schmidt ME, Hermann S, Arndt V, Steindorf K. Prevalence and severity of long-term physical, emotional, and cognitive fatigue across 15 different cancer entities. Cancer Med. 2020 Nov;9(21):8053-8061. doi: 10.1002/cam4.3413. Epub 2020 Sep 7.|Schmidt ME, Bergbold S, Hermann S, Steindorf K. Knowledge, perceptions, and management of cancer-related fatigue: the patients' perspective. Support Care Cancer. 2021 Apr;29(4):2063-2071. doi: 10.1007/s00520-020-05686-5. Epub 2020 Aug 29.","\tCancer-related Fatigue\tnone (observational study)\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","fatigue","NA","NA"]
["NCT03320278","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19593145|9602574|24257384","L'Hermite J, Nouvellon E, Cuvillon P, Fabbro-Peray P, Langeron O, Ripart J. The Simplified Predictive Intubation Difficulty Score: a new weighted score for difficult airway assessment. Eur J Anaesthesiol. 2009 Dec;26(12):1003-9. doi: 10.1097/EJA.0b013e32832efc71.|Arné J, Descoins P, Fusciardi J, Ingrand P, Ferrier B, Boudigues D, Ariès J. Preoperative assessment for difficult intubation in general and ENT surgery: predictive value of a clinical multivariate risk index. Br J Anaesth. 1998 Feb;80(2):140-6.|Etezadi F, Ahangari A, Shokri H, Najafi A, Khajavi MR, Daghigh M, Moharari RS. Thyromental height: a new clinical test for prediction of difficult laryngoscopy. Anesth Analg. 2013 Dec;117(6):1347-51. doi: 10.1213/ANE.0b013e3182a8c734.","\tDifficult Intubation|Facial Deformity|Head and Neck Disorder\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","congenital abnormalities","NA","NA"]
["NCT03342508","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18952016|12850607|27599604|24483234|26868074","Mancuso MS, Rouse DJ. Cesarean delivery for abnormal labor. Clin Perinatol. 2008 Sep;35(3):479-90, ix. doi: 10.1016/j.clp.2008.06.004. Review.|Myles TD, Santolaya J. Maternal and neonatal outcomes in patients with a prolonged second stage of labor. Obstet Gynecol. 2003 Jul;102(1):52-8.|Safa H, Beckmann M. Comparison of maternal and neonatal outcomes from full-dilatation cesarean deliveries using the Fetal Pillow or hand-push method. Int J Gynaecol Obstet. 2016 Dec;135(3):281-284. doi: 10.1016/j.ijgo.2016.06.013. Epub 2016 Aug 24.|Seal SL, Dey A, Barman SC, Kamilya G, Mukherji J. Does elevating the fetal head prior to delivery using a fetal pillow reduce maternal and fetal complications in a full dilatation caesarean section? A prospective study with historical controls. J Obstet Gynaecol. 2014 Apr;34(3):241-4. doi: 10.3109/01443615.2013.844108. Epub 2014 Jan 31.|Seal SL, Dey A, Barman SC, Kamilya G, Mukherji J, Onwude JL. Randomized controlled trial of elevation of the fetal head with a fetal pillow during cesarean delivery at full cervical dilatation. Int J Gynaecol Obstet. 2016 May;133(2):178-82. doi: 10.1016/j.ijgo.2015.09.019. Epub 2016 Jan 15.","\tLabor Complication\tFetal Pillow\tParallel Assignment\tPrevention\tRandomized\tDevice\tFemale\t","Fetal Pillow Randomized Controlled Trial","Interventional","Completed","N/A",2,60,"obstetric labor complications","NA","NA"]
["NCT03348670","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32877576,"Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter JD, Griffin P, Wilkinson B, Glenn GM. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020 Dec 10;383(24):2320-2332. doi: 10.1056/NEJMoa2026920. Epub 2020 Sep 2.","\tCovid19\tCOVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","NA","sargramostim|molgramostim","NA"]
["NCT03355495","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26416195|24629419|25910661","Vergis N, McGrath AK, Stoddart CH, Hoare JM. Right Or Left in COLonoscopy (ROLCOL)? A Randomized Controlled Trial of Right- versus Left-Sided Starting Position in Colonoscopy. Am J Gastroenterol. 2015 Nov;110(11):1576-81. doi: 10.1038/ajg.2015.298. Epub 2015 Sep 29.|Ou G, Kim E, Lakzadeh P, Tong J, Enns R, Ramji A, Whittaker S, Ko HH, Bressler B, Halparin L, Lam E, Amar J, Telford J. A randomized controlled trial assessing the effect of prescribed patient position changes during colonoscope withdrawal on adenoma detection. Gastrointest Endosc. 2014 Aug;80(2):277-83. doi: 10.1016/j.gie.2014.01.032. Epub 2014 Mar 12.|Ball AJ, Johal SS, Riley SA. Position change during colonoscope withdrawal increases polyp and adenoma detection in the right but not in the left side of the colon: results of a randomized controlled trial. Gastrointest Endosc. 2015 Sep;82(3):488-94. doi: 10.1016/j.gie.2015.01.035. Epub 2015 Apr 22.","\tColonic Adenoma|Colonic Cancer\tColonoscopy - Position Change\tParallel Assignment\tScreening\tRandomized\tProcedure\tAll\t","R vs L Lateral Decubitus Positioning in Colonoscopy","Interventional","Recruiting","N/A",2,172,"colonic neoplasms|adenoma","NA","NA"]
["NCT03365700","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27381589|27042964","Kuck KH, Fürnkranz A, Chun KR, Metzner A, Ouyang F, Schlüter M, Elvan A, Lim HW, Kueffer FJ, Arentz T, Albenque JP, Tondo C, Kühne M, Sticherling C, Brugada J; FIRE AND ICE Investigators. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. Eur Heart J. 2016 Oct 7;37(38):2858-2865. Epub 2016 Jul 5.|Kuck KH, Brugada J, Fürnkranz A, Metzner A, Ouyang F, Chun KR, Elvan A, Arentz T, Bestehorn K, Pocock SJ, Albenque JP, Tondo C; FIRE AND ICE Investigators. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2016 Jun 9;374(23):2235-45. doi: 10.1056/NEJMoa1602014. Epub 2016 Apr 4.","\tPersistent Atrial Fibrillation\tRadiofrequency Ablation|Cryoballoon ablation\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","Cryoballon Versus Radiofrequency Ablation for Persistent Atrial Fibrillation","Interventional","Unknown status","N/A",2,303,"atrial fibrillation","NA","NA"]
["NCT03374540","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31392894|30597611|31099460|31432074","Coleman CI, Kreutz R, Sood N, Bunz TJ, Meinecke AK, Eriksson D, Baker WL. Rivaroxaban's Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis. Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619868535. doi: 10.1177/1076029619868535.|Martinez BK, Baker WL, Sood NA, Bunz TJ, Meinecke AK, Eriksson D, Coleman CI. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation. Pharmacotherapy. 2019 Feb;39(2):196-203. doi: 10.1002/phar.2213. Epub 2019 Jan 28.|Baker WL, Beyer-Westendorf J, Bunz TJ, Eriksson D, Meinecke AK, Sood NA, Coleman CI. Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetes. Diabetes Obes Metab. 2019 Sep;21(9):2107-2114. doi: 10.1111/dom.13787. Epub 2019 Jun 11.|Hernandez AV, Bradley G, Khan M, Fratoni A, Gasparini A, Roman YM, Bunz TJ, Eriksson D, Meinecke AK, Coleman CI. Rivaroxaban vs. warfarin and renal outcomes in non-valvular atrial fibrillation patients with diabetes. Eur Heart J Qual Care Clin Outcomes. 2020 Oct 1;6(4):301-307. doi: 10.1093/ehjqcco/qcz047.","\tNonvalvular Atrial Fibrillation\tRivaroxaban (Xarelto, BAY59-7939)|Vitamin K antagonist (VKA)\tNA\tNA\tNA\tDrug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","atrial fibrillation","vitamin k|rivaroxaban","NA"]
["NCT03381001","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23040524|27203090|25747130|27817036|28333033","Roque M, Lattes K, Serra S, Solà I, Geber S, Carreras R, Checa MA. Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: a systematic review and meta-analysis. Fertil Steril. 2013 Jan;99(1):156-162. doi: 10.1016/j.fertnstert.2012.09.003. Epub 2012 Oct 3. Review.|Roque M, Valle M, Guimarães F, Sampaio M, Geber S. Cost-Effectiveness of the Freeze-All Policy. JBRA Assist Reprod. 2015 Aug 1;19(3):125-30. doi: 10.5935/1518-0557.20150028.|Roque M, Valle M, Guimarães F, Sampaio M, Geber S. Freeze-all policy: fresh vs. frozen-thawed embryo transfer. Fertil Steril. 2015 May;103(5):1190-3. doi: 10.1016/j.fertnstert.2015.01.045. Epub 2015 Mar 4.|Roque M, Valle M, Guimarães F, Sampaio M, Geber S. Freeze-all cycle for all normal responders? J Assist Reprod Genet. 2017 Feb;34(2):179-185. doi: 10.1007/s10815-016-0834-x. Epub 2016 Nov 5.|Roque M, Valle M, Kostolias A, Sampaio M, Geber S. Freeze-all cycle in reproductive medicine: current perspectives. JBRA Assist Reprod. 2017 Feb 1;21(1):49-53. doi: 10.5935/1518-0557.20170012.","\tInfertility\tembryo transfer after thaw and culture|embryo transfer with no culture\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tFemale\t","Influence of Post-thaw Embryo Culture Interval on Assisted Reproduction Success Rates","Interventional","Completed","N/A",2,268,"infertility","NA","NA"]
["NCT03383172","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","7113996|NA","Shure MB, Spivack G. Interpersonal problem-solving in young children: a cognitive approach to prevention. Am J Community Psychol. 1982 Jun;10(3):341-56.|Boyle D, Hassett-Walker C. Reducing Overt and Relational Aggression Among Young Children. Journal of School Violence, 7(1), 27-42, 2008. doi:10.1300/J202v07n01_03","\tAggressive Childhood Behavior|Mental Health|Problem Behavior|Social Behavior\tI Can Problem Solve (ICPS) Program\tParallel Assignment\tPrevention\tRandomized\tBehavioral\tAll\t","Mental Health Prevention Among Preschool Children Using a Culturally Adapted Version of ICPS","Interventional","Unknown status","N/A",3,240,"problem behavior","NA","NA"]
["NCT03413371","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25032676|23471754|24012235|24535604|25582785|22412772|16703549|12567343|11756886|10794256|24404359|12355695|10486687","Gruenewald M, Herz J, Schoenherr T, Thee C, Steinfath M, Bein B. Measurement of the nociceptive balance by Analgesia Nociception Index and Surgical Pleth Index during sevoflurane-remifentanil anesthesia. Minerva Anestesiol. 2015 May;81(5):480-9. Epub 2014 Jul 17.|Gruenewald M, Ilies C, Herz J, Schoenherr T, Fudickar A, Höcker J, Bein B. Influence of nociceptive stimulation on analgesia nociception index (ANI) during propofol-remifentanil anaesthesia. Br J Anaesth. 2013 Jun;110(6):1024-30. doi: 10.1093/bja/aet019. Epub 2013 Mar 6.|Gruenewald M, Ilies C. Monitoring the nociception-anti-nociception balance. Best Pract Res Clin Anaesthesiol. 2013 Jun;27(2):235-47. doi: 10.1016/j.bpa.2013.06.007. Review.|Gruenewald M, Willms S, Broch O, Kott M, Steinfath M, Bein B. Sufentanil administration guided by surgical pleth index vs standard practice during sevoflurane anaesthesia: a randomized controlled pilot study. Br J Anaesth. 2014 May;112(5):898-905. doi: 10.1093/bja/aet485. Epub 2014 Feb 16.|Jaichandran VV, Raman R, Gella L, Sharma T. Local anesthetic agents for vitreoretinal surgery: no advantage to mixing solutions. Ophthalmology. 2015 May;122(5):1030-3. doi: 10.1016/j.ophtha.2014.11.026. Epub 2015 Jan 10.|Ghali AM. The efficacy of 0.75% levobupivacaine versus 0.75% ropivacaine for peribulbar anesthesia in vitreoretinal surgery. Saudi J Anaesth. 2012 Jan;6(1):22-6. doi: 10.4103/1658-354X.93050.|Seidenari P, Santin G, Milani P, David A. Peribulbar and retrobulbar combined anesthesia for vitreoretinal surgery using ropivacaine. Eur J Ophthalmol. 2006 Mar-Apr;16(2):295-9.|Subramaniam R, Subbarayudu S, Rewari V, Singh RP, Madan R. Usefulness of pre-emptive peribulbar block in pediatric vitreoretinal surgery: a prospective study. Reg Anesth Pain Med. 2003 Jan-Feb;28(1):43-7.|Fekrat S, Elsing SH, Raja SC, Campochiaro PA, de Juan E Jr, Haller JA. Eye pain after vitreoretinal surgery: a prospective study of 185 patients. Retina. 2001;21(6):627-32.|Calenda E, Olle P, Muraine M, Brasseur G. Peribulbar anesthesia and sub-Tenon injection for vitreoretinal surgery: 300 cases. Acta Ophthalmol Scand. 2000 Apr;78(2):196-9.|Sajedi P, Nejad MS, Montazeri K, Baloochestani E. Comparing the preventive effect of 2 percent topical lidocaine and intravenous atropine on oculocardiac reflex in ophthalmological surgeries under general anesthesia. Int J Prev Med. 2013 Nov;4(11):1258-65.|Calenda E, Quintyn JC, Brasseur G. Peribulbar anaesthesia using a combination of lidocaine, bupivocaine and clonidine in vitreoretinal surgery. Indian J Ophthalmol. 2002 Sep;50(3):205-8.|Mandelcorn M, Taback N, Mandelcorn E, Ananthanarayan C. Risk factors for pain and nausea following retinal and vitreous surgery under conscious sedation. Can J Ophthalmol. 1999 Aug;34(5):281-5.","\tOculocardiac Reflex|Postoperative Nausea and Vomiting|Postoperative Pain|Vitreoretinal Surgeries\tparacetamol|0,5 % bupivacaine with of 2% lidocaine|1 % ropivacaine with of 2% lidocaine|1 % Ropivacaine|0,5 % bupivacaine\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug|Drug|Drug|Drug\tAll\t","Different Peribulbar Blocks With SPI-guided Anaesthesia for VRS (P&MSPIVRS)","Interventional","Recruiting","N/A",5,175,"pain, postoperative|vomiting|postoperative nausea and vomiting","acetaminophen|lidocaine|bupivacaine|ropivacaine","NA"]
["NCT03420638","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|18983373|24281921|20069307|16929992|21812940|NA|24815964","1. Exparel® [package insert]. Pacira Pharmaceuticals, Inc., San Diego, CA; 2015. https://www.exparel.com/sites/default/files/EXPAREL_Prescribing_Information.pdf. Accessed June 12, 2017.|3. Cullen KA, Hall MJ, Golosinskiy A. Ambulatory surgery in the United States, 2006. Natl Health Stat Report. 2009;(11):1-25. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19294964. Accessed December 5, 2014.|Grainger J, Saravanappa N. Local anaesthetic for post-tonsillectomy pain: a systematic review and meta-analysis. Clin Otolaryngol. 2008 Oct;33(5):411-9. doi: 10.1111/j.1749-4486.2008.01815.x. Review.|Bhattacharyya N, Kepnes LJ. Revisits and postoperative hemorrhage after adult tonsillectomy. Laryngoscope. 2014 Jul;124(7):1554-6. doi: 10.1002/lary.24541. Epub 2014 Jan 3.|Stelter K, Hiller J, Hempel JM, Berghaus A, Hagedorn H, Andratschke M, Canis M. Comparison of two different local anaesthetic infiltrations for postoperative pain relief in tonsillectomy: a prospective, randomised, double blind, clinical trial. Eur Arch Otorhinolaryngol. 2010 Jul;267(7):1129-34. doi: 10.1007/s00405-009-1200-8. Epub 2010 Jan 13.|Arikan OK, Ozcan S, Kazkayasi M, Akpinar S, Koc C. Preincisional infiltration of tonsils with ropivacaine in post-tonsillectomy pain relief: double-blind, randomized, placebo-controlled intraindividual study. J Otolaryngol. 2006 Jun;35(3):167-72.|Diakos EA, Gallos ID, El-Shunnar S, Clarke M, Kazi R, Mehanna H. Dexamethasone reduces pain, vomiting and overall complications following tonsillectomy in adults: a systematic review and meta-analysis of randomised controlled trials. Clin Otolaryngol. 2011 Dec;36(6):531-42. doi: 10.1111/j.1749-4486.2011.02373.x. Review.|10. Tamm-Daniels, Inge. Liposomal Bupivacaine: What Is All The Fuss? University of Wisconsin School of Medicine and Public Health Madison, 5 Nov 2014-video Department of Anesthesiology grand Rounds https://videos.med.wisc.edu/videos/56752. Accessed July 10, 2017.|Tong YC, Kaye AD, Urman RD. Liposomal bupivacaine and clinical outcomes. Best Pract Res Clin Anaesthesiol. 2014 Mar;28(1):15-27. doi: 10.1016/j.bpa.2014.02.001. Epub 2014 Mar 15. Review.","\tTonsillectomy\tAdjunct Exparel (bupivacaine liposome suspension 1.3%)|Standard Care\tParallel Assignment\tTreatment\tRandomized\tDrug|Other\tAll\t","EXPAREL Post-tonsillectomy Clinical Trial","Interventional","Recruiting","Phase 4",2,38,"NA","epinephrine|bupivacaine","NA"]
["NCT03425071","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29471254,"Romano P, da Luz Fernandes M, de Almeida Rezende Ebner P, Duarte de Oliveira N, Mitsue Okuda L, Agena F, Mendes ME, Massakazu Sumita N, Coelho V, David-Neto E, Zocoler Galante N. UPLC-MS/MS assay validation for tacrolimus quantitative determination in peripheral blood T CD4+ and B CD19+ lymphocytes. J Pharm Biomed Anal. 2018 Apr 15;152:306-314. doi: 10.1016/j.jpba.2018.01.002. Epub 2018 Jan 5.","\tKidney Transplantation|Rejection\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT03439592","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18299505,"Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T, Raskin P; American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2008 Mar 25;117(12):1610-9. doi: 10.1161/CIRCULATIONAHA.107.188629. Epub 2008 Feb 25. Erratum in: Circulation. 2010 Jun 15;121(23):e444.","\tDiabetes Mellitus|Microbial Colonization|STEMI\tcollection of fecal material\tNA\tNA\tNA\tDiagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","st elevation myocardial infarction|communicable diseases|infection","NA","NA"]
["NCT03446859","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",7521353,"Adams JM, Taylor AE, Schoenfeld DA, Crowley WF Jr, Hall JE. The midcycle gonadotropin surge in normal women occurs in the face of an unchanging gonadotropin-releasing hormone pulse frequency. J Clin Endocrinol Metab. 1994 Sep;79(3):858-64.","\tPrimary Dysmenorrhea\tTENS\tParallel Assignment\tTreatment\tRandomized\tOther\tFemale\t","TENS on Pain Intensity in Primary Dysmenorrhea","Interventional","Completed","N/A",2,25,"dysmenorrhea","NA","NA"]
["NCT03448900","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26053958|30590861","Pardavila-Belio MI, García-Vivar C, Pimenta AM, Canga-Armayor A, Pueyo-Garrigues S, Canga-Armayor N. Intervention study for smoking cessation in Spanish college students: pragmatic randomized controlled trial. Addiction. 2015 Oct;110(10):1676-83. doi: 10.1111/add.13009. Epub 2015 Jul 2.|Pardavila-Belio MI, Canga-Armayor A, Duaso MJ, Pueyo-Garrigues S, Pueyo-Garrigues M, Canga-Armayor N. Understanding how a smoking cessation intervention changes beliefs, self-efficacy, and intention to quit: a secondary analysis of a pragmatic randomized controlled trial. Transl Behav Med. 2019 Jan 1;9(1):58-66. doi: 10.1093/tbm/ibx070.","\tSmoking|Smoking Cessation\tBrief advice|Multicomponent intervention\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral\tAll\t","Intervention Study for Smoking Cessation in Spanish College Students","Interventional","Completed","N/A",2,255,"NA","NA","NA"]
["NCT03455634","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31444594|31118532|NA|NA|NA","Brumini M, Slaj M, Katic V, Pavlic A, Trinajstic Zrinski M, Spalj S. Parental influence is the most important predictor of child's orthodontic treatment demand in a preadolescent age. Odontology. 2020 Jan;108(1):109-116. doi: 10.1007/s10266-019-00447-1. Epub 2019 Aug 23.|Acev DP, Brumini M, Šlaj M, Katić V, Špalj S. Child Perceptions Questionnaire in Croatia: Two Domains for Measuring Oral Health. Acta Stomatol Croat. 2019 Mar;53(1):47-54. doi: 10.15644/asc53/1/5.|Uhac M, Zibar Belasic T, Perkovic V, Zigante M, Spalj S. Validation of the Parental-Caregivers Perception Questionnaire (P-CPQ) in Croatia. Abstract book 6th Congress of School of Dental Medicine, University of Zagreb. Acta Stomatol Croat. 2020;54:210:212.|Brumini M, Uhac M, Zibar Belasic T, Spalj S. Parental attitude and emotional well-being mediate orthodontic treatment demand in adolescents. Abstract book 6th Congress of School of Dental Medicine, University of Zagreb. Acta Stomatol Croat. 2020;54:210:212-3.|Brumini M. Predictors of orthodontic treatment demand in early adolescence (dissertation). Rijeka; University of Rijeka, Faculty of Medicine: 2020.","\tMalocclusion, Angle Class II\tTwin Block|Sander bite jumping appliance\tParallel Assignment\tTreatment\tRandomized\tDevice|Device\tAll\t","Predictors Associated With Seeking Orthodontic Treatment, Compliance and Treatment Success","Interventional","Recruiting","N/A",3,60,"malocclusion, angle class ii|overbite|malocclusion","NA","NA"]
["NCT03462212","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22237781|16946210|12460789|12217790|12241653|16394300|7494563|10623700|10793106|18268546|16239238|9377574|11533692|11309294|10628376|8962129|9714067|22204724|22204725|18024865|24637997|15829966|15829967|22711857|21720365|20606085|1581961|11331762|11459964|12205100|15905196|15327776|19779458|19049966|15665856|14701743|23047548|22912389|20609468|20609467|21862407|22203755|22452356|24882434|23810788|16912188|23118055|23512992|20551068|19553641|17714938|16357170|15367671|24862760|23810467|25218906|18955455|22576213",{"$cut":{"chars":18736,"head":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.|Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, Berek JS, Osann K. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol. 2006 Sep;108(3 Pt 1):521-8.|Engel J, Eckel R, Schubert-Fritschle G, Kerr J, Kuhn W, Diebold J, Kimmig R, Rehbock J, Hölzel D. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer. 2002 Dec;38(18):2435-45.|Harries M, Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol. 2002 Sep;3(9):529-36. Review.|International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002 Aug 17;360(9332):505-15. Erratum in: Lancet. 2003 Feb 22;361(9358):706.|Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43.|McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996 Jan 4;334(1):1-6.|Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000 Jan;18(1):106-15.|Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000 May 3;92(9):699-708.|Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol. 2008 Apr;5(4):194-204. doi: 10.1038/ncponc1051. Epub 2008 Feb 12. Review.|du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, Vasey P, Vergote I, Verheijen R, Wagner U; Gynecologic Cancer Intergroup; AGO-OVAR; ANZGOG; EORTC; GEICO; GINECO; GOG; JGOG; MRC/NCRI; NCIC-CTG; NCI-US; NSGO; RTOG; SGCTG; IGCS; Organizational team of the two prior International OCCC. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005;16 Suppl 8:viii7-viii12.|Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997 Oct 15;57(20):4593-9.|Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001 Sep;7(9):987-9. Review.|Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW Jr. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or "}},"\tAdvanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer\tCarboplatin|Paclitaxel|Bevacizumab|Rucaparib\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug\tFemale\t","Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination","Interventional","Active, not recruiting","Phase 1/Phase 2",3,290,"fallopian tube neoplasms","bevacizumab|carboplatin|paclitaxel|rucaparib","NA"]
["NCT03471455","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27297276,"Ardeshna KP, Rohatgi S, Jerajani HR. Successful treatment of recurrent dermatophytosis with isotretinoin and itraconazole. Indian J Dermatol Venereol Leprol. 2016 Sep-Oct;82(5):579-82. doi: 10.4103/0378-6323.183632.","\tTinea\tIsotretinoin|Terbinafine|Itraconazole 200 mg\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","Isotretinoin In Preventing Recurrences In Chronic Recurrent Dermatophytosis","Interventional","Unknown status","Phase 2",4,100,"recurrence|tinea","itraconazole|terbinafine|isotretinoin","NA"]
["NCT03478072","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28856676|25387515","Sar-Pomian M, Rudnicka L, Olszewska M. Trichoscopy - a useful tool in the preliminary differential diagnosis of autoimmune bullous diseases. Int J Dermatol. 2017 Oct;56(10):996-1002. doi: 10.1111/ijd.13725. Epub 2017 Aug 30.|Sar-Pomian M, Kurzeja M, Rudnicka L, Olszewska M. The value of trichoscopy in the differential diagnosis of scalp lesions in pemphigus vulgaris and pemphigus foliaceus. An Bras Dermatol. 2014 Nov-Dec;89(6):1007-12.","\tIMMUNOBULLOUS DISEASES\ttrichoscopy\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT03487315","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25601168,"Nilsson N, Sjölander S, Baar A, Berthold M, Pahr S, Vrtala S, Valenta R, Morita E, Hedlin G, Borres MP, Nilsson C. Wheat allergy in children evaluated with challenge and IgE antibodies to wheat components. Pediatr Allergy Immunol. 2015 Mar;26(2):119-25. doi: 10.1111/pai.12334.","\tAnaphylaxis Exercise|Anaphylaxis Food|Wheat Allergy\timmunoblot\tNA\tNA\tNA\tDiagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","shock|wheat hypersensitivity|anaphylaxis","NA","NA"]
["NCT03495492","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","9630463|22293416|22945569|1131339|11333192|27486361|21827276|26264017|24368178|19897186|3149183|6363310|1250252|15689032|15092991|4513535|2738890|1009120|25445091|14965792|25009099|4609793|1719661|10771143|22235210|1068773|7023931|11703167|6824602|26508811|26185180|21540277","Sandborgh-Englund G, Elinder CG, Johanson G, Lind B, Skare I, Ekstrand J. The absorption, blood levels, and excretion of mercury after a single dose of mercury vapor in humans. Toxicol Appl Pharmacol. 1998 May;150(1):146-53.|Yaginuma-Sakurai K, Murata K, Iwai-Shimada M, Nakai K, Kurokawa N, Tatsuta N, Satoh H. Hair-to-blood ratio and biological half-life of mercury: experimental study of methylmercury exposure through fish consumption in humans. J Toxicol Sci. 2012 Feb;37(1):123-30.|Tchounwou PB, Yedjou CG, Patlolla AK, Sutton DJ. Heavy metal toxicity and the environment. Exp Suppl. 2012;101:133-64. doi: 10.1007/978-3-7643-8340-4_6. Review.|Barry PS. A comparison of concentrations of lead in human tissues. Br J Ind Med. 1975 May;32(2):119-39.|Vaglenov A, Creus A, Laltchev S, Petkova V, Pavlova S, Marcos R. Occupational exposure to lead and induction of genetic damage. Environ Health Perspect. 2001 Mar;109(3):295-8.|Wani AL, Ara A, Usmani JA. Lead toxicity: a review. Interdiscip Toxicol. 2015 Jun;8(2):55-64. doi: 10.1515/intox-2015-0009. Review.|Nie LH, Wright RO, Bellinger DC, Hussain J, Amarasiriwardena C, Chettle DR, Pejović-Milić A, Woolf A, Shannon M. Blood lead levels and cumulative blood lead index (CBLI) as predictors of late neurodevelopment in lead poisoned children. Biomarkers. 2011 Sep;16(6):517-24. doi: 10.3109/1354750X.2011.604133. Epub 2011 Aug 9.|Jo S, Woo HD, Kwon HJ, Oh SY, Park JD, Hong YS, Pyo H, Park KS, Ha M, Kim H, Sohn SJ, Kim YM, Lim JA, Lee SA, Eom SY, Kim BG, Lee KM, Lee JH, Hwang MS, Kim J. Estimation of the Biological Half-Life of Methylmercury Using a Population Toxicokinetic Model. Int J Environ Res Public Health. 2015 Jul 31;12(8):9054-67. doi: 10.3390/ijerph120809054.|Rooney JP. The retention time of inorganic mercury in the brain--a systematic review of the evidence. Toxicol Appl Pharmacol. 2014 Feb 1;274(3):425-35. doi: 10.1016/j.taap.2013.12.011. Epub 2013 Dec 22. Review.|Cretacci Y, Parsons PJ. Localized accumulation of lead within and among bones from lead-dosed goats. Environ Res. 2010 Jan;110(1):26-32. doi: 10.1016/j.envres.2009.09.005.|Flood PR, Schmidt PF, Wesenberg GR, Gadeholt H. The distribution of lead in human hemopoietic tissue and spongy bone after lead poisoning and Ca-EDTA chelation therapy. Observations made by atomic absorption spectroscopy, laser microbeam mass analysis and electron microbeam X-ray analysis. Arch Toxicol. 1988;62(4):295-300.|Stelzer KJ, Pazdernik TL. Cadmium-induced immunotoxicity. Int J Immunopharmacol. 1983;5(6):541-8.|Bauchinger M, Schmid E, Einbrodt HJ, Dresp J. Chromosome aberrations in lymphocytes after occupational exposure to lead and cadmium. Mutat Res. 1976 Jan;40(1):57-62.|Grujić S, Ristić M, Lausević M. Heavy metals in petroleum-contaminated surface soils in Serbia. Ann Chim. 2004 Dec;94(12):961-70.|Stigter JB, de Haan HP, Guicherit R, Dekkers CP, Daane ML. Determination of cadmium, zinc, copper, chromium and arsenic in crude oil cargoes. Environ Pollut. 2000 Mar;107(3):451-64.|Cline DM, Hiott DW, Nunnery KE, Shealy RG, Towles WC, Watkins RW. Pneumatosis cystoides intestinalis. J S C Med Assoc. 1973 Jun;69(6):226-8.|Kang Y, Larson SB, Robins RK, Revankar GR. Synthesis and biological evaluation of certain 3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-b)pyridazines related to formycin prepared via ring closure of pyridazine precursors. J Med Chem. 1989 Jul;32(7):1547-51.|Farooqui AA, Roy AB. The sulphatase of ox liver. XX. The preparation of sulphatases B1alpha and B1beta. Biochim Biophys Acta. 1976 Dec 8;452(2):431-9.|Van Neste D. Why care about linear hair growth rates (LHGR)? a study using in vivo imaging and computer assisted image analysis after manual processing (CAIAMP) in unaffected male controls and men with male pattern hair loss (MPHL). Eur J Dermatol. 2014 Sep-Oct;24(5):568-76. doi: 10.1684/ejd.2014.2428.|Van Neste D. Thickness, medullation and growth rate of female scalp hair are subject to significant variation according to pigmentation and scalp location during ageing. Eur J Dermatol. 2004 Jan-Feb;14(1):28-32.|Li J, Cen D, Huang D, Li X, Xu J, Fu S, Cai R, Wu X, Tang M, Sun Y, Zhang J, Zheng J. Detection and analysis of 12 heavy metals in blood and hair sample from a general population of Pearl River Delta area. Cell Biochem Biophys. 2014 Dec;70(3):1663-9. doi: 10.1007/s12013-014-0110-6.|Vorob'ev VI, Kosjuk GN. Distribution of repetitive and non-repetitive nucleotide sequences in the DNA of sea urchin. FEBS Lett. 1974 Oct 1;47(1):43-6.|McCabe MJ Jr, Lawrence DA. Lead, a major environmental pollutant, is immunomodulatory by its differential effects on CD4+ T cells subsets. Toxicol Appl Pharmacol. 1991 Oct;111(1):13-23.|Devi KD, Banu BS, Grover P, Jamil K. Genotoxic effect of lead nitrate on mice using SCGE (comet assay). Toxicology. 2000 Apr 14;145(2-3):195-201.|Bernhoft RA. Mercury toxicity and treatment: a review of the literature. J Environ Public Health. 2012;2012:460508. doi: 10.1155/2012/460508. Epub 2011 Dec 22. Review.|Rose TP. Sterilization of carious dentine with silver nitrate. Chronicle. 1976 Oct;39(8):151, 159.|Vainio H, Sorsa M. Chromosome aberrations and their relevance to metal carcinogenesis. Environ Health Perspect. 1981 Aug;40:173-80. Review.|Bass DA, Hickock D, Quig D, Urek K. Trace element analysis in hair: factors determining accuracy, precision, and reliability. Altern Med Rev. 2001 Oct;6(5):472-81. Review.|Niculescu T, Dumitru R, Botha V, Alexandrescu R, Manolescu N. Relationship between the lead concentration in hair and occupational exposure. Br J Ind Med. 1983 Feb;40(1):67-70.|Mohamed Fel B, Zaky EA, El-Sayed AB, Elhossieny RM, Zahra SS, Salah Eldin W, Youssef WY, Khaled RA, Youssef AM. Assessment of Hair Aluminum, Lead, and Mercury in a Sample of Autistic Egyptian Children: Environmental Risk Factors of Heavy Metals in Autism. Behav Neurol. 2015;2015:545674. doi: 10.1155/2015/545674. Epub 2015 Oct 5.|Jung SY, Kim S, Lee K, Kim JY, Bae WK, Lee K, Han JS, Kim S. Association between secondhand smoke exposure and blood lead and cadmium concentration in community dwelling women: the fifth Korea National Health and Nutrition Examination Survey (2010-2012). BMJ Open. 2015 Jul 16;5(7):e008218. doi: 10.1136/bmjopen-2015-008218.|Horiguchi H, Oguma E, Kayama F. Cadmium induces anemia through interdependent progress of hemolysis, body iron accumulation, and insufficient erythropoietin production in rats. Toxicol Sci. 2011 Jul;122(1):198-210. doi: 10.1093/toxsci/kfr100. Epub 2011 May 3.","\tChronic Lymphocytic Leukemia\tDermal Chelation|Nutritional Therapy\tNA\tNA\tNA\tDevice|Dietary Supplement\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, lymphocytic, chronic, b-cell|leukemia|leukemia, lymphoid","NA","NA"]
["NCT03497858","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22257640,"Kalman DS, Feldman S, Krieger DR, Bloomer RJ. Comparison of coconut water and a carbohydrate-electrolyte sport drink on measures of hydration and physical performance in exercise-trained men. J Int Soc Sports Nutr. 2012 Jan 18;9(1):1. doi: 10.1186/1550-2783-9-1.","\tCoconut Water|Gatorade|Water\tCoconut Water|Placebo - water|Sports drink\tParallel Assignment\tTreatment\tRandomized\tOther|Other|Other\tAll\t","The Effect of Coconut Water on Varsity Basketball Performance","Interventional","Unknown status","N/A",3,20,"NA","NA","NA"]
["NCT03506217","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26309835,"Colli A, Zucchetta F, Torregrossa G, Manzan E, Bizzotto E, Besola L, Bellu R, Sarais C, Pittarello D, Gerosa G. Transapical off-pump mitral valve repair with Neochord Implantation (TOP-MINI): step-by-step guide. Ann Cardiothorac Surg. 2015 May;4(3):295-7. doi: 10.3978/j.issn.2225-319X.2015.05.01. Review.","\tMitral Valve Prolapse\tVigileo Flo-trac device\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","mitral valve prolapse|prolapse","NA","NA"]
["NCT03512613","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24795612|26063779|27571474|26334746|NA","Govindan RB, Massaro AN, Andescavage NN, Chang T, du Plessis A. Cerebral pressure passivity in newborns with encephalopathy undergoing therapeutic hypothermia. Front Hum Neurosci. 2014 Apr 24;8:266. doi: 10.3389/fnhum.2014.00266. eCollection 2014.|Massaro AN, Govindan RB, Vezina G, Chang T, Andescavage NN, Wang Y, Al-Shargabi T, Metzler M, Harris K, du Plessis AJ. Impaired cerebral autoregulation and brain injury in newborns with hypoxic-ischemic encephalopathy treated with hypothermia. J Neurophysiol. 2015 Aug;114(2):818-24. doi: 10.1152/jn.00353.2015. Epub 2015 Jun 10.|Tsalach A, Ratner E, Lokshin S, Silman Z, Breskin I, Budin N, Kamar M. Cerebral Autoregulation Real-Time Monitoring. PLoS One. 2016 Aug 29;11(8):e0161907. doi: 10.1371/journal.pone.0161907. eCollection 2016.|Hori D, Hogue CW Jr, Shah A, Brown C, Neufeld KJ, Conte JV, Price J, Sciortino C, Max L, Laflam A, Adachi H, Cameron DE, Mandal K. Cerebral Autoregulation Monitoring with Ultrasound-Tagged Near-Infrared Spectroscopy in Cardiac Surgery Patients. Anesth Analg. 2015 Nov;121(5):1187-93. doi: 10.1213/ANE.0000000000000930.|Rachelia, N. (2012). Non-Invasive Blood Flow Measurements Using Ultrasound Modulated Diffused Light. In Photons Plus Ultrasound: Imaging and Sensing 2012.","\tCerebrovascular Circulation|Congenital Heart Defect\tc-FLOW 3310-P\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","heart defects, congenital","NA","NA"]
["NCT03517592","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29230558,"Tirado-Muñoz J, Gilchrist G, Fischer G, Taylor A, Moskalewicz J, Giammarchi C, Köchl B, Munro A, Dąbrowska K, Shaw A, Di Furia L, Leeb I, Hopf C, Torrens M. Psychiatric comorbidity and intimate partner violence among women who inject drugs in Europe: a cross-sectional study. Arch Womens Ment Health. 2018 Jun;21(3):259-269. doi: 10.1007/s00737-017-0800-3. Epub 2017 Dec 11. Erratum in: Arch Womens Ment Health. 2018 Jan 16;:.","\tSubstance Use Disorders\tEMDR|Treatment as Usual\tParallel Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","EMDR Versus Treatment As Usual in Patients With Substance Use Disorder","Interventional","Recruiting","N/A",2,142,"substance-related disorders","NA","NA"]
["NCT03528707","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",30221912,"Kobyliak N, Abenavoli L, Falalyeyeva T, Mykhalchyshyn G, Boccuto L, Kononenko L, Kyriienko D, Komisarenko I, Dynnyk O. Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study. Minerva Med. 2018 Dec;109(6):418-428. doi: 10.23736/S0026-4806.18.05845-7. Epub 2018 Sep 13.","\tNAFLD|Omega-3 Fatty Acids|Probiotic|Type2 Diabetes\tSymbiter-Omega|Placebo\tParallel Assignment\tTreatment\tRandomized\tDietary Supplement|Dietary Supplement\tAll\t","Effect of Probiotic Co-administration With Omega-3 Fatty Acids on NAFLD","Interventional","Completed","N/A",2,48,"non-alcoholic fatty liver disease","NA","NA"]
["NCT03540823","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29297852|29346614|29409570","Korsun N, Angelova S, Trifonova I, Tzotcheva I, Mileva S, Voleva S, Georgieva I, Perenovska P. Predominance of influenza A(H3N2) viruses during the 2016/2017 season in Bulgaria. J Med Microbiol. 2018 Feb;67(2):228-239. doi: 10.1099/jmm.0.000668. Epub 2018 Jan 3.|Chiu SS, Kwan MYW, Feng S, Wong JSC, Leung CW, Chan ELY, Chan KH, Ng TK, To WK, Cowling BJ, Peiris JSM. Influenza Vaccine Effectiveness Against Influenza A(H3N2) Hospitalizations in Children in Hong Kong in a Prolonged Season, 2016/2017. J Infect Dis. 2018 Apr 11;217(9):1365-1371. doi: 10.1093/infdis/jiy027.|Skowronski DM, Chambers C, De Serres G, Dickinson JA, Winter AL, Hickman R, Chan T, Jassem AN, Drews SJ, Charest H, Gubbay JB, Bastien N, Li Y, Krajden M. Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018. Euro Surveill. 2018 Feb;23(5). doi: 10.2807/1560-7917.ES.2018.23.5.18-00035. Erratum in: Euro Surveill. 2018 Jul;23(30):.","\tSjogren's Syndrome|Systemic Lupus\tInactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)\tNA\tNA\tNA\tBiological\tAll\t","Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases","Interventional","Completed","Phase 4",2,300,"sjogren's syndrome","NA","NA"]
["NCT03546179","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22690040|25897397|16037184|15006570|11094507|15247205|27922879","Tympa A, Theodoraki K, Tsaroucha A, Arkadopoulos N, Vassiliou I, Smyrniotis V. Anesthetic Considerations in Hepatectomies under Hepatic Vascular Control. HPB Surg. 2012;2012:720754. doi: 10.1155/2012/720754. Epub 2012 May 28.|Navarro LH, Bloomstone JA, Auler JO Jr, Cannesson M, Rocca GD, Gan TJ, Kinsky M, Magder S, Miller TE, Mythen M, Perel A, Reuter DA, Pinsky MR, Kramer GC. Perioperative fluid therapy: a statement from the international Fluid Optimization Group. Perioper Med (Lond). 2015 Apr 10;4:3. doi: 10.1186/s13741-015-0014-z. eCollection 2015.|Joshi GP. Intraoperative fluid restriction improves outcome after major elective gastrointestinal surgery. Anesth Analg. 2005 Aug;101(2):601-5. Review.|Smyrniotis V, Kostopanagiotou G, Theodoraki K, Tsantoulas D, Contis JC. The role of central venous pressure and type of vascular control in blood loss during major liver resections. Am J Surg. 2004 Mar;187(3):398-402.|Michard F, Teboul JL. Using heart-lung interactions to assess fluid responsiveness during mechanical ventilation. Crit Care. 2000;4(5):282-9. Epub 2000 Sep 1. Review.|Michard F, Schmidt U. Prediction of fluid responsiveness: searching for the Holy Grail. J Appl Physiol (1985). 2004 Aug;97(2):790-1; author reply 791.|\"Myatra SN, Prabu NR, Divatia JV, Monnet X, Kulkarni AP, Teboul JL. The Changes in Pulse Pressure Variation or Stroke Volume Variation After a \"\"Tidal Volume Challenge\"\" Reliably Predict Fluid Responsiveness During Low Tidal Volume Ventilation. Crit Care Med. 2017 Mar;45(3):415-421. doi: 10.1097/CCM.0000000000002183.\"","\tAbdominal Cancer\ttidal volume challenge test|Volume loading\tNA\tNA\tNA\tOther|Other\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT03548571","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23817721,"Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, Rasmussen AM, Lote K, Aamdal S, Gaudernack G, Kvalheim G, Langmoen IA. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother. 2013 Sep;62(9):1499-509. doi: 10.1007/s00262-013-1453-3. Epub 2013 Jul 2.","\tGlioblastoma\tDendritic cell immunization|Adjuvant temozolomide\tParallel Assignment\tTreatment\tRandomized\tBiological|Drug\tAll\t","Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy","Interventional","Recruiting","Phase 2/Phase 3",2,60,"glioblastoma","vaccines|temozolomide","NA"]
["NCT03553368","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32898653,"Darçot E, Delacoste J, Dunet V, Dournes G, Rotzinger D, Bernasconi M, Vremaroiu P, Simons J, Long O, Rohner C, Ledoux JB, Stuber M, Lovis A, Beigelman-Aubry C. Lung MRI assessment with high-frequency noninvasive ventilation at 3 T. Magn Reson Imaging. 2020 Dec;74:64-73. doi: 10.1016/j.mri.2020.09.006. Epub 2020 Sep 6.","\tNeoplasms\tHF-NIV-MR|HF-NIV-PET|MR|PET/CT breath hold|CPAP-MR\tNA\tNA\tNA\tDiagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test\tAll\t","Chest Imaging of Lung Nodule(s) Under High-frequency Non-invasive Ventilation (HF-NIV)","Interventional","Completed","N/A",4,40,"NA","NA","NA"]
["NCT03562403","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12566335|8559296","Guttman M, Kish SJ, Furukawa Y. Current concepts in the diagnosis and management of Parkinson's disease. CMAJ. 2003 Feb 4;168(3):293-301. Review. Erratum in: CMAJ. 2003 Mar 4;168(5):544.|Jankovic J, Cardoso F, Grossman RG, Hamilton WJ. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery. 1995 Oct;37(4):680-6; discussion 686-7.","\tParkinson Disease, Essential Tremors and Dystonia\tDeep Brain Stimulation\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","tremor|movement disorders|essential tremor|dystonic disorders|parkinson disease|dystonia","NA","NA"]
["NCT03567538","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32564001|33217414","Sachs E, Jackson V, Sartipy U. Household disposable income and long-term survival after pulmonary resections for lung cancer. Thorax. 2020 Sep;75(9):764-770. doi: 10.1136/thoraxjnl-2019-214321. Epub 2020 Jun 20.|Sachs E, Sartipy U, Jackson V. Sex and Survival After Surgery for Lung Cancer: A Swedish Nationwide Cohort. Chest. 2020 Nov 17. pii: S0012-3692(20)35155-2. doi: 10.1016/j.chest.2020.11.010. [Epub ahead of print]","\tLung Cancer|Pulmonary Metastasis|Surgery\tThoracic surgery\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","neoplasm metastasis","NA","NA"]
["NCT03578484","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","13230442|13335513|3659165|2729845|3737757|15838205|16978973|20048631|20206751|25028852","PENN J. Breast reduction. Br J Plast Surg. 1955 Jan;7(4):357-71.|WISE RJ. A preliminary report on a method of planning the mammaplasty. Plast Reconstr Surg (1946). 1956 May;17(5):367-75.|Loughry CW, Sheffer DB, Price TE Jr, Lackney MJ, Bartfai RG, Morek WM. Breast volume measurement of 248 women using biostereometric analysis. Plast Reconstr Surg. 1987 Oct;80(4):553-8.|Loughry CW, Sheffer DB, Price TE, Einsporn RL, Bartfai RG, Morek WM, Meli NM. Breast volume measurement of 598 women using biostereometric analysis. Ann Plast Surg. 1989 May;22(5):380-5.|Smith DJ Jr, Palin WE Jr, Katch VL, Bennett JE. Breast volume and anthropomorphic measurements: normal values. Plast Reconstr Surg. 1986 Sep;78(3):331-5.|Losken A, Seify H, Denson DD, Paredes AA Jr, Carlson GW. Validating three-dimensional imaging of the breast. Ann Plast Surg. 2005 May;54(5):471-6; discussion 477-8.|Tepper OM, Small K, Rudolph L, Choi M, Karp N. Virtual 3-dimensional modeling as a valuable adjunct to aesthetic and reconstructive breast surgery. Am J Surg. 2006 Oct;192(4):548-51.|Tepper OM, Unger JG, Small KH, Feldman D, Kumar N, Choi M, Karp NS. Mammometrics: the standardization of aesthetic and reconstructive breast surgery. Plast Reconstr Surg. 2010 Jan;125(1):393-400. doi: 10.1097/PRS.0b013e3181c4966e.|Rohrich RJ, Bolden K. Ethnic rhinoplasty. Clin Plast Surg. 2010 Apr;37(2):353-70. doi: 10.1016/j.cps.2009.11.006.|Li Z, Unger JG, Roostaeian J, Constantine F, Rohrich RJ. Individualized Asian rhinoplasty: a systematic approach to facial balance. Plast Reconstr Surg. 2014 Jul;134(1):24e-32e. doi: 10.1097/PRS.0000000000000294.","\tBreast Cancer\tAesthetic assessment 3D breast scanning\tNA\tNA\tNA\tDiagnostic Test\tFemale\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT03580551","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",31338477,"McCaskill GM, Clay OJ, Motl RW, Ball KK. Older Veterans EmpoweRed To Use Regular Exercise (OVERTURE) II: Design and methods of a randomized controlled trial among older veterans with chronic health conditions. Contemp Clin Trials Commun. 2019 Jun 28;15:100395. doi: 10.1016/j.conctc.2019.100395. eCollection 2019 Sep.","\tAging|Quality of Life\tIntervention Group|Waitlist Control Group\tParallel Assignment\tOther\tRandomized\tBehavioral|Behavioral\tAll\t","Older Veterans EmpoweRed To Use Regular Exercise (OVERTURE) II","Interventional","Active, not recruiting","N/A",2,40,"NA","NA","NA"]
["NCT03590964","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24621196|14971260|18724852|12449303","Mahesh L, Kurtzman GM, Shukla S. Trephine core: an alternative sinus lift technique. J Oral Implantol. 2014 Jul;40 Spec No:391-6. doi: 10.1563/aaid-joi-D-14-00047. Epub 2014 Mar 12.|Wallace SS, Froum SJ. Effect of maxillary sinus augmentation on the survival of endosseous dental implants. A systematic review. Ann Periodontol. 2003 Dec;8(1):328-43. Review.|Pjetursson BE, Tan WC, Zwahlen M, Lang NP. A systematic review of the success of sinus floor elevation and survival of implants inserted in combination with sinus floor elevation. J Clin Periodontol. 2008 Sep;35(8 Suppl):216-40. doi: 10.1111/j.1600-051X.2008.01272.x. Review.|Wang PD, Klein S, Kaufman E. One-stage maxillary sinus elevation using a bone core containing a preosseointegrated implant from the mandibular symphysis. Int J Periodontics Restorative Dent. 2002 Oct;22(5):435-9.","\tAtrophied Posterior Maxilla\tOpen sinus lift using chin bone graft|Sinus lift using bone ring containing the implant.\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","One-stage Maxillary Sinus Elevation Using a Bone Core Containing an Implant From the Mandibular Symphysis","Interventional","Unknown status","N/A",2,30,"atrophy","NA","NA"]
["NCT03592134","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15858606|26769758|24071905|16688202","Liptsen E, Aghai ZH, Pyon KH, Saslow JG, Nakhla T, Long J, Steele AM, Habib RH, Courtney SE. Work of breathing during nasal continuous positive airway pressure in preterm infants: a comparison of bubble vs variable-flow devices. J Perinatol. 2005 Jul;25(7):453-8.|Shetty S, Hickey A, Rafferty GF, Peacock JL, Greenough A. Work of breathing during CPAP and heated humidified high-flow nasal cannula. Arch Dis Child Fetal Neonatal Ed. 2016 Sep;101(5):F404-7. doi: 10.1136/archdischild-2015-309310. Epub 2016 Jan 14.|de Jongh BE, Locke R, Mackley A, Emberger J, Bostick D, Stefano J, Rodriguez E, Shaffer TH. Work of breathing indices in infants with respiratory insufficiency receiving high-flow nasal cannula and nasal continuous positive airway pressure. J Perinatol. 2014 Jan;34(1):27-32. doi: 10.1038/jp.2013.120. Epub 2013 Sep 26.|Saslow JG, Aghai ZH, Nakhla TA, Hart JJ, Lawrysh R, Stahl GE, Pyon KH. Work of breathing using high-flow nasal cannula in preterm infants. J Perinatol. 2006 Aug;26(8):476-80. Epub 2006 May 11.","\tPreterm Infant|Respiratory Distress Syndrome\tesophageal pressure measurement\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","respiratory distress syndrome, newborn|respiratory distress syndrome, adult|premature birth","NA","NA"]
["NCT03599804","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19130972|18164986|11271438|11677737|8928631|NA|15354003|22481544","Krause E, Wechtenbruch J, Rader T, Gürkov R. Influence of cochlear implantation on sacculus function. Otolaryngol Head Neck Surg. 2009 Jan;140(1):108-113. doi: 10.1016/j.otohns.2008.10.008.|Todt I, Basta D, Ernst A. Does the surgical approach in cochlear implantation influence the occurrence of postoperative vertigo? Otolaryngol Head Neck Surg. 2008 Jan;138(1):8-12. doi: 10.1016/j.otohns.2007.09.003.|Kubo T, Yamamoto K, Iwaki T, Doi K, Tamura M. Different forms of dizziness occurring after cochlear implant. Eur Arch Otorhinolaryngol. 2001 Jan;258(1):9-12.|Vibert D, Häusler R, Kompis M, Vischer M. Vestibular function in patients with cochlear implantation. Acta Otolaryngol Suppl. 2001;545:29-34.|Vibert D, Liard P, Häusler R. Bilateral idiopathic loss of peripheral vestibular function with normal hearing. Acta Otolaryngol. 1995 Sep;115(5):611-5.|Frazza MM. (1999): Propedèutica otoneurológica básica. In: Gananҫ, FF (coordenator). Um giro pela vertigem. Sào Paulo: Alaúde; p.21-24.|Hempel JM, Jäger L, Baumann U, Krause E, Rasp G. Labyrinth dysfunction 8 months after cochlear implantation: a case report. Otol Neurotol. 2004 Sep;25(5):727-9.|Katsiari E, Balatsouras DG, Sengas J, Riga M, Korres GS, Xenelis J. Influence of cochlear implantation on the vestibular function. Eur Arch Otorhinolaryngol. 2013 Feb;270(2):489-95. doi: 10.1007/s00405-012-1950-6. Epub 2012 Apr 6.","\tVestibular Abnormality\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","hearing loss|deafness","NA","NA"]
["NCT03615807","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25805867,"Tone A, Nguyen S, Devemy F, Topolinski H, Valette M, Cazaubiel M, Fayard A, Beltrand É, Lemaire C, Senneville É. Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study. Diabetes Care 2015;38:302-307. Diabetes Care. 2015 Apr;38(4):735. doi: 10.2337/dc15-er04b.","\tDiabetic Foot\tSurgical debridement (if needed)|Microbiological sampling|Revascularisation (if needed).|Off-loading|Patient's education and instructions|Wound debridement|Antibiotic duration\tParallel Assignment\tTreatment\tRandomized\tProcedure|Diagnostic Test|Procedure|Device|Behavioral|Procedure|Drug\tAll\t","Less Infections for the Diabetic Foot","Interventional","Completed","N/A",2,182,"infection|diabetic foot","anti-bacterial agents","NA"]
["NCT03621683","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26635884|15149546|15014492|26788065|26029346|28264815|26829445|27255570","Bhartiya D, Parte S, Patel H, Sriraman K, Zaveri K, Hinduja I. Novel Action of FSH on Stem Cells in Adult Mammalian Ovary Induces Postnatal Oogenesis and Primordial Follicle Assembly. Stem Cells Int. 2016;2016:5096596. doi: 10.1155/2016/5096596. Epub 2015 Nov 9. Review.|Telfer EE. Germline stem cells in the postnatal mammalian ovary: a phenomenon of prosimian primates and mice? Reprod Biol Endocrinol. 2004 May 18;2:24.|Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature. 2004 Mar 11;428(6979):145-50. Erratum in: Nature. 2004 Aug 26;430(7003):1062.|Pan Z, Sun M, Liang X, Li J, Zhou F, Zhong Z, Zheng Y. The Controversy, Challenges, and Potential Benefits of Putative Female Germline Stem Cells Research in Mammals. Stem Cells Int. 2016;2016:1728278. doi: 10.1155/2016/1728278. Epub 2015 Dec 15. Review.|Ozakpinar OB, Maurer AM, Ozsavci D. Ovarian stem cells: From basic to clinical applications. World J Stem Cells. 2015 May 26;7(4):757-68. doi: 10.4252/wjsc.v7.i4.757. Review.|Diamanti-Kandarakis E, Dattilo M, Macut D, Duntas L, Gonos ES, Goulis DG, Gantenbein CK, Kapetanou M, Koukkou E, Lambrinoudaki I, Michalaki M, Eftekhari-Nader S, Pasquali R, Peppa M, Tzanela M, Vassilatou E, Vryonidou A; COMBO ENDO TEAM: 2016. MECHANISMS IN ENDOCRINOLOGY: Aging and anti-aging: a Combo-Endocrinology overview. Eur J Endocrinol. 2017 Jun;176(6):R283-R308. doi: 10.1530/EJE-16-1061. Epub 2017 Mar 6. Review.|Gat I, Blanco Mejia S, Balakier H, Librach CL, Claessens A, Ryan EA. The use of coenzyme Q10 and DHEA during IUI and IVF cycles in patients with decreased ovarian reserve. Gynecol Endocrinol. 2016 Jul;32(7):534-7. doi: 10.3109/09513590.2015.1137095. Epub 2016 Feb 1.|Özcan P, Fıçıcıoğlu C, Kizilkale O, Yesiladali M, Tok OE, Ozkan F, Esrefoglu M. Can Coenzyme Q10 supplementation protect the ovarian reserve against oxidative damage? J Assist Reprod Genet. 2016 Sep;33(9):1223-30. doi: 10.1007/s10815-016-0751-z. Epub 2016 Jun 3.","\tOvarian Reserve\tblood rich plasma platelets|Antioxidant therapy\tNA\tNA\tNA\tProcedure|Dietary Supplement\tFemale\t","Antioxidants vs. Ovarian Bio-stimulation Therapy to Rescue the Ovarian Reserve","Interventional","Completed","N/A",2,78,"NA","antioxidants","NA"]
["NCT03627507","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|NA|NA|29201750|NA|NA|20949113","Mushahwar I. Viral Hepatitis: Molecular Biology, Diagnosis, Epidemiology, and Control. 1st ed. Amsterdam: Elsevier; 2004. Page 31, 79|Ghosh, D., Ghosh, C., Nath, M., Safwath, S., Saha, S., & Rowshon, A. (2018). Prevalence of anti-HBc total positivity in an impoverished Urban Community in Banglades. Bangladesh Medical Research Council Bulletin, 43(2), 63-70|Ahad M, Alim M. Current Challenges in Hepatitis B. TAJ: The Journal of Teachers Association RMC, Rajshahi. 2006; 19 (1):38-44|Mahtab MA, Chaudhury M, Uddin MH, Noor-E Alam SM, Rahim MA, Alam MA, Moben AL, Khondaker FA, Choudhury MF, Sarkar MJ, Poddar PK, Foez SA, Akbar SM. Cost Assessment of Hepatitis B Virus-related Hepatitis in Bangladesh. Euroasian J Hepatogastroenterol. 2016 Jul-Dec;6(2):163-166. doi: 10.5005/jp-journals-10018-1190. Epub 2016 Dec 1. Review.|WHO. EPI Fact Sheet. 2016. http://www.searo.who.int/entity/immunization/data/bangladesh. pdf [Accessed 27 Nov. 2017].|WHO. Hepatitis B Fact Sheet. 2017. http://www.who.int/mediacentre/factsheets/fs204/en/ [Accessed 27 Nov. 2017]|Bzowej NH. Hepatitis B Therapy in Pregnancy. Curr Hepat Rep. 2010 Nov;9(4):197-204. Epub 2010 Sep 9.","\tHepatitis B Infection\tHepa-B|Engerix B\tParallel Assignment\tPrevention\tRandomized\tBiological|Biological\tAll\t","Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh.","Interventional","Completed","Phase 2/Phase 3",2,158,"hepatitis b|hepatitis|hepatitis a","NA","NA"]
["NCT03632278","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28374661,"Chien WT, Bressington D, Yip A, Karatzias T. An international multi-site, randomized controlled trial of a mindfulness-based psychoeducation group programme for people with schizophrenia. Psychol Med. 2017 Sep;47(12):2081-2096. doi: 10.1017/S0033291717000526. Epub 2017 Apr 4.","\tSchizophreniform Disorders\tMindfulness psychoeducation Programme\tParallel Assignment\tTreatment\tRandomized\tBehavioral\tAll\t","Mindfulness Psychoeducation Program for Schizophrenia","Interventional","Unknown status","N/A",2,58,"schizophrenia|psychotic disorders","NA","NA"]
["NCT03639467","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29438373,"Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou J, Lu Y, Shi Y, Wang Z, Jiang L, Luo Y, Zhang Y, Huang C, Li Q, Wu G. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018 Mar 6;118(5):654-661. doi: 10.1038/bjc.2017.478. Epub 2018 Feb 13.","\tMetastatic Nasopharyngeal Carcinoma|Recurrent Nasopharyngeal Carcinoma\tAnlotinib plus gemcitabine/cisplatin\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","nasopharyngeal carcinoma|carcinoma","gemcitabine","NA"]
["NCT03645109","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21706518|18771564|24353500|27247730","Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL. Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness. J Bone Miner Res. 2011 Oct;26(10):2341-57. doi: 10.1002/jbmr.463. Erratum in: J Bone Miner Res. 2011 Dec; 26(12):3001.|Yu CK, Sykes L, Sethi M, Teoh TG, Robinson S. Vitamin D deficiency and supplementation during pregnancy. Clin Endocrinol (Oxf). 2009 May;70(5):685-90. doi: 10.1111/j.1365-2265.2008.03403.x. Epub 2008 Sep 2.|Parildar H, Dogruk Unal A, Aksan Desteli G, Cigerli O, Guvener Demirag N. Frequency of Vitamin D deficiency in pregnant diabetics at Baskent University Hospital, Istanbul. Pak J Med Sci. 2013 Jan;29(1):15-20. doi: 10.12669/pjms.291.2896.|Yazdchi R, Gargari BP, Asghari-Jafarabadi M, Sahhaf F. Effects of vitamin D supplementation on metabolic indices and hs-CRP levels in gestational diabetes mellitus patients: a randomized, double-blinded, placebo-controlled clinical trial. Nutr Res Pract. 2016 Jun;10(3):328-35. doi: 10.4162/nrp.2016.10.3.328. Epub 2016 May 16.","\tGestational Diabetes Mellitus in Pregnancy|Vitamin D3\tVitamin D3|Capsules with placebo (talcum food grade)\tParallel Assignment\tTreatment\tRandomized\tDietary Supplement|Other\tFemale\t","Effect of Suplementation of Vitamin D in Gestational Diabetes Mellitus","Interventional","Completed","N/A",2,50,"diabetes, gestational|diabetes mellitus|pregnancy in diabetics","vitamin d|cholecalciferol","NA"]
["NCT03658031","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29227578|19490820|14578255|16644654|17315136|23668478|27814267|25739882|28615237|28096223|25425451|27679584|24631482|28428225","Abdul-Ghani M, Migahid O, Megahed A, Singh R, Kamal D, DeFronzo RA, Jayyousi A. Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study. Diabetes Obes Metab. 2018 Apr;20(4):1075-1079. doi: 10.1111/dom.13189. Epub 2018 Jan 15.|Abdul-Ghani MA, DeFronzo RA. Pathophysiology of prediabetes. Curr Diab Rep. 2009 Jun;9(3):193-9. Review.|Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003 Nov;26(11):3160-7. Review.|Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006 May;29(5):1130-9. Review.|Dankner R, Abdul-Ghani MA, Gerber Y, Chetrit A, Wainstein J, Raz I. Predicting the 20-year diabetes incidence rate. Diabetes Metab Res Rev. 2007 Oct;23(7):551-8.|Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013 Sep;15(9):853-62. doi: 10.1111/dom.12127. Epub 2013 Jun 5.|Al-Lawati JA, Sulaiman KJ, Al-Zakwani I, Alsheikh-Ali AA, Panduranga P, Al-Habib KF, Al-Suwaidi J, Al-Mahmeed W, Al-Faleh H, El-Asfar A, Al-Motarreb A, Ridha M, Bulbanat B, Al-Jarallah M, Bazargani N, Asaad N, Amin H. Systolic Blood Pressure on Admission and Mortality in Patients Hospitalized With Acute Heart Failure: Observations From the Gulf Acute Heart Failure Registry. Angiology. 2017 Aug;68(7):584-591. doi: 10.1177/0003319716672525. Epub 2016 Oct 7.|Sulaiman K, Panduranga P, Al-Zakwani I, Alsheikh-Ali AA, AlHabib KF, Al-Suwaidi J, Al-Mahmeed W, AlFaleh H, Elasfar A, Al-Motarreb A, Ridha M, Bulbanat B, Al-Jarallah M, Bazargani N, Asaad N, Amin H. Clinical characteristics, management, and outcomes of acute heart failure patients: observations from the Gulf acute heart failure registry (Gulf CARE). Eur J Heart Fail. 2015 Apr;17(4):374-84. doi: 10.1002/ejhf.245. Epub 2015 Mar 4.|Abdul-Ghani M, Migahid O, Megahed A, Adams J, Triplitt C, DeFronzo RA, Zirie M, Jayyousi A. Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325-331. Diabetes Care. 2017 Aug;40(8):1134. doi: 10.2337/dc17-er08d. Epub 2017 Jun 14.|Abdul-Ghani M, Migahid O, Megahed A, Adams J, Triplitt C, DeFronzo RA, Zirie M, Jayyousi A. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care. 2017 Mar;40(3):325-331. doi: 10.2337/dc16-1738. Epub 2017 Jan 17. Erratum in: Diabetes Care. 2017 Jun 14;:.|Abdul-Ghani MA, Puckett C, Triplitt C, Maggs D, Adams J, Cersosimo E, DeFronzo RA. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab. 2015 Mar;17(3):268-75. doi: 10.1111/dom.12417. Epub 2015 Jan 7.|Verma S, Garg A, Yan AT, Gupta AK, Al-Omran M, Sabongui A, Teoh H, Mazer CD, Connelly KA. Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial? Diabetes Care. 2016 Dec;39(12):e212-e213. Epub 2016 Sep 27.|Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014 May;8(5):330-9. doi: 10.1016/j.jash.2014.02.003. Epub 2014 Feb 12. Review.|Al-Jobori H, Daniele G, Cersosimo E, Triplitt C, Mehta R, Norton L, DeFronzo RA, Abdul-Ghani M. Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes. Diabetes. 2017 Jul;66(7):1999-2006. doi: 10.2337/db17-0100. Epub 2017 Apr 20.","\tCVD|Myocardial Infarction|PreDiabetes|T2DM (Type 2 Diabetes Mellitus)\tDapagliflozin 10mg\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction","Interventional","Not yet recruiting","Phase 3",2,576,"glucose intolerance|infarction|myocardial infarction|prediabetic state","2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2h-pyran-3,4,5-triol","NA"]
["NCT03663985","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25117521|9311098|8450679|8769910|19653045|27992617|23129676|19398490|18397244|20837830|25214508|NA","Krähenmann-Müller S, Virgini VS, Blum MR, da Costa BR, Collet TH, Martin Y, Cornuz J, Zimmerli L, Gaspoz JM, Bauer DC, Kerr EA, Aujesky D, Rodondi N. Patient and physician gender concordance in preventive care in university primary care settings. Prev Med. 2014 Oct;67:242-7. doi: 10.1016/j.ypmed.2014.08.004. Epub 2014 Aug 10.|Andersen MR, Urban N. Physician gender and screening: do patient differences account for differences in mammography use? Women Health. 1997;26(1):29-39.|Franks P, Clancy CM. Physician gender bias in clinical decisionmaking: screening for cancer in primary care. Med Care. 1993 Mar;31(3):213-8.|Frank E, Harvey LK. Prevention advice rates of women and men physicians. Arch Fam Med. 1996 Apr;5(4):215-9.|Arrington AK, Jarosek SL, Virnig BA, Habermann EB, Tuttle TM. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol. 2009 Oct;16(10):2697-704. doi: 10.1245/s10434-009-0641-z. Epub 2009 Aug 4.|Tsugawa Y, Jena AB, Figueroa JF, Orav EJ, Blumenthal DM, Jha AK. Comparison of Hospital Mortality and Readmission Rates for Medicare Patients Treated by Male vs Female Physicians. JAMA Intern Med. 2017 Feb 1;177(2):206-213. doi: 10.1001/jamainternmed.2016.7875.|Mehrotra A, Reid RO, Adams JL, Friedberg MW, McGlynn EA, Hussey PS. Physicians with the least experience have higher cost profiles than do physicians with the most experience. Health Aff (Millwood). 2012 Nov;31(11):2453-63. doi: 10.1377/hlthaff.2011.0252.|Meier P, Duvernoy CS. Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. Eur J Heart Fail. 2009 Jun;11(6):631; author reply 631-2. doi: 10.1093/eurjhf/hfp056. Epub 2009 Apr 27.|Berthold HK, Gouni-Berthold I, Bestehorn KP, Böhm M, Krone W. Physician gender is associated with the quality of type 2 diabetes care. J Intern Med. 2008 Oct;264(4):340-50. doi: 10.1111/j.1365-2796.2008.01967.x. Epub 2008 Apr 4.|Reid RO, Friedberg MW, Adams JL, McGlynn EA, Mehrotra A. Associations between physician characteristics and quality of care. Arch Intern Med. 2010 Sep 13;170(16):1442-9. doi: 10.1001/archinternmed.2010.307.|Schieber AC, Delpierre C, Lepage B, Afrite A, Pascal J, Cases C, Lombrail P, Lang T, Kelly-Irving M; INTERMEDE group. Do gender differences affect the doctor-patient interaction during consultations in general practice? Results from the INTERMEDE study. Fam Pract. 2014 Dec;31(6):706-13. doi: 10.1093/fampra/cmu057. Epub 2014 Sep 11.|Allais, M. (1953). L'extension des théories de l'équilibre économique général et du rendement social au cas du risque. Econometrica, Journal of the Econometric Society, 269-290.","\tHead and Neck Cancer|Head and Neck Carcinoma\tGroupe FALCOn\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","head and neck neoplasms","NA","NA"]
["NCT03669796","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30524707|30719283|31692759","Dale HF, Jensen C, Hausken T, Lied E, Hatlebakk JG, Brønstad I, Lihaug Hoff DA, Lied GA. Effect of a cod protein hydrolysate on postprandial glucose metabolism in healthy subjects: a double-blind cross-over trial. J Nutr Sci. 2018 Nov 28;7:e33. doi: 10.1017/jns.2018.23. eCollection 2018. Erratum in: J Nutr Sci. 2019 Jan 18;8:e1.|Dale HF, Jensen C, Hausken T, Lied E, Hatlebakk JG, Brønstad I, Hoff DAL, Lied GA. Erratum: Effect of a cod protein hydrolysate on postprandial glucose metabolism in healthy subjects: a double-blind cross-over trial - CORRIGENDUM. J Nutr Sci. 2019 Jan 18;8:e1. doi: 10.1017/jns.2018.30. eCollection 2019.|Dale HF, Jensen C, Hausken T, Lied E, Hatlebakk JG, Brønstad I, Hoff DAL, Lied GA. Acute effect of a cod protein hydrolysate on postprandial acylated ghrelin concentration and sensations associated with appetite in healthy subjects: a double-blind crossover trial. Food Nutr Res. 2019 Oct 22;63. doi: 10.29219/fnr.v63.3507. eCollection 2019.","\tHealthy Volunteers\tMarine protein hydrolysate (mph)|Control\tCrossover Assignment\tBasic Science\tRandomized\tDietary Supplement|Dietary Supplement\tAll\t","Marine Protein Hydrolysate as Dietary Supplement in Elderly Part I","Interventional","Completed","N/A",2,41,"NA","NA","NA"]
["NCT03671122","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27384611|29021611","Linde C, Eriksson MJ, Hage C, Wallén H, Persson B, Corbascio M, Lundeberg J, Maret E, Ugander M, Persson H; Stockholm County/Karolinska Institutet 4D heart failure investigators. Rationale and design of the PREFERS (Preserved and Reduced Ejection Fraction Epidemiological Regional Study) Stockholm heart failure study: an epidemiological regional study in Stockholm county of 2.1 million inhabitants. Eur J Heart Fail. 2016 Oct;18(10):1287-1297. doi: 10.1002/ejhf.599. Epub 2016 Jul 7.|Asp M, Salmén F, Ståhl PL, Vickovic S, Felldin U, Löfling M, Fernandez Navarro J, Maaskola J, Eriksson MJ, Persson B, Corbascio M, Persson H, Linde C, Lundeberg J. Spatial detection of fetal marker genes expressed at low level in adult human heart tissue. Sci Rep. 2017 Oct 11;7(1):12941. doi: 10.1038/s41598-017-13462-5.","\tHeart Failure，Congestive|Heart Failure, Diastolic\tCardiac imaging in the PREFERS and CABG PREFERS cohorts|Biomarker analysis in the PREFERS and CABG PREFERS chorts|Cardiac biopsies in the CABG PREFERS cohort\tNA\tNA\tNA\tDiagnostic Test|Other|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","heart failure|heart failure, diastolic","NA","NA"]
["NCT03676270","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29874526,"Chakiba C, Grellety T, Bellera C, Italiano A. Encouraging Trends in Modern Phase 1 Oncology Trials. N Engl J Med. 2018 Jun 7;378(23):2242-2243. doi: 10.1056/NEJMc1803837.","\tCancer\tPhase I\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT03686436","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","1- Agarwal D, Gelman R, Ponce CP, Stevenson W, and . Christoforidis J B the vitreo macular interface abnormalities in diabetic retinopathy . review. . journal of ophthalmology . 2015. 2- Bottós J, Elizalde J, Arevalo JF, Rodrigues EB, Maia M. Vitreomacular traction syndrome. J Ophthalmic Vis Res 2012 3- Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, et al. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology 2013 4- konsantanidis L , Wolfensberger TJ .cystoid macular edema and vitreomacular traction . a review .2015 5- Ryan SJ, Puliafito CA, Davis JL, Parel JM, Milne P. Retina. 4th ed. Philadelphia, PA:Elsevier Mosby; 2006. 6- Chandra A, Charteris DG, Yorston D. Posturing after macular hole surgery: a review. Ophthalmologica 2011","\ton Vitreomacular Interface Abnormalities in Diabetic Retinopathy\tocular coherence tomography\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","retinal diseases|diabetic retinopathy|congenital abnormalities","NA","NA"]
["NCT03696693","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24427691|26547604|22764607|11411480","Develioglu ON, Paltura C, Koleli H, Kulekci M. The effect of medical treatment on voice quality in allergic rhinitis. Indian J Otolaryngol Head Neck Surg. 2013 Aug;65(Suppl 2):426-30. doi: 10.1007/s12070-013-0639-5. Epub 2013 Mar 14.|Dlova NC, Fabbrocini G, Lauro C, Spano M, Tosti A, Hift RH. Quality of life in South African Black women with alopecia: a pilot study. Int J Dermatol. 2016 Aug;55(8):875-81. doi: 10.1111/ijd.13042. Epub 2015 Nov 6.|Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, Cohen N, Cervin A, Douglas R, Gevaert P, Georgalas C, Goossens H, Harvey R, Hellings P, Hopkins C, Jones N, Joos G, Kalogjera L, Kern B, Kowalski M, Price D, Riechelmann H, Schlosser R, Senior B, Thomas M, Toskala E, Voegels R, Wang de Y, Wormald PJ. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl. 2012 Mar;23:3 p preceding table of contents, 1-298.|Cecil M, Tindall L, Haydon R. The relationship between dysphonia and sinusitis: a pilot study. J Voice. 2001 Jun;15(2):270-7.","\tVoice Disorders in Children\tacoustic vocal analysis\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","voice disorders","NA","NA"]
["NCT03705988","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","3521373|9214809|16387997|18348596|22741094|23538086|24856571|25546850","Schmitt R, Capo T, Boyd E. Cranial electrotherapy stimulation as a treatment for anxiety in chemically dependent persons. Alcohol Clin Exp Res. 1986 Mar-Apr;10(2):158-60.|Ferdjallah M, Bostick FX Jr, Barr RE. Potential and current density distributions of cranial electrotherapy stimulation (CES) in a four-concentric-spheres model. IEEE Trans Biomed Eng. 1996 Sep;43(9):939-43.|Childs A. Cranial electrotherapy stimulation reduces aggression in a violent retarded population: a preliminary report. J Neuropsychiatry Clin Neurosci. 2005 Fall;17(4):548-51.|Bystritsky A, Kerwin L, Feusner J. A pilot study of cranial electrotherapy stimulation for generalized anxiety disorder. J Clin Psychiatry. 2008 Mar;69(3):412-7.|Feusner JD, Madsen S, Moody TD, Bohon C, Hembacher E, Bookheimer SY, Bystritsky A. Effects of cranial electrotherapy stimulation on resting state brain activity. Brain Behav. 2012 May;2(3):211-20. doi: 10.1002/brb3.45.|Kirsch DL, Nichols F. Cranial electrotherapy stimulation for treatment of anxiety, depression, and insomnia. Psychiatr Clin North Am. 2013 Mar;36(1):169-76. doi: 10.1016/j.psc.2013.01.006. Review.|Barclay TH, Barclay RD. A clinical trial of cranial electrotherapy stimulation for anxiety and comorbid depression. J Affect Disord. 2014 Aug;164:171-7. doi: 10.1016/j.jad.2014.04.029. Epub 2014 Apr 21.|Qiao J, Weng S, Wang P, Long J, Wang Z. Normalization of Intrinsic Neural Circuits Governing Tourette's Syndrome Using Cranial Electrotherapy Stimulation. IEEE Trans Biomed Eng. 2015 May;62(5):1272-80. doi: 10.1109/TBME.2014.2385151. Epub 2014 Dec 22.","\tTic Disorder, Childhood\tCranial Electrotherapy Stimulation(CES)|sham Cranial Electrotherapy Stimulation( sham CES)\tParallel Assignment\tTreatment\tRandomized\tDevice|Device\tAll\t","A Study of Cranial Electrotherapy Stimulation as an Add-on Treatment for Tic Disorders (SCATT)","Interventional","Unknown status","N/A",2,100,"disease|tics|tic disorders","NA","NA"]
["NCT03712215","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","662485|699047|2306029|775835|35040","Yabek SM, Jarmakani JM. Sinus node dysfunction in children, adolescents, and young adults. Pediatrics. 1978 Apr;61(4):593-8.|Wachtel SS, Basrur P, Koo GC. Recessive male-determining genes. Cell. 1978 Sep;15(1):279-81.|Geddes LA, Voorhees WD, Bourland JD, Riscili CE. Optimum stimulus frequency for contracting the inspiratory muscles with chest-surface electrodes to produce artificial respiration. Ann Biomed Eng. 1990;18(1):103-8.|Krymskiĭ LD, Nestaĭko GV. [Scanning electron microscopy of vessels in normal and pathologic states]. Vestn Akad Med Nauk SSSR. 1975;(11):71-6. Review. Russian.|Arguelles JE, Franatovic Y, Romo-Salas F, Aldrete JA. Intrabiliary pressure changes produced by narcotic drugs and inhalation anesthetics in guinea pigs. Anesth Analg. 1979 Mar-Apr;58(2):120-3.","\tRespiratory Distress Syndrome, Adult\tRehabilitation\tParallel Assignment\tTreatment\tRandomized\tOther\tAll\t","STUDY OF ELECTRICAL STIMULATION IN PULMONARY FUNCTION IN INTENSIVE CARE UNIT","Interventional","Completed","N/A",3,30,"respiratory distress syndrome, newborn|acute lung injury|respiratory distress syndrome, adult","NA","NA"]
["NCT03716687","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30267040|30047611|29718814|28885895|28692475","Sahebally SM, McKevitt K, Stephens I, Fitzpatrick F, Deasy J, Burke JP, McNamara D. Negative Pressure Wound Therapy for Closed Laparotomy Incisions in General and Colorectal Surgery: A Systematic Review and Meta-analysis. JAMA Surg. 2018 Nov 1;153(11):e183467. doi: 10.1001/jamasurg.2018.3467. Epub 2018 Nov 21.|Curran T, Alvarez D, Pastrana Del Valle J, Cataldo TE, Poylin V, Nagle D. Prophylactic closed-incision negative-pressure wound therapy is associated with decreased surgical site infection in high-risk colorectal surgery laparotomy wounds. Colorectal Dis. 2019 Jan;21(1):110-118. doi: 10.1111/codi.14350. Epub 2018 Aug 20.|Gachabayov M, You K, Sullivan R, Bergamaschi R. A Retrospective Cohort Study to Determine Predictive Factors for Abdominal Wound Disruption Following Colorectal Surgery. Ostomy Wound Manage. 2018 Apr;64(4):22-29.|Strugala V, Martin R. Meta-Analysis of Comparative Trials Evaluating a Prophylactic Single-Use Negative Pressure Wound Therapy System for the Prevention of Surgical Site Complications. Surg Infect (Larchmt). 2017 Oct;18(7):810-819. doi: 10.1089/sur.2017.156. Epub 2017 Sep 8. Review.|Athanasiou AN, Spartalis M, Spartalis E. Prophylactic Negative Pressure Dressing Use in Closed Laparotomy Wounds After Abdominal Operations: What We Really Know? Ann Surg. 2018 Jul;268(1):e19-e20. doi: 10.1097/SLA.0000000000002413.","\tDehiscence of Internal Surgical Wound|Surgical Site Infection|Surgical Wound|Wound Dehiscence, Surgical\tProphylactic negative pressure wound dressing after laparotomy\tParallel Assignment\tPrevention\tRandomized\tDevice\tAll\t","Prophylactic Negative Pressure Wound Therapy for High Risk Laparotomy Wounds. A Randomized Prospective Clinical Trial.","Interventional","Terminated","N/A",2,100,"surgical wound|surgical wound infection|surgical wound dehiscence|wounds and injuries","NA","NA"]
["NCT03720080","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27510442,"Lewis D, Leibrand S; #OpenAPS Community. Real-World Use of Open Source Artificial Pancreas Systems. J Diabetes Sci Technol. 2016 Nov 1;10(6):1411. Print 2016 Nov.","\tType1diabetes\tOpenAPS\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","diabetes mellitus, type 1","NA","NA"]
["NCT03727412","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20643821|21248083|25579873|26926930","Arnaoutoglou E, Papas N, Milionis H, Kouvelos G, Koulouras V, Matsagkas MI. Post-implantation syndrome after endovascular repair of aortic aneurysms: need for postdischarge surveillance. Interact Cardiovasc Thorac Surg. 2010 Oct;11(4):449-54. doi: 10.1510/icvts.2010.242628. Epub 2010 Jul 19.|Arnaoutoglou E, Kouvelos G, Milionis H, Mavridis A, Kolaitis N, Papa N, Papadopoulos G, Matsagkas M. Post-implantation syndrome following endovascular abdominal aortic aneurysm repair: preliminary data. Interact Cardiovasc Thorac Surg. 2011 Apr;12(4):609-14. doi: 10.1510/icvts.2010.256784. Epub 2011 Jan 19.|Arnaoutoglou E, Kouvelos G, Papa N, Kallinteri A, Milionis H, Koulouras V, Matsagkas M. Prospective evaluation of post-implantation inflammatory response after EVAR for AAA: influence on patients' 30 day outcome. Eur J Vasc Endovasc Surg. 2015 Feb;49(2):175-83. doi: 10.1016/j.ejvs.2014.12.006. Epub 2015 Jan 9.|Arnaoutoglou E, Kouvelos G, Papa N, Gartzonika K, Milionis H, Koulouras V, Matsagkas M. Prospective evaluation of postimplantation syndrome evolution on patient outcomes after endovascular aneurysm repair for abdominal aortic aneurysm. J Vasc Surg. 2016 May;63(5):1248-55. doi: 10.1016/j.jvs.2015.11.043. Epub 2016 Feb 28.","\tAneurysm Abdominal|Endovacular Repair\tDrugs, Generic (Naprosyn)|Placebo Oral Tablet\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug\tAll\t","Post Implantation Syndrome and Administration on NSAIDs in Patients Undergoing EVAR for AAA","Interventional","Recruiting","N/A",2,186,"aneurysm|aortic aneurysm, abdominal","naproxen","NA"]
["NCT03733912","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26545148|27875712","Hauser R, Gaskins AJ, Souter I, Smith KW, Dodge LE, Ehrlich S, Meeker JD, Calafat AM, Williams PL; EARTH Study Team. Urinary Phthalate Metabolite Concentrations and Reproductive Outcomes among Women Undergoing in Vitro Fertilization: Results from the EARTH Study. Environ Health Perspect. 2016 Jun;124(6):831-9. doi: 10.1289/ehp.1509760. Epub 2015 Nov 6.|Wu H, Olmsted A, Cantonwine DE, Shahsavari S, Rahil T, Sites C, Pilsner JR. Urinary phthalate and phthalate alternative metabolites and isoprostane among couples undergoing fertility treatment. Environ Res. 2017 Feb;153:1-7. doi: 10.1016/j.envres.2016.11.003. Epub 2016 Nov 19.","\tFertilization in Vitro\tPhthalate metabolites measurement\tNA\tNA\tNA\tOther\tFemale\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT03752372","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29788474,"Peng K, Qian X, Huang Z, Lu J, Wang Y, Zhou Y, Wang H, Wu B, Wang Y, Chen L, Zhai X, Huang Y. Umbilical Cord Blood Transplantation Corrects Very Early-Onset Inflammatory Bowel Disease in Chinese Patients With IL10RA-Associated Immune Deficiency. Inflamm Bowel Dis. 2018 Jun 8;24(7):1416-1427. doi: 10.1093/ibd/izy028.","\tInflammatory Bowel Diseases|Microbiota\thematopoietic stem cell transplantation\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","inflammatory bowel diseases","NA","NA"]
["NCT03754634","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19846889|19005182","Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010 Jan 14;115(2):168-86. doi: 10.1182/blood-2009-06-225565. Epub 2009 Oct 21. Review.|Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kühne T, Ruggeri M, George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009 Mar 12;113(11):2386-93. doi: 10.1182/blood-2008-07-162503. Epub 2008 Nov 12.","\tThrombocytopenia\tEltrombopag and Diacerein\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","thrombocytopenia","diacetylrhein","NA"]
["NCT03762486","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","14622666|10551571|20615859|24439637|12600800|9806695|26550304|25665520|18387854|25935320|22531569|27142864|24576720|25030646|22194125|25867874|24283391|15763419|25197104|22443026|26210558|21769308|22729304|22311059|14622708|22929602|24901753|19779370|9249122|24933788|21280458|21122849","Rakel B, Frantz R. Effectiveness of transcutaneous electrical nerve stimulation on postoperative pain with movement. J Pain. 2003 Oct;4(8):455-64.|Hamza MA, White PF, Ahmed HE, Ghoname EA. Effect of the frequency of transcutaneous electrical nerve stimulation on the postoperative opioid analgesic requirement and recovery profile. Anesthesiology. 1999 Nov;91(5):1232-8.|Dias M, Carneiro NM, Guerra LA, Velarde GC, de Souza PA, da Silva LL, de Abreu e Souza RR, Nolasco R, Olej B. Effects of electroacupuncture on local anaesthesia for inguinal hernia repair: a randomised placebo-controlled trial. Acupunct Med. 2010 Jun;28(2):65-70. doi: 10.1136/aim.2009.000570.|Bjerså K, Andersson T. High frequency TENS as a complement for pain relief in postoperative transition from epidural to general analgesia after pancreatic resection. Complement Ther Clin Pract. 2014 Feb;20(1):5-10. doi: 10.1016/j.ctcp.2013.11.004. Epub 2013 Nov 20.|Bjordal JM, Johnson MI, Ljunggreen AE. Transcutaneous electrical nerve stimulation (TENS) can reduce postoperative analgesic consumption. A meta-analysis with assessment of optimal treatment parameters for postoperative pain. Eur J Pain. 2003;7(2):181-8.|Chen L, Tang J, White PF, Sloninsky A, Wender RH, Naruse R, Kariger R. The effect of location of transcutaneous electrical nerve stimulation on postoperative opioid analgesic requirement: acupoint versus nonacupoint stimulation. Anesth Analg. 1998 Nov;87(5):1129-34.|Chen Y, Yang Y, Yao Y, Dai D, Qian B, Liu P. Does transcutaneous electric acupoint stimulation improve the quality of recovery after thyroidectomy? A prospective randomized controlled trial. Int J Clin Exp Med. 2015 Aug 15;8(8):13622-7. eCollection 2015.|da Silva MP, Liebano RE, Rodrigues VA, Abla LE, Ferreira LM. Transcutaneous electrical nerve stimulation for pain relief after liposuction: a randomized controlled trial. Aesthetic Plast Surg. 2015 Apr;39(2):262-9. doi: 10.1007/s00266-015-0451-6. Epub 2015 Feb 10.|DeSantana JM, Santana-Filho VJ, Guerra DR, Sluka KA, Gurgel RQ, da Silva WM Jr. Hypoalgesic effect of the transcutaneous electrical nerve stimulation following inguinal herniorrhaphy: a randomized, controlled trial. J Pain. 2008 Jul;9(7):623-9. doi: 10.1016/j.jpain.2008.01.337. Epub 2008 Apr 3.|Engen DJ, Carns PE, Allen MS, Bauer BA, Loehrer LL, Cha SS, Chartrand CM, Eggler EJ, Cutshall SM, Wahner-Roedler DL. Evaluating efficacy and feasibility of transcutaneous electrical nerve stimulation for postoperative pain after video-assisted thoracoscopic surgery: A randomized pilot trial. Complement Ther Clin Pract. 2016 May;23:141-8. doi: 10.1016/j.ctcp.2015.04.002. Epub 2015 Apr 20.|Lan F, Ma YH, Xue JX, Wang TL, Ma DQ. Transcutaneous electrical nerve stimulation on acupoints reduces fentanyl requirement for postoperative pain relief after total hip arthroplasty in elderly patients. Minerva Anestesiol. 2012 Aug;78(8):887-95. Epub 2012 Apr 24.|Feng X, Ye T, Wang Z, Chen X, Cong W, Chen Y, Chen P, Chen C, Shi B, Xie W. Transcutaneous acupoint electrical stimulation pain management after surgical abortion: A cohort study. Int J Surg. 2016 Jun;30:104-8. doi: 10.1016/j.ijsu.2016.04.042. Epub 2016 Apr 29.|Wang H, Xie Y, Zhang Q, Xu N, Zhong H, Dong H, Liu L, Jiang T, Wang Q, Xiong L. Transcutaneous electric acupoint stimulation reduces intra-operative remifentanil consumption and alleviates postoperative side-effects in patients undergoing sinusotomy: a prospective, randomized, placebo-controlled trial. Br J Anaesth. 2014 Jun;112(6):1075-82. doi: 10.1093/bja/aeu001. Epub 2014 Feb 26.|Hong SJ, Lee E. Effect of evidence-based postoperative pain guidelines via web for patients undergoing abdominal surgery in South Korea. Asian Nurs Res (Korean Soc Nurs Sci). 2014 Jun;8(2):135-42. doi: 10.1016/j.anr.2014.05.005. Epub 2014 May 21.|Kara B, Baskurt F, Acar S, Karadibak D, Ciftci L, Erbayraktar S, Gokmen AN. The effect of TENS on pain, function, depression, and analgesic consumption in the early postoperative period with spinal surgery patients. Turk Neurosurg. 2011;21(4):618-24. doi: 10.5137/1019-5149.JTN .4985-11.0.|Şenol Karataş S, Eti Z, Saraçoğlu KT, Göğüş FY. Does perioperative opioid infusion increase postoperative opioid requirement? Agri. 2015;27(1):47-53. doi: 10.5505/agri.2015.71676.|Kayman-Kose S, Arioz DT, Toktas H, Koken G, Kanat-Pektas M, Kose M, Yilmazer M. Transcutaneous electrical nerve stimulation (TENS) for pain control after vaginal delivery and cesarean section. J Matern Fetal Neonatal Med. 2014 Oct;27(15):1572-5. doi: 10.3109/14767058.2013.870549. Epub 2014 Jan 8.|Kehlet H. Procedure-specific postoperative pain management. Anesthesiol Clin North Am. 2005 Mar;23(1):203-10. Review.|Kerai S, Saxena KN, Taneja B, Sehrawat L. Role of transcutaneous electrical nerve stimulation in post-operative analgesia. Indian J Anaesth. 2014 Jul;58(4):388-93. doi: 10.4103/0019-5049.138966.|Francis RP, Johnson MI. The characteristics of acupuncture-like transcutaneous electrical nerve stimulation (acupuncture-like TENS): a literature review. Acupunct Electrother Res. 2011;36(3-4):231-58. Review.|Robleda G, Roche-Campo F, Sánchez V, Gich I, Baños JE. Postoperative Discomfort After Abdominal Surgery: An Observational Study. J Perianesth Nurs. 2015 Aug;30(4):272-9. doi: 10.1016/j.jopan.2014.06.005. Epub 2015 May 16.|Rosén HI, Bergh IH, Odén A, Mårtensson LB. Patients´ experiences of pain following day surgery - at 48 hours, seven days and three months. Open Nurs J. 2011;5:52-9. doi: 10.2174/1874434601105010052. Epub 2011 Jul 6.|Sbruzzi G, Silveira SA, Silva DV, Coronel CC, Plentz RD. Transcutaneous electrical nerve stimulation after thoracic surgery: systematic review and meta-analysis of 11 randomized trials. Rev Bras Cir Cardiovasc. 2012 Jan-Mar;27(1):75-87. Review. English, Portuguese.|Silva MB, de Melo PR, de Oliveira NM, Crema E, Fernandes LF. Analgesic effect of transcutaneous electrical nerve stimulation after laparoscopic cholecystectomy. Am J Phys Med Rehabil. 2012 Aug;91(8):652-7. doi: 10.1097/PHM.0b013e318246638f.|Sluka KA, Walsh D. Transcutaneous electrical nerve stimulation: basic science mechanisms and clinical effectiveness. J Pain. 2003 Apr;4(3):109-21. Review.|Gavronsky S, Koeniger-Donohue R, Steller J, Hawkins JW. Postoperative pain: acupuncture versus percutaneous electrical nerve stimulation. Pain Manag Nurs. 2012 Sep;13(3):150-6. doi: 10.1016/j.pmn.2009.08.001. Epub 2010 Jan 6.|Tokuda M, Tabira K, Masuda T, Nishiwada T, Shomoto K. Effect of modulated-frequency and modulated-intensity transcutaneous electrical nerve stimulation after abdominal surgery: a randomized controlled trial. Clin J Pain. 2014 Jul;30(7):565-70. doi: 10.1097/AJP.0b013e31829ea151.|Unterrainer AF, Friedrich C, Krenn MH, Piotrowski WP, Golaszewski SM, Hitzl W. Postoperative and preincisional electrical nerve stimulation TENS reduce postoperative opioid requirement after major spinal surgery. J Neurosurg Anesthesiol. 2010 Jan;22(1):1-5. doi: 10.1097/ANA.0b013e3181b7fef5.|Wang B, Tang J, White PF, Naruse R, Sloninsky A, Kariger R, Gold J, Wender RH. Effect of the intensity of transcutaneous acupoint electrical stimulation on the postoperative analgesic requirement. Anesth Analg. 1997 Aug;85(2):406-13.|Ward CW. Procedure-specific postoperative pain management. Medsurg Nurs. 2014 Mar-Apr;23(2):107-10.|Yeh ML, Chung YC, Chen KM, Tsou MY, Chen HH. Acupoint electrical stimulation reduces acute postoperative pain in surgical patients with patient-controlled analgesia: a randomized controlled study. Altern Ther Health Med. 2010 Nov-Dec;16(6):10-8.|Yeh ML, Chung YC, Chen KM, Chen HH. Pain reduction of acupoint electrical stimulation for patients with spinal surgery: a placebo-controlled study. Int J Nurs Stud. 2011 Jun;48(6):703-9. doi: 10.1016/j.ijnurstu.2010.10.009. Epub 2010 Nov 30.","\tTranscutaneous Electric Nerve Stimulation\tTENS|TAES\tNA\tNA\tNA\tOther|Other\tAll\t","The Pain Intensity of the Patients Who Had Undergone Abdominal Surgery With a Midline Incision","Interventional","Completed","N/A",3,48,"pain","NA","NA"]
["NCT03764189","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24326198,"Kau CH, Kantarci A, Shaughnessy T, Vachiramon A, Santiwong P, de la Fuente A, Skrenes D, Ma D, Brawn P. Photobiomodulation accelerates orthodontic alignment in the early phase of treatment. Prog Orthod. 2013 Sep 19;14:30. doi: 10.1186/2196-1042-14-30.","\tClass II Division 1 Malocclusion\tmicroosteoperforation\tParallel Assignment\tTreatment\tRandomized\tProcedure\tFemale\t","Evaluation of Micro-osteoperforation on Rate of Maxillary En-masse Retraction","Interventional","Unknown status","N/A",2,13,"malocclusion","NA","NA"]
["NCT03769961","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24112892|19452239|20926368","Nazzaro JM, Lyons KE, Pahwa R. Deep brain stimulation for essential tremor. Handb Clin Neurol. 2013;116:155-66. doi: 10.1016/B978-0-444-53497-2.00013-9.|Kronenbuerger M, Konczak J, Ziegler W, Buderath P, Frank B, Coenen VA, Kiening K, Reinacher P, Noth J, Timmann D. Balance and motor speech impairment in essential tremor. Cerebellum. 2009 Sep;8(3):389-98. doi: 10.1007/s12311-009-0111-y. Epub 2009 May 19.|Fasano A, Herzog J, Raethjen J, Rose FE, Muthuraman M, Volkmann J, Falk D, Elble R, Deuschl G. Gait ataxia in essential tremor is differentially modulated by thalamic stimulation. Brain. 2010 Dec;133(Pt 12):3635-48. doi: 10.1093/brain/awq267. Epub 2010 Oct 5.","\tAtaxia|Cerebellar Diseases|Deep Brain Stimulation|Essential Tremor\tNo intervention\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","tremor|cerebellar diseases|cerebellar ataxia|ataxia|essential tremor","NA","NA"]
["NCT03779165","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27138905|26318695","Darrat YH, Agarwal A, Morales GX, Thompson J, Abdel-Latif A, Waespe K, DI Biase L, Natale A, Patwardan A, Elayi CS. Radiofrequency and Cryo-Ablation Effect on Transvenous Pacing and Defibrillatory Lead Integrity: An In Vitro Study. J Cardiovasc Electrophysiol. 2016 Aug;27(8):976-80. doi: 10.1111/jce.13007. Epub 2016 Jun 14.|Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekvål TM, Spaulding C, Van Veldhuisen DJ; Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Europace. 2015 Nov;17(11):1601-87. doi: 10.1093/europace/euv319. Epub 2015 Aug 29. Review.","\tCatheter Ablation|Electrodes|Follow-Up Studies|Tachycardia, Ventricular\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","tachycardia, ventricular|tachycardia","NA","NA"]
["NCT03791905","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27152857,"Ku GY, Kriplani A, Janjigian YY, Kelsen DP, Rusch VW, Bains M, Chou J, Capanu M, Wu AJ, Goodman KA, Ilson DH. Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. Cancer. 2016 Jul 1;122(13):2083-90. doi: 10.1002/cncr.30028. Epub 2016 May 6.","\tNeoplasm, Esophageal|Squamous Cell Carcinoma\tPaclitaxel|Cisplatin|Oxaliplatin|5-FU|Leucovorin|Intensity-modulated radiotherapy|PET\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug|Drug|Drug|Radiation|Device\tAll\t","PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma","Interventional","Recruiting","Phase 2",2,216,"esophageal neoplasms|carcinoma, squamous cell|esophageal squamous cell carcinoma|carcinoma","cisplatin|fluorouracil|paclitaxel|oxaliplatin|leucovorin","NA"]
["NCT03799263","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","6805625|20471236|12091180|12917227|28624883|18550610","Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed). 1982 May 29;284(6329):1607-8.|Spruit MA, Watkins ML, Edwards LD, Vestbo J, Calverley PM, Pinto-Plata V, Celli BR, Tal-Singer R, Wouters EF; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators. Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med. 2010 Jun;104(6):849-57. doi: 10.1016/j.rmed.2009.12.007. Epub 2010 May 14.|ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. Erratum in: Am J Respir Crit Care Med. 2016 May 15;193(10):1185.|Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, Murray S, Kazerooni EA, Gross BH, Lynch JP 3rd, Martinez FJ. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003 Nov 1;168(9):1084-90. Epub 2003 Aug 13.|Rodríguez DA, Kortianou EA, Alison JA, Casas A, Giavedoni S, Barberan-Garcia A, Arbillaga A, Vilaró J, Gimeno-Santos E, Vogiatzis I, Rabinovich R, Roca J. Heart Rate Recovery After 6-min Walking Test Predicts Acute Exacerbation in COPD. Lung. 2017 Aug;195(4):463-467. doi: 10.1007/s00408-017-0027-0. Epub 2017 Jun 17.|Puhan MA, Mador MJ, Held U, Goldstein R, Guyatt GH, Schünemann HJ. Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur Respir J. 2008 Sep;32(3):637-43. doi: 10.1183/09031936.00140507. Epub 2008 Jun 11.","\tCOPD|Disease Exacerbation|Exercise Capacity|Mortality\tevaluation group\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","disease progression","NA","NA"]
["NCT03807752","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32635503,"Jensen C, Fjeldheim Dale H, Hausken T, Hatlebakk JG, Brønstad I, Lied GA, Hoff DAL. Supplementation with Low Doses of a Cod Protein Hydrolysate on Glucose Regulation and Lipid Metabolism in Adults with Metabolic Syndrome: A Randomized, Double-Blind Study. Nutrients. 2020 Jul 4;12(7). pii: E1991. doi: 10.3390/nu12071991.","\tMetabolic Syndrome\tMPH_active|MPH_placebo\tParallel Assignment\tTreatment\tRandomized\tDietary Supplement|Dietary Supplement\tAll\t","Marin Protein Hydrolysate and Metabolic Syndrome","Interventional","Completed","N/A",2,33,"syndrome|metabolic syndrome","NA","NA"]
["NCT03815032","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24799502,"Fearon WF. Percutaneous coronary intervention should be guided by fractional flow reserve measurement. Circulation. 2014 May 6;129(18):1860-70. doi: 10.1161/CIRCULATIONAHA.113.004300.","\tAngina, Stable|Angina, Unstable|Atherosclerosis|Atherosclerosis, Coronary|Coronary Artery Disease|Coronary Stenosis|NSTEMI - Non-ST Segment Elevation MI\tDrift assessment of OptoWire Deux FFR wire (1)|Drift assessment of OptoWire Deux FFR wire (2)\tNA\tNA\tNA\tDevice|Device\tAll\t","Assessing the Accuracy of the OptoWire DeuxTM in a Wire to Wire Comparison","Interventional","Completed","N/A",2,45,"coronary artery disease|myocardial ischemia|angina, unstable|atherosclerosis|coronary stenosis|angina, stable|angina pectoris","NA","NA"]
["NCT03817723","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21459631,"Buddingh KT, Weersma RK, Savenije RA, van Dam GM, Nieuwenhuijs VB. Lower rate of major bile duct injury and increased intraoperative management of common bile duct stones after implementation of routine intraoperative cholangiography. J Am Coll Surg. 2011 Aug;213(2):267-74. doi: 10.1016/j.jamcollsurg.2011.03.004. Epub 2011 Apr 3.","\tRadiation Exposure\tc-arm cholangiography\tNA\tNA\tNA\tRadiation\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT03823170","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28721667|24197517|19893971|20403301|24683770|23675985","Ghanim A, Silva MJ, Elfrink MEC, Lygidakis NA, Mariño RJ, Weerheijm KL, Manton DJ. Molar incisor hypomineralisation (MIH) training manual for clinical field surveys and practice. Eur Arch Paediatr Dent. 2017 Aug;18(4):225-242. doi: 10.1007/s40368-017-0293-9. Epub 2017 Jul 18.|Lopes AO, Eduardo Cde P, Aranha AC. Clinical evaluation of low-power laser and a desensitizing agent on dentin hypersensitivity. Lasers Med Sci. 2015 Feb;30(2):823-9. doi: 10.1007/s10103-013-1441-z. Epub 2013 Oct 4.|Aranha AC, Pimenta LA, Marchi GM. Clinical evaluation of desensitizing treatments for cervical dentin hypersensitivity. Braz Oral Res. 2009 Jul-Sep;23(3):333-9.|Lygidakis NA, Wong F, Jälevik B, Vierrou AM, Alaluusua S, Espelid I. Best Clinical Practice Guidance for clinicians dealing with children presenting with Molar-Incisor-Hypomineralisation (MIH): An EAPD Policy Document. Eur Arch Paediatr Dent. 2010 Apr;11(2):75-81.|Ozgül BM, Saat S, Sönmez H, Oz FT. Clinical evaluation of desensitizing treatment for incisor teeth affected by molar-incisor hypomineralization. J Clin Pediatr Dent. 2013 Winter;38(2):101-5.|Palazon MT, Scaramucci T, Aranha AC, Prates RA, Lachowski KM, Hanashiro FS, Youssef MN. Immediate and short-term effects of in-office desensitizing treatments for dentinal tubule occlusion. Photomed Laser Surg. 2013 Jun;31(6):274-82. doi: 10.1089/pho.2012.3405. Epub 2013 May 15.","\tHypomineralization Molar Incisor\tLaser therapy|Fluorotherapy|Laser therapy and Fluorotherapy\tParallel Assignment\tTreatment\tRandomized\tRadiation|Procedure|Combination Product\tAll\t","Laser Therapy and Flouride Therapy in Desensibilization Hypomineralized Teeth","Interventional","Completed","N/A",3,66,"NA","NA","NA"]
["NCT03830489","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28291237|28282690|25600879|22239959","Gimeno-García AZ, Hernandez G, Aldea A, Nicolás-Pérez D, Jiménez A, Carrillo M, Felipe V, Alarcón-Fernández O, Hernandez-Guerra M, Romero R, Alonso I, Gonzalez Y, Adrian Z, Moreno M, Ramos L, Quintero E. Comparison of Two Intensive Bowel Cleansing Regimens in Patients With Previous Poor Bowel Preparation: A Randomized Controlled Study. Am J Gastroenterol. 2017 Jun;112(6):951-958. doi: 10.1038/ajg.2017.53. Epub 2017 Mar 14.|Gimeno-García AZ, Baute JL, Hernandez G, Morales D, Gonzalez-Pérez CD, Nicolás-Pérez D, Alarcon-Fernández O, Jiménez A, Hernandez-Guerra M, Romero R, Alonso I, Gonzalez Y, Adrian Z, Carrillo M, Ramos L, Quintero E. Risk factors for inadequate bowel preparation: a validated predictive score. Endoscopy. 2017 Jun;49(6):536-543. doi: 10.1055/s-0043-101683. Epub 2017 Mar 10.|Dik VK, Moons LM, Hüyük M, van der Schaar P, de Vos Tot Nederveen Cappel WH, Ter Borg PC, Meijssen MA, Ouwendijk RJ, Le Fèvre DM, Stouten M, van der Galiën O, Hiemstra TJ, Monkelbaan JF, van Oijen MG, Siersema PD; Colonoscopy Quality Initiative. Predicting inadequate bowel preparation for colonoscopy in participants receiving split-dose bowel preparation: development and validation of a prediction score. Gastrointest Endosc. 2015 Mar;81(3):665-72. doi: 10.1016/j.gie.2014.09.066. Epub 2015 Jan 17.|Hassan C, Fuccio L, Bruno M, Pagano N, Spada C, Carrara S, Giordanino C, Rondonotti E, Curcio G, Dulbecco P, Fabbri C, Della Casa D, Maiero S, Simone A, Iacopini F, Feliciangeli G, Manes G, Rinaldi A, Zullo A, Rogai F, Repici A. A predictive model identifies patients most likely to have inadequate bowel preparation for colonoscopy. Clin Gastroenterol Hepatol. 2012 May;10(5):501-6. doi: 10.1016/j.cgh.2011.12.037. Epub 2012 Jan 10.","\tCleansing Quality of the Colon\tpolyethylene glycol|polyethylene glycol plus ascorbic acid\tParallel Assignment\tOther\tRandomized\tDrug|Drug\tAll\t","Impact of a Predictive Score of Bowel Preparation Quality in Clinical Practice","Interventional","Completed","Phase 4",2,260,"NA","ascorbic acid","NA"]
["NCT03839992","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","5442364|4683321|4684043|28151425|26079395","Mead J. The lung's \"quiet zone\". N Engl J Med. 1970 Jun 4;282(23):1318-9.|Gelb AF, Gold WM, Wright RR, Bruch HR, Nadel JA. Physiologic diagnosis of subclinical emphysema. Am Rev Respir Dis. 1973 Jan;107(1):50-63.|Gelb AF, Zamel N. Simplified diagnosis of small-airway obstruction. N Engl J Med. 1973 Feb 22;288(8):395-8.|Hogg JC, Paré PD, Hackett TL. The Contribution of Small Airway Obstruction to the Pathogenesis of Chronic Obstructive Pulmonary Disease. Physiol Rev. 2017 Apr;97(2):529-552. doi: 10.1152/physrev.00025.2015. Review. Erratum in: Physiol Rev. 2018 Jul 1;98(3):1909.|Lukic KZ, Coates AL. Does the FEF25-75 or the FEF75 have any value in assessing lung disease in children with cystic fibrosis or asthma? Pediatr Pulmonol. 2015 Sep;50(9):863-8. doi: 10.1002/ppul.23234. Epub 2015 Jun 16.","\tCystic Fibrosis in Children\tspirometry\tNA\tNA\tNA\tDiagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","cystic fibrosis|fibrosis","NA","NA"]
["NCT03850041","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18431116|25247853|19220528","Chung F, Yegneswaran B, Liao P, Chung SA, Vairavanathan S, Islam S, Khajehdehi A, Shapiro CM. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology. 2008 May;108(5):812-21. doi: 10.1097/ALN.0b013e31816d83e4.|Mutter TC, Chateau D, Moffatt M, Ramsey C, Roos LL, Kryger M. A matched cohort study of postoperative outcomes in obstructive sleep apnea: could preoperative diagnosis and treatment prevent complications? Anesthesiology. 2014 Oct;121(4):707-18. doi: 10.1097/ALN.0000000000000407.|Ng SS, Chan TO, To KW, Ngai J, Tung A, Ko FW, Hui DS. Validation of a portable recording device (ApneaLink) for identifying patients with suspected obstructive sleep apnoea syndrome. Intern Med J. 2009 Nov;39(11):757-62. doi: 10.1111/j.1445-5994.2008.01827.x. Epub 2008 Nov 3.","\tObstructive Sleep Apnea\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","apnea|sleep apnea syndromes|sleep apnea, obstructive","NA","NA"]
["NCT03855930","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24969474|12849487|24769029","Michels L, Blok BF, Gregorini F, Kurz M, Schurch B, Kessler TM, Kollias S, Mehnert U. Supraspinal Control of Urine Storage and Micturition in Men--An fMRI Study. Cereb Cortex. 2015 Oct;25(10):3369-80. doi: 10.1093/cercor/bhu140. Epub 2014 Jun 26.|Flor H. Phantom-limb pain: characteristics, causes, and treatment. Lancet Neurol. 2002 Jul;1(3):182-9. Review.|Shy M, Fung S, Boone TB, Karmonik C, Fletcher SG, Khavari R. Functional magnetic resonance imaging during urodynamic testing identifies brain structures initiating micturition. J Urol. 2014 Oct;192(4):1149-54. doi: 10.1016/j.juro.2014.04.090. Epub 2014 Apr 21.","\tPhantom Limb Pain\tfunctional MRI\tNA\tNA\tNA\tDiagnostic Test\tMale\t","NA","NA","NA","NA","NA","NA","phantom limb","NA","NA"]
["NCT03863886","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27660341|28158501|25574078|26855535|24612000","Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, Fiorino G, Juillerat P, Mantzaris GJ, Rizzello F, Vavricka S, Gionchetti P; ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017 Jan;11(1):3-25. doi: 10.1093/ecco-jcc/jjw168. Epub 2016 Sep 22.|Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P, Langner C, Limdi JK, Pellino G, Zagórowicz E, Raine T, Harbord M, Rieder F; European Crohn's and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017 Jun 1;11(6):649-670. doi: 10.1093/ecco-jcc/jjx008.|Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. World J Gastroenterol. 2015 Jan 7;21(1):21-46. doi: 10.3748/wjg.v21.i1.21. Review.|Cârțână ET, Gheonea DI, Săftoiu A. Advances in endoscopic ultrasound imaging of colorectal diseases. World J Gastroenterol. 2016 Feb 7;22(5):1756-66. doi: 10.3748/wjg.v22.i5.1756. Review.|Ellrichmann M, Wietzke-Braun P, Dhar S, Nikolaus S, Arlt A, Bethge J, Kuehbacher T, Wintermeyer L, Balschun K, Klapper W, Schreiber S, Fritscher-Ravens A. Endoscopic ultrasound of the colon for the differentiation of Crohn's disease and ulcerative colitis in comparison with healthy controls. Aliment Pharmacol Ther. 2014 Apr;39(8):823-33. doi: 10.1111/apt.12671. Epub 2014 Feb 25.","\tCrohn Disease|Ulcerative Colitis\tEndoscopic ultrasound catheter (UM-2R/3R, Olympus)\tNA\tNA\tNA\tProcedure\tAll\t","Endoscopic Ultrasound Determines Disease Activity in Crohn's Disease And Ulcerative Colitis","Interventional","Recruiting","N/A",3,60,"colitis|crohn disease|colitis, ulcerative|ulcer","NA","NA"]
["NCT03880149","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29985775|26085822|25203220","Black KE, Witard OC, Baker D, Healey P, Lewis V, Tavares F, Christensen S, Pease T, Smith B. Adding omega-3 fatty acids to a protein-based supplement during pre-season training results in reduced muscle soreness and the better maintenance of explosive power in professional Rugby Union players. Eur J Sport Sci. 2018 Nov;18(10):1357-1367. doi: 10.1080/17461391.2018.1491626. Epub 2018 Jul 9.|Lewis EJ, Radonic PW, Wolever TM, Wells GD. 21 days of mammalian omega-3 fatty acid supplementation improves aspects of neuromuscular function and performance in male athletes compared to olive oil placebo. J Int Soc Sports Nutr. 2015 Jun 18;12:28. doi: 10.1186/s12970-015-0089-4. eCollection 2015.|von Schacky C, Kemper M, Haslbauer R, Halle M. Low Omega-3 Index in 106 German elite winter endurance athletes: a pilot study. Int J Sport Nutr Exerc Metab. 2014 Oct;24(5):559-64. doi: 10.1123/ijsnem.2014-0041. Epub 2014 Sep 8.","\tInflammation|Tendon Injuries\tOmega-3|Placebo\tParallel Assignment\tOther\tRandomized\tDietary Supplement|Other\tAll\t","The Effects of Omega-3 Status and Supplementation on Tendon Structure in Competitive Athletes","Interventional","Recruiting","N/A",2,140,"inflammation|tendon injuries","NA","NA"]
["NCT03887611","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28071987,"Choi YJ, Baek JH, Park HS, Shim WH, Kim TY, Shong YK, Lee JH. A Computer-Aided Diagnosis System Using Artificial Intelligence for the Diagnosis and Characterization of Thyroid Nodules on Ultrasound: Initial Clinical Assessment. Thyroid. 2017 Apr;27(4):546-552. doi: 10.1089/thy.2016.0372. Epub 2017 Feb 28.","\tThyroid Nodule\tUltrasound diagnosis\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","thyroid diseases|thyroid nodule","NA","NA"]
["NCT03897335","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19007588|7092306|10502118|14602265|14726035|17944638|18379554|21798562|3046670|3883810|12954591|23093787|11734617|16049319|8618962|15086457|11171666|11181402|10484524|11532695|11380813|15313386|10561110|16012931|15591104|16493070|16816141|3404810|15947981|15583947|10742366|16887430|15840666|11981083|23087551|9396079|11138732|17936154|18926433|20925544|21545947","Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008 Nov 4;52(19):1527-39. doi: 10.1016/j.jacc.2008.07.051. Review.|Rigden SP, Barratt TM, Dillon MJ, De Leval M, Stark J. Acute renal failure complicating cardiopulmonary bypass surgery. Arch Dis Child. 1982 Jun;57(6):425-30.|Sorof JM, Stromberg D, Brewer ED, Feltes TF, Fraser CD Jr. Early initiation of peritoneal dialysis after surgical repair of congenital heart disease. Pediatr Nephrol. 1999 Oct;13(8):641-5.|Chan KL, Ip P, Chiu CS, Cheung YF. Peritoneal dialysis after surgery for congenital heart disease in infants and young children. Ann Thorac Surg. 2003 Nov;76(5):1443-9.|Boigner H, Brannath W, Hermon M, Stoll E, Burda G, Trittenwein G, Golej J. Predictors of mortality at initiation of peritoneal dialysis in children after cardiac surgery. Ann Thorac Surg. 2004 Jan;77(1):61-5.|Pedersen KR, Povlsen JV, Christensen S, Pedersen J, Hjortholm K, Larsen SH, Hjortdal VE. Risk factors for acute renal failure requiring dialysis after surgery for congenital heart disease in children. Acta Anaesthesiol Scand. 2007 Nov;51(10):1344-9.|Pedersen KR, Hjortdal VE, Christensen S, Pedersen J, Hjortholm K, Larsen SH, Povlsen JV. Clinical outcome in children with acute renal failure treated with peritoneal dialysis after surgery for congenital heart disease. Kidney Int Suppl. 2008 Apr;(108):S81-6. doi: 10.1038/sj.ki.5002607.|Blinder JJ, Goldstein SL, Lee VV, Baycroft A, Fraser CD, Nelson D, Jefferies JL. Congenital heart surgery in infants: effects of acute kidney injury on outcomes. J Thorac Cardiovasc Surg. 2012 Feb;143(2):368-74. doi: 10.1016/j.jtcvs.2011.06.021. Epub 2011 Jul 27.|Gouyon JB, Guignard JP. Functional renal insufficiency: role of adenosine. Biol Neonate. 1988;53(4):237-42. Review.|Hall JE, Granger JP, Hester RL. Interactions between adenosine and angiotensin II in controlling glomerular filtration. Am J Physiol. 1985 Mar;248(3 Pt 2):F340-6.|Hansen PB, Schnermann J. Vasoconstrictor and vasodilator effects of adenosine in the kidney. Am J Physiol Renal Physiol. 2003 Oct;285(4):F590-9. Review.|Rabb H. The promise of immune cell therapy for acute kidney injury. J Clin Invest. 2012 Nov;122(11):3852-4. doi: 10.1172/JCI66455. Epub 2012 Oct 24.|Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001 Dec;53(4):527-52. Review.|Pawelczyk T, Grden M, Rzepko R, Sakowicz M, Szutowicz A. Region-specific alterations of adenosine receptors expression level in kidney of diabetic rat. Am J Pathol. 2005 Aug;167(2):315-25.|Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD. Paracrine regulation of the renal microcirculation. Physiol Rev. 1996 Apr;76(2):425-536. Review.|Vitzthum H, Weiss B, Bachleitner W, Krämer BK, Kurtz A. Gene expression of adenosine receptors along the nephron. Kidney Int. 2004 Apr;65(4):1180-90.|Silldorff EP, Pallone TL. Adenosine signaling in outer medullary descending vasa recta. Am J Physiol Regul Integr Comp Physiol. 2001 Mar;280(3):R854-61.|Nishiyama A, Inscho EW, Navar LG. Interactions of adenosine A1 and A2a receptors on renal microvascular reactivity. Am J Physiol Renal Physiol. 2001 Mar;280(3):F406-14.|Okusa MD, Linden J, Macdonald T, Huang L. Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am J Physiol. 1999 Sep;277(3):F404-12. doi: 10.1152/ajprenal.1999.277.3.F404.|Lee HT, Emala CW. Systemic adenosine given after ischemia protects renal function via A(2a) adenosine receptor activation. Am J Kidney Dis. 2001 Sep;38(3):610-8.|Okusa MD, Linden J, Huang L, Rosin DL, Smith DF, Sullivan G. Enhanced protection from renal ischemia-reperfusion [correction of ischemia:reperfusion] injury with A(2A)-adenosine receptor activation and PDE 4 inhibition. Kidney Int. 2001 Jun;59(6):2114-25. Erratum in: Kidney Int 2001 Aug;60(2):820.|Reece TB, Davis JD, Okonkwo DO, Maxey TS, Ellman PI, Li X, Linden J, Tribble CG, Kron IL, Kern JA. Adenosine A2A analogue reduces long-term neurologic injury after blunt spinal trauma. J Surg Res. 2004 Sep;121(1):130-4.|Ross SD, Tribble CG, Linden J, Gangemi JJ, Lanpher BC, Wang AY, Kron IL. Selective adenosine-A2A activation reduces lung reperfusion injury following transplantation. J Heart Lung Transplant. 1999 Oct;18(10):994-1002.|Odashima M, Bamias G, Rivera-Nieves J, Linden J, Nast CC, Moskaluk CA, Marini M, Sugawara K, Kozaiwa K, Otaka M, Watanabe S, Cominelli F. Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology. 2005 Jul;129(1):26-33.|Glover DK, Riou LM, Ruiz M, Sullivan GW, Linden J, Rieger JM, Macdonald TL, Watson DD, Beller GA. Reduction of infarct size and postischemic inflammation from ATL-146e, a highly selective adenosine A2A receptor agonist, in reperfused canine myocardium. Am J Physiol Heart Circ Physiol. 2005 Apr;288(4):H1851-8. Epub 2004 Dec 9.|Day YJ, Huang L, Ye H, Li L, Linden J, Okusa MD. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: the role of CD4+ T cells and IFN-gamma. J Immunol. 2006 Mar 1;176(5):3108-14.|Vallon V, Mühlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev. 2006 Jul;86(3):901-40. Review.|Gouyon JB, Guignard JP. Theophylline prevents the hypoxemia-induced renal hemodynamic changes in rabbits. Kidney Int. 1988 Jun;33(6):1078-83.|Bakr AF. Prophylactic theophylline to prevent renal dysfunction in newborns exposed to perinatal asphyxia--a study in a developing country. Pediatr Nephrol. 2005 Sep;20(9):1249-52. Epub 2005 Jun 10.|Ng GY, Baker EH, Farrer KF. Aminophylline as an adjunct diuretic for neonates--a case series. Pediatr Nephrol. 2005 Feb;20(2):220-2. Epub 2004 Dec 4.|Jenik AG, Ceriani Cernadas JM, Gorenstein A, Ramirez JA, Vain N, Armadans M, Ferraris JR. A randomized, double-blind, placebo-controlled trial of the effects of prophylactic theophylline on renal function in term neonates with perinatal asphyxia. Pediatrics. 2000 Apr;105(4):E45.|Bhat MA, Shah ZA, Makhdoomi MS, Mufti MH. Theophylline for renal function in term neonates with perinatal asphyxia: a randomized, placebo-controlled trial. J Pediatr. 2006 Aug;149(2):180-4.|McLaughlin GE, Abitbol CL. Reversal of oliguric tacrolimus nephrotoxicity in children. Nephrol Dial Transplant. 2005 Jul;20(7):1471-5. Epub 2005 Apr 19.|Krämer BK, Preuner J, Ebenburger A, Kaiser M, Bergner U, Eilles C, Kammerl MC, Riegger GA, Birnbaum DE. Lack of renoprotective effect of theophylline during aortocoronary bypass surgery. Nephrol Dial Transplant. 2002 May;17(5):910-5.|Mahaldar AR, Sampathkumar K, Raghuram AR, Kumar S, Ramakrishnan M, Mahaldar DA. Risk prediction of acute kidney injury in cardiac surgery and prevention using aminophylline. Indian J Nephrol. 2012 May;22(3):179-83. doi: 10.4103/0971-4065.98752.|Aki Y, Tomohiro A, Nishiyama A, Kiyomoto K, Kimura S, Abe Y. Effects of KW-3902, a selective and potent adenosine A1 receptor antagonist, on renal hemodynamics and urine formation in anesthetized dogs. Pharmacology. 1997 Oct;55(4):193-201.|Yao K, Ina Y, Nagashima K, Ohno T, Karasawa A. Effect of the selective adenosine A1-receptor antagonist KW-3902 on lipopolysaccharide-induced reductions in urine volume and renal blood flow in anesthetized dogs. Jpn J Pharmacol. 2000 Nov;84(3):310-5.|Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC; CKI-201 and CKI-202 Investigators. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol. 2007 Oct 16;50(16):1551-60. Epub 2007 Oct 1.|Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, Massie BM; Protect Steering Committee, Investigators, and Coordinators. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail. 2008 Oct;14(8):631-40. doi: 10.1016/j.cardfail.2008.08.010. Epub 2008 Sep 14.|Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC; PROTECT Investigators and Committees. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010 Oct 7;363(15):1419-28. doi: 10.1056/NEJMoa0912613.|Voors AA, Dittrich HC, Massie BM, DeLucca P, Mansoor GA, Metra M, Cotter G, Weatherley BD, Ponikowski P, Teerlink JR, Cleland JG, O'Connor CM, Givertz MM. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J Am Coll Cardiol. 2011 May 10;57(19):1899-907. doi: 10.1016/j.jacc.2010.11.057.","\tAcute Kidney Injury\tAminophylline|Placebos\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Preventing Acute Kidney Injury (AKI) in Neonates","Interventional","Recruiting","Phase 3",2,120,"acute kidney injury|wounds and injuries","aminophylline","NA"]
["NCT03903107","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",30704289,"Sharma PS, Huang HD, Trohman RG, Naperkowski A, Ellenbogen KA, Vijayaraman P. Low Fluoroscopy Permanent His Bundle Pacing Using Electroanatomic Mapping: A Feasibility Study. Circ Arrhythm Electrophysiol. 2019 Feb;12(2):e006967. doi: 10.1161/CIRCEP.118.006967.","\tHeart Block AV|Heart Failure, Systolic|LBBB|Sinus Node Dysfunction\tConventional fluoroscopy guided HBP|Electroanatomic Mapping (fluoroless) guided HBP\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","Fluoroless vs Conventional HBP","Interventional","Enrolling by invitation","N/A",2,20,"heart block|sick sinus syndrome|heart failure, systolic","NA","NA"]
["NCT03912701","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20637974|22875955","Prytherch DR, Smith GB, Schmidt PE, Featherstone PI. ViEWS--Towards a national early warning score for detecting adult inpatient deterioration. Resuscitation. 2010 Aug;81(8):932-7. doi: 10.1016/j.resuscitation.2010.04.014.|McGinley A, Pearse RM. A national early warning score for acutely ill patients. BMJ. 2012 Aug 8;345:e5310. doi: 10.1136/bmj.e5310.","\tEarly Clinical Deterioration\tVitalpac early warning score (VIEWS)\tNA\tNA\tNA\tDiagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","clinical deterioration","NA","NA"]
["NCT03919474","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21859903,"Brand T, Anderson GM. The measurement of platelet-poor plasma serotonin: a systematic review of prior reports and recommendations for improved analysis. Clin Chem. 2011 Oct;57(10):1376-86. doi: 10.1373/clinchem.2011.163824. Epub 2011 Aug 22. Review.","\tAge Over 18|Idiopathic SSNHL\tmicrovascular markers\tNA\tNA\tNA\tDiagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","hearing loss","NA","NA"]
["NCT03922568","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",1351601,"Palermo G, Joris H, Devroey P, Van Steirteghem AC. Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet. 1992 Jul 4;340(8810):17-8.","\tGender Ratio of ICSI Outcome\tDensity Gradient Centrifugation|Physiological ICSI|Magnetic Activated Cell Sorting\tNA\tNA\tNA\tOther|Device|Device\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT03930901","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25179100,"Al-Delaimy AK, Al-Mekhlafi HM, Lim YA, Nasr NA, Sady H, Atroosh WM, Mahmud R. Developing and evaluating health education learning package (HELP) to control soil-transmitted helminth infections among Orang Asli children in Malaysia. Parasit Vectors. 2014 Sep 2;7:416. doi: 10.1186/1756-3305-7-416.","\tIntestinal Parasitic Infections|Knowledge, Attitudes, Practice\tHealth education learning package\tParallel Assignment\tPrevention\tRandomized\tOther\tAll\t","Impact of Health Education Learning Package Against Intestinal Parasitic Infections Among Orang Asli Children","Interventional","Completed","N/A",2,1142,"intestinal diseases, parasitic|parasitic diseases|infection|communicable diseases","NA","NA"]
["NCT03937414","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22924886,"Wang YS, Ou-yang T, Wu J, Liu YH, Cao XC, Sun X, Fu L, Liao N, Yang WT, Zhong WX, Lu AP. Comparative study of one-step nucleic acid amplification assay, frozen section, and touch imprint cytology for intraoperative assessment of breast sentinel lymph node in Chinese patients. Cancer Sci. 2012 Nov;103(11):1989-93. doi: 10.1111/cas.12001. Epub 2012 Oct 18.","\tSentinel Lymph Node Biopsy\tThe OSNA assay\tNA\tNA\tNA\tDevice\tFemale\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT03946475","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19445257|16920861|25733629|25773683|24379009|10951514","Alaofè H, Zee J, Dossa R, O'Brien HT. Education and improved iron intakes for treatment of mild iron-deficiency anemia in adolescent girls in southern Benin. Food Nutr Bull. 2009 Mar;30(1):24-36.|\"Ferguson EL, Darmon N, Fahmida U, Fitriyanti S, Harper TB, Premachandra IM. Design of optimal food-based complementary feeding recommendations and identification of key \"\"problem nutrients\"\" using goal programming. J Nutr. 2006 Sep;136(9):2399-404.\"|\"Fahmida U, Kolopaking R, Santika O, Sriani S, Umar J, Htet MK, Ferguson E. Effectiveness in improving knowledge, practices, and intakes of \"\"key problem nutrients\"\" of a complementary feeding intervention developed by using linear programming: experience in Lombok, Indonesia. Am J Clin Nutr. 2015 Mar;101(3):455-61. doi: 10.3945/ajcn.114.087775. Epub 2014 Dec 24.\"|Wang D, Stewart D, Chang C, Shi Y. Effect of a school-based nutrition education program on adolescents' nutrition-related knowledge, attitudes and behaviour in rural areas of China. Environ Health Prev Med. 2015 Jul;20(4):271-8. doi: 10.1007/s12199-015-0456-4. Epub 2015 Mar 15.|Blanton C. Improvements in iron status and cognitive function in young women consuming beef or non-beef lunches. Nutrients. 2013 Dec 27;6(1):90-110. doi: 10.3390/nu6010090.|Hallberg L, Hulthén L, Garby L. Iron stores and haemoglobin iron deficits in menstruating women. Calculations based on variations in iron requirements and bioavailability of dietary iron. Eur J Clin Nutr. 2000 Aug;54(8):650-7.","\tAnemia\tIntervention group\tParallel Assignment\tPrevention\tRandomized\tOther\tFemale\t","Remaja ASIK and Optimized Food-based Recommendations","Interventional","Completed","N/A",2,324,"anemia","NA","NA"]
["NCT03953625","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19635343|21451099|18206309|28187918|26501533|8167640|6222486","Greenhalgh S, Selfe J. A qualitative investigation of Red Flags for serious spinal pathology. Physiotherapy. 2009 Sep;95(3):224-7. doi: 10.1016/j.physio.2009.04.006. Epub 2009 Jul 8.|\"Nicholas MK, Linton SJ, Watson PJ, Main CJ; \"\"Decade of the Flags\"\" Working Group. Early identification and management of psychological risk factors (\"\"yellow flags\"\") in patients with low back pain: a reappraisal. Phys Ther. 2011 May;91(5):737-53. doi: 10.2522/ptj.20100224. Epub 2011 Mar 30. Review.\"|Bishop A, Foster NE, Thomas E, Hay EM. How does the self-reported clinical management of patients with low back pain relate to the attitudes and beliefs of health care practitioners? A survey of UK general practitioners and physiotherapists. Pain. 2008 Mar;135(1-2):187-95. doi: 10.1016/j.pain.2007.11.010.|Friedman BW, Irizarry E, Solorzano C, Khankel N, Zapata J, Zias E, Gallagher EJ. Diazepam Is No Better Than Placebo When Added to Naproxen for Acute Low Back Pain. Ann Emerg Med. 2017 Aug;70(2):169-176.e1. doi: 10.1016/j.annemergmed.2016.10.002. Epub 2017 Feb 7.|Friedman BW, Dym AA, Davitt M, Holden L, Solorzano C, Esses D, Bijur PE, Gallagher EJ. Naproxen With Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain: A Randomized Clinical Trial. JAMA. 2015 Oct 20;314(15):1572-80. doi: 10.1001/jama.2015.13043.|Coste J, Le Parc JM, Berge E, Delecoeuillerie G, Paolaggi JB. [French validation of a disability rating scale for the evaluation of low back pain (EIFEL questionnaire)]. Rev Rhum Ed Fr. 1993 May;60(5):335-41. French.|Roland M, Morris R. A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low-back pain. Spine (Phila Pa 1976). 1983 Mar;8(2):141-4.","\tLow Back Pain\tdelivery of the low back pain booklet\tParallel Assignment\tTreatment\tRandomized\tOther\tAll\t","Interest of the Return to Primary Care of the \"Low Back Pain Booklet\" of Health Insurance in the Recovery of Common Acute Low Back Pain","Interventional","Suspended","N/A",2,100,"back pain|low back pain","NA","NA"]
["NCT03998332","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25065927|24213466|21043816|20943645|18473355|20172187|26306904|25218177|18177818|12569593|18565894|20664471|22997444|25646366|24389729|1406819|15136447|20729444|16418242|9706973|19699548|23381206|29391287|29114469|28943940|28868578|29765234|28572122|28382303|28204910","Detterbeck FC. Clinical presentation and evaluation of neuroendocrine tumors of the lung. Thorac Surg Clin. 2014 Aug;24(3):267-76. doi: 10.1016/j.thorsurg.2014.04.002. Review.|Fisseler-Eckhoff A, Demes M. Neuroendocrine tumors of the lung. Cancers (Basel). 2012 Jul 31;4(3):777-98. doi: 10.3390/cancers4030777.|Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med. 2010 Nov;134(11):1628-38. doi: 10.1043/2009-0583-RAR.1. Review.|Travis WD. Advances in neuroendocrine lung tumors. Ann Oncol. 2010 Oct;21 Suppl 7:vii65-71. doi: 10.1093/annonc/mdq380. Review.|Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors. Cancer. 2008 Jul 1;113(1):5-21. doi: 10.1002/cncr.23542. Review.|Detterbeck FC. Management of carcinoid tumors. Ann Thorac Surg. 2010 Mar;89(3):998-1005. doi: 10.1016/j.athoracsur.2009.07.097. Review.|Wolin EM. Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations. Oncologist. 2015 Oct;20(10):1123-31. doi: 10.1634/theoncologist.2015-0198. Epub 2015 Aug 25. Review.|Chong CR, Wirth LJ, Nishino M, Chen AB, Sholl LM, Kulke MH, McNamee CJ, Jänne PA, Johnson BE. Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer. 2014 Nov;86(2):241-6. doi: 10.1016/j.lungcan.2014.08.012. Epub 2014 Aug 27.|Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008 Jan;9(1):61-72. doi: 10.1016/S1470-2045(07)70410-2. Review.|Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003 Feb 15;97(4):934-59.|\"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after \"\"carcinoid\"\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20;26(18):3063-72. doi: 10.1200/JCO.2007.15.4377. Review.\"|Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, Coppola D, Go VL; North American Neuroendocrine Tumor Society (NANETS). NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010 Aug;39(6):713-34. doi: 10.1097/MPA.0b013e3181ebaffd.|Öberg K, Hellman P, Ferolla P, Papotti M; ESMO Guidelines Working Group. Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct;23 Suppl 7:vii120-3.|Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, Travis WD; ENETS consensus conference participants. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015 Aug;26(8):1604-20. doi: 10.1093/annonc/mdv041. Epub 2015 Feb 2. Review.|Pieterman CR, Conemans EB, Dreijerink KM, de Laat JM, Timmers HT, Vriens MR, Valk GD. Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis. Endocr Relat Cancer. 2014 May 6;21(3):R121-42. doi: 10.1530/ERC-13-0482. Print 2014 Jun. Review.|Aguayo SM, Miller YE, Waldron JA Jr, Bogin RM, Sunday ME, Staton GW Jr, Beam WR, King TE Jr. Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. N Engl J Med. 1992 Oct 29;327(18):1285-8.|Gosney JR. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia as a precursor to pulmonary neuroendocrine tumors. Chest. 2004 May;125(5 Suppl):108S.|Koo CW, Baliff JP, Torigian DA, Litzky LA, Gefter WB, Akers SR. Spectrum of pulmonary neuroendocrine cell proliferation: diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, tumorlet, and carcinoids. AJR Am J Roentgenol. 2010 Sep;195(3):661-8. doi: 10.2214/AJR.09.3811. Review.|Chong S, Lee KS, Chung MJ, Han J, Kwon OJ, Kim TS. Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings. Radiographics. 2006 Jan-Feb;26(1):41-57; discussion 57-8. Review.|Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, Koss MN. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998 Aug;22(8):934-44.|Igawa S, Watanabe R, Ito I, Murakami H, Takahashi T, Nakamura Y, Tsuya A, Kaira K, Naito T, Endo M, Yamamoto N, Kameya T. Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. Lung Cancer. 2010 Jun;68(3):438-45. doi: 10.1016/j.lungcan.2009.07.003. Epub 2009 Aug 21.|Watanabe R, Ito I, Kenmotsu H, Endo M, Yamamoto N, Ohde Y, Kondo H, Nakajima T, Kameya T. Large cell neuroendocrine carcinoma of the lung: is it possible to diagnose from biopsy specimens? Jpn J Clin Oncol. 2013 Mar;43(3):294-304. doi: 10.1093/jjco/hys221. Epub 2013 Feb 3.|Kujtan L, Muthukumar V, Kennedy KF, Davis JR, Masood A, Subramanian J. The Role of Systemic Therapy in the Management of Stage I Large Cell Neuroendocrine Carcinoma of the Lung. J Thorac Oncol. 2018 May;13(5):707-714. doi: 10.1016/j.jtho.2018.01.019. Epub 2018 Jan 31.|Hiroshima K, Mino-Kenudson M. Update on large cell neuroendocrine carcinoma. Transl Lung Cancer Res. 2017 Oct;6(5):530-539. doi: 10.21037/tlcr.2017.06.12. Review.|Yang G, Pan Z, Ma N, Qu L, Yuan T, Pang X, Yang X, Dong L, Liu S. Leptomeningeal metastasis of pulmonary large-cell neuroendocrine carcinoma: A case report and review of the literature. Oncol Lett. 2017 Oct;14(4):4282-4286. doi: 10.3892/ol.2017.6676. Epub 2017 Jul 26.|Ramirez RA, Chauhan A, Gimenez J, Thomas KEH, Kokodis I, Voros BA. Management of pulmonary neuroendocrine tumors. Rev Endocr Metab Disord. 2017 Dec;18(4):433-442. doi: 10.1007/s11154-017-9429-9. Review.|Tang H, Wang H, Xi S, He C, Chang Y, Wang Q, Wu Y. Perioperative chemotherapy with pemetrexed and cisplatin for pulmonary large-cell neuroendocrine carcinoma: a case report and literature review. Onco Targets Ther. 2018 May 7;11:2557-2563. doi: 10.2147/OTT.S160565. eCollection 2018.|Derks JL, van Suylen RJ, Thunnissen E, den Bakker MA, Groen HJ, Smit EF, Damhuis RA, van den Broek EC, Speel EM, Dingemans AC; PALGA group. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? Eur Respir J. 2017 Jun 1;49(6). pii: 1601838. doi: 10.1183/13993003.01838-2016. Print 2017 Jun.|Prelaj A, Rebuzzi SE, Del Bene G, Giròn Berrìos JR, Emiliani A, De Filippis L, Prete AA, Pecorari S, Manna G, Ferrara C, Rossini D, Longo F. Evaluation of the efficacy of cisplatin-etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC. ERJ Open Res. 2017 Mar 29;3(1). pii: 00128-2016. doi: 10.1183/23120541.00128-2016. eCollection 2017 Jan.|Kim KW, Kim HK, Kim J, Shim YM, Ahn MJ, Choi YL. Outcomes of Curative-Intent Surgery and Adjuvant Treatment for Pulmonary Large Cell Neuroendocrine Carcinoma. World J Surg. 2017 Jul;41(7):1820-1827. doi: 10.1007/s00268-017-3908-8.","\tSurvival Outcomes of Patients With Pulmonary LCNEC\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms","NA","NA"]
["NCT04003870","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",31722697,"Lee KKW, Ling SKK, Yung PSH. Controlled trial to compare the Achilles tendon load during running in flatfeet participants using a customized arch support orthoses vs an orthotic heel lift. BMC Musculoskelet Disord. 2019 Nov 13;20(1):535. doi: 10.1186/s12891-019-2898-0.","\tAchilles Tendinopathy|Flatfoot|Sports Injury\tCASO|HL\tNA\tNA\tNA\tDevice|Device\tAll\t","NA","NA","NA","NA","NA","NA","tendinopathy|flatfoot|athletic injuries","NA","NA"]
["NCT04009603","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28142296|25949777|29664663|30256077","Ahmadi S, Jamilian M, Karamali M, Tajabadi-Ebrahimi M, Jafari P, Taghizadeh M, Memarzadeh MR, Asemi Z. Probiotic supplementation and the effects on weight loss, glycaemia and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Hum Fertil (Camb). 2017 Dec;20(4):254-261. doi: 10.1080/14647273.2017.1283446. Epub 2017 Feb 1.|Shoaei T, Heidari-Beni M, Tehrani HG, Feizi A, Esmaillzadeh A, Askari G. Effects of Probiotic Supplementation on Pancreatic β-cell Function and C-reactive Protein in Women with Polycystic Ovary Syndrome: A Randomized Double-blind Placebo-controlled Clinical Trial. Int J Prev Med. 2015 Mar 24;6:27. doi: 10.4103/2008-7802.153866. eCollection 2015.|Karamali M, Eghbalpour S, Rajabi S, Jamilian M, Bahmani F, Tajabadi-Ebrahimi M, Keneshlou F, Mirhashemi SM, Chamani M, Hashem Gelougerdi S, Asemi Z. Effects of Probiotic Supplementation on Hormonal Profiles, Biomarkers of Inflammation and Oxidative Stress in Women With Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Arch Iran Med. 2018 Jan 1;21(1):1-7.|Liao D, Zhong C, Li C, Mo L, Liu Y. Meta-analysis of the effects of probiotic supplementation on glycemia, lipidic profiles, weight loss and C-reactive protein in women with polycystic ovarian syndrome. Minerva Med. 2018 Dec;109(6):479-487. doi: 10.23736/S0026-4806.18.05728-2. Epub 2018 Sep 24.","\tPolycystic Ovary Syndrome\tProbiotic Agent|Metformin\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tFemale\t","Comparison of Probiotics, Metformin & Their Combination Therapy in the Treatment of PCOS","Interventional","Completed","N/A",3,78,"polycystic ovary syndrome|syndrome","metformin","NA"]
["NCT04020081","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24977005,"Liu XC, Pan L, Hu Q, Dong WP, Yan JH, Dong L. Effects of yoga training in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Thorac Dis. 2014 Jun;6(6):795-802. doi: 10.3978/j.issn.2072-1439.2014.06.05.","\tCOPD|Obstructive Pulmonary Disease\tYoga breathing exercises and Meditation\tNA\tNA\tNA\tOther\tAll\t","A Study to Evaluate the Effect of Yoga Exercises and Meditation on Lung Function and Quality of Life in COPD Patients.","Interventional","Recruiting","N/A",2,60,"lung diseases|lung diseases, obstructive","NA","NA"]
["NCT04030000","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21508697|8859187|21436701|8381710|8088602|7102898|8522260|2323606|6999399|2211199|7729725|2745205|8490920|2211200|4055452|2258085|7617840|1989916|2380095|15913742|2412690|3053592|11020574|16330675|15459211|8751561|15169803","Moore KN, Fader AN. Uterine papillary serous carcinoma. Clin Obstet Gynecol. 2011 Jun;54(2):278-91. doi: 10.1097/GRF.0b013e318218c755. Review.|Abeler VM, Vergote IB, Kjørstad KE, Tropé CG. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer. 1996 Oct 15;78(8):1740-7.|Gupta D, Gunter MJ, Yang K, Lee S, Zuckerwise L, Chen LM, Goldberg GL, Huang GS. Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma. Int J Gynecol Cancer. 2011 Apr;21(3):529-34. doi: 10.1097/IGC.0b013e31821091b5.|Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, Yordan E, Brady MF. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993 Feb 15;71(4 Suppl):1702-9.|Goff BA, Kato D, Schmidt RA, Ek M, Ferry JA, Muntz HG, Cain JM, Tamimi HK, Figge DC, Greer BE. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol. 1994 Sep;54(3):264-8.|Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982 Mar;6(2):93-108.|Kato DT, Ferry JA, Goodman A, Sullinger J, Scully RE, Goff BA, Fuller AF Jr, Rice LW. Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol Oncol. 1995 Dec;59(3):384-9.|O'Hanlan KA, Levine PA, Harbatkin D, Feiner C, Goldberg GL, Jones JG, Rodriguez-Rodriguez L. Virulence of papillary endometrial carcinoma. Gynecol Oncol. 1990 Apr;37(1):112-9.|Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980 Oct;56(4):419-27.|Calais G, Vitu L, Descamps P, Body G, Reynaud-Bougnoux A, Lansac J, Bougnoux P, Le Floch O. Preoperative or postoperative brachytherapy for patients with endometrial carcinoma stage I and II. Int J Radiat Oncol Biol Phys. 1990 Sep;19(3):523-7.|Carey MS, O'Connell GJ, Johanson CR, Goodyear MD, Murphy KJ, Daya DM, Schepansky A, Peloquin A, Lumsden BJ. Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium. Gynecol Oncol. 1995 May;57(2):138-44.|Greven KM, Curran WJ Jr, Whittington R, Fanning J, Randall ME, Wilder J, Peters AJ. Analysis of failure patterns in stage III endometrial carcinoma and therapeutic implications. Int J Radiat Oncol Biol Phys. 1989 Jul;17(1):35-9.|Greven KM, Lanciano RM, Corn B, Case D, Randall ME. Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence. Cancer. 1993 Jun 1;71(11):3697-702.|Greven KM, Randall M, Fanning J, Bahktar M, Duray P, Peters A, Curran WJ Jr. Patterns of failure in patients with stage I, grade 3 carcinoma of the endometrium. Int J Radiat Oncol Biol Phys. 1990 Sep;19(3):529-34.|Grigsby PW, Perez CA, Camel HM, Kao MS, Galakatos AE. Stage II carcinoma of the endometrium: results of therapy and prognostic factors. Int J Radiat Oncol Biol Phys. 1985 Nov;11(11):1915-23.|Lanciano RM, Curran WJ Jr, Greven KM, Fanning J, Stafford P, Randall ME, Hanks GE. Influence of grade, histologic subtype, and timing of radiotherapy on outcome among patients with stage II carcinoma of the endometrium. Gynecol Oncol. 1990 Dec;39(3):368-73.|Mayr NA, Wen BC, Benda JA, Sorosky JI, Davis CS, Fuller RW, Hussey DH. Postoperative radiation therapy in clinical stage I endometrial cancer: corpus, cervical, and lower uterine segment involvement--patterns of failure. Radiology. 1995 Aug;196(2):323-8.|Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, Graham JE. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991 Jan;40(1):55-65.|Randall ME, Wilder J, Greven K, Raben M. Role of intracavitary cuff boost after adjuvant external irradiation in early endometrial carcinoma. Int J Radiat Oncol Biol Phys. 1990 Jul;19(1):49-54.|Sutton G, Axelrod JH, Bundy BN, Roy T, Homesley HD, Malfetano JH, Mychalczak BR, King ME. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2005 Jun;97(3):755-63.|Mackillop WJ, Pringle JF. Stage III endometrial carcinoma. A review of 90 cases. Cancer. 1985 Nov 15;56(10):2519-23.|Martinez A, Podratz K, Schray M, Malkasian G. Results of whole abdominopelvic irradiation with nodal boost for patients with endometrial cancer at high risk of failure in the peritoneal cavity. A prospective clinical trial at the Mayo Clinic. Hematol Oncol Clin North Am. 1988 Sep;2(3):431-46.|Smith RS, Kapp DS, Chen Q, Teng NN. Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy. Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):767-78. Review.|Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA; Gynecologic Oncology Group Study. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006 Jan 1;24(1):36-44. Epub 2005 Dec 5.|Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, Liao S. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004 Oct 1;22(19):3902-8.|Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996 Aug;62(2):278-81.|Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004 Jun 1;22(11):2159-66.","\tUterine Carcinoma\tPaclitaxel/Carboplatin|Pelvic radiation therapy\tNA\tNA\tNA\tDrug|Radiation\tFemale\t","NA","NA","NA","NA","NA","NA","cystadenocarcinoma, serous|carcinoma","paclitaxel|carboplatin","NA"]
["NCT04035720","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28298899,"Saposnik G, Sempere AP, Prefasi D, Selchen D, Ruff CC, Maurino J, Tobler PN. Decision-making in Multiple Sclerosis: The Role of Aversion to Ambiguity for Therapeutic Inertia among Neurologists (DIScUTIR MS). Front Neurol. 2017 Mar 1;8:65. doi: 10.3389/fneur.2017.00065. eCollection 2017.","\tMultiple Sclerosis\tQuantitative risk\tParallel Assignment\tOther\tRandomized\tOther\tAll\t","Decision Making in Multiple Sclerosis Care Under Uncertainty","Interventional","Recruiting","N/A",2,450,"sclerosis|multiple sclerosis","NA","NA"]
["NCT04040647","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30094811|29183368|30540643","Eriksen JR, Munk-Madsen P, Kehlet H, Gögenur I. Orthostatic intolerance in enhanced recovery laparoscopic colorectal resection. Acta Anaesthesiol Scand. 2019 Feb;63(2):171-177. doi: 10.1111/aas.13238. Epub 2018 Aug 10.|Hanada M, Tawara Y, Miyazaki T, Sato S, Morimoto Y, Oikawa M, Niwa H, Eishi K, Nagayasu T, Eguchi S, Kozu R. Incidence of orthostatic hypotension and cardiovascular response to postoperative early mobilization in patients undergoing cardiothoracic and abdominal surgery. BMC Surg. 2017 Nov 28;17(1):111. doi: 10.1186/s12893-017-0314-y.|Skarin MU, Rice DA, McNair PJ, Kluger MT. Orthostatic intolerance following hip arthroplasty: incidence, risk factors and effect on length of stay: A prospective cohort study. Eur J Anaesthesiol. 2019 Feb;36(2):123-129. doi: 10.1097/EJA.0000000000000940.","\tAmbulation Difficulty|Bariatric Surgery|Colorectal Surgery\tmobilization and ambulation\tNA\tNA\tNA\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","mobility limitation","NA","NA"]
["NCT04052438","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","11782246|19368562|23652115","Adams EJ, Parham P. Species-specific evolution of MHC class I genes in the higher primates. Immunol Rev. 2001 Oct;183:41-64. Review.|Apps R, Murphy SP, Fernando R, Gardner L, Ahad T, Moffett A. Human leucocyte antigen (HLA) expression of primary trophoblast cells and placental cell lines, determined using single antigen beads to characterize allotype specificities of anti-HLA antibodies. Immunology. 2009 May;127(1):26-39. doi: 10.1111/j.1365-2567.2008.03019.x.|Arck PC, Hecher K. Fetomaternal immune cross-talk and its consequences for maternal and offspring's health. Nat Med. 2013 May;19(5):548-56. doi: 10.1038/nm.3160. Epub 2013 May 7. Review.","\tMaternal-Fetal KIR-HLA-C Compatibility\tHLA-C and KIR determination for patients, couples, oocyte or semen donors, abortive tissue and newborn.\tNA\tNA\tNA\tDiagnostic Test\tFemale\t","NA","NA","NA","NA","NA","NA","abortion, habitual","NA","NA"]
["NCT04056065","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Anil Gulati, Dinesh Jain, Nilesh Agrawal, Prashant Rahate, Soumen Das, Rajat Chowdhuri, Deba Dhibar, Madhav Prabhu, Sameer Haveri, Rohit Agarwal, Manish Lavhale. Clinical Phase II Results Of PMZ-2010 (centhaquin) As A Resuscitative Agent For Hypovolemic Shock. Critical Care Medicine Volume 47, Issue 1, Page 12.","\tBlood Loss|Hypovolemic Shock\tNormal Saline|Centhaquine\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","PMZ-2010 (Centhaquine) as a Resuscitative Agent for Hypovolemic Shock","Interventional","Completed","Phase 2",2,50,"shock|hypovolemia","NA","NA"]
["NCT04059692","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20534314|21335931","Rey-Eiriz G, Alburquerque-Sendín F, Barrera-Mellado I, Martín-Vallejo FJ, Fernández-de-las-Peñas C. Validity of the posterior-anterior middle cervical spine gliding test for the examination of intervertebral joint hypomobility in mechanical neck pain. J Manipulative Physiol Ther. 2010 May;33(4):279-85. doi: 10.1016/j.jmpt.2010.03.005.|Puentedura EJ, Landers MR, Cleland JA, Mintken PE, Huijbregts P, Fernández-de-Las-Peñas C. Thoracic spine thrust manipulation versus cervical spine thrust manipulation in patients with acute neck pain: a randomized clinical trial. J Orthop Sports Phys Ther. 2011 Apr;41(4):208-20. doi: 10.2519/jospt.2011.3640. Epub 2011 Feb 18.","\tNeck Pain\tCervical manipulation intervention|Placebo intervention\tParallel Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Immediate Effect of a Single Cervical Spinal Manipulation","Interventional","Completed","N/A",2,50,"neck pain","NA","NA"]
["NCT04077476","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21372060|10381705|26810220|24668767|25030795|25886805|26744309|25535016|19281517|23079176","Blackmore ER, Côté-Arsenault D, Tang W, Glover V, Evans J, Golding J, O'Connor TG. Previous prenatal loss as a predictor of perinatal depression and anxiety. Br J Psychiatry. 2011 May;198(5):373-8. doi: 10.1192/bjp.bp.110.083105. Epub 2011 Mar 3.|Hughes PM, Turton P, Evans CD. Stillbirth as risk factor for depression and anxiety in the subsequent pregnancy: cohort study. BMJ. 1999 Jun 26;318(7200):1721-4.|Ellis A, Chebsey C, Storey C, Bradley S, Jackson S, Flenady V, Heazell A, Siassakos D. Systematic review to understand and improve care after stillbirth: a review of parents' and healthcare professionals' experiences. BMC Pregnancy Childbirth. 2016 Jan 25;16:16. doi: 10.1186/s12884-016-0806-2. Review.|Mitchell KS, Dick AM, DiMartino DM, Smith BN, Niles B, Koenen KC, Street A. A pilot study of a randomized controlled trial of yoga as an intervention for PTSD symptoms in women. J Trauma Stress. 2014 Apr;27(2):121-8. doi: 10.1002/jts.21903. Epub 2014 Mar 25.|Park CL, Riley KE, Bedesin E, Stewart VM. Why practice yoga? Practitioners' motivations for adopting and maintaining yoga practice. J Health Psychol. 2016 Jun;21(6):887-96. doi: 10.1177/1359105314541314. Epub 2014 Jul 16.|Buttner MM, Brock RL, O'Hara MW, Stuart S. Efficacy of yoga for depressed postpartum women: A randomized controlled trial. Complement Ther Clin Pract. 2015 May;21(2):94-100. doi: 10.1016/j.ctcp.2015.03.003. Epub 2015 Apr 1.|Naslund JA, Aschbrenner KA, Marsch LA, Bartels SJ. The future of mental health care: peer-to-peer support and social media. Epidemiol Psychiatr Sci. 2016 Apr;25(2):113-22. doi: 10.1017/S2045796015001067. Epub 2016 Jan 8.|McAlpine H, Joubert L, Martin-Sanchez F, Merolli M, Drummond KJ. A systematic review of types and efficacy of online interventions for cancer patients. Patient Educ Couns. 2015 Mar;98(3):283-95. doi: 10.1016/j.pec.2014.11.002. Epub 2014 Nov 18. Review.|Cacciatore J, Schnebly S, Froen JF. The effects of social support on maternal anxiety and depression after stillbirth. Health Soc Care Community. 2009 Mar;17(2):167-76. doi: 10.1111/j.1365-2524.2008.00814.x.|Cavallo DN, Tate DF, Ries AV, Brown JD, DeVellis RF, Ammerman AS. A social media-based physical activity intervention: a randomized controlled trial. Am J Prev Med. 2012 Nov;43(5):527-32. doi: 10.1016/j.amepre.2012.07.019.","\tAnxiety|Depression|Post-traumatic Stress Disorder|Stillbirth\tOnline Yoga + Facebook|Online Yoga\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral\tFemale\t","Feasibility of Online Yoga With Facebook After Stillbirth","Interventional","Completed","N/A",2,60,"stress disorders, post-traumatic|stress disorders, traumatic|stillbirth","NA","NA"]
["NCT04090463","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24635869|28069018|24006012|29800971","Palta M, Willett C, Czito B. The role of intraoperative radiation therapy in patients with pancreatic cancer. Semin Radiat Oncol. 2014 Apr;24(2):126-31. doi: 10.1016/j.semradonc.2013.11.004. Review.|Krempien R, Roeder F. Intraoperative radiation therapy (IORT) in pancreatic cancer. Radiat Oncol. 2017 Jan 10;12(1):8. doi: 10.1186/s13014-016-0753-0. Review.|Cai S, Hong TS, Goldberg SI, Fernandez-del Castillo C, Thayer SP, Ferrone CR, Ryan DP, Blaszkowsky LS, Kwak EL, Willett CG, Lillemoe KD, Warshaw AL, Wo JY. Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. Cancer. 2013 Dec 1;119(23):4196-204. doi: 10.1002/cncr.28329. Epub 2013 Sep 4.|Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Faris JE, Zhu AX, Goyal L, Lillemoe KD, DeLaney TF, Fernández-Del Castillo C, Ferrone CR, Hong TS. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Jul 1;4(7):963-969. doi: 10.1001/jamaoncol.2018.0329. Erratum in: JAMA Oncol. 2018 Oct 1;4(10):1439.","\tBorderline Resectable Pancreatic Cancer\tIntraoperative radiotherapy\tNA\tNA\tNA\tRadiation\tAll\t","NA","NA","NA","NA","NA","NA","pancreatic neoplasms","NA","NA"]
["NCT04093726","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",16428535,"Schoenfelder RC, Ponnamma CM, Freyle D, Wang SM, Kain ZN. Residual gastric fluid volume and chewing gum before surgery. Anesth Analg. 2006 Feb;102(2):415-7.","\tGastric Volume\tlollipop\tCrossover Assignment\tOther\tRandomized\tOther\tAll\t","Lollipop on Gastric Volume","Interventional","Completed","N/A",2,20,"NA","NA","NA"]
["NCT04104061","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20580108,"Tay EL, Peset A, Papaphylactou M, Inuzuka R, Alonso-Gonzalez R, Giannakoulas G, Tzifa A, Goletto S, Broberg C, Dimopoulos K, Gatzoulis MA. Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. Int J Cardiol. 2011 Sep 15;151(3):307-12. doi: 10.1016/j.ijcard.2010.05.066. Epub 2010 Jul 1.","\tCongenital; Cyanotic Heart Disease\tiron profile\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","heart diseases","NA","NA"]
["NCT04124250","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28056015|28012943|25122037|25393404","Fischer PU, King CL, Jacobson JA, Weil GJ. Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa. PLoS Negl Trop Dis. 2017 Jan 5;11(1):e0005163. doi: 10.1371/journal.pntd.0005163. eCollection 2017 Jan.|Irvine MA, Stolk WA, Smith ME, Subramanian S, Singh BK, Weil GJ, Michael E, Hollingsworth TD. Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study. Lancet Infect Dis. 2017 Apr;17(4):451-458. doi: 10.1016/S1473-3099(16)30467-4. Epub 2016 Dec 22.|Schmaedick MA, Koppel AL, Pilotte N, Torres M, Williams SA, Dobson SL, Lammie PJ, Won KY. Molecular xenomonitoring using mosquitoes to map lymphatic filariasis after mass drug administration in American Samoa. PLoS Negl Trop Dis. 2014 Aug 14;8(8):e3087. doi: 10.1371/journal.pntd.0003087. eCollection 2014 Aug.|Rao RU, Nagodavithana KC, Samarasekera SD, Wijegunawardana AD, Premakumara WD, Perera SN, Settinayake S, Miller JP, Weil GJ. A comprehensive assessment of lymphatic filariasis in Sri Lanka six years after cessation of mass drug administration. PLoS Negl Trop Dis. 2014 Nov 13;8(11):e3281. doi: 10.1371/journal.pntd.0003281. eCollection 2014. Erratum in: PLoS Negl Trop Dis. 2014 Dec;(12):e3428.","\tAcceptability of Mass Drug Administration for Lymphatic Filariasis|Lymphatic Filariasis Elimination by Mass Drug Administration|Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis\tObservational\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","filariasis|elephantiasis|elephantiasis, filarial","NA","NA"]
["NCT04131855","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16448279|18331943","Burgess AM, Sherriff M, Ireland AJ. Self-etching primers: is prophylactic pumicing necessary? A randomized clinical trial. Angle Orthod. 2006 Jan;76(1):114-8.|Lill DJ, Lindauer SJ, Tüfekçi E, Shroff B. Importance of pumice prophylaxis for bonding with self-etch primer. Am J Orthod Dentofacial Orthop. 2008 Mar;133(3):423-6; quiz 476.e2. doi: 10.1016/j.ajodo.2006.03.039.","\tOrthodontic Appliance Complication\tPumice prophylaxis|No pumice prophylaxis\tParallel Assignment\tDiagnostic\tRandomized\tOther|Other\tAll\t","The Omission of Pumice Prophylaxis on Bracket Failure Rates Using Self Etch Primers","Interventional","Not yet recruiting","N/A",2,20,"NA","NA","NA"]
["NCT04139551","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31621619|31325988|32078894","Lu Z, Buchanan T, Kennard C, FitzGerald JJ, Antoniades CA. The effect of levodopa on saccades - Oxford Quantification in Parkinsonism study. Parkinsonism Relat Disord. 2019 Nov;68:49-56. doi: 10.1016/j.parkreldis.2019.09.029. Epub 2019 Sep 27.|Patel S, Fitzgerald JJ, Antoniades CA. Oculomotor effects of medical and surgical treatments of Parkinson's disease. Prog Brain Res. 2019;249:297-305. doi: 10.1016/bs.pbr.2019.04.020. Epub 2019 May 20.|De Vos M, Prince J, Buchanan T, FitzGerald JJ, Antoniades CA. Discriminating progressive supranuclear palsy from Parkinson's disease using wearable technology and machine learning. Gait Posture. 2020 Mar;77:257-263. doi: 10.1016/j.gaitpost.2020.02.007. Epub 2020 Feb 10.","\tParkinson Disease|Progressive Supranuclear Palsy\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","supranuclear palsy, progressive|parkinson disease|parkinsonian disorders","NA","NA"]
["NCT04146012","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15563567|12110026|26034590|NA","Manns B, Tonelli M, Yilmaz S, Lee H, Laupland K, Klarenbach S, Radkevich V, Murphy B. Establishment and maintenance of vascular access in incident hemodialysis patients: a prospective cost analysis. J Am Soc Nephrol. 2005 Jan;16(1):201-9. Epub 2004 Nov 24.|Pastan S, Soucie JM, McClellan WM. Vascular access and increased risk of death among hemodialysis patients. Kidney Int. 2002 Aug;62(2):620-6.|Al Shakarchi J, Inston N. Timing of cannulation of arteriovenous grafts: are we too cautious? Clin Kidney J. 2015 Jun;8(3):290-2. doi: 10.1093/ckj/sfu146. Epub 2015 Jan 20.|US Renal Data System, Annual Data Report: Atlas of Chronic Kidney Disease and End Stage Renal Disease in the United States, Bethesda MD, National Institutes of Health, National Institute of Diabetes and Kidney Diseases, 2009","\tRenal Insufficiency,Chronic\tArtegraft® Collagen Vascular Graft™ (Artegraft)\tParallel Assignment\tTreatment\tRandomized\tDevice\tAll\t","BEACH Trial: Bovine Early Access, Compatibility and Hemostasis Trial","Interventional","Terminated","Phase 3",2,5,"renal insufficiency, chronic|renal insufficiency","NA","NA"]
["NCT04149405",7867930,4296802,"Mean Difference (Final Values)",0.01,null,"NA",{"$nulls":3},0.01,"Kruskal-Wallis","16018754|26367496|24576302","Lane N, Armitage GC, Loomer P, Hsieh S, Majumdar S, Wang HY, Jeffcoat M, Munoz T. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. J Periodontol. 2005 Jul;76(7):1113-22.|Balli U, Aydogdu A, Dede FO, Turer CC, Guven B. Gingival Crevicular Fluid Levels of Sclerostin, Osteoprotegerin, and Receptor Activator of Nuclear Factor-κB Ligand in Periodontitis. J Periodontol. 2015 Dec;86(12):1396-404. doi: 10.1902/jop.2015.150270. Epub 2015 Sep 14.|Napimoga MH, Nametala C, da Silva FL, Miranda TS, Bossonaro JP, Demasi AP, Duarte PM. Involvement of the Wnt-β-catenin signalling antagonists, sclerostin and dickkopf-related protein 1, in chronic periodontitis. J Clin Periodontol. 2014 Jun;41(6):550-7. doi: 10.1111/jcpe.12245.","\tOsteoporosis, Postmenopausal|Periodontitis\tPhase 1 periodontal therapy|Bisphosphonate therapy\tNA\tNA\tNA\tProcedure|Drug\tFemale\t","Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis","Interventional","Completed","Phase 4",4,43,"periodontitis|osteoporosis|osteoporosis, postmenopausal","diphosphonates","Sost Values for 6th Month"]
["NCT04153773","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30410033|30303036|25662900|27986875|26585439|31059539|27011339|23165340|27840739|28920886|21611198|27142714|27225223|30646353|31323964|21387374|6685237|NA|NA|NA","Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA. Multiple sclerosis. Nat Rev Dis Primers. 2018 Nov 8;4(1):43. doi: 10.1038/s41572-018-0041-4. Review. Erratum in: Nat Rev Dis Primers. 2018 Nov 22;4(1):49.|Kalb R, Beier M, Benedict RH, Charvet L, Costello K, Feinstein A, Gingold J, Goverover Y, Halper J, Harris C, Kostich L, Krupp L, Lathi E, LaRocca N, Thrower B, DeLuca J. Recommendations for cognitive screening and management in multiple sclerosis care. Mult Scler. 2018 Nov;24(13):1665-1680. doi: 10.1177/1352458518803785. Epub 2018 Oct 10. Review.|Rocca MA, Amato MP, De Stefano N, Enzinger C, Geurts JJ, Penner IK, Rovira A, Sumowski JF, Valsasina P, Filippi M; MAGNIMS Study Group. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol. 2015 Mar;14(3):302-17. doi: 10.1016/S1474-4422(14)70250-9. Epub 2015 Feb 4. Review.|Rocca MA, Battaglini M, Benedict RH, De Stefano N, Geurts JJ, Henry RG, Horsfield MA, Jenkinson M, Pagani E, Filippi M. Brain MRI atrophy quantification in MS: From methods to clinical application. Neurology. 2017 Jan 24;88(4):403-413. doi: 10.1212/WNL.0000000000003542. Epub 2016 Dec 16. Review.|Kappos L, De Stefano N, Freedman MS, Cree BA, Radue EW, Sprenger T, Sormani MP, Smith T, Häring DA, Piani Meier D, Tomic D. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler. 2016 Sep;22(10):1297-305. doi: 10.1177/1352458515616701. Epub 2015 Nov 19.|Pérez Del Palomar A, Cegoñino J, Montolío A, Orduna E, Vilades E, Sebastián B, Pablo LE, Garcia-Martin E. Swept source optical coherence tomography to early detect multiple sclerosis disease. The use of machine learning techniques. PLoS One. 2019 May 6;14(5):e0216410. doi: 10.1371/journal.pone.0216410. eCollection 2019.|Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, Brandt AU, Pablo LE, Guerrieri S, Gonzalez I, Outteryck O, Mueller AK, Albrecht P, Chan W, Lukas S, Balk LJ, Fraser C, Frederiksen JL, Resto J, Frohman T, Cordano C, Zubizarreta I, Andorra M, Sanchez-Dalmau B, Saiz A, Bermel R, Klistorner A, Petzold A, Schippling S, Costello F, Aktas O, Vermersch P, Oreja-Guevara C, Comi G, Leocani L, Garcia-Martin E, Paul F, Havrdova E, Frohman E, Balcer LJ, Green AJ, Calabresi PA, Villoslada P; IMSVISUAL consortium. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurol. 2016 May;15(6):574-84. doi: 10.1016/S1474-4422(16)00068-5. Epub 2016 Mar 18.|London A, Benhar I, Schwartz M. The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol. 2013 Jan;9(1):44-53. doi: 10.1038/nrneurol.2012.227. Epub 2012 Nov 20. Review.|Satue M, Obis J, Rodrigo MJ, Otin S, Fuertes MI, Vilades E, Gracia H, Ara JR, Alarcia R, Polo V, Larrosa JM, Pablo LE, Garcia-Martin E. Optical Coherence Tomography as a Biomarker for Diagnosis, Progression, and Prognosis of Neurodegenerative Diseases. J Ophthalmol. 2016;2016:8503859. Epub 2016 Oct 20. Review.|Petzold A, Balcer LJ, Calabresi PA, Costello F, Frohman TC, Frohman EM, Martinez-Lapiscina EH, Green AJ, Kardon R, Outteryck O, Paul F, Schippling S, Vermersch P, Villoslada P, Balk LJ; ERN-EYE IMSVISUAL. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2017 Oct;16(10):797-812. doi: 10.1016/S1474-4422(17)30278-8. Epub 2017 Sep 12. Review.|Serbecic N, Aboul-Enein F, Beutelspacher SC, Vass C, Kristoferitsch W, Lassmann H, Reitner A, Schmidt-Erfurth U. High resolution spectral domain optical coherence tomography (SD-OCT) in multiple sclerosis: the first follow up study over two years. PLoS One. 2011;6(5):e19843. doi: 10.1371/journal.pone.0019843. Epub 2011 May 17.|Balk LJ, Cruz-Herranz A, Albrecht P, Arnow S, Gelfand JM, Tewarie P, Killestein J, Uitdehaag BM, Petzold A, Green AJ. Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study. J Neurol. 2016 Jul;263(7):1323-31. doi: 10.1007/s00415-016-8127-y. Epub 2016 May 3.|Cruz-Herranz A, Balk LJ, Oberwahrenbrock T, Saidha S, Martinez-Lapiscina EH, Lagreze WA, Schuman JS, Villoslada P, Calabresi P, Balcer L, Petzold A, Green AJ, Paul F, Brandt AU, Albrecht P; IMSVISUAL consortium. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology. 2016 Jun 14;86(24):2303-9. doi: 10.1212/WNL.0000000000002774. Epub 2016 May 25.|Méndez-Gómez JL, Pelletier A, Rougier MB, Korobelnik JF, Schweitzer C, Delyfer MN, Catheline G, Monfermé S, Dartigues JF, Delcourt C, Helmer C. Association of Retinal Nerve Fiber Layer Thickness With Brain Alterations in the Visual and Limbic Networks in Elderly Adults Without Dementia. JAMA Netw Open. 2018 Nov 2;1(7):e184406. doi: 10.1001/jamanetworkopen.2018.4406.|Cabrera DeBuc D, Gaca-Wysocka M, Grzybowski A, Kanclerz P. Identification of Retinal Biomarkers in Alzheimer's Disease Using Optical Coherence Tomography: Recent Insights, Challenges, and Opportunities. J Clin Med. 2019 Jul 9;8(7). pii: E996. doi: 10.3390/jcm8070996. Review.|Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 Feb;69(2):292-302. doi: 10.1002/ana.22366.|Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444-52.|Smith A. Symbol digit modalities test: manual. Western Psychological Corporation. Los Angeles (CA): Western Psychological Services; 2002.|Delis DC, Kramer JH, Kaplan E, et al. California verbal learning test - second edition. Adult version. Manual. San Antonio (TX): The Psychological Corporation; 2000.|Benedict RHB. Brief visuospatial memory testrevised. Odessa (Fla): Psychological Assessment Resources; 1997.","\tMultiple Sclerosis\tOCT\tNA\tNA\tNA\tDiagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","sclerosis|multiple sclerosis|cognitive dysfunction","NA","NA"]
["NCT04162054","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28100544,"Gerhardt F, Dumitrescu D, Gärtner C, Beccard R, Viethen T, Kramer T, Baldus S, Hellmich M, Schönau E, Rosenkranz S. Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study. Heart. 2017 Apr;103(8):592-598. doi: 10.1136/heartjnl-2016-309852. Epub 2017 Jan 18.","\tAcute Cardiopulmonary Effects\tObservational study to evaluate acute cardiopulmonary effects of whole body vibration (WBV) on healthy individuals analysed in non-invasive cardiopulmonary exercise test (CPX).\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04172883","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","11343485|20876603|9809895","Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9;285(18):2370-5.|Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH; ESC Committee for Practice Guidelines. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010 Oct;12(10):1360-420. doi: 10.1093/europace/euq350. Erratum in: Europace. 2011 Jul;13(7):1058. Dosage error in article text.|Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998 Oct 16;82(8A):2N-9N.","\tCardiovascular Diseases\tTreatment arm\tParallel Assignment\tTreatment\tRandomized\tOther\tAll\t","Management of Device Detected AT and Impact of Device Treatment Algorithms on Atrial Fibrillation","Interventional","Active, not recruiting","N/A",2,80,"cardiovascular diseases|atrial fibrillation","NA","NA"]
["NCT04173013","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29171130|26090341|31660885","Yang B, Foley S. First experience in the UK of treating women with recurrent urinary tract infections with the bacterial vaccine Uromune(®). BJU Int. 2018 Feb;121(2):289-292. doi: 10.1111/bju.14067. Epub 2017 Nov 23.|Lorenzo-Gómez MF, Padilla-Fernández B, García-Cenador MB, Virseda-Rodríguez ÁJ, Martín-García I, Sánchez-Escudero A, Vicente-Arroyo MJ, Mirón-Canelo JA. Comparison of sublingual therapeutic vaccine with antibiotics for the prophylaxis of recurrent urinary tract infections. Front Cell Infect Microbiol. 2015 Jun 3;5:50. doi: 10.3389/fcimb.2015.00050. eCollection 2015.|Ramírez Sevilla C, Gómez Lanza E, Manzanera JL, Martín JAR, Sanz MÁB. Active immunoprophyilaxis with uromune® decreases the recurrence of urinary tract infections at three and six months after treatment without relevant secondary effects. BMC Infect Dis. 2019 Oct 28;19(1):901. doi: 10.1186/s12879-019-4541-y.","\tBladder Infection|Chronic Urinary Tract Infection|Recurrent Urinary Tract Infection|Urinary Tract Infection Bacterial|Urinary Tract Infections\tUromune\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","bacterial infections|cystitis|urinary tract infections|communicable diseases|infection","NA","NA"]
["NCT04179994","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26694786|8295089|28652142|23248560|29789771|20370417","Azaripour A, Mahmoodi B, Habibi E, Willershausen I, Schmidtmann I, Willershausen B. Effectiveness of a miswak extract-containing toothpaste on gingival inflammation: a randomized clinical trial. Int J Dent Hyg. 2017 Aug;15(3):195-202. doi: 10.1111/idh.12195. Epub 2015 Dec 22.|Dragolich WE, Pashley DH, Brennan WA, O'Neal RB, Horner JA, Van Dyke TE. An in vitro study of dentinal tubule occlusion by ferric oxalate. J Periodontol. 1993 Nov;64(11):1045-51.|Gallob J, Sufi F, Amini P, Siddiqi M, Mason S. A randomised exploratory clinical evaluation of dentifrices used as controls in dentinal hypersensitivity studies. J Dent. 2017 Sep;64:80-87. doi: 10.1016/j.jdent.2017.06.009. Epub 2017 Jun 23.|Gupta P, Agarwal N, Anup N, Manujunath BC, Bhalla A. Evaluating the anti-plaque efficacy of meswak (Salvadora persica) containing dentifrice: A triple blind controlled trial. J Pharm Bioallied Sci. 2012 Oct;4(4):282-5. doi: 10.4103/0975-7406.103238.|Mason S, Kingston R, Shneyer L, Harding M. Clinical study to monitor dentinal hypersensitivity with episodic use of a desensitising dentifrice. BDJ Open. 2017 Jun 23;3:17011. doi: 10.1038/bdjopen.2017.11. eCollection 2017.|Pradeep AR, Sharma A. Comparison of clinical efficacy of a dentifrice containing calcium sodium phosphosilicate to a dentifrice containing potassium nitrate and to a placebo on dentinal hypersensitivity: a randomized clinical trial. J Periodontol. 2010 Aug;81(8):1167-73. doi: 10.1902/jop.2010.100056.","\tDentine Hypersensitivity\tMiswak extract-containing toothpaste|Potassium nitrates-containing toothpaste|Placebo\tParallel Assignment\tTreatment\tRandomized\tOther|Other|Other\tAll\t","Efficacy of Miswak Extract Toothpaste as Compared Potassium Nitrate in The Management of Dentinal Hypersensitivity","Interventional","Not yet recruiting","N/A",3,96,"dentin sensitivity|hypersensitivity","NA","NA"]
["NCT04189367","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29156085|19175713|27974236|24389028|21824510|24969368|19295226|26068429|15621359|11002408|9830647|22344742|22044166|22765925|25178949|26293497|28606830|27340102|26817897|23128097|25527314|28499829|28851349|22924055|24716178|26365451|26522135|25456420|976134|26847146|19610028|23297780|30439807|19142042|21120510|25091464|19905906|24905866","Adamo D, Sardella A, Varoni E, Lajolo C, Biasotto M, Ottaviani G, Vescovi P, Simonazzi T, Pentenero M, Ardore M, Spadari F, Bombeccari G, Montebugnoli L, Gissi DB, Campisi G, Panzarella V, Carbone M, Valpreda L, Giuliani M, Aria M, Lo Muzio L, Mignogna MD. The association between burning mouth syndrome and sleep disturbance: A case-control multicentre study. Oral Dis. 2018 May;24(4):638-649. doi: 10.1111/odi.12807. Epub 2018 Mar 13.|Cavalcanti DR, da Silveira FR. Alpha lipoic acid in burning mouth syndrome--a randomized double-blind placebo-controlled trial. J Oral Pathol Med. 2009 Mar;38(3):254-61. doi: 10.1111/j.1600-0714.2008.00735.x. Epub 2009 Jan 23.|Chang CM, Wu PC, Chiang JH, Wei YH, Chen FP, Chen TJ, Pan TL, Yen HR, Chang HH. Integrative therapy decreases the risk of lupus nephritis in patients with systemic lupus erythematosus: A population-based retrospective cohort study. J Ethnopharmacol. 2017 Jan 20;196:201-212. doi: 10.1016/j.jep.2016.12.016. Epub 2016 Dec 12. Erratum in: J Ethnopharmacol. 2017 Jul 12;206:426.|Chang YY, Tsai YT, Lai JN, Yeh CH, Lin SK. The traditional Chinese medicine prescription patterns for migraine patients in Taiwan: a population-based study. J Ethnopharmacol. 2014 Feb 12;151(3):1209-1217. doi: 10.1016/j.jep.2013.12.040. Epub 2014 Jan 2.|Chen HY, Lin YH, Wu JC, Chen YC, Yang SH, Chen JL, Chen TJ. Prescription patterns of Chinese herbal products for menopausal syndrome: analysis of a nationwide prescription database. J Ethnopharmacol. 2011 Oct 11;137(3):1261-6. doi: 10.1016/j.jep.2011.07.053. Epub 2011 Aug 2.|Chen HY, Huang BS, Lin YH, Su IH, Yang SH, Chen JL, Huang JW, Chen YC. Identifying Chinese herbal medicine for premenstrual syndrome: implications from a nationwide database. BMC Complement Altern Med. 2014 Jun 27;14:206. doi: 10.1186/1472-6882-14-206.|Chen LL, Lin JS, Lin JD, Chang CH, Kuo HW, Liang WM, Su YC. BCQ+: a body constitution questionnaire to assess Yang-Xu. Part II: Evaluation of reliability and validity. Forsch Komplementmed. 2009 Feb;16(1):20-7. doi: 10.1159/000197770. Epub 2009 Feb 17.|Chen YL, Lee CY, Huang KH, Kuan YH, Chen M. Prescription patterns of Chinese herbal products for patients with sleep disorder and major depressive disorder in Taiwan. J Ethnopharmacol. 2015 Aug 2;171:307-16. doi: 10.1016/j.jep.2015.05.045. Epub 2015 Jun 9.|Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J; IMMPACT. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005 Jan;113(1-2):9-19. Review.|Femiano F, Gombos F, Scully C, Busciolano M, De Luca P. Burning mouth syndrome (BMS): controlled open trial of the efficacy of alpha-lipoic acid (thioctic acid) on symptomatology. Oral Dis. 2000 Sep;6(5):274-7.|Grushka M, Epstein J, Mott A. An open-label, dose escalation pilot study of the effect of clonazepam in burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Nov;86(5):557-61.|Heckmann SM, Kirchner E, Grushka M, Wichmann MG, Hummel T. A double-blind study on clonazepam in patients with burning mouth syndrome. Laryngoscope. 2012 Apr;122(4):813-6. doi: 10.1002/lary.22490. Epub 2012 Feb 16.|Hens MJ, Alonso-Ferreira V, Villaverde-Hueso A, Abaitua I, Posada de la Paz M. Cost-effectiveness analysis of burning mouth syndrome therapy. Community Dent Oral Epidemiol. 2012 Apr;40(2):185-92. doi: 10.1111/j.1600-0528.2011.00645.x. Epub 2011 Nov 1.|Hidaka T, Yonezawa R, Saito S. Kami-shoyo-san, Kampo (Japanese traditional medicine), is effective for climacteric syndrome, especially in hormone-replacement-therapy-resistant patients who strongly complain of psychological symptoms. J Obstet Gynaecol Res. 2013 Jan;39(1):223-8. doi: 10.1111/j.1447-0756.2012.01936.x. Epub 2012 Jul 6.|Hsu PC, Tsai YT, Lai JN, Wu CT, Lin SK, Huang CY. Integrating traditional Chinese medicine healthcare into diabetes care by reducing the risk of developing kidney failure among type 2 diabetic patients: a population-based case control study. J Ethnopharmacol. 2014 Oct 28;156:358-64. doi: 10.1016/j.jep.2014.08.029. Epub 2014 Aug 29.|Imura H, Shimada M, Yamazaki Y, Sugimoto K. Characteristic changes of saliva and taste in burning mouth syndrome patients. J Oral Pathol Med. 2016 Mar;45(3):231-6. doi: 10.1111/jop.12350. Epub 2015 Aug 21.|Kuten-Shorrer M, Treister NS, Stock S, Kelley JM, Ji YD, Woo SB, Lerman MA, Palmason S, Sonis ST, Villa A. Safety and tolerability of topical clonazepam solution for management of oral dysesthesia. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Aug;124(2):146-151. doi: 10.1016/j.oooo.2017.05.470. Epub 2017 May 11.|Lien AS, Jiang YD, Mou CH, Sun MF, Gau BS, Yen HR. Integrative traditional Chinese medicine therapy reduces the risk of diabetic ketoacidosis in patients with type 1 diabetes mellitus. J Ethnopharmacol. 2016 Sep 15;191:324-330. doi: 10.1016/j.jep.2016.06.051. Epub 2016 Jun 20.|Lee AL, Chen BC, Mou CH, Sun MF, Yen HR. Association of Traditional Chinese Medicine Therapy and the Risk of Vascular Complications in Patients With Type II Diabetes Mellitus: A Nationwide, Retrospective, Taiwanese-Registry, Cohort Study. Medicine (Baltimore). 2016 Jan;95(3):e2536. doi: 10.1097/MD.0000000000002536.|Lin JD, Chen LL, Lin JS, Chang CH, Huang YC, Su YC. BCQ-: a body constitution questionnaire to assess Yin-Xu. Part I: establishment of a provisional version through a Delphi process. Forsch Komplementmed. 2012;19(5):234-41. doi: 10.1159/000343580. Epub 2012 Oct 18.|Lin SK, Tsai YT, Lai JN, Wu CT. Demographic and medication characteristics of traditional Chinese medicine users among dementia patients in Taiwan: a nationwide database study. J Ethnopharmacol. 2015 Feb 23;161:108-15. doi: 10.1016/j.jep.2014.12.015. Epub 2014 Dec 17.|Lin YC, Chang TT, Chen HJ, Wang CH, Sun MF, Yen HR. Characteristics of traditional Chinese medicine usage in children with precocious puberty: A nationwide population-based study. J Ethnopharmacol. 2017 Jun 9;205:231-239. doi: 10.1016/j.jep.2017.05.006. Epub 2017 May 10.|Lin YR, Wu MY, Chiang JH, Yen HR, Yang ST. The utilization of traditional Chinese medicine in patients with dysfunctional uterine bleeding in Taiwan: a nationwide population-based study. BMC Complement Altern Med. 2017 Aug 29;17(1):427. doi: 10.1186/s12906-017-1939-1.|Lo LC, Chen YF, Chen WJ, Cheng TL, Chiang JY. The Study on the Agreement between Automatic Tongue Diagnosis System and Traditional Chinese Medicine Practitioners. Evid Based Complement Alternat Med. 2012;2012:505063. doi: 10.1155/2012/505063. Epub 2012 Aug 8.|Lo LC, Cheng TL, Chiang JY, Damdinsuren N. Breast cancer index: a perspective on tongue diagnosis in traditional chinese medicine. J Tradit Complement Med. 2013 Jul;3(3):194-203. doi: 10.4103/2225-4110.114901.|Lo LC, Cheng TL, Chen YJ, Natsagdorj S, Chiang JY. TCM tongue diagnosis index of early-stage breast cancer. Complement Ther Med. 2015 Oct;23(5):705-13. doi: 10.1016/j.ctim.2015.07.001. Epub 2015 Jul 10.|Ma YC, Lin CC, Li CI, Chiang JH, Li TC, Lin JG. Traditional Chinese medicine therapy improves the survival of systemic lupus erythematosus patients. Semin Arthritis Rheum. 2016 Apr;45(5):596-603. doi: 10.1016/j.semarthrit.2015.09.006.|Park DM, Kim SH, Park YC, Kang WC, Lee SR, Jung IC. The comparative clinical study of efficacy of Gamisoyo-San (Jiaweixiaoyaosan) on generalized anxiety disorder according to differently manufactured preparations: multicenter, randomized, double blind, placebo controlled trial. J Ethnopharmacol. 2014 Dec 2;158 Pt A:11-7. doi: 10.1016/j.jep.2014.10.024. Epub 2014 Oct 23.|Pinder RM, Brogden RN, Speight TM, Avery GS. Clonazepam: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs. 1976 Nov;12(5):321-61.|Puhakka A, Forssell H, Soinila S, Virtanen A, Röyttä M, Laine M, Tenovuo O, Teerijoki-Oksa T, Jääskeläinen SK. Peripheral nervous system involvement in primary burning mouth syndrome--results of a pilot study. Oral Dis. 2016 May;22(4):338-44. doi: 10.1111/odi.12454. Epub 2016 Feb 26.|Qu Y, Gan HQ, Mei QB, Liu L. Study on the effect of Jia-Wei-Xiao-Yao-San decoction on patients with functional dyspepsia. Phytother Res. 2010 Feb;24(2):245-8. doi: 10.1002/ptr.2920.|Sun A, Lin HP, Wang YP, Chen HM, Cheng SJ, Chiang CP. Significant reduction of serum homocysteine level and oral symptoms after different vitamin-supplement treatments in patients with burning mouth syndrome. J Oral Pathol Med. 2013 Jul;42(6):474-9. doi: 10.1111/jop.12043. Epub 2013 Jan 9.|Sikora M, Verzak Ž, Matijević M, Včev A, Siber S, Musić L, Carek A. Anxiety and Depression Scores in Patients with Burning Mouth Syndrome. Psychiatr Danub. 2018 Dec;30(4):466-470. doi: 10.24869/psyd.2018.466.|Su YC, Chen LL, Lin JD, Lin JS, Huang YC, Lai JS. BCQ+: a body constitution questionnaire to assess Yang-Xu. Part I: establishment of a first final version through a Delphi process. Forsch Komplementmed. 2008 Dec;15(6):327-34. doi: 10.1159/000175938. Epub 2008 Dec 5.|Terauchi M, Hiramitsu S, Akiyoshi M, Owa Y, Kato K, Obayashi S, Matsushima E, Kubota T. Effects of three Kampo formulae: Tokishakuyakusan (TJ-23), Kamishoyosan (TJ-24), and Keishibukuryogan (TJ-25) on Japanese peri- and postmenopausal women with sleep disturbances. Arch Gynecol Obstet. 2011 Oct;284(4):913-21. doi: 10.1007/s00404-010-1779-4. Epub 2010 Dec 1.|Tsai DS, Chang YS, Li TC, Peng WH. Prescription pattern of Chinese herbal products for hypertension in Taiwan: a population-based study. J Ethnopharmacol. 2014 Sep 29;155(3):1534-40. doi: 10.1016/j.jep.2014.07.047. Epub 2014 Aug 1.|Yang YH, Chen PC, Wang JD, Lee CH, Lai JN. Prescription pattern of traditional Chinese medicine for climacteric women in Taiwan. Climacteric. 2009 Dec;12(6):541-7. doi: 10.3109/13697130903060081.|Yu MC, Lin SK, Lai JN, Wei JC, Cheng CY. The traditional Chinese medicine prescription patterns of Sjögren׳s patients in Taiwan: a population-based study. J Ethnopharmacol. 2014 Aug 8;155(1):435-42. doi: 10.1016/j.jep.2014.05.049. Epub 2014 Jun 4.","\tBurning Mouth Syndrome\tTraditional Chinese Medicine|Western medicine\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tFemale\t","Treatment of Burning Mouth Syndrome With Integration of Traditional Chinese Medicine and Western Medicine","Interventional","Not yet recruiting","Phase 3",2,80,"syndrome|burning mouth syndrome|burns","NA","NA"]
["NCT04192240","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26004813|16139747|26957733|22306625","Boukadida A, Piotte F, Dehail P, Nadeau S. Determinants of sit-to-stand tasks in individuals with hemiparesis post stroke: A review. Ann Phys Rehabil Med. 2015 Jun;58(3):167-72. doi: 10.1016/j.rehab.2015.04.007. Epub 2015 May 23. Review.|Lomaglio MJ, Eng JJ. Muscle strength and weight-bearing symmetry relate to sit-to-stand performance in individuals with stroke. Gait Posture. 2005 Oct;22(2):126-31.|Park GD, Choi JU, Kim YM. The effects of multidirectional stepping training on balance, gait ability, and falls efficacy following stroke. J Phys Ther Sci. 2016 Jan;28(1):82-6. doi: 10.1589/jpts.28.82. Epub 2016 Jan 30.|Tsaklis PV, Grooten WJ, Franzén E. Effects of weight-shift training on balance control and weight distribution in chronic stroke: a pilot study. Top Stroke Rehabil. 2012 Jan-Feb;19(1):23-31. doi: 10.1310/tsr1901-23.","\tStroke\tTraining with external feedback|Training without external feedback\tCrossover Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Immediate Effect of Sit to Stand and Stepping Training With External Feedback in Stroke Patients","Interventional","Completed","N/A",2,30,"stroke","NA","NA"]
["NCT04204434","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11224527,"Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001 Mar;2(3):261-8.","\tAdvanced Cancer|Neoplasms\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04207593","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28329240,"Ulrich S, Hasler ED, Saxer S, Furian M, Müller-Mottet S, Keusch S, Bloch KE. Effect of breathing oxygen-enriched air on exercise performance in patients with precapillary pulmonary hypertension: randomized, sham-controlled cross-over trial. Eur Heart J. 2017 Apr 14;38(15):1159-1168. doi: 10.1093/eurheartj/ehx099.","\tCTEPH|Oxygen Deficiency|Pulmonary Arterial Hypertension\tOxygen\tCrossover Assignment\tTreatment\tRandomized\tDrug\tAll\t","The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With Hypoxemia","Interventional","Recruiting","Phase 2",2,40,"hypoxia|hypertension","NA","NA"]
["NCT04224883","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21963582|8982828|8792684","Lagu T, Rothberg MB, Shieh MS, Pekow PS, Steingrub JS, Lindenauer PK. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med. 2012 Mar;40(3):754-61. doi: 10.1097/CCM.0b013e318232db65. Erratum in: Crit Care Med. 2012 Oct;40(10):2932.|Nieuwenhuijzen GA, Deitch EA, Goris RJ. The relationship between gut-derived bacteria and the development of the multiple organ dysfunction syndrome. J Anat. 1996 Dec;189 ( Pt 3):537-48. Review.|Pastores SM, Katz DP, Kvetan V. Splanchnic ischemia and gut mucosal injury in sepsis and the multiple organ dysfunction syndrome. Am J Gastroenterol. 1996 Sep;91(9):1697-710. Review.","\tCritical Illness|Gastrointestinal Dysfunction|Nutrition Disorders\tContinuously feeding|16-hours feeding|intermittent feeding\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure|Procedure\tAll\t","Effect of Different Feeding Method on Gastrointestinal Function of Critical Patients","Interventional","Not yet recruiting","N/A",3,90,"nutrition disorders|critical illness","NA","NA"]
["NCT04246333","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",7813274,"Radford PJ, Stillwell PC, Blue B, Hertel G. Aspiration complicating bronchopulmonary dysplasia. Chest. 1995 Jan;107(1):185-8.","\tBPD - Bronchopulmonary Dysplasia|Chronic Lung Disease of Prematurity|Feeding; Difficult, Newborn|Feeding Disorder Neonatal|Premature Birth|VLBW - Very Low Birth Weight Infant\tMode of Delivery of Feeds\tParallel Assignment\tPrevention\tRandomized\tOther\tAll\t","Duodenal Feeds in Very Low Birth Weight Infants","Interventional","Recruiting","N/A",2,30,"feeding and eating disorders|lung diseases|premature birth|body weight|birth weight|bronchopulmonary dysplasia","NA","NA"]
["NCT04252469","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29744564|30247201","Deschepper M, Waegeman W, Eeckloo K, Vogelaers D, Blot S. Effects of chlorhexidine gluconate oral care on hospital mortality: a hospital-wide, observational cohort study. Intensive Care Med. 2018 Jul;44(7):1017-1026. doi: 10.1007/s00134-018-5171-3. Epub 2018 May 9.|La Combe B, Mahérault AC, Messika J, Billard-Pomares T, Branger C, Landraud L, Dreyfuss D, Dib F, Massias L, Ricard JD. Oropharyngeal Bacterial Colonization after Chlorhexidine Mouthwash in Mechanically Ventilated Critically Ill Patients. Anesthesiology. 2018 Dec;129(6):1140-1148. doi: 10.1097/ALN.0000000000002451.","\tAnesthesia|Intratracheal Intubation|Surgery\tOral care\tParallel Assignment\tPrevention\tRandomized\tOther\tAll\t","Efficacy of Pre-intubation Chlorhexidine Oral Care on Health Outcomes","Interventional","Completed","N/A",2,210,"NA","NA","NA"]
["NCT04259528","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28611969|17043852","Tambucci R, Angelino G, De Angelis P, Torroni F, Caldaro T, Balassone V, Contini AC, Romeo E, Rea F, Faraci S, Federici di Abriola G, Dall'Oglio L. Anastomotic Strictures after Esophageal Atresia Repair: Incidence, Investigations, and Management, Including Treatment of Refractory and Recurrent Strictures. Front Pediatr. 2017 May 29;5:120. doi: 10.3389/fped.2017.00120. eCollection 2017. Review.|Khan KM, Foker JE. Use of high-resolution endoscopic ultrasonography to examine the effect of tension on the esophagus during primary repair of long-gap esophageal atresia. Pediatr Radiol. 2007 Jan;37(1):41-5. Epub 2006 Oct 17.","\tEsophageal Atresia\tPediatric endoscopic ultrasound\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","esophageal atresia","NA","NA"]
["NCT04262713","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29608134,"Westerman AP, Moor AR, Stone MH, Stewart TD. Hip stem fatigue: : The implications of increasing patient mass. Proc Inst Mech Eng H. 2018 May;232(5):520-530. doi: 10.1177/0954411918767200. Epub 2018 Apr 2.","\tHip Arthropathy Associated With Other Conditions\tRadiographs\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","joint diseases|rupture","NA","NA"]
["NCT04272372","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31815082|30333315|20027220","Forte AJ, Boczar D, Huayllani MT, Lu X, McLaughlin SA. Pharmacotherapy Agents in Lymphedema Treatment: A Systematic Review. Cureus. 2019 Dec 5;11(12):e6300. doi: 10.7759/cureus.6300. Review.|Rockson SG, Tian W, Jiang X, Kuznetsova T, Haddad F, Zampell J, Mehrara B, Sampson JP, Roche L, Kim J, Nicolls MR. Pilot studies demonstrate the potential benefits of antiinflammatory therapy in human lymphedema. JCI Insight. 2018 Oct 18;3(20). pii: 123775. doi: 10.1172/jci.insight.123775.|Nakamura K, Radhakrishnan K, Wong YM, Rockson SG. Anti-inflammatory pharmacotherapy with ketoprofen ameliorates experimental lymphatic vascular insufficiency in mice. PLoS One. 2009 Dec 21;4(12):e8380. doi: 10.1371/journal.pone.0008380.","\tBreast Cancer Lymphedema\tKetoprofen\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","breast cancer lymphedema|lymphedema","ketoprofen","NA"]
["NCT04278456","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24835540|24015137|26697084","Andersen LP, Werner MU, Rosenberg J, Gögenur I. A systematic review of peri-operative melatonin. Anaesthesia. 2014 Oct;69(10):1163-71. doi: 10.1111/anae.12717. Epub 2014 May 19. Review.|Maitra S, Baidya DK, Khanna P. Melatonin in perioperative medicine: Current perspective. Saudi J Anaesth. 2013 Jul;7(3):315-21. doi: 10.4103/1658-354X.115316. Review.|Dianatkhah M, Ghaeli P, Hajhossein Talasaz A, Karimi A, Salehiomran A, Bina P, Jalali A, Ghaffary S, Shahmansouri N, Vejdani S. Evaluating the Potential Effect of Melatonin on the post-Cardiac Surgery Sleep Disorder. J Tehran Heart Cent. 2015 Jul 3;10(3):122-8.","\tMelatonin|Postpartum Depression\tpostpartum depression\tNA\tNA\tNA\tBehavioral\tFemale\t","NA","NA","NA","NA","NA","NA","depression|depression, postpartum|depressive disorder","NA","NA"]
["NCT04300257","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28109409|29633281","Andritsch E, Beishon M, Bielack S, Bonvalot S, Casali P, Crul M, Delgado Bolton R, Donati DM, Douis H, Haas R, Hogendoorn P, Kozhaeva O, Lavender V, Lovey J, Negrouk A, Pereira P, Roca P, de Lempdes GR, Saarto T, van Berck B, Vassal G, Wartenberg M, Yared W, Costa A, Naredi P. ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review. Crit Rev Oncol Hematol. 2017 Feb;110:94-105. doi: 10.1016/j.critrevonc.2016.12.002. Epub 2016 Dec 8. Review.|Abarca T, Gao Y, Monga V, Tanas MR, Milhem MM, Miller BJ. Improved survival for extremity soft tissue sarcoma treated in high-volume facilities. J Surg Oncol. 2018 Jun;117(7):1479-1486. doi: 10.1002/jso.25052. Epub 2018 Apr 6.","\tSarcoma\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","sarcoma","NA","NA"]
["NCT04304183","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",30948148,"Macha MR. The feasibility of laparoscopic subtotal colectomy with cecorectal anastomosis in community practice for slow transit constipation. Am J Surg. 2019 May;217(5):974-978. doi: 10.1016/j.amjsurg.2019.03.018. Epub 2019 Mar 26.","\tDefecation Function|Quality of Life\ttotal colectomy, ileorectal anastomosis\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","constipation","NA","NA"]
["NCT04316247","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",31134761,"Chen S, Chen H, Yi Y, Jiang X, Lei H, Luo X, Chen Y, Liu S, Yuan D, Jia X, Li J. Comparative study of breast cancer with or without concomitant Paget disease: An analysis of the SEER database. Cancer Med. 2019 Jul;8(8):4043-4054. doi: 10.1002/cam4.2242. Epub 2019 May 28.","\tBreast Carcinoma\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","breast neoplasms","NA","NA"]
["NCT04319133","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29754952|28791787","Sutton EF, Beyl R, Early KS, Cefalu WT, Ravussin E, Peterson CM. Early Time-Restricted Feeding Improves Insulin Sensitivity, Blood Pressure, and Oxidative Stress Even without Weight Loss in Men with Prediabetes. Cell Metab. 2018 Jun 5;27(6):1212-1221.e3. doi: 10.1016/j.cmet.2018.04.010. Epub 2018 May 10.|Conley M, Le Fevre L, Haywood C, Proietto J. Is two days of intermittent energy restriction per week a feasible weight loss approach in obese males? A randomised pilot study. Nutr Diet. 2018 Feb;75(1):65-72. doi: 10.1111/1747-0080.12372. Epub 2017 Aug 9.","\tObesity\tFasting\tParallel Assignment\tTreatment\tRandomized\tBehavioral\tMale\t","Effect Of Intermittent Fasting To Metabolic And Oxidative Stress Marker","Interventional","Not yet recruiting","N/A",2,62,"insulin resistance|obesity","NA","NA"]
["NCT04328545","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18717717|15999258","Boggio PS, Zaghi S, Lopes M, Fregni F. Modulatory effects of anodal transcranial direct current stimulation on perception and pain thresholds in healthy volunteers. Eur J Neurol. 2008 Oct;15(10):1124-30. doi: 10.1111/j.1468-1331.2008.02270.x. Epub 2008 Aug 20.|Fregni F, Boggio PS, Nitsche M, Bermpohl F, Antal A, Feredoes E, Marcolin MA, Rigonatti SP, Silva MT, Paulus W, Pascual-Leone A. Anodal transcranial direct current stimulation of prefrontal cortex enhances working memory. Exp Brain Res. 2005 Sep;166(1):23-30. Epub 2005 Jul 6.","\tPain|Transcranial Direct Current Stimulation|Working Memory\tAnodal tDCS on DLPFC|Anodal tDCS on M1|Sham tDCS\tCrossover Assignment\tTreatment\tRandomized\tDevice|Device|Device\tFemale\t","Transcranial Direct Current Stimulation Effect on Pain Threshold and Working Memory: Impact of Age and Protocol Type","Interventional","Completed","N/A",3,30,"NA","NA","NA"]
["NCT04333875","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32223336|20961243|22078420|32171076","Yadgir S, Johnson CO, Aboyans V, Adebayo OM, Adedoyin RA, Afarideh M, Alahdab F, Alashi A, Alipour V, Arabloo J, Azari S, Barthelemy CM, Benziger CP, Berman AE, Bijani A, Carrero JJ, Carvalho F, Daryani A, Durães AR, Esteghamati A, Farid TA, Farzadfar F, Fernandes E, Filip I, Gad MM, Hamidi S, Hay SI, Ilesanmi OS, Naghibi Irvani SS, Jürisson M, Kasaeian A, Kengne AP, Khan AR, Kisa A, Kisa S, Kolte D, Manafi N, Manafi A, Mensah GA, Mirrakhimov EM, Mohammad Y, Mokdad AH, Negoi RI, Thi Nguyen HL, Nguyen TH, Nixon MR, Otto CM, Patel S, Pilgrim T, Radfar A, Rawaf DL, Rawaf S, Rawasia WF, Rezapour A, Roever L, Saad AM, Saadatagah S, Senthilkumaran S, Sliwa K, Tesfay BE, Tran BX, Ullah I, Vaduganathan M, Vasankari TJ, Wolfe CDA, Yonemoto N, Roth GA; Global Burden of Disease Study 2017 Nonrheumatic Valve Disease Collaborators. Global, Regional, and National Burden of Calcific Aortic Valve and Degenerative Mitral Valve Diseases, 1990-2017. Circulation. 2020 May 26;141(21):1670-1680. doi: 10.1161/CIRCULATIONAHA.119.043391. Epub 2020 Mar 29. Erratum in: Circulation. 2020 May 26;141(21):e836.|Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010 Oct 21;363(17):1597-607. doi: 10.1056/NEJMoa1008232. Epub 2010 Sep 22.|Wenaweser P, Pilgrim T, Kadner A, Huber C, Stortecky S, Buellesfeld L, Khattab AA, Meuli F, Roth N, Eberle B, Erdös G, Brinks H, Kalesan B, Meier B, Jüni P, Carrel T, Windecker S. Clinical outcomes of patients with severe aortic stenosis at increased surgical risk according to treatment modality. J Am Coll Cardiol. 2011 Nov 15;58(21):2151-62. doi: 10.1016/j.jacc.2011.05.063.|Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.","\tAortic Valve Stenosis\tTAVR or SAVR\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","aortic valve stenosis|constriction, pathologic","NA","NA"]
["NCT04344704","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24602062|25282033|29111168|21272746|23131066|25917337|15231370|26988379|28340005|28797351|25765588|28340096|17302687|26852908|28428489|26002818|24838360|24928948|27909501|26949427|21156772|22236222|23102659|18815386|28624331","Guédon-Moreau L, Kouakam C, Klug D, Marquié C, Brigadeau F, Boulé S, Blangy H, Lacroix D, Clémenty J, Sadoul N, Kacet S. Decreased delivery of inappropriate shocks achieved by remote monitoring of ICD: a substudy of the ECOST trial. J Cardiovasc Electrophysiol. 2014 Jul;25(7):763-70. doi: 10.1111/jce.12405. Epub 2014 Apr 10.|Kolb C, Sturmer M, Sick P, Reif S, Davy JM, Molon G, Schwab JO, Mantovani G, Dan D, Lennerz C, Borri-Brunetto A, Babuty D. Reduced risk for inappropriate implantable cardioverter-defibrillator shocks with dual-chamber therapy compared with single-chamber therapy: results of the randomized OPTION study. JACC Heart Fail. 2014 Dec;2(6):611-9. doi: 10.1016/j.jchf.2014.05.015. Epub 2014 Oct 1.|Boles U, Gul EE, Fitzgerald L, Sadiq Ali F, Nolan C, Aldworth-Gaumond K, Redfearn DR, Baranchuk A, Glover B, Simpson C, Abdollah H, Michael KA. Standardized programming to reduce the burden of inappropriate therapies in implantable cardioverter defibrillators - Single centre follow up results. Indian Pacing Electrophysiol J. 2018 Mar - Apr;18(2):56-60. doi: 10.1016/j.ipej.2017.10.010. Epub 2017 Oct 27.|van Rees JB, Borleffs CJ, de Bie MK, Stijnen T, van Erven L, Bax JJ, Schalij MJ. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am Coll Cardiol. 2011 Feb 1;57(5):556-62. doi: 10.1016/j.jacc.2010.06.059.|Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, Estes NA 3rd, Greenberg H, Hall WJ, Huang DT, Kautzner J, Klein H, McNitt S, Olshansky B, Shoda M, Wilber D, Zareba W; MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012 Dec 13;367(24):2275-83. doi: 10.1056/NEJMoa1211107. Epub 2012 Nov 6.|Kutyifa V, Moss AJ, Schuger C, McNitt S, Polonsky B, Ruwald AH, Ruwald MH, Daubert JP, Zareba W. Reduction in Inappropriate ICD Therapy in MADIT-RIT Patients Without History of Atrial Tachyarrhythmia. J Cardiovasc Electrophysiol. 2015 Aug;26(8):879-884. doi: 10.1111/jce.12692. Epub 2015 Jun 15.|Vanhees L, Kornaat M, Defoor J, Aufdemkampe G, Schepers D, Stevens A, Van Exel H, Van Den Beld J, Heidbüchel H, Fagard R. Effect of exercise training in patients with an implantable cardioverter defibrillator. Eur Heart J. 2004 Jul;25(13):1120-6.|Sterns LD, Meine M, Kurita T, Meijer A, Auricchio A, Ando K, Leng CT, Okumura K, Sapp JL, Brown ML, Lexcen DR, Gerritse B, Schloss EJ. Extended detection time to reduce shocks is safe in secondary prevention patients: The secondary prevention substudy of PainFree SST. Heart Rhythm. 2016 Jul;13(7):1489-96. doi: 10.1016/j.hrthm.2016.03.022. Epub 2016 Mar 14.|Auricchio A, Hudnall JH, Schloss EJ, Sterns LD, Kurita T, Meijer A, Fagan DH, Rogers T. Inappropriate shocks in single-chamber and subcutaneous implantable cardioverter-defibrillators: a systematic review and meta-analysis. Europace. 2017 Dec 1;19(12):1973-1980. doi: 10.1093/europace/euw415. Review.|Boersma L, Barr C, Knops R, Theuns D, Eckardt L, Neuzil P, Scholten M, Hood M, Kuschyk J, Jones P, Duffy E, Husby M, Stein K, Lambiase PD; EFFORTLESS Investigator Group. Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: The EFFORTLESS Study. J Am Coll Cardiol. 2017 Aug 15;70(7):830-841. doi: 10.1016/j.jacc.2017.06.040.|Cay S, Canpolat U, Ucar F, Ozeke O, Ozcan F, Topaloglu S, Aras D. Programming implantable cardioverter-defibrillator therapy zones to high ranges to prevent delivery of inappropriate device therapies in patients with primary prevention: results from the RISSY-ICD (Reduction of Inappropriate ShockS bY InCreaseD zones) trial. Am J Cardiol. 2015 May 1;115(9):1235-43. doi: 10.1016/j.amjcard.2015.01.558. Epub 2015 Feb 12.|Defaye P, Boveda S, Klug D, Beganton F, Piot O, Narayanan K, Périer MC, Gras D, Fauchier L, Bordachar P, Algalarrondo V, Babuty D, Deharo JC, Leclercq C, Marijon E, Sadoul N; DAI-PP Investigators. Dual- vs. single-chamber defibrillators for primary prevention of sudden cardiac death: long-term follow-up of the Défibrillateur Automatique Implantable-Prévention Primaire registry. Europace. 2017 Sep 1;19(9):1478-1484. doi: 10.1093/europace/euw230.|Kreuz J, Balta O, Liliegren N, Mellert F, Esmailzadeh B, Nickenig G, Schwab JO. Incidence and characteristics of appropriate and inappropriate therapies in recipients of ICD implanted for primary prevention of sudden cardiac death. Pacing Clin Electrophysiol. 2007 Jan;30 Suppl 1:S125-7. Erratum in: Pacing Clin Electrophysiol. 2007 Nov;30(11):1427.|Konstantino Y, Haim M, Boxer J, Goldenberg I, Feldman A, Michowitz Y, Glikson M, Suleiman M; Israeli Working Group on Pacing and Electrophysiology. Clinical Outcomes of Single- versus Dual-Chamber Implantable Cardioverter Defibrillators: Lessons from the Israeli ICD Registry. J Cardiovasc Electrophysiol. 2016 Jun;27(6):718-23. doi: 10.1111/jce.12953. Epub 2016 Mar 18.|Oginosawa Y, Kohno R, Honda T, Kikuchi K, Nozoe M, Uchida T, Minamiguchi H, Sonoda K, Ogawa M, Ideguchi T, Kizaki Y, Nakamura T, Oba K, Higa S, Yoshida K, Tsunoda S, Fujino Y, Abe H. Superior Rhythm Discrimination With the SmartShock Technology Algorithm - Results of the Implantable Defibrillator With Enhanced Features and Settings for Reduction of Inaccurate Detection (DEFENSE) Trial. Circ J. 2017 Aug 25;81(9):1272-1277. doi: 10.1253/circj.CJ-16-1330. Epub 2017 Apr 20.|Schwab JO, Bonnemeier H, Kleemann T, Brachmann J, Fischer S, Birkenhauer F, Eberhardt F. Reduction of inappropriate ICD therapies in patients with primary prevention of sudden cardiac death: DECREASE study. Clin Res Cardiol. 2015 Dec;104(12):1021-32. doi: 10.1007/s00392-015-0870-z. Epub 2015 May 23.|Kloppe A, Proclemer A, Arenal A, Lunati M, Martìnez Ferrer JB, Hersi A, Gulaj M, Wijffels MC, Santi E, Manotta L, Mangoni L, Gasparini M. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial. Circulation. 2014 Jul 22;130(4):308-14. doi: 10.1161/CIRCULATIONAHA.114.009468. Epub 2014 May 16.|Friedman PA, Bradley D, Koestler C, Slusser J, Hodge D, Bailey K, Kusumoto F, Munger TM, Militanu A, Glikson M. A prospective randomized trial of single- or dual-chamber implantable cardioverter-defibrillators to minimize inappropriate shock risk in primary sudden cardiac death prevention. Europace. 2014 Oct;16(10):1460-8. doi: 10.1093/europace/euu022. Epub 2014 Jun 13.|\"Worden NE, Alqasrawi M, Krothapalli SM, Mazur A. \"\"Two for the Price of One\"\": A Single-Lead Implantable Cardioverter-Defibrillator System with a Floating Atrial Dipole. J Atr Fibrillation. 2016 Apr 30;8(6):1396. doi: 10.4022/jafib.1396. eCollection 2016 Apr-May. Review.\"|Wilkoff BL, Fauchier L, Stiles MK, Morillo CA, Al-Khatib SM, Almendral J, Aguinaga L, Berger RD, Cuesta A, Daubert JP, Dubner S, Ellenbogen KA, Estes NA 3rd, Fenelon G, Garcia FC, Gasparini M, Haines DE, Healey JS, Hurtwitz JL, Keegan R, Kolb C, Kuck KH, Marinskis G, Martinelli M, McGuire M, Molina LG, Okumura K, Proclemer A, Russo AM, Singh JP, Swerdlow CD, Teo WS, Uribe W, Viskin S, Wang CC, Zhang S. 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. J Arrhythm. 2016 Feb;32(1):1-28. doi: 10.1016/j.joa.2015.12.001. Epub 2016 Feb 1. Erratum in: J Arrhythm. 2016 Oct;32(5):441-442.|Sticherling C, Zabel M, Spencker S, Meyerfeldt U, Eckardt L, Behrens S, Niehaus M; ADRIA Investigators. Comparison of a novel, single-lead atrial sensing system with a dual-chamber implantable cardioverter-defibrillator system in patients without antibradycardia pacing indications: results of a randomized study. Circ Arrhythm Electrophysiol. 2011 Feb;4(1):56-63. doi: 10.1161/CIRCEP.110.958397. Epub 2010 Dec 14.|Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012 Jan 12;366(2):120-9. doi: 10.1056/NEJMoa1105575. Erratum in: N Engl J Med. 2016 Mar 10;374(10):998.|Miller DJ, Khan MA, Schultz LR, Simpson JR, Katramados AM, Russman AN, Mitsias PD. Outpatient cardiac telemetry detects a high rate of atrial fibrillation in cryptogenic stroke. J Neurol Sci. 2013 Jan 15;324(1-2):57-61. doi: 10.1016/j.jns.2012.10.001. Epub 2012 Oct 24.|Tayal AH, Tian M, Kelly KM, Jones SC, Wright DG, Singh D, Jarouse J, Brillman J, Murali S, Gupta R. Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. Neurology. 2008 Nov 18;71(21):1696-701. doi: 10.1212/01.wnl.0000325059.86313.31. Epub 2008 Sep 24.|Ziegler PD, Rogers JD, Ferreira SW, Nichols AJ, Richards M, Koehler JL, Sarkar S. Long-term detection of atrial fibrillation with insertable cardiac monitors in a real-world cryptogenic stroke population. Int J Cardiol. 2017 Oct 1;244:175-179. doi: 10.1016/j.ijcard.2017.06.039. Epub 2017 Jun 10.","\tPrevention of Inappropriate Therapies and MACCE. Single-chamber ICD\tSingle chamber DAI device with floating atrial dipole\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04348578","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24171024|29069143|22892729|21787479|23349574","Abbaszadegan A, Nabavizadeh M, Hoseini Yekani A, Khayat A. Comparison of Endodontic Treatment Results Yielded from Using Normal Saline with IKI Final Rinse or NaOCl Irrigation: A 30-Month Follow-up Study. Iran Endod J. 2013 Fall;8(4):171-6. Epub 2013 Oct 7.|Holland R, Gomes JE Filho, Cintra LTA, Queiroz ÍOA, Estrela C. Factors affecting the periapical healing process of endodontically treated teeth. J Appl Oral Sci. 2017 Sep-Oct;25(5):465-476. doi: 10.1590/1678-7757-2016-0464. Review.|Paredes-Vieyra J, Enriquez FJ. Success rate of single- versus two-visit root canal treatment of teeth with apical periodontitis: a randomized controlled trial. J Endod. 2012 Sep;38(9):1164-9. doi: 10.1016/j.joen.2012.05.021. Epub 2012 Jul 26.|Pai S, Thomas MS. The effect of QMix, an experimental antibacterial root canal irrigant, on removal of canal wall smear layer and debris. J Endod. 2011 Jun;37(6):741; author reply 741-3. doi: 10.1016/j.joen.2011.04.006. Epub 2011 May 6.|Chandrasekhar V, Amulya V, Rani VS, Prakash TJ, Ranjani AS, Gayathri Ch. Evaluation of biocompatibility of a new root canal irrigant Q Mix™ 2 in 1- An in vivo study. J Conserv Dent. 2013 Jan;16(1):36-40. doi: 10.4103/0972-0707.105296.","\tPeriapical Diseases\tQMix 2in1\tParallel Assignment\tTreatment\tRandomized\tOther\tAll\t","Effect of QMix 2in1 as Final Irrigation Protocol on Periapical Healing","Interventional","Completed","N/A",2,60,"periapical diseases","NA","NA"]
["NCT04354532","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28822052|27048439|21890430|22161231|25391401|28214956|31285129|30552547|27143964|22701478|28266000|29671124|31928587|28914408|30302156|28261497|27063637|11997813","Welbourn R, Pournaras DJ, Dixon J, Higa K, Kinsman R, Ottosson J, Ramos A, van Wagensveld B, Walton P, Weiner R, Zundel N. Bariatric Surgery Worldwide: Baseline Demographic Description and One-Year Outcomes from the Second IFSO Global Registry Report 2013-2015. Obes Surg. 2018 Feb;28(2):313-322. doi: 10.1007/s11695-017-2845-9.|Lauti M, Kularatna M, Hill AG, MacCormick AD. Weight Regain Following Sleeve Gastrectomy-a Systematic Review. Obes Surg. 2016 Jun;26(6):1326-34. doi: 10.1007/s11695-016-2152-x. Review.|Sarela AI, Dexter SP, O'Kane M, Menon A, McMahon MJ. Long-term follow-up after laparoscopic sleeve gastrectomy: 8-9-year results. Surg Obes Relat Dis. 2012 Nov-Dec;8(6):679-84. doi: 10.1016/j.soard.2011.06.020. Epub 2011 Jul 20.|Awad W, Garay A, Martínez C. Ten years experience of banded gastric bypass: does it make a difference? Obes Surg. 2012 Feb;22(2):271-8. doi: 10.1007/s11695-011-0555-2.|Lemmens L, Karcz WK, Bukhari W, Fink J, Kuesters S. Banded gastric bypass - four years follow up in a prospective multicenter analysis. BMC Surg. 2014 Nov 12;14:88. doi: 10.1186/1471-2482-14-88.|Fink JM, Hoffmann N, Kuesters S, Seifert G, Laessle C, Glatz T, Hopt UT, Konrad Karcz W, Marjanovic G. Banding the Sleeve Improves Weight Loss in Midterm Follow-up. Obes Surg. 2017 Apr;27(4):1098-1103. doi: 10.1007/s11695-017-2610-0.|Fink JM, von Pigenot A, Seifert G, Laessle C, Fichtner-Feigl S, Marjanovic G. Banded versus nonbanded sleeve gastrectomy: 5-year results of a matched-pair analysis. Surg Obes Relat Dis. 2019 Aug;15(8):1233-1238. doi: 10.1016/j.soard.2019.05.023. Epub 2019 May 24.|Parmar CD, Efeotor O, Ali A, Sufi P, Mahawar KK. Primary Banded Sleeve Gastrectomy: a Systematic Review. Obes Surg. 2019 Feb;29(2):698-704. doi: 10.1007/s11695-018-03626-1.|Tognoni V, Benavoli D, Bianciardi E, Perrone F, Ippoliti S, Gaspari A, Gentileschi P. Laparoscopic Sleeve Gastrectomy versus Laparoscopic Banded Sleeve Gastrectomy: First Prospective Pilot Randomized Study. Gastroenterol Res Pract. 2016;2016:6419603. doi: 10.1155/2016/6419603. Epub 2016 Apr 10.|Gentileschi P. Laparoscopic sleeve gastrectomy as a primary operation for morbid obesity: experience with 200 patients. Gastroenterol Res Pract. 2012;2012:801325. doi: 10.1155/2012/801325. Epub 2012 Jun 3.|Perrone F, Bianciardi E, Ippoliti S, Nardella J, Fabi F, Gentileschi P. Long-term effects of laparoscopic sleeve gastrectomy versus Roux-en-Y gastric bypass for the treatment of morbid obesity: a monocentric prospective study with minimum follow-up of 5 years. Updates Surg. 2017 Mar;69(1):101-107. doi: 10.1007/s13304-017-0426-z. Epub 2017 Mar 6.|Lemmens L, Van Den Bossche J, Zaveri H, Surve A. Banded Sleeve Gastrectomy: Better Long-Term Results? A Long-Term Cohort Study Until 5 Years Follow-Up in Obese and Superobese Patients. Obes Surg. 2018 Sep;28(9):2687-2695. doi: 10.1007/s11695-018-3248-2.|Filip S, Hutopila I, Copaescu C. Re-sleeve Gastrectomy - An Efficient Revisional Bariatric Procedure - 3 Years Results. Chirurgia (Bucur). 2019 Nov-Dec;114(6):809-823. doi: 10.21614/chirurgia.114.6.809.|Hanssen A, Plotnikov S, Acosta G, Nuñez JT, Haddad J, Rodriguez C, Petrucci C, Hanssen D, Hanssen R. 3D Volumetry and its Correlation Between Postoperative Gastric Volume and Excess Weight Loss After Sleeve Gastrectomy. Obes Surg. 2018 Mar;28(3):775-780. doi: 10.1007/s11695-017-2927-8.|Cylke R, Skrzypek P, Ziemiański P, Domienik-Karlowicz J, Kosieradzki M, Lisik W. Single-anastomosis duodeno-ileal - new revision procedure in a patient with insufficient weight loss after sleeve gastrectomy. Wideochir Inne Tech Maloinwazyjne. 2018 Sep;13(3):407-411. doi: 10.5114/wiitm.2018.76686. Epub 2018 Jun 25.|Montuori M, Benavoli D, D'Ugo S, Di Benedetto L, Bianciardi E, Gaspari AL, Gentileschi P. Integrated Approaches for the Management of Staple Line Leaks following Sleeve Gastrectomy. J Obes. 2017;2017:4703236. doi: 10.1155/2017/4703236. Epub 2017 Feb 2.|Lemaître F, Léger P, Nedelcu M, Nocca D. Laparoscopic sleeve gastrectomy in the South Pacific. Retrospective evaluation of 510 patients in a single institution. Int J Surg. 2016 Jun;30:1-6. doi: 10.1016/j.ijsu.2016.04.002. Epub 2016 Apr 8.|Gentileschi P, Kini S, Catarci M, Gagner M. Evidence-based medicine: open and laparoscopic bariatric surgery. Surg Endosc. 2002 May;16(5):736-44. Epub 2002 Jan 4. Review.","\tObesity, Morbid|Surgery\tLaparoscopic Banded Sleeve Gastrectomy\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","obesity, morbid","NA","NA"]
["NCT04362735","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31633731|29788318|29869016","Perin RL, Damião AOMC, Flores C, Ludvig JC, Magro DO, Miranda EF, Moraes AC, Nones RB, Teixeira FV, Zeroncio M, Kotze PG. VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY. Arq Gastroenterol. 2019 Sep 30;56(3):312-317. doi: 10.1590/S0004-2803.201900000-58. eCollection 2019.|Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. Inflamm Bowel Dis. 2018 Oct 12;24(11):2442-2451. doi: 10.1093/ibd/izy155.|Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Mosli M, Curtis R, Khalid JM, Loftus EV Jr. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018 Sep;53(9):1048-1064. doi: 10.1007/s00535-018-1480-0. Epub 2018 Jun 4.","\tCrohn Disease\tVedolizumab\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","crohn disease","vedolizumab","NA"]
["NCT04367259","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31021311|29685386","Bayramoğlu Z, Tozoğlu S. Comparison of single- and double-puncture arthrocentesis for the treatment of temporomandibular joint disorders: A six-month, prospective study. Cranio. 2021 Mar;39(2):151-156. doi: 10.1080/08869634.2019.1603796. Epub 2019 Apr 25.|Şentürk MF, Yazıcı T, Fındık Y, Baykul T. Intraoperative comparison of single- and double-puncture techniques in temporomandibular joint arthrocentesis. Int J Oral Maxillofac Surg. 2018 Aug;47(8):1060-1064. doi: 10.1016/j.ijom.2018.03.029. Epub 2018 May 1.","\tArthrocentesis\tTMJ Arthrocentesis\tParallel Assignment\tTreatment\tRandomized\tProcedure\tAll\t","Single Puncture Arthrocentesis vs Double Puncture Arthrocentesis","Interventional","Completed","N/A",2,36,"NA","NA","NA"]
["NCT04375319","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29223438|30420093|30418164|23615849|28720725|30827782|29104179","Iliescu CA, Cilingiroglu M, Giza DE, Rosales O, Lebeau J, Guerrero-Mantilla I, Lopez-Mattei J, Song J, Silva G, Loyalka P, Paixao ARM, Yusuf SW, Perin E, Anderson VH, Marmagkiolis K. \"Bringing on the light\" in a complex clinical scenario: Optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry). Am Heart J. 2017 Dec;194:83-91. doi: 10.1016/j.ahj.2017.08.015. Epub 2017 Aug 23.|Shlofmitz E, Garcia-Garcia HM. The Role of OCT Guidance for Antiplatelet Therapy. Cardiovasc Revasc Med. 2018 Oct;19(7 Pt A):733-734. doi: 10.1016/j.carrev.2018.09.015.|Laine M, Dabry T, Combaret N, Motreff P, Puymirat E, Paganelli F, Thuny F, Cautela J, Peyrol M, Mancini J, Lemesle G, Bonello L. OCT Analysis of Very Early Strut Coverage of the Synergy Stent in Non-ST Segment Elevation Acute Coronary Syndrome Patients. J Invasive Cardiol. 2019 Jan;31(1):10-14. Epub 2018 Nov 11.|Won H, Shin DH, Kim BK, Mintz GS, Kim JS, Ko YG, Choi D, Jang Y, Hong MK. Optical coherence tomography derived cut-off value of uncovered stent struts to predict adverse clinical outcomes after drug-eluting stent implantation. Int J Cardiovasc Imaging. 2013 Aug;29(6):1255-63. doi: 10.1007/s10554-013-0223-9. Epub 2013 Apr 25.|Adriaenssens T, Joner M, Godschalk TC, Malik N, Alfonso F, Xhepa E, De Cock D, Komukai K, Tada T, Cuesta J, Sirbu V, Feldman LJ, Neumann FJ, Goodall AH, Heestermans T, Buysschaert I, Hlinomaz O, Belmans A, Desmet W, Ten Berg JM, Gershlick AH, Massberg S, Kastrati A, Guagliumi G, Byrne RA; Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort (PRESTIGE) Investigators. Optical Coherence Tomography Findings in Patients With Coronary Stent Thrombosis: A Report of the PRESTIGE Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort). Circulation. 2017 Sep 12;136(11):1007-1021. doi: 10.1161/CIRCULATIONAHA.117.026788. Epub 2017 Jul 18.|Zaman A, de Winter RJ, Kogame N, Chang CC, Modolo R, Spitzer E, Tonino P, Hofma S, Zurakowski A, Smits PC, Prokopczuk J, Moreno R, Choudhury A, Petrov I, Cequier A, Kukreja N, Hoye A, Iniguez A, Ungi I, Serra A, Gil RJ, Walsh S, Tonev G, Mathur A, Merkely B, Colombo A, Ijsselmuiden S, Soliman O, Kaul U, Onuma Y, Serruys PW; TALENT trial investigators. Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. Lancet. 2019 Mar 9;393(10175):987-997. doi: 10.1016/S0140-6736(18)32467-X. Epub 2019 Feb 28.|Lee BK, Kim JS, Lee OH, Min PK, Yoon YW, Hong BK, Shin DH, Kang TS, Kim BO, Cho DK, Jeon DW, Woo SI, Choi S, Kim YH, Kang WC, Kim S, Kim BK, Hong MK, Jang Y, Kwon HM. Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy. EuroIntervention. 2018 Mar 20;13(16):1923-1930. doi: 10.4244/EIJ-D-17-00792.","\tNon ST Segment Elevation Myocardial Infarction|Unstable Anginas\tOCT\tParallel Assignment\tTreatment\tRandomized\tDevice\tAll\t","OCT Evaluation of Early Vascular Repair in Patients With Non ST Elevation Acute Coronary Syndrome (NSTE-ACS)","Interventional","Recruiting","N/A",3,60,"myocardial infarction|acute coronary syndrome|infarction|angina, unstable","NA","NA"]
["NCT04381299","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20351977|31376814|30541396|27022685|21479340|18480812|30134239|29486615|30796792|32195207|27008889","Lacci KM, Dardik A. Platelet-rich plasma: support for its use in wound healing. Yale J Biol Med. 2010 Mar;83(1):1-9. Review.|Ford EA, Beckett EL, Roman SD, McLaughlin EA, Sutherland JM. Advances in human primordial follicle activation and premature ovarian insufficiency. Reproduction. 2020 Jan;159(1):R15-R29. doi: 10.1530/REP-19-0201. Review.|Zhang X, Han T, Yan L, Jiao X, Qin Y, Chen ZJ. Resumption of Ovarian Function After Ovarian Biopsy/Scratch in Patients With Premature Ovarian Insufficiency. Reprod Sci. 2019 Feb;26(2):207-213. doi: 10.1177/1933719118818906. Epub 2018 Dec 12.|Kawamura K, Kawamura N, Hsueh AJ. Activation of dormant follicles: a new treatment for premature ovarian failure? Curr Opin Obstet Gynecol. 2016 Jun;28(3):217-22. doi: 10.1097/GCO.0000000000000268. Review.|Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost. 2011 May;105 Suppl 1:S13-33. doi: 10.1160/THS10-11-0720. Epub 2011 Apr 11. Review.|Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008 May 15;453(7193):314-21. doi: 10.1038/nature07039. Review.|Sfakianoudis K, Simopoulou M, Nitsos N, Rapani A, Pantou A, Vaxevanoglou T, Kokkali G, Koutsilieris M, Pantos K. A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients. Gynecol Obstet Invest. 2019;84(1):99-106. doi: 10.1159/000491697. Epub 2018 Aug 22.|Sills ES, Rickers NS, Li X, Palermo GD. First data on in vitro fertilization and blastocyst formation after intraovarian injection of calcium gluconate-activated autologous platelet rich plasma. Gynecol Endocrinol. 2018 Sep;34(9):756-760. doi: 10.1080/09513590.2018.1445219. Epub 2018 Feb 28.|Sills ES, Li X, Rickers NS, Wood SH, Palermo GD. Metabolic and neurobehavioral response following intraovarian administration of autologous activated platelet rich plasma: First qualitative data. Neuro Endocrinol Lett. 2019 Jan;39(6):427-433.|Sills ES, Rickers NS, Svid CS, Rickers JM, Wood SH. Normalized Ploidy Following 20 Consecutive Blastocysts with Chromosomal Error: Healthy 46, XY Pregnancy with IVF after Intraovarian Injection of Autologous Enriched Platelet-derived Growth Factors. Int J Mol Cell Med. 2019 Winter;8(1):84-90. doi: 10.22088/IJMCM.BUMS.8.1.84. Epub 2019 May 15.|European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, Cifkova R, de Muinck Keizer-Schrama S, Hogervorst E, Janse F, Liao L, Vlaisavljevic V, Zillikens C, Vermeulen N. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016 May;31(5):926-37. doi: 10.1093/humrep/dew027. Epub 2016 Mar 22.","\tAnti-Mullerian Hormone Deficiency|Infertility|IVF|Premature Ovarian Failure\tautologous platelet rich plasma|saline solution\tNA\tNA\tNA\tOther|Other\tFemale\t","NA","NA","NA","NA","NA","NA","menopause, premature|primary ovarian insufficiency|infertility","NA","NA"]
["NCT04390698","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29643620,"Tripathy S, Rath S, Agrawal S, Rao PB, Panda A, Mishra TS, Nayak S. Opioid-free anesthesia for breast cancer surgery: An observational study. J Anaesthesiol Clin Pharmacol. 2018 Jan-Mar;34(1):35-40. doi: 10.4103/joacp.JOACP_143_17.","\tOpioid Free Anesthesia\tparavertebral block|opioid free anesthesia|sham block|opioid general anesthesia\tParallel Assignment\tTreatment\tRandomized\tProcedure|Drug|Procedure|Procedure\tFemale\t","Opioid Free Anesthesia in Breast Cancer Surgery","Interventional","Recruiting","N/A",2,78,"NA","anesthetics|analgesics, opioid","NA"]
["NCT04397367","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27892949|32119132|30808685|26228813|31958417","Ruutu T, Gratwohl A, Niederwieser D, de Witte T, van der Werf S, van Biezen A, Mohty M, Kröger N, Rambaldi A, McGrath E, Sureda A, Basak G, Greinix H, Duarte RF. The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis. Bone Marrow Transplant. 2017 Mar;52(3):357-362. doi: 10.1038/bmt.2016.298. Epub 2016 Nov 28.|Akahoshi Y, Igarashi A, Fukuda T, Uchida N, Tanaka M, Ozawa Y, Kanda Y, Onizuka M, Ichinohe T, Tanaka J, Atsuta Y, Kako S; Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia. Br J Haematol. 2020 Jul;190(1):84-92. doi: 10.1111/bjh.16540. Epub 2020 Mar 2.|Yeshurun M, Weisdorf D, Rowe JM, Tallman MS, Zhang MJ, Wang HL, Saber W, de Lima M, Sandmaier BM, Uy G, Kamble RT, Cairo MS, Cooper BW, Cahn JY, Ganguly S, Camitta B, Verdonck LF, Dandoy C, Diaz MA, Savani BN, George B, Liesveld J, McGuirk J, Byrne M, Grunwald MR, Drobyski WR, Pulsipher MA, Abdel-Azim H, Prestidge T, Wieduwilt MJ, Martino R, Norkin M, Beitinjaneh A, Seo S, Nishihori T, Wirk B, Frangoul H, Bashey A, Mori S, Marks DI, Bachanova V. The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Adv. 2019 Feb 26;3(4):670-680. doi: 10.1182/bloodadvances.2018027003.|Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015 Oct;29(10):2062-8. doi: 10.1038/leu.2015.212. Epub 2015 Jul 31.|Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, Gallagher G, Kerr H, Kuruvilla J, Lee SJ, Moore J, Nevill T, Popradi G, Roy J, Schultz KR, Szwajcer D, Toze C, Foley R; Cell Therapy Transplant Canada. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2020 Feb;7(2):e100-e111. doi: 10.1016/S2352-3026(19)30220-0. Epub 2020 Jan 17. Erratum in: Lancet Haematol. 2020 Jan 29;:.","\taGVHD|Stem Cell Transplant Complications\tRuxolitinib 10 mg twice a day combined with Corticosteroids|Ruxolitinib 5 mg twice a day combined with Corticosteroids|Ruxolitinib 5 mg once a day combined with Corticosteroids|Ruxolitinib 2.5 mg once a day combined with Corticosteroids\tNA\tNA\tNA\tDrug|Drug|Drug|Drug\tAll\t","Low Dose Ruxolitinib in Combination With Methylprednisolone","Interventional","Recruiting","Phase 1/Phase 2",4,32,"NA","NA","NA"]
["NCT04404907",7865679,4295971,null,"NA",null,"NA",{"$nulls":3},{"v":0.0004,"d":"4.00E-04"},"ANOVA",33067803,"Robinson JK, Wahood S, Stapleton JL. Motives for intentional sunlight exposure among young adult sexual minority men: appearance, relaxation and socialization in a cohort study. Br J Dermatol. 2021 Mar;184(3):563-564. doi: 10.1111/bjd.19609. Epub 2020 Nov 18.","\tSun Sensitivity\tno intervention\tNA\tNA\tNA\tOther\tMale\t","NA","NA","NA","NA","NA","NA","hypersensitivity","NA","Outdoor Tanning Motives"]
["NCT04407169","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32109013|29650407|32171076|32077115","Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.|Fang L, Gao P, Bao H, Tang X, Wang B, Feng Y, Cong S, Juan J, Fan J, Lu K, Wang N, Hu Y, Wang L. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med. 2018 Jun;6(6):421-430. doi: 10.1016/S2213-2600(18)30103-6. Epub 2018 Apr 9.|Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.|Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 Jul;75(7):1730-1741. doi: 10.1111/all.14238. Epub 2020 Feb 27.","\tCOVID\tno intervention\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","respiratory tract diseases|respiration disorders","NA","NA"]
["NCT04415528","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23567409|11773220|16805925|9720850","Vasiliadis HM, Dionne PA, Préville M, Gentil L, Berbiche D, Latimer E. The excess healthcare costs associated with depression and anxiety in elderly living in the community. Am J Geriatr Psychiatry. 2013 Jun;21(6):536-48. doi: 10.1016/j.jagp.2012.12.016. Epub 2013 Feb 6.|Troyer AK, Rich JB. Psychometric properties of a new metamemory questionnaire for older adults. J Gerontol B Psychol Sci Soc Sci. 2002 Jan;57(1):P19-27.|Pachana NA, Byrne GJ, Siddle H, Koloski N, Harley E, Arnold E. Development and validation of the Geriatric Anxiety Inventory. Int Psychogeriatr. 2007 Feb;19(1):103-14.|Carpenter JS, Andrykowski MA. Psychometric evaluation of the Pittsburgh Sleep Quality Index. J Psychosom Res. 1998 Jul;45(1):5-13.","\tAnxiety\tEmotion-Focused Mindfulness Therapy\tParallel Assignment\tTreatment\tRandomized\tOther\tAll\t","Emotion-Focused Mindfulness Therapy: A Feasibility Study for Late Life Anxiety","Interventional","Recruiting","N/A",2,48,"anxiety disorders","NA","NA"]
["NCT04417569","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","14714588|15036255|12413988|10221715|9696213|24890274|18191855|19246470|23040524|25747130|31248618|7250407|29037231|28319018|20097333|20539042|24083873|23827986|21665546|30927415","Bourgain C, Devroey P. The endometrium in stimulated cycles for IVF. Hum Reprod Update. 2003 Nov-Dec;9(6):515-22. Review.|Devroey P, Bourgain C, Macklon NS, Fauser BC. Reproductive biology and IVF: ovarian stimulation and endometrial receptivity. Trends Endocrinol Metab. 2004 Mar;15(2):84-90. Review.|Kolibianakis E, Bourgain C, Albano C, Osmanagaoglu K, Smitz J, Van Steirteghem A, Devroey P. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril. 2002 Nov;78(5):1025-9.|Nikas G, Develioglu OH, Toner JP, Jones HW Jr. Endometrial pinopodes indicate a shift in the window of receptivity in IVF cycles. Hum Reprod. 1999 Mar;14(3):787-92.|Simón C, Garcia Velasco JJ, Valbuena D, Peinado JA, Moreno C, Remohí J, Pellicer A. Increasing uterine receptivity by decreasing estradiol levels during the preimplantation period in high responders with the use of a follicle-stimulating hormone step-down regimen. Fertil Steril. 1998 Aug;70(2):234-9.|Weinerman R, Mainigi M. Why we should transfer frozen instead of fresh embryos: the translational rationale. Fertil Steril. 2014 Jul;102(1):10-8. doi: 10.1016/j.fertnstert.2014.05.019. Epub 2014 Jun 2. Review.|Liu Y, Lee KF, Ng EH, Yeung WS, Ho PC. Gene expression profiling of human peri-implantation endometria between natural and stimulated cycles. Fertil Steril. 2008 Dec;90(6):2152-64. doi: 10.1016/j.fertnstert.2007.10.020. Epub 2008 Jan 14.|Haouzi D, Assou S, Mahmoud K, Tondeur S, Rème T, Hedon B, De Vos J, Hamamah S. Gene expression profile of human endometrial receptivity: comparison between natural and stimulated cycles for the same patients. Hum Reprod. 2009 Jun;24(6):1436-45. doi: 10.1093/humrep/dep039. Epub 2009 Feb 26.|Roque M, Lattes K, Serra S, Solà I, Geber S, Carreras R, Checa MA. Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: a systematic review and meta-analysis. Fertil Steril. 2013 Jan;99(1):156-162. doi: 10.1016/j.fertnstert.2012.09.003. Epub 2012 Oct 3. Review.|Roque M, Valle M, Guimarães F, Sampaio M, Geber S. Freeze-all policy: fresh vs. frozen-thawed embryo transfer. Fertil Steril. 2015 May;103(5):1190-3. doi: 10.1016/j.fertnstert.2015.01.045. Epub 2015 Mar 4.|Haas J, Smith R, Zilberberg E, Nayot D, Meriano J, Barzilay E, Casper RF. Endometrial compaction (decreased thickness) in response to progesterone results in optimal pregnancy outcome in frozen-thawed embryo transfers. Fertil Steril. 2019 Sep;112(3):503-509.e1. doi: 10.1016/j.fertnstert.2019.05.001. Epub 2019 Jun 24.|Testart J, Frydman R, Feinstein MC, Thebault A, Roger M, Scholler R. Interpretation of plasma luteinizing hormone assay for the collection of mature oocytes from women: definition of a luteinizing hormone surge-initiating rise. Fertil Steril. 1981 Jul;36(1):50-4.|Irani M, Robles A, Gunnala V, Reichman D, Rosenwaks Z. Optimal parameters for determining the LH surge in natural cycle frozen-thawed embryo transfers. J Ovarian Res. 2017 Oct 16;10(1):70. doi: 10.1186/s13048-017-0367-7.|Groenewoud ER, Macklon NS, Cohlen BJ; ANTARCTICA Study Group. The effect of elevated progesterone levels before HCG triggering in modified natural cycle frozen-thawed embryo transfer cycles. Reprod Biomed Online. 2017 May;34(5):546-554. doi: 10.1016/j.rbmo.2017.02.008. Epub 2017 Feb 28.|Fatemi HM, Kyrou D, Bourgain C, Van den Abbeel E, Griesinger G, Devroey P. Cryopreserved-thawed human embryo transfer: spontaneous natural cycle is superior to human chorionic gonadotropin-induced natural cycle. Fertil Steril. 2010 Nov;94(6):2054-8. doi: 10.1016/j.fertnstert.2009.11.036. Epub 2010 Jan 25.|Bosch E, Labarta E, Crespo J, Simón C, Remohí J, Jenkins J, Pellicer A. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. Hum Reprod. 2010 Aug;25(8):2092-100. doi: 10.1093/humrep/deq125. Epub 2010 Jun 10.|Griesinger G, Mannaerts B, Andersen CY, Witjes H, Kolibianakis EM, Gordon K. Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in six trials. Fertil Steril. 2013 Dec;100(6):1622-8.e1-3. doi: 10.1016/j.fertnstert.2013.08.045. Epub 2013 Sep 29.|Venetis CA, Kolibianakis EM, Bosdou JK, Tarlatzis BC. Progesterone elevation and probability of pregnancy after IVF: a systematic review and meta-analysis of over 60 000 cycles. Hum Reprod Update. 2013 Sep-Oct;19(5):433-57. doi: 10.1093/humupd/dmt014. Epub 2013 Jul 4.|Yding Andersen C, Bungum L, Nyboe Andersen A, Humaidan P. Preovulatory progesterone concentration associates significantly to follicle number and LH concentration but not to pregnancy rate. Reprod Biomed Online. 2011 Aug;23(2):187-95. doi: 10.1016/j.rbmo.2011.04.003. Epub 2011 Apr 28.|Friis Wang N, Skouby SO, Humaidan P, Andersen CY. Response to ovulation trigger is correlated to late follicular phase progesterone levels: A hypothesis explaining reduced reproductive outcomes caused by increased late follicular progesterone rise. Hum Reprod. 2019 May 1;34(5):942-948. doi: 10.1093/humrep/dez023.","\thCG|Infertility|Infertility, Female|IVF\thCG|Ultrasound|Blood test\tNA\tNA\tNA\tDrug|Diagnostic Test|Other\tFemale\t","NA","NA","NA","NA","NA","NA","infertility|infertility, female","progesterone|chorionic gonadotropin|estradiol","NA"]
["NCT04428450","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",22060248,"Berger T, Hämmerli K, Gubser N, Andersson G, Caspar F. Internet-based treatment of depression: a randomized controlled trial comparing guided with unguided self-help. Cogn Behav Ther. 2011;40(4):251-66. doi: 10.1080/16506073.2011.616531.","\tDepression\tDeprexis\tParallel Assignment\tTreatment\tRandomized\tDevice\tAll\t","Internet-Based Treatment of Depression: Comparing Guided With Unguided Self-Help","Interventional","Completed","N/A",3,76,"depressive disorder|depression","NA","NA"]
["NCT04451629","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20493741|22901294|24856936|15243011|15575029|24230963|24631318|28042403|9817107","Eryilmaz G, Ozdemir F, Pasinlioglu T. Dysmenorrhea prevalence among adolescents in eastern Turkey: its effects on school performance and relationships with family and friends. J Pediatr Adolesc Gynecol. 2010 Oct;23(5):267-72. doi: 10.1016/j.jpag.2010.02.009. Epub 2010 May 21.|Guvenc G, Kilic A, Akyuz A, Ustunsoz A. Premenstrual syndrome and attitudes toward menstruation in a sample of nursing students. J Psychosom Obstet Gynaecol. 2012 Sep;33(3):106-11. doi: 10.3109/0167482X.2012.685906.|Kannan P, Claydon LS. Some physiotherapy treatments may relieve menstrual pain in women with primary dysmenorrhea: a systematic review. J Physiother. 2014 Mar;60(1):13-21. doi: 10.1016/j.jphys.2013.12.003. Epub 2014 Apr 24. Review.|Marsden JS, Strickland CD, Clements TL. Guaifenesin as a treatment for primary dysmenorrhea. J Am Board Fam Pract. 2004 Jul-Aug;17(4):240-6.|Nasir L, Bope ET. Management of pelvic pain from dysmenorrhea or endometriosis. J Am Board Fam Pract. 2004 Nov-Dec;17 Suppl:S43-7.|Potur DC, Bilgin NC, Komurcu N. Prevalence of dysmenorrhea in university students in Turkey: effect on daily activities and evaluation of different pain management methods. Pain Manag Nurs. 2014 Dec;15(4):768-77. doi: 10.1016/j.pmn.2013.07.012. Epub 2013 Nov 11.|Seven M, Güvenç G, Akyüz A, Eski F. Evaluating dysmenorrhea in a sample of Turkish nursing students. Pain Manag Nurs. 2014 Sep;15(3):664-71. doi: 10.1016/j.pmn.2013.07.006. Epub 2014 Mar 14.|Motahari-Tabari N, Shirvani MA, Alipour A. Comparison of the Effect of Stretching Exercises and Mefenamic Acid on the Reduction of Pain and Menstruation Characteristics in Primary Dysmenorrhea: A Randomized Clinical Trial. Oman Med J. 2017 Jan;32(1):47-53. doi: 10.5001/omj.2017.09.|Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998 Nov;51(11):903-12.","\tPrimary Dysmenorrhea\tpelvıc base exercıse, core exercise\tParallel Assignment\tSupportive Care\tRandomized\tBehavioral\tFemale\t","Effect of Exercise on Primary Dysmenorrhea","Interventional","Active, not recruiting","N/A",2,30,"dysmenorrhea","NA","NA"]
["NCT04460313","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31280295|29227464|28418829|26271823|21501471|22397629|29637893|30634919|31617912|25037572|27330068|23963858|23171127|24263220|22330166|22925540|18190319|17072121","Ouldali N, Cohen R, Levy C, Gelbert-Baudino N, Seror E, Corrard F, Vie Le Sage F, Michot AS, Romain O, Bechet S, Bonacorsi S, Angoulvant F, Varon E. Pneumococcal susceptibility to antibiotics in carriage: a 17 year time series analysis of the adaptive evolution of non-vaccine emerging serotypes to a new selective pressure environment. J Antimicrob Chemother. 2019 Oct 1;74(10):3077-3086. doi: 10.1093/jac/dkz281.|Rybak A, Levy C, Bonacorsi S, Béchet S, Vié le Sage F, Elbez A, Varon E, Cohen R. Antibiotic Resistance of Potential Otopathogens Isolated From Nasopharyngeal Flora of Children With Acute Otitis Media Before, During and After Pneumococcal Conjugate Vaccines Implementation. Pediatr Infect Dis J. 2018 Mar;37(3):e72-e78. doi: 10.1097/INF.0000000000001862.|Birgy A, Bidet P, Levy C, Sobral E, Cohen R, Bonacorsi S. CTX-M-27-Producing Escherichia coli of Sequence Type 131 and Clade C1-M27, France. Emerg Infect Dis. 2017 May;23(5):885. doi: 10.3201/eid2305.161865.|Cohen R, Varon E, Doit C, Schlemmer C, Romain O, Thollot F, Béchet S, Bonacorsi S, Levy C. A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation. Vaccine. 2015 Sep 22;33(39):5118-26. doi: 10.1016/j.vaccine.2015.08.010. Epub 2015 Aug 11.|Cohen R, Levy C, Bonnet E, Thollot F, Boucherat M, Fritzell B, Derkx V, Bingen E, Varon E. Risk factors for serotype 19A carriage after introduction of 7-valent pneumococcal vaccination. BMC Infect Dis. 2011 Apr 18;11:95. doi: 10.1186/1471-2334-11-95.|Cohen R, Bingen E, Levy C, Thollot F, Boucherat M, Derkx V, Varon E. Nasopharyngeal flora in children with acute otitis media before and after implementation of 7 valent pneumococcal conjugate vaccine in France. BMC Infect Dis. 2012 Mar 7;12:52. doi: 10.1186/1471-2334-12-52.|Levy C, Vie le Sage F, Varon E, Chalumeau M, Grimprel E, Cohen R. Pediatric Ambulatory and Hospital Networks for Surveillance and Clinical Epidemiology of Community-Acquired Infections. J Pediatr. 2018 Mar;194:269-270.e2. doi: 10.1016/j.jpeds.2017.11.050. Epub 2018 Feb 22.|Vermee Q, Cohen R, Hays C, Varon E, Bonacorsi S, Bechet S, Thollot F, Corrard F, Poyart C, Levy C, Raymond J. Biofilm production by Haemophilus influenzae and Streptococcus pneumoniae isolated from the nasopharynx of children with acute otitis media. BMC Infect Dis. 2019 Jan 11;19(1):44. doi: 10.1186/s12879-018-3657-9.|Birgy A, Madhi F, Jung C, Levy C, Cointe A, Bidet P, Hobson CA, Bechet S, Sobral E, Vuthien H, Ferroni A, Aberrane S, Cuzon G, Beraud L, Gajdos V, Launay E, Pinquier D, Haas H, Desmarest M, Dommergues MA, Cohen R, Bonacorsi S; Group of the National Observatory of Urinary tract Infection due to ESBL-producing Enterobacteriaceae in children. Diversity and trends in population structure of ESBL-producing Enterobacteriaceae in febrile urinary tract infections in children in France from 2014 to 2017. J Antimicrob Chemother. 2020 Jan 1;75(1):96-105. doi: 10.1093/jac/dkz423.|Mizrahi A, Cohen R, Varon E, Bonacorsi S, Bechet S, Poyart C, Levy C, Raymond J. Non typable-Haemophilus influenzae biofilm formation and acute otitis media. BMC Infect Dis. 2014 Jul 19;14:400. doi: 10.1186/1471-2334-14-400.|Birgy A, Levy C, Bidet P, Thollot F, Derkx V, Béchet S, Mariani-Kurkdjian P, Cohen R, Bonacorsi S. ESBL-producing Escherichia coli ST131 versus non-ST131: evolution and risk factors of carriage among French children in the community between 2010 and 2015. J Antimicrob Chemother. 2016 Oct;71(10):2949-56. doi: 10.1093/jac/dkw219. Epub 2016 Jun 20.|Hau I, Levy C, Caeymaex L, Cohen R. Impact of pneumococcal conjugate vaccines on microbial epidemiology and clinical outcomes of acute otitis media. Paediatr Drugs. 2014 Feb;16(1):1-12. doi: 10.1007/s40272-013-0044-2.|Birgy A, Cohen R, Levy C, Bidet P, Courroux C, Benani M, Thollot F, Bingen E. Community faecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in French children. BMC Infect Dis. 2012 Nov 21;12:315. doi: 10.1186/1471-2334-12-315.|Caeymaex L, Varon E, Levy C, Béchet S, Derkx V, Desvignes V, Doit C, Cohen R. Characteristics and outcomes of acute otitis media in children carrying streptococcus pneumoniae or haemophilus influenzae in their nasopharynx as a single otopathogen after introduction of the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2014 May;33(5):533-6. doi: 10.1097/INF.0000000000000213.|Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J. 2012 Mar;31(3):297-301. doi: 10.1097/INF.0b013e318247ef84.|Cohen R, Levy C, Bingen E, Bechet S, Derkx V, Werner A, Koskas M, Varon E. [Nasopharyngeal carriage of children 6 to 60 months during the implementation of the 13-valent pneumococcal conjugate vaccine]. Arch Pediatr. 2012 Oct;19(10):1132-9. doi: 10.1016/j.arcped.2012.07.013. Epub 2012 Aug 24. French.|Cohen R, Levy C, Thollot F, de La Rocque F, Koskas M, Bonnet E, Fritzell B, Varon E. Pneumococcal conjugate vaccine does not influence Staphylococcus aureus carriage in young children with acute otitis media. Clin Infect Dis. 2007 Dec 15;45(12):1583-7. doi: 10.1086/523734. Erratum in: Clin Infect Dis. 2008 Feb 1;46(3):489.|Cohen R, Levy C, de La Rocque F, Gelbert N, Wollner A, Fritzell B, Bonnet E, Tetelboum R, Varon E. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J. 2006 Nov;25(11):1001-7.","\tAntibiotic Resistant Strain|Children, Only|Nasopharyngeal Carriage\tnasopharyngeal sample\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","pneumonia","NA","NA"]
["NCT04465006","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24396203|26834368","Kim S, Yuk GC, Gak H. Effects of the horse riding simulator and ball exercises on balance of the elderly. J Phys Ther Sci. 2013 Nov;25(11):1425-8. doi: 10.1589/jpts.25.1425. Epub 2013 Dec 11.|Ciou SH, Hwang YS, Chen CC, Chen SC, Chou SW, Chen YL. Balance training using an interactive game to enhance the use of the affected side after stroke. J Phys Ther Sci. 2015 Dec;27(12):3855-61. doi: 10.1589/jpts.27.3855. Epub 2015 Dec 28.","\tStroke\tHippotherapy Simulator|Conventional Exercise\tParallel Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Efficacy of Hippotherapy Simulator Exercise Program in Stroke Patients","Interventional","Completed","N/A",2,26,"stroke","NA","NA"]
["NCT04469387","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22885827|28288396|26863261|22460400|31431873|21286714|25839385","Lawrence BD, Wang J, Arnold PM, Hermsmeyer J, Norvell DC, Brodke DS. Predicting the risk of adjacent segment pathology after lumbar fusion: a systematic review. Spine (Phila Pa 1976). 2012 Oct 15;37(22 Suppl):S123-32. doi: 10.1097/BRS.0b013e31826d60d8.|Zhong ZM, Deviren V, Tay B, Burch S, Berven SH. Adjacent segment disease after instrumented fusion for adult lumbar spondylolisthesis: Incidence and risk factors. Clin Neurol Neurosurg. 2017 May;156:29-34. doi: 10.1016/j.clineuro.2017.02.020. Epub 2017 Feb 27.|Alentado VJ, Lubelski D, Healy AT, Orr RD, Steinmetz MP, Benzel EC, Mroz TE. Predisposing Characteristics of Adjacent Segment Disease After Lumbar Fusion. Spine (Phila Pa 1976). 2016 Jul 15;41(14):1167-1172. doi: 10.1097/BRS.0000000000001493.|Hikata T, Kamata M, Furukawa M. Risk factors for adjacent segment disease after posterior lumbar interbody fusion and efficacy of simultaneous decompression surgery for symptomatic adjacent segment disease. J Spinal Disord Tech. 2014 Apr;27(2):70-5. doi: 10.1097/BSD.0b013e31824e5292.|Matsumoto T, Okuda S, Nagamoto Y, Sugiura T, Takahashi Y, Iwasaki M. Effects of Concomitant Decompression Adjacent to a Posterior Lumbar Interbody Fusion Segment on Clinical and Radiologic Outcomes: Comparative Analysis 5 Years After Surgery. Global Spine J. 2019 Aug;9(5):505-511. doi: 10.1177/2192568218803324. Epub 2018 Oct 8.|Lee GY, Lee JW, Choi HS, Oh KJ, Kang HS. A new grading system of lumbar central canal stenosis on MRI: an easy and reliable method. Skeletal Radiol. 2011 Aug;40(8):1033-9. doi: 10.1007/s00256-011-1102-x. Epub 2011 Feb 1. Erratum in: Skeletal Radiol. 2011 Aug;40(8):1127. Guen, Young Lee [corrected to Lee, Guen Young]; Joon, Woo Lee [corrected to Lee, Joon Woo]; Hee, Seok Choi [corrected to Choi, Hee Seok]; Kyoung-Jin, Oh [corrected to Oh, Kyoung-Jin]; Heung, Sik Kang [corrected to Kang, Heung Sik].|Nakashima H, Kawakami N, Tsuji T, Ohara T, Suzuki Y, Saito T, Nohara A, Tauchi R, Ohta K, Hamajima N, Imagama S. Adjacent Segment Disease After Posterior Lumbar Interbody Fusion: Based on Cases With a Minimum of 10 Years of Follow-up. Spine (Phila Pa 1976). 2015 Jul 15;40(14):E831-41. doi: 10.1097/BRS.0000000000000917.","\tDegeneration Spine|Degenerative Disc Disease|Degenerative Lumbar Spinal Stenosis\tLimited decompressions at adjacent segment with asymptomatic pre-existing spinal canal stenosis|Responsible segments fused\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","Preventive Effect of Limited Decompression on Adjacent Segment Following Posterior Lumbar Interbody Fusion","Interventional","Recruiting","N/A",2,200,"intervertebral disc degeneration|constriction, pathologic|spinal stenosis","NA","NA"]
["NCT04478435","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","8424572|1785235|21596885|29624530","Warner MA, Warner ME, Weber JG. Clinical significance of pulmonary aspiration during the perioperative period. Anesthesiology. 1993 Jan;78(1):56-62.|Read MS, Vaughan RS. Allowing pre-operative patients to drink: effects on patients' safety and comfort of unlimited oral water until 2 hours before anaesthesia. Acta Anaesthesiol Scand. 1991 Oct;35(7):591-5.|Perlas A, Davis L, Khan M, Mitsakakis N, Chan VW. Gastric sonography in the fasted surgical patient: a prospective descriptive study. Anesth Analg. 2011 Jul;113(1):93-7. doi: 10.1213/ANE.0b013e31821b98c0. Epub 2011 May 19.|Kruisselbrink R, Gharapetian A, Chaparro LE, Ami N, Richler D, Chan VWS, Perlas A. Diagnostic Accuracy of Point-of-Care Gastric Ultrasound. Anesth Analg. 2019 Jan;128(1):89-95. doi: 10.1213/ANE.0000000000003372.","\tHealthy Participants\tglucose loaded clear fluid\tParallel Assignment\tScreening\tRandomized\tOther\tAll\t","Gastric Volume Estimation by Ultrasonography After Glucose Loaded Clear Fluid Ingestion in Fasted Adult","Interventional","Completed","N/A",2,254,"NA","NA","NA"]
["NCT04482907","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22228959|23764360|25461470|24908232|29215302|27753646","Jana S, Shekhawat GS. Anethum graveolens: An Indian traditional medicinal herb and spice. Pharmacogn Rev. 2010 Jul;4(8):179-84. doi: 10.4103/0973-7847.70915.|Orhan IE, Senol FS, Ozturk N, Celik SA, Pulur A, Kan Y. Phytochemical contents and enzyme inhibitory and antioxidant properties of Anethum graveolens L. (dill) samples cultivated under organic and conventional agricultural conditions. Food Chem Toxicol. 2013 Sep;59:96-103. doi: 10.1016/j.fct.2013.05.053. Epub 2013 Jun 10.|Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. Autoimmun Rev. 2015 Feb;14(2):174-80. doi: 10.1016/j.autrev.2014.10.016. Epub 2014 Oct 25. Review.|Krátký J, Vítková H, Bartáková J, Telička Z, Antošová M, Límanová Z, Jiskra J. Thyroid nodules: pathophysiological insight on oncogenesis and novel diagnostic techniques. Physiol Res. 2014;63 Suppl 2(Suppl 2):S263-75. Review.|Yang ML, Lu B. Treatment of Goiter with Traditional Chinese Medicine Regimen Xing Qi Hua Ying Tang: A Clinical Study on 72 Patients with Multinodular and Diffuse Goiter. J Altern Complement Med. 2018 Apr;24(4):374-377. doi: 10.1089/acm.2017.0138. Epub 2017 Dec 7.|Altay M, Ateş İ, Kaplan Efe F, Karadağ İ. Does Use of Anethum Graveolens Affected Thyroid Hormone Levels and Thyroid Nodules? Am J Ther. 2017 Sep/Oct;24(5):e627-e629. doi: 10.1097/MJT.0000000000000511.","\tThyroid Nodule\tGiving dill by mouth capsule to the study group and placebo capsule by mouth to the control group.\tParallel Assignment\tSupportive Care\tRandomized\tDietary Supplement\tAll\t","Effect of Dill in Thyroiditis and Nodular Goiter Patients","Interventional","Completed","N/A",2,68,"goiter|thyroid nodule|thyroiditis|goiter, nodular","hormones","NA"]
["NCT04490876","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29621507|20182404|12644944|19107502|16829804|30451186|31744475","Foveau P, Leroy B, Berrod JP, Conart JB. Internal Limiting Membrane Peeling in Macula-off Retinal Detachment Complicated by Grade B Proliferative Vitreoretinopathy. Am J Ophthalmol. 2018 Jul;191:1-6. doi: 10.1016/j.ajo.2018.03.037. Epub 2018 Apr 3.|Odrobina DC, Michalewska Z, Michalewski J, Nawrocki J. High-speed, high-resolution spectral optical coherence tomography in patients after vitrectomy with internal limiting membrane peeling for proliferative vitreoretinopathy retinal detachment. Retina. 2010 Jun;30(6):881-6. doi: 10.1097/IAE.0b013e3181c96952.|Sakamoto H, Yamanaka I, Kubota T, Ishibashi T. Indocyanine green-assisted peeling of the epiretinal membrane in proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 2003 Mar;241(3):204-7. Epub 2003 Feb 20.|Aras C, Arici C, Akar S, Müftüoglu G, Yolar M, Arvas S, Baserer T, Koyluoglu N. Peeling of internal limiting membrane during vitrectomy for complicated retinal detachment prevents epimacular membrane formation. Graefes Arch Clin Exp Ophthalmol. 2009 May;247(5):619-23. doi: 10.1007/s00417-008-1025-y. Epub 2008 Dec 24.|Enaida H, Hisatomi T, Hata Y, Ueno A, Goto Y, Yamada T, Kubota T, Ishibashi T. Brilliant blue G selectively stains the internal limiting membrane/brilliant blue G-assisted membrane peeling. Retina. 2006 Jul-Aug;26(6):631-6.|\"Kumar A, Hasan N, Kakkar P, Mutha V, Karthikeya R, Sundar D, Ravani R. Comparison of clinical outcomes between \"\"heads-up\"\" 3D viewing system and conventional microscope in macular hole surgeries: A pilot study. Indian J Ophthalmol. 2018 Dec;66(12):1816-1819. doi: 10.4103/ijo.IJO_59_18.\"|Lai CT, Kung WH, Lin CJ, Chen HS, Bair H, Lin JM, Chen WL, Tien PT, Tsai YY. Outcome of primary rhegmatogenous retinal detachment using microincision vitrectomy and sutureless wide-angle viewing systems. BMC Ophthalmol. 2019 Nov 19;19(1):230. doi: 10.1186/s12886-019-1238-3.","\tProliferative Vitreoretinopathy\t3D Pars Plana Vitrectomy associated with Extensive Brilliant Blue G-Assisted ILM Peeling Method\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","vitreoretinopathy, proliferative|retinal detachment","NA","NA"]
["NCT04499508","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",9933290,"Brilstra EH, Rinkel GJ, van der Graaf Y, van Rooij WJ, Algra A. Treatment of intracranial aneurysms by embolization with coils: a systematic review. Stroke. 1999 Feb;30(2):470-6. Review.","\tAneurysm|Cerebral Aneurysm Unruptured|Intracranial Aneurysm|Ruptured Aneurysm|Subarachnoid Hemorrhage, Aneurysmal\tOptima Coil System\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","subarachnoid hemorrhage|intracranial aneurysm|aneurysm, ruptured|hemorrhage|aneurysm|rupture","NA","NA"]
["NCT04502914","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29211657|23262998","Yang D, Davies A, Burge B, Watkins P, Dissanaike S. Open-to-Air Is a Viable Option for Initial Wound Care in Necrotizing Soft Tissue Infection that Allows Early Detection of Recurrence without Need for Painful Dressing Changes or Return to Operating Room. Surg Infect (Larchmt). 2018 Jan;19(1):65-70. doi: 10.1089/sur.2017.080. Epub 2017 Dec 6.|Dai T, Gupta A, Huang YY, Yin R, Murray CK, Vrahas MS, Sherwood ME, Tegos GP, Hamblin MR. Blue light rescues mice from potentially fatal Pseudomonas aeruginosa burn infection: efficacy, safety, and mechanism of action. Antimicrob Agents Chemother. 2013 Mar;57(3):1238-45. doi: 10.1128/AAC.01652-12. Epub 2012 Dec 21.","\tBacterial Infections|Burns|Infection Wound\tOpen-to-air strategy|Traditional closed-wound management\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","The Study on Bacterial Load Following Open-to-air Management in Burn Patients.","Interventional","Recruiting","N/A",2,20,"communicable diseases|infection|burns|bacterial infections","NA","NA"]
["NCT04516395","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26903338|29276050|27080992|25737147|29444952|28013264|31765385|30761114|28442293","Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.|Tillotson G. A crucial list of pathogens. Lancet Infect Dis. 2018 Mar;18(3):234-236. doi: 10.1016/S1473-3099(17)30754-5. Epub 2017 Dec 21.|Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, Srinivasan A, Dellit TH, Falck-Ytter YT, Fishman NO, Hamilton CW, Jenkins TC, Lipsett PA, Malani PN, May LS, Moran GJ, Neuhauser MM, Newland JG, Ohl CA, Samore MH, Seo SK, Trivedi KK. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016 May 15;62(10):e51-77. doi: 10.1093/cid/ciw118. Epub 2016 Apr 13.|Asín-Prieto E, Rodríguez-Gascón A, Isla A. Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. J Infect Chemother. 2015 May;21(5):319-29. doi: 10.1016/j.jiac.2015.02.001. Epub 2015 Feb 12. Review.|Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. Clin Microbiol Rev. 2018 Feb 14;31(2). pii: e00079-17. doi: 10.1128/CMR.00079-17. Print 2018 Apr. Review.|Tamma PD, Goodman KE, Harris AD, Tekle T, Roberts A, Taiwo A, Simner PJ. Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia. Clin Infect Dis. 2017 Feb 1;64(3):257-264. doi: 10.1093/cid/ciw741. Epub 2016 Nov 9.|Demidenko E, Miller TW. Statistical determination of synergy based on Bliss definition of drugs independence. PLoS One. 2019 Nov 25;14(11):e0224137. doi: 10.1371/journal.pone.0224137. eCollection 2019.|Sheu CC, Chang YT, Lin SY, Chen YH, Hsueh PR. Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options. Front Microbiol. 2019 Jan 30;10:80. doi: 10.3389/fmicb.2019.00080. eCollection 2019. Review.|Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, Venditti M, Tumbarello M, Daikos G, Cantón R, Doi Y, Tuon FF, Karaiskos I, Pérez-Nadales E, Schwaber MJ, Azap ÖK, Souli M, Roilides E, Pournaras S, Akova M, Pérez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Investigators. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017 Jul;17(7):726-734. doi: 10.1016/S1473-3099(17)30228-1. Epub 2017 Apr 22.","\tCarbapenem-Resistant Enterobacteriaceae Infection|Clinical Outcomes|Critical Illness|Drug Resistance|Sepsis|Septic Shock|Treatment Outcomes\tCombined antibiotic regimens|Standard antibiotic regimens\tNA\tNA\tNA\tOther|Other\tAll\t","Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae","Interventional","Not yet recruiting","N/A",2,102,"communicable diseases|critical illness|infection|enterobacteriaceae infections","anti-bacterial agents|antibiotics, antitubercular","NA"]
["NCT04516733","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","8445433|8433390|23940216|16163448|24552318|27853959|22644537|28801008|27001588|24552317","Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993 Mar;11(3):570-9.|Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76.|Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, Degroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jürgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013 Sep 10;31(26):3212-8. doi: 10.1200/JCO.2012.47.2464. Epub 2013 Aug 12.|Brown PD, Ballman KV, Rummans TA, Maurer MJ, Sloan JA, Boeve BF, Gupta L, Tang-Wai DF, Arusell RM, Clark MM, Buckner JC. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J Neurooncol. 2006 Feb;76(3):283-91.|Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):709-22. doi: 10.1056/NEJMoa1308345.|Darlix A, Zouaoui S, Rigau V, Bessaoud F, Figarella-Branger D, Mathieu-Daudé H, Trétarre B, Bauchet F, Duffau H, Taillandier L, Bauchet L. Epidemiology for primary brain tumors: a nationwide population-based study. J Neurooncol. 2017 Feb;131(3):525-546. doi: 10.1007/s11060-016-2318-3. Epub 2016 Nov 16. Erratum in: J Neurooncol. 2017 Feb;131(3):547.|Flechl B, Ackerl M, Sax C, Dieckmann K, Crevenna R, Gaiger A, Widhalm G, Preusser M, Marosi C. Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors. J Neurooncol. 2012 Sep;109(2):331-9. doi: 10.1007/s11060-012-0897-1. Epub 2012 May 29.|Flechl B, Sax C, Ackerl M, Crevenna R, Woehrer A, Hainfellner J, Preusser M, Widhalm G, Kiesel B, Lütgendorf-Caucig C, Dieckmann K, Steffal C, Marosi C, Hassler MR. The course of quality of life and neurocognition in newly diagnosed patients with glioblastoma. Radiother Oncol. 2017 Nov;125(2):228-233. doi: 10.1016/j.radonc.2017.07.027. Epub 2017 Aug 8.|Gilbert MR. Antiangiogenic Therapy for Glioblastoma: Complex Biology and Complicated Results. J Clin Oncol. 2016 May 10;34(14):1567-9. doi: 10.1200/JCO.2016.66.5364. Epub 2016 Mar 21.|Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):699-708. doi: 10.1056/NEJMoa1308573.","\tGlioblastoma\tsupportive care\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","glioblastoma","NA","NA"]
["NCT04526184","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31156448|21385216|25430600|31684769|25338316|23446173|21436993","Patterson SD, Hughes L, Warmington S, Burr J, Scott BR, Owens J, Abe T, Nielsen JL, Libardi CA, Laurentino G, Neto GR, Brandner C, Martin-Hernandez J, Loenneke J. Blood Flow Restriction Exercise: Considerations of Methodology, Application, and Safety. Front Physiol. 2019 May 15;10:533. doi: 10.3389/fphys.2019.00533. eCollection 2019. Review. Erratum in: Front Physiol. 2019 Oct 22;10:1332.|Kacin A, Strazar K. Frequent low-load ischemic resistance exercise to failure enhances muscle oxygen delivery and endurance capacity. Scand J Med Sci Sports. 2011 Dec;21(6):e231-41. doi: 10.1111/j.1600-0838.2010.01260.x. Epub 2011 Mar 8.|Scott BR, Loenneke JP, Slattery KM, Dascombe BJ. Exercise with blood flow restriction: an updated evidence-based approach for enhanced muscular development. Sports Med. 2015 Mar;45(3):313-25. doi: 10.1007/s40279-014-0288-1. Review.|Nolan CM, Rochester CL. Exercise Training Modalities for People with Chronic Obstructive Pulmonary Disease. COPD. 2019 Dec;16(5-6):378-389. doi: 10.1080/15412555.2019.1637834. Epub 2019 Nov 4. Review.|Loenneke JP, Allen KM, Mouser JG, Thiebaud RS, Kim D, Abe T, Bemben MG. Blood flow restriction in the upper and lower limbs is predicted by limb circumference and systolic blood pressure. Eur J Appl Physiol. 2015 Feb;115(2):397-405. doi: 10.1007/s00421-014-3030-7. Epub 2014 Oct 22.|Wilson JM, Lowery RP, Joy JM, Loenneke JP, Naimo MA. Practical blood flow restriction training increases acute determinants of hypertrophy without increasing indices of muscle damage. J Strength Cond Res. 2013 Nov;27(11):3068-75. doi: 10.1519/JSC.0b013e31828a1ffa.|Berzosa C, Cebrián I, Fuentes-Broto L, Gómez-Trullén E, Piedrafita E, Martínez-Ballarín E, López-Pingarrón L, Reiter RJ, García JJ. Acute exercise increases plasma total antioxidant status and antioxidant enzyme activities in untrained men. J Biomed Biotechnol. 2011;2011:540458. doi: 10.1155/2011/540458. Epub 2011 Mar 9.","\tCOPD\taerobic exercise with blood flow restriction\tParallel Assignment\tTreatment\tRandomized\tProcedure\tMale\t","The Effect of Blood Flow Restricted Aerobic Exercise on Chronic Obstructive Pulmonary Patients","Interventional","Enrolling by invitation","N/A",2,50,"NA","NA","NA"]
["NCT04533867","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31384338|30976908|31198253","Aydin A, Kaçmaz M, Boyaci A. Comparison of ondansetron, tropisetron, and palonosetron for the prevention of postoperative nausea and vomiting after middle ear surgery. Curr Ther Res Clin Exp. 2019 Jun 22;91:17-21. doi: 10.1016/j.curtheres.2019.06.002. eCollection 2019.|Lee S, Kim I, Pyeon T, Lee S, Song J, Rhee J, Jeong S. Population pharmacokinetics of palonosetron and model-based assessment of dosing strategies. J Anesth. 2019 Jun;33(3):381-389. doi: 10.1007/s00540-019-02641-5. Epub 2019 Apr 11.|Rajnikant K, Bhukal I, Kaloria N, Soni SL, Kajal K. Comparison of Palonosetron and Dexamethasone with Ondansetron and Dexamethasone to Prevent Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Cholecystectomy. Anesth Essays Res. 2019 Apr-Jun;13(2):317-322. doi: 10.4103/aer.AER_21_19.","\tAntiemetics|Nausea, Postoperative|Pain, Postoperative|Patient Reported Outcomes|Vomiting, Postoperative\tLaparoscopic sleeve gastrectomy|Palonosetron 1mcg/kg|Ondansetron 1 mg/kg, max dose 8 mg\tNA\tNA\tNA\tProcedure|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","pain, postoperative|postoperative nausea and vomiting|nausea|vomiting","palonosetron|ondansetron","NA"]
["NCT04538261","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26868074|25828903|18456227|18055730","Seal SL, Dey A, Barman SC, Kamilya G, Mukherji J, Onwude JL. Randomized controlled trial of elevation of the fetal head with a fetal pillow during cesarean delivery at full cervical dilatation. Int J Gynaecol Obstet. 2016 May;133(2):178-82. doi: 10.1016/j.ijgo.2015.09.019. Epub 2016 Jan 15.|Hofmeyr GJ, Kulier R, West HM. External cephalic version for breech presentation at term. Cochrane Database Syst Rev. 2015 Apr 1;(4):CD000083. doi: 10.1002/14651858.CD000083.pub3. Review.|Kok M, Cnossen J, Gravendeel L, van der Post J, Opmeer B, Mol BW. Clinical factors to predict the outcome of external cephalic version: a metaanalysis. Am J Obstet Gynecol. 2008 Dec;199(6):630.e1-7; discussion e1-5. doi: 10.1016/j.ajog.2008.03.008. Epub 2008 May 23. Review.|Weiniger CF, Ginosar Y, Elchalal U, Sharon E, Nokrian M, Ezra Y. External cephalic version for breech presentation with or without spinal analgesia in nulliparous women at term: a randomized controlled trial. Obstet Gynecol. 2007 Dec;110(6):1343-50.","\tBreech Presentation|External Cephalic Version\tFetal Pillow insertion\tParallel Assignment\tTreatment\tRandomized\tDevice\tFemale\t","Elevation of the Fetal Buttocks Prior to External Cephalic Version","Interventional","Recruiting","N/A",2,92,"breech presentation","NA","NA"]
["NCT04555889","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22682464|27839855|10829971|12538782|24277660|21944681|19000577|14586055|22952169|17872453|26308427|10794783|16860155|24213917|21380992","Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, Adler A, Vera Garcia C, Rohde S, Say L, Lawn JE. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012 Jun 9;379(9832):2162-72. doi: 10.1016/S0140-6736(12)60820-4.|Liu L, Oza S, Hogan D, Chu Y, Perin J, Zhu J, Lawn JE, Cousens S, Mathers C, Black RE. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet. 2016 Dec 17;388(10063):3027-3035. doi: 10.1016/S0140-6736(16)31593-8. Epub 2016 Nov 11. Erratum in: Lancet. 2017 May 13;389(10082):1884.|Kumar A, Bhat BV. Epidemiology of respiratory distress of newborns. Indian J Pediatr. 1996 Jan-Feb;63(1):93-8.|van Kaam AH, de Jaegere A, Haitsma JJ, Van Aalderen WM, Kok JH, Lachmann B. Positive pressure ventilation with the open lung concept optimizes gas exchange and reduces ventilator-induced lung injury in newborn piglets. Pediatr Res. 2003 Feb;53(2):245-53.|Peng W, Zhu H, Shi H, Liu E. Volume-targeted ventilation is more suitable than pressure-limited ventilation for preterm infants: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2014 Mar;99(2):F158-65. doi: 10.1136/archdischild-2013-304613. Epub 2013 Nov 25. Review.|DiBlasi RM. Neonatal noninvasive ventilation techniques: do we really need to intubate? Respir Care. 2011 Sep;56(9):1273-94; discussion 1295-7. doi: 10.4187/respcare.01376. Review.|Haczku A. Protective role of the lung collectins surfactant protein A and surfactant protein D in airway inflammation. J Allergy Clin Immunol. 2008 Nov;122(5):861-79; quiz 880-1. doi: 10.1016/j.jaci.2008.10.014.|Eisner MD, Parsons P, Matthay MA, Ware L, Greene K; Acute Respiratory Distress Syndrome Network. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax. 2003 Nov;58(11):983-8.|Reid VL, Webster NR. Role of microparticles in sepsis. Br J Anaesth. 2012 Oct;109(4):503-13. doi: 10.1093/bja/aes321. Epub 2012 Sep 4. Review.|Woodfin A, Voisin MB, Nourshargh S. PECAM-1: a multi-functional molecule in inflammation and vascular biology. Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2514-23. Epub 2007 Sep 13. Review.|Cabrera-Benítez NE, Valladares F, García-Hernández S, Ramos-Nuez Á, Martín-Barrasa JL, Martínez-Saavedra MT, Rodríguez-Gallego C, Muros M, Flores C, Liu M, Slutsky AS, Villar J. Altered Profile of Circulating Endothelial-Derived Microparticles in Ventilator-Induced Lung Injury. Crit Care Med. 2015 Dec;43(12):e551-9. doi: 10.1097/CCM.0000000000001280. Erratum in: Crit Care Med. 2016 Mar;44(3):e180.|Kluckow M, Evans N. Superior vena cava flow in newborn infants: a novel marker of systemic blood flow. Arch Dis Child Fetal Neonatal Ed. 2000 May;82(3):F182-7.|Bancalari E, Claure N. Definitions and diagnostic criteria for bronchopulmonary dysplasia. Semin Perinatol. 2006 Aug;30(4):164-70. Review.|Madurga A, Mizíková I, Ruiz-Camp J, Morty RE. Recent advances in late lung development and the pathogenesis of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2013 Dec;305(12):L893-905. doi: 10.1152/ajplung.00267.2013. Epub 2013 Nov 8. Review.|Castoldi F, Daniele I, Fontana P, Cavigioli F, Lupo E, Lista G. Lung recruitment maneuver during volume guarantee ventilation of preterm infants with acute respiratory distress syndrome. Am J Perinatol. 2011 Aug;28(7):521-8. doi: 10.1055/s-0031-1272970. Epub 2011 Mar 4.","\tBronchopulmonary Dysplasia\tlung recruitment maneuver (LRM) with DrageerVN500\tParallel Assignment\tPrevention\tRandomized\tDevice\tAll\t","The Impact of Lung Recruitment Maneuver in 24-32 Weekers, and the Incidence of Bronchopulmonary Dysplasia","Interventional","Not yet recruiting","N/A",2,110,"hyperplasia|bronchopulmonary dysplasia","NA","NA"]
["NCT04559880","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24047059|21951473|27033428|30885778|30466669|25681402|24090728|31294373|31362007|23477634|28456509|25414987|29215478|30926155","Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, Inamura K, Kim SA, Kuchiba A, Yamauchi M, Imamura Y, Willett WC, Rosner BA, Fuchs CS, Giovannucci E, Ogino S, Chan AT. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013 Sep 19;369(12):1095-105. doi: 10.1056/NEJMoa1301969.|ASGE Standards of Practice Committee, Fisher DA, Maple JT, Ben-Menachem T, Cash BD, Decker GA, Early DS, Evans JA, Fanelli RD, Fukami N, Hwang JH, Jain R, Jue TL, Khan KM, Malpas PM, Sharaf RN, Shergill AK, Dominitz JA. Complications of colonoscopy. Gastrointest Endosc. 2011 Oct;74(4):745-52. doi: 10.1016/j.gie.2011.07.025. Erratum in: Gastrointest Endosc. 2016 Nov;84(5):883.|Albéniz E, Fraile M, Ibáñez B, Alonso-Aguirre P, Martínez-Ares D, Soto S, Gargallo CJ, Ramos Zabala F, Álvarez MA, Rodríguez-Sánchez J, Múgica F, Nogales Ó, Herreros de Tejada A, Redondo E, Pin N, León-Brito H, Pardeiro R, López-Roses L, Rodríguez-Téllez M, Jiménez A, Martínez-Alcalá F, García O, de la Peña J, Ono A, Alberca de Las Parras F, Pellisé M, Rivero L, Saperas E, Pérez-Roldán F, Pueyo Royo A, Eguaras Ros J, Zúñiga Ripa A, Concepción-Martín M, Huelin-Álvarez P, Colán-Hernández J, Cubiella J, Remedios D, Bessa I Caserras X, López-Viedma B, Cobian J, González-Haba M, Santiago J, Martínez-Cara JG, Valdivielso E, Guarner-Argente C; Endoscopic Mucosal Resection Endoscopic Spanish Society Group. A Scoring System to Determine Risk of Delayed Bleeding After Endoscopic Mucosal Resection of Large Colorectal Lesions. Clin Gastroenterol Hepatol. 2016 Aug;14(8):1140-7. doi: 10.1016/j.cgh.2016.03.021. Epub 2016 Mar 24. Erratum in: Clin Gastroenterol Hepatol. 2017 Mar;15(3):469.|Pohl H, Grimm IS, Moyer MT, Hasan MK, Pleskow D, Elmunzer BJ, Khashab MA, Sanaei O, Al-Kawas FH, Gordon SR, Mathew A, Levenick JM, Aslanian HR, Antaki F, von Renteln D, Crockett SD, Rastogi A, Gill JA, Law RJ, Elias PA, Pellise M, Wallace MB, Mackenzie TA, Rex DK. Clip Closure Prevents Bleeding After Endoscopic Resection of Large Colon Polyps in a Randomized Trial. Gastroenterology. 2019 Oct;157(4):977-984.e3. doi: 10.1053/j.gastro.2019.03.019. Epub 2019 Mar 15.|Feagins LA. Colonoscopy, Polypectomy, and the Risk of Bleeding. Med Clin North Am. 2019 Jan;103(1):125-135. doi: 10.1016/j.mcna.2018.08.003. Epub 2018 Nov 1. Review.|Hassan C, Repici A, Sharma P, Correale L, Zullo A, Bretthauer M, Senore C, Spada C, Bellisario C, Bhandari P, Rex DK. Efficacy and safety of endoscopic resection of large colorectal polyps: a systematic review and meta-analysis. Gut. 2016 May;65(5):806-20. doi: 10.1136/gutjnl-2014-308481. Epub 2015 Feb 13. Review.|Burgess NG, Metz AJ, Williams SJ, Singh R, Tam W, Hourigan LF, Zanati SA, Brown GJ, Sonson R, Bourke MJ. Risk factors for intraprocedural and clinically significant delayed bleeding after wide-field endoscopic mucosal resection of large colonic lesions. Clin Gastroenterol Hepatol. 2014 Apr;12(4):651-61.e1-3. doi: 10.1016/j.cgh.2013.09.049. Epub 2013 Oct 1.|Forbes N, Frehlich L, James MT, Hilsden RJ, Kaplan GG, Wilson TA, Lorenzetti DL, Tate DJ, Bourke MJ, Heitman SJ. Routine Prophylactic Endoscopic Clipping Is Not Efficacious in the Prevention of Delayed Post-Polypectomy Bleeding: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Can Assoc Gastroenterol. 2019 Aug;2(3):105-117. doi: 10.1093/jcag/gwy033. Epub 2018 Jul 20.|Albéniz E, Álvarez MA, Espinós JC, Nogales O, Guarner C, Alonso P, Rodríguez-Téllez M, Herreros de Tejada A, Santiago J, Bustamante-Balén M, Rodríguez Sánchez J, Ramos-Zabala F, Valdivielso E, Martínez-Alcalá F, Fraile M, Elosua A, Guerra Veloz MF, Ibáñez Beroiz B, Capdevila F, Enguita-Germán M. Clip Closure After Resection of Large Colorectal Lesions With Substantial Risk of Bleeding. Gastroenterology. 2019 Nov;157(5):1213-1221.e4. doi: 10.1053/j.gastro.2019.07.037. Epub 2019 Jul 27.|Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L, Cook L, Kawahara T, Perel P, Prieto-Merino D, Ramos M, Cairns J, Guerriero C. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013 Mar;17(10):1-79. doi: 10.3310/hta17100.|WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017 May 27;389(10084):2105-2116. doi: 10.1016/S0140-6736(17)30638-4. Epub 2017 Apr 26. Erratum in: Lancet. 2017 May 27;389(10084):2104.|Bennett C, Klingenberg SL, Langholz E, Gluud LL. Tranexamic acid for upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2014 Nov 21;(11):CD006640. doi: 10.1002/14651858.CD006640.pub3. Review.|Smith SR, Murray D, Pockney PG, Bendinelli C, Draganic BD, Carroll R. Tranexamic Acid for Lower GI Hemorrhage: A Randomized Placebo-Controlled Clinical Trial. Dis Colon Rectum. 2018 Jan;61(1):99-106. doi: 10.1097/DCR.0000000000000943.|Grass F, Braafladt S, Alabbad J, Lovely JK, Kelley SR, Mathis KL, Huebner M, Larson DW. The effects of tranexamic acid on blood loss and transfusion rate in colorectal surgery. Am J Surg. 2019 Nov;218(5):876-880. doi: 10.1016/j.amjsurg.2019.03.013. Epub 2019 Mar 15.","\tPolyp, Colorectal\tTranexamic Acid Injection [Cyklokapron]\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","polyps","tranexamic acid","NA"]
["NCT04567147","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27288567|28239408|29731182|26706022","Aizawa E, Tsuji H, Asahara T, Takahashi T, Teraishi T, Yoshida S, Ota M, Koga N, Hattori K, Kunugi H. Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder. J Affect Disord. 2016 Sep 15;202:254-7. doi: 10.1016/j.jad.2016.05.038. Epub 2016 May 24.|Wallace CJK, Milev R. The effects of probiotics on depressive symptoms in humans: a systematic review. Ann Gen Psychiatry. 2017 Feb 20;16:14. doi: 10.1186/s12991-017-0138-2. eCollection 2017. Review. Erratum in: Ann Gen Psychiatry. 2017 Mar 7;16:18.|Kazemi A, Noorbala AA, Azam K, Eskandari MH, Djafarian K. Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: A randomized clinical trial. Clin Nutr. 2019 Apr;38(2):522-528. doi: 10.1016/j.clnu.2018.04.010. Epub 2018 Apr 24.|Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M, Jafari P, Akbari H, Taghizadeh M, Memarzadeh MR, Asemi Z, Esmaillzadeh A. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. Nutrition. 2016 Mar;32(3):315-20. doi: 10.1016/j.nut.2015.09.003. Epub 2015 Sep 28.","\tDepression\tProbiotic|Placebo\tParallel Assignment\tTreatment\tRandomized\tDietary Supplement|Dietary Supplement\tAll\t","Effect of Probiotic on Depression","Interventional","Completed","Phase 1",2,89,"depressive disorder|depression","NA","NA"]
["NCT04575896","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32894697,"Durand CM, Barnaba B, Yu S, Brown DM, Chattergoon MA, Bair N, Naqvi FF, Sulkowski M, Segev DL, Desai NM. Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C-Viremic Donors to Hepatitis C-Negative Recipients: An Open-Label Nonrandomized Study. Ann Intern Med. 2021 Jan;174(1):137-138. doi: 10.7326/M20-1468. Epub 2020 Sep 8.","\tEnd Stage Renal Disease|Hepatitis C\tGlecaprevir/pibrentasvir\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","hepatitis c|hepatitis|kidney failure, chronic|hepatitis a","NA","NA"]
["NCT04589637","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25514304|30925611|27148044|27549203|12670059|20678818|25716889|31846833|30564155|31367408|31640593|32138680|15817019|12952543|20511102|24112089|28890585|31417393|27589518|32082139|30037778|30635850|28403222|21500282|21673136|31042720|23567430|31718564|32293307|12849297|32264881|30717700|29454305","Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. JAMA. 2014 Dec 17;312(23):2551-61. doi: 10.1001/jama.2014.13806. Review.|Qarni T, Salardini A. A Multifactor Approach to Mild Cognitive Impairment. Semin Neurol. 2019 Apr;39(2):179-187. doi: 10.1055/s-0039-1678585. Epub 2019 Mar 29. Review.|Ferreira AR, Dias CC, Fernandes L. Needs in Nursing Homes and Their Relation with Cognitive and Functional Decline, Behavioral and Psychological Symptoms. Front Aging Neurosci. 2016 Apr 21;8:72. doi: 10.3389/fnagi.2016.00072. eCollection 2016.|Björk S, Juthberg C, Lindkvist M, Wimo A, Sandman PO, Winblad B, Edvardsson D. Exploring the prevalence and variance of cognitive impairment, pain, neuropsychiatric symptoms and ADL dependency among persons living in nursing homes; a cross-sectional study. BMC Geriatr. 2016 Aug 22;16:154. doi: 10.1186/s12877-016-0328-9.|Martin MD, Hancock GA, Richardson B, Simmons P, Katona C, Mullan E, Orrell M. An evaluation of needs in elderly continuing-care settings. Int Psychogeriatr. 2002 Dec;14(4):379-88.|Ernsth Bravell M, Westerlind B, Midlöv P, Östgren CJ, Borgquist L, Lannering C, Mölstad S. How to assess frailty and the need for care? Report from the Study of Health and Drugs in the Elderly (SHADES) in community dwellings in Sweden. Arch Gerontol Geriatr. 2011 Jul-Aug;53(1):40-5. doi: 10.1016/j.archger.2010.06.011. Epub 2010 Aug 3.|Gustafsson M, Sandman PO, Karlsson S, Isaksson U, Schneede J, Sjölander M, Lövheim H. Reduction in the use of potentially inappropriate drugs among old people living in geriatric care units between 2007 and 2013. Eur J Clin Pharmacol. 2015 Apr;71(4):507-15. doi: 10.1007/s00228-015-1825-z. Epub 2015 Feb 26.|Zheng L, Li G, Gao D, Wang S, Meng X, Wang C, Yuan H, Chen L. Cognitive frailty as a predictor of dementia among older adults: A systematic review and meta-analysis. Arch Gerontol Geriatr. 2020 Mar - Apr;87:103997. doi: 10.1016/j.archger.2019.103997. Epub 2019 Dec 10. Erratum in: Arch Gerontol Geriatr. 2021 Jan - Feb;92:104250.|Zuckerman H, Pan Z, Park C, Brietzke E, Musial N, Shariq AS, Iacobucci M, Yim SJ, Lui LMW, Rong C, McIntyre RS. Recognition and Treatment of Cognitive Dysfunction in Major Depressive Disorder. Front Psychiatry. 2018 Dec 4;9:655. doi: 10.3389/fpsyt.2018.00655. eCollection 2018. Review.|Christiansen L, Sanmartin Berglund J, Lindberg C, Anderberg P, Skär L. Health-related quality of life and related factors among a sample of older people with cognitive impairment. Nurs Open. 2019 Mar 19;6(3):849-859. doi: 10.1002/nop2.265. eCollection 2019 Jul.|Park EY, Park SM, Kim JH. Psychometric properties of the geriatric quality of life-dementia in older adults with dementia or mild cognitive impairment living in nursing homes. BMC Geriatr. 2019 Oct 22;19(1):281. doi: 10.1186/s12877-019-1307-8.|Villeneuve R, Meillon C, Bergua V, Tabue-Teguo M, Amieva H. Influence of pre-admission factors on quality of life and adaptation in nursing home residents with dementia: the QOL-EHPAD study protocol. BMC Geriatr. 2020 Mar 6;20(1):92. doi: 10.1186/s12877-020-1434-2.|Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. Erratum in: J Am Geriatr Soc. 2019 Sep;67(9):1991.|Sabbah I, Drouby N, Sabbah S, Retel-Rude N, Mercier M. Quality of life in rural and urban populations in Lebanon using SF-36 health survey. Health Qual Life Outcomes. 2003 Aug 6;1:30.|Gobbens RJ, van Assen MA, Luijkx KG, Wijnen-Sponselee MT, Schols JM. The Tilburg Frailty Indicator: psychometric properties. J Am Med Dir Assoc. 2010 Jun;11(5):344-55. doi: 10.1016/j.jamda.2009.11.003. Epub 2010 May 8.|Bani-Issa W, Almomani F, Eldeirawi K. Urinary incontinence among adult women with diabetes in Jordan: epidemiology, correlates and perceived impact on emotional and social well-being. J Clin Nurs. 2014 Sep;23(17-18):2451-60. doi: 10.1111/jocn.12392. Epub 2013 Sep 21.|Hussein S, Ismail M. Ageing and Elderly Care in the Arab Region: Policy Challenges and Opportunities. Ageing Int. 2017;42(3):274-289. doi: 10.1007/s12126-016-9244-8. Epub 2016 Apr 6.|Li W, Sun L, Li G, Xiao S. Prevalence, Influence Factors and Cognitive Characteristics of Mild Cognitive Impairment in Type 2 Diabetes Mellitus. Front Aging Neurosci. 2019 Jul 30;11:180. doi: 10.3389/fnagi.2019.00180. eCollection 2019.|Makizako H, Shimada H, Doi T, Tsutsumimoto K, Hotta R, Nakakubo S, Makino K, Suzuki T. Comorbid Mild Cognitive Impairment and Depressive Symptoms Predict Future Dementia in Community Older Adults: A 24-Month Follow-Up Longitudinal Study. J Alzheimers Dis. 2016 Oct 18;54(4):1473-1482.|Ma L. Depression, Anxiety, and Apathy in Mild Cognitive Impairment: Current Perspectives. Front Aging Neurosci. 2020 Jan 30;12:9. doi: 10.3389/fnagi.2020.00009. eCollection 2020. Review.|Devanand DP, Pelton GH, D'Antonio K, Ciarleglio A, Scodes J, Andrews H, Lunsford J, Beyer JL, Petrella JR, Sneed J, Ciovacco M, Doraiswamy PM. Donepezil Treatment in Patients With Depression and Cognitive Impairment on Stable Antidepressant Treatment: A Randomized Controlled Trial. Am J Geriatr Psychiatry. 2018 Oct;26(10):1050-1060. doi: 10.1016/j.jagp.2018.05.008. Epub 2018 Jun 28.|Liu HY, Tsai WC, Chiu MJ, Tang LY, Lee HJ, Shyu YL. Mild cognitive impairment in combination with comorbid diabetes mellitus and hypertension is negatively associated with health-related quality of life among older persons in Taiwan. Qual Life Res. 2019 May;28(5):1281-1291. doi: 10.1007/s11136-019-02101-3. Epub 2019 Jan 11.|Chen TB, Yiao SY, Sun Y, Lee HJ, Yang SC, Chiu MJ, Chen TF, Lin KN, Tang LY, Lin CC, Wang PN. Comorbidity and dementia: A nationwide survey in Taiwan. PLoS One. 2017 Apr 12;12(4):e0175475. doi: 10.1371/journal.pone.0175475. eCollection 2017.|Solomon A, Dobranici L, Kåreholt I, Tudose C, Lăzărescu M. Comorbidity and the rate of cognitive decline in patients with Alzheimer dementia. Int J Geriatr Psychiatry. 2011 Dec;26(12):1244-51. doi: 10.1002/gps.2670. Epub 2011 Apr 16.|Stephan BC, Brayne C, Savva GM, Matthews FE; Medical Research Council Cognitive Function and Ageing Study. Occurrence of medical co-morbidity in mild cognitive impairment: implications for generalisation of MCI research. Age Ageing. 2011 Jul;40(4):501-7. doi: 10.1093/ageing/afr057.|Jacob L, Haro JM, Koyanagi A. Relationship between living alone and common mental disorders in the 1993, 2000 and 2007 National Psychiatric Morbidity Surveys. PLoS One. 2019 May 1;14(5):e0215182. doi: 10.1371/journal.pone.0215182. eCollection 2019.|Mathews SB, Arnold SE, Epperson CN. Hospitalization and cognitive decline: Can the nature of the relationship be deciphered? Am J Geriatr Psychiatry. 2014 May;22(5):465-80. doi: 10.1016/j.jagp.2012.08.012. Epub 2013 Feb 6. Review.|Qin T, Yan M, Fu Z, Song Y, Lu W, Fu A, Yin P. Association between anemia and cognitive decline among Chinese middle-aged and elderly: evidence from the China health and retirement longitudinal study. BMC Geriatr. 2019 Nov 12;19(1):305. doi: 10.1186/s12877-019-1308-7.|Li M, Huang Y, Liu Z, Shen R, Chen H, Ma C, Zhang T, Li S, Prince M. The association between frailty and incidence of dementia in Beijing: findings from 10/66 dementia research group population-based cohort study. BMC Geriatr. 2020 Apr 15;20(1):138. doi: 10.1186/s12877-020-01539-2.|DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol. 2003 Jan;2(1):15-21. Review.|Karrer M, Hirt J, Zeller A, Saxer S. What hinders and facilitates the implementation of nurse-led interventions in dementia care? A scoping review. BMC Geriatr. 2020 Apr 7;20(1):127. doi: 10.1186/s12877-020-01520-z. Review.|Goossens B, Sevenants A, Declercq A, Van Audenhove C. 'We DECide optimized' - training nursing home staff in shared decision-making skills for advance care planning conversations in dementia care: protocol of a pretest-posttest cluster randomized trial. BMC Geriatr. 2019 Feb 4;19(1):33. doi: 10.1186/s12877-019-1044-z.|Zahirovic I, Torisson G, Wattmo C, Londos E. Psychotropic and anti-dementia treatment in elderly persons with clinical signs of dementia with Lewy bodies: a cross-sectional study in 40 nursing homes in Sweden. BMC Geriatr. 2018 Feb 17;18(1):50. doi: 10.1186/s12877-018-0740-4.","\tDementia\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","dementia|cognitive dysfunction","NA","NA"]
["NCT04597346","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","8617067|10767238|23586738|24797257|25275338|25746631|27007334","Chechani V. Bronchoscopic diagnosis of solitary pulmonary nodules and lung masses in the absence of endobronchial abnormality. Chest. 1996 Mar;109(3):620-5.|Baaklini WA, Reinoso MA, Gorin AB, Sharafkaneh A, Manian P. Diagnostic yield of fiberoptic bronchoscopy in evaluating solitary pulmonary nodules. Chest. 2000 Apr;117(4):1049-54.|Tamiya M, Okamoto N, Sasada S, Shiroyama T, Morishita N, Suzuki H, Yoshida E, Hirashima T, Kawahara K, Kawase I. Diagnostic yield of combined bronchoscopy and endobronchial ultrasonography, under LungPoint guidance for small peripheral pulmonary lesions. Respirology. 2013 Jul;18(5):834-9. doi: 10.1111/resp.12095.|Gilbert C, Akulian J, Ortiz R, Lee H, Yarmus L. Novel bronchoscopic strategies for the diagnosis of peripheral lung lesions: present techniques and future directions. Respirology. 2014 Jul;19(5):636-44. doi: 10.1111/resp.12301. Epub 2014 May 6. Review.|Sterman DH, Keast T, Rai L, Gibbs J, Wibowo H, Draper J, Herth FJ, Silvestri GA. High yield of bronchoscopic transparenchymal nodule access real-time image-guided sampling in a novel model of small pulmonary nodules in canines. Chest. 2015 Mar;147(3):700-707. doi: 10.1378/chest.14-0724.|Herth FJ, Eberhardt R, Sterman D, Silvestri GA, Hoffmann H, Shah PL. Bronchoscopic transparenchymal nodule access (BTPNA): first in human trial of a novel procedure for sampling solitary pulmonary nodules. Thorax. 2015 Apr;70(4):326-32. doi: 10.1136/thoraxjnl-2014-206211. Epub 2015 Mar 6.|Harzheim D, Sterman D, Shah PL, Eberhardt R, Herth FJ. Bronchoscopic Transparenchymal Nodule Access: Feasibility and Safety in an Endoscopic Unit. Respiration. 2016;91(4):302-6. doi: 10.1159/000445032. Epub 2016 Mar 24.","\tPeripheral Pulmonary Lesion\tBronchoscopic Transparenchymal Nodule Access\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04605536","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26671584,"Argüelles-Arias F, Donat E, Fernández-Urien I, Alberca F, Argüelles-Martín F, Martínez MJ, Molina M, Varea V, Herrerías-Gutiérrez JM, Ribes-Koninckx C. Guideline for wireless capsule endoscopy in children and adolescents: A consensus document by the SEGHNP (Spanish Society for Pediatric Gastroenterology, Hepatology, and Nutrition) and the SEPD (Spanish Society for Digestive Diseases). Rev Esp Enferm Dig. 2015 Dec;107(12):714-31.","\tCapsule Endoscopy\tanimation videos|explanation about endoscopy endoscopy\tParallel Assignment\tSupportive Care\tRandomized\tOther|Other\tAll\t","Effect of Animation Video on the Success Rate of Children Swallowing Capsule Endoscopy","Interventional","Recruiting","N/A",2,232,"NA","NA","NA"]
["NCT04610567","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32122636|32007143|32653469|32211963|8961899","Shah A, Kashyap R, Tosh P, Sampathkumar P, O'Horo JC. Guide to Understanding the 2019 Novel Coronavirus. Mayo Clin Proc. 2020 Apr;95(4):646-652. doi: 10.1016/j.mayocp.2020.02.003. Epub 2020 Feb 28.|Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.|Mitchell WB. Thromboinflammation in COVID-19 acute lung injury. Paediatr Respir Rev. 2020 Sep;35:20-24. doi: 10.1016/j.prrv.2020.06.004. Epub 2020 Jun 11. Review.|Zhou Z, Guo D, Li C, Fang Z, Chen L, Yang R, Li X, Zeng W. Coronavirus disease 2019: initial chest CT findings. Eur Radiol. 2020 Aug;30(8):4398-4406. doi: 10.1007/s00330-020-06816-7. Epub 2020 Mar 24.|Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum. 1996 Dec;39(12):1951-60. Review.","\tCoronavirus|Covid19|Inflammation\tMethotrexate-LDE phase 1|Methotrexate-LDE phase 2|Placebo-LDE phase 2\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19)","Interventional","Recruiting","Phase 1/Phase 2",3,100,"coronavirus infections|inflammation","methotrexate","NA"]
["NCT04617223","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21605125|25631304|28972988","Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska J, Bockelbrink A, Bousquet PJ, Brozek G, Bruno A, Dahlén SE, Forsberg B, Gunnbjörnsdóttir M, Kasper L, Krämer U, Kowalski ML, Lange B, Lundbäck B, Salagean E, Todo-Bom A, Tomassen P, Toskala E, van Drunen CM, Bousquet J, Zuberbier T, Jarvis D, Burney P. Chronic rhinosinusitis in Europe--an underestimated disease. A GA²LEN study. Allergy. 2011 Sep;66(9):1216-23. doi: 10.1111/j.1398-9995.2011.02646.x. Epub 2011 May 24.|Shi JB, Fu QL, Zhang H, Cheng L, Wang YJ, Zhu DD, Lv W, Liu SX, Li PZ, Ou CQ, Xu G. Epidemiology of chronic rhinosinusitis: results from a cross-sectional survey in seven Chinese cities. Allergy. 2015 May;70(5):533-9. doi: 10.1111/all.12577. Epub 2015 Mar 4.|Chang YS, Chen PL, Hung JH, Chen HY, Lai CC, Ou CY, Chang CM, Wang CK, Cheng HC, Tseng SH. Orbital complications of paranasal sinusitis in Taiwan, 1988 through 2015: Acute ophthalmological manifestations, diagnosis, and management. PLoS One. 2017 Oct 3;12(10):e0184477. doi: 10.1371/journal.pone.0184477. eCollection 2017.","\tChronic Sinusitis\tEndoscopic sinus evacuation\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","sinusitis","NA","NA"]
["NCT04625400","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23993823|19084420|17695689|8521696|8365273|17883582|16949978|4939117|7877309|3398673|12755310|15450579|20689914|1545649|4942973","Puchalski J, Musani AI. Tracheobronchial stenosis: causes and advances in management. Clin Chest Med. 2013 Sep;34(3):557-67. doi: 10.1016/j.ccm.2013.05.002. Epub 2013 Jul 3. Review.|Galluccio G, Lucantoni G, Battistoni P, Paone G, Batzella S, Lucifora V, Dello Iacono R. Interventional endoscopy in the management of benign tracheal stenoses: definitive treatment at long-term follow-up. Eur J Cardiothorac Surg. 2009 Mar;35(3):429-33; discussion 933-4. doi: 10.1016/j.ejcts.2008.10.041. Epub 2008 Dec 11.|Cavaliere S, Bezzi M, Toninelli C, Foccoli P. Management of post-intubation tracheal stenoses using the endoscopic approach. Monaldi Arch Chest Dis. 2007 Jun;67(2):73-80.|Mehta AC, Harris RJ, De Boer GE. Endoscopic management of benign airway stenosis. Clin Chest Med. 1995 Sep;16(3):401-13. Review.|Mehta AC, Lee FY, Cordasco EM, Kirby T, Eliachar I, De Boer G. Concentric tracheal and subglottic stenosis. Management using the Nd-YAG laser for mucosal sparing followed by gentle dilatation. Chest. 1993 Sep;104(3):673-7.|Nouraei SA, Ma E, Patel A, Howard DJ, Sandhu GS. Estimating the population incidence of adult post-intubation laryngotracheal stenosis. Clin Otolaryngol. 2007 Oct;32(5):411-2.|Poetker DM, Ettema SL, Blumin JH, Toohill RJ, Merati AL. Association of airway abnormalities and risk factors in 37 subglottic stenosis patients. Otolaryngol Head Neck Surg. 2006 Sep;135(3):434-7.|Pearson FG, Andrews MJ. Detection and management of tracheal stenosis following cuffed tube tracheostomy. Ann Thorac Surg. 1971 Oct;12(4):359-74.|Grillo HC, Donahue DM, Mathisen DJ, Wain JC, Wright CD. Postintubation tracheal stenosis. Treatment and results. J Thorac Cardiovasc Surg. 1995 Mar;109(3):486-92; discussion 492-3.|Weymuller EA Jr. Laryngeal injury from prolonged endotracheal intubation. Laryngoscope. 1988 Aug;98(8 Pt 2 Suppl 45):1-15.|Wain JC. Postintubation tracheal stenosis. Chest Surg Clin N Am. 2003 May;13(2):231-46. Review.|Ciccone AM, De Giacomo T, Venuta F, Ibrahim M, Diso D, Coloni GF, Rendina EA. Operative and non-operative treatment of benign subglottic laryngotracheal stenosis. Eur J Cardiothorac Surg. 2004 Oct;26(4):818-22.|Estella A. Bronchoalveolar lavage for pandemic influenza A (H1N1)v pneumonia in critically ill patients. Intensive Care Med. 2010 Nov;36(11):1976-7. doi: 10.1007/s00134-010-2009-z. Epub 2010 Aug 6.|Anand VK, Alemar G, Warren ET. Surgical considerations in tracheal stenosis. Laryngoscope. 1992 Mar;102(3):237-43.|Grillo HC, Cooper JD, Geffin B, Pontoppidan H. A low-pressure cuff for tracheostomy tubes to minimize tracheal injury. A comparative clinical trial. J Thorac Cardiovasc Surg. 1971 Dec;62(6):898-907.","\tTracheal Stenosis\tbronchoscope\tNA\tNA\tNA\tDiagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","tracheal stenosis|constriction, pathologic","NA","NA"]
["NCT04632277","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26798400,"Murakami S, Goto Y, Ito K, Hayasaka S, Kurihara S, Soga T, Tomita M, Fukuda S. The Consumption of Bicarbonate-Rich Mineral Water Improves Glycemic Control. Evid Based Complement Alternat Med. 2015;2015:824395. doi: 10.1155/2015/824395. Epub 2015 Dec 21.","\tDiabetes Mellitus|Glucose, High Blood|Patients\tWater|Water with low Mg|Water with high Mg\tParallel Assignment\tPrevention\tRandomized\tOther|Dietary Supplement|Dietary Supplement\tAll\t","Is Mg do Improve the Glycemic Control in Patients Drink a Desalinate Water","Interventional","Recruiting","N/A",3,900,"diabetes mellitus|hyperglycemia","NA","NA"]
["NCT04639921","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26096570|26097727|22825366|24252792|24740495|29102613|11775787|25756293","Catassi C, Elli L, Bonaz B, Bouma G, Carroccio A, Castillejo G, Cellier C, Cristofori F, de Magistris L, Dolinsek J, Dieterich W, Francavilla R, Hadjivassiliou M, Holtmeier W, Körner U, Leffler DA, Lundin KE, Mazzarella G, Mulder CJ, Pellegrini N, Rostami K, Sanders D, Skodje GI, Schuppan D, Ullrich R, Volta U, Williams M, Zevallos VF, Zopf Y, Fasano A. Diagnosis of Non-Celiac Gluten Sensitivity (NCGS): The Salerno Experts' Criteria. Nutrients. 2015 Jun 18;7(6):4966-77. doi: 10.3390/nu7064966.|Husby S, Murray J. Non-celiac gluten hypersensitivity: What is all the fuss about? F1000Prime Rep. 2015 May 12;7:54. doi: 10.12703/P7-54. eCollection 2015. Review.|Carroccio A, Mansueto P, Iacono G, Soresi M, D'Alcamo A, Cavataio F, Brusca I, Florena AM, Ambrosiano G, Seidita A, Pirrone G, Rini GB. Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity. Am J Gastroenterol. 2012 Dec;107(12):1898-906; quiz 1907. doi: 10.1038/ajg.2012.236. Epub 2012 Jul 24.|Francavilla R, Cristofori F, Castellaneta S, Polloni C, Albano V, Dellatte S, Indrio F, Cavallo L, Catassi C. Clinical, serologic, and histologic features of gluten sensitivity in children. J Pediatr. 2014 Mar;164(3):463-7.e1. doi: 10.1016/j.jpeds.2013.10.007. Epub 2013 Nov 16.|Biesiekierski JR, Newnham ED, Shepherd SJ, Muir JG, Gibson PR. Characterization of Adults With a Self-Diagnosis of Nonceliac Gluten Sensitivity. Nutr Clin Pract. 2014 Aug;29(4):504-509. Epub 2014 Apr 16.|Skodje GI, Sarna VK, Minelle IH, Rolfsen KL, Muir JG, Gibson PR, Veierød MB, Henriksen C, Lundin KEA. Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported Non-Celiac Gluten Sensitivity. Gastroenterology. 2018 Feb;154(3):529-539.e2. doi: 10.1053/j.gastro.2017.10.040. Epub 2017 Nov 2.|Olsen J, Melbye M, Olsen SF, Sørensen TI, Aaby P, Andersen AM, Taxbøl D, Hansen KD, Juhl M, Schow TB, Sørensen HT, Andresen J, Mortensen EL, Olesen AW, Søndergaard C. The Danish National Birth Cohort--its background, structure and aim. Scand J Public Health. 2001 Dec;29(4):300-7.|Kyhl HB, Jensen TK, Barington T, Buhl S, Norberg LA, Jørgensen JS, Jensen DF, Christesen HT, Lamont RF, Husby S. The Odense Child Cohort: aims, design, and cohort profile. Paediatr Perinat Epidemiol. 2015 May;29(3):250-8. doi: 10.1111/ppe.12183. Epub 2015 Mar 10.","\tNon-celiac Gluten Sensitivity; Adolescents\tpositive test followed by gluten-free diet|Placebo\tCrossover Assignment\tDiagnostic\tRandomized\tDiagnostic Test|Dietary Supplement\tAll\t","Non Celiac Gluten Sensitivity, DBPCFC in Adolescents","Interventional","Enrolling by invitation","N/A",2,33,"hypersensitivity","NA","NA"]
["NCT04659915","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28604169|19299006|25815990|18253159|25390020|28554927|18349741","GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, Marczak L, Mokdad AH, Moradi-Lakeh M, Naghavi M, Salama JS, Vos T, Abate KH, Abbafati C, Ahmed MB, Al-Aly Z, Alkerwi A, Al-Raddadi R, Amare AT, Amberbir A, Amegah AK, Amini E, Amrock SM, Anjana RM, Ärnlöv J, Asayesh H, Banerjee A, Barac A, Baye E, Bennett DA, Beyene AS, Biadgilign S, Biryukov S, Bjertness E, Boneya DJ, Campos-Nonato I, Carrero JJ, Cecilio P, Cercy K, Ciobanu LG, Cornaby L, Damtew SA, Dandona L, Dandona R, Dharmaratne SD, Duncan BB, Eshrati B, Esteghamati A, Feigin VL, Fernandes JC, Fürst T, Gebrehiwot TT, Gold A, Gona PN, Goto A, Habtewold TD, Hadush KT, Hafezi-Nejad N, Hay SI, Horino M, Islami F, Kamal R, Kasaeian A, Katikireddi SV, Kengne AP, Kesavachandran CN, Khader YS, Khang YH, Khubchandani J, Kim D, Kim YJ, Kinfu Y, Kosen S, Ku T, Defo BK, Kumar GA, Larson HJ, Leinsalu M, Liang X, Lim SS, Liu P, Lopez AD, Lozano R, Majeed A, Malekzadeh R, Malta DC, Mazidi M, McAlinden C, McGarvey ST, Mengistu DT, Mensah GA, Mensink GBM, Mezgebe HB, Mirrakhimov EM, Mueller UO, Noubiap JJ, Obermeyer CM, Ogbo FA, Owolabi MO, Patton GC, Pourmalek F, Qorbani M, Rafay A, Rai RK, Ranabhat CL, Reinig N, Safiri S, Salomon JA, Sanabria JR, Santos IS, Sartorius B, Sawhney M, Schmidhuber J, Schutte AE, Schmidt MI, Sepanlou SG, Shamsizadeh M, Sheikhbahaei S, Shin MJ, Shiri R, Shiue I, Roba HS, Silva DAS, Silverberg JI, Singh JA, Stranges S, Swaminathan S, Tabarés-Seisdedos R, Tadese F, Tedla BA, Tegegne BS, Terkawi AS, Thakur JS, Tonelli M, Topor-Madry R, Tyrovolas S, Ukwaja KN, Uthman OA, Vaezghasemi M, Vasankari T, Vlassov VV, Vollset SE, Weiderpass E, Werdecker A, Wesana J, Westerman R, Yano Y, Yonemoto N, Yonga G, Zaidi Z, Zenebe ZM, Zipkin B, Murray CJL. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017 Jul 6;377(1):13-27. doi: 10.1056/NEJMoa1614362. Epub 2017 Jun 12.|Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009 Mar 28;373(9669):1083-96. doi: 10.1016/S0140-6736(09)60318-4. Epub 2009 Mar 18.|van der Klaauw AA, Farooqi IS. The hunger genes: pathways to obesity. Cell. 2015 Mar 26;161(1):119-132. doi: 10.1016/j.cell.2015.03.008. Review.|Vgontzas AN, Lin HM, Papaliaga M, Calhoun S, Vela-Bueno A, Chrousos GP, Bixler EO. Short sleep duration and obesity: the role of emotional stress and sleep disturbances. Int J Obes (Lond). 2008 May;32(5):801-9. doi: 10.1038/ijo.2008.4. Epub 2008 Feb 5.|de Guia RM, Rose AJ, Herzig S. Glucocorticoid hormones and energy homeostasis. Horm Mol Biol Clin Investig. 2014 Aug;19(2):117-28. doi: 10.1515/hmbci-2014-0021. Review.|Laugesen K, Jørgensen JOL, Sørensen HT, Petersen I. Systemic glucocorticoid use in Denmark: a population-based prevalence study. BMJ Open. 2017 May 29;7(5):e015237. doi: 10.1136/bmjopen-2016-015237.|McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol. 2008 Mar;20(2):131-7. doi: 10.1097/BOR.0b013e3282f51031. Review.","\tGlucocorticoid Effect\tMetformin 500 mg Oral Tablets + Prednisone 20mg Tablets|Placebo 500 mg Tablets + Prednisone 20mg Tablets\tCrossover Assignment\tPrevention\tRandomized\tDrug|Drug\tMale\t","Counteracting Deleterious Metabolic Glucocorticoid Effects With Metformin","Interventional","Recruiting","Phase 4",2,18,"NA","metformin|prednisone","NA"]
["NCT04681391","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30809675|23122848","Gaesser B, Hirschfeld-Kroen J, Wasserman EA, Horn M, Young L. A role for the medial temporal lobe subsystem in guiding prosociality: the effect of episodic processes on willingness to help others. Soc Cogn Affect Neurosci. 2019 May 17;14(4):397-410. doi: 10.1093/scan/nsz014.|Santiesteban I, Banissy MJ, Catmur C, Bird G. Enhancing social ability by stimulating right temporoparietal junction. Curr Biol. 2012 Dec 4;22(23):2274-7. doi: 10.1016/j.cub.2012.10.018. Epub 2012 Nov 1.","\tMorality\ttransCranial direct current stimulation\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04684290","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",3160067,"Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, Williams WG. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis. 1985 Jul-Aug;28(1):1-83. Review.","The aim of this randomized trial is to compare the improvement in exercise capacity among patients with highly symptomatic hypertrophic obstructive cardiomyopathy despite optimal medical treatment who undergo alcohol septal ablation (ASA) or surgical septal myectomy (SSM).","Hypertrophic Cardiomyopathy","Alcohol Septal Ablation|Surgical Septal Myectomy","Parallel Assignment","Treatment","Randomized","Procedure|Procedure","All","Inclusion Criteria:\tSurgical Septal Myectomy vs Percutaneous Transluminal Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy\tInterventional\tNot yet recruiting\tNot Applicable\t2\t100\tcardiomyopathy, hypertrophic|cardiomyopathies|hypertrophy\tNA\tNA\nNCT04684953\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t30594401\tKatna R, Kalyani N, Deshpande A; Mumbai Oncology Group - Head and Neck. Free thyroid transfer to anterolateral thigh for prevention of radiation induced hypothyroidism: An initial experience. Am J Otolaryngol. 2019 Mar - Apr;40(2):160-163. doi: 10.1016/j.amjoto.2018.12.013. Epub 2018 Dec 21.\t","Thyroid","Throid autotransplantation|Hormone","Parallel Assignment","Treatment","Randomized","Procedure|Drug","All","\tThyroid Autotransplantation in Quadriceps Femoris Muscle\tInterventional\tNot yet recruiting\tN/A\t2\t40\tthyroid diseases\thormones\tNA\nNCT04685018\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t28457484|23740049|21490964|23510580\tVervliet B, Lange I, Milad MR. Temporal dynamics of relief in avoidance conditioning and fear extinction: Experimental validation and clinical relevance. Behav Res Ther. 2017 Sep;96:66-78. doi: 10.1016/j.brat.2017.04.011. Epub 2017 Apr 23.|Milad MR, Furtak SC, Greenberg JL, Keshaviah A, Im JJ, Falkenstein MJ, Jenike M, Rauch SL, Wilhelm S. Deficits in conditioned fear extinction in obsessive-compulsive disorder and neurobiological changes in the fear circuit. JAMA Psychiatry. 2013 Jun;70(6):608-18; quiz 554. doi: 10.1001/jamapsychiatry.2013.914.|Leknes S, Lee M, Berna C, Andersson J, Tracey I. Relief as a reward: hedonic and neural responses to safety from pain. PLoS One. 2011 Apr 7;6(4):e17870. doi: 10.1371/journal.pone.0017870.|Gillan CM, Morein-Zamir S, Urcelay GP, Sule A, Voon V, Apergis-Schoute AM, Fineberg NA, Sahakian BJ, Robbins TW. Enhanced avoidance habits in obsessive-compulsive disorder. Biol Psychiatry. 2014 Apr 15;75(8):631-8. doi: 10.1016/j.biopsych.2013.02.002. Epub 2013 Mar 16.\t","Obsessive-Compulsive Disorder","fMRI acquisition","NA","NA","NA","Device","All","\tNA\tNA\tNA\tNA\tNA\tNA\tcompulsive personality disorder|disease|obsessive-compulsive disorder\tNA\tNA\nNCT04686812\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t25678459|NA\tGarcia-Rojas IJ, Choi B, Krause N. Psychosocial job factors and biological cardiovascular risk factors in Mexican workers. Am J Ind Med. 2015 Mar;58(3):331-51. doi: 10.1002/ajim.22410.|Garcia Rojas, I. J. (2014). Associations of job strain, isostrain, and job insecurity with cardiovascular risk factors and productivity in Mexican workers. UCLA. ProQuest ID: GarciaRojas_ucla_0031D_10853. Merritt ID: ark:/13030/m5322105. Retrieved from https://escholarship.org/uc/item/2qd9m61x\t","Cardiovascular Risk Factors","Worksite health promotion program","NA","NA","NA","Behavioral","All","\tWorksite Health Promotion Intervention to Promote Healthy Habits Among Workers From Mexican Companies\tInterventional\tCompleted\tN/A\t2\t2002\tNA\tNA\tNA\nNCT04687657\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t26376137|31429724|28280089|23673863|24488563|26779484\tDöhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015 Sep 17;373(12):1136-52. doi: 10.1056/NEJMra1406184. Review.|Li X, Dong Y, Li Y, Ren R, Wu W, Zhu H, Zhang Y, Hu J, Li J. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study. BMC Cancer. 2019 Aug 20;19(1):819. doi: 10.1186/s12885-019-5975-8.|Dolstra H, Roeven MWH, Spanholtz J, Hangalapura BN, Tordoir M, Maas F, Leenders M, Bohme F, Kok N, Trilsbeek C, Paardekooper J, van der Waart AB, Westerweel PE, Snijders TJF, Cornelissen J, Bos G, Pruijt HFM, de Graaf AO, van der Reijden BA, Jansen JH, van der Meer A, Huls G, Cany J, Preijers F, Blijlevens NMA, Schaap NM. Successful Transfer of Umbilical Cord Blood CD34(+) Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients. Clin Cancer Res. 2017 Aug 1;23(15):4107-4118. doi: 10.1158/1078-0432.CCR-16-2981. Epub 2017 Mar 9.|Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013 Jul 25;122(4):491-8. doi: 10.1182/blood-2013-02-453175. Epub 2013 May 14. Review.|Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R, Pavlu J, Brisley G, de Lavallade H, Sarvaria A, Marin D, Mielke S, Apperley JF, Shpall EJ, Barrett AJ, Rezvani K. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica. 2014 May;99(5):836-47. doi: 10.3324/haematol.2013.087536. Epub 2014 Jan 31.|Mehta RS, Shpall EJ, Rezvani K. Cord Blood as a Source of Natural Killer Cells. Front Med (Lausanne). 2016 Jan 5;2:93. doi: 10.3389/fmed.2015.00093. eCollection 2015. Review.\t","Leukemia, Myelomonocytic, Acute","umbilical cord blood","NA","NA","NA","Drug","All","\tNA\tNA\tNA\tNA\tNA\tNA\tleukemia|leukemia, myelomonocytic, acute|leukemia, myeloid, acute\tNA\tNA\nNCT04687735\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t3708230|25793166|17673588|9246090|24306579|3575423|20110457|16724200|29619123|13585158|25714415|29548325|24664198|29218231|22405512|25107826|20798446|25623916|16717171\tPal B, Anderson J, Dick WC, Griffiths ID. Limitation of joint mobility and shoulder capsulitis in insulin- and non-insulin-dependent diabetes mellitus. Br J Rheumatol. 1986 May;25(2):147-51.|Uppal HS, Evans JP, Smith C. Frozen shoulder: A systematic review of therapeutic options. World J Orthop. 2015 Mar 18;6(2):263-8. doi: 10.5312/wjo.v6.i2.263. eCollection 2015 Mar 18. Review.|Hand GC, Athanasou NA, Matthews T, Carr AJ. The pathology of frozen shoulder. J Bone Joint Surg Br. 2007 Jul;89(7):928-32.|Rodeo SA, Hannafin JA, Tom J, Warren RF, Wickiewicz TL. Immunolocalization of cytokines and their receptors in adhesive capsulitis of the shoulder. J Orthop Res. 1997 May;15(3):427-36.|Tamai K, Akutsu M, Yano Y. Primary frozen shoulder: brief review of pathology and imaging abnormalities. J Orthop Sci. 2014 Jan;19(1):1-5. doi: 10.1007/s00776-013-0495-x. Epub 2013 Dec 4. Review.|Riddle DL, Rothstein JM, Lamb RL. Goniometric reliability in a clinical setting. Shoulder measurements. Phys Ther. 1987 May;67(5):668-73.|Neviaser AS, Hannafin JA. Adhesive capsulitis: a review of current treatment. Am J Sports Med. 2010 Nov;38(11):2346-56. doi: 10.1177/0363546509348048. Epub 2010 Jan 28. Review.|Homsi C, Bordalo-Rodrigues M, da Silva JJ, Stump XM. Ultrasound in adhesive capsulitis of the shoulder: is assessment of the coracohumeral ligament a valuable diagnostic tool? Skeletal Radiol. 2006 Sep;35(9):673-8. Epub 2006 May 25.|Ando A, Hamada J, Hagiwara Y, Sekiguchi T, Koide M, Itoi E. Short-term Clinical Results of Manipulation Under Ultrasound-Guided Brachial Plexus Block in Patients with Idiopathic Frozen Shoulder and Diabetic Secondary Frozen Shoulder. Open Orthop J. 2018 Mar 16;12:99-104. doi: 10.2174/1874325001812010099. eCollection 2018.|YAMSHON LJ. Frozen shoulder: methods for bringing about early mobilization. Calif Med. 1958 Nov;89(5):333-4.|Hsu WC, Wang TL, Lin YJ, Hsieh LF, Tsai CM, Huang KH. Addition of lidocaine injection immediately before physiotherapy for frozen shoulder: a randomized controlled trial. PLoS One. 2015 Feb 25;10(2):e0118217. doi: 10.1371/journal.pone.0118217. eCollection 2015. Erratum in: PLoS One. 2015;10(4):e0125289.|Kanbe K. Clinical outcome of arthroscopic capsular release for frozen shoulder: essential technical points in 255 patients. J Orthop Surg Res. 2018 Mar 16;13(1):56. doi: 10.1186/s13018-018-0758-5.|Paul A, Rajkumar JS, Peter S, Lambert L. Effectiveness of sustained stretching of the inferior capsule in the management of a frozen shoulder. Clin Orthop Relat Res. 2014 Jul;472(7):2262-8. doi: 10.1007/s11999-014-3581-2. Epub 2014 Mar 25.|Rymaruk S, Peach C. Indications for hydrodilatation for frozen shoulder. EFORT Open Rev. 2017 Nov 22;2(11):462-468. doi: 10.1302/2058-5241.2.160061. eCollection 2017 Nov.|Maund E, Craig D, Suekarran S, Neilson A, Wright K, Brealey S, Dennis L, Goodchild L, Hanchard N, Rangan A, Richardson G, Robertson J, McDaid C. Management of frozen shoulder: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2012;16(11):1-264. doi: 10.3310/hta16110. Review.|Lewis J. Frozen shoulder contracture syndrome - Aetiology, diagnosis and management. Man Ther. 2015 Feb;20(1):2-9. doi: 10.1016/j.math.2014.07.006. Epub 2014 Jul 18. Review.|Rookmoneea M, Dennis L, Brealey S, Rangan A, White B, McDaid C, Harden M. The effectiveness of interventions in the management of patients with primary frozen shoulder. J Bone Joint Surg Br. 2010 Sep;92(9):1267-72. doi: 10.1302/0301-620X.92B9.24282. Review.|Vastamäki H, Varjonen L, Vastamäki M. Optimal time for manipulation of frozen shoulder may be between 6 and 9 months. Scand J Surg. 2015 Dec;104(4):260-6. doi: 10.1177/1457496914566637. Epub 2015 Jan 26.|Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7.\t","Frozen Shoulder","Intervention after nerve block","NA","NA","NA","Other","All","\tNA\tNA\tNA\tNA\tNA\tNA\tbursitis\tNA\tNA\nNCT04688359\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t26972954\tSeidu S, Walker NS, Bodicoat DH, Davies MJ, Khunti K. A systematic review of interventions targeting primary care or community based professionals on cardio-metabolic risk factor control in people with diabetes. Diabetes Res Clin Pract. 2016 Mar;113:1-13. doi: 10.1016/j.diabres.2016.01.022. Epub 2016 Jan 21. Review.\t","Cardiovascular Risk Factor|Pre-diabetes|Primary Health Care|T2DM (Type 2 Diabetes Mellitus)","Guided Self Determination","Parallel Assignment","Prevention","Randomized","Behavioral","All","\tEffectiveness of Nurse-coordinated Follow-up Program in Primary Care for People at Risk for T2DM\tInterventional\tRecruiting\tN/A\t2\t80\tglucose intolerance|prediabetic state|diabetes mellitus\tNA\tNA\nNCT04688528\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t32294522\tLongton E, Lawson G, Bihin B, Mathieu I, Hanin FX, Deheneffe S, Vander Borght T, Laloux M, Daisne JF. Individualized Prophylactic Neck Irradiation in Patients with cN0 Head and Neck Cancer Based on Sentinel Lymph Node(s) Identification: Definitive Results of a Prospective Phase 1-2 Study. Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):652-661. doi: 10.1016/j.ijrobp.2020.03.021. Epub 2020 Apr 12.\tThe study involves head and neck squamous cell carcinomas (HNSCC) of the oral cavity, oropharynx, larynx or hypopharynx with positive nodes on only one side of the neck and no distant metastasis treated by primary (chemo)radiotherapy.","Squamous Cell Carcinoma of Head and Neck","Dose de-escalation and / or Volume de-escalation","Parallel Assignment","Treatment","Randomized","Radiation","All","Inclusion Criteria:\tDose De-escalation and Sentinel Lymph Node Mapping Driven Radiotherapy of Contralateral Neck in cN1-2 HNSCC\tInterventional\tRecruiting\tNot Applicable\t3\t147\tcarcinoma, squamous cell|squamous cell carcinoma of head and neck|carcinoma\tNA\tNA\nNCT04688879\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t28794797|21889287|26820988\tBala M, Kashuk J, Moore EE, Kluger Y, Biffl W, Gomes CA, Ben-Ishay O, Rubinstein C, Balogh ZJ, Civil I, Coccolini F, Leppaniemi A, Peitzman A, Ansaloni L, Sugrue M, Sartelli M, Di Saverio S, Fraga GP, Catena F. Acute mesenteric ischemia: guidelines of the World Society of Emergency Surgery. World J Emerg Surg. 2017 Aug 7;12:38. doi: 10.1186/s13017-017-0150-5. eCollection 2017. Review.|Björnsson S, Björck M, Block T, Resch T, Acosta S. Thrombolysis for acute occlusion of the superior mesenteric artery. J Vasc Surg. 2011 Dec;54(6):1734-42. doi: 10.1016/j.jvs.2011.07.054. Epub 2011 Sep 1.|Tilsed JV, Casamassima A, Kurihara H, Mariani D, Martinez I, Pereira J, Ponchietti L, Shamiyeh A, Al-Ayoubi F, Barco LA, Ceolin M, D'Almeida AJ, Hilario S, Olavarria AL, Ozmen MM, Pinheiro LF, Poeze M, Triantos G, Fuentes FT, Sierra SU, Soreide K, Yanar H. ESTES guidelines: acute mesenteric ischaemia. Eur J Trauma Emerg Surg. 2016 Apr;42(2):253-70. doi: 10.1007/s00068-016-0634-0.\t","Arterial Occlusion Mesenteric Artery Superior","intra-arterial urokinase thrombolysis","NA","NA","NA","Procedure","All","\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\nNCT04689672\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t32444253|32275766|32881950|32386264|32692769\tKhalili N, Haseli S, Iranpour P. Lung Ultrasound in COVID-19 Pneumonia: Prospects and Limitations. Acad Radiol. 2020 Jul;27(7):1044-1045. doi: 10.1016/j.acra.2020.04.032. Epub 2020 May 3.|Smith MJ, Hayward SA, Innes SM, Miller ASC. Point-of-care lung ultrasound in patients with COVID-19 - a narrative review. Anaesthesia. 2020 Aug;75(8):1096-1104. doi: 10.1111/anae.15082. Epub 2020 Apr 28. Review.|Lu X, Zhang M, Qian A, Tang L, Xu S. Lung ultrasound score in establishing the timing of intubation in COVID-19 interstitial pneumonia: A preliminary retrospective observational study. PLoS One. 2020 Sep 3;15(9):e0238679. doi: 10.1371/journal.pone.0238679. eCollection 2020. Retraction in: PLoS One. 2020 Dec 31;15(12):e0245032.|Manivel V, Lesnewski A, Shamim S, Carbonatto G, Govindan T. CLUE: COVID-19 lung ultrasound in emergency department. Emerg Med Australas. 2020 Aug;32(4):694-696. doi: 10.1111/1742-6723.13546. Epub 2020 Jun 16.|Dargent A, Chatelain E, Kreitmann L, Quenot JP, Cour M, Argaud L; COVID-LUS study group. Lung ultrasound score to monitor COVID-19 pneumonia progression in patients with ARDS. PLoS One. 2020 Jul 21;15(7):e0236312. doi: 10.1371/journal.pone.0236312. eCollection 2020.\t","Covid19","Lung ultrasound","NA","NA","NA","Diagnostic Test","All","\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\nNCT04690764\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t10589606|20508787|29284900\tMaranets I, Kain ZN. Preoperative anxiety and intraoperative anesthetic requirements. Anesth Analg. 1999 Dec;89(6):1346-51.|Kim WS, Byeon GJ, Song BJ, Lee HJ. Availability of preoperative anxiety scale as a predictive factor for hemodynamic changes during induction of anesthesia. Korean J Anesthesiol. 2010 Apr;58(4):328-33. doi: 10.4097/kjae.2010.58.4.328. Epub 2010 Apr 28.|Ahmetovic-Djug J, Hasukic S, Djug H, Hasukic B, Jahic A. Impact of Preoperative Anxiety in Patients on Hemodynamic Changes and a Dose of Anesthetic During Induction of Anesthesia. Med Arch. 2017 Oct;71(5):330-333. doi: 10.5455/medarh.2017.71.330-333.\t","Preoperative Anxiety, Intraoperative Hemodynamics and Drug Consumption","NA","NA","NA","NA","NA","All","\tNA\tNA\tNA\tNA\tNA\tNA\tanxiety disorders\tNA\tNA\nNCT04690933\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t26538506|29596116\tBillat PA, Woillard JB, Essig M, Sauvage FL, Picard N, Alain S, Neely M, Marquet P, Saint-Marcoux F. Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity? J Antimicrob Chemother. 2016 Feb;71(2):484-9. doi: 10.1093/jac/dkv342. Epub 2015 Nov 3.|Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, Humar A; The Transplantation Society International CMV Consensus Group. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018 Jun;102(6):900-931. doi: 10.1097/TP.0000000000002191. Review.\t","Antiviral Drug Resistance|Antivirals|Cytomegalovirus Infections|Hematopoietic Stem Cell Transplantation","Real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients","NA","NA","NA","Other","All","\tNA\tNA\tNA\tNA\tNA\tNA\tcytomegalovirus infections\tNA\tNA\nNCT04691089\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t27031917|14625108\tAffatato R, Li Y, Ristagno G. See through ECG technology during cardiopulmonary resuscitation to analyze rhythm and predict defibrillation outcome. Curr Opin Crit Care. 2016 Jun;22(3):199-205. doi: 10.1097/MCC.0000000000000297. Review.|van Alem AP, Post J, Koster RW. VF recurrence: characteristics and patient outcome in out-of-hospital cardiac arrest. Resuscitation. 2003 Nov;59(2):181-8.\t","Cardiac Arrest, Sudden|Sudden Cardiac Death|Ventricular Fibrillation|Ventricular Tachycardia","NA","NA","NA","NA","NA","All","\tNA\tNA\tNA\tNA\tNA\tNA\ttachycardia, ventricular|death, sudden, cardiac|tachycardia|heart arrest|ventricular fibrillation|death\tNA\tNA\nNCT04691193\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t18438893\tHill JC, Dunn KM, Lewis M, Mullis R, Main CJ, Foster NE, Hay EM. A primary care back pain screening tool: identifying patient subgroups for initial treatment. Arthritis Rheum. 2008 May 15;59(5):632-41. doi: 10.1002/art.23563.\t","Low Back Pain","NA","NA","NA","NA","NA","All","\tNA\tNA\tNA\tNA\tNA\tNA\tlow back pain|back pain\tNA\tNA\nNCT04691674\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t23612857|21295641|27546389|31863440|16185975|15933689|7988829|15067627|30502123\tMazaki T, Mado K, Masuda H, Shiono M. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: an updated meta-analysis. J Gastroenterol. 2014 Feb;49(2):343-55. doi: 10.1007/s00535-013-0806-1. Epub 2013 Apr 24. Review.|Choudhary A, Bechtold ML, Arif M, Szary NM, Puli SR, Othman MO, Pais WP, Antillon MR, Roy PK. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointest Endosc. 2011 Feb;73(2):275-82. doi: 10.1016/j.gie.2010.10.039. Review.|ASGE Standards of Practice Committee, Chandrasekhara V, Khashab MA, Muthusamy VR, Acosta RD, Agrawal D, Bruining DH, Eloubeidi MA, Fanelli RD, Faulx AL, Gurudu SR, Kothari S, Lightdale JR, Qumseya BJ, Shaukat A, Wang A, Wani SB, Yang J, DeWitt JM. Adverse events associated with ERCP. Gastrointest Endosc. 2017 Jan;85(1):32-47. doi: 10.1016/j.gie.2016.06.051. Epub 2016 Aug 18. Review.|Dumonceau JM, Kapral C, Aabakken L, Papanikolaou IS, Tringali A, Vanbiervliet G, Beyna T, Dinis-Ribeiro M, Hritz I, Mariani A, Paspatis G, Radaelli F, Lakhtakia S, Veitch AM, van Hooft JE. ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2020 Feb;52(2):127-149. doi: 10.1055/a-1075-4080. Epub 2019 Dec 20.|Goldberg E, Titus M, Haluszka O, Darwin P. Pancreatic-duct stent placement facilitates difficult common bile duct cannulation. Gastrointest Endosc. 2005 Oct;62(4):592-6.|Devière J. Why do pancreatic stents become occluded? Gastrointest Endosc. 2005 Jun;61(7):867-8.|Ikenberry SO, Sherman S, Hawes RH, Smith M, Lehman GA. The occlusion rate of pancreatic stents. Gastrointest Endosc. 1994 Sep-Oct;40(5):611-3.|Rashdan A, Fogel EL, McHenry L Jr, Sherman S, Temkit M, Lehman GA. Improved stent characteristics for prophylaxis of post-ERCP pancreatitis. Clin Gastroenterol Hepatol. 2004 Apr;2(4):322-9.|Dultz G, Gerber L, Zeuzem S, Bojunga J, Friedrich-Rust M. Prolonged retention of prophylactic pancreatic stents is not associated with increased complications. Pancreatology. 2019 Jan;19(1):39-43. doi: 10.1016/j.pan.2018.11.011. Epub 2018 Nov 22.\t","Cholangitis|Post-ERCP Acute Pancreatitis|Stent Dislodgement","Endoscopy","Parallel Assignment","Prevention","Randomized","Procedure","All","\tOptimal Placement Duration of Pancreatic Duct Stent\tInterventional\tNot yet recruiting\tN/A\t2\t240\tcholangitis|pancreatitis\tNA\tNA\nNCT04691791\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t28335843|28274557|15583223|10807452|19221222|30089062|27358682\tCheezum MK, Liberthson RR, Shah NR, Villines TC, O'Gara PT, Landzberg MJ, Blankstein R. Anomalous Aortic Origin of a Coronary Artery From the Inappropriate Sinus of Valsalva. J Am Coll Cardiol. 2017 Mar 28;69(12):1592-1608. doi: 10.1016/j.jacc.2017.01.031. Review.|Brothers JA, Frommelt MA, Jaquiss RDB, Myerburg RJ, Fraser CD Jr, Tweddell JS. Expert consensus guidelines: Anomalous aortic origin of a coronary artery. J Thorac Cardiovasc Surg. 2017 Jun;153(6):1440-1457. doi: 10.1016/j.jtcvs.2016.06.066. Epub 2017 Feb 4. Review.|Eckart RE, Scoville SL, Campbell CL, Shry EA, Stajduhar KC, Potter RN, Pearse LA, Virmani R. Sudden death in young adults: a 25-year review of autopsies in military recruits. Ann Intern Med. 2004 Dec 7;141(11):829-34.|Basso C, Maron BJ, Corrado D, Thiene G. Clinical profile of congenital coronary artery anomalies with origin from the wrong aortic sinus leading to sudden death in young competitive athletes. J Am Coll Cardiol. 2000 May;35(6):1493-501. Review.|Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009 Mar 3;119(8):1085-92. doi: 10.1161/CIRCULATIONAHA.108.804617. Epub 2009 Feb 16.|Malhotra A, Dhutia H, Finocchiaro G, Gati S, Beasley I, Clift P, Cowie C, Kenny A, Mayet J, Oxborough D, Patel K, Pieles G, Rakhit D, Ramsdale D, Shapiro L, Somauroo J, Stuart G, Varnava A, Walsh J, Yousef Z, Tome M, Papadakis M, Sharma S. Outcomes of Cardiac Screening in Adolescent Soccer Players. N Engl J Med. 2018 Aug 9;379(6):524-534. doi: 10.1056/NEJMoa1714719.|Villa AD, Sammut E, Nair A, Rajani R, Bonamini R, Chiribiri A. Coronary artery anomalies overview: The normal and the abnormal. World J Radiol. 2016 Jun 28;8(6):537-55. doi: 10.4329/wjr.v8.i6.537. Review.\t","Congenital Coronary Artery Abnormality","NA","NA","NA","NA","NA","All","\tNA\tNA\tNA\tNA\tNA\tNA\tcongenital abnormalities\tNA\tNA\nNCT04691856\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t23360885\tTunali Y, Akçil EF, Dilmen OK, Tutuncu AC, Koksal GM, Akbas S, Vehid H, Yentur E. Efficacy of intravenous paracetamol and dexketoprofen on postoperative pain and morphine consumption after a lumbar disk surgery. J Neurosurg Anesthesiol. 2013 Apr;25(2):143-7. doi: 10.1097/ANA.0b013e31827464af.\t","Postoperative Pain Management","Morphine Sulfate|Intravenous paracetamol|Intravenous ibuprofen|Morphine","Parallel Assignment","Treatment","Randomized","Drug|Drug|Drug|Drug","Female","\tEfficacy of Intravenous Paracetamol and Ibuprofen on Postoperative Pain and Morphine Consumption in Hysterectomy\tInterventional\tEnrolling by invitation\tN/A\t3\t66\tpain, postoperative\tacetaminophen|ibuprofen|morphine\tNA\nNCT04691882\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t32252402\tLivovsky DM, Pribic T, Azpiroz F. Food, Eating, and the Gastrointestinal Tract. Nutrients. 2020 Apr 2;12(4). pii: E986. doi: 10.3390/nu12040986. Review.\t","Healthy","Diaphragmatic contraction|Diaphagmatic relaxation","Crossover Assignment","Other","Randomized","Behavioral|Behavioral","Female","\tEffect of Abdominal Wall Activity on the Responses to Meal Ingestion\tInterventional\tCompleted\tN/A\t2\t16\tNA\tNA\tNA\nNCT04691921\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t32091533|32412710\tWu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.|Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020 Dec 17;383(25):2451-2460. doi: 10.1056/NEJMcp2009575. Epub 2020 May 15. Review.\t","COVID-19","Current clinical practices of participating physicians","NA","NA","NA","Behavioral","All","\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\nNCT04692194\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t24422778|68184|31580261|31633186\tCracco N, Zinicola R. Is haemorrhoidectomy in inflammatory bowel disease harmful? An old dogma re-examined. Colorectal Dis. 2014 Jul;16(7):516-9. doi: 10.1111/codi.12555. Review.|Jeffery PJ, Parks AG, Ritchie JK. Treatment of haemorrhoids in patients with inflammatory bowel disease. Lancet. 1977 May 21;1(8021):1084-5.|McKenna NP, Lightner AL, Habermann EB, Mathis KL. Hemorrhoidectomy and Excision of Skin Tags in IBD: Harbinger of Doom or Simply a Disease Running Its Course? Dis Colon Rectum. 2019 Dec;62(12):1505-1511. doi: 10.1097/DCR.0000000000001524.|Lightner AL, Kearney D, Giugliano D, Hull T, Holubar SD, Koh S, Zaghiyan K, Fleshner PR. Excisional Hemorrhoidectomy: Safe in Patients With Crohn's Disease? Inflamm Bowel Dis. 2020 Aug 20;26(9):1390-1393. doi: 10.1093/ibd/izz255.\t","Chronic Inflammatory Bowel Disease|Hemorrhoids","NA","NA","NA","NA","NA","All","\tNA\tNA\tNA\tNA\tNA\tNA\tinflammatory bowel diseases|intestinal diseases|hemorrhoids\tNA\tNA\nNCT04692259\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t29287736|23377564|16955381|27090112|28101681|21484773|28283924|27593595|28732555|30796575|30899977\tSultana A, Brooke-Smith M, Ullah S, Figueras J, Rees M, Vauthey JN, Conrad C, Hugh TJ, Garden OJ, Fan ST, Crawford M, Makuuchi M, Yokoyama Y, Büchler M, Padbury R. Prospective evaluation of the International Study Group for Liver Surgery definition of post hepatectomy liver failure after liver resection: an international multicentre study. HPB (Oxford). 2018 May;20(5):462-469. doi: 10.1016/j.hpb.2017.11.007. Epub 2017 Dec 26.|Shindoh J, Tzeng CW, Aloia TA, Curley SA, Zimmitti G, Wei SH, Huang SY, Mahvash A, Gupta S, Wallace MJ, Vauthey JN. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol. 2013 Aug;20(8):2493-500. doi: 10.1245/s10434-012-2864-7. Epub 2013 Feb 3.|Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006 Oct;13(10):1271-80. Epub 2006 Sep 6.|Guiu B, Chevallier P, Denys A, Delhom E, Pierredon-Foulongne MA, Rouanet P, Fabre JM, Quenet F, Herrero A, Panaro F, Baudin G, Ramos J. Simultaneous trans-hepatic portal and hepatic vein embolization before major hepatectomy: the liver venous deprivation technique. Eur Radiol. 2016 Dec;26(12):4259-4267. Epub 2016 Apr 18.|Guiu B, Quenet F, Escal L, Bibeau F, Piron L, Rouanet P, Fabre JM, Jacquet E, Denys A, Kotzki PO, Verzilli D, Deshayes E. Extended liver venous deprivation before major hepatectomy induces marked and very rapid increase in future liver remnant function. Eur Radiol. 2017 Aug;27(8):3343-3352. doi: 10.1007/s00330-017-4744-9. Epub 2017 Jan 18.|de Graaf W, van Lienden KP, van den Esschert JW, Bennink RJ, van Gulik TM. Increase in future remnant liver function after preoperative portal vein embolization. Br J Surg. 2011 Jun;98(6):825-34. doi: 10.1002/bjs.7456. Epub 2011 Apr 11.|Sparrelid E, Jonas E, Tzortzakakis A, Dahlén U, Murquist G, Brismar T, Axelsson R, Isaksson B. Dynamic Evaluation of Liver Volume and Function in Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy. J Gastrointest Surg. 2017 Jun;21(6):967-974. doi: 10.1007/s11605-017-3389-y. Epub 2017 Mar 10.|Cieslak KP, Bennink RJ, de Graaf W, van Lienden KP, Besselink MG, Busch OR, Gouma DJ, van Gulik TM. Measurement of liver function using hepatobiliary scintigraphy improves risk assessment in patients undergoing major liver resection. HPB (Oxford). 2016 Sep;18(9):773-80. doi: 10.1016/j.hpb.2016.06.006. Epub 2016 Jul 25.|Olthof PB, Tomassini F, Huespe PE, Truant S, Pruvot FR, Troisi RI, Castro C, Schadde E, Axelsson R, Sparrelid E, Bennink RJ, Adam R, van Gulik TM, de Santibanes E. Hepatobiliary scintigraphy to evaluate liver function in associating liver partition and portal vein ligation for staged hepatectomy: Liver volume overestimates liver function. Surgery. 2017 Oct;162(4):775-783. doi: 10.1016/j.surg.2017.05.022. Epub 2017 Jul 18.|Rassam F, Zhang T, Cieslak KP, Lavini C, Stoker J, Bennink RJ, van Gulik TM, van Vliet LJ, Runge JH, Vos FM. Comparison between dynamic gadoxetate-enhanced MRI and (99m)Tc-mebrofenin hepatobiliary scintigraphy with SPECT for quantitative assessment of liver function. Eur Radiol. 2019 Sep;29(9):5063-5072. doi: 10.1007/s00330-019-06029-7. Epub 2019 Feb 22.|Theilig D, Steffen I, Malinowski M, Stockmann M, Seehofer D, Pratschke J, Hamm B, Denecke T, Geisel D. Predicting liver failure after extended right hepatectomy following right portal vein embolization with gadoxetic acid-enhanced MRI. Eur Radiol. 2019 Nov;29(11):5861-5872. doi: 10.1007/s00330-019-06101-2. Epub 2019 Mar 21.\t","Liver Failure as A Complication of Care|Liver Resection|MRI","MRI","NA","NA","NA","Diagnostic Test","All","\tNA\tNA\tNA\tNA\tNA\tNA\tliver failure|hepatic insufficiency\tNA\tNA\nNCT04692779\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t18195629|20851923|17316468|24364779|27324241|26806842|27899151|32191259|32007143|31986264|32031570|32167524|32105632|23688302|29068269|27794087|27400909|26493592|31060085|32291463|32437877|33158500\tArbelot C, Ferrari F, Bouhemad B, Rouby JJ. Lung ultrasound in acute respiratory distress syndrome and acute lung injury. Curr Opin Crit Care. 2008 Feb;14(1):70-4. doi: 10.1097/MCC.0b013e3282f43d05. Review.|Bouhemad B, Brisson H, Le-Guen M, Arbelot C, Lu Q, Rouby JJ. Bedside ultrasound assessment of positive end-expiratory pressure-induced lung recruitment. Am J Respir Crit Care Med. 2011 Feb 1;183(3):341-7. doi: 10.1164/rccm.201003-0369OC. Epub 2010 Sep 17.|Bouhemad B, Zhang M, Lu Q, Rouby JJ. Clinical review: Bedside lung ultrasound in critical care practice. Crit Care. 2007;11(1):205. Review.|Doerschug KC, Schmidt GA. Intensive care ultrasound: III. Lung and pleural ultrasound for the intensivist. Ann Am Thorac Soc. 2013 Dec;10(6):708-12. doi: 10.1513/AnnalsATS.201308-288OT.|Haddam M, Zieleskiewicz L, Perbet S, Baldovini A, Guervilly C, Arbelot C, Noel A, Vigne C, Hammad E, Antonini F, Lehingue S, Peytel E, Lu Q, Bouhemad B, Golmard JL, Langeron O, Martin C, Muller L, Rouby JJ, Constantin JM, Papazian L, Leone M; CAR'Echo Collaborative Network; AzuRea Collaborative Network. Lung ultrasonography for assessment of oxygenation response to prone position ventilation in ARDS. Intensive Care Med. 2016 Oct;42(10):1546-1556. doi: 10.1007/s00134-016-4411-7. Epub 2016 Jun 20.|Prat G, Guinard S, Bizien N, Nowak E, Tonnelier JM, Alavi Z, Renault A, Boles JM, L'Her E. Can lung ultrasonography predict prone positioning response in acute respiratory distress syndrome patients? J Crit Care. 2016 Apr;32:36-41. doi: 10.1016/j.jcrc.2015.12.015. Epub 2015 Dec 30.|Wang XT, Ding X, Zhang HM, Chen H, Su LX, Liu DW; Chinese Critical Ultrasound Study Group (CCUSG). Lung ultrasound can be used to predict the potential of prone positioning and assess prognosis in patients with acute respiratory distress syndrome. Crit Care. 2016 Nov 30;20(1):385.|Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Lee M. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020 Apr 28;323(16):1612-1614. doi: 10.1001/jama.2020.4326.|Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.|Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.|Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.|Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994. Erratum in: JAMA Intern Med. 2020 Jul 1;180(7):1031.|Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24. Erratum in: Lancet Respir Med. 2020 Apr;8(4):e26.|Guérin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, Mercier E, Badet M, Mercat A, Baudin O, Clavel M, Chatellier D, Jaber S, Rosselli S, Mancebo J, Sirodot M, Hilbert G, Bengler C, Richecoeur J, Gainnier M, Bayle F, Bourdin G, Leray V, Girard R, Baboi L, Ayzac L; PROSEVA Study Group. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013 Jun 6;368(23):2159-68. doi: 10.1056/NEJMoa1214103. Epub 2013 May 20.|Munshi L, Del Sorbo L, Adhikari NKJ, Hodgson CL, Wunsch H, Meade MO, Uleryk E, Mancebo J, Pesenti A, Ranieri VM, Fan E. Prone Position for Acute Respiratory Distress Syndrome. A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2017 Oct;14(Supplement_4):S280-S288. doi: 10.1513/AnnalsATS.201704-343OT. Review.|Marini JJ, Hurford WE. Should Early Prone Positioning Be a Standard of Care in ARDS With Refractory Hypoxemia? Wrong Question-Reply. Respir Care. 2016 Nov;61(11):1564-1565.|Scholten EL, Beitler JR, Prisk GK, Malhotra A. Treatment of ARDS With Prone Positioning. Chest. 2017 Jan;151(1):215-224. doi: 10.1016/j.chest.2016.06.032. Epub 2016 Jul 8. Review.|Kallet RH. A Comprehensive Review of Prone Position in ARDS. Respir Care. 2015 Nov;60(11):1660-87. doi: 10.4187/respcare.04271. Review.|Reilly JP, Calfee CS, Christie JD. Acute Respiratory Distress Syndrome Phenotypes. Semin Respir Crit Care Med. 2019 Feb;40(1):19-30. doi: 10.1055/s-0039-1684049. Epub 2019 May 6. Review.|Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, Camporota L. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020 Jun;46(6):1099-1102. doi: 10.1007/s00134-020-06033-2. Epub 2020 Apr 14.|Robba C, Battaglini D, Ball L, Patroniti N, Loconte M, Brunetti I, Vena A, Giacobbe DR, Bassetti M, Rocco PRM, Pelosi P. Distinct phenotypes require distinct respiratory management strategies in severe COVID-19. Respir Physiol Neurobiol. 2020 Aug;279:103455. doi: 10.1016/j.resp.2020.103455. Epub 2020 May 11. Review.|Weiss TT, Cerda F, Scott JB, Kaur R, Sungurlu S, Mirza SH, Alolaiwat AA, Kaur R, Augustynovich AE, Li J. Prone positioning for patients intubated for severe acute respiratory distress syndrome (ARDS) secondary to COVID-19: a retrospective observational cohort study. Br J Anaesth. 2021 Jan;126(1):48-55. doi: 10.1016/j.bja.2020.09.042. Epub 2020 Oct 10.\t","ARDS|Covid19","Lung Ultrasound (LUS)","NA","NA","NA","Other","All","\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\nNCT04693793\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t30328782|23667587|28036350|19224955\tBurgon TB, Cox-Chapman J, Czarnecki C, Kropp R, Guerriere R, Paculdo D, Peabody JW. Engaging Primary Care Providers to Reduce Unwanted Clinical Variation and Support ACO Cost and Quality Goals: A Unique Provider-Payer Collaboration. Popul Health Manag. 2019 Aug;22(4):321-329. doi: 10.1089/pop.2018.0111. Epub 2018 Oct 17.|Peabody JW, Strand V, Shimkhada R, Lee R, Chernoff D. Impact of rheumatoid arthritis disease activity test on clinical practice. PLoS One. 2013 May 7;8(5):e63215. doi: 10.1371/journal.pone.0063215. Print 2013.|Peabody J, Martin M, DeMaria L, Florentino J, Paculdo D, Paul M, Vanzo R, Wassman ER, Burgon T. Clinical Utility of a Comprehensive, Whole Genome CMA Testing Platform in Pediatrics: A Prospective Randomized Controlled Trial of Simulated Patients in Physician Practices. PLoS One. 2016 Dec 30;11(12):e0169064. doi: 10.1371/journal.pone.0169064. eCollection 2016.|Solon O, Woo K, Quimbo SA, Shimkhada R, Florentino J, Peabody JW. A novel method for measuring health care system performance: experience from QIDS in the Philippines. Health Policy Plan. 2009 May;24(3):167-74. doi: 10.1093/heapol/czp003. Epub 2009 Feb 18.\t","Dyspnea|Unexplained Chronic Dyspnea","Education Materials and Janssen Test","Parallel Assignment","Diagnostic","Randomized","Other","All","\tEstablishing Clinical Utility for a New Diagnostic Test for Patients With Shortness of Breath\tInterventional\tRecruiting\tN/A\t3\t249\tdyspnea\tNA\tNA\nNCT04693897\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t21371240|25369726|11412210|12811491|12579627|11857671|16813910|14693111|14973214|22310924|29140559|20132203|22258963|17574730|18565239|10027879|10188996|19254402|18311486|12007519|19816919|22981677|29556972|27092789|25130281|21501328|28102552|1939656|10797303|18423678|19089891|16753445|11176525|19220267|26310546|16406907|12579626|17010004|23452071|22531957|22588142|19281469|19889062\tCoyne KS, Sexton CC, Kopp ZS, Ebel-Bitoun C, Milsom I, Chapple C. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int. 2011 Nov;108(9):1459-71. doi: 10.1111/j.1464-410X.2010.10013.x. Epub 2011 Mar 3.|Jafarabadi M, Jafarabadi L, Shariat M, Rabie Salehi G, Haghollahi F, Rashidi BH. Considering the prominent complaint as a guide in medical therapy for overactive bladder syndrome in women over 45 years. J Obstet Gynaecol Res. 2015 Jan;41(1):120-6. doi: 10.1111/jog.12483. Epub 2014 Nov 5.|Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001 Jun;87(9):760-6. Erratum in: BJU Int 2001 Nov;88(7):807.|Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003 May;20(6):327-36. Epub 2002 Nov 15.|Chen GD, Lin TL, Hu SW, Chen YC, Lin LY. Prevalence and correlation of urinary incontinence and overactive bladder in Taiwanese women. Neurourol Urodyn. 2003;22(2):109-17.|Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-78.|Hung MJ, Ho ES, Shen PS, Sun MJ, Lin AT, Chen GD; Taiwan OAB Club. Urgency is the core symptom of female overactive bladder syndrome, as demonstrated by a statistical analysis. J Urol. 2006 Aug;176(2):636-40.|Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004 Jan;3(1):46-53. Review.|Ouslander JG. Management of overactive bladder. N Engl J Med. 2004 Feb 19;350(8):786-99. Review.|Luo D, Liu L, Han P, Wei Q, Shen H. Solifenacin for overactive bladder: a systematic review and meta-analysis. Int Urogynecol J. 2012 Aug;23(8):983-91. doi: 10.1007/s00192-011-1641-7. Epub 2012 Feb 7. Review.|Nazir J, Kelleher C, Aballéa S, Maman K, Hakimi Z, Mankowski C, Odeyemi I. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis. Neurourol Urodyn. 2018 Mar;37(3):986-996. doi: 10.1002/nau.23413. Epub 2017 Nov 15.|Cardozo L, Thorpe A, Warner J, Sidhu M. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. BJU Int. 2010 Aug;106(4):506-14. doi: 10.1111/j.1464-410X.2009.09160.x. Epub 2010 Feb 3.|Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012 Jan 18;1:CD005429. doi: 10.1002/14651858.CD005429.pub2. Review.|Chapple CR, Fianu-Jonsson A, Indig M, Khullar V, Rosa J, Scarpa RM, Mistry A, Wright DM, Bolodeoku J; STAR study group. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol. 2007 Oct;52(4):1195-203. Epub 2007 Jun 6.|Speakman M, Khullar V, Mundy A, Odeyemi I, Bolodeoku J. A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin. 2008 Aug;24(8):2173-9. doi: 10.1185/03007990802234829. Epub 2008 Jun 18.|Takeda M, Obara K, Mizusawa T, Tomita Y, Arai K, Tsutsui T, Hatano A, Takahashi K, Nomura S. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther. 1999 Mar;288(3):1367-73.|Igawa Y, Yamazaki Y, Takeda H, Hayakawa K, Akahane M, Ajisawa Y, Yoneyama T, Nishizawa O, Andersson KE. Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J Pharmacol. 1999 Feb;126(3):819-25.|Tyagi P, Thomas CA, Yoshimura N, Chancellor MB. Investigations into the presence of functional Beta1, Beta2 and Beta3-adrenoceptors in urothelium and detrusor of human bladder. Int Braz J Urol. 2009 Jan-Feb;35(1):76-83.|Otsuka A, Shinbo H, Matsumoto R, Kurita Y, Ozono S. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):473-81. doi: 10.1007/s00210-008-0274-y. Epub 2008 Mar 1.|Yamaguchi O. Beta3-adrenoceptors in human detrusor muscle. Urology. 2002 May;59(5 Suppl 1):25-9. Review.|Aizawa N, Igawa Y, Nishizawa O, Wyndaele JJ. Effects of CL316,243, a beta 3-adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat. Neurourol Urodyn. 2010 Jun;29(5):771-6. doi: 10.1002/nau.20826.|Aizawa N, Homma Y, Igawa Y. Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol. 2012 Dec;62(6):1165-73. doi: 10.1016/j.eururo.2012.08.056. Epub 2012 Sep 5.|Chen HL, Chen TC, Chang HM, Juan YS, Huang WH, Pan HF, Chang YC, Wu CM, Wang YL, Lee HY. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis. World J Urol. 2018 Aug;36(8):1285-1297. doi: 10.1007/s00345-018-2268-9. Epub 2018 Mar 19.|Vecchioli Scaldazza C, Morosetti C. Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study. Urol Int. 2016;97(3):325-329. Epub 2016 Apr 20.|Kuo HC, Lee KS, Na Y, Sood R, Nakaji S, Kubota Y, Kuroishi K. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn. 2015 Sep;34(7):685-92. doi: 10.1002/nau.22645. Epub 2014 Aug 17.|Hsiao SM, Chang TC, Wu WY, Chen CH, Yu HJ, Lin HH. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. J Obstet Gynaecol Res. 2011 Aug;37(8):1084-91. doi: 10.1111/j.1447-0756.2010.01493.x. Epub 2011 Apr 19.|Sheng W, Zhang H, Ruth KH. Could urinary nerve growth factor be a biomarker for overactive bladder? A meta-analysis. Neurourol Urodyn. 2017 Sep;36(7):1703-1710. doi: 10.1002/nau.23210. Epub 2017 Jan 19. Review.|Steers WD, Kolbeck S, Creedon D, Tuttle JB. Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest. 1991 Nov;88(5):1709-15.|Clemow DB, Steers WD, Tuttle JB. Stretch-activated signaling of nerve growth factor secretion in bladder and vascular smooth muscle cells from hypertensive and hyperactive rats. J Cell Physiol. 2000 Jun;183(3):289-300.|Liu HT, Kuo HC. Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol. 2008 Jun;179(6):2270-4. doi: 10.1016/j.juro.2008.01.146. Epub 2008 Apr 18.|Liu HT, Kuo HC. Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention. Neurourol Urodyn. 2009;28(1):78-81. doi: 10.1002/nau.20599.|Mukerji G, Yiangou Y, Grogono J, Underwood J, Agarwal SK, Khullar V, Anand P. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol. 2006 Jul;176(1):367-73.|Chuang YC, Fraser MO, Yu Y, Chancellor MB, de Groat WC, Yoshimura N. The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. J Urol. 2001 Mar;165(3):975-9.|Liu HT, Chancellor MB, Kuo HC. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int. 2009 Jun;103(12):1668-72. doi: 10.1111/j.1464-410X.2009.08380.x. Epub 2009 Feb 11.|Ciftci S, Ozkurkcugil C, Yilmaz H, Ustuner M, Yavuz U, Yuksekkaya M, Cekmen MB. Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder. Int Urogynecol J. 2016 Feb;27(2):275-80. doi: 10.1007/s00192-015-2825-3. Epub 2015 Aug 27.|Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol. 2006 Jan;175(1):191-4; discussion 194-5.|Digesu GA, Khullar V, Cardozo L, Salvatore S. Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn. 2003;22(2):105-8. Erratum in: Neurourol Urodyn. 2003;22(4):356.|Sekido N, Hinotsu S, Kawai K, Shimazui T, Akaza H. How many uncomplicated male and female overactive bladder patients reveal detrusor overactivity during urodynamic study? Int J Urol. 2006 Oct;13(10):1276-9.|Giarenis I, Mastoroudes H, Srikrishna S, Robinson D, Cardozo L. Is there a difference between women with or without detrusor overactivity complaining of symptoms of overactive bladder? BJU Int. 2013 Aug;112(4):501-7. doi: 10.1111/j.1464-410X.2012.11652.x. Epub 2013 Mar 4.|Diamond P, Hassonah S, Alarab M, Lovatsis D, Drutz HP. The prevalence of detrusor overactivity amongst patients with symptoms of overactive bladder: a retrospective cohort study. Int Urogynecol J. 2012 Nov;23(11):1577-80. doi: 10.1007/s00192-012-1781-4. Epub 2012 Apr 25.|Jeong SJ, Lee SC, Jeong CW, Hong SK, Byun SS, Lee SE. Clinical and urodynamic differences among women with overactive bladder according to the presence of detrusor overactivity. Int Urogynecol J. 2013 Feb;24(2):255-61. doi: 10.1007/s00192-012-1817-9. Epub 2012 May 16.|Malone-Lee JG, Al-Buheissi S. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int. 2009 Apr;103(7):931-7. doi: 10.1111/j.1464-410X.2009.08361.x. Epub 2009 Mar 5.|Nitti VW, Rovner ES, Bavendam T. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. BJU Int. 2010 May;105(9):1268-75. doi: 10.1111/j.1464-410X.2009.09037.x. Epub 2009 Nov 4.\t","Detrusor Overactivity|Overactive Bladder Syndrome","Mirabegron 50 MG|Solifenacin Succinate 5 MG","NA","NA","NA","Drug|Drug","Female","\tNA\tNA\tNA\tNA\tNA\tNA\turinary bladder, overactive\tsolifenacin succinate|mirabegron\tNA\nNCT04694105\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t17865904|26695877|23513068\tKulenkampff D. BRACHIAL PLEXUS ANAESTHESIA: ITS INDICATIONS, TECHNIQUE, AND DANGERS. Ann Surg. 1928 Jun;87(6):883-91.|Neal JM. Ultrasound-Guided Regional Anesthesia and Patient Safety: Update of an Evidence-Based Analysis. Reg Anesth Pain Med. 2016 Mar-Apr;41(2):195-204. doi: 10.1097/AAP.0000000000000295.|Ji F, Li Z, Nguyen H, Young N, Shi P, Fleming N, Liu H. Perioperative dexmedetomidine improves outcomes of cardiac surgery. Circulation. 2013 Apr 16;127(15):1576-84. doi: 10.1161/CIRCULATIONAHA.112.000936. Epub 2013 Mar 19.\t","Brachial Plexus Block","Dexmedetomidine injection|Dexamethasone|saline","Parallel Assignment","Other","Randomized","Drug|Drug|Drug","All","\tPeri-neural Dexmedetomidine Versus Dexamethasone for Supraaclavicular Block Adjuvant to Bupivacaine Supraclavicular Brachial Plexus Block\tInterventional\tCompleted\tN/A\t3\t42\tNA\tdexmedetomidine|dexamethasone\tNA\nNCT04694157\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t30248666|31974607|28862043|28618416|24802592\tZhang Y, Shen T, Liu B, Dai D, Cai J, Zhao C, Du L, Jia N, He Q. Cardiac Shock Wave Therapy Attenuates Cardiomyocyte Apoptosis after Acute Myocardial Infarction in Rats. Cell Physiol Biochem. 2018;49(5):1734-1746. doi: 10.1159/000493616. Epub 2018 Sep 24.|Qiu Q, Shen T, Wang Q, Yu X, Jia N, He Q. Cardiac shock wave therapy protects cardiomyocytes from hypoxia-induced injury by modulating miR-210. Mol Med Rep. 2020 Feb;21(2):631-640. doi: 10.3892/mmr.2019.10892. Epub 2019 Dec 18.|Liu B, Zhang Y, Jia N, Lan M, Du L, Zhao D, He Q. Study of the Safety of Extracorporeal Cardiac Shock Wave Therapy: Observation of the Ultrastructures in Myocardial Cells by Transmission Electron Microscopy. J Cardiovasc Pharmacol Ther. 2018 Jan;23(1):79-88. doi: 10.1177/1074248417725877. Epub 2017 Sep 1.|Du L, Shen T, Liu B, Zhang Y, Zhao C, Jia N, Wang Q, He Q. Shock Wave Therapy Promotes Cardiomyocyte Autophagy and Survival during Hypoxia. Cell Physiol Biochem. 2017;42(2):673-684. doi: 10.1159/000477885. Epub 2017 Jun 15.|Yu W, Shen T, Liu B, Wang S, Li J, Dai D, Cai J, He Q. Cardiac shock wave therapy attenuates H9c2 myoblast apoptosis by activating the AKT signal pathway. Cell Physiol Biochem. 2014;33(5):1293-303. doi: 10.1159/000358697. Epub 2014 Apr 28.\t","Coronary Artery Disease","cardiac shock wave therapy","NA","NA","NA","Device","All","\tNA\tNA\tNA\tNA\tNA\tNA\tmyocardial ischemia|coronary artery disease|coronary disease\tNA\tNA\nNCT04694274\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t32620810|32533874\tAlajbeg IZ, Vrbanović E, Lapić I, Alajbeg I, Vuletić L. Effect of occlusal splint on oxidative stress markers and psychological aspects of chronic temporomandibular pain: a randomized controlled trial. Sci Rep. 2020 Jul 3;10(1):10981. doi: 10.1038/s41598-020-67383-x.|Vrbanović E, Alajbeg IZ, Alajbeg I. COVID-19 pandemic and Zagreb earthquakes as stressors in patients with temporomandibular disorders. Oral Dis. 2021 Apr;27 Suppl 3:688-693. doi: 10.1111/odi.13488. Epub 2020 Jul 13.\t","Orofacial Pain|Temporomandibular Disorders","stabilization splint|physical therapy|placebo splint","NA","NA","NA","Device|Procedure|Device","All","\tNA\tNA\tNA\tNA\tNA\tNA\ttemporomandibular joint dysfunction syndrome|facial pain|temporomandibular joint disorders\tNA\tNA\nNCT04694898\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t23746780|27702425|33005722\tRuel MT, Alderman H; Maternal and Child Nutrition Study Group. Nutrition-sensitive interventions and programmes: how can they help to accelerate progress in improving maternal and child nutrition? Lancet. 2013 Aug 10;382(9891):536-51. doi: 10.1016/S0140-6736(13)60843-0. Epub 2013 Jun 6. Erratum in: Lancet. 2013 Aug 10;382(9891):506.|Reinbott A, Schelling A, Kuchenbecker J, Jeremias T, Russell I, Kevanna O, Krawinkel MB, Jordan I. Nutrition education linked to agricultural interventions improved child dietary diversity in rural Cambodia. Br J Nutr. 2016 Oct;116(8):1457-1468. Epub 2016 Oct 5.|Bahru BA, Jebena MG, Birner R, Zeller M. Impact of Ethiopia's productive safety net program on household food security and child nutrition: A marginal structural modeling approach. SSM Popul Health. 2020 Aug 26;12:100660. doi: 10.1016/j.ssmph.2020.100660. eCollection 2020 Dec.\t","Anemia|Dietary Deficiency|Stunting","Standard programme|SURE intervention","NA","NA","NA","Behavioral|Behavioral","All","\tSustainable Undernutrition Reduction in Ethiopia\tInterventional\tCompleted\tN/A\t2\t1292\tmalnutrition|growth disorders\tNA\tNA\nNCT04695990\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t29386200|17090774|9462531|21709062|19118718\tBenjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O'Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018 Mar 20;137(12):e67-e492. doi: 10.1161/CIR.0000000000000558. Epub 2018 Jan 31. Review. Erratum in: Circulation. 2018 Mar 20;137(12 ):e493.|Hildebrandt P. Systolic and nonsystolic heart failure: equally serious threats. JAMA. 2006 Nov 8;296(18):2259-60.|Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998 Jan 27;97(3):282-9. Review.|Gerber Y, Melton LJ 3rd, Weston SA, Roger VL. Association between myocardial infarction and fractures: an emerging phenomenon. Circulation. 2011 Jul 19;124(3):297-303. doi: 10.1161/CIRCULATIONAHA.110.007195. Epub 2011 Jun 27.|Ezekowitz JA, Kaul P, Bakal JA, Armstrong PW, Welsh RC, McAlister FA. Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol. 2009 Jan 6;53(1):13-20. doi: 10.1016/j.jacc.2008.08.067.\t","Heart Failure|Myocardial Infarction","Wenyang Huoxue Decoction|Wenyang Huoxue placebo","Parallel Assignment","Treatment","Randomized","Drug|Drug","All","\tStudy on the Clinical and Mechanism of Wenyang Huoxue Decoction in Treating Heart Failure After Myocardial Infarction\tInterventional\tNot yet recruiting\tPhase 2\t2\t200\tinfarction|myocardial infarction|heart failure\tNA\tNA\nNCT04696003\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t28710882\tTchirikov M, Schlabritz-Loutsevitch N, Maher J, Buchmann J, Naberezhnev Y, Winarno AS, Seliger G. Mid-trimester preterm premature rupture of membranes (PPROM): etiology, diagnosis, classification, international recommendations of treatment options and outcome. J Perinat Med. 2018 Jul 26;46(5):465-488. doi: 10.1515/jpm-2017-0027. Review.\t","Bronchopulmonary Dysplasia|Intracranial Hemorrhages|Necrotizing Enterocolitis","Continuous amnioinfusion with Amnion Flush Solution through the intraamniotic catheter","Parallel Assignment","Treatment","Randomized","Combination Product","Female","\tTreatment of Classic Mid-trimester PPROM by Means of Continuous Amnioinfusion\tInterventional\tNot yet recruiting\tPhase 3\t2\t68\tintracranial hemorrhages|hemorrhage|enterocolitis, necrotizing|bronchopulmonary dysplasia|enterocolitis\tNA\tNA\nNCT04696107\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t14715402\tMcCracken LM, Vowles KE, Eccleston C. Acceptance of chronic pain: component analysis and a revised assessment method. Pain. 2004 Jan;107(1-2):159-66.\t","Chronic Pain|Musculoskeletal Diseases|Pain Measurement|Quality of Life","Psychoeducative intervention","Parallel Assignment","Treatment","Randomized","Behavioral","All","\tEffectiveness of Coping Strategies on the Control of Chronic Non-Cancer Pain and Quality of Life (CNCP_CopQol)\tInterventional\tNot yet recruiting\tN/A\t2\t144\tmusculoskeletal diseases|chronic pain\tNA\tNA\nNCT04696224\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t29429857|23521080\tDíaz AR, Navas PZ. Risk factors for trochanteric and femoral neck fracture. Rev Esp Cir Ortop Traumatol. 2018 Mar - Apr;62(2):134-141. doi: 10.1016/j.recot.2017.09.002. Epub 2018 Feb 21. English, Spanish.|Boström J, Grant JA, Fjellström O, Thelin A, Gustafsson D. Potent fibrinolysis inhibitor discovered by shape and electrostatic complementarity to the drug tranexamic acid. J Med Chem. 2013 Apr 25;56(8):3273-80. doi: 10.1021/jm301818g. Epub 2013 Apr 10.\t","Fracture Femur|Hemorrhage","Tranexamic acid|Saline solution","Crossover Assignment","Treatment","Randomized","Drug|Other","All","\tComparative Use of Tranexamic Acid Intravenous and Topical Application in Intertrochanteric Fractures With PFNA\tInterventional\tRecruiting\tN/A\t3\t90\tfractures, bone|hip fractures|hemorrhage\ttranexamic acid\tNA\nNCT04696341\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t23621388|15924510|17369784\tTaspinar F, Aslan UB, Sabir N, Cavlak U. Implementation of matrix rhythm therapy and conventional massage in young females and comparison of their acute effects on circulation. J Altern Complement Med. 2013 Oct;19(10):826-32. doi: 10.1089/acm.2012.0932. Epub 2013 Apr 26.|Smidt N, de Vet HC, Bouter LM, Dekker J, Arendzen JH, de Bie RA, Bierma-Zeinstra SM, Helders PJ, Keus SH, Kwakkel G, Lenssen T, Oostendorp RA, Ostelo RW, Reijman M, Terwee CB, Theunissen C, Thomas S, van Baar ME, van 't Hul A, van Peppen RP, Verhagen A, van der Windt DA; Exercise Therapy Group. Effectiveness of exercise therapy: a best-evidence summary of systematic reviews. Aust J Physiother. 2005;51(2):71-85. Review.|Ylinen J. Physical exercises and functional rehabilitation for the management of chronic neck pain. Eura Medicophys. 2007 Mar;43(1):119-32. Review.\t","Chronic Pain|Physical Disability","Matrix Rhythm Therapy|Control","Parallel Assignment","Treatment","Randomized","Procedure|Procedure","All","\tThe Effect of Matrix Rhythm Therapy in Patients With Chronic Neck Pain\tInterventional\tCompleted\tN/A\t2\t30\tneck pain|chronic pain\tNA\tNA\nNCT04696510\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t14728706|10221784\tSances G, Tassorelli C, Pucci E, Ghiotto N, Sandrini G, Nappi G. Reliability of the nitroglycerin provocative test in the diagnosis of neurovascular headaches. Cephalalgia. 2004 Feb;24(2):110-9.|Tassorelli C, Joseph SA, Buzzi MG, Nappi G. The effects on the central nervous system of nitroglycerin--putative mechanisms and mediators. Prog Neurobiol. 1999 Apr;57(6):607-24. Review.\t","Migraine","NA","NA","NA","NA","NA","All","\tNA\tNA\tNA\tNA\tNA\tNA\tmigraine disorders\tNA\tNA\nNCT04696523\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t26978207|29169472\tLaitio R, Hynninen M, Arola O, Virtanen S, Parkkola R, Saunavaara J, Roine RO, Grönlund J, Ylikoski E, Wennervirta J, Bäcklund M, Silvasti P, Nukarinen E, Tiainen M, Saraste A, Pietilä M, Airaksinen J, Valanne L, Martola J, Silvennoinen H, Scheinin H, Harjola VP, Niiranen J, Korpi K, Varpula M, Inkinen O, Olkkola KT, Maze M, Vahlberg T, Laitio T. Effect of Inhaled Xenon on Cerebral White Matter Damage in Comatose Survivors of Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial. JAMA. 2016 Mar 15;315(11):1120-8. doi: 10.1001/jama.2016.1933.|Arola O, Saraste A, Laitio R, Airaksinen J, Hynninen M, Bäcklund M, Ylikoski E, Wennervirta J, Pietilä M, Roine RO, Harjola VP, Niiranen J, Korpi K, Varpula M, Scheinin H, Maze M, Vahlberg T, Laitio T; Xe-HYPOTHECA Study Group. Inhaled Xenon Attenuates Myocardial Damage in Comatose Survivors of Out-of-Hospital Cardiac Arrest: The Xe-Hypotheca Trial. J Am Coll Cardiol. 2017 Nov 28;70(21):2652-2660. doi: 10.1016/j.jacc.2017.09.1088.\t","Cardiac Event|Cardiac Failure|Cerebral Infarction|Cerebral Injury|Cerebral Ischemia|Subarachnoid Hemorrhage, Aneurysmal","Xenon|air/oxygen","Parallel Assignment","Treatment","Randomized","Drug|Drug","All","\tEffect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage\tInterventional\tNot yet recruiting\tPhase 2\t2\t160\tbrain ischemia|heart failure|infarction|brain injuries|cerebral infarction|hemorrhage|ischemia|wounds and injuries|subarachnoid hemorrhage\txenon\tNA\nNCT04696588\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t22156949|20634268|27965609|25415466|31364603|19842352|21808880|27965530|25025844|6662609\tMeikle MB, Henry JA, Griest SE, Stewart BJ, Abrams HB, McArdle R, Myers PJ, Newman CW, Sandridge S, Turk DC, Folmer RL, Frederick EJ, House JW, Jacobson GP, Kinney SE, Martin WH, Nagler SM, Reich GE, Searchfield G, Sweetow R, Vernon JA. The tinnitus functional index: development of a new clinical measure for chronic, intrusive tinnitus. Ear Hear. 2012 Mar-Apr;33(2):153-76. doi: 10.1097/AUD.0b013e31822f67c0. Erratum in: Ear Hear. 2012 May;33(3):443.|Cleland JA, Mintken PE, Carpenter K, Fritz JM, Glynn P, Whitman J, Childs JD. Examination of a clinical prediction rule to identify patients with neck pain likely to benefit from thoracic spine thrust manipulation and a general cervical range of motion exercise: multi-center randomized clinical trial. Phys Ther. 2010 Sep;90(9):1239-50. doi: 10.2522/ptj.20100123. Epub 2010 Jul 15.|Wrzosek M, Szymiec E, Klemens W, Kotyło P, Schlee W, Modrzyńska M, Lang-Małecka A, Preis A, Bulla J. Polish Translation and Validation of the Tinnitus Handicap Inventory and the Tinnitus Functional Index. Front Psychol. 2016 Nov 29;7:1871. eCollection 2016.|Michiels S, De Hertogh W, Truijen S, Van de Heyning P. Cervical spine dysfunctions in patients with chronic subjective tinnitus. Otol Neurotol. 2015 Apr;36(4):741-5. doi: 10.1097/MAO.0000000000000670.|Michiels S, Harrison S, Vesala M, Schlee W. The Presence of Physical Symptoms in Patients With Tinnitus: International Web-Based Survey. Interact J Med Res. 2019 Jul 30;8(3):e14519. doi: 10.2196/14519.|Latifpour DH, Grenner J, Sjödahl C. The effect of a new treatment based on somatosensory stimulation in a group of patients with somatically related tinnitus. Int Tinnitus J. 2009;15(1):94-9.|Sanchez TG, Rocha CB. Diagnosis and management of somatosensory tinnitus: review article. Clinics (Sao Paulo). 2011;66(6):1089-94. Review.|Michiels S, Naessens S, Van de Heyning P, Braem M, Visscher CM, Gilles A, De Hertogh W. The Effect of Physical Therapy Treatment in Patients with Subjective Tinnitus: A Systematic Review. Front Neurosci. 2016 Nov 29;10:545. eCollection 2016. Review.|Maitland GD. Palpation examination of the posterior cervical spine: the ideal, average and abnormal. Aust J Physiother. 1982 Jun;28(3):3-12. doi: 10.1016/S0004-9514(14)60768-6.|Gerhardt JJ. Clinical measurements of joint motion and position in the neutral-zero method and SFTR recording: basic principles. Int Rehabil Med. 1983;5(4):161-4.\t","Subjective Tinnitus","Complex set of kinesiotherapy of cervical spine and delicate massage","NA","NA","NA","Other","All","\tNeck Kinesiotherapy and Massage in Tinnitus Treatment\tInterventional\tCompleted\tN/A\t2\t118\ttinnitus\tNA\tNA\nNCT04696887\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t11833022|NA|3572711|19508982|17760999|2229948|19822941|2035588|21697139|25888654|20554116|NA|NA|NA\tWashburn RA, Zhu W, McAuley E, Frogley M, Figoni SF. The physical activity scale for individuals with physical disabilities: development and evaluation. Arch Phys Med Rehabil. 2002 Feb;83(2):193-200.|2Cunningham, G. B. (2020). Development of the Physical Activity Class Satisfaction Questionnaire (PACSQ). Measurement in Physical Education and Exercise Science, 11(3), 161-176.|Hays RD, DiMatteo MR. A short-form measure of loneliness. J Pers Assess. 1987 Spring;51(1):69-81.|Cornwell EY, Waite LJ. Measuring social isolation among older adults using multiple indicators from the NSHAP study. J Gerontol B Psychol Sci Soc Sci. 2009 Nov;64 Suppl 1:i38-46. doi: 10.1093/geronb/gbp037. Epub 2009 Jun 9.|Kroll T, Kehn M, Ho PS, Groah S. The SCI Exercise Self-Efficacy Scale (ESES): development and psychometric properties. Int J Behav Nutr Phys Act. 2007 Aug 30;4:34.|Tinetti ME, Richman D, Powell L. Falls efficacy as a measure of fear of falling. J Gerontol. 1990 Nov;45(6):P239-43.|Finlayson M, Peterson EW, Cho C. Pilot study of a fall risk management program for middle aged and older adults with MS. NeuroRehabilitation. 2009;25(2):107-15. doi: 10.3233/NRE-2009-0505.|Walker JE, Howland J. Falls and fear of falling among elderly persons living in the community: occupational therapy interventions. Am J Occup Ther. 1991 Feb;45(2):119-22.|Pilkonis PA, Choi SW, Reise SP, Stover AM, Riley WT, Cella D; PROMIS Cooperative Group. Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS®): depression, anxiety, and anger. Assessment. 2011 Sep;18(3):263-83. doi: 10.1177/1073191111411667. Epub 2011 Jun 21.|Siebens HC, Tsukerman D, Adkins RH, Kahan J, Kemp B. Correlates of a Single-Item Quality-of-Life Measure in People Aging with Disabilities. Am J Phys Med Rehabil. 2015 Dec;94(12):1065-74. doi: 10.1097/PHM.0000000000000298.|Amtmann D, Cook KF, Jensen MP, Chen WH, Choi S, Revicki D, Cella D, Rothrock N, Keefe F, Callahan L, Lai JS. Development of a PROMIS item bank to measure pain interference. Pain. 2010 Jul;150(1):173-182. doi: 10.1016/j.pain.2010.04.025.|Davis, F. D. (1989). Perceived usefulness, perceived ease of use, and user acceptance of information technology. MIS Quarterly, 13, 319-340.|Venkatesh, V. (2000). Determinants of perceived ease of use: Integrating perceived behavioral control, computer anxiety and enjoyment into the technology acceptance model. Information Systems Research, 11, 342-365.|Venkatesh, V., & Bala, H. (2008). Technology Acceptance Model 3 and a research agenda on interventions. Decision Sciences, 39(2), 273-315. https://doi.org/10.1111/j.1540-5915.2008.00192.x\t","Aging|Disability Physical","Tele Tai Chi Intervention for Persons Aging with Long-Term Mobility Disabilities","NA","NA","NA","Behavioral","All","\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\nNCT04698473\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t27976361\tLemyre B, Laughon M, Bose C, Davis PG. Early nasal intermittent positive pressure ventilation (NIPPV) versus early nasal continuous positive airway pressure (NCPAP) for preterm infants. Cochrane Database Syst Rev. 2016 Dec 15;12:CD005384. doi: 10.1002/14651858.CD005384.pub2. Review.\t","Respiratory Distress Syndrome","NCPAP|NIPPV","Parallel Assignment","Treatment","Randomized","Other|Other","All","\tComparison of Efficacy of Less Invasive Surfactant Treatment Under Nasal CPAP and Nasal IPPV\tInterventional\tRecruiting\tN/A\t2\t170\trespiratory distress syndrome, adult|respiratory distress syndrome, newborn\tNA\tNA\nNCT04698668\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t26826086|29954676\tRajagopal M, Venkatesan AM. Image fusion and navigation platforms for percutaneous image-guided interventions. Abdom Radiol (NY). 2016 Apr;41(4):620-8. doi: 10.1007/s00261-016-0645-7. Review.|Zhang H, Chen GY, Xiao L, Ma X, Shi L, Wang T, Yan HT, Zou H, Chen Q, Tang LJ, Liu WH. Ultrasonic/CT image fusion guidance facilitating percutaneous catheter drainage in treatment of acute pancreatitis complicated with infected walled-off necrosis. Pancreatology. 2018 Sep;18(6):635-641. doi: 10.1016/j.pan.2018.06.004. Epub 2018 Jun 18.\t","Pseudocyst|Walled Off Cavity","fusion imaging","NA","NA","NA","Device","All","\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\nNCT04698759\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t31109058\tTitaley CR, Ariawan I, Hapsari D, Muasyaroh A, Dibley MJ. Determinants of the Stunting of Children Under Two Years Old in Indonesia: A Multilevel Analysis of the 2013 Indonesia Basic Health Survey. Nutrients. 2019 May 18;11(5). pii: E1106. doi: 10.3390/nu11051106.\t","Fatty Acid|Immune Deficiency|Stunting","No Intervention","NA","NA","NA","Other","All","\tNA\tNA\tNA\tNA\tNA\tNA\timmunologic deficiency syndromes|growth disorders\tNA\tNA\nNCT04699071\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t22525820|23485770\tdel Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol. 2012 Sep;126(3):481-90. doi: 10.1016/j.ygyno.2012.04.021. Epub 2012 Apr 21. Review.|Brinton LA, Felix AS, McMeekin DS, Creasman WT, Sherman ME, Mutch D, Cohn DE, Walker JL, Moore RG, Downs LS, Soslow RA, Zaino R. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013 May;129(2):277-84. doi: 10.1016/j.ygyno.2013.02.023. Epub 2013 Feb 26.\t","Adenocarcinomas|Recurrent Gynecological","pembrolizumab and lenvatinib","NA","NA","NA","Drug","All","\tNA\tNA\tNA\tNA\tNA\tNA\tadenocarcinoma|adenocarcinoma, clear cell\tpembrolizumab|lenvatinib\tNA\nNCT04699344\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t33037018|15655554|19424173|28647394\tZeng S, Ying Y, Xing N, Wang B, Qian Z, Zhou Z, Zhang Z, Xu W, Wang H, Dai L, Gao L, Zhou T, Ji J, Xu C. Noninvasive Detection of Urothelial Carcinoma by Cost-effective Low-coverage Whole-genome Sequencing from Urine-Exfoliated Cell DNA. Clin Cancer Res. 2020 Nov 1;26(21):5646-5654. doi: 10.1158/1078-0432.CCR-20-0401. Epub 2020 Oct 9.|Thuret R, Chantrel-Groussard K, Azzouzi AR, Villette JM, Guimard S, Teillac P, Berthon P, Houlgatte A, Latil A, Cussenot O. Clinical relevance of genetic instability in prostatic cells obtained by prostatic massage in early prostate cancer. Br J Cancer. 2005 Jan 31;92(2):236-40.|Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol. 2009 May;6(5):255-61. doi: 10.1038/nrurol.2009.40. Review.|Özdemir TR, Şimşir A, Onay H, Cüreklibatır İ, Özkınay F, Akın H. Whole-genome gene expression analysis in urine samples of patients with prostate cancer and benign prostate hyperplasia. Urol Oncol. 2017 Oct;35(10):607.e15-607.e24. doi: 10.1016/j.urolonc.2017.05.020. Epub 2017 Jun 21.\t","Prostate Carcinoma","The level of CNV","NA","NA","NA","Diagnostic Test","Male","\tNA\tNA\tNA\tNA\tNA\tNA\tcarcinoma|prostatic neoplasms\tNA\tNA\nNCT04699435\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t21447488|19399574|3578856|1984382|1931404|32424516\tCook TM, Woodall N, Frerk C; Fourth National Audit Project. Major complications of airway management in the UK: results of the Fourth National Audit Project of the Royal College of Anaesthetists and the Difficult Airway Society. Part 1: anaesthesia. Br J Anaesth. 2011 May;106(5):617-31. doi: 10.1093/bja/aer058. Epub 2011 Mar 29.|Tanoubi I, Drolet P, Donati F. Optimizing preoxygenation in adults. Can J Anaesth. 2009 Jun;56(6):449-66. doi: 10.1007/s12630-009-9084-z. Epub 2009 Apr 28. Review.|Gambee AM, Hertzka RE, Fisher DM. Preoxygenation techniques: comparison of three minutes and four breaths. Anesth Analg. 1987 May;66(5):468-70.|Jense HG, Dubin SA, Silverstein PI, O'Leary-Escolas U. Effect of obesity on safe duration of apnea in anesthetized humans. Anesth Analg. 1991 Jan;72(1):89-93.|Berthoud MC, Peacock JE, Reilly CS. Effectiveness of preoxygenation in morbidly obese patients. Br J Anaesth. 1991 Oct;67(4):464-6.|Tsymbal E, Ayala S, Singh A, Applegate RL 2nd, Fleming NW. Study of early warning for desaturation provided by Oxygen Reserve Index in obese patients. J Clin Monit Comput. 2020 May 18. doi: 10.1007/s10877-020-00531-w. [Epub ahead of print]\t","Anesthesia","Control|PreOx_3min|PreOx_6min","Parallel Assignment","Prevention","Randomized","Other|Other|Other","All","\tEffect of the Duration of Pre-oxygenation on Apnea Tolerance in Obese Patients During the Induction of General Anesthesia\tInterventional\tRecruiting\tN/A\t3\t200\tNA\tNA\tNA\nNCT04699682\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t22856512|30123500|23995982\tFournier S, Brossier F, Fortineau N, Gillaizeau F, Akpabie A, Aubry A, Barbut F, Chedhomme FX, Kassis-Chikhani N, Lucet JC, Robert J, Seytre D, Simon I, Vanjak D, Zahar JR, Brun-Buisson C, Jarlier V. Long-term control of vancomycin-resistant Enterococcus faecium at the scale of a large multihospital institution: a seven-year experience. Euro Surveill. 2012 Jul 26;17(30). pii: 20229.|Davido B, Moussiegt A, Dinh A, Bouchand F, Matt M, Senard O, Deconinck L, Espinasse F, Lawrence C, Fortineau N, Saleh-Mghir A, Caballero S, Escaut L, Salomon J. Germs of thrones - spontaneous decolonization of Carbapenem-Resistant Enterobacteriaceae (CRE) and Vancomycin-Resistant Enterococci (VRE) in Western Europe: is this myth or reality? Antimicrob Resist Infect Control. 2018 Aug 13;7:100. doi: 10.1186/s13756-018-0390-5. eCollection 2018.|Zahar JR, Garrouste-Orgeas M, Vesin A, Schwebel C, Bonadona A, Philippart F, Ara-Somohano C, Misset B, Timsit JF. Impact of contact isolation for multidrug-resistant organisms on the occurrence of medical errors and adverse events. Intensive Care Med. 2013 Dec;39(12):2153-60. doi: 10.1007/s00134-013-3071-0. Epub 2013 Aug 31.\t","Chronic Kidney Diseases|Dialysis","Control|BHR Case","NA","NA","NA","Other|Other","All","\tCarriage Clearance of Emerging Highly Resistant Bacteria in Chronic Dialysis Patients\tInterventional\tRecruiting\tN/A\t2\t600\tkidney diseases|renal insufficiency, chronic\tNA\tNA\nNCT04699981\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t15325835|26571186|30204851|27890442|22057701|27358356|27989244\tWertheim HF, Vos MC, Ott A, van Belkum A, Voss A, Kluytmans JA, van Keulen PH, Vandenbroucke-Grauls CM, Meester MH, Verbrugh HA. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet. 2004 Aug 21-27;364(9435):703-5.|Bruyère R, Vigneron C, Bador J, Aho S, Toitot A, Quenot JP, Prin S, Charles PE. Significance of Prior Digestive Colonization With Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Patients With Ventilator-Associated Pneumonia. Crit Care Med. 2016 Apr;44(4):699-706. doi: 10.1097/CCM.0000000000001471.|Dubinsky-Pertzov B, Temkin E, Harbarth S, Fankhauser-Rodriguez C, Carevic B, Radovanovic I, Ris F, Kariv Y, Buchs NC, Schiffer E, Cohen Percia S, Nutman A, Fallach N, Klausner J, Carmeli Y; R-GNOSIS WP4 Study Group. Carriage of Extended-spectrum Beta-lactamase-producing Enterobacteriaceae and the Risk of Surgical Site Infection After Colorectal Surgery: A Prospective Cohort Study. Clin Infect Dis. 2019 May 2;68(10):1699-1704. doi: 10.1093/cid/ciy768.|Zahar JR, Lesprit P, Ruckly S, Eden A, Hikombo H, Bernard L, Harbarth S, Timsit JF, Brun-Buisson C; BacterCom Study Group. Predominance of healthcare-associated cases among episodes of community-onset bacteraemia due to extended-spectrum β-lactamase-producing Enterobacteriaceae. Int J Antimicrob Agents. 2017 Jan;49(1):67-73. doi: 10.1016/j.ijantimicag.2016.09.032. Epub 2016 Nov 16. Erratum in: Int J Antimicrob Agents. 2017 Apr;49(4):480-481.|Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual Á; Extended-Spectrum Beta-Lactamases-Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012 Jan 15;54(2):167-74. doi: 10.1093/cid/cir790. Epub 2011 Nov 4.|Goodman KE, Lessler J, Cosgrove SE, Harris AD, Lautenbach E, Han JH, Milstone AM, Massey CJ, Tamma PD; Antibacterial Resistance Leadership Group. A Clinical Decision Tree to Predict Whether a Bacteremic Patient Is Infected With an Extended-Spectrum β-Lactamase-Producing Organism. Clin Infect Dis. 2016 Oct 1;63(7):896-903. doi: 10.1093/cid/ciw425. Epub 2016 Jun 28.|Augustine MR, Testerman TL, Justo JA, Bookstaver PB, Kohn J, Albrecht H, Al-Hasan MN. Clinical Risk Score for Prediction of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Bloodstream Isolates. Infect Control Hosp Epidemiol. 2017 Mar;38(3):266-272. doi: 10.1017/ice.2016.292. Epub 2016 Dec 19.\t","Enterobacteria Infections","Control (Patients colonized rectally with ESBL-producing enterobacteria without antibiotic pressure)|Case (Patients colonized rectally with ESBL-producing enterobacteriaceae, with antibiotic pressure)","NA","NA","NA","Other|Other","All","\tCan the Relative Fecal Abundance of BLSE and the Digestive Microbiota be Predictive of the Risk of Infection in a Carrier Patient?\tInterventional\tRecruiting\tN/A\t2\t200\tcommunicable diseases|infection\tanti-bacterial agents|antibiotics, antitubercular\tNA\nNCT04700254\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t32987040|32563134|32503173|32759636|32645970\tAragona M, Rodia C, Bertolotto A, Campi F, Coppelli A, Giannarelli R, Bianchi C, Dardano A, Del Prato S. Type 1 diabetes and COVID-19: The \"\"lockdown effect\"\". Diabetes Res Clin Pract. 2020 Dec;170:108468. doi: 10.1016/j.diabres.2020.108468. Epub 2020 Sep 25.\"|Sakelliadis EI, Katsos KD, Zouzia EI, Spiliopoulou CA, Tsiodras S. Impact of Covid-19 lockdown on characteristics of autopsy cases in Greece. Comparison between 2019 and 2020. Forensic Sci Int. 2020 Aug;313:110365. doi: 10.1016/j.forsciint.2020.110365. Epub 2020 Jun 12.|Sidor A, Rzymski P. Dietary Choices and Habits during COVID-19 Lockdown: Experience from Poland. Nutrients. 2020 Jun 3;12(6). pii: E1657. doi: 10.3390/nu12061657.|Ruiz-Roso MB, Knott-Torcal C, Matilla-Escalante DC, Garcimartín A, Sampedro-Nuñez MA, Dávalos A, Marazuela M. COVID-19 Lockdown and Changes of the Dietary Pattern and Physical Activity Habits in a Cohort of Patients with Type 2 Diabetes Mellitus. Nutrients. 2020 Aug 4;12(8). pii: E2327. doi: 10.3390/nu12082327.|\"Pellegrini M, Ponzo V, Rosato R, Scumaci E, Goitre I, Benso A, Belcastro S, Crespi C, De Michieli F, Ghigo E, Broglio F, Bo S. Changes in Weight and Nutritional Habits in Adults with Obesity during the \"\"Lockdown\"\" Period Caused by the COVID-19 Virus Emergency. Nutrients. 2020 Jul 7;12(7). pii: E2016. doi: 10.3390/nu12072016.\"","\tDiabetes Mellitus|SARS-CoV-2\tDASS questionnaire|EAT-26 questionnaire\tNA\tNA\tNA\tOther|Other\tAll\t","NA","NA","NA","NA","NA","NA","depression|diabetes mellitus","NA","NA"]
["NCT04725058","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24570244|11832527|23625271|23323827|20633095","Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014 Feb 26;311(8):806-14. doi: 10.1001/jama.2014.732.|Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.|Ryan DH, Bray GA. Pharmacologic treatment options for obesity: what is old is new again. Curr Hypertens Rep. 2013 Jun;15(3):182-9. doi: 10.1007/s11906-013-0343-6. Review.|Carvajal R, Wadden TA, Tsai AG, Peck K, Moran CH. Managing obesity in primary care practice: a narrative review. Ann N Y Acad Sci. 2013 Apr;1281:191-206. doi: 10.1111/nyas.12004. Epub 2013 Jan 16. Review.|Vadheim LM, Brewer KA, Kassner DR, Vanderwood KK, Hall TO, Butcher MK, Helgerson SD, Harwell TS. Effectiveness of a lifestyle intervention program among persons at high risk for cardiovascular disease and diabetes in a rural community. J Rural Health. 2010 Summer;26(3):266-72. doi: 10.1111/j.1748-0361.2010.00288.x.","\tObesity\tMedical Group Visit|Dietitian Individual Visit\tParallel Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Obesity Group Visits. A Novel Way to Approach the Obesity Epidemic in an Inner-City Setting","Interventional","Recruiting","N/A",2,1000,"obesity","NA","NA"]
["NCT04734353","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",31475799,"Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flügel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Möllmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S, Allali A, Ndrepepa G, Schühlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A, Tölg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A; ISAR-REACT 5 Trial Investigators. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019 Oct 17;381(16):1524-1534. doi: 10.1056/NEJMoa1908973. Epub 2019 Sep 1.","\tCoronary Artery Disease\tPrasugrel 5mg|Ticagrelor 60mg\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION)","Interventional","Recruiting","Phase 4",2,492,"coronary disease|coronary artery disease|myocardial ischemia","ticagrelor|prasugrel hydrochloride","NA"]
["NCT04746157","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25491651,"Parmar P, Krishnamurthi R, Ikram MA, Hofman A, Mirza SS, Varakin Y, Kravchenko M, Piradov M, Thrift AG, Norrving B, Wang W, Mandal DK, Barker-Collo S, Sahathevan R, Davis S, Saposnik G, Kivipelto M, Sindi S, Bornstein NM, Giroud M, Béjot Y, Brainin M, Poulton R, Narayan KM, Correia M, Freire A, Kokubo Y, Wiebers D, Mensah G, BinDhim NF, Barber PA, Pandian JD, Hankey GJ, Mehndiratta MM, Azhagammal S, Ibrahim NM, Abbott M, Rush E, Hume P, Hussein T, Bhattacharjee R, Purohit M, Feigin VL; Stroke RiskometerTM Collaboration Writing Group. The Stroke Riskometer(TM) App: validation of a data collection tool and stroke risk predictor. Int J Stroke. 2015 Feb;10(2):231-44. doi: 10.1111/ijs.12411. Epub 2014 Dec 10.","\tStroke\tNurse intervention\tParallel Assignment\tHealth Services Research\tRandomized\tOther\tAll\t","A Nursing Support Intervention-based Project for Stroke Survivors","Interventional","Not yet recruiting","N/A",2,50,"stroke","NA","NA"]
["NCT04752124","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21698340,"Lau KW, Mak MK. Speed-dependent treadmill training is effective to improve gait and balance performance in patients with sub-acute stroke. J Rehabil Med. 2011 Jul;43(8):709-13. doi: 10.2340/16501977-0838.","\tStroke\tExercise Therapy|conventional therapy\tParallel Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Effects of High-intensity Aerobic Training on Balance, Walking Capacity, and Quality of Life in Patients With Sub-acute Stroke.","Interventional","Completed","N/A",2,50,"stroke","NA","NA"]
["NCT04770922","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21270794|25624441|23962279","Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011 Mar;89(3):387-91. doi: 10.1038/clpt.2010.320. Epub 2011 Jan 26. Erratum in: Clin Pharmacol Ther. 2011 Dec;90(6):894.|Yang JJ, Landier W, Yang W, Liu C, Hageman L, Cheng C, Pei D, Chen Y, Crews KR, Kornegay N, Wong FL, Evans WE, Pui CH, Bhatia S, Relling MV. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015 Apr 10;33(11):1235-42. doi: 10.1200/JCO.2014.59.4671. Epub 2015 Jan 26.|Lennard L. Implementation of TPMT testing. Br J Clin Pharmacol. 2014 Apr;77(4):704-14. doi: 10.1111/bcp.12226.","\tAcute Lymphoblastic Leukemia, Pediatric|Adverse Drug Event\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","leukemia, lymphoid|precursor cell lymphoblastic leukemia-lymphoma|leukemia|drug-related side effects and adverse reactions","NA","NA"]
["NCT04776603","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32371252,"Kane JX, Connell B. A Comparison of the Accuracy of 6 Modern Toric Intraocular Lens Formulas. Ophthalmology. 2020 Nov;127(11):1472-1486. doi: 10.1016/j.ophtha.2020.04.039. Epub 2020 May 1.","\tAstigmatism\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","astigmatism","NA","NA"]
["NCT04777097","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","9354828|24931841|22926249","Brecher ME, Monk T, Goodnough LT. A standardized method for calculating blood loss. Transfusion. 1997 Oct;37(10):1070-4.|Theusinger OM, Kind SL, Seifert B, Borgeat L, Gerber C, Spahn DR. Patient blood management in orthopaedic surgery: a four-year follow-up of transfusion requirements and blood loss from 2008 to 2011 at the Balgrist University Hospital in Zurich, Switzerland. Blood Transfus. 2014 Apr;12(2):195-203. doi: 10.2450/2014.0306-13.|de Lange NM, Lancé MD, de Groot R, Beckers EA, Henskens YM, Scheepers HC. Obstetric hemorrhage and coagulation: an update. Thromboelastography, thromboelastometry, and conventional coagulation tests in the diagnosis and prediction of postpartum hemorrhage. Obstet Gynecol Surv. 2012 Jul;67(7):426-35. doi: 10.1097/OGX.0b013e3182605861. Review.","\tBlood Loss|Coagulation Disorder|Pre-Eclampsia; Complicating Pregnancy\tBlood sample\tNA\tNA\tNA\tOther\tFemale\t","NA","NA","NA","NA","NA","NA","blood coagulation disorders|pregnancy complications|pre-eclampsia|eclampsia|hemorrhage|hemostatic disorders","NA","NA"]
["NCT04777682","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29097866|20581245|29437914|28039647","Atkinson NSS, Bryant RV, Dong Y, Maaser C, Kucharzik T, Maconi G, Asthana AK, Blaivas M, Goudie A, Gilja OH, Nuernberg D, Schreiber-Dietrich D, Dietrich CF. How to perform gastrointestinal ultrasound: Anatomy and normal findings. World J Gastroenterol. 2017 Oct 14;23(38):6931-6941. doi: 10.3748/wjg.v23.i38.6931. Review.|Beggs AD, Latchford AR, Vasen HF, Moslein G, Alonso A, Aretz S, Bertario L, Blanco I, Bülow S, Burn J, Capella G, Colas C, Friedl W, Møller P, Hes FJ, Järvinen H, Mecklin JP, Nagengast FM, Parc Y, Phillips RK, Hyer W, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJ, Wijnen JT, Clark SK, Hodgson SV. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut. 2010 Jul;59(7):975-86. doi: 10.1136/gut.2009.198499.|Bryant RV, Friedman AB, Wright EK, Taylor KM, Begun J, Maconi G, Maaser C, Novak KL, Kucharzik T, Atkinson NSS, Asthana A, Gibson PR. Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application. Gut. 2018 May;67(5):973-985. doi: 10.1136/gutjnl-2017-315655. Epub 2018 Feb 3. Review.|Cai JX, Diehl DL, Kiesslich R, Storm AC, El Zein MH, Tieu AH, Hoffman A, Singh VK, Khashab MA, Okolo PI 3rd, Kumbhari V. A multicenter experience of through-the-scope balloon-assisted enteroscopy in surgically altered gastrointestinal anatomy. Surg Endosc. 2017 Jul;31(7):2753-2762. doi: 10.1007/s00464-016-5282-2. Epub 2016 Dec 30.","\tMalabsorption Syndrome\tultrasound, double balloon enteroscopy\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","syndrome|malabsorption syndromes","NA","NA"]
["NCT04777695","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29274594,"Garcia Guerra G, Joffe AR, Sheppard C, Pugh J, Moez EK, Dinu IA, Jou H, Hartling L, Vohra S; SedationWithdrawal and Analgesia Team (SWAT); Canadian Critical Care Trials Group (CCCTG). Prospective cohort study on noise levels in a pediatric cardiac intensive care unit. J Crit Care. 2018 Apr;44:318-322. doi: 10.1016/j.jcrc.2017.12.008. Epub 2017 Dec 14.","\tNoise Exposure|Sedative Toxicity|Sedative Withdrawal Delirium\tDecibel Monitor\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","delirium","NA","NA"]
["NCT04778163","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25266473|21071099|24337476","Cai C, Yu L, Rong L, Zhong H. Effectiveness of humor intervention for patients with schizophrenia: a randomized controlled trial. J Psychiatr Res. 2014 Dec;59:174-8. doi: 10.1016/j.jpsychires.2014.09.010. Epub 2014 Sep 19.|Falkenberg I, Buchkremer G, Bartels M, Wild B. Implementation of a manual-based training of humor abilities in patients with depression: a pilot study. Psychiatry Res. 2011 Apr 30;186(2-3):454-7. doi: 10.1016/j.psychres.2010.10.009. Epub 2010 Nov 11.|Rudnick A, Kohn PM, Edwards KR, Podnar D, Caird S, Martin R. Humour-related interventions for people with mental illness: a randomized controlled pilot study. Community Ment Health J. 2014 Aug;50(6):737-42. doi: 10.1007/s10597-013-9685-4. Epub 2013 Dec 12.","\tPsychiatric Disorder|Treatment Adherence and Compliance\tClinical use of humor\tParallel Assignment\tTreatment\tRandomized\tBehavioral\tAll\t","The Use of Humor With Young Adults in Psychiatric Care","Interventional","Recruiting","N/A",2,34,"mental disorders|problem behavior","NA","NA"]
["NCT04778891","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",31639091,"Brajković A, Mucalo I, Vidović T, Gonzaga MM, Nascimento D, Balenović A, Protrka I, De Oliveira DR. Implementation of medication management services at the primary healthcare level - a pilot study. Acta Pharm. 2019 Dec 1;69(4):585-606. doi: 10.2478/acph-2019-0055.","\tCardiovascular Diseases in Old Age\tComprehensive Medication Management services\tNA\tNA\tNA\tOther\tAll\t","The Impact of Comprehensive Medication Management Services on Clinical Outcomes in Patients With Cardiovascular Diseases at Primary Care Level","Interventional","Completed","N/A",2,133,"cardiovascular diseases","NA","NA"]
["NCT04778930","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32086598|31910452|29845609|31677546|29637118|32161730","Novak I, Morgan C, Fahey M, Finch-Edmondson M, Galea C, Hines A, Langdon K, Namara MM, Paton MC, Popat H, Shore B, Khamis A, Stanton E, Finemore OP, Tricks A, Te Velde A, Dark L, Morton N, Badawi N. State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy. Curr Neurol Neurosci Rep. 2020 Feb 21;20(2):3. doi: 10.1007/s11910-020-1022-z.|Sellier E, McIntyre S, Smithers-Sheedy H, Platt MJ; SCPE and ACPR Groups. European and Australian Cerebral Palsy Surveillance Networks Working Together for Collaborative Research. Neuropediatrics. 2020 Apr;51(2):105-112. doi: 10.1055/s-0039-3402003. Epub 2020 Jan 7.|Schiariti V, Mahdi S, Bölte S. International Classification of Functioning, Disability and Health Core Sets for cerebral palsy, autism spectrum disorder, and attention-deficit-hyperactivity disorder. Dev Med Child Neurol. 2018 Sep;60(9):933-941. doi: 10.1111/dmcn.13922. Epub 2018 May 30.|Chakraborty S, Nandy A, Kesar TM. Gait deficits and dynamic stability in children and adolescents with cerebral palsy: A systematic review and meta-analysis. Clin Biomech (Bristol, Avon). 2020 Jan;71:11-23. doi: 10.1016/j.clinbiomech.2019.09.005. Epub 2019 Oct 18.|Toovey R, Bernie C, Harvey AR, McGinley JL, Spittle AJ. Task-specific gross motor skills training for ambulant school-aged children with cerebral palsy: a systematic review. BMJ Paediatr Open. 2017 Aug 11;1(1):e000078. doi: 10.1136/bmjpo-2017-000078. eCollection 2017.|Han YG, Yun CK. Effectiveness of treadmill training on gait function in children with cerebral palsy: meta-analysis. J Exerc Rehabil. 2020 Feb 26;16(1):10-19. doi: 10.12965/jer.1938748.374. eCollection 2020 Feb. Review.","\tCerebral Palsy|Physical Therapy|Telehealth|Therapeutic Education\tPhysical Therapy|THERAPEUTIC EDUCATION PROGRAM\tParallel Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Physical Therapy for Improving Functionality, Gait and Participation in Cerebral Palsy","Interventional","Not yet recruiting","N/A",2,66,"cerebral palsy|paralysis","NA","NA"]
["NCT04778995","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28263273|32292636|32167538","Veenema TG, Deruggiero K, Losinski S, Barnett D. Hospital Administration and Nursing Leadership in Disasters: An Exploratory Study Using Concept Mapping. Nurs Adm Q. 2017 Apr/Jun;41(2):151-163. doi: 10.1097/NAQ.0000000000000224.|Wang H, Feng J, Shao L, Wei J, Wang X, Xu X, Shao R, Zhang M, He J, Zhao X, Liang T. Contingency management strategies of the Nursing Department in centralized rescue of patients with coronavirus disease 2019. Int J Nurs Sci. 2020 Apr 4;7(2):139-142. doi: 10.1016/j.ijnss.2020.04.001. eCollection 2020 Apr 10.|Grasselli G, Pesenti A, Cecconi M. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response. JAMA. 2020 Apr 28;323(16):1545-1546. doi: 10.1001/jama.2020.4031.","\tCrisis State|Education|Nursing|Pandemics\tStructured online training program for effective management of nursing services\tParallel Assignment\tHealth Services Research\tRandomized\tOther\tAll\t","Online Training Program Model for Effective Management of Nursing Services in Times of Crisis Such as Pandemic","Interventional","Completed","N/A",2,60,"NA","NA","NA"]
["NCT04779281","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31208096|8665277|7958646|NA|30356594|30056755|11352068|17962710|21400082","Nocella C, Cammisotto V, Pigozzi F, Borrione P, Fossati C, D'Amico A, Cangemi R, Peruzzi M, Gobbi G, Ettorre E, Frati G, Cavarretta E, Carnevale R; SMiLe Group. Impairment between Oxidant and Antioxidant Systems: Short- and Long-term Implications for Athletes' Health. Nutrients. 2019 Jun 15;11(6). pii: E1353. doi: 10.3390/nu11061353. Review.|Pyne DB. Exercise-induced muscle damage and inflammation: a review. Aust J Sci Med Sport. 1994 Sep-Dec;26(3-4):49-58. Review.|Lopez AA, Preziosi JP, Chateau P, Auguste P, Plique O. [Digestive disorders and self medication observed during a competition in endurance athletes. Prospective epidemiological study during a championship of triathlon]. Gastroenterol Clin Biol. 1994;18(4):317-22. French.|Maughan RJ, Shirreffs SM. Sports Beverages for Optimizing Physical Performance. In: Wilson T., Temple N. (eds) Beverage Impacts on Health and Nutrition. Nutrition and Health. Humana Press, Cham. 2016.|Mach N, Fuster-Botella D. Endurance exercise and gut microbiota: A review. J Sport Health Sci. 2017 Jun;6(2):179-197. doi: 10.1016/j.jshs.2016.05.001. Epub 2016 May 10. Review.|Hoffman MD, Stellingwerff T, Costa RJS. Considerations for ultra-endurance activities: part 2 - hydration. Res Sports Med. 2019 Apr-Jun;27(2):182-194. doi: 10.1080/15438627.2018.1502189. Epub 2018 Jul 28. Review.|Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science. 2001 May 11;292(5519):1115-8. Review.|Kekkonen RA, Vasankari TJ, Vuorimaa T, Haahtela T, Julkunen I, Korpela R. The effect of probiotics on respiratory infections and gastrointestinal symptoms during training in marathon runners. Int J Sport Nutr Exerc Metab. 2007 Aug;17(4):352-63.|Martarelli D, Verdenelli MC, Scuri S, Cocchioni M, Silvi S, Cecchini C, Pompei P. Effect of a probiotic intake on oxidant and antioxidant parameters in plasma of athletes during intense exercise training. Curr Microbiol. 2011 Jun;62(6):1689-96. doi: 10.1007/s00284-011-9915-3. Epub 2011 Mar 12.","\tUltra-endurance Athletes With Gastrointestinal Symptoms\tOral Rehydration Salts supplemented with L. Rhamnosus GG|Oral Rehydration Salts only\tParallel Assignment\tTreatment\tRandomized\tDietary Supplement|Dietary Supplement\tAll\t","Effects of Probiotics and Nutritional Status on Exercise-Induced Symptoms, and Endurance Performance in Ultra-Endurance Athletes","Interventional","Completed","N/A",2,24,"NA","NA","NA"]
["NCT04779710","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30199856|31493069|31731452|31817883","Eltringham SA, Kilner K, Gee M, Sage K, Bray BD, Pownall S, Smith CJ. Impact of Dysphagia Assessment and Management on Risk of Stroke-Associated Pneumonia: A Systematic Review. Cerebrovasc Dis. 2018;46(3-4):99-107. doi: 10.1159/000492730. Epub 2018 Sep 10.|Eltringham SA, Kilner K, Gee M, Sage K, Bray BD, Smith CJ, Pownall S. Factors Associated with Risk of Stroke-Associated Pneumonia in Patients with Dysphagia: A Systematic Review. Dysphagia. 2020 Oct;35(5):735-744. doi: 10.1007/s00455-019-10061-6. Epub 2019 Sep 6. Review.|Eltringham SA, Smith CJ, Pownall S, Sage K, Bray B. Variation in Dysphagia Assessment and Management in Acute Stroke: An Interview Study. Geriatrics (Basel). 2019 Oct 25;4(4). pii: E60. doi: 10.3390/geriatrics4040060.|Eltringham SA, Pownall S, Bray B, Smith CJ, Piercy L, Sage K. Experiences of Dysphagia after Stroke: An Interview Study of Stroke Survivors and Their Informal Caregivers. Geriatrics (Basel). 2019 Dec 7;4(4). pii: E67. doi: 10.3390/geriatrics4040067.","\tAcute Stroke|Dysphagia|Pneumonia\tStaff Survey\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","stroke|deglutition disorders|pneumonia","NA","NA"]
["NCT04779944","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32179701|32217624|29420257","Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science. 2020 May 1;368(6490):489-493. doi: 10.1126/science.abb3221. Epub 2020 Mar 16.|Greenberg N, Docherty M, Gnanapragasam S, Wessely S. Managing mental health challenges faced by healthcare workers during covid-19 pandemic. BMJ. 2020 Mar 26;368:m1211. doi: 10.1136/bmj.m1211.|Brooks S, Amlôt R, Rubin GJ, Greenberg N. Psychological resilience and post-traumatic growth in disaster-exposed organisations: overview of the literature. BMJ Mil Health. 2020 Feb;166(1):52-56. doi: 10.1136/jramc-2017-000876. Epub 2018 Feb 2. Review.","\tSARS-CoV-2\tother\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04780126","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","2816807|21475695|20392703|21527165|24737557|28703496","Epidemiologic and methodologic problems in determining nutritional status of older persons. Proceedings of a conference. Albuquerque, New Mexico, October 19-21, 1988. Am J Clin Nutr. 1989 Nov;50(5 Suppl):1121-235.|von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. 2010 Dec;1(2):129-133. Epub 2010 Dec 17.|Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13.|Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, Abellan van Kan G, Andrieu S, Bauer J, Breuille D, Cederholm T, Chandler J, De Meynard C, Donini L, Harris T, Kannt A, Keime Guibert F, Onder G, Papanicolaou D, Rolland Y, Rooks D, Sieber C, Souhami E, Verlaan S, Zamboni M. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011 May;12(4):249-56. doi: 10.1016/j.jamda.2011.01.003. Epub 2011 Mar 4.|Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, Ferrucci L, Guralnik JM, Fragala MS, Kenny AM, Kiel DP, Kritchevsky SB, Shardell MD, Dam TT, Vassileva MT. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014 May;69(5):547-58. doi: 10.1093/gerona/glu010.|Nijholt W, Scafoglieri A, Jager-Wittenaar H, Hobbelen JSM, van der Schans CP. The reliability and validity of ultrasound to quantify muscles in older adults: a systematic review. J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):702-712. doi: 10.1002/jcsm.12210. Epub 2017 Jul 12. Review.","\tCovid19|Sarcopenia\tSarcopenia diagnosis\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","sarcopenia","NA","NA"]
["NCT04780503","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32329452|32232782|25143721|NA|11066187|15190137|28860265|26464393|11810114|27512505|22417884","Shrestha AP, Shrestha R, Shrestha SK, Pradhan A. Prevalence of Dyspnea among Patients Attending the Emergency Department of a Tertiary Care Hospital: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc. 2019 Sep-Oct;57(219):302-306.|Huang CC, Muo CH, Wu TF, Chi TY, Shen TC, Hsia TC, Shih CM. The application of non-invasive and invasive mechanical ventilation in the first episode of acute respiratory failure. Intern Emerg Med. 2021 Jan;16(1):83-91. doi: 10.1007/s11739-020-02315-1. Epub 2020 Mar 30.|Mas A, Masip J. Noninvasive ventilation in acute respiratory failure. Int J Chron Obstruct Pulmon Dis. 2014 Aug 11;9:837-52. doi: 10.2147/COPD.S42664. eCollection 2014. Review.|Hayzy RC, McSpasson JI. Noninvasive ventilation in adults with acute respiratory failure: Benefits and contraindications. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2020.|Girou E, Schortgen F, Delclaux C, Brun-Buisson C, Blot F, Lefort Y, Lemaire F, Brochard L. Association of noninvasive ventilation with nosocomial infections and survival in critically ill patients. JAMA. 2000 Nov 8;284(18):2361-7.|Esteban A, Frutos-Vivar F, Ferguson ND, Arabi Y, Apezteguía C, González M, Epstein SK, Hill NS, Nava S, Soares MA, D'Empaire G, Alía I, Anzueto A. Noninvasive positive-pressure ventilation for respiratory failure after extubation. N Engl J Med. 2004 Jun 10;350(24):2452-60.|Rochwerg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S, Navalesi P Members Of The Steering Committee, Antonelli M, Brozek J, Conti G, Ferrer M, Guntupalli K, Jaber S, Keenan S, Mancebo J, Mehta S, Raoof S Members Of The Task Force. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017 Aug 31;50(2). pii: 1602426. doi: 10.1183/13993003.02426-2016. Print 2017 Aug. Review.|Demoule A, Chevret S, Carlucci A, Kouatchet A, Jaber S, Meziani F, Schmidt M, Schnell D, Clergue C, Aboab J, Rabbat A, Eon B, Guérin C, Georges H, Zuber B, Dellamonica J, Das V, Cousson J, Perez D, Brochard L, Azoulay E; oVNI Study Group; REVA Network (Research Network in Mechanical Ventilation). Changing use of noninvasive ventilation in critically ill patients: trends over 15 years in francophone countries. Intensive Care Med. 2016 Jan;42(1):82-92. doi: 10.1007/s00134-015-4087-4. Epub 2015 Oct 13.|Antonelli M, Conti G, Moro ML, Esquinas A, Gonzalez-Diaz G, Confalonieri M, Pelaia P, Principi T, Gregoretti C, Beltrame F, Pennisi MA, Arcangeli A, Proietti R, Passariello M, Meduri GU. Predictors of failure of noninvasive positive pressure ventilation in patients with acute hypoxemic respiratory failure: a multi-center study. Intensive Care Med. 2001 Nov;27(11):1718-28. Epub 2001 Oct 16.|Karthika M, Al Enezi FA, Pillai LV, Arabi YM. Rapid shallow breathing index. Ann Thorac Med. 2016 Jul-Sep;11(3):167-76. doi: 10.4103/1817-1737.176876. Review.|Berg KM, Lang GR, Salciccioli JD, Bak E, Cocchi MN, Gautam S, Donnino MW. The rapid shallow breathing index as a predictor of failure of noninvasive ventilation for patients with acute respiratory failure. Respir Care. 2012 Oct;57(10):1548-54. Epub 2012 Mar 12.","\tAcute Respiratory Failure\tRapid Shallow Breathing Index\tNA\tNA\tNA\tDiagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","respiratory insufficiency|respiratory distress syndrome, adult","NA","NA"]
["NCT04781010","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25655951|11371752","Parikh S, Bernard G, Leventer RJ, van der Knaap MS, van Hove J, Pizzino A, McNeill NH, Helman G, Simons C, Schmidt JL, Rizzo WB, Patterson MC, Taft RJ, Vanderver A; GLIA Consortium. A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies. Mol Genet Metab. 2015 Apr;114(4):501-515. doi: 10.1016/j.ymgme.2014.12.434. Epub 2014 Dec 29. Review.|Berger J, Moser HW, Forss-Petter S. Leukodystrophies: recent developments in genetics, molecular biology, pathogenesis and treatment. Curr Opin Neurol. 2001 Jun;14(3):305-12. Review.","\tChildren With Leukodystrophy\tMRI\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04781036","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31190339|31420081|31419942|22895161|22310478|31160034|31152265|31228520|27324733|23945194|28824870|12392527|4062746|3722494|29951993|25386314|28924971|9292083|30415588|26177982","Li M, Budding AE, van der Lugt-Degen M, Du-Thumm L, Vandeven M, Fan A. The influence of age, gender and race/ethnicity on the composition of the human axillary microbiome. Int J Cosmet Sci. 2019 Aug;41(4):371-377. doi: 10.1111/ics.12549.|Zhu T, Liu X, Kong FQ, Duan YY, Yee AL, Kim M, Galzote C, Gilbert JA, Quan ZX. Age and Mothers: Potent Influences of Children's Skin Microbiota. J Invest Dermatol. 2019 Dec;139(12):2497-2505.e6. doi: 10.1016/j.jid.2019.05.018. Epub 2019 Aug 13.|Shami A, Al-Mijalli S, Pongchaikul P, Al-Barrag A, AbduRahim S. The prevalence of the culturable human skin aerobic bacteria in Riyadh, Saudi Arabia. BMC Microbiol. 2019 Aug 16;19(1):189. doi: 10.1186/s12866-019-1569-5.|Blaser MJ, Dominguez-Bello MG, Contreras M, Magris M, Hidalgo G, Estrada I, Gao Z, Clemente JC, Costello EK, Knight R. Distinct cutaneous bacterial assemblages in a sampling of South American Amerindians and US residents. ISME J. 2013 Jan;7(1):85-95. doi: 10.1038/ismej.2012.81. Epub 2012 Aug 16.|Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, Nomicos E, Polley EC, Komarow HD; NISC Comparative Sequence Program, Murray PR, Turner ML, Segre JA. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012 May;22(5):850-9. doi: 10.1101/gr.131029.111. Epub 2012 Feb 6.|Tsilochristou O, du Toit G, Sayre PH, Roberts G, Lawson K, Sever ML, Bahnson HT, Radulovic S, Basting M, Plaut M, Lack G; Immune Tolerance Network Learning Early About Peanut Allergy Study Team. Association of Staphylococcus aureus colonization with food allergy occurs independently of eczema severity. J Allergy Clin Immunol. 2019 Aug;144(2):494-503. doi: 10.1016/j.jaci.2019.04.025. Epub 2019 May 31.|Zheng Y, Wang Q, Ma L, Chen Y, Gao Y, Zhang G, Cui S, Liang H, He C, Song L. Alterations in the skin microbiome are associated with disease severity and treatment in the perioral zone of the skin of infants with atopic dermatitis. Eur J Clin Microbiol Infect Dis. 2019 Sep;38(9):1677-1685. doi: 10.1007/s10096-019-03598-9. Epub 2019 May 31.|Quan C, Chen XY, Li X, Xue F, Chen LH, Liu N, Wang B, Wang LQ, Wang XP, Yang H, Zheng J. Psoriatic lesions are characterized by higher bacterial load and imbalance between Cutibacterium and Corynebacterium. J Am Acad Dermatol. 2020 Apr;82(4):955-961. doi: 10.1016/j.jaad.2019.06.024. Epub 2019 Jun 19.|Dutkiewicz EP, Hsieh KT, Wang YS, Chiu HY, Urban PL. Hydrogel Micropatch and Mass Spectrometry-Assisted Screening for Psoriasis-Related Skin Metabolites. Clin Chem. 2016 Aug;62(8):1120-8. doi: 10.1373/clinchem.2016.256396. Epub 2016 Jun 20.|Sitter B, Johnsson MK, Halgunset J, Bathen TF. Metabolic changes in psoriatic skin under topical corticosteroid treatment. BMC Dermatol. 2013 Aug 14;13:8. doi: 10.1186/1471-5945-13-8.|Yan D, Afifi L, Jeon C, Trivedi M, Chang HW, Lee K, Liao W. The metabolomics of psoriatic disease. Psoriasis (Auckl). 2017;7:1-15. doi: 10.2147/PTT.S118348. Epub 2017 Jan 31.|Longshaw CM, Wright JD, Farrell AM, Holland KT. Kytococcus sedentarius, the organism associated with pitted keratolysis, produces two keratin-degrading enzymes. J Appl Microbiol. 2002;93(5):810-6.|Woodgyer AJ, Baxter M, Rush-Munro FM, Brown J, Kaplan W. Isolation of Dermatophilus congolensis from two New Zealand cases of pitted keratolysis. Australas J Dermatol. 1985 Apr;26(1):29-35.|Svejgaard E, Christophersen J, Jelsdorf HM. Tinea pedis and erythrasma in Danish recruits. Clinical signs, prevalence, incidence, and correlation to atopy. J Am Acad Dermatol. 1986 Jun;14(6):993-9.|Bunyaratavej S, Leeyaphan C, Chanyachailert P, Pattanaprichakul P, Ongsri P, Kulthanan K. Clinical manifestations, risk factors and quality of life in patients with pitted keratolysis: a cross-sectional study in cadets. Br J Dermatol. 2018 Nov;179(5):1220-1221. doi: 10.1111/bjd.16923. Epub 2018 Sep 14.|Kaptanoglu AF, Yuksel O, Ozyurt S. Plantar pitted keratolysis: a study from non-risk groups. Dermatol Reports. 2012 Feb 7;4(1):e4. doi: 10.4081/dr.2012.e4. eCollection 2012 Jan 2.|Makhecha M, Dass S, Singh T, Gandhi R, Yadav T, Rathod D. Pitted keratolysis - a study of various clinical manifestations. Int J Dermatol. 2017 Nov;56(11):1154-1160. doi: 10.1111/ijd.13744. Epub 2017 Sep 18.|Takama H, Tamada Y, Yano K, Nitta Y, Ikeya T. Pitted keratolysis: clinical manifestations in 53 cases. Br J Dermatol. 1997 Aug;137(2):282-5.|Leeyaphan C, Bunyaratavej S, Taychakhoonavudh S, Kulthanachairojana N, Pattanaprichakul P, Chanyachailert P, Ongsri P, Arunkajohnsak S, Limphoka P, Kulthanan K. Cost-effectiveness analysis and safety of erythromycin 4% gel and 4% chlorhexidine scrub for pitted keratolysis treatment. J Dermatolog Treat. 2019 Sep;30(6):627-629. doi: 10.1080/09546634.2018.1543846. Epub 2018 Dec 11.|Leung MH, Wilkins D, Lee PK. Insights into the pan-microbiome: skin microbial communities of Chinese individuals differ from other racial groups. Sci Rep. 2015 Jul 16;5:11845. doi: 10.1038/srep11845. Erratum in: Sci Rep. 2016;6:21355.","\tMetabolomics|Microbial Disease\t4%Chlorhexidine\tParallel Assignment\tBasic Science\tRandomized\tDrug\tMale\t","Foot-skin Microbiome and Metabolomics of Pitted Keratolysis","Interventional","Not yet recruiting","N/A",3,250,"NA","chlorhexidine","NA"]
["NCT04781049","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12559262|20963421|24602293|17130393|21475707|1279218|7354519|21883855|25466940|32868137","Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003 Jan;61(1):37-49. Review.|Martin SA, Haren MT, Marshall VR, Lange K, Wittert GA; Members of the Florey Adelaide Male Ageing Study. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J Urol. 2011 Apr;29(2):179-84. doi: 10.1007/s00345-010-0605-8. Epub 2010 Oct 21.|Gacci M, Corona G, Vignozzi L, Salvi M, Serni S, De Nunzio C, Tubaro A, Oelke M, Carini M, Maggi M. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int. 2015 Jan;115(1):24-31. doi: 10.1111/bju.12728. Epub 2014 Aug 16. Review.|Kupelian V, Wei JT, O'Leary MP, Kusek JW, Litman HJ, Link CL, McKinlay JB; BACH Survery Investigators. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med. 2006 Nov 27;166(21):2381-7.|Parsons JK. Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. Curr Bladder Dysfunct Rep. 2010 Dec;5(4):212-218. Epub 2010 Sep 7.|Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992 Nov;148(5):1549-57; discussion 1564.|Siroky MB, Olsson CA, Krane RJ. The flow rate nomogram: II. Clinical correlation. J Urol. 1980 Feb;123(2):208-10.|Biester K, Skipka G, Jahn R, Buchberger B, Rohde V, Lange S. Systematic review of surgical treatments for benign prostatic hyperplasia and presentation of an approach to investigate therapeutic equivalence (non-inferiority). BJU Int. 2012 Mar;109(5):722-30. doi: 10.1111/j.1464-410X.2011.10512.x. Epub 2011 Aug 22. Review.|Perera M, Roberts MJ, Doi SA, Bolton D. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol. 2015 Apr;67(4):704-13. doi: 10.1016/j.eururo.2014.10.031. Epub 2014 Nov 15. Review.|de Rienzo G, Lorusso A, Minafra P, Zingarelli M, Papapicco G, Lucarelli G, Battaglia M, Ditonno P. Transperineal interstitial laser ablation of the prostate, a novel option for minimally invasive treatment of benign prostatic obstruction. Eur Urol. 2020 Aug 28. pii: S0302-2838(20)30635-7. doi: 10.1016/j.eururo.2020.08.018. [Epub ahead of print]","\tBenign Prostatic Hyperplasia|Benign Prostatic Hypertrophy|Benign Prostatic Hypertrophy With Outflow Obstruction|Prostate Hyperplasia\tTrans-Perineal Laser Ablation of Prostate|Trans-Urethral Resection of Prostate\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tMale\t","Transperineal Laser Ablation vs Transurethral Resection for Benign Prostatic Obstruction: A Randomized Clinical Trial","Interventional","Recruiting","N/A",2,50,"prostatic hyperplasia|hyperplasia|hypertrophy","NA","NA"]
["NCT04781244","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17210977|29214505|27047542|25273231|20837684","Lipke MM. An armamentarium of wart treatments. Clin Med Res. 2006 Dec;4(4):273-93. Review.|Walczuk I, Eertmans F, Rossel B, Cegielska A, Stockfleth E, Antunes A, Adriaens E. Efficacy and Safety of Three Cryotherapy Devices for Wart Treatment: A Randomized, Controlled, Investigator-Blinded, Comparative Study. Dermatol Ther (Heidelb). 2018 Jun;8(2):203-216. doi: 10.1007/s13555-017-0210-5. Epub 2017 Dec 6.|Ghadgepatil SS, Gupta S, Sharma YK. Clinicoepidemiological Study of Different Types of Warts. Dermatol Res Pract. 2016;2016:7989817. doi: 10.1155/2016/7989817. Epub 2016 Mar 7.|Sterling JC, Gibbs S, Haque Hussain SS, Mohd Mustapa MF, Handfield-Jones SE. British Association of Dermatologists' guidelines for the management of cutaneous warts 2014. Br J Dermatol. 2014 Oct;171(4):696-712. doi: 10.1111/bjd.13310. Epub 2014 Oct 1.|Bruggink SC, Gussekloo J, Berger MY, Zaaijer K, Assendelft WJ, de Waal MW, Bavinck JN, Koes BW, Eekhof JA. Cryotherapy with liquid nitrogen versus topical salicylic acid application for cutaneous warts in primary care: randomized controlled trial. CMAJ. 2010 Oct 19;182(15):1624-30. doi: 10.1503/cmaj.092194. Epub 2010 Sep 13.","\tCryotherapy Effect|Warts\tEndWarts® FREEZE|Liquid nitrogen\tParallel Assignment\tTreatment\tRandomized\tDevice|Device\tAll\t","Cost-effectiveness of EndWarts® FREEZE - an Alternative Home Cryotherapy Device for Wart Treatment","Interventional","Recruiting","N/A",4,44,"warts","NA","NA"]
["NCT04781348","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20828761|23641301","Brusselaers N, Pirayesh A, Hoeksema H, Verbelen J, Blot S, Monstrey S. Burn scar assessment: a systematic review of different scar scales. J Surg Res. 2010 Nov;164(1):e115-23. doi: 10.1016/j.jss.2010.05.056. Epub 2010 Jun 16. Review.|Jin R, Zhang L, Zhang YG. Does platelet-rich plasma enhance the survival of grafted fat? An update review. Int J Clin Exp Med. 2013 Apr 12;6(4):252-8. Print 2013.","\tBurn\tPlatelet Rich Plasma plus fat grafting\tParallel Assignment\tTreatment\tRandomized\tProcedure\tAll\t","Efficacy of Platelet Rich Plasma Injection Plus Fat Grafting as Compared to Fat Grafting Alone on Burn Scar by Using Vancouver Scar Scale","Interventional","Not yet recruiting","Phase 4",2,1,"burns","NA","NA"]
["NCT04782063","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18824817|30421138|19602635|12198014|12915626|26865238|30968129|30092608","Satpathy HK, Fleming A, Frey D, Barsoom M, Satpathy C, Khandalavala J. Maternal obesity and pregnancy. Postgrad Med. 2008 Sep 15;120(3):E01-9. doi: 10.3810/pgm.2008.09.1920. Review.|Kaul P, Bowker SL, Savu A, Yeung RO, Donovan LE, Ryan EA. Association between maternal diabetes, being large for gestational age and breast-feeding on being overweight or obese in childhood. Diabetologia. 2019 Feb;62(2):249-258. doi: 10.1007/s00125-018-4758-0. Epub 2018 Nov 13.|Davenport MH, Cabrero MR. Maternal nutritional history predicts obesity in adult offspring independent of postnatal diet. J Physiol. 2009 Jul 15;587(Pt 14):3423-4. doi: 10.1113/jphysiol.2009.174896.|Guo SS, Wu W, Chumlea WC, Roche AF. Predicting overweight and obesity in adulthood from body mass index values in childhood and adolescence. Am J Clin Nutr. 2002 Sep;76(3):653-8.|Catalano PM. Obesity and pregnancy--the propagation of a viscous cycle? J Clin Endocrinol Metab. 2003 Aug;88(8):3505-6.|Prentice P, Ong KK, Schoemaker MH, van Tol EA, Vervoort J, Hughes IA, Acerini CL, Dunger DB. Breast milk nutrient content and infancy growth. Acta Paediatr. 2016 Jun;105(6):641-7. doi: 10.1111/apa.13362. Epub 2016 Apr 6.|Isganaitis E, Venditti S, Matthews TJ, Lerin C, Demerath EW, Fields DA. Maternal obesity and the human milk metabolome: associations with infant body composition and postnatal weight gain. Am J Clin Nutr. 2019 Jul 1;110(1):111-120. doi: 10.1093/ajcn/nqy334.|Young BE, Levek C, Reynolds RM, Rudolph MC, MacLean P, Hernandez TL, Friedman JE, Krebs NF. Bioactive components in human milk are differentially associated with rates of lean and fat mass deposition in infants of mothers with normal vs. elevated BMI. Pediatr Obes. 2018 Oct;13(10):598-606. doi: 10.1111/ijpo.12394. Epub 2018 Aug 9.","\tObesity, Infant\tCalibration of infant breast milk and formula milk intake\tParallel Assignment\tPrevention\tRandomized\tOther\tFemale\t","Prevention of Obesity in Infants of Overweight and Obese Women","Interventional","Not yet recruiting","N/A",2,240,"overweight|pediatric obesity|obesity","NA","NA"]
["NCT04782843","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20854372,"Cuker A, Arepally G, Crowther MA, Rice L, Datko F, Hook K, Propert KJ, Kuter DJ, Ortel TL, Konkle BA, Cines DB. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost. 2010 Dec;8(12):2642-50. doi: 10.1111/j.1538-7836.2010.04059.x.","\tHeparin-induced Thrombocytopenia\tHEP score assessement\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","thrombocytopenia","NA","NA"]
["NCT04783350","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28709880|31739167|30720478|24345389|30902640","Antal A, Alekseichuk I, Bikson M, Brockmöller J, Brunoni AR, Chen R, Cohen LG, Dowthwaite G, Ellrich J, Flöel A, Fregni F, George MS, Hamilton R, Haueisen J, Herrmann CS, Hummel FC, Lefaucheur JP, Liebetanz D, Loo CK, McCaig CD, Miniussi C, Miranda PC, Moliadze V, Nitsche MA, Nowak R, Padberg F, Pascual-Leone A, Poppendieck W, Priori A, Rossi S, Rossini PM, Rothwell J, Rueger MA, Ruffini G, Schellhorn K, Siebner HR, Ugawa Y, Wexler A, Ziemann U, Hallett M, Paulus W. Low intensity transcranial electric stimulation: Safety, ethical, legal regulatory and application guidelines. Clin Neurophysiol. 2017 Sep;128(9):1774-1809. doi: 10.1016/j.clinph.2017.06.001. Epub 2017 Jun 19. Review.|Babiloni C, Blinowska K, Bonanni L, Cichocki A, De Haan W, Del Percio C, Dubois B, Escudero J, Fernández A, Frisoni G, Guntekin B, Hajos M, Hampel H, Ifeachor E, Kilborn K, Kumar S, Johnsen K, Johannsson M, Jeong J, LeBeau F, Lizio R, Lopes da Silva F, Maestú F, McGeown WJ, McKeith I, Moretti DV, Nobili F, Olichney J, Onofrj M, Palop JJ, Rowan M, Stocchi F, Struzik ZM, Tanila H, Teipel S, Taylor JP, Weiergräber M, Yener G, Young-Pearse T, Drinkenburg WH, Randall F. What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. Neurobiol Aging. 2020 Jan;85:58-73. doi: 10.1016/j.neurobiolaging.2019.09.008. Epub 2019 Sep 19. Review.|Buss SS, Fried PJ, Pascual-Leone A. Therapeutic noninvasive brain stimulation in Alzheimer's disease and related dementias. Curr Opin Neurol. 2019 Apr;32(2):292-304. doi: 10.1097/WCO.0000000000000669. Review.|Ruffini G, Fox MD, Ripolles O, Miranda PC, Pascual-Leone A. Optimization of multifocal transcranial current stimulation for weighted cortical pattern targeting from realistic modeling of electric fields. Neuroimage. 2014 Apr 1;89:216-25. doi: 10.1016/j.neuroimage.2013.12.002. Epub 2013 Dec 15.|Bréchet L, Brunet D, Birot G, Gruetter R, Michel CM, Jorge J. Capturing the spatiotemporal dynamics of self-generated, task-initiated thoughts with EEG and fMRI. Neuroimage. 2019 Jul 1;194:82-92. doi: 10.1016/j.neuroimage.2019.03.029. Epub 2019 Mar 19.","\tAlzheimer Disease|Memory Loss\tTranscranial alternating current stimulation (tACS)\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","alzheimer disease|memory disorders","NA","NA"]
["NCT04784078","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31227393|30336816|30314833|31675155|31227393|30336816|30314833|31675155","Liontou C, Kontopodis E, Oikonomidis N, Maniotis C, Tassopoulos A, Tsiafoutis I, Lazaris E, Koutouzis M. Distal Radial Access: A Review Article. Cardiovasc Revasc Med. 2020 Mar;21(3):412-416. doi: 10.1016/j.carrev.2019.06.003. Epub 2019 Jun 8. Review.|Sgueglia GA, Di Giorgio A, Gaspardone A, Babunashvili A. Anatomic Basis and Physiological Rationale of Distal Radial Artery Access for Percutaneous Coronary and Endovascular Procedures. JACC Cardiovasc Interv. 2018 Oct 22;11(20):2113-2119. doi: 10.1016/j.jcin.2018.04.045. Review.|Koutouzis M, Kontopodis E, Tassopoulos A, Tsiafoutis I, Katsanou K, Rigatou A, Didagelos M, Andreou K, Lazaris E, Oikonomidis N, Maniotis C, Ziakas A. Distal Versus Traditional Radial Approach for Coronary Angiography. Cardiovasc Revasc Med. 2019 Aug;20(8):678-680. doi: 10.1016/j.carrev.2018.09.018. Epub 2018 Oct 2.|Xenogiannis I, Brilakis ES. Distal radial access at the anatomic snuffbox: The new standard for left radial access? Catheter Cardiovasc Interv. 2019 Nov 1;94(5):658-659. doi: 10.1002/ccd.28551.|Liontou C, Kontopodis E, Oikonomidis N, Maniotis C, Tassopoulos A, Tsiafoutis I, Lazaris E, Koutouzis M. Distal Radial Access: A Review Article. Cardiovasc Revasc Med. 2020 Mar;21(3):412-416. doi: 10.1016/j.carrev.2019.06.003. Epub 2019 Jun 8. Review.|Sgueglia GA, Di Giorgio A, Gaspardone A, Babunashvili A. Anatomic Basis and Physiological Rationale of Distal Radial Artery Access for Percutaneous Coronary and Endovascular Procedures. JACC Cardiovasc Interv. 2018 Oct 22;11(20):2113-2119. doi: 10.1016/j.jcin.2018.04.045. Review.|Koutouzis M, Kontopodis E, Tassopoulos A, Tsiafoutis I, Katsanou K, Rigatou A, Didagelos M, Andreou K, Lazaris E, Oikonomidis N, Maniotis C, Ziakas A. Distal Versus Traditional Radial Approach for Coronary Angiography. Cardiovasc Revasc Med. 2019 Aug;20(8):678-680. doi: 10.1016/j.carrev.2018.09.018. Epub 2018 Oct 2.|Xenogiannis I, Brilakis ES. Distal radial access at the anatomic snuffbox: The new standard for left radial access? Catheter Cardiovasc Interv. 2019 Nov 1;94(5):658-659. doi: 10.1002/ccd.28551.","\tCoronary Disease\tCoronary Angiography and Intervention\tParallel Assignment\tTreatment\tRandomized\tProcedure\tAll\t","Randomized Comparison of Distal Radial Versus Conventional Radial Access for Coronary Angiography and Intervention","Interventional","Not yet recruiting","N/A",2,938,"coronary disease","NA","NA"]
["NCT04784481","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32251768,"Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.","\tCovid19|SARS (Severe Acute Respiratory Syndrome)\tIvermectin\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Ivermectin Reproposing for Mild Stage COVID-19 Outpatients","Interventional","Completed","Phase 1/Phase 2",2,254,"severe acute respiratory syndrome","ivermectin","NA"]
["NCT04784598","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",31808352,"Costa ARA, de Almeida Silva HJ, Mendes AAMT, Scattone Silva R, de Almeida Lins CA, de Souza MC. Effects of insoles adapted in flip-flop sandals in people with plantar fasciopathy: a randomized, double-blind clinical, controlled study. Clin Rehabil. 2020 Mar;34(3):334-344. doi: 10.1177/0269215519893104. Epub 2019 Dec 6.","\tHeel|Heel Pain Syndrome\tInsoles adapted in flip-flop sandals\tParallel Assignment\tTreatment\tRandomized\tOther\tAll\t","Insoles Adapted in Flip-flop Sandals in People With Heel Pain","Interventional","Not yet recruiting","N/A",3,81,"NA","NA","NA"]
["NCT04784793","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25931684|32442143|28729234|31304380|27890121","Kim HJ; DH, Kim JS. The relationship between smartphone use and subjective musculoskeletal symptoms and university students. J Phys Ther Sci. 2015 Mar;27(3):575-9. doi: 10.1589/jpts.27.575. Epub 2015 Mar 31.|Slater H, Stinson JN, Jordan JE, Chua J, Low B, Lalloo C, Pham Q, Cafazzo JA, Briggs AM. Evaluation of Digital Technologies Tailored to Support Young People's Self-Management of Musculoskeletal Pain: Mixed Methods Study. J Med Internet Res. 2020 Jun 5;22(6):e18315. doi: 10.2196/18315.|Stütz T, Emsenhuber G, Huber D, Domhardt M, Tiefengrabner M, Oostingh GJ, Fötschl U, Matis N, Ginzinger S. Mobile Phone-Supported Physiotherapy for Frozen Shoulder: Feasibility Assessment Based on a Usability Study. JMIR Rehabil Assist Technol. 2017 Jul 20;4(2):e6. doi: 10.2196/rehab.7085.|Toelle TR, Utpadel-Fischler DA, Haas KK, Priebe JA. App-based multidisciplinary back pain treatment versus combined physiotherapy plus online education: a randomized controlled trial. NPJ Digit Med. 2019 May 3;2:34. doi: 10.1038/s41746-019-0109-x. eCollection 2019.|Xie Y, Szeto G, Dai J. Prevalence and risk factors associated with musculoskeletal complaints among users of mobile handheld devices: A systematic review. Appl Ergon. 2017 Mar;59(Pt A):132-142. doi: 10.1016/j.apergo.2016.08.020. Epub 2016 Sep 11. Review.","\tCervical and Thoracic Spine|Development and Design of Mobile App|Exercise Adherence|Preventive Physiotherapy\tApp-based group|Control group\tParallel Assignment\tPrevention\tRandomized\tOther|Other\tAll\t","Postural Alignment Exercise Mobile App for Cervical and Thoracic Spine Regions","Interventional","Completed","N/A",5,40,"aneurysm, dissecting","NA","NA"]
["NCT04785053","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30902640|24345389|31277878|32265551","Bréchet L, Brunet D, Birot G, Gruetter R, Michel CM, Jorge J. Capturing the spatiotemporal dynamics of self-generated, task-initiated thoughts with EEG and fMRI. Neuroimage. 2019 Jul 1;194:82-92. doi: 10.1016/j.neuroimage.2019.03.029. Epub 2019 Mar 19.|Ruffini G, Fox MD, Ripolles O, Miranda PC, Pascual-Leone A. Optimization of multifocal transcranial current stimulation for weighted cortical pattern targeting from realistic modeling of electric fields. Neuroimage. 2014 Apr 1;89:216-25. doi: 10.1016/j.neuroimage.2013.12.002. Epub 2013 Dec 15.|Michel CM, He B. EEG source localization. Handb Clin Neurol. 2019;160:85-101. doi: 10.1016/B978-0-444-64032-1.00006-0. Review.|Michel CM, Pascual-Leone A. Predicting antidepressant response by electroencephalography. Nat Biotechnol. 2020 Apr;38(4):417-419. doi: 10.1038/s41587-020-0476-5.","\tAlzheimer Disease\ttranscranial alternating current stimulation (tACS)\tParallel Assignment\tBasic Science\tRandomized\tDevice\tAll\t","Memory Functions in Mild Alzheimer's Disease","Interventional","Recruiting","N/A",3,60,"alzheimer disease","NA","NA"]
["NCT04785560","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",31141553,"Andersson J, Rosell M, Kockum K, Lilja-Lund O, Söderström L, Laurell K. Prevalence of idiopathic normal pressure hydrocephalus: A prospective, population-based study. PLoS One. 2019 May 29;14(5):e0217705. doi: 10.1371/journal.pone.0217705. eCollection 2019.","\tHydrocephalus Acquired|Hydrocephalus, Normal Pressure|Shunt; Complications|Ventriculomegaly, Cerebral\tInitial shunt setting post-operatively of the Certas Plus shunt valve.\tParallel Assignment\tTreatment\tRandomized\tDevice\tAll\t","Volumetrics and Proteomics in Shunted Normal Pressure Hydrocephalus","Interventional","Recruiting","N/A",2,30,"hydrocephalus, normal pressure|hydrocephalus","NA","NA"]
["NCT04785664","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27567441|33457318|16821500|29641436","Liotta G, O'Caoimh R, Gilardi F, Proietti MG, Rocco G, Alvaro R, Scarcella P, Molloy DW, Orlando S, Mancinelli S, Palombi L, Stievano A, Marazzi MC. Assessment of frailty in community-dwelling older adults residents in the Lazio region (Italy): A model to plan regional community-based services. Arch Gerontol Geriatr. 2017 Jan - Feb;68:1-7. doi: 10.1016/j.archger.2016.08.004. Epub 2016 Aug 12.|Liotta G, Madaro O, Scarcella P, Inzerilli MC, Frattini B, Riccardi F, Accarino N, Mancinelli S, Terracciano E, Orlando S, Marazzi MC. Assessing the Impact of A Community-Based Pro-Active Monitoring Program Addressing the need for Care of Community-Dwelling Citizens aged more than 80: Protocol for a Prospective Pragmatic Trial and Results of the Baseline Assessment. Transl Med UniSa. 2020 Dec 31;23:22-27. eCollection 2020 Dec.|Liotta G, Scarcella P, Mancinelli S, Palombi L, Cancelli A, Marazzi MC. [The evaluation of care needs in elderly people: the use of Geriatric Functional Evaluation Questionnaire]. Ann Ig. 2006 May-Jun;18(3):225-35. Italian.|Liotta G, Inzerilli MC, Palombi L, Madaro O, Orlando S, Scarcella P, Betti D, Marazzi MC. Social Interventions to Prevent Heat-Related Mortality in the Older Adult in Rome, Italy: A Quasi-Experimental Study. Int J Environ Res Public Health. 2018 Apr 11;15(4). pii: E715. doi: 10.3390/ijerph15040715.","\tFrailty|Social Isolation\tCommunity-based pro-Active Monitoring Program\tParallel Assignment\tHealth Services Research\tRandomized\tOther\tAll\t","Community-based Pro-Active Monitoring Program (CAMP) and Older Adults","Interventional","Active, not recruiting","N/A",2,1185,"frailty","NA","NA"]
["NCT04785755","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","11232182|22844565|24811138|19602136|24829672|30992841|26630543|21749847|17172977|15196097|28285098|28661458|680588|28932357|16474108|27991854|12660656|27941973|24462960|29608812|20346637|3522371","Reynolds TB. Ascites. Clin Liver Dis. 2000 Feb;4(1):151-68, vii. Review.|Gu XB, Yang XJ, Zhu HY, Xu BY. Effect of a diet with unrestricted sodium on ascites in patients with hepatic cirrhosis. Gut Liver. 2012 Jul;6(3):355-61. doi: 10.5009/gnl.2012.6.3.355. Epub 2012 Jul 12.|Morando F, Rosi S, Gola E, Nardi M, Piano S, Fasolato S, Stanco M, Cavallin M, Romano A, Sticca A, Caregaro L, Gatta A, Angeli P. Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sectional study. Liver Int. 2015 May;35(5):1508-15. doi: 10.1111/liv.12583. Epub 2014 May 21.|Sam J, Nguyen GC. Protein-calorie malnutrition as a prognostic indicator of mortality among patients hospitalized with cirrhosis and portal hypertension. Liver Int. 2009 Oct;29(9):1396-402. doi: 10.1111/j.1478-3231.2009.02077.x. Epub 2009 Jul 7.|Eghtesad S, Poustchi H, Malekzadeh R. Malnutrition in liver cirrhosis:the influence of protein and sodium. Middle East J Dig Dis. 2013 Apr;5(2):65-75. Review.|Arroyo V, Fernández J. Relationship between systemic hemodynamics, renal dysfunction, and fluid retention in cirrhosis. Clin Liver Dis (Hoboken). 2013 Jun 21;2(3):120-122. doi: 10.1002/cld.185. eCollection 2013 Jun. Review.|Guo TT, Yang Y, Song Y, Ren Y, Liu ZX, Cheng G. Effects of midodrine in patients with ascites due to cirrhosis: Systematic review and meta-analysis. J Dig Dis. 2016 Jan;17(1):11-9. doi: 10.1111/1751-2980.12304. Review.|Singh V, Dhungana SP, Singh B, Vijayverghia R, Nain CK, Sharma N, Bhalla A, Gupta PK. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol. 2012 Feb;56(2):348-54. doi: 10.1016/j.jhep.2011.04.027. Epub 2011 Jul 13.|Hatanaka E, Shimomi FM, Curi R, Campa A. Sodium chloride inhibits cytokine production by lipopolysaccharide-stimulated human neutrophils and mononuclear cells. Shock. 2007 Jan;27(1):32-5.|Kølsen-Petersen JA. Immune effect of hypertonic saline: fact or fiction? Acta Anaesthesiol Scand. 2004 Jul;48(6):667-78. Review.|Pérez-Pérez A, Vilariño-García T, Fernández-Riejos P, Martín-González J, Segura-Egea JJ, Sánchez-Margalet V. Role of leptin as a link between metabolism and the immune system. Cytokine Growth Factor Rev. 2017 Jun;35:71-84. doi: 10.1016/j.cytogfr.2017.03.001. Epub 2017 Mar 4. Review.|Buechler C, Haberl EM, Rein-Fischboeck L, Aslanidis C. Adipokines in Liver Cirrhosis. Int J Mol Sci. 2017 Jun 29;18(7). pii: E1392. doi: 10.3390/ijms18071392. Review.|Reynolds TB, Lieberman FL, Goodman AR. Advantages of treatment of ascites without sodium restriction and without complete removal of excess fluid. Gut. 1978 Jun;19(6):549-53.|Lafrenière G, Béliveau P, Bégin JY, Simonyan D, Côté S, Gaudreault V, Israeli Z, Lavi S, Bagur R. Effects of hypertonic saline solution on body weight and serum creatinine in patients with acute decompensated heart failure. World J Cardiol. 2017 Aug 26;9(8):685-692. doi: 10.4330/wjc.v9.i8.685.|Henriksen JH, Fuglsang S, Bendtsen F, Møller S. Arterial hypertension in cirrhosis: arterial compliance, volume distribution, and central haemodynamics. Gut. 2006 Mar;55(3):380-7.|Li H, Guo Z, Yang X, Sun D. Mean arterial pressure drop is an independent risk factor of death in patients with HBV-related cirrhosis ascites. Turk J Gastroenterol. 2017 Jan;28(1):26-30. doi: 10.5152/tjg.2016.0412. Epub 2016 Dec 19.|Drazner MH, Palmer BF. Hypertonic saline: a novel therapy for advanced heart failure? Am Heart J. 2003 Mar;145(3):377-9.|Tuttolomondo A, Di Raimondo D, Bellia C, Clemente G, Pecoraro R, Maida C, Simonetta I, Vassallo V, Di Bona D, Gulotta E, Ciaccio M, Pinto A. Immune-Inflammatory and Metabolic Effects of High Dose Furosemide plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects with Refractory Ascites. PLoS One. 2016 Dec 12;11(12):e0165443. doi: 10.1371/journal.pone.0165443. eCollection 2016.|Okuhara Y, Hirotani S, Naito Y, Nakabo A, Iwasaku T, Eguchi A, Morisawa D, Ando T, Sawada H, Manabe E, Masuyama T. Intravenous salt supplementation with low-dose furosemide for treatment of acute decompensated heart failure. J Card Fail. 2014 May;20(5):295-301. doi: 10.1016/j.cardfail.2014.01.012. Epub 2014 Jan 22.|Haberl J, Zollner G, Fickert P, Stadlbauer V. To salt or not to salt?-That is the question in cirrhosis. Liver Int. 2018 Jul;38(7):1148-1159. doi: 10.1111/liv.13750. Epub 2018 May 16. Review.|Tuttolomondo A, Pinto A, Di Raimondo D, Corrao S, Di Sciacca R, Scaglione R, Caruso C, Licata G. Changes in natriuretic peptide and cytokine plasma levels in patients with heart failure, after treatment with high dose of furosemide plus hypertonic saline solution (HSS) and after a saline loading. Nutr Metab Cardiovasc Dis. 2011 May;21(5):372-9. doi: 10.1016/j.numecd.2009.10.014. Epub 2010 Mar 25.|Gauthier A, Levy VG, Quinton A, Michel H, Rueff B, Descos L, Durbec JP, Fermanian J, Lancrenon S. Salt or no salt in the treatment of cirrhotic ascites: a randomised study. Gut. 1986 Jun;27(6):705-9.","\tHepatic Ascites\tOral standard diuretics therapy|Hypertonic saline solution|Etilefrine\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","Effects of Adding Hypertonic Saline Solutions and/or Etilefrine to Standard Diuretics Therapy in Hepatic Ascites","Interventional","Completed","Phase 2",4,90,"ascites","pharmaceutical solutions|diuretics|etilefrine|furosemide|spironolactone","NA"]
["NCT04786418","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26879684,"Leslie WS, Ford I, Sattar N, Hollingsworth KG, Adamson A, Sniehotta FF, McCombie L, Brosnahan N, Ross H, Mathers JC, Peters C, Thom G, Barnes A, Kean S, McIlvenna Y, Rodrigues A, Rehackova L, Zhyzhneuskaya S, Taylor R, Lean ME. The Diabetes Remission Clinical Trial (DiRECT): protocol for a cluster randomised trial. BMC Fam Pract. 2016 Feb 16;17:20. doi: 10.1186/s12875-016-0406-2.","\tFatty Liver|Metabolic Syndrome|NAFLD|Obesity|Pre Diabetes\tStandard of care|Low-calorie diet\tParallel Assignment\tPrevention\tRandomized\tOther|Dietary Supplement\tAll\t","Low-Calorie Diet in People With Prediabetes/Metabolic Syndrome","Interventional","Not yet recruiting","N/A",2,44,"fatty liver|glucose intolerance|syndrome|metabolic syndrome|prediabetic state","NA","NA"]
["NCT04786483","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32377489,"Sahu P. Closure of Universities Due to Coronavirus Disease 2019 (COVID-19): Impact on Education and Mental Health of Students and Academic Staff. Cureus. 2020 Apr 4;12(4):e7541. doi: 10.7759/cureus.7541. Review.","\tAnxiety|COVID-19|Laughter Yoga|Life Satisfaction|Psychological Well-being\tLaughter Theraphy\tParallel Assignment\tHealth Services Research\tRandomized\tOther\tAll\t","The Effect of Laughter Therapy on Students in the COVID-19 Pandemic","Interventional","Active, not recruiting","N/A",2,80,"anxiety disorders","NA","NA"]
["NCT04786522","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26183690|15610704|1577335|11232233|27124017|21694556|33389537|33493316|32514668|29181953|30683930|29679630|30759249|33053231|28394089|18455840","Kim HJ, So B, Choi M, Kang D, Song W. Resistance exercise training increases the expression of irisin concomitant with improvement of muscle function in aging mice and humans. Exp Gerontol. 2015 Oct;70:11-7. doi: 10.1016/j.exger.2015.07.006. Epub 2015 Jul 13.|Grandis M, Shy ME. Current Therapy for Charcot-Marie-Tooth Disease. Curr Treat Options Neurol. 2005 Jan;7(1):23-31.|Mann DC, Hsu JD. Triple arthrodesis in the treatment of fixed cavovarus deformity in adolescent patients with Charcot-Marie-Tooth disease. Foot Ankle. 1992 Jan;13(1):1-6.|Guyton GP, Mann RA. The pathogenesis and surgical management of foot deformity in Charcot-Marie-Tooth disease. Foot Ankle Clin. 2000 Jun;5(2):317-26. Review.|Corrado B, Ciardi G, Bargigli C. Rehabilitation Management of the Charcot-Marie-Tooth Syndrome: A Systematic Review of the Literature. Medicine (Baltimore). 2016 Apr;95(17):e3278. doi: 10.1097/MD.0000000000003278. Review.|Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, Nieman DC, Swain DP; American College of Sports Medicine. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc. 2011 Jul;43(7):1334-59. doi: 10.1249/MSS.0b013e318213fefb.|Ma J, Chen K. The role of Irisin in multiorgan protection. Mol Biol Rep. 2021 Jan;48(1):763-772. doi: 10.1007/s11033-020-06067-1. Epub 2021 Jan 3. Review.|Maak S, Norheim F, Drevon CA, Erickson HP. Progress and challenges in the biology of FNDC5 and irisin. Endocr Rev. 2021 Jan 25. pii: bnab003. doi: 10.1210/endrev/bnab003. [Epub ahead of print]|Colaianni G, Storlino G, Sanesi L, Colucci S, Grano M. Myokines and Osteokines in the Pathogenesis of Muscle and Bone Diseases. Curr Osteoporos Rep. 2020 Aug;18(4):401-407. doi: 10.1007/s11914-020-00600-8. Review.|Colaianni G, Notarnicola A, Sanesi L, Brunetti G, Lippo L, Celi M, Moretti L, Pesce V, Vicenti G, Moretti B, Colucci S, Grano M. Irisin levels correlate with bone mineral density in soccer players. J Biol Regul Homeost Agents. 2017 Oct-Dec,;31(4 suppl 1):21-28.|Colaianni G, Faienza MF, Sanesi L, Brunetti G, Pignataro P, Lippo L, Bortolotti S, Storlino G, Piacente L, D'Amato G, Colucci S, Grano M. Irisin serum levels are positively correlated with bone mineral status in a population of healthy children. Pediatr Res. 2019 Mar;85(4):484-488. doi: 10.1038/s41390-019-0278-y. Epub 2019 Jan 15.|Faienza MF, Brunetti G, Sanesi L, Colaianni G, Celi M, Piacente L, D'Amato G, Schipani E, Colucci S, Grano M. High irisin levels are associated with better glycemic control and bone health in children with Type 1 diabetes. Diabetes Res Clin Pract. 2018 Jul;141:10-17. doi: 10.1016/j.diabres.2018.03.046. Epub 2018 Apr 19.|Palermo A, Sanesi L, Colaianni G, Tabacco G, Naciu AM, Cesareo R, Pedone C, Lelli D, Brunetti G, Mori G, Colucci S, Manfrini S, Napoli N, Grano M. A Novel Interplay Between Irisin and PTH: From Basic Studies to Clinical Evidence in Hyperparathyroidism. J Clin Endocrinol Metab. 2019 Aug 1;104(8):3088-3096. doi: 10.1210/jc.2018-02216.|Colaianni G, Errede M, Sanesi L, Notarnicola A, Celi M, Zerlotin R, Storlino G, Pignataro P, Oranger A, Pesce V, Tarantino U, Moretti B, Grano M. Irisin Correlates Positively With BMD in a Cohort of Older Adult Patients and Downregulates the Senescent Marker p21 in Osteoblasts. J Bone Miner Res. 2021 Feb;36(2):305-314. doi: 10.1002/jbmr.4192. Epub 2020 Oct 29.|Chang JS, Kim TH, Nguyen TT, Park KS, Kim N, Kong ID. Circulating irisin levels as a predictive biomarker for sarcopenia: A cross-sectional community-based study. Geriatr Gerontol Int. 2017 Nov;17(11):2266-2273. doi: 10.1111/ggi.13030. Epub 2017 Apr 10.|Budziareck MB, Pureza Duarte RR, Barbosa-Silva MC. Reference values and determinants for handgrip strength in healthy subjects. Clin Nutr. 2008 Jun;27(3):357-62. doi: 10.1016/j.clnu.2008.03.008. Epub 2008 May 2.","\tCharcot-Marie-Tooth Disease\tBioimpedenziometry, Handgrip strenght evaluation|Evaluation on blood specimens\tNA\tNA\tNA\tDiagnostic Test|Diagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","charcot-marie-tooth disease|nerve compression syndromes|hereditary sensory and motor neuropathy|tooth diseases","NA","NA"]
["NCT04786535","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28486230|28853700|30281134|28085888|27587605","Ronco C. The Rise of Expanded Hemodialysis. Blood Purif. 2017;44(2):I-VIII. doi: 10.1159/000476012. Epub 2017 May 10.|Belmouaz M, Diolez J, Bauwens M, Duthe F, Ecotiere L, Desport E, Bridoux F. Comparison of hemodialysis with medium cut-off dialyzer and on-line hemodiafiltration on the removal of small and middle-sized molecules . Clin Nephrol. 2018 Jan;89 (2018)(1):50-56. doi: 10.5414/CN109133 .|Ronco C, Marchionna N, Brendolan A, Neri M, Lorenzin A, Martínez Rueda AJ. Expanded haemodialysis: from operational mechanism to clinical results. Nephrol Dial Transplant. 2018 Oct 1;33(suppl_3):iii41-iii47. doi: 10.1093/ndt/gfy202. Review.|Zickler D, Schindler R, Willy K, Martus P, Pawlak M, Storr M, Hulko M, Boehler T, Glomb MA, Liehr K, Henning C, Templin M, Trojanowicz B, Ulrich C, Werner K, Fiedler R, Girndt M. Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients-A Randomized Controlled Clinical Trial. PLoS One. 2017 Jan 13;12(1):e0169024. doi: 10.1371/journal.pone.0169024. eCollection 2017.|Kirsch AH, Lyko R, Nilsson LG, Beck W, Amdahl M, Lechner P, Schneider A, Wanner C, Rosenkranz AR, Krieter DH. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant. 2017 Jan 1;32(1):165-172. doi: 10.1093/ndt/gfw310.","\tEnd Stage Renal Disease\tExpanded Hemodialysis|High-flux Conventional Hemodialysis|Hemodiafiltration\tCrossover Assignment\tTreatment\tRandomized\tProcedure|Procedure|Procedure\tAll\t","Efficacy of Uremic Toxins Clearance With Expanded Hemodialysis","Interventional","Not yet recruiting","N/A",3,23,"kidney failure, chronic","NA","NA"]
["NCT04786834","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16926559|7818004|23620606|15650649|31289064|30327396|26341047|18926460|17512301|12368674|32089358|27440232|31531529|20096178|31718526|22099993|14502403","Pellegrini CA. Surgical education in the United States: navigating the white waters. Ann Surg. 2006 Sep;244(3):335-42.|Cuschieri A. Whither minimal access surgery: tribulations and expectations. Am J Surg. 1995 Jan;169(1):9-19.|Gallagher AG. Metric-based simulation training to proficiency in medical education:- what it is and how to do it. Ulster Med J. 2012 Sep;81(3):107-13. Review.|Gallagher AG, Ritter EM, Champion H, Higgins G, Fried MP, Moses G, Smith CD, Satava RM. Virtual reality simulation for the operating room: proficiency-based training as a paradigm shift in surgical skills training. Ann Surg. 2005 Feb;241(2):364-72.|Breen D, O'Brien S, McCarthy N, Gallagher A, Walshe N. Effect of a proficiency-based progression simulation programme on clinical communication for the deteriorating patient: a randomised controlled trial. BMJ Open. 2019 Jul 9;9(7):e025992. doi: 10.1136/bmjopen-2018-025992.|Kallidaikurichi Srinivasan K, Gallagher A, O'Brien N, Sudir V, Barrett N, O'Connor R, Holt F, Lee P, O'Donnell B, Shorten G. Proficiency-based progression training: an 'end to end' model for decreasing error applied to achievement of effective epidural analgesia during labour: a randomised control study. BMJ Open. 2018 Oct 15;8(10):e020099. doi: 10.1136/bmjopen-2017-020099.|Angelo RL, Ryu RK, Pedowitz RA, Beach W, Burns J, Dodds J, Field L, Getelman M, Hobgood R, McIntyre L, Gallagher AG. A Proficiency-Based Progression Training Curriculum Coupled With a Model Simulator Results in the Acquisition of a Superior Arthroscopic Bankart Skill Set. Arthroscopy. 2015 Oct;31(10):1854-71. doi: 10.1016/j.arthro.2015.07.001. Epub 2015 Sep 2.|Van Sickle KR, Ritter EM, Baghai M, Goldenberg AE, Huang IP, Gallagher AG, Smith CD. Prospective, randomized, double-blind trial of curriculum-based training for intracorporeal suturing and knot tying. J Am Coll Surg. 2008 Oct;207(4):560-8. doi: 10.1016/j.jamcollsurg.2008.05.007. Epub 2008 Jul 14.|Ahlberg G, Enochsson L, Gallagher AG, Hedman L, Hogman C, McClusky DA 3rd, Ramel S, Smith CD, Arvidsson D. Proficiency-based virtual reality training significantly reduces the error rate for residents during their first 10 laparoscopic cholecystectomies. Am J Surg. 2007 Jun;193(6):797-804.|Seymour NE, Gallagher AG, Roman SA, O'Brien MK, Bansal VK, Andersen DK, Satava RM. Virtual reality training improves operating room performance: results of a randomized, double-blinded study. Ann Surg. 2002 Oct;236(4):458-63; discussion 463-4.|Vanlander AE, Mazzone E, Collins JW, Mottrie AM, Rogiers XM, van der Poel HG, Van Herzeele I, Satava RM, Gallagher AG. Orsi Consensus Meeting on European Robotic Training (OCERT): Results from the First Multispecialty Consensus Meeting on Training in Robot-assisted Surgery. Eur Urol. 2020 Nov;78(5):713-716. doi: 10.1016/j.eururo.2020.02.003. Epub 2020 Feb 21. Review.|Cacciamani G, De Marco V, Siracusano S, De Marchi D, Bizzotto L, Cerruto MA, Motton G, Porcaro AB, Artibani W. A new training model for robot-assisted urethrovesical anastomosis and posterior muscle-fascial reconstruction: the Verona training technique. J Robot Surg. 2017 Jun;11(2):123-128. doi: 10.1007/s11701-016-0626-4. Epub 2016 Jul 20.|Santos DRD, Calvo FC, Feijó DH, Araújo NP, Teixeira RKC, Yasojima EY. New training model using chickens intestine for pediatric intestinal anastomosis. Acta Cir Bras. 2019 Sep 16;34(7):e201900709. doi: 10.1590/s0102-865020190070000009.|Sotelo RJ, Astigueta JC, Carmona OJ, De Andrade RJ, Moreira OE. Chicken gizzard: a new training model for laparoscopic urethrovesical anastomosis. Actas Urol Esp. 2009 Nov;33(10):1083-7. English, Spanish.|Ericsson KA. Towards a science of the acquisition of expert performance in sports: Clarifying the differences between deliberate practice and other types of practice. J Sports Sci. 2020 Jan;38(2):159-176. doi: 10.1080/02640414.2019.1688618. Epub 2019 Nov 12. Review.|Goh AC, Goldfarb DW, Sander JC, Miles BJ, Dunkin BJ. Global evaluative assessment of robotic skills: validation of a clinical assessment tool to measure robotic surgical skills. J Urol. 2012 Jan;187(1):247-52. doi: 10.1016/j.juro.2011.09.032. Epub 2011 Nov 17.|Gallagher AG, Ritter EM, Satava RM. Fundamental principles of validation, and reliability: rigorous science for the assessment of surgical education and training. Surg Endosc. 2003 Oct;17(10):1525-9. Epub 2003 Sep 19.","\tEducational Problems\tVesico urethral anastomosis on chicken model\tParallel Assignment\tOther\tRandomized\tProcedure\tAll\t","PBP Versus Halsted's Model: the PROVESA Trial","Interventional","Completed","N/A",2,36,"NA","NA","NA"]
["NCT04787068","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18786017|22251799|19689239|23341829|17379673","Etters L, Goodall D, Harrison BE. Caregiver burden among dementia patient caregivers: a review of the literature. J Am Acad Nurse Pract. 2008 Aug;20(8):423-8. doi: 10.1111/j.1745-7599.2008.00342.x. Review.|Dean K, Wilcock G. Living with mild cognitive impairment: the patient's and carer's experience. Int Psychogeriatr. 2012 Jun;24(6):871-81. doi: 10.1017/S104161021100264X. Epub 2012 Jan 17. Review.|Austrom MG, Lu Y. Long term caregiving: helping families of persons with mild cognitive impairment cope. Curr Alzheimer Res. 2009 Aug;6(4):392-8.|Beinart N, Weinman J, Wade D, Brady R. Caregiver burden and psychoeducational interventions in Alzheimer's disease: a review. Dement Geriatr Cogn Dis Extra. 2012 Jan;2(1):638-48. doi: 10.1159/000345777. Epub 2012 Dec 15.|Pinquart M, Sörensen S. Correlates of physical health of informal caregivers: a meta-analysis. J Gerontol B Psychol Sci Soc Sci. 2007 Mar;62(2):P126-37.","\tCaregiver Burden|Cognition|Confidence, Self|Depression|Fatigue|Function\tOccupational Therapy support\tParallel Assignment\tSupportive Care\tRandomized\tBehavioral\tAll\t","Support for Caregivers of Older Adults With Cognitive Decline","Interventional","Completed","N/A",2,35,"fatigue","NA","NA"]
["NCT04787172","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",24761701,"Goitein O, Salem Y, Jacobson J, Goitein D, Mishali D, Hamdan A, Kuperstein R, Di Segni E, Konen E. The role of cardiac computed tomography in infants with congenital heart disease. Isr Med Assoc J. 2014 Mar;16(3):147-52.","\tMSCT in Congenital Cardiovascular Disease\tMulti Slice computed tomography\tNA\tNA\tNA\tRadiation\tAll\t","NA","NA","NA","NA","NA","NA","cardiovascular diseases","NA","NA"]
["NCT04788108","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16293412|20005647|20007011","Omar MH, Mashita MK, Lim PS, Jamil MA. Dydrogesterone in threatened abortion: pregnancy outcome. J Steroid Biochem Mol Biol. 2005 Dec;97(5):421-5. Epub 2005 Nov 15.|Pandian RU. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas. 2009 Dec;65 Suppl 1:S47-50. doi: 10.1016/j.maturitas.2009.11.016. Epub 2009 Dec 14.|El-Zibdeh MY, Yousef LT. Dydrogesterone support in threatened miscarriage. Maturitas. 2009 Dec;65 Suppl 1:S43-6. doi: 10.1016/j.maturitas.2009.11.013. Epub 2009 Dec 14.","\tThreatened Abortion\tDydrogesterone|Placebo\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug\tFemale\t","Oral Progesterone for Prevention of Miscarriage in Threatened Abortion","Interventional","Not yet recruiting","Phase 4",2,200,"abortion, spontaneous|abortion, threatened","dydrogesterone","NA"]
["NCT04788134","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25184463,"Mailloux Z, Leão M, Becerra TA, Mori AB, Soechting E, Roley SS, Buss N, Cermak SA. Modification of the postrotary nystagmus test for evaluating young children. Am J Occup Ther. 2014 Sep-Oct;68(5):514-21. doi: 10.5014/ajot.2014.011031.","\tNystagmus Vestibular|Vestibular Function Tests\tPost-rotatory nystagmus test\tNA\tNA\tNA\tDiagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","nystagmus, pathologic","NA","NA"]
["NCT04788693","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26484518,"Santiago LM, de Oliveira DA, de Macêdo Ferreira LG, de Brito Pinto HY, Spaniol AP, de Lucena Trigueiro LC, Ribeiro TS, de Sousa AV, Piemonte ME, Lindquist AR. Immediate effects of adding mental practice to physical practice on the gait of individuals with Parkinson's disease: Randomized clinical trial. NeuroRehabilitation. 2015;37(2):263-71. doi: 10.3233/NRE-151259.","\tParkinson Disease\tPhysical rehabilitation of gait with motor imagery|Physical rehabilitation of gait without motor imagery\tParallel Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Effects of Gait Rehabilitation With Motor Imagery in People With Parkinson's Disease","Interventional","Not yet recruiting","N/A",2,60,"parkinson disease","NA","NA"]
["NCT04788771","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31613680|28194529","Nevešćanin A, Vickov J, Elezović Baloević S, Pogorelić Z. Laryngeal Mask Airway Versus Tracheal Intubation for Laparoscopic Hernia Repair in Children: Analysis of Respiratory Complications. J Laparoendosc Adv Surg Tech A. 2020 Jan;30(1):76-80. doi: 10.1089/lap.2019.0382. Epub 2019 Oct 15.|Nagahisa Y, Hashida K, Matsumoto R, Kawashima R, Okabe M, Kawamoto K. A randomized clinical study on postoperative pain comparing between the supraglottic airway device and endotracheal tubing in transabdominal preperitoneal repair (TAPP). Hernia. 2017 Jun;21(3):391-396. doi: 10.1007/s10029-017-1586-y. Epub 2017 Feb 13.","\tLung Functions|Pain Score\tTracheal intubation in laparoscopic extraperitoneal hernia repair\tParallel Assignment\tPrevention\tRandomized\tProcedure\tAll\t","Comparison of Tracheal Intubation vs Laryngeal Mask Airway in Laparoscopic Total Extraperitoneal Hernia Repair","Interventional","Enrolling by invitation","N/A",2,40,"hernia","NA","NA"]
["NCT04789135","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29777618|27790294","Malde S, Palmisani S, Al-Kaisy A, Sahai A. Guideline of guidelines: bladder pain syndrome. BJU Int. 2018 Nov;122(5):729-743. doi: 10.1111/bju.14399. Epub 2018 Jun 13. Review.|Cox A, Golda N, Nadeau G, Curtis Nickel J, Carr L, Corcos J, Teichman J. CUA guideline: Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Can Urol Assoc J. 2016 May-Jun;10(5-6):E136-E155. Epub 2016 May 12.","\tBladder Pain Syndrome|Interstitial Cystitis, Chronic\tOzone\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","somatoform disorders|cystitis, interstitial|syndrome|cystitis","NA","NA"]
["NCT04789161","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17060387|19103990|20194880|29096915|32338608","Steigen TK, Maeng M, Wiseth R, Erglis A, Kumsars I, Narbute I, Gunnes P, Mannsverk J, Meyerdierks O, Rotevatn S, Niemelä M, Kervinen K, Jensen JS, Galløe A, Nikus K, Vikman S, Ravkilde J, James S, Aarøe J, Ylitalo A, Helqvist S, Sjögren I, Thayssen P, Virtanen K, Puhakka M, Airaksinen J, Lassen JF, Thuesen L; Nordic PCI Study Group. Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study. Circulation. 2006 Oct 31;114(18):1955-61. Epub 2006 Oct 23.|Colombo A, Bramucci E, Saccà S, Violini R, Lettieri C, Zanini R, Sheiban I, Paloscia L, Grube E, Schofer J, Bolognese L, Orlandi M, Niccoli G, Latib A, Airoldi F. Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study. Circulation. 2009 Jan 6;119(1):71-8. doi: 10.1161/CIRCULATIONAHA.108.808402. Epub 2008 Dec 22.|Hildick-Smith D, de Belder AJ, Cooter N, Curzen NP, Clayton TC, Oldroyd KG, Bennett L, Holmberg S, Cotton JM, Glennon PE, Thomas MR, Maccarthy PA, Baumbach A, Mulvihill NT, Henderson RA, Redwood SR, Starkey IR, Stables RH. Randomized trial of simple versus complex drug-eluting stenting for bifurcation lesions: the British Bifurcation Coronary Study: old, new, and evolving strategies. Circulation. 2010 Mar 16;121(10):1235-43. doi: 10.1161/CIRCULATIONAHA.109.888297. Epub 2010 Mar 1.|Chen SL, Zhang JJ, Han Y, Kan J, Chen L, Qiu C, Jiang T, Tao L, Zeng H, Li L, Xia Y, Gao C, Santoso T, Paiboon C, Wang Y, Kwan TW, Ye F, Tian N, Liu Z, Lin S, Lu C, Wen S, Hong L, Zhang Q, Sheiban I, Xu Y, Wang L, Rab TS, Li Z, Cheng G, Cui L, Leon MB, Stone GW. Double Kissing Crush Versus Provisional Stenting for Left Main Distal Bifurcation Lesions: DKCRUSH-V Randomized Trial. J Am Coll Cardiol. 2017 Nov 28;70(21):2605-2617. doi: 10.1016/j.jacc.2017.09.1066. Epub 2017 Oct 30.|Toth GG, Sasi V, Franco D, Prassl AJ, Di Serafino L, Ng JCK, Szanto G, Schneller L, Ang HY, Plank G, Wijns W, Barbato E. Double-kissing culotte technique for coronary bifurcation stenting. EuroIntervention. 2020 Oct 9;16(9):e724-e733. doi: 10.4244/EIJ-D-20-00130.","\tCoronary Artery Disease\tdouble kissing crush stenting|double kissing culotte stenting\tNA\tNA\tNA\tProcedure|Procedure\tAll\t","NA","NA","NA","NA","NA","NA","coronary artery disease","NA","NA"]
["NCT04789590","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18816330|22117752|30284545|27370573|11129760|19054191|18585645|19638205|17522361|29950889|31849664|28224474|18786737|18280101|17179872|16931417|19709699","Clough-Gorr KM, Blozik E, Gillmann G, Beck JC, Ferrell BA, Anders J, Harari D, Stuck AE. The self-administered 24-item geriatric pain measure (GPM-24-SA): psychometric properties in three European populations of community-dwelling older adults. Pain Med. 2008 Sep;9(6):695-709. doi: 10.1111/j.1526-4637.2008.00497.x.|Cornally N, McCarthy G. Chronic pain: the help-seeking behavior, attitudes, and beliefs of older adults living in the community. Pain Manag Nurs. 2011 Dec;12(4):206-17. doi: 10.1016/j.pmn.2010.12.006. Epub 2011 Feb 26.|Damico V, Murano L, Cazzaniga F, Dal Molin A. Pain prevalence, severity, assessment and management in hospitalized adult patients: a result of a multicenter cross sectional study. Ann Ist Super Sanita. 2018 Jul-Sep;54(3):194-200. doi: 10.4415/ANN_18_03_05.|Dursun G, Bektas H. Cultural Validation and Reliability of the Turkish Version of the Geriatric Pain Measure in the Elderly. Pain Pract. 2017 Apr;17(4):505-513. doi: 10.1111/papr.12473. Epub 2016 Jul 2.|Ferrell BA, Stein WM, Beck JC. The Geriatric Pain Measure: validity, reliability and factor analysis. J Am Geriatr Soc. 2000 Dec;48(12):1669-73.|Horgas AL, Elliott AF, Marsiske M. Pain assessment in persons with dementia: relationship between self-report and behavioral observation. J Am Geriatr Soc. 2009 Jan;57(1):126-32. doi: 10.1111/j.1532-5415.2008.02071.x. Epub 2008 Nov 18.|Husebo BS, Strand LI, Moe-Nilssen R, Borgehusebo S, Aarsland D, Ljunggren AE. Who suffers most? Dementia and pain in nursing home patients: a cross-sectional study. J Am Med Dir Assoc. 2008 Jul;9(6):427-33. doi: 10.1016/j.jamda.2008.03.001. Epub 2008 Jun 2.|Iliffe S, Kharicha K, Carmaciu C, Harari D, Swift C, Gillman G, Stuck AE. The relationship between pain intensity and severity and depression in older people: exploratory study. BMC Fam Pract. 2009 Jul 28;10:54. doi: 10.1186/1471-2296-10-54.|Leong IY, Farrell MJ, Helme RD, Gibson SJ. The relationship between medical comorbidity and self-rated pain, mood disturbance, and function in older people with chronic pain. J Gerontol A Biol Sci Med Sci. 2007 May;62(5):550-5.|Liberman O, Freud T, Peleg R, Keren A, Press Y. Chronic pain and geriatric syndromes in community-dwelling patients aged ≥65 years. J Pain Res. 2018 Jun 19;11:1171-1180. doi: 10.2147/JPR.S160847. eCollection 2018.|Motter FR, Hilmer SN, Paniz VMV. Pain and Inflammation Management in Older Adults: A Brazilian Consensus of Potentially Inappropriate Medication and Their Alternative Therapies. Front Pharmacol. 2019 Dec 2;10:1408. doi: 10.3389/fphar.2019.01408. eCollection 2019.|Nawai A, Leveille SG, Shmerling RH, van der Leeuw G, Bean JF. Pain severity and pharmacologic pain management among community-living older adults: the MOBILIZE Boston study. Aging Clin Exp Res. 2017 Dec;29(6):1139-1147. doi: 10.1007/s40520-016-0700-9. Epub 2017 Feb 21.|Park J, Cho B, Paek Y, Kwon H, Yoo S. Development of a pain assessment tool for the older adults in Korea: the validity and reliability of a Korean version of the geriatric pain measure (GPM-K). Arch Gerontol Geriatr. 2009 Sep-Oct;49(2):199-203. doi: 10.1016/j.archger.2008.07.010. Epub 2008 Sep 10.|Reynolds KS, Hanson LC, DeVellis RF, Henderson M, Steinhauser KE. Disparities in pain management between cognitively intact and cognitively impaired nursing home residents. J Pain Symptom Manage. 2008 Apr;35(4):388-96. doi: 10.1016/j.jpainsymman.2008.01.001. Epub 2008 Feb 15.|van Herk R, van Dijk M, Baar FP, Tibboel D, de Wit R. Observation scales for pain assessment in older adults with cognitive impairments or communication difficulties. Nurs Res. 2007 Jan-Feb;56(1):34-43. Review.|Ware LJ, Epps CD, Herr K, Packard A. Evaluation of the Revised Faces Pain Scale, Verbal Descriptor Scale, Numeric Rating Scale, and Iowa Pain Thermometer in older minority adults. Pain Manag Nurs. 2006 Sep;7(3):117-25.|Woo J, Leung J, Lau E. Prevalence and correlates of musculoskeletal pain in Chinese elderly and the impact on 4-year physical function and quality of life. Public Health. 2009 Aug;123(8):549-56. doi: 10.1016/j.puhe.2009.07.006. Epub 2009 Aug 25.","\tPain\tNA\tNA\tNA\tNA\tNA\tFemale\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04789876","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31302884|28398983|32706698|29064141|19539185|27528215","Chan MW, Cheah HM, Mohd Padzil MB. Multidisciplinary education approach to optimize phosphate control among hemodialysis patients. Int J Clin Pharm. 2019 Oct;41(5):1282-1289. doi: 10.1007/s11096-019-00878-4. Epub 2019 Jul 13.|Milazi M, Bonner A, Douglas C. Effectiveness of educational or behavioral interventions on adherence to phosphate control in adults receiving hemodialysis: a systematic review. JBI Database System Rev Implement Rep. 2017 Apr;15(4):971-1010. doi: 10.11124/JBISRIR-2017-003360. Review.|Fakih El Khoury C, Crutzen R, Schols JMGA, Halfens RJG, Karavetian M. A Dietary Mobile App for Patients Undergoing Hemodialysis: Prospective Pilot Study to Improve Dietary Intakes. J Med Internet Res. 2020 Jul 20;22(7):e17817. doi: 10.2196/17817.|Elder GJ, Malik A, Lambert K. Role of dietary phosphate restriction in chronic kidney disease. Nephrology (Carlton). 2018 Dec;23(12):1107-1115. doi: 10.1111/nep.13188.|Reddy V, Symes F, Sethi N, Scally AJ, Scott J, Mumtaz R, Stoves J. Dietitian-led education program to improve phosphate control in a single-center hemodialysis population. J Ren Nutr. 2009 Jul;19(4):314-20. doi: 10.1053/j.jrn.2008.11.001.|Vrdoljak I, Panjkota Krbavčić I, Bituh M, Leko N, Pavlović D, Vrdoljak Margeta T. The impact of education and cooking methods on serum phosphate levels in patients on hemodialysis: 1-year study. Hemodial Int. 2017 Apr;21(2):256-264. doi: 10.1111/hdi.12468. Epub 2016 Aug 16.","\tEnd Stage Renal Disease on Dialysis|Hyperphosphatemia\tPhosphate mobile app|One-off dietary counselling with a phosphate booklet\tParallel Assignment\tTreatment\tRandomized\tOther|Behavioral\tAll\t","Effectiveness of The Phosphate Mobile App on Serum Phosphorus in Adult Hemodialysis Patients With Hyperphosphatemia","Interventional","Completed","N/A",2,74,"kidney failure, chronic|hyperphosphatemia","NA","NA"]
["NCT04789902","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31316707|32317277","Patey C, Norman P, Araee M, Asghari S, Heeley T, Boyd S, Hurley O, Aubrey-Bassler K. SurgeCon: Priming a Community Emergency Department for Patient Flow Management. West J Emerg Med. 2019 Jul;20(4):654-665. doi: 10.5811/westjem.2019.5.42027. Epub 2019 Jul 5.|Patey C, Asghari S, Norman P, Hurley O. Redesign of a rural emergency department to prepare for the COVID-19 pandemic. CMAJ. 2020 May 11;192(19):E518-E520. doi: 10.1503/cmaj.200509. Epub 2020 Apr 21.","\tEmergency Departments|Length of Stay\tSurgeCon\tCrossover Assignment\tHealth Services Research\tRandomized\tOther\tAll\t","SurgeCon: An Emergency Department Surge Management Platform","Interventional","Recruiting","N/A",4,20280,"emergencies","NA","NA"]
["NCT04790396","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","9259056|9025126|10825620|10524730|30902687|31003817|30013612","Bahr J, Klingler H, Panzer W, Rode H, Kettler D. Skills of lay people in checking the carotid pulse. Resuscitation. 1997 Aug;35(1):23-6.|Eberle B, Dick WF, Schneider T, Wisser G, Doetsch S, Tzanova I. Checking the carotid pulse check: diagnostic accuracy of first responders in patients with and without a pulse. Resuscitation. 1996 Dec;33(2):107-16.|Moule P. Checking the carotid pulse: diagnostic accuracy in students of the healthcare professions. Resuscitation. 2000 May;44(3):195-201.|Liberman M, Lavoie A, Mulder D, Sampalis J. Cardiopulmonary resuscitation: errors made by pre-hospital emergency medical personnel. Resuscitation. 1999 Sep;42(1):47-55.|Badra K, Coutin A, Simard R, Pinto R, Lee JS, Chenkin J. The POCUS pulse check: A randomized controlled crossover study comparing pulse detection by palpation versus by point-of-care ultrasound. Resuscitation. 2019 Jun;139:17-23. doi: 10.1016/j.resuscitation.2019.03.009. Epub 2019 Mar 20.|Simard RD, Unger AG, Betz M, Wu A, Chenkin J. The POCUS Pulse Check: A Case Series on a Novel Method for Determining the Presence of a Pulse Using Point-of-Care Ultrasound. J Emerg Med. 2019 Jun;56(6):674-679. doi: 10.1016/j.jemermed.2019.02.013. Epub 2019 Apr 16.|Germanoska B, Coady M, Ng S, Fermanis G, Miller M. The reliability of carotid ultrasound in determining the return of pulsatile flow: A pilot study. Ultrasound. 2018 May;26(2):118-126. doi: 10.1177/1742271X17753467. Epub 2018 Jan 29.","\tCardiac Arrest\tCarotid ultrasound under pulsed-wave doppler mode\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","heart arrest","NA","NA"]
["NCT04790487","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11332874,"Van Toor BS, Buchwald A, Stengele E, Trenk D, Gercek C, de Mey CM. Systemic bioavailability of nasally applied chlorphenamine maleate (0.4% nasal spray) relative to tablets administered perorally. Int J Clin Pharmacol Ther. 2001 Apr;39(4):173-8.","\tAllergic Rhinitis|Nasal Congestion\tCPM|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis","Interventional","Active, not recruiting","Phase 2/Phase 3",2,100,"rhinitis|rhinitis, allergic","chlorpheniramine","NA"]
["NCT04791202","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18182958|20452743|2712610","Cook GS, Lalonde DH. MOC-PSSM CME article: Management of thumb carpometacarpal joint arthritis. Plast Reconstr Surg. 2008 Jan;121(1 Suppl):1-9. doi: 10.1097/01.prs.0000294708.70340.8c. Review.|Merritt MM, Roddey TS, Costello C, Olson S. Diagnostic value of clinical grind test for carpometacarpal osteoarthritis of the thumb. J Hand Ther. 2010 Jul-Sep;23(3):261-7; quiz 268. doi: 10.1016/j.jht.2010.02.001. Epub 2010 May 10.|van Saase JL, van Romunde LK, Cats A, Vandenbroucke JP, Valkenburg HA. Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis. 1989 Apr;48(4):271-80.","\tFunctionality|Pain|Satisfaction, Patient\tDextrose|Methylprednisolone Acetate 40 MG/ML\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Hypertonic Dextrose Versus Corticosteroid Intra-Articular Injections for the Treatment of Trapeziometacarpal Arthritis","Interventional","Not yet recruiting","Phase 3",2,130,"arthritis","prednisolone phosphate|prednisolone hemisuccinate|methylprednisolone|methylprednisolone acetate|methylprednisolone hemisuccinate|prednisolone acetate|prednisolone","NA"]
["NCT04791592","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32665179,"Aydin ME, Ahiskalioglu A, Ates I, Tor IH, Borulu F, Erguney OD, Celik M, Dogan N. Efficacy of Ultrasound-Guided Transversus Thoracic Muscle Plane Block on Postoperative Opioid Consumption After Cardiac Surgery: A Prospective, Randomized, Double-Blind Study. J Cardiothorac Vasc Anesth. 2020 Nov;34(11):2996-3003. doi: 10.1053/j.jvca.2020.06.044. Epub 2020 Jun 18.","\tCoronary Artery Disease|Pain, Postoperative\tSingle-injection, ultrasound-guided bilateral PIF block.|Single-injection, ultrasound-guided bilateral TTMP block.\tParallel Assignment\tSupportive Care\tRandomized\tProcedure|Procedure\tAll\t","Pecto-Intercostal Fascial Block vs. Transversus Thoracic Muscle Plane Block in Cardiac Surgery","Interventional","Completed","N/A",2,42,"pain, postoperative|coronary artery disease","NA","NA"]
["NCT04792125","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25266357|15459518|20848671","Kaya S, Akbayrak T, Gursen C, Beksac S. Short-term effect of adding pelvic floor muscle training to bladder training for female urinary incontinence: a randomized controlled trial. Int Urogynecol J. 2015 Feb;26(2):285-93. doi: 10.1007/s00192-014-2517-4. Epub 2014 Sep 30.|Turkan A, Inci Y, Fazli D. The short-term effects of physical therapy in different intensities of urodynamic stress incontinence. Gynecol Obstet Invest. 2005;59(1):43-8. Epub 2004 Sep 29.|Huebner M, Riegel K, Hinninghofen H, Wallwiener D, Tunn R, Reisenauer C. Pelvic floor muscle training for stress urinary incontinence: a randomized, controlled trial comparing different conservative therapies. Physiother Res Int. 2011 Sep;16(3):133-40. doi: 10.1002/pri.489. Epub 2010 Sep 16.","\tElectrical Stimulation|Pelvic Floor Disorders|Urinary Incontinence|Urinary Incontinence, Stress\tExternal electrical stimulation (EES) added to pelvic floor muscle training (PFMT)|External electrical stimulation|Pelvic floor muscle training (PFMT)\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral|Behavioral\tFemale\t","Effect of External Electrical Stimulation and Pelvic Floor Muscle Training","Interventional","Completed","N/A",3,51,"urinary incontinence|urinary incontinence, stress|pelvic floor disorders|enuresis","NA","NA"]
["NCT04792190","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",11343485,"Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9;285(18):2370-5.","\tAtrial Fibrillation\tdapagliflozin|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation","Interventional","Not yet recruiting","Phase 4",2,100,"atrial fibrillation","2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2h-pyran-3,4,5-triol","NA"]
["NCT04792658","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31274696|15762817|29244060","Shinfuku M, Kishimoto T, Uchida H, Suzuki T, Mimura M, Kikuchi T. Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis. Int Clin Psychopharmacol. 2019 Sep;34(5):211-221. doi: 10.1097/YIC.0000000000000276.|O'brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry. 2005;66 Suppl 2:28-33. Review.|Crowe SF, Stranks EK. The Residual Medium and Long-term Cognitive Effects of Benzodiazepine Use: An Updated Meta-analysis. Arch Clin Neuropsychol. 2018 Nov 1;33(7):901-911. doi: 10.1093/arclin/acx120. Review.","\tBenzodiazepine-Related Disorders|Psychiatric Disorder\tDetailed interview with personal demographic data|Intelligence assessment using the Arabic version of the Wechsler Adult Intelligence Scale (WAIS)|The Arabic version of the Structured Interview for the Five-Factor Personality Model (SIFFM)|the Hamilton Depression Rating Scale|The Hamilton Anxiety Rating Scale|The Minnesota Multiphasic Personality Inventory-2 (MMPI-2)\tNA\tNA\tNA\tBehavioral|Behavioral|Behavioral|Behavioral|Behavioral|Behavioral\tAll\t","NA","NA","NA","NA","NA","NA","mental disorders|problem behavior|disease","NA","NA"]
["NCT04792671","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25896571|20872155","Sheffield KM, Woods-Giscombé CL. Efficacy, Feasibility, and Acceptability of Perinatal Yoga on Women's Mental Health and Well-Being: A Systematic Literature Review. J Holist Nurs. 2016 Mar;34(1):64-79. doi: 10.1177/0898010115577976. Epub 2015 Apr 20. Review.|Sharma V, Burt VK. DSM-V: modifying the postpartum-onset specifier to include hypomania. Arch Womens Ment Health. 2011 Feb;14(1):67-9. doi: 10.1007/s00737-010-0182-2. Epub 2010 Sep 25.","\tPsychiatric Problem|Wolman Disease\tSociodemographic variables|Family affluence scale (FAS)|Edinburgh postnatal depression scale (EPDS)|Symptom Checklist 90 \"\"SCL 90\"\":\"","NA","NA","NA","Behavioral|Behavioral|Behavioral|Behavioral","Female","\tNA\tNA\tNA\tNA\tNA\tNA\twolman disease|mental disorders\tNA\tNA\nNCT04792944\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t29801906|15508346|9402590|10525849|18456995|11846914|19847758|22368972|23328469|22700527|8559330|11452854|10978043|10825515|21125452|8922707|9952128|2295920|15018324|9055298|1704491|11563280|15898439|1866764\tAl-Mufti F, Amuluru K, Damodara N, El-Ghanem M, Nuoman R, Kamal N, Al-Marsoummi S, Morris NA, Dangayach NS, Mayer SA. Novel management strategies for medically-refractory vasospasm following aneurysmal subarachnoid hemorrhage. J Neurol Sci. 2018 Jul 15;390:44-51. doi: 10.1016/j.jns.2018.02.039. Epub 2018 Feb 23. Review.|Arakawa Y, Kikuta K, Hojo M, Goto Y, Yamagata S, Nozaki K, Hashimoto N. Milrinone reduces cerebral vasospasm after subarachnoid hemorrhage of WFNS grade IV or V. Neurol Med Chir (Tokyo). 2004 Aug;44(8):393-400; discussion 401.|Arthur AS, Fergus AH, Lanzino G, Mathys J, Kassell NF, Lee KS. Systemic administration of the iron chelator deferiprone attenuates subarachnoid hemorrhage-induced cerebral vasospasm in the rabbit. Neurosurgery. 1997 Dec;41(6):1385-91; discussion 1391-2.|Asano T. Oxyhemoglobin as the principal cause of cerebral vasospasm: a holistic view of its actions. Crit Rev Neurosurg. 1999 Sep 24;9(5):303-318.|Ayer RE, Zhang JH. Oxidative stress in subarachnoid haemorrhage: significance in acute brain injury and vasospasm. Acta Neurochir Suppl. 2008;104:33-41.|Barbosa MD, Arthur AS, Louis RH, MacDonald T, Polin RS, Gazak C, Kassell NF. The novel 5-lipoxygenase inhibitor ABT-761 attenuates cerebral vasospasm in a rabbit model of subarachnoid hemorrhage. Neurosurgery. 2001 Nov;49(5):1205-12; discussion 1212-3.|Bilginer B, Onal MB, Narin F, Soylemezoglu F, Ziyal IM, Ozgen T. The effects of intravenous cilostazol and nimodipine on cerebral vasospasm after subarachnoid hemorrhage in an experimental rabbit model. Turk Neurosurg. 2009 Oct;19(4):374-9.|Dalbayrak S, Altas M, Arslan R. The effects of timing of aneurysm surgery on vasospasm and mortality in patients with subarachnoid hemorrhage. Acta Neurol Belg. 2011 Dec;111(4):317-20.|Ding X, Wang ZG, Wang CW, Wang YH. [Timing of treatment on the prognosis of poor-grade aneurysmal subarachnoid hemorrhage patients]. Zhonghua Yi Xue Za Zhi. 2012 Dec 4;92(45):3211-4. Chinese.|Dorhout Mees SM, Molyneux AJ, Kerr RS, Algra A, Rinkel GJ. Timing of aneurysm treatment after subarachnoid hemorrhage: relationship with delayed cerebral ischemia and poor outcome. Stroke. 2012 Aug;43(8):2126-9. doi: 10.1161/STROKEAHA.111.639690. Epub 2012 Jun 14.|Findlay JM. A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm. Neurosurgery. 1995 Nov;37(5):1026-7. Erratum in: Neurosurgery 1995 Nov;37(5):1026-7.|Górski R, Zabek M, Jarmuzek P. Influence of intraoperative using of recombinant tissue plasminogen activator on the development of cerebral angiospasm after subarachnoid haemorrhage in patients with ruptured intracranial aneurysms. Neurol Neurochir Pol. 2000;34(6 Suppl):41-7.|Hamada J, Mizuno T, Kai Y, Morioka M, Ushio Y. Microcatheter intrathecal urokinase infusion into cisterna magna for prevention of cerebral vasospasm: preliminary report. Stroke. 2000 Sep;31(9):2141-8.|Handa Y, Kaneko M, Takeuchi H, Tsuchida A, Kobayashi H, Kubota T. Effect of an antioxidant, ebselen, on development of chronic cerebral vasospasm after subarachnoid hemorrhage in primates. Surg Neurol. 2000 Apr;53(4):323-9.|Hänggi D, Steiger HJ. The influence of cisternal and ventricular lavage on cerebral vasospasm in patients suffering from subarachnoid hemorrhage: analysis of effectiveness. Acta Neurochir Suppl. 2011;110(Pt 2):95-8. doi: 10.1007/978-3-7091-0356-2_17.|Hirashima Y, Endo S, Horie Y, Kurimoto M. Indications for cisternal irrigation with urokinase in postoperative patients with aneurysmal subarachnoid haemorrhage. Br J Neurosurg. 1996 Oct;10(5):477-81.|Hosoda K, Fujita S, Kawaguchi T, Shose Y, Hamano S, Iwakura M. Effect of clot removal and surgical manipulation on regional cerebral blood flow and delayed vasospasm in early aneurysm surgery for subarachnoid hemorrhage. Surg Neurol. 1999 Jan;51(1):81-8.|Inagawa T, Yamamoto M, Kamiya K. Effect of clot removal on cerebral vasospasm. J Neurosurg. 1990 Feb;72(2):224-30.|Jito J, Nakasu Y, Nakasu S, Hatsuda N, Matsuda M. Tissue plasminogen activator levels after single intracisternal injection in patients with subarachnoid hemorrhage. Neurol Med Chir (Tokyo). 2004 Feb;44(2):55-60; discussion 60.|Kajimoto Y, Ohta T, Kuroiwa T. Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs. Neurosurgery. 1997 Mar;40(3):572-7.|Kawakami M, Kodama N, Toda N. Suppression of the cerebral vasospastic actions of oxyhemoglobin by ascorbic acid. Neurosurgery. 1991 Jan;28(1):33-9; discussion 39-40.|Kodama N, Matsumoto M, Sasaki T, Konno Y, Sato T. Cisternal irrigation therapy with urokinase and ascorbic acid for prevention of vasospasm. Acta Neurochir Suppl. 2001;77:171-4.|Li YH, Guo K, Zi XH, Song Z. [Combining exchange of cerebrospinal fluid with small dose of urokinase injection for subarachnoid hemorrhage]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2005 Apr;30(2):217-20. Chinese.|Macdonald RL, Weir BK. A review of hemoglobin and the pathogenesis of cerebral vasospasm. Stroke. 1991 Aug;22(8):971-82. Review.\t","Hydrocephalus|Subarachnoid Hemorrhage, Aneurysmal|Vasospasm, Cerebral","Urokinase|Endovascular treatment|Clipping|External ventricular drain","NA","NA","NA","Drug|Procedure|Procedure|Procedure","All","\tNA\tNA\tNA\tNA\tNA\tNA\tsubarachnoid hemorrhage|aneurysm|hydrocephalus|vasospasm, intracranial|hemorrhage\tNA\tNA\nNCT04793178\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t20857254|16946280\tMerry AF, Cooper JB, Soyannwo O, Wilson IH, Eichhorn JH. International Standards for a Safe Practice of Anesthesia 2010. Can J Anaesth. 2010 Nov;57(11):1027-34. doi: 10.1007/s12630-010-9381-6. Epub 2010 Sep 21.|Sacchetti A, Senula G, Strickland J, Dubin R. Procedural sedation in the community emergency department: initial results of the ProSCED registry. Acad Emerg Med. 2007 Jan;14(1):41-6. Epub 2006 Aug 31.\t","Apnea|Hypercapnia|Hypoxemia|Procedural Sedation","Oxygen Reserve Index, Masimo Corporation, USA.","Parallel Assignment","Diagnostic","Randomized","Device","All","\tThe Effectivity of End-tidal CO2 and Oxygen Reserve Index (ORI) Monitoring in Sedation\tInterventional\tCompleted\tN/A\t2\t200\thypercapnia|hypoxia\tNA\tNA\nNCT04793581\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t30499198|28393673\tKhalili H, Jeon-Slaughter H, Armstrong EJ, Baskar A, Tejani I, Shammas NW, Prasad A, Abu-Fadel M, Brilakis ES, Banerjee S. Atherectomy in below-the-knee endovascular interventions: One-year outcomes from the XLPAD registry. Catheter Cardiovasc Interv. 2019 Feb 15;93(3):488-493. doi: 10.1002/ccd.27897. Epub 2018 Nov 30.|Schwindt AG, Bennett JG Jr, Crowder WH, Dohad S, Janzer SF, George JC, Tedder B, Davis TP, Cawich IM, Gammon RS, Muck PE, Pigott JP, Dishmon DA, Lopez LA, Golzar JA, Chamberlin JR, Moulton MJ, Zakir RM, Kaki AK, Fishbein GJ, McDaniel HB, Hezi-Yamit A, Simpson JB, Desai A. Lower Extremity Revascularization Using Optical Coherence Tomography-Guided Directional Atherectomy: Final Results of the EValuatIon of the PantheriS OptIcal COherence Tomography ImagiNg Atherectomy System for Use in the Peripheral Vasculature (VISION) Study. J Endovasc Ther. 2017 Jun;24(3):355-366. doi: 10.1177/1526602817701720. Epub 2017 Apr 10.\t","Peripheral Arterial Disease","Atherectomy","NA","NA","NA","Device","All","\tNA\tNA\tNA\tNA\tNA\tNA\tperipheral arterial disease|peripheral vascular diseases\tNA\tNA\nNCT04793607\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t30272503|17573451|18678767|16460928\tFeller-Kopman DJ, Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, Iyer NP, Lee YCG, Lewis SZ, Maskell NA, Rahman NM, Sterman DH, Wahidi MM, Balekian AA. Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline. Am J Respir Crit Care Med. 2018 Oct 1;198(7):839-849. doi: 10.1164/rccm.201807-1415ST.|Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist. 2007;12 Suppl 1:4-10. Review.|Minton O, Stone P. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann Oncol. 2009 Jan;20(1):17-25. doi: 10.1093/annonc/mdn537. Epub 2008 Aug 4. Review.|Prue G, Rankin J, Allen J, Gracey J, Cramp F. Cancer-related fatigue: A critical appraisal. Eur J Cancer. 2006 May;42(7):846-63. Epub 2006 Feb 7. Review.\t","Malignant Pleural Effusion","Pleural procedures","NA","NA","NA","Other","All","\tNA\tNA\tNA\tNA\tNA\tNA\tpleural effusion|fatigue|pleural effusion, malignant\tNA\tNA\nNCT04794257\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t32770679|22402975\tSchneider R, Machens A, Sekulla C, Lorenz K, Elwerr M, Dralle H. Superiority of continuous over intermittent intraoperative nerve monitoring in preventing vocal cord palsy. Br J Surg. 2020 Aug 8. doi: 10.1002/bjs.11901. [Epub ahead of print]|Barczyński M, Konturek A, Stopa M, Honowska A, Nowak W. Randomized controlled trial of visualization versus neuromonitoring of the external branch of the superior laryngeal nerve during thyroidectomy. World J Surg. 2012 Jun;36(6):1340-7. doi: 10.1007/s00268-012-1547-7.\t","Recurrent Laryngeal Nerve Injuries|Surgery|Thyroid Diseases","Neuromonitoring of the recurrent laryngeal nerves","Parallel Assignment","Prevention","Randomized","Device","All","\tNerveTrend vs. i-IONM in Prevention of Recurrent Laryngeal Nerve Events During Bilateral Thyroid Surgery.\tInterventional\tRecruiting\tN/A\t2\t264\tthyroid diseases|laryngeal nerve injuries|recurrent laryngeal nerve injuries\tNA\tNA\nNCT04794426\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t32522320\tEbrahimi M, Shirazi AS, Afshari E. Success and Behavior During Atraumatic Restorative Treatment, the Hall Technique, and the Stainless Steel Crown Technique for Primary Molar Teeth. Pediatr Dent. 2020 May 15;42(3):187-192.\t","Caries","Silver diamine fluoride|Hall Technique","Parallel Assignment","Treatment","Randomized","Drug|Device","All","\tPost-operative Pain and Child Behavior of Hall Technique Versus SDF in the Management of Carious Primary Molars: RCT\tInterventional\tNot yet recruiting\tPhase 3\t2\t40\tpain, postoperative\tfluorides\tNA\nNCT04795154\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t22399208|22884667\tBabbar S, Parks-Savage AC, Chauhan SP. Yoga during pregnancy: a review. Am J Perinatol. 2012 Jun;29(6):459-64. doi: 10.1055/s-0032-1304828. Epub 2012 Mar 7. Review.|Rakhshani A, Nagarathna R, Mhaskar R, Mhaskar A, Thomas A, Gunasheela S. The effects of yoga in prevention of pregnancy complications in high-risk pregnancies: a randomized controlled trial. Prev Med. 2012 Oct;55(4):333-340. doi: 10.1016/j.ypmed.2012.07.020. Epub 2012 Aug 2.\t","Pre-Eclampsia","Yoga excercise","NA","NA","NA","Other","Female","\tPrenatal Yoga as Complementary Therapy of Preeclampsia\tInterventional\tCompleted\tN/A\t2\t24\teclampsia|pre-eclampsia\tNA\tNA\nNCT04795518\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t29991865\tKaul R, Angrish P, Jain P, Saha S, V Sengupta A, Mukherjee S. A Survey on the Use of Antibiotics among the Dentists of Kolkata, West Bengal, India. Int J Clin Pediatr Dent. 2018 Mar-Apr;11(2):122-127. doi: 10.5005/jp-journals-10005-1497. Epub 2018 Apr 1.\t","Antibiotic Resistant Strain","NA","NA","NA","NA","NA","All","\tNA\tNA\tNA\tNA\tNA\tNA\tsprains and strains\tNA\tNA\nNCT04796090\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t19170869|26953828|10693114|10782451|20706119|18042215|27320034\tGraziottin A, Serafini A. HPV infection in women: psychosexual impact of genital warts and intraepithelial lesions. J Sex Med. 2009 Mar;6(3):633-45. doi: 10.1111/j.1743-6109.2008.01151.x. Epub 2009 Jan 13. Review.|McCabe MP, Sharlip ID, Atalla E, Balon R, Fisher AD, Laumann E, Lee SW, Lewis R, Segraves RT. Definitions of Sexual Dysfunctions in Women and Men: A Consensus Statement From the Fourth International Consultation on Sexual Medicine 2015. J Sex Med. 2016 Feb;13(2):135-43. doi: 10.1016/j.jsxm.2015.12.019.|McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, Manber R. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000 Jan-Mar;26(1):25-40.|Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino R Jr. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208.|Greydanus DE, Matytsina L. Female sexual dysfunction and adolescents. Curr Opin Obstet Gynecol. 2010 Oct;22(5):375-80. doi: 10.1097/GCO.0b013e32833d9418. Review.|Derogatis L, Clayton A, Lewis-D'Agostino D, Wunderlich G, Fu Y. Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med. 2008 Feb;5(2):357-64. Epub 2007 Nov 27.|O'Sullivan LF, Byers ES, Brotto LA, Majerovich JA, Fletcher J. A Longitudinal Study of Problems in Sexual Functioning and Related Sexual Distress Among Middle to Late Adolescents. J Adolesc Health. 2016 Sep;59(3):318-324. doi: 10.1016/j.jadohealth.2016.05.001. Epub 2016 Jun 16.\t","Adolescent Development|Genital Wart|Sexual Disorder, Physiological|Sexual Dysfunction","Clinical assessment","NA","NA","NA","Other","Female","\tNA\tNA\tNA\tNA\tNA\tNA\twarts|sexual dysfunction, physiological|condylomata acuminata\tNA\tNA\nNCT04796168\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t23152232\tLin CW, Donkers NA, Refshauge KM, Beckenkamp PR, Khera K, Moseley AM. Rehabilitation for ankle fractures in adults. Cochrane Database Syst Rev. 2012 Nov 14;11:CD005595. doi: 10.1002/14651858.CD005595.pub3. Review.\t","Ankle Fractures|Splints","Splinting (plaster of paris)","Parallel Assignment","Supportive Care","Randomized","Procedure","All","\tPost Operative Ankle Splint Study - Prospective Multi Center Randomized Controlled Trial\tInterventional\tRecruiting\tN/A\t2\t50\tankle fractures\tNA\tNA\nNCT04796519\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t32962591|31832694|23268822\tZora H, Güngör HR, Bayrak G, Şavkın R, Büker N. Does mini-midvastus approach have an advantageous effect on rapid recovery protocols over medial parapatellar approach in total knee arthroplasty? Jt Dis Relat Surg. 2020;31(3):571-581. doi: 10.5606/ehc.2020.76387.|Vala CH, Kärrholm J, Kanis JA, Johansson H, Sten S, Sundh V, Karlsson M, Lorentzon M, Mellström D. Risk for hip fracture before and after total knee replacement in Sweden. Osteoporos Int. 2020 May;31(5):887-895. doi: 10.1007/s00198-019-05241-x. Epub 2019 Dec 12.|Bakırhan S, Angın S, Karatosun V, Ünver B, Günal I. Physical performance parameters during standing up in patients with unilateral and bilateral total knee arthroplasty. Acta Orthop Traumatol Turc. 2012;46(5):367-72.\t","Knee Arthropathy","Total knee arthroplasty","NA","NA","NA","Procedure","All","\tComparison of Balance and Fall Risk in Unilateral and Bilateral Total Knee Arthroplasty\tInterventional\tCompleted\tN/A\t2\t45\tjoint diseases\tNA\tNA\nNCT04796727\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t27627616|20210602\tPatel N, Patel NJ, Macon CJ, Thakkar B, Desai M, Rengifo-Moreno P, Alfonso CE, Myerburg RJ, Bhatt DL, Cohen MG. Trends and Outcomes of Coronary Angiography and Percutaneous Coronary Intervention After Out-of-Hospital Cardiac Arrest Associated With Ventricular Fibrillation or Pulseless Ventricular Tachycardia. JAMA Cardiol. 2016 Nov 1;1(8):890-899. doi: 10.1001/jamacardio.2016.2860.|von Steinbüchel N, Wilson L, Gibbons H, Hawthorne G, Höfer S, Schmidt S, Bullinger M, Maas A, Neugebauer E, Powell J, von Wild K, Zitnay G, Bakx W, Christensen AL, Koskinen S, Formisano R, Saarajuri J, Sasse N, Truelle JL; QOLIBRI Task Force. Quality of Life after Brain Injury (QOLIBRI): scale validity and correlates of quality of life. J Neurotrauma. 2010 Jul;27(7):1157-65. doi: 10.1089/neu.2009.1077.\t","Cardiac Arrest","NA","NA","NA","NA","NA","All","\tNA\tNA\tNA\tNA\tNA\tNA\theart arrest\tNA\tNA\nNCT04797260\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t32322605\tGarcia-Perez L, van Eggermond M, van Roon L, Vloemans SA, Cordes M, Schambach A, Rothe M, Berghuis D, Lagresle-Peyrou C, Cavazzana M, Zhang F, Thrasher AJ, Salvatori D, Meij P, Villa A, Van Dongen JJM, Zwaginga JJ, van der Burg M, Gaspar HB, Lankester A, Staal FJT, Pike-Overzet K. Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID. Mol Ther Methods Clin Dev. 2020 Mar 31;17:666-682. doi: 10.1016/j.omtm.2020.03.016. eCollection 2020 Jun 12.\t","Severe Combined Immunodeficiency Due to RAG1 Deficiency","Gene therapy","NA","NA","NA","Genetic","All","\tNA\tNA\tNA\tNA\tNA\tNA\timmunologic deficiency syndromes|severe combined immunodeficiency\tNA\tNA\nNCT04798443\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t23602843|27061353\tGarcia-Aparicio L, Rovira J, Blazquez-Gomez E, García-García L, Giménez-Llort A, Rodo J, Morales L. Randomized clinical trial comparing endoscopic treatment with dextranomer hyaluronic acid copolymer and Cohen's ureteral reimplantation for vesicoureteral reflux: long-term results. J Pediatr Urol. 2013 Aug;9(4):483-7. doi: 10.1016/j.jpurol.2013.03.003. Epub 2013 Apr 18.|Karakus SC, User İR, Kılıc BD, Akçaer V, Ceylan H, Ozokutan BH. The comparison of dextranomer/hyaluronic acid and polyacrylate-polyalcohol copolymers in endoscopic treatment of vesicoureteral reflux. J Pediatr Surg. 2016 Sep;51(9):1496-500. doi: 10.1016/j.jpedsurg.2016.02.092. Epub 2016 Mar 12.\t","Vesico-Ureteral Reflux","subureteral endoscopic Injection of Dextranomer/Hyaluronic acid (Dexell)|open ureteral reimplantation (Lich-Gregoir)","Parallel Assignment","Treatment","Randomized","Procedure|Procedure","All","\tEndoscopic Injection of Dextranomer/Hyaluronic Acid Versus Ureteral Reimplantation In Treatment of Vesicoureteral Reflux\tInterventional\tCompleted\tN/A\t2\t60\tvesico-ureteral reflux|gastroesophageal reflux\thyaluronic acid\tNA\nNCT04798547\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t25088923|27513156|29972404|29315993|23973923|23871090|18722376|11413123|15633138|28989059|25469569|20354937|30054739|23891074\tChen WF, Li QL, Zhou PH, Yao LQ, Xu MD, Zhang YQ, Zhong YS, Ma LL, Qin WZ, Hu JW, Cai MY, He MJ, Cui Z. Long-term outcomes of peroral endoscopic myotomy for achalasia in pediatric patients: a prospective, single-center study. Gastrointest Endosc. 2015 Jan;81(1):91-100. doi: 10.1016/j.gie.2014.06.035. Epub 2014 Aug 1.|Hungness ES, Sternbach JM, Teitelbaum EN, Kahrilas PJ, Pandolfino JE, Soper NJ. Per-oral Endoscopic Myotomy (POEM) After the Learning Curve: Durable Long-term Results With a Low Complication Rate. Ann Surg. 2016 Sep;264(3):508-17. doi: 10.1097/SLA.0000000000001870.|Laurino-Neto RM, Herbella F, Schlottmann F, Patti M. EVALUATION OF ESOPHAGEAL ACHALASIA: FROM SYMPTOMS TO THE CHICAGO CLASSIFICATION. Arq Bras Cir Dig. 2018;31(2):e1376. doi: 10.1590/0102-672020180001e1376. Epub 2018 Jul 2. Review. English, Portuguese.|Taft TH, Carlson DA, Triggs J, Craft J, Starkey K, Yadlapati R, Gregory D, Pandolfino JE. Evaluating the reliability and construct validity of the Eckardt symptom score as a measure of achalasia severity. Neurogastroenterol Motil. 2018 Jun;30(6):e13287. doi: 10.1111/nmo.13287. Epub 2018 Jan 8.|Kahrilas PJ, Boeckxstaens G. The spectrum of achalasia: lessons from studies of pathophysiology and high-resolution manometry. Gastroenterology. 2013 Nov;145(5):954-65. doi: 10.1053/j.gastro.2013.08.038. Epub 2013 Aug 21. Review.|Boeckxstaens GE, Zaninotto G, Richter JE. Achalasia. Lancet. 2014 Jan 4;383(9911):83-93. doi: 10.1016/S0140-6736(13)60651-0. Epub 2013 Jul 17. Review.|Pandolfino JE, Kwiatek MA, Nealis T, Bulsiewicz W, Post J, Kahrilas PJ. Achalasia: a new clinically relevant classification by high-resolution manometry. Gastroenterology. 2008 Nov;135(5):1526-33. doi: 10.1053/j.gastro.2008.07.022. Epub 2008 Jul 22.|Spechler SJ, Castell DO. Classification of oesophageal motility abnormalities. Gut. 2001 Jul;49(1):145-51. Review.|Pandolfino JE, Kahrilas PJ; American Gastroenterological Association. AGA technical review on the clinical use of esophageal manometry. Gastroenterology. 2005 Jan;128(1):209-24. Review.|Kahrilas PJ, Katzka D, Richter JE. Clinical Practice Update: The Use of Per-Oral Endoscopic Myotomy in Achalasia: Expert Review and Best Practice Advice From the AGA Institute. Gastroenterology. 2017 Nov;153(5):1205-1211. doi: 10.1053/j.gastro.2017.10.001. Epub 2017 Oct 6. Review.|Kahrilas PJ, Bredenoord AJ, Fox M, Gyawali CP, Roman S, Smout AJ, Pandolfino JE; International High Resolution Manometry Working Group. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015 Feb;27(2):160-74. doi: 10.1111/nmo.12477. Epub 2014 Dec 3.|Inoue H, Minami H, Kobayashi Y, Sato Y, Kaga M, Suzuki M, Satodate H, Odaka N, Itoh H, Kudo S. Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy. 2010 Apr;42(4):265-71. doi: 10.1055/s-0029-1244080. Epub 2010 Mar 30.|Kane ED, Budhraja V, Desilets DJ, Romanelli JR. Myotomy length informed by high-resolution esophageal manometry (HREM) results in improved per-oral endoscopic myotomy (POEM) outcomes for type III achalasia. Surg Endosc. 2019 Mar;33(3):886-894. doi: 10.1007/s00464-018-6356-0. Epub 2018 Jul 27.|Li QL, Chen WF, Zhou PH, Yao LQ, Xu MD, Hu JW, Cai MY, Zhang YQ, Qin WZ, Ren Z. Peroral endoscopic myotomy for the treatment of achalasia: a clinical comparative study of endoscopic full-thickness and circular muscle myotomy. J Am Coll Surg. 2013 Sep;217(3):442-51. doi: 10.1016/j.jamcollsurg.2013.04.033. Epub 2013 Jul 25.\t","Achalasia","Short Myotomy|Standard Length Myotomy","Parallel Assignment","Treatment","Randomized","Procedure|Procedure","All","\tShort Vs Standard Length Myotomy in Achalasia\tInterventional\tEnrolling by invitation\tN/A\t2\t30\tesophageal achalasia\tNA\tNA\nNCT04799405\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t31005790|28709880|27056623\tAlonzo A, Fong J, Ball N, Martin D, Chand N, Loo C. Pilot trial of home-administered transcranial direct current stimulation for the treatment of depression. J Affect Disord. 2019 Jun 1;252:475-483. doi: 10.1016/j.jad.2019.04.041. Epub 2019 Apr 10.|Antal A, Alekseichuk I, Bikson M, Brockmöller J, Brunoni AR, Chen R, Cohen LG, Dowthwaite G, Ellrich J, Flöel A, Fregni F, George MS, Hamilton R, Haueisen J, Herrmann CS, Hummel FC, Lefaucheur JP, Liebetanz D, Loo CK, McCaig CD, Miniussi C, Miranda PC, Moliadze V, Nitsche MA, Nowak R, Padberg F, Pascual-Leone A, Poppendieck W, Priori A, Rossi S, Rossini PM, Rothwell J, Rueger MA, Ruffini G, Schellhorn K, Siebner HR, Ugawa Y, Wexler A, Ziemann U, Hallett M, Paulus W. Low intensity transcranial electric stimulation: Safety, ethical, legal regulatory and application guidelines. Clin Neurophysiol. 2017 Sep;128(9):1774-1809. doi: 10.1016/j.clinph.2017.06.001. Epub 2017 Jun 19. Review.|Brunoni AR, Moffa AH, Fregni F, Palm U, Padberg F, Blumberger DM, Daskalakis ZJ, Bennabi D, Haffen E, Alonzo A, Loo CK. Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data. Br J Psychiatry. 2016 Jun;208(6):522-31. doi: 10.1192/bjp.bp.115.164715. Epub 2016 Apr 7. Review.\t","Major Depressive Disorder","tDCS","NA","NA","NA","Device","All","\tNA\tNA\tNA\tNA\tNA\tNA\tdepressive disorder, major|depressive disorder|depression\tNA\tNA\nNCT04799444\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tLewek J, Jatczak-Pawlik I, Maciejewski M, Jankowski P, Banach M. COVID-19 and cardiovascular complications -the preliminary results of the LATE- COVID study. Arch Med Sci 2021; 17(5); in press.\t","Covid19","NA","NA","NA","NA","NA","All","\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\nNCT04799457\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t26489989|26522861|24680843|29215795\tBennich G, Rudnicki M, Wilken-Jensen C, Lousen T, Lassen PD, Wøjdemann K. Impact of adding a second layer to a single unlocked closure of a Cesarean uterine incision: randomized controlled trial. Ultrasound Obstet Gynecol. 2016 Apr;47(4):417-22. doi: 10.1002/uog.15792.|Roberge S, Demers S, Girard M, Vikhareva O, Markey S, Chaillet N, Moore L, Paris G, Bujold E. Impact of uterine closure on residual myometrial thickness after cesarean: a randomized controlled trial. Am J Obstet Gynecol. 2016 Apr;214(4):507.e1-507.e6. doi: 10.1016/j.ajog.2015.10.916. Epub 2015 Nov 11.|Sevket O, Ates S, Molla T, Ozkal F, Uysal O, Dansuk R. Hydrosonographic assessment of the effects of 2 different suturing techniques on healing of the uterine scar after cesarean delivery. Int J Gynaecol Obstet. 2014 Jun;125(3):219-22. doi: 10.1016/j.ijgo.2013.11.013. Epub 2014 Feb 28.|Stegwee SI, Jordans I, van der Voet LF, van de Ven PM, Ket J, Lambalk CB, de Groot C, Hehenkamp W, Huirne J. Uterine caesarean closure techniques affect ultrasound findings and maternal outcomes: a systematic review and meta-analysis. BJOG. 2018 Aug;125(9):1097-1108. doi: 10.1111/1471-0528.15048. Epub 2018 Jan 30. Erratum in: BJOG. 2019 Feb;126(3):431.\t","Closure; Incomplete, Uterus|Uterine Niche","Suture technique","Parallel Assignment","Prevention","Randomized","Other","Female","\tComparison the Effect of Uterine Closure Technique Difference on Uterine Niche After Caesarean Delivery.\tInterventional\tRecruiting\tN/A\t2\t100\tNA\tNA\tNA\nNCT04799574\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t20407227|28701205|28605284|26954480|25773637|28969645|24708142|26162459|31629355|30018825|26755421\tDrey M, Pfeifer K, Sieber CC, Bauer JM. The Fried frailty criteria as inclusion criteria for a randomized controlled trial: personal experience and literature review. Gerontology. 2011;57(1):11-8. doi: 10.1159/000313433. Epub 2010 Apr 21. Review.|Mahendran R, Rawtaer I, Fam J, Wong J, Kumar AP, Gandhi M, Jing KX, Feng L, Kua EH. Art therapy and music reminiscence activity in the prevention of cognitive decline: study protocol for a randomized controlled trial. Trials. 2017 Jul 12;18(1):324. doi: 10.1186/s13063-017-2080-7.|Castaneda-Gameros D, Redwood S, Thompson JL. Physical Activity, Sedentary Time, and Frailty in Older Migrant Women From Ethnically Diverse Backgrounds: A Mixed-Methods Study. J Aging Phys Act. 2018 Apr 1;26(2):194-203. doi: 10.1123/japa.2016-0287. Epub 2018 Mar 23.|Dumitrache CG, Rubio L, Rubio-Herrera R. Perceived health status and life satisfaction in old age, and the moderating role of social support. Aging Ment Health. 2017 Jul;21(7):751-757. doi: 10.1080/13607863.2016.1156048. Epub 2016 Mar 8.|Vuilleumier P, Trost W. Music and emotions: from enchantment to entrainment. Ann N Y Acad Sci. 2015 Mar;1337:212-22. doi: 10.1111/nyas.12676. Review.|Kim JH, Kim JM. Subjective life expectancy is a risk factor for perceived health status and mortality. Health Qual Life Outcomes. 2017 Oct 2;15(1):190. doi: 10.1186/s12955-017-0763-0.|Modig S, Midlöv P, Kristensson J. Depressive symptoms among frail elderly in ordinary living: who is affected and who is treated? Aging Ment Health. 2014;18(8):1022-8. doi: 10.1080/13607863.2014.903469. Epub 2014 Apr 7.|Ishikawa M, Yamanaka G, Yamamoto N, Nakaoka T, Okumiya K, Matsubayashi K, Otsuka K, Sakura H. Depression and Altitude: Cross-Sectional Community-Based Study Among Elderly High-Altitude Residents in the Himalayan Regions. Cult Med Psychiatry. 2016 Mar;40(1):1-11. doi: 10.1007/s11013-015-9462-7.|Costa SN, Vieira ER, Bento PCB. Effects of Home- and Center-Based Exercise Programs on the Strength, Function, and Gait of Prefrail Older Women: A Randomized Control Trial. J Aging Phys Act. 2020 Jan 1;28(1):122-130. doi: 10.1123/japa.2018-0363.|Leirós-Rodríguez R, Soto-Rodríguez A, Pérez-Ribao I, García-Soidán JL. Comparisons of the Health Benefits of Strength Training, Aqua-Fitness, and Aerobic Exercise for the Elderly. Rehabil Res Pract. 2018 Jun 19;2018:5230971. doi: 10.1155/2018/5230971. eCollection 2018.|Lohne-Seiler H, Kolle E, Anderssen SA, Hansen BH. Musculoskeletal fitness and balance in older individuals (65-85 years) and its association with steps per day: a cross sectional study. BMC Geriatr. 2016 Jan 12;16:6. doi: 10.1186/s12877-016-0188-3.\t","Depression|Frailty|Music Therapy|Physical Fitness","music therapy activities","Parallel Assignment","Prevention","Randomized","Other","All","\tEffect of Music Therapy in Improving the Physical Fitness and Depression in the Frailty of the Community Elderly\tInterventional\tCompleted\tN/A\t2\t75\tdepressive disorder|depression|frailty\tNA\tNA\nNCT04800705\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t27008889|20424285|29181820|31812447\tEuropean Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, Cifkova R, de Muinck Keizer-Schrama S, Hogervorst E, Janse F, Liao L, Vlaisavljevic V, Zillikens C, Vermeulen N. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016 May;31(5):926-37. doi: 10.1093/humrep/dew027. Epub 2016 Mar 22.|Maclaran K, Horner E, Panay N. Premature ovarian failure: long-term sequelae. Menopause Int. 2010 Mar;16(1):38-41. doi: 10.1258/mi.2010.010014. Review.|Verma P, K Sharma A, Shankar H, Sharma A, Rao DN. Role of Trace Elements, Oxidative Stress and Immune System: a Triad in Premature Ovarian Failure. Biol Trace Elem Res. 2018 Aug;184(2):325-333. doi: 10.1007/s12011-017-1197-6. Epub 2017 Nov 27.|Ekiz Yılmaz T, Taşdemir M, Kaya M, Arıcan N, Ahıshalı B. The effects of magnesium sulfate on cyclophosphamide-induced ovarian damage: Folliculogenesis. Acta Histochem. 2020 Feb;122(2):151470. doi: 10.1016/j.acthis.2019.151470. Epub 2019 Dec 4.\t","Premature Ovarian Failure","ultrasound assessment","NA","NA","NA","Other","Female","\tNA\tNA\tNA\tNA\tNA\tNA\tpremature birth|menopause, premature|primary ovarian insufficiency\tNA\tNA\nNCT04800770\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t12750889|28219057|32031570\tMurer H, Forster I, Biber J. The sodium phosphate cotransporter family SLC34. Pflugers Arch. 2004 Feb;447(5):763-7. Epub 2003 May 16. Review.|Pistolesi V, Zeppilli L, Polistena F, Sacco MI, Pierucci A, Tritapepe L, Regolisti G, Fiaccadori E, Morabito S. Preventing Continuous Renal Replacement Therapy-Induced Hypophosphatemia: An Extended Clinical Experience with a Phosphate-Containing Solution in the Setting of Regional Citrate Anticoagulation. Blood Purif. 2017;44(1):8-15. doi: 10.1159/000453443. Epub 2017 Feb 21.|Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.\t","Covid19|Mortality|Phosphate Deficiency","4C mortality score","NA","NA","NA","Diagnostic Test","All","\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\nNCT04801004\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t22192663|26130385|25499305|31816169|27388828|33231029|32885736|32583749\tTosaka A, Soga Y, Iida O, Ishihara T, Hirano K, Suzuki K, Yokoi H, Nanto S, Nobuyoshi M. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012 Jan 3;59(1):16-23. doi: 10.1016/j.jacc.2011.09.036.|Armstrong EJ, Thiruvoipati T, Tanganyika K, Singh GD, Laird JR. Laser Atherectomy for Treatment of Femoropopliteal In-Stent Restenosis. J Endovasc Ther. 2015 Aug;22(4):506-13. doi: 10.1177/1526602815592133. Epub 2015 Jun 30.|Dippel EJ, Makam P, Kovach R, George JC, Patlola R, Metzger DC, Mena-Hurtado C, Beasley R, Soukas P, Colon-Hernandez PJ, Stark MA, Walker C; EXCITE ISR Investigators. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC Cardiovasc Interv. 2015 Jan;8(1 Pt A):92-101. doi: 10.1016/j.jcin.2014.09.009. Epub 2014 Dec 10.|Kokkinidis DG, Behan S, Jawaid O, Hossain P, Giannopoulos S, Singh GD, Laird JR, Valle JA, Waldo SW, Armstrong EJ. Laser atherectomy and drug-coated balloons for the treatment of femoropopliteal in-stent restenosis: 2-Year outcomes. Catheter Cardiovasc Interv. 2020 Feb 15;95(3):439-446. doi: 10.1002/ccd.28636. Epub 2019 Dec 9.|Kinstner CM, Lammer J, Willfort-Ehringer A, Matzek W, Gschwandtner M, Javor D, Funovics M, Schoder M, Koppensteiner R, Loewe C, Ristl R, Wolf F. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial. JACC Cardiovasc Interv. 2016 Jul 11;9(13):1386-92. doi: 10.1016/j.jcin.2016.04.012.|Bosiers M, Deloose K, Callaert J, Verbist J, Hendriks J, Lauwers P, Schroë H, Lansink W, Scheinert D, Schmidt A, Zeller T, Beschorner U, Noory E, Torsello G, Austermann M, Wauters J. Stent-grafts are the best way to treat complex in-stent restenosis lesions in the superficial femoral artery: 24-month results from a multicenter randomized trial. J Cardiovasc Surg (Torino). 2020 Oct;61(5):617-625. doi: 10.23736/S0021-9509.20.11382-X.|Shammas NW, Petruzzi N, Henao S, Armstrong EJ, Shimshak T, Banerjee S, Latif F, Eaves B, Brothers T, Golzar J, Shammas GA, Jones-Miller S, Christensen L, Shammas WJ. JetStream Atherectomy for the Treatment of In-Stent Restenosis of the Femoropopliteal Segment: One-Year Results of the JET-ISR Study. J Endovasc Ther. 2021 Feb;28(1):107-116. doi: 10.1177/1526602820951916. Epub 2020 Sep 4.|Torsello G, Stavroulakis K, Brodmann M, Micari A, Tepe G, Veroux P, Benko A, Choi D, Vermassen FEG, Jaff MR, Guo J, Dobranszki R, Zeller T; IN.PACT Global Investigators. Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort. J Endovasc Ther. 2020 Oct;27(5):693-705. doi: 10.1177/1526602820931477. Epub 2020 Jun 25.\t","Peripheral Arterial Disease","NA","NA","NA","NA","NA","All","\tNA\tNA\tNA\tNA\tNA\tNA\tperipheral vascular diseases|peripheral arterial disease\tNA\tNA\nNCT04801134\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t31997703|31501238|26498462|32305533|12857544|12773286|12081837\tShi Q, Castillo F, Viswanathan K, Kupferman F, MacDermid JC. Facilitators and Barriers to Access to Pediatric Medical Services in a Community Hospital. J Prim Care Community Health. 2020 Jan-Dec;11:2150132720904518. doi: 10.1177/2150132720904518.|Peltz A, Garg A. Food Insecurity and Health Care Use. Pediatrics. 2019 Oct;144(4). pii: e20190347. doi: 10.1542/peds.2019-0347. Epub 2019 Sep 9.|COUNCIL ON COMMUNITY PEDIATRICS; COMMITTEE ON NUTRITION. Promoting Food Security for All Children. Pediatrics. 2015 Nov;136(5):e1431-8. doi: 10.1542/peds.2015-3301.|Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, Agha M, Agha R. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int J Surg. 2020 Jun;78:185-193. doi: 10.1016/j.ijsu.2020.04.018. Epub 2020 Apr 17. Review.|Keenan DP, Olson C, Hersey JC, Parmer SM. Measures of food insecurity/security. J Nutr Educ. 2001;33 Suppl 1:S49-58. Review.|Kaiser LL, Melgar-Quiñonez H, Townsend MS, Nicholson Y, Fujii ML, Martin AC, Lamp CL. Food insecurity and food supplies in Latino households with young children. J Nutr Educ Behav. 2003 May-Jun;35(3):148-53.|Matheson DM, Varady J, Varady A, Killen JD. Household food security and nutritional status of Hispanic children in the fifth grade. Am J Clin Nutr. 2002 Jul;76(1):210-7.\t","Children, Only|Covid19|Food Insecurity","Education","NA","NA","NA","Other","All","\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\nNCT04801238\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t24338858|10526025|19792866|24162138|24493296|27126621|23871320|12145577|20135172|20083751|29533266|29603004|29847616|27857966\tDasari BV, Tan CJ, Gurusamy KS, Martin DJ, Kirk G, McKie L, Diamond T, Taylor MA. Surgical versus endoscopic treatment of bile duct stones. Cochrane Database Syst Rev. 2013 Dec 12;(12):CD003327. doi: 10.1002/14651858.CD003327.pub4. Review.|Cuschieri A, Lezoche E, Morino M, Croce E, Lacy A, Toouli J, Faggioni A, Ribeiro VM, Jakimowicz J, Visa J, Hanna GB. E.A.E.S. multicenter prospective randomized trial comparing two-stage vs single-stage management of patients with gallstone disease and ductal calculi. Surg Endosc. 1999 Oct;13(10):952-7.|Noble H, Tranter S, Chesworth T, Norton S, Thompson M. A randomized, clinical trial to compare endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy with primary laparoscopic bile duct exploration during cholecystectomy in higher risk patients with choledocholithiasis. J Laparoendosc Adv Surg Tech A. 2009 Dec;19(6):713-20. doi: 10.1089/lap.2008.0428.|Bansal VK, Misra MC, Rajan K, Kilambi R, Kumar S, Krishna A, Kumar A, Pandav CS, Subramaniam R, Arora MK, Garg PK. Single-stage laparoscopic common bile duct exploration and cholecystectomy versus two-stage endoscopic stone extraction followed by laparoscopic cholecystectomy for patients with concomitant gallbladder stones and common bile duct stones: a randomized controlled trial. Surg Endosc. 2014 Mar;28(3):875-85. doi: 10.1007/s00464-013-3237-4. Epub 2013 Oct 26.|Ding G, Cai W, Qin M. Single-stage vs. two-stage management for concomitant gallstones and common bile duct stones: a prospective randomized trial with long-term follow-up. J Gastrointest Surg. 2014 May;18(5):947-51. doi: 10.1007/s11605-014-2467-7. Epub 2014 Feb 4.|Lv F, Zhang S, Ji M, Wang Y, Li P, Han W. Single-stage management with combined tri-endoscopic approach for concomitant cholecystolithiasis and choledocholithiasis. Surg Endosc. 2016 Dec;30(12):5615-5620. Epub 2016 Apr 28.|Koc B, Karahan S, Adas G, Tutal F, Guven H, Ozsoy A. Comparison of laparoscopic common bile duct exploration and endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy for choledocholithiasis: a prospective randomized study. Am J Surg. 2013 Oct;206(4):457-63. doi: 10.1016/j.amjsurg.2013.02.004. Epub 2013 Jul 17.|Sgourakis G, Karaliotas K. Laparoscopic common bile duct exploration and cholecystectomy versus endoscopic stone extraction and laparoscopic cholecystectomy for choledocholithiasis. A prospective randomized study. Minerva Chir. 2002 Aug;57(4):467-74.|Bansal VK, Misra MC, Garg P, Prabhu M. A prospective randomized trial comparing two-stage versus single-stage management of patients with gallstone disease and common bile duct stones. Surg Endosc. 2010 Aug;24(8):1986-9. doi: 10.1007/s00464-010-0891-7. Epub 2010 Feb 5.|Rogers SJ, Cello JP, Horn JK, Siperstein AE, Schecter WP, Campbell AR, Mackersie RC, Rodas A, Kreuwel HT, Harris HW. Prospective randomized trial of LC+LCBDE vs ERCP/S+LC for common bile duct stone disease. Arch Surg. 2010 Jan;145(1):28-33. doi: 10.1001/archsurg.2009.226.|Pan L, Chen M, Ji L, Zheng L, Yan P, Fang J, Zhang B, Cai X. The Safety and Efficacy of Laparoscopic Common Bile Duct Exploration Combined with Cholecystectomy for the Management of Cholecysto-choledocholithiasis: An Up-to-date Meta-analysis. Ann Surg. 2018 Aug;268(2):247-253. doi: 10.1097/SLA.0000000000002731.|Singh AN, Kilambi R. Single-stage laparoscopic common bile duct exploration and cholecystectomy versus two-stage endoscopic stone extraction followed by laparoscopic cholecystectomy for patients with gallbladder stones with common bile duct stones: systematic review and meta-analysis of randomized trials with trial sequential analysis. Surg Endosc. 2018 Sep;32(9):3763-3776. doi: 10.1007/s00464-018-6170-8. Epub 2018 Mar 30.|Ricci C, Pagano N, Taffurelli G, Pacilio CA, Migliori M, Bazzoli F, Casadei R, Minni F. Comparison of Efficacy and Safety of 4 Combinations of Laparoscopic and Intraoperative Techniques for Management of Gallstone Disease With Biliary Duct Calculi: A Systematic Review and Network Meta-analysis. JAMA Surg. 2018 Jul 18;153(7):e181167. doi: 10.1001/jamasurg.2018.1167. Epub 2018 Jul 18.|Barreras González JE, Torres Peña R, Ruiz Torres J, Martínez Alfonso MÁ, Brizuela Quintanilla R, Morera Pérez M. Endoscopic versus laparoscopic treatment for choledocholithiasis: a prospective randomized controlled trial. Endosc Int Open. 2016 Nov;4(11):E1188-E1193.\t","Cholangitis|Cholecystitis; Gallstone|Jaundice, Obstructive|Pancreatitis","LCBDE + LC|ERC + LC","Parallel Assignment","Treatment","Randomized","Procedure|Procedure","All","\tpreGallstep - A Clinical Pilot Trial\tInterventional\tNot yet recruiting\tN/A\t2\t150\tcholangitis|gallstones|pancreatitis|jaundice, obstructive|cholecystitis|jaundice\tNA\tNA\nNCT04801251\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t27530200|23910039|27324366\tChitra N, Vijayalakshmi IB. Fetal echocardiography for early detection of congenital heart diseases. J Echocardiogr. 2017 Mar;15(1):13-17. doi: 10.1007/s12574-016-0308-2. Epub 2016 Aug 16.|Hiremath G, Kamat D. When to call the cardiologist: treatment approaches to neonatal heart murmur. Pediatr Ann. 2013 Aug;42(8):329-33. doi: 10.3928/00904481-20130723-13.|Triedman JK, Newburger JW. Trends in Congenital Heart Disease: The Next Decade. Circulation. 2016 Jun 21;133(25):2716-33. doi: 10.1161/CIRCULATIONAHA.116.023544. Review.\t","Congenital Heart Disease","Echocardiographic examination","Crossover Assignment","Diagnostic","Randomized","Diagnostic Test","All","\tRed Flags for Cardiac Examination for Early Detection of Congenital Heart Disease\tInterventional\tNot yet recruiting\tN/A\t2\t70\theart defects, congenital|heart diseases\tNA\tNA\nNCT04801277\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t15935649|18043058|11861340\tBalki M, Carvalho JC. Intraoperative nausea and vomiting during cesarean section under regional anesthesia. Int J Obstet Anesth. 2005 Jul;14(3):230-41. Review.|Arnberger M, Stadelmann K, Alischer P, Ponert R, Melber A, Greif R. Monitoring of neuromuscular blockade at the P6 acupuncture point reduces the incidence of postoperative nausea and vomiting. Anesthesiology. 2007 Dec;107(6):903-8.|Pierre S, Benais H, Pouymayou J. Apfel's simplified score may favourably predict the risk of postoperative nausea and vomiting. Can J Anaesth. 2002 Mar;49(3):237-42.\t","Postoperative Nausea and Vomiting","Electroacupuncture on acupoints vs sham points","Parallel Assignment","Treatment","Randomized","Procedure","Female","\tEfficacy of PC6 Electroacupuncture in the Prevention of Nausea Vomiting in Caesarean Patient Under Spinal Anaesthesia\tInterventional\tRecruiting\tN/A\t2\t100\tnausea|vomiting|postoperative nausea and vomiting\tNA\tNA\nNCT04801563\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t21292771|24923299\tDi Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, Del Papa B, Zei T, Ostini RI, Cecchini D, Aloisi T, Perruccio K, Ruggeri L, Balucani C, Pierini A, Sportoletti P, Aristei C, Falini B, Reisner Y, Velardi A, Aversa F, Martelli MF. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011 Apr 7;117(14):3921-8. doi: 10.1182/blood-2010-10-311894. Epub 2011 Feb 3.|Martelli MF, Di Ianni M, Ruggeri L, Falzetti F, Carotti A, Terenzi A, Pierini A, Massei MS, Amico L, Urbani E, Del Papa B, Zei T, Iacucci Ostini R, Cecchini D, Tognellini R, Reisner Y, Aversa F, Falini B, Velardi A. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood. 2014 Jul 24;124(4):638-44. doi: 10.1182/blood-2014-03-564401. Epub 2014 Jun 12.\t","MDS and Allogeneic Stem Cell Transplantation","MDS and AlloHSCT","NA","NA","NA","Other","All","\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\nNCT04801576\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t28959909|23964631|28870895|19444240\tTadin A, Gavic L, Zeravica A, Ugrin K, Galic N, Zeljezic D. Assessment of cytotoxic and genotoxic effects of conventional and whitening kinds of toothpaste on oral mucosa cells. Acta Odontol Scand. 2018 Jan;76(1):64-70. doi: 10.1080/00016357.2017.1384567. Epub 2017 Sep 29.|Tadin A, Marovic D, Galic N, Kovacic I, Zeljezic D. Composite-induced toxicity in human gingival and pulp fibroblast cells. Acta Odontol Scand. 2014 May;72(4):304-11. doi: 10.3109/00016357.2013.824607. Epub 2013 Aug 22.|Ribeiro DA, Cardoso CM, Yujra VQ, DE Barros Viana M, Aguiar O Jr, Pisani LP, Oshima CTF. Fluoride Induces Apoptosis in Mammalian Cells: In Vitro and In Vivo Studies. Anticancer Res. 2017 Sep;37(9):4767-4777. Review.|Thomas P, Holland N, Bolognesi C, Kirsch-Volders M, Bonassi S, Zeiger E, Knasmueller S, Fenech M. Buccal micronucleus cytome assay. Nat Protoc. 2009;4(6):825-37. doi: 10.1038/nprot.2009.53. Epub 2009 May 7.\t","DNA Damage","Flouride in mouthrinses|Placebo mouthrinse","Parallel Assignment","Basic Science","Randomized","Other|Other","All","\tIn Vivo Assessment of Geno- and Cytotoxicity of Fluoridated Toothpastes and Mouthrinses on Buccal Epithelial Cells\tInterventional\tRecruiting\tN/A\t2\t40\tNA\tNA\tNA\nNCT04801992\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t22553713|18090888|19643497|16687454|17166341|13129879|10724823|16931257\tJiang T, Jiang J, Zhou Y, Zhao GQ, Li H, Zhao SY. Cataract surgery in aged patients: phacoemulsification or small-incision extracapsular cataract surgery. Int J Ophthalmol. 2011;4(5):513-8. doi: 10.3980/j.issn.2222-3959.2011.05.11. Epub 2011 Oct 18.|Packer M, Fine IH, Hoffman RS. Aspheric intraocular lens selection: the evolution of refractive cataract surgery. Curr Opin Ophthalmol. 2008 Jan;19(1):1-4.|Kohnen T, Klaproth OK, Bühren J. Effect of intraocular lens asphericity on quality of vision after cataract removal: an intraindividual comparison. Ophthalmology. 2009 Sep;116(9):1697-706. doi: 10.1016/j.ophtha.2009.03.052. Epub 2009 Jul 29.|Becker KA, Martin M, Rabsilber TM, Entz BB, Reuland AJ, Auffarth GU. Prospective, non-randomised, long term clinical evaluation of a foldable hydrophilic single piece intraocular lens: results of the Centerflex FDA study. Br J Ophthalmol. 2006 Aug;90(8):971-4. Epub 2006 May 10.|Lehmann R, Waycaster C, Hileman K. A comparison of patient-reported outcomes from an apodized diffractive intraocular lens and a conventional monofocal intraocular lens. Curr Med Res Opin. 2006 Dec;22(12):2591-602.|Leyland M, Zinicola E. Multifocal versus monofocal intraocular lenses in cataract surgery: a systematic review. Ophthalmology. 2003 Sep;110(9):1789-98. Review.|Steinert RF. Visual outcomes with multifocal intraocular lenses. Curr Opin Ophthalmol. 2000 Feb;11(1):12-21. Review.|Blaylock JF, Si Z, Vickers C. Visual and refractive status at different focal distances after implantation of the ReSTOR multifocal intraocular lens. J Cataract Refract Surg. 2006 Sep;32(9):1464-73.\t","Cataract","MINI WELL Ready (SIFI SpA, Italy)","NA","NA","NA","Device","All","\tNA\tNA\tNA\tNA\tNA\tNA\tcataract\tNA\tNA\nNCT04802694\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t15180195\tLund CH, Osborne JW. Validity and reliability of the neonatal skin condition score. J Obstet Gynecol Neonatal Nurs. 2004 May-Jun;33(3):320-7.\t","Skin Injury","Water-based barrier tape|Hydrocolloid barrier tape|Silk tape","Parallel Assignment","Prevention","Randomized","Device|Device|Device","All","\tThe Effects of The Products Used In Nazogastric Tube Fixation\tInterventional\tRecruiting\tN/A\t3\t108\tNA\tNA\tNA\nNCT04803110\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t33125754|29333449|23631704|28333394|24475930|27978602|31099929|29489581\tSeyssens L, De Lat L, Cosyn J. Immediate implant placement with or without connective tissue graft: A systematic review and meta-analysis. J Clin Periodontol. 2021 Feb;48(2):284-301. doi: 10.1111/jcpe.13397. Epub 2020 Nov 20. Review.|Mitsias ME, Siormpas KD, Kotsakis GA, Ganz SD, Mangano C, Iezzi G. The Root Membrane Technique: Human Histologic Evidence after Five Years of Function. Biomed Res Int. 2017;2017:7269467. doi: 10.1155/2017/7269467. Epub 2017 Nov 22.|Bäumer D, Zuhr O, Rebele S, Schneider D, Schupbach P, Hürzeler M. The socket-shield technique: first histological, clinical, and volumetrical observations after separation of the buccal tooth segment - a pilot study. Clin Implant Dent Relat Res. 2015 Feb;17(1):71-82. doi: 10.1111/cid.12076. Epub 2013 Apr 30.|Bäumer D, Zuhr O, Rebele S, Hürzeler M. Socket Shield Technique for immediate implant placement - clinical, radiographic and volumetric data after 5 years. Clin Oral Implants Res. 2017 Nov;28(11):1450-1458. doi: 10.1111/clr.13012. Epub 2017 Mar 23.|Barbisan A, Dias CS, Bavia PF, Sapata VM, César-Neto JB, Silva CO. Soft Tissues Changes After Immediate and Delayed Single Implant Placement in Esthetic Area: A Systematic Review. J Oral Implantol. 2015 Oct;41(5):612-9. doi: 10.1563/AAID-JOI-D-13-00095. Epub 2014 Jan 29.|Tonetti MS, Cortellini P, Graziani F, Cairo F, Lang NP, Abundo R, Conforti GP, Marquardt S, Rasperini G, Silvestri M, Wallkamm B, Wetzel A. Immediate versus delayed implant placement after anterior single tooth extraction: the timing randomized controlled clinical trial. J Clin Periodontol. 2017 Feb;44(2):215-224. doi: 10.1111/jcpe.12666. Epub 2017 Jan 31.|Huynh-Ba G, Hoders AB, Meister DJ, Prihoda TJ, Mills MP, Mealey BL, Cochran DL. Esthetic, clinical, and radiographic outcomes of two surgical approaches for single implant in the esthetic area: 1-year results of a randomized controlled trial with parallel design. Clin Oral Implants Res. 2019 Aug;30(8):745-759. doi: 10.1111/clr.13458. Epub 2019 Jun 7.|Bramanti E, Norcia A, Cicciù M, Matacena G, Cervino G, Troiano G, Zhurakivska K, Laino L. Postextraction Dental Implant in the Aesthetic Zone, Socket Shield Technique Versus Conventional Protocol. J Craniofac Surg. 2018 Jun;29(4):1037-1041. doi: 10.1097/SCS.0000000000004419.\t","Bone Resorption|Dental Implant|Tooth Extraction","Dental implant placement after tooth extraction","Parallel Assignment","Treatment","Randomized","Procedure","All","\tSoft Tissue Volume Changes After Immediate Implants With Three Different Techniques\tInterventional\tRecruiting\tN/A\t3\t30\tbone resorption\tNA\tNA\nNCT04803188\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t26492179|30565298|33172724|32294352|30522912|30898406|26880413|30646066|28165653|32418878|33570542|29566957|29552975\tEpstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committee. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016 Feb;40(2):244-52. doi: 10.1097/PAS.0000000000000530. Review.|Matoso A, Epstein JI. Defining clinically significant prostate cancer on the basis of pathological findings. Histopathology. 2019 Jan;74(1):135-145. doi: 10.1111/his.13712. Review.|Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Cornford P. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021 Feb;79(2):243-262. doi: 10.1016/j.eururo.2020.09.042. Epub 2020 Nov 7. Review.|Welch HG, Albertsen PC. Reconsidering Prostate Cancer Mortality - The Future of PSA Screening. N Engl J Med. 2020 Apr 16;382(16):1557-1563. doi: 10.1056/NEJMms1914228.|Wegelin O, Exterkate L, van der Leest M, Kummer JA, Vreuls W, de Bruin PC, Bosch JLHR, Barentsz JO, Somford DM, van Melick HHE. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. Eur Urol. 2019 Apr;75(4):582-590. doi: 10.1016/j.eururo.2018.11.040. Epub 2018 Dec 3.|Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, Tempany CM, Choyke PL, Cornud F, Margolis DJ, Thoeny HC, Verma S, Barentsz J, Weinreb JC. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019 Sep;76(3):340-351. doi: 10.1016/j.eururo.2019.02.033. Epub 2019 Mar 18. Review.|Nam RK, Wallis CJ, Stojcic-Bendavid J, Milot L, Sherman C, Sugar L, Haider MA. A Pilot Study to Evaluate the Role of Magnetic Resonance Imaging for Prostate Cancer Screening in the General Population. J Urol. 2016 Aug;196(2):361-6. doi: 10.1016/j.juro.2016.01.114. Epub 2016 Feb 13.|Boesen L, Nørgaard N, Løgager V, Balslev I, Bisbjerg R, Thestrup KC, Winther MD, Jakobsen H, Thomsen HS. Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men: The Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study. JAMA Netw Open. 2018 Jun 1;1(2):e180219. doi: 10.1001/jamanetworkopen.2018.0219.|Jambor I, Boström PJ, Taimen P, Syvänen K, Kähkönen E, Kallajoki M, Perez IM, Kauko T, Matomäki J, Ettala O, Merisaari H, Kiviniemi A, Dean PB, Aronen HJ. Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial). J Magn Reson Imaging. 2017 Oct;46(4):1089-1095. doi: 10.1002/jmri.25641. Epub 2017 Feb 6.|Knaapila J, Jambor I, Ettala O, Taimen P, Verho J, Perez IM, Kiviniemi A, Pahikkala T, Merisaari H, Lamminen T, Saunavaara J, Aronen HJ, Syvänen KT, Boström PJ. Negative Predictive Value of Biparametric Prostate Magnetic Resonance Imaging in Excluding Significant Prostate Cancer: A Pooled Data Analysis Based on Clinical Data from Four Prospective, Registered Studies. Eur Urol Focus. 2020 May 14. pii: S2405-4569(20)30106-1. doi: 10.1016/j.euf.2020.04.007. [Epub ahead of print]|Eldred-Evans D, Burak P, Connor MJ, Day E, Evans M, Fiorentino F, Gammon M, Hosking-Jervis F, Klimowska-Nassar N, McGuire W, Padhani AR, Prevost AT, Price D, Sokhi H, Tam H, Winkler M, Ahmed HU. Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study. JAMA Oncol. 2021 Mar 1;7(3):395-402. doi: 10.1001/jamaoncol.2020.7456.|Panebianco V, Barchetti G, Simone G, Del Monte M, Ciardi A, Grompone MD, Campa R, Indino EL, Barchetti F, Sciarra A, Leonardo C, Gallucci M, Catalano C. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next? Eur Urol. 2018 Jul;74(1):48-54. doi: 10.1016/j.eururo.2018.03.007. Epub 2018 Mar 19.|Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM; PRECISION Study Group Collaborators. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018 May 10;378(19):1767-1777. doi: 10.1056/NEJMoa1801993. Epub 2018 Mar 18.\t","Prostate Cancer (Diagnosis)","Magnetic Resonance","Parallel Assignment","Prevention","Randomized","Diagnostic Test","Male","\tProstate Cancer Secondary Screening in Sapienza and Policlinico Umberto I\tInterventional\tEnrolling by invitation\tN/A\t2\t710\tprostatic neoplasms|neoplasms\tNA\tNA\nNCT04803617\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t26957727|26768011|27173103\tHirano M, Katoh M, Kawaguchi S, Uemura T. Intrarater reliabilities of shoulder joint horizontal adductor muscle strength measurements using a handheld dynamometer for geriatric and stroke patients. J Phys Ther Sci. 2016 Jan;28(1):51-5. doi: 10.1589/jpts.28.51. Epub 2016 Jan 30.|Panagiotou M, Polychronopoulos V, Strange C. Respiratory and lower limb muscle function in interstitial lung disease. Chron Respir Dis. 2016 May;13(2):162-72. doi: 10.1177/1479972315626014. Epub 2016 Jan 14. Review.|Hanada M, Sakamoto N, Ishimatsu Y, Kakugawa T, Obase Y, Kozu R, Senjyu H, Izumikawa K, Mukae H, Kohno S. Effect of long-term treatment with corticosteroids on skeletal muscle strength, functional exercise capacity and health status in patients with interstitial lung disease. Respirology. 2016 Aug;21(6):1088-93. doi: 10.1111/resp.12807. Epub 2016 May 13.\t","Geriatric|Idiopathic Pulmonary Fibrosis|Interstitial Lung Disease|Sarcoidosis, Pulmonary","Assessment of pulmonary function and pectoralis muscle strength","NA","NA","NA","Other","All","\tNA\tNA\tNA\tNA\tNA\tNA\tidiopathic pulmonary fibrosis|lung diseases, interstitial|sarcoidosis|lung diseases|pulmonary fibrosis|sarcoidosis, pulmonary\tNA\tNA\nNCT04804917\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t33355633|33459884|33582966\tJeppesen P, Wolf RT, Nielsen SM, Christensen R, Plessen KJ, Bilenberg N, Thomsen PH, Thastum M, Neumer SP, Puggaard LB, Agner Pedersen MM, Pagsberg AK, Silverman WK, Correll CU. Effectiveness of Transdiagnostic Cognitive-Behavioral Psychotherapy Compared With Management as Usual for Youth With Common Mental Health Problems: A Randomized Clinical Trial. JAMA Psychiatry. 2021 Mar 1;78(3):250-260. doi: 10.1001/jamapsychiatry.2020.4045.|Wolf RT, Puggaard LB, Pedersen MMA, Pagsberg AK, Silverman WK, Correll CU, Plessen KJ, Neumer SP, Gyrd-Hansen D, Thastum M, Bilenberg N, Thomsen PH, Jeppesen P. Systematic identification and stratification of help-seeking school-aged youth with mental health problems: a novel approach to stage-based stepped-care. Eur Child Adolesc Psychiatry. 2021 Jan 18. doi: 10.1007/s00787-021-01718-5. [Epub ahead of print]|Wolf RT, Ratcliffe J, Chen G, Jeppesen P. The longitudinal validity of proxy-reported CHU9D. Qual Life Res. 2021 Feb 13. doi: 10.1007/s11136-021-02774-9. [Epub ahead of print]\t","Anxiety Disorder of Childhood|Behavior Problem of Childhood and Adolescence|Depressive Symptoms|Emotional Problem|Mental Health Disorder","NA","NA","NA","NA","NA","All","\tNA\tNA\tNA\tNA\tNA\tNA\tmental disorders|depression|anxiety disorders|disease|problem behavior\tNA\tNA\nNCT04805463\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t1527689\tMiller CS, Damm DD. Incidence of verapamil-induced gingival hyperplasia in a dental population. J Periodontol. 1992 May;63(5):453-6.\t","Gingival Enlargement|Gingival Overgrowth|Platelet Rich Fibrin|Wound Heal","Control group|PRF group|CGF group|AFG group","Parallel Assignment","Supportive Care","Randomized","Other|Other|Other|Other","All","\tDifferent Platelet Concentrates After Gingivectomy and Gingivoplasty Evaluation of Its Effect on Early Wound Healing.\tInterventional\tCompleted\tN/A\t4\t19\tgingival hypertrophy|wounds and injuries|gingival overgrowth|gingival hyperplasia\tNA\tNA\nNCT04805489\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t32632523|32979298|463858|32870239\tFikenzer S, Uhe T, Lavall D, Rudolph U, Falz R, Busse M, Hepp P, Laufs U. Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity. Clin Res Cardiol. 2020 Dec;109(12):1522-1530. doi: 10.1007/s00392-020-01704-y. Epub 2020 Jul 6.|Miller SL, Nazaroff WW, Jimenez JL, Boerstra A, Buonanno G, Dancer SJ, Kurnitski J, Marr LC, Morawska L, Noakes C. Transmission of SARS-CoV-2 by inhalation of respiratory aerosol in the Skagit Valley Chorale superspreading event. Indoor Air. 2021 Mar;31(2):314-323. doi: 10.1111/ina.12751. Epub 2020 Oct 13.|Moser MR, Bender TR, Margolis HS, Noble GR, Kendal AP, Ritter DG. An outbreak of influenza aboard a commercial airliner. Am J Epidemiol. 1979 Jul;110(1):1-6.|Shen Y, Li C, Dong H, Wang Z, Martinez L, Sun Z, Handel A, Chen Z, Chen E, Ebell MH, Wang F, Yi B, Wang H, Wang X, Wang A, Chen B, Qi Y, Liang L, Li Y, Ling F, Chen J, Xu G. Community Outbreak Investigation of SARS-CoV-2 Transmission Among Bus Riders in Eastern China. JAMA Intern Med. 2020 Dec 1;180(12):1665-1671. doi: 10.1001/jamainternmed.2020.5225. Erratum in: JAMA Intern Med. 2021 Jan 25;:.\t","Cardiovascular Check-up","Mask","NA","NA","NA","Other","All","\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\nNCT04805723\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t30207593|26342839|17976462|11093502|28692471|29921098|26904225|26597694|27790715|8205877\tBray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.|Cavalheri V, Jenkins S, Cecins N, Gain K, Phillips M, Sanders LH, Hill K. Impairments after curative intent treatment for non-small cell lung cancer: a comparison with age and gender-matched healthy controls. Respir Med. 2015 Oct;109(10):1332-9. doi: 10.1016/j.rmed.2015.08.015. Epub 2015 Aug 29.|Nagamatsu Y, Maeshiro K, Kimura NY, Nishi T, Shima I, Yamana H, Shirouzu K. Long-term recovery of exercise capacity and pulmonary function after lobectomy. J Thorac Cardiovasc Surg. 2007 Nov;134(5):1273-8.|Kaseda S, Aoki T, Hangai N, Shimizu K. Better pulmonary function and prognosis with video-assisted thoracic surgery than with thoracotomy. Ann Thorac Surg. 2000 Nov;70(5):1644-6.|Cheng X, Onaitis MW, D'amico TA, Chen H. Minimally Invasive Thoracic Surgery 3.0: Lessons Learned From the History of Lung Cancer Surgery. Ann Surg. 2018 Jan;267(1):37-38. doi: 10.1097/SLA.0000000000002405. Review.|Upham TC, Onaitis MW. Video-assisted thoracoscopic surgery versus robot-assisted thoracoscopic surgery versus thoracotomy for early-stage lung cancer. J Thorac Cardiovasc Surg. 2018 Jul;156(1):365-368. doi: 10.1016/j.jtcvs.2018.02.064. Epub 2018 Mar 2.|Park TY, Park YS. Long-term respiratory function recovery in patients with stage I lung cancer receiving video-assisted thoracic surgery versus thoracotomy. J Thorac Dis. 2016 Jan;8(1):161-8. doi: 10.3978/j.issn.2072-1439.2016.01.14.|Granger CL, Parry SM, Edbrooke L, Denehy L. Deterioration in physical activity and function differs according to treatment type in non-small cell lung cancer - future directions for physiotherapy management. Physiotherapy. 2016 Sep;102(3):256-63. doi: 10.1016/j.physio.2015.10.007. Epub 2015 Oct 23.|Schwartz RM, Yip R, Flores RM, Olkin I, Taioli E, Henschke C; I-ELCAP Investigators. The impact of resection method and patient factors on quality of life among stage IA non-small cell lung cancer surgical patients. J Surg Oncol. 2017 Feb;115(2):173-180. doi: 10.1002/jso.24478. Epub 2016 Oct 28.|Nomori H, Kobayashi R, Fuyuno G, Morinaga S, Yashima H. Preoperative respiratory muscle training. Assessment in thoracic surgery patients with special reference to postoperative pulmonary complications. Chest. 1994 Jun;105(6):1782-8.\t","Pulmonary Nodule","VATS|Thoracotomy","NA","NA","NA","Procedure|Procedure","All","\tEffects of Surgery Types in Patients With Pulmonary Nodules\tInterventional\tCompleted\tN/A\t2\t27\tmultiple pulmonary nodules\tNA\tNA\nNCT04806308\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t28059962|28166893\tPark AE, Zahiri HR, Hallbeck MS, Augenstein V, Sutton E, Yu D, Lowndes BR, Bingener J. Intraoperative \"\"Micro Breaks\"\" With Targeted Stretching Enhance Surgeon Physical Function and Mental Focus: A Multicenter Cohort Study. Ann Surg. 2017 Feb;265(2):340-346. doi: 10.1097/SLA.0000000000001665.\"|Hallbeck MS, Lowndes BR, Bingener J, Abdelrahman AM, Yu D, Bartley A, Park AE. The impact of intraoperative microbreaks with exercises on surgeons: A multi-center cohort study. Appl Ergon. 2017 Apr;60:334-341. doi: 10.1016/j.apergo.2016.12.006. Epub 2016 Dec 29.","\tPostural; Strain\tOtolaryngology stretching micro-breaks (OSMB)\tNA\tNA\tNA\tBehavioral\tAll\t","The Impact of Intraoperative Stretching Microbreaks on Otolaryngologists","Interventional","Recruiting","N/A",2,100,"sprains and strains","NA","NA"]
["NCT04806633","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24557146|31212638|27659469|16177006|32970396|26158396|27440829","Aurelio A, Durante A. Contrast-induced nephropathy in percutaneous coronary interventions: pathogenesis, risk factors, outcome, prevention and treatment. Cardiology. 2014;128(1):62-72. doi: 10.1159/000358042. Epub 2014 Feb 18. Review.|Garofalo C, Borrelli S, Liberti ME, Andreucci M, Conte G, Minutolo R, Provenzano M, De Nicola L. SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects. Medicina (Kaunas). 2019 Jun 11;55(6). pii: E268. doi: 10.3390/medicina55060268. Review.|McCullough PA, Choi JP, Feghali GA, Schussler JM, Stoler RM, Vallabahn RC, Mehta A. Contrast-Induced Acute Kidney Injury. J Am Coll Cardiol. 2016 Sep 27;68(13):1465-1473. doi: 10.1016/j.jacc.2016.05.099. Review.|Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005 Nov;16(11):3365-70. Epub 2005 Sep 21.|Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.|Ishibashi Y, Matsui T, Yamagishi S. Tofogliflozin, A Highly Selective Inhibitor of SGLT2 Blocks Proinflammatory and Proapoptotic Effects of Glucose Overload on Proximal Tubular Cells Partly by Suppressing Oxidative Stress Generation. Horm Metab Res. 2016 Mar;48(3):191-5. doi: 10.1055/s-0035-1555791. Epub 2015 Jul 9.|Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. SGLT2 Inhibitors and the Diabetic Kidney. Diabetes Care. 2016 Aug;39 Suppl 2:S165-71. doi: 10.2337/dcS15-3006.","\tAcute Kidney Injury|Left Cardiac Catheterization|Percutaneous Coronary Intervention|Sodium-glucose Co-transporter 2 Inhibitors\tDapagliflozin 5mg|Placebo\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug\tAll\t","Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention","Interventional","Not yet recruiting","Early Phase 1",2,1722,"acute kidney injury","2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2h-pyran-3,4,5-triol","NA"]
["NCT04806698","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27767354,"Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R, Sugimoto K. Long-term Efficacy of Orthokeratology Contact Lens Wear in Controlling the Progression of Childhood Myopia. Curr Eye Res. 2017 May;42(5):713-720. doi: 10.1080/02713683.2016.1221979. Epub 2016 Oct 21.","\tChildren, Only|Myopia, Progressive\tMenicon Z Night|Control\tNA\tNA\tNA\tDevice|Device\tAll\t","Long-term Efficacy of Orthokeratology Contact Lens Wear in Controlling the Progression of Childhood Myopia","Interventional","Completed","N/A",2,30,"myopia|myopia, degenerative","NA","NA"]
["NCT04806711","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22729437|27767354","Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R. Myopia control with orthokeratology contact lenses in Spain: refractive and biometric changes. Invest Ophthalmol Vis Sci. 2012 Jul 31;53(8):5060-5. doi: 10.1167/iovs.11-8005.|Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R, Sugimoto K. Long-term Efficacy of Orthokeratology Contact Lens Wear in Controlling the Progression of Childhood Myopia. Curr Eye Res. 2017 May;42(5):713-720. doi: 10.1080/02713683.2016.1221979. Epub 2016 Oct 21.","\tChildren, Only|Myopia, Progressive\tMenicon Z Night|Control\tNA\tNA\tNA\tDevice|Device\tAll\t","Eleven Years of Menicon Z Night Contact Lens Wear in Reducing Myopia Progression in Children","Interventional","Completed","N/A",2,20,"myopia|myopia, degenerative","NA","NA"]
["NCT04806763","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22729437|22773180|23392299","Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R. Myopia control with orthokeratology contact lenses in Spain: refractive and biometric changes. Invest Ophthalmol Vis Sci. 2012 Jul 31;53(8):5060-5. doi: 10.1167/iovs.11-8005.|Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R. Orthokeratology vs. spectacles: adverse events and discontinuations. Optom Vis Sci. 2012 Aug;89(8):1133-9. doi: 10.1097/OPX.0b013e318263c5af.|Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R. Myopia control with orthokeratology contact lenses in Spain: a comparison of vision-related quality-of-life measures between orthokeratology contact lenses and single-vision spectacles. Eye Contact Lens. 2013 Mar;39(2):153-7. doi: 10.1097/ICL.0b013e31827a0241.","\tAxial Myopia|Children, Only|Contact Lens Complication|Myopia, Progressive|Perception, Self\tMenicon Z Night|Control\tNA\tNA\tNA\tDevice|Device\tAll\t","Myopia Control With Orthokeratology Contact Lenses in Spain","Interventional","Completed","N/A",2,69,"myopia|myopia, degenerative","NA","NA"]
["NCT04807062","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22159859|32897401|20881634|32131684|30206655","Myeroff C, Archdeacon M. Autogenous bone graft: donor sites and techniques. J Bone Joint Surg Am. 2011 Dec 7;93(23):2227-36. doi: 10.2106/JBJS.J.01513. Review.|Wang Z, Tian S, Zhao K, Zhang R, Yin Y, Zhu Y, Hou Z, Zhang Y. Neutrophil to lymphocyte ratio and fracture severity in young and middle-aged patients with tibial plateau fractures. Int Orthop. 2020 Dec;44(12):2769-2777. doi: 10.1007/s00264-020-04793-6. Epub 2020 Sep 8.|Luo CF, Sun H, Zhang B, Zeng BF. Three-column fixation for complex tibial plateau fractures. J Orthop Trauma. 2010 Nov;24(11):683-92. doi: 10.1097/BOT.0b013e3181d436f3.|Greimel F, Weber M, Renkawitz T, Voellner F, Freude T, Grifka J, Craiovan B. Minimally invasive treatment of tibial plateau depression fractures using balloon tibioplasty: Clinical outcome and absorption of bioabsorbable calcium phosphate cement. J Orthop Surg (Hong Kong). 2020 Jan-Apr;28(1):2309499020908721. doi: 10.1177/2309499020908721.|Adams D, Patel JN, Tyagi V, Yoon RS, Liporace F. A simple method for bone graft insertion during Schatzker II and III plateau fixation. Knee Surg Sports Traumatol Arthrosc. 2019 Mar;27(3):850-853. doi: 10.1007/s00167-018-5134-9. Epub 2018 Sep 12.","\tDepressed Tibial Plateau Fractures\tsurgery\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","fractures, bone|depression","NA","NA"]
["NCT04807920","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22622849|29671033|20025020|27350947|12811491|17049716|15767530|21256571|20035977|28321473|21718275|31039103|18499184|23608668|20952013|28670786|22464310|28161352|23036134|21489081|28371019|33098213|33497068|20025017|30681419|20419366|17618768|31529007|26364180|33278293","Granese R, Adile G, Gugliotta G, Cucinella G, Saitta S, Adile B. Botox(®) for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection. Arch Gynecol Obstet. 2012 Oct;286(4):923-9. doi: 10.1007/s00404-012-2349-8. Epub 2012 May 24.|Shepherd JP, Carter-Brooks CM, Chermanksy C. A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder. Int Urogynecol J. 2018 Aug;29(8):1213-1219. doi: 10.1007/s00192-018-3653-z. Epub 2018 Apr 18.|Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, Cottenden A, Davila W, de Ridder D, Dmochowski R, Drake M, Dubeau C, Fry C, Hanno P, Smith JH, Herschorn S, Hosker G, Kelleher C, Koelbl H, Khoury S, Madoff R, Milsom I, Moore K, Newman D, Nitti V, Norton C, Nygaard I, Payne C, Smith A, Staskin D, Tekgul S, Thuroff J, Tubaro A, Vodusek D, Wein A, Wyndaele JJ; Members of Committees; Fourth International Consultation on Incontinence. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29(1):213-40. doi: 10.1002/nau.20870. Review.|Eapen RS, Radomski SB. Review of the epidemiology of overactive bladder. Res Rep Urol. 2016 Jun 6;8:71-6. doi: 10.2147/RRU.S102441. eCollection 2016. Review.|Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003 May;20(6):327-36. Epub 2002 Nov 15.|Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5. Epub 2006 Oct 2.|Melville JL, Katon W, Delaney K, Newton K. Urinary incontinence in US women: a population-based study. Arch Intern Med. 2005 Mar 14;165(5):537-42.|Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011 May;77(5):1081-7. doi: 10.1016/j.urology.2010.08.039. Epub 2011 Jan 22.|Ganz ML, Smalarz AM, Krupski TL, Anger JT, Hu JC, Wittrup-Jensen KU, Pashos CL. Economic costs of overactive bladder in the United States. Urology. 2010 Mar;75(3):526-32, 532.e1-18. doi: 10.1016/j.urology.2009.06.096. Epub 2009 Dec 29.|Minassian VA, Bazi T, Stewart WF. Clinical epidemiological insights into urinary incontinence. Int Urogynecol J. 2017 May;28(5):687-696. doi: 10.1007/s00192-017-3314-7. Epub 2017 Mar 20. Review.|Sexton CC, Coyne KS, Thompson C, Bavendam T, Chen CI, Markland A. Prevalence and effect on health-related quality of life of overactive bladder in older americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc. 2011 Aug;59(8):1465-70. doi: 10.1111/j.1532-5415.2011.03492.x. Epub 2011 Jun 30.|Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. J Urol. 2019 Sep;202(3):558-563. doi: 10.1097/JU.0000000000000309. Epub 2019 Aug 8.|Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, Barber MD, Menefee S, Schaffer J, Weber AM, Wei J; Pelvic Floor Disorders Network. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008 Jul;180(1):217-22. doi: 10.1016/j.juro.2008.03.028. Epub 2008 May 21.|Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013 Aug;64(2):249-56. doi: 10.1016/j.eururo.2013.04.001. Epub 2013 Apr 10.|Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, Daniell G, Zhou J, Haag-Molkenteller C. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010 Dec;184(6):2416-22. doi: 10.1016/j.juro.2010.08.021. Epub 2010 Oct 16.|Drake MJ, Nitti VW, Ginsberg DA, Brucker BM, Hepp Z, McCool R, Glanville JM, Fleetwood K, James D, Chapple CR. Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU Int. 2017 Nov;120(5):611-622. doi: 10.1111/bju.13945. Epub 2017 Aug 2. Review.|Fowler CJ, Auerbach S, Ginsberg D, Hale D, Radziszewski P, Rechberger T, Patel VD, Zhou J, Thompson C, Kowalski JW. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol. 2012 Jul;62(1):148-57. doi: 10.1016/j.eururo.2012.03.005. Epub 2012 Mar 14.|Herschorn S, Kohan A, Aliotta P, McCammon K, Sriram R, Abrams S, Lam W, Everaert K. The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial. J Urol. 2017 Jul;198(1):167-175. doi: 10.1016/j.juro.2017.01.069. Epub 2017 Feb 1.|Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MF, Menefee SA, Schaffer J, Lowder J, Khandwala S, Sirls L, Spino C, Nolen TL, Wallace D, Meikle SF; Pelvic Floor Disorders Network. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N Engl J Med. 2012 Nov 8;367(19):1803-13. doi: 10.1056/NEJMoa1208872. Epub 2012 Oct 4.|Sexton CC, Notte SM, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D, Coyne KS. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011 May;65(5):567-85. doi: 10.1111/j.1742-1241.2010.02626.x. Review.|Sussman D, Yehoshua A, Kowalski J, Lee W, Kish J, Chaudhari S, Murray B. Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis. Int J Clin Pract. 2017 Mar;71(3-4). doi: 10.1111/ijcp.12824.|Dmochowski RR, Thai S, Iglay K, Enemchukwu E, Tee S, Varano S, Girman C, Radican L, Mudd PN Jr, Poole C. Increased risk of incident dementia following use of anticholinergic agents: A systematic literature review and meta-analysis. Neurourol Urodyn. 2021 Jan;40(1):28-37. doi: 10.1002/nau.24536. Epub 2020 Oct 23. Review.|Clinical Consensus Statement: Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder. Female Pelvic Med Reconstr Surg. 2021 Feb 1;27(2):69-71. doi: 10.1097/SPV.0000000000001008.|de Boer TA, Salvatore S, Cardozo L, Chapple C, Kelleher C, van Kerrebroeck P, Kirby MG, Koelbl H, Espuna-Pons M, Milsom I, Tubaro A, Wagg A, Vierhout ME. Pelvic organ prolapse and overactive bladder. Neurourol Urodyn. 2010;29(1):30-9. doi: 10.1002/nau.20858. Review.|Johnson JR, High RA, Dziadek O, Ocon A, Muir TW, Xu J, Antosh DD. Overactive Bladder Symptoms After Pelvic Organ Prolapse Repair. Female Pelvic Med Reconstr Surg. 2020 Dec 1;26(12):742-745. doi: 10.1097/SPV.0000000000000700.|de Boer TA, Kluivers KB, Withagen MI, Milani AL, Vierhout ME. Predictive factors for overactive bladder symptoms after pelvic organ prolapse surgery. Int Urogynecol J. 2010 Sep;21(9):1143-9. doi: 10.1007/s00192-010-1152-y. Epub 2010 Apr 24.|Foster RT Sr, Barber MD, Parasio MF, Walters MD, Weidner AC, Amundsen CL. A prospective assessment of overactive bladder symptoms in a cohort of elderly women who underwent transvaginal surgery for advanced pelvic organ prolapse. Am J Obstet Gynecol. 2007 Jul;197(1):82.e1-4.|Sung VW, Borello-France D, Newman DK, Richter HE, Lukacz ES, Moalli P, Weidner AC, Smith AL, Dunivan G, Ridgeway B, Nguyen JN, Mazloomdoost D, Carper B, Gantz MG; NICHD Pelvic Floor Disorders Network. Effect of Behavioral and Pelvic Floor Muscle Therapy Combined With Surgery vs Surgery Alone on Incontinence Symptoms Among Women With Mixed Urinary Incontinence: The ESTEEM Randomized Clinical Trial. JAMA. 2019 Sep 17;322(11):1066-1076. doi: 10.1001/jama.2019.12467.|Miotla P, Futyma K, Cartwright R, Bogusiewicz M, Skorupska K, Markut-Miotla E, Rechberger T. Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery. Int Urogynecol J. 2016 Mar;27(3):393-8. doi: 10.1007/s00192-015-2839-x. Epub 2015 Sep 12.|Komar A, Bretschneider CE, Mueller MG, Lewicky-Gaupp C, Collins S, Geynisman-Tan J, Tavathia M, Kenton K. Concurrent Retropubic Midurethral Sling and OnabotulinumtoxinA for Mixed Urinary Incontinence: A Randomized Controlled Trial. Obstet Gynecol. 2021 Jan 1;137(1):12-20. doi: 10.1097/AOG.0000000000004198.","\tPelvic Organ Prolapse|Urinary Bladder, Overactive\tOnabotulinumtoxinA 100 UNT|Injectable saline\tParallel Assignment\tTreatment\tRandomized\tDrug|Other\tFemale\t","BOTOX® at the Time of Prolapse Surgery for OAB","Interventional","Not yet recruiting","N/A",2,138,"urinary bladder, overactive|prolapse|pelvic organ prolapse","botulinum toxins, type a|abobotulinumtoxina","NA"]
["NCT04808466","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","11813623|10091726|32306237|8156509","Yonemura Y, de Aretxabala X, Fujimura T, Fushida S, Katayama K, Bandou E, Sugiyama K, Kawamura T, Kinoshita K, Endou Y, Sasaki T. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterology. 2001 Nov-Dec;48(42):1776-82.|Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer. 1999 Feb 1;85(3):529-34.|Torphy RJ, Stewart C, Sharma P, Halpern AL, Oase K, Herter W, Bartsch C, Friedman C, Del Chiaro M, Schulick RD, Gleisner A, McCarter MD, Ahrendt SA. Dextrose-Containing Carrier Solution for Hyperthermic Intraperitoneal Chemotherapy: Increased Intraoperative Hyperglycemia and Postoperative Complications. Ann Surg Oncol. 2020 Dec;27(13):4874-4882. doi: 10.1245/s10434-020-08330-y. Epub 2020 Apr 19.|Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer. 1994 Apr 15;73(8):2048-52.","\tChemotherapy Effect|Gastric Cancer|Metastasis|Surgery|Survival\tPaclitaxel|Lobaplatin\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy","Interventional","Not yet recruiting","Phase 2",3,231,"stomach neoplasms|fever","paclitaxel","NA"]
["NCT04808765","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30586097|27170231|27536498|30324063","Singh D, Lobach V, Holton T. Use of Closed-Incision Negative-Pressure Therapy in Aesthetic Surgery. Plast Reconstr Surg. 2019 Jan;143(1S Management of Surgical Incisions Utilizing Closed-Incision Negative-Pressure Therapy):11S-14S. doi: 10.1097/PRS.0000000000005306. Review.|Willy C, Agarwal A, Andersen CA, Santis G, Gabriel A, Grauhan O, Guerra OM, Lipsky BA, Malas MB, Mathiesen LL, Singh DP, Reddy VS. Closed incision negative pressure therapy: international multidisciplinary consensus recommendations. Int Wound J. 2017 Apr;14(2):385-398. doi: 10.1111/iwj.12612. Epub 2016 May 12. Review.|Gabriel A, Sigalove SR, Maxwell GP. Initial Experience Using Closed Incision Negative Pressure Therapy after Immediate Postmastectomy Breast Reconstruction. Plast Reconstr Surg Glob Open. 2016 Jul 22;4(7):e819. doi: 10.1097/GOX.0000000000000803. eCollection 2016 Jul.|Gabriel A, Sigalove S, Sigalove N, Storm-Dickerson T, Rice J, Maxwell P, Griffin L. The Impact of Closed Incision Negative Pressure Therapy on Postoperative Breast Reconstruction Outcomes. Plast Reconstr Surg Glob Open. 2018 Aug 7;6(8):e1880. doi: 10.1097/GOX.0000000000001880. eCollection 2018 Aug.","\tBreast Cancer|Breast Reconstruction\tImmediate Breast reconstruction\tParallel Assignment\tPrevention\tRandomized\tProcedure\tFemale\t","Closed Incision Disposable Negative Pressure Wound Therapy in Immediate Postmastectomy Breast Reconstruction","Interventional","Active, not recruiting","N/A",2,60,"surgical wound","NA","NA"]
["NCT04810663","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","1- A. Schernberg,a E. Rivin del Campo,a B. Rousseau,b O. Matzinger,c M. Loi,d P. Maingon,e,f and F. Hugue. Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives. ClinTranslRadiatOncol. 2018 Mar 13: 13-22. 2- Karimi P., Islami F., Anandasabapathy S., Freedman N.D., Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700-713. 3- Forman D., Burley V.J. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res ClinGastroenterol. 2006;20(4):633-649. 4- Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. [Internet]. [cited 2014 Feb 22]. Available from: <http://globocan.iarc.fr/Pages/references.aspx>. 5- Ministry of Health and Population. Gharbiah Population Based Cancer Registry, Egypt. .Cancer in Egypt, triennial report of 2000-2002. 2007. MOH: Tanta, Egypt. 6-Alieldin N. NCI hospital-based registry 2002-2010 [Internet]. [cited 2014 Feb23].Availablefrom:<http://nci.cu.edu.eg/App_Files/registry/NCI_registry%202002-2010.pdf>. 7-Freedman L, Edwards B, Ries L, Young J, editors. Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) Compared with US SEER. National Cancer Institute, 2006. NIH Pub. No. 06-5873. Bethesda, MD [Internet]. [cited 2014 Feb 22]. 8- Zhou XM, Wong BC, Fan XM, Zhang HB, Lin MC, Kung HF, et al. Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through upregulation of bax and bak. Carcinogenesis. 2001;22:1393-97 9-Sasazuki S, Inoue M, Iwasaki M, Otani T, Yamamoto S, Ikeda S, et al. Effect of helicobacter pylori infection combined with cagA and pepsinogen status on gastric cancer development among Japanese men and women: A nested case-control study. Cancer Epidemiol. Biomarkers Prev. 2006;15:1341-47. 10- Tomonaga M, Oka M, Narasaki F, Fukuda M, Nakano R, Takatani H, et al. The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers. Jpn J Cancer Res. 1996;87:1263-70. 11-Buckland G, Travier N, Huerta JM, et al. Healthy lifestyle index and risk of gastric adenocarcinomaintheEPIC cohort study.IntJ Cancer. 2015;137(3):598-606. 12-Massarrat S, Stolte M. Development of gastric cancer and its prevention. Arch Iran Med. 2014;17(7):514-520. 13-Zhang ZX, ,Gu XZ, , Yin WB, , Huang GJ, , Zhang DW, , Zhang RG. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)-report on 370 patients. Int J RadiatOncolBiolPhys 1998; 42: 929-34. 14- Macdonald JS, , Smalley SR, , Benedetti J, , Hundahl SA, , Estes NC, , Stemmermann GN, et al. . Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-30. 15- M Fan W Hu Z Zhang. Chemoradiation for gastric cancer: controversies, updates and novel techniques. Br J Radiol July 2015; ( 88(1051).","\tGastric Adenocarcinoma\tRadiotherapy\tNA\tNA\tNA\tRadiation\tAll\t","NA","NA","NA","NA","NA","NA","adenocarcinoma|stomach neoplasms","NA","NA"]
["NCT04811287","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32034241,"Trull-Ahuir C, Sala D, Chismol-Abad J, Vila-Caballer M, Lisón JF. Efficacy of platelet-rich plasma as an adjuvant to surgical carpal ligament release: a prospective, randomized controlled clinical trial. Sci Rep. 2020 Feb 7;10(1):2085. doi: 10.1038/s41598-020-59113-0.","\tCarpal Tunnel Syndrome|PRP\tCarpal Tunnel Release with Platelet-Rich Plasma|Carpal Tunnel Release without Platelet-Rich Plasma\tParallel Assignment\tTreatment\tRandomized\tDevice|Procedure\tAll\t","PRP as Adjuvant Treatment to CTR for Severe CTS Tunnel Syndrome","Interventional","Not yet recruiting","N/A",2,46,"syndrome|carpal tunnel syndrome","NA","NA"]
["NCT04811495","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","33732211|33730126|33723117|33714614|33711819|33685496|33604763|33602632|33584275|33561277|33554774|33231980","Buvinic S, Balanta-Melo J, Kupczik K, Vásquez W, Beato C, Toro-Ibacache V. Muscle-Bone Crosstalk in the Masticatory System: From Biomechanical to Molecular Interactions. Front Endocrinol (Lausanne). 2021 Mar 1;11:606947. doi: 10.3389/fendo.2020.606947. eCollection 2020. Review.|Al-Jewair T, Shibeika D, Ohrbach R. Temporomandibular Disorders and Their Association with Sleep Disorders in Adults: A Systematic Review. J Oral Facial Pain Headache. 2021 Winter;35(1):41-53. doi: 10.11607/ofph.2780.|Kaya DI, Ataoglu H. Botulinum toxin treatment of temporomandibular joint pain in patients with bruxism: A prospective and randomized clinical study. Niger J Clin Pract. 2021 Mar;24(3):412-417. doi: 10.4103/njcp.njcp_251_20.|Ângelo DF, Moreira A, Sanz D, São João R. Hearing changes after temporomandibular joint arthroscopy: a prospective study. Int J Oral Maxillofac Surg. 2021 Mar 10. pii: S0901-5027(21)00054-0. doi: 10.1016/j.ijom.2021.02.013. [Epub ahead of print]|Cândido Dos Reis A, Theodoro de Oliveira T, Vidal CL, Borsatto MC, Lima da Costa Valente M. Effect of Auricular Acupuncture on the Reduction of Symptoms Related to Sleep Disorders, Anxiety and Temporomandibular Disorder (TMD). Altern Ther Health Med. 2021 Mar 13. pii: AT6326. [Epub ahead of print]|Asquini G, Rushton A, Pitance L, Heneghan N, Falla D. The effectiveness of manual therapy applied to craniomandibular structures in the treatment of temporomandibular disorders: protocol for a systematic review. Syst Rev. 2021 Mar 8;10(1):70. doi: 10.1186/s13643-021-01623-7.|Memmedova F, Emre U, Yalın OÖ, Doğan OC. Evaluation of temporomandibular joint disorder in headache patients. Neurol Sci. 2021 Feb 18. doi: 10.1007/s10072-021-05119-z. [Epub ahead of print]|Castien RF, Scholten-Peeters GG. Letter to the Editor concerning 'Effects of physical therapy for temporomandibular disorders on headache pain intensity: A systematic review' by van der Meer et al. Musculoskelet Sci Pract. 2021 Feb 15:102324. doi: 10.1016/j.msksp.2021.102324. [Epub ahead of print]|Wu M, Cai J, Yu Y, Hu S, Wang Y, Wu M. Therapeutic Agents for the Treatment of Temporomandibular Joint Disorders: Progress and Perspective. Front Pharmacol. 2021 Jan 29;11:596099. doi: 10.3389/fphar.2020.596099. eCollection 2020. Review.|Oliveira Peixoto K, da Silva Bezerra A, Albuquerque Melo R, Maria Bastos Machado de Resende C, De Almeida EO, Augusto Seabra Barbosa G. Short-term effect of scalp acupuncture on pain, sleep disorders and quality of life in patients with temporomandibular disorders: a randomized clinical trial. Pain Med. 2021 Feb 9. pii: pnab048. doi: 10.1093/pm/pnab048. [Epub ahead of print]|Onoda N, Mikami T, Saito N, Kobayashi T. Evaluation of oral health-related quality of life in patients with temporomandibular disorders. Cranio. 2021 Feb 8:1-8. doi: 10.1080/08869634.2021.1883378. [Epub ahead of print]|Nahian A, ÜNAL M, Mathew Jr J. Osteopathic Manipulative Treatment: Facial Muscle Energy, Direct MFR, and BLT Procedure - for TMJ Dysfunction. 2021 Feb 7. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK564310/","\tDisorders, Temporomandibular Joint|Range of Motion, Articular\tPhysiotherapy treatment\tNA\tNA\tNA\tOther\tFemale\t","NA","NA","NA","NA","NA","NA","temporomandibular joint disorders|temporomandibular joint dysfunction syndrome","NA","NA"]
["NCT04811755","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24886954|23754645|28101605|23294512","Azuhata T, Kinoshita K, Kawano D, Komatsu T, Sakurai A, Chiba Y, Tanjho K. Time from admission to initiation of surgery for source control is a critical determinant of survival in patients with gastrointestinal perforation with associated septic shock. Crit Care. 2014 May 2;18(3):R87. doi: 10.1186/cc13854.|Buck DL, Vester-Andersen M, Møller MH; Danish Clinical Register of Emergency Surgery. Surgical delay is a critical determinant of survival in perforated peptic ulcer. Br J Surg. 2013 Jul;100(8):1045-9. doi: 10.1002/bjs.9175.|Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017 Mar;43(3):304-377. doi: 10.1007/s00134-017-4683-6. Epub 2017 Jan 18.|Sartelli M, Viale P, Catena F, Ansaloni L, Moore E, Malangoni M, Moore FA, Velmahos G, Coimbra R, Ivatury R, Peitzman A, Koike K, Leppaniemi A, Biffl W, Burlew CC, Balogh ZJ, Boffard K, Bendinelli C, Gupta S, Kluger Y, Agresta F, Di Saverio S, Wani I, Escalona A, Ordonez C, Fraga GP, Junior GA, Bala M, Cui Y, Marwah S, Sakakushev B, Kong V, Naidoo N, Ahmed A, Abbas A, Guercioni G, Vettoretto N, Díaz-Nieto R, Gerych I, Tranà C, Faro MP, Yuan KC, Kok KY, Mefire AC, Lee JG, Hong SK, Ghnnam W, Siribumrungwong B, Sato N, Murata K, Irahara T, Coccolini F, Segovia Lohse HA, Verni A, Shoko T. 2013 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg. 2013 Jan 8;8(1):3. doi: 10.1186/1749-7922-8-3.","\tEmergency Surgery\tSurgical timing from ED admission to surgery\tNA\tNA\tNA\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","intestinal perforation|emergencies","NA","NA"]
["NCT04812041","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28263192|32907855","Khan BA, Perkins AJ, Gao S, Hui SL, Campbell NL, Farber MO, Chlan LL, Boustani MA. The Confusion Assessment Method for the ICU-7 Delirium Severity Scale: A Novel Delirium Severity Instrument for Use in the ICU. Crit Care Med. 2017 May;45(5):851-857. doi: 10.1097/CCM.0000000000002368.|Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, Dunning J, Fairfield CJ, Gamble C, Green CA, Gupta R, Halpin S, Hardwick HE, Holden KA, Horby PW, Jackson C, Mclean KA, Merson L, Nguyen-Van-Tam JS, Norman L, Noursadeghi M, Olliaro PL, Pritchard MG, Russell CD, Shaw CA, Sheikh A, Solomon T, Sudlow C, Swann OV, Turtle LC, Openshaw PJ, Baillie JK, Semple MG, Docherty AB, Harrison EM; ISARIC4C investigators. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ. 2020 Sep 9;370:m3339. doi: 10.1136/bmj.m3339. Erratum in: BMJ. 2020 Nov 13;371:m4334.","\tCovid19|Delirium|Intensive Care Unit Delirium\tCAM-ICU 7 score|4C Mortality Score\tNA\tNA\tNA\tOther|Other\tAll\t","NA","NA","NA","NA","NA","NA","delirium","NA","NA"]
["NCT04812834","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29706363|28029467|29373968|28587850|31813278","Searle SD, Rockwood K. What proportion of older adults in hospital are frail? Lancet. 2018 May 5;391(10132):1751-1752. doi: 10.1016/S0140-6736(18)30907-3. Epub 2018 Apr 26.|Amblàs-Novellas J, Martori JC, Molist Brunet N, Oller R, Gómez-Batiste X, Espaulella Panicot J. [Frail-VIG index: Design and evaluation of a new frailty index based on the Comprehensive Geriatric Assessment]. Rev Esp Geriatr Gerontol. 2017 May - Jun;52(3):119-127. doi: 10.1016/j.regg.2016.09.003. Epub 2016 Oct 28. Spanish.|Amblàs-Novellas J, Martori JC, Espaulella J, Oller R, Molist-Brunet N, Inzitari M, Romero-Ortuno R. Frail-VIG index: a concise frailty evaluation tool for rapid geriatric assessment. BMC Geriatr. 2018 Jan 26;18(1):29. doi: 10.1186/s12877-018-0718-2.|Chong E, Ho E, Baldevarona-Llego J, Chan M, Wu L, Tay L. Frailty and Risk of Adverse Outcomes in Hospitalized Older Adults: A Comparison of Different Frailty Measures. J Am Med Dir Assoc. 2017 Jul 1;18(7):638.e7-638.e11. doi: 10.1016/j.jamda.2017.04.011. Epub 2017 Jun 3.|Damluji AA, Forman DE, van Diepen S, Alexander KP, Page RL 2nd, Hummel SL, Menon V, Katz JN, Albert NM, Afilalo J, Cohen MG; American Heart Association Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Older Adults in the Cardiac Intensive Care Unit: Factoring Geriatric Syndromes in the Management, Prognosis, and Process of Care: A Scientific Statement From the American Heart Association. Circulation. 2020 Jan 14;141(2):e6-e32. doi: 10.1161/CIR.0000000000000741. Epub 2019 Dec 9.","\tFrail Elderly Syndrome\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","frailty|emergencies","NA","NA"]
["NCT04812938","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30207593|28443200|30835824|29450530|19282241|26707054|24950979|21720365|26166714|29061967|20229506|23303603|29563323|32609349|31340883|20080505|23396013|27268795","Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.|Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017 Feb;14(1):9-32. doi: 10.20892/j.issn.2095-3941.2016.0084.|Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. 2019 Jun 15;125(12):1963-1972. doi: 10.1002/cncr.32004. Epub 2019 Mar 5.|Henderson JT, Webber EM, Sawaya GF. Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018 Feb 13;319(6):595-606. doi: 10.1001/jama.2017.21421. Review.|Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009 Apr;10(4):327-40. doi: 10.1016/S1470-2045(09)70026-9. Epub 2009 Mar 11.|Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, Crump DN, Davies SK, Dawnay A, Dobbs S, Fletcher G, Ford J, Godfrey K, Gunu R, Habib M, Hallett R, Herod J, Jenkins H, Karpinskyj C, Leeson S, Lewis SJ, Liston WR, Lopes A, Mould T, Murdoch J, Oram D, Rabideau DJ, Reynolds K, Scott I, Seif MW, Sharma A, Singh N, Taylor J, Warburton F, Widschwendter M, Williamson K, Woolas R, Fallowfield L, McGuire AJ, Campbell S, Parmar M, Skates SJ. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016 Mar 5;387(10022):945-956. doi: 10.1016/S0140-6736(15)01224-6. Epub 2015 Dec 17. Erratum in: Lancet. 2016 Mar 5;387(10022):944. Erratum in: Lancet. 2016 Mar 5;387(10022):944.|Ciardiello F, Arnold D, Casali PG, Cervantes A, Douillard JY, Eggermont A, Eniu A, McGregor K, Peters S, Piccart M, Popescu R, Van Cutsem E, Zielinski C, Stahel R. Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol. 2014 Sep;25(9):1673-1678. doi: 10.1093/annonc/mdu217. Epub 2014 Jun 20.|Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 29;474(7353):609-15. doi: 10.1038/nature10166. Erratum in: Nature. 2012 Oct 11;490(7419):298.|Vang R, Levine DA, Soslow RA, Zaloudek C, Shih IeM, Kurman RJ. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. Int J Gynecol Pathol. 2016 Jan;35(1):48-55. doi: 10.1097/PGP.0000000000000207.|Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, Hruban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, Tille JC, Bowden M, Ayhan A, Wood LD, Scharpf RB, Kurman R, Wang TL, Shih IM, Karchin R, Drapkin R, Velculescu VE. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017 Oct 23;8(1):1093. doi: 10.1038/s41467-017-00962-1.|Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D, Brenton JD. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010 May;221(1):49-56. doi: 10.1002/path.2696.|Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih IeM, Kurman R, Dao F, Levine DA, Giuntoli R, Roden R, Eshleman JR, Carvalho JP, Marie SK, Papadopoulos N, Kinzler KW, Vogelstein B, Diaz LA Jr. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013 Jan 9;5(167):167ra4. doi: 10.1126/scitranslmed.3004952.|Wang Y, Li L, Douville C, Cohen JD, Yen TT, Kinde I, Sundfelt K, Kjær SK, Hruban RH, Shih IM, Wang TL, Kurman RJ, Springer S, Ptak J, Popoli M, Schaefer J, Silliman N, Dobbyn L, Tanner EJ, Angarita A, Lycke M, Jochumsen K, Afsari B, Danilova L, Levine DA, Jardon K, Zeng X, Arseneau J, Fu L, Diaz LA Jr, Karchin R, Tomasetti C, Kinzler KW, Vogelstein B, Fader AN, Gilbert L, Papadopoulos N. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci Transl Med. 2018 Mar 21;10(433). pii: eaap8793. doi: 10.1126/scitranslmed.aap8793.|Paracchini L, Pesenti C, Delle Marchette M, Beltrame L, Bianchi T, Grassi T, Buda A, Landoni F, Ceppi L, Bosetti C, Paderno M, Adorni M, Vicini D, Perego P, Leone BE, D'Incalci M, Marchini S, Fruscio R. Detection of TP53 Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis. JAMA Netw Open. 2020 Jul 1;3(7):e207566. doi: 10.1001/jamanetworkopen.2020.7566.|Cybulska P, Paula ADC, Tseng J, Leitao MM Jr, Bashashati A, Huntsman DG, Nazeran TM, Aghajanian C, Abu-Rustum NR, DeLair DF, Shah SP, Weigelt B. Molecular profiling and molecular classification of endometrioid ovarian carcinomas. Gynecol Oncol. 2019 Sep;154(3):516-523. doi: 10.1016/j.ygyno.2019.07.012. Epub 2019 Jul 21.|Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010 Mar 1;26(5):589-95. doi: 10.1093/bioinformatics/btp698. Epub 2010 Jan 15.|Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES, Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013 Mar;31(3):213-9. doi: 10.1038/nbt.2514. Epub 2013 Feb 10.|McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, Flicek P, Cunningham F. The Ensembl Variant Effect Predictor. Genome Biol. 2016 Jun 6;17(1):122. doi: 10.1186/s13059-016-0974-4.","\tOvarian Cancer\tPatients with Ovarian cancer and pap test available\tNA\tNA\tNA\tDiagnostic Test\tFemale\t","NA","NA","NA","NA","NA","NA","carcinoma, ovarian epithelial|ovarian neoplasms","NA","NA"]
["NCT04813081","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31461778|29926491|25034790|11553110|27554366","Zucchelli G, Tavelli L, McGuire MK, Rasperini G, Feinberg SE, Wang HL, Giannobile WV. Autogenous soft tissue grafting for periodontal and peri-implant plastic surgical reconstruction. J Periodontol. 2020 Jan;91(1):9-16. doi: 10.1002/JPER.19-0350. Epub 2019 Oct 6. Review.|Berglundh T, Armitage G, Araujo MG, Avila-Ortiz G, Blanco J, Camargo PM, Chen S, Cochran D, Derks J, Figuero E, Hämmerle CHF, Heitz-Mayfield LJA, Huynh-Ba G, Iacono V, Koo KT, Lambert F, McCauley L, Quirynen M, Renvert S, Salvi GE, Schwarz F, Tarnow D, Tomasi C, Wang HL, Zitzmann N. Peri-implant diseases and conditions: Consensus report of workgroup 4 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Clin Periodontol. 2018 Jun;45 Suppl 20:S286-S291. doi: 10.1111/jcpe.12957.|McGuire MK, Scheyer ET, Gwaltney C. Commentary: incorporating patient-reported outcomes in periodontal clinical trials. J Periodontol. 2014 Oct;85(10):1313-9. doi: 10.1902/jop.2014.130693. Epub 2014 Jul 18. Review.|Locker D, Matear D, Stephens M, Lawrence H, Payne B. Comparison of the GOHAI and OHIP-14 as measures of the oral health-related quality of life of the elderly. Community Dent Oral Epidemiol. 2001 Oct;29(5):373-81.|Mei CC, Lee FY, Yeh HC. Assessment of pain perception following periodontal and implant surgeries. J Clin Periodontol. 2016 Dec;43(12):1151-1159. doi: 10.1111/jcpe.12618. Epub 2016 Nov 2.","\tPatient Reported Outcome\tFree Gingival Graft\tNA\tNA\tNA\tProcedure\tAll\t","The Evaluation of Free Gingival Graft Operations Around Implant or Teeth on Quality of Life","Interventional","Completed","N/A",2,32,"NA","NA","NA"]
["NCT04813094","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32860505|27150174|24345399|23501173|16818816|23900699|26842113|27890386|27567408","Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group . 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.|Pistoia F, Sacco S, Tiseo C, Degan D, Ornello R, Carolei A. The Epidemiology of Atrial Fibrillation and Stroke. Cardiol Clin. 2016 May;34(2):255-68. doi: 10.1016/j.ccl.2015.12.002. Epub 2016 Mar 18. Review.|Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014 Feb 25;129(8):837-47. doi: 10.1161/CIRCULATIONAHA.113.005119. Epub 2013 Dec 17.|Tse HF, Wang YJ, Ahmed Ai-Abdullah M, Pizarro-Borromeo AB, Chiang CE, Krittayaphong R, Singh B, Vora A, Wang CX, Zubaid M, Clemens A, Lim P, Hu D. Stroke prevention in atrial fibrillation--an Asian stroke perspective. Heart Rhythm. 2013 Jul;10(7):1082-8. doi: 10.1016/j.hrthm.2013.03.017. Epub 2013 Mar 15. Review.|Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006 Jul 11;114(2):119-25. Epub 2006 Jul 3. Erratum in: Circulation. 2006 Sep 12;114(11):e498.|Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, Witteman JC, Stricker BH, Heeringa J. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013 Sep;34(35):2746-51. doi: 10.1093/eurheartj/eht280. Epub 2013 Jul 30.|Chiang CE, Wang KL, Lin SJ. Asian strategy for stroke prevention in atrial fibrillation. Europace. 2015 Oct;17 Suppl 2:ii31-9. doi: 10.1093/europace/euv231. Review.|Chiang CE, Wu TJ, Ueng KC, Chao TF, Chang KC, Wang CC, Lin YJ, Yin WH, Kuo JY, Lin WS, Tsai CT, Liu YB, Lee KT, Lin LJ, Lin LY, Wang KL, Chen YJ, Chen MC, Cheng CC, Wen MS, Chen WJ, Chen JH, Lai WT, Chiou CW, Lin JL, Yeh SJ, Chen SA. 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. J Formos Med Assoc. 2016 Nov;115(11):893-952. doi: 10.1016/j.jfma.2016.10.005. Epub 2016 Nov 24.|Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.","\tAtrial Fibrillation\tInternet-Based integrated-management Program|Control group\tParallel Assignment\tPrevention\tRandomized\tOther|Other\tAll\t","An Integrated-management Program to Control Health-related Quality of Life Among Patients With Atrial Fibrillation","Interventional","Completed","N/A",2,232,"atrial fibrillation","NA","NA"]
["NCT04813575","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32422177|32311448|NA|NA|32534945","Spagnolo P, Balestro E, Aliberti S, Cocconcelli E, Biondini D, Casa GD, Sverzellati N, Maher TM. Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir Med. 2020 Aug;8(8):750-752. doi: 10.1016/S2213-2600(20)30222-8. Epub 2020 May 15.|Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973. doi: 10.1016/j.jacc.2020.04.031. Epub 2020 Apr 17. Review.|Claudia R, Sara T, GianLuca C etl. Complications and mortality of transbronchial lung cryobiopsy and surgical lung biopsy in interstitial lung diseases. Europpean Respiratory Journal. 2015 46: PA2031; DOI: 10.1183/13993003.congress-2015.PA2031.|WHO Statement: Knowing the risks for COVID 19. https://www.who.int/indonesia/news/detail/08-03-2020-knowing-the-risk-for-covid-19.|Alsofayan YM, Althunayyan SM, Khan AA, Hakawi AM, Assiri AM. Clinical characteristics of COVID-19 in Saudi Arabia: A national retrospective study. J Infect Public Health. 2020 Jul;13(7):920-925. doi: 10.1016/j.jiph.2020.05.026. Epub 2020 Jun 8.","\tCovid19|Organising Pneumonia|Pulmonary Fibrosis|Thromboembolism\tCryo lung biopsies\tNA\tNA\tNA\tOther\tAll\t","COVID-19 Pathophysiology of Long Term Implications","Interventional","Enrolling by invitation","N/A",2,60,"fibrosis|pneumonia|pulmonary fibrosis|thromboembolism","NA","NA"]
["NCT04813900","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16984837|22392031|29466596|21925058|30372119|9372688|19809049|19168766|15888847|15135701|27906709|20221746|19633538|20851923|22584759|26298866","Volpicelli G, Mussa A, Garofalo G, Cardinale L, Casoli G, Perotto F, Fava C, Frascisco M. Bedside lung ultrasound in the assessment of alveolar-interstitial syndrome. Am J Emerg Med. 2006 Oct;24(6):689-96.|Volpicelli G, Elbarbary M, Blaivas M, Lichtenstein DA, Mathis G, Kirkpatrick AW, Melniker L, Gargani L, Noble VE, Via G, Dean A, Tsung JW, Soldati G, Copetti R, Bouhemad B, Reissig A, Agricola E, Rouby JJ, Arbelot C, Liteplo A, Sargsyan A, Silva F, Hoppmann R, Breitkreutz R, Seibel A, Neri L, Storti E, Petrovic T; International Liaison Committee on Lung Ultrasound (ILC-LUS) for International Consensus Conference on Lung Ultrasound (ICC-LUS). International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med. 2012 Apr;38(4):577-91. doi: 10.1007/s00134-012-2513-4. Epub 2012 Mar 6. Review.|Fan E, Brodie D, Slutsky AS. Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment. JAMA. 2018 Feb 20;319(7):698-710. doi: 10.1001/jama.2017.21907. Review.|Miñana G, Núñez J, Bañuls P, Sanchis J, Núñez E, Robles R, Mascarell B, Palau P, Chorro FJ, Llàcer A. Prognostic implications of arterial blood gases in acute decompensated heart failure. Eur J Intern Med. 2011 Oct;22(5):489-94. doi: 10.1016/j.ejim.2011.01.014. Epub 2011 Feb 25.|Mojoli F, Bouhemad B, Mongodi S, Lichtenstein D. Lung Ultrasound for Critically Ill Patients. Am J Respir Crit Care Med. 2019 Mar 15;199(6):701-714. doi: 10.1164/rccm.201802-0236CI. Review. Erratum in: Am J Respir Crit Care Med. 2020 Apr 15;201(8):1015. Am J Respir Crit Care Med. 2020 Jun 1;201(11):1454.|Lichtenstein D, Mézière G, Biderman P, Gepner A, Barré O. The comet-tail artifact. An ultrasound sign of alveolar-interstitial syndrome. Am J Respir Crit Care Med. 1997 Nov;156(5):1640-6.|Lichtenstein DA, Mezière GA, Lagoueyte JF, Biderman P, Goldstein I, Gepner A. A-lines and B-lines: lung ultrasound as a bedside tool for predicting pulmonary artery occlusion pressure in the critically ill. Chest. 2009 Oct;136(4):1014-1020. doi: 10.1378/chest.09-0001.|Soldati G, Copetti R, Sher S. Sonographic interstitial syndrome: the sound of lung water. J Ultrasound Med. 2009 Feb;28(2):163-74. Review.|\"Agricola E, Bove T, Oppizzi M, Marino G, Zangrillo A, Margonato A, Picano E. \"\"Ultrasound comet-tail images\"\": a marker of pulmonary edema: a comparative study with wedge pressure and extravascular lung water. Chest. 2005 May;127(5):1690-5.\"|Jambrik Z, Monti S, Coppola V, Agricola E, Mottola G, Miniati M, Picano E. Usefulness of ultrasound lung comets as a nonradiologic sign of extravascular lung water. Am J Cardiol. 2004 May 15;93(10):1265-70.|Bellani G, Rouby JJ, Constantin JM, Pesenti A. Looking closer at acute respiratory distress syndrome: the role of advanced imaging techniques. Curr Opin Crit Care. 2017 Feb;23(1):30-37. doi: 10.1097/MCC.0000000000000380. Review.|Via G, Lichtenstein D, Mojoli F, Rodi G, Neri L, Storti E, Klersy C, Iotti G, Braschi A. Whole lung lavage: a unique model for ultrasound assessment of lung aeration changes. Intensive Care Med. 2010 Jun;36(6):999-1007. doi: 10.1007/s00134-010-1834-4. Epub 2010 Mar 11.|Bouhemad B, Liu ZH, Arbelot C, Zhang M, Ferarri F, Le-Guen M, Girard M, Lu Q, Rouby JJ. Ultrasound assessment of antibiotic-induced pulmonary reaeration in ventilator-associated pneumonia. Crit Care Med. 2010 Jan;38(1):84-92. doi: 10.1097/CCM.0b013e3181b08cdb.|Bouhemad B, Brisson H, Le-Guen M, Arbelot C, Lu Q, Rouby JJ. Bedside ultrasound assessment of positive end-expiratory pressure-induced lung recruitment. Am J Respir Crit Care Med. 2011 Feb 1;183(3):341-7. doi: 10.1164/rccm.201003-0369OC. Epub 2010 Sep 17.|Soummer A, Perbet S, Brisson H, Arbelot C, Constantin JM, Lu Q, Rouby JJ; Lung Ultrasound Study Group. Ultrasound assessment of lung aeration loss during a successful weaning trial predicts postextubation distress*. Crit Care Med. 2012 Jul;40(7):2064-72. doi: 10.1097/CCM.0b013e31824e68ae.|Zhao Z, Jiang L, Xi X, Jiang Q, Zhu B, Wang M, Xing J, Zhang D. Prognostic value of extravascular lung water assessed with lung ultrasound score by chest sonography in patients with acute respiratory distress syndrome. BMC Pulm Med. 2015 Aug 23;15:98. doi: 10.1186/s12890-015-0091-2.","\tInterstitial Lung Disease\tLung ultrasound\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","emergencies|lung diseases, interstitial|hypoxia|lung diseases","NA","NA"]
["NCT04813952","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27413741|23277809","Doger C, Kahveci K, Ornek D, But A, Aksoy M, Gokcinar D, Katar D. Effects of Low-Flow Sevoflurane Anesthesia on Pulmonary Functions in Patients Undergoing Laparoscopic Abdominal Surgery. Biomed Res Int. 2016;2016:3068467. doi: 10.1155/2016/3068467. Epub 2016 Jun 20.|Park SY, Chung CJ, Jang JH, Bae JY, Choi SR. The safety and efficacy of minimal-flow desflurane anesthesia during prolonged laparoscopic surgery. Korean J Anesthesiol. 2012 Dec;63(6):498-503. doi: 10.4097/kjae.2012.63.6.498. Epub 2012 Dec 14.","Our aim is to investigate the effect of minimal flow anesthesia with sevoflurane on hemodynamics and arterial blood gas parameters in laparoscopic cholecystectomy operations.","Anesthesia Awareness|Anesthesia; Functional","Sevoflurane inhalant product","Parallel Assignment","Treatment","Randomized","Drug","All","Inclusion Criteria:\tThe Effect of Minimal Flow Sevoflurane Anesthesia\tInterventional\tCompleted\tNot Applicable\t2\t70\tintraoperative awareness\tsevoflurane\tNA\nNCT04814017\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t30171341|22139052|18469684|20354859\tKirály M, Bender T, Hodosi K. Comparative study of shockwave therapy and low-level laser therapy effects in patients with myofascial pain syndrome of the trapezius. Rheumatol Int. 2018 Nov;38(11):2045-2052. doi: 10.1007/s00296-018-4134-x. Epub 2018 Aug 31.|Williams MA, Williamson E, Gates S, Cooke MW. Reproducibility of the cervical range of motion (CROM) device for individuals with sub-acute whiplash associated disorders. Eur Spine J. 2012 May;21(5):872-8. doi: 10.1007/s00586-011-2096-8. Epub 2011 Dec 3.|Aslan E, Karaduman A, Yakut Y, Aras B, Simsek IE, Yaglý N. The cultural adaptation, reliability and validity of neck disability index in patients with neck pain: a Turkish version study. Spine (Phila Pa 1976). 2008 May 15;33(11):E362-5. doi: 10.1097/BRS.0b013e31817144e1.|Ay S, Doğan SK, Evcik D, Başer OC. Comparison the efficacy of phonophoresis and ultrasound therapy in myofascial pain syndrome. Rheumatol Int. 2011 Sep;31(9):1203-8. doi: 10.1007/s00296-010-1419-0. Epub 2010 Mar 31.\t","Chronic Pain|Myofascial Pain Syndrome","Radial Shock-Wave Therapy|Control","Parallel Assignment","Treatment","Randomized","Procedure|Procedure","All","\tEffectiveness of Shock-wave Therapy in Patients With Myofascial Pain Syndrome\tInterventional\tCompleted\tN/A\t2\t30\tmyofascial pain syndromes|somatoform disorders|syndrome|fibromyalgia|chronic pain\tNA\tNA\nNCT04814147\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t29581366|29100895|29156184|29420964|29204255\tNeeland IJ, Poirier P, Després JP. Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management. Circulation. 2018 Mar 27;137(13):1391-1406. doi: 10.1161/CIRCULATIONAHA.117.029617. Review.|Vecchié A, Dallegri F, Carbone F, Bonaventura A, Liberale L, Portincasa P, Frühbeck G, Montecucco F. Obesity phenotypes and their paradoxical association with cardiovascular diseases. Eur J Intern Med. 2018 Feb;48:6-17. doi: 10.1016/j.ejim.2017.10.020. Review.|le Roux CW, Heneghan HM. Bariatric Surgery for Obesity. Med Clin North Am. 2018 Jan;102(1):165-182. doi: 10.1016/j.mcna.2017.08.011. Review.|Pareek M, Schauer PR, Kaplan LM, Leiter LA, Rubino F, Bhatt DL. Metabolic Surgery: Weight Loss, Diabetes, and Beyond. J Am Coll Cardiol. 2018 Feb 13;71(6):670-687. doi: 10.1016/j.jacc.2017.12.014. Review.|Lupoli R, Lembo E, Saldalamacchia G, Avola CK, Angrisani L, Capaldo B. Bariatric surgery and long-term nutritional issues. World J Diabetes. 2017 Nov 15;8(11):464-474. doi: 10.4239/wjd.v8.i11.464. Review.\t","Obesity-Associated Insulin Resistance|Obesity Morbid","Sleeve gastrectomy","NA","NA","NA","Procedure","Female","\tNA\tNA\tNA\tNA\tNA\tNA\tinsulin resistance|weight loss|obesity\tNA\tNA\nNCT04814537\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t20613484|14639153|28067707\tNgan Kee WD, Ng FF, Khaw KS, Lee A, Gin T. Determination and comparison of graded dose-response curves for epidural bupivacaine and ropivacaine for analgesia in laboring nulliparous women. Anesthesiology. 2010 Aug;113(2):445-53. doi: 10.1097/ALN.0b013e3181bdf9da.|Benhamou D, Ghosh C, Mercier FJ. A randomized sequential allocation study to determine the minimum effective analgesic concentration of levobupivacaine and ropivacaine in patients receiving epidural analgesia for labor. Anesthesiology. 2003 Dec;99(6):1383-6.|Chau A, Bibbo C, Huang CC, Elterman KG, Cappiello EC, Robinson JN, Tsen LC. Dural Puncture Epidural Technique Improves Labor Analgesia Quality With Fewer Side Effects Compared With Epidural and Combined Spinal Epidural Techniques: A Randomized Clinical Trial. Anesth Analg. 2017 Feb;124(2):560-569. doi: 10.1213/ANE.0000000000001798.\t","Analgesia|Labor Pain","Bupivacaine Hydrochloride","Parallel Assignment","Treatment","Randomized","Drug","Female","\tOptimal Bupivacaine Dose for Initiation of Labor Epidural Techniques\tInterventional\tRecruiting\tPhase 4\t2\t100\tlabor pain\tbupivacaine\tNA\nNCT04815265\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t31112380|22190555\tShehabi Y, Howe BD, Bellomo R, Arabi YM, Bailey M, Bass FE, Bin Kadiman S, McArthur CJ, Murray L, Reade MC, Seppelt IM, Takala J, Wise MP, Webb SA; ANZICS Clinical Trials Group and the SPICE III Investigators. Early Sedation with Dexmedetomidine in Critically Ill Patients. N Engl J Med. 2019 Jun 27;380(26):2506-2517. doi: 10.1056/NEJMoa1904710. Epub 2019 May 19.|Antonik LJ, Goldwater DR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg. 2012 Aug;115(2):274-83. doi: 10.1213/ANE.0b013e31823f0c28. Epub 2011 Dec 20.\t","Sedation","Remimazolam|Dexmedetomidine","Parallel Assignment","Supportive Care","Randomized","Drug|Drug","All","\tRemimazolam for Sedation in ICU Patients Undergoing Mechanical Ventilation\tInterventional\tNot yet recruiting\tPhase 4\t2\t488\tNA\tdexmedetomidine\tNA\nNCT04816370\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t23710558|31233285\tMaddali Bongi S, Del Rosso A, Orlandi M, Matucci-Cerinic M. Gynaecological symptoms and sexual disability in women with primary Sjögren's syndrome and sicca syndrome. Clin Exp Rheumatol. 2013 Sep-Oct;31(5):683-90. Epub 2013 May 27.|McCoy SS, Sampene E, Baer AN. Association of Sjögren's Syndrome With Reduced Lifetime Sex Hormone Exposure: A Case-Control Study. Arthritis Care Res (Hoboken). 2020 Sep;72(9):1315-1322. doi: 10.1002/acr.24014.\t","Primary Sjögren Syndrome","FSFI","Crossover Assignment","Screening","Randomized","Diagnostic Test","Female","\tEffects of Primary Sjögren's Syndrome on Female Genitalia and Sexual Functions\tInterventional\tCompleted\tN/A\t4\t68\tsjogren's syndrome|syndrome\tNA\tNA\nNCT04816396\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t26572551|21631615|19694080|19345860|11743149\tAmieva H, Robert PH, Grandoulier AS, Meillon C, De Rotrou J, Andrieu S, Berr C, Desgranges B, Dubois B, Girtanner C, Joël ME, Lavallart B, Nourhashemi F, Pasquier F, Rainfray M, Touchon J, Chêne G, Dartigues JF. Group and individual cognitive therapies in Alzheimer's disease: the ETNA3 randomized trial. Int Psychogeriatr. 2016 May;28(5):707-17. doi: 10.1017/S1041610215001830. Epub 2015 Nov 17.|Wu LF. Group integrative reminiscence therapy on self-esteem, life satisfaction and depressive symptoms in institutionalised older veterans. J Clin Nurs. 2011 Aug;20(15-16):2195-203. doi: 10.1111/j.1365-2702.2011.03699.x. Epub 2011 Jun 1.|Roy C, Whetsell MV, Frederickson K. The Roy adaptation model and research. Nurs Sci Q. 2009 Jul;22(3):209-11.|Rogers C, Keller C. Roy's adaptation model to promote physical activity among sedentary older adults. Geriatr Nurs. 2009 Mar-Apr;30(2 Suppl):21-6. doi: 10.1016/j.gerinurse.2009.02.002.|Wagner C, van der Wal G, Groenewegen PP, de Bakker DH. The effectiveness of quality systems in nursing homes: a review. Qual Health Care. 2001 Dec;10(4):211-7. Review.\t","Elderly|Reminiscence Therapy","reminiscence Therapy","Parallel Assignment","Supportive Care","Randomized","Behavioral","All","\tThe Effect of Memory Therapy Based on the Roy Model on Adaptation, Life Satisfaction and Happines of the Elderly\tInterventional\tNot yet recruiting\tN/A\t2\t34\tNA\tNA\tNA\nNCT04816682\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t32517353\tBosch-Barrera J, Martin-Castillo B, Buxó M, Brunet J, Encinar JA, Menendez JA. Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients. J Clin Med. 2020 Jun 7;9(6). pii: E1770. doi: 10.3390/jcm9061770.\t","Covid19|Liver Diseases","Silymarin","NA","NA","NA","Drug","All","\tSilymarin in COVID-19 Patients Admitted to Hospital With Elevated Liver Enzymes\tInterventional\tRecruiting\tPhase 4\t2\t30\tliver diseases\tsilymarin\tNA\nNCT04816864\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t29535066|24509688|27016475|24733700|25446158|32703577|18987129|20806214|15670960|32817835\tAbdelrahman M, Subzposh FA, Beer D, Durr B, Naperkowski A, Sun H, Oren JW, Dandamudi G, Vijayaraman P. Clinical Outcomes of His Bundle Pacing Compared to Right Ventricular Pacing. J Am Coll Cardiol. 2018 May 22;71(20):2319-2330. doi: 10.1016/j.jacc.2018.02.048. Epub 2018 Mar 10.|Kronborg MB, Mortensen PT, Poulsen SH, Gerdes JC, Jensen HK, Nielsen JC. His or para-His pacing preserves left ventricular function in atrioventricular block: a double-blind, randomized, crossover study. Europace. 2014 Aug;16(8):1189-96. doi: 10.1093/europace/euu011. Epub 2014 Feb 7.|Dandamudi G, Vijayaraman P. How to perform permanent His bundle pacing in routine clinical practice. Heart Rhythm. 2016 Jun;13(6):1362-6. doi: 10.1016/j.hrthm.2016.03.040. Epub 2016 Mar 22. Review.|Josiak K, Nowak K, Fuglewicz A, Jagielski D, Banasiak W, Ponikowski P. Does right ventricular pacing increase the risk of ventricular arrhythmias in patients with an implantable cardioverter-defibrillator? Kardiol Pol. 2014;72(4):381-4. doi: 10.5603/KP.2014.0073. Review.|Sharma PS, Dandamudi G, Naperkowski A, Oren JW, Storm RH, Ellenbogen KA, Vijayaraman P. Permanent His-bundle pacing is feasible, safe, and superior to right ventricular pacing in routine clinical practice. Heart Rhythm. 2015 Feb;12(2):305-12. doi: 10.1016/j.hrthm.2014.10.021. Epub 2014 Oct 22.|Burri H, Jastrzebski M, Vijayaraman P. Electrocardiographic Analysis for His Bundle Pacing at Implantation and Follow-Up. JACC Clin Electrophysiol. 2020 Jul;6(7):883-900. doi: 10.1016/j.jacep.2020.03.005. Review.|Zyśko D, Gajek J, Koźluk E, Mazurek W. Electrocardiographic characteristics of atrioventricular block induced by tilt testing. Europace. 2009 Feb;11(2):225-30. doi: 10.1093/europace/eun299. Epub 2008 Nov 5.|Klank-Szafran M, Stec S, Sledź J, Janion M. [Radiofrequency ablation and cardioneuroablation for AVNRT and atrioventricular block]. Kardiol Pol. 2010 Jun;68(6):720-4. Polish.|Pachon JC, Pachon EI, Pachon JC, Lobo TJ, Pachon MZ, Vargas RN, Jatene AD. \"\"Cardioneuroablation\"\"--new treatment for neurocardiogenic syncope, functional AV block and sinus dysfunction using catheter RF-ablation. Europace. 2005 Jan;7(1):1-13.\"|Stec S, Dobaj Ł, Śledź A, Stępień-Wałek AM, Ton V, Śledź J. Cardioneuroablation for management of cardioinhibitory vasovagal syncope and pacemaker complications. HeartRhythm Case Rep. 2020 May 11;6(8):531-534. doi: 10.1016/j.hrcr.2020.04.021. eCollection 2020 Aug.","\tPermanent His Bundle Pacing|Permanent Left Bundle Branch Pacing\textracardiac vagal nerve stimulation (ECANS) + EPS\tParallel Assignment\tTreatment\tRandomized\tDiagnostic Test\tAll\t","Safety and Efficacy of His Bundle Pacing Validated by Extracardiac Vagal Nerve Stimulation","Interventional","Recruiting","N/A",2,60,"NA","NA","NA"]
["NCT04817813","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26170865|31230220|31396386|26445472|27485066|15177433|16420849|19080906|27298055|16754172|15273542|NA|21762295|25059275|21236455","Treska V, Cerna M, Kydlicek T, Treskova I. Prognostic factors of breast cancer liver metastasis surgery. Arch Med Sci. 2015 Jun 19;11(3):683-5. doi: 10.5114/aoms.2015.52376.|He X, Zhang Q, Feng Y, Li Z, Pan Q, Zhao Y, Zhu W, Zhang N, Zhou J, Wang L, Wang M, Liu Z, Zhu H, Shao Z, Wang L. Resection of liver metastases from breast cancer: a multicentre analysis. Clin Transl Oncol. 2020 Apr;22(4):512-521. doi: 10.1007/s12094-019-02155-2. Epub 2019 Jun 22.|Chen QF, Huang T, Shen L, Wu P, Huang ZL, Li W. Prognostic factors and survival according to tumor subtype in newly diagnosed breast cancer with liver metastases: A competing risk analysis. Mol Clin Oncol. 2019 Sep;11(3):259-269. doi: 10.3892/mco.2019.1890. Epub 2019 Jul 1.|Sadot E, Lee SY, Sofocleous CT, Solomon SB, Gönen M, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, Hudis CA, D'Angelica MI. Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis: A Case-control Study With Comparison to Medically Treated Patients. Ann Surg. 2016 Jul;264(1):147-154. doi: 10.1097/SLA.0000000000001371.|Margonis GA, Buettner S, Sasaki K, Kim Y, Ratti F, Russolillo N, Ferrero A, Berger N, Gamblin TC, Poultsides G, Tran T, Postlewait LM, Maithel S, Michaels AD, Bauer TW, Marques H, Barroso E, Aldrighetti L, Pawlik TM. The role of liver-directed surgery in patients with hepatic metastasis from primary breast cancer: a multi-institutional analysis. HPB (Oxford). 2016 Aug;18(8):700-5. doi: 10.1016/j.hpb.2016.05.014. Epub 2016 Jun 29.|Díaz R, Santaballa A, Munárriz B, Calderero V. Hepatic resection in breast cancer metastases: should it be considered standard treatment? Breast. 2004 Jun;13(3):254-8. Review.|Ramia JM, Villar J, Villegas T, Muffak K, Garrote D, Ferrón JA. [Surgical treatment of liver metastases from breast cancer]. Cir Esp. 2005 Nov;78(5):318-22. Spanish.|Figueras J, González HD. [Surgical treatment of breast cancer liver metastasis. The great assignment awaiting Spanish hepatic surgery]. Cir Esp. 2008 Nov;84(5):239-40. Spanish.|Roffman CE, Buchanan J, Allison GT. Charlson Comorbidities Index. J Physiother. 2016 Jul;62(3):171. doi: 10.1016/j.jphys.2016.05.008. Epub 2016 Jun 11.|Satava RM. Identification and reduction of surgical error using simulation. Minim Invasive Ther Allied Technol. 2005;14(4):257-61.|Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13.|The Royal College of Pathologists. Standards and Minimum Datasets for Reporting Cancers Minimum dataset for the histopathological reporting of pancreatic, ampulla of Vater and bile duct carcinoma. London R Coll Pathol. 2002.|Rahbari NN, Garden OJ, Padbury R, Maddern G, Koch M, Hugh TJ, Fan ST, Nimura Y, Figueras J, Vauthey JN, Rees M, Adam R, Dematteo RP, Greig P, Usatoff V, Banting S, Nagino M, Capussotti L, Yokoyama Y, Brooke-Smith M, Crawford M, Christophi C, Makuuchi M, Büchler MW, Weitz J. Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS). HPB (Oxford). 2011 Aug;13(8):528-35. doi: 10.1111/j.1477-2574.2011.00319.x. Epub 2011 Jun 7. Review.|Brooke-Smith M, Figueras J, Ullah S, Rees M, Vauthey JN, Hugh TJ, Garden OJ, Fan ST, Crawford M, Makuuchi M, Yokoyama Y, Büchler M, Weitz J, Padbury R. Prospective evaluation of the International Study Group for Liver Surgery definition of bile leak after a liver resection and the role of routine operative drainage: an international multicentre study. HPB (Oxford). 2015 Jan;17(1):46-51. doi: 10.1111/hpb.12322. Epub 2014 Jul 24.|Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, Koch M, Makuuchi M, Dematteo RP, Christophi C, Banting S, Usatoff V, Nagino M, Maddern G, Hugh TJ, Vauthey JN, Greig P, Rees M, Yokoyama Y, Fan ST, Nimura Y, Figueras J, Capussotti L, Büchler MW, Weitz J. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011 May;149(5):713-24. doi: 10.1016/j.surg.2010.10.001. Epub 2011 Jan 14.","\tBreast Cancer|Liver Metastases|Surgery\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms, second primary|breast neoplasms|neoplasm metastasis|liver neoplasms","NA","NA"]
["NCT04818450","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29605589|12460250|28769860|25317090|20124884","Carrera-Hernández L, Aizpitarte-Pejenaute E, Zugazagoitia-Ciarrusta N, Goñi-Viguria R. Patients' perceptions of sleep in a Critical Care Unit. Enferm Intensiva. 2018 Apr - Jun;29(2):53-63. doi: 10.1016/j.enfi.2018.01.002. Epub 2018 Mar 28. English, Spanish.|Foldvary-Schaefer N, De Leon Sanchez I, Karafa M, Mascha E, Dinner D, Morris HH. Gabapentin increases slow-wave sleep in normal adults. Epilepsia. 2002 Dec;43(12):1493-7.|Liu GJ, Karim MR, Xu LL, Wang SL, Yang C, Ding L, Wang YF. Efficacy and Tolerability of Gabapentin in Adults with Sleep Disturbance in Medical Illness: A Systematic Review and Meta-analysis. Front Neurol. 2017 Jul 14;8:316. doi: 10.3389/fneur.2017.00316. eCollection 2017.|Rosenberg RP, Hull SG, Lankford DA, Mayleben DW, Seiden DJ, Furey SA, Jayawardena S, Roth T. A randomized, double-blind, single-dose, placebo-controlled, multicenter, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance. J Clin Sleep Med. 2014 Oct 15;10(10):1093-100. doi: 10.5664/jcsm.4108.|Lo HS, Yang CM, Lo HG, Lee CY, Ting H, Tzang BS. Treatment effects of gabapentin for primary insomnia. Clin Neuropharmacol. 2010 Mar-Apr;33(2):84-90. doi: 10.1097/WNF.0b013e3181cda242.","\tCritically Ill|Sleep Deprivation\tGabapentin\tParallel Assignment\tPrevention\tRandomized\tDrug\tAll\t","Impact of Gabapentin on Slow Wave Sleep in Adult Critically Ill Patient","Interventional","Recruiting","N/A",2,60,"sleep deprivation|critical illness","gabapentin","NA"]
["NCT04818866","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32963090,"Azam TU, Shadid HR, Blakely P, O'Hayer P, Berlin H, Pan M, Zhao P, Zhao L, Pennathur S, Pop-Busui R, Altintas I, Tingleff J, Stauning MA, Andersen O, Adami ME, Solomonidi N, Tsilika M, Tober-Lau P, Arnaoutoglou E, Keitel V, Tacke F, Chalkias A, Loosen SH, Giamarellos-Bourboulis EJ, Eugen-Olsen J, Reiser J, Hayek SS; International Study of Inflammation in COVID-19. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI. J Am Soc Nephrol. 2020 Nov;31(11):2725-2735. doi: 10.1681/ASN.2020060829. Epub 2020 Sep 22.","This is a prospective multi-center observational study which purpose is to evaluate the ability of blood-based inflammatory markers to risk-stratify patients hospitalized for Covid-19. Blood-based biomarkers examined include: soluble urokinase plasminogen activator receptor (suPAR), C-reactive protein (CRP), procalcitonin, D-dimer, ferritin, lactate dehydrogenase and interleukin-6.","Acute Kidney Injury|Covid19|Inflammation|Outcome, Fatal|Respiratory Failure","SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase","NA","NA","NA","Diagnostic Test","All","Inclusion Criteria:\tNA\tNA\tNA\tNA\tNA\tNA\trespiratory insufficiency|acute kidney injury|inflammation\tfibrin fragment d\tNA\nNCT04819165\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t32299202|33223114|26903337|25029020|23856895|26966105|21168440|33388794\tTufan A, Avanoğlu Güler A, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020 Apr 21;50(SI-1):620-632. doi: 10.3906/sag-2004-168. Review.|Ripa M, Galli L, Poli A, Oltolini C, Spagnuolo V, Mastrangelo A, Muccini C, Monti G, De Luca G, Landoni G, Dagna L, Clementi M, Rovere Querini P, Ciceri F, Tresoldi M, Lazzarin A, Zangrillo A, Scarpellini P, Castagna A; COVID-BioB study group. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clin Microbiol Infect. 2021 Mar;27(3):451-457. doi: 10.1016/j.cmi.2020.10.021. Epub 2020 Oct 24.|Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson BT, Wrigge H, Slutsky AS, Pesenti A; LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016 Feb 23;315(8):788-800. doi: 10.1001/jama.2016.0291. Erratum in: JAMA. 2016 Jul 19;316(3):350. JAMA. 2016 Jul 19;316(3):350.|Kalanuria AA, Ziai W, Mirski M. Ventilator-associated pneumonia in the ICU. Crit Care. 2014 Mar 18;18(2):208. doi: 10.1186/cc13775. Review. Erratum in: Crit Care. 2016;20:29. Zai, Wendy [corrected to Ziai, Wendy].|Rouzé A, Nseir S. Continuous control of tracheal cuff pressure for the prevention of ventilator-associated pneumonia in critically ill patients: where is the evidence? Curr Opin Crit Care. 2013 Oct;19(5):440-7. doi: 10.1097/MCC.0b013e3283636b71. Review.|Duszyńska W, Rosenthal VD, Szczęsny A, Woźnica E, Ulfik K, Ostrowska E, Litwin A, Kübler A. Urinary tract infections in intensive care unit patients - a single-centre, 3-year observational study according to the INICC project. Anaesthesiol Intensive Ther. 2016;48(1):1-6. doi: 10.5603/AIT.2016.0001.|Rosenthal VD, Dwivedy A, Calderón ME, Esen S, Hernández HT, Abouqal R, Medeiros EA, Espinoza TA, Kanj SS, Gikas A, Barnett AG, Graves N; International Nosocomial Infection Control Consortium (INICC) Members. Time-dependent analysis of length of stay and mortality due to urinary tract infections in ten developing countries: INICC findings. J Infect. 2011 Feb;62(2):136-41. doi: 10.1016/j.jinf.2010.12.004. Epub 2010 Dec 17.|Rouzé A, Martin-Loeches I, Povoa P, Makris D, Artigas A, Bouchereau M, Lambiotte F, Metzelard M, Cuchet P, Boulle Geronimi C, Labruyere M, Tamion F, Nyunga M, Luyt CE, Labreuche J, Pouly O, Bardin J, Saade A, Asfar P, Baudel JL, Beurton A, Garot D, Ioannidou I, Kreitmann L, Llitjos JF, Magira E, Mégarbane B, Meguerditchian D, Moglia E, Mekontso-Dessap A, Reignier J, Turpin M, Pierre A, Plantefeve G, Vinsonneau C, Floch PE, Weiss N, Ceccato A, Torres A, Duhamel A, Nseir S; coVAPid study Group. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Med. 2021 Feb;47(2):188-198. doi: 10.1007/s00134-020-06323-9. Epub 2021 Jan 3.\t","COVID-19|Health Care Associated Infection|Respiration, Artificial","COVID-19","NA","NA","NA","Other","All","\tNA\tNA\tNA\tNA\tNA\tNA\tinfection|communicable diseases|cross infection\tNA\tNA\nNCT04819191\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t33325729\tWolff JL, Scerpella D, Cockey K, Hussain N, Funkhouser T, Echavarria D, Aufill J, Guo A, Sloan DH, Dy SM, Smith KM; SHARING Choices Investigators. SHARING Choices: A Pilot Study to Engage Family in Advance Care Planning of Older Adults With and Without Cognitive Impairment in the Primary Care Context. Am J Hosp Palliat Care. 2020 Dec 16:1049909120978771. doi: 10.1177/1049909120978771. [Epub ahead of print]\t","Advance Care Planning|Dementia","SHARING Choices","Parallel Assignment","Health Services Research","Randomized","Behavioral","All","\tImproving Communication for Primary Care Patients\tInterventional\tEnrolling by invitation\tN/A\t2\t87000\tdementia\tNA\tNA\nNCT04819529\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t19446324|21443796|27660922\tSchweickert WD, Pohlman MC, Pohlman AS, Nigos C, Pawlik AJ, Esbrook CL, Spears L, Miller M, Franczyk M, Deprizio D, Schmidt GA, Bowman A, Barr R, McCallister KE, Hall JB, Kress JP. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet. 2009 May 30;373(9678):1874-82. doi: 10.1016/S0140-6736(09)60658-9. Epub 2009 May 14.|Sacanella E, Pérez-Castejón JM, Nicolás JM, Masanés F, Navarro M, Castro P, López-Soto A. Functional status and quality of life 12 months after discharge from a medical ICU in healthy elderly patients: a prospective observational study. Crit Care. 2011;15(2):R105. doi: 10.1186/cc10121. Epub 2011 Mar 28.|Álvarez EA, Garrido MA, Tobar EA, Prieto SA, Vergara SO, Briceño CD, González FJ. Occupational therapy for delirium management in elderly patients without mechanical ventilation in an intensive care unit: A pilot randomized clinical trial. J Crit Care. 2017 Feb;37:85-90. doi: 10.1016/j.jcrc.2016.09.002. Epub 2016 Sep 10.\t","Critical Illness|Impairment, Cognitive|Impairment, Coordination|Ventilator Lung","Early and Intensive Occupational Therapy","Parallel Assignment","Treatment","Randomized","Behavioral","All","\tEarly and Intensive Occupational Therapy in Mechanical Ventilated Patients\tInterventional\tRecruiting\tN/A\t2\t226\tataxia|critical illness|cognitive dysfunction\tNA\tNA\nNCT04820101\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t30974433\tSweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Te Pas A, Plavka R, Roehr CC, Saugstad OD, Simeoni U, Speer CP, Vento M, Visser GHA, Halliday HL. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2019 Update. Neonatology. 2019;115(4):432-450. doi: 10.1159/000499361. Epub 2019 Apr 11.\t","RDS","Dexmedetomidine","NA","NA","NA","Drug","All","\tNA\tNA\tNA\tNA\tNA\tNA\tpremature birth\tdexmedetomidine\tNA\nNCT04820361\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t12620591|16697110|24420962\tJensen TS, Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain. 2003 Mar;102(1-2):1-8. Review.|Rolke R, Baron R, Maier C, Tölle TR, Treede -DR, Beyer A, Binder A, Birbaumer N, Birklein F, Bötefür IC, Braune S, Flor H, Huge V, Klug R, Landwehrmeyer GB, Magerl W, Maihöfner C, Rolko C, Schaub C, Scherens A, Sprenger T, Valet M, Wasserka B. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain. 2006 Aug;123(3):231-243. doi: 10.1016/j.pain.2006.01.041. Epub 2006 May 11. Erratum in: Pain. 2006 Nov;125(1-2):197.|Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, Ehler E. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain. 2014 Aug;18(7):999-1012. doi: 10.1002/j.1532-2149.2013.00445.x. Epub 2014 Jan 13.\t","Pain, Neuropathic","Cannabis sativa L., folium cum flore|Placebo","Crossover Assignment","Treatment","Randomized","Drug|Drug","All","\tEffect of Cannabinoids on Pain in Fabry Disease Patients\tInterventional\tNot yet recruiting\tN/A\t2\t22\tfabry disease|neuralgia\tparasympatholytics\tNA\nNCT04820790\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t23271820|19406863|28513453|29794207|30517340|15829471|25119490|31440044|29788482|30538444|27102885|18417444|32049065|30180835|30419185|31179777\tMcCoy RW. Options for home oxygen therapy equipment: storage and metering of oxygen in the home. Respir Care. 2013 Jan;58(1):65-85. doi: 10.4187/respcare.01932. Review.|Bott J, Blumenthal S, Buxton M, Ellum S, Falconer C, Garrod R, Harvey A, Hughes T, Lincoln M, Mikelsons C, Potter C, Pryor J, Rimington L, Sinfield F, Thompson C, Vaughn P, White J; British Thoracic Society Physiotherapy Guideline Development Group. Guidelines for the physiotherapy management of the adult, medical, spontaneously breathing patient. Thorax. 2009 May;64 Suppl 1:i1-51. doi: 10.1136/thx.2008.110726.|Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017 May 13;389(10082):1931-1940. doi: 10.1016/S0140-6736(17)31222-9. Epub 2017 May 11. Review.|Branson RD. Oxygen Therapy in COPD. Respir Care. 2018 Jun;63(6):734-748. doi: 10.4187/respcare.06312. Review.|Mesquita CB, Knaut C, Caram LMO, Ferrari R, Bazan SGZ, Godoy I, Tanni SE. Impact of adherence to long-term oxygen therapy on patients with COPD and exertional hypoxemia followed for one year. J Bras Pneumol. 2018 Sep-Oct;44(5):390-397. doi: 10.1590/S1806-37562017000000019. English, Portuguese.|Oh H, Rizo C, Enkin M, Jadad A. What is eHealth (3): a systematic review of published definitions. J Med Internet Res. 2005 Feb 24;7(1):e1. Review.|Mirkovic J, Kaufman DR, Ruland CM. Supporting cancer patients in illness management: usability evaluation of a mobile app. JMIR Mhealth Uhealth. 2014 Aug 13;2(3):e33. doi: 10.2196/mhealth.3359.|Hallensleben C, van Luenen S, Rolink E, Ossebaard HC, Chavannes NH. eHealth for people with COPD in the Netherlands: a scoping review. Int J Chron Obstruct Pulmon Dis. 2019 Jul 26;14:1681-1690. doi: 10.2147/COPD.S207187. eCollection 2019. Review.|Gurbeta L, Badnjevic A, Maksimovic M, Omanovic-Miklicanin E, Sejdic E. A telehealth system for automated diagnosis of asthma and chronical obstructive pulmonary disease. J Am Med Inform Assoc. 2018 Sep 1;25(9):1213-1217. doi: 10.1093/jamia/ocy055.|Rassouli F, Boutellier D, Duss J, Huber S, Brutsche MH. Digitalizing multidisciplinary pulmonary rehabilitation in COPD with a smartphone application: an international observational pilot study. Int J Chron Obstruct Pulmon Dis. 2018 Nov 23;13:3831-3836. doi: 10.2147/COPD.S182880. eCollection 2018.|Bitsaki M, Koutras C, Koutras G, Leymann F, Steimle F, Wagner S, Wieland M. ChronicOnline: Implementing a mHealth solution for monitoring and early alerting in chronic obstructive pulmonary disease. Health Informatics J. 2017 Sep;23(3):197-207. doi: 10.1177/1460458216641480. Epub 2016 Apr 21.|Nguyen HQ, Donesky-Cuenco D, Wolpin S, Reinke LF, Benditt JO, Paul SM, Carrieri-Kohlman V. Randomized controlled trial of an internet-based versus face-to-face dyspnea self-management program for patients with chronic obstructive pulmonary disease: pilot study. J Med Internet Res. 2008 Apr 16;10(2):e9. doi: 10.2196/jmir.990.|Hernández-Reyes A, Cámara-Martos F, Molina Recio G, Molina-Luque R, Romero-Saldaña M, Moreno Rojas R. Push Notifications From a Mobile App to Improve the Body Composition of Overweight or Obese Women: Randomized Controlled Trial. JMIR Mhealth Uhealth. 2020 Feb 12;8(2):e13747. doi: 10.2196/13747.|Yang F, Wang Y, Yang C, Hu H, Xiong Z. Mobile health applications in self-management of patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis of their efficacy. BMC Pulm Med. 2018 Sep 4;18(1):147. doi: 10.1186/s12890-018-0671-z.|Scott IA, Scuffham P, Gupta D, Harch TM, Borchi J, Richards B. Going digital: a narrative overview of the effects, quality and utility of mobile apps in chronic disease self-management. Aust Health Rev. 2020 Feb;44(1):62-82. doi: 10.1071/AH18064. Review.|Early J, Gonzalez C, Gordon-Dseagu V, Robles-Calderon L. Use of Mobile Health (mHealth) Technologies and Interventions Among Community Health Workers Globally: A Scoping Review. Health Promot Pract. 2019 Nov;20(6):805-817. doi: 10.1177/1524839919855391. Epub 2019 Jun 10. Review.\t","Oxygen-therapy","Mobile applications","Parallel Assignment","Supportive Care","Randomized","Other","All","\tMobile Application for Monitoring Patients With Home Oxygen. A Protocol of a Randomized and Controlled Clinical Trial.\tInterventional\tNot yet recruiting\tN/A\t2\t44\tNA\tNA\tNA\nNCT04821388\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t29534985|29150158|17848483|12425180|18272892|27621646|NA|28840466|12891111|17377972|25435665|29050631|21123095\tBunte MC, Shishehbor MH. Next Generation Endovascular Therapies in Peripheral Artery Disease. Prog Cardiovasc Dis. 2018 Mar - Apr;60(6):593-599. doi: 10.1016/j.pcad.2018.03.003. Epub 2018 Mar 10. Review.|Conte SM, Vale PR. Peripheral Arterial Disease. Heart Lung Circ. 2018 Apr;27(4):427-432. doi: 10.1016/j.hlc.2017.10.014. Epub 2017 Nov 7. Review.|Zeller T. Current state of endovascular treatment of femoro-popliteal artery disease. Vasc Med. 2007 Aug;12(3):223-34. Review.|Levy PJ. Epidemiology and pathophysiology of peripheral arterial disease. Clin Cornerstone. 2002;4(5):1-15. Review.|Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008 Feb 14;358(7):689-99. doi: 10.1056/NEJMoa0706356.|Herten M, Torsello GB, Schönefeld E, Stahlhoff S. Critical appraisal of paclitaxel balloon angioplasty for femoral-popliteal arterial disease. Vasc Health Risk Manag. 2016 Aug 29;12:341-56. doi: 10.2147/VHRM.S81122. eCollection 2016. Review.|Endovascular Today. The Iliac/SFA/Popliteal Center. DCBs available in Europe. https://evtoday.com/device-guide/europe/chart.asp?id=159|Al-Bawardy RF, Waldo SW, Rosenfield K. Advances in Percutaneous Therapies for Peripheral Artery Disease: Drug-Coated Balloons. Curr Cardiol Rep. 2017 Aug 24;19(10):99. doi: 10.1007/s11886-017-0913-3. Review.|Coyne KS, Margolis MK, Gilchrist KA, Grandy SP, Hiatt WR, Ratchford A, Revicki DA, Weintraub WS, Regensteiner JG. Evaluating effects of method of administration on Walking Impairment Questionnaire. J Vasc Surg. 2003 Aug;38(2):296-304.|Rocha-Singh KJ, Jaff MR, Crabtree TR, Bloch DA, Ansel G; VIVA Physicians, Inc. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv. 2007 May 1;69(6):910-9.|Hardman RL, Jazaeri O, Yi J, Smith M, Gupta R. Overview of classification systems in peripheral artery disease. Semin Intervent Radiol. 2014 Dec;31(4):378-88. doi: 10.1055/s-0034-1393976. Review.|Brodmann M, Keirse K, Scheinert D, Spak L, Jaff MR, Schmahl R, Li P, Zeller T; IN.PACT Global Study Investigators. Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort. JACC Cardiovasc Interv. 2017 Oct 23;10(20):2113-2123. doi: 10.1016/j.jcin.2017.06.018.|Mahe G, Ouedraogo N, Vasseur M, Faligant C, Saidi K, Leftheriotis G, Abraham P. Limitations of self-reported estimates of functional capacity using the Walking Impairment Questionnaire. Eur J Vasc Endovasc Surg. 2011 Jan;41(1):104-9. doi: 10.1016/j.ejvs.2010.10.002. Epub 2010 Nov 30.\t","Peripheral Artery Disease (PAD)","Rontis DCB","NA","NA","NA","Device","All","\tNA\tNA\tNA\tNA\tNA\tNA\tperipheral arterial disease\tNA\tNA\nNCT04821648\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA|23540074|NA\tAsds consumer survey on cosmetic dermatologic procedures: American Society for Dermatological Surgery; 2018. (Available from: https://www.asds.net/Portals/0/PDF/consumer-survey-2018-infographic.pdf.)|Schlessinger J, Weiss SR, Jewell M, Narurkar V, Weinkle S, Gold MH, Bazerkanian E. Perceptions and practices in submental fat treatment: a survey of physicians and patients. Skinmed. 2013 Jan-Feb;11(1):27-31.|Mukherjee A. Pharmacology review(s) of xiaflex. 2009.\t","Double Chin|Submental Fat (SMF)","RJV001","Parallel Assignment","Treatment","Randomized","Drug","All","\tRJV001 Study in Adults Receiving Abdominoplasty\tInterventional\tRecruiting\tPhase 1\t3\t18\tNA\tNA\tNA\nNCT04821986\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t33521007|33146320\tLa Rosa GRM, Libra M, De Pasquale R, Ferlito S, Pedullà E. Association of Viral Infections With Oral Cavity Lesions: Role of SARS-CoV-2 Infection. Front Med (Lausanne). 2021 Jan 14;7:571214. doi: 10.3389/fmed.2020.571214. eCollection 2020. Review.|Halboub E, Al-Maweri SA, Alanazi RH, Qaid NM, Abdulrab S. Orofacial manifestations of COVID-19: a brief review of the published literature. Braz Oral Res. 2020 Oct 30;34:e124. doi: 10.1590/1807-3107bor-2020.vol34.0124. eCollection 2020. Review.\t","SARS-CoV Infection","NA","NA","NA","NA","NA","All","\tNA\tNA\tNA\tNA\tNA\tNA\tsevere acute respiratory syndrome|communicable diseases|coronavirus infections|oral manifestations|infection\tNA\tNA\nNCT04822051\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t15525860|17228986|19819096|23269773|11920549|3203947|2292449|15712339|12803150|31928566|NA|NA\tBailey DE, Mishel MH, Belyea M, Stewart JL, Mohler J. Uncertainty intervention for watchful waiting in prostate cancer. Cancer Nurs. 2004 Sep-Oct;27(5):339-46.|Gil KM, Mishel MH, Belyea M, Germino B, Porter LS, Clayton M. Benefits of the uncertainty management intervention for African American and White older breast cancer survivors: 20-month outcomes. Int J Behav Med. 2006;13(4):286-94.|Mishel MH, Germino BB, Lin L, Pruthi RS, Wallen EM, Crandell J, Blyler D. Managing uncertainty about treatment decision making in early stage prostate cancer: a randomized clinical trial. Patient Educ Couns. 2009 Dec;77(3):349-59. doi: 10.1016/j.pec.2009.09.009. Epub 2009 Oct 9.|Germino BB, Mishel MH, Crandell J, Porter L, Blyler D, Jenerette C, Gil KM. Outcomes of an uncertainty management intervention in younger African American and Caucasian breast cancer survivors. Oncol Nurs Forum. 2013 Jan;40(1):82-92. doi: 10.1188/13.ONF.82-92.|Mishel MH, Belyea M, Germino BB, Stewart JL, Bailey DE Jr, Robertson C, Mohler J. Helping patients with localized prostate carcinoma manage uncertainty and treatment side effects: nurse-delivered psychoeducational intervention over the telephone. Cancer. 2002 Mar 15;94(6):1854-66.|Mishel MH. Uncertainty in illness. Image J Nurs Sch. 1988 Winter;20(4):225-32.|Mishel MH. Reconceptualization of the uncertainty in illness theory. Image J Nurs Sch. 1990 Winter;22(4):256-62.|Mishel MH, Germino BB, Gil KM, Belyea M, Laney IC, Stewart J, Porter L, Clayton M. Benefits from an uncertainty management intervention for African-American and Caucasian older long-term breast cancer survivors. Psychooncology. 2005 Nov;14(11):962-78.|Neville KL. Uncertainty in illness. An integrative review. Orthop Nurs. 2003 May-Jun;22(3):206-14. Review.|He H, Liu Q, Li N, Guo L, Gao F, Bai L, Gao F, Lyu J. Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017. Epidemiol Psychiatr Sci. 2020 Jan 13;29:e91. doi: 10.1017/S2045796019000891.|Taş S, Buldukoğlu K. Early period self-care ability and care requirements of schizophrenia patients after discharge. Journal of Psychiatric Nursing. 2018; 9(1):11-22.|Williams LA. Theory of caregiving dynamics. In Smith MJ, Liehr PR, eds. Middle Range Theory for Nursing. New York: Springer Publishing Company; 2008.\t","Psychiatric Nursing|Schizophrenia","The Uncertainty Management Psychoeducation Program","Parallel Assignment","Supportive Care","Randomized","Other","All","\tThe Effect of Psychoeducation Based on Uncertainty In Illness Theory On Schizophrenia Caregivers\tInterventional\tCompleted\tN/A\t2\t54\tschizophrenia\tNA\tNA\nNCT04822077\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t25260491|20859129|26895711|16332601\tChang JY, Li H, Zhu XR, Liao Z, Zhao L, Liu A, Li Y, Sahoo N, Poenisch F, Gomez DR, Wu R, Gillin M, Zhang X. Clinical implementation of intensity modulated proton therapy for thoracic malignancies. Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):809-18. doi: 10.1016/j.ijrobp.2014.07.045. Epub 2014 Sep 24.|Gomez D, Komaki R. Technical advances of radiation therapy for thymic malignancies. J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S336-43. doi: 10.1097/JTO.0b013e3181f20ea2. Review.|Vogel J, Berman AT, Lin L, Pechet TT, Levin WP, Gabriel P, Khella SL, Singhal S, Kucharczuk JK, Simone CB 2nd. Prospective study of proton beam radiation therapy for adjuvant and definitive treatment of thymoma and thymic carcinoma: Early response and toxicity assessment. Radiother Oncol. 2016 Mar;118(3):504-9. doi: 10.1016/j.radonc.2016.02.003. Epub 2016 Feb 16.|Björk-Eriksson T, Bjelkengren G, Glimelius B. The potentials of proton beam radiation therapy in malignant lymphoma, thymoma and sarcoma. Acta Oncol. 2005;44(8):913-7. Review.\t","Cardiotoxicity|Pulmonary Toxicity|Thymus Neoplasms","Proton radiation","NA","NA","NA","Radiation","All","\tNA\tNA\tNA\tNA\tNA\tNA\tcardiotoxicity|thymus neoplasms|thymoma\tNA\tNA\nNCT04822662\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t8410570|28360675|11468499|10063248|NA|NA\tAustin JK, Huberty TJ. Development of the Child Attitude Toward Illness Scale. J Pediatr Psychol. 1993 Aug;18(4):467-80.|Tutar Güven Ş, Işler A. Validity and Reliability of the Seizure Self-Efficacy Scale for Children with Epilepsy. Noro Psikiyatr Ars. 2015 Mar;52(1):47-53. doi: 10.5152/npa.2015.7399. Epub 2015 Mar 1.|Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001 Aug;39(8):800-12.|Miles MS, Carlson J, Brunssen S. The nurse parent support tool. J Pediatr Nurs. 1999 Feb;14(1):44-50.|Caplin D, Austin JK, Dunn DW, Shen J, Perkins S. Development of a self-efficacy scale for children and adolescents with epilepsy. Children's Health Care. 2002; 31(4): 295-309.|Ersun A, Bolışık B. VALIDITY AND RELIABILITY OF THE TURKISH ADAPTATION OF THE CHILD ATTITUDE TOWARD ILLNESS SCALE. EGEHFD. 2012; 28:37-45.\t","Epilepsy; Seizure|Quality of Life|Self Management","Epilepsy Education Programme","Parallel Assignment","Supportive Care","Randomized","Behavioral","All","\tThe Individual and Family Self Management Theory Based Epilepsy Education Program's Effectiveness\tInterventional\tRecruiting\tN/A\t2\t36\tseizures|epilepsy\tNA\tNA\nNCT04822714\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t32995304\tHo HH, Mohd Rasdi R, Ibrahim R, Md Khambari MN. Developing and evaluating the effectiveness of mobile phone-based career intervention for career competencies of Malaysian public managers: Protocol for a mixed method study. Internet Interv. 2020 Sep 3;22:100349. doi: 10.1016/j.invent.2020.100349. eCollection 2020 Dec.\t","Competence|Competency-Based Education","Mobile Career Competencies Intervention","Parallel Assignment","Treatment","Randomized","Behavioral","All","\tEffectiveness of Mobile-phone Career Competencies Intervention for Malaysian Public Sector Managers\tInterventional\tCompleted\tN/A\t2\t70\tNA\tNA\tNA\nNCT04822753\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t11172169|28027366|8208267|7702395|17325518|26218948|26906169|23632051|27906940|27989008|27159318|28509821|27123466|27215861|20117601\tDeyo RA, Weinstein JN. Low back pain. N Engl J Med. 2001 Feb 1;344(5):363-70. Review.|Dieleman JL, Baral R, Birger M, Bui AL, Bulchis A, Chapin A, Hamavid H, Horst C, Johnson EK, Joseph J, Lavado R, Lomsadze L, Reynolds A, Squires E, Campbell M, DeCenso B, Dicker D, Flaxman AD, Gabert R, Highfill T, Naghavi M, Nightingale N, Templin T, Tobias MI, Vos T, Murray CJ. US Spending on Personal Health Care and Public Health, 1996-2013. JAMA. 2016 Dec 27;316(24):2627-2646. doi: 10.1001/jama.2016.16885.|Jensen MC, Brant-Zawadzki MN, Obuchowski N, Modic MT, Malkasian D, Ross JS. Magnetic resonance imaging of the lumbar spine in people without back pain. N Engl J Med. 1994 Jul 14;331(2):69-73.|Schwarzer AC, Wang SC, Bogduk N, McNaught PJ, Laurent R. Prevalence and clinical features of lumbar zygapophysial joint pain: a study in an Australian population with chronic low back pain. Ann Rheum Dis. 1995 Feb;54(2):100-6.|Cohen SP, Raja SN. Pathogenesis, diagnosis, and treatment of lumbar zygapophysial (facet) joint pain. Anesthesiology. 2007 Mar;106(3):591-614. Review.|Manchikanti L, Kaye AD, Boswell MV, Bakshi S, Gharibo CG, Grami V, Grider JS, Gupta S, Jha SS, Mann DP, Nampiaparampil DE, Sharma ML, Shroyer LN, Singh V, Soin A, Vallejo R, Wargo BW, Hirsch JA. A Systematic Review and Best Evidence Synthesis of the Effectiveness of Therapeutic Facet Joint Interventions in Managing Chronic Spinal Pain. Pain Physician. 2015 Jul-Aug;18(4):E535-82. Review.|Vekaria R, Bhatt R, Ellard DR, Henschke N, Underwood M, Sandhu H. Intra-articular facet joint injections for low back pain: a systematic review. Eur Spine J. 2016 Apr;25(4):1266-81. doi: 10.1007/s00586-016-4455-y. Epub 2016 Feb 23. Review.|Lakemeier S, Lind M, Schultz W, Fuchs-Winkelmann S, Timmesfeld N, Foelsch C, Peterlein CD. A comparison of intraarticular lumbar facet joint steroid injections and lumbar facet joint radiofrequency denervation in the treatment of low back pain: a randomized, controlled, double-blind trial. Anesth Analg. 2013 Jul;117(1):228-35. doi: 10.1213/ANE.0b013e3182910c4d. Epub 2013 Apr 30.|Wu J, Du Z, Lv Y, Zhang J, Xiong W, Wang R, Liu R, Zhang G, Liu Q. A New Technique for the Treatment of Lumbar Facet Joint Syndrome Using Intra-articular Injection with Autologous Platelet Rich Plasma. Pain Physician. 2016 Nov-Dec;19(8):617-625.|Wu J, Zhou J, Liu C, Zhang J, Xiong W, Lv Y, Liu R, Wang R, Du Z, Zhang G, Liu Q. A Prospective Study Comparing Platelet-Rich Plasma and Local Anesthetic (LA)/Corticosteroid in Intra-Articular Injection for the Treatment of Lumbar Facet Joint Syndrome. Pain Pract. 2017 Sep;17(7):914-924. doi: 10.1111/papr.12544. Epub 2017 Feb 22.|LaPrade RF, Geeslin AG, Murray IR, Musahl V, Zlotnicki JP, Petrigliano F, Mann BJ. Biologic Treatments for Sports Injuries II Think Tank-Current Concepts, Future Research, and Barriers to Advancement, Part 1: Biologics Overview, Ligament Injury, Tendinopathy. Am J Sports Med. 2016 Dec;44(12):3270-3283. Epub 2016 Mar 29.|Murray IR, Geeslin AG, Goudie EB, Petrigliano FA, LaPrade RF. Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO): Platelet-Rich Plasma and Mesenchymal Stem Cells. J Bone Joint Surg Am. 2017 May 17;99(10):809-819. doi: 10.2106/JBJS.16.00793.|Zlotnicki JP, Geeslin AG, Murray IR, Petrigliano FA, LaPrade RF, Mann BJ, Musahl V. Biologic Treatments for Sports Injuries II Think Tank-Current Concepts, Future Research, and Barriers to Advancement, Part 3: Articular Cartilage. Orthop J Sports Med. 2016 Apr 15;4(4):2325967116642433. doi: 10.1177/2325967116642433. eCollection 2016 Apr.|Hauret KG, Pacha L, Taylor BJ, Jones BH. Surveillance of Disease and Nonbattle Injuries During US Army Operations in Afghanistan and Iraq. US Army Med Dep J. 2016 Apr-Sep;(2-16):15-23.|Hauret KG, Jones BH, Bullock SH, Canham-Chervak M, Canada S. Musculoskeletal injuries description of an under-recognized injury problem among military personnel. Am J Prev Med. 2010 Jan;38(1 Suppl):S61-70. doi: 10.1016/j.amepre.2009.10.021.\t","Facet Joint Pain; Low Back Pain","Platelet Rich Plasma injection to the lumbar facet joint","Crossover Assignment","Treatment","Randomized","Procedure","All","\tPlatelet Rich Plasma (PRP) for Facet Mediated Lumbar Low Back Pain\tInterventional\tNot yet recruiting\tN/A\t2\t170\tback pain|low back pain|arthralgia\tNA\tNA\nNCT04822857\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t28855169\tWang N, Shao H, Chen Y, Xia F, Chi C, Li Q, Han B, Teng Y, Lu Y. Follicle-Stimulating Hormone, Its Association with Cardiometabolic Risk Factors, and 10-Year Risk of Cardiovascular Disease in Postmenopausal Women. J Am Heart Assoc. 2017 Aug 30;6(9). pii: e005918. doi: 10.1161/JAHA.117.005918.\t","Hypertension|Menopause","AMH","NA","NA","NA","Diagnostic Test","Female","\tNA\tNA\tNA\tNA\tNA\tNA\theart failure|hypertension\tNA\tNA\nNCT04823676\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t24187469|30113661|24912386|17081293|19766548|32027858\tMa YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013 Oct 28;19(40):6911-8. doi: 10.3748/wjg.v19.i40.6911. Review.|Loman BR, Hernández-Saavedra D, An R, Rector RS. Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Nutr Rev. 2018 Nov 1;76(11):822-839. doi: 10.1093/nutrit/nuy031.|Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506-14. doi: 10.1038/nrgastro.2014.66. Epub 2014 Jun 10.|Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006 Nov 2;6:33.|Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, Kim YJ, Yoon JH, Cho SH, Sung MW, Lee HS. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010 Jul;42(7):503-8. doi: 10.1016/j.dld.2009.08.002. Epub 2009 Sep 18.|Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, Yilmaz Y, Czernichow S, Zheng MH, Wong VW, Allison M, Tsochatzis E, Anstee QM, Sheridan DA, Eddowes PJ, Guha IN, Cobbold JF, Paradis V, Bedossa P, Miette V, Fournier-Poizat C, Sandrin L, Harrison SA. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020 Apr;5(4):362-373. doi: 10.1016/S2468-1253(19)30383-8. Epub 2020 Feb 3. Erratum in: Lancet Gastroenterol Hepatol. 2020 Apr;5(4):e3.\t","Non Alcoholic Fatty Liver","Probiotic composition|Placebo","Parallel Assignment","Treatment","Randomized","Dietary Supplement|Other","All","\tEfficacy and Safety of a Probiotic Composition as Adjunct in MAFL Management\tInterventional\tRecruiting\tN/A\t2\t100\tfatty liver|non-alcoholic fatty liver disease\tNA\tNA\nNCT04823806\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t19801973|29371440|23332541|28529316|26254058\tEisenberg T, Knauer H, Schauer A, Büttner S, Ruckenstuhl C, Carmona-Gutierrez D, Ring J, Schroeder S, Magnes C, Antonacci L, Fussi H, Deszcz L, Hartl R, Schraml E, Criollo A, Megalou E, Weiskopf D, Laun P, Heeren G, Breitenbach M, Grubeck-Loebenstein B, Herker E, Fahrenkrog B, Fröhlich KU, Sinner F, Tavernarakis N, Minois N, Kroemer G, Madeo F. Induction of autophagy by spermidine promotes longevity. Nat Cell Biol. 2009 Nov;11(11):1305-14. doi: 10.1038/ncb1975. Epub 2009 Oct 4.|Madeo F, Eisenberg T, Pietrocola F, Kroemer G. Spermidine in health and disease. Science. 2018 Jan 26;359(6374). pii: eaan2788. doi: 10.1126/science.aan2788. Review.|Fond G, Macgregor A, Leboyer M, Michalsen A. Fasting in mood disorders: neurobiology and effectiveness. A review of the literature. Psychiatry Res. 2013 Oct 30;209(3):253-8. doi: 10.1016/j.psychres.2012.12.018. Epub 2013 Jan 15. Review.|Galluzzi L, Bravo-San Pedro JM, Levine B, Green DR, Kroemer G. Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat Rev Drug Discov. 2017 Jul;16(7):487-511. doi: 10.1038/nrd.2017.22. Epub 2017 May 19. Review.|Jia J, Le W. Molecular network of neuronal autophagy in the pathophysiology and treatment of depression. Neurosci Bull. 2015 Aug;31(4):427-34. doi: 10.1007/s12264-015-1548-2. Epub 2015 Aug 8.\t","Depression|Healthy","Spermidine (spermidineLIFE ®) OR Placebo","Parallel Assignment","Basic Science","Randomized","Dietary Supplement","All","\tAn Exploratory Clinical Study on Autophagy and Multi-level Molecular Profiling During Spermidine Supplementation\tInterventional\tRecruiting\tN/A\t2\t80\tdepression\tNA\tNA\nNCT04824664\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t33017138\tFransvea P, Sganga G, Cozza V, Di Grezia M, Fico V, Tirelli F, Pepe G, La Greca A. Set up of a dedicated COVID-19 surgical pathway and operating room for surgical emergencies. J Trauma Acute Care Surg. 2020 Oct;89(4):e97-e100. doi: 10.1097/TA.0000000000002852.\t","Surgery and covid19","survey","NA","NA","NA","Other","All","\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\nNCT04825028\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t33391020\tAi H, Feng Y, Gong Y, Zheng B, Jin Q, Zhang HP, Sun F, Li J, Chen Y, Huo Y, Huo Y. Coronary Angiography-Derived Index of Microvascular Resistance. Front Physiol. 2020 Dec 16;11:605356. doi: 10.3389/fphys.2020.605356. eCollection 2020.\t","Coronary Microvascular Dysfunction|Myocardial Ischemia","Angiography-drived Index of Microcirculatory Resistance","NA","NA","NA","Device","All","\tNA\tNA\tNA\tNA\tNA\tNA\tmyocardial ischemia|ischemia\tNA\tNA\nNCT04825249\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t32663065|30153852|31147110\tTakeuchi Y, Sugaya H, Takahashi N, Matsuki K, Tokai M, Morioka T, Ueda Y, Hoshika S. Repair Integrity and Retear Pattern After Arthroscopic Medial Knot-Tying After Suture-Bridge Lateral Row Rotator Cuff Repair. Am J Sports Med. 2020 Aug;48(10):2510-2517. doi: 10.1177/0363546520934786. Epub 2020 Jul 14.|Kim KC, Shin HD, Lee WY, Yeon KW, Han SC. Clinical outcomes and repair integrity of arthroscopic rotator cuff repair using suture-bridge technique with or without medial tying: prospective comparative study. J Orthop Surg Res. 2018 Aug 28;13(1):212. doi: 10.1186/s13018-018-0921-z.|Dukan R, Ledinot P, Donadio J, Boyer P. Arthroscopic Rotator Cuff Repair With a Knotless Suture Bridge Technique: Functional and Radiological Outcomes After a Minimum Follow-Up of 5 Years. Arthroscopy. 2019 Jul;35(7):2003-2011. doi: 10.1016/j.arthro.2019.02.028. Epub 2019 May 27.\t","Rotator Cuff Tears","traditional suture bridge technique|modified suture bridge technique","Parallel Assignment","Treatment","Randomized","Procedure|Procedure","All","\tA New Modified Suture Bridge Technique\tInterventional\tCompleted\tN/A\t2\t50\trotator cuff injuries\tNA\tNA\nNCT04825639\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t15636651\tGoldstein B, Giroir B, Randolph A; International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005 Jan;6(1):2-8. Review.\t","Acute Kidney Injury|Diabetic Ketoacidosis|Sepsis","No intervention","NA","NA","NA","Other","All","\tNA\tNA\tNA\tNA\tNA\tNA\tacute kidney injury|sepsis|toxemia|diabetic ketoacidosis|ketosis\tNA\tNA\nNCT04825951\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t11357217\tWorld Medical Association. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ. 2001;79(4):373-4. Epub 2003 Jul 2.\t","Malocclusion, Angle Class III","CS 2000","Parallel Assignment","Treatment","Randomized","Other","All","\tDentofacial Effects Of Two Non-Compliance Appliances In The Treatment Of Growing Skeletal Class III Patients\tInterventional\tRecruiting\tN/A\t3\t33\tprognathism|malocclusion, angle class iii|malocclusion\tNA\tNA\nNCT04826497\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t28886621|12607706|31147987|31118574|28966311|15791442|29495982\tIbanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018 Jan 7;39(2):119-177. doi: 10.1093/eurheartj/ehx393.|Piper HM, Meuter K, Schäfer C. Cellular mechanisms of ischemia-reperfusion injury. Ann Thorac Surg. 2003 Feb;75(2):S644-8. Review.|Ji Z, Zhang R, Lu W, Ma G, Qu Y. The effect of nicorandil in patients with acute myocardial infarction undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Ir J Med Sci. 2020 Feb;189(1):119-131. doi: 10.1007/s11845-019-02034-3. Epub 2019 May 30.|Xu L, Wang L, Li K, Zhang Z, Sun H, Yang X. Nicorandil prior to primary percutaneous coronary intervention improves clinical outcomes in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2019 Apr 29;13:1389-1400. doi: 10.2147/DDDT.S195918. eCollection 2019. Review.|Fukui Y, Nozawa T, Ihori H, Sobajima M, Nakadate T, Matsuki A, Nonomura M, Fujii N, Inoue H, Kinugawa K. Nicorandil Attenuates Ischemia-Reperfusion Injury Via Inhibition of Norepinephrine Release From Cardiac Sympathetic Nerve Terminals. Int Heart J. 2017 Oct 21;58(5):787-793. doi: 10.1536/ihj.16-391. Epub 2017 Sep 30.|Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Effects of nicorandil on cardiac sympathetic nerve activity after reperfusion therapy in patients with first anterior acute myocardial infarction. Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):322-8. Epub 2004 Oct 2.|Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Thanh Hai MT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ; Standardized Data Collection for Cardiovascular Trials Initiative (SCTI). 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. J Am Coll Cardiol. 2018 Mar 6;71(9):1021-1034. doi: 10.1016/j.jacc.2017.12.048. Review.\t","Coronary Heart Disease","nicorandil|Placebo（normal saline）","Parallel Assignment","Prevention","Randomized","Drug|Drug","All","\tEffect of Nicorandil on Cardiac Sympathetic Nerve for the Patients of Acute ST Segment Elevation Myocardial Infarction\tInterventional\tNot yet recruiting\tPhase 4\t2\t80\tmyocardial ischemia|coronary artery disease|coronary disease|st elevation myocardial infarction|infarction|myocardial infarction|heart diseases\tnicorandil\tNA\nNCT04827329\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t30540615|30882519|33393604|20463578\tHershner S, Kakkar R, Chung F, Singh M, Wong J, Auckley D. Narcolepsy, Anesthesia, and Sedation: A Survey of the Perioperative Experience of Patients With Narcolepsy. Anesth Analg. 2019 Nov;129(5):1374-1380. doi: 10.1213/ANE.0000000000003954.|Hershner S, Dauvilliers Y, Chung F, Singh M, Wong J, Gali B, Kakkar R, Mignot E, Thorpy M, Auckley D. Knowledge Gaps in the Perioperative Management of Adults With Narcolepsy: A Call for Further Research. Anesth Analg. 2019 Jul;129(1):204-211. doi: 10.1213/ANE.0000000000004088. Review.|Ohshita N, Yamagata K, Himejima A, Kaneda K, Yasutome T, Matsuda Y, Tsutsumi YM, Momota Y. Anesthetic Management of a Patient With Restless Legs Syndrome: A Case Report. Anesth Prog. 2020 Dec 1;67(4):226-229. doi: 10.2344/anpr-67-02-10.|Raux M, Karroum EG, Arnulf I. Case scenario: anesthetic implications of restless legs syndrome. Anesthesiology. 2010 Jun;112(6):1511-7. doi: 10.1097/ALN.0b013e3181de2d66. Review.\t","Idiopathic Hypersomnia|Narcolepsy|Restless Legs Syndrome","Questionnaire","NA","NA","NA","Other","All","\tNA\tNA\tNA\tNA\tNA\tNA\tsleep wake disorders|hypersomnolence, idiopathic|disorders of excessive somnolence|restless legs syndrome|narcolepsy|parasomnias\tNA\tNA\nNCT04827602\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t29800754|29678929|28370003\tLachover-Roth I, Sharon S, Rosman Y, Meir-Shafrir K, Confino-Cohen R. Long-Term Follow-Up After Penicillin Allergy Delabeling in Ambulatory Patients. J Allergy Clin Immunol Pract. 2019 Jan;7(1):231-235.e1. doi: 10.1016/j.jaip.2018.04.042. Epub 2018 May 22.|Vyles D, Chiu A, Routes J, Castells M, Phillips EJ, Kibicho J, Brousseau DC. Antibiotic Use After Removal of Penicillin Allergy Label. Pediatrics. 2018 May;141(5). pii: e20173466. doi: 10.1542/peds.2017-3466.|Sacco KA, Bates A, Brigham TJ, Imam JS, Burton MC. Clinical outcomes following inpatient penicillin allergy testing: A systematic review and meta-analysis. Allergy. 2017 Sep;72(9):1288-1296. doi: 10.1111/all.13168. Epub 2017 Apr 26. Review.\t","Drug Hypersensitivity","Drug allergy label status in electronic health records","NA","NA","NA","Other","All","\tNA\tNA\tNA\tNA\tNA\tNA\thypersensitivity|drug hypersensitivity\tNA\tNA\nNCT04827641\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t33353740\tZoeller C, Kuebler JF, Ure BM, Brendel J. Incidence of complications, organizational problems, and errors: Unexpected events in 1605 patients. J Pediatr Surg. 2020 Dec 13. pii: S0022-3468(20)30899-X. doi: 10.1016/j.jpedsurg.2020.12.004. [Epub ahead of print]\t","Complication of Surgical Procedure","Severity Grading assessment in children with perioperative unexpected events","NA","NA","NA","Other","All","\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\nNCT04827654\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t27334234|27471022|30024798\tOlsho LE, Klerman JA, Wilde PE, Bartlett S. Financial incentives increase fruit and vegetable intake among Supplemental Nutrition Assistance Program participants: a randomized controlled trial of the USDA Healthy Incentives Pilot. Am J Clin Nutr. 2016 Aug;104(2):423-35. doi: 10.3945/ajcn.115.129320. Epub 2016 Jun 22.|Sharma SV, Markham C, Chow J, Ranjit N, Pomeroy M, Raber M. Evaluating a school-based fruit and vegetable co-op in low-income children: A quasi-experimental study. Prev Med. 2016 Oct;91:8-17. doi: 10.1016/j.ypmed.2016.07.022. Epub 2016 Jul 25.|Seligman HK, Smith M, Rosenmoss S, Marshall MB, Waxman E. Comprehensive Diabetes Self-Management Support From Food Banks: A Randomized Controlled Trial. Am J Public Health. 2018 Sep;108(9):1227-1234. doi: 10.2105/AJPH.2018.304528. Epub 2018 Jul 19.\t","Diet, Healthy","Weekly produce box and gift card","Parallel Assignment","Health Services Research","Randomized","Dietary Supplement","All","\tIncreasing Adoption of Fruits and Vegetables Into Family Diet\tInterventional\tRecruiting\tN/A\t2\t120\tNA\tNA\tNA\nNCT04827784\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t23229236\tNascimento MM, Vasconcelos BC, Porto GG, Ferdinanda G, Nogueira CM, Raimundo RD. Physical therapy and anesthetic blockage for treating temporomandibular disorders: a clinical trial. Med Oral Patol Oral Cir Bucal. 2013 Jan 1;18(1):e81-5.\t","Arthralgia of TMJ|Temporomandibular Joint Disorders","local anaesthetic injection","NA","NA","NA","Procedure","All","\tNA\tNA\tNA\tNA\tNA\tNA\ttemporomandibular joint disorders|arthralgia|temporomandibular joint dysfunction syndrome|joint diseases|disease\tanesthetics|anesthetics, local\tNA\nNCT04827823\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t8258583|19085213|22546263|24683067|23550914|26091581|28513897\tMjör IA, Jokstad A. Five-year study of Class II restorations in permanent teeth using amalgam, glass polyalkenoate (ionomer) cerment and resin-based composite materials. J Dent. 1993 Dec;21(6):338-43.|Vidnes-Kopperud S, Tveit AB, Gaarden T, Sandvik L, Espelid I. Factors influencing dentists' choice of amalgam and tooth-colored restorative materials for Class II preparations in younger patients. Acta Odontol Scand. 2009;67(2):74-9. doi: 10.1080/00016350802577800.|Correa MB, Peres MA, Peres KG, Horta BL, Barros AD, Demarco FF. Amalgam or composite resin? Factors influencing the choice of restorative material. J Dent. 2012 Sep;40(9):703-10. doi: 10.1016/j.jdent.2012.04.020. Epub 2012 Apr 28.|Rasines Alcaraz MG, Veitz-Keenan A, Sahrmann P, Schmidlin PR, Davis D, Iheozor-Ejiofor Z. Direct composite resin fillings versus amalgam fillings for permanent or adult posterior teeth. Cochrane Database Syst Rev. 2014 Mar 31;(3):CD005620. doi: 10.1002/14651858.CD005620.pub2. Review.|Rho YJ, Namgung C, Jin BH, Lim BS, Cho BH. Longevity of direct restorations in stress-bearing posterior cavities: a retrospective study. Oper Dent. 2013 Nov-Dec;38(6):572-82. doi: 10.2341/12-432-C. Epub 2013 Apr 3.|Beck F, Lettner S, Graf A, Bitriol B, Dumitrescu N, Bauer P, Moritz A, Schedle A. Survival of direct resin restorations in posterior teeth within a 19-year period (1996-2015): A meta-analysis of prospective studies. Dent Mater. 2015 Aug;31(8):958-85. doi: 10.1016/j.dental.2015.05.004. Epub 2015 Jun 16. Review.|Borgia E, Baron R, Borgia JL. Quality and Survival of Direct Light-Activated Composite Resin Restorations in Posterior Teeth: A 5- to 20-Year Retrospective Longitudinal Study. J Prosthodont. 2019 Jan;28(1):e195-e203. doi: 10.1111/jopr.12630. Epub 2017 May 17. Review.\t","Dental Caries Class II","Retrospective evaluation of amalgam and composite restorations","NA","NA","NA","Other","All","\tNA\tNA\tNA\tNA\tNA\tNA\tdental caries\tNA\tNA\nNCT04828369\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t30697445|25435990|28542116|19159076|10934332|25519690|27786365|32028533\tBoregowda U, Umapathy C, Halim N, Desai M, Nanjappa A, Arekapudi S, Theethira T, Wong H, Roytman M, Saligram S. Update on the management of gastrointestinal varices. World J Gastrointest Pharmacol Ther. 2019 Jan 21;10(1):1-21. doi: 10.4292/wjgpt.v10.i1.1. Review.|Wu Q, Shen L, Chu J, Ma X, Jin B, Meng F, Chen J, Wang Y, Wu L, Han J, Zhang W, Ma W, Wang H, Li H. Characterization of uncommon portosystemic collateral circulations in patients with hepatic cirrhosis. Oncol Lett. 2015 Jan;9(1):347-350. Epub 2014 Oct 22.|Qi X, Qi X, Zhang Y, Shao X, Wu C, Wang Y, Wang R, Zhang X, Deng H, Hou F, Li J, Guo X. Prevalence and Clinical Characteristics of Spontaneous Splenorenal Shunt in Liver Cirrhosis: A Retrospective Observational Study Based on Contrast-Enhanced Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) Scans. Med Sci Monit. 2017 May 25;23:2527-2534.|Zardi EM, Uwechie V, Caccavo D, Pellegrino NM, Cacciapaglia F, Di Matteo F, Dobrina A, Laghi V, Afeltra A. Portosystemic shunts in a large cohort of patients with liver cirrhosis: detection rate and clinical relevance. J Gastroenterol. 2009;44(1):76-83. doi: 10.1007/s00535-008-2279-1. Epub 2009 Jan 22.|von Herbay A, Frieling T, Häussinger D. Color Doppler sonographic evaluation of spontaneous portosystemic shunts and inversion of portal venous flow in patients with cirrhosis. J Clin Ultrasound. 2000 Sep;28(7):332-9.|Park JK, Saab S, Kee ST, Busuttil RW, Kim HJ, Durazo F, Cho SK, Lee EW. Balloon-Occluded Retrograde Transvenous Obliteration (BRTO) for Treatment of Gastric Varices: Review and Meta-Analysis. Dig Dis Sci. 2015 Jun;60(6):1543-53. doi: 10.1007/s10620-014-3485-8. Epub 2014 Dec 18. Review.|Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017 Jan;65(1):310-335. doi: 10.1002/hep.28906. Epub 2016 Dec 1. Erratum in: Hepatology. 2017 Jul;66(1):304.|Mohan BP, Chandan S, Khan SR, Kassab LL, Trakroo S, Ponnada S, Asokkumar R, Adler DG. Efficacy and safety of endoscopic ultrasound-guided therapy versus direct endoscopic glue injection therapy for gastric varices: systematic review and meta-analysis. Endoscopy. 2020 Apr;52(4):259-267. doi: 10.1055/a-1098-1817. Epub 2020 Feb 6.\t","Gastric Varix|Liver Cirrhosis|Portal Hypertension|Portosystemic Shunt","EUS-guided coil embolization combined with endoscopic cyanoacrylate injection|balloon-occluded retrograde transvenous obliteration","NA","NA","NA","Procedure|Procedure","All","\tNA\tNA\tNA\tNA\tNA\tNA\tliver cirrhosis|hypertension, portal|esophageal and gastric varices\tNA\tNA\nNCT04828668\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t16918457|18422832|20191092|22420307|28861491|21532172|32784198\tLu D, Vemuri VK, Duclos RI Jr, Makriyannis A. The cannabinergic system as a target for anti-inflammatory therapies. Curr Top Med Chem. 2006;6(13):1401-26. Review.|Moreira FA, Lutz B. The endocannabinoid system: emotion, learning and addiction. Addict Biol. 2008 Jun;13(2):196-212. doi: 10.1111/j.1369-1600.2008.00104.x. Epub 2008 Apr 16. Review.|Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009 Oct;1(7):1333-49. doi: 10.4155/fmc.09.93. Review.|Pini A, Mannaioni G, Pellegrini-Giampietro D, Passani MB, Mastroianni R, Bani D, Masini E. The role of cannabinoids in inflammatory modulation of allergic respiratory disorders, inflammatory pain and ischemic stroke. Curr Drug Targets. 2012 Jun;13(7):984-93. Review.|Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis Cannabinoid Res. 2016 Jul 1;1(1):154-165. doi: 10.1089/can.2016.0009. eCollection 2016. Review.|Ruhaak LR, Felth J, Karlsson PC, Rafter JJ, Verpoorte R, Bohlin L. Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa. Biol Pharm Bull. 2011;34(5):774-8.|Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020 Aug 11;370:m3026. doi: 10.1136/bmj.m3026.\t","Covid 19","Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)","Crossover Assignment","Other","Randomized","Dietary Supplement","All","\tStudy to Evaluate Benefits & Safety of Endourage Formula C™ Oral Drops in People With Post-Acute COVID-19 Syndrome.\tInterventional\tRecruiting\tN/A\t2\t60\tNA\tNA\tNA\nNCT04828967\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t12822290|22866186|21297474|26156064|22419342|23550694|22805267|30342643\tPhilip B. Hyperemesis gravidarum: literature review. WMJ. 2003;102(3):46-51. Review.|Wegrzyniak LJ, Repke JT, Ural SH. Treatment of hyperemesis gravidarum. Rev Obstet Gynecol. 2012;5(2):78-84.|Tan PC, Omar SZ. Contemporary approaches to hyperemesis during pregnancy. Curr Opin Obstet Gynecol. 2011 Apr;23(2):87-93. doi: 10.1097/GCO.0b013e328342d208. Review.|Ergin M, Cendek BD, Neselioglu S, Avsar AF, Erel O. Dynamic thiol-disulfide homeostasis in hyperemesis gravidarum. J Perinatol. 2015 Oct;35(10):788-92. doi: 10.1038/jp.2015.81. Epub 2015 Jul 9.|Jones L, Othman M, Dowswell T, Alfirevic Z, Gates S, Newburn M, Jordan S, Lavender T, Neilson JP. Pain management for women in labour: an overview of systematic reviews. Cochrane Database Syst Rev. 2012 Mar 14;(3):CD009234. doi: 10.1002/14651858.CD009234.pub2. Review.|Werner A, Uldbjerg N, Zachariae R, Nohr EA. Effect of self-hypnosis on duration of labor and maternal and neonatal outcomes: a randomized controlled trial. Acta Obstet Gynecol Scand. 2013 Jul;92(7):816-23. doi: 10.1111/aogs.12141. Epub 2013 Apr 22.|Longo F, Mansueto G, Lapadula V, Stumbo L, Del Bene G, Adua D, De Filippis L, Bonizzoni E, Quadrini S. Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy. Int J Clin Pract. 2012 Aug;66(8):753-757. doi: 10.1111/j.1742-1241.2012.02969.x. Epub 2012 Jul 2.|Emami-Sahebi A, Elyasi F, Yazdani-Charati J, Shahhosseini Z. Psychological interventions for nausea and vomiting of pregnancy: A systematic review. Taiwan J Obstet Gynecol. 2018 Oct;57(5):644-649. doi: 10.1016/j.tjog.2018.08.005.\t","Hyperemesis Gravidarum|Nausea|Vomiting","Hypnosis","Parallel Assignment","Treatment","Randomized","Other","Female","\tUse of Hypnosis in Hyperemesis Gravidarum\tInterventional\tCompleted\tN/A\t2\t41\thyperemesis gravidarum|vomiting|nausea\tNA\tNA\nNCT04829942\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t3644262\tWalker SN, Sechrist KR, Pender NJ. The Health-Promoting Lifestyle Profile: development and psychometric characteristics. Nurs Res. 1987 Mar-Apr;36(2):76-81.\t","Health Literacy|School Health","positive health behavior","Parallel Assignment","Supportive Care","Randomized","Behavioral","All","\tEvaluation of the Effectiveness of \"\"School Health Nursing Program\"\" Implemented Under the Leadership of Nurse\"","Interventional","Not yet recruiting","N/A",2,60,"NA","NA","NA"]
["NCT04830189","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21430513|14523741|2059138|3399517|16492635|27184582|15674917|28145396","Kalichman L, Ratmansky M. Underlying pathology and associated factors of hemiplegic shoulder pain. Am J Phys Med Rehabil. 2011 Sep;90(9):768-80. doi: 10.1097/PHM.0b013e318214e976. Review.|Zorowitz RD. Recovery patterns of shoulder subluxation after stroke: a six-month follow-up study. Top Stroke Rehabil. 2001 Summer;8(2):1-9.|Brooke MM, de Lateur BJ, Diana-Rigby GC, Questad KA. Shoulder subluxation in hemiplegia: effects of three different supports. Arch Phys Med Rehabil. 1991 Jul;72(8):582-6.|Williams R, Taffs L, Minuk T. Evaluation of two support methods for the subluxated shoulder of hemiplegic patients. Phys Ther. 1988 Aug;68(8):1209-14. Erratum in: Phys Ther 1988 Dec;68(12):1969.|Turner-Stokes L, Jackson D. Assessment of shoulder pain in hemiplegia: sensitivity of the ShoulderQ. Disabil Rehabil. 2006 Mar 30;28(6):389-95.|Nadler M, Pauls M. Shoulder orthoses for the prevention and reduction of hemiplegic shoulder pain and subluxation: systematic review. Clin Rehabil. 2017 Apr;31(4):444-453. doi: 10.1177/0269215516648753. Epub 2016 Jul 10. Review.|Ada L, Foongchomcheay A, Canning C. Supportive devices for preventing and treating subluxation of the shoulder after stroke. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003863. Review.|van Bladel A, Lambrecht G, Oostra KM, Vanderstraeten G, Cambier D. A randomized controlled trial on the immediate and long-term effects of arm slings on shoulder subluxation in stroke patients. Eur J Phys Rehabil Med. 2017 Jun;53(3):400-409. doi: 10.23736/S1973-9087.17.04368-4. Epub 2017 Jan 30.","\tHemiplegia|Rehabilitation\tshoulder sling|forearm sling\tParallel Assignment\tTreatment\tRandomized\tDevice|Device\tAll\t","The Effectiveness of Two Different Types of Shoulder Slings in Stroke","Interventional","Completed","N/A",2,32,"hemiplegia","NA","NA"]
["NCT04830670","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32233183|32233185|23968289|20450402","Stacchi C, Spinato S, Lombardi T, Bernardello F, Bertoldi C, Zaffe D, Nevins M. Minimally Invasive Management of Implant-Supported Rehabilitation in the Posterior Maxilla, Part I. Sinus Floor Elevation: Biologic Principles and Materials. Int J Periodontics Restorative Dent. 2020 May/Jun;40(3):e85-e93. doi: 10.11607/prd.4497.|Stacchi C, Spinato S, Lombardi T, Bernardello F, Bertoldi C, Zaffe D, Nevins M. Minimally Invasive Management of Implant-Supported Rehabilitation in the Posterior Maxilla, Part II. Surgical Techniques and Decision Tree. Int J Periodontics Restorative Dent. 2020 May/Jun;40(3):e95-e102. doi: 10.11607/prd.4498.|Stacchi C, Vercellotti T, Toschetti A, Speroni S, Salgarello S, Di Lenarda R. Intraoperative complications during sinus floor elevation using two different ultrasonic approaches: a two-center, randomized, controlled clinical trial. Clin Implant Dent Relat Res. 2015 Jan;17 Suppl 1:e117-25. doi: 10.1111/cid.12136. Epub 2013 Aug 22.|Avila G, Wang HL, Galindo-Moreno P, Misch CE, Bagramian RA, Rudek I, Benavides E, Moreno-Riestra I, Braun T, Neiva R. The influence of the bucco-palatal distance on sinus augmentation outcomes. J Periodontol. 2010 Jul;81(7):1041-50. doi: 10.1902/jop.2010.090686.","\tAlveolar Bone Resorption\tsinus floor elevation with lateral approach\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","bone resorption","NA","NA"]
["NCT04830943","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32253535,"Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, Dequanter D, Blecic S, El Afia F, Distinguin L, Chekkoury-Idrissi Y, Hans S, Delgado IL, Calvo-Henriquez C, Lavigne P, Falanga C, Barillari MR, Cammaroto G, Khalife M, Leich P, Souchay C, Rossi C, Journe F, Hsieh J, Edjlali M, Carlier R, Ris L, Lovato A, De Filippis C, Coppee F, Fakhry N, Ayad T, Saussez S. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261. doi: 10.1007/s00405-020-05965-1. Epub 2020 Apr 6.","\tCovid19 Related Anosmia and Aguesia\tCerebrolysin\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","olfaction disorders","cerebrolysin","NA"]
["NCT04831931","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","3785962|21621130|31272309|18558277|25892374|1834753|15371043|NA|NA|NA","Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain. 1986 Oct;27(1):117-126. doi: 10.1016/0304-3959(86)90228-9.|Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, Fainsinger R, Aass N, Kaasa S; European Palliative Care Research Collaborative (EPCRC). Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 2011 Jun;41(6):1073-93. doi: 10.1016/j.jpainsymman.2010.08.016. Review.|Mani S, Sharma S, Singh DK. Concurrent validity and reliability of telerehabilitation-based physiotherapy assessment of cervical spine in adults with non-specific neck pain. J Telemed Telecare. 2021 Feb;27(2):88-97. doi: 10.1177/1357633X19861802. Epub 2019 Jul 4.|Edmondston SJ, Wallumrød ME, Macléid F, Kvamme LS, Joebges S, Brabham GC. Reliability of isometric muscle endurance tests in subjects with postural neck pain. J Manipulative Physiol Ther. 2008 Jun;31(5):348-54. doi: 10.1016/j.jmpt.2008.04.010.|Sebastian D, Chovvath R, Malladi R. Cervical extensor endurance test: a reliability study. J Bodyw Mov Ther. 2015 Apr;19(2):213-6. doi: 10.1016/j.jbmt.2014.04.014. Epub 2014 Apr 18.|Vernon H, Mior S. The Neck Disability Index: a study of reliability and validity. J Manipulative Physiol Ther. 1991 Sep;14(7):409-15. Erratum in: J Manipulative Physiol Ther 1992 Jan;15(1):followi.|Bicer A, Yazici A, Camdeviren H, Erdogan C. Assessment of pain and disability in patients with chronic neck pain: reliability and construct validity of the Turkish version of the neck pain and disability scale. Disabil Rehabil. 2004 Aug 19;26(16):959-62.|Aydemir Ö., Köroğlu E., Psikiyatride Kullanılan Klinik Ölçekler. 3'üncü baskı. Ankara. Hekimler Yayın Birliği , 2007; 346-353|Eser E, Fidaner H, Fidaner C, Eser SY ve ark. Psychometric properties of WHOQOL-100 and WHOQOL-BREF. 3P Dergisi 1999;7(2 Suppl.):23-40|Eser SY, Fidaner H, Fidaner C, Elbi H ve ark. Measure of quality of life WHOQOL-100 and WHOQOL-Bref. 3P Dergisi 1999;7(2 Suppl.):5-13.","\tNeck Pain\tExercise Program Applied by Telerehabilitation\tParallel Assignment\tTreatment\tRandomized\tOther\tAll\t","The Effectiveness of the Exercise Program Applied by Telerehabilitation Method in Individuals With Chronic Neck Pain","Interventional","Completed","N/A",3,66,"neck pain","NA","NA"]
["NCT04831970","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30307776|21656740|33482863|17869014|33227441|30605751|30464605|26867889|31291969","Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H. Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. J Clin Oncol. 2018 Oct 11:JCO1801097. doi: 10.1200/JCO.18.01097. [Epub ahead of print]|Kruser TJ, Jarrard DF, Graf AK, Hedican SP, Paolone DR, Wegenke JD, Liu G, Geye HM, Ritter MA. Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer. 2011 Jun 15;117(12):2629-36. doi: 10.1002/cncr.25824. Epub 2010 Dec 14.|Bell LJ, Eade T, Hruby G, Bromley R, Kneebone A. Intra-fraction displacement of the prostate bed during post-prostatectomy radiotherapy. Radiat Oncol. 2021 Jan 22;16(1):20. doi: 10.1186/s13014-020-01743-9.|Wong GW, Palazzi-Churas KL, Jarrard DF, Paolone DR, Graf AK, Hedican SP, Wegenke JD, Ritter MA. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):449-55. Epub 2007 Sep 14.|Wages NA, Sanders JC, Smith A, Wood S, Anscher MS, Varhegyi N, Krupski TL, Harris TJ, Showalter TN. Hypofractionated Postprostatectomy Radiation Therapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase 1/2 Trial. Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1254-1262. doi: 10.1016/j.ijrobp.2020.11.009. Epub 2020 Nov 21.|Ballas LK, Luo C, Chung E, Kishan AU, Shuryak I, Quinn DI, Dorff T, Jhimlee S, Chiu R, Abreu A, Jennelle R, Aron M, Groshen S. Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy. Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):50-60. doi: 10.1016/j.ijrobp.2018.12.047. Epub 2018 Dec 31.|Cuccia F, Mortellaro G, Serretta V, Valenti V, Tripoli A, Gueci M, Luca N, Lo Casto A, Ferrera G. Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes. Cancer Manag Res. 2018 Oct 29;10:5053-5060. doi: 10.2147/CMAR.S182016. eCollection 2018.|Lewis SL, Patel P, Song H, Freedland SJ, Bynum S, Oh D, Palta M, Yoo D, Oleson J, Salama JK. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):605-11. doi: 10.1016/j.ijrobp.2015.11.025. Epub 2015 Dec 2.|Koerber SA, Katayama S, Sander A, Jaekel C, Haefner MF, Debus J, Herfarth K. Prostate bed irradiation with alternative radio-oncological approaches (PAROS) - a prospective, multicenter and randomized phase III trial. Radiat Oncol. 2019 Jul 10;14(1):122. doi: 10.1186/s13014-019-1325-x.","\tRadiation Toxicity\tNA\tNA\tNA\tNA\tNA\tMale\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04832126","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA|21810866|15898165|27916777|16009809|24076289|NA|28146053|22995932|23128497|21459272|20513597|22000298|27993330|19926015|22715240|21403098|23994779|25741868|11136691|15454078|7889574|19017345","Abriel, H., & Zaklyazminskaya, E. V. (2013). Cardiac channelopathies: Genetic andmolecular mechanisms. Gene. https://doi.org/10.1016/j.gene.2012.12.061|Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, Gollob M, Hamilton R, Hershberger RE, Judge DP, Le Marec H, McKenna WJ, Schulze-Bahr E, Semsarian C, Towbin JA, Watkins H, Wilde A, Wolpert C, Zipes DP; Heart Rhythm Society (HRS); European Heart Rhythm Association (EHRA). HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011 Aug;13(8):1077-109. doi: 10.1093/europace/eur245. Erratum in: Europace. 2012 Feb;14(2):277. Probst, Vincent [added]; Schwartz, Peter J [added]; Kääb, Stefan [added]; Kirchhof, Paulus [added].|Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, Gussak I, LeMarec H, Nademanee K, Perez Riera AR, Shimizu W, Schulze-Bahr E, Tan H, Wilde A. Brugada syndrome: report of the second consensus conference. Heart Rhythm. 2005 Apr;2(4):429-40. Review. Erratum in: Heart Rhythm. 2005 Aug;2(8):905.|Bezzerides VJ, Zhang D, Pu WT. Modeling Inherited Arrhythmia Disorders Using Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Circ J. 2016 Dec 22;81(1):12-21. doi: 10.1253/circj.CJ-16-1113. Epub 2016 Dec 3. Review.|Brugada P, Brugada R, Brugada J. Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? Circulation. 2005 Jul 12;112(2):279-92; discussion 279-92.|Chugh SS, Huertas-Vazquez A. Inherited arrhythmia syndromes: exome sequencing opens a new door to diagnosis. J Am Coll Cardiol. 2014 Jan 28;63(3):267-8. doi: 10.1016/j.jacc.2013.07.089. Epub 2013 Sep 25.|Coumel P, Fidelle J, Lucet V, et al. Catecholamine-induced severe ventricular arrhythmias with Adams-Stokes syndrome in children: report of four cases. Br Heart J 1978;40(Suppl):28-37|Fernández-Falgueras A, Sarquella-Brugada G, Brugada J, Brugada R, Campuzano O. Cardiac Channelopathies and Sudden Death: Recent Clinical and Genetic Advances. Biology (Basel). 2017 Jan 29;6(1). pii: E7. doi: 10.3390/biology6010007. Review.|Giudicessi JR, Ackerman MJ. Determinants of incomplete penetrance and variable expressivity in heritable cardiac arrhythmia syndromes. Transl Res. 2013 Jan;161(1):1-14. doi: 10.1016/j.trsl.2012.08.005. Epub 2012 Sep 17. Review.|Giudicessi JR, Ackerman MJ. Genetic testing in heritable cardiac arrhythmia syndromes: differentiating pathogenic mutations from background genetic noise. Curr Opin Cardiol. 2013 Jan;28(1):63-71. doi: 10.1097/HCO.0b013e32835b0a41. Review.|Gollob MH, Blier L, Brugada R, Champagne J, Chauhan V, Connors S, Gardner M, Green MS, Gow R, Hamilton R, Harris L, Healey JS, Hodgkinson K, Honeywell C, Kantoch M, Kirsh J, Krahn A, Mullen M, Parkash R, Redfearn D, Rutberg J, Sanatani S, Woo A. Recommendations for the use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position paper. Can J Cardiol. 2011 Mar-Apr;27(2):232-45. doi: 10.1016/j.cjca.2010.12.078. Review.|Hofman N, Tan HL, Alders M, van Langen IM, Wilde AA. Active cascade screening in primary inherited arrhythmia syndromes: does it lead to prophylactic treatment? J Am Coll Cardiol. 2010 Jun 8;55(23):2570-6. doi: 10.1016/j.jacc.2009.12.063.|Ingles J, Zodgekar PR, Yeates L, Macciocca I, Semsarian C, Fatkin D; CSANZ Cardiac Genetic Diseases Council Writing Group. Guidelines for genetic testing of inherited cardiac disorders. Heart Lung Circ. 2011 Nov;20(11):681-7. doi: 10.1016/j.hlc.2011.07.013. Review.|Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, Nikiforova MN. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017 Jan;19(1):4-23. doi: 10.1016/j.jmoldx.2016.10.002. Review.|Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, Hofman N, Bikker H, van Tintelen JP, Mannens MM, Wilde AA, Ackerman MJ. The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis. J Am Coll Cardiol. 2009 Nov 24;54(22):2065-74. doi: 10.1016/j.jacc.2009.08.022.|Mizusawa Y, Wilde AA. Brugada syndrome. Circ Arrhythm Electrophysiol. 2012 Jun 1;5(3):606-16. doi: 10.1161/CIRCEP.111.964577. Review.|Nademanee K, Veerakul G, Chandanamattha P, Chaothawee L, Ariyachaipanich A, Jirasirirojanakorn K, Likittanasombat K, Bhuripanyo K, Ngarmukos T. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation. 2011 Mar 29;123(12):1270-9. doi: 10.1161/CIRCULATIONAHA.110.972612. Epub 2011 Mar 14.|Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang CE, Huikuri H, Kannankeril P, Krahn A, Leenhardt A, Moss A, Schwartz PJ, Shimizu W, Tomaselli G, Tracy C; Document Reviewers, Ackerman M, Belhassen B, Estes NA 3rd, Fatkin D, Kalman J, Kaufman E, Kirchhof P, Schulze-Bahr E, Wolpert C, Vohra J, Refaat M, Etheridge SP, Campbell RM, Martin ET, Quek SC; Heart Rhythm Society; European Heart Rhythm Association; Asia Pacific Heart Rhythm Society. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace. 2013 Oct;15(10):1389-406. doi: 10.1093/europace/eut272. Epub 2013 Aug 30. Review.|Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.|Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001 Jan 2;103(1):89-95.|Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, Napolitano C, Schwartz PJ, Joseph RM, Condouris K, Tager-Flusberg H, Priori SG, Sanguinetti MC, Keating MT. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 2004 Oct 1;119(1):19-31.|Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA, Keating MT. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995 Mar 10;80(5):805-11.|Zellerhoff S, Pistulli R, Mönnig G, Hinterseer M, Beckmann BM, Köbe J, Steinbeck G, Kääb S, Haverkamp W, Fabritz L, Gradaus R, Breithardt G, Schulze-Bahr E, Böcker D, Kirchhof P. Atrial Arrhythmias in long-QT syndrome under daily life conditions: a nested case control study. J Cardiovasc Electrophysiol. 2009 Apr;20(4):401-7. doi: 10.1111/j.1540-8167.2008.01339.x. Epub 2008 Oct 27.","\tChannelopathies\tGenetic analysis\tNA\tNA\tNA\tGenetic\tAll\t","NA","NA","NA","NA","NA","NA","channelopathies","NA","NA"]
["NCT04832581","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19469432|23885968|29653573|20225781|9378932","Amiri FN, Rooshan MH, Ahmady MH, Soliamani MJ. Hygiene practices and sexual activity associated with urinary tract infection in pregnant women. East Mediterr Health J. 2009 Jan-Feb;15(1):104-10.|Emiru T, Beyene G, Tsegaye W, Melaku S. Associated risk factors of urinary tract infection among pregnant women at Felege Hiwot Referral Hospital, Bahir Dar, North West Ethiopia. BMC Res Notes. 2013 Jul 25;6:292. doi: 10.1186/1756-0500-6-292.|Ghouri F, Hollywood A, Ryan K. A systematic review of non-antibiotic measures for the prevention of urinary tract infections in pregnancy. BMC Pregnancy Childbirth. 2018 Apr 13;18(1):99. doi: 10.1186/s12884-018-1732-2.|Haider G, Zehra N, Munir AA, Haider A. Risk factors of urinary tract infection in pregnancy. J Pak Med Assoc. 2010 Mar;60(3):213-6.|Stapleton A, Stamm WE. Prevention of urinary tract infection. Infect Dis Clin North Am. 1997 Sep;11(3):719-33. Review.","\tUrinary Tract Infection During Pregnancy\tThe Self-Care Behavior Development Program\tParallel Assignment\tPrevention\tRandomized\tBehavioral\tFemale\t","Developing Self-care Behaviors for Urinary Tract Infections","Interventional","Completed","N/A",2,67,"communicable diseases|urinary tract infections|infection","NA","NA"]
["NCT04833257","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27567279|31150573|25702326","Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, Peng P, Wu X, Lin Q, Xi X, Peng J, Xu M, Chen D, Lu X, Wang R, Cao X, Chen X, Lin Z, Xiong J, Lin Q, Xie C, Li Z, Pan J, Li J, Wu S, Lian Y, Yang Q, Zhao C. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016 Oct 15;388(10054):1883-1892. doi: 10.1016/S0140-6736(16)31388-5. Epub 2016 Aug 23. Erratum in: Lancet. 2016 Oct 15;388(10054):1882.|Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK, Xie FY, Sun Y, Ma J. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019 Sep 19;381(12):1124-1135. doi: 10.1056/NEJMoa1905287. Epub 2019 May 31.|Zhang J, Fang W, Qin T, Yang Y, Hong S, Liang W, Ma Y, Zhao H, Huang Y, Xue C, Huang P, Hu Z, Zhao Y, Zhang L. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. Med Oncol. 2015 Mar;32(3):86. doi: 10.1007/s12032-015-0501-6. Epub 2015 Feb 22.","\tNasopharyngeal Carcinoma\tGP combine with Tislelizumab neoadjuvant therapy+CCRT\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma|nasopharyngeal carcinoma","NA","NA"]
["NCT04833413","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25825361|25952532|28661564|30291106|26459273|28251792|29053215|28483786|26512041|33298426","Home PD, Dain MP, Freemantle N, Kawamori R, Pfohl M, Brette S, Pilorget V, Scherbaum WA, Vespasiani G, Vincent M, Balkau B. Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents. Diabetes Res Clin Pract. 2015 May;108(2):350-9. doi: 10.1016/j.diabres.2015.01.030. Epub 2015 Jan 23.|Jin SM, Kim JH, Min KW, Lee JH, Ahn KJ, Park JH, Jang HC, Park SW, Lee KW, Won KC, Kim YI, Chung CH, Park TS, Lee JH, Lee MK. Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: A 24-week randomized non-inferiority trial. J Diabetes. 2016 May;8(3):405-13. doi: 10.1111/1753-0407.12312. Epub 2015 Jun 29.|Weng J. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9. J Diabetes. 2017 Oct;9(10):890-893. doi: 10.1111/1753-0407.12581. Epub 2017 Aug 22.|Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Dec;41(12):2669-2701. doi: 10.2337/dci18-0033. Epub 2018 Oct 4.|Bellido V, Suarez L, Rodriguez MG, Sanchez C, Dieguez M, Riestra M, Casal F, Delgado E, Menendez E, Umpierrez GE. Comparison of Basal-Bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes. Diabetes Care. 2015 Dec;38(12):2211-6. doi: 10.2337/dc15-0160. Epub 2015 Oct 12.|Mauricio D, Meneghini L, Seufert J, Liao L, Wang H, Tong L, Cali A, Stella P, Carita P, Khunti K. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes Metab. 2017 Aug;19(8):1155-1164. doi: 10.1111/dom.12927. Epub 2017 Apr 10.|Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab. 2018 Mar;20(3):488-496. doi: 10.1111/dom.13132. Epub 2017 Nov 22. Review.|Bowering K, Case C, Harvey J, Reeves M, Sampson M, Strzinek R, Bretler DM, Bang RB, Bode BW. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial. Diabetes Care. 2017 Jul;40(7):951-957. doi: 10.2337/dc16-1770. Epub 2017 May 8.|Lind M, Hirsch IB, Tuomilehto J, Dahlqvist S, Ahrén B, Torffvit O, Attvall S, Ekelund M, Filipsson K, Tengmark BO, Sjöberg S, Pehrsson NG. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). BMJ. 2015 Oct 28;351:h5364. doi: 10.1136/bmj.h5364.|American Diabetes Association. 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S211-S220. doi: 10.2337/dc21-S015. Review.","\tInsulin\tContinuous intensive insulin therapy\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","NA","hypoglycemic agents|insulin, globin zinc|insulin","NA"]
["NCT04834102","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32607303|33226117|33190397|33310111","Asghar F, Shamim N, Farooque U, Sheikh H, Aqeel R. Telogen Effluvium: A Review of the Literature. Cureus. 2020 May 27;12(5):e8320. doi: 10.7759/cureus.8320. Review.|Mieczkowska K, Deutsch A, Borok J, Guzman AK, Fruchter R, Patel P, Wind O, McLellan BN, Mann RE, Halverstam CP. Telogen effluvium: a sequela of COVID-19. Int J Dermatol. 2021 Jan;60(1):122-124. doi: 10.1111/ijd.15313. Epub 2020 Nov 23.|Rizzetto G, Diotallevi F, Campanati A, Radi G, Bianchelli T, Molinelli E, Mazzanti S, Offidani A. Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical aspects and our management experience. Dermatol Ther. 2021 Jan;34(1):e14547. doi: 10.1111/dth.14547. Epub 2020 Nov 23.|Cline A, Kazemi A, Moy J, Safai B, Marmon S. A surge in the incidence of telogen effluvium in minority predominant communities heavily impacted by COVID-19. J Am Acad Dermatol. 2021 Mar;84(3):773-775. doi: 10.1016/j.jaad.2020.11.032. Epub 2020 Dec 10.","\tAlopecia|Covid19|SARS-CoV Infection|Telogen Effluvium\tBlood Tests\tNA\tNA\tNA\tDiagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","coronavirus infections|severe acute respiratory syndrome|alopecia|alopecia areata","NA","NA"]
["NCT04834843","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31883328|16403930|22690093|33300375","Sundaram V, Bloom C, Zakeri R, Halcox J, Cohen A, Bowrin K, Briere JB, Banerjee A, Simon DI, Cleland JGF, Rajagopalan S, Quint JK. Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006-2015. Eur Heart J. 2020 May 1;41(17):1636-1649. doi: 10.1093/eurheartj/ehz880.|Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Röther J, Wilson PW; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006 Jan 11;295(2):180-9.|Ahn S, Park YJ, Min SI, Kim SY, Ha J, Kim SJ, Kim HS, Yoon BW, Min SK. High prevalence of peripheral arterial disease in Korean patients with coronary or cerebrovascular disease. J Korean Med Sci. 2012 Jun;27(6):625-9. doi: 10.3346/jkms.2012.27.6.625. Epub 2012 May 26.|Søgaard M, Nielsen PB, Skjøth F, Eldrup N, Larsen TB. Temporal Changes in Secondary Prevention and Cardiovascular Outcomes After Revascularization for Peripheral Arterial Disease in Denmark: A Nationwide Cohort Study. Circulation. 2021 Mar 2;143(9):907-920. doi: 10.1161/CIRCULATIONAHA.120.047994. Epub 2020 Dec 10.","\tCardiovascular Diseases|Coronary Artery Disease|Peripheral Artery Disease\tObservational study, no intervention\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","cardiovascular diseases|myocardial ischemia|peripheral arterial disease|coronary disease|coronary artery disease","NA","NA"]
["NCT04835025","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32008623|30955514|27535388|32158220|31813004|29700092|32723363|32926760|32354698|30853981|30452687|32682248|33109224","Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med. 2020 Mar;41(1):1-24. doi: 10.1016/j.ccm.2019.10.001. Review.|Nasim F, Sabath BF, Eapen GA. Lung Cancer. Med Clin North Am. 2019 May;103(3):463-473. doi: 10.1016/j.mcna.2018.12.006. Review.|Rodriguez-Canales J, Parra-Cuentas E, Wistuba II. Diagnosis and Molecular Classification of Lung Cancer. Cancer Treat Res. 2016;170:25-46. doi: 10.1007/978-3-319-40389-2_2. Review.|Wang S, Hu C, Xie F, Liu Y. Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer. Onco Targets Ther. 2020 Jan 23;13:667-683. doi: 10.2147/OTT.S235714. eCollection 2020. Review.|Li W, Yu H. Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases. J Cancer Res Clin Oncol. 2020 Jan;146(1):137-152. doi: 10.1007/s00432-019-03094-9. Epub 2019 Dec 7. Review.|Jones GS, Baldwin DR. Recent advances in the management of lung cancer. Clin Med (Lond). 2018 Apr 1;18(Suppl 2):s41-s46. doi: 10.7861/clinmedicine.18-2-s41. Review.|Chen Y, Gao M, Huang Z, Yu J, Meng X. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. J Hematol Oncol. 2020 Jul 28;13(1):105. doi: 10.1186/s13045-020-00940-z. Review.|Qian JM, Martin AM, Martin K, Hammoudeh L, Catalano PJ, Hodi FS, Cagney DN, Haas-Kogan DA, Schoenfeld JD, Aizer AA. Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases. Cancer. 2020 Dec 15;126(24):5274-5282. doi: 10.1002/cncr.33196. Epub 2020 Sep 14.|Eguren-Santamaria I, Sanmamed MF, Goldberg SB, Kluger HM, Idoate MA, Lu BY, Corral J, Schalper KA, Herbst RS, Gil-Bazo I. PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. Clin Cancer Res. 2020 Aug 15;26(16):4186-4197. doi: 10.1158/1078-0432.CCR-20-0798. Epub 2020 Apr 30. Review.|Protopapa M, Kouloulias V, Nikoloudi S, Papadimitriou C, Gogalis G, Zygogianni A. From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC. J Oncol. 2019 Feb 3;2019:3267409. doi: 10.1155/2019/3267409. eCollection 2019. Review.|Miyamoto S, Nomura R, Sato K, Awano N, Kuse N, Inomata M, Izumo T, Terada Y, Furuhata Y, Bae Y, Kunitoh H. Nivolumab and stereotactic radiation therapy for the treatment of patients with Stage IV non-small-cell lung cancer. Jpn J Clin Oncol. 2019 Feb 1;49(2):160-164. doi: 10.1093/jjco/hyy171.|Vilariño N, Bruna J, Bosch-Barrera J, Valiente M, Nadal E. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. Cancer Treat Rev. 2020 Sep;89:102067. doi: 10.1016/j.ctrv.2020.102067. Epub 2020 Jul 7. Review.|Kowalski ES, Remick JS, Sun K, Alexander GS, Khairnar R, Morse E, Cherng HR, Berg LJ, Poirier Y, Lamichhane N, Becker S, Chen S, Molitoris JK, Kwok Y, Regine WF, Mishra MV. Immune checkpoint inhibition in patients treated with stereotactic radiation for brain metastases. Radiat Oncol. 2020 Oct 27;15(1):245. doi: 10.1186/s13014-020-01644-x.","\tNon Small Cell Lung Cancer\tPD-1/PD-L1 inhibitor\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","lung neoplasms|carcinoma, non-small-cell lung","NA","NA"]
["NCT04835155","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26252313|30721652|12183719|21730902|26803089|28376549|31013539|30851536","Tian X, Yi LJ, Zhang L, Zhou JG, Ma L, Ou YX, Shuai T, Zeng Z, Song GM. Oral Motor Intervention Improved the Oral Feeding in Preterm Infants: Evidence Based on a Meta-Analysis With Trial Sequential Analysis. Medicine (Baltimore). 2015 Aug;94(31):e1310. doi: 10.1097/MD.0000000000001310.|Lessen Knoll BS, Daramas T, Drake V. Randomized Controlled Trial of a Prefeeding Oral Motor Therapy and Its Effect on Feeding Improvement in a Thai NICU. J Obstet Gynecol Neonatal Nurs. 2019 Mar;48(2):176-188. doi: 10.1016/j.jogn.2019.01.003. Epub 2019 Feb 2.|Fucile S, Gisel E, Lau C. Oral stimulation accelerates the transition from tube to oral feeding in preterm infants. J Pediatr. 2002 Aug;141(2):230-6. Erratum in: J Pediatr 2002 Nov;141(5):743.|Lessen BS. Effect of the premature infant oral motor intervention on feeding progression and length of stay in preterm infants. Adv Neonatal Care. 2011 Apr;11(2):129-39. doi: 10.1097/ANC.0b013e3182115a2a.|Lessen BS, Morello CA, Williams LJ. Establishing Intervention Fidelity of an Oral Motor Intervention for Preterm Infants. Neonatal Netw. 2015;34(2):72-82. doi: 10.1891/0730-0832.34.2.72.|Kamitsuka MD, Nervik PA, Nielsen SL, Clark RH. Incidence of Nasogastric and Gastrostomy Tube at Discharge Is Reduced after Implementing an Oral Feeding Protocol in Premature (< 30 weeks) Infants. Am J Perinatol. 2017 May;34(6):606-613. doi: 10.1055/s-0037-1601443. Epub 2017 Apr 4.|Li XL, Liu Y, Liu M, Yang CY, Yang QZ. Early Premature Infant Oral Motor Intervention Improved Oral Feeding and Prognosis by Promoting Neurodevelopment. Am J Perinatol. 2020 May;37(6):626-632. doi: 10.1055/s-0039-1685448. Epub 2019 Apr 23.|Ghomi H, Yadegari F, Soleimani F, Knoll BL, Noroozi M, Mazouri A. The effects of premature infant oral motor intervention (PIOMI) on oral feeding of preterm infants: A randomized clinical trial. Int J Pediatr Otorhinolaryngol. 2019 May;120:202-209. doi: 10.1016/j.ijporl.2019.02.005. Epub 2019 Feb 5.","\tFeeding Behavior|Premature Birth|Sucking Behavior\tPremature Infant Oral Motor Intervention (PIOMI)\tParallel Assignment\tSupportive Care\tRandomized\tProcedure\tAll\t","The Effect of The Premature Infant Oral Motorınterventıon on Suckıng Capacıty in Preterm Infants","Interventional","Completed","N/A",2,60,"premature birth","NA","NA"]
["NCT04835922","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29288788,"Choi SW, Cho SJ, Moon HW, Lee KW, Lee SH, Hong SH, Choi YS, Bae WJ, Ha US, Hong SH, Lee JY, Kim SW, Cho HJ. Effect of Intercostal Nerve Block and Nephrostomy Tract Infiltration With Ropivacaine on Postoperative Pain Control After Tubeless Percutaneous Nephrolithotomy: A Prospective, Randomized, and Case-controlled Trial. Urology. 2018 Apr;114:49-55. doi: 10.1016/j.urology.2017.12.004. Epub 2017 Dec 27.","\tKidney Stone\tIntercostal Nerve Block|Peritract Infiltration\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","Comparison of Efficacy of Intercostal Nerve Block vs Peritract Infiltration With 0.25% Bupivacaine in PCNL","Interventional","Recruiting","N/A",2,60,"nephrolithiasis|kidney calculi","anesthetics","NA"]
["NCT04835961","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17537763|NA|NA|NA|32237004|22536582|19770241|20176271|31412856|29768147|29768149|32430423|22816878|23557023|29400090|11590294|NA|15918159|10573240|18080214|10489826|NA|19535666","Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J. 2007 Sep;30(3):452-6. Epub 2007 May 30.|8. P. Moraitaki, D. Papamichail, N. Georgatotu (2010) Severe Asthma: Definitions, risk factors and phenotype characterization. Pneumon, 23(3):276-292.|9. P. Latsi, M. Gaga (1999) Leukotriene antagonists, a new class of anti-asthmatic drugs. Pneumon, 12 (2): 123-132|1. Global Initiative for Asthma. Gglobal Strategy for Asthma Management and Prevention. (2020) Available from: www.ginasthma.org|Jenkins CR, Bateman ED, Sears MR, O'Byrne PM. What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever? Respirology. 2020 Aug;25(8):804-815. doi: 10.1111/resp.13804. Epub 2020 Mar 31. Review. Erratum in: Respirology. 2020 Oct;25(10):1103-1104.|Lougheed MD, Lemiere C, Ducharme FM, Licskai C, Dell SD, Rowe BH, Fitzgerald M, Leigh R, Watson W, Boulet LP; Canadian Thoracic Society Asthma Clinical Assembly. Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults. Can Respir J. 2012 Mar-Apr;19(2):127-64. Erratum in: Can Respir J. 2013 May-Jun;20(3):185.|Kaplan AG, Balter MS, Bell AD, Kim H, McIvor RA. Diagnosis of asthma in adults. CMAJ. 2009 Nov 10;181(10):E210-20. doi: 10.1503/cmaj.080006. Epub 2009 Sep 21. Review.|Lemanske RF Jr, Busse WW. Asthma: clinical expression and molecular mechanisms. J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S95-102. doi: 10.1016/j.jaci.2009.10.047. Review.|Muneswarao J, Hassali MA, Ibrahim B, Saini B, Ali IAH, Verma AK. It is time to change the way we manage mild asthma: an update in GINA 2019. Respir Res. 2019 Aug 14;20(1):183. doi: 10.1186/s12931-019-1159-y.|Bateman ED, Reddel HK, O'Byrne PM, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Siwek-Posluszna A, FitzGerald JM. As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. N Engl J Med. 2018 May 17;378(20):1877-1887. doi: 10.1056/NEJMoa1715275.|O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Ivanov S, Reddel HK. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. N Engl J Med. 2018 May 17;378(20):1865-1876. doi: 10.1056/NEJMoa1715274.|Rogliani P, Ritondo BL, Ora J, Cazzola M, Calzetta L. SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. Eur Respir J. 2020 Sep 10;56(3). pii: 2000625. doi: 10.1183/13993003.00625-2020. Print 2020 Sep.|Buhl R, Kuna P, Peters MJ, Andersson TL, Naya IP, Peterson S, Rabe KF. The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy. Respir Res. 2012 Jul 20;13:59. doi: 10.1186/1465-9921-13-59.|Zhong N, Lin J, Mehta P, Ngamjanyaporn P, Wu TC, Yunus F. Real-life effectiveness of budesonide/formoterol maintenance and reliever therapy in asthma patients across Asia: SMARTASIA study. BMC Pulm Med. 2013 Apr 4;13:22. doi: 10.1186/1471-2466-13-22.|Lin J, Zhou X, Wang C, Liu C, Cai S, Huang M. Symbicort® Maintenance and Reliever Therapy (SMART) and the evolution of asthma management within the GINA guidelines. Expert Rev Respir Med. 2018 Mar;12(3):191-202. doi: 10.1080/17476348.2018.1429921. Epub 2018 Feb 5. Review.|International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline: Guideline for Good Clinical Practice. J Postgrad Med. 2001 Jan-Mar;47(1):45-50.|19. World Medical Association Declaration of Helsinki. Ethical principles for Medical Research Involving Human Subjects, Helsinki 1964, amended in Tokyo 1975, Venice 1983, Hong Kong 1989, Somerset West 1996, Edinburgh 2000, Washington DC 2002, Tokyo 2004, Seoul 2008 and Fortaleza 2013.|Epstein M; International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2005 Aug;14(8):589-95.|Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999 Oct;14(4):902-7.|Grammatopoulou E, Skordilis E, Koutsouki D, Baltopoulos G. An 18-item standardized Asthma Quality of Life Questionnaire-AQLQ(S). Qual Life Res. 2008 Mar;17(2):323-32. Epub 2007 Dec 14.|Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J. 1999 Jul;14(1):32-8.|25. Grekas N., Athanassiou A., Iskos C., Panagiotakos D., Papataxiarchou A., Porichi O. (2011). Reliability of the FSI-10 questionnaire for the assessment of the usability of drug inhalers in Greek patients. Archives of Hellenic Medicine, 28(2):257-260|Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HA, Lazarus SC, Levy ML, O'Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Sullivan SD, Szefler SJ, Thomas MD, Wenzel SE; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009 Jul 1;180(1):59-99. doi: 10.1164/rccm.200801-060ST.","\tAsthma\tMaintenace and As needed\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","asthma","NA","NA"]
["NCT04836143","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23084240|30264133|26908540|30617580","Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012 Dec;119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006. Epub 2012 Oct 17. Erratum in: Ophthalmology. 2013 Jan;120(1):209-10.|Moore TJ, Zhang H, Anderson G, Alexander GC. Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016. JAMA Intern Med. 2018 Nov 1;178(11):1451-1457. doi: 10.1001/jamainternmed.2018.3931.|Sertkaya A, Wong HH, Jessup A, Beleche T. Key cost drivers of pharmaceutical clinical trials in the United States. Clin Trials. 2016 Apr;13(2):117-26. doi: 10.1177/1740774515625964. Epub 2016 Feb 8.|Kim JH, Chang YS, Kim JW, Kim CG, Lee DW. Age-related differences in the prevalence of subtypes of Neovascular age-related macular degeneration in the first diagnosed eye. Graefes Arch Clin Exp Ophthalmol. 2019 May;257(5):891-898. doi: 10.1007/s00417-018-04228-4. Epub 2019 Jan 7.","\tAge-related Macular Degeneration\tIntravitreal anti-vascular endothelial growth factor injection\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","macular degeneration","endothelial growth factors|mitogens","NA"]
["NCT04836325","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28421273|23820862|20461783|21285161|24243538|30792923|14744565|22349304|27866120|19189041|32116603|21807616|32109553|25595064|29500043|29497371|25581213|31982685|28475205|25444588|27698365","Eich W, Bär KJ, Bernateck M, Burgmer M, Dexl C, Petzke F, Sommer C, Winkelmann A, Häuser W. [Definition, classification, clinical diagnosis and prognosis of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles]. Schmerz. 2017 Jun;31(3):231-238. doi: 10.1007/s00482-017-0200-7. Review. German. Erratum in: Schmerz. 2017 Sep 7;:.|Wolfe F, Walitt B. Culture, science and the changing nature of fibromyalgia. Nat Rev Rheumatol. 2013 Dec;9(12):751-5. doi: 10.1038/nrrheum.2013.96. Epub 2013 Jul 2. Review.|Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010 May;62(5):600-10. doi: 10.1002/acr.20140.|Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol. 2011 Jun;38(6):1113-22. doi: 10.3899/jrheum.100594. Epub 2011 Feb 1.|Serra J, Collado A, Solà R, Antonelli F, Torres X, Salgueiro M, Quiles C, Bostock H. Hyperexcitable C nociceptors in fibromyalgia. Ann Neurol. 2014 Feb;75(2):196-208. doi: 10.1002/ana.24065. Epub 2014 Feb 12.|Gentile E, Ricci K, Delussi M, Brighina F, de Tommaso M. Motor Cortex Function in Fibromyalgia: A Study by Functional Near-Infrared Spectroscopy. Pain Res Treat. 2019 Jan 16;2019:2623161. doi: 10.1155/2019/2623161. eCollection 2019.|Di Lazzaro V, Oliviero A, Pilato F, Saturno E, Dileone M, Mazzone P, Insola A, Tonali PA, Rothwell JC. The physiological basis of transcranial motor cortex stimulation in conscious humans. Clin Neurophysiol. 2004 Feb;115(2):255-66. Review.|Groppa S, Oliviero A, Eisen A, Quartarone A, Cohen LG, Mall V, Kaelin-Lang A, Mima T, Rossi S, Thickbroom GW, Rossini PM, Ziemann U, Valls-Solé J, Siebner HR. A practical guide to diagnostic transcranial magnetic stimulation: report of an IFCN committee. Clin Neurophysiol. 2012 May;123(5):858-82. doi: 10.1016/j.clinph.2012.01.010. Epub 2012 Feb 19. Review.|Lefaucheur JP, Antal A, Ayache SS, Benninger DH, Brunelin J, Cogiamanian F, Cotelli M, De Ridder D, Ferrucci R, Langguth B, Marangolo P, Mylius V, Nitsche MA, Padberg F, Palm U, Poulet E, Priori A, Rossi S, Schecklmann M, Vanneste S, Ziemann U, Garcia-Larrea L, Paulus W. Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clin Neurophysiol. 2017 Jan;128(1):56-92. doi: 10.1016/j.clinph.2016.10.087. Epub 2016 Oct 29. Review.|Capone F, Dileone M, Profice P, Pilato F, Musumeci G, Minicuci G, Ranieri F, Cadossi R, Setti S, Tonali PA, Di Lazzaro V. Does exposure to extremely low frequency magnetic fields produce functional changes in human brain? J Neural Transm (Vienna). 2009 Mar;116(3):257-65. doi: 10.1007/s00702-009-0184-2. Epub 2009 Feb 3.|Capone F, Pellegrino G, Motolese F, Rossi M, Musumeci G, Di Lazzaro V. Extremely Low Frequency Magnetic Fields Do Not Affect LTP-Like Plasticity in Healthy Humans. Front Hum Neurosci. 2020 Feb 5;14:14. doi: 10.3389/fnhum.2020.00014. eCollection 2020.|Oliviero A, Mordillo-Mateos L, Arias P, Panyavin I, Foffani G, Aguilar J. Transcranial static magnetic field stimulation of the human motor cortex. J Physiol. 2011 Oct 15;589(Pt 20):4949-58. doi: 10.1113/jphysiol.2011.211953. Epub 2011 Aug 1.|Shibata S, Watanabe T, Yukawa Y, Minakuchi M, Shimomura R, Mima T. Effect of transcranial static magnetic stimulation on intracortical excitability in the contralateral primary motor cortex. Neurosci Lett. 2020 Apr 1;723:134871. doi: 10.1016/j.neulet.2020.134871. Epub 2020 Feb 25.|Oliviero A, Carrasco-López MC, Campolo M, Perez-Borrego YA, Soto-León V, Gonzalez-Rosa JJ, Higuero AM, Strange BA, Abad-Rodriguez J, Foffani G. Safety Study of Transcranial Static Magnetic Field Stimulation (tSMS) of the Human Cortex. Brain Stimul. 2015 May-Jun;8(3):481-5. doi: 10.1016/j.brs.2014.12.002. Epub 2014 Dec 11.|Dileone M, Mordillo-Mateos L, Oliviero A, Foffani G. Long-lasting effects of transcranial static magnetic field stimulation on motor cortex excitability. Brain Stimul. 2018 Jul - Aug;11(4):676-688. doi: 10.1016/j.brs.2018.02.005. Epub 2018 Feb 7.|Kirimoto H, Tamaki H, Otsuru N, Yamashiro K, Onishi H, Nojima I, Oliviero A. Transcranial Static Magnetic Field Stimulation over the Primary Motor Cortex Induces Plastic Changes in Cortical Nociceptive Processing. Front Hum Neurosci. 2018 Feb 15;12:63. doi: 10.3389/fnhum.2018.00063. eCollection 2018.|Knijnik LM, Dussán-Sarria JA, Rozisky JR, Torres IL, Brunoni AR, Fregni F, Caumo W. Repetitive Transcranial Magnetic Stimulation for Fibromyalgia: Systematic Review and Meta-Analysis. Pain Pract. 2016 Mar;16(3):294-304. doi: 10.1111/papr.12276. Epub 2015 Jan 12. Review.|Lloyd DM, Wittkopf PG, Arendsen LJ, Jones AKP. Is Transcranial Direct Current Stimulation (tDCS) Effective for the Treatment of Pain in Fibromyalgia? A Systematic Review and Meta-Analysis. J Pain. 2020 Nov - Dec;21(11-12):1085-1100. doi: 10.1016/j.jpain.2020.01.003. Epub 2020 Jan 23. Review.|Paolucci T, Piccinini G, Iosa M, Piermattei C, de Angelis S, Grasso MR, Zangrando F, Saraceni VM. Efficacy of extremely low-frequency magnetic field in fibromyalgia pain: A pilot study. J Rehabil Res Dev. 2016;53(6):1023-1034. doi: 10.1682/JRRD.2015.04.0061.|Kirimoto H, Tamaki H, Matsumoto T, Sugawara K, Suzuki M, Oyama M, Onishi H. Effect of transcranial static magnetic field stimulation over the sensorimotor cortex on somatosensory evoked potentials in humans. Brain Stimul. 2014 Nov-Dec;7(6):836-40. doi: 10.1016/j.brs.2014.09.016. Epub 2014 Sep 30.|Kirimoto H, Asao A, Tamaki H, Onishi H. Non-invasive modulation of somatosensory evoked potentials by the application of static magnetic fields over the primary and supplementary motor cortices. Sci Rep. 2016 Oct 4;6:34509. doi: 10.1038/srep34509.","\tFibromyalgia\ttranscranial static magnetic field stimulation (tSMS)|Sham transcranial static magnetic field stimulation\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","Effect of Transcranial Static Magnetic Field Stimulation in Fibromyalgia Syndrome","Interventional","Recruiting","N/A",2,16,"fibromyalgia|myofascial pain syndromes","NA","NA"]
["NCT04836481","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25761425|27307089|25169249|23425733|18828701|19898966|16886975|31523280|21950640|31977751|22771222|19054418|21048095|11454660|1244564","May CC, Arora S, Parli SE, Fraser JF, Bastin MT, Cook AM. Augmented Renal Clearance in Patients with Subarachnoid Hemorrhage. Neurocrit Care. 2015 Dec;23(3):374-9. doi: 10.1007/s12028-015-0127-8.|Zangbar B, Khalil M, Gruessner A, Joseph B, Friese R, Kulvatunyou N, Wynne J, Latifi R, Rhee P, O'Keeffe T. Levetiracetam Prophylaxis for Post-traumatic Brain Injury Seizures is Ineffective: A Propensity Score Analysis. World J Surg. 2016 Nov;40(11):2667-2672.|Gabriel WM, Rowe AS. Long-term comparison of GOS-E scores in patients treated with phenytoin or levetiracetam for posttraumatic seizure prophylaxis after traumatic brain injury. Ann Pharmacother. 2014 Nov;48(11):1440-4. doi: 10.1177/1060028014549013. Epub 2014 Aug 28.|Inaba K, Menaker J, Branco BC, Gooch J, Okoye OT, Herrold J, Scalea TM, Dubose J, Demetriades D. A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis. J Trauma Acute Care Surg. 2013 Mar;74(3):766-71; discussion 771-3. doi: 10.1097/TA.0b013e3182826e84.|Jones KE, Puccio AM, Harshman KJ, Falcione B, Benedict N, Jankowitz BT, Stippler M, Fischer M, Sauber-Schatz EK, Fabio A, Darby JM, Okonkwo DO. Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury. Neurosurg Focus. 2008 Oct;25(4):E3. doi: 10.3171/FOC.2008.25.10.E3.|Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care. 2010 Apr;12(2):165-72. doi: 10.1007/s12028-009-9304-y.|Ramael S, Daoust A, Otoul C, Toublanc N, Troenaru M, Lu ZS, Stockis A. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia. 2006 Jul;47(7):1128-35.|Steinhoff BJ, Staack AM. Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience. Ther Adv Neurol Disord. 2019 Sep 9;12:1756286419873518. doi: 10.1177/1756286419873518. eCollection 2019. Review.|Spencer DD, Jacobi J, Juenke JM, Fleck JD, Kays MB. Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. Pharmacotherapy. 2011 Oct;31(10):934-41. doi: 10.1592/phco.31.10.934.|Cotta MO, Abdul-Aziz MH, Frey OR, Sime FB, Roberts JA, Roehr AC. What Are the Predictors for Achieving Therapeutic Levetiracetam Serum Concentrations in Adult Neurological Patients? Ther Drug Monit. 2020 Aug;42(4):626-630. doi: 10.1097/FTD.0000000000000731.|Klein P, Herr D, Pearl PL, Natale J, Levine Z, Nogay C, Sandoval F, Trzcinsky S, Atabaki SM, Tsuchida T, van den Anker J, Soldin SJ, He J, McCarter R. Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. Epilepsy Behav. 2012 Aug;24(4):457-61. doi: 10.1016/j.yebeh.2012.05.011. Epub 2012 Jul 7.|Uges JW, van Huizen MD, Engelsman J, Wilms EB, Touw DJ, Peeters E, Vecht CJ. Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. Epilepsia. 2009 Mar;50(3):415-21. doi: 10.1111/j.1528-1167.2008.01889.x. Epub 2008 Nov 17.|Udy A, Boots R, Senthuran S, Stuart J, Deans R, Lassig-Smith M, Lipman J. Augmented creatinine clearance in traumatic brain injury. Anesth Analg. 2010 Dec;111(6):1505-10. doi: 10.1213/ANE.0b013e3181f7107d. Epub 2010 Nov 3.|Tong X, Patsalos PN. A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain. Br J Pharmacol. 2001 Jul;133(6):867-74.|Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.","\tTraumatic Brain Injury\tSerum Sample Collection\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","wounds and injuries|brain injuries, traumatic|brain injuries","NA","NA"]
["NCT04836767","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32475821|32085846|32246917|32064853|32764112","Barker-Davies RM, O'Sullivan O, Senaratne KPP, Baker P, Cranley M, Dharm-Datta S, Ellis H, Goodall D, Gough M, Lewis S, Norman J, Papadopoulou T, Roscoe D, Sherwood D, Turner P, Walker T, Mistlin A, Phillip R, Nicol AM, Bennett AN, Bahadur S. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. Br J Sports Med. 2020 Aug;54(16):949-959. doi: 10.1136/bjsports-2020-102596. Epub 2020 May 31.|Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18. Erratum in: Lancet Respir Med. 2020 Feb 25;:.|Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020 May;19(5):383-384. doi: 10.1016/S1474-4422(20)30109-5. Epub 2020 Apr 1.|Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003. Chinese.|Belli S, Balbi B, Prince I, Cattaneo D, Masocco F, Zaccaria S, Bertalli L, Cattini F, Lomazzo A, Dal Negro F, Giardini M, Franssen FME, Janssen DJA, Spruit MA. Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived hospitalisation. Eur Respir J. 2020 Oct 15;56(4). pii: 2002096. doi: 10.1183/13993003.02096-2020. Print 2020 Oct.","\tCorona Virus Infection|Covid19\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","coronavirus infections","NA","NA"]
["NCT04836780","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32105632|32362390|32217835|32678530|NA|32171390|33397463|32427279|32171076|32125452|31986264|32109013","Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24. Erratum in: Lancet Respir Med. 2020 Apr;8(4):e26.|Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020 May;39(5):405-407. doi: 10.1016/j.healun.2020.03.012. Epub 2020 Mar 20.|Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020 May 1;130(5):2620-2629. doi: 10.1172/JCI137244.|RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.|WHO/2019-nCoV/Corticosteroids/2020.1|Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. 2020 Jul;20(7):773. doi: 10.1016/S1473-3099(20)30195-X. Epub 2020 Mar 12.|Monedero P, Gea A, Castro P, Candela-Toha AM, Hernández-Sanz ML, Arruti E, Villar J, Ferrando C; COVID-19 Spanish ICU Network. Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study. Crit Care. 2021 Jan 4;25(1):2. doi: 10.1186/s13054-020-03422-3.|Fadel R, Morrison AR, Vahia A, Smith ZR, Chaudhry Z, Bhargava P, Miller J, Kenney RM, Alangaden G, Ramesh MS; Henry Ford COVID-19 Management Task Force. Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19. Clin Infect Dis. 2020 Nov 19;71(16):2114-2120. doi: 10.1093/cid/ciaa601.|Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.|Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3. Erratum in: Intensive Care Med. 2020 Apr 6;:.|Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.|Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.","\tAcute Respiratory Distress Syndrome|COVID-19|Pneumonia, Viral\tDexamethasone\tParallel Assignment\tPrevention\tRandomized\tDrug\tAll\t","DEXamethasone EARLY Administration in Hospitalized Patients With Covid-19 Pneumonia","Interventional","Not yet recruiting","Phase 3",2,126,"pneumonia|acute lung injury|respiratory distress syndrome, adult|respiratory distress syndrome, newborn|syndrome|pneumonia, viral","dexamethasone","NA"]
["NCT04838340","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26518597|19175270|28426160|23857334","Fenwick J, Toohill J, Gamble J, Creedy DK, Buist A, Turkstra E, Sneddon A, Scuffham PA, Ryding EL. Effects of a midwife psycho-education intervention to reduce childbirth fear on women's birth outcomes and postpartum psychological wellbeing. BMC Pregnancy Childbirth. 2015 Oct 30;15:284. doi: 10.1186/s12884-015-0721-y.|Phillips-Moore J. HypnoBirthing. Aust J Holist Nurs. 2005 Apr;12(1):41-2.|Kobayashi S, Hanada N, Matsuzaki M, Takehara K, Ota E, Sasaki H, Nagata C, Mori R. Assessment and support during early labour for improving birth outcomes. Cochrane Database Syst Rev. 2017 Apr 20;4:CD011516. doi: 10.1002/14651858.CD011516.pub2. Review.|Hodnett ED, Gates S, Hofmeyr GJ, Sakala C. Continuous support for women during childbirth. Cochrane Database Syst Rev. 2013 Jul 15;7:CD003766. doi: 10.1002/14651858.CD003766.pub5. Review. Update in: Cochrane Database Syst Rev. 2017 Jul 06;7:CD003766.","\tLabor Pain|Pregnancy Related|Prenatal Education\tStandart care|Hypnobirthig training\tParallel Assignment\tTreatment\tRandomized\tOther|Behavioral\tFemale\t","Effect of Hypnobirthing Training on Fear, Pain, Satisfaction and, Birth Outcomes","Interventional","Completed","N/A",2,80,"labor pain","NA","NA"]
["NCT04838366","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24417824|22035956|33731057|29786478","Bilku DK, Dennison AR, Hall TC, Metcalfe MS, Garcea G. Role of preoperative carbohydrate loading: a systematic review. Ann R Coll Surg Engl. 2014 Jan;96(1):15-22. doi: 10.1308/003588414X13824511650614. Review.|Breedveld-Peters JJ, Reijven PL, Wyers CE, van Helden S, Arts JJ, Meesters B, Prins MH, van der Weijden T, Dagnelie PC. Integrated nutritional intervention in the elderly after hip fracture. A process evaluation. Clin Nutr. 2012 Apr;31(2):199-205. doi: 10.1016/j.clnu.2011.10.004. Epub 2011 Oct 28.|Li ZE, Lu SB, Kong C, Sun WZ, Wang P, Zhang ST. Comparative short-term outcomes of enhanced recovery after surgery (ERAS) program and non-ERAS traditional care in elderly patients undergoing lumbar arthrodesis: a retrospective study. BMC Musculoskelet Disord. 2021 Mar 17;22(1):283. doi: 10.1186/s12891-021-04166-z.|From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR), Society of NeuroInterventional Surgery (SNIS), and World Stroke Organization (WSO), Sacks D, Baxter B, Campbell BCV, Carpenter JS, Cognard C, Dippel D, Eesa M, Fischer U, Hausegger K, Hirsch JA, Shazam Hussain M, Jansen O, Jayaraman MV, Khalessi AA, Kluck BW, Lavine S, Meyers PM, Ramee S, Rüfenacht DA, Schirmer CM, Vorwerk D. Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke. 2018 Aug;13(6):612-632. doi: 10.1177/1747493018778713. Epub 2018 May 22.","\tFemur Fracture\tCarbohydrate loading\tParallel Assignment\tSupportive Care\tRandomized\tDietary Supplement\tAll\t","Effect of Preoperative Carbohydrate Loading in Femur Fracture","Interventional","Not yet recruiting","N/A",2,66,"fractures, bone|femoral fractures","NA","NA"]
["NCT04839263","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","1. Bardram L, Funch-Jensen P, Jensen P, Crawford ME, Kehlet H. Recovery after laparoscopic colonic surgery with epidural analgesia, and early oral nutrition and mobilisation. Lancet. 1995 Mar 25;345(8952):763-4. 2. Basse L, Hjort Jakobsen D, Billesbølle P, Werner M, Kehlet H. A clinical pathway to accelerate recovery after colonic resection. Ann Surg. 2000 Jul;232(1):51-7. 3. Kehlet H, Wilmore DW. Multimodal strategies to improve surgical outcome. Am J Surg. 2002 Jun;183(6):630-41. 4. Kehlet H, Büchler MW, Beart RW Jr, Billingham RP, Williamson R. Care after colonic operation--is it evidence-based? Results from a multinational survey in Europe and the United States. J Am Coll Surg. 2006 Jan;202(1):45-54. 5. Fearon KC, Ljungqvist O, Von Meyenfeldt M, Revhaug A, Dejong CH, Lassen K, et al. Enhanced recovery after surgery: a consensus review of clinical care for patients undergoing colonic resection. Clin Nutr. 2005 Jun;24(3):466-77.","\tGynecologic Disease\t\"FAST TRACK\"\" protocol\"","Parallel Assignment","Supportive Care","Randomized","Procedure","Female","\tFast-track in Minimally Invasive Gynaecology\tInterventional\tCompleted\tN/A\t2\t170\tNA\tNA\tNA\nNCT04839445\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t33122942|32490608\tJones JH, Aldwinckle R. Interfascial Plane Blocks and Laparoscopic Abdominal Surgery: A Narrative Review. Local Reg Anesth. 2020 Oct 23;13:159-169. doi: 10.2147/LRA.S272694. eCollection 2020. Review.|Bagaphou CT, Santonastaso DP, Rispoli M, Piraccini E, Fusco P, Gori F. Bilateral continuous erector spinae plane block: an alternative to epidural catheter for major open abdominal surgery. Minerva Anestesiol. 2020 Sep;86(9):993-994. doi: 10.23736/S0375-9393.20.14557-7. Epub 2020 Jun 2.\t","Anesthesia|Gynecologic Cancer","General anesthesia + TAP block|General anesthesia + ESP block","Parallel Assignment","Treatment","Randomized","Procedure|Procedure","Female","\tESP vs TAP in Total Laparoscopic Hysterectomy\tInterventional\tRecruiting\tN/A\t2\t78\tNA\tanesthetics\tNA\nNCT04839887\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t24655479|32912563|32015089|26215135|27176617|30129475|25128182|32735024|31272664|32745720|31678939|25362090|15105517|30489673|32511173|33271487|24578210|21933424|32689648\tArntz RM, van Alebeek ME, Synhaeve NE, Brouwers PJ, van Dijk GW, Gons RA, den Heijer T, de Kort PL, de Laat KF, van Norden AG, Vermeer SE, van der Vlugt MJ, Kessels RP, van Dijk EJ, de Leeuw FE. Observational Dutch Young Symptomatic StrokE studY (ODYSSEY): study rationale and protocol of a multicentre prospective cohort study. BMC Neurol. 2014 Mar 22;14:55. doi: 10.1186/1471-2377-14-55.|Bartholomé L, Winter Y. Quality of Life and Resilience of Patients With Juvenile Stroke: A Systematic Review. J Stroke Cerebrovasc Dis. 2020 Oct;29(10):105129. doi: 10.1016/j.jstrokecerebrovasdis.2020.105129. Epub 2020 Jul 15.|Boot E, Ekker MS, Putaala J, Kittner S, De Leeuw FE, Tuladhar AM. Ischaemic stroke in young adults: a global perspective. J Neurol Neurosurg Psychiatry. 2020 Apr;91(4):411-417. doi: 10.1136/jnnp-2019-322424. Epub 2020 Feb 3. Review.|de Bruijn MA, Synhaeve NE, van Rijsbergen MW, de Leeuw FE, Mark RE, Jansen BP, de Kort PL. Quality of Life after Young Ischemic Stroke of Mild Severity Is Mainly Influenced by Psychological Factors. J Stroke Cerebrovasc Dis. 2015 Oct;24(10):2183-8. doi: 10.1016/j.jstrokecerebrovasdis.2015.04.040. Epub 2015 Jul 26.|Douven E, Schievink SH, Verhey FR, van Oostenbrugge RJ, Aalten P, Staals J, Köhler S. The Cognition and Affect after Stroke - a Prospective Evaluation of Risks (CASPER) study: rationale and design. BMC Neurol. 2016 May 12;16:65. doi: 10.1186/s12883-016-0588-1.|Ekker MS, Boot EM, Singhal AB, Tan KS, Debette S, Tuladhar AM, de Leeuw FE. Epidemiology, aetiology, and management of ischaemic stroke in young adults. Lancet Neurol. 2018 Sep;17(9):790-801. doi: 10.1016/S1474-4422(18)30233-3. Review.|Harno H, Haapaniemi E, Putaala J, Haanpää M, Mäkelä JP, Kalso E, Tatlisumak T. Central poststroke pain in young ischemic stroke survivors in the Helsinki Young Stroke Registry. Neurology. 2014 Sep 23;83(13):1147-54. doi: 10.1212/WNL.0000000000000818. Epub 2014 Aug 15.|Heiberg G, Friborg O, Pedersen SG, Thrane G, Holm Stabel H, Feldbæk Nielsen J, Anke A. Post-stroke health-related quality of life at 3 and 12 months and predictors of change in a Danish and Arctic Norwegian Region. J Rehabil Med. 2020 Sep 8;52(9):jrm00096. doi: 10.2340/16501977-2716.|Kapoor A, Scott C, Lanctot KL, Herrmann N, Murray BJ, Thorpe KE, Lien K, Sicard M, Swartz RH. Symptoms of depression and cognitive impairment in young adults after stroke/transient ischemic attack. Psychiatry Res. 2019 Sep;279:361-363. doi: 10.1016/j.psychres.2019.06.022. Epub 2019 Jul 1.|Kono Y, Terasawa Y, Sakai K, Iguchi Y, Nishiyama Y, Nito C, Suda S, Kimura K, Kanzawa T, Imafuku I, Nakayama T, Ueda M, Iwanaga T, Kono T, Yamashiro K, Tanaka R, Okubo S, Nakajima M, Nakajima N, Mishina M, Yaguchi H, Oka H, Suzuki M, Osaki M, Kaneko N, Kitagawa K, Okamoto S, Nomura K, Yamazaki M, Nagao T, Murakami Y. Risk factors, etiology, and outcome of ischemic stroke in young adults: A Japanese multicenter prospective study. J Neurol Sci. 2020 Oct 15;417:117068. doi: 10.1016/j.jns.2020.117068. Epub 2020 Jul 29.|Lam KH, Blom E, Kwa VIH. Predictors of quality of life 1 year after minor stroke or TIA: a prospective single-centre cohort study. BMJ Open. 2019 Nov 2;9(11):e029697. doi: 10.1136/bmjopen-2019-029697.|Maaijwee NA, Arntz RM, Rutten-Jacobs LC, Schaapsmeerders P, Schoonderwaldt HC, van Dijk EJ, de Leeuw FE. Post-stroke fatigue and its association with poor functional outcome after stroke in young adults. J Neurol Neurosurg Psychiatry. 2015 Oct;86(10):1120-6. doi: 10.1136/jnnp-2014-308784. Epub 2014 Oct 31.|McKevitt C, Redfern J, Mold F, Wolfe C. Qualitative studies of stroke: a systematic review. Stroke. 2004 Jun;35(6):1499-505. Epub 2004 Apr 22. Review.|Pinter D, Enzinger C, Gattringer T, Eppinger S, Niederkorn K, Horner S, Fandler S, Kneihsl M, Krenn K, Bachmaier G, Fazekas F. Prevalence and short-term changes of cognitive dysfunction in young ischaemic stroke patients. Eur J Neurol. 2019 May;26(5):727-732. doi: 10.1111/ene.13879. Epub 2019 Jan 9.|Rhudy LM, Wells-Pittman J, Flemming KD. Psychosocial Sequelae of Stroke in Working-Age Adults: A Pilot Study. J Neurosci Nurs. 2020 Aug;52(4):192-199. doi: 10.1097/JNN.0000000000000523.|Schneider S, Taba N, Saapar M, Vibo R, Kõrv J. Determinants of Long-Term Health-Related Quality of Life in Young Ischemic Stroke Patients. J Stroke Cerebrovasc Dis. 2021 Feb;30(2):105499. doi: 10.1016/j.jstrokecerebrovasdis.2020.105499. Epub 2020 Nov 30.|Synhaeve NE, Arntz RM, Maaijwee NA, Rutten-Jacobs LC, Schoonderwaldt HC, Dorresteijn LD, de Kort PL, van Dijk EJ, de Leeuw FE. Poor long-term functional outcome after stroke among adults aged 18 to 50 years: Follow-Up of Transient Ischemic Attack and Stroke Patients and Unelucidated Risk Factor Evaluation (FUTURE) study. Stroke. 2014 Apr;45(4):1157-60. doi: 10.1161/STROKEAHA.113.004411. Epub 2014 Feb 27.|Rutten-Jacobs LC, Maaijwee NA, Arntz RM, Van Alebeek ME, Schaapsmeerders P, Schoonderwaldt HC, Dorresteijn LD, Overeem S, Drost G, Janssen MC, van Heerde WL, Kessels RP, Zwiers MP, Norris DG, van der Vlugt MJ, van Dijk EJ, de Leeuw FE. Risk factors and prognosis of young stroke. The FUTURE study: a prospective cohort study. Study rationale and protocol. BMC Neurol. 2011 Sep 20;11:109. doi: 10.1186/1471-2377-11-109.|Zawawi NSM, Aziz NA, Fisher R, Ahmad K, Walker MF. The Unmet Needs of Stroke Survivors and Stroke Caregivers: A Systematic Narrative Review. J Stroke Cerebrovasc Dis. 2020 Aug;29(8):104875. doi: 10.1016/j.jstrokecerebrovasdis.2020.104875. Epub 2020 May 23.\t","Ischemic Stroke","NA","NA","NA","NA","NA","All","\tNA\tNA\tNA\tNA\tNA\tNA\tcerebral infarction|stroke|ischemia\tNA\tNA\nNCT04840173\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t12040306|24175165|11001602|26519453|24009169|7203086\tReady RE, Ott BR, Grace J, Fernandez I. The Cornell-Brown Scale for Quality of Life in dementia. Alzheimer Dis Assoc Disord. 2002 Apr-Jun;16(2):109-15.|Gerdner LA. Individualized music for dementia: Evolution and application of evidence-based protocol. World J Psychiatry. 2012 Apr 22;2(2):26-32. doi: 10.5498/wjp.v2.i2.26.|Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, DeKosky ST. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):233-9.|Ray KD, Mittelman MS. Music therapy: A nonpharmacological approach to the care of agitation and depressive symptoms for nursing home residents with dementia. Dementia (London). 2017 Aug;16(6):689-710. doi: 10.1177/1471301215613779. Epub 2015 Oct 29.|Särkämö T, Tervaniemi M, Laitinen S, Numminen A, Kurki M, Johnson JK, Rantanen P. Cognitive, emotional, and social benefits of regular musical activities in early dementia: randomized controlled study. Gerontologist. 2014 Aug;54(4):634-50. doi: 10.1093/geront/gnt100. Epub 2013 Sep 5.|Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist. 1980 Dec;20(6):649-55.\t","Alzheimer's Disease (Incl Subtypes)|Depressive Symptoms","Music","NA","NA","NA","Behavioral","Female","\tNA\tNA\tNA\tNA\tNA\tNA\talzheimer disease|depression\tNA\tNA\nNCT04840940\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t27418577|23622939|24162674|27925784|22258968|21418551|18421435|15447947|33211135|21740312|21839732|28875483|25319385|24393424|27389015|32333860|32530491|33147871|26030716|33095752|26357898|30611989\tKalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratalà J, El Solh AA, Ewig S, Fey PD, File TM Jr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016 Sep 1;63(5):e61-e111. doi: 10.1093/cid/ciw353. Epub 2016 Jul 14. Erratum in: Clin Infect Dis. 2017 May 1;64(9):1298. Erratum in: Clin Infect Dis. 2017 Oct 15;65(8):1435. Clin Infect Dis. 2017 Nov 29;65(12):2161.|Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT, Hanisch EW, Klarin B, Koeman M, Krueger WA, Lacherade JC, Lorente L, Memish ZA, Morrow LE, Nardi G, van Nieuwenhoven CA, O'Keefe GE, Nakos G, Scannapieco FA, Seguin P, Staudinger T, Topeli A, Ferrer M, Bonten MJ. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013 Aug;13(8):665-71. doi: 10.1016/S1473-3099(13)70081-1. Epub 2013 Apr 25.|Magill SS, Klompas M, Balk R, Burns SM, Deutschman CS, Diekema D, Fridkin S, Greene L, Guh A, Gutterman D, Hammer B, Henderson D, Hess D, Hill NS, Horan T, Kollef M, Levy M, Septimus E, VanAntwerpen C, Wright D, Lipsett P. Developing a new, national approach to surveillance for ventilator-associated events*. Crit Care Med. 2013 Nov;41(11):2467-75. doi: 10.1097/CCM.0b013e3182a262db.|Erb CT, Patel B, Orr JE, Bice T, Richards JB, Metersky ML, Wilson KC, Thomson CC. Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia. Ann Am Thorac Soc. 2016 Dec;13(12):2258-2260.|Berton DC, Kalil AC, Teixeira PJ. Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia. Cochrane Database Syst Rev. 2012 Jan 18;1:CD006482. doi: 10.1002/14651858.CD006482.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;10:CD006482.|Fagon JY. Biological markers and diagnosis of ventilator-associated pneumonia. Crit Care. 2011;15(2):130. doi: 10.1186/cc10050. Epub 2011 Mar 9.|Luyt CE, Combes A, Reynaud C, Hekimian G, Nieszkowska A, Tonnellier M, Aubry A, Trouillet JL, Bernard M, Chastre J. Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia. Intensive Care Med. 2008 Aug;34(8):1434-40. doi: 10.1007/s00134-008-1112-x. Epub 2008 Apr 18.|Luyt CE, Guérin V, Combes A, Trouillet JL, Ayed SB, Bernard M, Gibert C, Chastre J. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med. 2005 Jan 1;171(1):48-53. Epub 2004 Sep 24.|COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2021 Jan;47(1):60-73. doi: 10.1007/s00134-020-06294-x. Epub 2020 Oct 29.|Mussap M, Noto A, Fravega M, Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. J Matern Fetal Neonatal Med. 2011 Oct;24 Suppl 2:12-4. doi: 10.3109/14767058.2011.601923. Review.|Okamura Y, Yokoi H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clin Chim Acta. 2011 Nov 20;412(23-24):2157-61. doi: 10.1016/j.cca.2011.07.024. Epub 2011 Aug 3.|Wu CC, Lan HM, Han ST, Chaou CH, Yeh CF, Liu SH, Li CH, Blaney GN 3rd, Liu ZY, Chen KF. Comparison of diagnostic accuracy in sepsis between presepsin, procalcitonin, and C-reactive protein: a systematic review and meta-analysis. Ann Intensive Care. 2017 Sep 6;7(1):91. doi: 10.1186/s13613-017-0316-z.|Masson S, Caironi P, Fanizza C, Thomae R, Bernasconi R, Noto A, Oggioni R, Pasetti GS, Romero M, Tognoni G, Latini R, Gattinoni L. Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial. Intensive Care Med. 2015 Jan;41(1):12-20. doi: 10.1007/s00134-014-3514-2. Epub 2014 Oct 16. Erratum in: Intensive Care Med. 2015 Sep;41(9):1736.|Masson S, Caironi P, Spanuth E, Thomae R, Panigada M, Sangiorgi G, Fumagalli R, Mauri T, Isgrò S, Fanizza C, Romero M, Tognoni G, Latini R, Gattinoni L; ALBIOS Study Investigators. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. Crit Care. 2014 Jan 7;18(1):R6. doi: 10.1186/cc13183.|Klouche K, Cristol JP, Devin J, Gilles V, Kuster N, Larcher R, Amigues L, Corne P, Jonquet O, Dupuy AM. Diagnostic and prognostic value of soluble CD14 subtype (Presepsin) for sepsis and community-acquired pneumonia in ICU patients. Ann Intensive Care. 2016 Dec;6(1):59. doi: 10.1186/s13613-016-0160-6. Epub 2016 Jul 7.|Zaninotto M, Mion MM, Cosma C, Rinaldi D, Plebani M. Presepsin in risk stratification of SARS-CoV-2 patients. Clin Chim Acta. 2020 Aug;507:161-163. doi: 10.1016/j.cca.2020.04.020. Epub 2020 Apr 22.|Fukada A, Kitagawa Y, Matsuoka M, Sakai J, Imai K, Tarumoto N, Orihara Y, Kawamura R, Takeuchi S, Maesaki S, Maeda T. Presepsin as a predictive biomarker of severity in COVID-19: A case series. J Med Virol. 2021 Jan;93(1):99-101. doi: 10.1002/jmv.26164. Epub 2020 Jun 24.|Schirinzi A, Cazzolla AP, Lovero R, Lo Muzio L, Testa NF, Ciavarella D, Palmieri G, Pozzessere P, Procacci V, Di Serio F, Santacroce L. New Insights in Laboratory Testing for COVID-19 Patients: Looking for the Role and Predictive Value of Human epididymis secretory protein 4 (HE4) and the Innate Immunity of the Oral Cavity and Respiratory Tract. Microorganisms. 2020 Nov 2;8(11). pii: E1718. doi: 10.3390/microorganisms8111718.|Nagata T, Yasuda Y, Ando M, Abe T, Katsuno T, Kato S, Tsuboi N, Matsuo S, Maruyama S. Clinical impact of kidney function on presepsin levels. PLoS One. 2015 Jun 1;10(6):e0129159. doi: 10.1371/journal.pone.0129159. eCollection 2015.|Ferrarese A, Frigo AC, Mion MM, Plebani M, Russo FP, Germani G, Gambato M, Cillo U, Cattelan A, Burra P, Senzolo M. Diagnostic and prognostic role of presepsin in patients with cirrhosis and bacterial infection. Clin Chem Lab Med. 2020 Oct 23. pii: cclm-2020-1212. doi: 10.1515/cclm-2020-1212. [Epub ahead of print]|Zhang X, Liu D, Liu YN, Wang R, Xie LX. The accuracy of presepsin (sCD14-ST) for the diagnosis of sepsis in adults: a meta-analysis. Crit Care. 2015 Sep 11;19:323. doi: 10.1186/s13054-015-1032-4.|Memar MY, Baghi HB. Presepsin: A promising biomarker for the detection of bacterial infections. Biomed Pharmacother. 2019 Mar;111:649-656. doi: 10.1016/j.biopha.2018.12.124. Epub 2019 Jan 3. Review.\t","Covid19|Ventilator Associated Pneumonia","NA","NA","NA","NA","NA","All","\tNA\tNA\tNA\tNA\tNA\tNA\tpneumonia, ventilator-associated|pneumonia\tNA\tNA\nNCT04841213\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t33257353\tDiachkova E, Abramova EV, Blagushina NA, Tarasenko S. Surgical treatment with dental implants in a patient with secondary loss of teeth and osteoporosis caused by an imbalance of vitamin D. BMJ Case Rep. 2020 Nov 30;13(11). pii: e235585. doi: 10.1136/bcr-2020-235585.\t","Osteomalacia|Tooth Loss|Vitamin D3 Deficiency","Dental implantation","Parallel Assignment","Treatment","Randomized","Procedure","All","\tDental Implants Rehabilitation in Patients With Vitamin D3 Imbalance\tInterventional\tRecruiting\tN/A\t2\t384\ttooth loss|osteomalacia\tNA\tNA\nNCT04841343\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t20513050\tCôté DW, Wright ED. Triamcinolone-impregnated nasal dressing following endoscopic sinus surgery: a randomized, double-blind, placebo-controlled study. Laryngoscope. 2010 Jun;120(6):1269-73. doi: 10.1002/lary.20905.\t","Sinusitis","Triamcinolone","NA","NA","NA","Drug","All","\tNA\tNA\tNA\tNA\tNA\tNA\tsinusitis\ttriamcinolone\tNA\nNCT04841460\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t21525253\tGilmore LA, Walzem RL, Crouse SF, Smith DR, Adams TH, Vaidyanathan V, Cao X, Smith SB. Consumption of high-oleic acid ground beef increases HDL-cholesterol concentration but both high- and low-oleic acid ground beef decrease HDL particle diameter in normocholesterolemic men. J Nutr. 2011 Jun;141(6):1188-94. doi: 10.3945/jn.110.136085. Epub 2011 Apr 27.\t","Cholesterol, HDL|Cholesterol, LDL|Research Subjects","Low-fat ground beef|High-fat ground beef","Crossover Assignment","Basic Science","Randomized","Dietary Supplement|Dietary Supplement","Male","\tImpact of Beef's Unique Food Matrix on Human Health\tInterventional\tCompleted\tN/A\t2\t25\tNA\tNA\tNA\nNCT04841499\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t25660429|28915830|28041599|26491826|28816586|2554542|29883761|27552971|21525161\tParazzini F. Resveratrol, tryptophanum, glycine and vitamin E: a nutraceutical approach to sleep disturbance and irritability in peri- and post-menopause. Minerva Ginecol. 2015 Feb;67(1):1-5. Review.|Uberti F, Morsanuto V, Aprile S, Ghirlanda S, Stoppa I, Cochis A, Grosa G, Rimondini L, Molinari C. Biological effects of combined resveratrol and vitamin D3 on ovarian tissue. J Ovarian Res. 2017 Sep 15;10(1):61. doi: 10.1186/s13048-017-0357-9.|Davinelli S, Scapagnini G, Marzatico F, Nobile V, Ferrara N, Corbi G. Influence of equol and resveratrol supplementation on health-related quality of life in menopausal women: A randomized, placebo-controlled study. Maturitas. 2017 Feb;96:77-83. doi: 10.1016/j.maturitas.2016.11.016. Epub 2016 Nov 27.|Leo L, Surico D, Deambrogio F, Scatuzzi A, Marzullo P, Tinelli R, Molinari C, Surico N. [Preliminary data on the effectiveness of resveratrol in a new formulation in treatment of hot flushes]. Minerva Ginecol. 2015 Oct;67(5):475-83. Italian.|Narumi M, Takahashi K, Yamatani H, Seino M, Yamanouchi K, Ohta T, Takahashi T, Kurachi H, Nagase S. Oxidative Stress in the Visceral Fat Is Elevated in Postmenopausal Women with Gynecologic Cancer. J Womens Health (Larchmt). 2018 Jan;27(1):99-106. doi: 10.1089/jwh.2016.6301. Epub 2017 Aug 17.|Murugesan K, Vij U, Lal B, Farooq A. Effect of progestins, estradiol, and coenzymes NAD and NADPH on the interconversion of estradiol and estrone in rabbit uterus in vitro. Steroids. 1989 Jun;53(6):695-712.|Yaku K, Okabe K, Nakagawa T. NAD metabolism: Implications in aging and longevity. Ageing Res Rev. 2018 Nov;47:1-17. doi: 10.1016/j.arr.2018.05.006. Epub 2018 Jun 5. Review.|Bonkowski MS, Sinclair DA. Slowing ageing by design: the rise of NAD(+) and sirtuin-activating compounds. Nat Rev Mol Cell Biol. 2016 Nov;17(11):679-690. doi: 10.1038/nrm.2016.93. Epub 2016 Aug 24. Review.|Joffe H, Petrillo LF, Koukopoulos A, Viguera AC, Hirschberg A, Nonacs R, Somley B, Pasciullo E, White DP, Hall JE, Cohen LS. Increased estradiol and improved sleep, but not hot flashes, predict enhanced mood during the menopausal transition. J Clin Endocrinol Metab. 2011 Jul;96(7):E1044-54. doi: 10.1210/jc.2010-2503. Epub 2011 Apr 27.\t","Menopause","BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)","NA","NA","NA","Drug","Female","\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tniacinamide|niacin|nicotinic acids\tNA\nNCT04841681\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t32425006|32379667|22196836|33013503|32406348|32794128|32772205\tWei N, Huang BC, Lu SJ, Hu JB, Zhou XY, Hu CC, Chen JK, Huang JW, Li SG, Wang Z, Wang DD, Xu Y, Hu SH. Efficacy of internet-based integrated intervention on depression and anxiety symptoms in patients with COVID-19. J Zhejiang Univ Sci B. 2020 May;21(5):400-404. doi: 10.1631/jzus.B2010013. Epub 2020 Apr 1.|Liu K, Chen Y, Wu D, Lin R, Wang Z, Pan L. Effects of progressive muscle relaxation on anxiety and sleep quality in patients with COVID-19. Complement Ther Clin Pract. 2020 May;39:101132. doi: 10.1016/j.ctcp.2020.101132. Epub 2020 Mar 6.|Dekker RL, Moser DK, Peden AR, Lennie TA. Cognitive therapy improves three-month outcomes in hospitalized patients with heart failure. J Card Fail. 2012 Jan;18(1):10-20. doi: 10.1016/j.cardfail.2011.09.008. Epub 2011 Nov 9.|Conversano C, Di Giuseppe M, Miccoli M, Ciacchini R, Gemignani A, Orrù G. Mindfulness, Age and Gender as Protective Factors Against Psychological Distress During COVID-19 Pandemic. Front Psychol. 2020 Sep 11;11:1900. doi: 10.3389/fpsyg.2020.01900. eCollection 2020.|Behan C. The benefits of meditation and mindfulness practices during times of crisis such as COVID-19. Ir J Psychol Med. 2020 Dec;37(4):256-258. doi: 10.1017/ipm.2020.38. Epub 2020 May 14.|Grazzi L, Rizzoli P, Andrasik F. Effectiveness of mindfulness by smartphone, for patients with chronic migraine and medication overuse during the Covid-19 emergency. Neurol Sci. 2020 Dec;41(Suppl 2):461-462. doi: 10.1007/s10072-020-04659-0.|Reyes AT. A Mindfulness Mobile App for Traumatized COVID-19 Healthcare Workers and Recovered Patients: A Response to \"\"The Use of Digital Applications and COVID-19\"\". Community Ment Health J. 2020 Oct;56(7):1204-1205. doi: 10.1007/s10597-020-00690-9. Epub 2020 Aug 9.\"","\tCovid19|Distress, Emotional\tVideo-based Psychotherapy\tNA\tNA\tNA\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04841785","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32243281|33326716|6595298|31464823|32868447|33340043|32848205|NA|33151337|33125914|21672157|25072119|33168562|32785669|33301246|30876620|31477039|31024571|32640463","Ahn C, Amer H, Anglicheau D, Ascher NL, Baan CC, Battsetset G, Bat-Ireedui B, Berney T, Betjes MGH, Bichu S, Birn H, Brennan D, Bromberg J, Caillard S, Cannon RM, Cantarovich M, Chan A, Chen ZS, Chapman JR, Cole EH, Cross N, Durand F, Egawa H, Emond JC, Farrero M, Friend PJ, Geissler EK, Ha J, Haberal MA, Henderson ML, Hesselink DA, Humar A, Jassem W, Jeong JC, Kaplan B, Kee T, Kim SJ, Kumar D, Legendre CM, Man K, Moulin B, Muller E, Munkhbat R, Od-Erdene L, Perrin P, Rela M, Tanabe K, Tedesco Silva H, Tinckam KT, Tullius SG, Wong G. Global Transplantation COVID Report March 2020. Transplantation. 2020 Oct;104(10):1974-1983. doi: 10.1097/TP.0000000000003258.|Baric RS. Emergence of a Highly Fit SARS-CoV-2 Variant. N Engl J Med. 2020 Dec 31;383(27):2684-2686. doi: 10.1056/NEJMcibr2032888. Epub 2020 Dec 16.|Robison SF, Mayhew RB, Cowan RD, Hawley RJ. Comparative study of deflection characteristics and fragility of 25-, 27-, and 30-gauge short dental needles. J Am Dent Assoc. 1984 Dec;109(6):920-4.|Berends SE, Bloem K, de Vries A, Schaap T, Rispens T, Strik AS, Talwar R, Löwenberg M, D'Haens GR, Mathôt RA. Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples. Ther Drug Monit. 2020 Apr;42(2):289-294. doi: 10.1097/FTD.0000000000000686.|Dearlove B, Lewitus E, Bai H, Li Y, Reeves DB, Joyce MG, Scott PT, Amare MF, Vasan S, Michael NL, Modjarrad K, Rolland M. A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants. Proc Natl Acad Sci U S A. 2020 Sep 22;117(38):23652-23662. doi: 10.1073/pnas.2008281117. Epub 2020 Aug 31.|ERA-EDTA Council; ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transplant. 2021 Jan 1;36(1):87-94. doi: 10.1093/ndt/gfaa314.|Gansevoort RT, Hilbrands LB. CKD is a key risk factor for COVID-19 mortality. Nat Rev Nephrol. 2020 Dec;16(12):705-706. doi: 10.1038/s41581-020-00349-4.|Gezondheidsraad. Strategieën voor COVID-19-vaccinatie. Den Haag: Gezondheidsraad, 2020; publicatienr. 2020/23|Hilbrands LB, Duivenvoorden R, Vart P, Franssen CFM, Hemmelder MH, Jager KJ, Kieneker LM, Noordzij M, Pena MJ, Vries H, Arroyo D, Covic A, Crespo M, Goffin E, Islam M, Massy ZA, Montero N, Oliveira JP, Roca Muñoz A, Sanchez JE, Sridharan S, Winzeler R, Gansevoort RT; ERACODA Collaborators. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant. 2020 Nov 1;35(11):1973-1983. doi: 10.1093/ndt/gfaa261.|Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021 Feb;21(2):e26-e35. doi: 10.1016/S1473-3099(20)30773-8. Epub 2020 Oct 27. Review.|Katerinis I, Hadaya K, Duquesnoy R, Ferrari-Lacraz S, Meier S, van Delden C, Martin PY, Siegrist CA, Villard J. De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant. 2011 Aug;11(8):1727-33. doi: 10.1111/j.1600-6143.2011.03604.x. Epub 2011 Jun 14.|Kotton CN. Immunization after kidney transplantation-what is necessary and what is safe? Nat Rev Nephrol. 2014 Oct;10(10):555-62. doi: 10.1038/nrneph.2014.122. Epub 2014 Jul 29. Review.|Mahase E. Covid-19: Vaccine candidate may be more than 90% effective, interim results indicate. BMJ. 2020 Nov 9;371:m4347. doi: 10.1136/bmj.m4347.|Noordzij M, Duivenvoorden R, Pena MJ, de Vries H, Kieneker LM; collaborative ERACODA authors. ERACODA: the European database collecting clinical information of patients on kidney replacement therapy with COVID-19. Nephrol Dial Transplant. 2020 Dec 4;35(12):2023-2025. doi: 10.1093/ndt/gfaa179.|Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.|Reddy S, Chitturi C, Yee J. Vaccination in Chronic Kidney Disease. Adv Chronic Kidney Dis. 2019 Jan;26(1):72-78. doi: 10.1053/j.ackd.2018.10.002. Review.|van der Willik EM, Meuleman Y, Prantl K, van Rijn G, Bos WJW, van Ittersum FJ, Bart HAJ, Hemmelder MH, Dekker FW. Patient-reported outcome measures: selection of a valid questionnaire for routine symptom assessment in patients with advanced chronic kidney disease - a four-phase mixed methods study. BMC Nephrol. 2019 Sep 2;20(1):344. doi: 10.1186/s12882-019-1521-9.|van Besouw NM, Yan L, de Kuiper R, Klepper M, Reijerkerk D, Dieterich M, Roelen DL, Claas FHJ, Clahsen-van Groningen MC, Hesselink DA, Baan CC. The Number of Donor-Specific IL-21 Producing Cells Before and After Transplantation Predicts Kidney Graft Rejection. Front Immunol. 2019 Apr 9;10:748. doi: 10.3389/fimmu.2019.00748. eCollection 2019.|Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas IJ, Rentsch CT, Mathur R, Wong AYS, Grieve R, Harrison D, Forbes H, Schultze A, Croker R, Parry J, Hester F, Harper S, Perera R, Evans SJW, Smeeth L, Goldacre B. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 Aug;584(7821):430-436. doi: 10.1038/s41586-020-2521-4. Epub 2020 Jul 8.","\tChronic Kidney Diseases|Covid19|SARS-CoV Infection\tmailer-based finger-prick\tNA\tNA\tNA\tDiagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","kidney diseases|renal insufficiency, chronic|severe acute respiratory syndrome","NA","NA"]
["NCT04841993","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","33451073|33322849|33298281|33155722","Busardò FP, Pérez-Acevedo AP, Pacifici R, Mannocchi G, Gottardi M, Papaseit E, Pérez-Mañá C, Martin S, Poyatos L, Pichini S, Farré M. Disposition of Phytocannabinoids, Their Acidic Precursors and Their Metabolites in Biological Matrices of Healthy Individuals Treated with Vaporized Medical Cannabis. Pharmaceuticals (Basel). 2021 Jan 13;14(1). pii: 59. doi: 10.3390/ph14010059.|Pérez-Acevedo AP, Busardò FP, Pacifici R, Mannocchi G, Gottardi M, Poyatos L, Papaseit E, Pérez-Mañá C, Martin S, Di Trana A, Pichini S, Farré M. Disposition of Cannabidiol Metabolites in Serum and Urine from Healthy Individuals Treated with Pharmaceutical Preparations of Medical Cannabis. Pharmaceuticals (Basel). 2020 Dec 12;13(12). pii: E459. doi: 10.3390/ph13120459.|Pichini S, Malaca S, Gottardi M, Pérez-Acevedo AP, Papaseit E, Perez-Maña C, Farré M, Pacifici R, Tagliabracci A, Mannocchi G, Busardò FP. UHPLC-MS/MS analysis of cannabidiol metabolites in serum and urine samples. Application to an individual treated with medical cannabis. Talanta. 2021 Feb 1;223(Pt 2):121772. doi: 10.1016/j.talanta.2020.121772. Epub 2020 Oct 14.|Pérez-Acevedo AP, Pacifici R, Mannocchi G, Gottardi M, Poyatos L, Papaseit E, Pérez-Mañá C, Martin S, Busardò FP, Pichini S, Farré M. Disposition of cannabinoids and their metabolites in serum, oral fluid, sweat patch and urine from healthy individuals treated with pharmaceutical preparations of medical cannabis. Phytother Res. 2020 Nov 6. doi: 10.1002/ptr.6931. [Epub ahead of print]","\tCannabis Use|Healthy Subjects\tCannabis decoction|Cannabis oil|Vaporized cannabis\tNA\tNA\tNA\tDrug|Drug|Drug\tAll\t","Pharmacokinetics and Pharmacological Effects of a Standardized Cannabis Preparation","Interventional","Completed","Phase 1",3,43,"marijuana abuse","NA","NA"]
["NCT04842357","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19215895|21821220|22511182","Shippey S, Handa VL, Chen TL, Chou B, Bowen CW. Validation of an instrument for evaluation of subcuticular suturing using a plastic tissue model. J Surg Educ. 2009 Jan-Feb;66(1):31-4. doi: 10.1016/j.jsurg.2008.09.001.|Shippey SH, Chen TL, Chou B, Knoepp LR, Bowen CW, Handa VL. Teaching subcuticular suturing to medical students: video versus expert instructor feedback. J Surg Educ. 2011 Sep-Oct;68(5):397-402. doi: 10.1016/j.jsurg.2011.04.006. Epub 2011 Jun 25.|Oriot D, Darrieux E, Boureau-Voultoury A, Ragot S, Scépi M. Validation of a performance assessment scale for simulated intraosseous access. Simul Healthc. 2012 Jun;7(3):171-5. doi: 10.1097/SIH.0b013e31824a5c20.","\tClinical Skills|Education|Intra-osseous|Sutures\tstandardised video concerning clinical skill\tCrossover Assignment\tOther\tRandomized\tOther\tAll\t","Imparting of Practical Skills by Digital Methods","Interventional","Not yet recruiting","N/A",2,64,"NA","NA","NA"]
["NCT04843293","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21683194|23392317|17625573|30567878|30287775|30015674|21884372","Gay AN, Lazar DA, Stoll B, Naik-Mathuria B, Mushin OP, Rodriguez MA, Burrin DG, Olutoye OO. Near-infrared spectroscopy measurement of abdominal tissue oxygenation is a useful indicator of intestinal blood flow and necrotizing enterocolitis in premature piglets. J Pediatr Surg. 2011 Jun;46(6):1034-40. doi: 10.1016/j.jpedsurg.2011.03.025.|Gillam-Krakauer M, Cochran CM, Slaughter JC, Polavarapu S, McElroy SJ, Hernanz-Schulman M, Engelhardt B. Correlation of abdominal rSO2 with superior mesenteric artery velocities in preterm infants. J Perinatol. 2013 Aug;33(8):609-12. doi: 10.1038/jp.2013.3. Epub 2013 Feb 7.|Kirk AT, Alder SC, King JD. Cue-based oral feeding clinical pathway results in earlier attainment of full oral feeding in premature infants. J Perinatol. 2007 Sep;27(9):572-8. Epub 2007 Jul 12.|Neal-Kluever A, Fisher J, Grylack L, Kakiuchi-Kiyota S, Halpern W. Physiology of the Neonatal Gastrointestinal System Relevant to the Disposition of Orally Administered Medications. Drug Metab Dispos. 2019 Mar;47(3):296-313. doi: 10.1124/dmd.118.084418. Epub 2018 Dec 19.|Pillai A, Albersheim S, Matheson J, Lalari V, Wei S, Innis SM, Elango R. Evaluation of A Concentrated Preterm Formula as a Liquid Human Milk Fortifier in Preterm Babies at Increased Risk of Feed Intolerance. Nutrients. 2018 Oct 4;10(10). pii: E1433. doi: 10.3390/nu10101433.|Thomas S, Nesargi S, Roshan P, Raju R, Mathew S, P S, Rao S. Gastric Residual Volumes Versus Abdominal Girth Measurement in Assessment of Feed Tolerance in Preterm Neonates: A Randomized Controlled Trial. Adv Neonatal Care. 2018 Aug;18(4):E13-E19. doi: 10.1097/ANC.0000000000000532.|Yildiz A, Arikan D, Gözüm S, Taştekın A, Budancamanak I. The effect of the odor of breast milk on the time needed for transition from gavage to total oral feeding in preterm infants. J Nurs Scholarsh. 2011 Sep;43(3):265-73. doi: 10.1111/j.1547-5069.2011.01410.x. Epub 2011 Jul 25.","\tBreast Milk|Digestion|Nutrition|Preterm Birth|Smell Stimulation\tOlfactory stimulation\tParallel Assignment\tSupportive Care\tRandomized\tBehavioral\tAll\t","The Effect of Breast Milk Smell on Nutrition in Preterms","Interventional","Recruiting","N/A",2,56,"premature birth","NA","NA"]
["NCT04843462","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22132433|32775969","National Collaborating Centre for Mental Health (UK). Depression: The Treatment and Management of Depression in Adults (Updated Edition). Leicester (UK): British Psychological Society; 2010.|Luo C, Sanger N, Singhal N, Pattrick K, Shams I, Shahid H, Hoang P, Schmidt J, Lee J, Haber S, Puckering M, Buchanan N, Lee P, Ng K, Sun S, Kheyson S, Chung DC, Sanger S, Thabane L, Samaan Z. A comparison of electronically-delivered and face to face cognitive behavioural therapies in depressive disorders: A systematic review and meta-analysis. EClinicalMedicine. 2020 Jun 27;24:100442. doi: 10.1016/j.eclinm.2020.100442. eCollection 2020 Jul.","\tMajor Depressive Disorder|Therapy Resistant Depression\tedupression.com®|Esketamine nasal spray\tParallel Assignment\tTreatment\tRandomized\tDevice|Drug\tAll\t","Add-on Therapy With Edupression.Com® on Therapy Resistant Depressive Patients Treated With Nasal Esketamine Spray","Interventional","Recruiting","N/A",2,70,"depressive disorder|depressive disorder, treatment-resistant|depressive disorder, major|depression","esketamine","NA"]
["NCT04843605","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20206064,"Fuhrman C, Delmas MC; pour le groupe épidémiologie et recherche clinique de la SPLF. [Epidemiology of chronic obstructive pulmonary disease in France]. Rev Mal Respir. 2010 Feb;27(2):160-8. doi: 10.1016/j.rmr.2009.08.003. Epub 2010 Jan 19. French.","\tSmoking Cessation\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04843618","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26330893,"Bergstrom N, Horn SD, Rapp M, Stern A, Barrett R, Watkiss M, Krahn M. Preventing Pressure Ulcers: A Multisite Randomized Controlled Trial in Nursing Homes. Ont Health Technol Assess Ser. 2014 Oct 1;14(11):1-32. eCollection 2014.","\tPressure Ulcer\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","pressure ulcer|ulcer","NA","NA"]
["NCT04843917","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32896291|33545094|33301246|27836435|31583123|11061799|28728074|33440088|33306989|33510014","Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020 Sep 26;396(10255):887-897. doi: 10.1016/S0140-6736(20)31866-3. Epub 2020 Sep 4. Erratum in: Lancet. 2021 Jan 9;397(10269):98.|Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Egorova DA, Shmarov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zyryanov SK, Borisevich SV, Naroditsky BS, Gintsburg AL; Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2. Erratum in: Lancet. 2021 Feb 20;397(10275):670.|Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.|Di Pasquale A, Bonanni P, Garçon N, Stanberry LR, El-Hodhod M, Tavares Da Silva F. Vaccine safety evaluation: Practical aspects in assessing benefits and risks. Vaccine. 2016 Dec 20;34(52):6672-6680. doi: 10.1016/j.vaccine.2016.10.039. Epub 2016 Nov 8. Review.|Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F. The how's and what's of vaccine reactogenicity. NPJ Vaccines. 2019 Sep 24;4:39. doi: 10.1038/s41541-019-0132-6. eCollection 2019. Review.|Virtanen M, Peltola H, Paunio M, Heinonen OP. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics. 2000 Nov;106(5):E62.|Mitchell TC, Casella CR. No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines. Curr Opin Immunol. 2017 Aug;47:17-25. doi: 10.1016/j.coi.2017.06.009. Epub 2017 Jul 17. Review.|Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, Berghmans PJ, Kimmel M, Van Damme P, de Hoon J, Smith W, Stephenson KE, De Rosa SC, Cohen KW, McElrath MJ, Cormier E, Scheper G, Barouch DH, Hendriks J, Struyf F, Douoguih M, Van Hoof J, Schuitemaker H. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021 May 13;384(19):1824-1835. doi: 10.1056/NEJMoa2034201. Epub 2021 Jan 13.|Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O'Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. Erratum in: Lancet. 2021 Jan 9;397(10269):98.|Hope JL, Bradley LM. Lessons in antiviral immunity. Science. 2021 Jan 29;371(6528):464-465. doi: 10.1126/science.abf6446.","\tCoronavirus 2019|Healthcare Workers|Vaccine\tImmunoglobulin G detection\tNA\tNA\tNA\tDiagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","coronavirus infections","immunoglobulins, intravenous|immunoglobulin g|antibodies|immunoglobulins","NA"]
["NCT04844151","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",20357294,"Bock CT, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J Med. 2010 Apr 1;362(13):1248-9. doi: 10.1056/NEJMc0911362.","\tMyocarditis\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","myocarditis","NA","NA"]
["NCT04844190","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","3699409|23147521|18047541|28706426|20951838|25667028|24120337|31809720|25523288|29895073|26813266|17300288|12848636|15651544|30653937","Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology. 1986 Jun;90(6):1919-25.|Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L; American College of Gastroenterology. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013 Jan;108(1):18-37; quiz 38. doi: 10.1038/ajg.2012.373. Epub 2012 Nov 13.|Wang YR, Fisher RS, Parkman HP. Gastroparesis-related hospitalizations in the United States: trends, characteristics, and outcomes, 1995-2004. Am J Gastroenterol. 2008 Feb;103(2):313-22. Epub 2007 Nov 28.|Wadhwa V, Mehta D, Jobanputra Y, Lopez R, Thota PN, Sanaka MR. Healthcare utilization and costs associated with gastroparesis. World J Gastroenterol. 2017 Jun 28;23(24):4428-4436. doi: 10.3748/wjg.v23.i24.4428.|Camilleri M, Bharucha AE, Farrugia G. Epidemiology, mechanisms, and management of diabetic gastroparesis. Clin Gastroenterol Hepatol. 2011 Jan;9(1):5-12; quiz e7. doi: 10.1016/j.cgh.2010.09.022. Epub 2010 Oct 15. Review.|Clarke JO, Snape WJ Jr. Pyloric sphincter therapy: botulinum toxin, stents, and pyloromyotomy. Gastroenterol Clin North Am. 2015 Mar;44(1):127-36. doi: 10.1016/j.gtc.2014.11.010. Epub 2015 Jan 13. Review.|Khashab MA, Stein E, Clarke JO, Saxena P, Kumbhari V, Chander Roland B, Kalloo AN, Stavropoulos S, Pasricha P, Inoue H. Gastric peroral endoscopic myotomy for refractory gastroparesis: first human endoscopic pyloromyotomy (with video). Gastrointest Endosc. 2013 Nov;78(5):764-8. doi: 10.1016/j.gie.2013.07.019.|Spadaccini M, Maselli R, Chandrasekar VT, Anderloni A, Carrara S, Galtieri PA, Di Leo M, Fugazza A, Pellegatta G, Colombo M, Palma R, Hassan C, Sethi A, Khashab MA, Sharma P, Repici A. Gastric peroral endoscopic pyloromyotomy for refractory gastroparesis: a systematic review of early outcomes with pooled analysis. Gastrointest Endosc. 2020 Apr;91(4):746-752.e5. doi: 10.1016/j.gie.2019.11.039. Epub 2019 Dec 3.|Gourcerol G, Tissier F, Melchior C, Touchais JY, Huet E, Prevost G, Leroi AM, Ducrotte P. Impaired fasting pyloric compliance in gastroparesis and the therapeutic response to pyloric dilatation. Aliment Pharmacol Ther. 2015 Feb;41(4):360-7. doi: 10.1111/apt.13053. Epub 2014 Dec 19.|Jacques J, Pagnon L, Hure F, Legros R, Crepin S, Fauchais AL, Palat S, Ducrotté P, Marin B, Fontaine S, Boubaddi NE, Clement MP, Sautereau D, Loustaud-Ratti V, Gourcerol G, Monteil J. Peroral endoscopic pyloromyotomy is efficacious and safe for refractory gastroparesis: prospective trial with assessment of pyloric function. Endoscopy. 2019 Jan;51(1):40-49. doi: 10.1055/a-0628-6639. Epub 2018 Jun 12.|Snape WJ, Lin MS, Agarwal N, Shaw RE. Evaluation of the pylorus with concurrent intraluminal pressure and EndoFLIP in patients with nausea and vomiting. Neurogastroenterol Motil. 2016 May;28(5):758-64. doi: 10.1111/nmo.12772. Epub 2016 Jan 27.|Desipio J, Friedenberg FK, Korimilli A, Richter JE, Parkman HP, Fisher RS. High-resolution solid-state manometry of the antropyloroduodenal region. Neurogastroenterol Motil. 2007 Mar;19(3):188-95.|Revicki DA, Rentz AM, Dubois D, Kahrilas P, Stanghellini V, Talley NJ, Tack J. Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther. 2003 Jul 1;18(1):141-50.|Rentz AM, Kahrilas P, Stanghellini V, Tack J, Talley NJ, de la Loge C, Trudeau E, Dubois D, Revicki DA. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res. 2004 Dec;13(10):1737-49.|Mekaroonkamol P, Patel V, Shah R, Li B, Luo H, Shen S, Chen H, Shahnavaz N, Dacha S, Keilin S, Willingham FF, Christie J, Cai Q. Association between duration or etiology of gastroparesis and clinical response after gastric per-oral endoscopic pyloromyotomy. Gastrointest Endosc. 2019 May;89(5):969-976. doi: 10.1016/j.gie.2018.12.023. Epub 2019 Jan 14.","\tGastroparesis\tEndoFLIP|Antroduodenal Manometry\tNA\tNA\tNA\tDiagnostic Test|Diagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","gastroparesis","NA","NA"]
["NCT04845490","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22831982|22287157|25680955|32306237","Hompes D, Tiek J, Wolthuis A, Fieuws S, Penninckx F, Van Cutsem E, D'Hoore A. HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome? Ann Oncol. 2012 Dec;23(12):3123-3129. doi: 10.1093/annonc/mds173. Epub 2012 Jul 25.|Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012 May;99(5):699-705. doi: 10.1002/bjs.8679. Epub 2012 Jan 27.|Razenberg LG, van Gestel YR, Creemers GJ, Verwaal VJ, Lemmens VE, de Hingh IH. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands. Eur J Surg Oncol. 2015 Apr;41(4):466-71. doi: 10.1016/j.ejso.2015.01.018. Epub 2015 Jan 29.|Torphy RJ, Stewart C, Sharma P, Halpern AL, Oase K, Herter W, Bartsch C, Friedman C, Del Chiaro M, Schulick RD, Gleisner A, McCarter MD, Ahrendt SA. Dextrose-Containing Carrier Solution for Hyperthermic Intraperitoneal Chemotherapy: Increased Intraoperative Hyperglycemia and Postoperative Complications. Ann Surg Oncol. 2020 Dec;27(13):4874-4882. doi: 10.1245/s10434-020-08330-y. Epub 2020 Apr 19.","\tChemotherapy Effect|Colorectal Cancer|Metastasis|Surgery|Survival\tMitomycin|Lobaplatin\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy","Interventional","Not yet recruiting","Phase 2",3,201,"fever|colorectal neoplasms","mitomycins|mitomycin","NA"]
["NCT04845672","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22889522|21407241|22189793|9618454","Karki S, Cheng AC. Impact of non-rinse skin cleansing with chlorhexidine gluconate on prevention of healthcare-associated infections and colonization with multi-resistant organisms: a systematic review. J Hosp Infect. 2012 Oct;82(2):71-84. doi: 10.1016/j.jhin.2012.07.005. Epub 2012 Aug 11. Review.|Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol. 2011 Apr;9(4):244-53. doi: 10.1038/nrmicro2537. Review. Erratum in: Nat Rev Microbiol. 2011 Aug;9(8):626.|Kong HH, Segre JA. Skin microbiome: looking back to move forward. J Invest Dermatol. 2012 Mar;132(3 Pt 2):933-9. doi: 10.1038/jid.2011.417. Epub 2011 Dec 22. Review.|Whitman WB, Coleman DC, Wiebe WJ. Prokaryotes: the unseen majority. Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6578-83. Review.","\tSkin Microbiota\t2% chlorhexidine gluconate|soap-free body cleaning solution\tParallel Assignment\tPrevention\tRandomized\tOther|Other\tAll\t","Comparison of the Permanent Skin Flora of Children Who Had Bathing With Two Different Products","Interventional","Recruiting","N/A",2,60,"NA","chlorhexidine gluconate|chlorhexidine","NA"]
["NCT04846114","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23123097|29053656|19663955|10670599|32140914|26174061|32111278|19214196|29156176|25413495|27469549|10456621|22117941|18195197|15818034|9701094|11324133|26592859|26679334|31729076|23881695|28176599|22374059|31669068|17090725|26614041|3171356|2909235|30887189|20946205|17446442|32186289|22315257|12544725|24485810|28196633|31713746|25528251|17517299|20657853|7745335|17650169|23313715|25967723|25311541|1532608|12719198","van Diermen DE, van der Waal I, Hoogvliets MW, Ong FN, Hoogstraten J. Survey response of oral and maxillofacial surgeons on invasive procedures in patients using antithrombotic medication. Int J Oral Maxillofac Surg. 2013 Apr;42(4):502-7. doi: 10.1016/j.ijom.2012.09.018. Epub 2012 Nov 2.|Caliskan M, Tükel HC, Benlidayi ME, Deniz A. Is it necessary to alter anticoagulation therapy for tooth extraction in patients taking direct oral anticoagulants? Med Oral Patol Oral Cir Bucal. 2017 Nov 1;22(6):e767-e773. doi: 10.4317/medoral.21942.|Madrid C, Sanz M. What influence do anticoagulants have on oral implant therapy? A systematic review. Clin Oral Implants Res. 2009 Sep;20 Suppl 4:96-106. doi: 10.1111/j.1600-0501.2009.01770.x. Review.|Mehra P, Cottrell DA, Bestgen SC, Booth DF. Management of heparin therapy in the high-risk, chronically anticoagulated, oral surgery patient: a review and a proposed nomogram. J Oral Maxillofac Surg. 2000 Feb;58(2):198-202.|George C, Barras M, Coombes J, Winckel K. Unfractionated heparin dosing in obese patients. Int J Clin Pharm. 2020 Apr;42(2):462-473. doi: 10.1007/s11096-020-01004-5. Epub 2020 Mar 5.|Daniels PR. Peri-procedural management of patients taking oral anticoagulants. BMJ. 2015 Jul 14;351:h2391. doi: 10.1136/bmj.h2391. Review.|Halpern LR, Adams DR, Clarkson E. Treatment of the Dental Patient with Bleeding Dyscrasias: Etiologies and Management Options for Surgical Success in Practice. Dent Clin North Am. 2020 Apr;64(2):411-434. doi: 10.1016/j.cden.2019.12.010. Epub 2020 Jan 31. Review.|Dewan K, Bishop K, Muthukrishnan A. Management of patients on warfarin by general dental practitioners in South West Wales: continuing the audit cycle. Br Dent J. 2009 Feb 28;206(4):E8; discussion 214-5. doi: 10.1038/sj.bdj.2009.112. Epub 2009 Feb 13.|Suresh V, Bishawi M, Manning MW, Patel C, Rogers J, Milano C, Schroder J, Daneshmand M, Powers D. Management of Patients With Left Ventricular Assist Devices Requiring Teeth Extraction: Is Halting Anticoagulation Appropriate? J Oral Maxillofac Surg. 2018 Sep;76(9):1859-1863. doi: 10.1016/j.joms.2017.10.022. Epub 2017 Oct 31.|Kämmerer PW, Frerich B, Liese J, Schiegnitz E, Al-Nawas B. Oral surgery during therapy with anticoagulants-a systematic review. Clin Oral Investig. 2015 Mar;19(2):171-80. doi: 10.1007/s00784-014-1366-3. Epub 2014 Nov 22. Review.|Lopez MA, Andreasi Bassi M, Confalone L, Gaudio RM, Lombardo L, Lauritano D. Clinical outcome of 215 transmucosal implants with a conical connection: a retrospective study after 5-year follow-up. J Biol Regul Homeost Agents. 2016 Apr-Jun;30(2 Suppl 1):55-60.|Ascani A, Iorio A, Agnelli G. Withdrawal of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation. Blood Coagul Fibrinolysis. 1999 Jul;10(5):291-5.|Doonquah L, Mitchell AD. Oral surgery for patients on anticoagulant therapy: current thoughts on patient management. Dent Clin North Am. 2012 Jan;56(1):25-41, vii. doi: 10.1016/j.cden.2011.06.002. Review.|Garcia DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, Hylek EM. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008 Jan 14;168(1):63-9. doi: 10.1001/archinternmed.2007.23.|Akopov SE, Suzuki S, Fredieu A, Kidwell CS, Saver JL, Cohen SN. Withdrawal of warfarin prior to a surgical procedure: time to follow the guidelines? Cerebrovasc Dis. 2005;19(5):337-42. Epub 2005 Apr 8.|Wahl MJ. Dental surgery in anticoagulated patients. Arch Intern Med. 1998 Aug 10-24;158(15):1610-6. Review.|Wahl MJ. Demystifying medical complexities. J Calif Dent Assoc. 2000 Jul;28(7):510-8. Review.|Clemm R, Neukam FW, Rusche B, Bauersachs A, Musazada S, Schmitt CM. Management of anticoagulated patients in implant therapy: a clinical comparative study. Clin Oral Implants Res. 2016 Oct;27(10):1274-1282. doi: 10.1111/clr.12732. Epub 2015 Nov 23.|Weltman NJ, Al-Attar Y, Cheung J, Duncan DP, Katchky A, Azarpazhooh A, Abrahamyan L. MANAGEMENT OF DENTAL EXTRACTIONS IN PATIENTS TAKING WARFARIN AS ANTICOAGULANT TREATMENT: A SYSTEMATIC REVIEW. J Can Dent Assoc. 2015;81:f20. Review.|Cai J, Ribkoff J, Olson S, Raghunathan V, Al-Samkari H, DeLoughery TG, Shatzel JJ. The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients. Eur J Haematol. 2020 Feb;104(2):79-87. doi: 10.1111/ejh.13348. Epub 2019 Dec 16. Review.|Ker K, Beecher D, Roberts I. Topical application of tranexamic acid for the reduction of bleeding. Cochrane Database Syst Rev. 2013 Jul 23;(7):CD010562. doi: 10.1002/14651858.CD010562.pub2. Review.|Cankaya D, Dasar U, Satilmis AB, Basaran SH, Akkaya M, Bozkurt M. The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty. J Orthop Surg (Hong Kong). 2017 Jan;25(1):2309499016684725. doi: 10.1177/2309499016684725.|Perdigão JP, de Almeida PC, Rocha TD, Mota MR, Soares EC, Alves AP, Sousa FB. Postoperative bleeding after dental extraction in liver pretransplant patients. J Oral Maxillofac Surg. 2012 Mar;70(3):e177-84. doi: 10.1016/j.joms.2011.10.033.|Ockerman A, Vanhaverbeke M, Miclotte I, Belmans A, Vanassche T, Politis C, Jacobs R, Verhamme P. Tranexamic acid to reduce bleeding after dental extraction in patients treated with non-vitamin K oral anticoagulants: design and rationale of the EXTRACT-NOAC trial. Br J Oral Maxillofac Surg. 2019 Dec;57(10):1107-1112. doi: 10.1016/j.bjoms.2019.10.297. Epub 2019 Oct 25.|Patatanian E, Fugate SE. Hemostatic mouthwashes in anticoagulated patients undergoing dental extraction. Ann Pharmacother. 2006 Dec;40(12):2205-10. Epub 2006 Nov 7. Review.|Couto EV, Ballin CR, Sampaio CP, Maeda CA, Ballin CH, Dassi CS, Miura LY. Experimental study on the effects of bismuth subgallate on the inflammatory process and angiogenesis of the oral mucosa. Braz J Otorhinolaryngol. 2016 Jan-Feb;82(1):17-25. doi: 10.1016/j.bjorl.2014.12.009. Epub 2015 Oct 27.|Thorisdottir H, Ratnoff OD, Maniglia AJ. Activation of Hageman factor (factor XII) by bismuth subgallate, a hemostatic agent. J Lab Clin Med. 1988 Oct;112(4):481-6.|Maniglia AJ, Kushner H, Cozzi L. Adenotonsillectomy. A safe outpatient procedure. Arch Otolaryngol Head Neck Surg. 1989 Jan;115(1):92-4.|Radoï L, Hajage D, Giboin C, Maman L, Monnet-Corti V, Descroix V, Mahé I. Perioperative management of oral anticoagulated patients undergoing an oral, implant, or periodontal procedure: a survey of practices of members of two dental scientific societies, the PRADICO study. Clin Oral Investig. 2019 Dec;23(12):4311-4323. doi: 10.1007/s00784-019-02877-1. Epub 2019 Mar 19.|Bacci C, Berengo M, Favero L, Zanon E. Safety of dental implant surgery in patients undergoing anticoagulation therapy: a prospective case-control study. Clin Oral Implants Res. 2011 Feb;22(2):151-6. doi: 10.1111/j.1600-0501.2010.01963.x. Epub 2010 Oct 13.|Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, Newburger JW, Strom BL, Tani LY, Gerber M, Bonow RO, Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, Gardner T, Goff D, Durack DT; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007 Oct 9;116(15):1736-54. Epub 2007 Apr 19. Erratum in: Circulation. 2007 Oct 9;116(15):e376-7.|Sannino G, Capparé P, Montemezzi P, Alfieri O, Pantaleo G, Gherlone E. Postoperative bleeding in patients taking oral anticoagulation therapy after 'All-on-four' rehabilitation: A case-control study. Int J Oral Implantol (Berl). 2020;13(1):77-87.|Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):7S-47S. doi: 10.1378/chest.1412S3. Erratum in: Chest. 2012 Apr;141(4):1129. Dosage error in article text. Chest. 2012 Dec;142(6):1698. Dosage error in article text.|Zanon E, Martinelli F, Bacci C, Cordioli G, Girolami A. Safety of dental extraction among consecutive patients on oral anticoagulant treatment managed using a specific dental management protocol. Blood Coagul Fibrinolysis. 2003 Jan;14(1):27-30.|Broekema FI, van Minnen B, Jansma J, Bos RR. Risk of bleeding after dentoalveolar surgery in patients taking anticoagulants. Br J Oral Maxillofac Surg. 2014 Mar;52(3):e15-9. doi: 10.1016/j.bjoms.2014.01.006. Epub 2014 Jan 30.|Di Minno A, Frigerio B, Spadarella G, Ravani A, Sansaro D, Amato M, Kitzmiller JP, Pepi M, Tremoli E, Baldassarre D. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Rev. 2017 Jul;31(4):193-203. doi: 10.1016/j.blre.2017.02.001. Epub 2017 Feb 5. Review.|Schmitt CM, Rusche B, Clemm R, Neukam FW, Buchbender M. Management of anticoagulated patients in dentoalveolar surgery: a clinical comparative study. Clin Oral Investig. 2020 Aug;24(8):2653-2662. doi: 10.1007/s00784-019-03124-3. Epub 2019 Nov 12.|Soares EC, Costa FW, Bezerra TP, Nogueira CB, de Barros Silva PG, Batista SH, Sousa FB, Sá Roriz Fonteles C. Postoperative hemostatic efficacy of gauze soaked in tranexamic acid, fibrin sponge, and dry gauze compression following dental extractions in anticoagulated patients with cardiovascular disease: a prospective, randomized study. Oral Maxillofac Surg. 2015 Jun;19(2):209-16. doi: 10.1007/s10006-014-0479-9. Epub 2014 Dec 21.|Ferrieri GB, Castiglioni S, Carmagnola D, Cargnel M, Strohmenger L, Abati S. Oral surgery in patients on anticoagulant treatment without therapy interruption. J Oral Maxillofac Surg. 2007 Jun;65(6):1149-54.|Kim SH, Tramontina VA, Papalexiou V, Luczyszyn SM. Bismuth subgallate as a topical hemostatic agent at palatal donor sites. Quintessence Int. 2010 Sep;41(8):645-9.|Callanan V, Curran AJ, Smyth DA, Gormley PK. The influence of bismuth subgallate and adrenaline paste upon operating time and operative blood loss in tonsillectomy. J Laryngol Otol. 1995 Mar;109(3):206-8.|Scully C, Hobkirk J, Dios PD. Dental endosseous implants in the medically compromised patient. J Oral Rehabil. 2007 Aug;34(8):590-9. Review.|Diz P, Scully C, Sanz M. Dental implants in the medically compromised patient. J Dent. 2013 Mar;41(3):195-206. doi: 10.1016/j.jdent.2012.12.008. Epub 2013 Jan 11. Review.|Proietti R, Porto I, Levi M, Leo A, Russo V, Kalfon E, Biondi-Zoccai G, Roux JF, Birnie DH, Essebag V. Risk of pocket hematoma in patients on chronic anticoagulation with warfarin undergoing electrophysiological device implantation: a comparison of different peri-operative management strategies. Eur Rev Med Pharmacol Sci. 2015 Apr;19(8):1461-79. Review.|Bajkin BV, Urosevic IM, Stankov KM, Petrovic BB, Bajkin IA. Dental extractions and risk of bleeding in patients taking single and dual antiplatelet treatment. Br J Oral Maxillofac Surg. 2015 Jan;53(1):39-43. doi: 10.1016/j.bjoms.2014.09.009. Epub 2014 Oct 11.|DeClerck D, Vinckier F, Vermylen J. Influence of anticoagulation on blood loss following dental extractions. J Dent Res. 1992 Feb;71(2):387-90.|Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med. 2003 Apr 28;163(8):901-8. Review.","\tOral Anticoagulant Therapy\tDental implant surgery\tParallel Assignment\tTreatment\tRandomized\tProcedure\tAll\t","Dental Implants in Patients Under Oral Anticoagulant Therapy","Interventional","Completed","N/A",4,71,"NA","NA","NA"]
["NCT04846192","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",30902342,"Yugawa K, Itoh S, Kurihara T, Yoshiya S, Mano Y, Takeishi K, Harada N, Ikegami T, Soejima Y, Mori M, Yoshizumi T. Skeletal muscle mass predicts the prognosis of patients with intrahepatic cholangiocarcinoma. Am J Surg. 2019 Nov;218(5):952-958. doi: 10.1016/j.amjsurg.2019.03.010. Epub 2019 Mar 14.","\tPerihilar Cholangiocarcinoma\tNutritional evaluation\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","klatskin tumor|cholangiocarcinoma","NA","NA"]
["NCT04846296","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28889338,"Schulte TL, Thielsch MT, Gosheger G, Boertz P, Terheyden JH, Wetterkamp M. German validation of the quality of life profile for spinal disorders (QLPSD). Eur Spine J. 2018 Jan;27(1):83-92. doi: 10.1007/s00586-017-5284-3. Epub 2017 Sep 9.","\tQuality of Life|Scoliosis|Spinal Deformity\tQuestionnaire\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","congenital abnormalities|scoliosis","NA","NA"]
["NCT04846361","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29637269|21876923","Russo R, Edu A, De Seta F. Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota. Arch Gynecol Obstet. 2018 Jul;298(1):139-145. doi: 10.1007/s00404-018-4771-z. Epub 2018 Apr 10.|Bahamondes MV, Portugal PM, Brolazo EM, Simões JA, Bahamondes L. Use of a lactic acid plus lactoserum intimate liquid soap for external hygiene in the prevention of bacterial vaginosis recurrence after metronidazole oral treatment. Rev Assoc Med Bras (1992). 2011 Jul-Aug;57(4):415-20.","\tBacterial Vaginoses\tVaginal hygiene wash|placebo wash\tParallel Assignment\tTreatment\tRandomized\tOther|Other\tFemale\t","Vaginal Hygiene Wash as Adjunct Treatment in Bacterial Vaginosis","Interventional","Not yet recruiting","N/A",3,56,"vaginal diseases|vaginosis, bacterial","NA","NA"]
["NCT04846842","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",19819917,"Hurwitz JL, McCoy F, Scullin P, Fennell DA. New advances in the second-line treatment of small cell lung cancer. Oncologist. 2009 Oct;14(10):986-94. doi: 10.1634/theoncologist.2009-0026. Epub 2009 Oct 9. Review.","\tEpithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer\tGimatecan\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","fallopian tube neoplasms|peritoneal neoplasms|carcinoma, ovarian epithelial","NA","NA"]
["NCT04847284","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29528443|25614945|31654248|30094718","Giordano FA, Brehmer S, Mürle B, Welzel G, Sperk E, Keller A, Abo-Madyan Y, Scherzinger E, Clausen S, Schneider F, Herskind C, Glas M, Seiz-Rosenhagen M, Groden C, Hänggi D, Schmiedek P, Emami B, Souhami L, Petrecca K, Wenz F. Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma (INTRAGO): An Open-Label, Dose-Escalation Phase I/II Trial. Neurosurgery. 2019 Jan 1;84(1):41-49. doi: 10.1093/neuros/nyy018.|Weil RJ, Mavinkurve GG, Chao ST, Vogelbaum MA, Suh JH, Kolar M, Toms SA. Intraoperative radiotherapy to treat newly diagnosed solitary brain metastasis: initial experience and long-term outcomes. J Neurosurg. 2015 Apr;122(4):825-32. doi: 10.3171/2014.11.JNS1449. Epub 2015 Jan 23.|Cifarelli CP, Brehmer S, Vargo JA, Hack JD, Kahl KH, Sarria-Vargas G, Giordano FA. Intraoperative radiotherapy (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study. J Neurooncol. 2019 Nov;145(2):391-397. doi: 10.1007/s11060-019-03309-6. Epub 2019 Oct 25.|Vargo JA, Sparks KM, Singh R, Jacobson GM, Hack JD, Cifarelli CP. Feasibility of dose escalation using intraoperative radiotherapy following resection of large brain metastases compared to post-operative stereotactic radiosurgery. J Neurooncol. 2018 Nov;140(2):413-420. doi: 10.1007/s11060-018-2968-4. Epub 2018 Aug 9.","\tBrain Metastases\tIntraoperative radiotherapy\tNA\tNA\tNA\tRadiation\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms, second primary|neoplasm metastasis|brain neoplasms","NA","NA"]
["NCT04847375","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32199073|32087216|32692208|33734299|33176850|32908083|32085846","Takian A, Raoofi A, Kazempour-Ardebili S. COVID-19 battle during the toughest sanctions against Iran. Lancet. 2020 Mar 28;395(10229):1035-1036. doi: 10.1016/S0140-6736(20)30668-1. Epub 2020 Mar 18. Erratum in: Lancet. 2020 Apr 18;395(10232):1258.|Zhang Y, Xu J, Li H, Cao B. A Novel Coronavirus (COVID-19) Outbreak: A Call for Action. Chest. 2020 Apr;157(4):e99-e101. doi: 10.1016/j.chest.2020.02.014. Epub 2020 Feb 19.|Yue H, Bai X, Wang J, Yu Q, Liu W, Pu J, Wang X, Hu J, Xu D, Li X, Kang N, Li L, Lu W, Feng T, Ding L, Li X, Qi X; Gansu Provincial Medical Treatment Expert Group of COVID-19. Clinical characteristics of coronavirus disease 2019 in Gansu province, China. Ann Palliat Med. 2020 Jul;9(4):1404-1412. doi: 10.21037/apm-20-887. Epub 2020 Jul 13.|INSPIRATION Investigators, Sadeghipour P, Talasaz AH, Rashidi F, Sharif-Kashani B, Beigmohammadi MT, Farrokhpour M, Sezavar SH, Payandemehr P, Dabbagh A, Moghadam KG, Jamalkhani S, Khalili H, Yadollahzadeh M, Riahi T, Rezaeifar P, Tahamtan O, Matin S, Abedini A, Lookzadeh S, Rahmani H, Zoghi E, Mohammadi K, Sadeghipour P, Abri H, Tabrizi S, Mousavian SM, Shahmirzaei S, Bakhshandeh H, Amin A, Rafiee F, Baghizadeh E, Mohebbi B, Parhizgar SE, Aliannejad R, Eslami V, Kashefizadeh A, Kakavand H, Hosseini SH, Shafaghi S, Ghazi SF, Najafi A, Jimenez D, Gupta A, Madhavan MV, Sethi SS, Parikh SA, Monreal M, Hadavand N, Hajighasemi A, Maleki M, Sadeghian S, Piazza G, Kirtane AJ, Van Tassell BW, Dobesh PP, Stone GW, Lip GYH, Krumholz HM, Goldhaber SZ, Bikdeli B. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA. 2021 Apr 27;325(16):1620-1630. doi: 10.1001/jama.2021.4152.|Dabbagh A, Rajaei S, Ghahremani M, Fathi M, Massoudi N, Tavana S, Fani K, Nooraee N, Malekpour Alamdari N, Besharat S, Najafi Abrandabadi A, Pirsalehi A, Khabiri Khatiri MA. The effect of surfactant on clinical outcome of patients with COVID-19 under mechanical ventilation: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Nov 11;21(1):919. doi: 10.1186/s13063-020-04815-z.|Alamdari NM, Afaghi S, Rahimi FS, Tarki FE, Tavana S, Zali A, Fathi M, Besharat S, Bagheri L, Pourmotahari F, Irvani SSN, Dabbagh A, Mousavi SA. Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran. Tohoku J Exp Med. 2020 Sep;252(1):73-84. doi: 10.1620/tjem.252.73.|Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18. Erratum in: Lancet Respir Med. 2020 Feb 25;:.","\tCOVID-19|Respiratory Distress Syndrome|Surface-Active Agents\texogenous surfactant\tParallel Assignment\tTreatment\tRandomized\tDrug\tAll\t","Exogenous Surfactant Through Nebulizer Mask on Clinical Outcomes in Covid-19 Patients","Interventional","Not yet recruiting","N/A",2,60,"respiratory distress syndrome, newborn|respiratory distress syndrome, adult","pulmonary surfactants","NA"]
["NCT04848350","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30205934|29547610|32663929","Jaruzel CB, Gregoski M, Mueller M, Faircloth A, Kelechi T. Aromatherapy for Preoperative Anxiety: A Pilot Study. J Perianesth Nurs. 2019 Apr;34(2):259-264. doi: 10.1016/j.jopan.2018.05.007. Epub 2018 Sep 8.|Ozkaraman A, Dügüm Ö, Özen Yılmaz H, Usta Yesilbalkan Ö. Aromatherapy: The Effect of Lavender on Anxiety and Sleep Quality in Patients Treated With Chemotherapy. Clin J Oncol Nurs. 2018 Apr 1;22(2):203-210. doi: 10.1188/18.CJON.203-210.|Gong M, Dong H, Tang Y, Huang W, Lu F. Effects of aromatherapy on anxiety: A meta-analysis of randomized controlled trials. J Affect Disord. 2020 Sep 1;274:1028-1040. doi: 10.1016/j.jad.2020.05.118. Epub 2020 May 26. Review.","\tAnxiety|Aromatherapy|Pain, Procedural\tLavender essential oil\tParallel Assignment\tSupportive Care\tRandomized\tOther\tAll\t","Use of Inhaler Aromatherapy During SWL","Interventional","Completed","N/A",3,120,"pain, procedural","NA","NA"]
["NCT04849104","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32664956|31437842|30376356","Haldar K, George L, Wang Z, Mistry V, Ramsheh MY, Free RC, John C, Reeve NF, Miller BE, Tal-Singer R, Webb AJ, Brookes AJ, Tobin MD, Singh D, Donaldson GC, Wedzicha JA, Brown JR, Barer MR, Brightling CE. The sputum microbiome is distinct between COPD and health, independent of smoking history. Respir Res. 2020 Jul 14;21(1):183. doi: 10.1186/s12931-020-01448-3.|López Caro JC, Santibáñez M, García Rivero JL, Villanueva M, Sainz J, González Astorqui P, Hierro M, Rodríguez Porres M, Paras Bravo P, Mira A, Rodriguez JC, Galiana A; on behalf of the ACINAR-microbiome study group. Sputum Microbiome Dynamics in Chronic Obstructive Pulmonary Disease Patients during an Exacerbation Event and Post-Stabilization. Respiration. 2019;98(5):447-454. doi: 10.1159/000501988. Epub 2019 Aug 22.|Leitao Filho FS, Alotaibi NM, Ngan D, Tam S, Yang J, Hollander Z, Chen V, FitzGerald JM, Nislow C, Leung JM, Man SFP, Sin DD. Sputum Microbiome Is Associated with 1-Year Mortality after Chronic Obstructive Pulmonary Disease Hospitalizations. Am J Respir Crit Care Med. 2019 May 15;199(10):1205-1213. doi: 10.1164/rccm.201806-1135OC.","\tChronic Obstructive Pulmonary Disease\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","lung diseases|lung diseases, obstructive|pulmonary disease, chronic obstructive","NA","NA"]
["NCT04850079","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",31618453,"Vinks AA, Punt NC, Menke F, Kirkendall E, Butler D, Duggan TJ, Cortezzo DE, Kiger S, Dietrich T, Spencer P, Keefer R, Setchell KDR, Zhao J, Euteneuer JC, Mizuno T, Dufendach KR. Electronic Health Record-Embedded Decision Support Platform for Morphine Precision Dosing in Neonates. Clin Pharmacol Ther. 2020 Jan;107(1):186-194. doi: 10.1002/cpt.1684. Epub 2019 Dec 11.","\tPain, Acute|Pain, Chronic\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","acute pain|chronic pain","NA","NA"]
["NCT04850755","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30610226|24743138","Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019 Mar;18(3):197-218. doi: 10.1038/s41573-018-0007-y. Review.|Tan DS, Bedard PL, Kuruvilla J, Siu LL, Razak AR. Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy. Cancer Discov. 2014 May;4(5):527-37. doi: 10.1158/2159-8290.CD-13-1005. Epub 2014 Apr 17. Review.","\tAdvance Solid Malignancies|Metastatic Solid Malignancies\tSelinexor in combination with nivolumab and ipilimumab\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","neoplasms","ipilimumab|nivolumab","NA"]
["NCT04851366","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32402261|33182711|22642525|24960439|23046789|27771133","García-Escalera J, Valiente RM, Sandín B, Ehrenreich-May J, Prieto A, Chorot P. The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) Adapted as a School-Based Anxiety and Depression Prevention Program: An Initial Cluster Randomized Wait-List-Controlled Trial. Behav Ther. 2020 May;51(3):461-473. doi: 10.1016/j.beth.2019.08.003. Epub 2019 Aug 14.|Sandín B, García-Escalera J, Valiente RM, Espinosa V, Chorot P. Clinical Utility of an Internet-Delivered Version of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Adolescents (iUP-A): A Pilot Open Trial. Int J Environ Res Public Health. 2020 Nov 10;17(22). pii: E8306. doi: 10.3390/ijerph17228306.|Levin L, Henderson HA, Ehrenreich-May J. Interpersonal predictors of early therapeutic alliance in a transdiagnostic cognitive-behavioral treatment for adolescents with anxiety and depression. Psychotherapy (Chic). 2012 Jun;49(2):218-230. doi: 10.1037/a0028265.|Queen AH, Barlow DH, Ehrenreich-May J. The trajectories of adolescent anxiety and depressive symptoms over the course of a transdiagnostic treatment. J Anxiety Disord. 2014 Aug;28(6):511-21. doi: 10.1016/j.janxdis.2014.05.007. Epub 2014 Jun 2.|Bilek EL, Ehrenreich-May J. An open trial investigation of a transdiagnostic group treatment for children with anxiety and depressive symptoms. Behav Ther. 2012 Dec;43(4):887-97. doi: 10.1016/j.beth.2012.04.007. Epub 2012 May 1.|Ehrenreich-May J, Rosenfield D, Queen AH, Kennedy SM, Remmes CS, Barlow DH. An initial waitlist-controlled trial of the unified protocol for the treatment of emotional disorders in adolescents. J Anxiety Disord. 2017 Mar;46:46-55. doi: 10.1016/j.janxdis.2016.10.006. Epub 2016 Oct 17.","\tAnxiety Disorders and Symptoms|Depressive Symptoms\tPROCARE+ (with add-on modules)|PROCARE (UP-A for selective purposes)|Active control condition\tNA\tNA\tNA\tBehavioral|Behavioral|Behavioral\tAll\t","Selective Prevention Transdiagnostic Intervention for At-risk Adolescents","Interventional","Recruiting","N/A",3,318,"anxiety disorders|depression","NA","NA"]
["NCT04851730","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12763442|8115087|28694673|23115475|28240995|19130648|24700500|23684553|22196427","Bizzini M, Mannion AF. Reliability of a new, hand-held device for assessing skeletal muscle stiffness. Clin Biomech (Bristol, Avon). 2003 Jun;18(5):459-61.|Baker PK. Musculoskeletal origins of chronic pelvic pain. Diagnosis and treatment. Obstet Gynecol Clin North Am. 1993 Dec;20(4):719-42. Review.|Coronado RA, Bialosky JE. Manual physical therapy for chronic pain: the complex whole is greater than the sum of its parts. J Man Manip Ther. 2017 Jul;25(3):115-117. doi: 10.1080/10669817.2017.1309344. Epub 2017 Jun 12.|Dommerholt J. Dry needling - peripheral and central considerations. J Man Manip Ther. 2011 Nov;19(4):223-7. doi: 10.1179/106698111X13129729552065.|Jafari H, Courtois I, Van den Bergh O, Vlaeyen JWS, Van Diest I. Pain and respiration: a systematic review. Pain. 2017 Jun;158(6):995-1006. doi: 10.1097/j.pain.0000000000000865. Review.|Kinser AM, Sands WA, Stone MH. Reliability and validity of a pressure algometer. J Strength Cond Res. 2009 Jan;23(1):312-4.|Loving S, Thomsen T, Jaszczak P, Nordling J. Pelvic floor muscle dysfunctions are prevalent in female chronic pelvic pain: a cross-sectional population-based study. Eur J Pain. 2014 Oct;18(9):1259-70. doi: 10.1002/j.1532-2149.2014.485.x. Epub 2014 Apr 3.|Maher RM, Hayes DM, Shinohara M. Quantification of dry needling and posture effects on myofascial trigger points using ultrasound shear-wave elastography. Arch Phys Med Rehabil. 2013 Nov;94(11):2146-50. doi: 10.1016/j.apmr.2013.04.021. Epub 2013 May 14.|Neville CE, Fitzgerald CM, Mallinson T, Badillo S, Hynes C, Tu F. A preliminary report of musculoskeletal dysfunction in female chronic pelvic pain: a blinded study of examination findings. J Bodyw Mov Ther. 2012 Jan;16(1):50-6. doi: 10.1016/j.jbmt.2011.06.002. Epub 2011 Jul 6.","\tChronic Pain|Muscle Tightness|Pelvic Pain\tOrthopedic Physical Therapy Intervention|Dry Needling\tNA\tNA\tNA\tProcedure|Device\tFemale\t","NA","NA","NA","NA","NA","NA","chronic pain|pelvic pain","NA","NA"]
["NCT04851808","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16840363|26494423","Braman SS. The global burden of asthma. Chest. 2006 Jul;130(1 Suppl):4S-12S. Review.|López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016 Jan;21(1):14-23. doi: 10.1111/resp.12660. Epub 2015 Oct 23. Review.","\tChronic Respiratory Disease|COPD\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","respiratory tract diseases|respiration disorders","NA","NA"]
["NCT04851860","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27329923,"Chen Y, Zhou L, Yang Y. Effect of sublingual immunotherapy on platelet activity in children with allergic rhinitis. Braz J Otorhinolaryngol. 2017 Mar - Apr;83(2):190-194. doi: 10.1016/j.bjorl.2016.03.006. Epub 2016 Apr 22.","\tAllergic Rhinitis\tsublingual immunotherapy\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","rhinitis|rhinitis, allergic","NA","NA"]
["NCT04852770","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32021616|24142084|18373017|21955037|31769377|22790114|32450928|30525996|17716102|24469930|26653052|29801444|21458165|21912931","Neufeld CB, Palma PC, Caetano KAS, Brust-Renck PG, Curtiss J, Hofmann SG. A randomized clinical trial of group and individual Cognitive-Behavioral Therapy approaches for Social Anxiety Disorder. Int J Clin Health Psychol. 2020 Jan-Apr;20(1):29-37. doi: 10.1016/j.ijchp.2019.11.004. Epub 2019 Dec 24.|Powell VB, Oliveira OH, Seixas C, Almeida C, Grangeon MC, Caldas M, Bonfim TD, Castro M, Galvão-de Almeida A, Moraes Rde O, Sudak D, de-Oliveira IR. Changing core beliefs with trial-based cognitive therapy may improve quality of life in social phobia: a randomized study. Braz J Psychiatry. 2013 Jul-Sep;35(3):243-7. doi: 10.1590/1516-4446-2012-0863. Erratum in: Rev Bras Psiquiatr. 2013 Dec;35(4):445. Galvão-de Almeida [corrected to Galvão-de Almeida, Amanda].|Oliveira IR. Trial-Based Thought Record (TBTR): preliminary data on a strategy to deal with core beliefs by combining sentence reversion and the use of analogy with a judicial process. Braz J Psychiatry. 2008 Mar;30(1):12-8.|de Oliveira IR, Powell VB, Wenzel A, Caldas M, Seixas C, Almeida C, Bonfim T, Grangeon MC, Castro M, Galvão A, de Oliveira Moraes R, Sudak D. Efficacy of the trial-based thought record, a new cognitive therapy strategy designed to change core beliefs, in social phobia. J Clin Pharm Ther. 2012 Jun;37(3):328-34. doi: 10.1111/j.1365-2710.2011.01299.x. Epub 2011 Sep 28.|Hemanny C, Carvalho C, Maia N, Reis D, Botelho AC, Bonavides D, Seixas C, de Oliveira IR. Efficacy of trial-based cognitive therapy, behavioral activation and treatment as usual in the treatment of major depressive disorder: preliminary findings from a randomized clinical trial. CNS Spectr. 2020 Aug;25(4):535-544. doi: 10.1017/S1092852919001457. Epub 2019 Nov 26.|de Oliveira IR, Hemmany C, Powell VB, Bonfim TD, Duran EP, Novais N, Velasquez M, Di Sarno E, Alves GL, Cesnik JA; Brazilian TBTR Study Group. Trial-based psychotherapy and the efficacy of trial-based thought record in changing unhelpful core beliefs and reducing self-criticism. CNS Spectr. 2012 Mar;17(1):16-23. doi: 10.1017/S1092852912000399.|Duran ÉP, Corchs F, Vianna A, Araújo ÁC, Del Real N, Silva C, Ferreira AP, De Vitto Francez P, Godói C, Silveira H, Matsumoto L, Gebara CM, de Barros Neto TP, Chilvarquer R, de Siqueira LL, Bernik M, Neto FL. A randomized clinical trial to assess the efficacy of trial-based cognitive therapy compared to prolonged exposure for post-traumatic stress disorder: preliminary findings. CNS Spectr. 2020 May 26:1-8. doi: 10.1017/S1092852920001455. [Epub ahead of print]|Seligman MEP. Positive Psychology: A Personal History. Annu Rev Clin Psychol. 2019 May 7;15:1-23. doi: 10.1146/annurev-clinpsy-050718-095653. Epub 2018 Dec 10.|Duckworth AL, Steen TA, Seligman ME. Positive psychology in clinical practice. Annu Rev Clin Psychol. 2005;1:629-51. Review.|Mongrain M, Anselmo-Matthews T. Do positive psychology exercises work? A replication of Seligman et al. (2005). J Clin Psychol. 2012 Apr;68(4):382-9. doi: 10.1002/jclp.21839.|Bovin MJ, Marx BP, Weathers FW, Gallagher MW, Rodriguez P, Schnurr PP, Keane TM. Psychometric properties of the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (PCL-5) in veterans. Psychol Assess. 2016 Nov;28(11):1379-1391. doi: 10.1037/pas0000254. Epub 2015 Dec 14.|Trombka M, Demarzo M, Bacas DC, Antonio SB, Cicuto K, Salvo V, Claudino FCA, Ribeiro L, Christopher M, Garcia-Campayo J, Rocha NS. Study protocol of a multicenter randomized controlled trial of mindfulness training to reduce burnout and promote quality of life in police officers: the POLICE study. BMC Psychiatry. 2018 May 25;18(1):151. doi: 10.1186/s12888-018-1726-7.|de Oliveira IR. Kafka's trial dilemma: proposal of a practical solution to Joseph K.'s unknown accusation. Med Hypotheses. 2011 Jul;77(1):5-6. doi: 10.1016/j.mehy.2011.03.010. Epub 2011 Mar 31.|de Souza CM, Hidalgo MP. World Health Organization 5-item well-being index: validation of the Brazilian Portuguese version. Eur Arch Psychiatry Clin Neurosci. 2012 Apr;262(3):239-44. doi: 10.1007/s00406-011-0255-x. Epub 2011 Sep 7.","\tCovid19|Posttraumatic Stress Disorder\tTrial-Based Cognitive Therapy|Mindfulness-Based Health Promotion|Positive psychotherapy\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral|Behavioral\tAll\t","Efficacy of TBCT, MBHP and PPT for PTSD During the Covid-19 Pandemics","Interventional","Recruiting","N/A",3,135,"stress disorders, traumatic|stress disorders, post-traumatic","NA","NA"]
["NCT04853732","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30281768|31305871|31985765|32076968|32167785|32675265|33019676|33622822","Licciardone JC, Gatchel RJ, Aryal S. Effects of Opioids and Nonsteroidal Anti-Inflammatory Drugs on Chronic Low Back Pain and Related Measures: Results from the PRECISION Pain Research Registry. Tex Med. 2018 Oct 1;114(10):e1.|Licciardone JC, Schmitt ME, Aryal S. Empathy in Medicine Osteopathic and Allopathic Physician Interpersonal Manner, Empathy, and Communication Style and Clinical Status of Their Patients: A Pain Registry-Based Study. J Am Osteopath Assoc. 2019 Aug 1;119(8):499-510. doi: 10.7556/jaoa.2019.092.|Licciardone JC, Gatchel RJ. Osteopathic Medical Care With and Without Osteopathic Manipulative Treatment in Patients With Chronic Low Back Pain: A Pain Registry-Based Study. J Am Osteopath Assoc. 2020 Feb 1;120(2):64-73. doi: 10.7556/jaoa.2020.016.|Licciardone JC. Assessment of Longitudinal Clinical Outcome Measures for Chronic Low Back Pain over 12 Months. J Gen Intern Med. 2020 Dec;35(12):3733-3735. doi: 10.1007/s11606-020-05723-3. Epub 2020 Feb 19.|Licciardone JC, Pandya V. Use of Complementary Health Approaches for Chronic Low-Back Pain: A Pain Research Registry-Based Study. J Altern Complement Med. 2020 May;26(5):369-375. doi: 10.1089/acm.2019.0448. Epub 2020 Mar 11.|Licciardone JC, Pandya V. Prevalence and Impact of Comorbid Widespread Pain in Adults with Chronic Low Back Pain: A Registry-Based Study. J Am Board Fam Med. 2020 Jul-Aug;33(4):541-548. doi: 10.3122/jabfm.2020.04.190456.|Licciardone JC, Pandya V. Feasibility Trial of an eHealth Intervention for Health-Related Quality of Life: Implications for Managing Patients with Chronic Pain during the COVID-19 Pandemic. Healthcare (Basel). 2020 Oct 1;8(4). pii: E381. doi: 10.3390/healthcare8040381.|Licciardone JC. Demographic Characteristics Associated With Utilization of Noninvasive Treatments for Chronic Low Back Pain and Related Clinical Outcomes During the COVID-19 Pandemic in the United States. J Am Board Fam Med. 2021 Feb;34(Suppl):S77-S84. doi: 10.3122/jabfm.2021.S1.200352.","\tChronic Low Back Pain\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","low back pain","NA","NA"]
["NCT04853758","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19410718|29266804|11500748|6109902|20398860|2596992|7994859|29141857|25176015|30298996","Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion through control of neglected tropical diseases. Lancet. 2009 May 2;373(9674):1570-5. doi: 10.1016/S0140-6736(09)60233-6. Review.|Bocchi EA, Rassi S, Guimarães GV; Argentina, Chile, and Brazil SHIFT Investigators. Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial. ESC Heart Fail. 2018 Jun;5(3):249-256. doi: 10.1002/ehf2.12240. Epub 2017 Dec 20.|Ianni BM, Arteaga E, Frimm CC, Pereira Barretto AC, Mady C. Chagas' heart disease: evolutive evaluation of electrocardiographic and echocardiographic parameters in patients with the indeterminate form. Arq Bras Cardiol. 2001 Jul;77(1):59-62.|Araujo FG, Chiari E, Dias JC. Demonstration of Trypanosoma cruzi antigen in serum from patients with Chagas' disease. Lancet. 1981 Jan 31;1(8214):246-9.|Carod-Artal FJ, Gascon J. Chagas disease and stroke. Lancet Neurol. 2010 May;9(5):533-42. doi: 10.1016/S1474-4422(10)70042-9. Review.|Barretto AC, Higuchi ML, da Luz PL, Lopes EA, Bellotti G, Mady C, Stolf N, Arteaga-Fernández E, Pileggi F. [Comparison of histologic changes in Chagas' cardiomyopathy and dilated cardiomyopathy]. Arq Bras Cardiol. 1989 Feb;52(2):79-83. Portuguese.|Mady C, Cardoso RH, Barretto AC, da Luz PL, Bellotti G, Pileggi F. Survival and predictors of survival in patients with congestive heart failure due to Chagas' cardiomyopathy. Circulation. 1994 Dec;90(6):3098-102.|Shen L, Ramires F, Martinez F, Bodanese LC, Echeverría LE, Gómez EA, Abraham WT, Dickstein K, Køber L, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Jhund PS, Gimpelewicz CR, McMurray JJV; PARADIGM-HF and ATMOSPHERE Investigators and Committees. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circ Heart Fail. 2017 Nov;10(11). pii: e004361. doi: 10.1161/CIRCHEARTFAILURE.117.004361.|McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.|\"Ramires FJA, Martinez F, Gómez EA, Demacq C, Gimpelewicz CR, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV. Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: \"\"Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial\"\" by Bocchi et al. ESC Heart Fail. 2018 Dec;5(6):1069-1071. doi: 10.1002/ehf2.12355. Epub 2018 Oct 9.\"","\tChagas Cardiomyopathy\tSacubitril / Valsartan Oral Tablet [Entresto]|Enalapril\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.","Interventional","Recruiting","Phase 3",2,200,"cardiomyopathies|chagas cardiomyopathy","valsartan|enzyme inhibitors|enalapril|lcz 696|angiotensin-converting enzyme inhibitors","NA"]
["NCT04853953","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26380745|29984201|32325026","Makdisi G, Wang IW. Extra Corporeal Membrane Oxygenation (ECMO) review of a lifesaving technology. J Thorac Dis. 2015 Jul;7(7):E166-76. doi: 10.3978/j.issn.2072-1439.2015.07.17. Review.|Rawal G, Yadav S, Kumar R. Acute Respiratory Distress Syndrome: An Update and Review. J Transl Int Med. 2018 Jun 26;6(2):74-77. doi: 10.1515/jtim-2016-0012. eCollection 2018 Jun.|Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21.","\tAcute Respiratory Distress Syndrome|Corona Virus Infection|Extracorporeal Membrane Oxygenation Complication\tIncidence of bleeding complications in ARDS patients on veno-venous ECMO\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","syndrome|acute lung injury|coronavirus infections|severe acute respiratory syndrome|respiratory distress syndrome, newborn|respiratory distress syndrome, adult","NA","NA"]
["NCT04854278","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",33744093,"Soenens G, Doyen B, Vlerick P, Vermassen F, Grantcharov T, Van Herzeele I. Assessment of Endovascular Team Performances Using a Comprehensive Data Capture Platform in the Hybrid Room: A Pilot Study. Eur J Vasc Endovasc Surg. 2021 Mar 17. pii: S1078-5884(21)00171-4. doi: 10.1016/j.ejvs.2021.02.021. [Epub ahead of print]","\tEndovascular Procedures|Patient Safety|Quality Improvement\tMassive Open Online Course (MOOC)\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04855669","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26759141|29306491|31082741","Saravelos SH, Wong AW, Chan CP, Kong GW, Cheung LP, Chung CH, Chung JP, Li TC. Assessment of the embryo flash position and migration with 3D ultrasound within 60 min of embryo transfer. Hum Reprod. 2016 Mar;31(3):591-6. doi: 10.1093/humrep/dev343. Epub 2016 Jan 11.|Fıçıcıoğlu C, Özcan P, Koçer MG, Yeşiladalı M, Alagöz O, Özkara G, Tayyar AT, Altunok Ç. Effect of air bubbles localization and migration after embryo transfer on assisted reproductive technology outcome. Fertil Steril. 2018 Feb;109(2):310-314.e1. doi: 10.1016/j.fertnstert.2017.10.032. Epub 2018 Jan 4.|Ozdemir AZ, Ayas B, Guven D, Turkmen A. Embryo flash migration in fresh and frozen embryo transfers for day 3 and day 5 embryos. Eur J Obstet Gynecol Reprod Biol. 2019 Jul;238:33-37. doi: 10.1016/j.ejogrb.2019.04.025. Epub 2019 May 4.","\tInfertility\tNA\tNA\tNA\tNA\tNA\tFemale\t","NA","NA","NA","NA","NA","NA","infertility","NA","NA"]
["NCT04856306","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31971678|12423842","Schlaff WD, Ackerman RT, Al-Hendy A, Archer DF, Barnhart KT, Bradley LD, Carr BR, Feinberg EC, Hurtado SM, Kim J, Liu R, Mabey RG Jr, Owens CD, Poindexter A, Puscheck EE, Rodriguez-Ginorio H, Simon JA, Soliman AM, Stewart EA, Watts NB, Muneyyirci-Delale O. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. N Engl J Med. 2020 Jan 23;382(4):328-340. doi: 10.1056/NEJMoa1904351.|Broder MS, Goodwin S, Chen G, Tang LJ, Costantino MM, Nguyen MH, Yegul TN, Erberich H. Comparison of long-term outcomes of myomectomy and uterine artery embolization. Obstet Gynecol. 2002 Nov;100(5 Pt 1):864-8.","\tFibroid Uterus|Heavy Menstrual Bleeding\tGroups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure|Elagolix Oral Product\tNA\tNA\tNA\tOther|Drug\tFemale\t","NA","NA","NA","NA","NA","NA","myofibroma|menorrhagia|leiomyoma","NA","NA"]
["NCT04857268","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24963566|11343485|17577005|25833879|29414264|22236222|22503584","Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, Vaid H, O'Donnell M, Laupacis A, Côté R, Sharma M, Blakely JA, Shuaib A, Hachinski V, Coutts SB, Sahlas DJ, Teal P, Yip S, Spence JD, Buck B, Verreault S, Casaubon LK, Penn A, Selchen D, Jin A, Howse D, Mehdiratta M, Boyle K, Aviv R, Kapral MK, Mamdani M; EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014 Jun 26;370(26):2467-77. doi: 10.1056/NEJMoa1311376.|Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9;285(18):2370-5.|Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jun 19;146(12):857-67.|Potpara TS, Lane DA, Lip GY. Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from patients and physicians leads to better outcomes. Europace. 2015 Apr;17(4):507-8. doi: 10.1093/europace/euv041.|Waks JW, Buxton AE. Risk Stratification for Sudden Cardiac Death After Myocardial Infarction. Annu Rev Med. 2018 Jan 29;69:147-164. doi: 10.1146/annurev-med-041316-090046. Review.|Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012 Jan 12;366(2):120-9. doi: 10.1056/NEJMoa1105575. Erratum in: N Engl J Med. 2016 Mar 10;374(10):998.|Camm AJ, Corbucci G, Padeletti L. Usefulness of continuous electrocardiographic monitoring for atrial fibrillation. Am J Cardiol. 2012 Jul 15;110(2):270-6. doi: 10.1016/j.amjcard.2012.03.021. Epub 2012 Apr 12. Review.","\tAtrial Fibrillation New Onset\twearable continuous ECG monitoring patch, ATP-C120\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","atrial fibrillation","NA","NA"]
["NCT04857450","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","10966311|12873568|21563653|18790440|25478364|16703233|21263301|4036533|25535501|18274461|17338847|8387232|26871805","Corwin HL, Krantz SB. Anemia of the critically ill: \"acute\" anemia of chronic disease. Crit Care Med. 2000 Aug;28(8):3098-9.|van Leerdam ME, Vreeburg EM, Rauws EA, Geraedts AA, Tijssen JG, Reitsma JB, Tytgat GN. Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol. 2003 Jul;98(7):1494-9.|Colle I, Wilmer A, Le Moine O, Debruyne R, Delwaide J, Dhondt E, Macken E, Penaloza A, Piessevaux H, Stéphenne X, Van Biervliet S, Laterre PF. Upper gastrointestinal tract bleeding management: Belgian guidelines for adults and children. Acta Gastroenterol Belg. 2011 Mar;74(1):45-66. Erratum in: Acta Gastroenterol Belg. 2011 Jun;74(2):368.|Regula J, Sokol-Kobielska E. Sedation in endoscopy: when and how. Best Pract Res Clin Gastroenterol. 2008;22(5):945-57. doi: 10.1016/j.bpg.2008.06.002. Review.|Habibi MR, Baradari AG, Soleimani A, Emami Zeydi A, Nia HS, Habibi A, Onagh N. Hemodynamic responses to etomidate versus ketamine-thiopental sodium combination for anesthetic induction in coronary artery bypass graft surgery patients with low ejection fraction: a double-blind, randomized, clinical trial. J Clin Diagn Res. 2014 Oct;8(10):GC01-5. doi: 10.7860/JCDR/2014/10237.5006. Epub 2014 Oct 20.|Bovill JG. Intravenous anesthesia for the patient with left ventricular dysfunction. Semin Cardiothorac Vasc Anesth. 2006 Mar;10(1):43-8. Review.|Forman SA. Clinical and molecular pharmacology of etomidate. Anesthesiology. 2011 Mar;114(3):695-707. doi: 10.1097/ALN.0b013e3181ff72b5. Review.|Wanscher M, Tønnesen E, Hüttel M, Larsen K. Etomidate infusion and adrenocortical function. A study in elective surgery. Acta Anaesthesiol Scand. 1985 Jul;29(5):483-5.|Heidari SM, Loghmani P. Assessment of the effects of ketamine-fentanyl combination versus propofol-remifentanil combination for sedation during endoscopic retrograde cholangiopancreatography. J Res Med Sci. 2014 Sep;19(9):860-6.|Rai K, Hegde AM, Goel K. Sedation in uncooperative children undergoing dental procedures: a comparative evaluation of midazolam, propofol and ketamine. J Clin Pediatr Dent. 2007 Fall;32(1):1-4.|Zed PJ, Mabasa VH, Slavik RS, Abu-Laban RB. Etomidate for rapid sequence intubation in the emergency department: is adrenal suppression a concern? CJEM. 2006 Sep;8(5):347-50. Review.|Varga I, Rácz K, Kiss R, Fütö L, Tóth M, Sergev O, Gláz E. Direct inhibitory effect of etomidate on corticosteroid secretion in human pathologic adrenocortical cells. Steroids. 1993 Feb;58(2):64-8.|Wu GN, Xu HJ, Liu FF, Wu X, Zhou H. Low-Dose Ketamine Pretreatment Reduces the Incidence and Severity of Myoclonus Induced by Etomidate: A Randomized, Double-Blinded, Controlled Clinical Trial. Medicine (Baltimore). 2016 Feb;95(6):e2701. doi: 10.1097/MD.0000000000002701.","\tAnemia|Cardiomyopathies|Pulmonary Hypertension\tEtomidate|Ketamine Hydrochloride\tParallel Assignment\tSupportive Care\tRandomized\tDrug|Drug\tAll\t","Anesthesia for Upper Endoscopy and Colonoscopy in Cardiac Patients With Acute Anemia","Interventional","Recruiting","N/A",2,60,"cardiomyopathies|hypertension, pulmonary|anemia","ketamine|etomidate","NA"]
["NCT04858087","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",33767384,"Cohee LM, Valim C, Coalson JE, Nyambalo A, Chilombe M, Ngwira A, Bauleni A, Seydel KB, Wilson ML, Taylor TE, Mathanga DP, Laufer MK. School-based screening and treatment may reduce P. falciparum transmission. Sci Rep. 2021 Mar 25;11(1):6905. doi: 10.1038/s41598-021-86450-5.","\tAnemia|Malaria|Malaria,Falciparum\tScreening and treatment\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","malaria|malaria, falciparum","lumefantrine|artemether|artemether, lumefantrine drug combination","NA"]
["NCT04858204","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","1. Malhotra J, Jabbour SK, Aisner J. Current state of immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2017 Apr;6(2):196-211. 2. Kazandjian D, Suzman DL, Blumenthal G, Mushti S, He K, Libeg M et al. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. The Oncologist. 2016 May;21(5):634-42. 3. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 9;373(2):123-35. 4. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct 22;373(17):1627-39. 5. Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han JY et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet. 2016 Apr;387(10027):1540-50. 6. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet Lond Engl. 2017 21;389(10066):255-65. 7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 1990. 2009 Jan;45(2):228-47. 8. Common Terminology Criteria for Adverse Events (CTCAE) - CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf","\tNSCLC\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","carcinoma, non-small-cell lung","NA","NA"]
["NCT04859673","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26522903,"Wilson RD, Chae J. Hemiplegic Shoulder Pain. Phys Med Rehabil Clin N Am. 2015 Nov;26(4):641-55. doi: 10.1016/j.pmr.2015.06.007. Epub 2015 Sep 9. Review.","\tHemiplegia|Spastic\tradial extracorpeal shock wave\tParallel Assignment\tTreatment\tRandomized\tDevice\tAll\t","Influence of Radial Extracorpeal Shock Wave in Hemiplegic Shoulder Patients","Interventional","Not yet recruiting","N/A",2,30,"hemiplegia","NA","NA"]
["NCT04860115","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29457215,"Ní Eochagáin A, Burns D, Riedel B, Sessler DI, Buggy DJ. The effect of anaesthetic technique during primary breast cancer surgery on neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and return to intended oncological therapy. Anaesthesia. 2018 May;73(5):603-611. doi: 10.1111/anae.14207. Epub 2018 Feb 19.","\tInflammatory Markers\tModified pectoralis block (PEC II) and pecto-intercostal fascial plane block (PIFB)\tParallel Assignment\tTreatment\tRandomized\tProcedure\tFemale\t","Impact of Novel Thoracic Wall Blocks With Dexmetomidine on Inflammatory Markers Following Breast Cancer Surgery","Interventional","Not yet recruiting","N/A",2,120,"breast neoplasms","NA","NA"]
["NCT04860167","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28167118|27598398|12447291|17470884|19967620","Patai Á, Solymosi N, Mohácsi L, Patai ÁV. Indomethacin and diclofenac in the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis of prospective controlled trials. Gastrointest Endosc. 2017 Jun;85(6):1144-1156.e1. doi: 10.1016/j.gie.2017.01.033. Epub 2017 Feb 4. Review.|Quesada N, Júdez D, Martínez Ubieto J, Pascual A, Chacón E, De Pablo F, Mincholé E, Bello S. Bispectral Index Monitoring Reduces the Dosage of Propofol and Adverse Events in Sedation for Endobronchial Ultrasound. Respiration. 2016;92(3):166-75. doi: 10.1159/000448433. Epub 2016 Sep 7.|Wehrmann T, Grotkamp J, Stergiou N, Riphaus A, Kluge A, Lembcke B, Schultz A. Electroencephalogram monitoring facilitates sedation with propofol for routine ERCP: a randomized, controlled trial. Gastrointest Endosc. 2002 Dec;56(6):817-24.|White PF, Sacan O, Tufanogullari B, Eng M, Nuangchamnong N, Ogunnaike B. Effect of short-term postoperative celecoxib administration on patient outcome after outpatient laparoscopic surgery. Can J Anaesth. 2007 May;54(5):342-8.|Paspatis GA, Chainaki I, Manolaraki MM, Vardas E, Theodoropoulou A, Tribonias G, Konstantinidis K, Karmiris K, Chlouverakis G. Efficacy of bispectral index monitoring as an adjunct to propofol deep sedation for ERCP: a randomized controlled trial. Endoscopy. 2009 Dec;41(12):1046-51. doi: 10.1055/s-0029-1215342. Epub 2009 Dec 4.","\tBiliary Colic\tPropofol|Diclofenac Sodium and Lignocaine 10 % spray\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Sedation for Patients Undergoing Endoscopic Retrograde Cholangiopancreatography","Interventional","Completed","N/A",3,90,"NA","diclofenac|lidocaine|propofol","NA"]
["NCT04860479","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30063657|31022606|26337562|10589630|30132074","Girón-Arango L, Peng PWH, Chin KJ, Brull R, Perlas A. Pericapsular Nerve Group (PENG) Block for Hip Fracture. Reg Anesth Pain Med. 2018 Nov;43(8):859-863. doi: 10.1097/AAP.0000000000000847.|Orozco S, Muñoz D, Jaramillo S, Herrera AM. Pediatric use of Pericapsular Nerve Group (PENG) block for hip surgical procedures. J Clin Anesth. 2019 Nov;57:143-144. doi: 10.1016/j.jclinane.2019.04.010. Epub 2019 Apr 22.|Frković V, Wärmländer SK, Petaros A, Španjol-Pandelo I, Ažman J. Finger width as a measure of femoral block puncture site: an ultrasonographic anatomical-anthropometric study. J Clin Anesth. 2015 Nov;27(7):553-7. doi: 10.1016/j.jclinane.2015.07.015. Epub 2015 Aug 31.|Vloka JD, Hadzić A, Drobnik L, Ernest A, Reiss W, Thys DM. Anatomical landmarks for femoral nerve block: a comparison of four needle insertion sites. Anesth Analg. 1999 Dec;89(6):1467-70.|Yoshimura M, Nakanishi T, Sakamoto S, Toriumi T. Age is a predictive factor in the femoral nerve positioning: an anatomical ultrasound study. J Anesth. 2018 Oct;32(5):777-780. doi: 10.1007/s00540-018-2544-2. Epub 2018 Aug 21.","\tAnatomic Abnormality|Anatomic Landmarks|Anatomy|Anthropometry|Pediatrics\tultrasound\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","congenital abnormalities","NA","NA"]
["NCT04860544","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","8700982|14515225|19698095|28416356|28000297|28151027","Kroll SS, Schusterman MA, Reece GP, Miller MJ, Evans GR, Robb GL, Baldwin BJ. Choice of flap and incidence of free flap success. Plast Reconstr Surg. 1996 Sep;98(3):459-63.|Nakatsuka T, Harii K, Asato H, Takushima A, Ebihara S, Kimata Y, Yamada A, Ueda K, Ichioka S. Analytic review of 2372 free flap transfers for head and neck reconstruction following cancer resection. J Reconstr Microsurg. 2003 Aug;19(6):363-8; discussion 369.|Novakovic D, Patel RS, Goldstein DP, Gullane PJ. Salvage of failed free flaps used in head and neck reconstruction. Head Neck Oncol. 2009 Aug 21;1:33. doi: 10.1186/1758-3284-1-33. Review.|Zhou W, Zhang WB, Yu Y, Wang Y, Mao C, Guo CB, Yu GY, Peng X. Risk factors for free flap failure: a retrospective analysis of 881 free flaps for head and neck defect reconstruction. Int J Oral Maxillofac Surg. 2017 Aug;46(8):941-945. doi: 10.1016/j.ijom.2017.03.023. Epub 2017 Apr 14.|Cannady SB, Hatten KM, Bur AM, Brant J, Fischer JP, Newman JG, Chalian AA. Use of free tissue transfer in head and neck cancer surgery and risk of overall and serious complication(s): An American College of Surgeons-National Surgical Quality Improvement Project analysis of free tissue transfer to the head and neck. Head Neck. 2017 Apr;39(4):702-707. doi: 10.1002/hed.24669. Epub 2016 Dec 21.|Heidekrueger PI, Ninkovic M, Heine-Geldern A, Herter F, Broer PN. End-to-end versus end-to-side anastomoses in free flap reconstruction: single centre experiences. J Plast Surg Hand Surg. 2017 Oct;51(5):362-365. doi: 10.1080/2000656X.2017.1283321. Epub 2017 Feb 2.","\tVascular Thrombosis\tRED BLOOD CELLS TRANFUSION\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","thrombosis","NA","NA"]
["NCT04861402","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32283294|31978945|32015507|32230900|27012512|32150360|10969042|32314810","Ye M, Ren Y, Lv T. Encephalitis as a clinical manifestation of COVID-19. Brain Behav Immun. 2020 Aug;88:945-946. doi: 10.1016/j.bbi.2020.04.017. Epub 2020 Apr 10.|Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.|Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.|Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, Duan G. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020 Mar 27;12(4). pii: E372. doi: 10.3390/v12040372. Review.|Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, Liu W, Bi Y, Gao GF. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol. 2016 Jun;24(6):490-502. doi: 10.1016/j.tim.2016.03.003. Epub 2016 Mar 21. Review.|Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2021 Apr 20. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK554776/|Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000 Sep 1;87(5):E1-9.|Paniz-Mondolfi A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednicky J, Sordillo EM, Fowkes M. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol. 2020 Jul;92(7):699-702. doi: 10.1002/jmv.25915.","\tIntracranial Pressure\tThe ICP monitoring will be performed in a non-invasive method developed by Brain4Care\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04861870","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",29617375,"Doyle K, Levtov RG, Barker G, Bastian GG, Bingenheimer JB, Kazimbaya S, Nzabonimpa A, Pulerwitz J, Sayinzoga F, Sharma V, Shattuck D. Gender-transformative Bandebereho couples' intervention to promote male engagement in reproductive and maternal health and violence prevention in Rwanda: Findings from a randomized controlled trial. PLoS One. 2018 Apr 4;13(4):e0192756. doi: 10.1371/journal.pone.0192756. eCollection 2018.","\tChild Development|Contraception|Gender Relations|Partner Communication|Prenatal Care|Violence\tMenCare+/Bandebereho fathers'/couples' group education\tParallel Assignment\tPrevention\tRandomized\tBehavioral\tAll\t","Bandebereho 6 Year Follow up RCT in Rwanda","Interventional","Enrolling by invitation","N/A",2,3180,"NA","NA","NA"]
["NCT04862182","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28222431|32865824|12768551|30457229","Barak O, Levy R, Flidel O, Zaks S, Gillor M, Hagay Z, Vaisbuch E. The Routine Use of Intrapartum Ultrasound in Clinical Decision-Making during the Second Stage of Labor - Does It Have Any Impact on Delivery Outcomes? Gynecol Obstet Invest. 2018;83(1):9-14. doi: 10.1159/000455847. Epub 2017 Feb 22.|Brunelli E, Del Prete B, Casadio P, Pilu G, Youssef A. The dynamic change of the anteroposterior diameter of the levator hiatus under Valsalva maneuver at term and labor outcome. Neurourol Urodyn. 2020 Nov;39(8):2353-2360. doi: 10.1002/nau.24494. Epub 2020 Aug 31.|Sherer DM, Abulafia O. Intrapartum assessment of fetal head engagement: comparison between transvaginal digital and transabdominal ultrasound determinations. Ultrasound Obstet Gynecol. 2003 May;21(5):430-6.|Lipschuetz M, Cohen SM, Lewkowicz AA, Amsalem H, Haj Yahya R, Levitt L, Yagel S. [PROLONGED SECOND STAGE OF LABOR: CAUSES AND OUTCOMES]. Harefuah. 2018 Nov;157(11):685-690. Hebrew.","\tUltrasound Therapy; Complications\tTrans-perineal ultrasound\tNA\tNA\tNA\tDiagnostic Test\tFemale\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04862728","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","19682776|20398432|22568534|24050847|18753390","Hulst JM, Zwart H, Hop WC, Joosten KF. Dutch national survey to test the STRONGkids nutritional risk screening tool in hospitalized children. Clin Nutr. 2010 Feb;29(1):106-11. doi: 10.1016/j.clnu.2009.07.006. Epub 2009 Aug 13.|Gerasimidis K, Keane O, Macleod I, Flynn DM, Wright CM. A four-stage evaluation of the Paediatric Yorkhill Malnutrition Score in a tertiary paediatric hospital and a district general hospital. Br J Nutr. 2010 Sep;104(5):751-6. doi: 10.1017/S0007114510001121. Epub 2010 Apr 19.|McCarthy H, Dixon M, Crabtree I, Eaton-Evans MJ, McNulty H. The development and evaluation of the Screening Tool for the Assessment of Malnutrition in Paediatrics (STAMP©) for use by healthcare staff. J Hum Nutr Diet. 2012 Aug;25(4):311-8. doi: 10.1111/j.1365-277X.2012.01234.x. Epub 2012 May 9.|Joosten KF, Hulst JM. Nutritional screening tools for hospitalized children: methodological considerations. Clin Nutr. 2014 Feb;33(1):1-5. doi: 10.1016/j.clnu.2013.08.002. Epub 2013 Aug 31. Review.|Skillman HE, Wischmeyer PE. Nutrition therapy in critically ill infants and children. JPEN J Parenter Enteral Nutr. 2008 Sep-Oct;32(5):520-34. doi: 10.1177/0148607108322398. Review.","\tNutrition Disorder, Child\t- Strong kids screening tool - Stamp screening tool - PYMS screening tool\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","nutrition disorders|child nutrition disorders","NA","NA"]
["NCT04863066","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32868878,"Maldini CR, Claiborne DT, Okawa K, Chen T, Dopkin DL, Shan X, Power KA, Trifonova RT, Krupp K, Phelps M, Vrbanac VD, Tanno S, Bateson T, Leslie GJ, Hoxie JA, Boutwell CL, Riley JL, Allen TM. Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo. Nat Med. 2020 Nov;26(11):1776-1787. doi: 10.1038/s41591-020-1039-5. Epub 2020 Aug 31.","\tHIV-1\tCAR-T cells\tNA\tNA\tNA\tBiological\tAll\t","NA","NA","NA","NA","NA","NA","infection","NA","NA"]
["NCT04863807","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16385313|23403516|11837920|21872207|29766081|30740657|30687939","Simon BJ, Cushman J, Barraco R, Lane V, Luchette FA, Miglietta M, Roccaforte DJ, Spector R; EAST Practice Management Guidelines Work Group. Pain management guidelines for blunt thoracic trauma. J Trauma. 2005 Nov;59(5):1256-67.|Ahn Y, Görlinger K, Alam HB, Eikermann M. Pain-associated respiratory failure in chest trauma. Anesthesiology. 2013 Mar;118(3):701-8. doi: 10.1097/ALN.0b013e318283996b.|Barnea Y, Kashtan H, Skornick Y, Werbin N. Isolated rib fractures in elderly patients: mortality and morbidity. Can J Surg. 2002 Feb;45(1):43-6.|Jones KM, Reed RL 2nd, Luchette FA. The ribs or not the ribs: which influences mortality? Am J Surg. 2011 Nov;202(5):598-604. doi: 10.1016/j.amjsurg.2010.09.029. Epub 2011 Aug 26.|Witt CE, Bulger EM. Comprehensive approach to the management of the patient with multiple rib fractures: a review and introduction of a bundled rib fracture management protocol. Trauma Surg Acute Care Open. 2017 Jan 5;2(1):e000064. doi: 10.1136/tsaco-2016-000064. eCollection 2017. Review.|Adhikary SD, Liu WM, Fuller E, Cruz-Eng H, Chin KJ. The effect of erector spinae plane block on respiratory and analgesic outcomes in multiple rib fractures: a retrospective cohort study. Anaesthesia. 2019 May;74(5):585-593. doi: 10.1111/anae.14579. Epub 2019 Feb 10.|Womack J, Pearson JD, Walker IA, Stephens NM, Goodman BA. Safety, complications and clinical outcome after ultrasound-guided paravertebral catheter insertion for rib fracture analgesia: a single-centre retrospective observational study. Anaesthesia. 2019 May;74(5):594-601. doi: 10.1111/anae.14580. Epub 2019 Jan 27.","\tPain, Acute|Rib Fractures\tRegional Anaesthesia\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","rib fractures|fractures, bone|acute pain","anesthetics","NA"]
["NCT04863911","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22447236|21298428|16322973","Llopis E, Fernandez E, Cerezal L. MR and CT arthrography of the hip. Semin Musculoskelet Radiol. 2012 Feb;16(1):42-56. doi: 10.1055/s-0032-1304300. Epub 2012 Mar 23. Review.|Perdikakis E, Karachalios T, Katonis P, Karantanas A. Comparison of MR-arthrography and MDCT-arthrography for detection of labral and articular cartilage hip pathology. Skeletal Radiol. 2011 Nov;40(11):1441-7. doi: 10.1007/s00256-011-1111-9. Epub 2011 Feb 6.|Schneider G, Massmann A, Fries P, Kusma M, Dienst M. [Magnetic resonance tomography and arthrography of the hip joint]. Orthopade. 2006 Jan;35(1):22-6, 28-32. Review. German.","\tHip Disease\tcombined CT and MRI\tNA\tNA\tNA\tRadiation\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04864171","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","33706078|33822931|31449658|31180473|29799063|29445002|29040461","Kitahara S, Kataoka Y, Miura H, Nishii T, Nishimura K, Murai K, Iwai T, Nakamura H, Hosoda H, Matama H, Doi T, Nakashima T, Honda S, Fujino M, Nakao K, Yoneda S, Nishihira K, Kanaya T, Otsuka F, Asaumi Y, Tsujita K, Noguchi T, Yasuda S. The feasibility and limitation of coronary computed tomographic angiography imaging to identify coronary lipid-rich atheroma in vivo: Findings from near-infrared spectroscopy analysis. Atherosclerosis. 2021 Apr;322:1-7. doi: 10.1016/j.atherosclerosis.2021.02.019. Epub 2021 Feb 24.|Imamoto K, Kataoka Y, Hosoda H, Noguchi T. Suboptimal lipoprotein (a) control and residual plaque instability despite proprotein convertase subtilisin/kexin type 9 inhibitor use in heterozygous familial hypercholesterolaemia: insights from serial near-infrared spectroscopy imaging. Eur Heart J. 2021 Apr 5. pii: ehab218. doi: 10.1093/eurheartj/ehab218. [Epub ahead of print]|Hosoda H, Kataoka Y, Otsuka F, Yasuda S. Severely calcified lipidic atheroma on intravascular ultrasound and near-infrared spectroscopy imaging: its association with slow-flow phenomenon during percutaneous coronary intervention. Eur Heart J Case Rep. 2019 Jun 1;3(2). pii: ytz078. doi: 10.1093/ehjcr/ytz078.|Nishihira K, Yamashita A, Kataoka Y, Shibata Y, Asada Y. Visualization of oxidized low-density lipoprotein at lipid-rich plaque in a ST-segment elevation myocardial infarction case with heterozygous familial hypercholesterolaemia: insights from near-infrared spectroscopy and histopathological analysis. Eur Heart J Cardiovasc Imaging. 2019 Nov 1;20(11):1316. doi: 10.1093/ehjci/jez156.|Kaichi R, Kataoka Y, Yasuda S. Erupted coronary atheroma: insights from multi-modality imaging. Int J Cardiovasc Imaging. 2018 Oct;34(10):1669-1671. doi: 10.1007/s10554-018-1378-1. Epub 2018 May 24.|Nishihira K, Otsuka F, Kataoka Y, Asaumi Y, Kaneta K, Nakano H, Ohta-Ogo K, Ishibashi-Ueda H, Noguchi T, Yasuda S. Embolization of Neoatherosclerosis After Percutaneous Coronary Intervention: Insights From Near-Infrared Spectroscopy Imaging and Histopathological Analysis. Circ Cardiovasc Interv. 2018 Feb;11(2):e006175. doi: 10.1161/CIRCINTERVENTIONS.117.006175.|Nishihira K, Asaumi Y, Kataoka Y, Ishibashi-Ueda H, Yasuda S. In vivo comparison of lipid-rich plaque on near-infrared spectroscopy with histopathological analysis of coronary atherectomy specimens. Eur Heart J Cardiovasc Imaging. 2018 Jan 1;19(1):116. doi: 10.1093/ehjci/jex247.","\tLipid-Rich Atherosclerosis of Coronary Artery\tnear-infrared spectroscopy\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","atherosclerosis|coronary artery disease|myocardial ischemia","NA","NA"]
["NCT04864288","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16291031|28787549","Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am. 2005 Nov;32(4):379-95, v. Review.|Hamidi N, Altinbas NK, Gokce MI, Suer E, Yagci C, Baltaci S, Turkolmez K. Preliminary results of a new tool to evaluate cavernous body fibrosis following radical prostatectomy: penile elastography. Andrology. 2017 Sep;5(5):999-1006. doi: 10.1111/andr.12408. Epub 2017 Aug 8.","\tTo Investigate the Value of Penile Elastography in the Diagnosis of Fibrosis of CC\tShear Wave Elastography\tNA\tNA\tNA\tDevice\tMale\t","NA","NA","NA","NA","NA","NA","erectile dysfunction","NA","NA"]
["NCT04865003","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26829352|31862339|21820786|18952475|31747058","Prado-Calleros HM, Jiménez-Fuentes E, Jiménez-Escobar I. Descending necrotizing mediastinitis: Systematic review on its treatment in the last 6 years, 75 years after its description. Head Neck. 2016 Apr;38 Suppl 1:E2275-83. doi: 10.1002/hed.24183. Epub 2016 Feb 1. Review.|Qu L, Xu H, Liang X, Cai X, Zhang W, Qian W. A Retrospective Cohort Study of Risk Factors for Descending Necrotizing Mediastinitis Caused by Multispace Infection in the Maxillofacial Region. J Oral Maxillofac Surg. 2020 Mar;78(3):386-393. doi: 10.1016/j.joms.2019.11.017. Epub 2019 Nov 26.|Sarna T, Sengupta T, Miloro M, Kolokythas A. Cervical necrotizing fasciitis with descending mediastinitis: literature review and case report. J Oral Maxillofac Surg. 2012 Jun;70(6):1342-50. doi: 10.1016/j.joms.2011.05.007. Epub 2011 Aug 6. Review.|Boscolo-Rizzo P, Da Mosto MC. Submandibular space infection: a potentially lethal infection. Int J Infect Dis. 2009 May;13(3):327-33. doi: 10.1016/j.ijid.2008.07.007. Epub 2008 Oct 25.|Kimura A, Miyamoto S, Yamashita T. Clinical predictors of descending necrotizing mediastinitis after deep neck infections. Laryngoscope. 2020 Nov;130(11):E567-E572. doi: 10.1002/lary.28406. Epub 2019 Nov 20.","\tInfection|Inflammation|Mediastinitis|Neck Abscess\ttreatment of infection\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","communicable diseases|inflammation|mediastinitis|infection","NA","NA"]
["NCT04865198","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31215791|31191373|22269006|22153079|27780737|31068605|20837545|28776200|9428516|21336257|29911178","Alvares GA, Bebbington K, Cleary D, Evans K, Glasson EJ, Maybery MT, Pillar S, Uljarević M, Varcin K, Wray J, Whitehouse AJ. The misnomer of 'high functioning autism': Intelligence is an imprecise predictor of functional abilities at diagnosis. Autism. 2020 Jan;24(1):221-232. doi: 10.1177/1362361319852831. Epub 2019 Jun 19.|Jacobs D, Steyaert J, Dierickx K, Hens K. Physician View and Experience of the Diagnosis of Autism Spectrum Disorder in Young Children. Front Psychiatry. 2019 May 28;10:372. doi: 10.3389/fpsyt.2019.00372. eCollection 2019.|Goh S, Peterson BS. Imaging evidence for disturbances in multiple learning and memory systems in persons with autism spectrum disorders. Dev Med Child Neurol. 2012 Mar;54(3):208-13. doi: 10.1111/j.1469-8749.2011.04153.x. Epub 2012 Jan 23. Review.|Pavlopoulos E, Trifilieff P, Chevaleyre V, Fioriti L, Zairis S, Pagano A, Malleret G, Kandel ER. Neuralized1 activates CPEB3: a function for nonproteolytic ubiquitin in synaptic plasticity and memory storage. Cell. 2011 Dec 9;147(6):1369-83. doi: 10.1016/j.cell.2011.09.056.|Jaagura M, Taal K, Koppel I, Tuvikene J, Timmusk T, Tamme R. Rat NEURL1 3'UTR is alternatively spliced and targets mRNA to dendrites. Neurosci Lett. 2016 Dec 2;635:71-76. doi: 10.1016/j.neulet.2016.10.041. Epub 2016 Oct 22.|Taal K, Tuvikene J, Rullinkov G, Piirsoo M, Sepp M, Neuman T, Tamme R, Timmusk T. Neuralized family member NEURL1 is a ubiquitin ligase for the cGMP-specific phosphodiesterase 9A. Sci Rep. 2019 May 8;9(1):7104. doi: 10.1038/s41598-019-43069-x.|Lee SE, Simons SB, Heldt SA, Zhao M, Schroeder JP, Vellano CP, Cowan DP, Ramineni S, Yates CK, Feng Y, Smith Y, Sweatt JD, Weinshenker D, Ressler KJ, Dudek SM, Hepler JR. RGS14 is a natural suppressor of both synaptic plasticity in CA2 neurons and hippocampal-based learning and memory. Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16994-8. doi: 10.1073/pnas.1005362107. Epub 2010 Sep 13.|Squires KE, Gerber KJ, Pare JF, Branch MR, Smith Y, Hepler JR. Regulator of G protein signaling 14 (RGS14) is expressed pre- and postsynaptically in neurons of hippocampus, basal ganglia, and amygdala of monkey and human brain. Brain Struct Funct. 2018 Jan;223(1):233-253. doi: 10.1007/s00429-017-1487-y. Epub 2017 Aug 3.|Martin KC, Casadio A, Zhu H, Yaping E, Rose JC, Chen M, Bailey CH, Kandel ER. Synapse-specific, long-term facilitation of aplysia sensory to motor synapses: a function for local protein synthesis in memory storage. Cell. 1997 Dec 26;91(7):927-38.|Hosoda N, Funakoshi Y, Hirasawa M, Yamagishi R, Asano Y, Miyagawa R, Ogami K, Tsujimoto M, Hoshino S. Anti-proliferative protein Tob negatively regulates CPEB3 target by recruiting Caf1 deadenylase. EMBO J. 2011 Apr 6;30(7):1311-23. doi: 10.1038/emboj.2011.37. Epub 2011 Feb 18.|Evans PR, Parra-Bueno P, Smirnov MS, Lustberg DJ, Dudek SM, Hepler JR, Yasuda R. RGS14 Restricts Plasticity in Hippocampal CA2 by Limiting Postsynaptic Calcium Signaling. eNeuro. 2018 Jun 4;5(3). pii: ENEURO.0353-17.2018. doi: 10.1523/ENEURO.0353-17.2018. eCollection 2018 May-Jun.","\tAutism Spectrum Disorder|Healthy|High-functioning Autism\tNeurl1 gene expression|RGS14 gene expression\tNA\tNA\tNA\tDiagnostic Test|Diagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","autism spectrum disorder|autistic disorder","NA","NA"]
["NCT04865510","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","21345279|18549413|29118829|11193279|24993448|29185591|27474473|12722043|19672112|28821332","Oudemans-van Straaten HM, Kellum JA, Bellomo R. Clinical review: anticoagulation for continuous renal replacement therapy--heparin or citrate? Crit Care. 2011 Jan 24;15(1):202. doi: 10.1186/cc9358. Review.|Gatward JJ, Gibbon GJ, Wrathall G, Padkin A. Renal replacement therapy for acute renal failure: a survey of practice in adult intensive care units in the United Kingdom. Anaesthesia. 2008 Sep;63(9):959-66. doi: 10.1111/j.1365-2044.2008.05514.x. Epub 2008 Jun 28.|Borg R, Ugboma D, Walker DM, Partridge R. Evaluating the safety and efficacy of regional citrate compared to systemic heparin as anticoagulation for continuous renal replacement therapy in critically ill patients: A service evaluation following a change in practice. J Intensive Care Soc. 2017 Aug;18(3):184-192. doi: 10.1177/1751143717695835. Epub 2017 Mar 14.|Cutts MW, Thomas AN, Kishen R. Transfusion requirements during continuous veno-venous haemofiltration: -the importance of filter life. Intensive Care Med. 2000 Nov;26(11):1694-7.|Morabito S, Pistolesi V, Tritapepe L, Fiaccadori E. Regional citrate anticoagulation for RRTs in critically ill patients with AKI. Clin J Am Soc Nephrol. 2014 Dec 5;9(12):2173-88. doi: 10.2215/CJN.01280214. Epub 2014 Jul 3. Review.|Tuerdi B, Zuo L, Sun H, Wang K, Wang Z, Li G. Safety and efficacy of regional citrate anticoagulation in continuous blood purification treatment of patients with multiple organ dysfunction syndrome. Braz J Med Biol Res. 2017 Nov 17;51(1):e6378. doi: 10.1590/1414-431X20176378.|Schrezenmeier EV, Barasch J, Budde K, Westhoff T, Schmidt-Ott KM. Biomarkers in acute kidney injury - pathophysiological basis and clinical performance. Acta Physiol (Oxf). 2017 Mar;219(3):554-572. doi: 10.1111/apha.12764. Epub 2016 Aug 25. Review.|Kwon O, Molitoris BA, Pescovitz M, Kelly KJ. Urinary actin, interleukin-6, and interleukin-8 may predict sustained ARF after ischemic injury in renal allografts. Am J Kidney Dis. 2003 May;41(5):1074-87.|Liangos O, Kolyada A, Tighiouart H, Perianayagam MC, Wald R, Jaber BL. Interleukin-8 and acute kidney injury following cardiopulmonary bypass: a prospective cohort study. Nephron Clin Pract. 2009;113(3):c148-54. doi: 10.1159/000232595. Epub 2009 Aug 12.|de Fontnouvelle CA, Greenberg JH, Thiessen-Philbrook HR, Zappitelli M, Roth J, Kerr KF, Devarajan P, Shlipak M, Coca S, Parikh CR; TRIBE-AKI Consortium. Interleukin-8 and Tumor Necrosis Factor Predict Acute Kidney Injury After Pediatric Cardiac Surgery. Ann Thorac Surg. 2017 Dec;104(6):2072-2079. doi: 10.1016/j.athoracsur.2017.04.038. Epub 2017 Aug 16.","\tAcute Kidney Injury|Citrate|Cytokines|Hemodynamic Responses\tRegional citrate anticoagulation\tNA\tNA\tNA\tProcedure\tAll\t","Citrate Versus Heparin in Continuous Renal Replacement Therapy :","Interventional","Completed","N/A",2,41,"acute kidney injury","heparin","NA"]
["NCT04866732","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29941776|20677967|2772980|16245959|20652464|23122432|30776919|30746585|30388803|31863786|20449530","Abbott LS, Slate EH. Improving Cardiovascular Disease Knowledge among Rural Participants: The Results of a Cluster Randomized Trial. Healthcare (Basel). 2018 Jun 25;6(3). pii: E71. doi: 10.3390/healthcare6030071.|Abu Alhaija ES, Aldaikki A, Al-Omairi MK, Al-Khateeb SN. The relationship between personality traits, pain perception and attitude toward orthodontic treatment. Angle Orthod. 2010 Nov;80(6):1141-9. doi: 10.2319/012710-59.1.|Agrell B, Dehlin O. Comparison of six depression rating scales in geriatric stroke patients. Stroke. 1989 Sep;20(9):1190-4.|Andrawes WF, Bussy C, Belmin J. Prevention of cardiovascular events in elderly people. Drugs Aging. 2005;22(10):859-76. Review.|Angermayr L, Melchart D, Linde K. Multifactorial lifestyle interventions in the primary and secondary prevention of cardiovascular disease and type 2 diabetes mellitus--a systematic review of randomized controlled trials. Ann Behav Med. 2010 Aug;40(1):49-64. doi: 10.1007/s12160-010-9206-4. Review.|Bellet RN, Adams L, Morris NR. The 6-minute walk test in outpatient cardiac rehabilitation: validity, reliability and responsiveness--a systematic review. Physiotherapy. 2012 Dec;98(4):277-86. doi: 10.1016/j.physio.2011.11.003. Epub 2012 May 16. Review.|Cho D, Nguyen NT, Strong LL, Wu IHC, John JC, Escoto KH, Wetter DW, McNeill LH. Multiple Health Behaviors Engagement in an African American Cohort: Clustering Patterns and Correlates. Health Educ Behav. 2019 Jun;46(3):506-516. doi: 10.1177/1090198119826207. Epub 2019 Feb 18.|Colantonio LD, Monda KL, Rosenson RS, Brown TM, Mues KE, Howard G, Safford MM, Yedigarova L, Farkouh ME, Muntner P. Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria. Cardiovasc Drugs Ther. 2019 Apr;33(2):189-199. doi: 10.1007/s10557-019-06864-2.|Der Ananian C, Winham DM, Thompson SV, Tisue ME. Perceptions of Heart-Healthy Behaviors among African American Adults: A Mixed Methods Study. Int J Environ Res Public Health. 2018 Nov 1;15(11). pii: E2433. doi: 10.3390/ijerph15112433.|Ferdinand DP, Nedunchezhian S, Ferdinand KC. Hypertension in African Americans: Advances in community outreach and public health approaches. Prog Cardiovasc Dis. 2020 Jan - Feb;63(1):40-45. doi: 10.1016/j.pcad.2019.12.005. Epub 2019 Dec 19. Review.|Garatachea N, Torres Luque G, González Gallego J. Physical activity and energy expenditure measurements using accelerometers in older adults. Nutr Hosp. 2010 Mar-Apr;25(2):224-30. Review.","\tCardiovascular|Disease\tPhysical Activity Cardiac Health Program\tNA\tNA\tNA\tBehavioral\tFemale\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04866862","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31481761|20516446|28596308|30348638|32499235|30357594","Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Verlingue L, Ferrere G, Becharef S, Vétizou M, Daillère R, Messaoudene M, Enot DP, Stoll G, Ugel S, Marigo I, Foong Ngiow S, Marabelle A, Prevost-Blondel A, Gaudreau PO, Gopalakrishnan V, Eggermont AM, Opolon P, Klein C, Madonna G, Ascierto PA, Sucker A, Schadendorf D, Smyth MJ, Soria JC, Kroemer G, Bronte V, Wargo J, Zitvogel L. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res. 2019 Oct;29(10):846-861. doi: 10.1038/s41422-019-0224-x. Epub 2019 Sep 3.|Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010 Jul 1;28(19):3167-75. doi: 10.1200/JCO.2009.26.7609. Epub 2010 Jun 1.|Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.|Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, Zhang G, Zhao C, Zhang Y, Chen C, Wang Y, Yi X, Hu Z, Zou J, Wang Q. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. Clin Cancer Res. 2019 Jan 15;25(2):515-523. doi: 10.1158/1078-0432.CCR-18-2484. Epub 2018 Oct 22.|Mei Q, Zhang W, Liu Y, Yang Q, Rasko JEJ, Nie J, Liu J, Li X, Dong L, Chen M, Zhang Y, Shi L, Wu H, Han W. Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial. Clin Cancer Res. 2020 Sep 1;26(17):4521-4530. doi: 10.1158/1078-0432.CCR-20-0514. Epub 2020 Jun 4.|Shirley M. Fruquintinib: First Global Approval. Drugs. 2018 Nov;78(16):1757-1761. doi: 10.1007/s40265-018-0998-z. Review.","\tColorectal Neoplasm\tCombination of Fruquintinib and Camrelizumab\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","NA","NA"]
["NCT04866953","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15157244|15983575|30747681|32955420|25647203|10487591|24889805|10707230|27083965|9197854|20956766|12777902|17249446|24147731|28591469|12169936|21174480|26450364|15761334|21192812|17181593|2048855","Como JJ, Dutton RP, Scalea TM, Edelman BB, Hess JR. Blood transfusion rates in the care of acute trauma. Transfusion. 2004 Jun;44(6):809-13.|Criddle LM, Eldredge DH, Walker J. Variables predicting trauma patient survival following massive transfusion. J Emerg Nurs. 2005 Jun;31(3):236-42; quiz 320.|Yu AJ, Inaba K, Biswas S, de Leon LA, Wong M, Benjamin E, Lam L, Demetriades D. Supermassive Transfusion: A 15-Year Single Center Experience and Outcomes. Am Surg. 2018 Oct 1;84(10):1617-1621.|Consunji R, Elseed A, El-Menyar A, Sathian B, Rizoli S, Al-Thani H, Peralta R. The effect of massive transfusion protocol implementation on the survival of trauma patients: a systematic review and meta-analysis. Blood Transfus. 2020 Nov;18(6):434-445. doi: 10.2450/2020.0065-20. Epub 2020 Sep 18. Review.|Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, del Junco DJ, Brasel KJ, Bulger EM, Callcut RA, Cohen MJ, Cotton BA, Fabian TC, Inaba K, Kerby JD, Muskat P, O'Keeffe T, Rizoli S, Robinson BR, Scalea TM, Schreiber MA, Stein DM, Weinberg JA, Callum JL, Hess JR, Matijevic N, Miller CN, Pittet JF, Hoyt DB, Pearson GD, Leroux B, van Belle G; PROPPR Study Group. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015 Feb 3;313(5):471-82. doi: 10.1001/jama.2015.12.|Cinat ME, Wallace WC, Nastanski F, West J, Sloan S, Ocariz J, Wilson SE. Improved survival following massive transfusion in patients who have undergone trauma. Arch Surg. 1999 Sep;134(9):964-8; discussion 968-70.|McDaniel LM, Etchill EW, Raval JS, Neal MD. State of the art: massive transfusion. Transfus Med. 2014 Jun;24(3):138-44. doi: 10.1111/tme.12125. Review.|Hakala P, Hiippala S, Syrjälä M, Randell T. Massive blood transfusion exceeding 50 units of plasma poor red cells or whole blood: the survival rate and the occurrence of leukopenia and acidosis. Injury. 1999 Nov;30(9):619-22.|Giancarelli A, Birrer KL, Alban RF, Hobbs BP, Liu-DeRyke X. Hypocalcemia in trauma patients receiving massive transfusion. J Surg Res. 2016 May 1;202(1):182-7. doi: 10.1016/j.jss.2015.12.036. Epub 2015 Dec 30.|Moore FA, Moore EE, Sauaia A. Blood transfusion. An independent risk factor for postinjury multiple organ failure. Arch Surg. 1997 Jun;132(6):620-4; discussion 624-5.|Johnson JL, Moore EE, Kashuk JL, Banerjee A, Cothren CC, Biffl WL, Sauaia A. Effect of blood products transfusion on the development of postinjury multiple organ failure. Arch Surg. 2010 Oct;145(10):973-7. doi: 10.1001/archsurg.2010.216.|Malone DL, Dunne J, Tracy JK, Putnam AT, Scalea TM, Napolitano LM. Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. J Trauma. 2003 May;54(5):898-905; discussion 905-7.|Charles A, Shaikh AA, Walters M, Huehl S, Pomerantz R. Blood transfusion is an independent predictor of mortality after blunt trauma. Am Surg. 2007 Jan;73(1):1-5.|Mitra B, O'Reilly G, Cameron PA, Zatta A, Gruen RL. Effectiveness of massive transfusion protocols on mortality in trauma: a systematic review and meta-analysis. ANZ J Surg. 2013 Dec;83(12):918-23. doi: 10.1111/ans.12417. Epub 2013 Oct 21.|Ellingson KD, Sapiano MRP, Haass KA, Savinkina AA, Baker ML, Chung KW, Henry RA, Berger JJ, Kuehnert MJ, Basavaraju SV. Continued decline in blood collection and transfusion in the United States-2015. Transfusion. 2017 Jun;57 Suppl 2:1588-1598. doi: 10.1111/trf.14165.|Vaslef SN, Knudsen NW, Neligan PJ, Sebastian MW. Massive transfusion exceeding 50 units of blood products in trauma patients. J Trauma. 2002 Aug;53(2):291-5; discussion 295-6.|Toner RW, Pizzi L, Leas B, Ballas SK, Quigley A, Goldfarb NI. Costs to hospitals of acquiring and processing blood in the US: a survey of hospital-based blood banks and transfusion services. Appl Health Econ Health Policy. 2011;9(1):29-37. doi: 10.2165/11530740-000000000-00000.|Dzik WS, Ziman A, Cohn C, Pai M, Lozano M, Kaufman RM, Delaney M, Selleng K, Murphy MF, Hervig T, Yazer M; Biomedical Excellence for Safer Transfusion Collaborative. Survival after ultramassive transfusion: a review of 1360 cases. Transfusion. 2016 Mar;56(3):558-63. doi: 10.1111/trf.13370. Epub 2015 Oct 9. Review. Erratum in: Transfusion. 2016 May;56(5):1249.|Robinson WP 3rd, Ahn J, Stiffler A, Rutherford EJ, Hurd H, Zarzaur BL, Baker CC, Meyer AA, Rich PB. Blood transfusion is an independent predictor of increased mortality in nonoperatively managed blunt hepatic and splenic injuries. J Trauma. 2005 Mar;58(3):437-44; discussion 444-5.|Stanworth SJ, Morris TP, Gaarder C, Goslings JC, Maegele M, Cohen MJ, König TC, Davenport RA, Pittet JF, Johansson PI, Allard S, Johnson T, Brohi K. Reappraising the concept of massive transfusion in trauma. Crit Care. 2010;14(6):R239. doi: 10.1186/cc9394. Epub 2010 Dec 30.|Huber-Wagner S, Qvick M, Mussack T, Euler E, Kay MV, Mutschler W, Kanz KG; Working Group on Polytrauma of German Trauma Society (DGU). Massive blood transfusion and outcome in 1062 polytrauma patients: a prospective study based on the Trauma Registry of the German Trauma Society. Vox Sang. 2007 Jan;92(1):69-78.|Kivioja A, Myllynen P, Rokkanen P. Survival after massive transfusions exceeding four blood volumes in patients with blunt injuries. Am Surg. 1991 Jun;57(6):398-401.","\tBlood Transfusion Complication|Death|Trauma\tBlood transfusion\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","transfusion reaction|wounds and injuries","NA","NA"]
["NCT04867447","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28585740|15625195|31903545|26979256|18587677|27632064|28170004","Betancourt TS, Newnham EA, Birman D, Lee R, Ellis BH, Layne CM. Comparing Trauma Exposure, Mental Health Needs, and Service Utilization Across Clinical Samples of Refugee, Immigrant, and U.S.-Origin Children. J Trauma Stress. 2017 Jun;30(3):209-218. doi: 10.1002/jts.22186. Epub 2017 Jun 6.|Cantor-Graae E, Selten JP. Schizophrenia and migration: a meta-analysis and review. Am J Psychiatry. 2005 Jan;162(1):12-24. Review.|Anderson KK, Edwards J. Age at migration and the risk of psychotic disorders: a systematic review and meta-analysis. Acta Psychiatr Scand. 2020 May;141(5):410-420. doi: 10.1111/acps.13147. Epub 2020 Jan 20. Review.|Hollander AC, Dal H, Lewis G, Magnusson C, Kirkbride JB, Dalman C. Refugee migration and risk of schizophrenia and other non-affective psychoses: cohort study of 1.3 million people in Sweden. BMJ. 2016 Mar 15;352:i1030. doi: 10.1136/bmj.i1030. Erratum in: BMJ. 2016 May 27;353:i2865.|Selten JP, Hoek HW. Does misdiagnosis explain the schizophrenia epidemic among immigrants from developing countries to Western Europe? Soc Psychiatry Psychiatr Epidemiol. 2008 Dec;43(12):937-9. doi: 10.1007/s00127-008-0390-5.|Gibson LE, Alloy LB, Ellman LM. Trauma and the psychosis spectrum: A review of symptom specificity and explanatory mechanisms. Clin Psychol Rev. 2016 Nov;49:92-105. doi: 10.1016/j.cpr.2016.08.003. Epub 2016 Aug 31. Review.|Howes OD, McCutcheon R. Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization. Transl Psychiatry. 2017 Feb 7;7(2):e1024. doi: 10.1038/tp.2016.278. Review.","\tCross-Cultural Comparison|Psychological Trauma|Psychotic Disorders|Stress, Psychological\tPsychological trauma evaluation\tNA\tNA\tNA\tDiagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","mental disorders|stress, psychological|psychotic disorders|disease|psychological trauma","NA","NA"]
["NCT04868006","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32789249|23015864","Miura K, Tsuda E, Ishibashi Y. Glenohumeral Rotational Deficit and Suprascapular Neuropathy in the Hitting Shoulder in Male Collegiate Volleyball Players. Prog Rehabil Med. 2019 Jan 12;4:20190002. doi: 10.2490/prm.20190002. eCollection 2019.|Wilk KE, Reinold MM, Macrina LC, Porterfield R, Devine KM, Suarez K, Andrews JR. Glenohumeral internal rotation measurements differ depending on stabilization techniques. Sports Health. 2009 Mar;1(2):131-6.","\tSports Physical Therapy\tEnd-range Maitland mobilization + proprioception training|Non end-range Maitland mobilization + proprioception training|Sham manual therapy technique + proprioception training\tNA\tNA\tNA\tProcedure|Procedure|Procedure\tAll\t","End-range Maitland Mobilization on Glenohumeral Internal Rotation Deficit and Proprioception","Interventional","Not yet recruiting","N/A",3,60,"NA","NA","NA"]
["NCT04868149","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22330038|25379854|28806301|24866543|26079914|31592812|31305284|27816312|12163951|25379855","Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, Fichtner-Feigl S, Lorf T, Goralcyk A, Hörbelt R, Kroemer A, Loss M, Rümmele P, Scherer MN, Padberg W, Königsrainer A, Lang H, Obed A, Schlitt HJ. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012 Mar;255(3):405-14. doi: 10.1097/SLA.0b013e31824856f5.|Schadde E, Ardiles V, Robles-Campos R, Malago M, Machado M, Hernandez-Alejandro R, Soubrane O, Schnitzbauer AA, Raptis D, Tschuor C, Petrowsky H, De Santibanes E, Clavien PA; ALPPS Registry Group. Early survival and safety of ALPPS: first report of the International ALPPS Registry. Ann Surg. 2014 Nov;260(5):829-36; discussion 836-8. doi: 10.1097/SLA.0000000000000947.|Linecker M, Björnsson B, Stavrou GA, Oldhafer KJ, Lurje G, Neumann U, Adam R, Pruvot FR, Topp SA, Li J, Capobianco I, Nadalin S, Machado MA, Voskanyan S, Balci D, Hernandez-Alejandro R, Alvarez FA, De Santibañes E, Robles-Campos R, Malagó M, de Oliveira ML, Lesurtel M, Clavien PA, Petrowsky H. Risk Adjustment in ALPPS Is Associated With a Dramatic Decrease in Early Mortality and Morbidity. Ann Surg. 2017 Nov;266(5):779-786. doi: 10.1097/SLA.0000000000002446.|Chan AC, Pang R, Poon RT. Simplifying the ALPPS procedure by the anterior approach. Ann Surg. 2014 Aug;260(2):e3. doi: 10.1097/SLA.0000000000000736.|Chan AC, Poon RT, Chan C, Lo CM. Safety of ALPPS Procedure by the Anterior Approach for Hepatocellular Carcinoma. Ann Surg. 2016 Feb;263(2):e14-6. doi: 10.1097/SLA.0000000000001272.|Raptis DA, Linecker M, Kambakamba P, Tschuor C, Müller PC, Hadjittofi C, Stavrou GA, Fard-Aghaie MH, Tun-Abraham M, Ardiles V, Malagó M, Campos RR, Oldhafer KJ, Hernandez-Alejandro R, de Santibañes E, Machado MA, Petrowsky H, Clavien PA. Defining Benchmark Outcomes for ALPPS. Ann Surg. 2019 Nov;270(5):835-841. doi: 10.1097/SLA.0000000000003539.|Chan A, Zhang WY, Chok K, Dai J, Ji R, Kwan C, Man N, Poon R, Lo CM. ALPPS Versus Portal Vein Embolization for Hepatitis-related Hepatocellular Carcinoma: A Changing Paradigm in Modulation of Future Liver Remnant Before Major Hepatectomy. Ann Surg. 2021 May 1;273(5):957-965. doi: 10.1097/SLA.0000000000003433.|Machado MA, Makdissi FF, Surjan RC, Basseres T, Schadde E. Transition from open to laparoscopic ALPPS for patients with very small FLR: the initial experience. HPB (Oxford). 2017 Jan;19(1):59-66. doi: 10.1016/j.hpb.2016.10.004. Epub 2016 Nov 2.|Burpee SE, Kurian M, Murakame Y, Benevides S, Gagner M. The metabolic and immune response to laparoscopic versus open liver resection. Surg Endosc. 2002 Jun;16(6):899-904. Epub 2002 Feb 27.|Schlegel A, Lesurtel M, Melloul E, Limani P, Tschuor C, Graf R, Humar B, Clavien PA. ALPPS: from human to mice highlighting accelerated and novel mechanisms of liver regeneration. Ann Surg. 2014 Nov;260(5):839-46; discussion 846-7. doi: 10.1097/SLA.0000000000000949.","\tLiver Cancer\tAssociating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS)\tNA\tNA\tNA\tProcedure\tAll\t","Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPS","Interventional","Recruiting","N/A",2,20,"liver neoplasms","NA","NA"]
["NCT04869410","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",18782950,"Shih MH, Chung CY, Su BC, Hung CT, Wong SY, Wong TK. Accuracy of a new body length-based formula for predicting tracheal tube size in Chinese children. Chang Gung Med J. 2008 May-Jun;31(3):276-80.","\tPredicting Uncuffed Endotracheal Tube Size in Pediatric Anesthesia\tModification Broselow Tape|Cole Formula\tParallel Assignment\tOther\tRandomized\tProcedure|Procedure\tAll\t","Comparison of Modified Broselow Tape and Cole Formula","Interventional","Completed","N/A",2,110,"NA","NA","NA"]
["NCT04870619","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",31884902,"Moore JL, Nordvik JE, Erichsen A, Rosseland I, Bø E, Hornby TG; FIRST-Oslo Team. Implementation of High-Intensity Stepping Training During Inpatient Stroke Rehabilitation Improves Functional Outcomes. Stroke. 2020 Feb;51(2):563-570. doi: 10.1161/STROKEAHA.119.027450. Epub 2019 Dec 30.","\tStroke\tHigh Intensity Gait Training\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","stroke","NA","NA"]
["NCT04870983","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23905041|30442256|18438333","Cotena S, Piazza O. Sepsis-associated encephalopathy. Transl Med UniSa. 2012 Jan 18;2:20-7. Print 2012 Jan.|Azabou E, Rohaut B, Porcher R, Heming N, Kandelman S, Allary J, Moneger G, Faugeras F, Sitt JD, Annane D, Lofaso F, Chrétien F, Mantz J, Naccache L, Sharshar T; GENeR** (Groupe d'Explorations Neurologiques en Réanimation). Mismatch negativity to predict subsequent awakening in deeply sedated critically ill patients. Br J Anaesth. 2018 Dec;121(6):1290-1297. doi: 10.1016/j.bja.2018.06.029. Epub 2018 Sep 4.|Rinaldi S, Consales G, De Gaudio AR. Changes in auditory evoked potentials induced by postsurgical sepsis. Minerva Anestesiol. 2008 Jun;74(6):245-50. Epub 2008 Apr 30.","\tMismatch Negativity|Sepsis-Associated Encephalopathy\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","brain diseases|sepsis-associated encephalopathy|toxemia|sepsis","NA","NA"]
["NCT04871061","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",25068412,"Diakomi M, Papaioannou M, Mela A, Kouskouni E, Makris A. Preoperative fascia iliaca compartment block for positioning patients with hip fractures for central nervous blockade: a randomized trial. Reg Anesth Pain Med. 2014 Sep-Oct;39(5):394-8. doi: 10.1097/AAP.0000000000000133.","\tPain, Acute\tPENG Block|Conventional opioid analgesia (Fentanyl)\tParallel Assignment\tTreatment\tRandomized\tProcedure|Drug\tAll\t","Evaluation of Pericapsular Nerve Group Block on Positioning Pain for Spinal Anesthesia in Hip Fracture Patients","Interventional","Recruiting","N/A",2,80,"acute pain|hip fractures","fentanyl","NA"]
["NCT04871178","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28639841,"Norman J, Fu M, Ekman I, Björck L, Falk K. Effects of a mindfulness-based intervention on symptoms and signs in chronic heart failure: A feasibility study. Eur J Cardiovasc Nurs. 2018 Jan;17(1):54-65. doi: 10.1177/1474515117715843. Epub 2017 Jun 22.","\tChronic Heart Failure\tMindfulness-based intervention\tParallel Assignment\tSupportive Care\tRandomized\tBehavioral\tAll\t","Dissertation Project Title: Effects of a Mindfulness-Based Intervention in Chronic Heart Failure","Interventional","Completed","N/A",2,50,"heart failure","NA","NA"]
["NCT04871230","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","20463103|24513728|25867233","Rakotosamimanana N, Raharimanga V, Andriamandimby SF, Soares JL, Doherty TM, Ratsitorahina M, Ramarokoto H, Zumla A, Huggett J, Rook G, Richard V, Gicquel B, Rasolofo-Razanamparany V; VACSEL/VACSIS Study Group. Variation in gamma interferon responses to different infecting strains of Mycobacterium tuberculosis in acid-fast bacillus smear-positive patients and household contacts in Antananarivo, Madagascar. Clin Vaccine Immunol. 2010 Jul;17(7):1094-103. doi: 10.1128/CVI.00049-10. Epub 2010 May 12.|Ostler MW, Porter JH, Buxton OM. Dried blood spot collection of health biomarkers to maximize participation in population studies. J Vis Exp. 2014 Jan 28;(83):e50973. doi: 10.3791/50973.|Grüner N, Stambouli O, Ross RS. Dried blood spots--preparing and processing for use in immunoassays and in molecular techniques. J Vis Exp. 2015 Mar 13;(97). doi: 10.3791/52619.","\tTuberculosis\t3G DBS|Sputum Test|3G Veinous Blood\tNA\tNA\tNA\tDiagnostic Test|Diagnostic Test|Diagnostic Test\tFemale\t","NA","NA","NA","NA","NA","NA","tuberculosis","NA","NA"]
["NCT04871373","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30198774|31906577|23805818|31746683|17443571|23279918|27982007|24789647|32383274|14076341|26229382|5237684|29926944|32974991|17716083|26063554|28836375|30858274|26874558|19739205|31514978","Rigau-Gay MM, Claver-Garrido E, Benet M, Lusilla-Palacios P, Ustrell-Torrent JM. Effectiveness of motivational interviewing to improve oral hygiene in orthodontic patients: A randomized controlled trial. J Health Psychol. 2020 Nov-Dec;25(13-14):2362-2373. doi: 10.1177/1359105318793719. Epub 2018 Sep 10.|Madariaga ACP, Bucci R, Rongo R, Simeon V, D'Antò V, Valletta R. Impact of Fixed Orthodontic Appliance and Clear Aligners on the Periodontal Health: A Prospective Clinical Study. Dent J (Basel). 2020 Jan 2;8(1). pii: E4. doi: 10.3390/dj8010004.|Gao X, Lo EC, Kot SC, Chan KC. Motivational interviewing in improving oral health: a systematic review of randomized controlled trials. J Periodontol. 2014 Mar;85(3):426-37. doi: 10.1902/jop.2013.130205. Epub 2013 Jun 27. Review.|McGrath C. Behavioral Sciences in the Promotion of Oral Health. J Dent Res. 2019 Dec;98(13):1418-1424. doi: 10.1177/0022034519873842.|Renz A, Ide M, Newton T, Robinson PG, Smith D. Psychological interventions to improve adherence to oral hygiene instructions in adults with periodontal diseases. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005097. Review. Update in: Cochrane Database Syst Rev. 2016;2:CD005097.|Brand VS, Bray KK, MacNeill S, Catley D, Williams K. Impact of single-session motivational interviewing on clinical outcomes following periodontal maintenance therapy. Int J Dent Hyg. 2013 May;11(2):134-41. doi: 10.1111/idh.12012. Epub 2012 Dec 24.|Kay EJ, Vascott D, Hocking A, Nield H. Motivational interviewing in general dental practice: A review of the evidence. Br Dent J. 2016 Dec 16;221(12):785-791. doi: 10.1038/sj.bdj.2016.952. Review.|Cascaes AM, Bielemann RM, Clark VL, Barros AJ. Effectiveness of motivational interviewing at improving oral health: a systematic review. Rev Saude Publica. 2014 Feb;48(1):142-53. Review.|Sanz M, Herrera D, Kebschull M, Chapple I, Jepsen S, Beglundh T, Sculean A, Tonetti MS; EFP Workshop Participants and Methodological Consultants. Treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline. J Clin Periodontol. 2020 Jul;47 Suppl 22:4-60. doi: 10.1111/jcpe.13290. Erratum in: J Clin Periodontol. 2021 Jan;48(1):163.|GREENE JC, VERMILLION JR. THE SIMPLIFIED ORAL HYGIENE INDEX. J Am Dent Assoc. 1964 Jan;68:7-13.|Raju PK, Vasanti D, Kumar JR, Niranjani K, Kumar MS. Oral Hygiene Levels in Children of Tribal Population of Eastern Ghats: An Epidemiological Study. J Int Oral Health. 2015 Jul;7(7):108-10.|Löe H. The Gingival Index, the Plaque Index and the Retention Index Systems. J Periodontol. 1967 Nov-Dec;38(6):Suppl:610-6.|Chapple ILC, Mealey BL, Van Dyke TE, Bartold PM, Dommisch H, Eickholz P, Geisinger ML, Genco RJ, Glogauer M, Goldstein M, Griffin TJ, Holmstrup P, Johnson GK, Kapila Y, Lang NP, Meyle J, Murakami S, Plemons J, Romito GA, Shapira L, Tatakis DN, Teughels W, Trombelli L, Walter C, Wimmer G, Xenoudi P, Yoshie H. Periodontal health and gingival diseases and conditions on an intact and a reduced periodontium: Consensus report of workgroup 1 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 2018 Jun;89 Suppl 1:S74-S84. doi: 10.1002/JPER.17-0719.|Discepoli N, Mirra R, Marruganti C, Beneforti C, Doldo T. Efficacy of Behaviour Change Techniques to improve oral hygiene control of individuals undergoing orthodontic therapy. A systematic review. Int J Dent Hyg. 2021 Feb;19(1):3-17. doi: 10.1111/idh.12468. Epub 2020 Oct 15.|Hettema J, Steele J, Miller WR. Motivational interviewing. Annu Rev Clin Psychol. 2005;1:91-111. Review.|Borrelli B, Tooley EM, Scott-Sheldon LA. Motivational Interviewing for Parent-child Health Interventions: A Systematic Review and Meta-Analysis. Pediatr Dent. 2015 May-Jun;37(3):254-65. Review.|Stenman J, Wennström JL, Abrahamsson KH. A brief motivational interviewing as an adjunct to periodontal therapy-A potential tool to reduce relapse in oral hygiene behaviours. A three-year study. Int J Dent Hyg. 2018 May;16(2):298-304. doi: 10.1111/idh.12308. Epub 2017 Aug 24.|Faustino-Silva DD, Meyer E, Hugo FN, Hilgert JB. Effectiveness of Motivational Interviewing Training for Primary Care Dentists and Dental Health Technicians: Results from a Community Clinical Trial. J Dent Educ. 2019 May;83(5):585-594. doi: 10.21815/JDE.019.063. Epub 2019 Mar 11.|Moyers TB, Rowell LN, Manuel JK, Ernst D, Houck JM. The Motivational Interviewing Treatment Integrity Code (MITI 4): Rationale, Preliminary Reliability and Validity. J Subst Abuse Treat. 2016 Jun;65:36-42. doi: 10.1016/j.jsat.2016.01.001. Epub 2016 Jan 13.|Lundahl B, Burke BL. The effectiveness and applicability of motivational interviewing: a practice-friendly review of four meta-analyses. J Clin Psychol. 2009 Nov;65(11):1232-45. doi: 10.1002/jclp.20638. Review.|Lundahl B, Droubay BA, Burke B, Butters RP, Nelford K, Hardy C, Keovongsa K, Bowles M. Motivational interviewing adherence tools: A scoping review investigating content validity. Patient Educ Couns. 2019 Dec;102(12):2145-2155. doi: 10.1016/j.pec.2019.07.003. Epub 2019 Jul 25. Review.","\tMotivational Interviewing|Oral Hygiene|Orthodontic Appliance Complication\tMotivational interviewing|Oral Hygiene Instructions\tParallel Assignment\tPrevention\tRandomized\tBehavioral|Behavioral\tAll\t","Motivational Interview and Orthodontic Patients","Interventional","Completed","N/A",2,45,"NA","NA","NA"]
["NCT04871581","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",15613213,"Castillo J, Muñoz P, Guitera V, Pascual J. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache. 1999 Mar;39(3):190-6.","\tChronic Migraine, Headache\tNTI-tss|Placebo\tCrossover Assignment\tPrevention\tRandomized\tDevice|Device\tAll\t","Adjunctive Treatment of Chronic Migraine Using an Oral Dental Device","Interventional","Completed","N/A",2,25,"migraine disorders|headache","NA","NA"]
["NCT04872647","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31426060|27079342","Goel A. In type 2 diabetes, a primary care-led weight management program increased weight loss and diabetes remission at 2 years. Ann Intern Med. 2019 Aug 20;171(4):JC17. doi: 10.7326/ACPJ201908200-017.|Walker RJ, Strom Williams J, Egede LE. Influence of Race, Ethnicity and Social Determinants of Health on Diabetes Outcomes. Am J Med Sci. 2016 Apr;351(4):366-73. doi: 10.1016/j.amjms.2016.01.008. Review.","\tType2 Diabetes\tPhone-Based Health Coaching Utilizing Lifestyle Action Plans\tParallel Assignment\tHealth Services Research\tRandomized\tBehavioral\tAll\t","Pilot of Virtual Health Coaching Utilizing Lifestyle for Under-Resourced Patients With Type II Diabetes","Interventional","Active, not recruiting","N/A",2,45,"diabetes mellitus|diabetes mellitus, type 2","NA","NA"]
["NCT04872959","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28625374|30025570|29752128|29277252","DeVore AD, Thomas L, Albert NM, Butler J, Hernandez AF, Patterson JH, Spertus JA, Williams FB, Turner SJ, Chan WW, Duffy CI, McCague K, Mi X, Fonarow GC. Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry. Am Heart J. 2017 Jul;189:177-183. doi: 10.1016/j.ahj.2017.04.010. Epub 2017 Apr 29.|Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, Hill CL, McCague K, Mi X, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, Fonarow GC. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. J Am Coll Cardiol. 2018 Jul 24;72(4):351-366. doi: 10.1016/j.jacc.2018.04.070.|Ibrahim NE, Song Y, Cannon CP, Doros G, Trebnick A, Russo P, Ponirakis A, Alexanian C, Januzzi JL Jr. Retraction notice to Addition or removal of guideline directed medical therapy in ambulatory patients with heart failure with reduced ejection fraction relative to change in symptom severity: An analysis from the PINNACLE (Practice Innovation and Clinical Excellence) Registry® [International Journal of Cardiology 254 (2018) 222-223]. Int J Cardiol. 2018 Mar 1;254:R1. doi: 10.1016/j.ijcard.2018.05.008.|Yancy CW, Januzzi JL Jr, Allen LA, Butler J, Davis LL, Fonarow GC, Ibrahim NE, Jessup M, Lindenfeld J, Maddox TM, Masoudi FA, Motiwala SR, Patterson JH, Walsh MN, Wasserman A. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018 Jan 16;71(2):201-230. doi: 10.1016/j.jacc.2017.11.025. Epub 2017 Dec 22. Erratum in: J Am Coll Cardiol. 2018 Nov 13;72(20):2549.","\tHeart Failure, Systolic\tHealthReveal\tParallel Assignment\tTreatment\tRandomized\tOther\tAll\t","TRANSFORM Heart Failure With Reduced Ejection Fraction","Interventional","Not yet recruiting","N/A",2,3072,"heart failure, systolic|heart failure","NA","NA"]
["NCT04873635","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26587420|21476819|15642034|12608678|25004805|3285972|9511841|23101439|24508227|29656899|23773236|15777328|21087319|14724907|25054246|17604967|9305243|12969367|16982313|12562374|26689434|25358599|24280117","Kim HY. Statistical notes for clinical researchers: effect size. Restor Dent Endod. 2015 Nov;40(4):328-31. doi: 10.5395/rde.2015.40.4.328. Epub 2015 Oct 2.|King MT. A point of minimal important difference (MID): a critique of terminology and methods. Expert Rev Pharmacoecon Outcomes Res. 2011 Apr;11(2):171-84. doi: 10.1586/erp.11.9. Review.|Kramer FJ, Dempf R, Bremer B. Efficacy of dental implants placed into fibula-free flaps for orofacial reconstruction. Clin Oral Implants Res. 2005 Feb;16(1):80-8.|Leung AC, Cheung LK. Dental implants in reconstructed jaws: patients' evaluation of functional and quality-of-life outcomes. Int J Oral Maxillofac Implants. 2003 Jan-Feb;18(1):127-34.|Li X, Zhu K, Liu F, Li H. Assessment of quality of life in giant ameloblastoma adolescent patients who have had mandible defects reconstructed with a free fibula flap. World J Surg Oncol. 2014 Jul 8;12:201. doi: 10.1186/1477-7819-12-201.|Locker D. Measuring oral health: a conceptual framework. Community Dent Health. 1988 Mar;5(1):3-18. Review.|Locker D. Issues in measuring change in self-perceived oral health status. Community Dent Oral Epidemiol. 1998 Feb;26(1):41-7. Review.|Nordenram G, Davidson T, Gynther G, Helgesson G, Hultin M, Jemt T, Lekholm U, Nilner K, Norlund A, Rohlin M, Sunnegårdh-Grönberg K, Tranæus S. Qualitative studies of patients' perceptions of loss of teeth, the edentulous state and prosthetic rehabilitation: a systematic review with meta-synthesis. Acta Odontol Scand. 2013 May-Jul;71(3-4):937-51. doi: 10.3109/00016357.2012.734421. Epub 2012 Oct 29. Review.|Ooi A, Feng J, Tan HK, Ong YS. Primary treatment of mandibular ameloblastoma with segmental resection and free fibula reconstruction: achieving satisfactory outcomes with low implant-prosthetic rehabilitation uptake. J Plast Reconstr Aesthet Surg. 2014 Apr;67(4):498-505. doi: 10.1016/j.bjps.2014.01.005. Epub 2014 Jan 15.|Pappalardo M, Tsao CK, Tsang ML, Zheng J, Chang YM, Tsai CY. Long-term outcome of patients with or without osseointegrated implants after resection of mandibular ameloblastoma and reconstruction with vascularized bone graft: Functional assessment and quality of life. J Plast Reconstr Aesthet Surg. 2018 Jul;71(7):1076-1085. doi: 10.1016/j.bjps.2018.03.008. Epub 2018 Mar 28.|Parbo N, Murra NT, Andersen K, Buhl J, Kiil B, Nørholt SE. Outcome of partial mandibular reconstruction with fibula grafts and implant-supported prostheses. Int J Oral Maxillofac Surg. 2013 Nov;42(11):1403-8. doi: 10.1016/j.ijom.2013.05.007. Epub 2013 Jun 15.|Pjetursson BE, Karoussis I, Bürgin W, Brägger U, Lang NP. Patients' satisfaction following implant therapy. A 10-year prospective cohort study. Clin Oral Implants Res. 2005 Apr;16(2):185-93.|Pommer B, Zechner W, Watzak G, Ulm C, Watzek G, Tepper G. Progress and trends in patients' mindset on dental implants. I: level of information, sources of information and need for patient information. Clin Oral Implants Res. 2011 Feb;22(2):223-9. doi: 10.1111/j.1600-0501.2010.02035.x. Epub 2010 Nov 19.|Rogers SN, Devine J, Lowe D, Shokar P, Brown JS, Vaugman ED. Longitudinal health-related quality of life after mandibular resection for oral cancer: a comparison between rim and segment. Head Neck. 2004 Jan;26(1):54-62.|Chang YM, Wallace CG, Hsu YM, Shen YF, Tsai CY, Wei FC. Outcome of osseointegrated dental implants in double-barrel and vertically distracted fibula osteoseptocutaneous free flaps for segmental mandibular defect reconstruction. Plast Reconstr Surg. 2014 Nov;134(5):1033-1043. doi: 10.1097/PRS.0000000000000623.|Rustemeyer J, Bremerich A. Patients' knowledge and expectations regarding dental implants: assessment by questionnaire. Int J Oral Maxillofac Surg. 2007 Sep;36(9):814-7. Epub 2007 Jul 2.|Shpitzer T, Neligan PC, Gullane PJ, Freeman JE, Boyd BJ, Rotstein LE, Brown DH, Irish JC, Gur E. Oromandibular reconstruction with the fibular free flap. Analysis of 50 consecutive flaps. Arch Otolaryngol Head Neck Surg. 1997 Sep;123(9):939-44.|Tepper G, Haas R, Mailath G, Teller C, Zechner W, Watzak G, Watzek G. Representative marketing-oriented study on implants in the Austrian population. I. Level of information, sources of information and need for patient information. Clin Oral Implants Res. 2003 Oct;14(5):621-33.|Vayvada H, Mola F, Menderes A, Yilmaz M. Surgical management of ameloblastoma in the mandible: Segmental mandibulectomy and immediate reconstruction with free fibula or deep circumflex iliac artery flap (evaluation of the long-term esthetic and functional results). J Oral Maxillofac Surg. 2006 Oct;64(10):1532-9.|Vermylen K, Collaert B, Lindén U, Björn AL, De Bruyn H. Patient satisfaction and quality of single-tooth restorations. Clin Oral Implants Res. 2003 Feb;14(1):119-24.|Voutilainen A, Pitkäaho T, Kvist T, Vehviläinen-Julkunen K. How to ask about patient satisfaction? The visual analogue scale is less vulnerable to confounding factors and ceiling effect than a symmetric Likert scale. J Adv Nurs. 2016 Apr;72(4):946-57. doi: 10.1111/jan.12875. Epub 2015 Dec 22.|Yao J, Tang H, Gao XL, McGrath C, Mattheos N. Patients' expectations to dental implant: a systematic review of the literature. Health Qual Life Outcomes. 2014 Oct 29;12:153. doi: 10.1186/s12955-014-0153-9. Review.|Zhu J, Yang Y, Li W. Assessment of quality of life and sociocultural aspects in patients with ameloblastoma after immediate mandibular reconstruction with a fibular free flap. Br J Oral Maxillofac Surg. 2014 Feb;52(2):163-7. doi: 10.1016/j.bjoms.2013.10.012. Epub 2013 Nov 23.","\tMissing Teeth\tImplant support prostheses\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","tooth loss|anodontia","NA","NA"]
["NCT04875130","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30592365|29153200|29520277","Voors AA, Kremer D, Geven C, Ter Maaten JM, Struck J, Bergmann A, Pickkers P, Metra M, Mebazaa A, Düngen HD, Butler J. Adrenomedullin in heart failure: pathophysiology and therapeutic application. Eur J Heart Fail. 2019 Feb;21(2):163-171. doi: 10.1002/ejhf.1366. Epub 2018 Dec 28. Review.|Nishikimi T, Nakagawa Y. Adrenomedullin as a Biomarker of Heart Failure. Heart Fail Clin. 2018 Jan;14(1):49-55. doi: 10.1016/j.hfc.2017.08.006. Epub 2017 Oct 7. Review.|Geven C, Kox M, Pickkers P. Adrenomedullin and Adrenomedullin-Targeted Therapy As Treatment Strategies Relevant for Sepsis. Front Immunol. 2018 Feb 19;9:292. doi: 10.3389/fimmu.2018.00292. eCollection 2018. Review.","\tPulmonary Embolism\tblood samples\tNA\tNA\tNA\tDiagnostic Test\tAll\t","NA","NA","NA","NA","NA","NA","pulmonary embolism|embolism","NA","NA"]
["NCT04875338","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21705157,"Wolf JM, Ozer K, Scott F, Gordon MJ, Williams AE. Comparison of autologous blood, corticosteroid, and saline injection in the treatment of lateral epicondylitis: a prospective, randomized, controlled multicenter study. J Hand Surg Am. 2011 Aug;36(8):1269-72. doi: 10.1016/j.jhsa.2011.05.014. Epub 2011 Jun 25.","\tEpicondylitis, Lateral\tplate-rich plasma|saline (0.9 NACI)|betametazon\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tAll\t","Injection in the Treatment of Lateral Epicondylitis. Randomized Controlled Trial","Interventional","Recruiting","Phase 3",3,36,"tennis elbow","NA","NA"]
["NCT04875403","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32986997|32692782|33149117","Hirons A, Khoury G, Purcell DFJ. Human T-cell lymphotropic virus type-1: a lifelong persistent infection, yet never truly silent. Lancet Infect Dis. 2021 Jan;21(1):e2-e10. doi: 10.1016/S1473-3099(20)30328-5. Epub 2020 Sep 25. Review.|Pereira FM, Almeida MDCC, Santos FLN, Carreiro RP, Galvão-Castro B, Grassi MFR. Distribution of Human T-Lymphotropic Virus (HTLV) and Hepatitis C Co-infection in Bahia, Brazil. PLoS One. 2020 Jul 21;15(7):e0223087. doi: 10.1371/journal.pone.0223087. eCollection 2020.|Enríquez-Ruano P, Navarro CE, Ariza-Varón M, Calderón-Castro ADP. Myelopathy secondary to human T-lymphotropic virus and Treponema pallidum infection: case report. Spinal Cord Ser Cases. 2019 Nov 6;5(1):93. doi: 10.1038/s41394-019-0238-0.","\tHuman T-Lymphotropic Virus Type 1 Associated Myelopathy\tInspiratory muscle trainning|Exercise\tParallel Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Rehabilitation in Patients With Human Lymphotropic Virus Type I","Interventional","Recruiting","N/A",2,40,"paraparesis, tropical spastic|spinal cord diseases","NA","NA"]
["NCT04876014","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",21279709,"Ng SM, Fong TC, Wang XL, Wang YJ. Confirmatory factor analysis of the stagnation scale--a traditional Chinese medicine construct operationalized for mental health practice. Int J Behav Med. 2012 Jun;19(2):228-33. doi: 10.1007/s12529-011-9146-9.","\tMental Health Wellness 1|Psychological Distress\tGuided Mobile-Based Perinatal Mindfulness Intervention\tParallel Assignment\tTreatment\tRandomized\tOther\tFemale\t","A Guided Mobile-Based Perinatal Mindfulness Intervention","Interventional","Active, not recruiting","N/A",2,198,"NA","NA","NA"]
["NCT04876833","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28822787|29650248|31770495|33208745|32681029|29393240|22089028|31501577|26317628|22142891|26059026|30223529|33076910","GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017 Sep;5(9):691-706. doi: 10.1016/S2213-2600(17)30293-X. Epub 2017 Aug 16. Erratum in: Lancet Respir Med. 2017 Oct;5(10 ):e30.|Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Huang K, Yao W, Sun T, Shan G, Yang T, Lin Y, Wu S, Zhu J, Wang R, Shi Z, Zhao J, Ye X, Song Y, Wang Q, Zhou Y, Ding L, Yang T, Chen Y, Guo Y, Xiao F, Lu Y, Peng X, Zhang B, Xiao D, Chen CS, Wang Z, Zhang H, Bu X, Zhang X, An L, Zhang S, Cao Z, Zhan Q, Yang Y, Cao B, Dai H, Liang L, He J; China Pulmonary Health Study Group. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018 Apr 28;391(10131):1706-1717. doi: 10.1016/S0140-6736(18)30841-9. Epub 2018 Apr 9.|Çolak Y, Afzal S, Nordestgaard BG, Vestbo J, Lange P. Prevalence, Characteristics, and Prognosis of Early Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2020 Mar 15;201(6):671-680. doi: 10.1164/rccm.201908-1644OC.|Bowerman KL, Rehman SF, Vaughan A, Lachner N, Budden KF, Kim RY, Wood DLA, Gellatly SL, Shukla SD, Wood LG, Yang IA, Wark PA, Hugenholtz P, Hansbro PM. Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease. Nat Commun. 2020 Nov 18;11(1):5886. doi: 10.1038/s41467-020-19701-0.|Jang YO, Lee SH, Choi JJ, Kim DH, Choi JM, Kang MJ, Oh YM, Park YJ, Shin Y, Lee SW. Fecal microbial transplantation and a high fiber diet attenuates emphysema development by suppressing inflammation and apoptosis. Exp Mol Med. 2020 Jul;52(7):1128-1139. doi: 10.1038/s12276-020-0469-y. Epub 2020 Jul 17.|Sprooten RTM, Lenaerts K, Braeken DCW, Grimbergen I, Rutten EP, Wouters EFM, Rohde GGU. Increased Small Intestinal Permeability during Severe Acute Exacerbations of COPD. Respiration. 2018;95(5):334-342. doi: 10.1159/000485935. Epub 2018 Jan 25.|Keely S, Talley NJ, Hansbro PM. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol. 2012 Jan;5(1):7-18. doi: 10.1038/mi.2011.55. Epub 2011 Nov 16. Review.|Wypych TP, Wickramasinghe LC, Marsland BJ. The influence of the microbiome on respiratory health. Nat Immunol. 2019 Oct;20(10):1279-1290. doi: 10.1038/s41590-019-0451-9. Epub 2019 Sep 9. Review.|Mortaz E, Adcock IM, Ricciardolo FL, Varahram M, Jamaati H, Velayati AA, Folkerts G, Garssen J. Anti-Inflammatory Effects of Lactobacillus Rahmnosus and Bifidobacterium Breve on Cigarette Smoke Activated Human Macrophages. PLoS One. 2015 Aug 28;10(8):e0136455. doi: 10.1371/journal.pone.0136455. eCollection 2015.|Reale M, Boscolo P, Bellante V, Tarantelli C, Di Nicola M, Forcella L, Li Q, Morimoto K, Muraro R. Daily intake of Lactobacillus casei Shirota increases natural killer cell activity in smokers. Br J Nutr. 2012 Jul;108(2):308-14. doi: 10.1017/S0007114511005630. Epub 2011 Dec 6.|Tomoda K, Kubo K, Dairiki K, Yamaji T, Yamamoto Y, Nishii Y, Nakamura A, Yoshikawa M, Hamada K, Kimura H. Whey peptide-based enteral diet attenuated elastase-induced emphysema with increase in short chain fatty acids in mice. BMC Pulm Med. 2015 Jun 10;15:64. doi: 10.1186/s12890-015-0059-2.|Lee SH, Yun Y, Kim SJ, Lee EJ, Chang Y, Ryu S, Shin H, Kim HL, Kim HN, Lee JH. Association between Cigarette Smoking Status and Composition of Gut Microbiota: Population-Based Cross-Sectional Study. J Clin Med. 2018 Sep 14;7(9). pii: E282. doi: 10.3390/jcm7090282.|Li N, Yang Z, Liao B, Pan T, Pu J, Hao B, Fu Z, Cao W, Zhou Y, He F, Li B, Ran P. Chronic exposure to ambient particulate matter induces gut microbial dysbiosis in a rat COPD model. Respir Res. 2020 Oct 19;21(1):271. doi: 10.1186/s12931-020-01529-3.","\tChronic Obstructive Pulmonary Disease\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","lung diseases|lung diseases, obstructive|pulmonary disease, chronic obstructive","NA","NA"]
["NCT04876872","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28289051|25417037|22157421|18955610|28557729","Lambert V, Matthews A, MacDonell R, Fitzsimons J. Paediatric early warning systems for detecting and responding to clinical deterioration in children: a systematic review. BMJ Open. 2017 Mar 13;7(3):e014497. doi: 10.1136/bmjopen-2016-014497. Review.|Jagt EW. Improving Pediatric Survival from Resuscitation Events: The Role and Organization of Hospital-based Rapid Response Systems and Code Teams. Curr Pediatr Rev. 2013;9(2):158-74.|Skaletzky SM, Raszynski A, Totapally BR. Validation of a modified pediatric early warning system score: a retrospective case-control study. Clin Pediatr (Phila). 2012 May;51(5):431-5. doi: 10.1177/0009922811430342. Epub 2011 Dec 8.|Egdell P, Finlay L, Pedley DK. The PAWS score: validation of an early warning scoring system for the initial assessment of children in the emergency department. Emerg Med J. 2008 Nov;25(11):745-9. doi: 10.1136/emj.2007.054965.|Barak-Corren Y, Fine AM, Reis BY. Early Prediction Model of Patient Hospitalization From the Pediatric Emergency Department. Pediatrics. 2017 May;139(5). pii: e20162785. doi: 10.1542/peds.2016-2785.","\tCritical Illness\tno intervention\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","critical illness","NA","NA"]
["NCT04877340","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","1568614|21483464|21420083|27878861","Vilmann P, Jacobsen GK, Henriksen FW, Hancke S. Endoscopic ultrasonography with guided fine needle aspiration biopsy in pancreatic disease. Gastrointest Endosc. 1992 Mar-Apr;38(2):172-3.|Iglesias-Garcia J, Dominguez-Munoz JE, Abdulkader I, Larino-Noia J, Eugenyeva E, Lozano-Leon A, Forteza-Vila J. Influence of on-site cytopathology evaluation on the diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of solid pancreatic masses. Am J Gastroenterol. 2011 Sep;106(9):1705-10. doi: 10.1038/ajg.2011.119. Epub 2011 Apr 12.|Iglesias-Garcia J, Poley JW, Larghi A, Giovannini M, Petrone MC, Abdulkader I, Monges G, Costamagna G, Arcidiacono P, Biermann K, Rindi G, Bories E, Dogloni C, Bruno M, Dominguez-Muñoz JE. Feasibility and yield of a new EUS histology needle: results from a multicenter, pooled, cohort study. Gastrointest Endosc. 2011 Jun;73(6):1189-96. doi: 10.1016/j.gie.2011.01.053. Epub 2011 Mar 21.|Bang JY, Hebert-Magee S, Hasan MK, Navaneethan U, Hawes R, Varadarajulu S. Endoscopic ultrasonography-guided biopsy using a Franseen needle design: Initial assessment. Dig Endosc. 2017 May;29(3):338-346. doi: 10.1111/den.12769. Epub 2016 Dec 20.","\tPancreatic Neoplasms\tneedle punction\tParallel Assignment\tDiagnostic\tRandomized\tDevice\tAll\t","Comparation Between Needles for EUS-guided Sampling of Solid Pancreatic Lesions","Interventional","Recruiting","N/A",2,50,"pancreatic neoplasms","NA","NA"]
["NCT04877392","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17565285|20971562|32147068|27315487|30915309|22435980|18053656","Goubet N, Strasbaugh K, Chesney J. Familiarity breeds content? Soothing effect of a familiar odor on full-term newborns. J Dev Behav Pediatr. 2007 Jun;28(3):189-94.|Johnston CC, Fernandes AM, Campbell-Yeo M. Pain in neonates is different. Pain. 2011 Mar;152(3 Suppl):S65-S73. doi: 10.1016/j.pain.2010.10.008. Epub 2010 Oct 23. Review.|Razaghi N, Aemmi SZ, Sadat Hoseini AS, Boskabadi H, Mohebbi T, Ramezani M. The effectiveness of familiar olfactory stimulation with lavender scent and glucose on the pain of blood sampling in term neonates: A randomized controlled clinical trial. Complement Ther Med. 2020 Mar;49:102289. doi: 10.1016/j.ctim.2019.102289. Epub 2019 Dec 26.|Akcan E, Polat S. Comparative Effect of the Smells of Amniotic Fluid, Breast Milk, and Lavender on Newborns' Pain During Heel Lance. Breastfeed Med. 2016 Aug;11(6):309-314. Epub 2016 Jun 17.|Vaziri F, Khosropoor M, Hidari M, Pourahmad S, Morshed Behbahani B, Saki F. The Effect of Aromatherapy by Lavender Oil on Infant Vaccination Pain: a Double Blind Randomized Controlled Trial. J Caring Sci. 2019 Mar 1;8(1):17-21. doi: 10.15171/jcs.2019.003. eCollection 2019 Mar.|Çetinkaya B, Başbakkal Z. The effectiveness of aromatherapy massage using lavender oil as a treatment for infantile colic. Int J Nurs Pract. 2012 Apr;18(2):164-9. doi: 10.1111/j.1440-172X.2012.02015.x.|Field T, Field T, Cullen C, Largie S, Diego M, Schanberg S, Kuhn C. Lavender bath oil reduces stress and crying and enhances sleep in very young infants. Early Hum Dev. 2008 Jun;84(6):399-401. Epub 2007 Nov 28.","\tAnkyloglossia\tLavender essential oil\tParallel Assignment\tSupportive Care\tRandomized\tDietary Supplement\tAll\t","Analgesic Effect of Inhaled Lavender Essential Oil for Clipping of Tongue-ties","Interventional","Completed","N/A",2,142,"ankyloglossia","NA","NA"]
["NCT04877925","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29445612|29221298","Guerrera F, Filosso PL, Pompili C, Olivetti S, Roffinella M, Imperatori A, Brunelli A. Application of the coaxial smart drain in patients with a large air leak following anatomic lung resection: a prospective multicenter phase II analysis of efficacy and safety. J Vis Surg. 2018 Jan 29;4:26. doi: 10.21037/jovs.2018.01.07. eCollection 2018.|Rena O, Parini S, Papalia E, Massera F, Turello D, Baietto G, Casadio C. The Redax(®) Coaxial Drain in pulmonary lobectomy: a study of efficacy. J Thorac Dis. 2017 Sep;9(9):3215-3221. doi: 10.21037/jtd.2017.08.110.","\tLung Cancer\tstandard chest tubes|coaxial chest tube\tParallel Assignment\tTreatment\tRandomized\tDevice|Device\tAll\t","Coaxial Drainage Versus Standard Chest Tube After Pulmonary Lobectomy","Interventional","Completed","N/A",2,98,"NA","NA","NA"]
["NCT04878887","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",7125255,"Pyles ST, Scher KS, Vega ET, Harrah JD, Rubis LJ. Cannulation of the dorsal radial artery: a new technique. Anesth Analg. 1982 Oct;61(10):876-8.","\tUltrasonography\tIP-DRA vs IP- PRA\tParallel Assignment\tBasic Science\tRandomized\tProcedure\tAll\t","DRA vs PRA for US-guided Radial Artery Catheterization in ICU","Interventional","Recruiting","N/A",2,60,"NA","NA","NA"]
["NCT04879108","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16331341|17442449|18066640|9066400|15277962|16281665|19910359","Erdogan M, Erdogan A, Erbil N, Karakaya HK, Demircan A. Prospective, Randomized, Placebo-controlled Study of the Effect of TENS on postthoracotomy pain and pulmonary function. World J Surg. 2005 Dec;29(12):1563-70.|Cesario A, Ferri L, Galetta D, Pasqua F, Bonassi S, Clini E, Biscione G, Cardaci V, di Toro S, Zarzana A, Margaritora S, Piraino A, Russo P, Sterzi S, Granone P. Post-operative respiratory rehabilitation after lung resection for non-small cell lung cancer. Lung Cancer. 2007 Aug;57(2):175-80. Epub 2007 Apr 17.|Kaneda H, Saito Y, Okamoto M, Maniwa T, Minami K, Imamura H. Early postoperative mobilization with walking at 4 hours after lobectomy in lung cancer patients. Gen Thorac Cardiovasc Surg. 2007 Dec;55(12):493-8. Epub 2007 Dec 11.|Benedetti F, Amanzio M, Casadio C, Cavallo A, Cianci R, Giobbe R, Mancuso M, Ruffini E, Maggi G. Control of postoperative pain by transcutaneous electrical nerve stimulation after thoracic operations. Ann Thorac Surg. 1997 Mar;63(3):773-6.|Sancho J, Servera E, Díaz J, Marín J. Comparison of peak cough flows measured by pneumotachograph and a portable peak flow meter. Am J Phys Med Rehabil. 2004 Aug;83(8):608-12.|Meek PM. Measurement of dyspnea in chronic obstructive pulmonary disease: what is the tool telling you? Chron Respir Dis. 2004;1(1):29-37. Review.|Freynet A, Falcoz PE. Is transcutaneous electrical nerve stimulation effective in relieving postoperative pain after thoracotomy? Interact Cardiovasc Thorac Surg. 2010 Feb;10(2):283-8. doi: 10.1510/icvts.2009.219576. Epub 2009 Nov 12. Review.","\tFunctional Capacity|Pain|Pulmonary Function|Surgery|Thoracic\tPhysiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation|Physiotherapy Rehabilitation\tCrossover Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","The Effectiveness of Transcutaneous Electrical Nerve Stimulation After Thoracic Surgery","Interventional","Completed","N/A",2,60,"aneurysm, dissecting","NA","NA"]
["NCT04879472","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Ochieng' S.R., Kingori J., Awori K.O., Ating'a J.E.O. Early Functional Outcome of Operative Treatment Of Displaced Femoral Neck Fractures in Two Kenyan Orthopaedic Centres.","\tFemoral Neck Fracture|Fracture Neck of Femur|Hip Fracture\tOsteosynthesis\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","femoral neck fractures|fractures, bone|hip fractures","NA","NA"]
["NCT04879888","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27484900,"Bernal-Estévez D, Sánchez R, Tejada RE, Parra-López C. Chemotherapy and radiation therapy elicits tumor specific T cell responses in a breast cancer patient. BMC Cancer. 2016 Aug 3;16:591. doi: 10.1186/s12885-016-2625-2.","\tBreast Cancer Female\tPeptide pulsed Dendritic cell\tNA\tNA\tNA\tBiological\tFemale\t","NA","NA","NA","NA","NA","NA","breast neoplasms","NA","NA"]
["NCT04879914","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32476236,"Facchin S, Vitulo N, Calgaro M, Buda A, Romualdi C, Pohl D, Perini B, Lorenzon G, Marinelli C, D'Incà R, Sturniolo GC, Savarino EV. Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. Neurogastroenterol Motil. 2020 Oct;32(10):e13914. doi: 10.1111/nmo.13914. Epub 2020 May 31.","\tInflammatory Bowel Diseases|Irritable Bowel Syndrome\tButyrate|Placebo\tParallel Assignment\tTreatment\tRandomized\tDietary Supplement|Dietary Supplement\tAll\t","Analysis of Microbiota Changes Induced by Microencapsulated Sodium Butyrate in Patients With Inflammatory Bowel Disease","Interventional","Enrolling by invitation","N/A",2,200,"intestinal diseases|inflammatory bowel diseases|irritable bowel syndrome","NA","NA"]
["NCT04880148","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29784145|28279391","Charalambous M, Raftopoulos V, Paikousis L, Katodritis N, Lambrinou E, Vomvas D, Georgiou M, Charalambous A. The effect of the use of thyme honey in minimizing radiation - induced oral mucositis in head and neck cancer patients: A randomized controlled trial. Eur J Oncol Nurs. 2018 Jun;34:89-97. doi: 10.1016/j.ejon.2018.04.003. Epub 2018 Apr 30.|Charalambous A, Lambrinou E, Katodritis N, Vomvas D, Raftopoulos V, Georgiou M, Paikousis L, Charalambous M. The effectiveness of thyme honey for the management of treatment-induced xerostomia in head and neck cancer patients: A feasibility randomized control trial. Eur J Oncol Nurs. 2017 Apr;27:1-8. doi: 10.1016/j.ejon.2017.01.001. Epub 2017 Jan 16.","\tCancer of the Head and Neck|Oral Mucositis|Radiation Toxicity|Xerostomia\tThyme and Honey-based oral spray|Placebo oral spray\tParallel Assignment\tSupportive Care\tRandomized\tDietary Supplement|Dietary Supplement\tAll\t","The Effectiveness of a Thyme and Honey Spray for Oral Toxicities","Interventional","Not yet recruiting","N/A",2,200,"stomatitis|xerostomia|head and neck neoplasms|mucositis","NA","NA"]
["NCT04880707","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32633773|28990015","Quek SYP, Gomes-Zagury J, Subramanian G. Twin Block in Myogenous Orofacial Pain: Applied Anatomy, Technique Update, and Safety. Anesth Prog. 2020 Jun 1;67(2):103-106. doi: 10.2344/anpr-67-01-03. Review.|Kanti V, Ananthan S, Subramanian G, Quek SYP. Efficacy of the twin block, a peripheral nerve block for the management of chronic masticatory myofascial pain: A case series. Quintessence Int. 2017 Oct 6:725-729. doi: 10.3290/j.qi.a39094. [Epub ahead of print]","\tAcute Pain\tTwin block local anesthetic nerve block using standard dental anesthetic|Twin block with placebo\tParallel Assignment\tSupportive Care\tRandomized\tDrug|Other\tAll\t","Twin Block, Pain Medications and Third Molar Extractions","Interventional","Not yet recruiting","Phase 2",2,48,"acute pain","anesthetics, local|anesthetics","NA"]
["NCT04881435","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",12851547,"Joachims HZ, Segal J, Golz A, Netzer A, Goldenberg D. Antioxidants in treatment of idiopathic sudden hearing loss. Otol Neurotol. 2003 Jul;24(4):572-5.","\tHearing Loss, Sensorineural\tHydrogen gas therapy\tParallel Assignment\tTreatment\tRandomized\tDevice\tAll\t","Hydrogen-oxygen Gas Mixture Inhalation in Patients With Sudden Sensorineural Hearing Loss","Interventional","Recruiting","N/A",2,100,"deafness|hearing loss|hearing loss, sensorineural","NA","NA"]
["NCT04881838","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32987765|32730187|32661576|20679620|19139435|28273702|28787259","Mussolin L, Le Deley MC, Carraro E, Damm-Welk C, Attarbaschi A, Williams D, Burke A, Horibe K, Nakazawa A, Wrobel G, Mann G, Csóka M, Uyttebroeck A, Fernández-Delgado Cerdá RF, Beishuizen A, Mellgren K, Burkhardt B, Klapper W, Turner SD, D'Amore ESG, Lamant L, Reiter A, Woessmann W, Brugières L, Pillon MPOBOTEIFCNL. Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial. Cancers (Basel). 2020 Sep 24;12(10). pii: E2747. doi: 10.3390/cancers12102747.|Knörr F, Brugières L, Pillon M, Zimmermann M, Ruf S, Attarbaschi A, Mellgren K, Burke GAA, Uyttebroeck A, Wróbel G, Beishuizen A, Aladjidi N, Reiter A, Woessmann W; European Inter-Group for Childhood Non-Hodgkin Lymphoma. Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial. J Clin Oncol. 2020 Dec 1;38(34):3999-4009. doi: 10.1200/JCO.20.00157. Epub 2020 Jul 30.|Yuan Q, He Q, Mi Q, Yin MZ, Han YL, Gao YJ. Single-drug vinorelbine as a salvage re-induction regimen for 4 consecutive pediatric patients with relapsed anaplastic large-cell lymphoma in a single children's institution. Ann Hematol. 2021 Apr;100(4):1093-1095. doi: 10.1007/s00277-020-04175-3. Epub 2020 Jul 13.|Le Deley MC, Rosolen A, Williams DM, Horibe K, Wrobel G, Attarbaschi A, Zsiros J, Uyttebroeck A, Marky IM, Lamant L, Woessmann W, Pillon M, Hobson R, Mauguen A, Reiter A, Brugières L. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol. 2010 Sep 1;28(25):3987-93. doi: 10.1200/JCO.2010.28.5999. Epub 2010 Aug 2.|Brugières L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, Mann G, Zsiros J, Uyttebroeck A, Marky I, Lamant L, Reiter A. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009 Feb 20;27(6):897-903. doi: 10.1200/JCO.2008.18.1487. Epub 2009 Jan 12.|Lymphoma Study Group, Subspecialty Group of Hematology, the Society of Pediatrics, Chinese Medical Association; Lymphoma Study Group, Committee of Pediatrics, Chinese Anti-Cancer Association. [Diagnosis and treatment of anaplastic large-cell lymphoma in children and adolescents: a retrospective multicenter survey study]. Zhonghua Er Ke Za Zhi. 2017 Mar 2;55(3):194-199. doi: 10.3760/cma.j.issn.0578-1310.2017.03.006. Chinese.|Mossé YP, Voss SD, Lim MS, Rolland D, Minard CG, Fox E, Adamson P, Wilner K, Blaney SM, Weigel BJ. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. J Clin Oncol. 2017 Oct 1;35(28):3215-3221. doi: 10.1200/JCO.2017.73.4830. Epub 2017 Aug 8.","\tPediatric Anaplastic Large Cell Lymphoma\tP regimen|Course A1 + Vin|Course B1 +Vin|Course A2 + Vin|Course B2 +Vin|Course A3 + Vin|Course B3 +Vin|Maintenance therapy\tNA\tNA\tNA\tDrug|Drug|Drug|Drug|Drug|Drug|Drug|Drug\tAll\t","NA","NA","NA","NA","NA","NA","lymphoma|lymphoma, large-cell, anaplastic|lymphoma, non-hodgkin","NA","NA"]
["NCT04883580","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22987158|20862593|21079498|17556141|14563154|17268254|11927817|14673715|10905443|12897475|26686604|28463620","Tian W, Liu Y, Zheng S, Lv Y. Accuracy of lower cervical pedicle screw placement with assistance of distinct navigation systems: a human cadaveric study. Eur Spine J. 2013 Jan;22(1):148-55. doi: 10.1007/s00586-012-2494-6. Epub 2012 Sep 18.|Tian NF, Huang QS, Zhou P, Zhou Y, Wu RK, Lou Y, Xu HZ. Pedicle screw insertion accuracy with different assisted methods: a systematic review and meta-analysis of comparative studies. Eur Spine J. 2011 Jun;20(6):846-59. doi: 10.1007/s00586-010-1577-5. Epub 2010 Sep 23. Review.|Devito DP, Kaplan L, Dietl R, Pfeiffer M, Horne D, Silberstein B, Hardenbrook M, Kiriyanthan G, Barzilay Y, Bruskin A, Sackerer D, Alexandrovsky V, Stüer C, Burger R, Maeurer J, Donald GD, Schoenmayr R, Friedlander A, Knoller N, Schmieder K, Pechlivanis I, Kim IS, Meyer B, Shoham M. Clinical acceptance and accuracy assessment of spinal implants guided with SpineAssist surgical robot: retrospective study. Spine (Phila Pa 1976). 2010 Nov 15;35(24):2109-15. doi: 10.1097/BRS.0b013e3181d323ab. Erratum in: Spine (Phila Pa 1976). 2011 Jan 1;36(1):91. Gordon, Donald G [corrected to Donald, Gordon D].|Burch S. Surgical complications of spinal deformity surgery. Neurosurg Clin N Am. 2007 Apr;18(2):385-92. Review.|Holly LT, Foley KT. Three-dimensional fluoroscopy-guided percutaneous thoracolumbar pedicle screw placement. Technical note. J Neurosurg. 2003 Oct;99(3 Suppl):324-9.|Kosmopoulos V, Schizas C. Pedicle screw placement accuracy: a meta-analysis. Spine (Phila Pa 1976). 2007 Feb 1;32(3):E111-20.|\"Klein SA, Glassman SD, Dimar JR 2nd, Voor MJ. Evaluation of the fixation and strength of a \"\"rescue\"\" revision pedicle screw. J Spinal Disord Tech. 2002 Apr;15(2):100-4.\"|Tan SH, Teo EC, Chua HC. Quantitative three-dimensional anatomy of cervical, thoracic and lumbar vertebrae of Chinese Singaporeans. Eur Spine J. 2004 Mar;13(2):137-46. Epub 2003 Dec 12.|Laine T, Lund T, Ylikoski M, Lohikoski J, Schlenzka D. Accuracy of pedicle screw insertion with and without computer assistance: a randomised controlled clinical study in 100 consecutive patients. Eur Spine J. 2000 Jun;9(3):235-40.|Holly LT, Foley KT. Intraoperative spinal navigation. Spine (Phila Pa 1976). 2003 Aug 1;28(15 Suppl):S54-61. Review.|Mendelsohn D, Strelzow J, Dea N, Ford NL, Batke J, Pennington A, Yang K, Ailon T, Boyd M, Dvorak M, Kwon B, Paquette S, Fisher C, Street J. Patient and surgeon radiation exposure during spinal instrumentation using intraoperative computed tomography-based navigation. Spine J. 2016 Mar;16(3):343-54. doi: 10.1016/j.spinee.2015.11.020. Epub 2015 Dec 10.|Solomiichuk V, Fleischhammer J, Molliqaj G, Warda J, Alaid A, von Eckardstein K, Schaller K, Tessitore E, Rohde V, Schatlo B. Robotic versus fluoroscopy-guided pedicle screw insertion for metastatic spinal disease: a matched-cohort comparison. Neurosurg Focus. 2017 May;42(5):E13. doi: 10.3171/2017.3.FOCUS1710.","\tPedicle Screw Fixation of Spine\tNavigation and Positioning System for Orthopedic Surgeries\tParallel Assignment\tTreatment\tRandomized\tDevice\tAll\t","Navigation and Positioning System for Orthopedic Surgery","Interventional","Not yet recruiting","N/A",2,112,"NA","NA","NA"]
["NCT04883892","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27566242|26069591|20934692|25662594|27994723|19067120","Shapiro SA, Kazmerchak SE, Heckman MG, Zubair AC, O'Connor MI. A Prospective, Single-Blind, Placebo-Controlled Trial of Bone Marrow Aspirate Concentrate for Knee Osteoarthritis. Am J Sports Med. 2017 Jan;45(1):82-90. doi: 10.1177/0363546516662455. Epub 2016 Sep 30.|Kennedy JG, Murawski CD. The Treatment of Osteochondral Lesions of the Talus with Autologous Osteochondral Transplantation and Bone Marrow Aspirate Concentrate: Surgical Technique. Cartilage. 2011 Oct;2(4):327-36. doi: 10.1177/1947603511400726.|Giannini S, Buda R, Cavallo M, Ruffilli A, Cenacchi A, Cavallo C, Vannini F. Cartilage repair evolution in post-traumatic osteochondral lesions of the talus: from open field autologous chondrocyte to bone-marrow-derived cells transplantation. Injury. 2010 Nov;41(11):1196-203. doi: 10.1016/j.injury.2010.09.028. Epub 2010 Oct 8.|Buda R, Vannini F, Castagnini F, Cavallo M, Ruffilli A, Ramponi L, Pagliazzi G, Giannini S. Regenerative treatment in osteochondral lesions of the talus: autologous chondrocyte implantation versus one-step bone marrow derived cells transplantation. Int Orthop. 2015 May;39(5):893-900. doi: 10.1007/s00264-015-2685-y. Epub 2015 Feb 8.|Vannini F, Cavallo M, Ramponi L, Castagnini F, Massimi S, Giannini S, Buda RE. Return to Sports After Bone Marrow-Derived Cell Transplantation for Osteochondral Lesions of the Talus. Cartilage. 2017 Jan;8(1):80-87. Epub 2016 Apr 12.|Luciani D, Cadossi M, Tesei F, Chiarello E, Giannini S. Viscosupplementation for grade II osteoarthritis of the ankle: a prospective study at 18 months' follow-up. Chir Organi Mov. 2008 Dec;92(3):155-60. doi: 10.1007/s12306-008-0066-z. Epub 2008 Dec 6.","\tAnkle Osteoarthritis\tBMAC|HA\tCrossover Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","Evaluation of the Single Injection of BMAC vs HA in the Treatment of the Ankle Osteoarthritis","Interventional","Not yet recruiting","N/A",2,120,"osteoarthritis","hyaluronic acid","NA"]
["NCT04885140","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","References Alessandro S, E S V, De Wispelaere Marlies P, et al. Tandem Disc Herniation of the Lumbar and Cervical Spine: Case Series and Review of the Epidemiological, Pathophysiological and Genetic Literature.[J]. Cureus, 2019,11(2):22. An H. Surgical [M]. Beijing: People's Medical Publishing House, 2011: 849. Bandura A, Freeman W H, Lightsey R. Self-Efficacy: The Exercise of Control[J]. J Cogn Psychother, 1999,13(2). Baretich, Matt. National Quality Forum Releases Recommendations for Safe Practices[J]. Biomed Instrum Technol, 2010,44(4): 334-335. C S E, Feudjio F S, Hai Y, et al.","\tLumbar Disc Herniation\tFeedback-based health education|Routine health education\tParallel Assignment\tSupportive Care\tRandomized\tBehavioral|Behavioral\tAll\t","Effect of Feedback Health Education on Postoperative Rehabilitation of Patients With Lumbar Disc Herniation","Interventional","Completed","N/A",2,75,"hernia","NA","NA"]
["NCT04885257","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26361060|9749682","McAllister TW, Zafonte R, Jain S, Flashman LA, George MS, Grant GA, He F, Lohr JB, Andaluz N, Summerall L, Paulus MP, Raman R, Stein MB. Randomized Placebo-Controlled Trial of Methylphenidate or Galantamine for Persistent Emotional and Cognitive Symptoms Associated with PTSD and/or Traumatic Brain Injury. Neuropsychopharmacology. 2016 Apr;41(5):1191-8. doi: 10.1038/npp.2015.282. Epub 2015 Sep 11.|Grade C, Redford B, Chrostowski J, Toussaint L, Blackwell B. Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Arch Phys Med Rehabil. 1998 Sep;79(9):1047-50.","\tPTSD|Stroke\tMethylphenidate|Placebo\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug\tAll\t","Methylphenidate for Ptsd and Stroke Veterans","Interventional","Not yet recruiting","Phase 2",2,60,"stroke","methylphenidate","NA"]
["NCT04885478","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32880381|32943637","García-Sierra RM, Badia Perich E, Manresa Dominguez JM, Moreno Millan N, Sabaté Cintas V, Romero Martínez M, Moreno Gabriel E, Pera G, Seda Gombau G, Montellà Jordana N, Violan Fors C, Argerich González MJ, Bonet Simó JM, Prat Gil N, Torán Monserrat P. [Descriptive study of the health service workers of a Primary Care Department confined by Covid-19.]. Rev Esp Salud Publica. 2020 Sep 3;94. pii: e202009106. Spanish.|Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, Borgert BA, Moreno CA, Solomon BD, Trimmer-Smith L, Etienne V, Rodriguez-Barraquer I, Lessler J, Salje H, Burke DS, Wesolowski A, Cummings DAT. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun. 2020 Sep 17;11(1):4704. doi: 10.1038/s41467-020-18450-4.","\tCOVID-19|SARS-CoV-2\tImmune response monitoring , blood samples\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04885517","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32228035|32355007|32747395|32412581|33089348|32329799|32215647|31274034|27626833|32325004|33140181|32736637|31437406|32291463","Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. COVID-19 Does Not Lead to a \"Typical\" Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2020 May 15;201(10):1299-1300. doi: 10.1164/rccm.202003-0817LE.|Couzin-Frankel J. The mystery of the pandemic's 'happy hypoxia'. Science. 2020 May 1;368(6490):455-456. doi: 10.1126/science.368.6490.455.|Aliberti S, Radovanovic D, Billi F, Sotgiu G, Costanzo M, Pilocane T, Saderi L, Gramegna A, Rovellini A, Perotto L, Monzani V, Santus P, Blasi F. Helmet CPAP treatment in patients with COVID-19 pneumonia: a multicentre cohort study. Eur Respir J. 2020 Oct 15;56(4). pii: 2001935. doi: 10.1183/13993003.01935-2020. Print 2020 Oct.|Elharrar X, Trigui Y, Dols AM, Touchon F, Martinez S, Prud'homme E, Papazian L. Use of Prone Positioning in Nonintubated Patients With COVID-19 and Hypoxemic Acute Respiratory Failure. JAMA. 2020 Jun 9;323(22):2336-2338. doi: 10.1001/jama.2020.8255.|Chiumello D, Busana M, Coppola S, Romitti F, Formenti P, Bonifazi M, Pozzi T, Palumbo MM, Cressoni M, Herrmann P, Meissner K, Quintel M, Camporota L, Marini JJ, Gattinoni L. Physiological and quantitative CT-scan characterization of COVID-19 and typical ARDS: a matched cohort study. Intensive Care Med. 2020 Dec;46(12):2187-2196. doi: 10.1007/s00134-020-06281-2. Epub 2020 Oct 21.|Marini JJ, Gattinoni L. Management of COVID-19 Respiratory Distress. JAMA. 2020 Jun 9;323(22):2329-2330. doi: 10.1001/jama.2020.6825.|Poston JT, Patel BK, Davis AM. Management of Critically Ill Adults With COVID-19. JAMA. 2020 May 12;323(18):1839-1841. doi: 10.1001/jama.2020.4914.|Gattinoni L, Giosa L, Bonifazi M, Pasticci I, Busana M, Macri M, Romitti F, Vassalli F, Quintel M. Targeting transpulmonary pressure to prevent ventilator-induced lung injury. Expert Rev Respir Med. 2019 Aug;13(8):737-746. doi: 10.1080/17476348.2019.1638767. Epub 2019 Jul 5. Review.|Brochard L, Slutsky A, Pesenti A. Mechanical Ventilation to Minimize Progression of Lung Injury in Acute Respiratory Failure. Am J Respir Crit Care Med. 2017 Feb 15;195(4):438-442. doi: 10.1164/rccm.201605-1081CP.|Tonelli R, Fantini R, Tabbì L, Castaniere I, Pisani L, Pellegrino MR, Della Casa G, D'Amico R, Girardis M, Nava S, Clini EM, Marchioni A. Early Inspiratory Effort Assessment by Esophageal Manometry Predicts Noninvasive Ventilation Outcome in De Novo Respiratory Failure. A Pilot Study. Am J Respir Crit Care Med. 2020 Aug 15;202(4):558-567. doi: 10.1164/rccm.201912-2512OC.|Goligher EC, Jonkman AH, Dianti J, Vaporidi K, Beitler JR, Patel BK, Yoshida T, Jaber S, Dres M, Mauri T, Bellani G, Demoule A, Brochard L, Heunks L. Clinical strategies for implementing lung and diaphragm-protective ventilation: avoiding insufficient and excessive effort. Intensive Care Med. 2020 Dec;46(12):2314-2326. doi: 10.1007/s00134-020-06288-9. Epub 2020 Nov 2. Review.|Apigo M, Schechtman J, Dhliwayo N, Al Tameemi M, Gazmuri RJ. Development of a work of breathing scale and monitoring need of intubation in COVID-19 pneumonia. Crit Care. 2020 Jul 31;24(1):477. doi: 10.1186/s13054-020-03176-y.|Vaporidi K, Akoumianaki E, Telias I, Goligher EC, Brochard L, Georgopoulos D. Respiratory Drive in Critically Ill Patients. Pathophysiology and Clinical Implications. Am J Respir Crit Care Med. 2020 Jan 1;201(1):20-32. doi: 10.1164/rccm.201903-0596SO.|Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, Camporota L. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020 Jun;46(6):1099-1102. doi: 10.1007/s00134-020-06033-2. Epub 2020 Apr 14.","\tCOVID-19 Pneumonia\tEsophageal catheter\tCrossover Assignment\tOther\tRandomized\tDevice\tAll\t","Breathing Effort in Covid-19 Pneumonia: Effects of Positive Pressure, Inspired Oxygen Fraction and Decubitus","Interventional","Recruiting","N/A",8,72,"pneumonia","NA","NA"]
["NCT04885842","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","6988491|5250875","The gliding path of the mandible along the skull. Ferdinand Graf Spee (1855-1937), prosector at the Anatomy Institute of Kiel. J Am Dent Assoc. 1980 May;100(5):670-5.|Baldridge DW. Leveling the curve of Spee: its effect on mandibular arch length. JPO J Pract Orthod. 1969 Jan;3(1):26-41.","\tOrthodontic Pathological Resorption of External Root\tinjection I-PRF\tParallel Assignment\tHealth Services Research\tRandomized\tOther\tAll\t","Efficacy of Injection Platelet-rich Fibrin(I-PRF) in Accelerate Alignment and Leveling","Interventional","Completed","N/A",2,18,"tooth resorption","NA","NA"]
["NCT04886193","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30207593|26808342|27776843|27157491|29543932","Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.|Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.|Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016 Dec;17(12):1697-1708. doi: 10.1016/S1470-2045(16)30531-9. Epub 2016 Oct 22.|Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, McRee AJ, Lin CC, Pathiraja K, Lunceford J, Emancipator K, Juco J, Koshiji M, Bang YJ. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016 Jun;17(6):717-726. doi: 10.1016/S1470-2045(16)00175-3. Epub 2016 May 3.|Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013. Epub 2018 May 10. Erratum in: JAMA Oncol. 2019 Apr 1;5(4):579.","\tChemotherapy|Gastric Cancer\tFLOT(Docetaxel+oxaliplatin+leucovorin+5-FU), Treprizumab, Tiggio capsule (S-1)\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","stomach neoplasms|neoplasm metastasis","oxaliplatin|docetaxel|leucovorin","NA"]
["NCT04886557","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26335675,"St-Pierre GH, Jack A, Siddiqui MM, Henderson RL, Nataraj A. Nonfusion Does Not Prevent Adjacent Segment Disease: Dynesys Long-term Outcomes With Minimum Five-year Follow-up. Spine (Phila Pa 1976). 2016 Feb;41(3):265-73. doi: 10.1097/BRS.0000000000001158.","\tLumbar Spondylolisthesis\tL4-L5 decompression and dynamic instrumentation\tNA\tNA\tNA\tProcedure\tAll\t","NA","NA","NA","NA","NA","NA","spondylolisthesis","NA","NA"]
["NCT04886648","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30826725|24092866|23068310|23890458|19757875","Robertson AM, Detmer MR. The Effects of Contingent Lullaby Music on Parent-Infant Interaction and Amount of Infant Crying in the First Six Weeks of Life. J Pediatr Nurs. 2019 May - Jun;46:33-38. doi: 10.1016/j.pedn.2019.02.025. Epub 2019 Feb 28.|Peng NH, Chen LL, Li TC, Smith M, Chang YS, Huang LC. The effect of positioning on preterm infants' sleep-wake states and stress behaviours during exposure to environmental stressors. J Child Health Care. 2014 Dec;18(4):314-25. doi: 10.1177/1367493513496665. Epub 2013 Oct 3.|Liaw JJ, Yang L, Lee CM, Fan HC, Chang YC, Cheng LP. Effects of combined use of non-nutritive sucking, oral sucrose, and facilitated tucking on infant behavioural states across heel-stick procedures: a prospective, randomised controlled trial. Int J Nurs Stud. 2013 Jul;50(7):883-94. doi: 10.1016/j.ijnurstu.2012.08.021. Epub 2012 Oct 12.|Alipour Z, Eskandari N, Ahmari Tehran H, Eshagh Hossaini SK, Sangi S. Effects of music on physiological and behavioral responses of premature infants: a randomized controlled trial. Complement Ther Clin Pract. 2013 Aug;19(3):128-32. doi: 10.1016/j.ctcp.2013.02.007. Epub 2013 May 9.|Keith DR, Russell K, Weaver BS. The effects of music listening on inconsolable crying in premature infants. J Music Ther. 2009 Fall;46(3):191-203.","\tPreterm Birth\tMusic Therapy\tParallel Assignment\tPrevention\tRandomized\tBehavioral\tAll\t","THE EFFECT OF MOTHER'S VOICE AND LULLABY ON PRETERM INFANTS' PHYSIOLOGICAL PARAMETERS, STRESS AND SLEEPING- WAKING STATE","Interventional","Completed","N/A",3,90,"premature birth","NA","NA"]
["NCT04887181","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",31640741,"Mason S, Burnett GR, Patel N, Patil A, Maclure R. Impact of toothpaste on oral health-related quality of life in people with dentine hypersensitivity. BMC Oral Health. 2019 Oct 22;19(1):226. doi: 10.1186/s12903-019-0919-x.","\tDentin Hypersensitivity\tTeethmate Desensitizer|Gluma Desensitizer|Hybrid Bond\tParallel Assignment\tTreatment\tRandomized\tOther|Other|Other\tAll\t","The Effects of Different Dentin Hypersensitivity Treatment Methods on Quality of Life","Interventional","Completed","N/A",3,69,"hypersensitivity|dentin sensitivity","NA","NA"]
["NCT04887389","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","18491761|20129891|30854195|19498220|25506416|24818873","Azarpazhooh A, Main PA. Fluoride varnish in the prevention of dental caries in children and adolescents: a systematic review. Tex Dent J. 2008 Apr;125(4):318-37.|Chu CH, Mei ML, Lo EC. Use of fluorides in dental caries management. Gen Dent. 2010 Jan-Feb;58(1):37-43; quiz 44-5, 79-80. Review.|Abbass MMS, Mahmoud SA, El Moshy S, Rady D, AbuBakr N, Radwan IA, Ahmed A, Abdou A, Al Jawaldeh A. The prevalence of dental caries among Egyptian children and adolescences and its association with age, socioeconomic status, dietary habits and other risk factors. A cross-sectional study. F1000Res. 2019 Jan 3;8:8. doi: 10.12688/f1000research.17047.1. eCollection 2019.|Huang SB, Gao SS, Yu HY. Effect of nano-hydroxyapatite concentration on remineralization of initial enamel lesion in vitro. Biomed Mater. 2009 Jun;4(3):034104. doi: 10.1088/1748-6041/4/3/034104. Epub 2009 Jun 5.|Pepla E, Besharat LK, Palaia G, Tenore G, Migliau G. Nano-hydroxyapatite and its applications in preventive, restorative and regenerative dentistry: a review of literature. Ann Stomatol (Roma). 2014 Nov 20;5(3):108-14. eCollection 2014 Jul.|Targino AG, Flores MA, dos Santos Junior VE, de Godoy Bené Bezerra F, de Luna Freire H, Galembeck A, Rosenblatt A. An innovative approach to treating dental decay in children. A new anti-caries agent. J Mater Sci Mater Med. 2014 Aug;25(8):2041-7. doi: 10.1007/s10856-014-5221-5. Epub 2014 May 13.","\tCariostatic Agent|Dental Caries in Children|Fluoride Varnishes|Resistance, Dental Caries\tNano Silver Fluoride varnish|nano-hydroxyapatite varnish|sodium Fluoride Varnish\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug|Drug\tAll\t","Cariostatic and Remineralizing Effects of Three Different Dental Varnishes","Interventional","Not yet recruiting","Phase 4",3,150,"dental caries","fluorides|sodium fluoride|listerine|fluorides, topical","NA"]
["NCT04887402","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12849816|18950759|22431566|17720020|19401323|11597618|19405411|24009134|28331909|14726171|15827102|23809505","Atiomo WU, El-Mahdi E, Hardiman P. Familial associations in women with polycystic ovary syndrome. Fertil Steril. 2003 Jul;80(1):143-5.|Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF; Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009 Feb;91(2):456-88. doi: 10.1016/j.fertnstert.2008.06.035. Epub 2008 Oct 23. Review.|Misso ML, Wong JL, Teede HJ, Hart R, Rombauts L, Melder AM, Norman RJ, Costello MF. Aromatase inhibitors for PCOS: a systematic review and meta-analysis. Hum Reprod Update. 2012 May-Jun;18(3):301-12. doi: 10.1093/humupd/dms003. Epub 2012 Mar 19. Review.|Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007 Aug 25;370(9588):685-97. Review.|Overbeek A, Kuijper EA, Hendriks ML, Blankenstein MA, Ketel IJ, Twisk JW, Hompes PG, Homburg R, Lambalk CB. Clomiphene citrate resistance in relation to follicle-stimulating hormone receptor Ser680Ser-polymorphism in polycystic ovary syndrome. Hum Reprod. 2009 Aug;24(8):2007-13. doi: 10.1093/humrep/dep114. Epub 2009 Apr 28.|Parsanezhad ME, Alborzi S, Zarei A, Dehbashi S, Omrani G. Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin. Int J Gynaecol Obstet. 2001 Oct;75(1):43-50.|Radosh L. Drug treatments for polycystic ovary syndrome. Am Fam Physician. 2009 Apr 15;79(8):671-6. Review.|Dunaif A, Fauser BC. Renaming PCOS--a two-state solution. J Clin Endocrinol Metab. 2013 Nov;98(11):4325-8. doi: 10.1210/jc.2013-2040. Epub 2013 Sep 5.|Sohrevardi SM, Nosouhi F, Hossein Khalilzade S, Kafaie P, Karimi-Zarchi M, Halvaei I, Mohsenzadeh M. Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT. Int J Reprod Biomed. 2016 Dec;14(12):743-754.|WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004 Jan 10;363(9403):157-63. Review. Erratum in: Lancet. 2004 Mar 13;363(9412):902.|Wild RA, Vesely S, Beebe L, Whitsett T, Owen W. Ferriman Gallwey self-scoring I: performance assessment in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 Jul;90(7):4112-4. Epub 2005 Apr 12.|Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in infertile women: a committee opinion. Fertil Steril. 2013 Aug;100(2):341-8. doi: 10.1016/j.fertnstert.2013.05.033. Epub 2013 Jun 27.","\tClomiphene Citrate|Induction of Ovulation|PCO\tClomiphene Citrate\tNA\tNA\tNA\tDrug\tFemale\t","NA","NA","NA","NA","NA","NA","hypersensitivity","zuclomiphene|clomiphene|enclomiphene","NA"]
["NCT04887649","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Darío José PS, Ricardo N, Pedro H, Viviana C, Andrea G, Andrés G et al . Randomized double-blind controlled clinical trial for the evaluation of post-partum analgesia using epidural morphine: analgesic effectiveness of different dose regimes compared with placebo. Rev. colomb. anestesiol. 2012 Apr [cited 2021 May 04] ; 40( 1 ): 8-13. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-33472012000100004&lng=en. https://doi.org/10.1016/S0120-3347(12)70004-7.","\tLabor Pain\tMorphine|saline solution|Morphine\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Drug\tFemale\t","Randomized, Controlled, Double Blind, to Evaluate the Postpartum Analgesia With Epidural Morphine: Analgesic Effect of Two Different Doses Compared to Placebo","Interventional","Completed","Phase 3",3,114,"labor pain","morphine","NA"]
["NCT04888013","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30454075|29772012|19489810|30886935","Ayerle GM, Schäfers R, Mattern E, Striebich S, Haastert B, Vomhof M, Icks A, Ronniger Y, Seliger G. Effects of the birthing room environment on vaginal births and client-centred outcomes for women at term planning a vaginal birth: BE-UP, a multicentre randomised controlled trial. Trials. 2018 Nov 19;19(1):641. doi: 10.1186/s13063-018-2979-7.|Downe S, Finlayson K, Oladapo OT, Bonet M, Gülmezoglu AM. Correction: What matters to women during childbirth: A systematic qualitative review. PLoS One. 2018 May 17;13(5):e0197791. doi: 10.1371/journal.pone.0197791. eCollection 2018.|Hodnett ED, Stremler R, Weston JA, McKeever P. Re-conceptualizing the hospital labor room: the PLACE (pregnant and laboring in an ambient clinical environment) pilot trial. Birth. 2009 Jun;36(2):159-66. doi: 10.1111/j.1523-536X.2009.00311.x.|\"Lorentzen I, Andersen CS, Jensen HS, Fogsgaard A, Foureur M, Lauszus FF, Nohr EA. Study protocol for a randomised trial evaluating the effect of a \"\"birth environment room\"\" versus a standard labour room on birth outcomes and the birth experience. Contemp Clin Trials Commun. 2019 Feb 15;14:100336. doi: 10.1016/j.conctc.2019.100336. eCollection 2019 Jun. Erratum in: Contemp Clin Trials Commun. 2020 Dec 10;20:100690.\"","\tBirth; Delayed|Childbirth Problems\tPositive Birth Environment\tNA\tNA\tNA\tOther\tFemale\t","Birth Environment and Childbirth-stress, Control & Outcome","Interventional","Not yet recruiting","N/A",3,129,"NA","NA","NA"]
["NCT04888780","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30073784|21853415|28665946|28287201|28500868|27669176|21099675|30630442|24932599|25720348|26197465|27054599|27230752|30701953|28927506|24372443","Karahan Okuroğlu G, Ecevit Alpar Ş. Effect of Web-based diabetes training program on diabetes-related knowledge, attitudes, and skills of health professionals: A randomized controlled trial. Jpn J Nurs Sci. 2019 Apr;16(2):184-193. doi: 10.1111/jjns.12228. Epub 2018 Aug 2.|Jaser SS. Family interaction in pediatric diabetes. Curr Diab Rep. 2011 Dec;11(6):480-5. doi: 10.1007/s11892-011-0222-y.|Charalampopoulos D, Hesketh KR, Amin R, Paes VM, Viner RM, Stephenson T. Psycho-educational interventions for children and young people with Type 1 Diabetes in the UK: How effective are they? A systematic review and meta-analysis. PLoS One. 2017 Jun 30;12(6):e0179685. doi: 10.1371/journal.pone.0179685. eCollection 2017. Review.|Muscatello MR, Troili GM, Pandolfo G, Mento C, Gallo G, Lanza G, Pintaudi B, Di Vieste G, Di Benedetto A, Zoccali RA, Bruno A. [Depression, anxiety and anger in patients with type 1 diabetes mellitus.]. Recenti Prog Med. 2017 Feb;108(2):77-82. doi: 10.1701/2636.27098. Italian.|McGuire HC, Ji L, Kissimova-Skarbek K, Whiting D, Aguirre F, Zhang P, Lin S, Gong C, Zhao W, Lu J, Guo X, Ji Y, Seuring T, Hong T, Chen L, Weng J, Zhou Z. Type 1 diabetes mellitus care and education in China: The 3C study of coverage, cost, and care in Beijing and Shantou. Diabetes Res Clin Pract. 2017 Jul;129:32-42. doi: 10.1016/j.diabres.2017.02.027. Epub 2017 Feb 28.|Bentzen SM, Knudsen VK, Christiensen T, Ewers B. Relative validity of a web-based food frequency questionnaire for patients with type 1 and type 2 diabetes in Denmark. Nutr Diabetes. 2016 Sep 26;6(9):e232. doi: 10.1038/nutd.2016.40.|Avdal EU, Kizilci S, Demirel N. The effects of web-based diabetes education on diabetes care results: a randomized control study. Comput Inform Nurs. 2011 Feb;29(2):101-6. doi: 10.1097/NCN.0b013e3181fcbdc6.|Knox ECL, Quirk H, Glazebrook C, Randell T, Blake H. Impact of technology-based interventions for children and young people with type 1 diabetes on key diabetes self-management behaviours and prerequisites: a systematic review. BMC Endocr Disord. 2019 Jan 10;19(1):7. doi: 10.1186/s12902-018-0331-6.|Gökşen D, Atik Altınok Y, Ozen S, Demir G, Darcan S. Effects of carbohydrate counting method on metabolic control in children with type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol. 2014;6(2):74-8. doi: 10.4274/Jcrpe.1191.|Bächle C, Lange K, Stahl-Pehe A, Castillo K, Holl RW, Giani G, Rosenbauer J. Associations between HbA1c and depressive symptoms in young adults with early-onset type 1 diabetes. Psychoneuroendocrinology. 2015 May;55:48-58. doi: 10.1016/j.psyneuen.2015.01.026. Epub 2015 Feb 7.|Mutlu EK, Mutlu C, Taskiran H, Ozgen IT. Association of physical activity level with depression, anxiety, and quality of life in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2015 Nov 1;28(11-12):1273-8. doi: 10.1515/jpem-2015-0082.|Samardzic M, Tahirovic H, Popovic N, Popovic-Samardzic M. Health-related quality of life in children and adolescents with type 1 diabetes mellitus from Montenegro: relationship to metabolic control. J Pediatr Endocrinol Metab. 2016 Jun 1;29(6):663-8. doi: 10.1515/jpem-2015-0420.|Fredette J, Mawn B, Hood K, Fain J. Quality of Life of College Students Living With Type 1 Diabetes: A Qualitative View. West J Nurs Res. 2016 Dec;38(12):1595-1610. Epub 2016 May 25.|Demir G, Özen S, Çetin H, Darcan Ş, Gökşen D. Effect of Education on Impaired Hypoglycemia Awareness and Glycemic Variability in Children and Adolescents with Type 1 Diabetes Mellitus. J Clin Res Pediatr Endocrinol. 2019 May 28;11(2):189-195. doi: 10.4274/jcrpe.galenos.2019.2019.0009. Epub 2019 Jan 31.|Tektaş P, Çam O. The Effects of Nursing Care Based on Watson's Theory of Human Caring on the Mental Health of Pregnant Women After a Pregnancy Loss. Arch Psychiatr Nurs. 2017 Oct;31(5):440-446. doi: 10.1016/j.apnu.2017.07.002. Epub 2017 Jul 11.|Arslan-Özkan İ, Okumuş H, Buldukoğlu K. A randomized controlled trial of the effects of nursing care based on Watson's Theory of Human Caring on distress, self-efficacy and adjustment in infertile women. J Adv Nurs. 2014 Aug;70(8):1801-12. doi: 10.1111/jan.12338. Epub 2013 Dec 22.","\tBehavioral Symptoms|Mental Disorder in Adolescence|Problem Behavior\tThe web-based Watson's Human Care Theory oriented training\tParallel Assignment\tSupportive Care\tRandomized\tOther\tAll\t","Effects of Web-Based Training on HbA1c, Quality of Life and Depression Levels in Adolescents With Type 1 Diabetes","Interventional","Completed","N/A",2,30,"mental disorders|behavioral symptoms|problem behavior","NA","NA"]
["NCT04888910","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24589344|27924776|28784414","Wu W, Bleecker E, Moore W, Busse WW, Castro M, Chung KF, Calhoun WJ, Erzurum S, Gaston B, Israel E, Curran-Everett D, Wenzel SE. Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. J Allergy Clin Immunol. 2014 May;133(5):1280-8. doi: 10.1016/j.jaci.2013.11.042. Epub 2014 Feb 28.|Wenzel SE, Jayawardena S, Graham NM, Pirozzi G, Teper A. Severe asthma and asthma-chronic obstructive pulmonary disease syndrome - Authors' reply. Lancet. 2016 Dec 3;388(10061):2742. doi: 10.1016/S0140-6736(16)31720-2. Epub 2016 Dec 2.|Ray A, Kolls JK. Neutrophilic Inflammation in Asthma and Association with Disease Severity. Trends Immunol. 2017 Dec;38(12):942-954. doi: 10.1016/j.it.2017.07.003. Epub 2017 Aug 4. Review.","\tAsthma|Nasal Polyps\tobservational\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","nasal polyps|asthma","NA","NA"]
["NCT04889079","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",28038902,"Diedrich JT, Klein DA, Peipert JF. Long-acting reversible contraception in adolescents: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017 Apr;216(4):364.e1-364.e12. doi: 10.1016/j.ajog.2016.12.024. Epub 2016 Dec 28. Review.","\tContraception\tContraceptive use (continuation/switching/discontinuation)\tNA\tNA\tNA\tBehavioral\tFemale\t","NA","NA","NA","NA","NA","NA","NA","contraceptive agents","NA"]
["NCT04889196","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",31158253,"Elamin F, Abdelazeem N, Salah I, Mirghani Y, Wong F. A randomized clinical trial comparing Hall vs conventional technique in placing preformed metal crowns from Sudan. PLoS One. 2019 Jun 3;14(6):e0217740. doi: 10.1371/journal.pone.0217740. eCollection 2019.","\tCaries\thall technique|Silver diamine fluoride\tParallel Assignment\tTreatment\tRandomized\tDevice|Drug\tAll\t","The Efficiency and Gingival Health Status of Hall Versus SDF Techniques in the Management of Carious Primary Molars","Interventional","Not yet recruiting","Phase 3",2,40,"NA","fluorides","NA"]
["NCT04889274","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27893465|32576603|33035428","Rathod KS, Kapil V, Velmurugan S, Khambata RS, Siddique U, Khan S, Van Eijl S, Gee LC, Bansal J, Pitrola K, Shaw C, D'Acquisto F, Colas RA, Marelli-Berg F, Dalli J, Ahluwalia A. Accelerated resolution of inflammation underlies sex differences in inflammatory responses in humans. J Clin Invest. 2017 Jan 3;127(1):169-182. doi: 10.1172/JCI89429. Epub 2016 Nov 28.|Kapil V, Khambata RS, Jones DA, Rathod K, Primus C, Massimo G, Fukuto JM, Ahluwalia A. The Noncanonical Pathway for In Vivo Nitric Oxide Generation: The Nitrate-Nitrite-Nitric Oxide Pathway. Pharmacol Rev. 2020 Jul;72(3):692-766. doi: 10.1124/pr.120.019240. Review.|Shabbir A, Rathod KS, Khambata RS, Ahluwalia A. Sex Differences in the Inflammatory Response: Pharmacological Opportunities for Therapeutics for Coronary Artery Disease. Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:333-359. doi: 10.1146/annurev-pharmtox-010919-023229. Epub 2020 Oct 9.","\tCardiovascular Diseases|Endothelial Dysfunction\tCOVID-19 vaccine|Concentrate beetroot Juice|Nitrate-deplete beetroot juice\tParallel Assignment\tPrevention\tRandomized\tBiological|Biological|Biological\tAll\t","Investigation of the Effects of Dietary Nitrate and Sex on COVID-19 Vaccine Induced Vascular Dysfunction in Healthy Men and Women (DiNOVasc-COVID-19)","Interventional","Recruiting","Phase 1",4,98,"cardiovascular diseases","NA","NA"]
["NCT04889677","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",31573880,"Wiles JA, Galvan MD, Podos SD, Geffner M, Huang M. Discovery and Development of the Oral Complement Factor D Inhibitor Danicopan (ACH-4471). Curr Med Chem. 2020;27(25):4165-4180. doi: 10.2174/0929867326666191001130342. Review.","\tHealthy\tDanicopan|Placebo\tParallel Assignment\tBasic Science\tRandomized\tDrug|Drug\tAll\t","Study of a Single Dose of Danicopan in Healthy Participants","Interventional","Completed","Phase 1",5,44,"NA","NA","NA"]
["NCT04889820","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32528099,"Kye BH, Kim JH, Kim HJ, Lee YS, Lee IK, Kang WK, Cho HM, Ahn CH, Oh ST. The optimal time interval between the placement of self-expandable metallic stent and elective surgery in patients with obstructive colon cancer. Sci Rep. 2020 Jun 11;10(1):9502. doi: 10.1038/s41598-020-66508-6.","\tColon Cancer, Obstruction\tNeoadjuvant chemotherapy|Adjuvant chemotherapy|Curative resection\tParallel Assignment\tTreatment\tRandomized\tDrug|Drug|Procedure\tAll\t","Neoadjuvant Chemotherapy for Obstructive Colon Cancer After Colonoscopic Stent: a Randomized Controlled Trial","Interventional","Not yet recruiting","N/A",2,204,"colonic neoplasms","NA","NA"]
["NCT04890665","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","2748771|16717171|11556271|NA|469082|NA|20089179|12964174|32226353|16814632","Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213.|Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7.|Novy DM, Stanley MA, Averill P, Daza P. Psychometric comparability of English- and Spanish-language measures of anxiety and related affective symptoms. Psychol Assess. 2001 Sep;13(3):347-55.|Foa EB, Cashman L, Jaycox L, Perry K. The validation of a self-report measure of posttraumatic stress disorder: the Posttraumatic Diagnostic Scale. Psychological assessment. 1997 Dec;9(4):445.|Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol. 1979 Apr;47(2):343-52.|González-Forteza C, Torres CS, Tapia AJ, Fernández IH, González-González A, Garcia FJ, Medina-Mora ME, Mejía HFV. Confiabilidad y validez de la escala de depresión CES-D en un censo de estudiantes de nivel medio superior y superior, en la Ciudad de México [Reliability and validity of the depression scale CES-D in high school and college students from Mexico City: Results from a census]. Salud Mental. 2011; 34(1): 53-59.|García-Campayo J, Zamorano E, Ruiz MA, Pardo A, Pérez-Páramo M, López-Gómez V, Freire O, Rejas J. Cultural adaptation into Spanish of the generalized anxiety disorder-7 (GAD-7) scale as a screening tool. Health Qual Life Outcomes. 2010 Jan 20;8:8. doi: 10.1186/1477-7525-8-8.|Connor KM, Davidson JR. Development of a new resilience scale: the Connor-Davidson Resilience Scale (CD-RISC). Depress Anxiety. 2003;18(2):76-82.|Ahorsu DK, Lin CY, Imani V, Saffari M, Griffiths MD, Pakpour AH. The Fear of COVID-19 Scale: Development and Initial Validation. Int J Ment Health Addict. 2020 Mar 27:1-9. doi: 10.1007/s11469-020-00270-8. [Epub ahead of print]|Healy DJ, Barry K, Blow F, Welsh D, Milner KK. Routine use of the Beck Scale for Suicide Ideation in a psychiatric emergency department. Gen Hosp Psychiatry. 2006 Jul-Aug;28(4):323-9.","\tAnxiety|Burnout, Professional|Depression|Fatigue, Compassion|Quality of Life|Sleep Disturbance|Stress\tOnline psychological intervention for healtchare workers\tParallel Assignment\tTreatment\tRandomized\tBehavioral\tAll\t","Online Multi-component Psychological Intervention for Anxiety, Depression, and Burnout on Healthcare Workers During the COVID-19 Pandemic","Interventional","Not yet recruiting","N/A",2,42,"compassion fatigue|anxiety disorders|depression|burnout, psychological|fatigue|burnout, professional|depressive disorder","NA","NA"]
["NCT04890704","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","11979336|31141635|31700251|33081797|23314316|29130810","Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002 May;39(5):930-6.|Mehran R, Dangas GD, Weisbord SD. Contrast-Associated Acute Kidney Injury. N Engl J Med. 2019 May 30;380(22):2146-2155. doi: 10.1056/NEJMra1805256. Review.|Morcos R, Kucharik M, Bansal P, Al Taii H, Manam R, Casale J, Khalili H, Maini B. Contrast-Induced Acute Kidney Injury: Review and Practical Update. Clin Med Insights Cardiol. 2019 Nov 1;13:1179546819878680. doi: 10.1177/1179546819878680. eCollection 2019. Review.|Kusirisin P, Chattipakorn SC, Chattipakorn N. Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches. J Transl Med. 2020 Oct 20;18(1):400. doi: 10.1186/s12967-020-02574-8. Review.|Tasanarong A, Vohakiat A, Hutayanon P, Piyayotai D. New strategy of α- and γ-tocopherol to prevent contrast-induced acute kidney injury in chronic kidney disease patients undergoing elective coronary procedures. Nephrol Dial Transplant. 2013 Feb;28(2):337-44. doi: 10.1093/ndt/gfs525. Epub 2013 Jan 12.|Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin SS, Conner TA, Chertow GM, Bhatt DL, Shunk K, Parikh CR, McFalls EO, Brophy M, Ferguson R, Wu H, Androsenko M, Myles J, Kaufman J, Palevsky PM; PRESERVE Trial Group. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. N Engl J Med. 2018 Feb 15;378(7):603-614. doi: 10.1056/NEJMoa1710933. Epub 2017 Nov 12.","\tAcute Kidney Injury|Chronic Kidney Diseases|Contrast Media Toxicity|Curcuminoid\tCurcuminoid|Placebo\tParallel Assignment\tPrevention\tRandomized\tDrug|Drug\tAll\t","Curcuminoids and Contrast-induced Acute Kidney Injury","Interventional","Completed","Early Phase 1",2,96,"acute kidney injury|wounds and injuries|renal insufficiency, chronic|kidney diseases","NA","NA"]
["NCT04890743","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31830313|31987553","Martimbianco ALC, Porfírio GJ, Pacheco RL, Torloni MR, Riera R. Transcutaneous electrical nerve stimulation (TENS) for chronic neck pain. Cochrane Database Syst Rev. 2019 Dec 12;12:CD011927. doi: 10.1002/14651858.CD011927.pub2.|Martins-de-Sousa PH, Guimarães Almeida MQ, da Silva Junior JM, Santos AS, Costa Araújo GG, de Oliveira Pires F, Fidelis-de-Paula-Gomes CA, Koga Ferreira VT, Dibai-Filho AV. Program of therapeutic exercises associated with electrotherapy in patients with chronic neck pain: Protocol for a randomized controlled trial. J Bodyw Mov Ther. 2020 Jan;24(1):25-30. doi: 10.1016/j.jbmt.2019.04.008. Epub 2019 Apr 25.","\tCervical Spine Syndrome\tKinesiotherapy combined with electrotherapy (Convenctional TENS method).|Kinesiotherapy combined with electrotherapy (Pseudo-acupuncture TENS method).|Kinesiotherapy combined with electrotherapy (Trabert ultrastimulation method)|Kinesiotherapy combined with placebo electrotherapy\tParallel Assignment\tTreatment\tRandomized\tOther|Other|Other|Other\tAll\t","Effectiveness of Various Electrotherapy Methods in Treating People With Cervical Spine Pain Syndrome.","Interventional","Not yet recruiting","N/A",4,60,"syndrome","NA","NA"]
["NCT04890925","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","29873292|32567875|NA|12924684|29292069|27766587|31442093|30535623|26176913|29294714|29157025|31771689|27792852|12964174|33201041","Valera EM, Cao A, Pasternak O, Shenton ME, Kubicki M, Makris N, Adra N. White Matter Correlates of Mild Traumatic Brain Injuries in Women Subjected to Intimate-Partner Violence: A Preliminary Study. J Neurotrauma. 2019 Mar 1;36(5):661-668. doi: 10.1089/neu.2018.5734. Epub 2018 Oct 4.|Buttell F, Ferreira RJ. The hidden disaster of COVID-19: Intimate partner violence. Psychol Trauma. 2020 Aug;12(S1):S197-S198. doi: 10.1037/tra0000646. Epub 2020 Jun 22.|Colantonio A. Beyond Football: Intimate Partner Violence and Concussion/Brain Injury. Canadian Psychology. 2020.|Valera EM, Berenbaum H. Brain injury in battered women. J Consult Clin Psychol. 2003 Aug;71(4):797-804.|Patch M, Anderson JC, Campbell JC. Injuries of Women Surviving Intimate Partner Strangulation and Subsequent Emergency Health Care Seeking: An Integrative Evidence Review. J Emerg Nurs. 2018 Jul;44(4):384-393. doi: 10.1016/j.jen.2017.12.001. Epub 2017 Dec 30.|\"Valera E, Kucyi A. Brain injury in women experiencing intimate partner-violence: neural mechanistic evidence of an \"\"invisible\"\" trauma. Brain Imaging Behav. 2017 Dec;11(6):1664-1677. doi: 10.1007/s11682-016-9643-1.\"|Smirl JD, Jones KE, Copeland P, Khatra O, Taylor EH, Van Donkelaar P. Characterizing symptoms of traumatic brain injury in survivors of intimate partner violence. Brain Inj. 2019;33(12):1529-1538. doi: 10.1080/02699052.2019.1658129. Epub 2019 Aug 23.|Heyman RE, Slep AMS, Lorber MF, Mitnick DM, Xu S, Baucom KJW, Halford WK, Niolon PH. A Randomized, Controlled Trial of the Impact of the Couple CARE for Parents of Newborns Program on the Prevention of Intimate Partner Violence and Relationship Problems. Prev Sci. 2019 Jul;20(5):620-631. doi: 10.1007/s11121-018-0961-y.|Kondo A, Shahpasand K, Mannix R, Qiu J, Moncaster J, Chen CH, Yao Y, Lin YM, Driver JA, Sun Y, Wei S, Luo ML, Albayram O, Huang P, Rotenberg A, Ryo A, Goldstein LE, Pascual-Leone A, McKee AC, Meehan W, Zhou XZ, Lu KP. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature. 2015 Jul 23;523(7561):431-436. doi: 10.1038/nature14658. Epub 2015 Jul 15.|Iverson KM, Sayer NA, Meterko M, Stolzmann K, Suri P, Gormley K, Nealon Seibert M, Yan K, Pogoda TK. Intimate Partner Violence Among Female OEF/OIF/OND Veterans Who Were Evaluated for Traumatic Brain Injury in the Veterans Health Administration: A Preliminary Investigation. J Interpers Violence. 2020 Jul;35(13-14):2422-2445. doi: 10.1177/0886260517702491. Epub 2017 Apr 18.|Dobney DM, Miller MB, Tufts E. Non-pharmacological rehabilitation interventions for concussion in children: a scoping review. Disabil Rehabil. 2019 Mar;41(6):727-739. doi: 10.1080/09638288.2017.1400595. Epub 2017 Nov 20. Review.|Varner CE. Specialized concussion clinic referrals are not intended for all acute concussion patients in the emergency department. CJEM. 2019 Nov;21(6):694-697. doi: 10.1017/cem.2019.430.|Varner CE, McLeod S, Nahiddi N, Lougheed RE, Dear TE, Borgundvaag B. Cognitive Rest and Graduated Return to Usual Activities Versus Usual Care for Mild Traumatic Brain Injury: A Randomized Controlled Trial of Emergency Department Discharge Instructions. Acad Emerg Med. 2017 Jan;24(1):75-82. doi: 10.1111/acem.13073.|Connor KM, Davidson JR. Development of a new resilience scale: the Connor-Davidson Resilience Scale (CD-RISC). Depress Anxiety. 2003;18(2):76-82.|Teel E, Brossard-Racine M, Corbin-Berrigan LA, Gagnon I. Perceptual Cognitive Training Does Not Improve Clinical Outcomes at 4 and 12 Weeks Following Concussion in Children and Adolescents: A Randomized Controlled Trial. J Head Trauma Rehabil. 2021 Mar-Apr 01;36(2):E97-E107. doi: 10.1097/HTR.0000000000000633.","\tMild Traumatic Brain Injury\tCommunity Support Network (CSN) intervention|Usual care\tParallel Assignment\tTreatment\tRandomized\tBehavioral|Behavioral\tFemale\t","A Community Support Network Intervention in SOAR Project Intimate Partner Violence-Related Traumatic Brain Injury","Interventional","Not yet recruiting","N/A",3,78,"brain injuries|brain injuries, traumatic|brain concussion","NA","NA"]
["NCT04891146","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25271081|27066202","Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, Zhang X, Wang WM, Qiu SJ, Zhou J, Fan J. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014 Dec 1;20(23):6212-22. doi: 10.1158/1078-0432.CCR-14-0442. Epub 2014 Sep 30.|Lee JH, Kang SH, Kim Y, Kim HA, Kim BS. Effects of propofol-based total intravenous anesthesia on recurrence and overall survival in patients after modified radical mastectomy: a retrospective study. Korean J Anesthesiol. 2016 Apr;69(2):126-32. doi: 10.4097/kjae.2016.69.2.126. Epub 2016 Mar 30.","\tCancer Gi|Cancer of Endometrium|Systemic Immune Activation\tSystemic inflammatory immmune index\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","endometrial neoplasms","NA","NA"]
["NCT04891211","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",23936865,"Poon M, Craig ME, Kaur H, Cusumano J, Sasongko MB, Wong TY, Donaghue KC. Vitamin D deficiency is not associated with changes in retinal geometric parameters in young people with type 1 diabetes. J Diabetes Res. 2013;2013:280691. doi: 10.1155/2013/280691. Epub 2013 Jul 7.","\tChoroidal Disease|Optic Nerve Diseases|Pediatric Disorder|Retinal Disease|Vitamin D Deficiency\tVitamin D deficiency\tCrossover Assignment\tPrevention\tRandomized\tDietary Supplement\tAll\t","Retinal Changes in Vitamin D Deficiency","Interventional","Completed","N/A",2,150,"optic nerve diseases|nervous system diseases|retinal diseases|vitamin d deficiency|choroid diseases","vitamin d","NA"]
["NCT04891861","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",33470152,"Milling TJ Jr, Warach S, Johnston SC, Gajewski B, Costantini T, Price M, Wick J, Roward S, Mudaranthakam D, Dula AN, King B, Muddiman A, Lip GYH. Restart TICrH: An Adaptive Randomized Trial of Time Intervals to Restart Direct Oral Anticoagulants after Traumatic Intracranial Hemorrhage. J Neurotrauma. 2021 Apr 6. doi: 10.1089/neu.2020.7535. [Epub ahead of print]","\tAnticoagulants; Increased\tApixaban\tParallel Assignment\tPrevention\tRandomized\tDrug\tAll\t","Restart TICrH Alpha Pilot Protocol, Restarting DOACs After Traumatic Intracranial Hemorrhage","Interventional","Not yet recruiting","Phase 3",2,100,"intracranial hemorrhage, traumatic|intracranial hemorrhages|hemorrhage","rivaroxaban|apixaban|edoxaban|dabigatran","NA"]
["NCT04891939","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26581335|NA|32547350|10773438|29940292|24739452|26160239|7950669|NA|NA|NA|10946439","Hansen K, Lindström M, Rosvall M. Age at smoking initiation and self-rated health among second grade high school boys and girls in Scania, Sweden, a cross-sectional study. BMC Public Health. 2015 Nov 18;15:1143. doi: 10.1186/s12889-015-2457-z.|Jha P, Chaloupka FJ, Moore J, et al. (2006). Tobacco Addiction. In: Disease Control Priorities in Developing Countries. 2nd edition (Chapter 46; et al Jamison DT, Breman JG, Measham AR, Ed.). Washington (DC): The International Bank for Reconstruction and Development / The World Bank.|Logo DD, Kyei-Faried S, Oppong FB, Ae-Ngibise KA, Ansong J, Amenyaglo S, Ankrah ST, Singh A, Owusu-Dabo E. Waterpipe use among the youth in Ghana: Lessons from the Global Youth Tobacco Survey (GYTS) 2017. Tob Induc Dis. 2020 May 29;18:47. doi: 10.18332/tid/120937. eCollection 2020.|Mayhew KP, Flay BR, Mott JA. Stages in the development of adolescent smoking. Drug Alcohol Depend. 2000 May 1;59 Suppl 1:S61-81. Review.|Leiva A, Estela A, Bennasar-Veny M, Aguiló A, Llobera J, Yáñez AM. Effectiveness of a complex intervention on smoking in adolescents: A cluster-randomized controlled trial. Prev Med. 2018 Sep;114:88-94. doi: 10.1016/j.ypmed.2018.06.009. Epub 2018 Jun 22.|Leiva A, Estela A, Torrent M, Calafat A, Bennasar M, Yáñez A. Effectiveness of a complex intervention in reducing the prevalence of smoking among adolescents: study design of a cluster-randomized controlled trial. BMC Public Health. 2014 Apr 16;14:373. doi: 10.1186/1471-2458-14-373.|So ES, Yeo JY. Factors Associated with Early Smoking Initiation among Korean Adolescents. Asian Nurs Res (Korean Soc Nurs Sci). 2015 Jun;9(2):115-9. doi: 10.1016/j.anr.2015.05.002. Epub 2015 May 27.|Peto R. Smoking and death: the past 40 years and the next 40. BMJ. 1994 Oct 8;309(6959):937-9.|U.S Surgeon General. (2014). U.S. Department of Health and Human Services. The Health Consequences of Smoking -50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center.|Ghana-GYTS. (2017a). Centers for Disease Control and Prevention. Global Youth Tobacco Survey (Vol. 10). Retrieved from https://nccd.cdc.gov/GTSSDataSurveyResources/Ancillary/DataReports.aspx?CAID=1|Atlas, T. T. (2019). WHO report on the global tobacco epidemic, 2017. Tobacco Atlas. Retrieved from https://tobaccoatlas.org/topic/youth/|Etter JF, Bergman MM, Humair JP, Perneger TV. Development and validation of a scale measuring self-efficacy of current and former smokers. Addiction. 2000 Jun;95(6):901-13.","\tSmoking Behaviors|Smoking Cessation|Smoking Reduction|Smoking, Tobacco\tHealth education lessons (Smart-Kid's program)|School Health and Education Program (SHEP)\tParallel Assignment\tPrevention\tRandomized\tOther|Other\tAll\t","Development and Assessment of a Teacher-led Intervention in Preventing Tobacco Use Among the Youth in Ghana","Interventional","Not yet recruiting","N/A",2,2314,"NA","NA","NA"]
["NCT04893044","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26475403,"McDonell MG, Skalisky J, Leickly E, McPherson S, Battalio S, Nepom JR, Srebnik D, Roll J, Ries RK. Using ethyl glucuronide in urine to detect light and heavy drinking in alcohol dependent outpatients. Drug Alcohol Depend. 2015 Dec 1;157:184-7. doi: 10.1016/j.drugalcdep.2015.10.004. Epub 2015 Oct 9.","\tAlcohol Drinking|Alcohol Use Disorder\tVideo\tParallel Assignment\tScreening\tRandomized\tBehavioral\tAll\t","Alcohol Misuse Intervention in Active Duty US Navy Personnel","Interventional","Completed","N/A",2,100,"alcohol drinking|alcoholism","NA","NA"]
["NCT04894097","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",26522903,"Wilson RD, Chae J. Hemiplegic Shoulder Pain. Phys Med Rehabil Clin N Am. 2015 Nov;26(4):641-55. doi: 10.1016/j.pmr.2015.06.007. Epub 2015 Sep 9. Review.","\tHemiplegia\tradial extracorpeal shock wave\tParallel Assignment\tTreatment\tRandomized\tDevice\tAll\t","Effect of Radial Extracorpeal Shock Wave on Pain and Function","Interventional","Not yet recruiting","N/A",2,30,"hemiplegia","NA","NA"]
["NCT04894318","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23047015|22522068|24636181|10946017|25988764|17276177|20431054|28426445|26247089|28572872|21816443|31591002|24139973|23736858|22018588|23173107|11159775|17605096|25603407|27511499|26699442|30044444|16740651|12200749|28166253|16963151|23830843|23584084|20089729|18580399|16210719|21178615|23266836","Stock EO, Redberg R. Cardiovascular disease in women. Curr Probl Cardiol. 2012 Nov;37(11):450-526. doi: 10.1016/j.cpcardiol.2012.07.001. Review.|Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA; AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012 Mar-Apr;18 Suppl 1:1-78.|Bayram F, Kocer D, Gundogan K, Kaya A, Demir O, Coskun R, Sabuncu T, Karaman A, Cesur M, Rizzo M, Toth PP, Gedik V. Prevalence of dyslipidemia and associated risk factors in Turkish adults. J Clin Lipidol. 2014 Mar-Apr;8(2):206-16. doi: 10.1016/j.jacl.2013.12.011. Epub 2014 Jan 19.|Mahley RW, Pépin J, Palaoğlu KE, Malloy MJ, Kane JP, Bersot TP. Low levels of high density lipoproteins in Turks, a population with elevated hepatic lipase. High density lipoprotein characterization and gender-specific effects of apolipoprotein e genotype. J Lipid Res. 2000 Aug;41(8):1290-301.|Bédard A, Corneau L, Lamarche B, Dodin S, Lemieux S. Sex Differences in the Impact of the Mediterranean Diet on LDL Particle Size Distribution and Oxidation. Nutrients. 2015 May 15;7(5):3705-23. doi: 10.3390/nu7053705.|El Harchaoui K, van der Steeg WA, Stroes ES, Kuivenhoven JA, Otvos JD, Wareham NJ, Hutten BA, Kastelein JJ, Khaw KT, Boekholdt SM. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007 Feb 6;49(5):547-53. Epub 2007 Jan 22.|Ai M, Otokozawa S, Asztalos BF, Ito Y, Nakajima K, White CC, Cupples LA, Wilson PW, Schaefer EJ. Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem. 2010 Jun;56(6):967-76. doi: 10.1373/clinchem.2009.137489. Epub 2010 Apr 29.|Gerber PA, Nikolic D, Rizzo M. Small, dense LDL: an update. Curr Opin Cardiol. 2017 Jul;32(4):454-459. doi: 10.1097/HCO.0000000000000410.|Feingold KR. Introduction to Lipids and Lipoproteins. 2021 Jan 19. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Grossman A, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from http://www.ncbi.nlm.nih.gov/books/NBK305896/|Ivanova EA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN. Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxid Med Cell Longev. 2017;2017:1273042. doi: 10.1155/2017/1273042. Epub 2017 May 7. Review.|Guay V, Lamarche B, Charest A, Tremblay AJ, Couture P. Effect of short-term low- and high-fat diets on low-density lipoprotein particle size in normolipidemic subjects. Metabolism. 2012 Jan;61(1):76-83. doi: 10.1016/j.metabol.2011.06.002. Epub 2011 Aug 3.|Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019 Nov;290:140-205. doi: 10.1016/j.atherosclerosis.2019.08.014. Epub 2019 Aug 31. Review. Erratum in: Atherosclerosis. 2020 Jan;292:160-162. Atherosclerosis. 2020 Feb;294:80-82.|Schwingshackl L, Hoffmann G. Comparison of effects of long-term low-fat vs high-fat diets on blood lipid levels in overweight or obese patients: a systematic review and meta-analysis. J Acad Nutr Diet. 2013 Dec;113(12):1640-61. doi: 10.1016/j.jand.2013.07.010. Epub 2013 Oct 17. Review.|Wu L, Ma D, Walton-Moss B, He Z. Effects of low-fat diet on serum lipids in premenopausal and postmenopausal women: a meta-analysis of randomized controlled trials. Menopause. 2014 Jan;21(1):89-99. doi: 10.1097/GME.0b013e318291f5c2. Review.|Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the International Physical Activity Questionnaire Short Form (IPAQ-SF): a systematic review. Int J Behav Nutr Phys Act. 2011 Oct 21;8:115. doi: 10.1186/1479-5868-8-115. Review.|Zen V, Fuchs FD, Wainstein MV, Gonçalves SC, Biavatti K, Riedner CE, Fuchs FC, Wainstein RV, Rhoden EL, Ribeiro JP, Fuchs SC. Neck circumference and central obesity are independent predictors of coronary artery disease in patients undergoing coronary angiography. Am J Cardiovasc Dis. 2012;2(4):323-30. Epub 2012 Oct 25.|Hoefner DM, Hodel SD, O'Brien JF, Branum EL, Sun D, Meissner I, McConnell JP. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem. 2001 Feb;47(2):266-74.|Kostis JB. The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease. Cardiovasc Drugs Ther. 2007 Aug;21(4):297-309. Review.|Aoki T, Yagi H, Sumino H, Tsunekawa K, Araki O, Kimura T, Nara M, Ogiwara T, Nakajima K, Murakami M. Relationship between carotid artery intima-media thickness and small dense low-density lipoprotein cholesterol concentrations measured by homogenous assay in Japanese subjects. Clin Chim Acta. 2015 Mar 10;442:110-4. doi: 10.1016/j.cca.2015.01.010. Epub 2015 Jan 17.|Taylan E, Tuncel EP. Distribution of LDL subgroups in patients with hyperlipidemia. Turk J Med Sci. 2016 Feb 17;46(2):374-80. doi: 10.3906/sag-1410-40.|Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, La Forge R, Daniels SR, Wilson DP, Morris PB, Wild RA, Grundy SM, Daviglus M, Ferdinand KC, Vijayaraghavan K, Deedwania PC, Aberg JA, Liao KP, McKenney JM, Ross JL, Braun LT, Ito MK, Bays HE, Brown WV, Underberg JA; NLA Expert Panel. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. J Clin Lipidol. 2015 Nov-Dec;9(6 Suppl):S1-122.e1. doi: 10.1016/j.jacl.2015.09.002. Epub 2015 Sep 18. Erratum in: J Clin Lipidol. 2016 Jan-Feb;10(1):211. Underberg, James A [added].|Zhu Z, Wu F, Lu Y, Wang Z, Zang J, Yu H, Guo C, Jia X, Shen X, Ding G. The Association of Dietary Cholesterol and Fatty Acids with Dyslipidemia in Chinese Metropolitan Men and Women. Nutrients. 2018 Jul 25;10(8). pii: E961. doi: 10.3390/nu10080961.|Ensign W, Hill N, Heward CB. Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin Chem. 2006 Sep;52(9):1722-7. Epub 2006 Jun 1.|Ohmura H, Mokuno H, Sawano M, Hatsumi C, Mitsugi Y, Watanabe Y, Daida H, Yamaguchi H. Lipid compositional differences of small, dense low-density lipoprotein particle influence its oxidative susceptibility: possible implication of increased risk of coronary artery disease in subjects with phenotype B. Metabolism. 2002 Sep;51(9):1081-7.|Chiu S, Williams PT, Krauss RM. Effects of a very high saturated fat diet on LDL particles in adults with atherogenic dyslipidemia: A randomized controlled trial. PLoS One. 2017 Feb 6;12(2):e0170664. doi: 10.1371/journal.pone.0170664. eCollection 2017.|Hosaka S, Okada Y, Maruyama K, Maruyama D. Increased intima-media thickness of the carotid artery in Japanese female type 2 diabetic patients with 'midband lipoprotein'. Diabetes Res Clin Pract. 2007 Mar;75(3):333-8. Epub 2006 Sep 8.|Srisawasdi P, Vanavanan S, Rochanawutanon M, Pornsuriyasak P, Tantrakul V, Kruthkul K, Kotani K. Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations. Clin Biochem. 2013 Oct;46(15):1509-15. doi: 10.1016/j.clinbiochem.2013.06.021. Epub 2013 Jul 2.|Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013 Apr 12;5(4):1218-40. doi: 10.3390/nu5041218. Review.|Taylor AE, Ebrahim S, Ben-Shlomo Y, Martin RM, Whincup PH, Yarnell JW, Wannamethee SG, Lawlor DA. Comparison of the associations of body mass index and measures of central adiposity and fat mass with coronary heart disease, diabetes, and all-cause mortality: a study using data from 4 UK cohorts. Am J Clin Nutr. 2010 Mar;91(3):547-56. doi: 10.3945/ajcn.2009.28757. Epub 2010 Jan 20.|Frimel TN, Sinacore DR, Villareal DT. Exercise attenuates the weight-loss-induced reduction in muscle mass in frail obese older adults. Med Sci Sports Exerc. 2008 Jul;40(7):1213-9. doi: 10.1249/MSS.0b013e31816a85ce.|Newman AB, Lee JS, Visser M, Goodpaster BH, Kritchevsky SB, Tylavsky FA, Nevitt M, Harris TB. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr. 2005 Oct;82(4):872-8; quiz 915-6.|Yang XP, Reckelhoff JF. Estrogen, hormonal replacement therapy and cardiovascular disease. Curr Opin Nephrol Hypertens. 2011 Mar;20(2):133-8. doi: 10.1097/MNH.0b013e3283431921. Review.|Pai JK, Manson JE. Acceleration of cardiovascular risk during the late menopausal transition. Menopause. 2013 Jan;20(1):1-2. doi: 10.1097/gme.0b013e318278e9b4.","\tDyslipidemias\tLow-fat and low-cholesterol diet\tNA\tNA\tNA\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","dyslipidemias","NA","NA"]
["NCT04894344","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24338487|31196460|15470483|29507099|12147930|12682080|21071956|23936079|17890487|20194225|14704836|31239546|22364888|31540146|26498129|15788708|17449506|19139321|22907057|16935461|22171802|15173128|1987006|24192084|27160199|24244395|26482149|18556187|19934192|18586647","Manzel A, Muller DN, Hafler DA, Erdman SE, Linker RA, Kleinewietfeld M. Role of \"Western diet\" in inflammatory autoimmune diseases. Curr Allergy Asthma Rep. 2014 Jan;14(1):404. doi: 10.1007/s11882-013-0404-6. Review.|Bakris G, Ali W, Parati G. ACC/AHA Versus ESC/ESH on Hypertension Guidelines: JACC Guideline Comparison. J Am Coll Cardiol. 2019 Jun 18;73(23):3018-3026. doi: 10.1016/j.jacc.2019.03.507. Review.|Forrester T, Adeyemo A, Soarres-Wynter S, Sargent L, Bennett F, Wilks R, Luke A, Prewitt E, Kramer H, Cooper RS. A randomized trial on sodium reduction in two developing countries. J Hum Hypertens. 2005 Jan;19(1):55-60.|Stamler J, Chan Q, Daviglus ML, Dyer AR, Van Horn L, Garside DB, Miura K, Wu Y, Ueshima H, Zhao L, Elliott P; INTERMAP Research Group. Relation of Dietary Sodium (Salt) to Blood Pressure and Its Possible Modulation by Other Dietary Factors: The INTERMAP Study. Hypertension. 2018 Apr;71(4):631-637. doi: 10.1161/HYPERTENSIONAHA.117.09928.|Weinberger MH. Salt sensitivity is associated with an increased mortality in both normal and hypertensive humans. J Clin Hypertens (Greenwich). 2002 Jul-Aug;4(4):274-6.|Drenjancevic-Peric I, Frisbee JC, Lombard JH. Skeletal muscle arteriolar reactivity in SS.BN13 consomic rats and Dahl salt-sensitive rats. Hypertension. 2003 May;41(5):1012-5. Epub 2003 Apr 7.|Drenjančević-Perić I, Jelaković B, Lombard JH, Kunert MP, Kibel A, Gros M. High-salt diet and hypertension: focus on the renin-angiotensin system. Kidney Blood Press Res. 2011;34(1):1-11. doi: 10.1159/000320387. Epub 2010 Nov 12. Review.|Larsen SC, Ängquist L, Sørensen TI, Heitmann BL. 24h urinary sodium excretion and subsequent change in weight, waist circumference and body composition. PLoS One. 2013 Jul 25;8(7):e69689. doi: 10.1371/journal.pone.0069689. Print 2013.|Fonseca-Alaniz MH, Brito LC, Borges-Silva CN, Takada J, Andreotti S, Lima FB. High dietary sodium intake increases white adipose tissue mass and plasma leptin in rats. Obesity (Silver Spring). 2007 Sep;15(9):2200-8.|Smith-Spangler CM, Juusola JL, Enns EA, Owens DK, Garber AM. Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis. Ann Intern Med. 2010 Apr 20;152(8):481-7, W170-3. doi: 10.7326/0003-4819-152-8-201004200-00212. Epub 2010 Mar 1.|Vedovato M, Lepore G, Coracina A, Dodesini AR, Jori E, Tiengo A, Del Prato S, Trevisan R. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia. 2004 Feb;47(2):300-3. Epub 2003 Dec 24.|Wilck N, Balogh A, Markó L, Bartolomaeus H, Müller DN. The role of sodium in modulating immune cell function. Nat Rev Nephrol. 2019 Sep;15(9):546-558. doi: 10.1038/s41581-019-0167-y. Epub 2019 Jun 25. Review.|Strazzullo P, Cairella G, Campanozzi A, Carcea M, Galeone D, Galletti F, Giampaoli S, Iacoviello L, Scalfi L; GIRCSI Working Group. Population based strategy for dietary salt intake reduction: Italian initiatives in the European framework. Nutr Metab Cardiovasc Dis. 2012 Mar;22(3):161-6. doi: 10.1016/j.numecd.2011.10.004. Epub 2012 Feb 23.|Vega-Solano J, Blanco-Metzler A, Benavides-Aguilar KF, Arcand J. An Evaluation of the Sodium Content and Compliance with the National Sodium Reduction Targets among Packaged Foods Sold in Costa Rica in 2015 and 2018. Nutrients. 2019 Sep 15;11(9). pii: E2226. doi: 10.3390/nu11092226.|Cavka A, Cosic A, Jukic I, Jelakovic B, Lombard JH, Phillips SA, Seric V, Mihaljevic I, Drenjancevic I. The role of cyclo-oxygenase-1 in high-salt diet-induced microvascular dysfunction in humans. J Physiol. 2015 Dec 15;593(24):5313-24. doi: 10.1113/JP271631. Epub 2015 Dec 7.|Meneton P, Jeunemaitre X, de Wardener HE, MacGregor GA. Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. Physiol Rev. 2005 Apr;85(2):679-715. Review.|Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, Appel LJ, Whelton PK. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007 Apr 28;334(7599):885-8. Epub 2007 Apr 20.|Cook NR, Obarzanek E, Cutler JA, Buring JE, Rexrode KM, Kumanyika SK, Appel LJ, Whelton PK; Trials of Hypertension Prevention Collaborative Research Group. Joint effects of sodium and potassium intake on subsequent cardiovascular disease: the Trials of Hypertension Prevention follow-up study. Arch Intern Med. 2009 Jan 12;169(1):32-40. doi: 10.1001/archinternmed.2008.523.|Greaney JL, DuPont JJ, Lennon-Edwards SL, Sanders PW, Edwards DG, Farquhar WB. Dietary sodium loading impairs microvascular function independent of blood pressure in humans: role of oxidative stress. J Physiol. 2012 Nov 1;590(21):5519-28. doi: 10.1113/jphysiol.2012.236992. Epub 2012 Aug 20.|Rossi M, Carpi A, Galetta F, Franzoni F, Santoro G. The investigation of skin blood flowmotion: a new approach to study the microcirculatory impairment in vascular diseases? Biomed Pharmacother. 2006 Sep;60(8):437-42. Epub 2006 Aug 14. Review.|Todd AS, Macginley RJ, Schollum JB, Williams SM, Sutherland WH, Mann JI, Walker RJ. Dietary sodium loading in normotensive healthy volunteers does not increase arterial vascular reactivity or blood pressure. Nephrology (Carlton). 2012 Mar;17(3):249-56. doi: 10.1111/j.1440-1797.2011.01550.x.|Gates PE, Tanaka H, Hiatt WR, Seals DR. Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension. Hypertension. 2004 Jul;44(1):35-41. Epub 2004 Jun 1.|Mascioli S, Grimm R Jr, Launer C, Svendsen K, Flack J, Gonzalez N, Elmer P, Neaton J. Sodium chloride raises blood pressure in normotensive subjects. The study of sodium and blood pressure. Hypertension. 1991 Jan;17(1 Suppl):I21-6.|Caldeira D, Vaz-Carneiro A, Costa J. [What is the benefit of salt reduction on blood pressure? Assessment of the Cochrane Review: Effect of longer-term modest salt reduction on blood pressure. He FJ, Li J, Macgregor GA. Cochrane Database Syst Rev. 2013 Apr 30;4:CD004937]. Acta Med Port. 2013 Sep-Oct;26(5):490-2. Epub 2013 Oct 31. Portuguese.|Suckling RJ, He FJ, Markandu ND, MacGregor GA. Modest Salt Reduction Lowers Blood Pressure and Albumin Excretion in Impaired Glucose Tolerance and Type 2 Diabetes Mellitus: A Randomized Double-Blind Trial. Hypertension. 2016 Jun;67(6):1189-95. doi: 10.1161/HYPERTENSIONAHA.115.06637.|Chen J, Tian Y, Liao Y, Yang S, Li Z, He C, Tu D, Sun X. Salt-restriction-spoon improved the salt intake among residents in China. PLoS One. 2013 Nov 11;8(11):e78963. doi: 10.1371/journal.pone.0078963. eCollection 2013.|Aparicio A, Rodríguez-Rodríguez E, Cuadrado-Soto E, Navia B, López-Sobaler AM, Ortega RM. Estimation of salt intake assessed by urinary excretion of sodium over 24 h in Spanish subjects aged 7-11 years. Eur J Nutr. 2017 Feb;56(1):171-178. doi: 10.1007/s00394-015-1067-y. Epub 2015 Oct 19.|Hoffmann IS, Cubeddu LX. Salt and the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2009 Feb;19(2):123-8. doi: 10.1016/j.numecd.2008.02.011. Epub 2008 Jun 16.|Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ. 2009 Nov 24;339:b4567. doi: 10.1136/bmj.b4567. Review.|Kim J, Lim SY, Kim JH. Nutrient intake risk factors of osteoporosis in postmenopausal women. Asia Pac J Clin Nutr. 2008;17(2):270-5.","\tDiabetes Mellitus, Type 2|Hypertension|Overweight or Obesity\tEducation group\tParallel Assignment\tPrevention\tRandomized\tBehavioral\tAll\t","EDUCATION TO DECREASE IN SODIUM INTAKE EVALUATED WITH 24 HOUR URINARY SODIUM EXCRETION(RCT)","Interventional","Recruiting","N/A",2,114,"diabetes mellitus, type 2|overweight","NA","NA"]
["NCT04894929","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25657851|19468085|22699991|16401442|30883488|26913496|22071817|30108511|26511625|16143174|29698252|29979352|31152705|32253894|32553538|29866352","Iwasaki S, Yamasoba T. Dizziness and Imbalance in the Elderly: Age-related Decline in the Vestibular System. Aging Dis. 2014 Feb 9;6(1):38-47. doi: 10.14336/AD.2014.0128. eCollection 2015 Feb. Review.|Agrawal Y, Carey JP, Della Santina CC, Schubert MC, Minor LB. Disorders of balance and vestibular function in US adults: data from the National Health and Nutrition Examination Survey, 2001-2004. Arch Intern Med. 2009 May 25;169(10):938-44. doi: 10.1001/archinternmed.2009.66. Erratum in: Arch Intern Med. 2009 Aug 10;169(15):1419.|Agrawal Y, Zuniga MG, Davalos-Bichara M, Schubert MC, Walston JD, Hughes J, Carey JP. Decline in semicircular canal and otolith function with age. Otol Neurotol. 2012 Jul;33(5):832-9. doi: 10.1097/MAO.0b013e3182545061.|Brown KE, Whitney SL, Marchetti GF, Wrisley DM, Furman JM. Physical therapy for central vestibular dysfunction. Arch Phys Med Rehabil. 2006 Jan;87(1):76-81.|Klatt BN, Ries JD, Dunlap PM, Whitney SL, Agrawal Y. Vestibular Physical Therapy in Individuals With Cognitive Impairment: A Theoretical Framework. J Neurol Phys Ther. 2019 Apr;43 Suppl 2:S14-S19. doi: 10.1097/NPT.0000000000000266.|Hall CD, Herdman SJ, Whitney SL, Cass SP, Clendaniel RA, Fife TD, Furman JM, Getchius TS, Goebel JA, Shepard NT, Woodhouse SN. Vestibular Rehabilitation for Peripheral Vestibular Hypofunction: An Evidence-Based Clinical Practice Guideline: FROM THE AMERICAN PHYSICAL THERAPY ASSOCIATION NEUROLOGY SECTION. J Neurol Phys Ther. 2016 Apr;40(2):124-55. doi: 10.1097/NPT.0000000000000120.|Howe TE, Rochester L, Neil F, Skelton DA, Ballinger C. Exercise for improving balance in older people. Cochrane Database Syst Rev. 2011 Nov 9;(11):CD004963. doi: 10.1002/14651858.CD004963.pub3. Review.|Swanenburg J, Wild K, Straumann D, de Bruin ED. Exergaming in a Moving Virtual World to Train Vestibular Functions and Gait; a Proof-of-Concept-Study With Older Adults. Front Physiol. 2018 Jul 31;9:988. doi: 10.3389/fphys.2018.00988. eCollection 2018.|Martins E Silva DC, Bastos VH, de Oliveira Sanchez M, Nunes MK, Orsini M, Ribeiro P, Velasques B, Teixeira SS. Effects of vestibular rehabilitation in the elderly: a systematic review. Aging Clin Exp Res. 2016 Aug;28(4):599-606. doi: 10.1007/s40520-015-0479-0. Epub 2015 Oct 28. Review.|Macias JD, Massingale S, Gerkin RD. Efficacy of vestibular rehabilitation therapy in reducing falls. Otolaryngol Head Neck Surg. 2005 Sep;133(3):323-5.|Beato M, Dawson N, Svien L, Wharton T. Examining the Effects of an Otago-Based Home Exercise Program on Falls and Fall Risks in an Assisted Living Facility. J Geriatr Phys Ther. 2019 Oct/Dec;42(4):224-229. doi: 10.1519/JPT.0000000000000190.|Fishleder S, Petrescu-Prahova M, Harris JR, Leroux B, Bennett K, Helfrich CD, Kohn M, Hannon P. Predictors of Improvement in Physical Function in Older Adults in an Evidence-Based Physical Activity Program (EnhanceFitness). J Geriatr Phys Ther. 2019 Oct/Dec;42(4):230-242. doi: 10.1519/JPT.0000000000000202.|Bean JF, Brown L, DeAngelis TR, Ellis T, Kumar VSS, Latham NK, Lawler D, Ni M, Perloff J. The Rehabilitation Enhancing Aging Through Connected Health Prehabilitation Trial. Arch Phys Med Rehabil. 2019 Nov;100(11):1999-2005. doi: 10.1016/j.apmr.2019.04.015. Epub 2019 May 29.|Canli S, Ozyurda F. A multi-modal exercise intervention that improves cognitive function and physical performance, elderly with mobility-related disability: a randomized controlled trial. J Sports Med Phys Fitness. 2020 Jul;60(7):1027-1033. doi: 10.23736/S0022-4707.20.10286-X. Epub 2020 Apr 6.|Martín Lesende I, Mendibil Crespo LI, Berrizbeitia González A, Llamosas Luengo I. [Computerized geriatric assessment tool VALINTAN (www.valintan.com) for primary care]. Aten Primaria. 2020 Oct;52(8):590-591. doi: 10.1016/j.aprim.2020.04.016. Epub 2020 Jun 15. Spanish.|de Hoyos Alonso MDC, Gorroñogoitia Iturbe A, Martín Lesende I, Baena Díez JM, López-Torres Hidalgo J, Magán Tapia P, Acosta Benito MÁ, Herreros Herreros Y; Grupo de Actividades Preventivas en los Mayores del PAPPS. Actividades preventivas en los mayores. Actualización PAPPS 2018. Aten Primaria. 2018 May;50 Suppl 1:109-124. doi: 10.1016/S0212-6567(18)30365-2. Spanish.","\tAging|Physical Activity|Physiotherapy|Vestibular Disorder\tmulti component exercise|vestibular exercise\tParallel Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement","Interventional","Not yet recruiting","N/A",2,90,"vestibular diseases","NA","NA"]
["NCT04895137","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28159490|25539810|28734760|32698790|33189037|29398921|32358699|33282742|32824490|32514802|27389519|33607964","Scott E. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Department of Medicine; Department of Biostatistics and Computational Biology; Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston; Johns Hopkins University, Baltimore; University of Wisconsin Carbone Cancer Center; School of Medicine and Public Health; Madison; Fox Chase Cancer Center, Temple University Health System, Philadelphia; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis; Mayo Clinic, Rochester, MN; University Hospitals Case Medical Center, Seidman Cancer Center; Cleveland Clinic Taussig Cancer Institute; Both in Cleveland; University of Virginia Cancer Center, Charlottesville; Comprehensive Cancer Centers of Nevada, Las Vegas; Siteman Cancer Center, Washington University School of Medicine, St. Louis; NorthShore University Health System, Evanston, IL; University of Michigan Comprehensive Cancer Center, Ann Arbor; Rutgers Cancer Institute of New Jersey, New Brunswick.N Engl J Med. 2015 Aug 20;373(8):737-46. [Epub 2015 Aug 5]. doi: 10.1056/NEJMoa1503747. Urol Oncol. 2017 Mar;35(3):123. doi: 10.1016/j.urolonc.2016.12.021. Epub 2017 Feb 1.|Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol. 2015 Feb 1;194(3):950-9. doi: 10.4049/jimmunol.1401686. Epub 2014 Dec 24.|Sclafani F. PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer. Lancet Oncol. 2017 Sep;18(9):1141-1142. doi: 10.1016/S1470-2045(17)30512-0. Epub 2017 Jul 19.|Antoniotti C, Borelli B, Rossini D, Pietrantonio F, Morano F, Salvatore L, Lonardi S, Marmorino F, Tamberi S, Corallo S, Tortora G, Bergamo F, Brunella DS, Boccaccino A, Grassi E, Racca P, Tamburini E, Aprile G, Moretto R, Boni L, Falcone A, Cremolini C. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. BMC Cancer. 2020 Jul 22;20(1):683. doi: 10.1186/s12885-020-07169-6.|Bolhuis K, Kos M, van Oijen MGH, Swijnenburg RJ, Punt CJA. Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review. Eur J Cancer. 2020 Dec;141:225-238. doi: 10.1016/j.ejca.2020.09.037. Epub 2020 Nov 12.|Chang H, Yu X, Xiao WW, Wang QX, Zhou WH, Zeng ZF, Ding PR, Li LR, Gao YH. Neoadjuvant chemoradiotherapy followed by surgery in patients with unresectable locally advanced colon cancer: a prospective observational study. Onco Targets Ther. 2018 Jan 17;11:409-418. doi: 10.2147/OTT.S150367. eCollection 2018.|Kim SA, Kim JW, Suh KJ, Chang W, Kim JW, Oh HK, Cho JY, Kim DW, Cho S, Kim JH, Kim K, Kang SB, Jheon S, Lee KW. Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases. J Cancer Res Clin Oncol. 2020 Sep;146(9):2399-2410. doi: 10.1007/s00432-020-03233-7. Epub 2020 May 1.|Li J, Cong L, Liu J, Peng L, Wang J, Feng A, Yue J, Li L, Wang X, Wang X. The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study. Front Oncol. 2020 Nov 12;10:594125. doi: 10.3389/fonc.2020.594125. eCollection 2020.|Marmorino F, Boccaccino A, Germani MM, Falcone A, Cremolini C. Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge. Cancers (Basel). 2020 Aug 17;12(8). pii: E2317. doi: 10.3390/cancers12082317. Review.|Mise Y, Hasegawa K, Saiura A, Oba M, Yamamoto J, Nomura Y, Takayama T, Hashiguchi Y, Shibasaki M, Sakamoto H, Yamagata S, Aoyanagi N, Kaneko H, Koyama H, Miyagawa S, Shinozaki E, Yoshida S, Nozawa H, Kokudo N. A Multicenter Phase 2 Trial to Evaluate the Efficacy of mFOLFOX6 + Cetuximab as Induction Chemotherapy to Achieve R0 Surgical Resection for Advanced Colorectal Liver Metastases (NEXTO Trial). Ann Surg Oncol. 2020 Oct;27(11):4188-4195. doi: 10.1245/s10434-020-08627-y. Epub 2020 Jun 8.|Qiu B, Ding PR, Cai L, Xiao WW, Zeng ZF, Chen G, Lu ZH, Li LR, Wu XJ, Mirimanoff RO, Pan ZZ, Xu RH, Gao YH. Outcomes of preoperative chemoradiotherapy followed by surgery in patients with unresectable locally advanced sigmoid colon cancer. Chin J Cancer. 2016 Jul 7;35(1):65. doi: 10.1186/s40880-016-0126-y.|Yuan Y, Xiao WW, Xie WH, Cai PQ, Wang QX, Chang H, Chen BQ, Zhou WH, Zeng ZF, Wu XJ, Liu Q, Li LR, Zhang R, Gao YH. Neoadjuvant chemoradiotherapy for patients with unresectable radically locally advanced colon cancer: a potential improvement to overall survival and decrease to multivisceral resection. BMC Cancer. 2021 Feb 19;21(1):179. doi: 10.1186/s12885-021-07894-6.","\tColorectal Cancer|Immunotherapy\tmFOLFOX6+Bevacizumab+PD-1 monoclonal antibody treatment combinations\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","colorectal neoplasms","bevacizumab|antibodies|antibodies, monoclonal","NA"]
["NCT04895878","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","25916811|31720749|16996579","Guellec D, Cornec-Le Gall E, Groh M, Hachulla E, Karras A, Charles P, Dunogué B, Abad S, Alvarez F, Gérard F, Devauchelle-Pensec V, Pers JO, Puéchal X, Guillevin L, Saraux A, Cornec D; CRI (Club Rhumatismes et Inflammation) and the French Vasculitis Study Group. ANCA-associated vasculitis in patients with primary Sjögren's syndrome: detailed analysis of 7 new cases and systematic literature review. Autoimmun Rev. 2015 Aug;14(8):742-50. doi: 10.1016/j.autrev.2015.04.009. Epub 2015 Apr 24. Review.|Lee SB, Choi H, Kim MK, Jung SM, Song JJ, Park YB, Lee SW. Can antineutrophil cytoplasmic antibody positivity at diagnosis predict the poor outcomes of Sjögren's syndrome? Rheumatol Int. 2020 Jul;40(7):1063-1070. doi: 10.1007/s00296-019-04476-5. Epub 2019 Nov 12.|Ramos-Casals M, Brito-Zerón P, Font J. The overlap of Sjögren's syndrome with other systemic autoimmune diseases. Semin Arthritis Rheum. 2007 Feb;36(4):246-55. Epub 2006 Sep 22. Review.","\tANCA Associated Vasculitis|Sjogren's Syndrome\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","anti-neutrophil cytoplasmic antibody-associated vasculitis|sjogren's syndrome|vasculitis|syndrome","NA","NA"]
["NCT04895904","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","22688850|23732464|31634917|29671413|31785733","Laine L, Yang H, Chang SC, Datto C. Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009. Am J Gastroenterol. 2012 Aug;107(8):1190-5; quiz 1196. doi: 10.1038/ajg.2012.168. Epub 2012 Jun 12.|Rosenstock SJ, Møller MH, Larsson H, Johnsen SP, Madsen AH, Bendix J, Adamsen S, Jensen AG, Zimmermann-Nielsen E, Nielsen AS, Kallehave F, Oxholm D, Skarbye M, Jølving LR, Jørgensen HS, Schaffalitzky de Muckadell OB, Thomsen RW. Improving quality of care in peptic ulcer bleeding: nationwide cohort study of 13,498 consecutive patients in the Danish Clinical Register of Emergency Surgery. Am J Gastroenterol. 2013 Sep;108(9):1449-57. doi: 10.1038/ajg.2013.162. Epub 2013 Jun 4.|Barkun AN, Almadi M, Kuipers EJ, Laine L, Sung J, Tse F, Leontiadis GI, Abraham NS, Calvet X, Chan FKL, Douketis J, Enns R, Gralnek IM, Jairath V, Jensen D, Lau J, Lip GYH, Loffroy R, Maluf-Filho F, Meltzer AC, Reddy N, Saltzman JR, Marshall JK, Bardou M. Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group. Ann Intern Med. 2019 Dec 3;171(11):805-822. doi: 10.7326/M19-1795. Epub 2019 Oct 22.|Lanas A, Dumonceau JM, Hunt RH, Fujishiro M, Scheiman JM, Gralnek IM, Campbell HE, Rostom A, Villanueva C, Sung JJY. Non-variceal upper gastrointestinal bleeding. Nat Rev Dis Primers. 2018 Apr 19;4:18020. doi: 10.1038/nrdp.2018.20. Review.|Cañamares-Orbís P, Chan FKL. Endoscopic management of nonvariceal upper gastrointestinal bleeding. Best Pract Res Clin Gastroenterol. 2019 Oct - Dec;42-43:101608. doi: 10.1016/j.bpg.2019.04.001. Epub 2019 Apr 17. Review.","\tAcute Upper Gastrointestinal Non Variceal Hemorrhage\tNo intervention\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","gastrointestinal hemorrhage|hemorrhage","NA","NA"]
["NCT04896528","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","17825602|12506176|19446902|10758304|15254053|27688097|24613543","Lingen MW, Kalmar JR, Karrison T, Speight PM. Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol. 2008 Jan;44(1):10-22. Epub 2007 Sep 6. Review.|Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003 Jan 1;21(1):92-8.|Pignon JP, le Maître A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009 Jul;92(1):4-14. doi: 10.1016/j.radonc.2009.04.014. Epub 2009 May 14.|Suntharalingam M, Haas ML, Conley BA, Egorin MJ, Levy S, Sivasailam S, Herman JM, Jacobs MC, Gray WC, Ord RA, Aisner JA, Van Echo DA. The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):49-56.|Garden AS, Harris J, Vokes EE, Forastiere AA, Ridge JA, Jones C, Horwitz EM, Glisson BS, Nabell L, Cooper JS, Demas W, Gore E. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol. 2004 Jul 15;22(14):2856-64.|Adkins D, Ley J, Michel L, Wildes TM, Thorstad W, Gay HA, Daly M, Rich J, Paniello R, Uppaluri R, Jackson R, Trinkaus K, Nussenbaum B. nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma. Oral Oncol. 2016 Oct;61:1-7. doi: 10.1016/j.oraloncology.2016.07.015. Epub 2016 Jul 29.|Reddy BK, Lokesh V, Vidyasagar MS, Shenoy K, Babu KG, Shenoy A, Naveen T, Joseph B, Bonanthaya R, Nanjundappa, Bapsy PP, Loknatha, Shetty J, Prasad K, Tanvir Pasha CR. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients. Oral Oncol. 2014 May;50(5):498-505. doi: 10.1016/j.oraloncology.2013.11.008. Epub 2014 Mar 6.","\tAvatrombopag|Thrombocytopenia\tAvatrombopag\tNA\tNA\tNA\tDrug\tAll\t","NA","NA","NA","NA","NA","NA","thrombocytopenia","NA","NA"]
["NCT04896918","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",32109013,"Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.","\tCovid19\tTobacco use\tNA\tNA\tNA\tBehavioral\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04897204","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","12968085|27871122|25946280|27788847|29342299|32743641|30502771|25399274|27343417|32669982|27406602|28340073","Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003 Sep 11;349(11):1019-26.|Nyong J, Amit G, Adler AJ, Owolabi OO, Perel P, Prieto-Merino D, Lambiase P, Casas JP, Morillo CA. Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation. Cochrane Database Syst Rev. 2016 Nov 22;11:CD012088. Review.|Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, Macle L, Morillo CA, Haverkamp W, Weerasooriya R, Albenque JP, Nardi S, Menardi E, Novak P, Sanders P; STAR AF II Investigators. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015 May 7;372(19):1812-22. doi: 10.1056/NEJMoa1408288.|Di Biase L, Burkhardt JD, Mohanty P, Mohanty S, Sanchez JE, Trivedi C, Güneş M, Gökoğlan Y, Gianni C, Horton RP, Themistoclakis S, Gallinghouse GJ, Bailey S, Zagrodzky JD, Hongo RH, Beheiry S, Santangeli P, Casella M, Dello Russo A, Al-Ahmad A, Hranitzky P, Lakkireddy D, Tondo C, Natale A. Left Atrial Appendage Isolation in Patients With Longstanding Persistent AF Undergoing Catheter Ablation: BELIEF Trial. J Am Coll Cardiol. 2016 Nov 1;68(18):1929-1940. doi: 10.1016/j.jacc.2016.07.770.|Romero J, Michaud GF, Avendano R, Briceño DF, Kumar S, Carlos Diaz J, Mohanty S, Trivedi C, Gianni C, Della Rocca D, Proietti R, Perrotta L, Bordignon S, Chun JKR, Schmidt B, Garcia M, Natale A, Di Biase L. Benefit of left atrial appendage electrical isolation for persistent and long-standing persistent atrial fibrillation: a systematic review and meta-analysis. Europace. 2018 Aug 1;20(8):1268-1278. doi: 10.1093/europace/eux372.|Fink T, Ouyang F, Heeger CH, Sciacca V, Reissmann B, Keelani A, Schütte C, Wohlmuth P, Maurer T, Rottner L, Eitel C, Eitel I, Rillig A, Metzner A, Kuck KH, Tilz RR, Vogler J. Management of thrombus formation after electrical isolation of the left atrial appendage in patients with atrial fibrillation. Europace. 2020 Sep 1;22(9):1358-1366. doi: 10.1093/europace/euaa174.|Kim YG, Shim J, Oh SK, Lee KN, Choi JI, Kim YH. Electrical isolation of the left atrial appendage increases the risk of ischemic stroke and transient ischemic attack regardless of postisolation flow velocity. Heart Rhythm. 2018 Dec;15(12):1746-1753. doi: 10.1016/j.hrthm.2018.09.012.|Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, Huber K, Whisenant B, Kar S, Swarup V, Gordon N, Holmes D; PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014 Nov 19;312(19):1988-98. doi: 10.1001/jama.2014.15192. Erratum in: JAMA. 2015 Mar 10;313(10):1061.|Belgaid DR, Khan Z, Zaidi M, Hobbs A. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: The PREVAIL trial. Int J Cardiol. 2016 Sep 15;219:177-9. doi: 10.1016/j.ijcard.2016.06.041. Epub 2016 Jun 15. Review.|Mo BF, Sun J, Zhang PP, Li W, Chen M, Yuan JL, Yu Y, Wang QS, Li YG. Combined Therapy of Catheter Ablation and Left Atrial Appendage Closure for Patients with Atrial Fibrillation: A Case-Control Study. J Interv Cardiol. 2020 Jun 25;2020:8615410. doi: 10.1155/2020/8615410. eCollection 2020.|Panikker S, Jarman JW, Virmani R, Kutys R, Haldar S, Lim E, Butcher C, Khan H, Mantziari L, Nicol E, Foran JP, Markides V, Wong T. Left Atrial Appendage Electrical Isolation and Concomitant Device Occlusion to Treat Persistent Atrial Fibrillation: A First-in-Human Safety, Feasibility, and Efficacy Study. Circ Arrhythm Electrophysiol. 2016 Jul;9(7). pii: e003710. doi: 10.1161/CIRCEP.115.003710.|Yorgun H, Canpolat U, Kocyigit D, Çöteli C, Evranos B, Aytemir K. Left atrial appendage isolation in addition to pulmonary vein isolation in persistent atrial fibrillation: one-year clinical outcome after cryoballoon-based ablation. Europace. 2017 May 1;19(5):758-768. doi: 10.1093/europace/eux005.","\tAtrial Fibrillation|Catheter Ablation|Left Atrial Appendage|Left Atrial Appendage Occlusion\tCatheter ablation and left atrial appendage occlusion|Additional left atrial appendage electrical isolation combined with catheter ablation and left atrial appendage occlusion\tParallel Assignment\tTreatment\tRandomized\tProcedure|Procedure\tAll\t","Left Atrial Appendage Electrical Isolation in Persistent Atrial Fibrillation","Interventional","Not yet recruiting","N/A",2,120,"atrial fibrillation","NA","NA"]
["NCT04898959","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26890426|32039869|31354251|31210649","Alghwiri AA, Alghadir AH, Al-Momani MO, Whitney SL. The activities-specific balance confidence scale and berg balance scale: Reliability and validity in Arabic-speaking vestibular patients. J Vestib Res. 2016;25(5-6):253-9. doi: 10.3233/VES-160568.|Alghwiri AA, Khalil H, Al-Sharman A, El-Salem K. Psychometric properties of the Arabic Activities-specific Balance Confidence scale in people with multiple sclerosis: Reliability, validity, and minimal detectable change. NeuroRehabilitation. 2020;46(1):119-125. doi: 10.3233/NRE-192900.|Elboim-Gabyzon M, Agmon M, Azaiza F. Psychometric properties of the Arabic version of the Activities-Specific Balance Confidence (ABC) scale in ambulatory, community-dwelling, elderly people. Clin Interv Aging. 2019 Jun 18;14:1075-1084. doi: 10.2147/CIA.S194777. eCollection 2019.|Burger H, Giordano A, Bavec A, Franchignoni F. The Prosthetic Mobility Questionnaire, a tool for assessing mobility in people with lower-limb amputation: validation of PMQ 2.0 in Slovenia. Int J Rehabil Res. 2019 Sep;42(3):263-269. doi: 10.1097/MRR.0000000000000354.","\tFilling Out Questionnaires\tFilling out Questionaire\tNA\tNA\tNA\tOther\tAll\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04899375","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28950149|28855793|NA|NA","Driller M, Mackay K, Mills B, Tavares F. Tissue flossing on ankle range of motion, jump and sprint performance: A follow-up study. Phys Ther Sport. 2017 Nov;28:29-33. doi: 10.1016/j.ptsp.2017.08.081. Epub 2017 Aug 24.|Borda J, Selhorst M. The use of compression tack and flossing along with lacrosse ball massage to treat chronic Achilles tendinopathy in an adolescent athlete: a case report. J Man Manip Ther. 2017 Feb;25(1):57-61. doi: 10.1080/10669817.2016.1159403. Epub 2016 May 30.|Arce-Esquivel AA, Cage SA, Warner BJ, Stevenson P. Flossing bands to treat keinböck's disease in a collegiate men's basketball player: a case report. International Physical Medicine & Rehabilitation Journal. 2018;3(2).|Kiefer BN, Lemarr KE, Enriquez CC, Tivener KA, Daniel T. A Pilot Study: Perceptual Effects of the Voodoo Floss Band on Glenohumeral Flexibility. International Journal of Athletic Therapy and Training. 2017;22(4):29-33.","\tElbow Tendinopathy\tFloss band|ACE bandage\tNA\tNA\tNA\tDevice|Device\tAll\t","NA","NA","NA","NA","NA","NA","elbow tendinopathy|tendinopathy","NA","NA"]
["NCT04899700","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30635409|31711241|21392504|29539651","Kandel P, Brand EC, Pelt J, Ball CT, Chen WC, Bouras EP, Gomez V, Raimondo M, Woodward TA, Wallace MB; EMR SCAR Group. Endoscopic scar assessment after colorectal endoscopic mucosal resection scars: when is biopsy necessary (EMR Scar Assessment Project for Endoscope (ESCAPE) trial). Gut. 2019 Sep;68(9):1633-1641. doi: 10.1136/gutjnl-2018-316574. Epub 2019 Jan 11.|Bisschops R, East JE, Hassan C, Hazewinkel Y, Kamiński MF, Neumann H, Pellisé M, Antonelli G, Bustamante Balen M, Coron E, Cortas G, Iacucci M, Yuichi M, Longcroft-Wheaton G, Mouzyka S, Pilonis N, Puig I, van Hooft JE, Dekker E. Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2019. Endoscopy. 2019 Dec;51(12):1155-1179. doi: 10.1055/a-1031-7657. Epub 2019 Nov 11. Erratum in: Endoscopy. 2019 Dec;51(12):C6.|Moss A, Bourke MJ, Williams SJ, Hourigan LF, Brown G, Tam W, Singh R, Zanati S, Chen RY, Byth K. Endoscopic mucosal resection outcomes and prediction of submucosal cancer from advanced colonic mucosal neoplasia. Gastroenterology. 2011 Jun;140(7):1909-18. doi: 10.1053/j.gastro.2011.02.062. Epub 2011 Mar 8.|Paggi S, Mogavero G, Amato A, Rondonotti E, Andrealli A, Imperiali G, Lenoci N, Mandelli G, Terreni N, Conforti FS, Conte D, Spinzi G, Radaelli F. Linked color imaging reduces the miss rate of neoplastic lesions in the right colon: a randomized tandem colonoscopy study. Endoscopy. 2018 Apr;50(4):396-402. doi: 10.1055/a-0580-7405. Epub 2018 Mar 14.","\tPolyp of Colon\tLinked Color Imaging|White light endoscopy\tCrossover Assignment\tDiagnostic\tRandomized\tDevice|Other\tAll\t","Linked Color Imaging Versus White Light Endoscopy for the Evaluation of Scars of Non-pedunculated Polyps. LCI Scar Study.","Interventional","Not yet recruiting","N/A",2,160,"colonic polyps|polyps","NA","NA"]
["NCT04900129","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27344959,"de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016 Aug;14(8):523-34. doi: 10.1038/nrmicro.2016.81. Epub 2016 Jun 27. Review.","\tCovid19\tMenthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm%\tParallel Assignment\tTreatment\tRandomized\tCombination Product\tAll\t","Inhalation of Vapor With Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study","Interventional","Completed","Phase 1",2,43,"respiratory aspiration","methyl salicylate|menthol|n-monoacetylcystine|diclofenac|salicylates|acetylcysteine","NA"]
["NCT04900181","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24740658|28244911|28055062|25680450|31286577","Kurtz SM, Ong KL, Lau E, Bozic KJ. Impact of the economic downturn on total joint replacement demand in the United States: updated projections to 2021. J Bone Joint Surg Am. 2014 Apr 16;96(8):624-30. doi: 10.2106/JBJS.M.00285.|Molloy IB, Martin BI, Moschetti WE, Jevsevar DS. Effects of the Length of Stay on the Cost of Total Knee and Total Hip Arthroplasty from 2002 to 2013. J Bone Joint Surg Am. 2017 Mar 1;99(5):402-407. doi: 10.2106/JBJS.16.00019.|Navathe AS, Troxel AB, Liao JM, Nan N, Zhu J, Zhong W, Emanuel EJ. Cost of Joint Replacement Using Bundled Payment Models. JAMA Intern Med. 2017 Feb 1;177(2):214-222. doi: 10.1001/jamainternmed.2016.8263.|Doran JP, Zabinski SJ. Bundled payment initiatives for Medicare and non-Medicare total joint arthroplasty patients at a community hospital: bundles in the real world. J Arthroplasty. 2015 Mar;30(3):353-5. doi: 10.1016/j.arth.2015.01.035. Epub 2015 Jan 23.|Zeng JQ. The pilot results of 47 148 cases of BJ-DRGs-based payment in China. Int J Health Plann Manage. 2019 Oct;34(4):1386-1398. doi: 10.1002/hpm.2818. Epub 2019 Jul 8.","\tHip Arthropathy\tthe same-day discharge surgery\tParallel Assignment\tTreatment\tRandomized\tProcedure\tAll\t","Analysis of the Cost-Effectiveness of Same-day Discharge Surgery for Primary Total Hip Arthroplasty","Interventional","Recruiting","N/A",2,84,"joint diseases","NA","NA"]
["NCT04900194","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32923929|18507718","Nezamnia M, Iravani M, Bargard MS, Latify M. Effectiveness of cognitive-behavioral therapy on sexual function and sexual self-efficacy in pregnant women: An RCT. Int J Reprod Biomed. 2020 Aug 19;18(8):625-636. doi: 10.18502/ijrm.v13i8.7504. eCollection 2020 Aug.|Brotto LA, Basson R, Luria M. A mindfulness-based group psychoeducational intervention targeting sexual arousal disorder in women. J Sex Med. 2008 Jul;5(7):1646-59. doi: 10.1111/j.1743-6109.2008.00850.x.","\tCounseling\tmindfulness-based sexual counseling\tParallel Assignment\tPrevention\tRandomized\tBehavioral\tFemale\t","The Effect of Mindfulness-based Sexual Counseling on Sexual Distress in Pregnant Women","Interventional","Completed","N/A",2,134,"NA","NA","NA"]
["NCT04900285","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16772315|24242702|11398550|26094920","Cooke ME, Battagel JM. A thermoplastic mandibular advancement device for the management of non-apnoeic snoring: a randomized controlled trial. Eur J Orthod. 2006 Aug;28(4):327-38. Epub 2006 Jun 13.|Deeb R, Judge P, Peterson E, Lin JC, Yaremchuk K. Snoring and carotid artery intima-media thickness. Laryngoscope. 2014 Jun;124(6):1486-91. doi: 10.1002/lary.24527. Epub 2014 Jan 28.|Johnston CD, Gleadhill IC, Cinnamond MJ, Peden WM. Oral appliances for the management of severe snoring: a randomized controlled trial. Eur J Orthod. 2001 Apr;23(2):127-34.|Ramar K, Dort LC, Katz SG, Lettieri CJ, Harrod CG, Thomas SM, Chervin RD. Clinical Practice Guideline for the Treatment of Obstructive Sleep Apnea and Snoring with Oral Appliance Therapy: An Update for 2015. J Clin Sleep Med. 2015 Jul 15;11(7):773-827. doi: 10.5664/jcsm.4858. Review.","\tSnoring\tDelta Dental Oral Device\tNA\tNA\tNA\tDevice\tAll\t","NA","NA","NA","NA","NA","NA","snoring","NA","NA"]
["NCT04900610","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32196451|30717170|32391368|30689181|29561783|32899022|31401878","Roumeliotis S, Roumeliotis A, Dounousi E, Eleftheriadis T, Liakopoulos V. Vitamin K for the Treatment of Cardiovascular Disease in End-Stage Renal Disease Patients: Is there Hope? Curr Vasc Pharmacol. 2021;19(1):77-90. doi: 10.2174/1570161118666200320111745.|Roumeliotis S, Dounousi E, Eleftheriadis T, Liakopoulos V. Association of the Inactive Circulating Matrix Gla Protein with Vitamin K Intake, Calcification, Mortality, and Cardiovascular Disease: A Review. Int J Mol Sci. 2019 Feb 1;20(3). pii: E628. doi: 10.3390/ijms20030628. Review.|Roumeliotis S, Dounousi E, Salmas M, Eleftheriadis T, Liakopoulos V. Vascular Calcification in Chronic Kidney Disease: The Role of Vitamin K- Dependent Matrix Gla Protein. Front Med (Lausanne). 2020 Apr 24;7:154. doi: 10.3389/fmed.2020.00154. eCollection 2020. Review.|Xu Q, Guo H, Cao S, Zhou Q, Chen J, Su M, Chen S, Jiang S, Shi X, Wen Y. Associations of vitamin K status with mortality and cardiovascular events in peritoneal dialysis patients. Int Urol Nephrol. 2019 Mar;51(3):527-534. doi: 10.1007/s11255-019-02080-x. Epub 2019 Jan 28.|Peeters FECM, van Mourik MJW, Meex SJR, Bucerius J, Schalla SM, Gerretsen SC, Mihl C, Dweck MR, Schurgers LJ, Wildberger JE, Crijns HJGM, Kietselaer BLJH. Bicuspid Aortic Valve Stenosis and the Effect of Vitamin K2 on Calcification Using (18)F-Sodium Fluoride Positron Emission Tomography/Magnetic Resonance: The BASIK2 Rationale and Trial Design. Nutrients. 2018 Mar 21;10(4). pii: E386. doi: 10.3390/nu10040386.|Haroon SW, Tai BC, Ling LH, Teo L, Davenport A, Schurgers L, Teo BW, Khatri P, Ong CC, Low S, Yeo XE, Tan JN, Subramanian S, Chua HR, Tan SY, Wong WK, Lau TW. Treatment to reduce vascular calcification in hemodialysis patients using vitamin K (Trevasc-HDK): A study protocol for a randomized controlled trial. Medicine (Baltimore). 2020 Sep 4;99(36):e21906. doi: 10.1097/MD.0000000000021906.|Vaios V, Georgianos PI, Vareta G, Dounousi E, Dimitriadis C, Eleftheriadis T, Papagianni A, Zebekakis PE, Liakopoulos V. Clinic and Home Blood Pressure Monitoring for the Detection of Ambulatory Hypertension Among Patients on Peritoneal Dialysis. Hypertension. 2019 Oct;74(4):998-1004. doi: 10.1161/HYPERTENSIONAHA.119.13443. Epub 2019 Aug 12.","\tArterial Stiffness|Cardiovascular Morbidity|End Stage Renal Disease|Mortality|Peritoneal Dialysis|Vitamin K Deficiency\tMenaQ7 ®, Nattopharma, ASA, Hovik, Norway\tParallel Assignment\tTreatment\tRandomized\tDietary Supplement\tAll\t","The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis","Interventional","Not yet recruiting","N/A",2,120,"kidney diseases|kidney failure, chronic|vitamin k deficiency","NA","NA"]
["NCT04900649","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16567174|19961637","Lally KP, Bagolan P, Hosie S, Lally PA, Stewart M, Cotten CM, Van Meurs KP, Alexander G; Congenital Diaphragmatic Hernia Study Group. Corticosteroids for fetuses with congenital diaphragmatic hernia: can we show benefit? J Pediatr Surg. 2006 Apr;41(4):668-74; discussion 668-74.|Malaguti C, Rondelli RR, de Souza LM, Domingues M, Dal Corso S. Reliability of chest wall mobility and its correlation with pulmonary function in patients with chronic obstructive pulmonary disease. Respir Care. 2009 Dec;54(12):1703-11.","\tHernias, Diaphragmatic, Congenital\tchest resistance exercise|chest expansion exercises\tParallel Assignment\tTreatment\tRandomized\tOther|Other\tAll\t","Resistance Exercise in Children With Post-operative Congenital Diaphragmatic Hernia","Interventional","Completed","N/A",2,32,"hernia|hernia, diaphragmatic|hernias, diaphragmatic, congenital","NA","NA"]
["NCT04900987","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA",27308241,"Farahvash MR, Khorasani G, Mahdiani Y, Taheri AR. The Effect of Steri-Strip Dressing on Patients' Satisfaction and Reduction of Ecchymosis in Lower Eyelid, Malar and Cheek Following Rhinoplasty. World J Plast Surg. 2016 Jan;5(1):51-7.","\tAcute Coronary Syndrome|Requiring Left Heart Catheterization Via Radial Route\tSteri-strips\tParallel Assignment\tPrevention\tRandomized\tDevice\tAll\t","Steri-strips for Reducing Radial Artery Compression Duration","Interventional","Recruiting","N/A",2,200,"acute coronary syndrome","NA","NA"]
["NCT04901949","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23100216|28719397|21927663","Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013 Jan;62(1):102-11. doi: 10.1136/gutjnl-2012-302779. Epub 2012 Oct 25.|Khatua B, El-Kurdi B, Singh VP. Obesity and pancreatitis. Curr Opin Gastroenterol. 2017 Sep;33(5):374-382. doi: 10.1097/MOG.0000000000000386. Review.|Shin KY, Lee WS, Chung DW, Heo J, Jung MK, Tak WY, Kweon YO, Cho CM. Influence of obesity on the severity and clinical outcome of acute pancreatitis. Gut Liver. 2011 Sep;5(3):335-9. doi: 10.5009/gnl.2011.5.3.335. Epub 2011 Aug 18.","\tAcute Pancreatitis|Body Weight|Obesity\tNA\tNA\tNA\tNA\tNA\tAll\t","NA","NA","NA","NA","NA","NA","body weight|pancreatitis","NA","NA"]
["NCT04902716","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","32099853|31291884|29346524|32357858|28064173","Fu MR, Kurnat-Thoma E, Starkweather A, Henderson WA, Cashion AK, Williams JK, Katapodi MC, Reuter-Rice K, Hickey KT, Barcelona de Mendoza V, Calzone K, Conley YP, Anderson CM, Lyon DE, Weaver MT, Shiao PK, Constantino RE, Wung SF, Hammer MJ, Voss JG, Coleman B. Precision health: A nursing perspective. Int J Nurs Sci. 2019 Dec 24;7(1):5-12. doi: 10.1016/j.ijnss.2019.12.008. eCollection 2020 Jan 10. Review. Erratum in: Int J Nurs Sci. 2020 Dec 06;8(1):III.|Kidd T, Mold F, Jones C, Ream E, Grosvenor W, Sund-Levander M, Tingström P, Carey N. What are the most effective interventions to improve physical performance in pre-frail and frail adults? A systematic review of randomised control trials. BMC Geriatr. 2019 Jul 11;19(1):184. doi: 10.1186/s12877-019-1196-x.|Romera-Liebana L, Orfila F, Segura JM, Real J, Fabra ML, Möller M, Lancho S, Ramirez A, Marti N, Cullell M, Bastida N, Martinez D, Giné M, Cendrós P, Bistuer A, Perez E, Fabregat MA, Foz G. Effects of a Primary Care-Based Multifactorial Intervention on Physical and Cognitive Function in Frail, Elderly Individuals: A Randomized Controlled Trial. J Gerontol A Biol Sci Med Sci. 2018 Nov 10;73(12):1688-1674. doi: 10.1093/gerona/glx259.|Wang WL, Chen KH, Pan YC, Yang SN, Chan YY. The effect of yoga on sleep quality and insomnia in women with sleep problems: a systematic review and meta-analysis. BMC Psychiatry. 2020 May 1;20(1):195. doi: 10.1186/s12888-020-02566-4.|Puts MTE, Toubasi S, Andrew MK, Ashe MC, Ploeg J, Atkinson E, Ayala AP, Roy A, Rodríguez Monforte M, Bergman H, McGilton K. Interventions to prevent or reduce the level of frailty in community-dwelling older adults: a scoping review of the literature and international policies. Age Ageing. 2017 May 1;46(3):383-392. doi: 10.1093/ageing/afw247. Review.","\tThe Effectiveness of Precision Nursing Intervention Program on Cognitive Function、Sleep Quality and Emotional State of Frail Femal Elderly in the Community\tDesign course\tNA\tNA\tNA\tBehavioral\tFemale\t","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04903028","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","23485014|32534252","Li X, Hartwell KJ, Owens M, Lematty T, Borckardt JJ, Hanlon CA, Brady KT, George MS. Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex reduces nicotine cue craving. Biol Psychiatry. 2013 Apr 15;73(8):714-20. doi: 10.1016/j.biopsych.2013.01.003. Epub 2013 Feb 26.|Li X, Hartwell KJ, Henderson S, Badran BW, Brady KT, George MS. Two weeks of image-guided left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation improves smoking cessation: A double-blind, sham-controlled, randomized clinical trial. Brain Stimul. 2020 Sep - Oct;13(5):1271-1279. doi: 10.1016/j.brs.2020.06.007. Epub 2020 Jun 10.","\tCigarette Smoking|Tobacco Use\tActive rTMS 1 Hz mOFC|Sham rTMS|Active rTMS 10 Hz DLPFC\tParallel Assignment\tTreatment\tRandomized\tDevice|Device|Device\tAll\t","RTMS Targets Neural Circuits for Smoking Cessation","Interventional","Recruiting","Phase 1/Phase 2",3,45,"NA","NA","NA"]
["NCT04926662","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","30603075|30447104|30105393|28118039|28978564","Bhatt S, Isaac R, Finkel M, Evans J, Grant L, Paul B, Weller D. Mobile technology and cancer screening: Lessons from rural India. J Glob Health. 2018 Dec;8(2):020421. doi: 10.7189/jogh.08.020421.|Vang S, Margolies LR, Jandorf L. Mobile Mammography Participation Among Medically Underserved Women: A Systematic Review. Prev Chronic Dis. 2018 Nov 15;15:E140. doi: 10.5888/pcd15.180291.|Brenner AT, Malo TL, Margolis M, Elston Lafata J, James S, Vu MB, Reuland DS. Evaluating Shared Decision Making for Lung Cancer Screening. JAMA Intern Med. 2018 Oct 1;178(10):1311-1316. doi: 10.1001/jamainternmed.2018.3054.|Atkins GT, Kim T, Munson J. Residence in Rural Areas of the United States and Lung Cancer Mortality. Disease Incidence, Treatment Disparities, and Stage-Specific Survival. Ann Am Thorac Soc. 2017 Mar;14(3):403-411. doi: 10.1513/AnnalsATS.201606-469OC.|Greenwald ZR, El-Zein M, Bouten S, Ensha H, Vazquez FL, Franco EL. Mobile Screening Units for the Early Detection of Cancer: A Systematic Review. Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1679-1694. doi: 10.1158/1055-9965.EPI-17-0454. Epub 2017 Oct 4. Review.","The purpose of this study is to research patient preferences for lung cancer screening and pilot mobile units to address the barrier of access that decreases participation in lung cancer screening.","Lung Cancer","NA","NA","NA","NA","NA","All","Inclusion Criteria:\tNA\tNA\tNA\tNA\tNA\tNA\tlung neoplasms\tNA\tNA\nNCT04932356\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t9794328|23701944|26110131|23193208|12663564|22356525|24528195|20144303|23497735|25526482|25319572|26330299\tEdmonds M, Bauer M, Osborn S, Lutfiyya H, Mahon J, Doig G, Grundy P, Gittens C, Molenkamp G, Fenlon D. Using the Vista 350 telephone to communicate the results of home monitoring of diabetes mellitus to a central database and to provide feedback. Int J Med Inform. 1998 Aug-Sep;51(2-3):117-25.|Dennis SM, Harris M, Lloyd J, Powell Davies G, Faruqi N, Zwar N. Do people with existing chronic conditions benefit from telephone coaching? A rapid review. Aust Health Rev. 2013 Jun;37(3):381-8. doi: 10.1071/AH13005. Review.|Kaur R, Kajal KS, Kaur A, Singh P. Telephonic Consultation and follow-up in Diabetics: Impact on Metabolic Profile, Quality of Life, and Patient Compliance. N Am J Med Sci. 2015 May;7(5):199-207. doi: 10.4103/1947-2714.157483.|Munshi MN, Segal AR, Suhl E, Ryan C, Sternthal A, Giusti J, Lee Y, Fitzgerald S, Staum E, Bonsignor P, DesRochers L, McCartney R, Weinger K. Assessment of barriers to improve diabetes management in older adults: a randomized controlled study. Diabetes Care. 2013 Mar;36(3):543-9. doi: 10.2337/dc12-1303. Epub 2012 Nov 27.|Izquierdo RE, Knudson PE, Meyer S, Kearns J, Ploutz-Snyder R, Weinstock RS. A comparison of diabetes education administered through telemedicine versus in person. Diabetes Care. 2003 Apr;26(4):1002-7.|Holtz B, Lauckner C. Diabetes management via mobile phones: a systematic review. Telemed J E Health. 2012 Apr;18(3):175-84. doi: 10.1089/tmj.2011.0119. Epub 2012 Feb 22. Review.|Esmatjes E, Jansà M, Roca D, Pérez-Ferre N, del Valle L, Martínez-Hervás S, Ruiz de Adana M, Linares F, Batanero R, Vázquez F, Gomis R, de Solà-Morales O; Telemed-Diabetes Group. The efficiency of telemedicine to optimize metabolic control in patients with type 1 diabetes mellitus: Telemed study. Diabetes Technol Ther. 2014 Jul;16(7):435-41. doi: 10.1089/dia.2013.0313. Epub 2014 Feb 14.|Klonoff DC. Using telemedicine to improve outcomes in diabetes--an emerging technology. J Diabetes Sci Technol. 2009 Jul 1;3(4):624-8.|Zolfaghari M, Mousavifar SA, Haghani H. Mobile phone text messaging and Telephone follow-up in type 2 diabetic patients for 3 months: a comparative study. J Diabetes Metab Disord. 2012 Aug 24;11(1):7. doi: 10.1186/2251-6581-11-7. Retraction in: J Diabetes Metab Disord. 2013 Mar 07;11(1):21.|Zhai YK, Zhu WJ, Cai YL, Sun DX, Zhao J. Clinical- and cost-effectiveness of telemedicine in type 2 diabetes mellitus: a systematic review and meta-analysis. Medicine (Baltimore). 2014 Dec;93(28):e312. doi: 10.1097/MD.0000000000000312. Review.|McGloin H, Timmins F, Coates V, Boore J. A case study approach to the examination of a telephone-based health coaching intervention in facilitating behaviour change for adults with Type 2 diabetes. J Clin Nurs. 2015 May;24(9-10):1246-57. doi: 10.1111/jocn.12692. Epub 2014 Oct 16.|Nuti L, Turkcan A, Lawley MA, Zhang L, Sands L, McComb S. The impact of interventions on appointment and clinical outcomes for individuals with diabetes: a systematic review. BMC Health Serv Res. 2015 Sep 2;15:355. doi: 10.1186/s12913-015-0938-5. Review.\tDiabetes Mellitus (DM) is one of the most prevalent chronic diseases worldwide and with a significant impact on health spending.","Diabetes Mellitus, Type 2","Therapeutic education by phone|Therapeutical education traditional","Parallel Assignment","Supportive Care","Randomized","Other|Other","All","Inclusion Criteria:\tTelephone Therapeutic Education Program in DM2 Patients With Poor Metabolic Control\tInterventional\tRecruiting\tNot Applicable\t2\t76\tdiabetes mellitus|diabetes mellitus, type 2\tNA\tNA\nNCT04938518\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t22313953\tAjose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS. 2012 May 15;26(8):929-38. doi: 10.1097/QAD.0b013e328351f5b2. Review.\tIn 2014, the Joint United Nations Program on HIV/AIDS (UNAIDS) issued treatment goals for Human Immunodeficiency Virus (HIV), the 90-90-90 target. It is important to track success results at each stage of the HIV continuum of care to evaluate progress towards the 90-90-90 target. Although ART can suppress HIV-1 infection to undetectable levels of plasma viremia, HIV DNA integrate and persist in resting CD4+ T cells. Most of the HIV DNA in these cells is defective and cannot cause infection. However, latent HIV-1 genomes that encode replication-competent virus can resurface once ART is discontinued. This latent reservoir is believed to be the largest impediment to a cure by ART alone. There is need for expansion of research examining HIV latency in the context of sustained viral suppression with an eye towards developing a possible cure regimen that could be used on a large scale. To date, there have been no systematic studies to quantify the latent reservoir in virally suppressed HIV-infected patients in Africa. Detecting how much of the inducible virus is left in the human body after ART poses the greatest challenge to fully curing HIV. This study is designed to enroll 222 virally suppressed HIV infected men and women, who will be prospectively followed to document antiviral cocktail, viral suppression and incidences of rebound, measure the size of the latent HIV reservoir and examine the immunological correlates of the latent reservoir. Data generated through this study will provide a clear framework for high-burden countries to reduce gaps at each stage of the HIV continuum of care, maximize linkage, retention and health outcomes.\tHIV-1-infection\tNA\tNA\tNA\tNA\tNA\tAll\tInclusion Criteria:","NA","NA","NA","NA","NA","NA","NA","NA","NA"]
["NCT04960605","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","10531746|15740617|21443589|22563590","Isidor F, Brøndum K, Hansen HJ, Jensen J, Sindet-Pedersen S. Outcome of treatment with implant-retained dental prostheses in patients with Sjögren syndrome. Int J Oral Maxillofac Implants. 1999 Sep-Oct;14(5):736-43.|Pedersen AM, Bardow A, Nauntofte B. Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjogren's syndrome. BMC Clin Pathol. 2005 Mar 1;5(1):4.|Hosseini M, Gotfredsen K. A feasible, aesthetic quality evaluation of implant-supported single crowns: an analysis of validity and reliability. Clin Oral Implants Res. 2012 Apr;23(4):453-8. doi: 10.1111/j.1600-0501.2011.02162.x. Epub 2011 Mar 28.|Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, Schiødt M, Umehara H, Vivino F, Zhao Y, Dong Y, Greenspan D, Heidenreich AM, Helin P, Kirkham B, Kitagawa K, Larkin G, Li M, Lietman T, Lindegaard J, McNamara N, Sack K, Shirlaw P, Sugai S, Vollenweider C, Whitcher J, Wu A, Zhang S, Zhang W, Greenspan J, Daniels T; Sjögren's International Collaborative Clinical Alliance (SICCA) Research Groups. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012 Apr;64(4):475-87.","Primary Sj<U+FFFD><U+FFFD>gren's Syndrome (PSS) is a chronic autoimmune inflammatory disease primarily involving the salivary and lacrimal glands. Few data exist regarding survival and success rate of dental implants in patients with PSS. Although a previous study suggest lower success rate for dental implants we hypothesize that dental implants have similar survival and success rate in PSS as healthy controls.\tDental Implant|Primary Sjögren Syndrome\tDental implants\tNA\tNA\tNA\tProcedure\tAll\tInclusion Criteria:","Prognosis of Dental Implants in Patients With Primary Sjögren's Syndrome","Interventional","Active, not recruiting","Not Applicable",2,48,"syndrome|sjogren's syndrome","NA","NA"]
["NCT04961086","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","26184263|29562659|28168925|26394126|29947575|26931509","Nowak D, Jasionowski A. Analysis of the Consumption of Caffeinated Energy Drinks among Polish Adolescents. Int J Environ Res Public Health. 2015 Jul 10;12(7):7910-21. doi: 10.3390/ijerph120707910.|Nowak D, Gośliński M, Nowatkowska K. The Effect of Acute Consumption of Energy Drinks on Blood Pressure, Heart Rate and Blood Glucose in the Group of Young Adults. Int J Environ Res Public Health. 2018 Mar 19;15(3). pii: E544. doi: 10.3390/ijerph15030544.|Wesnes KA, Brooker H, Watson AW, Bal W, Okello E. Effects of the Red Bull energy drink on cognitive function and mood in healthy young volunteers. J Psychopharmacol. 2017 Feb;31(2):211-221. doi: 10.1177/0269881116681459. Epub 2016 Dec 14.|Buckenmeyer PJ, Bauer JA, Hokanson JF, Hendrick JL. Cognitive influence of a 5-h ENERGY® shot: Are effects perceived or real? Physiol Behav. 2015 Dec 1;152(Pt A):323-7. doi: 10.1016/j.physbeh.2015.09.003. Epub 2015 Sep 21.|Smith AP, Richards G. Energy drinks, caffeine, junk food, breakfast, depression and academic attainment of secondary school students. J Psychopharmacol. 2018 Aug;32(8):893-899. doi: 10.1177/0269881118783314. Epub 2018 Jun 27.|Brothers RM, Christmas KM, Patik JC, Bhella PS. Heart rate, blood pressure and repolarization effects of an energy drink as compared to coffee. Clin Physiol Funct Imaging. 2017 Nov;37(6):675-681. doi: 10.1111/cpf.12357. Epub 2016 Mar 1.","Energy drinks consumption has varied effects on the hemodynamic, blood glucose levels, brain functions and memory. The use of energy drinks is pervasive and especially young adults consume it often as binge drinking. The negative health effects of excessive use of energy drinks has been reported in the scientific literature. Often energy drinks are consumed to enhance alertness and cognition improvement. In this trial, the investigators intend to compare the effects of a widely available energy drink brand in the country with the usual black tea with 5gm sugar and milk. The aims of this study is:\tBlood Glucose, High|Blood Pressure|Cognitive Change\tenergy drink\tParallel Assignment\tBasic Science\tRandomized\tOther\tAll\tInclusion Criteria","Health Effect of Energy Drink Consumption","Interventional","Recruiting","Not Applicable",2,76,"hyperglycemia","NA","NA"]
["NCT04961385","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","16647790|31141635|32702298|33306989|33220855","Strauss K, van Zundert A, Frid A, Costigliola V. Pandemic influenza preparedness: the critical role of the syringe. Vaccine. 2006 May 29;24(22):4874-82. Epub 2006 Mar 20.|Mehran R, Dangas GD, Weisbord SD. Contrast-Associated Acute Kidney Injury. N Engl J Med. 2019 May 30;380(22):2146-2155. doi: 10.1056/NEJMra1805256. Review.|Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20. Erratum in: Lancet. 2020 Aug 15;396(10249):466. Erratum in: Lancet. 2020 Dec 12;396(10266):1884.|Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O'Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. Erratum in: Lancet. 2021 Jan 9;397(10269):98.|Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA, Colin-Jones R, Dold C, Emary KRW, Fedosyuk S, Fuskova M, Gbesemete D, Green C, Hallis B, Hou MM, Jenkin D, Joe CCD, Kelly EJ, Kerridge S, Lawrie AM, Lelliott A, Lwin MN, Makinson R, Marchevsky NG, Mujadidi Y, Munro APS, Pacurar M, Plested E, Rand J, Rawlinson T, Rhead S, Robinson H, Ritchie AJ, Ross-Russell AL, Saich S, Singh N, Smith CC, Snape MD, Song R, Tarrant R, Themistocleous Y, Thomas KM, Villafana TL, Warren SC, Watson MEE, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Faust SN, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19. Erratum in: Lancet. 2021 Dec 19;396(10267):1978. Lancet. 2021 Apr 10;397(10282):1350.","ChAd0x1 nCoV-19 (AZD 1222) is the main vaccine that is planned to roll-out in Thailand and involve vaccinating people especially in high-risk categories. This vaccine is contained in the multiple-dose vial for vaccinating 10 recipients for 0.5 mL each. However, the additional volume of vaccine was overfilled to 6.5 mL per vial which the vaccination can be administered to more than 10 doses. The University Hospital Network (UHOSNET) and Faculty of Medicine Vajira Hospital, Navamindradhiraj University have jointly stipulated the preparation and vaccination of ChAdox1 - n CoV-19 vaccine with 12 doses per vial injection with traditional 21 or 24 G needle. Taken together, The investigators planned to investigate the immune response of participants after first dose of ChAd0x1 nCoV-19 vaccination with such technique","Covid19|Immunogenicity|Vaccine","Immunogenicity after first dose of participants who received first dose of ChAdox-1 n COV-19 vaccine","NA","NA","NA","Biological","All","Inclusion Criteria:\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\nNCT04961424\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t20556438|23218510|7608226|25768686|28597302|24760464|30302540|33380952|31935784|32361024\tLeonardi MA, Zanetti M, Saupe N, Min K. Early postoperative MRI in detecting hematoma and dural compression after lumbar spinal decompression: prospective study of asymptomatic patients in comparison to patients requiring surgical revision. Eur Spine J. 2010 Dec;19(12):2216-22. doi: 10.1007/s00586-010-1483-x. Epub 2010 Jun 17.|Amiri AR, Fouyas IP, Cro S, Casey AT. Postoperative spinal epidural hematoma (SEH): incidence, risk factors, onset, and management. Spine J. 2013 Feb;13(2):134-40. doi: 10.1016/j.spinee.2012.10.028. Epub 2012 Dec 5.|Delamarter RB, Sherman J, Carr JB. Pathophysiology of spinal cord injury. Recovery after immediate and delayed decompression. J Bone Joint Surg Am. 1995 Jul;77(7):1042-9.|Yamada K, Abe Y, Satoh S, Yanagibashi Y, Hyakumachi T, Masuda T. Large Increase in Blood Pressure After Extubation and High Body Mass Index Elevate the Risk of Spinal Epidural Hematoma After Spinal Surgery. Spine (Phila Pa 1976). 2015 Jul 1;40(13):1046-52. doi: 10.1097/BRS.0000000000000876.|Fujiwara Y, Manabe H, Izumi B, Harada T, Nakanishi K, Tanaka N, Adachi N. The impact of hypertension on the occurrence of postoperative spinal epidural hematoma following single level microscopic posterior lumbar decompression surgery in a single institute. Eur Spine J. 2017 Oct;26(10):2606-2615. doi: 10.1007/s00586-017-5165-9. Epub 2017 Jun 9.|Kao FC, Tsai TT, Chen LH, Lai PL, Fu TS, Niu CC, Ho NY, Chen WJ, Chang CJ. Symptomatic epidural hematoma after lumbar decompression surgery. Eur Spine J. 2015 Feb;24(2):348-57. doi: 10.1007/s00586-014-3297-8. Epub 2014 Apr 24.|Fujita N, Michikawa T, Yagi M, Suzuki S, Tsuji O, Nagoshi N, Okada E, Tsuji T, Nakamura M, Matsumoto M, Watanabe K. Impact of lumbar hypolordosis on the incidence of symptomatic postoperative spinal epidural hematoma after decompression surgery for lumbar spinal canal stenosis. Eur Spine J. 2019 Jan;28(1):87-93. doi: 10.1007/s00586-018-5782-y. Epub 2018 Oct 9.|Knusel K, Du JY, Ren B, Kim CY, Ahn UM, Ahn NU. Symptomatic Epidural Hematoma after Elective Posterior Lumbar Decompression: Incidence, Timing, Risk Factors, and Associated Complications. HSS J. 2020 Dec;16(Suppl 2):230-237. doi: 10.1007/s11420-019-09690-2. Epub 2019 Jul 1.|Hohenberger C, Zeman F, Höhne J, Ullrich OW, Brawanski A, Schebesch KM. Symptomatic Postoperative Spinal Epidural Hematoma after Spinal Decompression Surgery: Prevalence, Risk Factors, and Functional Outcome. J Neurol Surg A Cent Eur Neurosurg. 2020 Jul;81(4):290-296. doi: 10.1055/s-0039-1697024. Epub 2020 Jan 14.|Mueller K, Altshuler M, Voyadzis JM, Sandhu FA. The incidence of symptomatic postoperative epidural hematoma after minimally invasive lumbar decompression: A single institution retrospective review. Clin Neurol Neurosurg. 2020 Aug;195:105868. doi: 10.1016/j.clineuro.2020.105868. Epub 2020 Apr 22.\tThis is a retrospective, observational single-center study. The studies is to investigate the incidence of posterior epidural spinal hematoma(PSEH) and recognize the risk factors for it in a cohort of patients undergoing posterior thoracic surgery in isolation.\tSpinal Epidural Hematoma|Thoracic Surgery\tNA\tNA\tNA\tNA\tNA\tAll\tInclusion Criteria:","NA","NA","NA","NA","NA","NA","hematoma, epidural, cranial|hematoma, epidural, spinal|hematoma","NA","NA"]
["NCT04968626","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","27811518|25070790|25278883|12768144|1510296|24636766|21336205|28306639|28161236|30201580","Randall RM, Silverstein M, Goodwin R. Review of Pediatric Spondylolysis and Spondylolisthesis. Sports Med Arthrosc Rev. 2016 Dec;24(4):184-187. Review.|Urrutia J, Cuellar J, Zamora T. Spondylolysis and spina bifida occulta in pediatric patients: prevalence study using computed tomography as a screening method. Eur Spine J. 2016 Feb;25(2):590-5. doi: 10.1007/s00586-014-3480-y. Epub 2014 Jul 29.|Ramadorai U, Hire J, DeVine JG, Brodt ED, Dettori JR. Incidental findings on magnetic resonance imaging of the spine in the asymptomatic pediatric population: a systematic review. Evid Based Spine Care J. 2014 Oct;5(2):95-100. doi: 10.1055/s-0034-1386753. Review.|Beutler WJ, Fredrickson BE, Murtland A, Sweeney CA, Grant WD, Baker D. The natural history of spondylolysis and spondylolisthesis: 45-year follow-up evaluation. Spine (Phila Pa 1976). 2003 May 15;28(10):1027-35; discussion 1035.|Duval-Beaupère G, Schmidt C, Cosson P. A Barycentremetric study of the sagittal shape of spine and pelvis: the conditions required for an economic standing position. Ann Biomed Eng. 1992;20(4):451-62.|Maciejczak A, Jabłońska K, Bączek D, Barnaś P, Czternastek M, Dudziak P, Georgiew F, Jagiełło-Bajer B, Litwora B, Maślanka P, Konior R, Orzech J. Changes in spino-pelvic alignment after surgical treatment of isthmic spondylolisthesis. Neurol Neurochir Pol. 2014 Jan-Feb;48(1):21-9. doi: 10.1016/j.pjnns.2013.05.001. Epub 2014 Jan 23.|Park SJ, Lee CS, Chung SS, Kang KC, Shin SK. Postoperative changes in pelvic parameters and sagittal balance in adult isthmic spondylolisthesis. Neurosurgery. 2011 Jun;68(2 Suppl Operative):355-63; discussion 362-3. doi: 10.1227/NEU.0b013e3182117249.|Lafage R, Liabaud B, Diebo BG, Oren JH, Vira S, Pesenti S, Protopsaltis TS, Errico TJ, Schwab FJ, Lafage V. Defining the Role of the Lower Limbs in Compensating for Sagittal Malalignment. Spine (Phila Pa 1976). 2017 Nov 15;42(22):E1282-E1288. doi: 10.1097/BRS.0000000000002157.|Minamide A, Yoshida M, Iwahashi H, Simpson AK, Yamada H, Hashizume H, Nakagawa Y, Iwasaki H, Tsutsui S, Kagotani R, Sonekatsu M, Sasaki T, Shinto K, Deguchi T. Minimally invasive decompression surgery for lumbar spinal stenosis with degenerative scoliosis: Predictive factors of radiographic and clinical outcomes. J Orthop Sci. 2017 May;22(3):377-383. doi: 10.1016/j.jos.2016.12.022. Epub 2017 Feb 1.|Shi L, Chen Y, Miao J, Shi J, Chen D. Reduction of Slippage Influences Surgical Outcomes of Grade II and III Lumbar Isthmic Spondylolisthesis. World Neurosurg. 2018 Dec;120:e1017-e1023. doi: 10.1016/j.wneu.2018.08.217. Epub 2018 Sep 7.","This was a retrospective study.PI and LL greatly influence IS and its progression. However, relationships between the spinopelvic parameters and clinical symptoms of patients with IS were not fully investigated in previous studies. Investigators hypothesized that spinopelvic parameters might be related to the clinical symptoms of IS patients. Therefore, the purpose of the present study was to investigate whether differences in spinopelvic parameters, especially spinopelvic alignment, may be associated with the clinical symptoms of low-grade IS patients.","Isthmic Spondylolisthesis","PI-LL","NA","NA","NA","Radiation","All","Inclusion Criteria:\tRelationship Between Spinopelvic Parameters and Clinical Symptoms of Low-grade Lumbar Isthmic Spondylolisthesis\tInterventional\tCompleted\tNot Applicable\t2\t226\tspondylolisthesis\tNA\tNA\nNCT04968873\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t26615165\tCopelan A, Kapoor BS. Choledocholithiasis: Diagnosis and Management. Tech Vasc Interv Radiol. 2015 Dec;18(4):244-55. doi: 10.1053/j.tvir.2015.07.008. Epub 2015 Jul 15. Review.\tA study that included patients of any gender between 15 and 70 years, with the diagnosis of choledocholithiasis who required a cholecystectomy with an exploration of bile ducts. Conventional cholecystectomy was performed and a T-tube was inserted in the common bile duct (CBD) to measure the intraluminal pressure immediately after the procedure, and weekly thereafter, with a 6-week follow-up. A control T-tube radiological study was performed at six weeks to exclude residual stones.\tCholedocholithiasis\tCholecystectomy and common bile duct exploration\tNA\tNA\tNA\tProcedure\tAll\tInclusion Criteria: Choledocholithiasis -","NA","NA","NA","NA","NA","NA","choledocholithiasis","NA","NA"]
["NCT04969302","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","31739120|27256458|21378634","Gezer S, Yalvaç HM, Güngör K, Yücesoy İ. Povidone-iodine vs chlorhexidine alcohol for skin preparation in malignant and premalignant gynaecologic diseases: A randomized controlled study. Eur J Obstet Gynecol Reprod Biol. 2020 Jan;244:45-50. doi: 10.1016/j.ejogrb.2019.10.035. Epub 2019 Nov 9.|Wistrand C, Söderquist B, Nilsson U. Positive impact on heat loss and patient experience of preheated skin disinfection: a randomised controlled trial. J Clin Nurs. 2016 Nov;25(21-22):3144-3151. doi: 10.1111/jocn.13263. Epub 2016 Jun 3.|Wistrand C, Nilsson U. Effects and experiences of warm versus cold skin disinfection. Br J Nurs. 2011 Feb 10-23;20(3):148,150-1.","Surgical Site Infections (SSI) develop as a complication of surgical care 30-90 days after surgery without implants and within 1 year after implanted operations. Despite advances in asepsis practices, sterilization methods, surgical technique and antibiotic prophylaxis, SSI is the most important cause of hospital stay, morbidity and even mortality. SSI, which constitutes approximately 20% of healthcare associated infections (HAI) all over the world, is also the HAI with the highest cost. Although it has been reported that 60% of the SSI can be prevented by using evidence-based guidelines, 2-5% of the operated patients develop SSI, the hospital stay of patients with SSI is 7-11 days longer, the risk of death increases 2-11 times, It was reported that the cause of death was direct SSI. In the United States of America (USA), SSI constitutes 31% of HAI, it is seen in 2-5% of inpatients, approximately 160,000-300,000 SSIs occur each year, the most common and costly HAI.Abdominal surgery; It includes the treatment of diseases of organs such as stomach, gall bladder, pancreas, spleen, liver, small intestine and large intestine. It has been reported that the incidence of SSIs after abdominal surgery is 15-25% higher than other types of surgery. In a study conducted by Alcan et al. (2020), 69.8% of nurses stated that they used Povidone Iodine as skin antisepsis. Wistrand et al. (2015) compared preoperative 36 <U+FFFD><U+FFFD> C and room temperature 20 <U+FFFD><U+FFFD> C Chlorhexidine Gluconate solutions, but reported that there was no difference in bacterial colonization and SSI rates. In their study in Turkey, Gezer et al. (2020) reported that the prevalence of SSI was significantly lower in the Povidone Iodine group heated to 37 <U+FFFD><U+FFFD> C before surgery compared to the Povidone Iodine group applied at 25 <U+FFFD><U+FFFD> C room temperature.","Surgical Site Infections","Follow-up","Parallel Assignment","Screening","Randomized","Diagnostic Test","All","Inclusion Criteria:\tExamination of the Effect of Skin Antisepsis With Pre-heated Povidone Iodine on Surgical Site Infections: A Randomized Controlled Trial\tInterventional\tRecruiting\tNot Applicable\t2\t124\tinfection|communicable diseases|surgical wound infection\tNA\tNA\nNCT04969354\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t28031562|23256743|28541315|29048935|31110702|23515080|24790793|25317870|28843072|25939063|23423337|20889925\tLinehan WM, Ricketts CJ. Kidney cancer in 2016: RCC - advances in targeted therapeutics and genomics. Nat Rev Urol. 2017 Feb;14(2):76-78. doi: 10.1038/nrurol.2016.260. Epub 2016 Dec 29. Review.|Zhang Q, Li H, Yang J, Li L, Zhang B, Li J, Zheng J. Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer. Curr Gene Ther. 2013 Feb;13(1):65-70. Review.|Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. Nature. 2017 May 24;545(7655):423-431. doi: 10.1038/nature22395. Review.|Xu J, Tian K, Zhang H, Li L, Liu H, Liu J, Zhang Q, Zheng J. Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens. Expert Rev Anticancer Ther. 2017 Dec;17(12):1099-1106. doi: 10.1080/14737140.2017.1395285. Epub 2017 Oct 26. Review.|Weinkove R, George P, Dasyam N, McLellan AD. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin Transl Immunology. 2019 May 11;8(5):e1049. doi: 10.1002/cti2.1049. eCollection 2019. Review.|Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013 Mar 20;5(177):177ra38. doi: 10.1126/scitranslmed.3005930.|Song C, Sadashivaiah K, Furusawa A, Davila E, Tamada K, Banerjee A. Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy. Oncoimmunology. 2014 Jan 1;3(1):e27680. Epub 2014 Feb 27.|Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222. Erratum in: N Engl J Med. 2016 Mar 10;374(10):998.|Kawalekar OU, O' Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, Patel PR, Guedan S, Scholler J, Keith B, Snyder NW, Blair IA, Milone MC, June CH. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity. 2016 Mar 15;44(3):712. doi: 10.1016/j.immuni.2016.02.023. Epub 2016 Mar 15.|Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, Kaplan RN, Patterson GH, Fry TJ, Orentas RJ, Mackall CL. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015 Jun;21(6):581-90. doi: 10.1038/nm.3838. Epub 2015 May 4.|Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, Vulto A, den Bakker M, Oosterwijk E, Debets R, Gratama JW. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013 Apr;21(4):904-12. doi: 10.1038/mt.2013.17. Epub 2013 Feb 19.|Lamers CH, Willemsen R, van Elzakker P, van Steenbergen-Langeveld S, Broertjes M, Oosterwijk-Wakka J, Oosterwijk E, Sleijfer S, Debets R, Gratama JW. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood. 2011 Jan 6;117(1):72-82. doi: 10.1182/blood-2010-07-294520. Epub 2010 Oct 1.\tThis is an experimental study to evaluate the safety and efficacy of CAR T cells targeting CAIX in the treatment of advanced renal cancer.\tImmunotherapy\tCAR-T cell immunotherapy\tNA\tNA\tNA\tBiological\tAll\tInclusion Criteria:","NA","NA","NA","NA","NA","NA","carcinoma, renal cell|carcinoma","NA","NA"]
["NCT04969484","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","15673356|21634072|9644392|19013934|20048355|26379704|31007055|21991894|22175816|25582118|16450663|26025176|28151923|23026981|23984636|18205757|12401699|21412898|21649622|27650008|27641157|29159368|16014595|11074779|12028168|21378067|23388081|17851378|11327480|9256845|14709580|15541622|20048371|19735904|31238934|21266284|21145468|23612520|27698303|22085114|24610324|20813893|19060793|10178473|15742987|10834899|18019116|20070161|19441951|19353687|22373619|25167382|26290500|12925553|16238833|17046097|16109300|11051950|24513226|18333736|22796362|20014004|16594230|16829207","Mitchell SL, Teno JM, Miller SC, Mor V. A national study of the location of death for older persons with dementia. J Am Geriatr Soc. 2005 Feb;53(2):299-305. Erratum in: J Am Geriatr Soc. 2005 Apr;53(4):741.|National Center for Health Statistics (US). Health, United States, 2010: With Special Feature on Death and Dying. Hyattsville (MD): National Center for Health Statistics (US); 2011 Feb.|Brock DB, Foley DJ. Demography and epidemiology of dying in the U.S. with emphasis on deaths of older persons. Hosp J. 1998;13(1-2):49-60.|Bercovitz A, Decker FH, Jones A, Remsburg RE. End-of-life care in nursing homes: 2004 National Nursing Home Survey. Natl Health Stat Report. 2008 Oct 8;(9):1-23.|Kaye HS, Harrington C, LaPlante MP. Long-term care: who gets it, who provides it, who pays, and how much? Health Aff (Millwood). 2010 Jan-Feb;29(1):11-21. doi: 10.1377/hlthaff.2009.0535. Erratum in: Health Aff (Millwood). 2010 Mar-Apr;29(3):567.|Stephens C, Halifax E, Bui N, Lee SJ, Harrington C, Shim J, Ritchie C. Provider Perspectives on the Influence of Family on Nursing Home Resident Transfers to the Emergency Department: Crises at the End of Life. Curr Gerontol Geriatr Res. 2015;2015:893062. doi: 10.1155/2015/893062. Epub 2015 Aug 24.|\"Stephens CE, Halifax E, David D, Bui N, Lee SJ, Shim J, Ritchie CS. \"\"They Don't Trust Us\"\": The Influence of Perceptions of Inadequate Nursing Home Care on Emergency Department Transfers and the Potential Role for Telehealth. Clin Nurs Res. 2020 Mar;29(3):157-168. doi: 10.1177/1054773819835015. Epub 2019 Apr 21.\"|Gozalo P, Teno JM, Mitchell SL, Skinner J, Bynum J, Tyler D, Mor V. End-of-life transitions among nursing home residents with cognitive issues. N Engl J Med. 2011 Sep 29;365(13):1212-21. doi: 10.1056/NEJMsa1100347.|Miller SC, Lima JC, Looze J, Mitchell SL. Dying in U.S. nursing homes with advanced dementia: how does health care use differ for residents with, versus without, end-of-life Medicare skilled nursing facility care? J Palliat Med. 2012 Jan;15(1):43-50. doi: 10.1089/jpm.2011.0210. Epub 2011 Dec 16.|Cohen A, Bulanda JR. Social Supports as Enabling Factors in Nursing Home Admissions: Rural, Suburban, and Urban Differences. J Appl Gerontol. 2016 Jul;35(7):721-43. doi: 10.1177/0733464814566677. Epub 2015 Jan 11.|Bolin JN, Phillips CD, Hawes C. Urban and rural differences in end-of-life pain and treatment status on admission to a nursing facility. Am J Hosp Palliat Care. 2006 Jan-Feb;23(1):51-7.|Douthit N, Kiv S, Dwolatzky T, Biswas S. Exposing some important barriers to health care access in the rural USA. Public Health. 2015 Jun;129(6):611-20. doi: 10.1016/j.puhe.2015.04.001. Epub 2015 May 27. Review.|Matthews KA, Croft JB, Liu Y, Lu H, Kanny D, Wheaton AG, Cunningham TJ, Khan LK, Caraballo RS, Holt JB, Eke PI, Giles WH. Health-Related Behaviors by Urban-Rural County Classification - United States, 2013. MMWR Surveill Summ. 2017 Feb 3;66(5):1-8. doi: 10.15585/mmwr.ss6605a1.|Aragon K, Covinsky K, Miao Y, Boscardin WJ, Flint L, Smith AK. Use of the Medicare posthospitalization skilled nursing benefit in the last 6 months of life. Arch Intern Med. 2012 Nov 12;172(20):1573-9. doi: 10.1001/archinternmed.2012.4451.|Ersek M, Carpenter JG. Geriatric palliative care in long-term care settings with a focus on nursing homes. J Palliat Med. 2013 Oct;16(10):1180-7. doi: 10.1089/jpm.2013.9474. Epub 2013 Aug 28.|Casarett D, Pickard A, Bailey FA, Ritchie C, Furman C, Rosenfeld K, Shreve S, Chen Z, Shea JA. Do palliative consultations improve patient outcomes? J Am Geriatr Soc. 2008 Apr;56(4):593-9. doi: 10.1111/j.1532-5415.2007.01610.x. Epub 2008 Jan 16.|Finlay IG, Higginson IJ, Goodwin DM, Cook AM, Edwards AG, Hood K, Douglas HR, Normand CE. Palliative care in hospital, hospice, at home: results from a systematic review. Ann Oncol. 2002;13 Suppl 4:257-64. Review.|Hall S, Kolliakou A, Petkova H, Froggatt K, Higginson IJ. Interventions for improving palliative care for older people living in nursing care homes. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD007132. doi: 10.1002/14651858.CD007132.pub2. Review.|Berkowitz RE, Jones RN, Rieder R, Bryan M, Schreiber R, Verney S, Paasche-Orlow MK. Improving disposition outcomes for patients in a geriatric skilled nursing facility. J Am Geriatr Soc. 2011 Jun;59(6):1130-6. doi: 10.1111/j.1532-5415.2011.03417.x. Epub 2011 Jun 7.|Miller SC, Dahal R, Lima JC, Intrator O, Martin E, Bull J, Hanson LC. Palliative Care Consultations in Nursing Homes and End-of-Life Hospitalizations. J Pain Symptom Manage. 2016 Dec;52(6):878-883. doi: 10.1016/j.jpainsymman.2016.05.017. Epub 2016 Sep 17.|Miller SC, Lima JC, Intrator O, Martin E, Bull J, Hanson LC. Palliative Care Consultations in Nursing Homes and Reductions in Acute Care Use and Potentially Burdensome End-of-Life Transitions. J Am Geriatr Soc. 2016 Nov;64(11):2280-2287. doi: 10.1111/jgs.14469. Epub 2016 Sep 19.|Stephens CE, Hunt LJ, Bui N, Halifax E, Ritchie CS, Lee SJ. Palliative Care Eligibility, Symptom Burden, and Quality-of-Life Ratings in Nursing Home Residents. JAMA Intern Med. 2018 Jan 1;178(1):141-142. doi: 10.1001/jamainternmed.2017.6299.|Casarett D, Karlawish J, Morales K, Crowley R, Mirsch T, Asch DA. Improving the use of hospice services in nursing homes: a randomized controlled trial. JAMA. 2005 Jul 13;294(2):211-7.|Zerzan J, Stearns S, Hanson L. Access to palliative care and hospice in nursing homes. JAMA. 2000 Nov 15;284(19):2489-94.|Happ MB, Capezuti E, Strumpf NE, Wagner L, Cunningham S, Evans L, Maislin G. Advance care planning and end-of-life care for hospitalized nursing home residents. J Am Geriatr Soc. 2002 May;50(5):829-35.|Johnston B, Kidd L, Wengstrom Y, Kearney N. An evaluation of the use of Telehealth within palliative care settings across Scotland. Palliat Med. 2012 Mar;26(2):152-61. doi: 10.1177/0269216311398698. Epub 2011 Mar 4.|Low JA, Beins G, Lee KK, Koh E. Last moments of life: can telemedicine play a role? Palliat Support Care. 2013 Aug;11(4):353-5. doi: 10.1017/S1478951512000995. Epub 2013 Feb 7.|Wowchuk SM, McClement S, Bond J Jr. The challenge of providing palliative care in the nursing home part II: internal factors. Int J Palliat Nurs. 2007 Jul;13(7):345-50. Review.|Travis SS, Loving G, McClanahan L, Bernard M. Hospitalization patterns and palliation in the last year of life among residents in long-term care. Gerontologist. 2001 Apr;41(2):153-60.|Teno JM, Branco KJ, Mor V, Phillips CD, Hawes C, Morris J, Fries BE. Changes in advance care planning in nursing homes before and after the patient Self-Determination Act: report of a 10-state survey. J Am Geriatr Soc. 1997 Aug;45(8):939-44.|Teno JM, Clarridge BR, Casey V, Welch LC, Wetle T, Shield R, Mor V. Family perspectives on end-of-life care at the last place of care. JAMA. 2004 Jan 7;291(1):88-93.|Miller SC, Teno JM, Mor V. Hospice and palliative care in nursing homes. Clin Geriatr Med. 2004 Nov;20(4):717-34, vii. Review.|Huskamp HA, Stevenson DG, Chernew ME, Newhouse JP. A new medicare end-of-life benefit for nursing home residents. Health Aff (Millwood). 2010 Jan-Feb;29(1):130-5. doi: 10.1377/hlthaff.2009.0523.|Stevenson DG, Bramson JS. Hospice care in the nursing home setting: a review of the literature. J Pain Symptom Manage. 2009 Sep;38(3):440-51. doi: 10.1016/j.jpainsymman.2009.05.006. Review.|Ding J, Saunders C, Cook A, Johnson CE. End-of-life care in rural general practice: how best to support commitment and meet challenges? BMC Palliat Care. 2019 Jun 25;18(1):51. doi: 10.1186/s12904-019-0435-4.|Carlson MD, Lim B, Meier DE. Strategies and innovative models for delivering palliative care in nursing homes. J Am Med Dir Assoc. 2011 Feb;12(2):91-8. doi: 10.1016/j.jamda.2010.07.016. Epub 2010 Nov 10.|Lupu D; American Academy of Hospice and Palliative Medicine Workforce Task Force. Estimate of current hospice and palliative medicine physician workforce shortage. J Pain Symptom Manage. 2010 Dec;40(6):899-911. doi: 10.1016/j.jpainsymman.2010.07.004.|Edirippulige S, Martin-Khan M, Beattie E, Smith AC, Gray LC. A systematic review of telemedicine services for residents in long term care facilities. J Telemed Telecare. 2013 Apr;19(3):127-132. Epub 2013 May 23. Review.|Rogante M, Giacomozzi C, Grigioni M, Kairy D. Telemedicine in palliative care: a review of systematic reviews. Ann Ist Super Sanita. 2016 Jul-Sep;52(3):434-442. doi: 10.4415/ANN_16_03_16. Review.|Oliver DP, Demiris G, Wittenberg-Lyles E, Washington K, Day T, Novak H. A systematic review of the evidence base for telehospice. Telemed J E Health. 2012 Jan-Feb;18(1):38-47. doi: 10.1089/tmj.2011.0061. Epub 2011 Nov 15. Review.|Capurro D, Ganzinger M, Perez-Lu J, Knaup P. Effectiveness of eHealth interventions and information needs in palliative care: a systematic literature review. J Med Internet Res. 2014 Mar 7;16(3):e72. doi: 10.2196/jmir.2812. Review.|Kidd L, Cayless S, Johnston B, Wengstrom Y. Telehealth in palliative care in the UK: a review of the evidence. J Telemed Telecare. 2010;16(7):394-402. doi: 10.1258/jtt.2010.091108. Epub 2010 Sep 2. Review.|McCall K, Keen J, Farrer K, Maguire R, McCann L, Johnston B, McGill M, Sage M, Kearney N. Perceptions of the use of a remote monitoring system in patients receiving palliative care at home. Int J Palliat Nurs. 2008 Sep;14(9):426-31.|Roglieri JL, Futterman R, McDonough KL, Malya G, Karwath KR, Bowman D, Skelly J, Warburton SW Jr. Disease management interventions to improve outcomes in congestive heart failure. Am J Manag Care. 1997 Dec;3(12):1831-9.|Lind L, Karlsson D. A system for symptom assessment in advanced palliative home healthcare using digital pens. Med Inform Internet Med. 2004 Sep-Dec;29(3-4):199-210.|Mair F, Whitten P. Systematic review of studies of patient satisfaction with telemedicine. BMJ. 2000 Jun 3;320(7248):1517-20. Review.|Hammett L, Harvath TA, Flaherty-Robb M, Sawyer G, Olson D. Remote wound care consultation for nursing homes: using a web-based assessment and care planning tool. J Gerontol Nurs. 2007 Nov;33(11):27-35; quiz 36-7. doi: 10.3928/00989134-20071101-09.|Rabinowitz T, Murphy KM, Amour JL, Ricci MA, Caputo MP, Newhouse PA. Benefits of a telepsychiatry consultation service for rural nursing home residents. Telemed J E Health. 2010 Jan-Feb;16(1):34-40. doi: 10.1089/tmj.2009.0088.|Yeung A, Johnson DP, Trinh NH, Weng WC, Kvedar J, Fava M. Feasibility and effectiveness of telepsychiatry services for chinese immigrants in a nursing home. Telemed J E Health. 2009 May;15(4):336-41. doi: 10.1089/tmj.2008.0138.|Biglan KM, Voss TS, Deuel LM, Miller D, Eason S, Fagnano M, George BP, Appler A, Polanowicz J, Viti L, Smith S, Joseph A, Dorsey ER. Telemedicine for the care of nursing home residents with Parkinson's disease. Mov Disord. 2009 May 15;24(7):1073-6. doi: 10.1002/mds.22498.|Michener L, Cook J, Ahmed SM, Yonas MA, Coyne-Beasley T, Aguilar-Gaxiola S. Aligning the goals of community-engaged research: why and how academic health centers can successfully engage with communities to improve health. Acad Med. 2012 Mar;87(3):285-91. doi: 10.1097/ACM.0b013e3182441680.|Frank L, Basch E, Selby JV; Patient-Centered Outcomes Research Institute. The PCORI perspective on patient-centered outcomes research. JAMA. 2014 Oct 15;312(15):1513-4. doi: 10.1001/jama.2014.11100.|Collier A, Morgan DD, Swetenham K, To TH, Currow DC, Tieman JJ. Implementation of a pilot telehealth programme in community palliative care: A qualitative study of clinicians' perspectives. Palliat Med. 2016 Apr;30(4):409-17. doi: 10.1177/0269216315600113. Epub 2015 Aug 19.|May C, Harrison R, Finch T, MacFarlane A, Mair F, Wallace P; Telemedicine Adoption Study Group. Understanding the normalization of telemedicine services through qualitative evaluation. J Am Med Inform Assoc. 2003 Nov-Dec;10(6):596-604. Epub 2003 Aug 4.|Yellowlees PM. Successfully developing a telemedicine system. J Telemed Telecare. 2005;11(7):331-5.|Miller EA. Solving the disjuncture between research and practice: telehealth trends in the 21st century. Health Policy. 2007 Jul;82(2):133-41. Epub 2006 Oct 13.|Stillman D, Strumpf N, Capezuti E, Tuch H. Staff perceptions concerning barriers and facilitators to end-of-life care in the nursing home. Geriatr Nurs. 2005 Jul-Aug;26(4):259-64.|Froggatt K. Evaluating a palliative care education project in nursing homes. Int J Palliat Nurs. 2000 Mar;6(3):140-6.|Ouslander JG, Bonner A, Herndon L, Shutes J. The Interventions to Reduce Acute Care Transfers (INTERACT) quality improvement program: an overview for medical directors and primary care clinicians in long term care. J Am Med Dir Assoc. 2014 Mar;15(3):162-170. doi: 10.1016/j.jamda.2013.12.005. Review.|Levy C, Morris M, Kramer A. Improving end-of-life outcomes in nursing homes by targeting residents at high-risk of mortality for palliative care: program description and evaluation. J Palliat Med. 2008 Mar;11(2):217-25. doi: 10.1089/jpm.2007.0147.|Saliba D, Buchanan J, Edelen MO, Streim J, Ouslander J, Berlowitz D, Chodosh J. MDS 3.0: brief interview for mental status. J Am Med Dir Assoc. 2012 Sep;13(7):611-7. doi: 10.1016/j.jamda.2012.06.004. Epub 2012 Jul 15.|Sandelowski M. What's in a name? Qualitative description revisited. Res Nurs Health. 2010 Feb;33(1):77-84. doi: 10.1002/nur.20362.|Steinhauser KE, Clipp EC, Bosworth HB, McNeilly M, Christakis NA, Voils CI, Tulsky JA. Measuring quality of life at the end of life: validation of the QUAL-E. Palliat Support Care. 2004 Mar;2(1):3-14.|Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster randomized trials. Contemp Clin Trials. 2007 Feb;28(2):182-91. Epub 2006 Jul 7. Review.","This project will focus on developing, optimizing and pilot-testing a multi-component Improving Access Through Technology (ImPAcTT) intervention that leverages existing telehealth technologies to provide staff education; family outreach, engagement and support; care coordination; and resident symptom management and facilitation of goals-of-care discussion.","Palliative Care|Telehealth","Telehealth visit","NA","NA","NA","Other","All","Purposeful sampling will take place in an attempt to collect data from a range of ethnically and racially diverse participants.\tImproving Palliative Care Access Through Technology\tInterventional\tSuspended\tNot Applicable\t2\t81\tNA\tNA\tNA\n"]